About   Help   FAQ
Mammalian Phenotype Ontology Annotations
Query Results - Summary
16314 genotypes with 53048 annotations displayed of selected term and subterms
Searched Term: immune system phenotype
Allelic Composition
(Genetic Background)
Annotated Term Reference
\1700016L21RikTg(Itgax-HBEGF/EGFP)57Lan/0
(C.FVB-1700016L21RikTg(Itgax-HBEGF/EGFP)57Lan)
abnormal CD8-positive, alpha-beta T cell differentiation J:93488
abnormal T cell activation J:93488
decreased CD8-positive, alpha-beta T cell number J:93488
decreased cytotoxic T cell cytolysis J:93488
decreased dendritic cell number J:93488
increased neutrophil cell number J:194800
\1700016L21RikTg(Itgax-HBEGF/EGFP)57Lan/0
(B6.FVB-1700016L21RikTg(Itgax-HBEGF/EGFP)57Lan/J)
abnormal NK cell physiology J:96123
abnormal NK T cell physiology J:96123
decreased circulating interferon-gamma level J:96123
decreased circulating interleukin-12 level J:96123
decreased dendritic cell number J:100867, J:113232, J:96123
decreased interferon-gamma secretion J:96123
decreased interleukin-4 secretion J:96123
decreased interleukin-12b secretion J:125611
immune system phenotype J:122114, J:96123
impaired natural killer cell mediated cytotoxicity J:125611
sepsis J:113232
\1700016L21RikTg(Itgax-HBEGF/EGFP)57Lan/0
(C.FVB-1700016L21RikTg(Itgax-HBEGF/EGFP)57Lan/J)
abnormal NK cell physiology J:96123
decreased circulating interferon-gamma level J:96123
decreased circulating interleukin-12 level J:96123
decreased dendritic cell number J:96123
decreased interferon-gamma secretion J:96123
immune system phenotype J:96123
\1700016L21RikTg(Itgax-HBEGF/EGFP)57Lan/0
(involves: C57BL/6 * FVB/N)
abnormal alveolar macrophage morphology J:137452
decreased dendritic cell number J:137452
decreased interferon-gamma secretion J:137452
increased susceptibility to Orthomyxoviridae infection J:137452
\1700016L21RikTg(Itgax-HBEGF/EGFP)57Lan/0
(NOD.FVB-1700016L21RikTg(Itgax-HBEGF/EGFP)57Lan/Jdk)
abnormal professional antigen presenting cell physiology J:137009
decreased dendritic cell number J:137009
decreased macrophage cell number J:137009
decreased NK T cell number J:137009
decreased susceptibility to autoimmune diabetes J:137009
increased interferon-gamma secretion J:137009
increased tumor necrosis factor secretion J:137009
insulitis J:137009
\1700016L21RikTg(Itgax-HBEGF/EGFP)57Lan/0
(involves: FVB/N)
abnormal response to infection J:189122
decreased gamma-delta T cell number J:193548
decreased interleukin-17 secretion J:193548
decreased leukocyte cell number J:193548
decreased neutrophil cell number J:193548
decreased susceptibility to bacterial infection J:210086
decreased T cell number J:193548
\1700016L21RikTg(Itgax-HBEGF/EGFP)57Lan/0
(B6.FVB-1700016L21RikTg(Itgax-HBEGF/EGFP)57Lan)
abnormal circulating cytokine level J:194800
abnormal susceptibility to infection J:194800
decreased dendritic cell number J:194800
decreased neutrophil cell number J:194800
impaired neutrophil recruitment J:194800
increased monocyte cell number J:194800
increased neutrophil cell number J:194800
increased susceptibility to bacterial infection J:194800
\1700019D03Riktm1.1(NCOM)Mfgc/\1700019D03Riktm1.1(NCOM)Mfgc
(C57BL/6N-1700019D03Riktm1.1(NCOM)Mfgc/Tcp)
enlarged lymph nodes J:211773
\1700025G04Rikem1(IMPC)Mbp/\1700025G04Rikem1(IMPC)Mbp
(C57BL/6NCrl-1700025G04Rikem1(IMPC)Mbp/Mmucd)
abnormal lymph node morphology J:211773
abnormal spleen morphology J:211773
enlarged lymph nodes J:211773
enlarged spleen J:211773
\1700034E13Rikem1(IMPC)Mbp/\1700034E13Rikem1(IMPC)Mbp
(C57BL/6NCrl-1700034E13Rikem1(IMPC)Mbp/Mmucd)
abnormal lymph node morphology J:211773
abnormal spleen morphology J:211773
enlarged lymph nodes J:211773
enlarged spleen J:211773
\1700067K01Riktm2a(KOMP)Wtsi/\1700067K01Riktm2a(KOMP)Wtsi
(C57BL/6N-1700067K01Riktm2a(KOMP)Wtsi/Wtsi)
blood in lymph vessels J:239583
\1700069L16Rikem1(IMPC)Mbp/\1700069L16Rikem1(IMPC)Mbp
(C57BL/6NCrl-1700069L16Rikem1(IMPC)Mbp/Mmucd)
abnormal thymus morphology J:211773
enlarged thymus J:211773
\2310022B05Riktm1a(EUCOMM)Hmgu/\2310022B05Riktm1a(EUCOMM)Hmgu
(C57BL/6N-2310022B05Riktm1a(EUCOMM)Hmgu/H)
increased B cell number J:165965
increased leukocyte cell number J:165965
\2810408A11Riktm1a(EUCOMM)Wtsi/\2810408A11Riktm1a(EUCOMM)Wtsi
(C57BL/6N-2810408A11Riktm1a(EUCOMM)Wtsi/H)
decreased NK cell number J:165965
increased CD4-positive, alpha-beta T cell number J:165965
increased NK cell number J:165965
\3425401B19Rikem2(IMPC)Ccpcz/\3425401B19Rikem2(IMPC)Ccpcz
(C57BL/6NCrl-3425401B19Rikem2(IMPC)Ccpcz/Ph)
increased effector memory T-helper cell number J:211773
increased eosinophil cell number J:211773
\4930444P10Rikem1(IMPC)Tcp/\4930444P10Rik+
(C57BL/6NCrl-4930444P10Rikem1(IMPC)Tcp/Cmmr)
decreased eosinophil cell number J:211773
\4931422A03Riktm1b(EUCOMM)Wtsi/\4931422A03Riktm1b(EUCOMM)Wtsi
(C57BL/6N-4931422A03Riktm1b(EUCOMM)Wtsi/Bay)
decreased leukocyte cell number J:211773
\4933434E20Riktm1a(EUCOMM)Wtsi/\4933434E20Riktm1a(EUCOMM)Wtsi
(C57BL/6N-4933434E20Riktm1a(EUCOMM)Wtsi/Wtsi)
blood in lymph vessels J:239583
enlarged lymphatic vessel J:239583
\5730403I07Rikem8Gpt/\5730403I07Rikem8Gpt
(involves: C57BL/6JGpt)
abnormal regulatory T cell physiology J:329871
abnormal T cell number J:329871
abnormal T cell physiology J:329871
increased inflammatory response J:329871
increased interferon-gamma secretion J:329871
\6430548M08Rikem1(IMPC)Mbp/\6430548M08Rikem1(IMPC)Mbp
(C57BL/6N-6430548M08Rikem1(IMPC)Mbp/MbpMmucd)
abnormal lymph node morphology J:211773
enlarged lymph nodes J:211773
\9030622O22Rikem1Eem/\9030622O22Rik+
\Foxa2tm1.1Khk/\Foxa2+

(involves: 129P2/OlaHsd * C57BL/6 * CD-1)
respiratory system inflammation J:284174
\9030622O22Rikem1Eem/\9030622O22Rikem1Eem
(involves: C57BL/6 * CD-1)
lung inflammation J:284174
\9430015G10Riktm1Lex/\9430015G10Riktm1Lex
(B6;129S5-9430015G10Riktm1Lex/Mmucd)
decreased CD4-positive, alpha-beta T cell number J:171883
increased B cell number J:171883
\A1cfTg(Myh6-cre/Esr1*)1Jmk/\A1cf+
\Tg(Myh6-2A)#Know/0

(involves: BALB/c * C57BL/6 * FVB/N)
heart inflammation J:128060
\A2ml1em1(IMPC)Tcp/\A2ml1+
(C57BL/6N-A2ml1em1(IMPC)Tcp/Tcp)
abnormal spleen morphology J:211773
\A2ml1em1(IMPC)Tcp/\A2ml1em1(IMPC)Tcp
(C57BL/6N-A2ml1em1(IMPC)Tcp/Tcp)
abnormal spleen morphology J:211773
\A3galt2tm1.1Hjg/\A3galt2tm1.1Hjg
(involves: 129P2/OlaHsd * BALB/cJ)
immune system phenotype J:120323
\A4galttm1.1Poru/\A4galttm1.1Poru
\Glatm1Kul/\Glatm1Kul

(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)
immune system phenotype J:189359
\A4gnttm1Jnaka/\A4gnttm1Jnaka
(B6.129S6-A4gnttm1Jnaka)
stomach inflammation J:184485
\A930024E05Rikem2Zfa/\A930024E05Rikem2Zfa
\Commd10Tg(Vav1-icre)A2Kio/\Commd10+

(involves: C57BL/6 * C57BL/10 * CBA/Ca)
immune system phenotype J:259392
\A930024E05Rikem2Zfa/\A930024E05Rikem2Zfa
\Satb1em1Zfa/\Satb1em1Zfa
\Tg(Rorc-cre)1Litt/0

(involves: C57BL/6 * FVB)
increased susceptibility to bacterial infection J:259392
increased susceptibility to bacterial infection induced morbidity/mortality J:259392
\A930024E05Rikem2Zfa/\A930024E05Rikem2Zfa
\Tg(Rorc-cre)1Litt/0

(involves: C57BL/6 * FVB)
abnormal interleukin secretion J:259392
increased susceptibility to bacterial infection J:259392
increased susceptibility to bacterial infection induced morbidity/mortality J:259392
\Atm1Brd/\Atm1Brd
\Ypel4tm1a(EUCOMM)Wtsi/\Ypel4tm1a(EUCOMM)Wtsi

(C57BL/6N-Atm1Brd Ypel4tm1a(EUCOMM)Wtsi/WtsiIeg)
immune system phenotype J:313842
\Ay/\a
\Apoetm1Unc/\Apoetm1Unc

(involves: 129P2/OlaHsd * C57BL/6J * KK/TaJcl)
abnormal inflammatory response J:177084
increased monocyte cell number J:177084
\AA467197em1Nyam/\AA467197em1Nyam
(C57BL/6J-AA467197em1Nyam)
abnormal thymus cortex morphology J:347271
abnormal thymus medulla morphology J:347271
decreased CD4-positive, alpha-beta T cell number J:347271
increased IgG level J:347271
kidney inflammation J:347271
liver inflammation J:347271
lung inflammation J:347271
\AA467197em1Nyam/\AA467197em1Nyam
(C.B6-AA467197em1Nyam)
increased susceptibility to autoimmune disorder J:347271
\AabprNZB/Slc/?
(involves: NZB/Slc * NZW/Slc)
increased B cell proliferation J:87690
\Aadacem1(IMPC)Mbp/\Aadacem1(IMPC)Mbp
(C57BL/6NCrl-Aadacem1(IMPC)Mbp/Mmucd)
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
small thymus J:211773
\Aadacl4em1(IMPC)Ccpcz/\Aadacl4em1(IMPC)Ccpcz
(C57BL/6NCrl-Aadacl4em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged thymus J:211773
\Aars2tm1(KOMP)Wtsi/\Aars2+
(C57BL/6N-Aars2tm1(KOMP)Wtsi/Nju)
increased basophil cell number J:211773
increased eosinophil cell number J:211773
increased neutrophil cell number J:211773
\Aassem1(IMPC)Tcp/\Aassem1(IMPC)Tcp
(C57BL/6NCrl-Aassem1(IMPC)Tcp/Cmmr)
enlarged lymph nodes J:211773
\Abattm1c(EUCOMM)Hmgu/\Abattm1c(EUCOMM)Hmgu
\Tg(Cd4-cre)1Cwi/0

(involves: 129S4/SvJaeSor * C57BL/6 * C57BL/6N * DBA/2)
abnormal CD4-positive T cell differentiation J:333883
abnormal CD4-positive, CD25-positive, alpha-beta regulatory T cell morphology J:333883
abnormal T-helper 1 cell differentiation J:333883
abnormal T-helper 17 cell differentiation J:333883
decreased susceptibility to experimental autoimmune encephalomyelitis J:333883
decreased T cell proliferation J:333883
immune system phenotype J:333883
\Abca1tm1Jdm/\Abca1tm1Jdm
(DBA/1LacJ-Abca1tm1Jdm)
enlarged spleen J:60210
impaired macrophage phagocytosis J:63265
\Abca1tm1Jdm/\Abca1tm1Jdm
(involves: C57BL/6 * DBA/1LacJ)
abnormal thymus morphology J:132254
impaired macrophage phagocytosis J:132254
\Abca1tm1Jdm/\Abca1tm1Jdm
\Abcg1tm1Dgen/\Abcg1tm1Dgen

(involves: 129P2/OlaHsd * C57BL/6 * DBA/1LacJ)
abnormal chemokine secretion J:130777
abnormal cytokine secretion J:130777
\Abca1tm1Jdm/\Abca1tm1Jdm
\Abcg1tm1Dgen/\Abcg1tm1Dgen

(involves: 129P2/OlaHsd * C57BL/6 * DBA * DBA/1LacJ)
decreased monocyte cell number J:190966
increased monocyte cell number J:190966
increased neutrophil cell number J:190966
\Abca1tm1Jdm/\Abca1tm1Jdm
\Tgm2tm1Gml/\Tgm2tm1Gml

(involves: C57BL/6 * DBA/1LacJ)
abnormal thymus morphology J:132254
impaired macrophage phagocytosis J:132254
\Abca1tm1Jp/\Abca1tm1Jp
\Abcg1tm1Tall/\Abcg1tm1Tall
\Lyz2tm1(cre)Ifo/\Lyz2+

(involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6)
increased interleukin-17 secretion J:190966
increased interleukin-23 secretion J:190966
\Abca1tm1Jp/\Abca1tm1Jp
\Abcg1tm1Tall/\Abcg1tm1Tall
\Tg(Itgax-cre,-EGFP)4097Ach/0

(involves: 129S6/SvEvTac * C57BL/6 * C57BL/6J)
increased interleukin-17 secretion J:190966
increased interleukin-23 secretion J:190966
\Abca1tm1Wpfl/\Abca1tm1Wpfl
(involves: 129P2/OlaHsd * C57BL/6J)
abnormal thymus morphology J:64390
glomerulonephritis J:64390
uterus inflammation J:64390
\Abca5em1(IMPC)Ccpcz/\Abca5em1(IMPC)Ccpcz
(C57BL/6NCrl-Abca5em1(IMPC)Ccpcz/Ccpcz)
abnormal lymph node morphology J:211773
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged lymph nodes J:211773
enlarged spleen J:211773
enlarged thymus J:211773
\Abcb1amds/\Abcb1amds
(involves: CF-1)
increased eosinophil cell number J:64725
\Abcb1atm1Bor/\Abcb1atm1Bor
(FVBTac.129P2-Abcb1atm1Bor)
abnormal CD8 positive, alpha-beta intraepithelial T cell morphology J:102640
decreased gamma-delta intraepithelial T cell number J:102640
\Abcb1atm1Bor/\Abcb1atm1Bor
(FVB.129P2-Abcb1atm1Bor/TacImx)
abnormal lymphocyte physiology J:51190
colitis J:51190
increased IgA level J:51190
increased IgE level J:51190
increased IgG1 level J:51190
increased IgG2 level J:51190
increased IgG2a level J:51190
increased IgG2b level J:51190
increased IgG3 level J:51190
increased IgM level J:51190
increased immunoglobulin level J:51190
large intestinal inflammation J:51190
\Abcb1atm1Bor/\Abcb1atm1Bor
\Abcb1btm1Bor/\Abcb1btm1Bor

(FVBTac.129P2-Abcb1btm1Bor Abcb1atm1Bor)
abnormal CD8 positive, alpha-beta intraepithelial T cell morphology J:102640
abnormal T cell physiology J:102640
decreased gamma-delta intraepithelial T cell number J:102640
increased double-positive T cell number J:102640
increased interferon-gamma secretion J:102640
increased interleukin-2 secretion J:102640
\Abcb4em1(IMPC)H/\Abcb4em1(IMPC)H
(C57BL/6NTac-Abcb4em1(IMPC)H/H)
increased basophil cell number J:211773
increased leukocyte cell number J:211773
increased lymphocyte cell number J:211773
increased monocyte cell number J:211773
increased neutrophil cell number J:211773
increased spleen weight J:211773
\Abcb4tm1Bor/\Abcb4tm1Bor
(either: (involves: 129P2/OlaHsd) or (involves: 129P2/OlaHsd * FVB/N))
bile duct inflammation J:15531, J:21232
liver inflammation J:15531
\Abcb4tm1Bor/\Abcb4tm1Bor
(involves: 129P2/OlaHsd * FVB/N)
bile duct inflammation J:175015
liver inflammation J:175015
\Abcb4tm1Bor/\Abcb4tm1Bor
(FVB.129P2-Abcb4tm1Bor/J)
bile duct inflammation J:105357
enlarged spleen J:217802
\Abcb4tm1Bor/\Abcb4tm1Bor
(involves: 129P2/OlaHsd * BALB/c)
bile duct inflammation J:168123
\Abcb4tm1Bor/\Abcb4tm1Bor
(CAnNCrl.12P2(FVB)-Abcb4tm1Bor)
enlarged spleen J:217802
\Abcb9tm1b(KOMP)Wtsi/\Abcb9tm1b(KOMP)Wtsi
(C57BL/6N-Abcb9tm1b(KOMP)Wtsi/Tcp)
enlarged lymph nodes J:211773
\Abcc1tm1Bor/\Abcc1tm1Bor
(involves: 129P2/OlaHsd * FVB)
abnormal mast cell physiology J:44110
decreased inflammatory response J:44110
\Abcc1tm1Bor/\Abcc1tm1Bor
\Tg(Thy1-APPSw,Thy1-PSEN1*L166P)21Jckr/0

(FVB.Cg-Abcc1tm1Bor Tg(Thy1-APPSw,Thy1-PSEN1*L166P)21Jckr)
microgliosis J:178230
\Abcc2tm2b(KOMP)Wtsi/\Abcc2tm2b(KOMP)Wtsi
(C57BL/6N-Abcc2tm2b(KOMP)Wtsi/H)
decreased lymphocyte cell number J:211773
increased neutrophil cell number J:211773
\Abcc4tm1Kruh/\Abcc4tm1Kruh
(B6.129-Abcc4tm1Kruh)
abnormal spleen B cell follicle morphology J:117326
abnormal spleen red pulp morphology J:117326
decreased spleen B cell follicle number J:117326
decreased spleen B cell follicle size J:117326
increased susceptibility to induced colitis J:117326
intestinal inflammation J:117326
small intestinal inflammation J:117326
small spleen J:117326
thymus cortex hypoplasia J:117326
\Abcc5em1(IMPC)H/\Abcc5em1(IMPC)H
(C57BL/6N-Abcc5em1(IMPC)H/H)
decreased eosinophil cell number J:211773
decreased leukocyte cell number J:211773
decreased lymphocyte cell number J:211773
\Abcc9em1(IMPC)H/\Abcc9+
(C57BL/6N-Abcc9em1(IMPC)H/H)
decreased lymphocyte cell number J:211773
increased monocyte cell number J:211773
\Abcc10tm1Eah/\Abcc10tm1Eah
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
abnormal spleen red pulp morphology J:172648
decreased leukocyte cell number J:172648
decreased spleen germinal center number J:172648
decreased spleen germinal center size J:172648
decreased spleen white pulp amount J:172648
small spleen J:172648
thymus cortex hypoplasia J:172648
\Abcd1tm1Kds/Y
(involves: 129S4/SvJae * C57BL/6J)
abnormal microglial cell morphology J:94583
\Abcd1tm1Kds/Y
\Abcd2tm1Apuj/\Abcd2tm1Apuj

(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6J)
abnormal microglial cell morphology J:94583
increased inflammatory response J:94583
\Abcd2tm1Apuj/\Abcd2tm1Apuj
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)
abnormal microglial cell morphology J:94583
\Abce1tm1.1(KOMP)Vlcg/\Abce1+
(C57BL/6N-Abce1tm1.1(KOMP)Vlcg/Tcp)
enlarged lymph nodes J:211773
increased neutrophil cell number J:211773
\Abce1tm1b(EUCOMM)Hmgu/\Abce1+
(C57BL/6N-Abce1tm1b(EUCOMM)Hmgu/H)
increased large unstained cell number J:211773
\Abcg1tm1Dgen/\Abcg1tm1Dgen
(B6.129P2-Abcg1tm1Dgen)
abnormal macrophage physiology J:117028
increased macrophage derived foam cell number J:117028
\Abcg1tm1Dgen/\Abcg1tm1Dgen
(involves: 129P2/OlaHsd * C57BL/6)
abnormal chemokine secretion J:130777
abnormal cytokine secretion J:130777
abnormal leukocyte morphology J:132952
abnormal macrophage morphology J:132952
abnormal monocyte differentiation J:132952
increased B cell number J:132952
increased CD4-positive, alpha-beta T cell number J:132952
increased CD8-positive, alpha-beta T cell number J:132952
increased dendritic cell number J:132952
increased eosinophil cell number J:132952
increased monocyte cell number J:132952
increased neutrophil cell number J:132952
lung inflammation J:132952
\Abcg2tm1.1Ssf/\Abcg2tm1.1Ssf
(involves: 129 * C57BL/6 * FVB)
liver inflammation J:201884
\Abcg5trac/\Abcg5trac
(A/J-Abcg5trac)
abnormal neutrophil morphology J:157223
decreased leukocyte cell number J:157223
\Abcg8tm1b(KOMP)Wtsi/\Abcg8tm1b(KOMP)Wtsi
(C57BL/6N-Abcg8tm1b(KOMP)Wtsi/Ccpcz)
abnormal spleen morphology J:211773
decreased B-2 B cell number J:211773
decreased CD4-negative NK T cell number J:211773
decreased CD4-positive, alpha-beta T cell number J:211773
decreased CD8-positive, alpha-beta T cell number J:211773
decreased memory-marker CD4-negative NK T cell number J:211773
decreased NK T cell number J:211773
decreased T cell number J:211773
enlarged spleen J:211773
immune system phenotype J:211773
\Abhd5tm1.1Lqyu/\Abhd5tm1.1Lqyu
\Speer6-ps1Tg(Alb-cre)21Mgn/\Speer6-ps1+

(involves: 129S1/Sv * 129S4/SvJaeSor * 129X1/SvJ * C57BL/6 * DBA)
liver inflammation J:199570
\Abhd5tm1.1Rze/\Abhd5tm1.1Rze
(involves: 129P2/OlaHsd * C57BL/6)
abnormal granulocyte morphology J:160725
\Abhd10em1(IMPC)Mbp/\Abhd10em1(IMPC)Mbp
(C57BL/6NCrl-Abhd10em1(IMPC)Mbp/Mmucd)
increased basophil cell number J:211773
increased eosinophil cell number J:211773
\Abhd12tm1Crv/\Abhd12tm1Crv
(involves: C57BL/6)
microgliosis J:193716
\Abhd13em1(IMPC)Mbp/\Abhd13em1(IMPC)Mbp
(C57BL/6NCrl-Abhd13em1(IMPC)Mbp/Mmucd)
decreased spleen weight J:211773
\Abhd16atm1a(EUCOMM)Wtsi/\Abhd16atm1a(EUCOMM)Wtsi
(involves: C57BL/6N * C57BL/6NTac)
abnormal macrophage physiology J:232688
decreased interleukin-1 beta secretion J:232688
decreased interleukin-6 secretion J:232688
decreased macrophage cytokine production J:232688
decreased tumor necrosis factor secretion J:232688
\Abhd17cem1(IMPC)Mbp/\Abhd17cem1(IMPC)Mbp
(C57BL/6N-Abhd17cem1(IMPC)Mbp/MbpMmucd)
abnormal lymph node morphology J:211773
abnormal spleen morphology J:211773
enlarged lymph nodes J:211773
enlarged spleen J:211773
\Abi1tm1Pen/\Abi1+
\Abi2tm1Pen/\Abi2tm1Pen

(Not Specified)
decreased interleukin-2 secretion J:104623
decreased T cell proliferation J:104623
immune system phenotype J:104623
\Abl1m1/\Abl1m1
(either: 129S/SvEv-Abl1m1 or (involves: 129S/SvEv * CD-1) or (involves: 129S/SvEv * C57BL/6 * DBA/2))
abnormal B cell differentiation J:14644
abnormal immune system cell morphology J:14644
abnormal immune system organ morphology J:14644
abnormal spleen germinal center morphology J:14644
abnormal spleen morphology J:14644
abnormal spleen white pulp morphology J:14644
abnormal T cell number J:14644
abnormal thymus morphology J:14644
decreased immature B cell number J:14644
decreased pre-B cell number J:14644
decreased pro-B cell number J:14644
decreased single-positive T cell number J:14644
decreased thymocyte number J:14644
increased single-positive T cell number J:14644
increased susceptibility to infection J:14644
spleen hypoplasia J:14644
thymus cortex hypoplasia J:14644
thymus hypoplasia J:14644
\Abl1m1/\Abl1m1
(involves: 129S/SvEv)
abnormal B cell differentiation J:28795
abnormal immune system cell morphology J:34903
abnormal splenocyte physiology J:34903
decreased mature B cell number J:28795
decreased pre-B cell number J:28795
decreased pro-B cell number J:28795
\Abl1m1/\Abl1m1
(involves: 129S/SvEv * C57BL/6)
abnormal B cell calcium ion homeostasis J:148105
abnormal lymphopoiesis J:148105
decreased pro-B cell number J:148105
\Abl1tm1Mlg/\Abl1tm1Mlg
(involves: 129S/SvEv * C57BL/6J)
decreased B cell number J:72875
decreased lymphocyte cell number J:72875
decreased T cell number J:72875
decreased thymocyte number J:72875
lung inflammation J:72875
spleen atrophy J:72875
thymus atrophy J:72875
\Abl1tm1Mlg/\Abl1tm1Mlg
(involves: 129S/SvEv * C57BL/6J * CBA)
abnormal spleen morphology J:34643
increased susceptibility to infection J:34643
\Abl1tm1Mlg/\Abl1tm1Mlg
\Tg(ACTB-Abl1*K290R)1Spg/0

(involves: 129S/SvEv * C57BL/6J * CBA)
abnormal spleen morphology J:34643
increased susceptibility to infection J:34643
\Abl1tm2.2Goff/\Abl1tm2.2Goff
(involves: 129P2/OlaHsd * C57BL/6J * FVB/N)
spleen atrophy J:166211
thymus atrophy J:166211
\Ablim3em1(IMPC)Tcp/\Ablim3em1(IMPC)Tcp
(C57BL/6N-Ablim3em1(IMPC)Tcp/Tcp)
decreased basophil cell number J:211773
enlarged lymph nodes J:211773
increased lymphocyte cell number J:211773
\AbmmDBA/2J/?
(involves: BALB/cByJ * DBA/2J)
myocarditis J:52296
\Abraxas2tm1.2Bwng/\Abraxas2+
(involves: 129S6/SvEvTac * C57BL/6 * C57BL/6NCrl)
enlarged spleen J:245949
\Abraxas2tm1.2Bwng/\Abraxas2tm1.2Bwng
(involves: 129S6/SvEvTac * C57BL/6 * C57BL/6NCrl)
enlarged spleen J:245949
increased inflammatory response J:245949
\Abtb1em1(IMPC)Ccpcz/\Abtb1em1(IMPC)Ccpcz
(C57BL/6N-Abtb1em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
enlarged spleen J:211773
\Abtb2tm1a(KOMP)Wtsi/\Abtb2tm1a(KOMP)Wtsi
(C57BL/6N-Atm1Brd Abtb2tm1a(KOMP)Wtsi/WtsiH)
decreased leukocyte cell number J:211773
\Acacatm1Dejs/\Acacatm1Dejs
\Tg(Cd4-cre)1Cwi/?

(involves: C57BL/6 * DBA/2)
abnormal T cell physiology J:209886
decreased memory T cell number J:209886
decreased T cell number J:209886
immune system phenotype J:209886
\Acacatm1Dejs/\Acacatm1Dejs
\Tg(Cd4-cre)1Cwi/?
\Tg(TcraTcrb)1100Mjb/?

(involves: C57BL/6 * DBA/2)
increased T cell proliferation J:209886
\Acad10em1(IMPC)Tcp/\Acad10em1(IMPC)Tcp
(C57BL/6N-Acad10em1(IMPC)Tcp/Tcp)
abnormal spleen morphology J:211773
\Acantm1b(EUCOMM)Hmgu/\Acan+
(C57BL/6N-Acantm1b(EUCOMM)Hmgu/H)
increased basophil cell number J:211773
\Acantm2Afos/\Acantm2Afos
(involves: C57BL/6)
decreased susceptibility to induced arthritis J:122102
\Acbd5tm1a(EUCOMM)Wtsi/\Acbd5tm1a(EUCOMM)Wtsi
(C57BL/6N-Atm1Brd Acbd5tm1a(EUCOMM)Wtsi/WtsiCnbc)
abnormal microglial cell morphology J:299448
brain inflammation J:299448
\Ace2em1(ACE2)Yowa/\Ace2em1(ACE2)Yowa
(C57BL/6-Ace2em1(ACE2)Yowa)
abnormal circulating cytokine level J:288243
increased circulating interferon-gamma level J:288243
increased circulating interleukin-9 level J:288243
increased susceptibility to Coronaviridae infection J:288243
interstitial pneumonia J:288243
\Ace2em1(IMPC)Ccpcz/Y
(C57BL/6NCrl-Ace2em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
enlarged spleen J:211773
\Ace2em1(IMPC)Ccpcz/\Ace2em1(IMPC)Ccpcz
(C57BL/6NCrl-Ace2em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged spleen J:211773
enlarged thymus J:211773
\Ace2em1Cya/Y
(C57BL/6J-Ace2em1Cya/Cya)
increased susceptibility to induced colitis J:299383
intestinal inflammation J:299383
\Ace2em2(ACE2)Gpt/Y
(C57BL/6JGpt-Ace2em2(ACE2)Gpt/Gpt)
increased susceptibility to Coronaviridae infection J:302150
lung inflammation J:302150
\Ace2em#Yngh/Y
(involves: Kunming)
increased susceptibility to induced colitis J:221616
\Ace2tm1a(KOMP)Wtsi/Y
\Tg(FOXJ1-cre)F26Htzm/0

(involves: C57BL/6N * C57BL/6NTac)
increased neutrophil cell number J:282139
increased susceptibility to bacterial infection J:282139
increased susceptibility to bacterial infection induced morbidity/mortality J:282139
lung inflammation J:282139
\Ace2tm1a(KOMP)Wtsi/\Ace2tm1a(KOMP)Wtsi
\Tg(FOXJ1-cre)F26Htzm/0

(involves: C57BL/6N * C57BL/6NTac)
increased neutrophil cell number J:282139
increased susceptibility to bacterial infection J:282139
increased susceptibility to bacterial infection induced morbidity/mortality J:282139
lung inflammation J:282139
\Ace2tm1Cof/\Ace2tm1Cof
(involves: 129S6/SvEvTac * C57BL/6)
increased incidence of corneal inflammation J:289503
\Ace2tm1Lex/\Ace2tm1Lex
(B6;129S5-Ace2tm1Lex/Mmucd)
lung inflammation J:264991
\Ace2tm1Pngr/Y
(involves: 129P2/OlaHsd * C57BL/6)
abnormal cytokine level J:124548
heart inflammation J:124548
\Ace2tm1Pngr/Y
(B6.129P2-Ace2tm1Pngr/J)
decreased susceptibility to Coronaviridae infection J:286299
\Ace2tm1Pngr/Y
(involves: 129P2/OlaHsd)
increased neutrophil cell number J:282139
increased susceptibility to bacterial infection J:282139
increased susceptibility to bacterial infection induced morbidity/mortality J:282139
lung inflammation J:282139, J:100334
\Ace2tm1Pngr/Y
(involves: 129P2/OlaHsd * C57BL/6J)
increased susceptibility to Orthomyxoviridae infection J:277074
increased susceptibility to Orthomyxoviridae infection induced morbidity/mortality J:277074
lung inflammation J:277074
\Ace2tm1Pngr/\Ace2tm1Pngr
(involves: 129P2/OlaHsd)
increased neutrophil cell number J:282139
increased susceptibility to bacterial infection J:282139
increased susceptibility to bacterial infection induced morbidity/mortality J:282139
lung inflammation J:282139, J:100334
\Ace2tm1Pngr/\Ace2tm1Pngr
(involves: 129P2/OlaHsd * C57BL/6J)
increased susceptibility to Orthomyxoviridae infection J:277074
increased susceptibility to Orthomyxoviridae infection induced morbidity/mortality J:277074
lung inflammation J:277074
\Ace2tm1Pngr/\Ace2tm1Pngr
(B6.129P2-Ace2tm1Pngr/J)
decreased susceptibility to Coronaviridae infection J:286299
\Acetm1.1(KOMP)Vlcg/\Ace+
(C57BL/6N-Acetm1.1(KOMP)Vlcg/MbpMmucd)
increased basophil cell number J:211773
\Acetm1Keb/\Acetm1Keb
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)
kidney inflammation J:33018
\Acetm1Mcf/\Acetm1Mcf
(Not Specified)
kidney inflammation J:32114
tubulointerstitial nephritis J:32114
\Acetm1Unc/\Acetm1Unc
(involves: 129P2/OlaHsd * C57BL/6J)
kidney inflammation J:25284
\Acetm6Keb/\Acetm6Keb
(involves: 129 * C57BL/6)
abnormal interleukin level J:122178
increased T cell number J:122178
\Acetm9Keb/\Acetm9Keb
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
kidney inflammation J:185888
\Acer1tm1a(EUCOMM)Wtsi/\Acer1tm1a(EUCOMM)Wtsi
(C57BL/6N-Acer1tm1a(EUCOMM)Wtsi)
increased eosinophil cell number J:235775
skin inflammation J:235775
\Acheem1(IMPC)Mbp/\Ache+
(C57BL/6N-Acheem1(IMPC)Mbp/MbpMmucd)
increased neutrophil cell number J:211773
\Ackr1tm1Scp/\Ackr1tm1Scp
(involves: 129P2/OlaHsd * C57BL/6)
increased inflammatory response J:64222
\Ackr1tm1Scp/\Ackr1tm1Scp
(involves: 129P2/OlaHsd)
abnormal circulating chemokine level J:162629
\Ackr1tm1Skmz/\Ackr1tm1Skmz
(involves: 129P2/OlaHsd * C57BL/6J)
abnormal chemokine level J:82938
\Ackr2tm1Gjg/\Ackr2tm1Gjg
(involves: 129/Sv * C57BL/6)
dermatitis J:97607
increased inflammatory response J:97806
\Ackr3tm1.1Fma/\Ackr3tm1.1Fma
(involves: BALB/cJ * C57BL/6)
decreased marginal zone B cell number J:124878
\Ackr3tm1.1Rodb/\Ackr3tm1.1Rodb
(involves: 129S6/SvEvTac * BALB/cJ * C57BL/6)
immune system phenotype J:165184
\Ackr3tm1Jgo/\Ackr3+
(involves: 129S/SvEvBrd * C57BL/6)
lung inflammation J:136246
\Ackr3tm1Jgo/\Ackr3tm1Jgo
(involves: 129S/SvEvBrd * C57BL/6)
lung inflammation J:136246
\Ackr4tm1.1Rjbn/\Ackr4tm1.1Rjbn
(B6.129S6-Ackr4tm1.1Rjbn)
abnormal CD4-positive, alpha-beta T cell number J:166490
abnormal CD4-positive, alpha-beta T cell physiology J:166490
abnormal chemokine level J:166490
abnormal circulating chemokine level J:166490
abnormal T-helper 17 cell differentiation J:166490
decreased T cell proliferation J:166490
increased interleukin-23 secretion J:166490
increased susceptibility to experimental autoimmune encephalomyelitis J:166490
increased T-helper 17 cell number J:166490
spleen hyperplasia J:166490
\Acla1BXSB/Slc/\Acla1BXSB/Slc
(involves: BXSB/Slc * NZW/Slc)
increased autoantibody level J:49899
\Acla1NZW/Slc/\Acla1BXSB/Slc
(involves: BXSB/Slc * NZW/Slc)
increased autoantibody level J:49899
\Acla2BXSB/Slc/\Acla2BXSB/Slc
(involves: BXSB/Slc * NZW/Slc)
increased autoantibody level J:49899
\Acla2NZW/Slc/\Acla2BXSB/Slc
(involves: BXSB/Slc * NZW/Slc)
increased autoantibody level J:49899
\Acod1tm1a(KOMP)Wtsi/\Acod1tm1a(KOMP)Wtsi
(involves: C57BL/6N)
abnormal macrophage physiology J:235002
\Acot11tm1Deco/\Acot11tm1Deco
(involves: 129S6/SvEvTac * C57BL/6)
decreased inflammatory response J:182660
\Acox1lampe1/\Acox1lampe1
(involves: C57BL/6J)
liver inflammation J:174942
\Acox2em1Jynz/\Acox2em1Jynz
(involves: C57BL/6N)
liver inflammation J:323193
\Acoxlem1(IMPC)Mbp/\Acoxlem1(IMPC)Mbp
(C57BL/6NCrl-Acoxlem1(IMPC)Mbp/Mmucd)
abnormal lymph node morphology J:211773
abnormal spleen morphology J:211773
decreased lymphocyte cell number J:211773
enlarged lymph nodes J:211773
enlarged spleen J:211773
increased neutrophil cell number J:211773
\Acp1tm1Lex/\Acp1tm1Lex
(involves: 129S5/SvEvBrd * C57BL/6J)
increased interleukin-6 secretion J:171883
\Acp2tm1a(EUCOMM)Wtsi/\Acp2tm1a(EUCOMM)Wtsi
(C57BL/6N-Acp2tm1a(EUCOMM)Wtsi/H)
decreased CD4-positive, alpha-beta T cell number J:165965
decreased CD8-positive, alpha-beta T cell number J:165965
decreased T cell number J:165965
increased B cell number J:165965
\Acp2tm1Psa/\Acp2tm1Psa
(involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6J)
abnormal microglial cell morphology J:41986
\Acp5tm1Ahdm/\Acp5tm1Ahdm
(involves: 129S/SvEv)
abnormal osteoclast physiology J:36232
\Acsl3Gt(OST148301)Lex/\Acsl3Gt(OST148301)Lex
(B6;129S5-Acsl3Gt(OST148301)Lex/Orl)
abnormal humoral immune response J:82809
decreased B cell number J:82809
increased CD4-positive, alpha-beta T cell number J:82809
\Acsl5tm1.1(KOMP)Vlcg/\Acsl5tm1.1(KOMP)Vlcg
(C57BL/6N-Acsl5tm1.1(KOMP)Vlcg/Ucd)
increased spleen weight J:211773
\Acsl6tm1.1Jeme/\Acsl6tm1.1Jeme
(involves: BALB/cJ * C57BL/6)
abnormal microglial cell activation J:267563
\Acsm1em1(IMPC)Mhzh/\Acsm1em1(IMPC)Mhzh
(C57BL/6N-Acsm1em1(IMPC)Mhzh/Mhzh)
increased basophil cell number J:211773
increased eosinophil cell number J:211773
\Acsns1A/J/\Acsns1A/J
(involves: A/J * SM/J)
decreased susceptibility to parasitic infection J:75549
\Acsns2SM/J/\Acsns2SM/J
(involves: A/J * SM/J)
increased susceptibility to parasitic infection J:75549
\Acsns2SM/J/\Acsns2SM/J
\Acsns3SM/J/\Acsns3SM/J

(involves: A/J * SM/J)
increased susceptibility to parasitic infection J:75549
\Acsns3SM/J/\Acsns3SM/J
(involves: A/J * SM/J)
increased susceptibility to parasitic infection J:75549
\Acss2em22Gpt/\Acss2em22Gpt
(C57BL/6JGpt-Acss2em22Gpt/Gpt)
decreased interleukin-1 beta secretion J:346990
decreased susceptibility to endotoxin shock J:346990
\Acss3em1(IMPC)Ccpcz/\Acss3em1(IMPC)Ccpcz
(C57BL/6NCrl-Acss3em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged thymus J:211773
increased effector memory CD8-positive, alpha-beta T cell number J:211773
increased effector memory T-helper cell number J:211773
\Acta2em1(IMPC)H/\Acta2em1(IMPC)H
(C57BL/6NTac-Acta2em1(IMPC)H/H)
decreased basophil cell number J:211773
decreased lymphocyte cell number J:211773
\Actbtm4(cre/ERT2)Npa/\Actb+
\Sgpl1tm1.1Npa/\Sgpl1tm1.1Npa

(involves: BALB/cJ * C57BL/6)
abnormal lymph node morphology J:199525
abnormal regulatory T cell number J:199525
abnormal type IV hypersensitivity reaction J:199525
decreased follicular B cell number J:199525
decreased marginal zone B cell number J:199525
decreased single-positive T cell number J:199525
decreased susceptibility to experimental autoimmune encephalomyelitis J:199525
increased thymocyte number J:199525
spleen hypoplasia J:199525
\Actl6atm1.1Grc/\Actl6a+
\Tg(Mx1-cre)1Cgn/0

(involves: 129S6/SvEvTac * C57BL/6J * CBA)
decreased granulocyte number J:192124
decreased macrophage cell number J:192124
\Actl6atm1.1Grc/\Actl6atm1.1Grc
\Tg(Mx1-cre)1Cgn/0

(involves: 129S6/SvEvTac * C57BL/6J * CBA)
decreased B cell number J:192124
decreased granulocyte number J:192124
decreased leukocyte cell number J:192124
decreased lymphocyte cell number J:192124
decreased macrophage cell number J:192124
decreased monocyte cell number J:192124
\Actn4tm1a(EUCOMM)Wtsi/\Actn4tm1a(EUCOMM)Wtsi
(C57BL/6N-Actn4tm1a(EUCOMM)Wtsi/Wtsi)
blood in lymph vessels J:239583
\Actn4tm1Mrpk/\Actn4tm1Mrpk
(involves: 129 * C57BL/6)
abnormal lymphocyte chemotaxis J:83911
\Acvr1tm1Emsh/\Acvr1+
(chimera involves: BALB/c * C57BL/6 * CD-1)
increased inflammatory response J:194134
\Acvr1btm1.1(KOMP)Vlcg/\Acvr1b+
(C57BL/6N-Acvr1btm1.1(KOMP)Vlcg/Ucd)
enlarged lymph nodes J:211773
\Acvr2atm1.1(KOMP)Vlcg/\Acvr2a+
(C57BL/6N-Acvr2atm1.1(KOMP)Vlcg/Ucd)
decreased eosinophil cell number J:211773
decreased neutrophil cell number J:211773
\Acvr2btm1Enl/\Acvr2btm1Enl
(either: (involves: 129S4/SvJae) or (involves: 129S4/SvJae * C57BL/6J))
abnormal spleen morphology J:42018
small spleen J:42018
\Adatm1Mw/\Adatm1Mw
(involves: 129S7/SvEvBrd * C57BL/6)
decreased T cell number J:25085
\Adatm1Mw/\Adatm1Mw
(involves: 129S7/SvEvBrd)
abnormal dendritic cell physiology J:138722
increased dendritic cell number J:138722
\Adatm1Mw/\Adatm1Mw
\Tg(PLADA)4118Rkmb/0

(involves: 129S7/SvEvBrd * C57BL/6)
abnormal spleen red pulp morphology J:73418
abnormal thymus corticomedullary boundary morphology J:73418
decreased double-positive T cell number J:73418
decreased immunoglobulin level J:73418
decreased leukocyte cell number J:73418
increased double-negative T cell number J:73418
increased eosinophil cell number J:73418
increased granulocyte number J:73418
increased macrophage cell number J:73418
lung inflammation J:73418
small spleen J:73418
small thymus J:73418
spleen hypoplasia J:73418
\Adam7tm1Tigm/\Adam7tm1Tigm
(involves: C57BL/6)
spermatic granuloma J:226260
\Adam8tm1.1Mdz/\Adam8tm1.1Mdz
(DBA/1LacJ-Adam8tm1.1Mdz)
decreased susceptibility to induced arthritis J:155243
immune system phenotype J:155243
\Adam8tm1.1Rood/\Adam8tm1.1Rood
(involves: 129/Sv * C57BL/6 * FVB/N)
abnormal osteoclast differentiation J:172936
\Adam10tm1.1Dhc/\Adam10tm1.1Dhc
\Cd19tm1(cre)Cgn/\Cd19+

(involves: 129P2/OlaHsd * C57BL/6 * C57BL/6J * SJL)
abnormal B cell differentiation J:158127
absent marginal zone B cells J:158127
decreased transitional stage T2 B cell number J:158127
increased follicular B cell number J:158127
increased transitional stage T1 B cell number J:158127
\Adam10tm1.1Khr/\Adam10tm1.1Khr
\Csf3rtm1Link/\Csf3rtm1Link
\Tg(Mx1-cre)1Cgn/0

(involves: 129S6/SvEvTac * 129X1/SvJ * C57BL/6 * C57BL/6N)
abnormal granulocyte differentiation J:179060
enlarged spleen J:179060
myeloid hyperplasia J:179060
spleen hyperplasia J:179060
\Adam10tm1.1Khr/\Adam10tm1.1Khr
\Tg(Mx1-cre)1Cgn/0

(involves: 129S6/SvEvTac * C57BL/6 * C57BL/6N)
abnormal granulocyte differentiation J:179060
abnormal spleen morphology J:179060
abnormal T cell differentiation J:179060
decreased CD4-positive, alpha-beta T cell number J:179060
decreased CD8-positive, alpha-beta T cell number J:179060
decreased double-positive T cell number J:179060
decreased T cell number J:179060
enlarged spleen J:179060
increased leukocyte cell number J:179060
increased neutrophil cell number J:179060
increased spleen red pulp amount J:179060
increased spleen weight J:179060
myeloid hyperplasia J:179060
small thymus J:179060
spleen hyperplasia J:179060
thymus hypoplasia J:179060
\Adam10tm1Zhu/\Adam10tm1.1Zhu
\Tg(Lck-cre)#Zhu/0

(involves: 129S6/SvEvTac * C57BL/6 * SJL * SJL/J)
abnormal T cell differentiation J:139042
decreased CD4-positive, alpha-beta T cell number J:139042
decreased double-positive T cell number J:139042
thymus hypoplasia J:139042
\Adam10tm1Zhu/\Adam10tm1Zhu
\Tg(Lck-cre)#Zhu/0

(involves: 129S6/SvEvTac * C57BL/6 * SJL/J)
abnormal T cell differentiation J:139042
decreased CD4-positive, alpha-beta T cell number J:139042
decreased double-positive T cell number J:139042
thymus hypoplasia J:139042
\Adam17m1Btlr/\Adam17m1Btlr
(C57BL/6J-Adam17m1Btlr)
decreased circulating tumor necrosis factor level J:166602
increased susceptibility to induced colitis J:166602
\Adam17tm1.1Srj/\Adam17tm1.1Srj
(involves: 129S/SvEv * C57BL/6 * SJL)
abnormal chemokine level J:163380
abnormal interleukin secretion J:163380
increased interleukin-10 secretion J:163380
increased susceptibility to induced colitis J:163380
skin inflammation J:163380
\Adam17tm1.2Bbl/\Adam17tm1.2Bbl
\Il17atm1Yiw/\Il17atm1Yiw
\Sox9tm3(cre)Crm/\Sox9+

(involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6 * SJL)
dermatitis J:229771
\Adam17tm1.2Bbl/\Adam17tm1.2Bbl
\Il23atm1Dnax/\Il23atm1Dnax
\Sox9tm3(cre)Crm/\Sox9+

(involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6 * SJL)
dermatitis J:229771
\Adam17tm1.2Bbl/\Adam17tm1.2Bbl
\Sox9tm3(cre)Crm/\Sox9+

(involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6)
abnormal spleen morphology J:144795
decreased B cell number J:144795
decreased lymphocyte cell number J:144795
decreased T cell number J:144795
enlarged spleen J:144795
increased circulating interleukin-17 level J:144795
increased interleukin-17 secretion J:144795
increased leukocyte cell number J:144795
increased macrophage cell number J:144795
increased neutrophil cell number J:144795
increased spleen red pulp amount J:144795
\Adam17tm1.2Bbl/\Adam17tm1.2Bbl
\Sox9tm3(cre)Crm/\Sox9+

(B6.129(SJL)-Sox9tm3(cre)Crm Adam17tm1.2Bbl)
abnormal circulating chemokine level J:229771
dermatitis J:229771
increased IgE level J:229771
increased T-helper 1 cell number J:229771
increased T-helper 2 cell number J:229771
increased T-helper 17 cell number J:229771
\Adam17tm1a(EUCOMM)Wtsi/\Adam17+
(involves: C57BL/6 * C57BL/6N)
myeloid hyperplasia J:213427
\Adam17tm1Bbl/\Adam17tm1Bbl
\Lyz2tm1(cre)Ifo/0

(involves: 129P2/OlaHsd)
abnormal macrophage physiology J:139846
decreased circulating tumor necrosis factor level J:139846
decreased susceptibility to endotoxin shock J:139846
\Adam17tm1Bbl/\Adam17tm1Bbl
\Tg(Mx1-cre)1Cgn/0

(involves: 129P2/OlaHsd * C57BL/6 * CBA)
decreased circulating tumor necrosis factor level J:139846
decreased susceptibility to endotoxin shock J:139846
\Adam17tm1Ckww/\Adam17tm1Ckww
(Not Specified)
abnormal dendritic cell physiology J:138782
\Adam17tm1Imx/\Adam17tm1Imx
(involves: 129 * C57BL/6)
increased incidence of corneal inflammation J:51053
\Adam17tm1Imx/\Adam17tm1Imx
(B6.129-Adam17tm1Imx)
enhanced leukocyte tethering or rolling J:174865
\Adam17tm1Rain/\Adam17tm1Rain
(involves: C57BL/6)
enhanced leukocyte tethering or rolling J:174865
\Adam17woe/\Adam17woe
(C57BL/6-Adam17woe)
dermatitis J:160781
increased incidence of corneal inflammation J:160781
\Adam28tm1.2Dica/\Adam28tm1.2Dica
(B6JRj.129-Adam28tm1.2Dica)
abnormal alpha-beta T cell morphology J:298188
abnormal lymphocyte morphology J:298188
decreased CD8-positive, alpha-beta T cell number J:298188
\Adam28tm1.2Dica/\Adam28tm1.2Dica
(CJRj.129-Adam28tm1.2Dica)
decreased CD8-positive, alpha-beta T cell number J:298188
\Adam29em1Otin/\Adam29em1Otin
(C57BL/6-Adam29em1Otin)
increased inflammatory response J:353244
\Adamdec1tm1Dgen/\Adamdec1+
(B6.129P2-Adamdec1tm1Dgen)
increased susceptibility to induced colitis J:301741
\Adamdec1tm1Dgen/\Adamdec1tm1Dgen
(B6.129P2-Adamdec1tm1Dgen)
decreased circulating interleukin-10 level J:301741
increased circulating interleukin-1 beta level J:301741
increased circulating interleukin-6 level J:301741
increased neutrophil cell number J:301741
increased susceptibility to bacterial infection J:301741
increased susceptibility to bacterial infection induced morbidity/mortality J:301741
increased susceptibility to colitis induced morbidity/mortality J:301741
increased susceptibility to induced colitis J:301741
intestinal inflammation J:301741
\Adamts1em1(IMPC)Mbp/\Adamts1+
(C57BL/6N-Adamts1em1(IMPC)Mbp/MbpMmucd)
abnormal spleen morphology J:211773
enlarged spleen J:211773
\Adamts2tm1Prc/\Adamts2tm1Prc
(involves: 129 * 129S1/Sv * 129X1/SvJ * C57BL/6)
increased interferon-gamma secretion J:271185
\Adamts3tm1.2Itl/\Adamts3tm1.2Itl
(involves: BALB/cJ * C57BL/6NTac * SJL)
abnormal lymphangiogenesis J:245044
absent lymphatic vessels J:245044
\Adamts5tm1.1Eam/\Adamts5+
(involves: 129S5/SvEvBrd)
decreased susceptibility to induced arthritis J:97590
\Adamts5tm1.1Eam/\Adamts5tm1.1Eam
(involves: 129S5/SvEvBrd)
decreased susceptibility to induced arthritis J:97590
\Adamts5tm1Lex/\Adamts5tm1Lex
\Tg(CMV-cre)1Cgn/0

(involves: 129S5/SvEvBrd * BALB/cJ)
osteoarthritis J:105138
\Adamts5tm2.2Lex/\Adamts5tm2.2Lex
(B6.129S5-Adamts5tm2.2Lex)
decreased susceptibility to induced arthritis J:175366
\Adamts6b2b1879.1Clo/\Adamts6b2b1879.1Clo
(C57BL/6J-Adamts6b2b1879.1Clo)
thymus hypoplasia J:175213
\Adamts6b2b2029Clo/\Adamts6b2b2029Clo
(C57BL/6J-Adamts6b2b2029Clo)
thymus hypoplasia J:175213
\Adamts6b2b2182Clo/\Adamts6b2b2182Clo
(C57BL/6J-Adamts6b2b2182Clo)
thymus hypoplasia J:175213
\Adamts6b2b2187.1Clo/\Adamts6b2b2187.1Clo
(C57BL/6J-Adamts6b2b2187.1Clo)
thymus hypoplasia J:175213
\Adamts6b2b2228Clo/\Adamts6b2b2228Clo
(C57BL/6J-Adamts6b2b2228Clo)
thymus hypoplasia J:175213
\Adamts6b2b2405Clo/\Adamts6b2b2405Clo
(C57BL/6J-Adamts6b2b2405Clo)
thymus hypoplasia J:175213
\Adamts6b2b2407Clo/\Adamts6b2b2407Clo
(C57BL/6J-Adamts6b2b2407Clo)
thymus hypoplasia J:175213
\Adamts6b2b2744Clo/\Adamts6b2b2744Clo
(C57BL/6J-Adamts6b2b2744Clo)
thymus hypoplasia J:175213
\Adamts6b2b2966.2Clo/\Adamts6b2b2966.2Clo
(C57BL/6J-Adamts6b2b2966.2Clo)
thymus hypoplasia J:175213
\Adamts9tm1b(KOMP)Wtsi/\Adamts9+
(C57BL/6N-Adamts9tm1b(KOMP)Wtsi/MbpMmucd)
abnormal lymph node morphology J:211773
\Adamts13tm1Dgi/\Adamts13tm1Dgi
(involves: 129X1/SvJ * C57BL/6J * CASA/Rk)
immune system phenotype J:101752
increased susceptibility to bacterial infection J:101752
\Adamts14Gt(511E11)Cmhd/\Adamts14Gt(511E11)Cmhd
(involves: 129 * 129S1/Sv * 129X1/SvJ * C57BL/6)
increased interferon-gamma secretion J:271185
increased interleukin-2 secretion J:271185
\Adamts14Gt(511E11)Cmhd/\Adamts14Gt(511E11)Cmhd
\Adamts2tm1Prc/\Adamts2tm1Prc

(involves: 129 * 129S1/Sv * 129X1/SvJ * C57BL/6)
abnormal T cell activation J:271185
cutaneous mastocytosis J:271185
decreased B cell number J:271185
decreased CD8-positive, alpha-beta T cell number J:271185
dermatitis J:271185
increased CD4-positive, alpha-beta T cell number J:271185
increased interferon-gamma secretion J:271185
increased interleukin-2 secretion J:271185
increased T cell proliferation J:271185
\Adamts16em1(IMPC)H/\Adamts16em1(IMPC)H
(C57BL/6N-Adamts16em1(IMPC)H/H)
decreased eosinophil cell number J:211773
decreased neutrophil cell number J:211773
\Adamts18tm1.1Wzha/\Adamts18tm1.1Wzha
(involves: 129 * C57BL/6)
increased acute inflammation J:258487
increased susceptibility to induced colitis J:258487
\Adamtsl3em1(IMPC)Tcp/\Adamtsl3em1(IMPC)Tcp
(C57BL/6N-Adamtsl3em1(IMPC)Tcp/Cmmr)
enlarged lymph nodes J:211773
small spleen J:211773
\Adap1tm1a(EUCOMM)Wtsi/\Adap1tm1a(EUCOMM)Wtsi
(C57BL/6N-Adap1tm1a(EUCOMM)Wtsi/Wtsi)
decreased memory-marker NK cell number J:211773
increased NK cell number J:211773
\Adarem1Stsn/\Adartm1Olds
(involves: 129S/SvEv * C57BL/6J)
abnormal spleen morphology J:308678
\Adarem2Qwan/\Adarem2Qwan
(Not Specified)
immune system phenotype J:325221
\Adarem3Qwan/\Adarem3Qwan
(Not Specified)
abnormal chemokine level J:325221
immune system phenotype J:325221
increased circulating interleukin-1 level J:325221
increased circulating interleukin-6 level J:325221
increased circulating interleukin-17 level J:325221
increased CXCL10 level J:325221
\Adartm1Olds/\Adartm1Olds
(involves: 129S/SvEv * C57BL/6J)
increased susceptibility to Orthomyxoviridae infection J:169014
increased susceptibility to Paramyxoviridae infection J:169014
\Adartm2Phs/\Adartm2Phs
(B6.Cg-Adartm2Phs)
abnormal circulating interferon-beta level J:142338
increased circulating interferon-alpha level J:142338
\Adarb2em1(IMPC)Tcp/\Adarb2em1(IMPC)Tcp
(C57BL/6NCrl-Adarb2em1(IMPC)Tcp/Tcp)
abnormal spleen morphology J:211773
\Adaz1NZM2328/J/\Adaz1NZM2328/J
(involves: C57L/J * NZM2328/J)
increased anti-double stranded DNA antibody level J:71397
\Adck1em2(IMPC)Tcp/\Adck1em2(IMPC)Tcp
(C57BL/6NCrl-Adck1em2(IMPC)Tcp/Tcp)
enlarged lymph nodes J:211773
\Adcy1tm1b(EUCOMM)Wtsi/\Adcy1tm1b(EUCOMM)Wtsi
(C57BL/6N-Adcy1tm1b(EUCOMM)Wtsi/H)
increased leukocyte cell number J:211773
\Adcy7tm1.1Pcst/\Adcy7tm1.1Pcst
\Lyz2tm1(cre)Ifo/\Lyz2+

(involves: 129P2/OlaHsd * C57BL/6J)
increased tumor necrosis factor secretion J:191067
peritoneal inflammation J:191067
\Adcy9Gt(OST193739)Lex/\Adcy9Gt(OST193739)Lex
(involves: 129S5/SvEvBrd * C57BL/6J)
increased IgG1 level J:103485
\Adcy9tm1b(EUCOMM)Wtsi/\Adcy9tm1b(EUCOMM)Wtsi
(C57BL/6N-Adcy9tm1b(EUCOMM)Wtsi/Wtsi)
blood in lymph vessels J:239583
\Adcyap1tm1Clw/\Adcyap1tm1Clw
(B6.129S4-Adcyap1tm1Clw)
abnormal regulatory T cell physiology J:194151
abnormal T cell activation J:194151
increased microglial cell activation J:194151
increased T-helper 17 cell number J:194151
\Adcyap1r1tm1Bbt/\Adcyap1r1tm1Bbt
(involves: 129 * C57BL/6J)
increased susceptibility to bacterial infection J:73990
\Add2tm1Feb/\Add2tm1Feb
(B6.129-Add2tm1Feb)
increased spleen weight J:63047
\Add2tm1Llp/\Add2tm1Llp
(involves: 129S4/SvJae * C57BL/6J)
enlarged spleen J:71029
increased spleen iron level J:71029
\Adgbem1(IMPC)Mbp/\Adgb+
(C57BL/6NCrl-Adgbem1(IMPC)Mbp/Mmucd)
increased eosinophil cell number J:211773
\Adgrb1tm2a(EUCOMM)Wtsi/\Adgrb1+
(C57BL/6N-Adgrb1tm2a(EUCOMM)Wtsi/Wtsi)
decreased leukocyte cell number J:211773
\Adgrd1tm1b(EUCOMM)Wtsi/\Adgrd1tm1b(EUCOMM)Wtsi
(C57BL/6N-Adgrd1tm1b(EUCOMM)Wtsi/Wtsi)
increased anti-nuclear antigen antibody level J:211773
\Adgre1m1Btlr/\Adgre1m1Btlr
(C57BL/6J-Adgre1m1Btlr)
immune system phenotype J:135219
\Adgre1m2Btlr/\Adgre1m2Btlr
(C57BL/6J-Adgre1m2Btlr)
abnormal macrophage physiology J:195410
decreased macrophage cell number J:195410
\Adgre1m3Btlr/\Adgre1m3Btlr
(C57BL/6J-Adgre1m3Btlr)
abnormal macrophage physiology J:234244
decreased macrophage cell number J:234244
\Adgre1M4Btlr/\Adgre1+
(C57BL/6J-Adgre1M4Btlr)
decreased macrophage cell number J:255001
\Adgre1M4Btlr/\Adgre1M4Btlr
(C57BL/6J-Adgre1M4Btlr)
decreased macrophage cell number J:255001
\Adgre1tm1Stst/\Adgre1tm1Stst
(B6.129S1-Emr1tm1Stst)
abnormal immune tolerance J:99213
abnormal regulatory T cell physiology J:99213
\Adgre5tm1.1Joha/\Adgre5tm1.1Joha
(involves: 129P2/OlaHsd * C57BL/6J * FVB/N)
immune system phenotype J:140713
increased granulocyte number J:140713
\Adgre5tm1Kake/\Adgre5tm1Kake
(B6.129S6-Adgre5tm1Kake)
decreased susceptibility to bacterial infection J:118705
decreased susceptibility to bacterial infection induced morbidity/mortality J:118705
immune system phenotype J:118705
increased granulocyte number J:118705
\Adgrf1em1(IMPC)Ccpcz/\Adgrf1em1(IMPC)Ccpcz
(C57BL/6NCrl-Adgrf1em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
enlarged spleen J:211773
\Adgrf5tm1.2Bstc/\Adgrf5tm1.2Bstc
(involves: 129S4/SvJae * C57BL/6J)
increased macrophage derived foam cell number J:196943
\Adgrf5tm1.2Jpbs/\Adgrf5tm1.2Jpbs
(BALB/c-Adgrf5tm1.2Jpbs)
abnormal alveolar macrophage morphology J:221769
\Adgrf5tm1b(KOMP)Wtsi/\Adgrf5tm1b(KOMP)Wtsi
(C57BL/6N-Adgrf5tm1b(KOMP)Wtsi/Tcp)
decreased leukocyte cell number J:211773
decreased lymphocyte cell number J:211773
decreased monocyte cell number J:211773
\Adgrf5tm1Shiro/\Adgrf5tm1Shiro
(B6.Cg-Adgrf5tm1Shiro)
abnormal alveolar macrophage morphology J:204701
increased macrophage cell number J:204701
\Adgrg3tm1Fwa/\Adgrg3tm1Fwa
(129S4/SvJae-Adgrg3tm1Fwa)
immune system phenotype J:62512
\Adgrg3tm1Zgwg/\Adgrg3tm1Zgwg
(involves: 129 * C57BL/6)
abnormal B cell morphology J:222670
abnormal IgG1 level J:222670
abnormal IgG2 level J:222670
abnormal IgG level J:222670
abnormal immune system morphology J:222670
abnormal immune system physiology J:222670
abnormal immunoglobulin level J:222670
abnormal spleen B cell follicle morphology J:222670
abnormal spleen B cell follicle shape J:222670
abnormal spleen marginal zone morphology J:222670
abnormal spleen morphology J:222670
decreased follicular B cell number J:222670
decreased IgA level J:222670
decreased IgG1 level J:222670
decreased IgG2b level J:222670
decreased IgG3 level J:222670
decreased IgM level J:222670
decreased mature B cell number J:222670
decreased transitional stage T1 B cell number J:222670
immune system phenotype J:222670
increased B cell apoptosis J:222670
increased IgG1 level J:222670
increased IgG2a level J:222670
increased marginal zone B cell number J:222670
increased transitional stage T2 B cell number J:222670
\Adgrl4em1(IMPC)Mbp/\Adgrl4em1(IMPC)Mbp
(C57BL/6N-Adgrl4em1(IMPC)Mbp/MbpMmucd)
increased neutrophil cell number J:211773
\Adh5tm1.1Llli/\Adh5tm1.1Llli
\Speer6-ps1Tg(Alb-cre)21Mgn/\Speer6-ps1+

(B6.Cg-Adh5tm1.1Llli Speer6-ps1Tg(Alb-cre)21Mgn)
increased susceptibility to bacterial infection induced morbidity/mortality J:173666
\Adh5tm1Stam/\Adh5tm1Stam
(B6.129-Adh5tm1Stam)
increased susceptibility to bacterial infection J:88337
increased susceptibility to bacterial infection induced morbidity/mortality J:88337
\Adip1LG/J/?
\Capn10tm1Chev/\Capn10+

((B6.129-Capn10tm1Chev x LG/J)F1)
increased spleen weight J:153477
\Adipoqtm1Chan/\Adipoq+
(B6.129-Adipoqtm1Chan)
abnormal leukocyte physiology J:122020
increased leukocyte cell number J:122020
\Adipoqtm1Chan/\Adipoqtm1Chan
(B6.129-Adipoqtm1Chan)
abnormal leukocyte physiology J:122020
increased leukocyte cell number J:122020
\Adipoqtm1Ish/\Adipoqtm1Ish
(involves: 129S7/SvEvBrd * C57BL/6J)
abnormal osteoclast morphology J:199264
\Adipor1tm1b(EUCOMM)Hmgu/\Adipor1tm1b(EUCOMM)Hmgu
(C57BL/6N-Adipor1tm1b(EUCOMM)Hmgu/H)
decreased lymphocyte cell number J:211773
increased neutrophil cell number J:211773
\Adipor2tm1b(EUCOMM)Hmgu/\Adipor2tm1b(EUCOMM)Hmgu
(C57BL/6N-Adipor2tm1b(EUCOMM)Hmgu/H)
decreased lymphocyte cell number J:211773
increased neutrophil cell number J:211773
\Adkem1(IMPC)Ccpcz/\Adk+
(C57BL/6N-Adkem1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged thymus J:211773
\Adm2em1Zhan/\Adm2em1Zhan
(Not Specified)
increased inflammatory response J:266495
increased Ly6C high monocyte number J:266495
increased susceptibility to infection J:266495
liver inflammation J:266495
\Admtm1Kmca/\Admtm1Kmca
(B6.129P2-Admtm1Kmca)
increased uterine NK cell number J:201446
\Admtm1Tfjt/\Adm+
(involves: C57BL/6 * CBA)
blood vessel inflammation J:102946
\Admtm1Unc/\Admtm1Unc
(involves: 129S6/SvEvTac)
decreased uterine NK cell number J:201446
\Admtm1Unc/\Admtm1Unc
(129S6/SvEvTac-Admtm1Unc)
abnormal lymph organ development J:130930
\Adnp2em3(IMPC)Tcp/\Adnp2+
(C57BL/6NCrl-Adnp2em3(IMPC)Tcp/Tcp)
abnormal thymus morphology J:211773
enlarged lymph nodes J:211773
small spleen J:211773
\Adora2aem1(IMPC)H/\Adora2aem1(IMPC)H
(C57BL/6N-Adora2aem1(IMPC)H/H)
decreased lymphocyte cell number J:211773
increased neutrophil cell number J:211773
\Adora2atm1Map/\Adora2atm1Map
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
decreased interleukin-10 secretion J:147023
\Adora2btm1.1Msit/\Adora2btm1.1Msit
(either: (involves: C57BL/6) or (involves: C57BL/6 * CD-1 * ICR))
abnormal macrophage physiology J:169155
increased interleukin-6 secretion J:169155
increased tumor necrosis factor secretion J:169155
\Adora2btm1Dgen/\Adora2btm1Dgen
(B6.129P2-Adora2btm1Dgen)
abnormal dendritic cell physiology J:138722
decreased interleukin-10 secretion J:147023
\Adora2btm1Kra/\Adora2btm1Kra
(involves: 129 * C57BL/6J)
abnormal cytokine level J:111715
abnormal inflammatory response J:111715
abnormal interleukin level J:111715
abnormal leukocyte adhesion J:111715
abnormal leukocyte migration J:111715
abnormal tumor necrosis factor level J:111715
decreased interleukin-10 secretion J:111715
enhanced leukocyte tethering or rolling J:111715
increased circulating interleukin-6 level J:111715
\Adora2btm1Till/\Adora2btm1Till
(B6.129P2-Adora2btm1Till)
abnormal cellular extravasation J:125297
increased interleukin-6 secretion J:125297
increased susceptibility to type I hypersensitivity reaction J:125297
\Adora3tm1(ADORA3)Msth/\Adora3tm1(ADORA3)Msth
(involves: 129S7/SvEvBrd * C57BL/6J)
abnormal mast cell physiology J:104494
decreased mast cell degranulation J:104494
\Adora3tm1Jbsn/\Adora3tm1Jbsn
(either: (involves: 129P2/OlaHsd * C57BL/6 * DBA/2) or (involves: 129P2/OlaHsd * C57BL/6))
abnormal mast cell physiology J:60293
decreased tumor necrosis factor secretion J:60293
\Adora3tm1Jbsn/\Adora3tm1Jbsn
(involves: 129P2/OlaHsd * C57BL/6 * DBA/2)
decreased acute inflammation J:120442
\Adora3tm1Jbsn/\Adora3tm1Jbsn
(B6.129P2-Adora3tm1Jbsn)
abnormal mast cell degranulation J:123463
impaired neutrophil recruitment J:123463
\Adprhtm1Jlms/\Adprhtm1Jlms
(involves: 129X1/SvJ * C57BL/6J)
increased susceptibility to infection J:123619
\Adrb2em1(IMPC)Mbp/\Adrb2em1(IMPC)Mbp
(C57BL/6N-Adrb2em1(IMPC)Mbp/MbpMmucd)
abnormal spleen morphology J:211773
enlarged spleen J:211773
\Adrb2tm1Bkk/\Adrb2+
(involves: 129S1/Sv * 129X1/SvJ)
abnormal osteoclast differentiation J:97566
\Adrb2tm1Bkk/\Adrb2tm1Bkk
(involves: 129S1/Sv * 129X1/SvJ)
abnormal osteoclast differentiation J:97566
abnormal osteoclast morphology J:97566
abnormal osteoclast physiology J:97566
\Adrb2tm1Bkk/\Adrb2tm1Bkk
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * DBA/2 * FVB/N)
increased tumor necrosis factor secretion J:204379
\Adrb3em1(IMPC)Krb/\Adrb3em1(IMPC)Krb
(C57BL/6NTac-Adrb3em1(IMPC)Krb/Krb)
increased CD4-negative, CD25-positive NK T cell number J:211773
\Adrm1Gt(OST128063)Lex/\Adrm1Gt(OST128063)Lex
(involves: 129S5/SvEvBrd * C57BL/6J)
abnormal single-positive T cell number J:166694
enlarged thymus J:166694
immune system phenotype J:166694
increased CD4-positive, alpha-beta T cell number J:166694
increased CD8-positive, alpha-beta T cell number J:166694
thymus hyperplasia J:166694
\Ads1NZB/\Ads1NZB
(involves: NZB * NZW)
increased anti-double stranded DNA antibody level J:7239, J:7111
increased susceptibility to autoimmune disorder J:7111
\Ads1NZB/\Ads1NZW
(involves: NZB * NZW)
increased anti-double stranded DNA antibody level J:7111
increased susceptibility to autoimmune disorder J:7111
\Ads2NZB/\Ads2NZB
(involves: NZB * NZW)
increased anti-double stranded DNA antibody level J:7111
increased susceptibility to autoimmune disorder J:7111
\Ads2NZB/\Ads2NZW
(involves: NZB * NZW)
increased anti-double stranded DNA antibody level J:7111
increased susceptibility to autoimmune disorder J:7111
\Ads3NZB/\Ads3NZW
(involves: NZB * NZW)
abnormal immunoglobulin level J:7111
increased susceptibility to autoimmune disorder J:7111
\Ads3NZW/\Ads3NZW
(involves: NZB * NZW)
abnormal immunoglobulin level J:7111
increased anti-double stranded DNA antibody level J:7239
increased susceptibility to autoimmune disorder J:7111
\Ads4NZB/\Ads4NZB
(involves: NZB * NZW)
decreased anti-double stranded DNA antibody level J:11074
\Ads4NZB/\Ads4NZW
(involves: NZB * NZW)
abnormal immunoglobulin level J:7111
increased susceptibility to autoimmune disorder J:7111
\Ads4NZW/\Ads4NZW
(involves: NZB * NZW)
abnormal immunoglobulin level J:7111
increased susceptibility to autoimmune disorder J:7111
\Adss2tm1b(EUCOMM)Wtsi/\Adss2+
(C57BL/6N-Adss2tm1b(EUCOMM)Wtsi/Bay)
decreased eosinophil cell number J:211773
\Adtrptm1.1Clu/\Adtrptm1.1Clu
(involves: 129S4/SvJaeSor * C57BL/6)
increased inflammatory response J:295059
increased mast cell number J:295059
\Aec1NOD/Uf/\Aec1NOD/Uf
\Aec2NOD/Uf/\Aec2NOD/Uf

(B6.NOD-Aec2NOD/Uf Aec1NOD/Uf)
increased anti-nuclear antigen antibody level J:129282
increased susceptibility to autoimmune disorder J:128900
lacrimal gland inflammation J:129282
salivary gland inflammation J:129282
\Aem1C57BL/6/\Aem1NZB
(involves: C57BL/6 * NZB)
decreased autoantibody level J:7191
\Aem2C57BL/6/\Aem2C57BL/6
(involves: C57BL/6 * NZB)
decreased autoantibody level J:59427
\Aem2C57BL/6/\Aem2NZB
(involves: C57BL/6 * NZB)
decreased autoantibody level J:59427
\Aem2C57BL/6/\Aem2NZB
\Aem3C57BL/6/\Aem3NZB

(involves: C57BL/6 * NZB)
decreased autoantibody level J:59427
\Aem3C57BL/6/?
(involves: C57BL/6 * NZB)
abnormal immune system physiology J:59427
\Afap1l2tm1b(KOMP)Wtsi/\Afap1l2tm1b(KOMP)Wtsi
(C57BL/6N-Afap1l2tm1b(KOMP)Wtsi/Ucd)
abnormal spleen morphology J:211773
increased neutrophil cell number J:211773
\Afdnem1(IMPC)Mbp/\Afdn+
(C57BL/6N-Afdnem1(IMPC)Mbp/MbpMmucd)
abnormal lymph node morphology J:211773
abnormal spleen morphology J:211773
decreased lymphocyte cell number J:211773
decreased spleen weight J:211773
enlarged lymph nodes J:211773
enlarged spleen J:211773
small spleen J:211773
\Aff1Rob/\Aff1+
(involves: BALB/cAnNCrl * C3H/HeN)
abnormal double-negative T cell morphology J:82265
decreased thymus weight J:82265
thymus hypoplasia J:82265
\Aff1tm1Cim/\Aff1tm1Cim
(involves: 129P2/OlaHsd * BALB/c)
abnormal immune system cell morphology J:63253
abnormal immune system organ morphology J:63253
abnormal T cell differentiation J:63253
decreased B cell number J:63253
decreased double-positive T cell number J:63253
decreased mature B cell number J:63253
decreased pre-B cell number J:63253
decreased single-positive T cell number J:63253
thymus hypoplasia J:63253
\Afg2bem1(IMPC)Bay/\Afg2b+
(C57BL/6N-Afg2bem1(IMPC)Bay/BayMmucd)
enlarged lymph nodes J:211773
\Afg3l1tm1.1Arte/\Afg3l1tm1.1Arte
\Afg3l2tm1Arte/\Afg3l2tm1Arte
\Tg(Plp1-cre/ERT)3Pop/0

(involves: C57BL/6J * C57BL/6N)
microgliosis J:237410
\Afg3l2tm1Arte/\Afg3l2tm1Arte
\Tg(Pcp2-cre)2Mpin/0

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
microgliosis J:193564
\Agbl1em1Zfa/\Agbl1em1Zfa
(Not Specified)
immune system phenotype J:231311
\Agbl2em1Zfa/\Agbl2em1Zfa
(Not Specified)
immune system phenotype J:231311
\Agbl3em1Zfa/\Agbl3em1Zfa
(Not Specified)
immune system phenotype J:231311
\Agbl4em1(IMPC)Mbp/\Agbl4em1(IMPC)Mbp
(C57BL/6NCrl-Agbl4em1(IMPC)Mbp/Mmucd)
increased monocyte cell number J:211773
\Agbl4Tn(pb-Act-RFP)1.080115015-HRAZhu/\Agbl4Tn(pb-Act-RFP)1.080115015-HRAZhu
(involves: FVB/N)
abnormal spleen morphology J:233744
increased spleen weight J:233744
increased susceptibility to Herpesvirales infection J:231311
increased susceptibility to Herpesvirales infection induced morbidity/mortality J:231311
increased susceptibility to Poxviridae infection J:231311
increased susceptibility to Poxviridae infection induced morbidity/mortality J:231311
\Agbl5em1Zfa/\Agbl5em1Zfa
(Not Specified)
increased susceptibility to Herpesvirales infection J:231311
increased susceptibility to Herpesvirales infection induced morbidity/mortality J:231311
increased susceptibility to Poxviridae infection J:231311
increased susceptibility to Poxviridae infection induced morbidity/mortality J:231311
\Agertm1.1Arnd/\Agertm1.1Arnd
(B6.129P2-Agertm1.1Arnd)
decreased circulating interleukin-6 level J:104998
decreased osteoclast cell number J:104998
\Agertm1.1Arnd/\Agertm1.1Arnd
(involves: 129P2/OlaHsd)
abnormal immune system physiology J:113376
\Agertm1Arnd/\Ager+
\Tg(Itgax-EGFP,-cre,-HBEGF,-luc)2Gjh/0

(involves: 129P2/OlaHsd * C57BL/6)
decreased dendritic cell number J:194800
decreased plasmacytoid dendritic cell number J:194800
\Agkem1Qiz/\Agkem1Qiz
(involves: C57BL/6 * DBA/2)
abnormal CD8-positive, alpha beta T cell morphology J:282052
abnormal CD8-positive, alpha-beta T cell physiology J:282052
decreased effector memory CD8-positive, alpha-beta T cell number J:282052
\Agktm1.1Smoc/\Agktm1.1Smoc
(Not Specified)
decreased effector memory CD8-positive, alpha-beta T cell number J:282052
immune system phenotype J:282052
\Aglna/?
(C57BL/6-Aglna/Anu)
abnormal spleen marginal zone morphology J:169366
increased activated T cell number J:169366
\Agnm1MRL/MpJ/\Agnm1MRL/MpJ
(involves: C3H/HeJ-Faslpr * MRL/MpJ-Faslpr)
glomerulonephritis J:97786
increased susceptibility to systemic lupus erythematosus J:97786
\Agnm2C3H/HeJ/\Agnm2MRL/MpJ
(involves: C3H/HeJ-Faslpr * MRL/MpJ-Faslpr)
glomerulonephritis J:97786
increased susceptibility to systemic lupus erythematosus J:97786
\Agnm2MRL/MpJ/\Agnm2MRL/MpJ
(involves: C3H/HeJ-Faslpr * MRL/MpJ-Faslpr)
glomerulonephritis J:97786
increased susceptibility to systemic lupus erythematosus J:97786
\Agnm3C3H/HeJ/\Agnm3MRL/MpJ
(involves: C3H/HeJ-Faslpr * MRL/MpJ-Faslpr)
glomerulonephritis J:97786
increased susceptibility to systemic lupus erythematosus J:97786
\Agnm3MRL/MpJ/\Agnm3MRL/MpJ
(involves: C3H/HeJ-Faslpr * MRL/MpJ-Faslpr)
glomerulonephritis J:97786
increased susceptibility to systemic lupus erythematosus J:97786
\Ago2tm1.1Tara/\Ago2tm1.1Tara
\Tg(Mx1-cre)1Cgn/0

(involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6 * CBA)
enlarged spleen J:165967
\Agp1NZB/\Agp1NZB
(involves: NZB * NZW)
increased susceptibility to type III hypersensitivity reaction J:6920
\Agp1NZB/\Agp1NZW
(involves: NZB * NZW)
increased susceptibility to type III hypersensitivity reaction J:6920
\Agp2NZB/\Agp2NZW
(involves: NZB * NZW)
increased susceptibility to type III hypersensitivity reaction J:6920
\Agp2NZW/\Agp2NZW
(involves: NZB * NZW)
increased susceptibility to type III hypersensitivity reaction J:6920
\Agpat2em1(IMPC)Ccpcz/\Agpat2+
(C57BL/6NCrl-Agpat2em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
enlarged spleen J:211773
\Agpat2Gt(OST438470)Lex/\Agpat2Gt(OST438470)Lex
(involves: 129S5/SvEvBrd * C57BL/6)
brown adipose tissue inflammation J:186035
granulomatous inflammation J:186035
liver inflammation J:186035
\Agpat2tm1Garg/\Agpat2tm1Garg
(involves: 129S6/SvEvTac)
increased spleen weight J:146649
\Agpat5em1(IMPC)Ccpcz/\Agpat5em1(IMPC)Ccpcz
(C57BL/6NCrl-Agpat5em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged spleen J:211773
enlarged thymus J:211773
\Agr2tm1.1Lpkn/\Agr2tm1.1Lpkn
\Gt(ROSA)26Sortm1(cre/ERT)Nat/\Gt(ROSA)26Sor+

(involves: 129 * 129S6/SvEvTac * C57BL/6)
colitis J:156704
\Agr2tm1.2Erle/\Agr2tm1.2Erle
(involves: 129S4/SvJae * FVB/N)
increased mast cell number J:148339
increased susceptibility to induced colitis J:148339
\Agr2tm1.2Lpkn/\Agr2tm1.2Lpkn
(involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6)
abnormal Peyer's patch follicle morphology J:156704
colitis J:156704
ileum inflammation J:156704
\Agttm1Afu/\Agttm1Afu
(involves: C57BL/6 * CBA)
tubulointerstitial nephritis J:46506
\Agttm1Unc/\Agttm1Unc
(involves: 129P2/OlaHsd * C57BL/6J)
tubulointerstitial nephritis J:24156
\Agtpbp1atms/\Agtpbp1atms
(MRL/Mp-Agtpbp1atms Faslpr)
decreased spleen weight J:103944
\Agtpbp1atms/\Agtpbp1atms
(MRL/Mp-Agtpbp1atms)
abnormal lymphocyte cell number J:103944
abnormal spleen morphology J:103944
abnormal T cell differentiation J:103944
abnormal T cell physiology J:103944
abnormal T cell subpopulation ratio J:103944
decreased B cell number J:103944
decreased spleen weight J:103944
increased CD4-positive, alpha-beta T cell number J:103944
increased CD8-positive, alpha-beta T cell number J:103944
spleen hypoplasia J:103944
\Agtpbp1atms/\Agtpbp1atms
\Faslpr/\Faslpr

(MRL/Mp-Agtpbp1atms Faslpr)
enlarged lymph nodes J:103944
enlarged spleen J:103944
\Agtpbp1pcd-3J/\Agtpbp1pcd-3J
(involves: BALB/cByJ)
immune system phenotype J:231311
\Agtr1aem1(IMPC)Rbrc/\Agtr1aem1(IMPC)Rbrc
(C57BL/6NJcl-Agtr1aem1(IMPC)Rbrc/Rbrc)
abnormal spleen morphology J:211773
enlarged spleen J:211773
increased spleen weight J:211773
\Agtr1atm1Unc/\Agtr1atm1Unc
\Agtr1btm1Cof/\Agtr1btm1Cof

(involves: 129P2/OlaHsd * C57BL/6)
kidney inflammation J:137944
\Agtrapem1(IMPC)Mbp/\Agtrapem1(IMPC)Mbp
(C57BL/6NCrl-Agtrapem1(IMPC)Mbp/MbpMmucd)
increased basophil cell number J:211773
increased neutrophil cell number J:211773
\Agtraptm1Tamk/\Agtraptm1Tamk
(involves: C57BL/6N)
abnormal macrophage morphology J:263253
\Ahcytm1b(EUCOMM)Hmgu/\Ahcy+
(C57BL/6N-Ahcytm1b(EUCOMM)Hmgu/Tcp)
increased basophil cell number J:211773
\Ahi1tm1Jgg/\Ahi1tm1Jgg
\Tg(TCF/Lef1-lacZ)34Efu/0

(involves: 129S1/Sv * 129X1/SvJ)
kidney inflammation J:154321
\Ahnaktm1b(KOMP)Mbp/\Ahnak+
(C57BL/6N-Ahnaktm1b(KOMP)Mbp/H)
increased large unstained cell number J:211773
increased monocyte cell number J:211773
\Ahnaktm1Vtm/\Ahnaktm1Vtm
(involves: 129S1/Sv * C57BL/6)
abnormal T cell activation J:131148
abnormal T-helper 1 physiology J:131148
decreased interferon-gamma secretion J:131148
decreased interleukin-2 secretion J:131148
decreased T cell proliferation J:131148
increased interleukin-4 secretion J:131148
increased susceptibility to parasitic infection J:131148
\Ahrb-1/\Ahrb-1
(C57BL/6J)
increased inflammatory response J:5244, J:5387
\Ahrb-1/\Ahrb-1
(involves: C57BL/6J * DBA/2J)
abnormal immune system physiology J:5387
\Ahrtm1Bra/\Ahrtm1Bra
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
abnormal cytokine secretion J:148870
abnormal Langerhans cell morphology J:148870
abnormal Langerhans cell physiology J:148870
decreased spleen germinal center size J:33827
decreased susceptibility to type IV hypersensitivity reaction J:148870
enlarged spleen J:33827
\Ahrtm1Bra/\Ahrtm1Bra
(B6.129-Ahrtm1Bra/J)
abnormal chemokine level J:118646
abnormal cytokine level J:118646
abnormal interleukin level J:118646
abnormal macrophage physiology J:118646
abnormal tumor necrosis factor level J:118646
increased susceptibility to bacterial infection J:118646
lung inflammation J:118646, J:100359
\Ahrtm1Gonz/\Ahrtm1Gonz
(involves: 129S4/SvJae * C57BL/6N)
abnormal spleen morphology J:44690
abnormal spleen red pulp morphology J:44690
bile duct inflammation J:25048
colitis J:44690
decreased spleen white pulp amount J:44690
enlarged spleen J:44690
folliculitis J:44690
heart inflammation J:44690
increased inflammatory response J:25048
small spleen J:25048
spleen hypoplasia J:25048
\Ahrtm1Yfk/\Ahrtm1Yfk
(involves: 129S/SvEv * C57BL/6J)
urinary bladder inflammation J:179919
\Ahrtm2Bra/\Ahrtm2Bra
(involves: 129/Sv * C57BL/6)
increased spleen weight J:83597
\Ahrtm4.1Bra/\Ahrtm4.1Bra
(involves: 129/Sv * C57BL/6)
enlarged spleen J:141978
\Ahsptm1.1Mjwe/\Ahsptm1.1Mjwe
(involves: 129S6/SvEvTac * C57BL/6)
enlarged spleen J:94421
\Ahsptm1Mjwe/\Ahsptm1Mjwe
(involves: 129S6/SvEvTac * C57BL/6)
enlarged spleen J:94421
\Aia1NZB/Omr/\Aia1NZB/Omr
(involves: NZB/Omr * NZC/Omr)
increased susceptibility to autoimmune hemolytic anemia J:6517
\Aia1NZB/Omr/\Aia1NZC/Omr
(involves: NZB/Omr * NZC/Omr)
increased susceptibility to autoimmune hemolytic anemia J:6517
\Aicdaem1Jaych/\Aicdaem1Jaych
(involves: C57BL/6J)
abnormal class switch recombination J:305843
abnormal lymph node cell ratio J:305843
abnormal Peyer's patch germinal center morphology J:305843
abnormal splenic cell ratio J:305843
increased IgM level J:305843
\Aicdam1Btlr/\Aicdam1Btlr
(C57BL/6J-Aicdam1Btlr)
abnormal humoral immune response J:265155
decreased IgE level J:265155
increased IgM level J:265155
\Aicdam2Btlr/\Aicdam2Btlr
(C57BL/6J-Aicdam2Btlr)
abnormal humoral immune response J:265156
decreased IgE level J:265156
increased IgM level J:265156
\Aicdatm1(cre)Mnz/\Aicda+
\Gt(ROSA)26Sortm2(sb11)Njen/\Gt(ROSA)26Sor+
\TgTn(sb-T2/Onc2)6070Njen/0

(involves: 129 * 129P2/OlaHsd * C57BL/6 * C57BL/6J)
increased T cell derived lymphoma incidence J:153656
\Aicdatm1(cre)Mnz/\Aicda+
\Ightm3Mnz/\Igh+
\Myctm37Mnz/\Myc+

(involves: 129P2/OlaHsd * C57BL/6)
abnormal B cell physiology J:145691
\Aicdatm1(cre)Mnz/\Aicda+
\Ightm3Mnz/\Igh+
\Myctm39Mnz/\Myc+

(involves: 129P2/OlaHsd * C57BL/6)
abnormal B cell physiology J:145691
\Aicdatm1.1Fwa/\Aicdatm1.1Fwa
(involves: 129S6/SvEvTac)
abnormal class switch recombination J:209271
abnormal somatic hypermutation frequency J:209271
immune system phenotype J:209271
\Aicdatm1b(EUCOMM)Hmgu/\Aicdatm1b(EUCOMM)Hmgu
(C57BL/6N-Aicdatm1b(EUCOMM)Hmgu/Wtsi)
decreased follicular B cell number J:211773
decreased late germinal center B cell number J:211773
increased early germinal center B cell number J:211773
increased germinal center B cell number J:211773
increased leukocyte cell number J:211773
\Aicdatm1Hon/\Aicda+
(involves: C57BL/6 * CBA)
abnormal class switch recombination J:136224, J:141427
abnormal somatic hypermutation frequency J:141427
immune system phenotype J:136224
\Aicdatm1Hon/\Aicdatm1.1Fwa
(involves: 129S/SvEv * C57BL/6NCrlj * CBA/JNCrlj)
abnormal class switch recombination J:209271
immune system phenotype J:209271
\Aicdatm1Hon/\Aicdatm1Hon
(involves: C57BL/6 * CBA)
abnormal class switch recombination J:141427, J:73659, J:120658
abnormal somatic hypermutation frequency J:136224, J:141427
decreased IgA level J:169227
decreased IgG1 level J:169227, J:73659
decreased IgG2a level J:73659
decreased IgG2b level J:169227
decreased IgG3 level J:169227
decreased IgG level J:169227
increased germinal center B cell number J:169227
increased IgM level J:169227, J:73659
increased susceptibility to bacterial infection induced morbidity/mortality J:169227
\Aicdatm1Hon/\Aicdatm1Hon
\Bcl6tm1.1Jwan/\Bcl6tm1.1Jwan

(involves: 129S6/SvEvTac * C57BL/6NCrlj * CBA/JNCrlj)
abnormal somatic hypermutation frequency J:190534
\Aicdatm1Hon/\Aicdatm1Hon
\Blmtm3Brd/\Blmtm3Brd
\Ightm4.1Mnz/\Igh+
\Trp53bp1tm1Jc/\Trp53bp1tm1Jc

(involves: 129S7/SvEvBrd * C57BL/6 * C57BL/6NCrlj * CBA/JNCrlj)
immune system phenotype J:194603
\Aicdatm1Hon/\Aicdatm1Hon
\Exo1tm1Wed/\Exo1tm1Wed
\Ightm4.1Mnz/\Igh+

(involves: C57BL/6 * CBA/JNCrlj * SJL)
abnormal immunoglobulin heavy chain V(D)J recombination J:194603
\Aicdatm1Hon/\Aicdatm1Hon
\Exo1tm1Wed/\Exo1tm1Wed
\Ightm4.1Mnz/\Igh+
\Trp53bp1tm1Jc/\Trp53bp1tm1Jc

(involves: 129 * C57BL/6 * CBA/JNCrlj * SJL)
abnormal immunoglobulin heavy chain V(D)J recombination J:194603
\Aicdatm1Hon/\Aicdatm1Hon
\Ightm3Mnz/\Ightm4.1Mnz
\Trp53bp1tm1Jc/\Trp53bp1tm1Jc

(involves: 129 * C57BL/6 * CBA)
abnormal class switch recombination J:159173
\Aicdatm1Hon/\Aicdatm1Hon
\Ightm4.1Mnz/\Igh+

(involves: C57BL/6 * C57BL/6NCrlj * CBA/JNCrlj)
abnormal immunoglobulin heavy chain V(D)J recombination J:194603
\Aicdatm1Hon/\Aicdatm1Hon
\Ightm4.1Mnz/\Igh+
\Trp53bp1tm1Jc/\Trp53bp1tm1Jc

(involves: 129 * C57BL/6 * C57BL/6NCrlj * CBA/JNCrlj)
abnormal immunoglobulin heavy chain V(D)J recombination J:194603
\Aicdatm1Hon/\Aicdatm1Hon
\Ighmtm1.1(IGH-2)Cog/\Ighm+

(involves: 129P2/OlaHsd * C57BL/6 * CBA * FVB/N)
abnormal B cell physiology J:157575
\Aicdatm1Hon/\Aicdatm1Hon
\Tg(Igkv3-5*-MYC)#Plbe/0

(involves: C57BL/6 * C57BL/6NCrlj * CBA/JNCrlj)
immune system phenotype J:131912
\Aicdatm1Hon/\Aicdatm2Mnz
(involves: C57BL/6 * CBA)
immune system phenotype J:136224
\Aicdatm1Hon/\Aicdatm3Mnz
(involves: C57BL/6 * CBA)
abnormal class switch recombination J:141427
abnormal somatic hypermutation frequency J:141427
\Aicdatm1Hon/\Aicdatm4Mnz
(involves: C57BL/6 * CBA)
abnormal class switch recombination J:141427
abnormal somatic hypermutation frequency J:141427
\Aicdatm2.1Hon/\Aicdatm2.1Hon
(C57BL/6-Aicdatm2.1Hon)
abnormal somatic hypermutation frequency J:169227
decreased IgG1 level J:169227
immune system phenotype J:169227
increased germinal center B cell number J:169227
increased susceptibility to bacterial infection J:169227
increased susceptibility to bacterial infection induced morbidity/mortality J:169227
\Aicdatm2.1Hon/\Aicdatm2.1Hon
(involves: BALB/c * C57BL/6)
increased germinal center B cell number J:169227
\Aicdatm2Mnz/\Aicdatm2Mnz
(B6.Cg-Aicdatm2Mnz)
immune system phenotype J:136224
\Aicdatm3.1Mnz/\Aicdatm3.1Mnz
(involves: C57BL/6)
abnormal class switch recombination J:147109
abnormal somatic hypermutation frequency J:147109
\Aicdatm3Mnz/\Aicda+
(involves: C57BL/6 * CBA)
abnormal class switch recombination J:141427
abnormal somatic hypermutation frequency J:141427
\Aicdatm4.1Mnz/\Aicdatm4.1Mnz
(involves: C57BL/6)
abnormal class switch recombination J:147109
abnormal somatic hypermutation frequency J:147109
\Aicdatm4Mnz/\Aicda+
(involves: C57BL/6 * CBA)
abnormal class switch recombination J:141427
abnormal somatic hypermutation frequency J:141427
\Aif1tm1Nsib/\Aif1tm1Nsib
(involves: 129S/SvEv * C57BL/6)
decreased spleen weight J:204462
decreased susceptibility to induced arthritis J:204462
\Aif1ltm1b(EUCOMM)Wtsi/\Aif1ltm1b(EUCOMM)Wtsi
(C57BL/6N-Aif1ltm1b(EUCOMM)Wtsi/Bay)
abnormal spleen morphology J:211773
enlarged spleen J:211773
increased spleen weight J:211773
small thymus J:211773
\Aim2em1(IMPC)Ccpcz/\Aim2em1(IMPC)Ccpcz
(C57BL/6N-Aim2em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged spleen J:211773
enlarged thymus J:211773
\Aim2Gt(CSG445)Byg/\Aim2Gt(CSG445)Byg
(involves: 129P2/OlaHsd * C57BL/6)
abnormal macrophage physiology J:158969
decreased circulating interleukin-18 level J:158969
decreased interleukin-1 beta secretion J:158969
decreased interleukin-18 secretion J:158969
decreased NK cell number J:158969
increased interferon-beta secretion J:158969
increased susceptibility to bacterial infection J:158969
increased susceptibility to Herpesvirales infection J:158969
increased susceptibility to Poxviridae infection J:158969
\Aim2Gt(CSG445)Byg/\Aim2Gt(CSG445)Byg
(involves: 129P2/OlaHsd)
immune system phenotype J:173245
\Aim2Gt(CSG445)Byg/\Aim2Gt(CSG445)Byg
(B6.129P2-Aim2Gt(CSG445)Byg/J)
abnormal interferon secretion J:234263
decreased interleukin-1 beta secretion J:234263
decreased macrophage apoptosis J:234263
\Aim2tm1.1Vmd/\Aim2tm1.1Vmd
(C57BL/6-Aim2tm1.1Vmd)
abnormal cytokine secretion J:160545
abnormal macrophage physiology J:160545
decreased interleukin-1 beta secretion J:160545
decreased interleukin-18 secretion J:160545
increased interferon-beta secretion J:160545
increased susceptibility to bacterial infection J:160545
increased tumor necrosis factor secretion J:160545
\Aim2tm1.2Arte/\Aim2tm1.2Arte
\Dnase2atm1Osa/\Dnase2atm1Osa
\Ifnar1tm1Agt/\Ifnar1tm1Agt

(involves: 129 * BALB/c * C57BL/6 * C57BL/6J)
abnormal spleen morphology J:238323
enlarged spleen J:238323
increased autoantibody level J:238323
increased circulating interleukin-10 level J:238323
increased circulating tumor necrosis factor level J:238323
increased spleen weight J:238323
rheumatoid arthritis J:238323
\Aim2tm1Ktak/\Aim2tm1Ktak
(involves: 129S4/SvJae * C57BL/6)
decreased circulating interleukin-18 level J:188013
decreased interferon-gamma secretion J:188013
decreased interleukin-1 beta secretion J:188013
decreased interleukin-18 secretion J:188013
increased susceptibility to bacterial infection J:188013
increased susceptibility to bacterial infection induced morbidity/mortality J:188013
\Aimp1em1(IMPC)Tcp/\Aimp1em1(IMPC)Tcp
(C57BL/6NCrl-Aimp1em1(IMPC)Tcp/Tcp)
enlarged spleen J:211773
\Aimp1Gt(OST58507)Lex/\Aimp1Gt(OST58507)Lex
(involves: 129S5/SvEvBrd * C57BL/6)
decreased inflammatory response J:95974
\Airetm1.1(cre)Ghr/\Airetm1.1(cre)Ghr
(Not Specified)
decreased dendritic cell number J:176844
decreased regulatory T cell number J:176844
increased dendritic cell number J:176844
\Airetm1.1(NCOM)Mfgc/\Airetm1.1(NCOM)Mfgc
(C57BL/6N-Airetm1.1(NCOM)Mfgc/Tcp)
increased monocyte cell number J:211773
\Airetm1.1Doi/\Airetm1.1Doi
(involves: 129S2/SvPas * C57BL/6)
abnormal thymus medulla morphology J:83422
increased autoantibody level J:119475
increased susceptibility to autoimmune disorder J:83422
increased T cell number J:83422
stomach inflammation J:119475
\Airetm1.1Doi/\Airetm1.1Doi
(B6.129S2-Airetm1.1Doi/Doi)
increased autoantibody level J:107432
increased incidence of corneal inflammation J:107432
lung inflammation J:107432
salivary gland inflammation J:107432
stomach inflammation J:107432
\Airetm1.1Doi/\Airetm1.1Doi
(NOD.129S2(B6)-Airetm1.1Doi/Doi)
increased autoantibody level J:107432
increased incidence of corneal inflammation J:107432
liver inflammation J:107432
lung inflammation J:107432
ovary inflammation J:107432
pancreas inflammation J:107432
prostate gland inflammation J:107432
salivary gland inflammation J:107432
stomach inflammation J:107432
thyroid gland inflammation J:107432
\Airetm1.1Doi/\Airetm1.1Doi
(C.129S2-Airetm1.1Doi/Doi)
increased autoantibody level J:107432
increased incidence of corneal inflammation J:107432
liver inflammation J:107432
lung inflammation J:107432
ovary inflammation J:107432
prostate gland inflammation J:107432
salivary gland inflammation J:107432
stomach inflammation J:107432
\Airetm1.1Doi/\Airetm1.1Doi
(SJL.129S2-Airetm1.1Doi/Doi)
increased autoantibody level J:107432
liver inflammation J:107432
lung inflammation J:107432
ovary inflammation J:107432
pancreas inflammation J:107432
prostate gland inflammation J:107432
salivary gland inflammation J:107432
stomach inflammation J:107432
\Airetm1.1Doi/\Airetm1.1Doi
(involves: 129S2/SvPas * C57BL/6 * NOD)
liver inflammation J:107432
lung inflammation J:107432
pancreas inflammation J:107432
salivary gland inflammation J:107432
stomach inflammation J:107432
\Airetm1.1Doi/\Airetm1.1Doi
(NOD.129S2-Airetm1.1Doi)
abnormal CD4-positive, alpha-beta T cell physiology J:135154
chronic pancreas inflammation J:135154
insulitis J:135154
lacrimal gland inflammation J:135154
lung inflammation J:135154
salivary gland inflammation J:135154
stomach inflammation J:135154
thyroid gland inflammation J:135154
uveitis J:135154
\Airetm1.1Doi/\Airetm1.1Doi
\H2b/\H2b

(NOD.Cg-Airetm1.1Doi H2b/Doi)
stomach inflammation J:107432
\Airetm1.1Doi/\Airetm1.1Doi
\Idd3C57BL/6/\Idd3C57BL/6
\Idd5C57BL/10SnJ/\Idd5C57BL/10SnJ

(NOD.Cg-Idd3C57BL/6 Idd5C57BL/10SnJ Airetm1.1Doi/Doi)
stomach inflammation J:107432
\Airetm1.1Doi/\Airetm1.1Doi
\Il1r1tm1Imx/\Il1r1+

(involves: 129S2/SvPas * 129S7/SvEvBrd * NOD)
keratoconjunctivitis J:163691
lacrimal gland inflammation J:163691
\Airetm1.1Doi/\Airetm1.1Doi
\Il1r1tm1Imx/\Il1r1tm1Imx

(involves: 129S2/SvPas * 129S7/SvEvBrd * NOD)
keratoconjunctivitis J:163691
lacrimal gland inflammation J:163691
\Airetm1.1Doi/\Airetm1.1Doi
\Tg(Ins2-TFRC/OVA)296Wehi/0
\Tg(TcraTcrb)425Cbn/0

(involves: 129P2/OlaHsd * C57BL/6)
abnormal T cell differentiation J:135154
decreased CD4-positive, alpha-beta T cell number J:135154
\Airetm1Mand/\Aire+
(involves: 129P2/OlaHsd * C57BL/6)
lacrimal gland inflammation J:135154
salivary gland inflammation J:135154
\Airetm1Mand/\Aire+
(NOD.129P2-Airetm1Mand)
abnormal CD4-positive, alpha-beta T cell physiology J:135154, J:188686
abnormal chemokine level J:188686
chronic pancreas inflammation J:135154
CNS inflammation J:135154
increased autoantibody level J:188686
increased CXCL10 level J:188686
increased inflammatory response J:188686
increased susceptibility to autoimmune diabetes J:135154, J:188686
insulitis J:135154
lacrimal gland inflammation J:135154
salivary gland inflammation J:135154
thyroid gland inflammation J:135154
\Airetm1Mand/\Aire+
\Tg(Ins2-TFRC/OVA)296Wehi/0
\Tg(TcraTcrb)425Cbn/0

(involves: 129P2/OlaHsd * C57BL/6)
abnormal T cell differentiation J:135154
\Airetm1Mand/\Airetm1.1Doi
(NOD.129-Airetm1Mand/Airetm1.1Doi)
abnormal CD4-positive, alpha-beta T cell physiology J:135154
chronic pancreas inflammation J:135154
insulitis J:135154
lacrimal gland inflammation J:135154
lung inflammation J:135154
salivary gland inflammation J:135154
stomach inflammation J:135154
thyroid gland inflammation J:135154
uveitis J:135154
\Airetm1Mand/\Airetm1Mand
(involves: 129P2/OlaHsd * C57BL/6)
eye inflammation J:135154
lacrimal gland inflammation J:135154
salivary gland inflammation J:135154
\Airetm1Mmat/\Airetm1Mmat
(involves: C57BL/6 * CBA)
autoimmune response J:96580
lacrimal gland inflammation J:96580
pancreas inflammation J:96580
parotid gland inflammation J:96580
stomach inflammation J:96580
submandibular gland inflammation J:96580
\Airetm1Mmat/\Airetm1Mmat
(C.Cg-Airetm1Mmat)
increased autoantibody level J:96580
stomach inflammation J:96580
\Airetm1Mmat/\Airetm1Mmat
(B6.Cg-Airetm1Mmat)
autoimmune response J:96580
salivary gland inflammation J:96580
\Airetm1Mmat/\Airetm2Mmat
(involves: C57BL/6 * CBA)
abnormal thymus morphology J:141379
autoimmune response J:141379
\Airetm1Mmat/\Airetm2Mmat
\Tg(TcraTcrb)425Cbn/?

(involves: BALB/c * C57BL/6 * CBA)
abnormal thymus morphology J:141379
immune system phenotype J:141379
\Airetm1Pltn/\Airetm1Pltn
(involves: 129S4/SvJae * C57BL/6)
abnormal T cell morphology J:77873
increased autoantibody level J:77873
increased T cell proliferation J:77873
liver inflammation J:77873
thymus atrophy J:77873
\Airetm1Pltn/\Airetm1Pltn
(B6.129S4-Airetm1Pltn)
abnormal metallophilic macrophage morphology J:115076
abnormal myelopoiesis J:115076
abnormal spleen marginal zone morphology J:115076
decreased follicular B cell number J:115076
enlarged spleen J:115076
immune system phenotype J:115076
increased B cell number J:115076
increased marginal zone B cell number J:115076
increased monocyte cell number J:115076
increased spleen weight J:115076
liver inflammation J:115076
\Airetm1Ptsn/\Airetm1Ptsn
(C57BL/6-Airetm1Ptsn)
abnormal T cell activation J:145910
abnormal thymus medulla morphology J:145910
increased autoantibody level J:145910
parotid gland inflammation J:145910
sublingual gland inflammation J:145910
uveitis J:145910
vitreous body inflammation J:145910
\Airetm1Ptsn/\Airetm1Ptsn
(C.B6-Airetm1Ptsn)
abnormal adaptive immunity J:174653
abnormal cytokine level J:174653
abnormal regulatory T cell physiology J:174653
abnormal T-helper 1 physiology J:174653
abnormal T-helper 17 cell physiology J:174653
decreased susceptibility to fungal infection J:174653
increased interleukin-6 secretion J:174653
increased interleukin-12 secretion J:174653
increased interleukin-23 secretion J:174653
increased susceptibility to autoimmune disorder J:174653
increased susceptibility to fungal infection J:174653
increased tumor necrosis factor secretion J:174653
stomach inflammation J:174653
\Airetm2Mmat/\Airetm2Mmat
(involves: C57BL/6 * CBA)
abnormal thymus morphology J:141379
abnormal thymus physiology J:141379
absent Hassall's corpuscle J:141379
autoimmune response J:141379
\Ajubaem1(IMPC)H/\Ajubaem1(IMPC)H
(C57BL/6N-Ajubaem1(IMPC)H/H)
decreased lymphocyte cell number J:211773
increased neutrophil cell number J:211773
increased spleen weight J:211773
\Ak7em1(IMPC)Ccpcz/\Ak7+
(C57BL/6NCrl-Ak7em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged thymus J:211773
\Ak7Gt(OST434404)Lex/\Ak7Gt(OST434404)Lex
(involves: 129S5/SvEvBrd * C57BL/6J)
rhinosinusitis J:185566
\Ak7Tg(tetO-Hmox1)67Sami/\Ak7Tg(tetO-Hmox1)67Sami
(FVB/N-Ak7Tg(tetO-Hmox1)67Sami)
respiratory system inflammation J:186062
rhinitis J:186062
\Akap9tm1a(KOMP)Wtsi/\Akap9+
(involves: C57BL/6 * C57BL/6N)
decreased B cell number J:213427
decreased mature B cell number J:213427
increased CD4-positive, alpha-beta T cell number J:213427
increased CD8-positive, alpha-beta T cell number J:213427
increased T cell number J:213427
\Akap11tm1b(EUCOMM)Hmgu/\Akap11tm1b(EUCOMM)Hmgu
(B6N(Cg)-Akap11tm1b(EUCOMM)Hmgu/J)
decreased leukocyte cell number J:211773
\Akap12tm1Ihg/\Akap12tm1Ihg
(involves: 129S4/SvJae * C57BL/6)
increased spleen red pulp amount J:138882
liver inflammation J:138882
\Akap13em1(IMPC)Mbp/\Akap13em1(IMPC)Mbp
(C57BL/6N-Akap13em1(IMPC)Mbp/MbpMmucd)
abnormal lymph node morphology J:211773
enlarged lymph nodes J:211773
\Akap13tm1Segj/\Akap13+
(involves: 129)
abnormal lymphocyte physiology J:111574
abnormal splenocyte physiology J:181088
decreased B cell number J:181088
decreased IgG1 level J:181088
decreased spleen B cell follicle size J:181088
decreased spleen weight J:181088
decreased splenocyte number J:181088
decreased transitional stage T2 B cell number J:181088
increased transitional stage T1 B cell number J:181088
small spleen J:181088
spleen hypoplasia J:181088
\Akip1em1Cya/\Akip1em1Cya
(C57BL/6N-Akip1em1Cya)
decreased susceptibility to endotoxin shock J:326919
decreased susceptibility to viral infection J:326919
\Aknatm1Mak/\Aknatm1Mak
(B6.129P2-Aknatm1Mak)
alveolitis J:233952
increased acute inflammation J:233952
increased neutrophil cell number J:233952
increased susceptibility to fungal infection J:233952
lung inflammation J:233952
\Aknatm2Mak/\Aknatm2Mak
(B6.129-Aknatm2Mak)
increased susceptibility to fungal infection J:233952
\Akr1a1Gt(OST222400)Lex/\Akr1a1Gt(OST222400)Lex
(B6.129S5-Akr1a1Gt(OST222400)Lex)
abnormal osteoclast physiology J:164548
increased osteoclast cell number J:164548
\Akr1b8tm1Dgen/\Akr1b8tm1Dgen
(Not Specified)
abnormal interferon level J:301852
abnormal interleukin level J:301852
increased susceptibility to induced colitis J:301852
\Akr1c21em1Wany/\Akr1c21em1Wany
(involves: C57BL/6)
increased acute inflammation J:322353
increased interleukin level J:322353
lung inflammation J:322353
\Akt1tm1Nhy/\Akt1tm1Nhy
(involves: 129/Sv * C57BL/6)
abnormal thymus morphology J:71404
\Akt1tm1Pnt/\Akt1tm1Pnt
\Akt2tm1.1Mbb/\Akt2tm1.1Mbb
\Akt3tm1Mbb/\Akt3tm1Mbb
\Tg(Lck-cre)1Cwi/0

(involves: 129P2/OlaHsd)
arrested T cell differentiation J:135903
decreased double-positive T cell number J:135903
increased double-negative T cell number J:135903
increased T cell apoptosis J:135903
thymus hypoplasia J:135903
\Akt1tm1Pnt/\Akt1tm1Pnt
\Akt2tm1.1Mbb/\Akt2tm1.1Mbb
\Tg(Lck-cre)1Cwi/0

(involves: 129P2/OlaHsd)
arrested T cell differentiation J:135903
decreased double-positive T cell number J:135903
increased double-negative T cell number J:135903
increased T cell apoptosis J:135903
thymus hypoplasia J:135903
\Akt1tm1Pnt/\Akt1tm1Pnt
\Akt3tm1Mbb/\Akt3tm1Mbb
\Tg(Lck-cre)1Cwi/0

(Not Specified)
decreased double-positive T cell number J:135903
thymus hypoplasia J:135903
\Akt2tm1.1Mbb/\Akt2tm1.1Mbb
(involves: 129P2/OlaHsd)
immune system phenotype J:135903
\Akt3tm1Mbb/\Akt3tm1Mbb
(Not Specified)
immune system phenotype J:135903
\Aktiptm1a(EUCOMM)Hmgu/\Aktiptm1a(EUCOMM)Hmgu
\Trp53tm1Tyj/\Trp53tm1Tyj

(involves: 129S2/SvPas * C57BL/6N)
kidney inflammation J:276210
liver inflammation J:276210
lung inflammation J:276210
peritoneal inflammation J:276210
\Aladem1(IMPC)Tcp/\Alad+
(C57BL/6NCrl-Aladem1(IMPC)Tcp/Cmmr)
enlarged lymph nodes J:211773
enlarged thymus J:211773
\Alan2B10.O20/Dem/\Alan2B10.O20/Dem
(involves: B10.O20/Dem * O20/A)
abnormal immune system physiology J:67657
\Alan2B10.O20/Dem/\Alan2O20/A
(involves: B10.O20/Dem * O20/A)
abnormal immune system physiology J:67657
\Aldh1a2tm1Dll/\Aldh1a2tm1Ipc
(involves: CD-1)
athymia J:81969
thymus hypoplasia J:81969
\Aldh1l2em1(IMPC)Kmpc/\Aldh1l2em1(IMPC)Kmpc
(C57BL/6NTac-Aldh1l2em1(IMPC)Kmpc/Kmpc)
increased B-1a cell number J:211773
increased CD8-positive, CD25-positive alpha-beta T cell number J:211773
\Aldh1l2tm2e(KOMP)Wtsi/\Aldh1l2tm2e(KOMP)Wtsi
(involves: C57BL/6 * C57BL/6N)
immune system phenotype J:299012
\Aldh2tm1.1Mak/\Aldh2+
(involves: 129S6/SvEvTac * C57BL/6J)
decreased leukocyte cell number J:223796
\Aldh2tm1.1Mak/\Aldh2tm1.1Mak
(involves: 129S6/SvEvTac * C57BL/6J)
decreased leukocyte cell number J:223796
\Aldh2tm1a(EUCOMM)Wtsi/\Aldh2tm1a(EUCOMM)Wtsi
(C57BL/6N-Aldh2tm1a(EUCOMM)Wtsi/Ieg)
decreased CD4-positive, alpha-beta T cell number J:165965
decreased CD8-positive, alpha-beta T cell number J:165965
decreased T cell number J:165965
\Aldh2tm1a(EUCOMM)Wtsi/\Aldh2tm1a(EUCOMM)Wtsi
\Fancd2tm1Hou/\Fancd2tm1Hou

(involves: 129S4/SvJae * C57BL/6J * C57BL/6N)
abnormal lymphopoiesis J:193232
abnormal spleen morphology J:188123
abnormal thymus morphology J:188123
decreased leukocyte cell number J:188123
enlarged spleen J:193232
increased CD8-positive, alpha-beta T cell number J:193232
increased double-positive T cell number J:193232
increased T cell derived lymphoma incidence J:193232
\Aldh18a1tm1a(KOMP)Wtsi/\Aldh18a1+
(C57BL/6N-Aldh18a1tm1a(KOMP)Wtsi/Wtsi)
skin inflammation J:232539
\Aldoatm1.1(KOMP)Wtsi/\Aldoa+
(C57BL/6N-Aldoatm1.1(KOMP)Wtsi/Bay)
decreased leukocyte cell number J:211773
\Aldobtm1(KOMP)Vlcg/\Aldobtm1(KOMP)Vlcg
(C57BL/6NTac-Aldobtm1(KOMP)Vlcg)
liver inflammation J:220330
\Alg1tm1b(KOMP)Wtsi/\Alg1+
(C57BL/6N-Alg1tm1b(KOMP)Wtsi/Nju)
increased basophil cell number J:211773
increased eosinophil cell number J:211773
increased leukocyte cell number J:211773
increased lymphocyte cell number J:211773
\Alg6em1(IMPC)Tcp/\Alg6+
(C57BL/6N-Alg6em1(IMPC)Tcp/Cmmr)
enlarged lymph nodes J:211773
\Alg13tm1a(KOMP)Wtsi/\Alg13tm1a(KOMP)Wtsi
(C57BL/6N-Alg13tm1a(KOMP)Wtsi/Wtsi)
increased leukocyte cell number J:211773
\Alkbh1tm1b(EUCOMM)Hmgu/\Alkbh1+
(C57BL/6N-Alkbh1tm1b(EUCOMM)Hmgu/Ieg)
abnormal spleen morphology J:211773
enlarged lymph nodes J:211773
\Alms1Gt(XH152)Byg/\Alms1Gt(XH152)Byg
(involves: 129P2/OlaHsd * C57BL/6J)
tubulointerstitial nephritis J:100403
\Alo1/\Alo1
(involves: C3H/HeJ * C57BL/6J)
abnormal lymph node morphology J:109802
enlarged lymph nodes J:109802
enlarged spleen J:109802
lymph node necrosis J:109802
\Alo1/\Alo1+
(involves: C3H/HeJ * C57BL/6J)
abnormal lymph node morphology J:109802
enlarged lymph nodes J:109802
enlarged spleen J:109802
lymph node necrosis J:109802
\Alo2/\Alo2
(involves: C3H/HeJ * C57BL/6J)
abnormal lymph node morphology J:109802
enlarged lymph nodes J:109802
enlarged spleen J:109802
lymph node necrosis J:109802
\Alo2/\Alo2+
(involves: C3H/HeJ * C57BL/6J)
abnormal lymph node morphology J:109802
enlarged lymph nodes J:109802
enlarged spleen J:109802
lymph node necrosis J:109802
\Alox5em1(IMPC)Ccpcz/\Alox5em1(IMPC)Ccpcz
(C57BL/6NCrl-Alox5em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
enlarged spleen J:211773
\Alox5tm1Bhk/\Alox5tm1Bhk
(either: (involves: 129P2/OlaHsd * C57BL/6) or (involves: 129P2/OlaHsd * C57BL/6 * DBA/2))
abnormal inflammatory response J:68714
abnormal neutrophil physiology J:68714
decreased acute inflammation J:68714
decreased susceptibility to type I hypersensitivity reaction J:68714
impaired neutrophil chemotaxis J:68714
impaired neutrophil recruitment J:68714
\Alox5tm1Fun/\Alox5tm1Fun
(involves: 129S2/SvPas * C57BL/6)
abnormal immune system physiology J:21372
decreased inflammatory response J:21372, J:75371
immune system phenotype J:21372
small spleen J:21372
\Alox5tm1Fun/\Alox5tm1Fun
(B6.129S2-Alox5tm1Fun)
immune system phenotype J:89268
\Alox5tm1Fun/\Alox5tm1Fun
(B6.129S2-Alox5tm1Fun/J)
decreased susceptibility to experimental autoimmune uveoretinitis J:108446
\Alox5aptm1Bhk/\Alox5aptm1Bhk
(involves: 129P2/OlaHsd * C57BL/6 * DBA/2)
decreased susceptibility to type I hypersensitivity reaction J:39229
\Alox5aptm1Bhk/\Alox5aptm1Bhk
(involves: 129P2/OlaHsd * 129S/SvEv)
decreased acute inflammation J:39229
impaired neutrophil recruitment J:39229
\Alox5aptm1Jdm/\Alox5ap+
(DBA/1LacJ-Alox5aptm1Jdm)
decreased susceptibility to induced arthritis J:100736
immune system phenotype J:100736
\Alox5aptm1Jdm/\Alox5aptm1Jdm
(DBA/1LacJ-Alox5aptm1Jdm)
decreased inflammatory response J:100736
decreased susceptibility to induced arthritis J:100736
immune system phenotype J:100736
\Alox8tm1a(KOMP)Wtsi/\Alox8tm1a(KOMP)Wtsi
(C57BL/6N-Alox8tm1a(KOMP)Wtsi/MbpMmucd)
abnormal susceptibility to Orthomyxoviridae infection J:277623
increased interleukin-6 secretion J:277623
lung inflammation J:277623
\Alox12tm1Fun/\Alox12tm1Fun
(involves: 129S2/SvPas * C57BL/6)
immune system phenotype J:55741
\Alox15tm1Fun/\Alox15tm1Fun
(involves: 129/Sv * C57BL/6)
abnormal immune system physiology J:44778
\Alox15tm1Fun/\Alox15tm1Fun
(B6.129S2-Alox15tm1Fun/J)
abnormal lymph node morphology J:119405
abnormal myelopoiesis J:119405
abnormal spleen red pulp morphology J:119405
abnormal spleen white pulp morphology J:119405
decreased spleen B cell follicle number J:119405
dermatitis J:119405
increased basophil cell number J:119405
increased leukocyte cell number J:119405
increased spleen weight J:119405
intermingled spleen red and white pulp J:119405
\Alox15tm1Fun/\Alox15tm1Fun
(B6.129S2-Alox15tm1Fun)
immune system phenotype J:197334
\Aloxe3em1(IMPC)Mbp/\Aloxe3+
(C57BL/6N-Aloxe3em1(IMPC)Mbp/MbpMmucd)
abnormal lymph node morphology J:211773
abnormal spleen morphology J:211773
enlarged lymph nodes J:211773
small spleen J:211773
\Alpk1em1Dlka/\Alpk1em1Dlka
\Crb1rd8/\Crb1rd8

(involves: C57BL/6N)
abnormal circulating chemokine level J:344848
immune system phenotype J:344848
increased circulating CXCL10 level J:344848
\Alplem1(IMPC)Ccpcz/\Alpl+
(C57BL/6NCrl-Alplem1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
\Alpltm1Jlm/\Alpltm1Jlm
(either: (involves: 129S2/SvPas) or (involves: 129S2/SvPas * C57BL/6J))
abnormal spleen morphology J:39015
abnormal thymus cortex morphology J:39015
decreased leukocyte cell number J:39015
pale spleen J:39015
small spleen J:39015
\Als2tm1Jei/\Als2tm1Jei
(involves: 129P2/OlaHsd * C57BL/6J)
CNS inflammation J:104446
\Altretm1.1Hbgl/\Altretm1.1Hbgl
\Foxp3tm4(YFP/icre)Ayr/Y

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)
abnormal regulatory T cell physiology J:342907
decreased regulatory T cell number J:342907
decreased T cell number J:342907
increased CD8-positive, alpha-beta T cell number J:342907
increased interleukin-17 secretion J:342907
increased memory T cell number J:342907
increased regulatory T cell apoptosis J:342907
\amdA/J/\amdA/J
(involves: A/J * C57BL/6J)
myocarditis J:2843, J:11025
\amdDBA/2J/\amdDBA/2J
(B10.D2-H8b/(57N)SnJ)
myocarditis J:11025
\Amdhd1tm2b(EUCOMM)Hmgu/\Amdhd1tm2b(EUCOMM)Hmgu
(C57BL/6N-Amdhd1tm2b(EUCOMM)Hmgu/BayMmucd)
increased lymphocyte cell number J:211773
\Amelxem1(IMPC)Ccpcz/Y
(C57BL/6N-Amelxem1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged thymus J:211773
small spleen J:211773
\Amelxem1(IMPC)Ccpcz/\Amelx+
(C57BL/6N-Amelxem1(IMPC)Ccpcz/Ccpcz)
abnormal lymph node morphology J:211773
decreased lymphocyte cell number J:211773
enlarged lymph nodes J:211773
increased eosinophil cell number J:211773
\Amelxem1(IMPC)Ccpcz/\Amelxem1(IMPC)Ccpcz
(C57BL/6N-Amelxem1(IMPC)Ccpcz/Ccpcz)
abnormal thymus morphology J:211773
enlarged thymus J:211773
\Amer1tm1.2Nbar/Y
(involves: 129S4/SvJae * C57BL/6 * CD-1 * SJL)
spleen hypoplasia J:173242
\AmfrGt(IST12797A11)Tigm/\AmfrGt(IST12797A11)Tigm
(C57BL/6-AmfrGt(IST12797A11)Tigm)
liver inflammation J:221247
\Amhr2tm3(cre)Bhr/\Amhr2+
\Ptentm1Hwu/\Ptentm1Hwu

(involves: 129S4/SvJae * 129S7/SvEvBrd * C57BL/6)
decreased uterine NK cell number J:170203
\Amotl2em1(IMPC)Mbp/\Amotl2em1(IMPC)Mbp
(C57BL/6NCrl-Amotl2em1(IMPC)Mbp/MbpMmucd)
increased monocyte cell number J:211773
\Ampd1tm1b(KOMP)Wtsi/\Ampd1+
(C57BL/6N-Ampd1tm1b(KOMP)Wtsi/Ucd)
decreased neutrophil cell number J:211773
\Ampd1tm1b(KOMP)Wtsi/\Ampd1tm1b(KOMP)Wtsi
(C57BL/6N-Ampd1tm1b(KOMP)Wtsi/Ucd)
enlarged lymph nodes J:211773
\Ampd2tm1Tm/\Ampd2tm1Tm
(involves: 129S2/SvPas)
immune system phenotype J:201211
\Ampd3tm1Tm/\Ampd3tm1Tm
(Not Specified)
lung inflammation J:201211
\Ampd3tm1Tm/\Ampd3tm1Tm
\Pklrslc/\Pklrslc

(involves: CBA/NSlc)
enlarged spleen J:203909
\Ampd3tm2a(KOMP)Wtsi/\Ampd3tm2a(KOMP)Wtsi
(B6JTyr;B6N-Ampd3tm2a(KOMP)Wtsi/Wtsi)
increased leukocyte cell number J:165965
\Amtem1(IMPC)Tcp/\Amt+
(C57BL/6N-Amtem1(IMPC)Tcp/Cmmr)
decreased lymphocyte cell number J:211773
\Amtnem1(IMPC)Mbp/\Amtnem1(IMPC)Mbp
(C57BL/6N-Amtnem1(IMPC)Mbp/MbpMmucd)
abnormal spleen morphology J:211773
enlarged lymph nodes J:211773
small spleen J:211773
\anan/\anan
(involves: C57BL/6 * C57BL/10Sg * C57BR/c)
increased anti-nuclear antigen antibody level J:169366
\anan/\anan+
(involves: C57BL/6 * C57BL/10Sg * C57BR/c)
increased anti-nuclear antigen antibody level J:169366
\anaya/\anaya
(involves: C57BL/6 * C57BL/10Sg * C57BR/c)
increased anti-nuclear antigen antibody level J:169366
\andra/\andra
(involves: C57BL/6 * C57BL/10Sg * C57BR/c)
increased anti-nuclear antigen antibody level J:169366
\anem/\anem
(BALB/c-anem)
increased leukocyte cell number J:227974
\Angtm1.1(KOMP)Vlcg/\Angtm1.1(KOMP)Vlcg
(C57BL/6N-Angtm1.1(KOMP)Vlcg/Ucd)
increased eosinophil cell number J:211773
\Angtm1Dats/\Angtm1Dats
(Not Specified)
decreased leukocyte cell number J:236081
increased lymphocyte cell number J:236081
\Angpt1tm1.1Seq/\Angpt1tm1.1Seq
\Angpt2tm1c(KOMP)Seq/\Angpt2tm1c(KOMP)Seq
\Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/?
\Tg(tetO-cre)1Jaw/0

(involves: 129 * C57BL/6NCr)
abnormal lymphatic vessel morphology J:217296
\Angpt2em1(IMPC)Mbp/\Angpt2+
(C57BL/6NCrl-Angpt2em1(IMPC)Mbp/Mmucd)
abnormal lymph node morphology J:211773
enlarged lymph nodes J:211773
\Angpt2em1(IMPC)Mbp/\Angpt2em1(IMPC)Mbp
(C57BL/6NCrl-Angpt2em1(IMPC)Mbp/Mmucd)
abnormal lymph node morphology J:211773
abnormal thymus morphology J:211773
enlarged lymph nodes J:211773
small thymus J:211773
\Angpt2tm1Gdy/\Angpt2tm1Gdy
(involves: 129P2/OlaHsd * C57BL/6)
abnormal lymphatic vessel morphology J:89618
\Angpt2tm2(Angpt1)Gdy/\Angpt2tm2(Angpt1)Gdy
(involves: 129P2/OlaHsd * C57BL/6)
immune system phenotype J:89618
\Angptl2tm1Yo/\Angptl2tm1Yo
(B6.Cg-Angptl2tm1Yo)
impaired macrophage chemotaxis J:152387
\Angptl3tm2b(KOMP)Wtsi/\Angptl3tm2b(KOMP)Wtsi
(C57BL/6N-Angptl3tm2b(KOMP)Wtsi/Ccpcz)
enlarged lymph nodes J:211773
\Angptl4Gt(OST352973)Lex/\Angptl4Gt(OST352973)Lex
(involves: 129S5/SvEvBrd * C57BL/6)
abnormal lymphatic vessel morphology J:122968
abnormal mesenteric lymph node morphology J:122968
\Angptl4tm1Lex/\Angptl4tm1Lex
(involves: 129S5/SvEvBrd * C57BL/6)
abnormal lymphatic vessel morphology J:122968
abnormal mesenteric lymph node morphology J:122968
\Ank1ity16/\Ank1+
(involves: 129S1/Sv * 129X1/SvJ * DBA/2J)
increased susceptibility to bacterial infection J:199427
increased susceptibility to bacterial infection induced morbidity/mortality J:199427
\Ank1ity16/\Ank1ity16
(involves: 129S1/Sv * 129X1/SvJ * DBA/2J)
decreased spleen iron level J:199427
enlarged spleen J:199427
glomerulonephritis J:199427
increased leukocyte cell number J:199427
increased lymphocyte cell number J:199427
increased neutrophil cell number J:199427
increased susceptibility to bacterial infection J:199427
increased susceptibility to bacterial infection induced morbidity/mortality J:199427
\Ank1M1Btlr/\Ank1M1Btlr
(C57BL/6J-Ank1m1Btlr)
abnormal spleen morphology J:203831
enlarged spleen J:203831
increased spleen iron level J:203831
\Ank1M1Wlst/\Ank1+
(involves: 129S1/SvImJ * C3H/HeJ * C57BL/6)
enlarged spleen J:170562
\Ank1M1Wlst/\Ank1M1Wlst
(involves: C3H/HeJ * C57BL/6)
abnormal leukocyte cell number J:170562
\Ank1M1Wlst/\Ank1M1Wlst
(involves: 129S1/SvImJ * C3H/HeJ * C57BL/6)
abnormal myelopoiesis J:170562
enlarged spleen J:170562
\Ank1MRI23420/\Ank1+
(SJL/J-Ank1MRI23420)
abnormal spleen morphology J:187820
decreased susceptibility to parasitic infection J:187820
decreased susceptibility to parasitic infection induced morbidity/mortality J:187820
enlarged spleen J:187820
increased spleen iron level J:187820
increased spleen weight J:187820
\Ank1MRI23420/\Ank1MRI23420
(SJL/J-Ank1MRI23420)
enlarged spleen J:187820
increased spleen weight J:187820
\Ank1nb/\Ank1+
(involves: C57BL/6J * WB/Re)
decreased susceptibility to parasitic infection J:111131
\Ank1nb/\Ank1nb
(either: (involves: non-inbred stock) or (involves: C57BL/6) or (involves: WB/Re))
abnormal thymus development J:30699
enlarged lymph nodes J:30699
enlarged spleen J:30699
increased leukocyte cell number J:30699
\Ank1nb/\Ank1nb
(involves: C57BL/6J * WB/Re)
decreased susceptibility to parasitic infection J:111131
\Ank1nb/\Ank1nb
((WB.Cg-Ank1nb/BrkJ x B6.Cg-Ank1nb/BrkJ)F1)
enlarged spleen J:162532
\Ank1Rbc2/\Ank1+
(involves: 129S1/Sv * BALB/c)
decreased susceptibility to parasitic infection J:148127
\Ank1Rbc2/\Ank1Rbc2
(involves: 129S1/Sv * BALB/c)
enlarged spleen J:148127
\Ankank/\Ankank
(involves: C3HeB/FeJ * C57BL/6J * JGBF/LeJ)
autoimmune arthritis J:63420
\Anktm1.1Ejr/\Ank+
(B6.129-Anktm1.1Ejr)
abnormal osteoclast differentiation J:168526
\Anktm1.1Ejr/\Anktm1.1Ejr
(B6.129-Anktm1.1Ejr)
abnormal osteoclast differentiation J:168526
\Ankfy1tm1b(KOMP)Mbp/\Ankfy1+
(C57BL/6N-Ankfy1tm1b(KOMP)Mbp/Tcp)
increased monocyte cell number J:211773
\Ankrd2tm1Krc/\Ankrd2tm1Krc
(involves: 129 * Black Swiss)
abnormal inflammatory response J:214867
\Ankrd11tm1c(EUCOMM)Wtsi/\Ankrd11tm1c(EUCOMM)Wtsi
\E2f1Tg(Wnt1-cre)2Sor/\E2f1+

(involves: C3H * C57BL/6 * C57BL/6N)
decreased osteoclast cell number J:306391
\Ankrd11Yod/\Ankrd11+
(involves: BALB/cAnNCrl * C3H/HeH)
decreased osteoclast cell number J:136455
\Ankrd31em1(IMPC)Hmgu/\Ankrd31em1(IMPC)Hmgu
(C57BL/6NCrl-Ankrd31em1(IMPC)Hmgu/Ieg)
abnormal spleen morphology J:211773
\Ankrd46em1(IMPC)Mbp/\Ankrd46em1(IMPC)Mbp
(C57BL/6NCrl-Ankrd46em1(IMPC)Mbp/MbpMmucd)
increased monocyte cell number J:211773
\Ankrd49em1(IMPC)Tcp/\Ankrd49+
(C57BL/6NCrl-Ankrd49em1(IMPC)Tcp/Cmmr)
enlarged lymph nodes J:211773
enlarged thymus J:211773
\Ankrd52em1(IMPC)J/\Ankrd52+
(C57BL/6NJ-Ankrd52em1(IMPC)J/Mmjax)
increased leukocyte cell number J:211773
\Ankrd60em1(IMPC)J/\Ankrd60em1(IMPC)J
(C57BL/6NJ-Ankrd60em1(IMPC)J/Mmjax)
decreased leukocyte cell number J:211773
\Ano2em1(IMPC)Ccpcz/\Ano2em1(IMPC)Ccpcz
(C57BL/6NCrl-Ano2em1(IMPC)Ccpcz/Ccpcz)
abnormal lymph node morphology J:211773
abnormal thymus morphology J:211773
enlarged lymph nodes J:211773
enlarged thymus J:211773
\Ano5em1Huyi/\Ano5em1Huyi
(C57BL/6N-Ano5em1Huyi)
periodontium inflammation J:294237
\Ano5em2Huyi/\Ano5em2Huyi
(C57BL/6-Ano5em2Huyi)
abnormal osteoclast physiology J:336715
decreased osteoclast cell number J:336715
osteomyelitis J:336715
\Ano6em3(IMPC)Tcp/\Ano6+
(C57BL/6NCrl-Ano6em3(IMPC)Tcp/Tcp)
enlarged lymph nodes J:211773
\Anpeptm1.1Lsha/\Anpeptm1.1Lsha
(B6.Cg-Anpeptm1.1Lsha)
abnormal macrophage physiology J:163945
immune system phenotype J:163945
increased CD4-positive, alpha-beta T cell number J:163945
\Anta/\Anta+
(involves: C57BL/6 * C57BL/10 * C57BR/cd)
glomerulonephritis J:169366
increased anti-nuclear antigen antibody level J:169366
\Anth2CBA/J/?
(involves: A/J * CBA/J)
decreased susceptibility to bacterial infection J:9501
\AnthC3H/HeNCrj/\AnthC3H/HeNCrj
(involves: C3H/HeNCrj * C57BL/6NCrj)
decreased susceptibility to bacterial infection J:11149
\AnthC3H/HeNCrj/\AnthC57BL/6NCrj
(involves: C3H/HeNCrj * C57BL/6NCrj)
decreased susceptibility to bacterial infection J:11149
\Antxr1tm1.2Lepp/\Antxr1tm1.2Lepp
(involves: 129 * C57BL/6)
immune system phenotype J:150952
\Antxr2tm1.1Jkit/\Antxr2tm1.1Jkit
(involves: 129 * C57BL/6)
lymphangiectasis J:187210
\Antxr2tm1.2Lepp/\Antxr2tm1.2Lepp
(involves: C57BL/6)
decreased susceptibility to bacterial infection induced morbidity/mortality J:150952
\anx/\anx
(B6C3Fe a/a-anx/J)
abnormal inflammatory response J:103396
decreased spleen weight J:7689
increased thymus weight J:7689
pale spleen J:7689
small spleen J:7689
\anx/\anx
(involves: DW/J * M. m. domesticus poschiavinus * Swiss)
abnormal spleen morphology J:13936
small spleen J:13936
\Anxa1em1(IMPC)Ccpcz/\Anxa1em1(IMPC)Ccpcz
(C57BL/6NCrl-Anxa1em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged spleen J:211773
enlarged thymus J:211773
small spleen J:211773
\Anxa1tm1Rjf/\Anxa1+
(Not Specified)
increased inflammatory response J:81498
\Anxa1tm1Rjf/\Anxa1tm1Rjf
(Not Specified)
abnormal leukocyte physiology J:81498
impaired macrophage phagocytosis J:81498
increased inflammatory response J:81498
\Anxa1tm1Rjf/\Anxa1tm1Rjf
(involves: BALB/c)
increased susceptibility to induced colitis J:142735
\Anxa5tm1Epo/\Anxa5tm1Epo
(involves: 129P2/OlaHsd * C57BL/6)
abnormal cytokine secretion J:117249
abnormal inflammatory response J:117249
decreased susceptibility to type IV hypersensitivity reaction J:117249
\Anxa5tm1Epo/\Anxa5tm1Epo
\Anxa6tm1Moss/\Anxa6tm1Moss

(involves: 129P2/OlaHsd * C57BL/6)
decreased dendritic cell number J:193886
increased B cell number J:193886
\Anxa5tm1Epo/\Anxa5tm1Epo
\Anxa6tm1Moss/\Anxa6tm1Moss
\Col10a1tm1Ksec/\Col10a1tm1Ksec

(involves: 129P2/OlaHsd * 129S/SvEv * C57BL/6)
decreased dendritic cell number J:193886
increased B cell number J:193886
increased T-helper cell number J:193886
\Anxa6tm1Moss/\Anxa6tm1Moss
(involves: 129P2/OlaHsd * C57BL/6)
immune system phenotype J:58609
\Anxa7tm1Pll/\Anxa7+
(Not Specified)
pancreas inflammation J:58572
\Anxa8tm1Resc/\Anxa8tm1Resc
\Tg(Pgk1-cre)1Lni/0

(involves: 129 * C57BL/6J * BALB/c)
impaired leukocyte tethering or rolling J:225224
\Aoahtm1Rsm/\Aoahtm1Rsm
(involves: 129S6/SvEvTac)
abnormal humoral immune response J:90493
\Aoc3tm1Salm/\Aoc3tm1Salm
(involves: 129S6/SvEvTac * 129S7/SvEvBrd)
abnormal cellular extravasation J:95656
abnormal leukocyte adhesion J:95656
abnormal leukocyte migration J:95656
decreased inflammatory response J:95656
impaired leukocyte tethering or rolling J:95656
\Aod1aA/J/?
(involves: A/J * C57BL/6J)
ovary inflammation J:83714
\Aod1bC57BL/6J/?
(involves: A/J * C57BL/6J)
ovary inflammation J:83714
\Aod3A/J/?
(A/J)
ovary inflammation J:78005
\aol/\aol
(involves: C3H * C57BL/6)
osteoarthritis J:115238
\Ap1b1b2b1660Clo/\Ap1b1b2b1660Clo
(C57BL/6J-Ap1b1b2b1660Clo)
absent spleen J:175213
spleen hypoplasia J:175213
\Ap1g1tm1Schu/\Ap1g1+
(either: (involves: 129P2/OlaHsd * 129X1/SvJ) or (involves: 129P2/OlaHsd * C57BL/6J))
decreased CD4-positive, alpha-beta T cell number J:53252
\Ap2b1b2b2321Clo/\Ap2b1b2b2321Clo
(C57BL/6J-Ap2b1b2b2321Clo)
thymus hypoplasia J:175213
\Ap3b1m1Btlr/\Ap3b1m1Btlr
(C57BL/6J-Ap3b1m1Btlr)
increased susceptibility to Herpesvirales infection J:132673
\Ap3b1pe/\Ap3b1pe
\Hps1ep/\Hps1ep

(involves: C3H/He * C3HeB/FeJ * C57BL/6J)
abnormal monocyte morphology J:85431
lung inflammation J:85431
\Ap4e1tm1b(KOMP)Wtsi/\Ap4e1tm1b(KOMP)Wtsi
(C57BL/6N-Ap4e1tm1b(KOMP)Wtsi/Bay)
abnormal spleen morphology J:211773
\Ap4e1tm1b(KOMP)Wtsi/\Ap4e1tm1b(KOMP)Wtsi
(C57BL/6N-Ap4e1tm1b(KOMP)Wtsi/Ucd)
enlarged lymph nodes J:211773
\Ap4e1tm1b(KOMP)Wtsi/\Ap4e1tm1b(KOMP)Wtsi
(C57BL/6N-Ap4e1tm1b(KOMP)Wtsi/MbpMmucd)
abnormal spleen morphology J:211773
enlarged spleen J:211773
\Ap4m1tm1b(EUCOMM)Wtsi/\Ap4m1tm1b(EUCOMM)Wtsi
(C57BL/6N-Ap4m1tm1b(EUCOMM)Wtsi/Wtsi)
increased leukocyte cell number J:211773
\Ap5m1em1(IMPC)Mbp/\Ap5m1em1(IMPC)Mbp
(C57BL/6N-Ap5m1em1(IMPC)Mbp/MbpMmucd)
abnormal lymph node morphology J:211773
enlarged lymph nodes J:211773
\Apaf1tm1Mak/\Apaf1tm1Mak
(either: (involves: 129P2/OlaHsd * C57BL/6) or (involves: 129P2/OlaHsd * CD-1))
immune system phenotype J:49841
\Apba3tm1.1Ski/\Apba3tm1.1Ski
\Lyz2tm1(cre)Ifo/\Lyz2+

(B6.129-Apba3tm1.1Ski Lyz2tm1(cre)Ifo)
decreased susceptibility to endotoxin shock J:176742
\Apba3tm1.2Ski/\Apba3tm1.2Ski
(B6.129-Apba3tm1.2Ski)
abnormal macrophage physiology J:176742
decreased circulating interleukin-12 level J:176742
decreased circulating tumor necrosis factor level J:176742
decreased interleukin-12 secretion J:176742
decreased susceptibility to endotoxin shock J:176742
decreased tumor necrosis factor secretion J:176742
\Apbb1ipem1(IMPC)Ccpcz/\Apbb1ipem1(IMPC)Ccpcz
(C57BL/6N-Apbb1ipem1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
decreased CD8-positive, alpha-beta T cell number J:211773
decreased CD8-positive, naive alpha-beta T cell number J:211773
enlarged spleen J:211773
enlarged thymus J:211773
increased effector memory CD8-positive, alpha-beta T cell number J:211773
increased eosinophil cell number J:211773
increased leukocyte cell number J:211773
increased monocyte cell number J:211773
increased neutrophil cell number J:211773
increased spleen weight J:211773
\ApcMin/\Apc+
(C57BL/6J-ApcMin)
decreased macrophage cell number J:85142
\ApcMin/\Apc+
(involves: 129 * C57BL/6)
decreased NK cell number J:156864
decreased splenocyte number J:156864
decreased T cell number J:156864
\ApcMin/\Apc+
(C57BL/6J-ApcMin/J)
abnormal interleukin secretion J:305794
\ApcMin/\Apc+
\Elp3tm1.1Tac/\Elp3tm1.1Tac
\Tg(Vil1-cre)997Gum/0

(involves: C57BL/6 * C57BL/6J * C57BL/6NTac * SJL)
immune system phenotype J:227334
\ApcMin/\Apc+
\Esr2tm1Mma/\Esr2tm1Mma

(involves: 129S2/SvPas * C57BL/6J)
colitis J:118600
\ApcMin/\Apc+
\Mapkapk2tm1.2Gkl/\Mapkapk2tm1.2Gkl

(involves: BALB/cJ * C57BL/6J)
abnormal chemokine secretion J:262876
decreased interleukin-6 secretion J:262876
\ApcMin/\Apc+
\Tg(Rorc-EGFP)1Ebe/?

(involves: C57BL/6)
abnormal effector T cell morphology J:137020
enlarged mesenteric lymph nodes J:137020
lymph node hyperplasia J:137020
\Apctm1Kk/\Apctm1Kk
\Tg(Lck-cre)1Cwi/?

(involves: 129S6/SvEvTac * C57BL/6 * DBA/2)
abnormal T cell differentiation J:100461
arrested T cell differentiation J:100461
increased circulating tumor necrosis factor level J:128606
increased double-negative T cell number J:100461
increased mast cell number J:128606
small thymus J:100461
thymus hypoplasia J:100461
\Apctm1Rak/\Apc+
\Smad4E6sad/\Smad4+

(B6.129P2-Apctm1Rak Smad4E6sad/+ +)
enlarged spleen J:107273
\Apctm1Tno/\Apc+
\Ptentm2Mak/\Ptentm2Mak
\Tg(Cyp1a1-cre/ERT)1Dwi/0

(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * CBA)
peritoneal inflammation J:143082
\Apctm2.1Cip/\Apc+
\Atg7tm1Tchi/\Atg7tm1Tchi
\Tg(Vil1-cre/ERT2)23Syr/0

(involves: 129P2/OlaHsd * C57BL/6 * C57BL/6NCrlj * CBA/JNCrlj * DBA/2)
abnormal immune system physiology J:227287
increased CD8-positive, alpha-beta T cell number J:227287
increased CD103-positive CD11b-low dendritic cell number J:227287
increased interleukin-1 beta secretion J:227287
increased interleukin-10 secretion J:227287
increased regulatory T cell number J:227287
\Apctm2.1Cip/\Apctm2.1Cip
\Lect2tm1Ymg/\Lect2tm1Ymg
\Tg(Ttr-cre/Esr1*)1Vco/0

(B6.Cg-Lect2tm1Ymg Apctm2.1Cip Tg(Ttr-cre/Esr1*)1Vco)
abnormal chemokine level J:184496
abnormal neutrophil physiology J:184496
abnormal NK T cell physiology J:184496
decreased interferon-gamma secretion J:184496
increased interleukin-4 secretion J:184496
increased NK T cell number J:184496
liver inflammation J:184496
\Apctm2.1Cip/\Apctm2.1Cip
\Tg(Ttr-cre/Esr1*)1Vco/0

(B6.Cg-Apctm2.1Cip Tg(Ttr-cre/Esr1*)1Vco)
abnormal NK T cell physiology J:184496
decreased NK T cell number J:184496
increased interferon-gamma secretion J:184496
increased interleukin-4 secretion J:184496
liver inflammation J:184496
\Apctm2Rak/\Apc+
\Trp53tm1Brn/\Trp53tm1Brn
\Tg(Pdx1-cre)6Tuv/0

(involves: 129/Sv * 129P2/OlaHsd * C57BL/6J * FVB/N * SJL)
abnormal cytokine level J:234310
\Apctm2Rak/\Apctm2Rak
\Tg(KRT14-cre)8Brn/0

(involves: 129/Sv * C57BL/6J * FVB/N * SJL)
abnormal Hassall's corpuscle morphology J:114152
abnormal thymus morphology J:114152
decreased thymocyte number J:114152
small thymus J:114152
\Apcstm1Mpe/\Apcs+
(B6.Cg-Apcstm1Mpe)
abnormal spleen red pulp morphology J:90502
abnormal spleen white pulp morphology J:90502
glomerulonephritis J:90502
increased autoantibody level J:90502
increased spleen white pulp amount J:90502
\Apcstm1Mpe/\Apcstm1Mpe
(B6.Cg-Apcstm1Mpe)
abnormal spleen morphology J:90502
abnormal spleen red pulp morphology J:90502
abnormal spleen white pulp morphology J:90502
decreased susceptibility to bacterial infection J:125473
decreased susceptibility to bacterial infection induced morbidity/mortality J:125473
glomerulonephritis J:90502
increased autoantibody level J:90502
increased spleen white pulp amount J:90502
increased susceptibility to bacterial infection induced morbidity/mortality J:125473
\Apcstm1Mpe/\Apcstm1Mpe
(129.Cg-Apcstm1Mpe)
decreased susceptibility to bacterial infection induced morbidity/mortality J:125473
glomerulonephritis J:90502
immune system phenotype J:90502
increased susceptibility to bacterial infection induced morbidity/mortality J:125473
\Apcstm1Smae/\Apcstm1Smae
(involves: 129S/SvEv * C57BL/6)
decreased susceptibility to endotoxin shock J:71194
increased autoantibody level J:71194
\Apex1tm1Cur/\Apex1+
(involves: 129S1/Sv)
increased circulating interleukin-1 alpha level J:119957
increased circulating interleukin-10 level J:119957
\Apex1tm1Ecf/\Apex1+
(either: (involves: 129/Sv) or (involves: 129/Sv * C57BL/6))
heart inflammation J:70397
myocarditis J:70397
pericarditis J:70397
\Apex2em1(IMPC)H/\Apex2em1(IMPC)H
(C57BL/6NTac-Apex2em1(IMPC)H/H)
decreased lymphocyte cell number J:211773
increased neutrophil cell number J:211773
\Apex2tm1Yun/Y
(B6.129S-Apex2tm1Yun)
decreased B cell number J:95267
decreased leukocyte cell number J:95267
decreased splenocyte proliferation J:95267
decreased T cell number J:95267
decreased thymocyte number J:95267
thymus atrophy J:95267
\AplfGt(RRF189)Byg/\AplfGt(RRF189)Byg
(involves: 129P2/OlaHsd * C57BL/6J)
abnormal class switch recombination J:168260
\Apoa4tm1Bres/\Apoa4tm1Bres
(B6.129S4-Apoa4tm1Bres)
increased susceptibility to induced colitis J:91357
\Apobtm2Sgy/\Apobtm2Sgy
\Ldlrtm1Her/\Ldlrtm1Her
\Tg(Ins-Igf2)1Fbos/?

(involves: 129S7/SvEvBrd * C57BL/6 * C57BL/6J * SJL)
aortitis J:227165
\Apobec1em1(IMPC)Ccpcz/\Apobec1em1(IMPC)Ccpcz
(C57BL/6NCrl-Apobec1em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged spleen J:211773
enlarged thymus J:211773
small spleen J:211773
\Apobec3Gt(XN450)Byg/\Apobec3Gt(XN450)Byg
(B6.Cg-Apobec3Gt(XN450)Byg)
increased susceptibility to Retroviridae infection J:118597
\Apobec3Gt(XN450)Byg/\Apobec3Gt(XN450)Byg
(B6.129P2-Apobec3Gt(XN450)Byg)
abnormal immunoglobulin level J:138778
increased susceptibility to Retroviridae infection J:138778
\Apobec3Gt(XN450)Byg/\Apobec3Gt(XN450)Byg
(129P2/OlaHsd-Apobec3Gt(XN450)Byg)
abnormal immunoglobulin level J:138778
increased susceptibility to Retroviridae infection J:138778
\Apobec3Gt(XN450)Byg/\Apobec3Rfv3-s
\H2b/\H2b

(involves: A.BY * C57BL/6)
abnormal immunoglobulin level J:138778
\Apobec3Gt(XN450)Byg/\Apobec3Rfv3-s
\H2b/\H2d

(involves: BALB/c * C57BL/6)
abnormal immunoglobulin level J:138778
increased susceptibility to Retroviridae infection J:138778
increased susceptibility to Retroviridae infection induced morbidity/mortality J:138778
\Apobec3Rfv3-r/\Apobec3+
((B10.A x A)F1)
decreased susceptibility to Retroviridae infection J:6147
immune system phenotype J:41946, J:6261, J:6147
\Apoc4tm1.1(KOMP)Mbp/\Apoc4tm1.1(KOMP)Mbp
(C57BL/6N-Apoc4tm1.1(KOMP)Mbp/Ieg)
increased leukocyte cell number J:211773
\Apoetm1.1Mae/\Apoetm1.1Mae
\Tg(Fabp4-cre)1Rev/0

(B6.Cg-Apoetm1.1Mae Tg(Fabp4-cre)1Rev)
decreased macrophage cell number J:219838
increased macrophage cell number J:219838
\Apoetm1Bres/\Apoetm1Bres
\Bcl2tm1Irt/\Bcl2tm1Irt
\Lyz2tm1(cre)Ifo/\Lyz2+

(involves: 129P2/OlaHsd * C57BL/6)
increased macrophage apoptosis J:144243
\Apoetm1Bres/\Apoetm1Bres
\Cx3cr1tm1Ifc/\Cx3cr1tm1Ifc

(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)
impaired macrophage chemotaxis J:81822
\Apoetm1Bres/\Apoetm1Bres
\Mapk9tm1Flv/\Mapk9tm1Flv

(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6)
abnormal macrophage morphology J:94044
abnormal macrophage physiology J:94044
increased macrophage derived foam cell number J:94044
\Apoetm1Khw/\Apoetm1Khw
\Tg(Mx1-cre)29-4Her/0

(B6.Cg-Apoetm1Khw Tg(Mx1-cre)29-4Her)
immune system phenotype J:196923
\Apoetm1Rraf/\Apoetm1Rraf
\Tg(Mx1-cre)29-4Her/0

(B6.Cg-Apoetm1Rraf Tg(Mx1-cre)29-4Her)
immune system phenotype J:196923
\Apoetm1Unc/\Apoetm1Unc
(B6.129P2-Apoetm1Unc/J)
abnormal B cell activation J:133606
abnormal CD4-positive, alpha-beta T cell number J:108154, J:47027
abnormal immune serum protein physiology J:61564
abnormal immune system morphology J:47027
abnormal immune system physiology J:61564
abnormal T cell number J:47027
blood vessel inflammation J:91058
decreased follicular B cell number J:133606
decreased interferon-gamma secretion J:47027
decreased marginal zone B cell number J:133606
decreased susceptibility to type IV hypersensitivity reaction J:61564
increased anti-double stranded DNA antibody level J:133606
increased anti-nuclear antigen antibody level J:133606
increased autoantibody level J:133606
increased B cell number J:133606
increased IgM level J:61564
increased immunoglobulin level J:133606
increased marginal zone B cell number J:133606
increased spleen weight J:61564
increased susceptibility to systemic lupus erythematosus J:133606
increased T-helper 2 cell number J:47027
\Apoetm1Unc/\Apoetm1Unc
(involves: 129P2/OlaHsd * C57BL/6)
lung inflammation J:83615
\Apoetm1Unc/\Apoetm1Unc
(B6.129P2-Apoetm1Unc)
abnormal cell-mediated immunity J:125366
abnormal dendritic cell physiology J:125366
increased CD4-positive, alpha-beta T cell number J:125366
increased susceptibility to parasitic infection J:125366
\Apoetm1Unc/\Apoetm1Unc
(B6.Cg-Apoetm1Unc Faslpr)
increased anti-double stranded DNA antibody level J:133606
increased anti-nuclear antigen antibody level J:133606
increased immunoglobulin level J:133606
increased susceptibility to systemic lupus erythematosus J:133606
\Apoetm1Unc/\Apoetm1Unc
\Cbstm1Unc/\Cbstm1Unc
\Tg(Mt1-CBS)25Waku/0

(involves: 129P2/OlaHsd * C3H * C57BL/6)
increased circulating tumor necrosis factor level J:168131
increased Ly6C high monocyte number J:168131
increased monocyte cell number J:168131
\Apoetm1Unc/\Apoetm1Unc
\Ccr1tm1Gao/\Ccr1tm1Gao

(involves: 129P2/OlaHsd * 129S4/SvJae)
increased interferon-gamma secretion J:128063
\Apoetm1Unc/\Apoetm1Unc
\Ccr2tm1Ifc/\Ccr2tm1Ifc

(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)
impaired macrophage chemotaxis J:111471
\Apoetm1Unc/\Apoetm1Unc
\Ccr2tm1Ifc/\Ccr2tm1Ifc

(B6.Cg-Apoetm1Unc Ccr2tm1Ifc)
decreased monocyte cell number J:153310
\Apoetm1Unc/\Apoetm1Unc
\Ccr2tm1Ifc/\Ccr2tm1Ifc
\Cx3cl1tm1Lira/\Cx3cl1tm1Lira

(B6.Cg-Apoetm1Unc Cx3cl1tm1Lira Ccr2tm1Ifc)
decreased monocyte cell number J:153310
\Apoetm1Unc/\Apoetm1Unc
\Ccr5tm1Blck/\Ccr5tm1Blck

(involves: 129P2/OlaHsd * C57BL/6)
abnormal cytokine secretion J:128063
abnormal lymphocyte physiology J:128063
abnormal mononuclear phagocyte morphology J:128063
decreased interferon-gamma secretion J:128063
decreased T cell number J:128063
increased interleukin-10 secretion J:128063
\Apoetm1Unc/\Apoetm1Unc
\Ccr5tm1Kuz/\Ccr5tm1Kuz

(involves: 129P2/OlaHsd * C57BL/6)
abnormal cytokine secretion J:128063
abnormal lymphocyte physiology J:128063
abnormal mononuclear phagocyte morphology J:128063
decreased interferon-gamma secretion J:128063
decreased T cell number J:128063
increased interleukin-10 secretion J:128063
\Apoetm1Unc/\Apoetm1Unc
\Cd36tm1Mfe/\Cd36tm1Mfe

(involves: 129P2/OlaHsd * 129S1/Sv * C57BL/6)
abnormal macrophage derived foam cell morphology J:61672
abnormal macrophage physiology J:61672
\Apoetm1Unc/\Apoetm1Unc
\Cx3cl1tm1Sgs/\Cx3cl1tm1Sgs

(B6.129-Apoetm1Unc Cx3cl1tm1Sgs)
impaired macrophage chemotaxis J:95279
increased macrophage derived foam cell number J:95279
\Apoetm1Unc/\Apoetm1Unc
\Cxcl10tm1Adl/\Cxcl10tm1Adl

(B6.129-Cxcl10tm1Adl Apoetm1Unc)
decreased CD4-positive, alpha-beta T cell number J:166204
impaired macrophage chemotaxis J:166204
\Apoetm1Unc/\Apoetm1Unc
\Cyp4f13Gt(OST14770)Lex/\Cyp4f13Gt(OST14770)Lex

(involves: 129P2/OlaHsd * 129S5/SvEvBrd * C57BL/6)
abnormal macrophage chemotaxis J:289999
\Apoetm1Unc/\Apoetm1Unc
\Cyp19a1tm1Esi/\Cyp19a1tm1Esi

(involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6)
increased circulating C-reactive protein level J:184647
increased circulating interleukin-6 level J:184647
increased circulating tumor necrosis factor level J:184647
\Apoetm1Unc/\Apoetm1Unc
\Faslpr/\Faslpr

(MRL.Cg-Apoetm1Unc Faslpr)
increased anti-double stranded DNA antibody level J:133606
increased anti-nuclear antigen antibody level J:133606
increased autoantibody level J:133606
increased immunoglobulin level J:133606
increased susceptibility to systemic lupus erythematosus J:133606
\Apoetm1Unc/\Apoetm1Unc
\Faslpr/\Faslpr

(B6.Cg-Apoetm1Unc Faslpr)
decreased autoantibody level J:121671
decreased CD4-positive, alpha-beta T cell number J:121671
decreased CD8-positive, alpha-beta T cell number J:121671
enlarged lymph nodes J:121671
enlarged spleen J:121671
enlarged thymus J:121671
glomerulonephritis J:121671
increased anti-double stranded DNA antibody level J:121671
increased autoantibody level J:121671
increased IgG level J:121671
\Apoetm1Unc/\Apoetm1Unc
\Faslgld/\Faslgld

(B6.Cg-Faslgld Apoetm1Unc)
abnormal lymph node morphology J:91058
blood vessel inflammation J:91058
enlarged lymph nodes J:200141, J:91058
enlarged spleen J:91058
impaired macrophage phagocytosis J:91058
increased anti-nuclear antigen antibody level J:200141, J:91058
increased autoantibody level J:91058
increased IgG level J:91058
increased spleen weight J:200141, J:91058
increased T cell number J:91058
kidney inflammation J:200141
\Apoetm1Unc/\Apoetm1Unc
\Gja5tm1Mchn/\Gja5tm1Mchn
\Tg(TIE2-lacZ)182Sato/0

(involves: 129P2/OlaHsd * BALB/c * C57BL/6)
abnormal neutrophil physiology J:162224
alveolitis J:162224
\Apoetm1Unc/\Apoetm1Unc
\Glg1Gt(RST092)Byg/\Glg1+

(B6J.129P2-Apoetm1Unc Glg1Gt(RST092)Byg)
decreased macrophage cell number J:226586
impaired macrophage chemotaxis J:226586
\Apoetm1Unc/\Apoetm1Unc
\Hptm1Alev/\Hptm1Alev

(involves: 129)
abnormal macrophage chemotaxis J:134942
\Apoetm1Unc/\Apoetm1Unc
\Hsd11b1tm1Lex/\Hsd11b1tm1Lex

(B6.129-Hsd11b1tm1Lex Apoetm1Unc)
abnormal cytokine secretion J:199430
abnormal macrophage derived foam cell morphology J:199430
decreased macrophage cell number J:199430
decreased tumor necrosis factor secretion J:199430
immune system phenotype J:199430
\Apoetm1Unc/\Apoetm1Unc
\Il1r1tm1Imx/\Il1r1tm1Imx

(B6.129-Il1r1tm1Imx Apoetm1Unc)
decreased circulating interleukin-6 level J:148173
\Apoetm1Unc/\Apoetm1Unc
\Il1rntm1Dih/\Il1rntm1Dih

(involves: 129P2/OlaHsd * 129S/SvEv * C57BL/6)
abnormal macrophage chemotaxis J:132570
\Apoetm1Unc/\Apoetm1Unc
\Il10tm1Cgn/\Il10tm1Cgn

(involves: 129P2/OlaHsd * C57BL/6)
abnormal circulating cytokine level J:105858
increased circulating interferon-gamma level J:105858
increased circulating interleukin-12 level J:105858
\Apoetm1Unc/\Apoetm1Unc
\Itgb3tm1Hyn/\Itgb3tm1Hyn

(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6)
lung inflammation J:83615
\Apoetm1Unc/\Apoetm1Unc
\Klf15tm2Jain/\Klf15tm2Jain
\Tg(Tagln-cre)1Jjl/0

(involves: 129P2/OlaHsd * FVB/N)
blood vessel inflammation J:203920
increased macrophage cell number J:203920
\Apoetm1Unc/\Apoetm1Unc
\Mmp9tm1Tvu/\Mmp9tm1Tvu

(involves: 129P2/OlaHsd * 129S6/SvEvTac)
decreased macrophage cell number J:110044
\Apoetm1Unc/\Apoetm1Unc
\Ncf1tm1Shl/\Ncf1tm1Shl

(involves: 129P2/OlaHsd * 129S2/SvPas)
decreased acute inflammation J:123854
\Apoetm1Unc/\Apoetm1Unc
\Nck1tm1Paw/\Nck1tm1Paw
\Nck2tm3Paw/\Nck2tm3Paw
\Tg(Cdh5-cre/ERT2)1Rha/0

(involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6)
decreased inflammatory response J:326659
\Apoetm1Unc/\Apoetm1Unc
\Nfe2l2tm1Mym/\Nfe2l2tm1Mym

(involves: 129P2/OlaHsd * C57BL/6J)
abnormal macrophage physiology J:143903
\Apoetm1Unc/\Apoetm1Unc
\Pla2g15tm1Ytan/\Pla2g15tm1Ytan

(involves: 129S/SvEv * B6.129P2-Apoetm1Unc/J)
abnormal macrophage morphology J:97471
\Apoetm1Unc/\Apoetm1Unc
\Soat1tm1Far/\Soat1tm1Far

(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6J)
skin inflammation J:61147
\Apoetm1Unc/\Apoetm1Unc
\Spp1tm1Blh/\Spp1tm1Blh

(involves: 129P2/OlaHsd * 129S6/SvEvTac * Black Swiss * C57BL/6J)
abnormal macrophage physiology J:86531
\Apoetm1Unc/\Apoetm1Unc
\Tg(CAG-IL1RN)1Cga/?

(involves: 129P2/OlaHsd * C57BL/6 * DBA/1 * FVB)
decreased circulating serum amyloid protein level J:132570
\Apoetm1Unc/\Apoetm1Unc
\Tg(CAG-IL1RN)2Cga/?

(involves: 129P2/OlaHsd * C57BL/6 * DBA/1 * FVB)
decreased circulating serum amyloid protein level J:132570
\Apoetm1Unc/\Apoetm1Unc
\Tg(MSR1-Plau)1Ddi/0

(involves: 129P2/OlaHsd * C57BL/6 * SJL)
heart inflammation J:101486
\Apoetm1Unc/\Apoetm1Unc
\Thbs4tm1Olsa/\Thbs4tm1Olsa

(involves: 129P2/OlaHsd * C57BL/6J)
increased chemokine level J:345752
increased circulating interleukin-10 level J:345752
increased circulating tumor necrosis factor level J:345752
increased macrophage cell number J:345752
\Apoetm2(APOE*3)Mae/\Apoetm2(APOE*3)Mae
(involves: 129P2/OlaHsd * C57BL/6J)
decreased interleukin-6 secretion J:86768
decreased tumor necrosis factor secretion J:86768
\Apoetm2(APOE*3)Mae/\Apoetm2(APOE*3)Mae
\Tg(Thy1-APPSwDutIowa)BWevn/?

(involves: 129P2/OlaHsd * C57BL/6)
abnormal microglial cell morphology J:136318
\Apoetm3(APOE*4)Mae/\Apoetm3(APOE*4)Mae
(involves: 129P2/OlaHsd * C57BL/6)
abnormal response to infection J:138241
increased interleukin-6 secretion J:86768
increased tumor necrosis factor secretion J:86768
\Apoetm3(APOE*4)Mae/\Apoetm3(APOE*4)Mae
\Tg(Thy1-APPSwDutIowa)BWevn/?

(involves: 129P2/OlaHsd * C57BL/6)
abnormal microglial cell morphology J:136318
\Apoftm1.1(KOMP)Vlcg/\Apoftm1.1(KOMP)Vlcg
(C57BL/6N-Apoftm1.1(KOMP)Vlcg/Ucd)
increased basophil cell number J:211773
\Apol6em1Hsul/\Apol6em1Hsul
(Not Specified)
decreased inflammatory response J:344362
\Apol7cem4Gpt/\Apol7cem4Gpt
(C57BL/6JGpt-Apol7cem4Gpt/Gpt)
abnormal dendritic cell antigen presentation J:362930
abnormal dendritic cell physiology J:362930
\Apptm1b(KOMP)Wtsi/\App+
(C57BL/6N-Apptm1b(KOMP)Wtsi/Ics)
increased monocyte cell number J:211773
increased neutrophil cell number J:211773
\Apptm1Ck/\Apptm1Ck
\Tg(PDGFB-PSEN1M146L)2Jhd/0

(involves: 129 * Black Swiss * C57BL/6 * DBA/2 * SW)
abnormal microglial cell morphology J:102542
\Apptm2.1Ldad/\Apptm2.1Ldad
(involves: 129 * C57BL/6J)
myositis J:166989
\Apptm2.1Tcs/\Apptm2.1Tcs
(involves: C57BL/6)
microgliosis J:212758
\Apptm2.1Tcs/\Apptm2.1Tcs
\Casttm1Tcs/\Casttm1Tcs

(involves: 129P2/OlaHsd * C57BL/6)
microgliosis J:212758
\Apptm3.1Tcs/\Apptm3.1Tcs
(involves: C57BL/6)
microgliosis J:212758
\Apptm3.1Tcs/\Apptm3.1Tcs
\Mapttm1.1(MAPT)Tcs/\Mapttm1.1(MAPT)Tcs

(involves: 129S/SvEv * C57BL/6)
CNS inflammation J:278451
\Appl1Gt(XM073)Byg/\Appl1Gt(XM073)Byg
(B6.129P2-Appl1Gt(XM073)Byg)
immune system phenotype J:164696
increased T cell proliferation J:164696
\Appl1tm1.2Test/\Appl1tm1.2Test
(involves: 129X1/SvJ)
increased T cell proliferation J:164696
\Aprttm1Dwm/\Aprttm1Dwm
(129P2/OlaHsd-Aprttm1Dwm)
pyelonephritis J:38450
\Aprttm1Jat/\Aprttm1Jat
(involves: 129S2/SvPas * Black Swiss)
kidney inflammation J:33255
\Aprttm1Jat/\Aprttm1Jat
(involves: 129S2/SvPas * C57BL/6J)
kidney inflammation J:33255
\Aprttm1Vri/\Aprttm1Vri
(involves: 129P2/OlaHsd * C57BL/6)
kidney inflammation J:50874
\Aptxtm1Pmc/\Aptxtm1Pmc
\Atmtm2.1Mfgc/\Atmtm2.1Mfgc

(involves: 129 * C57BL/6)
abnormal CD4-positive helper T cell morphology J:316365
abnormal T cell differentiation J:316365
decreased T cell number J:316365
increased CD8-positive, alpha-beta T cell number J:316365
\Aqp1tm1b(EUCOMM)Wtsi/\Aqp1tm1b(EUCOMM)Wtsi
(C57BL/6N-Aqp1tm1b(EUCOMM)Wtsi/H)
increased neutrophil cell number J:211773
\Aqp3m1Btlr/\Aqp3m1Btlr
(C57BL/6J-Aqp3m1Btlr)
abnormal gut-associated lymphoid tissue morphology J:153279
increased susceptibility to induced colitis J:153279
\Aqp4tm1.1Lmno/\Aqp4tm1.1Lmno
(B6.Cg-Aqp4tm1.1Lmno)
increased susceptibility to parasitic infection J:193622
increased susceptibility to parasitic infection induced morbidity/mortality J:193622
\Aqp4tm1.1Mysi/\Aqp4tm1.1Mysi
(involves: C57BL/6JJcl * C57BL/6NCrlj * CBA/JNCrlj)
abnormal microglial cell physiology J:214906
\Aqp9tm1Nlsn/\Aqp9tm1Nlsn
(involves: 129S1/Sv)
decreased susceptibility to parasitic infection J:123305
\Aqp11tm1.1(KOMP)Vlcg/\Aqp11+
(B6N(Cg)-Aqp11tm1.1(KOMP)Vlcg/J)
decreased leukocyte cell number J:211773
\Aqp12tm1Rai/\Aqp12tm1Rai
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
increased susceptibility to induced pancreatitis J:155920
\ArTfm/Y
(involves: STOCK EdaTa Atp7aMo-blo)
abnormal myeloid leukocyte morphology J:110923
increased immature B cell number J:110923
\Artm1Chc/Y
\Tmem163Tg(ACTB-cre)2Mrt/0

(involves: 129S/SvEv * C57BL/6J * FVB/N)
increased osteoclast cell number J:81789
\Artm1Chc/\Artm1.1Chc
\Tmem163Tg(ACTB-cre)2Mrt/0

(involves: 129S/SvEv * C57BL/6J * FVB/N)
enlarged thymus J:87193
\Artm1Verh/Y
\Rnase10tm1(cre)Hht/\Rnase10+

(involves: 129S7/SvEvBrd * C57BL/6)
testis inflammation J:173897
\Araftm1Mmc/Y
(involves: 129P2/OlaHsd * C57BL/6)
small thymus J:33951
\Araftm1Mmc/\Araftm1Mmc
(involves: 129P2/OlaHsd * C57BL/6)
small thymus J:33951
\Arb2aem2(IMPC)Ccpcz/\Arb2aem2(IMPC)Ccpcz
(C57BL/6NCrl-Arb2aem2(IMPC)Ccpcz/Ph)
abnormal thymus morphology J:211773
decreased Ly6C-positive NK T cell number J:211773
enlarged thymus J:211773
\Arb2aTg(Tyr)TpNpln/\Arb2aTg(Tyr)TpNpln
(involves: FVB/N)
thymus hypoplasia J:260599
\Aregtm1Dle/\Aregtm1Dle
\Egftm1Dle/\Egftm1Dle
\Tgfatm1Unc/\Tgfatm1Unc

(involves: 129P2/OlaHsd * C57BL/6)
dermatitis J:54980
\Aregtm2c(EUCOMM)Hmgu/\Aregtm2c(EUCOMM)Hmgu
\Foxp3tm4(YFP/icre)Ayr/\Foxp3+

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6N)
immune system phenotype J:224904
increased susceptibility to Orthomyxoviridae infection J:224904
\Aregtm2c(EUCOMM)Hmgu/\Aregtm2c(EUCOMM)Hmgu
\Tg(Cd4-cre)1Cwi/0

(involves: C57BL/6 * C57BL/6N * DBA/2)
immune system phenotype J:224904
increased susceptibility to Orthomyxoviridae infection J:224904
\Arel1em1Bbc/\Arel1+
(C57BL/6J-Arel1em1Bbc)
decreased acute inflammation J:280563
decreased response to antigen J:280563
\Arel1em1Bbc/\Arel1em1Bbc
(C57BL/6J-Arel1em1Bbc)
decreased acute inflammation J:280563
decreased response to antigen J:280563
\Arf4tm1b(KOMP)Wtsi/\Arf4+
(C57BL/6N-Arf4tm1b(KOMP)Wtsi/Ucd)
abnormal spleen morphology J:211773
enlarged spleen J:211773
increased spleen weight J:211773
\Arfgap2tm1c(EUCOMM)Hmgu/\Arfgap2tm1c(EUCOMM)Hmgu
\Commd10Tg(Vav1-icre)A2Kio/\Commd10+

(involves: 129S4/SvJae * C57BL/6J * C57BL/6N * C57BL/10 * CBA/Ca)
immune system phenotype J:363611
\Arfgap2tm1c(EUCOMM)Hmgu/\Arfgap2tm1c(EUCOMM)Hmgu
\Lyz2tm1(cre)Ifo/\Lyz2+

(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6J * C57BL/6N)
immune system phenotype J:363611
\Arfgap2tm1c(EUCOMM)Hmgu/\Arfgap2tm1c(EUCOMM)Hmgu
\Sting1em1Jmin/\Sting1em1Jmin
\Commd10Tg(Vav1-icre)A2Kio/\Commd10+

(Not Specified)
abnormal splenic cell ratio J:363611
decreased CD8-positive, alpha-beta T cell number J:363611
decreased effector memory CD4-positive, alpha-beta T cell number J:363611
decreased interferon-gamma secretion J:363611
decreased interleukin-1 beta secretion J:363611
decreased susceptibility to autoimmune disorder J:363611
increased CD4-positive, alpha-beta memory T cell number J:363611
increased CD4-positive, alpha-beta T cell number J:363611
increased regulatory T cell number J:363611
\Arfgap2tm1c(EUCOMM)Hmgu/\Arfgap2tm1c(EUCOMM)Hmgu
\Tg(CAG-cre/Esr1*)5Amc/0

(involves: 129S4/SvJae * C57BL/6J * C57BL/6N)
abnormal macrophage activation involved in immune response J:363611
decreased interferon-beta secretion J:363611
decreased interleukin-6 secretion J:363611
decreased level of surface class I molecules J:363611
decreased level of surface class II molecules J:363611
decreased macrophage cytokine production J:363611
immune system phenotype J:363611
\Arfgap2tm1c(EUCOMM)Hmgu/\Arfgap2tm1c(EUCOMM)Hmgu
\Tg(Cd4-cre)1Cwi/0

(involves: 129S4/SvJae * C57BL/6J * C57BL/6N)
immune system phenotype J:363611
\Arfip1em1(IMPC)Mbp/\Arfip1em1(IMPC)Mbp
(C57BL/6N-Arfip1em1(IMPC)Mbp/MbpMmucd)
abnormal lymph node morphology J:211773
enlarged lymph nodes J:211773
\Arg1tm1.1Lky/\Arg1+
\Tg(Sftpc-Chia)#Lky/0

(involves: 129S4/SvJae * BALB/c * C57BL/6 * DBA/2)
decreased macrophage cell number J:122735
\Arg1tm1.1Pmu/\Arg1tm1.1Pmu
(involves: C57BL/6 * NZB)
increased macrophage nitric oxide production J:143229
\Arg1tm1Ekoe/\Arg1tm1Ekoe
(involves: 129P2/OlaHsd)
abnormal macrophage physiology J:183882
\Arg1tm1Pmu/\Arg1tm1Pmu
\Lyz2tm1(cre)Ifo/?

(B6.Cg-Arg1tm1Pmu Lyz2tm1(cre)Ifo)
decreased susceptibility to parasitic infection J:143229
\Arg1tm1Pmu/\Arg1tm1Pmu
\Tg(Tek-cre)1Ywa/?

(B6.Cg-Tg(Tek-cre)1Ywa Arg1tm1Pmu)
abnormal macrophage physiology J:143229
decreased susceptibility to bacterial infection J:143229
increased macrophage nitric oxide production J:143229
\Arg2em1(IMPC)Ccpcz/\Arg2em1(IMPC)Ccpcz
(C57BL/6NCrl-Arg2em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged thymus J:211773
small spleen J:211773
\Arhgap1tm1Yizh/\Arhgap1tm1Yizh
(involves: 129S6/SvEvTac)
spleen hypoplasia J:101418
thymus hypoplasia J:101418
\Arhgap1tm1Yizh/\Arhgap1tm1Yizh
(involves: 129S6/SvEvTac * C57BL/6)
decreased spleen white pulp amount J:119516
spleen hypoplasia J:119516
\Arhgap5tm1Jset/\Arhgap5tm1Jset
(involves: 129S2/SvPas * C57BL/6J)
small thymus J:76484
\Arhgap10em1(IMPC)Tcp/\Arhgap10em1(IMPC)Tcp
(C57BL/6NCrl-Arhgap10em1(IMPC)Tcp/Cmmr)
enlarged lymph nodes J:211773
\Arhgap15tm1Ehi/\Arhgap15tm1Ehi
(B6.129-Arhgap15tm1Ehi)
abnormal leukocyte cell number J:174896
abnormal leukocyte morphology J:174896
abnormal macrophage morphology J:174896
abnormal neutrophil physiology J:174896
decreased lymphocyte cell number J:174896
decreased macrophage cell number J:174896
decreased monocyte cell number J:174896
decreased neutrophil cell number J:174896
decreased susceptibility to bacterial infection J:174896
immune system phenotype J:174896
\Arhgap17Gt(RRN062)Byg/\Arhgap17Gt(RRN062)Byg
(B6.129P2-Arhgap17Gt(RRN062)Byg)
increased susceptibility to induced colitis J:277297
increased tumor necrosis factor secretion J:277297
\Arhgap17tm1b(EUCOMM)Wtsi/\Arhgap17tm1b(EUCOMM)Wtsi
(C57BL/6N-Arhgap17tm1b(EUCOMM)Wtsi/Wtsi)
decreased B-1a cell number J:211773
decreased follicular B cell number J:211773
decreased mature B cell number J:211773
increased transitional stage T1 B cell number J:211773
\Arhgap21Gt(RRR629)Byg/\Arhgap21+
(B6.129P2-Arhgap21Gt(RRR629)Byg)
increased leukocyte cell number J:262703
increased neutrophil cell number J:262703
\Arhgap25tm1a(KOMP)Wtsi/\Arhgap25tm1a(KOMP)Wtsi
(involves: C57BL/6N)
abnormal cellular extravasation J:240521
abnormal neutrophil physiology J:240521
enhanced leukocyte migration J:240521
enhanced leukocyte tethering or rolling J:240521
increased acute inflammation J:240521
increased neutrophil cell number J:240521
\Arhgap26tm1b(EUCOMM)Hmgu/\Arhgap26tm1b(EUCOMM)Hmgu
(C57BL/6N-Arhgap26tm1b(EUCOMM)Hmgu/Ieg)
increased leukocyte cell number J:211773
\Arhgap28em1(IMPC)Mbp/\Arhgap28em1(IMPC)Mbp
(C57BL/6NCrl-Arhgap28em1(IMPC)Mbp/Mmucd)
abnormal spleen morphology J:211773
\Arhgap30tm1a(EUCOMM)Wtsi/\Arhgap30tm1a(EUCOMM)Wtsi
(C57BL/6N-Arhgap30tm1a(EUCOMM)Wtsi/Wtsi)
decreased leukocyte cell number J:211773
\Arhgap45em1Ciphe/\Arhgap45em1Ciphe
(C57BL/6-Arhgap45em1Ciphe)
decreased B cell number J:309971
decreased CD4-positive, alpha-beta T cell number J:309971
decreased CD8-positive, alpha-beta T cell number J:309971
decreased CD8-positive, naive alpha-beta T cell number J:309971
decreased DN1 thymic pro-T cell number J:309971
decreased lymphocyte chemotaxis J:309971
decreased naive B cell number J:309971
decreased T cell number J:309971
immune system phenotype J:309971
lymph node hypoplasia J:309971
\Arhgdiatm1Ytk/\Arhgdiatm1Ytk
(involves: 129S/SvEv * C57BL/6 * DBA)
decreased T cell number J:140671
tubulointerstitial nephritis J:57995
\Arhgdiatm1Ytk/\Arhgdiatm1Ytk
\Arhgdibtm1Miyo/\Arhgdibtm1Miyo

(involves: 129S/SvEv)
abnormal leukocyte cell number J:140671
abnormal lymph node B cell domain morphology J:140671
abnormal mesenteric lymph node morphology J:140671
abnormal T cell physiology J:140671
abnormal thymus medulla morphology J:140671
decreased double-positive T cell number J:140671
decreased follicular B cell number J:140671
decreased immature B cell number J:140671
decreased marginal zone B cell number J:140671
decreased mature B cell number J:140671
decreased pre-B cell number J:140671
decreased T cell number J:140671
decreased T cell proliferation J:140671
decreased transitional stage B cell number J:140671
disorganized spleen B cell follicle J:140671
enhanced B cell migration J:140671
increased B cell proliferation J:140671
increased circulating interleukin-5 level J:140671
increased eosinophil cell number J:140671
increased single-positive T cell number J:140671
spleen hypoplasia J:140671
\Arhgdibtm1Len/\Arhgdibtm1Len
(involves: 129S4/SvJae * C57BL/6)
immune system phenotype J:42604
increased B cell proliferation J:42604
\Arhgdibtm1Miyo/\Arhgdibtm1Miyo
(involves: 129S/SvEv)
decreased B cell number J:140671
decreased T cell number J:140671
\Arhgef1tm1.1Rmt/\Arhgef1tm1.1Rmt
(C57BL/6-Arhgef1tm1.1Rmt)
abnormal marginal zone B cell physiology J:113295
decreased B cell number J:113295
decreased B-1 B cell number J:113295
decreased follicular B cell number J:113295
decreased IgM level J:113295
decreased marginal zone B cell number J:113295
\Arhgef1tm1a(EUCOMM)Wtsi/\Arhgef1tm1a(EUCOMM)Wtsi
(C57BL/6N-Arhgef1tm1a(EUCOMM)Wtsi/Wtsi)
decreased CD8-positive, alpha-beta T cell number J:211773
decreased dendritic cell number J:211773
decreased immature NK cell number J:211773
decreased Ly6C-positive immature NK cell number J:211773
decreased marginal zone B cell number J:211773
decreased memory-marker CD4-positive NK T cell number J:211773
decreased memory-marker gamma-delta T cell number J:211773
increased CD4-positive, alpha-beta memory T cell number J:211773
increased CD4-positive, alpha-beta T cell number J:211773
increased CD8-positive, alpha-beta memory T cell number J:211773
increased effector memory CD8-positive, alpha-beta T cell number J:211773
increased gamma-delta T cell number J:211773
increased KLRG1-positive CD4-positive, CD25-positive, alpha-beta regulatory T cell number J:211773
increased KLRG1-positive NK cell number J:211773
increased Ly6C low monocyte number J:211773
increased Ly6C-positive NK T cell number J:211773
increased mature NK cell number J:211773
increased monocyte cell number J:211773
increased plasmacytoid dendritic cell number J:211773
\Arhgef1tm1Djle/\Arhgef1tm1Djle
(involves: 129S4/SvJae * C57BL/6)
abnormal neutrophil physiology J:129331
enlarged spleen J:129331
increased leukocyte cell number J:129331
\Arhgef1tm1Djle/\Arhgef1tm1Djle
(involves: 129S4/SvJae)
increased germinal center B cell number J:174313
\Arhgef1tm1Kdf/\Arhgef1tm1Kdf
(involves: 129S1/Sv * 129X1/SvJ)
abnormal humoral immune response J:99463
abnormal lymphocyte cell number J:99463
abnormal lymphocyte physiology J:99463
decreased B cell number J:99463
decreased B cell proliferation J:99463
decreased IgG level J:99463
decreased IgM level J:99463
decreased marginal zone B cell number J:99463
increased T cell proliferation J:99463
\Arhgef2em1(IMPC)Mbp/\Arhgef2em1(IMPC)Mbp
(C57BL/6N-Arhgef2em1(IMPC)Mbp/MbpMmucd)
abnormal spleen morphology J:211773
small spleen J:211773
\Arhgef2Gt(IST13976A8)Tigm/\Arhgef2Gt(IST13976A8)Tigm
(involves: C57BL/6N)
abnormal macrophage physiology J:209086
decreased interferon-beta secretion J:209086
immune system phenotype J:209086
increased susceptibility to Orthomyxoviridae infection J:209086
\Arhgef4tm1a(KOMP)Wtsi/\Arhgef4tm1a(KOMP)Wtsi
(C57BL/6N-Arhgef4tm1a(KOMP)Wtsi/Wtsi)
decreased IgE level J:165965
decreased IgG1 level J:165965
decreased T cell number J:165965
increased mature B cell number J:165965
\Arhgef5tm1.1Dwu/\Arhgef5tm1.1Dwu
(involves: 129S1/Sv * 129S6/SvEvTac)
abnormal CD4-positive, alpha-beta T cell physiology J:157812
abnormal dendritic cell physiology J:157812
decreased eosinophil cell number J:157812
decreased interleukin-4 secretion J:157812
immune system phenotype J:157812
\Arhgef6tm1Kdf/\Arhgef6tm1Kdf
(involves: 129P2/OlaHsd * C57BL/6)
abnormal B cell number J:137269
abnormal humoral immune response J:137269
abnormal T cell physiology J:137269
decreased B cell proliferation J:137269
decreased CD4-positive, alpha-beta T cell number J:137269
decreased CD8-positive, alpha-beta T cell number J:137269
decreased interleukin-2 secretion J:137269
decreased lymphocyte cell number J:137269
decreased mature B cell number J:137269
decreased T cell proliferation J:137269
enhanced B cell migration J:137269
\Arhgef6tm2e.1(EUCOMM)Wtsi/Y
(C57BL/6N-Arhgef6tm2e.1(EUCOMM)Wtsi/Tcp)
enlarged lymph nodes J:211773
\Arhgef6tm2e.1(EUCOMM)Wtsi/\Arhgef6tm2e.1(EUCOMM)Wtsi
(C57BL/6N-Arhgef6tm2e.1(EUCOMM)Wtsi/Tcp)
decreased lymphocyte cell number J:211773
\Arhgef12tm1.1Wet/\Arhgef12tm1.1Wet
\Tg(Lck-cre)548Jxm/0

(involves: 129 * C57BL/6 * CBA)
abnormal T cell proliferation J:149560
\Arhgef16em1(IMPC)Mbp/\Arhgef16em1(IMPC)Mbp
(C57BL/6NCrl-Arhgef16em1(IMPC)Mbp/Mmucd)
increased monocyte cell number J:211773
\Arid1atm1.1Mag/\Arid1atm1.1Mag
\Gt(ROSA)26Sortm1(Pik3ca*H1047R)Egan/\Gt(ROSA)26Sor+

(involves: 129S6/SvEvTac * CD-1)
increased interleukin-6 secretion J:219794
\Arid1bem1(IMPC)Tcp/\Arid1b+
(C57BL/6NCrl-Arid1bem1(IMPC)Tcp/Tcp)
abnormal spleen morphology J:211773
\Arid2tm1a(EUCOMM)Wtsi/\Arid2tm1a(EUCOMM)Wtsi
(involves: C57BL/6J * C57BL/6N)
immune system phenotype J:223458
\Arid3atm1Pwt/\Arid3atm1Pwt
(involves: 129S6/SvEvTac * C57BL/6)
abnormal B cell differentiation J:169178
abnormal class switch recombination J:169178
decreased B cell number J:169178
decreased B-1 B cell number J:169178
decreased B-1a cell number J:169178
decreased B-2 B cell number J:169178
decreased IgG1 level J:169178
decreased IgM level J:169178
decreased marginal zone B cell number J:169178
decreased pre-B cell number J:169178
decreased pro-B cell number J:169178
decreased transitional stage B cell number J:169178
decreased transitional stage T1 B cell number J:169178
decreased transitional stage T2 B cell number J:169178
\Arid3btm1c(KOMP)Wtsi/\Arid3btm1c(KOMP)Wtsi
\Tg(Mx1-cre)1Cgn/0

(involves: C57BL/6J * C57BL/6N * SJL)
abnormal B cell differentiation J:236980
decreased B cell number J:236980
decreased B-1b cell number J:236980
decreased CD4-positive, alpha-beta T cell number J:236980
decreased immature B cell number J:236980
decreased pre-B cell number J:236980
decreased pre-pro B cell number J:236980
decreased pro-B cell number J:236980
decreased transitional stage B cell number J:236980
increased B-1a cell number J:236980
increased follicular B cell number J:236980
\Arid3cem1(IMPC)J/\Arid3cem1(IMPC)J
(C57BL/6NJ-Arid3cem1(IMPC)J/Mmjax)
decreased leukocyte cell number J:211773
\Arid4atm1Alb/\Arid4atm1Alb
(involves: 129S7/SvEvBrd)
abnormal mononuclear cell differentiation J:141004
decreased B cell number J:141004
decreased leukocyte cell number J:141004
decreased lymphocyte cell number J:141004
decreased monocyte cell number J:141004
decreased neutrophil cell number J:141004
decreased T cell number J:141004
enlarged spleen J:141004
increased leukocyte cell number J:141004
increased T cell number J:141004
\Arid4atm1Alb/\Arid4atm1Alb
\Arid4btm1Alb/\Arid4b+

(involves: 129S7/SvEvBrd)
abnormal leukopoiesis J:141004
decreased B cell number J:141004
decreased lymphocyte cell number J:141004
decreased T cell number J:141004
enlarged spleen J:141004
hemophagocytosis J:141004
increased leukocyte cell number J:141004
increased monocyte cell number J:141004
increased neutrophil cell number J:141004
increased T cell number J:141004
\Arid5atm1Rnis/\Arid5atm1Rnis
(B6.Cg-Arid5atm1Rnis)
decreased circulating interleukin-6 level J:197418
decreased circulating tumor necrosis factor level J:197418
decreased susceptibility to experimental autoimmune encephalomyelitis J:197418
decreased T-helper 17 cell number J:197418
increased T cell number J:197418
\Arid5bGt(ROSA)75Sor/\Arid5bGt(ROSA)75Sor
(involves: 129S4/SvJaeSor)
kidney inflammation J:117491
\Arid5btm1Pjh/\Arid5btm1Pjh
(involves: 129S4/SvJae * BALB/c)
abnormal immune system organ morphology J:70658
abnormal lymphopoiesis J:70658
decreased double-positive T cell number J:70658
decreased pro-B cell number J:70658
increased single-positive T cell number J:70658
spleen hypoplasia J:70658
thymus cortex hypoplasia J:70658
thymus hypoplasia J:70658
\Arigg1NZB/BlNJ/?
(involves: BALB/cByJ * NZB/BlNJ)
increased anti-erythrocyte antigen antibody level J:93737
\Arigg2NZB/BlNJ/?
(involves: BALB/cByJ * NZB/BlNJ)
increased anti-erythrocyte antigen antibody level J:93737
\Arigg3NZB/BlNJ/?
(involves: BALB/cByJ * NZB/BlNJ)
increased anti-erythrocyte antigen antibody level J:93737
\Arigg4NZB/BlNJ/?
(involves: BALB/cByJ * NZB/BlNJ)
increased anti-erythrocyte antigen antibody level J:93737
\Arigg5NZB/BlNJ/?
(involves: BALB/cByJ * NZB/BlNJ)
increased anti-erythrocyte antigen antibody level J:93737
\Arigg6NZB/BlNJ/?
(involves: BALB/cByJ * NZB/BlNJ)
increased anti-erythrocyte antigen antibody level J:93737
\Arigg7NZB/BlNJ/?
(involves: BALB/cByJ * NZB/BlNJ)
increased anti-erythrocyte antigen antibody level J:93737
\Arigg8BALB/cByJ/?
(involves: BALB/cByJ * NZB/BlNJ)
increased anti-erythrocyte antigen antibody level J:93737
\Arigg9NZB/BlNJ/?
(involves: BALB/cByJ * NZB/BlNJ)
increased anti-erythrocyte antigen antibody level J:93737
\Arigg10BALB/cByJ/?
(involves: BALB/cByJ * NZB/BlNJ)
increased anti-erythrocyte antigen antibody level J:93737
\Arigm1BALB/cByJ/?
(involves: BALB/cByJ * NZB/BlNJ)
increased IgM level J:93737
\Arigm2NZB/BlNJ/?
(involves: BALB/cByJ * NZB/BlNJ)
increased IgM level J:93737
\Arigm3NZB/BlNJ/?
(involves: BALB/cByJ * NZB/BlNJ)
increased IgM level J:93737
\Arigm4NZB/BlNJ/?
(involves: BALB/cByJ * NZB/BlNJ)
increased IgM level J:93737
\Arigm5NZB/BlNJ/?
(involves: BALB/cByJ * NZB/BlNJ)
increased IgM level J:93737
\Arigm6NZB/BlNJ/?
(involves: BALB/cByJ * NZB/BlNJ)
increased IgM level J:93737
\Arigm7NZB/BlNJ/?
(involves: BALB/cByJ * NZB/BlNJ)
increased IgM level J:93737
\Arih1em3Gpt/\Arih1em3Gpt
\Gt(ROSA)26Sortm1(cre/ERT2)Tyj/\Gt(ROSA)26Sor+

(involves: 129S4/SvJae * C57BL/6JGpt)
decreased interferon-beta secretion J:330879
decreased interleukin-6 secretion J:330879
increased susceptibility to Herpesvirales infection J:330879
increased susceptibility to Herpesvirales infection induced morbidity/mortality J:330879
\Arih1em3Gpt/\Arih1em3Gpt
\Lyz2em1(icre)Gpt/\Lyz2+

(C57BL/6JGpt-Arih1em3Gpt Lyz2em1(icre)Gpt)
decreased circulating interferon-beta level J:330879
decreased circulating interleukin-6 level J:330879
decreased interferon-beta secretion J:330879
decreased interleukin-6 secretion J:330879
immune system phenotype J:330879
increased susceptibility to Herpesvirales infection J:330879
increased susceptibility to Herpesvirales infection induced morbidity/mortality J:330879
\Arih1em3Gpt/\Arih1em3Gpt
\Lyz2em1(icre)Gpt/\Lyz2+
\Trex1em1Gpt/\Trex1em1Gpt

(C57BL/6JGpt-Arih1em3Gpt Trex1em1Gpt Lyz2em1(icre)Gpt)
immune system phenotype J:330879
\Arih2tm1Mak/\Arih2tm1Mak
(involves: 129P2/OlaHsd * C57BL/6)
dermatitis J:191066
heart inflammation J:191066
increased inflammatory response J:191066
liver inflammation J:191066
lung inflammation J:191066
\Arih2tm1Mak/\Arih2tm1Mak
(B6.129P2-Arih2tm1Mak)
abnormal dendritic cell physiology J:191066
increased inflammatory response J:191066
\Arl3Gt(OST263303)Lex/\Arl3Gt(OST263303)Lex
(involves: 129S5/SvEvBrd)
bile duct inflammation J:107331
\Arl6ip5tm1.2Jwzh/\Arl6ip5tm1.2Jwzh
(B6.129X1-Arl6ip5tm1.2Jwzh)
abnormal immune system organ morphology J:187133
\Arl16em1(IMPC)Ccpcz/\Arl16em1(IMPC)Ccpcz
(C57BL/6NCrl-Arl16em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged thymus J:211773
small spleen J:211773
\Arlnem1(IMPC)Mbp/\Arlnem1(IMPC)Mbp
(C57BL/6NCrl-Arlnem1(IMPC)Mbp/MbpMmucd)
increased basophil cell number J:211773
\Armc2tm1b(EUCOMM)Hmgu/\Armc2+
(C57BL/6N-Armc2tm1b(EUCOMM)Hmgu/H)
increased neutrophil cell number J:211773
\Armcx1em1(IMPC)Mbp/Y
(C57BL/6N-Armcx1em1(IMPC)Mbp/MbpMmucd)
abnormal lymph node morphology J:211773
enlarged lymph nodes J:211773
\Armh4em1(IMPC)H/\Armh4em1(IMPC)H
(C57BL/6N-Armh4em1(IMPC)H/H)
enlarged spleen J:211773
\Arnttm1.1Gonz/\Arnttm1.2Gonz
\Tg(Lck-cre)I57Jxm/0

(involves: 129X1/SvJ * ICR)
abnormal immune system physiology J:85934
\ArpBALB/c/\ArpBALB/c
(involves: B10.D2 * BALB/c)
abnormal lymph node morphology J:7273
abnormal Peyer's patch morphology J:6549
lymph node hypoplasia J:6549
spleen hyperplasia J:6549
thymus hyperplasia J:6549
\ArpBALB/c/\ArpBALB/c
\LusC57BL/10/\LusC57BL/10

(involves: B10.D2 * BALB/c)
abnormal lymph node morphology J:7273
\Arpc1btm1a(EUCOMM)Wtsi/\Arpc1btm1a(EUCOMM)Wtsi
(C57BL/6N-Arpc1btm1a(EUCOMM)Wtsi/Wtsi)
decreased CD4-positive, alpha-beta T cell number J:211773
decreased KLRG1-positive NK cell number J:211773
decreased Ly6C-positive mature NK cell number J:211773
decreased macrophage cell number J:211773
decreased marginal zone precursor B cell number J:211773
decreased mature NK cell number J:211773
decreased NK cell number J:211773
decreased transitional stage T2 B cell number J:211773
increased CD4-positive, alpha-beta memory T cell number J:211773
increased CD4-positive, CD25-positive, alpha-beta regulatory T cell number J:211773
increased CD103-positive CD11b-low dendritic cell number J:211773
increased effector memory T-helper cell number J:211773
increased immature NK cell number J:211773
increased KLRG1+ CD4 alpha-beta T cell number J:211773
increased KLRG1-positive CD4-positive, CD25-positive, alpha-beta regulatory T cell number J:211773
increased KLRG1-positive T-helper cell number J:211773
increased leukocyte cell number J:211773
increased memory CD4-positive, CD25-positive, alpha-beta regulatory T cell number J:211773
increased memory-marker CD4-negative NK T cell number J:211773
increased memory-marker NK cell number J:211773
increased plasma cell number J:211773
\Arpc4tm1a(EUCOMM)Wtsi/\Arpc4+
(B6JTyr;B6N-Arpc4tm1a(EUCOMM)Wtsi/Wtsi)
increased leukocyte cell number J:165965
\Arpc4tm1c(EUCOMM)Wtsi/\Arpc4tm1c(EUCOMM)Wtsi
\Krt14tm1(cre)Wbm/\Krt14+

(B6.Cg-Arpc4tm1c(EUCOMM)Wtsi Krt14tm1(cre)Wbm)
dermatitis J:253986
\Arrb2tm1Rjl/\Arrb2tm1Rjl
(involves: 129X1/SvJ * C57BL/6)
abnormal circulating tumor necrosis factor level J:112607
abnormal lymphocyte physiology J:76872
increased acute inflammation J:112607
increased circulating interleukin-6 level J:112607
increased interleukin-6 secretion J:112607
increased interleukin-12b secretion J:112607
increased susceptibility to endotoxin shock J:112607
increased tumor necrosis factor secretion J:112607
\Arrdc4em1(IMPC)Tcp/\Arrdc4em1(IMPC)Tcp
(C57BL/6NCrl-Arrdc4em1(IMPC)Tcp/Cmmr)
enlarged lymph nodes J:211773
increased monocyte cell number J:211773
\Arsatm1Gie/\Arsatm1Gie
(involves: 129P2/OlaHsd * C57BL/6J)
abnormal microglial cell morphology J:37978
\Arsgtm1Tdi/\Arsgtm1Tdi
(involves: 129S2/SvPas * C57BL/6)
abnormal macrophage morphology J:185592
abnormal microglial cell morphology J:185592
abnormal perivascular macrophage morphology J:185592
microgliosis J:185592, J:254592
\Art1tm1b(EUCOMM)Wtsi/\Art1tm1b(EUCOMM)Wtsi
(C57BL/6N-Art1tm1b(EUCOMM)Wtsi/Tcp)
enlarged lymph nodes J:211773
increased basophil cell number J:211773
\Art2atm1Fkn/\Art2atm1Fkn
\Art2btm1Fkn/\Art2btm1Fkn

(NOD.129S4(B6)-Art2atm1Fkn Art2btm1Fkn/Lt)
decreased T cell apoptosis J:108097
\Art2atm1Fkn/\Art2atm1Fkn
\Art2btm1Fkn/\Art2btm1Fkn
\Cd38tm1Lnd/\Cd38tm1Lnd

(NOD.129(B6)-Cd38tm1Lnd Art2atm1Fkn Art2btm1Fkn/Lt)
decreased susceptibility to autoimmune diabetes J:108097
\Arti1C57BL/6J/\Arti1C57BL/6J
\Arti2C57BL/6J/\Arti2C57BL/6J

(involves: C57BL/6J * DBA/2J)
abnormal thymus involution J:85261
\Arti1DBA/2J/\Arti1DBA/2J
\Arti2DBA/2J/\Arti2DBA/2J

(involves: C57BL/6J * DBA/2J)
abnormal thymus involution J:85261
\Arvm2MRL/MpJ/\Arvm2MRL/MpJ
(involves: C3H/HeJ-Faslpr * MRL/MpJ-Faslpr)
abnormal immune system physiology J:63511
\asa/\asa
(either: A/J or BALB/c or DBA/2J)
increased autoantibody level J:2843
myocarditis J:2843
\Asah1tm1.2Geno/\Asah1tm1.2Geno
(involves: C57BL/6)
abnormal circulating cytokine level J:285931
abnormal lymph node morphology J:285931
abnormal thymus morphology J:285931
decreased B cell number J:285931
decreased CD4-positive, alpha-beta T cell number J:285931
decreased CD8-positive, alpha-beta T cell number J:285931
decreased double-positive T cell number J:285931
decreased leukocyte cell number J:285931
decreased lymphocyte cell number J:285931
decreased splenocyte number J:285931
decreased T cell number J:285931
enlarged spleen J:285931
increased circulating CXCL10 level J:285931
increased granulocyte number J:285931
increased macrophage cell number J:285931
increased macrophage derived foam cell number J:285931
increased monocyte cell number J:285931
lung inflammation J:285931
\Asah1tm1Medin/\Asah1tm1Medin
(involves: 129S6/SvEvTac * CD-1)
abnormal chemokine secretion J:232306
abnormal circulating chemokine level J:232306
enlarged lymph nodes J:232306
enlarged spleen J:232306
enlarged thymus J:232306
increased circulating interleukin-12b level J:232306
increased eosinophil cell number J:232306
increased leukocyte cell number J:232306
increased macrophage derived foam cell number J:232306
increased monocyte cell number J:232306
increased neutrophil cell number J:232306
increased spleen weight J:232306
pale spleen J:232306
\Asb1em1(IMPC)Ccpcz/\Asb1em1(IMPC)Ccpcz
(C57BL/6N-Asb1em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged spleen J:211773
enlarged thymus J:211773
\Asb1tm1Wehi/\Asb1tm1Wehi
(involves: C57BL/6)
small spleen J:71266
spleen hypoplasia J:71266
\Asb2tm1.1Lutz/\Asb2tm1.1Lutz
\Tg(Mx1-cre)1Cgn/0

(involves: 129S2/SvPas * C57BL/6 * CBA)
abnormal dendritic cell physiology J:200966
\Asb2tm2b(KOMP)Wtsi/\Asb2+
(C57BL/6N-Asb2tm2b(KOMP)Wtsi/Kmpc)
decreased Ly6C-positive immature NK cell number J:211773
increased Ly6C-positive immature NK cell number J:211773
increased T cell number J:211773
\Asb4em1(IMPC)Ccpcz/\Asb4em1(IMPC)Ccpcz
(C57BL/6N-Asb4em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
\Asb5em1(IMPC)Ccpcz/\Asb5em1(IMPC)Ccpcz
(C57BL/6N-Asb5em1(IMPC)Ccpcz/Ccpcz)
abnormal thymus morphology J:211773
enlarged thymus J:211773
\Asb7em1(IMPC)Ccpcz/\Asb7em1(IMPC)Ccpcz
(C57BL/6N-Asb7em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
decreased CD8-positive, alpha-beta T cell number J:211773
enlarged spleen J:211773
increased effector memory CD8-positive, alpha-beta T cell number J:211773
\Asb16em1(IMPC)Ccpcz/\Asb16em1(IMPC)Ccpcz
(C57BL/6N-Asb16em1(IMPC)Ccpcz/Ccpcz)
abnormal thymus morphology J:211773
enlarged thymus J:211773
\Asbb1BALB/c/\Asbb1BALB/c
(involves: BALB/c * C57BL/6J)
increased susceptibility to systemic lupus erythematosus J:76486
\Asbb2BALB/c/\Asbb2C57BL/6J
(involves: BALB/c * C57BL/6J)
increased susceptibility to systemic lupus erythematosus J:76486
\Asbb2C57BL/6J/\Asbb2C57BL/6J
(involves: BALB/c * C57BL/6J)
increased susceptibility to systemic lupus erythematosus J:76486
\Asbb3C57BL/6J/\Asbb3C57BL/6J
(involves: BALB/c * C57BL/6J)
increased susceptibility to systemic lupus erythematosus J:76486
\Ascc2tm1a(EUCOMM)Wtsi/\Ascc2+
(C57BL/6N-Ascc2tm1a(EUCOMM)Wtsi/Bay)
enlarged spleen J:211773
\Ascl4em1(IMPC)J/\Ascl4em1(IMPC)J
(C57BL/6NJ-Ascl4em1(IMPC)J/Mmjax)
increased leukocyte cell number J:211773
\Ascl5em1(IMPC)Ccpcz/\Ascl5em1(IMPC)Ccpcz
(C57BL/6NCrl-Ascl5em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged thymus J:211773
\Asf1bm1Btlr/\Asf1bm1Btlr
(C57BL/6J-Asf1bm1Btlr)
increased IgE level J:267479
\Asgr1tm1Sau/\Asgr1tm1Sau
(B6.129S4-Asgr1tm1Sau)
increased susceptibility to bacterial infection J:136946
\Asgr2tm1Her/\Asgr2tm1Her
(B6.129S7-Asgr2tm1Her)
increased susceptibility to bacterial infection J:136946
\Ash1lGt(AL0395)Wtsi/\Ash1lGt(AL0395)Wtsi
(involves: 129P2/OlaHsd * C57BL/6J)
blepharitis J:227516
\Ash1ltm2b(EUCOMM)Hmgu/\Ash1l+
(C57BL/6N-Ash1ltm2b(EUCOMM)Hmgu/Nju)
increased basophil cell number J:211773
increased eosinophil cell number J:211773
\Ash1lTn(pb-Act-RFP)1.AF0-180T25Zhu/\Ash1lTn(pb-Act-RFP)1.AF0-180T25Zhu
(B6.FVB-Ash1lTn(pb-Act-RFP)1.AF0-180T25Zhu)
glomerulonephritis J:208213
immune system phenotype J:208213
increased autoantibody level J:208213
increased circulating interleukin-6 level J:208213
increased circulating tumor necrosis factor level J:208213
increased IgA level J:208213
increased IgG1 level J:208213
increased IgG2a level J:208213
increased IgG2b level J:208213
increased IgM level J:208213
increased interleukin-6 secretion J:208213
increased susceptibility to autoimmune disorder J:208213
increased susceptibility to bacterial infection J:208213
increased susceptibility to bacterial infection induced morbidity/mortality J:208213
increased susceptibility to endotoxin shock J:208213
increased susceptibility to induced arthritis J:208213
increased tumor necrosis factor secretion J:208213
\Ash1lTn(pb-Act-RFP)1.AF0-180T25Zhu/\Ash1lTn(pb-Act-RFP)1.AF0-180T25Zhu
\Il6tm1Kopf/\Il6tm1Kopf

(B6.Cg-Ash1lTn(pb-Act-RFP)1.AF0-180T25Zhu Il6tm1Kopf)
abnormal inflammatory response J:208213
increased susceptibility to induced arthritis J:208213
\Asic2em1(IMPC)Mbp/\Asic2em1(IMPC)Mbp
(C57BL/6N-Asic2em1(IMPC)Mbp/MbpMmucd)
small spleen J:211773
\Asic3em1(IMPC)Mbp/\Asic3em1(IMPC)Mbp
(C57BL/6NCrl-Asic3em1(IMPC)Mbp/MbpMmucd)
abnormal spleen morphology J:211773
enlarged spleen J:211773
\Asltm1Brle/\Asltm1Brle
(involves: 129S7/SvEvBrd)
decreased lymphocyte cell number J:180208
decreased spleen germinal center number J:180208
increased macrophage cell number J:180208
increased spleen red pulp amount J:180208
thymus cortex hypoplasia J:180208
\Asm1MRL/MpJ/?
(involves: C3H/HeJ-Faslpr * MRL/MpJ-Faslpr)
abnormal immune system physiology J:66459
\Asm2MRL/MpJ/?
(involves: C3H/HeJ-Faslpr * MRL/MpJ-Faslpr)
salivary gland inflammation J:66459
\Asphd1em1(IMPC)Ccpcz/\Asphd1em1(IMPC)Ccpcz
(C57BL/6NCrl-Asphd1em1(IMPC)Ccpcz/Ccpcz)
abnormal thymus morphology J:211773
enlarged thymus J:211773
\Aspscr1em1(IMPC)Tcp/\Aspscr1em1(IMPC)Tcp
(C57BL/6NCrl-Aspscr1em1(IMPC)Tcp/Tcp)
decreased neutrophil cell number J:211773
enlarged lymph nodes J:211773
increased lymphocyte cell number J:211773
\Asq1IQI/\Asq1IQI
(involves: IQI * C57BL/6CrSlc)
salivary gland inflammation J:127310
\Ass1tm1.1Ekoe/\Ass1tm1.1Ekoe
\Tg(Vil1-cre)997Gum/0

(involves: 129P2/OlaHsd * C57BL/6 * SJL)
immune system phenotype J:203474
\Aste1tm1a(KOMP)Wtsi/\Aste1tm1a(KOMP)Wtsi
(B6JTyr;B6N-Aste1tm1a(KOMP)Wtsi/Wtsi)
decreased leukocyte cell number J:175295
\Asxl1tm1.1Iaai/\Asxl1tm1.1Iaai
\Tet2tm1.1Iaai/\Tet2tm1.1Iaai
\Tg(Mx1-cre)1Cgn/0

(involves: 129S/SvEv * C57BL/6 * CBA)
abnormal myelopoiesis J:208092
\Asxl1tm1.1Iaai/\Asxl1tm1.1Iaai
\Tg(Mx1-cre)1Cgn/0

(involves: 129S/SvEv * C57BL/6 * CBA)
abnormal myelopoiesis J:208092
decreased leukocyte cell number J:208092
decreased mature B cell number J:208092
decreased monocyte cell number J:208092
decreased neutrophil cell number J:208092
\Asxl1tm1.1Iaai/\Asxl1tm1.1Iaai
\Tg(VAV1-cre)1Graf/0

(involves: 129S/SvEv * C57BL/6)
abnormal myelopoiesis J:208092
decreased leukocyte cell number J:208092
decreased mature B cell number J:208092
decreased monocyte cell number J:208092
decreased neutrophil cell number J:208092
decreased splenocyte number J:208092
\Asxl1tm1.1Mjxu/\Asxl1+
(involves: 129 * C57BL/6)
abnormal leukocyte morphology J:208085
abnormal myelopoiesis J:208085
abnormal neutrophil morphology J:208085
abnormal neutrophil physiology J:208085
abnormal spleen morphology J:208085
decreased B cell number J:208085
decreased leukocyte cell number J:208085
decreased neutrophil cell number J:208085
enlarged spleen J:208085
increased leukocyte cell number J:208085
increased monocyte cell number J:208085
\Asxl1tm1.1Mjxu/\Asxl1tm1.1Mjxu
(involves: 129 * C57BL/6)
abnormal leukocyte morphology J:208085
abnormal neutrophil morphology J:208085
abnormal spleen white pulp morphology J:208085
decreased B cell number J:208085
decreased leukocyte cell number J:208085
decreased lymphocyte cell number J:208085
decreased spleen red pulp amount J:208085
decreased spleen weight J:208085
increased monocyte cell number J:208085
increased single-positive T cell number J:208085
myeloid hyperplasia J:208085
small spleen J:208085
spleen atrophy J:208085
\Asxl1tm1a(EUCOMM)Wtsi/\Asxl1+
(B6Dnk;B6Brd;B6N-Asxl1tm1a(EUCOMM)Wtsi Tyrc-Brd/WtsiH)
decreased leukocyte cell number J:175295
\Asxl1tm1a(EUCOMM)Wtsi/\Asxl1+
(C57BL/6N-Asxl1tm1a(EUCOMM)Wtsi/Cnrm)
decreased B cell number J:165965
\Asxl1tm1Bc/\Asxl1tm1Bc
(involves: 129P2/OlaHsd * C57BL/6J)
abnormal immune system cell morphology J:155898
abnormal immune system organ morphology J:155898
abnormal lymphopoiesis J:155898
abnormal thymus morphology J:155898
decreased B cell number J:155898
decreased CD4-positive, alpha-beta T cell number J:155898
decreased pre-B cell number J:155898
decreased T cell number J:155898
increased double-negative T cell number J:155898
spleen hyperplasia J:155898
\Atad2btm1b(EUCOMM)Hmgu/\Atad2btm1b(EUCOMM)Hmgu
(C57BL/6N-Atad2btm1b(EUCOMM)Hmgu/Ics)
decreased NK T cell number J:211773
\Atad5Gt(RRF055)Byg/\Atad5+
(involves: 129P2/OlaHsd)
increased T cell derived lymphoma incidence J:176672
\Atcayji/\Atcayji
(Not Specified)
abnormal thymus cortex morphology J:14903
abnormal thymus medulla morphology J:14903
abnormal thymus morphology J:14903
\Atf1tm1.1Arte/\Atf1tm1.1Arte
(involves: C57BL/6)
immune system phenotype J:191723
\Atf2Tg(Gzma-Klra1)7Wum/\Atf2+
(involves: C57BL/6)
abnormal NK cell physiology J:61178
decreased circulating interferon-gamma level J:61178
decreased NK cell number J:61178
decreased NK T cell number J:61178
immune system phenotype J:61178
\Atf2tm1b(EUCOMM)Hmgu/\Atf2+
(C57BL/6N-Atf2tm1b(EUCOMM)Hmgu/Ccpcz)
abnormal spleen morphology J:211773
\Atf2tm1Glm/\Atf2tm1Glm
(involves: 129S2/SvPas)
eye inflammation J:30611
increased susceptibility to bacterial infection J:30611
\Atf2tm1Glm/\Atf2tm1Glm
(C.Cg-Atf2tm1Glm)
abnormal cytokine secretion J:67176
immune system phenotype J:67176
increased susceptibility to endotoxin shock J:67176
increased susceptibility to Herpesvirales infection J:67176
increased susceptibility to Picornaviridae infection J:67176
\Atf3tm1Dron/\Atf3tm1Dron
(involves: 129X1/SvJ * C57BL/6)
abnormal T-helper 2 physiology J:140112
decreased IgG2a level J:140112
increased interleukin-4 secretion J:140112
increased interleukin-5 secretion J:140112
increased interleukin-13 secretion J:140112
lung inflammation J:140112
\Atf4tm1(KOMP)Mbp/\Atf4+
(C57BL/6NCrl-Atf4tm1(KOMP)Mbp/MbpMmucd)
decreased monocyte cell number J:211773
\Atg3tm1.1Ywh/\Atg3tm1.1Ywh
\Fnip1m1Btlr/\Fnip1m1Btlr
\Gt(ROSA)26Sortm1(cre/ERT)Nat/\Gt(ROSA)26Sor+

(involves: 129S/SvEv * 129S1/Sv * 129X1/SvJ * C57BL/6J)
absent B cells J:234285
\Atg3tm1.1Ywh/\Atg3tm1.1Ywh
\Gt(ROSA)26Sortm1(cre/ERT)Brn/\Gt(ROSA)26Sor+

(involves: 129P2/OlaHsd * 129S/SvEv * 129S4/SvJaeSor * C57BL/6)
abnormal T cell morphology J:172749
increased T cell apoptosis J:172749
\Atg3tm1.1Ywh/\Atg3tm1.1Ywh
\Tg(Lck-cre)548Jxm/0

(involves: 129S/SvEv * 129S4/SvJaeSor * C57BL/6 * CBA)
abnormal T cell morphology J:172749
decreased CD4-positive, alpha-beta T cell number J:172749
decreased CD8-positive, alpha-beta T cell number J:172749
decreased T cell proliferation J:172749
increased T cell apoptosis J:172749
spleen hypoplasia J:172749
thymus hypoplasia J:172749
\Atg4btm1b(EUCOMM)Hmgu/\Atg4btm1b(EUCOMM)Hmgu
(C57BL/6N-Atg4btm1b(EUCOMM)Hmgu/H)
increased leukocyte cell number J:211773
increased lymphocyte cell number J:211773
\Atg5tm1Myok/\Atg5tm1Myok
\Lyz2tm1(cre)Ifo/\Lyz2+

(involves: 129P2/OlaHsd * 129S/SvEv)
abnormal circulating chemokine level J:235399
abnormal macrophage physiology J:235399
decreased circulating interleukin-10 level J:235399
glomerulonephritis J:235399
increased anti-double stranded DNA antibody level J:235399
increased anti-nuclear antigen antibody level J:235399
increased autoantibody level J:235399
increased circulating interleukin-1 beta level J:235399
increased circulating interleukin-6 level J:235399
increased circulating interleukin-12b level J:235399
increased IgG level J:235399
increased lymphocyte cell number J:235399
increased monocyte cell number J:235399
increased neutrophil cell number J:235399
increased susceptibility to systemic lupus erythematosus J:235399
\Atg5tm1Nmz/\Atg5tm1Nmz
(involves: 129 * BALB/c * C57BL/6)
abnormal thymus cortex morphology J:140583
\Atg5tm1Nmz/\Atg5tm1Nmz
\Tg(CAG-EGFP/Map1lc3b)53Nmz/?

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
abnormal thymus morphology J:140583
abnormal thymus physiology J:140583
\Atg5tm1Nmz/\Atg5tm1Nmz
\Tg(Cd4-cre)1Cwi/?

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2)
abnormal T cell morphology J:211733
abnormal T cell physiology J:211733
abnormal T cell subpopulation ratio J:211733
decreased CD4-positive, alpha-beta T cell number J:211733
decreased CD8-positive, alpha-beta T cell number J:211733
decreased T cell number J:211733
decreased T cell proliferation J:211733
\Atg7tm1Tchi/\Atg7tm1Tchi
\Commd10Tg(Vav1-icre)A2Kio/\Commd10+

(involves: C57BL/6NCrlj * C57BL/10 * CBA/Ca * CBA/JNCrlj)
abnormal leukocyte morphology J:176843
decreased B cell number J:176843
decreased leukocyte cell number J:176843
decreased NK cell number J:176843
decreased T cell number J:176843
\Atg7tm1Tchi/\Atg7tm1Tchi
\Lyz2tm1(cre)Ifo/\Lyz2+

(involves: 129P2/OlaHsd * C57BL/6NCrlj * CBA/JNCrlj)
abnormal circulating chemokine level J:235399
abnormal macrophage physiology J:235399
decreased circulating interleukin-10 level J:235399
glomerulonephritis J:235399
increased anti-double stranded DNA antibody level J:235399
increased anti-nuclear antigen antibody level J:235399
increased autoantibody level J:235399
increased circulating interleukin-1 beta level J:235399
increased circulating interleukin-6 level J:235399
increased circulating interleukin-12b level J:235399
increased IgG level J:235399
increased lymphocyte cell number J:235399
increased monocyte cell number J:235399
increased neutrophil cell number J:235399
increased susceptibility to systemic lupus erythematosus J:235399
\Atg7tm1Tchi/\Atg7tm1Tchi
\Lyz2tm1(cre)Ifo/\Lyz2+
\Tg(CAG-EGFP/Map1lc3b)53Nmz/0

(involves: 129P2/OlaHsd * C57BL/6 * C57BL/6NCrlj * CBA/JNCrlj * DBA/2)
abnormal circulating chemokine level J:235399
abnormal macrophage physiology J:235399
decreased circulating interleukin-10 level J:235399
increased circulating interleukin-1 beta level J:235399
increased circulating interleukin-6 level J:235399
\Atg7tm1Tchi/\Atg7tm1Tchi
\Xbp1tm2Glm/\Xbp1tm2Glm
\Tg(Defa6-icre)1Rsb/0

(involves: 129S6/SvEvTac * C57BL/6 * CBA)
small intestinal inflammation J:206084
\Atg7tm1Tchi/\Atg7tm1Tchi
\Xbp1tm2Glm/\Xbp1tm2Glm
\Tg(Vil1-cre)997Gum/0

(involves: 129S6/SvEvTac * C57BL/6 * CBA * SJL)
ileum inflammation J:206084
intestinal inflammation J:206084
\Atg9atm1Aki/\Atg9atm1Aki
(involves: 129/Sv * C57BL/6)
abnormal innate immunity J:155552
increased interferon-beta secretion J:155552
increased interleukin-6 secretion J:155552
\Atg16l1tm1.1Mvlc/\Atg16l1tm1.1Mvlc
(C57BL/6-Atg16l1tm1.1Mvlc)
abnormal macrophage physiology J:206931
immune system phenotype J:206931
increased circulating interleukin-1 beta level J:206931
increased macrophage cytokine production J:206931
increased susceptibility to bacterial infection J:206931
\Atg16l1tm1a(EUCOMM)Wtsi/\Atg16l1tm1a(EUCOMM)Wtsi
(C57BL/6N-Atg16l1tm1a(EUCOMM)Wtsi/Wtsi)
abnormal thymus topology J:239583
absent connection between subcutaneous lymph vessels and lymph sac J:239583
blood in lymph vessels J:239583
\Atg16l1tm1Aki/\Atg16l1tm1Aki
(involves: 129/Sv * C57BL/6)
abnormal macrophage physiology J:141420
increased interleukin-1 beta secretion J:141420
increased interleukin-18 secretion J:141420
increased susceptibility to induced colitis J:141420
\Atg16l1tm1c(EUCOMM)Wtsi/\Atg16l1tm1c(EUCOMM)Wtsi
\Tcrdtm1Mom/\Tcrdtm1Mom
\Tg(Vil1-cre)997Gum/0

(involves: 129P2/OlaHsd * C57BL/6J * C57BL/6N * SJL)
abnormal cytokine level J:340266
increased susceptibility to colitis induced morbidity/mortality J:340266
\Atg16l1tm1c(EUCOMM)Wtsi/\Atg16l1tm1c(EUCOMM)Wtsi
\Tg(Defa6-icre)1Rsb/0

(involves: C57BL/6)
increased susceptibility to colitis induced morbidity/mortality J:340266
increased susceptibility to induced colitis J:340266
\Atg16l1tm1c(EUCOMM)Wtsi/\Atg16l1tm1c(EUCOMM)Wtsi
\Tg(Itgax-cre)1-1Reiz/?

(involves: C57BL/6 * C57BL/6N * CBA)
immune system phenotype J:221019
\Atg16l1tm1c(EUCOMM)Wtsi/\Atg16l1tm1c(EUCOMM)Wtsi
\Tg(Vil1-cre)997Gum/?

(involves: C57BL/6J * C57BL/6N * SJL)
abnormal chemokine level J:221019
abnormal circulating interleukin level J:221019
abnormal cytokine level J:221019
cecum inflammation J:221019
increased circulating interleukin-1 beta level J:221019
increased circulating interleukin-6 level J:221019
increased macrophage cell number J:221019
increased susceptibility to bacterial infection J:221019
\Atg16l1tm1Kuv/\Atg16l1tm1Kuv
\Tg(Vil1-cre)997Gum/0

(B6.Cg-Atg16l1tm1Kuv Tg(Vil1-cre)997Gum)
increased susceptibility to induced colitis J:269933
small intestinal inflammation J:269933
\Atg16l1tm1Kuv/\Atg16l1tm1Kuv
\Tg(Vil1-cre)997Gum/0
\Xbp1tm2Glm/\Xbp1tm2Glm

(B6.Cg-Atg16l1tm1Kuv Xbp1tm2Glm Tg(Vil1-cre)997Gum)
small intestinal inflammation J:269933
\Atg16l1tm1Kuv/\Atg16l1tm1Kuv
\Xbp1tm2Glm/\Xbp1tm2Glm
\Tg(Vil1-cre)997Gum/0

(involves: 129S6/SvEvTac * C57BL/6 * SJL)
ileum inflammation J:206084
intestinal inflammation J:206084
\Atg16l2m1Anu/\Atg16l2m1Anu
(C57BL/6NCrlAnu-Atg16l2m1Anu)
decreased lymphocyte cell number J:104190
\Atl1tm1.2Cbla/\Atl1tm1.2Cbla
\Reep1Gt(OST398247)Lex/\Reep1Gt(OST398247)Lex

(B6.Cg-Reep1Gt(OST398247)Lex Atl1tm1.2Cbla)
increased susceptibility to otitis media J:334532
\Atl2tm2b(EUCOMM)Hmgu/\Atl2+
(C57BL/6N-Atl2tm2b(EUCOMM)Hmgu/H)
decreased neutrophil cell number J:211773
decreased spleen weight J:211773
increased lymphocyte cell number J:211773
\Atl3em1(IMPC)Tcp/\Atl3em1(IMPC)Tcp
(C57BL/6N-Atl3em1(IMPC)Tcp/Tcp)
enlarged lymph nodes J:211773
\Atmm1Btlr/\Atmm1Btlr
(C57BL/6J-Atmm1Btlr)
decreased CD4-positive, alpha-beta T cell number J:265252
decreased CD8-positive, alpha-beta T cell number J:265252
decreased response to antigen J:265252
decreased single-positive T cell number J:265252
decreased T cell number J:265252
impaired humoral immune response J:265252
increased IgM level J:265252
\Atmm2Btlr/\Atmm2Btlr
(C57BL/6J-Atmm2Btlr)
decreased CD4-positive, alpha-beta T cell number J:265253
decreased CD8-positive, naive alpha-beta T cell number J:265253
decreased single-positive T cell number J:265253
increased central memory CD8 positive, alpha-beta T cell number J:265253
increased effector memory CD4-positive, alpha-beta T cell number J:265253
\Atmm3Btlr/\Atmm3Btlr
(C57BL/6J-Atmm3Btlr)
increased B-1a cell number J:272820
increased macrophage cell number J:272820
\AtmM4Btlr/\AtmM4Btlr
(C57BL/6J-AtmM4Btlr)
abnormal CD8-positive, alpha-beta T cell differentiation J:272821
\Atmm5Btlr/\Atmm5Btlr
(C57BL/6J-Atmm5Btlr)
abnormal lymphocyte morphology J:272824
decreased interleukin-1 beta secretion J:272824
impaired macrophage phagocytosis J:272824
increased B-1 B cell number J:272824
\Atmm6Btlr/\Atmm6Btlr
(C57BL/6J-Atmm6Btlr)
abnormal CD4-positive T cell differentiation J:274964
abnormal CD8-positive, alpha-beta T cell differentiation J:274964
abnormal T cell differentiation J:274964
decreased CD4-positive, alpha-beta T cell number J:274964
decreased CD8-positive, naive alpha-beta T cell number J:274964
decreased T cell number J:274964
increased CD8-positive, alpha-beta memory T cell number J:274964
increased central memory CD4-positive, alpha-beta T cell number J:274964
increased central memory CD8 positive, alpha-beta T cell number J:274964
increased effector memory CD4-positive, alpha-beta T cell number J:274964
\Atmtm1.1Mmpl/\Atmtm1.1Mmpl
(involves: 129S4/SvJaeSor * 129S6/SvEvTac * C57BL/6J)
decreased T cell number J:226414
increased B cell number J:226414
increased T cell derived lymphoma incidence J:226414
\Atmtm1Awb/\Atm+
\Rad50tm2Jpt/\Rad50tm2Jpt

(involves: 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6)
decreased macrophage cell number J:103922
\Atmtm1Awb/\Atmtm1Awb
(either: 129S6/SvEvTac-Atmtm1Awb or (involves: 129S6/SvEvTac * NIH Black Swiss))
decreased activated T cell number J:34193
decreased double-positive T cell number J:34193
decreased T cell number J:34193
immune system phenotype J:34193
increased double-positive T cell number J:34193
increased T cell derived lymphoma incidence J:34193
\Atmtm1Awb/\Atmtm1Awb
(involves: 129S6/SvEvTac * C57BL/6)
increased T cell derived lymphoma incidence J:103922
\Atmtm1Awb/\Atmtm1Awb
(involves: 129S6/SvEvTac)
abnormal class switch recombination J:150435
decreased CD4-positive, alpha-beta T cell number J:90941
decreased CD8-positive, alpha-beta T cell number J:90941
immune system phenotype J:126920
increased T cell derived lymphoma incidence J:90941
\Atmtm1Awb/\Atmtm1Awb
(CByJ.129S6-Atmtm1Awb)
increased T cell derived lymphoma incidence J:208539
\Atmtm1Awb/\Atmtm1Awb
(129S6/SvEvTac-Atmtm1Awb)
increased T cell derived lymphoma incidence J:208539
\Atmtm1Awb/\Atmtm1Awb
(either: (129S6/SvEvTac-Atmtm1Awb x B6.129S6-Atmtm1Awb)F1 or (B6.129S6-Atmtm1Awb x 129S6/SvEvTac-Atmtm1Awb)F1)
increased T cell derived lymphoma incidence J:208539
\Atmtm1Awb/\Atmtm1Awb
(either: (129S6/SvEvTac-Atmtm1Awb x A.129S6-Atmtm1Awb)F1 or (A.129S6-Atmtm1Awb x 129S6/SvEvTac-Atmtm1Awb)F1)
increased T cell derived lymphoma incidence J:208539
\Atmtm1Awb/\Atmtm1Awb
(129S6/SvEvTac-Atmtm1Awb/J)
decreased single-positive T cell number J:226414
decreased T cell number J:226414
increased B cell number J:226414
increased double-positive T cell number J:226414
increased T cell derived lymphoma incidence J:226414
\Atmtm1Awb/\Atmtm1Awb
\Paxxem1Spj/\Paxxem1Spj

(involves: A/J * C57BL/6NTac)
abnormal class switch recombination J:236776
decreased B cell number J:236776
decreased splenocyte number J:236776
decreased T cell number J:236776
\Atmtm1Awb/\Atmtm1Awb
\Rad52tm1Aps/\Rad52tm1Aps

(involves: 129P2/OlaHsd * 129S6/SvEvTac)
decreased CD4-positive, alpha-beta T cell number J:90941
decreased CD8-positive, alpha-beta T cell number J:90941
increased T cell derived lymphoma incidence J:90941
\Atmtm1Bal/\Atmtm1Bal
(involves: 129S4/SvJae)
abnormal microglial cell physiology J:44190
abnormal T cell physiology J:35914
decreased IgG2a level J:35914
decreased IgG2b level J:35914
decreased IgG3 level J:35914
decreased IgG level J:35914
decreased pre-B cell number J:35914
decreased thymocyte number J:35914
increased T cell derived lymphoma incidence J:35914
small thymus J:35914
\Atmtm1Fwa/\Atmtm1Fwa
(involves: 129S4/SvJae * C57BL/6)
decreased immature B cell number J:61201
decreased lymphocyte cell number J:61201
decreased pre-B cell number J:61201
decreased splenocyte number J:61201
decreased T cell number J:61201
decreased thymocyte number J:61201
increased T cell derived lymphoma incidence J:61201
\Atmtm1Fwa/\Atmtm1Fwa
(involves: 129S4/SvJae)
abnormal class switch recombination J:191288
\Atmtm1Led/\Atmtm1Led
(involves: 129S6/SvEvTac * Black Swiss)
abnormal T cell differentiation J:36561
decreased CD4-positive, alpha-beta T cell number J:36561
increased double-positive T cell number J:36561
increased T cell derived lymphoma incidence J:69726
small thymus J:36561
thymus cortex hypoplasia J:36561
\Atmtm1Mfl/\Atmtm1Mfl
(involves: 129T2/SvEms * C57BL/6J)
abnormal immune system cell morphology J:69726
abnormal immune system organ morphology J:69726
abnormal T cell differentiation J:69726
decreased thymocyte number J:69726
enlarged spleen J:69726
increased double-negative T cell number J:69726
increased single-positive T cell number J:69726
increased T cell derived lymphoma incidence J:69726
small lymph nodes J:69726
small spleen J:69726
small thymus J:69726
\Atmtm1Pmc/\Atmtm1Pmc
\Trp73tm2Mak/\Trp73tm2Mak

(involves: 129P2/OlaHsd * C57BL/6J)
decreased thymocyte apoptosis J:157905
\Atmtm1Shzh/\Atmtm2.1Fwa
\Gt(ROSA)26Sortm1(cre/ERT2)Thl/\Gt(ROSA)26Sor+

(involves: 129 * 129S6/SvEvTac)
abnormal class switch recombination J:191288
\Atmtm2.1Fwa/\Atmtm2.1Fwa
\Tg(VAV1-cre)1Graf/0

(involves: 129S6/SvEvTac)
decreased B cell number J:277750
decreased T cell number J:277750
decreased thymocyte number J:277750
increased T cell derived lymphoma incidence J:277750
\Atmtm2.1Mfgc/\Atmtm2.1Mfgc
(C57BL/6-Atmtm2.1Mfgc)
abnormal T cell differentiation J:316365
decreased T cell number J:316365
\Atmintm1.1Jhh/\Atmintm1.1Jhh
(C57BL/6-Atmintm1.1Jhh)
thymus hypoplasia J:167544
\Atmintm1.1Jhh/\Atmintm1.1Jhh
\Cd79atm1(cre)Reth/\Cd79a+

(B6.Cg-Cd79atm1(Cre)Reth Atmintm1.1Jhh)
decreased B cell number J:230105
decreased IgG1 level J:230105
decreased immature B cell number J:230105
increased B cell apoptosis J:230105
\Atmintm1.1Jhh/\Atmintm1.1Jhh
\Cd79atm1(cre)Reth/\Cd79a+
\Tg(IghMyc)22Bri/0

(B6.Cg-Cd79atm1(Cre)Reth Atmintm1.1Jhh Tg(IghMyc)22Bri)
decreased B cell number J:230105
decreased immature B cell number J:230105
increased B cell apoptosis J:230105
\Atmintm1.2Jhh/\Atmintm1.2Jhh
\Bcl2l11tm1.1Ast/\Bcl2l11tm1.1Ast
\Cd79atm1(cre)Reth/\Cd79a+

(involves: 129S1/Sv * BALB/c * C57BL/6)
enlarged spleen J:191832
immune system phenotype J:191832
increased B cell number J:191832
increased immature B cell number J:191832
increased pre-B cell number J:191832
increased spleen weight J:191832
\Atmintm1.2Jhh/\Atmintm1.2Jhh
\Cd79atm1(cre)Reth/\Cd79a+

(involves: BALB/c * C57BL/6)
abnormal B cell differentiation J:191832
abnormal B cell physiology J:191832
decreased immature B cell number J:191832
decreased mature B cell number J:191832
decreased pre-B cell number J:191832
decreased spleen weight J:191832
small spleen J:191832
\Atmintm1.2Jhh/\Atmintm1.2Jhh
\Tg(Mx1-cre)1Cgn/0

(involves: C57BL/6 * CBA)
decreased B cell number J:191832
decreased lymphocyte cell number J:191832
decreased mature B cell number J:191832
decreased pre-B cell number J:191832
immune system phenotype J:191832
\Atmintm1.2Jhh/\Atmintm1.2Jhh
\Trp53tm1Brn/\Trp53tm1Brn
\Cd79atm1(cre)Reth/\Cd79a+

(involves: 129P2/OlaHsd * BALB/c * C57BL/6)
decreased B cell number J:191832
decreased immature B cell number J:191832
\Atn1tm1b(EUCOMM)Wtsi/\Atn1tm1b(EUCOMM)Wtsi
(C57BL/6N-Atn1tm1b(EUCOMM)Wtsi/Cnrm)
decreased lymphocyte cell number J:211773
decreased monocyte cell number J:211773
increased neutrophil cell number J:211773
\Atp1a1em1(IMPC)Ccpcz/\Atp1a1+
(C57BL/6NCrl-Atp1a1em1(IMPC)Ccpcz/Ccpcz)
abnormal lymph node morphology J:211773
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged lymph nodes J:211773
enlarged thymus J:211773
\Atp1a3Myk/\Atp1a3+
(involves: 129S1/SvImJ * C57BL/6J * C57BL/6NCr * FVB/NCr)
microgliosis J:151948
\Atp2a2tm1Ges/\Atp2a2+
(involves: 129X1/SvJ)
abnormal osteoclast differentiation J:198051
\Atp2b4tm1Ges/\Atp2b4tm1Ges
(involves: 129X1/SvJ * Black Swiss)
enlarged submandibular lymph nodes J:91844
\Atp2c2em1(IMPC)Tcp/\Atp2c2em1(IMPC)Tcp
(C57BL/6NCrl-Atp2c2em1(IMPC)Tcp/Tcp)
enlarged lymph nodes J:211773
\Atp4am1Btlr/\Atp4am1Btlr
(involves: C57BL/6J)
abnormal spleen morphology J:179090
enlarged spleen J:179090
\Atp5if1em1Jpy/\Atp5if1em1Jpy
(C57BL/6J-Atp5if1em1Jpy)
decreased neutrophil cell number J:312819
decreased susceptibility to colitis induced morbidity/mortality J:312819
\Atp5mgtm1b(EUCOMM)Hmgu/\Atp5mg+
(C57BL/6N-Atp5mgtm1b(EUCOMM)Hmgu/H)
decreased eosinophil cell number J:211773
enlarged spleen J:211773
\Atp5mktm1b(EUCOMM)Wtsi/\Atp5mktm1b(EUCOMM)Wtsi
(C57BL/6N-Atp5mktm1b(EUCOMM)Wtsi/H)
increased leukocyte cell number J:211773
increased monocyte cell number J:211773
increased neutrophil cell number J:211773
\Atp6v0a2tm1Kdb/\Atp6v0a2tm1Kdb
\Commd10Tg(Vav1-icre)A2Kio/\Commd10+

(involves: C57BL/6 * C57BL/10 * CBA/Ca)
abnormal CD8-positive, alpha-beta cytotoxic T cell morphology J:274048
decreased alpha-beta T cell number J:274048
decreased CD4-positive, alpha-beta T cell number J:274048
decreased T cell number J:274048
\Atp6v0d1tm1b(EUCOMM)Hmgu/\Atp6v0d1+
(C57BL/6N-Atp6v0d1tm1b(EUCOMM)Hmgu/Tcp)
decreased lymphocyte cell number J:211773
increased neutrophil cell number J:211773
\Atp6v0d2tm1Ywc/\Atp6v0d2tm1Ywc
(involves: 129P2/OlaHsd * C57BL/6)
abnormal osteoclast differentiation J:117744
abnormal osteoclast morphology J:117744
\Atp6v1b2tm1b(KOMP)Wtsi/\Atp6v1b2+
(C57BL/6N-Atp6v1b2tm1b(KOMP)Wtsi/Tcp)
small lymph nodes J:211773
\Atp6v1c1tm1b(NCOM)Mfgc/\Atp6v1c1+
(C57BL/6N-Atp6v1c1tm1b(NCOM)Mfgc/Tcp)
increased leukocyte cell number J:211773
\Atp6v1hem1Xhd/\Atp6v1h+
(involves: C57BL/6)
abnormal osteoclast differentiation J:239439
abnormal osteoclast physiology J:239439
\Atp7aMo-3Btlr/Y
(C57BL/6J-Atp7aMo-3Btlr)
decreased susceptibility to prion infection J:188598
\Atp7aMo-blo/Y
(B6.Cg-Atp7aMo-blo/J)
osteoarthritis J:36378
\Atp7aMo-ml/Y
(involves: C3Hf/He)
decreased spleen weight J:12745
\Atp7btx-J/\Atp7btx-J
(C3H/HeJ-Atp7btx-J/J)
increased eosinophil cell number J:24233
\Atp8b1em1(IMPC)Tcp/\Atp8b1em1(IMPC)Tcp
(C57BL/6NCrl-Atp8b1em1(IMPC)Tcp/Tcp)
enlarged spleen J:211773
increased leukocyte cell number J:211773
\Atp10am1Anu/\Atp10am1Anu
(C57BL/6NCrlAnu-Atp10am1Anu)
immune system phenotype J:104190
\Atp11atm1a(KOMP)Wtsi/\Atp11atm1a(KOMP)Wtsi
(C57BL/6N-Atp11atm1a(KOMP)Wtsi/Wtsi)
abnormal thymus morphology J:239583
\Atp11cambr/Y
(C57BL/6-Atp11cambr)
abnormal B cell differentiation J:171924
abnormal humoral immune response J:171924
decreased B cell number J:171924
decreased B-1 B cell number J:171924
decreased B-1a cell number J:171924
decreased B-1b cell number J:171924
decreased B-2 B cell number J:171924
decreased follicular B cell number J:171924
decreased immature B cell number J:171924
decreased leukocyte cell number J:171924
decreased lymphocyte cell number J:171924
decreased mature B cell number J:171924
decreased pre-B cell number J:171924
decreased pro-B cell number J:171924
decreased T cell number J:171924
\Atp11cambr/Y
\Tg(H2-Ea-Il7)10Rhdr/0

(involves: C57BL/6 * C57BL/6JApb * DBA/2)
decreased B cell number J:171924
\Atp11cambr/Y
\Tg(IghelMD4)4Ccg/0

(involves: C57BL/6 * C57BL/6JApb)
decreased immature B cell number J:171924
decreased pro-B cell number J:171924
\Atp11cambr/Y
\Tg(Vav-BCL2)69Jad/0

(involves: C57BL/6 * C57BL/6J * C57BL/6JApb)
decreased B cell number J:171924
decreased immature B cell number J:171924
decreased pre-B cell number J:171924
\Atp11cem1(IMPC)J/Y
(C57BL/6NJ-Atp11cem1(IMPC)J/Mmjax)
decreased leukocyte cell number J:211773
\Atp11cem1(IMPC)J/\Atp11cem1(IMPC)J
(C57BL/6NJ-Atp11cem1(IMPC)J/Mmjax)
decreased leukocyte cell number J:211773
\Atp11cm1Btlr/Y
(involves: C57BL/6J)
absent follicular B cells J:171925
arrested B cell differentiation J:171925
decreased B cell number J:185495, J:171925
decreased B-1 B cell number J:171925
decreased B-2 B cell number J:171925
decreased IgA level J:171925
decreased IgG1 level J:171925
decreased IgM level J:171925
decreased immature B cell number J:171925
decreased transitional stage B cell number J:171925
decreased transitional stage T1 B cell number J:171925
decreased transitional stage T2 B cell number J:171925
decreased transitional stage T3 B cell number J:171925
immune system phenotype J:185495, J:171925
\Atp11cm1Btlr/Y
\Tg(BCL2)22Wehi/0

(involves: C57BL/6J * C57BL/6JWehi * SJL/Wehi)
decreased B cell number J:171925
decreased follicular B cell number J:171925
decreased mature B cell number J:171925
increased marginal zone B cell number J:171925
\Atp11cm1Btlr/Y
\Tg(IghmHyHEL10,IgkHyHEL10)4Ccg/0

(involves: C57BL/6 * C57BL/6J * C57BL/6JSfdAnu)
decreased B cell number J:171925
\Atp11cm1Btlr/\Atp11cm1Btlr
(involves: C57BL/6J)
decreased B cell number J:185495
immune system phenotype J:185495, J:171925
\Atp11cm1Btlr/\Atp11cm2Btlr
(involves: C57BL/6J)
decreased B cell number J:171925
\Atp11cm2Anu/Y
(C57BL/6JAnu-Atp11cm2Anu/AnuApb)
decreased B cell number J:171924
\Atp11cm2Btlr/Y
(involves: C57BL/6J)
decreased B cell number J:185495, J:171925
immune system phenotype J:185495
\Atp11cm2Btlr/\Atp11cm2Btlr
(involves: C57BL/6J)
decreased B cell number J:185495
immune system phenotype J:185495
\Atp13a3em1(IMPC)J/\Atp13a3em1(IMPC)J
(C57BL/6NJ-Atp13a3em1(IMPC)J/Mmjax)
increased leukocyte cell number J:211773
\Atp13a5tm1Lex/\Atp13a5tm1Lex
(B6;129S5-Atp13a5tm1Lex/Mmucd)
decreased NK cell number J:171883
\Atrtm1Bal/\Atrtm2Bal
\Ndor1Tg(UBC-cre/ERT2)1Ejb/0

(involves: 129S/SvEv * 129S2/SvPas * C57BL/6)
abnormal thymus involution J:123200
decreased thymocyte number J:123200
kidney inflammation J:123200
\Atrtm1Ofc/\Atrtm1Ofc
(Not Specified)
decreased spleen weight J:151542
decreased thymus weight J:151542
\Atxn3tm1a(KOMP)Wtsi/\Atxn3tm1a(KOMP)Wtsi
(C57BL/6N-Atxn3tm1a(KOMP)Wtsi/Wtsi)
increased anti-nuclear antigen antibody level J:211773
\AU040320em1Janc/\AU040320em2Janc
(FVB/N-AU040320em1Janc AU040320em2Janc)
decreased susceptibility to Parvoviridae infection J:229089
\Auhem1(IMPC)Tcp/\Auhem1(IMPC)Tcp
(C57BL/6NCrl-Auhem1(IMPC)Tcp/Tcp)
increased eosinophil cell number J:211773
\Aurkatm1b(EUCOMM)Hmgu/\Aurka+
(B6N(Cg)-Aurkatm1b(EUCOMM)Hmgu/J)
decreased leukocyte cell number J:211773
\Aviltm2(cre)Fawa/\Aviltm2(cre)Fawa
(B6J.129P2-Aviltm2(cre)Fawa)
increased susceptibility to experimental autoimmune encephalomyelitis J:265529
\Avptm1b(EUCOMM)Wtsi/\Avp+
(C57BL/6N-Avptm1b(EUCOMM)Wtsi/H)
decreased large unstained cell number J:211773
decreased neutrophil cell number J:211773
increased lymphocyte cell number J:211773
\Avpr1atm1Sbhu/\Avpr1atm1Sbhu
(involves: C57BL/6)
abnormal B cell differentiation J:105892
abnormal immunoglobulin level J:105892
decreased IgG2b level J:105892
increased B-1a cell number J:105892
increased IgG2a level J:105892
\AW112010em2Flv/\AW112010em2Flv
(involves: C57BL/6N)
decreased circulating interleukin-6 level J:267975
decreased circulating interleukin-12b level J:267975
decreased interleukin-6 secretion J:267975
decreased interleukin-12b secretion J:267975
decreased susceptibility to induced colitis J:267975
increased susceptibility to bacterial infection J:267975
increased susceptibility to bacterial infection induced morbidity/mortality J:267975
\Awat2em1(IMPC)Mbp/Y
(C57BL/6NCrl-Awat2em1(IMPC)Mbp/Mmucd)
abnormal lymph node morphology J:211773
\Awat2tm1.2Golc/Y
(involves: 129 * C57BL/6 * C57BL/6J)
abnormal lymphangiogenesis J:308387
blepharitis J:308387
eye inflammation J:308387
\Awat2tm1.2Golc/\Awat2tm1.2Golc
(involves: 129 * C57BL/6 * C57BL/6J)
abnormal lymphangiogenesis J:308387
blepharitis J:308387
eye inflammation J:308387
\awgTg(GBts1env)832Pkw/\awgTg(GBts1env)832Pkw
(involves: C57BL/6J * SJL)
thymus atrophy J:43273
\Axltm1Grl/\Axltm1Grl
\Mertktm1Grl/\Mertktm1Grl

(involves: C57BL/6J)
increased anti-double stranded DNA antibody level J:70420
\Axltm1Grl/\Axltm1Grl
\Mertktm1Grl/\Mertktm1Grl
\Tyro3tm1Grl/\Tyro3tm1Grl

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)
abnormal B cell activation J:70420
abnormal macrophage physiology J:70420
abnormal professional antigen presenting cell physiology J:70420
abnormal susceptibility to autoimmune disorder J:70420
abnormal T cell activation J:70420
enlarged lymph nodes J:70420
enlarged spleen J:54681, J:70420
increased anti-double stranded DNA antibody level J:70420
increased autoantibody level J:70420
increased B cell proliferation J:70420
increased circulating tumor necrosis factor level J:70420
increased lymphocyte cell number J:70420
increased splenocyte apoptosis J:54681
increased T cell proliferation J:70420
joint inflammation J:70420
\Axltm1Grl/\Axltm1Grl
\Tyro3tm1Grl/\Tyro3tm1Grl

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)
increased anti-double stranded DNA antibody level J:70420
\Azgp1tm1.1Sbah/\Azgp1tm1.1Sbah
(involves: 129P2/OlaHsd * C57BL/6)
enlarged spleen J:118213
\Azi2tm1Aki/\Azi2tm1Aki
(Not Specified)
abnormal dendritic cell differentiation J:204786
abnormal dendritic cell physiology J:204786
decreased interferon-alpha secretion J:204786
decreased interleukin-6 secretion J:204786
decreased tumor necrosis factor secretion J:204786
immune system phenotype J:204786
\Azi2tm1Aki/\Azi2tm1Aki
\Tbkbp1tm1Aki/\Tbkbp1tm1Aki

(Not Specified)
abnormal dendritic cell physiology J:204786
decreased interferon-alpha secretion J:204786
decreased interleukin-6 secretion J:204786
decreased tumor necrosis factor secretion J:204786
immune system phenotype J:204786
\b2b227Clo/\b2b227Clo
(C57BL/6J-b2b227Clo)
spleen hypoplasia J:175213
\b2b386.1Clo/\b2b386.1Clo
(C57BL/6J-b2b386.1Clo)
absent spleen J:175213
\b2b386Clo/\b2b386Clo
(C57BL/6J-b2b386Clo)
absent spleen J:175213
\b2b954Clo/\b2b954Clo
(C57BL/6J-b2b954Clo)
thymus hypoplasia J:175213
\b2b1249Clo/\b2b1249Clo
(C57BL/6J-b2b1249Clo)
thymus hypoplasia J:175213
\b2b1702Clo/\b2b1702Clo
(C57BL/6J-b2b1702Clo)
spleen hypoplasia J:175213
thymus hypoplasia J:175213
\b2b1941Clo/\b2b1941Clo
(C57BL/6J-b2b1941Clo)
athymia J:175213
\b2b2025Clo/\b2b2025Clo
(C57BL/6J-b2b2025Clo)
absent spleen J:175213
spleen hypoplasia J:175213
\b2b2059Clo/\b2b2059Clo
(C57BL/6J-b2b2059Clo)
spleen hypoplasia J:175213
\b2b2140Clo/\b2b2140Clo
(C57BL/6J-b2b2140Clo)
spleen hypoplasia J:175213
\b2b2187Clo/\b2b2187Clo
(C57BL/6J-b2b2187Clo)
thymus hypoplasia J:175213
\b2b2463Clo/\b2b2463Clo
(C57BL/6J-b2b2463Clo)
thymus hypoplasia J:175213
\b2b2588Clo/\b2b2588Clo
(C57BL/6J-b2b2588Clo)
thymus hypoplasia J:175213
\b2b2696.1Clo/\b2b2696.1Clo
(C57BL/6J-b2b2696.1Clo)
absent spleen J:175213
\b2b2696.2Clo/\b2b2696.2Clo
(C57BL/6J-b2b2696.2Clo)
thymus hypoplasia J:175213
\b2b2696Clo/\b2b2696Clo
(C57BL/6J-b2b2696Clo)
absent spleen J:175213
\b2b2736.2Clo/\b2b2736.2Clo
(C57BL/6J-b2b2736.2Clo)
thymus hypoplasia J:175213
\b2b2736Clo/\b2b2736Clo
(C57BL/6J-b2b2736Clo)
accessory spleen J:175213
spleen hypoplasia J:175213
thymus hypoplasia J:175213
\b2b2821Clo/\b2b2821Clo
(C57BL/6J-b2b2821Clo)
thymus hypoplasia J:175213
\b2b2966Clo/\b2b2966Clo
(C57BL/6J-b2b2966Clo)
thymus hypoplasia J:175213
\b2b3077.2Clo/\b2b3077.2Clo
(C57BL/6J-b2b3077.2Clo)
thymus hypoplasia J:175213
\b2b3077Clo/\b2b3077Clo
(C57BL/6J-b2b3077Clo)
thymus hypoplasia J:175213
\b2b3121Clo/\b2b3121Clo
(C57BL/6J-b2b3121Clo)
thymus hypoplasia J:175213
\b2b3260.2Clo/\b2b3260.2Clo
(C57BL/6J-b2b3260.2Clo)
abnormal thymus morphology J:175213
thymus hypoplasia J:175213
\b2b3260Clo/\b2b3260Clo
(C57BL/6J-b2b3260Clo)
abnormal thymus morphology J:175213
thymus hypoplasia J:175213
\B2mtm1Jae/\B2mtm1Jae
(involves: 129S2/SvPas * C57BL/6J)
abnormal CD8-positive, alpha-beta cytotoxic T cell morphology J:80910
abnormal cytotoxic T cell physiology J:80910
decreased CD8-positive, alpha-beta T cell number J:80910, J:744
increased gamma-delta intraepithelial T cell number J:744
increased gamma-delta T cell number J:744
\B2mtm1Jae/\B2mtm1Jae
(involves: 129S2/SvPas)
decreased CD8-positive, alpha-beta T cell number J:166104
\B2mtm1Jae/\B2mtm1Jae
(B6.129S2-B2mtm1Jae)
decreased interleukin-4 secretion J:64283
decreased susceptibility to parasitic infection J:64283
increased interleukin-3 secretion J:64283
increased tumor necrosis factor secretion J:64283
\B2mtm1Jae/\B2mtm1Jae
\Cd4tm1Jrp/\Cd4tm1Jrp

(involves: 129S2/SvPas * C57BL/6)
increased CD8-positive, alpha-beta T cell number J:45168
\B2mtm1Jae/\B2mtm1Jae
\Foxp3sf\Otcspf/Y

(involves: 129/Rl * 129S2/SvPas)
abnormal immune system organ morphology J:20865
abnormal interleukin level J:20865
abnormal lymph node morphology J:20865
abnormal tumor necrosis factor level J:20865
dermatitis J:20865
enlarged lymph nodes J:20865
enlarged spleen J:20865
increased CD4-positive, alpha-beta T cell number J:20865
increased IgG level J:20865
increased IgM level J:20865
increased immunoglobulin level J:20865
increased plasma cell number J:20865
\B2mtm1Jae/\B2mtm1Jae
\Rr94tm3.2Litt/\Rr94tm3.2Litt

(involves: 129P2/OlaHsd * 129S2/SvPas * FVB/N)
abnormal T cell differentiation J:158962
abnormal T cell subpopulation ratio J:158962
decreased CD4-positive, alpha-beta T cell number J:158962
increased CD8-positive, alpha-beta T cell number J:158962
increased T cell proliferation J:158962
\B2mtm1Jae/\B2mtm1Jae
\Rr96tm1.1Yzo/\Rr96tm1.1Yzo

(involves: 129P2/OlaHsd * 129S2/SvPas)
abnormal T cell differentiation J:130559
\B2mtm1Jae/\B2mtm1Jae
\Tg(H2-K-Cd86)27All/0

(involves: 129S2/SvPas * C57BL/6 * CBA)
absent B cells J:112475
\B2mtm1Jae/\B2mtm1Jae
\Tg(LckNotch1)9Erob/?

(involves: 129S2/SvPas * C57BL/6 * CBA)
increased CD8-positive, alpha-beta T cell number J:93005
lymph node hypoplasia J:93005
\B2mtm1Jae/\B2mtm1Jae
\Themistm1Lov/\Themistm1Lov

(involves: 129)
abnormal CD8-positive, alpha-beta T cell differentiation J:151075
\B2mtm1Jae/\B2mtm1Jae
\Tnftm2Gkl/\Tnf+

(involves: 129S/SvEv * 129S2/SvPas * C57BL/6J)
small intestinal inflammation J:108572
\B2mtm1Jae/\B2mtm1Jae
\Toxtm1.1Kay/\Toxtm1.1Kay

(involves: 129S6/SvEvTac * 129S2/SvPas)
abnormal CD8-positive, alpha-beta T cell number J:131287
\B2mtm1Jae/\B2mtm1Jae
\Zbtb7btm1Litt/\Zbtb7btm1.2Litt

(involves: 129S2/SvPas * C57BL/6)
abnormal CD8-positive, alpha-beta T cell differentiation J:141144
abnormal double-positive T cell morphology J:141144
\B2mtm1Unc/\B2m+
(involves: 129P2/OlaHsd * C57BL/6)
decreased CD8-positive, alpha-beta T cell number J:64451
decreased level of surface class I molecules J:64451
\B2mtm1Unc/\B2mtm1Unc
(involves: 129P2/OlaHsd * C57BL/6)
abnormal T cell number J:113083
absent CD8-positive, alpha-beta T cells J:64451
decreased level of surface class I molecules J:64451
\B2mtm1Unc/\B2mtm1Unc
(NOD.129P2-B2mtm1Unc)
absent CD8-positive, alpha-beta T cells J:121685
decreased susceptibility to autoimmune diabetes J:121685, J:17000
\B2mtm1Unc/\B2mtm1Unc
(involves: 129P2/OlaHsd * NOD/Lt)
insulitis J:93557
\B2mtm1Unc/\B2mtm1Unc
(B6.129P2-B2mtm1Unc/DcrJ)
abnormal interleukin level J:123934
abnormal tumor necrosis factor level J:123934
decreased CD8-positive, alpha-beta T cell number J:123934
decreased IgG level J:110885
decreased susceptibility to autoimmune diabetes J:135214
decreased susceptibility to bacterial infection J:123934
increased IgM level J:110885
increased susceptibility to infection induced morbidity/mortality J:123934
increased T-helper 1 cell number J:123934
\B2mtm1Unc/\B2mtm1Unc
\Cd4tm1Mak/\Cd4tm1Mak
\Cd8atm2.1(Cd4)Asin/\Cd8atm2.1(Cd4)Asin

(involves: 129 * C57BL/6)
abnormal T cell physiology J:180236
\B2mtm1Unc/\B2mtm1Unc
\Ciitatm1Ccum/\Ciitatm1Ccum

(NOD.Cg-B2mtm1Unc Ciitatm1Ccum)
decreased single-positive T cell number J:107051
decreased susceptibility to autoimmune diabetes J:107051
\B2mtm1Unc/\B2mtm1Unc
\Emv30b/\Emv30b
\Prkdcscid/\Prkdcscid
\Tg(B2M)55Hpl/?
\Mcph1Tg(HLA-A2.1)1Enge/?

(NOD.Cg-B2mtm1Unc Mcph1Tg(HLA-A2.1)1Enge Emv30b Prkdcscid Tg(B2M)55Hpl/Dvs)
decreased susceptibility to autoimmune diabetes J:109851
\B2mtm1Unc/\B2mtm1Unc
\H2-Ab1b-tm1Doi/\H2-Ab1b-tm1Doi
\Lattm1.1Mal/\Lattm1.1Mal

(involves: 129P2/OlaHsd * 129S2/SvPas)
absent CD4-positive, alpha-beta T cells J:77098
absent CD8-positive, alpha-beta T cells J:77098
immune system phenotype J:77098
\B2mtm1Unc/\B2mtm1Unc
\H2-D1b-tm1Bpe/\H2-D1b-tm1Bpe

(involves: 129P2/OlaHsd * C57BL/6)
decreased CD8-positive, alpha-beta T cell number J:41077
\B2mtm1Unc/\B2mtm1Unc
\Il2tm1Hor/\Il2tm1Hor

(involves: 129 * C57BL/6)
abnormal CD4-positive T cell differentiation J:39981
abnormal CD4-positive, alpha-beta T cell physiology J:51450
abnormal CD8 positive, alpha-beta intraepithelial T cell morphology J:39981
abnormal CD8-positive, alpha beta T cell morphology J:51450
abnormal CD8-positive, alpha-beta cytotoxic T cell morphology J:39981
colitis J:39981, J:51450
\B2mtm1Unc/\B2mtm1Unc
\Il2rgtm1.1Asin/\Il2rgtm1Wjl
\Tg(Cd8a*-cre)B8Asin/0

(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)
decreased CD8-positive, alpha-beta T cell number J:190889
\B2mtm1Unc/\B2mtm1Unc
\Il7rtm1.1Asin/\Il7rtm1Imx
\Tg(Cd8a*-cre)B8Asin/0

(involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6)
decreased CD8-positive, alpha-beta T cell number J:190889
\B2mtm1Unc/\B2mtm1Unc
\Lattm1.1Mal/\Lattm1.1Mal

(involves: 129P2/OlaHsd * 129S2/SvPas)
abnormal immune system morphology J:77098
\B2mtm1Unc/\B2mtm1Unc
\Prkdcscid/\Prkdcscid

(NOD.Cg-B2mtm1Unc Prkdcscid)
abnormal NK cell physiology J:102141
abnormal response to transplant J:102141
absent lymphocyte J:102141
arrested B cell differentiation J:102141
arrested T cell differentiation J:102141
decreased level of surface class I molecules J:102141
increased macrophage cell number J:102141
increased T cell derived lymphoma incidence J:102141
\B2mtm1Unc/\B2mtm1Unc
\Rr381em2Kap/\Rr381em2Kap

(involves: 129P2/OlaHsd * C57BL/6)
absent CD8-positive, alpha-beta T cells J:333471
\B2mtm1Unc/\B2mtm1Unc
\Tespa1tm1Smoc/\Tespa1tm1Smoc

(involves: 129 * 129P2/OlaHsd * C57BL/6)
abnormal CD8-positive, alpha beta T cell morphology J:186446
\B2mtm1Unc/\B2mtm1Unc
\Tg(B2M)55Hpl/0

(NOD.Cg-B2mtm1Unc Tg(B2M)55Hpl/Dvs)
decreased susceptibility to autoimmune diabetes J:71837
immune system phenotype J:71837
\B2mtm1Unc/\B2mtm1Unc
\Tg(B2M)55Hpl/\Tg(B2M)55Hpl
\Mcph1Tg(HLA-A2.1)1Enge/\Mcph1Tg(HLA-A2.1)1Enge

(NOD.Cg-B2mtm1Unc Mcph1Tg(HLA-A2.1)1Enge Tg(B2M)55Hpl)
increased susceptibility to autoimmune diabetes J:109851
\B2mtm1Unc/\B2mtm1Unc
\Tg(GFAP-B2m)9Mdos/?

(involves: 129P2/OlaHsd * C57BL/6 * NOD/ShiLtJ)
absent CD8-positive, alpha-beta T cells J:135214
decreased susceptibility to autoimmune diabetes J:135214
\B2mtm1Unc/\B2mtm1Unc
\Tg(GFAP-B2m)#Mdos/?

(involves: 129P2/OlaHsd * C57BL/6 * NOD/ShiLtJ)
absent CD8-positive, alpha-beta T cells J:135214
decreased susceptibility to autoimmune diabetes J:135214
\B2mtm1Unc/\B2mtm1Unc
\Tg(HLA-A/H2-D/B2M)1Dvs/0

(NOD.Cg-B2mtm1Unc Tg(HLA-A/H2-D/B2M)1Dvs)
abnormal CD8-positive, alpha-beta T cell physiology J:121685
abnormal cell-mediated immunity J:121685
abnormal cytotoxic T cell physiology J:121685
decreased CD8-positive, alpha-beta T cell number J:121685
increased susceptibility to autoimmune diabetes J:121685
\B2mtm1Unc/\B2mtm1Unc
\Tg(TcraAI4)1Dvs/0
\Tg(TcrbAI4)1Dvs/0

(NOD.Cg-B2mtm1Unc Tg(TcraAI4)1Dvs Tg(TcrbAI4)1Dvs)
abnormal CD8-positive, alpha beta T cell morphology J:93553
decreased susceptibility to autoimmune diabetes J:93553
\B2mtm1Unc/\B2mtm1Unc
X/\Yaa

(BXSB.129P2(B6)-B2mtm1Unc/Dcr)
increased anti-nuclear antigen antibody level J:179430
increased susceptibility to systemic lupus erythematosus J:179430
\B2mtm1Unc/\B2mtm1Unc
\Zbtb7btm4.1Itan/\Zbtb7btm4.1Itan

(involves: 129P2/OlaHsd)
increased CD8-positive, alpha-beta T cell number J:193321
\B3galt2tm1.1(KOMP)Vlcg/\B3galt2+
(C57BL/6N-B3galt2tm1.1(KOMP)Vlcg/Tcp)
decreased lymphocyte cell number J:211773
\B3gnt2Gt(OST237555)Lex/\B3gnt2Gt(OST237555)Lex
(involves: 129S5/SvEvBrd * C57BL/6N)
abnormal macrophage physiology J:125556
increased interleukin-1 beta secretion J:125556
increased interleukin-6 secretion J:125556
increased T cell proliferation J:125556
increased tumor necrosis factor secretion J:125556
\B3gnt5tm1Big/\B3gnt5tm1Big
(C57BL/6-B3gnt5tm1Big)
abnormal spleen germinal center morphology J:166763
abnormal spleen morphology J:166763
absent spleen marginal zone J:166763
decreased B cell number J:166763
enlarged lymph nodes J:166763
enlarged spleen J:166763
increased spleen white pulp amount J:166763
intermingled spleen red and white pulp J:166763
\B3gnt5tm1Nari/\B3gnt5tm1Nari
(involves: 129P2/OlaHsd * C57BL/6)
abnormal B cell morphology J:161366
increased IgG2a level J:161366
increased IgG2b level J:161366
increased IgG level J:161366
\B3gnt5tm2.1Big/\B3gnt5tm2.1Big
(involves: 129/Sv * C57BL/6 * FVB/N)
abnormal spleen germinal center morphology J:166763
abnormal spleen morphology J:166763
absent spleen marginal zone J:166763
decreased B cell number J:166763
enlarged lymph nodes J:166763
enlarged spleen J:166763
increased spleen white pulp amount J:166763
intermingled spleen red and white pulp J:166763
\B3gnt6tm1Lx/\B3gnt6tm1Lx
(involves: 129S1/Sv * C57BL/6J)
increased interferon-gamma secretion J:123826
increased interleukin-2 secretion J:123826
increased macrophage cell number J:123826
increased monocyte cell number J:123826
increased susceptibility to induced colitis J:123826
increased T cell number J:123826
increased tumor necrosis factor secretion J:123826
\B3gnt6tm1Lx/\B3gnt6tm1Lx
\C1galt1tm1.1Rpmc/\C1galt1tm1.1Rpmc
\Tg(Vil1-cre)997Gum/0

(involves: 129S1/Sv * C57BL/6J * SJL)
small intestinal inflammation J:239765
\B3gnt7tm1e.1(KOMP)Wtsi/\B3gnt7tm1e.1(KOMP)Wtsi
(C57BL/6N-B3gnt7tm1e.1(KOMP)Wtsi/Ucd)
enlarged spleen J:211773
\B4galnt1tm1Rlp/\B4galnt1tm1Rlp
\Hexbtm1Rlp/\Hexbtm1Rlp

(involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6)
abnormal macrophage morphology J:53080
\B4galnt2tm1Jbl/\B4galnt2tm1Jbl
(involves: 129S1/Sv)
abnormal B cell number J:217719
increased neutrophil cell number J:217719
\B4galnt3tm1a(EUCOMM)Wtsi/\B4galnt3tm1a(EUCOMM)Wtsi
(C57BL/6N-B4galnt3tm1a(EUCOMM)Wtsi/Ics)
increased CD8-positive, alpha-beta T cell number J:165965
\B4galt1tm1Yiw/\B4galt1tm1Yiw
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)
abnormal leukocyte physiology J:106669
abnormal neutrophil physiology J:106669
decreased acute inflammation J:106669
decreased susceptibility to type IV hypersensitivity reaction J:106669
enlarged spleen J:106669
impaired macrophage chemotaxis J:89125
impaired neutrophil recruitment J:89125
increased leukocyte cell number J:106669
increased lymphocyte cell number J:106669
increased neutrophil cell number J:106669
\B4galt1tm1Yiw/\B4galt1tm1Yiw
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
abnormal IgM level J:117891
glomerulonephritis J:117891
increased IgA level J:117891
\B4galt3em1Masn/\B4galt3em1Masn
(C57BL/6-B4galt3em1Masn)
abnormal CD8-positive, alpha-beta cytotoxic T cell morphology J:343168
decreased regulatory T cell number J:343168
increased CD8-positive, alpha-beta T cell number J:343168
\B4galt4em1(IMPC)J/\B4galt4em1(IMPC)J
(C57BL/6NJ-B4galt4em1(IMPC)J/Mmjax)
decreased leukocyte cell number J:211773
\B4galt5em1(IMPC)Tcp/\B4galt5+
(C57BL/6NCrl-B4galt5em1(IMPC)Tcp/Tcp)
enlarged lymph nodes J:211773
\B4gat1tm1Mifu/\B4gat1tm1Mifu
(B6.Cg-B4gat1tm1Mifu)
abnormal lymph node cell ratio J:120722
immune system phenotype J:120722
impaired leukocyte tethering or rolling J:120722
\B4gat1tm1Mifu/\B4gat1tm1Mifu
\Gcnt1tm1Jxm/\Gcnt1tm1Jxm

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
abnormal leukocyte migration J:120722
abnormal lymph node cell ratio J:120722
decreased susceptibility to type IV hypersensitivity reaction J:120722
impaired leukocyte tethering or rolling J:120722
\B9d2/Tgfb1tm1Flv/\B9d2/Tgfb1tm1Flv
\Tg(Cd4-cre)1Cwi/0

(involves: 129S6/SvEvTac * C57BL/6 * SJL)
abnormal regulatory T cell physiology J:204761
\B9d2/Tgfb1tm1Flv/\B9d2/Tgfb1tm1Flv
\Tg(CD207-cre)1Dhka/?

(involves: 129S6/SvEvTac * C57BL/6J * SJL/J)
decreased Langerhans cell number J:126147
\B9d2/Tgfb1tm1Flv/\Tgfb1tm2Flv
\Foxp3tm4(YFP/icre)Ayr/\Foxp3+

(involves: 129S1/Sv * 129S6/SvEvTac * 129X1/SvJ)
immune system phenotype J:169839
increased regulatory T cell number J:169839
\B9d2/Tgfb1tm1Flv/\Tgfb1tm2Flv
\Tg(Cd4-cre)1Cwi/0

(involves: 129S6/SvEvTac * C57BL/6 * DBA/2)
abnormal inflammatory response J:123547
abnormal interferon level J:123547
abnormal interleukin level J:123547
abnormal T cell activation J:123547
abnormal T cell differentiation J:123547
abnormal T-helper 17 cell differentiation J:169839
colitis J:123547
decreased susceptibility to experimental autoimmune encephalomyelitis J:123547
increased anti-double stranded DNA antibody level J:123547
increased anti-nuclear antigen antibody level J:123547
increased T cell proliferation J:123547
\B9d2/Tgfb1tm1Flv/\Tgfb1tm2Flv
\Tnfrsf4tm2(cre)Nik/\Tnfrsf4+

(involves: 129S6/SvEvTac * 129X1/SvJ)
abnormal T cell differentiation J:169839
colitis J:169839
decreased susceptibility to experimental autoimmune encephalomyelitis J:169839
decreased T-helper 17 cell number J:169839
increased regulatory T cell number J:169839
increased T-helper 1 cell number J:169839
liver inflammation J:169839
lung inflammation J:169839
\B9d2/Tgfb1tm1Flv/\B9d2/Tgfb1tm1Flv
\Tg(Cd4-cre)1Cwi/?

(involves: 129S6/SvEvTac * C57BL/6 * DBA/2)
abnormal inflammatory response J:123547
\B9d2/Tgfb1tm1Flv/\B9d2/Tgfb1tm1Flv
\Tg(Cd4-cre)1Cwi/0

(involves: 129S6/SvEvTac * C57BL/6 * SJL)
abnormal regulatory T cell physiology J:204761
\B9d2/Tgfb1tm1Flv/\B9d2/Tgfb1tm1Flv
\Tg(CD207-cre)1Dhka/?

(involves: 129S6/SvEvTac * C57BL/6J * SJL/J)
decreased Langerhans cell number J:126147
\B9d2/Tgfb1tm1Flv/\B9d2+
\Foxp3tm4(YFP/icre)Ayr/\Foxp3+

(involves: 129S1/Sv * 129S6/SvEvTac * 129X1/SvJ)
immune system phenotype J:169839
increased regulatory T cell number J:169839
\B9d2/Tgfb1tm1Flv/\B9d2+
\Tg(Cd4-cre)1Cwi/0

(involves: 129S6/SvEvTac * C57BL/6 * DBA/2)
abnormal T-helper 17 cell differentiation J:169839
\B9d2/Tgfb1tm1Flv/\B9d2+
\Tg(CD207-cre)1Dhka/?

(involves: 129S6/SvEvTac * C57BL/6J * SJL/J)
decreased Langerhans cell number J:126147
\B9d2/Tgfb1tm1Flv/\B9d2+
\Tnfrsf4tm2(cre)Nik/\Tnfrsf4+

(involves: 129S6/SvEvTac * 129X1/SvJ)
abnormal T cell differentiation J:169839
colitis J:169839
decreased susceptibility to experimental autoimmune encephalomyelitis J:169839
decreased T-helper 17 cell number J:169839
increased regulatory T cell number J:169839
increased T-helper 1 cell number J:169839
liver inflammation J:169839
lung inflammation J:169839
\B9d2tm1a(EUCOMM)Wtsi/\B9d2tm1a(EUCOMM)Wtsi
(C57BL/6N-B9d2tm1a(EUCOMM)Wtsi/Wtsi)
abnormal thymus topology J:239583
accessory spleen J:239583
blood in lymph vessels J:239583
enlarged lymphatic vessel J:239583
small spleen J:239583
\Baa1BALB/cJ/\Baa1NZW/LacJ
(involves: BALB/cJ * NZW/LacJ)
increased IgM level J:35434
\Baa2BALB/cJ/\Baa2NZW/LacJ
(involves: BALB/cJ * NZW/LacJ)
increased IgM level J:35434
\Baatem1(IMPC)Mbp/\Baatem1(IMPC)Mbp
(C57BL/6NCrl-Baatem1(IMPC)Mbp/Mmucd)
abnormal lymph node morphology J:211773
\Babam1em1(IMPC)Ccpcz/\Babam1em1(IMPC)Ccpcz
(C57BL/6NCrl-Babam1em1(IMPC)Ccpcz/Ccpcz)
abnormal thymus morphology J:211773
decreased NK T cell number J:211773
enlarged thymus J:211773
increased eosinophil cell number J:211773
\Bach2M1Btlr/\Bach2M1Btlr
(C57BL/6J-Bach2M1Btlr)
decreased CD4-positive, alpha-beta T cell number J:272023
increased B-1 B cell number J:272023
\Bach2m1Ccg/\Bach2m1Ccg
(C57BL/6-Bach2m1Ccg)
decreased B cell number J:94077
decreased marginal zone B cell number J:94077
myeloid hyperplasia J:94077
\Bach2m2Anu/\Bach2m2Anu
(C57BL/6NCrlAnu-Bach2m2Anu)
decreased mature B cell number J:104190
increased IgM level J:104190
increased immature B cell number J:104190
\Bach2tm1a(EUCOMM)Wtsi/\Bach2tm1a(EUCOMM)Wtsi
(C57BL/6N-Bach2tm1a(EUCOMM)Wtsi/Wtsi)
decreased B cell number J:211773
decreased CD8-positive, naive alpha-beta T cell number J:211773
decreased CD11b-high dendritic cell number J:211773
decreased effector memory CD8-positive, alpha-beta T cell number J:211773
decreased follicular B cell number J:211773
decreased mature B cell number J:211773
decreased memory-marker NK cell number J:211773
decreased regulatory T cell number J:211773
increased CD4-positive, alpha-beta memory T cell number J:211773
increased CD8-positive, alpha-beta memory T cell number J:211773
increased CD11b-low dendritic cell number J:211773
increased CD103-positive CD11b-low dendritic cell number J:211773
increased effector memory CD8-positive, alpha-beta T cell number J:211773
increased effector memory T-helper cell number J:211773
increased eosinophil cell number J:211773
increased immature B cell number J:211773
increased KLRG1+ CD4 alpha-beta T cell number J:211773
increased KLRG1+ CD8 alpha-beta T cell number J:211773
increased KLRG1-positive CD4-negative NK T cell number J:211773
increased KLRG1-positive CD4-positive, CD25-positive, alpha-beta regulatory T cell number J:211773
increased KLRG1-positive gamma-delta T cell number J:211773
increased KLRG1-positive NK cell number J:211773
increased Ly6C high monocyte number J:211773
increased Ly6C low monocyte number J:211773
increased macrophage cell number J:211773
increased memory CD4-positive, CD25-positive, alpha-beta regulatory T cell number J:211773
increased memory-marker CD4-negative NK T cell number J:211773
increased memory-marker NK cell number J:211773
increased monocyte cell number J:211773
increased neutrophil cell number J:211773
increased NK cell number J:211773
\Bach2tm1b(EUCOMM)Wtsi/\Bach2tm1b(EUCOMM)Wtsi
(C57BL/6N-Bach2tm1b(EUCOMM)Wtsi/Ieg)
decreased B cell number J:211773
decreased B-1a cell number J:211773
decreased B-2 B cell number J:211773
decreased CD4-negative NK T cell number J:211773
decreased CD8-positive, naive alpha-beta T cell number J:211773
decreased CD11b-high dendritic cell number J:211773
decreased follicular B cell number J:211773
decreased Ly6C-positive immature NK cell number J:211773
decreased Ly6C-positive mature NK cell number J:211773
decreased marginal zone B cell number J:211773
decreased memory-marker CD4-negative NK T cell number J:211773
decreased NK cell number J:211773
decreased NK T cell number J:211773
decreased transitional stage B cell number J:211773
immune system phenotype J:211773
increased effector memory CD8-positive, alpha-beta T cell number J:211773
increased eosinophil cell number J:211773
increased granulocyte number J:211773
increased memory-marker CD4-negative NK T cell number J:211773
increased monocyte cell number J:211773
increased NK T cell number J:211773
\Bach2tm1Igar/\Bach2tm1Igar
(involves: 129P2/OlaHsd * C57BL/6J)
abnormal B cell differentiation J:91110
abnormal B cell physiology J:91110
abnormal class switch recombination J:91110
abnormal somatic hypermutation frequency J:91110
absent germinal center B cells J:91110
decreased B cell number J:91110
decreased IgA level J:91110
decreased IgG1 level J:91110
decreased IgG2a level J:91110
decreased IgG2b level J:91110
decreased IgG3 level J:91110
decreased IgG level J:91110
decreased mature B cell number J:91110
increased IgM level J:91110
spleen hypoplasia J:91110
\Badtm1Meg/\Badtm1Meg
(involves: 129S4/SvJae)
abnormal B cell differentiation J:88139
abnormal T cell differentiation J:88139
decreased mature B cell number J:88139
decreased pro-B cell number J:88139
decreased thymus weight J:88139
small thymus J:88139
thymus hypoplasia J:88139
\Badtm1Sjk/\Badtm1Sjk
(either: 129X1/SvJ or (involves: 129X1/SvJ * C57BL/6))
abnormal B cell physiology J:84987
abnormal immune system cell morphology J:84987
abnormal T cell physiology J:84987
\Badtm1Sjk/\Badtm1Sjk
(involves: 129X1/SvJ)
immune system phenotype J:132819
\Bag3tm1.1Jhl/\Bag3tm1.1Jhl
(B6.129S2-Bag3tm1.1Jhl)
decreased leukocyte cell number J:144416
decreased lymphocyte cell number J:144416
decreased neutrophil cell number J:144416
decreased spleen weight J:144416
decreased thymus weight J:144416
spleen hypoplasia J:144416
thymus hypoplasia J:144416
\Bag4tm1Yeh/\Bag4tm1Yeh
(involves: 129P2/OlaHsd * C57BL/6)
abnormal macrophage physiology J:83559
increased circulating interleukin-6 level J:83559
increased inflammatory response J:83559
increased interleukin-6 secretion J:83559
spleen hypoplasia J:83559
thymus hypoplasia J:83559
\Bahd1tm1.1Ics/\Bahd1+
(involves: C57BL/6)
decreased susceptibility to bacterial infection J:169470
\Bahd1tm2b(KOMP)Wtsi/\Bahd1+
(C57BL/6N-Bahd1tm2b(KOMP)Wtsi/Ics)
decreased effector memory CD8-positive, alpha-beta T cell number J:211773
decreased leukocyte cell number J:211773
decreased lymphocyte cell number J:211773
increased CD4-negative NK T cell number J:211773
increased memory-marker CD4-negative NK T cell number J:211773
increased neutrophil cell number J:211773
increased NK cell number J:211773
increased NK T cell number J:211773
increased T cell number J:211773
\Bak1tm1Thsn/\Bak1tm1Thsn
\Baxtm1Sjk/\Baxtm1Sjk

(involves: 129S1/Sv * 129S1/SvImJ * 129X1/SvJ * C57BL/6)
abnormal B cell morphology J:66872
abnormal splenocyte physiology J:66872
abnormal T cell morphology J:66872
enlarged lymph nodes J:66872
enlarged spleen J:66872
increased leukocyte cell number J:66872
increased lymphocyte cell number J:66872
increased spleen red pulp amount J:66872
increased spleen white pulp amount J:66872
\Bak1tm1Thsn/\Bak1tm1Thsn
\Baxtm1Sjk/\Baxtm2Sjk
\Cd19tm1(cre)Cgn/\Cd19+

(involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ)
abnormal B cell number J:100463
abnormal B cell physiology J:100463
decreased marginal zone B cell number J:100463
increased B cell number J:100463
increased B-2 B cell number J:100463
increased follicular B cell number J:100463
increased IgA level J:100463
increased IgG level J:100463
increased IgM level J:100463
increased immunoglobulin level J:100463
increased pre-B cell number J:100463
increased pro-B cell number J:100463
increased transitional stage B cell number J:100463
\Bak1tm1Thsn/\Bak1tm1Thsn
\Baxtm1Sjk/\Baxtm2Sjk
\Tg(Mx1-cre)1Cgn/0

(involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA)
abnormal T cell differentiation J:100463
autoimmune arthritis J:100463
glomerulonephritis J:100463
increased anti-double stranded DNA antibody level J:100463
increased B cell number J:100463
increased leukocyte cell number J:100463
increased lymphocyte cell number J:100463
increased susceptibility to autoimmune disorder J:100463
\Bak1tm1Thsn/\Bak1tm1Thsn
\Baxtm2Sjk/\Baxtm2Sjk
\Tg(Lck-cre)1Cwi/?

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2)
decreased thymocyte apoptosis J:220951
\Bak1tm1Thsn/\Bak1tm1Thsn
\Baxtm2Sjk/\Baxtm2Sjk
\Tg(Lck-cre)548Jxm/0

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA)
increased regulatory T cell number J:208318
\Bank1tm1Kuro/\Bank1tm1Kuro
(Not Specified)
abnormal B cell physiology J:113321
abnormal lymphocyte physiology J:113321
abnormal spleen germinal center morphology J:113321
abnormal splenic cell ratio J:113321
increased B cell proliferation J:113321
increased B-1a cell number J:113321
increased IgG2a level J:113321
increased IgM level J:113321
increased mature B cell number J:113321
increased spleen germinal center number J:113321
increased spleen germinal center size J:113321
\Bank1tm1Kuro/\Bank1tm1Kuro
\Cd40tm1Kik/\Cd40tm1Kik

(involves: 129P2/OlaHsd)
immune system phenotype J:113321
\Bap1tm1.1Geno/\Bap1tm1.1Geno
\Gt(ROSA)26Sortm9(cre/ESR1)Arte/\Gt(ROSA)26Sor+

(involves: C57BL/6 * C57BL/6NTac)
abnormal granulocyte morphology J:187380
abnormal myelopoiesis J:187380
abnormal neutrophil morphology J:187380
enlarged spleen J:187380
heart inflammation J:187380
increased leukocyte cell number J:187380
increased monocyte cell number J:187380
increased neutrophil cell number J:187380
myeloid hyperplasia J:187380
\Batf2tm1Kmm/\Batf2tm1Kmm
(129S6/SvEvTac-Batf2tm1Kmm)
increased susceptibility to parasitic infection induced morbidity/mortality J:101977
\Batf3tm1Kmm/\Batf3tm1Kmm
(involves: 129S6/SvEvTac * BALB/cJ)
abnormal cytotoxic T cell physiology J:141064
abnormal dendritic cell antigen presentation J:141064
abnormal dendritic cell differentiation J:141064
abnormal dendritic cell physiology J:141064
abnormal immune system physiology J:141064
decreased cytotoxic T cell cytolysis J:141064
decreased memory T cell number J:141064
decreased myeloid dendritic cell number J:141064
\Batf3tm1Kmm/\Batf3tm1Kmm
(involves: 129S6/SvEvTac)
abnormal cytotoxic T cell physiology J:181366
abnormal dendritic cell antigen presentation J:362930
immune system phenotype J:181366
\Batf3tm1Kmm/\Batf3tm1Kmm
\Id2tm1Gtbz/\Id2tm1Gtbz

(B6.Cg-Batf3tm1Kmm Id2tm1Gtbz)
abnormal dendritic cell physiology J:194760
\Batftm1.1Ejt/\Batftm1.1Ejt
(involves: 129S/Sv * C57BL/6 * FVB/N)
abnormal class switch recombination J:160935
abnormal T-helper 2 cell differentiation J:160935
absent germinal center B cells J:160935
decreased CD4-positive, alpha-beta T cell number J:160935
decreased CD4-positive, CD25-positive, alpha-beta regulatory T cell number J:160935
decreased IgA level J:160935
decreased IgE level J:160935
decreased IgG1 level J:160935
decreased IgG2c level J:160935
decreased IgM level J:160935
decreased interleukin-4 secretion J:160935
decreased interleukin-17 secretion J:160935
decreased T follicular helper cell number J:160935
decreased T-helper 17 cell number J:160935
\Batftm1.1Kmm/\Batftm1.1Kmm
(129S6/SvEvTac-Batftm1.1Kmm)
abnormal CD4-positive T cell differentiation J:150643
decreased interleukin-17 secretion J:150643
decreased interleukin-21 secretion J:150643
decreased susceptibility to experimental autoimmune encephalomyelitis J:150643
\Baxtm1Sjk/\Baxtm1Sjk
(involves: 129X1/SvJ)
enlarged spleen J:29253
increased B cell number J:29253
increased thymocyte number J:29253
\Baz2aem1(IMPC)Tcp/\Baz2aem1(IMPC)Tcp
(C57BL/6NCrl-Baz2aem1(IMPC)Tcp/Tcp)
abnormal spleen morphology J:211773
\Baz2bem1(IMPC)Wtsi/\Baz2bem1(IMPC)Wtsi
(C57BL/6N-Baz2bem1(IMPC)Wtsi/Wtsi)
increased leukocyte cell number J:211773
\Bbaa1C3H/HeNCr/\Bbaa1C3H/HeNCr
(involves: C3H/HeNCr * C57BL/6NCr)
abnormal inflammatory response J:52017
\Bbaa1C3H/HeNCr/\Bbaa1C57BL/6NCr
(involves: C3H/HeNCr * C57BL/6NCr)
abnormal inflammatory response J:52017
\Bbaa2C3H/HeNCr/\Bbaa2C3H/HeNCr
(involves: C3H/HeNCr * C57BL/6NCr)
abnormal immune system physiology J:52017
\Bbaa3C3H/HeNCr/\Bbaa3C3H/HeNCr
(involves: C3H/HeNCr * C57BL/6NCr)
abnormal inflammatory response J:73060
\Bbaa3C3H/HeNCr/\Bbaa3C57BL/6NCr
(involves: C3H/HeNCr * C57BL/6NCr)
abnormal inflammatory response J:52017
\Bbaa5C57BL/6NCr/\Bbaa5C57BL/6NCr
(involves: C3H/HeNCr * C57BL/6NCr)
increased IgM level J:52017
\Bbaa9C57BL/6NCr/\Bbaa9C3H/HeNCr
(involves: C3H/HeNCr * C57BL/6NCr)
abnormal immunoglobulin level J:52017
\Bbaa9C57BL/6NCr/\Bbaa9C57BL/6NCr
(involves: C3H/HeNCr * C57BL/6NCr)
abnormal immunoglobulin level J:52017
\Bbaa10C3H/HeN/?
(involves: C3H/HeN * C57BL/6N)
increased inflammatory response J:73060
\Bbaa11C3H/HeN/?
(involves: C3H/HeN * C57BL/6N)
increased inflammatory response J:73060
\Bbaa12C3H/HeN/?
(involves: C3H/HeN * C57BL/6N)
increased inflammatory response J:73060
\Bbaa13C3H/HeN/?
(involves: C3H/HeN * C57BL/6N)
increased inflammatory response J:73060
\Bbaa14C3H/HeJ/?
(involves: C3H/HeN * C57BL/6N)
increased IgG level J:73060
increased inflammatory response J:73060
\Bbaa15C3H/HeN/?
(involves: C3H/HeN * C57BL/6N)
increased IgG level J:73060
\Bbaa16C3H/HeN/?
(involves: C3H/HeN * C57BL/6N)
increased inflammatory response J:73060
\Bbaa17C3H/HeN/?
(involves: C3H/HeN * C57BL/6N)
increased inflammatory response J:73060
\Bbaa18C3H/HeN/?
(involves: C3H/HeN * C57BL/6N)
increased inflammatory response J:73060
\Bbaa19C3H/HeN/?
(involves: C3H/HeN * C57BL/6N)
increased IgG level J:73060
\Bbaa20C3H/HeJ/?
(involves: C3H/HeN * C57BL/6N)
increased inflammatory response J:73060
\Bbaa21C3H/HeN/?
(involves: C3H/HeN * C57BL/6N)
increased susceptibility to bacterial infection J:73060
\Bbaa22C3H/HeN/?
(involves: C3H/HeN * C57BL/6N)
increased inflammatory response J:73060
\Bbaa23C3H/HeN/?
(involves: C3H/HeN * C57BL/6N)
increased inflammatory response J:73060
\Bbc3tm1Ast/\Bbc3tm1Ast
(involves: C57BL/6 * NZB)
abnormal CD8-positive, alpha-beta T cell physiology J:132819
abnormal splenic cell ratio J:132819
immune system phenotype J:132819
increased CD8-positive, alpha-beta T cell number J:132819
increased leukocyte cell number J:132819
\Bbc3tm1Gpz/\Bbc3tm1Gpz
\Trp53tm1Brd/\Trp53tm8Xu

(involves: 129P2/OlaHsd * 129S7/SvEvBrd)
decreased thymocyte number J:170216
\Bblntm1(KOMP)Wtsi/\Bbln+
(involves: C57BL/6N)
abnormal osteoclast differentiation J:296689
\Bblntm1(KOMP)Wtsi/\Bblntm1(KOMP)Wtsi
(involves: C57BL/6N)
abnormal osteoclast differentiation J:296689
increased osteoclast cell number J:296689
\Bbs4Gt1Nk/\Bbs4Gt1Nk
(involves: 129S7/SvEvBrd)
increased immunoglobulin level J:134093
\Bbs5tm1b(EUCOMM)Wtsi/\Bbs5tm1b(EUCOMM)Wtsi
(C57BL/6NTac-Bbs5tm1b(EUCOMM)Wtsi/H)
decreased spleen weight J:211773
increased leukocyte cell number J:211773
increased lymphocyte cell number J:211773
increased monocyte cell number J:211773
\Bbs9em1(IMPC)Bay/\Bbs9+
(C57BL/6N-Bbs9em1(IMPC)Bay/Bay)
increased leukocyte cell number J:211773
\Bbs12em1(IMPC)Ccpcz/\Bbs12+
(C57BL/6NCrl-Bbs12em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged spleen J:211773
enlarged thymus J:211773
\Bbs12tm1.1Vmar/\Bbs12tm1.1Vmar
(involves: 129S6/SvEvTac * C57BL/6)
decreased circulating interleukin-6 level J:189019
decreased circulating tumor necrosis factor level J:189019
decreased inflammatory response J:189019
\Bbxtm1a(EUCOMM)Wtsi/\Bbxtm1a(EUCOMM)Wtsi
(involves: C57BL/6 * C57BL/6N)
increased IgA level J:213427
\Bcap31tm1.1Bwang/\Bcap31tm1.1Bwang
\Lyz2tm1(cre)Ifo/\Lyz2+

(involves: 129P2/OlaHsd * C57BL/6)
increased inflammatory response J:292505
increased interleukin-1 beta secretion J:292505
increased microglial cell activation J:292505
increased tumor necrosis factor secretion J:292505
\Bcap31tm1.1Bwang/\Bcap31tm1.1Bwang
\Tg(Lck-cre)548Jxm/0

(involves: C57BL/6 * CBA)
abnormal T cell activation J:274469
decreased CD8-positive, naive alpha-beta T cell number J:274469
decreased interferon-gamma secretion J:274469
decreased interleukin-2 secretion J:274469
decreased single-positive T cell number J:274469
decreased T cell proliferation J:274469
decreased thymocyte number J:274469
decreased thymus weight J:274469
increased effector memory T-helper cell number J:274469
increased thymocyte apoptosis J:274469
small thymus J:274469
thymus hypoplasia J:274469
\Bcar3em1(IMPC)Mbp/\Bcar3em1(IMPC)Mbp
(C57BL/6N-Bcar3em1(IMPC)Mbp/MbpMmucd)
increased basophil cell number J:211773
\Bcas1tm1Himo/\Bcas1tm1Himo
(C57BL/6-Bcas1tm1Himo)
brain inflammation J:242041
\Bcat1tm1.2Eaa/\Bcat1tm1.2Eaa
(involves: C57BL/6)
abnormal T cell physiology J:216027
\Bckdhaem1(IMPC)Tcp/\Bckdha+
(C57BL/6NCrl-Bckdhaem1(IMPC)Tcp/Tcp)
decreased lymphocyte cell number J:211773
increased neutrophil cell number J:211773
\Bcl2tm1Dlo/\Bcl2tm1Dlo
(involves: 129P2/OlaHsd * C57BL/6)
abnormal T cell differentiation J:73660
decreased CD8-positive, alpha-beta T cell number J:73660
decreased lymphocyte cell number J:73660
decreased mature B cell number J:73660
decreased pre-B cell number J:73660
decreased thymocyte number J:73660
\Bcl2tm1Dlo/\Bcl2tm1Dlo
(B6.129P2-Bcl2tm1Dlo)
abnormal leukopoiesis J:73316
abnormal lymphocyte physiology J:104487, J:73316
decreased spleen weight J:153846
decreased spleen white pulp amount J:153846
increased B cell apoptosis J:73316
increased splenocyte apoptosis J:153846
increased T cell apoptosis J:73316
spleen atrophy J:153846
\Bcl2tm1Dlo/\Bcl2tm1Dlo
\Bcl2l11tm1.1Ast/\Bcl2l11+

(B6.129-Bcl2tm1Dlo Bcl2l11tm1.1Ast)
abnormal lymphocyte physiology J:73316
increased T cell apoptosis J:73316
\Bcl2tm1Dlo/\Bcl2tm1Dlo
\Bcl2l11tm1.1Ast/\Bcl2l11+

(B6.Cg-Bcl2tm1Dlo Bcl2l11tm1.1Ast)
increased leukocyte cell number J:153846
increased spleen weight J:153846
\Bcl2tm1Dlo/\Bcl2tm1Dlo
\Bcl2l11tm1.1Ast/\Bcl2l11tm1.1Ast

(B6.129-Bcl2tm1Dlo Bcl2l11tm1.1Ast)
abnormal leukopoiesis J:73316
abnormal lymphocyte physiology J:73316
decreased B cell apoptosis J:73316
increased T cell apoptosis J:73316
\Bcl2tm1Dlo/\Bcl2tm1Dlo
\Bcl2l11tm1.1Ast/\Bcl2l11tm1.1Ast

(B6.Cg-Bcl2tm1Dlo Bcl2l11tm1.1Ast)
increased leukocyte cell number J:153846
increased spleen weight J:153846
\Bcl2tm1Dlo/\Bcl2tm1Dlo
\Bcl2l11tm1.1Boui/\Bcl2l11tm1.1Boui

(B6.Cg-Bcl2tm1Dlo Bcl2l11tm1.1Boui)
immune system phenotype J:153846
\Bcl2tm1Dlo/\Bcl2tm1Dlo
\Bcl2l11tm1.1Boui/\Bcl2l11tm2.1Boui

(B6.Cg-Bcl2tm1Dlo Bcl2l11tm1.1Boui/Bcl2l11tm2.1Boui)
immune system phenotype J:153846
increased leukocyte cell number J:153846
increased spleen weight J:153846
\Bcl2tm1Dlo/\Bcl2tm1Dlo
\Bcl2l11tm2.1Boui/\Bcl2l11tm2.1Boui

(B6.Cg-Bcl2tm1Dlo Bcl2l11tm2.1Boui)
immune system phenotype J:153846
\Bcl2tm1Dlo/\Bcl2tm1Dlo
\Bcl2l11tm3.1Boui/\Bcl2l11tm3.1Boui

(B6.Cg-Bcl2tm1Dlo Bcl2l11tm3.1Boui)
decreased splenocyte apoptosis J:153846
immune system phenotype J:153846
increased leukocyte cell number J:153846
increased spleen weight J:153846
\Bcl2tm1Dlo/\Bcl2tm1Dlo
\Biktm1Ast/\Biktm1Ast

(B6.Cg-Bcl2tm1Dlo Biktm1Ast)
abnormal lymphocyte physiology J:104487
\Bcl2tm1Irt/\Bcl2tm1Irt
\Lyz2tm1(cre)Ifo/\Lyz2+

(involves: 129P2/OlaHsd * C57BL/6)
increased macrophage apoptosis J:144243
\Bcl2tm1Lbox/\Bcl2tm1Lbox
(involves: 129S1/Sv * 129X1/SvJ * FVB/N)
abnormal B cell activation J:114637
abnormal B cell differentiation J:114637
decreased B cell number J:114637
decreased B cell proliferation J:114637
decreased immature B cell number J:114637
decreased mature B cell number J:114637
decreased pre-B cell number J:114637
increased B cell apoptosis J:114637
\Bcl2tm1Sjk/\Bcl2tm1Sjk
(involves: 129S2/SvPas * C57BL/6)
abnormal CD4-positive, alpha beta T cell morphology J:15224
abnormal CD8-positive, alpha beta T cell morphology J:15224
abnormal immune system organ morphology J:15224
abnormal spleen morphology J:15224
abnormal spleen red pulp morphology J:15224
abnormal spleen white pulp morphology J:15224
abnormal thymus involution J:15224
abnormal thymus morphology J:15224
decreased B cell number J:15224
decreased double-positive T cell number J:15224
decreased lymphocyte cell number J:15224
decreased T cell number J:15224
increased double-negative T cell number J:15224
increased T cell apoptosis J:15224
small spleen J:15224
small thymus J:15224
\Bcl2tm1Tsu/\Bcl2tm1Tsu
(involves: 129P2/OlaHsd * ICR)
abnormal lymphocyte morphology J:22391
abnormal T cell physiology J:22391
small spleen J:22391
small thymus J:22391
spleen atrophy J:22391
thymus atrophy J:22391
\Bcl2tm2.1Lbox/\Bcl2+
(involves: 129S1/Sv * 129X1/SvJ * FVB/N)
abnormal B cell physiology J:175730
enlarged lymph nodes J:175730
enlarged spleen J:175730
increased B cell number J:175730
increased immature B cell number J:175730
increased mature B cell number J:175730
increased pre-B cell number J:175730
\Bcl2tm2.1Lbox/\Bcl2tm2.1Lbox
(involves: 129S1/Sv * 129X1/SvJ * FVB/N)
abnormal B cell physiology J:175730
enlarged lymph nodes J:175730
enlarged spleen J:175730
increased B cell number J:175730
increased immature B cell number J:175730
increased mature B cell number J:175730
increased pre-B cell number J:175730
\Bcl2a1atm1.1Tac/\Bcl2a1atm1.1Tac
\Bcl2a1btm1.1Tac/\Bcl2a1btm1.1Tac
\Bcl2a1dtm1.1Tac/\Bcl2a1dtm1.1Tac

(involves: BALB/cJ * C57BL/6NTac)
abnormal dendritic cell physiology J:258915
decreased CD4-positive, alpha-beta memory T cell number J:258915
decreased central memory CD4-positive, alpha-beta T cell number J:258915
decreased dendritic cell number J:258915
decreased effector memory CD4-positive, alpha-beta T cell number J:258915
decreased gamma-delta T cell number J:258915
decreased regulatory T cell number J:258915
immune system phenotype J:258915
\Bcl2a1atm1Prys/\Bcl2a1atm1Prys
(involves: 129/Sv * C57BL/6J * SJL)
abnormal neutrophil physiology J:74478
decreased inflammatory response J:74478
decreased susceptibility to parasitic infection J:74478
\Bcl2a1atm1Sen/\Bcl2a1atm1Sen
(involves: 129P2/OlaHsd * C57BL/6)
abnormal neutrophil physiology J:52127
\Bcl2l1tm1Cant/\Bcl2l1tm1Cant
(involves: 129S6/SvEvTac)
abnormal memory T cell physiology J:77507
abnormal T cell physiology J:77507
decreased interleukin-2 secretion J:77507
decreased memory T cell number J:77507
decreased susceptibility to experimental autoimmune encephalomyelitis J:77507
decreased T cell proliferation J:77507
\Bcl2l1tm1Dlo/\Bcl2l1tm1.1Mam
\Tg(Aicda-cre)9Mbu/0

(B6.Cg-Bcl2l1tm1Dlo/Bcl2l1tm1.1Mam Tg(Aicda-cre)9Mbu)
decreased IgG1 level J:166069
immune system phenotype J:166069
\Bcl2l1tm1Ywh/\Bcl2l1tm1Ywh
\Mcl1tm1Ywh/\Mcl1tm1Ywh
\Tg(Cd4-cre)1Cwi/0

(involves: 129S6/SvEvTac * C57BL/6 * DBA/2)
absent CD4-positive, alpha-beta T cells J:137400
absent CD8-positive, alpha-beta T cells J:137400
decreased double-positive T cell number J:137400
\Bcl2l1tm1Ywh/\Bcl2l1tm1Ywh
\Tg(Lck-cre)548Jxm/?

(involves: 129S4/SvJaeSor * 129S6/SvEvTac * C57BL/6 * CBA)
decreased double-positive T cell number J:99012
decreased thymocyte number J:99012
\Bcl2l11em1(IMPC)H/\Bcl2l11em1(IMPC)H
(C57BL/6NTac-Bcl2l11em1(IMPC)H/H)
increased large unstained cell number J:211773
increased leukocyte cell number J:211773
increased lymphocyte cell number J:211773
increased spleen weight J:211773
\Bcl2l11em1Flv/\Bcl2l11+
\Morrbid+/\Morrbidem1Flv

(C57BL/6N-Bcl2l11em1Flv +/+ Morrbidem1Flv)
decreased eosinophil cell number J:236609
decreased Ly6C high monocyte number J:236609
decreased neutrophil cell number J:236609
\Bcl2l11em1Flv/\Bcl2l11+
\Morrbidem1Flv/\Morrbid+

(C57BL/6N-Bcl2l11em1Flv Morrbidem1Flv /+ +)
immune system phenotype J:236609
\Bcl2l11tm1.1Ast/\Bcl2l11+
(involves: 129S1/Sv * C57BL/6)
abnormal lymphocyte physiology J:58641
glomerulonephritis J:58641
increased IgA level J:58641
increased IgG level J:58641
increased IgM level J:58641
increased susceptibility to autoimmune disorder J:58641
\Bcl2l11tm1.1Ast/\Bcl2l11+
(B6.129S1-Bcl2l11tm1.1Ast)
immune system phenotype J:153846
increased leukocyte cell number J:153846
increased spleen weight J:153846
\Bcl2l11tm1.1Ast/\Bcl2l11+
\Ptentm1Hwu/\Pten+
\Tg(CD2-icre)4Kio/0

(involves: 129S1/Sv * 129S4/SvJae * C57BL/10 * CBA/Ca)
abnormal T cell number J:133215
increased germinal center B cell number J:133215
\Bcl2l11tm1.1Ast/\Bcl2l11tm1.1Ast
(involves: 129S1/Sv * C57BL/6)
abnormal B cell proliferation J:90963
abnormal lymphocyte physiology J:58641
abnormal plasma cell morphology J:58641
abnormal spleen morphology J:58641
abnormal splenic cell ratio J:132217
decreased B cell apoptosis J:90963
decreased double-positive T cell number J:58641
enlarged spleen J:58641
glomerulonephritis J:58641
increased anti-double stranded DNA antibody level J:132217
increased anti-histone antibody level J:132217
increased anti-nuclear antigen antibody level J:132217
increased anti-single stranded DNA antibody level J:132217
increased autoantibody level J:132217
increased B cell number J:58641
increased CD4-positive, alpha-beta T cell number J:58641
increased CD8-positive, alpha-beta T cell number J:58641
increased double-negative T cell number J:58641
increased follicular B cell number J:132217
increased granulocyte number J:58641
increased IgA level J:58641
increased IgG level J:58641
increased IgM level J:58641
increased immature B cell number J:132217
increased inflammatory response J:58641
increased leukocyte cell number J:58641
increased marginal zone B cell number J:132217
increased monocyte cell number J:58641
increased splenocyte number J:132217
increased susceptibility to autoimmune disorder J:58641
increased T cell number J:58641
increased transitional stage B cell number J:132217
spleen hyperplasia J:58641
\Bcl2l11tm1.1Ast/\Bcl2l11tm1.1Ast
(B6.129S1-Bcl2l11tm1.1Ast)
abnormal B cell morphology J:133084
abnormal leukopoiesis J:73316
abnormal lymphocyte physiology J:73316
abnormal NK cell morphology J:123409
abnormal response to infection J:123409
decreased B cell apoptosis J:73316
decreased T cell apoptosis J:73316, J:133084
immune system phenotype J:153846
increased immature B cell number J:133084
increased leukocyte cell number J:153846
increased mature B cell number J:133084
increased NK cell number J:123409
increased regulatory T cell number J:208318
increased spleen weight J:153846
increased transitional stage B cell number J:133084
\Bcl2l11tm1.1Ast/\Bcl2l11tm1.1Ast
(B6.129-Bcl2l11tm1.1Ast/J)
decreased lymphocyte cell number J:137609
\Bcl2l11tm1.1Ast/\Bcl2l11tm1.1Ast
(involves: 129S1/Sv)
abnormal CD4-positive, alpha-beta T cell number J:132819
abnormal CD8-positive, alpha-beta T cell physiology J:132819
abnormal splenic cell ratio J:132819
decreased splenocyte apoptosis J:266833
decreased thymocyte apoptosis J:266833
increased B cell number J:132819
\Bcl2l11tm1.1Ast/\Bcl2l11tm1.1Ast
(B6.129S1-Bcl2l11tm1.1Ast/J)
decreased T cell apoptosis J:153652
increased B cell number J:153652
increased CD4-positive, alpha-beta T cell number J:153652
increased CD8-positive, alpha-beta T cell number J:153652
increased splenocyte number J:153652
\Bcl2l11tm1.1Ast/\Bcl2l11tm1.1Ast
\Biktm1Ast/\Biktm1Ast

(B6.Cg-Bcl2l11tm1.1Ast Biktm1Ast)
abnormal B cell differentiation J:103605
abnormal lymphocyte physiology J:103605
abnormal T cell differentiation J:103605
decreased immature B cell number J:103605
decreased pre-B cell number J:103605
decreased pro-B cell number J:103605
enlarged spleen J:103605
increased B cell number J:103605
increased granulocyte number J:103605
increased mature B cell number J:103605
increased monocyte cell number J:103605
increased T cell number J:103605
\Bcl2l11tm1.1Ast/\Bcl2l11tm1.1Ast
\Bmftm1Rjd/\Bmftm1Rjd

(B6.129S-Bcl2l11tm1.1Ast Bmftm1Rjd)
decreased T cell apoptosis J:153652
increased B cell number J:153652
increased CD4-positive, alpha-beta T cell number J:153652
increased CD8-positive, alpha-beta T cell number J:153652
increased splenocyte number J:153652
increased thymocyte number J:153652
\Bcl2l11tm1.1Ast/\Bcl2l11tm1.1Ast
\Bmftm2.1Rjd/\Bmftm2.1Rjd

(B6.129S-Bcl2l11tm1.1Ast Bmftm2.1Rjd)
increased B cell number J:153652
increased CD4-positive, alpha-beta T cell number J:153652
increased CD8-positive, alpha-beta T cell number J:153652
increased splenocyte number J:153652
\Bcl2l11tm1.1Ast/\Bcl2l11tm1.1Ast
\Bnip3lGt(XT0573)Wtsi/\Bnip3lGt(XT0573)Wtsi

(involves: 129S1/Sv * C57BL/6)
decreased lymphocyte cell number J:137609
\Bcl2l11tm1.1Ast/\Bcl2l11tm1.1Ast
\Dicer1tm1Mmk/\Dicer1tm1Mmk
\Cd79atm1(cre)Reth/\Cd79a+

(involves: 129S1/Sv * BALB/c)
decreased B cell number J:135783
decreased mature B cell number J:135783
\Bcl2l11tm1.1Ast/\Bcl2l11tm1.1Ast
\Faslpr/\Faslpr

(B6.Cg-Bcl2l11tm1.1Ast Faslpr)
abnormal effector T cell morphology J:132217
abnormal lymph node cell ratio J:132217
abnormal splenic cell ratio J:132217
abnormal T cell number J:132217
abnormal T cell subpopulation ratio J:132217
decreased B cell number J:132217
decreased spleen red pulp amount J:132217
enlarged lymph nodes J:132217
enlarged spleen J:132217
increased anti-double stranded DNA antibody level J:132217
increased anti-histone antibody level J:132217
increased anti-nuclear antigen antibody level J:132217
increased anti-single stranded DNA antibody level J:132217
increased autoantibody level J:132217
increased dendritic cell number J:132217
increased follicular B cell number J:132217
increased immature B cell number J:132217
increased leukocyte cell number J:132217
increased macrophage cell number J:132217
increased marginal zone B cell number J:132217
increased memory T cell number J:132217
increased spleen white pulp amount J:132217
increased susceptibility to autoimmune disorder J:132217
increased transitional stage B cell number J:132217
lymph node hyperplasia J:132217
spleen hyperplasia J:132217
\Bcl2l11tm1.1Ast/\Bcl2l11tm1.1Ast
\Il15tm1Imx/\Il15tm1Imx

(involves: C57BL/6)
immune system phenotype J:208318
\Bcl2l11tm1.1Ast/\Bcl2l11tm1.1Ast
\Mirc14tm1.2Flv/\Mirc14tm1.2Flv

(involves: 129S1/Sv * C57BL/6 * C57BL/6N * FVB/N * SJL)
decreased NK T cell number J:203157
\Bcl2l11tm1.1Ast/\Bcl2l11tm1.1Ast
\Mlf1tm1Swm/\Mlf1tm1Swm

(involves: 129S1/Sv * C57BL/6)
decreased splenocyte apoptosis J:266833
decreased thymocyte apoptosis J:266833
\Bcl2l11tm1.1Ast/\Bcl2l11tm1.1Ast
\Pmaip1tm1Ast/\Pmaip1tm1Ast

(involves: 129S1/Sv * C57BL/6)
abnormal NK cell morphology J:123409
\Bcl2l11tm1.1Ast/\Bcl2l11tm1.1Ast
\Zbtb1m1Btlr/\Zbtb1m1Btlr

(involves: 129S1/Sv * C3H/HeN * C57BL/6 * C57BL/6J)
absent T cells J:178820
\Bcl2l11tm1.1Boui/\Bcl2l11+
\Tg(IghMyc)22Bri/0

(involves: C57BL/6 * SJL)
increased leukocyte cell number J:186117
increased T cell derived lymphoma incidence J:186117
\Bcl2l11tm1.1Boui/\Bcl2l11tm1.1Boui
(C57BL/6-Bcl2l11tm1.1Boui)
immune system phenotype J:153846
increased leukocyte cell number J:153846
increased spleen weight J:153846
\Bcl2l11tm1.1Boui/\Bcl2l11tm1.1Boui
\Tg(IghMyc)22Bri/0

(involves: C57BL/6 * SJL)
increased leukocyte cell number J:186117
\Bcl2l11tm1.1Boui/\Bcl2l11tm2.1Boui
(C57BL/6-Bcl2l11tm1.1Boui/Bcl2l11tm2.1Boui)
immune system phenotype J:153846
increased leukocyte cell number J:153846
increased spleen weight J:153846
\Bcl2l11tm1Ast/\Bcl2l11tm1Ast
\Dicer1tm1Bdh/\Dicer1tm1Bdh
\Aicdatm1(cre)Njen/\Aicda+

(involves: 129S1/Sv * C57BL/6)
abnormal B cell differentiation J:181782
decreased germinal center B cell number J:181782
decreased plasma cell number J:181782
\Bcl2l11tm1Sjk/\Bcl2l11tm1Sjk
(involves: 129X1/SvJ)
abnormal B cell physiology J:100463
abnormal spleen marginal zone morphology J:100463
increased B cell number J:100463
increased B-2 B cell number J:100463
increased follicular B cell number J:100463
increased immunoglobulin level J:100463
increased transitional stage B cell number J:100463
\Bcl2l11tm2.1Boui/\Bcl2l11+
\Tg(IghMyc)22Bri/0

(involves: C57BL/6 * SJL)
increased leukocyte cell number J:186117
\Bcl2l11tm2.1Boui/\Bcl2l11tm2.1Boui
(C57BL/6-Bcl2l11tm2.1Boui)
immune system phenotype J:153846
increased leukocyte cell number J:153846
increased spleen weight J:153846
\Bcl2l11tm2.1Boui/\Bcl2l11tm2.1Boui
\Tg(IghMyc)22Bri/0

(involves: C57BL/6 * SJL)
increased leukocyte cell number J:186117
\Bcl2l11tm3.1Boui/\Bcl2l11tm3.1Boui
(C57BL/6-Bcl2l11tm3.1Boui)
immune system phenotype J:153846
increased leukocyte cell number J:153846
increased spleen weight J:153846
\Bcl2l11tm3Rjd/\Bcl2l11tm3Rjd
(B6.129S6-Bcl2l11tm3Rjd)
decreased thymocyte apoptosis J:137061
increased B cell number J:153652
increased CD4-positive, alpha-beta T cell number J:153652
increased CD8-positive, alpha-beta T cell number J:153652
increased splenocyte number J:153652
\Bcl2l11tm3Rjd/\Bcl2l11tm3Rjd
\Bmftm3.1Rjd/\Bmftm3.1Rjd

(B6.129S6-Bcl2l11tm3Rjd Bmftm3.1Rjd)
increased B cell number J:153652
increased CD4-positive, alpha-beta T cell number J:153652
increased CD8-positive, alpha-beta T cell number J:153652
increased splenocyte number J:153652
\Bcl2l11tm4Boul/\Bcl2l11tm4Boul
(involves: C57BL/6)
immune system phenotype J:203181
\Bcl2l11tm4Rjd/\Bcl2l11tm4Rjd
(involves: 129S6/SvEvTac * C57BL/6)
immune system phenotype J:203181
\Bcl2l11tm5Boul/\Bcl2l11tm5Boul
(involves: C57BL/6)
immune system phenotype J:203181
\Bcl2l11tm6.1Boui/\Bcl2l11tm6.1Boui
\Foxp3tm4(YFP/icre)Ayr/\Foxp3+

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL)
increased regulatory T cell number J:208318
\Bcl2l12tm1.1(KOMP)Vlcg/\Bcl2l12tm1.1(KOMP)Vlcg
(C57BL/6N-Bcl2l12tm1.1(KOMP)Vlcg/Ucd)
abnormal spleen morphology J:211773
enlarged spleen J:211773
increased spleen weight J:211773
\Bcl2l14tm1.1Boui/\Bcl2l14tm1.1Boui
(involves: C57BL/6)
abnormal susceptibility to induced colitis J:296081
\Bcl3m1Btlr/\Bcl3+
(C57BL/6J-Bcl3m1Btlr)
decreased B cell number J:255184
decreased B-1b cell number J:255184
increased CD8-positive, alpha-beta T cell number J:255184
increased macrophage cell number J:255184
\Bcl3m1Btlr/\Bcl3m1Btlr
(C57BL/6J-Bcl3m1Btlr)
abnormal humoral immune response J:255184
decreased B cell number J:255184
decreased B-1b cell number J:255184
decreased IgE level J:255184
decreased IgG level J:255184
increased B-1 B cell number J:255184
increased CD8-positive, alpha-beta T cell number J:255184
increased central memory CD4-positive, alpha-beta T cell number J:255184
increased macrophage cell number J:255184
\Bcl3m2Btlr/\Bcl3m2Btlr
(C57BL/6J-Bcl3m2Btlr)
decreased CD4-positive, alpha-beta T cell number J:264818
decreased IgD level J:264818
increased B-1 B cell number J:264818
increased CD8-positive, alpha-beta memory T cell number J:264818
increased IgM level J:264818
\Bcl3m3Btlr/\Bcl3m3Btlr
(C57BL/6J-Bcl3m3Btlr)
decreased central memory CD8 positive, alpha-beta T cell number J:274858
\Bcl3tm1b(EUCOMM)Wtsi/\Bcl3tm1b(EUCOMM)Wtsi
(C57BL/6N-Bcl3tm1b(EUCOMM)Wtsi/H)
increased spleen weight J:211773
\Bcl3tm1Rie/\Bcl3tm1Rie
(involves: 129)
abnormal dendritic cell number J:77049
abnormal follicular dendritic cell morphology J:77049
abnormal myeloid dendritic cell morphology J:77049
abnormal Peyer's patch follicle morphology J:77049
abnormal Peyer's patch germinal center morphology J:77049
abnormal Peyer's patch morphology J:77049
abnormal Peyer's patch T cell area morphology J:77049
decreased B cell number J:77049
decreased Peyer's patch number J:77049
increased plasmacytoid dendritic cell number J:77049
small Peyer's patches J:77049
\Bcl3tm1Rsch/\Bcl3tm1Rsch
(involves: 129P2/OlaHsd * CD-1)
abnormal cytokine secretion J:116724
abnormal innate immunity J:116724
increased susceptibility to bacterial infection J:116724
\Bcl3tm1Rsch/\Bcl3tm1Rsch
(B6.Cg-Bcl3tm1Rsch)
abnormal cytokine secretion J:116724
abnormal macrophage physiology J:116724
\Bcl3tm1Sbn/\Bcl3tm1Sbn
(involves: 129S4/SvJae * C57BL/6)
abnormal B cell differentiation J:39747
abnormal class switch recombination J:39747
abnormal cytotoxic T cell physiology J:39747
abnormal lymph node B cell domain morphology J:39747
abnormal lymphocyte morphology J:39747
abnormal metallophilic macrophage morphology J:39747
abnormal spleen marginal zone macrophage morphology J:39747
absent spleen germinal center J:39747
decreased B cell number J:39747
decreased IgG2a level J:39747
decreased interferon-gamma secretion J:39747
decreased interleukin-12 secretion J:39747
decreased macrophage cell number J:39747
decreased spleen germinal center size J:39747
disorganized spleen B cell follicle J:39747
increased susceptibility to parasitic infection J:39747
intermingled spleen red and white pulp J:39747
lymph node hypoplasia J:39747
\Bcl3tm1Sbn/\Bcl3tm1Sbn
(involves: 129S4/SvJae)
abnormal B cell physiology J:207111
decreased B cell proliferation J:207111
decreased follicular B cell number J:207111
decreased transitional stage T1 B cell number J:207111
decreased transitional stage T2 B cell number J:207111
increased B cell proliferation J:207111
increased marginal zone B cell number J:207111
\Bcl3tm1Ver/\Bcl3tm1Ver
(involves: 129P2/OlaHsd * FVB/NJ)
abnormal humoral immune response J:38092
absent spleen germinal center J:38092
immune system phenotype J:38092
increased susceptibility to bacterial infection J:38092
\Bcl6tm1.1Dent/\Bcl6tm1.1Dent
\Tg(Cd4-cre)1Cwi/0

(involves: 129S/SvEv * C57BL/6 * DBA/2 * FVB/N)
abnormal T follicular helper cell differentiation J:202372
decreased germinal center B cell number J:202372
decreased IgG level J:202372
decreased interleukin-4 secretion J:202372
decreased T follicular helper cell number J:202372
increased interleukin-10 secretion J:202372
\Bcl6tm1.1Jwan/\Bcl6tm1.1Jwan
(involves: 129S6/SvEvTac)
abnormal somatic hypermutation frequency J:190534
immune system phenotype J:190534
\Bcl6tm1.1Meln/\Bcl6tm1.1Meln
(involves: 129 * C57BL/6 * FVB/N)
abnormal adaptive immunity J:194821
abnormal germinal center B cell physiology J:194821
abnormal immune system organ morphology J:194821
abnormal Peyer's patch germinal center morphology J:194821
abnormal professional antigen presenting cell physiology J:194821
abnormal spleen germinal center morphology J:194821
decreased IgG1 level J:194821
decreased IgG2a level J:194821
decreased IgG level J:194821
decreased spleen germinal center number J:194821
decreased T follicular helper cell number J:194821
immune system phenotype J:194821
\Bcl6tm1.1Mtto/\Bcl6tm1.1Mtto
\Cd79atm1(cre)Reth/\Cd79a+

(involves: BALB/c * C57BL/6 * C57BL/6JJcl)
abnormal humoral immune response J:190943
abnormal memory B cell morphology J:190943
abnormal memory B cell physiology J:190943
abnormal somatic hypermutation frequency J:190943
decreased germinal center B cell number J:190943
\Bcl6tm1.1Mtto/\Bcl6tm1.1Mtto
\Cd79atm1(cre)Reth/\Cd79a+
\Tg(Cd4-cre)1Cwi/0

(involves: BALB/c * C57BL/6 * C57BL/6JJcl * DBA/2)
decreased germinal center B cell number J:190943
immune system phenotype J:190943
\Bcl6tm1.1Mtto/\Bcl6tm1.1Mtto
\Ighg1tm1(cre)Cgn/\Ighg1+

(involves: 129P2/OlaHsd * C57BL/6 * C57BL/6JJcl)
decreased germinal center B cell number J:190943
immune system phenotype J:190943
\Bcl6tm1.1Mtto/\Bcl6tm1.1Mtto
\Tg(Cd4-cre)1Cwi/0

(involves: C57BL/6 * C57BL/6JJcl * DBA/2)
abnormal humoral immune response J:190943
abnormal somatic hypermutation frequency J:190943
absent germinal center B cells J:190943
decreased germinal center B cell number J:190943
decreased T follicular helper cell number J:190943
\Bcl6tm1.1Toka/\Bcl6+
\Tg(TcraTcrb)425Cbn/0

(involves: BALB/c * C57BL/6 * NZB)
decreased T cell proliferation J:174014
\Bcl6tm1.1Toka/\Bcl6tm1.1Toka
(involves: C57BL/6 * NZB)
abnormal Peyer's patch morphology J:174014
decreased germinal center B cell number J:174014
decreased T follicular helper cell number J:174014
immune system phenotype J:174014
\Bcl6tm1.1Toka/\Bcl6tm1.1Toka
\Tg(IghelMD4)4Ccg/0

(involves: C57BL/6 * NZB)
abnormal germinal center B cell physiology J:174014
increased activation-induced B cell apoptosis J:174014
\Bcl6tm1Gdba/\Bcl6tm1Gdba
\Tg(Adipoq-cre)1Evdr/0

(involves: C57BL/6 * FVB/NJ)
white adipose tissue inflammation J:271078
\Bcl6tm1Htno/\Bcl6tm1Htno
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
abnormal spleen morphology J:55952
lung inflammation J:55952
myocarditis J:55952
\Bcl6tm1Rdf/\Bcl6tm1Rdf
(involves: 129S1/Sv)
abnormal B cell physiology J:40769
abnormal humoral immune response J:40769
abnormal immune system morphology J:40769
abnormal immune system physiology J:40769
abnormal Peyer's patch germinal center morphology J:40769
abnormal T-helper 2 physiology J:40769
absent lymph node germinal center J:40769
absent spleen germinal center J:40769
decreased IgG level J:40769
decreased IgM level J:40769
heart inflammation J:40769
increased eosinophil cell number J:40769
increased inflammatory response J:40769
increased susceptibility to bacterial infection J:40769
liver inflammation J:40769
lung inflammation J:40769
small thymus J:40769
spleen hyperplasia J:40769
\Bcl6tm1Sdt/\Bcl6tm1Sdt
(involves: 129/Sv * C57BL/6)
abnormal chemokine level J:123621
abnormal immune system physiology J:123621
spleen hypoplasia J:123621
\Bcl6tm1Sdt/\Bcl6tm1Sdt
\Bcl6btm2Dent/\Bcl6btm2Dent

(involves: 129/Sv * C57BL/6)
abnormal immune system physiology J:123621
\Bcl6tm2Rdf/\Bcl6tm2Rdf
(involves: 129S1/Sv)
abnormal B cell physiology J:40769
abnormal humoral immune response J:40769
abnormal immune system morphology J:40769
abnormal immune system physiology J:40769
abnormal Peyer's patch germinal center morphology J:40769
abnormal T-helper 2 physiology J:40769
absent lymph node germinal center J:40769
absent spleen germinal center J:40769
decreased B cell proliferation J:40769
decreased IgG level J:40769
decreased IgM level J:40769
heart inflammation J:40769
increased eosinophil cell number J:40769
increased inflammatory response J:40769
increased susceptibility to bacterial infection J:40769
liver inflammation J:40769
lung inflammation J:40769
small thymus J:40769
spleen hyperplasia J:40769
\Bcl6tm2Rdf/\Bcl6tm2Rdf
\Ighmtm1(Bcl6)Rdf/?

(involves: 129/Sv * 129S1/Sv * C57BL/6)
abnormal immune system morphology J:98937
abnormal spleen germinal center morphology J:98937
\Bcl6btm1Dtf/\Bcl6btm1Dtf
(involves: 129P2/OlaHsd)
abnormal response to infection J:99818
decreased memory T cell number J:99818
decreased T cell proliferation J:99818
\Bcl6btm1Tto/\Bcl6btm1Tto
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
abnormal CD4-positive, alpha beta T cell morphology J:93656
abnormal CD8-positive, alpha beta T cell morphology J:93656
\Bcl6btm2Dent/\Bcl6btm2Dent
(involves: 129/Sv * C57BL/6)
decreased neutrophil cell number J:123621
increased monocyte cell number J:123621
\Bcl6btm2Dent/\Bcl6btm2Dent
\Rag1tm1Mom/\Rag1tm1Mom

(involves: 129/Sv * 129S7/SvEvBrd * C57BL/6)
decreased lymphocyte cell number J:123621
\Bcl10m1Btlr/\Bcl10m1Btlr
(C57BL/6J-Bcl10m1Btlr)
abnormal humoral immune response J:265122
decreased B-1 B cell number J:265122
decreased IgG level J:265122
increased CD4-positive, alpha-beta T cell number J:265122
increased IgE level J:265122
increased IgM level J:265122
increased single-positive T cell number J:265122
increased T cell number J:265122
\Bcl10tm1Mak/\Bcl10tm1Mak
(involves: 129P2/OlaHsd)
abnormal cytotoxic T cell physiology J:67297
abnormal dendritic cell physiology J:111706
abnormal immune cell physiology J:67297
abnormal response to infection J:67297
abnormal T cell activation J:67297
abnormal T cell differentiation J:67297
decreased activated T cell number J:67297
decreased B cell proliferation J:109545, J:67297
decreased double-positive T cell number J:67297
decreased IgG level J:67297
decreased IgM level J:67297
decreased immunoglobulin level J:67297
decreased T cell proliferation J:109545, J:67297
decreased thymocyte number J:67297
increased double-negative T cell number J:67297
increased susceptibility to infection J:67297
\Bcl10tm1Mak/\Bcl10tm1Mak
\Cd19tm1(cre)Cgn/\Cd19+
\Gt(ROSA)26Sortm2(CARD11*L225LI)Jrld/\Gt(ROSA)26Sor+

(involves: 129P2/OlaHsd)
immune system phenotype J:228288
\Bcl10tm1Swm/\Bcl10tm1Swm
(involves: 129P2/OlaHsd)
abnormal B cell differentiation J:85147
abnormal humoral immune response J:85147
abnormal marginal zone B cell physiology J:85147
decreased B cell number J:85147
decreased B cell proliferation J:85147
decreased B-1 B cell number J:85147
decreased follicular B cell number J:85147
decreased marginal zone B cell number J:85147
decreased mature B cell number J:85147
increased susceptibility to bacterial infection J:85147
\Bcl10tm1Swm/\Bcl10tm1Swm
(involves: 129P2/OlaHsd * C57BL/6)
abnormal cytokine secretion J:122394
abnormal dendritic cell physiology J:122394
\Bcl11atm1Ngc/\Bcl11a+
(involves: 129S1/Sv)
abnormal T cell differentiation J:194616
decreased DN2 thymocyte number J:194616
decreased lymphocyte cell number J:207383
\Bcl11atm1Ngc/\Bcl11atm1Ngc
(involves: 129S1/Sv * C57BL/6J)
abnormal dendritic cell differentiation J:207383
abnormal immunoglobulin heavy chain V(D)J recombination J:83646
absent B cells J:207383, J:83646
absent CD4-positive, alpha-beta T cells J:83646
absent lymphocyte J:207383
decreased plasmacytoid dendritic cell number J:207383
decreased T cell number J:83646
increased CD8-positive, alpha-beta T cell number J:83646
increased double-negative T cell number J:83646
increased gamma-delta T cell number J:83646
small thymus J:83646
thymus hypoplasia J:83646
\Bcl11atm1Pwt/\Bcl11atm1Pwt
\Commd10Tg(Vav1-icre)A2Kio/\Commd10+

(involves: C57BL/6 * C57BL/10 * CBA/Ca)
decreased B cell number J:207383
decreased circulating interferon-alpha level J:207383
decreased plasmacytoid dendritic cell number J:207383
\Bcl11atm1Pwt/\Bcl11atm1Pwt
\Gt(ROSA)26Sortm1(EYFP)Cos/\Gt(ROSA)26Sor+
\Tg(Mx1-cre)1Cgn/0

(involves: 129X1/SvJ * C57BL/6 * CBA)
abnormal dendritic cell differentiation J:207383
decreased B cell number J:207383
decreased dendritic cell number J:207383
decreased plasmacytoid dendritic cell number J:207383
\Bcl11atm1Pwt/\Bcl11atm1Pwt
\Kdm1atm1.1Sho/\Kdm1atm1.1Sho
\Tg(Mx1-cre)1Cgn/0

(involves: 129 * C57BL/6 * CBA)
decreased leukocyte cell number J:196140
\Bcl11atm1Pwt/\Bcl11atm1Pwt
\Tg(Mx1-cre)1Cgn/0

(involves: C57BL/6 * CBA)
decreased leukocyte cell number J:196140
\Bcl11atm2.1Peli/\Bcl11atm2.1Peli
\Gt(ROSA)26Sortm2(cre/ERT2)Brn/\Gt(ROSA)26Sor+

(involves: 129P2/OlaHsd * 129S1/Sv)
abnormal immune system morphology J:194616
abnormal T cell differentiation J:194616
decreased B cell number J:194616
decreased DN2 thymocyte number J:194616
decreased immature B cell number J:194616
decreased pre-B cell number J:194616
decreased pro-B cell number J:194616
increased B cell apoptosis J:194616
\Bcl11atm2.1Peli/\Bcl11atm2.1Peli
\Trp53tm1Brn/\Trp53tm1Brn
\Gt(ROSA)26Sortm2(cre/ERT2)Brn/\Gt(ROSA)26Sor+

(involves: 129P2/OlaHsd * 129S1/Sv)
immune system phenotype J:194616
\Bcl11btm1.2Leid/\Bcl11btm1.2Leid
(involves: C57BL/6 * SJL)
absent T cells J:147182
thymus hypoplasia J:147182
\Bcl11btm1Avram/\Bcl11btm1Avram
\Tcratm1Mom/\Tcratm1Mom
\Tg(Cd4-cre)1Cwi/?

(involves: 129 * C57BL/6 * DBA/2)
abnormal positive T cell selection J:128515
decreased double-positive T cell number J:128515
thymus hypoplasia J:128515
\Bcl11btm1Avram/\Bcl11btm1Avram
\Tg(Cd4-cre)1Cwi/?

(involves: 129 * C57BL/6 * DBA/2)
abnormal leukocyte morphology J:128515
abnormal positive T cell selection J:128515
abnormal thymocyte activation J:128515
decreased CD4-positive, alpha-beta T cell number J:128515
decreased CD8-positive, alpha-beta T cell number J:128515
decreased double-negative T cell number J:128515
decreased double-positive T cell number J:128515
enlarged mesenteric lymph nodes J:128515
increased B cell number J:128515
increased dendritic cell number J:128515
increased gamma-delta T cell number J:128515
increased NK cell number J:128515
increased spleen weight J:128515
spleen hyperplasia J:128515
thymus hypoplasia J:128515
\Bcl11btm1Avram/\Bcl11btm1Avram
\Tg(Cd4-cre)1Cwi/?
\Tg(LCKprBCL2)36Sjk/?

(involves: 129 * C57BL/6 * DBA/2)
abnormal positive T cell selection J:128515
decreased CD4-positive, alpha-beta T cell number J:128515
decreased CD8-positive, alpha-beta T cell number J:128515
decreased double-positive T cell number J:128515
thymus hypoplasia J:128515
\Bcl11btm1Jpk/\Bcl11btm1Jpk
(involves: BALB/c * C57BL/6 * CBA)
abnormal T cell differentiation J:83651
abnormal T cell morphology J:83651
abnormal T cell receptor beta chain V(D)J recombination J:83651
abnormal thymus cortex morphology J:83651
abnormal thymus medulla morphology J:83651
absent thymus corticomedullary boundary J:83651
decreased double-positive T cell number J:83651
increased CD8-positive, alpha-beta T cell number J:83651
increased double-negative T cell number J:83651
increased thymocyte apoptosis J:83651
thymus hypoplasia J:83651
\Bcl11btm1Peli/\Bcl11btm1Peli
\Gt(ROSA)26Sortm2(cre/ERT2)Brn/\Gt(ROSA)26Sor+

(involves: 129P2/OlaHsd * 129S5/SvEvBrd * C57BL/6J)
abnormal NK cell differentiation J:161373
\Bcl11btm2.1Jpk/\Bcl11b+
\Tg(Cd4-cre)1Cwi/0

(involves: C57BL/6 * C57BL/6J * DBA/2)
immune system phenotype J:210122
\Bcl11btm2.1Jpk/\Bcl11b+
\Tg(Lck-cre)1Jtak/0

(involves: C57BL/6)
abnormal T cell number J:210122
decreased CD4-positive, alpha-beta T cell number J:210122
decreased CD8-positive, alpha-beta T cell number J:210122
decreased double-positive T cell number J:210122
decreased thymocyte number J:210122
increased double-negative T cell number J:210122
\Bclaf1tm1Raz/\Bclaf1+
(involves: 129P2/OlaHsd * C57BL/6)
decreased T cell proliferation J:158087
\Bclaf1tm1Raz/\Bclaf1tm1Raz
(involves: 129P2/OlaHsd * C57BL/6)
decreased CD8-positive, alpha-beta T cell number J:158087
decreased T cell proliferation J:158087
increased B cell number J:158087
\Bcmd2CAST/EiJ/\Bcmd2CAST/EiJ
(AW.CAST-Bcmd2)
increased mast cell number J:75340
\Bco2tm1Dnp/\Bco2tm1Dnp
(involves: 129S6/SvEvTac * C57BL/6)
enlarged spleen J:166153
increased spleen weight J:166153
\Bcortm1.1Vjba/Y
\Commd10Tg(Vav1-icre)A2Kio/\Commd10+

(involves: 129S1/Sv * C57BL/6 * CBA/Ca)
increased neutrophil cell number J:231455
\Bcrtm1(BCR/ABL)Tsr/\Bcr+
\Runx1tm3Dow/\Runx1+
\Tg(Vav1-cre)#Cgp/0

(involves: C57BL/6)
decreased lymphocyte cell number J:203111
increased monocyte cell number J:203111
increased neutrophil cell number J:203111
\Bcrtm1Hkp/\Bcrtm1Hkp
(involves: 129S2/SvPas)
abnormal neutrophil physiology J:23804
increased leukocyte cell number J:23804
increased neutrophil cell number J:23804
increased susceptibility to endotoxin shock J:23804
sepsis J:23804
\Bcs1ltm1.1Levp/\Bcs1ltm1.1Levp
(B6.129-Bcs1ltm1.1Levp)
abnormal macrophage morphology J:273501
increased macrophage cell number J:273501
increased neutrophil cell number J:273501
liver inflammation J:273501
\Bdkrb1tm1Bdr/\Bdkrb1tm1Bdr
(involves: 129P2/OlaHsd)
abnormal acute inflammation J:63271
decreased susceptibility to endotoxin shock J:135789
\Bdkrb1tm2Bdr/\Bdkrb1tm2Bdr
\Bdkrb2tm1Jfh/\Bdkrb2tm1Jfh

(involves: 129S7/SvEvBrd * C57BL/6)
decreased susceptibility to endotoxin shock J:135789
\Bdp1em1(IMPC)Tcp/\Bdp1+
(C57BL/6N-Bdp1em1(IMPC)Tcp/Cmmr)
abnormal spleen morphology J:211773
decreased neutrophil cell number J:211773
increased lymphocyte cell number J:211773
\Bean1em1(IMPC)H/\Bean1em1(IMPC)H
(C57BL/6N-Bean1em1(IMPC)H/H)
decreased lymphocyte cell number J:211773
increased eosinophil cell number J:211773
\Becn1tm1.1Bflu/\Becn1tm1.1Bflu
\Tg(Cd4-cre)1Cwi/0

(involves: 129S1/Sv * C57BL/6 * DBA/2)
abnormal CD4-positive, alpha-beta T cell physiology J:203090
decreased CD4-positive, alpha-beta T cell number J:203090
decreased CD8-positive, alpha-beta T cell number J:203090
decreased susceptibility to experimental autoimmune encephalomyelitis J:203090
decreased T cell proliferation J:203090
increased T cell apoptosis J:203090
\Becn1tm1b(KOMP)Wtsi/\Becn1+
(C57BL/6N-Becn1tm1b(KOMP)Wtsi/Ieg)
increased leukocyte cell number J:211773
\Becn1tm1Blev/\Becn1+
(involves: 129X1/SvJ * C57BL/6J)
abnormal immune system morphology J:86953
increased spleen germinal center number J:86953
increased spleen germinal center size J:86953
\Becn1tm1Ebr/\Becn1tm1Ebr
\Lyz2tm1(cre)Ifo/\Lyz2+

(involves: 129P2/OlaHsd)
abnormal circulating chemokine level J:235399
abnormal macrophage physiology J:235399
abnormal spleen morphology J:235399
decreased circulating interleukin-10 level J:235399
glomerulonephritis J:235399
increased anti-double stranded DNA antibody level J:235399
increased anti-nuclear antigen antibody level J:235399
increased autoantibody level J:235399
increased circulating interleukin-1 beta level J:235399
increased circulating interleukin-6 level J:235399
increased circulating interleukin-12b level J:235399
increased IgG level J:235399
increased lymphocyte cell number J:235399
increased monocyte cell number J:235399
increased neutrophil cell number J:235399
increased susceptibility to systemic lupus erythematosus J:235399
\Becn1tm1Smoc/\Becn1tm1Smoc
\Foxp3tm4(YFP/icre)Ayr/0

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
abnormal regulatory T cell physiology J:306129
\Becn1tm1Smoc/\Becn1tm1Smoc
\Zfp91tm1Smoc/\Zfp91tm1Smoc
\Foxp3tm4(YFP/icre)Ayr/Y

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
abnormal regulatory T cell physiology J:306129
\Belr1BALB/cJ/\Belr1BALB/cJ
(involves: BALB/cJ * C57BL/6J)
decreased susceptibility to parasitic infection J:133125
\Belr1BALB/cJ/\Belr1BALB/cJ
(B6.C-H2d/bByJ)
decreased susceptibility to parasitic infection J:133125
\Berr1WLA/Pas/?
(involves: C57BL/6JRj * WLA/Pas)
decreased susceptibility to parasitic infection J:78027
\Berr2WLA/Pas/?
(involves: C57BL/6JRj * WLA/Pas)
decreased susceptibility to parasitic infection J:78027
\Best3tm1.1Zhoj/\Best3tm1.1Zhoj
\Tg(Tagln-cre)1Her/0

(involves: C57BL/6 * SJL)
aortitis J:338981
\Bex2tm1b(EUCOMM)Hmgu/\Bex2tm1b(EUCOMM)Hmgu
(C57BL/6N-Bex2tm1b(EUCOMM)Hmgu/Ieg)
increased leukocyte cell number J:211773
\Bex6tm1.1(KOMP)Vlcg/\Bex6tm1.1(KOMP)Vlcg
(B6N(Cg)-Bex6tm1.1(KOMP)Vlcg/J)
increased leukocyte cell number J:211773
\Bgntm1Mfy/Y
(involves: 129S4/SvJae * C57BL/6)
osteoarthritis J:76203
\Bgntm1Mfy/Y
\Fmodtm1Aol/\Fmodtm1Aol

(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6)
osteoarthritis J:76203
\Bgntm1Mfy/Y
\Fmodtm1Aol/\Fmodtm1Aol

(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ)
accelerated temporomandibular joint osteoarthritis J:112779, J:117908
\Bgntm1Mfy/\Bgntm1Mfy
(involves: 129S4/SvJae)
osteoarthritis J:222369
\Bgntm1Mfy/\Bgntm1Mfy
\Epyctm1Mhok/\Epyctm1Mhok

(involves: 129S4/SvJae * 129S7/SvEvBrd * C57BL/6J)
osteoarthritis J:222369
\Bgntm1Mfy/\Bgntm1Mfy
\Fmodtm1Aol/\Fmodtm1Aol

(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ)
accelerated temporomandibular joint osteoarthritis J:117908
\bhe/\bhe
(Not Specified)
chronic inflammation J:85113
\Bhlhe40tm1Tan/\Bhlhe40tm1Tan
(either: (involves: 129S1/Sv * 129X1/SvJ) or (involves: 129S1/Sv * 129X1/SvJ * C57BL/6))
abnormal CD4-positive T cell differentiation J:72651
abnormal CD4-positive, alpha-beta T cell physiology J:72651
abnormal immune system cell morphology J:72651
abnormal immune system physiology J:72651
abnormal lymph node germinal center morphology J:72651
abnormal susceptibility to autoimmune disorder J:72651
abnormal T cell activation J:72651
decreased double-positive T cell number J:72651
decreased interleukin-2 secretion J:72651
decreased T cell proliferation J:72651
increased anti-nuclear antigen antibody level J:72651
increased CD4-positive, alpha-beta T cell number J:72651
increased CD8-positive, alpha-beta T cell number J:72651
increased double-negative T cell number J:72651
increased IgE level J:72651
increased IgG1 level J:72651
increased spleen germinal center number J:72651
increased spleen white pulp amount J:72651
lymph node hyperplasia J:72651
spleen hyperplasia J:72651
thymus hyperplasia J:72651
\Bhlhe41tm1.2Cdon/\Bhlhe41tm1.2Cdon
(B6.129S6-Bhlhe41tm1.2Cdon)
abnormal lymphocyte cell number J:157740
abnormal T-helper 2 cell differentiation J:157740
decreased eosinophil cell number J:157740
decreased interferon-gamma secretion J:157740
decreased interleukin-2 secretion J:157740
decreased interleukin-5 secretion J:157740
decreased interleukin-13 secretion J:157740
decreased macrophage cell number J:157740
decreased neutrophil cell number J:157740
decreased T cell proliferation J:157740
increased interleukin-4 secretion J:157740
increased interleukin-17 secretion J:157740
\Bhmttm1b(EUCOMM)Hmgu/\Bhmttm1b(EUCOMM)Hmgu
(C57BL/6N-Bhmttm1b(EUCOMM)Hmgu/Bay)
increased spleen weight J:211773
\Bicdl1tm2b(EUCOMM)Wtsi/\Bicdl1tm2b(EUCOMM)Wtsi
(C57BL/6N-Bicdl1tm2b(EUCOMM)Wtsi/Bay)
abnormal spleen morphology J:211773
enlarged spleen J:211773
\Bicdl2em1(IMPC)Mbp/\Bicdl2em1(IMPC)Mbp
(C57BL/6N-Bicdl2em1(IMPC)Mbp/MbpMmucd)
abnormal spleen morphology J:211773
enlarged spleen J:211773
\Bidtm1Sjk/\Bidtm1Sjk
(involves: 129X1/SvJ * C57BL/6)
decreased susceptibility to endotoxin shock J:117693
\Bin1tm1Gcp/\Bin1tm1Gcp
(involves: 129S6/SvEvTac * C57BL/6J)
immune system phenotype J:83753
\Bin1tm1Gcp/\Bin1tm2Gcp
\Tg(Wap-cre)11738Mam/0

(involves: 129S6/SvEvTac * C57BL/6 * FVB/N * SJL)
endometrium inflammation J:117330
\Bin3tm1Gcp/\Bin3tm1Gcp
(involves: 129 * C57BL/6)
enlarged spleen J:133313
liver inflammation J:133313
lung inflammation J:133313
\Birc2tm1Jda/\Birc2tm1Jda
(B6.129P2-Birc2tm1Jda)
decreased lymphocyte cell number J:97656
\Birc2tm1Rbr/\Birc2tm1Rbr
\Birc3tm1.1Rbr/\Birc3tm1.1Rbr

(involves: C57BL/6 * NZB)
immune system phenotype J:172843
\Birc2tm1Rbr/\Birc2tm1Rbr
\Birc3tm1.1Rbr/\Birc3tm1.1Rbr
\Cd19tm1(cre)Cgn/\Cd19+

(involves: 129P2/OlaHsd * C57BL/6 * NZB)
decreased B cell apoptosis J:172843
decreased germinal center B cell number J:172843
decreased spleen germinal center size J:172843
enlarged lymph nodes J:172843
enlarged spleen J:172843
increased B cell number J:172843
increased follicular B cell number J:172843
increased marginal zone B cell number J:172843
\Birc2tm1Rbr/\Birc2tm1Rbr
\Birc3tm1.1Rbr/\Birc3tm1.1Rbr
\Cd19tm1(cre)Cgn/\Cd19+
\Tnfrsf13ctm1Mass/\Tnfrsf13ctm1Mass

(involves: 129P2/OlaHsd * C57BL/6 * NZB)
immune system phenotype J:172843
\Birc2tm1Rbr/\Birc2tm1Rbr
\Birc3tm1Rbr/\Birc3tm1Rbr
\Cd19tm1(cre)Cgn/\Cd19+

(involves: 129P2/OlaHsd * C57BL/6 * NZB)
immune system phenotype J:172843
\Birc2tm2.1Jda/\Birc2tm2.1Jda
(B6.Cg-Birc2tm2.1Jda)
immune system phenotype J:199221
increased interferon-gamma secretion J:199221
increased T cell proliferation J:199221
\Birc3tm1Jda/\Birc3tm1Jda
(B6.Cg-Birc3tm1Jda)
abnormal gut-associated lymphoid tissue morphology J:166899
abnormal lymphocyte cell number J:166899
decreased B cell apoptosis J:166899
decreased follicular B cell number J:166899
decreased IgG1 level J:166899
decreased immature B cell number J:166899
enlarged mesenteric lymph nodes J:166899
increased B cell number J:166899
increased B cell proliferation J:166899
increased IgA level J:166899
increased IgG3 level J:166899
increased IgM level J:166899
increased marginal zone B cell number J:166899
increased T cell number J:166899
lymph node hyperplasia J:166899
\Birc3tm1Jda/\Birc3tm1Jda
(involves: 129 * C57BL/6)
increased interferon-gamma secretion J:199221
increased T cell proliferation J:199221
\Birc3tm1Rgk/\Birc3tm1Rgk
(B6.129X1-Birc3tm1Rgk)
abnormal cytokine secretion J:144012
abnormal immune cell physiology J:144012
abnormal interleukin-1 beta secretion J:144012
abnormal interleukin-12 secretion J:144012
abnormal leukocyte cell number J:144012
abnormal macrophage physiology J:144012
abnormal T cell physiology J:144012
abnormal tumor necrosis factor secretion J:144012
decreased macrophage cell number J:144012
decreased susceptibility to endotoxin shock J:144012
\Birc5tm1Mak/\Birc5tm1Mak
\Tg(Lck-cre)I57Jxm/0

(involves: 129P2/OlaHsd)
abnormal T cell morphology J:90892
abnormal thymus corticomedullary boundary morphology J:90892
decreased double-negative T cell number J:90892
decreased thymocyte number J:90892
increased T cell apoptosis J:90892
small thymus J:90892
\Birc5tm1Wnt/\Birc5tm1Emc
\Tg(Cd4-cre)1Cwi/0

(involves: 129S/SvEv * C57BL/6 * DBA/2)
abnormal T cell differentiation J:87435
\Birc5tm1Wnt/\Birc5tm1Emc
\Tg(Lck-cre)1Cwi/0

(involves: 129S/SvEv * C57BL/6 * DBA/2)
decreased double-positive T cell number J:87435
decreased T cell number J:87435
increased double-negative T cell number J:87435
small lymph nodes J:87435
thymus hypoplasia J:87435
\Birc6tm1Nai/\Birc6tm1Nai
(involves: 129S4/SvJae * C57BL/6J)
increased thymocyte apoptosis J:96768
\Bld/\Bld+
(involves: BALB/cCi)
increased incidence of corneal inflammation J:5076
\Blkm1Btlr/\Blkm1Btlr
(C57BL/6J-Blkm1Btlr)
increased IgE level J:255004
increased interleukin-1 beta secretion J:255004
\Blktm1Tara/\Blktm1Tara
\Fyntm1Sor/\Fyntm1Sor
\Lyntm1Ard/\Lyntm1Ard

(either: B6.129-Lyntm1Ard Fyntm1Sor Blktm1Tara or (involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6))
abnormal B cell differentiation J:115080
abnormal pro-B cell differentiation J:115080
arrested B cell differentiation J:115080
decreased B cell number J:115080
decreased immature B cell number J:115080
decreased pre-B cell number J:115080
\Blmtm3Brd/\Blmtm3Brd
(involves: 129S7/SvEvBrd * C57BL/6)
decreased IgM level J:66261
\Blmtm4Ches/\Blmtm4Ches
\Cd19tm1(cre)Cgn/\Cd19+
\Nsmce2tm2.1Ofc/\Nsmce2tm2.1Ofc

(involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * SJL)
abnormal B cell morphology J:227197
abnormal B cell physiology J:227197
decreased B cell number J:227197
small spleen J:227197
\Blmtm4Ches/\Blmtm4Ches
\Trp53bp1tm1Jc/\Trp53bp1tm1Jc
\Cd19tm1(cre)Cgn/\Cd19+

(involves: 129P2/OlaHsd * 129S6/SvEvTac)
abnormal class switch recombination J:194603
\Blmhtm1Geh/\Blmhtm1Geh
(either: (involves: 129S1/Sv * 129S6/SvEvTac * 129X1/SvJ) or (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J))
dermatitis J:54585
\Blnkem1(IMPC)H/\Blnkem1(IMPC)H
(C57BL/6N-Blnkem1(IMPC)H/H)
decreased basophil cell number J:211773
decreased leukocyte cell number J:211773
decreased lymphocyte cell number J:211773
decreased spleen weight J:211773
increased eosinophil cell number J:211773
increased neutrophil cell number J:211773
small spleen J:211773
\Blnkm1Btlr/\Blnkm1Btlr
(C57BL/6J-Blnkm1Btlr)
arrested B cell differentiation J:159439
decreased IgG level J:159439
decreased IgM level J:159439
decreased mature B cell number J:159439
increased CD4-positive, alpha-beta T cell number J:159439
increased CD8-positive, alpha-beta T cell number J:159439
\Blnkm1Btlr/\Blnkm1Btlr
(involves: C57BL/6J)
arrested B cell differentiation J:185495
decreased IgM level J:185495
immune system phenotype J:185495
\Blnktm1Achn/\Blnk+
(involves: 129S4/SvJae * 129X1/SvJ * BALB/c * C3H * C57BL/6)
decreased B cell proliferation J:82430
\Blnktm1Achn/\Blnk+
\Btktm1Wk/\Btktm1Wk
\Tg(IGH-Btk)1Witt/0

(involves: 129S4/SvJae * 129X1/SvJ * BALB/c * C3H * C57BL/6)
abnormal B cell physiology J:82430
decreased B cell proliferation J:82430
\Blnktm1Achn/\Blnktm1Achn
(involves: 129X1/SvJ)
abnormal B cell differentiation J:58805
abnormal mature B cell morphology J:58805
absent B-1b cells J:58805
arrested B cell differentiation J:58805
decreased B-1a cell number J:58805
decreased immunoglobulin level J:58805
decreased mature B cell number J:58805
decreased splenocyte number J:58805
increased pro-B cell number J:58805
\Blnktm1Dkit/\Blnktm1Dkit
(involves: C57BL/6)
abnormal B cell apoptosis J:143854
abnormal B cell differentiation J:84040
abnormal immature B cell morphology J:94297
abnormal plasma cell differentiation J:143854
abnormal pre-B cell morphology J:84040
arrested B cell differentiation J:143854
decreased follicular B cell number J:143854
decreased IgG3 level J:143854
decreased IgM level J:143854
decreased immature B cell number J:84040
decreased marginal zone B cell number J:143854
decreased mature B cell number J:84040
decreased transitional stage B cell number J:143854
increased anti-double stranded DNA antibody level J:94297
increased B cell apoptosis J:143854
\Blnktm1Dkit/\Blnktm1Dkit
\Cd19tm1(cre)Cgn/\Cd19tm1(cre)Cgn

(involves: 129P2/OlaHsd * C57BL/6 * NZB)
abnormal pre-B cell morphology J:84040
absent immature B cells J:84040
absent mature B cells J:84040
arrested B cell differentiation J:84040
decreased pre-B cell number J:84040
enlarged lymph nodes J:84040
enlarged spleen J:84040
\Blnktm1Dkit/\Blnktm1Dkit
\Igh-Jtm1(3H9-VDJ)Mwg/\Igh-J+

(involves: C57BL/6 * NZB)
abnormal immature B cell morphology J:94297
\Blnktm1Dkit/\Blnktm1Dkit
\Igh-Jtm1(3H9-VDJ)Mwg/\Igh-J+
\Igk-Jtm1Mwg/\Igk-J+

(involves: C57BL/6 * NZB)
abnormal immature B cell morphology J:94297
\Blnktm1Dkit/\Blnktm1Dkit
\Prkcdtm1Kin/\Prkcdtm1Kin

(involves: 129P2/OlaHsd * C57BL/6 * NZB)
abnormal B cell proliferation J:143854
abnormal immunoglobulin level J:143854
abnormal plasma cell differentiation J:143854
arrested B cell differentiation J:143854
decreased B-1 B cell number J:143854
decreased B-2 B cell number J:143854
decreased follicular B cell number J:143854
decreased marginal zone B cell number J:143854
increased B cell apoptosis J:143854
increased IgA level J:143854
increased IgG1 level J:143854
increased IgG2b level J:143854
increased IgG3 level J:143854
increased IgM level J:143854
\Blnktm1Kplm/\Blnktm1Kplm
(involves: 129P2/OlaHsd)
abnormal B cell activation J:61130, J:131161
abnormal B cell differentiation J:61130, J:131161
absent B-1a cells J:61130
decreased B cell number J:61130, J:131161
decreased B cell proliferation J:61130
decreased immature B cell number J:61130
decreased mature B cell number J:61130
decreased pre-B cell number J:61130, J:120460
increased B cell apoptosis J:131161
increased pro-B cell number J:61130, J:131161
spleen hypoplasia J:131161
\Blnktm1Kplm/\Blnktm1Kplm
\Ightm4Cgn/\Igh+
\Igktm1Rsky/\Igk+

(involves: 129P2/OlaHsd)
abnormal B cell differentiation J:120460
decreased B cell number J:120460
increased pre-B cell number J:120460
increased transitional stage B cell number J:120460
\Blnktm1Kplm/\Blnktm1Kplm
\Plcg2tm1.1Kuro/\Plcg2+

(involves: 129P2/OlaHsd)
abnormal B cell activation J:131161
decreased B cell number J:131161
increased B cell apoptosis J:131161
\Blnktm1Kplm/\Blnktm1Kplm
\Plcg2tm1.1Kuro/\Plcg2tm1.1Kuro

(involves: 129P2/OlaHsd)
decreased B cell number J:131161
increased B cell apoptosis J:131161
spleen hypoplasia J:131161
\Blnktm1Pjln/\Blnktm1Pjln
(involves: BALB/c)
abnormal pre-B cell morphology J:58740
arrested B cell differentiation J:58740
decreased IgG3 level J:58740
decreased IgM level J:58740
decreased mature B cell number J:58740
enlarged spleen J:80332
increased mature B cell number J:157575
increased pre-B cell number J:58740, J:80332
\Blnktm1Pjln/\Blnktm1Pjln
\Btktm1Gsv/Y

(involves: 129P2/OlaHsd * BALB/c * C57BL/6)
abnormal B cell differentiation J:94768
decreased IgG3 level J:94768
decreased IgM level J:94768
decreased immature B cell number J:94768
decreased immunoglobulin level J:94768
decreased mature B cell number J:94768
\Blnktm1Pjln/\Blnktm1Pjln
\Btktm1Gsv/Y
\Tg(CD19-BTK*K430R)XK24Rwhe/?

(involves: 129P2/OlaHsd * BALB/c * C57BL/6 * FVB)
abnormal B cell differentiation J:94768
decreased IgG3 level J:94768
decreased IgM level J:94768
decreased immunoglobulin level J:94768
\Blnktm1Pjln/\Blnktm1Pjln
\Btktm1Wk/\Btktm1Wk

(involves: 129S4/SvJae * BALB/c * C57BL/6)
arrested B cell differentiation J:70406
\Bloc1s3rp/\Bloc1s3rp
(involves: C57BL/10ScSn * C57BL/Tb)
abnormal NK cell physiology J:6801
\Bloc1s4em1(IMPC)Mbp/\Bloc1s4em1(IMPC)Mbp
(C57BL/6NCrl-Bloc1s4em1(IMPC)Mbp/MbpMmucd)
increased monocyte cell number J:211773
\Bloc1s5mu-Btlr/\Bloc1s5mu-Btlr
(C57BL/6J-Bloc1s5mu-Btlr)
immune system phenotype J:137494
\Bloc1s6em1(IMPC)Mbp/\Bloc1s6em1(IMPC)Mbp
(C57BL/6N-Bloc1s6em1(IMPC)Mbp/MbpMmucd)
abnormal lymph node morphology J:211773
\Bloc1s6pa/\Bloc1s6pa
(B6.Cg-Bloc1s6pa/J)
abnormal NK cell physiology J:6801
lung inflammation J:4098
\Bmal1em1Bwu/\Bmal1em1Bwu
(C57BL/6-Bmal1em1Bwu)
abnormal macrophage physiology J:340220
\Bmal1tm1Bra/\Bmal1tm1Bra
(B6.129-Bmal1tm1Bra)
decreased basophil cell number J:191844
decreased leukocyte cell number J:110697
decreased lymphocyte cell number J:110697
decreased spleen weight J:110697
impaired leukocyte tethering or rolling J:191844
increased circulating fibrinogen level J:191844
increased eosinophil cell number J:191844
increased incidence of corneal inflammation J:110697
increased leukocyte cell number J:191844
increased lymphocyte cell number J:191844
increased monocyte cell number J:110697
increased neutrophil cell number J:110697, J:191844
\Bmal1tm1Bra/\Bmal1tm1Bra
(involves: 129/Sv * C57BL/6)
abnormal B cell differentiation J:118522
abnormal T cell subpopulation ratio J:118522
decreased B cell number J:135933, J:118522
decreased follicular B cell number J:118522
decreased IgG1 level J:118522
decreased lymphocyte cell number J:135933, J:118522
decreased transitional stage B cell number J:118522
increased neutrophil cell number J:135933
\Bmftm1.1Ast/\Bmftm1.1Ast
(B6.Cg-Bmftm1.1Anst)
abnormal B cell morphology J:133084
abnormal immune system cell morphology J:133084
abnormal spleen morphology J:133084
decreased B cell apoptosis J:133084
decreased T cell apoptosis J:133084
enlarged spleen J:133084
increased follicular B cell number J:133084
increased immature B cell number J:133084
increased immunoglobulin level J:133084
increased mature B cell number J:133084
increased pre-B cell number J:133084
increased T cell derived lymphoma incidence J:133084
increased transitional stage B cell number J:133084
spleen hyperplasia J:133084
\Bmftm1Rjd/\Bmftm1Rjd
(B6.129S6-Bmftm1Rjd)
decreased T cell apoptosis J:153652
enlarged spleen J:153652
increased B cell number J:153652
increased CD8-positive, alpha-beta T cell number J:153652
increased splenocyte number J:153652
\Bmftm3.1Rjd/\Bmftm3.1Rjd
(B6.129S6-Bmftm3.1Rjd)
decreased CD4-positive, alpha-beta T cell number J:153652
\Bmgr2C57BL/6J/?
\Prf1tm1Sdz/\Prf1tm1Sdz

(involves: 129S6/SvEvTac * C57BL/6J)
abnormal response to transplant J:116666
\Bmgr3129S6/SvEvTac/\Bmgr3129S6/SvEvTac
\Prf1tm1Sdz/\Prf1tm1Sdz

(involves: 129S6/SvEvTac * C57BL/6J)
abnormal response to transplant J:116666
\Bmgr4C57BL/6J/?
\Ebmgr1129S6/SvEvTac/\Ebmgr1129S6/SvEvTac
\Prf1tm1Sdz/\Prf1tm1Sdz

(involves: 129S6/SvEvTac * C57BL/6J)
abnormal response to transplant J:116666
\Bmgr4C57BL/6J/?
\Prf1tm1Sdz/\Prf1tm1Sdz

(involves: 129S6/SvEvTac * C57BL/6J)
abnormal response to transplant J:116666
\Bmi1tm1Brn/\Bmi1tm1Brn
(either: (involves: 129P2/OlaHsd) or (involves: 129P2/OlaHsd * FVB))
abnormal double-negative T cell morphology J:17712
abnormal spleen red pulp morphology J:17712
abnormal spleen white pulp morphology J:17712
abnormal thymus involution J:17712
decreased IgM level J:17712
decreased immature B cell number J:17712
decreased mature B cell number J:17712
decreased splenocyte proliferation J:17712
decreased thymocyte number J:17712
lung inflammation J:17712
small spleen J:17712
thymus cortex hypoplasia J:17712
\Bmi1tm1Brn/\Bmi1tm1Brn
(involves: 129P2/OlaHsd)
decreased double-positive T cell number J:134271
\Bmi1tm1Brn/\Bmi1tm1Brn
\E2f6tm1Lees/\E2f6tm1Lees

(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)
decreased double-positive T cell number J:134271
\Bmi1tm1Sgon/\Bmi1tm1Sgon
\Commd10Tg(Vav1-icre)A2Kio/?

(involves: 129S1/Sv * 129X1/SvJ * C57BL/10 * CBA/Ca)
abnormal immune system cell morphology J:221849
abnormal immune system organ morphology J:221849
abnormal spleen morphology J:221849
abnormal spleen periarteriolar lymphoid sheath morphology J:221849
abnormal spleen white pulp morphology J:221849
abnormal thymus morphology J:221849
absent spleen germinal center J:221849
decreased B cell number J:221849
decreased spleen red pulp amount J:221849
decreased spleen white pulp amount J:221849
decreased T cell number J:221849
small spleen J:221849
small thymus J:221849
thymus atrophy J:221849
\Bmi1tm1Sgon/\Bmi1tm1Sgon
\Gt(ROSA)26Sortm1(cre/ERT2)Tyj/?

(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ)
decreased lymphocyte cell number J:221849
decreased spleen weight J:221849
immune system phenotype J:221849
\Bmp1tm1.1Dgr/\Bmp1tm1.1Dgr
\Tll1tm2.1Dgr/\Tll1tm2.1Dgr
\Ndor1Tg(UBC-cre/ERT2)1Ejb/0

(involves: 129S/SvEv * 129S6/SvEvTac * C57BL/6 * SJL)
increased osteoclast cell number J:210366
\Bmp2tm1.1Mis/\Bmp2tm1.2Mis
\Tg(Col1a1-cre)1Bek/0

(involves: 129S4/SvJaeSor * 129S7/SvEvBrd * CD-1)
decreased osteoclast cell number J:210409
\Bmp2tm1Cjt/\Bmp2tm1Cjt
\Bmp4tm1Jfm/\Bmp4tm1Jfm
\Tg(Prrx1-cre)1Cjt/0

(involves: 129S4/SvJaeSor * C57BL/6 * SJL)
abnormal bone marrow development J:118257
\Bmp5se-Ca/\Bmp5+
(SEACGn.CB-Bmp5se-Ca)
granulomatous inflammation J:5086
\Bmp5se-Ca/\Bmp5se-Ca
(CBA/Ca-Bmp5se-Ca)
granulomatous inflammation J:5086
\Bmp5se-Ca/\Bmp5se-Ca
(SEACGn.CB-Bmp5se-Ca)
granulomatous inflammation J:5086
\Bmp5se/\Bmp5se
(SEC/1Gn)
granulomatous inflammation J:5086
\Bmp5se/\Bmp5se
(SEAC/Gn)
granulomatous inflammation J:5086
\Bmp7tm1.1Dgra/\Bmp7tm1.1Dgra
\Tg(Prrx1-cre)1Cjt/0

(involves: 129S6/SvEvTac * C57BL/6J * C57BL/6NTac * SJL/J)
joint inflammation J:221175
osteoarthritis J:221175
\Bmp7tm1a(EUCOMM)Hmgu/\Bmp7+
(C57BL/6N-Bmp7tm1a(EUCOMM)Hmgu/H)
increased monocyte cell number J:165965
\Bmp7tm1Rob/\Bmp7+
\Bmp8atm1Blh/\Bmp8atm1Blh

(involves: 129S/SvEv * 129S6/SvEvTac * Black Swiss * C57BL/6)
granulomatous inflammation J:78867
\Bmp8atm1Blh/\Bmp8a+
\Bmp8btm1Blh/\Bmp8b+

(involves: 129/Sv * 129S6/SvEvTac * Black Swiss)
granulomatous inflammation J:46927
\Bmp8atm1Blh/\Bmp8atm1Blh
(involves: 129S6/SvEvTac * Black Swiss)
granulomatous inflammation J:46927
\Bmp10b2b2711Clo/\Bmp10b2b2711Clo
(C57BL/6J-Bmp10b2b2711Clo)
thymus hypoplasia J:175213
\Bmpr1atm2.1Bhr/\Bmpr1atm2.1Bhr
\Tg(CAG-cre/Esr1*)5Amc/0

(involves: 129S7/SvEvBrd * C57BL/6 * CBA)
stomach inflammation J:163367
\Bmpr1atm2.1Bhr/\Bmpr1atm2.1Bhr
\Tg(Col1a1-cre/Esr1*)1Mis/0

(involves: 129S7/SvEvBrd)
abnormal osteoclast differentiation J:143588
abnormal osteoclast physiology J:143588
decreased osteoclast cell number J:143588
\Bmpr1atm2.1Bhr/\Bmpr1atm2.2Bhr
\Tg(Gdf5-cre,-ALPP)1Kng/0

(involves: 129 * C57BL/6 * FVB/N-Tg(Gdf5-cre-ALPP)1Kng)
osteoarthritis J:97780
\Bmpr2tm1Kmi/\Bmpr2+
(involves: 129S4/SvJae * C57BL/6J)
abnormal leukocyte physiology J:117167
\Bmxtm1Ali/\Bmxtm1Ali
(involves: 129S1/Sv * 129X1/SvJ)
decreased susceptibility to induced arthritis J:173099
\Bnc1em1(IMPC)H/\Bnc1em1(IMPC)H
(C57BL/6NTac-Bnc1em1(IMPC)H/H)
abnormal spleen morphology J:211773
increased leukocyte cell number J:211773
increased lymphocyte cell number J:211773
increased neutrophil cell number J:211773
\Bnip1tm2b(KOMP)Wtsi/\Bnip1+
(C57BL/6N-Bnip1tm2b(KOMP)Wtsi/Nju)
increased eosinophil cell number J:211773
\Bnip3ltm1.1Gwd/\Bnip3ltm1.1Gwd
(involves: 129 * C57BL/6)
abnormal spleen morphology J:141583
abnormal thrombopoiesis J:141583
enlarged spleen J:141583
increased spleen red pulp amount J:141583
\Bnip3ltm1Ney/\Bnip3ltm1Ney
(Not Specified)
enlarged spleen J:141545
spleen hyperplasia J:141545
\Bnip5tm1.1(KOMP)Vlcg/\Bnip5tm1.1(KOMP)Vlcg
(C57BL/6N-Bnip5tm1.1(KOMP)Vlcg/MbpMmucd)
abnormal spleen morphology J:211773
small spleen J:211773
\Boctm1b(KOMP)Wtsi/\Boctm1b(KOMP)Wtsi
(C57BL/6N-Boctm1b(KOMP)Wtsi/H)
increased basophil cell number J:211773
\Bod1tm1b(KOMP)Wtsi/\Bod1+
(C57BL/6N-Bod1tm1b(KOMP)Wtsi/Nju)
increased basophil cell number J:211773
increased eosinophil cell number J:211773
\Bod1lem1Bltn/\Bod1lem1Bltn
\Cd19tm1(cre)Cgn/\Cd19+

(involves: 129P2/OlaHsd * C57BL/6J)
decreased IgG1 level J:337726
decreased IgG level J:337726
\Bod1lem1Bltn/\Bod1lem1Bltn
\Gt(ROSA)26Sortm9(cre/ESR1)Arte/\Gt(ROSA)26Sor+

(involves: C57BL/6J * C57BL/6NTac)
abnormal class switch recombination J:337726
decreased IgG1 level J:337726
\Boktm1.1Ast/\Boktm1.1Ast
(involves: BALB/cJ * C57BL/6)
immune system phenotype J:203179
increased spleen weight J:203179
increased thymus weight J:203179
\Boktm1b(EUCOMM)Hmgu/\Boktm1b(EUCOMM)Hmgu
(C57BL/6N-Boktm1b(EUCOMM)Hmgu/Tcp)
increased basophil cell number J:211773
increased eosinophil cell number J:211773
\Bomb1NSF/N/\Bomb1NSF/N
(involves: NFS/N * SL/Kh)
increased pre-B cell number J:55364
\Bomb1SL/Kh/\Bomb1SL/Kh
(involves: NFS/N * SL/Kh)
increased pre-B cell number J:55364
\Bpgmm1Pgrs/\Bpgmm1Pgrs
(involves: C57BL/6 * C57BL/10J)
decreased susceptibility to parasitic infection induced morbidity/mortality J:301620
enlarged spleen J:301620
immune system phenotype J:301620
\Bpgmm1Pgrs/\Bpgmm1Pgrs
(involves: A/J)
decreased susceptibility to parasitic infection induced morbidity/mortality J:301620
\Bpitm1.1Buls/\Bpitm1.1Buls
(involves: BALB/cJ * C57BL/6J)
abnormal circulating interleukin level J:346703
abnormal immune cell physiology J:346703
abnormal interleukin secretion J:346703
decreased circulating interferon-gamma level J:346703
enlarged mesenteric lymph nodes J:346703
immune system phenotype J:346703
increased susceptibility to induced colitis J:346703
increased T cell number J:346703
\Bpifa1m1Ingm/\Bpifa1m1Ingm
(involves: C3HeB/FeJ)
increased interleukin-1 alpha secretion J:195535
increased interleukin-1 beta secretion J:195535
increased susceptibility to bacterial infection J:195535
increased susceptibility to otitis media J:221346
increased tumor necrosis factor secretion J:195535
lung inflammation J:195535
\Bpifa1tm1(KOMP)Vlcg/\Bpifa1tm1(KOMP)Vlcg
(involves: C57BL/6J * C57BL/6NTac)
increased susceptibility to bacterial infection J:171589
\Bpifa1tm1.1Jpst/\Bpifa1tm1.1Jpst
\Scgb1a1tm1(cre/ERT)Blh/\Scgb1a1tm1(cre/ERT)Blh

(involves: 129S6/SvEvTac * C57BL/6 * C57BL/6J * SJL)
increased susceptibility to Orthomyxoviridae infection J:265391
increased susceptibility to Orthomyxoviridae infection induced morbidity/mortality J:265391
\Bpifa1tm1.2Jpst/\Bpifa1tm1.2Jpst
(involves: BALB/cJ * C57BL/6 * C57BL/6J * SJL)
increased susceptibility to Orthomyxoviridae infection J:265391
increased susceptibility to Orthomyxoviridae infection induced morbidity/mortality J:265391
\Bptfem1Zfa/\Bptfem1Zfa
\Tg(Rorc-cre)1Litt/0

(involves: C57BL/6 * FVB)
increased susceptibility to bacterial infection J:259392
increased susceptibility to bacterial infection induced morbidity/mortality J:259392
\Bptftm1.1Cwu/\Bptftm1.1Cwu
\Emx1tm1(cre)Krj/\Emx1+

(involves: 129S1/Sv * 129S2/SvPas * C57BL/6)
microgliosis J:334252
\Braftm1(ARAF)Urr/\Braftm1(ARAF)Urr
(involves: 129S1/Sv * C57BL/6 * CD-1)
decreased spleen weight J:112971
decreased thymus weight J:112971
\Braftm1Bbd/\Braf+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)
abnormal immune system physiology J:170095
abnormal thymus morphology J:170095
decreased thymocyte number J:170095
increased splenocyte apoptosis J:170095
increased thymocyte apoptosis J:170095
thymus atrophy J:170095
\Braftm1Bbd/\Braf+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * CD-1)
abnormal immune system physiology J:170095
abnormal thymus morphology J:170095
decreased thymocyte number J:170095
increased splenocyte apoptosis J:170095
increased thymocyte apoptosis J:170095
thymus atrophy J:170095
\Braftm1Bbd/\Braf+
(B6.129-Braftm1Bbd)
abnormal immune system physiology J:170095
abnormal thymus morphology J:170095
decreased thymocyte number J:170095
increased splenocyte apoptosis J:170095
increased thymocyte apoptosis J:170095
thymus atrophy J:170095
\Braftm1Cpri/\Braf+
\Tg(Mx1-cre)1Cgn/0

(involves: 129P2/OlaHsd * C57BL/6 * CBA)
decreased leukocyte cell number J:104375
enlarged spleen J:104375
\Braftm1Mmcm/\Braftm1Mmcm
\Cd207tm2.1(cre)Bjec/\Cd207+

(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)
increased dendritic cell number J:211690
liver inflammation J:211690
lung inflammation J:211690
\Braftm1Mmcm/\Braftm1Mmcm
\Tg(Itgax-cre)1-1Reiz/0

(involves: 129P2/OlaHsd * C57BL/6 * CBA)
cytokine storm J:211690
enlarged lymph nodes J:211690
granulomatous inflammation J:211690
hepatosplenomegaly J:211690
increased dendritic cell number J:211690
increased inflammatory response J:211690
\Braftm1Tumg/\Braf+
\Tg(CAG-cre)2Osb/0

(involves: C57BL * C57BL/6J * DBA)
abnormal lymph organ development J:216228
\Braftm1Wds/\Braftm1Wds
\Raf1tm2Bacc/\Raf1tm2Bacc
\H2az2Tg(Wnt1-cre)11Rth/\H2az2+

(involves: 129P2/OlaHsd * C57BL/6J * CBA/J)
small thymus J:144862
\Braftm2Cpri/\Braf+
\Tg(CMV-cre)1Cgn/0

(B6.Cg-Braftm2Cpri Tg(CMV-cre)1Cgn)
enlarged spleen J:187371
increased spleen weight J:187371
lymphoid hyperplasia J:187371
\Brapem1(IMPC)Mbp/\Brap+
(C57BL/6NCrl-Brapem1(IMPC)Mbp/Mmucd)
abnormal lymph node morphology J:211773
enlarged lymph nodes J:211773
\Brca1tm2.1Cxd/\Brca1tm2.1Cxd
\Shld1em1Nus/\Shld1em1Nus

(involves: 129S6/SvEvTac * C57BL/6NCrl)
abnormal class switch recombination J:307190
\Brca1tm2.1Cxd/\Brca1tm2.1Cxd
\Trp53tm1Brd/\Trp53+

(involves: 129S6/SvEvTac * 129S7/SvEvBrd)
enlarged thymus J:81541
increased T cell derived lymphoma incidence J:81541
\Brca1tm2.1Cxd/\Brca1tm2.1Cxd
\Trp53tm1Brd/\Trp53tm1Brd

(involves: 129S6/SvEvTac * 129S7/SvEvBrd)
increased T cell derived lymphoma incidence J:81541
\Brca1tm2.1Cxd/\Brca1tm2.1Cxd
\Trp53bp1tm1Jc/\Trp53bp1tm1Jc

(involves: 129 * 129S6/SvEvTac)
abnormal class switch recombination J:307190
\Brca1tm2Mak/\Brca1tm2Mak
\Cdkn1atm1Tyj/\Cdkn1atm1Tyj
\Tg(Lck-cre)548Jxm/?

(involves: 129P2/OlaHsd * C57BL/6 * CBA)
decreased thymocyte number J:63282
immune system phenotype J:63282
\Brca1tm2Mak/\Brca1tm2Mak
\Chek2tm1Mak/\Chek2tm1Mak
\Tg(Lck-cre)548Jxm/?

(involves: 129P2/OlaHsd * C57BL/6 * CBA)
immune system phenotype J:90512
increased T cell derived lymphoma incidence J:90512
\Brca1tm2Mak/\Brca1tm2Mak
\Tg(BCL2)36Wehi/?
\Tg(Lck-cre)548Jxm/?

(involves: 129P2/OlaHsd * C57BL/6 * CBA)
immune system phenotype J:63282
\Brca1tm2Mak/\Brca1tm2Mak
\Tg(Lck-cre)548Jxm/?

(involves: 129P2/OlaHsd * C57BL/6 * CBA)
abnormal immune system organ morphology J:63282
abnormal T cell number J:63282
decreased double-positive T cell number J:63282
decreased single-positive T cell number J:63282
decreased T cell proliferation J:63282
decreased thymocyte number J:63282
increased double-negative T cell number J:63282
\Brca1tm2Mak/\Brca1tm2Mak
\Tg(Lck-cre)548Jxm/?
\Tg(TcrLCMV)327Sdz/?

(involves: 129P2/OlaHsd * C57BL/6 * CBA)
abnormal T cell number J:63282
decreased double-positive T cell number J:63282
decreased T cell proliferation J:63282
decreased thymocyte number J:63282
increased double-negative T cell number J:63282
\Brca1tm2Mak/\Brca1tm2Mak
\Tg(Lck-cre)548Jxm/?
\Trp53tm1Brd/\Trp53tm1Brd

(involves: 129P2/OlaHsd * C57BL/6 * CBA)
immune system phenotype J:63282
increased T cell derived lymphoma incidence J:90512
\Brca1tm5.1Cxd/\Brca1tm5.1Cxd
(involves: 129S6/SvEvTac * FVB/N)
dermatitis J:155810
increased T cell derived lymphoma incidence J:155810
\Brca2tm1Cam/\Brca2tm1Cam
(involves: 129S/SvEv * MF1)
increased T cell derived lymphoma incidence J:46812
increased thymus weight J:46812
\Brca2tm1Cbl/\Brca2tm1Cbl
(either: (involves: 129S2/SvPas * C57BL/10) or (involves: 129S2/SvPas * C57BL/6 * DBA/2))
increased T cell derived lymphoma incidence J:44386
\Brca2tm1Hst/\Brca2tm1Hst
(involves: 129S7/SvEvBrd * C57BL/6)
sepsis J:82434
\Brca2tm1Kamc/\Brca2tm1Kamc
(involves: 129P2/OlaHsd * BALB/c)
spleen hypoplasia J:144998
\Brca2tm1Mak/\Brca2tm2Mak
\Tg(Lck-cre)548Jxm/0

(involves: 129P2/OlaHsd * C57BL/6 * CBA)
immune system phenotype J:79697
increased T cell apoptosis J:79697
\Brca2tm1Mak/\Brca2tm2Mak
\Trp53tm1Brd/\Trp53tm1Brd
\Tg(Lck-cre)548Jxm/0

(involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6 * CBA)
immune system phenotype J:79697
increased activated T cell number J:79697
\Brd2em1(IMPC)Wtsi/\Brd2+
(C57BL/6N-Brd2em1(IMPC)Wtsi/WtsiIeg)
decreased CD8-positive, alpha-beta T cell number J:211773
increased CD4-positive, alpha-beta T cell number J:211773
\Brd2em1(IMPC)Wtsi/\Brd2em1(IMPC)Wtsi
(C57BL/6N-Brd2em1(IMPC)Wtsi/WtsiIeg)
abnormal thymus topology J:239583
absent connection between subcutaneous lymph vessels and lymph sac J:239583
blood in lymph vessels J:239583
small thymus J:239583
\Brd2Gt(RRT234)Byg/\Brd2+
(B6.129P2-Brd2Gt(RRT234)Byg)
increased circulating interleukin-1 beta level J:159964
increased circulating tumor necrosis factor level J:159964
\Brd9em1(IMPC)Tcp/\Brd9+
(C57BL/6N-Brd9em1(IMPC)Tcp/Cmmr)
increased neutrophil cell number J:211773
\Brf1tm1Arte/\Brf1tm1Arte
\Tg(Cyp1a1-cre)1Dwi/0

(involves: C57BL/6 * CBA)
liver inflammation J:285667
\Brix1tm1b(KOMP)Mbp/\Brix1+
(C57BL/6N-Brix1tm1b(KOMP)Mbp/Mhzh)
increased basophil cell number J:211773
increased eosinophil cell number J:211773
\Brpf1tm1a(EUCOMM)Wtsi/\Brpf1+
(Not Specified)
decreased T cell number J:165965
increased monocyte cell number J:165965
\Brwd1em1(IMPC)Tcp/\Brwd1em1(IMPC)Tcp
(C57BL/6N-Brwd1em1(IMPC)Tcp/Cmmr)
abnormal spleen morphology J:211773
\Bscl2tm1.1Lchan/\Bscl2tm1.1Lchan
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)
enlarged spleen J:183701
\Bscl2tm1.2Gliu/\Bscl2tm1.2Gliu
(involves: 129 * 129S4/SvJaeSor * C57BL/6 * FVB/N)
enlarged spleen J:173404
\Bscl2tm1b(EUCOMM)Hmgu/\Bscl2tm1b(EUCOMM)Hmgu
(C57BL/6N-Bscl2tm1b(EUCOMM)Hmgu/Ics)
increased large unstained cell number J:211773
increased monocyte cell number J:211773
increased neutrophil cell number J:211773
\Bsgtm1.1Znc/\Bsgtm1.1Znc
\Tg(Lck-cre)19Hhan/0

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA)
abnormal T cell activation J:207886
decreased double-positive T cell number J:207886
decreased single-positive T cell number J:207886
decreased thymocyte number J:207886
decreased thymus weight J:207886
immune system phenotype J:207886
increased T cell proliferation J:207886
\Bsgtm1Tmu/\Bsgtm1Tmu
(involves: 129S2/SvPas * C57BL/6J)
interstitial pneumonia J:46376
\Bsgtm1Tmu/\Bsgtm1Tmu
(involves: 129/Sv * 129S2/SvPas)
interstitial pneumonia J:46376
\Bsgtm1Tmu/\Bsgtm1Tmu
(involves: 129S2/SvPas)
decreased circulating complement protein level J:287636
glomerulonephritis J:287636
increased spleen weight J:287636
increased splenocyte number J:287636
increased susceptibility to systemic lupus erythematosus J:287636
increased T-helper 17 cell number J:287636
\Bsp/\Bsp
(C57BL/6By)
abnormal spleen morphology J:6856
\Bsp/\Bsp+
(C57BL/6By)
abnormal spleen morphology J:6856
\Bst1tm1Thir/\Bst1tm1Thir
(involves: 129P2/OlaHsd * C57BL/6)
abnormal B cell physiology J:111424
abnormal humoral immune response J:111424
decreased B-1 B cell number J:111424
decreased IgA level J:111424
decreased IgG3 level J:111424
decreased immature B cell number J:111424
immune system phenotype J:111424
increased B cell number J:111424
\Bst2tm1.1Bsz/\Bst2tm1.1Bsz
(involves: C57BL/6)
enlarged lymph nodes J:180252
enlarged spleen J:180252
increased susceptibility to Retroviridae infection J:180252
\Btbd1tm1a(KOMP)Wtsi/\Btbd1tm1a(KOMP)Wtsi
(C57BL/6N-Btbd1tm1a(KOMP)Wtsi/Wtsi)
increased CD8-positive, naive alpha-beta T cell number J:211773
\Btbd2em1(IMPC)Mbp/\Btbd2em1(IMPC)Mbp
(C57BL/6N-Btbd2em1(IMPC)Mbp/MbpMmucd)
abnormal lymph node morphology J:211773
enlarged lymph nodes J:211773
\Btbd3tm1b(EUCOMM)Hmgu/\Btbd3tm1b(EUCOMM)Hmgu
(C57BL/6N-Btbd3tm1b(EUCOMM)Hmgu/Ccpcz)
increased CD8-positive, CD25-positive alpha-beta T cell number J:211773
\Btbd7em1(IMPC)Ccpcz/\Btbd7em1(IMPC)Ccpcz
(C57BL/6NCrl-Btbd7em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged spleen J:211773
enlarged thymus J:211773
\Btbd8em1Lych/\Btbd8em1Lych
(involves: C57BL/6)
decreased macrophage cytokine production J:349252
decreased susceptibility to induced colitis J:349252
\Btbd16tm2b(EUCOMM)Hmgu/\Btbd16tm2b(EUCOMM)Hmgu
(C57BL/6N-Btbd16tm2b(EUCOMM)Hmgu/Bay)
abnormal spleen morphology J:211773
enlarged spleen J:211773
increased spleen weight J:211773
\Btbd18em1(IMPC)Ccpcz/\Btbd18em1(IMPC)Ccpcz
(C57BL/6NCrl-Btbd18em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged spleen J:211773
enlarged thymus J:211773
\Btcem1(IMPC)Mbp/\Btcem1(IMPC)Mbp
(C57BL/6N-Btcem1(IMPC)Mbp/MbpMmucd)
abnormal lymph node morphology J:211773
enlarged lymph nodes J:211773
increased neutrophil cell number J:211773
\Btf3em1(IMPC)Tcp/\Btf3+
(C57BL/6NCrl-Btf3em1(IMPC)Tcp/Tcp)
decreased leukocyte cell number J:211773
decreased lymphocyte cell number J:211773
enlarged lymph nodes J:211773
\Btg1em1(IMPC)Mbp/\Btg1em1(IMPC)Mbp
(C57BL/6NCrl-Btg1em1(IMPC)Mbp/Mmucd)
decreased lymphocyte cell number J:211773
enlarged spleen J:211773
increased basophil cell number J:211773
increased eosinophil cell number J:211773
\Btkm1Anu/\Btkm1Anu
(involves: BXSB/MpJ * C57BL/6JAnu * SB/Le)
decreased B cell number J:104190
\Btkm1Anu/\Btkm1Anu
X/\Yaa

(involves: BXSB/MpJ * C57BL/6JAnu * SB/Le)
decreased B cell number J:104190
\Btkm2Anu/\Btkm2Anu
(C57BL/6NCrlAnu-Btkm2Anu)
increased IgM level J:104190
increased immature B cell number J:104190
\Btktm1a(EUCOMM)Hmgu/Y
(C57BL/6N-Btktm1a(EUCOMM)Hmgu/Ics)
increased CD4-positive, alpha-beta T cell number J:165965
\Btktm1Gsv/Y
(involves: 129P2/OlaHsd * C57BL/6)
abnormal B cell calcium ion homeostasis J:94768
abnormal B cell differentiation J:35769
abnormal humoral immune response J:120989
abnormal immune system physiology J:35769
absent B-1a cells J:35769
absent mature B cells J:35769
decreased B cell number J:35769
decreased IgG3 level J:35769
decreased IgM level J:35769
decreased immature B cell number J:35769
decreased immunoglobulin level J:120989
\Btktm1Gsv/Y
\Tg(CD19-BTK*K430R)XK24Rwhe/?

(involves: 129P2/OlaHsd * C57BL/6 * FVB)
abnormal lymphocyte cell number J:120989
abnormal pre-B cell morphology J:120989
absent B-1a cells J:120989
decreased B cell apoptosis J:120989
decreased B cell number J:120989
decreased immunoglobulin level J:120989
immune system phenotype J:94768
\Btktm1Gsv/\Btk+
(involves: 129P2/OlaHsd * C57BL/6)
absent B-1a cells J:35769
decreased B cell number J:35769
decreased mature B cell number J:35769
\Btktm1Witt/\Btktm1Wk
(involves: 129S4/SvJae * 129X1/SvJ)
immune system phenotype J:104167
\Btktm1Wk/\Btktm1Wk
(involves: 129S4/SvJae * C57BL/6)
abnormal B cell activation J:28968
abnormal B cell differentiation J:28968
abnormal lymph node germinal center morphology J:82298
decreased B cell proliferation J:82298
decreased IgG3 level J:28968, J:82298
decreased IgM level J:28968, J:82298
decreased mature B cell number J:28968, J:82298
decreased spleen germinal center number J:82298
decreased spleen germinal center size J:82298
increased pro-B cell number J:28968
\Btktm1Wk/\Btktm1Wk
\Cd40tm1Geha/\Cd40tm1Geha

(involves: 129S4/SvJae * C57BL/6)
abnormal humoral immune response J:82298
absent lymph node germinal center J:82298
absent spleen germinal center J:82298
decreased B cell number J:82298
decreased B cell proliferation J:82298
decreased IgA level J:82298
decreased IgG2a level J:82298
decreased IgG2b level J:82298
decreased IgG3 level J:82298
decreased IgM level J:82298
decreased mature B cell number J:82298
\Btktm1Wk/\Btktm1Wk
\Tectm1Welm/\Tectm1Welm

(involves: 129P2/OlaHsd * C57BL/6)
abnormal B cell differentiation J:66080
abnormal humoral immune response J:66080
abnormal spleen marginal zone morphology J:66080
abnormal spleen morphology J:66080
abnormal spleen white pulp morphology J:66080
decreased B cell number J:66080
decreased B cell proliferation J:66080
decreased IgG2a level J:66080
decreased IgG3 level J:66080
decreased IgM level J:66080
decreased immunoglobulin level J:66080
increased pre-B cell number J:66080
\Btktm1Wk/\Btktm1Wk
\Tg(IGH-Btk)1Witt/0

(involves: 129S4/SvJae * 129X1/SvJ * BALB/c * C3H * C57BL/6)
decreased B cell proliferation J:82430
\Btkvila/\Btkvila
(C57BL/6JAnu-Btkvila/AnuApb)
abnormal leukocyte morphology J:104190
decreased B cell number J:104190
decreased IgD level J:104190
increased IgE level J:104190
increased IgG level J:104190
\Btkxid/Y
(CBA/HN-Btkxid)
decreased B cell number J:81429
decreased B cell proliferation J:81429
decreased splenocyte number J:81429
\Btkxid/Y
(involves: CBA/HN * DBA/2N)
decreased B cell number J:81429
decreased B cell proliferation J:81429
spleen hypoplasia J:81429
\Btkxid/?
(involves: BALB/c * CBA/N)
decreased B cell proliferation J:108696
decreased B-1 B cell number J:108696
decreased IgG3 level J:108696
decreased IgM level J:108696
decreased mature B cell number J:108696
\Btkxid/Y
\Ikzf3tm1Kge/\Ikzf3tm1Kge

(involves: 129S4/SvJae * CBA/CaHN)
decreased follicular B cell number J:69477
\Btkxid/?
\Ptpn6me/\Ptpn6me

(involves: C57BL/6J * CBA/N * NFS)
increased autoantibody level J:30994
increased IgM level J:30994
increased splenocyte proliferation J:30994
\Btkxid/?
\Tg(IGH-Btk)1Witt/0

(involves: BALB/c * C3H * C57BL/6 * CBA/N)
decreased B cell proliferation J:108696
decreased B-1 B cell number J:108696
decreased IgG3 level J:108696
decreased IgM level J:108696
\Btkxid/?
\Tg(IGH-Btk)1Witt/\Tg(IGH-Btk)1Witt

(involves: BALB/c * C3H * C57BL/6 * CBA/N)
decreased B cell proliferation J:108696
decreased B-1 B cell number J:108696
decreased IgG3 level J:108696
decreased IgM level J:108696
\Btkxid/\Btkxid
(CBA/CaHN-Btkxid/J)
abnormal macrophage physiology J:92639
abnormal neutrophil physiology J:92639
decreased acute inflammation J:92639
decreased follicular B cell number J:69477
decreased neutrophil cell number J:92639
decreased susceptibility to experimental autoimmune encephalomyelitis J:92639
impaired myelopoiesis J:92639
impaired neutrophil phagocytosis J:92639
increased susceptibility to bacterial infection induced morbidity/mortality J:128518
increased susceptibility to induced colitis J:92639
\Btkxid/\Btkxid
(involves: CBA/HN * DBA/2N)
abnormal B cell physiology J:81429
abnormal B cell proliferation J:81429
decreased B cell number J:81429
spleen hypoplasia J:81429
\Btkxid/\Btkxid
(CBA/HN-Btkxid)
abnormal lymphopoiesis J:7981
abnormal pre-B cell morphology J:7981
autoimmune response J:125114
decreased B cell number J:81429
decreased B cell proliferation J:81429
decreased splenocyte number J:81429
\Btkxid/\Btkxid
(involves: C57BL/6 * CBA)
immune system phenotype J:113083
\Btkxid/\Btkxid
(B6.CBA-Btkxid)
decreased transitional stage B cell number J:145687
\Btkxid/\Btkxid
\Ikzf3tm1Kge/\Ikzf3tm1Kge

(involves: 129S4/SvJae * CBA/CaHN)
decreased follicular B cell number J:69477
\Btlatm1Dgra/\Btlatm1Dgra
(involves: C57BL/6)
abnormal peripheral T cell anergy J:147751
abnormal T cell activation J:147751
\Btlatm1Dgra/\Btlatm1Dgra
\Tg(TcraTcrb)425Cbn/?

(involves: C57BL/6)
abnormal peripheral T cell anergy J:147751
\Btlatm1Dgra/\Btlatm1Dgra
\Tg(TcraTcrb)1100Mjb/?

(involves: C57BL/6)
abnormal peripheral T cell anergy J:147751
\Btlatm1Kay/\Btlatm1Kay
(involves: 129S6/SvEvTac * C57BL/6J)
abnormal T cell activation J:89864
\Btlatm1Kmm/\Btlatm1Kmm
(involves: 129S/SvEv)
abnormal humoral immune response J:84084
increased B cell proliferation J:84084
increased IgG1 level J:84084
increased IgG2a level J:84084
increased IgG2b level J:84084
increased susceptibility to experimental autoimmune encephalomyelitis J:84084
increased T cell proliferation J:84084
\Btlatm1Kmm/\Btlatm1Kmm
(B6.129S-Btlatm1Kmm)
abnormal T cell activation J:119356
decreased interferon-gamma secretion J:119356
decreased interleukin-2 secretion J:119356
decreased T cell proliferation J:119356
increased length of allograft survival J:119356
increased T cell proliferation J:119356
\Btlatm1Kmm/\Btlatm1Kmm
\Pdcd1tm1Hon/\Pdcd1tm1Hon

(B6.129S-Pdcd1tm1Hon Btlatm1Kmm)
decreased length of allograft survival J:119356
increased T cell proliferation J:119356
\Btlatm1Kmm/\Btlatm1Kmm
\Tg(DO11.10)10Dlo/?

(involves: 129S/SvEv * BALB/c * C3H * C57BL/6)
increased T cell proliferation J:84084
\Btn2a2tm1.2Wrth/\Btn2a2tm1.2Wrth
(C57BL/6-Btn2a2tm1.2Wrth)
abnormal T-helper 1 physiology J:232636
abnormal T-helper 2 physiology J:232636
increased anti-nuclear antigen antibody level J:232636
increased IgG1 level J:232636
increased IgG2c level J:232636
increased IgG level J:232636
increased response to antigen J:232636
increased susceptibility to experimental autoimmune encephalomyelitis J:232636
\Btnl1em1Ahay/\Btnl1em1Ahay
(Not Specified)
abnormal CD8 positive, alpha-beta intraepithelial T cell morphology J:236526
decreased gamma-delta intraepithelial T cell number J:236526
\Btnl1em3Ahay/\Btnl1em3Ahay
\Btnl6em2Ahay/\Btnl6em2Ahay
\Tg(Vil1-cre/ERT2)23Syr/0

(involves: BALB/c * C57BL/6J * DBA/2)
immune system phenotype J:291989
\Btnl1em4Ahay/\Btnl1em4Ahay
\Tg(Vil1-cre/ERT2)23Syr/0

(involves: C57BL/6 * DBA/2)
immune system phenotype J:291989
\Btnl1tm1(KOMP)Mbp/\Btnl1tm1(KOMP)Mbp
(C57BL/6N-Btnl1tm1(KOMP)Mbp)
abnormal CD8 positive, alpha-beta intraepithelial T cell morphology J:236526
decreased gamma-delta intraepithelial T cell number J:236526
\Btnl1tm1(KOMP)Mbp/\Btnl1tm1(KOMP)Mbp
\Foxn1nu/\Foxn1nu

(involves: albino stock * C57BL/6N)
decreased gamma-delta intraepithelial T cell number J:236526
\Btnl1tm1(KOMP)Mbp/\Btnl1tm1(KOMP)Mbp
\Gt(ROSA)26Sortm1(rtTA*M2)Jae/0
\Tg(tetO-Btnl1)#Ahay/0

(involves: 129S4/SvJae * C57BL/6 * C57BL/6N)
decreased gamma-delta intraepithelial T cell number J:236526
\Btnl1tm1(KOMP)Mbp/\Btnl1tm1(KOMP)Mbp
\Tg(tetO-Btnl1)#Ahay/0
\Tg(Vil-rtTA2*M2)1Rsmi/0

(involves: C57BL/6N * FVB/N)
decreased gamma-delta intraepithelial T cell number J:236526
\Btnl2em1Wche/\Btnl2em1Wche
(C57BL/6-Btnl2em1Wche)
abnormal cytokine level J:321348
abnormal gamma-delta T cell morphology J:321348
large intestinal inflammation J:321348
\Btnl4em1(IMPC)Tcp/\Btnl4em1(IMPC)Tcp
(C57BL/6N-Btnl4em1(IMPC)Tcp/1Cmmr)
enlarged lymph nodes J:211773
enlarged spleen J:211773
\Btnl4tm1(KOMP)Mbp/\Btnl4tm1(KOMP)Mbp
(C57BL/6N-Btnl4tm1(KOMP)Mbp)
immune system phenotype J:291989
\Btnl6em1.1Ahay/\Btnl6em1.1Ahay
(Not Specified)
decreased CD4-positive, gamma-delta intraepithelial T cell number J:291989
\Btnl6em1Ahay/\Btnl6em1Ahay
\Tg(Vil1-cre)20Syr/0

(involves: C57BL/6 * DBA/2)
decreased CD4-positive, gamma-delta intraepithelial T cell number J:291989
\Btrctm1b(KOMP)Wtsi/\Btrctm1b(KOMP)Wtsi
(C57BL/6N-Btrctm1b(KOMP)Wtsi/H)
increased monocyte cell number J:211773
\Btrctm1Kin/\Btrctm1Kin
(involves: C57BL/6)
abnormal lymphocyte morphology J:84639
\Btrctm1Paga/\Btrctm1Paga
\Fbxw11tm1Ybn/\Fbxw11tm1Ybn
\Tg(Vil1-cre/ERT2)23Syr/?

(involves: 129S1/Sv * 129S2/SvPas * 129X1/SvJ * C57BL/6 * DBA/2)
increased circulating interleukin-1 beta level J:206654
intestinal inflammation J:206654
\Bub1tm1.1Tvd/\Bub1tm1.1Tvd
(B6.129P2-Bub1tm1.1Tvd)
increased leukocyte cell number J:143035
\Bub1bGt(neo-btk)1Dai/\Bub1b+
(involves: 129S4/SvJae * C57BL/6)
enlarged spleen J:88223
\Bub1btm1.1Hsl/\Bub1b+
(involves: 129 * C57BL/6)
enlarged spleen J:201641
increased B cell proliferation J:201641
increased spleen white pulp amount J:201641
\Bud13em1(IMPC)Ccpcz/\Bud13+
(C57BL/6NCrl-Bud13em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
increased effector memory CD8-positive, alpha-beta T cell number J:211773
\Bxs6BXSB/MpJ/\Bxs6BXSB/MpJ
(involves: BXSB/MpJ * C57BL/10ScSnOlaHsd)
autoimmune response J:145903
glomerulonephritis J:145903
increased autoantibody level J:145903
\Bxs6BXSB/MpJ/\Bxs6BXSB/MpJ
(B10.BXSB-(D13Mit3-D13Mit78))
autoimmune response J:145049
increased anti-double stranded DNA antibody level J:145049
increased anti-single stranded DNA antibody level J:145049
increased autoantibody level J:145049
\Bxs6BXSB/MpJ/\Bxs6BXSB/MpJ
\Gpab1C57BL/6J/?

(involves: BXSB/MpJ * C57BL/10ScSnOlaHsd)
autoimmune response J:145903
increased autoantibody level J:145903
\Bxs6BXSB/MpJ/\Bxs6BXSB/MpJ
X/\Yaa

(B10.BXSB-(D13Mit3-D13Mit78) Yaa)
autoimmune response J:145049
enlarged spleen J:145049
glomerulonephritis J:145049
increased anti-double stranded DNA antibody level J:145049
increased anti-single stranded DNA antibody level J:145049
increased autoantibody level J:145049
\C1galt1ptl1/\C1galt1ptl1
(C57BL/6-C1galt1ptl1)
abnormal thrombopoiesis J:115272
glomerulonephritis J:115272
kidney inflammation J:115272
\C1galt1ptl1/\C1galt1ptl1
\Rag1tm1Bal/\Rag1tm1Bal

(involves: 129S4/SvJae * C57BL/6)
kidney inflammation J:115272
\C1qatm1Mjw/\C1qatm1Mjw
(involves: 129P2/Ola * 129S/SvEv * C57BL/6)
glomerulonephritis J:47315
increased anti-histone antibody level J:47315
increased anti-nuclear antigen antibody level J:47315
increased susceptibility to bacterial infection J:83712
\C1qatm1Mjw/\C1qatm1Mjw
(involves: 129P2/Ola * 129S/SvEv)
immune system phenotype J:47315
\C1qatm1Mjw/\C1qatm1Mjw
\Sle16129S6/SvEvTac/\Sle16129S6/SvEvTac

(involves: 129S/SvEv * 129X1/Sv * C57BL/6)
increased anti-chromatin antibody level J:118645
increased anti-double stranded DNA antibody level J:118645
increased anti-nuclear antigen antibody level J:118645
increased anti-single stranded DNA antibody level J:118645
increased susceptibility to systemic lupus erythematosus J:118645
\C1qatm1Mjw/\C1qatm1Mjw
\Sle16129S6/SvEvTac/\Sle16C57BL/6

(involves: 129S/SvEv * 129X1/Sv * C57BL/6)
increased anti-chromatin antibody level J:118645
increased anti-double stranded DNA antibody level J:118645
increased anti-nuclear antigen antibody level J:118645
increased anti-single stranded DNA antibody level J:118645
increased susceptibility to systemic lupus erythematosus J:118645
\C1qatm1Mjw/\C1qatm1Mjw
\Sle18C57BL/6/\Sle18C57BL/6

(involves: 129S/SvEv * 129X1/Sv * C57BL/6)
increased anti-nuclear antigen antibody level J:118645
increased susceptibility to systemic lupus erythematosus J:118645
\C1qatm1Mjw/\C1qatm1Mjw
\Sle18C57BL/6/\Sle18C57BL/6

(involves: 129P2/Ola * 129S/SvEv * C57BL/6)
increased anti-nuclear antigen antibody level J:118645
increased susceptibility to systemic lupus erythematosus J:118645
\C1qatm1Mjw/\C1qatm1Mjw
\Sle19C57BL/6/?

(involves: 129S/SvEv * 129X1/Sv * C57BL/6)
increased anti-nuclear antigen antibody level J:118645
increased susceptibility to systemic lupus erythematosus J:118645
\C1qatm1Mjw/\C1qatm1Mjw
\Sle19C57BL/6/?

(involves: 129P2/Ola * 129S/SvEv * C57BL/6)
increased anti-nuclear antigen antibody level J:118645
increased susceptibility to systemic lupus erythematosus J:118645
\C1qatm1Mjw/\C1qatm1Mjw
\Sle21129P2/Ola/?
\Sle18C57BL/6/\Sle18C57BL/6

(involves: 129P2/Ola * 129S/SvEv * C57BL/6)
increased anti-nuclear antigen antibody level J:118645
increased susceptibility to systemic lupus erythematosus J:118645
\C1qatm1Mjw/\C1qatm1Mjw
\Sle21129P2/Ola/\Sle21129P2/Ola

(involves: 129P2/Ola * 129S/SvEv * C57BL/6)
increased anti-chromatin antibody level J:118645
increased anti-double stranded DNA antibody level J:118645
increased anti-nuclear antigen antibody level J:118645
increased anti-single stranded DNA antibody level J:118645
increased susceptibility to systemic lupus erythematosus J:118645
\C1qatm1Mjw/\C1qatm1Mjw
\Sle21129P2/Ola/\Sle21C57BL/6

(involves: 129P2/Ola * 129S/SvEv * C57BL/6)
increased anti-chromatin antibody level J:118645
increased anti-double stranded DNA antibody level J:118645
increased anti-nuclear antigen antibody level J:118645
increased anti-single stranded DNA antibody level J:118645
increased susceptibility to systemic lupus erythematosus J:118645
\C1ql2em1(IMPC)Mbp/\C1ql2em1(IMPC)Mbp
(C57BL/6N-C1ql2em1(IMPC)Mbp/MbpMmucd)
abnormal spleen morphology J:211773
\C1ql3em1(IMPC)H/\C1ql3em1(IMPC)H
(C57BL/6NTac-C1ql3em1(IMPC)H/H)
decreased eosinophil cell number J:211773
decreased leukocyte cell number J:211773
decreased lymphocyte cell number J:211773
decreased monocyte cell number J:211773
\C1ql4tm1Lex/\C1ql4tm1Lex
(B6.129S5-C1ql4tm1Lex)
decreased leukocyte cell number J:344722
decreased lymphocyte cell number J:344722
\C1qtnf1em1(IMPC)Mbp/\C1qtnf1em1(IMPC)Mbp
(C57BL/6N-C1qtnf1em1(IMPC)Mbp/MbpMmucd)
abnormal lymph node morphology J:211773
abnormal spleen morphology J:211773
enlarged lymph nodes J:211773
enlarged spleen J:211773
\C1qtnf3tm1Yiw/\C1qtnf3tm1Yiw
(involves: C57BL/6NSlc)
immune system phenotype J:211893
increased IgG level J:211893
increased susceptibility to induced arthritis J:211893
joint inflammation J:211893
\C1qtnf4em1Smoc/\C1qtnf4em1Smoc
(C57BL/6JSmoc-C1qtnf4em1Smoc/Smoc)
abnormal macrophage differentiation J:302282
increased circulating interleukin-6 level J:302282
increased circulating interleukin-18 level J:302282
increased circulating tumor necrosis factor level J:302282
increased susceptibility to endotoxin shock J:302282
increased tumor necrosis factor secretion J:302282
\C1qtnf6tm1Yiw/\C1qtnf6tm1Yiw
(involves: 129P2/OlaHsd * C57BL/6J)
immune system phenotype J:227217
increased anti-nuclear antigen antibody level J:227217
increased autoantibody level J:227217
\C1qtnf6tm1Yiw/\C1qtnf6tm1Yiw
(B6.129P2-C1qtnf6tm1Yiw)
abnormal complement pathway J:227217
abnormal complement protein level J:227217
immune system phenotype J:227217
increased B cell number J:227217
increased circulating complement protein level J:227217
increased IgG level J:227217
increased susceptibility to experimental autoimmune encephalomyelitis J:227217
increased susceptibility to induced arthritis J:227217
increased susceptibility to type III hypersensitivity reaction J:227217
\C1qtnf7tm1(KOMP)Vlcg/\C1qtnf7tm1(KOMP)Vlcg
(C57BL/6N-C1qtnf7tm1(KOMP)Vlcg)
increased macrophage cell number J:244352
\C2cd3em1(IMPC)Tcp/\C2cd3+
(C57BL/6N-C2cd3em1(IMPC)Tcp/Tcp)
decreased lymphocyte cell number J:211773
increased neutrophil cell number J:211773
\C3tm1Crr/\C3tm1Crr
(involves: 129S4/SvJae * C57BL/6)
abnormal cell-mediated immunity J:30152
abnormal humoral immune response J:64282
abnormal immune system morphology J:44240
abnormal immune system physiology J:44240
abnormal mast cell physiology J:44240
abnormal spleen germinal center morphology J:64282
abnormal tumor necrosis factor level J:44240
decreased circulating interleukin-6 level J:166640, J:152533
decreased circulating tumor necrosis factor level J:152533
decreased mast cell number J:44240
decreased neutrophil cell number J:44240
decreased osteoclast cell number J:166640
decreased spleen germinal center number J:64282
decreased spleen germinal center size J:64282
immune system phenotype J:64282
increased susceptibility to bacterial infection J:44240, J:30152
increased susceptibility to bacterial infection induced morbidity/mortality J:205353
liver inflammation J:30152
\C3tm1Crr/\C3tm1Crr
(B6.129S4-C3tm1Crr)
abnormal inflammatory response J:113463
abnormal neutrophil morphology J:113463
brain inflammation J:123658
decreased susceptibility to autoimmune hemolytic anemia J:145432
\C3tm1Crr/\C3tm1Crr
(B6;129S4-C3tm1Crr/J)
decreased susceptibility to Coronaviridae infection J:286325
increased susceptibility to bacterial infection J:136745
\C3tm1Crr/\C3tm1Crr
(involves: 129S4/SvJae)
glomerulonephritis J:44715
\C3tm1Crr/\C3tm1Crr
\C4btm1Crr/\C4btm1Crr
\Faslpr/\Faslpr

(involves: 129S4/SvJae * C57BL/6 * MRL)
abnormal immune system physiology J:127292
enlarged cervical lymph nodes J:127292
enlarged spleen J:127292
increased anti-double stranded DNA antibody level J:127292
increased anti-nuclear antigen antibody level J:127292
\C3tm1Crr/\C3tm1Crr
\Cd59atm1Bpm/\Cd59atm1Bpm

(B6.129-Cd59atm1Bpm C3tm1Crr)
increased T cell proliferation J:122201
\C3tm1Crr/\C3tm1Crr
\Faslpr/\Faslpr

(involves: 129S4/SvJae * C57BL/6 * MRL)
decreased susceptibility to autoimmune disorder J:127292
immune system phenotype J:127292
\C3tm1Crr/\C3tm1Crr
\Fcer1gtm1Rav/\Fcer1gtm1Rav
\Tg(Ins2-TFRC/OVA)296Wehi/0

(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)
decreased susceptibility to autoimmune diabetes J:122114
\C3tm1Crr/\C3tm1Crr
\Tg(Ins2-TFRC/OVA)296Wehi/0

(involves: 129S4/SvJae * C57BL/6)
decreased susceptibility to autoimmune diabetes J:122114
increased interferon-gamma secretion J:122114
increased T cell proliferation J:122114
insulitis J:122114
\C3tm1Crr/\C3tm1Crr
\Zbtb20Tg(PDGFB-APPSwInd)20Lms/?

(involves: 129S4/SvJae * C57BL/6)
increased microglial cell activation J:135902
\C3tm1Hrc/\C3tm1Hrc
(either: (involves: 129S2/SvPas * C57BL/6) or (involves: 129X1/SvJ * C57BL/6))
increased susceptibility to bacterial infection J:56193
\C3tm1Hrc/\C3tm1Hrc
(B6.129-C3tm1Hrc)
impaired complement alternative pathway J:177350
\C3tm1Hrc/\C3tm1Hrc
\Cr1ltm1Hmo/\Cr1ltm1Hmo

(involves: 129/Sv * 129X1/SvJ * C57BL/6)
abnormal complement pathway J:76578
\C3tm1Hrc/\C3tm1Hrc
\Lama2dy/\Lama2dy

(either: (involves: 129S2/SvPas * 129P1/ReJ) or (involves: 129X1/SvJ * 129P1/ReJ))
decreased IgM level J:102959
increased IgG level J:102959
increased IgM level J:102959
\C3tm1Hrc/\C3tm1Hrc
\Vsig4tm1Gne/\Vsig4tm1Gne

(involves: 129/Sv * C57BL/6N)
immune system phenotype J:138691
\C3tm1Pkna/\C3tm1Pkna
(D1.129P2-C3tm1Pkna)
decreased susceptibility to induced arthritis J:88872
\C3ar1tm1Cge/\C3ar1tm1Cge
(involves: 129S4/SvJae * C57BL/6)
decreased circulating interleukin-6 level J:166640
decreased osteoclast cell number J:166640
\C3ar1tm1Raw/\C3ar1+
(involves: 129X1/SvJ * C57BL/6)
abnormal immune system physiology J:68807
\C3ar1tm1Raw/\C3ar1tm1Raw
(involves: 129X1/SvJ * C57BL/6)
increased circulating interleukin-1 beta level J:68807
increased susceptibility to endotoxin shock J:68807
\C3ar1tm1Raw/\C3ar1tm1Raw
(B6.129X1(B6)-C3ar1tm1Raw)
abnormal adaptive immunity J:80071
abnormal eosinophil physiology J:80071
abnormal interleukin level J:80071
abnormal T-helper 2 cell differentiation J:80071
abnormal T-helper 2 physiology J:80071
decreased eosinophil cell number J:80071
decreased IgE level J:80071
decreased IgG1 level J:80071
decreased interleukin-4 secretion J:80071
decreased lymphocyte cell number J:80071
decreased neutrophil cell number J:80071
decreased susceptibility to experimental autoimmune encephalomyelitis J:93791
impaired neutrophil recruitment J:80071
increased circulating interleukin-1 beta level J:93791
increased susceptibility to type I hypersensitivity reaction J:80071
\C3ar1tm1Raw/\C3ar1tm1Raw
\Cpn1tm1Raw/\Cpn1tm1Raw

(B6.129-C3ar1tm1Raw Cpn1tm1Raw)
increased acute inflammation J:148315
\C4btm1Crr/\C4btm1Crr
(involves: 129S4/SvJae * C57BL/6)
abnormal humoral immune response J:64282
abnormal spleen germinal center morphology J:64282
decreased spleen germinal center number J:64282
decreased spleen germinal center size J:64282
decreased susceptibility to bacterial infection J:30152
immune system phenotype J:64282, J:30152
increased susceptibility to bacterial infection induced morbidity/mortality J:30152
liver inflammation J:30152
\C4btm1Crr/\C4btm1Crr
(involves: 129S4/SvJae * C57BL/6J)
abnormal immune system physiology J:111811
glomerulonephritis J:111811
increased anti-double stranded DNA antibody level J:111811
increased anti-nuclear antigen antibody level J:111811
increased anti-single stranded DNA antibody level J:111811
increased macrophage cell number J:111811
increased neutrophil cell number J:111811
increased spleen germinal center number J:111811
increased spleen weight J:111811
\C4btm1Crr/\C4btm1Crr
(involves: 129S4/SvJae)
decreased susceptibility to Coronaviridae infection J:286325
glomerulonephritis J:44715
\C4btm1Crr/\C4btm1Crr
\Faslpr/\Faslpr

(involves: 129S4/SvJae * C57BL/6 * MRL)
abnormal immune system physiology J:127292
enlarged cervical lymph nodes J:127292
enlarged spleen J:127292
increased anti-double stranded DNA antibody level J:127292
increased anti-nuclear antigen antibody level J:127292
\C4bptm1Raw/\C4bptm1Raw
(B6.129-C4bptm1Raw)
increased circulating interleukin-6 level J:244020
\C5ar1tm1Cge/\C5ar1tm1Cge
(involves: 129S4/SvJae)
abnormal humoral immune response J:35529
impaired neutrophil recruitment J:69177
increased susceptibility to bacterial infection J:69177
\C5ar1tm1Cge/\C5ar1tm1Cge
(involves: 129S4/SvJae * C57BL/6)
decreased circulating interleukin-6 level J:166640
decreased osteoclast cell number J:166640
\C5ar1tm1Raw/\C5ar1tm1Raw
(B6.Cg-C5ar1tm1Raw)
immune system phenotype J:139786
increased spleen germinal center number J:139786
\C5ar1tm1Song/\C5ar1tm1Song
(involves: 129S6/SvEvTac * C57BL/6)
abnormal neutrophil physiology J:184056
\C5ar2em1(IMPC)H/\C5ar2em1(IMPC)H
(C57BL/6NTac-C5ar2em1(IMPC)H/H)
decreased eosinophil cell number J:211773
increased neutrophil cell number J:211773
\C5ar2tm1Cge/\C5ar2tm1Cge
(B6.129S1-C5ar2tm1Cge)
abnormal immune cell physiology J:104092
increased inflammatory response J:104092
\C8atm1b(EUCOMM)Hmgu/\C8atm1b(EUCOMM)Hmgu
(C57BL/6N-C8atm1b(EUCOMM)Hmgu/Tcp)
increased lymphocyte cell number J:211773
\C9em1Sjlg/\C9+
(C57BL/6-C9em1Sjlg)
impaired complement classical pathway J:301607
\C9em1Sjlg/\C9em1Sjlg
(C57BL/6-C9em1Sjlg)
decreased interleukin-1 beta secretion J:301607
decreased susceptibility to endotoxin shock J:301607
impaired complement classical pathway J:301607
\C9orf72em1Eggn/\C9orf72em1Eggn
(involves: C57BL/6)
enlarged cervical lymph nodes J:240357
enlarged spleen J:240357
increased anti-double stranded DNA antibody level J:240357
\C9orf72em5Lutzy/\C9orf72em5Lutzy
(C57BL/6-C9orf72em5Lutzy)
abnormal macrophage physiology J:101977
abnormal microglial cell physiology J:101977
enlarged lymph nodes J:101977
enlarged spleen J:101977
\C9orf72tm1.1(KOMP)Mbp/\C9orf72tm1.1(KOMP)Mbp
(C57BL/6N-C9orf72tm1.1(KOMP)Mbp/Ucd)
abnormal spleen morphology J:211773
enlarged lymph nodes J:211773
enlarged spleen J:211773
increased spleen weight J:211773
\C9orf72tm1.1Eggn/\C9orf72+
(involves: C57BL/6 * C57BL/6N)
abnormal circulating interleukin level J:240357
decreased circulating interleukin-2 level J:240357
dermatitis J:240357
increased autoantibody level J:240357
increased IgG level J:240357
increased IgM level J:240357
\C9orf72tm1.1Eggn/\C9orf72tm1.1Eggn
(involves: C57BL/6 * C57BL/6N)
abnormal circulating cytokine level J:240357
abnormal lymphocyte morphology J:240357
abnormal spleen morphology J:240357
brain inflammation J:240357
dermatitis J:240357
enlarged spleen J:240357
increased anti-double stranded DNA antibody level J:240357
increased autoantibody level J:240357
increased CD4-positive, CD25-positive, alpha-beta regulatory T cell number J:240357
increased IgG level J:240357
increased IgM level J:240357
increased leukocyte cell number J:240357
increased neutrophil cell number J:240357
increased splenocyte number J:240357
increased susceptibility to autoimmune disorder J:240357
liver inflammation J:240357
\C9orf72tm1Eggn/\C9orf72+
(involves: C57BL/6 * C57BL/6N)
dermatitis J:240357
\C9orf72tm1Eggn/\C9orf72tm1Eggn
(involves: C57BL/6 * C57BL/6N)
abnormal circulating cytokine level J:240357
abnormal lymphocyte morphology J:240357
dermatitis J:240357
enlarged cervical lymph nodes J:240357
enlarged spleen J:240357
increased anti-double stranded DNA antibody level J:240357
increased leukocyte cell number J:240357
increased neutrophil cell number J:240357
increased susceptibility to autoimmune disorder J:240357
\C9orf72tm1Lagi/\C9orf72tm1Lagi
(involves: C57BL/6 * C57BL/6N)
abnormal celiac lymph node morphology J:232242
abnormal cervical lymph node morphology J:232242
abnormal lymph node cell ratio J:232242
decreased lymphocyte cell number J:232242
enlarged cervical lymph nodes J:232242
enlarged spleen J:232242
increased neutrophil cell number J:232242
\Cab39em1(IMPC)Tcp/\Cab39+
(C57BL/6NCrl-Cab39em1(IMPC)Tcp/Cmmr)
decreased leukocyte cell number J:211773
decreased lymphocyte cell number J:211773
increased monocyte cell number J:211773
\Cabin1em1(IMPC)Ccpcz/\Cabin1+
(C57BL/6NCrl-Cabin1em1(IMPC)Ccpcz/Ccpcz)
abnormal thymus morphology J:211773
enlarged thymus J:211773
\Cabin1tm1.1Che/\Cabin1tm1.1Che
(involves: 129S4/SvJae * BALB/c)
abnormal cytokine secretion J:72760
abnormal humoral immune response J:72760
immune system phenotype J:72760
increased IgE level J:72760
increased IgG1 level J:72760
increased IgG2b level J:72760
\Cabp1tm1b(EUCOMM)Wtsi/\Cabp1tm1b(EUCOMM)Wtsi
(C57BL/6N-Cabp1tm1b(EUCOMM)Wtsi/H)
decreased lymphocyte cell number J:211773
increased monocyte cell number J:211773
increased neutrophil cell number J:211773
increased spleen weight J:211773
\Cacna1atg-6J/\Cacna1atg-6J
(involves: BALB/cByJ * C57BL/6J)
abnormal spleen red pulp morphology J:82238
thymus atrophy J:82238
\Cacna1ctm2Itl/\Cacna1c+
(involves: 129S6/SvEvTac * C57BL/6NTac)
dermatitis J:201506
\Cacna1gem1(IMPC)Mbp/\Cacna1gem1(IMPC)Mbp
(C57BL/6N-Cacna1gem1(IMPC)Mbp/MbpMmucd)
abnormal spleen morphology J:211773
enlarged lymph nodes J:211773
\Cacna1itm1b(KOMP)Wtsi/\Cacna1itm1b(KOMP)Wtsi
(C57BL/6N-Cacna1itm1b(KOMP)Wtsi/Bay)
abnormal spleen morphology J:211773
\Cacna2d1em1(IMPC)Mbp/\Cacna2d1em1(IMPC)Mbp
(C57BL/6N-Cacna2d1em1(IMPC)Mbp/MbpMmucd)
abnormal spleen morphology J:211773
increased monocyte cell number J:211773
small spleen J:211773
\Cacna2d2du-td/\Cacna2d2du-td
(involves: DBA/2J)
abnormal thymus involution J:12166
\Cacna2d2em1(IMPC)Mbp/\Cacna2d2+
(C57BL/6N-Cacna2d2em1(IMPC)Mbp/MbpMmucd)
abnormal spleen morphology J:211773
enlarged spleen J:211773
increased spleen weight J:211773
\Cacna2d2em1(IMPC)Mbp/\Cacna2d2em1(IMPC)Mbp
(C57BL/6N-Cacna2d2em1(IMPC)Mbp/MbpMmucd)
abnormal spleen morphology J:211773
small spleen J:211773
\Cacna2d2tm1Svi/\Cacna2d2tm1Svi
(involves: 129S1/Sv * C57BL/6J)
rhinitis J:92396
thymus hypoplasia J:92396
\Cacna2d3Tn(pb-Act-RFP)1.1Zhu/\Cacna2d3Tn(pb-Act-RFP)1.1Zhu
(FVB/NJ-Cacna2d3Tn(pb-Act-RFP)1.1Zhu)
abnormal macrophage physiology J:267961
increased susceptibility to bacterial infection J:267961
\Cacnb3tm1Acv/\Cacnb3tm1Acv
(involves: 129S1/Sv * 129X1/SvJ)
abnormal CD4-positive, alpha-beta T cell physiology J:115345
abnormal interleukin secretion J:115345
decreased interferon-gamma secretion J:115345
\Cacnb4lh/\Cacnb4lh
(B6EiC3Sn a/A-Cacnb4lh/J)
abnormal CD4-positive, alpha-beta T cell physiology J:115345
abnormal interleukin secretion J:115345
abnormal lymph node morphology J:5281
abnormal Peyer's patch germinal center morphology J:5281
abnormal thymus involution J:5281
absent thymus corticomedullary boundary J:5281
decreased double-positive T cell number J:115345
decreased interferon-gamma secretion J:115345
decreased interleukin-2 secretion J:115345
decreased lymphocyte cell number J:5281
decreased Peyer's patch number J:5281
enlarged lymph nodes J:5281
small Peyer's patches J:5281
small spleen J:5281
small thymus J:5281
\Cacnb4lh/\Cacnb4lh
(BALB/cGn-Cacnb4lh)
abnormal thymus involution J:12166
increased length of allograft survival J:5766
\Cacnb4lh/\Cacnb4lh
(involves: BALB/cGn)
increased IgG1 level J:5883
\Cactinem1(IMPC)Ccpcz/\Cactin+
(C57BL/6NCrl-Cactinem1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged spleen J:211773
enlarged thymus J:211773
\CacybpGT(OST39970)Lex/\CacybpGT(OST39970)Lex
(involves: 129S5/SvEvBrd)
abnormal spleen white pulp morphology J:110899
abnormal T cell morphology J:110899
decreased thymocyte number J:110899
small thymus medulla J:110899
spleen hypoplasia J:110899
thymus hypoplasia J:110899
\Cacybptm1b(EUCOMM)Wtsi/\Cacybp+
(C57BL/6N-Cacybptm1b(EUCOMM)Wtsi/Tcp)
increased neutrophil cell number J:211773
\Cadm1Gt(Ayu21-W34)Imeg/\Cadm1Gt(Ayu21-W34)Imeg
(involves: C57BL/6 * CBA/JNCrlj)
abnormal T cell differentiation J:178612
abnormal T cell receptor V(D)J recombination J:178612
decreased CD4-positive, alpha-beta T cell number J:178612
decreased CD8-positive, alpha-beta T cell number J:178612
decreased interferon-gamma secretion J:178612
decreased interleukin-2 secretion J:178612
decreased interleukin-4 secretion J:178612
decreased T cell proliferation J:178612
increased double-positive T cell number J:178612
\Cadps2em1(IMPC)Rbrc/\Cadps2em1(IMPC)Rbrc
(C57BL/6NJcl-Cadps2em1(IMPC)Rbrc/Rbrc)
abnormal lymph node morphology J:211773
enlarged lymph nodes J:211773
\Calb1em1(IMPC)Ccpcz/\Calb1em1(IMPC)Ccpcz
(C57BL/6NCrl-Calb1em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged spleen J:211773
enlarged thymus J:211773
small spleen J:211773
\Calcrtm1Dgal/\Calcr+
\Iapptm1Sgm/\Iapp+

(involves: 129P2/OlaHsd)
increased osteoclast cell number J:88964
\Calcrtm1Rda/\Calcrtm1Rda
\Tg(CMV-cre)1Cgn/0

(B6.Cg-Calcrtm1Rda Tg(CMV-cre)1Cgn)
abnormal osteoclast physiology J:150982
\Calcrltm1Kmca/\Calcrltm1Kmca
(129S6/SvEvTac-Calcrltm1Kmca)
abnormal lymph organ development J:130930
\Calcrltm1Kmca/\Calcrltm1Kmca
(involves: 129S6/SvEvTac)
decreased uterine NK cell number J:201446
\Caluem1(IMPC)Tcp/\Calu+
(C57BL/6N-Caluem1(IMPC)Tcp/Tcp)
small lymph nodes J:211773
\Camk1dem1(IMPC)Mbp/\Camk1dem1(IMPC)Mbp
(C57BL/6NCrl-Camk1dem1(IMPC)Mbp/Mmucd)
abnormal spleen morphology J:211773
enlarged spleen J:211773
\Camk2gtm1.1Irt/\Camk2gtm1.1Irt
(involves: C57BL/6 * C57BL/6J)
decreased macrophage apoptosis J:154647
\Camk2gtm1.1Irt/\Camk2gtm1.1Irt
(involves: C57BL/6J)
increased susceptibility to colitis induced morbidity/mortality J:243363
increased susceptibility to induced colitis J:243363
\Camk4em1(IMPC)Ccpcz/\Camk4em1(IMPC)Ccpcz
(C57BL/6N-Camk4em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged thymus J:211773
small spleen J:211773
\Camk4tm1Tch/\Camk4tm1Tch
(B6.129X1-Camk4tm1Tch)
abnormal osteoclast differentiation J:129599
decreased osteoclast cell number J:129599
\Camltm1Rjb/\Camltm2Rjb
\Tg(Lck-cre)1Cwi/0

(involves: 129 * C57BL/6 * DBA/2)
decreased single-positive T cell number J:100536
decreased thymocyte number J:100536
increased T cell apoptosis J:100536
\Camltm1Rjb/\Camltm2Rjb
\Tg(Lck-cre)1Cwi/0
\Tg(TcraTcrb)1100Mjb/0

(involves: 129 * C57BL/6 * DBA/2)
abnormal negative T cell selection J:100536
abnormal positive T cell selection J:100536
decreased thymocyte number J:100536
\Camptm1.1Jimw/\Camptm1.1Jimw
(involves: C57BL/6)
decreased dendritic cell number J:199611
\Camptm1Rlg/\Camp+
(involves: 129X1/SvJ * C57BL/6)
increased susceptibility to bacterial infection J:72924
\Camptm1Rlg/\Camptm1Rlg
(involves: 129X1/SvJ * C57BL/6)
increased incidence of corneal inflammation J:199719
increased neutrophil cell number J:199719
increased susceptibility to bacterial infection J:72924
increased susceptibility to fungal infection J:199719
\Camptm1Rlg/\Camptm1Rlg
(129X1(B6)-Camptm1Rlg/Kini)
increased susceptibility to bacterial infection J:109553
increased susceptibility to bacterial infection induced morbidity/mortality J:109553
\Camsap3tm1a(EUCOMM)Wtsi/\Camsap3tm1a(EUCOMM)Wtsi
(C57BL/6N-Camsap3tm1a(EUCOMM)Wtsi/Wtsi)
increased gamma-delta T cell number J:211773
increased leukocyte cell number J:211773
increased neutrophil cell number J:211773
\Cand1em1(IMPC)Mbp/\Cand1+
(C57BL/6NCrl-Cand1em1(IMPC)Mbp/Mmucd)
abnormal lymph node morphology J:211773
abnormal spleen morphology J:211773
enlarged lymph nodes J:211773
enlarged spleen J:211773
\Canxem1(IMPC)Ccpcz/\Canx+
(C57BL/6NCrl-Canxem1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged spleen J:211773
enlarged thymus J:211773
\Canxem1(IMPC)Ccpcz/\Canxem1(IMPC)Ccpcz
(C57BL/6NCrl-Canxem1(IMPC)Ccpcz/Ccpcz)
abnormal thymus morphology J:211773
enlarged thymus J:211773
\CanxGt(KST286)Byg/\CanxGt(KST286)Byg
(involves: 129P2/OlaHsd * C57BL/6)
immune system phenotype J:164553
\Cap2tm1a(EUCOMM)Wtsi/\Cap2tm1a(EUCOMM)Wtsi
(involves: C57BL/6J * C57BL/6N)
eye inflammation J:234044
increased susceptibility to infection J:234044
\Capgtm1Djk/\Capgtm1Djk
(involves: 129S4/SvJae)
abnormal macrophage physiology J:86517
impaired macrophage phagocytosis J:86517
\Capgtm1Djk/\Capgtm1Djk
(involves: 129S4/SvJae * BALB/c * C57BL/6)
abnormal dendritic cell physiology J:86277
impaired macrophage phagocytosis J:86277
impaired neutrophil chemotaxis J:86277
increased susceptibility to bacterial infection J:86277
\Capgtm1Djk/\Capgtm1Djk
\Gsntm1Djk/\Gsntm1Djk

(involves: 129S4/SvJae)
abnormal macrophage physiology J:86517
impaired macrophage phagocytosis J:86517
\Capn1tm1Dgen/\Capn1tm1Dgen
(involves: 129P2/OlaHsd * C57BL/6)
abnormal leukocyte adhesion J:183585
\Capn5tm1Nde/\Capn5tm1Nde
(involves: 129X1/SvJ * C57BL/6J)
immune system phenotype J:87678
\CapopNOD/\CapopNOD
(involves: C57BL/6 * NOD)
decreased T cell apoptosis J:68151
\Capza1em1(IMPC)Tcp/\Capza1em1(IMPC)Tcp
(C57BL/6NCrl-Capza1em1(IMPC)Tcp/Tcp)
decreased leukocyte cell number J:211773
decreased lymphocyte cell number J:211773
increased monocyte cell number J:211773
\Capza2tm1b(KOMP)Wtsi/\Capza2tm1b(KOMP)Wtsi
(C57BL/6N-Capza2tm1b(KOMP)Wtsi/Wtsi)
blood in lymph vessels J:239583
\Car2tm1(KOMP)Vlcg/\Car2tm1(KOMP)Vlcg
(involves: C57BL/6 * C57BL/6NTac)
increased susceptibility to bacterial infection J:216402
pyelonephritis J:216402
\Car6em1(IMPC)Ccpcz/\Car6em1(IMPC)Ccpcz
(C57BL/6NCrl-Car6em1(IMPC)Ccpcz/Ccpcz)
abnormal lymph node morphology J:211773
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
decreased NK cell number J:211773
enlarged lymph nodes J:211773
enlarged spleen J:211773
enlarged thymus J:211773
increased eosinophil cell number J:211773
\Car6tm1Pwp/\Car6tm1Pwp
(B6.129S6-Car6tm1Pwp)
abnormal Peyer's patch follicle morphology J:172854
\Car9tm1Lex/\Car9tm1Lex
(B6;129S5-Car9tm1Lex/Mmucd)
increased mature B cell number J:171883
\Card6tm1.1Aldu/\Card6tm1.1Aldu
(B6.129P2-Card6tm1.1Aldu)
immune system phenotype J:132634
\Card9tm1Jrld/\Card9tm1Jrld
(involves: 129P2/OlaHsd)
abnormal dendritic cell physiology J:111706
increased susceptibility to fungal infection J:111706
\Card9tm1Tks/\Card9tm1Tks
(B6.129-Card9tm1Tks)
abnormal chemokine secretion J:141143
abnormal cytokine secretion J:122394
abnormal dendritic cell physiology J:122394
abnormal macrophage physiology J:141143, J:122394
decreased interleukin-6 secretion J:160680
decreased interleukin-10 secretion J:160680
decreased interleukin-12b secretion J:160680
decreased interleukin-23 secretion J:160680
decreased tumor necrosis factor secretion J:160680
immune system phenotype J:122394
increased susceptibility to bacterial infection J:122394
\Card9tm1Xlin/\Card9tm1Xlin
(involves: 129/Sv * C57BL/6)
abnormal cytokine level J:117799
abnormal innate immunity J:117799
abnormal macrophage physiology J:117799
increased susceptibility to bacterial infection J:117799
\Card11em1(IMPC)Ccpcz/\Card11em1(IMPC)Ccpcz
(C57BL/6NCrl-Card11em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
decreased CD4-positive, CD25-positive, alpha-beta regulatory T cell number J:211773
decreased effector memory CD8-positive, alpha-beta T cell number J:211773
decreased effector memory T-helper cell number J:211773
decreased spleen weight J:211773
enlarged thymus J:211773
increased CD4-positive, alpha-beta T cell number J:211773
increased CD8-positive, alpha-beta T cell number J:211773
increased CD8-positive, naive alpha-beta T cell number J:211773
increased leukocyte cell number J:211773
increased lymphocyte cell number J:211773
increased T cell number J:211773
increased T-helper cell number J:211773
small spleen J:211773
\Card11em1Welu/\Card11+
(involves: C57BL/6)
decreased marginal zone B cell number J:292926
decreased transitional stage T1 B cell number J:292926
decreased transitional stage T3 B cell number J:292926
impaired humoral immune response J:292926
increased transitional stage T2 B cell number J:292926
\Card11em1Welu/\Card11em1Welu
(involves: C57BL/6)
abnormal B cell differentiation J:292926
abnormal germinal center B cell morphology J:292926
abnormal plasma cell differentiation J:292926
decreased B cell proliferation J:292926
decreased B-1 B cell number J:292926
decreased B-1a cell number J:292926
decreased germinal center B cell number J:292926
decreased IgG level J:292926
decreased IgM level J:292926
decreased marginal zone B cell number J:292926
decreased pre-B cell number J:292926
decreased transitional stage T1 B cell number J:292926
decreased transitional stage T3 B cell number J:292926
impaired humoral immune response J:292926
increased follicular B cell number J:292926
increased transitional stage T2 B cell number J:292926
\Card11em2Welu/\Card11+
(involves: C57BL/6)
increased B-1 B cell number J:292926
increased marginal zone B cell number J:292926
\Card11em2Welu/\Card11em2Welu
(involves: C57BL/6)
abnormal plasma cell differentiation J:292926
decreased mature B cell number J:292926
enlarged spleen J:292926
increased B cell proliferation J:292926
increased B-1a cell number J:292926
increased B-1b cell number J:292926
increased germinal center B cell number J:292926
increased marginal zone B cell number J:292926
increased pre-B cell number J:292926
increased transitional stage T2 B cell number J:292926
\Card11em3Welu/\Card11em3Welu
(Not Specified)
decreased B-1 B cell number J:292926
decreased marginal zone B cell number J:292926
\Card11m1Btlr/\Card11m1Btlr
(C57BL/6J-Card11m1Btlr)
abnormal CD4-positive, CD25-positive, alpha-beta regulatory T cell morphology J:149767
abnormal cytokine secretion J:149767
abnormal cytotoxic T cell physiology J:139069
abnormal double-negative T cell morphology J:149767, J:139069
abnormal NK cell physiology J:139069
abnormal T cell activation J:139069
decreased B cell proliferation J:149767, J:139069
decreased B-1 B cell number J:149767, J:139069
decreased gamma-delta T cell number J:149767, J:139069
decreased IgG1 level J:149767, J:139069
decreased IgG2a level J:149767, J:139069
decreased IgG2b level J:149767, J:139069
decreased IgG2c level J:149767
decreased IgG3 level J:149767, J:139069
decreased IgM level J:149767, J:139069
decreased immunoglobulin level J:139069
decreased interferon-gamma secretion J:139069
decreased interleukin-2 secretion J:139069
decreased mature B cell number J:149767, J:139069
decreased memory T cell number J:149767, J:139069
decreased NK cell number J:149767, J:139069
decreased NK T cell number J:149767, J:139069
decreased regulatory T cell number J:149767
decreased T cell proliferation J:149767, J:139069
dermatitis J:149767, J:139069
immune system phenotype J:139069
\Card11M2Btlr/\Card11M2Btlr
(involves: C57BL/6J)
decreased IgM level J:198555
\Card11m3Btlr/\Card11m3Btlr
(C57BL/6J-Card11m3Btlr)
increased B-1a cell number J:221487
\Card11M4Btlr/\Card11+
(C57BL/6J-Card11M4Btlr)
decreased B-1a cell number J:254856
increased B-1b cell number J:254856
\Card11M4Btlr/\Card11M4Btlr
(C57BL/6J-Card11M4Btlr)
decreased B-1a cell number J:254856
decreased IgM level J:254856
impaired humoral immune response J:254856
increased B-1b cell number J:254856
\Card11M5Btlr/\Card11+
(C57BL/6J-Card11M5Btlr)
decreased IgM level J:254879
impaired humoral immune response J:254879
increased B-1 B cell number J:254879
increased B-1a cell number J:254879
\Card11M5Btlr/\Card11M5Btlr
(C57BL/6J-Card11M5Btlr)
decreased IgM level J:254879
impaired humoral immune response J:254879
increased B-1 B cell number J:254879
increased B-1a cell number J:254879
\Card11M6Btlr/\Card11M6Btlr
(C57BL/6J-Card11M6Btlr)
increased alpha-beta T cell number J:272116
\Card11M7Btlr/\Card11M7Btlr
(C57BL/6J-Card11M7Btlr)
abnormal T cell differentiation J:274762
decreased B cell number J:274762
decreased B-1 B cell number J:274762
decreased central memory CD4-positive, alpha-beta T cell number J:274762
decreased effector memory CD4-positive, alpha-beta T cell number J:274762
decreased effector memory CD8-positive, alpha-beta T cell number J:274762
increased CD4-positive, alpha-beta T cell number J:274762
increased CD8-positive, alpha-beta T cell number J:274762
increased T cell number J:274762
\Card11m8Btlr/\Card11m8Btlr
(C57BL/6J-Card11m8Btlr)
abnormal B cell differentiation J:274940
decreased B cell number J:274940
decreased B-1a cell number J:274940
decreased effector memory CD8-positive, alpha-beta T cell number J:274940
decreased IgG level J:274940
decreased IgM level J:274940
decreased response to antigen J:274940
impaired humoral immune response J:274940
increased B-1b cell number J:274940
increased CD4-positive, alpha-beta T cell number J:274940
increased CD8-positive, alpha-beta T cell number J:274940
increased NK T cell number J:274940
increased T cell number J:274940
\Card11tm1.1Litt/\Card11tm1.1Litt
\Gt(ROSA)26Sortm1(cre/ERT2)Thl/\Gt(ROSA)26Sor+
\Tg(TcraTcrb)425Cbn/?

(involves: 129/Sv * 129P2/OlaHsd * BALB/c * C57BL/6)
abnormal T cell activation J:180410
\Card11tm1.1Litt/\Card11tm1.1Litt
\Tnfrsf4tm2(cre)Nik/\Tnfrsf4+

(involves: 129P2/OlaHsd * 129X1/SvJ)
abnormal T cell activation J:180410
immune system phenotype J:180410
respiratory system inflammation J:180410
\Card11tm1Litt/\Card11tm1Litt
(involves: 129P2/OlaHsd)
abnormal B cell proliferation J:89322
abnormal double-negative T cell morphology J:89322
abnormal T cell activation J:89322
abnormal T cell differentiation J:89322
abnormal T cell proliferation J:89322
absent B-1a cells J:89322
decreased IgA level J:89322
decreased IgG1 level J:89322
decreased IgG2b level J:89322
decreased IgG3 level J:89322
decreased IgM level J:89322
decreased immunoglobulin level J:89322
\Card11tm1Pngr/\Card11tm1Pngr
(involves: 129P2/OlaHsd)
abnormal B cell differentiation J:84036
abnormal B cell physiology J:84036
abnormal interleukin-2 secretion J:84036
abnormal lymphocyte morphology J:84036
abnormal T cell activation J:84036
absent B-1a cells J:84036
decreased B cell proliferation J:84036
decreased IgA level J:84036
decreased IgE level J:84036
decreased IgG1 level J:84036
decreased IgG2a level J:84036
decreased IgG2b level J:84036
decreased IgG3 level J:84036
decreased IgG level J:84036
decreased IgM level J:84036
decreased immunoglobulin level J:84036
decreased NK cell number J:84036
\Card11tm1Pngr/\Card11tm1Pngr
(involves: 129P2/OlaHsd * C57BL/6)
immune system phenotype J:122394
\Card11tm1Vmd/\Card11+
(involves: 129S6/SvEvTac * C57BL/6N)
decreased B cell proliferation J:95800
\Card11tm1Vmd/\Card11tm1Vmd
(involves: 129S6/SvEvTac * C57BL/6N)
abnormal B cell physiology J:95800
absent immature B cells J:95800
decreased B cell proliferation J:95800
decreased IgA level J:95800
decreased IgG1 level J:95800
decreased IgG2a level J:95800
decreased IgG2b level J:95800
decreased IgG3 level J:95800
decreased IgG level J:95800
decreased IgM level J:95800
decreased T cell proliferation J:95800
\Card11tm1Xav/\Card11tm1Xav
(involves: 129 * C57BL/6)
abnormal T cell activation J:132226
abnormal T-helper 2 cell differentiation J:132226
decreased circulating interleukin-4 level J:132226
decreased circulating interleukin-5 level J:132226
decreased IgE level J:132226
increased CD4-positive, alpha-beta T cell number J:132226
increased CD8-positive, alpha-beta T cell number J:132226
lung inflammation J:132226
\Card11unm/\Card11unm
(C57BL/6JSfdAnu-Card11unm/Anu)
abnormal B cell differentiation J:84042
abnormal immune system physiology J:84042
abnormal T cell activation J:84042
decreased B-1 B cell number J:84042
decreased IgG3 level J:84042
decreased IgM level J:84042
decreased immunoglobulin level J:84042
dermatitis J:84042
erythroderma J:84042
increased IgE level J:84042
increased immunoglobulin level J:84042
increased inflammatory response J:84042
lymph node hyperplasia J:84042
spleen hyperplasia J:84042
\Card14em1(IMPC)Ccpcz/\Card14em1(IMPC)Ccpcz
(C57BL/6NCrl-Card14em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged spleen J:211773
enlarged thymus J:211773
\Card14em1Maak/\Card14em1Maak
(C57BL/6JJmsSlc-Card14em1Maak)
skin inflammation J:360877
\Card14em1Tshu/\Card14em1Tshu
(C57BL/6-Card14em1Tshu)
decreased susceptibility to chemically induced skin inflammation J:289239
\Card14em2Tshu/\Card14+
(involves: C57BL/6)
abnormal gamma-delta T cell number J:289239
increased alpha-beta T cell number J:289239
skin inflammation J:289239
\Card14em3Tshu/\Card14+
(involves: C57BL/6)
skin inflammation J:289239
\Card14em3Tshu/\Card14+
\Il17atm1Cdon/\Il17atm1Cdon

(involves: C57BL/6)
decreased inflammatory response J:289239
\Card14em9Lutzy/\Card14+
(C57BL/6J-Card14em9Lutzy/J)
skin inflammation J:262723
\Card14tm1Lex/\Card14tm1Lex
(B6.129S-Card14tm1Lex)
decreased susceptibility to chemically induced skin inflammation J:253409
\Card19tm1Rwen/\Card19tm1Rwen
(involves: 129P2/OlaHsd * C57BL/6)
decreased autoantibody level J:336763
immune system phenotype J:336763
\Card19tm1Rwen/\Card19tm1Rwen
\Tg(IghelMD4)4Ccg/0

(involves: 129P2/OlaHsd * C57BL/6)
abnormal B cell activation J:336763
\Card19tm1Rwen/\Card19tm1Rwen
\Tg(IghelMD4)4Ccg/0
\Tg(ML5sHEL)5Ccg/0

(involves: 129P2/OlaHsd * C57BL/6 * C57BL/6JSfd)
decreased B cell number J:336763
decreased B cell proliferation J:336763
increased B cell apoptosis J:336763
increased B cell number J:336763
\Carm1tm1b(EUCOMM)Hmgu/\Carm1+
(C57BL/6N-Carm1tm1b(EUCOMM)Hmgu/Nju)
decreased lymphocyte cell number J:211773
\Carm1tm1Mtb/\Carm1tm1Mtb
(involves: 129S6/SvEvTac)
arrested T cell differentiation J:159958
\Carm1tm2.1Mtb/\Carm1tm2.1Mtb
(involves: 129S4/SvJaeSor * 129S6/SvEvTac * Black Swiss)
arrested T cell differentiation J:159958
thymus hypoplasia J:159958
\carmelo/\carmelo
(involves: 129S1/SvImJ * C57BL/6J)
decreased susceptibility to parasitic infection induced morbidity/mortality J:220661
\Carmil2bas/\Carmil2bas
(involves: C3HeB/FeJ * C57BL/6)
decreased interferon-gamma secretion J:205441
decreased interleukin-2 secretion J:205441
decreased regulatory T cell number J:205441
decreased T cell proliferation J:205441
enlarged thymus J:205441
immune system phenotype J:205441
\Carmil2bas/\Carmil2tm1a(KOMP)Mbp
(involves: C3HeB/FeJ * C57BL/6 * C57BL/6N)
decreased interleukin-2 secretion J:205441
decreased regulatory T cell number J:205441
decreased T cell proliferation J:205441
\Carmil3em1(IMPC)Mbp/\Carmil3em1(IMPC)Mbp
(C57BL/6N-Carmil3em1(IMPC)Mbp/MbpMmucd)
abnormal lymph node morphology J:211773
enlarged lymph nodes J:211773
\Cartpttm1Hmh/\Cartpttm1Hmh
(Not Specified)
abnormal osteoclast morphology J:97566
increased osteoclast cell number J:97566
\Casp1tm1Flv/\Casp1tm1Flv
\Casp4del/\Casp4del

(involves: 129S2/SvPas * C57BL/6)
abnormal cytokine secretion J:24258
decreased circulating interferon-gamma level J:115310
decreased interferon-gamma secretion J:115310
decreased interleukin-1 alpha secretion J:24258
decreased interleukin-1 beta secretion J:24258
decreased interleukin-6 secretion J:24258
decreased interleukin-18 secretion J:115310
decreased susceptibility to endotoxin shock J:43088
decreased susceptibility to experimental autoimmune encephalomyelitis J:57101
decreased thymocyte apoptosis J:24258
decreased tumor necrosis factor secretion J:24258
impaired neutrophil chemotaxis J:124226
increased susceptibility to bacterial infection J:117251
\Casp1tm1Flv/\Casp1tm1Flv
\Casp4del/\Casp4del

(B6.129S2-Casp1tm1Flv)
decreased interleukin-1 beta secretion J:160545
increased susceptibility to induced colitis J:173245
\Casp1tm1Flv/\Casp1tm1Flv
\Casp4del/\Casp4del
\Il1r1tm1Imx/\Il1r1tm1Imx

(involves: 129S2/SvPas * 129S7/SvEvBrd * C57BL/6)
decreased susceptibility to endotoxin shock J:43088
\Casp1tm1Flv/\Casp1tm1Flv
\Casp4del/\Casp4del
\Slc11a1r/\Slc11a1r

(involves: 129S2/SvPas)
increased susceptibility to bacterial infection J:124378
\Casp1tm1Flv/\Casp1tm1Flv
\Casp4del/\Casp4del
\Slc11a1s/\Slc11a1s

(B6.129S2-Casp1tm1Flv)
cecum inflammation J:124378
increased susceptibility to bacterial infection J:124378
\Casp1tm1Sesh/\Casp1+
\Casp4del/\Casp4+

(involves: 129S2/SvPas * C57BL/6)
decreased interleukin-1 beta secretion J:22964
\Casp1tm1Sesh/\Casp1+
\Casp4del/\Casp4+

(involves: 129S1/SvImJ * 129S2/SvPas * NOD)
abnormal macrophage physiology J:99748
\Casp1tm1Sesh/\Casp1tm1Sesh
\Casp4del/\Casp4del

(involves: 129S2/SvPas * C57BL/6)
abnormal inflammatory response J:80568
abnormal macrophage physiology J:22964
abnormal neutrophil physiology J:80568
decreased circulating interleukin-1 alpha level J:22964
decreased circulating interleukin-1 beta level J:22964
decreased circulating interleukin-6 level J:22964
decreased circulating tumor necrosis factor level J:22964
decreased interleukin-1 alpha secretion J:22964
decreased interleukin-1 beta secretion J:88212, J:22964
decreased susceptibility to endotoxin shock J:22964, J:40691
decreased T cell apoptosis J:40691
immune system phenotype J:40691
\Casp1tm1Sesh/\Casp1tm1Sesh
\Casp4del/\Casp4del

(NOD.129S2(B6)-Casp1tm1Sesh Casp4del/LtJ)
decreased interleukin-1 alpha secretion J:87250
decreased interleukin-1 beta secretion J:87250
decreased interleukin-18 secretion J:87250
\Casp1tm1Sesh/\Casp1tm1Sesh
\Casp4del/\Casp4del

(C3N.129S2-Casp1tm1Sesh Casp4del)
abnormal response to infection J:86761
\Casp1tm1Sesh/\Casp1tm1Sesh
\Casp4del/\Casp4del

(B10.Cg-Casp1tm1Sesh Casp4del H2r H2-T18b)
decreased inflammatory response J:63488
decreased susceptibility to bacterial infection J:63488
decreased susceptibility to bacterial infection induced morbidity/mortality J:63488
\Casp1tm1Sesh/\Casp1tm1Sesh
\Casp4del/\Casp4del

(involves: 129 * 129S2/SvPas * C57BL/6)
decreased interleukin-1 beta secretion J:50775
\Casp1tm1Sesh/\Casp1tm1Sesh
\Casp4del/\Casp4del

(C3.129S2-Casp1tm1Sesh Casp4del)
abnormal macrophage physiology J:136368
decreased interleukin-1 beta secretion J:136368
increased susceptibility to bacterial infection J:136368
increased susceptibility to bacterial infection induced morbidity/mortality J:136368
\Casp1tm1Sesh/\Casp1tm1Sesh
\Casp4del/\Casp4del

(B6.129S2(NOD)-Casp1tm1Sesh Casp4del)
decreased circulating interleukin-1 alpha level J:193522
decreased circulating interleukin-1 beta level J:193522
decreased circulating interleukin-18 level J:193522
decreased interleukin-1 alpha secretion J:193522
decreased interleukin-1 beta secretion J:193522
decreased interleukin-18 secretion J:193522
decreased macrophage apoptosis J:193522
decreased susceptibility to endotoxin shock J:193522
\Casp1tm1Sesh/\Casp1tm1Sesh
\Casp4del/\Casp4del
\Slc11a1r/\Slc11a1s

(involves: 129/Sv * 129S2/SvPas * C57BL/6)
increased susceptibility to bacterial infection J:112400
\Casp1tm1Sesh/\Casp1tm1Sesh
\Casp4del/\Casp4del
\Slc11a1s/\Slc11a1s

(B6.129S2-Casp1tm1Sesh Casp4del)
abnormal macrophage physiology J:112400
increased susceptibility to bacterial infection J:112400
\Casp1tm1Sesh/\Casp1tm1Sesh
\Casp4del/\Casp4del
\Tg(Casp4)#Gne/0

(involves: 129S2/SvPas * C57BL/6 * NOD/ShiLtJ)
decreased circulating interleukin-1 beta level J:193522
decreased circulating interleukin-18 level J:193522
decreased interleukin-1 alpha secretion J:193522
decreased interleukin-1 beta secretion J:193522
decreased interleukin-18 secretion J:193522
decreased macrophage apoptosis J:193522
decreased susceptibility to endotoxin shock J:193522
\Casp1tm1Sesh/\Casp1tm1Sesh
\Nlrp1aNeut1/\Nlrp1aNeut1

(involves: 129S2/SvPas * C57BL/6)
immune system phenotype J:191055
increased circulating interleukin-18 level J:191055
\Casp2tm1Vaux/\Casp2tm1Vaux
\Casp9tm1Flv/\Casp9tm1Flv

(involves: 129S1/Sv * C57BL/6)
abnormal T cell physiology J:91156
\Casp2tm1Yuan/\Casp2tm1Yuan
(involves: 129S4/SvJae * C57BL/6J * DBA/2)
abnormal B cell apoptosis J:47601
\Casp3tm1Flv/\Casp3tm1Flv
(involves: 129S1/Sv * C57BL/6)
abnormal bone marrow development J:94703
abnormal osteoclast physiology J:94703
decreased thymocyte number J:36821
immune system phenotype J:36821
\Casp3tm1Flv/\Casp3tm1Flv
\Casp7tm1Flv/\Casp7+

(B6.129S-Casp3tm1Flv Casp7tm1Flv)
decreased thymocyte apoptosis J:105496
\Casp3tm1Flv/\Casp3tm1Flv
\Casp7tm1Flv/\Casp7tm1Flv

(B6.129S-Casp3tm1Flv Casp7tm1Flv)
decreased thymocyte apoptosis J:105496
\Casp3tm1Flv/\Casp3tm1Flv
\Tg(Scgb1a1-rtTA,tetO-Ifng)14Eli/0

(involves: 129S1/Sv * C57BL/6 * CBA)
increased lymphocyte cell number J:100854
increased macrophage cell number J:100854
increased neutrophil cell number J:100854
\Casp3tm1Mak/\Casp3tm1Mak
(B6.129P2-Casp3tm1Mak)
decreased inflammatory response J:97650, J:179279
\Casp3tm1Mak/\Casp3tm1Mak
\Tg(TcrLCMV)327Sdz/0

(B6.Cg-Casp3tm1Mak Tg(TcrLCMV)327Sdz)
abnormal CD8-positive, alpha beta T cell morphology J:97650
\Casp4tm1.1Vmd/\Casp4tm1.1Vmd
(involves: C57BL/6)
decreased circulating interleukin-1 alpha level J:193522
decreased circulating interleukin-1 beta level J:193522
decreased circulating interleukin-18 level J:193522
decreased interleukin-1 alpha secretion J:193522
decreased interleukin-1 beta secretion J:193522
decreased macrophage apoptosis J:193522
decreased susceptibility to endotoxin shock J:193522
\Casp4tm1Yuan/\Casp4tm1Yuan
(involves: 129S4/SvJae * C57BL/6J * DBA/2)
decreased circulating interleukin-1 alpha level J:46167
decreased circulating interleukin-1 beta level J:46167
decreased susceptibility to endotoxin shock J:46167
\Casp4tm1Yuan/\Casp4tm1Yuan
(B6.129S4(D2)-Casp4tm1Yuan/J)
decreased interleukin-1 beta secretion J:270123
decreased interleukin-18 secretion J:270123
\Casp7tm1.1Acau/\Casp7tm1.1Acau
(B6.Cg-Casp7tm1.1Acau)
immune system phenotype J:179279
\Casp7tm1Flv/\Casp7tm1Flv
(B6.129S6-Casp7tm1Flv)
immune system phenotype J:105496
\Casp8em1Hbz/\Casp8em1Hbz
(involves: C57BL/6)
decreased CD8-positive, alpha-beta T cell number J:342732
enlarged spleen J:342732
\Casp8em1Hbz/\Casp8em1Hbz
\Mlklem1Hbz/\Mlklem1Hbz

(involves: C57BL/6)
decreased B cell number J:342732
decreased leukocyte cell number J:342732
decreased lymphocyte cell number J:342732
decreased mature B cell number J:342732
decreased T cell number J:342732
enlarged spleen J:342732
increased CD11b-high dendritic cell number J:342732
increased granulocyte number J:342732
increased macrophage cell number J:342732
\Casp8em1Hbz/\Casp8em1Hbz
\Ripk1em1Hbz/\Ripk1em1Hbz
\Ripk3tm1Xidw/\Ripk3tm1Xidw

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
decreased leukocyte cell number J:342732
decreased lymphocyte cell number J:342732
decreased mature B cell number J:342732
decreased T cell number J:342732
\Casp8em1Hbz/\Casp8em1Hbz
\Ripk3tm1Xidw/\Ripk3tm1Xidw

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
decreased B cell number J:342732
decreased leukocyte cell number J:342732
decreased lymphocyte cell number J:342732
decreased mature B cell number J:342732
decreased T cell number J:342732
enlarged spleen J:342732
increased CD11b-high dendritic cell number J:342732
increased granulocyte number J:342732
increased macrophage cell number J:342732
\Casp8m1Btlr/\Casp8m1Btlr
(C57BL/6J-Casp8m1Btlr)
decreased CD4-positive, alpha-beta T cell number J:255007
decreased CD8-positive, naive alpha-beta T cell number J:255007
decreased T cell number J:255007
increased CD8-positive, alpha-beta T cell number J:255007
increased effector memory CD4-positive, alpha-beta T cell number J:255007
\Casp8M2Btlr/\Casp8M2Btlr
(C57BL/6J-Casp8M2Btlr)
increased effector memory CD8-positive, alpha-beta T cell number J:272851
\Casp8tm1.1Raz/\Casp8tm1.1Raz
\Otulinem1Gvl/\Otulinem1Gvl
\Ripk3tm1Vmd/\Ripk3tm1Vmd

(involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6J)
enlarged lymph nodes J:312394
immune system phenotype J:312394
\Casp8tm1.1Raz/\Casp8tm1.1Raz
\Ripk3tm1Vmd/\Ripk3tm1Vmd

(involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ)
abnormal macrophage physiology J:170815
decreased macrophage apoptosis J:170815
decreased thymocyte apoptosis J:170814
enlarged axillary lymph nodes J:170815
enlarged cervical lymph nodes J:170815
enlarged lymph nodes J:170814
enlarged spleen J:170815, J:170814
enlarged thymus J:170814
immune system phenotype J:170815
increased B cell number J:170815
increased inflammatory response J:170815
increased leukocyte cell number J:170815
increased spleen white pulp amount J:170815
increased T cell number J:170815, J:170814
large lymphoid organs J:170814
lymph node hyperplasia J:170815
\Casp8tm1.1Vmd/\Casp8tm1.1Vmd
\Ripk3tm2Vmd/\Ripk3tm2Vmd

(involves: C57BL/6N)
enlarged lymph nodes J:209137
enlarged spleen J:209137
increased T cell number J:209137
\Casp8tm1Clie/\Casp8tm1Clie
\Tg(Alb1-cre)7Gsc/0

(involves: 129P2/OlaHsd * C57BL/6 * FVB/N)
liver inflammation J:218665
\Casp8tm1Hed/\Casp8tm1Hed
\Cd19tm1(cre)Cgn/\Cd19+

(involves: 129P2/OlaHsd)
abnormal adaptive immunity J:116713
abnormal immunoglobulin level J:116713
decreased B cell number J:116713
decreased B cell proliferation J:116713
decreased B-1 B cell number J:116713
decreased marginal zone B cell number J:116713
spleen hypoplasia J:116713
\Casp8tm1Hed/\Casp8tm1Hed
\Tg(KRT14-cre)1Efu/0

(Not Specified)
abnormal T cell physiology J:167299
dermatitis J:167299
increased IgE level J:167299
increased IgG1 level J:167299
increased mast cell number J:167299
\Casp8tm1Raz/\Casp8tm1Raz
\Tg(Lck-cre)548Jxm/0

(involves: 129P2/OlaHsd * C57BL/6 * CBA)
abnormal CD8-positive, alpha-beta T cell physiology J:82759
abnormal lymphocyte morphology J:107455
abnormal T cell activation J:107455
abnormal T cell morphology J:82759
abnormal T cell physiology J:107455
abnormal T cell proliferation J:107455
abnormal T cell subpopulation ratio J:107455, J:82759
decreased CD4-positive, alpha-beta T cell number J:82759
decreased CD8-positive, alpha-beta T cell number J:82759
decreased leukocyte cell number J:107455
decreased T cell apoptosis J:82759
decreased T cell number J:82759
decreased T cell proliferation J:82759
enlarged lymph nodes J:107455
enlarged spleen J:107455
increased B cell number J:107455
increased lymphocyte cell number J:107455
increased T cell number J:107455
lymphoid hyperplasia J:107455
\Casp8tm1Wll/\Casp8tm1.1Yuan
\Lyz2tm1(cre)Ifo/\Lyz2+

(involves: 129S1/Sv * 129X1/SvJ * MF1)
abnormal macrophage differentiation J:92722
\Casp9tm1Flv/\Casp9tm1Flv
(involves: 129S1/Sv * C57BL/6)
abnormal thymocyte apoptosis J:49088
decreased T cell apoptosis J:91156
immune system phenotype J:49088
\Casp9tm1Mak/\Casp9tm1Mak
(either: (involves: 129P2/OlaHsd * C57BL/6J) or (involves: 129P2/OlaHsd * CD-1))
abnormal splenocyte apoptosis J:49087
abnormal thymocyte apoptosis J:49087
immune system phenotype J:49087
\Casp12tm1Dwni/\Casp12tm1Dwni
(involves: 129S1/SvImJ * C57BL/6)
decreased susceptibility to bacterial infection J:144912
decreased susceptibility to bacterial infection induced morbidity/mortality J:144912
increased circulating interleukin-18 level J:144912
increased interferon-gamma secretion J:144912
increased interleukin-1 beta secretion J:144912
increased susceptibility to endotoxin shock J:144912
\Casp14em1(IMPC)Ccpcz/\Casp14em1(IMPC)Ccpcz
(C57BL/6N-Casp14em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged thymus J:211773
\CasrNuf/\CasrNuf
(involves: 102/El * C3H/He)
tongue inflammation J:92612
\Casz1Gt(CJ0565)Wtsi/\Casz1Gt(CJ0565)Wtsi
(involves: 129P2/OlaHsd * C57BL/6)
abnormal lymphatic vessel morphology J:242127
enlarged lymphatic vessel J:242127
\Cav1tm1Mls/\Cav1tm1Mls
(involves: 129/Sv * C57BL/6 * SJL)
abnormal chemokine secretion J:115914
abnormal cytokine level J:115914
abnormal macrophage physiology J:115914
abnormal neutrophil physiology J:139304
abnormal osteoclast morphology J:141361
decreased susceptibility to endotoxin shock J:139304
impaired neutrophil recruitment J:115914
increased circulating CXCL10 level J:115914
increased circulating interferon-gamma level J:115914
increased circulating interleukin-6 level J:115914
increased circulating tumor necrosis factor level J:115914
increased susceptibility to bacterial infection J:115914
increased susceptibility to bacterial infection induced morbidity/mortality J:115914
lung inflammation J:87282
\Cav1tm1Mls/\Cav1tm1Mls
\Cav3tm1Mls/\Cav3tm1Mls

(involves: 129/Sv * C57BL/6J * SJL)
heart inflammation J:77372
\Cbfa2t2tm1Swh/\Cbfa2t2tm1Swh
(either: B6.129S6-Cbfa2t2tm1Swh or (involves: 129S6/SvEvTac * C57BL/6))
small intestinal inflammation J:102172
\Cbfa2t3tm1.1Swh/\Cbfa2t3tm1.1Swh
(involves: 129S6/SvEvTac * C57BL/6 * FVB/N)
abnormal myelopoiesis J:140967
decreased immature B cell number J:140967
enlarged spleen J:140967
\Cbfbtm1Itan/\Cbfbtm1Itan
\Rr94tm3.1Litt/\Rr94tm3.1Litt
\Tg(Cd4-cre)1Cwi/0

(involves: 129P2/OlaHsd * C57BL/6 * DBA/2 * FVB/N)
abnormal double-positive T cell morphology J:158962
abnormal T cell subpopulation ratio J:158962
decreased CD4-positive, alpha-beta T cell number J:158962
decreased double-positive T cell number J:158962
increased CD8-positive, alpha-beta T cell number J:158962
increased double-positive T cell number J:158962
\Cbfbtm1Itan/\Cbfbtm1Itan
\Tg(Cd4-cre)1Cwi/0

(involves: 129P2/OlaHsd * C57BL/6 * DBA/2)
abnormal CD8-positive, alpha beta T cell morphology J:158962, J:125953
abnormal CD8-positive, alpha-beta T cell number J:125953
abnormal T cell differentiation J:125953
abnormal T-helper 1 cell differentiation J:125953
decreased CD8-positive, alpha-beta T cell number J:158962
increased double-positive T cell number J:158962
increased IgA level J:125953
increased IgE level J:125953
increased IgG1 level J:125953
increased immunoglobulin level J:125953
lung inflammation J:125953
\Cbfbtm1Itan/\Cbfbtm1Itan
\Tg(Lck-cre)1Cwi/0

(involves: 129P2/OlaHsd)
abnormal CD4-positive T cell differentiation J:125953
abnormal CD8-positive, alpha-beta T cell differentiation J:125953
abnormal double-positive T cell morphology J:125953
abnormal T-helper 1 cell differentiation J:125953
decreased thymocyte number J:125953
\Cbfbtm1Itan/\Cbfbtm1Itan
\Zbtb7btm2Litt/\Zbtb7b+
\Tg(Lck-cre)1Cwi/0

(involves: 129P2/OlaHsd * C57BL/6)
abnormal T cell differentiation J:141144
decreased CD4-positive, alpha-beta T cell number J:141144
\Cbfbtm1Itan/\Cbfbtm1Itan
\Zbtb7btm2Litt/\Zbtb7btm1.2Litt
\Tg(Lck-cre)1Cwi/0

(involves: 129P2/OlaHsd * C57BL/6)
abnormal T cell differentiation J:141144
decreased CD4-positive, alpha-beta T cell number J:141144
\Cbfbtm1Lhc/\Cbfbtm1Lhc
\Tg(Mx1-cre)1Cgn/0

(involves: 129S6/SvEvTac * C57BL/6 * CBA)
abnormal myelopoiesis J:105040
abnormal spleen morphology J:105040
enlarged spleen J:105040
increased leukocyte cell number J:105040
\Cbfbtm1Spe/\Cbfbtm1Spe
\Tg(Tek-GFP/Cbfb)1Spe/0

(either: (involves: 129S4/SvJae * BALB/c * CD-1) or (involves: 129S4/SvJae * C57BL/6 * CD-1))
abnormal myelopoiesis J:80670
abnormal splenic cell ratio J:80670
increased CD4-positive, alpha-beta T cell number J:80670
small thymus J:80670
spleen hypoplasia J:80670
\Cbfbtm1Spe/\Cbfbtm1Spe
\Tg(Tek-GFP/Cbfb)2Spe/0

(either: (involves: 129S4/SvJae * BALB/c * CD-1 * Swiss Webster) or (involves: 129S4/SvJae * C57BL/6 * CD-1 * Swiss Webster))
abnormal myelopoiesis J:80670
abnormal splenic cell ratio J:80670
increased CD4-positive, alpha-beta T cell number J:80670
small thymus J:80670
spleen hypoplasia J:80670
\Cbfbtm1Spe/\Cbfbtm2.1Spe
(involves: 129S4/SvJae)
abnormal splenic cell ratio J:124224
abnormal T cell differentiation J:124224
abnormal thymus cell ratio J:124224
abnormal thymus morphology J:124224
decreased double-positive T cell number J:124224
increased CD4-positive, alpha-beta T cell number J:124224
thymus hypoplasia J:124224
\Cbfbtm1Tok/\Cbfbtm1Tok
\Tg(Gata1-Cbfb)1Tok/0

(involves: 129P2/OlaHsd * C57BL/6J)
absent T cells J:80668
decreased lymphocyte cell number J:80668
small spleen J:80668
small thymus J:80668
\Cbfbtm2.1Spe/\Cbfbtm2.1Spe
(involves: 129S4/SvJae)
abnormal splenic cell ratio J:124224
abnormal T cell differentiation J:124224
abnormal thymus cell ratio J:124224
abnormal thymus morphology J:124224
decreased double-positive T cell number J:124224
increased CD4-positive, alpha-beta T cell number J:124224
thymus hypoplasia J:124224
\Cbfbtm2Itan/\Cbfbtm2Itan
(Not Specified)
abnormal lymph organ development J:168918
abnormal peripheral lymph node morphology J:168918
absent Peyer's patches J:168918
decreased Peyer's patch number J:168918
\Cbfbtm5Ppl/\Cbfb+
(Not Specified)
abnormal mononuclear cell differentiation J:193140
myeloid hyperplasia J:193140
\Cbfbtm6Ppl/\Cbfb+
(involves: 129S/SvEv * C57BL/6)
decreased B cell number J:252447
\Cbltm1.1Hua/\Cbltm1.1Hua
\Lattm1Les/\Lattm1Les

(involves: 129P2/OlaHsd)
abnormal thymus development J:91369
increased CD4-positive, alpha-beta T cell number J:91369
liver inflammation J:91369
lung inflammation J:91369
thymus hypoplasia J:91369
\Cbltm1.1Hua/\Cbltm1.1Hua
\Lcp2tm1Gak/\Lcp2tm1Gak

(involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ)
abnormal cytokine secretion J:91369
abnormal T cell differentiation J:91369
enlarged spleen J:91369
increased CD4-positive, alpha-beta T cell number J:91369
liver inflammation J:91369
lung inflammation J:91369
\Cbltm1.1Hua/\Cbltm1.1Hua
\Lcp2tm1Gak/\Lcp2tm1Gak
\Rag2tm1Fwa/\Rag2tm1Fwa

(involves: 129P2/OlaHsd * 129S/SvEv * 129S1/Sv * 129X1/SvJ)
abnormal T cell differentiation J:91369
\Cbltm1Ddlb/\Cbltm1Ddlb
(involves: 129S1/Sv * C57BL/6J)
abnormal lymph node cell ratio J:76895
abnormal spleen morphology J:76895
abnormal splenic cell ratio J:76895
abnormal thymus cell ratio J:76895
enlarged lymph nodes J:76895
enlarged spleen J:76895
\Cbltm1Ddlb/\Cbltm1Ddlb
(involves: 129S1/Sv)
abnormal T cell physiology J:81965
enlarged spleen J:81965
increased spleen red pulp amount J:81965
spleen hyperplasia J:81965
\Cbltm1Ddlb/\Cbltm1Ddlb
(involves: 129S1/Sv * C57BL/6)
enlarged spleen J:103366
increased spleen red pulp amount J:103366
spleen hyperplasia J:103366
\Cbltm1Ddlb/\Cbltm2Wlan
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
abnormal double-negative T cell morphology J:103366
abnormal lymph node cell ratio J:103366
abnormal spleen morphology J:103366
abnormal splenic cell ratio J:103366
abnormal T cell activation J:103366
abnormal T cell differentiation J:103366
abnormal T cell physiology J:103366
abnormal thymus morphology J:103366
abnormal thymus size J:103366
decreased single-positive T cell number J:103366
enlarged spleen J:103366
increased spleen red pulp amount J:103366
spleen hyperplasia J:103366
thymus hypoplasia J:103366
\Cbltm1Soga/\Cbltm1Soga
(Not Specified)
enlarged spleen J:151543
\Cbltm1Soga/\Cbltm1Soga
\Tg(Tec-BCR/ABL1)5Hhi/0

(involves: C57BL/6 * DBA/2)
enlarged lymph nodes J:151543
\Cbltm1Wlan/\Cbltm1Wlan
(involves: 129S1/Sv * C57BL/6)
abnormal T cell physiology J:81965
enlarged spleen J:81965
increased spleen red pulp amount J:81965
myeloid hyperplasia J:81965
spleen hyperplasia J:81965
\Cbltm2Hua/\Cbltm2Hua
\Cblbtm1Hua/\Cblbtm1Hua
\Tg(Lck-cre)I57Jxm/0

(involves: 129P2/OlaHsd * C57BL/6 * ICR)
abnormal immune system physiology J:80427
abnormal T cell morphology J:80427
dermatitis J:80427
enlarged spleen J:80427
increased T cell proliferation J:80427
\Cbltm2Wlan/\Cbltm2Wlan
(involves: 129X1/SvJ * C57BL/6)
abnormal spleen morphology J:103366
abnormal thymus morphology J:103366
abnormal thymus size J:103366
enlarged spleen J:103366
increased spleen red pulp amount J:103366
spleen hyperplasia J:103366
thymus hypoplasia J:103366
\Cblbtm1Hua/\Cblbtm1Hua
(Not Specified)
increased T cell proliferation J:89761
\Cblbtm1Hua/\Cblbtm1Hua
(B6.129P2-Cblbtm1Hua)
increased interleukin-2 secretion J:94685
increased susceptibility to experimental autoimmune encephalomyelitis J:94685
increased T cell proliferation J:94685
\Cblbtm1Hua/\Cblbtm1Hua
\Ubash3btm1Jni/\Ubash3btm1Jni
\Ubash3atm1Jni/\Ubash3atm1Jni

(Not Specified)
increased susceptibility to experimental autoimmune encephalomyelitis J:89761
increased T cell proliferation J:89761
\Cblbtm1Pngr/\Cblbtm1Pngr
(involves: 129 * C57BL/6)
abnormal mast cell physiology J:126361
increased interleukin-6 secretion J:126361
increased tumor necrosis factor secretion J:126361
\Cblbtm1Pngr/\Cblbtm1Pngr
(B6.129P2-Cblbtm1Pngr)
increased T cell proliferation J:141390
\Cblbtm1Pngr/\Cblbtm1Pngr
\Itktm1Litt/\Itktm1Litt

(B6.129-Itktm1Litt Cblbtm1Pngr)
abnormal T cell morphology J:141390
abnormal T-helper 2 cell differentiation J:141390
decreased interleukin-2 secretion J:141390
decreased T cell number J:141390
immune system phenotype J:141390
\Cblbtm1Pngr/\Cblbtm1Pngr
\Vav1tm1Tyb/\Vav1tm1Tyb
\Wastm1Sbs/\Wastm1Sbs

(involves: 129P2/OlaHsd * 129S2/SvPas * 129S6/SvEvTac)
abnormal T cell physiology J:79550
\Cblbtm1Pngr/\Cblbtm1Pngr
\Wastm1Sbs/\Wastm1Sbs

(Not Specified)
abnormal T cell physiology J:79550
\Cblbtm1Wlan/\Cblbtm1Wlan
(involves: 129X1/SvJ * C57BL/6)
abnormal mast cell physiology J:126361
increased interleukin-6 secretion J:126361
increased tumor necrosis factor secretion J:126361
\Cbliftm1a(KOMP)Wtsi/\Cbliftm1a(KOMP)Wtsi
(C57BL/6N-Cbliftm1a(KOMP)Wtsi)
increased CD4-positive, alpha-beta T cell number J:236022
increased susceptibility to bacterial infection J:236022
increased susceptibility to bacterial infection induced morbidity/mortality J:236022
increased T cell number J:236022
\Cbstm1Unc/\Cbstm1Unc
(involves: 129P2/OlaHsd * C57BL/6J)
abnormal interleukin level J:101303
abnormal tumor necrosis factor level J:101303
absent uterine NK cells J:190486
decreased uterine NK cell number J:190486
liver inflammation J:101303
\Cbstm1Unc/\Cbstm1Unc
\Tg(Mt1-CBS*S466L)EB86Waku/0

(involves: 129P2/OlaHsd * C3H * C57BL/6)
increased Ly6C high monocyte number J:168131
increased monocyte cell number J:168131
\Cbx1em1(IMPC)Ccpcz/\Cbx1+
(C57BL/6NCrl-Cbx1em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
small spleen J:211773
\Cbx2tm1Cim/\Cbx2tm1Cim
(involves: 129P2/OlaHsd * BALB/c)
arrested T cell differentiation J:38487
decreased splenocyte proliferation J:38487
\Cbx3tm1Ics/\Cbx3tm1Ics
(involves: 129S2/SvPas * C57BL/6)
immune system phenotype J:186702
\Cbx4tm1.1Gxu/\Cbx4tm1.2Gxu
\Tg(Foxn1-cre)1Tbo/0

(involves: 129S2/SvPas * C57BL/6J)
abnormal lymphopoiesis J:194053
abnormal thymus development J:194053
abnormal thymus physiology J:194053
decreased double-positive T cell number J:194053
decreased T cell number J:194053
thymus atrophy J:194053
thymus hypoplasia J:194053
\Cbx4tm1.2Gxu/\Cbx4tm1.2Gxu
(involves: 129S2/SvPas * C57BL/6J)
abnormal thymus development J:194053
abnormal thymus physiology J:194053
thymus hypoplasia J:194053
\Cbx5em1(IMPC)Ccpcz/\Cbx5em1(IMPC)Ccpcz
(C57BL/6NCrl-Cbx5em1(IMPC)Ccpcz/Ccpcz)
increased monocyte cell number J:211773
\Cbx5tm1.1Ics/\Cbx5tm1.1Ics
(involves: 129S2/SvPas * C57BL/6)
abnormal T-helper 2 physiology J:186702
immune system phenotype J:186702
\Cbx6tm1a(EUCOMM)Wtsi/\Cbx6tm1a(EUCOMM)Wtsi
(C57BL/6N-Cbx6tm1a(EUCOMM)Wtsi/Wtsi)
blood in lymph vessels J:239583
\Cby1tm1Ktkm/\Cby1tm1Ktkm
(B6.129-Cby1tm1Ktkm)
increased susceptibility to bacterial infection J:147413
increased susceptibility to otitis media J:147413
sinus inflammation J:147413
\Cc2d1atm1a(KOMP)Wtsi/\Cc2d1atm1a(KOMP)Wtsi
(involves: C57BL/6J * C57BL/6N)
decreased interferon-beta secretion J:190401
decreased interleukin-6 secretion J:190401
\Ccar2Gt(XN876)Byg/\Ccar2Gt(XN876)Byg
(involves: 129P2/OlaHsd * C57BL/6)
decreased tumor necrosis factor secretion J:156677
\Ccbe1tm1Lex/\Ccbe1tm1Lex
(involves: 129S5/SvEvBrd)
abnormal lymphangiogenesis J:186594
absent lymphatic vessels J:186594
\Ccbe1tm1Mlkn/\Ccbe1tm1Mlkn
(either: B6.129-Ccbe1tm1Mlkn or (involves: 129 * C57BL/6))
abnormal macrophage physiology J:196696
absent lymphatic vessels J:196696
decreased macrophage cell number J:196696
\Ccdc18em1(IMPC)Ccpcz/\Ccdc18em1(IMPC)Ccpcz
(C57BL/6NCrl-Ccdc18em1(IMPC)Ccpcz/Ccpcz)
abnormal lymph node morphology J:211773
enlarged lymph nodes J:211773
\Ccdc25em1(IMPC)Mbp/\Ccdc25+
(C57BL/6N-Ccdc25em1(IMPC)Mbp/MbpMmucd)
small spleen J:211773
\Ccdc32em1(IMPC)J/\Ccdc32+
(C57BL/6NJ-Ccdc32em1(IMPC)J/Mmjax)
decreased leukocyte cell number J:211773
\Ccdc39b2b2025.1Clo/\Ccdc39b2b2025.1Clo
(C57BL/6J-Ccdc39b2b2025.1Clo)
absent spleen J:175213
spleen hypoplasia J:175213
\Ccdc40em1(IMPC)J/\Ccdc40em1(IMPC)J
(C57BL/6NJ-Ccdc40em1(IMPC)J/Mmjax)
increased leukocyte cell number J:211773
\Ccdc50em2Gpt/\Ccdc50em2Gpt
(C57BL/6J-Ccdc50em2Gpt)
decreased susceptibility to Herpesvirales infection J:345495
decreased susceptibility to Herpesvirales infection induced morbidity/mortality J:345495
increased circulating interferon-beta level J:345495
increased interferon-beta secretion J:345495
\Ccdc86tm1Hfuj/\Ccdc86+
(involves: C57BL/6NTac)
abnormal T cell morphology J:151722
decreased T cell apoptosis J:151722
\Ccdc88bem1(IMPC)Tcp/\Ccdc88bem1(IMPC)Tcp
(C57BL/6NCrl-Ccdc88bem1(IMPC)Tcp/Tcp)
decreased leukocyte cell number J:211773
decreased lymphocyte cell number J:211773
enlarged lymph nodes J:211773
\Ccdc88bm1Pgrs/\Ccdc88bm1Pgrs
(involves: C57BL/6J * C57BL/10J)
decreased CD8-positive, alpha-beta T cell number J:230618
decreased interferon-gamma secretion J:230618
decreased susceptibility to parasitic infection J:230618
decreased susceptibility to parasitic infection induced morbidity/mortality J:230618
decreased T cell proliferation J:230618
decreased tumor necrosis factor secretion J:230618
immune system phenotype J:230618
\Ccdc88bm1Pgrs/\Ccdc88bm1Pgrs
(involves: 129S1/SvImJ * C57BL/6J * C57BL/10J)
decreased susceptibility to parasitic infection induced morbidity/mortality J:230618
\Ccdc92tm1a(KOMP)Mbp/\Ccdc92tm1a(KOMP)Mbp
(C57BL/6N-Ccdc92tm1a(KOMP)Mbp)
decreased circulating interleukin-1 beta level J:332421
decreased circulating interleukin-18 level J:332421
decreased inflammatory response J:332421
decreased macrophage cell number J:332421
\Ccdc110em1(IMPC)Ccpcz/\Ccdc110em1(IMPC)Ccpcz
(C57BL/6NCrl-Ccdc110em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
enlarged spleen J:211773
\Ccdc124tm1b(KOMP)Wtsi/\Ccdc124tm1b(KOMP)Wtsi
(C57BL/6N-Ccdc124tm1b(KOMP)Wtsi/Nju)
small spleen J:211773
\Ccdc127tm1b(EUCOMM)Wtsi/\Ccdc127tm1b(EUCOMM)Wtsi
(C57BL/6N-Ccdc127tm1b(EUCOMM)Wtsi/Wtsi)
increased leukocyte cell number J:211773
\Ccdc154ntl/\Ccdc154ntl
(involves: 129S7/SvEvBrd * C57BL/6J)
enlarged spleen J:226596
\Ccdc166em1(IMPC)J/\Ccdc166em1(IMPC)J
(C57BL/6NJ-Ccdc166em1(IMPC)J/Mmjax)
decreased leukocyte cell number J:211773
\Ccdc171m1Anu/\Ccdc171+
(C57BL/NCrlAnu-Ccdc171m1Anu/Anu)
decreased IgD level J:104190
decreased mature B cell number J:104190
increased IgM level J:104190
\Ccdc171m1Anu/\Ccdc171m1Anu
(C57BL/NCrlAnu-Ccdc171m1Anu/Anu)
decreased IgD level J:104190
decreased mature B cell number J:104190
increased IgM level J:104190
\Ccdc183em1(IMPC)Hmgu/\Ccdc183em1(IMPC)Hmgu
(C57BL/6NCrl-Ccdc183em1(IMPC)Hmgu/Ieg)
increased neutrophil cell number J:211773
\Ccdc198em1(IMPC)Ccpcz/\Ccdc198em1(IMPC)Ccpcz
(C57BL/6NCrl-Ccdc198em1(IMPC)Ccpcz/Ph)
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
decreased eosinophil cell number J:337480
enlarged spleen J:211773
enlarged thymus J:211773
\Cchcr1em1Aoka/\Cchcr1+
(C57BL/6NJcl-Cchcr1em1Aoka)
immune system phenotype J:309941
\Cchcr1em1Aoka/\Cchcr1em1Aoka
(C57BL/6NJcl-Cchcr1em1Aoka)
immune system phenotype J:309941
\Cckbrtm1Tom/\Cckbrtm1Tom
(involves: 129S4/SvJae * C57BL/6J)
decreased susceptibility to endotoxin shock J:143853
\Ccl1tm1Sman/\Ccl1tm1Sman
(B6.129-Ccl1tm1Sman)
abnormal inflammatory response J:138942
abnormal regulatory T cell physiology J:138942
\Ccl2tm1.1Pame/\Ccl2tm1.1Pame
\Lyz2tm1(cre)Ifo/\Lyz2+

(involves: 129P2/OlaHsd * C57BL/6)
immune system phenotype J:171379
\Ccl2tm1.1Pame/\Ccl2tm1.1Pame
\Speer6-ps1Tg(Alb-cre)21Mgn/\Speer6-ps1+

(involves: C57BL/6 * DBA)
immune system phenotype J:171379
\Ccl2tm1.1Pame/\Ccl2tm1.1Pame
\Tg(Nes-cre)1Kln/0

(involves: C57BL/6 * SJL)
abnormal leukocyte migration J:171379
increased susceptibility to bacterial infection J:171379
\Ccl2tm1.1Pame/\Ccl2tm1.1Pame
\Tg(Tek-cre)12Flv/0

(involves: C3H * C57BL/6)
abnormal leukocyte migration J:171379
increased susceptibility to bacterial infection J:171379
\Ccl2tm1.1Tyos/\Ccl2tm1.1Tyos
(involves: 129S1/Sv * C57BL/6)
abnormal chemokine level J:151874
abnormal chemokine secretion J:151874
abnormal neutrophil physiology J:151874
impaired macrophage chemotaxis J:151874
\Ccl2tm1.1Tyos/\Ccl2tm1.1Tyos
(involves: 129S1/Sv)
abnormal dendritic cell chemotaxis J:199611
abnormal dendritic cell physiology J:199611
decreased dendritic cell number J:199611
\Ccl2tm1Lex/\Ccl2tm1Lex
(involves: 129S5/SvEvBrd * C57BL/6)
impaired macrophage chemotaxis J:191510
\Ccl2tm1Rol/\Ccl2+
\Mpztm1Msch/\Mpz+

(involves: 129S4/SvJae * 129S7/SvEvBrd)
abnormal macrophage derived foam cell morphology J:133028
decreased macrophage cell number J:133028
\Ccl2tm1Rol/\Ccl2+
\Tg(PMP22)C61Clh/0

(involves: 129S4/SvJae * C57BL/6J * CBA/Ca)
increased macrophage cell number J:158350
\Ccl2tm1Rol/\Ccl2tm1Rol
(involves: 129S4/SvJae * 129X1/SvJ * C57BL/6)
abnormal monocyte morphology J:45920
decreased interferon-gamma secretion J:45920
decreased interleukin-4 secretion J:45920
decreased interleukin-5 secretion J:45920
decreased susceptibility to type IV hypersensitivity reaction J:45920
impaired macrophage chemotaxis J:45920
\Ccl2tm1Rol/\Ccl2tm1Rol
(involves: 129S4/SvJae * C57BL/6)
abnormal macrophage chemotaxis J:116878
abnormal T cell physiology J:116878
decreased interferon-gamma secretion J:116878
decreased interleukin-1 beta secretion J:116878
decreased interleukin-12b secretion J:116878
decreased susceptibility to induced colitis J:116878
impaired macrophage chemotaxis J:108533
\Ccl2tm1Rol/\Ccl2tm1Rol
(involves: 129S4/SvJae)
abnormal macrophage physiology J:155025
abnormal monocyte morphology J:121281
decreased inflammatory response J:155025
decreased lymphocyte cell number J:147697
decreased macrophage cell number J:147697
impaired macrophage chemotaxis J:147697
increased circulating interferon-gamma level J:155025
increased circulating interleukin-10 level J:155025
increased circulating tumor necrosis factor level J:155025
increased susceptibility to infection induced morbidity/mortality J:155025
increased susceptibility to parasitic infection J:155025
\Ccl2tm1Rol/\Ccl2tm1Rol
(B6.129S4-Ccl2tm1Rol)
abnormal chemokine level J:151874, J:118606
abnormal chemokine secretion J:151874
abnormal cytokine secretion J:68145
abnormal macrophage chemotaxis J:109290
abnormal neutrophil physiology J:151874
decreased interferon-gamma secretion J:68145
decreased leukocyte cell number J:68145
decreased macrophage cell number J:147328
decreased susceptibility to experimental autoimmune encephalomyelitis J:68145
impaired macrophage chemotaxis J:151874, J:68145, J:118606
increased CD4-positive, alpha-beta T cell number J:68145
increased IgG1 level J:68145
increased IgG level J:147328
increased interleukin-10 secretion J:68145
increased neutrophil cell number J:118606
increased osteoclast cell number J:109290
\Ccl2tm1Rol/\Ccl2tm1Rol
(SJL.129S4-Ccl2tm1Rol)
decreased susceptibility to experimental autoimmune encephalomyelitis J:68145
\Ccl2tm1Rol/\Ccl2tm1Rol
((129S4/SvJae x C57BL/6)F1)
decreased macrophage cell number J:119615
\Ccl2tm1Rol/\Ccl2tm1Rol
(B6.129S4-Ccl2tm1Rol/J)
abnormal microglial cell physiology J:141739
\Ccl2tm1Rol/\Ccl2tm1Rol
\Cx3cr1tm1Litt/\Cx3cr1tm1Litt

(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6J)
abnormal macrophage physiology J:200877
abnormal microglial cell morphology J:200877
increased microglial cell activation J:200877
\Ccl2tm1Rol/\Ccl2tm1Rol
\Mpztm1Msch/\Mpz+

(involves: 129S4/SvJae * 129S7/SvEvBrd)
abnormal cytokine level J:133028
decreased macrophage cell number J:133028
increased macrophage cell number J:133028
\Ccl2tm1Rol/\Ccl2tm1Rol
\Tg(Ccr2-EGFP)8Pame/0

(involves: 129S4/SvJae * C57BL/6J)
abnormal leukocyte migration J:171379
\Ccl2tm1Rol/\Ccl2tm1Rol
\Tg(PMP22)C61Clh/0

(involves: 129S4/SvJae * C57BL/6J * CBA/Ca)
increased macrophage cell number J:158350
\Ccl2tm1Tyos/\Ccl2tm1Tyos
(involves: 129S1/Sv * C57BL/6)
abnormal chemokine level J:151874
abnormal chemokine secretion J:151874
\Ccl3tm1Unc/\Ccl3tm1Unc
(involves: 129P2/OlaHsd)
abnormal susceptibility to Orthomyxoviridae infection J:107677
cecum inflammation J:107677
decreased susceptibility to bacterial infection J:107677
decreased susceptibility to Orthomyxoviridae infection J:107677
decreased susceptibility to Picornaviridae infection J:28704
\Ccl3tm1Unc/\Ccl3tm1Unc
(B6.129P2-Ccl3tm1Unc/J)
decreased neutrophil cell number J:94599
decreased susceptibility to type III hypersensitivity reaction J:94599
\Ccl3tm1Unc/\Ccl3tm1Unc
(involves: 129P2/OlaHsd * C57BL/6)
decreased microglial cell activation J:153059
\Ccl3tm1Unc/\Ccl3tm1Unc
\Hexbtm1Rlp/\Hexbtm1Rlp

(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)
abnormal tumor necrosis factor level J:90687
CNS inflammation J:90687
\Ccl4em1Narl/\Ccl4em1Narl
(C57BL/6JNarl-Ccl4em1Narl)
decreased inflammatory response J:346348
decreased susceptibility to autoimmune diabetes J:346348
\Ccl5tm1Hso/\Ccl5tm1Hso
(involves: 129P2/OlaHsd * C57BL/6)
decreased CD4-positive, alpha-beta T cell number J:75842
decreased interferon-gamma secretion J:75842
decreased interleukin-2 secretion J:75842
decreased susceptibility to type IV hypersensitivity reaction J:75842
decreased T cell proliferation J:75842
\Ccl7tm1Ifc/\Ccl7tm1Ifc
(involves: 129S4/SvJae)
abnormal monocyte morphology J:121281
\Ccl11tm1Mer/\Ccl11tm1Mer
(involves: 129S6/SvEvTac * NIH Black Swiss)
decreased eosinophil cell number J:38945
impaired eosinophil recruitment J:38945
\Ccl11tm1Mer/\Ccl11tm1Mer
(129S.129S6-Ccl11tm1Mer)
decreased eosinophil cell number J:102034
\Ccl11tm1Mer/\Ccl11tm1Mer
\Ccl24tm1Mer/\Ccl24tm1Mer

(129S.129S6(Cg)-Ccl24tm1Mer Ccl11tm1Mer)
abnormal immune system physiology J:102034
abnormal inflammatory response J:102034
\Ccl11tm1Mer/\Ccl11tm1Mer
\Ccl24tm1Mer/\Ccl24tm1Mer

(involves: 129S6/SvEvTac)
decreased eosinophil cell number J:115273
\Ccl12tm1.1Ifc/\Ccl12tm1.1Ifc
(involves: 129S4/SvJae)
immune system phenotype J:121281
\Ccl12tm1Ifc/\Ccl12tm1Ifc
(involves: 129S4/SvJae)
immune system phenotype J:121281
\Ccl17em1(IMPC)H/\Ccl17em1(IMPC)H
(C57BL/6N-Ccl17em1(IMPC)H/H)
increased spleen weight J:211773
\Ccl17tm1.1Ifo/\Ccl17tm1.1Ifo
(involves: 129P2/OlaHsd * C57BL/6)
decreased susceptibility to type IV hypersensitivity reaction J:159098
increased length of allograft survival J:159098
\Ccl17tm2.1(cre)Ifo/\Ccl17+
\Hif1atm3Rsjo/\Hif1atm3Rsjo

(involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6)
abnormal dendritic cell number J:187773
abnormal interleukin-1 beta secretion J:187773
abnormal leukocyte migration J:187773
abnormal tumor necrosis factor secretion J:187773
immune system phenotype J:187773
\Ccl19tm1Cys/\Ccl19tm1Cys
(B6.129X1-Ccl19tm1Cys)
abnormal immune system morphology J:126345
decreased T cell number J:126345
\Ccl19tm1Cys/\Ccl19tm1Cys
(involves: 129X1/SvJ)
immune system phenotype J:244640
\Ccl21atm1Yout/\Ccl21atm1Yout
(involves: C57BL/6NCrlj * CBA/JNCrlj)
abnormal negative T cell selection J:244640
abnormal spleen morphology J:244640
decreased alpha-beta T cell number J:244640
decreased B cell number J:244640
decreased thymocyte number J:244640
immune system phenotype J:244640
lacrimal gland inflammation J:244640
small thymus medulla J:244640
\Ccl22tm1(KOMP)Vlcg/\Ccl22tm1(KOMP)Vlcg
(involves: C57BL/6NTac)
abnormal dendritic cell physiology J:236051
\Ccl24tm1Mer/\Ccl24tm1Mer
(129S.129S6-Ccl24tm1Mer)
abnormal immune system physiology J:98708, J:102034
\Ccl24tm1Mer/\Ccl24tm1Mer
(involves: 129S6/SvEvTac * C57BL/6J)
abnormal immune system physiology J:98708
\Ccl25em1(IMPC)H/\Ccl25em1(IMPC)H
(C57BL/6N-Ccl25em1(IMPC)H/H)
enlarged spleen J:211773
increased spleen weight J:211773
\Ccl25tm1.1Mal/\Ccl25tm1.1Mal
(B6.129S2-Ccl25tm1.1Mal)
abnormal gamma-delta T cell number J:136944
abnormal mesenteric lymph node morphology J:136944
abnormal T cell subpopulation ratio J:136944
decreased gamma-delta intraepithelial T cell number J:136944
\Ccl25tm1.1Mal/\Ccl25tm1.1Mal
\Tnftm2Gkl/\Tnf+

(involves: 129S/SvEv * 129S2/SvPas * C57BL/6)
abnormal alpha-beta intraepithelial T cell morphology J:136667
abnormal T cell subpopulation ratio J:136667
decreased gamma-delta intraepithelial T cell number J:136667
intestinal inflammation J:136667
\Ccl27aem1Nax/\Ccl27aem1Nax
\Ccl27alem1Nax/\Ccl27alem1Nax
\Ccl27bem1Nax/\Ccl27bem1Nax

(involves: C57BL/6)
impaired leukocyte migration J:330550
increased interleukin-17 secretion J:330550
increased susceptibility to chemically induced skin inflammation J:330550
\Ccl27aem1Nax/\Ccl27aem1Nax
\Ccl27alem1Nax/\Ccl27alem1Nax
\Ccl27bem1Nax/\Ccl27bem1Nax
\Ccr10tm1.1Nax/\Ccr10+

(involves: C57BL/6)
impaired leukocyte migration J:330550
increased interleukin-10 secretion J:330550
uterus inflammation J:330550
\Ccl27atm1.1(KOMP)Vlcg/\Ccl27atm1.1(KOMP)Vlcg
(C57BL/6N-Ccl27atm1.1(KOMP)Vlcg/MbpMmucd)
decreased regulatory T cell number J:330550
immune system phenotype J:330550
\Ccl27atm1.1(KOMP)Vlcg/\Ccl27atm1.1(KOMP)Vlcg
\Ccr10tm1.1Nax/\Ccr10+

(B6.Cg-Ccl27atm1.1(KOMP)Vlcg Ccr10tm1.1Nax)
immune system phenotype J:330550
\Ccl28em1(IMPC)Ccpcz/\Ccl28em1(IMPC)Ccpcz
(C57BL/6NCrl-Ccl28em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged spleen J:211773
enlarged thymus J:211773
\Ccl28tm1Takna/\Ccl28tm1Takna
(C57BL/6J-Ccl28tm1Takna)
abnormal immune system cell morphology J:256896
decreased IgA level J:256896
increased IgG level J:256896
increased susceptibility to induced colitis J:256896
\Ccm2tm1Kwhi/\Ccm2tm1.1Kwhi
\Tg(Pdgfb-icre/ERT2,-EGFP)1Frut/?

(involves: C57BL/6 * CBA)
CNS inflammation J:173947
\Ccm2tm2.1Sbn/\Ccm2tm2.1Sbn
\Tg(Mx1-cre)1Cgn/0

(involves: C57BL/6 * CBA)
microgliosis J:174085
\Ccn3em1(IMPC)Mbp/\Ccn3em1(IMPC)Mbp
(C57BL/6N-Ccn3em1(IMPC)Mbp/MbpMmucd)
abnormal spleen morphology J:211773
enlarged spleen J:211773
small spleen J:211773
\Ccn3tm1.1Ecan/\Ccn3tm1.1Ecan
(B6.Cg-Ccn3tm1.1Ecan)
abnormal osteoclast differentiation J:158478
abnormal osteoclast physiology J:158478
\Ccna1tm1Djw/\Ccna1tm1Djw
\Ccna2tm1.1Pisc/\Ccna2tm1.1Pisc
\Tg(Mx1-cre)1Cgn/0

(involves: 129S7/SvEvBrd * C57BL/6 * CBA)
decreased leukocyte cell number J:155178
\Ccnb1ip1em1(IMPC)Tcp/\Ccnb1ip1em1(IMPC)Tcp
(C57BL/6NCrl-Ccnb1ip1em1(IMPC)Tcp/Tcp)
enlarged lymph nodes J:211773
\Ccnb2tm1Thnt/\Ccnb2tm1Thnt
(involves: 129P2/OlaHsd * C57BL/6)
increased double-negative T cell number J:47430
small thymus J:47430
\Ccnctm1.1Pisc/\Ccnctm1.1Pisc
\Tg(Lck-LMO1)11Sjk/0
\Tg(Mx1-cre)1Cgn/0

(Not Specified)
increased T cell derived lymphoma incidence J:217695
\Ccnd1tm1Dsn/\Ccnd1tm1Dsn
\Ccnd2tm1Wbg/\Ccnd2tm1Wbg
\Ccnd3tm1Pisc/\Ccnd3tm1Pisc

(involves: 129P2/OlaHsd * 129S2/SvPas)
abnormal lymphopoiesis J:92563
\Ccnd1tm1Dsn/\Ccnd1tm1Dsn
\Cdkn1btm1Mlf/\Cdkn1btm1Mlf

(involves: 129 * C57BL/6)
enlarged spleen J:66707
enlarged thymus J:66707
thymus hyperplasia J:66707
\Ccnd3tm1.1(Ccnd2)Iaai/\Ccnd3tm1.1(Ccnd2)Iaai
(involves: 129S6/SvEvTac)
decreased B cell proliferation J:192031
decreased double-positive T cell number J:192031
decreased pre-B cell number J:192031
decreased T cell proliferation J:192031
small thymus J:192031
thymus hypoplasia J:192031
\Ccnd3tm1Pisc/\Ccnd3tm1Pisc
(Not Specified)
decreased B cell proliferation J:192031
decreased double-positive T cell number J:88120, J:192031
decreased lymphocyte cell number J:88120
decreased pre-B cell number J:192031
decreased T cell proliferation J:88120, J:192031
increased double-negative T cell number J:88120
small thymus J:192031
thymus hypoplasia J:88120, J:192031
\Ccnd3tm1Pisc/\Ccnd3tm1Pisc
\Cdkn1btm1Mlf/\Cdkn1btm1Mlf

(involves: 129S4/SvJaeSor)
decreased double-positive T cell number J:192031
decreased T cell proliferation J:192031
thymus hypoplasia J:192031
\Ccnd3tm1Pisc/\Ccnd3tm1Pisc
\Cdkn1btm1Mlf/\Cdkn1btm1Mlf
\Rb1tm2Brn/\Rb1tm2Brn
\Tg(Mx1-cre)1Cgn/0

(involves: 129S4/SvJaeSor * C57BL/6 * CBA)
immune system phenotype J:192031
\Ccnd3tm1Pisc/\Ccnd3tm1Pisc
\Rag2tm1Fwa/\Rag2tm1Fwa

(involves: 129S/SvEv)
increased T cell proliferation J:88120
\Ccnd3tm1Pisc/\Ccnd3tm1Pisc
\Rb1tm2Brn/\Rb1tm2Brn
\Tg(Mx1-cre)1Cgn/0

(involves: 129 * C57BL/6 * CBA)
decreased double-positive T cell number J:192031
decreased T cell proliferation J:192031
thymus hypoplasia J:192031
\Ccnd3tm1Pisc/\Ccnd3tm1Pisc
\Tg(Lck)4220Rmp/0

(involves: C57BL/6J * DBA/2)
increased T cell derived lymphoma incidence J:88120
\Ccnd3tm1Pisc/\Ccnd3tm1Pisc
\Trp53tm1Tyj/\Trp53tm1Tyj

(involves: 129S2/SvPas)
increased T cell derived lymphoma incidence J:88120
\Ccnd3tm2.1Pisc/\Ccnd3tm2.1Pisc
\Tg(Mx1-cre)1Cgn/0

(involves: C57BL/6 * CBA)
decreased double-positive T cell number J:192032
decreased leukocyte cell number J:192032
small thymus J:192032
\Ccne1tm1Clur/\Ccne1tm1Clur
(involves: 129S4/SvJae)
abnormal myeloid leukocyte morphology J:136692
abnormal spleen red pulp morphology J:136692
enlarged spleen J:136692
immune system phenotype J:136692
spleen hyperplasia J:136692
\Ccne1tm1Jro/\Ccne1tm1Jro
(either: 129-Ccne1tm1Jro or B6.129-Ccne1tm1Jro)
increased spleen weight J:99695
increased splenocyte proliferation J:99695
\Ccne1tm1Pisc/\Ccne1tm1Pisc
\Ccne2tm1Pisc/\Ccne2tm1Pisc

(involves: 129S2/SvPas)
abnormal thrombopoiesis J:85224
\Ccnotm1b(EUCOMM)Wtsi/\Ccnotm1b(EUCOMM)Wtsi
(involves: C57BL/6 * C57BL/6N * CBA)
immune system phenotype J:220709
\Ccnt1em1(IMPC)J/\Ccnt1+
(C57BL/6NJ-Ccnt1em1(IMPC)J/Mmjax)
increased leukocyte cell number J:211773
\Ccnt1em1(IMPC)J/\Ccnt1em1(IMPC)J
(C57BL/6NJ-Ccnt1em1(IMPC)J/Mmjax)
increased leukocyte cell number J:211773
\Ccnt1Gt(RRR115)Byg/\Ccnt1Gt(RRR115)Byg
(involves: 129P2/OlaHsd)
abnormal thymus physiology J:130071
autoimmune response J:130071
immune system phenotype J:130071
lacrimal gland inflammation J:130071
salivary gland inflammation J:130071
\Ccpg1tm1a(EUCOMM)Hmgu/\Ccpg1tm1a(EUCOMM)Hmgu
(C57BL/6N-Ccpg1tm1a(EUCOMM)Hmgu)
pancreas inflammation J:256708
\Ccr1tm1Cge/\Ccr1tm1Cge
(involves: 129S4/SvJae)
decreased tumor necrosis factor secretion J:43569
glomerulonephritis J:115119
immune system phenotype J:115119
impaired neutrophil recruitment J:43569
increased IgG2a level J:115119
increased interferon-gamma secretion J:115119
increased susceptibility to type IV hypersensitivity reaction J:115119
increased tumor necrosis factor secretion J:115119
lung inflammation J:43569
\Ccr1tm1Cge/\Ccr1tm1Cge
(involves: 129S4/SvJae * C57BL/6)
cecum inflammation J:107677
decreased susceptibility to bacterial infection J:107677
decreased susceptibility to experimental autoimmune encephalomyelitis J:63952
immune system phenotype J:63952
increased length of allograft survival J:59235
\Ccr1tm1Cge/\Ccr1tm1Cge
(involves: 129S4/SvJae * BALB/c)
abnormal chemokine secretion J:169909
abnormal circulating chemokine level J:169909
abnormal macrophage physiology J:169909
decreased circulating interferon-gamma level J:169909
decreased interleukin-10 secretion J:169909
decreased susceptibility to bacterial infection J:169909
decreased susceptibility to bacterial infection induced morbidity/mortality J:169909
decreased tumor necrosis factor secretion J:169909
increased interleukin-12 secretion J:169909
increased macrophage nitric oxide production J:169909
increased tumor necrosis factor secretion J:169909
\Ccr1tm1Cge/\Ccr1tm1Cge
(C.129S4-Ccr1tm1Cge)
decreased CD4-positive, alpha-beta T cell number J:95242
decreased CD8-positive, alpha-beta T cell number J:95242
decreased interleukin-13 secretion J:95242
decreased susceptibility to Riboviria infection J:95242
\Ccr1tm1Gao/\Ccr1tm1Gao
(involves: 129S4/SvJae * C57BL/6)
abnormal neutrophil physiology J:41324
granulomatous inflammation J:41324
immune system phenotype J:41324
increased susceptibility to fungal infection J:41324
increased susceptibility to parasitic infection J:41324
\Ccr1tm1Gao/\Ccr1tm1Gao
(involves: C57BL/6)
decreased mast cell number J:94599
decreased susceptibility to type III hypersensitivity reaction J:94599
\Ccr1tm1Gao/\Ccr1tm1Gao
(B6.129S4-Ccr1tm1Gao)
abnormal cellular extravasation J:104744
abnormal leukocyte adhesion J:104744
bronchiolitis J:162707
increased susceptibility to Coronaviridae infection J:162707
increased susceptibility to Coronaviridae infection induced morbidity/mortality J:162707
\Ccr1tm1Gao/\Ccr1tm1Gao
(involves: 129S4/SvJae)
abnormal Kupffer cell morphology J:152548
\Ccr1l1em1Semp/\Ccr1l1em1Semp
(C57BL/6NTac-Ccr1l1em1Semp)
immune system phenotype J:304824
\Ccr1l1em2Semp/\Ccr1l1em2Semp
(C57BL/6NTac-Ccr1l1em2Semp)
immune system phenotype J:304824
\Ccr2em1(IMPC)H/\Ccr2em1(IMPC)H
(C57BL/6N-Ccr2em1(IMPC)H/H)
decreased lymphocyte cell number J:211773
decreased monocyte cell number J:211773
decreased neutrophil cell number J:211773
increased eosinophil cell number J:211773
\Ccr2tm1.1(CCR2)Rodb/\Ccr2tm1.1(CCR2)Rodb
(involves: C57BL/6)
abnormal macrophage morphology J:203000
immune system phenotype J:203000
\Ccr2tm1.1Dnc/\Ccr2tm1.1Dnc
(Not Specified)
abnormal dendritic cell chemotaxis J:223508
decreased CD11b-high dendritic cell number J:223508
increased CD11b-high dendritic cell number J:223508
increased dendritic cell number J:223508
\Ccr2tm1.1Mpa/\Ccr2tm1.1Mpa
(involves: BALB/cJ * C57BL/6)
decreased macrophage cell number J:189044
decreased monocyte cell number J:189044
\Ccr2tm1Blck/\Ccr2tm1Blck
(B6.129P2-Ccr2tm1Blck)
abnormal cellular extravasation J:104744
abnormal leukocyte adhesion J:104744
\Ccr2tm1Blck/\Ccr2tm1Blck
\Faslpr/\Faslpr

(MRL.Cg-Ccr2tm1Blck Faslpr)
abnormal immune system organ morphology J:113343
abnormal interferon level J:113343
abnormal lymphocyte cell number J:113343
abnormal tumor necrosis factor level J:113343
enlarged lymph nodes J:113343
enlarged spleen J:113343
glomerulonephritis J:113343
kidney inflammation J:113343
\Ccr2tm1Brv/\Ccr2tm1Brv
(involves: 129S1/Sv * ICR)
abnormal spleen morphology J:111517
enlarged spleen J:111517
impaired macrophage chemotaxis J:111517
increased eosinophil cell number J:111517
increased susceptibility to bacterial infection J:111517
liver inflammation J:111517
\Ccr2tm1Ifc/\Ccr2+
(involves: 129S4/SvJae * C57BL/6)
impaired macrophage chemotaxis J:121703
\Ccr2tm1Ifc/\Ccr2tm1Ifc
(B6.129S4-Ccr2tm1Ifc/J)
abnormal leukocyte migration J:106738
abnormal leukocyte physiology J:122119
abnormal microglial cell physiology J:106738
abnormal osteoclast cell number J:149360
abnormal osteoclast differentiation J:149360
abnormal osteoclast physiology J:149360
decreased acute inflammation J:106738
decreased interferon-gamma secretion J:106738
decreased osteoclast cell number J:149360
increased susceptibility to Coronaviridae infection J:106738
increased susceptibility to Coronaviridae infection induced morbidity/mortality J:106738
\Ccr2tm1Ifc/\Ccr2tm1Ifc
(involves: 129S4/SvJae)
abnormal monocyte morphology J:121281
\Ccr2tm1Ifc/\Ccr2tm1Ifc
(involves: 129S4/SvJae * C57BL/6)
abnormal immune serum protein physiology J:118971
abnormal Langerhans cell physiology J:112594
abnormal macrophage chemotaxis J:44345
abnormal microglial cell physiology J:121703
decreased inflammatory response J:44345
decreased interferon-gamma secretion J:75838, J:44345
decreased interleukin-2 secretion J:44345
decreased interleukin-6 secretion J:75838
decreased splenocyte proliferation J:75838
decreased susceptibility to experimental autoimmune encephalomyelitis J:75838
decreased susceptibility to type I hypersensitivity reaction J:118971
decreased T cell proliferation J:75838
impaired macrophage chemotaxis J:81363, J:44345, J:121703
increased interferon-gamma secretion J:61542
increased tumor necrosis factor secretion J:61542
\Ccr2tm1Ifc/\Ccr2tm1Ifc
(B6.129S4-Ccr2tm1Ifc)
decreased susceptibility to induced colitis J:161138
immune system phenotype J:154558
impaired leukocyte tethering or rolling J:154558
\Ccr2tm1Ifc/\Ccr2tm1Ifc
\Tg(APPSWE)2576Kha/0

(involves: 129S4/SvJae * C57BL/6 * SJL)
abnormal microglial cell physiology J:121703
\Ccr2tm1Mae/\Ccr2tm1Mae
(involves: 129P2/OlaHsd * C57BL/6J)
abnormal cytokine secretion J:110814
decreased CD4-positive, alpha-beta T cell number J:110814
decreased inflammatory response J:110814
increased B cell number J:110814
increased CD8-positive, alpha-beta T cell number J:110814
increased susceptibility to induced colitis J:110814
\Ccr2tm1Mae/\Ccr2tm1Mae
(B6.129P2-Ccr2tm1Mae)
bronchiolitis J:162707
decreased macrophage cell number J:147328
increased IgG level J:147328
increased susceptibility to Coronaviridae infection J:162707
\Ccr2tm1Mae/\Ccr2tm1Mae
(involves: 129P2/OlaHsd)
abnormal chemokine secretion J:151874
abnormal leukocyte migration J:171379
impaired macrophage chemotaxis J:191510, J:151874
\Ccr2tm1Mae/\Ccr2tm1Mae
(involves: 129P2/OlaHsd * BALB/c)
abnormal leukocyte physiology J:162714
decreased neutrophil cell number J:162714
impaired macrophage chemotaxis J:162714
\Ccr2tm1Mpa/\Ccr2tm1Mpa
\Lyz2tm1(cre)Ifo/\Lyz2+

(involves: 129P2/OlaHsd * C57BL/6 * CBA)
decreased macrophage cell number J:189044
\Ccr2tm2.1Ifc/\Ccr2tm2.1Ifc
\Cx3cr1tm1Litt/\Cx3cr1+

(involves: 129P2/OlaHsd * C57BL/6 * FVB/N)
abnormal leukocyte physiology J:166664
decreased susceptibility to experimental autoimmune encephalomyelitis J:166664
\Ccr2tm2.1Ifc/\Ccr2tm2.1Ifc
\Cx3cr1tm1Litt/\Cx3cr1tm1Litt

(involves: 129P2/OlaHsd * C57BL/6 * FVB/N)
abnormal leukocyte physiology J:166664
decreased susceptibility to experimental autoimmune encephalomyelitis J:166664
\Ccr3em1(IMPC)Ccpcz/\Ccr3em1(IMPC)Ccpcz
(C57BL/6NCrl-Ccr3em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged spleen J:211773
enlarged thymus J:211773
\Ccr3tm1Cge/\Ccr3tm1Cge
(involves: 129S4/SvJae * BALB/c)
abnormal eosinophil cell number J:74509
abnormal eosinophil physiology J:74509, J:75347
abnormal mast cell physiology J:74509
decreased circulating interleukin-4 level J:115273
decreased eosinophil cell number J:115273, J:74509, J:75347
decreased monocyte cell number J:115273
impaired eosinophil chemotaxis J:74509
impaired eosinophil recruitment J:74509, J:75347
increased eosinophil cell number J:74509
increased mast cell degranulation J:74509
\Ccr4tm1Pwr/\Ccr4tm1Pwr
(involves: 129P2/OlaHsd * C57BL/6)
abnormal chemokine secretion J:70088
abnormal cytokine secretion J:120221
abnormal splenocyte physiology J:70088
decreased eosinophil cell number J:120221
decreased IgE level J:120221
decreased interleukin-1 beta secretion J:70088
decreased interleukin-4 secretion J:120221
decreased interleukin-5 secretion J:120221
decreased interleukin-10 secretion J:120221
decreased interleukin-13 secretion J:120221
decreased lymphocyte cell number J:70088
decreased macrophage cell number J:70088
decreased susceptibility to endotoxin shock J:70088
decreased susceptibility to fungal infection J:120221
decreased tumor necrosis factor secretion J:70088
immune system phenotype J:70088
increased IgE level J:120221
increased IgG1 level J:120221
increased interferon-gamma secretion J:120221
increased interleukin-4 secretion J:120221
increased interleukin-5 secretion J:120221
increased interleukin-10 secretion J:120221
increased macrophage cell number J:120221
increased neutrophil cell number J:120221
increased tumor necrosis factor secretion J:120221
\Ccr4tm1Pwr/\Ccr4tm1Pwr
(B6.129P2-Ccr4tm1Pwr)
increased CD8-positive, alpha-beta T cell number J:95239
increased length of allograft survival J:95239
increased NK T cell number J:95239
\Ccr5tm1Blck/\Ccr5tm1Blck
(B6.129P2-Ccr5tm1Blck)
abnormal cellular extravasation J:104744
abnormal leukocyte adhesion J:104744
increased length of allograft survival J:105072
\Ccr5tm1Brv/\Ccr5tm1Brv
(either: (involves: 129S1/Sv * ICR) or (involves: 129S1/Sv * 129X1/SvJ * ICR))
abnormal cytokine secretion J:46941
decreased interleukin-1 beta secretion J:46941
decreased interleukin-6 secretion J:46941
decreased susceptibility to endotoxin shock J:46941
increased IgG1 level J:46941
increased interferon-gamma secretion J:46941
increased interleukin-4 secretion J:46941
increased susceptibility to bacterial infection J:46941
increased susceptibility to type IV hypersensitivity reaction J:46941
\Ccr5tm1Kuz/\Ccr5tm1Kuz
(involves: 129P2/OlaHsd * C57BL/6)
abnormal CD4-positive, alpha beta T cell morphology J:110814
abnormal CD8-positive, alpha beta T cell morphology J:110814
abnormal cytokine level J:110814
abnormal Kupffer cell morphology J:152548
abnormal NK T cell physiology J:100869
decreased microglial cell activation J:153059
decreased NK cell number J:135308
decreased susceptibility to induced colitis J:110814
decreased susceptibility to Retroviridae infection J:132342
impaired macrophage chemotaxis J:153059, J:84243, J:64293
increased NK T cell number J:110814
increased susceptibility to fungal infection J:64293
\Ccr5tm1Kuz/\Ccr5tm1Kuz
(B6.129P2-Ccr5tm1Kuz)
bronchiolitis J:162707
increased susceptibility to Coronaviridae infection J:162707
\Ccr5tm1Kuz/\Ccr5tm1Kuz
(involves: 129P2/OlaHsd)
decreased inflammatory response J:227458
\Ccr5tm1Kuz/\Ccr5tm1Kuz
\Cxcr4tm1Qma/\Cxcr4tm1Qma

(involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6)
decreased susceptibility to Retroviridae infection J:132342
\Ccr5tm1Sush/\Ccr5tm1Sush
(B6.129P2-Ccr5tm1Sush)
abnormal leukocyte physiology J:94937
decreased T cell proliferation J:94937
\Ccr6tm1(EGFP)Irw/\Ccr6tm1(EGFP)Irw
(involves: 129S6/SvEvTac * C57BL/6)
abnormal alpha-beta intraepithelial T cell morphology J:85086
abnormal B cell physiology J:120122
abnormal CD4-positive, alpha-beta intraepithelial T cell morphology J:85086
abnormal CD8 positive, alpha-beta intraepithelial T cell morphology J:85086
abnormal follicular dendritic cell physiology J:113363
abnormal gut-associated lymphoid tissue morphology J:113363, J:120122
abnormal Peyer's patch morphology J:120122
abnormal T cell physiology J:85086
decreased B cell number J:120122
decreased Peyer's patch number J:120122
impaired B cell migration J:120122
increased T cell proliferation J:85086
\Ccr6tm1(EGFP)Irw/\Ccr6tm1(EGFP)Irw
(B6.129S6-Ccr6tm1(EGFP)Irw)
decreased interleukin-4 secretion J:132012
decreased interleukin-12 secretion J:132012
decreased susceptibility to bacterial infection J:132012
decreased tumor necrosis factor secretion J:132012
increased interferon-gamma secretion J:132012
\Ccr6tm1.1(KOMP)Vlcg/\Ccr6tm1.1(KOMP)Vlcg
(C57BL/6N-Ccr6tm1.1(KOMP)Vlcg/Ucd)
abnormal spleen morphology J:211773
\Ccr6tm1.1Jmf/\Ccr6tm1.1Jmf
(B6.129-Ccr6tm1.1Jmf)
abnormal CD4-positive, alpha-beta T cell physiology J:152716
abnormal dendritic cell physiology J:152716
abnormal interleukin secretion J:152716
decreased inflammatory response J:152716
\Ccr6tm1Gma/\Ccr6tm1Gma
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
abnormal CD4-positive, alpha-beta T cell physiology J:68191
abnormal myeloid dendritic cell morphology J:68191
abnormal Peyer's patch follicle morphology J:68191
abnormal Peyer's patch morphology J:68191
decreased inflammatory response J:68191
decreased leukocyte cell number J:68191
increased leukocyte cell number J:68191
\Ccr6tm1Gma/\Ccr6tm1Gma
\Tg(Rorc-EGFP)1Ebe/?

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
abnormal effector T cell morphology J:137020
\Ccr6tm1Lira/\Ccr6tm1Lira
(involves: 129)
abnormal follicular dendritic cell antigen presentation J:113363
abnormal Peyer's patch T cell area morphology J:113363
abnormal T cell physiology J:123150
\Ccr6tm1Lira/\Ccr6tm1Lira
(involves: 129 * C57BL/6)
abnormal CD4-positive, alpha beta T cell morphology J:148286
abnormal CD4-positive, alpha-beta T cell physiology J:148286
abnormal gut-associated lymphoid tissue morphology J:76461
abnormal intraepithelial T cell number J:76461
abnormal lymphocyte morphology J:148286
abnormal macrophage physiology J:124358
abnormal myeloid dendritic cell morphology J:124358
abnormal peritoneal macrophage morphology J:124358
abnormal Peyer's patch germinal center morphology J:76461
abnormal Peyer's patch morphology J:76461
decreased B cell number J:148286
decreased CD4-positive, alpha-beta T cell number J:148286
decreased CD8-positive, alpha-beta T cell number J:148286
decreased IgA level J:76461
decreased IgG3 level J:76461
decreased inflammatory response J:124358
decreased interleukin-10 secretion J:124358
decreased interleukin-12 secretion J:124358
decreased macrophage cytokine production J:124358
decreased macrophage nitric oxide production J:124358
decreased susceptibility to experimental autoimmune encephalomyelitis J:148286
decreased tumor necrosis factor secretion J:124358
increased activated T cell number J:76461
increased B-1 B cell number J:124358
increased double-positive T cell number J:76461
increased IgM level J:76461
increased susceptibility to Riboviria infection J:76461
increased T cell number J:76461
\Ccr6tm1Lira/\Ccr6tm1Lira
(B6.129-Ccr6tm1Lira)
decreased IgE level J:71096
decreased interleukin-5 secretion J:71096
decreased susceptibility to type I hypersensitivity reaction J:71096
impaired eosinophil recruitment J:71096
\Ccr7m1Btlr/\Ccr7+
(C57BL/6J-Ccr7m1Btlr)
decreased macrophage cell number J:221477
\Ccr7m1Btlr/\Ccr7m1Btlr
(C57BL/6J-Ccr7m1Btlr)
decreased macrophage cell number J:221477
increased single-positive T cell number J:221477
\Ccr7tm1Dgen/\Ccr7tm1Dgen
(involves: 129P2/OlaHsd * C57BL/6)
chronic inflammation J:101679
\Ccr7tm1Rfor/\Ccr7tm1Rfor
(involves: 129P2/OlaHsd * BALB/c)
abnormal B cell activation J:57976
abnormal class switch recombination J:57976
abnormal dendritic cell physiology J:57976
abnormal humoral immune response J:57976
abnormal leukocyte migration J:57976
abnormal lymph node cortex morphology J:57976
abnormal lymph node germinal center morphology J:57976
abnormal lymph node T cell domain morphology J:57976
abnormal Peyer's patch T cell area morphology J:57976
abnormal spleen marginal sinus morphology J:57976
abnormal spleen periarteriolar lymphoid sheath morphology J:57976
abnormal spleen red pulp morphology J:57976
abnormal T cell physiology J:57976
decreased CD4-positive, alpha-beta T cell number J:57976
decreased dendritic cell number J:57976
decreased IgG3 level J:57976
decreased susceptibility to type IV hypersensitivity reaction J:57976
decreased T cell number J:57976
enlarged spleen J:57976
impaired B cell migration J:57976
increased CD4-positive, alpha-beta T cell number J:57976
increased IgE level J:57976
increased IgG1 level J:57976
increased IgG2a level J:57976
increased T cell number J:57976
small lymph nodes J:57976
small Peyer's patches J:57976
\Ccr7tm1Rfor/\Ccr7tm1Rfor
(involves: 129/Sv * 129P2/OlaHsd * C57BL/6)
abnormal dendritic cell physiology J:134784
\Ccr7tm1Rfor/\Ccr7tm1Rfor
(B6.129P2-Ccr7tm1Rfor)
abnormal dendritic cell physiology J:183989
abnormal leukocyte migration J:93960, J:110910
abnormal thymus cortex morphology J:93960
immune system phenotype J:93960
increased inflammatory response J:110910
increased susceptibility to autoimmune disorder J:110910
lacrimal gland inflammation J:110910
parotid gland inflammation J:110910
salivary gland inflammation J:110910
small thymus medulla J:93960
submandibular gland inflammation J:110910
\Ccr7tm1Rfor/\Ccr7tm1Rfor
(B6.129P2(C)-Ccr7tm1Rfor/J)
decreased susceptibility to bacterial infection J:210086
\Ccr7tm1Rfor/\Ccr7tm1Rfor
(involves: 129P2/OlaHsd)
abnormal dendritic cell chemotaxis J:223508
decreased CD11b-high dendritic cell number J:223508
decreased CD103-positive CD11b-low dendritic cell number J:223508
\Ccr7tm1Rfor/\Ccr7tm1Rfor
\Tg(DO11.10)10Dlo/?

(involves: 129P2/OlaHsd * BALB/c * C3H * C57BL/6)
abnormal leukocyte migration J:123482
abnormal regulatory T cell physiology J:123482
\Ccr8tm1Lira/\Ccr8tm1Lira
(involves: 129S/SvEv * C57BL/6)
decreased susceptibility to experimental autoimmune encephalomyelitis J:118417
\Ccr9tm1.1Mal/\Ccr9tm1.1Mal
(involves: 129S2/SvPas * C57BL/6)
abnormal leukocyte cell number J:72386
abnormal T cell differentiation J:72386
decreased double-positive T cell number J:72386
decreased pro-B cell number J:72386
decreased T cell number J:72386
increased T cell number J:72386
\Ccr9tm1.1Mal/\Ccr9tm1.1Mal
(involves: 129S2/SvPas)
abnormal gamma-delta T cell number J:136944
abnormal mesenteric lymph node morphology J:136944
abnormal T cell subpopulation ratio J:136944
decreased gamma-delta intraepithelial T cell number J:136944
\Ccr9tm1.1Mal/\Ccr9tm1.1Mal
\Tnftm2Gkl/\Tnf+

(involves: 129S/SvEv * 129S2/SvPas * C57BL/6)
abnormal alpha-beta intraepithelial T cell morphology J:136667
abnormal T cell subpopulation ratio J:136667
decreased gamma-delta intraepithelial T cell number J:136667
intestinal inflammation J:136667
\Ccr9tm1Ccb/\Ccr9tm1Ccb
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
abnormal T cell differentiation J:94596
decreased thymocyte number J:94596
\Ccr9tm1Lov/\Ccr9tm1Lov
(involves: 129)
abnormal gamma-delta intraepithelial T cell morphology J:110846
decreased CD8-positive, gamma-delta intraepithelial T cell number J:110846
decreased lymphocyte cell number J:110846
increased gamma-delta T cell number J:110846
\Ccr10tm1.1Nax/\Ccr10tm1.1Nax
(B6.129S4(Cg)-Ccr10tm1.1Nax)
decreased gamma-delta intraepithelial T cell number J:165323
\Ccr10tm1Cge/\Ccr10tm1Cge
(C.129S4-Ccr10tm1Cge)
abnormal leukocyte migration J:140728
abnormal plasma cell morphology J:140728
decreased IgA level J:140728
\Ccrl2tm1Lex/\Ccrl2tm1Lex
(involves: 129S/SvEvBrd * C57BL/6)
decreased susceptibility to type I hypersensitivity reaction J:140110
\Ccrl2tm1Ssoz/\Ccrl2tm1Ssoz
(B6.129-Ccrl2tm1Ssoz)
abnormal dendritic cell chemotaxis J:165873
abnormal hypersensitivity reaction J:165873
abnormal T-helper 2 physiology J:165873
decreased interleukin-4 secretion J:165873
decreased interleukin-5 secretion J:165873
decreased interleukin-13 secretion J:165873
lymph node hypoplasia J:165873
\Cd1tm1Gru/\Cd1tm1Gru
(involves: 129S2/SvPas * BALB/c)
abnormal eosinophil cell number J:84720
absent NK T cells J:47769
decreased CD4-positive, alpha-beta T cell number J:126220
decreased interleukin-4 secretion J:47769
decreased susceptibility to infection induced morbidity/mortality J:126220
immune system phenotype J:47769
myocarditis J:126220
\Cd1d1em1(IMPC)H/\Cd1d1em1(IMPC)H
(C57BL/6NTac-Cd1d1em1(IMPC)H/H)
increased basophil cell number J:211773
\Cd1d1tm1.1Aben/\Cd1d1tm1.1Aben
\Lyz2tm1(cre)Ifo/\Lyz2+

(B6.Cg-Cd1d1tm1.1Aben Lyz2tm1(cre)Ifo)
decreased interferon-gamma secretion J:183087
decreased interleukin-4 secretion J:183087
immune system phenotype J:183087
\Cd1d1tm1.1Aben/\Cd1d1tm1.1Aben
\Tg(Cd4-cre)1Cwi/0

(B6.Cg-Cd1d1tm1.1Aben Tg(Cd4-cre)1Cwi)
decreased NK T cell number J:183087
\Cd1d1tm1.1Aben/\Cd1d1tm1.1Aben
\Tg(Itgax-cre,-EGFP)4097Ach/0

(C57BL/6-Cd1d1tm1.1Aben Tg(Itgax-cre,-EGFP)4097Ach)
decreased interferon-gamma secretion J:183087
decreased interleukin-4 secretion J:183087
immune system phenotype J:183087
\Cd1d1tm1.1Boes/\Cd1d1tm1.1Boes
(involves: C57BL/6)
abnormal dendritic cell antigen presentation J:151699
abnormal interleukin-4 secretion J:151699
abnormal NK T cell morphology J:151699
abnormal NK T cell physiology J:151699
decreased interleukin-2 secretion J:151699
decreased NK T cell number J:151699
\Cd1d1tm1.1Boes/\Cd1d1tm1.1Boes
\Cd74tm1Doi/\Cd74tm1Doi

(involves: 129S2/SvPas * C57BL/6)
abnormal dendritic cell antigen presentation J:151699
\Cd1d1tm1.2Aben/\Cd1d1tm1.2Aben
(B6(C)-Cd1d1tm1.2Aben/J)
abnormal CD4-positive T cell differentiation J:177038
abnormal T cell activation J:177038
increased susceptibility to bacterial infection J:177038
increased susceptibility to bacterial infection induced morbidity/mortality J:177038
lung inflammation J:177038
\Cd1d1tm1Crw/\Cd1d1tm1Crw
(involves: 129S4/SvJae * C57BL/6)
decreased NK T cell number J:76976
\Cd1d1tm1Crw/\Cd1d1tm1Crw
(B6.129S4-Cd1d1tm1Crw)
decreased IgG level J:99107
decreased susceptibility to induced arthritis J:99107
\Cd1d1tm1Luc/\Cd1d1tm1Luc
(B6.129S6-Cd1d1tm1Luc)
autoimmune response J:122245
decreased regulatory T cell number J:122245
\Cd1d1tm1Luc/\Cd1d1tm1Luc
(involves: 129S6/SvEvTac * C57BL/6)
arrested T cell differentiation J:125679
decreased acute inflammation J:93915
decreased interferon-gamma secretion J:93915, J:39748
decreased interleukin-4 secretion J:39748
decreased NK T cell number J:39748
decreased tumor necrosis factor secretion J:93915
\Cd1d1tm1Luc/\Cd1d1tm1Luc
(C.129S6-Cd1d1tm1Luc)
decreased interleukin-4 secretion J:121187
glomerulonephritis J:121187
increased anti-double stranded DNA antibody level J:121187
increased anti-nuclear antigen antibody level J:121187
increased IgG3 level J:121187
kidney inflammation J:121187
\Cd1d1tm1Luc/\Cd1d1tm1Luc
\Cx3cr1tm1Litt/\Cx3cr1tm1Litt

(B6.129-Cd1d1tm1Luc Cx3cr1tm1Litt)
decreased NK cell number J:129712
increased susceptibility to experimental autoimmune encephalomyelitis J:129712
\Cd1d1tm2Aben/\Del(3Cd1d2-Cd1d1)1Crw
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)
abnormal antigen presentation J:174337
\Cd1d1tm2Aben/\Cd1d1tm2Aben
(B6.129P2-Cd1d1tm2Aben)
abnormal antigen presentation J:174337
decreased NK T cell number J:174337
\Cd1d1tm2Aben/\Cd1d1tm2Aben
(involves: 129P2/OlaHsd * C57BL/6)
abnormal antigen presentation J:174337
decreased NK T cell number J:174337
\Cd2apem1Irgu/\Cd2apem1Irgu
(C57BL/6-Cd2apem1Irgu)
kidney inflammation J:294238
\Cd2aptm1Shaw/\Cd2aptm1Shaw
(involves: 129X1/SvJ)
decreased T cell proliferation J:57971
spleen atrophy J:57971
thymus atrophy J:57971
\Cd2bp2tm1.1Tbh/\Cd2bp2tm1.1Tbh
\Tg(Mx1-cre)1Cgn/0

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * C57BL/6N * CBA/J)
impaired macrophage phagocytosis J:283435
\Cd3dtm1Kap/\Cd3dtm1Kap
(C57BL/6-Cd3dtm1Kap)
arrested T cell differentiation J:39925
decreased CD4-positive, alpha-beta T cell number J:39925
decreased CD8-positive, alpha-beta T cell number J:39925
\Cd3em1Btlr/\Cd3em1Btlr
(C57BL/6J-Cd3em1Btlr)
abnormal thymus morphology J:132486
absent T cells J:132486
arrested T cell differentiation J:132486
increased T cell apoptosis J:132486
small thymus J:132486
\Cd3em1Btlr/\Cd3em1Btlr
(involves: C57BL/6J)
abnormal class switch recombination J:185495
\Cd3em2Btlr/\Cd3em2Btlr
(C57BL/6J-Cd3em2Btlr)
abnormal CD8-positive, alpha-beta T cell differentiation J:274934
abnormal T cell differentiation J:274934
decreased CD4-positive, alpha-beta T cell number J:274934
decreased CD8-positive, naive alpha-beta T cell number J:274934
increased CD8-positive, alpha-beta T cell number J:274934
increased central memory CD8 positive, alpha-beta T cell number J:274934
\Cd3etm1.1Geno/\Cd3etm1.1Geno
(involves: C57BL/6)
abnormal double-positive T cell morphology J:192604
abnormal T cell differentiation J:192604
abnormal T cell number J:192604
increased DN3 thymocyte number J:192604
\Cd3etm1.1Geno/\Cd3etm1.1Geno
\Tg(TcraH-Y,TcrbH-Y)71Vbo/0

(involves: C57BL/6 * C57BL/6J * DBA/2J)
abnormal negative T cell selection J:192604
abnormal positive T cell selection J:192604
increased DN3 thymocyte number J:192604
\Cd3etm1.1Geno/\Cd3etm1.1Geno
\Tg(TcrAND)53Hed/0

(involves: C57BL/6 * SJL)
abnormal CD4-positive T cell differentiation J:192604
abnormal positive T cell selection J:192604
increased DN3 thymocyte number J:192604
\Cd3etm1.1Geno/\Cd3etm1.1Geno
\Tg(TcraTcrb)1100Mjb/0

(involves: C57BL/6)
abnormal positive T cell selection J:192604
abnormal T cell differentiation J:192604
abnormal thymus cell ratio J:192604
decreased double-positive T cell number J:192604
decreased T cell number J:192604
increased DN3 thymocyte number J:192604
\Cd3etm1.1Lov/\Cd3etm1.1Lov
(Not Specified)
abnormal T cell morphology J:72144
arrested T cell differentiation J:72144
decreased double-positive T cell number J:72144
increased double-negative T cell number J:72144
\Cd3etm1.1Lov/\Cd3etm1.1Lov
\Trdctm1Mal/\Trdctm1Mal

(involves: C57BL/6)
abnormal double-negative T cell morphology J:112658
\Cd3etm1Cpt/\Cd3etm1Cpt
(involves: 129S4/SvJae * C57BL/6)
absent T cells J:54756
decreased double-positive T cell number J:54756
thymus hypoplasia J:54756
\Cd3etm1Cpt/\Cd3etm1Cpt
\Tg(CD3E)26Cpt/0

(involves: 129S4/SvJae * C57BL/6 * CBA)
decreased double-positive T cell number J:54756
decreased T cell number J:54756
thymus hypoplasia J:54756
\Cd3etm1Lov/\Cd3etm1Lov
(involves: 129S1/Sv * 129X1/SvJ)
abnormal T cell morphology J:72144
arrested T cell differentiation J:72144
decreased double-positive T cell number J:72144
increased double-negative T cell number J:72144
\Cd3etm1Mal/\Cd3etm1Mal
(involves: C57BL/6)
absent CD4-positive, alpha-beta T cells J:77098
absent CD8-positive, alpha-beta T cells J:77098
arrested T cell differentiation J:77098
\Cd3etm1Mal/\Cd3etm1Mal
(C57BL/6-Cd3etm1Mal)
abnormal B cell morphology J:81133
abnormal double-negative T cell morphology J:81133
abnormal regulatory T cell physiology J:125748
absent T cells J:131351
arrested T cell differentiation J:81133
\Cd3etm1Mal/\Cd3etm1Mal
\Lattm1.1Mal/\Lattm1.1Mal

(involves: 129S2/SvPas * C57BL/6)
absent CD4-positive, alpha-beta T cells J:77098
absent CD8-positive, alpha-beta T cells J:77098
arrested T cell differentiation J:77098
immune system phenotype J:77098
\Cd3etm1Mal/\Cd3etm1Mal
\Nlrp1aNeut1/\Nlrp1aNeut1

(involves: C57BL/6)
increased neutrophil cell number J:191055
increased susceptibility to infection induced morbidity/mortality J:191055
skin inflammation J:191055
\Cd3gtm1.1Cage/\Cd3gtm1.1Cage
(B6.129P2-Cd3gtm1.1Cage)
abnormal response to infection J:153813
decreased CD8-positive, alpha-beta T cell number J:153813
decreased thymocyte number J:153813
increased T cell apoptosis J:153813
spleen hypoplasia J:153813
\Cd3gtm1.1Cage/\Cd3gtm1.1Cage
\Tg(TcrLCMV)318Sdz/0

(involves: 129P2/OlaHsd * C57BL/6 * DBA/2 * FVB/N)
abnormal response to infection J:142387
abnormal T cell physiology J:142387
immune system phenotype J:142387
\Cd3gtm1Amk/\Cd3gtm1Amk
(involves: 129P2/OlaHsd)
abnormal CD8-positive, alpha-beta T cell physiology J:77504
abnormal T cell activation J:77504
abnormal T cell differentiation J:77504
abnormal T cell physiology J:77504
abnormal T cell proliferation J:77504
decreased cytotoxic T cell cytolysis J:77504
decreased thymocyte number J:114561
lymph node hypoplasia J:77504
thymus hypoplasia J:77504
\Cd3gtm1Amk/\Cd3gtm1Amk
\Tg(Igh-Pim1)1Brn/0

(involves: 129P2/OlaHsd * C57BL/6LiA * CBA)
decreased thymocyte number J:114561
\Cd3gtm2Amk/\Cd3gtm2Amk
(involves: 129P2/OlaHsd * FVB)
immune system phenotype J:77504
\Cd4del/\Cd4del
(C57BR/cdJ-Cd4del)
abnormal immune system organ morphology J:46692
abnormal lymph node T cell domain morphology J:46692
abnormal spleen morphology J:46692
absent CD4-positive, alpha-beta T cells J:46692
decreased IgG level J:46692
decreased IgM level J:46692
decreased immunoglobulin level J:46692
increased CD8-positive, alpha-beta T cell number J:46692
\Cd4em1Litt/\Cd4em1Litt
(involves: C57BL/6J)
immune system phenotype J:333574
\Cd4em1Litt/\Cd4em1Litt
\Rr386em1Pdi/\Rr386em1Pdi

(involves: C57BL/6J)
abnormal lymphocyte activation involved in immune response J:333574
decreased T helper 1 cell number J:333574
immune system phenotype J:333574
\Cd4m1Btlr/\Cd4m1Btlr
(C57BL/6J-Cd4m1Btlr)
absent CD4-positive, alpha-beta T cells J:212900
impaired humoral immune response J:212900
\Cd4maat/\Cd4maat
(C57BL/6JAnu-Cd4maat/Apb)
abnormal CD4-positive, alpha beta T cell morphology J:104190
abnormal double-positive T cell morphology J:104190
decreased CD4-positive, alpha-beta T cell number J:104190
increased CD8-positive, alpha-beta T cell number J:104190
\Cd4sesh/\Cd4sesh
(C57BL/6JAnu-Cd4sesh/AnuApb)
abnormal CD4-positive, alpha beta T cell morphology J:104190
abnormal double-positive T cell morphology J:104190
decreased T cell number J:104190
\Cd4thth/\Cd4thth
(C57BL/6JSfdAnu-Cd4thth)
absent CD4-positive, alpha-beta T cells J:104190
\Cd4tm1(cre/ERT2)Thbu/\Cd4+
\Gfm1tm1c(EUCOMM)Wtsi/\Gfm1tm1c(EUCOMM)Wtsi

(involves: C57BL/6 * C57BL/6N * SJL)
abnormal T-helper 17 cell differentiation J:302272
decreased susceptibility to experimental autoimmune encephalomyelitis J:302272
increased CD8-positive, alpha-beta T cell number J:302272
increased single-positive T cell number J:302272
\Cd4tm1(cre/ERT2)Thbu/\Cd4+
\Tgfbr2tm1Karl/\Tgfbr2tm1Karl

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
immune system phenotype J:204579
increased memory T cell number J:204579
increased regulatory T cell number J:204579
\Cd4tm1Doi/\Cd4tm1Doi
\Lag3tm1Doi/\Lag3tm1Doi

(involves: 129 * C57BL/6)
abnormal CD4-positive, alpha-beta T cell physiology J:33272
increased double-negative T cell number J:33272
\Cd4tm1Doi/\Cd4tm1Litt
\Lag3tm1Doi/\Lag3+

(involves: 129 * C57BL/6)
abnormal CD4-positive, alpha-beta T cell physiology J:33272
increased double-negative T cell number J:33272
\Cd4tm1Jrp/\Cd4tm1Jrp
(either: B6.129S2-Cd4tm1Jrp or B10.Cg-Cd4tm1Jrp)
abnormal T cell differentiation J:45168
decreased CD4-positive, alpha-beta T cell number J:45168
decreased double-positive T cell number J:45168
increased CD8-positive, alpha-beta T cell number J:45168
\Cd4tm1Jrp/\Cd4tm1Jrp
\Tg(TcrAND)53Hed/0

(either: (involves: 129S2/SvPas * C57BL/6 * SJL) or (involves: 129S2/SvPas * C57BL/6 * C57BL/10 * SJL))
abnormal T cell number J:45168
thymus hyperplasia J:45168
\Cd4tm1Knw/\Cd4tm1Knw
(B6.129S-Cd4tm1Knw/J)
decreased CD4-positive, alpha-beta T cell number J:87828
increased CD8-positive, alpha-beta T cell number J:87828
increased susceptibility to parasitic infection J:87828
\Cd4tm1Knw/\Cd4tm1Knw
(NOD.Cg-Cd4tm1Knw)
decreased susceptibility to autoimmune diabetes J:93553
\Cd4tm1Knw/\Cd4tm1Knw
\Tg(TcraAI4)1Dvs/0
\Tg(TcrbAI4)1Dvs/0

(NOD.Cg-Cd4tm1Knw Tg(TcraAI4)1Dvs Tg(TcrbAI4)1Dvs)
increased susceptibility to autoimmune diabetes J:93553
\Cd4tm1Litt/\Cd4tm1Litt
(involves: 129S2/SvPas)
abnormal CD4-positive, alpha-beta T cell physiology J:50435
absent CD4-positive, alpha-beta T cells J:50435
decreased CD4-positive, alpha-beta T cell number J:158962
decreased T cell proliferation J:50435
increased CD8-positive, alpha-beta T cell number J:158962, J:50435
\Cd4tm1Litt/\Cd4tm1Litt
\Foxp3sf\Otcspf/Y

(involves: 129/Rl * 129S2/SvPas)
abnormal CD8-positive, alpha beta T cell morphology J:20865
abnormal cytokine secretion J:20865
abnormal immune system organ morphology J:20865
enlarged lymph nodes J:20865
increased IgG level J:20865
increased IgM level J:20865
increased interleukin-4 secretion J:20865
increased interleukin-6 secretion J:20865
increased tumor necrosis factor secretion J:20865
\Cd4tm1Litt/\Cd4tm1Litt
\Tg(Cd4-CD4)2362Litt/0

(involves: 129S2/SvPas * C57BL/6 * SJL)
immune system phenotype J:50435
\Cd4tm1Litt/\Cd4tm1Nik
\Tg(Lck-cre)3778Nik/0

(involves: 129S2/SvPas * 129X1/SvJ * C57BL/6 * DBA/2)
abnormal CD4-positive, alpha-beta T cell physiology J:73479
abnormal interleukin-4 secretion J:73479
abnormal T-helper 2 physiology J:73479
decreased T cell proliferation J:73479
\Cd4tm1Litt/\Cd4tm1Nik
\Tg(Lck-cre)3785Nik/0

(involves: 129S2/SvPas * 129X1/SvJ * C57BL/6 * DBA/2)
abnormal CD4-positive, alpha-beta T cell physiology J:73479
decreased CD4-positive, alpha-beta T cell number J:73479
increased CD8-positive, alpha-beta T cell number J:73479
increased T cell apoptosis J:73479
increased T cell proliferation J:73479
\Cd4tm1Litt/\Cd4tm1Nik
\Tg(Lck-icre)3779Nik/0

(involves: 129S2/SvPas * 129X1/SvJ * C57BL/6 * DBA/2)
abnormal CD4-positive, alpha-beta T cell physiology J:73479
decreased T cell proliferation J:73479
\Cd4tm1Mak/\Cd4tm1Mak
(involves: 129S2/SvPas * C57BL/6 * DBA/2)
abnormal CD4-positive, alpha-beta T cell physiology J:68957
increased CD8-positive, alpha-beta T cell number J:68957
increased susceptibility to Picornaviridae infection J:92227
\Cd4tm1Mak/\Cd4tm1Mak
(PL.129S2(B6)-Cd4tm1Mak/Rdgz)
brain inflammation J:92227
increased susceptibility to Picornaviridae infection J:92227
\Cd4tm1Mak/\Cd4tm1Mak
(SJL.129S2(B6)-Cd4tm1Mak/Rdgz)
brain inflammation J:92227
increased susceptibility to Picornaviridae infection J:92227
\Cd4tm1Mak/\Cd4tm1Mak
(involves: 129S2/SvPas)
immune system phenotype J:110749
\Cd4tm1Mak/\Cd4tm1Mak
(B6.129S2-Cd4tm1Mak/J)
absent plasma cells J:133047
immune system phenotype J:133047
\Cd4tm1Mak/\Cd4tm1Mak
\Cd8atm1Mak/\Cd8atm1Mak

(involves: 129S2/SvPas * C57BL/6 * DBA/2)
abnormal double-negative T cell morphology J:12572
abnormal gamma-delta T cell number J:12572
abnormal T cell differentiation J:12572
abnormal T cell number J:12572
decreased cytotoxic T cell cytolysis J:12572
decreased double-positive T cell number J:12572
increased length of allograft survival J:12572
small thymus medulla J:12572
\Cd4tm1Mak/\Cd4tm1Mak
\Cd8atm1Mak/\Cd8atm1Mak

(involves: 129S2/SvPas)
increased susceptibility to viral infection J:110749
\Cd4tm1Mak/\Cd4tm1Mak
\Igh-Jtm2(3H9-VDJ*)Mwg/\Igh-J+

(B6.Cg-Cd4tm1Mak Igh-Jtm2(3H9-VDJ*)Mwg)
increased anti-double stranded DNA antibody level J:142389
\Cd4tm1Mak/\Cd4tm1Mak
\Tnftm2Gkl/\Tnf+

(involves: 129S/SvEv * 129S2/SvPas * C57BL/6J)
small intestinal inflammation J:108572
\Cd4tm1Nik/\Cd4tm1Nik
\Tnfrsf4tm2(cre)Nik/\Tnfrsf4+

(involves: 129X1/SvJ)
abnormal regulatory T cell physiology J:152472
\Cd4ts1BALB/c/?
(involves: BALB/c * C3H * C57BL/6 * DBA/2)
abnormal CD4-positive, alpha beta T cell morphology J:83220
\Cd4ts2DBA/2/?
(involves: BALB/c * C3H * C57BL/6 * DBA/2)
abnormal CD4-positive, alpha beta T cell morphology J:83220
\Cd4ts3BALB/c/?
(involves: BALB/c * C3H * C57BL/6 * DBA/2)
abnormal CD4-positive, alpha beta T cell morphology J:83220
\Cd4ts4C3H/?
(involves: BALB/c * C3H * C57BL/6 * DBA/2)
abnormal CD4-positive, alpha beta T cell morphology J:83220
\Cd4ts5BALB/c/?
(involves: BALB/c * C3H * C57BL/6 * DBA/2)
abnormal CD4-positive, alpha beta T cell morphology J:83220
\Cd4ts5C57BL/6/?
(involves: BALB/c * C3H * C57BL/6 * DBA/2)
increased memory T cell number J:83220
\Cd4ts6DBA/2/?
(involves: BALB/c * C3H * C57BL/6 * DBA/2)
abnormal CD4-positive, alpha beta T cell morphology J:83220
\Cd4vts1DBA/2/?
(involves: BALB/c * C3H * C57BL/6 * DBA/2)
abnormal CD4-positive, alpha beta T cell morphology J:83220
\Cd5tm1.1(KOMP)Mbp/\Cd5tm1.1(KOMP)Mbp
(C57BL/6N-Cd5tm1.1(KOMP)Mbp/Ucd)
abnormal spleen morphology J:211773
enlarged spleen J:211773
increased spleen weight J:211773
\Cd5tm1.1Chra/\Cd5tm1.1Chra
(involves: C57BL/6 * FVB/N)
abnormal T cell anergy J:189919
abnormal T cell physiology J:189919
decreased B cell number J:189919
decreased CD4-positive, alpha-beta T cell number J:189919
decreased double-positive T cell number J:189919
decreased follicular B cell number J:189919
decreased susceptibility to experimental autoimmune encephalomyelitis J:189919
decreased T cell proliferation J:189919
decreased T-helper 17 cell number J:189919
increased double-negative T cell number J:189919
increased T cell proliferation J:189919
\Cd5tm1.1Chra/\Cd5tm1.1Chra
\Tg(Tcra2D2,Tcrb2D2)1Kuch/0

(involves: C57BL/6 * FVB/N)
decreased interferon-gamma secretion J:189919
decreased interleukin-2 secretion J:189919
decreased T cell proliferation J:189919
decreased T helper 1 cell number J:189919
increased interferon-gamma secretion J:189919
increased interleukin-6 secretion J:189919
increased interleukin-17 secretion J:189919
\Cd5tm1Cgn/\Cd5tm1Cgn
(B6.129P2-Cd5tm1Cgn)
abnormal T cell anergy J:189919
decreased susceptibility to experimental autoimmune encephalomyelitis J:189919
increased regulatory T cell number J:189919
increased T cell proliferation J:189919
\Cd5ltm1Nto/\Cd5ltm1Nto
(involves: 129P2/OlaHsd * C57BL/6)
abnormal double-positive T cell morphology J:52195
decreased thymocyte number J:52195
immune system phenotype J:52195
increased susceptibility to bacterial infection J:82352
\Cd6tm1Linf/\Cd6tm1Linf
(D1.Cg-Cd6tm1Linf)
abnormal B cell physiology J:238478
decreased B cell proliferation J:238478
decreased B-1 B cell number J:238478
decreased B-1a cell number J:238478
decreased IgM level J:238478
decreased interleukin-6 secretion J:238478
increased B-1a cell number J:238478
increased B-1b cell number J:238478
\Cd7tm1Bfh/\Cd7tm1Bfh
(involves: 129 * C57BL/6)
immune system phenotype J:48758
increased double-positive T cell number J:48758
increased thymocyte number J:48758
\Cd7tm1Bfh/\Cd7tm1Bfh
(B6.129-Cd7tm1Bfh)
decreased cytotoxic T cell cytolysis J:48758
decreased interferon-gamma secretion J:48758
immune system phenotype J:48758
increased double-positive T cell number J:48758
increased thymocyte number J:48758
\Cd7tm1Fabo/\Cd7tm1Fabo
(involves: 129S4/SvJae * C57BL/6)
immune system phenotype J:45026
\Cd8am1Btlr/\Cd8am1Btlr
(C57BL/6J-Cd8am1Btlr)
abnormal CD4-positive T cell differentiation J:221492
abnormal CD8-positive, alpha-beta T cell differentiation J:221492
increased susceptibility to Herpesvirales infection J:221492
\Cd8am2Btlr/\Cd8am2Btlr
(C57BL/6J-Cd8am2Btlr)
abnormal CD8-positive, alpha-beta T cell physiology J:236677
increased CD8-positive, alpha-beta memory T cell proliferation J:236677
\Cd8atm1.1(cre)Koni/\Cd8atm1.1(cre)Koni
(involves: C57BL/6J * C57BL/6NHsd * SJL)
decreased CD8-positive, alpha-beta T cell number J:177182
\Cd8atm1.1Kio/\Cd8atm1.1Kio
(involves: 129S4/SvJae * C57BL/10 * CBA/Ca)
abnormal CD4-positive T cell differentiation J:76799
\Cd8atm1.1Litt/\Cd8atm1.1Litt
(either: (involves: 129P2/OlaHsd * AKR) or (involves: 129P2/OlaHsd * C57BL/6))
abnormal CD8-positive, alpha beta T cell morphology J:50624
\Cd8atm1.1Welm/\Cd8atm1.1Welm
(involves: 129P2/OlaHsd * C57BL/6)
immune system phenotype J:113136
\Cd8atm1Asin/\Cd8atm1Asin
(involves: 129S1/Sv * 129X1/SvJ * FVB/N)
abnormal double-positive T cell morphology J:126026
\Cd8atm1Asin/\Cd8atm1Asin
\Cd8b1tm1Litt/\Cd8b1tm1Litt
\H2-Ab1b-tm1Gru/\H2-Ab1b-tm1Gru

(involves: 129 * FVB/N)
decreased CD4-positive, alpha-beta T cell number J:126026
increased CD8-positive, alpha-beta T cell number J:126026
\Cd8atm1Asin/\Cd8atm1Asin
\Rag2tm1Fwa/\Rag2tm1Fwa
\Tg(TcraH-Y,TcrbH-Y)71Vbo/?

(involves: 129S/SvEv * 129S1/Sv * 129X1/SvJ * C57BL/6J * DBA/2J)
abnormal CD8-positive, alpha beta T cell morphology J:125259
\Cd8atm1Asin/\Cd8atm1Asin
\Tg(CD2-TcraF5,CD2-TcrbF5)1Kio/?

(involves: 129S1/Sv * 129X1/SvJ * C57BL/10 * FVB/N)
abnormal positive T cell selection J:126026
decreased CD4-positive, alpha-beta T cell number J:126026
increased CD8-positive, alpha-beta T cell number J:126026
\Cd8atm1Asin/\Cd8atm1Mak
(involves: 129S1/Sv * 129S2/SvPas * 129X1/SvJ * FVB/N)
abnormal positive T cell selection J:126026
abnormal T cell subpopulation ratio J:126026
increased CD8-positive, alpha-beta T cell number J:126026
\Cd8atm1Mak/\Cd8atm1Mak
(involves: 129S2/SvPas * C57BL/6 * DBA/2)
abnormal cytotoxic T cell physiology J:68956
absent CD8-positive, alpha-beta T cells J:68956
increased susceptibility to Picornaviridae infection J:92227
\Cd8atm1Mak/\Cd8atm1Mak
(PL.129S2(B6)-Cd8atm1Mak/Rdgz)
increased susceptibility to Picornaviridae infection J:92227
\Cd8atm1Mak/\Cd8atm1Mak
(SJL.129S2(B6)-Cd8atm1Mak/Rdgz)
increased susceptibility to Picornaviridae infection J:92227
\Cd8atm1Mak/\Cd8atm1Mak
(B6.129S2-Cd8atm1Mak)
abnormal response to transplant J:91742
\Cd8atm1Mak/\Cd8atm1Mak
(involves: 129S2/SvPas)
immune system phenotype J:110749
\Cd8atm1Mak/\Cd8atm1Mak
\Il15tm1Imx/\Il15tm1Imx
X/\Yaa

(BXSB.Cg-Cd8atm1Mak Il15tm1Imx/Dcr)
abnormal spleen B cell follicle morphology J:179430
increased anti-nuclear antigen antibody level J:179430
increased IgG1 level J:179430
increased IgG2a level J:179430
increased IgG2b level J:179430
increased monocyte cell number J:179430
increased splenocyte number J:179430
increased susceptibility to systemic lupus erythematosus J:179430
\Cd8atm1Mak/\Cd8atm1Mak
X/\Yaa

(BXSB.129S2(B6)-Cd8atm1Mak/4Dcr)
increased susceptibility to systemic lupus erythematosus J:179430
\Cd8atm1Mak/\Cd8atm1Mak
\Zbtb7bhd/\Zbtb7bhd

(involves: B6.129S2-Cd8atm1Mak * B6.Cg-Thpokhd)
absent CD4-positive, alpha-beta T cells J:95867
\Cd8b1M1Btlr/\Cd8b1+
(C57BL/6J-Cd8b1M1Btlr)
decreased CD8-positive, naive alpha-beta T cell number J:255009
increased CD4-positive, alpha-beta T cell number J:255009
\Cd8b1M1Btlr/\Cd8b1M1Btlr
(C57BL/6J-Cd8b1M1Btlr)
decreased CD8-positive, naive alpha-beta T cell number J:255009
enhanced humoral immune response J:255009
increased CD4-positive, alpha-beta T cell number J:255009
increased IgG level J:255009
\Cd8b1m2Btlr/\Cd8b1m2Btlr
(C57BL/6J-Cd8b1m2Btlr)
abnormal B cell differentiation J:274761
abnormal CD8-positive, alpha-beta T cell differentiation J:274761
decreased CD8-positive, alpha-beta T cell number J:274761
decreased CD8-positive, naive alpha-beta T cell number J:274761
decreased T cell number J:274761
increased CD4-positive, alpha-beta T cell number J:274761
increased central memory CD8 positive, alpha-beta T cell number J:274761
increased effector memory CD8-positive, alpha-beta T cell number J:274761
\Cd8b1tm1Litt/\Cd8b1+
\Tg(Cd8b1)46Erob/0

(involves: 129S4/SvJae * C57BL/6 * CBA)
abnormal T cell subpopulation ratio J:110916
decreased T cell number J:110916
decreased thymocyte number J:110916
\Cd8b1tm1Litt/\Cd8b1+
\Tg(TcraH-Y,TcrbH-Y)71Vbo/0

(involves: 129S4/SvJae * C57BL/6J * DBA/2)
decreased double-positive T cell number J:112551
\Cd8b1tm1Litt/\Cd8b1tm1Litt
(involves: 129S4/SvJae * C57BL/6J)
abnormal cytotoxic T cell physiology J:112551
abnormal T cell subpopulation ratio J:110916
decreased CD8-positive, alpha-beta T cell number J:112551, J:110916
decreased thymocyte number J:110916
\Cd8b1tm1Litt/\Cd8b1tm1Litt
\Tg(TcraH-Y,TcrbH-Y)71Vbo/0

(involves: 129S4/SvJae * C57BL/6J * DBA/2)
abnormal lymph node cell ratio J:112551
abnormal negative T cell selection J:112551
abnormal positive T cell selection J:112551
decreased CD8-positive, alpha-beta T cell number J:112551
increased CD4-positive, alpha-beta T cell number J:112551
\Cd8b1tm1Wpfl/\Cd8b1tm1Wpfl
(involves: 129S2/SvPas)
abnormal CD8-positive, alpha beta T cell morphology J:19928
abnormal CD8-positive, alpha-beta T cell differentiation J:19928
abnormal T cell subpopulation ratio J:19928
decreased CD8-positive, alpha-beta T cell number J:19928
decreased thymocyte number J:19928
immune system phenotype J:19928
\Cd8mts1DBA/2/?
(involves: BALB/c * C3H * C57BL/6 * DBA/2)
increased memory T cell number J:83220
\Cd8mts2BALB/c/?
(involves: BALB/c * C3H * C57BL/6 * DBA/2)
increased memory T cell number J:83220
\Cd8mts3C57BL/6/?
(involves: BALB/c * C3H * C57BL/6 * DBA/2)
increased memory T cell number J:83220
\Cd8mts4DBA/2/?
(involves: BALB/c * C3H * C57BL/6 * DBA/2)
increased memory T cell number J:83220
\Cd8mts5BALB/c/?
(involves: BALB/c * C3H * C57BL/6 * DBA/2)
abnormal CD4-positive, alpha beta T cell morphology J:83220
\Cd8mts5C57BL/6/?
(involves: BALB/c * C3H * C57BL/6 * DBA/2)
increased memory T cell number J:83220
\Cd8mts6C3H/?
(involves: BALB/c * C3H * C57BL/6 * DBA/2)
increased CD8-positive, alpha-beta T cell number J:83220
\Cd8ts1DBA/2/?
(involves: BALB/c * C3H * C57BL/6 * DBA/2)
increased CD8-positive, alpha-beta T cell number J:83220
\Cd8ts2C57BL/6/?
(involves: BALB/c * C3H * C57BL/6 * DBA/2)
increased CD8-positive, alpha-beta T cell number J:83220
\Cd8ts3C3H/?
(involves: BALB/c * C3H * C57BL/6 * DBA/2)
increased CD8-positive, alpha-beta T cell number J:83220
\Cd8ts3DBA/2/?
(involves: BALB/c * C3H * C57BL/6 * DBA/2)
abnormal CD4-positive, alpha beta T cell morphology J:83220
\Cd14hdl/\Cd14hdl
(C57BL/6-Cd14hdl)
abnormal interferon secretion J:98908
decreased susceptibility to endotoxin shock J:98908
decreased tumor necrosis factor secretion J:98908
increased susceptibility to Riboviria infection J:98908
\Cd14tm1Frm/\Cd14+
(involves: 129S4/SvJae * C57BL/6J)
abnormal cytokine secretion J:65107
decreased interleukin-6 secretion J:65107
decreased tumor necrosis factor secretion J:65107
\Cd14tm1Frm/\Cd14tm1Frm
(involves: 129S4/SvJae * C57BL/6J)
abnormal cytokine secretion J:65107
decreased interleukin-6 secretion J:65107
decreased tumor necrosis factor secretion J:65107
\Cd14tm1Frm/\Cd14tm1Frm
(involves: 129S4/SvJae)
abnormal interferon secretion J:98908
decreased susceptibility to endotoxin shock J:98908
increased susceptibility to Riboviria infection J:98908
\Cd14tm1Frm/\Cd14tm1Frm
(B6.129S4-Cd14tm1Frm)
abnormal cytokine level J:96680
abnormal interleukin level J:96680
abnormal tumor necrosis factor level J:96680
\Cd14tm1Smg/\Cd14tm1Smg
(involves: 129S1/Sv * C57BL/6)
decreased circulating interleukin-6 level J:32729
decreased circulating tumor necrosis factor level J:32729
decreased interleukin-6 secretion J:32729
decreased susceptibility to bacterial infection J:32729
decreased susceptibility to bacterial infection induced morbidity/mortality J:32729
decreased susceptibility to endotoxin shock J:32729
decreased tumor necrosis factor secretion J:32729
\Cd14tm1Smg/\Cd14tm1Smg
(C.129S1-CD14tm1Smg)
abnormal macrophage physiology J:116691
abnormal neutrophil physiology J:127072
decreased susceptibility to bacterial infection J:127072
decreased tumor necrosis factor secretion J:116691
\Cd14tm1Smg/\Cd14tm1Smg
(B6.129S1-CD14tm1Smg)
decreased susceptibility to bacterial infection J:127072
\Cd14tm1Smg/\Cd14tm1Smg
(involves: 129S1/Sv)
abnormal tumor necrosis factor level J:103464
\Cd14tm1Smg/\Cd14tm1Smg
\Tlr4Lps-d/\Tlr4Lps-d

(C3.129S1-CD14tm1Smg)
abnormal macrophage physiology J:116691
decreased tumor necrosis factor secretion J:116691
\Cd19em2(IMPC)Ics/\Cd19em2(IMPC)Ics
(C57BL/6N-Cd19em2(IMPC)Ics/Ics)
decreased lymphocyte cell number J:211773
increased monocyte cell number J:211773
\Cd19tm1(cre)Cgn/?
\Gt(ROSA)26Sortm1(HBEGF)Awai/\Gt(ROSA)26Sortm1(HBEGF)Awai

(involves: 129P2/OlaHsd * C57BL/6)
abnormal B cell morphology J:131076
abnormal lymph node cell ratio J:131076
abnormal lymphocyte cell number J:131076
abnormal lymphocyte morphology J:131076
abnormal splenic cell ratio J:131076
absent immature B cells J:131076
absent mature B cells J:131076
\Cd19tm1(cre)Cgn/\Cd19+
\Cd1d1tm1.1Aben/\Cd1d1tm1.1Aben

(B6.Cg-Cd1d1tm1.1Aben Cd19tm1(cre)Cgn)
immune system phenotype J:183087
\Cd19tm1(cre)Cgn/\Cd19+
\Ctnnbl1tm1.1Crad/\Ctnnbl1tm1.1Crad

(involves: 129P2/OlaHsd * C57BL/6 * SJL)
decreased B cell proliferation J:232010
\Cd19tm1(cre)Cgn/\Cd19+
\Cxcr4tm1Tng/\Cxcr4tm2Tng

(involves: 129P2/OlaHsd * C57BL/6)
decreased plasma cell number J:109147
\Cd19tm1(cre)Cgn/\Cd19+
\Derl2tm1.1Hpl/\Derl2tm1.1Hpl

(involves: 129P2/OlaHsd)
immune system phenotype J:170650
\Cd19tm1(cre)Cgn/\Cd19+
\Ell2tm1.1Cmil/\Ell2tm1.1Cmil

(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6)
decreased IgA level J:234692
decreased IgG1 level J:234692
decreased IgM level J:234692
decreased immunoglobulin level J:234692
decreased mature B cell number J:234692
decreased plasma cell number J:234692
decreased transitional stage T1 B cell number J:234692
decreased transitional stage T2 B cell number J:234692
decreased transitional stage T3 B cell number J:234692
impaired humoral immune response J:234692
increased follicular B cell number J:234692
increased immature B cell number J:234692
increased pre-B cell number J:234692
increased pro-B cell number J:234692
\Cd19tm1(cre)Cgn/\Cd19+
\Ell2tm2.1Cmil/\Ell2tm2.1Cmil

(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6)
decreased IgA level J:234692
decreased IgG1 level J:234692
decreased IgM level J:234692
decreased immunoglobulin level J:234692
decreased mature B cell number J:234692
\Cd19tm1(cre)Cgn/\Cd19+
\Ep300tm2Reck/\Ep300+

(involves: 129/Sv * 129P2/OlaHsd * C57BL/6)
abnormal adaptive immunity J:147840
abnormal B cell differentiation J:147840
abnormal humoral immune response J:147840
abnormal spleen marginal zone macrophage morphology J:147840
abnormal transitional stage B cell morphology J:147840
arteritis J:147840
decreased B cell proliferation J:147840
decreased marginal zone B cell number J:147840
enlarged lymph nodes J:147840
enlarged spleen J:147840
glomerulonephritis J:147840
increased activated T cell number J:147840
increased anti-double stranded DNA antibody level J:147840
increased B cell apoptosis J:147840
increased B cell number J:147840
increased IgG2b level J:147840
increased immunoglobulin level J:147840
increased spleen weight J:147840
increased susceptibility to systemic lupus erythematosus J:147840
intermingled spleen red and white pulp J:147840
kidney inflammation J:147840
\Cd19tm1(cre)Cgn/\Cd19+
\Ep300tm2Reck/\Ep300+

(involves: 129/Sv * 129P2/OlaHsd * FVB/N)
increased susceptibility to systemic lupus erythematosus J:147840
\Cd19tm1(cre)Cgn/\Cd19+
\Faslpr/\Fastm1Cgn

(involves: 129P2/OlaHsd * C57BL/6 * MRL)
enlarged lymph nodes J:114948
enlarged spleen J:114948
\Cd19tm1(cre)Cgn/\Cd19+
\Faslpr/\Fastm1Cgn
\Tg(Cd4-cre)1Cwi/0

(involves: 129P2/OlaHsd * C57BL/6 * DBA/2 * MRL)
enlarged lymph nodes J:114948
enlarged spleen J:114948
increased double-negative T cell number J:114948
\Cd19tm1(cre)Cgn/\Cd19+
\Fastm1Ach/\Fastm1Ach

(involves: 129P2/OlaHsd * BALB/c)
enlarged spleen J:123556
increased anti-nuclear antigen antibody level J:123556
increased immunoglobulin level J:123556
increased lymphocyte cell number J:123556
\Cd19tm1(cre)Cgn/\Cd19+
\Fastm1Cgn/\Fastm1Cgn

(B6.Cg-Cd19tm1(cre)Cgn Fastm1Cgn)
increased anti-single stranded DNA antibody level J:114948
\Cd19tm1(cre)Cgn/\Cd19+
\Gna12tm1Citb/\Gna12tm1Citb
\Gna13tm2.1Soff/\Gna13tm2.1Soff

(involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6N)
abnormal B cell physiology J:117663
decreased marginal zone B cell number J:117663
\Cd19tm1(cre)Cgn/\Cd19+
\Gt(ROSA)26Sortm1(CTNNB1)Nerl/\Gt(ROSA)26Sortm1(CTNNB1)Nerl

(involves: 129P2/OlaHsd * BALB/c)
immune system phenotype J:112660
\Cd19tm1(cre)Cgn/\Cd19+
\Gt(ROSA)26Sortm1(DTA)Riet/\Gt(ROSA)26Sor+

(involves: 129P2/OlaHsd)
decreased B cell number J:92789
\Cd19tm1(cre)Cgn/\Cd19+
\Gt(ROSA)26Sortm1(ITK/SYK)Jrld/\Gt(ROSA)26Sor+

(involves: 129P2/OlaHsd)
abnormal T cell activation J:160931
enlarged spleen J:160931
increased T cell derived lymphoma incidence J:160931
increased T cell proliferation J:160931
\Cd19tm1(cre)Cgn/\Cd19+
\Gt(ROSA)26Sortm1Uzs/\Gt(ROSA)26Sor+

(involves: 129P2/OlaHsd * BALB/c)
immune system phenotype J:130768
\Cd19tm1(cre)Cgn/\Cd19+
\Gt(ROSA)26Sortm2(CARD11*L225LI)Jrld/\Gt(ROSA)26Sor+

(involves: 129P2/OlaHsd)
abnormal B cell activation J:228288
abnormal plasmablast number J:228288
abnormal spleen morphology J:228288
enlarged lymph nodes J:228288
enlarged spleen J:228288
increased B cell number J:228288
increased B cell proliferation J:228288
increased plasma cell number J:228288
spleen hyperplasia J:228288
\Cd19tm1(cre)Cgn/\Cd19+
\Gt(ROSA)26Sortm2(CARD11*L225LI)Jrld/\Gt(ROSA)26Sor+
\Malt1tm1Mak/\Malt1tm1Mak

(involves: 129P2/OlaHsd)
immune system phenotype J:228288
\Cd19tm1(cre)Cgn/\Cd19+
\Gt(ROSA)26Sortm2(Cd74/MOG)Awai/\Gt(ROSA)26Sor+

(involves: 129P2/OlaHsd * C57BL/6)
abnormal B cell physiology J:140751
decreased susceptibility to experimental autoimmune encephalomyelitis J:140751
\Cd19tm1(cre)Cgn/\Cd19+
\Gt(ROSA)26Sortm2(Cd74/MOG)Awai/\Gt(ROSA)26Sor+
\Il10tm1Roer/\Il10tm1Roer

(involves: 129P2/OlaHsd * C57BL/6)
abnormal B cell physiology J:140751
decreased susceptibility to experimental autoimmune encephalomyelitis J:140751
\Cd19tm1(cre)Cgn/\Cd19+
\Gt(ROSA)26Sortm4(Ikbkb)Rsky/\Gt(ROSA)26Sor+

(involves: 129P2/OlaHsd * C57BL/6)
abnormal B cell physiology J:113365
abnormal splenic cell ratio J:113365
decreased B cell apoptosis J:113365
increased B cell number J:113365
\Cd19tm1(cre)Cgn/\Cd19+
\Gt(ROSA)26Sortm4(Ikbkb)Rsky/\Gt(ROSA)26Sor+
\Tnfrsf13ctm1Mass/\Tnfrsf13ctm1Mass

(involves: 129P2/OlaHsd * C57BL/6)
immune system phenotype J:113365
\Cd19tm1(cre)Cgn/\Cd19+
\Gt(ROSA)26Sortm5(Map3k14)Rsky/\Gt(ROSA)26Sortm5(Map3k14)Rsky

(involves: 129P2/OlaHsd * C57BL/6)
enlarged lymph nodes J:139293
enlarged spleen J:139293
increased marginal zone B cell number J:139293
increased mature B cell number J:139293
\Cd19tm1(cre)Cgn/\Cd19+
\Gt(ROSA)26Sortm5(Map3k14)Rsky/\Gt(ROSA)26Sortm5(Map3k14)Rsky
\Tnfrsf13ctm1Mass/\Tnfrsf13ctm1Mass

(involves: 129P2/OlaHsd * C57BL/6)
decreased lymphocyte cell number J:139293
decreased mature B cell number J:139293
\Cd19tm1(cre)Cgn/\Cd19+
\Gt(ROSA)26Sortm6(Map3k14*)Rsky/\Gt(ROSA)26Sortm6(Map3k14*)Rsky

(involves: 129P2/OlaHsd * C57BL/6)
abnormal Peyer's patch morphology J:139293
abnormal spleen B cell follicle morphology J:139293
decreased B-1 B cell number J:139293
enlarged lymph nodes J:139293
enlarged spleen J:139293
increased mature B cell number J:139293
\Cd19tm1(cre)Cgn/\Cd19+
\Gt(ROSA)26Sortm6(Map3k14*)Rsky/\Gt(ROSA)26Sortm6(Map3k14*)Rsky
\Tnfrsf13ctm1Mass/\Tnfrsf13ctm1Mass

(involves: 129P2/OlaHsd * C57BL/6)
increased lymphocyte cell number J:139293
increased mature B cell number J:139293
\Cd19tm1(cre)Cgn/\Cd19+
\Ifnar1tm1Uka/\Ifnar1tm1Uka

(B6.129P2-Cd19tm1(cre)Cgn Ifnar1tm1Uka)
decreased IgG1 level J:129128
decreased IgG2a level J:129128
decreased IgG3 level J:129128
decreased IgM level J:129128
\Cd19tm1(cre)Cgn/\Cd19+
\Igbp1tm1Imku/Y

(involves: 129P2/OlaHsd)
abnormal B cell physiology J:74619
abnormal somatic hypermutation frequency J:74619
abnormal spleen germinal center morphology J:74619
decreased B cell number J:74619
decreased B cell proliferation J:74619
decreased follicular B cell number J:74619
decreased immunoglobulin level J:74619
decreased pre-B cell number J:74619
\Cd19tm1(cre)Cgn/\Cd19+
\Ikbkbtm1Cgn/\Ikbkbtm1.1Cgn

(involves: 129P2/OlaHsd * C57BL/6)
decreased B-1 B cell number J:79132
decreased follicular B cell number J:79132
decreased immature B cell number J:79132
decreased marginal zone B cell number J:79132
decreased mature B cell number J:79132
increased B cell proliferation J:79132
\Cd19tm1(cre)Cgn/\Cd19+
\Ikbkbtm2Cgn/\Ikbkbtm2.1Cgn

(involves: 129P2/OlaHsd * C57BL/6)
decreased B-1 B cell number J:79132
decreased follicular B cell number J:79132
decreased marginal zone B cell number J:79132
decreased mature B cell number J:79132
\Cd19tm1(cre)Cgn/\Cd19+
\Ikbkbtm2Mka/\Ikbkbtm2Mka

(involves: 129/Sv * 129P2/OlaHsd * C57BL/6)
abnormal B cell activation J:82995
decreased B cell number J:82995
decreased B cell proliferation J:82995
decreased B-1 B cell number J:82995
decreased IgG level J:82995
decreased IgM level J:82995
decreased marginal zone B cell number J:82995
increased B cell apoptosis J:82995
\Cd19tm1(cre)Cgn/\Cd19+
\Ikbkgtm1.1Mpa/Y

(involves: 129P2/OlaHsd * C57BL/6)
decreased B-1 B cell number J:79132
decreased follicular B cell number J:79132
decreased immature B cell number J:79132
decreased marginal zone B cell number J:79132
decreased mature B cell number J:79132
increased B cell proliferation J:79132
\Cd19tm1(cre)Cgn/\Cd19+
\Il10tm1Roer/\Il10tm1Roer

(involves: 129P2/OlaHsd)
abnormal CD8-positive, alpha-beta T cell physiology J:151551
abnormal myeloid leukocyte morphology J:151551
decreased circulating interleukin-10 level J:151551
increased B cell number J:151551
increased CD4-positive, alpha-beta T cell number J:151551
increased plasma cell number J:151551
\Cd19tm1(cre)Cgn/\Cd19+
\Il10ratm1.1Jack/\Il10ratm1.1Jack

(involves: 129P2/OlaHsd * BALB/c * C57BL/6)
immune system phenotype J:157787
\Cd19tm1(cre)Cgn/\Cd19+
\Inpp5dtm1Rav/\Inpp5dtm1Rav
\Ptentm1Hwu/\Ptentm1Hwu

(involves: 129P2/OlaHsd * 129S4/SvJae)
abnormal B cell morphology J:166155
abnormal B cell physiology J:166155
abnormal myeloid leukocyte morphology J:166155
decreased B cell number J:166155
enlarged spleen J:166155
increased B cell number J:166155
increased B cell proliferation J:166155
increased spleen white pulp amount J:166155
\Cd19tm1(cre)Cgn/\Cd19+
\Irf8tm1.1Hm/\Irf8tm1.1Hm

(involves: 129P2/OlaHsd * C57BL/6)
abnormal spleen marginal zone morphology J:168923
decreased follicular B cell number J:168923
immune system phenotype J:168923
increased B cell number J:168923
increased B-2 B cell number J:168923
increased follicular B cell number J:168923
increased marginal zone B cell number J:168923
increased transitional stage B cell number J:168923
\Cd19tm1(cre)Cgn/\Cd19+
\Klhl6tm2Sato/\Klhl6tm2Sato

(either: (involves: 129P2/OlaHsd * 129T2/SvEms) or (involves: 129P2/OlaHsd * BALB/c) or (involves: 129P2/OlaHsd * CD-1))
abnormal B cell differentiation J:101363
abnormal lymph node germinal center morphology J:101363
decreased B cell number J:101363
\Cd19tm1(cre)Cgn/\Cd19+
\Kmt2atm1.1Erns/\Kmt2atm1.1Erns

(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 * SJL)
immune system phenotype J:147265
\Cd19tm1(cre)Cgn/\Cd19+
\Ltbtm1Avt/\Ltbtm1Avt

(involves: 129P2/OlaHsd * C57BL/6)
abnormal adaptive immunity J:79129
abnormal spleen B cell follicle morphology J:79129
abnormal spleen follicular dendritic cell network J:79129
decreased marginal zone B cell number J:79129
decreased spleen germinal center number J:79129
decreased spleen germinal center size J:79129
small Peyer's patches J:79129
\Cd19tm1(cre)Cgn/\Cd19+
\Ltbtm1Avt/\Ltbtm1Avt
\Tg(Lck-cre)1Jtak/?

(involves: 129P2/OlaHsd * C57BL/6)
absent follicular dendritic cells J:79129
\Cd19tm1(cre)Cgn/\Cd19+
\Ltbrtm1Avt/\Ltbrtm1Avt

(involves: 129P2/OlaHsd)
immune system phenotype J:158663
\Cd19tm1(cre)Cgn/\Cd19+
\Ltbrtm1Avt/\Ltbrtm1Avt
\Tg(Lck-cre)I57Jxm/0

(involves: 129P2/OlaHsd)
immune system phenotype J:158663
\Cd19tm1(cre)Cgn/\Cd19+
\Map3k7tm1Aki/\Map3k7tm1.1Aki

(involves: 129P2/OlaHsd * C57BL/6)
abnormal B cell physiology J:112597
decreased B cell proliferation J:112597
decreased B-1 B cell number J:112597
decreased IgG1 level J:112597
decreased IgG3 level J:112597
decreased IgG level J:112597
decreased immunoglobulin level J:112597
\Cd19tm1(cre)Cgn/\Cd19+
\Mcl1tm2Sjk/\Mcl1tm3Sjk

(involves: 129P2/OlaHsd * 129X1/SvJ)
abnormal B cell differentiation J:86906
absent early pro-B cells J:86906
absent late pro-B cells J:86906
absent pre-B cells J:86906
arrested B cell differentiation J:86906
decreased B cell number J:86906
increased B cell apoptosis J:86906
\Cd19tm1(cre)Cgn/\Cd19+
\Mirc30tm1.1Rdf/\Mirc30tm1.1Rdf

(involves: 129P2/OlaHsd * 129S1/Sv * 129S4/SvJaeSor * C57BL/6)
increased B cell number J:156946
increased B-1a cell number J:156946
increased spleen white pulp amount J:156946
\Cd19tm1(cre)Cgn/\Cd19+
\Myd88em1.1Rsky/\Myd88+

(involves: C57BL/6NTac)
abnormal splenic cell ratio J:308792
enlarged spleen J:308792
increased germinal center B cell number J:308792
increased IgM level J:308792
increased plasma cell number J:308792
\Cd19tm1(cre)Cgn/\Cd19+
\Myd88em1.1Rsky/\Myd88em1.1Rsky

(involves: C57BL/6NTac)
increased B cell proliferation J:308792
\Cd19tm1(cre)Cgn/\Cd19+
\Notch2tm1.1Hhi/\Notch2+

(involves: 129P2/OlaHsd * C57BL/6 * CBA)
decreased marginal zone B cell number J:83476
\Cd19tm1(cre)Cgn/\Cd19+
\Notch2tm2Hhi/\Notch2tm1.1Hhi

(involves: 129P2/OlaHsd * C57BL/6 * CBA)
abnormal spleen marginal zone morphology J:83476
absent marginal zone B cells J:83476
decreased transitional stage B cell number J:83476
\Cd19tm1(cre)Cgn/\Cd19+
\Pax5tm1Mbu/\Pax5tm3Mbu

(involves: 129P2/OlaHsd * 129S2/SvPas)
abnormal B cell differentiation J:75504
abnormal class switch recombination J:75504
decreased IgG1 level J:75504
decreased IgG3 level J:75504
decreased IgG level J:75504
decreased immature B cell number J:75504
decreased immunoglobulin level J:75504
decreased mature B cell number J:75504
decreased pre-B cell number J:75504
\Cd19tm1(cre)Cgn/\Cd19+
\Pdia3tm1Gjh/\Pdia3tm1Gjh

(involves: 129P2/OlaHsd * C57BL/6)
abnormal B cell physiology J:112606
\Cd19tm1(cre)Cgn/\Cd19+
\Prdm1tm1Clme/\Prdm1tm1Clme

(involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ)
abnormal B cell differentiation J:101890
abnormal memory B cell number J:101890
abnormal plasma cell differentiation J:101890
abnormal plasma cell morphology J:101890, J:114881
decreased IgG level J:101890
decreased IgM level J:101890
decreased immunoglobulin level J:101890
decreased plasma cell number J:101890
increased spleen germinal center number J:101890
increased spleen germinal center size J:101890
\Cd19tm1(cre)Cgn/\Cd19+
\Ptentm1Hwu/\Ptentm1Hwu

(involves: 129P2/OlaHsd * 129S4/SvJae)
abnormal B cell negative selection J:155314
abnormal B cell physiology J:83213
abnormal class switch recombination J:114881
abnormal plasma cell morphology J:114881
decreased IgG level J:114881
decreased spleen germinal center number J:83213
increased B cell apoptosis J:83213
increased B cell number J:83213
increased B cell proliferation J:155314, J:83213
increased B-1 B cell number J:83213
increased IgM level J:114881
increased marginal zone B cell number J:83213
\Cd19tm1(cre)Cgn/\Cd19+
\Ptentm1Hwu/\Ptentm1Hwu
\Tg(IghelMD4)4Ccg/0
\Tg(ML5sHEL)5Ccg/0

(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)
abnormal peripheral B cell anergy J:155314
\Cd19tm1(cre)Cgn/\Cd19+
\Ptpn6tm1Rsky/\Ptpn6tm1Rsky

(involves: 129P2/OlaHsd * C57BL/6)
abnormal humoral immune response J:123568
abnormal immune system physiology J:123568
abnormal leukocyte cell number J:123568
abnormal lymph organ size J:123568
decreased B cell proliferation J:123568
decreased follicular B cell number J:123568
decreased marginal zone B cell number J:123568
enlarged lymph nodes J:123568
enlarged spleen J:123568
increased B cell number J:123568
increased B-1a cell number J:123568
increased granulocyte number J:123568
increased macrophage cell number J:123568
increased plasma cell number J:123568
increased susceptibility to systemic lupus erythematosus J:123568
increased T cell number J:123568
\Cd19tm1(cre)Cgn/\Cd19+
\Rac1tm1Tyb/\Rac1tm1Tyb

(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)
immune system phenotype J:86765
\Cd19tm1(cre)Cgn/\Cd19+
\Rac1tm1Tyb/\Rac1tm1Tyb
\Rac2tm1Mddw/\Rac2tm1Mddw

(involves: 129P2/OlaHsd * 129S/SvEv * 129S4/SvJae * C57BL/6)
arrested B cell differentiation J:86765
decreased B cell number J:86765
decreased B-1 B cell number J:86765
decreased follicular B cell number J:86765
decreased marginal zone B cell number J:86765
decreased transitional stage B cell number J:86765
\Cd19tm1(cre)Cgn/\Cd19+
\Rapgef2tm1.1Hous/\Rapgef2tm1.1Hous

(involves: 129P2/OlaHsd * 129S1/Sv)
immune system phenotype J:165879
\Cd19tm1(cre)Cgn/\Cd19+
\Rbpjtm1Hon/\Rbpjtm1Hon

(involves: 129P2/OlaHsd * C57BL/6)
abnormal B cell differentiation J:76240
decreased marginal zone B cell number J:121523, J:76240
increased follicular B cell number J:121523, J:76240
increased IgG3 level J:76240
increased susceptibility to bacterial infection J:76240
increased susceptibility to bacterial infection induced morbidity/mortality J:76240
\Cd19tm1(cre)Cgn/\Cd19+
\Rbpjtm1Hon/\Rbpjtm1Hon
\Spentm2.1Hon/\Spentm2.1Hon

(involves: 129P2/OlaHsd * C57BL/6 * CBA)
decreased marginal zone B cell number J:121523
increased follicular B cell number J:121523
\Cd19tm1(cre)Cgn/\Cd19+
\Slc3a2tm1.1Mgin/\Slc3a2tm1.1Mgin

(involves: 129 * C57BL/6 * SJL)
abnormal B cell activation J:148000
abnormal B cell physiology J:148000
abnormal class switch recombination J:148000
abnormal plasma cell differentiation J:148000
decreased B cell proliferation J:148000
decreased germinal center B cell number J:148000
decreased IgG level J:148000
decreased IgM level J:148000
immune system phenotype J:148000
\Cd19tm1(cre)Cgn/\Cd19+
\Slc3a2tm1.1Mgin/\Slc3a2tm1Yai

(involves: 129 * C57BL/6 * SJL)
decreased IgG3 level J:148000
decreased IgM level J:148000
\Cd19tm1(cre)Cgn/\Cd19+
\Spentm2.1Hon/\Spentm2.1Hon

(involves: 129P2/OlaHsd * C57BL/6 * CBA)
decreased follicular B cell number J:121523
increased marginal zone B cell number J:121523
\Cd19tm1(cre)Cgn/\Cd19+
\Srsf3tm1Pjln/\Srsf3tm1Pjln

(involves: 129P2/OlaHsd * BALB/c)
decreased B cell number J:113645
\Cd19tm1(cre)Cgn/\Cd19+
\Tbl1xr1tm1c(EUCOMM)Hmgu/\Tbl1xr1tm1c(EUCOMM)Hmgu
\Tg(Vav-BCL2)69Jad/0

(involves: 129P2/OlaHsd * C57BL/6J * C57BL/6N)
abnormal B cell differentiation J:292118
abnormal lymphocyte morphology J:292118
abnormal spleen morphology J:292118
\Cd19tm1(cre)Cgn/\Cd19+
\Tcf3tm1Mbu/\Tcf3tm1.2Mbu

(involves: 129P2/OlaHsd * C57BL/6 * SJL)
decreased B cell number J:137719
decreased immature B cell number J:137719
decreased mature B cell number J:137719
decreased pre-B cell number J:137719
decreased pro-B cell number J:137719
decreased transitional stage B cell number J:137719
\Cd19tm1(cre)Cgn/\Cd19+
\Tcf3tm1Mbu/\Tcf3tm1.2Mbu
\Tg(Vav-BCL2)69Jad/0

(involves: 129P2/OlaHsd * C57BL/6 * C57BL/6J * SJL)
decreased pre-B cell number J:137719
\Cd19tm1(cre)Cgn/\Cd19+
\Tgfbr2tm1Roes/\Tgfbr2tm1Roes

(involves: 129P2/OlaHsd * BALB/c)
abnormal B cell physiology J:90558
abnormal B-1 B cell morphology J:90558
abnormal B-1 B cell number J:90558
absent plasma cells J:90558
decreased IgA level J:90558
enlarged Peyer's patches J:90558
increased IgG level J:90558
increased IgM level J:90558
increased leukocyte cell number J:90558
\Cd19tm1(cre)Cgn/\Cd19+
\Tnftm2.1Gkl/\Tnftm2.1Gkl

(involves: 129P2/OlaHsd * 129S/SvEv * 129S6/SvEvTac * C57BL/6J)
immune system phenotype J:108572
\Cd19tm1(cre)Cgn/\Cd19+
\Tnfaip3tm1.1Awai/\Tnfaip3tm1.1Awai

(involves: 129P2/OlaHsd)
decreased B-1a cell number J:175422
decreased B-1b cell number J:175422
decreased marginal zone B cell number J:175422
decreased mature B cell number J:175422
enlarged spleen J:175422
increased anti-nuclear antigen antibody level J:175422
increased B cell number J:175422
increased B cell proliferation J:175422
increased follicular B cell number J:175422
increased germinal center B cell number J:175422
increased IgA level J:175422
increased IgG2a level J:175422
increased IgM level J:175422
increased splenocyte number J:175422
increased T cell number J:175422
\Cd19tm1(cre)Cgn/\Cd19+
\Tnfaip3tm2Ama/\Tnfaip3+

(involves: 129P2/OlaHsd * C57BL/6)
decreased B cell apoptosis J:163917
increased autoantibody level J:163917
increased germinal center B cell number J:163917
increased immunoglobulin level J:163917
increased plasma cell number J:163917
increased susceptibility to autoimmune disorder J:163917
\Cd19tm1(cre)Cgn/\Cd19+
\Tnfrsf13ctm1Mass/\Tnfrsf13ctm1Mass

(involves: 129P2/OlaHsd * C57BL/6)
abnormal B cell differentiation J:172843
\Cd19tm1(cre)Cgn/\Cd19+
\Tnfsf13btm1Msc/\Tnfsf13btm1Msc
\Traf2tm1Rbr/\Traf2tm1Rbr

(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6)
increased follicular B cell number J:132877
increased marginal zone B cell number J:132877
\Cd19tm1(cre)Cgn/\Cd19+
\Traf2tm1Rbr/\Traf2tm1Rbr

(involves: 129P2/OlaHsd * C57BL/6)
abnormal B cell physiology J:132877
increased follicular B cell number J:132877
increased marginal zone B cell number J:132877
lymph node hyperplasia J:132877
\Cd19tm1(cre)Cgn/\Cd19+
\Traf2tm1Rbr/\Traf2tm1Rbr
\Traf3tm1Rbr/\Traf3tm1Rbr

(involves: 129P2/OlaHsd * C57BL/6 * SJL)
abnormal B cell physiology J:132877
increased marginal zone B cell number J:132877
\Cd19tm1(cre)Cgn/\Cd19+
\Traf3tm1Rbr/\Traf3tm1Rbr

(involves: 129P2/OlaHsd * C57BL/6 * SJL)
abnormal B cell physiology J:132877
increased follicular B cell number J:132877
increased marginal zone B cell number J:132877
lymph node hyperplasia J:132877
\Cd19tm1(cre)Cgn/\Cd19+
\Ube2ntm1Aki/\Ube2ntm1Aki

(involves: 129P2/OlaHsd * C57BL/6)
abnormal B cell physiology J:112287
abnormal humoral immune response J:112287
abnormal spleen marginal zone morphology J:112287
decreased B cell number J:112287
decreased B cell proliferation J:112287
decreased immunoglobulin level J:112287
decreased marginal zone B cell number J:112287
increased B cell apoptosis J:112287
\Cd19tm1(cre)Cgn/\Cd19+
\Wacem2Cya/\Wacem2Cya

(B6.Cg-Cd19tm1(cre)Cgn Wacem2Cya)
abnormal plasma cell differentiation J:345327
decreased B cell proliferation J:345327
decreased IgG1 level J:345327
decreased IgG2b level J:345327
decreased IgG3 level J:345327
decreased IgM level J:345327
decreased plasma cell number J:345327
impaired humoral immune response J:345327
\Cd19tm1(cre)Cgn/\Cd19tm1(cre)Cgn
(involves: 129P2/OlaHsd)
abnormal B cell differentiation J:27463
abnormal B cell physiology J:27463
abnormal immunoglobulin level J:27463
absent spleen germinal center J:83213, J:27463
decreased B-1 B cell number J:83213, J:27463
decreased IgE level J:27463
decreased IgG1 level J:27463
decreased IgM level J:27463
\Cd19tm1(cre)Cgn/\Cd19tm1(cre)Cgn
\Ightm1Mnz/\Ightm1Mnz

(involves: 129P2/OlaHsd * C57BL/6)
abnormal B cell physiology J:75653
\Cd19tm1(cre)Cgn/\Cd19tm1(cre)Cgn
\Ightm2Mnz/\Ightm2Mnz

(involves: 129P2/OlaHsd * C57BL/6)
abnormal B cell physiology J:75653
\Cd19tm1(cre)Cgn/\Cd19tm1(cre)Cgn
\Ptentm1Hwu/\Ptentm1Hwu

(involves: 129P2/OlaHsd * 129S4/SvJae)
immune system phenotype J:83213
\Cd19tm1(cre)Cgn/\Cd19tm1(cre)Cgn
\Tg(IghelMD4)4Ccg/0

(involves: 129P2/OlaHsd * C57BL/6)
decreased B cell number J:155314
immune system phenotype J:155314
\Cd19tm1(cre)Cgn/\Cd19tm1(cre)Cgn
\Tg(IghelMD4)4Ccg/0
\Tg(ML5sHEL)5Ccg/0

(involves: 129P2/OlaHsd * C57BL/6)
decreased B cell number J:155314
immune system phenotype J:155314
\Cd19tm1(cre/ERT2)Rsky/\Cd19+
\Myd88em1.1Rsky/\Myd88+

(involves: 129P2/OlaHsd * C57BL/6NTac)
increased IgM level J:308792
increased plasma cell number J:308792
\Cd19tm1Tft/\Cd19tm1Tft
(Not Specified)
abnormal B cell physiology J:27236
decreased B cell number J:27236
decreased B cell proliferation J:27236
decreased B-1 B cell number J:27236
decreased IgA level J:27236
decreased IgG1 level J:27236
decreased IgG2a level J:27236
decreased IgG2b level J:27236
decreased IgG3 level J:27236
decreased IgM level J:27236
\Cd19tm1Tft/\Cd19tm1Tft
(involves: 129/Sv * C57BL/6)
decreased neutrophil cell number J:66111
decreased tumor necrosis factor secretion J:66111
\Cd19tm1Tft/\Cd19tm1Tft
(involves: 129 * C57BL/6)
abnormal humoral immune response J:71174
decreased B cell number J:71174
decreased B cell proliferation J:71174
decreased B-1 B cell number J:71174
decreased IgA level J:71174
decreased IgG1 level J:71174
decreased IgG2b level J:71174
decreased IgM level J:71174
\Cd19tm1Tft/\Cd19tm1Tft
(B6.Cg-Cd19tm1Tft)
abnormal B cell physiology J:136210
decreased anti-double stranded DNA antibody level J:136210
decreased anti-nuclear antigen antibody level J:136210
decreased circulating interferon-gamma level J:136210
decreased circulating interleukin-4 level J:136210
decreased circulating interleukin-6 level J:136210
decreased circulating interleukin-10 level J:136210
decreased circulating tumor necrosis factor level J:136210
decreased IgA level J:136210
decreased IgG1 level J:136210
decreased IgG2a level J:136210
decreased IgG2b level J:136210
decreased IgG3 level J:136210
decreased IgM level J:136210
decreased interleukin-10 secretion J:106487
increased CD8-positive, alpha-beta T cell number J:106487
increased interferon-gamma secretion J:106487
increased susceptibility to experimental autoimmune encephalomyelitis J:106487
\Cd19tm1Tft/\Cd19tm1Tft
\Lyntm1Sor/\Lyntm1Sor

(involves: 129S4/SvJaeSor * C57BL/6)
abnormal humoral immune response J:71174
decreased anti-double stranded DNA antibody level J:71174
decreased B cell number J:71174
decreased B cell proliferation J:71174
decreased B-1 B cell number J:71174
decreased mature B cell number J:71174
decreased susceptibility to systemic lupus erythematosus J:71174
enlarged spleen J:71174
immune system phenotype J:71174
\Cd22m1Anu/\Cd22m1Anu
(C57BL/6JAnu-Cd22m1Anu/AnuApb)
arrested B cell differentiation J:104190
decreased B cell number J:104190
\Cd22m1Btlr/\Cd22m1Btlr
(C57BL/6J-Cd22m1Btlr)
abnormal B cell differentiation J:173079
abnormal humoral immune response J:173079
\Cd22m1Btlr/\Cd22m1Btlr
(involves: C57BL/6J)
abnormal B cell differentiation J:185495
decreased IgM level J:185495
immune system phenotype J:185495
\Cd22m2Btlr/\Cd22m2Btlr
(C57BL/6J-Cd22m2Btlr)
abnormal B cell differentiation J:215821
abnormal CD4-positive, alpha-beta T cell physiology J:215821
\Cd22m3Btlr/\Cd22m3Btlr
(C57BL/6J-Cd22m3Btlr)
decreased B cell number J:220066
increased B-1a cell number J:220066
\Cd22m4Btlr/\Cd22m4Btlr
(C57BL/6J-Cd22m4Btlr)
decreased B cell number J:224660
decreased B-2 B cell number J:224660
decreased memory B cell number J:224660
increased B-1a cell number J:224660
\Cd22m5Btlr/\Cd22m5Btlr
(C57BL/6J-Cd22m5Btlr)
decreased B cell number J:254827
increased CD4-positive, CD25-positive, alpha-beta regulatory T cell number J:254827
increased CD8-positive, alpha-beta memory T cell number J:254827
\Cd22tm1.1(CD22)Lnit/\Cd22tm1.1(CD22)Lnit
(involves: 129S4/SvJae)
abnormal B cell calcium ion homeostasis J:189017
abnormal B cell physiology J:189017
decreased B cell number J:189017
decreased marginal zone B cell number J:189017
decreased transitional stage T1 B cell number J:189017
decreased transitional stage T2 B cell number J:189017
immune system phenotype J:189017
impaired B cell migration J:189017
\Cd22tm1b(EUCOMM)Wtsi/\Cd22tm1b(EUCOMM)Wtsi
(C57BL/6N-Cd22tm1b(EUCOMM)Wtsi/Tcp)
increased monocyte cell number J:211773
\Cd22tm1Eac/\Cd22+
\Lyntm1Ard/\Lyn+
\Ptpn6me-v/\Ptpn6+
\Tg(IghelMD4)4Ccg/0

(involves: 129P2/OlaHsd * C57BL/6)
abnormal B cell negative selection J:110531
abnormal mature B cell morphology J:110531
increased IgM level J:110531
\Cd22tm1Eac/\Cd22+
\Lyntm1Ard/\Lyn+
\Tg(IghelMD4)4Ccg/0

(involves: 129P2/OlaHsd * C57BL/6)
abnormal B cell negative selection J:110531
abnormal mature B cell morphology J:110531
\Cd22tm1Eac/\Cd22+
\Ptpn6me-v/\Ptpn6+
\Tg(IghelMD4)4Ccg/0

(involves: 129P2/OlaHsd * C57BL/6)
abnormal B cell negative selection J:110531
abnormal mature B cell morphology J:110531
\Cd22tm1Eac/\Cd22+
\Tg(IghelMD4)4Ccg/0

(involves: 129P2/OlaHsd * C57BL/6)
abnormal mature B cell morphology J:110531
\Cd22tm1Eac/\Cd22tm1Eac
(involves: 129P2/OlaHsd * C57BL/6)
abnormal B cell activation J:37451
abnormal B cell proliferation J:37451, J:132991
abnormal mature B cell morphology J:37451
abnormal transitional stage B cell morphology J:132991
decreased IgG1 level J:37451
decreased IgG3 level J:37451
decreased IgM level J:37451
decreased marginal zone B cell number J:132991
decreased mature B cell number J:37451, J:132991
decreased memory B cell number J:37451
increased B cell apoptosis J:132991
\Cd22tm1Lam/\Cd22tm1Lam
(involves: 129 * C57BL/6)
abnormal B cell activation J:125719
decreased marginal zone B cell number J:125719
decreased mature B cell number J:125719
\Cd22tm1Lam/\Cd22tm1Lam
\Ightm1.2Rsky/\Igh+

(involves: 129 * BALB/c * C57BL/6)
abnormal class switch recombination J:125719
\Cd22tm1Lam/\Cd22tm1Lam
\Ightm1.2Rsky/\Ightm1.2Rsky

(involves: 129 * BALB/c * C57BL/6)
abnormal B cell activation J:125719
decreased B-1a cell number J:125719
\Cd22tm1Lnit/\Cd22tm1Lnit
(involves: 129P2/OlaHsd * C57BL/6)
decreased marginal zone B cell number J:198790
immune system phenotype J:198790
\Cd22tm1Msn/\Cd22tm1Msn
(either: (involves: 129S/SvEv * BALB/c) or (involves: 129S/SvEv * C57BL/6J))
abnormal B cell activation J:76974
abnormal B cell calcium ion homeostasis J:76974
abnormal immune system physiology J:76974
abnormal immunoglobulin level J:76974
abnormal mature B cell morphology J:76974
increased anti-double stranded DNA antibody level J:76974, J:76975
increased B-1 B cell number J:76974
increased IgG2a level J:76975
increased IgG level J:76975
increased IgM level J:76974
\Cd22tm1Tft/\Cd22tm1Tft
(involves: 129P2/OlaHsd * C57BL/6)
decreased B cell number J:92736
decreased marginal zone B cell number J:92736
decreased mature B cell number J:92736
increased B cell proliferation J:92736
\Cd22tm2Lnit/\Cd22tm2Lnit
(involves: 129P2/OlaHsd * C57BL/6)
absent mature B cells J:198790
autoimmune response J:198790
decreased marginal zone B cell number J:198790
immune system phenotype J:198790
\Cd22tm2Tft/\Cd22tm2Tft
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)
decreased B cell number J:92736
decreased B cell proliferation J:92736
increased B cell proliferation J:92736
\Cd22tm2Tft/\Cd22tm2Tft
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
abnormal peripheral B cell anergy J:208364
decreased B cell number J:208364
decreased B cell proliferation J:208364
increased activation-induced B cell apoptosis J:208364
\Cd22tm2Tft/\Cd22tm2Tft
\Endoutm1Tft/\Endoutm1Tft

(involves: 129S/SvEv * 129S1/Sv * 129X1/SvJ * C57BL/6)
immune system phenotype J:208364
\Cd22tm3Lnit/\Cd22tm3Lnit
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)
abnormal B cell physiology J:198790
abnormal immune system morphology J:198790
abnormal immune system physiology J:198790
absent mature B cells J:198790
autoimmune response J:198790
decreased B cell number J:198790
decreased marginal zone B cell number J:198790
decreased transitional stage B cell number J:198790
immune system phenotype J:198790
increased B cell apoptosis J:198790
increased IgG1 level J:198790
\Cd22tm3Tft/\Cd22tm3Tft
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)
decreased B cell number J:92736
decreased B cell proliferation J:92736
increased B cell proliferation J:92736
\Cd24atm1Pjln/\Cd24atm1Pjln
(C57BL/6-Cd24atm1Pjln)
abnormal B cell differentiation J:76695
dark spleen J:76695
decreased immature B cell number J:76695
decreased pre-B cell number J:76695
immune system phenotype J:76695
increased susceptibility to parasitic infection J:76695
\Cd27em1(IMPC)Ccpcz/\Cd27em1(IMPC)Ccpcz
(C57BL/6NCrl-Cd27em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
decreased CD4-positive, CD25-positive, alpha-beta regulatory T cell number J:211773
\Cd27tm1Jbo/\Cd27tm1Jbo
(either: B6.129P2-CD27tm1Jbo or 129P2/OlaHsd-Tnfrsf7tm1Jbo)
abnormal CD4-positive, alpha-beta T cell physiology J:65516
abnormal cytotoxic T cell physiology J:65516
abnormal T cell physiology J:65516
\Cd27tm1Jbo/\Cd27tm1Jbo
(B6.129P2-Cd27tm1Jbo)
abnormal leukopoiesis J:97606
decreased regulatory T cell number J:198200
immune system phenotype J:198200
increased leukocyte cell number J:97606
increased T cell apoptosis J:198200
\Cd27tm1Jbo/\Cd27tm1Jbo
\Tg(CD19-Tnfsf7)#Rvl/0

(involves: 129P2/OlaHsd * C57BL/6)
immune system phenotype J:88620
\Cd28tm1.1Huen/\Cd28tm1.1Huen
\Gt(ROSA)26Sortm9(cre/ESR1)Arte/\Gt(ROSA)26Sor+

(involves: C57BL/6 * C57BL/6NTac)
abnormal regulatory T cell physiology J:191101
decreased regulatory T cell number J:191101
\Cd28tm1a(EUCOMM)Hmgu/\Cd28tm1a(EUCOMM)Hmgu
(C57BL/6N-Cd28tm1a(EUCOMM)Hmgu/H)
decreased T cell number J:165965
increased CD4-positive, alpha-beta T cell number J:165965
increased leukocyte cell number J:165965
\Cd28tm1Jmg/\Cd28tm1Jmg
(involves: 129S2/SvPas * 129X1/SvJ * C57BL/6)
abnormal cytokine secretion J:124570
abnormal germinal center B cell physiology J:124570
abnormal lymphopoiesis J:124570
decreased immunoglobulin level J:124570
decreased interleukin-2 secretion J:124570
\Cd28tm1Jmg/\Cd28tm1Jmg
(B6.129X1-Cd28tm1Jmg)
decreased interleukin-2 secretion J:149888
decreased susceptibility to experimental autoimmune encephalomyelitis J:149888
increased susceptibility to type I hypersensitivity reaction J:149888
\Cd28tm1Jmg/\Cd28tm1Mak
(involves: 129S2/SvPas * 129X1/SvJ * C57BL/6)
abnormal cytokine secretion J:124570
abnormal germinal center B cell physiology J:124570
abnormal lymphopoiesis J:124570
decreased immunoglobulin level J:124570
decreased interleukin-2 secretion J:124570
decreased T cell proliferation J:149888, J:124570
\Cd28tm1Ltu/\Cd28tm1Ltu
\Foxp3tm4(YFP/icre)Ayr/\Foxp3+

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
decreased regulatory T cell number J:194503
decreased T cell proliferation J:194503
enlarged lymph nodes J:194503
enlarged spleen J:194503
increased activated T cell number J:194503
increased B cell number J:194503
increased susceptibility to autoimmune disorder J:194503
increased susceptibility to experimental autoimmune encephalomyelitis J:194503
skin inflammation J:194503
\Cd28tm1Mak/\Cd28+
\Cd5tm1Cgn/\Cd5tm1Cgn

(either: (involves: 129P2/OlaHsd * 129S2/SvPas * BALB/c * C57BL/6) or (involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 * DBA/1 * LP))
abnormal T cell clonal deletion J:110925
\Cd28tm1Mak/\Cd28tm1Mak
(involves: 129S2/SvPas * C57BL/6 * DBA/2)
abnormal CD4-positive, alpha-beta T cell physiology J:14194
abnormal class switch recombination J:14194
decreased IgG1 level J:14194
decreased IgG2b level J:14194
decreased immunoglobulin level J:14194
decreased interleukin-2 secretion J:14194
decreased T cell proliferation J:14194
increased IgG2a level J:14194
\Cd28tm1Mak/\Cd28tm1Mak
(NOD.129S2-Cd28tm1Mak)
abnormal CD4-positive, alpha-beta T cell physiology J:61905
abnormal response to transplant J:61905
increased susceptibility to autoimmune diabetes J:93421
increased T cell proliferation J:93421
\Cd28tm1Mak/\Cd28tm1Mak
(involves: 129S2/SvPas)
abnormal class switch recombination J:123989
abnormal regulatory T cell physiology J:191101
decreased interferon-gamma secretion J:205441
decreased interleukin-2 secretion J:205441, J:130882
decreased regulatory T cell number J:191101, J:205441
decreased spleen germinal center number J:123989
decreased T cell proliferation J:205441, J:130882, J:123989
enlarged thymus J:205441
\Cd28tm1Mak/\Cd28tm1Mak
(involves: 129S2/SvPas * NOD)
abnormal T-helper 1 physiology J:35353
abnormal T-helper 2 physiology J:35353
decreased IgG2a level J:35353
decreased interleukin-2 secretion J:35353
decreased interleukin-4 secretion J:35353
decreased T cell proliferation J:35353
increased interferon-gamma secretion J:35353
increased susceptibility to autoimmune diabetes J:35353
\Cd28tm1Mak/\Cd28tm1Mak
(involves: 129S2/SvPas * C57BL/6)
abnormal NK cell physiology J:95353
decreased circulating interferon-gamma level J:95353
decreased circulating interleukin-4 level J:95353
decreased interleukin-2 secretion J:149888
decreased susceptibility to experimental autoimmune encephalomyelitis J:149888
decreased T cell proliferation J:149888
increased susceptibility to type I hypersensitivity reaction J:149888
increased T cell apoptosis J:149888
\Cd28tm1Mak/\Cd28tm1Mak
(B6.129S2-Cd28tm1Mak)
abnormal cytotoxic T cell physiology J:76373
\Cd28tm1Mak/\Cd28tm1Mak
(B6.129S2-Cd28tm1Mak/J)
brain inflammation J:57613
decreased susceptibility to experimental autoimmune encephalomyelitis J:57613
\Cd28tm1Mak/\Cd28tm1Mak
\Cd5tm1Cgn/\Cd5+

(either: (involves: 129P2/OlaHsd * 129S2/SvPas * BALB/c * C57BL/6) or (involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 * DBA/1 * LP))
abnormal T cell clonal deletion J:110925
\Cd28tm1Mak/\Cd28tm1Mak
\Cd5tm1Cgn/\Cd5tm1Cgn

(either: (involves: 129P2/OlaHsd * 129S2/SvPas * BALB/c * C57BL/6) or (involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 * DBA/1 * LP))
abnormal T cell clonal deletion J:110925
increased CD4-positive, alpha-beta T cell number J:110925
increased CD8-positive, alpha-beta T cell number J:110925
\Cd28tm1Mak/\Cd28tm1Mak
\Cd40lgtm1Flv/\Cd40lgtm1Flv

(NOD.Cg-Cd40lgtm1Flv Cd28tm1Mak)
decreased regulatory T cell number J:93421
increased susceptibility to autoimmune diabetes J:93421
insulitis J:93421
\Cd28tm1Mak/\Cd28tm1Mak
\Ndfip1Gt(RRD002)Byg/\Ndfip1Gt(RRD002)Byg

(involves: 129P2/OlaHsd * 129S2/SvPas)
esophageal inflammation J:205692
increased eosinophil cell number J:205692
increased interleukin-2 secretion J:205692
increased interleukin-4 secretion J:205692
\Cd28tm1Mak/\Cd28tm1Mak
\Rc3h1san/\Rc3h1+

(involves: 129S2/SvPas * C57BL/6 * C57BL/6JSfdAnu)
increased T cell derived lymphoma incidence J:189087
\Cd28tm1Mak/\Cd28tm1Mak
\Stat6tm1Gru/\Stat6tm1Gru

(C.129S2(B6)-Cd28tm1Mak Stat6tm1Gru)
increased susceptibility to parasitic infection J:90987
\Cd28tm1Mak/\Cd28tm1Mak
\Tg(Cd4-cre)1Cwi/?
\Traf6tm2Ywc/\Traf6tm2Ywc

(involves: 129S2/SvPas * C57BL/6 * DBA/2)
decreased interleukin-2 secretion J:130882
decreased T cell proliferation J:130882
increased activated T cell number J:130882
increased memory T cell number J:130882
\Cd28tm1Mak/\Cd28tm1Mak
\Tg(H2-K-Cd86)7All/0

(involves: BALB/c * C57BL/6 * CBA)
abnormal T cell differentiation J:112266
\Cd28tm1Mak/\Cd28tm1Mak
\Tg(TcrLCMV)327Sdz/0

(involves: 129S2/SvPas * C57BL/6 * DBA/2)
abnormal T cell anergy J:123989
decreased cytotoxic T cell cytolysis J:123989
decreased splenocyte proliferation J:123989
decreased T cell proliferation J:123989
\Cd28tm1Mak/\Cd28tm1Mak
\Tnfsf9tm1Thw/\Tnfsf9tm1Thw

(involves: 129 * 129S2/SvPas * C57BL/6)
abnormal cytotoxic T cell physiology J:76373
increased length of allograft survival J:76373
\Cd28tm1Mak/\Cd28tm1Mak
\Tnfsf14tm1Kpf/\Tnfsf14tm1Kpf

(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6)
increased length of allograft survival J:77250
\Cd28tm1Pjl/\Cd28tm1Pjl
(involves: 129P2/OlaHsd * C57BL/6)
abnormal class switch recombination J:83722
abnormal cytotoxic T cell physiology J:83722
abnormal immunoglobulin level J:83722
decreased IgG1 level J:83722
decreased IgG2a level J:83722
decreased IgM level J:83722
decreased interleukin-12 secretion J:83722
decreased susceptibility to type IV hypersensitivity reaction J:83722
increased splenocyte proliferation J:83722
\Cd28tm1Pjl/\Cd28tm1Pjl
\Tg(DO11.10)10Dlo/0

(involves: 129P2/OlaHsd * BALB/c * C3H * C57BL/6)
abnormal T cell activation J:25536
abnormal T cell proliferation J:25536
abnormal thymocyte activation J:25536
decreased interleukin-2 secretion J:25536
\Cd28tm1Pjl/\Cd28tm1Pjl
\Tg(H2-K-Cd86)27All/0

(involves: 129P2/OlaHsd * C57BL/6 * CBA)
decreased B cell number J:112475
\Cd28tm1Pjl/\Cd28tm1Pjl
\Tnfrsf9tm1Byk/\Tnfrsf9tm1Byk

(either: B6.Cg-Cd28tm1Pjl Tnfrsf9tm1Byk or C.Cg-Cd28tm1Pjl Tnfrsf9tm1Byk)
abnormal class switch recombination J:83722
abnormal cytotoxic T cell physiology J:83722
decreased IgG1 level J:83722
decreased IgG2a level J:83722
decreased IgM level J:83722
decreased interleukin-12 secretion J:83722
decreased splenocyte proliferation J:83722
decreased susceptibility to type IV hypersensitivity reaction J:83722
\Cd28tm1Shr/\Cd28tm1Shr
(involves: 129S4/SvJae * BALB/c * C57BL/6)
decreased CD4-positive, alpha-beta T cell number J:68642
decreased interleukin-2 secretion J:68642
decreased T cell proliferation J:68642
\Cd28tm1Shr/\Cd28tm1Shr
\Ctla4tm1Shr/\Ctla4+

(C.129S4-Cd28tm1Shr Ctla4tm1Shr)
abnormal CD8-positive, alpha beta T cell morphology J:125259
increased susceptibility to autoimmune disorder J:125259
\Cd28tm1Shr/\Cd28tm1Shr
\Ctla4tm1Shr/\Ctla4tm1Shr

(C.129S4-Cd28tm1Shr Ctla4tm1Shr)
abnormal interferon level J:68642
abnormal interleukin secretion J:68642
decreased CD4-positive, alpha-beta T cell number J:68642
decreased T cell proliferation J:68642
increased length of allograft survival J:68642
\Cd33tm1Avrk/\Cd33tm1Avrk
(involves: 129X1/SvJ * C57BL/6)
decreased inflammatory response J:83728
\Cd34tm1Lal/\Cd34tm1Lal
(involves: 129S2/SvPas)
decreased splenocyte number J:30621
\Cd34tm1Szk/\Cd34tm1Szk
(involves: 129P2/OlaHsd * C57BL/6J)
decreased eosinophil cell number J:32799
immune system phenotype J:32799
\Cd36em1(IMPC)Mbp/\Cd36em1(IMPC)Mbp
(C57BL/6N-Cd36em1(IMPC)Mbp/MbpMmucd)
abnormal spleen morphology J:211773
enlarged spleen J:211773
\Cd36obl/\Cd36obl
(C57BL/6-Cd36obl)
abnormal cell-mediated immunity J:96018
abnormal macrophage physiology J:96018
endophthalmitis J:96018
increased susceptibility to bacterial infection J:96018
\Cd36tm1Frm/\Cd36tm1Frm
(involves: 129S4/SvJae)
abnormal microglial cell physiology J:140907
\Cd36tm1Frm/\Cd36tm1Frm
(involves: 129S4/SvJae * C57BL/6J)
abnormal chemokine level J:80658
abnormal macrophage physiology J:80658
\Cd36tm1Frm/\Cd36tm1Frm
(B6.129S4-Cd36tm1Frm)
abnormal response to infection J:100140
decreased interleukin-6 secretion J:100140
decreased interleukin-12 secretion J:100140
decreased tumor necrosis factor secretion J:100140
impaired macrophage phagocytosis J:100140
increased susceptibility to bacterial infection induced morbidity/mortality J:100140
sepsis J:100140
\Cd36tm1Mfe/\Cd36tm1Mfe
(B6.129S1-Cd36tm1Mfe)
abnormal B cell morphology J:130897
abnormal plasma cell differentiation J:130897
decreased IgG1 level J:130897
decreased IgG2a level J:130897
decreased IgG2c level J:130897
decreased IgG level J:130897
decreased IgM level J:130897
decreased immunoglobulin level J:130897
increased transitional stage B cell number J:130897
\Cd36tm1Mfe/\Cd36tm1Mfe
(involves: 129S1/Sv)
abnormal macrophage chemotaxis J:89664
\Cd37tm1Hor/\Cd37tm1Hor
(involves: 129P2/OlaHsd * C57BL/6)
abnormal class switch recombination J:63315
abnormal humoral immune response J:63315
abnormal lymph node germinal center morphology J:63315
decreased IgG1 level J:63315
decreased spleen germinal center number J:63315
decreased spleen germinal center size J:63315
immune system phenotype J:63315
\Cd38em1(IMPC)Ccpcz/\Cd38em1(IMPC)Ccpcz
(C57BL/6NCrl-Cd38em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
decreased CD4-positive NK T cell number J:211773
decreased CD4-positive, alpha-beta T cell number J:211773
decreased CD4-positive, CD25-positive, alpha-beta regulatory T cell number J:211773
decreased effector memory T-helper cell number J:211773
decreased memory-marker CD4-positive NK T cell number J:211773
decreased NK T cell number J:211773
decreased T-helper cell number J:211773
enlarged spleen J:211773
enlarged thymus J:211773
increased effector memory CD8-positive, alpha-beta T cell number J:211773
increased NK cell number J:211773
\Cd38tm1Lnd/\Cd38tm1Lnd
(involves: 129P2/OlaHsd * C57BL/6J)
abnormal humoral immune response J:49170
\Cd38tm1Lnd/\Cd38tm1Lnd
(NOD.129P2(B6)-Cd38tm1Lnd/LtJ)
increased susceptibility to autoimmune diabetes J:108097
increased T cell apoptosis J:108097
insulitis J:108097
\Cd40m1Btlr/\Cd40m1Btlr
(C57BL/6J-Cd40m1Btlr)
impaired humoral immune response J:221482
\Cd40m2Btlr/\Cd40m2Btlr
(C57BL/6J-Cd40m2Btlr)
abnormal humoral immune response J:254828
decreased IgG level J:254828
\Cd40tm1Arah/\Cd40tm1Arah
(B6.129S1-Cd40tm1Arah)
abnormal immunoglobulin level J:120512
abnormal response to transplant J:120512
absent spleen germinal center J:120512
decreased IgE level J:120512
decreased IgG1 level J:120512
decreased IgG2b level J:120512
decreased IgG level J:120512
decreased IgM level J:120512
increased IgG3 level J:120512
increased IgM level J:120512
\Cd40tm1Geha/\Cd40tm1Geha
(involves: 129S4/SvJae * C57BL/6)
abnormal lymph node germinal center morphology J:82298
decreased IgA level J:82298
decreased IgG1 level J:82298
decreased IgG2a level J:82298
decreased IgG2b level J:82298
decreased spleen germinal center number J:82298
decreased spleen germinal center size J:82298
\Cd40tm1Kik/\Cd40+
\Mir146tm1.1Lfl/\Mir146tm1.1Lfl
\Tg(Cr2-cre)3Cgn/0

(involves: 129P2/OlaHsd * C57BL/6)
immune system phenotype J:266124
increased T follicular helper cell number J:266124
\Cd40tm1Kik/\Cd40tm1Kik
(B6.129P2-Cd40tm1Kik/J)
abnormal dendritic cell physiology J:86998
increased susceptibility to bacterial infection J:86998
\Cd40tm1Kik/\Cd40tm1Kik
(involves: 129P2/OlaHsd * C57BL/6)
abnormal humoral immune response J:25007
absent spleen germinal center J:25007
decreased IgA level J:25007
decreased IgE level J:25007
decreased IgG1 level J:25007
decreased IgG2a level J:25007
decreased IgG2b level J:25007
decreased IgG3 level J:25007
decreased immunoglobulin level J:25007
decreased neutrophil cell number J:25007
decreased susceptibility to type II hypersensitivity reaction J:61673
immune system phenotype J:25007
\Cd40tm1Kik/\Cd40tm1Kik
(involves: 129P2/OlaHsd)
absent germinal center B cells J:190943
decreased B cell number J:190943
immune system phenotype J:173115
\Cd40tm1Kik/\Cd40tm1Kik
\Ltbrtm1Mmat/\Ltbrtm1Mmat

(involves: 129P2/OlaHsd * C57BL/6 * CBA)
abnormal thymus epithelium morphology J:173115
abnormal thymus medulla morphology J:173115
immune system phenotype J:173115
\Cd40tm1Kik/\Cd40tm1Kik
\Tg(Tnfsf13b)1Fma/?

(B6.Cg-Cd40tm1Kik Tg(Tnfsf13b)1Fma)
abnormal B cell activation J:113556
abnormal class switch recombination J:113556
absent spleen germinal center J:113556
glomerulonephritis J:113556
increased anti-double stranded DNA antibody level J:113556
increased marginal zone B cell number J:113556
\Cd40tm1Kik/\Cd40tm1Kik
\Tnfsf11tm1Pngr/\Tnfsf11tm1Pngr

(involves: 129P2/OlaHsd)
abnormal thymus epithelium morphology J:173115
\Cd40tm1Kik/\Cd40tm1Kik
\Traf3ip2tm1.1Lix/\Traf3ip2tm1.1Lix

(involves: 129 * 129P2/OlaHsd * BALB/c)
abnormal B cell physiology J:138560
enlarged lymph nodes J:93923
enlarged spleen J:93923
immune system phenotype J:138560
increased follicular B cell number J:138560
increased marginal zone B cell number J:138560
increased transitional stage B cell number J:138560
\Cd40lgm1Btlr/Y
(involves: C57BL/6J)
abnormal class switch recombination J:185495
decreased IgG level J:185495
immune system phenotype J:185495
\Cd40lgm1Btlr/\Cd40lgm1Btlr
(C57BL/6J-Cd40lgm1Btlr)
decreased IgG level J:162147
immune system phenotype J:162147
\Cd40lgm1Btlr/\Cd40lgm1Btlr
(involves: C57BL/6J)
abnormal class switch recombination J:185495
decreased IgG level J:185495
immune system phenotype J:185495
\Cd40lgtm1Flv/Y
\Faslpr/\Faslpr

(involves: 129P2/OlaHsd * 129S2/SvPas * MRL)
decreased autoantibody level J:38492
decreased IgG level J:38492
decreased immunoglobulin level J:38492
\Cd40lgtm1Flv/Y
\Faslpr/\Faslpr
\Tcratm1Mjo/\Tcratm1Mjo

(involves: 129P2/OlaHsd * 129S2/SvPas * MRL)
decreased autoantibody level J:38492
increased anti-double stranded DNA antibody level J:38492
\Cd40lgtm1Flv/\Cd40lgtm1Flv
(involves: 129S2/SvPas * C57BL/6)
abnormal adaptive immunity J:25010
abnormal class switch recombination J:25010
abnormal immune system morphology J:25010
abnormal immune system physiology J:25010
abnormal osteoclast differentiation J:120087
abnormal T cell differentiation J:25010
abnormal T-helper 2 physiology J:25010
absent spleen germinal center J:25010
decreased double-positive T cell number J:25010
decreased IgA level J:25010
decreased IgD level J:25010
decreased IgE level J:25010
decreased IgG1 level J:25010
decreased IgG3 level J:25010
decreased immunoglobulin level J:25010
increased CD4-positive, alpha-beta T cell number J:25010
\Cd40lgtm1Flv/\Cd40lgtm1Flv
(NOD.129S2-Cd40lgtm1Flv)
decreased regulatory T cell number J:93421
decreased susceptibility to autoimmune diabetes J:93421
\Cd40lgtm1Flv/\Cd40lgtm1Flv
\Faslpr/\Faslpr

(involves: 129P2/OlaHsd * 129S2/SvPas * MRL)
decreased autoantibody level J:38492
decreased IgG level J:38492
decreased immunoglobulin level J:38492
\Cd40lgtm1Flv/\Cd40lgtm1Flv
\Faslpr/\Faslpr
\Tcratm1Mjo/\Tcratm1Mjo

(involves: 129P2/OlaHsd * 129S2/SvPas * MRL)
decreased autoantibody level J:38492
increased anti-double stranded DNA antibody level J:38492
\Cd40lgtm1Imx/Y
(involves: 129S2/SvPas * C57BL/6)
abnormal antigen presentation J:21137
abnormal class switch recombination J:21137
abnormal immune system organ morphology J:21137
abnormal immune system physiology J:21137
abnormal lymph node morphology J:21137
absent lymph node germinal center J:21137
absent spleen germinal center J:21137
decreased IgA level J:21137
decreased IgE level J:21137
decreased IgG1 level J:21137
decreased IgG2b level J:21137
decreased immunoglobulin level J:21137
immune system phenotype J:21137
lymph node hypoplasia J:21137
\Cd40lgtm1Imx/Y
(B6.129S2-Cd40lgtm1Imx/J)
abnormal leukocyte adhesion J:108988
\Cd40lgtm1Imx/\Cd40lgtm1Imx
(involves: 129S2/SvPas * C57BL/6J * BALB/c)
abnormal T cell clonal deletion J:110925
\Cd40lgtm1Imx/\Cd40lgtm1Imx
(involves: 129S2/SvPas * C57BL/6)
increased susceptibility to prion infection J:115487
microgliosis J:115487
\Cd40lgtm1Parl/Y
\Commd10Tg(Vav1-icre)A2Kio/\Commd10+

(involves: 129 * C57BL/6 * C57BL/10 * CBA/Ca)
decreased IgM level J:213459
increased IgG1 level J:213459
\Cd40lgtm1Parl/Y
\Tg(Cd4-cre)1Cwi/0

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2)
immune system phenotype J:213459
\Cd40lgtm1Parl/Y
\Tg(Tek-cre)1Ywa/0

(involves: 129 * C57BL/6 * CD-1 * SJL)
decreased IgA level J:213459
decreased IgG1 level J:213459
decreased IgG2a level J:213459
decreased IgG3 level J:213459
decreased IgM level J:213459
\Cd40lgtm1Parl/\Cd40lgtm1Parl
\Commd10Tg(Vav1-icre)A2Kio/\Commd10+

(involves: 129 * C57BL/6 * C57BL/10 * CBA/Ca)
decreased IgM level J:213459
increased IgG1 level J:213459
\Cd40lgtm1Parl/\Cd40lgtm1Parl
\Tg(Cd4-cre)1Cwi/0

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2)
immune system phenotype J:213459
\Cd40lgtm1Parl/\Cd40lgtm1Parl
\Tg(Tek-cre)1Ywa/0

(involves: 129 * C57BL/6 * CD-1 * SJL)
decreased IgA level J:213459
decreased IgG1 level J:213459
decreased IgG2a level J:213459
decreased IgG3 level J:213459
decreased IgM level J:213459
\Cd44M1Btlr/\Cd44M1Btlr
(C57BL/6J-Cd44M1Btlr)
decreased alpha-beta T cell number J:267483
decreased CD4-positive, alpha-beta T cell number J:267483
decreased CD8-positive, alpha-beta T cell number J:267483
decreased central memory CD4-positive, alpha-beta T cell number J:267483
decreased central memory CD8 positive, alpha-beta T cell number J:267483
decreased effector memory CD4-positive, alpha-beta T cell number J:267483
\Cd44tm1.1Ugu/\Cd44tm1.1Ugu
(involves: 129/Sv * C57BL/6)
abnormal T-helper 1 physiology J:62867
abnormal T-helper 2 physiology J:62867
immune system phenotype J:62867
\Cd44tm1.1Ugu/\Cd44tm1.1Ugu
(B6.129(Cg)-Cd44tm1.1Ugu)
decreased susceptibility to experimental autoimmune encephalomyelitis J:199279
\Cd44tm1.1Ugu/\Cd44tm1.1Ugu
(SJL.129(Cg)-Cd44tm1.1Ugu)
decreased susceptibility to experimental autoimmune encephalomyelitis J:199279
decreased T cell proliferation J:199279
\Cd44tm1.1Ugu/\Cd44tm1.1Ugu
\Il10tm1Cgn/\Il10tm1Cgn

(involves: 129/Sv * C57BL/6)
abnormal immune system physiology J:62867
\Cd44tm1Hbg/\Cd44+
\Tnftm2Gkl/\Tnf+

(involves: 129S/SvEv * 129S1/Sv * 129X1/SvJ * C57BL/6)
ileum inflammation J:145626
\Cd44tm1Hbg/\Cd44tm1Hbg
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
abnormal CD4-positive, alpha beta T cell morphology J:68069
abnormal CD8-positive, alpha beta T cell morphology J:68069
abnormal leukocyte migration J:68069
abnormal neutrophil physiology J:94850
\Cd44tm1Hbg/\Cd44tm1Hbg
(involves: 129S1/Sv * 129X1/SvJ)
abnormal osteoclast differentiation J:101563
abnormal response to infection J:86947
increased acute inflammation J:131974
\Cd44tm1Hbg/\Cd44tm1Hbg
(B6.129-Cd44tm1Hbg)
decreased mast cell histamine storage J:146846
decreased mast cell number J:146846
\Cd44tm1Hbg/\Cd44tm1Hbg
\Tg(TNF)197Gkl/0

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA)
abnormal osteoclast differentiation J:97992
abnormal osteoclast morphology J:97992
autoimmune arthritis J:97992
increased circulating interleukin-1 level J:97992
increased circulating interleukin-6 level J:97992
increased interleukin-1 secretion J:97992
increased interleukin-6 secretion J:97992
increased osteoclast cell number J:97992
\Cd44tm1Hbg/\Cd44tm1Hbg
\Tnftm2Gkl/\Tnf+

(involves: 129S/SvEv * 129S1/Sv * 129X1/SvJ * C57BL/6)
immune system phenotype J:145626
\Cd44tm1Mak/\Cd44+
(involves: 129P2/OlaHsd * C57BL/6J)
abnormal leukocyte migration J:99032
\Cd44tm1Mak/\Cd44tm1Mak
(involves: 129P2/OlaHsd * C57BL/6J)
abnormal leukocyte migration J:99032
immune system phenotype J:72658
increased susceptibility to parasitic infection J:72658
\Cd44tm1Mak/\Cd44tm1Mak
(B6.129P2-Cd44tm1Mak)
abnormal circulating cytokine level J:69351
abnormal leukocyte migration J:108245
decreased activation-induced cell death of T cells J:69351
impaired macrophage phagocytosis J:111216
impaired natural killer cell mediated cytotoxicity J:110889
increased circulating interferon-gamma level J:69351
increased circulating interleukin-2 level J:69351
increased circulating tumor necrosis factor level J:69351
liver inflammation J:69351
lung inflammation J:111216, J:108245
\Cd44tm1Mak/\Cd44tm1Mak
(D1.129P2-Cd44tm1Mak)
increased susceptibility to induced arthritis J:95275
\Cd44tm1Mak/\Cd44tm1Mak
(involves: 129P2/OlaHsd * C57BL/6)
abnormal chemokine secretion J:155691
abnormal circulating chemokine level J:155691
abnormal interleukin secretion J:155691
decreased acute inflammation J:114341
decreased circulating tumor necrosis factor level J:155691
increased interleukin-1 beta secretion J:155691
increased interleukin-6 secretion J:155691
increased interleukin-10 secretion J:155691
increased tumor necrosis factor secretion J:155691
peritoneal inflammation J:155691
\Cd44tm1Mak/\Cd44tm1Mak
\Itgaltm1Mak/\Itgaltm1Mak

(B6.129P2-Cd44tm1Mak Itgaltm1Mak)
impaired natural killer cell mediated cytotoxicity J:110889
\Cd44tm1Ugu/\Cd44tm1Ugu
(involves: 129/Sv * C57BL/6)
abnormal T-helper 1 physiology J:62867
abnormal T-helper 2 physiology J:62867
immune system phenotype J:62867
\Cd44tm2.1Ugu/\Cd44tm2.1Ugu
(B6.129-Cd44tm2.1Ugu)
decreased susceptibility to experimental autoimmune encephalomyelitis J:199279
decreased T cell proliferation J:199279
\Cd44tm2Kmz/\Cd44tm2Kmz
(DBA/1LacJ-Cd44tm2Kmz)
decreased susceptibility to induced arthritis J:74268
\Cd44tm2Kmz/\Cd44tm2Kmz
(involves: BALB/c * DBA/1)
abnormal CD4-positive, alpha-beta T cell physiology J:114317
abnormal leukocyte adhesion J:114317
decreased susceptibility to type IV hypersensitivity reaction J:114317
impaired leukocyte tethering or rolling J:114317
impaired neutrophil recruitment J:114317
\Cd44tm2Kmz/\Cd44tm2Kmz
\Selltm2Hyn/\Selltm2Hyn

(involves: 129S2/SvPas * BALB/c * DBA/1)
abnormal CD4-positive, alpha-beta T cell physiology J:114317
abnormal leukocyte adhesion J:114317
decreased susceptibility to type IV hypersensitivity reaction J:114317
impaired leukocyte tethering or rolling J:114317
impaired neutrophil recruitment J:114317
\Cd47tm1Fpl/\Cd47+
(B6.129S7-Cd47tm1Fpl)
increased susceptibility to bacterial infection induced morbidity/mortality J:36489
\Cd47tm1Fpl/\Cd47tm1Fpl
(involves: 129S7/SvEvBrd)
decreased T cell number J:36489
impaired neutrophil recruitment J:148196
\Cd47tm1Fpl/\Cd47tm1Fpl
(B6.129S7-Cd47tm1Fpl)
abnormal neutrophil physiology J:36489
decreased osteoclast cell number J:116609
impaired granulocyte bactericidal activity J:36489
impaired neutrophil chemotaxis J:36489
impaired neutrophil phagocytosis J:36489
increased susceptibility to bacterial infection J:36489
increased susceptibility to bacterial infection induced morbidity/mortality J:36489
\Cd47tm1Fpl/\Cd47tm1Fpl
(C.129S7-Cd47tm1Fpl)
decreased osteoclast cell number J:116609
\Cd47tm1Fpl/\Cd47tm1Fpl
(NOD.129S7-Cd47tm1Fpl)
abnormal spleen morphology J:76580
abnormal splenic cell ratio J:76580
enlarged spleen J:76580
\Cd47tm1Fpl/\Cd47tm1Fpl
(involves: 129S7/SvEvBrd * C57BL/6)
abnormal cytokine level J:134866
abnormal osteoclast differentiation J:147367
abnormal tumor necrosis factor level J:134866
decreased leukocyte cell number J:134866
decreased neutrophil cell number J:134866
decreased susceptibility to bacterial infection induced morbidity/mortality J:134866
increased susceptibility to bacterial infection J:134866
\Cd48tm1Rsr/\Cd48tm1Rsr
(B6.129S4-Cd48tm1Rsr)
abnormal T cell activation J:53718
decreased T cell proliferation J:53718
increased CD4-positive, alpha-beta T cell number J:53718
\Cd52em1(IMPC)Ccpcz/\Cd52em1(IMPC)Ccpcz
(C57BL/6NCrl-Cd52em1(IMPC)Ccpcz/Ccpcz)
decreased NK T cell number J:211773
\Cd53tm1.1Nmg/\Cd53tm1.1Nmg
(involves: C57BL/6J)
abnormal B cell physiology J:260065
\Cd55tm1Mme/\Cd55tm1Mme
(involves: 129P2/OlaHsd * C57BL/6)
increased susceptibility to experimental autoimmune myasthenia gravis J:80116
\Cd55tm1Song/\Cd55tm1Song
(involves: 129S6/SvEvTac * C57BL/6)
abnormal complement pathway J:52968
immune system phenotype J:52968
impaired complement alternative pathway J:52968
impaired complement classical pathway J:52968
\Cd55tm1Song/\Cd55tm1Song
(involves: 129S6/SvEvTac)
abnormal complement pathway J:76578
\Cd55tm1Song/\Cd55tm1Song
(B6.129S6-Cd55tm1Song)
increased susceptibility to experimental autoimmune myasthenia gravis J:113567
\Cd55tm1Song/\Cd55tm1Song
\Cd59atm1Bpm/\Cd59atm1Bpm

(B6.129-Cd55tm1Song Cd59atm1Bpm)
abnormal complement pathway J:113567
increased susceptibility to experimental autoimmune myasthenia gravis J:113567
myositis J:113567
\Cd59atm1Bpm/\Cd59atm1Bpm
(involves: 129 * C57BL/6)
increased susceptibility to experimental autoimmune encephalomyelitis J:89014
\Cd59atm1Bpm/\Cd59atm1Bpm
(involves: 129)
abnormal complement pathway J:148367
increased macrophage cell number J:148367
increased susceptibility to induced arthritis J:146711
\Cd59atm1Bpm/\Cd59atm1Bpm
(B6.129-Cd59atm1Bpm)
abnormal CD4-positive, alpha-beta T cell physiology J:119703, J:123582
abnormal complement pathway J:92414
abnormal humoral immune response J:119703
decreased B cell proliferation J:119703
decreased IgG level J:119703
decreased plasma cell number J:119703
decreased susceptibility to Poxviridae infection J:122201
increased CD4-positive, alpha-beta T cell number J:123582
increased double-positive T cell number J:123582
increased neutrophil cell number J:123582
increased susceptibility to experimental autoimmune myasthenia gravis J:113567
increased susceptibility to Orthomyxoviridae infection J:123582
increased T cell proliferation J:122201
lung inflammation J:123582
myositis J:113567
\Cd59atm1Bpm/\Cd59atm1Bpm
(involves: 129 * BALB/c)
increased susceptibility to Orthomyxoviridae infection J:123582
\Cd59atm1Song/\Cd59atm1Song
(involves: 129S6/SvEvTac)
abnormal complement pathway J:76578
\Cd59atm1Song/\Cd59atm1Song
\Cd55tm1Song/\Cd55tm1Song

(involves: 129S6/SvEvTac * C57BL/6)
abnormal complement pathway J:76578
\Cd68tm1Shnd/\Cd68tm1Shnd
(either: B6.129-Cd68tm1Shnd or (involves: 129S1/Sv * 129X1/SvJ))
abnormal dendritic cell antigen presentation J:175275
\Cd68tm1Xfen/\Cd68tm1Xfen
(C57BL/6J-Cd68tm1Xfen)
abnormal osteoclast morphology J:178120
abnormal osteoclast physiology J:178120
\Cd69tm1Fsm/\Cd69tm1Fsm
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
abnormal B cell differentiation J:61329
abnormal humoral immune response J:61329
immune system phenotype J:61329
increased IgG2a level J:61329
increased IgM level J:61329
increased immature B cell number J:61329
increased pre-B cell number J:61329
\Cd69tm1Naka/\Cd69tm1Naka
(C.129P2-Cd69tm1Naka)
decreased susceptibility to induced arthritis J:84940
impaired neutrophil chemotaxis J:84940
impaired neutrophil recruitment J:84940
\Cd69tm1Naka/\Cd69tm1Naka
(B6.129P2-Cd69tm1Naka)
abnormal CD4-positive, alpha-beta T cell physiology J:184704
abnormal humoral immune response J:184704
abnormal memory T cell physiology J:184704
abnormal T cell physiology J:184704
decreased CD4-positive, alpha-beta T cell number J:184704
decreased interferon-gamma secretion J:184704
decreased tumor necrosis factor secretion J:184704
\Cd70tm1(cre)Jbo/\Cd70tm1(cre)Jbo
(B6.129P2-Cd70tm1(cre)Jbo)
decreased regulatory T cell number J:198200
immune system phenotype J:198200
\Cd70tm1.1Jda/\Cd70tm1.1Jda
(B6.Cg-Cd70tm1.1Jda)
abnormal CD8-positive, alpha-beta T cell physiology J:193042
abnormal immune system physiology J:193042
abnormal T cell physiology J:193042
decreased CD8-positive, alpha-beta T cell number J:193042
immune system phenotype J:193042
increased susceptibility to Riboviria infection J:193042
\Cd72b/\Cd72b
\Faslpr/\Faslpr

(involves: C57BL/6 * C57BL/6JJmsSlc * MRL/Mp)
abnormal B cell number J:204782
abnormal T cell number J:204782
autoimmune response J:204782
decreased anti-double stranded DNA antibody level J:204782
decreased anti-nuclear antigen antibody level J:204782
decreased IgG level J:204782
decreased spleen weight J:204782
decreased susceptibility to autoimmune disorder J:204782
\Cd72c/\Cd72c
(involves: C57BL/6 * MRL)
immune system phenotype J:204782
increased B cell proliferation J:204782
\Cd72c/\Cd72c
\Faslpr/\Faslpr

(involves: C57BL/6 * C57BL/6JJmsSlc * MRL/Mp)
abnormal B cell number J:204782
abnormal T cell number J:204782
autoimmune response J:204782
enlarged lymph nodes J:204782
increased anti-chromatin antibody level J:204782
increased anti-double stranded DNA antibody level J:204782
increased anti-single stranded DNA antibody level J:204782
increased IgG level J:204782
increased spleen weight J:204782
increased susceptibility to systemic lupus erythematosus J:204782
liver inflammation J:204782
lung inflammation J:204782
\Cd72tm1Jrp/\Cd72tm1Jrp
(either: (involves: 129P2/OlaHsd) or (involves: 129P2/OlaHsd * C57BL/6))
abnormal B cell activation J:76990
abnormal B cell calcium ion homeostasis J:76990
abnormal B cell differentiation J:76990
decreased B cell number J:76990
decreased B-2 B cell number J:76990
decreased follicular B cell number J:76990
decreased mature B cell number J:76990
increased B cell proliferation J:76990
increased B-1 B cell number J:76990
increased B-1a cell number J:76990
increased IgM level J:76990
increased immature B cell number J:76990
increased marginal zone B cell number J:76990
increased pre-B cell number J:76990
increased pro-B cell number J:76990
\Cd72tm1Jrp/\Cd72tm1Jrp
\Tg(BCL2)22Wehi/0

(either: (involves: 129P2/OlaHsd * C57BL/6JWehi * SJL/JWehi) or (involves: 129P2/OlaHsd * C57BL/6 * C57BL/6JWehi * SJL/JWehi))
abnormal B cell physiology J:76990
decreased mature B cell number J:76990
increased immature B cell number J:76990
\Cd72tm1Tsub/\Cd72tm1Tsub
(involves: C57BL/6J)
glomerulonephritis J:204782
immune system phenotype J:204782
increased anti-chromatin antibody level J:204782
increased anti-double stranded DNA antibody level J:204782
increased anti-single stranded DNA antibody level J:204782
increased B cell proliferation J:204782
increased spleen weight J:204782
lung inflammation J:204782
\Cd72tm1Tsub/\Cd72tm1Tsub
\Faslpr/\Faslpr

(involves: C57BL/6J * C57BL/6JJmsSlc * MRL/Mp)
abnormal B cell number J:204782
abnormal T cell number J:204782
autoimmune response J:204782
enlarged lymph nodes J:204782
glomerulonephritis J:204782
increased anti-chromatin antibody level J:204782
increased anti-double stranded DNA antibody level J:204782
increased anti-single stranded DNA antibody level J:204782
increased spleen weight J:204782
liver inflammation J:204782
lung inflammation J:204782
\Cd74em1(IMPC)H/\Cd74em1(IMPC)H
(C57BL/6N-Cd74em1(IMPC)H/H)
decreased leukocyte cell number J:211773
decreased lymphocyte cell number J:211773
increased eosinophil cell number J:211773
increased monocyte cell number J:211773
increased neutrophil cell number J:211773
\Cd74tm1Doi/\Cd74tm1Doi
(either: (involves: 129/Sv * B10.BR) or (involves: 129/Sv * C57BL/6))
abnormal antigen presentation J:4119
abnormal level of surface class II molecules J:45185
decreased CD4-positive, alpha-beta T cell number J:4119, J:45185
increased CD8-positive, alpha-beta T cell number J:4119
\Cd74tm1Doi/\Cd74tm1Doi
(involves: 129S2/SvPas)
abnormal dendritic cell antigen presentation J:151699
\Cd74tm1Doi/\Cd74tm1Doi
\H2-DMatm1Doi/\H2-DMatm1Doi

(involves: 129S2/SvPas * C57BL/6)
abnormal professional antigen presenting cell physiology J:42482
decreased CD4-positive, alpha-beta T cell number J:42482
increased CD8-positive, alpha-beta T cell number J:42482
\Cd74tm1Doi/\Cd74tm1Doi
\Tap1tm1Arp/\Tap1tm1Arp

(involves: 129S2/SvPas * C57BL/6)
abnormal T cell number J:113083
\Cd74tm1Eae/\Cd74tm1Eae
(involves: 129S2/SvPas)
abnormal level of surface class II molecules J:65917
decreased B cell proliferation J:113050, J:132865
decreased CD4-positive, alpha-beta T cell number J:113050
decreased IgM level J:113050
\Cd74tm1Eae/\Cd74tm1Eae
(B6.129S2-Cd74tm1Eae)
abnormal lymph node cell ratio J:112084
arrested B cell differentiation J:112084
\Cd74tm1Liz/\Cd74tm1Liz
(involves: 129S/SvEv * C57BL/6J)
abnormal antigen presentation J:72243
abnormal antigen presentation via MHC class II J:65918
abnormal level of surface class II molecules J:65918
decreased CD4-positive, alpha-beta T cell number J:65918
decreased interferon-gamma secretion J:72243
decreased susceptibility to experimental autoimmune encephalomyelitis J:72243
decreased T cell proliferation J:72243
defective assembly of class II molecules J:65918
\Cd74tm1Liz/\Cd74tm1Liz
(B6.129S-Cd74tm1Liz)
abnormal antigen presentation J:125654
abnormal antigen presentation via MHC class II J:28966
abnormal level of surface class II molecules J:28966
abnormal T-helper 1 physiology J:125654
decreased CD4-positive, alpha-beta T cell number J:28966
decreased susceptibility to experimental autoimmune encephalomyelitis J:125654
decreased susceptibility to type IV hypersensitivity reaction J:125654
decreased T cell proliferation J:28966
defective assembly of class II molecules J:28966
\Cd74tm1Liz/\Cd74tm1Liz
(involves: 129S/SvEv * C57BL/6)
abnormal antigen presentation via MHC class II J:111565
\Cd74tm1Liz/\Cd74tm1Liz
(involves: 129S/SvEv * BALB/cAn)
abnormal antigen presentation via MHC class II J:110927, J:113714
abnormal B cell differentiation J:110927
abnormal dendritic cell antigen presentation J:110927
abnormal professional antigen presenting cell physiology J:113714
decreased CD4-positive, alpha-beta T cell number J:110927, J:113714
increased immature B cell number J:110927
\Cd74tm1Liz/\Cd74tm1Liz
(involves: 129S/SvEv * BALB/c * C57BL)
abnormal antigen presentation via MHC class II J:110927
abnormal B cell differentiation J:110927
abnormal dendritic cell antigen presentation J:110927
abnormal T cell proliferation J:110927
increased immature B cell number J:110927
\Cd74tm1Liz/\Cd74tm1Liz
(involves: 129S/SvEv * C57BL * C57BL/10 * C57BR)
abnormal antigen presentation via MHC class II J:110927
abnormal B cell differentiation J:110927
abnormal dendritic cell antigen presentation J:110927
abnormal T cell proliferation J:110927
increased immature B cell number J:110927
\Cd74tm1Liz/\Cd74tm1Liz
(involves: 129S/SvEv)
abnormal positive T cell selection J:125548
\Cd74tm1Liz/\Cd74tm1Liz
(B6.129S-Cd74tm1Liz/J)
decreased B cell number J:194664
\Cd74tm1Liz/\Cd74tm1Liz
\H2-DMatm1Liz/\H2-DMatm1Liz

(involves: 129S/SvEv * BALB/c)
decreased CD4-positive, alpha-beta T cell number J:113714
\Cd74tm1Liz/\Cd74tm1Liz
\H2-DMatm1Luc/\H2-DMatm1Luc
\Tg(CD74)AR194Ayr/?

(involves: 129S/SvEv * 129S4/SvJae * C57BL/6J * DBA/2J)
abnormal antigen presentation via MHC class II J:88717
decreased CD4-positive, alpha-beta T cell number J:88717
\Cd74tm1Liz/\Cd74tm1Liz
\H2-DMatm1Luc/\H2-DMatm1Luc
\Tg(CD74*)1Ayr/0

(involves: 129S/SvEv * 129S4/SvJae * C57BL/6J * DBA/2J)
abnormal antigen presentation via MHC class II J:88717
decreased CD4-positive, alpha-beta T cell number J:88717
\Cd74tm1Liz/\Cd74tm1Liz
\Sppl2atm1Basc/\Sppl2atm1Basc

(B6.129-Sppl2atm1Basc Cd74tm1Liz)
decreased B cell number J:194664
decreased Peyer's patch number J:194664
immune system phenotype J:194664
\Cd74tm1Liz/\Cd74tm1Liz
\Sppl2atm1Dgen/\Sppl2atm1Dgen

(involves: 129P2/OlaHsd * 129S/SvEv * C57BL/6)
decreased follicular B cell number J:194595
immune system phenotype J:194595
\Cd74tm2Liz/\Cd74tm1Liz
(involves: 129S/SvEv * C57BL/6)
abnormal antigen presentation via MHC class II J:28966
immune system phenotype J:28966
increased T cell proliferation J:28966
\Cd74tm2Liz/\Cd74tm2Liz
(involves: 129S/SvEv * C57BL/6)
decreased interleukin-2 secretion J:72243
increased susceptibility to experimental autoimmune encephalomyelitis J:72243
\Cd74tm3Liz/\Cd74tm3Liz
(involves: 129S/SvEv * C57BL/6)
abnormal antigen presentation via MHC class II J:82880
abnormal level of surface class II molecules J:82880
decreased interleukin-2 secretion J:72243
defective assembly of class II molecules J:82880
immune system phenotype J:82880
increased susceptibility to experimental autoimmune encephalomyelitis J:72243
\Cd79am1Anu/\Cd79am1Anu
(involves: C57BL/6JSfdAnu * C57BL/10Sg * C57BR/cd)
absent pre-B cells J:104190
decreased IgG level J:104190
\Cd79am1Anu/\Cd79am1Anu
(C57BL/6-Cd79am1Anu)
absent pre-B cells J:171924
\Cd79am1Anu/\Cd79am1Anu
\Rasgrp1m1Anu/\Rasgrp1m1Anu

(involves: C57BL/6JSfdAnu * CBA/J)
immune system phenotype J:207898
\Cd79am1Btlr/\Cd79am1Btlr
(involves: C57BL/6J * C57BL/10J)
abnormal humoral immune response J:174338
decreased B cell number J:174338
decreased IgG level J:174338
decreased IgM level J:174338
\Cd79am1Btlr/\Cd79am1Btlr
(involves: C57BL/6J)
abnormal class switch recombination J:185495
decreased B cell number J:185495
decreased IgG level J:185495
decreased IgM level J:185495
\Cd79am2Btlr/\Cd79am2Btlr
(C57BL/6J-Cd79am2Btlr)
decreased B-1 B cell number J:254836
decreased IgM level J:254836
impaired humoral immune response J:254836
\Cd79atm1(cre)Reth/\Cd79a+
\Commd3tm1.1Ksuz/\Commd3tm1.1Ksuz

(involves: BALB/c * C57BL/6NSlc * SJL)
abnormal follicular B cell physiology J:278399
abnormal plasmablast number J:278399
abnormal spleen B cell follicle morphology J:278399
decreased follicular B cell number J:278399
decreased IgG1 level J:278399
decreased IgG2b level J:278399
decreased IgG2c level J:278399
decreased IgM level J:278399
decreased mature B cell number J:278399
decreased spleen germinal center number J:278399
immune system phenotype J:278399
\Cd79atm1(cre)Reth/\Cd79a+
\Commd8tm1.1Ksuz/\Commd8tm1.1Ksuz

(involves: BALB/c * C57BL/6NSlc * SJL)
abnormal follicular B cell physiology J:278399
abnormal plasmablast number J:278399
abnormal spleen B cell follicle morphology J:278399
decreased follicular B cell number J:278399
decreased IgG1 level J:278399
decreased IgG2b level J:278399
decreased IgG2c level J:278399
decreased IgG3 level J:278399
decreased IgM level J:278399
decreased mature B cell number J:278399
decreased spleen germinal center number J:278399
immune system phenotype J:278399
\Cd79atm1(cre)Reth/\Cd79a+
\Ctnnbl1tm1.1Crad/\Ctnnbl1tm1.1Crad

(involves: 129P2/OlaHsd * BALB/c * C57BL/6 * SJL)
abnormal B cell proliferation J:232010
abnormal class switch recombination J:232010
decreased B cell proliferation J:232010
immune system phenotype J:232010
\Cd79atm1(cre)Reth/\Cd79a+
\Dicer1tm1Mmk/\Dicer1tm1Mmk
\Tg(BCL2)22Wehi/0

(involves: BALB/c * C57BL/6JWehi * SJL/JWehi)
decreased B cell number J:135783
decreased mature B cell number J:135783
\Cd79atm1(cre)Reth/\Cd79a+
\Dynll1tm1.1Jhh/\Dynll1tm1.1Jhh

(B6.Cg-Dynll1tm1.1Jhh Cd79atm1(Cre)Reth)
abnormal B cell morphology J:230105
decreased immature B cell number J:230105
decreased mature B cell number J:230105
decreased pre-B cell number J:230105
\Cd79atm1(cre)Reth/\Cd79a+
\Dynll1tm1.1Jhh/\Dynll1tm1.1Jhh
\Tg(IghMyc)22Bri/0

(B6.Cg-Dynll1tm1.1Jhh Cd79atm1(Cre)Reth Tg(IghMyc)22Bri)
decreased immature B cell number J:230105
\Cd79atm1(cre)Reth/\Cd79a+
\Eif4a1tm1.1Bea/\Eif4a1tm1.1Bea

(involves: 129P2/OlaHsd * BALB/c * C57BL/6)
decreased B cell number J:344730
decreased pro-B cell number J:344730
\Cd79atm1(cre)Reth/\Cd79a+
\Eif4btm1.1Tnr/\Eif4btm1.1Tnr
\Eif4htm1c(EUCOMM)Wtsi/\Eif4htm1c(EUCOMM)Wtsi

(involves: BALB/c * C57BL/6 * C57BL/6N)
decreased IgG1 level J:344730
decreased mature B cell number J:344730
\Cd79atm1(cre)Reth/\Cd79a+
\Huwe1tm1.1Mak/Y

(B6.Cg-Cd79atm1(cre)Reth Huwe1tm1.1Mak)
abnormal B cell differentiation J:181705
abnormal class switch recombination J:181705
abnormal humoral immune response J:181705
absent B-1a cells J:181705
decreased B cell proliferation J:181705
decreased follicular B cell number J:181705
decreased IgA level J:181705
decreased IgG1 level J:181705
decreased IgG2a level J:181705
decreased IgG3 level J:181705
decreased IgM level J:181705
decreased marginal zone B cell number J:181705
decreased mature B cell number J:181705
decreased pre-B cell number J:181705
decreased transitional stage B cell number J:181705
increased B cell apoptosis J:181705
increased susceptibility to Riboviria infection J:181705
\Cd79atm1(cre)Reth/\Cd79a+
\Huwe1tm1.1Mak/Y
\Trp53tm1Brn/\Trp53tm1Brn

(involves: 129P2/OlaHsd * C57BL/6 * SJL)
abnormal class switch recombination J:181705
absent B-1a cells J:181705
decreased IgG1 level J:181705
decreased IgM level J:181705
immune system phenotype J:181705
\Cd79atm1(cre)Reth/\Cd79a+
\Ikzf1tm3.1Mbu/\Ikzf1tm3.1Mbu

(involves: 129P2/OlaHsd * BALB/c * C57BL/6 * SJL)
abnormal B cell differentiation J:209928
abnormal B cell number J:209928
decreased pre-B cell number J:209928
increased pro-B cell number J:209928
\Cd79atm1(cre)Reth/\Cd79a+
\Inpp5dtm1Rav/\Inpp5dtm1Rav

(involves: 129 * BALB/c * C57BL/6)
increased anti-chromatin antibody level J:178833
increased anti-double stranded DNA antibody level J:178833
increased anti-nuclear antigen antibody level J:178833
increased anti-single stranded DNA antibody level J:178833
increased autoantibody level J:178833
increased IgG level J:178833
increased susceptibility to systemic lupus erythematosus J:178833
\Cd79atm1(cre)Reth/\Cd79a+
\Nfkbiztm1.1Muta/\Nfkbiztm1.1Muta

(involves: BALB/c * C57BL/6)
immune system phenotype J:194832
\Cd79atm1(cre)Reth/\Cd79a+
\Nr4a1tm1Pcn/\Nr4a1tm1Pcn

(involves: 129 * BALB/c)
increased B cell proliferation J:306652
\Cd79atm1(cre)Reth/\Cd79a+
\Nr4a1tm1Pcn/\Nr4a1tm1Pcn
\Nr4a3em1Juz/\Nr4a3em1Juz

(involves: 129 * BALB/c * C57BL/6)
decreased B cell apoptosis J:306652
immune system phenotype J:306652
increased B cell proliferation J:306652
\Cd79atm1(cre)Reth/\Cd79a+
\Orai1tm1Smua/\Orai1tm1Smua

(involves: BALB/c * C57BL/6J)
abnormal B cell activation J:345485
abnormal B cell physiology J:345485
immune system phenotype J:345485
\Cd79atm1(cre)Reth/\Cd79a+
\Orai1tm1Smua/\Orai1tm1Smua
\Orai3em1.1Treb/\Orai3em1.1Treb

(involves: BALB/c * C57BL/6J * C57BL/6N)
abnormal B cell activation J:345485
abnormal B cell physiology J:345485
decreased B cell proliferation J:345485
immune system phenotype J:345485
\Cd79atm1(cre)Reth/\Cd79a+
\Orai3em1.1Treb/\Orai3em1.1Treb

(involves: BALB/c * C57BL/6J * C57BL/6N)
abnormal B cell activation J:345485
immune system phenotype J:345485
\Cd79atm1(cre)Reth/\Cd79a+
\Phf5atm1.1Oux/\Phf5atm1.1Oux

(involves: BALB/c * C57BL/6J)
abnormal B cell physiology J:345807
abnormal B cell receptor editing J:345807
abnormal immunoglobulin heavy chain V(D)J recombination J:345807
decreased B cell number J:345807
decreased early pro-B cell number J:345807
decreased immature B cell number J:345807
decreased late pro-B cell number J:345807
decreased mature B cell number J:345807
decreased pre-B cell number J:345807
increased pre-pro B cell number J:345807
small spleen J:345807
\Cd79atm1(cre)Reth/\Cd79a+
\Phf5atm1.1Oux/\Phf5atm1.1Oux
\Tg(IghelMD4)4Ccg/0

(involves: BALB/c * C57BL/6 * C57BL/6J)
abnormal B cell number J:345807
\Cd79atm1(cre)Reth/\Cd79a+
\Slc39a10tm1.1Tfk/\Slc39a10tm1.1Tfk

(involves: 129S1/Sv * 129X1/SvJ * BALB/c * C57BL/6J)
decreased B cell number J:213935
decreased IgA level J:213935
decreased IgE level J:213935
decreased IgG1 level J:213935
decreased IgG2b level J:213935
decreased IgG2c level J:213935
decreased IgG3 level J:213935
decreased IgM level J:213935
decreased immunoglobulin level J:213935
decreased pro-B cell number J:213935
spleen atrophy J:213935
\Cd79atm1(cre)Reth/\Cd79a+
\Wastm1.1Ldn/Y

(involves: BALB/c * C57BL/6)
abnormal B cell physiology J:182528
decreased B cell number J:182528
decreased follicular B cell number J:182528
decreased marginal zone B cell number J:182528
decreased mature B cell number J:182528
increased anti-chromatin antibody level J:182528
increased anti-double stranded DNA antibody level J:182528
increased anti-single stranded DNA antibody level J:182528
increased autoantibody level J:182528
increased germinal center B cell number J:182528
increased IgM level J:182528
increased plasma cell number J:182528
\Cd79atm1(cre)Reth/\Cd79a+
\Wastm1.1Ldn/\Was+

(involves: BALB/c * C57BL/6)
abnormal B cell number J:182528
abnormal B cell proliferation J:182528
\Cd79atm1(cre)Reth/\Cd79a+
\Wastm1.1Ldn/\Wastm1.1Ldn

(involves: BALB/c * C57BL/6)
abnormal B cell physiology J:182528
decreased B cell number J:182528
decreased follicular B cell number J:182528
decreased marginal zone B cell number J:182528
decreased mature B cell number J:182528
increased anti-chromatin antibody level J:182528
increased anti-double stranded DNA antibody level J:182528
increased anti-single stranded DNA antibody level J:182528
increased autoantibody level J:182528
increased germinal center B cell number J:182528
increased IgM level J:182528
increased plasma cell number J:182528
\Cd79atm1(cre)Reth/\Cd79atm1(cre)Reth
\Mzb1tm1.1Rug/\Mzb1tm1.1Rug

(involves: 129S2/SvPas * BALB/c * C57BL/6 * SJL)
abnormal B cell number J:211639
decreased pre-B cell number J:211639
increased late pro-B cell number J:211639
increased pro-B cell number J:211639
small spleen J:211639
\Cd79atm1.1(BAP31N-EGFP)Pld/\Cd79atm1.1(BAP31N-EGFP)Pld
(Not Specified)
abnormal immune system cell morphology J:75114
\Cd79atm1.1Cgn/\Cd79a+
\Cd79btm1Gzmn/\Cd79btm1Gzmn

(involves: 129P2/OlaHsd)
decreased B cell number J:179254
decreased pre-B cell number J:179254
increased pro-B cell number J:179254
\Cd79atm1.1Cgn/\Cd79atm1.1Cgn
(involves: 129P2/OlaHsd)
decreased B-1a cell number J:124400
\Cd79atm1.1Cgn/\Cd79atm1.1Cgn
(involves: 129P2/OlaHsd * C57BL/6)
abnormal B cell activation J:71100
decreased B-1 B cell number J:71100
decreased IgG1 level J:71100
decreased marginal zone B cell number J:71100
decreased mature B cell number J:71100
\Cd79atm1.1Cgn/\Cd79atm1.1Cgn
\Cd79btm1Gzmn/\Cd79b+

(involves: 129P2/OlaHsd)
decreased B cell number J:179254
decreased pre-B cell number J:179254
increased pro-B cell number J:179254
\Cd79atm1.1Cgn/\Cd79atm1.1Cgn
\Cd79btm1Gzmn/\Cd79btm1Gzmn

(involves: 129/Sv * 129P2/OlaHsd * C57BL/6)
abnormal B cell differentiation J:124400
\Cd79atm1.1Cgn/\Cd79atm1.1Cgn
\Cd79btm1Gzmn/\Cd79btm1Gzmn

(involves: 129P2/OlaHsd)
abnormal B cell differentiation J:179254
absent pre-B cells J:179254
decreased B cell number J:179254
increased pro-B cell number J:179254
\Cd79atm1.1Cgn/\Cd79atm1.1Cgn
\Cd79btm2.1Mnz/\Cd79btm2.1Mnz

(involves: 129/Sv * 129P2/OlaHsd * C57BL/6)
absent mature B cells J:71100
arrested B cell differentiation J:71100
\Cd79atm1.1Cgn/\Cd79atm1.1Cgn
\Cd79btm3Mnz/\Cd79btm3Mnz

(involves: 129/Sv * 129P2/OlaHsd * C57BL/6)
immune system phenotype J:128768
\Cd79atm1.1Rsky/\Cd79atm1.1Rsky
(involves: C57BL/6)
abnormal humoral immune response J:179254
decreased IgG2b level J:179254
decreased IgG2c level J:179254
decreased IgG3 level J:179254
decreased marginal zone B cell number J:179254
decreased mature B cell number J:179254
immune system phenotype J:179254
increased anti-single stranded DNA antibody level J:179254
increased IgG2b level J:179254
increased IgG2c level J:179254
increased immature B cell number J:179254
increased pre-B cell number J:179254
increased transitional stage B cell number J:179254
increased transitional stage T1 B cell number J:179254
increased transitional stage T2 B cell number J:179254
increased transitional stage T3 B cell number J:179254
\Cd79atm2(cre/Esr1*)Reth/\Cd79a+
\Rag1tm1.1Sadu/\Rag1tm1.1Sadu

(involves: BALB/c)
arrested B cell differentiation J:155473
\Cd79atm2(cre/Esr1*)Reth/\Cd79a+
\Rag1tm1.1Sadu/\Rag1tm1.1Sadu

(involves: BALB/c)
immune system phenotype J:155473
\Cd79atm2Cgn/\Cd79atm2Cgn
(involves: C57BL/6 * C.B-20)
decreased B cell number J:80885
decreased immunoglobulin level J:80885
decreased mature B cell number J:80885
\Cd79atm2Cgn/\Cd79atm2Cgn
(involves: C57BL/6)
decreased mature B cell number J:71100, J:66840
decreased pre-B cell number J:71100, J:66840
increased pro-B cell number J:66840
\Cd79atm2Cgn/\Cd79atm2Cgn
\Cd79btm2.1Mnz/\Cd79btm2.1Mnz

(involves: 129/Sv * C57BL/6)
arrested B cell differentiation J:66840
decreased transitional stage B cell number J:66840
\Cd79atm2Pld/\Cd79atm2Pld
(BALB/c-Cd79atm2Pld)
abnormal B cell differentiation J:87492
abnormal T cell differentiation J:87492
absent mature B cells J:87492
decreased double-positive T cell number J:87492
\Cd79atm2Pld/\Cd79atm2Pld
\Cd79btm1Mnz/\Cd79btm1Mnz

(involves: 129S1/Sv * BALB/c)
absent pre-B cells J:87492
\Cd79atm3Cgn/\Cd79atm3Cgn
\Tg(Mx1-cre)1Cgn/?

(involves: C57BL/6 * CBA)
abnormal metallophilic macrophage morphology J:88620
abnormal spleen marginal zone macrophage morphology J:88620
abnormal spleen red pulp morphology J:88620
decreased B cell number J:88620
\Cd79atm3Cgn/\Cd79atm4.1Cgn
(involves: C57BL/6 * CBA)
immune system phenotype J:88620
\Cd79atm4.1Cgn/\Cd79atm4.1Cgn
(involves: C57BL/6)
abnormal B cell differentiation J:91091
\Cd79atm4.1Cgn/\Cd79atm4.1Cgn
\Ightm1.2Rsky/\Igh+

(involves: BALB/c * C57BL/6)
abnormal pro-B cell differentiation J:125719
\Cd79atm4Cgn/\Cd79atm4.1Cgn
\Tg(Cr2-cre)3Cgn/0

(involves: 129P2/OlaHsd * C57BL/6)
decreased B cell number J:91091
decreased IgD level J:91091
decreased IgM level J:91091
\Cd79atm4Cgn/\Cd79atm4.1Cgn
\Tg(Mx1-cre)1Cgn/0

(involves: 129P2/OlaHsd * C57BL/6 * CBA)
absent immature B cells J:91091
arrested B cell differentiation J:91091
decreased B cell number J:91091
decreased follicular B cell number J:91091
decreased marginal zone B cell number J:91091
\Cd79atm5.1Cgn/\Cd79a+
\Ightm1.2Rsky/\Igh+

(involves: 129 * BALB/c * C57BL/6)
abnormal class switch recombination J:125719
\Cd79atm5.1Cgn/\Cd79atm5.1Cgn
(involves: 129P2/OlaHsd * C57BL/6)
abnormal B cell differentiation J:91091
\Cd79atm5.1Cgn/\Cd79atm5.1Cgn
(involves: 129 * C57BL/6)
abnormal B cell morphology J:125719
decreased B-1a cell number J:125719
decreased immature B cell number J:125719
decreased mature B cell number J:125719
decreased pre-B cell number J:125719
decreased T cell number J:125719
increased pro-B cell number J:125719
\Cd79atm5.1Cgn/\Cd79atm5.1Cgn
\Ightm1.2Rsky/\Igh+

(involves: 129 * BALB/c * C57BL/6)
abnormal class switch recombination J:125719
\Cd79atm5.1Cgn/\Cd79atm5.1Cgn
\Ightm1.2Rsky/\Ightm1.2Rsky

(involves: 129 * BALB/c * C57BL/6)
abnormal B cell morphology J:125719
abnormal class switch recombination J:125719
decreased immature B cell number J:125719
decreased mature B cell number J:125719
decreased pre-B cell number J:125719
decreased T cell number J:125719
increased B-1b cell number J:125719
increased pro-B cell number J:125719
\Cd79atm5Cgn/\Cd79atm5.1Cgn
\Tg(Cr2-cre)3Cgn/0

(involves: 129P2/OlaHsd * C57BL/6)
decreased B cell number J:91091
\Cd79atm5Cgn/\Cd79atm5.1Cgn
\Tg(Mx1-cre)1Cgn/0

(involves: 129P2/OlaHsd * C57BL/6 * CBA)
absent immature B cells J:91091
arrested B cell differentiation J:91091
decreased B cell number J:91091
\Cd79atm6Cgn/\Cd79atm6Cgn
(involves: C57BL/6)
abnormal B cell number J:113407
abnormal B cell physiology J:113407
abnormal humoral immune response J:113407
abnormal immunoglobulin level J:113407
decreased B cell proliferation J:113407
decreased B-1a cell number J:113407
decreased IgG2a level J:113407
decreased IgG3 level J:113407
decreased IgM level J:113407
immune system phenotype J:113407
increased transitional stage B cell number J:113407
\Cd79atm7Cgn/\Cd79atm7Cgn
(involves: C57BL/6)
abnormal immune system physiology J:113407
\Cd79bm1Btlr/\Cd79bm1Btlr
(C57BL/6J-Cd79bm1Btlr)
decreased B cell number J:267537
decreased B-1 B cell number J:267537
decreased NK cell number J:267537
increased alpha-beta T cell number J:267537
increased CD4-positive, alpha-beta T cell number J:267537
increased CD8-positive, alpha-beta T cell number J:267537
\Cd79bm1Ghost/\Cd79bm1Ghost
(B10.Cg-Ptprca Cd79bm1Ghost H2a)
abnormal B cell differentiation J:157450
absent B cells J:157450
absent Peyer's patches J:157450
arrested B cell differentiation J:157450
decreased IgA level J:157450
decreased IgG level J:157450
\Cd79bM2Btlr/\Cd79bM2Btlr
(C57BL/6J-Cd79bM2Btlr)
abnormal lymphocyte morphology J:272863
decreased B cell number J:272863
decreased B-1 B cell number J:272863
\Cd79btm1Gzmn/\Cd79btm1Gzmn
(involves: 129/Sv * C57BL/6)
abnormal immune system physiology J:124400
decreased B-1a cell number J:124400
decreased IgG1 level J:124400
increased IgD level J:124400
increased IgM level J:124400
\Cd79btm1Mnz/\Cd79btm1Mnz
(involves: 129S1/Sv)
abnormal pro-B cell differentiation J:78601
abnormal pro-B cell morphology J:78601
arrested B cell differentiation J:78601
\Cd79btm1Mnz/\Cd79btm1Mnz
\Tg(BCL2)22Wehi/0
\Tg(IghelMD4)4Ccg/0
\Tg(Rag2-Igb)1Mnz/0

(involves: 129S1/Sv * C57BL/6 * C57BL/6JWehi * SJL/JWehi)
arrested B cell differentiation J:78601
\Cd79btm1Mnz/\Cd79btm1Mnz
\Tg(BCL2)22Wehi/0
\Tg(Rag2-Igb)1Mnz/0

(involves: 129S1/Sv * C57BL/6JWehi * SJL/JWehi)
arrested B cell differentiation J:78601
\Cd79btm1Mnz/\Cd79btm1Mnz
\Tg(IghelMD4)4Ccg/0
\Tg(Rag2-Igb)1Mnz/0

(involves: 129S1/Sv * C57BL/6)
abnormal immature B cell morphology J:78601
arrested B cell differentiation J:78601
\Cd79btm1Mnz/\Cd79btm1Mnz
\Tg(Rag2-Igb)1Mnz/0

(involves: 129S1/Sv)
abnormal pre-B cell morphology J:78601
arrested B cell differentiation J:78601
\Cd79btm2.1Mnz/\Cd79btm2.1Mnz
(involves: 129 * C57BL/6)
decreased mature B cell number J:71100
\Cd79btm2.1Mnz/\Cd79btm2.1Mnz
(involves: 129/Sv * C57BL/6)
abnormal B cell activation J:66840
arrested B cell differentiation J:66840
decreased mature B cell number J:66840
decreased pre-B cell number J:66840
decreased transitional stage B cell number J:66840
increased pro-B cell number J:66840
\Cd79btm3Mnz/\Cd79btm3Mnz
(involves: 129/Sv * C57BL/6)
abnormal B cell physiology J:128768
abnormal immature B cell morphology J:128768
abnormal immune system physiology J:128768
decreased B cell number J:128768
decreased B cell proliferation J:128768
decreased B-1a cell number J:128768
decreased immature B cell number J:128768
decreased mature B cell number J:128768
increased marginal zone B cell number J:128768
increased pro-B cell number J:128768
\Cd80tm1Lbgn/\Cd80tm1Lbgn
(C3.Cg-Cd80tm1Lbgn)
abnormal T cell physiology J:110947
\Cd80tm1Shr/\Cd80tm1Shr
(involves: 129S4/SvJae)
abnormal immunoglobulin level J:39089
decreased B cell proliferation J:74662
\Cd80tm1Shr/\Cd80tm1Shr
\Cd86tm1Shr/\Cd86tm1Shr

(B6.129S4-Cd80tm1Shr Cd86tm1Shr)
brain inflammation J:57613
decreased susceptibility to experimental autoimmune encephalomyelitis J:57613
decreased T cell proliferation J:57613
increased interferon-gamma secretion J:57613
increased tumor necrosis factor secretion J:57613
\Cd80tm1Shr/\Cd80tm1Shr
\Cd86tm2Shr/\Cd86tm2Shr

(involves: 129S4/SvJae)
abnormal lymph node B cell domain morphology J:39089
abnormal spleen morphology J:39089
abnormal T cell physiology J:57090
abnormal T cell proliferation J:57090
decreased IgG1 level J:39089
decreased IgG2a level J:39089
decreased IgG level J:39089
decreased regulatory T cell number J:205441, J:113109
increased IgG3 level J:39089
increased IgM level J:39089
increased susceptibility to autoimmune diabetes J:113109
\Cd80tm1Shr/\Cd80tm1Shr
\Cd86tm2Shr/\Cd86tm2Shr

(involves: 129S4/SvJae * NOD)
abnormal CD4-positive, alpha-beta T cell physiology J:61905
abnormal cytokine secretion J:61905
increased susceptibility to autoimmune diabetes J:61905
insulitis J:61905
\Cd80tm1Shr/\Cd80tm1Shr
\Cd86tm2Shr/\Cd86tm2Shr

(129.SJL-Cd86tm2Shr)
decreased interleukin-2 secretion J:78992
decreased susceptibility to experimental autoimmune encephalomyelitis J:78992
increased susceptibility to experimental autoimmune encephalomyelitis J:78992
\Cd80tm1Shr/\Cd80tm1Shr
\Cd86tm2Shr/\Cd86tm2Shr

(involves: 129S4/SvJae * C57BL/6J * SJL)
decreased susceptibility to experimental autoimmune encephalomyelitis J:78992
\Cd80tm1Shr/\Cd80tm1Shr
\Cd86tm2Shr/\Cd86tm2Shr

(involves: 129S4/SvJae * BALB/c)
abnormal T cell number J:112266
decreased double-positive T cell number J:112266
\Cd80tm1Shr/\Cd80tm1Shr
\Cd86tm2Shr/\Cd86tm2Shr
\Ctla4tm1Shr/\Ctla4tm1Shr

(involves: 129S4/SvJae * BALB/c)
abnormal cytokine secretion J:57090
abnormal T cell physiology J:57090
increased T cell proliferation J:57090
\Cd80tm1Shr/\Cd80tm1Shr
\Cd86tm2Shr/\Cd86tm2Shr
\Tg(Ighm-Ctla4Ig/Cd80)1Jbs/0

(involves: 129S4/SvJae * FVB/N * NOD)
decreased regulatory T cell number J:113109
decreased susceptibility to autoimmune diabetes J:113109
insulitis J:113109
\Cd81tm1Geha/\Cd81tm1Geha
(involves: 129S4/SvJae * C57BL/6)
abnormal B cell morphology J:43975
decreased B-1 B cell number J:43975
decreased B-1a cell number J:43975
increased B cell proliferation J:43975
increased IgA level J:43975
increased IgG3 level J:43975
increased IgM level J:43975
\Cd81tm1Lvy/\Cd81tm1Lvy
(involves: 129S1/Sv * 129X1/SvJ)
abnormal B cell morphology J:40394
abnormal T-helper 2 physiology J:40394
decreased IgG1 level J:40394
decreased IgG level J:40394
decreased susceptibility to parasitic infection J:126000
\Cd81tm1Lvy/\Cd81tm1Lvy
(CByJ.129-Cd81tm1Lvy)
abnormal T-helper 2 physiology J:46171
decreased susceptibility to type I hypersensitivity reaction J:46171
\Cd81tm1Lvy/\Cd81tm1Lvy
(either: (B6ByJ.129-Cd81tm1Lvy x CByJ.129-Cd81tm1Lvy)F1 or (CByJ.129-Cd81tm1Lvy x B6ByJ.129-Cd81tm1Lvy)F1)
abnormal microglial cell morphology J:79426
\Cd81tm1Tmiy/\Cd81tm1Tmiy
(involves: 129/Sv * C57BL/6)
abnormal B cell differentiation J:41830
abnormal immune system cell morphology J:41830
abnormal macrophage physiology J:83795
abnormal T cell proliferation J:41830
decreased B cell proliferation J:41830
decreased B-1 B cell number J:41830
increased B cell proliferation J:41830
\Cd81tm1Tmiy/\Cd81tm1Tmiy
\Cd9tm1Mek/\Cd9tm1Mek

(involves: 129/Sv * C57BL/6)
abnormal macrophage physiology J:83795
increased osteoclast cell number J:83795
\Cd82tm1Kjbr/\Cd82tm1Kjbr
(Not Specified)
abnormal cellular extravasation J:326451
abnormal macrophage differentiation J:326451
abnormal neutrophil physiology J:326451
impaired leukocyte tethering or rolling J:326451
increased macrophage cell number J:326451
increased neutrophil cell number J:326451
increased susceptibility to bacterial infection J:326451
\Cd83anu/\Cd83anu
(involves: C57BL/6JAnu * CBA/CaJAnu)
abnormal B cell morphology J:104190
abnormal dendritic cell morphology J:104190
decreased CD4-positive, alpha-beta T cell number J:104190
\Cd83lcd4/\Cd83lcd4
(involves: C57BL/6J)
abnormal CD4-positive T cell differentiation J:92721
abnormal CD4-positive, alpha-beta T cell physiology J:92721
decreased susceptibility to type IV hypersensitivity reaction J:92721
decreased T cell proliferation J:92721
\Cd83tm1.1Lnjt/\Cd83tm1.1Lnjt
(involves: C57BL/6 * C57BL/6N)
decreased CD4-positive, alpha-beta T cell number J:236611
\Cd83tm1.1Lnjt/\Cd83tm1.1Lnjt
\H2-Ab1b-tm2Hpl/\H2-Ab1b-tm2Hpl

(involves: 129S4/SvJae * C57BL/6 * C57BL/6N)
immune system phenotype J:236611
\Cd83tm1.1Lnjt/\Cd83tm1.1Lnjt
\Marchf1tm1.1Sish/\Marchf1tm1.1Sish

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * C57BL/6N)
decreased CD4-positive, alpha-beta T cell number J:236611
\Cd83tm1.1Lnjt/\Cd83tm1.1Lnjt
\Marchf8tm1.1Lkle/\Marchf8tm1.1Lkle

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * C57BL/6N)
immune system phenotype J:236611
\Cd83tm1Tft/\Cd83tm1Tft
(involves: 129S4/SvJae * C57BL/6)
abnormal CD4-positive T cell differentiation J:75700
abnormal humoral immune response J:75700
arrested T cell differentiation J:75700
decreased CD4-positive, alpha-beta T cell number J:75700
decreased IgA level J:75700
decreased IgG1 level J:75700
decreased IgG2a level J:75700
decreased IgG2b level J:75700
decreased IgG3 level J:75700
decreased IgM level J:75700
decreased susceptibility to type IV hypersensitivity reaction J:75700
\Cd84tm1Pls/\Cd84tm1Pls
(C57BL/6J-Cd84tm1Pls)
abnormal CD4-positive, alpha-beta T cell physiology J:157915
abnormal long lived plasma cell morphology J:157915
decreased CD4-positive, alpha-beta T cell number J:157915
decreased germinal center B cell number J:157915
decreased IgG level J:157915
decreased interleukin-21 secretion J:157915
decreased spleen germinal center size J:157915
\Cd84tm1Pls/\Cd84tm1Pls
\Tg(TcraTcrb)425Cbn/?

(B6.Cg-Cd84tm1Pls Tg(TcraTcrb)425Cbn)
abnormal CD4-positive, alpha-beta T cell physiology J:157915
\Cd86tm1Shr/\Cd86tm1Shr
(NOD.129S4-Cd86tm1Shr)
abnormal T cell proliferation J:142046
decreased regulatory T cell number J:93421
decreased susceptibility to autoimmune diabetes J:71352
decreased T cell proliferation J:93421
increased autoantibody level J:142046
increased interferon-gamma secretion J:142046
increased susceptibility to autoimmune diabetes J:93421
\Cd86tm1Shr/\Cd86tm1Shr
(involves: 129S4/SvJae)
abnormal humoral immune response J:39089
absent spleen germinal center J:39089
decreased IgG level J:39089
\Cd86tm1Shr/\Cd86tm1Shr
(B6.129S4-Cd86tm1Shr)
decreased T cell proliferation J:57613
increased interferon-gamma secretion J:57613
\Cd86tm1Shr/\Cd86tm1Shr
\Marchf1tm1.1Sish/\Marchf1tm1.1Sish

(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ)
decreased interleukin-12 secretion J:157516
decreased tumor necrosis factor secretion J:157516
\Cd86tm2Shr/\Cd86tm2Shr
\Icostm1Flv/\Icostm1Flv

(involves: 129S1/Sv * 129S4/SvJaeSor)
abnormal cytokine level J:112600
\Cd93tm1Mbo/\Cd93tm1Mbo
(either: 129/Sv or B6.129-Cd93tm1Mbo or (involves: 129/Sv * C57BL/6))
impaired macrophage phagocytosis J:88610
\Cd96em1(IMPC)Wtsi/\Cd96em1(IMPC)Wtsi
(C57BL/6N-Cd96em1(IMPC)Wtsi/WtsiOulu)
increased leukocyte cell number J:211773
\Cd96tm1.1Mjs/\Cd96tm1.1Mjs
(B6.129P2(Cg)-Cd96tm1.1Mjs)
abnormal NK cell physiology J:209990
immune system phenotype J:209990
increased inflammatory response J:209990
increased susceptibility to endotoxin shock J:209990
\Cd99Gt(Ayu21-B6T44)Imeg/\Cd99Gt(Ayu21-B6T44)Imeg
(involves: C57BL/6)
immune system phenotype J:207031
\Cd99Gt(Ayu21-B6T44)Imeg/\Cd99Gt(Ayu21-B6T44)Imeg
(involves: C57BL/6 * C57BL/6NSlc)
abnormal splenocyte physiology J:212222
\Cd99l2tm1.1Dvst/\Cd99l2tm1.1Dvst
\Tg(Tek-cre)1Ywa/0

(involves: 129S6/SvEvTac * BALB/c * C57BL/6)
abnormal cellular extravasation J:193021
decreased susceptibility to type IV hypersensitivity reaction J:193021
\Cd99l2tm1.2Dvst/\Cd99l2tm1.2Dvst
(involves: 129S6/SvEvTac * BALB/c * C57BL/6)
abnormal cellular extravasation J:193021
\Cd101tm1.1Dil/\Cd101tm1.1Dil
(involves: BALB/cJ * C57BL/6 * C57BL/6NTac)
decreased granulocyte number J:175943
\Cd109tm1Mat/\Cd109tm1Mat
(involves: 129S6/SvEvTac * C57BL/6J)
skin inflammation J:188696
\Cd151tm1Lka/\Cd151tm1Lka
(C57BL/6-Cd151tm1Lka)
abnormal T cell proliferation J:91605
\Cd151tm1Nki/\Cd151tm1Nki
(involves: 129P2/OlaHsd * FVB/N)
tubulointerstitial nephritis J:114988
\Cd160tm1Yxf/\Cd160tm1Yxf
(C57BL/6-Cd160tm1Yxf)
decreased interferon-gamma secretion J:222131
\Cd160tm1Yxf/\Cd160tm1Yxf
\Rag1tm1Mom/\Rag1tm1Mom

(B6.Cg-Rag1tm1Mom Cd160tm1Yxf)
decreased interferon-gamma secretion J:222131
\Cd163tm1(KOMP)Vlcg/\Cd163tm1(KOMP)Vlcg
(involves: C57BL/6NTac)
abnormal circulating cytokine level J:224919
abnormal macrophage chemotaxis J:224919
\Cd163tm1(KOMP)Vlcg/\Cd163tm1(KOMP)Vlcg
(involves: C57BL/6NTac)
lung inflammation J:233977
\Cd177tm1(KOMP)Vlcg/\Cd177tm1(KOMP)Vlcg
(involves: C57BL/6NTac)
abnormal neutrophil physiology J:225335
decreased monocyte cell number J:225335
decreased neutrophil cell number J:225335
immune system phenotype J:225335
\Cd180tm1Kmiy/\Cd180tm1Kmiy
(involves: 129P2/OlaHsd * C57BL/6)
abnormal humoral immune response J:63145
decreased IgG2b level J:137066
decreased IgG3 level J:137066
\Cd180tm1Kmiy/\Cd180tm1Kmiy
(involves: 129P2/OlaHsd * C57BL/6 * NZB * NZW)
decreased IgG2a level J:137066
decreased IgG3 level J:137066
\Cd180tm1Kmiy/\Cd180tm1Kmiy
\Faslpr/\Faslpr

(MRL.Cg-Cd180tm1Kmiy Faslpr)
blood vessel inflammation J:137066
decreased B cell number J:137066
decreased CD8-positive, alpha-beta T cell number J:137066
decreased IgG2a level J:137066
decreased IgG3 level J:137066
enlarged lymph nodes J:137066
enlarged spleen J:137066
glomerulonephritis J:137066
increased anti-nuclear antigen antibody level J:137066
increased autoantibody level J:137066
increased double-negative T cell number J:137066
\Cd200tm1Jods/\Cd200tm1Jods
(C57BL/6-Cd200tm1Jods)
abnormal cytokine level J:95862
abnormal immune system organ morphology J:65982
abnormal immune system physiology J:65982
abnormal lymph node morphology J:65982
abnormal macrophage physiology J:65982
abnormal microglial cell morphology J:65982
abnormal microglial cell physiology J:65982
enlarged lymph nodes J:65982
increased macrophage cell number J:79906, J:65982
increased spleen red pulp amount J:65982
increased susceptibility to experimental autoimmune encephalomyelitis J:65982
increased susceptibility to experimental autoimmune uveoretinitis J:79906
increased susceptibility to induced arthritis J:65982
\Cd200r1tm1.1Rmgo/\Cd200r1tm1.1Rmgo
(C57BL/6-Cd200r1tm1.1Rmgo)
abnormal dendritic cell physiology J:134313
abnormal professional antigen presenting cell physiology J:135069
abnormal response to transplant J:135069
increased interleukin-12b secretion J:135069
increased tumor necrosis factor secretion J:135069
\Cd200r1tm1.1Rmgo/\Cd200r1tm1.1Rmgo
\Tg(tetO/CMV-CD200)1Rmgo/\Tg(tetO/CMV-CD200)1Rmgo

(involves: C57BL/6)
abnormal dendritic cell physiology J:134313
\Cd200r1tm1Eakj/\Cd200r1tm1Eakj
(Not Specified)
abnormal macrophage physiology J:326965
decreased interferon-beta secretion J:192198
decreased interleukin-1 beta secretion J:192198
decreased interleukin-6 secretion J:192198
decreased susceptibility to Herpesvirales infection J:192198
decreased susceptibility to Herpesvirales infection induced morbidity/mortality J:192198
\Cd207tm1(Hbegf/EGFP)Bjec/\Cd207+
(involves: C57BL/6 * SJL)
absent Langerhans cell J:137517
decreased dendritic cell number J:137452
decreased susceptibility to type IV hypersensitivity reaction J:137517
increased susceptibility to Orthomyxoviridae infection J:137452
\Cd207tm1(Hbegf/EGFP)Bjec/\Cd207+
(involves: C57BL/6)
abnormal type IV hypersensitivity reaction J:179630
\Cd207tm1.1Cfg/\Cd207tm1.1Cfg
(involves: C57BL/6)
abnormal Peyer's patch morphology J:217719
decreased IgA level J:217719
decreased IgG1 level J:217719
decreased IgG2a level J:217719
decreased IgG3 level J:217719
decreased IgM level J:217719
\Cd207tm1Mal/\Cd207tm1Mal
(B6.129S2-Cd207tm1Mal)
abnormal Langerhans cell morphology J:95147
\Cd207tm2.1(cre)Bjec/\Cd207+
(B6.Cg-CD207tm2.1(cre)Bjec)
immune system phenotype J:179630
\Cd207tm2.1(cre)Bjec/\Cd207+
\Tgfbr1tm1.1Karl/\Tgfbr1tm1.1Karl

(involves: 129S4/SvJaeSor * C57BL/6)
abnormal type IV hypersensitivity reaction J:179630
decreased dendritic cell number J:179630
\Cd207tm2.1Mal/\Cd207tm3.1(HBEGF/EGFP)Mal
(involves: 129S2/SvPas)
abnormal Langerhans cell morphology J:99114
absent Langerhans cell J:99114
decreased Langerhans cell number J:99114
\Cd209atm1.1Cfg/\Cd209atm1.1Cfg
(involves: C57BL/6)
decreased IgG2b level J:217719
increased inflammatory response J:217719
increased lymphocyte cell number J:217719
increased mature B cell number J:217719
increased monocyte cell number J:217719
increased plasma cell number J:217719
increased spleen germinal center size J:217719
increased T cell proliferation J:217719
\Cd209atm1.1Cfg/\Cd209atm1.1Cfg
(B6.Cg-Cd209atm1.1Cfg/Mmucd)
immune system phenotype J:194602
\Cd209atm1Olne/\Cd209atm1Olne
(involves: C57BL/6 * C57BL/6J)
immune system phenotype J:153503
\Cd209btm1.1Cfg/\Cd209btm1.1Cfg
(involves: C57BL/6 * C57BL/6J)
immune system phenotype J:153503
\Cd209btm1.1Cfg/\Cd209btm1.1Cfg
(involves: C57BL/6)
decreased mature B cell number J:217719
impaired macrophage phagocytosis J:288225
increased eosinophil cell number J:288225
increased IgG2b level J:217719
increased IgG3 level J:217719
increased IgM level J:217719
increased macrophage cell number J:217719
increased susceptibility to bacterial infection J:288225
urinary bladder inflammation J:288225
\Cd209btm1Anjm/\Cd209btm1Anjm
(involves: 129P2/OlaHsd * C57BL/6)
abnormal macrophage physiology J:94698
impaired macrophage phagocytosis J:94698
increased susceptibility to bacterial infection J:94698
increased susceptibility to bacterial infection induced morbidity/mortality J:94698
\Cd209btm1Anjm/\Cd209btm1Anjm
(B6.129P2-Cd209btm1Anjm)
decreased interleukin-1 beta secretion J:159646
decreased interleukin-18 secretion J:159646
decreased susceptibility to endotoxin shock J:159646
decreased susceptibility to induced colitis J:159646
increased susceptibility to bacterial infection induced morbidity/mortality J:94698
\Cd209btm1Anjm/\Cd209btm1Anjm
(involves: 129P2/OlaHsd * BALB/c)
immune system phenotype J:209808
\Cd209btm1Anjm/\Cd209btm1Anjm
(C.129P2-Cd209btm1Anjm)
immune system phenotype J:143766
\Cd209cem1(IMPC)Ccpcz/\Cd209cem1(IMPC)Ccpcz
(C57BL/6NCrl-Cd209cem1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
enlarged spleen J:211773
\Cd209dtm1.1Cfg/\Cd209dtm1.1Cfg
(involves: C57BL/6 * C57BL/6J)
increased circulating tumor necrosis factor level J:153503
increased susceptibility to bacterial infection J:153503
\Cd209dtm1.1Cfg/\Cd209dtm1.1Cfg
(involves: C57BL/6)
increased B cell number J:217719
increased B cell proliferation J:217719
\Cd226tm1.1Cln/\Cd226tm1.1Cln
(B6.129P2-Cd226tm1.1Cln)
decreased inflammatory response J:209990
decreased T cell proliferation J:159749
impaired natural killer cell mediated cytotoxicity J:159749
\Cd226tm1.1Cln/\Cd226tm1.1Cln
\Tg(TcraTcrb)1100Mjb/0

(B6.Cg-Cd226tm1.1Cln Tg(TcraTcrb)1100Mjb)
abnormal T cell activation J:159749
decreased cytotoxic T cell cytolysis J:159749
decreased interferon-gamma secretion J:159749
decreased T cell proliferation J:159749
\Cd226tm1Shib/\Cd226tm1Shib
(involves: BALB/c)
abnormal immune system physiology J:165704
decreased cytotoxic T cell cytolysis J:165704
impaired natural killer cell mediated cytotoxicity J:165704
\Cd244aChip/\Cd244a+
(C57BL/6J-Cd244aChip)
abnormal NK cell physiology J:196519
impaired natural killer cell mediated cytotoxicity J:196519
\Cd244aChip/\Cd244aChip
(C57BL/6J-Cd244aChip)
abnormal NK cell physiology J:196519
impaired natural killer cell mediated cytotoxicity J:196519
\Cd244atm1Kmle/\Cd244atm1Kmle
(involves: C57BL/6)
impaired natural killer cell mediated cytotoxicity J:166054
increased natural killer cell mediated cytotoxicity J:92740
\Cd247m1Btlr/\Cd247m1Btlr
(C57BL/6J-Cd247m1Btlr)
abnormal CD4-positive, alpha-beta T cell physiology J:158794
\Cd247tm1Lov/\Cd247tm1Lov
(involves: 129S4/SvJae)
abnormal single-positive T cell number J:14170
abnormal T-helper 1 cell morphology J:14170
abnormal T-helper 1 physiology J:46914
absent gamma-delta intraepithelial T cell J:46914
decreased CD4-positive, alpha-beta T cell number J:14170
decreased double-positive T cell number J:14170
decreased thymocyte number J:14170
\Cd247tm1Lov/\Cd247tm1Lov
\Fcer1gtm1Rav/\Fcer1gtm1Rav

(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)
abnormal effector T cell morphology J:46914
abnormal T cell activation J:46914
abnormal T-helper 1 physiology J:46914
absent gamma-delta intraepithelial T cell J:46914
decreased thymocyte number J:46914
impaired natural killer cell mediated cytotoxicity J:64764
\Cd247tm1Lov/\Cd247tm2.1Lov
(involves: 129S4/SvJae)
immune system phenotype J:192915
\Cd247tm1Mal/\Cd247tm1Mal
(either: C57BL/6-Cd247tm1Mal or (involves: BALB/c * C57BL/6))
abnormal intraepithelial T cell morphology J:15272
abnormal T cell differentiation J:15272
decreased CD4-positive, alpha-beta T cell number J:15272
decreased CD8-positive, alpha-beta T cell number J:15272
decreased double-positive T cell number J:15272
decreased single-positive T cell number J:15272
decreased thymocyte number J:15272
increased double-negative T cell number J:15272
\Cd247tm1Mal/\Cd247tm1Mal
(involves: C57BL/6)
abnormal double-negative T cell morphology J:112990, J:110847
abnormal T cell differentiation J:112990
abnormal T cell morphology J:110847
abnormal thymocyte activation J:110847
decreased double-positive T cell number J:110847
\Cd247tm1Mal/\Cd247tm1Mal
\Lcktm1Mak/\Lcktm1Mak

(involves: 129S2/SvPas * C57BL/6)
abnormal double-negative T cell morphology J:110847
abnormal T cell differentiation J:110847
abnormal T cell morphology J:110847
abnormal thymocyte activation J:110847
decreased double-positive T cell number J:110847
\Cd247tm1Mhu/\Cd247tm1Mhu
(involves: 129S7/SvEvBrd * C57BL/6)
abnormal T cell differentiation J:15579
decreased CD4-positive, alpha-beta T cell number J:15579
decreased CD8-positive, alpha-beta T cell number J:15579
decreased double-positive T cell number J:15579
decreased splenocyte proliferation J:15579
decreased T cell proliferation J:15579
decreased thymocyte number J:15579
enlarged lymph nodes J:15579
enlarged spleen J:15579
enlarged thymus cortex J:15579
immune system phenotype J:15579
increased double-negative T cell number J:15579
small thymus J:15579
small thymus medulla J:15579
thymus hypoplasia J:15579
\Cd247tm1Mhu/\Cd247tm1Mhu
\Fcer1gtm1Rav/\Fcer1gtm1Rav

(involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6)
decreased uterine NK cell number J:100668
\Cd247tm1Tks/\Cd247tm1Tks
(involves: 129P2/OlaHsd * C57BL/6)
abnormal alpha-beta intraepithelial T cell morphology J:15271
abnormal T cell proliferation J:15271
decreased CD4-positive, alpha-beta T cell number J:15271
decreased CD8-positive, alpha-beta T cell number J:15271
decreased double-positive T cell number J:15271
decreased single-positive T cell number J:15271
decreased thymocyte number J:15271
small thymus medulla J:15271
\Cd247tm1Tks/\Cd247tm1Tks
(B6.129P2-Cd247tm1Tks)
abnormal NK cell morphology J:66403
abnormal NK cell physiology J:66403
decreased NK T cell number J:28282
increased interferon-gamma secretion J:66403
increased natural killer cell mediated cytotoxicity J:66403
\Cd247tm2.1Lov/\Cd247tm2.1Lov
(Not Specified)
abnormal gamma-delta T cell differentiation J:192915
abnormal NK T cell morphology J:192915
abnormal regulatory T cell physiology J:192915
abnormal T cell differentiation J:192915
abnormal T cell physiology J:192915
abnormal T-helper 1 cell differentiation J:192915
decreased CD4-positive, alpha-beta T cell number J:192915
decreased CD8-positive, alpha-beta T cell number J:192915
decreased thymocyte apoptosis J:192915
decreased thymocyte number J:192915
immune system phenotype J:192915
increased regulatory T cell number J:192915
\Cd247tm2.1Lov/\Cd247tm2.1Lov
(B6.Cg-Cd247tm2.1Lov)
increased susceptibility to experimental autoimmune encephalomyelitis J:192915
\Cd247tm2.1Lov/\Cd247tm2.1Lov
\Tg(TcraH-Y,TcrbH-Y)71Vbo/0

(involves: C57BL/6J * DBA/2J)
abnormal T cell differentiation J:192915
\Cd248tm1Huso/\Cd248tm1Huso
(involves: 129S/SvEv * C57BL/6)
immune system phenotype J:107172
\Cd274tm1.1Lex/\Cd274tm1.1Lex
(involves: 129S5/SvEvBrd)
abnormal cytokine secretion J:126829
decreased CD8-positive, alpha-beta T cell number J:126829
increased susceptibility to experimental autoimmune encephalomyelitis J:126829
\Cd274tm1Igu/\Cd274tm1Igu
\Vsirtm1Lex/\Vsirtm1Lex

(involves: 129S5/SvEvBrd * C57BL/6)
abnormal T cell activation J:222944
\Cd274tm1Lpc/\Cd274tm1Lpc
(B6.129S-Cd274tm1Lpc)
abnormal CD8-positive, alpha-beta T cell physiology J:89781
decreased T cell apoptosis J:89781
increased activated T cell number J:89781
increased CD8-positive, alpha-beta T cell number J:89781
increased susceptibility to autoimmune disorder J:89781
\Cd274tm1Lpc/\Cd274tm1Lpc
(involves: 129S/SvEv)
abnormal chemokine secretion J:158023
increased tumor necrosis factor secretion J:158023
\Cd274tm1Lpc/\Cd274tm1Lpc
(involves: 129S/SvEv * C57BL/6)
abnormal dendritic cell physiology J:152305
abnormal T cell morphology J:136330
abnormal T-helper 1 cell differentiation J:162539
decreased susceptibility to Riboviria infection J:136330
decreased susceptibility to Riboviria infection induced morbidity/mortality J:136330
decreased T cell apoptosis J:136330
decreased T helper 1 cell number J:162539
increased CD8-positive, alpha-beta T cell number J:152305
increased IgG1 level J:162539
increased IgG2c level J:162539
increased susceptibility to bacterial infection J:162539
increased susceptibility to bacterial infection induced morbidity/mortality J:162539
increased susceptibility to experimental autoimmune encephalomyelitis J:142815
increased T cell number J:142815
\Cd274tm1Lpc/\Cd274tm1Lpc
(C.129S-Cd274tm1Lpc)
abnormal regulatory T cell physiology J:165841
abnormal T follicular helper cell physiology J:165841
decreased germinal center B cell number J:165841
decreased IgG1 level J:165841
decreased IgG2a level J:165841
decreased interleukin-17 secretion J:165841
decreased plasma cell number J:165841
decreased T-helper 17 cell number J:165841
immune system phenotype J:165841
increased interferon-gamma secretion J:165841
increased interleukin-4 secretion J:165841
increased susceptibility to induced arthritis J:165841
increased T cell proliferation J:165841
\Cd274tm1Shr/\Cd274tm1Shr
(involves: C57BL/6)
abnormal CD4-positive, alpha beta T cell morphology J:91480
abnormal CD8-positive, alpha beta T cell morphology J:91480
\Cd274tm1Shr/\Cd274tm1Shr
(C.B6-Cd274tm1Shr)
abnormal interleukin secretion J:123785
increased interferon-gamma secretion J:123785
increased susceptibility to autoimmune diabetes J:123785
\Cd274tm1Shr/\Cd274tm1Shr
\Pdcd1lg2tm3Shr/\Pdcd1lg2tm3Shr

(C.B6-Cd274tm1Shr Pdcd1lg2tm3Shr)
abnormal dendritic cell physiology J:123785
decreased interleukin-4 secretion J:123785
increased interferon-gamma secretion J:123785
increased interleukin-2 secretion J:123785
\Cd274tm1Shr/\Cd274tm1Shr
\Tg(TcraTcrb)1100Mjb/0

(involves: C57BL/6)
increased susceptibility to autoimmune diabetes J:153040
\Cd274tm2Shr/\Cd274tm2Shr
(involves: 129/Sv * 129S4/SvJae)
abnormal cytokine secretion J:113851
decreased susceptibility to parasitic infection J:113851
\Cd274tm2Shr/\Cd274tm2Shr
\Pdcd1lg2tm4Shr/\Pdcd1lg2tm4Shr

(involves: 129S4/SvJae)
abnormal immune system physiology J:160970
\Cd276tm1Lpc/\Cd276tm1Lpc
(B6.129-Cd276tm1Lpc)
abnormal T-helper 1 physiology J:237700
abnormal T-helper 2 physiology J:237700
decreased susceptibility to experimental autoimmune encephalomyelitis J:237700
increased susceptibility to type I hypersensitivity reaction J:237700
\Cd276tm1Lpc/\Cd276tm1Lpc
(D1J.129-Cd276tm1Lpc)
abnormal T-helper 1 physiology J:237700
abnormal T-helper 17 cell physiology J:237700
decreased susceptibility to induced arthritis J:237700
\Cd276tm1Mak/\Cd276tm1Mak
(involves: 129P2/OlaHsd * C57BL/6)
abnormal T-helper 1 physiology J:84973
immune system phenotype J:84973
increased anti-single stranded DNA antibody level J:84973
increased inflammatory response J:84973
increased susceptibility to experimental autoimmune encephalomyelitis J:84973
increased T cell proliferation J:84973
\Cd276tm1Mak/\Cd276tm1Mak
(C.129P2-Cd276tm1Mak)
abnormal T-helper 1 physiology J:84973
increased inflammatory response J:84973
increased interferon-gamma secretion J:84973
\Cd276tm1Wwh/\Cd276tm1Wwh
(B6.Cg-B7h3tm1Wwh)
abnormal cytokine secretion J:95550
abnormal response to transplant J:95550
\Cd300atm1b(EUCOMM)Hmgu/\Cd300atm1b(EUCOMM)Hmgu
(C57BL/6N-Cd300atm1b(EUCOMM)Hmgu/Bay)
decreased eosinophil cell number J:211773
\Cd300atm1Shib/\Cd300atm1Shib
(B6JJcl.C-Cd300atm1Shib)
abnormal chemokine secretion J:189144
abnormal mast cell physiology J:189144
increased interleukin-10 secretion J:189144
increased interleukin-13 secretion J:189144
increased neutrophil cell number J:189144
increased tumor necrosis factor secretion J:189144
\Cd300c2tm1Shib/\Cd300c2tm1Shib
(B6.Cg-Cd300c2tm1Shib)
increased B cell proliferation J:177613
\Cd300cem1(IMPC)Wtsi/\Cd300cem1(IMPC)Wtsi
(C57BL/6N-Cd300cem1(IMPC)Wtsi/WtsiOulu)
increased leukocyte cell number J:211773
\Cd300lbtm1Toki/\Cd300lbtm1Toki
(B6.Cg-Cd300lbtm1Toki)
immune system phenotype J:163402
\Cd300lftm1Gne/\Cd300lftm1Gne
(involves: C57BL/6N)
immune system phenotype J:156819
increased interleukin-1 alpha secretion J:156819
increased interleukin-1 beta secretion J:156819
increased interleukin-12 secretion J:156819
increased susceptibility to experimental autoimmune encephalomyelitis J:156819
\Cd300lftm1Toki/\Cd300lftm1Toki
(Not Specified)
abnormal interleukin secretion J:190979
abnormal mast cell physiology J:190979
immune system phenotype J:190979
increased interleukin-4 secretion J:190979
increased interleukin-5 secretion J:190979
increased interleukin-13 secretion J:190979
increased susceptibility to type I hypersensitivity reaction J:190979
respiratory system inflammation J:190979
\Cd302tm1.1Dnjh/\Cd302tm1.1Dnjh
(involves: C57BL/6)
abnormal CD8-positive, alpha-beta T cell physiology J:301848
abnormal dendritic cell physiology J:301848
decreased dendritic cell number J:301848
immune system phenotype J:301848
\Cd320Gt(CC0426)Wtsi/\Cd320Gt(CC0426)Wtsi
(involves: 129P2/OlaHsd * C57BL/6)
decreased leukocyte cell number J:199961
\Cdc7tm1.1(KOMP)Vlcg/\Cdc7+
(C57BL/6N-Cdc7tm1.1(KOMP)Vlcg/Tcp)
decreased neutrophil cell number J:211773
increased lymphocyte cell number J:211773
\Cdc7tm1Hmas/\Cdc7tm1Hmas
\Tg(EF1A-Cdc7)DKO28Hmas/0

(involves: 129S/Sv * C57BL/6)
immune system phenotype J:85942
\Cdc42tm1b(EUCOMM)Hmgu/\Cdc42+
(C57BL/6N-Cdc42tm1b(EUCOMM)Hmgu/H)
increased leukocyte cell number J:211773
increased lymphocyte cell number J:211773
increased neutrophil cell number J:211773
\Cdc42ep5tm1(KOMP)Wtsi/\Cdc42ep5tm1(KOMP)Wtsi
(C57BL/6N-Cdc42ep5tm1(KOMP)Wtsi/Nju)
increased basophil cell number J:211773
increased eosinophil cell number J:211773
\Cdc73tm1Btt/\Cdc73tm1Btt
\Tg(CAG-cre/Esr1*)5Amc/0

(involves: 129S4/SvJae * C57BL/6 * CBA)
small spleen J:135255
\Cdca7lem1(IMPC)Mbp/\Cdca7lem1(IMPC)Mbp
(C57BL/6NCrl-Cdca7lem1(IMPC)Mbp/Mmucd)
abnormal lymph node morphology J:211773
abnormal spleen morphology J:211773
enlarged lymph nodes J:211773
enlarged spleen J:211773
\Cdcp2em1(IMPC)Mbp/\Cdcp2em1(IMPC)Mbp
(C57BL/6N-Cdcp2em1(IMPC)Mbp/MbpMmucd)
small spleen J:211773
\Cdcs1C3H/HeJBir/\Cdcs1C3H/HeJBir
(involves: B6.129P2-Il10tm1Cgn/Lt * C3Bir.129P2(B6)-Il10tm1Cgn/Lt)
abnormal immune system physiology J:72978
\Cdcs1C3H/HeJBir/\Cdcs1C57BL/6J
(involves: C3H/HeJBir-Il10tm1Cgn * C57BL/6J-Il10tm1Cgn)
colitis J:72978
\Cdcs2C3H/HeJBir/\Cdcs2C3H/HeJBir
(involves: B6.129P2-Il10tm1Cgn/Lt * C3Bir.129P2(B6)-Il10tm1Cgn/Lt)
intestinal inflammation J:72978
\Cdcs2C3H/HeJBir/\Cdcs2C57BL/6J
(involves: B6.129P2-Il10tm1Cgn/Lt * C3Bir.129P2(B6)-Il10tm1Cgn/Lt)
intestinal inflammation J:72978
\Cdcs3C3H/HeJBir/\Cdcs3C3H/HeJBir
(involves: B6.129P2-Il10tm1Cgn/Lt * C3Bir.129P2(B6)-Il10tm1Cgn/Lt)
intestinal inflammation J:72978
\Cdcs4C3H/HeJBir/\Cdcs4C57BL/6J
(involves: C3H/HeJBir * C57BL/6J)
intestinal inflammation J:72978
\Cdcs4C57BL/6J/\Cdcs4C57BL/6J
(involves: C3H/HeJBir * C57BL/6J)
intestinal inflammation J:72978
\Cdcs5C57BL/6J/\Cdcs5C57BL/6J
(involves: C3H/HeJBir * C57BL/6J)
intestinal inflammation J:72978
\Cdcs6C57BL/6J/?
(involves: B6.129P2-Il10tm1Cgn/Lt * C3Bir.129P2(B6)-Il10tm1Cgn/Lt)
intestinal inflammation J:72978
\Cdcs7C3H/HeJBir/\Cdcs7C3H/HeJBir
(involves: C3H/HeJBir * C57BL/6J)
intestinal inflammation J:78917
\Cdcs8C57BL/6J/\Cdcs8C57BL/6J
(involves: C3H/HeJBir * C57BL/6J)
intestinal inflammation J:78917
\Cdcs9C3H/HeJBir/\Cdcs9C3H/HeJBir
(involves: C3H/HeJBir * C57BL/6J)
intestinal inflammation J:78917
\Cdcs9C3H/HeJBir/\Cdcs9C57BL/6J
(involves: C3H/HeJBir * C57BL/6J)
intestinal inflammation J:78917
\Cdcs10C3H/HeJBir/\Cdcs10C3H/HeJBir
(involves: C3H/HeJBir-Il10tm1Cgn * C57BL/6J-Il10tm1Cgn)
intestinal inflammation J:78917
\Cdcs10C3H/HeJBir/\Cdcs10C57BL/6J
(involves: C3H/HeJBir-Il10tm1Cgn * C57BL/6J-Il10tm1Cgn)
intestinal inflammation J:72978
\Cdh1tm1Mlec/\Cdh1tm1Mlec
(involves: 129S2/SvPas)
increased susceptibility to bacterial infection J:142843
\Cdh5tm3(Cdh5/Ctnna1)Dvst/\Cdh5tm3(Cdh5/Ctnna1)Dvst
(involves: 129 * C57BL/6)
abnormal cellular extravasation J:177191
abnormal leukocyte migration J:177191
abnormal lymphatic vessel endothelial cell morphology J:213676
immune system phenotype J:213676
increased leukocyte cell number J:177191
increased neutrophil cell number J:177191
\Cdh5tm3(Cdh5/Ctnna1)Dvst/\Cdh5tm3(Cdh5/Ctnna1)Dvst
(B6.Cg-Cdh5tm3(Cdh5/Ctnna1)Dvst)
abnormal lymphatic vessel endothelium morphology J:213676
abnormal lymphatic vessel morphology J:213676
\Cdh5tm4(Cdh5/Fkbp,Ptprb/Mtor*)Dvst/\Cdh5tm4(Cdh5/Fkbp,Ptprb/Mtor*)Dvst
(involves: C57BL/6)
abnormal cellular extravasation J:178759
impaired neutrophil recruitment J:178759
\Cdh5tm5Dvst/\Cdh5tm5Dvst
(B6.Cg-Cdh5tm5Dvst)
abnormal cellular extravasation J:209801
\Cdh5tm6Dvst/\Cdh5tm6Dvst
(B6.Cg-Cdh5tm6Dvst)
abnormal cellular extravasation J:209801
\Cdh10tm2b(KOMP)Wtsi/\Cdh10tm2b(KOMP)Wtsi
(C57BL/6N-Cdh10tm2b(KOMP)Wtsi/Ucd)
increased leukocyte cell number J:211773
increased lymphocyte cell number J:211773
increased monocyte cell number J:211773
increased neutrophil cell number J:211773
\Cdh17M1Btlr/\Cdh17M1Btlr
(C57BL/6J-Cdh17M1Btlr)
increased susceptibility to induced colitis J:272090
\Cdh17tm1Ohn/\Cdh17tm1Ohn
(involves: 129P2/OlaHsd * C57BL/6)
abnormal spleen marginal zone morphology J:96738
decreased B cell number J:96738
decreased B-1a cell number J:96738
decreased germinal center B cell number J:96738
decreased IgG level J:96738
decreased marginal zone B cell number J:96738
decreased mature B cell number J:96738
decreased spleen germinal center size J:96738
increased pre-B cell number J:96738
increased pro-B cell number J:96738
\Cdh23tm2b(EUCOMM)Wtsi/\Cdh23tm2b(EUCOMM)Wtsi
(C57BL/6N-Cdh23tm2b(EUCOMM)Wtsi/Wtsi)
decreased leukocyte cell number J:211773
\Cdhr3em1(IMPC)Wtsi/\Cdhr3em1(IMPC)Wtsi
(C57BL/6NCrl-Cdhr3em1(IMPC)Wtsi/Wtsi)
decreased lymphocyte cell number J:211773
increased neutrophil cell number J:211773
\Cdk2tm2Sgo/\Cdk2tm2Sgo
\Cdk4tm2.1Bbd/\Cdk4tm2.1Bbd
\Polr2atm1(cre/ERT2)Bbd/?

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL)
increased susceptibility to autoimmune diabetes J:125217
\Cdk4+/\Cdk4+
\Tg(Mt1-Hgf)#Lmb/0

(B6.Cg-Cdk4tm1.1Bbd Tg(Mt1-Hgf)#Lmb)
abnormal axillary lymph node morphology J:111992
abnormal inguinal lymph node morphology J:111992
\Cdk4tm1.1Bbd/\Cdk4+
\Tg(Mt1-Hgf)#Lmb/0

(B6.Cg-Cdk4tm1.1Bbd Tg(Mt1-Hgf)#Lmb)
abnormal axillary lymph node morphology J:111992
abnormal inguinal lymph node morphology J:111992
enlarged axillary lymph nodes J:111992
enlarged inguinal lymph nodes J:111992
\Cdk4tm1.1Bbd/\Cdk4tm1.1Bbd
\Tg(Mt1-Hgf)#Lmb/0

(B6.Cg-Cdk4tm1.1Bbd Tg(Mt1-Hgf)#Lmb)
abnormal axillary lymph node morphology J:111992
abnormal inguinal lymph node morphology J:111992
enlarged axillary lymph nodes J:111992
enlarged inguinal lymph nodes J:111992
\Cdk4tm1Kiyo/\Cdk4+
\Lin9tm1Orc/\Lin9+

(involves: 129S1/Sv)
decreased susceptibility to autoimmune diabetes J:111333
\Cdk5rap2an/\Cdk5rap2an
(Not Specified)
decreased leukocyte cell number J:5439
\Cdk5rap2Gt(RRO242)Byg/\Cdk5rap2+
(involves: 129P2/OlaHsd * C57BL/6J)
decreased leukocyte cell number J:160533
\Cdk5rap2Gt(RRO242)Byg/\Cdk5rap2an
(involves: 129P2/OlaHsd * C57BL/6J)
decreased leukocyte cell number J:160533
\Cdk5rap2tm1a(EUCOMM)Wtsi/\Cdk5rap2tm1a(EUCOMM)Wtsi
(C57BL/6N-Cdk5rap2tm1a(EUCOMM)Wtsi/Wtsi)
decreased leukocyte cell number J:175295
\Cdk6tm1.1Phin/\Cdk6tm1.1Phin
(involves: 129S4/SvJae * C57BL/6)
immune system phenotype J:144975
\Cdk6tm1Bbd/\Cdk6tm1Bbd
(involves: 129S1/Sv * 129X1/SvJ * CD-1)
abnormal spleen morphology J:92529
abnormal spleen red pulp morphology J:92529
abnormal thymus morphology J:92529
decreased leukocyte cell number J:92529
decreased T cell proliferation J:92529
increased single-positive T cell number J:92529
small spleen J:92529
spleen hypoplasia J:92529
thymus cortex atrophy J:92529
thymus hypoplasia J:92529
\Cdk6tm1Phin/\Cdk6+
\Tg(Lck-Akt1*E40K)E-3Pnt/0

(involves: 129S4/SvJae)
increased T cell derived lymphoma incidence J:144975
\Cdk6tm1Phin/\Cdk6tm1Phin
(involves: 129S4/SvJae)
abnormal lymphopoiesis J:144975
abnormal T cell differentiation J:144975
abnormal thymocyte activation J:144975
decreased CD8-positive, alpha-beta T cell number J:144975
decreased double-negative T cell number J:144975
decreased double-positive T cell number J:144975
decreased thymocyte apoptosis J:144975
decreased thymocyte number J:144975
thymus atrophy J:144975
thymus hypoplasia J:144975
\Cdk6tm1Phin/\Cdk6tm1Phin
(involves: 129S4/SvJae * C57BL/6)
decreased DN1 thymic pro-T cell number J:174697
decreased DN2 thymocyte number J:174697
decreased double-positive T cell number J:174697
immune system phenotype J:174697
increased CD4-positive, alpha-beta T cell number J:174697
increased CD8-positive, alpha-beta T cell number J:174697
increased DN3 thymocyte number J:174697
\Cdk6tm1Phin/\Cdk6tm1Phin
\Tg(Lck-Akt1*E40K)E-3Pnt/0

(involves: 129S4/SvJae)
abnormal T cell differentiation J:144975
\Cdk6tm2.1Phin/\Cdk6tm2.1Phin
(involves: 129 * C57BL/6 * FVB/N)
abnormal T cell differentiation J:174697
decreased DN1 thymic pro-T cell number J:174697
decreased DN2 thymocyte number J:174697
decreased DN4 thymocyte number J:174697
decreased double-positive T cell number J:174697
decreased thymocyte number J:174697
increased CD4-positive, alpha-beta T cell number J:174697
increased CD8-positive, alpha-beta T cell number J:174697
increased DN3 thymocyte number J:174697
increased double-negative T cell number J:174697
small thymus J:174697
\Cdk6tm2.1Phin/\Cdk6tm2.1Phin
\Il2ratm1Dw/\Il2ratm1Dw

(involves: 129S4/SvJae * C57BL/6 * FVB/N)
increased CD4-positive, alpha-beta T cell number J:174697
increased CD8-positive, alpha-beta T cell number J:174697
\Cdk6tm3.1Phin/\Cdk6tm3.1Phin
(involves: 129 * C57BL/6 * FVB/N)
abnormal T cell differentiation J:174697
enlarged thymus J:174697
immune system phenotype J:174697
increased CD4-positive, alpha-beta T cell number J:174697
increased DN1 thymic pro-T cell number J:174697
increased T cell apoptosis J:174697
increased thymocyte number J:174697
\Cdk6tm4.1Phin/\Cdk6tm4.1Phin
(involves: 129 * C57BL/6 * FVB/N)
abnormal T cell differentiation J:174697
decreased DN1 thymic pro-T cell number J:174697
decreased DN2 thymocyte number J:174697
decreased DN4 thymocyte number J:174697
decreased double-positive T cell number J:174697
decreased thymocyte number J:174697
immune system phenotype J:174697
increased CD4-positive, alpha-beta T cell number J:174697
increased CD8-positive, alpha-beta T cell number J:174697
increased DN3 thymocyte number J:174697
small thymus J:174697
\Cdk10tm1.2Kald/\Cdk10tm1.2Kald
(involves: 129 * C57BL/6 * FVB/N)
abnormal spleen morphology J:262333
\Cdk12em1(IMPC)Tcp/\Cdk12+
(C57BL/6NCrl-Cdk12em1(IMPC)Tcp/Tcp)
abnormal spleen morphology J:211773
enlarged spleen J:211773
increased spleen weight J:211773
\Cdkl2tm1b(EUCOMM)Hmgu/\Cdkl2tm1b(EUCOMM)Hmgu
(C57BL/6N-Cdkl2tm1b(EUCOMM)Hmgu/Bay)
abnormal spleen morphology J:211773
\Cdkn1atm1.1(KOMP)Vlcg/\Cdkn1atm1.1(KOMP)Vlcg
(C57BL/6N-Cdkn1atm1.1(KOMP)Vlcg/Ucd)
abnormal spleen morphology J:211773
enlarged spleen J:211773
\Cdkn1atm1Led/\Cdkn1atm1Led
(involves: 129S6/SvEvTac)
increased anti-double stranded DNA antibody level J:76041
increased anti-histone antibody level J:76041
increased anti-single stranded DNA antibody level J:76041
increased autoantibody level J:76041
increased T cell proliferation J:76041
\Cdkn1atm1Led/\Cdkn1atm1Led
\Gadd45atm1Ajf/\Gadd45atm1Ajf

(either: (involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6) or (involves: 129S6/SvEvTac * 129X1/SvJ * C57BL/6))
abnormal lymphopoiesis J:76041
abnormal T cell activation J:76041
decreased basophil cell number J:76041
decreased eosinophil cell number J:76041
decreased leukocyte cell number J:76041
decreased lymphocyte cell number J:76041
glomerulonephritis J:76041
increased anti-double stranded DNA antibody level J:76041
increased anti-histone antibody level J:76041
increased anti-single stranded DNA antibody level J:76041
increased autoantibody level J:76041
increased IgG1 level J:76041
increased IgM level J:76041
increased inflammatory response J:76041
increased T cell proliferation J:76041
\Cdkn1atm1Led/\Cdkn1atm1Led
\Zbtb17tm1Cksn/\Zbtb17tm1Cksn
\Commd10Tg(Vav1-icre)A2Kio/\Commd10+

(B6.Cg-Zbtb17tm1Cksn Cdkn1atm1Led Commd10Tg(Vav1-icre)A2Kio)
arrested T cell differentiation J:170508
\Cdkn1atm1Tyj/\Cdkn1atm1Tyj
(B6;129S2-Cdkn1atm1Tyj/J)
decreased monocyte cell number J:108569
decreased susceptibility to induced arthritis J:108569
impaired macrophage chemotaxis J:108569
\Cdkn1atm1Tyj/\Cdkn1atm1Tyj
(involves: 129S2/SvPas * C57BL/6)
abnormal CD4-positive, alpha beta T cell morphology J:60292
abnormal self tolerance J:60292
abnormal thymus physiology J:70894
enlarged cervical lymph nodes J:60292
enlarged lymph nodes J:60292
enlarged spleen J:60292
glomerulonephritis J:60292, J:70894
immune system phenotype J:60292
increased anti-double stranded DNA antibody level J:60292
increased anti-histone antibody level J:60292
increased anti-nuclear antigen antibody level J:60292
increased B cell number J:60292
increased IgG1 level J:60292
increased memory T cell number J:60292
increased spleen weight J:60292
increased T cell derived lymphoma incidence J:70894
increased T cell proliferation J:60292
lymph node hyperplasia J:60292
spleen hyperplasia J:60292
\Cdkn1atm1Tyj/\Cdkn1atm1Tyj
\Tg(MMTV-vHaras)SH1Led/0

(involves: 129S2/SvPas * C57BL/6J * CD-1 * FVB/N)
enlarged spleen J:66183
\Cdkn1btm1Ako/\Cdkn1btm1Ako
(involves: 129S1/Sv * C57BL/6)
increased spleen weight J:33401
increased thymocyte number J:33401
increased thymus weight J:33401
\Cdkn1btm1Ako/\Cdkn1btm1Ako
\Cdkn2ctm1Yxi/\Cdkn2ctm1Yxi

(involves: 129/Sv * 129S1/Sv * C57BL/6 * DBA/2)
enlarged spleen J:50053
enlarged thymus J:50053
\Cdkn1btm1Jro/\Cdkn1btm1Jro
(involves: 129S4/SvJaeSor * C57BL/6)
decreased T cell proliferation J:71780
\Cdkn1btm1Kin/\Cdkn1btm1Kin
(involves: 129P2/OlaHsd * C57BL/6)
enlarged spleen J:33402
enlarged thymus J:33402
increased T cell number J:33402
thymus hyperplasia J:33402
\Cdkn1btm1Kin/\Cdkn1btm1Kin
\Skp2tm1Kin/\Skp2tm1Kin

(involves: 129P2/OlaHsd * C57BL/6)
immune system phenotype J:74265
\Cdkn1btm1Mlf/\Cdkn1b+
\Crebbptm1Jvd/\Crebbptm1Jvd
\Tg(MMTV-cre)4Mam/0

(involves: 129 * C57BL/6 * CBA * FVB)
increased T cell derived lymphoma incidence J:88323
\Cdkn1btm1Mlf/\Cdkn1btm1Mlf
(involves: 129S4/SvJaeSor * C57BL/6J)
abnormal spleen morphology J:33400
abnormal thymus morphology J:33400
enlarged spleen J:33400
enlarged thymus J:33400
increased T cell proliferation J:33400
spleen hyperplasia J:33400
thymus hyperplasia J:33400
\Cdkn1btm1Mlf/\Cdkn1btm1Mlf
(involves: 129S4/SvJaeSor)
enlarged spleen J:107588
enlarged thymus J:107588
spleen hypoplasia J:107588
\Cdkn1btm1Mlf/\Cdkn1btm1Mlf
\Myctm1Atp/\Myc+

(involves: 129P2/OlaHsd * 129S4/SvJaeSor * FVB/N)
decreased T cell proliferation J:73369
\Cdkn1btm1Mlf/\Cdkn1btm1Mlf
\Tg(KRT5-CDK4)2303Mlrp/0

(involves: 129S4/SvJae * C57BL/6 * FVB * SENCAR * SSIN)
enlarged thymus J:107588
thymus hyperplasia J:107588
\Cdkn1btm1Mlf/\Cdkn1btm1Mlf
\Trp53tm1Brd/\Trp53tm1Brd

(involves: C3H * C57BL/6J * NIH)
increased T cell derived lymphoma incidence J:87536
\Cdkn1btm1Mlf/\Cdkn1btm1Mlf
\Trp53tm1Brd/\Trp53tm1Brd

(involves: 129S4/SvJaeSor * 129S7/SvEvBrd * C57BL/6J)
increased T cell derived lymphoma incidence J:87536
\Cdkn1btm2Kin/\Cdkn1btm2Kin
\Rassf5tm1Kina/\Rassf5tm1Kina

(involves: C57BL/6 * CBA)
immune system phenotype J:168749
\Cdkn1btm3Jro/\Cdkn1btm3Jro
(involves: 129S4/SvJaeSor)
enlarged spleen J:103819
enlarged thymus J:103819
\Cdkn1ctm1Kat/\Cdkn1ctm1Kat
(involves: 129P2/OlaHsd * C57BL/6)
abnormal spleen white pulp morphology J:61190
\Cdkn2atm1Cjs/\Cdkn2atm1Cjs
(involves: 129X1/SvJ * C57BL/6)
increased T cell derived lymphoma incidence J:44427
\Cdkn2atm1Cjs/\Cdkn2atm1Cjs
\Nop53tm2.1Asuz/\Nop53tm2.1Asuz
\Tg(Lck-cre)#Jxm/0

(involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6 * CBA)
decreased thymocyte number J:241062
\Cdkn2atm1Rdp/\Cdkn2atm1Rdp
(involves: 129/Sv * C57BL/6 * SJL)
abnormal spleen morphology J:53805
abnormal spleen red pulp morphology J:53805
increased spleen white pulp amount J:53805
\Cdkn2atm1Rdp/\Cdkn2atm1Rdp
\Rnf2tm1Mvi/\Rnf2tm1Mvi
\Tg(Mx1-cre)1Cgn/0

(involves: 129 * C57BL/6 * C57BL/10 * CBA * SJL)
enlarged spleen J:130397
\Cdkn2atm1Rdp/\Cdkn2atm1Rdp
\Tg(Tyr-NRAS*Q61K)1Bee/?

(involves: 129/Sv * C57BL/6 * DBA/2 * SJL)
enlarged lymph nodes J:98545
\Cdkn2atm2.1Rdp/\Cdkn2atm2.1Rdp
(involves: 129S6/SvEvTac * FVB/N)
increased CD4-positive, alpha-beta T cell number J:71394
increased CD8-positive, alpha-beta T cell number J:71394
increased double-positive T cell number J:71394
increased splenocyte proliferation J:71394
increased thymus weight J:71394
thymus hyperplasia J:71394
\Cdkn2btm1Bbd/\Cdkn2btm1Bbd
(involves: 129S1/Sv * C57BL/6)
abnormal lymph node germinal center morphology J:63299
abnormal lymph node secondary follicle morphology J:63299
abnormal lymphocyte morphology J:63299
abnormal spleen marginal zone morphology J:63299
abnormal spleen morphology J:63299
increased mature B cell number J:63299
lymph node hyperplasia J:63299
lymphoid hyperplasia J:63299
spleen hyperplasia J:63299
\Cdkn2btm1Bbd/\Cdkn2btm1Bbd
\Cdkn2ctm1Bbd/\Cdkn2ctm1Bbd

(involves: 129S1/Sv * C57BL/6)
abnormal Langerhans cell morphology J:63299
abnormal lymphocyte morphology J:63299
enlarged spleen J:63299
lymph node hyperplasia J:63299
lymphoid hyperplasia J:63299
\Cdkn2btm1Bbd/\Cdkn2btm1Bbd
\Pbx1tm1Koss/\Pbx1tm1Koss
\Nkx2-5tm2(cre)Rph/\Nkx2-5+

(involves: 129P2/OlaHsd * 129S1/Sv)
abnormal spleen mesenchyme morphology J:184521
abnormal spleen morphology J:184521
\Cdkn2btm1Wff/\Cdkn2btm1Wff
\Lyz2tm1(cre)Ifo/\Lyz2+

(involves: 129P2/OlaHsd * 129S1/Sv * C57BL/6)
increased monocyte cell number J:163498
myeloid hyperplasia J:163498
\Cdkn2ctm1Bbd/\Cdkn2ctm1Bbd
(involves: 129S1/Sv * C57BL/6)
abnormal lymph node medulla morphology J:63299
enlarged lymph nodes J:63299
enlarged spleen J:63299
increased spleen white pulp amount J:63299
increased T cell derived lymphoma incidence J:63299
lymphoid hyperplasia J:63299
\Cdkn2ctm1Yxi/\Cdkn2ctm1Yxi
(involves: 129/Sv * C57BL/6 * DBA/2)
abnormal T cell physiology J:50053
abnormal thymus size J:50053
enlarged spleen J:50053
increased B cell number J:50053
increased T cell number J:50053
spleen hyperplasia J:50053
thymus hyperplasia J:50053
\Cds2Gt(OST184358)Lex/\Cds2+
(involves: 129S5/SvEvBrd * C57BL/6J)
decreased B cell number J:103485
increased T cell number J:103485
\Cdsntm1.1Ics/\Cdsntm1.1Ics
\Tg(KRT14-cre/ERT2)1Ipc/0

(involves: 129S2/SvPas)
skin inflammation J:153292
\Ceacam1Hv2-r/\Ceacam1Hv2-r
(SJL/J)
decreased susceptibility to Coronaviridae infection J:92495
decreased susceptibility to viral infection J:25438
\Ceacam1Hv2-s/\Ceacam1Hv2-s
(Not Specified)
immune system phenotype J:92495
\Ceacam1tm1.1Fta/\Ceacam1tm1.1Fta
(C57BL/6(FVB)-Ceacam1tm1.1Fta)
decreased susceptibility to Coronaviridae infection J:198335
decreased susceptibility to Coronaviridae infection induced morbidity/mortality J:198335
\Ceacam1tm1Bcn/\Ceacam1tm1Bcn
(either: (involves: 129S1/Sv * 129X1/SvJ * BALB/c) or (involves: 129S1/Sv * 129X1/SvJ * C57BL/6))
decreased susceptibility to Coronaviridae infection induced morbidity/mortality J:70815
\Ceacam1tm1Rsb/\Ceacam1tm1Rsb
\Tg(Lck-cre)1Cwi/0

(involves: 129)
abnormal cytokine secretion J:116136
increased interferon-gamma secretion J:116136
increased interleukin-2 secretion J:116136
increased T cell proliferation J:116136
\Ceacam1tm2Bcn/\Ceacam1tm2Bcn
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
decreased susceptibility to Coronaviridae infection J:92376
\Ceacam3em1Btlr/\Ceacam3em1Btlr
(C57BL/6J-Ceacam3em1Btlr)
immune system phenotype J:354285
\Ceacam5em1(IMPC)Wtsi/\Ceacam5em1(IMPC)Wtsi
(C57BL/6N-Ceacam5em1(IMPC)Wtsi/Wtsi)
increased leukocyte cell number J:211773
\Ceat1CBA/J/\Ceat1NOD
(involves: CBA/J * NOD-H2k)
increased susceptibility to experimental autoimmune thyroiditis J:77545
\Ceat1NOD/\Ceat1NOD
(involves: CBA/J * NOD-H2k)
increased susceptibility to experimental autoimmune thyroiditis J:77545
\Cebpatm1.1(Cebpb)Ylee/\Cebpatm1.1(Cebpb)Ylee
(involves: 129X1/SvJ * C57BL/6 * FVB/N)
immune system phenotype J:77646
\Cebpatm1Dgt/\Cebpatm1Dgt
\Tg(Mx1-cre)1Cgn/0

(involves: 129S6/SvEvTac * C57BL/6 * CBA)
abnormal myelopoiesis J:94682
decreased granulocyte number J:94682
failure of myelopoiesis J:94682
sepsis J:94682
\Cebpatm1Gjd/\Cebpatm1Gjd
(B6.129S7-Cebpatm1Gjd)
failure of myelopoiesis J:94682
\Cebpatm1Nerl/\Cebpatm1Nerl
(involves: 129P2/OlaHsd * C57BL/6)
immune system phenotype J:72330
\Cebpatm2Btp/\Cebpatm2Btp
(B6.129P2-Cebpatm2Btp)
abnormal myelopoiesis J:187834
decreased neutrophil cell number J:187834
enlarged spleen J:187834
\Cebpatm2Nerl/\Cebpatm2Nerl
(involves: 129P2/OlaHsd * C57BL/6)
abnormal granulocyte morphology J:72330
decreased granulocyte number J:72330
immune system phenotype J:72330
\Cebpatm3Nerl/\Cebpatm3Nerl
(involves: 129P2/OlaHsd * C57BL/6)
immune system phenotype J:72330
\Cebpatm4Nerl/\Cebpatm4Nerl
(involves: 129P2/OlaHsd * C57BL/6)
abnormal granulocyte morphology J:72330
decreased granulocyte number J:72330
immune system phenotype J:72330
\Cebpatm8.1Nerl/\Cebpatm8.1Nerl
(involves: 129P2/OlaHsd * BALB/cJ * C57BL/6)
abnormal granulocyte morphology J:136134
abnormal leukocyte morphology J:136134
abnormal myeloid leukocyte morphology J:136134
decreased granulocyte number J:136134
decreased monocyte cell number J:136134
decreased neutrophil cell number J:136134
enlarged spleen J:136134
liver inflammation J:136134
\Cebpbtm1.1Acle/\Cebpbtm1.1Acle
(involves: 129P2/OlaHsd * BALB/c * C57BL/6)
abnormal osteoclast differentiation J:150006
abnormal osteoclast morphology J:150006
abnormal osteoclast physiology J:150006
\Cebpbtm1.1Elgaz/\Cebpbtm1.1Elgaz
\Lyz2em1.1(cre)Elgaz/\Lyz2+

(BALB/cJ-Cebpbtm1.1Elgaz Lyz2em1.1Elgaz/Elgaz)
decreased circulating interleukin-10 level J:247885
decreased susceptibility to bacterial infection J:247885
decreased susceptibility to bacterial infection induced morbidity/mortality J:247885
increased circulating interleukin-6 level J:247885
increased circulating tumor necrosis factor level J:247885
\Cebpbtm1Aki/\Cebpbtm1Aki
(involves: 129P2/OlaHsd * C57BL/6)
abnormal macrophage physiology J:153025
abnormal T-helper 1 physiology J:153025
decreased susceptibility to endotoxin shock J:153025
granulomatous inflammation J:153025
increased susceptibility to bacterial infection J:153025
\Cebpbtm1Kish/\Cebpbtm1Kish
(involves: 129P2/OlaHsd)
abnormal macrophage physiology J:77003
impaired macrophage phagocytosis J:77003
increased interleukin-12 secretion J:126085
increased susceptibility to bacterial infection J:77003
\Cebpbtm1Pfj/\Cebpbtm1Pfj
(involves: 129S1/Sv * C57BL/6)
abnormal osteoclast differentiation J:150006
abnormal osteoclast morphology J:150006
abnormal osteoclast physiology J:150006
abnormal tumor necrosis factor level J:192313
\Cebpbtm1Vpo/\Cebpbtm1Vpo
(involves: 129S/SvEv * MF1)
abnormal cell-mediated immunity J:25215
abnormal humoral immune response J:25215
abnormal innate immunity J:25215
abnormal lymph node B cell domain morphology J:25215
abnormal lymph node cortex morphology J:25215
abnormal lymph node medulla morphology J:25215
abnormal lymph node medullary cord morphology J:25215
abnormal lymph node secondary follicle morphology J:25215
abnormal lymph node T cell domain morphology J:25215
abnormal macrophage physiology J:25215
abnormal mucosa-associated lymphoid tissue morphology J:25215
abnormal plasma cell morphology J:25215
abnormal spleen red pulp morphology J:25215
abnormal spleen secondary B follicle morphology J:25215
abnormal spleen white pulp morphology J:25215
abnormal T-helper 1 physiology J:25215
abnormal T-helper 2 physiology J:25215
decreased circulating interleukin-12 level J:25215
decreased susceptibility to type IV hypersensitivity reaction J:25215
enlarged axillary lymph nodes J:25215
enlarged inguinal lymph nodes J:25215
enlarged lymph nodes J:25215
enlarged mesenteric lymph nodes J:25215
enlarged spleen J:25215
enlarged submandibular lymph nodes J:25215
glomerulonephritis J:25215
increased circulating interleukin-6 level J:25215
increased IgG level J:25215
increased susceptibility to fungal infection J:25215
\Cebpbtm2.1Acle/\Cebpbtm2.1Acle
(involves: 129P2/OlaHsd * BALB/cJ * C57BL/6)
abnormal osteoclast morphology J:155795
decreased osteoclast cell number J:155795
increased circulating interleukin-6 level J:155795
\Cebpbtm3Nerl/\Cebpbtm3Nerl
(either: B6.129P2-Cebpbtm3Nerl or (involves: 129P2/OlaHsd * C57BL/6))
myositis J:153686
\Cebpdtm1Pfj/\Cebpdtm1Pfj
(involves: 129S1/Sv * C57BL/6)
abnormal cytokine level J:192313
decreased inflammatory response J:192313
\Cebpetm1Kgx/\Cebpetm1Kgx
(involves: 129S6/SvEvTac * NIH Black Swiss)
abnormal eosinophil differentiation J:76024
abnormal granulocyte differentiation J:76024
abnormal myelopoiesis J:76024
abnormal neutrophil differentiation J:76024
abnormal neutrophil morphology J:76024
abnormal neutrophil physiology J:76024
colitis J:76024
conjunctivitis J:76024
decreased eosinophil cell number J:76024
decreased granulocyte number J:76024
enlarged lymph nodes J:76024
impaired myelopoiesis J:76024
increased inflammatory response J:76024
increased plasma cell number J:76024
increased susceptibility to bacterial infection J:76024
lung inflammation J:76024
osteomyelitis J:76024
peritoneal inflammation J:76024
rhinitis J:76024
\Cebpetm1Kgx/\Cebpetm1Kgx
(involves: 129S6/SvEvTac)
abnormal eosinophil differentiation J:76024
abnormal granulocyte differentiation J:76024
abnormal myelopoiesis J:76024
abnormal neutrophil differentiation J:76024
abnormal neutrophil morphology J:76024
abnormal neutrophil physiology J:76024
colitis J:76024
conjunctivitis J:76024
decreased eosinophil cell number J:76024
decreased granulocyte number J:76024
enlarged lymph nodes J:76024
impaired myelopoiesis J:76024
increased inflammatory response J:76024
increased plasma cell number J:76024
increased susceptibility to bacterial infection J:76024
lung inflammation J:76024
osteomyelitis J:76024
peritoneal inflammation J:76024
pleuritis J:76024
rhinitis J:76024
\Cebpgtm1Aki/\Cebpgtm1Aki
(involves: 129P2/OlaHsd)
abnormal NK cell physiology J:58801
impaired natural killer cell mediated cytotoxicity J:58801
\Cecr2tm2b(EUCOMM)Hmgu/\Cecr2+
(C57BL/6N-Cecr2tm2b(EUCOMM)Hmgu/Tcp)
enlarged lymph nodes J:211773
\Celf4tm1a(EUCOMM)Wtsi/\Celf4tm1a(EUCOMM)Wtsi
(C57BL/6N-Celf4tm1a(EUCOMM)Wtsi/Wtsi)
blood in lymph vessels J:239583
\Celsr1ctb-2J/\Celsr1ctb-2J
(STOCK Celsr1ctb-2J/GrsrJ)
increased susceptibility to otitis media J:229303
\Celsr1ctb/\Celsr1ctb
(CByJ.Cg-Celsr1ctb/GrsrJ)
increased susceptibility to otitis media J:229303
\Cemip2tm1.1Cya/\Cemip2tm1.1Cya
\Tg(CAG-cre/Esr1*)5Amc/0

(involves: C57BL/6 * CBA)
abnormal lymph node morphology J:317425
\Cemiptm1.1Okda/\Cemiptm1.1Okda
(involves: C57BL/6NCrlj * CBA/JNCrlj)
decreased osteoclast cell number J:241936
\Cep68em1(IMPC)J/\Cep68em1(IMPC)J
(C57BL/6NJ-Cep68em1(IMPC)J/Mmjax)
increased leukocyte cell number J:211773
\Cep76tm1b(EUCOMM)Hmgu/\Cep76tm1b(EUCOMM)Hmgu
(C57BL/6N-Cep76tm1b(EUCOMM)Hmgu/Bay)
abnormal spleen morphology J:211773
\Cep85lem1(IMPC)Mbp/\Cep85lem1(IMPC)Mbp
(C57BL/6N-Cep85lem1(IMPC)Mbp/MbpMmucd)
abnormal lymph node morphology J:211773
enlarged lymph nodes J:211773
\Cep290b2b1454Clo/\Cep290b2b1454Clo
(C57BL/6J-Cep290b2b1454Clo)
accessory spleen J:175213
spleen hypoplasia J:175213
\Cep290b2b1752Clo/\Cep290b2b1752Clo
(C57BL/6J-Cep290b2b1752Clo)
spleen hypoplasia J:175213
\Cer1em1(IMPC)Ccpcz/\Cer1em1(IMPC)Ccpcz
(C57BL/6NCrl-Cer1em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged spleen J:211773
enlarged thymus J:211773
\Cerktm1Fbor/\Cerktm1Fbor
(involves: BALB/c)
decreased granulocyte number J:131522
decreased neutrophil cell number J:131522
immune system phenotype J:131522
increased leukocyte cell number J:131522
increased susceptibility to bacterial infection J:131522
\Cers1tm1b(EUCOMM)Hmgu/\Cers1+
(C57BL/6N-Cers1tm1b(EUCOMM)Hmgu/H)
increased neutrophil cell number J:211773
\Cers3tm1.1Rsnd/\Cers3tm1.1Rsnd
(involves: 129P2/OlaHsd * C57BL/6)
increased susceptibility to fungal infection J:179754
\Cers6tm1.1Arte/\Cers6tm1.1Arte
(involves: BALB/cJ * C57BL/6N)
decreased inflammatory response J:215519
\Cers6tm1.1Kwi/\Cers6tm1.1Kwi
(involves: 129P2/OlaHsd * C57BL/6)
microgliosis J:201327
\Ces1cem1(IMPC)Ccpcz/\Ces1cem1(IMPC)Ccpcz
(C57BL/6NCrl-Ces1cem1(IMPC)Ccpcz/Ccpcz)
abnormal lymph node morphology J:211773
abnormal spleen morphology J:211773
enlarged lymph nodes J:211773
enlarged spleen J:211773
\Ces2atm1(KOMP)Vlcg/\Ces2atm1(KOMP)Vlcg
(C57BL6/N-Ces2atm1(KOMP)Vlcg)
liver inflammation J:335459
\Cfap20dcem1(IMPC)J/\Cfap20dcem1(IMPC)J
(C57BL/6NJ-Cfap20dcem1(IMPC)J/Mmjax)
increased leukocyte cell number J:211773
\Cfap47em1(IMPC)Hmgu/\Cfap47em1(IMPC)Hmgu
(C57BL/6NCrl-Cfap47em1(IMPC)Hmgu/Ieg)
decreased spleen weight J:211773
\Cfap53em1(IMPC)Wtsi/\Cfap53em1(IMPC)Wtsi
(C57BL/6N-Cfap53em1(IMPC)Wtsi/Wtsi)
abnormal thymus topology J:239583
blood in lymph vessels J:239583
small spleen J:239583
\Cfap161em1(IMPC)Ccpcz/\Cfap161em1(IMPC)Ccpcz
(C57BL/6NCrl-Cfap161em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
enlarged spleen J:211773
\Cfbtm1Hrc/\Cfb+
\Cfhtm1Mbo/\Cfhtm1Mbo

(involves: 129S/Sv * C57BL/6)
decreased circulating complement protein level J:78193
\Cfbtm1Hrc/\Cfbtm1Hrc
(involves: 129S/Sv * C57BL/6)
abnormal complement pathway J:42679
impaired complement alternative pathway J:42679
\Cfbtm1Hrc/\Cfbtm1Hrc
(involves: 129S/Sv)
decreased susceptibility to Coronaviridae infection J:286325
impaired complement classical pathway J:130108
\Cfbtm1Mbo/\Cfbtm1Mbo
(involves: 129/Sv * C57BL/6)
increased susceptibility to bacterial infection J:83712
\Cfbtm1Pkna/\Cfbtm1Pkna
(D1.129P2-Cfbtm1Pkna)
decreased susceptibility to induced arthritis J:88872
\Cfc1b2b2736.1Clo/\Cfc1b2b2736.1Clo
(C57BL/6J-Cfc1b2b2736.1Clo)
accessory spleen J:175213
spleen hypoplasia J:175213
\Cfc1tm1Cbm/\Cfc1tm1Cbm
(Not Specified)
small spleen J:58530
spleen hypoplasia J:58530
\Cfc1tm1Mms/\Cfc1tm1Mms
(either: (involves: 129S6/SvEvTac * Black Swiss) or (involves: 129S6/SvEvTac * C57BL/6J))
absent spleen J:58104
\Cfdtm1Yxu/\Cfdtm1Yxu
(involves: 129P2/OlaHsd * C57BL/6J)
impaired complement alternative pathway J:73125
\Cfdtm1Yxu/\Cfdtm1Yxu
(B6.129P2-Cfdtm1Yxu)
impaired complement alternative pathway J:94855
increased susceptibility to bacterial infection J:94855
\Cfhtm1.1Song/\Cfhtm1.1Song
(involves: C57BL/6)
decreased circulating complement protein level J:240426
decreased complement C5 level J:240426
decreased serum complement activity J:240426
\Cfhtm1Mbo/\Cfh+
(involves: 129/Sv * C57BL/6)
decreased circulating complement protein level J:78193
\Cfhtm1Mbo/\Cfhtm1Mbo
(involves: 129/Sv * C57BL/6)
decreased circulating complement protein level J:78193
glomerulonephritis J:78193
increased susceptibility to type III hypersensitivity reaction J:78193
\Cfhtm1Mbo/\Cfhtm1Mbo
(involves: 129)
abnormal complement protein level J:125860
decreased circulating complement protein level J:125860, J:131403
glomerulonephritis J:131403
\Cfhtm1Mbo/\Cfhtm1Mbo
\Tg(CAG-Cfh*)#Mcp/0

(involves: 129/Sv * C57BL/6 * CBA)
abnormal circulating complement protein level J:125860
abnormal complement protein level J:125860
\Cfiem1Jiwe/\Cfiem1Jiwe
(involves: C57BL/6J)
abnormal complement protein level J:308307
impaired complement alternative pathway J:308307
\Cfitm1Mcp/\Cfitm1Mcp
(involves: 129/Sv * C57BL/6)
decreased circulating complement protein level J:131403
\Cflartm1.1Pope/\Cflartm1.2Pope
\Lyz2tm1(cre)Ifo/\Lyz2+

(involves: 129P2/OlaHsd)
abnormal abdominal lymph node morphology J:167430
abnormal B cell number J:167430
abnormal CD4-positive, alpha-beta T cell number J:167430
abnormal CD8-positive, alpha-beta T cell number J:167430
abnormal lymphocyte cell number J:167430
abnormal myelopoiesis J:167430
abnormal spleen B cell follicle morphology J:167430
abnormal spleen marginal zone morphology J:167430
abnormal spleen morphology J:167430
abnormal spleen red pulp morphology J:167430
abnormal thymus corticomedullary boundary morphology J:167430
abnormal thymus morphology J:167430
decreased macrophage cell number J:167430
enlarged spleen J:167430
increased CD8-positive, alpha-beta T cell number J:167430
increased eosinophil cell number J:167430
increased granulocyte number J:167430
increased leukocyte cell number J:167430
increased monocyte cell number J:167430
increased neutrophil cell number J:167430
\Cflartm1Ywh/\Cflartm1Ywh
\Tg(Lck-cre)548Jxm/0

(involves: 129S4/SvJaeSor * 129S6/SvEvTac * C57BL/6 * CBA)
decreased single-positive T cell number J:100558
increased thymocyte apoptosis J:100558
\Cfmq1129X1/SvJ/\Cfmq1C57BL/6J
\Cftrtm1Unc/\Cftrtm1Unc

(involves: 129X1/SvJ * C57BL/6J)
intestinal inflammation J:101842
\Cfmq2129X1/SvJ/\Cfmq2129X1/SvJ
\Cftrtm1Unc/\Cftrtm1Unc

(involves: 129X1/SvJ * C57BL/6J)
intestinal inflammation J:101842
\Cfmq3129X1/SvJ/\Cfmq3C57BL/6J
\Cftrtm1Unc/\Cftrtm1Unc

(involves: 129X1/SvJ * C57BL/6J)
intestinal inflammation J:101842
\Cfptm1Cmst/\Cfptm1Cmst
(B6.129P2-Cfptm1Cmst)
sepsis J:131526
\Cfptm1Song/Y
(involves: 129 * C57BL/6)
abnormal complement pathway J:130108
impaired complement alternative pathway J:130108
impaired complement classical pathway J:130108
\Cfptm1Song/\Cfptm1Song
(involves: 129 * C57BL/6)
decreased susceptibility to induced arthritis J:165497
impaired complement alternative pathway J:165497
\Cfptm2.1Song/\Cfptm2.1Song
\Lyz2tm1(cre)Ifo/\Lyz2+

(involves: 129 * 129P2/OlaHsd * C57BL/6 * SJL)
decreased susceptibility to induced arthritis J:165497
impaired complement alternative pathway J:165497
\Cfptm2.1Song/\Cfptm2.1Song
\Tg(EIIa-cre)C5379Lmgd/0

(involves: 129 * C57BL/6 * FVB/N * SJL)
impaired complement alternative pathway J:165497
\Cftrtm1Bay/\Cftrtm1Bay
(involves: 129S7/SvEvBrd * C57BL/6J)
acute pancreas inflammation J:15244
\Cftrtm1Cam/\Cftrtm1Cam
(involves: 129S/SvEv)
increased susceptibility to infection J:23850
peritoneal inflammation J:23850
\Cftrtm1Hgu/\Cftrtm1Hgu
(involves: 129P2/OlaHsd)
increased susceptibility to bacterial infection J:24119
lung inflammation J:24119
\Cftrtm1Kth/\Cftrtm1Kth
(involves: 129S7/SvEvBrd * C57BL/6J)
peritoneal inflammation J:29074
\Cftrtm1Kth/\Cftrtm1Kth
(B6.129S7-Cftrtm1Kth)
increased susceptibility to bacterial infection induced morbidity/mortality J:112450
lung inflammation J:112450
\Cftrtm1Unc/\Cftrtm1Unc
(B6.129P2-Cftrtm1Unc/J)
increased susceptibility to bacterial infection induced morbidity/mortality J:112450
lung inflammation J:58571, J:112450
\Cftrtm1Unc/\Cftrtm1Unc
(involves: 129P2/OlaHsd)
abnormal thymus involution J:2079
peritoneal inflammation J:2079
spleen hyperplasia J:2079
\Cftrtm1Unc/\Cftrtm1Unc
(B6.129P2-Cftrtm1Unc)
lung inflammation J:44904
\Cftrtm1Unc/\Cftrtm1Unc
\Tg(FABPCFTR)1Jaw/0
\Tg(Scgb1a1-Scnn1b)6608Bouc/0

(involves: 129P2/OlaHsd * C3H * C57BL/6 * FVB/N)
respiratory system inflammation J:191673
\Cftrtm2Cam/\Cftrtm2Cam
(involves: 129S/SvEv)
peritoneal inflammation J:27734
\Cftrtm2Mrc/\Cftrtm2Mrc
(B6.129S6-Cftrtm2Mrc)
abnormal alveolar macrophage morphology J:112450
decreased neutrophil cell number J:112450
increased susceptibility to bacterial infection induced morbidity/mortality J:112450
lung inflammation J:112450
\Cftrtm3Hgu/\Cftrtm3Hgu
(involves: 129P2/OlaHsd)
gallbladder inflammation J:32766
peritoneal inflammation J:32766
\Cftrtm3Mrc/\Cftrtm3Mrc
(B6.129S6-Cftrtm3Mrc)
increased susceptibility to bacterial infection induced morbidity/mortality J:112450
lung inflammation J:112450
\Cgastm1a(EUCOMM)Hmgu/\Cgastm1a(EUCOMM)Hmgu
(C57BL/6N-Cgastm1a(EUCOMM)Hmgu)
abnormal dendritic cell physiology J:201167
abnormal immune cell physiology J:201167
abnormal macrophage physiology J:201167
abnormal plasmacytoid dendritic cell physiology J:201167
decreased circulating interferon-alpha level J:201167
decreased circulating interferon-beta level J:201167
increased susceptibility to Herpesvirales infection J:201167
increased susceptibility to Herpesvirales infection induced morbidity/mortality J:201167
\Cgastm1a(EUCOMM)Hmgu/\Cgastm1a(EUCOMM)Hmgu
(involves: C57BL/6N)
abnormal interferon secretion J:234263
\Cgastm1a(EUCOMM)Hmgu/\Cgastm1a(EUCOMM)Hmgu
\Rnaseh2atm1Crh/\Rnaseh2atm1Crh

(involves: C57BL/6N)
immune system phenotype J:232933
\Cgastm1a(EUCOMM)Hmgu/\Cgastm1a(EUCOMM)Hmgu
\Trex1tm1Tld/\Trex1tm1Tld

(involves: 129P2/OlaHsd * C57BL/6N)
increased susceptibility to Retroviridae infection J:234263
\Cgastm1d(EUCOMM)Hmgu/\Cgastm1d(EUCOMM)Hmgu
(involves: BALB/c * C57BL/6JJcl * C57BL/6N)
increased susceptibility to Flaviviridae infection J:207826
increased susceptibility to Flaviviridae infection induced morbidity/mortality J:207826
increased susceptibility to Herpesvirales infection J:207826
increased susceptibility to Poxviridae infection J:207826
increased susceptibility to Poxviridae infection induced morbidity/mortality J:207826
\Cgastm1d(EUCOMM)Hmgu/\Cgastm1d(EUCOMM)Hmgu
(involves: C57BL/6N)
immune system phenotype J:265023
increased susceptibility to Retroviridae infection J:265023
\Cgnz1NZM2328/J/\Cgnz1NZM2328/J
(involves: C57L/J * NZM2328/J)
increased susceptibility to systemic lupus erythematosus J:71397
kidney inflammation J:71397
\Cgref1em1(IMPC)J/\Cgref1em1(IMPC)J
(C57BL/6NJ-Cgref1em1(IMPC)J/Mmjax)
increased leukocyte cell number J:211773
\Cgrrf1tm1b(KOMP)Wtsi/\Cgrrf1tm1b(KOMP)Wtsi
(C57BL/6N-Cgrrf1tm1b(KOMP)Wtsi/Wtsi)
increased CD5-positive gamma-delta T cell number J:211773
increased gamma-delta T cell number J:211773
\Ch25htm1Rus/\Ch25htm1Rus
(B6.129S6-Ch25htm1Rus)
increased IgA level J:170807
increased IgG2a level J:170807
increased IgG2b level J:170807
increased IgG3 level J:170807
\Chaf1btm2c(EUCOMM)Hmgu/\Chaf1b+
\Krastm4Tyj/\Kras+
\Tg(Mx1-cre)1Cgn/0

(involves: 129S4/SvJae * C57BL/6J * C57BL/6N * CBA/J)
increased leukocyte cell number J:266848
\Champ1em1(IMPC)Mbp/\Champ1+
(C57BL/6NCrl-Champ1em1(IMPC)Mbp/MbpMmucd)
abnormal spleen morphology J:211773
enlarged spleen J:211773
small spleen J:211773
\Char2aC3H/HeJ/\Char2aC3H/HeJ
(involves: C3H/HeJ * C57BL/6J)
increased susceptibility to parasitic infection J:117548
\Char2bC3H/HeJ/\Char2bC3H/HeJ
(involves: C3H/HeJ * C57BL/6J)
increased susceptibility to parasitic infection J:117548
\Char3C3H/He/\Char3C57BL/6
(involves: C3H/He * C57BL/6)
decreased susceptibility to parasitic infection J:72455
\Char3C57BL/6/\Char3C57BL/6
(involves: C3H/He * C57BL/6)
decreased susceptibility to parasitic infection J:72455
\Char4C57BL/6J/\Char4C57BL/6J
(involves: A/J * C57BL/6J)
decreased susceptibility to parasitic infection J:71471
\Char9A/J/\Char9C57BL/6J
(involves: A/J * C57BL/6J)
decreased susceptibility to parasitic infection J:122131
\Char9C57BL/6J/\Char9C57BL/6J
(involves: A/J * C57BL/6J)
decreased susceptibility to parasitic infection J:122131
\Char11A/J/\Char11C57BL/6J
(involves: A/J * C57BL/6J)
decreased susceptibility to parasitic infection J:106220
\Char11C57BL/6J/\Char11C57BL/6J
(involves: A/J * C57BL/6J)
decreased susceptibility to parasitic infection J:106220
\Chchd7em3(IMPC)Tcp/\Chchd7em3(IMPC)Tcp
(C57BL/6NCrl-Chchd7em3(IMPC)Tcp/Tcp)
enlarged lymph nodes J:211773
\Chchd10em8Lutzy/\Chchd10+
(C57BL/6NJ-Chchd10em8Lutzy/J)
increased susceptibility to otitis media J:272524
\Chd2Gt(RRBO46)Byg/\Chd2+
(involves: 129P2/OlaHsd * C57BL/6)
arteritis J:146176
dark spleen J:146743
decreased lymphocyte cell number J:146176
enlarged lymph nodes J:146743
enlarged spleen J:146743
heart inflammation J:146176
increased CD4-positive, alpha-beta T cell number J:146176
increased spleen red pulp amount J:146743
increased T cell derived lymphoma incidence J:146176
interstitial pneumonia J:146743
liver inflammation J:146743
lymphoid hyperplasia J:146176
myocarditis J:146743
\Chd4tm1.1Kge/\Chd4tm1.1Kge
\Tg(Lck-cre)1Cwi/0

(involves: C57BL/6 * SJL)
abnormal CD4-positive, alpha beta T cell morphology J:109547
abnormal T cell physiology J:109547
arrested T cell differentiation J:109547
decreased double-positive T cell number J:109547
increased CD8-positive, alpha-beta T cell number J:109547
lymph node hypoplasia J:109547
spleen hypoplasia J:109547
\Chd4tm1.1Kge/\Chd4tm1.2Kge
\Tg(CAG-Bgeo/GFP)21Lbe/0
\Tg(Lck-cre)1Cwi/0

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL)
decreased T cell proliferation J:109547
\Chd4tm1.1Kge/\Chd4tm1.2Kge
\Tg(Lck-cre)1Cwi/0

(involves: C57BL/6 * SJL)
thymus hypoplasia J:109547
\Chd4tm1.2Kge/\Chd4tm1.2Kge
\Tg(Lck-cre)1Cwi/0

(involves: C57BL/6 * DBA/2 * SJL)
abnormal T cell differentiation J:109547
decreased double-positive T cell number J:109547
decreased T cell proliferation J:109547
increased CD8-positive, alpha-beta T cell number J:109547
increased double-negative T cell number J:109547
thymus hypoplasia J:109547
\Chd5em1(IMPC)Mbp/\Chd5em1(IMPC)Mbp
(C57BL/6NCrl-Chd5em1(IMPC)Mbp/MbpMmucd)
abnormal spleen morphology J:211773
enlarged spleen J:211773
\Chd7Flo/\Chd7+
(involves: C3HeB/FeJ)
keratoconjunctivitis sicca J:104123
\Chd7Gt(RRR136)Byg/\Chd7+
(involves: 129P2/OlaHsd * C57BL/6)
ectopic thymus J:154590
small thymus J:154590
thymus hypoplasia J:154590
\Chd7Gt(XK403)Byg/\Chd7+
\Tbx1tm1Bld/\Tbx1+

(either: (involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6) or (involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6 * CD-1))
ectopic thymus J:154590
\Chd7Looper/\Chd7+
(BALB/c-Chd7Looper)
blepharitis J:252089
conjunctivitis J:252089
\Chd7Ome/\Chd7+
(involves: BALB/cByJ * C57BL/6J)
increased susceptibility to otitis media J:187200
\Chd7tm2a(EUCOMM)Wtsi/\Chd7+
(involves: 129S5/SvEvBrd * C57BL/6N)
decreased leukocyte cell number J:330596
decreased monocyte cell number J:330596
increased NK T cell number J:330596
\Chd7Trooper/\Chd7+
(BALB/c-Chd7Trooper)
blepharitis J:262283
conjunctivitis J:262283
\Chd7Whi/\Chd7+
(C3HeB/FeJ-Chd7Whi)
decreased monocyte cell number J:330596
increased NK T cell number J:330596
\Chd7Whi/\Chd7+
(involves: C3HeB/FeJ)
keratoconjunctivitis sicca J:104123
\Chd8em1(IMPC)Mbp/\Chd8+
(C57BL/6N-Chd8em1(IMPC)Mbp/MbpMmucd)
abnormal spleen morphology J:211773
enlarged lymph nodes J:211773
increased lymphocyte cell number J:211773
\Chd9tm1a(EUCOMM)Wtsi/\Chd9tm1a(EUCOMM)Wtsi
(C57BL/6N-Chd9tm1a(EUCOMM)Wtsi/Wtsi)
increased Langerhans cell number J:211773
\Chek2tm1Mak/\Chek2+
\Rad50tm2Jpt/\Rad50tm2Jpt

(involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6)
abnormal pro-B cell morphology J:103922
decreased double-negative T cell number J:103922
decreased macrophage cell number J:103922
\Chfrtm1a(KOMP)Wtsi/\Chfrtm1a(KOMP)Wtsi
(C57BL/6NCrl-Chfrtm1a(KOMP)Wtsi/Ccpcz)
abnormal spleen morphology J:211773
\Chi3l1tm1Eli/\Chi3l1tm1Eli
(B6.Cg-Chi3l1tm1Eli)
abnormal dendritic cell physiology J:148490
abnormal macrophage morphology J:148490
abnormal plasmacytoid dendritic cell physiology J:148490
abnormal T-helper 2 physiology J:148490
decreased IgE level J:148490
decreased interleukin-4 secretion J:148490
decreased interleukin-13 secretion J:148490
decreased splenocyte proliferation J:148490
decreased T-helper 2 cell number J:148490
impaired eosinophil recruitment J:148490
impaired neutrophil recruitment J:148490
increased T cell apoptosis J:148490
\Chi3l1tm1Eli/\Chi3l1tm1Eli
\Tg(Scgb1a1-rtTA,-tTS,tetO-CHI3L1)1Eli/0

(involves: 129 * C57BL/6)
immune system phenotype J:148490
\Chi3l1tm1Eli/\Chi3l1tm1Eli
\Tg(Scgb1a1-rtTA,tetO-Il13)1Eli/0

(involves: C57BL/6 * CBA)
abnormal T-helper 2 cell number J:148490
abnormal T-helper 2 physiology J:148490
\Chia1tm1.1Lof/\Chia1tm1.1Lof
(C57BL/6-Chia1tm1.1Lof)
decreased interleukin-13 secretion J:257728
immune system phenotype J:257728
increased lymphocyte cell number J:257728
increased neutrophil cell number J:257728
\Chic2tm1b(EUCOMM)Wtsi/\Chic2+
(C57BL/6N-Chic2tm1b(EUCOMM)Wtsi/H)
enlarged spleen J:211773
\Chit1tm1Eli/\Chit1tm1Eli
(involves: C57BL/6)
decreased susceptibility to bacterial infection J:189872
\Chit1tm1Eli/\Chit1tm1Eli
\Tg(Scgb1a1-Il13)2Eli/0

(involves: C57BL/6 * CBA)
decreased susceptibility to bacterial infection J:189872
\Chit1tm1Eli/\Chit1tm1Eli
\Tg(Scgb1a1-rtTA,tetO-CHIT1)#Eli/0

(involves: C57BL/6)
decreased susceptibility to bacterial infection J:189872
\Chmp2bem1(IMPC)Mbp/\Chmp2b+
(C57BL/6NCrl-Chmp2bem1(IMPC)Mbp/Mmucd)
abnormal spleen morphology J:211773
enlarged spleen J:211773
\Chmp4ctm1b(EUCOMM)Wtsi/\Chmp4ctm1b(EUCOMM)Wtsi
(C57BL/6N-Chmp4ctm1b(EUCOMM)Wtsi/H)
decreased basophil cell number J:211773
\Chordc1em1(IMPC)Mbp/\Chordc1+
(C57BL/6N-Chordc1em1(IMPC)Mbp/MbpMmucd)
decreased lymphocyte cell number J:211773
increased neutrophil cell number J:211773
\Chordc1tm1Mbra/\Chordc1+
(involves: 129 * C57BL/6)
abnormal myelopoiesis J:222040
abnormal spleen morphology J:222040
enlarged spleen J:222040
increased leukocyte cell number J:222040
\Chrdtm1Emdr/\Chrdtm1Emdr
(either: B6SJL.129-Chrdtm1Emdr or (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * SJL/J))
athymia J:83662
\Chrdtm1Emdr/\Chrdtm1Emdr
(129S6.129-Chrdtm1Emdr)
athymia J:146769
\Chrdtm1Emdr/\Chrdtm1Emdr
\Tbx1m1Jlk/\Tbx1m1Jlk

(129/Sv-Tbx1m1Jlk Chrdtm1Emdr)
athymia J:146769
\Chrm1tm1Jwe/\Chrm1tm1Jwe
(involves: 129S6/SvEvTac * CF-1)
decreased cytotoxic T cell cytolysis J:106393
\Chrna3tm1Bay/\Chrna3tm1Bay
(involves: 129S7/SvEvBrd * C57BL/6)
increased susceptibility to bacterial infection J:54994
urinary bladder inflammation J:54994
\Chrna4tm1Jpc/\Chrna4tm1Jpc
(involves: C57BL/6)
decreased IgG level J:103908
decreased immunoglobulin level J:103908
immune system phenotype J:103908
increased IgG level J:103908
\Chrna5em1(IMPC)H/\Chrna5em1(IMPC)H
(C57BL/6N-Chrna5em1(IMPC)H/H)
decreased lymphocyte cell number J:211773
increased basophil cell number J:211773
increased neutrophil cell number J:211773
\Chrna7tm1Bay/\Chrna7tm1Bay
(involves: 129S7/SvEvBrd * C57BL/6J)
decreased neutrophil cell number J:140280
increased lymphocyte cell number J:140280
\Chrna7tm1Bay/\Chrna7tm1Bay
(B6.Cg-Chrna7tm1Bay)
abnormal interleukin level J:89610
abnormal tumor necrosis factor level J:89610
\Chrna7tm1Bay/\Chrna7tm1Bay
(involves: 129S7/SvEvBrd * C57BL/6)
decreased IgG level J:103908
decreased immunoglobulin level J:103908
immune system phenotype J:103908
\Chrnb2tm1Jpc/\Chrnb2tm1Jpc
(B6.129P2-Chrnb2tm1Jpc)
decreased B cell number J:112766
\Chrnb2tm1Jpc/\Chrnb2tm1Jpc
(involves: 129P2/OlaHsd * C57BL/6J)
myeloid hyperplasia J:140280
\Chrnb2tm1Jpc/\Chrnb2tm1Jpc
(involves: 129P2/OlaHsd * C57BL/6)
abnormal immune system physiology J:103908
abnormal immunoglobulin level J:103908
decreased B cell number J:103908
decreased immunoglobulin level J:103908
immune system phenotype J:103908
increased B cell proliferation J:103908
increased IgG level J:103908
\Chrnb2tm1Mdb/\Chrnb2tm1Mdb
\Chrnb4tm1Mdb/\Chrnb4tm1Mdb

(involves: 129S7/SvEvBrd * C57BL/6J)
increased susceptibility to bacterial infection J:73590
urinary bladder inflammation J:73590
\Chst1tm1(KOMP)Vlcg/\Chst1tm1(KOMP)Vlcg
(involves: C57BL/6NTac)
decreased B cell number J:204813
immune system phenotype J:204813
increased T cell number J:204813
\Chst1tm1(KOMP)Vlcg/\Chst1tm1(KOMP)Vlcg
\Chst2tm1Tmu/\Chst2tm1Tmu
\Chst4tm1Sdr/\Chst4tm1Sdr

(involves: 129S2/SvPas * C57BL/6NTac)
abnormal leukocyte migration J:204813
\Chst2em1(IMPC)Mbp/\Chst2em1(IMPC)Mbp
(C57BL/6N-Chst2em1(IMPC)Mbp/MbpMmucd)
abnormal lymph node morphology J:211773
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged lymph nodes J:211773
enlarged spleen J:211773
enlarged thymus J:211773
\Chst2tm1Tmu/\Chst2tm1Tmu
(involves: 129S2/SvPas * C57BL/6J)
abnormal leukocyte migration J:92231
abnormal leukocyte physiology J:92231
\Chst2tm1Tmu/\Chst2tm1Tmu
\Chst4tm1Sdr/\Chst4tm1Sdr

(involves: 129S2/SvPas)
abnormal leukocyte migration J:204813
\Chst3tm1Tmu/\Chst3tm1Tmu
(involves: 129S2/SvPas * 129X1/SvJ)
decreased T cell number J:73698
\Chst3tm1Tmu/\Chst3tm1Tmu
(involves: 129S2/SvPas)
decreased neutrophil cell number J:217719
increased T cell proliferation J:217719
lymph node hypoplasia J:217719
\Chst4tm1Mifu/\Chst4tm1Mifu
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
abnormal leukocyte migration J:113195
impaired leukocyte tethering or rolling J:113195
\Chst4tm1Mifu/\Chst4tm1Mifu
\Gcnt1tm1Jxm/\Gcnt1tm1Jxm

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
abnormal leukocyte migration J:113195
impaired leukocyte tethering or rolling J:113195
\Chst4tm1Sdr/\Chst4tm1Sdr
(involves: C57BL/6)
abnormal leukocyte adhesion J:86759
abnormal leukocyte migration J:86759
abnormal lymph node morphology J:86759
abnormal lymph node primary follicle morphology J:86759
\Chst10em1(IMPC)Hmgu/\Chst10em1(IMPC)Hmgu
(C57BL/6NCrl-Chst10em1(IMPC)Hmgu/Ieg)
increased spleen weight J:211773
\Chst11tm1a(KOMP)Wtsi/\Chst11tm1a(KOMP)Wtsi
(C57BL/6N-Chst11tm1a(KOMP)Wtsi/Wtsi)
abnormal thymus morphology J:239583
blood in lymph vessels J:239583
\Chst15tm1Oh/\Chst15tm1Oh
(involves: 129P2/OlaHsd * C57BL/6)
abnormal mast cell morphology J:165927
\Chsy1em1(IMPC)Mbp/\Chsy1em1(IMPC)Mbp
(C57BL/6NCrl-Chsy1em1(IMPC)Mbp/MbpMmucd)
abnormal lymph node morphology J:211773
abnormal spleen morphology J:211773
enlarged lymph nodes J:211773
enlarged spleen J:211773
\Chsy1skt/\Chsy1skt
\Pde6b+/\Pde6b+

(mixed)
decreased macrophage cell number J:286529
decreased neutrophil cell number J:286529
kidney inflammation J:286529
microgliosis J:286529
\Chsy1skt/\Chsy1tm1Lex
(mixed)
microgliosis J:286529
\Chsy1tm1Lex/\Chsy1tm1Lex
(involves: 129S5/SvEvBrd * C57BL/6J)
autoimmune arthritis J:171883
microgliosis J:286529
\Chtoptm1a(EUCOMM)Wtsi/\Chtoptm1a(EUCOMM)Wtsi
(C57BL/6N-Chtoptm1a(EUCOMM)Wtsi/Wtsi)
absent spleen J:239583
spleen hypoplasia J:239583
\Chukem1(IMPC)Ccpcz/\Chuk+
(C57BL/6NCrl-Chukem1(IMPC)Ccpcz/Ccpcz)
abnormal lymph node morphology J:211773
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged lymph nodes J:211773
enlarged thymus J:211773
\Chuktm1Lex/\Chuktm1Lex
\Lyz2tm1(cre)Ifo/\Lyz2+

(involves: 129P2/OlaHsd * 129S/SvEvBrd)
impaired macrophage chemotaxis J:159873
impaired neutrophil chemotaxis J:159873
impaired neutrophil recruitment J:159873
\Chuktm1Mka/\Chuktm1Mka
(B6.129-Chuktm1Mka)
abnormal B cell physiology J:113556
\Chuktm1Mpa/\Chuktm1Mpa
\Ikbkbtm2Cgn/\Ikbkbtm2Cgn
\Tg(Alb1-cre)7Gsc/0

(involves: C57BL/6 * FVB/N)
increased susceptibility to endotoxin shock J:137861
\Chuktm2Mka/\Chuktm2Mka
(B6.Cg-Chuktm2Mka)
abnormal B cell physiology J:113556
\Chuktm2Mka/\Chuktm2Mka
\Tg(Tnfsf13b)1Fma/?

(B6.Cg-Chuktm2Mka Tg(Tnfsf13b)1Fma)
abnormal B cell activation J:113556
absent spleen marginal zone J:113556
decreased marginal zone B cell number J:113556
increased anti-double stranded DNA antibody level J:113556
increased transitional stage B cell number J:113556
\Chuktm2Yhu/\Chuktm2Yhu
(involves: 129S1/Sv * 129X1/SvJ * FVB/N)
skin inflammation J:197037
\Chuktm2Yhu/\Chuktm2Yhu
\Tg(Lor-CHUK)8Yhu/0

(involves: 129S1/Sv * 129X1/SvJ * FVB/N)
absent lymph nodes J:197037
\Chuktm2Yhu/\Chuktm2Yhu
\Tg(Lor-CHUK)8Yhu/0

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * FVB/N)
increased CD4-positive, alpha-beta T cell number J:197037
increased CD8-positive, alpha-beta T cell number J:197037
increased macrophage cell number J:197037
increased neutrophil cell number J:197037
lung inflammation J:197037
\Churc1tm1b(EUCOMM)Wtsi/\Churc1tm1b(EUCOMM)Wtsi
(C57BL/6N-Churc1tm1b(EUCOMM)Wtsi/Wtsi)
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged thymus J:211773
increased effector memory T-helper cell number J:211773
\Cia2DBA/1J/\Cia2DBA/1J
(involves: DBA/1J * SWR/J)
abnormal immune system physiology J:53356
\Cia2DBA/1J/\Cia2DBA/1J
(involves: DBA/1J * FVB/N)
increased susceptibility to induced arthritis J:116665
\Cia2DBA/1J/\Cia2SWR/J
(involves: DBA/1J * SWR/J)
abnormal immune system physiology J:53356
\Cia5C57BL/10/\Cia5C57BL/10
(involves: B10.RIII * RIIIS/J)
abnormal inflammatory response J:50472
\Cia5bRIIIS/J/?
(involves: C57BL/10 * RIIIS/J)
decreased susceptibility to induced arthritis J:101767
\Cia5bRIIIS/J/\Cia5bRIIIS/J
\Cia32B10.RIII/\Cia32RIIIS/J

(involves: C57BL/10 * RIIIS/J)
decreased susceptibility to induced arthritis J:101767
\Cia5cRIIIS/J/?
(involves: C57BL/10 * RIIIS/J)
decreased susceptibility to induced arthritis J:101767
\Cia6C57BL/10SnSg/\Cia6C57BL/10SnSg
(involves: B10.Q * DBA/1)
abnormal inflammatory response J:57012
\Cia6C57BL/10SnSg/\Cia6DBA/1J
(involves: B10.Q * DBA/1)
abnormal inflammatory response J:57012
\Cia6DBA/1J/\Cia6DBA/1J
(involves: B10.Q * DBA/1)
decreased inflammatory response J:57012
\Cia7DBA/1J/\Cia7C57BL/10SnSg
(involves: B10.Q * DBA/1)
increased inflammatory response J:57012
\Cia7DBA/1J/\Cia7DBA/1J
(involves: B10.Q * DBA/1)
increased inflammatory response J:57012
increased susceptibility to induced arthritis J:122130
\Cia8DBA/1J/\Cia8DBA/1J
(involves: B10.Q * DBA/1)
increased inflammatory response J:57012
\Cia9C57BL/10SnSg/\Cia9NOD/ShiLtJ
(involves: B10.D1-H2q/SgJ * NOD.C3-H2q/Rhd)
increased inflammatory response J:69981
\Cia9NOD/ShiLtJ/\Cia9NOD/ShiLtJ
(involves: B10.D1-H2q/SgJ * NOD.C3-H2q/Rhd)
abnormal immune system physiology J:69981
\Cia10C57BL/10/\Cia10C57BL/10
(involves: C57BL/10 * RIIIS/J)
abnormal inflammatory response J:50472
\Cia10C57BL/10/\Cia10C57BL/10
\Cia5C57BL/10/\Cia5C57BL/10

(involves: C57BL/10 * RIIIS/J)
abnormal inflammatory response J:50472
\Cia23C57BL/10SnSg/\Cia23C57BL/10SnSg
(involves: B10.D1-H2q/SgJ * NOD.C3-H2q/Rhd)
abnormal inflammatory response J:69981
\Cia23C57BL/10SnSg/\Cia23NOD/ShiLtJ
(involves: B10.D1-H2q/SgJ * NOD.C3-H2q/Rhd)
abnormal inflammatory response J:69981
\Cia23C57BL/10SnSg/\Cia23NOD/ShiLtJ
\Cia9C57BL/10SnSg/\Cia9C57BL/10SnSg

(involves: B10.D1-H2q/SgJ * NOD.C3-H2q/Rhd)
decreased inflammatory response J:69981
\Cia26RIIIS/J/\Cia26RIIIS/J
\Cia30B10.RIII/?

(involves: B10.RIII * RIIIS/J)
autoimmune arthritis J:95848
\Cia27DBA/1J/?
(involves: DBA/1J * FVB/N)
increased IgG level J:116665, J:94347
\Cia30RIIIS/J/\Cia30RIIIS/J
\Cia5B10.RIII/\Cia5B10.RIII

(involves: B10.RIII * RIIIS/J)
decreased susceptibility to induced arthritis J:95848
\Cia31B10.RIII/\Cia31RIIIS/J
\Cia5B10.RIII/\Cia5B10.RIII

(involves: B10.RIII * RIIIS/J)
autoimmune arthritis J:95848
\Cia31B10.RIII/\Cia31RIIIS/J
\Cia5RIIIS/J/\Cia5RIIIS/J

(involves: C57BL/10 * RIIIS/J)
decreased susceptibility to induced arthritis J:101767
\Cia32B10.RIII/\Cia32RIIIS/J
\Cia5B10.RIII/\Cia5B10.RIII

(involves: B10.RIII * RIIIS/J)
autoimmune arthritis J:95848
\Cia34DBA/1J/\Cia34DBA/1J
(involves: C57BL/10 * DBA/1J)
decreased autoantibody level J:122130
decreased susceptibility to induced arthritis J:122130
\Cia35C57BL/10SnSg/\Cia35C57BL/10SnSg
\Cia42DBA/1J/\Cia42DBA/1J

(involves: B10.Q * DBA/1)
decreased susceptibility to induced arthritis J:122130
\Cia35C57BL/10SnSg/\Cia35DBA/1J
(involves: C57BL/10 * DBA/1J)
increased autoantibody level J:122130
increased susceptibility to induced arthritis J:122130
\Cia35C57BL/10SnSg/\Cia35DBA/1J
\Cia42DBA/1J/\Cia42DBA/1J

(involves: B10.Q * DBA/1)
decreased susceptibility to induced arthritis J:122130
\Cia35DBA/1J/\Cia35DBA/1J
\Cia42DBA/1J/\Cia42DBA/1J

(involves: B10.Q * DBA/1)
decreased susceptibility to induced arthritis J:122130
\Cia36DBA/1J/\Cia36DBA/1J
(involves: C57BL/10 * DBA/1J)
decreased autoantibody level J:122130
decreased susceptibility to induced arthritis J:122130
\Cia37C57BL/10SnSg/\Cia37DBA/1J
(involves: C57BL/10 * DBA/1J)
increased autoantibody level J:122130
increased susceptibility to induced arthritis J:122130
\Cia38DBA/1J/\Cia38DBA/1J
(involves: C57BL/10 * DBA/1J)
increased autoantibody level J:122130
increased susceptibility to induced arthritis J:122130
\Cia39C57BL/10Sn/\Cia39C57BL/10Sn
(involves: B10.Q/Lund-H2q * B10.RIII/Lund-H2r)
decreased susceptibility to induced arthritis J:97801
\Cia39RIII/WySn/\Cia39RIII/WySn
(involves: B10.Q/Lund-H2q * B10.RIII/Lund-H2r)
autoimmune arthritis J:97801
\Cia40C57BL/10SnSg/\Cia40C57BL/10SnSg
(involves: C57BL/10SnSg * DBA/1J * NFS/N)
increased susceptibility to induced arthritis J:106522
\Cia43DBA/1J/\Cia43FVB/N
(involves: DBA/1J * FVB/N)
increased susceptibility to induced arthritis J:146242
\Cia43FVB/N/\Cia43FVB/N
(involves: DBA/1J * FVB/N)
increased susceptibility to induced arthritis J:146242
\Ciaaq1DBA/1J/\Ciaaq1DBA/1J
(involves: DBA/1J * FVB/NJ)
increased autoantibody level J:122919
\Ciaaq1DBA/1J/\Ciaaq1FVB/NJ
(involves: DBA/1J * FVB/NJ)
increased autoantibody level J:122919
\Ciao2bem1(IMPC)Ccpcz/\Ciao2b+
(C57BL/6N-Ciao2bem1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
enlarged spleen J:211773
increased neutrophil cell number J:211773
increased spleen weight J:211773
\Cib1tm1b(EUCOMM)Hmgu/\Cib1tm1b(EUCOMM)Hmgu
(C57BL/6N-Cib1tm1b(EUCOMM)Hmgu/Bay)
decreased neutrophil cell number J:211773
\Cib2tm1b(EUCOMM)Wtsi/\Cib2tm1b(EUCOMM)Wtsi
(C57BL/6N-Cib2tm1b(EUCOMM)Wtsi/H)
increased basophil cell number J:211773
\Cibar1tm1b(KOMP)Wtsi/\Cibar1tm1b(KOMP)Wtsi
(C57BL/6N-Cibar1tm1b(KOMP)Wtsi/Wtsi)
decreased leukocyte cell number J:274784, J:211773
\Cidebtm1Pli/\Cidebtm1Pli
(Not Specified)
decreased spleen weight J:126556
\Cigs2tm1.1Anse/\Cigs2+
\Il4tm1(CD2)Mmrs/\Il4+

(involves: 129 * BALB/cJ * C57BL/6)
decreased basophil cell number J:181313
decreased IgE level J:181313
decreased IgG1 level J:181313
decreased interleukin-4 secretion J:181313
immune system phenotype J:181313
\Cigs2tm1.1Anse/\Cigs2tm1.1Anse
(involves: BALB/cJ * C57BL/6)
abnormal class switch recombination J:181313
abnormal humoral immune response J:181313
abnormal susceptibility to infection J:181313
decreased IgE level J:181313
decreased IgG1 level J:181313
decreased interleukin-4 secretion J:181313
decreased interleukin-13 secretion J:181313
increased IgG2b level J:181313
\Cigs2tm1.1Kubo/\Cigs2tm1.1Kubo
(B6.Cg-Cigs2tm1.1Kubo)
abnormal interleukin secretion J:129048
abnormal mast cell physiology J:129048
abnormal neutrophil physiology J:129048
decreased interleukin-4 secretion J:167446, J:129048
decreased interleukin-13 secretion J:129048
\Ciitam1Btlr/\Ciitam1Btlr
(C57BL/6J-Ciitam1Btlr)
abnormal CD4-positive T cell differentiation J:221483
abnormal CD8-positive, alpha-beta T cell differentiation J:221483
impaired humoral immune response J:221483
\Ciitatm1.1Dim/\Ciitatm1.1Dim
(involves: 129S2/SvPas * C57BL/6 * SJL)
abnormal level of surface class II molecules J:51885
decreased CD4-positive, alpha-beta T cell number J:51885
decreased dendritic cell number J:51885
\Ciitatm1Adm/\Ciita+
(involves: 129S1/Sv * C57BL/6)
abnormal immune system physiology J:117111
\Ciitatm1Adm/\Ciitatm1Adm
(involves: 129S1/Sv * C57BL/6)
abnormal immune system physiology J:117111
\Ciitatm1Ccum/\Ciitatm1Ccum
(involves: 129S2/SvPas * C57BL/6J)
abnormal B cell physiology J:96421
abnormal CD4-positive, alpha-beta T cell physiology J:31601
abnormal cytokine secretion J:64283
abnormal dendritic cell physiology J:96421
abnormal level of surface class II molecules J:31601, J:96421
abnormal lymphocyte physiology J:96421
abnormal MHC II cell surface expression on macrophages J:31601
abnormal popliteal lymph node morphology J:64283
abnormal susceptibility to infection J:64283
abnormal T cell differentiation J:64283
abnormal T cell physiology J:31601
decreased CD4-positive, alpha-beta T cell number J:31601
decreased susceptibility to parasitic infection J:64283
decreased T cell proliferation J:31601
increased CD4-positive, alpha-beta T cell number J:64283
increased CD8-positive, alpha-beta T cell number J:64283
increased susceptibility to parasitic infection J:64283
\Ciitatm1Ccum/\Ciitatm1Ccum
(NOD.129S2(B6)-Ciitatm1Ccum)
abnormal inflammatory response J:106081
abnormal level of surface class II molecules J:106081
abnormal T cell differentiation J:106081
decreased CD4-positive, alpha-beta T cell number J:106081
decreased susceptibility to autoimmune diabetes J:107051
increased CD8-positive, alpha-beta T cell number J:106081
insulitis J:107051
pancreas inflammation J:106081
periinsulitis J:106081
\Ciitatm1Ccum/\Ciitatm1Ccum
(involves: 129S2/SvPas * C57BL/6)
abnormal level of surface class II molecules J:67941
\Ciitatm1Jpyt/\Ciitatm1Jpyt
(involves: 129P2/OlaHsd * C57BL/6J)
abnormal T cell subpopulation ratio J:57100
decreased CD4-positive, alpha-beta T cell number J:57100
decreased IgG level J:57100
increased CD8-positive, alpha-beta T cell number J:57100
increased double-positive T cell number J:57100
increased IgM level J:57100
\Ciitatm1Jpyt/\Ciitatm1Jpyt
(B6.129P2-Ciitatm1Jpyt)
abnormal T-helper 1 physiology J:125654
decreased susceptibility to experimental autoimmune encephalomyelitis J:125654
\Ciitatm1Wrth/\Ciitatm1Wrth
(B6.129P2-Ciitatm1Wrth)
immune system phenotype J:117111
\Ciitatm1Wrth/\Ciitatm1Wrth
(involves: 129P2/OlaHsd * C57BL/6)
absent CD4-positive, alpha-beta T cells J:233241
increased osteoclast cell number J:233241
\Ciitatm2Wrth/\Ciitatm2Wrth
(involves: 129P2/OlaHsd * C57BL/6)
abnormal immunoglobulin level J:92170
decreased CD4-positive, alpha-beta T cell number J:92170
\Ciitatm2Wrth/\Ciitatm2Wrth
(B6.129P2-Ciitatm2Wrth)
immune system phenotype J:117111
\Cilk1tm1b(KOMP)Mbp/\Cilk1tm1b(KOMP)Mbp
(C57BL/6N-Cilk1tm1b(KOMP)Mbp/Ucd)
increased basophil cell number J:211773
increased neutrophil cell number J:211773
\Cimap1bem1(IMPC)Ccpcz/\Cimap1bem1(IMPC)Ccpcz
(C57BL/6NCrl-Cimap1bem1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged spleen J:211773
enlarged thymus J:211773
\Cimap2Retro/\Cimap2+
(involves: C57BL/6J)
increased CD8-positive, alpha-beta T cell number J:223336
increased cytotoxic T cell cytolysis J:223336
\Cimap2Retro/\Cimap2Retro
(involves: C57BL/6J)
abnormal CD8-positive, alpha-beta cytotoxic T cell morphology J:223336
increased activated T cell number J:223336
increased CD8-positive, alpha-beta T cell number J:223336
increased central memory CD8 positive, alpha-beta T cell number J:223336
increased cytotoxic T cell cytolysis J:223336
increased interferon-gamma secretion J:223336
increased susceptibility to Riboviria infection induced morbidity/mortality J:223336
increased T cell proliferation J:223336
\Cimap2tm1a(KOMP)Wtsi/\Cimap2+
(involves: C57BL/6)
decreased CD8-positive, alpha-beta T cell number J:223336
decreased cytotoxic T cell cytolysis J:223336
\Cimip2btm1(KOMP)Wtsi/\Cimip2btm1(KOMP)Wtsi
(C57BL/6N-Cimip2btm1(KOMP)Wtsi/Nju)
increased basophil cell number J:211773
increased eosinophil cell number J:211773
\Cinda1BALB/c/?
(involves: BALB/c * CcS-4/Dem)
increased T cell proliferation J:40728
\Cinda2STS/A/?
(involves: BALB/c * CcS-4/Dem)
increased T cell proliferation J:40728
\Cinda3O20/A/\Cinda3O20/A
(involves: O20/A * OcB-9/Dem)
decreased T cell proliferation J:95917
\Cinda3OcB9/Dem/\Cinda3O20/A
(involves: O20/A * OcB-9/Dem)
increased T cell proliferation J:95917
\Cinda4OcB9/Dem/\Cinda4O20/A
(involves: O20/A * OcB-9/Dem)
increased T cell proliferation J:95917
\Cinda4OcB9/Dem/\Cinda4OcB9/Dem
(involves: O20/A * OcB-9/Dem)
increased T cell proliferation J:95917
\Cinda5OcB9/Dem/\Cinda5O20/A
(involves: O20/A * OcB-9/Dem)
increased T cell proliferation J:95917
\Cinda5OcB9/Dem/\Cinda5OcB9/Dem
(involves: O20/A * OcB-9/Dem)
increased T cell proliferation J:95917
\Cirozb2b1167Clo/\Cirozb2b1167Clo
(C57BL/6J-Cirozb2b1167Clo)
spleen hypoplasia J:175213
\Cishtm1.1Cdon/\Cishtm1.1Cdon
\Foxp3tm4(YFP/icre)Ayr/\Foxp3+

(involves: 129S/Sv * 129X1/SvJ * C57BL/6)
immune system phenotype J:204829
\Cishtm1.1Cdon/\Cishtm1.1Cdon
\Tg(Cd4-cre)1Cwi/0

(involves: 129S4/SvJaeSor * 129S6/SvEvTac * C57BL/6 * DBA/2)
abnormal T-helper 2 cell differentiation J:204829
increased eosinophil cell number J:204829
increased interleukin-4 secretion J:204829
increased interleukin-5 secretion J:204829
increased interleukin-10 secretion J:204829
increased interleukin-13 secretion J:204829
increased susceptibility to type I hypersensitivity reaction J:204829
\Cishtm1.2Cdon/\Cishtm1.2Cdon
(B6.129S6(Cg)-Cishtm1.2Cdon)
abnormal CD4-positive T cell differentiation J:204829
abnormal immune system morphology J:204829
abnormal immune system physiology J:204829
abnormal T-helper 2 cell differentiation J:204829
immune system phenotype J:204829
increased eosinophil cell number J:204829
increased interleukin-4 secretion J:204829
increased interleukin-5 secretion J:204829
increased interleukin-9 secretion J:204829
increased interleukin-13 secretion J:204829
increased lymphocyte cell number J:204829
increased susceptibility to type I hypersensitivity reaction J:204829
increased T cell proliferation J:204829
lung inflammation J:204829
lymph node hyperplasia J:204829
spleen hyperplasia J:204829
thymus hyperplasia J:204829
\Cited2tm1Bha/\Cited2tm1Bha
(involves: 129P2/OlaHsd * C57BL/6J)
small spleen J:92872
\Cited2tm1Bha/\Cited2tm1Bha
(B6.129P2-Cited2tm1Bha)
small spleen J:92872
\Ciz1Gt(IST13830B6)Tigm/\Ciz1Gt(IST13830B6)Tigm
(B6J.B6N-Ciz1Gt(IST13830B6)Tigm)
increased monocyte cell number J:231433
increased neutrophil cell number J:231433
\Ciz1tm1.1Homy/\Ciz1tm1.1Homy
(involves: 129P2/OlaHsd * C57BL/6 * DBA)
enlarged spleen J:198470
lymph node hyperplasia J:198470
thymus hyperplasia J:198470
\Ckbtm1.1(KOMP)Wtsi/\Ckbtm1.1(KOMP)Wtsi
(C57BL/6N-Ckbtm1.1(KOMP)Wtsi/Ucd)
increased lymphocyte cell number J:211773
\Cks1btm1Sir/\Cks1btm1Sir
\Tg(IghMyc)22Bri/?

(involves: C57BL * C57BL/6 * SJL)
decreased B cell proliferation J:121564
decreased leukocyte cell number J:121564
decreased lymphocyte cell number J:121564
decreased spleen weight J:121564
\Clasp1em1(IMPC)Mbp/\Clasp1+
(C57BL/6NCrl-Clasp1em1(IMPC)Mbp/Mmucd)
abnormal spleen morphology J:211773
enlarged lymph nodes J:211773
enlarged spleen J:211773
\Clca1tm1.1Lex/\Clca1tm1.1Lex
(involves: 129S/SvEvBrd)
abnormal chemokine level J:125158
increased inflammatory response J:125158
increased neutrophil cell number J:125158
lung inflammation J:125158
\Clca1tm1Dgen/\Clca1tm1Dgen
(involves: 129P2/OlaHsd * C57BL/6)
abnormal inflammatory response J:112942
\Clcf1tm1.1(KOMP)Vlcg/\Clcf1+
(C57BL/6N-Clcf1tm1.1(KOMP)Vlcg/Ucd)
decreased leukocyte cell number J:211773
\Clcn1em1(IMPC)Mbp/\Clcn1em1(IMPC)Mbp
(C57BL/6NCrl-Clcn1em1(IMPC)Mbp/MbpMmucd)
increased eosinophil cell number J:211773
\Clcn2tm1Tjj/\Clcn2tm1Tjj
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
abnormal microglial cell physiology J:122365
\Clcn3tm1Lamb/\Clcn3tm1Lamb
(involves: 129S1/Sv * 129X1/SvJ)
abnormal neutrophil physiology J:112692
impaired neutrophil phagocytosis J:112692
sepsis J:112692
\Clcn3tm1Tjj/\Clcn3tm1Tjj
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
abnormal microglial cell physiology J:77635
\Clcn7tm1.1Lex/\Clcn7tm1.1Lex
(involves: 129S5/SvEvBrd * C57BL/6J)
microgliosis J:186049
\Clcn7tm1.1Mawa/\Clcn7+
(involves: C57BL/6J * C57BL/6N * CD-1)
increased osteoclast cell number J:254787
\Clcn7tm1.1Teti/\Clcn7+
(involves: 129S2/SvPas * C57BL/6)
abnormal osteoclast physiology J:203761
increased osteoclast cell number J:203761
\Clcn7tm1Tjj/\Clcn7tm1Tjj
(involves: 129P2/OlaHsd * C57BL/6)
abnormal osteoclast morphology J:67273
abnormal osteoclast physiology J:67273
\Clcn7tm2Tjj/\Clcn7tm2Tjj
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
abnormal osteoclast morphology J:67273, J:217031
abnormal osteoclast physiology J:67273
\Clcn7tm2Tjj/\Clcn7tm2Tjj
(involves: 129S1/Sv * 129X1/SvJ)
microgliosis J:155176
\Clcn7tm3.1Tjj/\Clcn7tm3.1Tjj
\Emx1tm1.1(cre)Ito/\Emx1+

(involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * BALB/cJ * C57BL/6)
microgliosis J:155176
\Clcn7tm4.1Tjj/\Clcn7tm4.1Tjj
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
abnormal osteoclast morphology J:160702, J:217031
abnormal osteoclast physiology J:160702
\Clcn7tm5.1Tjj/\Clcn7tm5.1Tjj
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
abnormal osteoclast morphology J:217031
\Clcnkam1Btlr/\Clcnkam1Btlr
(C57BL/6J-Clcnkam1Btlr)
increased susceptibility to induced colitis J:271974
\Clcnkbem1(IMPC)Mbp/\Clcnkbem1(IMPC)Mbp
(C57BL/6NCrl-Clcnkbem1(IMPC)Mbp/MbpMmucd)
abnormal lymph node morphology J:211773
abnormal spleen morphology J:211773
decreased lymphocyte cell number J:211773
enlarged lymph nodes J:211773
enlarged spleen J:211773
increased basophil cell number J:211773
increased neutrophil cell number J:211773
\Cldn3em1(IMPC)H/\Cldn3em1(IMPC)H
(C57BL/6N-Cldn3em1(IMPC)H/H)
decreased lymphocyte cell number J:211773
increased neutrophil cell number J:211773
\Cldn9em1(IMPC)H/\Cldn9em1(IMPC)H
(C57BL/6NTac-Cldn9em1(IMPC)H/H)
increased basophil cell number J:211773
\Cldn12tm1.1(KOMP)Vlcg/\Cldn12tm1.1(KOMP)Vlcg
(B6J.B6N-Cldn12tm1.1(KOMP)Vlcg)
immune system phenotype J:279934
increased leukocyte cell number J:279934
increased spleen weight J:279934
\Cldn18tm1Lex/\Cldn18tm1Lex
(involves: 129S5/SvEvBrd)
abnormal osteoclast differentiation J:195931
increased osteoclast cell number J:195931
\Clec1atm1Yiw/\Clec1atm1Yiw
(involves: C57BL/6J * C57BL/6NSlc)
abnormal dendritic cell antigen presentation J:329240
decreased CD8-positive, alpha-beta memory T cell proliferation J:329240
decreased susceptibility to experimental autoimmune encephalomyelitis J:329240
immune system phenotype J:329240
\Clec1btm1.1Arte/\Clec1btm1.1Arte
\Tg(Pf4-icre)Q3Rsko/0

(involves: C57BL/6)
abnormal lymphatic vessel endothelial cell morphology J:181715
abnormal lymphatic vessel morphology J:181715
\Clec1btm1.1Ksi/\Clec1btm1.1Ksi
(involves: C57BL/6)
abnormal lymphatic system physiology J:165898
abnormal lymphatic vessel morphology J:165898
\Clec1btm1.2Arte/\Clec1btm1.2Arte
(Not Specified)
abnormal lymphatic vessel morphology J:181715
decreased lymphatic vessel endothelial cell number J:181715
\Clec1btm1Ksi/\Clec1btm1Ksi
\Tg(Pf4-icre)Q3Rsko/0

(involves: C57BL/6)
abnormal lymphatic vessel morphology J:187533
\Clec1btm1Lex/\Clec1btm1Lex
(involves: 129S5/SvEvBrd * C57BL/6J)
abnormal mononuclear cell morphology J:161922
\Clec1btm1Mlkn/\Clec1btm1Mlkn
(involves: 129S4/SvJae * C57BL/6)
abnormal lymphatic vessel morphology J:162815
\Clec1btm2Mlkn/\Clec1btm2Mlkn
\Tg(Pf4-icre)Q3Rsko/0

(involves: C57BL/6 * SJL)
lymph node hemorrhage J:205423
\Clec2dtm1.1Mgil/\Clec2dtm1.1Mgil
(C57BL/6-Clec2dtm1.1Mgil)
abnormal osteoclast differentiation J:143122
increased osteoclast cell number J:143122
\Clec2dtm1.1Mgil/\Clec2dtm1.1Mgil
(involves: C57BL/6)
immune system phenotype J:222057
\Clec2htm1.1Apma/\Clec2htm1.1Apma
(B6(Cg)-Clec2htm1.1Apma)
kidney inflammation J:322835
\Clec2htm1.1Apma/\Clec2htm1.1Apma
\Rag1tm1Mom/\Rag1tm1Mom

(B6.Cg-Rag1tm1Mom Clec2htm1.1Apma)
kidney inflammation J:322835
\Clec4a2tm1.1Cfg/\Clec4a2tm1.1Cfg
(involves: C57BL/6)
enlarged lymph nodes J:217719
immune system phenotype J:217719
increased B cell proliferation J:217719
increased IgG2a level J:217719
increased IgG2b level J:217719
increased IgG3 level J:217719
increased inflammatory response J:217719
\Clec4a2tm1Yiw/\Clec4a2tm1Yiw
(involves: 129P2/OlaHsd * C57BL/6J)
abnormal circulating interleukin level J:217720
abnormal immune system morphology J:217720
abnormal immune system physiology J:217720
enthesitis J:217720
increased anti-nuclear antigen antibody level J:217720
increased autoantibody level J:217720
increased circulating interleukin-4 level J:217720
increased circulating interleukin-10 level J:217720
increased circulating interleukin-17 level J:217720
increased circulating interleukin-23 level J:217720
increased dendritic cell number J:217720
increased IgG1 level J:217720
increased IgG3 level J:217720
increased IgG level J:217720
increased inflammatory response J:217720
increased single-positive T cell number J:217720
increased susceptibility to induced arthritis J:217720
joint inflammation J:217720
salivary gland inflammation J:217720
\Clec4b1em#Tsak/\Clec4b1em#Tsak
(involves: C57BL/6N)
abnormal adaptive immunity J:258645
abnormal cytokine level J:258645
abnormal cytokine secretion J:258645
decreased interferon-gamma secretion J:258645
decreased interleukin-12 secretion J:258645
increased susceptibility to bacterial infection J:258645
\Clec4dtm1.1Cfg/\Clec4dtm1.1Cfg
(involves: C57BL/6)
decreased B cell proliferation J:217719
decreased T cell proliferation J:217719
immune system phenotype J:203221
increased B cell number J:217719
increased interferon-gamma secretion J:203221
increased interleukin-6 secretion J:203221
increased interleukin-10 secretion J:203221
increased interleukin-17 secretion J:203221
increased mature B cell number J:217719
increased susceptibility to bacterial infection J:203221
increased susceptibility to bacterial infection induced morbidity/mortality J:203221
increased tumor necrosis factor secretion J:203221
lung inflammation J:203221
\Clec4dtm1.1Shoy/\Clec4dtm1.1Shoy
(involves: 129P2/OlaHsd * C57BL/6)
abnormal antigen presentation J:203159
abnormal chemokine secretion J:203159
abnormal immune serum protein physiology J:203159
abnormal immune system physiology J:203159
abnormal interferon-gamma secretion J:203159
abnormal interleukin-17 secretion J:203159
abnormal response to infection J:203159
abnormal thymus morphology J:203159
decreased circulating interleukin-17 level J:203159
decreased dendritic cell number J:203159
decreased IgG level J:203159
decreased susceptibility to experimental autoimmune encephalomyelitis J:203159
decreased susceptibility to type IV hypersensitivity reaction J:203159
decreased tumor necrosis factor secretion J:203159
granulomatous inflammation J:203159
lung inflammation J:203159
\Clec4etm1.1Cfg/\Clec4etm1.1Cfg
(B6.Cg-Clec4etm1.1Cfg)
abnormal macrophage physiology J:136334
decreased lymphocyte cell number J:136334
decreased monocyte cell number J:136334
decreased neutrophil cell number J:136334
decreased tumor necrosis factor secretion J:136334
increased susceptibility to fungal infection J:136334
\Clec4etm1Tks/\Clec4etm1Tks
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
abnormal chemokine secretion J:172959
decreased interleukin-6 secretion J:172959
decreased interleukin-10 secretion J:172959
decreased neutrophil cell number J:172959
decreased susceptibility to fungal infection J:172959
decreased tumor necrosis factor secretion J:172959
\Clec4etm1Tks/\Clec4etm1Tks
(involves: 129S1/Sv * 129X1/SvJ)
abnormal chemokine secretion J:203159
abnormal immune serum protein physiology J:203159
abnormal interferon-gamma secretion J:203159
abnormal interleukin-17 secretion J:203159
abnormal response to infection J:203159
decreased circulating interleukin-17 level J:203159
decreased dendritic cell number J:203159
decreased IgG level J:203159
decreased susceptibility to experimental autoimmune encephalomyelitis J:203159
decreased susceptibility to type IV hypersensitivity reaction J:203159
decreased tumor necrosis factor secretion J:203159
\Clec4ftm1Ymed/\Clec4ftm1Ymed
(B6.129S7-Clec4ftm1Ymed)
abnormal macrophage cytokine production J:203199
decreased interferon-gamma secretion J:203199
immune system phenotype J:203199
\Clec4gtm1.1Cfg/\Clec4gtm1.1Cfg
(involves: C57BL/6)
increased lymphocyte cell number J:217719
increased monocyte cell number J:217719
\Clec4gtm1.1Fhe/\Clec4gtm1.1Fhe
(B6.129-Clec4gtm1.1Fhe)
abnormal immune system cell morphology J:200968
abnormal immune system physiology J:200968
decreased susceptibility to Adenoviridae infection J:194891
immune system phenotype J:200968
increased activated T cell number J:200968
increased CD4-positive, alpha-beta T cell number J:200968
increased CD8-positive, alpha-beta T cell number J:200968, J:194891
liver inflammation J:200968
\Clec4ntm1.2Mgne/\Clec4ntm1.2Mgne
(involves: C57BL/6 * C57BL/6J)
abnormal chemokine secretion J:209284
abnormal interferon secretion J:209284
abnormal interleukin secretion J:209284
abnormal macrophage physiology J:209284
abnormal neutrophil physiology J:209284
abnormal susceptibility to fungal infection J:209284
abnormal tumor necrosis factor secretion J:209284
decreased interferon-gamma secretion J:209284
decreased interleukin-17 secretion J:209284
decreased tumor necrosis factor secretion J:209284
impaired macrophage phagocytosis J:209284
impaired neutrophil phagocytosis J:209284
increased interferon-gamma secretion J:209284
increased interleukin-1 alpha secretion J:209284
increased interleukin-1 beta secretion J:209284
increased interleukin-6 secretion J:209284
increased interleukin-17 secretion J:209284
increased susceptibility to fungal infection J:209284
increased tumor necrosis factor secretion J:209284
\Clec4ntm1Yiw/\Clec4ntm1Yiw
(B6.129P2-Clec4ntm1Yiw)
abnormal CD4-positive T cell differentiation J:160680
decreased interferon-gamma secretion J:160680
decreased interleukin-6 secretion J:160680
decreased interleukin-10 secretion J:160680
decreased interleukin-12b secretion J:160680
decreased interleukin-17 secretion J:160680
decreased interleukin-23 secretion J:160680
decreased tumor necrosis factor secretion J:160680
increased susceptibility to infection induced morbidity/mortality J:160680
\Clec4ntm1Yiw/\Clec4ntm1Yiw
(involves: 129P2/OlaHsd)
increased susceptibility to fungal infection J:209284
\Clec5aem1(IMPC)Mbp/\Clec5aem1(IMPC)Mbp
(C57BL/6NCrl-Clec5aem1(IMPC)Mbp/MbpMmucd)
abnormal thymus morphology J:211773
enlarged thymus J:211773
\Clec5atm1Cua/\Clec5atm1Cua
(involves: C57BL/6)
decreased susceptibility to induced arthritis J:158811
\Clec7atm1.1Bpip/\Clec7atm1.1Bpip
\Lyz2tm1(cre)Ifo/\Lyz2+

(involves: 129P2/OlaHsd * C57BL/6J)
abnormal macrophage physiology J:203908
decreased tumor necrosis factor secretion J:203908
impaired macrophage phagocytosis J:203908
increased susceptibility to fungal infection J:203908
\Clec7atm1Gdb/\Clec7atm1Gdb
(involves: 129S6/SvEvTac * C57BL/6)
abnormal cytokine secretion J:116669
abnormal inflammatory response J:116669
abnormal macrophage physiology J:116669
abnormal neutrophil physiology J:116669
increased susceptibility to fungal infection J:116669
\Clec7atm1Gdb/\Clec7atm1Gdb
(B6.129S6-Clec7atm1Gdb)
abnormal circulating interleukin level J:179011
decreased circulating interleukin-17 level J:179011
increased susceptibility to fungal infection J:179011
lung inflammation J:179011
\Clec7atm1Yiw/\Clec7atm1Yiw
(C.129P2-Clec7atm1Yiw)
abnormal cytokine secretion J:116670
abnormal dendritic cell physiology J:116670
abnormal macrophage physiology J:116670
increased susceptibility to fungal infection J:116670
\Clec7atm1Yiw/\Clec7atm1Yiw
(involves: 129P2/OlaHsd * C57BL/6)
abnormal dendritic cell physiology J:122394
immune system phenotype J:122394
\Clec7atm1Yiw/\Clec7atm1Yiw
\Myd88tm1Aki/\Myd88tm1Aki

(involves: 129P2/OlaHsd * BALB/cA * C57BL/6J)
abnormal cytokine secretion J:116670
abnormal dendritic cell physiology J:116670
\Clec9atm1.1Crs/\Clec9atm1.1Crs
(C57BL/6-Clec9atm1.1Crs)
abnormal dendritic cell antigen presentation J:178441
\Clec9atm1.1Kens/\Clec9atm1.1Kens
(involves: C57BL/6)
abnormal humoral immune response J:181366
\Clec9atm1Crs/\Clec9atm1Crs
(involves: 129S6/SvEvTac * C57BL/6)
abnormal dendritic cell antigen presentation J:147472
\Clec10am1/\Clec10am1
(NC/Nga)
dermatitis J:283174
immune system phenotype J:283174
increased neutrophil cell number J:283174
\Clec10atm1Hed/\Clec10a+
\St3gal1tm1Jxm/\St3gal1tm1Jxm

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)
decreased CD8-positive, alpha-beta T cell number J:78035
\Clec10atm1Hed/\Clec10atm1Hed
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)
dermatitis J:283174
immune system phenotype J:78035, J:283174
increased neutrophil cell number J:283174
\Clec10atm1Hed/\Clec10atm1Hed
\St3gal1tm1Jxm/\St3gal1tm1Jxm

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)
decreased CD8-positive, alpha-beta T cell number J:78035
\Clec12atm1Gdb/\Clec12atm1Gdb
(involves: C57BL/6)
increased susceptibility to bacterial infection J:224869
increased susceptibility to bacterial infection induced morbidity/mortality J:224869
\Clec12atm1Jrld/\Clec12atm1Jrld
(B6J.129-Clec12atm1Jrld)
abnormal chemokine secretion J:210326
abnormal neutrophil physiology J:210326
immune system phenotype J:210326
increased inflammatory response J:210326
increased tumor necrosis factor secretion J:210326
\Clic4tm1.1Aidi/\Clic4tm1.1Aidi
(involves: C57BL/6 * C57BL/6J)
abnormal chemokine secretion J:175404
decreased circulating interleukin-6 level J:175404
decreased circulating tumor necrosis factor level J:175404
decreased interleukin-6 secretion J:175404
decreased interleukin-12 secretion J:175404
decreased susceptibility to endotoxin shock J:175404
decreased tumor necrosis factor secretion J:175404
increased susceptibility to bacterial infection J:175404
\Clic4tm1.1Yus/\Clic4tm1.1Yus
(involves: 129S4/SvJae * C57BL/6J)
impaired macrophage phagocytosis J:183611
\Clic5jbg/\Clic5jbg
(involves: C3H/HeJ * C57BL/6)
decreased eosinophil cell number J:160186
decreased monocyte cell number J:160186
decreased neutrophil cell number J:160186
\Clip2em1(IMPC)Ccpcz/\Clip2em1(IMPC)Ccpcz
(C57BL/6NCrl-Clip2em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged thymus J:211773
increased effector memory CD8-positive, alpha-beta T cell number J:211773
\Clk1tm1a(EUCOMM)Wtsi/\Clk1tm1a(EUCOMM)Wtsi
(C57BL/6N-Clk1tm1a(EUCOMM)Wtsi/Ics)
decreased granulocyte number J:165965
\Cln3em1Dprc/\Cln3em1Dprc
(C57BL/6-Cln3em1Dprc)
increased microglial cell activation J:294634
\Cln3tm1Nbm/\Cln3tm1Nbm
(involves: 129S6/SvEvTac * C57BL/6J)
abnormal dendritic cell physiology J:233445
abnormal macrophage physiology J:233445
abnormal professional antigen presenting cell morphology J:233445
decreased macrophage cytokine production J:233445
\Cln8em1(IMPC)Mbp/\Cln8em1(IMPC)Mbp
(C57BL/6N-Cln8em1(IMPC)Mbp/MbpMmucd)
abnormal spleen morphology J:211773
enlarged spleen J:211773
\Clnkem1(IMPC)Ccpcz/\Clnkem1(IMPC)Ccpcz
(C57BL/6NCrl-Clnkem1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged spleen J:211773
enlarged thymus J:211773
\Clnktm1Rygo/\Clnktm1Rygo
(B6.129P2-Clnktm1Rygo)
abnormal interferon-gamma secretion J:131738
abnormal NK T cell physiology J:131738
decreased interleukin-4 secretion J:131738
immune system phenotype J:131738
increased natural killer cell mediated cytotoxicity J:131738
\Clnktm1Rygo/\Clnktm1Rygo
(involves: 129P2/OlaHsd * BALB/c)
immune system phenotype J:131621
increased interferon-gamma secretion J:131621
increased natural killer cell mediated cytotoxicity J:131621
\Clnktm1Rygo/\Clnktm1Rygo
\Lcp2tm1Geha/\Lcp2tm1Geha

(involves: 129P2/OlaHsd * 129S4/SvJae * BALB/c)
decreased interferon-gamma secretion J:131621
impaired natural killer cell mediated cytotoxicity J:131621
increased NK cell number J:131621
\Clnktm1Vei/\Clnktm1Vei
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
abnormal mast cell physiology J:91590
immune system phenotype J:91590
increased natural killer cell mediated cytotoxicity J:91590
\Clockem1(IMPC)Ccpcz/\Clockem1(IMPC)Ccpcz
(C57BL/6NCrl-Clockem1(IMPC)Ccpcz/Ccpcz)
abnormal thymus morphology J:211773
decreased CD8-positive, naive alpha-beta T cell number J:211773
decreased effector memory T-helper cell number J:211773
decreased spleen weight J:211773
enlarged thymus J:211773
increased CD4-positive, alpha-beta T cell number J:211773
increased eosinophil cell number J:211773
increased leukocyte cell number J:211773
increased lymphocyte cell number J:211773
increased T-helper cell number J:211773
\Clp1tm1.1Pngr/\Clp1tm1.1Pngr
(CBA.Cg-Clp1tm1.1Pngr)
abnormal microglial cell morphology J:209564
\ClppGt(IST11134F10)Tigm/\ClppGt(IST11134F10)Tigm
(involves: C57BL/6N)
abnormal T cell activation J:203140
dermatitis J:203140
\ClppGt(IST13563G11)Tigm/\ClppGt(IST13563G11)Tigm
(involves: C57BL/6N)
abnormal T cell activation J:203140
dermatitis J:203140
\Clpptm1a(EUCOMM)Wtsi/\Clpptm1a(EUCOMM)Wtsi
(C57BL/6N-Clpptm1a(EUCOMM)Wtsi/Wtsi)
decreased CD4-positive NK T cell number J:211773
decreased effector memory CD8-positive, alpha-beta T cell number J:211773
decreased gamma-delta T cell number J:211773
decreased memory-marker CD4-negative NK T cell number J:211773
decreased memory-marker CD4-positive NK T cell number J:211773
decreased NK T cell number J:211773
increased B cell number J:211773
increased KLRG1-positive NK cell number J:211773
increased leukocyte cell number J:211773
increased Ly6C high monocyte number J:211773
increased Ly6C low monocyte number J:211773
increased mature B cell number J:211773
increased monocyte cell number J:211773
\Clptm1em1(IMPC)Tcp/\Clptm1+
(C57BL/6N-Clptm1em1(IMPC)Tcp/Cmmr)
enlarged lymph nodes J:211773
increased monocyte cell number J:211773
\Clptm1ltm1d(EUCOMM)Wtsi/\Clptm1l+
(involves: 129S4/SvJaeSor * BALB/cJ * C57BL/6N)
abnormal class switch recombination J:265892
\Clptm1ltm1d(EUCOMM)Wtsi/\Clptm1ltm1d(EUCOMM)Wtsi
(involves: 129S4/SvJaeSor * BALB/cJ * C57BL/6N)
immune system phenotype J:265892
\Clptm1ltm1d(EUCOMM)Wtsi/\Clptm1ltm1d(EUCOMM)Wtsi
\Prdm1tm1Nutt/\Prdm1+

(involves: 129S4/SvJaeSor * BALB/cJ * C57BL/6 * C57BL/6N)
immune system phenotype J:265892
\Clptq1NZB/BlNJ/\Clptq1NZB/BlNJ
(B6.NZB-(D4Mit193-D4Mit33))
enlarged spleen J:143646
enlarged thymus J:143646
increased B-1a cell number J:143646
increased NK T cell number J:143646
\Clrn1tm1.1(KOMP)Vlcg/\Clrn1tm1.1(KOMP)Vlcg
(C57BL/6N-Clrn1tm1.1(KOMP)Vlcg/Ucd)
abnormal spleen morphology J:211773
\cls/\cls
(involves: DBA/1Lac)
immune system phenotype J:15088
\Clspntm1(KOMP)Vlcg/\Clspn+
(C57BL/6N-Clspntm1(KOMP)Vlcg)
increased B cell number J:332163
lymphoid hyperplasia J:332163
\Clstn1tm1b(EUCOMM)Hmgu/\Clstn1tm1b(EUCOMM)Hmgu
(C57BL/6N-Clstn1tm1b(EUCOMM)Hmgu/H)
increased basophil cell number J:211773
\Cltatm1.2Fmb/\Cltatm1.2Fmb
(involves: C57BL/6)
abnormal class switch recombination J:235591
decreased germinal center B cell number J:235591
\Clutm1Jakh/\Clutm1Jakh
(involves: Black Swiss * FVB/N)
heart inflammation J:65660
myocarditis J:65660
\Cluhem1(IMPC)Ccpcz/\Cluh+
(C57BL/6N-Cluhem1(IMPC)Ccpcz/Ccpcz)
increased Ly6C-positive mature NK cell number J:211773
\Cma1tm1Mfg/\Cma1tm1Mfg
(either: (involves: 129 * C57BL/6) or (involves: 129 * BALB/c))
abnormal mast cell physiology J:98963
\Cmahtm1Avrk/\Cmahtm1Avrk
\Dmdmdx/\Dmdmdx

(involves: 129X1/SvJ * C57BL/10ScSn)
increased macrophage cell number J:164594
increased monocyte cell number J:164594
\Cmahtm1Avrk/\Cmahtm1Avrk
\Dock2m1Hsd/\Dock2m1Hsd

(B6NHsd.Cg-Dock2m1Hsd Cmahtm1Avrk)
abnormal B cell activation J:144035
decreased follicular B cell number J:144035
decreased marginal zone B cell number J:144035
\Cmahtm1Avrk/\Cmahtm1Avrk
\Dock2m1Hsd/\Dock2m1Hsd
\Siaetm1.2Avrk/\Siaetm1.2Avrk

(B6NHsd.Cg-Siaetm1.2Avrk Dock2m1Hsd Cmahtm1Avrk)
abnormal B cell activation J:144035
decreased follicular B cell number J:144035
decreased marginal zone B cell number J:144035
\Cmahtm1Ykoz/\Cmahtm1Ykoz
(B6.129P2-Cmahtm1Ykoz)
abnormal B cell physiology J:121365
abnormal humoral immune response J:121365
abnormal interleukin secretion J:121365
abnormal T cell physiology J:121365
decreased interferon-gamma secretion J:121365
immune system phenotype J:121365
increased B cell proliferation J:121365
increased IgG1 level J:121365
\Cmastm1.1Bwei/\Cmastm1.1Bwei
\Tg(NPHS2-cre)295Lbh/0

(involves: 129P2/OlaHsd * C57BL/6 * SJL)
tubular nephritis J:286022
\CmcsCBA/N/?
(involves: CBA/N * DBA/2)
abnormal immune system physiology J:94127
\CmcsDBA/2/?
(involves: CBA/N * DBA/2)
abnormal immune system physiology J:94127
\Cmiptm1a(EUCOMM)Wtsi/\Cmiptm1a(EUCOMM)Wtsi
(C57BL/6N-Cmiptm1a(EUCOMM)Wtsi/Wtsi)
abnormal lymphatic vessel morphology J:239583
\Cmklr1tm1Dgen/\Cmklr1tm1Dgen
(B6.Cg-Cmklr1tm1Dgen)
abnormal alveolar macrophage morphology J:157190
abnormal dendritic cell physiology J:157190
abnormal immune system morphology J:157190
abnormal macrophage chemotaxis J:157190
abnormal professional antigen presenting cell physiology J:157190
increased neutrophil cell number J:157190
increased susceptibility to endotoxin shock J:157190
lung inflammation J:157190
\Cmklr1tm1Drg/\Cmklr1tm1Drg
(Not Specified)
impaired macrophage chemotaxis J:133968
impaired neutrophil recruitment J:133968
\Cms1DBA/2J/?
(involves: C57BL/6J * DBA/2J)
decreased susceptibility to fungal infection J:55132
\Cms2DBA/2J/?
(involves: C57BL/6J * DBA/2J)
decreased susceptibility to infection J:55132
\Cmtm4tm1d(EUCOMM)Wtsi/\Cmtm4tm1d(EUCOMM)Wtsi
(involves: C57BL/6J * C57BL/6N)
decreased CD8-positive, alpha-beta T cell number J:333836
decreased inflammatory response J:333836
decreased susceptibility to chemically induced skin inflammation J:333836
immune system phenotype J:333836
increased B cell number J:333836
\Cmtm5tm1c(KOMP)Wtsi/\Cmtm5tm1c(KOMP)Wtsi
\Cnptm1(cre)Kan/\Cnp+

(B6.Cg-Cnptm1(cre)Kan Cmtm5tm1c(KOMP)Wtsi)
microgliosis J:327261
\Cmtm7tm2a(EUCOMM)Hmgu/\Cmtm7+
\Rag1tm1Fwa/\Rag1tm1Fwa

(chimera involves: C57BL/6 * C57BL/6N)
abnormal B cell physiology J:207033
abnormal B-1a B cell morphology J:207033
decreased B cell proliferation J:207033
decreased B-1a cell number J:207033
decreased IgG2b level J:207033
decreased IgM level J:207033
decreased plasma cell number J:207033
\Cmtr1tm1b(EUCOMM)Hmgu/\Cmtr1tm1b(EUCOMM)Hmgu
\Emx1tm1(cre)Krj/\Emx1+
\Tg(Thy1-YFP)HJrs/0

(involves: 129S2/SvPas * C57BL/6J * C57BL/6N * CBA)
abnormal susceptibility to Riboviria infection J:300305
\Cndp2em1(IMPC)Mbp/\Cndp2em1(IMPC)Mbp
(C57BL/6NCrl-Cndp2em1(IMPC)Mbp/Mmucd)
abnormal lymph node morphology J:211773
enlarged lymph nodes J:211773
\Cnga3tm1.1(KOMP)Vlcg/\Cnga3+
(C57BL/6N-Cnga3tm1.1(KOMP)Vlcg/Ucd)
enlarged spleen J:211773
\Cngb3em1(IMPC)Ccpcz/\Cngb3em1(IMPC)Ccpcz
(C57BL/6NCrl-Cngb3em1(IMPC)Ccpcz/Ccpcz)
abnormal lymph node morphology J:211773
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged lymph nodes J:211773
enlarged spleen J:211773
enlarged thymus J:211773
\Cnmdtm1Ska/\Cnmdtm1Ska
(involves: C57BL/6 * CBA)
abnormal osteoclast physiology J:81137
\Cnn2tm1.1Jin/\Cnn2tm1.1Jin
\Cnn3tm1.1Hjum/\Cnn3tm1.1Hjum
\Cd79atm1(cre)Reth/\Cd79a+

(involves: 129S6/SvEvTac * 129X1/SvJ * BALB/c)
immune system phenotype J:237712
\Cnn2tm1.2Jin/\Cnn2tm1.2Jin
(B6.129X1-Cnn2tm1.2Jin)
abnormal immune system cell morphology J:141867
abnormal macrophage chemotaxis J:141867
abnormal macrophage physiology J:141867
decreased granulocyte number J:141867
decreased monocyte cell number J:141867
decreased neutrophil cell number J:141867
immune system phenotype J:141867
increased macrophage cell number J:141867
\Cnn2tm1Jin/\Cnn2tm1Jin
(B6.129X1-Cnn2tm1Jin)
decreased monocyte cell number J:141867
decreased neutrophil cell number J:141867
immune system phenotype J:141867
\Cnn3tm1.1Hjum/\Cnn3tm1.1Hjum
\Cd79atm1(cre)Reth/\Cd79a+

(involves: 129S6/SvEvTac * BALB/c)
immune system phenotype J:237712
\Cnot3tm1.1Tya/\Cnot3+
(B6.129P2(Cg)-Cnot3tm1.1Tya)
abnormal osteoclast differentiation J:206802
increased osteoclast cell number J:206802
\Cnot4tm1b(EUCOMM)Wtsi/\Cnot4+
(C57BL/6N-Cnot4tm1b(EUCOMM)Wtsi/Wtsi)
decreased KLRG1-positive NK cell number J:211773
\Cnppd1tm1.1(KOMP)Vlcg/\Cnppd1tm1.1(KOMP)Vlcg
(B6N(Cg)-Cnppd1tm1.1(KOMP)Vlcg/J)
increased leukocyte cell number J:211773
\Cnpy2em1(IMPC)Wtsi/\Cnpy2+
(C57BL/6N-Cnpy2em1(IMPC)Wtsi/Wtsi)
increased effector memory T-helper cell number J:211773
\Cnpy3tm1Kmiy/\Cnpy3tm1Kmiy
(involves: C57BL/6)
abnormal lymphocyte physiology J:128513
abnormal macrophage physiology J:128513
decreased interleukin-6 secretion J:128513
decreased tumor necrosis factor secretion J:128513
\Cnr2tm1Zim/\Cnr2tm1Zim
(involves: 129 * C57BL/6)
abnormal macrophage physiology J:62417
immune system phenotype J:62417
\Cntftm1Mpin/\Cntftm1Mpin
(involves: 129S2/SvPas)
abnormal microglial cell morphology J:15313
\Cntftm1Mpin/\Cntftm1Mpin
(B6.129S2-Cntftm1Mpin)
increased susceptibility to experimental autoimmune encephalomyelitis J:126852
\Cntn5em1(IMPC)Mbp/\Cntn5em1(IMPC)Mbp
(C57BL/6N-Cntn5em1(IMPC)Mbp/MbpMmucd)
abnormal lymph node morphology J:211773
enlarged lymph nodes J:211773
\Coasyem1(IMPC)H/\Coasy+
(C57BL/6NTac-Coasyem1(IMPC)H/H)
increased neutrophil cell number J:211773
\Coblem1(IMPC)Ccpcz/\Coblem1(IMPC)Ccpcz
(C57BL/6NCrl-Coblem1(IMPC)Ccpcz/Ccpcz)
abnormal thymus morphology J:211773
enlarged thymus J:211773
increased effector memory T-helper cell number J:211773
\Cobll1em1(IMPC)Ccpcz/\Cobll1em1(IMPC)Ccpcz
(C57BL/6NCrl-Cobll1em1(IMPC)Ccpcz/Ccpcz)
abnormal lymph node morphology J:211773
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged lymph nodes J:211773
enlarged spleen J:211773
enlarged thymus J:211773
\Cog5em1(IMPC)Ccpcz/\Cog5+
(C57BL/6NCrl-Cog5em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
enlarged spleen J:211773
\Cog6tm1a(EUCOMM)Wtsi/\Cog6tm1a(EUCOMM)Wtsi
(C57BL/6N-Cog6tm1a(EUCOMM)Wtsi/Wtsi)
decreased alpha-beta T cell number J:211773
decreased CD4-positive NK T cell number J:211773
decreased CD8-positive, alpha-beta T cell number J:211773
decreased CD8-positive, naive alpha-beta T cell number J:211773
decreased effector memory CD8-positive, alpha-beta T cell number J:211773
decreased Ly6C-positive immature NK cell number J:211773
decreased Ly6C-positive mature NK cell number J:211773
decreased marginal zone B cell number J:211773
decreased memory-marker CD4-negative NK T cell number J:211773
decreased memory-marker CD4-positive NK T cell number J:211773
decreased memory-marker gamma-delta T cell number J:211773
decreased memory-marker NK cell number J:211773
decreased NK cell number J:211773
decreased NK T cell number J:211773
decreased T cell number J:211773
decreased T-helper cell number J:211773
decreased transitional stage T2 B cell number J:211773
increased anti-nuclear antigen antibody level J:211773
increased B-2 B cell number J:211773
increased CD4-negative NK T cell number J:211773
increased CD4-positive, alpha-beta memory T cell number J:211773
increased CD4-positive, alpha-beta T cell number J:211773
increased CD4-positive, CD25-positive, alpha-beta regulatory T cell number J:211773
increased CD5-positive gamma-delta T cell number J:211773
increased effector memory T-helper cell number J:211773
increased eosinophil cell number J:211773
increased follicular B cell number J:211773
increased gamma-delta T cell number J:211773
increased granulocyte number J:211773
increased KLRG1+ CD4 alpha-beta T cell number J:211773
increased KLRG1+ CD8 alpha-beta T cell number J:211773
increased KLRG1-positive CD4-positive, CD25-positive, alpha-beta regulatory T cell number J:211773
increased KLRG1-positive NK cell number J:211773
increased KLRG1-positive T-helper cell number J:211773
increased leukocyte cell number J:211773
increased Ly6C high monocyte number J:211773
increased memory CD4-positive, CD25-positive, alpha-beta regulatory T cell number J:211773
increased memory-marker gamma-delta T cell number J:211773
increased memory-marker NK cell number J:211773
increased monocyte cell number J:211773
increased plasma cell number J:211773
\Col1a1Aga2/\Col1a1+
(C3HeB/FeJ-Col1a1Aga2)
lung inflammation J:185988
\Col1a1M1Jrt/\Col1a1+
(involves: C3H/HeJ * C57BL/6J * FVB/NJ)
osteoarthritis J:216423
\Col1a1M1Jrt/\Col1a1+
(involves: C57BL/6 * FVB/N)
autoimmune arthritis J:228439
\Col1a1tm1(CAG-Ezh2*)Meln/\Col1a1+
\Ighg1tm1(cre)Cgn/\Ighg1+

(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)
immune system phenotype J:199122
increased germinal center B cell number J:199122
increased spleen germinal center number J:199122
increased spleen germinal center size J:199122
\Col1a1tm1(CAG-Mir22)Ppp/\Col1a1tm1(CAG-Mir22)Ppp
\Tg(Mx1-cre)1Cgn/0

(Not Specified)
decreased leukocyte cell number J:199366
enlarged spleen J:199366
increased myeloid dendritic cell number J:199366
increased T cell derived lymphoma incidence J:199366
\Col1a1tm1(tetO-Cyp26b1)Mfra/\Col1a1+
\Gt(ROSA)26Sortm1(rtTA*M2)Jae/\Gt(ROSA)26Sor+

(involves: 129S4/SvJae * C57BL/6)
abnormal lymphatic vessel morphology J:206581
\Col1a1tm1(tetO-Fos)Wag/\Col1a1+
\Tg(KRT5-rtTA)T2D6Sgkd/0

(involves: 129S4/SvJae * C57BL/6 * FVB/N)
immune system phenotype J:201145
increased CD4-positive, alpha-beta T cell number J:201145
increased granulocyte number J:201145
skin inflammation J:201145
\Col1a1tm1(tetO-GFP/RNAi:Rad21)Iaai/\Col1a1+
\Gt(ROSA)26Sortm1(rtTA*M2)Jae/\Gt(ROSA)26Sor+

(involves: 129S4/SvJae * C57BL/6)
decreased B cell number J:229031
\Col1a1tm1(tetO-Irf4)Sing/\Col1a1tm1(tetO-Irf4)Sing
\Gt(ROSA)26Sortm1(rtTA*M2)Jae/\Gt(ROSA)26Sor+
\Irf4tm1Mak/\Irf4+

(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)
abnormal class switch recombination J:203903
abnormal plasma cell differentiation J:203903
\Col1a1tm1(tetO-Irf4)Sing/\Col1a1tm1(tetO-Irf4)Sing
\Gt(ROSA)26Sortm1(rtTA*M2)Jae/\Gt(ROSA)26Sor+
\Irf4tm1Mak/\Irf4tm1Mak

(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)
abnormal class switch recombination J:203903
abnormal plasma cell differentiation J:203903
\Col1a1tm1(tetO-RNAi:Rps19)Karl/\Col1a1+
\Gt(ROSA)26Sortm1(rtTA*M2)Jae/\Gt(ROSA)26Sortm1(rtTA*M2)Jae

(involves: 129S4/SvJae * C57BL/6)
decreased lymphocyte cell number J:179085
\Col1a1tm1(tetO-RNAi:Rps19)Karl/\Col1a1tm1(tetO-RNAi:Rps19)Karl
\Gt(ROSA)26Sortm1(rtTA*M2)Jae/\Gt(ROSA)26Sortm1(rtTA*M2)Jae

(involves: 129S4/SvJae * C57BL/6)
decreased lymphocyte cell number J:179085
decreased neutrophil cell number J:179085
\Col1a1tm1(tetO-Stat1)Biat/\Col1a1tm1(tetO-Stat1)Biat
\Gt(ROSA)26Sortm1(rtTA*M2)Jae/\Gt(ROSA)26Sortm1(rtTA*M2)Jae
\Stat1tm1Dlv/\Stat1tm1Dlv

(involves: 129S/SvEv * 129S4/SvJae * C57BL/6)
abnormal susceptibility to infection induced morbidity/mortality J:212694
\Col1a1tm1(tetO-Tcfap2c)Hsc/\Col1a1+
\Gt(ROSA)26Sortm1(rtTA*M2)Jae/\Gt(ROSA)26Sor+

(involves: 129S4/SvJae * C57BL/6)
immune system phenotype J:174049
\Col1a1tm1(tetO-Yod1*)Hpl/\Col1a1tm1(tetO-Yod1*)Hpl
\Gt(ROSA)26Sortm1(rtTA*M2)Jae/\Gt(ROSA)26Sortm1(rtTA*M2)Jae

(involves: 129S4/SvJae * C57BL/6)
abnormal CD8-positive, alpha-beta T cell physiology J:194608
abnormal professional antigen presenting cell physiology J:194608
immune system phenotype J:194608
\Col1a1tm1(tetO-Yod1*)Hpl/\Col1a1tm1(tetO-Yod1*)Hpl
\Gt(ROSA)26Sortm1(rtTA*M2)Jae/\Gt(ROSA)26Sortm1(rtTA*M2)Jae
\Tap1tm1Arp/\Tap1tm1Arp

(involves: 129S2/SvPas * 129S4/SvJae * C57BL/6)
abnormal professional antigen presenting cell physiology J:194608
\Col1a1tm1Jae/\Col1a1tm1Jae
(involves: 129S4/SvJae * C57BL/6)
abnormal osteoclast physiology J:53079
\Col1a1tm2(tetO-Fosl2,-DsRed)Wag/\Col1a1+
\Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0

(involves: 129S4/SvJae * C57BL/6 * CD-1)
abnormal osteoclast morphology J:211215
\Col1a1tm2(tetO-GFP/RNAi:Smc1a)Iaai/\Col1a1+
\Gt(ROSA)26Sortm1(rtTA*M2)Jae/\Gt(ROSA)26Sor+

(involves: 129S4/SvJae * C57BL/6)
decreased B cell number J:229031
enlarged spleen J:229031
increased neutrophil cell number J:229031
increased spleen red pulp amount J:229031
myeloid hyperplasia J:229031
myeloid metaplasia J:229031
\Col1a1tm2(tetO-GFP/RNAi:Smc1a)Iaai/\Col1a1tm3(tetO-GFP/RNAi:Stag2)Iaai
\Gt(ROSA)26Sortm1(rtTA*M2)Jae/\Gt(ROSA)26Sor+

(involves: 129S4/SvJae * C57BL/6)
abnormal spleen morphology J:229031
decreased B cell number J:229031
enlarged spleen J:229031
myeloid hyperplasia J:229031
\Col1a1tm2(tetO-IDH2*R140Q)Ppp/\Col1a1tm2(tetO-IDH2*R140Q)Ppp
\Gt(ROSA)26Sortm1(rtTA*M2)Jae/?

(involves: 129S4/SvJae * C57BL/6)
enlarged spleen J:210097
\Col1a1tm2(tetO-Pou5f1)Jae/\Col1a1+
\Gt(ROSA)26Sortm1(rtTA*M2)Jae/\Gt(ROSA)26Sor+

(involves: 129S4/SvJae * C57BL/6)
spleen atrophy J:98920
thymus atrophy J:98920
\Col1a1tm2(tetO-RNAi:Rps19)Karl/\Col1a1+
\Gt(ROSA)26Sortm1(rtTA*M2)Jae/\Gt(ROSA)26Sortm1(rtTA*M2)Jae

(involves: 129S4/SvJae * C57BL/6)
decreased lymphocyte cell number J:179085
\Col1a1tm2(tetO-RNAi:Rps19)Karl/\Col1a1tm2(tetO-RNAi:Rps19)Karl
\Gt(ROSA)26Sortm1(rtTA*M2)Jae/\Gt(ROSA)26Sortm1(rtTA*M2)Jae

(involves: 129S4/SvJae * C57BL/6)
decreased lymphocyte cell number J:179085
decreased neutrophil cell number J:179085
\Col1a1tm3(tetO-Fosl1,-DsRed)Wag/\Col1a1+
\Gt(ROSA)26Sortm1(rtTA*M2)Jae/\Gt(ROSA)26Sor+

(involves: 129S4/SvJae * C57BL/6)
enlarged spleen J:213764
\Col1a1tm3(tetO-Fosl1,-DsRed)Wag/\Col1a1+
\Tg(Cebpb-tTA)5Bjd/0

(involves: 129S4/SvJae * C57BL/6 * NMRI)
decreased circulating interleukin-6 level J:210545
liver inflammation J:210545
\Col1a1tm3(tetO-GFP/RNAi:Apc)Slowe/\Col1a1+
\Gt(ROSA)26Sortm1(rtTA*M2)Jae/\Gt(ROSA)26Sor+

(involves: 129S4/SvJae * C57BL/6)
increased T cell derived lymphoma incidence J:171191
\Col1a1tm3(tetO-GFP/RNAi:Stag2)Iaai/\Col1a1+
\Gt(ROSA)26Sortm1(rtTA*M2)Jae/\Gt(ROSA)26Sor+

(involves: 129S4/SvJae * C57BL/6)
decreased B cell number J:229031
\Col1a1tm4(tetO-GFP/RNAi:Apc)Slowe/\Col1a1+
\Gt(ROSA)26Sortm1(rtTA*M2)Jae/\Gt(ROSA)26Sor+

(involves: 129S4/SvJae * C57BL/6)
increased T cell derived lymphoma incidence J:171191
\Col1a1tm6(tetO-MSI2)Jae/\Col1a1+
\Gt(ROSA)26Sortm1(rtTA*M2)Jae/\Gt(ROSA)26Sor+

(involves: 129S4/SvJae * C57BL/6)
abnormal leukocyte morphology J:163322
abnormal myelopoiesis J:163322
decreased lymphocyte cell number J:163322
decreased neutrophil cell number J:163322
enlarged spleen J:163322
increased leukocyte cell number J:163322
increased spleen weight J:163322
spleen hyperplasia J:163322
\Col1a2tm1b(EUCOMM)Wtsi/\Col1a2tm1b(EUCOMM)Wtsi
(C57BL/6N-Col1a2tm1b(EUCOMM)Wtsi/BayMmucd)
decreased lymphocyte cell number J:211773
enlarged spleen J:211773
increased large unstained cell number J:211773
increased leukocyte cell number J:211773
increased neutrophil cell number J:211773
\Col2a1em1(IMPC)Ccpcz/\Col2a1+
(C57BL/6NCrl-Col2a1em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
increased monocyte cell number J:211773
\Col2a1tm1Prc/\Col2a1+
\Col9a1tm1Jae/\Col9a1tm1Jae

(involves: 129/Sv * 129S2/SvPas)
osteoarthritis J:117910
\Col2a1tm1Prc/\Col2a1tm1Prc
(involves: 129/Sv * C57BL/6)
immune system phenotype J:30041
\Col3a1m1Btlr/\Col3a1m1Btlr
(C57BL/6J-Col3a1m1Btlr)
increased alpha-beta T cell number J:271973
increased CD4-positive, alpha-beta T cell number J:271973
increased CD8-positive, alpha-beta T cell number J:271973
increased susceptibility to induced colitis J:271973
\Col3a1Tsk2/\Col3a1+
(C3H101H-Col3a1Tsk2/H)
adipose tissue inflammation J:31216
skin inflammation J:31216
\Col4a1tm1.1Ics/\Col4a1+
(involves: 129S2/SvPas * C57BL/6)
kidney inflammation J:240798
\Col4a1tm1.1Ics/\Col4a1tm1.1Ics
(involves: 129S2/SvPas * C57BL/6)
kidney inflammation J:240798
\Col4a2em1(IMPC)Wtsi/\Col4a2em1(IMPC)Wtsi
(C57BL/6N-Col4a2em1(IMPC)Wtsi/WtsiOulu)
abnormal thymus topology J:239583
blood in lymph vessels J:239583
small thymus J:239583
\Col4a3tm1.1Rkl/\Col4a3+
(involves: C57BL/6)
glomerulonephritis J:167404
\Col4a3tm1b(EUCOMM)Wtsi/\Col4a3tm1b(EUCOMM)Wtsi
(C57BL/6N-Col4a3tm1b(EUCOMM)Wtsi/H)
decreased basophil cell number J:211773
decreased lymphocyte cell number J:211773
increased large unstained cell number J:211773
increased neutrophil cell number J:211773
\Col4a3tm1Dec/\Col4a3tm1Dec
(involves: 129X1/SvJ * C57BL/6)
glomerulonephritis J:37963
\Col4a3tm1Dec/\Col4a3tm1Dec
(129-Col4a3tm1Dec/J)
glomerulonephritis J:158731
\Col4a3tm1Dec/\Col4a3tm1Dec
(B6.129X1-Col4a3tm1Dec)
glomerulonephritis J:167404
\Col4a3tm1Dec/\Col4a3tm1Dec
\Itga1tm1Gdnr/\Itga1tm1Gdnr

(involves: 129S4/SvJae * 129X1/SvJ * BALB/c)
tubular nephritis J:71378
\Col4a3tm1Dec/\Col4a3tm1Dec
\Sostdc1tm1Myan/\Sostdc1tm1Myan

(involves: 129X1/SvJ)
glomerulonephritis J:158731
\Col4a3tm1Jhm/\Col4a3tm1Jhm
(involves: 129S1/Sv * 129X1/SvJ)
glomerulonephritis J:37017
\Col4a3tm1Jhm/\Col4a3tm1Jhm
\Mmp9tm1Tvu/\Mmp9tm1Tvu

(involves: 129S1/Sv * 129S6/SvEvTac * 129X1/SvJ)
glomerulonephritis J:63137
\Col4a4bwk/\Col4a4bwk
(NON;NZO-Col4a4bwk/J)
kidney inflammation J:223185
tubulointerstitial nephritis J:223185
\Col4a4bwk/\Col4a4bwk
(D2.NON(NZO)-Col4a4bwk/GrsrJ)
kidney inflammation J:223185
\Col4a4bwk/\Col4a4bwk
(129S1.NON(NZO)-Col4a4bwk/PgnJ)
kidney inflammation J:223185
\Col4a4m1H/\Col4a4m1H
(involves: C3H/HeH * C57BL/6J)
increased leukocyte cell number J:285510
\Col4a5tm1b(EUCOMM)Wtsi/Y
(C57BL/6N-Col4a5tm1b(EUCOMM)Wtsi/Cnrm)
increased leukocyte cell number J:211773
\Col4a5tm1b(EUCOMM)Wtsi/\Col4a5tm1b(EUCOMM)Wtsi
(C57BL/6N-Col4a5tm1b(EUCOMM)Wtsi/Cnrm)
increased large unstained cell number J:211773
increased neutrophil cell number J:211773
increased spleen weight J:211773
\Col4a5tm1Yseg/Y
(B6.Cg-Col4a5tm1Yseg)
tubulointerstitial nephritis J:102306
\Col5a2em1(IMPC)Ccpcz/\Col5a2+
(C57BL/6NCrl-Col5a2em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged thymus J:211773
\Col6a3em1(IMPC)Tcp/\Col6a3em1(IMPC)Tcp
(C57BL/6N-Col6a3em1(IMPC)Tcp/Tcp)
enlarged lymph nodes J:211773
\Col7a1em#Jtol/\Col7a1em#Jtol
(involves: 129S4/SvJae * BALB/c * C57BL/Ka * NOD)
absent B cells J:280214
absent NK T cells J:280214
absent T cells J:280214
\Col9a1tm1Jae/\Col9a1tm1Jae
(either: (involves: 129S2/SvPas * BALB/c) or (involves: 129S2/SvPas * C57BL))
osteoarthritis J:18628
\Col9a1tm1Jae/\Col9a1tm1Jae
(involves: 129S2/SvPas)
osteoarthritis J:117910
\Col9a3em1(IMPC)Tcp/\Col9a3em1(IMPC)Tcp
(C57BL/6N-Col9a3em1(IMPC)Tcp/Tcp)
enlarged lymph nodes J:211773
enlarged spleen J:211773
\Col10a1tm1.1Rpbh/\Col10a1tm1.1Rpbh
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
decreased osteoclast cell number J:154052
\Col10a1tm1Bhr/\Col10a1tm1Bhr
(involves: 129S7/SvEvBrd * C57BL/6)
abnormal spleen morphology J:62230
absent lymph nodes J:62230
decreased B cell number J:62230
decreased double-positive T cell number J:62230
decreased spleen red pulp amount J:62230
decreased spleen weight J:62230
decreased thymocyte number J:62230
decreased thymus weight J:62230
increased CD4-positive, alpha-beta T cell number J:62230
increased double-negative T cell number J:62230
increased single-positive T cell number J:62230
small spleen J:62230
small thymus J:62230
spleen hypoplasia J:62230
thymus hypoplasia J:62230
\Col10a1tm1Ksec/\Col10a1tm1Ksec
(involves: 129S/SvEv * C57BL/6)
abnormal T-helper 2 cell differentiation J:193886
decreased dendritic cell number J:193886
decreased interleukin-2 secretion J:193886
decreased interleukin-4 secretion J:193886
decreased interleukin-10 secretion J:193886
decreased interleukin-17 secretion J:193886
increased B cell number J:193886
increased interleukin-4 secretion J:193886
increased T-helper cell number J:193886
\Col11a1cho/\Col11a1+
(involves: C57BL/6Fr)
osteoarthritis J:106282
\Col13a1tm1Pih/\Col13a1tm1Pih
(either: (involves: 129S1/Sv * 129X1/SvJ) or (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J))
myositis J:71939
\Col17a1em1Dcr/\Col17a1em1Dcr
\Lamc2jeb/\Lamc2jeb

(B6.Cg-Lamc2jeb Col17a1em1Dcr/Dcr)
ear inflammation J:352187
\Col17a1em2Dcr/\Col17a1em2Dcr
\Lamc2jeb/\Lamc2jeb

(C57BL/6J-Col17a1em2Dcr/Dcr)
ear inflammation J:352187
\Col17a1tm1.1(COL17A1)Zliu/\Col17a1tm1.1(COL17A1)Zliu
(involves: 129P2/OlaHsd * C57BL/6J)
increased mast cell degranulation J:261781
increased neutrophil cell number J:261781
\Col17a1tm1Shzu/\Col17a1tm1Shzu
\Tg(KRT14-COL17A1)1Shzu/0

(involves: 129S/SvEv * C57BL/6J * C57BL/6Ncr)
decreased autoantibody level J:121695
\Col17a1tm1Tiin/\Col17a1tm1Tiin
(involves: C57BL/6)
increased autoantibody level J:220622
increased basophil cell number J:220622
increased eosinophil cell number J:220622
increased IgE level J:220622
increased monocyte cell number J:220622
increased neutrophil cell number J:220622
skin inflammation J:220622
\Col26a1em3(IMPC)Tcp/\Col26a1em3(IMPC)Tcp
(C57BL/6NCrl-Col26a1em3(IMPC)Tcp/Tcp)
enlarged lymph nodes J:211773
\Col27a1em1(IMPC)Mbp/\Col27a1+
(C57BL/6N-Col27a1em1(IMPC)Mbp/MbpMmucd)
enlarged spleen J:211773
small spleen J:211773
\Colec11tm1Lex/\Colec11tm1Lex
(involves: 129S5/SvEvBrd * C57BL/6)
abnormal complement protein level J:234934
\Colec12em1(IMPC)Mbp/\Colec12em1(IMPC)Mbp
(C57BL/6N-Colec12em1(IMPC)Mbp/MbpMmucd)
small spleen J:211773
\Colgalt2tm1.1Hwei/\Colgalt2tm1.1Hwei
(involves: C57BL/6J)
abnormal CD4-positive, CD25-positive, alpha-beta regulatory T cell number J:310468
abnormal regulatory T cell morphology J:310468
increased circulating interleukin-1 beta level J:310468
increased circulating interleukin-4 level J:310468
increased circulating interleukin-6 level J:310468
increased circulating interleukin-9 level J:310468
increased T cell apoptosis J:310468
\Commd8tm1.1Ksuz/\Commd8tm1.1Ksuz
\Ightm1Mnz/\Igh+
\Cd79atm1(cre)Reth/\Cd79a+

(involves: 129P2/OlaHsd * BALB/c * C57BL/6NSlc * SJL)
abnormal spleen B cell follicle morphology J:278399
\Commd9tm1b(KOMP)Wtsi/\Commd9+
(C57BL/6N-Commd9tm1b(KOMP)Wtsi/H)
decreased lymphocyte cell number J:211773
increased neutrophil cell number J:211773
\Commd10Tg(Vav1-icre)A2Kio/0
\Map3k7tm1.1Arte/\Map3k7tm1.1Arte

(involves: C57BL/10 * C57BL/6J * C57BL/6NTac * CBA/Ca)
decreased interleukin-6 secretion J:332172
decreased interleukin-10 secretion J:332172
decreased interleukin-12b secretion J:332172
decreased macrophage cell number J:332172
decreased tumor necrosis factor secretion J:332172
enlarged axillary lymph nodes J:332172
enlarged inguinal lymph nodes J:332172
enlarged spleen J:332172
increased B cell number J:332172
increased lymphocyte cell number J:332172
increased neutrophil cell number J:332172
increased splenocyte number J:332172
\Commd10Tg(Vav1-icre)A2Kio/0
\Nfil3tm1.2Kubo/\Nfil3tm1.2Kubo

(involves: 129 * C57BL/6 * C57BL/10 * CBA/Ca)
decreased dendritic cell number J:334296
\Commd10Tg(Vav1-icre)A2Kio/?
\Tnfrsf14tm1.1Kro/\Tnfrsf14tm1.1Kro

(involves: C57BL/6NCrl * C57BL/10 * CBA * SJL)
decreased susceptibility to Herpesvirales infection J:243038
\Commd10Tg(Vav1-icre)A2Kio/\Commd10+
\Zbtb11tm1.1Lieg/\Zbtb11tm1.1Lieg

(involves: C57BL/6J * C57BL/10 * CBA/Ca)
abnormal lymphopoiesis J:343208
abnormal myelopoiesis J:343208
\Comptm1Mbri/\Comptm1Mbri
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
osteoarthritis J:125086
\Comttm1Kara/\Comttm1Kara
(involves: 129S4/SvJaeSor)
increased interferon-gamma secretion J:137276
increased uterine NK cell number J:137276
\Cop1Gt(XR0653)1.1Wtsi/\Cop1Gt(XR0653)1.1Wtsi
(involves: 129P2/OlaHsd * C57BL/6 * CBA)
increased T cell derived lymphoma incidence J:178271
\Copatm1.1Shum/\Copa+
(B6(CBA)-Copatm1.1Shum)
abnormal B cell morphology J:288425
abnormal T cell activation J:288425
bronchiolitis J:288425
decreased double-positive T cell number J:288425
increased effector memory T-helper cell number J:288425
increased single-positive T cell number J:288425
lung inflammation J:288425
\Copg1em1Geha/\Copg1em1Geha
(involves: C57BL/6)
abnormal B cell physiology J:345528
abnormal IgG level J:345528
decreased circulating interferon-gamma level J:345528
immune system phenotype J:345528
increased susceptibility to bacterial infection induced morbidity/mortality J:345528
increased T cell apoptosis J:345528
\Cops5tm1Rpar/\Cops5tm1Rpar
\Tg(Lck-cre)548Jxm/0

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA * SJL)
decreased double-positive T cell number J:132114
decreased single-positive T cell number J:132114
decreased thymocyte number J:132114
increased T cell apoptosis J:132114
thymus medulla hypoplasia J:132114
\Cops5tm1Rpar/\Cops5tm1Rpar
\Tg(Lck-cre)548Jxm/0
\Tg(TcraTcrb)425Cbn/0

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA * SJL)
decreased thymocyte number J:132114
\Cops5tm1Rpar/\Cops5tm1Rpar
\Tg(Lck-cre)548Jxm/0
\Trp53tm1Tyj/\Trp53tm1Tyj

(involves: 129 * C57BL/6 * CBA * SJL)
decreased thymocyte number J:132114
\Cops6Gt(RRI087)Byg/\Cops6+
(involves: 129P2/OlaHsd * C57BL/6J)
increased thymocyte apoptosis J:172038
\Cops7atm1b(KOMP)Mbp/\Cops7atm1b(KOMP)Mbp
(C57BL/6N-Cops7atm1b(KOMP)Mbp/Ucd)
increased monocyte cell number J:211773
\Cops8em1(IMPC)Ccpcz/\Cops8+
(C57BL/6NCrl-Cops8em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged thymus J:211773
\Cops8tm1Nwe/\Cops8tm1.1Nwe
\Tg(Cd4-cre)1Cwi/?

(involves: 129S1/Sv * C57BL/6 * DBA/2)
abnormal CD4-positive, alpha-beta T cell physiology J:126339
abnormal T cell activation J:126339
decreased interleukin-2 secretion J:126339
decreased T cell number J:126339
decreased T cell proliferation J:126339
\Coq6em1Shcm/\Coq6em1Shcm
(C57BL/6-Coq6em1Shcm)
increased susceptibility to bacterial infection J:360514
increased susceptibility to bacterial infection induced morbidity/mortality J:360514
\Cora1BALB/c/\Cora1BALB/c
(involves: BALB/c * STS/A)
abnormal cytokine secretion J:52119
\Cora1STS/A/\Cora1STS/A
(involves: BALB/c * STS/A)
abnormal cytokine secretion J:52119
\Coro1akoy/\Coro1akoy
(C57BL/6-Coro1akoy)
abnormal T cell physiology J:141431
decreased CD4-positive, alpha-beta T cell number J:141431
decreased CD8-positive, alpha-beta T cell number J:141431
decreased thymocyte number J:141431
\Coro1aLmb3-C57BL/6Scr/\Coro1aLmb3-C57BL/6Scr
(MRL.Cg-Coro1aC57BL/6Scr Faslpr)
decreased autoantibody level J:125557
decreased spleen weight J:125557
decreased susceptibility to systemic lupus erythematosus J:125557
glomerulonephritis J:125557
small lymph nodes J:125557
\Coro1aLmb3-MRL/MpScr/\Coro1aLmb3-MRL/MpScr
(involves: C57BL/6-Faslpr * MRL-Faslpr)
enlarged lymph nodes J:45708
enlarged spleen J:45708
\Coro1aLmb3-MRL/MpScr/\Coro1aLmb3-MRL/MpScr
(B6.MRL-Coro1aMRL/MpScr Faslpr)
enlarged lymph nodes J:125557
increased spleen weight J:125557
increased susceptibility to systemic lupus erythematosus J:125557
\Coro1aptcd/\Coro1aptcd
(B6.CTS-Coro1aptcd)
abnormal effector T cell morphology J:141431
abnormal T cell activation J:141431
abnormal T cell physiology J:141431
decreased CD4-positive, alpha-beta T cell number J:141431
decreased CD8-positive, alpha-beta T cell number J:141431
increased T cell apoptosis J:141431
increased thymocyte number J:141431
\Coro1aptcd/\Coro1atm1Achn
(B6.Cg-Coro1aptcd Coro1atm1Achn)
abnormal effector T cell morphology J:141431
abnormal T cell activation J:141431
abnormal T cell physiology J:141431
decreased CD4-positive, alpha-beta T cell number J:141431
decreased CD8-positive, alpha-beta T cell number J:141431
increased thymocyte number J:141431
\Coro1atm1Achn/\Coro1atm1Achn
(involves: 129X1/SvJ * C57BL/6)
abnormal leukocyte migration J:111593
decreased CD4-positive, alpha-beta T cell number J:111593
decreased CD8-positive, alpha-beta T cell number J:111593
decreased memory T cell number J:111593
decreased T cell number J:111593
\Coro1atm1Achn/\Coro1atm1Achn
(B6.129X1-Coro1atm1Achn)
decreased thymocyte number J:141431
increased T cell apoptosis J:141431
\Coro1atm1Achn/\Coro1atm1Achn
(involves: 129X1/SvJ)
decreased interleukin-6 secretion J:177785
decreased tumor necrosis factor secretion J:177785
increased mast cell degranulation J:177785
\Coro1atm1Achn/\Coro1atm1Achn
\Coro1btm1.1Nfoe/\Coro1btm1.1Nfoe

(involves: 129X1/SvJ * C57BL/6N)
decreased interleukin-6 secretion J:177785
decreased tumor necrosis factor secretion J:177785
increased mast cell degranulation J:177785
increased susceptibility to type I hypersensitivity reaction J:177785
\Coro1atm1Jpie/\Coro1atm1Jpie
(involves: 129 * C57BL/6)
abnormal T cell activation J:133258
abnormal thymocyte activation J:133258
decreased B cell number J:133258
decreased CD4-positive, alpha-beta T cell number J:133258
decreased CD8-positive, alpha-beta T cell number J:133258
decreased interleukin-2 secretion J:133258
decreased monocyte cell number J:133258
decreased susceptibility to bacterial infection J:133404
decreased T cell proliferation J:133258
impaired macrophage phagocytosis J:133404
\Coro1btm1.1Nfoe/\Coro1btm1.1Nfoe
(B6N.129X1-Coro1btm1.1Nfoe)
immune system phenotype J:177785
\Coro1ctm1a(KOMP)Wtsi/\Coro1ctm1a(KOMP)Wtsi
(C57BL/6N-Coro1ctm1a(KOMP)Wtsi/Wtsi)
blood in lymph vessels J:239583
\Cotl1tm1b(EUCOMM)Hmgu/\Cotl1tm1b(EUCOMM)Hmgu
(C57BL/6N-Cotl1tm1b(EUCOMM)Hmgu/Ieg)
increased leukocyte cell number J:211773
\Cox4i2tm1Hutt/\Cox4i2+
(B6.129-Cox4i2tm1Hutt)
lung inflammation J:187640
\Cox4i2tm1Hutt/\Cox4i2tm1Hutt
(B6.129-Cox4i2tm1Hutt)
immune system phenotype J:233986
lung inflammation J:187640
\Cox6b1em1(IMPC)Tcp/\Cox6b1+
(C57BL/6NCrl-Cox6b1em1(IMPC)Tcp/Tcp)
increased spleen weight J:211773
\Cox10tm1Ctm/\Cox10tm1Ctm
\Slc6a3tm1.1(cre)Bkmn/?

(B6.Cg-Cox10tm1Ctm Slc6a3tm1.1(cre)Bkmn)
abnormal chemokine secretion J:231810
increased interleukin-1 beta secretion J:231810
increased microglial cell activation J:231810
microgliosis J:231810
\Cox19tm1b(EUCOMM)Hmgu/\Cox19+
(C57BL/6N-Cox19tm1b(EUCOMM)Hmgu/Tcp)
enlarged lymph nodes J:211773
\Cptm1Hrs/\Cptm1Hrs
(involves: 129X1/SvJ * Black Swiss)
increased spleen iron level J:57730
\Cptm1Hrs/\Cptm1Hrs
\Hephsla/Y

(involves: 129X1/SvJ * C57BL/6)
eye inflammation J:136925
\Cptm1Yos/\Cptm1Yos
(involves: 129P2/OlaHsd * BALB/c)
abnormal Kupffer cell morphology J:79916
\Cpa1tm1.1Satom/\Cpa1tm1.1Satom
(involves: C57BL/6NCrl * FVB/N)
pancreas inflammation J:300042
\Cpa3tm1Hrr/\Cpa3tm1Hrr
(involves: 129P2/OlaHsd * C57BL/6)
abnormal mast cell morphology J:99367
\Cpa3tm3(icre)Hrr/\Cpa3+
(B6.129P2-Cpa3tm3(icre)Hrr)
abnormal inflammatory response J:178942
absent mast cells J:178942
decreased basophil cell number J:178942
immune system phenotype J:178942
\Cpa3tm3(icre)Hrr/\Cpa3+
(involves: 129P2/OlaHsd * BALB/c * C57BL/6)
decreased susceptibility to type I hypersensitivity reaction J:178942
\Cpa3tm3(icre)Hrr/\Cpa3+
\Fgfr1tm1Upir/\Fgfr1tm1Upir
\Fgfr2tm1Dor/\Fgfr2tm1Dor
\Tg(KRT5-cre)5132Jlj/0

(involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6 * C57BL/6J * DBA/2J)
absent mast cells J:221184
skin inflammation J:221184
\Cpa3tm3(icre)Hrr/\Cpa3+
\Gt(ROSA)26Sortm1Hjf/?
\Notch1tm1Agt/\Notch1tm1Agt

(involves: 129 * C57BL/6)
abnormal dendritic cell differentiation J:143731
abnormal T cell receptor beta chain V(D)J recombination J:143731
\Cpa3tm3(icre)Hrr/\Cpa3+
\Notch1tm1Agt/\Notch1tm1Agt

(involves: 129 * C57BL/6)
abnormal B cell differentiation J:143731
abnormal B cell morphology J:143731
abnormal T cell receptor beta chain V(D)J recombination J:143731
decreased double-negative T cell number J:143731
decreased double-positive T cell number J:143731
increased single-positive T cell number J:143731
thymus hypoplasia J:143731
\Cpaptm1a(EUCOMM)Wtsi/\Cpaptm1a(EUCOMM)Wtsi
(B6Brd;B6N-Tyrc-Brd Cpaptm1a(EUCOMM)Wtsi/Wtsi)
increased CD8-positive, alpha-beta T cell number J:194085
increased T cell number J:194085
\Cpb2tm1Efp/\Cpb2+
\Plgtm1Dco/\Plg+

(involves: 129S1/Sv * 129S2/SvPas * 129X1/SvJ * C57BL/6)
abnormal inflammatory response J:80114
\Cpb2tm1Efp/\Cpb2tm1Efp
\Plgtm1Dco/\Plg+

(involves: 129S1/Sv * 129S2/SvPas * 129X1/SvJ * C57BL/6)
abnormal inflammatory response J:80114
\Cpb2tm1Mng/\Cpb2tm1Mng
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
abnormal chemokine level J:107340
abnormal tumor necrosis factor level J:107340
\Cpb2tm1Nok/\Cpb2tm1Nok
(involves: 129P2/OlaHsd * BALB/c)
impaired complement alternative pathway J:93733
increased inflammatory response J:93733
\Cpetm1b(EUCOMM)Hmgu/\Cpetm1b(EUCOMM)Hmgu
(C57BL/6N-Cpetm1b(EUCOMM)Hmgu/Ieg)
increased leukocyte cell number J:211773
\Cpgi5563tm1.1(NCC)Wcs/\Cpgi5563tm1.1(NCC)Wcs
(C57BL/6N-Cpgi5563tm1.1(NCC)Wcs/Wtsi)
decreased CD4-positive, CD25-positive, alpha-beta regulatory T cell number J:277622
decreased CD8-positive, alpha-beta T cell number J:277622
decreased effector memory CD4-positive, alpha-beta T cell number J:277622
decreased gamma-delta T cell number J:277622
\Cplane2b2b2827Clo/\Cplane2b2b2827Clo
(C57BL/6J-Cplane2b2b2827Clo)
thymus hypoplasia J:175213
\Cpmem1(IMPC)Ccpcz/\Cpmem1(IMPC)Ccpcz
(C57BL/6NCrl-Cpmem1(IMPC)Ccpcz/Ccpcz)
decreased CD8-positive, alpha-beta T cell number J:211773
immune system phenotype J:211773
increased effector memory CD8-positive, alpha-beta T cell number J:211773
increased effector memory T-helper cell number J:211773
\Cpn1tm1Raw/\Cpn1tm1Raw
(B6.129S1-Cpn1tm1Raw)
abnormal complement pathway J:148315
increased acute inflammation J:148315
\Cpne5tm2b(EUCOMM)Hmgu/\Cpne5tm2b(EUCOMM)Hmgu
(C57BL/6N-Cpne5tm2b(EUCOMM)Hmgu/Bay)
abnormal spleen morphology J:211773
\CpoxRbc16/\Cpox+
(involves: C57BL/6)
enlarged spleen J:244493
increased spleen red pulp amount J:244493
\Cpqem1(IMPC)Tcp/\Cpqem1(IMPC)Tcp
(C57BL/6N-Cpqem1(IMPC)Tcp/Tcp)
enlarged lymph nodes J:211773
\Cps1em1(IMPC)H/\Cps1+
(C57BL/6NTac-Cps1em1(IMPC)H/H)
decreased neutrophil cell number J:211773
increased lymphocyte cell number J:211773
\Cpsf6em1Bcgen/\Cpsf6+
(Not Specified)
decreased susceptibility to Riboviria infection J:346988
increased interferon-beta secretion J:346988
\Cpt1cGt(XL823)Byg/\Cpt1c+
\Nf1tm1Tyj/\Nf1+
\Trp53tm1Tyj/\Trp53+

(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6)
spleen hyperplasia J:228258
\Cpt2tm1b(KOMP)Wtsi/\Cpt2tm1b(KOMP)Wtsi
(C57BL/6N-Cpt2tm1b(KOMP)Wtsi/Wtsi)
blood in lymph vessels J:239583
\Cpvlem1(IMPC)Tcp/\Cpvlem1(IMPC)Tcp
(C57BL/6NCrl-Cpvlem1(IMPC)Tcp/Tcp)
enlarged lymph nodes J:211773
\Cpxm1em1(IMPC)Tcp/\Cpxm1em1(IMPC)Tcp
(C57BL/6N-Cpxm1em1(IMPC)Tcp/Tcp)
enlarged lymph nodes J:211773
increased monocyte cell number J:211773
\Cr1ltm1.1Song/\Cr1ltm1.1Song
\Tg(Cd4-cre)1Cwi/0

(involves: 129S6/SvEvTac * C57BL/6 * DBA/2 * SJL)
decreased CD4-positive, alpha-beta T cell number J:146538
decreased CD8-positive, alpha-beta T cell number J:146538
decreased lymphocyte cell number J:146538
increased B cell number J:146538
lymph node hypoplasia J:146538
\Cr1ltm1.1Song/\Cr1ltm1.1Song
\Tg(Lck-cre)548Jxm/0

(involves: 129S6/SvEvTac * C57BL/6 * DBA/2 * SJL)
decreased CD4-positive, alpha-beta T cell number J:146538
decreased CD8-positive, alpha-beta T cell number J:146538
decreased lymphocyte cell number J:146538
increased B cell number J:146538
lymph node hypoplasia J:146538
\Cr1ltm1.1Song/\Cr1ltm1.1Song
\Vsig4tm1Gne/\Vsig4tm1Gne
\Tg(Cd4-cre)1Cwi/0

(involves: 129S6/SvEvTac * C57BL/6N * DBA/2 * SJL)
decreased lymphocyte cell number J:146538
\Cr1ltm1Hmo/\Cr1ltm1Hmo
(involves: 129X1/SvJ)
increased inflammatory response J:59432
\Cr2M1Btlr/\Cr2M1Btlr
(C57BL/6J-Cr2M1Btlr)
decreased IgG level J:267527
impaired humoral immune response J:267527
\Cr2tm1.1Jhws/\Cr2tm1.1Jhws
(B6.Cg-Cr2tm1.1Jhws)
immune system phenotype J:155241
\Cr2tm1.1Jhws/\Cr2tm1.1Jhws
(Not Specified)
abnormal germinal center B cell physiology J:205353
decreased B-1a cell number J:205353
decreased IgG2b level J:205353
decreased IgG2c level J:205353
decreased IgG3 level J:205353
decreased IgM level J:205353
immune system phenotype J:205353
increased susceptibility to bacterial infection induced morbidity/mortality J:205353
\Cr2tm1Crr/\Cr2tm1Crr
(involves: 129S7/SvEvBrd * C57BL/6)
abnormal B-1 B cell morphology J:31942
abnormal humoral immune response J:31942, J:69452
abnormal immune system morphology J:69452
abnormal spleen germinal center morphology J:31942
decreased B cell number J:31942
decreased B-1a cell number J:69452
decreased IgG2a level J:31942
decreased IgG2b level J:31942
decreased IgG3 level J:31942
decreased IgG level J:31942, J:69452
decreased IgM level J:69452
decreased immunoglobulin level J:69452
decreased neutrophil cell number J:66111
decreased spleen germinal center number J:31942, J:69452
decreased spleen germinal center size J:31942
decreased tumor necrosis factor secretion J:66111
immune system phenotype J:31942
\Cr2tm1Crr/\Cr2tm1Crr
(involves: 129S7/SvEvBrd * C57BL/6J)
increased anti-double stranded DNA antibody level J:111811
\Cr2tm1Crr/\Cr2tm1Crr
(involves: 129S7/SvEvBrd)
decreased follicular B cell number J:69477
increased marginal zone B cell number J:69477
\Cr2tm1Crr/\Cr2tm1Crr
\Ggta1tm1Jbl/\Ggta1tm1Jbl

(involves: 129S2/SvPas * 129S7/SvEvBrd)
abnormal humoral immune response J:113488
\Cr2tm1Hmo/\Cr2tm1Hmo
(involves: 129S7/SvEvBrd)
decreased IgG level J:35112
decreased IgM level J:35112
\Cr2tm1Hmo/\Cr2tm1Hmo
(B6.129S7-Cr2tm1Hmo)
increased susceptibility to bacterial infection J:94855
\Cr2tm1Hmo/\Cr2tm1Hmo
(involves: 129S7/SvEvBrd * C57BL/6)
abnormal B cell activation J:151991
abnormal B cell physiology J:151991
abnormal class switch recombination J:151991
abnormal memory B cell differentiation J:151991
\Cr2tm1Tft/\Cr2tm1Tft
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)
abnormal adaptive immunity J:95979
decreased IgG1 level J:95979
decreased IgG2b level J:95979
decreased IgG3 level J:95979
decreased IgG level J:95979
decreased IgM level J:95979
decreased spleen germinal center number J:95979
increased susceptibility to bacterial infection J:95979
\Cr2tm2.1(HLA-A)Crr/\Cr2tm2.1(HLA-A)Crr
(involves: C57BL/6)
abnormal B cell physiology J:151991
abnormal class switch recombination J:151991
abnormal memory B cell differentiation J:151991
\Cr2tm2.1(HLA-A)Crr/\Cr2tm2.1(HLA-A)Crr
\Tg(IghelMD4)4Ccg/?

(involves: C57BL/6)
abnormal B cell activation J:151991
\Cr2tm2.1Jhws/\Cr2tm2.1Jhws
(B6.129-Cr2tm2.1Jhws)
abnormal germinal center B cell physiology J:205353
decreased IgG3 level J:205353
decreased IgM level J:205353
immune system phenotype J:205353
increased IgM level J:205353
\Crabp1tm1b(EUCOMM)Wtsi/\Crabp1tm1b(EUCOMM)Wtsi
(C57BL/6N-Crabp1tm1b(EUCOMM)Wtsi/Tcp)
increased monocyte cell number J:211773
\Cracr2atm1.1Ygwa/\Cracr2atm1.1Ygwa
\Tg(Cd4-cre)1Cwi/0

(B6.Cg-Cracr2atm1.1Ygwa Tg(Cd4-cre)1Cwi)
abnormal CD4-positive, alpha-beta T cell physiology J:259523
decreased interleukin-2 secretion J:259523
\Cratem1(IMPC)Bay/\Cratem1(IMPC)Bay
(C57BL/6N-Cratem1(IMPC)Bay/Bay)
small lymph nodes J:211773
\Crb1rd8+em1Boc/\Crb1rd8+em1Boc
\Jak3m1J/\Jak3m1J

(B6.Cg-Crb1rd8+em1Boc Jak3m1J/Boc)
small spleen J:265859
small thymus J:265859
\Crb1rd8/\Crb1rd8
\Jak3m1J/\Jak3m1J

(B6.Cg-Crb1rd8 Jak3m1J/BocJ)
decreased spleen weight J:265859
small spleen J:265859
small thymus J:265859
\Crbntm1.1Ble/\Crbntm1.1Ble
(involves: C57BL/6)
decreased B cell number J:267091
decreased granulocyte number J:267091
decreased leukocyte cell number J:267091
decreased T cell number J:267091
\Creb3l2em1(IMPC)Ccpcz/\Creb3l2+
(C57BL/6NCrl-Creb3l2em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
enlarged spleen J:211773
\Creb3l3tm1.1Sad/\Creb3l3tm1.1Sad
(involves: 129 * C57BL/6 * FVB/N)
decreased acute inflammation J:140018
decreased circulating serum amyloid protein level J:140018
\CrebbpGt(U-San)112Imeg/\Crebbp+
(involves: C57BL/6 * CBA)
abnormal tumor necrosis factor level J:75361
\Crebbptm1Dli/\Crebbp+
(involves: 129S6/SvEvTac * C57BL/6)
abnormal granulocyte morphology J:191503
abnormal leukocyte morphology J:191503
absent pre-B cells J:60630
decreased B cell number J:60630
decreased lymphocyte cell number J:191503
enlarged spleen J:191503, J:60630
increased granulocyte number J:191503
\Crebbptm1Jvd/\Crebbptm1Jvd
\Ep300tm2Pkb/\Ep300tm2Pkb
\Tg(Lck-cre)548Jxm/0

(involves: 129P2/OlaHsd * C57BL/6 * CBA)
abnormal T cell number J:105505
decreased double-positive T cell number J:105505
increased double-negative T cell number J:105505
\Crebbptm1Jvd/\Crebbptm1Jvd
\Tg(Lck-cre)548Jxm/0

(involves: 129 * C57BL/6 * CBA)
decreased CD4-positive, alpha-beta T cell number J:105505
decreased T cell number J:105505
decreased thymocyte number J:105505
increased double-positive T cell number J:105505
increased T cell derived lymphoma incidence J:105505
small thymus J:105505
\Crebbptm1Jvd/\Crebbptm1Jvd
\Tg(MMTV-cre)4Mam/0

(involves: 129 * C57BL/6 * FVB)
decreased double-positive T cell number J:88323
increased CD8-positive, alpha-beta T cell number J:88323
increased T cell derived lymphoma incidence J:88323
\Crebbptm1Pkb/\Crebbptm1Pkb
(involves: 129P2/OlaHsd * C57BL/6)
decreased thymocyte number J:98329
\Crhtm1Maj/\Crhtm1Maj
(involves: 129S2/SvPas * C57BL/6)
abnormal cell-mediated immunity J:98419
abnormal cytokine secretion J:98419
abnormal inflammatory response J:98419
abnormal professional antigen presenting cell physiology J:98419
decreased inflammatory response J:90690, J:72196
decreased susceptibility to experimental autoimmune encephalomyelitis J:98419
decreased T cell proliferation J:98419
increased circulating interleukin-6 level J:72196
increased splenocyte number J:98419
\Crhr2tm1Mpsp/\Crhr2tm1Mpsp
(involves: 129X1/SvJ * C57BL/6J)
immune system phenotype J:61510
\cri/\cri
(involves: DBA/2J)
decreased leukocyte cell number J:6327
decreased neutrophil cell number J:6327
\Crim1em1(IMPC)Wtsi/\Crim1em1(IMPC)Wtsi
(C57BL/6N-Crim1em1(IMPC)Wtsi/WtsiOrl)
absent connection between subcutaneous lymph vessels and lymph sac J:239583
blood in lymph vessels J:239583
\Crim1Gt(KST264)Byg/\Crim1Gt(KST264)Byg
(involves: 129P2/OlaHsd * C57BL/6 * CD-1)
kidney inflammation J:172334
\Crip3tm1Mjb/\Crip3tm1Mjb
(either: (involves: 129S/Sv) or (involves: 129S/Sv * C57BL/6))
decreased thymocyte number J:72942
small thymus J:72942
thymus hypoplasia J:72942
\Crispld2tm1Lex/\Crispld2tm1Lex
(B6;129S5-Crispld2tm1Lex/Mmucd)
abnormal immune system morphology J:171883
abnormal immune system physiology J:171883
\Crkltm1Imo/\Crkltm1Imo
(involves: 129S4/SvJaeSor * C57BL/6J)
abnormal thymus development J:67826
\Crl1A/WySnJ/\Crl1A/WySnJ
(B10.A-H2a/SgSnJ)
abnormal B cell physiology J:5442
\Crl1AKR/J/\Crl1AKR/J
(involves: AKR/J * DBA/2J)
abnormal B cell physiology J:5442
\Crl1DBA/2J/\Crl1DBA/2J
(involves: AKR/J * DBA/2J)
abnormal B cell physiology J:5442
\Crlf2em1(IMPC)Mbp/\Crlf2em1(IMPC)Mbp
(C57BL/6N-Crlf2em1(IMPC)Mbp/MbpMmucd)
abnormal lymph node morphology J:211773
abnormal spleen morphology J:211773
enlarged lymph nodes J:211773
enlarged spleen J:211773
\Crlf2tm1Jni/\Crlf2tm1Jni
(involves: 129P2/OlaHsd * C57BL/6)
immune system phenotype J:89031
\Crlf2tm1Jni/\Crlf2tm1Jni
(involves: 129P2/OlaHsd)
respiratory system inflammation J:187770
\Crlf2tm1Wjl/\Crlf2tm1Wjl
(involves: 129 * C57BL/6)
abnormal lymphopoiesis J:108209
decreased B cell number J:108209
decreased single-positive T cell number J:108209
\Crlf2tm1Wjl/\Crlf2tm1Wjl
(involves: BALB/c)
abnormal cytokine secretion J:107431
abnormal T cell proliferation J:107431
decreased immunoglobulin level J:107431
decreased splenocyte proliferation J:107431
lung inflammation J:107431
\Crlf2tm1Wjl/\Crlf2tm1Wjl
(Not Specified)
colitis J:175844
\Crocc2em1(IMPC)Ccpcz/\Crocc2em1(IMPC)Ccpcz
(C57BL/6NCrl-Crocc2em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
enlarged spleen J:211773
\Crocctm1Tili/\Crocctm1Tili
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
lung inflammation J:98885
\Crotem1Akw/\Crotem1Akw
\Ldlrtm1Her/\Ldlrtm1Her

(B6.Cg-Crotem1Akw Ldlrtm1Her)
blood vessel inflammation J:331161
\Crptm1Hjf/\Crp+
(C57BL/6-Crptm1Hjf)
decreased circulating C-reactive protein level J:170409
\Crptm1Hjf/\Crptm1Hjf
(C57BL/6-Crptm1Hjf)
decreased circulating C-reactive protein level J:170409
\Crppaem1(IMPC)H/\Crppa+
(C57BL/6NTac-Crppaem1(IMPC)H/H)
increased neutrophil cell number J:211773
\Crsl/\Crsl+
(involves: C3HeB/FeJ)
keratoconjunctivitis sicca J:104123
\Crtamtm1Achn/\Crtamtm1Achn
(involves: 129 * C57BL/6)
abnormal CD4-positive, alpha-beta T cell physiology J:145314
abnormal interleukin secretion J:145314
abnormal T cell activation J:145314
abnormal T-helper 1 physiology J:145314
decreased interferon-gamma secretion J:145314
decreased interleukin-17 secretion J:145314
increased CD4-positive, alpha-beta T cell number J:145314
increased CD8-positive, alpha-beta T cell number J:145314
increased susceptibility to bacterial infection J:145314
increased T cell proliferation J:145314
\Crtamtm1Tks/\Crtamtm1Tks
(B6.Cg-Crtamtm1Tks)
abnormal response to infection J:152770
immune system phenotype J:152770
\Crtc1tm1a(EUCOMM)Wtsi/\Crtc1+
(C57BL/6N-Crtc1tm1a(EUCOMM)Wtsi/Ics)
increased IgG2b level J:165965
\Crxem1(IMPC)Ccpcz/\Crxem1(IMPC)Ccpcz
(C57BL/6N-Crxem1(IMPC)Ccpcz/Ccpcz)
abnormal thymus morphology J:211773
enlarged thymus J:211773
increased NK cell number J:211773
small thymus J:211773
\Cry1em1(IMPC)H/\Cry1em1(IMPC)H
(C57BL/6N-Cry1em1(IMPC)H/H)
increased leukocyte cell number J:211773
\Cry1tm1Jhjh/\Cry1tm1Jhjh
\Cry2tm1Jhjh/\Cry2tm1Jhjh

(involves: 129P2/OlaHsd * C57BL/6)
abnormal T cell activation J:159504
increased circulating interleukin-1 beta level J:159504
increased circulating interleukin-6 level J:159504
increased circulating tumor necrosis factor level J:159504
increased susceptibility to induced arthritis J:159504
increased tumor necrosis factor secretion J:159504
\Cry2tm1Jhjh/\Cry2tm1Jhjh
(involves: 129P2/OlaHsd * C57BL/6)
abnormal osteoclast physiology J:163112
\Csf1op/\Csf1op
(C57BL/6J-Csf1op)
abnormal osteoclast morphology J:5634
abnormal spleen red pulp morphology J:5634
decreased macrophage cell number J:110981
decreased osteoclast cell number J:5634
\Csf1op/\Csf1op
(B6C3Fe a/a-Csf1op/J)
abnormal Kupffer cell morphology J:26978
abnormal Langerhans cell morphology J:112594
abnormal Langerhans cell physiology J:112594
abnormal microglial cell morphology J:49613
abnormal osteoclast differentiation J:19549, J:4732
abnormal osteoclast morphology J:26978
abnormal perivascular macrophage morphology J:49613
abnormal spleen red pulp morphology J:26978
abnormal splenic cell ratio J:104139
abnormal splenocyte physiology J:19549
absent Langerhans cell J:112594
decreased leukocyte cell number J:104139
decreased macrophage cell number J:26978, J:104139
decreased monocyte cell number J:104139
decreased osteoclast cell number J:73663
thymus cortex hypoplasia J:26978
thymus medulla atrophy J:26978
\Csf1op/\Csf1op
(involves: C3HeB/FeJ * C57BL/6J)
abnormal osteoclast cell number J:33189
abnormal osteoclast differentiation J:38039
decreased osteoclast cell number J:33189
\Csf1op/\Csf1op
(B6;C3Fe a/a-Csf1op/J)
abnormal microglial cell morphology J:170081
decreased macrophage cell number J:30863, J:147697
impaired macrophage chemotaxis J:147697
\Csf1op/\Csf1op
\Csf2tm1Ard/\Csf2tm1Ard

(involves: 129P2/OlaHsd * C57BL/6)
decreased leukocyte cell number J:19089
increased neutrophil cell number J:19089
interstitial pneumonia J:19089
lung inflammation J:19089
\Csf1op/\Csf1op
\Galctwi/\Galctwi

(involves: C3HeB/Fe * C57BL/6J * CE/J)
impaired macrophage chemotaxis J:170081
\Csf1op/\Csf1op
\Mpztm1Msch/\Mpz+

(involves: 129S7/SvEvBrd * C57BL/6)
immune system phenotype J:67581
\Csf1op/\Csf1op
\Sh3bp2tm1Bjro/\Sh3bp2tm1Bjro

(involves: 129S4/SvJae * BALB/cJ * C57BL/6J)
abnormal lymph node cell ratio J:117880
increased circulating tumor necrosis factor level J:117880
liver inflammation J:117880
\Csf1tm1.1(CSF1)Flv/\Csf1tm1.1(CSF1)Flv
\Csf2/Il3tm1.1(CSF2,IL3)Flv/\Csf2/Il3tm1.1(CSF2,IL3)Flv
\Il2rgtm1.1Flv/\Il2rgtm1.1Flv
\Rag2tm1.1Flv/\Rag2tm1.1Flv
\Tg(SIRPA)1Flv/0
\Thpotm1.1(TPO)Flv/\Thpotm1.1(TPO)Flv

(involves: 129S4/SvJae * BALB/cAnNTac)
abnormal response to transplant J:207289
\Csf1tm1.1(CSF1)Flv/\Csf1tm1.1(CSF1)Flv
\Csf2/Il3tm1.1(CSF2,IL3)Flv/\Csf2/Il3tm1.1(CSF2,IL3)Flv
\Il2rgtm1.1Flv/\Il2rgtm1.1Flv
\Rag2tm1.1Flv/\Rag2tm1.1Flv
\Thpotm1.1(TPO)Flv/\Thpotm1.1(TPO)Flv

(involves: 129S4/SvJae * BALB/cAnNTac)
abnormal response to transplant J:207289
\Csf1tm1.1(CSF1)Flv/\Csf1tm1.1(CSF1)Flv
\Il2rgtm1.1Flv/\Il2rgtm1.1Flv
\Csf2/Il3tm1.1(CSF2,IL3)Flv/\Csf2/Il3tm1.1(CSF2,IL3)Flv
\Rag2tm1.1Flv/\Rag2tm1.1Flv
\Tg(SIRPA)1Flv/0
\Thpotm1.1(TPO)Flv/\Thpotm1.1(TPO)Flv

(involves: 129S4/SvJae * BALB/cAnNTac)
abnormal response to transplant J:207289
\Csf1tm1.1(CSF1)Flv/\Csf1tm1.1(CSF1)Flv
\Il2rgtm1.1Flv/\Il2rgtm1.1Flv
\Csf2/Il3tm1.1(CSF2,IL3)Flv/\Csf2/Il3tm1.1(CSF2,IL3)Flv
\Rag2tm1.1Flv/\Rag2tm1.1Flv
\Thpotm1.1(TPO)Flv/\Thpotm1.1(TPO)Flv

(involves: 129S4/SvJae * BALB/cAnNTac)
abnormal response to transplant J:207289
\Csf1tm1.1(CSF1)Flv/\Csf1tm1.1(CSF1)Flv
\Il2rgtm1.1Flv/\Il2rgtm1.1Flv
\Rag2tm1.1Flv/\Rag2tm1.1Flv

(involves: 129P2/OlaHsd * 129S/SvEv * 129S4/SvJae * BALB/cAnNTac)
abnormal immune system physiology J:177073
immune system phenotype J:177073
\Csf1tm1.2Sabw/\Csf1tm1.2Sabw
(involves: 129S4/SvJaeSor * C57BL/6)
abnormal Kupffer cell morphology J:180199
abnormal myeloid leukocyte morphology J:180199
decreased B cell number J:180199
decreased lymphocyte cell number J:180199
decreased macrophage cell number J:180199
decreased monocyte cell number J:180199
decreased osteoclast cell number J:180199
decreased spleen weight J:180199
increased granulocyte number J:180199
increased T cell number J:180199
small spleen J:180199
\Csf1rtm1Ers/\Csf1r+
(B6.129X1-Csf1rtm1Ers)
microgliosis J:219294
\Csf1rtm1Ers/\Csf1rtm1Ers
(involves: 129X1/SvJ * C3Heb/FeJ * C57BL/6J)
abnormal circulating cytokine level J:73663
abnormal leukocyte cell number J:73663
abnormal osteoclast differentiation J:73663
abnormal spleen morphology J:73663
decreased Langerhans cell number J:73663
decreased lymphocyte cell number J:73663
decreased macrophage cell number J:73663
decreased monocyte cell number J:73663
increased granulocyte number J:73663
increased spleen weight J:73663
\Csf1rtm1Ers/\Csf1rtm1Ers
(FVB.129X1-Csf1rtm1Ers)
abnormal Langerhans cell physiology J:112594
abnormal macrophage differentiation J:112594
abnormal osteoclast morphology J:111489
absent Langerhans cell J:112594
\Csf2/Il3tm1.1(CSF2,IL3)Flv/\Csf2/Il3tm1.1(CSF2,IL3)Flv
\Il2rgtm1.1Flv/\Il2rgtm1.1Flv
\Rag2tm1.1Flv/\Rag2tm1.1Flv

(involves: 129S4/SvJae * BALB/cAnNCr * BALB/cAnNTac)
abnormal response to transplant J:168302
\Csf2tm1Ard/\Csf2tm1Ard
(involves: 129P2/OlaHsd * C57BL/6)
abnormal alveolar macrophage morphology J:18747
abnormal leukocyte physiology J:86386
abnormal MHC II cell surface expression on macrophages J:86386
abnormal spleen size J:67766
impaired macrophage chemotaxis J:86386
increased susceptibility to bacterial infection J:18747, J:53659
increased susceptibility to fungal infection J:18747
increased susceptibility to parasitic infection J:67766
lung inflammation J:18747
lymphoid hyperplasia J:18747
\Csf2tm1Dran/\Csf2tm1Dran
\Ifngtm1Ts/\Ifngtm1Ts
\Il3tm1Glli/\Il3tm1Glli

(involves: 129S2/SvPas * 129S7/SvEvBrd * C57BL/6)
increased eosinophil cell number J:83086
increased IgE level J:83086
increased IgG1 level J:83086
increased immunoglobulin level J:83086
increased inflammatory response J:83086
\Csf2tm1Dran/\Csf2tm1Dran
\Il3tm1Glli/\Il3tm1Glli

(B6.129S2-Csf2tm1Dran Il3tm1Glli)
abnormal leukocyte physiology J:83086
decreased susceptibility to type IV hypersensitivity reaction J:67404
glomerulonephritis J:83086
increased anti-double stranded DNA antibody level J:83086
increased eosinophil cell number J:67404
lung inflammation J:67404
\Csf2tm1Dran/\Csf2tm1Dran
\Il3tm1Glli/\Il3tm1Glli

(C.129S2-Csf2tm1Dran Il3tm1Glli)
decreased susceptibility to type IV hypersensitivity reaction J:67404
increased eosinophil cell number J:67404
lung inflammation J:67404
\Csf2tm1Mlg/\Csf2tm1Mlg
(involves: 129S2/SvPas)
abnormal alveolar macrophage morphology J:17978
decreased susceptibility to experimental autoimmune encephalomyelitis J:148120
lymphoid hyperplasia J:17978
\Csf2raem1Szut/\Csf2raem1Szut
(C57BL/6-Csf2raem1Szut)
abnormal alveolar macrophage morphology J:322934
impaired macrophage phagocytosis J:322934
increased lymphocyte cell number J:322934
lung inflammation J:322934
\Csf2rbtm1Cgb/\Csf2rbtm1Cgb
(involves: 129S1/Sv * C57BL/6)
decreased eosinophil cell number J:29737
lung inflammation J:29737
\Csf2rbtm1Clsc/\Csf2rbtm1Clsc
\Csf2rb2tm1Cgb/\Csf2rb2tm1Cgb

(C.129S1-Csf2rb2tm1Cgb Csf2rbtm1Clsc)
abnormal dendritic cell physiology J:130939
abnormal interleukin secretion J:130939
abnormal plasmacytoid dendritic cell physiology J:130939
abnormal T cell activation J:130939
abnormal T cell physiology J:130939
decreased interleukin-4 secretion J:130939
decreased interleukin-5 secretion J:130939
decreased interleukin-13 secretion J:130939
decreased susceptibility to type I hypersensitivity reaction J:130939
decreased T cell proliferation J:130939
impaired eosinophil recruitment J:130939
increased IgG1 level J:130939
lymph node hyperplasia J:130939
\Csf2rbtm1Mur/\Csf2rbtm1Mur
(involves: 129P2/OlaHsd * C57BL/6)
abnormal eosinophil physiology J:35829
decreased eosinophil cell number J:35829
lung inflammation J:35829
\Csf2rbtm1Mur/\Csf2rbtm1Mur
(involves: 129P2/OlaHsd)
abnormal eosinophil physiology J:24122
decreased eosinophil cell number J:24122
increased susceptibility to infection J:24122
lung inflammation J:24122
\Csf2rbtm1Mur/\Csf2rbtm1Mur
\Il3tm1Tyb/\Il3tm1Tyb

(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6)
abnormal eosinophil physiology J:35829
decreased eosinophil cell number J:35829
lung inflammation J:35829
\Csf2rbtm2b(EUCOMM)Hmgu/\Csf2rb+
(C57BL/6N-Csf2rbtm2b(EUCOMM)Hmgu/Orl)
increased eosinophil cell number J:211773
\Csf3em1(IMPC)H/\Csf3em1(IMPC)H
(C57BL/6NTac-Csf3em1(IMPC)H/H)
decreased eosinophil cell number J:211773
decreased neutrophil cell number J:211773
increased lymphocyte cell number J:211773
\Csf3tm1Ard/\Csf3+
(involves: 129P2/OlaHsd * C57BL/6)
decreased neutrophil cell number J:20400
\Csf3tm1Ard/\Csf3tm1Ard
(involves: 129P2/OlaHsd * C57BL/6)
abnormal neutrophil physiology J:20400
decreased leukocyte cell number J:20400
decreased monocyte cell number J:20400
decreased neutrophil cell number J:20400
impaired myelopoiesis J:20400
increased susceptibility to bacterial infection J:20400
\Csf3tm1Ard/\Csf3tm1Ard
\Junbtm3Wag/\Junbtm3Wag
\Tg(KRT5-cre)1Tak/0

(involves: 129/Sv * 129P2/OlaHsd * C3H * C57BL/6)
increased susceptibility to systemic lupus erythematosus J:155575
\Csf3rtm1Eur/\Csf3rtm1Eur
(involves: 129P2/OlaHsd * C57BL/6 * FVB)
abnormal neutrophil differentiation J:48503
decreased neutrophil cell number J:48503
\Csf3rtm1Link/\Csf3rtm1Link
(involves: 129X1/SvJ * NIH Black Swiss)
abnormal monocyte morphology J:37618
decreased monocyte cell number J:37618
decreased neutrophil cell number J:37618
\Csf3rtm1Link/\Csf3rtm1Link
(involves: 129X1/SvJ)
impaired neutrophil chemotaxis J:79825
\Csf3rtm1Link/\Csf3rtm1Link
(B6.129X1-Csf3rtm1Link)
impaired neutrophil chemotaxis J:79567
\Csf3rtm2Eur/\Csf3rtm2Eur
(involves: 129P2/OlaHsd * FVB)
decreased neutrophil cell number J:185115
\Csf3rtm2Link/\Csf3r+
\Elanetm1Link/\Elane+

(involves: 129X1/SvJ * C57BL/6)
immune system phenotype J:131496
\Csf3rtm2Link/\Csf3rtm2Link
(B6.129X1-Csf3rtm2Link)
abnormal neutrophil physiology J:79567
\Csf3rtm3Link/\Csf3rtm3Link
(B6.129X1-Csf3rtm3Link)
immune system phenotype J:79567
\Csf3rtm3Link/\Csf3rtm3Link
(involves: 129X1/SvJ * C57BL/6)
decreased neutrophil cell number J:67612
\Csf3rtm4(Epor)Link/\Csf3rtm4(Epor)Link
(involves: 129X1/SvJ * C57BL/6)
decreased granulocyte number J:79825
decreased neutrophil cell number J:79825
impaired neutrophil chemotaxis J:79825
\Csf3rtm4(Epor)Link/\Csf3rtm4(Epor)Link
(B6.129X1-Csf3rtm4(Epor)Link)
decreased neutrophil cell number J:79567
impaired neutrophil chemotaxis J:79567
\Csgalnact1tm1.1Migar/\Csgalnact1tm1.1Migar
(involves: C57BL/6N * C57BL/6NCrlj * CBA/JNCrlj)
periodontium inflammation J:269621
\Csktm1Sor/\Csk+
\Ptprcltng/\Ptprcltng

(involves: 129S7/SvEvBrd * C57BL/6)
thymus hypoplasia J:158876
\Csktm1Sor/\Csk+
\Ptprcltng/\Ptprctm1Mak

(involves: 129S7/SvEvBrd * C57BL/6)
abnormal T cell differentiation J:158876
thymus hypoplasia J:158876
\Csktm1Tara/\Csktm1Tara
\Tg(Mx1-cre)1Cgn/0

(involves: 129P2/OlaHsd * C57BL/6 * CB20 * CBA)
abnormal CD4-positive T cell differentiation J:49654
absent CD8-positive, alpha-beta T cells J:49654
enlarged thymus J:49654
\Csktm1Tara/\Csktm2Tara
\Elanetm1(cre)Roes/\Elane+

(involves: 129P2/OlaHsd * CB20 * C57BL/6)
abnormal granulocyte physiology J:89716
abnormal myelopoiesis J:89716
increased acute inflammation J:89716
increased susceptibility to bacterial infection J:89716
\Csmd3em1(IMPC)Mbp/\Csmd3em1(IMPC)Mbp
(C57BL/6NCrl-Csmd3em1(IMPC)Mbp/Mmucd)
abnormal lymph node morphology J:211773
abnormal spleen morphology J:211773
enlarged lymph nodes J:211773
\Csnk1a1tm1c(KOMP)Wtsi/\Csnk1a1tm1c(KOMP)Wtsi
\Tg(Mx1-cre)1Cgn/0

(involves: C57BL/6 * C57BL/6N * CBA)
abnormal spleen red pulp morphology J:216977
bone marrow failure J:216977
\Csnk1g1em1(IMPC)J/\Csnk1g1em1(IMPC)J
(C57BL/6NJ-Csnk1g1em1(IMPC)J/Mmjax)
increased leukocyte cell number J:211773
\Csnk2a2em1(IMPC)Mbp/\Csnk2a2em1(IMPC)Mbp
(C57BL/6N-Csnk2a2em1(IMPC)Mbp/MbpMmucd)
abnormal spleen morphology J:211773
enlarged spleen J:211773
\Cspg4tm1Wbst/\Cspg4tm1Wbst
(involves: 129S1/Sv * 129X1/SvJ)
abnormal macrophage physiology J:184220
\CsptC57BL/6/\CsptC57BL/6
(involves: C57BL/6 * NOD/ShLtDoi * SJL)
increased CD8-positive, alpha-beta T cell number J:97046
\CsptC57BL/6/\CsptNOD/ShiLtDoi
(involves: C57BL/6 * NOD/ShLtDoi * SJL)
increased CD8-positive, alpha-beta T cell number J:97046
\Csrnp1tm1Jni/\Csrnp1tm1Jni
(involves: 129P2/OlaHsd * C57BL/6)
immune system phenotype J:129366
\Csrnp1tm1Jni/\Csrnp1tm1Jni
\Csrnp2tm1Jni/\Csrnp2tm1Jni

(involves: 129P2/OlaHsd * C57BL/6)
immune system phenotype J:129366
\Csrnp2tm1Jni/\Csrnp2tm1Jni
(involves: 129P2/OlaHsd * C57BL/6)
immune system phenotype J:129366
\Csrnp3tm1Jni/\Csrnp3tm1Jni
(involves: 129P2/OlaHsd * C57BL/6)
immune system phenotype J:129366
\Cst6em1(IMPC)Ccpcz/\Cst6+
(C57BL/6NCrl-Cst6em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
enlarged spleen J:211773
small spleen J:211773
\Cst7tm1.2Arte/\Cst7tm1.2Arte
(involves: C57BL/6)
abnormal eosinophil morphology J:258944
abnormal eosinophil physiology J:258944
abnormal hypersensitivity reaction J:258944
decreased eosinophil cell number J:258944
increased susceptibility to parasitic infection J:258944
\Cstbtm1b(EUCOMM)Wtsi/\Cstbtm1b(EUCOMM)Wtsi
(C57BL/6N-Cstbtm1b(EUCOMM)Wtsi/Orl)
decreased lymphocyte cell number J:211773
increased monocyte cell number J:211773
\Cstbtm1Rm/\Cstbtm1Rm
(either: (involves: 129S1/Sv * 129X1/SvJ) or (involves: 129S1/Sv * 129X1/SvJ * C57BL/6))
increased incidence of corneal inflammation J:50587
uveitis J:50587
\Ct55em1Xdzg/\Ct55em1Xdzg
(involves: C57BL/6)
decreased susceptibility to induced colitis J:280149
\Ctbstm1Tbec/\Ctbstm1Tbec
(involves: 129S2/SvPas * C57BL/6N)
abnormal Kupffer cell morphology J:185162
\Ctc1tm1.1Schg/\Ctc1tm1.1Schg
(involves: 129S7/SvEvBrd * C57BL/6)
decreased splenocyte proliferation J:184809
small spleen J:184809
small thymus J:184809
\Ctcftm2Gal/\Ctcf+
\Tg(Lck-cre)1Cwi/0

(involves: 129P2/OlaHsd * C57BL/6)
decreased CD4-positive, alpha-beta T cell number J:143271
decreased CD8-positive, alpha-beta T cell number J:143271
thymus hypoplasia J:143271
\Ctcftm2Gal/\Ctcftm2Gal
\Rag2tm1Fwa/\Rag2tm1Fwa
\Tg(Lck-cre)1Cwi/0

(involves: 129P2/OlaHsd * 129S/SvEv * C57BL/6 * C57BL/10)
decreased double-positive T cell number J:143271
\Ctcftm2Gal/\Ctcftm2Gal
\Tg(Lck-cre)1Cwi/0

(involves: 129P2/OlaHsd * C57BL/6)
abnormal T cell differentiation J:143271
abnormal T cell morphology J:143271
decreased CD4-positive, alpha-beta T cell number J:143271
decreased CD8-positive, alpha-beta T cell number J:143271
decreased double-positive T cell number J:143271
decreased single-positive T cell number J:143271
increased double-negative T cell number J:143271
increased single-positive T cell number J:143271
thymus hypoplasia J:143271
\Ctcftm2Gal/\Ctcftm2Gal
\Tg(Lck-cre)1Cwi/0
\Tg(TcraH-Y,TcrbH-Y)71Vbo/0

(involves: 129P2/OlaHsd * C57BL/6 * C57BL/10 * DBA/2J)
abnormal T cell differentiation J:143271
decreased CD4-positive, alpha-beta T cell number J:143271
decreased CD8-positive, alpha-beta T cell number J:143271
decreased double-positive T cell number J:143271
\Ctcftm2Gal/\Ctcftm2Gal
\Tg(Lck-cre)1Cwi/0
\Tg(TcraTcrb)425Cbn/0

(involves: 129P2/OlaHsd * C57BL/6)
abnormal T cell differentiation J:143271
decreased CD4-positive, alpha-beta T cell number J:143271
decreased double-positive T cell number J:143271
decreased T cell number J:143271
increased double-negative T cell number J:143271
increased single-positive T cell number J:143271
\Ctdspl2tm2b(KOMP)Wtsi/\Ctdspl2+
(C57BL/6N-Ctdspl2tm2b(KOMP)Wtsi/Bay)
increased spleen weight J:211773
\ctl/\ctl
(A/WySnJ-ctl/GrsrJ)
autoimmune arthritis J:91389
\Ctl1NZB/BlN/\Ctl1C57BL/10
(involves: C57BL/10 * NZB/BlN)
abnormal T cell physiology J:6736
\Ctla4m1Btlr/\Ctla4m1Btlr
(C57BL/6J-Ctla4m1Btlr)
decreased CD8-positive, naive alpha-beta T cell number J:265263
increased effector memory CD4-positive, alpha-beta T cell number J:265263
increased effector memory CD8-positive, alpha-beta T cell number J:265263
\Ctla4tm1All/\Ctla4tm1All
(involves: 129S1/Sv * 129X1/SvJ)
abnormal thymus morphology J:42481
decreased double-positive T cell number J:42481
decreased T cell number J:42481
increased double-negative T cell number J:42481
lymph node hypoplasia J:42481
\Ctla4tm1All/\Ctla4tm1All
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * NOD)
increased acute inflammation J:109887
\Ctla4tm1All/\Ctla4tm1All
\Rag1tm1Mom/\Rag1tm1Mom
\Tg(TcrAND)53Hed/0

(involves: 129S/Sv * 129X1/SvJ * C57BL/6 * SJL)
abnormal T cell activation J:119845
increased interleukin-4 secretion J:119845
increased T cell proliferation J:119845
\Ctla4tm1All/\Ctla4tm1All
\Rag1tm1Mom/\Rag1tm1Mom
\Tg(TcraTcrb)8Rest/0

(involves: 129S1/Sv * 129S7/SvEvBrd * 129X1/SvJ * C57BL/6)
immune system phenotype J:140448
\Ctla4tm1All/\Ctla4tm1All
\Tg(TcraBDC2.5,TcrbBDC2.5)1Doi/0

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * NOD * SJL)
abnormal splenocyte physiology J:109887
enlarged spleen J:109887
increased acute inflammation J:109887
insulitis J:109887
\Ctla4tm1All/\Ctla4tm1All
\Tg(TcrAND)53Hed/0

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL)
abnormal lymphopoiesis J:119845
abnormal T cell activation J:119845
abnormal T cell subpopulation ratio J:119845
increased CD4-positive, alpha-beta T cell number J:119845
increased CD8-positive, alpha-beta T cell number J:119845
\Ctla4tm1All/\Ctla4tm1All
\Tg(TcraTcrb)8Rest/0

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
decreased CD8-positive, alpha-beta T cell number J:140448
increased CD4-positive, alpha-beta T cell number J:140448
increased interferon-gamma secretion J:140448
\Ctla4tm1Mak/\Ctla4tm1Mak
(involves: 129P2/OlaHsd * BALB/c)
increased interferon-gamma secretion J:140085
increased interleukin-2 secretion J:140085
increased interleukin-4 secretion J:140085
increased interleukin-17 secretion J:140085
\Ctla4tm1Saka/\Ctla4tm1Saka
\Foxp3tm1(cre)Saka/Y

(involves: BALB/c)
abnormal immunoglobulin level J:140085
abnormal regulatory T cell physiology J:140085
abnormal splenic cell ratio J:140085
increased autoantibody level J:140085
increased IgE level J:140085
increased IgG level J:140085
increased inflammatory response J:140085
increased interferon-gamma secretion J:140085
increased interleukin-2 secretion J:140085
increased interleukin-4 secretion J:140085
increased regulatory T cell number J:140085
lung inflammation J:140085
lymph node hyperplasia J:140085
myocarditis J:140085
salivary gland inflammation J:140085
spleen hyperplasia J:140085
stomach inflammation J:140085
\Ctla4tm1Shr/\Ctla4tm1Shr
(either: (involves: 129S4/SvJae * BALB/c) or (involves: 129S4/SvJae * C57BL/6))
abnormal cytokine secretion J:30393
abnormal lymph node cell ratio J:30393
abnormal splenic cell ratio J:30393
abnormal T cell differentiation J:30393
abnormal T cell morphology J:30393
decreased double-positive T cell number J:30393
enlarged lymph nodes J:30393
enlarged spleen J:30393
increased double-negative T cell number J:30393
increased T cell number J:30393
increased T cell proliferation J:30393
joint inflammation J:30393
lung inflammation J:30393
myocarditis J:30393
pancreas inflammation J:30393
salivary gland inflammation J:30393
\Ctla4tm1Shr/\Ctla4tm1Shr
(B6.129S4-Ctla4tm1Shr)
abnormal regulatory T cell physiology J:146644
abnormal T cell physiology J:146644
autoimmune response J:146644
\Ctla4tm1Shr/\Ctla4tm1Shr
\Rag2tm1Fwa/\Rag2tm1Fwa
\Tg(DO11.10)10Dlo/0

(involves: 129S/Sv * BALB/c * C3H * C57BL/6)
abnormal cytokine secretion J:110446
abnormal T cell physiology J:110446
immune system phenotype J:110446
\Ctla4tm1Shr/\Ctla4tm1Shr
\Tg(DO11.10)10Dlo/0

(involves: 129S4/SvJae * BALB/c * C3H * C57BL/6)
abnormal T cell physiology J:57090
enlarged lymph nodes J:57090
enlarged spleen J:57090
increased T cell proliferation J:57090
\Ctnnb1tm1(Nfkbia)Rsu/\Ctnnb1+
(involves: 129P2/OlaHsd * C57BL/6)
abnormal cervical lymph node morphology J:71744
abnormal macrophage physiology J:71744
abnormal peripheral lymph node morphology J:71744
absent peripheral lymph nodes J:71744
absent Peyer's patches J:71744
absent popliteal lymph nodes J:71744
conjunctivitis J:71744
decreased Peyer's patch number J:71744
increased granulocyte number J:71744
increased inflammatory response J:71744
increased leukocyte cell number J:71744
increased susceptibility to otitis media J:71744
increased susceptibility to parasitic infection J:71744
keratoconjunctivitis sicca J:71744
small axillary lymph nodes J:71744
small brachial lymph nodes J:71744
small Peyer's patches J:71744
\Ctnnb1tm1Mmt/\Ctnnb1+
\Ctsktm1(cre)Ska/\Ctsk+

(involves: 129X1/SvJ * C57BL/6NCrlj * CBA/JNCrlj)
abnormal osteoclast differentiation J:178340
\Ctnnb1tm1Mmt/\Ctnnb1+
\Lyz2tm1(cre)Ifo/\Lyz2+

(involves: 129P2/OlaHsd * 129X1/SvJ)
abnormal osteoclast differentiation J:178340
\Ctnnb1tm1Mmt/\Ctnnb1+
\Ppargtm1.1(tTA)Jmgr/\Pparg+
\Tg(tetO-cre)1Jaw/0

(involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6)
abnormal osteoclast differentiation J:178340
decreased osteoclast cell number J:178340
increased splenocyte number J:178340
\Ctnnb1tm1Mmt/\Ctnnb1+
\Tg(Col1a1-cre)1Kry/0

(involves: 129X1/SvJ * FVB)
decreased osteoclast cell number J:98430
\Ctnnb1tm1Mmt/\Ctnnb1+
\Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0

(involves: 129X1/SvJ * CD-1)
abnormal osteoclast differentiation J:114494
\Ctnnb1tm2(Nfkbia)Rsu/\Ctnnb1+
\Tg(CMV-cre)1Cgn/0

(involves: 129P2/OlaHsd * BALB/cJ * C57BL/6)
abnormal lymph node morphology J:71744
abnormal macrophage physiology J:71744
abnormal Peyer's patch morphology J:71744
increased granulocyte number J:71744
increased inflammatory response J:71744
increased leukocyte cell number J:71744
increased susceptibility to otitis media J:71744
keratoconjunctivitis sicca J:71744
\Ctnnb1tm2Kem/\Ctnnb1+
\Ctsktm1(cre)Ska/\Ctsk+

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6NCrlj * CBA/JNCrlj)
increased osteoclast cell number J:178340
\Ctnnb1tm2Kem/\Ctnnb1+
\Lyz2tm1(cre)Ifo/\Lyz2+

(involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ)
increased osteoclast cell number J:178340
\Ctnnb1tm2Kem/\Ctnnb1+
\Ppargtm1.1(tTA)Jmgr/\Pparg+
\Tg(tetO-cre)1Jaw/0

(involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6)
abnormal osteoclast physiology J:178340
increased osteoclast cell number J:178340
\Ctnnb1tm2Kem/\Ctnnb1+
\Tg(Tek-cre)1Ywa/0

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL)
increased osteoclast cell number J:178340
\Ctnnb1tm2Kem/\Ctnnb1tm2Kem
\Ctsktm1(cre)Ska/\Ctsk+

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6NCrlj * CBA/JNCrlj)
increased osteoclast cell number J:178340
\Ctnnb1tm2Kem/\Ctnnb1tm2Kem
\Lyz2tm1(cre)Ifo/\Lyz2+

(involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ)
increased osteoclast cell number J:178340
\Ctnnb1tm2Kem/\Ctnnb1tm2Kem
\Ppargtm1.1(tTA)Jmgr/\Pparg+
\Tg(tetO-cre)1Jaw/0

(involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6)
abnormal osteoclast physiology J:178340
decreased osteoclast cell number J:178340
\Ctnnb1tm2Kem/\Ctnnb1tm2Kem
\Ppargtm1.1(tTA)Jmgr/\Pparg+
\Tg(tetO-cre)1Jaw/0
\Tg(tetO-HIST1H2BJ/GFP)47Efu/0

(involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6 * CD-1)
abnormal osteoclast differentiation J:178340
\Ctnnb1tm2Kem/\Ctnnb1tm2Kem
\Tg(Col1a1-cre)1Kry/0

(involves: 129S1/Sv * 129X1/SvJ * FVB)
increased osteoclast cell number J:98430
\Ctnnb1tm2Kem/\Ctnnb1tm2Kem
\Tg(KRT14-cre/ERT)20Efu/0

(involves: 129S1/Sv * 129X1/SvJ * CD-1)
cutaneous mastocytosis J:204142
\Ctnnb1tm2Kem/\Ctnnb1tm2Kem
\Tg(Tek-cre)1Ywa/0

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL)
decreased osteoclast cell number J:178340
\Ctnnb1tm4Wbm/\Ctnnb1tm4Wbm
\Krt14tm1(cre)Wbm/\Krt14+

(involves: 129P2/OlaHsd)
decreased gamma-delta T cell number J:202499
increased neutrophil cell number J:202499
\Ctnnb1tm4Wbm/\Ctnnb1tm4Wbm
\Tg(Pdx1-cre)6Tuv/0

(involves: 129P2/OlaHsd * FVB/N)
pancreas inflammation J:119908
\Ctps1em1(IMPC)Tcp/\Ctps1+
(C57BL/6N-Ctps1em1(IMPC)Tcp/Tcp)
enlarged lymph nodes J:211773
\Ctps1tm1c(KOMP)Wtsi/\Ctps1tm1c(KOMP)Wtsi
\Commd10Tg(Vav1-icre)A2Kio/0

(B6.Cg-Ctps1tm1c(KOMP)Wtsi Commd10Tg(Vav1-icre)A2Kio)
abnormal spleen morphology J:348981
decreased B cell number J:348981
decreased double-positive T cell number J:348981
decreased NK cell number J:348981
decreased T cell number J:348981
decreased T cell proliferation J:348981
increased CD4-positive, alpha-beta T cell number J:348981
increased CD8-positive, alpha-beta T cell number J:348981
small thymus J:348981
thymus hypoplasia J:348981
\Ctps1tm1c(KOMP)Wtsi/\Ctps1tm1c(KOMP)Wtsi
\Ctps2tm1c(EUCOMM)Hmgu/\Ctps2+
\Tg(Cd4-cre)1Cwi/0

(involves: 129S/Sv * C57BL/6 * DBA/2)
decreased T cell proliferation J:348981
\Ctps1tm1c(KOMP)Wtsi/\Ctps1tm1c(KOMP)Wtsi
\Ctps2tm1c(EUCOMM)Hmgu/\Ctps2tm1c(EUCOMM)Hmgu
\Tg(Cd4-cre)1Cwi/0

(involves: 129S/Sv * C57BL/6 * DBA/2)
decreased T cell number J:348981
decreased T cell proliferation J:348981
\Ctps1tm1c(KOMP)Wtsi/\Ctps1tm1c(KOMP)Wtsi
\Gt(ROSA)26Sortm1(cre/ERT2)Tyj/\Gt(ROSA)26Sor+

(B6.Cg-Ctps1tm1c(KOMP)Wtsi Gt(ROSA)26Sortm1(cre/ERT2)Tyj)
abnormal spleen morphology J:348981
abnormal thymus physiology J:348981
decreased germinal center B cell number J:348981
decreased IgM level J:348981
decreased lymphocyte cell number J:348981
decreased T cell proliferation J:348981
decreased T follicular helper cell number J:348981
impaired humoral immune response J:348981
increased CD8-positive, alpha-beta T cell number J:348981
small thymus J:348981
thymus hypoplasia J:348981
\Ctps1tm1c(KOMP)Wtsi/\Ctps1tm1c(KOMP)Wtsi
\Tg(Cd4-cre)1Cwi/0

(involves: 129S/Sv * C57BL/6 * DBA/2)
decreased effector memory T-helper cell number J:348981
decreased T cell proliferation J:348981
increased CD8-positive, naive alpha-beta T cell number J:348981
\Ctps1tm1c(KOMP)Wtsi/\Ctps1tm1c(KOMP)Wtsi
\Tg(Cd4-cre)1Cwi/0
\Foxp3sf/Y
\Rag1tm1Mom/\Rag1+

(mixed)
decreased inflammatory response J:348981
decreased regulatory T cell number J:348981
decreased T cell proliferation J:348981
enlarged spleen J:348981
thymus hypoplasia J:348981
\Ctps1tm1c(KOMP)Wtsi/\Ctps1tm1c(KOMP)Wtsi
\Tg(Cd8a-cre)1Itan/0

(B6(129S4)-Ctps1tm1c(KOMP)Wtsi Tg(Cd8a-cre)1Itan)
decreased T cell proliferation J:348981
\Ctrb1em1Toth/\Ctrb1em1Toth
(C57BL/6N-Ctrb1em1Toth)
increased susceptibility to induced pancreatitis J:294171, J:294035
\Ctrcm1/\Ctrcm1
(C57BL/6-Ctrcm1)
increased susceptibility to induced pancreatitis J:291240
\Ctrq1C3H/HeJ/\Ctrq1C3H/HeJ
(involves: C3H/HeJ * C57BL/6J)
increased susceptibility to bacterial infection J:106111
\Ctrq2C3H/HeJ/\Ctrq2C3H/HeJ
(involves: C3H/HeJ * C57BL/6J)
decreased susceptibility to bacterial infection J:106111
\Ctrq2C3H/HeJ/\Ctrq2C57BL/6J
(involves: C3H/HeJ * C57BL/6J)
decreased susceptibility to bacterial infection J:106111
\Ctrq3C3H/HeJ/\Ctrq3C3H/HeJ
(involves: C3H/HeJ * C57BL/6J)
increased susceptibility to bacterial infection J:106111
\Ctrq3C3H/HeJ/\Ctrq3C57BL/6J
(involves: C3H/HeJ * C57BL/6J)
increased susceptibility to bacterial infection J:106111
\Ctsatm1Adz/\Ctsatm1Adz
(either: (involves: 129P2/OlaHsd * C57BL/6) or (involves: 129P2/OlaHsd * FVB/NJ))
enlarged spleen J:29674
\Ctsatm2b(EUCOMM)Hmgu/\Ctsatm2b(EUCOMM)Hmgu
(C57BL/6N-Ctsatm2b(EUCOMM)Hmgu/H)
enlarged spleen J:211773
increased monocyte cell number J:211773
increased spleen weight J:211773
\Ctsbtm1Jde/\Ctsb+
(NOD.129P2-Ctsbtm1Jde)
decreased susceptibility to autoimmune diabetes J:153355
insulitis J:153355
\Ctsbtm1Jde/\Ctsbtm1Jde
(either: (involves: 129P2/OlaHsd * 129/Sv) or (involves: 129P2/OlaHsd * C57BL/6))
immune system phenotype J:47432
\Ctsbtm1Jde/\Ctsbtm1Jde
(NOD.129P2-Ctsbtm1Jde)
decreased susceptibility to autoimmune diabetes J:153355
insulitis J:153355
salivary gland inflammation J:153355
\Ctsbtm1Jde/\Ctsbtm1Jde
\Serpina3gtm1.1Arp/\Serpina3gtm1.1Arp

(involves: 129P2/OlaHsd * C57BL/6)
immune system phenotype J:189782
\Ctsctm1Ley/\Ctsctm1Ley
(either: 129X1/SvJ-Ctsctm1Ley or (involves: 129X1/SvJ * C57BL/6))
abnormal cytotoxic T cell physiology J:77312
abnormal T cell physiology J:77312
\Ctsctm1Ley/\Ctsctm1Ley
(B6.129X1-Ctsctm1Ley)
abnormal chemokine level J:131520
abnormal leukocyte migration J:131520
abnormal response to infection J:131520
decreased circulating interleukin-6 level J:131520
impaired neutrophil recruitment J:131520
increased circulating interleukin-6 level J:88160
sepsis J:88160
\Ctsctm1Ley/\Ctsctm1Ley
\Il6tm1Kopf/\Il6tm1Kopf

(involves: 129S2/SvPas * 129X1/SvJ * C57BL/6)
immune system phenotype J:88160
\Ctsdm1J/\Ctsdm1J
(C3HeB/FeJ-Ctsdm1J/GrsrJ)
thymus atrophy J:229377
\Ctsdtm1.1Thre/\Ctsdtm1.1Thre
\Edil3Tg(Sox2-cre)1Amc/\Edil3+

(involves: C57BL/6 * C57BL/6N * CBA * SJL)
decreased double-positive T cell number J:227618
microgliosis J:227618
thymus atrophy J:227618
\Ctsdtm1.1Thre/\Ctsdtm1.1Thre
\Tg(Nes-cre)1Kln/0

(involves: C57BL/6 * C57BL/6N * SJL)
abnormal thymus morphology J:227618
decreased double-positive T cell number J:227618
microgliosis J:227618
\Ctsdtm1Cptr/\Ctsdtm1Cptr
(either: (involves: 129P2/OlaHsd * C57BL/6) or (involves: 129P2/OlaHsd))
abnormal antigen presentation J:47432
abnormal microglial cell morphology J:71688
abnormal spleen B cell follicle morphology J:28201
abnormal spleen white pulp morphology J:28201
decreased double-positive T cell number J:28201
decreased lymphocyte cell number J:28201
thymus hypoplasia J:28201
\CtseC57BL/6JOlaHsd/\CtseC57BL/6JOlaHsd
(involves: 129S2/SvPasHsd * C57BL/6JOlaHsd)
abnormal dendritic cell antigen presentation J:128538
abnormal dendritic cell physiology J:128538
abnormal immune system physiology J:128538
\Ctsetm1Kjy/\Ctse+
(involves: C57BL/6)
increased IgE level J:108745
\Ctsetm1Kjy/\Ctsetm1Kjy
(involves: C57BL/6)
dermatitis J:108745
increased circulating interleukin-1 beta level J:108745
increased circulating interleukin-18 level J:108745
increased double-positive T cell number J:108745
increased eosinophil cell number J:108745
increased IgE level J:108745
increased interleukin-4 secretion J:108745
increased interleukin-5 secretion J:108745
\Ctsgtm1.1Roes/\Ctsgtm1.1Roes
(involves: 129P2/OlaHsd)
decreased susceptibility to bacterial infection induced morbidity/mortality J:77597
increased susceptibility to infection induced morbidity/mortality J:77597
\Ctsgtm1.1Roes/\Ctsgtm1.1Roes
\Elanetm1(cre)Roes/\Elanetm1(cre)Roes

(involves: 129P2/OlaHsd)
decreased susceptibility to endotoxin shock J:77597
increased susceptibility to fungal infection J:77597
\Ctsgtm1Ley/\Ctsgtm1Ley
(either: (involves: 129X1/SvJ * C57BL/6) or (involves: 129X1/SvJ))
immune system phenotype J:59006
\Ctsgtm1Ley/\Ctsgtm1Ley
\Elanetm1Sds/\Elanetm1Sds

(involves: 129X1/SvJ)
immune system phenotype J:131496
\Ctsgtm1Ley/\Ctsgtm1Ley
\Elanetm1Sds/\Elanetm1Sds

(B6.129X1-Elanetm1Sds Ctsgtm1Ley)
immune system phenotype J:131520
\Ctsgtm2.1(PML/RARA)Ley/\Ctsg+
(involves: 129X1/SvJ * C57BL/6)
abnormal myelopoiesis J:84230, J:86458
enlarged spleen J:84230
increased leukocyte cell number J:84230
\Ctsgtm2.1(PML/RARA)Ley/\Ctsg+
(involves: 129 * 129X1/SvJ * C57BL/6)
abnormal spleen morphology J:166479
enlarged spleen J:166479
increased spleen weight J:166479
\Ctsgtm2.1(PML/RARA)Ley/\Ctsg+
\Elanetm1Sds/\Elanetm1Sds

(involves: 129S/SvEv * 129X1/SvJ * C57BL/6)
abnormal myelopoiesis J:86458
\Ctsgtm3.1(PML/RARA)Ley/\Ctsg+
(involves: 129 * C57BL/6)
abnormal spleen morphology J:166479
enlarged spleen J:166479
increased spleen weight J:166479
\Ctsktm1(cre)Ska/\Ctsk+
\Esr1tm1Mma/\Esr1tm1Mma

(involves: 129S2/SvPas * C57BL/6 * SJL)
abnormal osteoclast physiology J:127179
increased osteoclast cell number J:127179
\Ctsktm1(cre)Ska/\Ctsk+
\Plekhm1tm1.1Hzhao/\Plekhm1tm1.1Hzhao

(involves: C57BL/6J * C57BL/6NCrlj * CBA/JNCrlj)
abnormal osteoclast morphology J:236517
abnormal osteoclast physiology J:236517
\Ctsktm1(cre)Ska/\Ctsk+
\Snx10tm1c(EUCOMM)Raba/\Snx10tm1c(EUCOMM)Raba

(involves: 129S4/SvJae * C57BL/6 * C57BL/6J * C57BL/6NCrlj * CBA/JNCrlj)
abnormal osteoclast physiology J:224711
\Ctsktm1.1Rbar/\Ctsktm1.1Rbar
\Tg(Itgam-cre)AJva/0

(involves: C57BL/6)
increased osteoclast cell number J:194492
\Ctsktm1.1Rbar/\Ctsktm1.1Rbar
\Tg(Mx1-cre)1Cgn/0

(involves: C57BL/6 * CBA)
abnormal osteoclast differentiation J:194492
abnormal osteoclast physiology J:194492
increased osteoclast cell number J:194492
\Ctsktm1Mbs/\Ctsktm1Mbs
(B6.129-Ctsktm1Mbs)
abnormal osteoclast physiology J:128098
increased osteoclast cell number J:128098
\Ctsktm1Psa/\Ctsktm1Psa
(involves: 129X1/SvJ * C57BL/6J)
abnormal osteoclast physiology J:50934
\Ctsktm1Vuo/\Ctsktm1Vuo
(involves: 129S7/SvEvBrd * C57BL/6J)
abnormal osteoclast morphology J:95525
increased osteoclast cell number J:95525
\Ctsktm1Ypl/\Ctsktm1Ypl
(B6.129S4-Ctsktm1Ypl)
increased osteoclast cell number J:117870
\Ctsktm1Ypl/\Ctsktm1Ypl
(129S4/SvJae-Ctsktm1Ypl)
increased osteoclast cell number J:117870
\Ctslm1Btlr/\Ctslm1Btlr
(C57BL/6J-Ctslm1Btlr)
abnormal CD4-positive T cell differentiation J:272869
abnormal CD8-positive, alpha beta T cell morphology J:272869
abnormal CD8-positive, alpha-beta T cell differentiation J:272869
abnormal T cell differentiation J:272869
decreased alpha-beta T cell number J:272869
decreased CD4-positive, alpha-beta T cell number J:272869
increased alpha-beta T cell number J:272869
increased CD8-positive, alpha-beta T cell number J:272869
increased central memory CD4-positive, alpha-beta T cell number J:272869
increased central memory CD8 positive, alpha-beta T cell number J:272869
increased effector memory CD4-positive, alpha-beta T cell number J:272869
\Ctslnkt/\Ctslnkt
(either: (involves: 129S2/SvPas * BALB/c) or (involves: 129S2/SvPas * C57BL/6) or (involves: 129S2/SvPas * DBA/2))
abnormal immune system organ morphology J:54856
decreased CD4-positive, alpha-beta T cell number J:54856
dermatitis J:54856
increased inflammatory response J:54856
liver inflammation J:54856
lymph node hyperplasia J:54856
lymph node inflammation J:54856
thymus atrophy J:54856
\Ctslnkt/\Ctslnkt
(B6.Cg-Ctslnkt)
dermatitis J:78460
enlarged lymph nodes J:78460
\Ctslnkt/\Ctslnkt
(C.Cg-Ctslnkt)
abnormal immune system organ morphology J:78460
abnormal leukocyte cell number J:99009
abnormal lymph node cortex morphology J:99009
abnormal lymph node morphology J:99009
abnormal thymus corticomedullary boundary morphology J:99009
abnormal thymus lobule morphology J:99009
abnormal thymus morphology J:99009
decreased CD4-positive, alpha-beta T cell number J:99009
dermatitis J:78460
dilated lymph node medullary sinus J:99009
enlarged lymph nodes J:78460, J:99009
enlarged thymus cortex J:99009
increased CD8-positive, alpha-beta T cell number J:99009
\Ctsltm1.2Thre/\Ctsltm1.2Thre
(involves: C57BL/6 * C57BL/6N)
decreased CD4-positive, alpha-beta T cell number J:216506
\Ctsltm1Alpk/\Ctsltm1Alpk
(involves: 129P2/OlaHsd * C57BL/6)
abnormal osteoclast physiology J:99755
decreased osteoclast cell number J:99755
dermatitis J:99755
folliculitis J:99755
granulomatous inflammation J:99755
\Ctsltm1Alpk/\Ctsltm1Alpk
(B6.129P2-Ctsltm1Alpk)
granulomatous inflammation J:99755
\Ctsltm1Cptr/\Ctsl+
(NOD.129P2-Ctsltm1Cptr)
decreased susceptibility to autoimmune diabetes J:153355
insulitis J:153355
\Ctsltm1Cptr/\Ctsltm1Cptr
(involves: 129P2/OlaHsd * C57BL/6J)
increased regulatory T cell number J:153355
\Ctsltm1Cptr/\Ctsltm1Cptr
(NOD.129P2-Ctsltm1Cptr)
decreased CD4-positive, alpha-beta T cell number J:153355
decreased susceptibility to autoimmune diabetes J:153355
increased regulatory T cell number J:153355
salivary gland inflammation J:153355
\Ctsltm1Cptr/\Ctsltm1Cptr
(involves: 129P2/OlaHsd)
decreased CD4-positive, alpha-beta T cell number J:216506
\Ctsmtm1(KOMP)Wtsi/\Ctsmtm1(KOMP)Wtsi
(C57BL/6N-Ctsmtm1(KOMP)Wtsi/Nju)
increased monocyte cell number J:211773
\Ctssem1(IMPC)H/\Ctssem1(IMPC)H
(C57BL/6NTac-Ctssem1(IMPC)H/H)
decreased spleen weight J:211773
\Ctssm1Btlr/\Ctssm1Btlr
(C57BL/6J-Ctssm1Btlr)
decreased IgG level J:267491
impaired humoral immune response J:267491
\Ctsstm1Eae/\Ctss+
(NOD.D1-Ctsstm1Eae)
insulitis J:153355
\Ctsstm1Eae/\Ctsstm1Eae
(involves: C57BL/6 * DBA/1LacJ)
abnormal B lymphocyte antigen presentation J:53399
decreased susceptibility to induced arthritis J:53399
\Ctsstm1Eae/\Ctsstm1Eae
(NOD.D1-Ctsstm1Eae)
decreased susceptibility to autoimmune diabetes J:153355
insulitis J:153355
salivary gland inflammation J:153355
\Ctsstm1Hap/\Ctsstm1Hap
(B6.129S2-Ctsstm1Hap)
abnormal B cell physiology J:96401
abnormal cytokine secretion J:96401
abnormal humoral immune response J:96401
abnormal interleukin secretion J:96401
abnormal professional antigen presenting cell physiology J:96401
abnormal T cell physiology J:96401
decreased IgG level J:96401
decreased IgM level J:96401
decreased susceptibility to experimental autoimmune myasthenia gravis J:96401
\Ctsstm1Hap/\Ctsstm1Hap
\Ldlrtm1Her/\Ldlrtm1Her

(B6.129S-Ctsstm1Hap Ldlrtm1Her)
abnormal leukocyte migration J:82520
\Ctsstm1Hap/\Ctsstm1Hap
\Tg(Scgb1a1-rtTA,tetO-Ifng)14Eli/0

(involves: 129S2/SvPas * C57BL/6 * CBA)
increased lymphocyte cell number J:100854
increased macrophage cell number J:100854
increased neutrophil cell number J:100854
\Ctswtm1Ctnp/\Ctswtm1Ctnp
(involves: 129X1/SvJ * C57BL/6)
immune system phenotype J:91265
\Cttntm1.2Dvst/\Cttntm1.2Dvst
(either: B6.Cg-Cttntm1.2Dvst or (involves: 129S6/SvEvTac * C57BL/6 * C57BL/6J * DBA/2 * SJL))
abnormal cellular extravasation J:177602
abnormal leukocyte adhesion J:177602
abnormal leukocyte migration J:177602
abnormal neutrophil physiology J:177602
\Cttnbp2tm1b(KOMP)Wtsi/\Cttnbp2tm1b(KOMP)Wtsi
(C57BL/6N-Cttnbp2tm1b(KOMP)Wtsi/Wtsi)
decreased transitional stage T1 B cell number J:211773
increased memory CD4-positive, CD25-positive, alpha-beta regulatory T cell number J:211773
increased plasma cell number J:211773
\Ctu2tm1(KOMP)Wtsi/\Ctu2+
(C57BL/6N-Ctu2tm1(KOMP)Wtsi/Nju)
increased basophil cell number J:211773
increased eosinophil cell number J:211773
\Cuedc2tm1Qxia/\Cuedc2tm1Qxia
(involves: 129S6/SvEvTac * C57BL/6 * C57BL/6NTac)
abnormal macrophage physiology J:211782
increased macrophage cytokine production J:211782
increased susceptibility to induced colitis J:211782
\Cul4a/Pcid2tm2Ktc/\Cul4a/Pcid2tm2Ktc
\Tg(Mx1-cre)1Cgn/0

(involves: 129S/SvEv * C57BL/6 * CBA * FVB/N)
abnormal leukocyte morphology J:138468
abnormal spleen capsule morphology J:138468
abnormal spleen morphology J:138468
decreased lymphocyte cell number J:138468
decreased monocyte cell number J:138468
decreased neutrophil cell number J:138468
decreased spleen red pulp amount J:138468
decreased spleen weight J:138468
decreased spleen white pulp amount J:138468
small thymus J:138468
spleen hypoplasia J:138468
\Cul4a/Pcid2tm2Ktc/\Cul4a/Pcid2tm2Ktc
\Tg(Mx1-cre)1Cgn/0

(involves: 129S/SvEv * C57BL/6 * CBA * FVB/N)
abnormal leukocyte morphology J:138468
abnormal spleen capsule morphology J:138468
abnormal spleen morphology J:138468
decreased lymphocyte cell number J:138468
decreased monocyte cell number J:138468
decreased neutrophil cell number J:138468
decreased spleen red pulp amount J:138468
decreased spleen weight J:138468
decreased spleen white pulp amount J:138468
small thymus J:138468
spleen hypoplasia J:138468
\Cul4atm1b(EUCOMM)Hmgu/\Cul4atm1b(EUCOMM)Hmgu
(C57BL/6N-Cul4atm1b(EUCOMM)Hmgu/Ccpcz)
decreased spleen weight J:211773
\Cul5tm1.1(KOMP)Vlcg/\Cul5+
(involves: C57BL/6NTac)
decreased interleukin-1 alpha secretion J:244502
decreased interleukin-6 secretion J:244502
decreased tumor necrosis factor secretion J:244502
\Cul5tm1.1(KOMP)Vlcg/\Cul5+
(C57BL/6N-Cul5tm1.1(KOMP)Vlcg/Ucd)
abnormal spleen morphology J:211773
enlarged spleen J:211773
increased spleen weight J:211773
\Cul9em1(IMPC)Ccpcz/\Cul9em1(IMPC)Ccpcz
(C57BL/6N-Cul9em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged spleen J:211773
enlarged thymus J:211773
\Cux1tm1Rhsc/\Cux1tm1Rhsc
(involves: 129S1/Sv * C57BL/6J)
abnormal myelopoiesis J:100055
abnormal T cell differentiation J:100055
abnormal tumor necrosis factor level J:100055
decreased B cell number J:100055
decreased double-positive T cell number J:100055
decreased thymocyte number J:100055
small thymus J:100055
thymus cortex hypoplasia J:100055
thymus hypoplasia J:100055
\Cux1tm2Ejn/\Cux1tm2Ejn
(involves: 129S4/SvJae * C57BL/6)
increased susceptibility to bacterial infection J:74660
rhinitis J:74660
\Cuzd1tm1Ljm/\Cuzd1tm1Ljm
(involves: 129S6/SvEvTac * Black Swiss)
increased susceptibility to induced pancreatitis J:80980
\Cwc22em1(IMPC)Mbp/\Cwc22+
(C57BL/6NCrl-Cwc22em1(IMPC)Mbp/Mmucd)
abnormal spleen morphology J:211773
\Cwc27tm1Lex/\Cwc27tm1Lex
(B6;129S5-Cwc27tm1Lex/Mmucd)
abnormal immune system physiology J:171883
\Cx3cl1tm1.1Yono/\Cx3cl1tm1.1Yono
(involves: C57BL/6J)
abnormal dendritic cell physiology J:271242
decreased inflammatory response J:271242
\Cx3cl1tm1Lira/\Cx3cl1tm1Lira
(involves: 129S/SvEv * C57BL/6)
immune system phenotype J:68831
\Cx3cl1tm1Lira/\Cx3cl1tm1Lira
(involves: C57BL/6)
decreased monocyte cell number J:145036
\Cx3cl1tm1Sgs/\Cx3cl1tm1Sgs
\Ldlrtm1Her/\Ldlrtm1Her

(involves: B6.129S4-Cx3cl1tm1Sgs * B6.129S7-Ldlrtm1Her/J)
impaired macrophage chemotaxis J:95279
\Cx3cr1tm1Ifc/\Cx3cr1tm1Ifc
(involves: 129S4/SvJae * C57BL/6)
abnormal NK cell physiology J:82033
abnormal response to transplant J:82033
immune system phenotype J:82033
impaired macrophage chemotaxis J:82033
\Cx3cr1tm1Litt/\Cx3cr1+
(B6.129P2-Cx3cr1tm1Litt)
increased susceptibility to experimental autoimmune encephalomyelitis J:129712
microgliosis J:110266
\Cx3cr1tm1Litt/\Cx3cr1+
\Psen1tm1Mpm/\Psen1tm1Mpm
\Tg(APPSwe,tauP301L)1Lfa/0
\Tg(Thy1-YFP)HJrs/0

(involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA)
abnormal microglial cell morphology J:159680
abnormal microglial cell physiology J:159680
\Cx3cr1tm1Litt/\Cx3cr1tm1Litt
(involves: 129P2/OlaHsd * C57BL/6)
abnormal leukocyte physiology J:162714
decreased monocyte cell number J:145036
immune system phenotype J:84544
impaired macrophage chemotaxis J:162714
\Cx3cr1tm1Litt/\Cx3cr1tm1Litt
(C.129P2-Cx3cr1tm1Litt)
immune system phenotype J:84544
\Cx3cr1tm1Litt/\Cx3cr1tm1Litt
(involves: 129P2/OlaHsd)
abnormal dendritic cell physiology J:271242, J:95694
decreased inflammatory response J:271242
increased dendritic cell number J:210086
increased susceptibility to bacterial infection induced morbidity/mortality J:95694
\Cx3cr1tm1Litt/\Cx3cr1tm1Litt
(B6.129P2-Cx3cr1tm1Litt)
abnormal leukocyte physiology J:124722
abnormal microglial cell morphology J:265696
abnormal microglial cell physiology J:110266, J:265696
abnormal NK cell physiology J:129712
brain inflammation J:129712
decreased NK cell number J:129712
immune system phenotype J:129712
increased susceptibility to experimental autoimmune encephalomyelitis J:129712
microgliosis J:110266
\Cx3cr1tm1Litt/\Cx3cr1tm1Litt
\H2-Ab1b-tm1Hpl/\H2-Ab1+

(involves: 129P2/OlaHsd * 129S4/SvJae)
abnormal response to infection J:95694
\Cx3cr1tm1Zm/\Cx3cr1tm1Zm
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
abnormal splenocyte physiology J:103047
\Cx3cr1tm2.1(cre/ERT2)Litt/\Cx3cr1+
\Vps35Gt(RRK261)Byg/\Vps35Gt(RRK261)Byg

(involves: 129P2/OlaHsd * C57BL/6)
decreased interleukin-1 beta secretion J:292365
decreased interleukin-6 secretion J:292365
decreased tumor necrosis factor secretion J:292365
increased interleukin-4 secretion J:292365
increased interleukin-10 secretion J:292365
increased macrophage cell number J:292365
microgliosis J:292365
\Cx3cr1tm3(Hbegf)Litt/\Cx3cr1tm3(Hbegf)Litt
\Tg(Itgax-cre)1-1Reiz/?

(involves: 129P2/OlaHsd * C57BL/6 * CBA)
decreased susceptibility to bacterial infection J:210086
\Cxadrem1(IMPC)Mbp/\Cxadr+
(C57BL/6N-Cxadrem1(IMPC)Mbp/MbpMmucd)
abnormal spleen morphology J:211773
small spleen J:211773
\Cxadrtm1.1Ics/\Cxadrtm1.1Ics
\Tg(CAG-cre/Esr1*)5Amc/0

(involves: 129S2/SvPas * C57BL/6 * C57BL/6J * CBA)
enlarged thymus J:174138
increased thymocyte number J:174138
\Cxcl1em1(IMPC)Mbp/\Cxcl1em1(IMPC)Mbp
(C57BL/6N-Cxcl1em1(IMPC)Mbp/MbpMmucd)
abnormal lymph node morphology J:211773
enlarged lymph nodes J:211773
increased monocyte cell number J:211773
\Cxcl5tm1.1Mkch/\Cxcl5tm1.1Mkch
(B6.129P2-Cxcl5tm1.1Mkch)
decreased interferon-alpha secretion J:208901
decreased interleukin-1 alpha secretion J:208901
decreased interleukin-6 secretion J:208901
decreased neutrophil cell number J:208901
decreased susceptibility to bacterial infection J:208901
decreased susceptibility to bacterial infection induced morbidity/mortality J:208901
decreased tumor necrosis factor secretion J:208901
immune system phenotype J:208901
\Cxcl5tm1Gscw/\Cxcl5tm1Gscw
(involves: 129)
abnormal circulating chemokine level J:162629
abnormal neutrophil physiology J:162629
decreased circulating interleukin-6 level J:162629
decreased susceptibility to bacterial infection J:162629
decreased susceptibility to bacterial infection induced morbidity/mortality J:162629
decreased susceptibility to endotoxin shock J:162629
increased granulocyte number J:162629
\Cxcl5tm1Gscw/\Cxcl5tm1Gscw
\Ackr1tm1Scp/\Ackr1tm1Scp

(involves: 129/Sv * 129P2/OlaHsd * C57BL/6)
abnormal circulating chemokine level J:162629
\Cxcl9tm1b(EUCOMM)Wtsi/\Cxcl9tm1b(EUCOMM)Wtsi
(C57BL/6N-Cxcl9tm1b(EUCOMM)Wtsi/H)
decreased neutrophil cell number J:211773
increased lymphocyte cell number J:211773
\Cxcl9tm1Jmf/\Cxcl9tm1Jmf
(either: B6.129S4-Cxcl9tm1Jmf or (involves: 129S4/SvJae * C57BL/6))
decreased IgG level J:121818
decreased immunoglobulin level J:121818
immune system phenotype J:121818
\Cxcl9tm1Jmf/\Cxcl9tm1Jmf
(B6.129S4-Cxcl9tm1Jmf)
abnormal cytokine secretion J:120743
decreased inflammatory response J:120743
\Cxcl10tm1Adl/\Cxcl10tm1Adl
(involves: 129S4/SvJae * 129X1/SvJ)
decreased IgG2a level J:75584
decreased interferon-gamma secretion J:75584
decreased splenocyte proliferation J:75584
decreased susceptibility to type IV hypersensitivity reaction J:75584
\Cxcl10tm1Adl/\Cxcl10tm1Adl
(involves: 129S4/SvJae * C57BL/6)
abnormal interferon level J:75584
abnormal T cell physiology J:75584
decreased CD8-positive, alpha-beta T cell number J:75584
increased susceptibility to Hepadnaviridae infection J:75584
\Cxcl10tm1Adl/\Cxcl10tm1Adl
(B6.129S4-Cxcl10tm1Adl)
abnormal cytokine secretion J:120743
CNS inflammation J:87076
increased susceptibility to experimental autoimmune encephalomyelitis J:87076
increased susceptibility to Herpesvirales infection J:120743
\Cxcl11em1Groj/\Cxcl11em1Groj
(C57BL/6J-Cxcl11em1Groj)
abnormal B cell morphology J:345391
immune system phenotype J:345391
increased CD8-positive, alpha-beta T cell number J:345391
\Cxcl12tm1.1Sjm/\Cxcl12tm1.1Sjm
\Ndor1Tg(UBC-cre/ERT2)1Ejb/?

(involves: 129S/SvEv * C57BL/6)
decreased leukocyte cell number J:194748
decreased lymphocyte cell number J:194748
\Cxcl12tm1.1Sjm/\Cxcl12tm1.1Sjm
\Tg(Prrx1-cre)1Cjt/?

(involves: C57BL/6 * SJL/J)
abnormal B cell differentiation J:194748
\Cxcl12tm1.1Ystz/\Cxcl12tm1.2Ystz
\Tg(CAG-cre/Esr1*)5Amc/0

(involves: 129X1/SvJ * C57BL/6 * CBA * FVB/N)
decreased pro-B cell number J:168434
increased neutrophil cell number J:168434
\Cxcl12tm1Tng/\Cxcl12tm1.1Link
\Tg(BGLAP-cre)1Clem/0

(involves: 129P2/OlaHsd * C57BL/6J * C57BL/6NTac * FVB/N)
decreased B cell number J:193594
\Cxcl12tm1Tng/\Cxcl12tm1.1Link
\Tg(Prrx1-cre)1Cjt/0

(involves: 129P2/OlaHsd * C57BL/6 * FVB/N * SJL/J)
decreased B cell number J:193594
decreased pre-pro B cell number J:193594
\Cxcl12tm1Tng/\Cxcl12tm1.1Link
\Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0

(involves: 129P2/OlaHsd * C57BL/6 * CD-1 * FVB/N)
decreased B cell number J:193594
decreased pre-pro B cell number J:193594
\Cxcl12tm1Tng/\Cxcl12tm1Tng
(involves: 129P2/OlaHsd)
decreased pre-B cell number J:34750
decreased pro-B cell number J:34750
impaired myelopoiesis J:49070
\Cxcl12tm3.1(HBEGF/EGFP)Tng/\Cxcl12+
(B6.Cg-Cxcl12tm3.1(HBEGF/EGFP)Tng)
decreased pro-B cell number J:164657
increased B cell apoptosis J:164657
\Cxcl13em2(IMPC)H/\Cxcl13em2(IMPC)H
(C57BL/6NTac-Cxcl13em2(IMPC)H/H)
increased basophil cell number J:211773
increased leukocyte cell number J:211773
increased lymphocyte cell number J:211773
\Cxcl13m1Btlr/\Cxcl13m1Btlr
(C57BL/6J-Cxcl13m1Btlr)
increased B-1 B cell number J:221480
\Cxcl13tm1Cys/\Cxcl13tm1Cys
(involves: 129X1/SvJ * C57BL/6)
abnormal B cell physiology J:78282
abnormal lymph node germinal center morphology J:78282
abnormal Peyer's patch morphology J:78282
abnormal spleen B cell follicle morphology J:78282
abnormal spleen marginal zone morphology J:78282
absent axillary lymph nodes J:78282
absent brachial lymph nodes J:78282
absent follicular dendritic cells J:78282
absent inguinal lymph nodes J:78282
decreased lymph node number J:78282
decreased Peyer's patch number J:78282
decreased spleen germinal center size J:78282
small Peyer's patches J:78282
\Cxcl13tm1Cys/\Cxcl13tm1Cys
(B6.129X1-Cxcl13tm1Cys)
impaired B cell migration J:118931
\Cxcl13tm1Mmi/\Cxcl13tm1Mmi
(involves: C57BL/6)
abnormal B cell physiology J:84804
abnormal leukocyte adhesion J:84804
abnormal leukocyte migration J:84804
\Cxcl14tm1Bmsr/\Cxcl14tm1Bmsr
(involves: 129/Sv * C57BL/6)
immune system phenotype J:118303
\Cxcl14tm1Tha/\Cxcl14tm1Tha
(involves: C57BL/6 * CBA)
decreased macrophage cell number J:126841
\Cxcl15tm1Lira/\Cxcl15tm1Lira
(involves: 129 * C57BL/6J)
decreased neutrophil cell number J:67605
immune system phenotype J:67605
increased susceptibility to bacterial infection J:67605
\Cxcl16tm1Syon/\Cxcl16tm1Syon
(B6.129P2-Cxcl16tm1Syon)
decreased circulating interferon-gamma level J:155199
decreased circulating interleukin-4 level J:155199
decreased interferon-gamma secretion J:155199
decreased interleukin-4 secretion J:155199
decreased NK T cell number J:155199
decreased susceptibility to bacterial infection J:155199
\Cxcr2tm1(IL8RB)Dktr/\Cxcr2tm1(IL8RB)Dktr
(involves: 129S2/SvPas * C57BL/6)
decreased spleen weight J:113489
immune system phenotype J:113489
increased granulocyte number J:113489
increased leukocyte cell number J:113489
\Cxcr2tm1a(EUCOMM)Wtsi/\Cxcr2tm1a(EUCOMM)Wtsi
(C57BL/6N-Cxcr2tm1a(EUCOMM)Wtsi/Wtsi)
decreased B cell number J:211773
decreased CD8-positive, alpha-beta T cell number J:211773
decreased immature B cell number J:211773
decreased mature B cell number J:211773
decreased pre-B cell number J:211773
decreased pre-pro B cell number J:211773
decreased T cell number J:211773
increased anti-nuclear antigen antibody level J:211773
increased CD4-positive, alpha-beta memory T cell number J:211773
increased CD8-positive, alpha-beta memory T cell number J:211773
increased CD103-positive CD11b-low dendritic cell number J:211773
increased effector memory CD8-positive, alpha-beta T cell number J:211773
increased effector memory T-helper cell number J:211773
increased eosinophil cell number J:211773
increased gamma-delta T cell number J:211773
increased granulocyte number J:211773
increased KLRG1+ CD4 alpha-beta T cell number J:211773
increased KLRG1+ CD8 alpha-beta T cell number J:211773
increased leukocyte cell number J:211773
increased Ly6C high monocyte number J:211773
increased Ly6C low monocyte number J:211773
increased memory-marker CD4-positive NK T cell number J:211773
increased memory-marker gamma-delta T cell number J:211773
increased memory-marker NK cell number J:211773
increased monocyte cell number J:211773
increased neutrophil cell number J:211773
\Cxcr2tm1Mwm/\Cxcr2+
(C.129S2(B6)-Cxcr2tm1Mwm/J)
impaired neutrophil recruitment J:63935
\Cxcr2tm1Mwm/\Cxcr2tm1Mwm
(involves: 129S2/SvPas * C57BL/6J)
abnormal granulocyte differentiation J:19570
abnormal myelopoiesis J:19570
abnormal spleen white pulp morphology J:19570
enlarged cervical lymph nodes J:19570
enlarged lymph nodes J:19570
enlarged spleen J:19570
impaired neutrophil chemotaxis J:19570
increased B cell number J:19570
increased circulating interleukin-6 level J:19570
increased neutrophil cell number J:19570
lymph node medullary cord hyperplasia J:19570
myeloid hyperplasia J:19570
\Cxcr2tm1Mwm/\Cxcr2tm1Mwm
(C.129S2(B6)-Cxcr2tm1Mwm/J)
abnormal chemokine level J:73947
abnormal cytokine secretion J:72824
abnormal eosinophil physiology J:73947
abnormal interleukin level J:73947, J:87365
abnormal leukocyte physiology J:94170
abnormal neutrophil physiology J:93946, J:73947
abnormal NK T cell physiology J:66399
abnormal T cell physiology J:73947
abnormal T-helper 1 physiology J:73947
abnormal T-helper 2 physiology J:73947
decreased susceptibility to fungal infection J:73947
decreased susceptibility to induced arthritis J:142880
impaired neutrophil chemotaxis J:65905, J:72824
impaired neutrophil recruitment J:65425, J:63935, J:93116
increased IgE level J:73947
increased susceptibility to bacterial infection J:65905
increased susceptibility to Herpesvirales infection J:87365
increased susceptibility to parasitic infection J:72824
\Cxcr2tm1Mwm/\Cxcr2tm1Mwm
(involves: 129S2/SvPas * BALB/c)
abnormal myelopoiesis J:113489
abnormal neutrophil physiology J:113489
decreased thymus weight J:113489
increased granulocyte number J:113489
increased spleen weight J:113489
\Cxcr2tm1Mwm/\Cxcr2tm1Mwm
(involves: 129S2/SvPas)
decreased susceptibility to bacterial infection induced morbidity/mortality J:208901
\Cxcr2tm1Rmra/\Cxcr2tm1Rmra
\Tg(Mx1-cre)1Cgn/0

(involves: 129S/SvEv * C57BL/6 * C57BL/6NTac * CBA)
abnormal neutrophil physiology J:204482
\Cxcr3tm1Raks/\Cxcr3tm1Raks
(B6.129P2-Cxcr3tm1Raks)
kidney inflammation J:152790
\Cxcr3tm1Wwh/Y
(B6.Cg-Cxcr3tm1Wwh)
abnormal cellular extravasation J:107646
abnormal interferon level J:91359
impaired macrophage chemotaxis J:107646
increased length of allograft survival J:65916
lung inflammation J:91359
\Cxcr3tm1Wwh/\Cxcr3tm1Wwh
(B6.Cg-Cxcr3tm1Wwh)
abnormal cellular extravasation J:96905, J:107646
abnormal interferon level J:91359
decreased susceptibility to Riboviria infection J:96905
decreased susceptibility to Riboviria infection induced morbidity/mortality J:96905
impaired macrophage chemotaxis J:107646
increased length of allograft survival J:65916
lung inflammation J:91359
\Cxcr4em1(IMPC)Mbp/\Cxcr4+
(C57BL/6NCrl-Cxcr4em1(IMPC)Mbp/MbpMmucd)
increased leukocyte cell number J:211773
increased lymphocyte cell number J:211773
increased monocyte cell number J:211773
\Cxcr4tm1.1Bala/\Cxcr4+
(B6.129S2-Cxcr4tm1.1Bala)
abnormal CD4-positive, alpha-beta T cell number J:186735
abnormal immune system cell morphology J:186735
abnormal immune system morphology J:186735
abnormal immune system organ morphology J:186735
abnormal immune system physiology J:186735
abnormal lymph node B cell domain morphology J:186735
abnormal lymph node morphology J:186735
abnormal neutrophil morphology J:186735
abnormal NK cell physiology J:178789
abnormal spleen morphology J:186735
abnormal spleen white pulp morphology J:186735
abnormal thymus morphology J:186735
decreased B cell apoptosis J:186735
decreased B cell number J:186735
decreased immature B cell number J:186735
decreased leukocyte cell number J:186735
decreased NK cell number J:178789
decreased spleen weight J:186735
decreased T cell number J:186735
increased IgG level J:186735
increased IgM level J:186735
increased immunoglobulin level J:186735
increased mature B cell number J:186735
increased NK cell number J:178789
\Cxcr4tm1Qma/\Cxcr4tm1Qma
(involves: 129X1/SvJ)
decreased pro-B cell number J:49070
impaired myelopoiesis J:49070
\Cxcr4tm1Qma/\Cxcr4tm1Qma
(involves: 129X1/SvJ * C57BL/6)
decreased susceptibility to Retroviridae infection J:132342
increased susceptibility to Retroviridae infection induced morbidity/mortality J:132342
\Cxcr4tm1Tng/\Cxcr4tm1Tng
(involves: 129P2/OlaHsd)
abnormal B cell differentiation J:69256
failure of myelopoiesis J:69256
\Cxcr4tm1Tng/\Cxcr4tm1Tng
(B6.Cg-Cxcr4tm1Tng)
abnormal T cell differentiation J:82996
decreased double-positive T cell number J:82996
\Cxcr4tm1Yiw/\Cxcr4tm1Yiw
\Tg(Lck-cre)1Jtak/0

(involves: 129P2/OlaHsd)
abnormal leukocyte migration J:164872
decreased susceptibility to induced arthritis J:164872
decreased thymocyte number J:164872
\Cxcr4tm1Yzo/\Cxcr4tm1Yzo
(Not Specified)
abnormal B cell differentiation J:167314
abnormal B cell physiology J:167314
abnormal leukopoiesis J:69255
abnormal lymphopoiesis J:69255
impaired myelopoiesis J:69255
\Cxcr4tm2Yzo/\Cxcr4tm2Yzo
\Cd19tm1(cre)Cgn/\Cd19+

(involves: 129P2/OlaHsd)
abnormal B cell differentiation J:94911
abnormal Peyer's patch follicle morphology J:94911
decreased B-1 B cell number J:94911
decreased B-2 B cell number J:94911
decreased immunoglobulin level J:94911
decreased mature B cell number J:94911
decreased plasma cell number J:94911
\Cxcr4tm2Yzo/\Cxcr4tm2Yzo
\Lyz2tm1(cre)Ifo/\Lyz2+

(involves: 129P2/OlaHsd * C57BL/6)
increased lymphocyte cell number J:217569
increased monocyte cell number J:217569
increased neutrophil cell number J:217569
\Cxcr4tm2Yzo/\Cxcr4tm2Yzo
\Tg(Fabp4-cre)1Rev/0

(involves: 129P2/OlaHsd * C57BL/6)
abnormal macrophage cell number J:217569
decreased B cell number J:217569
decreased CD4-positive, alpha-beta T cell number J:217569
increased CD8-positive, alpha-beta T cell number J:217569
\Cxcr4tm2Yzo/\Cxcr4tm3.1Yzo
\Cd19tm1(cre)Cgn/\Cd19+

(involves: 129P2/OlaHsd)
abnormal B cell differentiation J:167314
\Cxcr4tm3.1Yzo/\Cxcr4tm3.1Yzo
(Not Specified)
abnormal B cell physiology J:167314
decreased pro-B cell number J:167314
impaired myelopoiesis J:167314
\Cxcr5tm1.1Namt/\Cxcr5tm1.1Namt
\Tg(Itgax-cre)1-1Reiz/0

(involves: C57BL/6 * C57BL/6J * CBA)
abnormal dendritic cell chemotaxis J:241561
decreased follicular dendritic cell number J:241561
decreased susceptibility to prion infection J:241561
immune system phenotype J:241561
\Cxcr5tm1.1Namt/\Cxcr5tm1.1Namt
\Tg(Itgax-cre)1-1Reiz/0
\Tg(Prnp)a20Cwe/0

(involves: C57BL/6 * C57BL/6J * CBA)
decreased susceptibility to prion infection J:241561
\Cxcr5tm1Lipp/\Cxcr5tm1Lipp
(involves: 129S2/SvPas * CD-1)
abnormal leukocyte migration J:37126
abnormal Peyer's patch morphology J:37126
abnormal spleen primary B follicle morphology J:37126
abnormal spleen secondary B follicle morphology J:37126
absent axillary lymph nodes J:78282
absent brachial lymph nodes J:78282
absent cervical lymph nodes J:78282
absent follicular dendritic cells J:78282
absent inguinal lymph nodes J:78282, J:37126
absent lymph nodes J:78282
absent Peyer's patches J:37126
absent spleen germinal center J:37126
increased B cell number J:37126
\Cxv1F/St/\Cxv1F/St
(involves: AKR/J * F/St)
abnormal immune cell physiology J:7030
\Cxv2DBA/2J/?
(involves: C57BL/6J * DBA/2J)
abnormal immune cell physiology J:6143
\Cyb5d1tm1.1(KOMP)Vlcg/\Cyb5d1tm1.1(KOMP)Vlcg
(B6N(Cg)-Cyb5d1tm1.1(KOMP)Vlcg/J)
increased leukocyte cell number J:211773
\Cyb5r3tm1c(KOMP)Wtsi/\Cyb5r3tm1c(KOMP)Wtsi
\Tg(Myh11-icre/ERT2)1Soff/0

(B6.Cg-Cyb5r3tm1c(KOMP)Wtsi Tg(Myh11-icre/ERT2)1Soff)
decreased monocyte cell number J:280543
\Cyb561d2tm1b(EUCOMM)Wtsi/\Cyb561d2tm1b(EUCOMM)Wtsi
(C57BL/6N-Cyb561d2tm1b(EUCOMM)Wtsi/Bay)
abnormal spleen morphology J:211773
\Cybanmf333/\Cybanmf333
(A.B6 Tyr+-Cybanmf333/J)
abnormal neutrophil physiology J:132359
increased inflammatory response J:132359
increased susceptibility to bacterial infection J:132359
lung inflammation J:132359
sepsis J:132359
\Cybatm1a(EUCOMM)Wtsi/\Cybatm1a(EUCOMM)Wtsi
(C57BL/6N-Cybatm1a(EUCOMM)Wtsi/Wtsi)
increased leukocyte cell number J:211773
\Cybatm1Dgh/\Cybatm1Dgh
(B6.Cg-Cybatm1Dgh)
abnormal T cell activation J:231269
decreased inflammatory response J:231269
\Cybbtm1.1Abk/\Cybbtm1.1Abk
\Lyz2tm1(cre)Ifo/?

(B6.Cg-Lyz2tm1(cre)Ifo Cybbtm1.1Abk)
abnormal macrophage chemotaxis J:245699
enlarged spleen J:245699
\Cybbtm1Din/Y
(involves: 129S/SvEv * C57BL/6)
abnormal immune system physiology J:22868
abnormal macrophage physiology J:22868
abnormal neutrophil physiology J:22868
increased inflammatory response J:22868
increased susceptibility to bacterial infection J:22868
increased susceptibility to infection J:22868
\Cybbtm1Din/\Cybbtm1Din
(involves: 129S/SvEv * C57BL/6)
immune system phenotype J:64232
\Cybbtm1Din/\Cybbtm1Din
(B6.129S-Cybbtm1Din)
granulomatous inflammation J:146231
immune system phenotype J:113463
increased acute inflammation J:110181
\Cybbtm1Din/\Cybbtm1Din
(B6.129S-Cybbtm1Din/J)
abnormal circulating chemokine level J:235399
abnormal macrophage physiology J:235399
decreased circulating interleukin-10 level J:235399
glomerulonephritis J:235399
increased anti-double stranded DNA antibody level J:235399
increased anti-nuclear antigen antibody level J:235399
increased autoantibody level J:235399
increased circulating interleukin-1 beta level J:235399
increased circulating interleukin-6 level J:235399
increased circulating interleukin-12b level J:235399
increased IgG level J:235399
increased lymphocyte cell number J:235399
increased monocyte cell number J:235399
increased neutrophil cell number J:235399
increased susceptibility to systemic lupus erythematosus J:235399
\Cybbtm1Din/\Cybbtm1Din
\Nrrostm1Lex/\Nrrostm1Lex

(B6.129S-Nrrostm1Lex Cybbtm1Din)
immune system phenotype J:209569
\Cybbtm2b(KOMP)Wtsi/\Cybbtm2b(KOMP)Wtsi
(C57BL/6N-Cybbtm2b(KOMP)Wtsi/H)
increased spleen weight J:211773
\Cycstm1Mak/\Cycstm1Mak
(involves: C57BL/6)
absent pre-B cells J:98949
decreased B cell number J:98949
decreased leukocyte cell number J:98949
decreased T cell number J:98949
increased spleen weight J:98949
spleen hyperplasia J:98949
thymus atrophy J:98949
thymus hypoplasia J:98949
\Cyldtm1.1Awai/\Cyldtm1.1Awai
(Not Specified)
abnormal B cell differentiation J:126113
abnormal B cell morphology J:126113
abnormal B cell physiology J:126113
abnormal class switch recombination J:126113
abnormal humoral immune response J:126113
abnormal Peyer's patch germinal center morphology J:126113
abnormal spleen marginal zone morphology J:126113
abnormal spleen morphology J:126113
decreased B-1 B cell number J:126113
decreased IgG3 level J:126113
decreased IgM level J:126113
decreased immature B cell number J:126113
enlarged lymph nodes J:126113
enlarged Peyer's patches J:126113
enlarged spleen J:126113
increased B cell number J:126113
increased follicular B cell number J:126113
increased IgA level J:126113
increased IgG1 level J:126113
increased IgG2a level J:126113
increased IgG2b level J:126113
increased marginal zone B cell number J:126113
increased pro-B cell number J:126113
\Cyldtm1.1Mpa/\Cyldtm1.1Mpa
\Faddtm1Mpa/\Faddtm1Mpa
\Tg(Vil1-cre)997Gum/0

(B6.Cg-Faddtm1Mpa Cyldtm1.1Mpa Tg(Vil1-cre)997Gum)
cecum inflammation J:175865
\Cyldtm1.1Mpa/\Cyldtm1.1Mpa
\Ikbkgtm1.1Mpa/Y
\Tg(Vil1-cre)997Gum/0

(B6.Cg-Cyldtm1.1Mpa Ikbkgtm1.1Mpa Tg(Vil1-cre)997Gum)
colitis J:175865
\Cyldtm1.1Mpa/\Cyldtm1.1Mpa
\Ikbkgtm1.1Mpa/\Ikbkgtm1.1Mpa
\Tg(Vil1-cre)997Gum/0

(B6.Cg-Cyldtm1.1Mpa Ikbkgtm1.1Mpa Tg(Vil1-cre)997Gum)
colitis J:175865
\Cyldtm1Awai/\Cyldtm1Awai
\Tg(CD19-cre/ERT2)1Cgn/?

(Not Specified)
abnormal mature B cell morphology J:126113
decreased B-1 B cell number J:126113
decreased immature B cell number J:126113
enlarged lymph nodes J:126113
enlarged Peyer's patches J:126113
enlarged spleen J:126113
increased B cell number J:126113
\Cyldtm1Jdgl/\Cyldtm1Jdgl
(involves: 129 * C57BL/6J)
decreased susceptibility to bacterial infection J:124327
decreased susceptibility to bacterial infection induced morbidity/mortality J:124327
\Cyldtm1Lex/\Cyldtm1Lex
(involves: 129S5/SvEvBrd * C57BL/6)
abnormal inflammatory response J:114972
immune system phenotype J:114972
increased susceptibility to induced colitis J:114972
thymus hyperplasia J:114972
\Cyldtm1Ref/\Cyldtm1Ref
(Not Specified)
immune system phenotype J:126113
\Cyldtm1Scs/\Cyldtm1Scs
(involves: 129S1/Sv * 129X1/SvJ)
abnormal B cell differentiation J:112392
abnormal T cell number J:112392
decreased CD4-positive, alpha-beta T cell number J:112392
decreased CD8-positive, alpha-beta T cell number J:112392
increased double-positive T cell number J:112392
\Cyp1a1tm1.1Dwn/\Cyp1a1tm1.1Dwn
(B6.129P2-Cyp1a1tm1.1Dwn)
decreased lymphocyte cell number J:163973
decreased spleen weight J:163973
decreased thymus weight J:163973
increased neutrophil cell number J:163973
\Cyp1a1tm1.1Dwn/\Cyp1a1tm1.1Dwn
(involves: 129P2/OlaHsd * C57BL/6)
decreased leukocyte cell number J:122409
small spleen J:122409
small thymus J:122409
\Cyp1a1tm4.1Dwn/\Cyp1a1tm4.1Dwn
(B6.129X1-Cyp1a1tm4.1Dwn)
decreased lymphocyte cell number J:163973
decreased spleen weight J:163973
decreased thymus weight J:163973
increased neutrophil cell number J:163973
\Cyp1atm1Dwn/\Cyp1atm1Dwn
(B6.129-Cyp1atm1Dwn)
decreased leukocyte cell number J:122409
small spleen J:122409
small thymus J:122409
\Cyp2ab1tm1b(KOMP)Wtsi/\Cyp2ab1tm1b(KOMP)Wtsi
(C57BL/6N-Cyp2ab1tm1b(KOMP)Wtsi/Bay)
abnormal spleen morphology J:211773
\Cyp2c70em1Sjka/\Cyp2c70em1Sjka
(C57BL/6-Cyp2c70em1Sjka)
increased spleen weight J:330641
liver inflammation J:330641
\Cyp2c70em1Utr/\Cyp2c70em1Utr
(C57BL/6J-Cyp2c70em1Utr)
liver inflammation J:302190
\Cyp2ctm1104Arte/\Cyp2ctm1104Arte
(B6NTac(Cg)-Cyp2ctm1104Arte/Arte)
liver inflammation J:241121
\Cyp2ctm1897.1(Alb-CYP2C9)Arte/\Cyp2ctm1897.1(Alb-CYP2C9)Arte
(B6(Cg)-Cyp2ctm1897.1(Alb-CYP2C9)Arte/Arte)
liver inflammation J:241121
\Cyp2d22em1(IMPC)Tcp/\Cyp2d22em1(IMPC)Tcp
(C57BL/6NCrl-Cyp2d22em1(IMPC)Tcp/Tcp)
enlarged lymph nodes J:211773
\Cyp2f2em1(IMPC)H/\Cyp2f2em1(IMPC)H
(C57BL/6N-Cyp2f2em1(IMPC)H/H)
enlarged spleen J:211773
\Cyp2g1tm1(rtTA)Lane/\Cyp2g1+
\Tg(SFTPC-rtTA,tetO-Tnf)320-1Gwho/0

(involves: 129 * C57BL/6 * SJL)
increased macrophage cell number J:157842
rhinitis J:157842
\Cyp4v3em1Xsu/\Cyp4v3em1Xsu
(C57BL/6J-Cyp4v3em1Xsu)
increased microglial cell activation J:321817
\Cyp7a1tm1b(EUCOMM)Wtsi/\Cyp7a1tm1b(EUCOMM)Wtsi
(C57BL/6N-Cyp7a1tm1b(EUCOMM)Wtsi/Ieg)
increased leukocyte cell number J:211773
\Cyp7b1tm1Rus/\Cyp7b1tm1Rus
(involves: 129S/SvEv * C57BL/6J)
decreased IgA level J:170807
\Cyp11a1tm2Bcc/\Cyp11a1tm2Bcc
(Not Specified)
decreased T cell apoptosis J:133007
\Cyp11b1tm1Chjk/\Cyp11b1tm1Chjk
(involves: 129P2/OlaHsd * C57BL/6J)
decreased thymus weight J:147610
\Cyp19a1tm1b(EUCOMM)Hmgu/\Cyp19a1tm1b(EUCOMM)Hmgu
(C57BL/6N-Cyp19a1tm1b(EUCOMM)Hmgu/H)
decreased leukocyte cell number J:211773
decreased lymphocyte cell number J:211773
increased neutrophil cell number J:211773
\Cyp19a1tm1Esi/\Cyp19a1tm1Esi
(involves: 129S6/SvEvTac * C57BL/6)
abnormal spleen germinal center morphology J:92438
enlarged mesenteric lymph nodes J:92438
enlarged spleen J:92438
increased autoantibody level J:92438
increased B cell number J:92438
increased granulocyte number J:92438
increased IgG level J:92438
increased leukocyte cell number J:92438
increased lymphocyte cell number J:92438
increased mature B cell number J:92438
kidney inflammation J:92438
salivary gland inflammation J:92438
spleen hyperplasia J:92438
\Cyp19a1tm1Sih/\Cyp19a1tm1Sih
(involves: 129S/SvEv)
increased anti-single stranded DNA antibody level J:216958
increased autoantibody level J:216958
increased dendritic cell number J:216958
increased macrophage cell number J:216958
increased susceptibility to autoimmune disorder J:216958
lacrimal gland inflammation J:216958
salivary gland inflammation J:216958
\Cyp19a1tm1Toda/\Cyp19a1tm1Toda
(involves: 129P2/OlaHsd * C57BL/6J)
increased osteoclast cell number J:114305
\Cyp21a1em1(IMPC)Tcp/\Cyp21a1+
(C57BL/6NCrl-Cyp21a1em1(IMPC)Tcp/Tcp)
enlarged spleen J:211773
\Cyp26b1tm1Hmd/\Cyp26b1tm1Hmd
(involves: 129S1/Sv * 129X1/SvJ)
abnormal lymphatic vessel endothelial cell morphology J:206581
\Cyp26b1tm1Hmd/\Cyp26b1tm1Hmd
\Tg(Prox1-EGFP)KY221Gsat/0

(involves: 129S1/Sv * 129X1/SvJ * FVB/NTac)
abnormal lymphatic vessel endothelial cell morphology J:206581
abnormal lymphatic vessel morphology J:206581
\Cyp27b1tm1b(EUCOMM)Hmgu/\Cyp27b1tm1b(EUCOMM)Hmgu
(C57BL/6N-Cyp27b1tm1b(EUCOMM)Hmgu/Tcp)
decreased leukocyte cell number J:211773
decreased lymphocyte cell number J:211773
\Cyp27b1tm1Dgo/\Cyp27b1tm1Dgo
(involves: 129S1/Sv * 129X1/SvJ * BALB/c)
decreased osteoclast cell number J:70030
decreased T cell number J:70030
enlarged lymph nodes J:70030
\Cyp51tm1.1Bfro/\Cyp51tm1.1Bfro
(involves: 129P2/OlaHsd * C57BL/6)
abnormal lymphatic vessel morphology J:173366
abnormal lymphatic vessel smooth muscle morphology J:173366
\Cypr1STS/A/?
(involves: BALB/c * STS/A)
abnormal cytokine secretion J:52119
\Cypr2BALB/c/?
(involves: BALB/c * STS/A)
abnormal cytokine secretion J:52119
\Cypr3BALB/c/?
(involves: BALB/c * STS/A)
abnormal cytokine secretion J:52119
\Cyrenem1Vokh/\Cyrenem1Vokh
(C57BL/6-Cyrenem1Vokh)
abnormal class switch recombination J:306598
\Cyrentm1.1(KOMP)Vlcg/\Cyrentm1.1(KOMP)Vlcg
(involves: C57BL/6NTac)
abnormal class switch recombination J:265834
\Cyribm1Ivdi/\Cyribm1Ivdi
(involves: 129S1/Sv * 129X1/SvJ * DBA/2J)
abnormal spleen morphology J:282597
abnormal spleen white pulp morphology J:282597
increased circulating interleukin-6 level J:282597
increased circulating interleukin-10 level J:282597
increased circulating tumor necrosis factor level J:282597
increased neutrophil cell number J:282597
increased susceptibility to bacterial infection induced morbidity/mortality J:282597
\Cyribtm1c(KOMP)Wtsi/\Cyribtm1d(KOMP)Wtsi
\Lyz2tm1(cre)Ifo/\Lyz2+

(involves: 129P2/OlaHsd * 129S4/SvJaeSor * BcA17/Skmn * C57BL/6N)
abnormal circulating chemokine level J:282597
abnormal neutrophil physiology J:282597
increased circulating CXCL10 level J:282597
increased circulating interleukin-6 level J:282597
increased circulating interleukin-10 level J:282597
increased circulating tumor necrosis factor level J:282597
increased susceptibility to bacterial infection induced morbidity/mortality J:282597
\Cys1cpk/\Cys1cpk
(involves: C57BL/6J * CD-1)
spleen hypoplasia J:33739
thymus hypoplasia J:33739
\Cys1cpk/\Cys1cpk
(129.B6-Cys1cpk)
liver inflammation J:116210
\Cysltr1tm1Ykn/\Cysltr1tm1Ykn
(involves: C57BL/6)
decreased susceptibility to type I hypersensitivity reaction J:77087
respiratory system inflammation J:88647
\Cysltr1tm1Ykn/\Cysltr1tm1Ykn
(C.B6-Cysltr1tm1Ykn)
immune system phenotype J:182213
\Cysltr1tm1Ykn/\Cysltr1tm1Ykn
\Cysltr2tm1Ykn/\Cysltr2tm1Ykn

(involves: BALB/c * C57BL/6)
abnormal immune system physiology J:198383
\Cysltr1tm1Ykn/\Cysltr1tm1Ykn
\Cysltr2tm1Ykn/\Cysltr2tm1Ykn
\Oxgr1tm1(KOMP)Vlcg/\Oxgr1tm1(KOMP)Vlcg

(involves: BALB/c * C57BL/6 * C57BL/6NTac)
abnormal immune system physiology J:198383
\Cysltr2tm1Ykn/\Cysltr2tm1Ykn
(C57BL/6-Cysltr2tm1Ykn)
decreased susceptibility to type I hypersensitivity reaction J:94488
\Cysltr2tm1Ykn/\Cysltr2tm1Ykn
(C.B6-Cysltr2tm1Ykn)
autoimmune response J:182213
\Cystm1tm1b(EUCOMM)Hmgu/\Cystm1tm1b(EUCOMM)Hmgu
(C57BL/6N-Cystm1tm1b(EUCOMM)Hmgu/Ieg)
increased leukocyte cell number J:211773
\Cyth2tm1d(EUCOMM)Wtsi/\Cyth2tm1d(EUCOMM)Wtsi
(involves: C57BL/6N)
decreased eosinophil cell number J:307633
decreased susceptibility to type I hypersensitivity reaction J:307633
\Cytiptm1Tes/\Cytiptm1Tes
(involves: 129S1/Sv * FVB/N)
abnormal CD8-positive, alpha-beta cytotoxic T cell morphology J:110320
abnormal cellular extravasation J:110320
abnormal leukocyte migration J:110320
decreased leukocyte cell number J:110320
decreased lymphocyte cell number J:110320
lymph node hypoplasia J:110320
\Cytiptm1Wtw/\Cytiptm1Wtw
(involves: 129S6/SvEvTac * C57BL/6)
abnormal response to transplant J:112168
immune system phenotype J:112168
\Cytl1tm1Chun/\Cytl1tm1Chun
(involves: 129S4/SvJae * C57BL/6)
increased susceptibility to induced arthritis J:175377
\D6Wsu163etm1b(EUCOMM)Wtsi/\D6Wsu163etm1b(EUCOMM)Wtsi
(C57BL/6N-D6Wsu163etm1b(EUCOMM)Wtsi/Wtsi)
decreased CD4-positive, alpha-beta T cell number J:211773
decreased memory-marker NK cell number J:211773
increased CD8-positive, alpha-beta T cell number J:211773
increased CD8-positive, naive alpha-beta T cell number J:211773
\D630045J12Riktm1b(KOMP)Wtsi/\D630045J12Riktm1b(KOMP)Wtsi
(C57BL/6N-D630045J12Riktm1b(KOMP)Wtsi/Tcp)
enlarged lymph nodes J:211773
\Daam2tm1b(KOMP)Wtsi/\Daam2tm1b(KOMP)Wtsi
(C57BL/6N-Daam2tm1b(KOMP)Wtsi/Wtsi)
increased large unstained cell number J:211773
\Dab1scm-4J/\Dab1scm-4J
(CBA/J-Dab1scm-4J/GrsrJ)
thymus atrophy J:153275
\Dach2em1(IMPC)Ccpcz/\Dach2em1(IMPC)Ccpcz
(C57BL/6NCrl-Dach2em1(IMPC)Ccpcz/Ccpcz)
abnormal lymph node morphology J:211773
abnormal spleen morphology J:211773
enlarged lymph nodes J:211773
enlarged spleen J:211773
increased eosinophil cell number J:211773
small lymph nodes J:211773
small spleen J:211773
\Dact2tm1b(EUCOMM)Wtsi/\Dact2tm1b(EUCOMM)Wtsi
(C57BL/6N-Dact2tm1b(EUCOMM)Wtsi/Bay)
abnormal spleen morphology J:211773
\Dad1tm1Kni/\Dad1+
(involves: 129S/SvEv)
decreased thymus weight J:99897
\Daglatm1a(EUCOMM)Wtsi/\Daglatm1a(EUCOMM)Wtsi
(C57BL/6N-Daglatm1a(EUCOMM)Wtsi/Nju)
small spleen J:211773
small thymus J:211773
\Dapp1Gt(OST111213)Lex/\Dapp1Gt(OST111213)Lex
(B6.Cg-Dapp1Gt(OST111213)Lex)
abnormal humoral immune response J:110009
decreased B cell proliferation J:110009
decreased IgG3 level J:110009
increased susceptibility to bacterial infection J:110009
\Dapp1tm1Mnz/\Dapp1tm1Mnz
(B6.129P2-Dapp1tm1Mnz)
abnormal B cell activation J:86182
decreased B cell proliferation J:86182
decreased B-1a cell number J:86182
decreased IgG3 level J:86182
decreased IgM level J:86182
\Daw1b2b1116Clo/\Daw1b2b1116Clo
(C57BL/6J-Daw1b2b1116Clo)
spleen hypoplasia J:175213
\Daw1b2b1584Clo/\Daw1b2b1584Clo
(C57BL/6J-Daw1b2b1584Clo)
absent spleen J:175213
\DbaclC57BL/6Jcl/\DbaclC57BL/6Jcl
(NOD.B6-(D4Mit193-D4Mit17))
increased susceptibility to autoimmune diabetes J:144964
insulitis J:144964
\Dbn1tm1a(KOMP)Wtsi/\Dbn1+
(C57BL/6N-Dbn1tm1a(KOMP)Wtsi/Wtsi)
increased leukocyte cell number J:211773
\Dbn1tm1b(KOMP)Wtsi/\Dbn1+
(C57BL/6N-Dbn1tm1b(KOMP)Wtsi/Wtsi)
increased CD8-positive, alpha-beta T cell number J:211773
\DbnlGt(betageo)11Byg/\DbnlGt(betageo)11Byg
(involves: 129P2/OlaHsd * C57BL/6)
abnormal T cell activation J:119847
abnormal T cell physiology J:119847
decreased IgG1 level J:119847
decreased IgM level J:119847
decreased immunoglobulin level J:119847
decreased interleukin-2 secretion J:119847
decreased T cell proliferation J:119847
immune system phenotype J:119847
\Dbnltm1Jwnd/\Dbnl+
(involves: BALB/c)
increased spleen weight J:109363
\Dbnltm1Jwnd/\Dbnltm1Jwnd
(involves: BALB/c)
increased spleen weight J:109363
\Dbr1Gt(YTA280)Byg/\Dbr1+
(involves: 129P2/OlaHsd)
abnormal class switch recombination J:223318
\Dcaf5em1(IMPC)Ccpcz/\Dcaf5em1(IMPC)Ccpcz
(C57BL/6NCrl-Dcaf5em1(IMPC)Ccpcz/Ccpcz)
abnormal lymph node morphology J:211773
abnormal spleen morphology J:211773
enlarged lymph nodes J:211773
enlarged spleen J:211773
increased effector memory CD8-positive, alpha-beta T cell number J:211773
increased NK cell number J:211773
increased spleen weight J:211773
small spleen J:211773
\Dcaf8em1(IMPC)Ccpcz/\Dcaf8em1(IMPC)Ccpcz
(C57BL/6N-Dcaf8em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
enlarged spleen J:211773
\Dcaf12em1(IMPC)Ccpcz/\Dcaf12em1(IMPC)Ccpcz
(C57BL/6N-Dcaf12em1(IMPC)Ccpcz/Ccpcz)
decreased CD8-positive, naive alpha-beta T cell number J:211773
increased effector memory T-helper cell number J:211773
\Dcaf15tm1a(EUCOMM)Hmgu/\Dcaf15tm1a(EUCOMM)Hmgu
(C57BL/6NCrl-Dcaf15tm1a(EUCOMM)Hmgu/Ccpcz)
abnormal thymus morphology J:211773
decreased effector memory CD8-positive, alpha-beta T cell number J:211773
decreased effector memory T-helper cell number J:211773
decreased spleen weight J:211773
enlarged thymus J:211773
increased CD4-positive, alpha-beta T cell number J:211773
increased CD4-positive, CD25-positive, alpha-beta regulatory T cell number J:211773
increased CD8-positive, alpha-beta T cell number J:211773
increased CD8-positive, naive alpha-beta T cell number J:211773
increased effector memory CD8-positive, alpha-beta T cell number J:211773
increased NK cell number J:211773
increased T cell number J:211773
increased T-helper cell number J:211773
\Dcbld2tm1a(KOMP)Wtsi/\Dcbld2tm1a(KOMP)Wtsi
(C57BL/6N-Dcbld2tm1a(KOMP)Wtsi/Wtsi)
increased anti-nuclear antigen antibody level J:211773
\DccTg(H2-Kb-Jak2*V617F)1Shmd/\Dcc+
(involves: C57BL/6 * DBA/2)
abnormal neutrophil morphology J:130189
abnormal spleen morphology J:130189
decreased spleen white pulp amount J:130189
enlarged spleen J:130189
increased granulocyte number J:130189
increased leukocyte cell number J:130189
increased spleen red pulp amount J:130189
increased spleen weight J:130189
myeloid hyperplasia J:130189
\Dcctm1b(NCOM)Mfgc/\Dcc+
(C57BL/6N-Dcctm1b(NCOM)Mfgc/Tcp)
increased neutrophil cell number J:211773
\Dckm1Btlr/\Dck+
(C57BL/6J-Dckm1Btlr)
decreased B cell number J:236696
\Dckm1Btlr/\Dckm1Btlr
(C57BL/6J-Dckm1Btlr)
decreased B cell number J:236696
decreased CD4-positive, alpha-beta T cell number J:236696
decreased IgG level J:236696
decreased response to antigen J:236696
increased CD8-positive, alpha-beta T cell number J:236696
increased IgE level J:236696
increased macrophage cell number J:236696
\Dckmemi/\Dckmemi
(C57BL/6J-Dckmemi)
abnormal myeloid leukocyte morphology J:184080
abnormal response to infection J:184080
abnormal T cell differentiation J:184080
decreased B cell number J:184080
decreased CD4-positive, alpha-beta T cell number J:184080
enlarged spleen J:184080
increased effector memory CD4-positive, alpha-beta T cell number J:184080
increased effector memory CD8-positive, alpha-beta T cell number J:184080
increased T cell apoptosis J:184080
increased T cell proliferation J:184080
small thymus J:184080
thymus hypoplasia J:184080
\Dcktm1.1Radu/\Dcktm1.1Radu
(involves: 129S4/SvJae * BALB/cJ * C57BL/6 * C57BL/6J)
abnormal double-negative T cell morphology J:158373
abnormal peripheral lymph node morphology J:158373
abnormal spleen morphology J:158373
abnormal T cell differentiation J:158373
abnormal thymus morphology J:158373
absent spleen white pulp J:158373
decreased B cell number J:158373
decreased double-positive T cell number J:158373
decreased pre-B cell number J:158373
decreased T cell number J:158373
increased double-negative T cell number J:158373
increased pro-B cell number J:158373
increased spleen weight J:158373
thymus hypoplasia J:158373
\Dclk1tm1a(EUCOMM)Wtsi/\Dclk1+
(C57BL/6N-Dclk1tm1a(EUCOMM)Wtsi/Wtsi)
increased anti-nuclear antigen antibody level J:211773
\Dclk1tm1a(EUCOMM)Wtsi/\Dclk1tm1a(EUCOMM)Wtsi
(C57BL/6N-Dclk1tm1a(EUCOMM)Wtsi/Wtsi)
increased anti-nuclear antigen antibody level J:211773
\Dclre1atm1Rleg/\Dclre1atm1Rleg
(involves: 129S7/SvEvBrd)
immune system phenotype J:102381
increased susceptibility to bacterial infection J:102381
\Dclre1atm1Rleg/\Dclre1atm1Rleg
\Trp53tm1Tyj/\Trp53tm1Tyj

(involves: 129S2/SvPas * 129S7/SvEvBrd)
increased T cell derived lymphoma incidence J:102381
\Dclre1cm1Brck/\Dclre1cm1Brck
(involves: C3H * C57BL/6)
absent B cells J:207533
absent T cells J:207533
\Dclre1cm1Brck/\Dclre1cm1Brck
(involves: C57BL/6)
absent B cells J:207533
absent CD4-positive, alpha-beta T cells J:207533
absent CD8-positive, alpha-beta T cells J:207533
decreased DN1 thymic pro-T cell number J:207533
decreased DN4 thymocyte number J:207533
decreased double-positive T cell number J:207533
decreased pre-B cell number J:207533
immune system phenotype J:207533
\Dclre1cm1Btlr/\Dclre1cm1Btlr
(C57BL/6J-Dclre1cm1Btlr)
decreased B cell number J:217790
decreased IgM level J:217790
decreased response to antigen J:217790
decreased single-positive T cell number J:217790
decreased T cell number J:217790
impaired humoral immune response J:217790
increased macrophage cell number J:217790
increased neutrophil cell number J:217790
increased NK cell number J:217790
\Dclre1cM2Btlr/\Dclre1cM2Btlr
(C57BL/6J-Dclre1cM2Btlr)
decreased CD4-positive, alpha-beta T cell number J:265131
decreased CD8-positive, naive alpha-beta T cell number J:265131
decreased single-positive T cell number J:265131
decreased T cell number J:265131
increased central memory CD8 positive, alpha-beta T cell number J:265131
increased effector memory CD4-positive, alpha-beta T cell number J:265131
increased effector memory CD8-positive, alpha-beta T cell number J:265131
\Dclre1cm3Btlr/\Dclre1cm3Btlr
(C57BL/6J-Dclre1cm3Btlr)
decreased B cell number J:265132
decreased B-1 B cell number J:265132
decreased CD4-positive, alpha-beta T cell number J:265132
decreased CD8-positive, alpha-beta T cell number J:265132
decreased CD8-positive, naive alpha-beta T cell number J:265132
decreased NK T cell number J:265132
decreased single-positive T cell number J:265132
decreased T cell number J:265132
increased central memory CD4-positive, alpha-beta T cell number J:265132
increased effector memory CD4-positive, alpha-beta T cell number J:265132
increased effector memory CD8-positive, alpha-beta T cell number J:265132
\Dclre1ctm1.1Fwa/\Dclre1ctm1.1Fwa
(involves: 129S6/SvEvTac * C57BL/6)
arrested B cell differentiation J:80995
arrested T cell differentiation J:80995
\Dclre1ctm1.1Jpdv/\Dclre1ctm1.1Jpdv
(involves: 129P1/ReJ)
abnormal B cell differentiation J:137743
abnormal T cell receptor V(D)J recombination J:194422
arrested T cell differentiation J:137712
\Dclre1ctm1Fwa/\Dclre1ctm1Fwa
(involves: 129S6/SvEvTac * C57BL/6)
absent immature B cells J:80995
arrested B cell differentiation J:80995
arrested T cell differentiation J:80995
decreased thymocyte number J:80995
\Dclre1ctm1Fwa/\Dclre1ctm1Fwa
(involves: 129S6/SvEvTac)
abnormal T cell receptor beta chain V(D)J recombination J:147864
absent B cells J:147864
arrested B cell differentiation J:147864
decreased CD4-positive, alpha-beta T cell number J:147864
decreased CD8-positive, alpha-beta T cell number J:147864
decreased double-positive T cell number J:147864
decreased thymocyte number J:147864
spleen hypoplasia J:147864
\Dclre1ctm1Jsek/\Dclre1ctm1Jsek
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
abnormal immunoglobulin heavy chain V(D)J recombination J:147864
abnormal T cell receptor beta chain V(D)J recombination J:147864
decreased B cell number J:147864
decreased CD4-positive, alpha-beta T cell number J:147864
decreased CD8-positive, alpha-beta T cell number J:147864
decreased double-positive T cell number J:147864
decreased pre-B cell number J:147864
decreased thymocyte number J:147864
increased pro-B cell number J:147864
spleen hypoplasia J:147864
\Dclre1ctm2.1Jpdv/\Dclre1ctm2.2Jpdv
\Tg(Cr2-cre)3Cgn/0

(involves: 129S2/SvPas * C57BL/6)
abnormal class switch recombination J:153841
immune system phenotype J:153841
\Dclre1ctm2.2Jpdv/\Dclre1ctm2.2Jpdv
(B6.129S2-Dclre1ctm2.2Jpdv)
abnormal mononuclear cell morphology J:153841
absent immature B cells J:153841
arrested B cell differentiation J:153841
arrested T cell differentiation J:153841
decreased CD4-positive, alpha-beta T cell number J:153841
decreased CD8-positive, alpha-beta T cell number J:153841
decreased double-positive T cell number J:153841
decreased mature B cell number J:153841
decreased splenocyte number J:153841
decreased thymocyte number J:153841
\Dclre1ctm2Mcow/\Dclre1ctm2Mcow
(involves: 129/Sv * C57BL/6)
abnormal leukocyte physiology J:96535
abnormal lymph node morphology J:96535
abnormal spleen B cell follicle morphology J:96535
absent thymus cortex J:96535
arrested B cell differentiation J:96535
arrested T cell differentiation J:96535
decreased B cell proliferation J:96535
decreased lymphocyte cell number J:96535
decreased T cell proliferation J:96535
decreased thymocyte number J:96535
decreased thymus weight J:96535
small lymph nodes J:96535
small spleen J:96535
\Dcntm1Ioz/\Dcn+
(either: C.Cg-Dcntm1Ioz or C3.Cg-Dcntm1Ioz)
decreased susceptibility to bacterial infection J:68640
\Dcntm1Ioz/\Dcn+
\Trp53tm1Brd/\Trp53tm1Brd

(involves: 129/Sv * Black Swiss * C57BL/6)
increased T cell derived lymphoma incidence J:53511
\Dcntm1Ioz/\Dcntm1Ioz
(involves: 129S1/Sv * 129X1/SvJ * Black Swiss)
immune system phenotype J:39212
tubular nephritis J:75298
\Dcntm1Ioz/\Dcntm1Ioz
(either: C.Cg-Dcntm1Ioz or C3.Cg-Dcntm1Ioz)
decreased susceptibility to bacterial infection J:68640
\Dcntm1Ioz/\Dcntm1Ioz
(C.129(Cg)-Dcntm1Ioz)
abnormal humoral immune response J:92428
\Dcntm1Ioz/\Dcntm1Ioz
\Trp53tm1Brd/\Trp53tm1Brd

(involves: 129/Sv * Black Swiss * C57BL/6)
enlarged thymus J:53511
increased T cell derived lymphoma incidence J:53511
thymus hyperplasia J:53511
\Dcstamptm1Suda/\Dcstamptm1Suda
(Not Specified)
abnormal macrophage physiology J:100555
abnormal osteoclast differentiation J:100555
abnormal osteoclast physiology J:100555
\Dctn1tm2.1Cai/\Dctn1tm2.1Cai
\Tg(Thy1-cre)1Vln/?

(involves: 129S4/SvJaeSor * 129X1/SvJ * C57BL/6 * FVB/N)
microgliosis J:264431
\Dcun1d1Gt(RRR261)Byg/\Dcun1d1Gt(RRR261)Byg
(involves: 129P2/OlaHsd)
lymphoid hypoplasia J:262901
spleen hypoplasia J:262901
\Ddb1em1(IMPC)Ccpcz/\Ddb1+
(C57BL/6N-Ddb1em1(IMPC)Ccpcz/Ccpcz)
abnormal thymus morphology J:211773
enlarged thymus J:211773
\Ddctm1.1Rhrs/\Ddctm1.1Rhrs
\Tg(Ggt1-cre)M3Egn/0

(involves: 129 * C57BL/6 * SJL)
tubulointerstitial nephritis J:175630
\Ddctm1.1Rhrs/\Ddctm1.1Rhrs
\Tg(Ggt1-cre)M3Egn/0

(129.Cg-Ddctm1.1Rhrs Tg(Ggt1-cre)M3Egn)
tubulointerstitial nephritis J:175630
\Ddit3tm1Dron/\Ddit3tm1Dron
(involves: 129S1/Sv * 129X1/SvJ * FVB/N)
decreased susceptibility to Retroviridae infection J:112354
\Ddit3tm1Dron/\Ddit3tm1Dron
(B6.129-Ddit3tm1Dron)
abnormal macrophage activation involved in immune response J:153833
decreased macrophage apoptosis J:153833
\Ddit3tm1Dron/\Ddit3tm1Dron
\Tg(Col2a1-rtTA,tetO-COMP*)2Jath/0

(involves: 129X1/SvJ * 129S1/Sv * C57BL/6)
decreased inflammatory response J:233238
\Ddit3tm2.1Dron/\Ddit3tm2.1Dron
(B6.129S(Cg)-Ddit3tm2.1Dron/J)
abnormal T cell morphology J:214136
white adipose tissue inflammation J:214136
\Ddosttm1.1(KOMP)Vlcg/\Ddost+
(C57BL/6N-Ddosttm1.1(KOMP)Vlcg/Ucd)
enlarged lymph nodes J:211773
small spleen J:211773
\Ddr1tm1Wfv/\Ddr1tm1Wfv
\Ldlrtm1Her/\Ldlrtm1Her

(involves: 129S1/Sv * 129S7/SvEvBrd * 129X1/SvJ)
decreased macrophage cell number J:149015
\Ddrgk1tm1c(EUCOMM)Hmgu/\Ddrgk1tm1c(EUCOMM)Hmgu
\Gt(ROSA)26Sortm1(cre/ERT2)Tyj/\Gt(ROSA)26Sor+

(involves: 129S4/SvJae * C3H * C57BL/6 * C57BL/6N)
decreased granulocyte number J:231701
decreased lymphocyte cell number J:231701
decreased monocyte cell number J:231701
\Ddx19bem1Chaw/\Ddx19b+
(C57BL/6-Ddx19bem1Chaw)
increased interferon-alpha secretion J:289833
increased interferon-beta secretion J:289833
\Ddx23em1(IMPC)Wtsi/\Ddx23+
(C57BL/6N-Ddx23em1(IMPC)Wtsi/Wtsi)
increased leukocyte cell number J:211773
\Ddx41tm1.1Arte/\Ddx41tm1.1Arte
\Lyz2tm1(cre)Ifo/\Lyz2+

(involves: 129P2/OlaHsd * C57BL/6N)
immune system phenotype J:265023
increased susceptibility to Retroviridae infection J:265023
\Ddx41tm1.1Arte/\Ddx41tm1.1Arte
\Tg(Itgax-cre)1-1Reiz/0

(involves: C57BL/6 * C57BL/6N * CBA)
immune system phenotype J:265023
increased susceptibility to Retroviridae infection J:265023
\Ddx46em1(IMPC)Tcp/\Ddx46+
(C57BL/6N-Ddx46em1(IMPC)Tcp/Cmmr)
enlarged lymph nodes J:211773
\Ddx46em1Caox/\Ddx46+
(involves: C57BL/6J)
abnormal innate immunity J:271836
abnormal macrophage physiology J:271836
decreased susceptibility to Riboviria infection J:271836
increased circulating interferon-beta level J:271836
increased interferon-beta secretion J:271836
increased interleukin-1 beta secretion J:271836
increased interleukin-6 secretion J:271836
increased macrophage cytokine production J:271836
increased tumor necrosis factor secretion J:271836
\Ddx52tm1a(EUCOMM)Wtsi/\Ddx52+
(C57BL/6N-Ddx52tm1a(EUCOMM)Wtsi/Ics)
decreased NK cell number J:165965
\Ddx60tm1b(EUCOMM)Wtsi/\Ddx60tm1b(EUCOMM)Wtsi
(involves: C57BL/6N)
decreased circulating interferon-beta level J:228452
increased circulating interferon-alpha level J:228452
increased susceptibility to Riboviria infection J:228452
increased susceptibility to Riboviria infection induced morbidity/mortality J:228452
\Ddx60tm1b(EUCOMM)Wtsi/\Ddx60tm1b(EUCOMM)Wtsi
\Mavstm1Tsse/\Mavstm1Tsse

(involves: 129 * C57BL/6N)
increased susceptibility to Riboviria infection induced morbidity/mortality J:228452
\Deddtm1Tmiy/\Deddtm1Tmiy
(B6.Cg-Deddtm1Tmiy)
decreased spleen weight J:119734
\Def6Gt(OST307148)Lex/\Def6Gt(OST307148)Lex
(involves: 129S5/SvEvBrd * C57BL/6)
abnormal cytokine secretion J:106469
abnormal spleen germinal center morphology J:106469
decreased T cell apoptosis J:106469
enlarged lymph nodes J:106469
enlarged spleen J:106469
increased anti-nuclear antigen antibody level J:106469
increased IgG level J:106469
increased immature B cell number J:106469
increased immunoglobulin level J:106469
increased memory T cell number J:106469
increased T cell number J:106469
\Defb1tm1Hgu/\Defb1tm1Hgu
(involves: 129P2/OlaHsd * C57BL/6N)
immune system phenotype J:76528
\Defb1tm1Jmw/\Defb1+
(B6.129S5-Defb1tm1Jmw)
increased susceptibility to bacterial infection J:76529
\Defb1tm1Jmw/\Defb1tm1Jmw
(B6.129S5-Defb1tm1Jmw)
increased susceptibility to bacterial infection J:76529
\Defb3tm1Lex/\Defb3tm1Lex
(B6;129S5-Defb3tm1Lex/Mmucd)
increased susceptibility to bacterial infection J:168725
\Defb3tm1Xen/\Defb3tm1Xen
(involves: C57BL/6)
increased incidence of corneal inflammation J:199719
increased neutrophil cell number J:199719
increased susceptibility to fungal infection J:199719
\Defb14tm1Wme/\Defb14tm1Wme
(B6.129P2-Defb14tm1Wme)
immune system phenotype J:180788
\Del(1)1Brk/\Del(1)1Brk
(involves: 129S6/SvEvTac * C57BL/6J * CBA/J)
abnormal spleen morphology J:100202
abnormal spleen white pulp morphology J:100202
enlarged spleen J:100202
increased leukocyte cell number J:100202
increased spleen red pulp amount J:100202
\Del(1Aim2-Ifi205)1Stsn/\+
\Trex1tm1Tld/\Trex1tm1Tld

(involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6N)
heart inflammation J:234263
increased autoantibody level J:234263
increased inflammatory response J:234263
kidney inflammation J:234263
myositis J:234263
stomach inflammation J:234263
\Del(1Aim2-Ifi205)1Stsn/\Del(1Aim2-Ifi205)1Stsn
(B6(129S4)-Del(1Aim2-Ifi205)1Stsn)
abnormal interferon secretion J:234263
decreased interleukin-1 beta secretion J:234263
decreased macrophage apoptosis J:234263
\Del(1Aim2-Ifi205)1Stsn/\Del(1Aim2-Ifi205)1Stsn
(involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6N)
stomach inflammation J:234263
\Del(1Aim2-Ifi205)1Stsn/\Del(1Aim2-Ifi205)1Stsn
\Trex1tm1Tld/\Trex1tm1Tld

(involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6N)
heart inflammation J:234263
increased autoantibody level J:234263
increased inflammatory response J:234263
kidney inflammation J:234263
myositis J:234263
stomach inflammation J:234263
\Del(2Duoxa2-Duoxa1)1Sref/\Del(2Duoxa2-Duoxa1)1Sref
(involves: 129S6/SvEvTac * C57BL/6J)
decreased spleen weight J:205165
\Del(3Bglap2-Bglap)2Kry/\Del(3Bglap2-Bglap)2Kry
(involves: 129S7/SvEvBrd * C57BL/6)
increased osteoclast cell number J:34440
\Del(3Cd1d2-Cd1d1)1Crw/\Del(3Cd1d2-Cd1d1)1Crw
(involves: 129S4/SvJae * C57BL/6)
abnormal antigen presentation J:174337
abnormal NK T cell physiology J:112657
decreased CD4-positive, alpha-beta T cell number J:174337
decreased interleukin-4 secretion J:39749
decreased NK T cell number J:112657, J:174337, J:39749, J:76976
\Del(3Cd1d2-Cd1d1)1Crw/\Del(3Cd1d2-Cd1d1)1Crw
\TcraLn1Ogu/\Tcra+

(involves: 129/Sv * C57BL/6)
abnormal NK T cell morphology J:152041
\Del(3Cd1d2-Cd1d1)1Crw/\Del(3Cd1d2-Cd1d1)1Crw
\Tg(TcraAV19AJ33)1Shima/0

(involves: 129S4/SvJae * C57BL/6)
abnormal NK T cell morphology J:112657
decreased susceptibility to experimental autoimmune encephalomyelitis J:112657
increased interleukin-10 secretion J:112657
\Del(3Cd1d2-Cd1d1)1Sbp/\Del(3Cd1d2-Cd1d1)1Sbp
(either: B6NTac.129S6-Del(3Cd1d2-Cd1d1)1Sbp or (involves: 129S6/SvEvTac * C57BL/6NTac))
abnormal immune tolerance J:58315
\Del(3Cd1d2-Cd1d1)1Sbp/\Del(3Cd1d2-Cd1d1)1Sbp
(involves: 129S6/SvEvTac)
abnormal dendritic cell antigen presentation J:151699
decreased NK T cell number J:151699
\Del(3Gbp2-ps-Gbp5)1Ktak/\Del(3Gbp2-ps-Gbp5)1Ktak
(involves: C57BL/6)
immune system phenotype J:187397
increased susceptibility to parasitic infection J:187397
increased susceptibility to parasitic infection induced morbidity/mortality J:187397
\Del(4C4-C5)1Lap/\+
(involves: 129S6/SvEvTac)
enlarged spleen J:158126
\Del(4C4-C5)1Lap/\Del(4C4-C5)1Lap
(involves: 129S6/SvEvTac)
enlarged spleen J:158126
\Del(4D4Mit190-D4Mit51)2Aam/\+
(involves: 129S7/SvEvBrd)
spleen hyperplasia J:121726
\Del(6Ephb6-Trpv6)1Mhed/\+
(involves: 129S/SvEv)
dermatitis J:133151
\Del(6Ephb6-Trpv6)1Mhed/\Del(6Ephb6-Trpv6)1Mhed
(involves: 129S/SvEv)
dermatitis J:133151
\Del(6Gimap5-Gimap3)1Yout/\Del(6Gimap5-Gimap3)1Yout
(involves: C57BL/6 * C57BL/6NCrlj * CBA/JNCrlj)
abnormal T cell physiology J:209926
decreased B cell number J:209926
decreased NK cell number J:209926
decreased T cell number J:209926
\Del(6Snca)1Slab/\Del(6Snca)1Slab
\Tg(Th-SNCA*)1Mgsp/0

(involves: C57BL/6J * C57BL/6JOlaHsd * CBA/Ca)
abnormal microglial cell morphology J:108310
brain inflammation J:108310
\Del(7)Tyrc-3H/\Del(7)Tyrc-3H
(involves: 101/H * C3H/HeH)
abnormal thymus morphology J:5063
\Del(7Ifitm5-Ifitm6)1Masu/\+
(involves: 129P2/OlaHsd * C57BL/6)
immune system phenotype J:137940
\Del(7Mrgpra2a-Mrgpra2b)1Xzd/\Del(7Mrgpra2a-Mrgpra2b)1Xzd
(C57BL/6J-Del(7Mrgpra2a-Mrgpra2b)1Xzd)
abnormal neutrophil physiology J:332494
decreased interleukin-1 beta secretion J:332494
increased susceptibility to bacterial infection J:332494
\Del(7Pira1-Lilra6)1Fgla/\Del(7Pira1-Lilra6)1Fgla
(involves: C57BL/6)
decreased susceptibility to graft versus host disease J:290663
\Del(7Pira1-Lilra6)1Fgla/\Del(7Pira1-Lilra6)1Fgla
\Il2rgtm1Wjl/\Il2rgtm1Wjl
\Rag2tm1Fwa/\Rag2tm1Fwa

(involves: C57BL/6J * C57BL/6NTac)
abnormal response to transplant J:290663
\Del(8A4-B3)7H/\+
(involves: 101/H * C3H/HeH)
abnormal lymphatic vessel morphology J:123074
\Del(8Ddx19a-Ddx19b)1Chaw/\+
(C57BL/6-Del(8Ddx19a-Ddx19b)1Chaw)
decreased susceptibility to Picornaviridae infection J:289833
decreased susceptibility to Picornaviridae infection induced morbidity/mortality J:289833
increased interferon-alpha secretion J:289833
increased interferon-beta secretion J:289833
\Del(8Ddx19a-Ddx19b)2Chaw/\+
(C57BL/6-Del(8Ddx19a-Ddx19b)2Chaw)
increased interferon-alpha secretion J:289833
increased interferon-beta secretion J:289833
\Del(8Defa1-Def)2Xzd/\Del(8Defa1-Def)2Xzd
\Tg(KRT14-cre)1Amc/0

(involves: C57BL/6J * CBA)
increased susceptibility to bacterial infection J:332494
\Del(8Defb1-Defb13)1Jrdo/\Del(8Defb1-Defb13)1Jrdo
(involves: 129P2/OlaHsd * C57BL/6N)
immune system phenotype J:204187
\Del(9Apoa1-Apoa4)1Hmez/\Del(9Apoa1-Apoa4)1Hmez
(involves: 129P2/OlaHsd * C57BL/6)
increased macrophage derived foam cell number J:109005
\Del(9Casp1-Casp4)1Bhk/\Del(9Casp1-Casp4)1Bhk
(129-Del(9Casp1-Casp4)1Bhk)
abnormal macrophage physiology J:189777
decreased interleukin-1 alpha secretion J:189777
decreased interleukin-1 beta secretion J:189777
\Del(9Cd3g-Cd3d)1Cpt/\Del(9Cd3g-Cd3d)1Cpt
(involves: 129S4/SvJae * C57BL/6)
absent gamma-delta T cells J:76991
arrested T cell differentiation J:76991
decreased alpha-beta T cell number J:76991
thymus hypoplasia J:76991
\Del(9Hspb2-Cryab)1Wawr/\Del(9Hspb2-Cryab)1Wawr
(involves: 129S4/SvJae)
osteoarthritis J:72926
\Del(10Prmt2-Col6a1)1Yah/\+
(involves: 129P2/OlaHsd * C57BL/6 * SJL)
abnormal cytokine level J:167506
abnormal macrophage physiology J:167506
lung inflammation J:167506
respiratory system inflammation J:167506
\Del(10Prtn3-Elane)1Deje/\Del(10Prtn3-Elane)1Deje
(involves: 129S1/Sv * 129S6/SvEvTac * 129X1/SvJ)
abnormal neutrophil physiology J:137674
immune system phenotype J:137674
impaired neutrophil recruitment J:137674
\Del(11Cxcl16-Zmynd15)1Ifc/\Del(11Cxcl16-Zmynd15)1Ifc
(B6.129S-Ldlrtm1Her Del(11Cxcl16-Zmynd15)1Ifc)
abnormal macrophage physiology J:123851
\Del(11Hoxb3-Hoxb4)1Karl/\Del(11Hoxb3-Hoxb4)1Karl
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)
abnormal spleen morphology J:83563
decreased spleen weight J:83563
spleen hypoplasia J:83563
\Del(11Hoxb3-Hoxb4)1Karl/\Del(11Hoxb3-Hoxb4)1Karl
\Hoxa9tm1Mrc/\Hoxa9tm1Mrc

(involves: 129S1/Sv * 129S7/SvEvBrd * 129X1/SvJ * C57BL/6)
decreased spleen weight J:126371
spleen hypoplasia J:126371
\Del(11Jmjd6-Mettl23)1Ysfk/\Del(11Jmjd6-Mettl23)1Ysfk
(involves: C57BL/6)
abnormal thymus development J:90288
impaired macrophage chemotaxis J:90288
impaired macrophage phagocytosis J:90288
thymus hypoplasia J:90288
\Del(11Nlrp1a-Nlrp1c-ps)1Smas/\Del(11Nlrp1a-Nlrp1c-ps)1Smas
(Not Specified)
decreased neutrophil cell number J:191055
increased susceptibility to Riboviria infection J:191055
\Del(11Stat5a-Stat5b)1Mam/\Del(11Stat5a-Stat5b)1Mam
(involves: 129 * 129S6/SvEvTac * C57BL/6)
absent gamma-delta T cells J:122463
arrested B cell differentiation J:122463
decreased B cell number J:122463
decreased CD8-positive, alpha-beta T cell number J:122463
small lymph nodes J:122463
small spleen J:122463
small thymus J:122463
\Del(13Naip1-Naip5)1Vnce/\Del(13Naip1-Naip5)1Vnce
(involves: C57BL/6)
decreased inflammatory response J:294930
\Del(13Naip1-Naip5)1Vnce/\Del(13Naip1-Naip5)1Vnce
\Nlrc4em2Vnce/\Nlrc4em2Vnce

(involves: C57BL/6)
decreased inflammatory response J:294930
\Del(13Naip1-Naip5)1Vnce/\Del(13Naip1-Naip5)1Vnce
\Nlrp3tm1Vmd/\Nlrp3tm1Vmd

(involves: C57BL/6J * C57BL/6N)
decreased inflammatory response J:294930
\Del(14Ltb4r2-Ltb4r1)1Bodd/\+
(involves: 129S4/SvJaeSor * C57BL/6)
decreased susceptibility to induced arthritis J:131779
\Del(14Ltb4r2-Ltb4r1)1Bodd/\Del(14Ltb4r2-Ltb4r1)1Bodd
(involves: 129S4/SvJaeSor * C57BL/6)
decreased susceptibility to induced arthritis J:131779
immune system phenotype J:131779
impaired neutrophil chemotaxis J:163271
\Del(14Trim13-Dleu2)4Rdf/\Del(14Trim13-Dleu2)4Rdf
(involves: 129S1/Sv * 129S4/SvJaeSor * C57BL/6)
abnormal B cell proliferation J:156946
increased B cell number J:156946
increased B-1a cell number J:156946
increased spleen white pulp amount J:156946
\Del(14Trim13-Rnaseh2b)6Rdf/\+
\Cd19tm1(cre)Cgn/\Cd19+

(involves: 129P2/OlaHsd * 129S1/Sv * 129S4/SvJaeSor * C57BL/6)
abnormal lymphopoiesis J:179879
increased B cell number J:179879
\Del(15Rr357-Rr303293)2Jta/\Del(15Rr357-Rr303293)2Jta
(involves: C57BL/6)
immune system phenotype J:257088
\Del(15Rr316124-Rr313939)2Fsp/\+
\Myctm1Atp/\Myc+

(involves: 129P2/OlaHsd * C57BL/6)
decreased B cell number J:257739
decreased granulocyte number J:257739
\Del(15Rr316124-Rr313939)2Fsp/\+
\Rr331em1Fsp/\Rr331+

(involves: C57BL/6)
decreased B cell number J:257739
increased pre-B cell number J:257739
\Del(15Rr316124-Rr313939)2Fsp/\+
\Rr307328em1Fsp/\Rr307328+

(involves: C57BL/6)
decreased B cell number J:257739
increased pre-B cell number J:257739
\Del(15Rr316124-Rr313939)2Fsp/\Del(15Rr316124-Rr313939)2Fsp
(Not Specified)
decreased B cell number J:257739
decreased granulocyte number J:257739
\Del(16Dgcr2-Hira)1Rak/\+
(involves: 129/Sv * 129S6/SvEvTac * C57BL/6 * FVB/N * SJL)
immune system phenotype J:67796
\Del(16Es2el-Ufd1l)217Bld/\+
(involves: 129S7/SvEvBrd * C57BL/6)
immune system phenotype J:57757
\Del(16Pi4ka-Hira)1Atai/\+
(C57BL/6N-Del(16Pi4ka-Hira)1Atai)
thymus hypoplasia J:285407
\Del(17Btnl1-Btnl6)1Ahay/\Del(17Btnl1-Btnl6)1Ahay
(involves: BALB/c * C57BL/6J)
decreased CD4-positive, gamma-delta intraepithelial T cell number J:291989
\Del(17Trem1-Trem3)1Jkt/\Del(17Trem1-Trem3)1Jkt
(involves: 129P2/OlaHsd * BALB/cJ * C57BL/6)
abnormal chemokine level J:194295
abnormal circulating chemokine level J:194295
abnormal cytokine level J:194295
abnormal cytokine secretion J:194295
impaired neutrophil chemotaxis J:194295
increased circulating interleukin-1 alpha level J:194295
increased circulating interleukin-6 level J:194295
increased circulating interleukin-10 level J:194295
increased circulating tumor necrosis factor level J:194295
increased interleukin-1 alpha secretion J:194295
increased interleukin-1 beta secretion J:194295
increased interleukin-6 secretion J:194295
increased interleukin-10 secretion J:194295
increased interleukin-17 secretion J:194295
increased susceptibility to bacterial infection J:194295
increased susceptibility to bacterial infection induced morbidity/mortality J:194295
\Del(18Pcdhg)1Xzw/\Del(18Pcdhg)1Xzw
(Not Specified)
microgliosis J:188341
\Del(19Poll-Dcpd)1Nmt/\Del(19Poll-Dcpd)1Nmt
(involves: 129P2/OlaHsd)
sinus inflammation J:75779
\Dennd1btm1.1Achn/\Dennd1btm1.1Achn
\Tg(Cd4-cre)1Cwi/0

(involves: C57BL/6 * DBA/2)
lymph node hyperplasia J:229307
\Dennd1btm1.2Achn/\Dennd1btm1.2Achn
(involves: C57BL/6)
abnormal interleukin secretion J:229307
abnormal T cell number J:229307
abnormal T-helper 2 physiology J:229307
immune system phenotype J:229307
lymph node hyperplasia J:229307
\Dennd5bem1(IMPC)Tcp/\Dennd5bem1(IMPC)Tcp
(C57BL/6N-Dennd5bem1(IMPC)Tcp/Tcp)
abnormal spleen morphology J:211773
increased leukocyte cell number J:211773
increased lymphocyte cell number J:211773
\Dennd5bm1Anu/\Dennd5bm1Anu
(C57BL/6NCrlAnu-Dennd5bm1Anu)
immune system phenotype J:104190
\Dennd10em1(IMPC)Ccpcz/\Dennd10em1(IMPC)Ccpcz
(C57BL/6NCrl-Dennd10em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
enlarged spleen J:211773
\Derm1NC/Nga/\Derm1NC/Nga
(involves: MSM/Ms * NC/Nga)
dermatitis J:68698
\DermsBALB/cByJ/?
(involves: BALB/cByJ * C3H/HeJ * C57BL/6J * DBA/2J)
dermatitis J:80574
\DermsDBA/2J/?
(involves: BALB/cByJ * C3H/HeJ * C57BL/6J * DBA/2J)
dermatitis J:80574
\Dexiem1Kslr/\Dexiem1Kslr
(NOD/ShiLtJ-Dexiem1Kslr)
immune system phenotype J:285312
\Dffbem1(IMPC)Wtsi/\Dffbem1(IMPC)Wtsi
(C57BL/6N-Dffbem1(IMPC)Wtsi/Wtsi)
increased anti-nuclear antigen antibody level J:211773
\Dffbtm1Osa/\Dffbtm1Osa
\Dnase2atm1Osa/\Dnase2atm1Osa

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
abnormal T cell differentiation J:81474
abnormal thymus morphology J:81474
decreased double-positive T cell number J:81474
increased double-negative T cell number J:81474
small thymus J:81474
thymus hypoplasia J:81474
\Dgcr2tm1b(EUCOMM)Wtsi/\Dgcr2tm1b(EUCOMM)Wtsi
(C57BL/6N-Dgcr2tm1b(EUCOMM)Wtsi/Bay)
abnormal spleen morphology J:211773
\Dgkatm1Xpz/\Dgkatm1Xpz
(involves: 129 * C57BL/6)
abnormal lymphocyte anergy J:113564
increased interleukin-2 secretion J:113564
increased T cell number J:113564
\Dgkatm1Xpz/\Dgkatm1Xpz
\Dgkztm1Gak/\Dgkztm1Gak

(involves: 129 * 129X1/SvJ * C57BL/6)
abnormal T cell differentiation J:113564
abnormal thymocyte activation J:113564
\Dgkztm1Gak/\Dgkztm1Gak
(involves: 129X1/SvJ * C57BL/6)
abnormal cytokine level J:293120
abnormal cytokine secretion J:293120
abnormal inflammatory response J:293120
abnormal interferon level J:85149
abnormal macrophage physiology J:293120
abnormal T cell activation J:85149
abnormal T cell physiology J:85149
decreased CD4-positive, alpha-beta T cell number J:85149
decreased CD8-positive, alpha-beta T cell number J:85149
decreased interleukin-6 secretion J:293120
decreased susceptibility to induced arthritis J:293120
decreased susceptibility to Riboviria infection J:85149
increased B cell number J:85149
increased T cell proliferation J:85149
\Dgkztm1Gak/\Dgkztm1Gak
(B6.129X1-Dgkztm1Gak)
abnormal interleukin-2 secretion J:113564
abnormal lymphocyte anergy J:113564
increased T cell number J:113564
\Dh/\Dh
(Not Specified)
absent spleen J:152370, J:112
\Dh/\Dh+
(Not Specified)
absent spleen J:152370, J:112
enlarged lymph nodes J:30753
increased granulocyte number J:30753
increased lymphocyte cell number J:30753
\Dh/\Dh+
(B6.CBA-Dh)
abnormal T cell differentiation J:5834
absent spleen J:5834
decreased immunoglobulin level J:5834
\Dh/\Dh+
\Foxn1nu/\Foxn1nu

(involves: N:NIH(S))
abnormal Peyer's patch morphology J:6062
absent spleen J:6062
athymia J:6062
decreased leukocyte cell number J:6062
increased IgA level J:6062
\Dh/\Dh+
\H2d/\H2d

(NZB.Cg-Dh)
absent spleen J:12036
decreased B cell proliferation J:12036
decreased IgG1 level J:12036
decreased IgG level J:12036
decreased IgM level J:12036
decreased susceptibility to graft versus host disease J:12036
glomerulonephritis J:12036
increased anti-erythrocyte antigen antibody level J:12036
increased anti-nuclear antigen antibody level J:12036
increased anti-single stranded DNA antibody level J:12036
increased autoantibody level J:12036
increased T cell proliferation J:12036
\Dhcr7em1(IMPC)Mbp/\Dhcr7+
(C57BL/6N-Dhcr7em1(IMPC)Mbp/MbpMmucd)
abnormal spleen morphology J:211773
enlarged spleen J:211773
\Dhfrorana/\Dhfr+
(involves: C57BL/6JAnu)
enlarged spleen J:236197
\Dhpstm2c(EUCOMM)Wtsi/\Dhpstm2c(EUCOMM)Wtsi
\Tg(CAG-cre/Esr1*)5Amc/0

(involves: C57BL/6J * C57BL/6N * CBA * SJL)
decreased spleen red pulp amount J:236582
spleen hypoplasia J:236582
\Dhrs4tm1Lex/\Dhrs4tm1Lex
(involves: 129S5/SvEvBrd * C57BL/6J)
abnormal humoral immune response J:171883
decreased IgG2a level J:171883
\Dhrs7bGt(OST255410)Lex/\Dhrs7bGt(OST255410)Lex
(B6;129S5-Dhrs7bGt(OST255410)Lex/Mmucd)
thymus atrophy J:171883
\Dhx8em1(IMPC)Mbp/\Dhx8+
(C57BL/6NCrl-Dhx8em1(IMPC)Mbp/Mmucd)
abnormal spleen morphology J:211773
enlarged thymus J:211773
\Dhx9Tn(pb-Act-RFP)1.071225026-HRAZhu/\Dhx9+
(involves: FVB/NJ)
immune system phenotype J:207361
\Dhx9Tn(pb-Act-RFP)1.071225026-HRAZhu/\Dhx9+
\Igs12tm1Zhu/\Igs12tm1Zhu
\Ptprca/\Ptprcb
\Tg(Lck-cre)#Zhu/0

(involves: 129S6/SvEvTac * C57BL/6 * FVB/NJ * SJL/J)
abnormal T cell differentiation J:207361
\Dhx15tm1c(EUCOMM)Wtsi/\Dhx15tm1c(EUCOMM)Wtsi
\Cd19tm1(cre)Cgn/\Cd19+

(involves: 129P2/OlaHsd * C3H * C57BL/6N)
abnormal B cell differentiation J:284624
decreased B cell number J:284624
decreased B cell proliferation J:284624
decreased pre-B cell number J:284624
decreased spleen weight J:284624
spleen hypoplasia J:284624
\Dhx15tm1c(EUCOMM)Wtsi/\Dhx15tm1c(EUCOMM)Wtsi
\Tg(Cd4-cre)1Cwi/0

(involves: C3H * C57BL/6N * DBA/2)
decreased CD4-positive, alpha-beta T cell number J:284624
decreased CD8-positive, alpha-beta T cell number J:284624
\Dhx35tm1b(EUCOMM)Wtsi/\Dhx35tm1b(EUCOMM)Wtsi
(C57BL/6N-Dhx35tm1b(EUCOMM)Wtsi/Wtsi)
absent connection between subcutaneous lymph vessels and lymph sac J:239583
\Dhx36tm1.2Pmt/\Dhx36tm1.2Pmt
\Commd10Tg(Vav1-icre)A2Kio/\Commd10+

(involves: 129P2/Ola * 129S4/SvJaeSor * C57BL/6 * C57BL/10 * CBA/Ca)
enlarged spleen J:185179
intermingled spleen red and white pulp J:185179
thymus hypoplasia J:185179
\Dhx36tm1.2Pmt/\Dhx36tm1.2Pmt
\Tg(Mx1-cre)1Cgn/0

(involves: 129P2/Ola * 129S4/SvJaeSor * C57BL/6 * CBA)
abnormal leukopoiesis J:185179
\Dhx40tm1b(KOMP)Wtsi/\Dhx40tm1b(KOMP)Wtsi
(C57BL/6N-Dhx40tm1b(KOMP)Wtsi/Wtsi)
increased spleen weight J:211773
\Dhx58tm1Aki/\Dhx58tm1Aki
(involves: 129/Sv * C57BL/6)
decreased circulating interferon-beta level J:156867
decreased interferon-beta secretion J:156867
decreased interleukin-6 secretion J:156867
increased susceptibility to Picornaviridae infection J:156867
increased susceptibility to Picornaviridae infection induced morbidity/mortality J:156867
\Dhx58tm1Gnb/\Dhx58tm1Gnb
(involves: 129P2/OlaHsd * C57BL/6J)
abnormal interferon secretion J:146113
abnormal susceptibility to Riboviria infection J:146113
decreased interferon-alpha secretion J:146113
decreased interferon-beta secretion J:146113
decreased susceptibility to Riboviria infection J:146113
increased circulating interferon-gamma level J:146113
increased circulating interleukin-12 level J:146113
increased interferon-alpha secretion J:146113
increased interferon-beta secretion J:146113
increased susceptibility to Picornaviridae infection J:146113
\Dhx58tm1Itl/\Dhx58tm1Itl
(C57BL/6-Dhx58tm1Itl)
decreased interferon-beta secretion J:187386
decreased interferon-gamma secretion J:187386
decreased tumor necrosis factor secretion J:187386
increased susceptibility to Flaviviridae infection J:187386
increased susceptibility to Flaviviridae infection induced morbidity/mortality J:187386
increased T cell apoptosis J:187386
\Dhx58tm2.1Aki/\Dhx58tm2.1Aki
(involves: 129/Sv * C57BL/6)
decreased interferon-beta secretion J:156867
decreased interleukin-6 secretion J:156867
increased susceptibility to Picornaviridae infection J:156867
increased susceptibility to Picornaviridae infection induced morbidity/mortality J:156867
\Diaph1M1Btlr/\Diaph1+
(C57BL/6J-Diaph1M1Btlr)
abnormal CD4-positive, alpha-beta T cell number J:254820
abnormal CD8-positive, alpha-beta T cell number J:254820
decreased IgE level J:254820
increased central memory CD4-positive, alpha-beta T cell number J:254820
increased central memory CD8 positive, alpha-beta T cell number J:254820
\Diaph1M1Btlr/\Diaph1M1Btlr
(C57BL/6J-Diaph1M1Btlr)
abnormal CD4-positive, alpha-beta T cell number J:254820
abnormal CD8-positive, alpha-beta T cell number J:254820
decreased effector memory CD8-positive, alpha-beta T cell number J:254820
decreased IgE level J:254820
increased central memory CD4-positive, alpha-beta T cell number J:254820
increased central memory CD8 positive, alpha-beta T cell number J:254820
increased susceptibility to Herpesvirales infection induced morbidity/mortality J:254820
\Diaph1M2Btlr/\Diaph1+
(C57BL/6J-Diaph1M2Btlr)
decreased B-1 B cell number J:254819
\Diaph1M2Btlr/\Diaph1M2Btlr
(C57BL/6J-Diaph1M2Btlr)
decreased B-1 B cell number J:254819
decreased CD8-positive, alpha-beta memory T cell number J:254819
\Diaph1m3Btlr/\Diaph1m3Btlr
(C57BL/6J-Diaph1m3Btlr)
decreased CD4-positive, CD25-positive, alpha-beta regulatory T cell number J:254818
decreased CD8-positive, naive alpha-beta T cell number J:254818
increased CD4-positive, CD25-positive, alpha-beta regulatory T cell number J:254818
increased CD8-positive, alpha-beta memory T cell number J:254818
increased central memory CD4-positive, alpha-beta T cell number J:254818
increased central memory CD8 positive, alpha-beta T cell number J:254818
increased effector memory CD4-positive, alpha-beta T cell number J:254818
increased effector memory CD8-positive, alpha-beta T cell number J:254818
\Diaph1tm1.1Sna/\Diaph1tm1.1Sna
(B6.Cg-Diaph1tm1.1Sna)
abnormal humoral immune response J:126090
abnormal leukocyte migration J:126090
decreased CD4-positive, alpha-beta T cell number J:126090
decreased CD8-positive, alpha-beta T cell number J:126090
decreased T cell number J:126090
decreased T cell proliferation J:126090
increased single-positive T cell number J:126090
\Diaph1tm1Asal/\Diaph1tm1Asal
(involves: 129S1/Sv * C57BL/6)
abnormal lymph node morphology J:124319
abnormal spleen germinal center morphology J:124319
abnormal spleen morphology J:124319
absent spleen white pulp J:124319
decreased lymphocyte cell number J:124319
dermatitis J:124319
increased granulocyte number J:124319
increased leukocyte cell number J:124319
increased monocyte cell number J:124319
increased neutrophil cell number J:124319
increased spleen weight J:124319
\Diaph3tm1.1Pji/\Diaph3tm1.1Pji
\Tg(Mx1-cre)1Cgn/0

(involves: C57BL/6J * CBA/J)
enlarged spleen J:293763
\Dice1bC57BL/10Sn/\Dice1bC57BL/10Sn
(involves: B10.D2-H2d/oSnJ * BALB/cAnN)
decreased susceptibility to parasitic infection J:95337
\Dicer1Gt(RRF266)Byg/\Dicer1Gt(RRF266)Byg
(involves: 129P2/OlaHsd * C57BL/6)
decreased susceptibility to Riboviria infection J:123635
increased susceptibility to Herpesvirales infection J:123635
increased susceptibility to Riboviria infection J:123635
\Dicer1m1Btlr/\Dicer1m1Btlr
(C57BL/6J-Dicer1m1Btlr)
decreased CD4-positive, alpha-beta T cell number J:265172
decreased CD8-positive, alpha-beta T cell number J:265172
decreased CD8-positive, naive alpha-beta T cell number J:265172
decreased single-positive T cell number J:265172
decreased T cell number J:265172
increased B-1 B cell number J:265172
increased central memory CD8 positive, alpha-beta T cell number J:265172
increased effector memory CD4-positive, alpha-beta T cell number J:265172
increased effector memory CD8-positive, alpha-beta T cell number J:265172
\Dicer1tm1b(EUCOMM)Wtsi/\Dicer1+
(C57BL/6N-Dicer1tm1b(EUCOMM)Wtsi/H)
absent spleen J:211773
decreased neutrophil cell number J:211773
decreased spleen weight J:211773
\Dicer1tm1Bdh/\Dicer1+
\H2az2Tg(Wnt1-cre)11Rth/\H2az2+

(involves: 129 * C57BL/6 * CBA/J)
abnormal thymus development J:166758
\Dicer1tm1Bdh/\Dicer1tm1Bdh
\Aicdatm1(cre)Njen/\Aicda+

(involves: 129 * C57BL/6)
abnormal germinal center B cell physiology J:181782
abnormal humoral immune response J:181782
absent memory B cells J:181782
absent plasma cells J:181782
decreased germinal center B cell number J:181782
decreased immunoglobulin level J:181782
immune system phenotype J:181782
\Dicer1tm1Bdh/\Dicer1tm1Bdh
\Foxp3tm4(YFP/icre)Ayr/Y

(involves: 129S1/Sv * 129X1/SvJ)
blood vessel inflammation J:138683
enlarged lymph nodes J:138683
enlarged spleen J:138683
liver inflammation J:138683
lung inflammation J:138683
\Dicer1tm1Bdh/\Dicer1tm1Bdh
\Foxp3tm4(YFP/icre)Ayr/\Foxp3tm4(YFP/icre)Ayr

(involves: 129S1/Sv * 129X1/SvJ)
blood vessel inflammation J:138683
enlarged lymph nodes J:138683
enlarged spleen J:138683
liver inflammation J:138683
lung inflammation J:138683
\Dicer1tm1Bdh/\Dicer1tm1Bdh
\H2az2Tg(Wnt1-cre)11Rth/\H2az2+

(involves: 129 * C57BL/6 * CBA/J)
athymia J:166758
\Dicer1tm1Bdh/\Dicer1tm1Bdh
\Tg(Cd4-cre)1Cwi/0

(involves: 129 * C57BL/6 * DBA/2)
decreased regulatory T cell number J:138683
\Dicer1tm1Bdh/\Dicer1tm1Bdh
\Tg(Foxp3-EGFP/icre)1aJbs/0

(involves: 129 * NOD/ShiLt)
abnormal CD4-positive, alpha-beta T cell physiology J:138808
abnormal effector T cell morphology J:138808
abnormal lymph node cell ratio J:138808
abnormal regulatory T cell morphology J:138808
abnormal regulatory T cell physiology J:138808
abnormal splenic cell ratio J:138808
decreased regulatory T cell number J:138808
enlarged lymph nodes J:138808
enlarged spleen J:138808
liver inflammation J:138808
lung inflammation J:138808
\Dicer1tm1Dli/\Dicer1tm1Dli
\Tg(Cd4-cre)1Cwi/?

(involves: 129 * C57BL/6 * DBA/2)
abnormal cytotoxic T cell physiology J:100546
abnormal T-helper 1 physiology J:100546
abnormal T-helper 2 physiology J:100546
decreased T cell number J:100546
decreased T cell proliferation J:100546
immune system phenotype J:100546
increased T cell apoptosis J:100546
\Dicer1tm1Mmk/\Dicer1tm1.1Mmk
\Cd79atm1(cre)Reth/\Cd79a+

(involves: BALB/c)
abnormal immunoglobulin V(D)J recombination J:135783
decreased B cell number J:135783
\Dicer1tm1Mmk/\Dicer1tm1Mmk
\Cd79atm1(cre)Reth/\Cd79a+

(involves: BALB/c)
arrested B cell differentiation J:135783
decreased immature B cell number J:135783
decreased mature B cell number J:135783
decreased pre-B cell number J:135783
increased pro-B cell number J:135783
\Dicer1tm1Mmk/\Dicer1tm1Mmk
\Tg(IghelMD4)4Ccg/0
\Cd79atm1(cre)Reth/\Cd79a+

(involves: BALB/c)
decreased B cell number J:135783
decreased mature B cell number J:135783
\Dicer1tm1Mmk/\Dicer1tm1Mmk
\Tg(Lck-cre)1Cwi/0

(involves: C57BL/6 * DBA/2)
decreased T cell number J:98192
decreased thymocyte number J:98192
increased gamma-delta T cell number J:98192
\Dicer1tm1Mmk/\Dicer1tm1Mmk
\Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0

(involves: 129 * C57BL/6 * CD-1)
abnormal granulocyte differentiation J:158901
abnormal myeloid leukocyte morphology J:158901
abnormal neutrophil morphology J:158901
decreased B cell number J:158901
decreased leukocyte cell number J:158901
enlarged spleen J:158901
\Dicer1tm1Tara/\Dicer1tm1Tara
\Foxn1tm3(cre)Nrm/\Foxn1+

(involves: 129P2/OlaHsd * C57BL/6NHsd)
abnormal positive T cell selection J:180783
abnormal thymus cortex morphology J:180783
abnormal thymus epithelium morphology J:180783
abnormal thymus involution J:180783
abnormal thymus medulla morphology J:180783
abnormal thymus morphology J:180783
abnormal thymus physiology J:180783
decreased CD4-positive, alpha-beta T cell number J:180783
decreased CD8-positive, alpha-beta T cell number J:180783
increased susceptibility to induced arthritis J:180783
\Dido1tm1Cmar/\Dido1+
(involves: 129S1/Sv * 129X1/SvJ)
abnormal splenic cell ratio J:101201
abnormal splenocyte morphology J:101201
increased granulocyte number J:101201
increased monocyte cell number J:101201
increased spleen weight J:101201
spleen hyperplasia J:101201
\Dido1tm1Cmar/\Dido1tm1Cmar
(involves: 129S1/Sv * 129X1/SvJ)
abnormal splenic cell ratio J:101201
abnormal splenocyte morphology J:101201
immune system phenotype J:101201
increased granulocyte number J:101201
increased monocyte cell number J:101201
increased spleen weight J:101201
increased spleen white pulp amount J:101201
spleen hyperplasia J:101201
\Dido1tm3Cmar/\Dido1tm3.1Cmar
\Ndor1Tg(UBC-cre/ERT2)1Ejb/\Ndor1+

(involves: 129S/SvEv * C57BL/6)
liver inflammation J:328215
\Dip2btm1a(EUCOMM)Wtsi/\Dip2b+
(B6JTyr;B6N-Dip2btm1a(EUCOMM)Wtsi/Wtsi)
decreased leukocyte cell number J:175295
\Dip2cem1(IMPC)Tcp/\Dip2c+
(C57BL/6N-Dip2cem1(IMPC)Tcp/Tcp)
enlarged lymph nodes J:211773
increased monocyte cell number J:211773
small thymus J:211773
\Dipk2bem1(IMPC)Mbp/\Dipk2bem1(IMPC)Mbp
(C57BL/6N-Dipk2bem1(IMPC)Mbp/MbpMmucd)
abnormal lymph node morphology J:211773
enlarged lymph nodes J:211773
\Dis3tm1.1Uba/\Dis3tm1.1Uba
\Gt(ROSA)26Sortm9(cre/ESR1)Arte/\Gt(ROSA)26Sor+

(involves: 129S6/SvEvTac * C57BL/6 * C57BL/6NTac)
abnormal B cell morphology J:302856
abnormal class switch recombination J:302856
\Dis3lem1(IMPC)Ccpcz/\Dis3l+
(C57BL/6NCrl-Dis3lem1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
increased eosinophil cell number J:211773
\Disc1em1(IMPC)Mbp/\Disc1em1(IMPC)Mbp
(C57BL/6N-Disc1em1(IMPC)Mbp/MbpMmucd)
abnormal spleen morphology J:211773
\Disp3em1(IMPC)Mbp/\Disp3em1(IMPC)Mbp
(C57BL/6N-Disp3em1(IMPC)Mbp/Ucd)
abnormal lymph node morphology J:211773
abnormal spleen morphology J:211773
enlarged lymph nodes J:211773
enlarged spleen J:211773
\Dkc1tm1.1Pjma/Y
(B6.129X1(FVB)-Dkc1tm1.1Pjma)
decreased B cell number J:217050
decreased T cell number J:217050
\Dkc1tm1Ppp/Y
(involves: 129S1/Sv)
abnormal spleen morphology J:81054
decreased B cell number J:81054
decreased leukocyte cell number J:81054
decreased lymphocyte cell number J:81054
decreased pre-B cell number J:81054
decreased spleen red pulp amount J:81054
decreased spleen white pulp amount J:81054
enlarged spleen J:81054
lung inflammation J:81054
\Dkc1tm1Ppp/\Dkc1+
(involves: 129S1/Sv)
abnormal immune system cell morphology J:81054
abnormal immune system organ morphology J:81054
\Dkk2tm1Dwu/\Dkk2tm1Dwu
(involves: 129)
abnormal osteoclast differentiation J:100858
increased osteoclast cell number J:100858
\Dkk3tm1Cni/\Dkk3tm1Cni
(involves: 129X1/SvJ * C57BL/6)
decreased NK cell number J:106922
increased IgM level J:106922
\Dlg1tm1Rlh/\Dlg1tm1Rlh
\Tg(Cd4-cre)1Cwi/0

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2)
abnormal CD4-positive, alpha-beta T cell physiology J:191788
abnormal cytokine secretion J:191788
abnormal T-helper 1 physiology J:191788
abnormal T-helper 2 physiology J:191788
decreased interferon-gamma secretion J:191788
decreased interleukin-2 secretion J:191788
decreased tumor necrosis factor secretion J:191788
increased interleukin-4 secretion J:191788
increased interleukin-5 secretion J:191788
\Dlgap2em1(IMPC)Mhzh/\Dlgap2em1(IMPC)Mhzh
(C57BL/6N-Dlgap2em1(IMPC)Mhzh/Mhzh)
decreased lymphocyte cell number J:211773
increased eosinophil cell number J:211773
increased neutrophil cell number J:211773
\Dlk1tm1.1Jvs/\Dlk1+
\Myf5tm3(cre)Sor/\Myf5+

(involves: 129P2/SvPas * 129S4/SvJaeSor * C57BL/6 * FVB/N)
increased inflammatory response J:167124
\Dlk1tm1Srba/\Dlk1tm1Srba
(involves: 129X1/SvJ * C57BL/6)
abnormal B cell number J:145076
abnormal spleen B cell follicle morphology J:145076
abnormal spleen marginal zone morphology J:145076
decreased immature B cell number J:145076
decreased mature B cell number J:145076
increased IgG1 level J:145076
increased IgG2a level J:145076
increased IgG2b level J:145076
increased IgG2c level J:145076
increased IgG3 level J:145076
increased IgM level J:145076
increased immature B cell number J:145076
increased immunoglobulin level J:145076
increased marginal zone B cell number J:145076
increased transitional stage B cell number J:145076
\Dll1m1Mhda/\Dll1+
(C3HeB/FeJ-Dll1m1Mhda)
immune system phenotype J:150183
\Dll1tm1Gos/\Dll1+
(C3Fe.129-Dll1tm1Gos)
decreased B-1 B cell number J:150183
decreased CD4-positive, alpha-beta T cell number J:150183
decreased CD8-positive, alpha-beta T cell number J:150183
decreased IgA level J:150183
decreased IgG1 level J:150183
decreased IgG2b level J:150183
decreased IgG3 level J:150183
increased B cell number J:150183
increased CD8-positive, alpha-beta T cell number J:150183
\Dll1tm1Gos/\Dll1+
(involves: 129S1/Sv * 129X1/SvJ)
decreased CD4-positive, alpha-beta T cell number J:150183
increased B cell number J:150183
\Dll1tm1Mjo/\Dll1tm1Mjo
\Tg(KRT5-cre)1Tak/?
\Tg(Mx1-cre)1Cgn/?

(involves: 129 * C3H * C57BL/6 * CBA)
immune system phenotype J:90630
\Dll1tm1Mjo/\Dll1tm1Mjo
\Tg(Mx1-cre)1Cgn/?

(involves: 129 * C57BL/6 * CBA)
absent marginal zone B cells J:90630
\Dll1tm3.1Gos/\Dll1tm3.1Gos
(Not Specified)
immune system phenotype J:213529
\Dll4tm1Frad/\Dll4tm1Frad
\Foxn1tm3(cre)Nrm/\Foxn1+

(B6.Cg-Dll4tm1Frad Foxn1tm3(cre)Nrm)
abnormal T cell differentiation J:143472
abnormal thymus cell ratio J:143472
decreased CD4-positive, alpha-beta T cell number J:143472
decreased CD8-positive, alpha-beta T cell number J:143472
decreased double-positive T cell number J:143472
decreased thymocyte number J:143472
increased immature B cell number J:143472
\Dll4tm1Frad/\Dll4tm1Frad
\Tg(Mx1-cre)1Cgn/0

(B6.Cg-Dll4tm1Frad Tg(Mx1-cre)1Cgn)
immune system phenotype J:143472
\Dll4tm1Kaho/\Dll4tm1Kaho
\Tg(Foxn1-cre)8Ghr/0

(involves: C57BL/6 * DBA/2)
abnormal lymphopoiesis J:143473
absent CD4-positive, alpha-beta T cells J:143473
absent CD8-positive, alpha-beta T cells J:143473
decreased double-positive T cell number J:143473
thymus hypoplasia J:143473
\Dmbt1tm1Janm/\Dmbt1tm1Janm
(involves: 129P2/OlaHsd * C57BL/6)
increased susceptibility to induced colitis J:130258
\Dmdem1Cmusr/Y
(BALB/c-Dmdem1Cmusr)
enlarged spleen J:353371
\Dmdem1Eno/Y
(involves: C57BL/6J)
myositis J:253191
\Dmdem4Eno/Y
(C57BL/6-Dmdem4Eno)
myositis J:285447
\Dmdem4Eno/\Dmdem4Eno
(C57BL/6-Dmdem4Eno)
myositis J:285447
\Dmdmdx/Y
(C57BL/10ScSn-Dmdmdx/J)
increased interferon-gamma secretion J:150572
increased interleukin-2 secretion J:150572
increased interleukin-4 secretion J:150572
increased interleukin-6 secretion J:150572
increased interleukin-12 secretion J:150572
increased tumor necrosis factor secretion J:150572
\Dmdmdx/Y
(involves: C57BL/10ScSn)
diaphragmitis J:140282
myositis J:140282
\Dmdmdx/Y
\Spp1tm1Blh/\Spp1tm1Blh

(involves: 129S6/SvEvTac * C57BL/6 * C57BL/10 * C57BL/10ScSn)
decreased granulocyte number J:150572
decreased neutrophil cell number J:150572
decreased T cell number J:150572
increased regulatory T cell number J:150572
increased T cell number J:150572
\Dmdmdx/Y
\Terctm1Rdp/\Terctm1Rdp

(involves: 129/Sv * C57BL/6J * C57BL/10ScSn * SJL)
myositis J:167294
\Dmdmdx/Y
\Tg(DMD*)#Spc/0

(involves: 129P2/OlaHsd * C57BL/10ScSn * DBA/2)
myositis J:280218
\Dmdmdx/Y
\Utrntm1Jrs/\Utrn+

(involves: 129S1/Sv * 129X1/SvJ * C57BL/10ScSn)
diaphragmitis J:140282
myositis J:140282
\Dmdmdx/\Dmdmdx
(C57BL/10ScSn-Dmdmdx/J)
increased interferon-gamma secretion J:150572
increased interleukin-2 secretion J:150572
increased interleukin-4 secretion J:150572
increased interleukin-6 secretion J:150572
increased interleukin-12 secretion J:150572
increased tumor necrosis factor secretion J:150572
myositis J:226314
\Dmdmdx/\Dmdmdx
(D2.B10-Dmdmdx/J)
heart inflammation J:226314
myositis J:226314
\Dmdmdx/\Dmdmdx
\Dusp1tm1Brv/\Dusp1tm1Brv

(involves: 129S2/SvPas * C57BL/6 * C57BL/10ScSn)
myositis J:162340
\Dmdmdx/\Dmdmdx
\Mmp9tm1Tvu/\Mmp9+

(B10.Cg-Mmp9tm1Tvu Dmdmdx)
decreased macrophage cell number J:150030
\Dmdmdx/\Dmdmdx
\Mmp9tm1Tvu/\Mmp9tm1Tvu

(B10.Cg-Mmp9tm1Tvu Dmdmdx)
decreased macrophage cell number J:150030
\Dmdmdx/\Dmdmdx
\Prkdcscid/\Prkdcscid

(involves: BALB/c * C57BL/10ScSn * C57BL/Ka)
absent CD4-positive, alpha-beta T cells J:125527
absent CD8-positive, alpha-beta T cells J:125527
decreased B cell number J:125527
\Dmdmdx/\Dmdmdx
\Spp1tm1Blh/\Spp1tm1Blh

(involves: 129S6/SvEvTac * C57BL/6 * C57BL/10 * C57BL/10ScSn)
decreased granulocyte number J:150572
decreased neutrophil cell number J:150572
decreased T cell number J:150572
increased regulatory T cell number J:150572
increased T cell number J:150572
\Dmdtm1.1Know/\Dmdtm1.1Know
(involves: C3H)
decreased susceptibility to Picornaviridae infection J:207775
myocarditis J:207775
\Dmdtm1Kmf/Y
(involves: C57BL/6)
myositis J:233298
\Dmp1tm1Mis/\Dmp1tm1Mis
(involves: 129S7/SvEvBrd * C57BL/6)
increased susceptibility to bacterial infection J:241769
\Dmp1tm1Mis/\Dmp1tm1Mis
(involves: 129S7/SvEvBrd * CD-1)
abnormal bone marrow development J:184352
decreased osteoclast cell number J:184352
\Dmtf1tm1Cjs/\Dmtf1+
\Krastm2Tyj/\Kras+

(involves: 129S2/SvPas * C57BL/6)
increased T cell derived lymphoma incidence J:126002
\Dmtf1tm1Cjs/\Dmtf1+
\Krastm3Tyj/\Kras+

(involves: 129S4/SvJae * C57BL/6)
increased T cell derived lymphoma incidence J:126002
\Dmtf1tm1Cjs/\Dmtf1tm1Cjs
(involves: 129/Sv * C57BL/6)
abnormal T cell physiology J:63444
decreased thymocyte number J:63444
\Dmtf1tm1Cjs/\Dmtf1tm1Cjs
\Krastm2Tyj/\Kras+

(involves: 129S2/SvPas * C57BL/6)
increased T cell derived lymphoma incidence J:126002
\Dmtf1tm1Cjs/\Dmtf1tm1Cjs
\Krastm3Tyj/\Kras+

(involves: 129S4/SvJae * C57BL/6)
increased T cell derived lymphoma incidence J:126002
\Dmxl2tm1a(EUCOMM)Wtsi/\Dmxl2tm1a(EUCOMM)Wtsi
(C57BL/6N-Atm1Brd Dmxl2tm1a(EUCOMM)Wtsi/WtsiH)
blood in lymph vessels J:239583
\Dnaaf4b2b811.1Clo/\Dnaaf4b2b811.1Clo
(C57BL/6J-Dnaaf4b2b811.1Clo)
abnormal spleen morphology J:205312
\Dnaaf4tm1.2Jjlo/\Dnaaf4tm1.2Jjlo
(involves: 129S1/Sv * 129S4/SvJaeSor * 129S6/SvEvTac * C57BL/6J)
abnormal spleen morphology J:205312
\Dnaaf5em1Slb/\Dnaaf5em1Slb
(C57BL/6-Dnaaf5em1Slb)
sinus inflammation J:342770
\Dnaaf5em1Slb/\Dnaaf5em2Slb
(C57BL/6-Dnaaf5em1Slb Dnaaf5em2Slb)
sinus inflammation J:342770
\Dnaaf9tm1b(EUCOMM)Hmgu/\Dnaaf9tm1b(EUCOMM)Hmgu
(C57BL/6N-Dnaaf9tm1b(EUCOMM)Hmgu/Tcp)
increased neutrophil cell number J:211773
\Dnah2em1(IMPC)Tcp/\Dnah2em1(IMPC)Tcp
(C57BL/6N-Dnah2em1(IMPC)Tcp/Tcp)
abnormal lymph node morphology J:211773
\Dnah5b2b2451Clo/\Dnah5b2b2451Clo
(C57BL/6J-Dnah5b2b2451Clo)
abnormal spleen morphology J:175213
\Dnah5b2b2925Clo/\Dnah5b2b2925Clo
(C57BL/6J-Dnah5b2b2925Clo)
absent spleen J:175213
\Dnah5hlb612/\Dnah5hlb612
(involves: C57BL/6J)
abnormal spleen morphology J:130755
absent spleen J:130755
\Dnah5Tg1Htz/\Dnah5Tg1Htz
(involves: C57BL/6 * CBA/J)
increased susceptibility to otitis media J:76189
sinus inflammation J:76189
\Dnah11b2b1289Clo/\Dnah11b2b1289Clo
(C57BL/6J-Dnah11b2b1289Clo)
accessory spleen J:175213
\Dnah11b2b1727Clo/\Dnah11b2b1727Clo
(C57BL/6J-Dnah11b2b1727Clo)
spleen hypoplasia J:175213
\Dnah11b2b1775Clo/\Dnah11b2b1775Clo
(C57BL/6J-Dnah11b2b1775Clo)
spleen hypoplasia J:175213
\Dnah11iv/\Dnah11iv
(SI/Col Tyrp1b Dnah11iv/J)
abnormal spleen morphology J:4058
\Dnai1b2b1526Clo/\Dnai1b2b1526Clo
(C57BL/6J-Dnai1b2b1526Clo)
spleen hypoplasia J:175213
\Dnai1tm1.1Leo/\Dnai1tm1.1Leo
\Gt(ROSA)26Sortm1(cre/ERT)Nat/\Gt(ROSA)26Sor+

(involves: 129 * C57BL/6)
rhinosinusitis J:155730
\Dnai2em1(IMPC)Tcp/\Dnai2+
(C57BL/6NCrl-Dnai2em1(IMPC)Tcp/Tcp)
enlarged lymph nodes J:211773
\Dnajc2em1(IMPC)J/\Dnajc2+
(C57BL/6NJ-Dnajc2em1(IMPC)J/Mmjax)
increased leukocyte cell number J:211773
\Dnajc3m1Btlr/\Dnajc3m1Btlr
(C57BL/6J-Dnajc3m1Btlr)
increased CD4-positive, alpha-beta T cell number J:265248
increased CD8-positive, alpha-beta memory T cell number J:265248
increased single-positive T cell number J:265248
increased susceptibility to induced colitis J:265248
increased T cell number J:265248
\Dnajc11spc/\Dnajc11spc
(B6.Cg-Dnajc11spc)
decreased B cell number J:221543
decreased double-positive T cell number J:221543
decreased leukocyte cell number J:221543
decreased thymus weight J:221543
enlarged thymus medulla J:221543
increased CD4-positive, alpha-beta T cell number J:221543
increased CD8-positive, alpha-beta T cell number J:221543
increased DN1 thymic pro-T cell number J:221543
increased double-negative T cell number J:221543
spleen hypoplasia J:221543
thymus cortex atrophy J:221543
thymus hypoplasia J:221543
\Dnajc15Gt(RRN226)Byg/\Dnajc15Gt(RRN226)Byg
(B6.129P2-Dnajc15Gt(RRN226)Byg)
abnormal CD8-positive, alpha beta T cell morphology J:204025
immune system phenotype J:204025
\Dnajc15tm1b(KOMP)Wtsi/\Dnajc15tm1b(KOMP)Wtsi
(C57BL/6N-Dnajc15tm1b(KOMP)Wtsi/Bay)
abnormal spleen morphology J:211773
\Dnal1tm1.1(KOMP)Vlcg/\Dnal1+
(C57BL/6N-Dnal1tm1.1(KOMP)Vlcg/Ucd)
decreased eosinophil cell number J:211773
\Dnase1tm1Tmo/\Dnase1+
(involves: 129P2/OlaHsd * C57BL/6)
enlarged spleen J:62549
glomerulonephritis J:62549
increased anti-nuclear antigen antibody level J:62549
kidney inflammation J:62549
\Dnase1tm1Tmo/\Dnase1tm1Tmo
(involves: 129P2/OlaHsd * C57BL/6)
enlarged spleen J:62549
glomerulonephritis J:62549
increased anti-nuclear antigen antibody level J:62549
increased susceptibility to systemic lupus erythematosus J:62549
kidney inflammation J:62549
\Dnase1tm1Tmo/\Dnase1tm1Tmo
(involves: 129P2/OlaHsd * CD-1)
decreased susceptibility to systemic lupus erythematosus J:110060
\Dnase1tm2092.1Arte/\Dnase1tm2092.1Arte
(involves: C57BL/6)
glomerulonephritis J:277126
increased anti-double stranded DNA antibody level J:277126
increased anti-histone antibody level J:277126
increased anti-nuclear antigen antibody level J:277126
increased autoantibody level J:277126
increased susceptibility to systemic lupus erythematosus J:277126
\Dnase1l2em1(IMPC)Bay/\Dnase1l2em1(IMPC)Bay
(C57BL/6N-Dnase1l2em1(IMPC)Bay/Bay)
abnormal spleen morphology J:211773
\Dnase1l2tm1.1(KOMP)Wtsi/\Dnase1l2tm1.1(KOMP)Wtsi
(C57BL/6N-Dnase1l2tm1.1(KOMP)Wtsi/Bay)
abnormal spleen morphology J:211773
\Dnase1l3em1(IMPC)Mbp/\Dnase1l3em1(IMPC)Mbp
(C57BL/6NCrl-Dnase1l3em1(IMPC)Mbp/MbpMmucd)
abnormal spleen morphology J:211773
enlarged spleen J:211773
increased spleen weight J:211773
\Dnase2atm1Osa/\Dnase2atm1Osa
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
abnormal thymus morphology J:81474
small thymus J:81474
thymus hypoplasia J:81474
\Dnase2atm1Osa/\Dnase2atm1Osa
\Ifnar1tm1Agt/\Ifnar1tm1Agt

(involves: 129S1/Sv * 129S2/SvPas * 129X1/SvJ * C57BL/6)
abnormal cytokine level J:114982
abnormal macrophage morphology J:114982
abnormal spleen morphology J:238323
enlarged spleen J:238323, J:114982
increased anti-double stranded DNA antibody level J:114982
increased autoantibody level J:238323
increased circulating interleukin-10 level J:238323
increased circulating interleukin-18 level J:114982
increased circulating tumor necrosis factor level J:238323, J:114982
increased spleen red pulp amount J:114982
increased spleen weight J:238323
joint inflammation J:238323, J:114982
rheumatoid arthritis J:238323, J:114982
\Dnase2atm1Osa/\Dnase2atm2Osa
\Tg(Mx1-cre)1Cgn/0

(involves: 129S1/Sv * 129S2/SvPas * 129X1/SvJ * C57BL/6 * CBA)
abnormal cytokine level J:114982
abnormal macrophage morphology J:114982
increased circulating interleukin-18 level J:114982
increased circulating tumor necrosis factor level J:114982
joint inflammation J:114982
rheumatoid arthritis J:114982
\Dnm2tm2.1Ics/\Dnm2+
(involves: C57BL/6J)
immune system phenotype J:288372
increased macrophage cell number J:288372
\Dnmbpem1(IMPC)Mbp/\Dnmbpem1(IMPC)Mbp
(C57BL/6N-Dnmbpem1(IMPC)Mbp/Ucd)
abnormal spleen morphology J:211773
enlarged spleen J:211773
\Dnmt1tm1(tetO-BCL2)Sjk/\Dnmt1+
\Tg(IghMyc)22Bri/0
\Tg(MMTVtTA)1Mam/0

(involves: 129S4/SvJae * C57BL/6)
enlarged spleen J:93549
\Dnmt1tm2Jae/\Dnmt1tm2Jae
\Cd79atm1(cre)Reth/\Cd79a+

(involves: 129S4/SvJae * BALB/c * C57BL/6)
abnormal B cell differentiation J:113645
decreased pro-B cell number J:113645
\Dnmt3btm1Enl/\Dnmt3btm6Enl
(involves: 129S4/SvJae * C57BL/6)
decreased thymocyte number J:106540
increased thymocyte apoptosis J:106540
small thymus J:106540
\Dnmt3btm1Enl/\Dnmt3btm7Enl
(involves: 129S4/SvJae * C57BL/6)
decreased double-positive T cell number J:106540
decreased thymocyte number J:106540
increased double-negative T cell number J:106540
increased thymocyte apoptosis J:106540
small thymus J:106540
\Dnmt3btm6Enl/\Dnmt3btm6Enl
(involves: 129S4/SvJae * C57BL/6)
decreased thymocyte number J:106540
increased thymocyte apoptosis J:106540
small thymus J:106540
\Dnmt3btm6Enl/\Dnmt3btm7Enl
(involves: 129S4/SvJae * C57BL/6)
decreased thymocyte number J:106540
increased thymocyte apoptosis J:106540
\Dnmt3btm7Enl/\Dnmt3btm7Enl
(involves: 129S4/SvJae * C57BL/6)
decreased thymocyte number J:106540
increased thymocyte apoptosis J:106540
small thymus J:106540
\Dntttm1Fwa/\Dntttm1Fwa
(chimera involves: 129S/SvEv)
abnormal immune system morphology J:75921
\Dntttm1Gfn/\Dntttm1Gfn
\Faslpr/\Faslpr

(involves: 129S2/SvPas * C57BL/6 * MRL/MpJ)
decreased autoantibody level J:110248
\Dntttm1Gfn/\Dntttm1Gfn
\Polmtm1Crey/\Polmtm1Crey

(involves: 129P2/OlaHsd * 129S2/SvPas)
abnormal immunoglobulin light chain V-J recombination J:113406
immune system phenotype J:113406
\Dntttm1Tok/\Dntttm1Tok
(involves: 129P2/OlaHsd * C57BL/6)
abnormal lymphocyte cell number J:61801
abnormal T cell morphology J:61801
decreased gamma-delta T cell number J:61801
\Dnttip1em1Shmc/\Dnttip1em1Shmc
(C57BL/6J-Dnttip1em1Shmc)
immune system phenotype J:291786
\Dock1b2b3190Clo/\Dock1b2b3190Clo
(C57BL/6J-Dock1b2b3190Clo)
thymus hypoplasia J:175213
\Dock2m1Anu/\Dock2m1Anu
(C57BL/6JAnu-Dock2m1Anu)
decreased B cell number J:104190
decreased T cell number J:104190
\Dock2m1Btlr/\Dock2m1Btlr
(involves: C57BL/6J)
abnormal B cell differentiation J:173592
abnormal class switch recombination J:185495
abnormal humoral immune response J:173592
decreased B cell number J:185495
decreased IgG level J:185495
decreased T cell number J:185495
immune system phenotype J:185495
\Dock2m1Hsd/\Dock2m1Hsd
\Irf5tm1Ttg/\Irf5tm1Ttg

(B6NHsd.Cg-Irf5tm1Ttg Dock2m1Hsd)
abnormal B cell differentiation J:182658
abnormal response to infection J:182658
absent marginal zone B cells J:182658
decreased follicular B cell number J:182658
decreased interferon-alpha secretion J:182658
decreased plasmacytoid dendritic cell number J:182658
decreased splenocyte number J:182658
increased B cell number J:182658
increased immature B cell number J:182658
increased plasmacytoid dendritic cell number J:182658
\Dock2m1Hsd/\Dock2m1Hsd
\Siaetm1.2Avrk/\Siaetm1.2Avrk

(B6NHsd.Cg-Siaetm1.2Avrk Dock2m1Hsd)
abnormal B cell activation J:144035
abnormal immunoglobulin level J:144035
decreased B-1a cell number J:144035
decreased follicular B cell number J:144035
decreased marginal zone B cell number J:231437, J:144035
decreased T cell number J:144035
glomerulonephritis J:144035
increased anti-double stranded DNA antibody level J:144035
increased anti-histone antibody level J:144035
increased anti-single stranded DNA antibody level J:144035
increased B cell proliferation J:144035
increased B-1b cell number J:144035
increased CD4-positive, alpha-beta memory T cell number J:231437
increased IgE level J:144035
increased IgG1 level J:144035
increased IgG2a level J:144035
increased IgG2b level J:144035
increased IgG3 level J:144035
increased IgM level J:144035
spleen hypoplasia J:144035
\Dock2m2Anu/\Dock2m2Anu
(C57BL/6JAnu-Dock2m2Anu)
abnormal T cell morphology J:104190
decreased mature B cell number J:104190
decreased T cell number J:104190
\Dock2m2Btlr/\Dock2m2Btlr
(C57BL/6J-Dock2m2Btlr)
abnormal humoral immune response J:173670
decreased B cell number J:173670
decreased CD4-positive, alpha-beta T cell number J:173670
decreased CD8-positive, alpha-beta T cell number J:173670
\Dock2m2Btlr/\Dock2m2Btlr
(involves: C57BL/6J)
abnormal B cell differentiation J:185495
abnormal class switch recombination J:185495
abnormal humoral immune response J:185495
decreased B cell number J:185495
decreased IgG level J:185495
decreased T cell number J:185495
immune system phenotype J:185495
\Dock2m3Anu/\Dock2m3Anu
(C57BL/6NCrlAnu-Dock2m3Anu)
abnormal CD4-positive, alpha beta T cell morphology J:104190
abnormal CD8-positive, alpha beta T cell morphology J:104190
decreased CD4-positive, alpha-beta T cell number J:104190
\Dock2m3Btlr/\Dock2m3Btlr
(C57BL/6J-Dock2m3Btlr)
abnormal CD4-positive T cell differentiation J:191187
abnormal CD8-positive, alpha-beta T cell differentiation J:191187
abnormal humoral immune response J:191187
abnormal immune system physiology J:191187
decreased CD4-positive, alpha-beta T cell number J:191187
decreased CD8-positive, alpha-beta T cell number J:191187
\Dock2m4Btlr/\Dock2m4Btlr
(C57BL/6J-Dock2m4Btlr)
abnormal B cell differentiation J:221486
abnormal CD4-positive T cell differentiation J:221486
abnormal CD8-positive, alpha-beta T cell differentiation J:221486
\Dock2m5Btlr/\Dock2+
(C57BL/6J-Dock2m5Btlr)
abnormal CD4-positive T cell differentiation J:225938
abnormal CD8-positive, alpha-beta T cell differentiation J:225938
decreased CD4-positive, alpha-beta T cell number J:225938
decreased single-positive T cell number J:225938
increased CD8-positive, alpha-beta T cell number J:225938
increased single-positive T cell number J:225938
\Dock2m5Btlr/\Dock2m5Btlr
(C57BL/6J-Dock2m5Btlr)
abnormal B cell differentiation J:225938
abnormal CD4-positive T cell differentiation J:225938
abnormal CD8-positive, alpha-beta T cell differentiation J:225938
decreased CD4-positive, alpha-beta T cell number J:225938
decreased single-positive T cell number J:225938
increased B cell number J:225938
increased CD8-positive, alpha-beta T cell number J:225938
increased single-positive T cell number J:225938
\Dock2m6Btlr/\Dock2m6Btlr
(C57BL/6J-Dock2m6Btlr)
decreased IgE level J:236689
decreased response to antigen J:236689
\Dock2m7Btlr/\Dock2+
(C57BL/6J-Dock2m7Btlr)
decreased B cell number J:255181
increased macrophage cell number J:255181
increased neutrophil cell number J:255181
\Dock2m7Btlr/\Dock2m7Btlr
(C57BL/6J-Dock2m7Btlr)
decreased B cell number J:255181
increased IgE level J:255181
increased macrophage cell number J:255181
increased neutrophil cell number J:255181
increased NK cell number J:255181
\Dock2m8Btlr/\Dock2m8Btlr
(C57BL/6J-Dock2m8Btlr)
decreased CD4-positive, alpha-beta T cell number J:272402
increased CD8-positive, alpha-beta T cell number J:272402
\Dock2M9Btlr/\Dock2M9Btlr
(C57BL/6J-Dock2M9Btlr)
increased CD8-positive, alpha-beta T cell number J:272403
\Dock2m10Btlr/\Dock2m10Btlr
(C57BL/6J-Dock2m10Btlr)
decreased B-1b cell number J:272404
increased NK cell number J:272404
\Dock2m11Btlr/\Dock2m11Btlr
(C57BL/6J-Dock2m11Btlr)
abnormal B cell differentiation J:272405
abnormal CD4-positive T cell differentiation J:272405
abnormal CD8-positive, alpha-beta cytotoxic T cell morphology J:272405
decreased B cell number J:272405
decreased CD4-positive, alpha-beta T cell number J:272405
decreased CD8-positive, naive alpha-beta T cell number J:272405
decreased NK cell number J:272405
increased B-1 B cell number J:272405
increased CD8-positive, alpha-beta T cell number J:272405
increased central memory CD4-positive, alpha-beta T cell number J:272405
increased central memory CD8 positive, alpha-beta T cell number J:272405
increased effector memory CD4-positive, alpha-beta T cell number J:272405
\Dock2M12Btlr/\Dock2M12Btlr
(C57BL/6J-Dock2M12Btlr)
decreased B-1a cell number J:272406
\Dock2m13Btlr/\Dock2m13Btlr
(C57BL/6J-Dock2m13Btlr)
increased alpha-beta T cell number J:272437
increased CD8-positive, alpha-beta T cell number J:272437
\Dock2M14Btlr/\Dock2M14Btlr
(C57BL/6J-Dock2M14Btlr)
abnormal lymphocyte morphology J:272438
increased CD8-positive, alpha-beta T cell number J:272438
\Dock2m15Btlr/\Dock2m15Btlr
(C57BL/6J-Dock2m15Btlr)
decreased B cell number J:274942
decreased CD4-positive, alpha-beta T cell number J:274942
decreased CD8-positive, naive alpha-beta T cell number J:274942
decreased T cell number J:274942
increased B-1 B cell number J:274942
increased CD8-positive, alpha-beta T cell number J:274942
increased central memory CD8 positive, alpha-beta T cell number J:274942
increased NK cell number J:274942
\Dock2M16Btlr/\Dock2M16Btlr
(C57BL/6J-Dock2M16Btlr)
abnormal CD8-positive, alpha-beta T cell number J:274971
\Dock2tm1b(EUCOMM)Wtsi/\Dock2tm1b(EUCOMM)Wtsi
(C57BL/6N-Dock2tm1b(EUCOMM)Wtsi/BayMmucd)
increased spleen weight J:211773
\Dock2tm1Tsas/\Dock2tm1Tsas
(involves: C57BL/6)
abnormal immune system morphology J:71005
abnormal leukocyte migration J:71005
abnormal Peyer's patch morphology J:71005
abnormal spleen morphology J:71005
abnormal spleen white pulp morphology J:71005
decreased marginal zone B cell number J:71005
lymph node hypoplasia J:71005
spleen hypoplasia J:71005
\Dock2tm1Tsas/\Dock2tm1Tsas
(B6.Cg-Dock2tm1Tsas)
decreased lymphocyte cell number J:130919
decreased mature B cell number J:130919
decreased T cell number J:130919
impaired neutrophil chemotaxis J:113266
\Dock2tm1Tsas/\Dock2tm1Tsas
\Tg(Tcra2B4)1Mmd/?
\Tg(Tcrb2B4)1Mmd/?

(involves: C57BL/6)
abnormal CD4-positive, alpha beta T cell morphology J:84581
abnormal T cell physiology J:84581
decreased double-positive T cell number J:84581
\Dock3tm1Dasc/\Dock3tm1Dasc
(B6.Cg-Dock3tm1Dasc)
abnormal microglial cell physiology J:144341
\Dock7mnlt/\Dock7mnlt
(C57BL/6J-Dock7mnlt)
immune system phenotype J:146458
\Dock8cpm/\Dock8cpm
(C57BL/6JSfdAnu-Dock8cpm)
abnormal humoral immune response J:155516
decreased marginal zone B cell number J:155516
decreased spleen germinal center size J:155516
decreased T cell number J:155516
\Dock8cpm/\Dock8pri
(C57BL/6J-Dock8cpm/Dock8pri)
decreased marginal zone B cell number J:155516
decreased T cell number J:155516
\Dock8m1Anu/\Dock8m1Anu
(C57BL/6NCrlAnu-Dock8m1Anu)
decreased activated T cell number J:104190
decreased IgM level J:104190
decreased T cell number J:104190
\Dock8m1Btlr/\Dock8m1Btlr
(C57BL/6J-Dock8m1Btlr)
decreased IgG level J:234247
impaired humoral immune response J:234247
\Dock8m2Anu/\Dock8m2Anu
(C57BL/6NCrlAnu-Dock8m2Anu)
absent marginal zone B cells J:104190
decreased activated T cell number J:104190
decreased IgM level J:104190
decreased T cell number J:104190
\Dock8M2Btlr/\Dock8M2Btlr
(C57BL/6J-Dock8M2Btlr)
decreased CD8-positive, alpha-beta T cell number J:272530
\Dock8M3Btlr/\Dock8M3Btlr
(C57BL/6J-Dock8M3Btlr)
decreased IgG level J:272531
impaired humoral immune response J:272531
\Dock8m4Btlr/\Dock8m4Btlr
(C57BL/6J-Dock8m4Btlr)
abnormal B cell differentiation J:274856
abnormal CD4-positive T cell differentiation J:274856
abnormal CD8-positive, alpha-beta T cell differentiation J:274856
abnormal T cell differentiation J:274856
decreased B-1 B cell number J:274856
decreased CD4-positive, alpha-beta T cell number J:274856
decreased CD8-positive, alpha-beta T cell number J:274856
decreased CD8-positive, naive alpha-beta T cell number J:274856
decreased T cell number J:274856
increased CD4-positive, alpha-beta T cell number J:274856
increased central memory CD4-positive, alpha-beta T cell number J:274856
increased central memory CD8 positive, alpha-beta T cell number J:274856
increased effector memory CD4-positive, alpha-beta T cell number J:274856
increased effector memory CD8-positive, alpha-beta T cell number J:274856
\Dock8pri/\Dock8pri
(C57BL/6JAnu-Dock8pri)
abnormal humoral immune response J:155516
decreased B-1 B cell number J:155516
decreased germinal center B cell number J:155516
decreased marginal zone B cell number J:155516
decreased spleen germinal center size J:155516
decreased T cell number J:155516
\Dock8pri/\Dock8pri
(involves: C57BL/6JAnu)
abnormal cellular extravasation J:238772
decreased susceptibility to experimental autoimmune encephalomyelitis J:238772
\Dock8tm1Ysfk/\Dock8tm1Ysfk
(B6.Cg-Dock8tm1Ysfk)
abnormal dendritic cell physiology J:185165
decreased CD4-positive, alpha-beta T cell number J:185165
decreased CD8-positive, alpha-beta T cell number J:185165
decreased follicular dendritic cell number J:185165
decreased IgG level J:185165
decreased marginal zone B cell number J:185165
decreased T cell proliferation J:185165
\Dock8tm1Ysfk/\Dock8tm1Ysfk
\Tg(TcrAND)53Hed/0

(involves: C57BL/6 * SJL)
dermatitis J:305132
\Dock9tm1Thar/\Dock9tm1Thar
(involves: C57BL/6)
immune system phenotype J:300632
\Dock10tm1a(EUCOMM)Hmgu/\Dock10tm1a(EUCOMM)Hmgu
(C57BL/6N-Dock10tm1a(EUCOMM)Hmgu/Ieg)
abnormal B cell physiology J:236911
abnormal follicular B cell physiology J:236911
abnormal spleen marginal zone morphology J:238172
abnormal thymus cell ratio J:238172
arrested B cell differentiation J:236911
decreased B cell number J:236911
decreased follicular B cell number J:236911
decreased marginal zone B cell number J:236911
immune system phenotype J:238172
increased single-positive T cell number J:236911
increased T cell number J:236911
\Dock10tm1Thar/\Dock10tm1Thar
(involves: C57BL/6)
abnormal microglial cell chemotaxis J:300632
decreased B cell number J:300632
decreased susceptibility to experimental autoimmune encephalomyelitis J:300632
impaired macrophage chemotaxis J:300632
\Dock11tm1.1Mmar/\Dock11tm1.1Mmar
(Not Specified)
abnormal metallophilic macrophage morphology J:238172
abnormal spleen marginal zone morphology J:238172
abnormal thymus cell ratio J:238172
decreased marginal zone B cell number J:238172
immune system phenotype J:238172
\Dock11tm1Thar/\Dock11tm1Thar
(involves: C57BL/6)
immune system phenotype J:300632
impaired macrophage chemotaxis J:300632
\Dohhtm1.2Sbal/\Dohh+
(B6.129(Cg)-Dohhtm1.2Sbal)
abnormal spleen morphology J:214321
\Dok1tm1Ppp/\Dok1tm1Ppp
(129S1/Sv-Dok1tm1Ppp)
abnormal T cell proliferation J:95640
\Dok1tm1Ppp/\Dok1tm1Ppp
\Dok2tm1Ppp/\Dok2tm1Ppp

(129S1/Sv-Dok1tm1Ppp Dok2tm1Ppp)
abnormal leukocyte physiology J:95334
enlarged spleen J:95334
increased leukocyte cell number J:95334
increased monocyte cell number J:95334
increased neutrophil cell number J:95334
\Dok1tm1Ppp/\Dok1tm1Ppp
\Dok2tm1Ppp/\Dok2tm1Ppp
\Dok3tm1Ppp/\Dok3tm1Ppp

(129S1/Sv-Dok1tm1Ppp Dok2tm1Ppp Dok3tm1Ppp)
increased leukocyte cell number J:158011
\Dok1tm1Yyam/\Dok1tm1Yyam
(involves: 129S4/SvJae * C57BL/6)
decreased IgM level J:95641
increased B cell proliferation J:95641
\Dok1tm1Yyam/\Dok1tm1Yyam
\Dok2tm1Yyam/\Dok2tm1Yyam

(B6.129-Dok1tm1Yyam Dok2tm1Yyam)
abnormal leukocyte physiology J:95335
abnormal myelopoiesis J:95335
enlarged spleen J:95335
increased leukocyte cell number J:95335
increased monocyte cell number J:95335
increased neutrophil cell number J:95335
\Dok1tm1Yyam/\Dok1tm1Yyam
\Dok2tm1Yyam/\Dok2tm1Yyam

(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)
abnormal macrophage physiology J:163407
\Dok1tm1Yyam/\Dok1tm1Yyam
\Dok2tm1Yyam/\Dok2tm1Yyam
\Dok3tm1Brs/\Dok3tm1Brs

(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)
abnormal macrophage physiology J:163407
increased macrophage cell number J:163407
\Dok1tm1Yyam/\Dok1tm1Yyam
\Dok2tm1Yyam/\Dok2tm1Yyam
\Tg(Tec-BCR/ABL1)5Hhi/0

(involves: C57BL/6)
enlarged lymph nodes J:95335
enlarged thymus J:95335
\Dok1tm1Yyam/\Dok1tm1Yyam
\Tg(Tec-BCR/ABL1)5Hhi/0

(involves: C57BL/6)
enlarged lymph nodes J:95335
enlarged thymus J:95335
\Dok2tm1Ppp/\Dok2tm1Ppp
(129S1/Sv-Dok2tm1Ppp)
abnormal granulocyte physiology J:95334
\Dok2tm1Yyam/\Dok2tm1Yyam
\Tg(Tec-BCR/ABL1)5Hhi/0

(involves: C57BL/6)
enlarged lymph nodes J:95335
enlarged thymus J:95335
\Dok3tm1Brs/\Dok3tm1Brs
(involves: C57BL/6)
increased macrophage cell number J:163407
\Dok3tm1Kplm/\Dok3tm1Kplm
(involves: 129P2/OlaHsd)
abnormal B cell calcium ion homeostasis J:280795
abnormal B cell physiology J:280795
enhanced humoral immune response J:280795
increased B cell proliferation J:280795
increased IgG3 level J:280795
increased IgM level J:280795
\Dok7tm1.1(KOMP)Vlcg/\Dok7+
(C57BL/6N-Dok7tm1.1(KOMP)Vlcg/Ucd)
decreased lymphocyte cell number J:211773
increased neutrophil cell number J:211773
\Dop1btm1a(EUCOMM)Wtsi/\Dop1btm1a(EUCOMM)Wtsi
(C57BL/6N-Dop1btm1a(EUCOMM)Wtsi/Wtsi)
increased leukocyte cell number J:211773
\Dot1ltm1.1Saam/\Dot1ltm1.1Saam
\Tg(VAV1-cre)1Graf/0

(involves: 129S1/Sv * C57BL/6)
abnormal leukopoiesis J:193161
decreased lymphocyte cell number J:193161
decreased neutrophil cell number J:193161
\Dp(11Cops3-Rnf112)1Jrl/0
(involves: 129S7/SvEvBrd * C57BL/6)
decreased spleen weight J:83302
\Dp(16Cbr1-Fam3b)1Rhr/0
\Gata1tm8.2Sho/Y

(involves: 129S1/Sv * 129S6/SvEvTac)
enlarged spleen J:184564
increased monocyte cell number J:184564
\Dp(17Nfkbil1-Or2h1)1Cogr/0
(involves: 129S6/SvEvTac * C57BL/6J)
immune system phenotype J:190754
\Dpcd/PollGt(OST280355)Lex/\Dpcd/PollGt(OST280355)Lex
(involves: 129S5/SvEvBrd * C57BL/6Brd)
increased susceptibility to otitis media J:185566
\Dph6tm1a(KOMP)Wtsi/\Dph6tm1a(KOMP)Wtsi
(C57BL/6N-Dph6tm1a(KOMP)Wtsi/Wtsi)
decreased CD8-positive, alpha-beta T cell number J:211773
decreased CD8-positive, naive alpha-beta T cell number J:211773
decreased effector memory CD8-positive, alpha-beta T cell number J:211773
decreased Ly6C-positive mature NK cell number J:211773
decreased mature B cell number J:211773
decreased NK T cell number J:211773
decreased T-helper cell number J:211773
increased CD4-positive, alpha-beta memory T cell number J:211773
increased CD4-positive, alpha-beta T cell number J:211773
increased CD4-positive, CD25-positive, alpha-beta regulatory T cell number J:211773
increased CD5-positive gamma-delta T cell number J:211773
increased CD11b-low dendritic cell number J:211773
increased dendritic cell number J:211773
increased effector memory T-helper cell number J:211773
increased gamma-delta T cell number J:211773
increased granulocyte number J:211773
increased KLRG1-positive CD4-positive, CD25-positive, alpha-beta regulatory T cell number J:211773
increased KLRG1-positive T-helper cell number J:211773
increased marginal zone B cell number J:211773
increased memory CD4-positive, CD25-positive, alpha-beta regulatory T cell number J:211773
increased memory-marker CD4-negative NK T cell number J:211773
increased memory-marker gamma-delta T cell number J:211773
increased monocyte cell number J:211773
increased plasma cell number J:211773
increased plasmacytoid dendritic cell number J:211773
\Dpp3tm1d(EUCOMM)Hmgu/\Dpp3tm1d(EUCOMM)Hmgu
(involves: BALB/c * C57BL/6 * C57BL/6J * C57BL/6N * SJL)
abnormal interferon-gamma secretion J:294242
increased interleukin-1 beta secretion J:294242
increased interleukin-6 secretion J:294242
increased interleukin-10 secretion J:294242
increased osteoclast cell number J:294242
increased tumor necrosis factor secretion J:294242
\Dpp4em1Rba/\Dpp4+
(C57BL/6J-Dpp4em1Rba)
decreased susceptibility to Coronaviridae infection induced morbidity/mortality J:279834
increased susceptibility to Coronaviridae infection J:279834
lung inflammation J:279834
\Dpp4em1Rba/\Dpp4em1Rba
(C57BL/6J-Dpp4em1Rba)
decreased lymphocyte cell number J:279723
increased monocyte cell number J:279723
increased neutrophil cell number J:279723
increased susceptibility to Coronaviridae infection J:279723, J:279834
increased susceptibility to Coronaviridae infection induced morbidity/mortality J:279834
lung inflammation J:279834
\Dpp4em3Gpt/\Dpp4em3Gpt
(C57BL/6JGpt-Dpp4em3Gpt)
immune system phenotype J:324112
\Dpp4tm1(DPP4)Vlcg/?
(involves: 129S6/SvEvTac * C57BL/6NTac)
increased susceptibility to Coronaviridae infection J:223728
interstitial pneumonia J:223728
lung inflammation J:223728
\Dpp4tm1(DPP4)Vlcg/?
(involves: 129S6/SvEvTac * C57BL/6 * C57BL/6NTac)
increased CD4-positive, alpha-beta T cell number J:238079
increased CD8-positive, alpha-beta T cell number J:238079
increased macrophage cell number J:238079
increased neutrophil cell number J:238079
increased susceptibility to Coronaviridae infection J:238079
lung inflammation J:238079
pleuritis J:238079
\Dpp4tm1.1(DPP4)Pbmj/\Dpp4tm1.1(DPP4)Pbmj
(involves: C57BL/6 * C57BL/6NTac)
increased susceptibility to Coronaviridae infection J:242025
increased susceptibility to Coronaviridae infection induced morbidity/mortality J:242025
lung inflammation J:242025
\Dpp4tm1b(EUCOMM)Wtsi/\Dpp4tm1b(EUCOMM)Wtsi
(C57BL/6N-Dpp4tm1b(EUCOMM)Wtsi/Ics)
decreased lymphocyte cell number J:211773
\Dpp9em1(IMPC)Ccpcz/\Dpp9+
(C57BL/6NCrl-Dpp9em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
\Dppa1tm1b(KOMP)Wtsi/\Dppa1+
(C57BL/6N-Dppa1tm1b(KOMP)Wtsi/Bay)
abnormal spleen morphology J:211773
\Dpy19l4em1(IMPC)J/\Dpy19l4em1(IMPC)J
(C57BL/6NJ-Dpy19l4em1(IMPC)J/Mmjax)
increased leukocyte cell number J:211773
\Drc1b2b1654Clo/\Drc1b2b1654Clo
(C57BL/6J-Drc1b2b1654Clo)
absent spleen J:175213
\Drd1tm1Jcd/\Drd1tm1Jcd
\Drd2tm1Ebo/\Drd2+

(involves: 129S2/SvPas * 129S4/SvJae * C57BL/6)
small intestinal inflammation J:91781
\Drd1tm2Jcd/\Drd1+
\Tg(Camk2a-cre)2Gsc/0

(involves: 129S4/SvJae * FVB/N)
abnormal microglial cell physiology J:120070
\Drd2tm1Low/\Drd2tm1Low
(B6.129S2-Drd2tm1Low/J)
decreased spleen weight J:106832
increased interleukin-1 beta secretion J:194407
microgliosis J:194407
\Drd3em1(IMPC)Mbp/\Drd3em1(IMPC)Mbp
(C57BL/6N-Drd3em1(IMPC)Mbp/MbpMmucd)
small spleen J:211773
\Drgxem1(IMPC)Mbp/\Drgx+
(C57BL/6N-Drgxem1(IMPC)Mbp/MbpMmucd)
abnormal lymph node morphology J:211773
abnormal spleen morphology J:211773
enlarged lymph nodes J:211773
enlarged spleen J:211773
\Droshatm1Litt/\Droshatm1.1Litt
\Foxp3tm4(YFP/icre)Ayr/Y

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * FVB/N)
abnormal interferon-gamma secretion J:138683
abnormal interleukin-4 secretion J:138683
abnormal T cell activation J:138683
blood vessel inflammation J:138683
enlarged lymph nodes J:138683
enlarged spleen J:138683
increased CD8-positive, alpha-beta T cell number J:138683
increased leukocyte cell number J:138683
liver inflammation J:138683
lung inflammation J:138683
\Droshatm1Litt/\Droshatm1.1Litt
\Foxp3tm4(YFP/icre)Ayr/\Foxp3tm4(YFP/icre)Ayr

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * FVB/N)
abnormal interferon-gamma secretion J:138683
abnormal interleukin-4 secretion J:138683
abnormal regulatory T cell morphology J:138683
abnormal T cell activation J:138683
blood vessel inflammation J:138683
enlarged lymph nodes J:138683
enlarged spleen J:138683
increased CD8-positive, alpha-beta T cell number J:138683
increased leukocyte cell number J:138683
liver inflammation J:138683
lung inflammation J:138683
\Droshatm1Litt/\Droshatm1.1Litt
\Gt(ROSA)26Sortm1(cre/ERT)Nat/\Gt(ROSA)26Sor+

(involves: 129 * 129P2/OlaHsd * C57BL/6 * FVB/N)
abnormal interferon-gamma secretion J:138683
\Droshatm1Litt/\Droshatm1.1Litt
\Tg(Cd4-cre)1Cwi/0

(involves: 129P2/OlaHsd * C57BL/6 * DBA/2 * FVB/N)
abnormal immune system physiology J:138683
decreased CD8-positive, alpha-beta T cell number J:138683
decreased double-positive T cell number J:138683
decreased lymphocyte cell number J:138683
decreased regulatory T cell number J:138683
decreased thymocyte number J:138683
immune system phenotype J:138683
increased activated T cell number J:138683
increased gamma-delta T cell number J:138683
increased granulocyte number J:138683
intestinal inflammation J:138683
liver inflammation J:138683
lung inflammation J:138683
\Dsc1tm1Dga/\Dsc1tm1Dga
(involves: C57BL/6J)
dermatitis J:73102
\Dsc2tm1.1Leu/\Dsc2tm1.1Leu
\Tg(Vil1-cre)20Syr/0

(involves: 129P2/OlaHsd * C57BL/6 * DBA/2)
immune system phenotype J:302333
\Dsg2m1Btlr/\Dsg2m1Btlr
(C57BL/6J-Dsg2m1Btlr)
increased susceptibility to induced colitis J:271975
\Dsg2m2Btlr/\Dsg2m2Btlr
(C57BL/6J-Dsg2m2Btlr)
increased susceptibility to induced colitis J:271976
\Dsg2m3Btlr/\Dsg2m3Btlr
(C57BL/6J-Dsg2m3Btlr)
increased susceptibility to induced colitis J:271977
\Dsg2tm1d(EUCOMM)Wtsi/\Dsg2tm1d(EUCOMM)Wtsi
(involves: C57BL/6J * C57BL/6N)
heart inflammation J:235770
\Dsg2tm3.1Leu/\Dsg2tm3.1Leu
\Tg(Vil1-cre)20Syr/0

(involves: 129S7/SvEvBrd * C57BL/6 * DBA/2)
increased susceptibility to colitis induced morbidity/mortality J:302333
increased susceptibility to induced colitis J:302333
\Dsg3bal/\Dsg3bal
(C57BL/6J-Dsg3bal/J)
cutaneous mastocytosis J:18223
increased IgE level J:18223
\Dsg3sqk/\Dsg3sqk
(C57BL/6-Dsg3sqk)
conjunctivitis J:219200
decreased B cell number J:219200
decreased double-positive T cell number J:219200
decreased immature B cell number J:219200
decreased lymphocyte cell number J:219200
decreased pre-B cell number J:219200
decreased single-positive T cell number J:219200
decreased transitional stage B cell number J:219200
increased neutrophil cell number J:219200
increased susceptibility to infection J:219200
\Dsg3tm1Stan/\Dsg3tm1Stan
(involves: 129X1/SvJ * C57BL/6J)
conjunctivitis J:40804
\Dsg4hage/\Dsg4hage
\Faslpr/\Faslpr
X/\Yaa

(EOD-Dsg4hage)
abnormal effector T cell morphology J:140028
abnormal mast cell morphology J:140028
\Dsg4lah-J/\Dsg4lah-J
(involves: DBA/1LacJ)
abnormal peripheral lymph node morphology J:83117
dermatitis J:83117
increased IgE level J:83117
\Dsg4lah/\Dsg4lah
(LAH/Pas)
dermatitis J:33849
\Dspem1(IMPC)Mbp/\Dsp+
(C57BL/6N-Dspem1(IMPC)Mbp/MbpMmucd)
abnormal lymph node morphology J:211773
enlarged lymph nodes J:211773
\Dspptm1Kul/\Dspptm1Kul
(B6;129-Dspptm1Kul/Mmnc)
periodontium inflammation J:241990
\Dssc1C3H/HeJ/\Dssc1C57BL/6J
(involves: C3H/HeJ * C57BL/6J)
colitis J:52852
\Dssc1C57BL/6J/\Dssc1C57BL/6J
(involves: C3H/HeJ * C57BL/6J)
colitis J:52852
\Dssc2C3H/HeJ/\Dssc2C3H/HeJ
(involves: C3H/HeJ * C57BL/6J)
colitis J:52852
\Dssc2C3H/HeJ/\Dssc2C57BL/6J
(involves: C3H/HeJ * C57BL/6J)
colitis J:52852
\DstTg4/\DstTg4
(involves: C57BL/6 * CD-1)
conjunctivitis J:209161
\Dstncorn1/\Dstncorn1
(A.BY-H2bc H2-T18f/SnJ)
abnormal lymphangiogenesis J:98465
immune system phenotype J:98465
\Dstncorn1/\Dstncorn1
(A.BY-H2bc H2-T18f/SnJ-Dstncorn1/J)
immune system phenotype J:139239
\Dtnbp1sdy-Btlr/\Dtnbp1sdy-Btlr
(C57BL/6J-Dtnbp1sdy-Btlr)
impaired natural killer cell mediated cytotoxicity J:133620
increased susceptibility to Herpesvirales infection J:133620
\Dtnbp1tm1b(EUCOMM)Hmgu/\Dtnbp1tm1b(EUCOMM)Hmgu
(C57BL/6N-Dtnbp1tm1b(EUCOMM)Hmgu/Tcp)
decreased lymphocyte cell number J:211773
increased leukocyte cell number J:211773
increased lymphocyte cell number J:211773
increased neutrophil cell number J:211773
\Dtx1tm1.1Mzl/\Dtx1tm1.1Mzl
\Tg(Cd4-cre)1Cwi/0

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2)
abnormal thymocyte activation J:151605
increased anti-double stranded DNA antibody level J:151605
increased anti-histone antibody level J:151605
increased autoantibody level J:151605
increased interleukin-2 secretion J:151605
increased T cell proliferation J:151605
\Dtx1tm1.2Mzl/\Dtx1tm1.2Mzl
(B6.129-Dtx1tm1.2Mzl)
abnormal lymphocyte morphology J:151605
abnormal lymphocyte physiology J:151605
abnormal regulatory T cell physiology J:151605
abnormal T cell anergy J:151605
abnormal thymocyte activation J:151605
decreased marginal zone B cell number J:151605
decreased thymocyte apoptosis J:151605
glomerulonephritis J:151605
increased anti-double stranded DNA antibody level J:151605
increased anti-histone antibody level J:151605
increased B cell proliferation J:151605
increased interferon-gamma secretion J:151605
increased interleukin-2 secretion J:151605
increased interleukin-4 secretion J:151605
increased T cell proliferation J:151605
liver inflammation J:151605
lung inflammation J:151605
spleen hyperplasia J:151605
\Dtx1tm1Mjb/\Dtx1tm1Mjb
(either: B6.129S6-Dtx1tm1Mjb or (involves: 129S6/SvEvTac * C57BL/6))
immune system phenotype J:114658
\Dtx1tm1Mjb/\Dtx1tm1Mjb
\Dtx2tm1Mjb/\Dtx2tm1Mjb

(involves: 129S6/SvEvTac * C57BL/6)
immune system phenotype J:114658
\Dtx2tm1Mjb/\Dtx2tm1Mjb
(involves: 129S6/SvEvTac)
immune system phenotype J:114658
\Dtx4em1(IMPC)Ccpcz/\Dtx4+
(C57BL/6N-Dtx4em1(IMPC)Ccpcz/Ccpcz)
abnormal thymus morphology J:211773
enlarged thymus J:211773
\Ducm1129X1/SvJ/\Ducm1129X1/SvJ
(involves: 129X1/SvJ * C57BL/6J)
abnormal professional antigen presenting cell physiology J:86617
\Ducm1129X1/SvJ/\Ducm1C57BL/6J
(involves: 129X1/SvJ * C57BL/6J)
abnormal professional antigen presenting cell physiology J:86617
\Duox2em1(IMPC)Mbp/\Duox2em1(IMPC)Mbp
(C57BL/6N-Duox2em1(IMPC)Mbp/MbpMmucd)
abnormal lymph node morphology J:211773
abnormal spleen morphology J:211773
decreased lymphocyte cell number J:211773
enlarged lymph nodes J:211773
enlarged spleen J:211773
increased neutrophil cell number J:211773
small spleen J:211773
\Duoxa2tm1b(KOMP)Wtsi/\Duoxa2tm1b(KOMP)Wtsi
(C57BL/6N-Duoxa2tm1b(KOMP)Wtsi/Wtsi)
decreased B cell number J:211773
decreased B-2 B cell number J:211773
decreased CD8-positive, alpha-beta T cell number J:211773
decreased CD11b-high dendritic cell number J:211773
decreased effector memory T-helper cell number J:211773
decreased follicular B cell number J:211773
decreased immature B cell number J:211773
decreased KLRG1-positive NK cell number J:211773
decreased leukocyte cell number J:211773
decreased Ly6C low monocyte number J:211773
decreased mature B cell number J:211773
decreased memory CD4-positive, CD25-positive, alpha-beta regulatory T cell number J:211773
decreased memory-marker gamma-delta T cell number J:211773
decreased NK cell number J:211773
decreased transitional stage T1 B cell number J:211773
increased alpha-beta T cell number J:211773
increased CD4-positive, alpha-beta T cell number J:211773
increased CD4-positive, CD25-positive, alpha-beta regulatory T cell number J:211773
increased CD8-positive, alpha-beta T cell number J:211773
increased CD8-positive, naive alpha-beta T cell number J:211773
increased effector memory CD8-positive, alpha-beta T cell number J:211773
increased neutrophil cell number J:211773
increased plasmacytoid dendritic cell number J:211773
increased T cell number J:211773
increased T-helper cell number J:211773
\Dusp1tm1Brv/\Dusp1tm1Brv
(involves: 129S2/SvPas)
abnormal cytokine secretion J:118832
lung inflammation J:118832
\Dusp1tm1Brv/\Dusp1tm1Brv
(involves: 129S2/SvPas * C57BL/6)
increased circulating interleukin-6 level J:118833
increased circulating interleukin-10 level J:118833
increased circulating tumor necrosis factor level J:118833
increased interleukin-6 secretion J:118833
increased susceptibility to endotoxin shock J:118833
increased tumor necrosis factor secretion J:118833
\Dusp1tm1Brv/\Dusp1tm1Brv
(involves: 129S2/SvPas * various)
immune system phenotype J:125919
increased mast cell degranulation J:125919
increased susceptibility to type I hypersensitivity reaction J:125919
\Dusp1tm1Brv/\Dusp1tm1Brv
(C3.129S2-Dusp1tm1Brv)
abnormal chemokine secretion J:164929
increased granulocyte number J:164929
increased interleukin-1 beta secretion J:164929
increased interleukin-6 secretion J:164929
increased susceptibility to bacterial infection J:164929
lung inflammation J:164929
\Dusp1tm1Lex/\Dusp1tm1Lex
(involves: 129S5/SvEvBrd * C57BL/6)
abnormal chemokine level J:126383
abnormal innate immunity J:126383
abnormal interleukin level J:126383
increased circulating interferon-gamma level J:126383
increased circulating interleukin-6 level J:126383
increased circulating interleukin-10 level J:126383
increased circulating tumor necrosis factor level J:126383
increased susceptibility to endotoxin shock J:126383
increased susceptibility to induced arthritis J:126383
\Dusp2tm1Cmac/\Dusp2tm1Cmac
(B6.Cg-Dusp2tm1Cmac)
abnormal cytokine secretion J:112609
abnormal macrophage activation involved in immune response J:112609
abnormal mast cell physiology J:112609
decreased susceptibility to induced arthritis J:112609
\Dusp4Gt(XG164)Byg/\Dusp4Gt(XG164)Byg
(B6.129P2-Dusp4Gt(XG164)Byg)
immune system phenotype J:180366
increased CD4-positive, alpha-beta T cell number J:180366
increased interleukin-10 secretion J:180366
increased T cell proliferation J:180366
\Dusp4tm1Jmol/\Dusp4tm1Jmol
(involves: 129)
decreased B cell apoptosis J:140567
\Dusp4tm1Plev/\Dusp4tm1Plev
(involves: 129/Sv * C57BL/6)
abnormal macrophage physiology J:170774
decreased IgG2a level J:170774
decreased interferon-gamma secretion J:170774
decreased interleukin-10 secretion J:170774
increased IgG1 level J:170774
increased interleukin-4 secretion J:170774
increased interleukin-6 secretion J:170774
increased interleukin-12 secretion J:170774
increased interleukin-13 secretion J:170774
increased susceptibility to parasitic infection J:170774
increased tumor necrosis factor secretion J:170774
\Dusp5tm1.1Achn/\Dusp5tm1.1Achn
(involves: C57BL/6NCrl)
abnormal susceptibility to parasitic infection J:218203
immune system phenotype J:218203
increased T cell proliferation J:218203
increased thymocyte number J:218203
\Dusp5tm1.1Achn/\Dusp5tm1.1Achn
\Rag2tm1.1Cgn/\Rag2tm1.1Cgn

(involves: C57BL/6NCrl)
abnormal eosinophil physiology J:218203
abnormal susceptibility to parasitic infection J:218203
increased eosinophil cell number J:218203
\Dusp5tm1a(KOMP)Wtsi/\Dusp5tm1a(KOMP)Wtsi
(C57BL/6-Dusp5tm1a(KOMP)Wtsi)
abnormal CD8-positive, alpha beta T cell morphology J:240637
abnormal T cell physiology J:240637
increased effector memory CD8-positive, alpha-beta T cell number J:240637
increased T cell apoptosis J:240637
increased T cell proliferation J:240637
\Dusp5tm1d(KOMP)Wtsi/\Dusp5tm1d(KOMP)Wtsi
(B6(Cg)-Dusp5tm1d(KOMP)Wtsi)
increased T cell apoptosis J:240637
\Dusp6tm1Jmol/\Dusp6tm1Jmol
(involves: 129 * C57BL/6)
increased spleen weight J:142966
\Dusp10tm1Flv/\Dusp10tm1Flv
(involves: 129S6/SvEvTac)
abnormal adaptive immunity J:92104
abnormal cytokine secretion J:92104
abnormal interleukin secretion J:92104
decreased susceptibility to experimental autoimmune encephalomyelitis J:92104
decreased T cell proliferation J:92104
increased activated T cell number J:92104
increased interferon-gamma secretion J:92104
increased susceptibility to type I hypersensitivity reaction J:92104
increased tumor necrosis factor secretion J:92104
\Dusp11Gt(BB0198)Wtsi/\Dusp11Gt(BB0198)Wtsi
(B6.129P2-Dusp11Gt(BB0198)Wtsi)
abnormal macrophage activation involved in immune response J:301503
immune system phenotype J:301503
increased circulating interleukin-1 beta level J:301503
increased circulating interleukin-6 level J:301503
increased circulating tumor necrosis factor level J:301503
increased macrophage cytokine production J:301503
increased susceptibility to endotoxin shock J:301503
\Dusp12em1(IMPC)Mbp/\Dusp12+
(C57BL/6N-Dusp12em1(IMPC)Mbp/Ucd)
increased basophil cell number J:211773
\Dusp14Gt(OST210117)Lex/\Dusp14Gt(OST210117)Lex
(B6.129S5-Dusp14Gt(OST210117)Lex)
abnormal cytokine secretion J:209403
abnormal humoral immune response J:209403
abnormal T cell activation J:209403
immune system phenotype J:209403
increased susceptibility to experimental autoimmune encephalomyelitis J:209403
increased T cell proliferation J:209403
increased T-helper 1 cell number J:209403
increased T-helper 17 cell number J:209403
\Dusp16em1(IMPC)Tcp/\Dusp16em1(IMPC)Tcp
(C57BL/6NCrl-Dusp16em1(IMPC)Tcp/Tcp)
enlarged lymph nodes J:211773
enlarged spleen J:211773
increased spleen weight J:211773
\Dusp22tm1Tht/\Dusp22tm1Tht
(B6.129S7-Dusp22tm1Tht)
abnormal B cell activation J:213253
abnormal cytokine level J:213253
abnormal T cell activation J:213253
decreased B cell proliferation J:213253
decreased IgG3 level J:213253
decreased IgM level J:213253
decreased immunoglobulin level J:213253
enlarged spleen J:213253
increased circulating interferon-gamma level J:213253
increased circulating interleukin-6 level J:213253
increased circulating interleukin-17 level J:213253
increased circulating tumor necrosis factor level J:213253
increased inflammatory response J:213253
increased interferon-gamma secretion J:213253
increased interleukin-2 secretion J:213253
increased interleukin-4 secretion J:213253
increased interleukin-17 secretion J:213253
increased spleen white pulp amount J:213253
increased susceptibility to autoimmune disorder J:213253
increased susceptibility to experimental autoimmune encephalomyelitis J:213253
increased T cell proliferation J:213253
kidney inflammation J:213253
liver inflammation J:213253
lung inflammation J:213253
\Dvl3b2b2866Clo/\Dvl3b2b2866Clo
(C57BL/6J-Dvl3b2b2866Clo)
thymus hypoplasia J:175213
\Dync1li1em1(IMPC)Tcp/\Dync1li1+
(C57BL/6NCrl-Dync1li1em1(IMPC)Tcp/Tcp)
enlarged lymph nodes J:211773
\Dyrk1atm1Jdc/\Dyrk1atm1Jdc
\Tg(Mx1-cre)1Cgn/0

(involves: 129/Sv * C57BL/6J * C57BL/6NTac * CBA/J)
decreased B cell number J:223138
decreased double-positive T cell number J:223138
decreased immature B cell number J:223138
decreased mature B cell number J:223138
decreased pre-B cell number J:223138
decreased thymocyte number J:223138
increased T cell apoptosis J:223138
\Dyrk1btm1b(EUCOMM)Wtsi/\Dyrk1b+
(C57BL/6N-Dyrk1btm1b(EUCOMM)Wtsi/Ics)
decreased large unstained cell number J:211773
decreased lymphocyte cell number J:211773
\Dyrk2em1(IMPC)Ics/\Dyrk2+
(C57BL/6N-Dyrk2em1(IMPC)Ics/Ics)
decreased large unstained cell number J:211773
\Dysfim/\Dysf+
\Large1myd/\Large1myd

(involves: C57BL/6 * SJL/J)
myositis J:221523
\Dysfim/\Dysfim
\Fktntm1Ttd/\Fktntm2(FCMD)Ttd

(involves: 129S7/SvEvBrd * C57BL/6 * SJL/J)
myositis J:221523
\Dysfim/\Dysfim
\Large1myd/\Large1myd

(involves: C57BL/6 * SJL/J)
myositis J:221523
\Dysftm1Kcam/\Dysftm1Kcam
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
myositis J:171870
\Dytnem1(IMPC)J/\Dytnem1(IMPC)J
(C57BL/6NJ-Dytnem1(IMPC)J/Mmjax)
increased leukocyte cell number J:211773
\E2f1Tg(Wnt1-cre)2Sor/\E2f1+
\Snrpbem1Lajm/\Snrpb+

(involves: C3H * C57BL/6 * C57BL/6J * CD1)
athymia J:326544
\E2f1tm1Meg/\E2f1tm1Meg
(either: (involves: 129/Sv * 129S4/SvJae) or (involves: 129/Sv * 129S4/SvJae * C57BL/6))
abnormal double-positive T cell morphology J:33100
enlarged thymus J:33100
increased CD4-positive, alpha-beta T cell number J:33100
increased CD8-positive, alpha-beta T cell number J:33100
increased T cell derived lymphoma incidence J:33100
increased thymocyte number J:33100
increased thymus weight J:33100
\E2f1tm1Meg/\E2f1tm1Meg
(NOD.Cg-E2f1tm1Meg)
abnormal CD4-positive, alpha beta T cell morphology J:93708
abnormal CD8-positive, alpha beta T cell morphology J:93708
abnormal double-positive T cell morphology J:93708
decreased double-positive T cell number J:93708
decreased regulatory T cell number J:93708
enlarged thymus J:93708
increased interferon-gamma secretion J:93708
increased interleukin-4 secretion J:93708
increased susceptibility to autoimmune diabetes J:93708
increased T cell number J:93708
increased thymocyte number J:93708
insulitis J:93708
salivary gland inflammation J:93708
\E2f1tm1Meg/\E2f1tm1Meg
(involves: 129S4/SvJae * C57BL/6)
decreased T cell proliferation J:76318
\E2f2tm1Zubi/\E2f2tm1Zubi
(involves: 129S1/Sv * C57BL/6)
abnormal immune system morphology J:76318
abnormal immune system physiology J:76318
abnormal spleen white pulp morphology J:76318
abnormal T cell differentiation J:76318
abnormal T cell subpopulation ratio J:76318
enlarged spleen J:76318
glomerulonephritis J:76318
increased anti-double stranded DNA antibody level J:76318
increased inflammatory response J:76318
increased memory T cell number J:76318
increased spleen weight J:76318
increased susceptibility to autoimmune disorder J:76318
increased T cell proliferation J:76318
liver inflammation J:76318
lung inflammation J:76318
\E2f2tm1Zubi/\E2f2tm1Zubi
\Tg(TcraH-Y,TcrbH-Y)71Vbo/?

(involves: 129S1/Sv * C57BL/6 * C57BL/6J * DBA/2J)
abnormal immune system morphology J:76318
abnormal immune system physiology J:76318
enlarged spleen J:76318
increased CD8-positive, alpha-beta T cell number J:76318
increased inflammatory response J:76318
increased susceptibility to autoimmune disorder J:76318
increased T cell proliferation J:76318
thymus hypoplasia J:76318
\E2f3tm1Lees/\E2f3tm1Lees
(involves: 129S2/SvPas * C57BL/6)
lung inflammation J:75765
\E2f4tm1Jrn/\E2f4tm1Jrn
(involves: 129P2/OlaHsd * C57BL/6)
abnormal granulocyte morphology J:64192
decreased double-positive T cell number J:64192
decreased granulocyte number J:64192
decreased thymocyte number J:64192
increased double-negative T cell number J:64192
increased NK cell number J:64192
thymus hypoplasia J:64192
\E2f4tm1Lees/\E2f4tm1Lees
(involves: 129S2/SvPas * C57BL/6)
increased susceptibility to bacterial infection J:64193
increased susceptibility to otitis media J:64193
rhinitis J:64193
\E2f4tm1Lees/\E2f4tm1Lees
\Rb1tm1Tyj/\Rb1+

(involves: 129S2/SvPas * C57BL/6)
increased susceptibility to infection J:81082
\E2f6em1(IMPC)Ccpcz/\E2f6em1(IMPC)Ccpcz
(C57BL/6NCrl-E2f6em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
small spleen J:211773
small thymus J:211773
\Eae1A/J/\Eae1A/J
(involves: A/J * C57BL/10SnJ)
increased susceptibility to experimental autoimmune encephalomyelitis J:30574
\Eae1PL/J/\Eae1PL/J
(involves: C57BL/10SnJ * PL/J)
increased susceptibility to experimental autoimmune encephalomyelitis J:30574
\Eae2B10.RIII/\Eae2RIIIS/J
(involves: B10.RIII * RIIIS/J)
autoimmune arthritis J:95848
\Eae2RIIIS/J/\Eae2RIIIS/J
(involves: B10.RIII * RIIIS/J)
decreased susceptibility to induced arthritis J:95848
\Eae2bC57BL/10SnSg/\Eae2bC57BL/10SnSg
(involves: B10.RIII * RIIIS/J)
CNS inflammation J:96204
\Eae4ABH/?
(involves: ABH * NOD)
increased susceptibility to experimental autoimmune encephalomyelitis J:29171
\Eae5B10.S/DvTe/\Eae5SJL/J
(involves: B10.S/DvTe * SJL/J)
increased susceptibility to experimental autoimmune encephalomyelitis J:49054
\Eae5SJL/J/\Eae5SJL/J
(involves: B10.S/DvTe * SJL/J)
increased susceptibility to experimental autoimmune encephalomyelitis J:49054
\Eae7B10.S/DvTe/\Eae7B10.S/DvTe
(involves: B10.S/DvTe * SJL/J)
brain inflammation J:49054
increased susceptibility to experimental autoimmune encephalomyelitis J:49054
\Eae7B10.S/DvTe/\Eae7SJL/J
(involves: B10.S/DvTe * SJL/J)
brain inflammation J:49054
increased susceptibility to experimental autoimmune encephalomyelitis J:49054
\Eae7SJL/J/\Eae7SJL/J
(involves: B10.S/DvTe * SJL/J)
brain inflammation J:49054
decreased susceptibility to experimental autoimmune encephalomyelitis J:49054
\Eae9B10.S/DvTe/\Eae9SJL/J
(involves: B10.S/DvTe * SJL/J)
decreased susceptibility to experimental autoimmune encephalomyelitis J:49054
\Eae10SJL/J/\Eae10SJL/J
(involves: B10.S/DvTe * SJL/J)
increased susceptibility to experimental autoimmune encephalomyelitis J:49054
\Eae11SJL/J/?
(involves: B10.S/DvTe * SJL/J)
increased susceptibility to experimental autoimmune encephalomyelitis J:53193
\Eae12SJL/J/\Eae12SJL/J
(involves: B10.S/DvTe * SJL/J)
increased susceptibility to experimental autoimmune encephalomyelitis J:53193
\Eae13SJL/J/?
(involves: B10.S/DvTe * SJL/J)
increased susceptibility to experimental autoimmune encephalomyelitis J:53193
\Eae14C57BL/10/?
(involves: B10.S/DvTe * SJL/J)
increased susceptibility to experimental autoimmune encephalomyelitis J:69083
\Eae16SJL/J/?
(involves: B10.S/DvTe * SJL/J)
increased inflammatory response J:67840
\Eae17SJL/J/?
(involves: B10.S/DvTe * SJL/J)
increased susceptibility to experimental autoimmune encephalomyelitis J:69083
\Eae18NOD/\Eae18NOD
(involves: ABH * NOD)
decreased susceptibility to experimental autoimmune encephalomyelitis J:29171
\Eae21SJL/J/?
(involves: B10.S/DvTe * SJL/J)
increased inflammatory response J:67840
\Eae22SJL/J/?
(involves: B10.S/DvTe * SJL/J)
increased inflammatory response J:67840
\Eae23SJL/J/?
(involves: B10.S/DvTe * SJL/J)
increased inflammatory response J:67840
\Eae25SJL/J/?
(involves: B10.S/DvTe * SJL/J)
increased inflammatory response J:69083
\Eae26B10.RIII/\Eae26B10.RIII
(involves: B10.RIII * RIIIS/J)
increased susceptibility to experimental autoimmune encephalomyelitis J:73850
\Eae26B10.RIII/\Eae26RIIIS/J
(involves: B10.RIII * RIIIS/J)
increased susceptibility to experimental autoimmune encephalomyelitis J:73850
\Eae27C57BL/10SnSg/\Eae27RIIIS/J
(involves: B10.RIII * RIIIS/J)
CNS inflammation J:96204
\Eae27RIIIS/J/\Eae27RIIIS/J
(involves: B10.RIII * RIIIS/J)
CNS inflammation J:96204
\Eae33C57BL/10SnSg/?
(involves: B10.S * SJL/J)
increased susceptibility to experimental autoimmune encephalomyelitis J:99793
\Eae34C57BL/10SnSg/?
(involves: B10.S * SJL/J)
increased susceptibility to experimental autoimmune encephalomyelitis J:99793
\Eae35C57BL/10SnSg/?
(involves: B10.S * SJL/J)
increased susceptibility to experimental autoimmune encephalomyelitis J:99793
\Eae36SJL/J/?
(involves: B10.S * SJL/J)
increased susceptibility to autoimmune disorder J:99793
\Eae37C57BL/10SnSg/?
(involves: B10.S * SJL/J)
increased susceptibility to autoimmune disorder J:99793
\Eae38C57BL/10SnSg/?
(involves: B10.S * SJL/J)
increased susceptibility to autoimmune disorder J:99793
\Eae39C57BL/10SnSg/\Eae39RIIIS/J
(involves: B10.RIII * RIIIS/J)
CNS inflammation J:96204
\Eae39RIIIS/J/\Eae39RIIIS/J
(involves: B10.RIII * RIIIS/J)
CNS inflammation J:96204
\Eae41C57BL/10SnSg/\Eae41C57BL/10SnSg
(involves: B10.RIII * RIIIS/J)
CNS inflammation J:96204
\Eae42C57BL/10SnSg/?
(involves: B10.S * SJL/J)
decreased susceptibility to experimental autoimmune encephalomyelitis J:34892
\Eae42SJL/J/?
(involves: B10.S * SJL/J)
increased susceptibility to experimental autoimmune encephalomyelitis J:34892
\Eae43B10.S/DvTe/?
(involves: B10.S/DvTe * SJL/J)
increased susceptibility to experimental autoimmune encephalomyelitis J:53193
\Eae43B10.S/DvTe/\Eae43B10.S/DvTe
(involves: B10.S/DvTe * SJL/J)
increased susceptibility to experimental autoimmune encephalomyelitis J:49054
\Eae44aB10.S/DvTe/\Eae44aB10.S/DvTe
(involves: B10.S/DvTe * SJL/J)
increased susceptibility to experimental autoimmune encephalomyelitis J:56752
\Eae44aB10.S/DvTe/\Eae44aSJL/J
(involves: B10.S/DvTe * SJL/J)
brain inflammation J:49054
\Eae44aSJL/J/\Eae44aSJL/J
(involves: B10.S/DvTe * SJL/J)
brain inflammation J:49054
\Eae44bB10.S/DvTe/\Eae44bSJL/J
(involves: B10.S/DvTe * SJL/J)
decreased susceptibility to experimental autoimmune encephalomyelitis J:56752
\Eae44bSJL/J/\Eae44bSJL/J
(involves: B10.S/DvTe * SJL/J)
decreased susceptibility to experimental autoimmune encephalomyelitis J:56752
\Eaf1tm1.1Zhow/\Eaf1tm1.1Zhow
\Eaf2tm1Zhow/\Eaf2tm1Zhow
\Tg(Pbsn-cre)4Prb/0

(involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6J * DBA/2)
prostate gland inflammation J:288972
\Eaf1tm1.1Zhow/\Eaf1tm1.1Zhow
\Tg(Pbsn-cre)4Prb/0

(B6(Cg)-Eaf1tm1.1Zhow Tg(Pbsn-cre)4Prb)
prostate gland inflammation J:288972
\Eaf2tm1Zhow/\Eaf2tm1Zhow
(involves: 129P2/OlaHsd)
prostate gland inflammation J:288972
\Eamcd1A/WySn/\Eamcd1A/WySn
(B10.A-(D1Mit65-D1Mit334))
myocarditis J:145043
\Eamcd2A/WySn/\Eamcd2A/WySn
(involves: A.SW-H2s/J * B10.S-H2s/J)
myocarditis J:96562
\Ebag9tm1Rehm/\Ebag9tm1Rehm
(either: (involves: 129P2/OlaHsd * BALB/c) or (involves: 129P2/OlaHsd * C57BL/6))
abnormal CD8-positive, alpha beta T cell morphology J:152534
abnormal cytotoxic T cell physiology J:152534
abnormal memory T cell physiology J:152534
decreased susceptibility to bacterial infection J:152534
\Ebf1em1(IMPC)Mbp/\Ebf1+
(C57BL/6N-Ebf1em1(IMPC)Mbp/MbpMmucd)
abnormal spleen morphology J:211773
enlarged lymph nodes J:211773
\Ebf1m1Btlr/\Ebf1m1Btlr
(C57BL/6J-Ebf1m1Btlr)
decreased B cell number J:265157
decreased IgD level J:265157
increased CD4-positive, alpha-beta T cell number J:265157
increased single-positive T cell number J:265157
increased T cell number J:265157
\Ebf1m2Btlr/\Ebf1m2Btlr
(C57BL/6J-Ebf1m2Btlr)
abnormal humoral immune response J:265158
decreased B cell number J:265158
decreased B-1 B cell number J:265158
decreased B-2 B cell number J:265158
decreased IgD level J:265158
decreased IgM level J:265158
increased B-1a cell number J:265158
increased B-1b cell number J:265158
increased CD4-positive, alpha-beta T cell number J:265158
increased IgM level J:265158
increased single-positive T cell number J:265158
increased T cell number J:265158
increased tumor necrosis factor secretion J:265158
\Ebf1M3Btlr/\Ebf1M3Btlr
(C57BL/6J-Ebf1M3Btlr)
decreased B-1 B cell number J:265160
increased CD4-positive, alpha-beta T cell number J:265160
increased single-positive T cell number J:265160
increased T cell number J:265160
\Ebf1M4Btlr/\Ebf1M4Btlr
(C57BL/6J-Ebf1M4Btlr)
decreased B cell number J:267560
decreased NK cell number J:267560
increased alpha-beta T cell number J:267560
increased CD4-positive, alpha-beta T cell number J:267560
increased CD8-positive, alpha-beta T cell number J:267560
\Ebf1M5Btlr/\Ebf1M5Btlr
(C57BL/6J-Ebf1M5Btlr)
abnormal lymphocyte morphology J:272841
decreased B cell number J:272841
decreased B-1 B cell number J:272841
\Ebf1m6Btlr/\Ebf1m6Btlr
(C57BL/6J-Ebf1m6Btlr)
abnormal lymphocyte morphology J:272842
decreased B cell number J:272842
decreased B-1 B cell number J:272842
decreased effector memory CD4-positive, alpha-beta T cell number J:272842
decreased IgD level J:272842
increased alpha-beta T cell number J:272842
increased CD4-positive, alpha-beta T cell number J:272842
increased CD8-positive, alpha-beta T cell number J:272842
\Ebf1Serv/\Ebf1+
(C57BL/6JAnu-Ebf1Serv)
decreased B cell number J:104190
\Ebf1tm1.1Rug/\Ebf1tm1.1Rug
\Cd19tm1(cre)Cgn/\Cd19+

(involves: 129P2/OlaHsd * C57BL/6 * SJL)
decreased B-1 B cell number J:182210
decreased marginal zone B cell number J:182210
\Ebf1tm1.1Rug/\Ebf1tm1.1Rug
\Cd79atm1(cre)Reth/\Cd79a+

(involves: BALB/c * C57BL/6 * SJL)
arrested B cell differentiation J:182210
\Ebf1tm1.1Rug/\Ebf1tm1.1Rug
\Ighg1tm1(cre)Cgn/\Ighg1+

(involves: 129P2/OlaHsd * C57BL/6 * SJL)
decreased germinal center B cell number J:182210
\Ebf1tm1.1Rug/\Ebf1tm1.1Rug
\Polr2atm1(cre/ERT2)Bbd/\Polr2a+

(involves: C57BL/6 * SJL)
abnormal germinal center B cell physiology J:182210
arrested B cell differentiation J:182210
decreased B cell proliferation J:182210
decreased germinal center B cell number J:182210
decreased IgG1 level J:182210
decreased IgG3 level J:182210
decreased immature B cell number J:182210
decreased marginal zone B cell number J:182210
decreased pre-B cell number J:182210
decreased spleen germinal center number J:182210
decreased transitional stage B cell number J:182210
immune system phenotype J:182210
increased B cell apoptosis J:182210
increased B cell number J:182210
\Ebf1tm1.1Rug/\Ebf1tm1.1Rug
\Polr2atm1(cre/ERT2)Bbd/\Polr2a+
\Tg(BCL2)#Wehi/0

(involves: C57BL/6 * C57BL/6JWehi * SJL * SJL/JWehi)
decreased immature B cell number J:182210
decreased pre-B cell number J:182210
\Ebf1tm1.1Rug/\Ebf1tm1.1Rug
\Tg(Cr2-cre)3Cgn/0

(involves: C57BL/6 * SJL)
decreased B-1 B cell number J:182210
decreased marginal zone B cell number J:182210
\Ebf1tm1Rug/\Ebf1tm1Rug
(involves: 129S2/SvPas)
abnormal B cell morphology J:52607
absent B-1 B cells J:52607
absent mature B cells J:52607
arrested B cell differentiation J:52607
decreased IgM level J:52607
decreased pro-B cell number J:52607
\Ebf1tm1Rug/\Ebf1tm1Rug
(involves: 129S2/SvPas * 129X1/SvJ * C57BL/6)
increased osteoclast cell number J:147179
\Ebf2em1(IMPC)Mbp/\Ebf2+
(C57BL/6N-Ebf2em1(IMPC)Mbp/MbpMmucd)
abnormal spleen morphology J:211773
enlarged spleen J:211773
small spleen J:211773
\Ebi3Gt716Lex/\Ebi3Gt716Lex
(involves: 129S5/SvEvBrd * C57BL/6)
abnormal CD4-positive, alpha-beta T cell number J:286951
abnormal T cell activation J:286951
brain inflammation J:286951
decreased interleukin-10 secretion J:286951
increased CD8-positive, alpha-beta T cell number J:286951
increased interferon-gamma secretion J:286951
increased macrophage cell number J:286951
increased susceptibility to Coronaviridae infection J:286951
increased susceptibility to Coronaviridae infection induced morbidity/mortality J:286951
\Ebi3Gt716Lex/\Ebi3Gt716Lex
\Tg(DO11.10)10Dlo/0

(involves: 129S5/SvEvBrd * BALB/c * C3H * C57BL/6)
abnormal circulating interleukin level J:134148
abnormal T cell differentiation J:134148
decreased susceptibility to bacterial infection J:134148
increased circulating interleukin-17 level J:134148
increased interleukin-17 secretion J:134148
\Ebi3tm1Nkma/\Ebi3tm1Nkma
\Faslpr/\Faslpr

(MRL.Cg-Ebi3tm1Nkma Faslpr)
abnormal cytokine level J:181669
decreased circulating interferon-gamma level J:181669
increased circulating interleukin-4 level J:181669
increased IgE level J:181669
increased IgG1 level J:181669
increased IgG level J:181669
increased immunoglobulin level J:181669
\Ebi3tm1Rsb/\Ebi3tm1Rsb
(involves: 129X1/SvJ * C57BL/6)
abnormal immune system morphology J:81014
abnormal immune system physiology J:81014
abnormal T-helper 1 cell morphology J:97822
abnormal T-helper 2 cell morphology J:97822
decreased interleukin-4 secretion J:81014
decreased NK cell number J:81014
decreased susceptibility to induced colitis J:81014
decreased T-helper 2 cell number J:81014
increased interferon-gamma secretion J:81014
increased susceptibility to parasitic infection J:97822
\Ebna1bp2em1(IMPC)Tcp/\Ebna1bp2+
(C57BL/6N-Ebna1bp2em1(IMPC)Tcp/Cmmr)
enlarged spleen J:211773
\Ece1tm1Reh/\Ece1tm1Reh
(involves: 129S6/SvEvTac * C57BL/6)
persistent cervical thymus J:46640
\Ecm1tm1b(EUCOMM)Hmgu/\Ecm1+
(C57BL/6N-Ecm1tm1b(EUCOMM)Hmgu/H)
decreased neutrophil cell number J:211773
\Ecm1tm1Bsun/\Ecm1tm1Bsun
(involves: 129 * C57BL/6)
abnormal T-helper 2 physiology J:168252
decreased IgE level J:168252
decreased susceptibility to type I hypersensitivity reaction J:168252
immune system phenotype J:168252
increased susceptibility to autoimmune disorder J:168252
\Ecrg4tm1b(EUCOMM)Hmgu/\Ecrg4tm1b(EUCOMM)Hmgu
(C57BL/6N-Ecrg4tm1b(EUCOMM)Hmgu/Orl)
decreased large unstained cell number J:211773
\Ecscrtm1.1(KOMP)Vlcg/\Ecscrtm1.1(KOMP)Vlcg
(C57BL/6N-Ecscrtm1.1(KOMP)Vlcg/Ucd)
abnormal thymus morphology J:211773
small thymus J:211773
\EdaTa-6J/Y
(C57BL/6J Aw-J-EdaTa-6J/J)
blepharitis J:99510
conjunctivitis J:99510
corneal limbitis J:99510
eye inflammation J:99510
increased incidence of corneal inflammation J:99510
\EdaTa-6J/Y
\Tg(MMTVtTA)1Mam/0
\Tg(tetO-Eda*A1)1Dsch/0

(involves: C57BL/6J)
immune system phenotype J:99510
\Edc3em1(IMPC)Tcp/\Edc3+
(C57BL/6NCrl-Edc3em1(IMPC)Tcp/Tcp)
enlarged lymph nodes J:211773
\Edc3em1(IMPC)Tcp/\Edc3em1(IMPC)Tcp
(C57BL/6NCrl-Edc3em1(IMPC)Tcp/Tcp)
enlarged lymph nodes J:211773
\Eddm3btm1b(KOMP)Wtsi/\Eddm3btm1b(KOMP)Wtsi
(C57BL/6N-Eddm3btm1b(KOMP)Wtsi/Nju)
increased basophil cell number J:211773
increased eosinophil cell number J:211773
\Edil3Tg(lacZ)1Tq/\Edil3Tg(lacZ)1Tq
(Not Specified)
increased susceptibility to induced arthritis J:254384
\Edil3tm1Tq/\Edil3tm1Tq
(B6.129S6-Edil3tm1Tq)
abnormal cellular extravasation J:141063
abnormal leukocyte adhesion J:141063
abnormal neutrophil physiology J:141063
enhanced leukocyte tethering or rolling J:141063
\Edil3tm1Tq/\Edil3tm1Tq
\Itgaltm1Bll/\Itgaltm1Bll

(involves: 129 * C57BL/6)
abnormal cellular extravasation J:141063
abnormal neutrophil physiology J:141063
\Ednratm1Ywa/\Ednratm1Ywa
(129S/SvEv-Ednratm1Ywa)
ectopic thymus J:46639
thymus hypoplasia J:46639
\Ednrbtm1Nrd/\Ednrbtm1Nrd
\Gt(ROSA)26Sortm14(CAG-tdTomato)Hze/\Gt(ROSA)26Sor+
\H2az2Tg(Wnt1-cre)11Rth/\H2az2+

(involves: 129S1/Sv * 129S6/SvEvTac * 129X1/SvJ * C57BL/6 * CBA/J)
abnormal mature B cell number J:233811
abnormal Peyer's patch morphology J:233811
abnormal spleen morphology J:233811
abnormal splenic cell ratio J:233811
decreased B cell number J:233811
decreased germinal center B cell number J:233811
decreased IgA level J:233811
decreased marginal zone B cell number J:233811
decreased spleen red pulp amount J:233811
decreased spleen weight J:233811
decreased spleen white pulp amount J:233811
large intestinal inflammation J:233811
small Peyer's patches J:233811
small spleen J:233811
\Ednrbtm1Ywa/\Ednrb+
(involves: 129S/SvEvBrd)
decreased acute inflammation J:103977
\Ednrbtm1Ywa/\Ednrbtm1Ywa
(involves: 129S5/SvEvBrd)
decreased acute inflammation J:103977
\Eef1a1tm2Arge/\Eef1a1+
\Tg(Mx1-cre)1Cgn/0

(involves: C57BL/6 * CBA)
abnormal double-positive T cell morphology J:197167
\Eef1a2wst/\Eef1a2wst
(B6C3Fe a/a-Eef1a2wst/J)
decreased plasma cell number J:7903
decreased spleen weight J:6766
decreased susceptibility to type IV hypersensitivity reaction J:6766
decreased thymus weight J:6766
lymphoid hypoplasia J:6766
small lymph nodes J:6766
\Eef1a2wst/\Eef1a2wst
(Not Specified)
thymus atrophy J:50410
\Eef1dem1(IMPC)Mbp/\Eef1d+
(C57BL/6NCrl-Eef1dem1(IMPC)Mbp/MbpMmucd)
increased neutrophil cell number J:211773
\Eef1e1Gt(OST377244)Lex/\Eef1e1+
(involves: 129S5/SvEvBrd * C57BL/6)
decreased splenocyte apoptosis J:96923
increased splenocyte proliferation J:96923
\Efemp1tm2Lmar/\Efemp1tm2Lmar
(involves: 129X1/SvJ * C57BL/6)
abnormal spleen morphology J:132043
decreased spleen weight J:132043
\Efhd2tm1(KOMP)Vlcg/\Efhd2tm1(KOMP)Vlcg
(C57BL/6-Efhd2tm1(KOMP)Vlcg)
abnormal response to infection J:228565
immune system phenotype J:228565
increased germinal center B cell number J:228565
increased IgE level J:228565
increased IgG1 level J:228565
increased IgG2a level J:228565
increased IgM level J:228565
increased plasma cell number J:228565
increased spleen germinal center size J:228565
\Efnb1tm1.1Jwu/\Efnb1tm1.1Jwu
\Efnb2tm1.1Jwu/\Efnb2tm1.1Jwu
\Tg(Lck-cre)I540Jxm/0

(B6.Cg-Efnb2tm1.1Jwu Efnb1tm1.1Jwu Tg(Lck-cre)I540Jxm)
abnormal T cell differentiation J:178148
abnormal T-helper 1 cell differentiation J:178148
abnormal T-helper 17 cell differentiation J:178148
decreased CD4-positive, alpha-beta T cell number J:178148
decreased CD8-positive, alpha-beta T cell number J:178148
decreased DN4 thymocyte number J:178148
decreased double-positive T cell number J:178148
decreased spleen weight J:178148
decreased T cell number J:178148
decreased thymus weight J:178148
increased DN3 thymocyte number J:178148
increased double-negative T cell number J:178148
increased length of allograft survival J:178148
increased susceptibility to Riboviria infection J:178148
increased thymocyte apoptosis J:178148
small spleen J:178148
small thymus J:178148
spleen hypoplasia J:178148
thymus hypoplasia J:178148
\Efnb1tm1.1Jwu/\Efnb1tm1.1Jwu
\Tg(Lck-cre)I540Jxm/0

(B6.Cg-Efnb1tm1.1Jwu Tg(Lck-cre)I540Jxm)
immune system phenotype J:178148
\Efnb2tm1.1Jwu/\Efnb2tm1.1Jwu
\Tg(Lck-cre)I540Jxm/0

(B6.Cg-Efnb2tm1.1Jwu Tg(Lck-cre)I540Jxm)
immune system phenotype J:178148
\Efnb2tm5.1Kln/\Efnb2tm5.1Kln
(involves: C57BL/6)
abnormal afferent lymphatic vessel morphology J:95885
abnormal lymph circulation J:95885
abnormal lymphatic vessel morphology J:95885
\Efnb2tm5.1Kln/\Efnb2tm5.1Kln
(involves: CD-1)
abnormal lymphatic vessel morphology J:95885
\Efnb2tm5.1Kln/\Efnb2tm5.1Kln
\Flt4tm1Ali/\Flt4+

(involves: C57BL/6)
abnormal afferent lymphatic vessel morphology J:95885
abnormal lymphatic vessel morphology J:95885
\Efnb2tm6Kln/\Efnb2tm6Kln
(involves: C57BL/6)
abnormal lymph circulation J:95885
abnormal lymphatic vessel morphology J:95885
\Efstm1Kale/\Efs+
(either: (involves: 129X1/SvJ) or (involves: 129X1/SvJ * C57BL/6J))
increased IgA level J:103757
increased IgG level J:103757
increased inflammatory response J:103757
small intestinal inflammation J:103757
\Efstm1Kale/\Efstm1Kale
(either: (involves: 129X1/SvJ) or (involves: 129X1/SvJ * C57BL/6J))
abnormal interleukin secretion J:103757
abnormal T cell physiology J:103757
increased IgA level J:103757
increased IgG level J:103757
increased immunoglobulin level J:103757
increased inflammatory response J:103757
increased interferon-gamma secretion J:103757
kidney inflammation J:103757
liver inflammation J:103757
lung inflammation J:103757
small intestinal inflammation J:103757
\Eftud2tm1b(KOMP)Wtsi/\Eftud2+
(C57BL/6N-Eftud2tm1b(KOMP)Wtsi/Ics)
decreased leukocyte cell number J:211773
decreased lymphocyte cell number J:211773
\EgfrMhdadsk5/\Egfr+
(involves: 129S1/SvImJ * C3HeB/FeJ)
increased susceptibility to Coronaviridae infection J:243599
increased susceptibility to Coronaviridae infection induced morbidity/mortality J:243599
\Egfrtm1a(EUCOMM)Wtsi/\Egfr+
(C57BL/6N-Egfrtm1a(EUCOMM)Wtsi/Wtsi)
decreased leukocyte cell number J:175295
\Egfrtm1Dwt/\Egfrtm1Dwt
\Sox9tm3(cre)Crm/\Sox9+

(involves: 129S6/SvEvTac * 129S7/SvEvBrd)
dermatitis J:229771
increased IgE level J:229771
increased T-helper 1 cell number J:229771
increased T-helper 2 cell number J:229771
increased T-helper 17 cell number J:229771
\Egfrtm1Msi/\Egfrtm1Msi
\Tg(Alb1-cre)7Gsc/?

(involves: 129P2/OlaHsd * C57BL/6 * FVB/N)
increased circulating tumor necrosis factor level J:125912
\Egfrtm1Msi/\Egfrtm1Msi
\Tg(Mx1-cre)1Cgn/?

(involves: 129P2/OlaHsd * C57BL/6 * CBA)
increased circulating tumor necrosis factor level J:125912
\Egln1tm1.1Brei/\Egln1tm1.1Brei
\Tg(CD68-icre)1Bwlx/0

(involves: C57BL/6)
abnormal lymphocyte cell number J:194598
abnormal spleen morphology J:194598
enlarged spleen J:194598
increased spleen weight J:194598
\Egln1tm1.1Fsl/\Egln1+
(C57BL/6-Egln1tm1.1Fsl)
increased spleen weight J:202737
\Egln1tm1Fong/\Egln1tm1Fong
(involves: 129S6/SvEvTac * C57BL/6 * CD-1 * FVB/N * SJL)
abnormal lymph organ development J:114669
\Egln1tm2.1Fsl/\Egln1tm2.1Fsl
\Gt(ROSA)26Sortm9(cre/ESR1)Arte/\Gt(ROSA)26Sor+

(B6.Cg-Gt(ROSA)26Sortm9(cre/ESR1)Arte Egln1tm2.1Fsl)
increased spleen weight J:202737
\Egln1tm2.1Fsl/\Egln1tm2.1Fsl
\Gt(ROSA)26Sortm9(cre/ESR1)Arte/\Gt(ROSA)26Sor+
\Hif1atm3Rsjo/\Hif1atm3Rsjo

(B6.Cg-Gt(ROSA)26Sortm9(cre/ESR1)Arte Egln1tm2.1Fsl Hif1atm3Rsjo)
increased spleen weight J:202737
\Egln1tm2.1Fsl/\Egln1tm2.1Fsl
\Pax3tm1(cre)Joe/\Pax3+

(involves: 129 * C57BL/6)
increased spleen weight J:202737
\Egln1tm2.2Fsl/\Egln1+
(B6.Cg-Egln1tm2.2Fsl)
increased spleen weight J:202737
\Egln1tm2Fong/\Egln1tm2Fong
\Gt(ROSA)26Sortm1(cre/ERT2)Alj/\Gt(ROSA)26Sor+

(involves: 129S6/SvEvTac * C57BL/6)
abnormal splenic cell ratio J:132720
enlarged spleen J:132720
increased leukocyte cell number J:132720
\Egln2tm1Fong/\Egln2tm1Fong
\Egln3tm1Fong/\Egln3tm1Fong

(involves: 129S6/SvEvTac * C57BL/6)
abnormal splenic cell ratio J:132720
enlarged spleen J:132720
\Egr1tm1b(NCOM)Mfgc/\Egr1+
(C57BL/6N-Egr1tm1b(NCOM)Mfgc/Tcp)
increased lymphocyte cell number J:211773
\Egr1tm1Jmi/\Egr1tm1Jmi
(B6.129-Egr1tm1Jmi)
abnormal circulating tumor necrosis factor level J:128421
increased osteoclast cell number J:51107
liver inflammation J:128421
\Egr1tm1Jmi/\Egr1tm1Jmi
(involves: 129 * C57BL/6)
abnormal leukocyte cell number J:123870
abnormal leukocyte morphology J:123870
abnormal microglial cell physiology J:135238
abnormal neutrophil morphology J:123870
abnormal tumor necrosis factor level J:105638
decreased inflammatory response J:152898
immune system phenotype J:105638
increased lymphocyte cell number J:123870
increased spleen weight J:123870
increased T cell derived lymphoma incidence J:123870
\Egr1tm1Jmi/\Egr1tm1Jmi
\Tg(Scgb1a1-rtTA,-tTS,tetO-TGFB1*)1Eli/?

(involves: 129 * C57BL/6)
lung inflammation J:92469
\Ehbp1l1tm1a(EUCOMM)Wtsi/\Ehbp1l1tm1a(EUCOMM)Wtsi
(C57BL/6N-Ehbp1l1tm1a(EUCOMM)Wtsi/Wtsi)
blood in lymph vessels J:239583
\Ehmt1tm1b(EUCOMM)Hmgu/\Ehmt1+
(C57BL/6N-Ehmt1tm1b(EUCOMM)Hmgu/Nju)
increased neutrophil cell number J:211773
\Ehmt2tm1.1Cza/\Ehmt2tm1.1Cza
\Tg(Cd4-cre)1Cwi/0

(involves: C57BL/6 * DBA/2 * SJL)
decreased IgG1 level J:160938
decreased interleukin-4 secretion J:160938
increased IgG2a level J:160938
increased interferon-gamma secretion J:160938
increased susceptibility to parasitic infection J:160938
\Ehmt2tm1.1Cza/\Ehmt2tm1.1Cza
\Tg(VAV1-cre)1Graf/0

(involves: C57BL/6 * SJL)
decreased interleukin-4 secretion J:160938
decreased interleukin-5 secretion J:160938
decreased interleukin-13 secretion J:160938
increased interferon-gamma secretion J:160938
increased interleukin-17 secretion J:160938
increased susceptibility to parasitic infection J:160938
\Eid2bem1(IMPC)J/\Eid2b+
(C57BL/6NJ-Eid2bem1(IMPC)J/Mmjax)
increased leukocyte cell number J:211773
\Eif1adtm1b(EUCOMM)Hmgu/\Eif1ad+
(C57BL/6N-Eif1adtm1b(EUCOMM)Hmgu/Bay)
increased large unstained cell number J:211773
\Eif2aem1(IMPC)Mbp/\Eif2aem1(IMPC)Mbp
(C57BL/6N-Eif2aem1(IMPC)Mbp/Ucd)
abnormal spleen morphology J:211773
enlarged spleen J:211773
\Eif2ak1em1(IMPC)Bay/\Eif2ak1em1(IMPC)Bay
(C57BL/6N-Eif2ak1em1(IMPC)Bay/BayMmucd)
increased spleen weight J:211773
\Eif2ak2em1(IMPC)Mbp/\Eif2ak2em1(IMPC)Mbp
(C57BL/6N-Eif2ak2em1(IMPC)Mbp/MbpMmucd)
abnormal spleen morphology J:211773
small spleen J:211773
\Eif2ak2em1Btlr/\Eif2ak2em1Btlr
(C57BL/6J-Eif2ak2em1Btlr)
immune system phenotype J:354285
\Eif2ak2em1Btlr/\Eif2ak2em1Btlr
\Zfp574em1Btlr/\Zfp574em1Btlr

(C57BL/6J-Zfp574em1Btlr Eif2ak2em1Btlr)
abnormal B cell physiology J:354285
abnormal class switch recombination J:354285
abnormal humoral immune response J:354285
decreased lymphocyte cell number J:354285
\Eif2ak2tm1Cwe/\Eif2ak2tm1Cwe
(involves: 129S/SvEv * C57BL/6)
increased interleukin-4 secretion J:66112
increased susceptibility to Picornaviridae infection J:30617
increased susceptibility to type IV hypersensitivity reaction J:66112
increased T cell proliferation J:66112
\Eif2ak2tm1Cwe/\Eif2ak2tm1Cwe
(involves: 129)
immune system phenotype J:114555
\Eif2ak2tm1Cwe/\Eif2ak2tm1Cwe
\Rnaseltm1Slvm/\Rnaseltm1Slvm

(involves: 129P2/OlaHsd * 129S/SvEv * C57BL/6)
increased susceptibility to Picornaviridae infection J:55974
\Eif2ak2tm1Jcbe/\Eif2ak2tm1Jcbe
(involves: 129S4/SvJae * BALB/c)
immune system phenotype J:53258
\Eif2ak2tm1Jcbe/\Eif2ak2tm1Jcbe
(involves: 129S4/SvJae)
immune system phenotype J:63671
increased susceptibility to Orthomyxoviridae infection J:63671
increased susceptibility to Riboviria infection J:167126, J:63671
\Eif2ak3tm1.1Drc/\Eif2ak3tm1.1Drc
\Tg(Ela1-cre)16Eps/0

(involves: 129S6/SvEvTac)
acute pancreas inflammation J:129974
\Eif2ak4m1Btlr/\Eif2ak4m1Btlr
(C57BL/6J-Eif2ak4m1Btlr)
abnormal macrophage physiology J:173669
increased susceptibility to Adenoviridae infection J:173669
increased susceptibility to Herpesvirales infection J:173669
\Eif2ak4tm1.2Dron/\Eif2ak4tm1.2Dron
(involves: 129S6/SvEvTac * C57BL/6 * CBA)
abnormal cytokine secretion J:120813
abnormal dendritic cell physiology J:120813
\Eif2b5tm1Itl/\Eif2b5tm1Itl
(involves: 129S/SvEv)
abnormal microglial cell physiology J:192103
\Eif2dem1(IMPC)Mbp/\Eif2dem1(IMPC)Mbp
(C57BL/6N-Eif2dem1(IMPC)Mbp/MbpMmucd)
abnormal lymph node morphology J:211773
abnormal spleen morphology J:211773
enlarged lymph nodes J:211773
enlarged spleen J:211773
\Eif2s2em3(IMPC)Bay/\Eif2s2+
(C57BL/6N-Eif2s2em3(IMPC)Bay/Bay)
abnormal spleen morphology J:211773
\Eif4a1tm1.1Bea/\Eif4a1tm1.1Bea
\Tg(Fcer2a-cre)5Mbu/0

(involves: 129P2/OlaHsd * C57BL/6 * CBA)
decreased B cell proliferation J:344730
decreased germinal center B cell number J:344730
decreased IgG1 level J:344730
\Eif4btm1.1Smoc/\Eif4b+
\Tg(SFTPC-rtTA)5Jaw/0
\Tg(tetO-cre)1Jaw/0

(involves: 129 * C57BL/6)
increased susceptibility to Riboviria infection J:311140
\Eif4btm1.1Smoc/\Eif4btm1.1Smoc
\Ndor1Tg(UBC-cre/ERT2)1Ejb/\Ndor1+

(involves: 129 * C57BL/6)
decreased leukocyte cell number J:311140
decreased lymphocyte cell number J:311140
decreased NK cell number J:311140
increased macrophage cell number J:311140
increased neutrophil cell number J:311140
increased susceptibility to induced colitis J:311140
increased susceptibility to Orthomyxoviridae infection J:311140
increased susceptibility to Orthomyxoviridae infection induced morbidity/mortality J:311140
lung inflammation J:311140
small spleen J:311140
small thymus J:311140
\Eif4btm1.1Smoc/\Eif4btm1.1Smoc
\Tg(SFTPC-rtTA)5Jaw/0
\Tg(tetO-cre)1Jaw/0

(involves: 129 * C57BL/6)
increased susceptibility to Orthomyxoviridae infection J:311140
\Eif4g1em1(IMPC)Hmgu/\Eif4g1+
(C57BL/6NCrl-Eif4g1em1(IMPC)Hmgu/Ieg)
decreased spleen weight J:211773
\Elac2em1Afi/\Elac2em1Afi
(C57BL/6N-Elac2em1Afi)
prostate gland inflammation J:336403
\ElaneM1Btlr/\ElaneM1Btlr
(C57BL/6J-ElaneM1Btlr)
decreased tumor necrosis factor secretion J:218967
\Elanetm1(cre)Roes/\Elanetm1(cre)Roes
(involves: 129)
decreased susceptibility to bacterial infection induced morbidity/mortality J:77597
increased susceptibility to infection induced morbidity/mortality J:77597
\Elanetm1(cre)Roes/\Elanetm1(cre)Roes
(involves: 129S6/SvEvTac)
impaired neutrophil recruitment J:137674
\Elanetm1Link/\Elanetm1Link
(involves: 129X1/SvJ * C57BL/6)
immune system phenotype J:131496
\Elanetm1Sds/\Elanetm1Sds
(129X1/SvJ-Elanetm1Sds)
abnormal neutrophil physiology J:47420
decreased susceptibility to bacterial infection induced morbidity/mortality J:47420
increased susceptibility to bacterial infection J:47420
increased susceptibility to bacterial infection induced morbidity/mortality J:47420
\Elanetm1Sds/\Elanetm1Sds
(involves: 129X1/SvJ * C57BL/6)
abnormal inflammatory response J:113463
\Elapor1tm1b(EUCOMM)Hmgu/\Elapor1+
(C57BL/6N-Elapor1tm1b(EUCOMM)Hmgu/Ics)
decreased lymphocyte cell number J:211773
\Elavl1tm1.1Atas/\Elavl1tm1.1Atas
\Tnfrsf4tm2(cre)Nik/\Tnfrsf4+

(involves: 129X1/SvJ * C57BL/6)
decreased susceptibility to experimental autoimmune encephalomyelitis J:207013
decreased T cell proliferation J:207013
decreased T-helper 17 cell number J:207013
\Elavl1tm1.1Dkon/\Elavl1tm1.1Dkon
\Lyz2tm1(cre)Ifo/\Lyz2+

(B6.129P2-Elavl1tm1.1Dkon Lyz2tm1(cre)Ifo)
abnormal macrophage chemotaxis J:184388
immune system phenotype J:184388
increased circulating interleukin-1 beta level J:184388
increased circulating interleukin-6 level J:184388
increased circulating interleukin-12 level J:184388
increased circulating tumor necrosis factor level J:184388
increased macrophage cell number J:184388
increased monocyte cell number J:184388
increased susceptibility to endotoxin shock J:184388
increased susceptibility to induced colitis J:184388
\Elavl1tm1.1Dkon/\Elavl1tm1.1Dkon
\Lyz2tm1(cre)Ifo/\Lyz2+

(involves: 129P2/OlaHsd * C57BL/6J)
immune system phenotype J:184388
increased circulating interleukin-1 beta level J:184388
increased circulating interleukin-6 level J:184388
increased circulating interleukin-12 level J:184388
increased circulating tumor necrosis factor level J:184388
increased susceptibility to endotoxin shock J:184388
\Elavl1tm1.1Thla/\Elavl1+
(involves: 129S1/Sv)
spleen hypoplasia J:155109
thymus hypoplasia J:155109
\Elavl1tm1Dkon/\Elavl1tm1Dkon
\Edil3Tg(Sox2-cre)1Amc/\Edil3+

(involves: 129P2/OlaHsd * C57BL/6 * CBA)
abnormal spleen development J:149149
absent spleen J:149149
\Elavl1tm1Dkon/\Elavl1tm1Dkon
\Tg(Lck-cre)I57Jxm/0

(B6.Cg-Elavl1tm1Dkon Tg(Lck-cre)I57Jxm)
abnormal positive T cell selection J:148866
abnormal T cell physiology J:148866
abnormal thymocyte activation J:148866
decreased CD4-positive, alpha-beta T cell number J:148866
decreased CD8-positive, alpha-beta T cell number J:148866
increased double-negative T cell number J:148866
increased double-positive T cell number J:148866
increased single-positive T cell number J:148866
\Elavl1tm1Dkon/\Elavl1tm1Dkon
\Tg(Lck-cre)I57Jxm/0
\Tg(TcraH-Y,TcrbH-Y)71Vbo/?

(B6.Cg-Elavl1tm1Dkon Tg(Lck-cre)I57Jxm Tg(TcraH-Y,TcrbH-Y)71Vbo)
abnormal negative T cell selection J:148866
increased thymocyte number J:148866
\Elavl1tm1Lix/\Elavl1tm1Lix
\Tg(Scgb1a1-rtTA)2Jaw/0
\Tg(tetO-cre)1Jaw/0

(involves: 129 * C57BL/6)
decreased inflammatory response J:204952
lung inflammation J:204952
\Elavl1tm1Thla/\Elavl1tm1Thla
\Gt(ROSA)26Sortm1(cre/ERT2)Alj/\Gt(ROSA)26Sor+

(involves: 129)
abnormal B cell physiology J:155109
abnormal myeloid leukocyte morphology J:155109
decreased B cell apoptosis J:155109
decreased double-positive T cell number J:155109
decreased granulocyte number J:155109
decreased leukocyte cell number J:155109
increased granulocyte number J:155109
increased T cell apoptosis J:155109
lymph node hypoplasia J:155109
spleen hypoplasia J:155109
thymus hypoplasia J:155109
\Elf1tm1Jml/\Elf1tm1Jml
(Not Specified)
abnormal B cell differentiation J:100734
abnormal B cell physiology J:100734
\Elf4em1Hdu/\Elf4em1Hdu
(C57BL/6-Elf4em1Hdu)
abnormal CD4-positive T cell differentiation J:328935
abnormal interferon level J:328935
abnormal interleukin level J:328935
abnormal macrophage physiology J:328935
abnormal tumor necrosis factor level J:328935
increased susceptibility to viral infection J:328935
\Elf4tm1Nim/\Elf4tm1Nim
(B6.129S1-Elf4tm1Nim)
abnormal inflammatory response J:79568
abnormal lymphocyte morphology J:79568
abnormal lymphocyte physiology J:79568
abnormal NK cell physiology J:79568
abnormal T cell differentiation J:79568
decreased cytotoxic T cell cytolysis J:79568
decreased NK cell number J:79568
decreased NK T cell number J:79568
impaired natural killer cell mediated cytotoxicity J:79568
increased B cell number J:79568
increased B cell proliferation J:79568
increased T cell proliferation J:79568
large lymphoid organs J:79568
\Elfn2tm1.1(KOMP)Vlcg/\Elfn2tm1.1(KOMP)Vlcg
(C57BL/6N-Elfn2tm1.1(KOMP)Vlcg/Ucd)
increased eosinophil cell number J:211773
\Elk1tm1Nor/Y
(involves: 129P2/OlaHsd * C57BL/6N)
immune system phenotype J:87597
\Elk3tm1Wlyk/\Elk3tm1Wlyk
(either: (involves: 129/Sv) or (involves: 129/Sv * C57BL/6))
lymphangiectasis J:71816
\Elk4tm1a(EUCOMM)Wtsi/\Elk4tm1a(EUCOMM)Wtsi
(C57BL/6N-Elk4tm1a(EUCOMM)Wtsi/H)
decreased CD4-positive, alpha-beta T cell number J:165965
decreased CD8-positive, alpha-beta T cell number J:165965
decreased mature B cell number J:165965
decreased T cell number J:165965
increased B cell number J:165965
increased T cell number J:165965
\Elk4tm1Rtr/\Elk4tm1Rtr
(either: (involves: 129/Sv) or (involves: 129/Sv * C57BL/6))
abnormal positive T cell selection J:88515
abnormal T cell selection J:88515
decreased CD4-positive, alpha-beta T cell number J:88515
decreased CD8-positive, alpha-beta T cell number J:88515
decreased single-positive T cell number J:88515
decreased T cell number J:88515
decreased thymocyte number J:88515
\Elk4tm1Rtr/\Elk4tm1Rtr
\Tg(TcraH-Y,TcrbH-Y)71Vbo/?

(involves: 129/Sv * C57BL/6 * DBA/2J)
abnormal positive T cell selection J:88515
decreased CD8-positive, alpha-beta T cell number J:88515
\Elk4tm1Rtr/\Elk4tm1Rtr
\Tg(TcraTcrb)425Cbn/?

(involves: 129/Sv * C57BL/6)
abnormal positive T cell selection J:88515
abnormal splenic cell ratio J:88515
decreased CD4-positive, alpha-beta T cell number J:88515
\Elk4tm1Rtr/\Elk4tm1Rtr
\Tg(TcrLCMV)327Sdz/?

(involves: 129/Sv * C57BL/6 * DBA/2)
abnormal positive T cell selection J:88515
decreased CD8-positive, alpha-beta T cell number J:88515
\Elmo1M1Btlr/\Elmo1M1Btlr
(C57BL/6J-Elmo1M1Btlr)
decreased B cell number J:265231
decreased CD4-positive, CD25-positive, alpha-beta regulatory T cell number J:265231
decreased IgM level J:265231
impaired humoral immune response J:265231
increased B-1 B cell number J:265231
increased CD8-positive, alpha-beta memory T cell number J:265231
\Elmo1m2Btlr/\Elmo1m2Btlr
(C57BL/6J-Elmo1m2Btlr)
decreased B cell number J:265232
\Elmo1m3Btlr/\Elmo1m3Btlr
(C57BL/6J-Elmo1m3Btlr)
decreased central memory CD8 positive, alpha-beta T cell number J:271894
decreased NK cell number J:271894
increased CD8-positive, alpha-beta T cell number J:271894
\Elmo1M4Btlr/\Elmo1M4Btlr
(C57BL/6J-Elmo1M4Btlr)
abnormal B cell morphology J:271969
abnormal T cell morphology J:271969
decreased CD4-positive, alpha-beta T cell number J:271969
increased B-1 B cell number J:271969
increased CD8-positive, alpha-beta T cell number J:271969
\Elmo1tm1a(EUCOMM)Wtsi/\Elmo1tm1a(EUCOMM)Wtsi
(C57BL/6N-Elmo1tm1a(EUCOMM)Wtsi/Wtsi)
increased leukocyte cell number J:211773
\Elmod1tm1a(EUCOMM)Hmgu/\Elmod1tm1a(EUCOMM)Hmgu
(C57BL/6N-Elmod1tm1a(EUCOMM)Hmgu/H)
decreased B cell number J:165965
decreased leukocyte cell number J:165965
\Elmod1tm1b(EUCOMM)Hmgu/\Elmod1tm1b(EUCOMM)Hmgu
(C57BL/6N-Elmod1tm1b(EUCOMM)Hmgu/H)
decreased large unstained cell number J:211773
decreased leukocyte cell number J:211773
decreased lymphocyte cell number J:211773
decreased monocyte cell number J:211773
increased eosinophil cell number J:211773
\Elovl3tm1Jaco/\Elovl3tm1Jaco
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)
dermatitis J:88477
\Elp1tm1.1Id/\Elp1tm1.2Id
(involves: 129S1/Sv * C57BL/6 * C57BL/6J * CBA)
conjunctivitis J:188923
\Elp1tm1.2Id/\Elp1tm1.2Id
(involves: 129S1/Sv * C57BL/6 * C57BL/6J * CBA)
conjunctivitis J:188923
\Elsgp1C57BL/6J/\Elsgp1NZB/BlNJ
(involves: C57BL/6J * NZB/BlNJ)
abnormal immune serum protein physiology J:63674
\Elsgp1NZB/BlNJ/\Elsgp1NZB/BlNJ
(involves: C57BL/6J * NZB/BlNJ)
abnormal immune serum protein physiology J:63674
\Elsgp1NZB/BlNJ/\Elsgp1NZB/BlNJ
\Elsgp2NZB/BlNJ/\Elsgp2NZB/BlNJ

(involves: C57BL/6J * NZB/BlNJ)
abnormal immune serum protein physiology J:63674
\Elsgp2C57BL/6J/\Elsgp2NZB/BlNJ
(involves: C57BL/6J * NZB/BlNJ)
abnormal immune serum protein physiology J:63674
\Elsgp2NZB/BlNJ/\Elsgp2NZB/BlNJ
(involves: C57BL/6J * NZB/BlNJ)
abnormal immune serum protein physiology J:63674
\Elsgp3C57BL/6J/\Elsgp3NZB/BlNJ
(involves: C57BL/6J * NZB/BlNJ)
abnormal immune serum protein physiology J:63674
\Elsgp3NZB/BlNJ/\Elsgp3NZB/BlNJ
(involves: C57BL/6J * NZB/BlNJ)
abnormal immune serum protein physiology J:63674
\Elsgp4NZB/BlNJ/\Elsgp4NZB/BlNJ
(involves: BALB/cByJ * NZB/BlNJ)
abnormal immune serum protein physiology J:89134
\Elsgp4NZW/LacJ/?
(involves: BALB/cByJ * NZW/LacJ)
abnormal immune serum protein physiology J:89134
\Emc4tm1(KOMP)Wtsi/\Emc4+
(C57BL/6N-Emc4tm1(KOMP)Wtsi/Nju)
increased basophil cell number J:211773
increased eosinophil cell number J:211773
\Emc8tm1b(EUCOMM)Hmgu/\Emc8+
(C57BL/6N-Emc8tm1b(EUCOMM)Hmgu/H)
increased neutrophil cell number J:211773
\Eme1tm1.1(KOMP)Wtsi/\Eme1tm1.1(KOMP)Wtsi
(C57BL/6N-Eme1tm1.1(KOMP)Wtsi/Bay)
abnormal spleen morphology J:211773
\Eml3em1(IMPC)J/\Eml3+
(C57BL/6NJ-Eml3em1(IMPC)J/Mmjax)
decreased leukocyte cell number J:211773
\Emp2tm1.1Tac/\Emp2tm1.1Tac
\Tg(Zp3-cre)93Knw/0

(involves: C57BL/6 * C57BL/6J * C57BL/6N)
increased leukocyte cell number J:243365
increased uterine NK cell number J:243365
\Emsyem1(IMPC)Ccpcz/\Emsy+
(C57BL/6NCrl-Emsyem1(IMPC)Ccpcz/Ccpcz)
increased NK cell number J:211773
\Emv30b/\Emv30b
\Prkdcscid/\Prkdcscid

(NOD.Cg-Emv30b Prkdcscid/Dvs)
increased T cell derived lymphoma incidence J:29951
\Emv72a/\Emv72a
(involves: BALB/cAnNCr * C57BL/6NCr)
abnormal cytotoxic T cell physiology J:194735
\Emv72b/\Emv72b
(CAnNCr.B6NCr-Emv72b)
abnormal cytotoxic T cell physiology J:194735
abnormal T cell morphology J:194735
\Emv72b/\Emv72b
(involves: BALB/cAnNCr * C57BL/6NCr)
abnormal cytotoxic T cell physiology J:194735
\En1tm1(Tnf)Fpit/\En1tm1(Tnf)Fpit
(involves: C57BL/6)
increased monocyte cell number J:170743
microgliosis J:170743
\Endoutm1Tft/\Endoutm1Tft
(involves: 129S/SvEv * C57BL/6)
immune system phenotype J:208364
\Endoutm1Tft/\Endoutm1Tft
\Tg(IghelMD4)4Ccg/0
\Tg(ML5sHEL)5Ccg/0

(involves: 129S/SvEv * C57BL/6 * C57BL/6JSfd)
decreased activation-induced B cell apoptosis J:208364
immune system phenotype J:208364
increased autoantibody level J:208364
\Engem1(IMPC)Mbp/\Eng+
(C57BL/6N-Engem1(IMPC)Mbp/MbpMmucd)
increased neutrophil cell number J:211773
\Enkurtm1Hmf/\Enkurtm1Hmf
(involves: 129 * C57BL/6J)
abnormal spleen morphology J:253966
absent spleen J:253966
\Enpeptm1Mdc/\Enpeptm1Mdc
(involves: 129P2/OlaHsd * C57BL/6)
immune system phenotype J:47424
\Enpp1asj/\Enpp1asj
(C57BL/6J-Enpp1asj/GrsrJ)
increased susceptibility to otitis media J:251638
joint inflammation J:174912
osteoarthritis J:174912
osteomyelitis J:174912
\Enpp1em1(IMPC)Ccpcz/\Enpp1em1(IMPC)Ccpcz
(C57BL/6NCrl-Enpp1em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged spleen J:211773
small thymus J:211773
\Enpp1ttw/\Enpp1ttw
(involves: ICR)
osteoarthritis J:19124, J:37369
\Enpp2tm1Lex/\Enpp2+
(involves: 129S/SvEvBrd * C57BL/6J)
abnormal chemokine level J:103485
decreased circulating interleukin-6 level J:103485
decreased circulating tumor necrosis factor level J:103485
decreased susceptibility to endotoxin shock J:103485
\Enpp3tm1Ktak/\Enpp3tm1Ktak
(either: (involves: 129S4/SvJae * C57BL/6) or (involves: 129S4/SvJae * BALB/c * C57BL/6))
abnormal basophil physiology J:223825
abnormal mast cell physiology J:223825
immune system phenotype J:223825
increased basophil cell number J:223825
increased IgE level J:223825
increased interleukin-4 secretion J:223825
increased mast cell number J:223825
increased susceptibility to type I hypersensitivity reaction J:223825
intestinal inflammation J:223825
lung inflammation J:223825
\Enpp3tm1Ktak/\Enpp3tm1Ktak
\P2rx7tm1Gab/\P2rx7tm1Gab

(either: (involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6) or (involves: 129P2/OlaHsd * 129S4/SvJae * BALB/c * C57BL/6))
immune system phenotype J:223825
increased basophil cell number J:223825
increased mast cell number J:223825
\Entpd1tm1a(EUCOMM)Wtsi/\Entpd1tm1a(EUCOMM)Wtsi
(C57BL/6N-Entpd1tm1a(EUCOMM)Wtsi/Ieg)
increased T cell number J:165965
\Entpd1tm1Rdr/\Entpd1tm1Rdr
(involves: 129S2/SvPas)
abnormal neutrophil physiology J:129091
spleen fibrosis J:57505
\Entpd5tm1Rre/\Entpd5tm1Rre
(involves: 129S5/SvEvBrd * C57BL/6J)
abnormal Kupffer cell morphology J:163795
liver inflammation J:163795
\Entpd7tm1Ktak/\Entpd7tm1Ktak
(B6.Cg-Entpd7tm1Ktak)
abnormal CD4-positive, alpha-beta T cell number J:191188
decreased susceptibility to bacterial infection J:191188
increased susceptibility to experimental autoimmune encephalomyelitis J:191188
increased T-helper 17 cell number J:191188
\Entpd8tm1Ktak/\Entpd8tm1Ktak
(C.Cg-Entpd8tm1Ktak)
increased susceptibility to induced colitis J:311564
\Entpd8tm1Ktak/\Entpd8tm1Ktak
\P2rx4tm1Ando/\P2rx4tm1Ando

(involves: 129S4/SvJae * BALB/c * C57BL/6)
abnormal susceptibility to induced colitis J:311564
\Eomestm1.1Bflu/\Eomestm1.1Bflu
\Tbx21tm1Glm/\Tbx21tm1Glm
\Tg(Cd4-cre)1Cwi/0

(involves: 129S6/SvEvTac * C57BL/6 * DBA/2 * SJL)
abnormal leukocyte migration J:163822
decreased CD4-positive, alpha-beta T cell number J:163822
decreased CD8-positive, alpha-beta T cell number J:163822
decreased interferon-gamma secretion J:163822
decreased memory T cell number J:163822
increased interleukin-4 secretion J:163822
increased interleukin-17 secretion J:163822
\Eomestm1.1Bflu/\Eomestm1.1Bflu
\Tg(Cd4-cre)1Cwi/0

(involves: C57BL/6 * DBA/2 * SJL)
abnormal leukocyte migration J:163822
decreased memory T cell number J:163822
\Eomestm1.1Twa/?
\Il15tm1Imx/\Il15tm1Imx

(involves: C57BL/6 * C57BL/6N)
abnormal NK cell differentiation J:210160
\Eomestm1.1Twa/?
\Tbx21tm1Glm/\Tbx21tm1Glm

(involves: 129S6/SvEvTac * C57BL/6N)
abnormal NK cell differentiation J:210160
\Eomestm1.1Twa/?
\Tg(CD2-Tbx21)#Staka/?

(involves: C57BL/6N)
abnormal NK cell differentiation J:210160
\Eomestm1.1Twa/?
\Tg(Itgax-TGFBR2)1Flv/?

(involves: C3H * C57BL/6 * C57BL/6N)
abnormal NK cell differentiation J:210160
\Eomestm1Apr/\Eomes+
(involves: C57BL/6)
decreased memory T cell number J:112679
decreased NK cell number J:112679
\Eomestm1Apr/\Eomes+
\Tbx21tm1Srnr/\Tbx21tm1Srnr

(involves: C57BL/6)
decreased interferon-gamma secretion J:112679
decreased memory T cell number J:112679
decreased NK cell number J:112679
decreased NK T cell number J:112679
\Eomestm1Srnr/\Eomestm1Srnr
\Tbx21tm1Srnr/\Tbx21tm1Srnr
\Tg(Cd4-cre)1Cwi/0

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2)
abnormal CD8-positive, alpha-beta T cell differentiation J:137655
abnormal immune system physiology J:137655
abnormal interleukin level J:137655
abnormal leukocyte physiology J:137655
abnormal T cell morphology J:137655
decreased CD8-positive, alpha-beta T cell number J:137655
decreased memory T cell number J:137655
increased neutrophil cell number J:137655
increased susceptibility to Riboviria infection J:137655
\Eomestm1Srnr/\Eomestm1Srnr
\Tg(Cd4-cre)1Cwi/0

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2)
decreased memory T cell number J:137655
immune system phenotype J:137655
\Ep300Plt6/\Ep300+
\Mpltm1Wsa/\Mpltm1Wsa

(involves: 129S1/Sv * C57BL/6)
increased eosinophil cell number J:140200
\Ep300Plt6/\Ep300Plt6
(involves: 129S1/Sv * C57BL/6)
decreased B cell number J:140200
decreased eosinophil cell number J:140200
decreased leukocyte cell number J:140200
decreased lymphocyte cell number J:140200
\Ep300tm1Pkb/\Ep300+
\Mybtm1Ssp/\Myb+

(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6)
decreased thymocyte number J:98329
\Ep300tm1Pkb/\Ep300tm1Pkb
(involves: 129P2/OlaHsd * C57BL/6)
decreased thymocyte number J:98329
\Ep300tm2Pkb/\Ep300tm2Pkb
\Tg(Lck-cre)548Jxm/0

(involves: 129P2/OlaHsd * C57BL/6 * CBA)
decreased single-positive T cell number J:105505
decreased thymocyte number J:105505
increased double-positive T cell number J:105505
small thymus J:105505
\Epas1tm1.1Fsl/\Epas1+
(involves: C57BL/6 * C57BL/6NTac)
increased leukocyte cell number J:199595
increased lymphocyte cell number J:199595
increased monocyte cell number J:199595
\Epas1tm1.1Fsl/\Epas1tm1.1Fsl
(involves: C57BL/6 * C57BL/6NTac)
increased leukocyte cell number J:199595
increased monocyte cell number J:199595
increased spleen weight J:199595
\Epas1tm1Mcs/\Epas1tm1.1Mcs
\Ndor1Tg(UBC-cre/ERT2)1Ejb/0

(involves: 129X1/SvJ * FVB/N)
enlarged spleen J:119731
\Epb41tm1Cnby/\Epb41tm1Cnby
(involves: 129S/SvEv * 129S1/Sv * 129X1/SvJ)
decreased spleen iron level J:77852
enlarged spleen J:77852
increased spleen red pulp amount J:77852
\Epb42tm1Llp/\Epb42tm1Llp
(involves: 129P2/OlaHsd * C57BL/6J)
increased spleen iron level J:67412
increased spleen weight J:67412
\Epc1tm1a(EUCOMM)Wtsi/\Epc1+
(Not Specified)
decreased leukocyte cell number J:175295
\Epcamtm1.1Mcu/\Epcamtm1.1Mcu
\Tg(CD207-cre)1Dhka/0

(involves: 129 * C57BL/6 * C57BL/6J * SJL/J)
abnormal Langerhans cell morphology J:182665
abnormal Langerhans cell physiology J:182665
increased susceptibility to type IV hypersensitivity reaction J:182665
\Epcamtm1.2Msiv/\Epcamtm1.2Msiv
(involves: C57BL/6 * FVB/N * SJL)
small intestinal inflammation J:210901
\Epdr1tm1b(NCOM)Mfgc/\Epdr1tm1b(NCOM)Mfgc
(C57BL/6N-Epdr1tm1b(NCOM)Mfgc/Tcp)
decreased lymphocyte cell number J:211773
increased neutrophil cell number J:211773
\Epg5em1(IMPC)H/\Epg5em1(IMPC)H
(C57BL/6NTac-Epg5em1(IMPC)H/H)
decreased lymphocyte cell number J:211773
increased basophil cell number J:211773
increased large unstained cell number J:211773
increased leukocyte cell number J:211773
increased lymphocyte cell number J:211773
increased monocyte cell number J:211773
increased neutrophil cell number J:211773
increased spleen weight J:211773
\Epg5tm1Ygz/\Epg5tm1Ygz
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6N)
microgliosis J:196603
\Epgntm1.1Msdr/\Epgntm1.1Msdr
(involves: 129P2/OlaHsd * C57BL/6N)
increased spleen weight J:194427
\Epha1tm1Sld/\Epha1tm1Sld
(involves: 129 * C57BL/6J)
endometrium inflammation J:142722
vaginal inflammation J:142722
\Epha2em1(IMPC)Mbp/\Epha2em1(IMPC)Mbp
(C57BL/6N-Epha2em1(IMPC)Mbp/MbpMmucd)
abnormal lymph node morphology J:211773
enlarged lymph nodes J:211773
\Epha3em1(IMPC)Mbp/\Epha3em1(IMPC)Mbp
(C57BL/6N-Epha3em1(IMPC)Mbp/MbpMmucd)
abnormal spleen morphology J:211773
small spleen J:211773
\Epha6tm1b(KOMP)Wtsi/\Epha6tm1b(KOMP)Wtsi
(C57BL/6N-Epha6tm1b(KOMP)Wtsi/Tcp)
abnormal spleen morphology J:211773
\Ephb1em1(IMPC)Mbp/\Ephb1em1(IMPC)Mbp
(C57BL/6N-Ephb1em1(IMPC)Mbp/MbpMmucd)
abnormal spleen morphology J:211773
enlarged spleen J:211773
small spleen J:211773
\Ephb2em1(IMPC)Mbp/\Ephb2em1(IMPC)Mbp
(C57BL/6N-Ephb2em1(IMPC)Mbp/MbpMmucd)
enlarged spleen J:211773
small spleen J:211773
\Ephb4tm1.1Jwu/\Ephb4tm1.1Jwu
\Tg(KRT5-cre)1Tak/0

(involves: 129 * C3H * C57BL/6)
immune system phenotype J:206160
\Ephb6tm1Jwu/\Ephb6tm1Jwu
(involves: 129)
abnormal cytokine secretion J:94701
decreased susceptibility to experimental autoimmune encephalomyelitis J:94701
decreased susceptibility to type IV hypersensitivity reaction J:94701
decreased T cell proliferation J:94701
\Ephb6tm1Tom/\Ephb6tm1Tom
(involves: 129S4/SvJae * C57BL/6J)
immune system phenotype J:79747
\Ephb6tm2Tom/\Ephb6tm2Tom
(involves: 129S4/SvJae * C57BL/6J)
immune system phenotype J:79747
\epi/?
(involves: CBA/J)
decreased leukocyte cell number J:27487
decreased lymphocyte cell number J:27487
increased neutrophil cell number J:27487
\Epm2aTg(TcraK,TcrbK)TG-BFlv/\Epm2a+
(involves: C57BL/6J * CBA/J)
increased CD8-positive, alpha-beta T cell number J:107545
\Epm2aTg(TcraK,TcrbK)TG-BFlv/\Epm2a+
(involves: C57BL/6 * C57BL/10 * C57BR/cd * CBA/J)
increased T cell derived lymphoma incidence J:112696
\Epm2aTg(TcraK,TcrbK)TG-BFlv/\Epm2a+
\Tg(Ela1-TAg)18Bri/0

(involves: C57BL/6 * CBA/J * SJL)
pancreas inflammation J:107545
\EpoTg(TAg/Epo)134.3LCPjr/\EpoTg(TAg/Epo)134.3LCPjr
(involves: C57BL/6 * CBA)
increased spleen weight J:79374
\Eportm1.2(EPOR)Jtp/\Eportm1.2(EPOR)Jtp
(involves: 129P2/OlaHsd * C57BL/6)
decreased spleen weight J:67205
\Eppinem1(IMPC)Mbp/\Eppinem1(IMPC)Mbp
(C57BL/6N-Eppinem1(IMPC)Mbp/MbpMmucd)
abnormal lymph node morphology J:211773
abnormal spleen morphology J:211773
enlarged lymph nodes J:211773
enlarged spleen J:211773
\Eps8l2tm1b(EUCOMM)Wtsi/\Eps8l2tm1b(EUCOMM)Wtsi
(C57BL/6N-Eps8l2tm1b(EUCOMM)Wtsi/H)
increased basophil cell number J:211773
increased large unstained cell number J:211773
increased monocyte cell number J:211773
\Eps15tm1a(KOMP)Wtsi/\Eps15tm1a(KOMP)Wtsi
(B6JTyr;B6N-Eps15tm1a(KOMP)Wtsi/Wtsi)
decreased leukocyte cell number J:165965
\Eps15tm1a(KOMP)Wtsi/\Eps15tm1a(KOMP)Wtsi
(involves: C57BL/6 * C57BL/6N)
dermatitis J:213427
\Eps15tm1Noff/\Eps15tm1Noff
(B6.129-Eps15tm1Noff)
abnormal spleen B cell follicle morphology J:195689
abnormal spleen marginal zone morphology J:195689
abnormal spleen white pulp morphology J:195689
decreased B cell number J:195689
decreased leukocyte cell number J:195689
decreased lymphocyte cell number J:195689
immune system phenotype J:195689
increased marginal zone B cell number J:195689
\Eps15tm1Noff/\Eps15tm1Noff
(involves: 129 * C57BL/6)
abnormal marginal zone B cell morphology J:195689
increased marginal zone B cell number J:195689
increased transitional stage T1 B cell number J:195689
\Epsti1em1Mjnh/\Epsti1em1Mjnh
(Not Specified)
abnormal macrophage differentiation J:272013
decreased macrophage cell number J:272013
\Epxtm1.1(cre)Jlee/\Epx+
\Gt(ROSA)26Sortm1(DTA)Lky/\Gt(ROSA)26Sor+

(involves: 129P2/OlaHsd * C57BL/6)
decreased eosinophil cell number J:198489
\Epxtm1.1(cre)Jlee/\Epxtm1.1(cre)Jlee
(B6.Cg-Epxtm1.1(cre)Jlee/Jlee)
immune system phenotype J:198489
\Epxtm1b(EUCOMM)Wtsi/\Epxtm1b(EUCOMM)Wtsi
(C57BL/6N-Epxtm1b(EUCOMM)Wtsi/Orl)
increased monocyte cell number J:211773
\Epxtm1Nal/\Epxtm1Nal
(involves: 129P2/OlaHsd * 129X1/SvJ)
abnormal eosinophil morphology J:70567
immune system phenotype J:70567
\Epyctm1Mhok/\Epyctm1Mhok
(involves: 129S7/SvEvBrd * C57BL/6J)
osteoarthritis J:222369
\Erap1tm1.1Gnie/\Erap1tm1.1Gnie
(involves: 129S6/SvEvTac * C57BL/6)
abnormal antigen presentation J:143988
abnormal cytotoxic T cell physiology J:143988
abnormal response to infection J:143988
decreased interferon-gamma secretion J:143988
decreased level of surface class I molecules J:143988
decreased T cell proliferation J:143988
\Erap1tm1Dgen/\Erap1tm1Dgen
(involves: 129P2/OlaHsd * C57BL/6)
enlarged spleen J:101679
thymus hyperplasia J:101679
\Erap1tm1Iay/\Erap1tm1Iay
(involves: C57BL/6)
abnormal cytotoxic T cell physiology J:111047
decreased level of surface class I molecules J:111047
\Erap1tm1Luc/\Erap1+
(involves: 129S6/SvEvTac)
abnormal antigen presentation J:122479
decreased level of surface class I molecules J:122479
\Erap1tm1Luc/\Erap1tm1Luc
(involves: 129S6/SvEvTac)
abnormal antigen presentation J:122479
abnormal CD8-positive, alpha-beta T cell physiology J:122479
abnormal lymphocyte physiology J:122479
decreased level of surface class I molecules J:122479
immune system phenotype J:122479
increased level of surface class I molecules J:122479
\Erap1tm1Luc/\Erap1tm1Luc
\Rag2tm1Fwa/\Rag2tm1Fwa
\Tg(TcrLCMV)327Sdz/\Tg(TcrLCMV)327Sdz

(involves: 129S/SvEv * 129S6/SvEvTac * C57BL/6 * C57BL/10SgSnAi * DBA/2)
immune system phenotype J:122479
\Erap1tm1Nsha/\Erap1tm1Nsha
(B6.129S6-Erap1tm1Nsha)
abnormal antigen presentation via MHC class I J:112389, J:116606
abnormal CD8-positive, alpha-beta T cell physiology J:112389, J:116606
abnormal cytokine secretion J:116606
decreased level of surface class I molecules J:112389
\Erap1tm1Nsha/\Erap1tm1Nsha
\Tap1tm1Arp/\Tap1tm1Arp

(B6.129-Erap1tm1Nsha Tap1tm1Arp)
abnormal antigen presentation via MHC class I J:112389
\Erap1tm1Nsha/\Erap1tm1Nsha
\Tap1tm1Arp/\Tap1tm1Arp

(involves: 129S2/SvPas * 129S6/SvEvTac * C57BL/10 * DBA/2)
abnormal antigen presentation via MHC class I J:116606
\Erars1DBA/2J/?
(involves: BXD2/TyJ * C57BL/6J * DBA/2J)
increased anti-nuclear antigen antibody level J:96064
increased immunoglobulin level J:96064
\Erars2C57BL/6J/?
(involves: BXD2/TyJ * C57BL/6J * DBA/2J)
abnormal humoral immune response J:96064
increased immunoglobulin level J:96064
\Erbb3tm1.1Dwt/\Erbb3tm2.1Dwt
\Tg(Vil1-cre)997Gum/0

(involves: 129S6/SvEvTac * C57BL/6 * SJL)
increased susceptibility to induced colitis J:152703
\Erbb4tm1Grl/\Erbb4tm1Grl
\Tg(Myh6-ERBB4)HT2Gass/0

(involves: 129S1/Sv * 129X1/SvJ)
increased granulocyte number J:132190
lung inflammation J:132190
\Ercc1tm1Jhjh/\Ercc1tm1Jhjh
(involves: C57BL/6 * FVB/N)
abnormal class switch recombination J:92471
decreased B cell proliferation J:92471
spleen hypoplasia J:92471
\Ercc1tm2Jhjh/\Ercc1tm2Jhjh
(involves: 129P2/OlaHsd * C57BL/6)
abnormal spleen morphology J:41161
\Ercc2tm2(ERCC2)Jhjh/\Ercc2tm2(ERCC2)Jhjh
(involves: 129P2/OlaHsd * C57BL/6)
enlarged spleen J:76608
\Ercc2tm2(ERCC2)Jhjh/\Ercc2tm2(ERCC2)Jhjh
(involves: 129P2/OlaHsd)
immune system phenotype J:47993
\Ercc2tm3Jhjh/\Ercc2tm3Jhjh
(involves: 129 * C57BL/6J)
microgliosis J:179808
\Ercc5tm1Shm/\Ercc5tm1Shm
(involves: 129S2/SvPas * C57BL/6J)
decreased spleen weight J:53756
\Ercc6tm1Gvh/\Ercc6tm1Gvh
(involves: 129P2/OlaHsd * C57BL/6J)
microgliosis J:179808
\Ercc6tm1Gvh/\Ercc6tm1Gvh
\Xpatm1Gvh/\Xpatm1Hvs
\Tg(Camk2a-cre)1Szi/0

(involves: 129P2/OlaHsd * C57BL/6J * CBA)
microgliosis J:179808
\Ercc6tm1Gvh/\Ercc6tm1Gvh
\Xpatm1Gvh/\Xpatm1Hvs
\Tg(Pcp2-cre)2Mpin/0

(involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6J)
microgliosis J:179808
\Ercc6l2em1Mengf/\Ercc6l2em1Mengf
(Not Specified)
abnormal class switch recombination J:311900
decreased IgA level J:311900
decreased IgG1 level J:311900
decreased IgG2b level J:311900
decreased IgG3 level J:311900
decreased IgG level J:311900
decreased T cell number J:311900
immune system phenotype J:311900
\Ercc6l2em1Mengf/\Ercc6l2em1Mengf
\Nhej1em1Mengf/\Nhej1em1Mengf

(Not Specified)
abnormal T cell receptor V(D)J recombination J:311900
\Ercc6l2em2Mengf/\Ercc6l2em2Mengf
(Not Specified)
abnormal class switch recombination J:311900
immune system phenotype J:311900
\Ercc8tm1Jhjh/\Ercc8tm1Jhjh
(involves: 129P2/OlaHsd * C57BL/6J)
microgliosis J:179808
\Eregtm1Dwt/\Eregtm1Dwt
(129S6/SvEvTac-Eregtm1Dwt)
increased susceptibility to induced colitis J:93327
\Eregtm1Sawa/\Eregtm1Sawa
(involves: 129X1/SvJ * C57BL/6J)
dermatitis J:92618
\Ergem1(IMPC)Bay/\Erg+
(C57BL/6N-Ergem1(IMPC)Bay/Bay)
abnormal spleen morphology J:211773
decreased leukocyte cell number J:211773
\Ergmld2/\Erg+
(involves: 129S1/Sv * C57BL/6)
decreased transitional stage B cell number J:137835
\Ergmld2/\Erg+
\Mpltm1Wsa/\Mpltm1Wsa

(B6.Cg-Mpltm1Wsa Ergmld2)
decreased leukocyte cell number J:137835
\Ergtm1.1Iwamo/\Ergtm1.1Iwamo
\Tg(Gdf5-cre,-ALPP)1Kng/?

(involves: 129S4/SvJaeSor * C57BL/6 * FVB/N)
increased susceptibility to induced arthritis J:243715
osteoarthritis J:243715
\Erlec1em1(IMPC)Mbp/\Erlec1em1(IMPC)Mbp
(C57BL/6N-Erlec1em1(IMPC)Mbp/Ucd)
abnormal lymph node morphology J:211773
enlarged lymph nodes J:211773
\Erlin1em1(IMPC)Tcp/\Erlin1em1(IMPC)Tcp
(C57BL/6N-Erlin1em1(IMPC)Tcp/Tcp)
abnormal spleen morphology J:211773
enlarged lymph nodes J:211773
\Ermp1em1Gjom/\Ermp1+
(Not Specified)
kidney inflammation J:361886
\Ern1tm1Rjk/\Ern1tm1Rjk
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)
abnormal pro-B cell morphology J:106975
\Ern1tm2.1Tiw/\Ern1tm2.1Tiw
\Xbp1tm2Glm/\Xbp1tm2Glm
\Tg(Vil1-cre)997Gum/0

(involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6 * SJL)
small intestinal inflammation J:206084
\Ern2m1Btlr/\Ern2m1Btlr
(C57BL/6J-Ern2m1Btlr)
increased susceptibility to induced colitis J:216045
\Ern2M2Btlr/\Ern2M2Btlr
(C57BL/6J-Ern2M2Btlr)
increased susceptibility to induced colitis J:234237
\Ern2m3Btlr/\Ern2m3Btlr
(C57BL/6J-Ern2m3Btlr)
increased susceptibility to induced colitis J:236686
\Ern2tm1Dron/\Ern2tm1Dron
(either: 129S6/SvEvTac-Ern2tm1Dron or B6.129S6-Ern2tm1Dron)
increased susceptibility to induced colitis J:67934
\Ero1aGt(XST171)Byg/\Ero1aGt(XST171)Byg
(involves: 129P2/OlaHsd * C57BL/6J)
abnormal macrophage physiology J:153833
decreased macrophage apoptosis J:153833
\Errfi1tm1Gvw/\Errfi1tm1Gvw
(Not Specified)
accelerated temporomandibular joint osteoarthritis J:100927
enlarged thymus J:100927
osteoarthritis J:100927
\Errfi1tm1Gvw/\Errfi1tm1Gvw
\Rag2tm1Fwa/\Rag2tm1Fwa

(involves: 129S/SvEv)
osteoarthritis J:100927
\Errfi1tm3.1Gvw/\Errfi1tm3.1Gvw
\Tg(CMV-cre)1Cgn/0

(involves: 129 * 129S4/SvJaeSor * BALB/cJ)
osteoarthritis J:206807
\Errfi1tm3.1Gvw/\Errfi1tm3.1Gvw
\Tg(Col2a1-cre)1Asz/0

(involves: 129S1/Sv * 129S4/SvJaeSor * C57BL/6 * CBA)
osteoarthritis J:206807
\Esamtm1Dvst/\Esamtm1Dvst
(B6.129-Esam1tm1Dvst)
abnormal cellular extravasation J:124397
abnormal leukocyte migration J:124397
\Esm1tm1.1Rha/\Esm1tm1.1Rha
(involves: 129S6/SvEvTac * BALB/c * C57BL/6 * C57BL/6NTac)
abnormal cellular extravasation J:246778
\EsmrDBA/2NCrj/\EsmrDBA/2NCrj
(involves: C57BL/6NCrj * DBA/2NCrj)
decreased susceptibility to parasitic infection J:74563
\Espl1Gt(XL058)Byg/\Espl1+
\Trp53tm1Tyj/\Trp53tm1Tyj

(B6.129-Trp53tm1Tyj Espl1Gt(XL058)Byg)
abnormal splenocyte morphology J:174926
increased splenocyte proliferation J:174926
\Espnje/?
\f/\f
\Hps6ru/\Hps6ru

(JE/LeJ)
abnormal mast cell degranulation J:37255
\Esr1tm1.1Lja/\Esr1tm1.1Mma
(involves: 129P2/OlaHsd * 129S2/SvPas * 129X1/SvJ * C57BL/6)
abnormal osteoclast physiology J:128135
\Esr1tm1.1Mma/\Esr1tm1.1Mma
(involves: 129S2/SvPas * C57BL/6)
abnormal immunoglobulin level J:171276
abnormal thymus physiology J:171276
\Esr1tm1.1Ohl/\Esr1tm1.1Ohl
(involves: 129S2/SvPas * C57BL/6)
abnormal immunoglobulin level J:171276
abnormal thymus physiology J:171276
\Esr1tm1.1Scma/\Esr1tm1.1Scma
\Lyz2tm1(cre)Ifo/\Lyz2+

(involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6)
abnormal osteoclast physiology J:156947
increased osteoclast cell number J:156947
\Esr1tm1Arnal/\Esr1tm1Arnal
(involves: C57BL/6)
abnormal immunoglobulin level J:171276
increased osteoclast cell number J:171276
\Esr1tm1Ksk/\Esr1tm1Ksk
(involves: 129P2/OlaHsd * C57BL/6J)
abnormal B cell number J:82423
abnormal class switch recombination J:82423
abnormal immunoglobulin level J:82423
abnormal lymph node cell ratio J:88156
abnormal spleen physiology J:88156
decreased CD4-positive, alpha-beta T cell number J:110416
decreased CD8-positive, alpha-beta T cell number J:110416
glomerulonephritis J:88156
increased anti-double stranded DNA antibody level J:88156
increased double-positive T cell number J:110416
increased IgG3 level J:88156
increased plasma cell number J:88156
increased spleen germinal center number J:88156
thymus hypoplasia J:110416
\Esr1tm1Ksk/\Esr1tm1Ksk
(involves: 129P2/OlaHsd)
decreased immature B cell number J:110923
decreased mature B cell number J:110923
spermatic granuloma J:60490
\Esr1tm1Ksk/\Esr1tm1Ksk
(involves: 129P2/OlaHsd * C57BL/6N)
abnormal B cell differentiation J:63462
abnormal thymus physiology J:111590
decreased B cell number J:63462
decreased immature B cell number J:63462
decreased mature B cell number J:63462
decreased thymocyte number J:111590
decreased thymus weight J:111590
\Esr1tm1Ksk/\Esr1tm1Ksk
\Esr2tm1Unc/\Esr2tm1Unc

(involves: 129P2/OlaHsd * C57BL/6J)
abnormal B cell number J:82423
abnormal class switch recombination J:82423
abnormal immunoglobulin level J:82423
decreased CD4-positive, alpha-beta T cell number J:110416
decreased CD8-positive, alpha-beta T cell number J:110416
decreased spleen weight J:110416
increased double-positive T cell number J:110416
thymus hypoplasia J:110416
\Esr1tm1Ksk/\Esr1tm1Ksk
\Inhatm1Bay/\Inhatm1Bay

(involves: 129P2/OlaHsd * 129S6/SvEvTac * 129S7/SvEvBrd)
liver inflammation J:84989
\Esr2tm1.2Pcn/\Esr2tm1.2Pcn
(involves: 129S2/SvPas * C57BL/6 * SJL)
immune system phenotype J:132171
\Esr2tm1Mma/\Esr2tm1Mma
(involves: 129S2/SvPas)
increased neutrophil cell number J:165719
\Esr2tm1Unc/\Esr2tm1Unc
(involves: 129P2/OlaHsd * C57BL/6J)
abnormal B cell number J:82423
abnormal leukopoiesis J:83617
abnormal lymphopoiesis J:83617
enlarged lymph nodes J:83617
enlarged spleen J:83617
increased granulocyte number J:83617
increased leukocyte cell number J:83617
increased monocyte cell number J:83617
increased neutrophil cell number J:83617
increased pre-B cell number J:83617
increased pro-B cell number J:83617
spleen hyperplasia J:83617
spleen hypoplasia J:110416
\Esr2tm1Unc/\Esr2tm1Unc
(involves: 129P2/OlaHsd)
colitis J:107308
urinary bladder inflammation J:122274
\Esrp2em1(IMPC)Tcp/\Esrp2em1(IMPC)Tcp
(C57BL/6NCrl-Esrp2em1(IMPC)Tcp/Tcp)
enlarged lymph nodes J:211773
\Esrratm1Vgi/\Esrratm1Vgi
(involves: 129S1/Sv * 129X1/SvJ)
abnormal osteoclast differentiation J:160910
decreased osteoclast cell number J:160910
increased splenocyte number J:160910
\Ess2tm1.1Nbioc/\Ess2tm1.1Nbioc
\Tg(Cd4-cre)1Cwi/0

(involves: C57BL/6N * DBA/2)
abnormal CD4-positive, alpha-beta T cell physiology J:339504
decreased CD4-positive, alpha-beta T cell number J:339504
decreased CD8-positive, alpha-beta T cell number J:339504
decreased CD8-positive, naive alpha-beta T cell number J:339504
decreased memory T cell number J:339504
immune system phenotype J:339504
increased gamma-delta T cell number J:339504
increased NK T cell number J:339504
\Esyt2tm2b(KOMP)Wtsi/\Esyt2+
(C57BL/6N-Esyt2tm2b(KOMP)Wtsi/Bay)
enlarged spleen J:211773
\Etfbem1(IMPC)Hmgu/\Etfb+
(C57BL/6NCrl-Etfbem1(IMPC)Hmgu/Ieg)
increased spleen weight J:211773
\Etnk1tm1b(EUCOMM)Wtsi/\Etnk1tm1b(EUCOMM)Wtsi
(C57BL/6N-Etnk1tm1b(EUCOMM)Wtsi/Bay)
abnormal spleen morphology J:211773
\Ets1m1Anu/\Ets1m1Anu
(C57BL/6NCrlAnu-Ets1m1Anu)
immune system phenotype J:104190
\Ets1tm1.1Dds/\Ets1+
(129S6/SvEvTac-Ets1tm1.1Dds)
abnormal thymus morphology J:121460
decreased memory T cell number J:121460
decreased thymocyte apoptosis J:121460
enlarged thymus J:121460
increased splenocyte apoptosis J:121460
increased thymus weight J:121460
\Ets1tm1.1Dds/\Ets1tm1.1Dds
(129S6/SvEvTac-Ets1tm1.1Dds)
abnormal CD8-positive, alpha beta T cell morphology J:121460
abnormal lymphopoiesis J:121460
abnormal spleen morphology J:121460
abnormal spleen red pulp morphology J:121460
abnormal thymus cortex morphology J:121460
abnormal thymus morphology J:121460
abnormal thymus subcapsular epithelium morphology J:121460
decreased B cell number J:121460
decreased CD4-positive, alpha-beta T cell number J:121460
decreased leukocyte cell number J:121460
decreased memory T cell number J:121460
decreased spleen weight J:121460
decreased thymocyte apoptosis J:121460
enlarged thymus J:121460
increased double-positive T cell number J:121460
increased splenocyte apoptosis J:121460
increased thymus weight J:121460
small spleen J:121460
\Ets1tm1Fwa/\Ets1tm1Fwa
(B6.129S4-Ets1tm1Fwa)
abnormal B cell differentiation J:93845
absent B-1a cells J:93845
decreased B cell number J:93845
decreased B cell proliferation J:93845
decreased mature B cell number J:93845
decreased pro-B cell number J:93845
immune system phenotype J:93845
increased B cell apoptosis J:93845
increased pro-B cell number J:93845
\Ets1tm1Jml/\Ets1tm1Jml
(involves: 129S/SvEv * C57BL/6)
abnormal CD8-positive, alpha-beta T cell differentiation J:125056
decreased CD4-positive, alpha-beta T cell number J:125056
decreased CD8-positive, alpha-beta T cell number J:125056
increased double-negative T cell number J:125056
thymus hypoplasia J:125056
\Ets1tm1Jml/\Ets1tm1Jml
\Tg(TcraH-Y,TcrbH-Y)71Vbo/0

(involves: 129S/SvEv * C57BL/6 * C57BL/6J * DBA/2J)
decreased CD8-positive, alpha-beta T cell number J:125056
immune system phenotype J:125056
increased double-negative T cell number J:125056
\Ets1tm2Jml/\Ets1tm2Jml
(involves: 129X1/SvJ * C57BL/6)
abnormal CD8-positive, alpha beta T cell morphology J:50627
abnormal leukocyte physiology J:50627
abnormal NK cell physiology J:50627
abnormal T cell activation J:50627
decreased NK cell number J:50627
decreased T cell number J:50627
decreased T cell proliferation J:50627
decreased thymocyte number J:50627
impaired natural killer cell mediated cytotoxicity J:50627
increased plasma cell number J:50627
\Etv2tm1Dlim/\Etv2tm2.1Dlim
\Tg(Mx1-cre)1Cgn/0

(involves: 129S4/SvJaeSor * C57BL/6 * CBA)
decreased leukocyte cell number J:172687
impaired myelopoiesis J:172687
spleen hypoplasia J:172687
\Etv6em1(IMPC)Rbrc/\Etv6+
(C57BL/6NJcl-Etv6em1(IMPC)Rbrc/Rbrc)
increased large unstained cell number J:211773
increased spleen weight J:211773
\Etv6em3Knic/\Etv6+
(involves: C57BL/6J)
abnormal B cell number J:342774
\Etv6tm1(RUNX1)Haho/\Etv6+
\Tg(CD2-icre)4Kio/0

(involves: 129S1/Sv * C57BL/6 * C57BL/10 * CBA/Ca)
immune system phenotype J:151639
\Etv6tm1(RUNX1)Haho/\Etv6+
\Tg(Gata1-cre)1Sho/0

(involves: 129S1/Sv * C57BL/6 * CD-1 * Swiss Webster)
abnormal B cell differentiation J:151639
immune system phenotype J:151639
\Etv6tm1(RUNX1)Haho/\Etv6+
\Tg(Mx1-cre)1Cgn/0

(involves: 129S1/Sv * C57BL/6 * CBA)
abnormal lymphopoiesis J:151639
decreased B cell number J:151639
decreased lymphocyte cell number J:151639
decreased neutrophil cell number J:151639
immune system phenotype J:151639
myeloid hyperplasia J:151639
\Etv6tm1(RUNX1)Haho/\Etv6+
\Tg(VAV1-cre)1Graf/0

(involves: 129S1/Sv * C57BL/6)
arrested B cell differentiation J:151639
decreased B cell number J:151639
decreased pre-B cell number J:151639
decreased pro-B cell number J:151639
\Etv6tm2Sho/\Etv6tm2Sho
\Tg(Mx1-cre)1Cgn/?

(involves: 129S1/Sv * C57BL/6 * CBA)
decreased neutrophil cell number J:93052
\Evc2em1(IMPC)Mbp/\Evc2em1(IMPC)Mbp
(C57BL/6N-Evc2em1(IMPC)Mbp/MbpMmucd)
abnormal spleen morphology J:211773
small spleen J:211773
\Evltm1Lfr/\Evltm1Lfr
(involves: 129X1/SvJ * C57BL/6)
abnormal leukocyte migration J:94077
\Ewsr1tm1(ERG)Thr/\Ewsr1+
\Rag1tm1(cre)Thr/\Rag1+

(involves: 129S/SvEv)
increased lymphocyte cell number J:98679
increased T cell derived lymphoma incidence J:98679
\Ewsr1tm1b(EUCOMM)Wtsi/\Ewsr1+
(C57BL/6N-Ewsr1tm1b(EUCOMM)Wtsi/Tcp)
increased leukocyte cell number J:211773
increased lymphocyte cell number J:211773
\Ewsr1tm1Sblee/\Ewsr1tm1Sblee
(involves: 129S6/SvEvTac * Black Swiss)
decreased double-positive T cell number J:122058
decreased immature B cell number J:122058
decreased leukocyte cell number J:122058
decreased mature B cell number J:122058
decreased pre-B cell number J:122058
spleen hypoplasia J:122058
thymus hypoplasia J:122058
\exf/\exf
(involves: C3H/HeN(MTV-))
conjunctivitis J:5649
increased susceptibility to bacterial infection J:5649
\Exo1tm2Wed/\Exo1tm2Wed
(involves: 129 * C57BL/6)
abnormal class switch recombination J:198719
abnormal somatic hypermutation frequency J:198719
\Exo1tm3.1Wed/\Exo1tm3.1Wed
(involves: 129 * C57BL/6)
immune system phenotype J:198719
\Exoc6hbd/\Exoc6hbd
(AB.Cg-Exoc6hbd)
decreased spleen iron level J:8251
enlarged spleen J:8251
\Exph5tm1Tiz/\Exph5tm1Tiz
(B6NJcl.Cg-Exph5tm1Tiz/Tiz)
abnormal interleukin secretion J:313415
abnormal T-helper 2 physiology J:313415
increased interleukin-5 secretion J:313415
increased interleukin-13 secretion J:313415
increased susceptibility to type I hypersensitivity reaction J:313415
\Extl1em1Caox/\Extl1em1Caox
\Tg(Itgax-cre)1-1Reiz/0

(involves: C57BL/6 * CBA)
abnormal dendritic cell chemotaxis J:333437
abnormal dendritic cell migration J:333437
abnormal dendritic cell physiology J:333437
abnormal regulatory T cell morphology J:333437
chronic inflammation J:333437
decreased acute inflammation J:333437
decreased dendritic cell number J:333437
decreased T helper 1 cell number J:333437
enlarged lymph nodes J:333437
enlarged spleen J:333437
immune system phenotype J:333437
increased B cell number J:333437
increased circulating interleukin-6 level J:333437
increased circulating interleukin-17 level J:333437
increased circulating tumor necrosis factor level J:333437
increased IgG level J:333437
increased immunoglobulin level J:333437
increased interleukin-6 secretion J:333437
increased Ly6C high monocyte number J:333437
increased susceptibility to autoimmune disorder J:333437
increased susceptibility to bacterial infection induced morbidity/mortality J:333437
increased T cell number J:333437
increased T-helper 17 cell number J:333437
\Extl3em1(IMPC)Mbp/\Extl3+
(C57BL/6N-Extl3em1(IMPC)Mbp/MbpMmucd)
abnormal spleen morphology J:211773
enlarged spleen J:211773
\Eya1tm1Rilm/\Eya1tm1Rilm
(either: (involves: 129S1/Sv * 129X1/SvJ) or (involves: 129S1/Sv * 129X1/SvJ * BALB/c) or (involves: 129S1/Sv * 129X1/SvJ * C57BL/6))
athymia J:79848, J:57313
\Eya2em1(IMPC)Mbp/\Eya2em1(IMPC)Mbp
(C57BL/6N-Eya2em1(IMPC)Mbp/MbpMmucd)
abnormal lymph node morphology J:211773
abnormal spleen morphology J:211773
enlarged lymph nodes J:211773
enlarged spleen J:211773
small spleen J:211773
\Eya2tm2Px/\Eya2tm2Px
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)
small thymus J:311538
\Eya4tm1Jse/\Eya4tm1Jse
(involves: 129S6/SvEvTac * CBA/J)
increased susceptibility to otitis media J:131873
\Ezh1tm1Sgon/\Ezh1tm1Sgon
\Tg(VAV1-cre)1Graf/0

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
abnormal myeloid leukocyte morphology J:193722
absent spleen germinal center J:193722
decreased B cell number J:193722
decreased immature B cell number J:193722
decreased pro-B cell number J:193722
decreased spleen red pulp amount J:193722
decreased spleen white pulp amount J:193722
lymphoid hypoplasia J:193722
small spleen J:193722
\Ezh2em1Jbn/\Ezh2+
(C57BL/6J-Ezh2em1Jbn)
increased spleen weight J:267184
\Ezh2tm1.1Nesh/\Ezh2+
\Cd19tm1(cre)Cgn/\Cd19+

(involves: 129 * 129P2/OlaHsd * C57BL/6)
abnormal spleen morphology J:239472
abnormal spleen white pulp morphology J:239472
enlarged lymph nodes J:239472
enlarged spleen J:239472
\Ezh2tm1.1Nesh/\Ezh2tm1.1Nesh
\Cd19tm1(cre)Cgn/\Cd19+

(involves: 129 * 129P2/OlaHsd * C57BL/6)
enlarged lymph nodes J:239472
enlarged spleen J:239472
\Ezh2tm1Tara/\Ezh2tm1Tara
\Cd19tm1(cre)Cgn/?

(involves: 129P2/OlaHsd)
immune system phenotype J:83216
\Ezh2tm1Tara/\Ezh2tm1Tara
\Ightm2Cgn/?
\Tg(Mx1-cre)1Cgn/0

(involves: 129P2/OlaHsd * C57BL/6 * CBA)
immune system phenotype J:83216
\Ezh2tm1Tara/\Ezh2tm1Tara
\Ighg1tm1(cre)Cgn/\Ighg1+

(involves: 129P2/OlaHsd)
decreased B cell proliferation J:199122
decreased germinal center B cell number J:199122
decreased IgG1 level J:199122
decreased IgG2b level J:199122
decreased IgG3 level J:199122
decreased spleen germinal center number J:199122
decreased spleen germinal center size J:199122
immune system phenotype J:199122
\Ezh2tm1Tara/\Ezh2tm1Tara
\Tg(Mx1-cre)1Cgn/0

(involves: 129P2/OlaHsd * C57BL/6 * CBA)
abnormal B cell differentiation J:83216
abnormal immunoglobulin V(D)J recombination J:83216
abnormal pro-B cell morphology J:83216
decreased immature B cell number J:83216
decreased pre-B cell number J:83216
\Ezh2tm2Sho/\Ezh2tm2.1Sho
\Tg(Mx1-cre)1Cgn/0

(involves: 129S1/Sv * C57BL/6 * CBA)
decreased double-positive T cell number J:182211
decreased thymocyte number J:182211
enlarged lymph nodes J:182211
enlarged spleen J:182211
increased double-negative T cell number J:182211
\Ezh2tm2Sho/\Ezh2tm2Sho
\Pgrtm2(cre)Lyd/\Pgr+

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
decreased uterine NK cell number J:290765
\Ezh2tm2Sho/\Ezh2tm2Sho
\Tg(Mx1-cre)1Cgn/0

(involves: 129S1/Sv * C57BL/6 * CBA)
decreased double-positive T cell number J:182211
decreased thymocyte number J:182211
enlarged lymph nodes J:182211
enlarged spleen J:182211
increased double-negative T cell number J:182211
\Ezrtm2Aim/\Ezrtm2Aim
\Tg(Cd4-cre)1Cwi/0

(involves: 129S4/SvJae * C57BL/6 * DBA/2)
decreased interleukin-2 secretion J:143487
\F2tm1Jld/\F2tm1Jld
\Tg(Mx1-cre)1Cgn/0

(B6.Cg-F2tm1Jld Tg(Mx1-cre)1Cgn)
increased susceptibility to bacterial infection J:144572
\F2tm2Jld/\F2+
(B6.129P2-F2tm2Jld)
decreased susceptibility to endotoxin shock J:174629
\F2tm2Jld/\F2+
(involves: 129P2/OlaHsd * C57BL/6 * DBA/2J)
decreased susceptibility to induced arthritis J:174629
\F2rtm1Ajc/\F2rtm1Ajc
(involves: 129S4/SvJae * C57BL/6)
immune system phenotype J:132733
\F2rtm1Ajc/\F2rtm1Ajc
\F2rl1tm1Cgh/\F2rl1tm1Cgh

(involves: 129S4/SvJae * C57BL/6)
increased susceptibility to endotoxin shock J:132733
\F2rtm1Pago/\F2rtm1Pago
(involves: 129P2/OlaHsd * C57BL/6)
decreased inflammatory response J:124648
decreased susceptibility to induced colitis J:94420
\F2rtm1Pago/\F2rtm1Pago
(B6.129P2-F2rtm1Pago)
immune system phenotype J:88245
\F2rtm1Pago/\F2rtm1Pago
(involves: 129P2/OlaHsd)
abnormal cytokine level J:133917
abnormal lymph node morphology J:133917
decreased susceptibility to endotoxin shock J:133917
enlarged mesenteric lymph nodes J:133917
\F2rl1tm1Bpd/\F2rl1tm1Bpd
(involves: 129P2/OlaHsd * C57BL/6)
decreased inflammatory response J:124648
increased inflammatory response J:96196
increased susceptibility to induced pancreatitis J:96196
\F2rl1tm1Bpd/\F2rl1tm1Bpd
(B6.129P2-F2rl1tm1Bpd)
decreased susceptibility to endotoxin shock J:88245
immune system phenotype J:88245
\F2rl1tm1Cgh/\F2rl1tm1Cgh
(involves: 129S4/SvJae * C57BL/6)
glomerulonephritis J:124303
immune system phenotype J:132733
impaired leukocyte tethering or rolling J:76626
\F2rl1tm1Cgh/\F2rl1tm1Cgh
(B6.129S4-F2rl1tm1Cgh)
decreased dendritic cell number J:113591
\F2rl1tm1Jkaw/\F2rl1tm1Jkaw
(involves: 129P2/OlaHsd * C57BL/6)
decreased susceptibility to type IV hypersensitivity reaction J:106127
\F2rl1tm1Mslb/\F2rl1tm1Mslb
(involves: 129X1/SvJ * C57BL/6)
decreased IgE level J:79757
decreased inflammatory response J:79757
\F2rl1tm1Wrf/\F2rl1tm1Wrf
(involves: 129P2/OlaHsd * C57BL/6)
decreased susceptibility to induced arthritis J:81119
\F2rl1tm1Wrf/\F2rl1tm1Wrf
(involves: 129P2/OlaHsd)
decreased circulating interleukin-18 level J:102762
liver inflammation J:102762
\F2rl3tm1Cgh/\F2rl3tm1Cgh
(involves: 129S4/SvJae * C57BL/6)
immune system phenotype J:132733
\F3tm1.1Dwr/\F3tm1.1Dwr
(involves: 129S1/Sv * 129X1/SvJ * MF1 * Swiss)
abnormal cellular extravasation J:91165
abnormal leukocyte adhesion J:91165
decreased B cell number J:91165
decreased circulating interleukin-1 beta level J:91165
decreased circulating interleukin-6 level J:91165
decreased circulating tumor necrosis factor level J:91165
decreased leukocyte cell number J:91165
decreased neutrophil cell number J:91165
decreased susceptibility to endotoxin shock J:91165
impaired leukocyte tethering or rolling J:91165
\F3tm1Dco/\F3tm1Dco
\Tg(F3)1Nmk/0

(B6.Cg-F3tm1Dco Tg(F3)1Nmk)
abnormal interleukin level J:88245
decreased susceptibility to endotoxin shock J:88245
\F3tm1Gjb/\F3+
(involves: 129X1/SvJ * C57BL/6)
abnormal chemokine secretion J:128891
abnormal macrophage physiology J:128891
decreased interleukin-6 secretion J:128891
immune system phenotype J:128891
\F8tm1.1Len/Y
(B6.Cg-F8tm1.1Len)
abnormal immune tolerance J:266699
\F8tm1Kaz/Y
(involves: 129S4/SvJae * C57BL/6)
abnormal immune tolerance J:266699, J:178969
\F8tm1Kaz/Y
\Tg(Alb-F8*R593C)T4Mcal/0

(involves: 129S4/SvJae * C57BL/6 * FVB/N)
immune system phenotype J:178969
\F9tm1Dws/Y
(involves: 129P2/OlaHsd * C57BL/6)
enlarged spleen J:44497
\F11tm1Gjb/\F11tm1Gjb
\Proctm1Fjc/\Proctm1Fjc

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
abnormal lymph circulation J:67398
abnormal lymph node cortex morphology J:67398
abnormal lymph node morphology J:67398
abnormal neutrophil morphology J:67398
decreased leukocyte cell number J:67398
decreased neutrophil cell number J:67398
enlarged lymph nodes J:67398
lung inflammation J:67398
lymph node hemorrhage J:67398
\F11rtm1.1Dej/\F11rtm1.1Dej
(Not Specified)
abnormal dendritic cell physiology J:92592
increased susceptibility to type IV hypersensitivity reaction J:92592
\F11rtm1Dej/\F11rtm1.1Dej
\Tg(Tek-cre)1Ywa/0

(Not Specified)
immune system phenotype J:92592
\Fa2hem1(IMPC)Mbp/\Fa2hem1(IMPC)Mbp
(C57BL/6NCrl-Fa2hem1(IMPC)Mbp/MbpMmucd)
abnormal spleen morphology J:211773
enlarged spleen J:211773
\Fabp1tm1b(EUCOMM)Hmgu/\Fabp1tm1b(EUCOMM)Hmgu
(C57BL/6N-Fabp1tm1b(EUCOMM)Hmgu/Cnrm)
decreased large unstained cell number J:211773
decreased leukocyte cell number J:211773
decreased lymphocyte cell number J:211773
decreased monocyte cell number J:211773
\Fabp2em1(IMPC)Hmgu/\Fabp2em1(IMPC)Hmgu
(C57BL/6N-Fabp2em1(IMPC)Hmgu/Ieg)
enlarged lymph nodes J:211773
\Fabp5tm1Kdo/\Fabp5tm1Kdo
(involves: C57BL/6)
immune system phenotype J:75715
\Faddtm1Mpa/\Faddtm1Mpa
\Ikbkgtm1.1Mpa/\Ikbkgtm1.1Mpa
\Tg(Alb1-cre)7Gsc/0

(involves: C57BL/6 * FVB/N)
liver inflammation J:118336
\Faddtm1Mpa/\Faddtm1Mpa
\Mlkltm1.1Wsa/\Mlkltm1.1Wsa
\Otulintm1c(EUCOMM)Hmgu/\Otulintm1c(EUCOMM)Hmgu
\Tg(KRT14-cre)1Cgn/0

(involves: C57BL/6 * C57BL/6N * DBA/2)
immune system phenotype J:312394
\Faddtm1Mpa/\Faddtm1Mpa
\Mogtm1(cre)Gkl/\Mog+

(involves: C57BL/6 * SJL)
decreased susceptibility to experimental autoimmune encephalomyelitis J:167475
immune system phenotype J:167475
\Faddtm1Mpa/\Faddtm1Mpa
\Myd88tm1Aki/\Myd88tm1Aki
\Tg(Vil1-cre)997Gum/0

(B6.Cg-Faddtm1Mpa Myd88tm1Aki Tg(Vil1-cre)997Gum)
cecum inflammation J:175865
\Faddtm1Mpa/\Faddtm1Mpa
\Tg(Vil1-cre)997Gum/0

(B6.Cg-Faddtm1Mpa Tg(Vil1-cre)997Gum)
cecum inflammation J:175865
colitis J:175865
\Faddtm1Mpa/\Faddtm1Mpa
\Tnftm1Gkl/\Tnftm1Gkl
\Tg(Vil1-cre)997Gum/0

(B6.Cg-Faddtm1Mpa Tnftm1Gkl Tg(Vil1-cre)997Gum)
cecum inflammation J:175865
colitis J:175865
\Faddtm1Wnt/\Faddtm1Wnt
\Tg(Fadd)33Wnt/0

(involves: 129S4/SvJae * C57BL/6 * CBA)
immune system phenotype J:69617
\Faddtm1Wnt/\Faddtm1Wnt
\Tg(Fadd)33Wnt/0
\Tg(Lck-cre)I57Jxm/0

(involves: 129S4/SvJae * C57BL/6 * CBA * ICR)
abnormal T cell differentiation J:69617
decreased CD4-positive, alpha-beta T cell number J:69617
decreased CD8-positive, alpha-beta T cell number J:69617
decreased double-positive T cell number J:69617
increased B cell number J:69617
increased double-negative T cell number J:69617
thymus hypoplasia J:69617
\Faddtm1Wnt/\Faddtm1Wnt
\Tg(Fadd)33Wnt/0
\Tg(Lck-cre)I57Jxm/0
\Tg(Tcra2C,Tcrb2C)1Dlo/0

(involves: 129S4/SvJae * C57BL/6 * C57L * CBA * ICR * SJL)
increased double-negative T cell number J:69617
thymus hypoplasia J:69617
\Faddtm1Wnt/\Faddtm1Wnt
\Tg(Fadd/EGFP)#Jizh/?
\Tg(Cd4-cre)1Cwi/?

(involves: 129S4/SvJae * C57BL/6 * DBA/2)
decreased activated T cell number J:113207
decreased single-positive T cell number J:113207
immune system phenotype J:113207
increased B cell number J:113207
\Faddtm1Wnt/\Faddtm1Wnt
\Tg(Fadd/EGFP)#Jizh/?
\Tg(Lck-cre)1Cwi/?

(involves: 129S4/SvJae)
decreased activated T cell number J:113207
decreased single-positive T cell number J:113207
immune system phenotype J:113207
increased B cell number J:113207
\Faddtm1Wnt/\Faddtm1Wnt
\Tg(Fadd/EGFP)#Jizh/?
\Tg(Mx1-cre)1Cgn/?

(involves: 129S4/SvJae * C57BL/6 * CBA)
spleen hypoplasia J:168722
thymus hypoplasia J:168722
\Faddtm2.1Wnt/\Faddtm2.1Wnt
\Tg(Cd4-cre)1Cwi/?

(B6.Cg-Tg(Cd4-cre)1Cwi Faddtm2.1Wnt)
abnormal T cell proliferation J:162312
abnormal T cell subpopulation ratio J:162312
abnormal thymocyte apoptosis J:162312
enlarged lymph nodes J:162312
enlarged spleen J:162312
increased B cell number J:162312
increased susceptibility to parasitic infection J:162312
\Fads1Gt(IST11525H2)Tigm/\Fads1+
(C57BL/6-Fads1Gt(IST11525H2)Tigm)
decreased interferon-gamma secretion J:186265
decreased tumor necrosis factor secretion J:186265
\Fads1Gt(IST11525H2)Tigm/\Fads1Gt(IST11525H2)Tigm
(C57BL/6-Fads1Gt(IST11525H2)Tigm)
abnormal mononuclear cell morphology J:186265
decreased interferon-gamma secretion J:186265
decreased regulatory T cell number J:186265
decreased tumor necrosis factor secretion J:186265
\Fads2tm1Mtna/\Fads2tm1Mtna
(involves: 129S6/SvEvTac * C57BL/6J)
abnormal spleen white pulp morphology J:153293
abnormal thymus cortex morphology J:153293
dermatitis J:153293
enlarged spleen J:153293
increased spleen red pulp amount J:153293
lymphoid hypoplasia J:153293
small thymus J:153293
\Fads2tm1Wst/\Fads2tm1Wst
(involves: 129P2/OlaHsd)
abnormal macrophage physiology J:140341
\Fahem1(IMPC)Mbp/\Fah+
(C57BL/6N-Fahem1(IMPC)Mbp/MbpMmucd)
abnormal spleen morphology J:211773
enlarged spleen J:211773
\Fahtm1Mgo/\Fahtm1Mgo
(involves: 129S7/SvEvBrd * PT)
kidney inflammation J:77295
\Fahtm1Mgo/\Fahtm1Mgo
(involves: 129S7/SvEvBrd * C57BL)
liver inflammation J:27735
\Fahtm1Mgo/\Fahtm1Mgo
\Hgdaku/\Hgd+

(involves: 129S7/SvEvBrd * NB)
kidney inflammation J:77295
\Faim2em1(IMPC)Ccpcz/\Faim2em1(IMPC)Ccpcz
(C57BL/6NCrl-Faim2em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
small spleen J:211773
\Faimtm1Kplm/\Faimtm1Kplm
(involves: 129P2/OlaHsd * C57BL/6)
increased B cell apoptosis J:164184
increased thymocyte apoptosis J:164184
liver inflammation J:164184
\Fam3aem1Cya/\Fam3aem1Cya
(involves: C57BL/6)
increased macrophage cell number J:295206
increased NK T cell number J:295206
increased T cell number J:295206
\Fam3dem1Wko/\Fam3dem1Wko
(C57BL/6-Fam3dem1Wko)
abnormal cytokine level J:300819
abnormal neutrophil physiology J:304594
colitis J:300819
decreased Ly6C high monocyte number J:304594
decreased macrophage cell number J:304594
decreased neutrophil cell number J:304594
enlarged spleen J:300819
increased leukocyte cell number J:300819
increased neutrophil cell number J:304594, J:300819
increased susceptibility to colitis induced morbidity/mortality J:300819
increased susceptibility to induced colitis J:300819
\Fam13atm1e(KOMP)Wtsi/\Fam13atm1e(KOMP)Wtsi
(C57BL/6N-Fam13atm1e(KOMP)Wtsi)
white adipose tissue inflammation J:258290
\Fam20ctm1.1Cqi/\Fam20ctm1.1Cqi
\Tg(Col1a1-cre)2Bek/0

(involves: 129S6/SvEvTac * CD-1)
dental pulp inflammation J:225679
periodontium inflammation J:225679
\Fam53aem1(IMPC)Ccpcz/\Fam53aem1(IMPC)Ccpcz
(C57BL/6N-Fam53aem1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged thymus J:211773
\Fam72atm1.1(KOMP)Vlcg/\Fam72atm1.1(KOMP)Vlcg
(C57BL/6NTac-Fam72atm1.1(KOMP)Vlcg)
abnormal class switch recombination J:326431
abnormal somatic hypermutation frequency J:326431
increased B cell apoptosis J:326431
increased germinal center B cell number J:326431
\Fam72atm1.1(KOMP)Vlcg/\Fam72atm1.1(KOMP)Vlcg
\Msh2tm1Mak/\Msh2tm1Mak

(C57BL/6NTac-Fam72atm1.1(KOMP)Vlcg Msh2tm1Mak)
abnormal class switch recombination J:326431
abnormal somatic hypermutation frequency J:326431
\Fam76bGt(IST14004H1)Tigm/\Fam76bGt(IST14004H1)Tigm
(C57BL/6-Fam76bGt(IST14004H1)Tigm)
abnormal macrophage physiology J:358021
abnormal spleen germinal center morphology J:358021
abnormal spleen white pulp morphology J:358021
abnormal splenic cell ratio J:358021
decreased B cell number J:358021
enlarged spleen J:358021
increased inflammatory response J:358021
increased interleukin-6 secretion J:358021
increased microglial cell activation J:358021
increased spleen weight J:358021
increased tumor necrosis factor secretion J:358021
microgliosis J:358021
\Fam81aem1(IMPC)Ccpcz/\Fam81aem1(IMPC)Ccpcz
(C57BL/6N-Fam81aem1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged spleen J:211773
enlarged thymus J:211773
\Fam83dem1(IMPC)Ccpcz/\Fam83dem1(IMPC)Ccpcz
(C57BL/6N-Fam83dem1(IMPC)Ccpcz/Ccpcz)
abnormal thymus morphology J:211773
enlarged thymus J:211773
\Fam83hem1(IMPC)Ccpcz/\Fam83hem1(IMPC)Ccpcz
(C57BL/6N-Fam83hem1(IMPC)Ccpcz/Ccpcz)
increased CD4-positive, CD25-positive, alpha-beta regulatory T cell number J:211773
\Fam83hem2(IMPC)Ccpcz/\Fam83h+
(C57BL/6NCrl-Fam83hem2(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
\Fam110btm1a(EUCOMM)Wtsi/\Fam110b+
(C57BL/6N-Fam110btm1a(EUCOMM)Wtsi/Cnrm)
decreased mature B cell number J:165965
increased leukocyte cell number J:165965
\Fam120cem1(IMPC)Ccpcz/Y
(C57BL/6NCrl-Fam120cem1(IMPC)Ccpcz/Ccpcz)
decreased NK cell number J:211773
\Fam120cem1(IMPC)Ccpcz/\Fam120cem1(IMPC)Ccpcz
(C57BL/6NCrl-Fam120cem1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged spleen J:211773
enlarged thymus J:211773
\Fam124aem1(IMPC)Ccpcz/\Fam124aem1(IMPC)Ccpcz
(C57BL/6N-Fam124aem1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged spleen J:211773
enlarged thymus J:211773
\Fam151btm1b(EUCOMM)Hmgu/\Fam151btm1b(EUCOMM)Hmgu
(C57BL/6N-Fam151btm1b(EUCOMM)Hmgu/H)
increased neutrophil cell number J:211773
\Fam161aGt(462E7)Cmhd/\Fam161aGt(462E7)Cmhd
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)
microgliosis J:214319
\Fam161bem1(IMPC)Ccpcz/\Fam161bem1(IMPC)Ccpcz
(C57BL/6N-Fam161bem1(IMPC)Ccpcz/Ccpcz)
abnormal lymph node morphology J:211773
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged lymph nodes J:211773
enlarged spleen J:211773
enlarged thymus J:211773
\Fam163atm2b(KOMP)Wtsi/\Fam163atm2b(KOMP)Wtsi
(C57BL/6N-Fam163atm2b(KOMP)Wtsi/Wtsi)
increased leukocyte cell number J:211773
\Fam167aem1(IMPC)Ccpcz/\Fam167aem1(IMPC)Ccpcz
(C57BL/6NCrl-Fam167aem1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged spleen J:211773
enlarged thymus J:211773
\Fam185aem1(IMPC)Ccpcz/\Fam185aem1(IMPC)Ccpcz
(C57BL/6N-Fam185aem1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged thymus J:211773
\Fam209tm1b(KOMP)Wtsi/\Fam209tm1b(KOMP)Wtsi
(C57BL/6N-Fam209tm1b(KOMP)Wtsi/Bay)
abnormal spleen morphology J:211773
\Fam210atm1b(EUCOMM)Wtsi/\Fam210a+
(involves: BALB/cJ * C57BL/6N)
increased osteoclast cell number J:261817
\Fam210atm1c(EUCOMM)Wtsi/\Fam210atm1c(EUCOMM)Wtsi
\Tg(ACTA1-cre/Esr1*)2Kesr/0

(involves: C3H * C57BL/6N * SJL)
increased osteoclast cell number J:261817
\Fam210atm1c(EUCOMM)Wtsi/\Fam210atm1c(EUCOMM)Wtsi
\Tg(CAG-cre/Esr1*)5Amc/0

(involves: C57BL/6N * CBA * SJL)
increased osteoclast cell number J:261817
\Fam210bem1Cya/\Fam210bem1Cya
(involves: C57BL/6N)
abnormal splenocyte physiology J:351618
enlarged spleen J:351618
glomerulonephritis J:351618
increased anti-double stranded DNA antibody level J:351618
increased anti-nuclear antigen antibody level J:351618
increased IgG level J:351618
increased splenocyte number J:351618
\Fam210btm1b(KOMP)Mbp/\Fam210btm1b(KOMP)Mbp
(C57BL/6N-Fam210btm1b(KOMP)Mbp/Ucd)
increased monocyte cell number J:211773
increased neutrophil cell number J:211773
\Fam219aem1(IMPC)Ccpcz/\Fam219aem1(IMPC)Ccpcz
(C57BL/6N-Fam219aem1(IMPC)Ccpcz/Ccpcz)
abnormal thymus morphology J:211773
enlarged thymus J:211773
\Fam221aem1(IMPC)Ccpcz/\Fam221aem1(IMPC)Ccpcz
(C57BL/6N-Fam221aem1(IMPC)Ccpcz/Ccpcz)
abnormal lymph node morphology J:211773
enlarged lymph nodes J:211773
increased CD8-positive, naive alpha-beta T cell number J:211773
increased neutrophil cell number J:211773
\Fam227bem1(IMPC)Ccpcz/\Fam227bem1(IMPC)Ccpcz
(C57BL/6NCrl-Fam227bem1(IMPC)Ccpcz/Ccpcz)
abnormal lymph node morphology J:211773
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged lymph nodes J:211773
enlarged spleen J:211773
enlarged thymus J:211773
\Fam229bem1(IMPC)Mbp/\Fam229bem1(IMPC)Mbp
(C57BL/6NCrl-Fam229bem1(IMPC)Mbp/MbpMmucd)
increased basophil cell number J:211773
\Fam234btm1a(EUCOMM)Wtsi/\Fam234btm1a(EUCOMM)Wtsi
(C57BL/6N-Fam234btm1a(EUCOMM)Wtsi/Cnrm)
decreased CD8-positive, alpha-beta T cell number J:165965
\Fan1tm1a(KOMP)Wtsi/\Fan1tm1a(KOMP)Wtsi
(129S1.B6-Fan1tm1a(KOMP)Wtsi)
tubulointerstitial nephritis J:242198
\Fancctm1Mab/\Fancctm1Mab
\Sod1tm1Cep/\Sod1tm1Cep

(involves: 129S1/Sv * 129X1/SvJ)
abnormal lymphocyte morphology J:71134
decreased leukocyte cell number J:71134
decreased lymphocyte cell number J:71134
decreased neutrophil cell number J:71134
\Fancd2em1Tzh/\Fancd2em1Tzh
(C57BL/6-Fancd2em1Tzh)
enlarged spleen J:284566
\Fancltm1b(EUCOMM)Hmgu/\Fancltm1b(EUCOMM)Hmgu
(C57BL/6N-Fancltm1b(EUCOMM)Hmgu/Nju)
increased basophil cell number J:211773
increased eosinophil cell number J:211773
\Farp2tm1Akum/\Farp2tm1Akum
(B6.Cg-Farp2tm1Akum)
abnormal osteoclast physiology J:166376
decreased osteoclast cell number J:166376
increased osteoclast cell number J:166376
\Farsatm2a(EUCOMM)Wtsi/\Farsa+
(C57BL/6N-Farsatm2a(EUCOMM)Wtsi/Wtsi)
decreased leukocyte cell number J:211773
\Faslpr-cg/\Faslpr-cg
(CBA/KlJms-Faslpr-cg/J)
abnormal hypersensitivity reaction J:24805, J:81770
abnormal lymph organ size J:24805
abnormal T cell differentiation J:24805
autoimmune response J:24805, J:81770
enlarged lymph nodes J:24805, J:81770
enlarged spleen J:24805
increased anti-nuclear antigen antibody level J:24805
increased autoantibody level J:81770
increased IgG level J:24805, J:81770
increased IgM level J:24805, J:81770
increased immunoglobulin level J:24805
increased spleen weight J:81770
\Faslpr/\Fas+
\Tg(TcraTcrb)1100Mjb/?

(involves: C57BL/6 * MRL/Mp)
liver inflammation J:72817
\Faslpr/\Faslpr
(MRL/Mp-Faslpr)
abnormal B cell morphology J:108760
abnormal B cell receptor editing J:131138
abnormal cytotoxic T cell physiology J:7488
abnormal immune system organ morphology J:28885
abnormal immune system physiology J:28885
abnormal interleukin level J:8267
abnormal lymph node cell ratio J:6257
abnormal lymph node morphology J:27634
abnormal marginal zone B cell morphology J:131138
abnormal T cell morphology J:108760, J:8267
abnormal T cell physiology J:8267
abnormal T cell proliferation J:8267
abnormal T-helper 2 physiology J:6257
abnormal thymus medulla morphology J:28885
abnormal type III hypersensitivity reaction J:28885
blood vessel inflammation J:28885
decreased interleukin-2 secretion J:6638, J:7488
enlarged lymph nodes J:27634, J:108760, J:13757, J:28885
enlarged Peyer's patches J:28885
enlarged spleen J:28885
enlarged thymus J:13757
glomerulonephritis J:27634, J:13757, J:28885
increased anti-double stranded DNA antibody level J:27634, J:131138, J:6257
increased anti-erythrocyte antigen antibody level J:27634
increased anti-nuclear antigen antibody level J:27634, J:28885
increased anti-single stranded DNA antibody level J:27634
increased autoantibody level J:28885
increased IgA level J:28885
increased IgG1 level J:13757, J:28885
increased IgG2a level J:13757, J:28885
increased IgG2b level J:28885
increased IgG level J:27634
increased IgM level J:28885
increased immunoglobulin level J:13757, J:28885, J:6257
increased susceptibility to autoimmune disorder J:108760
increased thymus weight J:28885
lacrimal gland inflammation J:18512
lymph node hemorrhage J:27634
lymph node hyperplasia J:27634
lymph node necrosis J:27634
salivary gland inflammation J:18512
submandibular gland inflammation J:21965
thymus atrophy J:27634
thymus cortex atrophy J:13757, J:28885
thyroid gland inflammation J:28171
\Faslpr/\Faslpr
(MRL/Mp-Agtpbp1atms Faslpr)
enlarged lymph nodes J:103944
enlarged spleen J:103944
enlarged thymus J:103944
\Faslpr/\Faslpr
(NOD.MRL(B6)-Faslpr)
decreased susceptibility to autoimmune diabetes J:64051
\Faslpr/\Faslpr
(MRL/MpJ-Faslpr/J)
abnormal immunoglobulin level J:122315
CNS inflammation J:14151
conjunctivitis J:123192
decreased IgG level J:122315
decreased immature B cell number J:122315
decreased marginal zone B cell number J:122315
decreased mature B cell number J:122315
decreased spleen germinal center number J:122315
decreased transitional stage B cell number J:122315
enlarged lymph nodes J:92084, J:7454
glomerulonephritis J:92084, J:122315, J:127199, J:7454
increased anti-double stranded DNA antibody level J:92084, J:122315, J:7454
increased anti-nuclear antigen antibody level J:111811, J:92084, J:14151, J:7454
increased autoantibody level J:92084, J:14151
increased IgG level J:92084
increased immunoglobulin level J:122315, J:7454
increased neutrophil cell number J:127199
increased plasma cell number J:122315
increased susceptibility to systemic lupus erythematosus J:92084
lymph node hemorrhage J:7454
lymph node necrosis J:7454
salivary gland inflammation J:92084
\Faslpr/\Faslpr
(NOD.MRL-Faslpr)
decreased susceptibility to autoimmune diabetes J:78679
\Faslpr/\Faslpr
(involves: C3H * MRL/Mp)
autoimmune response J:1060
increased anti-nuclear antigen antibody level J:34296
increased spleen weight J:34296
increased susceptibility to systemic lupus erythematosus J:34296
increased susceptibility to type III hypersensitivity reaction J:34296
\Faslpr/\Faslpr
(B6.MRL-Faslpr/J)
abnormal NK cell physiology J:115033
abnormal splenic cell ratio J:132217
brain inflammation J:120427
CNS inflammation J:120427
decreased B cell apoptosis J:135830
enlarged lymph nodes J:119584
increased anti-double stranded DNA antibody level J:132217
increased anti-histone antibody level J:132217
increased anti-nuclear antigen antibody level J:132217
increased anti-single stranded DNA antibody level J:132217
increased autoantibody level J:132217
increased follicular B cell number J:132217
increased immature B cell number J:132217
increased marginal zone B cell number J:132217
increased splenocyte number J:132217
increased susceptibility to bacterial infection J:136745
increased susceptibility to Picornaviridae infection J:120427
increased transitional stage B cell number J:132217
lymph node hyperplasia J:132217
\Faslpr/\Faslpr
(MRL-Faslpr)
abnormal T-helper 2 physiology J:6257
enlarged lymph nodes J:126261
glomerulonephritis J:126261
increased anti-double stranded DNA antibody level J:126261
increased anti-nuclear antigen antibody level J:126261
increased IgG level J:126261
increased IgM level J:126261
increased immunoglobulin level J:6257
increased spleen weight J:126261
\Faslpr/\Faslpr
(MRL.Cg-Irf1tm1Mak Faslpr)
glomerulonephritis J:114771
increased anti-double stranded DNA antibody level J:114771
\Faslpr/\Faslpr
(C3.MRL-Faslpr/J)
abnormal B cell activation J:7454
abnormal T cell morphology J:7454
decreased eosinophil cell number J:106288
decreased interleukin-2 secretion J:7454
enlarged lymph nodes J:7454
glomerulonephritis J:7454
immune system phenotype J:7454
increased anti-double stranded DNA antibody level J:7454
increased anti-nuclear antigen antibody level J:7454
increased autoantibody level J:7454
increased immunoglobulin level J:7454
lymph node hemorrhage J:7454
lymph node hyperplasia J:7454
lymph node necrosis J:7454
\Faslpr/\Faslpr
(B6.MRL-Faslpr)
decreased interleukin-2 secretion J:6638
enlarged lymph nodes J:6638, J:135036, J:7454
enlarged spleen J:135036
glomerulonephritis J:135036, J:7454
increased anti-double stranded DNA antibody level J:7454
increased anti-nuclear antigen antibody level J:6638, J:135036
increased autoantibody level J:135036, J:7454
increased double-negative T cell number J:135036
increased immunoglobulin level J:7454
lymph node hemorrhage J:7454
lymph node necrosis J:7454
\Faslpr/\Faslpr
(AK.MRL-Faslpr)
enlarged lymph nodes J:7454
glomerulonephritis J:7454
increased anti-double stranded DNA antibody level J:7454
increased anti-nuclear antigen antibody level J:7454
increased autoantibody level J:7454
increased immunoglobulin level J:7454
lymph node hemorrhage J:7454
lymph node necrosis J:7454
\Faslpr/\Faslpr
(C3.MRL-Faslpr)
abnormal interleukin level J:8267
abnormal T cell morphology J:8267
abnormal T cell physiology J:8267
abnormal T cell proliferation J:8267
lacrimal gland inflammation J:1028
salivary gland inflammation J:1028
\Faslpr/\Faslpr
(MRL/MpJ-Faslpr)
abnormal leukocyte adhesion J:126009
abnormal leukocyte morphology J:126009
autoimmune response J:125114
blood vessel inflammation J:137066
decreased activated T cell number J:137066
decreased B cell number J:137066
decreased CD4-positive, alpha-beta T cell number J:137066
decreased CD8-positive, alpha-beta T cell number J:137066
enlarged lymph nodes J:137066
enlarged spleen J:137066
glomerulonephritis J:125114, J:132514, J:137066
impaired leukocyte tethering or rolling J:126009
increased anti-nuclear antigen antibody level J:137066
increased autoantibody level J:137066
increased double-negative T cell number J:137066
increased immunoglobulin level J:125114
\Faslpr/\Faslpr
(involves: MRL/Mp)
decreased macrophage apoptosis J:154647
increased susceptibility to bacterial infection J:50903
\Faslpr/\Faslpr
(involves: C57BL/6 * MRL/Mp)
enlarged spleen J:73396
increased anti-double stranded DNA antibody level J:73396
increased anti-single stranded DNA antibody level J:73396
increased IgA level J:73396
increased IgG1 level J:73396
increased IgG2a level J:73396
increased IgG2b level J:73396
increased IgG3 level J:73396
increased IgM level J:73396
lymph node hyperplasia J:73396
\Faslpr/\Faslpr
(involves: 129P2/OlaHsd * MRL)
enlarged lymph nodes J:26250
glomerulonephritis J:45448
increased double-negative T cell number J:26250
increased gamma-delta T cell number J:26250
kidney inflammation J:45448
\Faslpr/\Faslpr
\Fcer1gtm1Tks/\Fcer1gtm1Tks

(MRL.Cg-Fcer1gtm1Tks Faslpr)
arteritis J:106188
decreased susceptibility to type III hypersensitivity reaction J:106188
glomerulonephritis J:106188
immune system phenotype J:106188
increased anti-double stranded DNA antibody level J:106188
increased double-negative T cell number J:106188
increased IgG level J:106188
increased spleen weight J:106188
\Faslpr/\Faslpr
\Havcr1tm1Kuch/\Havcr1tm1Kuch

(B6.Cg-Havcr1tm1Kuch Faslpr)
abnormal immunoglobulin level J:186484
enlarged lymph nodes J:186484
enlarged spleen J:186484
increased activated T cell number J:186484
increased anti-double stranded DNA antibody level J:186484
increased autoantibody level J:186484
increased B cell number J:186484
increased CD4-positive, alpha-beta T cell number J:186484
increased CD8-positive, alpha-beta T cell number J:186484
increased double-negative T cell number J:186484
increased IgG1 level J:186484
increased IgG2a level J:186484
increased IgG2b level J:186484
increased IgG3 level J:186484
increased susceptibility to systemic lupus erythematosus J:186484
increased T cell number J:186484
\Faslpr/\Faslpr
\Hspa13tm1.1Smoc/\Hspa13tm1.1Smoc
\Cd19tm1(cre)Cgn/\Cd19+

(involves: 129P2/OlaHsd * 129S * C57BL/6 * MRL/Mp)
decreased autoantibody level J:303927
decreased susceptibility to systemic lupus erythematosus J:303927
\Faslpr/\Faslpr
\Ifnar1tm1Agt/\Ifnar1tm1Agt

(MRL.Cg-Ifnar1tm1Agt Faslpr)
enlarged lymph nodes J:92084
glomerulonephritis J:92084
increased anti-nuclear antigen antibody level J:92084
increased autoantibody level J:92084
increased IgA level J:92084
increased IgG2b level J:92084
increased IgG3 level J:92084
increased IgG level J:92084
increased IgM level J:92084
increased susceptibility to systemic lupus erythematosus J:92084
salivary gland inflammation J:92084
\Faslpr/\Faslpr
\Ifnar1tm1Agt/\Ifnar1tm1Agt
\Ifngr1tm1Agt/\Ifngr1tm1Agt

(MRL.Cg-Ifngr1tm1Agt Ifnar1tm1Agt Faslpr)
decreased anti-nuclear antigen antibody level J:92084
decreased autoantibody level J:92084
decreased IgG level J:92084
decreased susceptibility to systemic lupus erythematosus J:92084
glomerulonephritis J:92084
increased IgG level J:92084
increased susceptibility to systemic lupus erythematosus J:92084
salivary gland inflammation J:92084
small lymph nodes J:92084
\Faslpr/\Faslpr
\Ifngtm1Ts/\Ifng+

(MRL.Cg-Ifngtm1Ts Faslpr)
abnormal macrophage chemotaxis J:123834
glomerulonephritis J:123834
increased autoantibody level J:123834
\Faslpr/\Faslpr
\Ifngtm1Ts/\Ifngtm1Ts

(MRL.Cg-Ifngtm1Ts Faslpr)
abnormal macrophage chemotaxis J:123834
immune system phenotype J:123834
kidney inflammation J:123834
lung inflammation J:123834
\Faslpr/\Faslpr
\Ifngtm1Ts/\Ifngtm1Ts

(involves: 129S7/SvEvBrd * DBA/1 * MRL/Mp)
abnormal lymph node size J:39600
abnormal spleen size J:39600
decreased anti-double stranded DNA antibody level J:39600
decreased anti-nuclear antigen antibody level J:39600
decreased autoantibody level J:39600
decreased double-negative T cell number J:39600
decreased IgA level J:39600
decreased IgG2a level J:39600
decreased IgG2b level J:39600
decreased IgM level J:39600
decreased immunoglobulin level J:39600
decreased susceptibility to systemic lupus erythematosus J:39600
enlarged lymph nodes J:39600
enlarged spleen J:39600
\Faslpr/\Faslpr
\Ifngr1tm1Agt/\Ifngr1tm1Agt

(MRL.Cg-Ifngr1tm1Agt Faslpr)
decreased anti-nuclear antigen antibody level J:92084
decreased autoantibody level J:92084
decreased IgA level J:92084
decreased IgG2a level J:92084
decreased IgG2b level J:92084
decreased IgG3 level J:92084
decreased IgM level J:92084
decreased susceptibility to systemic lupus erythematosus J:92084
glomerulonephritis J:92084
increased IgG1 level J:92084
increased IgG level J:92084
small lymph nodes J:92084
\Faslpr/\Faslpr
\Igh-Jtm2(3H9-VDJ*)Mwg/\Igh-J+

(MRL.Cg-Faslpr Igh-Jtm2(3H9-VDJ*)Mwg)
abnormal B cell receptor editing J:131138
abnormal marginal zone B cell morphology J:131138
increased anti-double stranded DNA antibody level J:131138
\Faslpr/\Faslpr
\Ighmtm1Cgn/\Ighmtm1Cgn

(involves: 129S2/SvPas * C57BL/6 * MRL/Mp)
abnormal humoral immune response J:119584
abnormal immunoglobulin level J:119584
arrested B cell differentiation J:119584
decreased IgM level J:119584
decreased mature B cell number J:119584
enlarged lymph nodes J:119584
increased autoantibody level J:119584
increased T cell number J:119584
\Faslpr/\Faslpr
\Il2ratm1Dw/\Il2ratm1Dw
\Tg(CD2-Ccdc86)1Hfuj/?

(B6.Cg-Il2ratm1Dw Faslpr Tg(CD2-Ccdc86)1Hfuj)
enlarged spleen J:151722
\Faslpr/\Faslpr
\Il4tm1Cgn/\Il4tm1Cgn

(MRL.Cg-Il4tm1Cgn Faslpr)
glomerulonephritis J:132514
lacrimal gland inflammation J:132514
\Faslpr/\Faslpr
\Il4tm1Cgn/\Il4tm1Cgn

(involves: 129P2/OlaHsd * C57BL/6J * MRL/Mp)
abnormal lymph node size J:39600
abnormal spleen size J:39600
decreased anti-nuclear antigen antibody level J:39600
decreased IgA level J:39600
decreased IgE level J:39600
decreased IgG1 level J:39600
decreased IgG3 level J:39600
decreased immunoglobulin level J:39600
decreased susceptibility to systemic lupus erythematosus J:39600
enlarged spleen J:39600
increased spleen weight J:39600
spleen hyperplasia J:39600
\Faslpr/\Faslpr
\Il27ratm1Mak/\Il27ratm1Mak

(MRL.Cg-Il27ratm1Mak Faslpr)
abnormal T-helper 2 physiology J:122148
decreased anti-double stranded DNA antibody level J:122148
decreased IgG2a level J:122148
decreased interferon-gamma secretion J:122148
decreased susceptibility to systemic lupus erythematosus J:122148
glomerulonephritis J:122148
immune system phenotype J:122148
increased circulating interleukin-4 level J:122148
increased circulating interleukin-5 level J:122148
increased IgE level J:122148
increased IgG1 level J:122148
\Faslpr/\Faslpr
\Irf1tm1Mak/\Irf1+

(MRL.Cg-Irf1tm1Mak Faslpr)
glomerulonephritis J:114771
immune system phenotype J:114771
increased anti-double stranded DNA antibody level J:114771
increased CD4-positive, alpha-beta T cell number J:114771
\Faslpr/\Faslpr
\Irf1tm1Mak/\Irf1tm1Mak

(MRL.Cg-Irf1tm1Mak Faslpr)
abnormal cytokine secretion J:114771
decreased anti-double stranded DNA antibody level J:114771
glomerulonephritis J:114771
immune system phenotype J:114771
increased CD4-positive, alpha-beta T cell number J:114771
\Faslpr/\Faslpr
\Itfg2Gt(OST215121)Lex/\Itfg2Gt(OST215121)Lex

(involves: 129S5/SvEvBrd * C57BL/6J * MRL/Mp)
decreased B cell number J:205951
enlarged lymph nodes J:205951
enlarged spleen J:205951
increased anti-double stranded DNA antibody level J:205951
increased anti-nuclear antigen antibody level J:205951
increased double-negative T cell number J:205951
increased IgG2a level J:205951
increased IgM level J:205951
increased susceptibility to systemic lupus erythematosus J:205951
\Faslpr/\Faslpr
\Kdelr1m1Btlr/\Kdelr1m1Btlr

(involves: C57BL/6J * MRL/Mp)
immune system phenotype J:224970
\Faslpr/\Faslpr
\Nos2tm1Mrl/\Nos2tm1Mrl

(involves: 129S7/SvEvBrd * MRL)
abnormal immunoglobulin level J:42666
decreased IgG level J:42666
decreased IgM level J:42666
immune system phenotype J:42666
\Faslpr/\Faslpr
\Pou2af1tm1Pmt/\Pou2af1tm1Pmt

(involves: 129P2/OlaHsd * C57BL/6 * MRL)
abnormal T cell number J:125114
autoimmune response J:125114
decreased immunoglobulin level J:125114
decreased plasma cell number J:125114
increased B cell number J:125114
\Faslpr/\Faslpr
\Selptm1Bay/\Selptm1Bay

(MRL.Cg-Selptm1Bay Faslpr)
abnormal chemokine secretion J:127199
abnormal leukocyte adhesion J:126009
dermatitis J:127199
glomerulonephritis J:127199
impaired leukocyte tethering or rolling J:126009
increased neutrophil cell number J:127199
\Faslpr/\Faslpr
\Selplgtm1Fur/\Selplgtm1Fur

(MRL.Cg-Selplgtm1Fur Faslpr)
abnormal chemokine level J:127199
dermatitis J:127199
glomerulonephritis J:127199
\Faslpr/\Faslpr
\Sh2d1arpl/\Sh2d1arpl

(MRL/Mp-Faslpr Sh2d1arpl)
abnormal immune system physiology J:126261
increased anti-nuclear antigen antibody level J:126261
\Faslpr/\Faslpr
\Spp1tm1Rit/\Spp1tm1Rit

(involves: 129S7/SvEvBrd * C57BL/6 * MRL/Mp)
enlarged spleen J:73396
increased anti-double stranded DNA antibody level J:73396
increased anti-single stranded DNA antibody level J:73396
increased IgA level J:73396
increased IgG1 level J:73396
increased IgG2a level J:73396
increased IgG2b level J:73396
increased IgG3 level J:73396
increased IgM level J:73396
kidney inflammation J:73396
lymph node hyperplasia J:73396
\Faslpr/\Faslpr
\Tcratm1Mjo/\Tcra+

(MRL.Cg-Tcratm1Mjo Faslpr)
immune system phenotype J:108590
\Faslpr/\Faslpr
\Tcratm1Mjo/\Tcratm1Mjo

(involves: 129P2/OlaHsd * MRL)
immune system phenotype J:26250
increased gamma-delta intraepithelial T cell number J:26250
increased gamma-delta T cell number J:26250
increased T cell number J:26250
kidney inflammation J:45448
\Faslpr/\Faslpr
\Tcratm1Mjo/\Tcratm1Mjo

(involves: 129P2/OlaHsd * 129S2/SvPas * MRL)
decreased autoantibody level J:38492
decreased immunoglobulin level J:38492
\Faslpr/\Faslpr
\Tg(CD2-Foxj1)#Stlp/0

(MRL.Cg-Faslpr Tg(CD2-Foxj1)#Stlp)
abnormal T cell physiology J:122222
decreased CD4-positive, alpha-beta T cell number J:122222
decreased susceptibility to systemic lupus erythematosus J:122222
enlarged lymph nodes J:122222
enlarged spleen J:122222
increased anti-nuclear antigen antibody level J:122222
increased double-negative T cell number J:122222
kidney inflammation J:122222
liver inflammation J:122222
lung inflammation J:122222
salivary gland inflammation J:122222
\Faslpr/\Faslpr
\Tg(H2-K-Cd86)27All/0

(involves: C57BL/6 * CBA * MRL/MpJ)
decreased B cell number J:112475
\Faslpr/\Faslpr
\Tg(Ins2-Fasl)24Ach/0

(NOD.Cg-Faslpr Tg(Ins2-Fasl)24Ach)
decreased susceptibility to autoimmune diabetes J:81416
\Faslpr/\Faslpr
\Tg(INS-Il10)#Sar/0

(NOD.Cg-Faslpr Tg(INS-Il10)#Sar)
increased susceptibility to autoimmune diabetes J:64051
insulitis J:64051
\Faslpr/\Faslpr
\Tlr7tm1Flv/Y

(involves: 129S1/Sv * C57BL/6 * MRL/Mp)
abnormal B cell activation J:113557
abnormal CD4-positive, alpha beta T cell morphology J:113557
abnormal lymph node size J:113557
abnormal plasmacytoid dendritic cell physiology J:113557
decreased autoantibody level J:113557
decreased double-negative T cell number J:113557
decreased IgG2a level J:113557
decreased IgG3 level J:113557
decreased spleen weight J:113557
decreased susceptibility to systemic lupus erythematosus J:113557
increased anti-chromatin antibody level J:113557
increased autoantibody level J:113557
\Faslpr/\Faslpr
\Tlr9tm1Aki/\Tlr9tm1Aki

(B6.Cg-Tlr9tm1Aki Faslpr)
autoimmune response J:135036
decreased IgM level J:135036
enlarged lymph nodes J:135036
enlarged spleen J:135036
glomerulonephritis J:135036
increased double-negative T cell number J:135036
increased IgG level J:135036
\Faslpr/\Faslpr
\Tlr9tm1Aki/\Tlr9tm1Aki

(MRL.Cg-Tlr9tm1Aki Faslpr)
abnormal B cell activation J:113557
abnormal plasmacytoid dendritic cell physiology J:113557
decreased autoantibody level J:113557
enlarged lymph nodes J:113557
enlarged spleen J:113557
glomerulonephritis J:113557
increased autoantibody level J:113557
increased CD4-positive, alpha-beta T cell number J:113557
increased circulating interferon-alpha level J:113557
increased double-negative T cell number J:113557
increased IgG2a level J:113557
increased IgG3 level J:113557
increased IgG level J:113557
increased susceptibility to systemic lupus erythematosus J:113557
kidney inflammation J:113557
\Faslpr/\Faslpr
\Tnfrsf1atm1.1Gkl/\Tnfrsf1atm1.1Gkl

(involves: 129/Sv * C57BL/6)
liver inflammation J:92470
\Faslpr/\Faslpr
\Tnfrsf9tm1Byk/\Tnfrsf9tm1Byk

(MRL.Cg-Tnfrsf9tm1Byk Faslpr)
enlarged lymph nodes J:127197
enlarged spleen J:127197
increased anti-nuclear antigen antibody level J:127197
increased B-1 B cell number J:127197
increased B-2 B cell number J:127197
increased CD4-positive, alpha-beta T cell number J:127197, J:126929
increased double-negative T cell number J:127197, J:126929
increased immunoglobulin level J:127197
increased interleukin-4 secretion J:126929
increased spleen germinal center number J:127197
increased susceptibility to systemic lupus erythematosus J:127197
lacrimal gland inflammation J:126929
\Faslpr/\Faslpr
\Tnfrsf13cBcmd1/\Tnfrsf13c+

(MRL.Cg-Tnfrsf13cBcmd1 Faslpr)
decreased B cell number J:122315
decreased marginal zone B cell number J:122315
\Faslpr/\Fastm1.1Cgn
(involves: C57BL/6 * MRL)
abnormal immune system morphology J:114948
enlarged lymph nodes J:114948
enlarged spleen J:114948
\Faslpr/\Fastm1Cgn
\Tg(Cd4-cre)1Cwi/0

(involves: C57BL/6 * DBA/2 * MRL)
enlarged lymph nodes J:114948
enlarged spleen J:114948
increased double-negative T cell number J:114948
\Fasm1Btlr/\Fasm1Btlr
(C57BL/6J-Fasm1Btlr)
decreased CD4-positive, alpha-beta T cell number J:216052
decreased CD8-positive, alpha-beta T cell number J:216052
increased neutrophil cell number J:216052
increased NK cell number J:216052
\Fasm2Btlr/\Fasm2Btlr
(C57BL/6J-Fasm2Btlr)
increased central memory CD4-positive, alpha-beta T cell number J:271891
increased effector memory CD4-positive, alpha-beta T cell number J:271891
\Fastheo/\Fastheo
(either: (involves: C57BL/6JAnu * C57BL/10SnSg * C57BR/cd) or (involves: C57BL/6JAnu * C57BL/10SnSg * C57BR/cd * CBA/CaJAnu))
enlarged lymph nodes J:104190
increased anti-nuclear antigen antibody level J:104190
\Fastm1.1Cgn/\Fastm1.1Cgn
(involves: C57BL/6)
abnormal immune system morphology J:114948
enlarged lymph nodes J:114948
enlarged spleen J:114948
\Fastm1Ach/\Fastm1Ach
\Tg(GZMB-cre)1Jcb/?

(involves: C57BL/6 * FVB/N)
increased anti-nuclear antigen antibody level J:123556
increased double-positive T cell number J:123556
\Fastm1Ach/\Fastm1Ach
\Tg(Itgax-cre,-EGFP)4097Ach/?

(Not Specified)
abnormal spleen morphology J:123556
abnormal spleen periarteriolar lymphoid sheath morphology J:123556
enlarged spleen J:123556
increased anti-nuclear antigen antibody level J:123556
increased dendritic cell number J:123556
increased IgG level J:123556
increased IgM level J:123556
increased immunoglobulin level J:123556
\Fastm1Ach/\Fastm1Ach
\Tg(Lck-cre)548Jxm/?

(involves: C57BL/6 * CBA)
increased anti-nuclear antigen antibody level J:123556
increased double-positive T cell number J:123556
\Fastm1Cgn/\Fastm1Cgn
(C57BL/6-Fastm1Cgn)
immune system phenotype J:114948
\Fastm1Cgn/\Fastm1Cgn
\Cd19tm1(cre)Cgn/\Cd19+
\Tg(Cd4-cre)1Cwi/0

(B6.Cg-Tg(Cd4-cre)1Cwi Cd19tm1(cre)Cgn Fastm1Cgn)
increased anti-single stranded DNA antibody level J:114948
\Fastm1Cgn/\Fastm1Cgn
\Mogtm1(cre)Gkl/\Mog+

(involves: C57BL/6)
decreased susceptibility to experimental autoimmune encephalomyelitis J:114741
immune system phenotype J:114741
\Fastm1Cgn/\Fastm1Cgn
\Mogtm1(cre)Gkl/\Mog+
\Tnfrsf1atm1Mak/\Tnfrsf1atm1Mak

(involves: 129S2/SvPas * C57BL/6)
decreased susceptibility to experimental autoimmune encephalomyelitis J:114741
immune system phenotype J:114741
\Fastm1Cgn/\Fastm1Cgn
\Tg(Cd4-cre)1Cwi/0

(B6.Cg-Tg(Cd4-cre)1Cwi Fastm1Cgn)
abnormal immune system cell morphology J:114948
abnormal immune system organ morphology J:114948
abnormal thymus involution J:114948
alveolitis J:114948
decreased B cell number J:114948
decreased T cell number J:114948
enlarged spleen J:114948
increased activated T cell number J:114948
increased anti-single stranded DNA antibody level J:114948
increased double-negative T cell number J:114948
increased inflammatory response J:114948
increased memory T cell number J:114948
increased T cell apoptosis J:114948
kidney inflammation J:114948
liver inflammation J:114948
lung inflammation J:114948
lymph node hypoplasia J:114948
spleen hypoplasia J:114948
\Fastm1Cgn/\Fastm1Cgn
\Tg(Lck-cre)I57Jxm/0

(B6.Cg-Fastm1Cgn Tg(Lck-cre)I57Jxm)
lymph node hypoplasia J:114948
\Fastm1Cgn/\Fastm1Cgn
\Tg(Mx1-cre)1Cgn/0

(B6.Cg-Fastm1Cgn Tg(Mx1-cre)1Cgn)
abnormal immune system morphology J:114948
enlarged lymph nodes J:114948
enlarged spleen J:114948
\Fastm1Cgn/\Fastm1Cgn
\Tnfrsf1atm1Mak/\Tnfrsf1atm1Mak

(involves: 129S2/SvPas * C57BL/6)
decreased susceptibility to experimental autoimmune encephalomyelitis J:114741
\Fastm1Dlo/\Fastm1Dlo
(involves: 129P2/OlaHsd * C57BL/6)
abnormal thymus involution J:90750
enlarged lymph nodes J:31847
enlarged spleen J:31847
increased immunoglobulin level J:31847
\Fastm1Osa/\Fastm1Osa
(involves: 129P2/OlaHsd * C57BL/6)
abnormal hypersensitivity reaction J:64296, J:32125
abnormal lymph organ size J:64296
abnormal T cell clonal deletion J:32125
enlarged lymph nodes J:64296, J:32125
enlarged spleen J:64296, J:32125
increased anti-double stranded DNA antibody level J:32125
increased anti-single stranded DNA antibody level J:32125
increased autoantibody level J:32125
increased B cell number J:32125
increased IgG1 level J:32125
increased IgG2a level J:32125
increased IgG2b level J:32125
increased IgG3 level J:32125
increased IgG level J:32125
increased leukocyte cell number J:32125
increased lymphocyte cell number J:64296, J:32125
increased susceptibility to parasitic infection J:81397
lymphoid hyperplasia J:64296
\Fastm1Osa/\Fastm1Osa
\Gzmatm1Simn/\Gzmatm1Simn
\Gzmbtm1Ley/\Gzmbtm1Ley

(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6)
increased susceptibility to parasitic infection J:81397
\Fastm1Vbo/\Fastm1Vbo
\Tg(Ins2-cre)25Mgn/0
\Tg(Ins2-HA)165Bri/0
\Tg(Tcra/Tcrb)1Vbo/0

(Not Specified)
increased susceptibility to autoimmune diabetes J:85985
\Fasldel1Hong/\Fasldel1Hong
(either: (involves: 129 * BALB/c * C57BL/6) or (involves: 129X1/SvJ * C3H/HeJ * C57BL/6))
abnormal thymus cell ratio J:112563
enlarged lymph nodes J:112563
enlarged spleen J:112563
enlarged thymus J:112563
increased IgG level J:112563
increased IgM level J:112563
\Faslgld/\Faslgld
(C3H/HeJ-Faslgld/J)
abnormal lymph node morphology J:7306
abnormal T cell differentiation J:12002, J:8267
decreased B cell number J:29572
decreased cytotoxic T cell cytolysis J:17698
enlarged lymph nodes J:7306, J:29572
enlarged spleen J:7306, J:29572
increased anti-double stranded DNA antibody level J:7306
increased anti-nuclear antigen antibody level J:7306, J:29572
increased autoantibody level J:7306
increased IgA level J:7306, J:29572
increased IgG1 level J:7306
increased IgG2a level J:7306
increased IgG2b level J:7306
increased IgG level J:29572
increased IgM level J:7306, J:29572
increased immunoglobulin level J:7306, J:29572
increased leukocyte cell number J:7306
increased lymphocyte cell number J:7306, J:29572
increased neutrophil cell number J:7306
increased T cell number J:29572
interstitial pneumonia J:7306
\Faslgld/\Faslgld
(B6Smn.C3-Faslgld/J)
abnormal NK cell physiology J:115033
abnormal osteoclast physiology J:127179
brain inflammation J:120427
CNS inflammation J:120427
decreased granulocyte number J:136745
eye inflammation J:136745
increased susceptibility to bacterial infection J:136745
increased susceptibility to Picornaviridae infection J:120427
liver inflammation J:135830
\Faslgld/\Faslgld
(C3H/HeJ-Faslgld)
abnormal interleukin level J:8267
abnormal T cell morphology J:8267
abnormal T cell physiology J:8267
abnormal T cell proliferation J:8267
\Faslgld/\Faslgld
(involves: C3H/HeJ * C57BL/6)
dermatitis J:153501
enlarged lymph nodes J:153501
enlarged spleen J:153501
immune system phenotype J:153501
increased anti-nuclear antigen antibody level J:153501
increased circulating tumor necrosis factor level J:153501
increased IgE level J:153501
increased IgG1 level J:153501
increased IgG2a level J:153501
increased IgG2b level J:153501
increased IgG level J:153501
increased susceptibility to systemic lupus erythematosus J:153501
increased T cell number J:153501
\Faslgld/\Faslgld
(involves: C3H/HeJ)
abnormal osteoclast physiology J:156947
enlarged lymph nodes J:171440
enlarged spleen J:171440
increased spleen weight J:171440
\Faslgld/\Faslgld
(B6.C3-Faslgld)
abnormal lymph node morphology J:91058
enlarged lymph nodes J:91058
enlarged spleen J:91058
impaired macrophage phagocytosis J:91058
increased anti-nuclear antigen antibody level J:91058
increased autoantibody level J:91058
increased spleen weight J:91058
\Faslgld/\Faslgld
\Ighmtm1Cgn/\Ighmtm1Cgn

(involves: 129S2/SvPas * C3H/HeJ * C57BL/6)
immune system phenotype J:119584
\Faslm1Btlr/\Faslm1Btlr
(C57BL/6J-Faslm1Btlr)
abnormal humoral immune response J:212067
\Faslm2Btlr/\Faslm2Btlr
(C57BL/6J-Faslm2Btlr)
decreased IgG level J:224659
impaired humoral immune response J:224659
\Fasltm1.1Ast/\Fasltm1.1Ast
(involves: BALB/cJ * C57BL/6)
decreased cytotoxic T cell cytolysis J:153501
dermatitis J:153501
enlarged lymph nodes J:153501
enlarged spleen J:153501
glomerulonephritis J:153501
immune system phenotype J:153501
increased anti-double stranded DNA antibody level J:153501
increased anti-nuclear antigen antibody level J:153501
increased circulating tumor necrosis factor level J:153501
increased IgA level J:153501
increased IgE level J:153501
increased IgG1 level J:153501
increased IgG2a level J:153501
increased IgG2b level J:153501
increased IgG level J:153501
increased IgM level J:153501
increased immunoglobulin level J:153501
increased susceptibility to systemic lupus erythematosus J:153501
\Fasltm1.1Bksa/\Fasltm1.1Bksa
(involves: 129)
enlarged lymph nodes J:171440
enlarged spleen J:171440
increased spleen weight J:171440
\Fasltm1.1Cgm/\Fasltm1.1Cgm
(involves: 129S2/SvPas * C57BL/6 * C57BL/6N)
immune system phenotype J:168406
increased B cell proliferation J:168406
increased germinal center B cell number J:168406
increased IgM level J:168406
increased plasma cell number J:168406
increased T cell proliferation J:168406
\Fasltm1.1Lest/\Fasltm1.1Lest
(involves: 129 * C57BL/6)
abnormal double-negative T cell morphology J:87990
abnormal lymph node morphology J:87990
autoimmune response J:87990
enlarged lymph nodes J:87990
enlarged spleen J:87990
glomerulonephritis J:87990
increased IgG level J:87990
lymphoid hyperplasia J:87990
\Fasltm1.1Lest/\Fasltm1.1Lest
(B6.129-Fasltm1.1Lest)
glomerulonephritis J:87990
\Fasltm2.1Ast/\Fasltm2.1Ast
(involves: BALB/cJ * C57BL/6)
abnormal cytotoxic T cell physiology J:153501
\Fastktm1.1Andp/\Fastktm1.1Andp
(B6.129S6-Fastktm1.1Andp)
abnormal chemokine secretion J:160443
abnormal neutrophil physiology J:160443
decreased interleukin-6 secretion J:160443
decreased interleukin-23 secretion J:160443
decreased neutrophil cell number J:160443
decreased tumor necrosis factor secretion J:160443
\Fastkd2tm1b(EUCOMM)Wtsi/\Fastkd2tm1b(EUCOMM)Wtsi
(C57BL/6N-Fastkd2tm1b(EUCOMM)Wtsi/Bay)
decreased spleen weight J:211773
\Fat1Gt(KST249)Byg/\Fat1Gt(KST249)Byg
\Tg(Myl1-lacZ)1Ibdml/0

(involves: 129P2/OlaHsd)
lymphangiectasis J:199157
myositis J:199157
\Fat1tm1.2Fhel/\Fat1tm1.2Fhel
\Tg(Myl1-lacZ)1Ibdml/0

(involves: 129S6/SvEvTac * BALB/cJ * C57BL/6J * SJL)
myositis J:199157
\Fat3em1(IMPC)Ccpcz/\Fat3em1(IMPC)Ccpcz
(C57BL/6NCrl-Fat3em1(IMPC)Ccpcz/Ccpcz)
abnormal lymph node morphology J:211773
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged lymph nodes J:211773
enlarged spleen J:211773
enlarged thymus J:211773
\Fbf1tm1a(EUCOMM)Wtsi/\Fbf1tm1a(EUCOMM)Wtsi
(C57BL/6N-Fbf1tm1a(EUCOMM)Wtsi/Wtsi)
increased leukocyte cell number J:211773
\Fblim1tm1.1Chen/\Fblim1tm1.1Chen
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ)
abnormal osteoclast differentiation J:186501
abnormal osteoclast physiology J:186501
increased osteoclast cell number J:186501
\Fbln1Gt(XST011)Byg/\Fbln1Gt(XST011)Byg
(involves: 129P2/OlaHsd * C57BL/6)
thymus hypoplasia J:137690
\Fbln1tm1Tmpl/\Fbln1tm1Tmpl
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
thymus hypoplasia J:137690
\Fbn1em1(IMPC)H/\Fbn1+
(C57BL/6NTac-Fbn1em1(IMPC)H/H)
decreased lymphocyte cell number J:211773
increased neutrophil cell number J:211773
increased spleen weight J:211773
\Fbn1tm1Lper/\Fbn1+
(involves: 129/Sv * CD-1)
lung inflammation J:167276
\Fbn1tm2.1Hcd/\Fbn1+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * FVB/N)
abnormal interleukin secretion J:206074
abnormal T-helper 1 cell morphology J:206074
increased anti-nuclear antigen antibody level J:206074
increased autoantibody level J:206074
increased B cell number J:206074
increased interleukin-9 secretion J:206074
increased interleukin-13 secretion J:206074
increased plasma cell number J:206074
\Fbn1tm2Rmz/\Fbn1tm2Rmz
(involves: 129S1/Sv * 129X1/SvJ)
aortitis J:54081
lung inflammation J:91815
\Fbn1tm3.1Hcd/\Fbn1+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * FVB/N)
abnormal interleukin secretion J:206074
abnormal T-helper 1 cell morphology J:206074
increased anti-nuclear antigen antibody level J:206074
increased autoantibody level J:206074
increased B cell number J:206074
increased interleukin-9 secretion J:206074
increased interleukin-13 secretion J:206074
increased plasma cell number J:206074
\Fbn1Tsk/\Fbn1+
(B6.Cg-Fbn1Tsk)
abnormal uterine NK cell morphology J:1377
alveolitis J:15018, J:30961, J:6566
increased autoantibody level J:21987, J:14166
increased mast cell number J:8047
increased susceptibility to type IV hypersensitivity reaction J:7185
lung inflammation J:30961, J:6566
\Fbn1Tsk/\Fbn1+
\Il4tm1Nnt/\Il4tm1Nnt

(involves: C57BL/6 * C57BL/10 * DBA/2)
decreased interleukin-4 secretion J:57957
\Fbn1Tsk/\Fbn1+
\Il4ratm1Sz/\Il4ra+

(involves: BALB/cJ * C57BL/6J * C57BL/10 * DBA/2)
increased autoantibody level J:68448
\Fbn1Tsk/\Fbn1+
\Il4ratm1Sz/\Il4ratm1Sz

(involves: BALB/cJ * C57BL/6J * C57BL/10 * DBA/2)
immune system phenotype J:68448
\Fbn1Tsk/\Fbn1+
\KitW/\KitW-v

(involves: C57BL/6 * C57BL/10 * DBA/2 * WB/ReJ)
absent mast cells J:24076
\Fbn1Tsk/\Fbn1+
\Stat6tm1Gru/\Stat6tm1Gru

(involves: 129S2/SvPas * C57BL/10 * DBA/2)
decreased interleukin-4 secretion J:57957
\Fbn1Tsk/\Fbn1+
\Tgfb1tm1N/\Tgfb1+

(involves: 129S/SvEv * C57BL/6J * C57BL/10 * DBA/2)
immune system phenotype J:68448
\Fbp2tm2b(EUCOMM)Hmgu/\Fbp2+
(C57BL/6N-Fbp2tm2b(EUCOMM)Hmgu/Ieg)
increased leukocyte cell number J:211773
\Fbrsl1em1(IMPC)Tcp/\Fbrsl1em1(IMPC)Tcp
(C57BL/6N-Fbrsl1em1(IMPC)Tcp/Tcp)
enlarged spleen J:211773
small thymus J:211773
\Fbxl3em1(IMPC)Ccpcz/\Fbxl3em1(IMPC)Ccpcz
(C57BL/6NCrl-Fbxl3em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
decreased effector memory T-helper cell number J:211773
decreased spleen weight J:211773
\Fbxl4tm1.2Lrsn/\Fbxl4tm1.2Lrsn
(involves: C57BL/6N)
liver inflammation J:303084
\Fbxl5Gt(OST386421)Lex/\Fbxl5+
(involves: 129S5/SvEvBrd * C57BL/6)
increased spleen iron level J:193752
\Fbxl5tm2.1Kei/\Fbxl5tm2.1Kei
\Speer6-ps1Tg(Alb-cre)21Mgn/\Speer6-ps1+

(involves: C57BL/6 * DBA)
liver inflammation J:176655
\Fbxl18tm1b(EUCOMM)Hmgu/\Fbxl18tm1b(EUCOMM)Hmgu
(C57BL/6N-Fbxl18tm1b(EUCOMM)Hmgu/Mhzh)
increased basophil cell number J:211773
increased eosinophil cell number J:211773
\Fbxl19tm1b(EUCOMM)Wtsi/\Fbxl19+
(C57BL/6N-Fbxl19tm1b(EUCOMM)Wtsi/Nju)
decreased lymphocyte cell number J:211773
increased basophil cell number J:211773
increased eosinophil cell number J:211773
increased leukocyte cell number J:211773
increased monocyte cell number J:211773
increased neutrophil cell number J:211773
\Fbxo4tm1.1Jadi/\Fbxo4+
(Not Specified)
myeloid hyperplasia J:178645
\Fbxo4tm1.1Jadi/\Fbxo4tm1.1Jadi
(Not Specified)
myeloid hyperplasia J:178645
\Fbxo7tm1a(EUCOMM)Hmgu/\Fbxo7tm1a(EUCOMM)Hmgu
(involves: C57BL/6N)
increased pro-B cell number J:183053
\Fbxo7tm1a(EUCOMM)Wtsi/\Fbxo7tm1a(EUCOMM)Wtsi
(C57BL/6N-Fbxo7tm1a(EUCOMM)Wtsi/Wtsi)
decreased leukocyte cell number J:211773
\Fbxo7tm1a(EUCOMM)Wtsi/\Fbxo7tm1a(EUCOMM)Wtsi
(involves: C57BL/6N)
abnormal effector T cell number J:272313
abnormal T cell differentiation J:272313
decreased CD4-positive, alpha-beta T cell number J:272313
decreased CD8-positive, alpha-beta T cell number J:272313
decreased T cell number J:272313
enlarged spleen J:272313
increased activated T cell number J:272313
increased double-negative T cell number J:272313
increased effector memory CD4-positive, alpha-beta T cell number J:272313
increased effector memory CD8-positive, alpha-beta T cell number J:272313
increased memory T cell number J:272313
increased spleen weight J:272313
increased susceptibility to bacterial infection J:272313
increased susceptibility to bacterial infection induced morbidity/mortality J:272313
thymus atrophy J:272313
thymus hypoplasia J:272313
\Fbxo7tm1c(EUCOMM)Wtsi/\Fbxo7tm1c(EUCOMM)Wtsi
\Tg(Cd4-cre)1Cwi/0

(involves: C57BL/6J * C57BL/6N)
decreased CD8-positive, alpha-beta T cell number J:272313
decreased T cell number J:272313
immune system phenotype J:272313
\Fbxo9tm1b(EUCOMM)Hmgu/\Fbxo9tm1b(EUCOMM)Hmgu
(C57BL/6N-Fbxo9tm1b(EUCOMM)Hmgu/Tcp)
increased basophil cell number J:211773
increased eosinophil cell number J:211773
\Fbxo10tm1b(KOMP)Wtsi/\Fbxo10tm1b(KOMP)Wtsi
(C57BL/6N-Fbxo10tm1b(KOMP)Wtsi/Nju)
decreased neutrophil cell number J:211773
\Fbxo11Jf/\Fbxo11+
(involves: BALB/cAnNCrl * C3H/HeN)
abnormal cytokine secretion J:85263
increased susceptibility to otitis media J:85263
\Fbxo11Jf/\Fbxo11+
(involves: BALB/cAnNCrl * C3H/HeN * C57BL/6J)
increased susceptibility to otitis media J:114851
\Fbxo11Jf/\Fbxo11+
(involves: BALB/cAnNCrl)
increased susceptibility to otitis media J:250208
\Fbxo11Jf/\Fbxo11Mutt
(involves: BALB/c * C3H/HeN)
increased susceptibility to otitis media J:114851
\Fbxo21em1Smbk/\Fbxo21em1Smbk
\Commd10Tg(Vav1-icre)A2Kio/\Commd10+

(B6.Cg-Fbxo21em1Smbk Commd10Tg(Vav1-icre)A2Kio)
decreased spleen weight J:333469
increased T cell number J:333469
\Fbxo25em1(IMPC)Ccpcz/\Fbxo25em1(IMPC)Ccpcz
(C57BL/6N-Fbxo25em1(IMPC)Ccpcz/Ccpcz)
abnormal lymph node morphology J:211773
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged lymph nodes J:211773
enlarged spleen J:211773
enlarged thymus J:211773
\Fbxo28em1(IMPC)Mhzh/\Fbxo28+
(C57BL/6N-Fbxo28em1(IMPC)Mhzh/Mhzh)
increased basophil cell number J:211773
increased eosinophil cell number J:211773
\Fbxo36tm1b(KOMP)Wtsi/\Fbxo36tm1b(KOMP)Wtsi
(C57BL/6N-Fbxo36tm1b(KOMP)Wtsi/Nju)
decreased monocyte cell number J:211773
increased basophil cell number J:211773
increased neutrophil cell number J:211773
\Fbxw2tm1b(EUCOMM)Hmgu/\Fbxw2tm1b(EUCOMM)Hmgu
(C57BL/6N-Fbxw2tm1b(EUCOMM)Hmgu/Nju)
increased basophil cell number J:211773
\Fbxw7tm1Iaai/\Fbxw7tm1Iaai
\Tg(Lck-cre)1Cwi/0

(involves: 129/Sv * C57BL/6)
immune system phenotype J:137138
increased T cell derived lymphoma incidence J:137138
\Fbxw7tm1Iaai/\Fbxw7tm1Iaai
\Tg(Mx1-cre)1Cgn/0

(involves: 129/Sv * C57BL/6 * CBA)
abnormal T cell differentiation J:137138
decreased double-negative T cell number J:137138
thymus hypoplasia J:137138
\Fbxw7tm1Iaai/\Fbxw7tm1Iaai
\Tg(Mx1-cre)1Cgn/0

(involves: 129 * C57BL/6 * CBA)
abnormal T cell differentiation J:200006
\Fbxw7tm1Kei/\Fbxw7tm1Kei
\Myctm2Fwa/\Myctm2Fwa
\Tg(Cd4-cre)1Cwi/?

(involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * DBA/2)
immune system phenotype J:128523
\Fbxw7tm1Kei/\Fbxw7tm1Kei
\Rbpjtm1Hon/\Rbpjtm1Hon
\Tg(Cd4-cre)1Cwi/?

(involves: 129P2/OlaHsd * C57BL/6 * DBA/2)
increased double-positive T cell number J:128523
\Fbxw7tm1Kei/\Fbxw7tm1Kei
\Tg(Cd4-cre)1Cwi/?

(involves: 129P2/OlaHsd * C57BL/6)
increased double-positive T cell number J:128523
\Fbxw7tm1Kei/\Fbxw7tm1Kei
\Tg(Lck-cre)1Cwi/?

(involves: 129P2/OlaHsd * C57BL/6)
abnormal T cell activation J:128523
arrested T cell differentiation J:128523
decreased single-positive T cell number J:128523
enlarged thymus J:128523
increased double-positive T cell number J:128523
increased T cell apoptosis J:128523
\Fbxw7tm1Kei/\Fbxw7tm1Kei
\Trp53tm1Tyj/\Trp53tm1Tyj
\Tg(Lck-cre)1Cwi/?

(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6)
immune system phenotype J:128523
increased T cell derived lymphoma incidence J:128523
\Fbxw7tm2Iaai/\Fbxw7+
\Tg(Mx1-cre)1Cgn/0

(involves: C57BL/6 * CBA)
immune system phenotype J:200006
\Fbxw8tm1b(EUCOMM)Hmgu/\Fbxw8+
(C57BL/6N-Fbxw8tm1b(EUCOMM)Hmgu/Nju)
decreased lymphocyte cell number J:211773
increased basophil cell number J:211773
increased eosinophil cell number J:211773
increased neutrophil cell number J:211773
\Fbxw9tm1a(EUCOMM)Wtsi/\Fbxw9+
(C57BL/6N-Fbxw9tm1a(EUCOMM)Wtsi/Bay)
absent spleen J:211773
\Fbxw9tm1a(EUCOMM)Wtsi/\Fbxw9tm1a(EUCOMM)Wtsi
(C57BL/6N-Fbxw9tm1a(EUCOMM)Wtsi/Bay)
absent lymph nodes J:211773
\Fbxw9tm1b(EUCOMM)Wtsi/\Fbxw9tm1b(EUCOMM)Wtsi
(C57BL/6N-Fbxw9tm1b(EUCOMM)Wtsi/Bay)
abnormal spleen morphology J:211773
\Fbxw10em1(IMPC)Tcp/\Fbxw10em1(IMPC)Tcp
(C57BL/6N-Fbxw10em1(IMPC)Tcp/Tcp)
enlarged lymph nodes J:211773
\Fbxw16em1(IMPC)Ccpcz/\Fbxw16+
(C57BL/6N-Fbxw16em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged spleen J:211773
enlarged thymus J:211773
increased CD8-positive, naive alpha-beta T cell number J:211773
small thymus J:211773
\Fbxw18em1(IMPC)Ccpcz/\Fbxw18+
(C57BL/6N-Fbxw18em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged spleen J:211773
enlarged thymus J:211773
small spleen J:211773
\Fbxw20em1(IMPC)Ccpcz/\Fbxw20em1(IMPC)Ccpcz
(C57BL/6N-Fbxw20em1(IMPC)Ccpcz/Ccpcz)
abnormal lymph node morphology J:211773
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged lymph nodes J:211773
enlarged spleen J:211773
enlarged thymus J:211773
\Fbxw25em1(IMPC)Ccpcz/\Fbxw25em1(IMPC)Ccpcz
(C57BL/6NCrl-Fbxw25em1(IMPC)Ccpcz/Ccpcz)
abnormal thymus morphology J:211773
enlarged thymus J:211773
\Fbxw26tm1b(KOMP)Wtsi/\Fbxw26tm1b(KOMP)Wtsi
(C57BL/6N-Fbxw26tm1b(KOMP)Wtsi/Wtsi)
decreased memory-marker NK cell number J:211773
increased KLRG1-positive NK cell number J:211773
increased NK cell number J:211773
\Fcamrtm1Shib/\Fcamrtm1Shib
(involves: 129P2/OlaHsd * C57BL/6)
abnormal follicular dendritic cell antigen presentation J:150824
abnormal marginal zone B cell physiology J:150824
abnormal memory B cell differentiation J:150824
abnormal somatic hypermutation frequency J:150824
abnormal spleen germinal center morphology J:150824
increased spleen germinal center number J:150824
increased spleen germinal center size J:150824
\Fcamrtm2Shib/\Fcamrtm2Shib
(BALB/c-Fcamrtm2Shib)
abnormal follicular dendritic cell antigen presentation J:150824
abnormal marginal zone B cell physiology J:150824
increased spleen germinal center number J:150824
increased spleen germinal center size J:150824
\Fcer1atm1Ftl/\Fcer1atm1Ftl
(CBy.129S2-Fcer1atm1Ftl)
abnormal humoral immune response J:120702
abnormal mast cell physiology J:120702
decreased circulating interleukin-4 level J:120702
decreased eosinophil cell number J:120702
\Fcer1atm1Knt/\Fcer1atm1Knt
(either: (involves: 129 * C57BL/6) or (involves: 129 * C57BL/6 * DBA/2))
abnormal mast cell physiology J:39250
decreased susceptibility to type I hypersensitivity reaction J:113572, J:39250
\Fcer1atm1Knt/\Fcer1atm1Knt
(involves: 129 * BALB/c)
abnormal mast cell physiology J:78659
increased susceptibility to type I hypersensitivity reaction J:78659
\Fcer1atm1Knt/\Fcer1atm1Knt
\Fcer2atm1Max/\Fcer2atm1Max

(B6.Cg-Fcer1atm1Knt Fcer2atm1Max)
abnormal mast cell physiology J:144620
\Fcer1atm1Knt/\Fcer1atm1Knt
\Fcer2atm1Max/\Fcer2atm1Max
\Fcgr1tm1Jsv/\Fcgr1tm1Jsv
\Fcgr2btm1Ttk/\Fcgr2btm1Ttk
\Fcgr3tm1Jsv/\Fcgr3tm1Jsv

(B6.Cg-Fcgr2btm1Ttk Fcgr3tm1Jsv Fcer1atm1Knt Fcgr1tm1Jsv Fcer2atm1Max)
abnormal macrophage physiology J:144620
abnormal mast cell physiology J:144620
increased susceptibility to type I hypersensitivity reaction J:144620
\Fcer1atm1Knt/\Fcer1atm1Knt
\Tg(FCER1A)1Bhk/?

(B6.129-Fcer1atm1Knt Tg(FCER1A)1Bhk)
abnormal macrophage physiology J:144620
increased tumor necrosis factor secretion J:144620
\Fcer1atm1Knt/\Fcer1atm1Knt
\Tg(SV40/HTLV-FCER1A)1Bhk/0

(either: (involves: 129 * C57BL/6) or (involves: 129 * C57BL/6 * DBA/2))
abnormal type I hypersensitivity reaction J:113572
\Fcer1gtm1Rav/\Fcer1gtm1Rav
(involves: 129P2/OlaHsd * C57BL/6)
abnormal dendritic cell antigen presentation J:83995
abnormal immune cell physiology J:39248
abnormal immunoglobulin level J:78659
abnormal mast cell physiology J:39248
abnormal NK cell physiology J:39248
decreased susceptibility to experimental autoimmune encephalomyelitis J:126520
decreased susceptibility to type I hypersensitivity reaction J:78659, J:39248
immune system phenotype J:28282
impaired macrophage phagocytosis J:39248
increased IgE level J:78659
\Fcer1gtm1Rav/\Fcer1gtm1Rav
(B6.129P2-Fcer1gtm1Rav)
decreased interleukin-1 beta secretion J:160680
decreased interleukin-6 secretion J:160680
decreased interleukin-10 secretion J:160680
decreased interleukin-12b secretion J:160680
decreased interleukin-23 secretion J:160680
decreased tumor necrosis factor secretion J:160680
\Fcer1gtm1Rav/\Fcer1gtm1Rav
(involves: 129P2/OlaHsd)
increased susceptibility to parasitic infection J:163761
\Fcer1gtm1Rav/\Fcer1gtm1Rav
\Del(7Tyrobp-Hcst)1Ttk/\Del(7Tyrobp-Hcst)1Ttk

(involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6)
abnormal osteoclast physiology J:147155
\Fcer1gtm1Rav/\Fcer1gtm1Rav
\Hexbtm1Rlp/\Hexbtm1Rlp

(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)
increased immunoglobulin level J:87617
\Fcer1gtm1Rav/\Fcer1gtm1Rav
\Tg(Ins2-TFRC/OVA)296Wehi/0

(involves: 129P2/OlaHsd * C57BL/6)
decreased susceptibility to autoimmune diabetes J:122114
decreased T cell proliferation J:122114
\Fcer1gtm1Rav/\Fcer1gtm1Rav
\Tyrobptm1.1Viv/\Tyrobptm1.1Viv

(involves: 129P2/OlaHsd * C57BL/6)
decreased interferon-gamma secretion J:100668
decreased uterine NK cell number J:100668
\Fcer1gtm1Rav/\Fcer1gtm1Rav
\Tyrobptm1Lll/\Tyrobptm1Lll

(involves: 129P2/OlaHsd * C57BL/6)
abnormal osteoclast differentiation J:89583
\Fcer1gtm1Rav/\Fcer1gtm1Rav
\Tyrobptm1Lll/\Tyrobptm1Lll

(involves: 129P2/OlaHsd)
abnormal osteoclast physiology J:147155
\Fcer1gtm1Tks/\Fcer1gtm1Tks
(involves: C57BL/6)
abnormal antigen presentation J:112160
abnormal CD4-positive, alpha-beta T cell physiology J:112160
abnormal chemokine secretion J:141143
abnormal cytokine level J:258645
abnormal macrophage physiology J:141143
abnormal NK cell physiology J:111365
abnormal NK T cell physiology J:111365
decreased IgG1 level J:112160
decreased IgG2a level J:112160
decreased IgG2b level J:112160
decreased IgG3 level J:112160
decreased IgG level J:112160
decreased inflammatory response J:50023
decreased interferon-gamma secretion J:111365, J:112160
decreased interleukin-2 secretion J:112160
decreased susceptibility to type IV hypersensitivity reaction J:112160
decreased T cell proliferation J:112160
impaired macrophage phagocytosis J:50023
impaired natural killer cell mediated cytotoxicity J:111365
\Fcer1gtm1Tks/\Fcer1gtm1Tks
(C57BL/6-Fcer1gtm1Tks)
decreased susceptibility to autoimmune hemolytic anemia J:145432
\Fcer1gtm1Tks/\Fcer1gtm1Tks
(involves: C57BL/6J)
abnormal chemokine secretion J:203159
abnormal interferon-gamma secretion J:203159
abnormal interleukin-17 secretion J:203159
decreased dendritic cell number J:203159
decreased tumor necrosis factor secretion J:203159
\Fcer2aHie/\Fcer2aHie
(NZB)
increased IgE level J:93999
\Fcer2atm1Kik/\Fcer2atm1Kik
(involves: 129P2/OlaHsd * C57BL/6)
abnormal cytokine secretion J:129296
abnormal humoral immune response J:19437
abnormal immune system physiology J:129296
increased immunoglobulin level J:129296
\Fcer2atm1Max/\Fcer2atm1Max
(involves: C57BL/6)
abnormal macrophage chemotaxis J:57738
decreased IgG1 level J:18952
decreased IgG2b level J:18952
impaired eosinophil recruitment J:57738
increased IgE level J:57738, J:18952, J:107857
increased IgM level J:18952
increased susceptibility to type I hypersensitivity reaction J:57738
\Fcer2atm1Max/\Fcer2atm1Max
\Ighg1tm1.1Pyu/\Ighg1+

(involves: 129 * BALB/cJ * C57BL/6 * C57BL/6J)
decreased IgG1 level J:198154
decreased IgG2c level J:198154
decreased IgG level J:198154
increased IgE level J:198154
increased IgG2a level J:198154
increased susceptibility to type I hypersensitivity reaction J:198154
\Fcer2atm1Max/\Fcer2atm1Max
\Ighg1tm1.1Pyu/\Ighg1tm1.1Pyu

(involves: 129 * BALB/cJ * C57BL/6 * C57BL/6J)
abnormal immunoglobulin level J:198154
decreased IgG2c level J:198154
decreased IgG level J:198154
increased IgE level J:198154
increased IgG2a level J:198154
increased susceptibility to type I hypersensitivity reaction J:198154
\Fcer2atm1Putt/\Fcer2a+
(involves: 129S/SvEv * C57BL/6)
increased IgE level J:69547
\Fcer2atm1Putt/\Fcer2atm1Putt
(involves: 129S/SvEv * C57BL/6)
abnormal B cell proliferation J:69547
\Fcgr1tm1Hoga/\Fcgr1tm1Hoga
(involves: 129S1/Sv * 129X1/SvJ)
abnormal cell-mediated immunity J:86281
abnormal macrophage antigen presentation J:86281
decreased inflammatory response J:86281
impaired macrophage phagocytosis J:86281
increased IgG level J:86281
\Fcgr1tm1Jgjw/\Fcgr1tm1Jgjw
(involves: 129 * C57BL/6)
abnormal dendritic cell antigen presentation J:112436
abnormal dendritic cell differentiation J:112436
\Fcgr1tm1Jsv/\Fcgr1tm1Jsv
(involves: 129P2/OlaHsd * BALB/c)
abnormal dendritic cell antigen presentation J:83995
abnormal macrophage physiology J:83995
abnormal type I hypersensitivity reaction J:83995
decreased susceptibility to autoimmune hemolytic anemia J:83995
decreased susceptibility to induced arthritis J:83995
increased susceptibility to bacterial infection J:83995
\Fcgr1tm1Jsv/\Fcgr1tm1Jsv
\Fcgr2btm1Ttk/\Fcgr2btm1Ttk
\Fcgr3tm1Jsv/\Fcgr3tm1Jsv

(involves: 129P2/OlaHsd * 129S4/SvJae * BALB/c * C57BL/6)
impaired macrophage phagocytosis J:83995
\Fcgr2btm1.2Jsv/\Fcgr2b+
X/\Yaa

(involves: C57BL/6 * FVB/N * SB/Le)
enlarged spleen J:179175
increased anti-chromatin antibody level J:179175
increased anti-double stranded DNA antibody level J:179175
increased monocyte cell number J:179175
increased susceptibility to systemic lupus erythematosus J:179175
\Fcgr2btm1.2Jsv/\Fcgr2btm1.2Jsv
\Sle16C57BL/6/\Sle16C57BL/6

(involves: C57BL/6 * FVB/N)
abnormal adaptive immunity J:179175
immune system phenotype J:179175
increased immunoglobulin level J:179175
increased susceptibility to induced arthritis J:179175
kidney inflammation J:179175
\Fcgr2btm1Kgcs/\Fcgr2b+
(involves: C57BL/6)
decreased B cell apoptosis J:190890
increased anti-chromatin antibody level J:190890
increased anti-double stranded DNA antibody level J:190890
increased germinal center B cell number J:190890
increased IgG1 level J:190890
increased IgG3 level J:190890
increased IgM level J:190890
increased susceptibility to induced arthritis J:190890
\Fcgr2btm1Ttk/\Fcgr2b+
X/\Yaa

(involves: 129S4/SvJae * C57BL/6 * SB/Le)
increased monocyte cell number J:129409
\Fcgr2btm1Ttk/\Fcgr2btm1.2Jsv
\Sle21129P2/Ola/\Sle21C57BL/6

(involves: 129P2/Ola * 129S4/SvJae * C57BL/6 * FVB/N)
enlarged spleen J:179175
increased anti-chromatin antibody level J:179175
increased anti-double stranded DNA antibody level J:179175
increased anti-histone antibody level J:179175
increased anti-single stranded DNA antibody level J:179175
increased spleen weight J:179175
increased susceptibility to systemic lupus erythematosus J:179175
\Fcgr2btm1Ttk/\Fcgr2btm1Ttk
(involves: 129S4/SvJae)
abnormal mast cell physiology J:31133
increased IgA level J:31133
increased IgG1 level J:31133
increased IgG2a level J:31133
increased IgG2b level J:31133
increased IgG3 level J:31133
increased IgG level J:31133
increased IgM level J:31133
increased susceptibility to type I hypersensitivity reaction J:31133
\Fcgr2btm1Ttk/\Fcgr2btm1Ttk
(C.129S4-Fcgr2btm1Ttk)
decreased susceptibility to parasitic infection J:120905
\Fcgr2btm1Ttk/\Fcgr2btm1Ttk
(B6.129S4-Fcgr2btm1Ttk)
abnormal hypersensitivity reaction J:64152
enlarged lymph nodes J:64152
enlarged spleen J:64152
glomerulonephritis J:64152
increased immunoglobulin level J:64152
increased inflammatory response J:64152
kidney inflammation J:64152
liver inflammation J:64152
lung inflammation J:64152
pancreas inflammation J:64152
salivary gland inflammation J:64152
\Fcgr2btm1Ttk/\Fcgr2btm1Ttk
(Not Specified)
increased susceptibility to induced arthritis J:106191
\Fcgr2btm1Ttk/\Fcgr2btm1Ttk
\Il17atm1Yiw/\Il17a+

(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)
glomerulonephritis J:191090
increased plasma cell number J:191090
increased spleen germinal center number J:191090
kidney inflammation J:191090
\Fcgr2btm1Ttk/\Fcgr2btm1Ttk
\Il17atm1Yiw/\Il17atm1Yiw

(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)
decreased susceptibility to systemic lupus erythematosus J:191090
increased anti-double stranded DNA antibody level J:191090
increased anti-nuclear antigen antibody level J:191090
increased double-negative T cell number J:191090
increased plasma cell number J:191090
increased spleen germinal center number J:191090
\Fcgr2btm1Ttk/\Fcgr2btm1Ttk
\Pdcd1tm1Hon/\Pdcd1tm1Hon

(involves: 129S2/SvPas * 129S4/SvJae * BALB/c)
abnormal cytokine level J:207275
abnormal urine cytokine level J:207275
increased autoantibody level J:207275
urinary bladder inflammation J:207275
\Fcgr2btm1Ttk/\Fcgr2btm1Ttk
\Sle21129P2/Ola/\Sle21129P2/Ola

(B6.129S4-Fcgr2btm1Ttk)
abnormal adaptive immunity J:179175
enlarged spleen J:179175
increased anti-chromatin antibody level J:179175
increased anti-double stranded DNA antibody level J:179175
increased anti-histone antibody level J:179175
increased anti-single stranded DNA antibody level J:179175
increased autoantibody level J:179175
increased IgG2a level J:179175
increased immunoglobulin level J:179175
increased spleen weight J:179175
increased susceptibility to induced arthritis J:179175
increased susceptibility to systemic lupus erythematosus J:179175
kidney inflammation J:179175
\Fcgr2btm1Ttk/\Fcgr2btm1Ttk
\Tg(Ins2-TFRC/OVA)296Wehi/0

(involves: 129S4/SvJae * C57BL/6)
increased susceptibility to autoimmune diabetes J:122114
\Fcgr2btm1Ttk/\Fcgr2btm1Ttk
\Tlr7tm1Flv/Y
X/\Yaa

(B6.Cg-Fcgr2btm1Ttk Tlr7tm1Flv Yaa)
abnormal splenocyte physiology J:127600
autoimmune response J:127600
enlarged spleen J:127600
increased anti-nuclear antigen antibody level J:127600
increased susceptibility to systemic lupus erythematosus J:127600
\Fcgr2btm1Ttk/\Fcgr2btm1Ttk
\Traf3ip2tm1Sbn/\Traf3ip2+

(involves: 129 * 129S4/SvJae * C57BL/6)
abnormal neutrophil morphology J:191090
abnormal T cell morphology J:191090
increased anti-double stranded DNA antibody level J:191090
increased anti-nuclear antigen antibody level J:191090
increased autoantibody level J:191090
increased double-negative T cell number J:191090
increased IgG level J:191090
increased memory T cell number J:191090
increased monocyte cell number J:191090
increased myeloid dendritic cell number J:191090
increased neutrophil cell number J:191090
increased plasma cell number J:191090
increased plasmacytoid dendritic cell number J:191090
increased single-positive T cell number J:191090
increased spleen germinal center number J:191090
increased susceptibility to systemic lupus erythematosus J:191090
kidney inflammation J:191090
\Fcgr2btm1Ttk/\Fcgr2btm1Ttk
\Traf3ip2tm1Sbn/\Traf3ip2tm1Sbn

(involves: 129 * 129S4/SvJae * C57BL/6)
abnormal T cell morphology J:191090
decreased susceptibility to systemic lupus erythematosus J:191090
increased anti-double stranded DNA antibody level J:191090
increased anti-nuclear antigen antibody level J:191090
increased autoantibody level J:191090
increased double-negative T cell number J:191090
increased IgG level J:191090
\Fcgr2btm1Ttk/\Fcgr2btm1Ttk
\Traf3ip2tm2Sbn/\Traf3ip2+

(involves: 129S4/SvJae * BALB/c * C57BL/6)
enlarged spleen J:191090
increased germinal center B cell number J:191090
increased plasma cell number J:191090
increased spleen weight J:191090
spleen hyperplasia J:191090
\Fcgr2btm1Ttk/\Fcgr2btm1Ttk
\Traf3ip2tm2Sbn/\Traf3ip2tm2Sbn
\Cd79atm1(cre)Reth/\Cd79a+

(involves: 129S4/SvJae * BALB/c * C57BL/6)
glomerulonephritis J:191090
increased germinal center B cell number J:191090
increased plasma cell number J:191090
\Fcgr2btm1Ttk/\Fcgr2btm1Ttk
X/\Yaa

(B6.Cg-Fcgr2btm1Ttk Yaa)
autoimmune response J:127600
enlarged spleen J:127600
increased anti-nuclear antigen antibody level J:127600
increased susceptibility to systemic lupus erythematosus J:127600
\Fcgr3tm1Jsv/\Fcgr3tm1Jsv
(involves: 129P2/OlaHsd * C57BL/6)
abnormal dendritic cell antigen presentation J:83995
abnormal type I hypersensitivity reaction J:83995
decreased mast cell degranulation J:35057
decreased susceptibility to autoimmune hemolytic anemia J:83995
decreased susceptibility to type II hypersensitivity reaction J:35057
impaired macrophage phagocytosis J:35057
impaired natural killer cell mediated cytotoxicity J:35057
\Fcgr3tm1Jsv/\Fcgr3tm1Jsv
(B6.129P2-Fcgr3tm1Jsv/J)
abnormal leukocyte cell number J:78297
abnormal neutrophil physiology J:78297
decreased susceptibility to experimental autoimmune encephalomyelitis J:126520
decreased susceptibility to induced arthritis J:106191
impaired neutrophil recruitment J:78297
increased neutrophil cell number J:78297
\Fcgr3tm1Jsv/\Fcgr3tm1Jsv
\Sle21129P2/Ola/\Sle21129P2/Ola

(B6.129P2-Fcgr3tm1Jsv)
enlarged spleen J:179175
increased activated T cell number J:179175
increased anti-chromatin antibody level J:179175
increased anti-double stranded DNA antibody level J:179175
increased anti-histone antibody level J:179175
increased anti-single stranded DNA antibody level J:179175
increased B cell number J:179175
increased spleen weight J:179175
\Fcgr3tm1Ttk/\Fcgr3tm1Ttk
(involves: 129X1/SvJ)
decreased susceptibility to type I hypersensitivity reaction J:107371
\Fcgr4tm1.1Rav/\Fcgr4tm1.1Rav
(involves: C57BL/6)
decreased susceptibility to induced arthritis J:167375
immune system phenotype J:167375
\Fcgr4tm1Rav/\Fcgr4tm1Rav
\Tg(Ctsk-cre)1Rda/0

(involves: C57BL/6)
autoimmune arthritis J:197378
decreased osteoclast cell number J:197378
\Fcgrttm1Dcr/\Fcgrttm1Dcr
(either: 129 or (involves: 129 * C57BL/6))
decreased IgG level J:94189
\Fcgrttm1Dcr/\Fcgrttm1Dcr
(B6.129X1-Fcgrttm1Dcr/DcrJ)
decreased IgG level J:110885
\Fcgrttm1Dcr/\Fcgrttm1Dcr
\Tg(CAG-FCGRT)276Dcr/0

(involves: 129X1/SvJ * C57BL/6 * C57BL/6J)
immune system phenotype J:110885
\Fcgrttm1Esw/\Fcgrttm1Esw
\Tg(Tek-cre)1Ywa/0

(B6.Cg-Tg(Tek-cre)1Ywa Fcgrttm1Esw)
abnormal humoral immune response J:146640
decreased IgG1 level J:146640
\Fcmrtm1.2Khl/\Fcmrtm1.2Khl
(involves: C57BL/6)
abnormal granulocyte physiology J:194323
decreased B cell number J:174871
immune system phenotype J:174871
increased T cell apoptosis J:174871
\Fcmrtm1Mak/\Fcmrtm1Mak
(B6.129S2-Fcmrtm1Mak)
abnormal cytokine secretion J:194323
abnormal granulocyte physiology J:194323
decreased interleukin-6 secretion J:194323
decreased susceptibility to bacterial infection induced morbidity/mortality J:194323
decreased tumor necrosis factor secretion J:194323
impaired granulocyte bactericidal activity J:194323
increased susceptibility to bacterial infection J:194323
increased susceptibility to bacterial infection induced morbidity/mortality J:194323
\Fcmrtm1Ohno/\Fcmrtm1Ohno
(B6.129-Fcmrtm1Ohno)
abnormal B cell morphology J:190117
abnormal immunoglobulin level J:190117
abnormal response to infection J:190117
decreased IgG1 level J:190117
decreased IgM level J:190117
decreased marginal zone B cell number J:190117
increased anti-chromatin antibody level J:190117
increased anti-double stranded DNA antibody level J:190117
increased B-1 B cell number J:190117
increased IgG3 level J:190117
increased IgM level J:190117
increased T cell number J:190117
\Fcnatm1Tefu/\Fcnatm1Tefu
(involves: 129S4/SvJae)
immune system phenotype J:177350
\Fcnatm1Tefu/\Fcnatm1Tefu
(B6.129-Fcnatm1Tefu)
impaired lectin complement pathway J:190858
increased susceptibility to bacterial infection J:190858
increased susceptibility to bacterial infection induced morbidity/mortality J:190858
\Fcnatm1Tefu/\Fcnatm1Tefu
\Fcnbtm1Tefu/\Fcnbtm1Tefu

(B6.129-Fcnatm1Tefu Fcnbtm1Yend)
impaired lectin complement pathway J:190858
increased susceptibility to bacterial infection J:190858
increased susceptibility to bacterial infection induced morbidity/mortality J:190858
\Fcnatm1Tefu/\Fcnatm1Tefu
\Mbl1tm1Kata/\Mbl1tm1Kata
\Mbl2tm1Kata/\Mbl2tm1Kata

(involves: 129S4/SvJae)
immune system phenotype J:177350
\Fcnbtm1Tefu/\Fcnbtm1Tefu
(B6.129-Fcnbtm1Yend)
increased susceptibility to bacterial infection J:190858
increased susceptibility to bacterial infection induced morbidity/mortality J:190858
\Fcrl2tm1Lex/\Fcrl2tm1Lex
(B6;129S5-Fcrl2tm1Lex/Mmucd)
decreased CD8-positive, alpha-beta T cell number J:171883
\Fcrlatm1.1Cln/\Fcrlatm1.1Cln
(involves: 129P2/OlaHsd * C57BL/6)
abnormal humoral immune response J:163261
immune system phenotype J:163261
increased IgG1 level J:163261
\Fcrlatm1b(KOMP)Wtsi/\Fcrlatm1b(KOMP)Wtsi
(C57BL/6N-Fcrlatm1b(KOMP)Wtsi/Ucd)
abnormal spleen morphology J:211773
enlarged spleen J:211773
\Fcrlbtm1Pdb/\Fcrlbtm1Pdb
(B6.129-Fcrlbtm1Pdb)
increased anti-nuclear antigen antibody level J:165408
increased IgG1 level J:165408
\Fdx2em1(IMPC)Rbrc/\Fdx2em1(IMPC)Rbrc
(C57BL/6NJcl-Fdx2em1(IMPC)Rbrc/Rbrc)
abnormal spleen morphology J:211773
enlarged spleen J:211773
increased large unstained cell number J:211773
increased spleen weight J:211773
\Fdxrtm1Xch/\Fdxr+
(B6.Cg-Fdxrtm1Xch)
chronic liver inflammation J:244082
increased T cell derived lymphoma incidence J:244082
\Fechm1Pas/\Fechm1Pas
(involves: 129/Sv * BALB/c)
increased spleen weight J:2021
\Fechm1Pas/\Fechtm1.1(FECH*)Emi
(involves: 129 * BALB/cJ * C57BL/6J)
decreased eosinophil cell number J:239515
enlarged spleen J:239515
\Fem1atm1Seno/\Fem1atm1Seno
(C57BL/6-Fem1atm1Seno)
increased susceptibility to colitis induced morbidity/mortality J:228893
increased susceptibility to induced colitis J:228893
\Fen1tm1Bhsh/\Fen1tm1Bhsh
(involves: 129S1/Sv)
pale spleen J:121378
\Fen1tm1Rak/\Fen1+
(involves: 129/Sv * C57BL/6 * SJL/J)
thymus atrophy J:77962
\Fen1tm2.1Bhsh/\Fen1tm2.1Bhsh
(involves: 129S1/Sv)
increased thymus tumor incidence J:218627
\Fen1tm2Klng/\Fen1tm2Klng
(involves: 129X1/SvJ * C57BL/6)
abnormal spleen B cell follicle morphology J:138901
abnormal spleen marginal zone morphology J:138901
enlarged spleen J:138901
immune system phenotype J:138901
increased spleen B cell follicle number J:138901
increased spleen B cell follicle size J:138901
lymphoid hyperplasia J:138901
\Fen1tm3.1Bhsh/\Fen1+
(Not Specified)
chronic inflammation J:231218
enlarged spleen J:231218
glomerulonephritis J:231218
increased anti-double stranded DNA antibody level J:231218
increased anti-nuclear antigen antibody level J:231218
increased plasma cell number J:231218
increased susceptibility to autoimmune disorder J:231218
interstitial pneumonia J:231218
lung inflammation J:231218
lymphoid hyperplasia J:231218
\Fen1tm3.1Bhsh/\Fen1tm3.1Bhsh
(Not Specified)
chronic inflammation J:231218
enlarged spleen J:231218
glomerulonephritis J:231218
increased anti-double stranded DNA antibody level J:231218
increased anti-nuclear antigen antibody level J:231218
increased plasma cell number J:231218
increased susceptibility to autoimmune disorder J:231218
interstitial pneumonia J:231218
lung inflammation J:231218
lymphoid hyperplasia J:231218
\Ferem1(IMPC)Tcp/\Fer+
(C57BL/6N-Ferem1(IMPC)Tcp/Tcp)
abnormal spleen morphology J:211773
increased spleen weight J:211773
\Ferem1(IMPC)Tcp/\Ferem1(IMPC)Tcp
(C57BL/6N-Ferem1(IMPC)Tcp/Tcp)
enlarged spleen J:211773
\Fermt1tm1Ref/\Fermt1tm1Ref
(involves: 129S1/Sv * 129X1/SvJ)
ileum inflammation J:142913
large intestinal inflammation J:142913
\Fermt3tm1.1Efp/\Fermt3tm1.1Efp
(involves: C57BL/6)
increased leukocyte cell number J:227094
\Fermt3tm2.1Ref/\Fermt3tm2.1Ref
\Tg(Cd4-cre)1Cwi/0

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2)
abnormal effector T cell morphology J:203436
abnormal T cell physiology J:203436
\Festm1Mcs/\Festm1Mcs
(involves: 129X1/SvJ)
abnormal leukocyte cell number J:64748
abnormal macrophage physiology J:64748
conjunctivitis J:64748
decreased B cell number J:64748
increased granulocyte number J:64748
increased monocyte cell number J:64748
increased neutrophil cell number J:64748
increased susceptibility to bacterial infection J:64748
thymus hypoplasia J:64748
\Festm2Pag/\Festm2Pag
(involves: 129S1/Sv * 129X1/SvJ * CD-1)
abnormal myelopoiesis J:98590
decreased B cell number J:98590
increased pre-B cell number J:98590
increased pro-B cell number J:98590
increased susceptibility to endotoxin shock J:98590
\Fezf2em1(IMPC)Hmgu/\Fezf2em1(IMPC)Hmgu
(C57BL/6NCrl-Fezf2em1(IMPC)Hmgu/Ieg)
increased leukocyte cell number J:211773
\Ffar2tm1Dgen/\Ffar2tm1Dgen
(involves: C57BL/6)
abnormal granulocyte physiology J:153951
abnormal neutrophil physiology J:153951
impaired neutrophil chemotaxis J:153951
impaired neutrophil phagocytosis J:153951
increased susceptibility to induced arthritis J:153951
increased susceptibility to induced colitis J:153951
increased T cell number J:153951
lung inflammation J:153951
\Ffar2tm2Lex/\Ffar2tm2Lex
(involves: 129S7/SvEvBrd * C57BL/6)
abnormal cytokine level J:157383
abnormal inflammatory response J:157383
abnormal neutrophil morphology J:157383
decreased circulating tumor necrosis factor level J:157383
decreased susceptibility to induced colitis J:157383
decreased tumor necrosis factor secretion J:157383
impaired neutrophil chemotaxis J:157383
increased circulating tumor necrosis factor level J:157383
large intestinal inflammation J:157383
sepsis J:157383
\Fgatm1Jld/\Fgatm1Jld
(involves: 129P2/OlaHsd * CF-1)
decreased circulating fibrinogen level J:28436
\Fgatm1Jld/\Fgatm1Jld
(B6.129P2-Fgatm1Jld)
decreased circulating fibrinogen level J:28436
\Fgatm1Jld/\Fgatm1Jld
\Plgtm1Jld/\Plgtm1Jld

(involves: 129P2/OlaHsd * Black Swiss * CF-1)
immune system phenotype J:36591
\Fgd1em1(IMPC)Tcp/\Fgd1+
(C57BL/6NCrl-Fgd1em1(IMPC)Tcp/Tcp)
enlarged thymus J:211773
\Fgd3em1(IMPC)Ccpcz/\Fgd3em1(IMPC)Ccpcz
(C57BL/6N-Fgd3em1(IMPC)Ccpcz/Ccpcz)
decreased leukocyte cell number J:211773
decreased lymphocyte cell number J:211773
\Fgd5em1(IMPC)Mbp/\Fgd5+
(C57BL/6NCrl-Fgd5em1(IMPC)Mbp/MbpMmucd)
abnormal spleen morphology J:211773
enlarged spleen J:211773
\Fgf3tm4b(EUCOMM)Hmgu/\Fgf3+
(C57BL/6N-Fgf3tm4b(EUCOMM)Hmgu/Bay)
enlarged lymph nodes J:211773
\Fgf7tm1Efu/\Fgf7tm1Efu
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
abnormal immune system physiology J:129368
abnormal response to transplant J:129368
immune system phenotype J:129368
spleen hypoplasia J:129368
\Fgf8tm1.3Mrt/\Fgf8tm1.4Mrt
\Tg(Tbx1-cre)1Joe/0

(involves: 129P2/OlaHsd)
abnormal thymus morphology J:88814
small thymus J:88814
\Fgf8tm1.4Mrt/\Fgf8+
\Tbx1tm1Bld/\Tbx1+

(involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6 * ICR)
thymus hypoplasia J:78686
\Fgf8tm1Mrc/\Fgf8tm1Moon
\Hoxa3tm1(cre)Moon/\Hoxa3+

(involves: 129/Sv * C57BL/6)
ectopic thymus J:87304
thymus hypoplasia J:87304
\Fgf8tm1Mrc/\Fgf8tm2Mrc
\Hoxa3tm1(cre)Moon/\Hoxa3+

(involves: 129/Sv * C57BL/6)
ectopic thymus J:87304
thymus hypoplasia J:87304
\Fgf10tm1b(EUCOMM)Wtsi/\Fgf10+
(C57BL/6N-Fgf10tm1b(EUCOMM)Wtsi/H)
decreased leukocyte cell number J:211773
\Fgf10tm1Ska/\Fgf10tm1Ska
(involves: C57BL/6 * CBA)
small thymus J:114183
\Fgf14em1(IMPC)Ccpcz/\Fgf14em1(IMPC)Ccpcz
(C57BL/6N-Fgf14em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
\Fgf20em1(IMPC)Ccpcz/\Fgf20em1(IMPC)Ccpcz
(C57BL/6NCrl-Fgf20em1(IMPC)Ccpcz/Ccpcz)
abnormal lymph node morphology J:211773
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged lymph nodes J:211773
enlarged spleen J:211773
enlarged thymus J:211773
\Fgf23em1(IMPC)Ccpcz/\Fgf23+
(C57BL/6NCrl-Fgf23em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
\Fgf23tm1Blan/\Fgf23tm1Blan
(involves: 129/Sv * C57BL/6)
small spleen J:121006
\Fgf23tm1Tyam/\Fgf23tm1Tyam
(involves: C57BL/6 * CBA)
decreased lymphocyte cell number J:88172
spleen hypoplasia J:88172
thymus atrophy J:88172
\Fgfbp3tm1.1(KOMP)Wtsi/\Fgfbp3tm1.1(KOMP)Wtsi
(C57BL/6N-Fgfbp3tm1.1(KOMP)Wtsi/Ucd)
increased neutrophil cell number J:211773
\Fgfr1Hspy/\Fgfr1+
(C3HeB/FeJ-Hspy)
increased susceptibility to otitis media J:95895
\Fgfr1tm1Upir/\Fgfr1tm1Upir
\Fgfr2tm1Dor/\Fgfr2tm1Dor
\Tg(KRT5-cre)5132Jlj/0

(involves: 129X1/SvJ * C57BL/6 * C57BL/6J * DBA/2J)
abnormal chemokine level J:221184
abnormal mast cell morphology J:221184
dermatitis J:221184
increased IgE level J:158802
increased IgG1 level J:158802
increased IgG2a level J:158802
increased mast cell number J:221184
skin inflammation J:158802, J:221184
\Fgfr2tm1Dor/\Fgfr2tm1.1Dor
\Twist2tm1(cre)Dor/\Twist2+

(involves: 129X1/SvJ)
abnormal osteoclast differentiation J:90391
\Fgfr2tm1Dsn/\Fgfr2tm1Dsn
\Tg(KRT5-cre)5132Jlj/0

(involves: 129P2/OlaHsd * C57BL/6J * DBA/2J)
adipose tissue inflammation J:119723
increased gamma-delta T cell number J:119723
skin inflammation J:119723
\Fgfr2tm1Ewj/\Fgfr2+
\Tg(EIIa-cre)C5379Lmgd/0

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * FVB/N)
abnormal thymus morphology J:101174
bronchiolectasis J:101174
decreased osteoclast cell number J:101174
\Fgfr2tm3Dsn/\Fgfr2tm3Dsn
(involves: 129P2/OlaHsd * C57BL/6)
abnormal thymus development J:67731
\Fgfr3tm1.1(FGFR3*)Ytc/\Fgfr3+
(involves: 129)
decreased osteoclast cell number J:287271
\Fgfr3tm1.1(FGFR3*)Ytc/\Fgfr3tm1.1(FGFR3*)Ytc
(involves: 129)
decreased osteoclast cell number J:287271
\Fgfr3tm1Led/\Fgfr3tm1Led
(involves: 129S6/SvEvTac)
increased osteoclast cell number J:32105
\Fgfr3tm2Llm/\Fgfr3+
\Tg(CMV-cre)1Ipc/?

(involves: 129S2/SvPas * C57BL/6 * SJL)
increased osteoclast cell number J:183772
\Fgfr3tm2Llm/\Fgfr3+
\Tg(Col2a1-cre)1Bhr/?

(involves: 129S2/SvPas * C57BL/6 * SJL)
increased osteoclast cell number J:183772
\Fgfr3tm3.1Cxd/\Fgfr3tm3.1Cxd
(involves: 129S6/SvEvTac)
abnormal osteoclast physiology J:69849
\Fgfr4M1Btlr/\Fgfr4M1Btlr
(C57BL/6J-Fgfr4M1Btlr)
decreased B-1a cell number J:265097
\Fggtm1Lord/\Fgg+
(involves: 129P2/OlaHsd * C57BL/6)
decreased circulating fibrinogen level J:129828
\Fggtm1Lord/\Fggtm1Lord
(involves: 129P2/OlaHsd * C57BL/6)
decreased circulating fibrinogen level J:129828
increased leukocyte cell number J:129828
\Fggtm2Jld/\Fggtm2Jld
(involves: 129P2/OlaHsd * Black Swiss * C57BL/6)
abnormal neutrophil physiology J:90908
increased susceptibility to bacterial infection J:90908
\Fgl1tm1b(EUCOMM)Hmgu/\Fgl1tm1b(EUCOMM)Hmgu
(involves: BALB/cJ * C57BL/6N)
decreased B cell number J:269578
dermatitis J:269578
increased anti-double stranded DNA antibody level J:269578
increased central memory CD8 positive, alpha-beta T cell number J:269578
\Fgl2tm1Pam/\Fgl2+
(involves: 129X1/SvJ * C57BL/6)
decreased susceptibility to Coronaviridae infection J:99453
\Fgl2tm1Pam/\Fgl2tm1Pam
(involves: 129X1/SvJ * C57BL/6)
decreased susceptibility to Coronaviridae infection J:99453
decreased susceptibility to Coronaviridae infection induced morbidity/mortality J:99453
\Fgl2tm1Pam/\Fgl2tm1Pam
(B6.129X1-Fgl2tm1Pam)
abnormal B cell physiology J:130895
abnormal dendritic cell physiology J:130895
abnormal Peyer's patch follicle morphology J:130895
abnormal regulatory T cell physiology J:130895
abnormal T cell physiology J:130895
decreased dendritic cell apoptosis J:130895
decreased Peyer's patch number J:130895
decreased susceptibility to Coronaviridae infection J:99453
decreased susceptibility to Coronaviridae infection induced morbidity/mortality J:99453
enlarged spleen J:130895
glomerulonephritis J:130895
increased dendritic cell number J:130895
increased IgA level J:130895
increased IgG level J:130895
increased IgM level J:130895
increased regulatory T cell number J:130895
increased T cell proliferation J:130895
\Fgl2tm1Pam/\Fgl2tm1Pam
(involves: 129X1/SvJ * C57BL/6J)
increased length of allograft survival J:98997
\Fgl2tm1Stsm/\Fgl2tm1Stsm
(C57BL/6-Fgl2tm1Stsm)
immune system phenotype J:88648
\FgrMhdaali18/\Fgr+
(C3HeB/FeJ-FgrMhdaali18)
dermatitis J:112868
increased inflammatory response J:112868
\FgrMhdaali18/\FgrMhdaali18
(C3HeB/FeJ-FgrMhdaali18)
autoimmune arthritis J:112868
dermatitis J:112868
\Fgrtm1Hev/\Fgrtm1Hev
(involves: 129S7/SvEvBrd * C57BL/6)
abnormal interferon-gamma secretion J:131738
\Fgrtm1Hev/\Fgrtm1Hev
(B6.129S7-Fgrtm1Hev)
abnormal inflammatory response J:113463
\Fgrtm1Hev/\Fgrtm1Hev
\Hcktm1Hev/\Hcktm1Hev

(involves: 129S7/SvEvBrd * C57BL/6J)
abnormal macrophage morphology J:59037
abnormal macrophage physiology J:59037
impaired macrophage phagocytosis J:16994
increased susceptibility to bacterial infection J:16994
\Fgrtm1Hev/\Fgrtm1Hev
\Hcktm1Hev/\Hcktm1Hev
\Lyntm1Sor/\Lyntm1Sor

(B6.Cg-Hcktm1Hev Fgrtm1Hev Lyntm1Sor)
abnormal inflammatory response J:113463
abnormal neutrophil physiology J:113463
\Fhip1bem1(IMPC)Tcp/\Fhip1bem1(IMPC)Tcp
(C57BL/6NCrl-Fhip1bem1(IMPC)Tcp/Tcp)
decreased lymphocyte cell number J:211773
increased neutrophil cell number J:211773
\Fhip2bem1(IMPC)Ccpcz/\Fhip2bem1(IMPC)Ccpcz
(C57BL/6N-Fhip2bem1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged spleen J:211773
enlarged thymus J:211773
\Fhip2bem1Wwan/\Fhip2bem1Wwan
(involves: C57BL/6)
abnormal cytokine level J:302658, J:285283
enlarged spleen J:285283
increased leukocyte cell number J:285283
increased susceptibility to induced colitis J:285283
liver inflammation J:302658
\Fhittm1Hbn/\Fhit+
(involves: 129X1/SvJ * C57BL/6)
decreased granulocyte number J:71303
increased susceptibility to infection J:71303
\Fhittm1Hbn/\Fhittm1Hbn
(involves: 129X1/SvJ * C57BL/6)
decreased granulocyte number J:71303
increased susceptibility to infection J:71303
\Fibcd1tm1Spte/\Fibcd1tm1Spte
(B6.129S1-Fibcd1tm1Spte)
abnormal interferon secretion J:340107
abnormal tumor necrosis factor level J:340107
decreased cytokine level J:340107
decreased lymphocyte cell number J:340107
decreased susceptibility to fungal infection J:340107
decreased susceptibility to infection induced morbidity/mortality J:340107
increased cytokine level J:340107
\Fig4plt1/\Fig4plt1
(involves: 129P2/OlaHsd * C3H * C57BL/6 * CAST/Ei * SJL)
spleen hypoplasia J:122737
\Fignfi/\Fignfi
(mixed)
conjunctivitis J:13035
eye inflammation J:13035
\Fis1tm1.1Itl/\Fis1tm1.1Itl
\Tg(Ckmm-cre)5Khn/0

(involves: C57BL/6NTac * FVB)
increased circulating interferon-beta level J:290485
increased circulating interleukin-6 level J:290485
increased circulating interleukin-12b level J:290485
increased circulating interleukin-13 level J:290485
\Fitm2tm1.1Dls/\Fitm2tm1.1Dls
\Tg(Fabp4-cre)1Rev/?

(involves: 129S6/SvEvTac * C57BL/6J)
increased circulating tumor necrosis factor level J:212437
\Fkbp4em1(IMPC)Mbp/\Fkbp4em1(IMPC)Mbp
(C57BL/6N-Fkbp4em1(IMPC)Mbp/MbpMmucd)
abnormal lymph node morphology J:211773
abnormal spleen morphology J:211773
enlarged lymph nodes J:211773
enlarged spleen J:211773
\Fkbp5tm1b(KOMP)Wtsi/\Fkbp5tm1b(KOMP)Wtsi
(C57BL/6N-Fkbp5tm1b(KOMP)Wtsi/MbpMmucd)
increased basophil cell number J:211773
increased neutrophil cell number J:211773
\Fkbp11em1(IMPC)Mbp/\Fkbp11em1(IMPC)Mbp
(C57BL/6N-Fkbp11em1(IMPC)Mbp/MbpMmucd)
abnormal lymph node morphology J:211773
abnormal spleen morphology J:211773
enlarged lymph nodes J:211773
small spleen J:211773
\Fkbp11Gt(OST298786)Lex/\Fkbp11Gt(OST298786)Lex
(involves: 129S5/SvEvBrd * C57BL/6J)
increased immunoglobulin level J:103485
increased inflammatory response J:103485
\Fkrptm1Scbr/\Fkrptm1Scbr
\Sox1tm1(cre)Take/\Sox1+

(involves: C57BL/6NCrlj * CBA/JNCrlj)
myositis J:207119
\Fkrptm1Scbr/\Fkrptm1Scbr
\Sox1tm1(cre)Take/\Sox1+
\Tg(CAG-LARGE)126Fmu/0

(involves: C57BL/6NCrlj * C57BL/10 * CBA/Ca * CBA/JNCrlj)
myositis J:207119
\Flcntm1Baba/\Flcntm1.1Lss
\Tg(CAG-cre/Esr1*)1Lbe/0

(involves: 129S1/Sv * 129X1/SvJ)
arrested B cell differentiation J:189078
decreased B cell number J:189078
\Flgft/\Flgft
(involves: C57BL/6)
skin inflammation J:151110
\Flgft/\Flgft
(B6.Cg-Flgft)
immune system phenotype J:202453, J:151110
increased IgE level J:202453, J:151110
increased IgG1 level J:151110
increased IgG2a level J:151110
increased IgG level J:151110
increased interferon-gamma secretion J:151110
increased interleukin-4 secretion J:151110
increased interleukin-5 secretion J:151110
increased interleukin-10 secretion J:151110
increased interleukin-13 secretion J:151110
increased interleukin-17 secretion J:151110
increased splenocyte proliferation J:151110
\Flgft/\Flgft
(Not Specified)
dermatitis J:198332
\Flgft/\Flgft
(STOCK a/a Tmem79ma Flgft/J)
abnormal cytokine level J:204304
dermatitis J:204304
\Flgft/\Flgft
\Tmem79ma/\Tmem79ma

(involves: CBA/CaGr)
blepharitis J:202453
increased IgE level J:202453
skin inflammation J:202453
\Flgtm1Amag/\Flgtm1Amag
(involves: 129S6/SvEvTac * BALB/c * C57BL/6NTac)
abnormal humoral immune response J:198332
dermatitis J:198332
increased IgE level J:198332
increased IgG1 level J:198332
increased inflammatory response J:229771
increased susceptibility to type IV hypersensitivity reaction J:198332
\Flgtm1Amag/\Flgtm1Amag
\Tg(CD207-Dta)312Dhka/0

(involves: 129S6/SvEvTac * BALB/c * C57BL/6NTac * FVB)
decreased inflammatory response J:229771
\Fli1tm1.1Dkw/\Fli1+
(B6.129S6-Fli1tm1.1Dkw)
decreased B cell number J:137876
\Fli1tm1.1Dkw/\Fli1tm1.1Dkw
(B6.129S6-Fli1tm1.1Dkw)
abnormal B cell differentiation J:137876
abnormal class switch recombination J:137876
abnormal humoral immune response J:137876
abnormal splenic cell ratio J:137876
decreased B cell number J:137876
decreased B cell proliferation J:137876
decreased follicular B cell number J:137876
decreased IgG1 level J:137876
decreased IgG3 level J:137876
increased marginal zone B cell number J:137876
increased transitional stage B cell number J:137876
spleen hyperplasia J:137876
\Fli1tm1Ber/\Fli1tm1Ber
(either: (involves: 129S1/Sv * 129X1/SvJ * C57BL/6) or (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CD-1))
decreased thymocyte number J:33052
\Fli1tm1Ber/\Fli1tm1Ber
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CD-1)
enlarged spleen J:33052
\Fli1tm1Morl/\Fli1tm1Morl
\Tg(Mx1-cre)1Cgn/0

(involves: 129/Sv * C57BL/6 * CBA)
abnormal leukocyte morphology J:167426
abnormal thrombopoiesis J:167426
decreased granulocyte number J:167426
increased monocyte cell number J:167426
increased NK cell number J:167426
\Flicrem1Doi/\Flicrem1Doi
(NOD/ShiLtDoi-Flicrem1Doi)
decreased susceptibility to autoimmune diabetes J:241346
insulitis J:241346
\Flnatm1.2Caw/\Flna+
(involves: 129S4/SvJae * C57BL/6)
increased leukocyte cell number J:118252
\Flnbtm1b(KOMP)Wtsi/\Flnb+
(C57BL/6N-Flnbtm1b(KOMP)Wtsi/H)
decreased neutrophil cell number J:211773
\Flot1tm1.1Arte/\Flot1tm1.1Arte
(involves: C57BL/6J)
abnormal leukocyte physiology J:166672
impaired neutrophil chemotaxis J:166672
impaired neutrophil recruitment J:166672
\Flt1tm1.1Fong/\Flt1tm1.1Fong
\Gt(ROSA)26Sortm1(cre/ERT2)Thl/\Gt(ROSA)26Sor+

(involves: 129S6/SvEvTac * C57BL/6NCr * CD-1)
increased macrophage cell number J:202202
\Flt1tm1Msh/\Flt1tm1Msh
(involves: 129S4/SvJae * C57BL/6J)
impaired macrophage chemotaxis J:49507
\Flt3em1(IMPC)Ccpcz/\Flt3em1(IMPC)Ccpcz
(C57BL/6NCrl-Flt3em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
decreased effector memory T-helper cell number J:211773
decreased NK cell number J:211773
\Flt3m1Btlr/\Flt3m1Btlr
(C57BL/6J-Flt3m1Btlr)
abnormal dendritic cell antigen presentation J:159599
abnormal dendritic cell physiology J:159599
abnormal macrophage physiology J:105543
abnormal NK cell physiology J:159599
decreased circulating interferon-alpha level J:159599
decreased circulating interferon-gamma level J:159599
decreased circulating interleukin-12 level J:159599
decreased dendritic cell number J:159599
decreased interferon-alpha secretion J:159599
decreased interferon-gamma secretion J:159599
decreased interleukin-12 secretion J:159599
decreased NK cell number J:159599
decreased plasmacytoid dendritic cell number J:159599
decreased splenocyte number J:159599
increased circulating interleukin-6 level J:159599
increased circulating tumor necrosis factor level J:159599
increased susceptibility to Herpesvirales infection J:105543
increased susceptibility to Herpesvirales infection induced morbidity/mortality J:159599
increased susceptibility to Riboviria infection J:105543
small lymph nodes J:159599
\Flt3tm1.1Dosm/\Flt3+
(B6.129(C)-Flt3tm1.1Dosm)
abnormal spleen morphology J:205200
arrested B cell differentiation J:205200
enlarged spleen J:205200
increased spleen white pulp amount J:205200
\Flt3tm1Dgg/\Flt3+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
abnormal B cell differentiation J:126003
decreased B cell number J:126003
decreased mature B cell number J:126003
decreased T cell number J:126003
enlarged spleen J:126003
increased granulocyte number J:126003
increased leukocyte cell number J:126003
increased monocyte cell number J:126003
increased spleen red pulp amount J:126003
increased spleen white pulp amount J:126003
\Flt3tm1Dgg/\Flt3+
\Kmt2atm1Clgr/\Kmt2a+

(involves: 129S1/Sv * 129X1/SvJ * BALB/c * C57BL/6J)
enlarged spleen J:189096
increased leukocyte cell number J:189096
\Flt3tm1Dgg/\Flt3tm1Dgg
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
abnormal B cell differentiation J:126003
decreased B cell number J:126003
decreased mature B cell number J:126003
decreased T cell number J:126003
enlarged spleen J:126003
increased granulocyte number J:126003
increased leukocyte cell number J:126003
increased monocyte cell number J:126003
increased spleen red pulp amount J:126003
increased spleen white pulp amount J:126003
\Flt3tm1Dgg/\Flt3tm1Dgg
\Kmt2atm1Clgr/\Kmt2a+

(involves: 129S1/Sv * 129X1/SvJ * BALB/c * C57BL/6J)
enlarged spleen J:189096
increased leukocyte cell number J:189096
\Flt3tm1Dosm/\Flt3+
\Tg(Mx1-cre)1Cgn/0

(B6.Cg-Flt3tm1Dosm Tg(Mx1-cre)1Cgn)
abnormal spleen white pulp morphology J:133528
arrested B cell differentiation J:133528
decreased B cell number J:133528
decreased leukocyte cell number J:133528
decreased lymphocyte cell number J:133528
decreased neutrophil cell number J:133528
decreased pre-B cell number J:133528
enlarged spleen J:133528
increased dendritic cell number J:133528
increased granulocyte number J:133528
increased leukocyte cell number J:133528
increased monocyte cell number J:133528
increased neutrophil cell number J:133528
increased pro-B cell number J:133528
intermingled spleen red and white pulp J:133528
\Flt3tm1Irl/\Flt3tm1Irl
(either: 129S/SvEv-Flt3tm1Irl or (involves: 129S/SvEv * C57BL/6J))
abnormal B cell differentiation J:27238, J:99149
decreased pre-B cell number J:27238
decreased pro-B cell number J:27238
\Flt3tm1Irl/\Flt3tm1Irl
\KitW/\KitW-v

(involves: 129S/SvEv * C57BL/6)
abnormal leukocyte morphology J:27238
abnormal myelopoiesis J:27238
abnormal T cell number J:27238
decreased B cell number J:27238
decreased double-negative T cell number J:27238
decreased double-positive T cell number J:27238
decreased lymphocyte cell number J:27238
decreased pre-B cell number J:27238
decreased pro-B cell number J:27238
thymus hypoplasia J:27238
\Flt3tm2.1Dosm/\Flt3+
(B6.129(C)-Flt3tm2.1Dosm)
abnormal B cell morphology J:205200
abnormal myelopoiesis J:205200
abnormal spleen morphology J:205200
enlarged spleen J:205200
increased leukocyte cell number J:205200
increased pre-pro B cell number J:205200
increased pro-B cell number J:205200
increased spleen white pulp amount J:205200
intermingled spleen red and white pulp J:205200
myeloid hyperplasia J:205200
\Flt3ltm1Imx/\Flt3ltm1Imx
(C57BL/6-Flt3ltm1Imx)
abnormal dendritic cell morphology J:62536, J:89868
abnormal immature B cell morphology J:62536
abnormal immune system cell morphology J:62536
abnormal immune system organ morphology J:62536
abnormal leukocyte morphology J:62536
decreased B cell number J:79569
decreased double-negative T cell number J:79569
decreased leukocyte cell number J:62536
decreased lymphocyte cell number J:62536
decreased myeloid dendritic cell number J:62536, J:89868
decreased NK cell number J:62536
decreased plasmacytoid dendritic cell number J:62536, J:89868
decreased pre-B cell number J:79569
decreased pro-B cell number J:79569, J:62536
impaired myelopoiesis J:62536
increased IgM level J:62536
increased length of allograft survival J:89868
increased neutrophil cell number J:62536
lymph node hypoplasia J:62536
spleen hypoplasia J:62536
\Flt3ltm1Imx/\Flt3ltm1Imx
(involves: C57BL/6)
abnormal dendritic cell antigen presentation J:223508
abnormal dendritic cell chemotaxis J:223508
abnormal memory T cell physiology J:189122
abnormal T-helper 1 physiology J:189122
decreased CD11b-high dendritic cell number J:223508
decreased CD103-positive CD11b-low dendritic cell number J:223508
decreased dendritic cell number J:189122
decreased macrophage cell number J:189122
decreased monocyte cell number J:189122
decreased NK cell number J:189122
decreased plasmacytoid dendritic cell number J:189122
increased neutrophil cell number J:189122
increased susceptibility to parasitic infection J:189122
\Flt4Chy/\Flt4+
(involves: C3H)
abnormal lymph circulation J:72387
abnormal lymphangiogenesis J:177405
abnormal lymphatic vessel morphology J:72387
\Flt4Chy/\Flt4Chy
(involves: C3H)
abnormal lymphangiogenesis J:177405
absent lymphatic vessels J:177405
\Flt4tm1.1Ichi/\Flt4+
\Krastm1Mok/\Kras+

(involves: 129S/SvEv * C57BL/6)
lymphatic vessel hypoplasia J:159024
\Flt4tm1.1Ichi/\Flt4+
\Krastm1Mok/\Kras+
\Tg(HRAS)2Jic/0

(involves: 129S/SvEv * BALB/c * C57BL/6 * DBA/2)
lymphatic vessel hypoplasia J:159024
\Flt4tm1.2Yhe/\Flt4tm1.2Yhe
(involves: 129/Sv * C57BL/6J * FVB/N)
abnormal lymphangiogenesis J:177405
absent lymphatic vessels J:177405
\Flt4tm1Ali/\Flt4+
\Nrp2tm1Ddg/\Nrp2+

(involves: C57BL/6)
abnormal lymphangiogenesis J:156869
\Flt4tm1Ali/\Flt4+
\Nrp2tm1Ddg/\Nrp2tm1Ddg

(involves: C57BL/6)
abnormal lymphangiogenesis J:156869
\Flt4tm1Ali/\Flt4+
\Tmem204tm1.1Ali/\Tmem204tm1.1Ali

(involves: BALB/c * C57BL/6)
abnormal lymphatic vessel smooth muscle morphology J:159519
enlarged lymphatic vessel J:159519
\Flt4tm1Ali/\Flt4tm2Ali
(involves: 129S1/Sv * 129X1/SvJ * ICR)
absent lymphatic vessels J:137909
\Flt4tm2Ali/\Flt4+
(involves: 129S1/Sv * 129X1/SvJ * ICR)
abnormal lymph circulation J:137909
abnormal lymphatic vessel morphology J:137909
\Flt4tm2Ali/\Flt4tm2Ali
(involves: 129S1/Sv * 129X1/SvJ * ICR)
absent lymphatic vessels J:137909
\Flvcr1tm1.1Jlab/\Flvcr1tm1.1Jlab
(involves: 129S4/SvJae * C57BL/6 * DBA/2)
abnormal spleen morphology J:132057
enlarged spleen J:132057
\Flvcr2tm1.2Tda/\Flvcr2tm1.2Tda
(involves: C57BL/6J)
brain inflammation J:287134
\Flvcr2tm1a(EUCOMM)Hmgu/\Flvcr2tm1a(EUCOMM)Hmgu
(C57BL/6N-Flvcr2tm1a(EUCOMM)Hmgu/Wtsi)
blood in lymph vessels J:239583
\fm/\fm
(involves: CBA/H)
abnormal lymph node morphology J:275
abnormal Peyer's patch morphology J:275
abnormal spleen morphology J:5417, J:275
abnormal thymus morphology J:275
\Fmnl1tm1.2Sdb/\Fmnl1tm1.2Sdb
\Lyz2tm1(cre)Ifo/\Lyz2tm1(cre)Ifo

(involves: C3H * C57BL/6 * FVB/N)
abnormal Kupffer cell morphology J:250144
abnormal macrophage morphology J:250144
abnormal macrophage physiology J:250144
decreased macrophage cell number J:250144
impaired macrophage chemotaxis J:250144
\Fmo1em1Anz/\Fmo1em1Anz
(involves: C57BL/6N)
increased cytokine level J:312983
\Fmo3em1(IMPC)Mbp/\Fmo3em1(IMPC)Mbp
(C57BL/6N-Fmo3em1(IMPC)Mbp/MbpMmucd)
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged lymph nodes J:211773
enlarged spleen J:211773
enlarged thymus J:211773
\Fmo5em1(IMPC)Mbp/\Fmo5em1(IMPC)Mbp
(C57BL/6N-Fmo5em1(IMPC)Mbp/MbpMmucd)
abnormal spleen morphology J:211773
enlarged spleen J:211773
\Fmodtm1Aol/\Fmodtm1Aol
(involves: 129S1/Sv * 129X1/SvJ * CD-1)
osteoarthritis J:79115
\Fmodtm1Aol/\Fmodtm1Aol
\Lumtm1Chak/\Lumtm1Chak

(involves: 129S1/Sv * 129X1/SvJ * CD-1)
osteoarthritis J:79115
\Fn1tm1Bwg/\Fn1tm1Bwg
(involves: 129S4/SvJae * C57BL/6)
immune system phenotype J:90917
\Fndc3aem1(IMPC)Tcp/\Fndc3aem1(IMPC)Tcp
(C57BL/6N-Fndc3aem1(IMPC)Tcp/Tcp)
increased leukocyte cell number J:211773
increased lymphocyte cell number J:211773
\Fndc4tm1.1Mabo/\Fndc4tm1.1Mabo
(involves: C57BL/6 * BALB/c)
increased susceptibility to induced colitis J:236896
\Fndc9tm1.1(KOMP)Vlcg/\Fndc9tm1.1(KOMP)Vlcg
(C57BL/6N-Fndc9tm1.1(KOMP)Vlcg/Ucd)
decreased lymphocyte cell number J:211773
increased neutrophil cell number J:211773
\Fnip1em1(IMPC)Ccpcz/\Fnip1+
(C57BL/6NCrl-Fnip1em1(IMPC)Ccpcz/Ccpcz)
abnormal thymus morphology J:211773
small thymus J:211773
\Fnip1em1(IMPC)Ccpcz/\Fnip1em1(IMPC)Ccpcz
(C57BL/6NCrl-Fnip1em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
decreased CD4-positive NK T cell number J:211773
decreased effector memory CD8-positive, alpha-beta T cell number J:211773
decreased effector memory T-helper cell number J:211773
decreased lymphocyte cell number J:211773
decreased memory-marker CD4-positive NK T cell number J:211773
decreased spleen weight J:211773
enlarged thymus J:211773
increased CD4-positive, alpha-beta T cell number J:211773
increased CD8-positive, alpha-beta T cell number J:211773
increased effector memory CD8-positive, alpha-beta T cell number J:211773
increased neutrophil cell number J:211773
increased T cell number J:211773
increased T-helper cell number J:211773
small spleen J:211773
\Fnip1Gt(RRM154)Byg/\Fnip1Gt(RRM154)Byg
(involves: 129P2/OlaHsd * C57BL/6J)
absent B cells J:189078
absent B-2 B cells J:189078
arrested B cell differentiation J:189078
decreased B cell number J:189078
decreased B-1 B cell number J:189078
decreased mature B cell number J:189078
decreased pre-B cell number J:189078
decreased transitional stage B cell number J:189078
increased B cell apoptosis J:189078
increased pro-B cell number J:189078
small spleen J:189078
\Fnip1Gt(RRM154)Byg/\Fnip1Gt(RRM154)Byg
\Ightm2Cgn/\Ightm2Cgn

(involves: 129P2/OlaHsd * C57BL/6 * FVB/N * SJL)
absent B cells J:189078
absent B-2 B cells J:189078
decreased B-1 B cell number J:189078
\Fnip1Gt(RRM154)Byg/\Fnip1Gt(RRM154)Byg
\Tg(BCL2)22Wehi/0

(involves: 129P2/OlaHsd * C57BL/6 * FVB/N * SJL)
increased B cell number J:189078
\Fnip1Gt(RRM154)Byg/\Fnip1Gt(RRM154)Byg
\Tg(IghelMD4)4Ccg/0

(involves: 129P2/OlaHsd * C57BL/6 * FVB/N * SJL)
absent B cells J:189078
absent B-2 B cells J:189078
decreased B-1 B cell number J:189078
increased immature B cell number J:189078
\Fnip1LPAB.1/\Fnip1LPAB.1
(C57BL/6J-Fnip1LPAB.1)
abnormal B cell physiology J:187318
absent B cells J:187318
arrested B cell differentiation J:187318
decreased B-1 B cell number J:187318
decreased IgE level J:187318
decreased IgG1 level J:187318
decreased IgG2a level J:187318
decreased IgG level J:187318
decreased IgM level J:187318
increased B cell apoptosis J:187318
\Fnip1LPAB.1/\Fnip1LPAB.1
\Tg(IghMyc)22Bri/0

(involves: C57BL * C57BL/6J * SJL)
increased B cell apoptosis J:187318
\Fnip1m1Btlr/\Fnip1m1Btlr
(C57BL/6J-Fnip1m1Btlr)
abnormal splenocyte morphology J:234285
absent B cells J:234285
decreased IgM level J:234285
decreased marginal zone B cell number J:234285
\Fnip1m2Btlr/\Fnip1m2Btlr
(C57BL/6J-Fnip1m2Btlr)
decreased B cell number J:265134
increased B-1 B cell number J:265134
increased CD4-positive, alpha-beta T cell number J:265134
increased single-positive T cell number J:265134
increased T cell number J:265134
\Fnip1M3Btlr/\Fnip1M3Btlr
(C57BL/6J-Fnip1M3Btlr)
abnormal B cell differentiation J:272802
\Fnip1tm1.2Baba/\Fnip1tm1.2Baba
(involves: C57BL/6 * C57BL/6J * FVB/N * SJL)
absent B cells J:189078
absent B-2 B cells J:189078
arrested B cell differentiation J:189078
decreased B cell number J:189078
decreased B-1 B cell number J:189078
decreased mature B cell number J:189078
decreased pre-B cell number J:189078
decreased transitional stage B cell number J:189078
increased B cell apoptosis J:189078
increased pro-B cell number J:189078
small spleen J:189078
\Fnip1tm1.2Baba/\Fnip1tm1.2Baba
\Ightm2Cgn/\Ightm2Cgn

(involves: 129P2/OlaHsd * C57BL/6 * FVB/N * SJL)
absent B cells J:189078
absent B-2 B cells J:189078
decreased B-1 B cell number J:189078
\Fnip1tm1.2Baba/\Fnip1tm1.2Baba
\Tg(BCL2)22Wehi/0

(involves: C57BL/6 * FVB/N * SJL)
increased B cell number J:189078
\Fnip1tm1.2Baba/\Fnip1tm1.2Baba
\Tg(IghelMD4)4Ccg/0

(involves: C57BL/6 * C57BL/6J * FVB/N * SJL)
absent B cells J:189078
absent B-2 B cells J:189078
decreased B-1 B cell number J:189078
increased immature B cell number J:189078
\Fntbtm1Bbd/\Fntbtm1.1Bbd
\Polr2atm1(cre/ERT2)Bbd/\Polr2atm1(cre/ERT2)Bbd

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CD-1 * SJL)
small spleen J:98944
\Fntbtm1Bbd/\Fntbtm1Bbd
\Polr2atm1(cre/ERT2)Bbd/\Polr2atm1(cre/ERT2)Bbd

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CD-1 * SJL)
small spleen J:98944
\Focadem1(IMPC)Bay/\Focad+
(C57BL/6N-Focadem1(IMPC)Bay/BayMmucd)
decreased spleen weight J:211773
\Fostm1Pa/\Fostm1Pa
(involves: 129X1/SvJ * C57BL/6J)
abnormal lymphopoiesis J:3233
\Fostm1Wag/\Fostm1Wag
(involves: 129S2/SvPas)
decreased osteoclast cell number J:65766
\Fostm1Wag/\Fostm1Wag
(involves: 129S2/SvPas * C57BL/6)
abnormal cytokine secretion J:118693
abnormal macrophage physiology J:118693
abnormal spleen morphology J:3493
abnormal spleen white pulp morphology J:3493
abnormal thymus size J:3493
decreased B cell number J:3493
decreased double-positive T cell number J:3493
decreased splenocyte number J:3493
decreased thymocyte number J:3493
increased macrophage apoptosis J:118693
increased macrophage cytokine production J:118693
increased susceptibility to bacterial infection J:118693
increased T cell number J:3493
\Fostm1Wag/\Fostm2(Fosl1)Wag
(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6)
decreased osteoclast cell number J:65766
\Fostm3.1Wag/\Fostm3.1Wag
(involves: 129P2/OlaHsd * C57BL/6 * SJL)
decreased interleukin-10 secretion J:175064
increased susceptibility to endotoxin shock J:175064
increased tumor necrosis factor secretion J:175064
\Fostm4.1Wag/\Fostm4.1Wag
(involves: 129P2/OlaHsd * C57BL/6 * SJL)
decreased interleukin-10 secretion J:175064
increased interleukin-6 secretion J:175064
increased susceptibility to endotoxin shock J:175064
increased tumor necrosis factor secretion J:175064
\Fostm5.1Wag/\Fostm5.1Wag
(involves: 129P2/OlaHsd * C57BL/6 * SJL)
abnormal osteoclast differentiation J:175064
decreased interleukin-10 secretion J:175064
decreased osteoclast cell number J:175064
increased circulating tumor necrosis factor level J:175064
increased interleukin-6 secretion J:175064
increased susceptibility to endotoxin shock J:175064
increased tumor necrosis factor secretion J:175064
\Fostm6.1Wag/\Fostm6.1Wag
(involves: 129P2/OlaHsd * C57BL/6 * SJL)
abnormal osteoclast differentiation J:175064
increased circulating interleukin-6 level J:175064
increased circulating interleukin-10 level J:175064
increased circulating tumor necrosis factor level J:175064
increased susceptibility to endotoxin shock J:175064
\Fostm7Wag/\Fostm7Wag
\Lyz2tm1(cre)Ifo/\Lyz2+

(involves: 129P2/OlaHsd * C57BL/6)
decreased interleukin-10 secretion J:175064
increased circulating interleukin-6 level J:175064
increased circulating interleukin-10 level J:175064
increased circulating tumor necrosis factor level J:175064
increased interleukin-6 secretion J:175064
increased susceptibility to endotoxin shock J:175064
increased tumor necrosis factor secretion J:175064
\Fostm7Wag/\Fostm7Wag
\Tg(Cd4-cre)1Cwi/0

(involves: 129P2/OlaHsd * C57BL/6 * DBA/2)
decreased CD4-positive, alpha-beta T cell number J:190150
\Fosl2tm2.1Wag/\Fosl2tm2.1Wag
(involves: 129P2/OlaHsd * C57BL/6)
abnormal osteoclast differentiation J:137646
abnormal osteoclast morphology J:137646
abnormal osteoclast physiology J:137646
increased osteoclast cell number J:137646
\Fosl2tm2Wag/\Fosl2tm2Wag
\Lyz2tm1(cre)Ifo/\Lyz2+

(involves: 129P2/OlaHsd * C57BL/6)
abnormal osteoclast differentiation J:137646
\Fosl2tm2Wag/\Fosl2tm2Wag
\Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0

(involves: 129P2/OlaHsd * C57BL/6 * CD-1)
abnormal osteoclast morphology J:211215
\Foxa1tm1(cre)Sew/\Foxa1+
\Mst1rtm1Sew/\Mst1rtm1Sew

(involves: 129P2/OlaHsd * CD-1 * NIH Black Swiss)
decreased susceptibility to bacterial infection J:105979
\Foxa2tm1.1Khk/\Foxa2+
(involves: 129P2/OlaHsd * C57BL/6 * CD-1)
respiratory system inflammation J:284174
\Foxa2tm1Khk/\Foxa2tm1Khk
\Tg(Scgb1a1-rtTA)1Jaw/0
\Tg(tetO-cre)1Jaw/0

(Not Specified)
immune system phenotype J:88601
\Foxa2tm1Khk/\Foxa2tm1Khk
\Tg(SFTPC-rtTA)5Jaw/0
\Tg(tetO-cre)1Jaw/0

(involves: 129 * 129P2/OlaHsd * C57BL/6)
increased macrophage cell number J:88601
increased neutrophil cell number J:88601
\Foxc2tm1.1Miu/\Foxc2tm1.1Miu
\Tg(Tek-cre)1Ywa/0

(involves: C57BL/6 * C57BL/6J * SJL)
abnormal lymphatic vessel morphology J:316530
\Foxc2tm1Miu/\Foxc2+
(involves: 129P2/OlaHsd * C57BL/6 * C57BL/6J)
abnormal lymph circulation J:83436
abnormal thoracic duct morphology J:83436
enlarged lymph nodes J:83436
increased lymph node number J:83436
lymphangiectasis J:83436
lymphatic vessel hyperplasia J:83436
\Foxf1em1Vvk/\Foxf1+
(involves: C57BL/6 * DBA/2)
lung inflammation J:296328
\Foxh1b2b2662Clo/\Foxh1b2b2662Clo
(C57BL/6J-Foxh1b2b2662Clo)
absent spleen J:175213
thymus hypoplasia J:175213
\Foxh1tm1Hmd/\Foxh1tm1.1Hmd
\Tg(Leftb-cre)1Hmd/0

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6Cr)
spleen hypoplasia J:82311
\Foxi3em3Akg/\Foxi3tm1.2Akg
(involves: 129X1/SvJ * C57BL/6)
athymia J:336768
\Foxj3tm1b(EUCOMM)Wtsi/\Foxj3+
(C57BL/6N-Foxj3tm1b(EUCOMM)Wtsi/Bay)
increased leukocyte cell number J:211773
\Foxm1tm1Rhc/\Foxm1tm1Rhc
\Tg(Tek-cre)1Ywa/0

(involves: 129X1/SvJ * C57BL/6 * SJL)
lung inflammation J:167773
\Foxn1nu-2J/\Foxn1nu-2J
(B6(SJL)-Foxn1nu-2J/GrsrJ)
athymia J:192383
\Foxn1nu-StL/\Foxn1nu-StL
(involves: C57BL/6)
absent T cells J:63313
athymia J:63313
\Foxn1nu-StL/\Foxn1tm1Tbo
(involves: 129S1/Sv * C57BL/6)
abnormal thymus development J:63313
athymia J:63313
\Foxn1nu-str/\Foxn1nu-str
(AKR/J-Foxn1nu-str/J)
abnormal humoral immune response J:30715
abnormal immune system cell morphology J:30715
abnormal immune system morphology J:24755
abnormal immune system organ morphology J:30715
abnormal immune system physiology J:30715
abnormal Peyer's patch germinal center morphology J:30715
abnormal Peyer's patch morphology J:30715
athymia J:24755
decreased immunoglobulin level J:30715
decreased lymphocyte cell number J:30715
decreased T cell number J:30715
increased eosinophil cell number J:30715
increased granulocyte number J:30715
increased length of allograft survival J:30715
increased neutrophil cell number J:30715
lymph node hypoplasia J:30715
spleen hypoplasia J:30715
\Foxn1nu-Y/\Foxn1nu-Y
(101/HY-Foxn1nu-Y)
abnormal thymus development J:4060
absent T cells J:4060
athymia J:4060, J:29022
\Foxn1nu/\Foxn1+
(C.Cg-Foxn1nu)
small thymus J:7330
\Foxn1nu/\Foxn1+
(involves: BALB/c)
blepharitis J:12543
increased incidence of corneal inflammation J:12543
increased susceptibility to Herpesvirales infection J:12543
\Foxn1nu/\Foxn1+
(NFS.Cg-Foxn1nu)
abnormal thymus morphology J:7330
small thymus J:7330
\Foxn1nu/\Foxn1+
(B6N.Cg-Foxn1nu)
small thymus J:7330
\Foxn1nu/\Foxn1+
(C3N.Cg-Foxn1nu)
small thymus J:7330
\Foxn1nu/\Foxn1nu
(involves: NMRI)
abnormal thymus development J:6363
\Foxn1nu/\Foxn1nu
(Not Specified)
abnormal lymph node T cell domain morphology J:202296
abnormal Peyer's patch germinal center morphology J:202296
abnormal spleen morphology J:202296
abnormal splenic cell ratio J:202296
abnormal thymus morphology J:202297
athymia J:202296, J:5059
decreased leukocyte cell number J:5059
small spleen J:202296
\Foxn1nu/\Foxn1nu
(B6NTac.Cg-Foxn1nu/Tac)
decreased susceptibility to parasitic infection J:64283
\Foxn1nu/\Foxn1nu
(involves: BALB/c)
abnormal circulating cytokine level J:50903
blepharitis J:12543
decreased circulating interleukin-2 level J:50903
decreased circulating interleukin-6 level J:50903
decreased circulating tumor necrosis factor level J:50903
decreased interferon-gamma secretion J:50903
decreased susceptibility to bacterial infection J:50903
increased susceptibility to Herpesvirales infection J:12543
increased susceptibility to Herpesvirales infection induced morbidity/mortality J:12543
\Foxn1nu/\Foxn1nu
(involves: C57BL/10Sn * C57BR/cd)
abnormal thymus development J:7898
\Foxn1nu/\Foxn1nu
(involves: CD-1)
athymia J:106251
\Foxn1nu/\Foxn1nu
(involves: CBA)
abnormal lymph node morphology J:202808
abnormal spleen physiology J:202299
abnormal T cell activation J:202299
decreased leukocyte cell number J:202299
decreased lymphocyte cell number J:202299
decreased T cell number J:202808
increased length of allograft survival J:202299
\Foxn1nu/\Foxn1nu
\Fv4r/\Fv4r

(involves: BALB/c)
decreased susceptibility to Retroviridae infection J:5714, J:5684
\Foxn1nu/\Foxn1nu
\Map3k14aly/\Map3k14aly

(involves: BALB/cAJcl * C57BL/6J)
absent B cells J:96579
absent lymph nodes J:96579
absent Peyer's patches J:96579
athymia J:96579
decreased gamma-delta intraepithelial T cell number J:96579
decreased T cell number J:96579
\Foxn1nu/\Foxn1nu
\Tg(Foxn1)E1Hon/0

(involves: CD-1)
athymia J:33866
\Foxn1nu/\Foxn1nu
\Tgfb1tm1Doe/\Tgfb1tm1Doe

(involves: 129S2/SvPas * BALB/c * CF-1)
abnormal T cell physiology J:99033
decreased inflammatory response J:99033
\Foxn1nu/\Foxn1tm1.1Dmsu
\Tg(CAG-cre/Esr1*)5Amc/0

(involves: 129/Sv * C57BL/6 * CBA * SJL)
abnormal thymus epithelium morphology J:159773
decreased thymocyte number J:159773
increased thymocyte apoptosis J:159773
\Foxn1sepe/\Foxn1sepe
(BALB/c-Foxn1sepe)
athymia J:227974
\Foxn1tm1.1(KOMP)Vlcg/\Foxn1tm1.1(KOMP)Vlcg
(C57BL/6N-Foxn1tm1.1(KOMP)Vlcg/Tcp)
abnormal thymus morphology J:211773
athymia J:211773
\Foxn1tm1.1Cbln/\Foxn1+
(involves: 129P2/OlaHsd * C57BL/6)
thymus hyperplasia J:177992
\Foxn1tm1.1Cbln/\Foxn1+
\Tg(Zp3-cre)3Mrt/?

(involves: 129P2/OlaHsd * 129S1/Sv * C57BL/6 * FVB/N)
immune system phenotype J:177992
\Foxn1tm1.1Cbln/\Foxn1tm1.1Cbln
(involves: 129P2/OlaHsd * C57BL/6)
abnormal lymphocyte cell number J:177992
decreased single-positive T cell number J:177992
increased DN1 thymic pro-T cell number J:177992
increased double-positive T cell number J:177992
thymus hypoplasia J:177992
\Foxn1tm1.1Cbln/\Foxn1tm1Tbo
(involves: 129P2/OlaHsd * 129S1/Sv * C57BL/6)
absent T cells J:177992
small thymus J:177992
\Foxn1tm1.1Cbln/\Foxn1tm1Tbo
\Gt(ROSA)26Sortm2(cre/ERT2)Brn/\Gt(ROSA)26Sor+

(involves: 129P2/OlaHsd * 129S1/Sv * C57BL/6)
immune system phenotype J:177992
\Foxn1tm1.1Dmsu/\Foxn1tm1.1Dmsu
\Tg(CAG-cre/Esr1*)5Amc/0

(involves: 129/Sv * C57BL/6 * CBA * SJL)
abnormal thymus morphology J:159773
decreased double-positive T cell number J:159773
decreased thymocyte number J:159773
small thymus J:159773
thymus atrophy J:159773
\Foxn1tm1.1Dmsu/\Foxn1tm1.1Dmsu
\Tg(KRT5-cre/ERT2)2Ipc/0

(involves: 129/Sv * C57BL/6 * SJL)
abnormal thymus corticomedullary boundary morphology J:159773
abnormal thymus medulla morphology J:159773
decreased thymocyte number J:159773
small thymus J:159773
thymus atrophy J:159773
\Foxn1tm1.1Dmsu/\Foxn1tm1.1Dmsu
\Tg(KRT18-cre/ERT2)1Rgo/0

(involves: 129/Sv * C57BL/6 * FVB/N * SJL)
immune system phenotype J:159773
\Foxn1tm1Dmsu/\Foxn1tm1Dmsu
(involves: 129/Sv * C57BL/6)
athymia J:159773
\Foxn1tm1Nrm/\Foxn1tm1Nrm
(involves: 129X1/SvJ * C57BL/6J)
abnormal CD4-positive, alpha beta T cell morphology J:86255
abnormal CD8-positive, alpha beta T cell morphology J:86255
abnormal T cell differentiation J:86255
abnormal thymus development J:86255
abnormal thymus epithelium morphology J:86255
absent thymus cortex J:86255
absent thymus medulla J:86255
decreased CD4-positive, alpha-beta T cell number J:86255
decreased double-negative T cell number J:86255
decreased double-positive T cell number J:86255
decreased T cell number J:86255
decreased thymocyte number J:86255
small thymus J:86255
thymus cyst J:86255
\Foxn1tm1Tbo/\Foxn1tm1Tbo
(involves: 129S1/Sv)
abnormal leukocyte cell number J:33796
abnormal thymus development J:33796
abnormal thymus epithelium morphology J:177992
abnormal thymus morphology J:33796
absent T cells J:33796
athymia J:33796
increased B cell number J:33796
\Foxn1tm2Nrm/\Foxn1tm2Nrm
(either: (involves: 129/Sv) or (involves: C57BL/6))
immune system phenotype J:125817
\Foxn1tm2Tbo/\Foxn1tm2Tbo
\Tg(KRT14-cre/ERT2)1Ipc/0

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
increased T cell number J:110046
\Foxn1tm3(cre)Nrm/\Foxn1+
\Gt(ROSA)26Sortm1(Tbx1)Rche/\Gt(ROSA)26Sor+

(involves: C57BL/6 * C57BL/6NHsd)
abnormal thymus development J:214094
abnormal thymus epithelium morphology J:214094
decreased thymocyte number J:214094
thymus hypoplasia J:214094
\Foxn1tm3(cre)Nrm/\Foxn1+
\Mir205hgtm1Oers/\Mir205hgtm1Oers

(B6(Cg)-Mir205hgtm1Oers Foxn1tm3(cre)Nrm)
decreased thymocyte number J:278363
decreased thymus weight J:278363
thymus hypoplasia J:278363
\Foxn1tm3(cre)Nrm/\Foxn1tm3(cre)Nrm
(either: (involves: 129/Sv) or (involves: C57BL/6))
immune system phenotype J:125817
\Foxn4em1(IMPC)Ccpcz/\Foxn4+
(C57BL/6NCrl-Foxn4em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
increased CD4-positive, CD25-positive, alpha-beta regulatory T cell number J:211773
\Foxo1tm1.1Rdp/\Foxo1+
\Igh-Jtm1Cgn/\Ightm4Cgn
\Tg(Cr2-cre)3Cgn/0

(involves: 129P2/OlaHsd * 129S1/Sv)
increased B cell number J:157297
\Foxo1tm1.1Stlp/\Foxo1tm1.1Stlp
\Tg(Lck-cre)1Cwi/0

(involves: 129S4/SvJae)
abnormal single-positive T cell number J:154205
decreased CD8-positive, alpha-beta T cell number J:154205
decreased double-positive T cell number J:154205
decreased T cell number J:154205
decreased T cell proliferation J:154205
decreased thymocyte apoptosis J:154205
increased CD4-positive, alpha-beta T cell number J:154205
increased CD8-positive, alpha-beta T cell number J:154205
small lymphoid organs J:154205
small spleen J:154205
\Foxo1tm1Flv/\Foxo1tm1Flv
\Foxp3tm4(YFP/icre)Ayr/\Foxp3+

(involves: 129S1/Sv * 129S6/SvEvTac * 129X1/SvJ)
abnormal inflammatory response J:189962
abnormal regulatory T cell physiology J:189962
enlarged lymph nodes J:189962
enlarged spleen J:189962
increased CD4-positive, alpha-beta T cell number J:189962
increased CD8-positive, alpha-beta T cell number J:189962
increased interferon-gamma secretion J:189962
increased regulatory T cell number J:189962
increased T cell number J:189962
increased T cell proliferation J:189962
\Foxo1tm1Flv/\Foxo1tm1Flv
\Gt(ROSA)26Sortm1(CAG-FOXO1,GFP)Moli/\Gt(ROSA)26Sor+
\Foxp3tm4(YFP/icre)Ayr/\Foxp3+

(involves: 129S1/Sv * 129S6/SvEvTac * 129X1/SvJ * C57BL/6)
immune system phenotype J:189962
\Foxo1tm1Flv/\Foxo1tm1Flv
\Ifngtm1Ts/\Ifngtm1Ts
\Foxp3tm4(YFP/icre)Ayr/\Foxp3+

(involves: 129S1/Sv * 129S6/SvEvTac * 129S7/SvEvBrd * 129X1/SvJ)
immune system phenotype J:189962
increased CD4-positive, alpha-beta T cell number J:189962
increased CD8-positive, alpha-beta T cell number J:189962
\Foxo1tm1Flv/\Foxo1tm1Flv
\Ndor1Tg(UBC-cre/ERT2)1Ejb/0

(involves: 129S/SvEv * 129S6/SvEvTac * C57BL/6)
increased interferon-gamma secretion J:189962
\Foxo1tm1Flv/\Foxo1tm1Flv
\Rag1tm1Mom/\Rag1tm1Mom
\Tg(CD2-Il7r)1Asin/?
\Tg(Cd4-cre)1Cwi/?
\Tg(TcraTcrb)425Cbn/?

(involves: 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6 * DBA/2)
decreased T cell number J:147057
\Foxo1tm1Flv/\Foxo1tm1Flv
\Rag1tm1Mom/\Rag1tm1Mom
\Tg(Cd4-cre)1Cwi/?
\Tg(TcraTcrb)425Cbn/?

(involves: 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6 * DBA/2)
decreased T cell number J:147057
\Foxo1tm1Flv/\Foxo1tm1Flv
\Tg(Cd4-cre)1Cwi/?

(involves: 129S6/SvEvTac * C57BL/6 * DBA/2)
abnormal CD4-positive, alpha-beta T cell physiology J:147057
abnormal CD8-positive, alpha-beta T cell physiology J:147057
abnormal T cell activation J:147057
abnormal T cell physiology J:147057
enlarged lymph nodes J:147057
increased anti-double stranded DNA antibody level J:147057
increased anti-nuclear antigen antibody level J:147057
increased single-positive T cell number J:147057
increased susceptibility to induced colitis J:147057
increased T cell proliferation J:147057
\Foxo1tm1Rdp/\Foxo1tm1.1Rdp
\Igh-Jtm1Cgn/\Ightm4Cgn
\Tg(Cr2-cre)3Cgn/0

(involves: 129P2/OlaHsd * 129S1/Sv)
absent marginal zone B cells J:157297
increased B cell number J:157297
\Foxo1tm1Rdp/\Foxo1tm1Rdp
\Foxo3tm1Rdp/\Foxo3tm1Rdp
\Foxo4tm1Rdp/\Foxo4tm1Rdp
\Tg(Mx1-cre)1Cgn/0

(involves: 129S6/SvEvTac * C57BL/6 * CBA * FVB/N)
increased T cell derived lymphoma incidence J:118179
\Foxo1tm2.1Dac/\Foxo1tm2.1Dac
(B6.Cg-Foxo1tm2.1Dac)
decreased circulating tumor necrosis factor level J:179687
\Foxo3Gt(XAO26)Byg/\Foxo3Gt(XAO26)Byg
(involves: 129P2/OlaHsd)
abnormal immune system organ morphology J:93593
abnormal T cell activation J:93593
abnormal T cell physiology J:93593
enlarged lymph nodes J:93593
enlarged spleen J:93593
increased inflammatory response J:93593
increased T cell proliferation J:93593
kidney inflammation J:93593
lung inflammation J:93593
lymphoid hyperplasia J:93593
salivary gland inflammation J:93593
spleen hyperplasia J:93593
\Foxo3tm1.1Rdp/\Foxo3tm1.1Rdp
(involves: 129S6/SvEvTac * FVB/N)
dermatitis J:118179
\Foxo3tm1Nmt/\Foxo3tm1Nmt
(B6.Cg-Foxo3tm1Nmt)
abnormal NK cell morphology J:123409
increased NK cell number J:123409
\Foxo6tm1(KOMP)Vlcg/\Foxo6tm1(KOMP)Vlcg
(B6J.B6NTac-Foxo6tm1(KOMP)Vlcg)
abnormal Kupffer cell morphology J:236585
impaired macrophage chemotaxis J:236585
\Foxp1tm1.1Pwt/\Foxp1tm1.1Pwt
\Tg(Cd4-cre)1Cwi/0

(involves: 129 * C57BL/6 * DBA/2)
abnormal T cell activation J:156832
decreased CD4-positive, alpha-beta T cell number J:156832
decreased CD8-positive, alpha-beta T cell number J:156832
immune system phenotype J:156832
increased T cell apoptosis J:156832
\Foxp1tm1Rao/\Foxp1tm1Rao
(B6.129-Foxp1tm1Rao)
abnormal B cell differentiation J:112644
abnormal B cell physiology J:112644
arrested B cell differentiation J:112644
decreased mature B cell number J:112644
\Foxp2tm2.2Woen/\Foxp2+
(involves: C57BL/6 * C57BL/6J)
increased CD4-positive, alpha-beta T cell number J:150425
increased CD8-positive, alpha-beta T cell number J:150425
\Foxp3sf/Y
(either: 129Rl.Cg-Foxp3sf or (involves: 101/Rl * C3Hf/Rl * STOCK MR))
abnormal B cell physiology J:11262
abnormal lymph node B cell domain morphology J:11262
abnormal lymph node medullary cord morphology J:11262
abnormal lymph node morphology J:11262
abnormal lymph node T cell domain morphology J:11262
abnormal lymphocyte morphology J:11262
abnormal macrophage morphology J:11262
abnormal spleen morphology J:11262
abnormal spleen white pulp morphology J:11262
abnormal thymus cortex morphology J:11262
abnormal thymus morphology J:11262
absent spleen marginal zone J:11262
blepharitis J:11262
decreased spleen B cell follicle number J:11262
dermatitis J:11262
enlarged lymph nodes J:11262
increased IgG level J:11262
increased IgM level J:11262
increased inflammatory response J:11262
increased leukocyte cell number J:11262
increased spleen red pulp amount J:11262
increased spleen weight J:11262
liver inflammation J:11262
small thymus J:11262
\Foxp3sf/Y
(involves: 101/H * C3H/HeH * STOCK MR)
abnormal spleen morphology J:10398
conjunctivitis J:10398
increased leukocyte cell number J:10398
increased spleen red pulp amount J:10398
increased spleen weight J:10398
increased spleen white pulp amount J:10398
intermingled spleen red and white pulp J:10398
\Foxp3sf/?
(Not Specified)
liver inflammation J:138808
lung inflammation J:138808
\Foxp3sf/Y
(B6.Cg-Foxp3sf)
abnormal CD4-positive, alpha beta T cell morphology J:82560
abnormal CD4-positive, alpha-beta T cell physiology J:82560
decreased CD4-positive, CD25-positive, alpha-beta regulatory T cell number J:82560
\Foxp3sf/Y
(B6.Cg-Foxp3sf/J)
lung inflammation J:125129
salivary gland inflammation J:125129
skin inflammation J:125129
\Foxp3sf\Otcspf/Y
(involves: 129/Rl)
enlarged lymph nodes J:20865
enlarged spleen J:20865
increased CD4-positive, alpha-beta T cell number J:20865
\Foxp3sf/\Foxp3sf
\Tg(Rorc-EGFP)1Ebe/?

(involves: C57BL/6)
abnormal effector T cell morphology J:137020
\Foxp3tm1(CD2/CD52)Shori/\Foxp3tm1(CD2/CD52)Shori
(involves: C57BL/6)
decreased regulatory T cell number J:171378
increased susceptibility to type IV hypersensitivity reaction J:171378
\Foxp3tm1(cre)Saka/Y
(involves: BALB/c)
increased autoantibody level J:140085
stomach inflammation J:140085
\Foxp3tm1.1Ayr/Y
(involves: 129S1/Sv * 129X1/SvJ)
abnormal CD4-positive, alpha beta T cell morphology J:82560
abnormal CD4-positive, CD25-positive, alpha-beta regulatory T cell morphology J:82560
enlarged lymph nodes J:82560
enlarged spleen J:82560
increased susceptibility to autoimmune disorder J:82560
skin inflammation J:82560
\Foxp3tm1.1Ayr/Y
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
dermatitis J:117743
enlarged spleen J:117743
increased susceptibility to autoimmune disorder J:117743
liver inflammation J:117743
lung inflammation J:117743
lymph node inflammation J:117743
\Foxp3tm1.1Ayr/Y
\Rag1tm1Mom/\Rag1tm1Mom
\Tg(TcraTcrb)425Cbn/0

(Not Specified)
immune system phenotype J:97029
\Foxp3tm1.1Ayr/\Foxp3tm1.1Ayr
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
abnormal T cell differentiation J:125405
decreased double-positive T cell number J:125405
dermatitis J:117743
enlarged spleen J:117743
increased susceptibility to autoimmune disorder J:117743
liver inflammation J:117743
lung inflammation J:117743
lymph node inflammation J:117743
thymus hypoplasia J:125405
\Foxp3tm1.1Ayr/\Foxp3tm1.1Ayr
\Mir146tm1.1Bal/\Mir146tm1.1Bal

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
abnormal lymphocyte physiology J:167922
blepharitis J:167922
conjunctivitis J:167922
decreased interferon-gamma secretion J:167922
dermatitis J:167922
increased regulatory T cell number J:167922
\Foxp3tm1.1Mal/\Foxp3tm1.1Mal
\Lattm1.1Mal/\Lattm1.1Mal

(involves: 129S2/SvPas * C57BL/6)
abnormal regulatory T cell physiology J:131351
decreased regulatory T cell number J:131351
thymus hypoplasia J:131351
\Foxp3tm1Ayr/Y
\Tg(Cd4-cre)1Cwi/0

(involves: C57BL/6 * DBA/2)
dermatitis J:97029
enlarged lymph nodes J:97029
enlarged spleen J:97029
increased susceptibility to autoimmune disorder J:97029
\Foxp3tm1Ayr/\Foxp3tm1Ayr
\Foxn1tm3(cre)Nrm/\Foxn1+

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
immune system phenotype J:125405
\Foxp3tm1Ayr/\Foxp3tm1Ayr
\Tg(Cd4-cre)1Cwi/?

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2)
abnormal T cell differentiation J:125405
decreased double-positive T cell number J:125405
thymus hypoplasia J:125405
\Foxp3tm1Flv/\Foxp3+
\B9d2/Tgfb1tm1Flv/\Tgfb1tm2Flv
\Tg(Cd4-cre)1Cwi/?

(involves: 129S6/SvEvTac * C57BL/6 * DBA/2)
increased regulatory T cell number J:123547
\Foxp3tm1Kuch/?
\Il6tm1Kopf/\Il6tm1Kopf

(involves: 129S2/SvPas * C57BL/6)
abnormal CD4-positive T cell differentiation J:123352
decreased circulating interleukin-6 level J:123352
decreased interleukin-17 secretion J:123352
decreased susceptibility to experimental autoimmune encephalomyelitis J:123352
increased regulatory T cell number J:123352
\Foxp3tm1Tch/Y
(C.129X1-Foxp3tm1Tch)
abnormal chemokine level J:117165
abnormal cytokine secretion J:117165
abnormal inflammatory response J:117165
abnormal lymphocyte physiology J:117165
absent regulatory T cells J:117165
dermatitis J:117165
enlarged spleen J:117165
increased activated T cell number J:117165
increased CD4-positive, alpha-beta T cell number J:117165
increased CD8-positive, alpha-beta T cell number J:117165
increased circulating interferon-gamma level J:117165
increased circulating interleukin-4 level J:117165
increased circulating interleukin-5 level J:117165
increased circulating interleukin-6 level J:117165
increased circulating interleukin-10 level J:117165
increased circulating tumor necrosis factor level J:117165
increased eosinophil cell number J:117165
increased IgE level J:117165
increased IgG1 level J:117165
increased leukocyte cell number J:117165
increased lymphocyte cell number J:117165
increased monocyte cell number J:117165
respiratory system inflammation J:117165
\Foxp3tm1Tch/Y
(B6.129X1-Foxp3tm1Tch)
abnormal inflammatory response J:117165
dermatitis J:117165
increased eosinophil cell number J:117165
increased IgE level J:117165
increased leukocyte cell number J:117165
increased lymphocyte cell number J:117165
increased monocyte cell number J:117165
respiratory system inflammation J:117165
\Foxp3tm1Tch/Y
\Stat6tm1Gru/\Stat6tm1Gru

(C.129-Stat6tm1Gru Foxp3tm1Tch)
abnormal cytokine secretion J:117165
immune system phenotype J:117165
increased circulating interferon-gamma level J:117165
increased eosinophil cell number J:117165
\Foxp3tm2.1(EGFP/cre)Shori/Y
(involves: 129 * C57BL/6)
decreased regulatory T cell number J:234397
\Foxp3tm2.1(EGFP/cre)Shori/Y
\Pdcd1tm1Hon/\Pdcd1tm1Hon

(involves: 129 * 129S2/SvPas * C57BL/6)
enlarged lymph nodes J:234397
enlarged spleen J:234397
increased effector memory T-helper cell number J:234397
increased susceptibility to autoimmune disorder J:234397
lymph node hyperplasia J:234397
pancreas inflammation J:234397
spleen hyperplasia J:234397
\Foxp3tm2Ayr/Y
(involves: 129S1/Sv * 129X1/SvJ)
immune system phenotype J:97029
\Foxp3tm2Ayr/?
\Zap70rps/\Zap70rps

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
abnormal CD4-positive, alpha beta T cell morphology J:211510
abnormal double-positive T cell morphology J:211510
abnormal regulatory T cell number J:211510
abnormal T cell differentiation J:211510
decreased CD4-positive, alpha-beta T cell number J:211510
decreased CD8-positive, alpha-beta T cell number J:211510
immune system phenotype J:211510
\Foxp3tm2Ayr/\Foxp3+
\Rnf128tm1Cdon/\Rnf128tm1Cdon

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
abnormal regulatory T cell physiology J:160681
\Foxp3tm2Ayr/\Foxp3tm2Ayr
(involves: 129S1/Sv * 129X1/SvJ)
immune system phenotype J:97029
\Foxp3tm2Flv/Y
(involves: C57BL/6)
abnormal CD4-positive, alpha-beta T cell physiology J:118631
abnormal CD8-positive, alpha-beta T cell physiology J:118631
abnormal immune system physiology J:118631
blepharitis J:118631
enlarged lymph nodes J:118631
enlarged spleen J:118631
increased autoantibody level J:118631
\Foxp3tm2Tch/Y
(C.129X1-Foxp3tm2Tch)
immune system phenotype J:120713
\Foxp3tm2Tch/\Foxp3+
(C.129X1-Foxp3tm2Tch)
immune system phenotype J:120713
\Foxp3tm3(HBEGF/GFP)Ayr/\Foxp3+
\Gpr174tm1Cys/\Gpr174+

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)
decreased susceptibility to experimental autoimmune encephalomyelitis J:222307
\Foxp3tm3(HBEGF/GFP)Ayr/\Foxp3tm3(HBEGF/GFP)Ayr
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
abnormal CD4-positive, alpha-beta T cell physiology J:117743
abnormal dendritic cell physiology J:117743
conjunctivitis J:117743
decreased T cell number J:117743
dermatitis J:117743
enlarged spleen J:117743
increased dendritic cell number J:117743
increased susceptibility to autoimmune disorder J:117743
liver inflammation J:117743
lung inflammation J:117743
lymph node inflammation J:117743
\Foxp3tm3Tch/Y
(C.129X1-Foxp3tm3Tch)
abnormal CD4-positive, alpha beta T cell morphology J:120636
abnormal CD4-positive, alpha-beta T cell physiology J:120636
abnormal cytokine secretion J:120636
abnormal immune system organ morphology J:120636
abnormal lymphocyte physiology J:120636
abnormal regulatory T cell physiology J:120636
abnormal T cell subpopulation ratio J:120636
colitis J:120636
enlarged lymph nodes J:120636
enlarged spleen J:120636
increased T cell proliferation J:120636
thymus hypoplasia J:120636
\Foxp3tm3Tch/\Foxp3+
(C.129X1-Foxp3tm3Tch)
abnormal CD4-positive, alpha-beta T cell physiology J:120636
decreased T cell number J:120636
decreased thymocyte number J:120636
increased T cell apoptosis J:120636
\Foxp3tm4(YFP/icre)Ayr/Y
\Zfp91tm1Smoc/\Zfp91tm1Smoc

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
abnormal regulatory T cell physiology J:306129
decreased regulatory T cell number J:306129
increased CD8-positive, alpha-beta T cell number J:306129
increased susceptibility to autoimmune disorder J:306129
increased susceptibility to induced colitis J:306129
\Foxp3tm4(YFP/icre)Ayr/\Foxp3+
\Nr4a2tm1.1Pcn/\Nr4a2tm1.1Pcn

(involves: 129S1/Sv * 129X1/SvJ)
abnormal regulatory T cell morphology J:205658
abnormal regulatory T cell physiology J:205658
\Foxp3tm4(YFP/icre)Ayr/\Foxp3tm4(YFP/icre)Ayr
\Ikzf4tm1Djr/\Ikzf4tm1Djr

(involves: 129S1/Sv * 129X1/SvJ)
chronic inflammation J:294549
decreased regulatory T cell number J:294549
enlarged lymph nodes J:294549
enlarged spleen J:294549
glomerulonephritis J:294549
granulomatous inflammation J:294549
increased germinal center B cell number J:294549
increased immunoglobulin level J:294549
increased spleen B cell follicle number J:294549
increased spleen germinal center number J:294549
increased susceptibility to experimental autoimmune encephalomyelitis J:294549
increased T cell number J:294549
increased T follicular helper cell number J:294549
small intestinal inflammation J:294549
\Foxp3tm5.2Ayr/\Foxp3tm5.2Ayr
(involves: 129S1/Sv * 129S4/SvJaeSor * 129X1/SvJ)
abnormal gut-associated lymphoid tissue morphology J:156942
abnormal intraepithelial T cell morphology J:156942
abnormal mesenteric lymph node morphology J:156942
abnormal Peyer's patch morphology J:156942
abnormal T cell differentiation J:156942
decreased regulatory T cell number J:156942
increased T cell number J:156942
\Foxp3tm6.2Ayr/\Foxp3tm6.2Ayr
(involves: 129S1/Sv * 129S4/SvJaeSor * 129X1/SvJ)
decreased regulatory T cell number J:156942
\Foxp3tm7.2Ayr/\Foxp3+
(involves: 129S1/Sv * 129S4/SvJaeSor * 129X1/SvJ)
decreased regulatory T cell number J:156942
\Foxp3tm7.2Ayr/\Foxp3tm7.2Ayr
(involves: 129S1/Sv * 129S4/SvJaeSor * 129X1/SvJ)
abnormal regulatory T cell morphology J:156942
decreased regulatory T cell number J:156942
\Foxp3tm8Ayr/Y
(B6.129-Foxp3tm8Ayr)
autoimmune response J:157377
\Foxp3tm9(EGFP/cre/ERT2)Ayr/\Foxp3+
\Il1r2tm1.1Epi/\Il1r2tm1.1Epi

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * C57BL/6NTac)
abnormal adaptive immunity J:347877
abnormal alpha-beta T cell number J:347877
increased CD4-positive, alpha-beta T cell number J:347877
increased IgG level J:347877
increased spleen germinal center size J:347877
increased T follicular helper cell number J:347877
\Foxq1sa-e1/\Foxq1sa-e1
(involves: 101/Rl * C3H/Rl)
abnormal lymphocyte cell number J:75422
\Foxq1sa/\Foxq1sa
(involves: 101/Rl * C3H/Rl)
impaired natural killer cell mediated cytotoxicity J:7649
\Foxq1sa/\Foxq1sa
\Lystbg/\Lystbg

(involves: 101/Rl * C3H/Rl * C57BL/6J * C57BL10/Rl)
enlarged lymph nodes J:5311
increased susceptibility to infection J:5311
interstitial pneumonia J:15166, J:5311
\Foxq1sa/\Foxq1sa
\Lystbg/\Lystbg

(involves: 101/Rl * C3H/Rl * C57BL10/Rl)
enlarged spleen J:5311
interstitial pneumonia J:5311
lung inflammation J:5311
\Foxr1em1(IMPC)Tcp/\Foxr1+
(C57BL/6NCrl-Foxr1em1(IMPC)Tcp/Tcp)
enlarged lymph nodes J:211773
small spleen J:211773
\Foxr1em1(IMPC)Tcp/\Foxr1em1(IMPC)Tcp
(C57BL/6NCrl-Foxr1em1(IMPC)Tcp/Tcp)
abnormal spleen morphology J:211773
enlarged lymph nodes J:211773
\Foxred1em1(IMPC)Bay/\Foxred1+
(C57BL/6N-Foxred1em1(IMPC)Bay/Bay)
increased spleen weight J:211773
\Fpr1tm1Gao/\Fpr1tm1Gao
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
abnormal innate immunity J:53354
impaired neutrophil chemotaxis J:53354
increased susceptibility to bacterial infection J:53354
increased susceptibility to bacterial infection induced morbidity/mortality J:53354
\Fpr2tm1.1Jimw/\Fpr2tm1.1Jimw
\Lyz2tm1(cre)Ifo/\Lyz2+

(involves: 129P2/OlaHsd * 129X1/SvJ)
decreased susceptibility to induced colitis J:197568
\Fpr2tm1.2Jimw/\Fpr2tm1.2Jimw
(B6.129X1-Fpr2tm1.2Jimw)
abnormal cytokine secretion J:160074
abnormal dendritic cell physiology J:160074
abnormal innate immunity J:160074
decreased dendritic cell number J:160074
decreased IgE level J:160074
decreased IgG1 level J:160074
decreased IgG2b level J:160074
decreased immunoglobulin level J:160074
decreased inflammatory response J:160074
decreased interferon-gamma secretion J:160074
decreased interleukin-2 secretion J:160074
decreased interleukin-4 secretion J:160074
decreased interleukin-5 secretion J:160074
decreased interleukin-13 secretion J:160074
impaired macrophage chemotaxis J:160074
impaired neutrophil chemotaxis J:160074
small lymph nodes J:160074
\Fpr2tm1.2Jimw/\Fpr2tm1.2Jimw
(involves: 129X1/SvJ)
abnormal dendritic cell chemotaxis J:199611
abnormal dendritic cell physiology J:199611
colitis J:197568
decreased acute inflammation J:197568
decreased dendritic cell number J:199611
\Fpr2tm1Rjf/\Fpr2tm1Rjf
(involves: 129S/SvEv * C57BL/6)
abnormal neutrophil physiology J:159658
impaired macrophage chemotaxis J:159658
increased acute inflammation J:159658
increased susceptibility to induced arthritis J:159658
\fpw/\fpw
(involves: C3H/HeJ * C57BL/6J)
decreased circulating interferon-gamma level J:151726
decreased circulating interleukin-1 alpha level J:151726
decreased circulating interleukin-6 level J:151726
increased circulating interleukin-10 level J:151726
increased circulating tumor necrosis factor level J:151726
\Fras1em1(IMPC)Ccpcz/\Fras1+
(C57BL/6NCrl-Fras1em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
\Frmd3em1(IMPC)J/\Frmd3em1(IMPC)J
(C57BL/6NJ-Frmd3em1(IMPC)J/Mmjax)
decreased leukocyte cell number J:211773
\Frmd8em2Smoc/\Frmd8em2Smoc
\Tg(Vil1-cre)997Gum/0

(involves: C57BL/6J * SJL)
increased spleen weight J:338904
increased susceptibility to colitis induced morbidity/mortality J:338904
increased susceptibility to induced colitis J:338904
\FrylGt(Ayu21-T312)Imeg/\FrylGt(Ayu21-T312)Imeg
(B6J.Cg-FrylGt(Ayu21-T312)Imeg)
kidney inflammation J:260667
\Fscn1Gt(OST124903)Lex/\Fscn1Gt(OST124903)Lex
(B6.129S5-Fscn1Gt(OST124903)Lex)
abnormal dendritic cell chemotaxis J:169408
abnormal dendritic cell physiology J:169408
abnormal Langerhans cell physiology J:169408
\Fsd2em1(IMPC)Mbp/\Fsd2em1(IMPC)Mbp
(C57BL/6N-Fsd2em1(IMPC)Mbp/Ucd)
abnormal lymph node morphology J:211773
abnormal spleen morphology J:211773
enlarged lymph nodes J:211773
enlarged spleen J:211773
\Fshrtm1Saco/\Fshrtm1Saco
(involves: 129)
enlarged spleen J:70933
increased pre-B cell number J:65577
\Fstl1tm1b(EUCOMM)Hmgu/\Fstl1tm1b(EUCOMM)Hmgu
(C57BL/6N-Fstl1tm1b(EUCOMM)Hmgu/H)
decreased neutrophil cell number J:211773
increased lymphocyte cell number J:211773
\Fth1tm1.1Lck/\Fth1tm1.1Lck
\Tg(Mx1-cre)1Cgn/0

(B6.Cg-Fth1tm1.1Lck Tg(Mx1-cre)1Cgn)
decreased spleen iron level J:166515
liver inflammation J:166515
\Ftl1tm1.1Ruvi/\Ftl1tm1.1Ruvi
(involves: 129 * C57BL/6)
abnormal mononuclear phagocyte morphology J:244236
\Ftotm1.2Pzg/\Ftotm1.2Pzg
(involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6)
dermatitis J:166984
\Ftotm1.3Pzg/\Ftotm1.3Pzg
(involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6)
dermatitis J:166984
\Fts/\Fts+
(involves: C57BL/6 * SJL)
thymus hyperplasia J:20159
\Fts/\Fts+
(B6.Cg-Fts)
abnormal CD4-positive T cell differentiation J:108193
abnormal T cell morphology J:108193
abnormal T cell physiology J:108193
increased thymocyte number J:108193
thymus hyperplasia J:108193
\Fubp1em1(IMPC)Mbp/\Fubp1+
(C57BL/6N-Fubp1em1(IMPC)Mbp/Ucd)
abnormal lymph node morphology J:211773
enlarged lymph nodes J:211773
\Fubp1tm1.1Dlev/\Fubp1tm1.1Dlev
(involves: 129 * C57BL/6)
decreased B cell number J:229985
lymphoid hypoplasia J:229985
spleen hypoplasia J:229985
thymus hypoplasia J:229985
\Fundc2tm1Qim/\Fundc2tm1Qim
(involves: C57BL/6)
immune system phenotype J:301633
\Furintm1Jwmc/\Furintm1Jwmc
\Tg(Cd4-cre)1Cwi/0

(involves: 129P2/OlaHsd * C57BL/6 * SJL)
abnormal regulatory T cell physiology J:204761
\FusGt(U3NeoSV1)HO14Ggh/\FusGt(U3NeoSV1)HO14Ggh
(B6.129S2-FusGt(U3NeoSV1)HO14Ggh)
abnormal immunoglobulin level J:60213
decreased B cell number J:60213
decreased lymphocyte cell number J:60213
lymphoid hypoplasia J:60213
small thymus J:60213
\Fut2tm1Sdo/\Fut2tm1Sdo
(B6.129X1-Fut2tm1Sdo)
increased susceptibility to fungal infection J:90993
\Fut4tm1Jbl/\Fut4tm1Jbl
(B6.129S2-Fut4tm1Jbl)
impaired leukocyte tethering or rolling J:79397
increased eosinophil cell number J:79397
increased granulocyte number J:79397
increased monocyte cell number J:79397
increased neutrophil cell number J:79397
\Fut4tm1Jbl/\Fut4tm1Jbl
\Fut7tm1Jbl/\Fut7tm1Jbl

(B6.129S2-Fut7tm1Jbl Fut4tm1Jbl)
abnormal immune system organ morphology J:79397
abnormal leukocyte migration J:79397
abnormal leukocyte physiology J:79397
abnormal lymph node primary follicle morphology J:79397
abnormal neutrophil physiology J:79397
decreased susceptibility to bacterial infection J:115682
decreased susceptibility to type IV hypersensitivity reaction J:79388
impaired leukocyte tethering or rolling J:79397
increased leukocyte cell number J:79397
increased neutrophil cell number J:79397
lymph node hypoplasia J:79388, J:79397
small lymph nodes J:79397
\Fut7tm1Brs/\Fut7tm1Brs
(involves: 129 * C57BL/6)
immune system phenotype J:64232
\Fut7tm1Jbl/\Fut7tm1Jbl
(involves: 129S2/SvPas * C57BL/6J * DBA/2J)
abnormal granulocyte physiology J:35023
abnormal immune system physiology J:35023
abnormal leukocyte adhesion J:35023
abnormal leukocyte migration J:35023
abnormal leukocyte physiology J:35023
abnormal leukocyte tethering or rolling J:35023
abnormal lymph node primary follicle morphology J:35023
impaired neutrophil recruitment J:35023
\Fut7tm1Jbl/\Fut7tm1Jbl
(B6.129S2-Fut7tm1Jbl)
decreased susceptibility to type IV hypersensitivity reaction J:79388, J:74776
impaired neutrophil recruitment J:79397
\Fut8em1(IMPC)Wtsi/\Fut8em1(IMPC)Wtsi
(C57BL/6N-Fut8em1(IMPC)Wtsi/Wtsi)
blood in lymph vessels J:239583
\Fv4r/\Fv4+
(involves: AKR/J * BALB/c * FRG)
decreased susceptibility to Retroviridae infection J:5714, J:5684
\Fxntm1Mkn/\Fxntm1Mkn
\Tg(FXN)YG8Pook/0

(involves: 129/Sv * C57BL/6 * CBA)
brain inflammation J:216422
\Fxntm1Mkn/\Fxntm1Pand
(involves: 129/Sv * C57BL/6)
brain inflammation J:216422
\Fxr1tm1Dln/\Fxr1tm1Dln
(involves: 129P2/OlaHsd * C57BL/6)
small spleen J:91191
\Fyb1tm1Gak/\Fyb1tm1Gak
(B6.129-Fyb1tm1Gak)
immune system phenotype J:112087
\Fyb1tm1Gak/\Fyb1tm1Gak
(involves: 129S1/Sv * 129X1/SvJ)
abnormal leukocyte adhesion J:111368
abnormal T cell physiology J:126545
decreased interleukin-2 secretion J:111368, J:126545
decreased T cell proliferation J:111368, J:126545
decreased thymocyte number J:111368
\Fyntm1Rmp/\Fyntm1Rmp
(involves: 129S2/SvPas * C57BL/6)
abnormal T cell activation J:70886
abnormal thymocyte activation J:70886
decreased T cell proliferation J:70886
\Fyntm1Rmp/\Fyntm1Rmp
(involves: 129S2/SvPas)
decreased gamma-delta T cell number J:37062
decreased T cell number J:37062
\Fyntm1Rmp/\Fyntm1Rmp
(B6.129S2-Fyntm1Rmp)
abnormal eosinophil physiology J:114287
abnormal interleukin-4 secretion J:114287
decreased IgE level J:114287
decreased interleukin-2 secretion J:114287
increased interleukin-5 secretion J:114287
increased susceptibility to type I hypersensitivity reaction J:114287
\Fyntm1Rmp/\Fyntm1Rmp
\Lcktm1Mak/\Lcktm1Mak

(involves: 129S2/SvPas)
abnormal alpha-beta intraepithelial T cell morphology J:112977
abnormal NK T cell number J:37940
absent CD4-positive, alpha-beta T cells J:37940
absent CD8-positive, alpha-beta T cells J:37940
absent T cells J:37062
arrested T cell differentiation J:37062, J:37940
decreased double-positive T cell number J:37940
decreased gamma-delta intraepithelial T cell number J:112977, J:37940
thymus hypoplasia J:37062, J:37940
\Fyntm1Sor/\Fyntm1Sor
(either: 129S7/SvEvBrd-Fyntm1Sor or (involves: 129S7/SvEvBrd * C57BL/6J))
abnormal immune cell physiology J:2242
abnormal T cell clonal deletion J:2242
abnormal T cell physiology J:2242
abnormal thymocyte activation J:2242
decreased interleukin-2 secretion J:2242
decreased T cell proliferation J:2242
increased IgG2a level J:2242
increased IgM level J:2242
\Fyntm1Sor/\Fyntm1Sor
(B6.129S7-Fyntm1Sor)
abnormal CD4-positive, alpha-beta T cell physiology J:93886
abnormal NK cell physiology J:187430
abnormal T cell proliferation J:93886
decreased IgE level J:93886
decreased interferon-gamma secretion J:187430
\Fyntm1Sor/\Fyntm1Sor
(involves: 129S7/SvEvBrd)
abnormal chemokine level J:80658
abnormal macrophage physiology J:80658
\Fyntm1Sor/\Fyntm1Sor
\Lcktm1Litt/\Lcktm1.1Litt
\Tnfrsf4tm2(cre)Nik/\Tnfrsf4+

(involves: 129S7/SvEvBrd * 129X1/SvJ)
abnormal regulatory T cell physiology J:152472
decreased regulatory T cell number J:152472
decreased T cell proliferation J:152472
enlarged lymph nodes J:152472
increased regulatory T cell number J:152472
increased T cell number J:152472
\Fyntm1Sor/\Fyntm1Sor
\Yes1tm1Sor/\Yes1tm1Sor

(involves: 129S7/SvEvBrd)
enlarged spleen J:20346
increased spleen white pulp amount J:20346
myeloid hyperplasia J:20346
\Fyntm1Yik/\Fyntm1Yik
(involves: C57BL/6 * CBA)
abnormal cytokine secretion J:99347
abnormal interleukin secretion J:99347
increased susceptibility to experimental autoimmune uveoretinitis J:99347
increased tumor necrosis factor secretion J:99347
\Fyntm1Yik/\Fyntm1Yik
\Ptk2tm1Lfr/\Ptk2+

(involves: 129X1/SvJ * C57BL/6 * CBA)
abnormal T cell differentiation J:110771
decreased double-positive T cell number J:110771
decreased thymocyte number J:110771
thymus cortex atrophy J:110771
\Fzd1em1(IMPC)Mbp/\Fzd1em1(IMPC)Mbp
(C57BL/6N-Fzd1em1(IMPC)Mbp/MbpMmucd)
increased eosinophil cell number J:211773
increased leukocyte cell number J:211773
increased lymphocyte cell number J:211773
increased monocyte cell number J:211773
\Fzd9tm1Uta/\Fzd9tm1Uta
(involves: 129S6/SvEvTac * 129X1/SvJ)
abnormal lymph node medullary cord morphology J:98133
abnormal lymph node morphology J:98133
abnormal spleen marginal zone morphology J:98133
abnormal spleen red pulp morphology J:98133
decreased B cell number J:98133
decreased pre-B cell number J:98133
decreased pro-B cell number J:98133
enlarged lymph nodes J:98133
enlarged spleen J:98133
increased eosinophil cell number J:98133
increased leukocyte cell number J:98133
increased monocyte cell number J:98133
increased neutrophil cell number J:98133
thymus atrophy J:98133
\G2e3em1(IMPC)Tcp/\G2e3em1(IMPC)Tcp
(C57BL/6NCrl-G2e3em1(IMPC)Tcp/Tcp)
abnormal spleen morphology J:211773
\G6pc2tm1.1Pesa/\G6pc2tm1.1Pesa
(NOD.129S2-G6pc2tm1.1Pesa)
abnormal CD8-positive, alpha beta T cell morphology J:160286
abnormal CD8-positive, alpha-beta T cell physiology J:160286
decreased interferon-gamma secretion J:160286
decreased T cell proliferation J:160286
immune system phenotype J:160286
\G6pc3tm1Jyc/\G6pc3tm1Jyc
(involves: 129S4/SvJae * C57BL/6)
abnormal neutrophil physiology J:120741
decreased neutrophil cell number J:120741
impaired granulocyte bactericidal activity J:120741
increased granulocyte number J:120741
increased susceptibility to bacterial infection J:120741
\G6pd2em1(IMPC)Tcp/\G6pd2em1(IMPC)Tcp
(C57BL/6NCrl-G6pd2em1(IMPC)Tcp/Tcp)
enlarged lymph nodes J:211773
\Gab2tm1Gsf/\Gab2tm1Gsf
(involves: BALB/c)
abnormal response to infection J:122213
decreased susceptibility to Retroviridae infection J:122429
\Gab2tm1Hhg/\Gab2tm1Hhg
(involves: 129S4/SvJae)
decreased mast cell degranulation J:70424
decreased mast cell number J:70424
decreased susceptibility to type I hypersensitivity reaction J:70424
immune system phenotype J:70424
\Gab2tm1Pngr/\Gab2tm1Pngr
(B6.Cg-Gab2tm1Pngr)
abnormal osteoclast differentiation J:97515
abnormal osteoclast morphology J:97515
decreased osteoclast cell number J:97515
\Gab2tm1Thir/\Gab2tm1Thir
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
abnormal mast cell differentiation J:75092
abnormal mast cell physiology J:75092
decreased mast cell number J:75092
\Gab2tm2.1Thir/\Gab2tm2.1Thir
(involves: 129T/SvJcl * C57BL/6Jcl)
immune system phenotype J:178045
\Gab2tm3.1Thir/\Gab2tm3.1Thir
(involves: 129T/SvJcl * C57BL/6Jcl)
decreased mast cell degranulation J:178045
decreased mast cell number J:178045
decreased susceptibility to type I hypersensitivity reaction J:178045
immune system phenotype J:178045
\Gab2tm4.1Thir/\Gab2tm4.1Thir
(involves: 129T/SvJcl * C57BL/6Jcl)
decreased mast cell degranulation J:178045
decreased mast cell number J:178045
decreased susceptibility to type I hypersensitivity reaction J:178045
immune system phenotype J:178045
\Gab3em1Khoe/\Gab3em1Khoe
(C57BL/6-Gab3em1Khoe)
abnormal mature NK cell morphology J:291290
abnormal NK cell physiology J:291290
abnormal uterine NK cell morphology J:291290
decreased NK cell number J:291290
immune system phenotype J:291290
\Gab3m1Khoe/\Gab3m1Khoe
(C57BL/6-Gab3m1Khoe)
abnormal mature NK cell morphology J:291290
abnormal NK cell physiology J:291290
abnormal uterine NK cell morphology J:291290
decreased NK cell number J:291290
immune system phenotype J:291290
\Gabarapl2tm1b(EUCOMM)Hmgu/\Gabarapl2+
(C57BL/6N-Gabarapl2tm1b(EUCOMM)Hmgu/H)
decreased lymphocyte cell number J:211773
increased monocyte cell number J:211773
increased neutrophil cell number J:211773
\GabpaGt(XH074)Byg/\GabpaGt(XH074)Byg
(involves: 129P2/OlaHsd * C57BL/6)
decreased thymocyte number J:92671
small thymus J:92671
\Gabpb1tm1Hhx/\Gabpb1tm1Hhx
(involves: 129 * C57BL/6)
immune system phenotype J:137300
\Gabpb2Gt(RRJ488)Byg/\Gabpb2Gt(RRJ488)Byg
(involves: 129P2/OlaHsd)
increased B cell proliferation J:141846
increased IgG1 level J:141846
increased IgM level J:141846
increased spleen germinal center number J:141846
\Gabra5em1(IMPC)Ccpcz/\Gabra5em1(IMPC)Ccpcz
(C57BL/6N-Gabra5em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged thymus J:211773
small spleen J:211773
\Gabrb3tm2.1Geh/\Gabrb3tm2.1Geh
\Tg(Cd4-cre)1Cwi/0

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2)
abnormal CD4-positive T cell differentiation J:333883
abnormal CD4-positive, CD25-positive, alpha-beta regulatory T cell morphology J:333883
abnormal T-helper 17 cell differentiation J:333883
immune system phenotype J:333883
increased susceptibility to experimental autoimmune encephalomyelitis J:333883
\Gabrg1em1(IMPC)Ccpcz/\Gabrg1em1(IMPC)Ccpcz
(C57BL/6NCrl-Gabrg1em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
small spleen J:211773
\Gad2tm1Miya/\Gad2tm1Miya
(NOD.129P2-Gad2tm1Miya)
pancreas inflammation J:88785
\Gadd45atm1Ajf/\Gadd45atm1Ajf
(either: (involves: 129P2/OlaHsd * C57BL/6) or (involves: 129X1/SvJ * C57BL/6))
abnormal lymphopoiesis J:76041
decreased basophil cell number J:76041
decreased eosinophil cell number J:76041
decreased leukocyte cell number J:76041
decreased lymphocyte cell number J:76041
glomerulonephritis J:76041
increased anti-double stranded DNA antibody level J:76041
increased anti-histone antibody level J:76041
increased anti-single stranded DNA antibody level J:76041
increased autoantibody level J:76041
increased IgG1 level J:76041
increased IgM level J:76041
increased inflammatory response J:76041
increased T cell number J:76041
increased T cell proliferation J:76041
increased thymocyte number J:57882
increased thymus weight J:57882
\Gadd45btm1Flv/\Gadd45btm1Flv
(involves: 129S6/SvEvTac)
abnormal CD4-positive, alpha-beta T cell physiology J:87396
abnormal dendritic cell physiology J:87396
abnormal T-helper 1 cell differentiation J:87396
abnormal T-helper 1 physiology J:87396
abnormal T-helper 2 physiology J:87396
decreased interferon-gamma secretion J:87396
decreased interleukin-2 secretion J:87396
decreased interleukin-4 secretion J:87396
decreased interleukin-6 secretion J:87396
decreased interleukin-12 secretion J:87396
\Gadd45btm1Flv/\Gadd45btm1Flv
(B6.129S6-Gadd45btm1Flv)
abnormal T-helper 1 physiology J:118837
glomerulonephritis J:118837
increased interferon-gamma secretion J:118837
increased susceptibility to experimental autoimmune encephalomyelitis J:118837
increased T cell proliferation J:118837
spleen hyperplasia J:118837
\Gadd45btm1Flv/\Gadd45btm1Flv
\Gadd45gtm1Flv/\Gadd45gtm1Flv

(involves: 129S1/Sv * 129S6/SvEvTac)
abnormal T-helper 1 cell differentiation J:87396
\Gadd45btm1Flv/\Gadd45btm1Flv
\Gadd45gtm1Flv/\Gadd45gtm1Flv

(involves: 129S1/Sv * 129S6/SvEvTac * C57BL/6)
glomerulonephritis J:118837
increased anti-double stranded DNA antibody level J:118837
increased anti-histone antibody level J:118837
increased IgG1 level J:118837
increased IgM level J:118837
increased mature B cell number J:118837
increased memory T cell number J:118837
spleen hyperplasia J:118837
\Gadd45gtm1Flv/\Gadd45gtm1Flv
(involves: 129S1/Sv)
abnormal NK cell physiology J:87396
abnormal T-helper 1 cell differentiation J:87396
abnormal T-helper 1 physiology J:69475
abnormal type IV hypersensitivity reaction J:69475
decreased interferon-gamma secretion J:87396, J:69475
\Gadd45gtm1Jni/\Gadd45gtm1Jni
(involves: 129P2/OlaHsd)
immune system phenotype J:68832
\Gakem1(IMPC)Ccpcz/\Gak+
(C57BL/6NCrl-Gakem1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged spleen J:211773
enlarged thymus J:211773
\Galctm1Wngr/\Galctm1Wngr
(involves: 129S2/SvPas)
abnormal immune system physiology J:78691
\Galctwi-5J/\Galctwi-5J
(BXD32/TyJ-Galctwi-5J/J)
abnormal leukocyte morphology J:199132
\Galctwi/\Galctwi
(B6.CE-Galctwi/J)
abnormal microglial cell morphology J:108359
abnormal osteoclast physiology J:165361
\Galctwi/\Galctwi
(involves: C57BL/6J * CE/J)
abnormal macrophage morphology J:6390
\Galctwi/\Galctwi
(involves: CE/J)
CNS inflammation J:78223
\Galctwi/\Galctwi
\Glb1tm1Adz/\Glb1+

(involves: 129P2/OlaHsd * C57BL/6J * CE/J)
immune system phenotype J:63197
\Galctwi/\Galctwi
\Glb1tm1Adz/\Glb1tm1Adz

(involves: 129P2/OlaHsd * C57BL/6J * CE/J)
abnormal macrophage physiology J:63197
enlarged spleen J:63197
\Galctwi/\Galctwi
\Il6+/?

(involves: 129S2/SvPas * C57BL/6J * CE/J)
abnormal tumor necrosis factor level J:56656
\Galctwi/\Galctwi
\Il6tm1Kopf/\Il6tm1Kopf

(involves: 129S2/SvPas * C57BL/6J * CE/J)
abnormal tumor necrosis factor level J:56656
\Galnt1tm1.1Jxm/\Galnt1tm1.1Jxm
(B6NHsd.Cg-Galnt1tm1.1Jxm)
abnormal immune system physiology J:128982
decreased B cell number J:128982
decreased basophil cell number J:128982
decreased eosinophil cell number J:128982
decreased germinal center B cell number J:128982
decreased IgG level J:128982
decreased leukocyte cell number J:128982
decreased plasma cell number J:128982
decreased spleen germinal center number J:128982
decreased T cell number J:128982
impaired leukocyte tethering or rolling J:128982
increased lymphocyte cell number J:128982
lymph node hypoplasia J:128982
\Galnt3em1(IMPC)Ccpcz/\Galnt3em1(IMPC)Ccpcz
(C57BL/6NCrl-Galnt3em1(IMPC)Ccpcz/Ccpcz)
increased eosinophil cell number J:211773
\Galnt3tm1.1Cfg/\Galnt3tm1.1Cfg
(involves: C57BL/6)
decreased monocyte cell number J:217719
\Galnt13em1(IMPC)Mbp/\Galnt13em1(IMPC)Mbp
(C57BL/6N-Galnt13em1(IMPC)Mbp/MbpMmucd)
abnormal spleen morphology J:211773
enlarged spleen J:211773
small spleen J:211773
\Galnt18tm1b(KOMP)Wtsi/\Galnt18tm1b(KOMP)Wtsi
(C57BL/6N-Galnt18tm1b(KOMP)Wtsi/Wtsi)
increased NK cell number J:211773
\Galr1em1(IMPC)H/\Galr1em1(IMPC)H
(C57BL/6N-Galr1em1(IMPC)H/H)
decreased lymphocyte cell number J:211773
enlarged spleen J:211773
increased eosinophil cell number J:211773
\Galr2Gt(OST105469)Lex/\Galr2Gt(OST105469)Lex
(involves: 129S5/SvEvBrd * C57BL/6J)
decreased B cell number J:103485
increased T cell number J:103485
\GaltGt(E285B04)Wrst/\GaltGt(E285B04)Wrst
(involves: 129P2/OlaHsd * C57BL/6J)
brain inflammation J:234753
liver inflammation J:234753
\Gapttm1.1Wz/\Gapttm1.1Wz
(Not Specified)
immune system phenotype J:138146
increased B cell proliferation J:138146
increased IgG2b level J:138146
increased IgG3 level J:138146
increased IgM level J:138146
increased marginal zone B cell number J:138146
\Gapvd1em1(IMPC)Mbp/\Gapvd1+
(C57BL/6N-Gapvd1em1(IMPC)Mbp/Ucd)
abnormal lymph node morphology J:211773
abnormal spleen morphology J:211773
enlarged lymph nodes J:211773
enlarged spleen J:211773
\Garem1em1(IMPC)Mbp/\Garem1em1(IMPC)Mbp
(C57BL/6N-Garem1em1(IMPC)Mbp/MbpMmucd)
abnormal spleen morphology J:211773
small spleen J:211773
\Garin1aem1(IMPC)Ccpcz/\Garin1aem1(IMPC)Ccpcz
(C57BL/6N-Garin1aem1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged spleen J:211773
enlarged thymus J:211773
\Garin1bem1(IMPC)Ccpcz/\Garin1bem1(IMPC)Ccpcz
(C57BL/6N-Garin1bem1(IMPC)Ccpcz/Ccpcz)
abnormal thymus morphology J:211773
enlarged thymus J:211773
\Garin2em1(IMPC)Ccpcz/\Garin2em1(IMPC)Ccpcz
(C57BL/6N-Garin2em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged spleen J:211773
enlarged thymus J:211773
\Gars1em1(IMPC)Tcp/\Gars1+
(C57BL/6NCrl-Gars1em1(IMPC)Tcp/Tcp)
small spleen J:211773
\Gas2l2tm1a(KOMP)Wtsi/\Gas2l2tm1a(KOMP)Wtsi
(C57BL/6N-Gas2l2tm1a(KOMP)Wtsi/Wtsi)
abnormal thymus topology J:239583
\Gas6tm1Hiar/\Gas6tm1Hiar
(B6.129P2-Gas6tm1Hiar)
immune system phenotype J:112430
\Gasa1BALB/cCrSlc/\Gasa1BALB/cCrSlc
(involves: BALB/cCrSlc * C57BL/6)
stomach inflammation J:54699
\Gasa1BALB/cCrSlc/\Gasa1C57BL/6
(involves: BALB/cCrSlc * C57BL/6)
stomach inflammation J:54699
\Gasa2BALB/cCrSlc/\Gasa2BALB/cCrSlc
(involves: BALB/cCrSlc * C57BL/6)
stomach inflammation J:54699
\Gasa2BALB/cCrSlc/\Gasa2BALB/cCrSlc
\Gasa4BALB/cCrSlc/\Gasa4C57BL/6

(involves: BALB/cCrSlc * C57BL/6)
stomach inflammation J:75277
\Gasa2BALB/cCrSlc/\Gasa2C57BL/6
(involves: BALB/cCrSlc * C57BL/6)
stomach inflammation J:54699
\Gasa3BALB/cCrSlc/\Gasa3C57BL/6
(involves: BALB/cCrSlc * C57BL/6)
stomach inflammation J:75277
\Gasa4BALB/cCrSlc/\Gasa4C57BL/6
(involves: BALB/cCrSlc * C57BL/6)
stomach inflammation J:75277
\Gasttm1Lcs/\Gasttm1Lcs
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)
stomach inflammation J:97527
\Gata1Plt13/\Gata1+
(BALB/c-Gata1Plt13)
abnormal myelopoiesis J:113720
abnormal thrombopoiesis J:113720
enlarged spleen J:113720
increased spleen weight J:113720
\Gata1tm1Mym/Y
\Tg(Gata1*)#Mym/0

(involves: 129P2/OlaHsd * C57BL/6 * DBA/2J)
increased leukocyte cell number J:158252
\Gata1tm1Mym/Y
\Tg(Gata1*V205G)1Mym/0

(involves: C57BL/6 * DBA/2)
abnormal mononuclear cell morphology J:89054
abnormal thrombopoiesis J:89054
\Gata1tm1Mym/\Gata1+
(involves: 129P2/OlaHsd)
decreased spleen red pulp amount J:88685
decreased spleen white pulp amount J:88685
enlarged spleen J:88685
pale spleen J:88685
\Gata1tm1Mym/\Gata1tm1Mym
\Tg(Gata1*)#Mym/0

(involves: 129P2/OlaHsd * C57BL/6 * DBA/2J)
increased leukocyte cell number J:158252
\Gata1tm1Sho/Y
\Tg(Gata1*)#Mym/0

(involves: 129S4/SvJae * C57BL/6 * DBA/2J)
increased leukocyte cell number J:158252
\Gata1tm1Sho/\Gata1+
(involves: 129S4/SvJae * C57BL/6)
decreased eosinophil cell number J:88711
\Gata1tm1Sho/\Gata1tm1Sho
\Tg(Gata1*)#Mym/0

(involves: 129S4/SvJae * C57BL/6 * DBA/2J)
increased leukocyte cell number J:158252
\Gata1tm2Sho/Y
(involves: 129S4/SvJae * C57BL/6 * CD-1)
abnormal spleen morphology J:78348
abnormal spleen red pulp morphology J:78540
decreased lymphocyte cell number J:78348
enlarged spleen J:78348, J:78540
increased neutrophil cell number J:78348
increased splenocyte number J:78540
\Gata1tm2Sho/\Gata1tm2Sho
(involves: 129S4/SvJae * C57BL/6 * CD-1)
abnormal spleen morphology J:78348
abnormal spleen red pulp morphology J:78540
decreased lymphocyte cell number J:78348
enlarged spleen J:78348, J:78540
increased neutrophil cell number J:78348
increased splenocyte number J:78540
\Gata1tm2Sho/\Gata1tm2Sho
(involves: 129S4/SvJae)
increased osteoclast cell number J:111270
\Gata1tm6Sho/Y
(involves: 129S1/Sv)
decreased eosinophil cell number J:88711
enlarged spleen J:88711
\Gata1tm6Sho/\Gata1tm6Sho
(involves: 129S1/Sv)
decreased eosinophil cell number J:88711
\Gata1tm6Sho/\Gata1tm6Sho
(involves: 129S1/Sv * BALB/c)
abnormal leukocyte cell number J:115273
decreased circulating interleukin-4 level J:115273
decreased circulating interleukin-13 level J:115273
decreased eosinophil cell number J:115273
decreased lymphocyte cell number J:115273
increased neutrophil cell number J:115273
\Gata1tm6Sho/\Gata1tm6Sho
(C.129S1-Gata1tm6Sho)
autoimmune response J:182213
\Gata3tm1.1Mbu/\Gata3tm1.1Mbu
(involves: 129P2/OlaHsd * C57BL/6 * SJL)
abnormal humoral immune response J:123631
decreased interleukin-4 secretion J:123631
increased interferon-gamma secretion J:123631
\Gata3tm1Iho/\Gata3tm1Iho
\Il13tm1(YFP/cre)Lky/\Il13+

(involves: 129S4/SvJae)
decreased eosinophil cell number J:178986
increased susceptibility to parasitic infection J:178986
\Gata3tm1Iho/\Gata3tm1Iho
\Tg(Cd4-cre)1Cwi/0

(involves: C57BL/6 * DBA/2)
abnormal T cell differentiation J:86996
decreased CD4-positive, alpha-beta T cell number J:86996
\Gata3tm1Iho/\Gata3tm1Iho
\Tg(Cd4-cre)1Cwi/0
\Tg(DO11.10)10Dlo/0

(involves: BALB/c * C3H * C57BL/6 * DBA/2)
decreased CD4-positive, alpha-beta T cell number J:86996
\Gata3tm1Iho/\Gata3tm1Iho
\Tg(DO11.10)10Dlo/0
\Tg(Lck-cre)1Cwi/0

(involves: BALB/c * C3H * C57BL/6)
arrested T cell differentiation J:86996
decreased CD4-positive, alpha-beta T cell number J:86996
decreased CD8-positive, alpha-beta T cell number J:86996
decreased double-positive T cell number J:86996
small thymus J:86996
\Gata3tm1Iho/\Gata3tm1Iho
\Tg(Lck-cre)1Cwi/0

(involves: BALB/c)
abnormal CD8-positive, alpha-beta T cell number J:86996
abnormal T cell subpopulation ratio J:86996
arrested T cell differentiation J:86996
decreased CD4-positive, alpha-beta T cell number J:86996
decreased double-positive T cell number J:86996
decreased thymocyte number J:86996
increased T cell apoptosis J:86996
small thymus J:86996
\Gata3tm1Jeng/\Gata3tm1Jeng
(involves: 129S7/SvEvBrd)
abnormal immune system organ morphology J:62552
\Gata3tm1Jfz/\Gata3tm1Jfz
\Rag2tm1Fwa/\Rag2tm1Fwa
\Tg(Cd4-cre)1Cwi/0
\Tg(Tcra5CC7,Tcrb5CC7)IWep/0

(involves: 129S/SvEv * C57BL/6 * DBA/2)
abnormal T cell differentiation J:141145
\Gata3tm1Jfz/\Gata3tm1Jfz
\Tg(Cd4-cre)1Cwi/0

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2)
abnormal CD4-positive, alpha beta T cell morphology J:93538
abnormal T cell differentiation J:141145
decreased CD4-positive, alpha-beta T cell number J:141145
decreased interleukin-13 secretion J:172134
\Gata3tm1Jfz/\Gata3tm1Jfz
\Tg(Tnfrsf4-cre)1Nik/0

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
abnormal CD4-positive, alpha beta T cell morphology J:93538
decreased IgE level J:93538
decreased T-helper 2 cell number J:93538
increased susceptibility to parasitic infection J:93538
increased T-helper 1 cell number J:93538
\Gata3tm1Jml/\Gata3tm1Jml
(involves: 129S/SvEv * C57BL/6)
abnormal immune system cell morphology J:37093
\Gata3tm2Jeng/\Gata3tm2Jeng
(Not Specified)
abnormal double-positive T cell morphology J:155686
abnormal T cell differentiation J:155686
abnormal T cell number J:155686
decreased double-negative T cell number J:155686
decreased gamma-delta T cell number J:155686
decreased thymocyte number J:155686
\Gata3tm3Gsv/\Gata3tm3Gsv
\Tg(KRT14-cre)8Brn/0

(involves: 129P2/OlaHsd * FVB/N)
decreased T cell number J:117058
\Gata5tm1.2Nemr/\Gata5tm1.2Nemr
(Not Specified)
kidney inflammation J:227997
\Gata5tm1Eno/\Gata5tm1Eno
(involves: 129S6/SvEvTac * C57BL/6)
urethritis J:63036
vaginal inflammation J:63036
\Gatad2btm1b(EUCOMM)Hmgu/\Gatad2b+
(C57BL/6N-Gatad2btm1b(EUCOMM)Hmgu/Ics)
increased monocyte cell number J:211773
\Gatmem1Btlr/\Gatmem1Btlr
(C57BL/6J-Gatmem1Btlr)
immune system phenotype J:252049
increased susceptibility to induced colitis J:252049
\Gatmem1Btlr/\Gatmm1Btlr
(C57BL/6J-Gatmem1Btlr/Gatmm1Btlr)
increased susceptibility to induced colitis J:252049
\Gatmm1Btlr/\Gatm+
(C57BL/6J-Gatmm1Btlr)
increased susceptibility to induced colitis J:252049
\Gatmm1Btlr/\Gatmm1Btlr
(C57BL/6J-Gatmm1Btlr)
increased susceptibility to induced colitis J:252049
\Gba1tm1.1Pmis/\Gba1tm1.1Pmis
\Tg(Mx1-cre)1Cgn/0

(involves: C57BL/6 * CBA)
abnormal circulating chemokine level J:167081
abnormal circulating cytokine level J:167081
abnormal T cell differentiation J:167081
abnormal thymus morphology J:167081
decreased circulating interleukin-1 alpha level J:167081
decreased circulating interleukin-1 beta level J:167081
decreased circulating interleukin-6 level J:167081
decreased circulating tumor necrosis factor level J:167081
decreased double-positive T cell number J:167081
enlarged spleen J:167081
increased circulating interferon-gamma level J:167081
increased circulating interleukin-2 level J:167081
increased circulating interleukin-3 level J:167081
increased circulating interleukin-9 level J:167081
increased circulating interleukin-10 level J:167081
increased circulating interleukin-13 level J:167081
spleen hyperplasia J:167081
\Gba1tm1.1Pmis/\Gba1tm1.2Pmis
\Tg(Mx1-cre)1Cgn/0

(involves: C57BL/6 * CBA)
abnormal circulating chemokine level J:167081
abnormal circulating cytokine level J:167081
abnormal T cell differentiation J:167081
abnormal thymus morphology J:167081
decreased circulating interleukin-1 alpha level J:167081
decreased circulating interleukin-1 beta level J:167081
decreased circulating interleukin-6 level J:167081
decreased circulating tumor necrosis factor level J:167081
decreased double-positive T cell number J:167081
enlarged spleen J:167081
increased circulating interferon-gamma level J:167081
increased circulating interleukin-2 level J:167081
increased circulating interleukin-3 level J:167081
increased circulating interleukin-9 level J:167081
increased circulating interleukin-10 level J:167081
increased circulating interleukin-13 level J:167081
spleen hyperplasia J:167081
\Gba1tm1Clk/\Gba1tm1.1Clk
\Tg(Tek-cre)12Flv/0

(involves: 129S1/Sv * 129X1/SvJ * C3H * C57BL/6J)
abnormal macrophage morphology J:117763
abnormal spleen morphology J:117763
increased spleen weight J:117763
\Gba1tm1Karl/\Gba1tm1.1Karl
\Tg(Mx1-cre)1Cgn/0

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA)
abnormal immune system organ morphology J:113751
abnormal response to transplant J:113751
abnormal spleen morphology J:113751
enlarged spleen J:113751
intermingled spleen red and white pulp J:113751
\Gba1tm1Karl/\Gba1tm1Karl
\Tg(Nes-cre)1Kln/?

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL)
abnormal microglial cell morphology J:127108
\Gba1tm1Nsb/\Gba1tm1Nsb
(involves: 129S/SvEv * C57BL/6)
abnormal macrophage morphology J:1100
\Gba1tm1Rlp/\Gba1tm1Rlp
(involves: 129S4/SvJae * C57BL/6)
abnormal inflammatory response J:76409
abnormal Kupffer cell morphology J:76409
abnormal lymph node morphology J:76409
abnormal macrophage morphology J:76409
abnormal spleen physiology J:76409
decreased leukocyte cell number J:76409
increased IgG level J:76409
increased spleen weight J:76409
liver inflammation J:76409
lung inflammation J:76409
lymph node inflammation J:76409
skin inflammation J:76409
\Gba1tm2Ggb/\Gba1tm1Nsb
(involves: 129S/SvEv * 129S5/SvEvBrd * C57BL/6)
abnormal spleen morphology J:86334
\Gba1tm2Ggb/\Gba1tm2Ggb
(involves: 129S5/SvEvBrd * C57BL/6)
abnormal spleen morphology J:86334
\Gba1tm2Karl/\Gba1tm2Karl
\Tg(KRT14-cre)8Brn/?

(involves: 129S1/Sv * 129X1/SvJ * FVB/N)
abnormal macrophage morphology J:127108
\Gba1tm3Ggb/\Gba1tm1Nsb
(involves: 129S/SvEv * 129S5/SvEvBrd * C57BL/6)
abnormal spleen morphology J:86334
\Gba1tm3Ggb/\Gba1tm3Ggb
(involves: 129S5/SvEvBrd)
abnormal spleen morphology J:86334
\Gba1tm4Ggb/\Gba1tm1Nsb
(involves: 129S/SvEv * 129S5/SvEvBrd * C57BL/6)
abnormal spleen morphology J:86334
\Gba1tm4Ggb/\Gba1tm4Ggb
(involves: 129S5/SvEvBrd * C57BL/6)
abnormal spleen morphology J:86334
\Gbp2-pstm1.1Ktak/\Gbp2-pstm1.1Ktak
(involves: C57BL/6)
immune system phenotype J:187397
\Gbp2-pstm1.1Ktak/\Gbp2-pstm1.1Ktak
\Gbp5tm1Ktak/\Gbp5tm1Ktak

(involves: C57BL/6)
immune system phenotype J:187397
\Gbp2tm1.1Kpf/\Gbp2tm1.1Kpf
(involves: 129P2/OlaHsd)
immune system phenotype J:192526
increased susceptibility to parasitic infection J:192526
increased susceptibility to parasitic infection induced morbidity/mortality J:192526
\Gbp2btm1Tigm/\Gbp2btm1Tigm
(B6.129S5-Gbp2btm1Tigm/Jdmm)
abnormal macrophage physiology J:172364
immune system phenotype J:172364
increased susceptibility to bacterial infection J:172364
increased susceptibility to bacterial infection induced morbidity/mortality J:172364
\Gbp5tm1Tigm/\Gbp5tm1Tigm
(B6.Cg-Gbp5tm1Tigm)
decreased circulating interleukin-1 beta level J:183942
decreased circulating interleukin-18 level J:183942
decreased interleukin-1 beta secretion J:183942
decreased interleukin-18 secretion J:183942
impaired neutrophil recruitment J:183942
increased susceptibility to bacterial infection J:183942
\Gbp7tm1Ddgd/\Gbp7tm1Ddgd
(B6.129P2-Gbp7tm1Ddgd)
increased susceptibility to bacterial infection J:314959
increased susceptibility to bacterial infection induced morbidity/mortality J:314959
\Gbx2tm1.1Mrt/\Gbx2tm1.1Mrt
\Fgf8tm1.4Mrt/\Fgf8+

(B6.129-Gbx2tm1.1Mrt Fgf8tm1.4Mrt)
abnormal thymus development J:100584
\Gcatm1Roes/\Gcatm1Roes
(involves: 129P2/OlaHsd * 129S2/SvPas)
decreased susceptibility to endotoxin shock J:81436
\Gcc2em1Cya/\Gcc2em1Cya
(C57BL/6J-Gcc2em1Cya)
increased autoantibody level J:346915
\Gcnt1em1(IMPC)Ccpcz/\Gcnt1em1(IMPC)Ccpcz
(C57BL/6NCrl-Gcnt1em1(IMPC)Ccpcz/Ccpcz)
abnormal lymph node morphology J:211773
abnormal spleen morphology J:211773
decreased lymphocyte cell number J:211773
enlarged lymph nodes J:211773
increased eosinophil cell number J:211773
increased monocyte cell number J:211773
increased neutrophil cell number J:211773
\Gcnt1tm1Jxm/\Gcnt1tm1Jxm
(involves: 129/Sv * C57BL/6)
abnormal acute inflammation J:86387
abnormal B cell differentiation J:86387
abnormal immune system cell morphology J:86387
abnormal immune system physiology J:86387
abnormal inflammatory response J:86387
increased leukocyte cell number J:86387
increased neutrophil cell number J:86387
\Gcnt1tm1Jxm/\Gcnt1tm1Jxm
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
abnormal leukocyte migration J:113195
impaired leukocyte tethering or rolling J:113195
\Gcnt2tm1Tmu/\Gcnt2tm1Tmu
(involves: 129S2/SvPas * C57BL/6)
decreased B cell number J:100533
\Gcnt3tm1.1Jxm/\Gcnt3tm1.1Jxm
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
decreased IgA level J:149909
decreased IgG1 level J:149909
decreased IgG2a level J:149909
decreased IgG2b level J:149909
increased susceptibility to induced colitis J:149909
\Gcnt4tm1.1Jxm/\Gcnt4tm1.1Jxm
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
increased neutrophil cell number J:149909
\Gcsamtm1.1Rsky/\Gcsamtm1.1Rsky
(involves: BALB/cJ * C57BL/6)
decreased Peyer's patch number J:125784
immune system phenotype J:125784
small Peyer's patches J:125784
\GcsfisC57BL/6J/?
(involves: C57BL/6J * DBA/2J)
enlarged spleen J:61462
\GcsfisC57BL/6J/\GcsfisC57BL/6J
(B6.SJL-Ptprca Pepcb/BoyJ)
enlarged spleen J:61462
\Gcshem1(IMPC)H/\Gcsh+
(C57BL/6N-Gcshem1(IMPC)H/H)
increased basophil cell number J:211773
\Gdatm1a(KOMP)Wtsi/\Gdatm1a(KOMP)Wtsi
(C57BL/6N-Gdatm1a(KOMP)Wtsi/Wtsi)
decreased T-helper cell number J:211773
increased effector memory T-helper cell number J:211773
\Gdap1tm2b(KOMP)Wtsi/\Gdap1tm2b(KOMP)Wtsi
(C57BL/6N-Gdap1tm2b(KOMP)Wtsi/Ucd)
abnormal thymus morphology J:211773
small thymus J:211773
\Gdf1tm1Sjl/\Gdf1tm1Sjl
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
abnormal spleen morphology J:60755
\Gdf2tm1Lex/\Gdf2tm1Lex
(involves: 129S5/SvEvBrd * C57BL/6)
abnormal lymphatic vessel morphology J:222016
lymphangiectasis J:222016
\Gdf5em1(IMPC)H/\Gdf5em1(IMPC)H
(C57BL/6NTac-Gdf5em1(IMPC)H/H)
decreased lymphocyte cell number J:211773
\Gdf6em1(IMPC)Ccpcz/\Gdf6+
(C57BL/6NCrl-Gdf6em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged spleen J:211773
enlarged thymus J:211773
\Gdf11tm1Sjl/\Gdf11tm1Sjl
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)
abnormal spleen morphology J:94455
\Gdi2Gt(S1-11F1)Sor/\Gdi2+
(B6.129S4-Gdi2Gt(S1-11F1)Sor)
immune system phenotype J:326029
\Gdnftm1Lmgd/\Gdnf+
(B6.129-Gdnftm1Lmgd)
tubulointerstitial nephritis J:103081
\Gdnftm1Rosl/\Gdnftm1Rosl
(involves: 129S2/SvPas)
abnormal spleen red pulp morphology J:33808
\Gdpd3m1Anu/\Gdpd3m1Anu
(C57BL/6NCrlAnu-Gdpd3m1Anu)
immune system phenotype J:104190
\Gdpd5tm1b(EUCOMM)Hmgu/\Gdpd5+
(C57BL/6N-Gdpd5tm1b(EUCOMM)Hmgu/Bay)
abnormal spleen morphology J:211773
\Gfaptm1Pkny/\Gfaptm1Pkny
\Ppt1tm1Hof/\Ppt1tm1Hof
\Vimtm1Cba/\Vimtm1Cba

(involves: 129P2/OlaHsd * 129S2/SvPas * 129S6/SvEvTac * C57BL/6)
abnormal cytokine level J:177265
brain inflammation J:177265
\Gfaptm1Pkny/\Gfaptm1Pkny
\Vimtm1Cba/\Vimtm1Cba

(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6)
decreased inflammatory response J:123278
\Gfertm1.1Crg/\Gfertm1.1Crg
\Speer6-ps1Tg(Alb-cre)21Mgn/\Speer6-ps1+

(involves: 129 * C57BL/6 * DBA)
liver inflammation J:227242
\Gfi1Gen/\Gfi1+
(C57BL/6J-Gfi1Gen)
abnormal myelopoiesis J:182679
abnormal NK cell differentiation J:182679
abnormal NK cell physiology J:182679
absent neutrophils J:182679
decreased NK cell degranulation J:182679
immune system phenotype J:182679
\Gfi1tm1.1Wep/\Gfi1tm1.1Wep
(B6.129-Gfi1tm1.1Wep)
arrested T cell differentiation J:117105
decreased B cell number J:117105
small thymus J:117105
thymus hypoplasia J:117105
\Gfi1tm1Tmo/\Gfi1tm1Tmo
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
abnormal cytokine secretion J:75143
abnormal granulocyte differentiation J:75143
abnormal monocyte differentiation J:75143
abnormal myelopoiesis J:75143
abnormal T cell differentiation J:75143
decreased B cell number J:75143
decreased granulocyte number J:75143
decreased lymphocyte cell number J:75143
decreased neutrophil cell number J:75143
decreased T cell number J:75143
decreased thymocyte number J:75143
increased interleukin-1 beta secretion J:75143
increased interleukin-10 secretion J:75143
increased susceptibility to endotoxin shock J:75143
increased tumor necrosis factor secretion J:75143
\Gfi1tm1Tmo/\Gfi1tm1Tmo
(involves: 129S1/Sv * 129X1/SvJ)
decreased B cell number J:192927
decreased granulocyte number J:192927
decreased neutrophil cell number J:192927
decreased thymocyte number J:192927
increased monocyte cell number J:192927
\Gfi1tm1Wep/\Gfi1tm1Wep
(B6.129-Gfi1tm1Wep)
abnormal T cell proliferation J:117105
\Gfi1tm1Wep/\Gfi1tm1Wep
\Tg(Cd4-cre)1Cwi/0

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2)
abnormal T cell proliferation J:117105
abnormal T cell subpopulation ratio J:117105
abnormal T-helper 2 physiology J:117105
\Gfi1tm2Tmo/\Gfi1tm2Tmo
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
abnormal T cell differentiation J:93337
decreased neutrophil cell number J:93337
decreased thymocyte number J:93337
\Gfi1tm3(Gfib1)Tmo/\Gfi1tm3(Gfib1)Tmo
(involves: 129S1/Sv * 129X1/SvJ)
abnormal monocyte morphology J:116870
decreased granulocyte number J:116870
\Gfi1tm4Tmo/\Gfi1tm4Tmo
(involves: 129S1/Sv * 129X1/SvJ)
abnormal lymphopoiesis J:116870
abnormal monocyte morphology J:116870
abnormal neutrophil morphology J:116870
abnormal T cell differentiation J:116870
decreased double-negative T cell number J:116870
decreased lymphocyte cell number J:116870
decreased neutrophil cell number J:116870
decreased thymocyte number J:116870
\Gfi1tm5.1(GFI1*)Tmo/\Gfi1+
\Krastm4Tyj/\Kras+
\Tg(Mx1-cre)1Cgn/0

(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6 * CBA)
myeloid hyperplasia J:192927
\Gfi1tm5.1(GFI1*)Tmo/\Gfi1tm5.1(GFI1*)Tmo
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
increased monocyte cell number J:192927
\Gfi1tm5.1(GFI1*)Tmo/\Gfi1tm5.1(GFI1*)Tmo
\Krastm4Tyj/\Kras+
\Tg(Mx1-cre)1Cgn/0

(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6 * CBA)
myeloid hyperplasia J:192927
\Gfi1tm6.1(GFI1)Tmo/\Gfi1tm6.1(GFI1)Tmo
\Krastm4Tyj/\Kras+
\Tg(Mx1-cre)1Cgn/0

(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6 * CBA)
myeloid hyperplasia J:192927
\Gfi1bem1(IMPC)Ccpcz/\Gfi1b+
(C57BL/6NCrl-Gfi1bem1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged thymus J:211773
\Gfi1btm1b(EUCOMM)Hmgu/\Gfi1b+
(C57BL/6N-Gfi1btm1b(EUCOMM)Hmgu/H)
decreased neutrophil cell number J:211773
increased lymphocyte cell number J:211773
\Gfi1btm2Tmo/\Gfi1btm2Tmo
\Tg(Mx1-cre)1Cgn/?

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA)
increased splenocyte number J:167416
\Gfra1tm1Rosl/\Gfra1tm1Rosl
(either: (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J) or (involves: 129S1/Sv * 129X1/SvJ * CD-1))
decreased Peyer's patch number J:120816
\Gfustm1Jbl/\Gfustm1Jbl
(involves: 129S2/SvPas * C57BL/6J)
increased leukocyte cell number J:82239
increased neutrophil cell number J:82239
large intestinal inflammation J:82239
\Ggctem1.2Smoc/\Ggctem1.2Smoc
(involves: C57BL/6J)
enlarged spleen J:322242
increased spleen red pulp amount J:322242
\Gghem1(IMPC)Tcp/\Gghem1(IMPC)Tcp
(C57BL/6N-Gghem1(IMPC)Tcp/Tcp)
enlarged lymph nodes J:211773
\ggld/\ggld
(MRL/MpJ-Faslpr/J-ggld)
decreased IgG1 level J:14258
\Ggps1tm1b(EUCOMM)Wtsi/\Ggps1+
(C57BL/6N-Ggps1tm1b(EUCOMM)Wtsi/Ieg)
increased leukocyte cell number J:211773
\Ggt1dwg/\Ggt1dwg
((STOCK Pou1f1dw x T(8;16)17H)F1)
decreased spleen red pulp amount J:14281
increased osteoclast cell number J:14281
\Ggt5tm1Mwl/\Ggt5tm1Mwl
(involves: 129S7/SvEvBrd * C57BL/6J)
decreased acute inflammation J:77691
\Ggta1tm1Jbl/\Ggta1+
\Ightm1Jiac/\Igh+
\Igktm1Jiac/\Igktm1Jiac

(involves: 129S2/SvPas * 129S4/SvJae * C57BL/6)
decreased mature B cell number J:133032
\Ggta1tm1Jbl/\Ggta1+
\Ightm1Jiac/\Ightm1Jiac
\Igktm1Jiac/\Igk+

(involves: 129S2/SvPas * 129S4/SvJae * C57BL/6)
decreased mature B cell number J:133032
\Ggta1tm1Jbl/\Ggta1+
\Ightm1Jiac/\Ightm1Jiac
\Igktm1Jiac/\Igktm1Jiac

(involves: 129S2/SvPas * 129S4/SvJae * C57BL/6)
abnormal B cell physiology J:133032
abnormal B cell selection J:133032
decreased mature B cell number J:133032
\Ggta1tm1Jbl/\Ggta1tm1Jbl
(involves: 129S2/SvPas)
abnormal humoral immune response J:113488, J:90851
abnormal immunoglobulin level J:113488
abnormal response to transplant J:90851
decreased IgG level J:90851
increased IgM level J:90851
\Ghtm1.1(KOMP)Vlcg/\Ghtm1.1(KOMP)Vlcg
(C57BL/6N-Ghtm1.1(KOMP)Vlcg/Ucd)
abnormal spleen morphology J:211773
decreased spleen weight J:211773
small spleen J:211773
\Ghrtm1Arge/\Ghrtm1Arge
(involves: 129S/SvEv * C57BL/6J)
small spleen J:66913
\Ghrtm1c(KOMP)Wtsi/\Ghrtm1c(KOMP)Wtsi
\Tg(Fabp4-cre)1Rev/0

(involves: C57BL/6N)
decreased spleen weight J:206358
increased circulating interleukin-6 level J:206358
\Ghrtm1Jjk/\Ghrtm1Jjk
(involves: 129P2/OlaHsd * BALB/c)
decreased spleen weight J:60207
decreased susceptibility to autoimmune diabetes J:59132
\Ghrtm2Mwat/\Ghrtm2Mwat
(involves: 129X1/SvJ * C57BL)
small spleen J:95149
\Ghrhtm1Salv/\Ghrhtm1Salv
(involves: 129 * C57BL/6)
decreased susceptibility to experimental autoimmune encephalomyelitis J:177054
\Ghrhrlit/\Ghrhrlit
(C57BL/6J-Ghrhrlit)
decreased susceptibility to experimental autoimmune encephalomyelitis J:85381
\Gigyf2tm1b(EUCOMM)Wtsi/\Gigyf2tm1b(EUCOMM)Wtsi
(C57BL/6N-Gigyf2tm1b(EUCOMM)Wtsi/Bay)
decreased eosinophil cell number J:211773
increased spleen weight J:211773
\Gimap1m1Btlr/\Gimap1m1Btlr
(C57BL/6J-Gimap1m1Btlr)
decreased B cell number J:267546
decreased B-1 B cell number J:267546
decreased CD8-positive, alpha-beta T cell number J:267546
decreased IgD level J:267546
increased CD4-positive, alpha-beta T cell number J:267546
increased IgM level J:267546
\Gimap1tm1.1Gwb/\Gimap1tm1.1Gwb
\Tg(CD2-icre)4Kio/0

(involves: 129 * C57BL/6 * C57BL/10 * CBA/Ca)
abnormal CD4-positive, alpha-beta T cell physiology J:160782
abnormal CD8-positive, alpha-beta T cell physiology J:160782
decreased B cell number J:160782
decreased B-1a cell number J:160782
decreased B-1b cell number J:160782
decreased B-2 B cell number J:160782
decreased CD4-positive, alpha-beta T cell number J:160782
decreased CD8-positive, alpha-beta T cell number J:160782
decreased follicular B cell number J:160782
decreased lymphocyte cell number J:160782
decreased marginal zone B cell number J:160782
decreased T cell number J:160782
decreased thymocyte number J:160782
decreased transitional stage T2 B cell number J:160782
\Gimap3tm1.1Yout/\Gimap3tm1.1Yout
(involves: C57BL/6 * C57BL/6NCrlj * CBA/JNCrlj)
decreased T cell number J:209926
decreased thymocyte number J:209926
\Gimap4tm1Jcbs/\Gimap4tm1Jcbs
(B6.129P2-Gimap4tm1Jcbs)
abnormal T cell physiology J:135744
\Gimap5m1Btlr/\Gimap5m1Btlr
(involves: C57BL/6J)
abnormal B cell physiology J:160090
abnormal B cell proliferation J:160090
abnormal NK T cell physiology J:160090
abnormal response to transplant J:160090
abnormal spleen B cell follicle morphology J:160090
colitis J:160090
decreased B cell number J:160090
decreased B cell proliferation J:160090
decreased B-1 B cell number J:160090
decreased CD8-positive, alpha-beta T cell number J:160090
decreased circulating interferon-gamma level J:160090
decreased circulating interleukin-4 level J:160090
decreased IgG1 level J:160090
decreased IgG2a level J:160090
decreased IgG2b level J:160090
decreased IgG3 level J:160090
decreased IgG level J:160090
decreased IgM level J:160090
decreased interferon-gamma secretion J:160090
decreased interleukin-4 secretion J:160090
decreased lymphocyte cell number J:160090
decreased mature B cell number J:160090
decreased NK cell number J:160090
decreased NK T cell number J:160090
decreased spleen B cell follicle number J:160090
decreased spleen B cell follicle size J:160090
decreased tumor necrosis factor secretion J:160090
increased granulocyte number J:160090
increased neutrophil cell number J:160090
intestinal inflammation J:160090
thymus atrophy J:160090
\Gimap5m1Btlr/\Gimap5m1Btlr
\Tg(TcraH-Y,TcrbH-Y)71Vbo/0

(involves: C57BL/6J * DBA/2J)
decreased CD8-positive, alpha-beta T cell number J:160090
decreased thymocyte number J:160090
\Gimap5tm1Wlr/\Gimap5tm1Wlr
(either: B6.129-Gimap5tm1Wlr or C.129-Gimap5tm1Wlr)
abnormal CD8-positive, alpha-beta T cell differentiation J:143620
abnormal leukocyte morphology J:143620
abnormal lymphocyte cell number J:143620
abnormal response to transplant J:143620
abnormal spleen morphology J:143620
decreased B cell number J:143620
decreased CD4-positive, alpha-beta T cell number J:143620
decreased CD8-positive, alpha-beta T cell number J:143620
decreased NK cell number J:143620
decreased NK T cell number J:143620
decreased T cell number J:143620
increased granulocyte number J:143620
small lymph nodes J:143620
spleen hypoplasia J:143620
\Gimap5tm1Yout/\Gimap5tm1Yout
(involves: C57BL/6 * C57BL/6NCrlj * CBA/JNCrlj)
decreased T cell number J:209926
\Gimap6tm1.1Gwb/\Gimap6tm1.1Gwb
\Tg(CD2-icre)4Kio/0

(involves: C57BL/6 * C57BL/10 * CBA/Ca)
abnormal leukocyte morphology J:262059
abnormal T cell physiology J:262059
decreased B cell number J:262059
decreased T cell number J:262059
increased B cell number J:262059
increased T cell apoptosis J:262059
\Gimap6tm1a(KOMP)Wtsi/\Gimap6tm1a(KOMP)Wtsi
(C57BL/6N-Gimap6tm1a(KOMP)Wtsi/Wtsi)
decreased CD4-negative NK T cell number J:211773
decreased memory-marker CD4-negative NK T cell number J:211773
increased memory-marker CD4-negative NK T cell number J:211773
increased monocyte cell number J:211773
\Gin1em1(IMPC)Mbp/\Gin1em1(IMPC)Mbp
(C57BL/6N-Gin1em1(IMPC)Mbp/MbpMmucd)
abnormal thymus morphology J:211773
enlarged thymus J:211773
\Git2Gt(XG510)Byg/\Git2Gt(XG510)Byg
(B6.129P2-Git2Gt(XG510)Byg)
decreased marginal zone B cell number J:160613
\Git2Gt(XG510)Byg/\Git2Gt(XG510)Byg
(C.129P2-Git2Gt(XG510)Byg)
decreased marginal zone B cell number J:160613
\Git2Gt(XG510)Byg/\Git2Gt(XG510)Byg
\Tg(DO11.10)10Dlo/0

(involves: 129P2/OlaHsd * BALB/c * C3H * C57BL/6)
decreased CD4-positive, alpha-beta T cell number J:160613
\Git2Gt(XG510)Byg/\Git2Gt(XG510)Byg
\Tg(TcraH-Y,TcrbH-Y)71Vbo/0

(involves: 129 * C57BL/6J * DBA/2J)
abnormal CD4-positive, alpha-beta T cell physiology J:160613
abnormal CD8-positive, alpha-beta T cell physiology J:160613
abnormal positive T cell selection J:160613
decreased CD8-positive, alpha-beta T cell number J:160613
\Git2Gt(XG510)Byg/\Git2Gt(XG510)Byg
\Tg(TcraTcrb)425Cbn/0

(involves: 129P2/OlaHsd * C57BL/6)
decreased CD4-positive, alpha-beta T cell number J:160613
\Git2tm1Hsb/\Git2tm1Hsb
(involves: C57BL/6 * CBA)
abnormal neutrophil differentiation J:112663
abnormal neutrophil physiology J:112663
enlarged spleen J:112663
impaired neutrophil chemotaxis J:112663
increased susceptibility to fungal infection J:112663
lung inflammation J:112663
\Gja1em1(IMPC)Ccpcz/\Gja1+
(C57BL/6NCrl-Gja1em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
\Gja1M1Jrt/\Gja1+
(involves: C3H/HeJ * C57BL/6J)
heart inflammation J:101733
\Gja1tm1.1Kwi/\Gja1+
(involves: 129P2/OlaHsd)
abnormal neutrophil physiology J:129091
\Gja1tm1Kwi/\Gja1+
\Tg(KRT5-cre)5132Jlj/0

(involves: 129P2/OlaHsd * C57BL/6J * DBA/2J)
abnormal lymphatic vessel morphology J:188626
absent lymphatic vessels J:188626
\Gja1tm1Kwi/\Gja1tm5(cre/ERT)Kwi
(involves: 129P2/OlaHsd)
abnormal neutrophil physiology J:129091
\Gjb1tm1Kwi/Y
\Gjc2tm1(EGFP)Kwi/\Gjc2tm1(EGFP)Kwi

(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)
microgliosis J:219594
optic nerve inflammation J:219594
spinal cord inflammation J:219594
\Gjb2tm3.1(Gjb1)Kwi/\Gjb2+
\Tg(KRT5-cre)5132Jlj/0

(involves: 129P2/OlaHsd * C57BL/6 * DBA/2J * SJL)
abnormal lymphatic vessel morphology J:188626
\Gjb2tm3.2(Gjb1)Kwi/\Gjb2+
(involves: 129P2/OlaHsd * BALB/c * C57BL/6 * SJL)
abnormal lymphatic vessel morphology J:188626
absent lymphatic vessels J:188626
\Gjb4tm1.1(KOMP)Vlcg/\Gjb4tm1.1(KOMP)Vlcg
(C57BL/6N-Gjb4tm1.1(KOMP)Vlcg/Ucd)
abnormal spleen morphology J:211773
enlarged spleen J:211773
\Gjb6tm1Kwi/\Gjb6tm1Kwi
(involves: 129P2/OlaHsd * C57BL/6)
immune system phenotype J:85065
\Gjc2tm1(EGFP)Kwi/\Gjc2tm1(EGFP)Kwi
(involves: 129P2/OlaHsd * C57BL/6)
microgliosis J:174197
\Gjc2tm1(EGFP)Kwi/\Gjc2tm1(EGFP)Kwi
\Gjb1tm1Kwi/\Gjb1tm1Kwi

(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)
microgliosis J:219594
optic nerve inflammation J:219594
spinal cord inflammation J:219594
\Gjc2tm2.1Kwi/\Gjc2+
(involves: C57BL/6 * SJL)
microgliosis J:174197
\Gjc2tm2.1Kwi/\Gjc2tm2.1Kwi
(involves: C57BL/6 * SJL)
microgliosis J:174197
\Gjd4tm1.1Malt/\Gjd4tm1.1Malt
(involves: 129S2/SvPas * C57BL/6 * SJL)
decreased macrophage cell number J:172698
\Gk5m5Btlr/\Gk5m5Btlr
(C57BL/6J-Gk5m5Btlr)
increased alpha-beta T cell number J:265118
increased CD8-positive, alpha-beta memory T cell number J:265118
increased central memory CD8 positive, alpha-beta T cell number J:265118
\Gkn2tm1.1(KOMP)Vlcg/\Gkn2tm1.1(KOMP)Vlcg
(involves: C57BL/6NTac)
abnormal chemokine level J:234656
abnormal cytokine level J:234656
abnormal innate immunity J:234656
abnormal interleukin level J:234656
abnormal susceptibility to bacterial infection J:234656
abnormal T-helper 1 physiology J:234656
abnormal tumor necrosis factor level J:234656
increased susceptibility to bacterial infection J:234656
stomach inflammation J:234656
\Glb1tm1Jmat/\Glb1tm1Jmat
(involves: C57BL/6 * CBA * ICR)
abnormal lymphopoiesis J:43534
abnormal macrophage chemotaxis J:102576
small spleen J:43534
\Glb1l2tm1Lex/\Glb1l2tm1Lex
(B6;129S5-Glb1l2tm1Lex/Mmucd)
decreased leukocyte cell number J:171883
decreased lymphocyte cell number J:171883
decreased NK cell number J:171883
\Glg1Gt(RST092)Byg/\Glg1+
(B6J.129P2-Glg1Gt(RST092)Byg)
abnormal cellular extravasation J:226586
abnormal leukocyte adhesion J:226586
enhanced leukocyte tethering or rolling J:226586
\Glis2tm1Amj/\Glis2tm1Amj
(involves: 129P2/OlaHsd * C57BL/6)
glomerulonephritis J:134208
\GlmpGt(P084H04)Wrst/\GlmpGt(P084H04)Wrst
(involves: 129S2/SvPas * C57BL/6)
abnormal Kupffer cell morphology J:208774
increased spleen weight J:208774
liver inflammation J:208774
\Glmptm1Lex/\Glmptm1Lex
(B6;129S5-Glmptm1Lex/Mmucd)
abnormal immune system physiology J:171883
liver inflammation J:171883
\Glra1nmf11/\Glra1nmf11
(C57BL/6J-Glra1nmf11/J)
small spleen J:78134
thymus atrophy J:78134
\Glra2tm1b(KOMP)Wtsi/Y
(C57BL/6N-Glra2tm1b(KOMP)Wtsi/H)
decreased monocyte cell number J:211773
decreased neutrophil cell number J:211773
increased lymphocyte cell number J:211773
\Glrbem1(IMPC)Tcp/\Glrb+
(C57BL/6NCrl-Glrbem1(IMPC)Tcp/Tcp)
increased neutrophil cell number J:211773
increased spleen weight J:211773
\Gls2em1(IMPC)Tcp/\Gls2em1(IMPC)Tcp
(C57BL/6N-Gls2em1(IMPC)Tcp/Tcp)
enlarged lymph nodes J:211773
enlarged spleen J:211773
\Glt8d2tm1Lex/\Glt8d2tm1Lex
(B6;129S5-Glt8d2tm1Lex/Mmucd)
abnormal adaptive immunity J:171883
decreased IgG1 level J:171883
decreased IgG2a level J:171883
\Glyr1em1(IMPC)Tcp/\Glyr1em1(IMPC)Tcp
(C57BL/6N-Glyr1em1(IMPC)Tcp/Tcp)
enlarged lymph nodes J:211773
\Gm614tm1.1Cya/\Gm614tm1.1Cya
\Ighg1tm1(cre)Cgn/\Ighg1+

(involves: 129P2/OlaHsd * C57BL/6 * C57BL/6N)
decreased susceptibility to systemic lupus erythematosus J:307345
immune system phenotype J:307345
increased B cell apoptosis J:307345
\Gm4922em1(IMPC)Tcp/\Gm4922em1(IMPC)Tcp
(C57BL/6NCrl-Gm4922em1(IMPC)Tcp/Tcp)
enlarged lymph nodes J:211773
\Gm5148em1(IMPC)Ccpcz/\Gm5148+
(C57BL/6NCrl-Gm5148em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
decreased CD4-positive, CD25-positive, alpha-beta regulatory T cell number J:211773
enlarged spleen J:211773
enlarged thymus J:211773
\Gm5148em1(IMPC)Ccpcz/\Gm5148em1(IMPC)Ccpcz
(C57BL/6NCrl-Gm5148em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
\Gm5544tm1a(KOMP)Wtsi/\Gm5544+
(C57BL/6N-Gm5544tm1a(KOMP)Wtsi/Wtsi)
decreased marginal zone B cell number J:211773
\Gm5544tm1a(KOMP)Wtsi/\Gm5544tm1a(KOMP)Wtsi
(C57BL/6N-Gm5544tm1a(KOMP)Wtsi/Wtsi)
blood in lymph vessels J:239583
\Gm7694em1(IMPC)J/\Gm7694em1(IMPC)J
(C57BL/6NJ-Gm7694em1(IMPC)J/Mmjax)
increased leukocyte cell number J:211773
\Gm10800em1(IMPC)Mbp/\Gm10800em1(IMPC)Mbp
(C57BL/6N-Gm10800em1(IMPC)Mbp/MbpMmucd)
abnormal spleen morphology J:211773
enlarged lymph nodes J:211773
enlarged spleen J:211773
\Gm10851em1(IMPC)Ccpcz/\Gm10851em1(IMPC)Ccpcz
(C57BL/6NCrl-Gm10851em1(IMPC)Ccpcz/Ccpcz)
abnormal lymph node morphology J:211773
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged lymph nodes J:211773
enlarged thymus J:211773
\Gm15551em1(IMPC)Ccpcz/\Gm15551em1(IMPC)Ccpcz
(C57BL/6NCrl-Gm15551em1(IMPC)Ccpcz/Ccpcz)
abnormal thymus morphology J:211773
enlarged thymus J:211773
\Gm16685em1Osb/\Gm16685em1Osb
(C57BL/6N-Gm16685em1Osb)
decreased susceptibility to colitis induced morbidity/mortality J:303079
\Gm26330em1Liuq/\Gm26330em1Liuq
(C57BL/6-Gm26330em1Liuq)
decreased NK cell number J:341056
\Gm36723em1Flv/\Gm36723em1Flv
(C57BL/6-Gm36723em1Flv)
abnormal lymphopoiesis J:258967
abnormal NK cell physiology J:258967
decreased interferon-gamma secretion J:258967
decreased lymphocyte cell number J:258967
decreased mature NK cell number J:258967
decreased NK cell number J:258967
decreased susceptibility to bacterial infection J:258967
immune system phenotype J:258967
impaired natural killer cell mediated cytotoxicity J:258967
increased immature NK cell number J:258967
\Gm36723em2Flv/\Gm36723em2Flv
(C57BL/6-Gm36723em2Flv)
immune system phenotype J:258967
\Gm36723em3Flv/\Gm36723em3Flv
(C57BL/6-Gm36723em3Flv)
decreased mature NK cell number J:258967
\Gm40600em1Cya/\Gm40600em1Cya
(C57BL/6-Gm40600em1Cya)
abnormal plasmablast number J:311878
decreased B cell number J:311878
decreased IgA level J:311878
decreased IgE level J:311878
decreased IgG1 level J:311878
decreased IgG2b level J:311878
decreased IgG2c level J:311878
decreased IgG3 level J:311878
decreased IgG level J:311878
decreased IgM level J:311878
decreased plasma cell number J:311878
immune system phenotype J:311878
increased B cell number J:311878
increased IgA level J:311878
increased IgE level J:311878
increased IgG1 level J:311878
increased IgG2b level J:311878
increased IgG2c level J:311878
increased IgG3 level J:311878
increased IgG level J:311878
increased IgM level J:311878
increased plasma cell number J:311878
\Gm41610em1Scrp/\Gm41610em1Scrp
(C57BL/6-Gm41610em1Scrp)
decreased susceptibility to endotoxin shock J:302605
immune system phenotype J:302605
increased circulating interleukin-5 level J:302605
increased circulating interleukin-13 level J:302605
\Gmdstm1a(KOMP)Wtsi/\Gmdstm1a(KOMP)Wtsi
(C57BL/6N-Gmdstm1a(KOMP)Wtsi/Wtsi)
decreased alpha-beta T cell number J:211773
decreased CD4-positive NK T cell number J:211773
decreased CD4-positive, alpha-beta T cell number J:211773
decreased CD4-positive, CD25-positive, alpha-beta regulatory T cell number J:211773
decreased CD8-positive, alpha-beta T cell number J:211773
decreased CD8-positive, naive alpha-beta T cell number J:211773
decreased dendritic cell number J:211773
decreased effector memory CD8-positive, alpha-beta T cell number J:211773
decreased KLRG1+ CD8 alpha-beta T cell number J:211773
decreased KLRG1-positive NK cell number J:211773
decreased Ly6C-positive mature NK cell number J:211773
decreased macrophage cell number J:211773
decreased mature NK cell number J:211773
decreased memory CD4-positive, CD25-positive, alpha-beta regulatory T cell number J:211773
decreased memory-marker CD4-negative NK T cell number J:211773
decreased memory-marker CD4-positive NK T cell number J:211773
decreased NK cell number J:211773
decreased plasmacytoid dendritic cell number J:211773
decreased regulatory T cell number J:211773
decreased T-helper cell number J:211773
decreased transitional stage T2 B cell number J:211773
increased CD4-negative NK T cell number J:211773
increased CD4-positive, alpha-beta T cell number J:211773
increased CD8-positive, alpha-beta T cell number J:211773
increased gamma-delta T cell number J:211773
increased granulocyte number J:211773
increased immature NK cell number J:211773
increased leukocyte cell number J:211773
increased Ly6C-positive NK T cell number J:211773
increased memory CD4-positive, CD25-positive, alpha-beta regulatory T cell number J:211773
increased memory-marker NK cell number J:211773
increased monocyte cell number J:211773
increased neutrophil cell number J:211773
increased NK T cell number J:211773
\Gmfgtm1Jyw/\Gmfgtm1Jyw
(B6.Cg-Gmfgtm1Jyw)
abnormal marginal zone B cell physiology J:345500
decreased lymphocyte chemotaxis J:345500
impaired B cell migration J:345500
increased IgM level J:345500
\Gmnntm1.1Kio/\Gmnntm1.2Kio
\Tg(CD2-icre)4Kio/0

(involves: 129S4/SvJae * C57BL/10 * CBA/Ca)
decreased CD4-positive, alpha-beta T cell number J:159657
decreased CD4-positive, CD25-positive, alpha-beta regulatory T cell number J:159657
decreased CD8-positive, alpha-beta T cell number J:159657
decreased DN1 thymic pro-T cell number J:159657
decreased DN4 thymocyte number J:159657
decreased double-positive T cell number J:159657
decreased memory T cell number J:159657
decreased T cell proliferation J:159657
decreased thymocyte number J:159657
\Gmnntm1Tjm/\Gmnntm1Tjm
\Tg(Mx1-cre)1Cgn/0

(involves: 129/Sv * C57BL/6 * C57BL/6J * CBA)
abnormal spleen red pulp morphology J:171741
decreased granulocyte number J:171741
decreased leukocyte cell number J:171741
decreased neutrophil cell number J:171741
\Gmppaem1(IMPC)Tcp/\Gmppaem1(IMPC)Tcp
(C57BL/6N-Gmppaem1(IMPC)Tcp/Tcp)
enlarged lymph nodes J:211773
\Gmpsem1(IMPC)Tcp/\Gmps+
(C57BL/6NCrl-Gmpsem1(IMPC)Tcp/Tcp)
increased leukocyte cell number J:211773
increased lymphocyte cell number J:211773
\Gna11tm1Soff/\Gna11tm1Soff
(involves: 129S7/SvEvBrd)
decreased susceptibility to type I hypersensitivity reaction J:146132
\Gna11tm1Soff/\Gna11tm1Soff
\Gnaqtm2Soff/\Gnaqtm2Soff
\Tg(Tek-icre/ERT2)1Soff/?

(involves: 129P2/OlaHsd * 129S7/SvEvBrd * FVB/N)
decreased susceptibility to type I hypersensitivity reaction J:146132
immune system phenotype J:146132
\Gna12tm1.1Cgh/\Gna12tm1.1Cgh
\Gna13tm2Cgh/\Gna13tm2Cgh
\Tg(Mx1-cre)1Cgn/0

(involves: 129S4/SvJae * C57BL/6 * CBA)
abnormal germinal center B cell morphology J:174313
decreased B cell apoptosis J:174313
increased germinal center B cell number J:174313
\Gna12tm1Citb/\Gna12tm1Citb
\Gna13tm2.1Soff/\Gna13tm2.1Soff
\Tg(Lck-cre)548Jxm/0

(involves: 129S1/Sv * C57BL/6 * CBA)
abnormal CD4-positive, alpha-beta T cell physiology J:149560
increased CD4-positive, alpha-beta T cell number J:149560
increased CD8-positive, alpha-beta T cell number J:149560
increased interleukin-2 secretion J:149560
increased susceptibility to autoimmune diabetes J:149560
increased susceptibility to type IV hypersensitivity reaction J:149560
increased T cell proliferation J:149560
lymph node hyperplasia J:149560
thymus hyperplasia J:149560
\Gnai1tm1b(EUCOMM)Wtsi/\Gnai1tm1b(EUCOMM)Wtsi
(C57BL/6N-Gnai1tm1b(EUCOMM)Wtsi/Bay)
abnormal spleen morphology J:211773
\Gnai1tm1Drs/\Gnai1tm1Drs
\Gnai3tm1Lbi/\Gnai3tm1Lbi

(involves: 129S/SvEv)
decreased interleukin-10 secretion J:104683
increased tumor necrosis factor secretion J:104683
\Gnai2tm1Lbi/\Gnai2tm1Lbi
(involves: 129S7/SvEvBrd * C57BL/6J)
colitis J:24434
\Gnai2tm1Lbi/\Gnai2tm1Lbi
(involves: 129S7/SvEvBrd)
abnormal cytokine level J:121471
abnormal cytokine secretion J:30507
abnormal immune system morphology J:30507
abnormal immune system physiology J:30507
abnormal neutrophil physiology J:121471
colitis J:24434
increased circulating interferon-gamma level J:121471
increased circulating interleukin-4 level J:121471
increased circulating interleukin-5 level J:121471
increased granulocyte number J:30507
increased IgA level J:30507
increased IgG level J:30507
increased immunoglobulin level J:30507
increased inflammatory response J:30507
increased interferon-gamma secretion J:30507
increased interleukin-2 secretion J:30507
increased single-positive T cell number J:30507
increased susceptibility to parasitic infection J:121471
increased T cell number J:30507
increased T cell proliferation J:30507
increased tumor necrosis factor secretion J:30507
large intestinal inflammation J:30507
peritoneal inflammation J:30507
\Gnai2tm1Lbi/\Gnai2tm1Lbi
(either: 129 or (involves: 129S7/SvEvBrd * C57BL/6J))
abnormal cytokine secretion J:24434
increased granulocyte number J:24434
increased IgG level J:24434
increased IgM level J:24434
increased thymocyte number J:24434
\Gnai2tm1Lbi/\Gnai2tm1Lbi
(129-Gnai2tm1Lbi)
abnormal cytokine secretion J:91100
immune system phenotype J:91100
increased interleukin-1 beta secretion J:91100
increased tumor necrosis factor secretion J:91100
\Gnai2tm1Lbi/\Gnai2tm1Lbi
(B6.129S7-Gnai2tm1Lbi)
abnormal cellular extravasation J:120069
abnormal eosinophil physiology J:120069
abnormal leukocyte adhesion J:120069
abnormal leukocyte cell number J:121161
abnormal T cell physiology J:121161
decreased eosinophil cell number J:120069
increased eosinophil cell number J:120069
increased lymphocyte cell number J:120069
increased monocyte cell number J:120069
increased neutrophil cell number J:120069
\Gnai2tm1Lbi/\Gnai2tm1Lbi
(involves: 129S7/SvEvBrd * C57BL/6)
abnormal cytokine secretion J:91100
colitis J:91100
increased interleukin-1 beta secretion J:91100
increased tumor necrosis factor secretion J:91100
\Gnai2tm2.1Lbi/\Gnai2tm2.1Lbi
\Tg(Cd4-cre)1Cwi/0

(involves: 129S/SvEv * C57BL/6 * C57BL/6NTac * DBA)
decreased T-helper 17 cell number J:194587
increased susceptibility to induced colitis J:194587
\Gnai3tm1Lbi/\Gnai3tm1Lbi
(involves: 129S/SvEv * C57BL/6)
immune system phenotype J:120069
\Gnai3tm1Lbi/\Gnai3tm1Lbi
(B6.129S-Gnai3tm1Lbi)
abnormal T cell physiology J:121161
\Gnao1tm1b(EUCOMM)Hmgu/\Gnao1+
(C57BL/6N-Gnao1tm1b(EUCOMM)Hmgu/H)
decreased eosinophil cell number J:211773
\GnasOedsml/\Gnas+
(involves: 101/H * C3H/HeH)
abnormal inflammatory response J:65007
\Gnastm1Lsw/\Gnas+
(involves: 129S4/SvJae * CD-1)
thymus cortex atrophy J:49340
\Gnb1lem1(IMPC)Tcp/\Gnb1l+
(C57BL/6NCrl-Gnb1lem1(IMPC)Tcp/Tcp)
increased neutrophil cell number J:211773
\Gnb1lGt(OST35527)Lex/\Gnb1l+
(B6;129S5-Gnb1lGt(OST35527)Lex/Orl)
abnormal spleen B cell follicle morphology J:82809
glomerulonephritis J:82809
\Gnb2em1(IMPC)J/\Gnb2em1(IMPC)J
(C57BL/6NJ-Gnb2em1(IMPC)J/Mmjax)
increased leukocyte cell number J:211773
\Gnb4em1(IMPC)H/\Gnb4em1(IMPC)H
(C57BL/6NTac-Gnb4em1(IMPC)H/H)
enlarged spleen J:211773
\Gnetm1.1Masn/\Gnetm1.1Masn
(involves: 129P2/OlaHsd * C57BL/6)
kidney inflammation J:184315
\Gngt2em1(IMPC)Bay/\Gngt2em1(IMPC)Bay
(C57BL/6N-Gngt2em1(IMPC)Bay/BayMmucd)
increased spleen weight J:211773
\Gnl2em1(IMPC)Ccpcz/\Gnl2+
(C57BL/6NCrl-Gnl2em1(IMPC)Ccpcz/Ccpcz)
abnormal lymph node morphology J:211773
abnormal spleen morphology J:211773
enlarged lymph nodes J:211773
enlarged spleen J:211773
\Gnmttm1Ymac/\Gnmttm1Ymac
(involves: 129 * C57BL/6)
decreased leukocyte cell number J:147857
decreased monocyte cell number J:147857
decreased neutrophil cell number J:147857
\Gnpda1tm1b(KOMP)Mbp/\Gnpda1+
(C57BL/6N-Gnpda1tm1b(KOMP)Mbp/Tcp)
increased neutrophil cell number J:211773
\Gnptabem1(IMPC)Mbp/\Gnptab+
(C57BL/6N-Gnptabem1(IMPC)Mbp/MbpMmucd)
abnormal lymph node morphology J:211773
abnormal spleen morphology J:211773
enlarged lymph nodes J:211773
enlarged spleen J:211773
\Gnptabnym/\Gnptabnym
(involves: BALB/cAnNHsd * C3H/HeNHsd)
brain inflammation J:218156
\Gnptabtm1Dkji/\Gnptabtm1Dkji
(involves: 129 * C57BL/6)
increased interleukin-6 secretion J:231531
\Gnptabtm1Kkol/\Gnptabtm1Kkol
(involves: 129 * C57BL/6)
abnormal osteoclast physiology J:202751
increased osteoclast cell number J:202751
\Gnrh1hpg/\Gnrh1hpg
(HPG/BmJ)
abnormal splenic cell ratio J:19436
increased B cell number J:19436
increased immature B cell number J:19436
increased mature B cell number J:19436
\Gnstm1e(EUCOMM)Hmgu/\Gnstm1e(EUCOMM)Hmgu
(C57BL/6N-Atm1Brd Gnstm1e(EUCOMM)Hmgu)
microgliosis J:242250
\Golga2tm1(KOMP)Vlcg/\Golga2tm1(KOMP)Vlcg
(involves: C57BL/6NTac)
increased alveolar macrophage number J:270564
\Golm1Gt(KST273)Byg/\Golm1Gt(KST273)Byg
(involves: 129P2/OlaHsd * C57BL/6)
kidney inflammation J:151282
liver inflammation J:151282
\Golph3em1(IMPC)Tcp/\Golph3+
(C57BL/6NCrl-Golph3em1(IMPC)Tcp/Tcp)
enlarged lymph nodes J:211773
\Golph3em1(IMPC)Tcp/\Golph3em1(IMPC)Tcp
(C57BL/6NCrl-Golph3em1(IMPC)Tcp/Tcp)
abnormal spleen morphology J:211773
enlarged thymus J:211773
\Golt1btm1b(EUCOMM)Wtsi/\Golt1btm1b(EUCOMM)Wtsi
(C57BL/6N-Golt1btm1b(EUCOMM)Wtsi/Ieg)
enlarged lymph nodes J:211773
enlarged spleen J:211773
enlarged thymus J:211773
\Gon4ljusty/\Gon4ljusty
(C3HeB/FeJ-Gon4ljusty)
abnormal humoral immune response J:163412
absent B cells J:163412
arrested B cell differentiation J:163412
decreased B cell number J:163412
decreased immature B cell number J:163412
decreased immunoglobulin level J:163412
decreased pro-B cell number J:163412
decreased spleen white pulp amount J:163412
decreased T cell number J:163412
small spleen J:163412
spleen hypoplasia J:163412
\Got1tm1b(EUCOMM)Hmgu/\Got1+
(C57BL/6N-Got1tm1b(EUCOMM)Hmgu/H)
decreased basophil cell number J:211773
decreased leukocyte cell number J:211773
decreased lymphocyte cell number J:211773
\Got2em1(IMPC)Mbp/\Got2+
(C57BL/6N-Got2em1(IMPC)Mbp/MbpMmucd)
enlarged spleen J:211773
small spleen J:211773
\Gp2em1(IMPC)Mbp/\Gp2em1(IMPC)Mbp
(C57BL/6N-Gp2em1(IMPC)Mbp/MbpMmucd)
abnormal lymph node morphology J:211773
abnormal spleen morphology J:211773
enlarged lymph nodes J:211773
enlarged spleen J:211773
\Gp6tm1Beni/\Gp6tm1Beni
\Clec1btm1.1Arte/\Clec1btm1.1Arte
\Tg(Pf4-icre)Q3Rsko/0

(involves: 129 * C57BL/6)
abnormal lymphatic vessel morphology J:217963
\Gp6tm2b(EUCOMM)Hmgu/\Gp6tm2b(EUCOMM)Hmgu
(C57BL/6N-Gp6tm2b(EUCOMM)Hmgu/Orl)
increased lymphocyte cell number J:211773
\Gp9tm1.1(KOMP)Vlcg/\Gp9tm1.1(KOMP)Vlcg
(C57BL/6N-Gp9tm1.1(KOMP)Vlcg/Ucd)
increased basophil cell number J:211773
\Gpa33tm1Jkhh/\Gpa33tm1Jkhh
(B6.129-Gpa33tm1Jkhh)
abnormal immune tolerance J:224768
increased dendritic cell number J:224768
increased susceptibility to induced colitis J:224768
increased susceptibility to type IV hypersensitivity reaction J:224768
\Gpa33tm1Jkhh/\Gpa33tm1Jkhh
(involves: 129 * C57BL/6)
increased susceptibility to colitis induced morbidity/mortality J:231808
increased susceptibility to induced colitis J:231808
\Gpatch2em1Boui/\Gpatch2em1Boui
(C57BL/6-Gpatch2em1Boui)
decreased B cell number J:336774
immune system phenotype J:336774
\Gpatch3em1(IMPC)Mbp/\Gpatch3em1(IMPC)Mbp
(C57BL/6N-Gpatch3em1(IMPC)Mbp/MbpMmucd)
enlarged lymph nodes J:211773
small spleen J:211773
\Gpatch4em1(IMPC)Ccpcz/\Gpatch4em1(IMPC)Ccpcz
(C57BL/6NCrl-Gpatch4em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
decreased CD8-positive, alpha-beta T cell number J:211773
immune system phenotype J:211773
small spleen J:211773
\Gpbar1tm1.1(KOMP)Vlcg/\Gpbar1tm1.1(KOMP)Vlcg
(C57BL/6N-Gpbar1tm1.1(KOMP)Vlcg/Ucd)
abnormal lymph node morphology J:211773
\Gpc1em1(IMPC)Mbp/\Gpc1em1(IMPC)Mbp
(C57BL/6N-Gpc1em1(IMPC)Mbp/MbpMmucd)
abnormal lymph node morphology J:211773
enlarged lymph nodes J:211773
\Gpc3tm1Arge/Y
(either: (involves: 129S/SvEv * 129S1/Sv) or (involves: 129S1/Sv * C57BL/6J))
decreased spleen weight J:75054
increased spleen B cell follicle size J:75054
small spleen J:75054
\Gpc3tm1Fil/Y
(B6.Cg-Gpc3tm1Fil)
increased susceptibility to bacterial infection J:73877
lung inflammation J:73877
rhinitis J:73877
\Gpc3tm1Fil/\Gpc3tm1Fil
(B6.Cg-Gpc3tm1Fil)
increased susceptibility to bacterial infection J:73877
lung inflammation J:73877
\Gpc3tm1Snd/Y
(involves: 129X1/SvJ * C57BL/6)
abnormal osteoclast differentiation J:104555
\Gpcpd1em1(IMPC)Tcp/\Gpcpd1+
(C57BL/6N-Gpcpd1em1(IMPC)Tcp/Tcp)
enlarged lymph nodes J:211773
\Gpdc1C3H/HeN/\Gpdc1C3H/HeN
(involves: C3H/HeN-Gnai2tm1Uru * C57BL/6J-Gna2tm1Uru)
colitis J:95140
\Gpdc2C3H/HeN/\Gpdc2C3H/HeN
(involves: C3H/HeN-Gnai2tm1Uru * C57BL/6J-Gna2tm1Uru)
colitis J:95140
\Gpdc3C3H/HeN/?
(involves: C3H/HeN-Gnai2tm1Uru * C57BL/6J-Gna2tm1Uru)
colitis J:95140
\Gper1tm1Dgen/\Gper1tm1Dgen
(B6.129-Gper1tm1Dgen)
decreased CD4-positive, alpha-beta T cell number J:151816
decreased CD8-positive, alpha-beta T cell number J:151816
decreased T cell number J:151816
\Gpi1b-m1Neu/\Gpi1b-m1Neu
(C3.Cg-Gpi1b-m1Neu)
increased spleen weight J:35956
\Gpi1b-m2Neu/\Gpi1b-m2Neu
(C3.Cg-Gpi1b-m2Neu)
increased spleen weight J:35956
\Gpld1tm1.1(KOMP)Vlcg/\Gpld1tm1.1(KOMP)Vlcg
(C57BL/6N-Gpld1tm1.1(KOMP)Vlcg/Ucd)
increased spleen weight J:211773
\Gpm6btm1Kan\Plp1tm1Kan/Y
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)
microgliosis J:193310
\Gpnmbtm1Ari/\Gpnmbtm1Ari
(C57BL/6-Gpnmbtm1Ari)
abnormal dendritic cell physiology J:215931
\Gpr15tm1.1Litt/\Gpr15tm1.1Litt
(B6.129P2-Gpr15tm1.1Litt)
abnormal regulatory T cell physiology J:199126
decreased CD4-positive, alpha-beta T cell number J:199126
decreased double-negative T cell number J:199126
decreased regulatory T cell number J:199126
immune system phenotype J:199126
increased CD8-positive, alpha-beta T cell number J:199126
increased susceptibility to bacterial infection J:199126
increased susceptibility to bacterial infection induced morbidity/mortality J:199126
increased susceptibility to induced colitis J:199126
\Gpr15tm1.1Litt/\Gpr15tm1.1Litt
(involves: 129P2/OlaHsd * C57BL/6)
decreased regulatory T cell number J:199126
increased interferon-gamma secretion J:199126
increased interleukin-17 secretion J:199126
\Gpr15tm1.1Litt/\Gpr15tm1.1Litt
\Rag2tm1Fwa/\Rag2tm1Fwa
\Tg(TcraTcrb)425Cbn/0

(involves: 129P2/OlaHsd * 129S/SvEv * BALB/c * C57BL/6)
abnormal immune system physiology J:199126
\Gpr15lgtm1Lex/\Gpr15lgtm1Lex
(B6;129S5-Gpr15lgtm1Lex/Mmucd)
increased IgG2a level J:171883
\Gpr17tm1b(KOMP)Mbp/\Gpr17tm1b(KOMP)Mbp
(C57BL/6N-Gpr17tm1b(KOMP)Mbp/Tcp)
increased neutrophil cell number J:211773
\Gpr18tm1.1Cys/\Gpr18tm1.1Cys
(involves: C57BL/6)
decreased CD8-positive, alpha-beta T cell number J:219661
decreased CD8-positive, gamma-delta intraepithelial T cell number J:219661
immune system phenotype J:219661
\Gpr18tm1Lex/\Gpr18tm1Lex
(involves: 129S/SvEv * C57BL/6)
increased susceptibility to bacterial infection J:226433
\Gpr21tm1Dgen/\Gpr21tm1Dgen
(B6.129P2-Gpr21tm1Dgen)
abnormal circulating chemokine level J:181127
decreased circulating serum amyloid protein level J:181127
\Gpr31btm1Ktak/\Gpr31btm1Ktak
(B6.Cg-Gpr31btm1Ktak)
abnormal dendritic cell physiology J:271242
decreased inflammatory response J:271242
increased susceptibility to bacterial infection J:271242
\Gpr34tm1.1Shbg/\Gpr34tm1.1Shbg
(B6.Cg-Gpr34tm1.1Shbg)
abnormal chemokine secretion J:168120
abnormal cytokine secretion J:168120
abnormal leukocyte migration J:168120
increased interferon-gamma secretion J:168120
increased interleukin-2 secretion J:168120
increased interleukin-4 secretion J:168120
increased interleukin-5 secretion J:168120
increased interleukin-10 secretion J:168120
increased interleukin-12 secretion J:168120
increased susceptibility to fungal infection J:168120
increased susceptibility to type IV hypersensitivity reaction J:168120
increased tumor necrosis factor secretion J:168120
\Gpr35em1Niess/\Gpr35em1Niess
(C57BL/6N-Gpr35em1Niess)
immune system phenotype J:300275
increased susceptibility to induced colitis J:300275
\Gpr35em2Niess/\Gpr35em2Niess
\Cx3cr1tm2.1(cre/ERT2)Litt/\Cx3cr1+

(involves: 129P2/OlaHsd * C57BL/6N)
increased susceptibility to induced colitis J:300275
\Gpr35tm1(KOMP)Vlcg/\Gpr35tm1(KOMP)Vlcg
(C57BL/6N-Gpr35tm1(KOMP)Vlcg/MbpMmucd)
abnormal chemokine level J:306520
abnormal interleukin level J:306520
decreased susceptibility to colitis induced morbidity/mortality J:306520
decreased susceptibility to induced colitis J:306520
\Gpr55tm1.1Mijr/\Gpr55tm1.1Mijr
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
abnormal osteoclast differentiation J:153225
abnormal osteoclast morphology J:153225
abnormal osteoclast physiology J:153225
decreased osteoclast cell number J:153225
increased osteoclast cell number J:153225
\Gpr65tm1Witt/\Gpr65tm1Witt
(B6.Cg-Gpr65tm1Witt)
abnormal immune cell physiology J:96112
abnormal leukocyte physiology J:96112
\Gpr65tm1Witt/\Gpr65tm1Witt
(C.Cg-Gpr65tm1Witt)
abnormal leukocyte physiology J:96112
\Gpr65Tn(sb-lacZ,GFP)T1.88Jtak/\Gpr65Tn(sb-lacZ,GFP)T1.88Jtak
(B6.Cg-Gpr65Tn(sb-lacZ,GFP)T1.88Jtak)
abnormal interleukin-1 beta secretion J:208788
abnormal macrophage physiology J:146233
decreased tumor necrosis factor secretion J:146233
\Gpr68em1(IMPC)Bay/\Gpr68em1(IMPC)Bay
(C57BL/6N-Gpr68em1(IMPC)Bay/Bay)
decreased leukocyte cell number J:211773
\Gpr68tm1.1Yaxu/\Gpr68tm1.1Yaxu
(B6.Cg-Gpr68tm1.1Yaxu)
abnormal osteoclast differentiation J:149315
abnormal osteoclast physiology J:149315
immune system phenotype J:149315
\Gpr68tm1.1Yaxu/\Gpr68tm1.1Yaxu
(involves: 129S4/SvJae * C57BL/6 * FVB/N)
abnormal macrophage physiology J:149315
abnormal osteoclast differentiation J:149315
abnormal osteoclast physiology J:149315
decreased macrophage cell number J:149315
increased monocyte cell number J:149315
\Gpr68tm1Aha/\Gpr68tm1Aha
(B6.129-Gpr68tm1Aha)
immune system phenotype J:146233
\Gpr68tm1Yaxu/\Gpr68tm1Yaxu
(involves: C57BL/6)
abnormal macrophage physiology J:149315
abnormal osteoclast differentiation J:149315
abnormal osteoclast physiology J:149315
decreased monocyte cell number J:149315
\Gpr83em1(IMPC)Ccpcz/\Gpr83em1(IMPC)Ccpcz
(C57BL/6NCrl-Gpr83em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
decreased CD4-positive NK T cell number J:211773
decreased memory-marker CD4-positive NK T cell number J:211773
decreased NK T cell number J:211773
enlarged spleen J:211773
enlarged thymus J:211773
\Gpr83tm1.1Fpow/\Gpr83tm1.1Fpow
(C.129-Gpr83tm1.1Fpow)
decreased CD4-positive, alpha-beta T cell number J:144445
immune system phenotype J:144445
spleen hyperplasia J:144445
\Gpr84tm1Lex/\Gpr84tm1Lex
(involves: 129S/SvEvBrd * C57BL/6)
abnormal T-helper 2 physiology J:186985
immune system phenotype J:186985
increased interleukin-4 secretion J:186985
increased interleukin-5 secretion J:186985
increased interleukin-13 secretion J:186985
\Gpr89ex/\Gpr89ex
(C57BL/6J-Gpr89ex)
abnormal T cell morphology J:287198
abnormal T cell number J:287198
\Gpr89tm1.1Ymae/\Gpr89tm1.1Ymae
\Tg(KRT5-cre)1Tak/0

(involves: C3H * C57BL/6)
dermatitis J:189574
\Gpr101em7036Tac/Y
(C57BL/6NTac-Gpr101em7036Tac)
abnormal microglial cell activation J:347398
abnormal microglial cell morphology J:347398
increased circulating tumor necrosis factor level J:347398
increased inflammatory response J:347398
increased monocyte cell number J:347398
\Gpr108tm1.1Brs/\Gpr108tm1.1Brs
(involves: 129S6/SvEvTac)
decreased susceptibility to bacterial infection induced morbidity/mortality J:266821
decreased tumor necrosis factor secretion J:266821
increased interleukin-6 secretion J:266821
increased susceptibility to endotoxin shock J:266821
increased tumor necrosis factor secretion J:266821
\Gpr132tm1Witt/\Gpr132tm1Witt
(B6.129X1-Gpr132tm1Witt)
impaired macrophage chemotaxis J:96613
\Gpr132tm1Witt/\Gpr132tm1Witt
(involves: 129X1/SvJ * BALB/c)
abnormal immune system organ morphology J:69473
abnormal lymph node morphology J:69473
abnormal lymphocyte physiology J:69473
enlarged inguinal lymph nodes J:69473
enlarged spleen J:69473
increased anti-nuclear antigen antibody level J:69473
increased B cell proliferation J:69473
increased IgA level J:69473
increased IgG1 level J:69473
increased immunoglobulin level J:69473
increased inflammatory response J:69473
increased T cell proliferation J:69473
kidney inflammation J:69473
liver inflammation J:69473
lung inflammation J:69473
\Gpr132tm1Witt/\Gpr132tm1Witt
\Ldlrtm1Her/\Ldlrtm1Her

(B6.129-Ldlrtm1Her Gpr132tm1Witt)
decreased macrophage apoptosis J:100498
\Gpr137btm1b(KOMP)Wtsi/\Gpr137btm1b(KOMP)Wtsi
(C57BL/6N-Gpr137btm1b(KOMP)Wtsi/H)
increased neutrophil cell number J:211773
\Gpr146em1(IMPC)H/\Gpr146em1(IMPC)H
(C57BL/6NTac-Gpr146em1(IMPC)H/H)
increased spleen weight J:211773
\Gpr146em1Bdu/\Gpr146em1Bdu
(C57BL/6-Gpr146em1Bdu)
immune system phenotype J:247263
\Gpr155em1(IMPC)Mbp/\Gpr155em1(IMPC)Mbp
(C57BL/6N-Gpr155em1(IMPC)Mbp/Ucd)
abnormal lymph node morphology J:211773
enlarged lymph nodes J:211773
\Gpr174tm1Cys/Y
(B6.129-Gpr174tm1Cys)
abnormal regulatory T cell physiology J:222307
abnormal T-helper 1 cell differentiation J:222307
decreased susceptibility to experimental autoimmune encephalomyelitis J:222307
immune system phenotype J:222307
increased single-positive T cell number J:222307
increased T cell proliferation J:222307
\Gpr174tm1Cys/\Gpr174+
(B6.129-Gpr174tm1Cys)
decreased susceptibility to experimental autoimmune encephalomyelitis J:222307
\Gpr182tm2b(KOMP)Wtsi/\Gpr182tm2b(KOMP)Wtsi
(C57BL/6N-Gpr182tm2b(KOMP)Wtsi/Ucd)
increased spleen weight J:211773
\Gpr182tm2c(KOMP)Wtsi/\Gpr182tm2c(KOMP)Wtsi
\Tg(Cdh5-cre/ERT2)1Rha/0

(B6.Cg-Gpr182tm2c(KOMP)Wtsi Tg(Cdh5-cre/ERT2)1Rha)
abnormal circulating chemokine level J:305796
increased circulating CXCL10 level J:305796
increased monocyte cell number J:305796
increased neutrophil cell number J:305796
\Gpr183tm1.1Cys/\Gpr183tm1.1Cys
(B6.129P2-Gpr183tm1.1Cys)
abnormal follicular B cell physiology J:151077
\Gpr183tm1.2Rbr/\Gpr183tm1.2Rbr
(involves: C57BL/6 * FVB/N * SJL)
abnormal B cell physiology J:151883
decreased plasma cell number J:151883
\Gpr183tm1.2Rbr/\Gpr183tm1.2Rbr
\Ightm1Rbr/\Ightm1Rbr
\Tg(IgkHyHEL10)1Rbr/0

(involves: C57BL/6 * FVB/N * SJL)
abnormal B cell physiology J:151883
abnormal B cell proliferation J:151883
decreased B cell number J:151883
decreased IgG1 level J:151883
decreased IgM level J:151883
decreased plasma cell number J:151883
impaired B cell migration J:151883
\Gpr183tm1Lex/\Gpr183tm1Lex
(involves: 129S5/SvEvBrd * C57BL/6)
abnormal circulating interferon-beta level J:211122
decreased myeloid dendritic cell number J:211122
decreased plasmacytoid dendritic cell number J:211122
increased circulating interferon-alpha level J:211122
increased circulating interferon-gamma level J:211122
\Gprc5atm1Rlo/\Gprc5atm1Rlo
(involves: 129 * C57BL/6)
lung inflammation J:127821
\Gprc5ctm1Yhir/\Gprc5ctm1Yhir
(B6.Cg-Gprc5ctm1Yhir)
increased basophil cell number J:176063
\Gprc6atm1.1(KOMP)Vlcg/\Gprc6atm1.1(KOMP)Vlcg
(C57BL/6N-Gprc6atm1.1(KOMP)Vlcg/Ucd)
increased thymus weight J:211773
\Gpsm3Gt(IST12408A1)Tigm/\Gpsm3Gt(IST12408A1)Tigm
(involves: C57BL/6N)
abnormal leukocyte migration J:193270
abnormal leukocyte physiology J:193270
decreased monocyte cell number J:193270
decreased susceptibility to induced arthritis J:193270
\Gpx1tm1Kola/\Gpx1tm1Kola
(involves: 129S2/SvPas * BALB/c * CF-1)
increased inflammatory response J:79183
\Gpx1tm1Kola/\Gpx1tm1Kola
(B6.129S2(CF1)-Gpx1tm1Kola)
immune system phenotype J:100436
\Gpx1tm1Ysh/\Gpx1+
\Gpx2tm2Coh/\Gpx2tm2Coh

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)
intestinal inflammation J:71506
\Gpx1tm1Ysh/\Gpx1tm1Ysh
\Gpx2tm2Coh/\Gpx2+

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)
intestinal inflammation J:71506
\Gpx1tm1Ysh/\Gpx1tm1Ysh
\Gpx2tm2Coh/\Gpx2tm2Coh

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)
colitis J:71506
intestinal inflammation J:71506
small intestinal inflammation J:71506
\Gpx7tm1Whle/\Gpx7tm1Whle
(involves: 129P2/OlaHsd * C57BL/6)
abnormal humoral immune response J:193993
enlarged spleen J:193993
glomerulonephritis J:193993
increased anti-nuclear antigen antibody level J:193993
\Gpx8tm1Lex/\Gpx8tm1Lex
(B6;129S5-Gpx8tm1Lex/Mmucd)
dermatitis J:171883
\Gramd2aem1(IMPC)Tcp/\Gramd2aem1(IMPC)Tcp
(C57BL/6NCrl-Gramd2aem1(IMPC)Tcp/Tcp)
enlarged lymph nodes J:211773
\Grap2tm1Amch/\Grap2tm1Amch
(involves: 129S1/Sv * 129X1/SvJ)
arrested T cell differentiation J:76696
decreased CD4-positive, alpha-beta T cell number J:76696
decreased CD8-positive, alpha-beta T cell number J:76696
decreased thymocyte number J:76696
increased double-negative T cell number J:76696
\Grap2tm1Amch/\Grap2tm1Amch
\Lcp2tm1.1Wz/\Lcp2tm1.1Wz

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
abnormal T cell differentiation J:150304
decreased CD4-positive, alpha-beta T cell number J:150304
decreased CD8-positive, alpha-beta T cell number J:150304
decreased double-positive T cell number J:150304
decreased single-positive T cell number J:150304
\Grap2tm1Eac/\Grap2tm1Eac
(involves: C57BL/6)
abnormal CD4-positive, alpha beta T cell morphology J:92023
abnormal double-negative T cell morphology J:92023
decreased T cell number J:92023
decreased thymocyte number J:92023
increased activated T cell number J:92023
increased memory T cell number J:92023
\Graptm1Gsf/\Graptm1Gsf
(B6.129-Graptm1Gsf)
increased CD4-positive, alpha-beta T cell number J:76243
increased T cell proliferation J:76243
\Grass1C57BL/6J/\Grass1C57BL/6J
(involves: C57BL/6J * DBA/2J)
decreased susceptibility to bacterial infection J:134374
decreased susceptibility to bacterial infection induced morbidity/mortality J:134374
sepsis J:134374
\Grass1C57BL/6J/\Grass1DBA/2J
(involves: C57BL/6J * DBA/2J)
increased susceptibility to bacterial infection J:134374
sepsis J:134374
\Grass1DBA/2J/\Grass1DBA/2J
(involves: C57BL/6J * DBA/2J)
increased susceptibility to bacterial infection J:134374
sepsis J:134374
\Grb2tm1.1Hua/\Grb2tm1.1Hua
\Tg(DO11.10)10Dlo/0
\Tg(Lck-cre)1Jtak/0

(involves: 129 * BALB/c * C3H * C57BL/6)
abnormal T cell differentiation J:161294
decreased CD4-positive, alpha-beta T cell number J:161294
\Grb2tm1.1Hua/\Grb2tm1.1Hua
\Tg(Lck-cre)1Jtak/0

(involves: 129 * C57BL/6)
abnormal T cell differentiation J:161294
decreased CD4-positive, alpha-beta T cell number J:161294
decreased CD8-positive, alpha-beta T cell number J:161294
decreased double-positive T cell number J:161294
decreased thymocyte number J:161294
\Grb2tm1.1Hua/\Grb2tm1.1Hua
\Tg(Lck-cre)1Jtak/0
\Tg(TcraH-Y,TcrbH-Y)71Vbo/0

(involves: 129 * C57BL/6 * C57BL/6J * DBA/2J)
abnormal T cell differentiation J:161294
decreased CD4-positive, alpha-beta T cell number J:161294
decreased CD8-positive, alpha-beta T cell number J:161294
increased CD8-positive, alpha-beta T cell number J:161294
increased double-positive T cell number J:161294
\Grb2tm1Lnit/\Grb2tm1Lnit
\Cd79atm1(cre)Reth/\Cd79a+

(involves: BALB/c * BALB/cJ)
abnormal B cell differentiation J:171222
abnormal B cell physiology J:171222
abnormal memory B cell physiology J:171222
decreased B cell number J:171222
decreased follicular B cell number J:171222
decreased IgG3 level J:171222
decreased IgG level J:171222
decreased mature B cell number J:171222
decreased spleen germinal center number J:171222
decreased spleen germinal center size J:171222
decreased transitional stage T1 B cell number J:171222
decreased transitional stage T2 B cell number J:171222
increased B cell apoptosis J:171222
increased B cell proliferation J:171222
increased IgM level J:171222
increased plasma cell number J:171222
\Grb2tm1Paw/\Grb2+
(involves: 129S1/Sv * 129X1/SvJ * BALB/c)
decreased susceptibility to Retroviridae infection J:122429
\Grb2tm1Paw/\Grb2+
\Ptentm2Mak/\Ptentm2Mak
\Tg(Lck-cre)548Jxm/0

(involves: 129P2/OlaHsd * C57BL/6 * CBA)
increased T cell derived lymphoma incidence J:93530
\Grb14tm1Daly/\Grb14tm1Daly
(involves: 129X1/SvJ * C57BL/6)
decreased spleen weight J:87892
\Greb1em1Rkom/\Greb1em1Rkom
(C57BL/6NJ-Greb1em1Rkom)
abnormal response to transplant J:346713
\Grem2em1Stpg/\Grem2em1Stpg
(involves: 129S7/SvEvBrd * C57BL/6 * C57BL/6J)
ovary inflammation J:318711
\Grem2tm1Akh/\Grem2tm1Akh
(involves: 129/Sv * C57BL/6)
abnormal chemokine level J:250034
increased inflammatory response J:250034
increased interleukin-10 secretion J:250034
increased leukocyte cell number J:250034
\Grem2tm1Lex/\Grem2tm1Lex
(involves: 129S5/SvEvBrd * C57BL/6)
immune system phenotype J:227246
\Grhl3tm1a(EUCOMM)Wtsi/\Grhl3+
(C57BL/6N-Grhl3tm1a(EUCOMM)Wtsi/Ics)
decreased IgE level J:165965
\GrhprGt(OST383093)Lex/\GrhprGt(OST383093)Lex
(involves: 129S5/SvEvBrd * C57BL/6)
urinary bladder inflammation J:181969
\Grik3em1(IMPC)Mbp/\Grik3em1(IMPC)Mbp
(C57BL/6N-Grik3em1(IMPC)Mbp/MbpMmucd)
abnormal spleen morphology J:211773
\Grk2tm1Gwd/\Grk2tm1Gwd
\Cd79atm1(cre)Reth/\Cd79a+

(involves: 129 * BALB/c * C57BL/6)
abnormal B cell physiology J:176118
decreased B cell number J:176118
increased B cell number J:176118
increased CD4-positive, alpha-beta T cell number J:176118
increased CD8-positive, alpha-beta T cell number J:176118
increased follicular B cell number J:176118
increased marginal zone B cell number J:176118
\Grk2tm1Gwd/\Grk2tm1Mca
\Tg(Cd4-cre)1Cwi/0

(involves: 129 * C57BL/6 * DBA/2)
abnormal T cell physiology J:176118
decreased CD4-positive, alpha-beta T cell number J:176118
decreased CD8-positive, alpha-beta T cell number J:176118
decreased T cell number J:176118
impaired leukocyte tethering or rolling J:176118
increased B cell number J:176118
\Grk6tm1.1Mca/\Grk6tm1.1Mca
(involves: 129S4/SvJae * C57BL/6J)
abnormal B cell physiology J:76872
abnormal T cell physiology J:76872
\Grk6tm1.1Mca/\Grk6tm1.1Mca
(B6.129S4-Grk6tm1.1Mca)
abnormal T cell subpopulation ratio J:225063
decreased CD8-positive, alpha-beta T cell number J:225063
decreased CD8-positive, naive alpha-beta T cell number J:225063
enlarged spleen J:225063
glomerulonephritis J:225063
impaired macrophage phagocytosis J:225063
increased anti-double stranded DNA antibody level J:225063
increased IgG level J:225063
increased memory T cell number J:225063
increased spleen iron level J:225063
increased spleen weight J:225063
increased spleen white pulp amount J:225063
increased splenocyte number J:225063
\Grntm1.1Aidi/\Grntm1.1Aidi
(involves: C57BL/6 * C57BL/6J)
abnormal chemokine secretion J:156824
abnormal macrophage physiology J:156824
abnormal microglial cell physiology J:156824
increased interleukin-6 secretion J:156824
increased interleukin-12 secretion J:156824
increased susceptibility to bacterial infection J:156824
increased tumor necrosis factor secretion J:156824
microgliosis J:156824
\Grntm1.1Aidi/\Grntm1.1Aidi
(involves: C57BL/6J)
kidney inflammation J:268827
\Grntm1.1Far/\Grntm1.1Far
(involves: 129S4/SvJae * FVB/N)
abnormal macrophage physiology J:170823
\Grntm1.1Far/\Grntm1.1Far
(involves: 129S4/SvJae * C57BL/6J * FVB/N)
increased interleukin-1 beta secretion J:188324
increased interleukin-6 secretion J:188324
increased interleukin-10 secretion J:188324
increased tumor necrosis factor secretion J:188324
microgliosis J:188324
\Grntm1.1Geno/\Grntm1.1Geno
(involves: 129 * C57BL/6J)
microgliosis J:188420
\Grntm1Blrl/\Grntm1Blrl
(involves: C57BL/6J)
microgliosis J:182051
\Grntm1Far/\Grntm1Far
\Tg(ITGAM-cre)2781Gkl/0

(involves: 129S4/SvJae * C57BL/6 * CBA * FVB/N)
microgliosis J:188324
\Grntm2.1Far/\Grntm2.1Far
(involves: 129S4/SvJae * C57BL/6)
abnormal macrophage physiology J:259651
microgliosis J:259651
\Grpem1(IMPC)H/\Grpem1(IMPC)H
(C57BL/6NTac-Grpem1(IMPC)H/H)
decreased monocyte cell number J:211773
\Grsf1tm1b(EUCOMM)Wtsi/\Grsf1tm1b(EUCOMM)Wtsi
(C57BL/6N-Grsf1tm1b(EUCOMM)Wtsi/Wtsi)
decreased leukocyte cell number J:211773
\Gsdma3Ae/\Gsdma3+
(involves: C57BL/6J * CAST/Ei)
enlarged lymph nodes J:180149
enlarged spleen J:180149
enlarged thymus J:180149
skin inflammation J:180149
\Gsdma3M2Btlr/\Gsdma3M2Btlr
(involves: C57BL/6J)
dermatitis J:209203
\Gsdma3tm1(KOMP)Vlcg/\Gsdma3tm1(KOMP)Vlcg
(C57BL/6N-Gsdma3tm1(KOMP)Vlcg/Nju)
increased lymphocyte cell number J:211773
\Gsdmaem1Cya/\Gsdmaem1Cya
(C57BL/6J-Gsdmaem1Cya)
increased susceptibility to bacterial infection J:326434
increased susceptibility to bacterial infection induced morbidity/mortality J:326434
\Gsdmcem1(IMPC)Tcp/\Gsdmcem1(IMPC)Tcp
(C57BL/6NCrl-Gsdmcem1(IMPC)Tcp/TcpMmucd)
enlarged lymph nodes J:211773
increased monocyte cell number J:211773
\Gsdmdem1Fcw/\Gsdmdem2Fcw
(involves: C57BL/6)
abnormal macrophage apoptosis J:226781
decreased interleukin-1 beta secretion J:226781
\Gsdmdem1Flv/\Gsdmdem1Flv
(C57BL/6N-Gsdmdem1Flv)
increased susceptibility to Riboviria infection induced morbidity/mortality J:243487
\Gsdmdem3Fcw/\Gsdmdem3Fcw
(involves: C57BL/6)
abnormal macrophage apoptosis J:226781
decreased interleukin-1 beta secretion J:226781
\Gsdmdem4Fcw/\Gsdmdem4Fcw
(C57BL/6N-Gsdmdem4Fcw/J)
abnormal macrophage apoptosis J:101977
abnormal susceptibility to bacterial infection J:101977
\Gsdmdm1Btlr/\Gsdmdm1Btlr
(C57BL/6J-Gsdmdm1Btlr)
decreased interleukin-1 beta secretion J:267555
\Gsk3atm1Dral/\Gsk3atm1Dral
\Gsk3btm1Dral/\Gsk3btm1Dral

(involves: 129P2/OlaHsd)
increased circulating interleukin-6 level J:200517
\Gsntm1Djk/\Gsntm1Djk
(either: (involves: 129S4/SvJae * BALB/c) or (involves: 129S4/SvJae * C57BL/6))
abnormal immune system physiology J:24346
abnormal osteoclast differentiation J:60625
abnormal osteoclast physiology J:60625
decreased inflammatory response J:24346
impaired neutrophil chemotaxis J:24346
impaired neutrophil recruitment J:24346
increased leukocyte cell number J:24346
increased neutrophil cell number J:24346
\Gsta4tm1Pzim/\Gsta4+
(involves: 129S1/Sv * 129S6/SvEvTac)
increased susceptibility to bacterial infection J:87983
\Gsta4tm1Pzim/\Gsta4tm1Pzim
(involves: 129S1/Sv * 129S6/SvEvTac)
abnormal bone marrow development J:87983
increased susceptibility to bacterial infection J:87983
\Gstcdtm1b(EUCOMM)Wtsi/\Gstcdtm1b(EUCOMM)Wtsi
(C57BL/6N-Gstcdtm1b(EUCOMM)Wtsi/Bay)
enlarged spleen J:211773
\Gstcdtm1b(EUCOMM)Wtsi/\Gstcdtm1b(EUCOMM)Wtsi
(C57BL/6-Gstcdtm1b(EUCOMM)Wtsi)
increased tumor necrosis factor secretion J:279480
\Gstk1tm1Pgb/\Gstk1tm1Pgb
(BALB/c-Gstk1tm1Pgb)
decreased spleen red pulp amount J:177201
decreased spleen weight J:177201
glomerulonephritis J:177201
urethritis J:177201
urinary bladder inflammation J:177201
\Gstm4tm2b(EUCOMM)Hmgu/\Gstm4tm2b(EUCOMM)Hmgu
(C57BL/6N-Gstm4tm2b(EUCOMM)Hmgu/Bay)
abnormal spleen morphology J:211773
\Gstt2em1Rmah/\Gstt2em1Rmah
(Not Specified)
decreased interleukin-12 secretion J:358834
decreased tumor necrosis factor secretion J:358834
increased inflammatory response J:358834
increased interleukin-6 secretion J:358834
increased interleukin-10 secretion J:358834
increased interleukin-12 secretion J:358834
increased tumor necrosis factor secretion J:358834
\Gstz1tm1Pgb/\Gstz1tm1Pgb
(BALB/c-Gstz1tm1Pgb/AnuApb)
chronic inflammation J:91519
decreased leukocyte cell number J:91519
decreased spleen weight J:91519
liver inflammation J:91519
\Gsx1tm1Ssp/\Gsx1tm1Ssp
(involves: 129P2/OlaHsd)
decreased leukocyte cell number J:31764
decreased lymphocyte cell number J:31764
decreased neutrophil cell number J:31764
\Gt(ROSA)26Sorem1(DPP4)Yowa/\Gt(ROSA)26Sorem1(DPP4)Yowa
(C57BL/6-Gt(ROSA)26Sorem1(DPP4)Yowa)
increased susceptibility to Coronaviridae infection J:279060
\Gt(ROSA)26Sorem1(Ube2s)Chaw/?
(involves: C57BL/6)
decreased interferon level J:306461
increased susceptibility to Picornaviridae infection induced morbidity/mortality J:306461
\Gt(ROSA)26Sortm1(B4galt1)Clib/\Gt(ROSA)26Sortm1(B4galt1)Clib
\Tg(Nes-cre)Wme/?

(involves: 129S6/SvEvTac * C57BL/6 * CBA)
decreased acute inflammation J:209737
decreased circulating interleukin-6 level J:209737
decreased susceptibility to induced colitis J:209737
\Gt(ROSA)26Sortm1(CAG-Bcl3,-EGFP)Hoev/\Gt(ROSA)26Sor+
\Cd19tm1(cre)Cgn/\Cd19+

(involves: 129P2/OlaHsd)
abnormal B cell differentiation J:208980
abnormal B-2 B cell morphology J:208980
abnormal class switch recombination J:208980
abnormal follicular B cell morphology J:208980
abnormal Peyer's patch germinal center morphology J:208980
abnormal transitional stage T3 B cell morphology J:208980
absent marginal zone B cells J:208980
decreased B cell apoptosis J:208980
decreased B cell proliferation J:208980
decreased B-1 B cell number J:208980
decreased B-1a cell number J:208980
decreased IgG1 level J:208980
decreased IgG2b level J:208980
decreased IgG3 level J:208980
decreased IgM level J:208980
decreased immature B cell number J:208980
decreased marginal zone B cell number J:208980
decreased transitional stage T1 B cell number J:208980
enlarged spleen J:208980
increased lymphocyte cell number J:208980
\Gt(ROSA)26Sortm1(CAG-CAMK2G*T287D,-EGFP)Whua/\Gt(ROSA)26Sor+
\Tg(Vil1-cre)997Gum/0

(involves: 129 * C57BL/6)
decreased susceptibility to induced colitis J:243363
\Gt(ROSA)26Sortm1(CAG-Foxn1/ERT2,-GFP)Cbln/\Gt(ROSA)26Sor+
\Foxn1tm3(cre)Nrm/\Foxn1+

(involves: 129P2/OlaHsd * C57BL/6)
abnormal thymus involution J:208852
increased T cell number J:208852
\Gt(ROSA)26Sortm1(CAG-FOXO1,GFP)Moli/\Gt(ROSA)26Sor+
\Foxp3tm4(YFP/icre)Ayr/\Foxp3+

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
immune system phenotype J:189962
\Gt(ROSA)26Sortm1(CAG-NPM1*)Geno/\Gt(ROSA)26Sor+
\Tg(Mx1-cre)1Cgn/0

(involves: C57BL/6 * CBA)
enlarged spleen J:196690
myeloid hyperplasia J:196690
\Gt(ROSA)26Sortm1(CAG-NPM1*)Geno/\Gt(ROSA)26Sortm1(CAG-NPM1*)Geno
\Tg(Mx1-cre)1Cgn/0

(involves: C57BL/6 * CBA)
enlarged spleen J:196690
\Gt(ROSA)26Sortm1(CAG-SETBP1*G870S,-EGFP)Ase/\Gt(ROSA)26Sor+
\Commd10Tg(Vav1-icre)A2Kio/\Commd10+

(involves: C57BL/6N * C57BL/10 * CBA/Ca)
abnormal spleen morphology J:363041
decreased lymphocyte cell number J:363041
hepatosplenomegaly J:363041
increased leukocyte cell number J:363041
myeloid hyperplasia J:363041
\Gt(ROSA)26Sortm1(CAG-SETBP1*G870S,-EGFP)Ase/\Gt(ROSA)26Sortm1(CAG-SETBP1*G870S,-EGFP)Ase
\Commd10Tg(Vav1-icre)A2Kio/\Commd10+

(involves: C57BL/6N * C57BL/10 * CBA/Ca)
abnormal myelopoiesis J:363041
decreased leukocyte cell number J:363041
increased neutrophil cell number J:363041
\Gt(ROSA)26Sortm1(CAG-Slc39a14*L438R)Wvh/\Gt(ROSA)26Sor+
\Tg(Runx2-icre)1Jtuc/0

(involves: FVB/N)
increased osteoclast cell number J:261326
\Gt(ROSA)26Sortm1(CARD14*)Ribt/\Gt(ROSA)26Sor+
\Malt1tm1c(EUCOMM)Hmgu/\Malt1tm1c(EUCOMM)Hmgu
\Tg(KRT14-cre/ERT)20Efu/0

(involves: 129S6/SvEvTac * C57BL/6NCrl * CD-1)
increased dendritic cell number J:292094
increased neutrophil cell number J:292094
skin inflammation J:292094
\Gt(ROSA)26Sortm1(CARD14*)Ribt/\Gt(ROSA)26Sor+
\Tg(KRT14-cre/ERT)20Efu/0

(involves: 129S6/SvEvTac * C57BL/6NCrl * CD-1)
increased dendritic cell number J:292094
increased neutrophil cell number J:292094
skin inflammation J:292094
\Gt(ROSA)26Sortm1(cre/ERT2)Thl/\Gt(ROSA)26Sor+
\Mcl1tm1Ywh/\Mcl1tm1Ywh

(involves: 129/Sv * 129S6/SvEvTac * C57BL/6)
increased T cell apoptosis J:137400
\Gt(ROSA)26Sortm1(cre/ERT2)Thl/\Gt(ROSA)26Sortm1(Tcfe2a/Tal1)Xhsu
(involves: 129/Sv * C57BL/6)
abnormal lymphopoiesis J:144569
abnormal myelopoiesis J:144569
\Gt(ROSA)26Sortm1(cre/ERT2)Tyj/\Gt(ROSA)26Sor+
\Tacc3tm1.1Tno/\Tacc3+
\Trp53tm1Tyj/\Trp53tm1Tyj

(involves: 129S2/SvPas * 129S4/SvJae * C57BL/6)
increased T cell derived lymphoma incidence J:179414
\Gt(ROSA)26Sortm1(cre/ERT2)Tyj/\Gt(ROSA)26Sor+
\Tacc3tm1.1Tno/\Tacc3tm1.2Tno
\Trp53tm1Tyj/\Trp53tm1Tyj

(involves: 129S2/SvPas * 129S4/SvJae * C57BL/6)
increased T cell derived lymphoma incidence J:179414
\Gt(ROSA)26Sortm1(cre/ERT2)Tyj/\Gt(ROSA)26Sortm1(Pyy)Paba
(involves: 129S4/SvJae)
abnormal osteoclast morphology J:189512
increased osteoclast cell number J:189512
\Gt(ROSA)26Sortm1(cre/ERT)Nat/\Gt(ROSA)26Sor+
\Il1r2tm1.1Epi/\Il1r2tm1.1Epi

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * C57BL/6NTac)
abnormal adaptive immunity J:347877
increased IgG level J:347877
increased spleen germinal center size J:347877
increased T follicular helper cell number J:347877
\Gt(ROSA)26Sortm1(cre/ERT)Nat/\Gt(ROSA)26Sor+
\Ptentm1Hwu/\Ptentm1Hwu

(involves: 129 * 129S4/SvJae * BALB/c * C57BL/6)
increased T cell derived lymphoma incidence J:130367
\Gt(ROSA)26Sortm1(CTNNB1)Nerl/\Gt(ROSA)26Sortm1(CTNNB1)Nerl
\Tg(Mx1-cre)1Cgn/0

(involves: 129P2/OlaHsd * BALB/c * C57BL/6 * CBA)
arrested T cell differentiation J:112660
decreased double-negative T cell number J:112660
decreased granulocyte number J:112660
decreased leukocyte cell number J:112660
impaired myelopoiesis J:112660
thymus hypoplasia J:112660
\Gt(ROSA)26Sortm1(DTA)Jpmb/\Gt(ROSA)26Sor+
\Tg(Plp1-cre/ERT)3Pop/0

(involves: 129S/SvEv * C57BL/6 * DBA/2)
autoimmune response J:234435
CNS inflammation J:234435
increased activated T cell number J:234435
lymph node inflammation J:234435
\Gt(ROSA)26Sortm1(DTA)Jpmb/\Gt(ROSA)26Sor+
\Tg(Trpv1-cre)1Hoon/0

(involves: 129S1/Sv)
decreased inflammatory response J:169256
\Gt(ROSA)26Sortm1(DTA)Lky/?
\Il5tm1.1(icre)Lky/\Il5+
\Rag1tm1Mom/\Rag1tm1Mom

(involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6)
abnormal immune system physiology J:206097
\Gt(ROSA)26Sortm1(DTA)Lky/\Gt(ROSA)26Sor+
\Il13tm1(YFP/cre)Lky/\Il13tm1(YFP/cre)Lky

(involves: 129P2/OlaHsd * 129S4/SvJae)
decreased eosinophil cell number J:178986
decreased IgG1 level J:178986
decreased interleukin-5 secretion J:178986
decreased interleukin-13 secretion J:178986
increased susceptibility to parasitic infection J:178986
\Gt(ROSA)26Sortm1(DTA)Lky/\Gt(ROSA)26Sortm1(DTA)Lky
\Tg(Cd4-cre)1Cwi/0

(involves: 129P2/OlaHsd * C57BL/6 * DBA/2)
abnormal CD4-positive, alpha-beta T cell physiology J:133382
abnormal CD8-positive, alpha-beta T cell differentiation J:133382
abnormal lymph node T cell domain morphology J:133382
abnormal spleen morphology J:133382
abnormal T cell receptor V(D)J recombination J:133382
decreased CD4-positive, alpha-beta T cell number J:133382
decreased CD8-positive, alpha-beta T cell number J:133382
decreased double-positive T cell number J:133382
decreased lymphocyte cell number J:133382
decreased NK T cell number J:133382
decreased regulatory T cell number J:133382
immune system phenotype J:133382
increased susceptibility to parasitic infection J:133382
\Gt(ROSA)26Sortm1(DTA)Riet/\Gt(ROSA)26Sortm1(DTA)Riet
\Tg(Rorc-cre)1Litt/?

(involves: 129P2/OlaHsd)
abnormal effector T cell morphology J:137020
\Gt(ROSA)26Sortm1(DUX4)Sqh/\Gt(ROSA)26Sor+
\Tg(ACTA1-cre/Esr1*)2Kesr/0

(involves: 129S6/SvEvTac * C3H * C57BL/6)
abnormal acute inflammation J:268959
\Gt(ROSA)26Sortm1(ETV6/SYK)Hjum/\Gt(ROSA)26Sor+
\Cd79atm3(cre/ERT2)Reth/\Cd79a+

(involves: 129S6/SvEvTac * BALB/c)
abnormal circulating chemokine level J:208904
abnormal cytokine level J:208904
abnormal plasma cell differentiation J:208904
enlarged lymph nodes J:208904
enlarged spleen J:208904
increased B cell apoptosis J:208904
increased B cell number J:208904
increased B cell proliferation J:208904
increased circulating interferon-gamma level J:208904
increased circulating interleukin-6 level J:208904
increased circulating interleukin-10 level J:208904
increased circulating tumor necrosis factor level J:208904
increased IgM level J:208904
increased interferon-gamma secretion J:208904
increased interleukin-10 secretion J:208904
increased tumor necrosis factor secretion J:208904
\Gt(ROSA)26Sortm1(ETV6/SYK)Hjum/\Gt(ROSA)26Sor+
\Cd79atm3(cre/ERT2)Reth/\Cd79a+
\Tg(BCL2)22Wehi/0

(involves: 129S6/SvEvTac * BALB/c * C57BL/6JWehi * SJL/JWehi)
abnormal B cell physiology J:208904
abnormal plasma cell differentiation J:208904
enlarged lymph nodes J:208904
enlarged spleen J:208904
\Gt(ROSA)26Sortm1(EWSR1/FLI1)Sbk/\Gt(ROSA)26Sor+
\Tg(Mx1-cre)1Cgn/?

(involves: 129S1/Sv * C57BL/6 * CBA)
abnormal lymph node B cell domain morphology J:129039
abnormal myelopoiesis J:129039
enlarged spleen J:129039
increased leukocyte cell number J:129039
increased spleen red pulp amount J:129039
\Gt(ROSA)26Sortm1(EYFP)Cos/\Gt(ROSA)26Sor+
\Ighg1tm1(cre)Cgn/\Ighg1+
\Prdm1tm2Masu/\Prdm1tm2Masu

(involves: 129P2/OlaHsd * 129X1/SvJ)
abnormal germinal center B cell physiology J:167612
abnormal plasma cell differentiation J:167612
decreased IgG1 level J:167612
enlarged lymph nodes J:167612
enlarged spleen J:167612
increased germinal center B cell number J:167612
\Gt(ROSA)26Sortm1(EYFP)Cos/\Gt(ROSA)26Sor+
\Il22tm1.1(icre)Stck/\Il22+

(involves: 129X1/SvJ * C57BL/6N)
abnormal susceptibility to bacterial infection J:220074
\Gt(ROSA)26Sortm1(EYFP)Cos/\Gt(ROSA)26Sor+
\Krastm4Tyj/\Kras+
\Tg(Pdx1-cre)89.1Dam/0

(involves: 129 * C57BL/6 * CBA)
increased susceptibility to induced pancreatitis J:289183
\Gt(ROSA)26Sortm1(EYFP)Cos/\Gt(ROSA)26Sor+
\Plcg1tm1Gcrp/\Plcg1tm1Rwen
\Tg(Cd4-cre)1Cwi/0

(involves: 129X1/SvJ * C57BL/6 * DBA/2)
abnormal CD4-positive T cell differentiation J:157757
abnormal CD8-positive, alpha-beta T cell differentiation J:157757
abnormal regulatory T cell physiology J:157757
abnormal T cell activation J:157757
decreased CD4-positive, alpha-beta T cell number J:157757
decreased CD8-positive, alpha-beta T cell number J:157757
decreased interferon-gamma secretion J:157757
decreased interleukin-2 secretion J:157757
decreased single-positive T cell number J:157757
decreased T cell number J:157757
decreased T cell proliferation J:157757
dermatitis J:157757
increased double-positive T cell number J:157757
increased T cell apoptosis J:157757
\Gt(ROSA)26Sortm1(EYFP)Cos/\Gt(ROSA)26Sor+
\Cd19tm1(cre)Cgn/\Cd19+
\Rev3ltm1.1Diaz/\Rev3ltm1.1Diaz

(involves: 129P2/OlaHsd * 129X1/SvJ * BALB/c * C57BL/6 * C57BL/6NTac)
abnormal class switch recombination J:188723
abnormal somatic hypermutation frequency J:188723
decreased B cell proliferation J:188723
immune system phenotype J:188723
\Gt(ROSA)26Sortm1(GNAQ*)Cvrk/\Gt(ROSA)26Sor+
\Tg(Mitf-cre)7114Gsb/0

(C3FeJ.Cg-Gt(ROSA)26Sortm1(GNAQ*)Cvkr Tg(Mitf-cre)7114Gsb/Cvrk)
enlarged lymph nodes J:225597
\Gt(ROSA)26Sortm1(gp80)Eces/\Gt(ROSA)26Sor+
\Cd19tm1(cre)Cgn/\Cd19+

(either: (involves: 129/Sv * 129P2/OlaHsd * C57BL/6) or (involves: 129/Sv * 129P2/OlaHsd * BALB/c * C57BL/6))
abnormal class switch recombination J:172031
absent spleen germinal center J:172031
decreased B cell apoptosis J:172031
decreased B cell number J:172031
decreased germinal center B cell number J:172031
decreased IgA level J:172031
decreased IgG1 level J:172031
decreased IgG2a level J:172031
decreased IgG3 level J:172031
decreased plasma cell number J:172031
enlarged spleen J:172031
increased B cell number J:172031
increased IgE level J:172031
increased macrophage cell number J:172031
increased marginal zone B cell number J:172031
increased spleen weight J:172031
increased T cell number J:172031
\Gt(ROSA)26Sortm1(gp80)Eces/\Gt(ROSA)26Sor+
\Ighg1tm1(cre)Cgn/\Ighg1+

(either: (involves: 129/Sv * 129P2/OlaHsd * C57BL/6) or (involves: 129/Sv * 129P2/OlaHsd * BALB/c * C57BL/6))
abnormal class switch recombination J:172031
absent spleen germinal center J:172031
decreased B cell number J:172031
decreased follicular B cell number J:172031
decreased germinal center B cell number J:172031
decreased IgA level J:172031
decreased IgG1 level J:172031
decreased IgG2a level J:172031
decreased IgG2b level J:172031
decreased IgG3 level J:172031
decreased plasma cell number J:172031
enlarged spleen J:172031
increased B cell number J:172031
increased IgE level J:172031
increased macrophage cell number J:172031
increased marginal zone B cell number J:172031
increased spleen weight J:172031
\Gt(ROSA)26Sortm1(H1/tetO-RNAi:Pdpk1)Mrl/\Gt(ROSA)26Sortm9(cre/ESR1)Arte
\Ptentm1Hwu/\Ptentm1Hwu

(involves: 129S4/SvJae * C57BL/6)
decreased B cell number J:170965
enlarged lymph nodes J:170965
enlarged spleen J:170965
increased memory B cell number J:170965
increased spleen weight J:170965
\Gt(ROSA)26Sortm1(HA)Libl/\Gt(ROSA)26Sortm1(HA)Libl
\Mogtm1(cre)Gkl/?

(involves: 129/Sv * C57BL/6)
immune system phenotype J:137838
\Gt(ROSA)26Sortm1(HA)Libl/\Gt(ROSA)26Sortm1(HA)Libl
\Mogtm1(cre)Gkl/?
\Tg(TcraCl4,TcrbCl4)1Shrm/0

(involves: 129/Sv * BALB/c * C57BL/6)
brain inflammation J:137838
optic nerve inflammation J:137838
spinal cord inflammation J:137838
\Gt(ROSA)26Sortm1(HBEGF)Awai/\Gt(ROSA)26Sortm1(HBEGF)Awai
\Mogtm1(cre)Gkl/?

(involves: C57BL/6)
abnormal immune system physiology J:131076
\Gt(ROSA)26Sortm1(HBEGF)Awai/\Gt(ROSA)26Sortm1(HBEGF)Awai
\Tg(Cd4-cre)1Cwi/0

(involves: C57BL/6 * DBA/2)
abnormal lymphocyte cell number J:131076
decreased single-positive T cell number J:131076
\Gt(ROSA)26Sortm1(ITK/SYK)Jrld/\Gt(ROSA)26Sor+
\Tg(Cd4-cre)1Cwi/0

(involves: 129P2/OlaHsd * C57BL/6 * DBA/2)
abnormal spleen morphology J:160931
abnormal T cell activation J:160931
abnormal T cell differentiation J:160931
decreased double-positive T cell number J:160931
decreased single-positive T cell number J:160931
decreased T cell number J:160931
enlarged spleen J:160931
immune system phenotype J:160931
increased T cell derived lymphoma incidence J:160931
increased T cell proliferation J:160931
\Gt(ROSA)26Sortm1(MAML1)Wsp/\Gt(ROSA)26Sor+
\Tg(Cd4-cre)1Cwi/0

(B6.Cg-Tg(Cd4-cre)1Cwi Gt(ROSA)26Sortm1(MAML1)Wsp)
abnormal immunoglobulin level J:113262
abnormal T-helper 1 physiology J:113262
abnormal T-helper 2 physiology J:113262
decreased susceptibility to parasitic infection J:113262
increased susceptibility to parasitic infection J:113262
\Gt(ROSA)26Sortm1(MAML1)Wsp/\Gt(ROSA)26Sor+
\Tg(KRT14-rtTA)F42Efu/0
\Tg(tetO-cre)1Jaw/0

(involves: 129 * C57BL/6 * FVB)
conjunctivitis J:194073
\Gt(ROSA)26Sortm1(Mirn155)Rsky/\Gt(ROSA)26Sortm1(Mirn155)Rsky
(involves: BALB/c * C57BL/6)
abnormal humoral immune response J:121084
increased germinal center B cell number J:121084
\Gt(ROSA)26Sortm1(Nfatc2*)Rao/\Gt(ROSA)26Sor+
\Tg(Cd4-cre)1Cwi/0

(involves: C57BL/6 * DBA/2)
abnormal interferon level J:148341
abnormal T cell activation J:148341
\Gt(ROSA)26Sortm1(Notch1)Dam/\Gt(ROSA)26Sor+
\Hes1tm1.1Frad/\Hes1tm1.1Frad
\Tg(Mx1-cre)1Cgn/0

(involves: 129S4/SvJaeSor * C57BL/6 * CBA)
decreased B cell number J:167000
\Gt(ROSA)26Sortm1(Notch1)Dam/\Gt(ROSA)26Sor+
\Tg(Mx1-cre)1Cgn/0

(involves: 129S4/SvJaeSor * C57BL/6 * CBA)
decreased B cell number J:167000
enlarged spleen J:167000
increased leukocyte cell number J:167000
\Gt(ROSA)26Sortm1(NOTCH1/GFP)Xhsu/\Gt(ROSA)26Sor+
\Tg(Lck-cre)548Jxm/0

(B6.Cg-Gt(ROSA)26Sortm1(NOTCH1/GFP)Xhsu Tg(Lck-cre)548Jxm)
increased T cell derived lymphoma incidence J:185287
\Gt(ROSA)26Sortm1(Ntn4)Dyl/\Gt(ROSA)26Sor+
\Tg(KRT14-cre)1Amc/0

(involves: 129/Sv * C57BL/6 * CBA)
abnormal lymphangiogenesis J:162807
abnormal lymphatic vessel morphology J:162807
lymphatic vessel hyperplasia J:162807
\Gt(ROSA)26Sortm1(OVAL/fla,GFP)Vnce/\Gt(ROSA)26Sor+
\Lyz2tm1(cre)Ifo/\Lyz2+

(involves: 129P2/OlaHsd * C57BL/6J)
abnormal circulating cytokine level J:260047
decreased B cell number J:260047
decreased lymphocyte cell number J:260047
enlarged lymph nodes J:260047
enlarged spleen J:260047
glomerulonephritis J:260047
increased inflammatory response J:260047
increased monocyte cell number J:260047
increased neutrophil cell number J:260047
increased T cell number J:260047
joint inflammation J:260047
small intestinal inflammation J:260047
\Gt(ROSA)26Sortm1(OVAL/fla,GFP)Vnce/\Gt(ROSA)26Sor+
\Lyz2tm1(cre)Ifo/\Lyz2+
\Nlrc4tm1Vmd/\Nlrc4tm1Vmd

(involves: 129P2/OlaHsd * C57BL/6J * C57BL/6NCrl)
immune system phenotype J:260047
\Gt(ROSA)26Sortm1(OVAL/fla,GFP)Vnce/\Gt(ROSA)26Sor+
\Lyz2tm1(cre)Ifo/\Lyz2+
\Pycardtm1Vmd/\Pycardtm1Vmd

(involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6J)
immune system phenotype J:260047
increased circulating interferon-gamma level J:260047
increased circulating interleukin-6 level J:260047
increased circulating tumor necrosis factor level J:260047
\Gt(ROSA)26Sortm1(OVAL/fla,GFP)Vnce/\Gt(ROSA)26Sor+
\Tg(Itgax-cre)1-1Reiz/0

(involves: C3H * C57BL/6 * C57BL/6J)
increased monocyte cell number J:260047
increased neutrophil cell number J:260047
\Gt(ROSA)26Sortm1(OVAL/fla,GFP)Vnce/\Gt(ROSA)26Sor+
\Tg(S100A8-cre,-EGFP)1Ilw/0

(involves: C3H * C57BL/6 * C57BL/6J)
abnormal circulating cytokine level J:260047
increased circulating interleukin-18 level J:260047
increased monocyte cell number J:260047
increased neutrophil cell number J:260047
\Gt(ROSA)26Sortm1(Pik3ca*H1047R)Egan/\Gt(ROSA)26Sor+
\Tg(MMTV-cre)#Tfln/0
\Trp53tm1Brn/\Trp53+

(involves: 129P2/OlaHsd * 129S6/SvEvTac)
increased T cell derived lymphoma incidence J:170898
\Gt(ROSA)26Sortm1(Pik3ca*H1047R)Egan/\Gt(ROSA)26Sor+
\Trp53tm1Brn/\Trp53tm1Brn
\Tg(MMTV-cre)#Tfln/0

(involves: 129P2/OlaHsd * 129S6/SvEvTac)
increased T cell derived lymphoma incidence J:170898
\Gt(ROSA)26Sortm1(Ptpn22*)Draw/\Gt(ROSA)26Sor+
\Cd19tm1(cre)Cgn/\Cd19+

(involves: 129P2/OlaHsd * C57BL/6)
enlarged spleen J:201448
glomerulonephritis J:201448
increased anti-double stranded DNA antibody level J:201448
increased autoantibody level J:201448
increased B cell number J:201448
increased germinal center B cell number J:201448
spleen hyperplasia J:201448
\Gt(ROSA)26Sortm1(RNAi:Bmpr2)Dliu/\Gt(ROSA)26Sor+
(involves: 129 * C57BL/6J)
abnormal spleen morphology J:145514
abnormal spleen white pulp morphology J:145514
enlarged spleen J:145514
\Gt(ROSA)26Sortm1(rtTA)Awu/\Gt(ROSA)26Sortm1(rtTA)Awu
\Xisttm1Awu/Y

(involves: 129S4/SvJae)
abnormal B cell differentiation J:112954
abnormal myelopoiesis J:112954
abnormal T cell differentiation J:112954
abnormal thymus morphology J:112954
absent pre-B cells J:112954
decreased double-positive T cell number J:112954
decreased granulocyte number J:112954
decreased immature B cell number J:112954
decreased macrophage cell number J:112954
decreased pro-B cell number J:112954
decreased thymocyte number J:112954
small thymus J:112954
thymus hypoplasia J:112954
\Gt(ROSA)26Sortm1(rtTA)Awu/\Gt(ROSA)26Sortm1(rtTA)Awu
\Xisttm1Awu/\Xisttm1Awu

(involves: 129S4/SvJae)
small thymus J:112954
\Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/\Gt(ROSA)26Sor+
\Tg(CAG-cre)1Nagy/0
\Tg(tetO-Vegfa)90Ala/0

(involves: 129S1/Sv * 129X1/SvJ * FVB/N * ICR)
enlarged lymph nodes J:99607
thymus atrophy J:99607
\Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/\Gt(ROSA)26Sor+
\Tg(Col2a1-cre)1Bhr/0
\Tg(tetO-Vegfa)90Ala/0

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * FVB/N * SJL)
decreased osteoclast cell number J:156474
enlarged spleen J:156474
\Gt(ROSA)26Sortm1(sb11)Njen/\Gt(ROSA)26Sor+
\TgTn(sb-T2/Onc2)6057Njen/0

(involves: C3H * C57BL/6)
increased T cell derived lymphoma incidence J:102234
\Gt(ROSA)26Sortm1(sb11)Njen/\Gt(ROSA)26Sor+
\TgTn(sb-T2/Onc2)6070Njen/0

(involves: C3H * C57BL/6)
increased T cell derived lymphoma incidence J:102234
\Gt(ROSA)26Sortm1(sb11)Njen/\Gt(ROSA)26Sor+
\TgTn(sb-T2/Onc2)6113Njen/0

(involves: C3H * C57BL/6)
increased T cell derived lymphoma incidence J:102234
\Gt(ROSA)26Sortm1(sb11)Njen/\Gt(ROSA)26Sor+
\TgTn(sb-T2/Onc3)12740Njen/0

(involves: C3H * C57BL/6J)
increased T cell derived lymphoma incidence J:153656
\Gt(ROSA)26Sortm1(Stat3*A661C*N663C)Sbkv/\Gt(ROSA)26Sortm1(Stat3*A661C*N663C)Sbkv
(involves: C57BL/6)
abnormal T-helper 17 cell differentiation J:205858
\Gt(ROSA)26Sortm1(Stat3*A661C*N663C)Sbkv/\Gt(ROSA)26Sortm1(Stat3*A661C*N663C)Sbkv
\Tg(Cd4-cre)1Cwi/0

(involves: C57BL/6 * DBA/2)
increased circulating interleukin-17 level J:205858
increased interleukin-17 secretion J:205858
increased regulatory T cell number J:205858
increased T-helper 1 cell number J:205858
increased T-helper 17 cell number J:205858
lung inflammation J:205858
\Gt(ROSA)26Sortm1(Tbx1/GFP)Bem/\Gt(ROSA)26Sor+
\Foxg1tm1(cre)Skm/\Foxg1+

(involves: 129P2/OlaHsd * C57BL/6 * SJL)
athymia J:204435
\Gt(ROSA)26Sortm1(tTA,tetO-Mir21)Fjsl/\Gt(ROSA)26Sor+
\Tg(Nes-cre)1Wmz/0

(involves: C57BL/6 * C57BL/6J * SJL/J)
abnormal spleen morphology J:163919
abnormal thymus corticomedullary boundary morphology J:163919
abnormal thymus morphology J:163919
decreased leukocyte cell number J:163919
enlarged lymph nodes J:163919
enlarged spleen J:163919
enlarged thymus J:163919
intermingled spleen red and white pulp J:163919
\Gt(ROSA)26Sortm1(tTA,tetO-Mir155)Fjsl/\Gt(ROSA)26Sor+
\Tg(Nes-cre)1Wmz/0

(involves: 129 * C57BL/6 * FVB/N * SJL/J)
abnormal immune system morphology J:185598
enlarged lymph nodes J:185598
enlarged spleen J:185598
increased spleen weight J:185598
increased spleen white pulp amount J:185598
thymus hyperplasia J:185598
\Gt(ROSA)26Sortm1.1(Aco1*)Mwh/\Gt(ROSA)26Sortm1.1(Aco1*)Mwh
(B6.129P2(129S1)-Gt(ROSA)26Sortm1.1(Aco1*)Mwh)
increased spleen iron level J:196374
\Gt(ROSA)26Sortm1.1(CAG-PSTPIP1)Dtg/\Gt(ROSA)26Sor+
(involves: BALB/cJ * C57BL/6)
immune system phenotype J:196002
\Gt(ROSA)26Sortm1.1(CAG-Trp53*,-EGFP)Medz/\Gt(ROSA)26Sortm1.1(CAG-Trp53*,-EGFP)Medz
(involves: C57BL/6)
decreased thymocyte apoptosis J:158953
\Gt(ROSA)26Sortm1.1(DUX4*)Plj/\Gt(ROSA)26Sor+
(B6(Cg)-Gt(ROSA)26Sortm1.1(DUX4*)Plj)
enlarged lymph nodes J:256652
enlarged popliteal lymph nodes J:256652
\Gt(ROSA)26Sortm1.1(DUX4*)Plj/\Gt(ROSA)26Sor+
\Ndor1Tg(UBC-cre/ERT2)1Ejb/0

(involves: 129S/SvEv * C57BL/6)
enlarged lymph nodes J:256652
enlarged popliteal lymph nodes J:256652
\Gt(ROSA)26Sortm1.1(DUX4*)Plj/\Gt(ROSA)26Sor+
\Tg(ACTA1-cre/Esr1*)2Kesr/0

(involves: C3H * C57BL/6)
increased acute inflammation J:256652
\Gt(ROSA)26Sortm1.1(DUX4*)Plj/\Gt(ROSA)26Sortm1.1(DUX4*)Plj
(B6(Cg)-Gt(ROSA)26Sortm1.1(DUX4*)Plj)
preputial gland inflammation J:256652
\Gt(ROSA)26Sortm1.1(Loxl2)Acan/\Gt(ROSA)26Sortm1.1(Loxl2)Acan
(Not Specified)
epididymis inflammation J:220689
increased inflammatory response J:220689
\Gt(ROSA)26Sortm1.1(Ubc-BCL3)Sbn/\Gt(ROSA)26Sor+
\Cd79atm1(cre)Reth/\Cd79a+

(involves: BALB/c * C57BL/6)
decreased B cell proliferation J:207111
decreased follicular B cell number J:207111
decreased marginal zone B cell number J:207111
increased follicular B cell number J:207111
\Gt(ROSA)26Sortm1.1(Wls/YFP)Mbtr/\Gt(ROSA)26Sor+
(involves: C57BL/6)
decreased neutrophil cell number J:202499
\Gt(ROSA)26Sortm1.2(CAG-PLS3,-GFP)Bwir/\Gt(ROSA)26Sor+
(B6N.Cg-Gt(ROSA)26Sortm1.1(CAG-PLS3,-GFP)Bwir)
decreased osteoclast cell number J:267292
\Gt(ROSA)26Sortm1Fia/\Gt(ROSA)26Sor+
\Nf1tm1Fcr/\Nf1tm1Par
\Tg(Tek-cre)1Ywa/0

(involves: 129S/SvEv * 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL)
abnormal spleen morphology J:114455
\Gt(ROSA)26Sortm1Jus/\Gt(ROSA)26Sor+
\Tg(Lck-icre)3779Nik/0

(involves: C57BL/6 * C57BL/6J * C57BL/6N * DBA/2)
immune system phenotype J:202090
\Gt(ROSA)26Sortm1Jus/\Gt(ROSA)26Sor+
\Tg(MMTV-cre)4Mam/0

(involves: C57BL/6J * C57BL/6N * FVB/N)
abnormal leukocyte morphology J:202090
abnormal thymus physiology J:202090
arrested B cell differentiation J:202090
decreased B cell number J:202090
decreased double-positive T cell number J:202090
decreased mature B cell number J:202090
decreased pre-B cell number J:202090
decreased pro-B cell number J:202090
enlarged lymph nodes J:202090
enlarged spleen J:202090
enlarged thymus J:202090
increased CD8-positive, alpha-beta T cell number J:202090
increased inflammatory response J:202090
increased large unstained cell number J:202090
increased leukocyte cell number J:202090
increased single-positive T cell number J:202090
intermingled spleen red and white pulp J:202090
intestinal inflammation J:202090
kidney inflammation J:202090
liver inflammation J:202090
meningitis J:202090
stomach inflammation J:202090
\Gt(ROSA)26Sortm1Jus/\Gt(ROSA)26Sor+
\Tg(Mx1-cre)1Cgn/0

(involves: C57BL/6 * C57BL/6J * C57BL/6N * CBA)
abnormal leukocyte morphology J:202090
abnormal thymus physiology J:202090
arrested B cell differentiation J:202090
decreased B cell number J:202090
decreased double-positive T cell number J:202090
decreased mature B cell number J:202090
decreased pre-B cell number J:202090
decreased pro-B cell number J:202090
enlarged lymph nodes J:202090
enlarged spleen J:202090
enlarged thymus J:202090
increased CD8-positive, alpha-beta T cell number J:202090
increased inflammatory response J:202090
increased large unstained cell number J:202090
increased leukocyte cell number J:202090
increased single-positive T cell number J:202090
intermingled spleen red and white pulp J:202090
intestinal inflammation J:202090
kidney inflammation J:202090
liver inflammation J:202090
meningitis J:202090
stomach inflammation J:202090
\Gt(ROSA)26Sortm1Sor/\Gt(ROSA)26Sor+
\Id3tm2.1Zhu/\Id3tm2.1Zhu
\Tg(Lck-cre)#Zhu/0

(involves: 129S4/SvJaeSor * 129S6/SvEvTac * C57BL/6 * SJL)
decreased T cell number J:172701
\Gt(ROSA)26Sortm1Sor/\Gt(ROSA)26Sor+
\Nr2f2tm2.1Tsa/\Nr2f2tm2.1Tsa
\Prox1tm3(cre/ERT2)Gco/\Prox1+

(involves: 129S1/Sv * 129S4/SvJaeSor * 129S7/SvEvBrd * C57BL/6)
abnormal lymphatic vessel morphology J:158959
\Gt(ROSA)26Sortm1Sor/\Gt(ROSA)26Sor+
\Tbx1tm3.1Bld/\Tbx1tm6(cre)Bld

(involves: 129S4/SvJaeSor * 129S7/SvEvBrd)
abnormal lymphatic vessel morphology J:159824
\Gt(ROSA)26Sortm2(CAG-Notch2*)Uzs/\Gt(ROSA)26Sor+
\Cd19tm1(cre)Cgn/\Cd19+

(involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6J)
abnormal B cell differentiation J:179036
abnormal marginal zone B cell physiology J:179036
abnormal spleen marginal zone morphology J:179036
decreased B cell number J:179036
decreased B-1a cell number J:179036
decreased B-2 B cell number J:179036
decreased follicular B cell number J:179036
decreased IgG1 level J:179036
decreased IgG3 level J:179036
decreased IgM level J:179036
decreased spleen B cell follicle size J:179036
decreased spleen germinal center number J:179036
decreased transitional stage T2 B cell number J:179036
increased B cell proliferation J:179036
increased marginal zone B cell number J:179036
increased spleen weight J:179036
increased T cell number J:179036
increased transitional stage T1 B cell number J:179036
\Gt(ROSA)26Sortm2(CAG-Notch2*)Uzs/\Gt(ROSA)26Sor+
\Cd19tm1(cre)Cgn/\Cd19tm1(cre)Cgn

(involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6J)
abnormal B cell differentiation J:179036
abnormal spleen marginal zone morphology J:179036
decreased follicular B cell number J:179036
decreased mature B cell number J:179036
decreased pre-B cell number J:179036
decreased transitional stage T2 B cell number J:179036
increased marginal zone B cell number J:179036
increased transitional stage T1 B cell number J:179036
\Gt(ROSA)26Sortm2(CAG-Notch2*)Uzs/\Gt(ROSA)26Sor+
\Cd79atm1(cre)Reth/\Cd79a+

(involves: 129S6/SvEvTac * BALB/c * C57BL/6J)
arrested B cell differentiation J:179036
decreased B cell number J:179036
decreased splenocyte number J:179036
increased T cell number J:179036
\Gt(ROSA)26Sortm2(CAG-Nr5a1)Fjd/\Gt(ROSA)26Sor+
\Pgrtm2(cre)Lyd/\Pgr+

(involves: 129S1/Sv * 129X1/SvJ)
uterus inflammation J:269597
\Gt(ROSA)26Sortm2(CAG-PSTPIP1*)Dtg/\Gt(ROSA)26Sor+
\Commd10Tg(Vav1-icre)A2Kio/\Commd10+

(involves: C57BL/6 * C57BL/10 * CBA/Ca)
immune system phenotype J:196002
\Gt(ROSA)26Sortm2(cre/ERT2)Brn/0
\Tg(Sftpc-Grem1)105Mmyl/0

(involves: 129P2/OlaHsd * C57BL/6N)
lung inflammation J:82809
\Gt(ROSA)26Sortm2(H1/tetO-RNAi:Kdm1a)Arte/\Gt(ROSA)26Sor+
(involves: C57BL/6)
abnormal granulocyte differentiation J:192055
abnormal monocyte differentiation J:192055
enlarged spleen J:192055
increased leukocyte cell number J:192055
\Gt(ROSA)26Sortm2(ITK/Syk)Hjum/\Gt(ROSA)26Sor+
\Tg(Cd4-cre)1Cwi/0

(involves: 129S6/SvEvTac * C57BL/6 * DBA/2)
abnormal circulating cytokine level J:207306
abnormal cytokine secretion J:207306
abnormal immunoglobulin level J:207306
abnormal spleen morphology J:207306
enlarged spleen J:207306
immune system phenotype J:207306
increased activated T cell number J:207306
increased CD4-positive, alpha-beta T cell number J:207306
increased circulating interferon-gamma level J:207306
increased circulating interleukin-2 level J:207306
increased circulating interleukin-4 level J:207306
increased circulating interleukin-6 level J:207306
increased circulating interleukin-10 level J:207306
increased circulating tumor necrosis factor level J:207306
increased IgA level J:207306
increased IgG level J:207306
increased IgM level J:207306
increased inflammatory response J:207306
increased interferon-gamma secretion J:207306
increased interleukin-2 secretion J:207306
increased interleukin-4 secretion J:207306
increased interleukin-6 secretion J:207306
increased interleukin-10 secretion J:207306
increased mature B cell number J:207306
increased plasma cell number J:207306
increased tumor necrosis factor secretion J:207306
\Gt(ROSA)26Sortm2(ITK/Syk)Hjum/\Gt(ROSA)26Sor+
\Tg(Lck-cre)I57Jxm/0

(involves: 129S6/SvEvTac * ICR)
abnormal circulating cytokine level J:207306
abnormal cytokine secretion J:207306
abnormal immunoglobulin level J:207306
abnormal spleen morphology J:207306
enlarged spleen J:207306
immune system phenotype J:207306
increased activated T cell number J:207306
increased CD4-positive, alpha-beta T cell number J:207306
increased circulating interferon-gamma level J:207306
increased circulating interleukin-2 level J:207306
increased circulating interleukin-4 level J:207306
increased circulating interleukin-6 level J:207306
increased circulating interleukin-10 level J:207306
increased circulating tumor necrosis factor level J:207306
increased IgA level J:207306
increased IgG level J:207306
increased IgM level J:207306
increased inflammatory response J:207306
increased interferon-gamma secretion J:207306
increased interleukin-2 secretion J:207306
increased interleukin-4 secretion J:207306
increased interleukin-6 secretion J:207306
increased interleukin-10 secretion J:207306
increased mature B cell number J:207306
increased plasma cell number J:207306
increased tumor necrosis factor secretion J:207306
\Gt(ROSA)26Sortm2(Lmp1/CD40)Uzs/\Gt(ROSA)26Sor+
\Cd19tm1(cre)Cgn/\Cd19+

(involves: 129P2/OlaHsd * BALB/c * C57BL/6)
abnormal B cell activation J:137122
abnormal B cell physiology J:137122
abnormal class switch recombination J:137122
abnormal humoral immune response J:137122
abnormal T cell activation J:137122
enlarged inguinal lymph nodes J:137122
enlarged spleen J:137122
increased B cell number J:137122
increased B cell proliferation J:137122
increased follicular B cell number J:137122
increased marginal zone B cell number J:137122
increased spleen B cell follicle size J:137122
increased spleen weight J:137122
increased T cell number J:137122
\Gt(ROSA)26Sortm2(Lmp1/CD40)Uzs/\Gt(ROSA)26Sor+
\Tg(Cr2-cre)3Cgn/0

(involves: BALB/c * C57BL/6)
abnormal immune system morphology J:137122
abnormal immune system physiology J:137122
\Gt(ROSA)26Sortm2(Mirn150)Rsky/\Gt(ROSA)26Sor+
(involves: C57BL/6 * SJL/J)
decreased mature B cell number J:127234
\Gt(ROSA)26Sortm2(Mirn150)Rsky/\Gt(ROSA)26Sortm2(Mirn150)Rsky
(involves: C57BL/6 * SJL/J)
decreased B-1 B cell number J:127234
decreased B-2 B cell number J:127234
decreased CD4-positive, alpha-beta T cell number J:127234
decreased CD8-positive, alpha-beta T cell number J:127234
increased B cell apoptosis J:127234
\Gt(ROSA)26Sortm2(Nfatc2*)Rao/\Gt(ROSA)26Sor+
\Tg(Cd4-cre)1Cwi/0

(involves: C57BL/6 * DBA/2)
abnormal interferon level J:148341
abnormal T cell activation J:148341
\Gt(ROSA)26Sortm2(sb11)Njen/\Gt(ROSA)26Sor+
\TgTn(sb-T2/Onc2)6070Njen/0

(involves: 129 * C57BL/6 * C57BL/6J)
increased susceptibility to infection J:153656
\Gt(ROSA)26Sortm2.1(CAG-PSTPIP1*)Dtg/\Gt(ROSA)26Sor+
(involves: BALB/cJ * C57BL/6)
increased circulating interleukin-1 alpha level J:196002
increased circulating interleukin-1 beta level J:196002
increased circulating tumor necrosis factor level J:196002
\Gt(ROSA)26Sortm2.1(Cd74/MOG)Awai/\Gt(ROSA)26Sor+
(involves: C57BL/6 * BALB/cJ)
abnormal humoral immune response J:140751
decreased susceptibility to experimental autoimmune encephalomyelitis J:140751
\Gt(ROSA)26Sortm2.1(Mirn150)Rsky/\Gt(ROSA)26Sor+
(involves: C57BL/6 * SJL/J)
decreased mature B cell number J:127234
\Gt(ROSA)26Sortm2.1(Mirn150)Rsky/\Gt(ROSA)26Sortm2.1(Mirn150)Rsky
(involves: C57BL/6 * SJL/J)
arrested B cell differentiation J:127234
arrested T cell differentiation J:127234
decreased B-1 B cell number J:127234
decreased B-2 B cell number J:127234
decreased lymphocyte cell number J:127234
increased B cell apoptosis J:127234
\Gt(ROSA)26Sortm2.1(sb11)Njen/\Gt(ROSA)26Sor+
\TgTn(sb-T2/Onc2)6070Njen/0

(involves: 129 * C57BL/6 * C57BL/6J)
increased T cell derived lymphoma incidence J:153656
\Gt(ROSA)26Sortm2Sho/\Gt(ROSA)26Sor+
\Lef1tm1Hhx/\Lef1tm1Hhx
\Tg(GZMB-cre)1Jcb/0

(involves: 129S4/SvJaeSor * C57BL/6 * FVB/N)
abnormal memory T cell physiology J:189838
decreased CD8-positive, alpha-beta T cell number J:189838
\Gt(ROSA)26Sortm3(CAG-EYFP)Hze/\Gt(ROSA)26Sor+
\Stat5atm2Mam \Stat5btm1Mam/\Del(11Stat5a-Stat5b)1Mam
\Tg(Mx1-cre)1Cgn/0

(involves: 129S6/SvEvTac * C57BL/6 * C57BL/6NCr * CBA)
abnormal CD4-positive T cell differentiation J:204829
\Gt(ROSA)26Sortm3(CAG-Il17a)Awai/\Gt(ROSA)26Sor+
\Tg(Cd4-cre)1Cwi/0

(involves: C57BL/6 * DBA/2)
abnormal immune system physiology J:144710
abnormal neutrophil physiology J:144710
increased circulating interleukin-17 level J:144710
increased granulocyte number J:144710
increased interleukin-17 secretion J:144710
\Gt(ROSA)26Sortm3(CAG-MIR17-92,-EGFP)Rsky/\Gt(ROSA)26Sor+
\Tg(CD2-icre)4Kio/0

(involves: C57BL/6 * C57BL/10 * CBA/Ca)
decreased marginal zone B cell number J:133215
increased B-1a cell number J:133215
\Gt(ROSA)26Sortm3(CAG-MIR17-92,-EGFP)Rsky/\Gt(ROSA)26Sortm3(CAG-MIR17-92,-EGFP)Rsky
\Tg(CD2-icre)4Kio/0

(involves: C57BL/6 * C57BL/10 * CBA/Ca)
abnormal B cell activation J:133215
abnormal B cell morphology J:133215
abnormal CD4-positive, alpha beta T cell morphology J:133215
abnormal CD4-positive, alpha-beta T cell physiology J:133215
abnormal immune system morphology J:133215
abnormal immune system physiology J:133215
abnormal immunoglobulin level J:133215
abnormal spleen marginal zone morphology J:133215
abnormal T cell activation J:133215
abnormal T cell differentiation J:133215
decreased marginal zone B cell number J:133215
decreased spleen red pulp amount J:133215
enlarged lymph nodes J:133215
immune system phenotype J:133215
increased anti-double stranded DNA antibody level J:133215
increased anti-single stranded DNA antibody level J:133215
increased B cell number J:133215
increased B cell proliferation J:133215
increased B-1a cell number J:133215
increased CD4-positive, alpha-beta T cell number J:133215
increased CD8-positive, alpha-beta T cell number J:133215
increased germinal center B cell number J:133215
increased IgG2a level J:133215
increased IgG2b level J:133215
increased IgG3 level J:133215
increased IgM level J:133215
increased lymphocyte cell number J:133215
increased spleen weight J:133215
increased spleen white pulp amount J:133215
intermingled spleen red and white pulp J:133215
lymph node hyperplasia J:133215
spleen hyperplasia J:133215
\Gt(ROSA)26Sortm3.1(CAG-Il17a)Awai/\Gt(ROSA)26Sor+
(involves: BALB/c * C57BL/6)
increased granulocyte number J:144710
increased interleukin-17 secretion J:144710
skin inflammation J:144710
\Gt(ROSA)26Sortm4(ACTB-tdTomato,-EGFP)Luo/\Gt(ROSA)26Sor+
\Hnrnpltm1.1Tmo/\Hnrnpltm1.1Tmo
\Tg(Lck-cre)548Jxm/0

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA)
abnormal T cell differentiation J:188749
\Gt(ROSA)26Sortm4(CAG-hsb5)Nki/\Gt(ROSA)26Sor+
\Tg(Mx1-cre)1Cgn/0
\Tg(Tal1-tTA)19Dgt/0
\Tg(tetO-BCR/ABL1)2Dgt/0
\TgTn(pb-sb-GrOnc)#aGsva/0

(involves: 129P2/OlaHsd * C57BL/6 * CBA/J * DBA/2 * FVB/N)
increased basophil cell number J:227558
increased granulocyte number J:227558
increased leukocyte cell number J:227558
increased spleen weight J:227558
\Gt(ROSA)26Sortm4(H1/tetO-RNAi:Ezh2)Arte/\Gt(ROSA)26Sor+
(C57BL/6-Gt(ROSA)26Sortm4(H1/tetO-RNAi:Ezh2)Arte)
small lymph nodes J:202724
\Gt(ROSA)26Sortm4(HIF2A*)Kael/\Gt(ROSA)26Sortm4(HIF2A*)Kael
\Tg(Vil1-cre/ERT2)23Syr/0

(involves: 129S6/SvEvTac * C57BL/6 * DBA/2)
increased susceptibility to colitis induced morbidity/mortality J:307422
\Gt(ROSA)26Sortm4(Ikbkb)Rsky/\Gt(ROSA)26Sor+
\Ighg1tm1(cre)Cgn/\Ighg1+

(involves: 129P2/OlaHsd * C57BL/6)
abnormal spleen morphology J:167612
decreased germinal center B cell number J:167612
enlarged spleen J:167612
increased B cell number J:167612
increased IgG1 level J:167612
increased IgM level J:167612
increased plasma cell number J:167612
\Gt(ROSA)26Sortm4(Ikbkb)Rsky/\Gt(ROSA)26Sor+
\Ighg1tm1(cre)Cgn/\Ighg1+
\Prdm1tm2Masu/\Prdm1tm2Masu

(involves: 129P2/OlaHsd * C57BL/6)
abnormal germinal center B cell physiology J:167612
abnormal plasma cell differentiation J:167612
decreased IgG1 level J:167612
increased germinal center B cell number J:167612
\Gt(ROSA)26Sortm4(Ikbkb)Rsky/\Gt(ROSA)26Sortm4(Ikbkb)Rsky
\Igh-Jtm1Cgn/\Ightm4Cgn
\Tg(Cr2-cre)3Cgn/0

(involves: 129P2/OlaHsd * C57BL/6)
increased B cell number J:157297
\Gt(ROSA)26Sortm4(Wnt7b)Flng/\Gt(ROSA)26Sor+
\Tg(Col1a1-cre)1Ack/0

(involves: FVB/N)
decreased osteoclast cell number J:208766
enlarged spleen J:208766
increased spleen weight J:208766
\Gt(ROSA)26Sortm4(Wnt7b)Flng/\Gt(ROSA)26Sor+
\Tg(Runx2-rtTA*M2)#Flng/0
\Tg(tetO-cre)1Jaw/0

(involves: 129 * C57BL/6)
decreased osteoclast cell number J:208766
\Gt(ROSA)26Sortm5(H1/tetO-RNAi:Ezh2)Arte/\Gt(ROSA)26Sor+
(C57BL/6-Gt(ROSA)26Sortm5(H1/tetO-RNAi:Ezh2)Arte)
small lymph nodes J:202724
\Gt(ROSA)26Sortm7(Pik3ca*,-EGFP)Rsky/\Gt(ROSA)26Sor+
\Tg(CAG-cre/Esr1*)5Amc/0

(B6.Cg-Gt(ROSA)26Sortm7(Pik3ca*,-EGFP)Rsky Tg(CAG-cre/Esr1*)5Amc)
abnormal spleen morphology J:264410
enlarged lymphatic vessel J:264410
\Gt(ROSA)26Sortm7(Pik3ca*,-EGFP)Rsky/\Gt(ROSA)26Sortm13(CAG-MYC,-CD2*)Rsky
\Ighg1tm1(cre)Cgn/\Ighg1+

(involves: 129P2/OlaHsd * C57BL/6)
abnormal class switch recombination J:191824
increased germinal center B cell number J:191824
\Gt(ROSA)26Sortm8(Map2k1*,-EGFP)Rsky/\Gt(ROSA)26Sor+
\Tg(Cd4-cre)1Cwi/0
\Traf3ip3tm1c(KOMP)Wtsi/\Traf3ip3tm1c(KOMP)Wtsi

(involves: C57BL/6 * C57BL/6N * DBA/2)
immune system phenotype J:226431
\Gt(ROSA)26Sortm8(Map2k1*,-EGFP)Rsky/\Gt(ROSA)26Sortm8(Map2k1*,-EGFP)Rsky
\Igh-Jtm1Cgn/\Ightm4Cgn
\Tg(Cr2-cre)3Cgn/0

(involves: 129P2/OlaHsd * C57BL/6)
decreased mature B cell number J:157297
\Gt(ROSA)26Sortm9(cre/ESR1)Arte/?
\Tnfaip3tm1Homy/\Tnfaip3tm1Homy

(involves: 129S6/SvEvTac * C57BL/6J * C57BL/6NTac)
abnormal circulating cytokine level J:212681
abnormal circulating interleukin level J:212681
increased circulating interferon-gamma level J:212681
increased circulating interleukin-1 beta level J:212681
increased circulating interleukin-6 level J:212681
increased circulating tumor necrosis factor level J:212681
pale spleen J:212681
thymus atrophy J:212681
\Gt(ROSA)26Sortm9(cre/ESR1)Arte/\Gt(ROSA)26Sor+
\Map3k14tm1.1Gne/\Map3k14tm1.1Gne

(B6(Cg)-Map3k14tm1.1Gne Gt(ROSA)26Sortm9(cre/ESR1)Arte)
abnormal immunoglobulin level J:240453
decreased B cell number J:240453
decreased B cell proliferation J:240453
decreased germinal center B cell number J:240453
decreased IgA level J:240453
decreased IgG1 level J:240453
decreased IgM level J:240453
decreased Peyer's patch number J:240453
immune system phenotype J:240453
\Gt(ROSA)26Sortm9(cre/ESR1)Arte/\Gt(ROSA)26Sor+
\Ptentm1Hwu/\Ptentm1Hwu

(involves: 129S4/SvJae * C57BL/6)
enlarged lymph nodes J:170965
enlarged spleen J:170965
increased spleen weight J:170965
\Gt(ROSA)26Sortm9(cre/ESR1)Arte/\Gt(ROSA)26Sor+
\Ripk3tm1Arte/\Ripk3tm1Arte

(involves: C57BL/6NTac)
abnormal lymphocyte morphology J:209137
intestinal inflammation J:209137
thymus atrophy J:209137
\Gt(ROSA)26Sortm9(Rac1*,-EGFP)Rsky/\Gt(ROSA)26Sortm9(Rac1*,-EGFP)Rsky
\Igh-Jtm1Cgn/\Ightm4Cgn
\Tg(Cr2-cre)3Cgn/0

(involves: 129P2/OlaHsd * C57BL/6)
decreased mature B cell number J:157297
\Gt(ROSA)26Sortm10(Lmp1)Rsky/\Gt(ROSA)26Sor+
(involves: BALB/cJ)
abnormal B cell morphology J:181546
increased B cell proliferation J:181546
\Gt(ROSA)26Sortm10(Lmp1)Rsky/\Gt(ROSA)26Sor+
\Cd19tm1(cre)Cgn/\Cd19+

(involves: 129P2/OlaHsd * BALB/cJ)
abnormal B cell differentiation J:181546
abnormal CD8-positive, alpha-beta T cell physiology J:181546
abnormal immune system physiology J:181546
decreased B cell number J:181546
decreased mature B cell number J:181546
decreased pre-B cell number J:181546
enlarged spleen J:181546
increased B cell number J:181546
increased B cell proliferation J:181546
increased CD4-positive, alpha-beta T cell number J:181546
increased CD8-positive, alpha-beta T cell number J:181546
increased pro-B cell number J:181546
\Gt(ROSA)26Sortm10(Lmp1)Rsky/\Gt(ROSA)26Sor+
\Tcrbtm1Mom/\Tcrb+
\Tcrdtm1Mom/\Tcrdtm1Mom
\Cd19tm1(cre)Cgn/\Cd19+

(involves: 129P2/OlaHsd * 129S2/SvPas * BALB/cJ)
enlarged spleen J:181546
increased B cell number J:181546
\Gt(ROSA)26Sortm10(Lmp1)Rsky/\Gt(ROSA)26Sor+
\Tcrbtm1Mom/\Tcrbtm1Mom
\Tcrdtm1Mom/\Tcrdtm1Mom
\Cd19tm1(cre)Cgn/\Cd19+

(involves: 129P2/OlaHsd * 129S2/SvPas * BALB/cJ)
enlarged spleen J:181546
increased B cell number J:181546
\Gt(ROSA)26Sortm11(Lmp1)Rsky/\Gt(ROSA)26Sor+
(involves: C57BL/6)
abnormal B cell morphology J:181546
increased B cell proliferation J:181546
\Gt(ROSA)26Sortm11(Lmp1)Rsky/\Gt(ROSA)26Sor+
\Cd19tm1(cre)Cgn/\Cd19+

(involves: 129P2/OlaHsd * C57BL/6)
abnormal B cell differentiation J:181546
abnormal CD4-positive, alpha-beta T cell physiology J:181546
abnormal CD8-positive, alpha-beta T cell physiology J:181546
abnormal immune system physiology J:181546
decreased B cell number J:181546
decreased mature B cell number J:181546
decreased pre-B cell number J:181546
enlarged spleen J:181546
increased B cell number J:181546
increased B cell proliferation J:181546
increased CD4-positive, alpha-beta T cell number J:181546
increased CD8-positive, alpha-beta T cell number J:181546
increased interferon-gamma secretion J:181546
increased pro-B cell number J:181546
increased tumor necrosis factor secretion J:181546
\Gt(ROSA)26Sortm11(Lmp1)Rsky/\Gt(ROSA)26Sor+
\Cd19tm1(cre/ERT2)Rsky/\Cd19+

(involves: 129P2/OlaHsd * C57BL/6J)
abnormal T cell physiology J:217520
enlarged spleen J:217520
increased activated T cell number J:217520
increased B cell number J:217520
increased CD4-positive, alpha-beta T cell number J:217520
increased CD8-positive, alpha-beta T cell number J:217520
\Gt(ROSA)26Sortm11(Lmp1)Rsky/\Gt(ROSA)26Sor+
\Tcrbtm1Mom/\Tcrb+
\Tcrdtm1Mom/\Tcrdtm1Mom
\Cd19tm1(cre)Cgn/\Cd19+

(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6)
enlarged spleen J:181546
increased B cell number J:181546
\Gt(ROSA)26Sortm11(Lmp1)Rsky/\Gt(ROSA)26Sor+
\Tcrbtm1Mom/\Tcrbtm1Mom
\Tcrdtm1Mom/\Tcrdtm1Mom
\Cd19tm1(cre)Cgn/\Cd19+

(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6)
enlarged spleen J:181546
increased B cell number J:181546
\Gt(ROSA)26Sortm12(CD2*)Rsky/\Gt(ROSA)26Sor+
\Myctm2Fwa/\Myctm2Fwa
\Ighg1tm1(cre)Cgn/\Ighg1+

(involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6)
decreased spleen germinal center size J:188564
\Gt(ROSA)26Sortm13(CAG-MYC,-CD2*)Rsky/\Gt(ROSA)26Sor+
\Myctm2Fwa/\Myctm2Fwa
\Ighg1tm1(cre)Cgn/\Ighg1+

(involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6)
immune system phenotype J:188564
\Gt(ROSA)26Sortm18(Zeb2)Jhai/\Gt(ROSA)26Sor+
\Tg(Tek-cre)1Ywa/0
\Trp53tm1Brn/\Trp53tm1Brn

(involves: 129P2/OlaHsd * C57BL/6 * CD-1 * SJL)
increased T cell derived lymphoma incidence J:263520
\Gt(ROSA)26Sortm18(Zeb2)Jhai/\Gt(ROSA)26Sortm18(Zeb2)Jhai
\Tg(Tek-cre)1Ywa/0

(involves: C57BL/6 * CD-1 * SJL)
increased thymus tumor incidence J:263520
\Gt(ROSA)26Sortm18(Zeb2)Jhai/\Gt(ROSA)26Sortm18(Zeb2)Jhai
\Tg(Tek-cre)1Ywa/0
\Trp53tm1Brn/\Trp53tm1Brn

(involves: 129P2/OlaHsd * C57BL/6 * CD-1 * SJL)
increased T cell derived lymphoma incidence J:263520
\Gtf2a1lem1(IMPC)J/\Gtf2a1lem1(IMPC)J
(C57BL/6NJ-Gtf2a1lem1(IMPC)J/Mmjax)
decreased leukocyte cell number J:211773
\Gtf2ird1em1(IMPC)Ccpcz/\Gtf2ird1em1(IMPC)Ccpcz
(C57BL/6NCrl-Gtf2ird1em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged thymus J:211773
small spleen J:211773
\Gtpbp2tm1b(KOMP)Mbp/\Gtpbp2+
(C57BL/6N-Gtpbp2tm1b(KOMP)Mbp/Ucd)
enlarged lymph nodes J:211773
\Gtpbp2tm1b(KOMP)Mbp/\Gtpbp2tm1b(KOMP)Mbp
(C57BL/6N-Gtpbp2tm1b(KOMP)Mbp/Ucd)
enlarged lymph nodes J:211773
\Gtsf1lem1(IMPC)J/\Gtsf1lem1(IMPC)J
(C57BL/6NJ-Gtsf1lem1(IMPC)J/Mmjax)
increased leukocyte cell number J:211773
\Guca2aem1(IMPC)Mbp/\Guca2aem1(IMPC)Mbp
(C57BL/6N-Guca2aem1(IMPC)Mbp/MbpMmucd)
abnormal lymph node morphology J:211773
enlarged lymph nodes J:211773
\Gucy1b1tm1.1Frb/\Gucy1b1tm1.1Frb
(involves: 129 * C57BL/6 * FVB/N)
peritoneal inflammation J:121321
\Gucy2ctm1Gar/\Gucy2ctm1Gar
(either: (involves: 129S6/SvEvTac * Black Swiss) or (involves: 129S6/SvEvTac * C57BL/6J))
decreased susceptibility to bacterial infection J:43046
decreased susceptibility to bacterial infection induced morbidity/mortality J:43046
\Gucy2ctm1Gian/\Gucy2ctm1Gian
(involves: 129P2/OlaHsd * Black Swiss)
decreased susceptibility to infection J:43682
\Guk1em1(IMPC)J/\Guk1+
(C57BL/6NJ-Guk1em1(IMPC)J/Mmjax)
decreased leukocyte cell number J:211773
\Guloem1(IMPC)Ccpcz/\Guloem1(IMPC)Ccpcz
(C57BL/6NCrl-Guloem1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
enlarged spleen J:211773
\Gulosfx/\Gulosfx
(BALB/cBy-Gulosfx/J)
abnormal osteoclast differentiation J:66648
small spleen J:66648
small thymus J:66648
\Gulp1tm1.2Kimj/\Gulp1tm1.2Kimj
(involves: 129S4/SvJae * C57BL/6 * SJL)
abnormal osteoclast differentiation J:340688
abnormal osteoclast morphology J:340688
abnormal osteoclast physiology J:340688
increased osteoclast cell number J:340688
\Gvhd1C57BL/10J/\Gvhd1C57BL/10J
(involves: B10.D2-H2d * C57BL/10J)
increased susceptibility to graft versus host disease J:52834
\Gvhd1C57BL/10J/\Gvhd1C57BL/10J
\Gvhd2C57BL/10J/\Gvhd2C57BL/10J

(involves: B10.D2-H2d * C57BL/10J)
increased susceptibility to graft versus host disease J:52834
\Gvhd2C57BL/10J/\Gvhd2C57BL/10J
(involves: B10.D2-H2d * DBA/2J)
increased susceptibility to graft versus host disease J:52834
\Gvhd4DBA/2J/\Gvhd4DBA/2J
(involves: C57BL/10 * DBA/2J)
increased anti-single stranded DNA antibody level J:66655
\Gvhd4DBA/2J/\Gvhd4DBA/2J
\Gvhd5DBA/2J/\Gvhd5DBA/2J

(involves: C57BL/10 * DBA/2J)
increased anti-single stranded DNA antibody level J:66655
\Gvhd5DBA/2J/\Gvhd5DBA/2J
(involves: C57BL/10 * DBA/2J)
increased anti-single stranded DNA antibody level J:66655
\Gy/Y
(involves: 101/H * C3H/HeH)
blepharitis J:8335
\Gzmatm1Ley/\Gzmatm1Ley
(involves: 129X1/SvJ * C57BL/6)
decreased cytotoxic T cell cytolysis J:49361
\Gzmatm1Simn/\Gzmatm1Simn
(B6.Cg-Gzmatm1Simn)
immune system phenotype J:92718, J:28773
\Gzmatm1Simn/\Gzmatm1Simn
\Gzmbtm1Ley/\Gzmbtm1Ley

(involves: 129S2/SvPas * C57BL/6)
abnormal leukocyte physiology J:44204
immune system phenotype J:44204
\Gzmatm1Simn/\Gzmatm1Simn
\Gzmbtm1Ley/\Gzmbtm1Ley

(B6.Cg-Gzmatm1Simn Gzmbtm1Ley)
immune system phenotype J:92718
increased susceptibility to Flaviviridae infection J:90852
increased susceptibility to parasitic infection J:81397
\Gzmatm1Simn/\Gzmatm1Simn
\Gzmbtm1Ley/\Gzmbtm1Ley
\Prf1tm1Sdz/\Prf1tm1Sdz

(B6.Cg-Gzmatm1Simn Gzmbtm1Ley Prf1tm1Sdz)
immune system phenotype J:92718
increased susceptibility to Flaviviridae infection J:90852
increased susceptibility to parasitic infection J:81397
\Gzmbtm1Asmv/\Gzmbtm1Asmv
(involves: C57BL/6)
immune system phenotype J:203720
\Gzmbtm1Ley/\Gzmbtm1Ley
(involves: 129S2/SvPas * C57BL/6J)
decreased cytotoxic T cell cytolysis J:23560
\Gzmbtm1Ley/\Gzmbtm1Ley
(B6.129S2-Gzmbtm1Ley)
impaired natural killer cell mediated cytotoxicity J:113213
\Gzmbtm1Ley/\Gzmbtm1Ley
(involves: 129X1/SvJ)
abnormal NK cell physiology J:126114
decreased T cell apoptosis J:126114
\Gzmbtm1Ley/\Gzmbtm1Ley
\Serpinb9tm1.1Pib/\Serpinb9tm1.1Pib

(involves: 129S2/SvPas * BALB/cJ * C57BL/6J)
decreased cytotoxic T cell apoptosis J:252016
\Gzmbtm1Ley/\Gzmbtm1Ley
\Serpinb9tm1Arp/\Serpinb9tm1Arp

(involves: 129S2/SvPas * C57BL/6)
abnormal CD8-positive, alpha-beta cytotoxic T cell morphology J:113349
abnormal cytotoxic T cell physiology J:113349
\Gzmbtm2.1Ley/\Gzmbtm2.1Ley
(129X1/SvJ-Gzmbtm2.1Ley)
decreased cytotoxic T cell cytolysis J:96538
\Gzmbtm2Ley/\Gzmbtm2Ley
(129X1/SvJ-Gzmbtm2Ley)
abnormal immune system physiology J:96538
decreased cytotoxic T cell cytolysis J:96538
\Gzmktm1.1Pib/\Gzmktm1.1Pib
(B6(Cg)-Gzmktm1.1Pib)
immune system phenotype J:302067
\Gzmmtm1(cre)Mjs/\Gzmmtm1(cre)Mjs
(C57BL/6-Gzmmtm1(cre)Mjs)
increased susceptibility to Herpesvirales infection J:113213
\H1f0tm1Ais/\H1f0tm1Ais
\H1f2tm2Ais/\H1f2tm2Ais
\H1f4tm2Ais/\H1f4tm2Ais

(involves: 129/Sv * C57BL/6 * SJL)
small thymus J:83954
\H1f2tm2Ais/\H1f2tm2Ais
\H1f3tm2Ais/\H1f3+
\H1f4tm2Ais/\H1f4tm2Ais

(involves: 129/Sv * C57BL/6 * SJL)
small thymus J:83954
\H2-Aab-tm1Blt/\H2-Aab-tm1Blt
(C57BL/6-H2-Aab-tm1Blt)
abnormal MHC II cell surface expression on macrophages J:67924
abnormal splenocyte physiology J:16372
abnormal T cell morphology J:16372
decreased CD4-positive, alpha-beta T cell number J:16372
enlarged lymph nodes J:16372
enlarged thymus J:16372
increased CD8-positive, alpha-beta T cell number J:16372
thymus hyperplasia J:16372
\H2-Ab1b-tm1.1Jssh/\H2-Ab1b-tm1.1Jssh
(C57BL/6-H2-Ab1b-tm1.1Jssh)
abnormal dendritic cell antigen presentation J:201198
abnormal T cell differentiation J:201198
decreased regulatory T cell number J:201198
\H2-Ab1b-tm1.1Sish/\H2-Ab1b-tm1.1Sish
(involves: 129S1/Sv * 129X1/SvJ)
abnormal dendritic cell physiology J:157516
decreased interleukin-12 secretion J:157516
decreased tumor necrosis factor secretion J:157516
\H2-Ab1b-tm1Doi/\H2-Ab1+
(involves: 129S2/SvPas * C57BL/6 * NOD/Lt)
insulitis J:93557
\H2-Ab1b-tm1Doi/\H2-Ab1b-tm1Doi
(involves: 129S2/SvPas * C57BL/6)
abnormal B cell physiology J:65736
abnormal CD4-positive, alpha beta T cell morphology J:65736
abnormal CD4-positive, alpha-beta T cell physiology J:65736
abnormal cytokine secretion J:64283
abnormal immune system cell morphology J:65736
abnormal immune system morphology J:65736
abnormal immune system organ morphology J:65736
abnormal immune system physiology J:65736
abnormal lymph node cell ratio J:65736
abnormal spleen B cell follicle morphology J:65736
abnormal spleen marginal zone morphology J:65736
abnormal spleen morphology J:65736
abnormal spleen periarteriolar lymphoid sheath morphology J:65736
abnormal T cell physiology J:65736
absent spleen germinal center J:65736
decreased CD4-positive, alpha-beta T cell number J:51885, J:65736
decreased IgG1 level J:65736
decreased susceptibility to parasitic infection J:64283
increased CD4-positive, alpha-beta T cell number J:64283
increased CD8-positive, alpha-beta T cell number J:65736, J:64283
increased susceptibility to parasitic infection J:64283
\H2-Ab1b-tm1Doi/\H2-Ab1b-tm1Doi
(involves: 129S2/SvPas * C57BL/6 * NOD/Lt)
insulitis J:93557
\H2-Ab1b-tm1Gru/\H2-Ab1b-tm1Gru
(involves: 129S2/SvPas * C57BL/6J)
abnormal humoral immune response J:74418
abnormal response to transplant J:91742
decreased CD4-positive, alpha-beta T cell number J:74418
decreased IgG level J:74418
increased CD8-positive, alpha-beta T cell number J:74418
increased IgM level J:74418
\H2-Ab1b-tm1Gru/\H2-Ab1b-tm1Gru
(NOD.129S2-H2-Ab1b-tm1Gru)
immune system phenotype J:86540
\H2-Ab1b-tm1Gru/\H2-Ab1b-tm1Gru
(B6.129S2-H2-Ab1b-tm1Gru)
abnormal B cell physiology J:91341
abnormal lymphocyte physiology J:91341
decreased CD4-positive, alpha-beta T cell number J:91341
\H2-Ab1b-tm1Gru/\H2-Ab1b-tm1Gru
(involves: 129S2/SvPas * C57BL/6)
abnormal level of surface class II molecules J:67941
decreased CD4-positive, alpha-beta T cell number J:67941
decreased IgG1 level J:67941
decreased IgM level J:67941
decreased single-positive T cell number J:67941
\H2-Ab1b-tm1Gru/\H2-Ab1b-tm1Gru
\Ighmtm1Cgn/\Ighmtm1Cgn
\Tg(CD2-CD4,HLA-DQA1,HLA-DQB1)1Ell/\Tg(CD2-CD4,HLA-DQA1,HLA-DQB1)1Ell

(NOD.Cg-Ighmtm1Cgn H2-Ab1b-tm1Gru Tg(CD2-CD4,HLA-DQA1,HLA-DQB1)1Ell)
heart inflammation J:113267
\H2-Ab1b-tm1Gru/\H2-Ab1b-tm1Gru
\Rag1tm1Mom/\Rag1tm1Mom
\Tg(CD2-CD4,HLA-DQA1,HLA-DQB1)1Ell/\Tg(CD2-CD4,HLA-DQA1,HLA-DQB1)1Ell

(NOD.Cg-Rag1tm1Mom H2-Ab1b-tm1Gru Tg(CD2-CD4,HLA-DQA1,HLA-DQB1)1Ell)
abnormal response to transplant J:113267
heart inflammation J:113267
increased autoantibody level J:113267
myocarditis J:113267
\H2-Ab1b-tm1Gru/\H2-Ab1b-tm1Gru
\Rag1tm1Mom/\Rag1tm1Mom
\Tg(HLA-DQA1,HLA-DQB1)73Myl/0

(NOD.Cg-Rag1tm1Mom H2-Ab1b-tm1Gru Tg(HLA-DQA1,HLA-DQB1)73Myl)
abnormal response to transplant J:88055
myocarditis J:88055
\H2-Ab1b-tm1Gru/\H2-Ab1b-tm1Gru
\Runx1tm1Toku/\Runx1tm1Toku
\Runx3tm1Itan/\Runx3tm1Itan
\Tg(Cd4-cre)1Cwi/0

(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 * DBA/2)
abnormal interferon secretion J:131081
increased CD4-positive, alpha-beta T cell number J:131081
\H2-Ab1b-tm1Gru/\H2-Ab1b-tm1Gru
\Tespa1tm1Smoc/\Tespa1tm1Smoc

(involves: 129 * 129S2/SvPas * C57BL/6)
absent CD4-positive, alpha-beta T cells J:186446
decreased CD8-positive, alpha-beta T cell number J:186446
\H2-Ab1b-tm1Gru/\H2-Ab1b-tm1Gru
\Tg(Ab1TL)1Gru/0

(B6.Cg-H2-Ab1b-tm1Gru Tg(Ab1TL)1Gru)
abnormal CD4-positive T cell differentiation J:91341
abnormal macrophage antigen presentation J:91341
abnormal professional antigen presenting cell physiology J:91341
\H2-Ab1b-tm1Gru/\H2-Ab1b-tm1Gru
\Tg(CD2-CD4,HLA-DQA1,HLA-DQB1)1Ell/\Tg(CD2-CD4,HLA-DQA1,HLA-DQB1)1Ell

(NOD.Cg-H2-Ab1b-tm1Gru Tg(CD2-CD4,HLA-DQA1,HLA-DQB1)1Ell)
autoimmune response J:87013, J:86540
decreased susceptibility to autoimmune disorder J:87013
heart inflammation J:87013, J:86540
immune system phenotype J:87013
increased autoantibody level J:113267
lung inflammation J:86540
myositis J:86540
salivary gland inflammation J:86540
\H2-Ab1b-tm1Gru/\H2-Ab1b-tm1Gru
\Tg(CD4,HLA-DQA1,HLA-DQB1)N8Ell/\Tg(CD4,HLA-DQA1,HLA-DQB1)N8Ell

(NOD.Cg-H2-Ab1b-tm1Gru Tg(CD4,HLA-DQA1,HLA-DQB1)N8Ell)
immune system phenotype J:113267
increased autoantibody level J:113509
thyroid gland inflammation J:113509
\H2-Ab1b-tm1Gru/\H2-Ab1b-tm1Gru
\Tg(HLA-DQA1,HLA-DQB1)1Dv/0
\Tg(HLA-DRB1)31Dmz/0
\Tg(Ins2-CD80)3B7Flv/0

(involves: 129S2/SvPas * C57BL/6 * C57BL/10SnJ * CBA * SJL)
abnormal CD4-positive, alpha beta T cell morphology J:68641
abnormal CD8-positive, alpha beta T cell morphology J:68641
decreased susceptibility to autoimmune diabetes J:68641
salivary gland inflammation J:68641
\H2-Ab1b-tm1Gru/\H2-Ab1b-tm1Gru
\Tg(HLA-DQA1,HLA-DQB1)1Dv/0
\Tg(Ins2-CD80)3B7Flv/0

(B6.Cg-H2-Ab1b-tm1Gru Tg(HLA-DQA1,HLA-DQB1)1Dv Tg(Ins2-CD80)3B7Flv)
increased susceptibility to autoimmune diabetes J:59245
salivary gland inflammation J:59245
\H2-Ab1b-tm1Gru/\H2-Ab1b-tm1Gru
\Tg(HLA-DQA1,HLA-DQB1)1Dv/0
\Tg(Ins2-CD80)3B7Flv/0

(involves: 129S2/SvPas * C57BL/6 * C57BL/10SnJ * CBA)
decreased interleukin-6 secretion J:68641
increased interferon-gamma secretion J:68641
increased susceptibility to autoimmune diabetes J:68641
\H2-Ab1b-tm1Gru/\H2-Ab1b-tm1Gru
\Tg(HLA-DQA1,HLA-DQB1)70Myl/0

(NOD.Cg-H2-Ab1b-tm1Gru Tg(HLA-DQA1,HLA-DQB1)70Myl)
heart inflammation J:88055
increased autoantibody level J:88055
insulitis J:88055
myocarditis J:88055
salivary gland inflammation J:88055
\H2-Ab1b-tm1Gru/\H2-Ab1b-tm1Gru
\Tg(HLA-DQA1,HLA-DQB1)73Myl/0

(NOD.Cg-H2-Ab1b-tm1Gru Tg(HLA-DQA1,HLA-DQB1)73Myl)
heart inflammation J:88055
increased autoantibody level J:88055
insulitis J:88055
myocarditis J:88055
salivary gland inflammation J:88055
\H2-Ab1b-tm1Gru/\H2-Ab1b-tm1Gru
\Tg(HLA-DRB1)31Dmz/0
\Tg(Ins2-CD80)3B7Flv/0

(involves: 129S2/SvPas * C57BL/6 * CBA * SJL)
abnormal CD4-positive, alpha beta T cell morphology J:68641
abnormal CD8-positive, alpha beta T cell morphology J:68641
decreased susceptibility to autoimmune diabetes J:68641
salivary gland inflammation J:68641
\H2-Ab1b-tm1Gru/\H2-Ab1b-tm1Gru
\Tg(Ins2-CD80)3B7Flv/0

(involves: 129S2/SvPas * C57BL/6 * CBA)
decreased susceptibility to autoimmune diabetes J:68641
\H2-Ab1b-tm1Gru/\H2-Ab1b-tm1Gru
\Themistm1Lov/\Themistm1Lov

(involves: 129)
abnormal negative T cell selection J:151075
\H2-Ab1b-tm1Koni/\H2-Ab1b-tm1.1Koni
\Tg(Tek-cre)12Flv/0

(involves: 129X1/SvJ * C3H * C57BL/6 * C57BL/6J)
abnormal CD4-positive, CD25-positive, alpha-beta regulatory T cell morphology J:131774
abnormal T cell activation J:131774
decreased CD4-positive, CD25-positive, alpha-beta regulatory T cell number J:131774
decreased level of surface class II molecules J:131774
immune system phenotype J:131774
increased CD4-positive, alpha-beta T cell number J:131774
\H2-Ab1b-tm1Wug/\H2-Ab1b-tm1Wug
(involves: C57BL/6)
abnormal B cell physiology J:204951
abnormal dendritic cell physiology J:204951
absent CD4-positive, alpha-beta T cells J:204951
decreased susceptibility to experimental autoimmune encephalomyelitis J:204951
\H2-Ab1b-tm1Wug/\H2-Ab1b-tm1Wug
\Cd19tm1(cre)Cgn/\Cd19+

(involves: 129S2/SvPas * C57BL/6)
abnormal B cell physiology J:204951
abnormal dendritic cell physiology J:204951
decreased susceptibility to experimental autoimmune encephalomyelitis J:204951
immune system phenotype J:204951
\H2-Ab1bm12/\H2-Ab1bm12
(B6(C)-H2-Ab1bm12/KhEgJ)
abnormal level of surface class II molecules J:100194
abnormal T cell physiology J:100123
decreased susceptibility to autoimmune disorder J:100123
decreased susceptibility to experimental autoimmune myasthenia gravis J:100213
decreased susceptibility to parasitic infection J:48242
\H2-Ab1bm12/\H2-Ab1bm12
(NZB.B6(C)-H2-Ab1bm12)
abnormal immunoglobulin level J:104189
abnormal level of surface class II molecules J:104189
autoimmune response J:4554
decreased CD8-positive, alpha-beta T cell number J:4554
increased anti-double stranded DNA antibody level J:104189
increased anti-erythrocyte antigen antibody level J:4554
increased anti-single stranded DNA antibody level J:104189
increased B cell number J:104189
increased CD4-positive, alpha-beta T cell number J:4554
increased double-negative T cell number J:4554
\H2-Ab1g7-em1Dvs/\H2-Ab1g7-em1Dvs
\H2-D1b-em5Dvs/\H2-D1b-em5Dvs
\H2-K1d-em1Dvs/\H2-K1d-em1Dvs

(NOD/ShiLtDvs-H2-K1d-em1Dvs H2-Ab1g7-em1Dvs H2-D1em5Dvs/Dvs)
abnormal T cell subpopulation ratio J:257229
decreased alpha-beta T cell number J:257229
decreased CD4-positive, alpha-beta T cell number J:257229
decreased susceptibility to autoimmune diabetes J:257229
\H2-Ab1g7-em1Ygch/\H2-Ab1g7-em1Ygch
(NOD/ShiLtJ-H2-Ab1g7-em1Ygch)
decreased CD4-positive, alpha-beta T cell number J:101977
\H2-D1b-em1Dvs/\H2-D1b-em1Dvs
(NOD/ShiLtDvs-H2-D1b-em1Dvs/Dvs)
abnormal immune system physiology J:257229
decreased susceptibility to autoimmune diabetes J:257229
\H2-D1b-em2Dvs/\H2-D1b-em2Dvs
(NOD/ShiLtDvs-H2-D1b-em2Dvs/Dvs)
abnormal immune system physiology J:257229
decreased susceptibility to autoimmune diabetes J:257229
\H2-D1b-em3Dvs/\H2-D1b-em3Dvs
(NOD/ShiLtDvs-H2-D1b-em3Dvs/Dvs)
abnormal immune system physiology J:257229
decreased susceptibility to autoimmune diabetes J:257229
\H2-D1b-em4Dvs/\H2-D1b-em4Dvs
(NOD/ShiLtDvs-H2-D1b-em4Dvs/Dvs)
abnormal immune system physiology J:257229
decreased susceptibility to autoimmune diabetes J:257229
\H2-D1b-em5Dvs/\H2-D1b-em5Dvs
\H2-K1d-em1Dvs/\H2-K1d-em1Dvs

(NOD/ShiLtDvs-H2-K1d-em1Dvs H2-D1b-em5Dvs/Dvs)
abnormal T cell subpopulation ratio J:257229
decreased susceptibility to autoimmune diabetes J:257229
\H2-D1b-em5Dvs/\H2-D1b-em5Dvs
\H2-K1d-em1Dvs/\H2-K1d-em1Dvs
\Tg(HLA-A/H2-D/B2M)1Dvs/?

(NOD/ShiLtDvs-H2-K1d-em1Dvs H2-D1b-em5Dvs Tg(HLA-A/H2-D/B2M)1Dvs/Dvs)
autoimmune response J:257229
increased susceptibility to autoimmune diabetes J:257229
insulitis J:257229
\H2-D1b-em5Dvs/\H2-D1b-em5Dvs
\H2-K1d-em1Dvs/\H2-K1d-em1Dvs
\Tg(HLA-B39/H2-D/B2m)2Dvs/?

(NOD/ShiLtDvs-H2-K1d-em1Dvs H2-D1b-em5Dvs Tg(HLA-B39/H2-D/B2M)2Dvs/Dvs)
autoimmune response J:257229
increased susceptibility to autoimmune diabetes J:257229
insulitis J:257229
\H2-D1b-tm1Bpe/\H2-D1b-tm1Bpe
\H2-K1b-tm1Bpe/\H2-K1b-tm1Bpe

(involves: 129P2/OlaHsd * C57BL/6)
absent CD8-positive, alpha-beta T cells J:57703
decreased CD8-positive, alpha-beta T cell number J:54709
decreased susceptibility to Riboviria infection induced morbidity/mortality J:54709
increased CD4-positive, alpha-beta T cell number J:54709
\H2-D1b-tm1Bpe/\H2-D1b-tm1Bpe
\H2-K1b-tm1Bpe/\H2-K1b-tm1Bpe

(B6.129P-H2-D1b-tm1Bpe H2-K1b-tm1Bpe)
abnormal cytotoxic T cell physiology J:118960
\H2-D1b-tm1Bpe/\H2-D1b-tm1Bpe
\H2-K1b-tm1Bpe/\H2-K1b-tm1Bpe
\Klra1tm1.1Wyok/\Klra1tm1.1Wyok
\Tg(H2-Dd)28Bee/0

(involves: 129P2/OlaHsd * BALB/cJ * C57BL/6NTac * DBA/2)
abnormal NK cell physiology J:252851
\H2-D1b-tm1Bpe/\H2-D1b-tm1Bpe
\H2-K1b-tm1Bpe/\H2-K1b-tm1Bpe
X/\Yaa

(BXSB.129P2(B6)-H2-K1b-tm1Bpe H2-D1b-tm1Bpe/Dcr)
increased susceptibility to systemic lupus erythematosus J:179430
\H2-D1bm14/\H2-D1bm14
(C57BL/6)
abnormal T cell activation J:97717
spinal cord inflammation J:97717
\H2-DMatm1Doi/\H2-DMatm1Doi
(involves: 129S2/SvPas * C57BL/6)
abnormal professional antigen presenting cell physiology J:31624
immune system phenotype J:31624
\H2-DMatm1Liz/\H2-DMatm1Liz
(involves: BALB/cJ)
abnormal antigen presentation via MHC class II J:113714
abnormal CD4-positive, alpha beta T cell morphology J:113714
abnormal professional antigen presenting cell physiology J:111565, J:113714
defective assembly of class II molecules J:113714
\H2-DMatm1Lkrl/\H2-DMatm1Lkrl
(involves: 129P2/OlaHsd)
abnormal antigen presentation J:31786
abnormal CD4-positive, alpha-beta T cell physiology J:31786
abnormal positive T cell selection J:31786
abnormal professional antigen presenting cell physiology J:31786
decreased CD4-positive, alpha-beta T cell number J:31786
\H2-DMatm1Luc/\H2-DMatm1Luc
(involves: 129S4/SvJae)
abnormal antigen presentation via MHC class II J:31625
abnormal CD4-positive, alpha-beta T cell physiology J:31625
abnormal level of surface class II molecules J:45185
abnormal positive T cell selection J:125548
decreased CD4-positive, alpha-beta T cell number J:31625, J:45185
decreased interferon-gamma secretion J:45185
increased susceptibility to bacterial infection J:45185
\H2-DMatm1Luc/\H2-DMatm1Luc
(involves: 129S4/SvJae * C57BL/6)
abnormal antigen presentation J:72243
decreased susceptibility to experimental autoimmune encephalomyelitis J:72243
\H2-DMatm1Luc/\H2-DMatm1Luc
(B6.129S4-H2-Dmatm1Luc)
abnormal antigen presentation J:125654
abnormal T-helper 1 physiology J:125654
decreased susceptibility to experimental autoimmune encephalomyelitis J:125654
decreased susceptibility to type IV hypersensitivity reaction J:125654
\H2-DMatm1Luc/\H2-DMatm1Luc
\Cd74tm1Doi/\Cd74tm1Doi

(involves: 129S2/SvPas * 129S4/SvJae * C57BL/6)
abnormal level of surface class II molecules J:45185
increased susceptibility to parasitic infection J:45185
\H2-DMatm2Liz/\H2-DMatm2Liz
(involves: C57BL/6 * C57BL/10 * C57BR * CBA)
abnormal antigen presentation via MHC class II J:111565
abnormal professional antigen presenting cell physiology J:111565
decreased T cell proliferation J:111565
\H2-K1b-tm1Bpe/\H2-K1b-tm1Bpe
(involves: 129P2/OlaHsd * C57BL/6)
decreased CD8-positive, alpha-beta T cell number J:54709
increased CD4-positive, alpha-beta T cell number J:54709
\H2-K1d-em4Dvs/\H2-K1d-em4Dvs
(NOD/ShiLtDvs-H2-K1d-em4Dvs/Dvs)
abnormal immune system physiology J:257229
decreased susceptibility to autoimmune diabetes J:257229
\H2-K1d-em5Dvs/\H2-K1d-em5Dvs
(NOD/ShiLtDvs-H2-K1d-em5Dvs/Dvs)
abnormal immune system physiology J:257229
decreased susceptibility to autoimmune diabetes J:257229
\H2-K1d-em7Dvs/\H2-K1d-em7Dvs
(NOD/ShiLtDvs-H2-K1d-em7Dvs/Dvs)
abnormal immune system physiology J:257229
decreased susceptibility to autoimmune diabetes J:257229
\H2-Kbm1/\H2-Kbm1
\Tg(TcraTcrb)1100Mjb/?

(involves: C57BL/6)
abnormal positive T cell selection J:92867
\H2-Kbm5/\H2-Kbm5
\Tg(TcraTcrb)1100Mjb/?

(involves: C57BL/6)
abnormal positive T cell selection J:133645
\H2-Kdm4/\H2-Kdm4
(involves: BALB/cKh * C57BL/6Kh)
immune system phenotype J:109272
\H2-Kdm5/\H2-Kdm5
(involves: BALB/cKh * C57BL/6Kh)
immune system phenotype J:109272
\H2-M3tm1Crw/\H2-M3tm1Crw
(B6.129-H2-M3tm1Crw)
abnormal CD8-positive, alpha beta T cell morphology J:118960
abnormal cytotoxic T cell physiology J:118960
abnormal innate immunity J:118960
decreased activated T cell number J:118960
decreased interferon-gamma secretion J:118960
decreased macrophage nitric oxide production J:118960
impaired natural killer cell mediated cytotoxicity J:118960
increased susceptibility to bacterial infection J:118960
\H2-Oatm1Dma/\H2-Oatm1Dma
(involves: 129/Sv * C57BL/6)
abnormal antigen presentation via MHC class II J:65235
increased CD4-positive, alpha-beta T cell number J:65235
\H2-Oatm1Lkar/\H2-Oatm1Lkar
(involves: 129P2/OlaHsd)
abnormal antigen presentation via MHC class II J:85084
immune system phenotype J:85084
increased IgG1 level J:85084
\H2-Obem1Tvg/\H2-Obem1Tvg
(C57BL/6J-H2-Obem1Tvg/Tvg)
decreased susceptibility to Retroviridae infection J:254532
defective assembly of class II molecules J:254532
immune system phenotype J:254532
\H2-Obvic1/\H2-Obvic1
(I/LnJ)
decreased susceptibility to Retroviridae infection J:163153
decreased susceptibility to viral infection J:81554, J:60602
\H2-Obvic1/\H2-Obvic1
(C3N.I-H2-Obvic1)
decreased susceptibility to Retroviridae infection J:254532
\H2-Obvic1/\H2-Obvic1
(B6.I-H2-Obvic1)
decreased susceptibility to Retroviridae infection J:254532
\H2-Obvic1/\H2-Obvic1
(C.I-H2-Obvic1)
decreased susceptibility to Retroviridae infection J:254532
\H2-Q10tm1.1(KOMP)Mbp/\H2-Q10tm1.1(KOMP)Mbp
(involves: C57BL/6 * C57BL/6N)
decreased gamma-delta T cell number J:294888
decreased immature NK cell number J:294888
decreased mature NK cell number J:294888
decreased NK cell number J:294888
increased NK cell number J:294888
\H2-T18b/\H2-T18b
\H2-T3tm1Luc/\H2-T3tm1Luc

(C57BL/6-H2-T3tm1Luc)
abnormal CD8 positive, alpha-beta intraepithelial T cell morphology J:142515
abnormal CD8-positive, gamma-delta intraepithelial T cell morphology J:142515
abnormal intraepithelial T cell morphology J:142515
increased interferon-gamma secretion J:142515
\H2-T18b/\H2-T18b
\H2-T3tm1Luc/\H2-T3tm1Luc
\Tcratm1Mom/\Tcratm1Mom

(B6.Cg-Tcratm1Mom H2-T3tm1Luc)
abnormal intraepithelial T cell number J:142515
colitis J:142515
enlarged mesenteric lymph nodes J:142515
increased interleukin-4 secretion J:142515
\H2-T23tm1Cant/\H2-T23tm1Cant
(involves: 129S6/SvEvTac * C57BL/6)
abnormal CD4-positive, alpha-beta T cell physiology J:142087, J:123555
abnormal memory T cell physiology J:123555
increased susceptibility to bacterial infection J:89808
increased susceptibility to experimental autoimmune encephalomyelitis J:89808
increased susceptibility to Herpesvirales infection J:89808
\H2-T23tm2Cant/\H2-T23tm2Cant
(involves: 129S6/SvEvTac)
abnormal CD4-positive, alpha-beta T cell physiology J:123555
\H2-T23tm2Cant/\H2-T23tm2Cant
(B6.129S6-H2-T23tm2Cant)
abnormal CD4-positive, alpha-beta T cell physiology J:142087
decreased susceptibility to experimental autoimmune encephalomyelitis J:142087
\H2-T23tm2Cant/\H2-T23tm2Cant
\Tg(Tcra2D2,Tcrb2D2)1Kuch/?

(involves: 129S6/SvEvTac)
abnormal CD4-positive, alpha-beta T cell physiology J:142087
increased susceptibility to experimental autoimmune encephalomyelitis J:142087
\H2-T23tm3Cant/\H2-T23tm3Cant
(B6.129S6-H2-T23tm3Cant)
increased susceptibility to experimental autoimmune encephalomyelitis J:142087
\H2-T23tm3Cant/\H2-T23tm3Cant
\Tg(Tcra2D2,Tcrb2D2)1Kuch/?

(involves: 129S6/SvEvTac * C57BL/6)
abnormal CD4-positive, alpha-beta T cell physiology J:142087
\H2-T23tm3Cant/\H2-T23tm3Cant
\Tg(TcraTcrb)425Cbn/?

(involves: 129S6/SvEvTac * C57BL/6)
abnormal CD4-positive, alpha-beta T cell physiology J:142087
\H2-T24em1(IMPC)Wtsi/\H2-T24em1(IMPC)Wtsi
(C57BL/6N-H2-T24em1(IMPC)Wtsi/Wtsi)
increased leukocyte cell number J:211773
\H2b/\H2b
(NOD.B10SnJ-H2b)
decreased susceptibility to autoimmune diabetes J:14178
periinsulitis J:14178
\H2b/\H2b
\Itktm1Ljb/\Itktm1Ljb
\Tg(TcrAND)53Hed/?

(involves: C3H/HeJ * C57BL/6 * C57BL/10)
abnormal positive T cell selection J:123795
decreased CD4-positive, alpha-beta T cell number J:123795
\H2b/\H2b
\Nfkbidtm1Clay/\Nfkbidtm1Clay
\Rag2tm1Fwa/\Rag2tm1Fwa
\Tg(TcraN15,TcrbN15)L2Elre/?

(involves: 129S/SvEv * 129S6/SvEvTac * C57BL/6)
abnormal thymocyte activation J:132071
decreased interleukin-2 secretion J:132071
decreased T cell proliferation J:132071
\H2b/\H2b
\Ptcratm1Vbo/\Ptcratm1Vbo

(involves: 129P2/OlaHsd)
decreased double-positive T cell number J:131357
decreased thymocyte number J:131357
spleen hypoplasia J:131357
\H2b/\H2b
\Ptcratm1Vbo/\Ptcratm1Vbo
\Tcratm1Mom/\Tcra/Tcrdtm1.1(Tcra)Rsky
\Tg(Tcrb)93Vbo/?

(involves: 129P2/OlaHsd * C57BL/6J * DBA/2J)
abnormal T cell differentiation J:131357
decreased thymocyte number J:131357
\H2b/\H2b
\Ptcratm1Vbo/\Ptcratm1Vbo
\Tg(TcraH-Y,TcrbH-Y)71Vbo/?

(involves: 129P2/OlaHsd * C57BL/6J * DBA/2J)
abnormal T cell differentiation J:131357
\H2b/\H2b
\Rag1tm1Mom/\Rag1tm1Mom
\Tg(Tcra19,Tcrb19)#Stl/0

(involves: 129S7/SvEvBrd * C57BL/6)
immune system phenotype J:19795
\H2b/\H2b
\Rag2tm1Fwa/\Rag2tm1Fwa
\Tg(TcraN15,TcrbN15)L2Elre/?

(involves: 129S/SvEv * C57BL/6)
abnormal cytotoxic T cell physiology J:133112
arrested T cell differentiation J:133112
decreased CD4-positive, alpha-beta T cell number J:133112
increased CD8-positive, alpha-beta T cell number J:133112
increased T cell proliferation J:133112
\H2b/\H2b
\Tcra/Tcrdtm1.1(Tcra)Rsky/\Tcra/Tcrdtm1.1(Tcra)Rsky
\Tg(Tcrb)93Vbo/?

(involves: 129P2/OlaHsd * C57BL/6J * DBA/2J)
abnormal negative T cell selection J:81564
abnormal T cell differentiation J:81564
\H2b/\H2b
\Tcra/Tcrdtm1.1(Tcra)Rsky/\Tcra/Tcrdtm1.1(Tcra)Rsky
\Tg(Tcrb)93Vbo/?

(involves: 129P2/OlaHsd * C57BL/6J * DBA/2J)
abnormal negative T cell selection J:81564
abnormal T cell differentiation J:81564
\H2b/\H2b
\Tcratm1Mom/\Tcra/Tcrdtm1.1(Tcra)Rsky
\Tg(Tcrb)93Vbo/?

(involves: 129P2/OlaHsd * C57BL/6J * DBA/2J)
abnormal double-negative T cell morphology J:131357
abnormal double-positive T cell morphology J:81564
abnormal negative T cell selection J:81564
abnormal T cell differentiation J:81564
decreased double-positive T cell number J:131357
decreased thymocyte number J:131357
\H2b/\H2d
((C57BL/6 x DBA/2)F1)
abnormal cytokine secretion J:106141
abnormal T cell differentiation J:106141
decreased susceptibility to parasitic infection J:106141
increased autoantibody level J:106141
\H2b/\H2d
\Tg(Ins2-E3)1Dvs/0

(involves: BALB/c * C57BL/6 * DBA/2J)
increased length of allograft survival J:109763
\H2b/\H2d
\Tg(TcraTcrb)1100Mjb/?

(involves: BALB/c * C57BL/6)
abnormal negative T cell selection J:133645
decreased CD8-positive, alpha-beta T cell number J:133645
small thymus J:133645
\H2b/\H2d
\Themistm1Gasc/\Themistm1Gasc

(involves: 129S6/SvEvTac * C57BL/6 * C57BL/10 * DBA/2)
abnormal negative T cell selection J:151074
\H2b/\H2g7
(NOD.B10SnJ-H2b)
decreased susceptibility to autoimmune diabetes J:14178
\H2b/\H2g7
\Tg(TcraR28,TcrbR28)KRNDim/0

(involves: C57BL/6 * NOD * SJL)
mitral valve inflammation J:275827
rheumatoid arthritis J:36815, J:275827
\H2b/\H2k
\Itktm1Ljb/\Itktm1Ljb
\Tg(TcrAND)53Hed/?

(involves: C3H/HeJ * C57BL/6 * C57BL/10)
abnormal positive T cell selection J:123795
decreased CD4-positive, alpha-beta T cell number J:123795
\H2b/\H2k
\Tg(TcraTcrb)1100Mjb/?

(involves: C57BL/6 * C57BL/10Sg * C57BR/c)
abnormal negative T cell selection J:133645
decreased CD8-positive, alpha-beta T cell number J:133645
small thymus J:133645
\H2b/\H2s
\Tg(TcraTcrb)1100Mjb/?

(involves: A/WySn * C57BL/6 * C57BL/10Sg * Swiss)
abnormal negative T cell selection J:133645
decreased CD8-positive, alpha-beta T cell number J:133645
small thymus J:133645
\H2d/\H2d
(DBA/2)
abnormal cytokine secretion J:106141
abnormal T cell differentiation J:106141
decreased susceptibility to parasitic infection J:106141
increased autoantibody level J:106141
\H2d/\H2d
\Rag2tm1Fwa/\Rag2tm1Fwa
\Tg(TcraN15,TcrbN15)L2Elre/?

(involves: 129S/SvEv * C57BL/6)
arrested T cell differentiation J:133112
decreased CD4-positive, alpha-beta T cell number J:133112
decreased CD8-positive, alpha-beta T cell number J:133112
\H2d/\H2d
\Tcra/Tcrdtm1.1(Tcra)Rsky/\Tcra/Tcrdtm1.1(Tcra)Rsky
\Tg(Tcrb)93Vbo/0

(involves: 129P2/OlaHsd * C57BL/6J * DBA/2J)
abnormal T cell differentiation J:131357
decreased thymocyte number J:131357
\H2d/\H2d
\Tg(TcraP1.5,TcrbP1.5)29Amsv/0
\Trap1atm1.1Jvde/Y

(involves: 129 * BALB/cJ * C57BL/10 * DBA/2)
abnormal T cell clonal deletion J:180807
\H2d/\H2d
\Trap1atm1.1Jvde/Y

(involves: 129 * BALB/cJ * C57BL/10 * DBA/2)
abnormal CD8-positive, alpha-beta T cell physiology J:180807
abnormal immune tolerance J:180807
\H2dlAb1-Ea/\H2dlAb1-Ea
(B6.129S2-H2dlAb1-Ea/J)
increased susceptibility to bacterial infection J:123934
\H2dlAb1-Ea/\H2dlAb1-Ea
(involves: 129S2/SvPas * C57BL/6)
abnormal immunoglobulin level J:57484
abnormal T cell number J:57484
decreased CD4-positive, alpha-beta T cell number J:57484
decreased IgG1 level J:57484
decreased IgG2a level J:57484
immune system phenotype J:157516
increased CD8-positive, alpha-beta T cell number J:57484
increased IgM level J:57484
\H2dlAb1-Ea/\H2dlAb1-Ea
\Marchf1tm1.1Sish/\Marchf1tm1.1Sish

(involves: 129S1/Sv * 129S2/SvPas * 129X1/SvJ * C57BL/6)
immune system phenotype J:157516
\H2dlAb1-Ea/\H2dlAb1-Ea
\Psmb11tm1(Psmb8)Khog/\Psmb11tm1(Psmb8)Khog

(involves: 129S2/SvPas * C57BL/6)
abnormal T cell differentiation J:196156
decreased CD8-positive, alpha-beta T cell number J:196156
\H2dlAb1-Ea/\H2dlAb1-Ea
\Rag1tm1Mom/\Rag1tm1Mom
\Tg(HLA-DRA,HLA-DRB5*0101)hiKito/0
\Tg(TRATL3A6,TRBTL3A6)#Kito/0

(involves: 129S2/SvPas * 129S7/SvEvBrd * C57BL/6)
brain inflammation J:189816
\H2dlAb1-Ea/\H2dlAb1-Ea
\Rag1tm1Mom/\Rag1tm1Mom
\Tg(HLA-DRA,HLA-DRB5*0101)loKito/0
\Tg(TRATL3A6,TRBTL3A6)#Kito/0

(involves: 129S2/SvPas * 129S7/SvEvBrd * C57BL/6)
brain inflammation J:189816
\H2dlAb1-Ea/\H2dlAb1-Ea
\Rr381em2Kap/\Rr381em2Kap

(involves: 129S2/SvPas * C57BL/6)
absent CD4-positive, alpha-beta T cells J:333471
\H2dlAb1-Ea/\H2dlAb1-Ea
\Rr381em4Kap/\Rr381em4Kap

(involves: 129S2/SvPas * C57BL/6)
absent CD8-positive, alpha-beta T cells J:333471
\H2dlAb1-Ea/\H2dlAb1-Ea
\Rr381em5Kap/\Rr381em5Kap

(involves: 129S2/SvPas * C57BL/6)
absent CD8-positive, alpha-beta T cells J:333471
\H2dlAb1-Ea/\H2dlAb1-Ea
\Tg(HLA-DRA,HLA-DRB5*0101)hiKito/0
\Tg(TRATL3A6,TRBTL3A6)#Kito/0

(involves: 129S2/SvPas * C57BL/6)
abnormal cytokine secretion J:189816
brain inflammation J:189816
CNS inflammation J:189816
increased CD4-positive, alpha-beta T cell number J:189816
increased inflammatory response J:189816
increased interferon-gamma secretion J:189816
increased interleukin-17 secretion J:189816
increased susceptibility to experimental autoimmune encephalomyelitis J:189816
increased T-helper 1 cell number J:189816
increased T-helper 17 cell number J:189816
\H2dlAb1-Ea/\H2dlAb1-Ea
\Tg(HLA-DRA,HLA-DRB5*0101)loKito/0
\Tg(TRATL3A6,TRBTL3A6)#Kito/0

(involves: 129S2/SvPas * C57BL/6)
brain inflammation J:189816
increased susceptibility to experimental autoimmune encephalomyelitis J:189816
\H2g7/\H2g7
\Ins2tm1Jja/\Ins2tm1Jja
\Rag1tm1Mom/\Rag1tm1Mom
\Tg(TcraBDC12-4.1)10Jos/0
\Tg(TcrbBDC12-4.1)82Gse/0

(involves: 129S2/SvPas * 129S7/SvEvBrd * C57BL/6 * FVB * NOD)
increased susceptibility to autoimmune diabetes J:111874
\H2g7/\H2g7
\Rag1tm1Mom/\Rag1tm1Mom
\Tg(TcraBDC12-4.1)10Jos/0
\Tg(TcrbBDC12-4.1)82Gse/0

(involves: 129S7/SvEvBrd * C57BL/6 * FVB * NOD)
increased susceptibility to autoimmune diabetes J:111874
insulitis J:111874
\H2g7/\H2g7
\Tg(Ins2-Vtcn1)#Xxz/0
\Tg(TcraBDC2.5,TcrbBDC2.5)1Doi/0

(involves: C57BL/6 * NOD * SJL)
decreased interferon-gamma secretion J:177612
decreased interleukin-17 secretion J:177612
decreased regulatory T cell number J:177612
decreased susceptibility to autoimmune diabetes J:177612
\H2g7/\H2g7
\Tg(TcraAI4)1Dvs/0
\Tg(TcrbAI4)1Dvs/0

(B6.NOD-(D17Mit21-D17Mit10) Tg(TcraAI4)1Dvs Tg(TcrbAI4)1Dvs)
increased susceptibility to autoimmune diabetes J:167508
\H2g7/\H2g7
\Tg(TcraBDC2.5,TcrbBDC2.5)1Doi/0

(B6.Cg-H2g7 Tg(TcraBDC2.5,TcrbBDC2.5)1Doi)
decreased susceptibility to autoimmune diabetes J:86926
\H2g7/\H2g7
\Tg(TcraBDC12-4.1)10Jos/0
\Tg(TcrbBDC12-4.1)82Gse/0

(involves: 129S7/SvEvBrd * C57BL/6 * FVB * NOD)
decreased susceptibility to autoimmune diabetes J:111874
insulitis J:111874
\H2g7/\H2q
\Rag1tm1Mom/\Rag1tm1Mom
\Tg(TcraBDC12-4.1)10Jos/0
\Tg(TcrbBDC12-4.1)82Gse/0

(involves: 129S7/SvEvBrd * C57BL/6 * FVB * NOD)
increased susceptibility to autoimmune diabetes J:111874
\H2h2/\H2g7
(NOD.Cg-H2h2)
decreased susceptibility to autoimmune diabetes J:14178
\H2h2/\H2h2
(NOD.Cg-H2h2)
decreased susceptibility to autoimmune diabetes J:14178
insulitis J:14178
periinsulitis J:14178
\H2h4/\H2g7
(NOD.Cg-H2h4)
decreased susceptibility to autoimmune diabetes J:14178
\H2h4/\H2h4
(NOD.Cg-H2h4)
abnormal cytokine secretion J:54563
decreased susceptibility to autoimmune diabetes J:14178
insulitis J:14178
periinsulitis J:14178
thyroid gland inflammation J:54563
\H2i5/\H2g7
(NOD.Cg-H2i5)
decreased susceptibility to autoimmune diabetes J:14178
\H2i5/\H2i5
(NOD.Cg-H2i5)
decreased susceptibility to autoimmune diabetes J:14178
periinsulitis J:14178
\H2i7/\H2g7
(NOD.Cg-H2i7)
decreased susceptibility to autoimmune diabetes J:14178
\H2i7/\H2g7
((NOD x NOD.Cg-H2i7)F1)
insulitis J:14178
\H2i7/\H2i7
(NOD.Cg-H2i7)
decreased susceptibility to autoimmune diabetes J:14178
periinsulitis J:14178
\H2k/\H2g7
(NOD.Cg-H2k)
decreased susceptibility to autoimmune diabetes J:14178
\H2k/\H2k
(NOD.Cg-H2k)
increased susceptibility to autoimmune diabetes J:14178
periinsulitis J:14178
\H2k/\H2k
\Tg(TcraTcrbAD10)1Hed/?

(involves: C57BL/6 * SJL)
increased CD4-positive, alpha-beta T cell number J:124701
\H2q/?
\Ncf1m1J/\Ncf1m1J

(B6.Cg-Ncf1m1J H2q)
decreased susceptibility to experimental autoimmune encephalomyelitis J:92437
increased susceptibility to experimental autoimmune encephalomyelitis J:92437
increased susceptibility to induced arthritis J:92437
increased susceptibility to type IV hypersensitivity reaction J:92437
rheumatoid arthritis J:92437
\H2q/\H2q
\Rag1tm1Mom/\Rag1tm1Mom
\Tg(TcraBDC12-4.1)10Jos/0
\Tg(TcrbBDC12-4.1)82Gse/0

(involves: 129S7/SvEvBrd * C57BL/6 * FVB * NOD)
decreased susceptibility to autoimmune diabetes J:111874
\H2u/\H2u
\Rag1tm1Mom/\Rag1tm1Mom
\Tg(Tcra19,Tcrb19)#Stl/0

(either: (involves: 129S7/SvEvBrd * C57BL/6 * PL/J) or (involves: 129S7/SvEvBrd * C57BL/6 * C57BL/10 * PL/J))
increased susceptibility to autoimmune disorder J:19795
\H2u/\H2u
\Tg(Tcra19,Tcrb19)#Stl/0

(either: (involves: C57BL/6 * PL/J) or (involves: C57BL/6 * C57BL/10 * PL/J))
increased susceptibility to autoimmune disorder J:19795
increased susceptibility to experimental autoimmune encephalomyelitis J:19795
\H2u/\H2u
\Tg(TCRA)B1Jg/0

(B10.PL-H2u H2-T18a/(73NS)Sn-Tg(TCRA)B1Jg/J)
abnormal thymus cell ratio J:92992
decreased CD4-positive, alpha-beta T cell number J:92992
decreased double-positive T cell number J:92992
decreased thymocyte number J:92992
increased double-negative T cell number J:92992
increased T cell derived lymphoma incidence J:92992
\H2u/\H2u
\Tg(TCRA)B1Jg/?
\Tg(TCRB)C14Jg/?

(involves: C57BL/6 * C57BL/10SnSg * DBA/2 * PL/J)
abnormal CD4-positive, alpha-beta T cell physiology J:92991
abnormal effector T cell morphology J:92991
decreased CD8-positive, alpha-beta T cell number J:92991
decreased double-positive T cell number J:92991
increased autoantibody level J:92991
increased CD4-positive, alpha-beta T cell number J:92991
increased susceptibility to experimental autoimmune encephalomyelitis J:92991
\H2u/\H2u
\Tg(TCRA)B1Jg/0
\Tg(TCRB)C14Jg/0

(B10.PL-H2u H2-T18a/(73NS)Sn-Tg(TCRA)B1Jg Tg(TCRB)C14Jg)
abnormal double-negative T cell morphology J:92992
abnormal double-positive T cell morphology J:92992
abnormal thymus cell ratio J:92992
absent gamma-delta T cells J:92992
decreased double-positive T cell number J:92992
increased CD4-positive, alpha-beta T cell number J:92992
increased double-negative T cell number J:92992
increased T cell derived lymphoma incidence J:92992
\H2u/\H2u
\Tg(TCRB)C14Jg/0

(B10.PL-H2u H2-T18a/(73NS)Sn-Tg(TCRB)C14Jg/J)
abnormal double-negative T cell morphology J:92992
abnormal double-positive T cell morphology J:92992
absent gamma-delta T cells J:92992
\H2axtm1Fwa/\H2ax+
\Trp53tm1Brd/\Trp53tm1Brd

(involves: 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6)
increased T cell derived lymphoma incidence J:84879
\H2axtm1Fwa/\H2axtm1Fwa
(involves: 129S6/SvEvTac)
abnormal class switch recombination J:84879
decreased lymphocyte cell number J:84879
increased T cell derived lymphoma incidence J:84879
\H2axtm1Fwa/\H2axtm1Fwa
\Trp53tm1Brd/\Trp53tm1Brd

(involves: 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6)
increased T cell derived lymphoma incidence J:84879
\H2axtm1Nus/\H2axtm1Nus
(Not Specified)
abnormal class switch recombination J:194603, J:120658
decreased B cell number J:76360
decreased IgG level J:73342
decreased T cell number J:76360
\H2axtm1Nus/\H2axtm1Nus
\Ightm1Mnz/\Ightm1Mnz

(involves: 129P2/OlaHsd)
immune system phenotype J:120658
\H2axtm1Nus/\H2axtm1Nus
\Ightm2Mnz/\Ightm2Mnz

(involves: 129P2/OlaHsd)
immune system phenotype J:120658
\H2bc4em1(IMPC)Tcp/\H2bc4em1(IMPC)Tcp
(C57BL/6N-H2bc4em1(IMPC)Tcp/Tcp)
enlarged spleen J:211773
\H4c1em1(IMPC)Ccpcz/\H4c1em1(IMPC)Ccpcz
(C57BL/6NCrl-H4c1em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
\H4c16em1(IMPC)Mbp/\H4c16em1(IMPC)Mbp
(C57BL/6N-H4c16em1(IMPC)Mbp/MbpMmucd)
enlarged thymus J:211773
\H13tm1b(KOMP)Wtsi/\H13tm1b(KOMP)Wtsi
(C57BL/6N-H13tm1b(KOMP)Wtsi/Wtsi)
abnormal thymus topology J:239583
blood in lymph vessels J:239583
\Habp2tm1Lex/\Habp2tm1Lex
(involves: 129S7/SvEvBrd * BALB/c * C57BL/6)
liver inflammation J:207454
\Hace1tm1Pngr/\Hace1tm1Pngr
(involves: 129P2/OlaHsd * C57BL/6)
increased T cell derived lymphoma incidence J:125183
\Hamptm1Svl/\Hamptm1Svl
(involves: 129S2/SvPas * C57BL/6)
decreased spleen iron level J:119004
\Hamptm1Svl/\Hamptm1Svl
(involves: 129S2/SvPas * 129S6/SvEvTac * C57BL/6)
increased susceptibility to bacterial infection induced morbidity/mortality J:199427
\Hand2tm1Cse/\Hand2+
\H2az2Tg(Wnt1-cre)11Rth/\H2az2+

(involves: 129S1/Sv * C57BL/6J * CBA/J)
abnormal thymus development J:155265
\Hapln3em1(IMPC)Hmgu/\Hapln3em1(IMPC)Hmgu
(C57BL/6NCrl-Hapln3em1(IMPC)Hmgu/Ieg)
increased eosinophil cell number J:211773
\Hapstr1tm1.1Menm/\Hapstr1tm1.1Menm
\Tg(CAG-cre/Esr1*)5Amc/0

(involves: C57BL/6 * C57BL/6J * CBA)
large intestinal inflammation J:348964
\Has1tm1b(KOMP)Wtsi/\Has1tm1b(KOMP)Wtsi
(C57BL/6N-Has1tm1b(KOMP)Wtsi/H)
decreased eosinophil cell number J:211773
increased basophil cell number J:211773
\Havcr1tm1Kuch/\Havcr1tm1Kuch
(B6.Cg-Havcr1tm1Kuch)
abnormal B cell physiology J:186484
abnormal CD4-positive, alpha-beta T cell physiology J:186484
abnormal dendritic cell physiology J:186484
abnormal T cell differentiation J:186484
autoimmune response J:186484
enlarged spleen J:186484
increased activated T cell number J:186484
increased anti-double stranded DNA antibody level J:186484
increased CD4-positive, alpha-beta T cell number J:186484
increased CD8-positive, alpha-beta T cell number J:186484
increased double-negative T cell number J:186484
increased T cell number J:186484
\Havcr1tm1Shw/\Havcr1tm1Shw
(C.129P2-Havcr1tm1Shw)
immune system phenotype J:166400
\Havcr1tm1Vlcg/\Havcr1tm1Vlcg
(B6.129-Havcr1tm1Vlcg)
immune system phenotype J:187793
increased interleukin-5 secretion J:187793
increased interleukin-13 secretion J:187793
\Havcr1tm1Vlcg/\Havcr1tm1Vlcg
(C.129-Havcr1tm1Vlcg)
abnormal cytokine secretion J:187793
immune system phenotype J:187793
increased interleukin-4 secretion J:187793
increased interleukin-5 secretion J:187793
increased interleukin-10 secretion J:187793
increased interleukin-13 secretion J:187793
increased interleukin-17 secretion J:187793
respiratory system inflammation J:187793
\Havcr2tm1b(KOMP)Wtsi/\Havcr2tm1b(KOMP)Wtsi
(C57BL/6N-Havcr2tm1b(KOMP)Wtsi/Ucd)
increased spleen weight J:211773
\Havcr2tm1Bmed/\Havcr2tm1Bmed
(B6.Cg-Havcr2tm1Bmed)
abnormal CD8-positive, alpha-beta T cell physiology J:189839
decreased activation-induced cell death of T cells J:189839
decreased interferon-gamma secretion J:189839
decreased susceptibility to Orthomyxoviridae infection J:189839
decreased susceptibility to Orthomyxoviridae infection induced morbidity/mortality J:189839
decreased T cell proliferation J:189839
\Havcr2tm1Tbs/\Havcr2tm1Tbs
(C.Cg-Havcr2tm1Tbs)
immune system phenotype J:86260
\Havcr2tm1Vlcg/\Havcr2tm1Vlcg
(B6.129-Havcr2tm1Vlcg)
decreased interferon-gamma secretion J:209885
decreased T cell number J:209885
\Havcr2tm1Vlcg/\Havcr2tm1Vlcg
\Tg(TcraTcrb)1100Mjb/?

(B6.Cg-Havcr2tm1Vlcg Tg(TcraTcrb)1100Mjb)
decreased interferon-gamma secretion J:209885
decreased T cell number J:209885
\Hax1tm1.1Gach/\Hax1tm1.1Gach
(involves: BALB/c)
abnormal B cell number J:174159
abnormal lymphocyte morphology J:174159
abnormal T cell number J:174159
decreased B cell number J:174159
decreased B-1a cell number J:174159
decreased CD4-positive, alpha-beta T cell number J:174159
decreased CD8-positive, alpha-beta T cell number J:174159
decreased double-positive T cell number J:174159
decreased IgG2a level J:174159
decreased immature B cell number J:174159
decreased marginal zone B cell number J:174159
decreased mature B cell number J:174159
decreased pre-B cell number J:174159
decreased pro-B cell number J:174159
decreased thymocyte number J:174159
decreased transitional stage T1 B cell number J:174159
decreased transitional stage T2 B cell number J:174159
increased follicular B cell number J:174159
spleen hypoplasia J:174159
thymus hypoplasia J:174159
\Hax1tm1Jni/\Hax1tm1Jni
(involves: 129P2/OlaHsd * C57BL/6)
decreased double-positive T cell number J:132627
decreased immature B cell number J:132627
decreased leukocyte cell number J:132627
decreased lymphocyte cell number J:132627
decreased neutrophil cell number J:132627
decreased single-positive T cell number J:132627
decreased T cell number J:132627
\Hbab2(th)/\Hba+
(either: (involves: 101 * SEC) or (involves: 101 * C57BL * SEC))
increased leukocyte cell number J:123943
\Hbatm1(HBA)Tow/\Hbatm1(HBA)Tow
\Hbbtm2(HBG1,HBB*)Tow/\Hbbtm2(HBG1,HBB*)Tow

(Not Specified)
abnormal Kupffer cell morphology J:134980
abnormal spleen white pulp morphology J:134980
enlarged spleen J:134980
increased spleen red pulp amount J:134980
spleen vascular congestion J:134980
\Hbatm1(HBA)Tow/\Hbatm1(HBA)Tow
\Hbbtm2(HBG1,HBB*)Tow/\Hbbtm2(HBG1,HBB*)Tow
\Slc12a4Rbc10/\Slc12a4+

(involves: 129 * BALB/c * C57BL/6J)
enlarged spleen J:227339
liver inflammation J:227339
\Hbatm1(HBA)Tow/\Hbatm1(HBA)Tow
\Hbbtm2(HBG1,HBD,HBB*)Ryan/\Hbbtm2(HBG1,HBD,HBB*)Ryan

(Not Specified)
intermingled spleen red and white pulp J:148521
spleen hyperplasia J:148521
\Hbatm1(HBA)Tow/\Hbatm1(HBA)Tow
\Hbbtm2(HBG1,HBD,HBB*)Ryan/\Hbbtm3(HBG1,HBB)Tow

(Not Specified)
spleen hyperplasia J:148521
\Hbatm1Paz/\Hbatm1Paz
\Hbbtm1Tow/\Hbbtm1Tow
\Tg(HBA-HBBs)41Paz/?

(involves: 129S2/SvPas * 129S7/SvEvBrd * Black Swiss * C57BL/6 * DBA/2* FVB/N)
increased spleen weight J:44161
spleen vascular congestion J:44161
\Hbb-b1MommeD7/\Hbb-b1+
(involves: FVB/N)
enlarged spleen J:142335, J:190446
increased spleen red pulp amount J:190446
\Hbb-b1Rbc13/\Hbb-b1+
(involves: BALB/c * C57BL/6)
enlarged spleen J:190446
increased spleen red pulp amount J:190446
\Hbb-b1tm1Shs/\Hbb-b1tm1Shs
(involves: C57BL/6)
enlarged spleen J:78271
increased spleen iron level J:78271
\Hbb-b1tm1Unc/\Hbb-b1+
\Hbb-b2tm1Unc/\Hbb-b2+

(involves: 129P2/OlaHsd * C57BL/6J)
abnormal spleen morphology J:88672, J:30155
decreased spleen white pulp amount J:30155
increased spleen weight J:30155
intermingled spleen red and white pulp J:30155
\Hbb-b1tm1Unc/\Hbb-b1+
\Hbb-b2tm1Unc/\Hbb-b2+

(involves: 129P2/OlaHsd * C57BL/6N)
enlarged spleen J:185154
increased spleen iron level J:185154
\Hbb-b1tm1Unc/\Hbb-b1+
\Hbb-b2tm1Unc/\Hbb-b2+

(B6;129-Hbb-b1tm1Unc Hbb-b2tm1Unc/J)
abnormal spleen morphology J:211331
\Hbb-b1tm1Unc/\Hbb-b1+
\Hbb-b2tm1Unc/\Hbb-b2+

(involves: 129P2/OlaHsd)
enlarged spleen J:97548
\Hbb-b1tm1Unc/\Hbb-b1+
\Hbb-b2tm1Unc/\Hbb-b2+
\Tg(HBB*)L2Pai/0

(involves: 129P2/OlaHsd * C57BL/6)
enlarged spleen J:97548
\Hbb-b1tm1Unc/\Hbb-b1+
\Hbb-b2tm1Unc/\Hbb-b2+
\Tmprss6tm1Otin/\Tmprss6+

(involves: 129P2/OlaHsd * C57BL/6 * C57BL/6N)
abnormal spleen iron level J:185154
abnormal spleen size J:185154
\Hbb-b1tm1Unc/\Hbb-b1+
\Hbb-b2tm1Unc/\Hbb-b2+
\Tmprss6tm1Otin/\Tmprss6tm1Otin

(involves: 129P2/OlaHsd * C57BL/6 * C57BL/6N)
abnormal spleen size J:185154
\Hbbd3th/\Hbb+
\Tg(LCR-HBA1,LCR-HBB*)1Tow/0

(involves: C57BL/6 * DBA/2J * SJL)
enlarged spleen J:127701
\Hbbd3th/\Hbb+
\Tg(LCR-HBA2,LCR-HBB*)1Cos/0

(involves: C57BL/6J * CBA/J * DBA/2J)
enlarged spleen J:94193
\Hbbd3th/\Hbbd3th
\Tg(HBB-AR-HBA2,-HBB*)58Rub/0
\Tg(LCR-HBA2,LCR-HBB)11Cos/0

(involves: FVB/N * Swiss Webster)
abnormal spleen morphology J:94190
enlarged spleen J:94190
increased spleen red pulp amount J:94190
spleen fibrosis J:94190
spleen vascular congestion J:94190
\Hbbd4/\Hbbd4
(involves: 101/H)
abnormal macrophage morphology J:7972
enlarged spleen J:7972
increased spleen red pulp amount J:7972
\Hbbtm1.1(HBG1,HBB*)Ryan/\Hbb+
(involves: C57BL/6J)
abnormal spleen morphology J:147906
enlarged spleen J:147906
increased spleen iron level J:147906
increased spleen red pulp amount J:147906
intermingled spleen red and white pulp J:147906
\Hbbtm1Tow/\Hbb+
(involves: 129S2/SvPas * C57BL/6)
enlarged spleen J:29087
increased spleen weight J:29087
\Hbbtm2Unc/\Hbb+
(involves: 129P2/OlaHsd * C57BL/6J)
enlarged spleen J:64295
increased spleen iron level J:64295
\Hbnr1CBA/\Hbnr1SWR
(involves: CBA * SWR)
decreased susceptibility to parasitic infection J:82261, J:85787
\Hbnr1SWR/\Hbnr1SWR
(involves: CBA * SWR)
decreased susceptibility to parasitic infection J:82261, J:110034, J:85787
\Hbnr2CBA/\Hbnr2SWR
(involves: CBA * SWR)
granulomatous inflammation J:85787
\Hbnr2SWR/?
(involves: CBA * SWR)
decreased susceptibility to parasitic infection J:82261
\Hbnr2SWR/\Hbnr2SWR
(involves: CBA * SWR)
decreased IgE level J:85787
decreased susceptibility to parasitic infection J:110034
granulomatous inflammation J:85787
\Hbnr3CBA/\Hbnr3SWR
(involves: CBA * SWR)
decreased susceptibility to parasitic infection J:85787
increased susceptibility to parasitic infection J:82261
\Hbnr3SWR/\Hbnr3SWR
(involves: CBA * SWR)
increased susceptibility to parasitic infection J:82261, J:85787
\Hbnr4SWR/\Hbnr4SWR
(involves: CBA * SWR)
abnormal immune serum protein physiology J:85787
\Hbnr5CBA/\Hbnr5SWR
(involves: CBA * SWR)
decreased susceptibility to parasitic infection J:85787
\Hbnr5SWR/\Hbnr5SWR
(involves: CBA * SWR)
decreased susceptibility to parasitic infection J:85787
\Hbnr6SWR/\Hbnr6SWR
(involves: CBA * SWR)
increased IgE level J:85787
\Hbnr7CBA/\Hbnr7SWR
(involves: CBA * SWR)
decreased IgG1 level J:85787
\Hbnr7SWR/\Hbnr7SWR
(involves: CBA * SWR)
decreased IgG2b level J:85787
\Hbnr8CBA/\Hbnr8SWR
(involves: CBA * SWR)
decreased susceptibility to parasitic infection J:85787
\Hbnr8SWR/\Hbnr8SWR
(involves: CBA * SWR)
decreased susceptibility to parasitic infection J:85787
\Hbs1ltm1a(KOMP)Wtsi/\Hbs1ltm1a(KOMP)Wtsi
(C57BL/6N-Hbs1ltm1a(KOMP)Wtsi/Wtsi)
decreased effector memory CD8-positive, alpha-beta T cell number J:211773
decreased Langerhans cell number J:211773
decreased mature B cell number J:211773
decreased memory-marker CD4-negative NK T cell number J:211773
decreased monocyte cell number J:211773
decreased T-helper cell number J:211773
increased CD4-positive, alpha-beta memory T cell number J:211773
increased CD4-positive, CD25-positive, alpha-beta regulatory T cell number J:211773
increased CD5-positive gamma-delta T cell number J:211773
increased effector memory CD8-positive, alpha-beta T cell number J:211773
increased leukocyte cell number J:211773
increased memory CD4-positive, CD25-positive, alpha-beta regulatory T cell number J:211773
increased regulatory T cell number J:211773
\Hc0/\Hc0
(involves: C57BL/10SnJ)
increased susceptibility to bacterial infection J:44240
\Hc0/\Hc0
\Tg(TcrbBL17)1Lmor/0

(involves: DBA/1J * SWR/J)
decreased susceptibility to induced arthritis J:134111
\Hc1/?
\Tg(TcrbBL17)1Lmor/0

(involves: DBA/1J * SWR/J)
increased susceptibility to induced arthritis J:134111
\Hcar1em1(IMPC)Ccpcz/\Hcar1em1(IMPC)Ccpcz
(C57BL/6N-Hcar1em1(IMPC)Ccpcz/Ccpcz)
decreased effector memory T-helper cell number J:211773
\Hcfc2em1Btlr/\Hcfc2em1Btlr
(C57BL/6J-Hcfc2em1Btlr)
decreased tumor necrosis factor secretion J:251008
\Hcfc2fkls/\Hcfc2+
(involves: C57BL/6J)
decreased interferon-beta secretion J:251008
decreased tumor necrosis factor secretion J:251008
\Hcfc2fkls/\Hcfc2fkls
(C57BL/6J-Hcfc2fkls)
abnormal innate immunity J:94077
\Hcfc2fkls/\Hcfc2fkls
(involves: C57BL/6J)
decreased circulating interferon-alpha level J:251008
decreased circulating interferon-beta level J:251008
decreased interferon-beta secretion J:251008
decreased tumor necrosis factor secretion J:251008
increased susceptibility to Herpesvirales infection J:251008
increased susceptibility to Herpesvirales infection induced morbidity/mortality J:251008
increased susceptibility to Orthomyxoviridae infection induced morbidity/mortality J:251008
\Hcfc2fkls/\Hcfc2min
(involves: C57BL/6J)
decreased tumor necrosis factor secretion J:251008
\Hcfc2fkls/\Hcfc2sca
(involves: C57BL/6J)
decreased tumor necrosis factor secretion J:251008
\Hcktm1Ern/\Hcktm1Ern
(involves: 129S1/Sv * C57BL/6)
abnormal alveolar macrophage morphology J:111432
abnormal immune system physiology J:111432
abnormal macrophage physiology J:111432
increased circulating tumor necrosis factor level J:111432
increased eosinophil cell number J:111432
increased interleukin-5 secretion J:111432
lung inflammation J:111432
\Hcktm1Hev/\Hcktm1Hev
(involves: 129S7/SvEvBrd * C57BL/6J)
impaired macrophage phagocytosis J:16994
\Hcktm1Hev/\Hcktm1Hev
(B6.129S7-Hcktm1Hev)
abnormal inflammatory response J:113463
abnormal neutrophil physiology J:113463
\Hcktm1Hev/\Hcktm1Hev
\Srctm1Sor/\Srctm1Sor

(involves: 129S7/SvEvBrd * C57BL/6J)
abnormal immune system organ morphology J:31647
abnormal spleen germinal center morphology J:31647
abnormal spleen morphology J:31647
abnormal splenic cell ratio J:31647
decreased leukocyte cell number J:31647
increased macrophage cell number J:31647
lymph node hypoplasia J:31647
thymus hypoplasia J:31647
\Hcls1em1(IMPC)Ccpcz/\Hcls1em1(IMPC)Ccpcz
(C57BL/6NCrl-Hcls1em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged spleen J:211773
enlarged thymus J:211773
\Hcls1tm1Wtn/\Hcls1tm1Wtn
(involves: 129P2/OlaHsd * C57BL/6)
abnormal B cell physiology J:28146
abnormal humoral immune response J:28146
decreased B cell number J:28146
decreased T cell proliferation J:28146
\Hcls1tm1Wtn/\Hcls1tm1Wtn
\Tg(TcraH-Y,TcrbH-Y)71Vbo/0

(involves: 129P2/OlaHsd * C57BL/6J * DBA/2J)
abnormal negative T cell selection J:28146
decreased double-positive T cell number J:28146
\Hcls1tm2Wtn/\Hcls1tm2Wtn
(involves: 129P2/OlaHsd * C57BL/6)
abnormal B cell physiology J:28146
abnormal humoral immune response J:28146
decreased B cell number J:28146
decreased T cell proliferation J:28146
\Hcn2m1Btlr/\Hcn2m1Btlr
(C57BL/6J-Hcn2m1Btlr)
decreased CD8-positive, alpha-beta T cell number J:255187
increased CD4-positive, alpha-beta T cell number J:255187
\Hcrttm1.1(KOMP)Vlcg/\Hcrttm1.1(KOMP)Vlcg
(C57BL/6N-Hcrttm1.1(KOMP)Vlcg/Ucd)
increased lymphocyte cell number J:211773
\Hcsttm1.1Cln/\Hcsttm1.1Cln
(involves: 129P2/OlaHsd * BALB/cJ * C57BL/6)
decreased CD8-positive, alpha-beta T cell number J:80426
immune system phenotype J:80426
impaired natural killer cell mediated cytotoxicity J:80426
\Hcsttm1.1Cln/\Hcsttm1.1Cln
(involves: 129P2/OlaHsd * C57BL/6)
decreased interferon-gamma secretion J:100668
decreased uterine NK cell number J:100668
\Hcsttm1.1Cln/\Hcsttm1.1Cln
(B6.129P2-Hcsttm1.1Cln)
abnormal osteoclast differentiation J:147155
abnormal osteoclast physiology J:147155
decreased osteoclast cell number J:147155
\Hcsttm1.1Cln/\Hcsttm1.1Cln
\Tyrobptm1Lll/\Tyrobptm1Lll

(B6.Cg-Hcsttm1.1Cln Tyrobptm1Lll)
abnormal NK T cell physiology J:147867
abnormal response to infection J:147867
\Hcsttm1.1Dnax/\Hcsttm1.1Dnax
(involves: C57BL/6)
abnormal NK T cell physiology J:147867, J:148086
abnormal response to infection J:147867
decreased interferon-gamma secretion J:147867
immune system phenotype J:148086
impaired natural killer cell mediated cytotoxicity J:148086
increased interferon-gamma secretion J:148086
increased interleukin-4 secretion J:148086
increased spleen weight J:148086
increased susceptibility to experimental autoimmune encephalomyelitis J:148086
\Hdac1tm1.1Pmt/\Hdac1tm1.1Pmt
\Hdac2tm1.1Pmt/\Hdac2tm1.1Pmt
\Cd79atm1(cre)Reth/\Cd79a+

(involves: 129P2/OlaHsd * BALB/c * C57BL/6 * FVB/N)
abnormal spleen morphology J:157903
arrested B cell differentiation J:157903
decreased B cell number J:157903
decreased pre-B cell number J:157903
decreased pro-B cell number J:157903
increased B cell apoptosis J:157903
\Hdac1tm1.1Pmt/\Hdac1tm1.1Pmt
\Hdac2tm1.1Pmt/\Hdac2tm1.1Pmt
\Tg(Fcer2a-cre)5Mbu/0

(involves: 129P2/OlaHsd * C57BL/6 * CBA * FVB/N)
decreased B cell proliferation J:157903
increased B cell apoptosis J:157903
\Hdac1tm1.1Shmc/\Hdac1+
\Hdac2tm1.1Shmc/\Hdac2tm1.1Shmc
\Tg(Lck-cre)1Cwi/0

(involves: 129S7/SvEvBrd)
immune system phenotype J:194769
\Hdac1tm1.1Shmc/\Hdac1tm1.1Shmc
\Hdac2tm1.1Shmc/\Hdac2+
\Tg(Lck-cre)1Cwi/0

(involves: 129S7/SvEvBrd)
arrested T cell differentiation J:194769
decreased CD4-positive, alpha-beta T cell number J:194769
decreased CD8-positive, alpha-beta T cell number J:194769
decreased double-positive T cell number J:194769
enlarged spleen J:194769
enlarged thymus J:194769
increased double-negative T cell number J:194769
increased double-positive T cell number J:194769
increased single-positive T cell number J:194769
thymus hypoplasia J:194769
\Hdac1tm1.1Shmc/\Hdac1tm1.1Shmc
\Hdac2tm1.1Shmc/\Hdac2tm1.1Shmc
\Tg(Lck-cre)1Cwi/0

(involves: 129S7/SvEvBrd)
abnormal thymus corticomedullary boundary morphology J:194769
arrested T cell differentiation J:194769
decreased double-positive T cell number J:194769
decreased thymocyte number J:194769
enlarged spleen J:194769
enlarged thymus J:194769
increased double-positive T cell number J:194769
increased single-positive T cell number J:194769
increased T cell derived lymphoma incidence J:194769
increased T cell proliferation J:194769
increased thymocyte apoptosis J:194769
increased thymocyte number J:194769
\Hdac1tm1.1Shmc/\Hdac1tm1.1Shmc
\Tg(Lck-cre)1Cwi/0

(involves: 129S7/SvEvBrd)
immune system phenotype J:194769
\Hdac2tm1.1Shmc/\Hdac2tm1.1Shmc
\Tg(Lck-cre)1Cwi/0

(involves: 129S7/SvEvBrd)
immune system phenotype J:194769
\Hdac4em1(IMPC)Ccpcz/\Hdac4+
(C57BL/6N-Hdac4em1(IMPC)Ccpcz/Ccpcz)
increased NK cell number J:211773
\Hdac6tm1.1Pmt/Y
(involves: 129P2/OlaHsd * C57BL/6)
decreased IgG level J:132629
decreased IgM level J:132629
immune system phenotype J:132629
\Hdac6tm1.1Pmt/\Hdac6tm1.1Pmt
(involves: 129P2/OlaHsd * C57BL/6)
decreased IgG level J:132629
decreased IgM level J:132629
immune system phenotype J:132629
\Hdac6tm1.1Pmt/\Hdac6tm1.1Pmt
(involves: 129P2/OlaHsd)
decreased circulating interleukin-10 level J:228570
decreased interleukin-10 secretion J:228570
\Hdac11tm1.2Mrl/\Hdac11tm1.2Mrl
(involves: C57BL/6NTac)
decreased interferon-gamma secretion J:222335
increased interleukin-10 secretion J:228570
\Hdctm1Nagy/\Hdctm1Nagy
(involves: 129S1/Sv * 129X1/SvJ)
abnormal mast cell morphology J:70702
decreased mast cell histamine storage J:70702
decreased mast cell number J:70702
decreased mast cell protease storage J:70702
\Hddc2em1(IMPC)H/\Hddc2em1(IMPC)H
(C57BL/6NTac-Hddc2em1(IMPC)H/H)
decreased lymphocyte cell number J:211773
increased basophil cell number J:211773
increased neutrophil cell number J:211773
\Hddc3tm1.1(KOMP)Vlcg/\Hddc3tm1.1(KOMP)Vlcg
(C57BL/6N-Hddc3tm1.1(KOMP)Vlcg/Ucd)
abnormal spleen morphology J:211773
enlarged spleen J:211773
\Hectd1tm1b(EUCOMM)Hmgu/\Hectd1+
(C57BL/6N-Hectd1tm1b(EUCOMM)Hmgu/Nju)
increased basophil cell number J:211773
increased eosinophil cell number J:211773
\Hectd3tm1(NCOM)Cmhd/\Hectd3tm1(NCOM)Cmhd
(C57BL/6N-Hectd3tm1(NCOM)Cmhd/Nju)
small spleen J:211773
small thymus J:211773
\Hectd3tm1Lex/\Hectd3tm1Lex
(FVB.129S5(B6)-Hectd3tm1Lex)
decreased circulating interferon-beta level J:266602
decreased circulating interleukin-1 beta level J:266602
decreased circulating interleukin-6 level J:266602
decreased circulating tumor necrosis factor level J:266602
decreased susceptibility to bacterial infection J:266602
decreased susceptibility to bacterial infection induced morbidity/mortality J:266602
\Heg1tm1Mlkn/\Heg1tm1Mlkn
(either: B6.129-Heg1tm1Mlkn or (involves: 129 * C57BL/6))
abnormal lymph circulation J:146528
abnormal lymphatic vessel endothelium morphology J:146528
lymphangiectasis J:146528
\Helbtm1(KOMP)Vlcg/\Helbtm1(KOMP)Vlcg
(involves: C57BL/6NTac)
immune system phenotype J:231089
\Hellstm1a(EUCOMM)Wtsi/\Hellstm1a(EUCOMM)Wtsi
(C57BL/6N-Hellstm1a(EUCOMM)Wtsi/Ieg)
decreased granulocyte number J:165965
decreased IgG1 level J:165965
\Hellstm1Kmu/\Hellstm1Kmu
(involves: 129S1/Sv)
decreased B cell number J:61948
increased CD8-positive, alpha-beta T cell number J:61948
increased double-negative T cell number J:61948
small spleen J:61948
small thymus J:61948
\Hellstm1Rarc/\Hellstm1Rarc
(involves: 129X1/SvJ * C57BL/6J)
small thymus J:107145
thymus hypoplasia J:107145
\hem1/\hem1
(Not Specified)
decreased leukocyte cell number J:85113
\hem2/\hem2
(Not Specified)
decreased leukocyte cell number J:85113
\Hephem1(IMPC)Ccpcz/Y
(C57BL/6NCrl-Hephem1(IMPC)Ccpcz/Ccpcz)
abnormal lymph node morphology J:211773
enlarged lymph nodes J:211773
\Hephem1(IMPC)Ccpcz/\Hephem1(IMPC)Ccpcz
(C57BL/6NCrl-Hephem1(IMPC)Ccpcz/Ccpcz)
abnormal lymph node morphology J:211773
enlarged lymph nodes J:211773
\Hephl1cw-thd/\Hephl1cw-thd
(SJL/J)
abnormal humoral immune response J:15004
\Hephl1cw/\Hephl1cw
(CWD/LeJ)
abnormal immune system morphology J:24875
abnormal lymph node morphology J:24875
abnormal spleen morphology J:24875
enlarged spleen J:24875
enlarged thymus J:24875
\Herc1em3(IMPC)Wtsi/\Herc1em3(IMPC)Wtsi
(C57BL/6N-Herc1em3(IMPC)Wtsi/Wtsi)
increased eosinophil cell number J:211773
increased leukocyte cell number J:211773
increased Ly6C high monocyte number J:211773
increased Ly6C low monocyte number J:211773
increased monocyte cell number J:211773
\Herc4tm1b(KOMP)Wtsi/\Herc4tm1b(KOMP)Wtsi
(C57BL/6N-Herc4tm1b(KOMP)Wtsi/Nju)
increased basophil cell number J:211773
increased eosinophil cell number J:211773
\Herc6tm1b(EUCOMM)Hmgu/\Herc6tm1b(EUCOMM)Hmgu
(C57BL/6N-Herc6tm1b(EUCOMM)Hmgu/Nju)
increased basophil cell number J:211773
increased eosinophil cell number J:211773
\Herc6tm1Kshim/\Herc6tm1Kshim
(either: B6.Cg-Herc6tm1Kshim or (involves: C57BL/6NCrlj * CBA/JNCrlj))
immune system phenotype J:330459
\Hes1tm1.1Frad/\Hes1tm1.1Frad
\Tg(Cd4-cre)1Cwi/0

(involves: C57BL/6 * DBA/2)
immune system phenotype J:167000
\Hes1tm1.1Frad/\Hes1tm1.1Frad
\Tg(Lck-cre)1Cwi/0

(involves: C57BL/6)
immune system phenotype J:167000
\Hes1tm1.1Frad/\Hes1tm1.1Frad
\Tg(Mx1-cre)1Cgn/0

(involves: C57BL/6 * CBA)
abnormal T cell differentiation J:167000
decreased DN1 thymic pro-T cell number J:167000
decreased DN2 thymocyte number J:167000
decreased DN3 thymocyte number J:167000
decreased DN4 thymocyte number J:167000
decreased double-positive T cell number J:167000
decreased gamma-delta T cell number J:167000
increased DN1 thymic pro-T cell number J:167000
increased immature B cell number J:167000
thymus hypoplasia J:167000
\Hexbtm1b(EUCOMM)Hmgu/\Hexbtm1b(EUCOMM)Hmgu
(C57BL/6N-Hexbtm1b(EUCOMM)Hmgu/H)
increased monocyte cell number J:211773
\Hexbtm1Rlp/\Hexbtm1Rlp
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)
CNS inflammation J:90687
increased circulating interleukin-4 level J:87617
increased immunoglobulin level J:87617
\Hexbtm1Rlp/\Hexbtm1Rlp
\Tg(Hexb-tTA2S,tetO-Hexb)#Tjsa/0

(involves: 129S4/SvJae * C57BL/6 * CBA)
microgliosis J:190450
\Hexbtm1Rlp/\Hexbtm1Rlp
\Tg(SYN1-tTA2S,tetO-Hexb)#Tjsa/0

(involves: 129S4/SvJae * C57BL/6 * CBA)
microgliosis J:190450
\Hfetm1.1Wsr/\Hfetm1.1Wsr
(involves: 129P2/OlaHsd * C57BL/6)
decreased spleen iron level J:132134
\Hfetm1Gfn/\Hfetm1Gfn
(involves: 129P2/OlaHsd * C57BL/6)
increased osteoclast cell number J:262906
increased spleen iron level J:68025
\Hfetm1Wsr/\Hfetm1Wsr
\Tg(Alb1-cre)7Gsc/?

(involves: 129P2/OlaHsd * C57BL/6 * FVB/N)
decreased spleen iron level J:132134
\Hfetm2Nca/\Hfetm2Nca
(involves: 129S6/SvEvTac)
decreased spleen iron level J:78536
\Hfetm2Nca/\Hfetm2Nca
(involves: 129S6/SvEvTac * C57BL/6J)
decreased spleen iron level J:78536
\Hfgi1C57BL/6Ola/?
(involves: C57BL/6Ola * BALB/cOla)
abnormal lymphopoiesis J:123483
stomach inflammation J:123483
\Hfgi2C57BL/6Ola/?
(involves: C57BL/6Ola * BALB/cOla)
abnormal lymphopoiesis J:123483
stomach inflammation J:123483
\Hgsnatem4(IMPC)Tcp/\Hgsnatem4(IMPC)Tcp
(C57BL/6NCrl-Hgsnatem4(IMPC)Tcp/Tcp)
enlarged lymph nodes J:211773
\Hgsnattm1a(EUCOMM)Wtsi/\Hgsnattm1a(EUCOMM)Wtsi
(involves: C57BL/6N * C57BL/6NTac)
abnormal Kupffer cell morphology J:235361
enlarged spleen J:235361
increased spleen weight J:235361
microgliosis J:235361
\Hhatem1(IMPC)Ccpcz/\Hhat+
(C57BL/6NCrl-Hhatem1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged spleen J:211773
enlarged thymus J:211773
increased memory-marker CD4-positive NK T cell number J:211773
\Hhextm1Ngu/\Hhextm1Ngu
(involves: 129/Sv * C57BL/6)
abnormal monocyte differentiation J:65105
\Hhiptm1Amc/\Hhiptm1Amc
(involves: 129S1/Sv * 129X1/SvJ)
abnormal spleen morphology J:85472
small spleen J:85472
\Hic1tm1Sbb/\Hic1+
(involves: 129S4/SvJae * C57BL/6)
dermatitis J:81448
\Hif1atm1Kats/\Hif1atm1Kats
(involves: 129 * C57BL/6)
abnormal cytokine level J:117857
abnormal interleukin secretion J:117857
increased interferon-gamma secretion J:117857
increased tumor necrosis factor secretion J:117857
\Hif1atm3Rsjo/\Hif1atm3Rsjo
\Gt(ROSA)26Sortm1Sor/\Gt(ROSA)26Sor+
\Hprt1tm1(Pck1-cre)Vhh/Y

(involves: 129P2/OlaHsd * 129S1/Sv * 129S4/SvJaeSor * 129X1/SvJ)
kidney inflammation J:130751
\Hif1atm3Rsjo/\Hif1atm3Rsjo
\Hprt1tm1(Pck1-cre)Vhh/Y
\Vhltm1Jae/\Vhltm1Jae

(involves: 129 * BALB/c * C57BL/6)
kidney inflammation J:106705
\Hif1atm3Rsjo/\Hif1atm3Rsjo
\Lyz2tm1(cre)Ifo/\Lyz2+

(involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ)
abnormal leukocyte physiology J:117348
abnormal macrophage physiology J:107682
decreased inflammatory response J:107682
decreased susceptibility to induced arthritis J:107682
decreased tumor necrosis factor secretion J:107682
impaired macrophage chemotaxis J:107682
\Hif1atm3Rsjo/\Hif1atm3Rsjo
\Lyz2tm1(cre)Ifo/\Lyz2+

(involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6)
decreased interleukin-1 alpha secretion J:148597
decreased interleukin-1 beta secretion J:148597
decreased interleukin-6 secretion J:148597
decreased interleukin-12 secretion J:148597
decreased susceptibility to endotoxin shock J:148597
decreased tumor necrosis factor secretion J:148597
\Hif1atm3Rsjo/\Hif1atm3Rsjo
\Ndor1Tg(UBC-cre/ERT2)1Ejb/0

(involves: 129S1/Sv * 129X1/SvJ)
immune system phenotype J:119731
\Hif1atm3Rsjo/\Hif1atm3Rsjo
\Tg(Fabp1-cre)1Jig/0

(involves: 129S1/Sv * 129X1/SvJ * BALB/c * FVB/N)
increased susceptibility to induced colitis J:93476
\Hif1atm3Rsjo/\Hif1atm3Rsjo
\Tg(Itgax-cre)1-1Reiz/0

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA)
abnormal dendritic cell number J:187773
abnormal leukocyte migration J:187773
immune system phenotype J:187773
\Hif1atm3Rsjo/\Hif1atm3Rsjo
\Tg(Lck-cre)1Jtak/0

(involves: 129S1/Sv * 129X1/SvJ)
increased interferon-gamma secretion J:117857
\Hif1atm3Rsjo/\Hif1atm3Rsjo
\Tg(Tal1-cre/ERT)42-056Jrg/0

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
abnormal B cell differentiation J:192126
abnormal T cell differentiation J:192126
\Hif1anem1(IMPC)Mbp/\Hif1anem1(IMPC)Mbp
(C57BL/6N-Hif1anem1(IMPC)Mbp/MbpMmucd)
abnormal spleen morphology J:211773
enlarged spleen J:211773
increased neutrophil cell number J:211773
\Hip1tm4Tsr/\Hip1+
\Runx1tm3Dow/\Runx1+
\Tg(Mx1-cre)1Cgn/0

(involves: 129X1/SvJ * C57BL/6 * CBA)
abnormal myelopoiesis J:151974
abnormal spleen B cell follicle morphology J:151974
abnormal spleen morphology J:151974
enlarged spleen J:151974
increased granulocyte number J:151974
increased leukocyte cell number J:151974
increased neutrophil cell number J:151974
increased spleen red pulp amount J:151974
increased spleen weight J:151974
spleen hyperplasia J:151974
\Hip1tm4Tsr/\Hip1+
\Tg(Mx1-cre)1Cgn/0

(involves: 129X1/SvJ * C57BL/6 * CBA)
abnormal myelopoiesis J:151974
abnormal spleen morphology J:151974
enlarged spleen J:151974
increased spleen red pulp amount J:151974
increased T cell derived lymphoma incidence J:151974
\Hiratm1a(EUCOMM)Wtsi/\Hira+
(C57BL/6N-Hiratm1a(EUCOMM)Wtsi/Wtsi)
decreased leukocyte cell number J:175295
\Hirip3tm1.1(KOMP)Mbp/\Hirip3tm1.1(KOMP)Mbp
(C57BL/6N-Hirip3tm1.1(KOMP)Mbp/Ucd)
increased basophil cell number J:211773
increased neutrophil cell number J:211773
\Hivep2tm1Sis/\Hivep2+
(involves: BALB/cA * C57BL/6NCrlj * CBA/JNCrlj)
decreased CD8-positive, alpha-beta T cell number J:72249
decreased single-positive T cell number J:72249
\Hivep2tm1Sis/\Hivep2tm1Sis
(involves: BALB/cA * C57BL/6NCrlj * CBA/JNCrlj)
abnormal immune system cell morphology J:72249
abnormal thymus cortex morphology J:72249
abnormal thymus lobule morphology J:72249
abnormal thymus medulla morphology J:72249
decreased single-positive T cell number J:72249
enlarged thymus cortex J:72249
\Hivep2tm1Sis/\Hivep2tm1Sis
(C.Cg-Hivep2tm1Sis)
abnormal T-helper 2 cell morphology J:96024
\Hivep2tm1Sis/\Hivep2tm1Sis
(either: (involves: BALB/cA * C57BL/6NCrlj * CBA/JNCrlj) or (involves: C57BL/6J * C57BL/6NCrlj * CBA/JNCrlj))
CNS inflammation J:263351
\Hivep2tm1Sis/\Hivep2tm1Sis
\Tg(DO11.10)10Dlo/?

(involves: BALB/cA * C3H * C57BL/6NCrlj * CBA/JNCrlj)
abnormal positive T cell selection J:96024
abnormal T-helper 2 cell morphology J:96024
decreased single-positive T cell number J:72249
\Hivep3tm1Glm/\Hivep3tm1Glm
(involves: 129 * C57BL/6)
decreased interleukin-2 secretion J:100058
\Hivep3tm1Glm/\Hivep3tm1Glm
(Not Specified)
abnormal osteoclast differentiation J:184764
abnormal osteoclast physiology J:184764
decreased osteoclast cell number J:184764
\Hivep3tm1Lcw/\Hivep3tm1Lcw
(chimera involves: 129S/SvEv * 129X1/SvJ)
decreased double-positive T cell number J:79652
\Hjvtm1Arbr/\Hjvtm1Arbr
(involves: 129S4/SvJae * 129X1/SvJ)
decreased spleen iron level J:100173
\Hjvtm1Kpan/\Hjvtm1Kpan
\Speer6-ps1Tg(Alb-cre)21Mgn/\Speer6-ps1+

(involves: 129S6/SvEvTac * C57BL/6)
abnormal macrophage morphology J:231428
decreased spleen iron level J:231428
\Hjvtm1Nca/\Hjvtm1Nca
(involves: 129S4/SvJae * 129S6/SvEvTac)
decreased spleen iron level J:100178
\Hjvtm1Nca/\Hjvtm1Nca
(involves: 129P2/OlaHsd * 129S4/SvJae * 129S6/SvEvTac * C57BL/6)
abnormal macrophage morphology J:160248
decreased spleen iron level J:160248
\Hjvtm1Nca/\Hjvtm1Nca
\Tmprss6tm1Dgen/\Tmprss6+

(involves: 129P2/OlaHsd * 129S4/SvJae * 129S6/SvEvTac * C57BL/6)
abnormal macrophage morphology J:160248
decreased spleen iron level J:160248
\Hjvtm1Nca/\Hjvtm1Nca
\Tmprss6tm1Dgen/\Tmprss6tm1Dgen

(involves: 129P2/OlaHsd * 129S4/SvJae * 129S6/SvEvTac * C57BL/6)
abnormal macrophage morphology J:160248
decreased spleen iron level J:160248
\Hk1dea/\Hk1dea
(A/J-Hk1dea/J)
abnormal spleen morphology J:72146
increased spleen red pulp amount J:72146
increased spleen weight J:72146
\Hk3em1(IMPC)Tcp/\Hk3em1(IMPC)Tcp
(C57BL/6N-Hk3em1(IMPC)Tcp/Tcp)
enlarged lymph nodes J:211773
\Hlb18/?
(C57BL/6J-Hlb18)
increased leukocyte cell number J:82961
\Hlb95/?
(C57BL/6J-Hlb95)
increased leukocyte cell number J:82961
\Hlb141/?
(C57BL/6J-Hlb141)
decreased leukocyte cell number J:82961
decreased neutrophil cell number J:82961
\hlb145/?
(C57BL/6J-hlb145/J)
decreased leukocyte cell number J:82961
\hlb156/?
(C57BL/6J-hlb156/J)
decreased neutrophil cell number J:82961
\hlb258/?
(involves: 129S4/SvJae * C57BL/6J)
decreased circulating fibrinogen level J:82961
\hlb385/?
(C57BL/6J-hlb385/J)
decreased leukocyte cell number J:82961
\Hltftm1.1Hdin/\Hltftm1.1Hdin
\ShprhGt(RRJ453)Byg/\ShprhGt(RRJ453)Byg

(involves: 129 * C57BL/6 * SJL)
immune system phenotype J:177630
\Hltftm1.1Hdin/\Hltftm1.1Hdin
\Shprhtm1Jhjh/\Shprhtm1Jhjh

(involves: 129 * C57BL/6 * SJL)
immune system phenotype J:177630
\Hmbox1em1(IMPC)Tcp/\Hmbox1em1(IMPC)Tcp
(C57BL/6N-Hmbox1em1(IMPC)Tcp/Tcp)
decreased lymphocyte cell number J:211773
enlarged lymph nodes J:211773
\Hmga1tm1Afus/\Hmga1+
(involves: 129S7/SvEvBrd * C57BL/6)
enlarged spleen J:106702
\Hmga1tm1Afus/\Hmga1tm1Afus
(involves: 129S7/SvEvBrd * C57BL/6)
enlarged spleen J:106702
lymphoid hyperplasia J:106702
myeloid hyperplasia J:106702
\Hmgb1tm1.1Dltg/\Hmgb1tm1.1Dltg
\Tg(Pdx1-cre)6Tuv/0

(involves: C57BL/6 * FVB/N)
increased circulating interleukin-6 level J:225260
increased circulating tumor necrosis factor level J:225260
increased susceptibility to induced pancreatitis J:225260
\Hmgb1tm1.1Ttg/\Hmgb1tm1.1Ttg
\Lyz2tm1(cre)Ifo/\Lyz2+

(involves: 129P2/OlaHsd)
abnormal macrophage physiology J:205499
decreased macrophage cell number J:205499
impaired macrophage phagocytosis J:205499
increased circulating interleukin-1 beta level J:205499
increased circulating interleukin-18 level J:205499
increased interleukin-1 beta secretion J:205499
increased interleukin-18 secretion J:205499
increased macrophage apoptosis J:205499
increased susceptibility to bacterial infection J:205499
increased susceptibility to endotoxin shock J:205499
\Hmgb1tm1.1Ttg/\Hmgb1tm1.1Ttg
\Speer6-ps1Tg(Alb-cre)21Mgn/\Speer6-ps1+

(involves: 129P2/OlaHsd * C57BL/6 * DBA)
increased circulating interleukin-1 beta level J:205499
increased circulating interleukin-18 level J:205499
\Hmgb1tm1.1Ttg/\Hmgb1tm1.1Ttg
\Tg(Itgax-cre)1-1Reiz/0

(involves: 129P2/OlaHsd * C57BL/6 * CBA)
increased circulating interleukin-1 beta level J:205499
increased circulating interleukin-18 level J:205499
\Hmgb3tm1Dmb/Y
(involves: 129S6/SvEvTac * 129X1/SvJ)
abnormal leukopoiesis J:96514
\Hmgn5tm1.2Mbus/Y
(involves: 129S4/SvJae * C57BL/6J)
decreased granulocyte number J:199604
decreased IgE level J:199604
increased CD8-positive, alpha-beta T cell number J:199604
increased IgA level J:199604
\Hmgn5tm1.2Mbus/\Hmgn5tm1.2Mbus
(involves: 129S4/SvJae * C57BL/6J)
decreased granulocyte number J:199604
decreased IgE level J:199604
increased CD8-positive, alpha-beta T cell number J:199604
increased IgA level J:199604
\Hmgxb3tm1a(EUCOMM)Wtsi/\Hmgxb3tm1a(EUCOMM)Wtsi
(C57BL/6N-Hmgxb3tm1a(EUCOMM)Wtsi/Wtsi)
blood in lymph vessels J:239583
\Hmgxb4tm1.2Zhji/\Hmgxb4tm1.2Zhji
(B6(Cg)-Hmgxb4tm1.2Zhji)
decreased macrophage nitric oxide production J:302603
decreased susceptibility to endotoxin shock J:302603
\Hmox1tm1.1Gkl/\Hmox1tm1.1Gkl
\Lyz2tm1(cre)Ifo/\Lyz2+

(involves: 129 * 129P2/OlaHsd * BALB/cJ * C57BL/6)
decreased interferon-beta secretion J:148498
decreased susceptibility to bacterial infection induced morbidity/mortality J:148498
decreased susceptibility to Paramyxoviridae infection J:148498
increased B cell number J:148498
increased CD4-positive, alpha-beta T cell number J:148498
increased CD8-positive, alpha-beta T cell number J:148498
increased circulating tumor necrosis factor level J:148498
increased granulocyte number J:148498
increased interferon-gamma secretion J:148498
increased macrophage cell number J:148498
increased splenocyte proliferation J:148498
increased susceptibility to experimental autoimmune encephalomyelitis J:148498
\Hmox1tm1.1Hes/\Hmox1tm1.1Hes
\Lyz2tm1(cre)Ifo/\Lyz2+

(involves: 129P2/OlaHsd * C57BL/6J * C57BL/6N)
decreased inflammatory response J:214639
decreased interleukin-1 beta secretion J:214639
decreased interleukin-6 secretion J:214639
decreased tumor necrosis factor secretion J:214639
\Hmox1tm1.2Gkl/\Hmox1tm1.2Gkl
(involves: 129 * BALB/cJ * C57BL/6)
enlarged spleen J:148498
increased inflammatory response J:148498
liver inflammation J:148498
\Hmox1tm1Mlee/\Hmox1tm1Mlee
(involves: 129S2/SvPas * BALB/c)
increased susceptibility to parasitic infection J:153083
increased susceptibility to parasitic infection induced morbidity/mortality J:153083
\Hmox1tm1Poss/\Hmox1+
\Slc48a1em1Ih/\Slc48a1em1Ih

(involves: 129 * 129S2/SvPas * C57BL/6J)
decreased macrophage cell number J:282829
\Hmox1tm1Poss/\Hmox1tm1Poss
(involves: 129S2/SvPas * C57BL/6)
abnormal leukocyte cell number J:79254
abnormal lymph node cell ratio J:79254
abnormal splenic cell ratio J:79254
chronic inflammation J:79254
enlarged lymph nodes J:79254
enlarged spleen J:79254
glomerulonephritis J:79254
liver inflammation J:79254
lung inflammation J:79254
spleen hyperplasia J:79254
\Hmox1tm1Poss/\Hmox1tm1Poss
(involves: 129 * 129S2/SvPas * C57BL/6J)
decreased macrophage cell number J:282829
\Hmox1tm1Poss/\Hmox1tm1Poss
\Slc48a1em1Ih/\Slc48a1em1Ih

(involves: 129 * 129S2/SvPas * C57BL/6J)
decreased macrophage cell number J:282829
\Hmox1tm1Poss/\Hmox1tm1Poss
\Spictm2Kmm/\Spictm2Kmm

(involves: 129S2/SvPas * 129S6/SvEvTac * C57BL/6 * FVB/N)
decreased macrophage cell number J:210804
\Hmox2tm1b(EUCOMM)Hmgu/\Hmox2tm1b(EUCOMM)Hmgu
(C57BL/6N-Hmox2tm1b(EUCOMM)Hmgu/H)
decreased monocyte cell number J:211773
increased spleen weight J:211773
\Hnf1btm1Mya/\Hnf1btm3Mya
\Tg(Alb1-cre)7Gsc/0

(involves: 129S2/SvPas * C57BL/6 * FVB/N)
liver inflammation J:75935
\Hnf1btm2Ics/\Hnf1b+
(involves: 129 * C57BL/6N)
chronic pancreas inflammation J:306082
\Hnrnpa2b1tm1.1Caox/\Hnrnpa2b1tm1.1Caox
\Lyz2tm1(cre)Ifo/\Lyz2+

(involves: 129P2/OlaHsd)
abnormal interferon level J:283622
decreased circulating interferon-beta level J:283622
decreased interferon-beta secretion J:283622
immune system phenotype J:283622
increased susceptibility to Herpesvirales infection J:283622
increased susceptibility to Herpesvirales infection induced morbidity/mortality J:283622
\Hnrnpdtm1b(KOMP)Wtsi/\Hnrnpd+
(C57BL/6N-Hnrnpdtm1b(KOMP)Wtsi/Nju)
decreased leukocyte cell number J:211773
decreased lymphocyte cell number J:211773
increased basophil cell number J:211773
increased eosinophil cell number J:211773
\Hnrnpdtm1Rjsc/\Hnrnpdtm1Rjsc
(involves: 129S6/SvEvTac * C57BL/6J)
abnormal macrophage physiology J:116112
increased circulating tumor necrosis factor level J:116112
increased susceptibility to bacterial infection J:116112
increased susceptibility to endotoxin shock J:116112
\Hnrnph1tm1b(KOMP)Wtsi/\Hnrnph1+
(C57BL/6N-Hnrnph1tm1b(KOMP)Wtsi/Nju)
decreased neutrophil cell number J:211773
increased lymphocyte cell number J:211773
\Hnrnpltm1.1Tmo/\Hnrnpltm1.1Tmo
\Tg(Lck-cre)548Jxm/0

(B6.Cg-Hnrnpltm1.1Tmo Tg(Lck-cre)548Jxm)
abnormal T cell differentiation J:188749
decreased CD4-positive, alpha-beta T cell number J:188749
decreased CD8-positive, alpha-beta T cell number J:188749
decreased double-positive T cell number J:188749
decreased T cell number J:188749
increased double-negative T cell number J:188749
increased T cell proliferation J:188749
thymus hypoplasia J:188749
\Hnrnpllthdr/\Hnrnpllthdr
(C57BL/6JSfdAnu-Hnrnpllthdr/Anu)
abnormal memory T cell morphology J:142641
abnormal memory T cell physiology J:142641
abnormal T cell differentiation J:142641
decreased CD4-positive, alpha-beta T cell number J:142641
\Hook1em1(IMPC)Tcp/\Hook1em1(IMPC)Tcp
(C57BL/6NCrl-Hook1em1(IMPC)Tcp/Tcp)
enlarged lymph nodes J:211773
small spleen J:211773
\Hook2em1(IMPC)Tcp/\Hook2em1(IMPC)Tcp
(C57BL/6N-Hook2em1(IMPC)Tcp/Tcp)
enlarged lymph nodes J:211773
\Hook3tm1b(NCOM)Mfgc/\Hook3tm1b(NCOM)Mfgc
(C57BL/6N-Hook3tm1b(NCOM)Mfgc/Tcp)
increased basophil cell number J:211773
\Hormad2em1(IMPC)Ccpcz/\Hormad2em1(IMPC)Ccpcz
(C57BL/6NCrl-Hormad2em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged spleen J:211773
enlarged thymus J:211773
small spleen J:211773
\Hoxa1tm3.1Mrc/\Hoxa1tm3.1Mrc
(involves: 129S1/Sv * 129X1/SvJ)
thymus hypoplasia J:178887
\Hoxa1tm3.1Mrc/\Hoxa1tm3.1Mrc
\Hoxb1tm3Mrc/\Hoxb1+

(involves: 129S1/Sv * 129X1/SvJ)
small thymus J:41540
\Hoxa1tm3.1Mrc/\Hoxa1tm3.1Mrc
\Hoxb1tm3Mrc/\Hoxb1tm3Mrc

(involves: 129S1/Sv * 129X1/SvJ)
athymia J:41540
\Hoxa3tm1Kth/\Hoxa3tm1Kth
(involves: 129S1/Sv * 129X1/SvJ)
athymia J:60296
\Hoxa3tm1Kth/\Hoxa3tm1Kth
\Hoxd3tm3(Hoxa3)Mrc/\Hoxd3+

(involves: 129S1/Sv * 129X1/SvJ)
athymia J:60296
\Hoxa3tm1Kth/\Hoxa3tm2(Hoxd3)Mrc
(involves: 129S1/Sv * 129X1/SvJ)
immune system phenotype J:60296
\Hoxa3tm1Mrc/\Hoxa3+
\Hoxb3tm1Mrc/\Hoxb3tm1Mrc

(involves: 129S4/SvJae * 129S7/SvEvBrd * C57BL/6J)
ectopic thymus J:46523
\Hoxa3tm1Mrc/\Hoxa3+
\Hoxd3tm1Mrc/\Hoxd3tm1Mrc

(involves: 129S7/SvEvBrd * C57BL/6J)
ectopic thymus J:46523
\Hoxa3tm1Mrc/\Hoxa3tm1Mrc
(involves: 129S7/SvEvBrd)
athymia J:17753, J:161296
\Hoxa3tm1Mrc/\Hoxa3tm1Mrc
\Hoxd3tm1Mrc/\Hoxd3tm1Mrc

(involves: 129S7/SvEvBrd * C57BL/6J)
athymia J:19447
\Hoxa3tm1Mrc/\Hoxa3tm2Nrm
(involves: 129S7/SvEvBrd * C3H * C57BL/6 * C57BL/6NHsd)
athymia J:161296
\Hoxa3tm1Mrc/\Hoxa3tm3.1Nrm
\H2az2Tg(Wnt1-cre)11Rth/\H2az2+

(involves: 129S7/SvEvBrd * C57BL/6J * CBA/J)
ectopic thymus J:161296
\Hoxa3tm1Nrm/\Hoxa3tm1Mrc
(involves: 129S7/SvEvBrd * C3H * C57BL/6 * C57BL/6NHsd)
athymia J:161296
\Hoxa3tm1Nrm/\Hoxa3tm1Nrm
(involves: C3H * C57BL/6 * C57BL/6NHsd)
athymia J:161296
\Hoxa3tm2(Hoxd3)Mrc/\Hoxa3tm2(Hoxd3)Mrc
(involves: 129S1/Sv * 129X1/SvJ)
immune system phenotype J:60296
\Hoxa3tm2Nrm/\Hoxa3tm2Nrm
(involves: C3H * C57BL/6 * C57BL/6NHsd)
athymia J:161296
\Hoxa3tm2Nrm/\Hoxa3tm3.1Nrm
\H2az2Tg(Wnt1-cre)11Rth/\H2az2+

(involves: C3H * C57BL/6 * CBA/J)
ectopic thymus J:161296
\Hoxa5tm1Rob/\Hoxa5tm1Rob
(involves: 129S/SvEv * C57BL/6 * MF1)
abnormal alveolar macrophage morphology J:113378
lung inflammation J:113378
\Hoxa7tm1Mrc/\Hoxa7tm1Mrc
\Hoxb7tm1Mrc/\Hoxb7tm1Mrc

(involves: 129S1/Sv * 129S7/SvEvBrd * 129X1/SvJ)
small thymus J:50942
\Hoxa9tm1Mrc/\Hoxa9tm1Mrc
(B6.129S7-Hoxa9tm1Mrc)
decreased spleen weight J:126371
spleen hypoplasia J:126371
\Hoxa11osem1Kaf/\Hoxa11osem1Kaf
(C57BL/6-Hoxa11osem1Kaf)
abnormal cytokine secretion J:344661
increased susceptibility to induced colitis J:344661
intestinal inflammation J:344661
\Hoxb4tm1.1Karl/\Hoxb4tm1.1Karl
(involves: 129 * C57BL/6J)
spleen hypoplasia J:90976
\Hoxb6tm1Cka/\Hoxb6tm1Cka
(involves: 129P2/OlaHsd * C57BL/6)
immune system phenotype J:133561
\Hoxb8tm1.1Mrc/\Hoxb8tm1.1Mrc
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL)
abnormal microglial cell morphology J:162102
\Hoxb9tm1Mrc/\Hoxb9tm1Mrc
(involves: 129S7/SvEvBrd)
small thymus J:37847
\Hoxc4tm2.1Mrc/\Hoxc4tm2.1Mrc
(involves: 129S/SvEv * C57BL/6)
abnormal class switch recombination J:148278
abnormal somatic hypermutation frequency J:148278
decreased IgA level J:148278
decreased IgE level J:148278
decreased IgG1 level J:148278
decreased IgG2a level J:148278
decreased IgG2b level J:148278
decreased IgG3 level J:148278
decreased IgM level J:148278
immune system phenotype J:148278
\Hptm1Skl/\Hptm1Skl
\Hpxtm1Altr/\Hpxtm1Altr

(involves: 129/Sv * 129P2/OlaHsd * C57BL/6J)
enlarged spleen J:80539
increased spleen red pulp amount J:80539
liver inflammation J:80539
\Hpgdstm1Urad/\Hpgdstm1Urad
(B6.129-Hpgdstm1Urad)
abnormal cytokine secretion J:107651
abnormal lymph node morphology J:107651
increased acute inflammation J:107651
increased inflammatory response J:107651
increased susceptibility to type I hypersensitivity reaction J:197334
\Hpi1C57BL/6J/?
(involves: A/J * C57BL/6J)
abnormal inflammatory response J:69153
\Hpi1C57BL/6J/\Hpi1C57BL/6J
\Hpi2C57BL/6J/\Hpi2C57BL/6J

(involves: A/J * C57BL/6J)
abnormal inflammatory response J:69153
\Hpi2C57BL/6J/?
(involves: A/J * C57BL/6J)
abnormal inflammatory response J:69153
\Hprt1b-m3/Y
\Impdh1tm1Bmi/\Impdh1tm1Bmi

(involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6)
abnormal lymphopoiesis J:85443
decreased cytotoxic T cell cytolysis J:85443
decreased interleukin-4 secretion J:85443
decreased splenocyte proliferation J:85443
decreased T cell proliferation J:85443
\Hprt1b-m3/Y
\Impdh2tm1Bmi/\Impdh2+

(involves: 129P2/OlaHsd)
abnormal cytotoxic T cell physiology J:86045
abnormal lymphocyte cell number J:86045
\Hprt1tm1(CAG-Tgfbr1*)Lba/Y
\Tg(Cd4-cre)1Cwi/0

(involves: 129 * C57BL/6 * DBA/2)
abnormal T cell activation J:148747
\Hprt1tm1(CAG-Tgfbr1*)Lba/Y
\Tgfbr2tm1.2Hlm/\Tgfbr2tm1.2Hlm
\Tg(Cd4-cre)1Cwi/0

(involves: 129 * 129S6/SvEvTac * C57BL/6 * DBA/2)
immune system phenotype J:148747
\Hprt1tm1(CAG-Tgfbr1*)Lba/\Hprt1tm1(CAG-Tgfbr1*)Lba
\Tg(Cd4-cre)1Cwi/0

(involves: 129 * C57BL/6 * DBA/2)
abnormal T cell activation J:148747
\Hprt1tm1(CAG-Tgfbr1*)Lba/\Hprt1tm1(CAG-Tgfbr1*)Lba
\Tgfbr2tm1.2Hlm/\Tgfbr2tm1.2Hlm
\Tg(Cd4-cre)1Cwi/0

(involves: 129 * 129S6/SvEvTac * C57BL/6 * DBA/2)
immune system phenotype J:148747
\Hprt1tm1(CUX1)Anep/\Hprt1+
(either: (involves: 129P2/OlaHsd * C57BL/6) or (involves: 129P2/OlaHsd * C57BL/6 * FVB))
abnormal spleen white pulp morphology J:113393
abnormal splenic cell ratio J:113393
decreased B cell number J:113393
enlarged lymph nodes J:113393
enlarged spleen J:113393
increased leukocyte cell number J:113393
increased neutrophil cell number J:113393
myeloid hyperplasia J:113393
spleen hyperplasia J:113393
\Hprt1tm1(Pck1-cre)Vhh/Y
\Vhltm1Jae/\Vhltm1Jae

(involves: 129P2/OlaHsd * 129S4/SvJae * BALB/c * C57BL/6)
kidney inflammation J:106705
\Hprt1tm2(CUX1)Anep/\Hprt1+
(either: (involves: 129P2/OlaHsd * C57BL/6) or (involves: 129P2/OlaHsd * C57BL/6 * FVB))
immune system phenotype J:113393
\Hps1ep/\Hps1ep
(involves: C3HeB/FeJ * C57BL/6J)
abnormal macrophage physiology J:7869
\Hps1ep/\Hps1ep
(B6.C3Fe-Hps1ep/J)
abnormal NK cell physiology J:6801
alveolitis J:110157
\Hps3coa-Btlr/\Hps3coa-Btlr
(C57BL/6J-Hps3coa-Btlr)
immune system phenotype J:137495
\Hps5ru2-2Btlr/\Hps5ru2-2Btlr
(C57BL/6J-Hps5ru2-2Btlr)
immune system phenotype J:135220
\Hps5ru2-Btlr/\Hps5ru2-Btlr
(C57BL/6J-Hps5ru2-Btlr)
increased susceptibility to bacterial infection J:133272
increased susceptibility to Herpesvirales infection J:133272
\Hps6em1(IMPC)Tcp/\Hps6em1(IMPC)Tcp
(C57BL/6N-Hps6em1(IMPC)Tcp/Tcp)
small spleen J:211773
small thymus J:211773
\Hps6ru-2J/\Hps6ru-2J
(C57BL/10J-Hps6ru-2J)
immune system phenotype J:6485
\Hps6ru-Btlr/\Hps6ru-Btlr
(C57BL/6J-Hps6ru-Btlr)
immune system phenotype J:137496
\Hpsetm1.2Mdh/\Hpsetm1.2Mdh
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
abnormal dendritic cell chemotaxis J:209913
abnormal Langerhans cell morphology J:209913
decreased acute inflammation J:209913
decreased leukocyte cell number J:209913
impaired eosinophil recruitment J:209913
increased eosinophil cell number J:209913
\Hrem1(IMPC)H/\Hrem1(IMPC)H
(C57BL/6NTac-Hrem1(IMPC)H/H)
decreased lymphocyte cell number J:211773
increased neutrophil cell number J:211773
\Hrhr/\Hrhr
(HRS/J)
decreased T cell number J:6087
decreased T cell proliferation J:6375
increased macrophage cell number J:150402
\Hrhr/\Hrhr
\Tg(CD2-Stat6*V625A*T626A)78Mhk/0

(involves: C3H * SKH1)
blepharitis J:230018
eye inflammation J:230018
Meibomian gland inflammation J:230018
uveitis J:230018
\Hrm1Btlr/\Hrm1Btlr
(C57BL/6J-Hrm1Btlr)
immune system phenotype J:138686
\Hrm1Enu/\Hrm1Enu
(BALB/cJ-Hrm1Enu)
granulomatous inflammation J:108173
\Hrrh-bmh/\Hrrh-bmh
(involves: C57BL/6JRj * CBA/JRj)
immune system phenotype J:89321
\Hrrh-R/\Hrrh-R
(involves: 101 * C3H/Rl * C57BL/RlEl * C57BL/10Rl * SEC/El)
decreased thymus weight J:156542
\Hrrh/\Hrrh
(Not Specified)
eye inflammation J:16021
\Hrrh/\Hrrh
(RHJ/LeJ)
thymus atrophy J:57947
\Hrrhsl/\Hrrhsl
(involves: BALB/c)
thymus atrophy J:98859
\HrUSP/\HrUSP
(either: (involves: A/J * BALB/c) or (involves: BALB/c * C57BL/6) or (involves: BALB/c * DBA/2))
abnormal immunoglobulin level J:21316
abnormal lymph node secondary follicle morphology J:21316
abnormal thymus involution J:21316
decreased IgM level J:21316
enlarged inguinal lymph nodes J:21316
enlarged popliteal lymph nodes J:21316
glomerulonephritis J:21316
increased IgG level J:21316
increased susceptibility to autoimmune disorder J:21316
lymph node inflammation J:21316
lymph node medullary cord hyperplasia J:21316
thymus cortex atrophy J:21316
\Hrgtm1Wja/\Hrgtm1Wja
(involves: 129P2/OlaHsd * C57BL/6)
increased circulating fibrinogen level J:134621
increased monocyte cell number J:134621
\Hrh1Bphs-r/\Hrh1Bphs-r
(C3H/HeJ)
immune system phenotype J:4933, J:77938
\Hrh1Bphs-r/\Hrh1Bphs-s
((C3H/HeJ x SJL/J)F1)
abnormal immune system physiology J:77938
abnormal response to infection J:77938
increased susceptibility to bacterial infection J:77938
increased susceptibility to bacterial infection induced morbidity/mortality J:77938
\Hrh1Bphs-s/\Hrh1Bphs-s
(C3.SJL-Hrh1Bphs-s)
abnormal response to infection J:77938
increased susceptibility to bacterial infection J:77938
increased susceptibility to bacterial infection induced morbidity/mortality J:77938
\Hrh1tm1Wtn/\Hrh1tm1Wtn
(involves: 129P2/OlaHsd * C57BL/6)
decreased B cell proliferation J:111704
decreased IgG3 level J:111704
decreased IgM level J:111704
decreased interferon-gamma secretion J:111704
decreased interleukin-2 secretion J:111704
decreased T cell number J:111704
decreased T cell proliferation J:111704
increased interleukin-4 secretion J:111704
\Hrh1tm1Wtn/\Hrh1tm1Wtn
(B6.129P2-Hrh1tm1Wtn)
decreased inflammatory response J:110367
decreased interferon-gamma secretion J:110367
decreased interleukin-5 secretion J:110367
decreased interleukin-13 secretion J:110367
increased IgG level J:110367
increased IgM level J:110367
\Hrh3Eae8-r/?
(B10.S-H2s/SgMcdJ)
decreased susceptibility to experimental autoimmune encephalomyelitis J:34892
\Hrh3Eae8-r/\Hrh3Eae8-r
(involves: B10.S/DvTe * SJL/J)
decreased susceptibility to experimental autoimmune encephalomyelitis J:49054
\Hrh3Eae8-s/?
(involves: B10.S * SJL/J)
increased susceptibility to experimental autoimmune encephalomyelitis J:49054
\Hrh3tm1Twl/\Hrh3tm1Twl
(involves: 129P2/OlaHsd)
immune system phenotype J:132140
\Hrh3tm1Twl/\Hrh3tm1Twl
(B6.129X1-Hrh3tm1Twl)
increased susceptibility to experimental autoimmune encephalomyelitis J:122269
\Hrh4tm1Lex/\Hrh4+
(involves: 129S/SvEv * C57BL/6)
abnormal mast cell physiology J:132140
\Hrh4tm1Lex/\Hrh4tm1Lex
(involves: 129S/SvEv * C57BL/6)
abnormal mast cell physiology J:131785
\Hrh4tm1Lex/\Hrh4tm1Lex
(involves: 129S/SvEv * BALB/c)
abnormal chemokine level J:131785
abnormal dendritic cell physiology J:131785
abnormal interleukin level J:131785
decreased IgE level J:131785
decreased IgG1 level J:131785
decreased inflammatory response J:131785
\Hrl129S6/SvEvTac/\HrlC57BL/6J
(involves: 129S6/SvEvTac * C57BL/6J)
decreased susceptibility to Herpesvirales infection J:86189
\HrlC57BL/6J/\HrlC57BL/6J
(involves: 129S6/SvEvTac * C57BL/6J)
decreased susceptibility to Herpesvirales infection J:86189
\Hs1bp3em1(IMPC)J/\Hs1bp3em1(IMPC)J
(C57BL/6NJ-Hs1bp3em1(IMPC)J/Mmjax)
decreased leukocyte cell number J:211773
\Hs3st3b1em2(IMPC)Mbp/\Hs3st3b1em2(IMPC)Mbp
(C57BL/6N-Hs3st3b1em2(IMPC)Mbp/MbpMmucd)
abnormal spleen morphology J:211773
enlarged spleen J:211773
\Hsd17b3tm1.2Mpo/\Hsd17b3tm1.2Mpo
(involves: 129S6/SvEvTac * C57BL/6N * C57BL/6NCrl)
increased spleen weight J:301756
\Hsd17b4em1(IMPC)Tcp/\Hsd17b4em1(IMPC)Tcp
(C57BL/6NCrl-Hsd17b4em1(IMPC)Tcp/Tcp)
abnormal spleen morphology J:211773
\Hsd17b4tm1Baes/\Hsd17b4tm1Baes
(involves: 129S1/Sv * 129X1/SvJ)
microgliosis J:201698
\Hsd17b4tm2Baes/\Hsd17b4tm2Baes
\Tg(Nes-cre)1Kln/0

(involves: 129 * C57BL/6 * SJL)
microgliosis J:201698
\Hsd17b11Gt(OST237628)Lex/\Hsd17b11Gt(OST237628)Lex
(B6;129S5-Hsd17b11Gt(OST237628)Lex/Mmucd)
increased IgG2a level J:171883
increased immature B cell number J:171883
\Hsd17b13tm1Lex/\Hsd17b13tm1Lex
(involves: 129S5/SvEvBrd * C57BL/6N)
liver inflammation J:273927
\Hsd17b14tm1Lex/\Hsd17b14tm1Lex
(B6;129S5-Hsd17b14tm1Lex/Mmucd)
increased IgG2a level J:171883
\Hsf1tm1Ijb/\Hsf1tm1Ijb
(either: (involves: 129S6/SvEvTac * 129X1/SvJ) or (involves: 129S6/SvEvTac * BALB/c) or (involves: 129S6/SvEvTac * C57BL/6J) or (involves: 129S6/SvEvTac * ICR))
increased susceptibility to bacterial infection J:58383
increased tumor necrosis factor secretion J:58383
\Hsf1tm1Ijb/\Hsf1tm1Ijb
\Tg(TTR-V30M)15Imeg/0

(involves: 129S6/SvEvTac * BALB/c * C57BL/6)
increased interleukin-1 beta secretion J:156658
increased tumor necrosis factor secretion J:156658
\Hsf2bptm1b(EUCOMM)Hmgu/\Hsf2bptm1b(EUCOMM)Hmgu
(C57BL/6N-Hsf2bptm1b(EUCOMM)Hmgu/Ieg)
enlarged lymph nodes J:211773
\Hsfy2em1(IMPC)J/\Hsfy2em1(IMPC)J
(C57BL/6NJ-Hsfy2em1(IMPC)J/Mmjax)
increased leukocyte cell number J:211773
\Hsh2dtm1Viss/\Hsh2dtm1Viss
(B6.129-Hsh2dtm1Viss)
immune system phenotype J:111408
increased interleukin-2 secretion J:111408
increased T cell proliferation J:111408
\Hsh2dtm1Viss/\Hsh2dtm1Viss
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
abnormal CD4-positive, alpha-beta T cell physiology J:111408
abnormal CD8-positive, alpha-beta T cell physiology J:111408
increased spleen weight J:111408
\Hsp90aa1tm1.1Udon/\Hsp90aa1tm1.1Udon
(involves: C57BL/6)
abnormal dendritic cell antigen presentation J:177143
abnormal dendritic cell physiology J:177143
decreased interferon-gamma secretion J:177143
\Hsp90b1tm1Zhli/\Hsp90b1tm1.1Zhli
\Lyz2tm1(cre)Ifo/\Lyz2+

(involves: 129P2/OlaHsd * 129S/SvEv)
abnormal cytokine secretion J:118427
abnormal inflammatory response J:118427
abnormal macrophage physiology J:118427
increased susceptibility to bacterial infection J:118427
\Hspa1btm1Clib/\Hspa1btm1Clib
(involves: 129P2/OlaHsd * C57BL/6J)
increased interleukin-6 secretion J:76801
\Hspa9Gt(IST14901H6)Tigm/\Hspa9+
(involves: C57BL/6N)
decreased pre-B cell number J:227164
\Hspa12atm1.1Zdi/\Hspa12atm1.1Zdi
(involves: 129 * C57BL/6)
abnormal macrophage morphology J:302786
increased susceptibility to endotoxin shock J:302787
\Hspa13tm1.1Smoc/\Hspa13tm1.1Smoc
\Cd19tm1(cre)Cgn/\Cd19+

(involves: 129P2/OlaHsd * 129S * C57BL/6)
abnormal class switch recombination J:303927
abnormal humoral immune response J:303927
abnormal plasmablast number J:303927
abnormal somatic hypermutation frequency J:303927
decreased autoantibody level J:303927
decreased IgA level J:303927
decreased IgE level J:303927
decreased IgG1 level J:303927
decreased IgG2b level J:303927
decreased IgG2c level J:303927
decreased IgG3 level J:303927
decreased IgG level J:303927
decreased IgM level J:303927
decreased plasma cell number J:303927
\Hspb1tm1.1Jdn/\Hspb1tm1.1Jdn
(B6.129S2(Cg)-Hspb1tm1.1Jdn)
abnormal chemokine secretion J:209117
abnormal macrophage physiology J:209117
abnormal neutrophil physiology J:209117
increased inflammatory response J:209117
increased interleukin-6 secretion J:209117
\Hspb8em1(IMPC)J/\Hspb8em1(IMPC)J
(C57BL/6NJ-Hspb8em1(IMPC)J/Mmjax)
decreased leukocyte cell number J:211773
\Hspb8tm1.1Depr/\Hspb8tm1.1Depr
(B.129-Hspb8tm1.1Depr)
decreased circulating interleukin-6 level J:186292
\Hspbap1tm1b(EUCOMM)Hmgu/\Hspbap1tm1b(EUCOMM)Hmgu
(C57BL/6N-Hspbap1tm1b(EUCOMM)Hmgu/Bay)
increased spleen weight J:211773
\Hspg2tm1Rdgr/\Hspg2tm1Rdgr
(involves: 129S1/Sv * 129X1/SvJ)
abnormal osteoclast morphology J:121855
increased osteoclast cell number J:121855
osteoarthritis J:121855
\Htr2ctm1Jul/Y
(B6.129S-Htr2ctm1Jul)
abnormal tumor necrosis factor level J:50262
\Htr3atm1Ckn/\Htr3atm1Ckn
(involves: 129S1/Sv * C57BL/6J * DBA/2)
decreased lymphocyte cell number J:90942
kidney inflammation J:90942
prostate gland inflammation J:90942
pyelonephritis J:90942
seminal vesiculitis J:90942
tubulointerstitial nephritis J:90942
\Htra2mnd2/\Htra2mnd2
(involves: C3H/HeJ * C57BL/6J * CAST/Ei)
abnormal thymus morphology J:12780
spleen atrophy J:12780
\Htra2mnd2/\Htra2mnd2
(B6.Cg-Htra2mnd2)
abnormal interleukin level J:76481
abnormal tumor necrosis factor level J:76481
\Htra2mnd2/\Htra2mnd2
(involves: C57BL/6J)
abnormal immune system morphology J:132627
decreased double-positive T cell number J:132627
decreased pre-B cell number J:132627
decreased pro-B cell number J:132627
decreased single-positive T cell number J:132627
\Htra2tm1.1Hohj/\Htra2tm1.1Hohj
\Tg(Nes-cre)1Kln/0

(involves: C57BL/6J)
spleen atrophy J:225666
thymus atrophy J:225666
\Htra2tm1.2Hohj/\Htra2tm1.2Hohj
(involves: C57BL/6 * C57BL/6J)
decreased lymphocyte cell number J:225666
spleen atrophy J:225666
thymus atrophy J:225666
\Htra2tm1Jdo/\Htra2tm1Jdo
(involves: 129P/Ola * C57BL/6)
small spleen J:94227
small thymus J:94227
\Htttm2Detl/\Htt+
(B6J.129P2-Htttm2Detl)
microgliosis J:220868
\hubb/\hubb
(involves: ICR)
increased spleen weight J:8170
\Hvcn1Gt(RRN293)Byg/\Hvcn1Gt(RRN293)Byg
(B6.129P2-Hvcn1Gt(RRN293)Byg)
abnormal macrophage physiology J:148032
abnormal neutrophil physiology J:148032
\hvlk/\hvlk
(C57BL/6J-hvlk)
increased susceptibility to Herpesvirales infection J:105543
\Hyal1tm1Stn/\Hyal1tm1Stn
(involves: 129X1/SvJ * C57BL/6J)
osteoarthritis J:136860
\Hyal2tm1.1Bfla/\Hyal2tm1.1Bfla
(involves: 129P2/OlaHsd * BALB/c * C57BL/6)
increased spleen iron level J:146040
\Hycc1em1(IMPC)Ccpcz/\Hycc1em1(IMPC)Ccpcz
(C57BL/6N-Hycc1em1(IMPC)Ccpcz/Ccpcz)
enlarged thymus J:211773
increased monocyte cell number J:211773
increased neutrophil cell number J:211773
\Hydinhyrh/\Hydinhyrh
(involves: C57BL/6J * C57BL/10J * RIII)
rhinitis J:137815
thymus atrophy J:137815
\Iapptm1Sgm/\Iapp+
(involves: 129P2/OlaHsd)
increased osteoclast cell number J:88964
\Iapptm1Sgm/\Iapptm1Sgm
(involves: 129P2/OlaHsd)
increased osteoclast cell number J:88964
\Ibdq1C57BL/6J/\Ibdq1SAMP1/YitFcs
(involves: C57BL/6J * SAMP1/YitFc)
ileum inflammation J:84661
\Ibdq1SAMP1/YitFcs/\Ibdq1SAMP1/YitFcs
(involves: C57BL/6J * SAMP1/YitFc)
ileum inflammation J:84661
\Ibdq2SAMP1/YitFcs/\Ibdq2SAMP1/YitFcs
(involves: AKR/J * SAMP1/YitFcs)
small intestinal inflammation J:105411
\Ibsptm1Jeau/\Ibsptm1Jeau
(involves: 129S1/Sv * 129X1/SvJ * CD-1)
abnormal osteoclast morphology J:228156, J:136223
decreased osteoclast cell number J:136223
increased osteoclast cell number J:228156
\IbtkGt(XF224)Byg/\IbtkGt(XF224)Byg
(involves: 129P2/OlaHsd * C57BL/6)
abnormal splenocyte physiology J:174707
immune system phenotype J:174707
\Ica1tm1b(EUCOMM)Wtsi/\Ica1tm1b(EUCOMM)Wtsi
(C57BL/6N-Ica1tm1b(EUCOMM)Wtsi/Tcp)
abnormal spleen morphology J:211773
small spleen J:211773
\Ica1tm1Mdos/\Ica1tm1Mdos
(NOD.129-Ica1tm1Mdos)
abnormal T cell physiology J:83526
decreased susceptibility to autoimmune diabetes J:83526
\Icam1tm1Alb/\Icam1tm1Alb
(B6.Cg-Icam1tm1Alb)
abnormal leukocyte adhesion J:100242
abnormal leukocyte tethering or rolling J:100242
increased leukocyte cell number J:100242
increased neutrophil cell number J:100242
\Icam1tm1Bay/\Icam1tm1Bay
(involves: 129S7/SvEvBrd * C57BL/6J)
abnormal cellular extravasation J:14565
abnormal immune system physiology J:14565
decreased susceptibility to type IV hypersensitivity reaction J:14565
increased neutrophil cell number J:14565
\Icam1tm1Bay/\Icam1tm1Bay
(B6.129S7-Icam1tm1Bay)
abnormal cellular extravasation J:48271
abnormal leukocyte migration J:24239
abnormal leukocyte tethering or rolling J:48271
decreased susceptibility to endotoxin shock J:123460
increased eosinophil cell number J:48271
increased lymphocyte cell number J:48271
increased monocyte cell number J:48271
increased neutrophil cell number J:48271, J:24239
\Icam1tm1Bay/\Icam1tm1Bay
(either: B6.129S7-Icam1tm1Bay or (involves: 129S7/SvEvBrd * C57BL/6))
abnormal leukocyte tethering or rolling J:31374
increased leukocyte cell number J:31374
\Icam1tm1Bay/\Icam1tm1Bay
(B6.129S7-Icam1tm1Bay/J)
decreased susceptibility to parasitic infection induced morbidity/mortality J:193592
immune system phenotype J:193592
\Icam1tm1Bay/\Icam1tm1Bay
(involves: 129S7/SvEvBrd * C57BL/6)
decreased susceptibility to induced colitis J:111227
impaired neutrophil recruitment J:112286
increased neutrophil cell number J:112286
large intestinal inflammation J:111227
\Icam1tm1Bay/\Icam1tm1Bay
\Seletm2Alb/\Seletm2Alb
\Selptm1Bay/\Selptm1Bay

(involves: 129S7/SvEvBrd * C57BL/6)
decreased acute inflammation J:112286
impaired neutrophil chemotaxis J:112286
increased neutrophil cell number J:112286
\Icam1tm1Bay/\Icam1tm1Bay
\Selltm1Tft/\Selltm1Tft

(B6.129-Selltm1Tft Icam1tm1Bay)
abnormal cellular extravasation J:48271
abnormal inflammatory response J:124291
abnormal leukocyte tethering or rolling J:48271
abnormal macrophage physiology J:124291
abnormal mast cell physiology J:124291
impaired macrophage chemotaxis J:124291
increased eosinophil cell number J:48271
increased lymphocyte cell number J:48271
increased monocyte cell number J:48271
increased neutrophil cell number J:48271
\Icam1tm1Bay/\Icam1tm1Bay
\Selptm1Bay/\Selptm1Bay

(involves: 129S7/SvEvBrd * C57BL/6J)
abnormal leukocyte migration J:24239
increased neutrophil cell number J:24239
\Icam1tm1Bay/\Icam1tm1Bay
\Selptm1Bay/\Selptm1Bay

(either: B6.129S7-Selptm1Bay Icam1tm1Bay or (involves: 129S7/SvEvBrd * C57BL/6))
impaired leukocyte tethering or rolling J:31374
\Icam1tm1Bay/\Icam1tm1Bay
\Selptm1Bay/\Selptm1Bay

(B6.129S7-Icam1tm1Bay Selptm1Bay/J)
immune system phenotype J:119906
\Icam1tm1Cws/\Icam1tm1Cws
(involves: C57BL/6)
abnormal macrophage morphology J:100353
\Icam1tm1Jcgr/\Icam1tm1Jcgr
(involves: 129S4/SvJae * C57BL/6 * DBA/2)
abnormal interleukin level J:18743
abnormal T cell physiology J:18743
abnormal tumor necrosis factor level J:18743
decreased susceptibility to bacterial infection induced morbidity/mortality J:18743
decreased susceptibility to type IV hypersensitivity reaction J:18743
increased lymphocyte cell number J:18743
increased neutrophil cell number J:18743
\Icam1tm1Jcgr/\Icam1tm1Jcgr
(B6.129S4-Icam1tm1Jcgr)
immune system phenotype J:113463
\Icam1tm1Jcgr/\Icam1tm1Jcgr
\Ldlrtm1Her/\Ldlrtm1Her

(involves: 129S4/SvJae * 129S7/SvEvBrd)
increased neutrophil cell number J:69597
\Icam1tm1Jcgr/\Icam1tm1Jcgr
\Ldlrtm1Her/\Ldlrtm1Her
\Vcam1tm1Dmil/\Vcam1tm1Dmil

(involves: 129S4/SvJae * 129S7/SvEvBrd * C57BL/6)
increased leukocyte cell number J:69597
increased lymphocyte cell number J:69597
increased monocyte cell number J:69597
increased neutrophil cell number J:69597
\Icam1tm1Jcgr/\Icam1tm1Jcgr
\Tg(INS-Il10)#Sar/0

(NOD.Cg-Icam1tm1Jcgr Tg(INS-Il10)#Sar)
decreased susceptibility to autoimmune diabetes J:66103
periinsulitis J:66103
\Icam1tm1Jcgr/\Icam1tm1Jcgr
\Vcam1tm1Dmil/\Vcam1tm1Dmil

(involves: 129S4/SvJae * C57BL/6)
impaired macrophage chemotaxis J:227109
\Icam2tm1Jcgr/\Icam2tm1Jcgr
(involves: 129S4/SvJae * C57BL/6)
abnormal eosinophil physiology J:54748
\IchsC57BL/6J/\IchsC57BL/6J
(involves: A/J * C57BL/6J * C57BL/6JOlaHsd)
abnormal type I hypersensitivity reaction J:63737
\IchsC57BL/6JOlaHsd/\IchsC57BL/6JOlaHsd
(involves: A/J * C57BL/6J * C57BL/6JOlaHsd)
abnormal type I hypersensitivity reaction J:63737
\Icostm1.1Wks/\Icostm1.1Wks
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
abnormal B cell number J:155586
abnormal B cell physiology J:155586
abnormal B cell selection J:155586
abnormal class switch recombination J:155586
abnormal immune system physiology J:155586
abnormal Peyer's patch germinal center morphology J:155586
abnormal spleen morphology J:155586
decreased CD4-positive, alpha-beta T cell number J:155586
decreased IgA level J:155586
decreased IgG1 level J:155586
decreased IgG2b level J:155586
decreased IgG2c level J:155586
decreased interleukin-4 secretion J:155586
decreased interleukin-21 secretion J:155586
decreased spleen germinal center number J:155586
small Peyer's patches J:155586
\Icostm1Dgry/\Icostm1Dgry
(B6.129P2-Icostm1Dgry)
abnormal CD4-positive, alpha-beta T cell physiology J:123477
abnormal immune system physiology J:123477
abnormal interleukin secretion J:123477
abnormal leukocyte cell number J:123477
abnormal memory B cell number J:123477
abnormal response to infection J:123477
abnormal T cell physiology J:123477
decreased germinal center B cell number J:123477
decreased IgG level J:123477
decreased interleukin-4 secretion J:123477
decreased interleukin-5 secretion J:123477
decreased plasma cell number J:123477
increased plasma cell number J:123477
\Icostm1Flv/\Icos+
(NOD.129S1-Icostm1Flv)
insulitis J:131529
\Icostm1Flv/\Icostm1Flv
(involves: 129/Sv * C57BL/6)
abnormal immunoglobulin level J:87123
abnormal interferon level J:87123
abnormal interleukin level J:87123
abnormal T-helper 2 physiology J:87123
decreased IgE level J:87123
decreased IgG1 level J:87123
immune system phenotype J:87123
increased susceptibility to experimental autoimmune encephalomyelitis J:87123
small lymph nodes J:87123
\Icostm1Flv/\Icostm1Flv
(NOD.129S1-Icostm1Flv)
decreased anti-insulin autoantibody level J:131529
decreased autoantibody level J:131529
decreased IgG level J:131529
decreased interferon-gamma secretion J:131529
decreased susceptibility to autoimmune diabetes J:131529
decreased T cell number J:131529
immune system phenotype J:131529
insulitis J:131529
\Icostm1Flv/\Icostm1Flv
(involves: 129S1/Sv)
abnormal cytokine secretion J:112600
\Icostm1Flv/\Icostm1Flv
\Rc3h1san/\Rc3h1+

(involves: 129S1/Sv * C57BL/6 * C57BL/6JSfdAnu)
increased T cell derived lymphoma incidence J:189087
\Icostm1Flv/\Icostm1Flv
\Tg(Cd4-Maf)6666Glm/0

(involves: 129S1/Sv * C57BL/6)
abnormal cytokine secretion J:112600
\Icostm1Flv/\Icostm1Flv
\Tg(TcraTcrb)425Cbn/0

(involves: 129S1/Sv * C57BL/6)
abnormal cytokine secretion J:112600
\Icostm1Mak/\Icostm1Mak
(involves: 129P2/OlaHsd * C57BL/6)
abnormal B cell number J:155586
abnormal B cell physiology J:66702
abnormal class switch recombination J:66702
abnormal immune system physiology J:66702
abnormal Peyer's patch germinal center morphology J:155586
abnormal spleen morphology J:66702
abnormal T cell physiology J:66702
decreased CD4-positive, alpha-beta T cell number J:155586
decreased IgA level J:155586
decreased IgE level J:66702
decreased IgG1 level J:66702, J:155586
decreased IgG2b level J:155586
decreased IgG2c level J:155586
decreased interleukin-21 secretion J:155586
decreased spleen germinal center number J:66702, J:155586
decreased spleen germinal center size J:66702
decreased T cell proliferation J:66702
small Peyer's patches J:155586
\Icostm1Shr/\Icostm1Shr
(Not Specified)
abnormal CD4-positive, alpha-beta T cell physiology J:87124
abnormal immunoglobulin level J:87124
abnormal interleukin level J:87124
abnormal spleen germinal center morphology J:87124
abnormal T cell differentiation J:87124
decreased IgE level J:87124
decreased IgG1 level J:87124
decreased IgG2a level J:87124
decreased IgG level J:87124
increased IgG3 level J:87124
\Icostm1Tkan/\Icostm1Tkan
(involves: 129S7/SvEvBrd * C57BL/6)
abnormal NK cell physiology J:95353
abnormal Peyer's patch germinal center morphology J:95728
decreased circulating interferon-gamma level J:95353
decreased circulating interleukin-4 level J:95353
small Peyer's patches J:95728
\Icosltm1Cdon/\Icosltm1Cdon
(involves: 129S6/SvEvTac)
abnormal immunoglobulin level J:86697
abnormal interferon level J:86697
abnormal interleukin secretion J:86697
abnormal T cell differentiation J:86697
abnormal T-helper 2 physiology J:86697
decreased IgE level J:86697
decreased IgG1 level J:86697
decreased IgG2a level J:86697
decreased IgG level J:86697
decreased IgM level J:86697
small spleen J:86697
\Icosltm1Kplm/\Icosltm1Kplm
(involves: 129P2/OlaHsd)
abnormal humoral immune response J:84893
abnormal immune serum protein physiology J:84893
abnormal spleen germinal center morphology J:84893
decreased IgA level J:84893
decreased IgG2a level J:84893
decreased IgG2b level J:84893
decreased interleukin-4 secretion J:84893
decreased interleukin-10 secretion J:84893
increased interferon-gamma secretion J:84893
\Icosltm1Mak/\Icosltm1Mak
(involves: 129P2/OlaHsd * C57BL/6)
abnormal class switch recombination J:84668
abnormal immune system physiology J:84668
abnormal spleen morphology J:84668
abnormal T-helper 2 cell differentiation J:84668
decreased IgG1 level J:84668
decreased inflammatory response J:84668
decreased spleen germinal center number J:84668
decreased spleen germinal center size J:84668
immune system phenotype J:84668
\Id1tm1Zhu/\Id1+
\Id3tm1Zhu/\Id3tm1Zhu

(involves: 129S1/Sv * 129S4/SvJaeSor)
increased susceptibility to otitis media J:311050
\Id1tm1Zhu/\Id1tm1Zhu
(involves: 129S1/Sv * C57BL/6)
abnormal myelopoiesis J:155384
abnormal osteoclast differentiation J:155384
decreased lymphocyte cell number J:119519
increased monocyte cell number J:155384
increased neutrophil cell number J:155384
increased osteoclast cell number J:155384
myeloid hyperplasia J:155384
\Id1tm1Zhu/\Id1tm1Zhu
\Id3tm1Zhu/\Id3+

(involves: 129S1/Sv * 129S4/SvJaeSor)
increased susceptibility to otitis media J:311050
\Id1tm1Zhu/\Id1tm1Zhu
\Tcf3tm1Wein/\Tcf3tm1Wein

(involves: 129S1/Sv * 129S4/SvJaeSor * C57BL/6)
abnormal thymus corticomedullary boundary morphology J:44278
absent B cells J:44278
arrested B cell differentiation J:44278
decreased lymphocyte cell number J:44278
increased T cell derived lymphoma incidence J:44278
intermingled spleen red and white pulp J:44278
\Id2tm1Ago/\Id2tm1Ago
(B6.129-Id2tm1Ago)
absent lymph nodes J:116119
absent NK cells J:116119
decreased CD8-positive, alpha-beta T cell number J:116119
\Id2tm1Ago/\Id2tm1Ago
\Tg(TcraTcrb)1100Mjb/0

(B6.Cg-Id2tm1Ago Tg(TcraTcrb)1100Mjb)
abnormal T cell activation J:116119
\Id2tm1Gtbz/\Id2tm1Gtbz
\Nfil3tm1.1Brad/\Nfil3tm1.1Brad

(involves: C57BL/6)
immune system phenotype J:194760
\Id2tm1Mais/\Id2tm1Mais
(involves: 129X1/SvJ * C57BL/6)
abnormal immune system physiology J:146624
\Id2tm1Yyk/\Id2tm1Yyk
(involves: 129S1/Sv * 129X1/SvJ)
abnormal oropharyngeal lymphoid tissue morphology J:78101
absent Peyer's patches J:53267
decreased lymph node number J:53267
decreased NK cell number J:53267
\Id2tm1Yyk/\Id2tm1Yyk
(involves: 129S1/Sv * 129X1/SvJ * NMRI)
abnormal oropharyngeal lymphoid tissue morphology J:78101
absent Peyer's patches J:53267
decreased lymph node number J:53267
decreased NK cell number J:53267
\Id2tm1Yyk/\Id2tm1Yyk
(either: (involves: 129S1/Sv * 129X1/SvJ) or (involves: 129S1/Sv * 129X1/SvJ * FVB/NJ))
absent lymph nodes J:125739
absent Peyer's patches J:125739
decreased NK T cell number J:125739
\Id2tm1Yyk/\Id2tm1Yyk
\Rorctm2Litt/\Rorc+

(involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ)
abnormal gut-associated lymphoid tissue morphology J:87395
abnormal immune system cell morphology J:87395
abnormal lymph organ development J:87395
\Id2tm1Yyk/\Id2tm1Yyk
\Tcf3tm1Cmu/\Tcf3+

(involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ)
absent axillary lymph nodes J:125739
absent brachial lymph nodes J:125739
absent inguinal lymph nodes J:125739
decreased NK T cell number J:125739
\Id2tm1Yyk/\Id2tm1Yyk
\Tcf3tm1Cmu/\Tcf3tm1Cmu

(involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ)
decreased B cell number J:125739
decreased NK T cell number J:125739
immune system phenotype J:125739
small lymph nodes J:125739
\Id2tm2.1Ago/\Id2+
\Id3tm2.1Cmu/\Id3+

(involves: C57BL/6)
immune system phenotype J:179006
\Id2tm2.1Gtbz/\Id2tm2.1Gtbz
\Tg(Itgax-cre)1-1Reiz/0

(involves: C57BL/6 * CBA)
immune system phenotype J:194760
\Id3em1(IMPC)Mbp/\Id3em1(IMPC)Mbp
(C57BL/6N-Id3em1(IMPC)Mbp/MbpMmucd)
abnormal spleen morphology J:211773
enlarged spleen J:211773
increased spleen weight J:211773
\Id3tm1Cmu/\Id3tm1Cmu
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)
abnormal double-positive T cell morphology J:59969
abnormal T cell differentiation J:59969
\Id3tm1Zhu/\Id3tm1Zhu
(involves: 129/Sv * C57BL/6)
abnormal T cell physiology J:56950
decreased B cell proliferation J:56950
decreased immunoglobulin level J:56950
immune system phenotype J:56950
\Id3tm1Zhu/\Id3tm1Zhu
(involves: 129S4/SvJaeSor * C57BL/6)
abnormal T cell differentiation J:144696
\Id3tm1Zhu/\Id3tm1Zhu
(involves: 129S4/SvJaeSor)
immune system phenotype J:93916
increased autoantibody level J:93916
lacrimal gland inflammation J:93916
salivary gland inflammation J:93916
\Id3tm2.1Cmu/\Id3tm2.1Cmu
(Not Specified)
decreased thymocyte number J:176462
increased B cell number J:176462
increased gamma-delta T cell number J:176462
increased T follicular helper cell number J:176462
\Id3tm2.1Cmu/\Id3tm2.1Cmu
\Tcf3tm4Zhu/\Tcf3tm4Zhu
\Tg(Cd4-cre)1Cwi/0

(involves: 129S4/SvJaeSor * C57BL/6 * DBA/2)
decreased thymocyte number J:176462
immune system phenotype J:176462
\Id3tm2.1Zhu/\Id3tm2.1Zhu
\Tg(Lck-cre)#Zhu/0

(involves: 129S6/SvEvTac * C57BL/6 * SJL * SJL/J)
abnormal T cell differentiation J:172701
decreased CD4-positive, alpha-beta T cell number J:172701
decreased CD8-positive, alpha-beta T cell number J:172701
decreased T cell number J:172701
increased CD4-positive, alpha-beta memory T cell number J:172701
increased CD8-positive, alpha-beta memory T cell number J:172701
increased gamma-delta T cell number J:172701
parotid gland inflammation J:172701
submandibular gland inflammation J:172701
\Idc/\Idc+
(involves: 101 * C3H)
blepharitis J:6686
\Idd1NOD/Uf/\Idd1NOD/Uf
(involves: C57BL/6 * NOD/Uf)
periinsulitis J:33172
\Idd1NOD/Uf/\Idd1NOD/Uf
(B6.NOD-(D17Mit164-D17Mit152))
increased CD4-positive, alpha-beta T cell number J:92304
\Idd2NOD/Smrf/\Idd2NOD/Smrf
(involves: NON/Lt * NOD/Smrf)
increased CD4-positive, alpha-beta T cell number J:30526
\Idd3A/J/\Idd3A/J
(NOD.A-Idd3A/J)
increased susceptibility to autoimmune diabetes J:120349
\Idd3C57BL/6/\Idd3C57BL/6
(NOD.B6-Idd3C57BL/6)
decreased susceptibility to autoimmune diabetes J:120349
\Idd3C57BL/10SnJ/\Idd3C57BL/10SnJ
\Idd5.2C57BL/10SnJ/\Idd5.2C57BL/10SnJ

(involves: C57BL/10SnJ * NOD/MrkTac)
insulitis J:143549
\Idd3C57BL/10SnJ/\Idd3C57BL/10SnJ
\Idd5C57BL/10SnJ/\Idd5C57BL/10SnJ

(involves: C57BL/10 * NOD/MrkTac)
pancreas inflammation J:88667
\Idd3CAST/EiJ/\Idd3CAST/EiJ
(NOD.CAST-Idd3CAST/EiJ)
increased susceptibility to autoimmune diabetes J:120349
\Idd3CZECHI/EiJ/\Idd3CZECHI/EiJ
(NOD.CZECH-Idd3CZECHI/EiJ)
decreased susceptibility to autoimmune diabetes J:120349
\Idd3NOD/?
(involves: C57BL/10 * NOD)
pancreas inflammation J:17906
\Idd3SWR/J/\Idd3SWR/J
(NOD.SWR-Idd3SWR/J)
increased susceptibility to autoimmune diabetes J:120349
\Idd4.3C57L/\Idd4.3C57L
(involves: C57L/J * NOD)
abnormal cytokine secretion J:118951
abnormal macrophage physiology J:118951
increased susceptibility to autoimmune diabetes J:118951
\Idd4C57BL/6/\Idd4C57BL/6
(involves: C57BL/6 * DBA/2)
increased T cell proliferation J:25969
\Idd4C57BL/6/\Idd4C57BL/6
(involves: C57BL/6 * NOD)
increased T cell proliferation J:25969
\Idd4C57BL/6J/?
(involves: C57BL/6J * NOD)
pancreas inflammation J:73763
\Idd4NOD/Jsd/?
(involves: NOD/Jsd * NOR/LtJ)
pancreas inflammation J:99002
\Idd4NOD/Jsd/\Idd4NOD/Jsd
\Idd9NOD/Jsd/\Idd9NOD/Jsd

(involves: NOD/Jsd * NOR/LtJ)
pancreas inflammation J:99002
\Idd4NOD/\Idd4NOD
(B6.NOD-Idd4)
abnormal cytokine secretion J:85823
decreased NK T cell number J:85823
\Idd4NOR/LtJ/?
(involves: NOD/Jsd * NOR/LtJ)
pancreas inflammation J:99002
\Idd5NOD/Uf/\Idd5NOD/Uf
(involves: C57BL/6 * NOD/Uf)
periinsulitis J:33172
\Idd6.1C3H/HeJ/\Idd6.1C3H/HeJ
(involves: C3H/HeJ * NOD)
decreased susceptibility to autoimmune diabetes J:115021
\Idd6.2C3H/HeJ/\Idd6.2C3H/HeJ
(involves: C3H/HeJ * NOD)
decreased susceptibility to autoimmune diabetes J:115021
\Idd6.2C3H/HeJ/\Idd6.2C3H/HeJ
(NOD.C3-Idd6.2C3H/HeJ)
decreased NK cell number J:137837
\Idd6.2NOD/\Idd6.2NOD
(B6.NOD-(D6Mit259-D6Mit304))
abnormal T cell differentiation J:120148
\Idd6.3C3H/HeJ/\Idd6.3C3H/HeJ
(involves: C3H/HeJ * NOD)
decreased susceptibility to autoimmune diabetes J:115021
\Idd6C3H/HeJ/\Idd6C3H/HeJ
(NOD.C3-Idd6C3H/HeJ)
decreased interferon-gamma secretion J:137837
decreased interleukin-4 secretion J:137837
decreased NK cell number J:137837
\Idd6C57BL/6/\Idd6NOD
(involves: C57BL/6 * NOD)
decreased T cell proliferation J:72360
\Idd6NOD/\Idd6NOD
(involves: C57BL/6 * NOD)
decreased T cell proliferation J:72360
\Idd6NOD/\Idd6NOD
(B6.NOD-Idd6)
abnormal NK cell physiology J:85823
\Idd7NOD/ShiLt/\Idd7NOD/ShiLt
(involves: C57BL/6 * NOD/ShiLt)
abnormal T cell clonal deletion J:131557
\Idd9.1C57BL/10SnJ/\Idd9.1C57BL/10SnJ
(NOD.B10-Idd9.1C57BL/10SnJ)
increased NK T cell number J:85823
\Idd9NOD/Jsd/?
(involves: NOD/Jsd * NOR/LtJ)
pancreas inflammation J:99002
\Idd9NOR/LtJ/?
(involves: NOD/Jsd * NOR/LtJ)
pancreas inflammation J:99002
\Idd10NOD/ShiLt/\Idd10NOD/ShiLt
\Idd3NOD/\Idd3NOD

(B6.NOD-Idd3NOD Idd10NOD/Lt)
abnormal cytokine secretion J:85823
abnormal NK T cell physiology J:85823
\Idd13NOD/ShiLt/\Idd13NOD/ShiLt
(B6.NOD-Idd13)
abnormal cytokine secretion J:85823
abnormal NK T cell physiology J:85823
\Idd16.1ALR/LtJ/\Idd16.1ALR/LtJ
(involves: ALR/LtJ * NOD/LtJ)
pancreas inflammation J:98187
\Idh1tm1Mak/\Idh1tm1Mak
\Lyz2tm1(cre)Ifo/\Lyz2+

(involves: 129P2/OlaHsd * C57BL/6)
abnormal spleen morphology J:186700
decreased B cell number J:186700
decreased CD4-positive, alpha-beta T cell number J:186700
decreased CD8-positive, alpha-beta T cell number J:186700
enlarged spleen J:186700
increased CD4-positive, alpha-beta T cell number J:186700
\Idh1tm2Mak/\Idh1tm2Mak
\Lyz2tm1(cre)Ifo/\Lyz2+

(involves: 129P2/OlaHsd * C57BL/6)
abnormal spleen morphology J:186700
decreased B cell number J:186700
decreased CD4-positive, alpha-beta T cell number J:186700
decreased CD8-positive, alpha-beta T cell number J:186700
enlarged spleen J:186700
increased CD4-positive, alpha-beta T cell number J:186700
\Idh2tm1Jwpk/\Idh2tm1Jwpk
(involves: 129S4/SvJae * C57BL/6)
increased osteoclast cell number J:272241
\Idh3gem1(IMPC)Bay/\Idh3gem1(IMPC)Bay
(C57BL/6N-Idh3gem1(IMPC)Bay/Bay)
abnormal spleen morphology J:211773
\Ido1tm1Alm/\Ido1tm1Alm
(involves: 129X1/SvJ * C57BL/6 * CBA)
abnormal cytokine secretion J:120813
abnormal dendritic cell physiology J:120813
\Ido1tm1Alm/\Ido1tm1Alm
(involves: 129X1/SvJ * BALB/c)
abnormal cytokine level J:170565
decreased leukocyte cell number J:170565
epididymis inflammation J:170565
\Ido1tm1Alm/\Ido1tm1Alm
(involves: 129X1/SvJ * C57BL/6J * FVB/N)
decreased susceptibility to type IV hypersensitivity reaction J:211949
increased interferon-gamma secretion J:211949
increased interleukin-6 secretion J:211949
increased tumor necrosis factor secretion J:211949
\Ido1tm1Alm/\Ido1tm1Alm
(involves: 129X1/SvJ * C57BL/6J)
abnormal macrophage morphology J:282516
abnormal macrophage physiology J:282516
\Ido2em1Lamn/\Ido2em1Lamn
(involves: BALB/c * C57BL/6J)
decreased susceptibility to type IV hypersensitivity reaction J:342726
\Ido2em1Lamn/\Ido2em1Lamn
\Tg(TcraR28,TcrbR28)KRNDim/0

(involves: C57BL/6 * C57BL/6J * SJL)
autoimmune arthritis J:342726
\Ido2em2Lamn/\Ido2em2Lamn
(involves: BALB/c * C57BL/6J)
decreased susceptibility to type IV hypersensitivity reaction J:342726
\Ido2em2Lamn/\Ido2em2Lamn
\Tg(TcraR28,TcrbR28)KRNDim/0

(involves: C57BL/6 * C57BL/6J * SJL)
autoimmune arthritis J:342726
\Ido2tm1.2Gcp/\Ido2tm1.2Gcp
(involves: C57BL/6J * FVB/N)
abnormal chemokine secretion J:211949
abnormal regulatory T cell physiology J:211949
decreased interferon-gamma secretion J:211949
decreased interleukin-6 secretion J:211949
decreased susceptibility to type IV hypersensitivity reaction J:211949
decreased tumor necrosis factor secretion J:211949
\Idstm1Muen/Y
(Not Specified)
abnormal lymph node morphology J:108761
\Idstm1Muen/Y
(involves: C57BL/6)
increased spleen weight J:259752
\Iduatm1Efn/\Iduatm1Efn
(involves: C57BL/6)
abnormal microglial cell morphology J:81974
abnormal microglial cell physiology J:81974
increased susceptibility to otitis media J:123676
\Ier3tm1Mxw/\Ier3tm1Mxw
(involves: 129 * C57BL/6)
abnormal CD4-positive, alpha-beta T cell physiology J:157504
abnormal interleukin level J:157504
abnormal macrophage physiology J:157504
abnormal response to infection J:157504
abnormal tumor necrosis factor level J:157504
abnormal tumor necrosis factor secretion J:157504
decreased regulatory T cell number J:157504
impaired macrophage phagocytosis J:157504
increased granulocyte number J:157504
increased neutrophil cell number J:157504
increased susceptibility to parasitic infection J:157504
\Ier3tm1Mxw/\Ier3tm1Mxw
(involves: C57BL/6)
decreased susceptibility to induced colitis J:194587
increased T-helper 17 cell number J:194587
\Ier3tm1Mxw/\Ier3tm1Mxw
\Rag1tm1Mom/\Rag1tm1Mom

(involves: 129S7/SvEvBrd * C57BL/6)
decreased susceptibility to induced colitis J:194587
\If1l/\If1l
(involves: BALB/c)
abnormal circulating interferon level J:5113
abnormal response to infection J:38004
\If1l/\If1l
(B6.C-Ifi44lH28-c If1l/(HW81)aByJ)
abnormal response to infection J:38004
\Ifi27l2atm1(KOMP)Vlcg/\Ifi27l2atm1(KOMP)Vlcg
(involves: C57BL/6NTac)
immune system phenotype J:221531
\Ifi30tm1Cres/\Ifi30tm1Cres
(involves: 129S1/Sv * C57BL/6)
abnormal professional antigen presenting cell physiology J:72708
\Ifi35em1Hhl/\Ifi35em1Hhl
(C57BL/6-Ifi35em1Hhl)
decreased circulating interleukin-6 level J:298909
decreased circulating tumor necrosis factor level J:298909
decreased susceptibility to bacterial infection induced morbidity/mortality J:298909
decreased susceptibility to endotoxin shock J:298909
\Ifi44tm1b(KOMP)Wtsi/\Ifi44tm1b(KOMP)Wtsi
(C57BL/6N-Ifi44tm1b(KOMP)Wtsi/Tcp)
enlarged lymph nodes J:211773
increased basophil cell number J:211773
increased eosinophil cell number J:211773
\Ifi44tm1b(KOMP)Wtsi/\Ifi44tm1b(KOMP)Wtsi
(involves: C57BL/6N)
decreased CXCL10 secretion J:297991
decreased interleukin-1 beta secretion J:297991
increased CD8-positive, alpha-beta T cell number J:297991
increased susceptibility to Riboviria infection J:297991
\Ifi47tm1Gat/\Ifi47tm1Gat
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
immune system phenotype J:87535
increased susceptibility to parasitic infection J:87535
\Ifi204tm1.1Cjul/\Ifi204tm1.1Cjul
(B6.129(Cg)-Ifi204tm1.1Cjul)
decreased circulating interferon-beta level J:270123
decreased circulating interleukin-1 beta level J:270123
decreased circulating interleukin-6 level J:270123
decreased circulating tumor necrosis factor level J:270123
decreased interferon-beta secretion J:270123
decreased interleukin-6 secretion J:270123
decreased susceptibility to endotoxin shock J:270123
decreased tumor necrosis factor secretion J:270123
\Ifi204tm1b(KOMP)Wtsi/\Ifi204tm1b(KOMP)Wtsi
(involves: BALB/cJ * C57BL/6J * C57BL/6N)
immune system phenotype J:354143
\Ifi207em1(IMPC)Wtsi/\Ifi207+
(C57BL/6N-Ifi207em1(IMPC)Wtsi)
increased susceptibility to Retroviridae infection J:354143
\Ifi207em1(IMPC)Wtsi/\Ifi207em1(IMPC)Wtsi
(C57BL/6N-Ifi207em1(IMPC)Wtsi)
decreased interferon-beta secretion J:354143
immune system phenotype J:354143
increased susceptibility to Retroviridae infection J:354143
\Ifi208em1(IMPC)Mbp/\Ifi208em1(IMPC)Mbp
(C57BL/6N-Ifi208em1(IMPC)Mbp/MbpMmucd)
abnormal spleen morphology J:211773
small spleen J:211773
\Ifih1Rgsc422/\Ifih1+
(D2JJcl.B6JJcl-Ifih1Rgsc422)
abnormal chemokine level J:209917
abnormal cytokine level J:209917
abnormal dendritic cell antigen presentation J:209917
abnormal leukocyte cell number J:209917
abnormal macrophage activation involved in immune response J:209917
abnormal T cell activation J:209917
autoimmune response J:209917
chronic liver inflammation J:209917
glomerulonephritis J:209917
increased anti-double stranded DNA antibody level J:209917
increased anti-nuclear antigen antibody level J:209917
increased dendritic cell number J:209917
increased granulocyte number J:209917
increased IgA level J:209917
increased IgG level J:209917
increased IgM level J:209917
increased immunoglobulin level J:209917
increased inflammatory response J:209917
increased macrophage cell number J:209917
increased plasma cell number J:209917
increased susceptibility to systemic lupus erythematosus J:209917
skin inflammation J:209917
\Ifih1Rgsc422/\Ifih1+
\Ifnar1tm1Agt/\Ifnar1+

(involves: 129S2/SvPas * C57BL/6JJcl * DBA/2JJcl)
glomerulonephritis J:209917
\Ifih1Rgsc422/\Ifih1+
\Mavstm1Aki/\Mavs+

(involves: C57BL/6JJcl * DBA/2JJcl)
glomerulonephritis J:209917
\Ifih1Rgsc422/\Ifih1+
\Mavstm1Aki/\Mavstm1Aki

(involves: C57BL/6JJcl * DBA/2JJcl)
immune system phenotype J:209917
\Ifih1Rgsc422/\Ifih1Rgsc422
(D2JJcl.B6JJcl-Ifih1Rgsc422)
glomerulonephritis J:209917
increased susceptibility to systemic lupus erythematosus J:209917
\Ifih1tm1.1Cln/\Ifih1tm1.1Cln
(involves: 129X1/SvJ * C57BL/6)
abnormal cytokine secretion J:110201
decreased interferon-alpha secretion J:110201
decreased interleukin-6 secretion J:110201
increased susceptibility to Picornaviridae infection J:110201
\Ifih1tm1.1Cln/\Ifih1tm1.1Cln
(involves: 129X1/SvJ)
decreased interferon-beta secretion J:240099
\Ifih1tm1Aki/\Ifih1tm1Aki
(involves: 129/Sv * C57BL/6)
abnormal dendritic cell physiology J:137522
abnormal interferon level J:137522
abnormal interleukin level J:137522
increased susceptibility to Picornaviridae infection J:137522
\Ifih1tm1Aki/\Ifih1tm1Aki
\Ticam1tm1Aki/\Ticam1tm1Aki

(involves: 129P2/OlaHsd)
abnormal interferon level J:137522
abnormal interleukin level J:137522
\Ifit1tm1(KOMP)Vlcg/\Ifit1tm1(KOMP)Vlcg
(involves: C57BL/6NTac)
increased susceptibility to Riboviria infection J:187549
increased susceptibility to Riboviria infection induced morbidity/mortality J:187549
\Ifit1tm1(KOMP)Vlcg/\Ifit1tm1(KOMP)Vlcg
(involves: C57BL/6 * C57BL/6NTac)
abnormal interferon level J:205203
abnormal T cell physiology J:205203
brain inflammation J:205203
increased susceptibility to Coronaviridae infection J:205203
increased susceptibility to Coronaviridae infection induced morbidity/mortality J:205203
\Ifit2tm1.1Ebsb/\Ifit2tm1.1Ebsb
(B6NCrl.129P2(C)-Ifit2tm1.1Ebsb)
decreased circulating interleukin-1 beta level J:199862
decreased circulating interleukin-6 level J:199862
decreased circulating interleukin-12b level J:199862
decreased circulating tumor necrosis factor level J:199862
decreased interleukin-6 secretion J:199862
decreased tumor necrosis factor secretion J:199862
increased susceptibility to bacterial infection induced morbidity/mortality J:199862
\Ifit2tm1.1Ebsb/\Ifit2tm1.1Ebsb
(B6.129P2(C)-Ifit2tm1.1Ebsb)
enhanced humoral immune response J:233986
increased IgE level J:233986
increased IgG1 level J:233986
increased IgG3 level J:233986
increased IgM level J:233986
\Ifit2tm1.1Gcs/\Ifit2+
(involves: C57BL/6)
increased susceptibility to Riboviria infection induced morbidity/mortality J:195382
\Ifit2tm1.1Gcs/\Ifit2tm1.1Gcs
(involves: C57BL/6)
increased susceptibility to Riboviria infection J:195382
increased susceptibility to Riboviria infection induced morbidity/mortality J:195382
\Ifitm1tm1.1Ieg/\Ifitm1tm1.1Ieg
(B6.129P2-Ifitm1tm1.1Ieg)
decreased granulocyte number J:192287
decreased T cell number J:192287
immune system phenotype J:192287
increased IgE level J:192287
\Ifitm3tm1Masu/\Ifitm3tm1Masu
(involves: 129P2/OlaHsd * C57BL/6)
increased susceptibility to Orthomyxoviridae infection J:183865
increased susceptibility to Orthomyxoviridae infection induced morbidity/mortality J:183865
increased susceptibility to Riboviria infection J:209781
\Ifitm5em1Pmof/\Ifitm5+
(involves: CD-1)
abnormal osteoclast morphology J:255349
\Ifna6tm1Aki/\Ifna6+
\Myd88tm1Aki/\Myd88tm1Aki

(involves: 129P2/OlaHsd)
abnormal plasmacytoid dendritic cell morphology J:124340
decreased interferon-alpha secretion J:124340
\Ifnar1m1Btlr/\Ifnar1m1Btlr
(C57BL/6J-Ifnar1m1Btlr)
abnormal macrophage physiology J:142790
decreased interferon-alpha secretion J:142790
decreased interferon-beta secretion J:142790
immune system phenotype J:142790
increased susceptibility to Adenoviridae infection J:142790
increased susceptibility to Herpesvirales infection J:142790
increased susceptibility to Orthomyxoviridae infection J:142790
increased susceptibility to Riboviria infection J:142790
\Ifnar1m2Btlr/\Ifnar1m2Btlr
(involves: C57BL/6J)
decreased interferon-beta secretion J:198556
\Ifnar1tm1Agt/\Ifnar1tm1Agt
(involves: 129S2/SvPas)
abnormal cytokine secretion J:114555
abnormal dendritic cell physiology J:114555
abnormal immunoglobulin level J:101427
abnormal inflammatory response J:114555
abnormal NK cell physiology J:79552, J:139001
immune system phenotype J:286237
impaired natural killer cell mediated cytotoxicity J:79552
increased susceptibility to Coronaviridae infection J:144400
increased susceptibility to Coronaviridae infection induced morbidity/mortality J:144400
increased susceptibility to Herpesvirales infection J:197569, J:81243
increased susceptibility to Herpesvirales infection induced morbidity/mortality J:115139
increased susceptibility to Paramyxoviridae infection J:160878
increased susceptibility to Paramyxoviridae infection induced morbidity/mortality J:160878
increased susceptibility to Picornaviridae infection J:137522
increased susceptibility to Poxviridae infection J:101427
\Ifnar1tm1Agt/\Ifnar1tm1Agt
(involves: 129S2/SvPas * C57BL/6)
abnormal susceptibility to infection J:120938
immune system phenotype J:238323
\Ifnar1tm1Agt/\Ifnar1tm1Agt
(B6.129S2-Ifnar1tm1Agt)
abnormal osteoclast morphology J:76097
abnormal response to infection J:116703
decreased interferon-alpha secretion J:125611
decreased interferon-beta secretion J:125611
decreased interleukin-6 secretion J:199862
decreased tumor necrosis factor secretion J:199862
impaired natural killer cell mediated cytotoxicity J:118750
increased susceptibility to bacterial infection induced morbidity/mortality J:199862
\Ifnar1tm1Agt/\Ifnar1tm1Agt
(involves: 129S2/SvPas * BALB/c * C57BL/6 * SJL)
increased susceptibility to Orthomyxoviridae infection J:119783
\Ifnar1tm1Agt/\Ifnar1tm1Agt
(involves: 129S2/SvPas * 129S6/SvEvTac)
abnormal CD8-positive, alpha-beta T cell physiology J:54482
abnormal interferon-gamma secretion J:54482
increased circulating interleukin-12 level J:54482
increased susceptibility to Riboviria infection J:54482
\Ifnar1tm1Agt/\Ifnar1tm1Agt
(involves: 129S2/SvPas * BALB/c)
abnormal cytokine level J:291874
abnormal mononuclear phagocyte morphology J:291874
decreased Ly6C high monocyte number J:291874
decreased susceptibility to Coronaviridae infection J:291874
decreased T cell apoptosis J:291874
increased CD4-positive, alpha-beta T cell number J:291874
increased CD8-positive, alpha-beta T cell number J:291874
increased susceptibility to Coronaviridae infection induced morbidity/mortality J:291874
increased susceptibility to Orthomyxoviridae infection induced morbidity/mortality J:291874
\Ifnar1tm1Agt/\Ifnar1tm1Agt
\Ifngr1tm1Agt/\Ifngr1tm1Agt

(involves: 129S2/SvPas * 129S7/SvEvBrd)
abnormal immunoglobulin level J:101427
immune system phenotype J:286237
increased susceptibility to Herpesvirales infection J:81243
increased susceptibility to Herpesvirales infection induced morbidity/mortality J:115139
increased susceptibility to Poxviridae infection J:101427
increased susceptibility to Togaviridae infection J:81243
\Ifnar1tm1Agt/\Ifnar1tm1Agt
\Myd88tm1Aki/\Myd88+

(B6.129-Myd88tm1Aki Ifnar1tm1Agt)
increased susceptibility to parasitic infection J:140485
\Ifnar1tm1Agt/\Ifnar1tm1Agt
\Myd88tm1Aki/\Myd88tm1Aki

(involves: 129P2/OlaHsd * 129S2/SvPas)
abnormal leukocyte migration J:171379
\Ifnar1tm1Agt/\Ifnar1tm1Agt
\Myd88tm1Aki/\Myd88tm1Aki

(B6.129-Myd88tm1Aki Ifnar1tm1Agt)
increased susceptibility to parasitic infection J:140485
increased susceptibility to parasitic infection induced morbidity/mortality J:140485
\Ifnar1tm1Agt/\Ifnar1tm1Agt
\Otulintm1c(EUCOMM)Hmgu/\Otulintm1c(EUCOMM)Hmgu
\Tg(KRT14-cre)1Cgn/0

(involves: 129S2/SvPas * C57BL/6 * C57BL/6N * DBA/2)
dermatitis J:312394
immune system phenotype J:312394
\Ifnar1tm1Agt/\Ifnar1tm1Agt
\Slamf1tm1Oono/\Slamf1tm1Oono

(B6.129-Slamf1tm1Oono Ifnar1tm1Agt)
abnormal lymphopoiesis J:117810
increased susceptibility to Paramyxoviridae infection J:117810
\Ifnar1tm1Agt/\Ifnar1tm1Agt
\Sp140em1Vnce/\Sp140em1Vnce

(B6.Cg-Sp140em1Vnce Ifnar1tm1Agt)
immune system phenotype J:313901
\Ifnar1tm1Agt/\Ifnar1tm1Agt
\Tg(CD46)373Zbz/\Tg(CD46)373Zbz

(involves: 129S2/SvPas * C3H/He * C57BL/6)
brain inflammation J:160878
increased susceptibility to Paramyxoviridae infection J:160878
increased susceptibility to Paramyxoviridae infection induced morbidity/mortality J:160878
lung inflammation J:160878
meningitis J:160878
\Ifnar1tm1Agt/\Ifnar1tm1Agt
\Tg(Hmgcr-MX1)LStae/\Tg(Hmgcr-MX1)LStae

(involves: 129S2/SvPas * BALB/c * C57BL/6 * SJL)
decreased susceptibility to Orthomyxoviridae infection J:119783
decreased susceptibility to Orthomyxoviridae infection induced morbidity/mortality J:119783
\Ifnar1tm1Agt/\Ifnar1tm1Agt
\Ythdf3em1Caox/\Ythdf3em1Caox

(involves: C57BL/6J)
abnormal macrophage physiology J:276397
\Ifnar1tm1Pjh/\Ifnar1tm1Pjh
(involves: 129S2/SvPas * BALB/c)
abnormal macrophage physiology J:36004
increased leukocyte cell number J:36004
increased susceptibility to Picornaviridae infection J:36004
increased susceptibility to Picornaviridae infection induced morbidity/mortality J:36004
increased susceptibility to Togaviridae infection J:36004
increased susceptibility to Togaviridae infection induced morbidity/mortality J:36004
\Ifnar1tm1Pjh/\Ifnar1tm1Pjh
(B6.129S2-Ifnar1tm1Pjh)
decreased NK cell number J:125812
impaired natural killer cell mediated cytotoxicity J:125812
\Ifnar2m1Btlr/\Ifnar2m1Btlr
(C57BL/6J-Ifnar2m1Btlr)
abnormal macrophage physiology J:147329
decreased interferon-alpha secretion J:147329
decreased interferon-beta secretion J:147329
increased susceptibility to Adenoviridae infection J:147329
increased susceptibility to Herpesvirales infection J:147329
increased susceptibility to Orthomyxoviridae infection J:147329
increased susceptibility to Riboviria infection J:147329
\Ifnar2tm1Pjh/\Ifnar2tm1Pjh
(B6.Cg-Ifnar2tm1Pjh)
decreased NK cell number J:125812
impaired natural killer cell mediated cytotoxicity J:125812
\Ifnar2tm1Pjh/\Ifnar2tm1Pjh
(involves: C57BL/6)
abnormal CD4-positive, alpha-beta T cell physiology J:132662
abnormal cytotoxic T cell physiology J:132662
decreased IgG1 level J:132662
decreased IgG2a level J:132662
decreased IgG level J:132662
decreased interferon-gamma secretion J:132662
\Ifnar2tm1Pjh/\Ifnar2tm1Pjh
\Il6sttm1Ern/\Il6sttm1Ern

(involves: 129S1/Sv)
increased circulating interleukin-6 level J:168781
increased susceptibility to endotoxin shock J:168781
\Ifnb1tm1Acgp/\Ifnb1tm1Acgp
(involves: 129P2/OlaHsd * C57BL/6)
decreased circulating interferon-beta level J:61048
increased susceptibility to Poxviridae infection J:61048
\Ifnb1tm1Acgp/\Ifnb1tm1Acgp
(involves: 129P2/OlaHsd)
abnormal spleen primary B follicle morphology J:86527
decreased macrophage cell number J:86527
decreased mature B cell number J:86527
decreased monocyte cell number J:86527
decreased neutrophil cell number J:86527
decreased pro-B cell number J:86527
decreased tumor necrosis factor secretion J:86527
increased T cell proliferation J:86527
\Ifnb1tm1Acgp/\Ifnb1tm1Acgp
(B6.129P2-Ifnb1tm1Acgp)
abnormal macrophage physiology J:136368
decreased interleukin-1 beta secretion J:136368
\Ifnb1tm1Tl/\Ifnb1tm1Tl
(B10.129P2-Ifnb1tm1Tl)
abnormal macrophage physiology J:83021
abnormal microglial cell physiology J:83021
CNS inflammation J:83021
increased interferon-gamma secretion J:83021
increased interleukin-4 secretion J:83021
increased susceptibility to experimental autoimmune encephalomyelitis J:83021
increased tumor necrosis factor secretion J:83021
\Ifnb1tm1Tl/\Ifnb1tm1Tl
(B6.129P2-Ifnb1tm1Tl)
decreased circulating interferon-alpha level J:172226
decreased circulating interferon-beta level J:172226
decreased susceptibility to bacterial infection J:172226
\Ifnb1tm1Ttg/\Ifnb1tm1Ttg
(B6.Cg-Ifnb1tm1Ttg)
abnormal osteoclast morphology J:76097
\Ifnb1tm1Ttg/\Ifnb1tm1Ttg
(involves: C57BL/6)
abnormal response to infection J:116703
\Ifnb1tm2.1Lien/\Ifnb1tm2.1Lien
\Tg(Itgax-cre)1-1Reiz/0
\Tyrc-2J/\Tyrc-2J

(involves: C57BL/6 * CBA)
immune system phenotype J:172226
\Ifnb1tm2.1Lien/\Ifnb1tm2.1Lien
\Tyrc-2J/\Tyrc-2J

(involves: C57BL/6)
immune system phenotype J:172226
\Ifnb1tm2.1Lien/\Ifnb1tm2.1Lien
\Tyrc-2J/\Tyrc-2J
\Lyz2tm1(cre)Ifo/\Lyz2+

(involves: 129P2/OlaHsd * C57BL/6)
decreased circulating interferon-alpha level J:172226
decreased circulating interferon-beta level J:172226
decreased susceptibility to bacterial infection J:172226
\Ifnetm1.2Pjh/\Ifnetm1.2Pjh
(involves: C57BL/6)
decreased NK cell number J:197569
increased susceptibility to bacterial infection J:197569
increased susceptibility to Herpesvirales infection J:197569
\Ifngtm1.1Hayg/\Ifngtm1.1Hayg
(involves: 129S4/SvJae * C57BL/6J)
abnormal B cell differentiation J:220784
abnormal circulating cytokine level J:220784
abnormal cytokine level J:220784
abnormal lymph node morphology J:220784
abnormal T cell activation J:220784
decreased leukocyte cell number J:220784
decreased mature B cell number J:220784
decreased pre-B cell number J:220784
increased T cell number J:220784
spleen atrophy J:220784
thymus atrophy J:220784
\Ifngtm1Lky/\Ifngtm1Lky
(involves: 129S4/SvJae * C57BL/6)
immune system phenotype J:189794
\Ifngtm1Ts/\Ifngtm1Ts
(involves: 129S7/SvEvBrd * C57BL/6)
abnormal macrophage physiology J:66802
abnormal MHC II cell surface expression on macrophages J:66802
abnormal NK cell physiology J:66802, J:115033
abnormal type IV hypersensitivity reaction J:55740
decreased length of allograft survival J:44346
decreased susceptibility to parasitic infection J:189794
decreased susceptibility to parasitic infection induced morbidity/mortality J:189794
immune system phenotype J:119206
increased splenocyte proliferation J:66802
increased susceptibility to bacterial infection J:66802
\Ifngtm1Ts/\Ifngtm1Ts
(NOD.129S7-Ifngtm1Ts)
abnormal susceptibility to autoimmune disorder J:33427
decreased susceptibility to autoimmune diabetes J:95105
\Ifngtm1Ts/\Ifngtm1Ts
(NOD.Cg-Ifngtm1Ts Prkdcscid)
decreased susceptibility to autoimmune diabetes J:72818
\Ifngtm1Ts/\Ifngtm1Ts
(NOD.129S7(B6)-Ifngtm1Ts/DvsJ)
abnormal cytotoxic T cell physiology J:72818
abnormal diapedesis J:72818
decreased susceptibility to autoimmune diabetes J:72818
\Ifngtm1Ts/\Ifngtm1Ts
(involves: 129S7/SvEvBrd)
abnormal cytokine level J:112600
abnormal immunoglobulin level J:29170
abnormal response to infection J:110721, J:29170
decreased susceptibility to type IV hypersensitivity reaction J:29170
impaired natural killer cell mediated cytotoxicity J:73948
increased IgG1 level J:110721
increased interleukin-17 secretion J:132905
increased susceptibility to bacterial infection J:110856
increased susceptibility to bacterial infection induced morbidity/mortality J:110856
increased susceptibility to Herpesvirales infection J:29170
increased susceptibility to Herpesvirales infection induced morbidity/mortality J:29170
\Ifngtm1Ts/\Ifngtm1Ts
(B6.129S7-Ifngtm1Ts/J)
abnormal circulating cytokine level J:47459
abnormal cytokine secretion J:120556
abnormal dendritic cell antigen presentation J:134949
abnormal dendritic cell chemotaxis J:134949
abnormal dendritic cell physiology J:134949
abnormal humoral immune response J:45665
abnormal immune tolerance J:45665
abnormal immunoglobulin level J:45665
abnormal Langerhans cell physiology J:134949
abnormal macrophage chemotaxis J:136628
abnormal spleen morphology J:47459
abnormal spleen red pulp morphology J:47459
abnormal spleen white pulp morphology J:47459
abnormal type IV hypersensitivity reaction J:45665
decreased interferon-gamma secretion J:120556
decreased interleukin-10 secretion J:120556, J:134949
decreased length of allograft survival J:44346
enlarged mesenteric lymph nodes J:50832
enlarged spleen J:47459
glomerulonephritis J:118730
immune system phenotype J:114783
increased circulating interleukin-6 level J:47459
increased granulocyte number J:47459
increased interleukin-4 secretion J:120556
increased interleukin-12 secretion J:134949
increased leukocyte cell number J:47459
increased monocyte cell number J:47459
increased NK T cell number J:122801
increased susceptibility to bacterial infection J:47459
increased susceptibility to bacterial infection induced morbidity/mortality J:47459
increased susceptibility to parasitic infection J:50832
increased susceptibility to parasitic infection induced morbidity/mortality J:50832
increased susceptibility to type IV hypersensitivity reaction J:118730
pale spleen J:47459
stomach inflammation J:120556
\Ifngtm1Ts/\Ifngtm1Ts
(B6.129S7-Ifngtm1Ts)
abnormal B cell physiology J:112084
abnormal cytokine secretion J:18801, J:110826
abnormal immunoglobulin level J:18801
abnormal lymph node cell ratio J:112084
abnormal response to infection J:18801, J:110826
abnormal response to transplant J:42090
decreased IgG2a level J:18801
decreased IgG3 level J:18801
increased CD8-positive, alpha-beta T cell number J:112048
increased IgE level J:18801
increased IgG1 level J:18801, J:112048
increased interleukin-2 secretion J:112048
increased interleukin-5 secretion J:112048
increased interleukin-10 secretion J:112048
increased susceptibility to Coronaviridae infection J:112048
increased susceptibility to Coronaviridae infection induced morbidity/mortality J:112048
increased susceptibility to parasitic infection J:18801
increased susceptibility to parasitic infection induced morbidity/mortality J:18801, J:110826
increased T cell derived lymphoma incidence J:77491
\Ifngtm1Ts/\Ifngtm1Ts
(involves: 129S7/SvEvBrd * C57BL/6J)
increased susceptibility to bacterial infection J:15723
increased susceptibility to bacterial infection induced morbidity/mortality J:15723
\Ifngtm1Ts/\Ifngtm1Ts
(C.129S7-Ifngtm1Ts)
abnormal cytokine secretion J:110826
abnormal humoral immune response J:45665
abnormal immune tolerance J:45665
abnormal immunoglobulin level J:45665
abnormal response to infection J:110826
increased interleukin-5 secretion J:110826
increased susceptibility to bacterial infection induced morbidity/mortality J:83180
increased susceptibility to experimental autoimmune encephalomyelitis J:34161
increased susceptibility to parasitic infection J:110826
increased susceptibility to parasitic infection induced morbidity/mortality J:110826
\Ifngtm1Ts/\Ifngtm1Ts
(involves: 129S7/SvEvBrd * NOD)
immune system phenotype J:33427
\Ifngtm1Ts/\Ifngtm1Ts
(involves: 129S7/SvEvBrd * BALB/c)
abnormal susceptibility to infection J:39478
decreased IgE level J:114213
decreased inflammatory response J:114213
immune system phenotype J:39881
\Ifngtm1Ts/\Ifngtm1Ts
(involves: 129S7/SvEvBrd * DBA/1 * MRL/Mp)
decreased anti-double stranded DNA antibody level J:39600
decreased anti-nuclear antigen antibody level J:39600
decreased autoantibody level J:39600
decreased IgA level J:39600
decreased IgG2a level J:39600
decreased IgG2b level J:39600
decreased IgG3 level J:39600
decreased IgM level J:39600
decreased immunoglobulin level J:39600
decreased susceptibility to autoimmune disorder J:39600
\Ifngtm1Ts/\Ifngtm1Ts
(C.129S7(B6)-Ifngtm1Ts/J)
abnormal adaptive immunity J:115144
abnormal circulating cytokine level J:47459
abnormal cytokine secretion J:115144
abnormal cytotoxic T cell physiology J:115144
abnormal inflammatory response J:115144
abnormal macrophage physiology J:115144
abnormal NK cell physiology J:115144
abnormal spleen morphology J:115144
abnormal spleen red pulp morphology J:47459
abnormal spleen white pulp morphology J:47459
abnormal uterine NK cell morphology J:56503
abnormal uterine NK cell physiology J:56503
decreased susceptibility to parasitic infection J:50832
enlarged spleen J:47459
increased circulating interleukin-6 level J:47459
increased granulocyte number J:47459
increased leukocyte cell number J:47459
increased monocyte cell number J:47459
increased susceptibility to bacterial infection J:47459
increased susceptibility to bacterial infection induced morbidity/mortality J:47459
increased uterine NK cell number J:56503
pale spleen J:47459
\Ifngtm1Ts/\Ifngtm1Ts
(involves: 129S7/SvEvBrd * A/WySn * C57BL/10SnSg * Swiss)
decreased IgG2a level J:119207
decreased IgG level J:119207
decreased susceptibility to autoimmune disorder J:119207
increased IgG1 level J:119207
\Ifngtm1Ts/\Ifngtm1Ts
\Ldlrtm1Her/\Ldlrtm1Her

(B6.129S7-Ldlrtm1Her Ifngtm1Ts)
increased T cell number J:103072
\Ifngtm1Ts/\Ifngtm1Ts
\Nlrp1aNeut1/\Nlrp1aNeut1

(involves: 129S7/SvEvBrd * C57BL/6)
brain inflammation J:191055
immune system phenotype J:191055
\Ifngtm1Ts/\Ifngtm1Ts
\Pld4tm1.2Nemz/\Pld4tm1.2Nemz

(involves: 129 * 129S7/SvEvBrd * C57BL/6J * FVB/N)
decreased NK T cell number J:281205
\Ifngtm1Ts/\Ifngtm1Ts
\Socs1tm1Jni/\Socs1tm1Jni

(involves: 129S7/SvEvBrd)
increased interleukin-17 secretion J:132905
\Ifngtm1Ts/\Ifngtm1Ts
\Socs1tm1Wehi/\Socs1tm1Wehi

(involves: 129S1/Sv * 129S7/SvEvBrd * C57BL/6)
enlarged thymus medulla J:57474
\Ifngtm1Ts/\Ifngtm1Ts
\Tg(SFTPC-Il18)AThos/0

(involves: 129S7/SvEvBrd * C57BL/6 * C57BL/6N * DBA/2)
lung inflammation J:147547
\Ifngtm1Ts/\Ifngtm1Ts
\Tgfb1tm1Doe/\Tgfb1tm1Doe

(C.129-Ifngtm1Ts Tgfb1tm1Doe)
liver inflammation J:69346
\Ifngtm1Ts/\Ifngtm1Ts
\Tgfbr2tm1.2Hlm/\Tgfbr2tm1.2Hlm
\Tg(TcraBDC2.5,TcrbBDC2.5)1Doi/0
\Tg(Cd4-cre)1Cwi/0

(involves: 129 * C57BL/6 * DBA/2 * NOD * SJL)
immune system phenotype J:196160
\Ifngtm1Ts/\Ifngtm1Ts
\Tnftm2Gkl/\Tnf+

(involves: 129S/SvEv * 129S7/SvEvBrd * C57BL/6J)
small intestinal inflammation J:108572
\Ifngtm1Ts/\Ifngtm1Ts
\Tnfrsf1atm1Blt/\Tnfrsf1atm1Blt
\Tnfrsf1btm1Mwm/\Tnfrsf1btm1Mwm

(involves: 129P2/OlaHsd * 129S2/SvPas * 129S7/SvEvBrd * C57BL/6)
abnormal lymph node cortex morphology J:119206
abnormal lymph node primary follicle morphology J:119206
abnormal lymph node secondary follicle morphology J:119206
absent lymph node germinal center J:119206
absent spleen germinal center J:119206
increased eosinophil cell number J:119206
increased leukocyte cell number J:119206
increased lymphocyte cell number J:119206
increased susceptibility to fungal infection J:119206
lung inflammation J:119206
small Peyer's patches J:119206
\Ifngtm1Yiw/\Ifngtm1Yiw
(involves: 129X1/SvJ * C57BL/6)
decreased inflammatory response J:41632, J:88226
\Ifngtm1Yiw/\Ifngtm1Yiw
(B6.129X1-Ifngtm1Yiw)
abnormal circulating interferon level J:91691
increased susceptibility to Coronaviridae infection J:91691, J:50405
increased susceptibility to Coronaviridae infection induced morbidity/mortality J:91691, J:50405
liver inflammation J:50405
peritoneal inflammation J:50405
\Ifngtm1Yiw/\Ifngtm1Yiw
(C.129X1-Ifngtm1Yiw)
abnormal circulating interferon level J:91691
increased susceptibility to Coronaviridae infection J:91691
increased susceptibility to Coronaviridae infection induced morbidity/mortality J:91691
\Ifngr1m1Btlr/\Ifngr1m1Btlr
(C57BL/6J-Ifngr1m1Btlr)
decreased macrophage cell number J:236694
decreased tumor necrosis factor secretion J:236694
increased B cell number J:236694
\Ifngr1tm1.1Rds/\Ifngr1tm1.1Rds
\Commd10Tg(Vav1-icre)A2Kio/\Commd10+

(B6NTac.Cg-Ifngr1tm1.1Rds Commd10Tg(Vav1-icre)A2Kio)
increased susceptibility to bacterial infection J:206257
increased susceptibility to bacterial infection induced morbidity/mortality J:206257
\Ifngr1tm1.1Rds/\Ifngr1tm1.1Rds
\Tg(Itgax-cre,-EGFP)4097Ach/0

(B6NTac.Cg-Ifngr1tm1.1Rds Tg(Itgax-cre,-EGFP)4097Ach)
decreased interferon-gamma secretion J:206257
decreased interleukin-12b secretion J:206257
increased susceptibility to bacterial infection J:206257
increased susceptibility to bacterial infection induced morbidity/mortality J:206257
\Ifngr1tm1.1Rost/\Ifngr1tm1.1Rost
(involves: BALB/cJ * C57BL/6)
abnormal chemokine level J:152785
decreased circulating interferon-gamma level J:152785
decreased circulating interleukin-12 level J:152785
immune system phenotype J:152785
\Ifngr1tm1.2Rds/\Ifngr1tm1.2Rds
(C57BL/6NTac-Ifngr1tm1.2Rds)
decreased interleukin-12b secretion J:206257
increased susceptibility to bacterial infection J:206257
increased susceptibility to bacterial infection induced morbidity/mortality J:206257
\Ifngr1tm1Agt/\Ifngr1tm1Agt
(involves: 129S7/SvEvBrd)
abnormal immunoglobulin level J:38363, J:101427
abnormal response to infection J:115139
abnormal uterine NK cell morphology J:56503
abnormal uterine NK cell physiology J:56503
aortitis J:115139
arteritis J:115139
decreased circulating tumor necrosis factor level J:17878
decreased IgG2a level J:38363
decreased susceptibility to endotoxin shock J:17878
increased circulating interferon-gamma level J:314959
increased circulating interleukin-1 beta level J:314959
increased circulating interleukin-6 level J:174397
increased interferon-gamma secretion J:38363
increased susceptibility to bacterial infection J:314959, J:174397
increased susceptibility to bacterial infection induced morbidity/mortality J:314959, J:174397
increased susceptibility to experimental autoimmune encephalomyelitis J:38363
increased susceptibility to Herpesvirales infection J:81243
increased susceptibility to Herpesvirales infection induced morbidity/mortality J:115139
increased susceptibility to parasitic infection J:114203
increased susceptibility to Poxviridae infection J:101427
increased tumor necrosis factor secretion J:38363
increased uterine NK cell number J:56503
\Ifngr1tm1Agt/\Ifngr1tm1Agt
(involves: 129S7/SvEvBrd * C57BL/6)
abnormal cytotoxic T cell physiology J:63815
decreased IgG2a level J:63815
decreased IgG3 level J:63815
decreased susceptibility to experimental autoimmune myasthenia gravis J:53577
increased interferon-gamma secretion J:99347
increased interleukin-6 secretion J:99347
increased splenocyte proliferation J:99347
increased susceptibility to bacterial infection J:63815
increased susceptibility to experimental autoimmune uveoretinitis J:99347
increased susceptibility to Riboviria infection J:63815
increased susceptibility to Riboviria infection induced morbidity/mortality J:63815
\Ifngr1tm1Agt/\Ifngr1tm1Agt
(B6.129S7-Ifngr1tm1Agt/J)
abnormal circulating chemokine level J:152785
abnormal lymphopoiesis J:138728
abnormal osteoclast differentiation J:233116
decreased CD4-positive, alpha-beta T cell number J:138728
decreased CD8-positive, alpha-beta T cell number J:138728
decreased circulating interleukin-12 level J:152785
decreased lymphocyte cell number J:138728
decreased susceptibility to bacterial infection J:147443
increased interferon-gamma secretion J:138728
increased susceptibility to graft versus host disease J:138728
spleen hypoplasia J:138728
\Ifngr1tm1Agt/\Ifngr1tm1Agt
(involves: 129S7/SvEvBrd * DBA/1OlaHsd)
decreased IgG2a level J:40634
increased susceptibility to induced arthritis J:40634
\Ifngr1tm1Agt/\Ifngr1tm1Agt
(129-Ifngr1tm1Agt/J)
immune system phenotype J:286237
\Ifngr1tm1Agt/\Ifngr1tm1Agt
\Tg(GZMB-Tax)#Lera/0

(involves: 129S7/SvEvBrd * C57BL/6)
abnormal osteoclast differentiation J:147601
abnormal osteoclast physiology J:147601
increased osteoclast cell number J:147601
\Ifngr1tm1Dmer/\Ifngr1tm1Dmer
(B6.Cg-Ifngr1tm1Dmer)
abnormal response to infection J:202844
\Ifngr1tm1Dmer/\Ifngr1tm1Dmer
\Tg(Thy1-cre)1Vln/0

(B6.Cg-Ifngr1tm1Dmer Tg(Thy1-cre)1Vln)
abnormal response to infection J:202844
\Ifngr2tm1Pbro/\Ifngr2tm1Pbro
(involves: 129S1/Sv)
abnormal class switch recombination J:48016
abnormal T-helper 1 cell differentiation J:48016
decreased susceptibility to type IV hypersensitivity reaction J:48016
increased susceptibility to bacterial infection J:48016
\Ifngr2tm1Pbro/\Ifngr2tm1Pbro
(NOD.129S1-Ifngr2tm1Pbro)
abnormal cytotoxic T cell physiology J:72818
abnormal diapedesis J:72818
abnormal T-helper 2 physiology J:65986
decreased susceptibility to autoimmune diabetes J:72818
\Ifnktm1.1(KOMP)Vlcg/\Ifnktm1.1(KOMP)Vlcg
(C57BL/6NTac-Ifnktm1.1(KOMP)Vlcg)
decreased susceptibility to chemically induced skin inflammation J:322130
enlarged spleen J:322130
\Ifnl3em1Mtba/\Ifnl3em1Mtba
(involves: C57BL/6)
abnormal circulating interferon level J:287260
increased susceptibility to Orthomyxoviridae infection J:287260
increased susceptibility to Riboviria infection J:287260
increased susceptibility to viral infection J:287260
\Ifnlr1tm1b(EUCOMM)Wtsi/\Ifnlr1tm1b(EUCOMM)Wtsi
(B6(Cg)-Ifnlr1tm1b(EUCOMM)Wtsi)
increased susceptibility to Orthomyxoviridae infection J:287260
increased susceptibility to Riboviria infection J:287260
increased susceptibility to viral infection J:287260
\Ifnlr1tm1Palu/\Ifnlr1tm1Palu
(B6.Cg-Ifnlr1tm1Palu)
abnormal susceptibility to infection J:131989
\Ifnlr1tm1Palu/\Ifnlr1tm1Palu
(involves: BALB/c * C57BL/6)
immune system phenotype J:286237
\Ift70bem1(IMPC)Bay/\Ift70bem1(IMPC)Bay
(C57BL/6N-Ift70bem1(IMPC)Bay/Bay)
abnormal spleen morphology J:211773
\Ift140b2b1283Clo/\Ift140b2b1283Clo
(C57BL/6J-Ift140b2b1283Clo)
absent spleen J:175213
\Iftaptm1Mnz/\Iftaptm1Mnz
(Not Specified)
immune system phenotype J:254587
\Igbp1tm1Cbt/Y
\Tg(Lck-cre)1Cwi/0

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2)
decreased thymocyte number J:93221
\Igbp1tm1Cbt/\Igbp1+
\Tg(Lck-cre)1Cwi/0

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2)
decreased thymocyte number J:93221
\Igbp1tm1Imku/Y
\Tg(Lck-cre)I57Jxm/?

(involves: 129P2/OlaHsd * ICR)
abnormal thymus cortex morphology J:84395
abnormal thymus corticomedullary boundary morphology J:84395
decreased double-negative T cell number J:84395
decreased T cell number J:84395
decreased thymocyte number J:84395
\Igdcc4em1Bcgen/\Igdcc4em1Bcgen
(involves: C57BL/6J)
decreased susceptibility to Orthomyxoviridae infection J:320015
decreased susceptibility to Orthomyxoviridae infection induced morbidity/mortality J:320015
\Igf1tm1.1Dlr/\Igf1tm1.1Dlr
\Tg(Ttr-IGF1)1Sykr/0

(FVB.Cg-Igf1tm1.1Dlr Tg(Ttr-IGF1)1Sykr)
increased spleen weight J:157350
\Igf1rtm1Jcbr/\Igf1rtm1Jcbr
\Ndor1Tg(UBC-cre/ERT2)1Ejb/0

(B6.Cg-Ndor1Tg(UBC-cre/ERT2)1Ejb Igf1rtm1Jcbr)
decreased susceptibility to type I hypersensitivity reaction J:241924
\Igf1rtm2Arge/\Igf1rtm2Arge
\Tg(BGLAP-cre)1Clem/0

(involves: 129 * FVB/N)
abnormal osteoclast physiology J:80190
decreased osteoclast cell number J:80190
\Igf1sl2C3H/HeJ/\Igf1sl2C3H/HeJ
(B6.C3H-Igf1sl2C3H/HeJ)
increased osteoclast cell number J:111677
\Igf2tm1Snha/\Igf2+
(involves: 129S1/Sv * 129X1/SvJ * ICR)
abnormal osteoclast differentiation J:167738
\Igf2bp1Gt(OST33739)Lex/\Igf2bp1Gt(OST33739)Lex
(involves: 129S5/SvEvBrd * C57BL/6)
spleen hypoplasia J:89882
\Igfbp1tm1Taub/\Igfbp1tm1Taub
(involves: 129X1/SvJ * C57BL/6)
liver inflammation J:81123
\Igfbp2tm1Jep/\Igfbp2tm1Jep
(either: (involves: 129P1/ReJ * 129S/SvEv) or (involves: 129S/SvEv * C57BL/6))
small spleen J:64338
\Igh-7tm1.1Lam/\Igh-7tm1.1Lam
(involves: BALB/c)
decreased IgE level J:146733
decreased mature B cell number J:146733
\Igh-7tm1Gach/\Igh-7tm1Gach
(BALB/c-Igh-7tm1Gach)
abnormal B cell number J:143266
enhanced B cell migration J:143266
increased IgE level J:143266
increased memory B cell number J:143266
increased plasma cell number J:143266
\Igh-7tm1Lam/\Igh-7tm1Lam
(involves: BALB/c)
decreased IgE level J:146733
decreased mature B cell number J:146733
\Igh-7tm1Lcwu/\Igh-7tm1Lcwu
(involves: C57BL/6)
decreased IgE level J:161452
decreased mature B cell number J:161452
\Igh-7tm1Led/\Igh-7tm1Led
(involves: 129S4/SvJae * Black Swiss)
immune system phenotype J:19552
\Igh-7tm1Led/\Igh-7tm1Led
(C.129S4-Igh-7tm1Led)
impaired eosinophil recruitment J:133373
\Igh-7tm1Led/\Igh-7tm1Led
\Lyntm1Ard/\Lyntm1Ard

(involves: 129P2/OlaHsd * 129S4/SvJae)
abnormal circulating complement protein level J:161523
decreased B cell number J:161523
increased anti-double stranded DNA antibody level J:161523
increased anti-nuclear antigen antibody level J:161523
increased basophil cell number J:161523
increased IgA level J:161523
increased IgM level J:161523
\Igh-8tm1.1Aak/\Igh-8tm1.1Aak
(involves: 129S2/SvPas * C57BL/6)
abnormal class switch recombination J:171251
\Igh-8tm1Aak/\Igh-8tm1Aak
(involves: 129S2/SvPas * C57BL/6)
abnormal class switch recombination J:107063
\Igh-8tm1Schr/\Igh-8tm1Schr
(involves: 129P2/OlaHsd * Black Swiss)
increased IgM level J:49847
\Igh-8tm1Schr/\Igh-8tm1Schr
(C.129P2(BKSW)-Igh-8tm1Schr)
increased IgG level J:75577
increased IgM level J:75577
increased susceptibility to bacterial infection J:75577
\Igh-8tm2(Ighg1)Aak/\Igh-8tm2(Ighg1)Aak
(involves: 129S2/SvPas)
abnormal class switch recombination J:130574
decreased IgG3 level J:130574
\Igh-8tm2.1Aak/\Igh-8tm2.1Aak
(involves: 129S2/SvPas * C57BL/6)
immune system phenotype J:171251
\Igh-Jtm1(3H9-VDJ)Mwg/\Igh-Jtm1(3H9-VDJ)Mwg
(involves: 129P2/OlaHsd * BALB/c * C57BL/6)
abnormal B cell receptor editing J:126940
\Igh-Jtm1(CB20)Riho/\Igh-J+
(involves: C57BL/10 * DBA/1)
abnormal B cell differentiation J:179456
decreased pre-B cell number J:179456
increased immature B cell number J:179456
increased marginal zone B cell number J:179456
increased mature B cell number J:179456
increased susceptibility to induced arthritis J:179456
\Igh-Jtm1(CB20)Riho/\Igh-Jtm1(CB20)Riho
(involves: C57BL/10 * DBA/1)
abnormal B cell differentiation J:179456
decreased pre-B cell number J:179456
increased immature B cell number J:179456
increased marginal zone B cell number J:179456
increased mature B cell number J:179456
increased susceptibility to induced arthritis J:179456
\Igh-Jtm1(Ighel)Cys/\Igh-Jtm1(Ighel)Cys
\Myd88tm1Aki/\Myd88tm1Aki
\Igkj1tm1(IgkHyHEL10)Mnz/0

(involves: 129P2/OlaHsd)
increased IgM level J:115059
\Igh-Jtm1(VDJ-KL25)Zbz/\Igh-J+
(involves: C57BL/6 * C57BL/6J * BALB/cJ)
increased IgG level J:86411
increased IgM level J:86411
\Igh-Jtm1(VDJ-VI10)Zbz/\Igh-J+
(involves: C57BL/6 * C57BL/6J * BALB/cJ)
abnormal immune serum protein physiology J:86411
\Igh-Jtm1.1Lave/\Igh-J+
(Not Specified)
abnormal B cell differentiation J:155798
decreased B cell number J:155798
decreased immature B cell number J:155798
decreased mature B cell number J:155798
decreased spleen weight J:155798
decreased T cell number J:155798
decreased transitional stage B cell number J:155798
decreased transitional stage T1 B cell number J:155798
decreased transitional stage T2 B cell number J:155798
increased pre-B cell number J:155798
increased pro-B cell number J:155798
\Igh-Jtm1.1Lave/\Igh-Jtm1.1Lave
(Not Specified)
abnormal B cell differentiation J:155798
abnormal immunoglobulin level J:179317
arrested B cell differentiation J:179317
decreased B cell number J:155798, J:179317
decreased IgM level J:155798
decreased immature B cell number J:155798
decreased mature B cell number J:155798
decreased spleen weight J:155798
decreased T cell number J:155798
decreased transitional stage B cell number J:155798
decreased transitional stage T1 B cell number J:155798
decreased transitional stage T2 B cell number J:155798
increased IgG level J:155798
increased pre-B cell number J:155798
increased pro-B cell number J:155798
\Igh-Jtm1.1Lave/\Igh-Jtm1.1Lave
\Igk-Jtm1.1Lave/\Igk-Jtm1.1Lave

(Not Specified)
abnormal B cell clonal deletion J:179317
abnormal B cell differentiation J:205708
abnormal B cell physiology J:205708
abnormal immunoglobulin level J:179317
arrested B cell differentiation J:205708, J:179317
decreased B cell number J:205708, J:179317
decreased immature B cell number J:205708
decreased mature B cell number J:205708
\Igh-Jtm1.1Lave/\Igh-Jtm1.1Lave
\Igk-Jtm1.1Lave/\Igk-Jtm1.1Lave
\Tg(BCL2)22Wehi/0

(involves: C57BL/6JWehi * SJL/JWehi)
abnormal B cell differentiation J:179317
\Igh-Jtm1Aigl/\Igh-J+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
abnormal B cell morphology J:111543
decreased B cell number J:111543
decreased B-1 B cell number J:111543
increased susceptibility to experimental autoimmune encephalomyelitis J:111543
\Igh-Jtm1Aigl/\Igh-J+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL)
increased susceptibility to experimental autoimmune encephalomyelitis J:111543
\Igh-Jtm1Aigl/\Igh-J+
\Mogtm1Dpd/\Mogtm1Dpd
\Tg(Tcra2D2,Tcrb2D2)1Kuch/0

(involves: 129S1/Sv * 129S2/SvPas * 129X1/SvJ * C57BL/6)
CNS inflammation J:151335
increased susceptibility to experimental autoimmune encephalomyelitis J:151335
\Igh-Jtm1Aigl/\Igh-J+
\Tg(Tcra2D2,Tcrb2D2)1Kuch/0

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
CNS inflammation J:151335
increased susceptibility to experimental autoimmune encephalomyelitis J:151335
\Igh-Jtm1Aigl/\Igh-Jtm1Aigl
\Tg(H2-Kb-Tcra,-Tcrb)1640Kurs/0

(involves: 129S1/Sv * 129X1/SvJ * FVB/N * SJL/J)
increased autoantibody level J:149511
increased susceptibility to experimental autoimmune encephalomyelitis J:149511
\Igh-Jtm1Cgn/\Ightm4Cgn
\Tg(Cr2-cre)3Cgn/0

(Not Specified)
decreased B cell number J:79299
decreased follicular B cell number J:79299
decreased marginal zone B cell number J:79299
\Igh-Jtm1Cgn/\Ightm4Cgn
\Tg(Cr2-cre)3Cgn/0

(involves: 129P2/OlaHsd)
decreased mature B cell number J:157297
\Igh-Jtm1Cgn/\Ightm11.1Cgn
(involves: 129P2/OlaHsd)
abnormal B cell differentiation J:113434
\Igh-Jtm1Cgn/\Igh-J+
(involves: 129P2/OlaHsd * C57BL/6)
abnormal B cell differentiation J:64285
\Igh-Jtm1Cgn/\Ightm1Leck
(involves: 129P2/OlaHsd * C57BL/6)
abnormal immunoglobulin light chain V-J recombination J:144033
\Igh-Jtm1Cgn/\Igh-Jtm1Cgn
(involves: 129P2/OlaHsd * C57BL/6)
absent mature B cells J:64285
arrested B cell differentiation J:64285
\Igh-Jtm1Dhu/\Ightm3Tim
(involves: 129 * C57BL/6)
abnormal B cell differentiation J:102308
decreased B cell number J:102308
\Igh-Jtm1Dhu/\Ightm1Tim
(involves: 129X1/SvJ * C57BL/6)
abnormal B cell differentiation J:88410
abnormal B cell morphology J:87624
abnormal immune system organ morphology J:87624
abnormal spleen marginal zone morphology J:87624
abnormal spleen morphology J:87624
\Igh-Jtm1Dhu/\Ightm2Tim
(involves: 129X1/SvJ * C57BL/6)
abnormal lymph node morphology J:87624
abnormal spleen morphology J:87624
decreased marginal zone B cell number J:87624
\Igh-Jtm1Dhu/\Igh-J+
\Il2tm1Hor/\Il2tm1Hor

(involves: 129/Sv * C57BL/6)
colitis J:29999
enlarged mesenteric lymph nodes J:29999
\Igh-Jtm1Dhu/\Igh-Jtm1(VDJ-17.2.25)Wabl
\Igktm1Dhu/\Igktm1Dhu

(Not Specified)
abnormal B cell differentiation J:33628
abnormal immature B cell morphology J:89757
\Igh-Jtm1Dhu/\Igh-Jtm1Dhu
\Il2tm1Hor/\Il2tm1Hor

(involves: 129/Sv * C57BL/6)
colitis J:29999
enlarged mesenteric lymph nodes J:29999
\Igh-Jtm1Dhu/\Igh-Jtm1Dhu
\Wdr1rede/\Wdr1rede

(involves: 129S7/SvEvBrd * BALB/c * C57BL/6)
abnormal immune system physiology J:134092
\Igh-Jtm1Dim/\Igh-J+
\Igk-Jtm1Dim/\Igk-J+

(involves: 129S4/SvJae * C57BL/6)
abnormal B cell differentiation J:107241
increased IgG level J:107241
increased IgM level J:107241
\Igh-Jtm1Jkbv/\Igh-Jtm1Jkbv
(involves: 129P2/OlaHsd * C57BL/6)
abnormal T cell number J:113083
absent B cells J:70038
decreased IgM level J:70038
\Igh-Jtm1Jkbv/\Igh-Jtm1Jkbv
(involves: 129P2/OlaHsd)
absent mature B cells J:137738
arrested B cell differentiation J:137738
increased late pro-B cell number J:137738
\Igh-Jtm1Jkbv/\Igh-Jtm1Jkbv
\Igkctm1Jkbv/\Igkctm1Jkbv

(involves: 129P2/OlaHsd)
absent B cells J:23827
absent mature B cells J:137738, J:70620
arrested B cell differentiation J:137738, J:23827
increased late pro-B cell number J:137738
\Igh-Jtm1Jkbv/\Igh-Jtm1Jkbv
\Igkctm1Jkbv/\Igkctm1Jkbv
\Tg(IGH@yH1)2BJkbv/0
\Tg(IGK@yK1)9.2CJkbv/0

(involves: 129P2/OlaHsd)
abnormal B cell morphology J:23827
abnormal immunoglobulin level J:23827
increased mature B cell number J:23827
\Igh-Jtm1Jkbv/\Igh-Jtm1Jkbv
\Igkctm1Jkbv/\Igkctm1Jkbv
\Tg(IGH@yH1)2BJkbv/0
\Tg(IGK@yK1)9.2CJkbv/\Tg(IGK@yK1)9.2CJkbv

(involves: 129P2/OlaHsd)
abnormal B cell differentiation J:137738
decreased immature B cell number J:137738
decreased mature B cell number J:137738
decreased pre-B cell number J:137738
increased late pro-B cell number J:137738
\Igh-Jtm1Jkbv/\Igh-Jtm1Jkbv
\Igkctm1Jkbv/\Igkctm1Jkbv
\Tg(IGH@yH1)2BJkbv/\Tg(IGH@yH1)2BJkbv
\Tg(IGK@yK1)9.2CJkbv/\Tg(IGK@yK1)9.2CJkbv

(involves: 129P2/OlaHsd)
abnormal B cell differentiation J:137738
abnormal immunoglobulin level J:137738
decreased immature B cell number J:137738
decreased mature B cell number J:137738
decreased pre-B cell number J:137738
increased late pro-B cell number J:137738
\Igh-Jtm1Jkbv/\Igh-Jtm1Jkbv
\Igkctm1Jkbv/\Igkctm1Jkbv
\Tg(IGH@yH1)2BJkbv/\Tg(IGH@yH1)2BJkbv
\Tg(IGK@yK2)J23.1Jkbv/\Tg(IGK@yK2)J23.1Jkbv

(involves: 129P2/OlaHsd)
abnormal B cell differentiation J:137738
decreased immature B cell number J:137738
decreased mature B cell number J:137738
decreased pre-B cell number J:137738
increased late pro-B cell number J:137738
\Igh-Jtm1Jkbv/\Igh-Jtm1Jkbv
\Igkctm1Jkbv/\Igkctm1Jkbv
\Tg(IGH@yH2)J9.2Jkbv/0
\Tg(IGK@yK2)J23.1Jkbv/0

(involves: 129P2/OlaHsd * C57BL/6J)
abnormal B cell morphology J:70620
abnormal immunoglobulin heavy chain V(D)J recombination J:70620
abnormal immunoglobulin level J:70620
abnormal immunoglobulin light chain V-J recombination J:70620
increased mature B cell number J:70620
\Igh-Jtm1Jkbv/\Igh-Jtm1Jkbv
\Igkctm1Jkbv/\Igkctm1Jkbv
\Tg(IGH@yH2)J9.2Jkbv/0
\Tg(IGK@yK2)J23.1Jkbv/\Tg(IGK@yK2)J23.1Jkbv

(involves: 129P2/OlaHsd)
abnormal immunoglobulin level J:137738
decreased immature B cell number J:137738
decreased mature B cell number J:137738
immune system phenotype J:137738
\Igh-Jtm1Jkbv/\Igh-Jtm1Jkbv
\Igkctm1Jkbv/\Igkctm1Jkbv
\Tg(IGH@yH2BM)7Amgn/0
\Tg(IGK@yK2)J23.1Jkbv/0

(involves: 129P2/OlaHsd)
abnormal immunoglobulin level J:139792
decreased B cell number J:139792
\Igh-Jtm1Jkbv/\Igh-Jtm1Jkbv
\Igkctm1Jkbv/\Igkctm1Jkbv
\Tg(IGH@yH2CM)2Amgn/0
\Tg(IGK@yK2)J23.1Jkbv/0

(involves: 129P2/OlaHsd)
abnormal immunoglobulin level J:139792
decreased B cell number J:139792
\Igh-Jtm1Jkbv/\Igh-Jtm1Jkbv
\Igkctm1Jkbv/\Igkctm1Jkbv
\Tg(IGH@yHG1/2)1Amgn/0
\Tg(IGK@yK2)J23.1Jkbv/0

(involves: 129P2/OlaHsd)
abnormal immunoglobulin level J:139792
\Igh-Jtm1Jkbv/\Igh-Jtm1Jkbv
\Igkctm1Jkbv/\Igkctm1Jkbv
\Tg(IGH@yHG4)1Amgn/0
\Tg(IGK@yK2)J23.1Jkbv/0

(involves: 129P2/OlaHsd)
abnormal immunoglobulin level J:139792
\Igh-Jtm1Jkbv/\Igh-Jtm1Jkbv
\Tg(IGH@*)SALed/0

(involves: 129P2/OlaHsd)
decreased mature B cell number J:137738
immune system phenotype J:137738
\Igh-Jtm1Jkbv/\Igh-Jtm1Jkbv
\Tg(IGH@yH1)2BJkbv/0

(involves: 129P2/OlaHsd)
abnormal B cell differentiation J:137738
decreased mature B cell number J:137738
decreased pre-B cell number J:137738
increased late pro-B cell number J:137738
\Igh-Jtm1Jkbv/\Igh-Jtm1Jkbv
\Tg(IGH@yH1)2BJkbv/0
\Tg(IGK@yK1)9.2CJkbv/0

(involves: 129P2/OlaHsd)
abnormal B cell morphology J:23827
abnormal immunoglobulin level J:23827
increased late pro-B cell number J:23827
increased mature B cell number J:23827
\Igh-Jtm1Jkbv/\Igh-Jtm1Jkbv
\Tg(IGH@yH1)2BJkbv/\Tg(IGH@yH1)2BJkbv

(involves: 129P2/OlaHsd)
abnormal B cell differentiation J:137738
abnormal immunoglobulin level J:137738
decreased immature B cell number J:137738
decreased mature B cell number J:137738
decreased pre-B cell number J:137738
increased late pro-B cell number J:137738
\Igh-Jtm1Jkbv/\Igh-Jtm1Jkbv
\Tg(IGH@yH2)J9.2Jkbv/0

(involves: 129P2/OlaHsd)
abnormal immunoglobulin level J:137738
decreased mature B cell number J:137738
immune system phenotype J:137738
\Igh-Jtm1Khyk/\Igh-J+
(CB17.129X1-Igh-Jtm1Khyk)
increased B-1 B cell number J:109979
\Igh-Jtm1Mcdl/\Igh-Jtm1Mcdl
\Igk-Jtm1Mcdl/\Igk-Jtm1Mcdl
\Rag1tm1Mom/\Rag1tm1Mom
\Tg(DO11.10)10Dlo/?

(involves: 129S/Sv * BALB/c * C3H * C57BL/6)
abnormal spleen germinal center morphology J:100072
abnormal T cell differentiation J:100072
increased IgE level J:100072
increased IgG level J:100072
\Igh-Jtm2(3H9-VDJ*)Mwg/\Igh-J+
(involves: 129P2/OlaHsd * BALB/c * C57BL/6)
abnormal B cell receptor editing J:126940
increased anti-double stranded DNA antibody level J:126940
\Igh-Jtm2(3H9-VDJ*)Mwg/\Igh-J+
(involves: 129P2/OlaHsd * BALB/c)
abnormal B cell receptor editing J:131138
abnormal marginal zone B cell morphology J:131138
increased anti-double stranded DNA antibody level J:131138
\Igh-Jtm2(3H9-VDJ*)Mwg/\Igh-J+
(B6.129P2-Igh-Jtm2(3H9-VDJ*)Mwg)
decreased B cell number J:142389
increased anti-double stranded DNA antibody level J:142389
increased marginal zone B cell number J:142389
spleen hypoplasia J:142389
\Igh-Jtm2.1(4E10)Lave/\Igh-Jtm2.1(4E10)Lave
(involves: C57BL/6)
arrested B cell differentiation J:205708
decreased B-1a cell number J:205708
decreased IgG1 level J:205708
decreased IgG2b level J:205708
decreased IgG3 level J:205708
decreased IgG level J:205708
decreased IgM level J:205708
\Igh-Jtm2.1(4E10)Lave/\Igh-Jtm2.1(4E10)Lave
\Igk-Jtm2.1(4E10)Lave/\Igk-Jtm2.1(4E10)Lave

(involves: C57BL/6)
abnormal B cell differentiation J:205708
abnormal B cell physiology J:205708
arrested B cell differentiation J:205708
decreased immature B cell number J:205708
decreased mature B cell number J:205708
\Igh-Jtm3(3H9-VDJ*)Mwg/\Igh-Jtm3(3H9-VDJ*)Mwg
(involves: 129P2/OlaHsd * BALB/c * C57BL/6)
abnormal B cell receptor editing J:126940
increased anti-double stranded DNA antibody level J:126940
\Igh-Jtm3.1(48d)Lave/\Igh-Jtm3.1(48d)Lave
(involves: C57BL/6)
decreased B-1a cell number J:205708
decreased IgG1 level J:205708
decreased IgG2b level J:205708
decreased IgM level J:205708
immune system phenotype J:205708
\Igh-V7183tm1Cgn/\Igh-V7183tm1Cgn
(either: (involves: 129P2/OlaHsd) or (involves: 129P2/OlaHsd * C57BL/6))
immune system phenotype J:112978
\Igh-Vtm1(Igh-Vx24)Hmb/\Igh-Vtm1(Igh-Vx24)Hmb
(involves: 129/Sv * C57BL/6)
increased T cell derived lymphoma incidence J:54380
\Igh-Vtm1Jjk/\Igh-Vtm1Jjk
(involves: 129S4/SvJae * C57BL/6)
abnormal adaptive immunity J:62284
increased susceptibility to bacterial infection J:62284
\IghdeltaD/\Igh+
(involves: C57BL/6 * DBA/2)
abnormal B cell differentiation J:95981
decreased B cell number J:95981
decreased immunoglobulin level J:95981
\IghdeltaD/\IghdeltaD
(involves: C57BL/6 * DBA/2)
abnormal B cell differentiation J:95981
abnormal immunoglobulin level J:95981
abnormal spleen morphology J:95981
arrested B cell differentiation J:95981
decreased B cell number J:95981
decreased follicular B cell number J:95981
decreased IgG1 level J:95981
increased IgA level J:95981
increased marginal zone B cell number J:95981
\IghdeltaD/\Ightm11.1Cgn
(involves: C57BL/6 * DBA/2)
abnormal B cell differentiation J:113434
\Ightm1(IGH)Vlcg/\Ightm1(IGH)Vlcg
\Igktm1(IGK)Vlcg/\Igktm1(IGK)Vlcg

(involves: 129S6/SvEvTac * C57BL/6N)
immune system phenotype J:208620
\Ightm1(Ighppc1-5)Cche/\Igh+
(B6.Cg-Ightm1(Ighppc1-5)Cche)
immune system phenotype J:138356
increased autoantibody level J:138356
\Ightm1(Myc)Janz/\Igh+
(involves: 129X1/SvJ * C57BL/6)
enlarged lymph nodes J:96785
enlarged spleen J:96785
increased B cell apoptosis J:96785
increased B cell proliferation J:96785
lymphoid hyperplasia J:96785
\Ightm1(Myc)Janz/\Igh+
\Mdm4tm1.1Wahl/\Mdm4tm1.1Wahl

(involves: 129S/Sv * C57BL/6)
enlarged lymph nodes J:150341
enlarged spleen J:150341
increased splenocyte proliferation J:150341
\Ightm1(PAX5)Mbu/\Igh+
(B6.Cg-Ightm1(PAX5)Mbu)
abnormal lymph node morphology J:118111
abnormal spleen morphology J:118111
abnormal T cell differentiation J:118111
abnormal thymus morphology J:118111
decreased double-negative T cell number J:118111
decreased double-positive T cell number J:118111
enlarged lymph nodes J:118111
enlarged spleen J:118111
enlarged thymus J:118111
increased pro-B cell number J:118111
increased T cell derived lymphoma incidence J:118111
thymus hypoplasia J:118111
\Ightm1(PAX5)Mbu/\Igh+
\Pax5tm1Mbu/\Pax5tm1Mbu

(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 * CBA)
abnormal B cell differentiation J:118111
decreased B cell number J:118111
immune system phenotype J:118111
\Ightm1(PAX5)Mbu/\Ightm1(PAX5)Mbu
(B6.Cg-Ightm1(PAX5)Mbu)
abnormal lymph node morphology J:118111
abnormal spleen morphology J:118111
abnormal T cell differentiation J:118111
abnormal thymus morphology J:118111
decreased double-negative T cell number J:118111
decreased double-positive T cell number J:118111
enlarged lymph nodes J:118111
enlarged spleen J:118111
enlarged thymus J:118111
increased pro-B cell number J:118111
increased T cell derived lymphoma incidence J:118111
thymus hypoplasia J:118111
\Ightm1(VH558)Mss/\Igh+
(involves: FVB/N)
abnormal B cell differentiation J:130421
\Ightm1(VH558)Mss/\Ightm1(VH558)Mss
(involves: FVB/N)
abnormal B cell differentiation J:130421
\Ightm1.1(b12)Nemz/\Ightm1.1(b12)Nemz
(involves: C57BL/6N * FVB/N)
decreased IgM level J:205766
decreased immature B cell number J:205766
increased B cell number J:205766
\Ightm1.1(b12)Nemz/\Ightm1.1(b12)Nemz
\Igktm1.1(b12)Nemz/\Igktm1.1(b12)Nemz

(involves: C57BL/6N * C57BL/6NTac * FVB/N)
decreased IgM level J:205766
decreased immature B cell number J:205766
immune system phenotype J:205766
increased B cell number J:205766
\Ightm1.1(Igh564)Tik/\Ightm1.1(Igh564)Tik
\Igktm1(Igk564)Tik/\Igktm1(Igk564)Tik

(B6.129S4-Igktm1(Igk564)Tik Ightm1(Igh564)Tik)
glomerulonephritis J:113555
\Ightm1.1(Rr361-HBB)Aak/\Ightm1.1(Rr361-HBB)Aak
(129.129S2(Cg)-Ightm1.1(Rr361-HBB)Aak)
abnormal class switch recombination J:333279
decreased IgA level J:333279
decreased IgE level J:333279
decreased IgG1 level J:333279
decreased IgG2a level J:333279
decreased IgG2b level J:333279
\Ightm1.1(Tag)Rwhe/\Igh+
(involves: 129P2/OlaHsd * C57BL/6)
abnormal B cell morphology J:150315
enlarged spleen J:150315
increased B cell number J:150315
lymph node hyperplasia J:150315
\Ightm1.1Hmj/\Ightm1.1Hmj
(involves: 129S6/SvEvTac * C57BL/6J * FVB/N)
abnormal B cell differentiation J:140486
abnormal immunoglobulin heavy chain V(D)J recombination J:140486
decreased mature B cell number J:140486
immune system phenotype J:140486
spleen hypoplasia J:140486
\Ightm1.1Hws/\Ightm1.1Hws
(BALB/cJ-Ightm1.1Hws)
decreased IgM level J:119391
decreased immature B cell number J:119391
decreased immunoglobulin level J:119391
decreased pre-B cell number J:119391
increased late pro-B cell number J:119391
\Ightm1.1Hws/\Ightm1.1Hws
(involves: BALB/c)
decreased immature B cell number J:142069
decreased late pro-B cell number J:142069
increased early pro-B cell number J:142069
increased IgG3 level J:142069
increased IgM level J:142069
\Ightm1.1Lnit/\Igh+
(involves: BALB/c * C57BL/6)
abnormal B cell differentiation J:119484
\Ightm1.1Rsky/\Ightm1.1Rsky
(BALB/c-Ightm1.1Rsky)
abnormal class switch recombination J:125719
decreased IgM level J:125719
\Ightm1.1Twin/\Igh+
(involves: 129 * 129S4/SvJae * C57BL/6)
decreased pre-B cell number J:174233
increased pro-B cell number J:174233
\Ightm1.1Twin/\Ightm1.1Twin
(involves: 129 * 129S4/SvJae * C57BL/6)
abnormal B cell differentiation J:174233
abnormal B cell morphology J:174233
abnormal B cell number J:174233
abnormal marginal zone B cell morphology J:174233
abnormal marginal zone B cell physiology J:174233
absent plasma cells J:174233
decreased B cell number J:174233
decreased B-1a cell number J:174233
decreased follicular B cell number J:174233
decreased IgG3 level J:174233
decreased IgG level J:174233
decreased IgM level J:174233
decreased immature B cell number J:174233
decreased mature B cell number J:174233
decreased transitional stage T2 B cell number J:174233
immune system phenotype J:174233
\Ightm1.1Twin/\Ightm1.1Twin
\Plcg2Ali5/\Plcg2+

(involves: 129 * 129S4/SvJae * C3HeB/FeJ * C57BL/6)
immune system phenotype J:174233
increased B-1a cell number J:174233
\Ightm1.1Twin/\Ightm1.1Twin
\Siglecgtm1Lnit/\Siglecgtm1Lnit

(involves: 129 * 129S4/SvJae * BALB/c * C57BL/6)
immune system phenotype J:174233
\Ightm1.1Vmd/\Igh+
(involves: C57BL/6)
abnormal class switch recombination J:201147
\Ightm1.1Vmd/\Ightm1.1Vmd
(involves: C57BL/6)
abnormal class switch recombination J:201147
decreased IgG1 level J:201147
decreased IgG3 level J:201147
immune system phenotype J:201147
increased IgE level J:201147
\Ightm1.2Rsky/\Igh+
(BALB/c-Ightm1.2Rsky)
increased IgG1 level J:125719
\Ightm1.2Rsky/\Igh+
\Tnfrsf13ctm1Mass/\Tnfrsf13ctm1Mass

(involves: BALB/c * C57BL/6)
decreased mature B cell number J:125719
\Ightm1.2Rsky/\Ightm1.2Rsky
(BALB/c-Ightm1.2Rsky)
abnormal B cell activation J:125719
abnormal B cell morphology J:125719
abnormal B cell proliferation J:125719
abnormal mature B cell morphology J:125719
decreased B-1a cell number J:125719
decreased IgA level J:125719
decreased IgD level J:125719
decreased IgE level J:125719
decreased IgM level J:125719
decreased immunoglobulin level J:125719
decreased pre-B cell number J:125719
decreased transitional stage B cell number J:125719
increased marginal zone B cell number J:125719
increased pro-B cell number J:125719
\Ightm1.2Rsky/\Ightm1.2Rsky
\Tg(CD19-cre/ERT2)1Cgn/?

(involves: BALB/c)
abnormal B cell activation J:125719
abnormal class switch recombination J:125719
\Ightm1Aak/\Ightm1Aak
(Not Specified)
abnormal B cell differentiation J:158402
decreased B cell number J:158402
decreased pre-B cell number J:158402
increased pro-B cell number J:158402
\Ightm1Cgn/\Igh+
(involves: 129P2/OlaHsd)
abnormal B cell differentiation J:79556
\Ightm1Cgn/\Ightm2Cgn
(involves: 129P2/OlaHsd * BALB/c * C57BL/Ka)
abnormal B cell differentiation J:79556
\Ightm1Cog/\Ightm1Cog
(involves: 129S2/SvPas * C57BL/6)
abnormal immunoglobulin heavy chain V(D)J recombination J:80654
absent B cells J:80654
arrested B cell differentiation J:80654
decreased IgA level J:80654
decreased IgE level J:80654
decreased IgG1 level J:80654
decreased IgG2a level J:80654
decreased IgG2b level J:80654
decreased IgG3 level J:80654
decreased IgM level J:80654
decreased immunoglobulin level J:80654
\Ightm1Cys/\Igh+
\Tg(Igk)5Cys/0

(B6.Cg-Ightm1Cys Tg(Igk)5Cys)
abnormal B cell physiology J:118931
immune system phenotype J:118931
\Ightm1Cys/\Igh+
\Tg(Igk)5Cys/0
\Tg(UBC-GFP)30Scha/\Tg(UBC-GFP)30Scha

(involves: 129X1/SvJ * C57BL/6 * CBA)
immune system phenotype J:118931
\Ightm1Emo/\Ightm1Emo
(involves: 129S1/Sv * C57BL/6 * FVB/N)
immune system phenotype J:108098
\Ightm1Kplm/\Igh+
(involves: A/WySnJ * BALB/c)
abnormal B-1 B cell morphology J:115788
\Ightm1Kplm/\Igh+
(Not Specified)
abnormal B cell differentiation J:115292
increased B cell number J:115292
\Ightm1Kplm/\Igh+
\Tg(Igk-V4CH27)1-2Shc/0

(involves: C57BL/6 * SJL)
increased B cell number J:115292
\Ightm1Kplm/\Ightm3Cgn
(involves: C57BL/6)
abnormal B cell differentiation J:115292
abnormal B cell number J:115292
\Ightm1Kplm/\Ightm4Cgn
(involves: 129P2/OlaHsd)
abnormal B cell differentiation J:115292
abnormal B cell number J:115292
abnormal B-1 B cell morphology J:115292
\Ightm1Kplm/\Ightm4Cgn
\Tg(Igk-V4CH27)1-2Shc/0

(involves: 129P2/OlaHsd * C57BL/6 * SJL)
increased B cell number J:115292
\Ightm1Ktom/\Ightm1Ktom
(involves: ICR)
abnormal B cell physiology J:59894
abnormal immunoglobulin level J:178635
absent mature B cells J:178635
\Ightm1Ktom/\Ightm1Ktom
\Igktm1Ktom/\Igktm1Ktom
\Tc(HSA14)SC20Ktom/0
\Tc(HSA2)W23Ktom/0

(involves: C57BL/6NCrlj * CBA/JNCrlj * ICR)
abnormal B cell physiology J:59894
\Ightm1Ktom/\Ightm1Ktom
\Tc(HSA2)W23Ktom/0

(involves: C57BL/6NCrlj * CBA/JNCrlj * ICR)
abnormal B cell physiology J:59894
\Ightm1Leck/\Igh+
(involves: 129P2/OlaHsd * C57BL/6)
abnormal B cell morphology J:144033
abnormal B-1a B cell morphology J:144033
abnormal immature B cell morphology J:144033
abnormal immunoglobulin light chain V-J recombination J:144033
abnormal mature B cell morphology J:144033
\Ightm1Leck/\Ightm1Leck
(involves: 129P2/OlaHsd * C57BL/6)
decreased B cell number J:144033
\Ightm1Mnz/\Ightm1Mnz
(B6.129P2-Ightm1Mnz)
abnormal B cell physiology J:75653
increased B cell apoptosis J:75653
increased B cell proliferation J:75653
increased IgG level J:75653
increased IgM level J:75653
\Ightm1Mnz/\Ightm1Mnz
\Dis3tm1.1Uba/\Dis3tm1.1Uba
\Aicdatm1(cre)Uba/\Aicda+

(involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6)
abnormal somatic hypermutation frequency J:302856
\Ightm1Mnz/\Ightm1Mnz
\Lyntm1Sor/\Lyntm1Sor

(involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6)
abnormal B cell physiology J:75653
increased B cell proliferation J:75653
\Ightm1Rbr/\Igh+
(C57BL/6-Ightm1Rbr)
abnormal B cell morphology J:132538
\Ightm1Rbr/\Igh+
\Tg(IgkHyHEL10)1Rbr/0

(involves: C57BL/6)
abnormal B cell morphology J:132538
abnormal B-2 B cell morphology J:132538
increased IgA level J:132538
increased IgG1 level J:132538
increased IgG2a level J:132538
increased IgG2b level J:132538
increased IgG3 level J:132538
increased IgM level J:132538
increased immature B cell number J:132538
increased immunoglobulin level J:132538
\Ightm1Rbr/\Igh+
\Tg(IgkHyHEL10)1Rbr/0
\Tg(ML5sHEL)5Ccg/0

(involves: C57BL/6 * C57BL/6JSfd)
abnormal B cell anergy J:132538
abnormal B cell morphology J:132538
decreased follicular B cell number J:132538
decreased marginal zone B cell number J:132538
increased immature B cell number J:132538
\Ightm2(IGH)Vlcg/\Ightm2(IGH)Vlcg
\Igktm2(IGK)Vlcg/\Igktm2(IGK)Vlcg

(involves: 129S6/SvEvTac * C57BL/6N)
immune system phenotype J:208620
\Ightm2.1(4E10)Nemz/\Ightm2.1(4E10)Nemz
\Igktm2.1(4E10)Nemz/\Igktm2.1(4E10)Nemz

(involves: C57BL/6 * C57BL/6N * C57BL/6NTac * FVB/N)
decreased B cell number J:101977
decreased IgG level J:101977
decreased IgM level J:101977
\Ightm2.1(Tag)Rwhe/\Igh+
(involves: 129P2/OlaHsd * C57BL/6)
abnormal B cell morphology J:150315
enlarged spleen J:150315
increased B cell number J:150315
lymph node hyperplasia J:150315
\Ightm2.1Fwa/\Ightm2.1Fwa
(involves: 129S/SvEv * C57BL/6)
abnormal class switch recombination J:161437
abnormal somatic hypermutation frequency J:161437
decreased IgG1 level J:161437
decreased mature B cell number J:161437
immune system phenotype J:161437
increased IgE level J:161437
\Ightm2.1Hws/\Ightm2.1Hws
(involves: BALB/c * C57BL/6NCrl * DBA/2NCrl)
abnormal humoral immune response J:124421
decreased B cell number J:124421
decreased B-1a cell number J:124421
decreased B-1b cell number J:124421
decreased follicular B cell number J:124421
decreased IgG level J:124421
decreased IgM level J:124421
decreased pre-B cell number J:124421
decreased transitional stage B cell number J:124421
increased early pro-B cell number J:124421
increased marginal zone B cell number J:124421
\Ightm2.1Hws/\Ightm2.1Hws
(involves: BALB/c)
abnormal B cell differentiation J:142069
decreased B-1a cell number J:142069
decreased follicular B cell number J:142069
decreased IgM level J:142069
decreased immature B cell number J:142069
decreased late pro-B cell number J:142069
decreased mature B cell number J:142069
decreased transitional stage B cell number J:142069
increased anti-nuclear antigen antibody level J:142069
increased early pro-B cell number J:142069
increased marginal zone B cell number J:142069
\Ightm2Cgn/\Igh+
(involves: 129P2/OlaHsd * BALB/c * C57BL/Ka)
abnormal B cell differentiation J:79556
\Ightm2Cgn/\Igh+
(involves: 129P2/OlaHsd * C57BL/6)
abnormal immunoglobulin light chain V-J recombination J:144033
\Ightm2Cgn/\Igh+
\Igktm1Rsky/\Igk+

(either: (involves: 129P2/OlaHsd) or (involves: 129P2/OlaHsd * BALB/c))
abnormal B cell differentiation J:111431
absent pre-B cells J:111431
\Ightm2Cgn/\Igh+
\Igktm2Rsky/\Igk+

(involves: 129P2/OlaHsd)
abnormal class switch recombination J:150435
\Ightm2Cgn/\Igh+
\Igktm2Rsky/\Igk+
\Prkdcscid/\Prkdcscid

(involves: 129P2/OlaHsd * BALB/c * C57BL/Ka)
abnormal class switch recombination J:150435
\Ightm2Cgn/\Igh+
\Rr158tm1Cgn/\Rr158tm1Cgn
\Arhgef1tm1.1Rmt/\Arhgef1tm1.1Rmt

(involves: 129P2/OlaHsd * C57BL/6)
abnormal B cell migration J:113295
\Ightm2Cgn/\Igh+
\Xrcc6tm1Fwa/\Xrcc6tm1Fwa

(involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6)
abnormal B cell differentiation J:44361
\Ightm2Cgn/\Ightm2Cgn
\Igktm1Rsky/\Igktm1Rsky
\Lig4tm1Fwa/\Lig4tm1Fwa
\Trp53tm1Tyj/\Trp53tm1Tyj

(involves: 129P2/OlaHsd * 129S2/SvPas * 129S6/SvEvTac)
abnormal class switch recombination J:126758
\Ightm2Cgn/\Ightm2Cgn
\Igktm1Rsky/\Igktm1Rsky
\Trp53tm1Tyj/\Trp53tm1Tyj
\Xrcc4tm1Fwa/\Xrcc4tm1Fwa

(involves: 129P2/OlaHsd * 129S2/SvPas * 129S6/SvEvTac)
abnormal class switch recombination J:126758
\Ightm2Cgn/\Ightm3Cgn
(involves: 129P2/OlaHsd * BALB/c * C57BL/6 * C57BL/Ka)
abnormal B cell differentiation J:79556
\Ightm2Cgn/\Ightm4.1Fwa
(involves: 129P2/OlaHsd * 129S6/SvEvTac)
abnormal immunoglobulin V(D)J recombination J:176649
\Ightm2Emo/\Ightm2Emo
(involves: 129S1/Sv * C57BL/6 * FVB/N)
abnormal B cell differentiation J:108098
absent pre-B cells J:108098
\Ightm2Mnz/\Ightm2Mnz
(B6.129P2-Ightm2Mnz)
increased B cell proliferation J:75653
increased IgG level J:75653
increased IgM level J:75653
\Ightm2Mnz/\Ightm2Mnz
\Lyntm1Sor/\Lyntm1Sor

(involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6)
abnormal B cell physiology J:75653
increased B cell proliferation J:75653
\Ightm2Rsky/\Igh+
\Igktm1Rsky/\Igk+

(either: (involves: 129P2/OlaHsd) or (involves: 129P2/OlaHsd * BALB/c))
abnormal B cell differentiation J:111431
\Ightm2Rsky/\Igh+
\Igktm2Rsky/\Igk+

(either: (involves: 129P2/OlaHsd) or (involves: 129P2/OlaHsd * BALB/c))
abnormal B cell differentiation J:111431
\Ightm3.1(IGH)Vlcg/\Ightm3.1(IGH)Vlcg
\Igktm3.1(IGK)Vlcg/\Igktm3.1(IGK)Vlcg

(involves: 129S6/SvEvTac * C57BL/6N)
immune system phenotype J:208620
\Ightm3.1Tim/\Igh+
(involves: 129 * C57BL/6)
abnormal B cell differentiation J:102308
abnormal spleen B cell follicle morphology J:102308
\Ightm3Cgn/\Igh+
(involves: C57BL/6)
abnormal B cell differentiation J:79556, J:115292
\Ightm3Cgn/\Ightm3Cgn
(involves: C57BL/6)
abnormal immune system physiology J:76117
decreased immature B cell number J:76117
\Ightm3Hws/\Ightm3Hws
(BALB/c-Ightm3Hws)
abnormal immunoglobulin heavy chain V(D)J recombination J:142068
\Ightm3Hws/\Ightm3Hws
(involves: BALB/c)
abnormal immunoglobulin level J:142069
decreased B cell number J:142069
decreased follicular B cell number J:142069
decreased IgG1 level J:142069
decreased IgG2a level J:142069
decreased IgG2b level J:142069
decreased IgM level J:142069
decreased immature B cell number J:142069
decreased late pro-B cell number J:142069
decreased mature B cell number J:142069
decreased transitional stage B cell number J:142069
increased IgM level J:142069
spleen hypoplasia J:142069
\Ightm3Mnz/\Ightm4.1Mnz
(involves: C57BL/6)
immune system phenotype J:159173
\Ightm3Tim/\Igh+
(involves: 129 * C57BL/6)
abnormal B cell differentiation J:102308
abnormal spleen B cell follicle morphology J:102308
\Ightm4.1Cog/\Ightm4.1Cog
(involves: 129P2/OlaHsd * C57BL/6 * FVB/N)
abnormal class switch recombination J:184094
decreased IgA level J:184094
immune system phenotype J:184094
increased IgM level J:184094
\Ightm4.1Fwa/\Igh+
(involves: 129S6/SvEvTac)
abnormal B cell differentiation J:176649
abnormal immunoglobulin V(D)J recombination J:176649
\Ightm4.1Fwa/\Ightm4.1Fwa
(involves: 129S6/SvEvTac)
abnormal B cell differentiation J:176649
abnormal immunoglobulin V(D)J recombination J:176649
\Ightm4Cgn/\Igh+
(involves: 129P2/OlaHsd)
abnormal B cell differentiation J:115292
\Ightm4Cog/\Igh+
(involves: 129S2/SvPas * C57BL/6)
decreased IgM level J:109988
increased IgA level J:109988
\Ightm4Cog/\Ightm4Cog
(involves: 129S2/SvPas * C57BL/6)
absent Peyer's patches J:109988
absent spleen germinal center J:109988
small spleen J:109988
\Ightm5.1Cgn/\Ightm5.1Cgn
(BALB/c-Ightm5.1Cgn)
abnormal B cell activation J:88472
abnormal B cell differentiation J:88472
abnormal gut-associated lymphoid tissue morphology J:88472
abnormal lymph node germinal center morphology J:88472
abnormal mature B cell morphology J:88472
abnormal Peyer's patch germinal center morphology J:88472
absent B-1 B cells J:88472
absent B-1a cells J:88472
absent B-1b cells J:88472
absent spleen germinal center J:88472
decreased B cell number J:88472
decreased immature B cell number J:88472
decreased marginal zone B cell number J:88472
increased pro-B cell number J:88472
\Ightm5.1Fwa/\Igh+
(involves: 129S6/SvEvTac)
abnormal B cell differentiation J:176649
decreased pre-B cell number J:176649
immune system phenotype J:176649
\Ightm5.1Fwa/\Ightm5.1Fwa
(involves: 129S6/SvEvTac)
abnormal B cell differentiation J:176649
decreased pre-B cell number J:176649
immune system phenotype J:176649
\Ightm5Cgn/\Ightm5Cgn
(involves: BALB/c)
absent B cells J:88472
arrested B cell differentiation J:88472
\Ightm5Cgn/\Ightm5Cgn
\Tg(CD19-cre/ERT2)1Cgn/0

(C.Cg-Ightm5Cgn Tg(CD19-cre/ERT2)1Cgn)
abnormal B cell differentiation J:88472
abnormal mature B cell morphology J:88472
abnormal Peyer's patch germinal center morphology J:88472
absent follicular B cells J:88472
absent marginal zone B cells J:88472
increased B cell number J:88472
increased pro-B cell number J:88472
\Ightm6Fwa/\Ightm6Fwa
(Not Specified)
immune system phenotype J:176649
\Ightm7(VHB1-8)Cgn/\Igh+
(involves: 129P2/OlaHsd * C57BL/6)
abnormal somatic hypermutation frequency J:48835
\Ightm7.1Fwa/\Ightm7.1Fwa
(Not Specified)
immune system phenotype J:176649
\Ightm8(VHB1-8)Cgn/\Igh+
(involves: 129P2/OlaHsd * C57BL/6)
abnormal somatic hypermutation frequency J:48835
\Ightm9(VHB1-8)Cgn/\Igh+
(involves: 129P2/OlaHsd * C57BL/6)
abnormal somatic hypermutation frequency J:48835
\Ightm11.1Cgn/\Ightm11.1Cgn
(Not Specified)
abnormal B cell differentiation J:113434
decreased B cell number J:113434
decreased immature B cell number J:113434
decreased mature B cell number J:113434
increased pro-B cell number J:113434
\Ightm12Cgn/\Ightm12Cgn
(involves: 129P2/OlaHsd)
abnormal somatic hypermutation frequency J:66031
\Ighatm1(Myc)Janz/\Igha+
(involves: 129S1/Sv * C57BL/6)
increased B cell apoptosis J:90901
increased B cell proliferation J:90901
increased plasma cell number J:90901
\Ighatm1(Myc)Janz/\Igha+
\Tg(Igk-V21-Bax)1967Bvn/0

(involves: 129S1/Sv * C57BL/6 * FVB/N)
abnormal B cell apoptosis J:90901
abnormal plasma cell morphology J:90901
enlarged spleen J:90901
increased IgG level J:90901
increased IgM level J:90901
increased plasma cell number J:90901
\Ighatm1(Myc)Janz/\Igha+
\Tg(Tnfsf13b)1Fma/0

(involves: 129S1/Sv * C57BL/6 * DBA/2J)
enlarged spleen J:166158
increased B cell number J:166158
increased lymphocyte cell number J:166158
increased mature B cell number J:166158
increased spleen white pulp amount J:166158
\Ighatm1Grh/\Ighatm1Grh
(involves: 129S7/SvEvBrd * C57BL/6)
abnormal dendritic cell physiology J:125472
abnormal immunoglobulin level J:125472
abnormal memory T cell physiology J:125472
abnormal T cell activation J:53217
decreased IgA level J:53217, J:125472
decreased IgE level J:53217
decreased IgG3 level J:53217
decreased interferon-gamma secretion J:53217
decreased T cell proliferation J:125472
immune system phenotype J:53218
increased IgG1 level J:53217, J:125472
increased IgG2a level J:53217
increased IgG2b level J:53217
increased IgG level J:53217
increased IgM level J:53217, J:125472
increased interferon-gamma secretion J:125472
increased interleukin-4 secretion J:53217
increased susceptibility to Orthomyxoviridae infection J:125472
\Ighatm1Grh/\Ighatm1Grh
(involves: 129 * C57BL/6)
increased susceptibility to parasitic infection J:140515, J:74568
\Ighatm1Grh/\Ighatm1Grh
\Tg(Tnfsf13b)1Fma/\Tg(Tnfsf13b)1Fma

(involves: 129S7/SvEvBrd * C57BL/6 * DBA/2)
immune system phenotype J:178227
\Ighatm2Grh/\Ighatm2Grh
(involves: 129S7/SvEvBrd * C57BL/6)
abnormal class switch recombination J:72521
\Ighddmit/\Ighddmit
(C57BL/6JAnu-Ighddmit/AnuApb)
abnormal immunoglobulin level J:104190
\IghdM1Btlr/\Ighd+
(C57BL/6J-IghdM1Btlr)
decreased B cell number J:255202
\IghdM1Btlr/\IghdM1Btlr
(C57BL/6J-IghdM1Btlr)
decreased B cell number J:255202
decreased IgD level J:255202
\Ighdm2Btlr/\Ighd+
(C57BL/6J-Ighdm2Btlr)
decreased B cell number J:255203
\Ighdm2Btlr/\Ighdm2Btlr
(C57BL/6J-Ighdm2Btlr)
decreased B cell number J:255203
decreased IgD level J:255203
\Ighdtm1Cgn/\Ighdtm1Cgn
(involves: 129P2/OlaHsd * C57BL/6)
abnormal immune system physiology J:64281
decreased IgE level J:64281
\Ighdtm1Lam/\Ighd+
(involves: 129S2/SvPas * C57BL/6)
decreased B cell number J:111020
\Ighdtm1Lam/\Ighdtm1Lam
(involves: 129S2/SvPas * C57BL/6)
abnormal B cell physiology J:111020
abnormal leukopoiesis J:111020
decreased IgG2b level J:111020
increased IgA level J:111020
\IgheM1Btlr/\IgheM1Btlr
(C57BL/6J-IgheM1Btlr)
decreased IgE level J:267480
\Ighg1em1Wliu/\Ighg1em1Wliu
(C57BL/6-Ighg1em1Wliu)
abnormal plasma cell differentiation J:266937
enhanced humoral immune response J:266937
increased anti-double stranded DNA antibody level J:266937
increased anti-nuclear antigen antibody level J:266937
increased autoantibody level J:266937
increased germinal center B cell number J:266937
increased IgG1 level J:266937
increased plasma cell number J:266937
\Ighg1tm1(cre)Cgn/0
\Mef2btm1.1Rdf/\Mef2b+

(involves: 129P2/OlaHsd * C57BL/6)
decreased germinal center B cell number J:265465
\Ighg1tm1(cre)Cgn/0
\Mef2btm1.1Rdf/\Mef2btm1.1Rdf

(involves: 129P2/OlaHsd * C57BL/6)
abnormal mature B cell morphology J:265465
decreased germinal center B cell number J:265465
\Ighg1tm1(cre)Cgn/0
\Mef2btm1.1Rdf/\Mef2btm1.1Rdf
\Mef2ctm2Eno/\Mef2ctm2Eno

(involves: 129P2/OlaHsd * 129S/SvEv * C57BL/6)
decreased germinal center B cell number J:265465
\Ighg1tm1(cre)Cgn/0
\Mef2btm2Rdf/\Mef2b+

(involves: 129P2/OlaHsd * C57BL/6)
abnormal mature B cell morphology J:265465
increased germinal center B cell number J:265465
\Ighg1tm1(cre)Cgn/0
\Mef2btm2Rdf/\Mef2btm1.1Rdf

(involves: 129P2/OlaHsd * C57BL/6)
abnormal mature B cell morphology J:265465
increased germinal center B cell number J:265465
\Ighg1tm1(cre)Cgn/0
\Mef2ctm2Eno/\Mef2ctm2Eno

(involves: 129P2/OlaHsd * 129S/SvEv * C57BL/6)
decreased germinal center B cell number J:265465
\Ighg1tm1(cre)Cgn/\Ighg1+
\Irf4tm1Rdf/\Irf4tm1.1Rdf

(involves: 129P2/OlaHsd * 129S1/Sv * 129S4/SvJaeSor * C57BL/6)
abnormal class switch recombination J:112643
abnormal memory B cell morphology J:112643
absent plasma cells J:112643
decreased IgG1 level J:112643
immune system phenotype J:112643
\Ighg1tm1(cre)Cgn/\Ighg1+
\Myd88em1.1Rsky/\Myd88+

(involves: 129P2/OlaHsd * C57BL/6NTac)
abnormal somatic hypermutation frequency J:308792
abnormal splenic cell ratio J:308792
increased germinal center B cell number J:308792
increased IgM level J:308792
increased plasma cell number J:308792
\Ighg1tm1(cre)Cgn/\Ighg1+
\Tbl1xr1tm1.1Meln/\Tbl1xr1+

(involves: 129P2/OlaHsd * C57BL/6J)
abnormal B cell differentiation J:292118
abnormal spleen morphology J:292118
\Ighg1tm1(cre)Cgn/\Ighg1+
\Tbl1xr1tm1c(EUCOMM)Hmgu/\Tbl1xr1tm1c(EUCOMM)Hmgu

(involves: 129P2/OlaHsd * C57BL/6J)
abnormal B cell differentiation J:292118
abnormal spleen morphology J:292118
\Ighg1tm1.1Ksho/\Ighg1+
(involves: 129P2/OlaHsd * C57BL/6)
abnormal B cell physiology J:39568
decreased IgG1 level J:39568
\Ighg1tm1.1Ksho/\Ighg1tm1.1Ksho
(involves: 129P2/OlaHsd * C57BL/6)
abnormal B cell physiology J:39568
decreased IgG1 level J:39568
\Ighg1tm1.1Pyu/\Ighg1+
(B6.C(Cg)-Ighg1tm1.1Pyu)
decreased IgG1 level J:198154
decreased IgG2c level J:198154
immune system phenotype J:198154
increased IgE level J:198154
increased IgG2a level J:198154
increased susceptibility to type I hypersensitivity reaction J:198154
\Ighg1tm1.1Pyu/\Ighg1tm1.1Pyu
(B6.C(Cg)-Ighg1tm1.1Pyu)
decreased IgG1 level J:198154
decreased IgG2c level J:198154
immune system phenotype J:198154
increased IgE level J:198154
increased IgG2a level J:198154
increased IgG2b level J:198154
increased susceptibility to type I hypersensitivity reaction J:198154
\Ighg1tm1Ksho/\Ighg1+
(involves: 129P2/OlaHsd * C57BL/6)
abnormal B cell physiology J:39568
decreased IgG1 level J:39568
\Ighg1tm1Ksho/\Ighg1tm1Ksho
(involves: 129P2/OlaHsd * C57BL/6)
abnormal B cell physiology J:39568
absent memory B cells J:39568
decreased IgG1 level J:39568
\Ighg1tm2Cgn/\Ighg1+
((C57BL/6 x 129P2/OlaHsd)F1)
abnormal class switch recombination J:146428
decreased IgG1 level J:146428
\Ighg1tm3Cgn/\Ighg1+
(involves: 129P2/OlaHsd * BALB/c * C57BL/6)
abnormal class switch recombination J:166887
decreased IgG1 level J:166887
\Ighg1tm4Cgn/\Ighg1tm4Cgn
(involves: 129P2/OlaHsd * C57BL/6)
immune system phenotype J:166887
\Ighg2cem1Wliu/\Ighg2cem1Wliu
(C57BL/6J-Ighg2cem1Wliu)
abnormal dendritic cell physiology J:322180
abnormal macrophage activation involved in immune response J:322180
abnormal macrophage physiology J:322180
abnormal plasma cell differentiation J:322180
decreased susceptibility to induced colitis J:322180
increased CD8-positive, alpha-beta T cell number J:322180
increased CD103-positive CD11b-low dendritic cell number J:322180
increased effector memory CD8-positive, alpha-beta T cell number J:322180
increased germinal center B cell number J:322180
increased IgG2c level J:322180
increased memory B cell number J:322180
\Ighg2cem2Wliu/\Ighg2cem2Wliu
(C57BL/6J-Ighg2cem2Wliu)
abnormal macrophage activation involved in immune response J:322180
abnormal plasma cell differentiation J:322180
decreased germinal center B cell number J:322180
decreased IgG2c level J:322180
decreased memory B cell number J:322180
impaired macrophage phagocytosis J:322180
\Ighmtm1(Bcl6)Rdf/?
(involves: 129/Sv * C57BL/6)
abnormal B cell proliferation J:98937
abnormal spleen B cell follicle morphology J:98937
abnormal spleen morphology J:98937
decreased immunoglobulin level J:98937
decreased plasma cell number J:98937
enlarged spleen J:98937
increased spleen germinal center number J:98937
increased spleen white pulp amount J:98937
\Ighmtm1.1(IGH-2)Cog/\Ighmtm1.1(IGH-2)Cog
(involves: 129P2/OlaHsd * C57BL/6 * FVB/N)
abnormal B cell differentiation J:157575
abnormal plasma cell differentiation J:157575
decreased B cell number J:157575
decreased B cell proliferation J:157575
decreased B-1 B cell number J:157575
decreased follicular B cell number J:157575
decreased IgA level J:157575
decreased IgG1 level J:157575
decreased IgG2a level J:157575
decreased IgG3 level J:157575
decreased IgG level J:157575
decreased IgM level J:157575
decreased marginal zone B cell number J:157575
decreased mature B cell number J:157575
decreased Peyer's patch number J:157575
decreased pre-B cell number J:157575
decreased transitional stage B cell number J:157575
immune system phenotype J:157575
increased B cell number J:157575
increased B cell proliferation J:157575
increased plasma cell number J:157575
increased pro-B cell number J:157575
small lymph nodes J:157575
small Peyer's patches J:157575
\Ighmtm1.1Aak/\Ighmtm1.1Aak
(involves: 129S2/SvPas * C57BL/6)
abnormal class switch recombination J:171251
decreased B cell number J:171251
decreased pre-B cell number J:171251
immune system phenotype J:171251
increased pro-B cell number J:171251
\Ighmtm1Bhe/\Ighmtm1Bhe
(C.Cg-Ighmtm1Bhe)
abnormal complement pathway J:177421
abnormal immune serum protein physiology J:177421
impaired complement classical pathway J:177421
\Ighmtm1Cgn/\Ightm3Tim
(involves: 129 * C57BL/6)
abnormal B cell differentiation J:102308
decreased B cell number J:102308
\Ighmtm1Cgn/\Ighm+
(NOD.129S2-Ighmtm1Cgn)
increased susceptibility to autoimmune diabetes J:37287
\Ighmtm1Cgn/\Ighm+
(involves: 129S2/SvPas * C57BL/6)
arrested B cell differentiation J:70398
\Ighmtm1Cgn/\Ighm+
\Tg(Igh-6/Igh-V125)2Jwt/0
\Tg(Igk-C/Igk-V125)1Jwt/0

(NOD.Cg-Ighmtm1Cgn Tg(Igh-6/Igh-V125)2Jwt Tg(Igk-C/Igk-V125)1Jwt)
increased susceptibility to autoimmune diabetes J:91865
insulitis J:91865
\Ighmtm1Cgn/\Ighm+
\Tg(Igh-6/Igh-V281)3Jwt/0

(NOD.Cg-Ighmtm1Cgn Tg(Igh-6/Igh-V281)3Jwt)
insulitis J:91865
\Ighmtm1Cgn/\Ighm+
\Tgfb1tm1Doe/\Tgfb1tm1Doe

(involves: 129S2/SvPas * C57BL/6 * CF-1)
thymus hypoplasia J:99033
\Ighmtm1Cgn/\Ighmtm1Cgn
(involves: 129S2/SvPas * C57BL/6)
abnormal B cell differentiation J:64298, J:70398
abnormal lymphatic vessel morphology J:119344
abnormal response to infection J:119344
absent immature B cells J:64298
absent mature B cells J:64298
arrested B cell differentiation J:64298
decreased IgM level J:64298
immune system phenotype J:113083
\Ighmtm1Cgn/\Ighmtm1Cgn
(NODCaj.129S2-Ighmtm1Cgn)
insulitis J:93190
\Ighmtm1Cgn/\Ighmtm1Cgn
(NOD.129S2-Ighmtm1Cgn)
decreased susceptibility to autoimmune diabetes J:37287
\Ighmtm1Cgn/\Ighmtm1Cgn
(B6.129S2-Ighmtm1Cgn/J)
abnormal cytokine secretion J:118565
abnormal humoral immune response J:119584
abnormal spleen morphology J:73100
arrested B cell differentiation J:119584
decreased CD4-positive, alpha-beta T cell number J:73100, J:118565
decreased CD8-positive, alpha-beta T cell number J:73100
decreased dendritic cell number J:73100
decreased IgE level J:125656
decreased IgG1 level J:125656
decreased IgG level J:119584, J:125656
decreased immunoglobulin level J:119584
decreased spleen weight J:73100
immune system phenotype J:73100, J:118565
increased susceptibility to parasitic infection J:74568
\Ighmtm1Cgn/\Ighmtm1Cgn
(involves: 129S2/SvPas)
abnormal antigen presentation J:112160
abnormal CD4-positive, alpha-beta T cell physiology J:112160
abnormal metallophilic macrophage morphology J:88620
abnormal spleen marginal sinus morphology J:88620
abnormal spleen marginal zone macrophage morphology J:88620
absent follicular dendritic cells J:88620
absent mature B cells J:118453
arrested B cell differentiation J:118453
decreased IgA level J:157450
decreased IgG level J:157450
decreased susceptibility to type IV hypersensitivity reaction J:112160
decreased T cell proliferation J:112160
increased osteoclast cell number J:157619
increased susceptibility to induced arthritis J:157619
increased susceptibility to parasitic infection J:163761
\Ighmtm1Cgn/\Ighmtm1Cgn
(B6.129S2-Ighmtm1Cgn)
abnormal CD8 positive, alpha-beta intraepithelial T cell morphology J:126867
\Ighmtm1Cgn/\Ighmtm1Cgn
(NOD.129S2-Ighmtm1Cgn/DvsJ)
abnormal T cell number J:80859
abnormal T cell proliferation J:80859
absent B cells J:80859
decreased spleen B cell follicle number J:80859
decreased susceptibility to autoimmune diabetes J:80859
\Ighmtm1Cgn/\Ighmtm1Cgn
\Igkctm1Bgmn/\Igkctm1Bgmn
\Igltm2.1Bgmn/\Igltm2.1Bgmn

(involves: 129)
decreased IgG level J:130864
decreased IgM level J:130864
\Ighmtm1Cgn/\Ighmtm1Cgn
\Nlrp1aNeut1/\Nlrp1aNeut1

(involves: 129S2/SvPas * C57BL/6)
immune system phenotype J:191055
\Ighmtm1Cgn/\Ighmtm1Cgn
\Tg(Igh-6/Igh-V125)2Jwt/0
\Tg(Igk-C/Igk-V125)1Jwt/0

(NOD.Cg-Ighmtm1Cgn Tg(Igh-6/Igh-V125)2Jwt Tg(Igk-C/Igk-V125)1Jwt)
insulitis J:91865
\Ighmtm1Cgn/\Ighmtm1Cgn
\Tg(Igh-6/Igh-V281)3Jwt/0

(NOD.Cg-Ighmtm1Cgn Tg(Igh-6/Igh-V281)3Jwt)
insulitis J:91865
\Ighmtm1Cgn/\Ighmtm1Cgn
\Tg(Igh-VB1-8/Igh-6m)1Mjsk/?

(NODCaj.Cg-Ighmtm1Cgn Tg(Igh-VB1-8/Igh-6m)1Mjsk/FswJ)
increased susceptibility to autoimmune diabetes J:93190
\Ighmtm1Cgn/\Ighmtm1Cgn
\Tg(IghelMD4)4Ccg/\Tg(IghelMD4)4Ccg

(NOD.Cg-Ighmtm1Cgn Tg(IghelMD4)4Ccg/DvsJ)
abnormal B lymphocyte antigen presentation J:80859
abnormal mature B cell morphology J:80859
abnormal T cell proliferation J:80859
decreased CD8-positive, alpha-beta T cell number J:80859
decreased susceptibility to autoimmune diabetes J:80859
insulitis J:80859
\Ighmtm1Cgn/\Ighmtm1Cgn
\Tg(TcraR28,TcrbR28)KRNDim/0

(involves: 129S2/SvPas * C57BL/6 * NOD * SJL)
immune system phenotype J:36815
\Ighmtm1Cgn/\Ighmtm1Cgn
\Tgfb1tm1Doe/\Tgfb1tm1Doe

(involves: 129S2/SvPas * C57BL/6 * CF-1)
abnormal inflammatory response J:99033
thymus hypoplasia J:99033
\Ighmtm1Cgn/\Ighmtm1Cgn
\Tnftm2Gkl/\Tnf+

(involves: 129S/SvEv * 129S2/SvPas * C57BL/6J)
small intestinal inflammation J:108572
\Ighmtm1Cgn/\Ighmtm1Cgn
\Trex1tm1Tld/\Trex1tm1Tld

(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6)
increased inflammatory response J:181257
kidney inflammation J:181257
myocarditis J:181257
tubular nephritis J:181257
\Ighmtm1Cgn/\Ighmtm1Cgn
X/\Yaa

(BXSB.129S2(B6)-Ighmtm1Cgn/Dcr)
decreased susceptibility to systemic lupus erythematosus J:206236
\Ighmtm1Che/\Ighmtm1Che
(involves: 129S4/SvJae * C57BL/6)
abnormal B cell physiology J:47425
abnormal follicular dendritic cell antigen presentation J:47425
abnormal humoral immune response J:47425
abnormal immune system physiology J:47425
abnormal metallophilic macrophage morphology J:125338
abnormal spleen B cell follicle morphology J:125338
abnormal spleen germinal center morphology J:47425
abnormal spleen marginal zone morphology J:125338
abnormal spleen morphology J:125338
abnormal spleen periarteriolar lymphoid sheath morphology J:125338
abnormal spleen white pulp morphology J:125338
decreased IgG1 level J:47425
decreased IgG2b level J:47425
decreased IgM level J:47425
increased B-1 B cell number J:47425
increased IgA level J:47425
increased IgG2a level J:47425
increased IgG3 level J:47425
\Ighmtm1Che/\Ighmtm1Che
(involves: 129 * C57BL/6)
increased susceptibility to parasitic infection J:74568
\Ighmtm1Fbb/\Ighmtm1Fbb
(involves: BALB/cJ)
immune system phenotype J:57600
increased susceptibility to Riboviria infection J:57600
\Ighmtm1Msn/\Ighm+
(involves: 129S/SvEv)
decreased IgM level J:49405
\Ighmtm1Msn/\Ighmtm1Msn
(involves: 129S/SvEv)
abnormal B-1a B cell morphology J:49405
abnormal immature B cell morphology J:49405
abnormal mature B cell morphology J:49405
decreased IgG1 level J:49405
decreased IgM level J:49405
increased IgG3 level J:49405
\Ighmtm1Msn/\Ighmtm1Msn
(involves: 129S/SvEv * C57BL/6)
increased anti-double stranded DNA antibody level J:111817
increased autoantibody level J:111817
kidney inflammation J:111817
\Ighmtm1Msn/\Ighmtm1Msn
(B6.129S-Ighmtm1Msn)
abnormal B-1a B cell morphology J:80656
abnormal splenic cell ratio J:80656
decreased follicular B cell number J:80656
decreased IgM level J:80656
increased marginal zone B cell number J:80656
\Ighmtm1Msn/\Ighmtm1Msn
\Tg(Igh-6)1Msn/?

(B6.129S-Ighmtm1Msn)
abnormal B-1a B cell morphology J:80656
abnormal splenic cell ratio J:80656
decreased follicular B cell number J:80656
decreased IgM level J:80656
increased marginal zone B cell number J:80656
\Ighmtm1Sls/\Ighmtm1Sls
(Not Specified)
abnormal class switch recombination J:99465
decreased IgG1 level J:99465
decreased IgG2b level J:99465
decreased IgG3 level J:99465
decreased IgG level J:99465
increased IgM level J:99465
\Ighmtm2.1Bgmn/\Ighmtm2.1Bgmn
(involves: 129/Sv * C57BL/6 * CBA)
abnormal immune system physiology J:118453
absent mature B cells J:118453
arrested B cell differentiation J:118453
decreased immunoglobulin level J:118453
\Ighmtm3Bgmn/\Ighmtm3Bgmn
(involves: 129)
abnormal B cell activation J:131633
decreased B cell proliferation J:131633
decreased IgM level J:131633
decreased immature B cell number J:131633
decreased mature B cell number J:131633
increased B-1 B cell number J:131633
\Ighmtm3Bgmn/\Ighmtm3Bgmn
\Igkctm1Bgmn/\Igkctm1Bgmn
\Igltm2.1Bgmn/\Igltm2.1Bgmn

(involves: 129P2/OlaHsd * 129/Sv)
abnormal B cell differentiation J:130864
decreased IgG level J:130864
decreased IgM level J:130864
\Ighmtm4Bgmn/\Ighmtm4Bgmn
(involves: 129)
abnormal B cell activation J:131633
decreased B cell proliferation J:131633
decreased IgM level J:131633
decreased immature B cell number J:131633
decreased mature B cell number J:131633
increased B-1 B cell number J:131633
\Igk-Jtm1.1Lave/\Igk-Jtm1.1Lave
(Not Specified)
immune system phenotype J:179317
\Igk-Jtm1Cog/\Igk-Jtm1.1Cog
(involves: 129P2/OlaHsd * C57BL/6)
abnormal B cell number J:110100
abnormal plasma cell morphology J:110100
decreased B cell number J:110100
decreased naive B cell number J:110100
immune system phenotype J:110100
increased plasma cell number J:110100
increased pre-B cell number J:110100
\Igk-Jtm1Cog/\Igk-Jtm1Cog
(involves: 129P2/OlaHsd * C57BL/6)
abnormal B cell physiology J:110100
decreased B cell number J:110100
\Igk-Jtm1Mwg/\Igktm1Dhu
(involves: 129S7/SvEvBrd * C57BL/6)
immune system phenotype J:76116
\Igk-Jtm2Mwg/\Igktm1Dhu
(involves: 129P2/OlaHsd * 129S7/SvEvBrd)
immune system phenotype J:76116
\Igktm1.1(b12)Nemz/\Igktm1.1(b12)Nemz
(involves: C57BL/6NTac * FVB/N)
immune system phenotype J:205766
\Igktm1Dhu/\Igktm1Dhu
\Iglc1tm1.1Ust/\Iglc1+

(involves: 129S7/SvEvBrd * C57BL/6 * FVB/N)
decreased B cell number J:68144
\Igktm1Dhu/\Igktm1Dhu
\Iglc1tm1.1Ust/\Iglc1tm1.1Ust

(involves: 129S7/SvEvBrd * C57BL/6 * FVB/N)
decreased B cell number J:68144
\Igktm1Dhu/\Igktm1Dhu
\Iglc1tm1Ust/\Iglc1+

(involves: 129S7/SvEvBrd * C57BL/6)
abnormal B cell differentiation J:68144
increased B cell number J:68144
\Igktm1Dhu/\Igktm1Dhu
\Iglc1tm1Ust/\Iglc1tm1Ust

(involves: 129S7/SvEvBrd * C57BL/6)
increased B cell number J:68144
\Igktm1Dhu/\Igktm1Dhu
\Iglc1tm2Ust/\Iglc1tm2Ust

(involves: 129S7/SvEvBrd * C57BL/6J)
abnormal B cell differentiation J:74717
decreased B cell number J:74717
decreased immature B cell number J:74717
decreased marginal zone B cell number J:74717
decreased mature B cell number J:74717
decreased transitional stage T1 B cell number J:74717
decreased transitional stage T2 B cell number J:74717
\Igktm1Dhu/\Igktm1Dhu
\Iglc1tm2Ust/\Iglc1tm2Ust

(involves: 129S7/SvEvBrd)
increased B-1a cell number J:113218
\Igktm1Dhu/\Igktm1Dhu
\Tg(H2-Ea-HA)HACIIAjca/0
\Tg(Tcra/Tcrb)1Vbo/0

(C.Cg-Igktm1Dhu Tg(H2-Ea-HA)HACIIAjca Tg(Tcra/Tcrb)1Vbo)
autoimmune arthritis J:209872
\Igktm1Dhu/\Igktm1Dhu
\Tg(H2-Ea-HA)HACIIAjca/0
\Tg(TcraS106-1,TcrbS106-1)TS1SWAjca/0

(C.Cg-Igktm1Dhu Tg(H2-Ea-HA)HACIIAjca Tg(TcraS106-1,TcrbS106-1)TS1SWAjca)
abnormal CD4-positive, alpha beta T cell morphology J:209872
abnormal lymph node morphology J:209872
abnormal spleen morphology J:209872
absent B cells J:209872
decreased susceptibility to autoimmune disorder J:209872
increased CD4-positive, alpha-beta T cell number J:209872
\Igktm1Rsky/\Igk+
\Igll1tm1Cgn/\Igll1tm1Cgn

(involves: 129P2/OlaHsd * 129S2/SvPas * BALB/c * C57BL/6)
abnormal B cell differentiation J:35357
decreased B cell number J:35357
decreased immature B cell number J:35357
decreased mature B cell number J:35357
decreased pre-B cell number J:35357
\Igktm2Ybgn/\Igktm2Ybgn
(Not Specified)
decreased pre-B cell number J:123344
increased immature B cell number J:123344
\Igkctm1(IGKC)Mnz/\Igkc+
\Igk-Jtm1(CD4*)Mss/\Igk-J+

(involves: 129S4/SvJae)
abnormal immunoglobulin light chain V-J recombination J:143876
\Igkctm1(IGKC)Mnz/\Igkc+
\Rr158tm1(Igh)Xu/\Rr158+

(Not Specified)
abnormal immune system morphology J:124407
decreased B cell number J:124407
\Igkctm1(IGKC)Mnz/\Rr166tm4.1Wtg
(involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6)
abnormal B cell physiology J:193015
abnormal immunoglobulin level J:193015
\Igkctm1Bgmn/\Igkctm1Bgmn
(involves: 129P2/OlaHsd)
abnormal B cell number J:28868, J:118712
abnormal humoral immune response J:28868
abnormal Peyer's patch germinal center morphology J:28868
abnormal Peyer's patch morphology J:28868
\Igkctm1Bgmn/\Igkctm1Bgmn
\Igltm1.1Bgmn/\Igltm1.1Bgmn

(involves: 129P2/OlaHsd * BALB/c * C57BL/6 * CBA)
abnormal immature B cell morphology J:118712
absent B cells J:118712
absent B-1 B cells J:118712
absent B-2 B cells J:118712
decreased B cell number J:118712
spleen hypoplasia J:118712
\Igkctm1Bgmn/\Igkctm1Bgmn
\Igltm1Bgmn/\Igltm1Bgmn

(involves: 129P2/OlaHsd * BALB/c * C57BL/6 * CBA)
abnormal immature B cell morphology J:118712
absent B-1 B cells J:118712
absent B-2 B cells J:118712
absent mature B cells J:118712
decreased B cell number J:118712
spleen hypoplasia J:118712
\Igkctm1Bgmn/\Igkctm1Bgmn
\Igltm2.1Bgmn/\Igltm2.1Bgmn

(involves: 129P2/OlaHsd * BALB/c * C57BL/6 * CBA)
absent B cells J:118712
arrested B cell differentiation J:118712
\Igkctm1Bgmn/\Igkctm1Bgmn
\Igltm2.1Bgmn/\Igltm2.1Bgmn

(involves: 129P2/OlaHsd)
abnormal B cell differentiation J:130864
abnormal immunoglobulin heavy chain V(D)J recombination J:130864
abnormal plasma cell morphology J:130864
decreased IgG level J:130864
decreased IgM level J:130864
\Igkctm1Bgmn/\Igkctm1Bgmn
\Igltm2Bgmn/\Igltm2Bgmn

(involves: 129P2/OlaHsd * BALB/c * C57BL/6 * CBA)
absent B cells J:118712
arrested B cell differentiation J:118712
\Igkctm1Cgn/\Igkc+
(involves: C57BL/6)
increased mature B cell number J:64287
\Igkctm1Cgn/\Igkctm1Cgn
(involves: C57BL/6)
abnormal B cell differentiation J:64287
decreased mature B cell number J:64287
increased immature B cell number J:64287
increased mature B cell number J:64287
spleen hypoplasia J:64287
\Igkctm1Jkbv/\Igkctm1Jkbv
(Not Specified)
abnormal B cell differentiation J:137738
abnormal immunoglobulin level J:137738
abnormal immunoglobulin light chain V-J recombination J:137738
decreased immature B cell number J:137738
decreased mature B cell number J:137738
increased pre-B cell number J:137738
\Igkctm1Jkbv/\Igkctm1Jkbv
\Tg(IGK@yK1)9.2CJkbv/0

(involves: 129P2/OlaHsd)
abnormal immunoglobulin level J:137738
decreased immature B cell number J:137738
decreased mature B cell number J:137738
increased pre-B cell number J:137738
\Igkctm1Jkbv/\Igkctm1Jkbv
\Tg(IGK@yK1)9.2CJkbv/\Tg(IGK@yK1)9.2CJkbv

(involves: 129P2/OlaHsd)
abnormal B cell differentiation J:137738
abnormal immunoglobulin level J:137738
decreased immature B cell number J:137738
decreased mature B cell number J:137738
increased pre-B cell number J:137738
\Igkctm1Jkbv/\Igkctm1Jkbv
\Tg(IGK@yK2)J23.1Jkbv/0

(involves: 129P2/OlaHsd)
abnormal B cell morphology J:137738
abnormal immunoglobulin level J:137738
immune system phenotype J:137738
\Igkctm1Jkbv/\Igkctm1Jkbv
\Tg(IGK@yK2)J23.1Jkbv/\Tg(IGK@yK2)J23.1Jkbv

(involves: 129P2/OlaHsd)
abnormal B cell morphology J:137738
immune system phenotype J:137738
\Igkctm2(IGKC)Cgn/\Igkctm2(IGKC)Cgn
(involves: 129P2/OlaHsd)
abnormal B cell differentiation J:113008
immune system phenotype J:113008
\Igkctm2(IGKC)Cgn/\Igkctm2(IGKC)Cgn
\Ighg1tm1(IGHG1)Rsky/\Ighg1tm1(IGHG1)Rsky

(involves: 129P2/OlaHsd)
immune system phenotype J:127217
\Igkrstm1Nemz/\Igkrstm1Nemz
(B6.129-Igkrstm1Nemz)
abnormal immunoglobulin light chain V-J recombination J:132125
decreased immature B cell number J:132125
decreased mature B cell number J:132125
\Igkrstm1Nemz/\Igkrstm1Nemz
\Tg(BCL2)22Wehi/?

(involves: 129 * C57BL)
increased anti-double stranded DNA antibody level J:132125
\Igkrstm1Nemz/\Igkrstm1Nemz
\Tg(UBC-scFv)2Nemz/?

(involves: 129 * C57BL/6 * DBA/2)
abnormal B cell clonal deletion J:132125
decreased immature B cell number J:132125
decreased mature B cell number J:132125
\Igltm1Cgn/\Igltm1Cgn
(involves: C57BL/6)
immune system phenotype J:83289
\Iglc1tm1Ust/\Iglc1tm1Ust
(involves: 129S7/SvEvBrd * C57BL/6)
abnormal B cell number J:68144
increased lymphocyte cell number J:68144
\Iglc1tm2Ust/\Iglc1+
(involves: 129S7/SvEvBrd * C57BL/6J)
abnormal immunoglobulin light chain V-J recombination J:74717
\Iglc1tm2Ust/\Iglc1tm2Ust
(involves: 129S7/SvEvBrd)
decreased B cell number J:113218
\Iglc1tm2Ust/\Iglc1tm2Ust
\Ptpn6me-v/\Ptpn6me-v

(involves: 129S7/SvEvBrd * C57BL/6J)
decreased B cell number J:113218
\Igll1tm1Cgn/\Igll1tm1Cgn
(involves: 129S2/SvPas * C57BL/6)
abnormal B cell morphology J:64284
abnormal B-1 B cell number J:64284
abnormal lymphopoiesis J:64284
abnormal pre-B cell morphology J:64284
decreased B cell number J:64284, J:35357
decreased IgG1 level J:64284
decreased IgG2b level J:64284
decreased IgG3 level J:64284
decreased IgG level J:64284
increased pro-B cell number J:64284
spleen hypoplasia J:64284
\Igll1tm1Cgn/\Igll1tm1Cgn
\Tg(Igk-V4CH27)1-2Shc/0

(involves: 129S2/SvPas * BALB/c * C57BL/6 * SJL)
abnormal B cell differentiation J:35357
decreased pre-B cell number J:35357
\Igll1tm1Shim/\Igll1tm1Shim
\Vpreb1atm1Shim/\Vpreb1atm1Shim
\Vpreb1btm1Shim/\Vpreb1btm1Shim

(involves: 129P2/OlaHsd * C57BL/6)
abnormal B cell differentiation J:76947
decreased B cell number J:76947
decreased B-1a cell number J:76947
decreased immature B cell number J:76947
decreased mature B cell number J:76947
decreased pre-B cell number J:76947
immune system phenotype J:76947
increased late pro-B cell number J:76947
\Iglon5em1(IMPC)Mbp/\Iglon5em1(IMPC)Mbp
(C57BL/6NCrl-Iglon5em1(IMPC)Mbp/Mmucd)
abnormal spleen morphology J:211773
enlarged lymph nodes J:211773
enlarged spleen J:211773
\Ignpq1BALB/cAJcl/\Ignpq1HIGA/Nsc
(involves: BALB/cAJcl * HIGA/Nsc)
increased IgA level J:116904
\Ignpq1HIGA/Nsc/\Ignpq1HIGA/Nsc
(involves: BALB/cAJcl * HIGA/Nsc)
increased IgA level J:116904
\Ignpq2BALB/cAJcl/\Ignpq2HIGA/Nsc
(involves: BALB/cAJcl * HIGA/Nsc)
increased IgA level J:116904
\Ignpq2HIGA/Nsc/\Ignpq2HIGA/Nsc
(involves: BALB/cAJcl * HIGA/Nsc)
increased IgA level J:116904
\Ignpq3BALB/cAJcl/\Ignpq3HIGA/Nsc
(involves: BALB/cAJcl * HIGA/Nsc)
glomerulonephritis J:116904
\Ignpq3HIGA/Nsc/\Ignpq3HIGA/Nsc
(involves: BALB/cAJcl * HIGA/Nsc)
glomerulonephritis J:116904
\Igs2em1(Alb-Golm1)Jdon/\Igs2+
(involves: C57BL/6N)
decreased CD8-positive, alpha-beta T cell number J:306528
\Igs2tm1(CAG-Ptgs2os)Scrp/\Igs2tm1(CAG-Ptgs2os)Scrp
(involves: C57BL/6)
abnormal circulating cytokine level J:325487
increased circulating interleukin-10 level J:325487
\Igs2tm1(CAG-Ptgs2os)Scrp/\Igs2tm1(CAG-Ptgs2os)Scrp
\Ptgs2osem1Scrp/\Ptgs2osem1Scrp

(involves: C57BL/6)
immune system phenotype J:325487
\Igtpem1Myam/\Igtpem1Myam
\Irgm1em1Myam/\Irgm1em1Myam

(C57BL/6-Irgm1em1Myam Igtpem1Myam)
increased susceptibility to parasitic infection J:308470
\Igtpem1Myam/\Igtpem1Myam
\Irgm1em1Myam/\Irgm1em1Myam
\Irgm2em2Myam/\Irgm2em2Myam

(C57BL/6-Irgm1em1Myam Igtpem1Myam Irgm2em2Myam)
increased susceptibility to parasitic infection J:308470
\Igtptm1Gvw/\Igtptm1Gvw
(involves: 129S1/Sv * C57BL/6)
immune system phenotype J:59891
increased circulating interferon-gamma level J:59891
increased circulating interleukin-12b level J:59891
increased susceptibility to parasitic infection J:99144, J:59891
\Iigp1tm1.1Jcho/\Iigp1tm1.1Jcho
(involves: C57BL/6)
increased susceptibility to parasitic infection J:135070
\Iigp1cem1(IMPC)Hmgu/\Iigp1cem1(IMPC)Hmgu
(C57BL/6N-Iigp1cem1(IMPC)Hmgu/Ieg)
abnormal lymph node morphology J:211773
\Ikbipem1Bcgen/\Ikbipem1Bcgen
\Lyz2tm1(cre)Ifo/\Lyz2+

(involves: 129P2/OlaHsd)
abnormal cytokine level J:282971
decreased macrophage cytokine production J:282971
increased circulating interleukin-6 level J:282971
increased circulating tumor necrosis factor level J:282971
increased susceptibility to bacterial infection induced morbidity/mortality J:282971
increased susceptibility to induced colitis J:282971
lung inflammation J:282971
\Ikbkbem1Macc/\Ikbkb+
(involves: C57BL/6NCrl)
abnormal effector T cell number J:290616
abnormal T cell activation J:290616
decreased B cell number J:290616
decreased CD4-positive, alpha-beta T cell number J:290616
decreased CD8-positive, alpha-beta T cell number J:290616
decreased memory B cell number J:290616
decreased T cell number J:290616
increased regulatory T cell number J:290616
\Ikbkbem1Macc/\Ikbkbem1Macc
(involves: C57BL/6NCrl)
abnormal effector T cell number J:290616
abnormal T cell activation J:290616
decreased B cell number J:290616
decreased CD4-positive, alpha-beta T cell number J:290616
decreased CD8-positive, alpha-beta T cell number J:290616
decreased memory B cell number J:290616
decreased T cell number J:290616
increased regulatory T cell number J:290616
\Ikbkbem1Smoc/\Ikbkbem1Smoc
(C57BL/6J-Ikbkbem1Smoc)
decreased CD4-positive, CD25-positive, alpha-beta regulatory T cell number J:309163
\IkbkbM1Btlr/\Ikbkb+
(C57BL/6J-IkbkbM1Btlr)
abnormal B cell physiology J:225271
abnormal CD8-positive, alpha-beta T cell differentiation J:225271
abnormal response to infection J:225271
increased response to antigen J:225271
\IkbkbM1Btlr/\IkbkbM1Btlr
(C57BL/6J-IkbkbM1Btlr)
abnormal B cell physiology J:225271
abnormal CD8-positive, alpha-beta T cell differentiation J:225271
increased susceptibility to viral infection J:225271
\IkbkbM2Btlr/\IkbkbM2Btlr
(C57BL/6J-IkbkbM2Btlr)
decreased central memory CD4-positive, alpha-beta T cell number J:274802
\Ikbkbtm1.1Cgn/\Ikbkbtm1.1Cgn
(involves: C57BL/6)
decreased interleukin-6 secretion J:79132, J:85810
\Ikbkbtm1Cgn/\Ikbkbtm1.1Cgn
\Tg(Cd4-cre)1Cwi/0

(involves: C57BL/6 * DBA/2)
decreased CD4-positive, alpha-beta T cell number J:85810
decreased CD8-positive, alpha-beta T cell number J:85810
decreased single-positive T cell number J:85810
decreased T cell number J:85810
\Ikbkbtm1Cgn/\Ikbkbtm1Cgn
\Il20ratm1Rsab/\Il20ratm1Rsab
\Tg(KRT14-cre)1Cgn/0

(involves: C57BL/6 * DBA/2)
skin inflammation J:208995
\Ikbkbtm1Cgn/\Ikbkbtm1Cgn
\Il22tm1Jcrd/\Il22tm1Jcrd
\Tg(KRT14-cre)1Cgn/0

(involves: C57BL/6 * DBA/2)
skin inflammation J:208995
\Ikbkbtm1Cgn/\Ikbkbtm1Cgn
\Il22ra1tm1Rsab/\Il22ra1tm1Rsab
\Tg(KRT14-cre)1Cgn/0

(involves: C57BL/6 * DBA/2)
skin inflammation J:208995
\Ikbkbtm1Cgn/\Ikbkbtm1Cgn
\Tg(KRT14-cre)1Cgn/0

(involves: C57BL/6 * DBA/2)
skin inflammation J:208995
\Ikbkbtm1Cgn/\Ikbkbtm1Cgn
\Tg(Lck-cre)I57Jxm/0

(involves: C57BL/6 * ICR)
decreased CD4-positive, alpha-beta T cell number J:85810
decreased CD8-positive, alpha-beta T cell number J:85810
\Ikbkbtm1Cgn/\Ikbkbtm1Cgn
\Tnfrsf1atm2Gkl/\Tnfrsf1atm2Gkl
\Tg(KRT14-cre)1Cgn/0

(involves: 129S/SvEv * C57BL/6 * DBA/2)
skin inflammation J:208995
\Ikbkbtm1Lex/\Ikbkbtm1Lex
\Lyz2tm1(cre)Ifo/\Lyz2+

(involves: 129P2/OlaHsd * 129S/SvEvBrd)
impaired macrophage chemotaxis J:159873
impaired neutrophil chemotaxis J:159873
impaired neutrophil recruitment J:159873
\Ikbkbtm2.1Cgn/\Ikbkbtm2.1Cgn
(involves: C57BL/6)
decreased interleukin-6 secretion J:79132
\Ikbkbtm2Cgn/\Ikbkbtm2.1Cgn
\Tg(Cd4-cre)1Cwi/0

(involves: C57BL/6 * DBA/2)
abnormal humoral immune response J:85810
decreased CD4-positive, alpha-beta T cell number J:85810
decreased CD8-positive, alpha-beta T cell number J:85810
decreased IgE level J:85810
\Ikbkbtm2Cgn/\Ikbkbtm2Cgn
\Tg(Cd4-cre)1Cwi/0

(involves: C57BL/6 * DBA/2)
decreased CD4-positive, alpha-beta T cell number J:85810
decreased memory T cell number J:85810
decreased regulatory T cell number J:85810
\Ikbkbtm2Mka/\Ikbkbtm2.1Mka
\Tg(Vil-cre)1Mka/0

(involves: 129/Sv * C57BL/6)
decreased acute inflammation J:83313
decreased circulating tumor necrosis factor level J:83313
impaired neutrophil recruitment J:83313
\Ikbkbtm2Mka/\Ikbkbtm2Mka
\Lyz2tm1(cre)Ifo/\Lyz2+

(involves: 129/Sv * 129P2/OlaHsd)
increased macrophage apoptosis J:80159
\Ikbketm1Tman/\Ikbketm1Tman
(B6.Cg-Ikbketm1Tman)
increased susceptibility to Orthomyxoviridae infection J:119791
lung inflammation J:119791
\Ikbkgm1Btlr/Y
(C57BL/6J-Ikbkgm1Btlr)
decreased regulatory T cell number J:139558
decreased tumor necrosis factor secretion J:139558
immune system phenotype J:139558
\Ikbkgtm1.1Chtr/Y
\Tg(Alb1-cre)7Gsc/0

(involves: C57BL/6 * FVB/N * SJL)
abnormal NK cell physiology J:151485
abnormal NK T cell physiology J:151485
decreased NK cell number J:151485
decreased NK T cell number J:151485
increased interferon-gamma secretion J:151485
liver inflammation J:151485
\Ikbkgtm1.1Chtr/\Ikbkgtm1.1Chtr
\Tg(Alb1-cre)7Gsc/0

(involves: C57BL/6 * FVB/N * SJL)
abnormal NK cell physiology J:151485
abnormal NK T cell physiology J:151485
decreased NK cell number J:151485
decreased NK T cell number J:151485
increased circulating tumor necrosis factor level J:151485
increased interferon-gamma secretion J:151485
liver inflammation J:151485
\Ikbkgtm1.1Dwat/Y
\Tnfrsf1atm1Imx/\Tnfrsf1atm1Imx

(involves: 129S6/SvEvTac * C57BL/6 * C57BL/6NTac)
immune system phenotype J:202106
liver inflammation J:202106
\Ikbkgtm1.1Dwat/\Ikbkg+
(B6.Cg-Ikbkgtm1.1Dwat)
decreased B cell number J:202106
enlarged spleen J:202106
\Ikbkgtm1.1Mpa/Y
\Tg(Cd4-cre)1Cwi/0

(involves: C57BL/6 * DBA/2)
decreased CD4-positive, alpha-beta T cell number J:85810
decreased CD8-positive, alpha-beta T cell number J:85810
decreased single-positive T cell number J:85810
decreased T cell number J:85810
increased T cell apoptosis J:85810
\Ikbkgtm1.1Mpa/Y
\Tg(Vil1-cre)997Gum/0

(B6.Cg-Ikbkgtm1.1Mpa Tg(Vil1-cre)997Gum)
colitis J:175865
\Ikbkgtm1.1Mpa/\Ikbkgtm1.1Mpa
\Cd79atm1(cre)Reth/\Cd79a+

(involves: BALB/c * C57BL/6)
abnormal B cell differentiation J:113365
decreased B cell number J:113365
decreased mature B cell number J:113365
\Ikbkgtm1.1Mpa/\Ikbkgtm1.1Mpa
\Tg(Alb1-cre)7Gsc/0

(involves: C57BL/6 * FVB/N)
abnormal cytokine secretion J:118336
abnormal inflammatory response J:118336
increased susceptibility to endotoxin shock J:137861
liver inflammation J:118336
\Ikbkgtm1.1Mpa/\Ikbkgtm1.1Mpa
\Tg(Vil1-cre)997Gum/0

(B6.Cg-Ikbkgtm1.1Mpa Tg(Vil1-cre)997Gum)
colitis J:175865
\Ikbkgtm1Dwb/\Ikbkgtm1Dwb
(Not Specified)
abnormal chemokine secretion J:136353
abnormal humoral immune response J:136353
decreased interleukin-6 secretion J:136353
decreased interleukin-12b secretion J:136353
decreased susceptibility to endotoxin shock J:136353
decreased tumor necrosis factor secretion J:136353
\Ikbkgtm1Mak/Y
(involves: 129P2/OlaHsd * C57BL/6)
increased interleukin-6 secretion J:61666
\Ikbkgtm1Mka/\Ikbkg+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)
erythroderma J:63054
small spleen J:63054
small thymus J:63054
\Ikbkgtm1Mpa/Y
(involves: C57BL/6)
decreased interleukin-6 secretion J:63055
decreased tumor necrosis factor secretion J:63055
\Ikbkgtm1Mpa/\Ikbkg+
(involves: C57BL/6)
skin inflammation J:63055
\Ikzf1m1Btlr/\Ikzf1m1Btlr
(C57BL/6J-Ikzf1m1Btlr)
abnormal natural killer cell mediated cytotoxicity J:265249
decreased CD4-positive, CD25-positive, alpha-beta regulatory T cell number J:265249
decreased CD8-positive, naive alpha-beta T cell number J:265249
enhanced humoral immune response J:265249
increased B-1 B cell number J:265249
increased CD4-positive, alpha-beta T cell number J:265249
increased CD8-positive, alpha-beta T cell number J:265249
increased central memory CD4-positive, alpha-beta T cell number J:265249
increased central memory CD8 positive, alpha-beta T cell number J:265249
increased effector memory CD4-positive, alpha-beta T cell number J:265249
increased IgG level J:265249
increased response to antigen J:265249
increased single-positive T cell number J:265249
increased T cell number J:265249
\Ikzf1m2Btlr/\Ikzf1m2Btlr
(C57BL/6J-Ikzf1m2Btlr)
decreased B cell number J:265250
decreased CD4-positive, alpha-beta T cell number J:265250
decreased CD8-positive, naive alpha-beta T cell number J:265250
decreased single-positive T cell number J:265250
decreased T cell number J:265250
increased CD8-positive, alpha-beta T cell number J:265250
increased central memory CD4-positive, alpha-beta T cell number J:265250
increased central memory CD8 positive, alpha-beta T cell number J:265250
increased effector memory CD4-positive, alpha-beta T cell number J:265250
increased effector memory CD8-positive, alpha-beta T cell number J:265250
increased single-positive T cell number J:265250
\Ikzf1m3Btlr/\Ikzf1m3Btlr
(C57BL/6J-Ikzf1m3Btlr)
decreased CD4-positive, alpha-beta T cell number J:265251
increased B-1 B cell number J:265251
increased CD8-positive, alpha-beta T cell number J:265251
increased single-positive T cell number J:265251
increased T cell number J:265251
\Ikzf1plstc/\Ikzf1+
(C57BL/6JSfdAnu-Ikzf1plstc)
abnormal B cell differentiation J:84569
abnormal lymphopoiesis J:84569
abnormal T cell differentiation J:84569
decreased double-negative T cell number J:84569
decreased double-positive T cell number J:84569
decreased mature B cell number J:84569
decreased pre-B cell number J:84569
decreased thymocyte number J:84569
increased pro-B cell number J:84569
increased T cell derived lymphoma incidence J:84569
myeloid hyperplasia J:84569
\Ikzf1plstc/\Ikzf1plstc
(C57BL/6JSfdAnu-Ikzf1plstc)
abnormal granulocyte differentiation J:84569
abnormal lymphopoiesis J:84569
abnormal macrophage differentiation J:84569
abnormal myelopoiesis J:84569
absent pro-B cells J:84569
absent T cells J:84569
arrested B cell differentiation J:84569
decreased granulocyte number J:84569
increased macrophage cell number J:84569
thymus hypoplasia J:84569
\Ikzf1tm1(Pax5)Mbu/\Ikzf1+
\Tg(Lck-cre)1Cwi/0

(involves: 129P2/OlaHsd * C57BL/6)
increased T cell derived lymphoma incidence J:118111
\Ikzf1tm1(Pax5)Mbu/\Ikzf1tm1(Pax5)Mbu
(involves: 129P2/OlaHsd * C57BL/6)
abnormal B cell number J:80815
abnormal dendritic cell morphology J:80815
abnormal T cell differentiation J:80815
\Ikzf1tm1(Pax5)Mbu/\Ikzf1tm1(Pax5)Mbu
\Tg(Mx1-cre)1Cgn/0

(involves: 129P2/OlaHsd * C57BL/6 * CBA)
abnormal T cell differentiation J:80815
arrested T cell differentiation J:80815
increased B cell number J:80815
increased early pro-B cell number J:80815
thymus hypoplasia J:80815
\Ikzf1tm1.1(Pax5)Mbu/\Ikzf1+
(involves: 129P2/OlaHsd * C57BL/6)
abnormal B cell differentiation J:80815
decreased double-positive T cell number J:118111
enlarged lymph nodes J:118111
enlarged spleen J:118111
enlarged thymus J:118111
increased B cell number J:80815
increased pro-B cell number J:80815
increased T cell derived lymphoma incidence J:118111
thymus hypoplasia J:118111
\Ikzf1tm1.1(Pax5)Mbu/\Ikzf1+
\Tcf3tm1Mbu/\Tcf3tm1Mbu
\Commd10Tg(Vav1-icre)A2Kio/\Commd10+

(involves: 129P2/OlaHsd * C57BL/10 * CBA/Ca)
abnormal immunoglobulin heavy chain V(D)J recombination J:137719
immune system phenotype J:137719
\Ikzf1tm1.1Smale/\Ikzf1tm1.1Smale
(B6.Cg-Ikzf1tm1.1Smale)
decreased B cell number J:208211
decreased B-1a cell number J:208211
decreased B-1b cell number J:208211
decreased DN1 thymic pro-T cell number J:208211
decreased immature B cell number J:208211
decreased mature B cell number J:208211
decreased pre-B cell number J:208211
immune system phenotype J:208211
thymus hypoplasia J:208211
\Ikzf1tm1Kast/\Ikzf1tm1Kast
(involves: 129S2/SvPas)
abnormal B cell activation J:82813
abnormal B cell differentiation J:82813
decreased B cell number J:82813
decreased B cell proliferation J:82813
decreased B-1a cell number J:82813
decreased B-1b cell number J:82813
decreased IgG3 level J:82813
decreased spleen germinal center number J:82813
\Ikzf1tm1Kge/\Ikzf1+
(involves: 129S4/SvJae * C57BL/6)
abnormal lymph node cortex morphology J:29355
abnormal lymph node medulla morphology J:29355
abnormal T cell differentiation J:29355
abnormal thymocyte activation J:29355
abnormal thymus lobule morphology J:29355
abnormal thymus medulla morphology J:29355
decreased spleen red pulp amount J:29355
enlarged cervical lymph nodes J:29355
enlarged mesenteric lymph nodes J:29355
enlarged thymus J:29355
increased spleen white pulp amount J:29355
increased T cell proliferation J:29355
lymph node hyperplasia J:29355
spleen hyperplasia J:29355
thymus cortex hypoplasia J:29355
\Ikzf1tm1Kge/\Ikzf1+
(involves: 129S4/SvJae * BALB/c)
abnormal lymph node cortex morphology J:29355
abnormal lymph node medulla morphology J:29355
abnormal T cell differentiation J:29355
abnormal thymocyte activation J:29355
abnormal thymus lobule morphology J:29355
abnormal thymus medulla morphology J:29355
decreased spleen red pulp amount J:29355
enlarged cervical lymph nodes J:29355
enlarged mesenteric lymph nodes J:29355
enlarged thymus J:29355
increased spleen white pulp amount J:29355
increased T cell proliferation J:29355
lymph node hyperplasia J:29355
spleen hyperplasia J:29355
thymus cortex hypoplasia J:29355
\Ikzf1tm1Kge/\Ikzf1tm1Kge
(involves: 129S4/SvJae * C57BL/6)
abnormal eosinophil morphology J:20671
abnormal immune system organ morphology J:20671
abnormal NK cell morphology J:20671
abnormal spleen morphology J:20671
abnormal thymus cortex morphology J:20671
abnormal thymus morphology J:20671
absent axillary lymph nodes J:20671
absent B cells J:20671
absent cervical lymph nodes J:20671
absent inguinal lymph nodes J:20671
absent mesenteric lymph nodes J:20671
absent Peyer's patches J:20671
absent pre-B cells J:20671
arrested T cell differentiation J:20671
decreased gamma-delta intraepithelial T cell number J:20671
enlarged spleen J:20671
increased basophil cell number J:20671
increased susceptibility to bacterial infection J:20671
intermingled spleen red and white pulp J:20671
lung inflammation J:20671
thymus hypoplasia J:20671
\Ikzf1tm1Kge/\Ikzf1tm1Kge
(involves: 129S4/SvJae * BALB/c)
abnormal eosinophil morphology J:20671
abnormal immune system organ morphology J:20671
abnormal NK cell morphology J:20671
abnormal spleen morphology J:20671
abnormal thymus cortex morphology J:20671
abnormal thymus morphology J:20671
absent axillary lymph nodes J:20671
absent B cells J:20671
absent cervical lymph nodes J:20671
absent inguinal lymph nodes J:20671
absent mesenteric lymph nodes J:20671
absent Peyer's patches J:20671
absent pre-B cells J:20671
arrested T cell differentiation J:20671
decreased gamma-delta intraepithelial T cell number J:20671
enlarged spleen J:20671
increased basophil cell number J:20671
increased susceptibility to bacterial infection J:20671
intermingled spleen red and white pulp J:20671
lung inflammation J:20671
thymus hypoplasia J:20671
\Ikzf1tm2.1Smale/\Ikzf1tm2.1Smale
(B6.Cg-Ikzf1tm2.1Smale)
abnormal lymphopoiesis J:208211
abnormal peripheral lymph node morphology J:208211
abnormal T cell differentiation J:208211
absent inguinal lymph nodes J:208211
absent NK cells J:208211
absent Peyer's patches J:208211
decreased B cell number J:208211
decreased DN2 thymocyte number J:208211
decreased DN3 thymocyte number J:208211
decreased double-negative T cell number J:208211
decreased double-positive T cell number J:208211
decreased immature B cell number J:208211
decreased mature B cell number J:208211
decreased plasmacytoid dendritic cell number J:208211
decreased pre-pro B cell number J:208211
immune system phenotype J:208211
increased gamma-delta T cell number J:208211
increased pre-B cell number J:208211
thymus cortex hypoplasia J:208211
thymus hypoplasia J:208211
\Ikzf1tm2Kge/\Ikzf1tm2Kge
(involves: 129S4/SvJae)
abnormal dendritic cell number J:37317
abnormal splenic cell ratio J:37317
abnormal T cell differentiation J:208211, J:37317
abnormal thymus development J:37317
absent axillary lymph nodes J:37317
absent B cells J:208211, J:37317
absent B-1a cells J:37317
absent cervical lymph nodes J:37317
absent inguinal lymph nodes J:37317
absent mesenteric lymph nodes J:37317
absent NK cells J:208211, J:37317
absent Peyer's patches J:37317
absent pre-B cells J:37317
absent pro-B cells J:37317
decreased double-positive T cell number J:37317
decreased gamma-delta intraepithelial T cell number J:37317
decreased granulocyte number J:37317
decreased mature gamma-delta T cell number J:37317
decreased plasmacytoid dendritic cell number J:208211
decreased splenocyte number J:37317
increased T cell proliferation J:37317
thymus hypoplasia J:37317
\Ikzf1tm3.1Mbu/\Ikzf1tm3.1Mbu
\Cd79atm1(cre)Reth/\Cd79a+
\Rag2tm1Fwa/\Rag2tm1Fwa

(involves: 129P2/OlaHsd * 129S/SvEv * BALB/c * C57BL/6 * SJL)
decreased pro-B cell number J:209928
\Ikzf1tm3.1Mbu/\Ikzf1tm3.1Mbu
\Il7rtm1.1(icre)Hrr/\Il7r+

(involves: 129P2/OlaHsd * C57BL/6 * SJL)
increased T cell derived lymphoma incidence J:209928
\Ikzf1tm3Kge/\Ikzf1tm3Kge
\Tg(CD2-icre)4Kio/?

(involves: C57BL/10 * CBA/Ca)
abnormal B cell physiology J:209927
impaired B cell migration J:209927
increased T cell derived lymphoma incidence J:209927
\Ikzf1tm3Kge/\Ikzf1tm3Kge
\Tg(CD19-cre/ERT2)1Cgn/?

(Not Specified)
abnormal B cell apoptosis J:209927
absent pre-B cells J:209927
decreased pre-B cell number J:209927
\Ikzf2tm1.1Etms/\Ikzf2tm1.1Etms
\Tg(Cd4-cre)1Cwi/0

(involves: C57BL/6 * DBA/2)
abnormal regulatory T cell physiology J:160098
\Ikzf3tm1(KOMP)Vlcg/\Ikzf3tm1(KOMP)Vlcg
(C57BL/6N-Ikzf3tm1(KOMP)Vlcg/Rbrc)
decreased large unstained cell number J:211773
decreased leukocyte cell number J:211773
decreased lymphocyte cell number J:211773
increased neutrophil cell number J:211773
\Ikzf3tm1Kge/\Ikzf3tm1Kge
(involves: 129S4/SvJae * C57BL/6)
abnormal B cell differentiation J:50626
abnormal spleen marginal zone morphology J:50626
abnormal type III hypersensitivity reaction J:81805
autoimmune response J:81805
decreased B cell number J:81805
decreased IgG2b level J:50626
decreased IgG3 level J:50626
decreased IgM level J:50626
decreased naive B cell number J:81805
enlarged spleen J:50626
glomerulonephritis J:81805
increased anti-double stranded DNA antibody level J:81805
increased anti-histone antibody level J:81805
increased anti-nuclear antigen antibody level J:81805
increased anti-single stranded DNA antibody level J:81805
increased autoantibody level J:81805, J:50626
increased B cell proliferation J:50626
increased IgE level J:50626
increased IgG1 level J:50626
increased IgG2a level J:50626
increased pre-B cell number J:50626
increased spleen germinal center number J:50626
increased T cell proliferation J:50626
\Ikzf3tm1Kge/\Ikzf3tm1Kge
(involves: 129S4/SvJae)
decreased marginal zone B cell number J:69477
increased follicular B cell number J:69477
\Ikzf4tm1.1Etms/\Ikzf4tm1.1Etms
(Not Specified)
chronic inflammation J:294549
decreased T cell proliferation J:295208
immune system phenotype J:295208
increased susceptibility to experimental autoimmune encephalomyelitis J:295208
\Ikzf4tm1Djr/\Ikzf4tm1Djr
\Tg(Cd4-cre)1Cwi/0

(involves: C57BL/6 * DBA/2)
chronic inflammation J:294549
\Ikzf5tm1(KOMP)Wtsi/\Ikzf5tm1(KOMP)Wtsi
(C57BL/6N-Ikzf5tm1(KOMP)Wtsi/Rbrc)
increased large unstained cell number J:211773
\Il1atm1Yiw/\Il1atm1Yiw
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
decreased circulating interleukin-1 alpha level J:47429
decreased interleukin-1 beta secretion J:47429
\Il1atm1Yiw/\Il1atm1Yiw
\Il1btm1Yiw/\Il1btm1Yiw

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
decreased circulating interleukin-1 alpha level J:47429
decreased circulating interleukin-1 beta level J:47429
decreased susceptibility to experimental autoimmune encephalomyelitis J:165513
decreased susceptibility to type IV hypersensitivity reaction J:165513
\Il1atm1Yiw/\Il1atm1Yiw
\Il1btm1Yiw/\Il1btm1Yiw

(involves: 129S1/Sv * 129X1/SvJ * BALB/c)
impaired neutrophil recruitment J:50775
\Il1atm1Yiw/\Il1atm1Yiw
\Il1btm1Yiw/\Il1btm1Yiw
\Tg(KRT14-CASP1)1Miz/0

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
dermatitis J:78602
\Il1atm1Yiw/\Il1atm1Yiw
\Nlrp1aNeut1/\Nlrp1aNeut1

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
abnormal inflammatory response J:191055
increased neutrophil cell number J:191055
\Il1btm1Dch/\Il1btm1Dch
(involves: 129S2/SvPas)
decreased interleukin-1 beta secretion J:33465
decreased susceptibility to type IV hypersensitivity reaction J:33465
immune system phenotype J:189777
increased susceptibility to bacterial infection J:112400
\Il1btm1Lvp/\Il1btm1Lvp
(involves: 129S7/SvEvBrd * C57BL/6)
abnormal interleukin-6 secretion J:27234
abnormal lymphocyte physiology J:67001
decreased acute inflammation J:27234
decreased circulating interleukin-1 beta level J:27234
decreased inflammatory response J:27234
decreased interferon-gamma secretion J:67001
decreased interleukin-2 secretion J:67001
decreased interleukin-4 secretion J:67001
decreased susceptibility to experimental autoimmune myasthenia gravis J:67001
\Il1btm1Lvp/\Il1btm1Lvp
(involves: 129S7/SvEvBrd)
abnormal macrophage physiology J:136368
decreased interleukin-1 beta secretion J:136368
decreased susceptibility to Togaviridae infection J:52841
decreased susceptibility to Togaviridae infection induced morbidity/mortality J:52841
decreased susceptibility to viral infection J:135243
decreased tumor necrosis factor secretion J:82394
increased susceptibility to bacterial infection induced morbidity/mortality J:136368
\Il1btm1Lvp/\Il1btm1Lvp
(129S7/SvEvBrd-Il1btm1Lvp)
immune system phenotype J:173245
\Il1btm1Yiw/\Il1btm1Yiw
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
decreased circulating interleukin-1 beta level J:47429
\Il1f10tm1Gpa/\Il1f10tm1Gpa
(C.129-Il1f10tm1Gpa)
immune system phenotype J:260118
\Il1r1em1(IMPC)Ccpcz/\Il1r1em1(IMPC)Ccpcz
(C57BL/6NCrl-Il1r1em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
enlarged spleen J:211773
\Il1r1em1Qizh/\Il1r1em1Qizh
(C57BL/6-Il1r1em1Qizh)
increased circulating interleukin-6 level J:338375
increased circulating tumor necrosis factor level J:338375
increased susceptibility to induced arthritis J:338375
\Il1r1tm1Imx/\Il1r1tm1Imx
(involves: 129 * C57BL/6)
decreased circulating interleukin-6 level J:43088
increased susceptibility to bacterial infection J:58851
osteomyelitis J:58851
\Il1r1tm1Imx/\Il1r1tm1Imx
(involves: 129S7/SvEvBrd)
abnormal neutrophil physiology J:113110
\Il1r1tm1Imx/\Il1r1tm1Imx
(involves: 129S7/SvEvBrd * C57BL/6)
abnormal neutrophil physiology J:112999
decreased susceptibility to experimental autoimmune uveoretinitis J:115094
\Il1r1tm1Imx/\Il1r1tm1Imx
(B6.129S7-Il1r1tm1Imx/J)
decreased circulating interleukin-6 level J:125570
decreased circulating interleukin-18 level J:125570
decreased interleukin-6 secretion J:148779, J:125570
decreased tumor necrosis factor secretion J:125570
increased circulating interleukin-1 beta level J:125570
increased circulating interleukin-18 level J:125570
increased susceptibility to bacterial infection J:125570
increased susceptibility to bacterial infection induced morbidity/mortality J:125570
increased susceptibility to induced arthritis J:125570
sepsis J:125570
\Il1r1tm1Imx/\Il1r1tm1Imx
(B6.129S7-Il1r1tm1Imx)
immune system phenotype J:173245
\Il1r1tm1Imx/\Il1r1tm1Imx
\Tnfrsf1atm1Imx/\Tnfrsf1atm1Imx

(involves: 129S7/SvEvBrd * C57BL/6)
abnormal chemokine level J:126652
decreased interleukin-6 secretion J:115094
decreased susceptibility to experimental autoimmune uveoretinitis J:115094
impaired neutrophil recruitment J:126652
increased susceptibility to bacterial infection J:58851
interstitial pneumonia J:126652
lung inflammation J:126652
osteomyelitis J:58851
\Il1r1tm1Imx/\Il1r1tm1Imx
\Vsig4tm1Gne/\Vsig4tm1Gne

(B6.Cg-Il1r1tm1Imx Vsig4tm1Gne)
decreased susceptibility to experimental autoimmune encephalomyelitis J:281762
decreased T helper 1 cell number J:281762
decreased T-helper 17 cell number J:281762
increased susceptibility to induced colitis J:281762
\Il1r1tm1Quan/\Il1r1tm1Quan
(involves: C57BL/6)
abnormal inflammatory response J:219864
abnormal microglial cell activation J:219864
\Il1r1tm1Quan/\Il1r1tm1Quan
\Lyz2tm1(cre)Ifo/\Lyz2tm1(cre)Ifo

(involves: 129P2/OlaHsd * C57BL/6)
abnormal inflammatory response J:219864
abnormal microglial cell activation J:219864
\Il1r1tm1Quan/\Il1r1tm1Quan
\Tg(Tek-cre)12Flv/0

(involves: C3H * C57BL/6)
abnormal inflammatory response J:219864
abnormal microglial cell activation J:219864
\Il1r1tm1Roml/\Il1r1tm1Roml
(involves: 129S1/Sv * C57BL/6)
decreased circulating interleukin-6 level J:42373
decreased circulating serum amyloid protein level J:42373
decreased interleukin-6 secretion J:42373
decreased susceptibility to type IV hypersensitivity reaction J:42373
increased susceptibility to bacterial infection J:42373
\Il1r1tm1Roml/\Il1r1tm1Roml
(NOD.Cg-Il1r1tm1Roml)
decreased susceptibility to autoimmune diabetes J:87251
\Il1r1tm1Roml/\Il1r1tm1Roml
(C.Cg-Il1r1tm1Roml)
decreased eosinophil cell number J:82863
decreased immunoglobulin level J:82863
decreased T cell number J:82863
decreased T cell proliferation J:82863
\Il1r1tm1Roml/\Il1r1tm1Roml
(involves: 129S1/Sv * BALB/c)
impaired neutrophil chemotaxis J:124226
\Il1r1tm1Roml/\Il1r1tm1Roml
(involves: 129S1/Sv)
decreased neutrophil cell number J:193548
decreased susceptibility to induced arthritis J:120707
\Il1r1tm1Roml/\Il1r1tm1Roml
\Mefvtm5.1(MEFV)Chae/\Mefvtm5.1(MEFV)Chae

(involves: 129S1/Sv * 129S6/SvEvTac * C57BL/6)
immune system phenotype J:172117
increased interleukin-1 beta secretion J:172117
\Il1r1tm1Roml/\Il1r1tm1Roml
\Nlrp1aNeut1/\Nlrp1aNeut1

(involves: 129S1/Sv * C57BL/6)
abnormal leukocyte cell number J:191055
abnormal leukopoiesis J:191055
decreased eosinophil cell number J:191055
decreased lymphocyte cell number J:191055
decreased monocyte cell number J:191055
immune system phenotype J:191055
increased susceptibility to Riboviria infection J:191055
\Il1r1tm1Roml/\Il1r1tm1Roml
\Nlrp3tm1Hhf/\Nlrp3+
\Lyz2tm1(cre)Ifo/\Lyz2+

(involves: 129 * C57BL/6)
skin inflammation J:150054
\Il1r2tm1.2Epi/\Il1r2tm1.2Epi
(involves: BALB/cJ * C57BL/6J * C57BL/6NTac)
abnormal CD8-positive, alpha-beta T cell number J:347877
abnormal T cell physiology J:347877
increased CD4-positive, alpha-beta T cell number J:347877
increased circulating interleukin-1 alpha level J:347877
increased circulating interleukin-6 level J:347877
increased inflammatory response J:347877
\Il1r2tm1Yiw/\Il1r2tm1Yiw
(B6.129P2-Il1r2tm1Yiw)
abnormal macrophage physiology J:274653
immune system phenotype J:274653
increased macrophage cytokine production J:274653
increased susceptibility to induced arthritis J:274653
\Il1r2tm1Yiw/\Il1r2tm1Yiw
\Il1rntm1Yiw/\Il1rntm1Yiw

(B6.129-Il1r2tm1Yiw Il1rntm1Yiw)
increased circulating tumor necrosis factor level J:274653
\Il1raptm1Roml/\Il1raptm1Roml
(involves: 129S1/Sv)
decreased interleukin-6 secretion J:68065
\Il1rl1tm1Anjm/\Il1rl1tm1Anjm
(involves: 129P2/OlaHsd * C57BL/6)
abnormal eosinophil physiology J:61108
abnormal interleukin secretion J:61108
abnormal T-helper 2 physiology J:61108
decreased interleukin-4 secretion J:61108
decreased interleukin-5 secretion J:61108
granulomatous inflammation J:61108
\Il1rl1tm1Anjm/\Il1rl1tm1Anjm
(involves: 129P2/OlaHsd)
decreased eosinophil cell number J:159464
decreased IgE level J:159464
\Il1rl1tm1Anjm/\Il1rl1tm1Anjm
(C.129P2-Il1rl1tm1Anjm)
increased susceptibility to induced pancreatitis J:184801
\Il1rl1tm1Brl/\Il1rl1tm1Brl
(involves: 129S/SvEv * C57BL/6)
abnormal response to infection J:63507
decreased interleukin-5 secretion J:63507
increased eosinophil cell number J:63507
\Il1rl2tm1Hblu/\Il1rl2tm1Hblu
(involves: 129 * C57BL/6)
abnormal dendritic cell physiology J:296074
abnormal macrophage activation involved in immune response J:296074
\Il1rl2tm1Hblu/\Il1rl2tm1Hblu
(involves: 129)
abnormal lymph node morphology J:193548
decreased gamma-delta T cell number J:193548
decreased interleukin-9 secretion J:256437
decreased interleukin-17 secretion J:193548
decreased leukocyte cell number J:193548
decreased macrophage cell number J:193548
decreased neutrophil cell number J:193548
decreased susceptibility to induced colitis J:256437
increased regulatory T cell number J:256437
\Il1rntm1.1Cga/\Il1rntm1.1Cga
\Lyz2tm1(cre)Ifo/\Lyz2+

(D1.Cg-Il1rntm1.1Cga Lyz2tm1(cre)Ifo)
abnormal chemokine secretion J:162760
increased interferon-gamma secretion J:162760
increased interleukin-1 beta secretion J:162760
increased interleukin-6 secretion J:162760
increased interleukin-17 secretion J:162760
increased susceptibility to induced arthritis J:162760
increased T cell proliferation J:162760
\Il1rntm1Dih/\Il1rn+
(involves: 129S/SvEv * C57BL/6J)
decreased susceptibility to bacterial infection J:36387
increased susceptibility to endotoxin shock J:36387
\Il1rntm1Dih/\Il1rntm1Dih
(involves: 129S/SvEv * C57BL/6J)
decreased circulating interleukin-1 level J:36387
decreased susceptibility to bacterial infection J:36387
increased acute inflammation J:61600, J:88605
increased circulating interleukin-6 level J:61600
increased circulating serum amyloid protein level J:61600
increased susceptibility to endotoxin shock J:36387
\Il1rntm1Nick/\Il1rn+
(involves: 129P2/OlaHsd * MF1)
aortitis J:59410
\Il1rntm1Nick/\Il1rntm1Nick
(involves: 129P2/OlaHsd * MF1)
aortitis J:59410
chronic inflammation J:59410
\Il1rntm1Nick/\Il1rntm1Nick
(involves: 129P2/OlaHsd * MF1 * BALB/cAnNHsd)
aortitis J:89034
immune system phenotype J:89034
skin inflammation J:89034
\Il1rntm1Nick/\Il1rntm1Nick
(involves: BALB/cAnNHsd)
aortitis J:89034
rheumatoid arthritis J:89034
skin inflammation J:89034
\Il1rntm1Nick/\Il1rntm1Nick
(involves: C57BL/6)
immune system phenotype J:89034
\Il1rntm1Nick/\Il1rntm1Nick
(involves: BALB/cAnNHsd * C57BL/6)
aortitis J:89034
immune system phenotype J:89034
rheumatoid arthritis J:89034
\Il1rntm1Sush/\Il1rntm1Sush
(involves: 129P2/OlaHsd * C57BL/6)
abnormal CD4-positive, alpha beta T cell morphology J:97684
abnormal dendritic cell differentiation J:97684
abnormal dendritic cell number J:97684
abnormal immune system organ morphology J:97684
abnormal T-helper 1 cell morphology J:97684
abnormal T-helper 2 cell morphology J:97684
granulomatous inflammation J:97684
\Il1rntm1Yiw/\Il1rntm1Yiw
(C.129-Il1rntm1Yiw)
increased interleukin-17 secretion J:143719
rheumatoid arthritis J:143719
\Il1rntm1Yiw/\Il1rntm1Yiw
\Il17atm1Yiw/\Il17a+

(involves: 129P2/OlaHsd * BALB/cA * C57BL/6J)
decreased susceptibility to induced arthritis J:83408
\Il2m1/\Il2m1
(MRL/MpJ)
abnormal T cell activation J:75331
\Il2tm1.1Flv/\Il2tm1.1Flv
(NOD/ShiLtJ-Il2tm1.1Flv)
abnormal susceptibility to autoimmune disorder J:150823
\Il2tm1.1Kasm/\Il2tm1.1Kasm
\Ndor1Tg(UBC-cre/ERT2)1Ejb/?

(involves: 129S/SvEv * C57BL/6)
decreased circulating interleukin-17 level J:190168
immune system phenotype J:190168
\Il2tm1Hor/\Il2+
(NOD.129P2(B6)-Il2tm1Hor/DvsJ)
increased susceptibility to autoimmune diabetes J:120349
\Il2tm1Hor/\Il2tm1Hor
(involves: 129P2/OlaHsd * C57BL/6)
abnormal CD4-positive, alpha-beta T cell physiology J:39981, J:39989, J:15573
abnormal CD8 positive, alpha-beta intraepithelial T cell morphology J:39981, J:15223
abnormal class switch recombination J:15573
abnormal cytotoxic T cell physiology J:39981
abnormal gamma-delta intraepithelial T cell morphology J:15223
abnormal level of surface class II molecules J:15223
abnormal lymphocyte cell number J:15223
abnormal lymphocyte morphology J:37220
abnormal lymphocyte physiology J:15223
abnormal susceptibility to Riboviria infection J:26861
abnormal T-helper 1 cell differentiation J:37220
abnormal thymocyte activation J:37220, J:39989
colitis J:37220, J:29999, J:15223
decreased cytotoxic T cell cytolysis J:15573, J:26198, J:26861
decreased double-negative T cell number J:15223
decreased double-positive T cell number J:37220
decreased splenocyte proliferation J:79241
decreased T cell proliferation J:39989, J:26198
enlarged lymph nodes J:15223
enlarged mesenteric lymph nodes J:29999
enlarged spleen J:15223
impaired natural killer cell mediated cytotoxicity J:15573
increased B cell proliferation J:16662
increased double-negative T cell number J:37220
increased IgA level J:15223
increased IgE level J:16662
increased IgG1 level J:39989, J:15223, J:16662
increased IgG2a level J:16662
increased IgG2b level J:16662
increased length of allograft survival J:26198
increased pre-B cell number J:16662
increased pro-B cell number J:16662
increased single-positive T cell number J:37220
increased T cell proliferation J:15223, J:16662
lymph node hyperplasia J:16662
\Il2tm1Hor/\Il2tm1Hor
(C.129P2-Il2tm1Hor)
abnormal lymphocyte morphology J:29799
abnormal regulatory T cell physiology J:112603
abnormal spleen morphology J:29799
enlarged lymph nodes J:29799
heart inflammation J:29799
increased B cell proliferation J:29799
increased germinal center B cell number J:29799
increased IgG level J:29799
increased inflammatory response J:29799
increased plasma cell number J:29799
increased spleen red pulp amount J:29799
increased susceptibility to autoimmune hemolytic anemia J:29799
increased T cell proliferation J:29799
liver inflammation J:29799
lung inflammation J:29799
pancreas inflammation J:29799
spleen hyperplasia J:29799
\Il2tm1Hor/\Il2tm1Hor
(B6.129P2-Il2tm1Hor)
immune system phenotype J:125748
increased activated T cell number J:28924
increased CD4-positive, alpha-beta T cell number J:28924
increased CD8-positive, alpha-beta T cell number J:28924
increased T cell number J:125748
increased T cell proliferation J:28924
\Il2tm1Hor/\Il2tm1Hor
(C3.129P2-Il2tm1Hor)
increased CD4-positive, alpha-beta T cell number J:28924
increased CD8-positive, alpha-beta T cell number J:28924
\Il2tm1Hor/\Il2tm1Hor
(B6.129P2-Il2tm1Hor/J)
abnormal circulating cytokine level J:190168
abnormal response to transplant J:113547
abnormal T cell activation J:190168
abnormal T cell proliferation J:190168
decreased CD4-positive, CD25-positive, alpha-beta regulatory T cell number J:131774
decreased circulating interferon-gamma level J:190168
decreased circulating interleukin-4 level J:190168
decreased circulating interleukin-13 level J:190168
decreased regulatory T cell number J:113547
enlarged lymph nodes J:113547
increased CD4-positive, alpha-beta T cell number J:131774
increased splenocyte number J:131774
increased susceptibility to autoimmune disorder J:113547
lacrimal gland inflammation J:125129
large intestinal inflammation J:125129
salivary gland inflammation J:125129
\Il2tm1Hor/\Il2tm1Hor
(involves: 129P2/OlaHsd)
increased regulatory T cell number J:208318
\Il2tm1Hor/\Il2tm1Hor
(involves: 129P2/OlaHsd * C57BL/6J)
increased circulating interleukin-17 level J:120176
increased T-helper 17 cell number J:120176
\Il2tm1Hor/\Il2tm1Hor
\Il4tm1Cgn/\Il4tm1Cgn

(involves: 129P2/OlaHsd * C57BL/6)
abnormal susceptibility to Riboviria infection J:26861
decreased cytotoxic T cell cytolysis J:26861
decreased IgG level J:16662, J:26861
increased B cell proliferation J:16662
increased pre-B cell number J:16662
increased pro-B cell number J:16662
increased T cell proliferation J:16662
\Il2tm1Hor/\Il2tm1Hor
\Rag2tm1Fwa/\Rag2+

(involves: 129P2/OlaHsd * 129S/SvEv * C57BL/6)
colitis J:29999
enlarged mesenteric lymph nodes J:29999
\Il2tm1Hor/\Il2tm1Hor
\Rag2tm1Fwa/\Rag2tm1Fwa

(involves: 129P2/OlaHsd * 129S/SvEv * C57BL/6)
immune system phenotype J:29999
\Il2tm1Hor/\Il2tm1Hor
\Rag2tm1Fwa/\Rag2tm1Fwa
\Tg(Tcra5CC7,Tcrb5CC7)IWep/0

(involves: 129P2/OlaHsd * C57BL/10)
abnormal T cell number J:120176
increased T-helper 17 cell number J:120176
\Il2tm1Hor/\Il2tm1Hor
\Tcrbtm1Mom/\Tcrbtm1Mom

(involves: 129P2/OlaHsd * C57BL/6)
immune system phenotype J:135589
\Il2tm1Hor/\Il2tm1Hor
\Tg(DO11.10)10Dlo/?

(C.Cg-Il2tm1Hor Tg(DO11.10)10Dlo)
abnormal regulatory T cell physiology J:88349
increased activated T cell number J:88349
increased T cell proliferation J:88349
\Il2tm1Hor/\Il2tm1Hor
\Tg(Pgk1-HA)1.1Vbo/?
\Tg(Tcra/Tcrb)1Vbo/?

(C.Cg-Il2tm1Hor Tg(Pgk1-HA)1.1Vbo Tg(Tcra/Tcrb)1Vbo)
abnormal regulatory T cell physiology J:112603
decreased regulatory T cell number J:112603
increased regulatory T cell number J:112603
\Il2raM1J/\Il2raM1J
(involves: 129S4/SvJae * C57BL/6)
abnormal regulatory T cell physiology J:268677
\Il2ratm1b(EUCOMM)Wtsi/\Il2ratm1b(EUCOMM)Wtsi
(C57BL/6N-Il2ratm1b(EUCOMM)Wtsi/Orl)
abnormal spleen morphology J:211773
decreased lymphocyte cell number J:211773
enlarged lymph nodes J:211773
increased large unstained cell number J:211773
increased neutrophil cell number J:211773
\Il2ratm1Dw/\Il2ratm1Dw
(involves: 129S4/SvJae * C57BL/6)
abnormal B cell physiology J:64279
abnormal lymph organ size J:64279
abnormal T cell morphology J:64279
abnormal T cell physiology J:64279
colitis J:64279
enlarged lymph nodes J:64279
enlarged spleen J:64279
increased IgA level J:64279
increased IgG1 level J:64279
increased IgG2a level J:64279
increased IgG2b level J:64279
increased IgG level J:64279
increased lymphocyte cell number J:64279
increased memory T cell number J:64279
\Il2ratm1Dw/\Il2ratm1Dw
(B6.129S4-Il2ratm1Dw)
abnormal regulatory T cell physiology J:125748
abnormal T cell activation J:125748
lymphoid hyperplasia J:125748
\Il2ratm1Dw/\Il2ratm1Dw
(B6.129S4-Il2ratm1Dw/J)
lacrimal gland inflammation J:125129
large intestinal inflammation J:125129
lung inflammation J:125129
salivary gland inflammation J:125129
\Il2ratm1Dw/\Il2ratm1Dw
\Tg(CD2-Ccdc86)1Hfuj/?

(B6.Cg-Il2ratm1Dw Tg(CD2-Ccdc86)1Hfuj)
immune system phenotype J:151722
increased activated T cell number J:151722
\Il2ratm1Dw/\Il2ratm1Dw
\Tg(Pgk1-HA)1.1Vbo/?
\Tg(Tcra/Tcrb)1Vbo/?

(C.Cg-Il2ratm1Dw Tg(Pgk1-HA)1.1Vbo Tg(Tcra/Tcrb)1Vbo)
abnormal regulatory T cell physiology J:112603
decreased regulatory T cell number J:112603
increased regulatory T cell number J:112603
\Il2rbm1Btlr/\Il2rbm1Btlr
(C57BL/6J-Il2rbm1Btlr)
decreased B cell number J:267694
decreased CD4-positive, alpha-beta T cell number J:267694
decreased CD8-positive, naive alpha-beta T cell number J:267694
increased effector memory CD4-positive, alpha-beta T cell number J:267694
increased effector memory CD8-positive, alpha-beta T cell number J:267694
\Il2rbm2Btlr/\Il2rbm2Btlr
(C57BL/6J-Il2rbm2Btlr)
increased IgE level J:272832
\Il2rbM3Btlr/\Il2rbM3Btlr
(C57BL/6J-Il2rbM3Btlr)
abnormal CD8-positive, alpha-beta T cell differentiation J:272833
abnormal T cell morphology J:272833
decreased CD8-positive, alpha-beta T cell number J:272833
decreased central memory CD8 positive, alpha-beta T cell number J:272833
decreased NK cell number J:272833
decreased NK T cell number J:272833
increased CD4-positive, alpha-beta T cell number J:272833
increased IgM level J:272833
\Il2rbtm1Mak/\Il2rbtm1Mak
(either: (involves: 129P2/OlaHsd) or (involves: 129S2/SvPas))
abnormal B cell activation J:25940
abnormal mononuclear cell morphology J:25940
abnormal T cell activation J:25940
decreased B cell number J:25940
decreased double-positive T cell number J:25940
decreased memory T cell number J:25940
enlarged lymph nodes J:25940
enlarged spleen J:25940
increased activated T cell number J:25940
increased anti-nuclear antigen antibody level J:25940
increased CD4-positive, alpha-beta T cell number J:25940
increased CD8-positive, alpha-beta T cell number J:25940
increased granulocyte number J:25940
increased IgE level J:25940
increased IgG1 level J:25940
increased neutrophil cell number J:25940
increased plasma cell number J:25940
increased susceptibility to autoimmune hemolytic anemia J:25940
thymus hypoplasia J:25940
\Il2rbtm1Mak/\Il2rbtm1Mak
(B6.129-Il2rbtm1Mak)
abnormal lymphocyte morphology J:113547
abnormal response to transplant J:113547
abnormal spleen periarteriolar lymphoid sheath morphology J:113547
abnormal T cell activation J:113547
decreased regulatory T cell number J:113547
decreased T cell proliferation J:113547
enlarged lymph nodes J:113547
enlarged spleen J:113547
increased anti-double stranded DNA antibody level J:113547
increased susceptibility to autoimmune hemolytic anemia J:113547
\Il2rbtm1Mak/\Il2rbtm1Mak
(C.129-Il2rbtm1Mak)
abnormal immune system organ morphology J:113547
abnormal lymphocyte morphology J:113547
abnormal marginal zone B cell morphology J:113547
abnormal spleen periarteriolar lymphoid sheath morphology J:113547
abnormal T cell activation J:113547
abnormal T cell clonal deletion J:113547
decreased CD8-positive, alpha-beta T cell number J:113547
decreased T cell proliferation J:113547
enlarged lymph nodes J:113547
enlarged spleen J:113547
increased anti-double stranded DNA antibody level J:113547
increased susceptibility to autoimmune hemolytic anemia J:113547
liver inflammation J:113547
\Il2rbtm1Mak/\Il2rbtm1Mak
(D2.129-Il2rbtm1Mak)
abnormal T cell clonal deletion J:113547
\Il2rbtm1Mak/\Il2rbtm1Mak
\Lcktm1Mak/\Lcktm1Mak

(involves: 129)
absent uterine NK cells J:134589
\Il2rbtm1Mak/\Il2rbtm1Mak
\Rag2tm1Fwa/\Rag2tm1Fwa

(involves: 129 * 129S/SvEv)
decreased NK cell number J:142654
\Il2rgtm1.1Asin/\Il2rgtm1Wjl
\Tg(Cd4-cre)1Cwi/0

(involves: 129S4/SvJae * C57BL/6 * DBA/2)
decreased CD4-positive, alpha-beta T cell number J:190889
decreased CD8-positive, alpha-beta T cell number J:190889
\Il2rgtm1.1Asin/\Il2rgtm1Wjl
\Tg(Cd8a*-cre)B8Asin/0

(involves: 129S4/SvJae * C57BL/6)
decreased CD4-positive, alpha-beta T cell number J:190889
decreased CD8-positive, alpha-beta T cell number J:190889
decreased NK T cell number J:190889
decreased regulatory T cell number J:190889
\Il2rgtm1.1Asin/\Il2rgtm1Wjl
\Tg(Cd8a*-cre)B8Asin/0
\Tg(LCKprBCL2)36Sjk/0

(involves: 129S4/SvJae * C57BL/6)
decreased NK T cell number J:190889
\Il2rgtm1.1Flv/Y
\Rag2tm1.1Flv/\Rag2tm1.1Flv

(involves: 129S4/SvJae * BALB/cAnNTac)
abnormal response to transplant J:168303
increased susceptibility to bacterial infection J:168303
\Il2rgtm1.1Flv/\Il2rgtm1.1Flv
\Csf2/Il3tm1.1(CSF2,IL3)Flv/\Csf2/Il3tm1.1(CSF2,IL3)Flv
\Rag2tm1.1Flv/\Rag2tm1.1Flv

(involves: 129S4/SvJae * BALB/cAnNCr * BALB/cAnNTac)
abnormal response to transplant J:168302
\Il2rgtm1.1Flv/\Il2rgtm1.1Flv
\Rag2tm1.1Flv/\Rag2tm1.1Flv

(involves: 129S4/SvJae * BALB/cAnNTac)
abnormal response to transplant J:168303
increased susceptibility to bacterial infection J:168303
\Il2rgtm1.1Flv/\Il2rgtm1.1Flv
\Rag2tm1.1Flv/\Rag2tm1.1Flv
\Thpotm1.1(TPO)Flv/\Thpotm1.1(TPO)Flv

(involves: 129S4/SvJae * BALB/cAnNTac)
abnormal response to transplant J:168301
\Il2rgtm1Cgn/Y
(involves: 129 * CB20)
abnormal alpha-beta intraepithelial T cell morphology J:22521
abnormal class switch recombination J:22521
abnormal gamma-delta T cell differentiation J:111821
abnormal leukocyte morphology J:22521
abnormal thymocyte activation J:22521
absent gamma-delta intraepithelial T cell J:111821
absent gamma-delta T cells J:111821
absent NK cells J:22521
absent Peyer's patches J:22521
absent spleen germinal center J:22521
decreased IgE level J:22521
decreased IgM level J:22521
decreased mature B cell number J:22521
decreased plasma cell number J:22521
decreased pre-B cell number J:22521
decreased spleen white pulp amount J:22521
decreased T cell number J:22521
decreased T cell proliferation J:22521
impaired natural killer cell mediated cytotoxicity J:22521
spleen hypoplasia J:22521
thymus hypoplasia J:111821, J:22521
\Il2rgtm1Cgn/Y
\Rag2tm1Fwa/\Rag2tm1Fwa

(B6.129-Rag2tm1Fwa Il2rgtm1Cgn)
absent B cells J:132257
absent NK cells J:132257
absent T cells J:132257
\Il2rgtm1Cgn/\Il2rgtm1Cgn
(involves: 129 * CB20)
abnormal alpha-beta intraepithelial T cell morphology J:22521
abnormal class switch recombination J:22521
abnormal leukocyte morphology J:22521
abnormal thymocyte activation J:22521
absent NK cells J:22521
absent Peyer's patches J:22521
absent spleen germinal center J:22521
decreased IgE level J:22521
decreased IgM level J:22521
decreased mature B cell number J:22521
decreased plasma cell number J:22521
decreased pre-B cell number J:22521
decreased spleen white pulp amount J:22521
decreased T cell number J:22521
decreased T cell proliferation J:22521
impaired natural killer cell mediated cytotoxicity J:22521
spleen hypoplasia J:22521
thymus hypoplasia J:22521
\Il2rgtm1Cgn/\Il2rgtm1Cgn
\Kittm1.1Bsm/\Kittm1.1Bsm

(involves: 129P2/OlaHsd * 129S1/Sv * C57BL/6)
arrested T cell differentiation J:90485
\Il2rgtm1Cgn/\Il2rgtm1Cgn
\Rag2tm1Fwa/\Rag2tm1Fwa

(involves: 129P2/OlaHsd * 129S/SvEv)
abnormal interleukin secretion J:142654
decreased NK cell number J:142654
increased susceptibility to bacterial infection J:142654
\Il2rgtm1Krf/\Il2rgtm1Krf
(either: (involves: 129P2/OlaHsd * C57BL/6) or (involves: 129P2/OlaHsd * FVB/N))
decreased thymocyte number J:114561
\Il2rgtm1Krf/\Il2rgtm1Krf
\Tg(BCL2/IGH)1Tjd/0

(either: (involves: 129P2/OlaHsd * C3H/He * C57BL/6) or (involves: 129P2/OlaHsd * C3H/He * C57BL/6 * FVB/N))
decreased thymocyte number J:114561
\Il2rgtm1Krf/\Il2rgtm1Krf
\Tg(Igh-Pim1)1Brn/0

(either: (involves: 129P2/OlaHsd * C57BL/6 * CBA) or (involves: 129P2/OlaHsd * C57BL/6 * CBA * FVB/N))
decreased thymocyte number J:114561
\Il2rgtm1Sug/Y
(either: (involves: 129P2/OlaHsd * C57BL/6) or (involves: 129S6/SvEvTac * C57BL/6))
abnormal immune serum protein physiology J:31167
abnormal immune system cell morphology J:31167
abnormal immune system organ morphology J:31167
abnormal immunoglobulin level J:31167
abnormal myelopoiesis J:31167
abnormal splenic cell ratio J:31167
absent NK cells J:31167
absent spleen white pulp J:31167
arrested B cell differentiation J:31167
decreased IgG3 level J:31167
decreased IgG level J:31167
decreased lymphocyte cell number J:31167
decreased T cell number J:31167
decreased thymocyte number J:31167
enlarged Peyer's patches J:31167
enlarged spleen J:31167
increased macrophage cell number J:31167
increased monocyte cell number J:31167
increased neutrophil cell number J:31167
small lymph nodes J:31167
small thymus J:31167
thymus cortex hypoplasia J:31167
thymus hypoplasia J:31167
\Il2rgtm1Sug/\Il2rgtm1Sug
(B6.129-Il2rgtm1Sug)
absent uterine NK cells J:116952
\Il2rgtm1Wjl/Y
(involves: 129S4/SvJae * C57BL/6)
abnormal B cell number J:108209
abnormal basophil physiology J:24117
abnormal CD4-positive, alpha beta T cell morphology J:108209
abnormal cell-mediated immunity J:108209
abnormal gut-associated lymphoid tissue morphology J:24117
abnormal immune serum protein physiology J:108209
abnormal immune system organ morphology J:108209
abnormal lymphocyte morphology J:108209
abnormal mast cell physiology J:24117
abnormal mesenteric lymph node morphology J:24117
abnormal thymocyte activation J:24117
absent gamma-delta intraepithelial T cell J:24117
absent gamma-delta T cells J:24117
absent NK cells J:24117
cecum inflammation J:24117
decreased CD8-positive, alpha-beta T cell number J:24117
decreased double-negative T cell number J:24117
decreased double-positive T cell number J:24117
decreased immature B cell number J:24117
decreased immunoglobulin level J:24117
decreased interferon-gamma secretion J:24117
decreased interleukin-2 secretion J:24117
decreased interleukin-4 secretion J:24117
decreased single-positive T cell number J:24117
decreased T cell proliferation J:24117
impaired natural killer cell mediated cytotoxicity J:24117
small lymph nodes J:24117
small thymus J:24117
small thymus cortex J:24117
spleen hyperplasia J:24117
spleen hypoplasia J:24117
thymus hyperplasia J:108209
\Il2rgtm1Wjl/Y
\Crlf2tm1Wjl/\Crlf2tm1Wjl

(involves: 129S4/SvJae * C57BL/6)
thymus hypoplasia J:108209
\Il2rgtm1Wjl/Y
\Prkdcscid/\Prkdcscid

(NOD.Cg-Prkdcscid Il2rgtm1Wjl/Sz)
abnormal immune system organ morphology J:109833
abnormal response to transplant J:109833, J:140388
abnormal splenic cell ratio J:109833
abnormal thymus morphology J:109833
decreased CD4-positive, alpha-beta T cell number J:109833
decreased CD8-positive, alpha-beta T cell number J:109833
decreased immature B cell number J:109833
decreased immunoglobulin level J:109833
decreased leukocyte cell number J:109833
decreased mature B cell number J:109833
decreased NK cell number J:109833
decreased spleen B cell follicle number J:109833
lymph node hypoplasia J:109833
small lymph nodes J:109833
\Il2rgtm1Wjl/Y
\Rag1tm1Mom/\Rag1tm1Mom

(NOD.Cg-Rag1tm1Mom Il2rgtm1Wjl/SzJ)
abnormal adaptive immunity J:140388
abnormal innate immunity J:140388
abnormal response to transplant J:140388
abnormal spleen morphology J:140388
abnormal thymus morphology J:140388
absent NK T cells J:140388
absent thymus cortex J:140388
absent thymus medulla J:140388
decreased macrophage cell number J:140388
decreased spleen B cell follicle number J:140388
thymus cyst J:140388
\Il2rgtm1Wjl/\Il2rgtm1Wjl
(B6.129S4-Il2rgtm1Wjl/J)
abnormal dendritic cell physiology J:123902
abnormal splenic cell ratio J:123902
decreased myeloid dendritic cell number J:123902
\Il2rgtm1Wjl/\Il2rgtm1Wjl
\Prkdcscid/\Prkdcscid

(NOD.Cg-Prkdcscid Il2rgtm1Wjl/Sz)
abnormal immune system organ morphology J:109833
abnormal response to transplant J:109833
abnormal splenic cell ratio J:109833
abnormal thymus morphology J:109833
decreased CD4-positive, alpha-beta T cell number J:109833
decreased CD8-positive, alpha-beta T cell number J:109833
decreased immature B cell number J:109833
decreased immunoglobulin level J:109833
decreased leukocyte cell number J:109833
decreased mature B cell number J:109833
decreased NK cell number J:109833
decreased spleen B cell follicle number J:109833
lymph node hypoplasia J:109833
small lymph nodes J:109833
thymus cyst J:109833
\Il2rgtm1Wjl/\Il2rgtm1Wjl
\Rag2tm1Fwa/\Rag2tm1Fwa

(involves: 129S/SvEv * 129S4/SvJae)
abnormal interferon secretion J:140483
absent NK cells J:140483
absent T cells J:140483
increased susceptibility to bacterial infection J:140483
lung inflammation J:140483
\Il2rgtm1Wjl/\Il2rgtm1Wjl
\Tg(CD2-Ccdc86)1Hfuj/?

(B6.Cg-Il2rgtm1Wjl Tg(CD2-Ccdc86)1Hfuj)
decreased CD4-positive, alpha-beta T cell number J:151722
decreased CD8-positive, alpha-beta T cell number J:151722
decreased regulatory T cell number J:151722
decreased splenocyte number J:151722
immune system phenotype J:151722
\Il2rgtm2Cgn/Y
\Tg(Mx1-cre)1Cgn/?

(involves: 129P2/OlaHsd * C57BL/6 * CBA)
decreased NK cell number J:132257
\Il3tm1Glli/\Il3tm1Glli
(either: (involves: 129S2/SvPas * BALB/c) or (involves: 129S2/SvPas * C57BL/6))
abnormal mast cell differentiation J:80500
decreased susceptibility to type IV hypersensitivity reaction J:80640
increased susceptibility to parasitic infection J:80500
\Il3tm1Glli/\Il3tm1Glli
\KitW/\KitW-v

(involves: 129S2/SvPas * C57BL/6 * WB)
increased susceptibility to parasitic infection J:80500
\Il3ram1/\Il3ram1
(A/J)
abnormal leukopoiesis J:23971
\Il4/Il13tm3Anjm/\Il4/Il13tm3Anjm
(involves: 129P2/OlaHsd * C57BL/6)
abnormal immune system physiology J:89095
abnormal splenocyte physiology J:72587
abnormal susceptibility to infection J:113543
abnormal T-helper 2 physiology J:89095
decreased IgE level J:113543, J:72587
decreased IgG1 level J:72587
decreased IgG level J:89095
decreased susceptibility to parasitic infection J:72587
granulomatous inflammation J:113543
increased eosinophil cell number J:113543
increased susceptibility to parasitic infection J:113543, J:89095
increased susceptibility to parasitic infection induced morbidity/mortality J:60609
\Il4/Il13tm3Anjm/\Il4/Il13tm3Anjm
(C.129P2/OlaHsd-Il4/Il13tm3Anjm)
abnormal interleukin-4 secretion J:91403
decreased IgE level J:91403
decreased interferon-gamma secretion J:91403
decreased interleukin-5 secretion J:91403
decreased interleukin-13 secretion J:91403
decreased susceptibility to autoimmune disorder J:91403
increased IgG2a level J:91403
\Il4/Il13tm3Anjm/\Il4/Il13tm3Anjm
(involves: 129P2/OlaHsd * BALB/c)
abnormal splenocyte physiology J:60609
abnormal susceptibility to infection J:60609, J:131994
decreased IgG1 level J:178986
decreased inflammatory response J:60609, J:165513
ileum inflammation J:60609
increased susceptibility to parasitic infection J:60609
increased susceptibility to parasitic infection induced morbidity/mortality J:60609
\Il4/Il13tm3Anjm/\Il4/Il13tm3Anjm
(involves: 129P2/OlaHsd * C57BL/6)
abnormal immune system physiology J:89095
abnormal splenocyte physiology J:72587
abnormal susceptibility to infection J:113543
abnormal T-helper 2 physiology J:89095
decreased IgE level J:113543, J:72587
decreased IgG1 level J:72587
decreased IgG level J:89095
decreased susceptibility to parasitic infection J:72587
granulomatous inflammation J:113543
increased eosinophil cell number J:113543
increased susceptibility to parasitic infection J:113543, J:89095
increased susceptibility to parasitic infection induced morbidity/mortality J:60609
\Il4/Il13tm3Anjm/\Il4/Il13tm3Anjm
(C.129P2/OlaHsd-Il4/Il13tm3Anjm)
abnormal interleukin-4 secretion J:91403
decreased IgE level J:91403
decreased interferon-gamma secretion J:91403
decreased interleukin-5 secretion J:91403
decreased interleukin-13 secretion J:91403
decreased susceptibility to autoimmune disorder J:91403
increased IgG2a level J:91403
\Il4/Il13tm3Anjm/\Il4/Il13tm3Anjm
(involves: 129P2/OlaHsd * BALB/c)
abnormal splenocyte physiology J:60609
abnormal susceptibility to infection J:60609, J:131994
decreased IgG1 level J:178986
decreased inflammatory response J:60609, J:165513
ileum inflammation J:60609
increased susceptibility to parasitic infection J:60609
increased susceptibility to parasitic infection induced morbidity/mortality J:60609
\Il4tm1(CD2)Irvr/\Il4+
(involves: 129P2/OlaHsd * C57BL/6)
immune system phenotype J:111440
\Il4tm1(CD2)Mmrs/\Il4tm1(CD2)Mmrs
(involves: 129)
decreased basophil cell number J:181313
decreased IgE level J:178986
decreased IgG1 level J:178986
decreased interleukin-4 secretion J:181313
\Il4tm1.1Wep/\Il4+
(C.129P2-Il4tm1.1Wep)
decreased IgE level J:138827
\Il4tm1.1Wep/\Il4+
\Stat6tm1Gru/\Stat6tm1Gru

(C.129-Stat6tm1Gru Il4tm1.1Wep)
abnormal T-helper 2 cell differentiation J:138827
decreased IgE level J:138827
impaired eosinophil recruitment J:138827
\Il4tm1.1Wep/\Il4tm1.1Wep
(involves: 129P2/OlaHsd * C57BL/6)
decreased interleukin-4 secretion J:67964
\Il4tm1.1Wep/\Il4tm1.1Wep
(C.129P2-Il4tm1.1Wep)
abnormal T-helper 2 cell differentiation J:138827
decreased IgE level J:138827
impaired eosinophil recruitment J:138827
\Il4tm1.1Wep/\Il4tm1.1Wep
\Stat6tm1Gru/\Stat6tm1Gru

(C.129-Stat6tm1Gru Il4tm1.1Wep)
abnormal T-helper 2 cell differentiation J:138827
decreased IgE level J:138827
impaired eosinophil recruitment J:138827
\Il4tm1Cgn/\Il4tm1Cgn
(B6.Cg-Il4tm1Cgn)
abnormal humoral immune response J:89095
abnormal T-helper 2 physiology J:89095
\Il4tm1Cgn/\Il4tm1Cgn
(NOD.129P2-Il4tm1Cgn)
decreased susceptibility to autoimmune disorder J:95105
increased susceptibility to autoimmune disorder J:95105
\Il4tm1Cgn/\Il4tm1Cgn
(NOD.Cg-H2b Il4tm1Cgn)
lacrimal gland inflammation J:105803
salivary gland inflammation J:105803
\Il4tm1Cgn/\Il4tm1Cgn
(involves: 129P2/OlaHsd * NOD)
abnormal cytokine secretion J:85924
decreased IgG1 level J:85924
\Il4tm1Cgn/\Il4tm1Cgn
(either: NOD.129-Il4tm1Cgn or (involves: 129 * NOD))
autoimmune response J:85924
insulitis J:85924
\Il4tm1Cgn/\Il4tm1Cgn
(involves: 129P2/OlaHsd * C57BL/6)
abnormal cytokine secretion J:704
decreased IgE level J:704
decreased IgG1 level J:704
granulomatous inflammation J:113543
\Il4tm1Cgn/\Il4tm1Cgn
(MRL.129P2-Il4tm1Cgn)
lacrimal gland inflammation J:132514
\Il4tm1Cgn/\Il4tm1Cgn
(B6.129P2-Il4tm1Cgn/J)
immune system phenotype J:160119, J:44346
\Il4tm1Cgn/\Il4tm1Cgn
(involves: 129P2/OlaHsd * C57BL/6J * MRL/Mp)
decreased IgE level J:39600
decreased IgG1 level J:39600
\Il4tm1Cgn/\Il4tm1Cgn
(involves: 129P2/OlaHsd * A/WySn * C57BL/10SnSg * Swiss)
decreased IgG1 level J:119207
increased IgG2a level J:119207
\Il4tm1Cgn/\Il4tm1Cgn
\Ndfip1Gt(RRD002)Byg/\Ndfip1Gt(RRD002)Byg

(involves: 129P2/OlaHsd)
esophageal inflammation J:205692
increased CD4-positive, alpha-beta T cell number J:205692
increased eosinophil cell number J:205692
increased inflammatory response J:205692
increased interleukin-2 secretion J:205692
increased neutrophil cell number J:205692
increased T cell number J:205692
lung inflammation J:205692
\Il4tm1Cgn/\Il4tm1Cgn
\Tg(TcraBDC2.5,TcrbBDC2.5)1Doi/0

(NOD.Cg-Il4tm1Cgn Tg(TcraBDC2.5,TcrbBDC2.5)1Doi)
decreased susceptibility to autoimmune diabetes J:85924
insulitis J:85924
\Il4tm1Kopf/\Il4tm1Kopf
(involves: 129S2/SvPas * C57BL/6)
abnormal response to infection J:14593
decreased IgE level J:14593
decreased IgG1 level J:14593
decreased interleukin-3 secretion J:14593
decreased interleukin-4 secretion J:14593
decreased interleukin-5 secretion J:14593
decreased interleukin-10 secretion J:14593
increased IgG level J:14593
\Il4tm1Kopf/\Il4tm1Kopf
(involves: 129S2/SvPas)
decreased eosinophil cell number J:113065
decreased IgE level J:113065
decreased interleukin-5 secretion J:113065
\Il4tm1Kopf/\Il4tm1Kopf
\Lyntm1Ard/\Lyntm1Ard

(involves: 129P2/OlaHsd * 129S2/SvPas)
abnormal circulating complement protein level J:161523
decreased B cell number J:161523
decreased IgE level J:161523
decreased IgG1 level J:161523
increased anti-double stranded DNA antibody level J:161523
increased anti-nuclear antigen antibody level J:161523
increased basophil cell number J:161523
increased IgA level J:161523
increased IgG2a level J:161523
increased IgG2b level J:161523
increased IgM level J:161523
increased mast cell number J:161523
\Il4tm1Lky/\Il4+
\Lattm1.1Mal/\Lattm1.1Mal

(involves: 129S2/SvPas * C57BL/6)
abnormal T-helper 2 physiology J:151840
\Il4tm1Lky/\Il4tm1Lky
\Itktm1Litt/\Itktm1Litt

(involves: 129S4/SvJae * BALB/c * C57BL/6J)
abnormal cytokine secretion J:129883
abnormal response to infection J:129883
abnormal T-helper 2 physiology J:129883
immune system phenotype J:129883
\Il4tm1Nnt/\Il4tm1Nnt
(C57BL/6-Il4tm1Nnt/J)
abnormal microglial cell morphology J:125605
abnormal T-helper 2 physiology J:37196
CNS inflammation J:125605
decreased IgE level J:37196
decreased IgG1 level J:37196
decreased IgM level J:37196
decreased interleukin-4 secretion J:37196
decreased interleukin-5 secretion J:37196
decreased interleukin-10 secretion J:120556, J:37196
granulomatous inflammation J:37196
increased IgA level J:37196
increased interferon-gamma secretion J:120556, J:37196
stomach inflammation J:120556
\Il4tm1Nnt/\Il4tm1Nnt
(involves: C57BL/6)
abnormal interleukin-4 secretion J:91403
decreased susceptibility to autoimmune disorder J:91403
\Il4tm1Rao/\Il4tm1Rao
(involves: 129S6/SvEvTac * C57BL/6)
abnormal mast cell physiology J:78089
abnormal T-helper 2 physiology J:78089
decreased interleukin-4 secretion J:78089
decreased interleukin-13 secretion J:78089
\Il4tm2.1Kubo/\Il4tm2.1Kubo
(B6.Cg-Il4tm2.1Kubo)
decreased IgE level J:167446
decreased IgG1 level J:167446
decreased interleukin-4 secretion J:167446
impaired eosinophil recruitment J:167446
increased IgG2c level J:167446
increased interleukin-5 secretion J:167446
increased interleukin-13 secretion J:167446
\Il4tm2Nnt/\Il4tm2Nnt
(BALB/c-Il4tm2Nnt/J)
abnormal dendritic cell antigen presentation J:141937
abnormal dendritic cell differentiation J:141937
decreased IgE level J:31486
decreased IgG1 level J:31486
decreased interleukin-5 secretion J:141937
decreased interleukin-13 secretion J:141937
decreased susceptibility to autoimmune disorder J:141937
increased interferon-gamma secretion J:141937
\Il4tm2Nnt/\Il4tm2Nnt
(BALB/c-Il4tm2Nnt)
abnormal splenocyte physiology J:60609
abnormal susceptibility to infection J:60609
ileum inflammation J:60609
increased susceptibility to parasitic infection J:60609
increased susceptibility to parasitic infection induced morbidity/mortality J:60609
\Il4tm2Nnt/\Il4tm2Nnt
\Tgfb1tm1Doe/\Tgfb1tm1Doe

(C.Cg-Tgfb1tm1Doe Il4tm2Nnt)
liver inflammation J:69346
\Il4tm3.1Kubo/\Il4tm3.1Kubo
(B6.Cg-Il4tm3.1Kubo)
decreased interleukin-4 secretion J:167446
\Il4ppqNZB/Slc/\Il4ppqNZW/Slc
(involves: NZB/Slc * NZW/Slc)
abnormal cytokine secretion J:117863
\Il4raM1Btlr/\Il4raM1Btlr
(C57BL/6J-Il4raM1Btlr)
decreased IgE level J:267558
\Il4raM2Btlr/\Il4raM2Btlr
(C57BL/6J-Il4raM2Btlr)
decreased IgE level J:272804
\Il4ratm1Fbb/\Il4ratm1Fbb
(involves: BALB/c)
abnormal susceptibility to infection J:55526
\Il4ratm1Fbb/\Il4ratm1Fbb
(involves: BALB/cJ)
abnormal circulating cytokine level J:133518
abnormal circulating interferon-gamma level J:133518
abnormal cytokine secretion J:114751
abnormal immune system physiology J:114751
abnormal macrophage physiology J:114751
decreased T-helper 2 cell number J:172134
granulomatous inflammation J:114751
impaired macrophage chemotaxis J:114751
increased circulating interleukin-4 level J:133518
increased susceptibility to infection J:114751
increased susceptibility to parasitic infection J:114751
liver inflammation J:114751
\Il4ratm1Fbb/\Il4ratm2Fbb
\Lyz2tm1(cre)Ifo/\Lyz2+

(involves: 129P2/OlaHsd * BALB/c)
abnormal immune system physiology J:114751
abnormal macrophage physiology J:114751
decreased susceptibility to parasitic infection J:114751
granulomatous inflammation J:114751
increased susceptibility to parasitic infection J:114751
liver inflammation J:114751
\Il4ratm1Sz/\Il4ratm1Sz
(BALB/c-Il4ratm1Sz/J)
abnormal microglial cell morphology J:125605
abnormal susceptibility to infection J:131994
abnormal T-helper 2 physiology J:43656
decreased IgE level J:43656
decreased IgG1 level J:43656
decreased interleukin-4 secretion J:43656
decreased interleukin-5 secretion J:43656
decreased interleukin-10 secretion J:43656
increased IgG2a level J:43656
\Il4ratm1Sz/\Il4ratm1Sz
(BALB/c-Il4ratm1Sz)
increased IgG2a level J:110429
increased susceptibility to parasitic infection J:110429
\Il4ratm1Sz/\Il4ratm1Sz
\Il7rtm1.1Asin/\Il7rtm1Imx
\Tg(Cd8a*-cre)B8Asin/0

(involves: 129S7/SvEvBrd * BALB/cJ * C57BL/6)
decreased CD8-positive, alpha-beta T cell number J:190889
\Il4ratm1Tch/\Il4ratm1Tch
(involves: 129X1/SvJ * BALB/c)
abnormal immune serum protein physiology J:86215
abnormal T-helper 2 cell morphology J:86215
decreased T cell proliferation J:86215
increased IgE level J:86215
increased IgG level J:86215
respiratory system inflammation J:86215
\Il4ratm2Tch/\Il4ratm2Tch
(C.129X1-Il4ratm2Tch)
abnormal T-helper 2 physiology J:152376
increased circulating interleukin-4 level J:152376
increased eosinophil cell number J:152376
increased IgE level J:152376
increased monocyte cell number J:152376
increased susceptibility to type I hypersensitivity reaction J:152376
respiratory system inflammation J:152376
\Il4ratm2Tch/\Il4ratm2Tch
\Tg(Scgb1a1-rtTA,tetO-Il13)1Eli/?

(B6.Cg-Il4ratm2Tch Tg(Scgb1a1-rtTA,tetO-IL13)1Eli)
increased eosinophil cell number J:152376
respiratory system inflammation J:152376
\Il4ratm3.1Tch/\Il4ratm3.1Tch
(C.129X1-Il4ratm3.1Tch)
abnormal macrophage activation involved in immune response J:160806
increased IgE level J:160806
increased interleukin-4 secretion J:160806
increased susceptibility to type I hypersensitivity reaction J:160806
\Il5tm1.1(icre)Lky/\Il5+
(C57BL/6-Il5tm1.1(icre)Lky)
decreased circulating interleukin-5 level J:206097
\Il5tm1Anjm/\Il5tm1Anjm
(involves: 129P2/OlaHsd * C57BL/6)
abnormal mast cell morphology J:113543
abnormal mast cell physiology J:113543
abnormal susceptibility to infection J:113543
decreased eosinophil cell number J:113543
decreased IgE level J:113543
granulomatous inflammation J:113543
increased susceptibility to parasitic infection J:113543
\Il5tm1Anjm/\Il5tm1Anjm
\Il9tm1Anjm/\Il9tm1Anjm

(involves: 129P2/OlaHsd * C57BL/6)
abnormal humoral immune response J:113543
abnormal interleukin level J:113543
abnormal mast cell morphology J:113543
abnormal mast cell physiology J:113543
abnormal susceptibility to infection J:113543
decreased eosinophil cell number J:113543
decreased IgE level J:113543
granulomatous inflammation J:113543
increased susceptibility to parasitic infection J:113543
\Il5tm1Kopf/\Il5tm1Kopf
(C57BL/6-Il5tm1Kopf/J)
increased eosinophil cell number J:30867
\Il5tm1Kopf/\Il5tm1Kopf
(C57BL/6-Il5tm1Kopf)
granulomatous inflammation J:107418
increased interferon-gamma secretion J:107418
increased lymphocyte cell number J:30641
increased neutrophil cell number J:30641
\Il5tm1Ktk/\Il5+
(B6.129S4-Il5tm1Ktk)
decreased interleukin-5 secretion J:180790
\Il5tm1Ktk/\Il5tm1Ktk
(B6.129S4-Il5tm1Ktk)
abnormal B-1 B cell morphology J:180790
decreased interleukin-5 secretion J:180790
\Il5tm2Anjm/\Il5tm2Anjm
\Il9tm1Anjm/\Il9tm1Anjm

(involves: 129P2/OlaHsd * C57BL/6)
abnormal immunoglobulin level J:113543
abnormal interleukin level J:113543
abnormal susceptibility to infection J:113543
granulomatous inflammation J:113543
increased eosinophil cell number J:113543
increased susceptibility to parasitic infection J:113543
\Il5tm3Anjm/\Il5tm3Anjm
(involves: 129P2/OlaHsd * C57BL/6)
granulomatous inflammation J:113543
\Il5tm3Anjm/\Il5tm3Anjm
\Il9tm1Anjm/\Il9tm1Anjm

(involves: 129P2/OlaHsd * C57BL/6)
granulomatous inflammation J:113543
\Il5ratm1Ktk/\Il5ratm1Ktk
(involves: 129P2/OlaHsd * C57BL/6)
abnormal B cell differentiation J:33140
abnormal eosinophil cell number J:33140
abnormal immune system physiology J:33140
abnormal lymphopoiesis J:33140
abnormal T cell differentiation J:33140
decreased CD4-positive, alpha-beta T cell number J:33140
decreased IgA level J:33140
decreased IgG3 level J:33140
decreased IgM level J:33140
decreased immunoglobulin level J:33140
increased susceptibility to parasitic infection J:33140
\Il5ratm1Ktk/\Il5ratm1Ktk
(B6.129P2-Il5ratm1Ktk)
abnormal B-1 B cell morphology J:89849
decreased B cell proliferation J:89849
decreased B-1 B cell number J:89849
decreased IgA level J:89849
decreased IgG1 level J:89849
decreased IgG3 level J:89849
decreased IgM level J:89849
\Il5ratm1Ktk/\Il5ratm1Ktk
\Lyntm1Tya/\Lyntm1Tya

(involves: 129P2/OlaHsd * C57BL/6)
abnormal immune system organ morphology J:91089
abnormal spleen B cell corona morphology J:91089
abnormal spleen white pulp morphology J:91089
decreased B-1 B cell number J:91089
enlarged lymph nodes J:91089
enlarged spleen J:91089
glomerulonephritis J:91089
increased anti-double stranded DNA antibody level J:91089
increased IgA level J:91089
increased IgM level J:91089
increased immunoglobulin level J:91089
\Il6tm1.1Jho/\Il6tm1.1Jho
\Tg(GFAP-cre)8Gtm/0

(involves: 129S4/SvJaeSor * 129X1/SvJ * C57BL/6 * CBA)
microgliosis J:211914
\Il6tm1Kopf/\Il6+
\Prdm1tm1Clme/\Prdm1tm1Clme
\Tg(Itgax-cre)1-1Reiz/0

(involves: 129S1/Sv * 129S2/SvPas * 129X1/SvJ * C57BL/6 * CBA)
immune system phenotype J:178876
\Il6tm1Kopf/\Il6+
\Tg(ED-L2-IL1RN/IL1B)#Tcw/?

(B6.Cg-Il6tm1Kopf Tg(ED-L2-IL1RN/IL1B)#Tcw)
esophageal inflammation J:180282
\Il6tm1Kopf/\Il6tm1Kopf
(involves: 129S2/SvPas * C57BL/6)
abnormal acute phase protein level J:17360
abnormal microglial cell morphology J:79142
abnormal T cell differentiation J:17360
decreased cytotoxic T cell cytolysis J:17360
decreased T cell number J:17360
increased susceptibility to bacterial infection J:17360
increased susceptibility to induced colitis J:79073
increased susceptibility to Poxviridae infection J:17360
\Il6tm1Kopf/\Il6tm1Kopf
(B6.129S2-Il6tm1Kopf/J)
abnormal interleukin-6 secretion J:109359
decreased interferon-gamma secretion J:123351
decreased pro-B cell number J:117320
decreased susceptibility to induced arthritis J:208213
increased interleukin-4 secretion J:123351
\Il6tm1Kopf/\Il6tm1Kopf
(involves: 129S2/SvPas)
abnormal inflammatory response J:160966
abnormal T cell physiology J:159479
decreased interleukin-17 secretion J:159479
increased susceptibility to bacterial infection induced morbidity/mortality J:161073
\Il6tm1Kopf/\Il6tm1Kopf
\Il6sttm1Ern/\Il6sttm1Ern

(involves: 129S1/Sv * 129S2/SvPas)
decreased susceptibility to endotoxin shock J:168781
immune system phenotype J:139226
\Il6tm1Kopf/\Il6tm1Kopf
\Inpp5dtm1Rkh/\Inpp5dtm1Rkh

(involves: 129 * C57BL/6)
abnormal lymphopoiesis J:117320
abnormal myelopoiesis J:117320
decreased pro-B cell number J:117320
\Il6tm1Kopf/\Il6tm1Kopf
\Junbtm3Wag/\Junbtm3Wag
\Tg(KRT5-cre)1Tak/0

(involves: 129/Sv * 129P2/OlaHsd * 129S2/SvPas * C3H * C57BL/6)
immune system phenotype J:155575
skin inflammation J:155575
\Il6tm1Kopf/\Il6tm1Kopf
\Tanktm1Aki/\Tanktm1Aki

(involves: 129/Sv * 129S2/SvPas * C57BL/6)
immune system phenotype J:151757
\Il6tm1Kopf/\Il6tm1Kopf
\Tg(ED-L2-IL1RN/IL1B)#Tcw/?

(B6.Cg-Il6tm1Kopf Tg(ED-L2-IL1RN/IL1B)#Tcw)
esophageal inflammation J:180282
\Il6tm1Kopf/\Il6tm1Kopf
\Tg(Rorc-EGFP)1Ebe/?

(involves: 129S2/SvPas * C57BL/6)
abnormal effector T cell morphology J:137020
\Il6tm1Mur/\Il6tm1Mur
(involves: 129P2/OlaHsd * C57BL/6)
abnormal neutrophil physiology J:25684
immune system phenotype J:25684
increased susceptibility to bacterial infection J:25684
\Il6tm1Mur/\Il6tm1Mur
(involves: 129/Sv * C57BL/6)
abnormal interferon level J:40579
abnormal lymphocyte cell number J:40579
absent NK cells J:40579
brain inflammation J:40579
increased susceptibility to parasitic infection J:40579
\Il6tm1Mur/\Il6tm1Mur
(B6.129P2(B6)-Il6tm1Mur)
abnormal inflammatory response J:85581
abnormal microglial cell morphology J:85581
abnormal microglial cell physiology J:85581
abnormal osteoclast differentiation J:65093
abnormal osteoclast physiology J:65093
\Il6tm1Poli/\Il6tm1Poli
(involves: 129S/SvEv * MF1)
abnormal macrophage physiology J:79314
abnormal neutrophil physiology J:79314
abnormal osteoclast physiology J:17249
abnormal T-helper 1 cell morphology J:79314
abnormal T-helper 1 physiology J:79314
abnormal T-helper 2 physiology J:79314
decreased circulating interleukin-12 level J:79314
decreased IgA level J:79314
decreased IgE level J:79314
immune system phenotype J:17249
increased circulating interleukin-10 level J:79314
increased IgG2a level J:79314
increased susceptibility to fungal infection J:79314
\Il6tm1Poli/\Il6tm1Poli
(involves: 129S/SvEv * C57BL/6)
decreased inflammatory response J:68063
impaired neutrophil recruitment J:68063
\Il6tm1Poli/\Il6tm1Poli
(CAnNCrl.129S(Cg)-Il6tm1Poli)
abnormal B cell proliferation J:42869
abnormal immune system physiology J:96706
decreased inflammatory response J:42869
\Il6ratm1.1(IL6R)Csk/\Il6ratm1.1(IL6R)Csk
(involves: 129S6/SvEvTac * C57BL/6)
abnormal circulating serum amyloid protein level J:207264
\Il6ratm1.1(IL6R)Csk/\Il6ratm1.1(IL6R)Csk
\Tg(H2-L-IL6)40Csk/0

(involves: 129S6/SvEvTac * C57BL/6)
enlarged lymph nodes J:207264
enlarged spleen J:207264
increased plasma cell number J:207264
increased spleen weight J:207264
increased spleen white pulp amount J:207264
\Il6ratm1.1Drew/\Il6ratm1.1Drew
\Lyz2tm1(cre)Ifo/\Lyz2+

(involves: C57BL/6 * C57BL/6N * SJL)
immune system phenotype J:160966
\Il6ratm1.1Drew/\Il6ratm1.1Drew
\Speer6-ps1Tg(Alb-cre)21Mgn/\Speer6-ps1+

(involves: C57BL/6 * C57BL/6N * SJL)
decreased acute inflammation J:160966
\Il6ratm1.1Jcbr/\Il6ratm1.1Jcbr
\Lyz2tm1(cre)Ifo/\Lyz2+

(involves: 129P2/OlaHsd * C57BL/6)
decreased circulating interleukin-1 beta level J:188445
decreased circulating tumor necrosis factor level J:188445
decreased susceptibility to parasitic infection J:188445
\Il6ratm1.1Jcbr/\Il6ratm1.1Jcbr
\Tg(Alb1-cre)7Gsc/0

(involves: C57BL/6 * FVB/N)
decreased circulating interleukin-1 beta level J:188445
decreased circulating tumor necrosis factor level J:188445
decreased susceptibility to parasitic infection J:188445
increased circulating interleukin-6 level J:166367
increased circulating tumor necrosis factor level J:166367
\Il6ratm1.2Drew/\Il6ratm1.2Drew
(involves: C57BL/6 * C57BL/6N * FVB/N * SJL)
abnormal inflammatory response J:160966
\Il6ratm1.2Jcbr/\Il6ratm1.2Jcbr
(involves: C57BL/6)
decreased circulating interleukin-1 beta level J:188445
decreased circulating tumor necrosis factor level J:188445
decreased susceptibility to parasitic infection J:188445
decreased susceptibility to parasitic infection induced morbidity/mortality J:188445
liver inflammation J:202764
\Il6ratm1Saj/\Il6ratm1Saj
(involves: 129P2/OlaHsd * C57BL/6J)
abnormal CD4-positive, alpha-beta T cell physiology J:159479
\Il6sttm1Ard/\Il6sttm1Ard
(involves: 129S1/Sv * C57BL/6)
abnormal leukocyte cell number J:110742
abnormal thrombopoiesis J:110742
cecum inflammation J:79555
conjunctivitis J:79555
decreased IgA level J:79555
decreased IgG level J:79555
decreased immunoglobulin level J:79555
increased inflammatory response J:79555
increased susceptibility to induced colitis J:79073
increased susceptibility to parasitic infection J:79555
\Il6sttm1Ern/\Il6sttm1Ern
(involves: 129S1/Sv * C57BL/6)
abnormal inflammatory response J:139226
decreased susceptibility to induced colitis J:79073
enlarged spleen J:79073
increased osteoclast cell number J:87612
increased susceptibility to induced arthritis J:142883
stomach inflammation J:87206
\Il6sttm1Ern/\Il6sttm1Ern
(involves: 129S1/Sv)
increased circulating interleukin-6 level J:168781
increased interleukin-6 secretion J:168781
increased neutrophil cell number J:168781
increased susceptibility to endotoxin shock J:168781
\Il6sttm1Ern/\Il6sttm1Ern
\Stat1tm1Rds/\Stat1tm1Rds

(involves: 129S1/Sv)
abnormal inflammatory response J:139226
\Il6sttm1Ern/\Il6sttm1Ern
\Stat3tm1Aki/\Stat3+

(involves: 129P2/OlaHsd * 129S1/Sv)
decreased circulating interleukin-6 level J:168781
decreased susceptibility to endotoxin shock J:168781
immune system phenotype J:100160, J:142883, J:139226
\Il6sttm1Ern/\Il6sttm1Ern
\Tg(RP11-H2112)5Trme/0

(involves: 129S1/Sv * C57BL/6J * DBA/2J)
abnormal spleen size J:234656
\Il6sttm1Ern/\Il6sttm1Ern
\Tg(RP11-H2112)9Trme/0

(involves: 129S1/Sv * C57BL/6J * DBA/2J)
abnormal spleen size J:234656
\Il6sttm1Ern/\Il6sttm1Ern
\Tiraptm1.1Pjh/\Tiraptm1.1Pjh

(involves: 129S1/Sv)
decreased circulating interleukin-6 level J:168781
decreased susceptibility to endotoxin shock J:168781
\Il6sttm1Kish/\Il6sttm1Kish
(involves: 129P2/OlaHsd * C57BL/6)
thymus hypoplasia J:75419
\Il6sttm1Kish/\Il6sttm1Kish
(involves: 129P2/OlaHsd * CD-1)
abnormal bone marrow development J:88710
abnormal osteoclast differentiation J:88710
abnormal osteoclast morphology J:88710
abnormal osteoclast physiology J:88710
increased osteoclast cell number J:88710
\Il6sttm1Thir/\Il6sttm1Thir
(Not Specified)
abnormal B cell physiology J:59922
abnormal dendritic cell antigen presentation J:113335
decreased interleukin-4 secretion J:59922
enlarged axillary lymph nodes J:59922
enlarged cervical lymph nodes J:59922
enlarged inguinal lymph nodes J:59922
enlarged mesenteric lymph nodes J:59922
increased B cell number J:59922
increased CD4-positive, alpha-beta T cell number J:59922
increased CD8-positive, alpha-beta T cell number J:59922
increased IgG2a level J:59922
increased IgG2b level J:59922
increased interferon-gamma secretion J:59922
lymph node hyperplasia J:59922
spleen hyperplasia J:59922
\Il6sttm1Thir/\Il6sttm1Thir
(involves: 129 * C57BL/6)
abnormal T cell activation J:133059
abnormal T cell clonal deletion J:133059
abnormal thymocyte activation J:133059
decreased double-positive T cell number J:133059
increased activated T cell number J:133059
increased anti-double stranded DNA antibody level J:133059
increased anti-nuclear antigen antibody level J:133059
increased anti-single stranded DNA antibody level J:133059
increased autoantibody level J:133059
increased double-negative T cell number J:133059
increased IgA level J:133059
increased IgG1 level J:133059
increased IgG2a level J:133059
increased IgG2b level J:133059
increased neutrophil cell number J:133059
increased single-positive T cell number J:133059
rheumatoid arthritis J:133059
\Il6sttm1Thir/\Il6sttm1Thir
\Rag2tm1Fwa/\Rag2tm1Fwa

(involves: 129S/SvEv * C57BL/6)
immune system phenotype J:133059
\Il6sttm1Thir/\Il6sttm1Thir
\Tg(TcraH-Y,TcrbH-Y)71Vbo/?

(involves: 129 * C57BL/6 * DBA)
abnormal negative T cell selection J:133059
\Il6sttm1Wme/\Il6sttm1Wme
(involves: 129P2/OlaHsd * C57BL/6)
abnormal immunoglobulin level J:67677
abnormal T cell differentiation J:67677
abnormal thrombopoiesis J:67677
decreased thymocyte number J:67677
increased IgE level J:67677
increased IgG level J:67677
increased leukocyte cell number J:67677
\Il6sttm2Thir/\Il6sttm2Thir
(Not Specified)
abnormal dendritic cell antigen presentation J:113335
decreased B-1a cell number J:59922
decreased IgG1 level J:59922
decreased IgG2a level J:59922
decreased IgG2b level J:59922
decreased interferon-gamma secretion J:59922
increased IgM level J:59922
\Il6sttm3Thir/\Il6sttm3Thir
(Not Specified)
decreased IgA level J:59922
decreased IgG2a level J:59922
decreased IgG2b level J:59922
\Il7hlb368/\Il7hlb368
(C57BL/6J-Il7hlb368/J)
abnormal T cell subpopulation ratio J:118450
absent axillary lymph nodes J:118450
absent cervical lymph nodes J:118450
absent mesenteric lymph nodes J:118450
absent Peyer's patches J:118450
absent popliteal lymph nodes J:118450
decreased leukocyte cell number J:82961, J:118450
decreased T cell number J:118450
small inguinal lymph nodes J:118450
small spleen J:118450
small thymus J:118450
spleen hypoplasia J:118450
thymus hypoplasia J:118450
\Il7m1Jyen/\Il7m1Jyen
(involves: C3H * C57BL/6)
abnormal myeloid leukocyte morphology J:136470
decreased B cell number J:136470
decreased single-positive T cell number J:136470
lymph node hypoplasia J:136470
spleen hypoplasia J:136470
thymus hypoplasia J:136470
\Il7tm1.1Mysl/\Il7+
(B6.129P2(Cg)-Il7tm1.1Mysl)
decreased T cell number J:200544
small lymph nodes J:200544
\Il7tm1.1Mysl/\Il7tm1.1Mysl
(B6.129P2(Cg)-Il7tm1.1Mysl)
abnormal mesenteric lymph node morphology J:200544
arrested B cell differentiation J:200544
decreased T cell number J:200544
decreased thymocyte number J:200544
immune system phenotype J:200544
small lymph nodes J:200544
thymus hypoplasia J:200544
\Il7tm1Dnax/\Il7tm1Dnax
(involves: 129P2/OlaHsd * C57BL/6)
abnormal CD8-positive, alpha beta T cell morphology J:125259
absent lymph nodes J:24165
absent Peyer's patches J:24165
arrested B cell differentiation J:24165
decreased lymphocyte cell number J:24165
decreased spleen weight J:24165
decreased thymus weight J:24165
small spleen J:24165
small thymus J:24165
spleen hypoplasia J:24165
thymus hypoplasia J:24165
\Il7tm1Dnax/\Il7tm1Dnax
(involves: 129P2/OlaHsd)
decreased thymocyte number J:64861
\Il7tm1Dnax/\Il7tm1Dnax
\Rag2tm1Fwa/\Rag2tm1Fwa

(involves: 129P2/OlaHsd * 129S/SvEv)
decreased NK cell number J:132257
\Il7tm1Hms/\Il7tm1Hms
(involves: 129S6/SvEvTac)
spleen hypoplasia J:43971
thymus hypoplasia J:43971
\Il7tm2.1Iku/\Il7tm2.1Iku
\Speer6-ps1Tg(Alb-cre)21Mgn/\Speer6-ps1+

(involves: 129S6/SvEvTac * C57BL/6 * C57BL/6J * DBA)
abnormal B cell differentiation J:190615
abnormal NK T cell physiology J:190615
decreased B cell number J:190615
decreased double-negative T cell number J:190615
decreased lymphocyte cell number J:190615
decreased NK T cell number J:190615
decreased T cell number J:190615
immune system phenotype J:190615
\Il7rtm1.1Asin/\Il7rtm1Imx
\Tg(Cd4-cre)1Cwi/0

(involves: 129S7/SvEvBrd * C57BL/6 * DBA/2)
decreased CD8-positive, alpha-beta T cell number J:190889
\Il7rtm1.1Asin/\Il7rtm1Imx
\Tg(Cd8a*-cre)B8Asin/0

(involves: 129S7/SvEvBrd * C57BL/6)
decreased CD8-positive, alpha-beta T cell number J:190889
\Il7rtm1Abra/\Il7rtm1Abra
(B6.129S4-Il7rtm1Abra)
abnormal CD4-positive, alpha-beta T cell physiology J:125360
abnormal T cell differentiation J:125360
abnormal T cell proliferation J:125360
decreased B cell number J:125360
decreased CD4-positive, alpha-beta T cell number J:125360
decreased CD8-positive, alpha-beta T cell number J:125360
decreased memory T cell number J:125360
decreased thymocyte number J:125360
increased double-positive T cell number J:125360
\Il7rtm1Iku/\Il7rtm1Iku
(involves: 129P2/OlaHsd * C57BL/6J)
abnormal B cell differentiation J:34658
abnormal gamma-delta T cell differentiation J:34658
abnormal T cell subpopulation ratio J:34658
absent mature gamma-delta T cells J:34658
absent Peyer's patches J:45633
decreased B-1 B cell number J:34658
decreased double-positive T cell number J:34658
decreased immature B cell number J:34658
decreased leukocyte cell number J:34658
decreased lymphocyte cell number J:34658
decreased mature B cell number J:34658
decreased T cell number J:34658
immune system phenotype J:34658
increased double-negative T cell number J:34658
small thymus J:34658
spleen hypoplasia J:34658
thymus hypoplasia J:34658
\Il7rtm1Imx/\Il7rtm1Imx
(involves: 129P3/J * 129S7/SvEvBrd)
arrested B cell differentiation J:21135
arrested T cell differentiation J:21135
decreased B cell number J:21135
decreased T cell number J:21135
lymph node hypoplasia J:21135
spleen hypoplasia J:21135
thymus hypoplasia J:21135
\Il7rtm1Imx/\Il7rtm1Imx
(B6.129S7-Il7rtm1Imx)
abnormal T cell differentiation J:125360
decreased double-positive T cell number J:125360
decreased thymocyte number J:125360
\Il7rtm1Imx/\Il7rtm1Imx
(involves: 129S7/SvEvBrd)
decreased thymocyte number J:64861
\Il7rtm1Imx/\Il7rtm1Imx
\Tg(Lck-Il7r)1676Trma/?

(involves: 129S7/SvEvBrd * C57BL/6 * SJL)
decreased T cell proliferation J:66400
decreased thymocyte number J:66400
increased thymocyte apoptosis J:66400
\Il7rtm2Iku/\Il7rtm2Iku
\Tg(Cd4-cre)1Cwi/?

(involves: 129S6/SvEvTac * C57BL/6 * DBA/2)
abnormal CD4-positive T cell differentiation J:193283
abnormal CD8-positive, alpha-beta T cell differentiation J:193283
abnormal T cell morphology J:193283
decreased NK T cell number J:193283
increased B cell number J:193283
increased gamma-delta T cell number J:193283
increased thymocyte number J:193283
\Il7rtm2Iku/\Il7rtm2Iku
\Tg(Cd4-cre)1Cwi/?
\Tg(H2-K-BCL2)1Josd/?

(involves: 129S6/SvEvTac * C57BL/6 * C3H * DBA/2)
immune system phenotype J:193283
\Il9tm1Anjm/\Il9tm1Anjm
(involves: 129P2/OlaHsd * C57BL/6)
abnormal mast cell morphology J:82881
abnormal response to infection J:82881
granulomatous inflammation J:82881, J:113543
increased susceptibility to parasitic infection J:82881
\Il9tm1Anjm/\Il9tm1Anjm
(involves: C57BL/6)
abnormal cytokine secretion J:115764
immune system phenotype J:115764
\Il9tm1Flv/\Il9tm1Flv
(BALB/c-Il9tm1Flv)
increased susceptibility to parasitic infection J:208730
\Il9rtm1Jcrd/\Il9rtm1Jcrd
(involves: C57BL/6)
abnormal regulatory T cell physiology J:151907
immune system phenotype J:115764
increased susceptibility to experimental autoimmune encephalomyelitis J:151907
increased T-helper 1 cell number J:151907
\Il10tm1.1Roer/\Il10tm1.1Roer
(involves: 129P2/OlaHsd * C57BL/6)
abnormal cytokine secretion J:94537
abnormal hypersensitivity reaction J:94537
abnormal innate immunity J:94537
increased susceptibility to bacterial infection J:94537
intestinal inflammation J:94537
\Il10tm1.1Roer/\Il10tm1.1Roer
(involves: 129P2/OlaHsd)
abnormal myeloid leukocyte morphology J:151551
decreased circulating interleukin-10 level J:151551
increased B cell number J:151551
increased myeloid dendritic cell number J:151551
increased plasma cell number J:151551
increased susceptibility to endotoxin shock J:151551
increased T cell number J:151551
spleen hyperplasia J:151551
\Il10tm1Cgn/\Il10tm1Cgn
(involves: 129P2/OlaHsd * C57BL/6)
abnormal cytokine level J:35020
abnormal immune system physiology J:35020
abnormal interferon level J:35020, J:107077, J:125760
abnormal interleukin level J:35020, J:107077, J:51636
abnormal Langerhans cell physiology J:51636
abnormal leukocyte morphology J:35020
abnormal level of surface class II molecules J:15222
abnormal lymphocyte cell number J:35020
abnormal myelopoiesis J:15222
abnormal response to infection J:15222
abnormal tumor necrosis factor level J:107077, J:51636
abnormal type IV hypersensitivity reaction J:35510
cecum inflammation J:35020
chronic inflammation J:15222
colitis J:68476
decreased length of allograft survival J:44346
decreased spleen iron level J:15222
decreased spleen red pulp amount J:15222
decreased T cell proliferation J:125760
immune system phenotype J:107077, J:15222
increased CD4-positive, alpha-beta T cell number J:35020
increased granulocyte number J:35020, J:15222
increased IgE level J:62283
increased IgG1 level J:62283
increased IgG2a level J:62283
increased interferon-gamma secretion J:15222
increased susceptibility to parasitic infection J:123927
increased susceptibility to type IV hypersensitivity reaction J:51636
increased thymus weight J:107077
intestinal inflammation J:35020, J:107077, J:15222
large intestinal inflammation J:35020
small intestinal inflammation J:35020
thymus hyperplasia J:107077
\Il10tm1Cgn/\Il10tm1Cgn
(involves: 129P2/OlaHsd)
abnormal cytokine secretion J:117122
abnormal inflammatory response J:117122
increased circulating interleukin-12 level J:118833
increased circulating tumor necrosis factor level J:118833
increased susceptibility to endotoxin shock J:117122, J:118833
intestinal inflammation J:113376
\Il10tm1Cgn/\Il10tm1Cgn
(B6.129P2-Il10tm1Cgn/J)
abnormal chemokine level J:157787
abnormal cytokine level J:157787, J:139972
abnormal regulatory T cell physiology J:125748
cecum inflammation J:157787
increased circulating interferon-gamma level J:157787
increased circulating interleukin-1 alpha level J:157787
increased circulating interleukin-1 beta level J:157787, J:139972
increased circulating interleukin-2 level J:157787
increased circulating interleukin-6 level J:157787, J:139972
increased circulating interleukin-12 level J:157787
increased circulating interleukin-17 level J:157787
increased circulating tumor necrosis factor level J:157787
increased susceptibility to induced colitis J:157787
increased susceptibility to parasitic infection J:157787
large intestinal inflammation J:149347
\Il10tm1Cgn/\Il10tm1Cgn
(involves: 129P2/OlaHsd * C57BL/6 * DBA/1)
colitis J:84100
\Il10tm1Cgn/\Il10tm1Cgn
(involves: 129P2/OlaHsd * 129S/SvEv)
colitis J:59872
\Il10tm1Cgn/\Il10tm1Cgn
(B10.129P2(B6)-Il10tm1Cgn/J)
decreased length of allograft survival J:44346
\Il10tm1Cgn/\Il10tm1Cgn
(B6.129P2-Il10tm1Cgn)
abnormal circulating interleukin-6 level J:191723
abnormal circulating interleukin-12b level J:191723
\Il10tm1Cgn/\Il10tm1Cgn
\Il4tm1Cgn/\Il4tm1Cgn

(involves: 129P2/OlaHsd * C57BL/6)
abnormal T-helper 1 cell differentiation J:111712
increased interferon-gamma secretion J:111712
\Il10tm1Cgn/\Il10tm1Cgn
\Il12btm1Jm/\Il12btm1Jm

(involves: 129P2/OlaHsd * 129S1/Sv * C57BL/6)
abnormal T-helper 2 cell differentiation J:111712
increased interleukin-13 secretion J:111712
\Il10tm1Cgn/\Il10tm1Cgn
\Il27ratm1Mak/\Il27ratm1Mak

(involves: 129P2/OlaHsd * C57BL/6)
abnormal T-helper 1 physiology J:136179
abnormal T-helper 2 physiology J:136179
colitis J:136179
decreased interferon-gamma secretion J:136179
decreased susceptibility to induced colitis J:136179
increased interleukin-13 secretion J:136179
\Il10tm1Cgn/\Il10tm1Cgn
\Nfil3tm1Look/\Nfil3tm1Look

(involves: 129P2/OlaHsd * 129X1/SvJ)
colitis J:209365
increased interleukin-12 secretion J:209365
\Il10tm1Cgn/\Il10tm1Cgn
\Nfil3tm1Pbro/\Nfil3tm1Pbro

(involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6)
colitis J:209365
increased interleukin-12 secretion J:209365
\Il10tm1Cgn/\Il10tm1Cgn
\Rps6ka4tm1Jsca/\Rps6ka4tm1Jsca
\Rps6ka5tm1Jsca/\Rps6ka5tm1Jsca

(B6.Cg-Il10tm1Cgn Rps6ka5tm1Jsca Rps6ka4tm1Jsca)
decreased interleukin-10 secretion J:139576
increased interleukin-6 secretion J:139576
increased interleukin-12a secretion J:139576
increased interleukin-12b secretion J:139576
increased tumor necrosis factor secretion J:139576
\Il10tm1Cgn/\Il10tm1Cgn
\Tg(MUC1)79.24Gend/0

(B6.Cg-Il10tm1Cgn Tg(MUC1)79.24Gend)
large intestinal inflammation J:149347
\Il10tm1Cgn/\Il10tm1Cgn
\Tg(Vil1-cre)997Gum/?
\Tlr5tm1.1Gewr/\Tlr5tm1.1Gewr

(involves: 129P2/OlaHsd * C57BL/6J * C57BL/6NTac * SJL)
colitis J:229155
\Il10tm1Cgn/\Il10tm1Cgn
\Tlr5tm1.1Gewr/\Tlr5tm1.1Gewr

(involves: 129P2/OlaHsd * C57BL/6J * C57BL/6NTac)
colitis J:229155
\Il10tm1Cgn/\Il10tm1Cgn
\Vdrtm1Mbd/\Vdrtm1Mbd

(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)
abnormal CD4-positive, alpha-beta T cell physiology J:107077
abnormal cytokine level J:107077
abnormal lymph node cell ratio J:107077
abnormal splenic cell ratio J:107077
abnormal thymus corticomedullary boundary morphology J:107077
abnormal thymus involution J:107077
absent spleen white pulp J:107077
colitis J:107077
decreased lymphocyte cell number J:107077
decreased T cell proliferation J:107077
enlarged mesenteric lymph nodes J:107077
enlarged spleen J:107077
increased macrophage cell number J:107077
increased neutrophil cell number J:107077
increased spleen red pulp amount J:107077
increased T cell apoptosis J:107077
intestinal inflammation J:107077
thymus hypoplasia J:107077
\Il10tm1Keny/\Il10+
\Nfil3tm1.1Kubo/\Nfil3tm1.1Kubo

(involves: 129 * C57BL/6)
decreased interleukin-10 secretion J:172134
\Il10tm1Mhry/\Il10tm1Mhry
(involves: 129P2/OlaHsd * C57BL/6)
intestinal inflammation J:117628
\Il10tm1Roer/\Il10tm1Roer
\Foxp3tm4(YFP/icre)Ayr/Y

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
abnormal regulatory T cell physiology J:134513
abnormal type IV hypersensitivity reaction J:134513
colitis J:134513
decreased interleukin-10 secretion J:134513
lung inflammation J:134513
\Il10tm1Roer/\Il10tm1Roer
\Tg(Cd4-cre)1Cwi/0

(involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6 * DBA/2)
abnormal cytokine secretion J:94537
abnormal hypersensitivity reaction J:94537
abnormal lymph node morphology J:94537
increased susceptibility to parasitic infection J:94537
intestinal inflammation J:94537
liver inflammation J:94537
peritoneal inflammation J:94537
\Il10tm2Roer/\Il10tm2Roer
\Lyz2tm1(cre)Ifo/\Lyz2+

(involves: 129P2/OlaHsd * C57BL/6)
abnormal cytokine secretion J:117122
abnormal inflammatory response J:117122
increased susceptibility to endotoxin shock J:117122
\Il10tm2Roer/\Il10tm2Roer
\Tg(Cd4-cre)1Cwi/0

(involves: C57BL/6 * DBA/2)
abnormal inflammatory response J:117122
increased susceptibility to endotoxin shock J:117122
\Il10ram1Jskg/\Il10ram1Jskg
(B6.Cg-Il10ram1Jskg)
colitis J:146644
\Il10raNZW/\Il10ra+
((NZB x NZW)F1)
increased anti-chromatin antibody level J:102087
increased IgG level J:102087
\Il10ratm1.1Jack/\Il10ratm1.1Jack
\Lyz2tm1(cre)Ifo/\Lyz2+

(involves: 129P2/OlaHsd * BALB/c * C57BL/6)
abnormal chemokine level J:157787
abnormal cytokine level J:157787
increased circulating interferon-gamma level J:157787
increased circulating interleukin-1 alpha level J:157787
increased circulating interleukin-1 beta level J:157787
increased circulating interleukin-2 level J:157787
increased circulating interleukin-12 level J:157787
increased circulating interleukin-17 level J:157787
increased circulating tumor necrosis factor level J:157787
increased susceptibility to parasitic infection J:157787
\Il10ratm1.1Jack/\Il10ratm1.1Jack
\Tg(Cd4-cre)1Cwi/0

(involves: 129P2/OlaHsd * BALB/c * C57BL/6 * DBA/2)
immune system phenotype J:157787
\Il10ratm1.1Tlg/\Il10ratm1.1Tlg
\Tg(Cd4-cre)1Cwi/?

(B6.Cg-Tg(Cd4-cre)1Cwi Il10ratm1.1Tlg)
abnormal lymphocyte cell number J:189797
abnormal regulatory T cell number J:189797
autoimmune response J:189797
decreased splenocyte proliferation J:189797
decreased T cell number J:189797
immune system phenotype J:189797
\Il10ratm1.2Jack/\Il10ratm1.2Jack
(involves: 129P2/OlaHsd * BALB/c * C57BL/6 * DBA/2)
abnormal chemokine level J:157787
abnormal cytokine level J:157787
cecum inflammation J:157787
increased circulating interferon-gamma level J:157787
increased circulating interleukin-1 alpha level J:157787
increased circulating interleukin-1 beta level J:157787
increased circulating interleukin-2 level J:157787
increased circulating interleukin-6 level J:157787
increased circulating interleukin-12 level J:157787
increased circulating interleukin-17 level J:157787
increased circulating tumor necrosis factor level J:157787
increased susceptibility to induced colitis J:157787
increased susceptibility to parasitic infection J:157787
\Il10ratm1b(KOMP)Wtsi/\Il10ratm1b(KOMP)Wtsi
(C57BL/6N-Il10ratm1b(KOMP)Wtsi/Orl)
decreased lymphocyte cell number J:211773
increased neutrophil cell number J:211773
\Il10rbtm1Agt/\Il10rbtm1Agt
(involves: 129S2/SvPas * C57BL/6)
abnormal granulocyte differentiation J:45917
abnormal lymph node medullary cord morphology J:45917
abnormal mesenteric lymph node morphology J:45917
abnormal spleen morphology J:45917
colitis J:134156
increased interferon-gamma secretion J:134156
increased interleukin-17 secretion J:134156
increased leukocyte cell number J:45917
increased spleen weight J:45917
large intestinal inflammation J:45917
spleen hyperplasia J:45917
\Il10rbtm1Agt/\Il10rbtm1Agt
\Tg(Cd4-TGFBR2)16Flv/?

(involves: 129S2/SvPas * C3H * C57BL/6)
abnormal cytokine level J:134156
abnormal cytokine secretion J:134156
colitis J:134156
increased circulating interferon-gamma level J:134156
increased circulating interleukin-6 level J:134156
increased circulating tumor necrosis factor level J:134156
increased interferon-gamma secretion J:134156
increased interleukin-17 secretion J:134156
increased tumor necrosis factor secretion J:134156
liver inflammation J:134156
lung inflammation J:134156
proctitis J:134156
\Il11tm2.1Moto/\Il11tm2.1Moto
\Tg(BGLAP-cre)1Clem/0

(involves: C57BL/6NCrlj * CBA/JNCrlj * FVB/NJ)
abnormal circulating interleukin level J:345337
\Il11ra1tm1Gos/\Il11ra1tm1Gos
(involves: 129S2/SvPas * C57BL/6J)
immune system phenotype J:48920
\Il11ra1tm1Gos/\Il11ra1tm1Gos
(involves: 129S2/SvPas * C57BL/6J * CD-1)
abnormal NK cell differentiation J:93811
abnormal uterine NK cell morphology J:93811
\Il11ra1tm1Wehi/\Il11ra1tm1Wehi
(involves: 129S1/Sv * C57BL/6)
immune system phenotype J:42921, J:79073
\Il11ra1tm1Wehi/\Il11ra1tm1Wehi
\Il6tm1Kopf/\Il6tm1Kopf

(involves: 129/Sv * C57BL/6)
increased susceptibility to induced colitis J:79073
\Il12am1Btlr/\Il12am1Btlr
(C57BL/6J-Il12am1Btlr)
increased susceptibility to Herpesvirales infection J:267667
\Il12atm1Cab/\Il12atm1Cab
(involves: 129S4/SvJae * C57BL/6)
decreased circulating interferon-gamma level J:54482
decreased circulating interleukin-12 level J:54482
\Il12atm1Cab/\Il12atm1Cab
(B6.129S4-Il12atm1Cab)
abnormal NK cell physiology J:79552
decreased circulating interferon-gamma level J:79552
\Il12atm1Cab/\Il12atm1Cab
\Il23atm1.1Thak/\Il23atm1.1Thak

(B6.Cg-Il12atm1Cab Il23atm1.1Thak)
decreased susceptibility to experimental autoimmune encephalomyelitis J:143970
\Il12atm1Jm/\Il12atm1Jm
(129S1/Sv-Il12atm1Jm)
abnormal CD4-positive, alpha-beta T cell physiology J:34164
decreased susceptibility to type IV hypersensitivity reaction J:34164
increased susceptibility to parasitic infection J:34164
\Il12atm1Jm/\Il12atm1Jm
(B6.129S1-Il12atm1Jm)
immune system phenotype J:120806
\Il12atm1Jm/\Il12atm1Jm
(C.129S1-Il12atm1Jm)
impaired natural killer cell mediated cytotoxicity J:125611
\Il12atm1Jm/\Il12atm1Jm
(involves: 129S1/Sv)
abnormal NK cell physiology J:139001
\Il12atm1Jm/\Il12atm1Jm
\Il12btm1Jm/\Il12btm1Jm

(B6.129S1-Il12atm1Jm Il12btm1Jm)
impaired natural killer cell mediated cytotoxicity J:125611
\Il12atm1Jm/\Il12atm1Jm
\Rag2tm1Fwa/\Rag2tm1Fwa

(involves: 129S/SvEv * 129S1/Sv * 129S6/SvEvTac)
abnormal interferon secretion J:140483
decreased susceptibility to bacterial infection J:140483
lung inflammation J:140483
\Il12btm1Jm/\Il12btm1Jm
(B6.129S1-Il12btm1Jm/J)
abnormal CD8-positive, alpha-beta T cell physiology J:111568
abnormal granulocyte physiology J:111568
abnormal lymphocyte physiology J:120806
abnormal macrophage physiology J:111568
abnormal NK cell physiology J:120806
decreased circulating interferon-gamma level J:120806
decreased interleukin-17 secretion J:111568
decreased susceptibility to type IV hypersensitivity reaction J:120806
increased susceptibility to bacterial infection J:120806
\Il12btm1Jm/\Il12btm1Jm
(129S1/Sv-Il12btm1Jm)
abnormal CD4-positive, alpha-beta T cell physiology J:34164
decreased susceptibility to type IV hypersensitivity reaction J:34164
increased susceptibility to parasitic infection J:34164
\Il12btm1Jm/\Il12btm1Jm
(involves: 129S1/SvImJ)
abnormal T-helper 1 physiology J:46514
decreased interferon-gamma secretion J:46514
impaired natural killer cell mediated cytotoxicity J:46514
\Il12btm1Jm/\Il12btm1Jm
(involves: 129S1/Sv)
increased susceptibility to bacterial infection induced morbidity/mortality J:161073
\Il12btm1Jm/\Il12btm1Jm
\Il18tm1Aki/\Il18tm1Aki

(involves: 129P2/OlaHsd * 129S1/SvImJ)
abnormal T-helper 1 physiology J:46514
decreased interferon-gamma secretion J:46514
impaired natural killer cell mediated cytotoxicity J:46514
\Il12btm1Jm/\Il12btm1Jm
\Rag2tm1Fwa/\Rag2tm1Fwa

(involves: 129S/SvEv * 129S1/Sv)
abnormal chemokine secretion J:140483
abnormal interferon secretion J:140483
increased susceptibility to bacterial infection J:140483
lung inflammation J:140483
\Il12btm1Jm/\Il12btm1Jm
\Tnftm2Gkl/\Tnf+

(involves: 129S/SvEv * 129S1/Sv * C57BL/6J)
small intestinal inflammation J:108572
\Il12rb1tm1Jm/\Il12rb1tm1Jm
(involves: 129S1/Sv * C57BL/6J)
abnormal lymphocyte physiology J:42105
decreased circulating interferon-gamma level J:42105
decreased interferon-gamma secretion J:42105
\Il12rb1tm1Jm/\Il12rb1tm1Jm
\Tg(Rorc-EGFP)1Ebe/?

(involves: 129S1/Sv * C57BL/6)
abnormal effector T cell morphology J:137020
\Il12rb2Ifnm-d/\Il12rb2Ifnm-d
\Tlr4lps-del/\Tlr4lps-del

(C57BL/10ScCr)
abnormal dendritic cell physiology J:91014
abnormal granulocyte physiology J:91014
abnormal immune cell physiology J:91014
abnormal macrophage physiology J:91014
abnormal NK cell physiology J:91014
decreased interferon-gamma secretion J:91014, J:70821
increased interleukin-4 secretion J:91014
increased susceptibility to bacterial infection J:91014, J:70821
\Il12rb2tm1Jm/\Il12rb2tm1Jm
(either: (involves: 129S1/Sv * BALB/cByJ) or (involves: 129S1/Sv * C57BL/6J))
abnormal lymphocyte physiology J:65891
abnormal NK cell physiology J:65891
\Il12rb2tm1Jm/\Il12rb2tm1Jm
(B6;129S1-Il12rb2tm1Jm/J)
abnormal B cell activation J:106805
abnormal T cell activation J:106805
glomerulonephritis J:106805
increased anti-nuclear antigen antibody level J:106805
increased circulating interleukin-12 level J:120061
increased interleukin-6 secretion J:106805
liver inflammation J:106805
lymphoid hyperplasia J:106805
parotid gland inflammation J:106805
salivary gland inflammation J:106805
submandibular gland inflammation J:106805
\Il13tm1(YFP/cre)Lky/\Il13+
\Il4tm1(CD2)Mmrs/\Il4+
\Gt(ROSA)26Sortm1(DTA)Lky/\Gt(ROSA)26Sor+

(involves: 129P2/OlaHsd * 129S4/SvJae)
decreased eosinophil cell number J:178986
increased susceptibility to parasitic infection J:178986
\Il13tm1.1Anjm/\Il13tm1.1Anjm
(involves: 129P2/OlaHsd * C57BL/6)
abnormal T-helper 2 cell differentiation J:67965
decreased circulating interleukin-13 level J:67965
decreased IgE level J:67965
decreased interleukin-4 secretion J:67965
decreased interleukin-5 secretion J:67965
decreased interleukin-10 secretion J:67965
decreased T-helper 2 cell number J:67965
increased IgG2b level J:67965
increased IgM level J:67965
increased interferon-gamma secretion J:67965
\Il13tm1.1Anjm/\Il13tm1.1Anjm
(C.129P2-Il13tm1.1Anjm)
abnormal dendritic cell antigen presentation J:141937
abnormal dendritic cell differentiation J:141937
decreased IgE level J:91403
decreased interleukin-5 secretion J:141937
decreased interleukin-13 secretion J:141937, J:91403
decreased susceptibility to autoimmune disorder J:141937, J:91403
increased IgG2a level J:91403
increased interferon-gamma secretion J:141937
\Il13tm1.1Anjm/\Il13tm1.1Anjm
\Tg(DO11.10)10Dlo/0

(involves: 129P2/OlaHsd * BALB/c * C3H * C57BL/6)
abnormal CD4-positive, alpha-beta T cell physiology J:91403
decreased interleukin-13 secretion J:91403
\Il13tm1Anjm/\Il13+
\Il4tm1.1Wep/\Il4+

(involves: 129P2/OlaHsd * BALB/c * C57BL/6)
decreased interleukin-4 secretion J:69099
\Il13tm1Anjm/\Il13tm1Anjm
(involves: 129P2/OlaHsd * C57BL/6)
abnormal interleukin secretion J:82881
decreased eosinophil cell number J:82881
decreased interleukin-4 secretion J:82881
decreased interleukin-5 secretion J:82881
decreased interleukin-9 secretion J:82881
granulomatous inflammation J:82881, J:113543
increased susceptibility to parasitic infection J:113543
\Il13tm1Anjm/\Il13tm1Anjm
(C.129P2-Il13tm1Anjm)
decreased interleukin-4 secretion J:69099
decreased interleukin-13 secretion J:69099
\Il13tm1Anjm/\Il13tm1Anjm
\Il5tm3Anjm/\Il5tm3Anjm

(involves: 129P2/OlaHsd * C57BL/6)
granulomatous inflammation J:113543
increased susceptibility to parasitic infection J:113543
\Il13tm2Anjm/\Il13tm2Anjm
(involves: 129P2/OlaHsd * C57BL/6)
abnormal splenocyte physiology J:72587
abnormal T-helper 2 physiology J:89095
decreased susceptibility to parasitic infection induced morbidity/mortality J:60609
immune system phenotype J:72587
increased susceptibility to parasitic infection J:89095
\Il13tm2Anjm/\Il13tm2Anjm
(C.129P2(B6)-Il13tm2Anjm)
abnormal response to transplant J:110188
abnormal type I hypersensitivity reaction J:123772
increased length of allograft survival J:110188
increased susceptibility to type I hypersensitivity reaction J:123772
\Il13tm2Anjm/\Il13tm2Anjm
(involves: 129)
abnormal T-helper 2 cell differentiation J:67965
decreased circulating interleukin-13 level J:67965
decreased IgE level J:67965
decreased interleukin-4 secretion J:67965
decreased interleukin-5 secretion J:67965
decreased interleukin-10 secretion J:67965
decreased T-helper 2 cell number J:67965
increased IgG2b level J:67965
increased IgM level J:67965
increased interferon-gamma secretion J:67965
\Il13tm2Anjm/\Il13tm2Anjm
(involves: 129P2/OlaHsd * BALB/c * C57BL/6)
abnormal chemokine level J:131994
abnormal macrophage physiology J:176092
abnormal susceptibility to infection J:131994
decreased susceptibility to bacterial infection J:176092
decreased susceptibility to parasitic infection J:60609
decreased susceptibility to parasitic infection induced morbidity/mortality J:60609
impaired eosinophil recruitment J:126675
impaired neutrophil recruitment J:105813
\Il13tm2Anjm/\Il13tm2Anjm
(B6.129P2-Il13tm2Anjm)
abnormal antigen presentation J:131969
abnormal leukocyte physiology J:131969
decreased macrophage cell number J:131969
decreased susceptibility to experimental autoimmune encephalomyelitis J:131969
\Il13tm3.1Anjm/\Il13+
\Il1rl1tm1Anjm/\Il1rl1tm1Anjm

(involves: 129P2/OlaHsd * BALB/c)
decreased eosinophil cell number J:159464
\Il13tm3.1Anjm/\Il13+
\Il17rbtm1Anjm/\Il17rbtm1Anjm

(involves: BALB/c * C57BL/6)
decreased eosinophil cell number J:159464
\Il13tm3.1Anjm/\Il13+
\Il17rbtm1Anjm/\Il17rbtm1Anjm
\Il1rl1tm1Anjm/\Il1rl1tm1Anjm

(involves: 129P2/OlaHsd * BALB/c)
decreased eosinophil cell number J:159464
\Il13ra1tm1Twy/Y
(C.Cg-Il13ra1tm1Twy)
abnormal response to infection J:130488
abnormal T-helper 2 physiology J:130488
decreased IgE level J:130488
decreased susceptibility to parasitic infection J:130488
increased CD4-positive, alpha-beta T cell number J:130488
increased circulating interleukin-5 level J:130488
increased eosinophil cell number J:130488
increased IgA level J:130488
increased IgG1 level J:130488
increased IgG3 level J:130488
increased T-helper 2 cell number J:130488
\Il13ra1tm1Zagh/\Il13ra1tm1Zagh
(involves: BALB/c * C57BL/6)
abnormal thymus development J:183111
impaired myelopoiesis J:183111
\Il13ra2tm1Gru/\Il13ra2tm1Gru
(C.Cg-Il13ra2tm1Gru)
abnormal macrophage physiology J:82376
decreased circulating interleukin-13 level J:82376
decreased interleukin-4 secretion J:82376
decreased susceptibility to endotoxin shock J:82376
increased IgA level J:82376
increased IgE level J:82376
increased IgG2a level J:82376
increased IgG2b level J:82376
increased interferon-gamma secretion J:82376
increased interleukin-10 secretion J:82376
\Il15m1Hwata/\Il15m1Hwata
(Not Specified)
abnormal interleukin secretion J:184570
abnormal NK T cell number J:184570
decreased interferon-gamma secretion J:184570
decreased NK cell number J:184570
decreased NK T cell number J:184570
\Il15tm1.1Iku/\Il15+
(B6.Cg-Il15tm1.1Iku)
immune system phenotype J:206571
\Il15tm1Imx/\Il15+
\Myctm1Atp/\Myc+

(involves: 129P2/OlaHsd * C57BL/6)
decreased memory T cell number J:132730
\Il15tm1Imx/\Il15tm1Imx
(involves: C57BL/6)
abnormal CD8-positive, alpha-beta T cell physiology J:95221
abnormal cytokine secretion J:97620
abnormal immune system morphology J:60915
abnormal immune system physiology J:60915
abnormal lymphocyte morphology J:60915
abnormal susceptibility to infection J:60915
absent uterine NK cells J:84009
decreased CD8-positive, alpha-beta T cell number J:113408, J:60915
decreased CD8-positive, gamma-delta intraepithelial T cell number J:155298
decreased dendritic cell number J:97620
decreased IgG level J:97620
decreased IgM level J:97620
decreased immunoglobulin level J:97620
decreased interferon-gamma secretion J:97620
decreased interleukin-12 secretion J:97620
decreased memory T cell number J:132730
decreased NK cell number J:132730, J:142654, J:60915
decreased regulatory T cell number J:208318
decreased susceptibility to bacterial infection induced morbidity/mortality J:84009
decreased susceptibility to type IV hypersensitivity reaction J:87137
impaired natural killer cell mediated cytotoxicity J:97620
increased susceptibility to Herpesvirales infection induced morbidity/mortality J:97038
increased susceptibility to parasitic infection J:97620
increased susceptibility to Poxviridae infection induced morbidity/mortality J:60915
small lymph nodes J:60915
\Il15tm1Imx/\Il15tm1Imx
(C57BL/6-Il15tm1Imx)
abnormal dendritic cell physiology J:123902
\Il15tm1Imx/\Il15tm1Imx
(C57BL/6-Il15tm1Imx/Tac)
abnormal CD8-positive, alpha-beta T cell differentiation J:111786
abnormal thymus cell ratio J:111786
decreased CD8-positive, alpha-beta T cell number J:111786
\Il15tm1Imx/\Il15tm1Imx
\Il7rtm1.1Asin/\Il7rtm1Imx
\Tg(Cd8a*-cre)B8Asin/0

(involves: 129S7/SvEvBrd * C57BL/6)
decreased CD8-positive, alpha-beta T cell number J:190889
\Il15tm1Imx/\Il15tm1Imx
\Itktm1Litt/\Itktm1Litt

(involves: 129S4/SvJae * C57BL/6)
abnormal thymus cell ratio J:111786
\Il15tm1Imx/\Il15tm1Imx
\Itktm1Ljb/\Itktm1Ljb

(involves: 129 * C57BL/6 * C57BL/10)
decreased CD8-positive, alpha-beta T cell number J:113408
\Il15tm1Imx/\Il15tm1Imx
\Myctm1Atp/\Myc+

(involves: 129P2/OlaHsd * C57BL/6)
decreased memory T cell number J:132730
decreased NK cell number J:132730
\Il15tm1Imx/\Il15tm1Imx
\Rag2tm1Fwa/\Rag2tm1Fwa

(involves: 129S/SvEv * C57BL/6)
decreased NK cell number J:132257
\Il15tm1Imx/\Il15tm1Imx
X/\Yaa

(BXSB.B6-Il15tm1Imx/Dcr)
increased susceptibility to systemic lupus erythematosus J:179430
\Il15ratm1.1Nsl/\Il15ratm1.1Nsl
(involves: 129X1/SvJ * C57BL/6)
abnormal T cell apoptosis J:73738
decreased CD8-positive, alpha-beta T cell number J:73738
decreased memory T cell number J:73738
decreased NK cell number J:73738
decreased NK T cell number J:73738
decreased single-positive T cell number J:73738
increased CD4-positive, alpha-beta T cell number J:73738
increased thymocyte apoptosis J:73738
lymph node hypoplasia J:73738
\Il15ratm1.1Nsl/\Il15ratm1.1Nsl
(B6.129X1-Il15ratm1.1Nsl)
abnormal T cell activation J:92705
abnormal T cell proliferation J:92705
increased interleukin-2 secretion J:92705
increased T cell proliferation J:92705
\Il15ratm1.1Nsl/\Il15ratm1.1Nsl
\Tg(TcrAND)53Hed/?

(involves: 129X1/SvJ * C57BL/6 * SJL)
increased T cell proliferation J:92705
\Il15ratm1Ama/\Il15ratm1Ama
(involves: 129X1/SvJ)
abnormal NK cell physiology J:119213
decreased CD8-positive, alpha-beta T cell number J:142570
decreased CD8-positive, gamma-delta intraepithelial T cell number J:155298
decreased memory T cell number J:142570
decreased NK cell number J:119213, J:142570
decreased NK T cell number J:142570
decreased T cell proliferation J:142570
impaired natural killer cell mediated cytotoxicity J:142570
\Il15ratm1Ama/\Il15ratm2.1Ama
\Lyz2tm1(cre)Ifo/0
\Tg(Itgax-cre)1-1Reiz/0

(involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6 * CBA)
abnormal immune system physiology J:155298
decreased CD8-positive, alpha-beta T cell number J:155298
decreased memory T cell number J:155298
decreased NK cell number J:155298
\Il15ratm1Ama/\Il15ratm2.1Ama
\Lyz2tm1(cre)Ifo/\Lyz2+

(involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6J)
abnormal immune system physiology J:155298
abnormal NK cell differentiation J:155298
abnormal NK cell physiology J:155298
decreased CD8-positive, alpha-beta T cell number J:155298
decreased memory T cell number J:155298
decreased NK cell number J:155298
\Il15ratm1Ama/\Il15ratm2.1Ama
\Tg(Itgax-cre)1-1Reiz/0

(involves: 129X1/SvJ * C57BL/6J * CBA)
abnormal NK cell differentiation J:155298
abnormal NK cell physiology J:155298
abnormal T cell subpopulation ratio J:155298
decreased CD8-positive, alpha-beta T cell number J:155298
decreased memory T cell number J:155298
decreased NK cell number J:155298
\Il15ratm1Ama/\Il15ratm2.1Ama
\Tg(Vil1-cre)997Gum/0

(involves: C57BL/6J * SJL)
decreased CD8-positive, gamma-delta intraepithelial T cell number J:155298
\Il15ratm1Wjl/\Il15ratm1Wjl
(involves: 129 * C57BL/6)
abnormal T cell physiology J:142570
decreased CD8-positive, alpha-beta T cell number J:142570
decreased memory T cell number J:142570
decreased NK cell number J:142570
decreased NK T cell number J:142570
decreased T cell proliferation J:142570
\Il16tm1Korn/\Il16tm1Korn
(either: B6.129X1-Il16tm1Korn or C.129X1-Il16tm1Korn)
abnormal T cell physiology J:97739
\Il17a/Il17ftm1.1Impr/\Il17a/Il17ftm1.1Impr
(involves: C57BL/6)
abnormal effector T cell morphology J:187400
absent gamma-delta T cells J:187400
decreased interleukin-17 secretion J:187400
immune system phenotype J:187400, J:189794
increased gamma-delta T cell number J:187400
increased T cell proliferation J:187400
\Il17a/Il17ftm1.1Impr/\Il17a/Il17ftm1.1Impr
(involves: C57BL/6)
abnormal effector T cell morphology J:187400
absent gamma-delta T cells J:187400
decreased interleukin-17 secretion J:187400
immune system phenotype J:187400, J:189794
increased gamma-delta T cell number J:187400
increased T cell proliferation J:187400
\Il17aem1(IMPC)Mbp/\Il17aem1(IMPC)Mbp
(C57BL/6N-Il17aem1(IMPC)Mbp/MbpMmucd)
abnormal spleen morphology J:211773
enlarged spleen J:211773
\Il17atm1Cdon/\Il17atm1Cdon
(involves: C57BL/6)
chronic inflammation J:136279
decreased CD4-positive, alpha-beta T cell number J:136279
decreased IgG1 level J:136279
decreased IgG2a level J:136279
decreased IgG2b level J:136279
decreased IgM level J:136279
decreased interleukin-17 secretion J:136279
decreased susceptibility to experimental autoimmune encephalomyelitis J:136279
increased susceptibility to induced colitis J:136279
\Il17atm1Yiw/\Il17atm1Yiw
(involves: 129P2/OlaHsd * C57BL/6J)
decreased IgG level J:79127
decreased immunoglobulin level J:79127
decreased interferon-gamma secretion J:79127
decreased susceptibility to type IV hypersensitivity reaction J:79127
\Il17atm1Yiw/\Il17atm1Yiw
(involves: 129P2/OlaHsd * BALB/cA * C57BL/6J)
abnormal interleukin level J:79127
abnormal Langerhans cell physiology J:79127
decreased IgE level J:79127
decreased IgG1 level J:79127
decreased immunoglobulin level J:79127
decreased susceptibility to type IV hypersensitivity reaction J:79127
\Il17atm1Yiw/\Il17atm1Yiw
(involves: 129P2/OlaHsd * C57BL/6)
increased susceptibility to bacterial infection J:143719
\Il17atm1Yiw/\Il17atm1Yiw
(involves: 129P2/OlaHsd)
abnormal immune system physiology J:144710
decreased neutrophil cell number J:193548
increased gamma-delta T cell number J:193548
\Il17atm1Yiw/\Il17atm1Yiw
(B6.129P2-Il17atm1Yiw)
increased susceptibility to infection induced morbidity/mortality J:160680
\Il17atm1Yiw/\Il17atm1Yiw
\Il1rntm1Yiw/\Il1rntm1Yiw

(involves: 129P2/OlaHsd * BALB/cA * C57BL/6J)
decreased susceptibility to induced arthritis J:83408
\Il17atm1Yiw/\Il17atm1Yiw
\Il17ftm1Yiw/\Il17ftm1Yiw

(involves: 129P2/OlaHsd * C57BL/6)
increased susceptibility to bacterial infection J:143719
\Il17atm1Yiw/\Il17atm1Yiw
\Il17ftm1Yiw/\Il17ftm1Yiw
\Il1rntm1Yiw/\Il1rntm1Yiw

(involves: 129 * BALB/c)
rheumatoid arthritis J:143719
\Il17atm1Yiw/\Il17atm1Yiw
\Il17ftm2Yiw/\Il17ftm2Yiw

(involves: 129P2/OlaHsd * BALB/c)
decreased IgG3 level J:143719
enlarged submandibular lymph nodes J:143719
increased IgG1 level J:143719
increased IgG2a level J:143719
increased IgG2b level J:143719
increased susceptibility to bacterial infection J:143719
nasal inflammation J:143719
\Il17atm1Yiw/\Il17atm1Yiw
\Il17ftm2Yiw/\Il17ftm2Yiw

(B6.129P2-Il17atm1Yiw Il17ftm2Yiw)
decreased IgG3 level J:143719
enlarged submandibular lymph nodes J:143719
increased IgG1 level J:143719
increased IgG2a level J:143719
increased IgG2b level J:143719
increased susceptibility to infection induced morbidity/mortality J:160680
\Il17atm1Yiw/\Il17atm1Yiw
\Tg(CD2-Rorc)#Staka/0

(involves: 129P2/OlaHsd * C57BL/6)
increased susceptibility to autoimmune disorder J:230700
\Il17bem1Cya/\Il17bem1Cya
(C57BL/6-Il17bem1Cya)
abnormal cytokine level J:339366
increased macrophage cytokine production J:339366
increased neutrophil cell number J:339366
increased susceptibility to induced colitis J:339366
\Il17bGt(371C12)Cmhd/\Il17bGt(371C12)Cmhd
(B6.129-Il17bGt(371C12)Cmhd)
abnormal chemokine secretion J:229778
abnormal interleukin secretion J:229778
decreased interleukin-4 secretion J:229778
increased eosinophil cell number J:229778
increased interleukin-1 beta secretion J:229778
increased interleukin-5 secretion J:229778
increased interleukin-6 secretion J:229778
increased interleukin-13 secretion J:229778
increased susceptibility to bacterial infection J:229778
increased susceptibility to induced colitis J:229778
increased T-helper 2 cell number J:229778
increased tumor necrosis factor secretion J:229778
\Il17bGt(371C12)Cmhd/\Il17bGt(371C12)Cmhd
\Il25tm1.1Cdon/\Il25tm1.1Cdon

(involves: 129S1/Sv * 129S6/SvEvTac * 129X1/SvJ * C57BL/6)
immune system phenotype J:229778
\Il17ctm1.1Cdon/\Il17ctm1.1Cdon
(involves: 129S6/SvEvTac)
decreased CD4-positive, alpha-beta T cell number J:177650
decreased interferon-gamma secretion J:177650
decreased interleukin-17 secretion J:177650
decreased susceptibility to experimental autoimmune encephalomyelitis J:177650
\Il17ctm1Lex/\Il17ctm1Lex
(B6.129S5-Il17ctm1Lex)
immune system phenotype J:178967
\Il17ftm1Awai/\Il17f+
(involves: 129S6/SvEvTac * C57BL/6)
decreased interleukin-17 secretion J:144710
\Il17ftm1Awai/\Il17ftm1Awai
(involves: 129S6/SvEvTac * C57BL/6)
abnormal immune system physiology J:144710
decreased interleukin-17 secretion J:144710
\Il17ftm1Cdon/\Il17ftm1Cdon
(involves: C57BL/6)
chronic inflammation J:136279
decreased acute inflammation J:136279
decreased interleukin-17 secretion J:136279
decreased susceptibility to experimental autoimmune encephalomyelitis J:136279
decreased susceptibility to induced colitis J:136279
increased IgG2a level J:136279
\Il17ftm1Yiw/\Il17ftm1Yiw
(involves: 129P2/OlaHsd * C57BL/6)
increased susceptibility to bacterial infection J:143719
\Il17ftm1Yiw/\Il17ftm1Yiw
\Il1rntm1Yiw/\Il1rntm1Yiw

(involves: 129 * BALB/c)
rheumatoid arthritis J:143719
\Il17ratm1.2Kurs/\Il17ratm1.2Kurs
(involves: 129S4/SvJae * BALB/cJ * C57BL/6 * SJL)
abnormal interleukin secretion J:196483
increased CD4-positive, alpha-beta T cell number J:196483
increased gamma-delta T cell number J:196483
increased interleukin-6 secretion J:196483
increased interleukin-17 secretion J:196483
increased T-helper 17 cell number J:196483
skin inflammation J:196483
\Il17ratm1Koll/\Il17ratm1Koll
(involves: 129 * C57BL/6)
abnormal granulocyte differentiation J:71097
abnormal interleukin-5 secretion J:139080
abnormal interleukin-13 secretion J:139080
decreased inflammatory response J:139080
decreased neutrophil cell number J:71097
impaired neutrophil recruitment J:71097
increased susceptibility to infection J:71097
\Il17ratm1Koll/\Il17ratm1Koll
(involves: 129)
abnormal T-helper 2 cell differentiation J:158594
decreased interleukin-9 secretion J:158594
decreased interleukin-17 secretion J:177650
impaired neutrophil recruitment J:136279
\Il17rbtm1Anjm/\Il17rbtm1Anjm
(BALB/c-Il17rbtm1Anjm)
decreased eosinophil cell number J:159464
decreased IgE level J:159464
increased susceptibility to parasitic infection J:159464
\Il17rbtm1Anjm/\Il17rbtm1Anjm
\Il1rl1tm1Anjm/\Il1rl1tm1Anjm

(involves: 129P2/OlaHsd * BALB/c)
decreased eosinophil cell number J:159464
decreased IgE level J:159464
increased susceptibility to parasitic infection J:159464
\Il17rbtm1Bud/\Il17rbtm1Bud
(B6.129-Il17rbtm1Bud)
decreased inflammatory response J:139080
decreased interleukin-5 secretion J:139080
decreased interleukin-13 secretion J:139080
\Il17rbtm1Lex/\Il17rbtm1Lex
(C.129-Il17rbtm1Lex)
abnormal chemokine secretion J:159874
abnormal osteoclast differentiation J:159874
decreased interleukin-5 secretion J:159874
decreased interleukin-6 secretion J:159874
\Il17rbtm1Tgi/\Il17rb+
(Not Specified)
decreased susceptibility to induced colitis J:229778
\Il17rbtm1Tgi/\Il17rbtm1Tgi
(B6.Cg-Il17rbtm1Tgi)
abnormal interleukin secretion J:184570
decreased interleukin-9 secretion J:184570
decreased interleukin-10 secretion J:184570
decreased interleukin-13 secretion J:184570
decreased interleukin-17 secretion J:184570
decreased NK T cell number J:184570
\Il17rbtm1Tgi/\Il17rbtm1Tgi
(C.Cg-Il17rbtm1Tgi)
abnormal interleukin secretion J:184570
decreased interleukin-5 secretion J:184570
decreased interleukin-9 secretion J:184570
decreased interleukin-10 secretion J:184570
decreased interleukin-13 secretion J:184570
decreased interleukin-17 secretion J:184570
\Il17rbtm1Tgi/\Il17rbtm1Tgi
(Not Specified)
decreased susceptibility to induced colitis J:229778
\Il17rcem1(IMPC)Mbp/\Il17rcem1(IMPC)Mbp
(C57BL/6NCrl-Il17rcem1(IMPC)Mbp/MbpMmucd)
abnormal spleen morphology J:211773
enlarged spleen J:211773
\Il17rctm1Lex/\Il17rctm1Lex
(involves: C57BL/6)
abnormal chemokine level J:159874
decreased inflammatory response J:159874
decreased susceptibility to experimental autoimmune encephalomyelitis J:159874
increased interleukin-17 secretion J:159874
\Il17retm1Lex/\Il17retm1Lex
(B6.129S5-Il17retm1Lex)
increased susceptibility to induced colitis J:178967
\Il17retm1Sdl/\Il17retm1Sdl
(involves: C57BL/6)
increased susceptibility to bacterial infection J:178966
increased susceptibility to bacterial infection induced morbidity/mortality J:178966
\Il18tm1Aki/\Il18tm1Aki
(involves: 129P2/OlaHsd)
abnormal macrophage physiology J:112400
abnormal T-helper 1 physiology J:46514
decreased circulating interferon-gamma level J:46514
decreased circulating interleukin-18 level J:122588, J:46514
decreased interferon-gamma secretion J:46514
impaired natural killer cell mediated cytotoxicity J:46514
increased susceptibility to bacterial infection J:112400
\Il18tm1Aki/\Il18tm1Aki
(involves: 129P2/OlaHsd * C57BL/6)
abnormal microglial cell morphology J:122031
\Il18tm1Aki/\Il18tm1Aki
(C.129P2-Il18tm1Aki)
stomach inflammation J:120594
\Il18tm1Aki/\Il18tm1Aki
(B6.129P2-Il18tm1Aki)
impaired neutrophil chemotaxis J:125285
increased susceptibility to bacterial infection J:125285
increased susceptibility to induced colitis J:173245
\Il18tm1Aki/\Il18tm1Aki
\Il1btm1Dch/\Il1btm1Dch

(involves: 129P2/OlaHsd * 129S2/SvPas)
increased susceptibility to bacterial infection J:112400
\Il18tm1Aki/\Il18tm1Aki
\Nlrp1aNeut1/\Nlrp1aNeut1

(involves: 129P2/OlaHsd * C57BL/6)
abnormal inflammatory response J:191055
increased neutrophil cell number J:191055
myocarditis J:191055
\Il18tm1Aki/\Il18tm1Aki
\Tg(KRT14-CASP1)1Miz/0

(involves: 129P2/OlaHsd * C57BL/6)
decreased IgE level J:78602
decreased IgG1 level J:78602
immune system phenotype J:78602
\Il18tm1Khe/\Il18tm1Khe
(involves: 129P2/OlaHsd)
abnormal T cell morphology J:62263
decreased circulating interferon-gamma level J:62263
decreased circulating interleukin-18 level J:62263
decreased susceptibility to endotoxin shock J:62263
increased circulating tumor necrosis factor level J:62263
\Il18tm1Khe/\Il18tm1Khe
(B6.129P2-Il18tm1Khe)
abnormal cytokine level J:138759
decreased circulating interferon-gamma level J:138759
decreased circulating interleukin-6 level J:138759
decreased circulating interleukin-18 level J:138759
decreased interferon-gamma secretion J:138759
decreased susceptibility to bacterial infection J:138759
decreased tumor necrosis factor secretion J:138759
increased dendritic cell number J:138759
increased macrophage cell number J:138759
increased NK cell number J:138759
\Il18tm1Liew/\Il18tm1Liew
(involves: 129P2/OlaHsd * CD-1)
abnormal interferon level J:86621
abnormal interleukin level J:86621
abnormal tumor necrosis factor level J:86621
increased susceptibility to bacterial infection J:86621
increased susceptibility to parasitic infection J:86621
sepsis J:86621
\Il18bptm1(KOMP)Vlcg/\Il18bptm1(KOMP)Vlcg
(C57BL/6-Il18bptm1(KOMP)Vlcg)
abnormal NK cell differentiation J:255309
decreased interferon-gamma secretion J:255309
decreased KLRG1-positive NK cell number J:255309
decreased mature NK cell number J:255309
decreased NK cell number J:255309
increased circulating interferon-gamma level J:255309
increased immature NK cell number J:255309
\Il18bptm1.1(KOMP)Vlcg/\Il18bptm1.1(KOMP)Vlcg
(involves: C57BL/6N)
abnormal circulating chemokine level J:261967
abnormal lymph node morphology J:261967
abnormal macrophage activation involved in immune response J:261967
abnormal phagocyte morphology J:261967
abnormal spleen morphology J:261967
enlarged spleen J:261967
immune system phenotype J:261967
increased B cell number J:261967
increased circulating interferon-gamma level J:261967
increased circulating interleukin-18 level J:261967
increased macrophage cell number J:261967
increased monocyte cell number J:261967
\Il18r1tm1Aki/\Il18r1tm1Aki
(either: (involves: 129P2/OlaHsd) or (involves: 129P2/OlaHsd * C57BL/6))
abnormal T-helper 1 physiology J:70298
decreased interferon-gamma secretion J:70298
impaired natural killer cell mediated cytotoxicity J:70298
\Il18raptm1Yeh/\Il18raptm1Yeh
(Not Specified)
abnormal cytokine secretion J:98417
abnormal leukocyte physiology J:98417
\Il19tm2Vlcg/\Il19tm2Vlcg
(B6.Cg-Il19tm2Vlcg)
decreased interleukin-6 secretion J:229575
decreased interleukin-10 secretion J:229575
decreased interleukin-13 secretion J:229575
immune system phenotype J:229575
increased interferon-gamma secretion J:229575
increased interleukin-1 beta secretion J:229575
increased interleukin-6 secretion J:229575
increased interleukin-12 secretion J:229575
increased susceptibility to colitis induced morbidity/mortality J:229575
increased susceptibility to induced colitis J:229575
increased tumor necrosis factor secretion J:229575
\Il20tm1Lex/\Il20tm1Lex
(B6;129S5-Il20tm1Lex/Mmucd)
abnormal type IV hypersensitivity reaction J:171883
\Il20ratm1.1Misc/\Il20ratm1.1Misc
(involves: C57BL/6)
abnormal osteoclast differentiation J:177783
\Il20rbtm1Uwe/\Il20rbtm1Uwe
(B6.129P2-Il20rbtm1Uwe)
abnormal cytotoxic T cell physiology J:143497
abnormal T-helper 1 physiology J:143497
decreased interleukin-4 secretion J:143497
decreased interleukin-10 secretion J:143497
increased interferon-gamma secretion J:143497
increased interleukin-2 secretion J:143497
increased memory T cell number J:143497
increased T cell proliferation J:143497
\Il20rbtm1Uwe/\Il20rbtm1Uwe
(C.129P2-Il20rbtm1Uwe)
increased susceptibility to type IV hypersensitivity reaction J:143497
\Il21tm1Lex/\Il21tm1Lex
(involves: 129S5/SvEvBrd * C57BL/6J)
abnormal gamma-delta T cell morphology J:123351
abnormal interleukin level J:123351
abnormal T cell differentiation J:123351
decreased CD4-positive, alpha-beta T cell number J:123351
decreased susceptibility to experimental autoimmune encephalomyelitis J:123351
increased susceptibility to experimental autoimmune encephalomyelitis J:137377
\Il21tm1Lex/\Il21tm1Lex
(involves: 129S5/SvEvBrd * C57BL/6)
abnormal CD4-positive, alpha beta T cell morphology J:137867
abnormal CD4-positive, alpha-beta T cell physiology J:137867
abnormal germinal center B cell physiology J:137867
abnormal spleen germinal center morphology J:137867
decreased germinal center B cell number J:137867
decreased IgG1 level J:137867
decreased spleen germinal center number J:137867
\Il21tm1Llit/\Il21tm1Llit
(involves: 129 * C57BL/6J)
abnormal class switch recombination J:114783
increased IgE level J:114783
\Il21rtm1Day/\Il21rtm1Day
(involves: BALB/c * C57BL/6)
abnormal CD4-positive T cell differentiation J:136955, J:123352
abnormal dendritic cell physiology J:144708
abnormal Langerhans cell physiology J:144708
abnormal memory T cell physiology J:76043
abnormal NK cell physiology J:76043
abnormal plasmacytoid dendritic cell physiology J:144708
abnormal T cell activation J:76043
abnormal T cell physiology J:76043
abnormal thymocyte activation J:76043
decreased CD4-positive, alpha-beta T cell number J:123352
decreased cytotoxic T cell cytolysis J:76043
decreased IgE level J:144708
decreased IgG1 level J:76043, J:144708
decreased IgG2a level J:144708
decreased IgG2b level J:76043
decreased interferon-gamma secretion J:144708
decreased interleukin-4 secretion J:144708
decreased interleukin-13 secretion J:144708
decreased interleukin-17 secretion J:123352
decreased susceptibility to type IV hypersensitivity reaction J:144708
impaired natural killer cell mediated cytotoxicity J:76043
increased IgE level J:76043
increased interferon-gamma secretion J:76043, J:123352
\Il21rtm1Day/\Il21rtm1Day
(C57BL/6-Il21rtm1Day)
abnormal susceptibility to infection J:111712
abnormal T-helper 2 physiology J:111712
decreased IgG1 level J:111712
decreased IgG2b level J:111712
decreased interleukin-4 secretion J:111712
decreased interleukin-13 secretion J:111712
decreased interleukin-21 secretion J:111712
\Il21rtm1Kopf/\Il21rtm1Kopf
(involves: 129/Sv * BALB/c)
abnormal immunoglobulin level J:137508
abnormal lymphocyte physiology J:137508
decreased IgA level J:137508
decreased IgG1 level J:137508
immune system phenotype J:137377
impaired eosinophil recruitment J:137508
increased IgE level J:137508
\Il21rtm1Kopf/\Il21rtm1Kopf
(B6.129-Il21rtm1Kopf)
abnormal immune system morphology J:137508
abnormal immune system physiology J:137508
abnormal immunoglobulin level J:137508
abnormal leukocyte physiology J:137508
abnormal lymphocyte physiology J:137508
abnormal T-helper 1 physiology J:137508
abnormal T-helper 2 physiology J:137508
decreased basophil cell number J:137508
decreased eosinophil cell number J:137508
decreased granulocyte number J:137508
decreased IgA level J:137508
decreased IgG1 level J:137508
granulomatous inflammation J:137508
impaired eosinophil recruitment J:137508
increased IgE level J:137508
increased susceptibility to experimental autoimmune encephalomyelitis J:137377
\Il21rtm1Wjl/\Il21rtm1Wjl
(involves: 129 * C57BL/6)
abnormal CD8-positive, alpha-beta T cell physiology J:95221
abnormal immunoglobulin level J:80474
decreased cytotoxic T cell cytolysis J:95221
decreased IgG1 level J:80474
decreased IgG2a level J:80474
decreased IgG2b level J:80474
decreased IgG3 level J:80474
decreased interleukin-17 secretion J:124293
increased IgE level J:80474
\Il21rtm1Wjl/\Il21rtm1Wjl
(NOD.Cg-Il21rtm1Wjl)
abnormal CD4-positive T cell differentiation J:139075
decreased interleukin-17 secretion J:139075
decreased susceptibility to autoimmune diabetes J:139075
decreased T cell proliferation J:139075
\Il21rtm1Wjl/\Il21rtm1Wjl
\Il4tm1Cgn/\Il4tm1Cgn

(involves: 129 * C57BL/6)
abnormal immunoglobulin level J:80474
abnormal lymph node germinal center morphology J:80474
decreased IgA level J:80474
decreased IgG1 level J:80474
decreased IgG2a level J:80474
decreased IgG2b level J:80474
decreased IgG3 level J:80474
decreased IgM level J:80474
\Il21rtm1Wjl/\Il21rtm1Wjl
X/\Yaa

(BXSB.129(Cg)-Il21rtm1Wjl/Dcr)
decreased susceptibility to systemic lupus erythematosus J:144484
\Il22tm1.1(icre)Stck/\Il22tm1.1(icre)Stck
(involves: 129X1/SvJ * C57BL/6N)
increased susceptibility to bacterial infection J:220074
\Il22tm1.1Lex/\Il22tm1.1Lex
(involves: 129S5/SvEvBrd * C57BL/6)
abnormal cytokine secretion J:118261
ear inflammation J:118261
\Il22tm1.1Lex/\Il22tm1.1Lex
(involves: 129S5/SvEvBrd)
abnormal circulating cytokine level J:179011
colitis J:161073
decreased circulating interleukin-1 alpha level J:179011
decreased circulating interleukin-12 level J:179011
decreased circulating interleukin-12b level J:179011
decreased circulating tumor necrosis factor level J:179011
increased circulating interleukin-17 level J:179011
increased susceptibility to bacterial infection induced morbidity/mortality J:161073
increased susceptibility to fungal infection J:179011
lung inflammation J:179011
\Il22tm1Flv/\Il22+
(B6.Cg-Il22tm1Flv)
increased susceptibility to endotoxin shock J:126103
\Il22tm1Flv/\Il22tm1Flv
(B6.Cg-Il22tm1Flv)
increased susceptibility to endotoxin shock J:126103
liver inflammation J:126103
\Il22tm1Flv/\Il22tm1Flv
(involves: 129/Sv * C57BL/6)
increased susceptibility to induced colitis J:189217
\Il22tm1Jcrd/\Il22tm1Jcrd
(B6.Cg-Il22tm1Jcrd)
immune system phenotype J:155038
\Il22tm1Jcrd/\Il22tm1Jcrd
(Not Specified)
decreased neutrophil cell number J:193548
increased interleukin-17 secretion J:193548
\Il22ra2tm2Vlcg/\Il22ra2tm2Vlcg
(B6.Cg-Il22ra2tm2Vlcg)
colitis J:189217
\Il23atm1.1Thak/\Il23atm1.1Thak
(C57BL/6-Il23atm1.1Thak)
decreased interferon-gamma secretion J:143970
decreased interleukin-17 secretion J:143970
decreased susceptibility to experimental autoimmune encephalomyelitis J:143970
decreased T cell proliferation J:143970
\Il23atm1Dnax/\Il23atm1Dnax
(involves: 129 * C57BL/6)
abnormal CD4-positive, alpha-beta T cell physiology J:95542
decreased interleukin-17 secretion J:95542
decreased susceptibility to experimental autoimmune encephalomyelitis J:95542
\Il23atm1Dnax/\Il23atm1Dnax
(B6.Cg-Il23atm1Dnax)
abnormal CD8-positive, alpha-beta T cell physiology J:111568
abnormal granulocyte physiology J:111568
abnormal interleukin level J:111568
abnormal macrophage physiology J:111568
\Il23atm1Dnax/\Il23atm1Dnax
(Not Specified)
decreased gamma-delta T cell number J:193548
decreased interleukin-17 secretion J:193548
decreased leukocyte cell number J:193548
decreased neutrophil cell number J:193548
decreased T cell number J:193548
\Il23atm1Gdy/\Il23a+
(B6.Cg-Il23atm1Gdy)
increased susceptibility to induced colitis J:139557
\Il23atm1Gdy/\Il23atm1Gdy
(B6.Cg-Il23atm1Gdy)
increased susceptibility to induced colitis J:139557
\Il23atm1Ngh/\Il23atm1Ngh
(involves: 129S/SvEv * C57BL/6)
abnormal CD4-positive, alpha-beta T cell physiology J:88235
abnormal CD8-positive, alpha beta T cell morphology J:88235
abnormal memory T cell physiology J:88235
decreased IgA level J:88235
decreased IgG2a level J:88235
decreased immunoglobulin level J:88235
\Il23atm1Ngh/\Il23atm1Ngh
(involves: 129 * C57BL/6)
abnormal circulating interleukin level J:216867
abnormal memory T cell physiology J:120806
decreased activated T cell number J:120806
decreased susceptibility to induced colitis J:216867
granulomatous inflammation J:120806
increased circulating interleukin-17 level J:216867
increased susceptibility to bacterial infection J:120806
\Il23atm1Ngh/\Il23atm1Ngh
(involves: 129)
increased susceptibility to bacterial infection induced morbidity/mortality J:161073
\Il23rtm1.1Kuch/\Il23rtm1.1Kuch
(involves: C57BL/6)
abnormal CD4-positive, alpha-beta T cell physiology J:151907
decreased interleukin-9 secretion J:151907
\Il23rtm1.1Ngh/\Il23rtm1.1Ngh
(involves: C57BL/6)
abnormal circulating interleukin level J:216867
decreased susceptibility to induced colitis J:216867
increased circulating interleukin-17 level J:216867
\Il23rtm1.1Ngh/\Il23rtm1.1Ngh
\Rag2tm1Fwa/\Rag2tm1Fwa

(involves: 129S/SvEv * C57BL/6)
abnormal circulating interleukin level J:216867
decreased interleukin-17 secretion J:216867
\Il23rtm1Dnax/\Il23rtm1Dnax
(C57BL/6-Il23rtm1Dnax)
immune system phenotype J:111568
\Il23rtm1Kuch/\Il23rtm1Kuch
(C57BL/6-Il23rtm1Kuch)
abnormal CD4-positive T cell differentiation J:148248
abnormal CD4-positive, alpha-beta T cell physiology J:148248
decreased susceptibility to experimental autoimmune encephalomyelitis J:148248
\Il25tm1.1Cdon/\Il25tm1.1Cdon
(involves: 129S6/SvEvTac)
abnormal chemokine secretion J:229778
abnormal interleukin secretion J:229778
decreased eosinophil cell number J:229778
decreased interleukin-1 beta secretion J:229778
decreased interleukin-4 secretion J:229778, J:158594
decreased interleukin-5 secretion J:229778, J:158594
decreased interleukin-9 secretion J:158594
decreased interleukin-13 secretion J:229778, J:158594
decreased susceptibility to bacterial infection J:229778
decreased susceptibility to induced colitis J:229778
decreased T-helper 2 cell number J:229778
decreased tumor necrosis factor secretion J:229778
increased susceptibility to type I hypersensitivity reaction J:158594
lung inflammation J:158594
\Il25tm1Anjm/\Il25tm1Anjm
(involves: 129P2/OlaHsd * C57BL/6)
abnormal interleukin secretion J:123748
abnormal mesenteric lymph node morphology J:123748
decreased eosinophil cell number J:123748
decreased interleukin-5 secretion J:123748
decreased interleukin-13 secretion J:123748
increased IgE level J:123748
increased susceptibility to parasitic infection J:123748
\Il25tm1Cdon/\Il25tm1Cdon
\Tg(Vil1-cre)997Gum/0

(involves: 129S6/SvEvTac * C57BL/6J * C57BL/6N * SJL)
decreased susceptibility to induced colitis J:229778
\Il25tm1Dart/\Il25tm1Dart
(C57BL/6-Il25tm1Dart)
abnormal interferon level J:123808
abnormal interleukin level J:123808
abnormal response to infection J:123808
decreased IgG2a level J:123808
increased susceptibility to parasitic infection J:123808
intestinal inflammation J:123808
\Il25tm1Dart/\Il25tm1Dart
(involves: C57BL/6)
abnormal interleukin level J:125296
increased susceptibility to experimental autoimmune encephalomyelitis J:125296
increased T cell number J:125296
\Il27tm1b(EUCOMM)Wtsi/\Il27tm1b(EUCOMM)Wtsi
(C57BL/6N-Il27tm1b(EUCOMM)Wtsi/Wtsi)
decreased CD4-positive, alpha-beta memory T cell number J:211773
increased KLRG1-positive CD4-positive, CD25-positive, alpha-beta regulatory T cell number J:211773
\Il27tm1Cua/\Il27tm1Cua
(C57BL/6-Il27tm1Cua)
abnormal CD4-positive T cell differentiation J:147706
increased susceptibility to experimental autoimmune encephalomyelitis J:147706
increased susceptibility to type IV hypersensitivity reaction J:147706
\Il27tm1Lex/\Il27tm1Lex
(involves: 129S/SvEvBrd)
increased circulating interleukin-12b level J:187660
increased interferon-gamma secretion J:187660
increased susceptibility to parasitic infection induced morbidity/mortality J:187660
\Il27ratm1Fjs/\Il27ratm1Fjs
(B6.Cg-Il27ratm1Fjs)
abnormal T-helper 1 physiology J:94856
decreased susceptibility to bacterial infection J:94856
increased lymphocyte cell number J:94856
\Il27ratm1Mak/\Il27ratm1Mak
(B6.129P2-Il27ratm1Mak)
abnormal T-helper 1 physiology J:116610, J:89509
decreased circulating interferon-gamma level J:116610
decreased interferon-gamma secretion J:116610, J:89509
decreased susceptibility to experimental autoimmune uveoretinitis J:116610
immune system phenotype J:88618
increased circulating interferon-gamma level J:88618
increased circulating interleukin-1 beta level J:88618
increased circulating interleukin-4 level J:88618
increased circulating interleukin-6 level J:88618
increased circulating interleukin-12 level J:88618
increased circulating tumor necrosis factor level J:88618
increased interferon-gamma secretion J:88618
increased interleukin-4 secretion J:88618
increased susceptibility to bacterial infection J:89509
increased susceptibility to parasitic infection J:89509
increased T cell proliferation J:89509
\Il27ratm1Mak/\Il27ratm1Mak
(involves: 129P2/OlaHsd * C57BL/6)
increased susceptibility to induced arthritis J:151552
\Il31tm1.1Snak/\Il31tm1.1Snak
(B6N(Cg)-Il31tm1.1Snak)
immune system phenotype J:263831
\Il31ratm1Jagr/\Il31ratm1Jagr
(involves: 129S5/SvEvBrd)
immune system phenotype J:91124
\Il31ratm1Ngh/\Il31ratm1Ngh
(C57BL/6-Il31ratm1Ngh)
spleen hypoplasia J:123111
\Il31ratm1Ngh/\Il31ratm1Ngh
(involves: C57BL/6)
abnormal interleukin level J:123198
abnormal macrophage physiology J:123198
granulomatous inflammation J:123198
increased IgE level J:123198
increased susceptibility to parasitic infection J:123198
increased T cell proliferation J:123198
\Il33tm1(KOMP)Vlcg/\Il33tm1(KOMP)Vlcg
(C57BL/6-Il33tm1(KOMP)Vlcg)
impaired macrophage chemotaxis J:232676
\Il33tm1Aki/\Il33tm1Aki
(involves: 129X1/SvJ * C57BL/6)
abnormal T-helper 2 physiology J:182160
decreased eosinophil cell number J:182160
decreased IgE level J:182160
immune system phenotype J:182160
increased susceptibility to parasitic infection J:182160
\Il33tm1Amgn/\Il33tm1Amgn
(B6.129-Il33tm1Amgn)
abnormal immune cell physiology J:192531
decreased lymphocyte cell number J:192531
increased susceptibility to parasitic infection J:192531
\Il33tm1Snak/\Il33tm1Snak
(involves: C57BL/6 * CBA)
decreased inflammatory response J:165513
decreased interleukin-1 alpha secretion J:165513
decreased interleukin-1 beta secretion J:165513
decreased interleukin-6 secretion J:165513
decreased susceptibility to endotoxin shock J:165513
immune system phenotype J:165513
increased susceptibility to induced colitis J:165513
lung inflammation J:165513
\Il33tm2.1(IL33)Arte/\Il33tm2.1(IL33)Arte
(involves: BALB/c * BALB/cJBomTac)
immune system phenotype J:227003
\Il34tm1b(EUCOMM)Wtsi/\Il34tm1b(EUCOMM)Wtsi
(involves: BALB/cJ * C57BL/6N)
abnormal microglial cell morphology J:187643
absent Langerhans cell J:187643
decreased dendritic cell number J:187643
decreased interferon-gamma secretion J:187643
decreased Langerhans cell number J:187643
decreased susceptibility to fungal infection J:187643
decreased susceptibility to type IV hypersensitivity reaction J:187643
immune system phenotype J:187643
increased susceptibility to Flaviviridae infection J:187643
increased susceptibility to Flaviviridae infection induced morbidity/mortality J:187643
lymph node hypoplasia J:187643
\Il36atm1Yiw/\Il36atm1Yiw
(B6.129P2-Il36atm1Yiw)
abnormal cytokine level J:263315
immune system phenotype J:263315
\Il36gtm1Lex/\Il36gtm1Lex
(involves: 129S5/SvEvBrd * C57BL/6J)
abnormal interleukin level J:264077
abnormal macrophage morphology J:264077
abnormal tumor necrosis factor level J:264077
decreased alveolar macrophage number J:264077
increased CD11b-high dendritic cell number J:264077
increased macrophage apoptosis J:264077
increased susceptibility to Orthomyxoviridae infection J:264077
increased susceptibility to Orthomyxoviridae infection induced morbidity/mortality J:264077
\Il36gtm1Lex/\Il36gtm1Lex
(involves: 129S5/SvEvBrd)
decreased CD4-positive, alpha-beta T cell number J:256437
decreased interleukin-9 secretion J:256437
decreased susceptibility to induced colitis J:256437
impaired neutrophil recruitment J:280917
increased CD4-positive, alpha-beta T cell number J:256437
increased regulatory T cell number J:256437
increased susceptibility to Herpesvirales infection J:280917
increased susceptibility to Herpesvirales infection induced morbidity/mortality J:280917
\Il36gtm1Lex/\Il36gtm1Lex
(involves: 129S5/SvEvBrd * C57BL/6)
abnormal cytokine level J:296074
abnormal macrophage activation involved in immune response J:296074
impaired macrophage phagocytosis J:296074
increased susceptibility to bacterial infection J:296074
increased susceptibility to bacterial infection induced morbidity/mortality J:296074
\Il36rntm1Hblu/\Il36rn+
\Tg(KRT14-Il1f6)1Hblu/?

(involves: 129 * C57BL/6 * DBA/2)
skin inflammation J:126327
\Il36rntm1Hblu/\Il36rntm1Hblu
(C.129(B6)-Il36rntm1Hblu)
increased susceptibility to chemically induced skin inflammation J:260118
\Il36rntm1Hblu/\Il36rntm1Hblu
\Tg(KRT14-Il1f6)1Hblu/?

(involves: 129 * C57BL/6 * DBA/2)
skin inflammation J:126327
\Il36rntm1Kopf/\Il36rntm1Kopf
(B6.129S5-Il36rntm1Kopf)
dermatitis J:193548
increased leukocyte cell number J:193548
increased neutrophil cell number J:193548
\Ilf2tm1Pnk/\Ilf2+
(involves: C57BL/6)
immune system phenotype J:161086
\Ilf3tm1.1Itl/\Ilf3tm1.1Itl
(Not Specified)
increased susceptibility to Adenoviridae infection J:167126
\Ilf3tm1Pnk/\Ilf3+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
immune system phenotype J:161086
\Ilktm1Star/\Ilktm1Star
\Tg(KRT14-cre)1Amc/0

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA)
skin inflammation J:172934
\Ilktm1Star/\Ilktm1Star
\Tg(NPHS2-cre)295Lbh/0

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL)
tubulointerstitial nephritis J:129286, J:129244
\Ilktm1Star/\Ilktm2Star
\Tg(Acp5-cre)1Star/0

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
abnormal osteoclast physiology J:197593
increased osteoclast cell number J:197593
\Im1Bioz:BP1/?
(involves: Bioz:BP1 * Bioz:MP1)
abnormal humoral immune response J:46394
\Im2Bioz:BP1/?
(involves: Bioz:BP1 * Bioz:MP1)
abnormal humoral immune response J:37251
\Im2Bioz:BP1/\Im2Bioz:BP1
(involves: Bioz:BP1 * Bioz:MP1)
abnormal humoral immune response J:65671
\Im3Bioz:BP1/?
(involves: Bioz:BP1 * Bioz:MP1)
abnormal humoral immune response J:46394
\Im4Bioz:BP1/?
(involves: Bioz:BP1 * Bioz:MP1)
abnormal humoral immune response J:37251
\Im5Bioz:BP1/?
(involves: Bioz:BP1 * Bioz:MP1)
abnormal humoral immune response J:37251
\Im6Bioz:BP1/?
(involves: Bioz:BP1 * Bioz:MP1)
abnormal humoral immune response J:37251
\Im7Bioz:BP1/?
(involves: Bioz:BP1 * Bioz:MP1)
abnormal humoral immune response J:37251
\Imebt1DU6/?
(involves: DU6 * DUKs)
increased spleen weight J:99475
\Imh1NZB/\Imh1NZB
(involves: NZB * NZW)
increased IgM level J:26266
increased susceptibility to systemic lupus erythematosus J:26266
\Imh1NZB/\Imh1NZW
(involves: NZB * NZW)
increased IgM level J:26266
increased susceptibility to systemic lupus erythematosus J:22353
\Imm1NZW/\Imm1NZB
(involves: NZB * NZW)
abnormal immune system physiology J:26266
\Imm1NZW/\Imm1NZW
(involves: NZB * NZW)
abnormal immune system physiology J:26266
\Immp2lTg(HLA-A/H2-D)2Enge/?
((C57BL/6 x CBA)F1)
abnormal cytotoxic T cell physiology J:31937
abnormal negative T cell selection J:31937
abnormal positive T cell selection J:31937
\Impactem1(IMPC)Ccpcz/\Impactem1(IMPC)Ccpcz
(C57BL/6NCrl-Impactem1(IMPC)Ccpcz/Ccpcz)
abnormal lymph node morphology J:211773
enlarged lymph nodes J:211773
\Impdh1tm1Bmi/\Impdh1tm1Bmi
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
abnormal immune system cell morphology J:85443
decreased T cell proliferation J:85443
\Impdh1tm1Bmi/\Impdh1tm1Bmi
\Impdh2tm1Bmi/\Impdh2+

(involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6)
abnormal cytotoxic T cell physiology J:85443
abnormal immune system cell morphology J:85443
abnormal lymphopoiesis J:85443
decreased splenocyte proliferation J:85443
decreased T cell proliferation J:85443
\Impdh2tm1Bmi/\Impdh2+
(involves: 129P2/OlaHsd * C57BL/6)
abnormal lymphocyte cell number J:86045
\Impg1em1Visu/\Impg1em1Visu
\Impg2em1Visu/\Impg2em1Visu

(involves: C57BL/6J * DBA/2)
microgliosis J:288311
\Impg2em1Visu/\Impg2em1Visu
(involves: C57BL/6J * DBA/2)
microgliosis J:288311
\Imraq1DBA/2J/?
(involves: C57BL/6J * DBA/2J)
increased IgG level J:100370
\Imraq2DBA/2J/?
\Imraq3C57BL/6J/?

(involves: C57BL/6J * DBA/2J)
increased IgG level J:100370
\Imrfq1C57BL/6J/?
\Imrfq2C57BL/6J/?

(involves: C57BL/6J * DBA/2J)
increased IgG level J:100370
\In(2a;Itch)18H/\In(2a;Itch)18H
(involves: 101/H * C3H/HeH)
abnormal alveolar macrophage morphology J:24934
chronic inflammation J:24934
immune system phenotype J:205692
increased inflammatory response J:45910
increased spleen red pulp amount J:24934
interstitial pneumonia J:24934
lung inflammation J:24934
lymph node hyperplasia J:24934
\Inavatm1.1Itl/\Inavatm1.1Itl
(involves: 129S6/SvEvTac * C57BL/6NTac)
increased susceptibility to bacterial infection J:257317
increased susceptibility to induced colitis J:257317
\Inca1tm1Cmt/\Inca1tm1Cmt
(involves: 129 * C57BL/6N)
abnormal spleen B cell follicle morphology J:175667
abnormal spleen morphology J:175667
abnormal spleen white pulp morphology J:175667
increased IgA level J:175667
\Ing1Gt(OST206270)Lex/\Ing1Gt(OST206270)Lex
(involves: 129S5/SvEvBrd * C57BL/6)
decreased thymocyte number J:118602
increased thymocyte apoptosis J:118602
\Ing1tm1Avg/\Ing1tm1Avg
(involves: 129S1/Sv * C57BL/6)
enlarged spleen J:105658
\Ing2tm1.1Ccha/\Ing2tm1.1Ccha
(involves: 129 * C57BL/6J * FVB/N)
spleen hyperplasia J:167311
\Ing4em1(IMPC)Tcp/\Ing4em1(IMPC)Tcp
(C57BL/6NCrl-Ing4em2(IMPC)Tcp/Tcp)
increased neutrophil cell number J:211773
\Ing4Gt(XG370)Byg/\Ing4Gt(XG370)Byg
(involves: 129P2/OlaHsd * C57BL/6)
abnormal chemokine level J:161381
increased circulating interleukin-6 level J:161381
increased interleukin-6 secretion J:161381
\Ing5tm1.1Avo/\Ing5tm1.1Avo
(B6.Cg-Ing5tm1.1Avo)
spleen hypoplasia J:345308
\Inhatm1Bay/\Inhatm1Bay
(involves: 129S7/SvEvBrd * C57BL/6)
chronic liver inflammation J:20450
\Inhbbtm1Jae/\Inhbbtm1Jae
(either: (129S4/SvJae-Inhbbtm1Jae) or (involves: 129S4/SvJae * BALB/c) or (involves: 129S4/SvJae * C57BL/6))
increased incidence of corneal inflammation J:16995
\Inmtem1(IMPC)Mbp/\Inmtem1(IMPC)Mbp
(C57BL/6N-Inmtem1(IMPC)Mbp/MbpMmucd)
abnormal lymph node morphology J:211773
enlarged lymph nodes J:211773
\Ino80tm1.1Schg/\Ino80+
\Trp53tm1Tyj/\Trp53tm1Tyj

(involves: 129S2/SvPas * C57BL/6J)
increased T cell derived lymphoma incidence J:221224
\Inpp1tm1a(KOMP)Wtsi/\Inpp1tm1a(KOMP)Wtsi
(involves: C57BL/6 * C57BL/6N)
decreased susceptibility to bacterial infection J:213427
\Inpp4btm1.1Jva/\Inpp4btm1.1Jva
(B6.129-Inpp4btm1.1Jva)
abnormal osteoclast differentiation J:177648
abnormal osteoclast morphology J:177648
increased osteoclast cell number J:177648
\Inpp5del20/\Inpp5del20
(B6.129-Inpp5del20)
abnormal lymphocyte cell number J:173266
decreased lymphocyte cell number J:173266
decreased pre-B cell number J:173266
decreased thymocyte number J:173266
enlarged spleen J:173266
increased circulating interleukin-6 level J:173266
increased IgG2a level J:173266
increased IgM level J:173266
increased immunoglobulin level J:173266
increased macrophage cell number J:173266
small thymus J:173266
\Inpp5dm1Anu/\Inpp5dm1Anu
(C57BL/6JAnu-Inpp5dm1Anu)
lung inflammation J:104190
\Inpp5dm1Btlr/\Inpp5dm1Btlr
(C57BL/6J-Inpp5dm1Btlr)
abnormal B cell differentiation J:140987
abnormal eosinophil physiology J:140987
abnormal neutrophil physiology J:140987
decreased cytotoxic T cell cytolysis J:140987
enlarged spleen J:140987
enlarged thymus J:140987
impaired natural killer cell mediated cytotoxicity J:140987
\Inpp5dm2Btlr/\Inpp5dm2Btlr
(C57BL/6J-Inpp5dm2Btlr)
decreased B cell number J:216053
\Inpp5dM3Btlr/\Inpp5d+
(C57BL/6J-Inpp5dM3Btlr)
decreased NK cell number J:254907
\Inpp5dm4Btlr/\Inpp5dm4Btlr
(C57BL/6J-Inpp5dm4Btlr)
increased interferon-beta secretion J:272854
increased tumor necrosis factor secretion J:272854
\Inpp5dm5Btlr/\Inpp5dm5Btlr
(C57BL/6J-Inpp5dm5Btlr)
abnormal CD8-positive, alpha-beta T cell differentiation J:272856
abnormal lymphocyte morphology J:272856
abnormal T cell differentiation J:272856
decreased alpha-beta T cell number J:272856
decreased B cell number J:272856
decreased CD4-positive, alpha-beta T cell number J:272856
decreased CD8-positive, alpha-beta T cell number J:272856
decreased CD8-positive, naive alpha-beta T cell number J:272856
decreased NK cell number J:272856
increased B-1 B cell number J:272856
increased CD8-positive, alpha-beta T cell number J:272856
increased central memory CD8 positive, alpha-beta T cell number J:272856
increased effector memory CD4-positive, alpha-beta T cell number J:272856
increased effector memory CD8-positive, alpha-beta T cell number J:272856
\Inpp5dtm1.1Wgk/\Inpp5dtm1.1Wgk
(involves: 129S6/SvEvTac * C57BL/6J)
abnormal leukocyte physiology J:94861
abnormal mononuclear cell differentiation J:94861
abnormal NK cell morphology J:95215
decreased susceptibility to graft versus host disease J:95215, J:94861
increased dendritic cell number J:94861
increased monocyte cell number J:94861
increased NK cell number J:95215
\Inpp5dtm1Dmt/\Inpp5dtm1Dmt
(involves: 129P2/OlaHsd)
abnormal leukocyte physiology J:77739
decreased B cell number J:77739
enlarged lymph nodes J:77739
enlarged spleen J:77739
increased leukocyte cell number J:77739
\Inpp5dtm1Dmt/\Inpp5dtm1Dmt
(B6.129P2/OlaHsd-Inpp5dtm1Dmt)
decreased lymphocyte cell number J:173266
decreased pre-B cell number J:173266
increased circulating interleukin-6 level J:173266
\Inpp5dtm1Rav/\Inpp5dtm1.1Rav
\Lyz2tm1(cre)Ifo/\Lyz2+

(involves: 129P2/OlaHsd * C57BL/6)
abnormal spleen marginal zone macrophage morphology J:119256
absent marginal zone B cells J:119256
enlarged spleen J:119256
\Inpp5dtm1Rav/\Inpp5dtm1Rav
\Cd79atm1(cre)Reth/\Cd79a+
\Tg(IghAb36-65)1Wys/0

(involves: 129 * BALB/c * C57BL/6 * FVB/N)
abnormal B cell anergy J:178833
abnormal B cell negative selection J:178833
decreased B cell number J:178833
increased autoantibody level J:178833
increased plasma cell number J:178833
\Inpp5dtm1Rav/\Inpp5dtm1Rav
\Tg(Cd4-cre)1Cwi/?

(involves: C57BL/6 * DBA/2)
abnormal cytotoxic T cell physiology J:122796
abnormal humoral immune response J:122796
abnormal interferon level J:122796
abnormal interleukin secretion J:122796
abnormal lymph node germinal center morphology J:122796
decreased susceptibility to parasitic infection J:122796
\Inpp5dtm1Rkh/\Inpp5dtm1Rkh
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)
abnormal granulocyte differentiation J:48193
abnormal lymphopoiesis J:48193
abnormal macrophage chemotaxis J:48193
abnormal monocyte differentiation J:48193
decreased lymphocyte cell number J:48193
increased monocyte cell number J:48193
increased neutrophil cell number J:48193
increased spleen weight J:48193
spleen hyperplasia J:48193
\Inpp5dtm1Rkh/\Inpp5dtm1Rkh
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
abnormal interleukin level J:173301
abnormal myelopoiesis J:117320
decreased pro-B cell number J:117320
ileum inflammation J:173301
increased circulating interleukin-6 level J:117320
intestinal inflammation J:173301
\Inpp5dtm1Rkh/\Inpp5dtm1Rkh
(involves: 129S1/Sv * 129X1/SvJ)
abnormal CD4-positive, alpha-beta T cell physiology J:110864
abnormal CD8-positive, alpha-beta T cell physiology J:110864
abnormal cell-mediated immunity J:110864
abnormal macrophage chemotaxis J:110864
abnormal osteoclast differentiation J:78771
abnormal osteoclast morphology J:78771
abnormal osteoclast physiology J:78771
abnormal T cell physiology J:110864
enhanced B cell migration J:110864
increased circulating interleukin-6 level J:78771
increased mast cell degranulation J:120426
increased osteoclast cell number J:78771
\Inpp5dtm1Rkh/\Inpp5dtm1Rkh
\Rag1tm1(GFP)Imku/\Rag1+

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA)
abnormal lymphopoiesis J:117320
\Inpp5dtm1Wgk/\Inpp5dtm1.1Wgk
\Tg(Mx1-cre)1Cgn/0

(B6.Cg-Inpp5dtm1Wgk/Inpp5dtm1.1Wgk Tg(Mx1-cre)1Cgn)
abnormal leukocyte physiology J:144110
abnormal myeloid leukocyte morphology J:144110
\Inpp5dtm1Wgk/\Inpp5dtm1Wgk
\Tg(Mx1-cre)1Cgn/0

(B6.Cg-Inpp5dtm1Wgk Tg(Mx1-cre)1Cgn)
decreased susceptibility to graft versus host disease J:144110
\Inpp5kem1(IMPC)H/\Inpp5k+
(C57BL/6NTac-Inpp5kem1(IMPC)H/H)
increased neutrophil cell number J:211773
\Ins1tm1Jja/\Ins1tm1Jja
(NOD.129S2-Ins1tm1Jja)
decreased susceptibility to autoimmune diabetes J:85309
\Ins1tm1Jja/\Ins1tm1Jja
\Ins2tm1Jja/\Ins2tm1Jja
\Tg(Ins2*Y16A)1Ell/0

(NOD.Cg-Ins1tm1Jja Ins2tm1Jja Tg(Ins2*Y16A)1Ell)
decreased susceptibility to autoimmune diabetes J:98583
salivary gland inflammation J:98583
\Ins1tm1Jja/\Ins1tm1Jja
\Ins2tm1Jja/\Ins2tm1Jja
\Tg(Ins2*Y16A)3Ell/0

(NOD.Cg-Ins1tm1Jja Ins2tm1Jja Tg(Ins2*Y16A)3Ell)
decreased anti-insulin autoantibody level J:98583
decreased susceptibility to autoimmune diabetes J:98583
salivary gland inflammation J:98583
\Ins1tm1Jja/\Ins1tm1Jja
\Ins2tm1Mnt/\Ins2tm1Mnt
\Tg(Aire-cre)1Mnt/0

(involves: 129S2/SvPas * 129S4/SvJaeSor * C57BL/6 * FVB/N)
abnormal immune system physiology J:152798
abnormal interferon-gamma secretion J:152798
abnormal T cell physiology J:152798
increased anti-insulin autoantibody level J:152798
pancreas inflammation J:152798
\Ins1tm1Jja/\Ins1tm1Jja
\Tg(Ins2*Y16A)1Ell/0

(NOD.Cg-Ins1tm1Jja Tg(Ins2*Y16A)1Ell)
increased susceptibility to autoimmune diabetes J:98583
\Ins1tm1Jja/\Ins1tm1Jja
\Tg(Ins2*Y16A)3Ell/0

(NOD.Cg-Ins1tm1Jja Tg(Ins2*Y16A)3Ell)
autoimmune response J:98583
\Ins2Akita/\Ins2+
(C57BL/6-Ins2Akita/J)
abnormal microglial cell morphology J:99412
abnormal response to transplant J:76224
increased leukocyte cell number J:99412
\Ins2Akita/\Ins2+
\Prf1tm1Sdz/\Prf1tm1Sdz
\Rag1tm1Mom/\Rag1tm1Mom

(NOD.Cg-Rag1tm1Mom Ins2Akita Prf1tm1Sdz)
absent mature B cells J:138005
absent T cells J:138005
increased granulocyte number J:138005
increased macrophage cell number J:138005
increased monocyte cell number J:138005
\Ins2C95S/\Ins2+
(C3HeB/FeJ-Ins2C95S)
increased susceptibility to autoimmune diabetes J:122098
\Ins2C95S/\Ins2C95S
(C3HeB/FeJ-Ins2C95S)
increased susceptibility to autoimmune diabetes J:122098
\Ins2tm1Jja/\Ins2tm1Jja
(NOD.129S2-Ins2tm1Jja)
increased anti-insulin autoantibody level J:85309
insulitis J:85309
\Ins2tm1Jja/\Ins2tm1Jja
\Tg(Ins2*Y16A)3Ell/0

(NOD.Cg-Ins2tm1Jja Tg(Ins2*Y16A)3Ell)
autoimmune response J:98583
increased anti-insulin autoantibody level J:98583
\Insrm1Btlr/\Insrm1Btlr
(C57BL/6J-Insrm1Btlr)
increased susceptibility to induced colitis J:267534
\Insrtm1Khn/\Insrtm1Khn
\Leprtm1.1Chua/\Leprtm1.1Chua
\Tg(Pomc1-cre)16Lowl/0

(involves: 129 * 129S4/SvJae * 129S6/SvEvTac * C57BL/6J * FVB/N)
liver inflammation J:192274
ovary inflammation J:192274
white adipose tissue inflammation J:192274
\Insyn2bem1(IMPC)J/\Insyn2bem1(IMPC)J
(C57BL/6NJ-Insyn2bem1(IMPC)J/Mmjax)
increased leukocyte cell number J:211773
\Invsinv/\Invsinv
(FVB/N-Invsinv)
abnormal spleen morphology J:48533
spleen hypoplasia J:48533
\Ip6k2tm1.1Snyd/\Ip6k2tm1.1Snyd
(B6.129-Ip6k2tm1.1Snyd)
abnormal B cell physiology J:212482
\Ipo7em1(IMPC)Mbp/\Ipo7+
(C57BL/6N-Ipo7em1(IMPC)Mbp/Ucd)
abnormal lymph node morphology J:211773
abnormal spleen morphology J:211773
enlarged lymph nodes J:211773
enlarged spleen J:211773
\Ipptm1.1(KOMP)Vlcg/\Ipptm1.1(KOMP)Vlcg
(C57BL/6N-Ipptm1.1(KOMP)Vlcg/J)
decreased leukocyte cell number J:211773
\Iqcetm1b(EUCOMM)Hmgu/\Iqcetm1b(EUCOMM)Hmgu
(C57BL/6N-Iqcetm1b(EUCOMM)Hmgu/Ics)
decreased lymphocyte cell number J:211773
increased neutrophil cell number J:211773
\Iqcmem1(IMPC)Tcp/\Iqcm+
(C57BL/6NCrl-Iqcmem1(IMPC)Tcp/Cmmr)
increased monocyte cell number J:211773
\Iqcmem1(IMPC)Tcp/\Iqcmem1(IMPC)Tcp
(C57BL/6NCrl-Iqcmem1(IMPC)Tcp/Cmmr)
enlarged lymph nodes J:211773
enlarged spleen J:211773
increased monocyte cell number J:211773
\Iqgap1tm1b(EUCOMM)Wtsi/\Iqgap1tm1b(EUCOMM)Wtsi
(C57BL/6N-Iqgap1tm1b(EUCOMM)Wtsi/Tcp)
increased leukocyte cell number J:211773
increased lymphocyte cell number J:211773
\Irag1em1(IMPC)Ccpcz/\Irag1em1(IMPC)Ccpcz
(C57BL/6NCrl-Irag1em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
decreased lymphocyte cell number J:211773
enlarged spleen J:211773
increased eosinophil cell number J:211773
increased neutrophil cell number J:211773
increased spleen weight J:211773
\Irak1tm1.1Pcoh/?
(involves: 129P2/OlaHsd)
decreased interferon-alpha secretion J:205798
immune system phenotype J:205798
\Irak1tm1.1Pcoh/?
\Irak2tm1.1Pcoh/?

(involves: 129P2/OlaHsd * C57BL/6)
decreased interferon-alpha secretion J:205798
\Irak1tm1Jth/Y
(B6.Cg-Irak1tm1Jth)
decreased susceptibility to experimental autoimmune encephalomyelitis J:82302
\Irak1tm1Jth/Y
\Irak2tm1Aki/\Irak2tm1Aki

(involves: 129/Sv * C57BL/6)
abnormal dendritic cell physiology J:136290
abnormal macrophage physiology J:136290
decreased susceptibility to endotoxin shock J:136290
\Irak1tm1Jth/Y
\Tg(Myh6-Tnf)1Brgi/?

(involves: 129/Sv * C57BL/6J * SJL)
myocarditis J:84829
\Irak1tm1Jth/\Irak1tm1Jth
(B6.Cg-Irak1tm1Jth)
decreased susceptibility to experimental autoimmune encephalomyelitis J:82302
\Irak1tm1Jth/\Irak1tm1Jth
\Tg(Myh6-Tnf)1Brgi/?

(involves: 129/Sv * C57BL/6J * SJL)
myocarditis J:84829
\Irak2tm1.1Pcoh/?
(involves: C57BL/6)
decreased interferon-alpha secretion J:205798
\Irak2tm1Aki/\Irak2tm1Aki
(involves: 129/Sv * C57BL/6)
abnormal macrophage physiology J:136290
decreased susceptibility to endotoxin shock J:136290
\Irak2tm1Jth/\Irak2tm1Jth
(involves: 129 * C57BL/6)
abnormal chemokine level J:149258
decreased circulating interleukin-6 level J:149258
decreased circulating tumor necrosis factor level J:149258
decreased interleukin-6 secretion J:149258
decreased susceptibility to endotoxin shock J:149258
decreased tumor necrosis factor secretion J:149258
\Irak3tm1Flv/\Irak3tm1Flv
(involves: 129S1/Sv * C57BL/6)
abnormal immune system morphology J:78189
abnormal inflammatory response J:78189
abnormal innate immunity J:78189
abnormal osteoclast physiology J:98035
abnormal Peyer's patch morphology J:78189
enlarged Peyer's patches J:78189
increased interleukin-6 secretion J:78189
increased interleukin-12b secretion J:78189
increased neutrophil cell number J:78189
increased osteoclast cell number J:98035
increased susceptibility to endotoxin shock J:78189
increased tumor necrosis factor secretion J:78189
\Irak3tm1Flv/\Irak3tm1Flv
(NOD.129S1(B6)-Irak3tm1Flv)
abnormal dendritic cell physiology J:229884
abnormal professional antigen presenting cell physiology J:229884
abnormal T cell activation J:229884
abnormal T cell differentiation J:229884
increased anti-insulin autoantibody level J:229884
increased effector memory T-helper cell number J:229884
increased susceptibility to autoimmune diabetes J:229884
insulitis J:229884
\Irak4em1(IMPC)Ccpcz/\Irak4em1(IMPC)Ccpcz
(C57BL/6NCrl-Irak4em1(IMPC)Ccpcz/Ccpcz)
abnormal thymus morphology J:211773
enlarged thymus J:211773
\Irak4m1Btlr/\Irak4m1Btlr
(C57BL/6J-Irak4m1Btlr)
decreased tumor necrosis factor secretion J:133271
\Irak4m1Btlr/\Irak4m1Btlr
\Ptpn6m1Btlr/\Ptpn6m1Btlr

(C57BL/6J-Ptpn6m1Btlr Irak4m1Btlr)
immune system phenotype J:142845
\Irak4m1Btlr/\Irak4m1Btlr
\Ticam1Lps2/\Ticam1Lps2

(involves: C57BL/6J)
decreased tumor necrosis factor secretion J:187583
\Irak4tm1Aki/\Irak4tm1Aki
(involves: 129X1/SvJ * C57BL/6)
abnormal cytokine secretion J:125729
decreased B cell proliferation J:125729
decreased interferon-alpha secretion J:125729
decreased interleukin-6 secretion J:125729
decreased interleukin-12b secretion J:125729
decreased susceptibility to endotoxin shock J:125729
decreased tumor necrosis factor secretion J:125729
immune system phenotype J:125729
\Irak4tm1Gram/\Irak4tm1Gram
(involves: BALB/c)
abnormal chemokine secretion J:121912
abnormal cytokine secretion J:121912
\Irak4tm1Lix/\Irak4tm1Lix
(involves: C57BL/6)
abnormal chemokine secretion J:125732
decreased acute inflammation J:125732
decreased circulating interleukin-6 level J:125732
decreased circulating tumor necrosis factor level J:125732
decreased interferon-alpha secretion J:125732
decreased interferon-beta secretion J:125732
decreased interleukin-6 secretion J:125732
decreased susceptibility to endotoxin shock J:125732
decreased tumor necrosis factor secretion J:125732
\Irak4tm1Yeh/\Irak4tm1Yeh
(involves: 129P2/OlaHsd * C57BL/6J)
abnormal cytokine level J:76098
abnormal cytokine secretion J:76098
abnormal macrophage physiology J:76098
abnormal NK cell physiology J:76098
decreased B cell proliferation J:76098
decreased circulating interferon-gamma level J:76098
decreased circulating interleukin-1 level J:76098
decreased circulating interleukin-6 level J:76098
decreased circulating tumor necrosis factor level J:76098
decreased interleukin-6 secretion J:76098
decreased susceptibility to endotoxin shock J:76098
decreased tumor necrosis factor secretion J:76098
increased susceptibility to bacterial infection J:76098
\Irak4tm2Aki/\Irak4tm2Aki
(involves: 129X1/SvJ * C57BL/6)
abnormal cytokine secretion J:125729
decreased B cell proliferation J:125729
decreased interferon-alpha secretion J:125729
decreased interleukin-6 secretion J:125729
decreased interleukin-12b secretion J:125729
decreased susceptibility to endotoxin shock J:125729
decreased tumor necrosis factor secretion J:125729
immune system phenotype J:125729
\Irav1C57BL/J/\Irav1DBA/2J
(involves: C57BL/6J * DBA/2J)
abnormal cell-mediated immunity J:122129
abnormal cytokine secretion J:122129
\Irav1DBA/2J/\Irav1DBA/2J
(involves: C57BL/6J * DBA/2J)
abnormal cell-mediated immunity J:122129
abnormal cytokine secretion J:122129
\Ireb2tm1.2Mwh/\Ireb2tm1.2Mwh
(involves: 129P2/OlaHsd * BALB/c * C57BL/6 * SJL)
decreased spleen iron level J:103414
\Ireb2tm1Mwh/\Ireb2tm1Mwh
(involves: 129P2/OlaHsd * C57BL/6J)
decreased spleen iron level J:105124
\Ireb2tm1Roua/\Ireb2tm1Roua
(B6.Cg-Ireb2tm1Roua)
decreased spleen iron level J:176655
\Irf1M1Btlr/\Irf1+
(C57BL/6J-Irf1M1Btlr)
decreased CD8-positive, alpha-beta T cell number J:162995
decreased NK cell number J:162995
immune system phenotype J:162995
impaired natural killer cell mediated cytotoxicity J:162995
increased susceptibility to Herpesvirales infection J:162995
\Irf1M1Btlr/\Irf1M1Btlr
(C57BL/6J-Irf1M1Btlr)
decreased CD8-positive, alpha-beta T cell number J:162995
decreased interferon-alpha secretion J:162995
decreased interferon-beta secretion J:162995
decreased NK cell number J:162995
immune system phenotype J:162995
impaired natural killer cell mediated cytotoxicity J:162995
increased susceptibility to Herpesvirales infection J:162995
\Irf1m2Btlr/\Irf1m2Btlr
(C57BL/6J-Irf1m2Btlr)
decreased CD8-positive, alpha-beta T cell number J:267675
decreased NK cell number J:267675
increased B-1 B cell number J:267675
increased CD4-positive, alpha-beta T cell number J:267675
\Irf1M3Btlr/\Irf1M3Btlr
(C57BL/6J-Irf1M3Btlr)
decreased CD8-positive, alpha-beta T cell number J:267677
increased CD4-positive, alpha-beta T cell number J:267677
\Irf1tm1Cwe/\Irf1tm1Cwe
(involves: 129/Sv * C57BL/6)
abnormal cytokine level J:110672
abnormal immune system morphology J:21235
abnormal immune system physiology J:43086
abnormal immunoglobulin level J:101427
abnormal macrophage physiology J:43086
abnormal splenocyte morphology J:21235
abnormal T cell morphology J:21235, J:36025
abnormal thymus cell ratio J:36025
decreased CD8-positive, alpha-beta T cell number J:21235
decreased circulating interleukin-2 level J:110672
decreased susceptibility to induced arthritis J:43086
increased circulating interferon-gamma level J:110672
increased circulating interleukin-3 level J:110672
increased circulating interleukin-4 level J:110672
increased circulating interleukin-5 level J:110672
increased circulating interleukin-6 level J:110672
increased susceptibility to Poxviridae infection J:101427
increased T-helper 2 cell number J:110672
\Irf1tm1Cwe/\Irf1tm1Cwe
(involves: 129)
abnormal circulating interleukin-4 level J:84367
abnormal circulating interleukin-10 level J:84367
abnormal cytokine level J:84367
abnormal T cell proliferation J:84367
decreased circulating interferon-gamma level J:84367
decreased susceptibility to experimental autoimmune encephalomyelitis J:84367
increased circulating interleukin-5 level J:84367
increased circulating interleukin-6 level J:84367
increased circulating interleukin-13 level J:84367
\Irf1tm1Mak/\Irf1tm1Mak
(either: (involves: 129S2/SvPas * C57BL/6J) or (involves: 129S2/SvPas * C57BL/6J * DBA/2))
abnormal response to infection J:64286
abnormal T cell number J:64286
decreased CD8-positive, alpha-beta T cell number J:64286
immune system phenotype J:64286
increased CD4-positive, alpha-beta T cell number J:64286
increased double-positive T cell number J:64286
\Irf1tm1Mak/\Irf1tm1Mak
(B6.129S2-Irf1tm1Mak/J)
abnormal lymphocyte physiology J:91927
decreased interferon-gamma secretion J:91927
\Irf2tm1Mak/\Irf2tm1Mak
(either: (involves: 129S2/SvPas * C57BL/6J) or (involves: 129S2/SvPas * C57BL/6J * DBA/2))
abnormal immune system physiology J:64286
abnormal response to infection J:64286
decreased B cell proliferation J:64286
decreased IgG2a level J:64286
decreased mature B cell number J:64286
decreased T cell number J:64286
immune system phenotype J:64286
\Irf2tm1Mak/\Irf2tm1Mak
(involves: 129S2/SvPas * C57BL/6)
dermatitis J:66034
enlarged inguinal lymph nodes J:66034
increased memory T cell number J:66034
lymph node hyperplasia J:66034
\Irf3em1(IMPC)Mbp/\Irf3em1(IMPC)Mbp
(C57BL/6N-Irf3em1(IMPC)Mbp/MbpMmucd)
enlarged lymph nodes J:211773
\Irf3tm1Ttg/\Irf3tm1Ttg
(involves: 129S/SvEv * C57BL/6J)
abnormal circulating interferon level J:98127
increased susceptibility to Picornaviridae infection J:98127
\Irf3tm1Ttg/\Irf3tm1Ttg
\Irf7tm1Ttg/\Irf7tm1Ttg

(involves: 129P2/OlaHsd * 129S/SvEv)
decreased interferon-beta secretion J:158969
decreased interleukin-1 beta secretion J:158969
increased susceptibility to bacterial infection J:158969
increased susceptibility to Herpesvirales infection J:158969
increased susceptibility to Paramyxoviridae infection J:158969
\Irf3tm1Ttg/\Irf3tm1Ttg
\Irf9tm1Ttg/\Irf9tm1Ttg

(involves: 129S/SvEv * C57BL/6J)
abnormal cytokine secretion J:98127
\Irf3tm1Ttg/\Irf3tm1Ttg
\Sting1em1Jmin/\Sting1em1Jmin

(involves: 129S/SvEv * C57BL/6N)
decreased single-positive T cell number J:251372
lung inflammation J:251372
\Irf4em1(IMPC)Mbp/\Irf4em1(IMPC)Mbp
(C57BL/6N-Irf4em1(IMPC)Mbp/MbpMmucd)
abnormal lymph node morphology J:211773
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
decreased lymphocyte cell number J:211773
enlarged lymph nodes J:211773
enlarged spleen J:211773
enlarged thymus J:211773
increased neutrophil cell number J:211773
increased spleen weight J:211773
\Irf4m1Btlr/\Irf4m1Btlr
(C57BL/6J-Irf4m1Btlr)
abnormal B cell activation J:160882
decreased IgG level J:160882
decreased IgM level J:160882
\Irf4m1Btlr/\Irf4m1Btlr
(involves: C57BL/6J)
abnormal class switch recombination J:185495
decreased IgG level J:185495
decreased IgM level J:185495
immune system phenotype J:185495
\Irf4M2Btlr/\Irf4+
(C57BL/6J-Irf4M2Btlr)
abnormal B cell activation J:234245
decreased IgG level J:234245
decreased IgM level J:234245
\Irf4M2Btlr/\Irf4M2Btlr
(C57BL/6J-Irf4M2Btlr)
abnormal B cell activation J:234245
decreased IgG level J:234245
decreased IgM level J:234245
\Irf4tm1.1Rdf/\Irf4tm1.1Rdf
(involves: 129S1/Sv * 129S4/SvJae * C57BL/6)
abnormal B cell differentiation J:112643
abnormal B cell physiology J:112643
absent spleen germinal center J:112643
decreased B cell proliferation J:112643
decreased IgG1 level J:112643
\Irf4tm1Mak/\Irf4tm1Mak
(involves: 129P2/OlaHsd)
abnormal B cell differentiation J:42683
abnormal immune system cell morphology J:42683
abnormal immune system physiology J:42683
abnormal lymph node morphology J:42683
abnormal spleen morphology J:42683
absent lymph node germinal center J:42683
absent plasma cells J:42683
absent spleen germinal center J:42683
arrested B cell differentiation J:42683
decreased B cell proliferation J:42683
decreased dendritic cell number J:91043
decreased immunoglobulin level J:42683
decreased T cell proliferation J:42683
enlarged lymph nodes J:42683
enlarged spleen J:42683
immune system phenotype J:169863
increased lymphocyte cell number J:42683
increased susceptibility to Riboviria infection J:42683
\Irf4tm1Mak/\Irf4tm1Mak
(B6.129P2-Irf4tm1Mak)
abnormal CD4-positive, alpha beta T cell morphology J:78909
abnormal T-helper 1 cell differentiation J:78909
increased susceptibility to bacterial infection J:78909
\Irf4tm1Mak/\Irf4tm1Mak
(involves: 129P2/OlaHsd * C57BL/6)
decreased plasmacytoid dendritic cell number J:97716
increased susceptibility to bacterial infection J:81744
\Irf4tm1Rdf/\Irf4tm1.1Rdf
(involves: 129S1/Sv * 129S4/SvJae * C57BL/6)
immune system phenotype J:112643
\Irf4tm1Rdf/\Irf4tm1.1Rdf
(involves: 129S1/Sv * 129S4/SvJae * C57BL/6)
abnormal B cell physiology J:112643
\Irf5tm1e(EUCOMM)Wtsi/\Irf5tm1e(EUCOMM)Wtsi
(C57BL/6N-Irf5tm1e(EUCOMM)Wtsi/Wtsi)
decreased CD4-positive, alpha-beta memory T cell number J:211773
decreased leukocyte cell number J:211773
\Irf5tm1Ttg/\Irf5tm1Ttg
(involves: 129P2/OlaHsd * C57BL/6)
abnormal T-helper 1 physiology J:97567
decreased circulating interleukin-6 level J:97567
decreased circulating interleukin-12b level J:97567
decreased circulating tumor necrosis factor level J:97567
decreased susceptibility to bacterial infection J:97567
immune system phenotype J:182658
\Irf5tm1Ttg/\Irf5tm1Ttg
(B6.129P2-Irf5tm1Ttg)
abnormal response to infection J:182658
decreased interferon-alpha secretion J:182658
decreased interleukin-6 secretion J:182658
decreased tumor necrosis factor secretion J:182658
immune system phenotype J:182658
\Irf7m1Btlr/\Irf7+
(C57BL/6J-Irf7m1Btlr)
decreased interferon-alpha secretion J:159358
decreased interferon-beta secretion J:159358
\Irf7m1Btlr/\Irf7m1Btlr
(C57BL/6J-Irf7m1Btlr)
decreased interferon-alpha secretion J:159358
decreased interferon-beta secretion J:159358
\Irf7M2Btlr/\Irf7+
(C57BL/6J-Irf7M2Btlr)
decreased circulating interferon-beta level J:217798
\Irf7M2Btlr/\Irf7M2Btlr
(C57BL/6J-Irf7M2Btlr)
decreased circulating interferon-beta level J:217798
\Irf7tm1Ttg/\Irf7tm1Ttg
(involves: 129P2/OlaHsd)
abnormal interferon level J:97662
abnormal T cell physiology J:97662
increased susceptibility to Herpesvirales infection J:97662
increased susceptibility to Picornaviridae infection J:97662
\Irf7tm1Ttg/\Irf7tm1Ttg
(B6.129P2-Irf7tm1Ttg)
increased susceptibility to Orthomyxoviridae infection J:233979
increased susceptibility to Orthomyxoviridae infection induced morbidity/mortality J:233979
\Irf8M1Btlr/\Irf8M1Btlr
(C57BL/6J-Irf8M1Btlr)
abnormal interferon secretion J:166600
decreased macrophage cell number J:166600
decreased monocyte cell number J:166600
increased neutrophil cell number J:166600
\Irf8m2Btlr/\Irf8m2Btlr
(C57BL/6J-Irf8m2Btlr)
decreased CD8-positive, alpha-beta T cell number J:274937
increased CD4-positive, alpha-beta T cell number J:274937
\Irf8myls/\Irf8+
(involves: BXH2/TyJ * C57BL/6)
increased B cell number J:168923
increased B-1b cell number J:168923
increased follicular B cell number J:168923
increased transitional stage B cell number J:168923
\Irf8myls/\Irf8myls
(involves: BALB/cJ * BXH2/TyJ-Irf8myls)
abnormal myelopoiesis J:97931
enlarged spleen J:97931
\Irf8myls/\Irf8myls
\Slc11a1r/\Slc11a1r

(BXH2/TyJ)
abnormal myelopoiesis J:97931
decreased interferon-gamma secretion J:97931
decreased interleukin-12 secretion J:97931
enlarged spleen J:97931
increased susceptibility to bacterial infection J:97931
\Irf8myls/\Irf8myls
\Slc11a1r/\Slc11a1r

(involves: BXH2/TyJ * C57BL/6J)
increased susceptibility to bacterial infection J:97931
\Irf8myls/\Irf8myls
\Slc11a1r/\Slc11a1r

(involves: BALB/cJ * BXH2/TyJ)
increased susceptibility to bacterial infection J:97931
\Irf8myls/\Irf8myls
\Slc11a1r/\Slc11a1r

(involves: BXH2/TyJ * C3H/HeJ)
enlarged spleen J:97931
increased susceptibility to bacterial infection J:97931
\Irf8myls/\Irf8myls
\Slc11a1r/\Slc11a1s

(involves: BXH2/TyJ * C57BL/6J)
increased susceptibility to bacterial infection J:97931
\Irf8myls/\Irf8myls
\Slc11a1r/\Slc11a1s

(involves: BALB/cJ * BXH2/TyJ)
increased susceptibility to bacterial infection J:97931
\Irf8myls/\Irf8myls
\Slc11a1s/\Slc11a1s

(involves: BALB/cJ * BXH2/TyJ)
increased susceptibility to bacterial infection J:97931
\Irf8tm1Hor/\Irf8tm1Hor
(either: (involves: 129P2/OlaHsd) or (involves: 129P2/OlaHsd * C57BL/6))
abnormal cytotoxic T cell physiology J:36038
abnormal plasma cell number J:36038
decreased B cell number J:36038
decreased interferon-gamma secretion J:36038
decreased lymphocyte cell number J:36038
decreased T cell number J:36038
enlarged lymph nodes J:36038
hepatosplenomegaly J:36038
increased B cell number J:36038
increased granulocyte number J:36038
increased immunoglobulin level J:36038
increased leukocyte cell number J:36038
increased lymphocyte cell number J:36038
increased macrophage cell number J:36038
increased mature B cell number J:36038
increased spleen red pulp amount J:36038
increased spleen weight J:36038
increased susceptibility to Riboviria infection J:36038
spleen hyperplasia J:36038
\Irf8tm1Hor/\Irf8tm1Hor
(B6.129P2-Irf8tm1Hor)
decreased follicular B cell number J:168923
increased B-1b cell number J:168923
increased marginal zone B cell number J:168923
\Irf8tm1Hor/\Irf8tm1Hor
(involves: 129P2/OlaHsd * C57BL/6)
abnormal humoral immune response J:181366
\Irf8tm1Hor/\Irf8tm1Hor
\Irf4tm1Mak/\Irf4tm1Mak

(involves: 129P2/OlaHsd * C57BL/6)
abnormal B cell differentiation J:84577
abnormal pre-B cell morphology J:84577
absent B cells J:84577
arrested B cell differentiation J:84577
decreased dendritic cell number J:97716
decreased IgM level J:84577
decreased lymphocyte cell number J:84577
decreased plasmacytoid dendritic cell number J:97716
decreased T cell number J:84577
increased pre-B cell number J:84577
\Irf9M1Btlr/\Irf9+
(C57BL/6J-Irf9M1Btlr)
increased circulating interferon-beta level J:236674
\Irf9M1Btlr/\Irf9M1Btlr
(C57BL/6J-Irf9M1Btlr)
increased circulating interferon-beta level J:236674
\Irf9tm1Ttg/\Irf9tm1Ttg
(B6.Cg-Irf9tm1Ttg)
decreased interferon-alpha secretion J:97662
\Irf9tm1Ttg/\Irf9tm1Ttg
(either: (involves: C57BL/6 * CBA * ICR) or (involves: A/J * C57BL/6 * CBA))
increased susceptibility to viral infection J:77456
\Irgcem1(IMPC)Tcp/\Irgcem1(IMPC)Tcp
(C57BL/6N-Irgcem1(IMPC)Tcp/Tcp)
increased monocyte cell number J:211773
\Irgm1tm1Gat/\Irgm1tm1Gat
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
immune system phenotype J:87535
increased circulating interferon-gamma level J:87535
increased circulating interleukin-12 level J:87535
increased susceptibility to bacterial infection J:87535
increased susceptibility to parasitic infection J:87535
\Irgm2em1Myam/\Irgm2em1Myam
(C57BL/6-Irgm2em1Myam)
increased susceptibility to parasitic infection J:308470
increased susceptibility to parasitic infection induced morbidity/mortality J:308470
\Irs1Sml/\Irs1Sml
(C3.Cg-Irs1Sml H2b/GrsrJ)
increased osteoclast cell number J:163661
\Irs1tm1Mfw/\Irs1tm1Mfw
\Irs2tm2Mfw/\Irs2tm2Mfw
\Speer6-ps1Tg(Alb-cre)21Mgn/\Speer6-ps1+

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA)
increased susceptibility to autoimmune diabetes J:137845
\Irs1tm1Tka/\Irs1tm1Tka
(involves: C57BL/6 * CBA)
abnormal osteoclast differentiation J:61479
abnormal osteoclast physiology J:61479
\Irs1tm2Tka/\Irs1tm2Tka
\Irs2tm2Tka/\Irs2tm2Tka
\Speer6-ps1Tg(Alb-cre)21Mgn/\Speer6-ps1+

(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * DBA)
increased susceptibility to autoimmune diabetes J:137846
\Is(14)1Rdf \Is(14)2Rdf/\Del(14Trim13-Dleu2)4Rdf
\Cd19tm1(cre)Cgn/\Cd19+

(involves: 129P2/OlaHsd * 129S1/Sv * 129S4/SvJaeSor * C57BL/6)
increased B cell number J:156946
increased B-1a cell number J:156946
increased spleen white pulp amount J:156946
\Is(14)1Rdf \Is(14)5Rdf/\Del(14Trim13-Rnaseh2b)6Rdf
\Cd19tm1(cre)Cgn/\Cd19+

(involves: 129P2/OlaHsd * 129S1/Sv * 129S4/SvJaeSor * C57BL/6)
abnormal lymphopoiesis J:179879
increased B cell number J:179879
\Is(14)1Rdf/\Is(14)1Rdf
\Is(14)5Rdf/\Is(14)5Rdf
\Cd19tm1(cre)Cgn/\Cd19+

(involves: 129P2/OlaHsd * 129S1/Sv * 129S4/SvJaeSor * C57BL/6)
abnormal lymphopoiesis J:179879
increased B cell number J:179879
\Isg15tm1Kpk/\Isg15tm1Kpk
(involves: 129P2/OlaHsd * C57BL/6)
immune system phenotype J:100028
\Isg20em1Cya/\Isg20em1Cya
\Tg(Cdh16-cre)91Igr/0

(involves: C57BL/6N * ICR)
kidney inflammation J:343183
\Isl1Drsh/\Isl1+
(C3HeB/FeJ-Isl1Drsh)
increased susceptibility to otitis media J:202214
\Isl1tm1(cre)Sev/\Isl1+
\Pax9tm1Rbal/\Pax9tm1.1Hpt

(involves: 129 * C57BL/6J)
ectopic thymus J:311535
thymus hypoplasia J:311535
\Ism1em1(IMPC)Ccpcz/\Ism1em1(IMPC)Ccpcz
(C57BL/6NCrl-Ism1em1(IMPC)Ccpcz/Ccpcz)
abnormal lymph node morphology J:211773
abnormal thymus morphology J:211773
enlarged lymph nodes J:211773
enlarged thymus J:211773
\Isy1em1(IMPC)J/\Isy1+
(C57BL/6NJ-Isy1em1(IMPC)J/Mmjax)
decreased leukocyte cell number J:211773
\Itchtm1.1Alta/\Itchtm1.1Alta
\Foxp3tm4(YFP/icre)Ayr/\Foxp3+

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
abnormal immunoglobulin level J:204685
abnormal interleukin secretion J:204685
abnormal lymph organ size J:204685
abnormal lymphopoiesis J:204685
abnormal regulatory T cell physiology J:204685
abnormal T-helper 2 cell differentiation J:204685
abnormal T-helper 2 physiology J:204685
decreased CD4-positive, alpha-beta T cell number J:204685
dermatitis J:204685
enlarged lymph nodes J:204685
enlarged spleen J:204685
immune system phenotype J:204685
increased CD4-positive, alpha-beta T cell number J:204685
increased CD8-positive, alpha-beta T cell number J:204685
increased eosinophil cell number J:204685
increased IgA level J:204685
increased IgE level J:204685
increased IgG1 level J:204685
increased inflammatory response J:204685
increased interleukin-4 secretion J:204685
increased interleukin-5 secretion J:204685
increased interleukin-10 secretion J:204685
increased interleukin-13 secretion J:204685
increased interleukin-17 secretion J:204685
increased leukocyte cell number J:204685
increased regulatory T cell apoptosis J:204685
increased regulatory T cell number J:204685
lung inflammation J:204685
\Itchtm1.1Alta/\Itchtm1.1Alta
\Gt(ROSA)26Sortm1Hjf/\Gt(ROSA)26Sor+
\Foxp3tm4(YFP/icre)Ayr/\Foxp3+

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
immune system phenotype J:204685
increased inflammatory response J:204685
\Itchtm1b(EUCOMM)Hmgu/\Itchtm1b(EUCOMM)Hmgu
(C57BL/6N-Itchtm1b(EUCOMM)Hmgu/H)
decreased lymphocyte cell number J:211773
enlarged spleen J:211773
increased basophil cell number J:211773
increased eosinophil cell number J:211773
increased large unstained cell number J:211773
increased leukocyte cell number J:211773
increased lymphocyte cell number J:211773
increased neutrophil cell number J:211773
increased spleen weight J:211773
\Itfg2Gt(OST215121)Lex/\Itfg2Gt(OST215121)Lex
(involves: 129S5/SvEvBrd * C57BL/6J)
abnormal B cell activation J:205951
abnormal humoral immune response J:205951
abnormal splenocyte physiology J:205951
decreased B cell number J:205951
decreased IgE level J:205951
decreased IgG1 level J:205951
decreased IgG2a level J:205951
decreased IgG2b level J:205951
decreased IgG3 level J:205951
decreased lymphocyte cell number J:205951
decreased spleen germinal center number J:205951
decreased T follicular helper cell number J:205951
immune system phenotype J:205951
increased B cell number J:205951
spleen hyperplasia J:205951
\Itga2btm1Tlr/\Itga2btm1Tlr
(either: (involves: 129S1/Sv * 129X1/SvJ * BALB/c) or (involves: 129S1/Sv * 129X1/SvJ * C57BL/6))
enlarged spleen J:63961
\Itga3tm1Son/\Itga3tm1Son
\Krt14tm1(cre)Wbm/\Krt14+

(involves: 129P2/OlaHsd * FVB/N)
skin inflammation J:145988
\Itga3tm1Son/\Itga3tm1Son
\Tg(KRT5-cre)5132Jlj/?

(involves: 129P2/OlaHsd * C57BL/6 * DBA)
skin inflammation J:145988
\Itga4tm1Mgin/\Itga4tm1Mgin
(B6.129-Itga4tm1Mgin)
abnormal B cell physiology J:106471
abnormal lymphocyte physiology J:106471
abnormal T cell physiology J:106471
decreased monocyte cell number J:106471
decreased Peyer's patch number J:106471
impaired macrophage chemotaxis J:106471
\Itga4tm1Mshi/\Itga4tm1Mshi
(C57BL/6-Itga4tm1Mshi)
abnormal cellular extravasation J:144092
abnormal leukocyte adhesion J:144092
abnormal leukocyte migration J:144092
abnormal mononuclear cell morphology J:144092
decreased B cell number J:144092
decreased lymphocyte cell number J:144092
decreased T cell number J:144092
small Peyer's patches J:144092
\Itga4tm1Tpa/\Itga4tm1Tpa
\Tg(Mx1-cre)1Cgn/?

(involves: 129S4/SvJaeSor * C57BL/6 * CBA)
abnormal B cell differentiation J:86861
decreased CD4-positive, alpha-beta T cell number J:86861
increased leukocyte cell number J:86861
\Itga5tm1Hyn/\Itga5+
\Nischedsn/\Nisch+

(C3H.Cg-Nischedsn Itga5tm1Hyn)
increased susceptibility to otitis media J:244907
\Itga5tm1Hyn/\Itga5+
\Nischedsn/\Nischedsn

(C3H.Cg-Nischedsn Itga5tm1Hyn)
increased susceptibility to otitis media J:244907
\Itga6tm1Son/\Itga6tm1Son
(involves: 129P2/OlaHsd * FVB)
abnormal lymph node morphology J:50235
abnormal T cell physiology J:50235
decreased T cell number J:50235
\Itga9tm1Des/\Itga9tm1Des
(involves: 129S4/SvJae * C57BL/6)
abnormal lymph circulation J:63038
\Itgadtm1.1Zimm/\Itgadtm1.1Zimm
(involves: 129S6/SvEvTac * C57BL/6)
abnormal immune system physiology J:130908
abnormal macrophage physiology J:130908
abnormal susceptibility to infection J:130908
decreased susceptibility to parasitic infection J:130908
increased circulating interleukin-12 level J:130908
increased spleen weight J:130908
increased susceptibility to bacterial infection J:130908
\Itgadtm1Bll/\Itgadtm1Bll
(B6.129S7-Itgadtm1Bll)
abnormal lymphocyte cell number J:90954
abnormal T cell activation J:90954
abnormal T cell subpopulation ratio J:90954
decreased CD4-positive, alpha-beta T cell number J:90954
decreased T cell proliferation J:90954
increased CD8-positive, alpha-beta T cell number J:90954
\Itgaetm1b(EUCOMM)Wtsi/\Itgaetm1b(EUCOMM)Wtsi
(C57BL/6N-Itgaetm1b(EUCOMM)Wtsi/H)
decreased large unstained cell number J:211773
decreased leukocyte cell number J:211773
decreased lymphocyte cell number J:211773
decreased monocyte cell number J:211773
decreased neutrophil cell number J:211773
\Itgaetm1Cmp/\Itgaetm1Cmp
(involves: 129S2/SvPas * BALB/c)
decreased lymphocyte cell number J:55333
decreased T cell number J:55333
\Itgalem1(IMPC)H/\Itgalem1(IMPC)H
(C57BL/6NTac-Itgalem1(IMPC)H/H)
increased spleen weight J:211773
\Itgaltm1.1Mshi/\Itgaltm1.1Mshi
(involves: C57BL/6)
abnormal diapedesis J:168533
abnormal leukocyte adhesion J:168533
abnormal leukocyte migration J:168533
decreased lymphocyte cell number J:168533
enhanced leukocyte tethering or rolling J:168533
small lymph nodes J:168533
\Itgaltm1Bll/\Itgal+
(involves: 129S7/SvEvBrd)
abnormal CD4-positive, alpha-beta T cell physiology J:267548
\Itgaltm1Bll/\Itgaltm1Bll
(involves: 129S7/SvEvBrd * C57BL/6J)
abnormal cellular extravasation J:83226
abnormal leukocyte adhesion J:83226
abnormal leukocyte migration J:83226
increased eosinophil cell number J:83226
increased leukocyte cell number J:83226
increased monocyte cell number J:83226
increased neutrophil cell number J:83226
\Itgaltm1Bll/\Itgaltm1Bll
(B6.129S7-Itgaltm1Bll)
abnormal leukocyte adhesion J:100242
abnormal leukocyte tethering or rolling J:100242
decreased T cell proliferation J:90954
impaired natural killer cell mediated cytotoxicity J:90954
increased leukocyte cell number J:100242
increased neutrophil cell number J:100242
\Itgaltm1Bll/\Itgaltm1Bll
(B6.129S7-Itgaltm1Bll/J)
abnormal inflammatory response J:113463
\Itgaltm1Bll/\Itgaltm1Bll
(involves: 129S7/SvEvBrd)
abnormal CD4-positive, alpha-beta T cell physiology J:267548
abnormal cellular extravasation J:141063
abnormal leukocyte adhesion J:141063
abnormal neutrophil physiology J:141063
\Itgaltm1Hlz/\Itgaltm1Hlz
(involves: 129P2/OlaHsd)
abnormal cellular extravasation J:99286
abnormal humoral immune response J:99286
abnormal leukocyte adhesion J:99286
abnormal T cell activation J:99286
decreased cytotoxic T cell cytolysis J:99286
decreased lymphocyte cell number J:99286
decreased neutrophil cell number J:99286
spleen hyperplasia J:99286
\Itgaltm1Hogg/\Itgaltm1Hogg
(involves: 129P2/OlaHsd)
abnormal leukocyte adhesion J:82587
abnormal leukocyte migration J:82587
abnormal lymph node morphology J:82587
decreased B cell number J:82587
decreased CD4-positive, alpha-beta T cell number J:82587
decreased CD8-positive, alpha-beta T cell number J:82587
decreased lymphocyte cell number J:82587
enlarged spleen J:82587
increased CD4-positive, alpha-beta T cell number J:82587
increased CD8-positive, alpha-beta T cell number J:82587
small lymph nodes J:82587
\Itgaltm1Mak/\Itgal+
(B6.129P2-Itgaltm1Mak)
decreased susceptibility to endotoxin shock J:123460
\Itgaltm1Mak/\Itgaltm1Mak
(B6.129P2-Itgaltm1Mak)
decreased susceptibility to endotoxin shock J:123460
impaired natural killer cell mediated cytotoxicity J:110889
increased circulating interleukin-2 level J:123460
increased circulating interleukin-10 level J:123460
increased circulating tumor necrosis factor level J:123460
\Itgaltm1Wpfl/\Itgaltm1Wpfl
(involves: 129)
abnormal cytotoxic T cell physiology J:37160
abnormal leukocyte physiology J:37160
abnormal lymphocyte physiology J:37160
immune system phenotype J:37160
lymph node hyperplasia J:37160
\Itgamm1Btlr/\Itgam+
(C57BL/6J-Itgamm1Btlr)
abnormal dendritic cell number J:236681
decreased macrophage cell number J:236681
decreased neutrophil cell number J:236681
increased plasmacytoid dendritic cell number J:236681
\Itgamm1Btlr/\Itgamm1Btlr
(C57BL/6J-Itgamm1Btlr)
abnormal dendritic cell number J:236681
decreased macrophage cell number J:236681
decreased neutrophil cell number J:236681
increased plasmacytoid dendritic cell number J:236681
\Itgamm2Btlr/\Itgamm2Btlr
(C57BL/6J-Itgamm2Btlr)
decreased CD11b-high dendritic cell number J:272532
\Itgamm3Btlr/\Itgamm3Btlr
(C57BL/6J-Itgamm3Btlr)
decreased CD11b-high dendritic cell number J:272533
\Itgamtm1Bll/\Itgamtm1Bll
(B6.129S7-Itgamtm1Bll)
abnormal leukocyte adhesion J:100242
abnormal lymphocyte cell number J:90954
abnormal T cell activation J:90954
abnormal T cell subpopulation ratio J:90954
decreased CD4-positive, alpha-beta T cell number J:90954
decreased T cell proliferation J:90954
increased CD8-positive, alpha-beta T cell number J:90954
increased leukocyte cell number J:100242
increased neutrophil cell number J:100242
increased susceptibility to bacterial infection J:94855
\Itgamtm1Bll/\Itgamtm1Bll
(involves: 129S7/SvEvBrd * C57BL/6J)
abnormal cellular extravasation J:83226
abnormal leukocyte adhesion J:83226
abnormal leukocyte migration J:83226
abnormal neutrophil physiology J:39092
decreased eosinophil cell number J:83226
impaired neutrophil phagocytosis J:39092
\Itgamtm1Myd/\Itgamtm1Myd
(involves: 129S4/SvJae * BALB/c * C57BL/6)
abnormal leukocyte adhesion J:38052
impaired neutrophil phagocytosis J:38052
increased eosinophil cell number J:38052
increased neutrophil cell number J:38052
\Itgamtm1Myd/\Itgamtm1Myd
(involves: 129S4/SvJae * C57BL/6)
decreased neutrophil cell number J:103873
\Itgamtm1Myd/\Itgamtm1Myd
(B6.129S4-Itgamtm1Myd)
abnormal inflammatory response J:113463
abnormal neutrophil morphology J:113463
abnormal neutrophil physiology J:113463
\Itgamtm1Myd/\Itgamtm1Myd
(involves: 129S4/SvJae)
impaired leukocyte tethering or rolling J:198197
impaired neutrophil phagocytosis J:155479
\Itgamtm1Myd/\Itgamtm1Myd
\Syktm1Tyb/\Syktm1.2Tara
\Lyz2tm1(cre)Ifo/\Lyz2+

(involves: 129P2/OlaHsd * 129S2/SvPas * 129S4/SvJae * C57BL/6)
impaired granulocyte bactericidal activity J:155479
\Itgamtm1Rws/\Itgamtm1Rws
(involves: 129P2/OlaHsd * C57BL/6J)
abnormal macrophage physiology J:65847
\Itgavtm1Blb/\Itgavtm1Blb
\Itgb1tm1Ref/\Itgb1tm1Ref
\Itgb2tm2Bay/\Itgb2tm2Bay
\Itgb7tm1Cgn/\Itgb7tm1Cgn
\Tg(Mx1-cre)1Cgn/0

(involves: 129S1/Sv * 129S7/SvEvBrd * 129X1/SvJ * C57BL/6 * CBA)
abnormal cellular extravasation J:134784
abnormal dendritic cell physiology J:134784
immune system phenotype J:134784
\Itgavtm2Hyn/\Itgavtm2.1Hyn
\Lyz2tm1(cre)Ifo/\Lyz2+

(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 * FVB)
colitis J:125508
impaired macrophage phagocytosis J:125508
increased autoantibody level J:125508
\Itgavtm2Hyn/\Itgavtm2.1Hyn
\Tg(Nes-cre)1Kln/0

(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * FVB * SJL)
increased susceptibility to bacterial infection induced morbidity/mortality J:94376
\Itgavtm2Hyn/\Itgavtm2.1Hyn
\Tg(Tek-cre)1Ywa/?

(involves: 129S2/SvPas * C57BL/6 * FVB * SJL)
abnormal dendritic cell differentiation J:125508
abnormal immune system morphology J:125508
abnormal immune system physiology J:125508
abnormal interferon level J:125508
abnormal interleukin level J:125508
abnormal leukocyte morphology J:125508
abnormal tumor necrosis factor level J:125508
colitis J:125508
decreased regulatory T cell number J:125508
enlarged mesenteric lymph nodes J:125508
enlarged Peyer's patches J:125508
impaired macrophage phagocytosis J:125508
increased autoantibody level J:125508
increased inflammatory response J:125508
increased regulatory T cell number J:125508
large intestinal inflammation J:125508
\ItgaxM1Btlr/\Itgax+
(C57BL/6J-ItgaxM1Btlr)
decreased dendritic cell number J:236684
increased plasmacytoid dendritic cell number J:236684
\ItgaxM1Btlr/\ItgaxM1Btlr
(C57BL/6J-ItgaxM1Btlr)
decreased dendritic cell number J:236684
increased plasmacytoid dendritic cell number J:236684
\Itgaxtm1.1(HBEGF)Ktak/\Itgax+
(involves: 129S4/SvJae * C57BL/6)
abnormal response to infection J:162397
\Itgaxtm1Bll/\Itgaxtm1Bll
(B6.129S7-Itgaxtm1Bll)
decreased interferon-gamma secretion J:122187
decreased interleukin-17 secretion J:122187
decreased susceptibility to experimental autoimmune encephalomyelitis J:122187
decreased tumor necrosis factor secretion J:122187
increased interleukin-2 secretion J:122187
increased interleukin-12 secretion J:122187
increased susceptibility to bacterial infection J:94855
increased T cell proliferation J:122187
\Itgb1tm1Ref/\Itgb1tm1Ref
\Tg(KRT5-cre)5132Jlj/0

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * DBA/2J)
skin inflammation J:65038
\Itgb2M1Btlr/\Itgb2M1Btlr
(C57BL/6J-Itgb2M1Btlr)
abnormal NK cell differentiation J:139559
decreased interferon-gamma secretion J:139559
immune system phenotype J:139559
\Itgb2m2Btlr/\Itgb2m2Btlr
(C57BL/6J-Itgb2m2Btlr)
increased interferon-beta secretion J:265125
\Itgb2m3Btlr/\Itgb2m3Btlr
(C57BL/6J-Itgb2m3Btlr)
abnormal cytotoxic T cell cytolysis J:265126
decreased B cell number J:265126
decreased CD4-positive, alpha-beta T cell number J:265126
decreased CD8-positive, alpha-beta T cell number J:265126
decreased dendritic cell number J:265126
decreased IgG level J:265126
decreased macrophage cell number J:265126
decreased neutrophil cell number J:265126
decreased single-positive T cell number J:265126
impaired humoral immune response J:265126
impaired natural killer cell mediated cytotoxicity J:265126
increased dendritic cell number J:265126
increased effector memory CD4-positive, alpha-beta T cell number J:265126
increased IgE level J:265126
increased NK T cell number J:265126
\Itgb2M4Btlr/\Itgb2M4Btlr
(C57BL/6J-Itgb2M4Btlr)
abnormal T cell differentiation J:272843
increased effector memory CD4-positive, alpha-beta T cell number J:272843
\Itgb2m5Btlr/\Itgb2m5Btlr
(C57BL/6J-Itgb2m5Btlr)
increased B-1b cell number J:272844
\Itgb2tm1.1Arte/\Itgb2tm1.1Arte
(involves: C57BL/6NTac)
abnormal T cell physiology J:202261
decreased T cell proliferation J:202261
enlarged spleen J:202261
increased B cell number J:202261
increased dendritic cell number J:202261
increased neutrophil cell number J:202261
increased T cell number J:202261
lymph node hypoplasia J:202261
\Itgb2tm1Bay/\Itgb2tm1Bay
(involves: 129S7/SvEvBrd)
decreased inflammatory response J:13599
increased granulocyte number J:13599
increased leukocyte cell number J:13599, J:32126
increased lymphocyte cell number J:13599
\Itgb2tm1Bay/\Itgb2tm1Bay
(involves: 129S7/SvEvBrd * PL/J)
abnormal cytokine level J:109598
abnormal spleen morphology J:32126
abnormal T cell activation J:109598
dermatitis J:109598, J:32126
enlarged lymph nodes J:32126
increased basophil cell number J:32126
increased eosinophil cell number J:32126
increased interferon-gamma secretion J:109598
increased leukocyte cell number J:32126
increased lymphocyte cell number J:32126
increased monocyte cell number J:32126
increased neutrophil cell number J:32126
increased T cell number J:109598
increased T-helper 1 cell number J:109598
myeloid hyperplasia J:32126
\Itgb2tm1Bay/\Itgb2tm1Bay
(involves: 129S7/SvEvBrd * C57BL/6J)
abnormal spleen red pulp morphology J:13599
myeloid hyperplasia J:13599
\Itgb2tm1Bay/\Itgb2tm1Bay
(involves: 129S7/SvEvBrd * C57BL/6J * PL/J)
dermatitis J:84126
\Itgb2tm1Bay/\Itgb2tm1Bay
\Psrs1PL/J/\Psrs1PL/J

(B6.Cg-(D10Mit126-D10Mit38) Itgb2tm1Bay)
rheumatoid arthritis J:134251
\Itgb2tm1Bay/\Itgb2tm1Bay
\Psrs1PL/J/\Psrs1PL/J

(B6.Cg-(D10Mit75-D10Mit271) Itgb2tm1Bay)
rheumatoid arthritis J:134251
\Itgb2tm1Bay/\Itgb2tm2Bay
(PL.129S7-Itgb2tm1Bay Itgb2tm2Bay)
dermatitis J:84126
\Itgb2tm1Bay/\Itgb2tm2Bay
(involves: 129S7/SvEvBrd * C57BL/6J * PL/J)
dermatitis J:84126
\Itgb2tm2Bay/\Itgb2tm2Bay
(involves: 129S7/SvEvBrd * C57BL/6J)
abnormal immune system cell morphology J:48542
abnormal leukocyte physiology J:48542
abnormal lymph organ size J:48542
abnormal neutrophil morphology J:48542
abnormal neutrophil physiology J:48542
abnormal T cell proliferation J:48542
conjunctivitis J:48542
dermatitis J:48542
enlarged lymph nodes J:48542
enlarged spleen J:48542
increased circulating interleukin-3 level J:48542
increased circulating interleukin-6 level J:48542
increased IgA level J:48542
increased IgG level J:48542
increased IgM level J:48542
increased immunoglobulin level J:48542
increased inflammatory response J:48542
increased leukocyte cell number J:48542
increased lymphocyte cell number J:48542
increased monocyte cell number J:48542
increased neutrophil cell number J:48542
increased susceptibility to bacterial infection J:48542
myeloid hyperplasia J:48542
\Itgb2tm2Bay/\Itgb2tm2Bay
(involves: 129S7/SvEvBrd)
decreased T cell proliferation J:90954
\Itgb2tm2Bay/\Itgb2tm2Bay
(B6.129S7-Itgb2tm2Bay)
abnormal leukocyte adhesion J:83226
abnormal leukocyte migration J:83226
decreased susceptibility to bacterial infection J:94855
increased eosinophil cell number J:83226
increased leukocyte cell number J:83226
increased lymphocyte cell number J:83226
increased monocyte cell number J:83226
increased neutrophil cell number J:83226
\Itgb2tm2Bay/\Itgb2tm2Bay
(involves: 129S7/SvEvBrd * C57BL/6)
decreased acute inflammation J:112286
impaired neutrophil recruitment J:112286
increased neutrophil cell number J:112286
\Itgb2tm2Bay/\Itgb2tm2Bay
(PL.129S7-Itgb2tm2Bay)
decreased susceptibility to type IV hypersensitivity reaction J:109598
\Itgb2ltm1Jhws/\Itgb2ltm1Jhws
(involves: 129/Sv * C57BL/6)
immune system phenotype J:118477
\Itgb3tm1Hyn/\Itgb3tm1.1Wlbcr
\Lyz2tm1(cre)Ifo/\Lyz2+

(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6)
abnormal osteoclast differentiation J:224675
abnormal osteoclast morphology J:224675
decreased osteoclast cell number J:224675
\Itgb3tm1Hyn/\Itgb3tm1.1Wlbcr
\Tg(Pf4-icre)Q3Rsko/0

(involves: 129S2/SvPas * C57BL/6)
enlarged spleen J:224675
\Itgb3tm1Hyn/\Itgb3tm1Hyn
(involves: 129S2/SvPas * C57BL/6)
abnormal macrophage physiology J:119666
dermatitis J:52262
enlarged spleen J:52262
impaired macrophage chemotaxis J:119666
increased monocyte cell number J:119666
myositis J:119666
\Itgb3tm1Hyn/\Itgb3tm1Hyn
(involves: 129S2/SvPas)
abnormal osteoclast morphology J:60672
abnormal osteoclast physiology J:60672
decreased macrophage cell number J:96049
increased osteoclast cell number J:60672
\Itgb3tm1Hyn/\Itgb3tm1Hyn
(involves: 129S2/SvPas * BALB/c)
immune system phenotype J:131241
increased IgG level J:131241
\Itgb4tm1Son/\Itgb4tm1Son
(129P2/OlaHsd-Itgb4tm1Son)
immune system phenotype J:33713
\Itgb4tm2Son/\Itgb4tm2Son
\Tg(KRT14-cre)8Brn/0

(involves: 129P2/OlaHsd * FVB/N)
ear inflammation J:96543
\Itgb5tm1a(EUCOMM)Wtsi/\Itgb5tm1a(EUCOMM)Wtsi
(C57BL/6N-Itgb5tm1a(EUCOMM)Wtsi/Ics)
increased leukocyte cell number J:165965
\Itgb6em1(IMPC)Ccpcz/\Itgb6em1(IMPC)Ccpcz
(C57BL/6NCrl-Itgb6em1(IMPC)Ccpcz/Ccpcz)
abnormal thymus morphology J:211773
enlarged thymus J:211773
\Itgb6tm1Des/\Itgb6tm1Des
(involves: 129S4/SvJae * C57BL/6J)
respiratory system inflammation J:33139
\Itgb6tm1Des/\Itgb6tm1Des
(involves: 129S4/SvJae)
abnormal immune system physiology J:120085
absent Langerhans cell J:120085
decreased Langerhans cell number J:120085
\Itgb6tm1Des/\Itgb6tm1Des
(involves: 129S4/SvJae * C57BL/6 * SJL)
respiratory system inflammation J:51592
\Itgb6tm1Des/\Itgb6tm1Des
\Mmp12tm1Sds/\Mmp12tm1Sds

(involves: 129/Sv * 129T2/SvEms)
lung inflammation J:89578
\Itgb6tm1Des/\Itgb6tm1Des
\Tg(SFTPC-ITGB6)1Des/?

(involves: 129S4/SvJae * C57BL/6 * SJL)
respiratory system inflammation J:51592
\Itgb7tm1Cgn/\Itgb7tm1Cgn
(involves: C57BL/6)
abnormal gut-associated lymphoid tissue morphology J:34306
abnormal immune system morphology J:34306
abnormal immune system physiology J:34306
abnormal lymphocyte physiology J:34306
abnormal Peyer's patch follicle morphology J:34306
abnormal response to infection J:62733
abnormal uterine NK cell morphology J:44813
decreased B cell number J:34306
decreased CD4-positive, alpha-beta T cell number J:34306
decreased eosinophil cell number J:62733
decreased mast cell number J:62733
immune system phenotype J:111227
impaired leukocyte tethering or rolling J:34306
increased susceptibility to parasitic infection J:90262
increased uterine NK cell number J:44813
small Peyer's patches J:34306
\Itgb7tm1Cgn/\Itgb7tm1Cgn
(C57BL/6-Itgb7tm1Cgn/J)
abnormal leukocyte migration J:127413
colitis J:127413
\Itgb7tm1Cgn/\Itgb7tm1Cgn
\Tnftm2Gkl/\Tnf+

(involves: 129S/SvEv * C57BL/6)
abnormal inflammatory response J:136667
autoimmune arthritis J:136667
\Itgb7tm1Mshi/\Itgb7tm1Mshi
(involves: C57BL/6)
abnormal leukocyte adhesion J:127413
abnormal leukocyte migration J:127413
colitis J:127413
small Peyer's patches J:127413
\Itkm1Btlr/\Itkm1Btlr
(C57BL/6J-Itkm1Btlr)
abnormal CD4-positive, alpha-beta T cell physiology J:236673
abnormal CD8-positive, alpha-beta T cell physiology J:236673
increased CD8-positive, alpha-beta memory T cell proliferation J:236673
increased IgE level J:236673
\Itkm2Btlr/\Itkm2Btlr
(C57BL/6J-Itkm2Btlr)
decreased CD4-positive, CD25-positive, alpha-beta regulatory T cell number J:254826
decreased CD8-positive, alpha-beta memory T cell number J:254826
decreased CD8-positive, naive alpha-beta T cell number J:254826
increased B cell number J:254826
increased central memory CD4-positive, alpha-beta T cell number J:254826
increased central memory CD8 positive, alpha-beta T cell number J:254826
increased effector memory CD4-positive, alpha-beta T cell number J:254826
\Itktm1Lex/\Itktm1Lex
(involves: 129S5/SvEvBrd * C57BL/6J)
decreased CD4-positive, alpha-beta T cell number J:103485
decreased CD8-positive, alpha-beta T cell number J:103485
increased B cell number J:103485
\Itktm1Litt/\Itktm1Litt
(involves: 129S4/SvJae * C57BL/6J)
decreased B cell number J:31230
decreased CD4-positive, alpha-beta T cell number J:31230
decreased T cell number J:31230
decreased T cell proliferation J:31230
immune system phenotype J:31230
\Itktm1Litt/\Itktm1Litt
(involves: 129S4/SvJae)
decreased T cell proliferation J:54449
increased susceptibility to parasitic infection J:54449
\Itktm1Litt/\Itktm1Litt
(involves: 129S4/SvJae * C57BL/6)
abnormal CD8-positive, alpha-beta T cell differentiation J:111786
abnormal thymus cell ratio J:111786
decreased CD8-positive, alpha-beta T cell number J:111786
\Itktm1Litt/\Itktm1Litt
(B6.129S4-Itktm1Litt)
abnormal positive T cell selection J:141390
abnormal T cell morphology J:141390
decreased interleukin-2 secretion J:141390
decreased T cell number J:141390
decreased T cell proliferation J:141390
increased double-negative T cell number J:141390
\Itktm1Litt/\Itktm1Litt
\Tg(DO11.10)10Dlo/0

(involves: 129S4/SvJae * BALB/c * C3H * C57BL/6J)
abnormal T-helper 2 physiology J:129883
\Itktm1Litt/\Itktm1Litt
\Tg(TcraH-Y,TcrbH-Y)71Vbo/0

(involves: 129S4/SvJae * C57BL/6 * DBA/2J)
abnormal positive T cell selection J:31230
decreased CD4-positive, alpha-beta T cell number J:31230
increased double-positive T cell number J:31230
\Itktm1Litt/\Itktm1Litt
\Tg(TcrAND)53Hed/0

(involves: 129S4/SvJae * C57BL/6 * SJL)
abnormal lymphocyte morphology J:31230
decreased CD4-positive, alpha-beta T cell number J:31230
increased double-negative T cell number J:31230
\Itktm1Litt/\Itktm1Litt
\Txktm1Pls/\Txktm1Pls

(involves: 129S4/SvJae * 129S6/SvEvTac)
decreased CD4-positive, alpha-beta T cell number J:54449
decreased single-positive T cell number J:54449
decreased T cell proliferation J:54449
increased susceptibility to parasitic infection J:54449
\Itktm1Litt/\Itktm1Litt
\Vav1tm2Bbd/\Vav1tm2Bbd

(B6.129-Itktm1Litt Vav1tm2Bbd)
abnormal CD4-positive T cell differentiation J:141390
abnormal CD8-positive, alpha-beta T cell differentiation J:141390
abnormal positive T cell selection J:141390
abnormal T cell morphology J:141390
abnormal T cell physiology J:141390
decreased CD4-positive, alpha-beta T cell number J:141390
decreased CD8-positive, alpha-beta T cell number J:141390
decreased double-positive T cell number J:141390
decreased T cell number J:141390
decreased thymocyte number J:141390
increased B cell number J:141390
increased T cell apoptosis J:141390
\Itktm1Ljb/\Itktm1Ljb
(B6.129-Itktm1Ljb)
abnormal NK T cell morphology J:120689
decreased NK T cell number J:120689
\Itktm1Ljb/\Itktm1Ljb
(involves: 129 * C57BL/6)
abnormal T cell activation J:48231
decreased CD4-positive, alpha-beta T cell number J:48231
decreased interleukin-2 secretion J:48231
\Itktm1Ljb/\Itktm1Ljb
(B10.129-Itktm1Ljb)
abnormal CD8-positive, alpha-beta T cell differentiation J:113408
abnormal CD8-positive, alpha-beta T cell physiology J:113408
abnormal gamma-delta T cell morphology J:148531
decreased CD4-positive, alpha-beta T cell number J:123795
decreased interferon-gamma secretion J:148531
increased CD8-positive, alpha-beta T cell number J:113408, J:123795
increased germinal center B cell number J:148531
increased IgE level J:148531
increased interferon-gamma secretion J:113408
increased interleukin-4 secretion J:148531
increased interleukin-10 secretion J:148531
increased interleukin-13 secretion J:148531
increased mature gamma-delta T cell number J:148531
increased memory T cell number J:113408
\Itktm1Ljb/\Itktm1Ljb
\Rag1tm1Mom/\Rag1tm1Mom
\Tg(Tcra5CC7,Tcrb5CC7)IWep/?

(involves: 129 * C57BL/10)
abnormal CD4-positive T cell differentiation J:93606
decreased interferon-gamma secretion J:93606
decreased interleukin-4 secretion J:93606
decreased interleukin-5 secretion J:93606
decreased interleukin-10 secretion J:93606
\Itktm1Ljb/\Itktm1Ljb
\Tcrdtm1Mom/\Tcrdtm1Mom

(involves: 129 * C57BL/6 * C57BL/10)
immune system phenotype J:148531
\Itktm1Ljb/\Itktm1Ljb
\Tg(Tcra2B4)1Mmd/?
\Tg(Tcrb2B4)1Mmd/?

(involves: C3H/HeJ * C57BL/6 * C57BL/10)
decreased CD4-positive, alpha-beta T cell number J:123795
\Itktm1Ljb/\Itktm1Ljb
\Tg(Tcra5CC7,Tcrb5CC7)IWep/?

(involves: 129 * C57BL/10)
decreased CD4-positive, alpha-beta T cell number J:123795
\Itktm1Ljb/\Itktm1Ljb
\Tg(TcraTcrb)1100Mjb/?

(involves: 129 * C57BL/6 * C57BL/10)
immune system phenotype J:113408
\Itktm1Ljb/\Itktm1Ljb
\Txktm1Pls/\Txktm1Pls

(B6.129-Txktm1Pls Itktm1Ljb)
abnormal CD8-positive, alpha-beta T cell physiology J:113408
increased CD8-positive, alpha-beta T cell number J:113408
increased interferon-gamma secretion J:113408
increased memory T cell number J:113408
\Itln1em1Cya/\Itln1em1Cya
(involves: C57BL/6)
abnormal cytokine level J:282124
abnormal osteoclast physiology J:282124
increased circulating interleukin-1 alpha level J:282124
increased circulating interleukin-6 level J:282124
increased circulating interleukin-10 level J:282124
increased circulating tumor necrosis factor level J:282124
increased osteoclast cell number J:282124
\Itm2cem1Nutt/\Itm2cem1Nutt
\Prdm1tm1Nutt/\Prdm1+

(involves: C57BL/6 * C57BL/6J)
immune system phenotype J:265892
\ItpkbT-less/\ItpkbT-less
(C57BL/6-ItpkbT-less)
abnormal T cell physiology J:89286
arrested T cell differentiation J:89286
\Itpkbtm1Ssch/\Itpkbtm1Ssch
(involves: 129S1/Sv * 129X1/SvJ * CD-1)
abnormal thymocyte activation J:86257
abnormal thymus involution J:86257
absent CD4-positive, alpha-beta T cells J:86257
absent CD8-positive, alpha-beta T cells J:86257
absent T cells J:86257
absent thymus medulla J:86257
arrested T cell differentiation J:86257
decreased IgG1 level J:86257
decreased IgG2a level J:86257
decreased IgG2b level J:86257
decreased IgG level J:86257
increased double-positive T cell number J:86257
increased susceptibility to parasitic infection J:86257
\Itpkbtm1Ssch/\Itpkbtm1Ssch
\Itpkctm1Ssch/\Itpkctm1Ssch

(involves: 129S1/Sv * 129X1/SvJ * CD-1)
abnormal thymocyte activation J:86257
absent CD4-positive, alpha-beta T cells J:86257
absent CD8-positive, alpha-beta T cells J:86257
arrested T cell differentiation J:86257
\Ity2C57BL/6J/\Ity2MOLF/EiJ
(involves: C57BL/6J * MOLF/Ei)
decreased susceptibility to bacterial infection J:45962
\Ity2MOLF/EiJ/\Ity2MOLF/EiJ
(involves: C57BL/6J * MOLF/Ei)
decreased susceptibility to bacterial infection J:126552, J:45962
\Ity2aMOLF/EiJ/\Ity2aMOLF/EiJ
(involves: C57BL/6J * MOLF/Ei)
decreased susceptibility to bacterial infection J:126552
\Ity2bMOLF/EiJ/\Ity2bMOLF/EiJ
(involves: C57BL/6J * MOLF/Ei)
decreased susceptibility to bacterial infection J:126552
\Ity3C57BL/6J/\Ity3C57BL/6J
(involves: C57BL/6J * MOLF/Ei)
decreased susceptibility to bacterial infection J:45962
\Ity3C57BL/6J/\Ity3MOLF/EiJ
(involves: C57BL/6J * MOLF/Ei)
decreased susceptibility to bacterial infection J:45962
\Ity3MOLF/EiJ/\Ity3MOLF/EiJ
(involves: C57BL/6J * MOLF/Ei)
increased susceptibility to bacterial infection J:126552, J:45962
\Ity3MOLF/EiJ/\Ity3MOLF/EiJ
(B6.MOLF-Slc11a1r Ity3MOLF/EiJ)
abnormal cytokine secretion J:108692
\Jade2em1(IMPC)Tcp/\Jade2em1(IMPC)Tcp
(C57BL/6N-Jade2em1(IMPC)Tcp/Tcp)
small spleen J:211773
\Jag2tm1Grid/\Jag2tm1Grid
(involves: 129S1/Sv * C57BL/6J)
abnormal gamma-delta T cell differentiation J:46930
abnormal thymus medulla morphology J:46930
abnormal thymus morphology J:46930
decreased gamma-delta T cell number J:46930
\Jagn1tm1c(EUCOMM)Hmgu/\Jagn1tm1c(EUCOMM)Hmgu
\Commd10Tg(Vav1-icre)A2Kio/\Commd10+

(involves: C57BL/6N * C57BL/10 * CBA/Ca)
abnormal neutrophil morphology J:214828
abnormal neutrophil physiology J:214828
impaired neutrophil chemotaxis J:214828
impaired neutrophil recruitment J:214828
increased susceptibility to fungal infection J:214828
\Jak1M1Mhda/\Jak1+
(C3HeB/FeJ-Jak1M1Mhda)
abnormal plasma cell morphology J:199153
ear inflammation J:199153
enlarged spleen J:199153
increased anti-nuclear antigen antibody level J:199153
increased IgA level J:199153
increased IgG1 level J:199153
increased IgG2a level J:199153
increased IgM level J:199153
increased immunoglobulin level J:199153
increased plasma cell number J:199153
skin inflammation J:199153
\Jak1tm1Rds/\Jak1tm1Rds
(involves: 129)
abnormal B cell differentiation J:47300
abnormal lymphopoiesis J:47300
abnormal T cell differentiation J:47300
arrested B cell differentiation J:47300
decreased B cell number J:47300
decreased thymocyte number J:47300
increased double-negative T cell number J:47300
small thymus J:47300
\Jak2tm1(JAK2)Argr/\Jak2+
\Dppa3tm1(cre)Peli/\Dppa3+

(involves: 129S5/SvEvBrd * 129S7/SvEvBrd * C57BL/6)
increased leukocyte cell number J:233169
increased spleen weight J:233169
\Jak2tm1(JAK2)Argr/\Jak2+
\Tg(Mx1-cre)1Cgn/0

(involves: 129S7/SvEvBrd * C57BL/6 * CBA)
decreased leukocyte cell number J:164539
enlarged spleen J:164539
increased leukocyte cell number J:164539
\Jak2tm1.1Ble/\Jak2+
\Commd10Tg(Vav1-icre)A2Kio/\Commd10+

(involves: 129 * C57BL/6 * C57BL/10 * CBA/Ca)
abnormal cytokine level J:257910
enlarged spleen J:257910
increased granulocyte number J:257910
increased leukocyte cell number J:257910
increased neutrophil cell number J:257910
\Jak2tm1.1Jlvl/\Jak2tm1.1Jlvl
(involves: 129S2/SvPas * C57BL/6)
abnormal spleen morphology J:163497
decreased spleen white pulp amount J:163497
enlarged spleen J:163497
increased granulocyte number J:163497
increased leukocyte cell number J:163497
increased lymphocyte cell number J:163497
increased monocyte cell number J:163497
increased spleen red pulp amount J:163497
\Jak2tm1.2Ble/\Jak2+
(involves: 129S6/SvEvTac * C57BL/6 * FVB/N)
abnormal spleen morphology J:160883
abnormal spleen red pulp morphology J:160883
enlarged spleen J:160883
increased leukocyte cell number J:160883
\Jak2tm1.2Ble/\Jak2+
\Picalmtm1.1Tmae/\Picalmtm1.1Tmae
\Commd10Tg(Vav1-icre)A2Kio/\Commd10+

(involves: 129S6/SvEvTac * C57BL/6 * C57BL/10 * CBA * SJL)
decreased CD4-positive, alpha-beta T cell number J:220728
decreased CD8-positive, alpha-beta T cell number J:220728
\Jak2tm1Mohi/\Jak2+
\Tg(Mx1-cre)1Cgn/0

(involves: C57BL/6 * CBA)
abnormal spleen red pulp morphology J:183821
abnormal spleen white pulp morphology J:183821
decreased B cell number J:183821
enlarged spleen J:183821
increased leukocyte cell number J:183821
increased neutrophil cell number J:183821
increased spleen red pulp amount J:183821
increased spleen weight J:183821
myeloid hyperplasia J:183821
spleen fibrosis J:183821
\Jak2tm1Mohi/\Jak2tm1Mohi
\Tg(Mx1-cre)1Cgn/0

(involves: C57BL/6 * CBA)
abnormal spleen red pulp morphology J:183821
abnormal spleen white pulp morphology J:183821
decreased B cell number J:183821
decreased spleen white pulp amount J:183821
enlarged spleen J:183821
increased leukocyte cell number J:183821
increased neutrophil cell number J:183821
increased spleen red pulp amount J:183821
increased spleen weight J:183821
myeloid hyperplasia J:183821
spleen fibrosis J:183821
\Jak2tm2.1Jlvl/\Jak2+
\Tg(Vav1-cre)#Cgp/0

(involves: 129S2/SvPas * C57BL/6NTac)
abnormal myelopoiesis J:202234
decreased B cell number J:202234
enlarged spleen J:202234
increased granulocyte number J:202234
increased leukocyte cell number J:202234
increased spleen weight J:202234
myeloid hyperplasia J:202234
spleen fibrosis J:202234
\Jak2tm2.2Jlvl/\Jak2+
(involves: 129S2/SvPas * C57BL/6 * C57BL/6NTac * SJL)
enlarged spleen J:202234
increased leukocyte cell number J:202234
\Jak3bfy/\Jak3bfy
(C57BL/6JSfdAnu-Jak3bfy/AnuApb)
abnormal lymphopoiesis J:104190
abnormal T cell subpopulation ratio J:104190
decreased B cell number J:104190
decreased lymphocyte cell number J:104190
decreased T cell number J:104190
decreased thymocyte number J:104190
small thymus J:104190
\Jak3em1(IMPC)Mbp/\Jak3+
(C57BL/6N-Jak3em1(IMPC)Mbp/MbpMmucd)
abnormal lymph node morphology J:211773
enlarged lymph nodes J:211773
\Jak3m1Btlr/\Jak3m1Btlr
(C57BL/6J-Jak3m1Btlr)
abnormal T cell subpopulation ratio J:217795
decreased IgG level J:217795
decreased NK cell number J:217795
decreased response to antigen J:217795
decreased single-positive T cell number J:217795
decreased T cell number J:217795
impaired humoral immune response J:217795
increased effector memory CD4-positive, alpha-beta T cell number J:217795
increased effector memory CD8-positive, alpha-beta T cell number J:217795
increased IgE level J:217795
increased neutrophil cell number J:217795
increased single-positive T cell number J:217795
increased susceptibility to Herpesvirales infection J:217795
\Jak3m1J/\Jak3m1J
(B6.Cg-Crb1+ Jak3m1J/Boc)
decreased spleen weight J:265859
decreased thymus weight J:265859
small spleen J:265859
small thymus J:265859
\Jak3M1Pgrs/\Jak3+
(involves: C57BL/6J * C57BL/10J)
decreased susceptibility to parasitic infection induced morbidity/mortality J:185217
\Jak3M1Pgrs/\Jak3M1Pgrs
(involves: C57BL/6J * C57BL/10J)
absent B cells J:185217
decreased B cell number J:185217
decreased interferon-gamma secretion J:185217
decreased NK cell number J:185217
decreased susceptibility to parasitic infection induced morbidity/mortality J:185217
enlarged spleen J:185217
increased CD4-positive, alpha-beta T cell number J:185217
increased CD8-positive, alpha-beta T cell number J:185217
increased susceptibility to bacterial infection J:185217
increased susceptibility to bacterial infection induced morbidity/mortality J:185217
small thymus J:185217
\Jak3M1Pgrs/\Jak3tm1Ljb
(involves: 129S4/SvJae * C57BL/6J * C57BL/10J)
decreased susceptibility to parasitic infection induced morbidity/mortality J:185217
\Jak3m2Btlr/\Jak3m2Btlr
(C57BL/6J-Jak3m2Btlr)
increased B cell number J:217796
increased memory B cell number J:217796
\Jak3m3Btlr/\Jak3m3Btlr
(C57BL/6J-Jak3m3Btlr)
abnormal T cell subpopulation ratio J:225935
decreased B cell number J:225935
decreased B-1 B cell number J:225935
decreased IgG level J:225935
decreased immature B cell number J:225935
decreased mature B cell number J:225935
decreased memory B cell number J:225935
decreased NK cell number J:225935
decreased single-positive T cell number J:225935
decreased T cell number J:225935
impaired humoral immune response J:225935
increased effector memory CD8-positive, alpha-beta T cell number J:225935
increased macrophage cell number J:225935
increased myeloid dendritic cell number J:225935
\Jak3m4Btlr/\Jak3m4Btlr
(C57BL/6J-Jak3m4Btlr)
increased CD4-positive, alpha-beta T cell number J:272398
\Jak3M5Btlr/\Jak3M5Btlr
(C57BL/6J-Jak3M5Btlr)
decreased NK T cell number J:272399
\Jak3m6Btlr/\Jak3m6Btlr
(C57BL/6J-Jak3m6Btlr)
decreased CD8-positive, alpha-beta T cell number J:272400
decreased IgG level J:272400
impaired humoral immune response J:272400
increased CD4-positive, alpha-beta T cell number J:272400
\Jak3M7Btlr/\Jak3M7Btlr
(C57BL/6J-Jak3M7Btlr)
abnormal CD4-positive T cell differentiation J:272401
\Jak3m8Btlr/\Jak3m8Btlr
(C57BL/6J-Jak3m8Btlr)
decreased B cell number J:274939
decreased B-1 B cell number J:274939
decreased B-2 B cell number J:274939
decreased CD4-positive, alpha-beta T cell number J:274939
decreased CD8-positive, alpha-beta T cell number J:274939
decreased CD8-positive, naive alpha-beta T cell number J:274939
decreased dendritic cell number J:274939
decreased IgG level J:274939
decreased IgM level J:274939
decreased response to antigen J:274939
decreased T cell number J:274939
impaired humoral immune response J:274939
increased B-1b cell number J:274939
increased effector memory CD4-positive, alpha-beta T cell number J:274939
\Jak3tm1Flv/\Jak3tm1Flv
(involves: 129S1/Sv)
abnormal T cell proliferation J:95794
arrested B cell differentiation J:95794
decreased CD8-positive, alpha-beta T cell number J:95794
enlarged spleen J:95794
increased CD4-positive, alpha-beta T cell number J:95794
small lymph nodes J:95794
thymus hypoplasia J:95794
\Jak3tm1Jni/\Jak3tm1Jni
\Crlf2tm1Jni/\Crlf2tm1Jni

(involves: 129P2/OlaHsd * C57BL/6)
abnormal B cell differentiation J:89031
decreased B cell number J:89031
\Jak3tm1Ljb/\Jak3+
(involves: 129S4/SvJae)
abnormal leukocyte morphology J:56629
decreased lymphocyte cell number J:56629
increased leukocyte cell number J:56629
increased monocyte cell number J:56629
increased neutrophil cell number J:56629
\Jak3tm1Ljb/\Jak3tm1Ljb
(involves: 129S4/SvJae * C57BL/6)
abnormal B cell morphology J:29722
abnormal immune system physiology J:29722
abnormal leukocyte physiology J:90510
abnormal lymphocyte physiology J:90510
abnormal response to infection J:29722
abnormal splenic cell ratio J:29722
abnormal T cell activation J:29722
arrested B cell differentiation J:29722
decreased IgG level J:29722
decreased immature B cell number J:29722
decreased mature B cell number J:29722
decreased T cell proliferation J:29722
lymph node hypoplasia J:29722
small lymph nodes J:29722
small Peyer's patches J:29722
small thymus J:29722
spleen hypoplasia J:29722
thymus hypoplasia J:29722
\Jak3tm1Ljb/\Jak3tm1Ljb
(involves: 129S4/SvJae)
abnormal leukocyte morphology J:56629
abnormal myelopoiesis J:56629
abnormal spleen morphology J:56629
abnormal spleen white pulp morphology J:56629
abnormal T cell activation J:128694, J:56629
abnormal T cell differentiation J:64861
abnormal T cell physiology J:128694
abnormal thymus cell ratio J:128694
absent B cells J:128694
absent lymph nodes J:128694
chronic inflammation J:56629
decreased lymphocyte cell number J:56629
decreased T cell proliferation J:128694
decreased thymocyte number J:64861
enlarged spleen J:56629
increased leukocyte cell number J:56629
increased monocyte cell number J:56629
increased neutrophil cell number J:56629
thymus hypoplasia J:128694
\Jak3tm1Ljb/\Jak3tm1Ljb
(B6;129S4-Jak3tm1Ljb/J)
abnormal dendritic cell differentiation J:123902
abnormal dendritic cell morphology J:123902
abnormal dendritic cell physiology J:123902
abnormal splenic cell ratio J:123902
decreased CD4-positive, alpha-beta T cell number J:123902
decreased CD8-positive, alpha-beta T cell number J:123902
decreased myeloid dendritic cell number J:123902
\Jak3tm1Ljb/\Jak3tm1Ljb
\Rag1tm1Mom/\Rag1tm1Mom

(involves: 129S4/SvJae * 129S7/SvEvBrd)
abnormal splenic cell ratio J:56629
immune system phenotype J:56629
\Jak3tm1Ljb/\Jak3tm1Ljb
\Tg(Lck-Jak3)1Ljb/0

(involves: 129S4/SvJae * C3H * C57BL/6 * C57BL/10)
absent B cells J:128694
absent lymph nodes J:128694
decreased T cell proliferation J:128694
immune system phenotype J:128694
\Jak3tm1Ljb/\Jak3tm1Ljb
\Tg(Lck-Jak3)2Ljb/0

(involves: 129S4/SvJae * C3H * C57BL/6)
abnormal T cell activation J:56629
enlarged spleen J:56629
immune system phenotype J:56629
increased leukocyte cell number J:56629
\Jak3tm1Ljb/\Jak3tm1Ljb
\Tg(Lck-Jak3)2Ljb/0

(involves: 129S4/SvJae * C3H * C57BL/6 * C57BL/10)
abnormal T cell activation J:128694
abnormal T cell physiology J:128694
absent B cells J:128694
absent lymph nodes J:128694
decreased T cell proliferation J:128694
immune system phenotype J:128694
\Jak3tm1Tks/\Jak3+
(involves: 129P2/OlaHsd * C57BL/6)
abnormal leukocyte physiology J:31231
\Jak3tm1Tks/\Jak3tm1Tks
(involves: 129P2/OlaHsd * C57BL/6)
abnormal B cell differentiation J:31231
abnormal CD4-positive, alpha beta T cell morphology J:31231
abnormal lymphopoiesis J:31231
abnormal mesenteric lymph node morphology J:31231
abnormal spleen periarteriolar lymphoid sheath morphology J:31231
abnormal spleen white pulp morphology J:31231
abnormal T cell morphology J:31231
abnormal T cell number J:31231
abnormal T cell physiology J:31231
abnormal thymus cortex morphology J:31231
abnormal thymus corticomedullary boundary morphology J:31231
abnormal thymus medulla morphology J:31231
absent Hassall's corpuscle J:31231
absent lymph nodes J:31231
absent NK cells J:31231
decreased B cell number J:31231
decreased pre-B cell number J:31231
decreased thymocyte number J:31231
small spleen J:31231
small thymus medulla J:31231
spleen hypoplasia J:31231
thymus cortex hypoplasia J:31231
thymus hypoplasia J:31231
\Jak3wil/\Jak3wil
(C57BL/6JSfdAnu-Jak3wil/Anu)
arrested B cell differentiation J:104190
decreased CD8-positive, alpha-beta T cell number J:104190
decreased leukocyte cell number J:104190
large intestinal inflammation J:104190
\Jak3X887Y/\Jak3X887Y
(Not Specified)
abnormal immune system organ morphology J:112658
abnormal lymph node morphology J:112658
abnormal lymphocyte morphology J:112658
abnormal spleen morphology J:112658
abnormal thymus morphology J:112658
\Jak3X887Y/\Jak3X887Y
\Trdctm1Mal/\Trdctm1Mal

(involves: C57BL/6)
immune system phenotype J:112658
\Jakmip2em1(IMPC)J/\Jakmip2em1(IMPC)J
(C57BL/6NJ-Jakmip2em1(IMPC)J/Mmjax)
increased leukocyte cell number J:211773
\Jam3tm1Lex/\Jam3tm1Lex
(involves: 129S5/SvEvBrd * C57BL/6)
decreased neutrophil cell number J:145994
increased granulocyte number J:145994
\Jam3tm1Rha/\Jam3tm1Rha
(involves: 129P2/OlaHsd * C57BL/6)
increased granulocyte number J:121841
increased susceptibility to bacterial infection J:121841
lung inflammation J:121841
\Jam3tm1Rha/\Jam3tm1Rha
\Tg(Tek-Jam3)1Maal/?

(involves: 129P2/OlaHsd * C57BL/6 * C57BL/6J * CBA)
immune system phenotype J:121841
\Jarid2jumonji/\Jarid2jumonji
(C.129P2-Jarid2jumonji)
abnormal splenic cell ratio J:42772
abnormal thymus cell ratio J:42772
spleen hypoplasia J:42772
thymus hypoplasia J:42772
\Jarid2jumonji/\Jarid2jumonji
(either: B6.129P2-Jarid2jumonji or D2.129P2-Jarid2jumonji)
spleen hypoplasia J:42772
thymus hypoplasia J:42772
\JchainMat1/?
\MijuC3HeB/FeJ/\MijuC57BL/6J

(involves: C3HeB/FeJ * C57BL/6J)
increased IgA level J:91062
\Jchaintm1Jse/\Jchaintm1Jse
(involves: 129X1/SvJ)
abnormal B cell physiology J:75843
increased IgA level J:34042, J:75843
\Jchaintm1Jse/\Jchaintm1Jse
(C.129X1-Jchaintm1Jse)
decreased susceptibility to Herpesvirales infection J:62298
decreased susceptibility to Herpesvirales infection induced morbidity/mortality J:62298
increased susceptibility to parasitic infection J:140515
\Jchaintm1Tl/\Jchaintm1Tl
(involves: 129P2/OlaHsd * BALB/cJ * C57BL/6)
abnormal humoral immune response J:71355
decreased IgG level J:71355
decreased IgM level J:71355
increased IgA level J:71355
\Jchaintm2(Myc)Tl/\Jchaintm2(Myc)Tl
(involves: 129P2/OlaHsd * BALB/cJ * C57BL/6)
abnormal humoral immune response J:71355
\Jchaintm3Tl/\Jchain+
(involves: 129P2/OlaHsd)
abnormal B cell physiology J:56158
abnormal immune cell physiology J:49168
decreased IgM level J:49168, J:56158
decreased plasma cell number J:49168
impaired complement classical pathway J:49168
increased IgA level J:56158
increased susceptibility to bacterial infection J:56158
\Jchaintm3Tl/\Jchaintm3Tl
(involves: 129P2/OlaHsd)
abnormal B cell physiology J:56158
abnormal immune cell physiology J:49168
decreased IgG level J:49168
decreased IgM level J:49168, J:56158
decreased plasma cell number J:49168, J:56158
impaired complement classical pathway J:49168
increased IgA level J:49168, J:56158
increased susceptibility to bacterial infection J:56158
\Jdp2tm1Aki/\Jdp2tm1Aki
(Not Specified)
abnormal neutrophil physiology J:191061
abnormal osteoclast differentiation J:191061
abnormal osteoclast morphology J:191061
increased susceptibility to bacterial infection J:191061
increased susceptibility to fungal infection J:191061
\Jmjd4em1(IMPC)Wtsi/\Jmjd4em1(IMPC)Wtsi
(C57BL/6N-Jmjd4em1(IMPC)Wtsi/Wtsi)
increased leukocyte cell number J:211773
\Jmjd6tm1Gbf/\Jmjd6tm1Gbf
(C57BL/6-Ptdsrtm1Gbf)
abnormal macrophage activation involved in immune response J:98905
small thymus J:102098
thymus hypoplasia J:102098
\Jmjd8em1Kaso/\Jmjd8em1Kaso
(C57BL/6-Jmjd8em1Kaso)
decreased circulating interleukin-1 beta level J:319518
decreased inflammatory response J:319518
\Jph4tm1Hta/\Jph4tm1Hta
(involves: 129S4/SvJae * C57BL/6J)
abnormal interleukin level J:230995
abnormal T cell activation J:230995
\Junem1(IMPC)Mbp/\Jun+
(C57BL/6N-Junem1(IMPC)Mbp/MbpMmucd)
abnormal lymph node morphology J:211773
enlarged lymph nodes J:211773
\Juntm1Rsjo/\Juntm1Rsjo
\Tg(KRT14-cre)8Brn/0

(involves: 129S1/Sv * 129X1/SvJ * FVB/N)
increased incidence of corneal inflammation J:84743
\Juntm4Wag/\Juntm4Wag
\Junbtm3Wag/\Junbtm3Wag
\Tg(Krt1-5-cre/ERT)1Ipc/0

(involves: 129P2/OlaHsd * C57BL/6 * SJL)
autoimmune arthritis J:116380
increased inflammatory response J:116380
skin inflammation J:116380
\Juntm4Wag/\Juntm4Wag
\Tg(Sftpc-cre)1Blh/0

(involves: 129P2/OlaHsd * C57BL/6 * DBA/2)
abnormal cytokine level J:179883
abnormal tumor necrosis factor level J:179883
lung inflammation J:179883
\Junbtm1b(EUCOMM)Hmgu/\Junb+
(C57BL/6N-Junbtm1b(EUCOMM)Hmgu/Bay)
increased spleen weight J:211773
\Junbtm3Wag/\Junbtm3Wag
\Lyz2tm1(cre)Ifo/\Lyz2+

(involves: 129P2/OlaHsd * C57BL/6)
abnormal osteoclast morphology J:88126
\Junbtm3Wag/\Junbtm3Wag
\Meox2tm1(cre)Sor/\Meox2+

(involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6)
abnormal osteoclast differentiation J:88126
decreased osteoclast cell number J:88126
\Junbtm3Wag/\Junbtm3Wag
\Tg(KRT5-cre)1Tak/0

(involves: 129/Sv * 129P2/OlaHsd * C3H * C57BL/6)
dermatitis J:155575
glomerulonephritis J:155575
increased anti-histone antibody level J:155575
increased circulating interleukin-6 level J:155575
increased IgE level J:155575
increased inflammatory response J:155575
increased interleukin-6 secretion J:155575
increased plasma cell number J:155575
increased susceptibility to systemic lupus erythematosus J:155575
tubulointerstitial nephritis J:155575
\Jundtm1Mya/\Jundtm1Mya
(either: 129S2/SvPas or (involves: 129S2/SvPas * C57BL/6))
abnormal T-helper 2 physiology J:89085
immune system phenotype J:53906
increased susceptibility to endotoxin shock J:65879
increased T cell proliferation J:89085
liver inflammation J:65879
\Juptm1.1Glr/\Juptm1.1Glr
\A1cfTg(Myh6-cre/Esr1*)1Jmk/\A1cf+

(involves: 129S6/SvEvTac * C57BL/6 * FVB/N * SJL)
abnormal interleukin level J:170618
heart inflammation J:170618
\Kash5em1(IMPC)J/\Kash5em1(IMPC)J
(C57BL/6NJ-Kash5em1(IMPC)J/Mmjax)
increased leukocyte cell number J:211773
\Kat5tm1Jwl/\Kat5+
\Tg(IghMyc)22Bri/0

(involves: 129S1/Sv * 129X1/SvJ * C57BL * C57BL/6 * SJL)
abnormal B cell physiology J:125164
\Kat6atm1.1Glac/\Kat6atm1.1Glac
(involves: 129P2/OlaHsd * C57BL/6)
abnormal B cell differentiation J:148955
decreased immature B cell number J:148955
decreased pre-B cell number J:148955
decreased pro-B cell number J:148955
decreased spleen weight J:148955
decreased thymus weight J:148955
spleen hypoplasia J:148955
thymus hypoplasia J:148955
\Kat6atm1Avo/\Kat6a+
(involves: 129 * BALB/c * FVB/N)
small thymus J:188772
\Kat6atm1Avo/\Kat6atm1Avo
(involves: 129/Sv * BALB/c * FVB/N)
abnormal thymus development J:108453
absent spleen J:108453
athymia J:188772
decreased double-negative T cell number J:108453
small thymus J:108453, J:188772
thymus hypoplasia J:108453
\Kat6atm1Iki/\Kat6atm1Iki
(Not Specified)
abnormal myelopoiesis J:108699
decreased B cell number J:108699
\Kat6atm2.2Avo/\Kat6a+
\Tbx1tm1Bld/\Tbx1+

(involves: 129S7/SvEvBrd * C57BL/6)
small thymus J:188772
\Kat8em1(IMPC)Mbp/\Kat8+
(C57BL/6N-Kat8em1(IMPC)Mbp/MbpMmucd)
abnormal lymph node morphology J:211773
enlarged lymph nodes J:211773
\Kat14tm1a(KOMP)Wtsi/\Kat14tm1a(KOMP)Wtsi
(involves: C57BL/6 * C57BL/6N)
decreased susceptibility to bacterial infection J:213427
\Katnal1em1(IMPC)Tcp/\Katnal1+
(C57BL/6NCrl-Katnal1em1(IMPC)Tcp/Tcp)
enlarged lymph nodes J:211773
\Katnal1em1(IMPC)Tcp/\Katnal1em1(IMPC)Tcp
(C57BL/6NCrl-Katnal1em1(IMPC)Tcp/Tcp)
abnormal spleen morphology J:211773
\Katnal2em1(IMPC)Tcp/\Katnal2em1(IMPC)Tcp
(C57BL/6N-Katnal2em1(IMPC)Tcp/Tcp)
enlarged lymph nodes J:211773
enlarged spleen J:211773
increased monocyte cell number J:211773
small spleen J:211773
\Kbtbd3em1(IMPC)Ccpcz/\Kbtbd3em1(IMPC)Ccpcz
(C57BL/6NCrl-Kbtbd3em1(IMPC)Ccpcz/Ccpcz)
abnormal thymus morphology J:211773
enlarged thymus J:211773
increased neutrophil cell number J:211773
\Kbtbd11em1(IMPC)Wtsi/\Kbtbd11em1(IMPC)Wtsi
(C57BL/6N-Kbtbd11em1(IMPC)Wtsi/Wtsi)
abnormal spleen morphology J:211773
enlarged spleen J:211773
\Kcna1mceph/\Kcna1mceph
(BALB/cByJ-Kcna1mceph/J)
ear inflammation J:119491
eye inflammation J:119491
\Kcna1tm1Tem/\Kcna1tm1Tem
(involves: 129S7/SvEvBrd * BALB/cByJ * C3HeB/FeJ)
ear inflammation J:119491
eye inflammation J:119491
\Kcna5tm1Hket/\Kcna5tm1Hket
(involves: 129S6/SvEvTac * 129S7/SvEvBrd)
abnormal microglial cell morphology J:116545
\Kcna10em3(IMPC)Mbp/\Kcna10+
(C57BL/6N-Kcna10em3(IMPC)Mbp/Ucd)
abnormal spleen morphology J:211773
enlarged spleen J:211773
\Kcnab2em1(IMPC)Mbp/\Kcnab2em1(IMPC)Mbp
(C57BL/6NCrl-Kcnab2em1(IMPC)Mbp/MbpMmucd)
abnormal lymph node morphology J:211773
enlarged lymph nodes J:211773
\Kcne1tm1b(EUCOMM)Hmgu/\Kcne1tm1b(EUCOMM)Hmgu
(C57BL/6N-Kcne1tm1b(EUCOMM)Hmgu/Ics)
decreased lymphocyte cell number J:211773
increased monocyte cell number J:211773
increased neutrophil cell number J:211773
\Kcne2tm1a(EUCOMM)Wtsi/\Kcne2tm1a(EUCOMM)Wtsi
(C57BL/6N-Kcne2tm1a(EUCOMM)Wtsi)
decreased spleen iron level J:230226
stomach inflammation J:230226
\Kcne3tm1Gwab/\Kcne3tm1Gwab
(involves: C57BL/6)
increased inflammatory response J:210381
\Kcnh8em1(IMPC)Mbp/\Kcnh8em1(IMPC)Mbp
(C57BL/6N-Kcnh8em1(IMPC)Mbp/Ucd)
abnormal spleen morphology J:211773
enlarged lymph nodes J:211773
enlarged spleen J:211773
\Kcnip1em1(IMPC)H/\Kcnip1em1(IMPC)H
(C57BL/6N-Kcnip1em1(IMPC)H/H)
increased eosinophil cell number J:211773
\Kcnj8gnite/\Kcnj8gnite
(involves: C57BL/6J)
increased susceptibility to Herpesvirales infection induced morbidity/mortality J:126658, J:105543
\Kcnj8mydy/\Kcnj8mydy
(involves: C57BL/6J)
increased susceptibility to endotoxin shock J:126658
increased susceptibility to Herpesvirales infection J:126658
\Kcnj8slmbr/\Kcnj8slmbr
(involves: C57BL/6J)
increased susceptibility to Herpesvirales infection induced morbidity/mortality J:126658, J:105543
\Kcnj8sltr/\Kcnj8sltr
(involves: C57BL/6J)
increased susceptibility to Herpesvirales infection induced morbidity/mortality J:126658, J:105543
increased susceptibility to Riboviria infection J:105543
\Kcnj8sos/\Kcnj8sos
(C57BL/6J-Kcnj8sos)
increased susceptibility to endotoxin shock J:149353
\Kcnj9tm1b(EUCOMM)Hmgu/\Kcnj9tm1b(EUCOMM)Hmgu
(C57BL/6N-Kcnj9tm1b(EUCOMM)Hmgu/H)
increased basophil cell number J:211773
increased neutrophil cell number J:211773
\Kcnj10tm1b(KOMP)Wtsi/\Kcnj10+
(C57BL/6N-Kcnj10tm1b(KOMP)Wtsi/H)
decreased basophil cell number J:211773
\Kcnk13em1(IMPC)H/\Kcnk13em1(IMPC)H
(involves: C57BL/6NTac)
abnormal microglial cell morphology J:256020
abnormal microglial cell physiology J:256020
\Kcnk13em1(IMPC)H/\Kcnk13em1(IMPC)H
(C57BL/6N-Kcnk13em1(IMPC)H/H)
increased basophil cell number J:211773
increased monocyte cell number J:211773
\Kcnmb4em1(IMPC)Mbp/\Kcnmb4em1(IMPC)Mbp
(C57BL/6N-Kcnmb4em1(IMPC)Mbp/MbpMmucd)
abnormal lymph node morphology J:211773
enlarged lymph nodes J:211773
\Kcnn4em1(IMPC)Ccpcz/\Kcnn4em1(IMPC)Ccpcz
(C57BL/6NCrl-Kcnn4em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged spleen J:211773
enlarged thymus J:211773
increased spleen weight J:211773
small thymus J:211773
\Kcnn4tm1Jemn/\Kcnn4tm1Jemn
(involves: 129S1/Sv * C57BL/6J)
abnormal T cell physiology J:94478
\Kcnn4tm1Rklr/\Kcnn4tm1Rklr
(involves: 129S/SvEv * C57BL/6)
enlarged spleen J:148910
increased spleen iron level J:148910
increased spleen weight J:148910
\Kcnt1em1(IMPC)Mbp/\Kcnt1em1(IMPC)Mbp
(C57BL/6N-Kcnt1em1(IMPC)Mbp/MbpMmucd)
abnormal spleen morphology J:211773
small spleen J:211773
\Kcnt2em1(IMPC)Mbp/\Kcnt2em1(IMPC)Mbp
(C57BL/6N-Kcnt2em1(IMPC)Mbp/MbpMmucd)
small spleen J:211773
\Kctd1em1(IMPC)J/\Kctd1em1(IMPC)J
(C57BL/6NJ-Kctd1em1(IMPC)J/Mmjax)
increased leukocyte cell number J:211773
\Kctd9em1Beij/\Kctd9em1Beij
(BALB/c-Kctd9em1Beij)
abnormal immature NK cell morphology J:281803
abnormal NK cell differentiation J:281803
abnormal NK cell physiology J:281803
decreased mature NK cell number J:281803
decreased susceptibility to Coronaviridae infection J:281803
decreased susceptibility to Coronaviridae infection induced morbidity/mortality J:281803
impaired natural killer cell mediated cytotoxicity J:281803
increased immature NK cell number J:281803
increased NK cell number J:281803
\Kdelr1em1Btlr/\Kdelr1em1Btlr
(involves: C57BL/6J * C57BL/6JJcl)
decreased lymphocyte cell number J:224970
\Kdelr1em1Btlr/\Kdelr1em1Btlr
\Tg(Gt(ROSA)26Sor-Kdelr1)#Btlr/0

(C57BL/6J-Kdelr1em1Btlr Tg(Gt(ROSA)26Sor-Kdelr1)#Btlr)
abnormal lymphocyte morphology J:224970
\Kdelr1m1Btlr/\Kdelr1m1Btlr
(C57BL/6J-Kdelr1m1Btlr)
abnormal lymphocyte morphology J:224970
abnormal response to infection J:224970
abnormal T cell differentiation J:224970
absent NK T cells J:224970
decreased B cell number J:224970
decreased CD4-positive, alpha-beta T cell number J:224970, J:158794
decreased CD8-positive, alpha-beta T cell number J:224970, J:158794
decreased follicular B cell number J:224970
decreased lymphocyte cell number J:224970
decreased transitional stage T1 B cell number J:224970
decreased transitional stage T2 B cell number J:224970
immune system phenotype J:224970
increased marginal zone B cell number J:224970
increased susceptibility to Riboviria infection J:224970
thymus hypoplasia J:158794
\Kdm1atm1(NCOM)Mfgc/\Kdm1a+
(C57BL/6N-Kdm1atm1(NCOM)Mfgc/Nju)
increased basophil cell number J:211773
increased eosinophil cell number J:211773
small spleen J:211773
\Kdm1atm1.1Sho/\Kdm1atm1.1Sho
\Commd10Tg(Vav1-icre)A2Kio/\Commd10+

(involves: 129 * C57BL/6 * C57BL/10 * CBA/Ca)
decreased leukocyte cell number J:201572
\Kdm1atm1.1Sho/\Kdm1atm1.1Sho
\Tg(Mx1-cre)1Cgn/?

(involves: 129 * C57BL/6 * CBA/Ca)
decreased granulocyte number J:201572
decreased neutrophil cell number J:201572
\Kdm3aem1(IMPC)Mbp/\Kdm3aem1(IMPC)Mbp
(C57BL/6N-Kdm3aem1(IMPC)Mbp/MbpMmucd)
enlarged spleen J:211773
small spleen J:211773
\Kdm4ctm1a(KOMP)Wtsi/\Kdm4c+
(C57BL/6N-Kdm4ctm1a(KOMP)Wtsi/Wtsi)
increased B cell number J:165965
\Kdm5atm1.1Kael/\Kdm5atm1.1Kael
(involves: 129S6/SvEvTac * C57BL/6 * FVB/N * SJL)
increased neutrophil cell number J:137185
\Kdm6atm1.1Afst/\Kdm6atm1.1Afst
\Gt(ROSA)26Sortm9(cre/ESR1)Arte/\Gt(ROSA)26Sor+

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * C57BL/6NTac)
abnormal granulocyte morphology J:196401
decreased leukocyte cell number J:196401
enlarged spleen J:196401
increased B cell number J:196401
increased spleen weight J:196401
\Kdm6atm1Cdcn/Y
\Tg(CAG-cre/Esr1*)5Amc/0

(involves: C57BL/6J * CBA)
enlarged spleen J:263565
increased granulocyte number J:263565
increased monocyte cell number J:263565
increased neutrophil cell number J:263565
\Kdm6atm1Cdcn/Y
\Tg(CAG-cre/Esr1*)5Amc/0
\Trp53tm1Tyj/\Trp53tm1Tyj

(involves: 129S2/SvPas * C57BL/6J * CBA * FVB/N)
enlarged spleen J:263565
increased monocyte cell number J:263565
increased neutrophil cell number J:263565
\Kdm6atm1Cdcn/\Kdm6atm1Cdcn
\Tg(CAG-cre/Esr1*)5Amc/0

(involves: C57BL/6J * CBA)
enlarged spleen J:263565
increased granulocyte number J:263565
increased monocyte cell number J:263565
increased neutrophil cell number J:263565
\Kdm6btm1Aki/\Kdm6btm1Aki
(involves: 129X1/SvJ * C57BL/6)
abnormal response to infection J:164690
impaired eosinophil recruitment J:164690
\Kdm8tm1a(EUCOMM)Wtsi/\Kdm8+
(C57BL/6N-Kdm8tm1a(EUCOMM)Wtsi/Ics)
increased B cell number J:165965
\Kdrtm1.1Jamb/\Kdrtm1.1Jamb
(involves: 129S1/Sv * 129X1/SvJ * ICR)
abnormal lymphangiogenesis J:154336
lymphatic vessel hyperplasia J:154336
\Kdrtm1.1Jamb/\Kdrtm1.1Jamb
\Tg(KRT14-cre)1Efu/0

(involves: 129S1/Sv * 129X1/SvJ * ICR)
lymphatic vessel hyperplasia J:154336
\Kdrtm1.1Jamb/\Kdrtm1.1Jamb
\Tg(Pax6-cre,GFP)1Pgr/0

(involves: 129S1/Sv * 129X1/SvJ * FVB/N * ICR)
abnormal lymphatic vessel morphology J:154336
lymphatic vessel hyperplasia J:154336
\Kdrtm1Jrt/\Kdr+
\Tmem204tm1.1Ali/\Tmem204tm1.1Ali

(involves: 129S1/Sv * 129X1/SvJ * BALB/c * C57BL/6)
abnormal lymphatic vessel smooth muscle morphology J:159519
enlarged lymphatic vessel J:159519
\Kdrtm1Ykub/\Kdrtm1Ykub
(Not Specified)
enlarged lymphatic vessel J:217533
lymphatic vessel hyperplasia J:217533
\Keratm1Cyl/\Keratm1Cyl
(involves: 129S6/SvEvTac)
abnormal inflammatory response J:128992
decreased neutrophil cell number J:128992
\Khdrbs1tm1Rchd/\Khdrbs1tm1Rchd
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
abnormal bone marrow development J:115775
\Khsrptm1.1Cyc/\Khsrptm1.1Cyc
(B6.Cg-Khsrptm1.1Cyc)
decreased susceptibility to Herpesvirales infection J:175084
decreased susceptibility to Herpesvirales infection induced morbidity/mortality J:175084
increased interferon-beta secretion J:175084
\Kif1cLtxs1-DBA/2NCr/\Kif1cLtxs1-DBA/2NCr
(involves: BALB/cAnPt * DBA/2NCr)
decreased susceptibility to infection J:103336
\Kif1cLtxs1-DBA/2NCr/\Kif1cLtxs1-DBA/2NCr
\Ltxs2DBA/2NCr/\Ltxs2DBA/2NCr
\Ltxs3DBA/2NCr/\Ltxs3DBA/2NCr

(involves: BALB/cAnPt * DBA/2NCr)
decreased susceptibility to infection J:103336
\Kif1cLtxs1/\Kif1c+
(involves: C3H/HeJ * C57BL/6J)
increased susceptibility to bacterial infection J:49726
\Kif1cLtxs1/\Kif1cLtxs1
(involves: C3H/HeJ * C57BL/6J)
increased susceptibility to bacterial infection J:49726
\Kif1cOrch3-BALB/cByJ/\Kif1cOrch3-BALB/cByJ
(involves: BALB/cByJ * DBA/2)
testis inflammation J:35331
\Kif1cOrch3-BALB/cByJ/\Kif1cOrch3-DBA/2J
(involves: BALB/cByJ * DBA/2)
decreased inflammatory response J:35331
\Kif1cOrch3-DBA/2J/\Kif1cOrch3-DBA/2J
(involves: BALB/cByJ * DBA/2)
decreased inflammatory response J:35331
\Kif5ctm1dIcs/\Kif5c+
(C57BL/6N-Kif5ctm1dIcs/Ics)
decreased lymphocyte cell number J:211773
increased eosinophil cell number J:211773
\Kif9em1(IMPC)Mbp/\Kif9em1(IMPC)Mbp
(C57BL/6N-Kif9em1(IMPC)Mbp/MbpMmucd)
small spleen J:211773
\Kif13btm1b(EUCOMM)Wtsi/\Kif13btm1b(EUCOMM)Wtsi
(C57BL/6N-Kif13btm1b(EUCOMM)Wtsi/Wtsi)
decreased leukocyte cell number J:211773
\Kif15em1Lium/\Kif15em1Lium
(C57BL/6-Kif15em1Lium)
decreased spleen white pulp amount J:336767
increased CD8-positive, alpha-beta T cell number J:336767
increased spleen red pulp amount J:336767
increased spleen weight J:336767
intermingled spleen red and white pulp J:336767
\Kif16bem1(IMPC)Ccpcz/\Kif16bem1(IMPC)Ccpcz
(C57BL/6NCrl-Kif16bem1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged spleen J:211773
enlarged thymus J:211773
\Kif27Gt(OST441915)Lex/\Kif27Gt(OST441915)Lex
(involves: 129S5/SvEvBrd * C57BL/6J)
increased susceptibility to otitis media J:185566
maxillary sinus inflammation J:185566
\Kifbptm1a(KOMP)Wtsi/\Kifbptm1a(KOMP)Wtsi
(C57BL/6N-Kifbptm1a(KOMP)Wtsi/Wtsi)
blood in lymph vessels J:239583
\Kiss1rtm1.1(KOMP)Vlcg/\Kiss1rtm1.1(KOMP)Vlcg
(C57BL/6N-Kiss1rtm1.1(KOMP)Vlcg/Ucd)
increased spleen weight J:211773
increased thymus weight J:211773
\Kiss1rtm1.1Lex/\Kiss1r+
(involves: 129S4/SvJae)
decreased eosinophil cell number J:181650
decreased lymphocyte cell number J:181650
\Kiss1rtm1.1Lex/\Kiss1rtm1.1Lex
(involves: 129S4/SvJae)
decreased basophil cell number J:181650
decreased lymphocyte cell number J:181650
decreased monocyte cell number J:181650
decreased neutrophil cell number J:181650
increased spleen weight J:181650
increased thymus weight J:181650
\Kiss1rtm1Gstn/\Kiss1rtm1Gstn
(involves: 129P2/OlaHsd)
increased thymus weight J:102113
\Kittm1.1Bsm/\Kittm1.1Bsm
(involves: 129S1/Sv * BALB/c * C57BL/6J * FVB/N)
abnormal mast cell physiology J:61141
decreased mast cell number J:61141
\Kittm1.1Bsm/\Kittm1.1Bsm
(B6.129S1-Kittm1.1Bsm)
immune system phenotype J:90485
\Kittm1Ber/\Kittm1Ber
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
decreased mast cell number J:89602
immune system phenotype J:89602
\Kittm1Bpr/\Kittm1Bpr
(either: (involves: 129/Sv) or (involves: 129/Sv * C57BL/6))
decreased mast cell number J:100778
\Kittm1Bsm/\Kittm1Bsm
(involves: 129S1/Sv * C57BL/6J)
decreased mast cell number J:61141
\Kittm2Ber/\Kittm2Ber
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
decreased mast cell number J:89602
immune system phenotype J:89602
\Kittm2Bsm/\Kit+
(involves: 129X1/SvJ * C57BL/6J)
increased mast cell degranulation J:83616
increased mast cell number J:83616
\Kittm3.1Bsm/\Kittm3.1Bsm
(involves: 129S1/Sv * C57BL/6)
abnormal B cell differentiation J:90485
abnormal mast cell physiology J:90485
abnormal T cell differentiation J:90485
decreased B cell number J:90485
decreased mast cell number J:90485
immune system phenotype J:90485
\Kittm3.1Bsm/\Kittm3.1Bsm
(B6.129S1-Kittm3.1Bsm)
spleen hypoplasia J:146561
\Kittm3Ber/\Kittm3Ber
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
arrested B cell differentiation J:89602
decreased mast cell number J:89602
enlarged spleen J:89602
increased B cell number J:89602
spleen hyperplasia J:89602
\Kittm4.1Bsm/\Kit+
(involves: 129S1/Sv * C57BL/6J * FVB/N)
enlarged spleen J:188434
increased mast cell number J:188434
spleen hyperplasia J:188434
\KitW-37J/\Kit+
(involves: C57BL/6 * C57BL/6J)
decreased mast cell number J:27513
\KitW-37J/\KitW
(involves: C57BL/6 * C57BL/6J * WB)
abnormal mast cell physiology J:27513
decreased mast cell number J:27513
\KitW-42J/\Kit+
(involves: C57BL/6 * C57BL/6J * WB)
decreased mast cell number J:27513
\KitW-42J/\KitW
(involves: C57BL/6 * C57BL/6J * WB)
abnormal mast cell physiology J:27513
decreased mast cell number J:27513
\KitW-Btlr/\KitW-Btlr
(C57BL/6J-KitW-Btlr)
decreased mast cell number J:133270
\KitW-f/\KitW-f
(involves: C3H/HePas)
decreased mast cell number J:27513
\KitW-Jic/\Kit+
(involves: C57BL/6)
decreased mast cell number J:27513
\KitW-Jic/\KitW
(involves: C57BL/6 * WB)
abnormal mast cell physiology J:27513
decreased mast cell number J:27513
\KitW-n/\KitW-n
(Not Specified)
decreased mast cell number J:12107
\KitW-n/\KitW
(involves: WB)
abnormal mast cell physiology J:27513
decreased mast cell number J:27513
\KitW-sh/\KitW-sh
(involves: 101/H * C3H/HeH)
decreased mast cell degranulation J:157470
decreased mast cell number J:145444
increased susceptibility to parasitic infection J:163761
\KitW-sh/\KitW-sh
(involves: C57BL/6J)
decreased susceptibility to type I hypersensitivity reaction J:197334
\KitW-sh/\KitW-sh
(B6.Cg-KitW-sh/HNihrJaeBsmGlliJ)
decreased susceptibility to type I hypersensitivity reaction J:275367
\KitW-sh/\KitW-sh
\Lyntm1Ard/\Lyntm1Ard

(involves: 101 * 129P2/OlaHsd * C3H/HeH)
abnormal circulating complement protein level J:161523
decreased B cell number J:161523
glomerulonephritis J:161523
increased anti-double stranded DNA antibody level J:161523
increased anti-nuclear antigen antibody level J:161523
increased basophil cell number J:161523
increased IgA level J:161523
increased IgE level J:161523
increased IgG2b level J:161523
increased IgM level J:161523
\KitW-v/\Kit+
(involves: C57BL * C57BL/6)
decreased mast cell number J:27513
\KitW-vkd/\KitW-vkd
(involves: 129P2/OlaHsd * BALB/c * C57BL/6 * WB)
abnormal B cell differentiation J:79128
abnormal T cell differentiation J:79128
decreased B cell number J:79128
decreased thymocyte number J:79128
\KitW/\Kit+
\Tg(PGK1-KITLG*220)441Daw/0

(involves: C3H/HeJ)
decreased mast cell number J:32600
\KitW/\KitW-v
(involves: C57BL/6 * WB)
abnormal response to transplant J:6084
\KitW/\KitW-v
((WB/ReJ x C57BL/6J-KitW-v/J)F1-KitW/KitW-v/J)
abnormal interferon level J:131785
abnormal interleukin level J:131785
decreased inflammatory response J:131785
immune system phenotype J:125656
impaired neutrophil recruitment J:123463
kidney inflammation J:113500
\KitW/\KitW-v
(involves: C57BL/6)
decreased basophil cell number J:178942
decreased mast cell number J:178942
immune system phenotype J:178942
\KitW/\KitW-v
((WB KitW x B6.Cg-KitW-v)F1)
decreased susceptibility to induced arthritis J:178942
decreased susceptibility to type I hypersensitivity reaction J:197334
\KitW/\KitW
\Tg(PDGFB-EPO)321Zbz/?

(involves: C3H * C57BL/6)
abnormal B cell differentiation J:79128
abnormal T cell differentiation J:79128
decreased B cell number J:79128
decreased thymocyte number J:79128
\KitWads/\KitWads
(C57BL/6J-KitWads)
decreased mast cell number J:96391
\KitlSl-con/\KitlSl-con
(either: (involves: C3H/HeJ) or (involves: C3H/HeN))
increased mast cell number J:23593
\KitlSl-d/\Kitl+
(either: (involves: C57BL/6 * DBA/2J) or (involves: C3H * C57BL/6 * DBA/2J * WC))
decreased mast cell number J:6084
\KitlSl/\Kitl+
(either: (involves: C3H * WC) or (involves: C3H * C57BL/6 * DBA/2J * WC))
decreased mast cell number J:6084
\KitlSl/\Kitl+
\Tg(PGK1-KITLG*220)441Daw/0

(involves: C3H)
decreased mast cell number J:32600
\KitlSl/\KitlSl-d
(involves: C57BL/6 * WC)
dermatitis J:5758
stomach inflammation J:2777
thymus atrophy J:5758
\KitlSl/\KitlSl-d
(involves: C3H * C57BL/6 * DBA/2J * WC)
abnormal response to transplant J:6084
decreased mast cell number J:6084
\KitlSl/\KitlSl-d
((WC/ReJ KitlSl x B6.D2-KitlSl-d/J)F1-KitlSl/KitlSl-d/J)
abnormal osteoclast morphology J:111273
\Kitltm1.1Sjm/\Kitltm2.1Sjm
\Leprtm2(cre)Rck/\Lepr+

(involves: 129S6/SvEvTac * C57BL/6 * C57BL/Ka * SJL)
enlarged spleen J:180431
spleen hyperplasia J:180431
\Kitltm1.1Sjm/\Kitltm2.1Sjm
\Leprtm2(cre)Rck/\Lepr+
\Tg(Tek-cre)12Flv/0

(involves: 129S6/SvEvTac * C3H * C57BL/6 * C57BL/Ka * SJL)
spleen hyperplasia J:180431
\Kitltm1Pbes/\Kitltm1Pbes
(involves: 129S1/Sv * C57BL/6J)
decreased mast cell number J:50150
\Kitltm2.1Pbes/\Kitltm2.1Pbes
(involves: 129S1/Sv * C57BL/6J * FVB/N)
increased mast cell number J:157170
\Kitltm3.1Pbes/\Kitltm3.1Pbes
(involves: 129S1/Sv * C57BL/6J * FVB/N)
decreased double-negative T cell number J:157170
decreased double-positive T cell number J:157170
decreased mast cell number J:157170
decreased T cell number J:157170
decreased thymocyte number J:157170
\Klecalc1/\Klecalc1
(involves: C3H/HeH * C57BL/6J)
lung inflammation J:229255
\Klkl/\Klkl
(either: C.Cg-Klkl or (involves: C3H/HeJ * C57BL/6J))
abnormal leukocyte cell number J:44109
decreased osteoclast cell number J:44109
thymus atrophy J:44109
\Klkl/\Klkl
(involves: C3H/HeJ * C57BL/6J)
decreased B cell number J:80503
decreased osteoclast cell number J:80503
\Klkl/\Klkl
(involves: C3H/J * C57BL/6J)
abnormal osteoclast morphology J:56666
\Klkl/\Klkl
\Tnfrsf11btm1Khs/\Tnfrsf11b+

(involves: 129P2/OlaHsd * C3H * C57BL/6)
decreased B cell number J:80503
\Klm1Anu/\Klm1Anu
(C57BL/6NCrlAnu-Klm1Anu)
abnormal spleen morphology J:104190
small spleen J:104190
\Klf1Nan/\Klf1+
(either: B6.Cg-Klf1Nan or WB.Cg-Klf1Nan)
increased spleen weight J:162530
\Klf1Nan/\Klf1+
(involves: 101/H * C3H/HeH * PT)
enlarged spleen J:13933
increased spleen iron level J:13933
\Klf2tm1Ling/\Klf2tm1Ling
(involves: 129P2/OlaHsd * C57BL/6J)
immune system phenotype J:51402
\Klf2tm1Mlkn/\Klf2tm1Mlkn
\Tg(VAV1-cre)1Graf/0

(Not Specified)
absent T cells J:127228
\Klf2tm2Ling/\Klf2tm2Ling
\Lyz2tm1(cre)Ifo/0

(involves: 129P2/OlaHsd * 129S6/SvEvTac)
decreased Ly6C low monocyte number J:239509
\Klf2tm2Ling/\Klf2tm2Ling
\Tg(Cd4-cre)1Cwi/?

(involves: 129S6/SvEvTac * C57BL/6 * DBA/2)
abnormal T cell differentiation J:151604
decreased T cell number J:151604
increased IgE level J:151604
increased IgG1 level J:151604
increased interleukin-4 secretion J:151604
increased single-positive T cell number J:151604
\Klf3Gt(CH0516)Wtsi/\Klf3Gt(CH0516)Wtsi
(involves: 129P2/OlaHsd * C57BL/6)
increased leukocyte cell number J:206507
increased spleen weight J:206507
\Klf3Gt(XS0187)Wtsi/\Klf3Gt(XS0187)Wtsi
(involves: 129P2/OlaHsd * C57BL/6)
increased leukocyte cell number J:206507
increased spleen weight J:206507
\Klf3m1Cmhd/\Klf3+
(involves: C3H/HeJ * C57BL/6J)
increased spleen weight J:206507
\Klf4tm1Khk/\Klf4tm1Khk
\Lyz2tm1(cre)Ifo/0

(involves: 129P2/OlaHsd * 129S6/SvEvTac)
decreased Ly6C low monocyte number J:239509
\Klf4tm1Khk/\Klf4tm1Khk
\Tg(Pax6-cre,GFP)1Pgr/0

(involves: 129S6/SvEvTac * FVB/N)
blepharitis J:117671
\Klf5Gt(XB751)Byg/\Klf5+
(B6.129P2-Klf5Gt(XB751)Byg)
abnormal response to infection J:136125
\Klf5M1Btlr/\Klf5M1Btlr
(C57BL/6J-Klf5M1Btlr)
increased susceptibility to induced colitis J:265229
\Klf5tm1Jaw/\Klf5tm1Jaw
\Tg(Pax6-cre,GFP)1Pgr/0

(involves: FVB)
lacrimal gland inflammation J:175263
\Klf13tm1Coll/\Klf13tm1Coll
(involves: 129S/SvEv)
decreased leukocyte cell number J:136545
decreased lymphocyte cell number J:136545
enlarged spleen J:136545
spleen hyperplasia J:136545
\Klf13tm1Kren/\Klf13tm1Kren
(B6.129-Klf13tm1Kren)
abnormal immune system cell morphology J:145839
abnormal immune system organ morphology J:145839
abnormal spleen morphology J:145839
abnormal T cell number J:145839
decreased splenocyte apoptosis J:145839
decreased thymocyte apoptosis J:145839
decreased thymocyte number J:145839
increased double-positive T cell number J:145839
increased splenocyte number J:145839
increased thymocyte number J:145839
spleen hyperplasia J:145839
thymus hyperplasia J:145839
\Klf15tm1Jain/\Klf15tm1Jain
(involves: 129X1/SvJ)
blood vessel inflammation J:203920
increased macrophage cell number J:203920
\Klf16em1(IMPC)J/\Klf16+
(C57BL/6NJ-Klf16em1(IMPC)J/Mmjax)
decreased leukocyte cell number J:211773
\Klhdc2tm1b(EUCOMM)Hmgu/\Klhdc2+
(C57BL/6N-Klhdc2tm1b(EUCOMM)Hmgu/H)
decreased lymphocyte cell number J:211773
increased neutrophil cell number J:211773
\Klhdc7bem1(IMPC)H/\Klhdc7bem1(IMPC)H
(C57BL/6N-Klhdc7bem1(IMPC)H/H)
decreased lymphocyte cell number J:211773
increased eosinophil cell number J:211773
\Klhdc10tm1Hijo/\Klhdc10tm1Hijo
(B6J.B6N-Klhdc10tm1Hijo)
decreased circulating interleukin-6 level J:251158
decreased inflammatory response J:251158
decreased interleukin-6 secretion J:251158
\Klhl1em1(IMPC)Ccpcz/\Klhl1em1(IMPC)Ccpcz
(C57BL/6N-Klhl1em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged spleen J:211773
enlarged thymus J:211773
small spleen J:211773
\Klhl6em1(IMPC)Ccpcz/\Klhl6em1(IMPC)Ccpcz
(C57BL/6NCrl-Klhl6em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
decreased effector memory T-helper cell number J:211773
decreased lymphocyte cell number J:211773
enlarged thymus J:211773
increased CD4-positive, alpha-beta T cell number J:211773
increased CD8-positive, alpha-beta T cell number J:211773
increased CD8-positive, naive alpha-beta T cell number J:211773
increased T cell number J:211773
increased T-helper cell number J:211773
small spleen J:211773
\Klhl6m1Anu/\Klhl6m1Anu
(C57BL/6JAnu-Klhl6m1Anu)
decreased B cell number J:104190
decreased mature B cell number J:104190
increased immature B cell number J:104190
\Klhl6m1Btlr/\Klhl6m1Btlr
(C57BL/6J-Klhl6m1Btlr)
decreased B cell number J:265167
decreased central memory CD4-positive, alpha-beta T cell number J:265167
increased B-1b cell number J:265167
increased CD4-positive, alpha-beta T cell number J:265167
increased single-positive T cell number J:265167
increased T cell number J:265167
\Klhl6m2Btlr/\Klhl6m2Btlr
(C57BL/6J-Klhl6m2Btlr)
decreased CD8-positive, alpha-beta T cell number J:265168
increased CD4-positive, alpha-beta T cell number J:265168
increased single-positive T cell number J:265168
increased T cell number J:265168
\Klhl6M3Btlr/\Klhl6M3Btlr
(C57BL/6J-Klhl6M3Btlr)
increased alpha-beta T cell number J:267699
increased B-1a cell number J:267699
increased CD4-positive, alpha-beta T cell number J:267699
increased CD8-positive, alpha-beta T cell number J:267699
\Klhl6m4Btlr/\Klhl6m4Btlr
(C57BL/6J-Klhl6m4Btlr)
increased B-1 B cell number J:272394
\Klhl6M5Btlr/\Klhl6M5Btlr
(C57BL/6J-Klhl6M5Btlr)
increased B-1 B cell number J:272395
\Klhl6m6Btlr/\Klhl6m6Btlr
(C57BL/6J-Klhl6m6Btlr)
increased alpha-beta T cell number J:272396
increased CD4-positive, alpha-beta T cell number J:272396
\Klhl6M7Btlr/\Klhl6M7Btlr
(C57BL/6J-Klhl6M7Btlr)
abnormal B cell differentiation J:272397
\Klhl6M8Btlr/\Klhl6M8Btlr
(C57BL/6J-Klhl6M8Btlr)
decreased B cell number J:274963
increased CD4-positive, alpha-beta T cell number J:274963
increased T cell number J:274963
\Klhl6tm1Sato/\Klhl6tm1Sato
(either: (involves: 129T2/SvEms) or (involves: BALB/c) or (involves: CD-1))
abnormal adaptive immunity J:101363
abnormal B cell differentiation J:101363
abnormal lymph node germinal center morphology J:101363
abnormal spleen morphology J:101363
decreased B cell number J:101363
decreased follicular B cell number J:101363
decreased spleen weight J:101363
spleen hypoplasia J:101363
\Klhl14tm1.1Jyw/\Klhl14+
(involves: C57BL/6)
decreased B-1a cell number J:263511
immune system phenotype J:263511
increased B-1b cell number J:263511
\Klhl22em1Cya/\Klhl22em1Cya
(C57BL/6N-Klhl22em1Cya/Cya)
decreased interferon-gamma secretion J:297538
decreased tumor necrosis factor secretion J:297538
\Klhl29tm1b(EUCOMM)Hmgu/\Klhl29+
(C57BL/6N-Klhl29tm1b(EUCOMM)Hmgu/Ics)
increased large unstained cell number J:211773
\Klk4tm1.1(KOMP)Vlcg/\Klk4tm1.1(KOMP)Vlcg
(C57BL/6N-Klk4tm1.1(KOMP)Vlcg/Ucd)
increased basophil cell number J:211773
increased neutrophil cell number J:211773
\Klk5em1Mer/\Klk5em1Mer
(BALB/c-Klk5em1Mer)
abnormal acute inflammation J:344772
\Klk6tm1Gsot/\Klk6+
(involves: C57BL/6)
decreased inflammatory response J:270051
decreased susceptibility to chemically induced skin inflammation J:270051
\Klk6tm1Gsot/\Klk6tm1Gsot
(involves: C57BL/6)
abnormal cytokine level J:270051
decreased inflammatory response J:270051
decreased susceptibility to chemically induced skin inflammation J:270051
\Klk6tm1Gsot/\Klk6tm1Gsot
\Spink5tm1Drh/\Spink5tm1Drh

(involves: 129P2/OlaHsd * C57BL/6)
abnormal cytokine level J:289877
decreased inflammatory response J:289877
\Klk8em1(IMPC)Ccpcz/\Klk8em1(IMPC)Ccpcz
(C57BL/6N-Klk8em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
decreased lymphocyte cell number J:211773
enlarged spleen J:211773
\Klk10em1(IMPC)Ccpcz/\Klk10em1(IMPC)Ccpcz
(C57BL/6NCrl-Klk10em1(IMPC)Ccpcz/Ccpcz)
abnormal thymus morphology J:211773
decreased CD8-positive, naive alpha-beta T cell number J:211773
enlarged thymus J:211773
increased effector memory CD8-positive, alpha-beta T cell number J:211773
increased effector memory T-helper cell number J:211773
\Klk11em1(IMPC)Ccpcz/\Klk11em1(IMPC)Ccpcz
(C57BL/6N-Klk11em1(IMPC)Ccpcz/Ccpcz)
abnormal thymus morphology J:211773
enlarged thymus J:211773
\Klra1tm1.1Wyok/\Klra1tm1.1Wyok
(involves: BALB/cJ * C57BL/6NTac)
abnormal natural killer cell mediated cytotoxicity J:252851
\Klra5tm1.1Cgbr/\Klra5tm1.1Cgbr
(involves: C57BL/6 * SJL)
immune system phenotype J:169142
\Klra5tm1.2Glec/\Klra5tm1.2Glec
(involves: C57BL/6)
immune system phenotype J:201231
\Klra8Cmv1-del/\Klra8Cmv1-r
((BXD8/TyJ x C57BL/6)F1)
decreased susceptibility to Herpesvirales infection J:79093
\Klra8Cmv1-del/\Klra8Cmv1-s
((BXD8/TyJ x BALB/c)F1)
increased susceptibility to Herpesvirales infection J:79093
\Klra8Cmv1-del/\Klra8Cmv1-s
((BXD8/TyJ x DBA/2)F1)
increased susceptibility to Herpesvirales infection J:79093
\Klra8Cmv1-r/\Klra8Cmv1-r
(C.B6-Klra8Cmv1-r)
decreased IgG1 level J:97203
decreased IgG2a level J:97203
decreased IgG2b level J:97203
decreased IgG3 level J:97203
decreased IgG level J:97203
decreased interleukin-4 secretion J:97203
decreased susceptibility to Herpesvirales infection J:22486, J:79093
increased circulating interferon-gamma level J:97203
increased IgM level J:97203
increased susceptibility to infection induced morbidity/mortality J:97203
increased susceptibility to parasitic infection J:97203
\Klra15tm1.1Apma/\Klra15tm1.1Apma
(B6.129-Klra15tm1.1Apma)
impaired natural killer cell mediated cytotoxicity J:189106
\Klra17tm1.1Apma/\Klra17tm1.1Apma
(involves: 129S1/Sv * 129X1/SvJ)
abnormal plasmacytoid dendritic cell physiology J:152288
abnormal response to infection J:152288
decreased circulating interferon-alpha level J:152288
decreased circulating interleukin-12 level J:152288
decreased interferon-alpha secretion J:152288
decreased interleukin-12 secretion J:152288
increased plasmacytoid dendritic cell number J:152288
increased susceptibility to Herpesvirales infection J:152288
\Klrb1tm1b(EUCOMM)Wtsi/\Klrb1tm1b(EUCOMM)Wtsi
(C57BL/6N-Klrb1tm1b(EUCOMM)Wtsi/Ieg)
decreased leukocyte cell number J:211773
increased follicular B cell number J:211773
\Klrb1btm1.1Apma/\Klrb1btm1.1Apma
(B6.Cg-Klrb1btm1.1Apma)
abnormal NK cell physiology J:222057
\Klrc1tm1Mmka/\Klrc1tm1Mmka
(B6.129-Klrc1tm1Mmka)
decreased CD8-positive, alpha-beta T cell number J:222503
decreased tumor necrosis factor secretion J:222503
immune system phenotype J:222503
increased interferon-gamma secretion J:222503
increased interleukin-2 secretion J:222503
increased susceptibility to Adenoviridae infection J:222503
increased susceptibility to Orthomyxoviridae infection J:222503
increased tumor necrosis factor secretion J:222503
liver inflammation J:222503
lung inflammation J:222503
\Klrd1tm1.1Lll/\Klrd1tm1.1Lll
(B6.129X1-Klrd1tm1.1Lll)
immune system phenotype J:167730
\Klre1tm1Tgi/\Klre1tm1Tgi
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
impaired natural killer cell mediated cytotoxicity J:92262
\Klrg2em1(IMPC)H/\Klrg2em1(IMPC)H
(C57BL/6NTac-Klrg2em1(IMPC)H/H)
enlarged spleen J:211773
\Klrk1em1(IMPC)Mbp/\Klrk1em1(IMPC)Mbp
(C57BL/6NCrl-Klrk1em1(IMPC)Mbp/MbpMmucd)
abnormal spleen morphology J:211773
enlarged spleen J:211773
\Klrk1tm1.1Bpol/\Klrk1tm1.1Bpol
(C57BL/6-Klrk1tm1.1Bpol)
abnormal NK cell differentiation J:151878
abnormal NK cell physiology J:151878
decreased B cell number J:151878
decreased susceptibility to Herpesvirales infection J:151878
decreased susceptibility to Herpesvirales infection induced morbidity/mortality J:151878
decreased T cell number J:151878
impaired natural killer cell mediated cytotoxicity J:151878
increased interferon-gamma secretion J:151878
spleen hypoplasia J:151878
\Klrk1tm1Dhr/\Klrk1tm1Dhr
(involves: C57BL/6 * CD-1)
impaired natural killer cell mediated cytotoxicity J:134509
\Klrk1tm1Dhr/\Klrk1tm1Dhr
(B6.Cg-Klrk1tm1Dhr/J)
increased natural killer cell mediated cytotoxicity J:221188
\Klrk1tm2.1Bpol/\Klrk1tm2.1Bpol
(Not Specified)
abnormal NK cell differentiation J:215590
decreased susceptibility to Herpesvirales infection J:215590
\Kmt2atm1(AFF1)Ksy/\Kmt2a+
(involves: 129S1/Sv * C57BL/6 * FVB)
abnormal lymphocyte morphology J:110241
enlarged spleen J:110241
increased leukocyte cell number J:110241
increased monocyte cell number J:110241
increased neutrophil cell number J:110241
increased pro-B cell number J:110241
lymphoid hyperplasia J:110241
myeloid hyperplasia J:110241
\Kmt2atm1(MLL1/ERT)Divo/?
(involves: 129S4/SvJae * C57BL/6)
enlarged spleen J:189329
myeloid hyperplasia J:189329
\Kmt2atm1.1(Sh3gl1)Lcc/\Kmt2a+
\Lyz2tm1(cre)Ifo/\Lyz2+

(involves: 129P2/OlaHsd * 129S/SvEv * C57BL/6)
enlarged lymph nodes J:205605
enlarged spleen J:205605
myeloid hyperplasia J:205605
\Kmt2atm1.1Erns/\Kmt2atm1.1Erns
\Lyz2tm1(cre)Ifo/\Lyz2+

(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 * SJL)
immune system phenotype J:147265
\Kmt2atm1.1Erns/\Kmt2atm1.1Erns
\Tg(Lck-cre)1Cwi/0

(involves: 129S2/SvPas * C57BL/6 * SJL)
immune system phenotype J:147265
\Kmt2atm1Brad/\Kmt2atm1Brad
\Commd10Tg(Vav1-icre)A2Kio/?

(involves: 129S4/SvJae * C57BL/6 * C57BL/10 * CBA/Ca)
decreased pre-B cell number J:149811
\Kmt2atm1Clgr/\Kmt2a+
(B6.129-Kmt2atm1Clgr)
abnormal myelopoiesis J:115001
\Kmt2atm1Sjk/\Kmt2a+
(involves: 129S2/SvPas * C3H * C57BL/6)
decreased B cell number J:29958
\Kmt2atm1Thr/\Kmt2a+
\Mllt3tm2Thr/\Mllt3+
\Tg(Lck-cre)1Thr/?

(involves: 129S/SvEv)
abnormal spleen red pulp morphology J:100794
abnormal spleen white pulp morphology J:100794
enlarged spleen J:100794
increased T cell derived lymphoma incidence J:100794
\Kmt2atm2(MLLT3)Thr/\Kmt2a+
(involves: 129P2/OlaHsd)
enlarged spleen J:56340
\Kmt2atm2(MLLT3)Thr/\Kmt2atm2(MLLT3)Thr
(involves: 129P2/OlaHsd * C57BL/6 * FVB)
increased leukocyte cell number J:110241
increased neutrophil cell number J:110241
increased pro-B cell number J:110241
\Kmt2atm2Sjk/\Kmt2a+
\Tg(Mx1-cre)1Cgn/0

(involves: 129X1/SvJ * C57BL/6 * CBA)
abnormal spleen morphology J:95914
enlarged spleen J:95914
increased leukocyte cell number J:95914
increased spleen red pulp amount J:95914
myeloid hyperplasia J:95914
\Kmt2dtm1.1Kaig/\Kmt2d+
\Cd19tm1(cre)Cgn/\Cd19+

(involves: 129P2/OlaHsd * C57BL/6)
increased germinal center B cell number J:228913
increased spleen germinal center size J:228913
\Kmt2dtm1.1Kaig/\Kmt2dtm1.1Kaig
\Cd19tm1(cre)Cgn/\Cd19+

(involves: 129P2/OlaHsd * C57BL/6)
abnormal B cell differentiation J:228913
decreased B cell number J:228913
decreased follicular B cell number J:228913
decreased IgG1 level J:228913
decreased IgM level J:228913
decreased mature B cell number J:228913
immune system phenotype J:228913
increased B cell proliferation J:228913
increased germinal center B cell number J:228913
increased spleen germinal center number J:228913
increased spleen germinal center size J:228913
\Kmt2dtm1.1Kaig/\Kmt2dtm1.1Kaig
\Ighg1tm1(cre)Cgn/\Ighg1+

(involves: 129P2/OlaHsd * C57BL/6)
immune system phenotype J:228913
\Kmt2dtm1.2(IMPC)Wtsi/\Kmt2d+
(C57BL/6N-Kmt2dtm1.2(IMPC)Wtsi/Wtsi)
decreased leukocyte cell number J:211773
\Kmt2etm1.1Hjf/\Kmt2e+
(B6.129P2-Kmtetm1.1Hjf)
decreased thymocyte number J:145579
spleen hypoplasia J:145579
thymus hypoplasia J:145579
\Kmt2etm1.1Hjf/\Kmt2etm1.1Hjf
(B6.129P2-Kmtetm1.1Hjf)
abnormal lymphopoiesis J:145579
decreased B cell number J:145579
decreased double-negative T cell number J:145579
decreased double-positive T cell number J:145579
decreased leukocyte cell number J:145579
decreased macrophage cell number J:145579
decreased pre-B cell number J:145579
decreased pro-B cell number J:145579
decreased T cell number J:145579
decreased thymocyte number J:145579
immune system phenotype J:145579
small lymph nodes J:145579
small spleen J:145579
small thymus J:145579
spleen hypoplasia J:145579
thymus hypoplasia J:145579
\Kmt2etm1Apa/\Kmt2etm1Apa
(129S6/SvEvTac-Kmt2etm1Apa)
abnormal granulocyte differentiation J:145445
abnormal neutrophil differentiation J:145445
abnormal neutrophil physiology J:145445
blepharitis J:145445
increased susceptibility to bacterial infection J:145445
\Kmt2etm1Nik/\Kmt2etm1Nik
(B6.Cg-Kmtetm1Nik)
decreased NK cell number J:145449
decreased NK T cell number J:145449
increased neutrophil cell number J:145449
\Kmt5btm1Jnw/\Kmt5btm1Jnw
\Kmt5ctm1.1Jnw/\Kmt5ctm1.1Jnw
\Commd10Tg(Vav1-icre)A2Kio/\Commd10+

(involves: 129/Sv * C57BL/6J * C57BL/10 * CBA/Ca)
abnormal class switch recombination J:139510
abnormal lymphopoiesis J:139510
decreased B cell number J:139510
decreased double-positive T cell number J:139510
immune system phenotype J:139510
\Knl1tm1c(EUCOMM)Hmgu/\Knl1tm1c(EUCOMM)Hmgu
\Tg(GFAP-cre)25Mes/0

(involves: 129S4/SvJaeSor * C57BL/6N * FVB/N)
microgliosis J:278483
\Knop1tm1b(EUCOMM)Wtsi/\Knop1tm1b(EUCOMM)Wtsi
(C57BL/6N-Knop1tm1b(EUCOMM)Wtsi/Bay)
increased spleen weight J:211773
\Kpna2em1(IMPC)Mbp/\Kpna2+
(C57BL/6N-Kpna2em1(IMPC)Mbp/Ucd)
abnormal spleen morphology J:211773
\Kpna4tm1Bdr/\Kpna4tm1Bdr
(B6.Cg-Kpna4tm1Bdr)
increased susceptibility to Orthomyxoviridae infection J:302003
\Kprptm1Msug/\Kprp+
(involves: C57BL/6)
increased IgE level J:286659
increased susceptibility to chemically induced skin inflammation J:286659
\Kptntm1a(EUCOMM)Wtsi/\Kptntm1a(EUCOMM)Wtsi
(involves: C57BL/6N)
increased susceptibility to bacterial infection J:200082
\Krastm1.1Khai/\Kras+
\Tg(Mx1-cre)1Cgn/0

(involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6 * C57BL/6J * CBA/J)
enlarged spleen J:276349
increased leukocyte cell number J:276349
\Krastm1Mok/\Kras+
\Nrastm1Mok/\Nras+

(involves: 129S/SvEv * C57BL/6 * DBA/2)
abnormal lymphatic vessel morphology J:159024
\Krastm2Tyj/\Kras+
(involves: 129S2/SvPas * C57BL/6)
increased T cell derived lymphoma incidence J:68981
\Krastm2Tyj/\Kras+
(involves: 129S2/SvPas)
increased T cell derived lymphoma incidence J:68981
\Krastm2Tyj/\Kras+
\Trp53tm1Tyj/\Trp53+

(involves: 129S2/SvPas * C57BL/6)
increased T cell derived lymphoma incidence J:68981
\Krastm2Tyj/\Kras+
\Trp53tm1Tyj/\Trp53tm1Tyj

(involves: 129S2/SvPas * C57BL/6)
increased T cell derived lymphoma incidence J:68981
\Krastm3Tyj/\Kras+
(involves: 129S4/SvJae * C57BL/6)
increased T cell derived lymphoma incidence J:68981
\Krastm3Tyj/\Kras+
(involves: 129S4/SvJae)
increased T cell derived lymphoma incidence J:68981
\Krastm3Tyj/\Kras+
\Mir21atm1.1Eno/\Mir21atm1.1Eno

(involves: 129S/SvEv * 129S4/SvJae * C57BL/6)
increased T cell derived lymphoma incidence J:164198
\Krastm3Tyj/\Krastm3Tyj
(involves: 129S4/SvJae)
increased T cell derived lymphoma incidence J:237900
\Krastm4.1Bbd/\Kras+
(involves: 129S1/Sv * 129S2/SvPas * 129X1/SvJ * C57BL/6J * FVB/N)
enlarged spleen J:223433
\Krastm4.1Bbd/\Krastm4.1Bbd
(involves: 129S1/Sv * 129S2/SvPas * 129X1/SvJ * C57BL/6J * FVB/N)
decreased CD8-positive, alpha-beta T cell number J:223433
enlarged spleen J:223433
increased basophil cell number J:223433
increased eosinophil cell number J:223433
increased leukocyte cell number J:223433
increased neutrophil cell number J:223433
spleen vascular congestion J:223433
\Krastm4Tyj/\Kras+
(involves: 129S4/SvJae)
increased regulatory T cell number J:154046
\Krastm4Tyj/\Kras+
\Gt(ROSA)26Sortm4(ACTB-tdTomato,-EGFP)Luo/\Gt(ROSA)26Sor+
\Tg(Flt3-cre)#Ccb/0

(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6)
decreased B cell number J:247853
decreased double-negative T cell number J:247853
decreased double-positive T cell number J:247853
decreased T cell number J:247853
hepatosplenomegaly J:247853
increased dendritic cell number J:247853
increased leukocyte cell number J:247853
increased monocyte cell number J:247853
thymus atrophy J:247853
\Krastm4Tyj/\Kras+
\Krt19tm1(cre/ERT)Ggu/\Krt19+
\Ptentm2Mak/\Ptentm2Mak

(involves: 129P2/OlaHsd * 129S4/SvJae * 129S6/SvEvTac)
lung inflammation J:254370
\Krastm4Tyj/\Kras+
\Lrrc17tm1Nik/\Lrrc17+
\Srpk2tm1Nik/\Srpk2+
\Tg(Mx1-cre)1Cgn/0

(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * CBA)
increased leukocyte cell number J:161558
\Krastm4Tyj/\Kras+
\Pggt1btm1Mbrg/\Pggt1b+
\Lyz2tm1(cre)Ifo/\Lyz2+

(involves: 129/Sv * 129P2/OlaHsd * C57BL/6)
abnormal spleen morphology J:122107
decreased lymphocyte cell number J:122107
increased neutrophil cell number J:122107
\Krastm4Tyj/\Kras+
\Ptentm1Hwu/\Ptentm1Hwu
\Scgb1a1tm1.1(cre)Fjd/\Scgb1a1+

(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ)
lung inflammation J:131721
\Krastm4Tyj/\Kras+
\Stk11tm1.2Rdp/\Stk11tm1.2Rdp

(involves: 129S4/SvJae * 129S6/SvEvTac)
increased macrophage cell number J:197037
\Krastm4Tyj/\Kras+
\Tg(MUC1)79.24Gend/0

(involves: 129S4/SvJae * C57BL/6)
decreased interferon-gamma secretion J:154046
increased IgG level J:154046
increased IgM level J:154046
increased regulatory T cell number J:154046
\Krastm4Tyj/\Kras+
\Tg(Mx1-cre)1Cgn/0

(involves: 129S4/SvJae * BALB/c * C57BL/6 * CBA)
abnormal myelopoiesis J:88163
enlarged spleen J:88163
increased granulocyte number J:88163
increased leukocyte cell number J:88163
increased lymphoblastic lymphoma incidence J:88163
increased spleen red pulp amount J:88163
lymphoid hyperplasia J:88163
myeloid hyperplasia J:88163
\Krastm4Tyj/\Kras+
\Tg(Mx1-cre)1Cgn/0

(involves: 129S4/SvJae * C57BL/6 * CBA)
abnormal myelopoiesis J:87429
enlarged spleen J:87429, J:115071
increased leukocyte cell number J:87429
increased monocyte cell number J:87429
increased splenocyte proliferation J:87429
myeloid hyperplasia J:87429
\Krastm4Tyj/\Kras+
\Tg(Mx1-cre)1Cgn/0

(involves: 129S4/SvJae * C57BL/6 * C57BL/6J * CBA/J)
enlarged spleen J:276349
\Krastm4Tyj/\Kras+
\Tg(Scgb1a1-cre)1Kkw/?

(involves: 129 * C57BL/6 * FVB/N)
increased inflammatory response J:107260
\Krastm4Tyj/\Kras+
\Tgfbr2tm1.2Hlm/\Tgfbr2tm1.2Hlm

(B6.129-Krastm4Tyj Tgfbr2tm1.2Hlm)
abnormal myeloid leukocyte morphology J:177379
increased B cell number J:177379
increased T cell number J:177379
\Krastm4Tyj/\Kras+
\Tgfbr2tm1.2Hlm/\Tgfbr2tm1.2Hlm
\Ptf1atm1.1(cre)Cvw/\Ptf1a+

(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6 * DBA/2)
enlarged spleen J:116129
\Krastm4Tyj/\Kras+
\Trp53tm2Tyj/\Trp53+

(involves: 129S4/SvJae)
lung inflammation J:191425
\Krastm4Tyj/\Kras+
\Trp53tm2Tyj/\Trp53+
\Tg(Pdx1-cre)6Tuv/0

(involves: 129S4/SvJae * C57BL/6 * FVB/N)
increased T cell derived lymphoma incidence J:98936
\Krastm4Tyj/\Krastm4Tyj
\Trim33tm1Los/\Trim33tm1Los
\Tg(Pdx1-cre)89.1Dam/0

(involves: 129S2/SvPas * 129S4/SvJae * C57BL/6 * DBA/2)
pancreas inflammation J:151781
\Kremen1em1(IMPC)Ccpcz/\Kremen1em1(IMPC)Ccpcz
(C57BL/6NCrl-Kremen1em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
small spleen J:211773
\Krt1em1(IMPC)Ccpcz/\Krt1em1(IMPC)Ccpcz
(C57BL/6NCrl-Krt1em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
decreased NK cell number J:211773
enlarged spleen J:211773
enlarged thymus J:211773
increased CD4-positive, CD25-positive, alpha-beta regulatory T cell number J:211773
increased CD8-positive, naive alpha-beta T cell number J:211773
increased effector memory CD8-positive, alpha-beta T cell number J:211773
increased effector memory T-helper cell number J:211773
increased spleen weight J:211773
\Krt1tm1Tmm/\Krt1tm1Tmm
(involves: 129 * C57BL/6)
abnormal circulating interleukin level J:200244
abnormal interleukin secretion J:200244
increased circulating interleukin-18 level J:200244
\Krt2tm1a(KOMP)Wtsi/\Krt2tm1a(KOMP)Wtsi
(involves: C57BL/6N)
skin inflammation J:214772
\Krt5tm1.1(KOMP)Vlcg/\Krt5+
(C57BL/6N-Krt5tm1.1(KOMP)Vlcg/Tcp)
abnormal lymph node morphology J:211773
\Krt8tm1b(EUCOMM)Hmgu/\Krt8+
(C57BL/6N-Krt8tm1b(EUCOMM)Hmgu/Ics)
increased neutrophil cell number J:211773
\Krt8tm1Rgo/\Krt8tm1Rgo
(involves: 129S2/SvPas * C57BL/6 * FVB/N)
chronic inflammation J:86719, J:98058
enlarged spleen J:22116
\Krt10tm1Tmm/\Krt10+
(either: (involves: 129P2/OlaHsd * C57BL/6) or (involves: 129P2/OlaHsd * BALB/c * C57BL/6))
increased susceptibility to infection J:31853
\Krt18tm1Tmm/\Krt18+
(involves: 129P2/OlaHsd)
liver inflammation J:309021
\Krt18tm1Tmm/\Krt18tm1Tmm
(involves: 129P2/OlaHsd)
liver inflammation J:309021
\Krt27em1(IMPC)Ccpcz/\Krt27em1(IMPC)Ccpcz
(C57BL/6N-Krt27em1(IMPC)Ccpcz/Ccpcz)
abnormal lymph node morphology J:211773
abnormal thymus morphology J:211773
enlarged lymph nodes J:211773
enlarged thymus J:211773
\Krt28em1(IMPC)Ccpcz/\Krt28em1(IMPC)Ccpcz
(C57BL/6N-Krt28em1(IMPC)Ccpcz/Ccpcz)
abnormal lymph node morphology J:211773
enlarged lymph nodes J:211773
\Krt33aem1(IMPC)Ccpcz/\Krt33aem1(IMPC)Ccpcz
(C57BL/6N-Krt33aem1(IMPC)Ccpcz/Ccpcz)
abnormal thymus morphology J:211773
enlarged thymus J:211773
\Krt33aPlsh-3Btlr/\Krt33a+
(C57BL/6J-Krt33aPlsh-3Btlr)
immune system phenotype J:145290
\Krt33bem1(IMPC)Ccpcz/\Krt33bem1(IMPC)Ccpcz
(C57BL/6N-Krt33bem1(IMPC)Ccpcz/Ccpcz)
abnormal thymus morphology J:211773
enlarged thymus J:211773
increased eosinophil cell number J:211773
\Krt34em1(IMPC)Ccpcz/\Krt34em1(IMPC)Ccpcz
(C57BL/6NCrl-Krt34em1(IMPC)Ccpcz/Ccpcz)
abnormal lymph node morphology J:211773
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged lymph nodes J:211773
enlarged spleen J:211773
enlarged thymus J:211773
\Krt72em1(IMPC)Ccpcz/\Krt72em1(IMPC)Ccpcz
(C57BL/6N-Krt72em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged thymus J:211773
\Krt76tm1a(KOMP)Wtsi/\Krt76tm1a(KOMP)Wtsi
(involves: C57BL/6 * C57BL/6N)
skin inflammation J:232539
\Krtap7-1em1(IMPC)Ccpcz/\Krtap7-1em1(IMPC)Ccpcz
(C57BL/6NCrl-Krtap7-1em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged thymus J:211773
small spleen J:211773
\Krtap8-1em1(IMPC)Ccpcz/\Krtap8-1em1(IMPC)Ccpcz
(C57BL/6N-Krtap8-1em1(IMPC)Ccpcz/Ccpcz)
decreased CD4-positive, alpha-beta T cell number J:211773
decreased NK T cell number J:211773
decreased T-helper cell number J:211773
\Krtap9-5em1(IMPC)Ccpcz/\Krtap9-5em1(IMPC)Ccpcz
(C57BL/6N-Krtap9-5em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged thymus J:211773
\Ksr1tm1Shaw/\Ksr1tm1Shaw
(Not Specified)
decreased susceptibility to induced arthritis J:140520
decreased T cell proliferation J:75739
\Ksr1tm1Shaw/\Ksr1tm1Shaw
\Tg(DO11.10)10Dlo/0

(involves: BALB/c * C3H * C57BL/6)
abnormal CD4-positive T cell differentiation J:75739
decreased interleukin-2 secretion J:75739
decreased T cell proliferation J:75739
\Kyem1(IMPC)J/\Ky+
(C57BL/6NJ-Kyem1(IMPC)J/Mmjax)
increased leukocyte cell number J:211773
\L3mbtl1tm1.1Haho/\L3mbtl1tm1.1Haho
(involves: 129S4/SvJae * C57BL/6)
immune system phenotype J:166180
\Lacc1em1Arkr/\Lacc1em1Arkr
(C57BL/6NTac-Lacc1em1Arkr)
abnormal macrophage physiology J:244365
decreased circulating interleukin-1 beta level J:244365
decreased susceptibility to endotoxin shock J:244365
\Lacc1em2Arkr/\Lacc1em2Arkr
(C57BL/6NTac-Lacc1em2Arkr)
abnormal macrophage physiology J:244365
decreased circulating interleukin-1 beta level J:244365
decreased susceptibility to endotoxin shock J:244365
\Lacc1em3Arkr/\Lacc1em3Arkr
(C57BL/6NTac-Lacc1em3Arkr)
abnormal macrophage physiology J:244365
increased circulating interleukin-1 beta level J:244365
increased susceptibility to endotoxin shock J:244365
\Lacc1em4Arkr/\Lacc1em4Arkr
(C57BL/6NTac-Lacc1em4Arkr)
abnormal macrophage physiology J:244365
increased circulating interleukin-1 beta level J:244365
increased susceptibility to endotoxin shock J:244365
\Lacc1tm1a(KOMP)Wtsi/\Lacc1tm1a(KOMP)Wtsi
(involves: C57BL/6N * C57BL/6NTac)
abnormal macrophage morphology J:244365
abnormal macrophage physiology J:244365
decreased circulating tumor necrosis factor level J:244365
decreased interleukin-1 beta secretion J:244365
increased circulating interleukin-1 beta level J:244365
increased susceptibility to endotoxin shock J:244365
\Lag3tm1Daav/\Lag3+
\Tg(Foxp3-EGFP/cre)1cJbs/0

(NOD.Cg-Lag3tm1Daav Tg(Foxp3-EGFP/cre)1cJbs)
decreased susceptibility to autoimmune diabetes J:260063
\Lag3tm1Daav/\Lag3tm1Daav
\Tg(Foxp3-EGFP/cre)1cJbs/0

(NOD.Cg-Lag3tm1Daav Tg(Foxp3-EGFP/cre)1cJbs)
abnormal CD8-positive, alpha-beta T cell physiology J:260063
abnormal effector T cell number J:260063
abnormal interleukin level J:260063
abnormal tumor necrosis factor level J:260063
decreased susceptibility to autoimmune diabetes J:260063
\Lag3tm1Doi/\Lag3tm1Doi
(involves: 129S2/SvPas * C57BL/6)
abnormal NK cell physiology J:32509
abnormal T cell physiology J:89653
enlarged spleen J:89653
increased CD4-positive, alpha-beta T cell number J:89653
increased CD8-positive, alpha-beta T cell number J:89653
increased single-positive T cell number J:89653
\Lage3em1(IMPC)Tcp/\Lage3em1(IMPC)Tcp
(C57BL/6N-Lage3em1(IMPC)Tcp/Tcp)
increased neutrophil cell number J:211773
\Lair1tm1.1Jco/\Lair1tm1.1Jco
(involves: C57BL/6)
decreased CD4-positive, alpha-beta T cell number J:180203
decreased CD8-positive, alpha-beta T cell number J:180203
decreased IgG1 level J:180203
decreased thymocyte number J:180203
increased activated T cell number J:180203
increased B cell number J:180203
increased CD4-positive, alpha-beta memory T cell number J:180203
increased CD4-positive, CD25-positive, alpha-beta regulatory T cell number J:180203
increased CD8-positive, alpha-beta memory T cell number J:180203
increased dendritic cell number J:180203
increased eosinophil cell number J:180203
increased marginal zone B cell number J:180203
\Lair1tm1Jco/\Lair1tm1Jco
\Tg(Cd4-cre)1Cwi/?

(involves: C57BL/6 * DBA/2)
decreased IgG2a level J:180203
decreased IgG2b level J:180203
\Lama2dy/\Lama2dy
(involves: 129P1/ReJ)
increased IgG level J:102959
increased IgM level J:102959
\Lama2tm1Eeng/\Lama2tm1Eeng
(involves: 129S1/Sv)
myositis J:170192
\Lama2tm1Stk/\Lama2tm1Stk
(involves: 129P2/OlaHsd * BALB/c)
abnormal thymus corticomedullary boundary morphology J:61802
abnormal thymus physiology J:61802
decreased double-positive T cell number J:61802
decreased T cell number J:61802
thymus cortex hypoplasia J:61802
\Lama3tm1.1Grsb/\Lama3tm1.1Grsb
(involves: C57BL/6)
abnormal chemokine level J:235712
abnormal tumor necrosis factor level J:235712
increased alveolar macrophage number J:235712
lung inflammation J:235712
\Lama3tm1Arte/\Lama3tm1Arte
\Tg(KRT14-cre/ERT)20Efu/0

(involves: C57BL/6 * CD-1)
skin inflammation J:240054
\Lama4tm1.1(KOMP)Vlcg/\Lama4tm1.1(KOMP)Vlcg
(C57BL/6N-Lama4tm1.1(KOMP)Vlcg/Ucd)
increased basophil cell number J:211773
\Lama5b2b2966.1Clo/\Lama5b2b2966.1Clo
(C57BL/6J-Lama5b2b2966.1Clo)
thymus hypoplasia J:175213
\Lama5tm1Lsor/\Lama5tm1Lsor
\Tg(Tek-cre)1Ywa/0

(involves: C57BL/6 * SJL)
abnormal marginal zone B cell physiology J:198783
decreased marginal zone B cell number J:198783
decreased transitional stage T2 B cell number J:198783
increased B cell number J:198783
increased IgM level J:198783
increased transitional stage T1 B cell number J:198783
\Lama5tm2Jhm/\Lama5tm1Jhm
\Tg(NPHS2-cre)295Lbh/0

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA * SJL)
tubulointerstitial nephritis J:185850
\Lamb2tm1Jrs/\Lamb2tm1Jrs
(involves: 129S1/Sv * 129X1/SvJ)
glomerulonephritis J:23783
\Lamc2jeb/\Lamc2jeb
(129X1/SvJ-Lamc2jeb)
ear inflammation J:158873
\Lamp1em1(IMPC)Mbp/\Lamp1em1(IMPC)Mbp
(C57BL/6N-Lamp1em1(IMPC)Mbp/MbpMmucd)
increased leukocyte cell number J:211773
increased lymphocyte cell number J:211773
small spleen J:211773
\Lamp2tm1Psa/\Lamp2tm1Psa
(either: (involves: 129P2/OlaHsd * 129/Sv * C57BL/6J) or (involves: 129P2/OlaHsd * 129/Sv))
abnormal thymus morphology J:64151
intermingled spleen red and white pulp J:64151
\Lamp3em1(IMPC)Tcp/\Lamp3em1(IMPC)Tcp
(C57BL/6N-Lamp3em1(IMPC)Tcp/Tcp)
abnormal lymph node morphology J:211773
\Lamp3em1Damme/\Lamp3em1Damme
(involves: C57BL/6N)
increased macrophage cell number J:324174
\Lancl1tm1.1Pfw/\Lancl1tm1.1Pfw
(involves: 129 * C57BL/6)
brain inflammation J:214805
\Lancl2tm2a(KOMP)Wtsi/\Lancl2tm2a(KOMP)Wtsi
(involves: C57BL/6N)
decreased macrophage cell number J:250673
decreased regulatory T cell number J:250673
decreased susceptibility to bacterial infection J:250673
\Lancl2tm2c(KOMP)Wtsi/\Lancl2tm2c(KOMP)Wtsi
\Lyz2tm1(cre)Ifo/\Lyz2+

(involves: C57BL/6N)
decreased macrophage cell number J:250673
decreased regulatory T cell number J:250673
decreased susceptibility to bacterial infection J:250673
\Lao1tm1Oka/\Lao1tm1Oka
(involves: 129S2/SvPas * C57BL/6J)
abnormal interleukin level J:260668
increased susceptibility to bacterial infection J:260668
increased susceptibility to bacterial infection induced morbidity/mortality J:260668
mastitis J:260668
\Lap3tm1Klr/\Lap3tm1Klr
(involves: 129 * C57BL/6)
immune system phenotype J:119392
\Laptm5tm1Jow/\Laptm5tm1Jow
(C57BL/6-Laptm5tm1Jow)
abnormal T cell activation J:137841
abnormal type IV hypersensitivity reaction J:137841
immune system phenotype J:137841
increased interleukin-2 secretion J:137841
increased T cell proliferation J:137841
\Laq1MRL/\Laq1MRL
(involves: C57BL/6 * MRL)
increased susceptibility to autoimmune disorder J:45708
\LarSAMP1/?
(involves: C57BL/10 * SAMP1)
abnormal humoral immune response J:1953
\Large1myd/\Large1myd
(MYD/Le-Os +/+ Largemyd/J)
myositis J:5670
\Large1myd/\Large1myd
(B6C3Fe a/a-Large1myd/J)
myositis J:27793
\Larp1em1(IMPC)Mbp/\Larp1+
(C57BL/6N-Larp1em1(IMPC)Mbp/Ucd)
abnormal spleen morphology J:211773
enlarged spleen J:211773
\Lat2tm1Mal/\Lat2tm1Mal
(involves: 129S2/SvPas)
abnormal mast cell physiology J:93950
\Lat2tm1Mal/\Lat2tm1Mal
(B6.129S2-Lat2tm1Mal)
increased anti-nuclear antigen antibody level J:126321
\Lat2tm1Mal/\Lat2tm1Mal
\Lime1tm1.1Mal/\Lime1tm1.1Mal

(involves: 129 * C57BL/6)
increased anti-nuclear antigen antibody level J:126321
\Lat2tm1Wz/\Lat2tm1Wz
(involves: C57BL/6)
abnormal mast cell physiology J:93951
\Lat2tm1Wz/\Lat2tm1Wz
(B6.Cg-Lat2tm1Wz)
abnormal CD8-positive, alpha-beta T cell physiology J:116157
abnormal cytokine secretion J:116157
abnormal T cell physiology J:116157
increased anti-double stranded DNA antibody level J:116157
increased autoantibody level J:116157
increased T cell proliferation J:116157
spleen hyperplasia J:116157
\Lat2tm1Wz/\Lat2tm1Wz
(Not Specified)
abnormal T cell physiology J:181866
decreased interleukin-12 secretion J:181866
increased circulating interleukin-6 level J:181866
increased circulating tumor necrosis factor level J:181866
increased interferon-gamma secretion J:181866
increased interleukin-10 secretion J:181866
increased mast cell degranulation J:181866
increased susceptibility to endotoxin shock J:181866
\Lat2tm2Wz/\Lat2tm2Wz
\Tg(Lck-cre)548Jxm/0

(involves: C57BL/6)
abnormal CD4-positive, alpha-beta T cell physiology J:116157
enlarged spleen J:116157
increased activated T cell number J:116157
increased anti-double stranded DNA antibody level J:116157
\Lat2tm3.1Wz/\Lat2tm3.1Wz
(B6.Cg-Lat2tm3.1Wz)
abnormal T cell physiology J:181866
enlarged spleen J:181866
immune system phenotype J:181866
increased interferon-gamma secretion J:181866
increased mast cell degranulation J:181866
increased memory T cell number J:181866
increased susceptibility to endotoxin shock J:181866
\Lattm1.1Lov/\Lattm1.1Lov
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
abnormal CD4-positive, alpha beta T cell morphology J:116157, J:77099
abnormal CD8-positive, alpha beta T cell morphology J:77099
abnormal cytokine secretion J:77099
abnormal double-negative T cell morphology J:77099
abnormal immunoglobulin level J:77099
abnormal lymph organ size J:77099
abnormal T cell differentiation J:77099
abnormal T cell physiology J:77099
decreased double-positive T cell number J:77099
decreased T cell proliferation J:77099
decreased thymocyte number J:77099
enlarged lymph nodes J:116157, J:77099
enlarged spleen J:116157, J:77099
increased activated T cell number J:77099
increased anti-double stranded DNA antibody level J:116157
increased anti-nuclear antigen antibody level J:77099
increased autoantibody level J:77099
increased IgE level J:77099
increased IgG1 level J:77099
increased IgM level J:77099
increased T cell proliferation J:77099
small thymus J:77099
spleen hyperplasia J:116157
\Lattm1.1Lov/\Lattm1.1Lov
\Lat2tm1Wz/\Lat2tm1Wz

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
abnormal CD4-positive, alpha beta T cell morphology J:116157
enlarged lymph nodes J:116157
enlarged spleen J:116157
increased anti-double stranded DNA antibody level J:116157
spleen hyperplasia J:116157
\Lattm1.1Mal/\Lattm1.1Mal
(involves: 129S2/SvPas)
abnormal B cell activation J:77098
abnormal gamma-delta T cell differentiation J:77098
abnormal immune serum protein physiology J:77098
abnormal immune system organ morphology J:77098
abnormal lymph node germinal center morphology J:125722
abnormal lymph node secondary follicle morphology J:125722
abnormal lymphocyte morphology J:77098
abnormal spleen periarteriolar lymphoid sheath morphology J:125722
abnormal T cell selection J:77098
abnormal T cell subpopulation ratio J:77098
abnormal T-helper 2 physiology J:125722
chronic inflammation J:77098
decreased double-positive T cell number J:77098
enlarged lymph nodes J:77098
enlarged spleen J:77098
glomerulonephritis J:125722
increased anti-chromatin antibody level J:125722
increased anti-erythrocyte antigen antibody level J:125722
increased anti-nuclear antigen antibody level J:125722
increased B cell number J:77098
increased CD4-positive, alpha-beta T cell number J:125722, J:77098
increased eosinophil cell number J:77098
increased IgE level J:125722, J:77098
increased IgG1 level J:262891, J:125722, J:77098
increased IgM level J:125722
increased inflammatory response J:262891
increased interferon-gamma secretion J:77098
increased interleukin-4 secretion J:77098
increased memory T cell number J:77098
increased plasma cell number J:125722
increased spleen germinal center number J:125722
increased spleen weight J:262891
increased susceptibility to autoimmune hemolytic anemia J:125722
increased T cell proliferation J:77098
increased T-helper 2 cell number J:77098
kidney inflammation J:262891
liver inflammation J:125722
lung inflammation J:125722
pancreas inflammation J:262891
phlebitis J:262891
salivary gland inflammation J:262891
spleen hyperplasia J:77098
thymus hypoplasia J:77098
\Lattm1.1Mal/\Lattm1.1Mal
(involves: 129S2/SvPas * C57BL/6)
abnormal T cell proliferation J:131351
abnormal T-helper 2 physiology J:131351
\Lattm1.1Mal/\Lattm6.1(HBEGF/EGFP)Mal
(involves: 129S2/SvPas * C57BL/6)
abnormal T-helper 2 physiology J:151840
\Lattm1Bpay/\Lattm1Bpay
(involves: 129S2/SvPas)
abnormal T cell differentiation J:103904
arrested T cell differentiation J:103904
decreased double-negative T cell number J:103904
decreased T cell number J:103904
decreased thymocyte number J:103904
immune system phenotype J:103904
small thymus J:103904
\Lattm1Les/\Lattm1.1Wz
(involves: C57BL/6)
abnormal effector T cell morphology J:147946
\Lattm1Les/\Lattm1.1Wz
\Tg(Cd4-cre)1Cwi/0

(involves: C57BL/6 * DBA/2)
abnormal effector T cell morphology J:147946
abnormal T cell differentiation J:147946
abnormal T cell physiology J:147946
decreased CD4-positive, alpha-beta T cell number J:147946
decreased CD8-positive, alpha-beta T cell number J:147946
decreased regulatory T cell number J:147946
decreased thymocyte number J:147946
increased double-positive T cell number J:147946
increased gamma-delta T cell number J:147946
small thymus J:147946
\Lattm1Les/\Lattm1.2Wz
(involves: C57BL/6 * FVB/N)
absent T cells J:147946
arrested T cell differentiation J:147946
\Lattm1Les/\Lattm1Les
(Not Specified)
abnormal T cell morphology J:54059
arrested T cell differentiation J:116964, J:54059
decreased double-negative T cell number J:54059
decreased T cell number J:54059
decreased thymocyte number J:54059
small thymus J:54059
\Lattm1Les/\Lattm1Les
\Lat2tm1Wz/\Lat2tm1Wz

(involves: C57BL/6)
abnormal mast cell physiology J:93951
\Lattm1Les/\Lattm1Les
\Lcp2tm5(Lat/Lcp2)Gak/\Lcp2tm5(Lat/Lcp2)Gak

(involves: 129S1/Sv * 129X1/SvJ)
arrested T cell differentiation J:147721
decreased double-positive T cell number J:147721
\Lattm1Les/\Lattm1Les
\Tg(CD2-LAT2)1Wz/0

(Not Specified)
abnormal B cell physiology J:116964
abnormal interferon secretion J:116964
abnormal interleukin secretion J:116964
abnormal leukocyte physiology J:116964
abnormal single-positive T cell number J:116964
abnormal spleen periarteriolar lymphoid sheath morphology J:116964
abnormal T cell differentiation J:116964
decreased double-positive T cell number J:116964
enlarged spleen J:116964
increased IgG1 level J:116964
increased IgM level J:116964
increased interleukin-4 secretion J:116964
increased interleukin-10 secretion J:116964
small thymus J:116964
spleen hyperplasia J:116964
\Lattm2.1Lov/\Lattm2.1Lov
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * FVB/N)
abnormal T cell differentiation J:77695
decreased T cell number J:77695
small thymus J:77695
\Lattm2.1Mal/\Lattm2.1Mal
(involves: 129S2/SvPas)
abnormal B cell activation J:94074
abnormal B cell differentiation J:94074
abnormal gamma-delta T cell differentiation J:94074
abnormal immune system organ morphology J:94074
abnormal lymphocyte morphology J:94074
abnormal lymphopoiesis J:94074
abnormal mature gamma-delta T cell morphology J:94074
abnormal plasma cell morphology J:94074
abnormal spleen morphology J:94074
abnormal spleen periarteriolar lymphoid sheath morphology J:94074
abnormal spleen white pulp morphology J:94074
abnormal T cell activation J:94074
abnormal T-helper 2 cell morphology J:94074
abnormal thymocyte activation J:94074
absent CD4-positive, alpha-beta T cells J:94074
absent CD8-positive, alpha-beta T cells J:94074
arrested T cell differentiation J:94074
decreased double-positive T cell number J:94074
enlarged lymph nodes J:94074
enlarged spleen J:94074
increased B cell number J:94074
increased IgE level J:94074
increased IgG1 level J:94074
increased immunoglobulin level J:94074
increased interleukin-4 secretion J:94074
increased mature gamma-delta T cell number J:94074
thymus hypoplasia J:94074
\Lattm2.1Mal/\Lattm2.1Mal
\Lat2tm1Mal/\Lat2tm1Mal

(involves: 129S2/SvPas)
abnormal mast cell physiology J:93950
\Lattm3.1Mal/\Lattm3.1Mal
(involves: 129S2/SvPas)
abnormal gamma-delta T cell differentiation J:94074
abnormal lymph node cell ratio J:94074
abnormal splenic cell ratio J:94074
abnormal thymocyte activation J:94074
abnormal thymus cell ratio J:94074
absent CD4-positive, alpha-beta T cells J:94074
absent CD8-positive, alpha-beta T cells J:94074
absent mature gamma-delta T cells J:94074
arrested T cell differentiation J:94074
decreased double-positive T cell number J:94074
decreased T cell number J:94074
increased T cell number J:94074
\Lattm4.1Mal/\Lattm4.1Mal
(involves: 129P2/OlaHsd)
abnormal gamma-delta T cell differentiation J:94074
abnormal lymph node cell ratio J:94074
abnormal lymphocyte morphology J:94074
abnormal splenic cell ratio J:94074
abnormal thymocyte activation J:94074
abnormal thymus cell ratio J:94074
absent CD4-positive, alpha-beta T cells J:94074
absent CD8-positive, alpha-beta T cells J:94074
absent mature gamma-delta T cells J:94074
arrested T cell differentiation J:94074
decreased double-positive T cell number J:94074
decreased T cell number J:94074
\Lattm4.1Mal/\Lattm4.1Mal
\Tg(Lck*F505)3073Rmp/?

(involves: 129P2/OlaHsd * C57BL/6 * DBA/2)
abnormal T-helper 2 physiology J:151840
increased CD4-positive, alpha-beta T cell number J:151840
increased IgE level J:151840
increased IgG1 level J:151840
increased interleukin-4 secretion J:151840
spleen hyperplasia J:151840
\Lattm4.1Mal/\Lattm4.1Mal
\Trdctm1Mal/\Trdctm1Mal

(involves: 129P2/OlaHsd * C57BL/6)
abnormal double-negative T cell morphology J:112658
\Lattm4.1Mal/\Lattm6.1(HBEGF/EGFP)Mal
(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6)
abnormal T-helper 2 physiology J:151840
\Lattm5.1Mal/\Lattm5.1Mal
(involves: C57BL/6)
arrested T cell differentiation J:152363
\Lattm6.1(HBEGF/EGFP)Mal/?
\Rag2tm1Fwa/\Rag2tm1Fwa
\Tg(TcraH-Y,TcrbH-Y)1Pas/?

(involves: 129S/SvEv * 129S2/SvPas * C57BL/6)
abnormal T cell physiology J:138401
\Lattm6.1(HBEGF/EGFP)Mal/\Lattm6.1(HBEGF/EGFP)Mal
(involves: 129S2/SvPas * C57BL/6)
abnormal T cell activation J:151840
abnormal T-helper 2 physiology J:151840
decreased interferon-gamma secretion J:151840
\Lattm8.1(CD2,-ECFP)Mal/\Lattm8.1(CD2,-ECFP)Mal
(involves: 129S2/SvPas * C57BL/6)
abnormal lymphocyte morphology J:152149
abnormal T cell receptor delta chain V(D)J recombination J:152149
abnormal T cell receptor gamma chain V-J recombination J:152149
arrested T cell differentiation J:152149
increased double-negative T cell number J:152149
\Lattm9Mal/\Lattm9Mal
(involves: C57BL/6)
abnormal B cell number J:205441
abnormal immune system morphology J:205441
abnormal immune system physiology J:205441
abnormal lymphopoiesis J:205441
increased T-helper 2 cell number J:205441
\Lattm9Mal/\Lattm9Mal
\Carmil2bas/\Carmil2bas

(involves: C3HeB/FeJ * C57BL/6)
immune system phenotype J:205441
\Lax1tm1Wz/\Lax1tm1Wz
(involves: C57BL/6)
abnormal B cell calcium ion homeostasis J:98403
abnormal B cell physiology J:98403
abnormal spleen germinal center morphology J:98403
abnormal splenic cell ratio J:98403
abnormal T cell activation J:98403
abnormal T cell physiology J:98403
increased IgE level J:98403
increased IgG1 level J:98403
increased IgG2a level J:98403
\Laynem1Romd/\Laynem1Romd
\Tg(Cd8a-cre,-GFP)1Yzo/0

(involves: C57BL/6)
abnormal CD8-positive, alpha-beta T cell physiology J:302853
immune system phenotype J:302853
\Lbca1C57BL/6Igc/\Lbca1C57BL/6Igc
(involves: BALB/cIgc * C57BL/6Igc)
abnormal B cell activation J:139348
increased B cell proliferation J:139348
\Lbca2BALB/cIgc/\Lbca2C57BL/6Igc
(involves: BALB/cIgc * C57BL/6Igc)
abnormal B cell activation J:139348
increased B cell proliferation J:139348
\Lbca2C57BL/6Igc/\Lbca2C57BL/6Igc
(involves: BALB/cIgc * C57BL/6Igc)
abnormal B cell activation J:139348
increased B cell proliferation J:139348
\Lbptm1b(EUCOMM)Hmgu/\Lbptm1b(EUCOMM)Hmgu
(C57BL/6N-Lbptm1b(EUCOMM)Hmgu/H)
decreased eosinophil cell number J:211773
increased spleen weight J:211773
\Lbptm1Buru/\Lbptm1Buru
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
abnormal immune serum protein physiology J:44878
decreased tumor necrosis factor secretion J:44878
\Lbptm1Buru/\Lbptm1Buru
(involves: 129S1/Sv * 129X1/SvJ * BALB/c)
decreased susceptibility to type I hypersensitivity reaction J:67090
\Lbptm1Buru/\Lbptm1Buru
(B6.129-Lbptm1Buru)
abnormal acute inflammation J:129411
abnormal chemokine level J:129411
abnormal innate immunity J:129411
abnormal neutrophil physiology J:129411
abnormal tumor necrosis factor secretion J:129411
\Lbptm1Jack/\Lbptm1Jack
(involves: 129P2/OlaHsd * BALB/c)
increased susceptibility to bacterial infection J:43514
\Lbrem1(IMPC)Tcp/\Lbrem1(IMPC)Tcp
(C57BL/6N-Lbrem1(IMPC)Tcp/Tcp)
decreased lymphocyte cell number J:211773
enlarged lymph nodes J:211773
increased monocyte cell number J:211773
increased neutrophil cell number J:211773
\LbrGt(XE569)Byg/\LbrGt(XE569)Byg
(involves: 129P2/OlaHsd * C57BL/6Cr)
abnormal granulocyte differentiation J:138854
abnormal granulocyte morphology J:138854
abnormal lymphocyte morphology J:138854
abnormal neutrophil morphology J:138854
enlarged lymph nodes J:138854
\Lbric-2J/\Lbric-2J
(involves: A/J)
abnormal immune system cell morphology J:80915
\Lbric-3J/\Lbric-3J
(involves: A/J)
abnormal immune system cell morphology J:80915
\Lbric-J/\Lbr+
(C57BL/6J-Lbric-J)
abnormal granulocyte morphology J:80915
\Lbric-J/\Lbr+
((NZW/LacJ x C57BL/6J-Lbric-J/J)F1)
abnormal neutrophil morphology J:234168
enlarged spleen J:234168
increased anti-chromatin antibody level J:234168
increased anti-nuclear antigen antibody level J:234168
increased autoantibody level J:234168
increased susceptibility to systemic lupus erythematosus J:234168
\Lbric-J/\Lbr+
\Tm7sf2tm1Fdp/\Tm7sf2tm1Fdp

(involves: 129S4/SvJae * C57BL/6)
abnormal spleen morphology J:143838
\Lbric-J/\Lbric-J
(C57BL/6J-Lbric-J)
abnormal eosinophil morphology J:80915
abnormal lymphocyte morphology J:80915
abnormal neutrophil morphology J:80915
\Lbric-J/\Lbric-J
(involves: 129S4/SvJae * C57BL/6)
abnormal neutrophil differentiation J:143838
abnormal spleen morphology J:143838
\Lbric-J/\Lbrlym3
(C57BL/6-Lbric-J/Lbrlym3)
decreased leukocyte cell number J:180355
decreased lymphocyte cell number J:180355
\Lbrlym3/\Lbr+
(C57BL/6-Lbrlym3)
abnormal neutrophil morphology J:180355
\Lbrlym3/\Lbrlym3
(C57BL/6-Lbrlym3)
abnormal B cell physiology J:180355
abnormal lymphocyte cell number J:180355
abnormal lymphocyte morphology J:180355
abnormal neutrophil morphology J:180355
abnormal T cell physiology J:180355
decreased B cell number J:180355
decreased CD4-positive, alpha-beta T cell number J:180355
decreased CD8-positive, alpha-beta T cell number J:180355
decreased leukocyte cell number J:180355
decreased lymphocyte cell number J:180355
decreased T cell number J:180355
decreased T cell proliferation J:180355
lymph node hypoplasia J:180355
spleen hypoplasia J:180355
thymus hypoplasia J:180355
\Lbw2NZB/BlScr/\Lbw2NZB/BlScr
(involves: NZB * NZW)
glomerulonephritis J:45708
increased anti-chromatin antibody level J:98150
increased autoantibody level J:98150
increased spleen weight J:98150
\Lbw2NZB/BlScr/\Lbw2NZW/LacScr
(involves: NZB * NZW)
glomerulonephritis J:20991
increased anti-chromatin antibody level J:98150
increased autoantibody level J:98150
\Lbw2NZW/LacScr/\Lbw2NZW/LacScr
(involves: NZB * NZW)
decreased autoantibody level J:98150
decreased IgG level J:98150
decreased IgM level J:98150
\Lbw4NZW/LacScr/?
(involves: C57BL/6J * NZM2410/Aeg)
decreased immunoglobulin level J:52863
\Lbw5NZW/LacScr/\Lbw5NZB/BlScr
(involves: NZB/BlScr * NZW/LacScr)
increased susceptibility to systemic lupus erythematosus J:20991
\Lbw5NZW/LacScr/\Lbw5NZW/LacScr
(involves: NZB/BlScr * NZW/LacScr)
increased susceptibility to systemic lupus erythematosus J:20991
\Lbw6NZW/LacScr/\Lbw6NZW/LacScr
(involves: NZB/BlScr * NZW/LacScr)
increased susceptibility to systemic lupus erythematosus J:20991
\Lbw7NZB/BlScr/\Lbw7NZB/BlScr
(involves: NZB/BlScr * NZW/LacScr)
increased susceptibility to systemic lupus erythematosus J:20991
\Lbw7NZB/BlScr/\Lbw7NZW/LacScr
(involves: NZB/BlScr * NZW/LacScr)
increased susceptibility to systemic lupus erythematosus J:20991
\Lbw8NZB/BlScr/\Lbw8NZB/BlScr
(involves: NZB/BlScr * NZW/LacScr)
increased susceptibility to autoimmune disorder J:20991
\Lbw8NZB/BlScr/\Lbw8NZW/LacScr
(involves: NZB/BlScr * NZW/LacScr)
increased susceptibility to autoimmune disorder J:20991
\Lckm1Btlr/\Lckm1Btlr
(C57BL/6J-Lckm1Btlr)
abnormal CD4-positive T cell differentiation J:144695
abnormal CD8-positive, alpha-beta T cell differentiation J:144695
decreased CD4-positive, alpha-beta T cell number J:144695
decreased CD8-positive, alpha-beta T cell number J:144695
decreased cytotoxic T cell cytolysis J:144695
thymus atrophy J:144695
thymus hypoplasia J:144695
\Lckm2Btlr/\Lckm2Btlr
(C57BL/6J-Lckm2Btlr)
decreased CD4-positive, alpha-beta T cell number J:203759
decreased CD8-positive, alpha-beta T cell number J:203759
decreased IgG level J:203759
\Lckm3Btlr/\Lckm3Btlr
(C57BL/6J-Lckm3Btlr)
abnormal T cell subpopulation ratio J:217863
decreased single-positive T cell number J:217863
increased activated T cell number J:217863
increased single-positive T cell number J:217863
\Lcktm1.1Litt/\Lcktm1.1Litt
(Not Specified)
abnormal immunoglobulin level J:152472
abnormal lymphocyte morphology J:152472
abnormal thymus morphology J:152472
\Lcktm1Dbs/\Lcktm1Dbs
(involves: C3H * C57BL/6)
abnormal CD4-positive, alpha beta T cell morphology J:114660
abnormal CD8-positive, alpha beta T cell morphology J:114660
abnormal double-negative T cell morphology J:114660
abnormal T cell differentiation J:114660
decreased T cell number J:114660
decreased T cell proliferation J:114660
decreased thymocyte number J:114660
\Lcktm1Dbs/\Lcktm1Dbs
\Tg(TcraH-Y,TcrbH-Y)71Vbo/0

(involves: C3H * C57BL/6 * DBA/2J)
abnormal positive T cell selection J:114660
abnormal T cell differentiation J:114660
arrested T cell differentiation J:114660
\Lcktm1Dbs/\Lcktm1Dbs
\Tg(TcraTcrb)425Cbn/0

(involves: C3H * C57BL/6)
abnormal positive T cell selection J:114660
arrested T cell differentiation J:114660
\Lcktm1Dbs/\Lcktm1Dbs
\Tg(TcraTcrb)1100Mjb/0

(involves: C3H * C57BL/6)
abnormal positive T cell selection J:114660
decreased T cell proliferation J:114660
\Lcktm1Litt/\Lcktm1.1Litt
\Tnfrsf4tm2(cre)Nik/\Tnfrsf4+

(involves: 129X1/SvJ)
abnormal regulatory T cell physiology J:152472
decreased regulatory T cell number J:152472
decreased T cell proliferation J:152472
enlarged lymph nodes J:152472
increased regulatory T cell number J:152472
increased T cell number J:152472
\Lcktm1Mak/\Lcktm1Mak
(involves: 129S2/SvPas)
abnormal alpha-beta intraepithelial T cell morphology J:112977
abnormal double-negative T cell morphology J:110847
abnormal lymphocyte morphology J:1119
abnormal single-positive T cell number J:37062
abnormal T cell morphology J:110847
abnormal thymocyte activation J:110847
decreased CD4-positive, alpha-beta T cell number J:37940
decreased CD8-positive, alpha-beta T cell number J:37940
decreased double-positive T cell number J:1119, J:110847
decreased gamma-delta intraepithelial T cell number J:112977, J:37940
decreased gamma-delta T cell number J:37062
decreased IgG1 level J:1119
decreased T cell number J:1119, J:37062
decreased thymocyte number J:1119
increased IgG2a level J:1119
increased IgG3 level J:1119
increased IgM level J:1119
thymus atrophy J:1119
thymus hypoplasia J:37062, J:37940
\Lcktm1Mak/\Lcktm1Mak
(B6.129S2-Lcktm1Mak)
abnormal intraepithelial T cell morphology J:111646
abnormal intraepithelial T cell number J:111646
abnormal T cell differentiation J:111646
decreased cytotoxic T cell cytolysis J:111646
decreased gamma-delta intraepithelial T cell number J:111646
\Lcktm1Mak/\Lcktm1Mak
\Rag1tm1Mom/\Rag1+
\Tg(Lck-Fyn*Y528F)5525Cjg/0

(involves: 129S2/SvPas * 129S7/SvEvBrd * C57BL/6)
abnormal T cell differentiation J:37062
decreased T cell number J:37062
\Lcmt1em1(IMPC)Rbrc/\Lcmt1+
(C57BL/6NJcl-Lcmt1em1(IMPC)Rbrc/Rbrc)
increased large unstained cell number J:211773
increased spleen weight J:211773
\Lcn2tm1Aade/\Lcn2tm1Aade
(involves: 129P2/OlaHsd * C57BL/6)
increased susceptibility to bacterial infection J:95107
sepsis J:95107
\Lcn2tm1Aade/\Lcn2tm1Aade
(B6.129P2-Lcn2tm1Aade)
increased spleen weight J:169355
\Lcn2tm1Mak/\Lcn2tm1Mak
(involves: 129P2/OlaHsd * C57BL/6J)
increased susceptibility to bacterial infection J:106079
\Lcn2tm1Mrgr/\Lcn2tm1Mrgr
(129(B6)-Lcn2tm1Mrgr)
abnormal mast cell physiology J:173490
abnormal myelopoiesis J:173490
decreased thymocyte apoptosis J:173490
increased B cell number J:173490
increased leukocyte cell number J:173490
increased lymphocyte cell number J:173490
increased macrophage cell number J:173490
increased monocyte cell number J:173490
increased neutrophil cell number J:173490
increased splenocyte number J:173490
myeloid hyperplasia J:173490
spleen hyperplasia J:173490
thymus hyperplasia J:173490
\Lcn2tm1Mrgr/\Lcn2tm1Mrgr
(B6.129-Lcn2tm1Mrgr)
abnormal mast cell physiology J:173490
\Lcn2tm1Mrgr/\Lcn2tm1Mrgr
(involves: 129 * C57BL/6)
abnormal mast cell physiology J:173490
\Lcn10tm1.1(KOMP)Vlcg/\Lcn10tm1.1(KOMP)Vlcg
(C57BL/6N-Lcn10tm1.1(KOMP)Vlcg/MbpMmucd)
increased susceptibility to endotoxin shock J:359002
\Lcp1tm1Erjb/\Lcp1tm1Erjb
(involves: 129X1/SvJ)
abnormal macrophage physiology J:161042
abnormal neutrophil physiology J:161042
decreased interleukin-1 secretion J:161042
immune system phenotype J:161042
increased susceptibility to bacterial infection J:161042
\Lcp2m1Khoe/\Lcp2m1Khoe
(C57BL/6J-Lcp2m1Khoe)
abnormal NK cell physiology J:196519
impaired natural killer cell mediated cytotoxicity J:196519
\Lcp2tm1.1Wz/\Lcp2tm1.1Wz
(B6.Cg-Lcp2tm1.1Wz)
abnormal effector T cell morphology J:150304
abnormal T cell differentiation J:150304
abnormal T cell subpopulation ratio J:150304
decreased CD4-positive, alpha-beta T cell number J:150304
decreased CD8-positive, alpha-beta T cell number J:150304
decreased double-negative T cell number J:150304
decreased interleukin-2 secretion J:150304
decreased T cell number J:150304
decreased T cell proliferation J:150304
decreased thymocyte number J:150304
immune system phenotype J:150304
increased double-negative T cell number J:150304
lymph node hypoplasia J:150304
small thymus J:150304
\Lcp2tm1.1Wz/\Lcp2tm1.1Wz
\Tg(TcraH-Y,TcrbH-Y)71Vbo/0

(involves: C57BL/6 * C57BL/6J * DBA/2J)
abnormal T cell differentiation J:150304
\Lcp2tm1Gak/\Lcp2tm2Gak
\Tg(Pf4-icre)Q3Rsko/0
\Gt(ROSA)26Sortm1(EYFP)Cos/\Gt(ROSA)26Sor+

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
abnormal lymphatic vessel morphology J:162815
abnormal Peyer's patch morphology J:162815
\Lcp2tm1Gak/\Lcp2tm2Gak
\Tg(VAV1-cre)1Graf/0
\Gt(ROSA)26Sortm1(EYFP)Cos/\Gt(ROSA)26Sor+

(involves: 129S1/Sv * 129X1/SvJ)
abnormal lymphatic vessel morphology J:162815
\Lcp2tm1Geha/\Lcp2tm1Geha
(involves: 129S4/SvJae)
decreased interferon-gamma secretion J:131621
impaired natural killer cell mediated cytotoxicity J:131621
increased NK cell number J:131621
\Lcp2tm2Gak/\Lcp2tm2Gak
\Tg(Cd4-cre)1Cwi/0

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2)
decreased CD4-positive, alpha-beta T cell number J:107467
decreased T cell apoptosis J:107467
increased CD8-positive, alpha-beta T cell number J:107467
increased gamma-delta T cell number J:107467
thymus hypoplasia J:107467
\Lcp2tm3Gak/\Lcp2tm3Gak
(involves: 129S6/SvEvTac * C57BL/6)
abnormal double-negative T cell morphology J:132995
abnormal negative T cell selection J:132995
abnormal T cell activation J:132995
abnormal T cell subpopulation ratio J:132995
decreased NK T cell number J:132995
\Lcp2tm3Gak/\Lcp2tm3Gak
(involves: 129S6/SvEvTac * BALB/c * C57BL/6)
abnormal negative T cell selection J:132995
\Lcp2tm3Gak/\Lcp2tm3Gak
\Tg(TcraH-Y,TcrbH-Y)71Vbo/?

(involves: 129S6/SvEvTac * C57BL/6 * DBA/2J)
abnormal negative T cell selection J:132995
immune system phenotype J:132995
increased CD8-positive, alpha-beta T cell number J:132995
increased double-positive T cell number J:132995
\Lcp2tm3Gak/\Lcp2tm3Gak
\Tg(TcrAND)53Hed/?

(involves: 129S6/SvEvTac * C57BL/6 * SJL)
abnormal positive T cell selection J:132995
abnormal thymocyte activation J:132995
\Lcp2tm3Gak/\Lcp2tm4Gak
(involves: 129S6/SvEvTac * C57BL/6 * FVB/N)
immune system phenotype J:132995
\Lcp2tm4Gak/\Lcp2tm4Gak
(involves: 129S6/SvEvTac * C57BL/6 * FVB/N)
abnormal double-negative T cell morphology J:132995
abnormal negative T cell selection J:132995
abnormal T cell activation J:132995
abnormal T cell subpopulation ratio J:132995
decreased NK T cell number J:132995
\Lcp2tm4Gak/\Lcp2tm4Gak
(involves: 129S6/SvEvTac * BALB/c * C57BL/6)
abnormal negative T cell selection J:132995
\Lcp2tm4Gak/\Lcp2tm4Gak
\Tg(TcraH-Y,TcrbH-Y)71Vbo/?

(involves: 129S6/SvEvTac * C57BL/6 * DBA * FVB/N)
abnormal negative T cell selection J:132995
increased double-positive T cell number J:132995
\Lcp2tm4Gak/\Lcp2tm4Gak
\Tg(TcrAND)53Hed/?

(involves: 129S6/SvEvTac * C57BL/6 * SJL)
abnormal positive T cell selection J:132995
abnormal thymocyte activation J:132995
\Lcp2tm5(Lat/Lcp2)Gak/\Lcp2tm5(Lat/Lcp2)Gak
(involves: 129S1/Sv * 129X1/SvJ)
abnormal thymocyte activation J:147721
arrested T cell differentiation J:147721
decreased double-positive T cell number J:147721
decreased single-positive T cell number J:147721
thymus hypoplasia J:147721
\Lcp2twm/\Lcp2twm
(C57BL/6JSfdAnu-Lcp2twm/Anu)
abnormal double-positive T cell morphology J:104190
abnormal negative T cell selection J:104190
abnormal positive T cell selection J:104190
abnormal T cell physiology J:104190
arrested T cell differentiation J:104190
autoimmune response J:104190
decreased T cell number J:104190
decreased thymocyte number J:104190
increased IgE level J:104190
increased IgG level J:104190
\Lctlp1DBA/1J/\Lctlp1DBA/1J
(involves: DBA/1J * FVB/NJ)
increased CD8-positive, alpha-beta T cell number J:122919
\Lctlp1DBA/1J/\Lctlp1FVB/NJ
(involves: DBA/1J * FVB/NJ)
increased CD8-positive, alpha-beta T cell number J:122919
\Lctlp1FVB/NJ/\Lctlp1FVB/NJ
(involves: DBA/1J * FVB/NJ)
increased susceptibility to induced arthritis J:122919
\Lctlp2DBA/1J/\Lctlp2DBA/1J
(involves: DBA/1J * FVB/NJ)
increased CD8-positive, alpha-beta T cell number J:122919
\Lctlp2DBA/1J/\Lctlp2FVB/NJ
(involves: DBA/1J * FVB/NJ)
increased CD8-positive, alpha-beta T cell number J:122919
\Lctlp2FVB/NJ/\Lctlp2FVB/NJ
(involves: DBA/1J * FVB/NJ)
increased susceptibility to induced arthritis J:122919
\Ldb3tm2b(EUCOMM)Hmgu/\Ldb3+
(C57BL/6N-Ldb3tm2b(EUCOMM)Hmgu/Bay)
increased basophil cell number J:211773
increased large unstained cell number J:211773
\Ldhaa-m1Neu/\Ldhaa-m1Neu
(involves: 101/El * C3H/El)
abnormal leukocyte morphology J:132674
increased neutrophil cell number J:132674
increased spleen weight J:132674
spleen hyperplasia J:132674
\LdlrHlb301/\Ldlr+
(C57BL/6J-LdlrHlb301/J)
increased macrophage derived foam cell number J:82961
\LdlrHlb301/\LdlrHlb301
(C57BL/6J-LdlrHlb301/J)
increased macrophage derived foam cell number J:82961
\Ldlrtm1Her/\Ldlrtm1Her
(involves: 129S7/SvEvBrd * C57BL/6)
abnormal microglial cell morphology J:116493
liver inflammation J:175559
\Ldlrtm1Her/\Ldlrtm1Her
(B6.129S7-Ldlrtm1Her)
abnormal microglial cell morphology J:137264
decreased circulating interleukin-10 level J:130794
increased circulating interleukin-1 beta level J:137264
increased circulating interleukin-6 level J:137264
increased circulating tumor necrosis factor level J:137264
\Ldlrtm1Her/\Ldlrtm1Her
\Lrp1tm2Her/\Lrp1tm2Her
\Lyz2tm1(cre)Ifo/\Lyz2+

(involves: 129P2/OlaHsd * 129S7/SvEvBrd)
impaired macrophage phagocytosis J:137404
\Ldlrtm1Her/\Ldlrtm1Her
\Lrp1tm2Her/\Lrp1tm2Her
\Lyz2tm1(cre)Ifo/\Lyz2+

(involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6J)
abnormal microglial cell physiology J:144185
\Ldlrtm1Her/\Ldlrtm1Her
\Mapkapk2tm1Mgl/\Mapkapk2tm1Mgl

(involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6)
abnormal macrophage derived foam cell morphology J:142788
decreased macrophage cell number J:142788
\Ldlrtm1Her/\Ldlrtm1Her
\Olr1tm1Meht/\Olr1tm1Meht

(involves: 129S7/SvEvBrd * 129X1/SvJ * C57BL/6)
increased circulating interleukin-10 level J:130794
\Ldlrtm1Her/\Ldlrtm1Her
\Pfn1tm1Wit/\Pfn1+

(B6.129S-Ldlrtm1Her Pfn1tm1Wit)
impaired macrophage chemotaxis J:140294
\Ldlrtm1Her/\Ldlrtm1Her
\Soat1tm1Far/\Soat1tm1Far

(involves: 129S4/SvJae * 129S7/SvEvBrd * C57BL/6J)
skin inflammation J:61147
\Ldlrtm1Her/\Ldlrtm1Her
\Tbx21tm1Glm/\Tbx21tm1Glm

(involves: 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6)
abnormal interleukin secretion J:96110
decreased IgG level J:96110
decreased interferon-gamma secretion J:96110
increased IgM level J:96110
\Ldlrtm1Her/\Ldlrtm1Her
\Tcra-Jtm1Tgi/\Tcra-Jtm1Tgi

(B6.129-Ldlrtm1Her Tcra-Jtm1Tgi)
decreased interferon-gamma secretion J:140276
\Ldlrtm1Her/\Ldlrtm1Her
\Tg(H2-K-AKR1B1)1Tj/0

(involves: 129S7/SvEvBrd * C57BL/6 * DBA/2)
abnormal macrophage physiology J:100916
\Ldlrtm1Her/\Ldlrtm1Her
\Tlr2tm1Kir/\Tlr2tm1Kir

(B6.129-Tlr2tm1Kir Ldlrtm1Her)
abnormal cellular extravasation J:131783
decreased tumor necrosis factor secretion J:131783
\Ldlrtm1Her/\Ldlrtm1Her
\Vwftm1Wgr/\Vwftm1Wgr

(B6.129S-Vwftm1Wgr Ldlrtm1Her)
impaired leukocyte tethering or rolling J:106677
\Ldlrad3em1Diam/\Ldlrad3em1Diam
(C57BL/6-Ldlrad3em1Diam)
decreased susceptibility to Togaviridae infection J:300132
\Ldlrad3em1Diam/\Ldlrad3em2Diam
(C57BL/6-Ldlrad3em1Diam Ldlrad3em2Diam)
decreased susceptibility to Togaviridae infection J:300132
\Ldlrad3em2Diam/\Ldlrad3em2Diam
(C57BL/6-Ldlrad3em2Diam)
decreased susceptibility to Togaviridae infection J:300132
\Ldlrad4tm1b(EUCOMM)Wtsi/\Ldlrad4tm1b(EUCOMM)Wtsi
(C57BL/6N-Ldlrad4tm1b(EUCOMM)Wtsi/Wtsi)
decreased monocyte cell number J:211773
\Lect2tm1Ymg/\Lect2tm1Ymg
(involves: 129P2/OlaHsd * C57BL/6J)
abnormal cytokine secretion J:90961
abnormal leukocyte physiology J:90961
increased T cell apoptosis J:90961
increased T cell number J:90961
liver inflammation J:90961
\Lef1tm1.1(KOMP)Vlcg/\Lef1+
(C57BL/6N-Lef1tm1.1(KOMP)Vlcg/Ucd)
increased monocyte cell number J:211773
\Lef1tm1Hhx/\Lef1tm1Hhx
\Tcf7tm1Cle/\Tcf7tm1Cle
\Gt(ROSA)26Sortm2Sho/\Gt(ROSA)26Sor+
\Tg(GZMB-cre)1Jcb/0

(involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6 * FVB/N)
abnormal memory T cell physiology J:189838
decreased CD8-positive, alpha-beta T cell number J:189838
decreased tumor necrosis factor secretion J:189838
\Lef1tm1Rug/\Lef1tm1Rug
(involves: 129S2/SvPas * C57BL/6)
immune system phenotype J:18378
\Lefty2tm2Hmd/\Lefty2tm2Hmd
(involves: 129P2/OlaHsd * C57BL/6)
accessory spleen J:70483
\Lemd2em1(IMPC)Bay/\Lemd2+
(C57BL/6N-Lemd2em1(IMPC)Bay/Bay)
abnormal spleen morphology J:211773
\Lepm1Yst/\Lepm1Yst
(C57BL/6J-Lepm1Yst)
increased macrophage cell number J:167736
\Lepob/\Lepob
(involves: C57BL/6J)
abnormal osteoclast differentiation J:60001
\Lepob/\Lepob
(B6.Cg-Lepob/J)
decreased NK cell number J:117826
lung inflammation J:115772
\Lepob/\Lepob
(B6.Cg-Lepob/OlaHsd)
abnormal acute inflammation J:124815
abnormal chemokine secretion J:124815
increased interleukin-6 secretion J:124815
increased susceptibility to endotoxin shock J:124815
liver inflammation J:124815
\Lepob/\Lepob
(involves: STOCK Mlphln a Tgfawa1 Cdh23v Ednrbs)
abnormal microglial cell physiology J:115569
decreased circulating tumor necrosis factor level J:115569
\Lepob/\Lepob
(involves: C57BL/6)
decreased CD4-positive, alpha-beta T cell number J:164339
decreased splenocyte number J:164339
decreased T cell proliferation J:164339
\Lepob/\Lepob
(B6.Cg-Lepob/JRj)
liver inflammation J:277927
\Lepob/\Lepob
\Serpine1tm1Mlg/\Serpine1tm1Mlg

(involves: 129S2/SvPas * C57BL/6)
abnormal tumor necrosis factor level J:70695
\Leptm1b(EUCOMM)Hmgu/\Leptm1b(EUCOMM)Hmgu
(C57BL/6N-Leptm1b(EUCOMM)Hmgu/Bay)
decreased spleen weight J:211773
\Leprdb-5J/\Leprdb-5J
(NOD/ShiLt-Leprdb-5J)
abnormal CD4-positive, alpha beta T cell morphology J:118304
abnormal CD8-positive, alpha beta T cell morphology J:118304
pancreas inflammation J:118305
periinsulitis J:118305
\Leprdb-lb/\Leprdb-lb
(C57BL/6NCrl-Leprdb-lb/Crl)
white adipose tissue inflammation J:171755
\Leprdb-Pas/\Leprdb-Pas
(involves: DW/Pas)
enlarged spleen J:174584
\Leprdb/\Leprdb
(involves: C57BLKS/J)
increased susceptibility to autoimmune diabetes J:7005
\Leprdb/\Leprdb
(B6.Cg-Dock7m +/+ Leprdb/J)
abnormal chemokine level J:115772
abnormal interleukin level J:115772
abnormal leukocyte morphology J:115772
decreased leukocyte cell number J:115772
increased circulating interleukin-6 level J:115772
increased neutrophil cell number J:115772
lung inflammation J:115772
\Leprdb/\Leprdb
(BKS.Cg-Dock7m +/+ Leprdb/OlaHsd)
abnormal acute inflammation J:124815
abnormal chemokine secretion J:124815
increased interleukin-6 secretion J:124815
increased susceptibility to endotoxin shock J:124815
liver inflammation J:124815
\Leprdb/\Leprdb
(involves: C57BL/6)
abnormal osteoclast differentiation J:60001
\Leprdb/\Leprdb
(B6.BKS(D)-Leprdb/JOrlRj)
liver inflammation J:277927
\Leprdb/\Leprdb
(BKS.Cg-Dock7m +/+ Leprdb)
kidney inflammation J:346348
\Leprm7Btlr/\Leprm7Btlr
(C57BL/6J-Leprm7Btlr)
decreased response to antigen J:236685
increased IgE level J:236685
\Leprm8Btlr/\Leprm8Btlr
(C57BL/6J-Leprm8Btlr)
decreased CD8-positive, naive alpha-beta T cell number J:267679
increased effector memory CD4-positive, alpha-beta T cell number J:267679
increased effector memory CD8-positive, alpha-beta T cell number J:267679
\Leprtm1.1Rll/\Lepr+
(129P3/J-Leprtm1.1Rll)
increased susceptibility to parasitic infection J:172012
\Leprtm1.1Rll/\Leprtm1.1Rll
(129P3/J-Leprtm1.1Rll)
increased susceptibility to parasitic infection J:172012
\Leprtm1b(EUCOMM)Wtsi/\Leprtm1b(EUCOMM)Wtsi
(C57BL/6N-Leprtm1b(EUCOMM)Wtsi/H)
decreased leukocyte cell number J:211773
decreased lymphocyte cell number J:211773
decreased spleen weight J:211773
increased eosinophil cell number J:211773
increased monocyte cell number J:211773
increased neutrophil cell number J:211773
\Leprtm4Mgmj/\Leprtm4Mgmj
(B6.Cg-Leprtm4Mgmj)
decreased CD4-positive, alpha-beta T cell number J:164339
decreased splenocyte number J:164339
decreased T cell proliferation J:164339
\Leprottm1.2Damj/\Leprottm1.2Damj
(involves: 129S2/SvPas * C57BL/6N * FVB/N)
decreased cytokine level J:349250
decreased inflammatory response J:349250
\Lgals1tm1Rob/\Lgals1tm1Rob
(involves: 129S/SvEv)
increased interferon-gamma secretion J:123416
increased interleukin-2 secretion J:123416
increased susceptibility to experimental autoimmune encephalomyelitis J:123416
\Lgals1tm1Rob/\Lgals1tm1Rob
(involves: 129S/SvEv * 129S1/SvImJ * DBA/2J)
abnormal cytokine secretion J:130208
\Lgals2tm1.1Cfg/\Lgals2tm1.1Cfg
(involves: C57BL/6)
abnormal immune system physiology J:217719
decreased neutrophil cell number J:217719
enhanced humoral immune response J:217719
increased CD4-positive, alpha-beta T cell number J:217719
increased CD8-positive, alpha-beta T cell number J:217719
increased IgG2b level J:217719
increased IgG3 level J:217719
increased leukocyte cell number J:217719
increased lymphocyte cell number J:217719
increased spleen red pulp amount J:217719
increased susceptibility to type IV hypersensitivity reaction J:217719
increased T cell number J:217719
\Lgals3tm1Ftl/\Lgals3tm1Ftl
(B6.129S2-Lgals3tm1Ftl)
abnormal CD8-positive, alpha-beta cytotoxic T cell morphology J:109126
abnormal dendritic cell physiology J:109126
abnormal interferon secretion J:109126
abnormal response to infection J:109126
brain inflammation J:109126
decreased macrophage cell number J:109126
increased IgG level J:109126
increased interleukin-12b secretion J:109126
increased susceptibility to parasitic infection J:109126
lung inflammation J:109126
small intestinal inflammation J:109126
\Lgals3tm1Ftl/\Lgals3tm1Ftl
(involves: 129S2/SvPas * C57BL/6)
abnormal leukocyte physiology J:60741
abnormal macrophage physiology J:60741
abnormal monocyte morphology J:60741
decreased lymphocyte cell number J:60741
decreased macrophage cell number J:313172, J:60741
decreased monocyte cell number J:60741
increased eosinophil cell number J:60741
increased macrophage apoptosis J:60741
peritoneal inflammation J:60741
\Lgals3tm1Ftl/\Lgals3tm1Ftl
(involves: 129S2/SvPas * CD-1)
liver inflammation J:221030
\Lgals3tm1Poi/\Lgals3tm1Poi
(involves: 129/Sv * C57BL/6 * SJL)
abnormal macrophage physiology J:131971
impaired macrophage chemotaxis J:131971
impaired macrophage phagocytosis J:131407
impaired neutrophil recruitment J:131407
increased interleukin-6 secretion J:131407
increased susceptibility to bacterial infection J:131407
increased tumor necrosis factor secretion J:131407
lung inflammation J:131407
sepsis J:131407
\Lgals3tm1Poi/\Lgals3tm1Poi
(involves: 129/Sv * C57BL/6 * MF1 * SJL)
decreased granulocyte number J:110422
\Lgals3bptm1Megt/\Lgals3bptm1Megt
(involves: 129P2/OlaHsd * C57BL/Ka)
increased circulating interferon-gamma level J:94936
increased circulating interleukin-12 level J:94936
increased susceptibility to endotoxin shock J:94936
increased tumor necrosis factor secretion J:94936
\Lgals8tm1(KOMP)Vlcg/\Lgals8tm1(KOMP)Vlcg
(involves: C57BL/6NTac)
abnormal lymphangiogenesis J:235778
decreased susceptibility to Herpesvirales infection J:235778
\Lgals9tm1.1Cfg/\Lgals9tm1.1Cfg
(involves: C57BL/6)
abnormal lymph node germinal center morphology J:217719
abnormal Peyer's patch morphology J:217719
enhanced humoral immune response J:217719
increased B cell proliferation J:217719
increased lymphocyte cell number J:217719
increased neutrophil cell number J:217719
increased spleen germinal center size J:217719
lymph node hyperplasia J:217719
spleen hyperplasia J:217719
thymus hyperplasia J:217719
\Lgals9tm1Glp/\Lgals9tm1Glp
(B6.129S6-Lgals9tm1Glp)
decreased regulatory T cell number J:132889
increased susceptibility to induced arthritis J:132889
increased T-helper 1 cell number J:132889
\Lgmntm1Cptr/\Lgmntm1Cptr
(B6.129S6-Lgmntm1Cptr)
abnormal adaptive immunity J:155339
decreased interleukin-6 secretion J:155339
decreased interleukin-12b secretion J:155339
decreased tumor necrosis factor secretion J:155339
enlarged spleen J:172774
\Lgmntm1Ihn/\Lgmntm1Ihn
(involves: 129P2/OlaHsd * C57BL/6)
abnormal macrophage physiology J:143886
abnormal NK cell physiology J:143886
dark spleen J:143886
immune system phenotype J:143886
increased circulating tumor necrosis factor level J:143886
increased lymphocyte cell number J:143886
increased spleen weight J:143886
\lgr/\lgr
(Not Specified)
eye inflammation J:13879
\Lgr4Gt(LST020)Byg/\Lgr4Gt(LST020)Byg
(involves: 129P2/OlaHsd * C57BL/6)
increased incidence of corneal inflammation J:134299
\Lgr5em1(IMPC)Kmpc/\Lgr5+
(C57BL/6NTac-Lgr5em1(IMPC)Kmpc/Kmpc)
increased CD8-positive, CD25-positive alpha-beta T cell number J:211773
increased CD11b-high dendritic cell number J:211773
\Lgr6em1(IMPC)Ccpcz/\Lgr6em1(IMPC)Ccpcz
(C57BL/6NCrl-Lgr6em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged thymus J:211773
increased lymphocyte cell number J:211773
\Lhcgrtm1(KOMP)Vlcg/\Lhcgrtm1(KOMP)Vlcg
(C57BL/6N-Lhcgrtm1(KOMP)Vlcg/Nju)
increased leukocyte cell number J:211773
increased lymphocyte cell number J:211773
small spleen J:211773
small thymus J:211773
\Lhcgrtm1Hht/\Lhcgrtm1Hht
(involves: 129S7/SvEvBrd * C57BL/6J)
enlarged spleen J:105533
epididymis inflammation J:105533
prostate gland inflammation J:105533
reproductive system inflammation J:105533
\Lhx5em1(IMPC)Ccpcz/\Lhx5+
(C57BL/6N-Lhx5em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged spleen J:211773
enlarged thymus J:211773
increased leukocyte cell number J:211773
\Liftm1Cgre/\Liftm1Cgre
(involves: MF1)
abnormal macrophage morphology J:96965
increased eosinophil cell number J:96965
increased uterine NK cell number J:96965
\Liftm1Phb/\Lif+
(involves: 129S2/SvPas * C57BL/6 * DBA/2)
decreased T cell proliferation J:77410
\Liftm1Phb/\Liftm1Phb
(involves: 129S2/SvPas * C57BL/6 * DBA/2)
decreased T cell proliferation J:77410
\Liftm1Stw/\Liftm1Stw
(involves: 129S1/Sv * C57BL/6)
increased acute inflammation J:119777
increased circulating interleukin-1 beta level J:119777
\Liftm1Stw/\Liftm1Stw
(involves: 129S1/Sv * BALB/c)
decreased interleukin-10 secretion J:136940
decreased leukocyte cell number J:136940
increased circulating interleukin-6 level J:136940
increased circulating serum amyloid protein level J:136940
increased circulating tumor necrosis factor level J:136940
increased susceptibility to bacterial infection induced morbidity/mortality J:136940
increased susceptibility to endotoxin shock J:136940
\Liftm1Stw/\Liftm1Stw
(involves: 129S1/Sv * MF1)
abnormal osteoclast differentiation J:137646
abnormal osteoclast morphology J:137646
abnormal osteoclast physiology J:137646
increased osteoclast cell number J:137646
\Lifrtm1Imx/\Lifrtm1Imx
(involves: 129P3/J * 129S7/SvEvBrd * C57BL/6)
increased osteoclast cell number J:25253
\Lig1tm1Dwm/\Lig1tm1Dwm
(involves: 129P2/OlaHsd)
enlarged spleen J:75962
\Lig1tm3Dwm/\Lig1tm3Dwm
(involves: 129P2/OlaHsd * C57BL/6)
abnormal spleen physiology J:77902
abnormal thymus physiology J:77902
enlarged spleen J:77902
\Lig4em1(IMPC)Ccpcz/\Lig4+
(C57BL/6NCrl-Lig4em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged spleen J:211773
enlarged thymus J:211773
\Lig4m1Btlr/\Lig4m1Btlr
(C57BL/6J-Lig4m1Btlr)
decreased B cell number J:267684
decreased CD4-positive, alpha-beta T cell number J:267684
decreased CD8-positive, naive alpha-beta T cell number J:267684
decreased IgD level J:267684
decreased IgG level J:267684
impaired humoral immune response J:267684
increased CD8-positive, alpha-beta T cell number J:267684
increased central memory CD8 positive, alpha-beta T cell number J:267684
increased effector memory CD4-positive, alpha-beta T cell number J:267684
increased NK cell number J:267684
\Lig4m2Btlr/\Lig4m2Btlr
(C57BL/6J-Lig4m2Btlr)
decreased CD4-positive, alpha-beta T cell number J:267692
increased effector memory CD4-positive, alpha-beta T cell number J:267692
\Lig4tiny/\Lig4tiny
(C57BL/6-Lig4tiny)
absent CD8-positive, alpha-beta T cells J:104190
decreased B cell number J:122725
decreased lymphocyte cell number J:122725
\Lig4tm1Fwa/\Lig4tm1Fwa
(involves: 129S6/SvEvTac * C57BL/6)
abnormal B cell differentiation J:50865
abnormal lymphopoiesis J:50865
abnormal T cell differentiation J:63078
arrested B cell differentiation J:63078
arrested T cell differentiation J:50865
decreased thymocyte number J:63078
small thymus J:50865
\Lig4tm1Fwa/\Lig4tm1Fwa
\Tg(Cr2-cre)3Cgn/0
\Xrcc4tm2Fwa/\Xrcc4tm2Fwa

(involves: 129S6/SvEvTac)
abnormal class switch recombination J:126758
\Lig4tm1Fwa/\Lig4tm1Fwa
\Trp53tm1Brd/\Trp53tm1Brd

(involves: 129S6/SvEvTac * 129S7/SvEvBrd)
decreased thymocyte number J:63078
increased B cell number J:63078
\Lig4tm2.1Fwa/\Lig4tm2.1Fwa
(involves: 129S6/SvEvTac)
abnormal B cell activation J:157574
abnormal B cell differentiation J:157574
abnormal immune system cell morphology J:157574
abnormal immune system morphology J:157574
abnormal immune system organ morphology J:157574
abnormal immune system physiology J:157574
abnormal lymphocyte cell number J:157574
abnormal regulatory T cell morphology J:157574
abnormal T cell activation J:157574
abnormal T cell differentiation J:157574
abnormal T cell receptor beta chain V(D)J recombination J:157574
abnormal T cell receptor V(D)J recombination J:157574
abnormal thymus morphology J:157574
decreased B cell number J:157574
decreased CD4-positive, alpha-beta T cell number J:157574
decreased CD8-positive, alpha-beta T cell number J:157574
decreased double-negative T cell number J:157574
decreased double-positive T cell number J:157574
decreased IgA level J:157574
decreased IgG2b level J:157574
decreased IgG3 level J:157574
decreased IgG level J:157574
decreased IgM level J:157574
decreased immunoglobulin level J:157574
decreased interferon-gamma secretion J:157574
decreased interleukin-13 secretion J:157574
decreased spleen weight J:157574
decreased splenocyte number J:157574
decreased T cell proliferation J:157574
decreased thymocyte number J:157574
decreased thymus weight J:157574
increased anti-chromatin antibody level J:157574
increased anti-double stranded DNA antibody level J:157574
increased T cell apoptosis J:157574
increased T cell derived lymphoma incidence J:157574
intestinal inflammation J:157574
liver inflammation J:157574
small spleen J:157574
small thymus J:157574
\Lig4tm3.1Fwa/\Lig4tm3.1Fwa
\Tg(Cr2-cre)3Cgn/0

(Not Specified)
abnormal class switch recombination J:157537
\Lilrb4atm1Eol/\Lilrb4atm1Eol
(B6.129P2-Lilrb4atm1Eol)
abnormal cellular extravasation J:129969
abnormal cytokine level J:129969
abnormal immune system cell morphology J:129969
abnormal immune system physiology J:129969
abnormal interferon level J:129969
abnormal interleukin level J:129969
abnormal leukocyte physiology J:129969
decreased IgE level J:129969
increased inflammatory response J:129969
increased macrophage cell number J:129969
increased mast cell degranulation J:129969
increased plasma cell number J:129969
\Lilrb4atm1Hrk/\Lilrb4atm1Hrk
(involves: 129/Sv * BALB/c)
abnormal mast cell physiology J:70491
increased mast cell degranulation J:70491
increased susceptibility to type I hypersensitivity reaction J:70491
\Lilrb4atm1Ttk/\Lilrb4atm1Ttk
(B6.129X1-Lilrb4atm1Ttk)
abnormal dendritic cell antigen presentation J:141234
increased susceptibility to graft versus host disease J:141234
\Limd1em1(IMPC)H/\Limd1em1(IMPC)H
(C57BL/6NTac-Limd1em1(IMPC)H/H)
increased basophil cell number J:211773
\Limd1tm1Gdl/\Limd1tm1Gdl
(involves: 129X1/SvJ)
abnormal macrophage physiology J:118130
abnormal osteoclast cell number J:118130
abnormal osteoclast physiology J:118130
\Lime1tm1.1Mal/\Lime1tm1.1Mal
(involves: 129S2/SvPas * C57BL/6)
immune system phenotype J:126321
\Lime1tm1.1Mal/\Lime1tm1.1Mal
\Rag2tm1Fwa/\Rag2tm1Fwa
\Tg(TcraH-Y,TcrbH-Y)1Pas/?

(B6.Cg-Rag2tm1Fwa Lime1tm1.1Mal Tg(TcraH-Y,TcrbH-Y)1Pas)
abnormal CD4-positive T cell differentiation J:126321
increased CD4-positive, alpha-beta T cell number J:126321
\Limk2Gt(OST80053)Lex/\Limk2Gt(OST80053)Lex
(involves: 129S5/SvEvBrd * C57BL/6)
increased incidence of corneal inflammation J:192231
\Limk2whe/\Limk2whe
(B6.Cg-Lepob Limk2whe/GrsrJ)
increased incidence of corneal inflammation J:127016
\Lipatm1c(EUCOMM)Hmgu/\Lipatm1c(EUCOMM)Hmgu
\Speer6-ps1Tg(Alb-cre)21Mgn/\Speer6-ps1Tg(Alb-cre)21Mgn

(involves: C57BL/6J * C57BL/6N * C57BL/6NTac)
liver inflammation J:270182
\Lipatm1Hodu/\Lipatm1Hodu
(involves: 129P2/OlaHsd * CF-1)
abnormal alveolar macrophage morphology J:101217
abnormal Kupffer cell morphology J:68812
abnormal spleen morphology J:49674, J:68812
chronic inflammation J:101217
enlarged mesenteric lymph nodes J:68812
enlarged spleen J:68812
hepatosplenomegaly J:68812
increased spleen weight J:49674, J:68812
lung inflammation J:101217
\Lipt1em1(IMPC)Bay/\Lipt1+
(C57BL/6N-Lipt1em1(IMPC)Bay/Bay)
abnormal spleen morphology J:211773
\Listr1BALB/cByJ/?
(involves: BALB/cByJ * C57BL/6ByJ)
decreased susceptibility to bacterial infection J:68879
\Listr1BALB/cByJ/?
\Listr2C57BL/6ByJ/?

(involves: BALB/cByJ * C57BL/6ByJ)
decreased susceptibility to bacterial infection J:68879
\Listr2C57BL/6ByJ/?
(involves: BALB/cByJ * C57BL/6ByJ)
decreased susceptibility to bacterial infection J:68879
\Litaftm1.1Ics/\Litaftm1.1Ics
(Not Specified)
impaired macrophage chemotaxis J:186411
increased macrophage cell number J:186411
\Litaftm1Samr/\Litaftm1Samr
(involves: 129S4/SvJae)
abnormal cytokine secretion J:113750
decreased susceptibility to endotoxin shock J:113750
\ll/\ll
X/\Yaa

(BXSB/MpJScr-ll)
abnormal monocyte morphology J:10973
decreased anti-nuclear antigen antibody level J:10973
decreased CD4-positive, alpha-beta T cell number J:10973
decreased IgG level J:10973
decreased susceptibility to autoimmune disorder J:10973
increased T cell derived lymphoma incidence J:10973
\Lmb1C57BL/6Scr/\Lmb1C57BL/6Scr
(involves: C57BL/6-Faslpr * MRL-Faslpr)
enlarged lymph nodes J:45708
enlarged spleen J:45708
increased anti-double stranded DNA antibody level J:45708
\Lmb1C57BL/6Scr/\Lmb1C57BL/6Scr
(MRL.Cg-Lmb1C57BL/6Scr Faslpr)
increased CD8-positive, alpha-beta T cell number J:125557
increased double-negative T cell number J:125557
increased spleen weight J:125557
\Lmb1C57BL/6Scr/\Lmb1MRL/MpScr
(involves: C57BL/6-Faslpr * MRL-Faslpr)
enlarged lymph nodes J:45708
enlarged spleen J:45708
increased anti-double stranded DNA antibody level J:45708
\Lmb1MRL/MpScr/\Lmb1MRL/MpScr
(B6.MRL-Lmb1MRL/MpScr Faslpr)
enlarged lymph nodes J:125557
\Lmb2C57BL/6Scr/\Lmb2MRL/MpScr
(involves: C57BL/6-Faslpr * MRL-Faslpr)
enlarged lymph nodes J:45708
enlarged spleen J:45708
increased anti-double stranded DNA antibody level J:45708
\Lmb2MRL/MpScr/\Lmb2MRL/MpScr
(involves: C57BL/6-Faslpr * MRL-Faslpr)
enlarged lymph nodes J:45708
enlarged spleen J:45708
increased anti-double stranded DNA antibody level J:45708
\Lmb2MRL/MpScr/\Lmb2MRL/MpScr
(B6.MRL-Lmb2MRL/MpScr Faslpr)
decreased double-negative T cell number J:125557
\Lmb4MRL/MpScr/\Lmb4MRL/MpScr
(involves: C57BL/6-Faslpr * MRL-Faslpr)
enlarged lymph nodes J:45708
enlarged spleen J:45708
\Lmb4MRL/MpScr/\Lmb4MRL/MpScr
(B6.MRL-Lmb4MRL/MpScr Faslpr)
enlarged lymph nodes J:125557
\Lmbr1lem1Btlr/\Lmbr1lem1Btlr
(C57BL/6J-Lmbr1lem1Btlr)
abnormal alpha-beta T cell morphology J:274568
abnormal B cell differentiation J:274568
abnormal cytotoxic T cell physiology J:274568
abnormal lymphocyte morphology J:274568
decreased CD4-positive, alpha-beta T cell number J:274568
decreased IgD level J:274568
decreased IgG level J:274568
decreased IgM level J:274568
decreased leukocyte cell number J:274568
decreased lymphocyte cell number J:274568
decreased monocyte cell number J:274568
decreased T cell number J:274568
impaired humoral immune response J:274568
impaired natural killer cell mediated cytotoxicity J:274568
increased IgM level J:274568
\Lmbr1lm1Btlr/\Lmbr1lm1Btlr
(C57BL/6J-Lmbr1lm1Btlr)
abnormal CD4-positive T cell differentiation J:274568
abnormal CD8-positive, alpha-beta T cell differentiation J:274568
abnormal cytotoxic T cell physiology J:274568
abnormal T cell differentiation J:274568
decreased CD4-positive, alpha-beta T cell number J:274568
decreased CD8-positive, alpha-beta T cell number J:274568
decreased CD8-positive, naive alpha-beta T cell number J:274568
decreased dendritic cell number J:274568
decreased IgE level J:274568
decreased IgG level J:274568
decreased IgM level J:274568
decreased NK cell number J:274568
decreased NK T cell number J:274568
decreased T cell number J:274568
impaired humoral immune response J:274568
impaired natural killer cell mediated cytotoxicity J:274568
increased B-1 B cell number J:274568
increased central memory CD8 positive, alpha-beta T cell number J:274568
increased effector memory CD4-positive, alpha-beta T cell number J:274568
increased macrophage cell number J:274568
increased neutrophil cell number J:274568
\Lmbr1lm2Btlr/\Lmbr1lm2Btlr
(C57BL/6J-Lmbr1lm2Btlr)
increased central memory CD4-positive, alpha-beta T cell number J:274857
\LmnaDhe/\Lmna+
(B6(D2)-LmnaDhe/TyGrsrJ)
abnormal peritoneal macrophage morphology J:188496
increased susceptibility to otitis media J:188496
\Lmnatm1.1Otin/\Lmnatm1.1Otin
(involves: 129P2/OlaHsd * C57BL/6)
small spleen J:177632
small thymus J:177632
\Lmnatm1.1Otin/\Lmnatm1.1Otin
(involves: 129P2/OlaHsd * C57BL/6NTac)
keratoconjunctivitis sicca J:261974
\Lmnatm1Stw/\Lmnatm1Stw
(involves: 129S1/Sv)
small spleen J:58702
thymus atrophy J:58702
\Lmo2tm2(cre)Thr/\Lmo2+
(involves: 129P2/OlaHsd * C57BL/6)
decreased granulocyte number J:155870
decreased monocyte cell number J:155870
\Lmo2tm2(cre)Thr/\Lmo2+
\Kmt2atm1Thr/\Kmt2a+
\Mllt1tm1Thr/\Mllt1+

(involves: 129S/SvEv)
abnormal spleen red pulp morphology J:100794
abnormal spleen white pulp morphology J:100794
enlarged spleen J:84518, J:100794
\Lmo2tm3Thr/\Lmo2tm4Thr
\Cd19tm1(cre)Thr/\Cd19+

(involves: 129S/SvEv)
immune system phenotype J:86869
\Lmo2tm3Thr/\Lmo2tm4Thr
\Rag1tm1(cre)Thr/\Rag1+

(involves: 129S/SvEv)
immune system phenotype J:86869
\Lmo2tm3Thr/\Lmo2tm4Thr
\Tg(Lck-cre)1Thr/0

(involves: 129S/SvEv)
immune system phenotype J:86869
\Lmo4tm1Slp/\Lmo4tm1Slp
\Commd10Tg(Vav1-icre)A2Kio/\Commd10+

(involves: 129S1/Sv * C57BL/6 * C57BL/10 * CBA/Ca)
abnormal acute inflammation J:282740
abnormal gut-associated lymphoid tissue morphology J:282740
abnormal lymphocyte physiology J:282740
abnormal lymphopoiesis J:282740
decreased Peyer's patch number J:282740
increased susceptibility to bacterial infection J:282740
\Lmo4tm1Slp/\Lmo4tm1Slp
\Yeats4em1Zfa/\Yeats4em1Zfa
\Commd10Tg(Vav1-icre)A2Kio/\Commd10+

(involves: 129S1/Sv * C57BL/6 * C57BL/10 * CBA/Ca)
abnormal acute inflammation J:282740
abnormal lymphocyte physiology J:282740
abnormal lymphopoiesis J:282740
increased susceptibility to bacterial infection J:282740
\Lmod3em1(IMPC)Mbp/\Lmod3+
(C57BL/6N-Lmod3em1(IMPC)Mbp/Ucd)
abnormal spleen morphology J:211773
enlarged spleen J:211773
\Lmod3em1(IMPC)Mbp/\Lmod3em1(IMPC)Mbp
(C57BL/6N-Lmod3em1(IMPC)Mbp/Ucd)
decreased lymphocyte cell number J:211773
enlarged lymph nodes J:211773
enlarged spleen J:211773
enlarged thymus J:211773
increased neutrophil cell number J:211773
\Lmr1BALB/c/\Lmr1BALB/c
(involves: BALB/c * C57BL/6J)
increased susceptibility to parasitic infection J:40874
\Lmr1BALB/c/\Lmr1BALB/c
\Lmr30C57BL/6/\Lmr30BALB/c

(involves: BALB/c * C57BL/6)
increased susceptibility to parasitic infection J:57691
\Lmr1BALB/c/\Lmr1BALB/c
\Lmr30C57BL/6/\Lmr30C57BL/6

(involves: BALB/c * C57BL/6)
increased susceptibility to parasitic infection J:57691
\Lmr1BALB/c/\Lmr1C57BL/6J
(involves: BALB/c * C57BL/6J)
decreased susceptibility to parasitic infection J:40874
\Lmr1C57BL/6J/\Lmr1C57BL/6J
(involves: BALB/c * C57BL/6J)
decreased susceptibility to parasitic infection J:40874
\Lmr2BALB/c/\Lmr2BALB/c
(involves: BALB/c * C57BL/6J)
increased susceptibility to parasitic infection J:40874
\Lmr2BALB/c/\Lmr2C57BL/6J
(involves: BALB/c * C57BL/6J)
decreased susceptibility to parasitic infection J:40874
\Lmr2C57BL/6J/\Lmr2C57BL/6J
(involves: BALB/c * C57BL/6J)
decreased susceptibility to parasitic infection J:40874
\Lmr3BALB/cHeA/?
(involves: BALB/cHeA * STS/A)
abnormal tumor necrosis factor level J:82715
enlarged spleen J:82715
increased IgE level J:82715
\Lmr3BALB/cHeA/\Lmr3BALB/cHeA
(involves: BALB/cHeA * STS/A)
spleen hyperplasia J:108764
\Lmr3BALB/cHeA/\Lmr3CcS5/Dem
(involves: BALB/cHeA * STS/A)
spleen hyperplasia J:108764
\Lmr4BALB/cHeA/?
\Lmr5BALB/cHeA/?

(involves: BALB/cHeA * STS/A)
abnormal tumor necrosis factor level J:82715
\Lmr5BALB/cHeA/?
(involves: BALB/cHeA * STS/A)
abnormal interleukin level J:82715
abnormal tumor necrosis factor level J:82715
increased IgE level J:82715
\Lmr5CcS5/Dem/\Lmr5CcS5/Dem
(involves: BALB/cHeA * STS/A)
increased circulating interleukin-12 level J:108764
\Lmr7BALB/cHeA/?
(involves: BALB/cHeA * STS/A)
decreased splenocyte proliferation J:108764
\Lmr7CcS5/Dem/?
(involves: BALB/cHeA * STS/A)
spleen hyperplasia J:82715
\Lmr8BALB/cHeA/?
(involves: BALB/cHeA * STS/A)
increased IgE level J:82717
\Lmr8BALB/cHeA/\Lmr8BALB/cHeA
(involves: BALB/cHeA * STS/A)
spleen hyperplasia J:108764
\Lmr8BALB/cHeA/\Lmr8CcS20/Dem
(involves: BALB/cHeA * STS/A)
spleen hyperplasia J:108764
\Lmr9BALB/cHeA/?
(involves: BALB/cHeA * STS/A)
increased IgE level J:82717
\Lmr9BALB/cHeA/\Lmr9CcS20/Dem
(involves: BALB/cHeA * STS/A)
increased circulating interleukin-6 level J:108764
\Lmr9CcS20/Dem/?
(involves: BALB/cHeA * STS/A)
decreased IgE level J:82717
\Lmr9CcS20/Dem/\Lmr9CcS20/Dem
(involves: BALB/cHeA * STS/A)
increased circulating interleukin-6 level J:108764
\Lmr10BALB/cHeA/?
(involves: BALB/cHeA * STS/A)
increased IgE level J:82717
\Lmr10CcS20/Dem/?
(involves: BALB/cHeA * STS/A)
decreased IgE level J:82717
\Lmr11BALB/cHeA/\Lmr11BALB/cHeA
\Lmr8CcS20/Dem/\Lmr8CcS20/Dem

(involves: BALB/cHeA * STS/A)
decreased IgE level J:82717
\Lmr11BALB/cHeA/\Lmr11CcS20/Dem
(involves: BALB/cHeA * STS/A)
increased circulating interleukin-6 level J:108764
\Lmr11CcS20/Dem/\Lmr11CcS20/Dem
(involves: BALB/cHeA * STS/A)
increased circulating interleukin-6 level J:108764
\Lmr12BALB/cHeA/?
(involves: BALB/cHeA * STS/A)
decreased IgE level J:82717
\Lmr12BALB/cHeA/\Lmr12BALB/cHeA
\Lmr14BALB/cHeA/\Lmr14BALB/cHeA

(involves: BALB/cHeA * STS/A)
increased circulating tumor necrosis factor level J:108764
\Lmr12BALB/cHeA/\Lmr12CcS16/Dem
(involves: BALB/cHeA * STS/A)
increased circulating interleukin-4 level J:108764
\Lmr12CcS16/Dem/?
(involves: BALB/cHeA * STS/A)
increased IgE level J:82717
\Lmr12CcS16/Dem/\Lmr12CcS16/Dem
(involves: BALB/cHeA * STS/A)
increased circulating interleukin-4 level J:108764
\Lmr12CcS16/Dem/\Lmr12CcS16/Dem
\Lmr19BALB/cHeA/\Lmr19BALB/cHeA

(involves: BALB/cHeA * STS/A)
spleen hyperplasia J:108764
\Lmr13BALB/cHeA/?
(involves: BALB/cHeA * STS/A)
decreased IgE level J:82717
\Lmr13CcS16/Dem/\Lmr13CcS16/Dem
\Lmr14CcS16/Dem/\Lmr14CcS16/Dem

(involves: BALB/cHeA * STS/A)
decreased circulating tumor necrosis factor level J:108764
\Lmr14BALB/cHeA/?
(involves: BALB/cHeA * STS/A)
spleen hyperplasia J:108764
\Lmr14BALB/cHeA/\Lmr14BALB/cHeA
\Lmr5BALB/cHeA/?

(involves: BALB/cHeA * STS/A)
increased IgE level J:82715
\Lmr14BALB/cHeA/\Lmr14BALB/cHeA
\Lmr5BALB/cHeA/\Lmr5BALB/cHeA

(involves: BALB/cHeA * STS/A)
increased IgE level J:82717
\Lmr14BALB/cHeA/\Lmr14CcS16/Dem
(involves: BALB/cHeA * STS/A)
increased circulating interferon-gamma level J:108764
\Lmr14CcS16/Dem/?
(involves: BALB/cHeA * STS/A)
enlarged spleen J:82716
\Lmr14CcS16/Dem/\Lmr14CcS16/Dem
(involves: BALB/cHeA * STS/A)
increased circulating interferon-gamma level J:108764
\Lmr14CcS16/Dem/\Lmr14CcS16/Dem
\Lmr5BALB/cHeA/?

(involves: BALB/cHeA * STS/A)
increased IgE level J:82715
\Lmr14CcS16/Dem/\Lmr14CcS16/Dem
\Lmr5BALB/cHeA/\Lmr5BALB/cHeA

(involves: BALB/cHeA * STS/A)
increased IgE level J:82717
\Lmr14CcS16/Dem/\Lmr14CcS16/Dem
\Lmr5CcS5/Dem/\Lmr5CcS5/Dem

(involves: BALB/cHeA * STS/A)
increased circulating interleukin-12 level J:108764
\Lmr15BALB/cHeA/\Lmr15CcS16/Dem
(involves: BALB/cHeA * STS/A)
decreased circulating interferon-gamma level J:108764
\Lmr15CcS16/Dem/\Lmr15CcS16/Dem
(involves: BALB/cHeA * STS/A)
decreased circulating interferon-gamma level J:108764
\Lmr16STS/A/\Lmr16STS/A
\Lmr18BALB/cHeA/\Lmr18BALB/cHeA

(involves: BALB/cHeA * STS/A)
spleen hyperplasia J:108764
\Lmr17BALB/cHeA/\Lmr17CcS20/Dem
(involves: BALB/cHeA * STS/A)
increased circulating tumor necrosis factor level J:108764
\Lmr17CcS20/Dem/\Lmr17CcS20/Dem
(involves: BALB/cHeA * STS/A)
increased circulating tumor necrosis factor level J:108764
\Lmr17CcS20/Dem/\Lmr17CcS20/Dem
\Lmr3BALB/cHeA/\Lmr3BALB/cHeA

(involves: BALB/cHeA * STS/A)
increased circulating interferon-gamma level J:108764
\Lmr18BALB/cHeA/\Lmr18BALB/cHeA
(involves: BALB/cHeA * STS/A)
decreased splenocyte proliferation J:108764
\Lmr18BALB/cHeA/\Lmr18CcS20/Dem
(involves: BALB/cHeA * STS/A)
decreased splenocyte proliferation J:108764
\Lmrq1BALB/cAnSim/\Lmrq1C57BL/10Sn
(involves: BALB/cAnNSim * C57BL/10J)
decreased susceptibility to parasitic infection J:40624
\Lmrq2BALB/cAnSim/\Lmrq2C57BL/10Sn
(involves: BALB/cAnNSim * C57BL/10J)
decreased susceptibility to parasitic infection J:40624
\Lmrq3BALB/cAnSim/\Lmrq3C57BL/10Sn
(involves: BALB/cAnNSim * C57BL/10J)
decreased susceptibility to parasitic infection J:40624
\Lmrq4BALB/cAnSim/\Lmrq4C57BL/10Sn
(involves: BALB/cAnNSim * C57BL/10J)
decreased susceptibility to parasitic infection J:40624
\Lmrq4C57BL/10Sn/\Lmrq4C57BL/10Sn
(C.B10-(D11Mit2-D11Mit29))
decreased susceptibility to parasitic infection J:40624
\Lmrq5BALB/cAnNSim/\Lmrq5C57BL/10Sn
(involves: BALB/cAnNSim * C57BL/10J)
decreased susceptibility to parasitic infection J:40624
\Lmrq6BALB/cAnSim/\Lmrq6C57BL/10Sn
(involves: BALB/cAnNSim * C57BL/10J)
decreased susceptibility to parasitic infection J:40624
\Lncucc1em1Bwu/\Lncucc1em1Bwu
(C57BL/6-Lncucc1em1Bwu)
abnormal susceptibility to colitis induced morbidity/mortality J:340220
increased susceptibility to induced colitis J:340220
\Lnx1tm1Lex/\Lnx1tm1Lex
(involves: 129S5/SvEvBrd * C57BL/6J)
increased B-1b cell number J:171883
\Loricrintm1.1(KOMP)Vlcg/\Loricrin+
(C57BL/6N-Loricrintm1.1(KOMP)Vlcg/Ucd)
abnormal spleen morphology J:211773
enlarged spleen J:211773
\Loricrintm1.1(KOMP)Vlcg/\Loricrintm1.1(KOMP)Vlcg
(C57BL/6N-Loricrintm1.1(KOMP)Vlcg/Ucd)
increased spleen weight J:211773
\Loricrintm1Der/\Loricrintm1Der
(FVB.129S7-Loricrintm1Der)
erythroderma J:65187
\Loxtm1.1Khki/\Loxtm1.1Khki
(involves: C57BL/6)
increased lymphocyte cell number J:264295
\Loxl2tm1.2Acan/\Loxl2tm1.2Acan
(Not Specified)
decreased inflammatory response J:220689
\Lpar2tm1Dgen/\Lpar2tm1Dgen
(B6.Cg-Lpar2tm1Dgen)
abnormal dendritic cell physiology J:184061
decreased interleukin-10 secretion J:184061
increased IgE level J:184061
increased interleukin-13 secretion J:184061
increased susceptibility to type I hypersensitivity reaction J:184061
increased tumor necrosis factor secretion J:184061
lung inflammation J:184061
\Lpar4tm1Sati/Y
(involves: C57BL/6)
abnormal cellular extravasation J:253134
immune system phenotype J:253134
lymphangiectasis J:167262
\Lpar4tm1Sati/\Lpar4+
(involves: C57BL/6)
abnormal cellular extravasation J:253134
\Lpar4tm1Sati/\Lpar4tm1Sati
(involves: C57BL/6)
abnormal cellular extravasation J:253134
immune system phenotype J:253134
lymphangiectasis J:167262
\Lpar6tm1.1Sati/\Lpar6tm1.1Sati
(involves: C57BL/6 * C57BL/6NJcl * CBA)
abnormal cellular extravasation J:253134
immune system phenotype J:253134
\Lpin2tm1b(KOMP)Wtsi/\Lpin2tm1b(KOMP)Wtsi
(C57BL/6N-Lpin2tm1b(KOMP)Wtsi/Tcp)
enlarged lymph nodes J:211773
\Lpin2tm1Reue/\Lpin2tm1Reue
(involves: C57BL/6J)
immune system phenotype J:189894
\Lpin3tm1b(KOMP)Wtsi/\Lpin3tm1b(KOMP)Wtsi
(C57BL/6N-Lpin3tm1b(KOMP)Wtsi/Ucd)
increased basophil cell number J:211773
increased eosinophil cell number J:211773
increased leukocyte cell number J:211773
increased lymphocyte cell number J:211773
increased monocyte cell number J:211773
increased neutrophil cell number J:211773
\Lpn1NZB/\Lpn1NZB
(involves: NZB * NZW)
kidney inflammation J:6026
\Lpn1NZB/\Lpn1NZW
(involves: NZB * NZW)
kidney inflammation J:6026
\Lpn2NZB/\Lpn2NZW
(involves: NZB * NZW)
kidney inflammation J:6026
\Lpn2NZW/\Lpn2NZW
(involves: NZB * NZW)
kidney inflammation J:6026
\Lpoem1Zlu/\Lpoem1Zlu
(involves: C57BL/6 * SJL)
aortitis J:307289
arteritis J:307289
blood vessel inflammation J:307289
cardiovalvulitis J:307289
gallbladder inflammation J:307289
glomerulonephritis J:307289
increased inflammatory response J:307289
intestinal inflammation J:307289
liver inflammation J:307289
lung inflammation J:307289
mastitis J:307289
myocarditis J:307289
myositis J:307289
pancreas inflammation J:307289
stomach inflammation J:307289
\Lppl1C57BL/6J/?
(involves: C57BL/6J * DBA/2J)
abnormal leukocyte physiology J:90647
\Lprm3MRL/MpJ/\Lprm3MRL/MpJ
(involves: C3H/HeJ-Faslpr * MRL/MpJ-Faslpr)
glomerulonephritis J:44625
\Lprm4MRL/MpJ/\Lprm4MRL/MpJ
(involves: C3H/HeJ-Faslpr * MRL/MpJ-Faslpr)
enlarged spleen J:44625
\Lprm5MRL/MpJ/\Lprm5MRL/MpJ
(involves: C3H/HeJ-Faslpr * MRL/MpJ-Faslpr)
abnormal humoral immune response J:44625
\Lptl1DBA/2J/?
(involves: C57BL/6J * DBA/2J)
abnormal tumor necrosis factor level J:90647
\Lptl1DBA/2J/\Lptl1DBA/2J
\Lptl2DBA/2J/\Lptl2DBA/2J

(involves: C57BL/6J * DBA/2J)
abnormal tumor necrosis factor level J:90647
\Lptl2DBA/2J/?
(involves: C57BL/6J * DBA/2J)
abnormal tumor necrosis factor level J:90647
\Lpxntm1b(EUCOMM)Hmgu/\Lpxntm1b(EUCOMM)Hmgu
(C57BL/6N-Lpxntm1b(EUCOMM)Hmgu/Wtsi)
abnormal plasma cell differentiation J:305662
decreased IgM level J:305662
immune system phenotype J:305662
\Lratd2em1(IMPC)Ccpcz/\Lratd2em1(IMPC)Ccpcz
(C57BL/6N-Lratd2em1(IMPC)Ccpcz/Ccpcz)
decreased eosinophil cell number J:211773
increased B-2 B cell number J:211773
\Lrbaem1Btlr/\Lrbaem1Btlr
(C57BL/6J-Lrbaem1Btlr)
increased susceptibility to induced colitis J:274652
\Lrbaem2Btlr/\Lrbaem2Btlr
(C57BL/6J-Lrbaem2Btlr)
increased susceptibility to induced colitis J:274652
\Lrbaem3Btlr/\Lrbaem3Btlr
(C57BL/6J-Lrbaem3Btlr)
increased susceptibility to induced colitis J:274652
\LrbaGt(OST69142)Lex/\LrbaGt(OST69142)Lex
(involves: 129 * 129S5/SvEvBrd)
abnormal NK cell physiology J:237187
decreased susceptibility to graft versus host disease J:237187
impaired natural killer cell mediated cytotoxicity J:237187
increased length of allograft survival J:237187
increased regulatory T cell number J:237187
\Lrbam1Btlr/\Lrbam1Btlr
(C57BL/6J-Lrbam1Btlr)
increased susceptibility to induced colitis J:274652
\Lrbam2Btlr/\Lrbam2Btlr
(C57BL/6J-Lrbam2Btlr)
increased susceptibility to induced colitis J:274652
\Lrch1em1Hwa/\Lrch1em1Hwa
(Not Specified)
abnormal cellular extravasation J:238772
immune system phenotype J:238772
increased susceptibility to experimental autoimmune encephalomyelitis J:238772
\Lrdm1MRL/MpJ/?
(involves: CAST/Ei * MRL/MpJ-Faslpr/J)
kidney inflammation J:3304
\Lrdm2MRL/MpJ/?
(involves: CAST/Ei * MRL/MpJ-Faslpr/J)
kidney inflammation J:3304
\Lrfn2Tg(CD2-Myb/en)5Kmw/\Lrfn2+
(involves: C57BL/10 * CBA)
abnormal lymph node morphology J:125805
decreased T cell number J:126456
decreased T cell proliferation J:126456
\Lrfn2Tg(CD2-Myb/en)5Kmw/\Lrfn2+
\Tg(H2-K-Myc)1Brn/?

(involves: C57BL/10 * CBA * FVB/N)
abnormal lymph node morphology J:125805
enlarged lymph nodes J:125805
enlarged spleen J:125805
lymph node hemorrhage J:125805
lymph node necrosis J:125805
spleen hyperplasia J:125805
\Lrfn2Tg(CD2-Myb/en)5Kmw/\Lrfn2Tg(CD2-Myb/en)5Kmw
(involves: C57BL/10 * CBA)
abnormal thymus cortex morphology J:126456
abnormal thymus medulla morphology J:126456
decreased CD8-positive, alpha-beta T cell number J:126456
decreased double-negative T cell number J:126456
decreased T cell number J:126456
decreased T cell proliferation J:126456
small spleen J:126456
small thymus J:126456
\Lrfn2tm1.1Jaru/\Lrfn2tm1.1Jaru
(B6.129P2(Cg)-Lrfn2tm1.1Jaru)
decreased granulocyte number J:301285
decreased leukocyte cell number J:301285
decreased lymphocyte cell number J:301285
\Lrig1m1Anu/\Lrig1m1Anu
(C57BL/NCrlAnu-Lrig1m1Anu)
immune system phenotype J:104190
\Lrig1tm1a(EUCOMM)Wtsi/\Lrig1tm1a(EUCOMM)Wtsi
(involves: C57BL/6 * C57BL/6N)
increased susceptibility to bacterial infection J:213427
\Lrig2tm1.1Hhed/\Lrig2tm1.1Hhed
(involves: 129 * C57BL/6 * FVB/N)
increased inflammatory response J:205929
\Lrig3em1(IMPC)Ccpcz/\Lrig3em1(IMPC)Ccpcz
(C57BL/6NCrl-Lrig3em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged thymus J:211773
\Lrp1tm2Her/\Lrp1tm2Her
\Tg(Camk2a-cre)T29-1Stl/0

(involves: 129S7/SvEvBrd * BALB/c * C57BL)
brain inflammation J:167724
\Lrp2b2b2671Clo/\Lrp2b2b2671Clo
(C57BL/6J-Lrp2b2b2671Clo)
thymus hypoplasia J:175213
\Lrp3em1Cya/\Lrp3em1Cya
(C57BL/6N-Lrp3em1Cya/Cya)
increased susceptibility to induced arthritis J:345338
osteoarthritis J:345338
\Lrp5tm1Grw/\Lrp5tm1Grw
(involves: 129S1/Sv * 129X1/SvJ)
decreased osteoclast cell number J:104382
\Lrp6tm1Arma/\Lrp6tm1Arma
(C57BL/6-Lrp6tm1Arma)
liver inflammation J:225450
\Lrp12em1Gpt/\Lrp12em1Gpt
\Tg(Cd4-cre)1Cwi/0

(involves: C57BL/6 * C57BL/6JGpt * DBA/2)
abnormal CD4-positive, alpha-beta T cell physiology J:338432
enhanced leukocyte migration J:338432
immune system phenotype J:338432
increased susceptibility to induced colitis J:338432
increased T cell number J:338432
\Lrrc3tm1b(EUCOMM)Hmgu/\Lrrc3tm1b(EUCOMM)Hmgu
(C57BL/6N-Lrrc3tm1b(EUCOMM)Hmgu/Ics)
decreased lymphocyte cell number J:211773
\Lrrc4ctm1Lex/\Lrrc4ctm1Lex
(involves: 129S5/SvEvBrd * C57BL/6J)
increased circulating interleukin-6 level J:171883
\Lrrc8atm1.1Geha/\Lrrc8atm1.1Geha
(B6.129S1(Cg)-Lrrc8atm1.1Geha)
abnormal B cell differentiation J:211308
abnormal T cell differentiation J:211308
abnormal T cell physiology J:211308
abnormal T cell selection J:211308
abnormal thymus apoptosis J:211308
abnormal thymus medulla morphology J:211308
abnormal thymus morphology J:211308
abnormal thymus physiology J:211308
absent thymus corticomedullary boundary J:211308
decreased B cell number J:211308
decreased CD4-positive, alpha-beta T cell number J:211308
decreased CD8-positive, alpha-beta T cell number J:211308
decreased DN2 thymocyte number J:211308
decreased DN3 thymocyte number J:211308
decreased DN4 thymocyte number J:211308
decreased double-negative T cell number J:211308
decreased double-positive T cell number J:211308
decreased immature B cell number J:211308
decreased marginal zone B cell number J:211308
decreased pre-B cell number J:211308
decreased T cell number J:211308
decreased T cell proliferation J:211308
decreased thymocyte number J:211308
decreased transitional stage B cell number J:211308
increased IgG2a level J:211308
increased pro-B cell number J:211308
increased regulatory T cell number J:211308
increased thymocyte apoptosis J:211308
small spleen J:211308
small thymus J:211308
small thymus cortex J:211308
thymus hypoplasia J:211308
\Lrrc8bem1Bcgen/\Lrrc8bem1Bcgen
(C57BL/6N-Lrrc8bem1Bcgen)
immune system phenotype J:288504
\Lrrc8cem1(IMPC)Mbp/\Lrrc8cem1(IMPC)Mbp
(C57BL/6N-Lrrc8cem1(IMPC)Mbp/MbpMmucd)
abnormal spleen morphology J:211773
\Lrrc8dem1Bcgen/\Lrrc8dem1Bcgen
(C57BL/6N-Lrrc8dem1Bcgen)
immune system phenotype J:288504
\Lrrc8eem1Bcgen/\Lrrc8eem1Bcgen
(C57BL/6N-Lrrc8eem1Bcgen)
abnormal circulating cytokine level J:288504
decreased circulating interferon-beta level J:288504
decreased circulating tumor necrosis factor level J:288504
decreased interferon-beta secretion J:288504
increased susceptibility to viral infection J:288504
increased susceptibility to viral infection induced morbidity/mortality J:288504
\Lrrc17em1(IMPC)Ccpcz/\Lrrc17em1(IMPC)Ccpcz
(C57BL/6N-Lrrc17em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged spleen J:211773
enlarged thymus J:211773
\Lrrc17tm1Nik/\Lrrc17+
\Nf1tm1Par/\Nf1tm1Par
\Srpk2tm1Nik/\Srpk2+
\Tg(Mx1-cre)1Cgn/0

(involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA)
increased leukocyte cell number J:161558
\Lrrc19tm1Ryag/\Lrrc19tm1Ryag
(involves: C57BL/6J * C57BL/6NTac)
decreased circulating interleukin-6 level J:271376
decreased circulating tumor necrosis factor level J:271376
increased susceptibility to bacterial infection J:271376
\Lrrc25em1Cya/\Lrrc25em1Cya
(C57BL/6J-Lrrc25em1Cya/Cya)
abnormal tumor necrosis factor level J:270157
heart inflammation J:270157
\Lrrc30em1(IMPC)Rbrc/\Lrrc30em1(IMPC)Rbrc
(C57BL/6NJcl-Lrrc30em1(IMPC)Rbrc/Rbrc)
abnormal lymph node morphology J:211773
enlarged lymph nodes J:211773
\Lrrc32tm1.1Hfuj/\Lrrc32tm1.1Hfuj
\Tg(Cd4-cre)1Cwi/0

(involves: 129S6/SvEvTac * C57BL/6 * C57BL/6NTac * DBA/2)
abnormal regulatory T cell physiology J:204761
immune system phenotype J:204761
\Lrrc55osem1Caox/\Lrrc55osem1Caox
(C57BL/6-Lrrc55osem1Caox)
decreased circulating interferon-beta level J:293325
immune system phenotype J:293325
increased susceptibility to Riboviria infection J:293325
increased susceptibility to Riboviria infection induced morbidity/mortality J:293325
\Lrrc56em1(IMPC)Tcp/\Lrrc56em1(IMPC)Tcp
(C57BL/6N-Lrrc56em1(IMPC)Tcp/Tcp)
enlarged lymph nodes J:211773
\Lrrk1tm1.1Smo/\Lrrk1tm1.1Smo
(involves: 129S/Sv)
abnormal osteoclast physiology J:208677
increased osteoclast cell number J:208677
\Lrrk1tm1b(KOMP)Wtsi/\Lrrk1tm1b(KOMP)Wtsi
(C57BL/6N-Lrrk1tm1b(KOMP)Wtsi/H)
decreased eosinophil cell number J:211773
decreased leukocyte cell number J:211773
decreased lymphocyte cell number J:211773
increased neutrophil cell number J:211773
increased spleen weight J:211773
\Lrrk2tm1.1Cai/\Lrrk2+
\Tg(Camk2a-tTA)1Mmay/0
\Tg(tetO-SNCA*A53T)E2Cai/0

(involves: 129X1/SvJ * C57BL/6)
microgliosis J:156512
\Lrrk2tm1.1Cai/\Lrrk2tm1.1Cai
(involves: 129X1/SvJ * C57BL/6)
microgliosis J:156512
\Lrrk2tm2.1Shn/\Lrrk2tm2.1Shn
(involves: 129 * C57BL/6)
kidney inflammation J:160542
\Lrrtm1em1(IMPC)Mbp/\Lrrtm1em1(IMPC)Mbp
(C57BL/6N-Lrrtm1em1(IMPC)Mbp/Ucd)
increased monocyte cell number J:211773
\Lrrtm2em1(IMPC)Mbp/\Lrrtm2em1(IMPC)Mbp
(C57BL/6N-Lrrtm2em1(IMPC)Mbp/MbpMmucd)
abnormal lymph node morphology J:211773
abnormal spleen morphology J:211773
enlarged lymph nodes J:211773
enlarged spleen J:211773
\Lse/\Lse+
(B6C3Fe a/a-Lse/J)
keratoconjunctivitis sicca J:338204
\Lsm3em1Caox/\Lsm3em1Caox
(involves: C57BL/6J)
decreased susceptibility to Orthomyxoviridae infection J:262834
decreased susceptibility to Riboviria infection J:262834
decreased susceptibility to Riboviria infection induced morbidity/mortality J:262834
increased circulating interferon-alpha level J:262834
increased circulating interferon-beta level J:262834
increased circulating interleukin-6 level J:262834
\Lsm8em1(IMPC)Mbp/\Lsm8+
(C57BL/6N-Lsm8em1(IMPC)Mbp/MbpMmucd)
abnormal lymph node morphology J:211773
enlarged lymph nodes J:211773
\Lsm14atm1b(KOMP)Wtsi/\Lsm14a+
(C57BL/6N-Lsm14atm1b(KOMP)Wtsi/Nju)
increased basophil cell number J:211773
\Lsp1tm1Jejb/\Lsp1tm1Jejb
(involves: 129S1/Sv * 129X1/SvJ)
abnormal cellular extravasation J:96022
abnormal immune system morphology J:64219
abnormal leukocyte physiology J:68128
abnormal lymphopoiesis J:64219
impaired neutrophil chemotaxis J:68128
increased macrophage cell number J:64219
\Lsr1A/J/?
(involves: A/J * C57BL/6J)
increased susceptibility to bacterial infection J:7345
\Lsr1C57BL/6J/?
(involves: A/J * C57BL/6J)
decreased susceptibility to bacterial infection J:7345
\Lsstm1b(KOMP)Wtsi/\Lss+
(C57BL/6N-Lsstm1b(KOMP)Wtsi/Ieg)
increased leukocyte cell number J:211773
\Lst1tm1(KOMP)Vlcg/\Lst1tm1(KOMP)Vlcg
(C57BL/6N-Lst1tm1(KOMP)Vlcg)
immune system phenotype J:235700
increased susceptibility to Orthomyxoviridae infection J:235700
increased susceptibility to Orthomyxoviridae infection induced morbidity/mortality J:235700
\Lta4htm1Bhk/\Lta4htm1Bhk
(involves: 129P2/OlaHsd * 129S/SvEv)
decreased acute inflammation J:58985
decreased susceptibility to type I hypersensitivity reaction J:58985
\Lta/Tnftm1Eug/\Lta/Tnftm1Eug
(involves: 129)
abnormal humoral immune response J:31129
abnormal spleen marginal zone morphology J:31129
abnormal spleen morphology J:31129
absent lymph nodes J:31129
absent Peyer's patches J:31129
decreased IgA level J:31129
decreased T cell number J:31129
increased B cell number J:31129
increased leukocyte cell number J:31129
increased susceptibility to parasitic infection J:31129
increased susceptibility to Poxviridae infection J:31129
increased susceptibility to Riboviria infection J:31129
\Lta/Tnftm1Eug/\Lta/Tnftm1Eug
(involves: 129/Sv * C57BL/6)
decreased susceptibility to experimental autoimmune encephalomyelitis J:115225
decreased susceptibility to parasitic infection J:37696
\Lta/Tnftm1Eug/\Lta/Tnftm1Eug
(B6.129-Lta/Tnftm1Eug)
decreased circulating interferon-gamma level J:115034
decreased IgG1 level J:115034
decreased IgG2a level J:115034
decreased IgG3 level J:115034
decreased interferon-gamma secretion J:115034
decreased susceptibility to induced arthritis J:115034
impaired macrophage phagocytosis J:115034
increased IgM level J:115034
increased susceptibility to bacterial infection J:115034
increased susceptibility to bacterial infection induced morbidity/mortality J:115034
\Lta/Tnftm1Eug/\Lta/Tnftm1Eug
(involves: 129 * C57BL/6J)
increased spleen weight J:112797
\Lta/Tnftm1Eug/\Lta/Tnftm1Eug
(involves: 129)
abnormal humoral immune response J:31129
abnormal spleen marginal zone morphology J:31129
abnormal spleen morphology J:31129
absent lymph nodes J:31129
absent Peyer's patches J:31129
decreased IgA level J:31129
decreased T cell number J:31129
increased B cell number J:31129
increased leukocyte cell number J:31129
increased susceptibility to bacterial infection J:31129
increased susceptibility to Poxviridae infection J:31129
increased susceptibility to Riboviria infection J:31129
\Lta/Tnftm1Eug/\Lta/Tnftm1Eug
(involves: 129/Sv * C57BL/6)
decreased susceptibility to experimental autoimmune encephalomyelitis J:115225
decreased susceptibility to parasitic infection J:37696
\Lta/Tnftm1Eug/\Lta/Tnftm1Eug
(B6.129-Lta/Tnftm1Eug)
decreased circulating interferon-gamma level J:115034
decreased IgG1 level J:115034
decreased IgG2a level J:115034
decreased IgG3 level J:115034
decreased interferon-gamma secretion J:115034
decreased susceptibility to induced arthritis J:115034
impaired macrophage phagocytosis J:115034
increased IgM level J:115034
increased susceptibility to bacterial infection J:115034
increased susceptibility to bacterial infection induced morbidity/mortality J:115034
\Lta/Tnftm1Eug/\Lta/Tnftm1Eug
(involves: 129 * C57BL/6J)
increased spleen weight J:112797
\Lta/Tnftm1Fda/\Lta/Tnftm1Fda
(involves: 129S1/Sv * 129X1/SvJ)
decreased susceptibility to endotoxin shock J:39519
decreased tumor necrosis factor secretion J:39519
increased susceptibility to bacterial infection J:39519
\Lta/Tnftm1Fda/\Lta+
(involves: 129S1/Sv * 129X1/SvJ)
decreased susceptibility to endotoxin shock J:39519
decreased tumor necrosis factor secretion J:39519
increased susceptibility to bacterial infection J:39519
\Lta/Tnftm1Fda/\Lta/Tnftm1Fda
(involves: 129S1/Sv * 129X1/SvJ)
decreased susceptibility to endotoxin shock J:39519
decreased tumor necrosis factor secretion J:39519
increased susceptibility to bacterial infection J:39519
\Lta/Tnftm1Fda/\Tnf+
(involves: 129S1/Sv * 129X1/SvJ)
decreased susceptibility to endotoxin shock J:39519
decreased tumor necrosis factor secretion J:39519
increased susceptibility to bacterial infection J:39519
\Lta/Tnftm1Jods/\Lta/Tnftm1Jods
(C57BL/6J-Lta/Tnftm1Jods)
abnormal spleen morphology J:43602
abnormal spleen white pulp morphology J:43602
absent lymph nodes J:43602
absent Peyer's patches J:43602
decreased immunoglobulin level J:43602
enlarged spleen J:43602
increased leukocyte cell number J:43602
\Lta/Tnftm1Jods/\Lta/Tnftm1Jods
(C57BL/6-Lta/Tnftm1Jods)
abnormal spleen white pulp morphology J:78229
decreased susceptibility to experimental autoimmune encephalomyelitis J:47428
\Lta/Tnftm1Jods/\Lta/Tnftm1Jods
(involves: C57BL/6)
abnormal gamma-delta T cell morphology J:169863
\Lta/Tnftm1Jods/\Lta/Tnftm1Jods
(C57BL/6J-Lta/Tnftm1Jods)
abnormal spleen morphology J:43602
absent lymph nodes J:43602
absent Peyer's patches J:43602
decreased immunoglobulin level J:43602
enlarged spleen J:43602
increased leukocyte cell number J:43602
\Lta/Tnftm1Jods/\Lta/Tnftm1Jods
(C57BL/6-Lta/Tnftm1Jods)
abnormal spleen white pulp morphology J:78229
decreased susceptibility to experimental autoimmune encephalomyelitis J:47428
\Lta/Tnftm1Jods/\Lta/Tnftm1Jods
(involves: C57BL/6)
abnormal gamma-delta T cell morphology J:169863
\Ltahlb382/\Ltahlb382
(C57BL/6J-Ltahlb382/J)
abnormal immune system organ morphology J:134498
absent lymph nodes J:134498
absent marginal zone B cells J:134498
absent mesenteric lymph nodes J:134498
absent Peyer's patches J:134498
absent spleen germinal center J:134498
absent spleen marginal zone J:134498
decreased NK cell number J:134498
decreased transitional stage B cell number J:134498
increased B-1b cell number J:134498
increased leukocyte cell number J:82961
liver inflammation J:134498
lung inflammation J:134498
\Ltatm1.1(KOMP)Vlcg/\Ltatm1.1(KOMP)Vlcg
(C57BL/6N-Ltatm1.1(KOMP)Vlcg/Ucd)
decreased monocyte cell number J:211773
increased eosinophil cell number J:211773
increased leukocyte cell number J:211773
increased lymphocyte cell number J:211773
increased neutrophil cell number J:211773
\Ltatm1.1Sned/\Ltatm1.1Sned
(B6.129-Ltatm1.1Sned)
abnormal circulating tumor necrosis factor level J:109621
abnormal class switch recombination J:109621
abnormal humoral immune response J:109621
abnormal immune system morphology J:109621
abnormal lymphopoiesis J:109621
absent Peyer's patches J:109621
decreased spleen white pulp amount J:109621
enlarged spleen J:109621
increased susceptibility to bacterial infection induced morbidity/mortality J:109621
\Ltatm1Dch/\Ltatm1Dch
(B6.129S2-Ltatm1Dch)
abnormal class switch recombination J:80616
abnormal cytokine secretion J:95222
abnormal immune serum protein physiology J:80616
abnormal mucosa-associated lymphoid tissue morphology J:95222
abnormal spleen morphology J:80616
absent Peyer's patches J:80616
absent spleen germinal center J:80616
absent spleen marginal zone J:80616
decreased IgG level J:80616
decreased spleen B cell follicle number J:80616
decreased spleen white pulp amount J:80616
increased IgM level J:80616
increased leukocyte cell number J:80616
\Ltatm1Dch/\Ltatm1Dch
(involves: 129S2/SvPas * C57BL/6)
abnormal class switch recombination J:109621
abnormal humoral immune response J:39746
abnormal leukocyte cell number J:17976
abnormal lymph node morphology J:17976
abnormal lymph node primary follicle morphology J:109621
abnormal spleen morphology J:17976, J:39746
abnormal spleen periarteriolar lymphoid sheath morphology J:17976
absent axillary lymph nodes J:17976
absent cervical lymph nodes J:17976
absent inguinal lymph nodes J:17976
absent mesenteric lymph nodes J:17976, J:39746
absent Peyer's patches J:17976
absent popliteal lymph nodes J:17976
absent spleen marginal zone J:17976
decreased interferon-gamma secretion J:109621
decreased spleen white pulp amount J:109621
decreased T cell number J:17976
decreased tumor necrosis factor secretion J:109621
increased B cell number J:17976
increased leukocyte cell number J:17976
\Ltatm1Dch/\Ltatm1Dch
(B6.129S2-Ltatm1Dch/J)
abnormal lymph organ development J:73100
\Ltatm1Dch/\Ltatm1Dch
(involves: 129S2/SvPas)
abnormal lymphocyte morphology J:173115
abnormal thymus epithelium morphology J:173115
abnormal thymus medulla morphology J:173115
small thymus medulla J:173115
\Ltatm1Dch/\Ltatm1Dch
\Rorctm2Litt/\Rorc+

(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6)
abnormal gut-associated lymphoid tissue morphology J:91566
\Ltatm1Dch/\Ltatm1Dch
\Tg(Igk-Lta/Ltb)4Cys/0

(involves: 129S2/SvPas * C57BL/6J * DBA/2J)
abnormal lymph organ development J:73100
abnormal spleen morphology J:73100
immune system phenotype J:73100
\Ltatm1Dch/\Ltatm1Dch
\Tnfsf14tm1Lpc/\Tnfsf14tm1Lpc

(involves: 129S2/SvPas * 129X1/SvJ)
abnormal lymphocyte morphology J:173115
abnormal thymus epithelium morphology J:173115
small thymus medulla J:173115
\Ltatm1Jods/\Ltatm1Jods
(C57BL/6-Ltatm1Jods)
abnormal immune system organ morphology J:47428
abnormal spleen morphology J:47428
abnormal spleen white pulp morphology J:78229
absent peripheral lymph nodes J:47428
absent Peyer's patches J:47428
increased lymphocyte cell number J:47428
\Ltatm1Jods/\Ltatm1Jods
(involves: C57BL/6)
abnormal thymus epithelium morphology J:125864
\Ltatm1Tab/\Ltatm1Tab
(either: (involves: 129S2/SvPas * C57BL/6J) or (involves: 129S2/SvPas * CF-1))
abnormal humoral immune response J:28061
absent lymph nodes J:28061
absent Peyer's patches J:28061
absent spleen marginal zone J:28061
decreased IgA level J:28061
decreased spleen white pulp amount J:28061
increased IgM level J:28061
increased leukocyte cell number J:28061
increased spleen weight J:28061
\Ltatm1Tab/\Ltatm1Tab
(involves: 129S2/SvPas * C57BL/6)
decreased tumor necrosis factor secretion J:109621
\Ltatm1Tab/\Ltatm1Tab
(B6.129S2-Ltatm1Tab)
decreased susceptibility to parasitic infection J:121070
\Ltb4r1tm1Adl/\Ltb4r1tm1Adl
(involves: 129S4/SvJae * C57BL/6)
abnormal leukocyte adhesion J:63873
abnormal leukocyte migration J:63873
abnormal macrophage physiology J:63873
abnormal neutrophil physiology J:63873
impaired eosinophil recruitment J:63873
impaired neutrophil chemotaxis J:63873
\Ltb4r1tm1Bodd/\Ltb4r1tm1Bodd
(involves: 129S4/SvJaeSor * C57BL/6)
decreased susceptibility to autoimmune disorder J:108446
\Ltb4r1tm1Bodd/\Ltb4r1tm1Bodd
(involves: 129S4/SvJaeSor)
decreased susceptibility to induced arthritis J:131779
\Ltb4r1tm1Bodd/\Ltb4r1tm1Bodd
(either: (involves: 129S4/SvJaeSor * BALB/c ) or (involves: 129S4/SvJaeSor * C57BL/6))
decreased susceptibility to induced arthritis J:163271
impaired neutrophil chemotaxis J:163271
\Ltb4r1tm1Tksh/\Ltb4r1tm1Tksh
(B6.Cg-Ltb4r1tm1Tksh)
abnormal cytokine secretion J:118995
decreased eosinophil cell number J:118995
decreased IgE level J:118995
decreased susceptibility to type I hypersensitivity reaction J:197334
lung inflammation J:118995
\Ltb4r1tm1Tksh/\Ltb4r1tm1Tksh
(C.Cg-Ltb4r1tm1Tksh)
abnormal mast cell physiology J:133998
\Ltb4r1tm1Tksh/\Ltb4r1tm1Tksh
(involves: C57BL/6 * C57BL/6NCrlj * CBA/JNCrlj)
abnormal granulocyte physiology J:118995
\Ltb4r2tm1Bodd/\Ltb4r2tm1Bodd
(involves: 129S4/SvJaeSor * C57BL/6)
decreased susceptibility to induced arthritis J:163271
immune system phenotype J:163271
\Ltb4r2tm1Tksh/\Ltb4r2tm1Tksh
(C.Cg-Ltb4r2tm1Tksh)
abnormal mast cell physiology J:133998
\Ltb4r2tm1Tksh/\Ltb4r2tm1Tksh
(B6.Cg-Ltb4r2tm1Tksh)
decreased susceptibility to type I hypersensitivity reaction J:197334
\Ltb/Tnf/Ltatm1Dvk/\Ltb/Tnf/Ltatm1Dvk
(involves: C57BL/6)
decreased spleen white pulp amount J:109621
\Ltb/Tnf/Ltatm1Dvk/\Ltb/Tnf/Ltatm1Dvk
(B6.Cg-Ltb/Tnf/Ltatm1Dvk)
abnormal class switch recombination J:80616
abnormal spleen morphology J:80616
absent axillary lymph nodes J:80616
absent brachial lymph nodes J:80616
absent inguinal lymph nodes J:80616
absent lymph nodes J:80616
absent mesenteric lymph nodes J:80616
absent Peyer's patches J:80616
absent popliteal lymph nodes J:80616
absent spleen germinal center J:80616
absent spleen marginal zone J:80616
decreased IgG level J:80616
decreased spleen B cell follicle number J:80616
decreased spleen white pulp amount J:80616
increased leukocyte cell number J:80616
increased susceptibility to bacterial infection J:80616
\Ltb/Tnf/Ltatm1Dvk/\Ltb/Tnf/Ltatm1Dvk
(involves: C57BL/6)
decreased spleen white pulp amount J:109621
\Ltb/Tnf/Ltatm1Dvk/\Ltb/Tnf/Ltatm1Dvk
(B6.Cg-Ltb/Tnf/Ltatm1Dvk)
abnormal class switch recombination J:80616
abnormal spleen morphology J:80616
absent axillary lymph nodes J:80616
absent brachial lymph nodes J:80616
absent inguinal lymph nodes J:80616
absent lymph nodes J:80616
absent mesenteric lymph nodes J:80616
absent Peyer's patches J:80616
absent popliteal lymph nodes J:80616
absent spleen germinal center J:80616
absent spleen marginal zone J:80616
decreased IgG level J:80616
decreased spleen B cell follicle number J:80616
decreased spleen white pulp amount J:80616
increased leukocyte cell number J:80616
increased susceptibility to bacterial infection J:80616
\Ltb/Tnf/Ltatm1Dvk/\Ltb/Tnf/Ltatm1Dvk
(involves: C57BL/6)
decreased spleen white pulp amount J:109621
\Ltb/Tnf/Ltatm1Dvk/\Ltb/Tnf/Ltatm1Dvk
(B6.Cg-Ltb/Tnf/Ltatm1Dvk)
abnormal class switch recombination J:80616
abnormal spleen morphology J:80616
absent axillary lymph nodes J:80616
absent brachial lymph nodes J:80616
absent inguinal lymph nodes J:80616
absent lymph nodes J:80616
absent mesenteric lymph nodes J:80616
absent Peyer's patches J:80616
absent popliteal lymph nodes J:80616
absent spleen germinal center J:80616
absent spleen marginal zone J:80616
decreased IgG level J:80616
decreased spleen B cell follicle number J:80616
decreased spleen white pulp amount J:80616
increased leukocyte cell number J:80616
increased susceptibility to bacterial infection J:80616
\Ltb/Tnftm1.1Dvk/\Ltb/Tnftm1.1Dvk
(involves: 129P2/OlaHsd * BALB/cJ * C57BL/6)
abnormal mesenteric lymph node morphology J:58981
abnormal spleen morphology J:58981
absent axillary lymph nodes J:58981
absent brachial lymph nodes J:58981
absent cervical lymph nodes J:58981
absent follicular dendritic cells J:58981
absent germinal center B cells J:58981
absent inguinal lymph nodes J:58981
absent peripheral lymph nodes J:58981
absent Peyer's patches J:58981
absent popliteal lymph nodes J:58981
absent spleen marginal zone J:58981
intermingled spleen red and white pulp J:58981
\Ltb/Tnftm1.1Dvk/\Ltb/Tnftm1.1Dvk
(involves: 129P2/OlaHsd * BALB/cJ * C57BL/6)
abnormal mesenteric lymph node morphology J:58981
abnormal spleen morphology J:58981
absent axillary lymph nodes J:58981
absent brachial lymph nodes J:58981
absent cervical lymph nodes J:58981
absent follicular dendritic cells J:58981
absent germinal center B cells J:58981
absent inguinal lymph nodes J:58981
absent peripheral lymph nodes J:58981
absent Peyer's patches J:58981
absent popliteal lymph nodes J:58981
absent spleen marginal zone J:58981
intermingled spleen red and white pulp J:58981
\Ltbtm1Flv/\Ltbtm1Flv
(involves: 129S1/Sv * C57BL/6J)
abnormal humoral immune response J:39746
abnormal mesenteric lymph node morphology J:39746
abnormal spleen morphology J:39746
abnormal spleen red pulp morphology J:39746
abnormal spleen white pulp morphology J:39746
absent peripheral lymph nodes J:39746
absent Peyer's patches J:39746
decreased IgA level J:39746
\Ltbtm1Kpf/\Ltbtm1Kpf
(B6.129P2-Ltbtm1Kpf)
abnormal class switch recombination J:80616
abnormal spleen morphology J:80616
absent spleen marginal zone J:80616
colitis J:158663
decreased IgG level J:80616
decreased spleen B cell follicle number J:80616
decreased spleen white pulp amount J:80616
increased IgM level J:80616
increased leukocyte cell number J:80616
increased susceptibility to bacterial infection J:80616, J:158663
increased susceptibility to bacterial infection induced morbidity/mortality J:158663
\Ltbtm1Kpf/\Ltbtm1Kpf
(involves: 129P2/OlaHsd * C57BL/6)
abnormal mesenteric lymph node morphology J:58981, J:42508
abnormal spleen follicular dendritic cell network J:42508
abnormal spleen germinal center morphology J:42508
abnormal spleen marginal zone morphology J:42508
abnormal spleen morphology J:58981, J:42508
abnormal spleen red pulp morphology J:42508
absent axillary lymph nodes J:42508
absent brachial lymph nodes J:42508
absent cervical lymph nodes J:58981
absent follicular dendritic cells J:58981
absent inguinal lymph nodes J:42508
absent Peyer's patches J:42508
absent popliteal lymph nodes J:42508
absent spleen marginal zone J:58981
decreased spleen white pulp amount J:109621
increased lymphocyte cell number J:42508
\Ltbtm1Kpf/\Ltbtm1Kpf
\Tnfsf14tm1Kpf/\Tnfsf14tm1Kpf

(involves: 129P2/OlaHsd * C57BL/6)
abnormal mesenteric lymph node morphology J:77250
abnormal spleen morphology J:77250
absent axillary lymph nodes J:77250
absent brachial lymph nodes J:77250
absent inguinal lymph nodes J:77250
absent lymph nodes J:77250
absent Peyer's patches J:77250
absent popliteal lymph nodes J:77250
\Ltbtm1Krn/\Ltbtm1Krn
(C57BL/6-Ltbtm1Krn)
abnormal humoral immune response J:78229
abnormal mesenteric lymph node morphology J:78229
abnormal spleen morphology J:78229
absent cervical lymph nodes J:78229
absent peripheral lymph nodes J:78229
absent Peyer's patches J:78229
decreased IgG1 level J:78229
decreased IgG2a level J:78229
increased IgM level J:78229
increased susceptibility to parasitic infection J:78229
spleen hyperplasia J:78229
\Ltbp1tm1a(EUCOMM)Wtsi/\Ltbp1+
(B6JTyr;B6N-Ltbp1tm1a(EUCOMM)Wtsi/Wtsi)
increased leukocyte cell number J:175295
\Ltbp3em1(IMPC)Ccpcz/\Ltbp3+
(C57BL/6NCrl-Ltbp3em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
\Ltbp3tm1Bdvc/\Ltbp3tm1Bdvc
(involves: 129S6/SvEvTac)
osteoarthritis J:76213, J:79920
\Ltbp4em1(IMPC)Tcp/\Ltbp4em1(IMPC)Tcp
(C57BL/6NCrl-Ltbp4em1(IMPC)Tcp/Tcp)
decreased basophil cell number J:211773
enlarged spleen J:211773
increased monocyte cell number J:211773
\Ltbp4Gt(U3Cre)1Vmel/\Ltbp4Gt(U3Cre)1Vmel
(B6.129S2-Ltbp4Gt(U3Cre)1Vmel)
colitis J:78819
enlarged spleen J:78819
proctitis J:78819
\Ltbrm1Btlr/\Ltbrm1Btlr
(C57BL/6J-Ltbrm1Btlr)
abnormal B cell physiology J:212068
abnormal humoral immune response J:212068
\Ltbrm2Btlr/\Ltbrm2Btlr
(C57BL/6J-Ltbrm2Btlr)
abnormal humoral immune response J:254823
abnormal IgG level J:254823
\Ltbrm3Btlr/\Ltbrm3Btlr
(C57BL/6J-Ltbrm3Btlr)
impaired natural killer cell mediated cytotoxicity J:264642
increased NK T cell number J:264642
\Ltbrm4Btlr/\Ltbrm4Btlr
(C57BL/6J-Ltbrm4Btlr)
decreased alpha-beta T cell number J:264820
decreased CD4-positive, alpha-beta T cell number J:264820
decreased CD8-positive, alpha-beta T cell number J:264820
decreased NK cell number J:264820
decreased single-positive T cell number J:264820
increased B cell number J:264820
increased B-1 B cell number J:264820
\Ltbrtm1.1Thhe/\Ltbrtm1.1Thhe
\Lyz2tm1(cre)Ifo/\Lyz2+

(involves: 129P2/OlaHsd * C57BL/6 * SJL)
abnormal macrophage physiology J:183109
\Ltbrtm1Avt/\Ltbrtm1Avt
\Lyz2tm1(cre)Ifo/\Lyz2+

(involves: 129P2/OlaHsd)
increased susceptibility to bacterial infection J:158663
\Ltbrtm1Avt/\Ltbrtm1Avt
\Tg(Lck-cre)I57Jxm/0

(Not Specified)
immune system phenotype J:158663
\Ltbrtm1Avt/\Ltbrtm1Avt
\Tg(Rorc-cre)1Litt/0

(Not Specified)
abnormal chemokine level J:158663
decreased neutrophil cell number J:158663
increased susceptibility to bacterial infection J:158663
increased susceptibility to bacterial infection induced morbidity/mortality J:158663
\Ltbrtm1Avt/\Ltbrtm1Avt
\Tg(Vil1-cre)997Gum/0

(involves: C57BL/6J * SJL)
decreased neutrophil cell number J:158663
increased susceptibility to bacterial infection J:158663
\Ltbrtm1Kpf/\Ltbrtm1Kpf
(involves: 129P2/OlaHsd)
abnormal gamma-delta T cell morphology J:169863
abnormal immune system morphology J:48837
abnormal immune system organ morphology J:48837
abnormal immune system physiology J:48837
abnormal spleen B cell follicle morphology J:48837
abnormal spleen morphology J:48837
abnormal spleen periarteriolar lymphoid sheath morphology J:48837
absent marginal zone B cells J:48837
absent peripheral lymph nodes J:48837
absent Peyer's patches J:48837
decreased IgE level J:86810
decreased interleukin-17 secretion J:169863
enlarged spleen J:48837
immune system phenotype J:169863
increased B cell number J:48837
increased lymphocyte cell number J:48837
increased T cell number J:48837
\Ltbrtm1Kpf/\Ltbrtm1Kpf
(involves: 129P2/OlaHsd * C57BL/6)
decreased spleen white pulp amount J:109621
\Ltbrtm1Kpf/\Ltbrtm1Kpf
(B6.129P2-Ltbrtm1Kpf)
decreased neutrophil cell number J:158663
\Ltbrtm1Kpf/\Ltbrtm1Kpf
\Tg(Lck-Tnfsf14)24Yxf/?

(B6.Cg-Ltbrtm1Kpf Tg(Lck-Tnfsf14)24Yxf)
immune system phenotype J:128976
\Ltbrtm1Mmat/\Ltbrtm1Mmat
(involves: C57BL/6 * CBA)
abnormal lymphocyte morphology J:173115
abnormal spleen morphology J:173115
abnormal thymus epithelium morphology J:173115
abnormal thymus medulla morphology J:173115
absent follicular dendritic cells J:173115
absent mesenteric lymph nodes J:173115
absent spleen germinal center J:173115
small thymus medulla J:173115
\Ltbrtm1Mmat/\Ltbrtm1Mmat
\Tnfsf11tm1Pngr/\Tnfsf11tm1Pngr

(involves: 129P2/OlaHsd * C57BL/6 * CBA)
abnormal thymus epithelium morphology J:173115
\Ltc4stm1Blam/\Ltc4stm1Blam
(involves: 129S7/SvEvBrd * C57BL/6)
immune system phenotype J:110309
respiratory system inflammation J:88647
\Ltc4stm1Blam/\Ltc4stm1Blam
(involves: 129S7/SvEvBrd * BALB/c)
abnormal hypersensitivity reaction J:87909
abnormal type I hypersensitivity reaction J:87909
\Ltc4stm1Blam/\Ltc4stm1Blam
(C.129S7-Ltc4stm1Blam)
autoimmune response J:182213
\Ltc4stm1Blam/\Ltc4stm1Blam
(B6.129S7-Ltc4stm1Blam)
decreased susceptibility to type I hypersensitivity reaction J:197334
\Ltftm1Omc/\Ltftm1Omc
(either: 129S/SvEv or (involves: 129S/SvEv * C57BL/6))
decreased spleen iron level J:81005
\Ltn1tm1b(EUCOMM)Hmgu/\Ltn1tm1b(EUCOMM)Hmgu
(C57BL/6N-Ltn1tm1b(EUCOMM)Hmgu/Ccpcz)
increased CD4-positive, CD25-positive, alpha-beta regulatory T cell number J:211773
\Ltv1em1(IMPC)J/\Ltv1+
(C57BL/6NJ-Ltv1em1(IMPC)J/Mmjax)
decreased leukocyte cell number J:211773
\Ltxs2BALB/cAnPt/\Ltxs2DBA/2NCr
(involves: BALB/cAnPt * DBA/2NCr)
decreased susceptibility to infection J:103336
\Ltxs2DBA/2NCr/\Ltxs2DBA/2NCr
(involves: BALB/cAnPt * DBA/2NCr)
decreased susceptibility to infection J:103336
\Ltxs3BALB/cAnPt/\Ltxs3DBA/2NCr
(involves: BALB/cAnPt * DBA/2NCr)
decreased susceptibility to infection J:103336
\Ltxs3DBA/2NCr/\Ltxs3DBA/2NCr
(involves: BALB/cAnPt * DBA/2NCr)
decreased susceptibility to infection J:103336
\Luc7lem1(IMPC)Mbp/\Luc7lem1(IMPC)Mbp
(C57BL/6N-Luc7lem1(IMPC)Mbp/MbpMmucd)
abnormal spleen morphology J:211773
enlarged lymph nodes J:211773
enlarged spleen J:211773
\Lumtm1Wwk/\Lumtm1Wwk
(involves: 129P2/OlaHsd)
abnormal inflammatory response J:128992
decreased neutrophil cell number J:128992
\Lxw1BXSB/Scr/?
(involves: BXSB/Scr * NZW/LacScr)
increased anti-chromatin antibody level J:86924
\Lxw2NZW/LacScr/\Lxw2NZW/LacScr
(involves: BXSB/Scr * NZW/LacScr)
glomerulonephritis J:86924
\Lxw3NZW/LacScr/?
(involves: BXSB/Scr * NZW/LacScr)
increased anti-chromatin antibody level J:86924
\Lxw5BXSB/Scr/\Lxw5BXSB/Scr
(involves: BXSB/Scr * NZW/LacScr)
enlarged spleen J:86924
\Lxw5NZW/LacScr/\Lxw5BXSB/Scr
(involves: BXSB/Scr * NZW/LacScr)
enlarged spleen J:86924
\Lxw6NZW/LacScr/\Lxw6NZW/LacScr
(involves: BXSB/Scr * NZW/LacScr)
enlarged spleen J:86924
\Ly6atm1Pmf/\Ly6atm1Pmf
(B6.129P2-Ly6atm1Pmf)
abnormal immunoglobulin level J:42594
abnormal myeloid leukocyte morphology J:81387
abnormal T cell proliferation J:42594
decreased granulocyte number J:81387
decreased monocyte cell number J:81387
increased lymphocyte cell number J:81387
\Ly6atm1Pmf/\Ly6atm1Pmf
(C.129P2-Ly6atm1Pmf)
abnormal osteoclast differentiation J:83409
decreased osteoclast cell number J:83409
\Ly6atm2(RUNX1)Grau/\Ly6a+
(involves: 129X1/SvJ * C57BL/6J)
abnormal spleen B cell follicle morphology J:93408
enlarged spleen J:93408
increased leukocyte cell number J:93408
increased neutrophil cell number J:93408
myeloid hyperplasia J:93408
\Ly6etm1c(EUCOMM)Hmgu/\Ly6etm1c(EUCOMM)Hmgu
\Commd10Tg(Vav1-icre)A2Kio/\Commd10+

(B6.Cg-Ly6etm1c(EUCOMM)Hmgu Commd10Tg(Vav1-icre)A2Kio)
abnormal mononuclear cell morphology J:291868
decreased B cell number J:291868
decreased CD4-positive, alpha-beta T cell number J:291868
decreased dendritic cell number J:291868
decreased inflammatory response J:291868
decreased macrophage cell number J:291868
decreased neutrophil cell number J:291868
decreased NK cell number J:291868
increased susceptibility to Coronaviridae infection J:291868
increased susceptibility to Coronaviridae infection induced morbidity/mortality J:291868
\Ly6gtm2621(cre)Arte/\Ly6gtm2621(cre)Arte
(involves: C57BL/6)
immune system phenotype J:227159
\Ly9tm1Mckn/\Ly9tm1Mckn
(involves: 129/Sv * C57BL/6)
abnormal cytokine secretion J:105482
abnormal T-helper 2 cell morphology J:105482
decreased T cell proliferation J:105482
\Ly75tm1Mnz/\Ly75tm1Mnz
(Not Specified)
abnormal CD8-positive, alpha beta T cell morphology J:97290
abnormal cytotoxic T cell physiology J:97289
\Ly86tm1a(KOMP)Wtsi/\Ly86+
(C57BL/6N-Ly86tm1a(KOMP)Wtsi/MbpMmucd)
increased leukocyte cell number J:211773
increased lymphocyte cell number J:211773
\Ly86tm1a(KOMP)Wtsi/\Ly86tm1a(KOMP)Wtsi
(C57BL/6N-Ly86tm1a(KOMP)Wtsi/MbpMmucd)
increased leukocyte cell number J:211773
increased lymphocyte cell number J:211773
\Ly86tm1Kmiy/\Ly86tm1Kmiy
(involves: 129P2/OlaHsd * C57BL/6)
decreased B cell proliferation J:109720
decreased IgG2b level J:137066
decreased IgG3 level J:137066
increased IgG level J:109720
increased IgM level J:109720
\Ly96m1Btlr/\Ly96m1Btlr
(C57BL/6J-Ly96m1Btlr)
decreased interleukin-1 beta secretion J:265259
decreased macrophage apoptosis J:265259
decreased tumor necrosis factor secretion J:265259
\Ly96tm1Kmiy/\Ly96tm1Kmiy
(involves: 129P2/OlaHsd * C57BL/6)
abnormal immune cell physiology J:92494
abnormal macrophage physiology J:92494
decreased B cell proliferation J:92494
decreased interleukin-6 secretion J:92494
decreased susceptibility to endotoxin shock J:92494
decreased tumor necrosis factor secretion J:92494
impaired neutrophil recruitment J:92479
increased susceptibility to bacterial infection J:92494
\LyarGt(RRG292)Byg/\LyarGt(RRG292)Byg
\Trp53tm1Tyj/\Trp53tm1Tyj

(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6)
increased T cell derived lymphoma incidence J:263530
\Lyg1tm1(KOMP)Vlcg/\Lyg1tm1(KOMP)Vlcg
(involves: C57BL/6NTac)
decreased CD4-positive, alpha-beta T cell number J:256594
decreased CD8-positive, alpha-beta T cell number J:256594
decreased interferon-gamma secretion J:256594
\Lyl1tm1Fsky/\Lyl1tm1Fsky
(involves: 129P2/OlaHsd * C57BL/6)
abnormal T cell differentiation J:116300
arrested B cell differentiation J:116300
decreased B cell number J:116300
decreased pro-B cell number J:116300
\Lynm1Anu/\Lynm1Anu
(C57BL/6JAnu-Lynm1Anu)
decreased B cell number J:195155
\LynM1Btlr/\Lyn+
(C57BL/6J-LynM1Btlr)
decreased B cell number J:214511
increased neutrophil cell number J:214511
\LynM1Btlr/\LynM1Btlr
(C57BL/6J-LynM1Btlr)
decreased B cell number J:214511
increased neutrophil cell number J:214511
\Lynm2Anu/\Lynm2Anu
(C57B/6JAnu-Lynm2Anu/AnuApb)
decreased mature B cell number J:104190
increased immature B cell number J:104190
\LynM2Btlr/\Lyn+
(C57BL/6J-LynM2Btlr)
decreased IgG level J:217146
decreased IgM level J:217146
impaired humoral immune response J:217146
\LynM2Btlr/\LynM2Btlr
(C57BL/6J-LynM2Btlr)
decreased IgG level J:217146
decreased IgM level J:217146
impaired humoral immune response J:217146
\LynM3Btlr/\Lyn+
(C57BL/6J-LynM3Btlr)
decreased T cell number J:236679
increased B-1 B cell number J:236679
increased dendritic cell number J:236679
increased macrophage cell number J:236679
\LynM3Btlr/\LynM3Btlr
(C57BL/6J-LynM3Btlr)
decreased T cell number J:236679
increased B-1 B cell number J:236679
increased dendritic cell number J:236679
increased macrophage cell number J:236679
\Lynm4Btlr/\Lynm4Btlr
(C57BL/6J-Lynm4Btlr)
decreased IgG level J:272816
impaired humoral immune response J:272816
\Lynmld4/\Lynmld4
(involves: C57BL/6)
abnormal B cell activation J:144799
abnormal B cell morphology J:144799
abnormal myelopoiesis J:144799
decreased follicular B cell number J:144799
decreased marginal zone B cell number J:144799
decreased transitional stage B cell number J:144799
glomerulonephritis J:144799
increased anti-double stranded DNA antibody level J:144799
increased IgE level J:144799
increased IgM level J:144799
increased macrophage cell number J:144799
increased neutrophil cell number J:144799
increased T cell number J:144799
peritoneal inflammation J:144799
spleen hypoplasia J:144799
\Lynmld4/\Lynmld4
\Mpltm1Wsa/\Mpltm1Wsa

(B6.129S1-Mpltm1Wsa)
decreased leukocyte cell number J:144799
\Lyntm1.1Calo/\Lyntm1.1Calo
\Myd88tm1Defr/\Myd88tm1Defr
\Tg(Itgax-cre)1-1Reiz/0

(involves: 129P2/OlaHsd * C57BL/6 * CBA)
immune system phenotype J:200745
\Lyntm1.1Calo/\Lyntm1.1Calo
\Tg(Itgax-cre)1-1Reiz/0

(involves: 129P2/OlaHsd * C57BL/6 * CBA)
abnormal circulating chemokine level J:200745
abnormal circulating cytokine level J:200745
abnormal dendritic cell physiology J:200745
abnormal leukocyte physiology J:200745
abnormal T cell activation J:200745
enlarged lymph nodes J:200745
enlarged spleen J:200745
glomerulonephritis J:200745
increased activated T cell number J:200745
increased autoantibody level J:200745
increased circulating interferon-gamma level J:200745
increased circulating interleukin-1 beta level J:200745
increased circulating interleukin-6 level J:200745
increased circulating interleukin-12 level J:200745
increased circulating interleukin-17 level J:200745
increased circulating tumor necrosis factor level J:200745
increased dendritic cell number J:200745
increased granulocyte number J:200745
increased inflammatory response J:200745
increased leukocyte cell number J:200745
increased monocyte cell number J:200745
increased plasma cell number J:200745
increased T cell number J:200745
liver inflammation J:200745
lung inflammation J:200745
lymph node hyperplasia J:200745
myeloid hyperplasia J:200745
skin inflammation J:200745
\Lyntm1Ard/\Lyn+
\Ptpn6me-v/\Ptpn6+
\Tg(IghelMD4)4Ccg/0

(involves: 129P2/OlaHsd * C57BL/6)
abnormal mature B cell morphology J:110531
\Lyntm1Ard/\Lyn+
\Tg(IghelMD4)4Ccg/0

(involves: 129P2/OlaHsd * C57BL/6)
abnormal mature B cell morphology J:110531
\Lyntm1Ard/\Lyntm1Ard
(involves: 129P2/OlaHsd)
abnormal circulating complement protein level J:161523
abnormal level of surface class II molecules J:161523
decreased spleen red pulp amount J:72269
decreased spleen white pulp amount J:72269
enlarged spleen J:72269
glomerulonephritis J:161523
increased anti-double stranded DNA antibody level J:161523
increased anti-nuclear antigen antibody level J:161523
increased basophil cell number J:161523
increased IgA level J:161523
increased IgE level J:161523
increased IgG2b level J:161523
increased IgM level J:161523
increased mast cell number J:161523
increased neutrophil cell number J:72269
\Lyntm1Ard/\Lyntm1Ard
(B6.129P2-Lyntm1Ard)
abnormal B cell activation J:144799
abnormal B cell morphology J:144799
abnormal myelopoiesis J:144799
decreased follicular B cell number J:144799
decreased marginal zone B cell number J:144799
decreased transitional stage B cell number J:144799
glomerulonephritis J:144799
increased anti-double stranded DNA antibody level J:144799
increased anti-nuclear antigen antibody level J:144799
increased T cell number J:144799
peritoneal inflammation J:144799
spleen hypoplasia J:144799
\Lyntm1Ard/\Lyntm1Ard
\Tg(IghelMD4)4Ccg/0

(involves: 129P2/OlaHsd * C57BL/6)
abnormal B cell activation J:110531
abnormal B cell negative selection J:110531
abnormal mature B cell morphology J:110531
absent B-1 B cells J:110531
increased IgM level J:110531
\Lyntm1b(EUCOMM)Hmgu/\Lyntm1b(EUCOMM)Hmgu
(C57BL/6N-Lyntm1b(EUCOMM)Hmgu/H)
decreased leukocyte cell number J:211773
decreased lymphocyte cell number J:211773
enlarged spleen J:211773
increased eosinophil cell number J:211773
increased large unstained cell number J:211773
increased monocyte cell number J:211773
increased neutrophil cell number J:211773
increased spleen weight J:211773
small thymus J:211773
\Lyntm1Mhi/\Lyntm1Mhi
(involves: 129S1/Sv)
decreased spleen weight J:72269
increased neutrophil cell number J:72269
\Lyntm1Sor/\Lyntm1Sor
(involves: 129S4/SvJae)
decreased B cell number J:42037
decreased mature B cell number J:42037
enlarged lymph nodes J:42037
enlarged spleen J:42037
increased anti-double stranded DNA antibody level J:42037
increased B cell proliferation J:42037
\Lyntm1Sor/\Lyntm1Sor
(B6.129S4-Lyntm1Sor)
abnormal inflammatory response J:113463
\Lyntm1Sor/\Lyntm1Sor
(involves: 129S4/SvJaeSor)
abnormal chemokine level J:80658
abnormal circulating chemokine level J:200745
abnormal circulating cytokine level J:200745
abnormal dendritic cell physiology J:200745
abnormal macrophage physiology J:80658
abnormal microglial cell physiology J:80658
decreased B cell number J:200745
decreased follicular B cell number J:146161
decreased marginal zone B cell number J:146161
decreased mature B cell number J:146161
decreased transitional stage B cell number J:146161
glomerulonephritis J:146161, J:200745
increased anti-double stranded DNA antibody level J:146161
increased autoantibody level J:200745
increased B cell proliferation J:146161
increased circulating interferon-gamma level J:200745
increased circulating interleukin-6 level J:200745
increased circulating interleukin-12 level J:200745
increased circulating interleukin-17 level J:200745
increased IgA level J:146161
increased IgM level J:146161
increased plasma cell number J:200745
liver inflammation J:146161
myeloid hyperplasia J:146161
spleen hyperplasia J:146161
\Lyntm1Sor/\Lyntm1Sor
(involves: 129S4/SvJaeSor * C57BL/6)
decreased B cell number J:71174
decreased B-1 B cell number J:71174
decreased mature B cell number J:71174
enlarged spleen J:71174
glomerulonephritis J:71174
increased anti-double stranded DNA antibody level J:71174
increased B cell proliferation J:71174
increased IgA level J:71174
increased IgG1 level J:71174
increased IgG2b level J:71174
increased IgG level J:71174
increased IgM level J:71174
increased susceptibility to systemic lupus erythematosus J:71174
\Lyntm1Tya/\Lyntm1Tya
(involves: 129P2/OlaHsd * C57BL/6)
abnormal B cell physiology J:29751
abnormal class switch recombination J:29751
abnormal spleen morphology J:29751
decreased B cell number J:29751
decreased B cell proliferation J:29751
decreased lymphocyte cell number J:29751
enlarged lymph nodes J:29751
enlarged spleen J:29751
glomerulonephritis J:29751
increased anti-double stranded DNA antibody level J:29751
increased IgA level J:29751
increased IgM level J:29751
increased immunoglobulin level J:29751
increased spleen white pulp amount J:29751
small Peyer's patches J:29751
\Lynweeb/\Lynweeb
(C57BL/6-Lynweeb)
decreased follicular B cell number J:146161
decreased marginal zone B cell number J:146161
decreased mature B cell number J:146161
decreased transitional stage B cell number J:146161
disorganized spleen B cell follicle J:146161
glomerulonephritis J:146161
increased anti-double stranded DNA antibody level J:146161
increased B cell proliferation J:146161
increased IgM level J:146161
liver inflammation J:146161
spleen hyperplasia J:146161
\Lynf1C57BL/10J/\Lynf1C57BL/10J
\Lynf3C57BL/10J/\Lynf3C57BL/10J

(involves: B10.O20 * O20/A)
abnormal acute inflammation J:128728
\Lynf2C57BL/10J/\Lynf2C57BL/10J
\Lynf3C57BL/10J/\Lynf3C57BL/10J

(involves: B10.O20 * O20/A)
abnormal acute inflammation J:128728
\Lynf2O20/A/\Lynf2O20/A
(involves: B10.O20 * O20/A)
abnormal acute inflammation J:128728
\Lynf4C57BL/10J/\Lynf4C57BL/10J
(involves: B10.O20 * O20/A)
abnormal acute inflammation J:128728
\Lynf4C57BL/10J/\Lynf4O20/A
(involves: B10.O20 * O20/A)
abnormal acute inflammation J:128728
\Lypd8tm2Ktak/\Lypd8tm2Ktak
(B6.Cg-Lypd8tm2Ktak)
increased susceptibility to colitis induced morbidity/mortality J:232706
increased susceptibility to induced colitis J:232706
\Lysetem1Janc/\Lysetem1Janc
(C57BL/6J-Tmem251em1Janc)
decreased susceptibility to viral infection J:330704
\Lysetem1Janc/\Lysetem2Janc
(C57BL/6J-Tmem251em1Janc Tmem251em2Janc)
decreased susceptibility to viral infection J:330704
\Lysetem2Janc/\Lysetem2Janc
(C57BL/6J-Tmem251em2Janc)
decreased susceptibility to viral infection J:330704
\Lystbg-2Btlr/\Lystbg-2Btlr
(C57BL/6J-Lystbg-2Btlr)
abnormal NK cell physiology J:133617
increased susceptibility to Herpesvirales infection J:133617
\Lystbg-2J/\Lystbg-2J
(C3.Cg-Lystbg-2J/J)
abnormal susceptibility to infection J:147940
decreased susceptibility to fungal infection J:147940
\Lystbg-5Btlr/\Lyst+
(C57BL/6J-Lystbg-5Btlr)
impaired macrophage phagocytosis J:217864
\Lystbg-5Btlr/\Lystbg-5Btlr
(C57BL/6J-Lystbg-5Btlr)
impaired macrophage phagocytosis J:217864
\Lystbg-6Btlr/\Lystbg-6Btlr
(C57BL/6J-Lystbg-6Btlr)
increased susceptibility to Herpesvirales infection J:220065
\Lystbg-Btlr/\Lystbg-Btlr
(C57BL/6J-Lystbg-Btlr)
abnormal NK cell physiology J:133616
increased susceptibility to bacterial infection J:133616
increased susceptibility to Herpesvirales infection J:133616
\Lystbg-grey/\Lystbg-grey
(C57BL/6-Lystbg-grey)
abnormal dermal mast cell morphology J:106442
\Lystbg-J/\Lystbg-J
(C57BL/6J-Lystbg-J/J)
abnormal granulocyte morphology J:34814
abnormal neutrophil morphology J:34814
decreased macrophage cell number J:34814
impaired natural killer cell mediated cytotoxicity J:34814
\Lystbg-J/\Lystbg-J
\Prkdcscid/\Prkdcscid

(B6.Cg-Lystbg-J Prkdcscid/Sz)
abnormal complement pathway J:34814
abnormal granulocyte morphology J:34814
abnormal level of surface class II molecules J:34814
abnormal lymph node morphology J:34814
abnormal neutrophil morphology J:34814
abnormal Peyer's patch morphology J:34814
abnormal spleen white pulp morphology J:34814
abnormal thymus morphology J:34814
decreased B cell number J:34814
decreased CD4-positive, alpha-beta T cell number J:34814
decreased CD8-positive, alpha-beta T cell number J:34814
decreased immunoglobulin level J:34814
decreased lymphocyte cell number J:34814
decreased pre-B cell number J:34814
decreased T cell number J:34814
impaired natural killer cell mediated cytotoxicity J:34814
increased eosinophil cell number J:34814
increased granulocyte number J:34814
increased macrophage cell number J:34814
increased monocyte cell number J:34814
increased neutrophil cell number J:34814
increased NK cell number J:34814
small Peyer's patches J:34814
small thymus J:34814
spleen hypoplasia J:34814
thymus cyst J:34814
\Lystbg-Lac/\Lystbg-Lac
(CBA/CaLac-Lystbg-Lac)
absent NK T cells J:29745
\Lystbg/\Lystbg
(B6.C3Rl-Lystbg)
abnormal eosinophil morphology J:5078
abnormal lymphocyte morphology J:5078
abnormal neutrophil morphology J:5078
alveolitis J:110157
decreased cytotoxic T cell cytolysis J:6692
impaired natural killer cell mediated cytotoxicity J:6302, J:6213
\Lystbg/\Lystbg
(B6.C3Rl-Lystbg/J)
abnormal NK cell physiology J:6801
increased susceptibility to parasitic infection J:6946
\Lystbg/\Lystbg
\Prkdcscid/\Prkdcscid

(Not Specified)
increased susceptibility to infection J:4752
\Lyve1tm1.1(EGFP/cre)Cys/\Lyve1+
\Sphk1tm2Cgh/\Sphk1tm2Cgh
\Sphk2tm1.1Cgh/\Sphk2tm1.1Cgh

(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)
abnormal leukocyte migration J:156826
abnormal lymph node morphology J:156826
abnormal lymphatic vessel morphology J:156826
abnormal lymphocyte cell number J:156826
abnormal Peyer's patch T cell area morphology J:156826
decreased B cell number J:156826
decreased splenocyte number J:156826
decreased T cell number J:156826
immune system phenotype J:156826
\Lyve1tm1Dgjk/\Lyve1tm1Dgjk
(involves: 129 * C57BL/6)
immune system phenotype J:117678
\Lyve1tm1Lhua/\Lyve1tm1Lhua
(B6.129S1-Lyve1tm1Lhua)
abnormal lymph circulation J:117713
lymphangiectasis J:117713
\Lyz2tm1(cre)Ifo/0
\Nup85tm1.1Yter/\Nup85tm1.1Yter

(involves: 129P2/OlaHsd * C57BL/6)
decreased macrophage cell number J:292726
\Lyz2tm1(cre)Ifo/\Lyz2+
(involves: 129P2/OlaHsd * C57BL/6)
enlarged spleen J:172024
\Lyz2tm1(cre)Ifo/\Lyz2+
\Nfkbiztm1.1Muta/\Nfkbiztm1.1Muta

(involves: 129P2/OlaHsd * C57BL/6)
immune system phenotype J:194832
\Lyz2tm1(cre)Ifo/\Lyz2+
\Nsd3tm1.1Caox/\Nsd3tm1.1Caox

(involves: 129P2/OlaHsd * C57BL/6 * C57BL/6J * SJL)
decreased macrophage cytokine production J:251909
increased susceptibility to Riboviria infection J:251909
increased susceptibility to Riboviria infection induced morbidity/mortality J:251909
\Lyz2tm1(cre)Ifo/\Lyz2+
\Pdcd10tm1Wami/\Pdcd10tm1Wami

(involves: 129 * 129P2/OlaHsd * C57BL/6)
abnormal neutrophil morphology J:256076
abnormal neutrophil physiology J:256076
\Lyz2tm1(cre)Ifo/\Lyz2+
\Pikfyvetm1b(EUCOMM)Hmgu/\Pikfyvetm1b(EUCOMM)Hmgu

(involves: 129P2/OlaHsd * C57BL/6N)
abnormal alveolar macrophage morphology J:244776
decreased alveolar macrophage number J:244776
decreased regulatory T cell number J:244776
immune system phenotype J:244776
increased eosinophil cell number J:244776
increased interleukin-4 secretion J:244776
increased interleukin-13 secretion J:244776
increased susceptibility to type I hypersensitivity reaction J:244776
\Lyz2tm1(cre)Ifo/\Lyz2+
\Rnf217tm1.1Fudi/\Rnf217tm1.1Fudi

(involves: 129P2/OlaHsd)
decreased spleen iron level J:315675
\Lyz2tm1(cre)Ifo/\Lyz2+
\Selenowtm1c(EUCOMM)Wtsi/\Selenowtm1c(EUCOMM)Wtsi

(B6.Cg-Selenowtm1c(EUCOMM)Wtsi Lyz2tm1(cre)Ifo)
abnormal osteoclast differentiation J:317012
\Lyz2tm1(cre)Ifo/\Lyz2+
\St18tm1c(KOMP)Wtsi/\St18tm1c(KOMP)Wtsi

(involves: 129P2/OlaHsd * C57BL/6 * C57BL/6N)
immune system phenotype J:298828
increased circulating interleukin-1 beta level J:298828
increased inflammatory response J:298828
\Lyz2tm1(cre)Ifo/\Lyz2tm1(cre)Ifo
\Nrrostm1Wouy/\Nrrostm1Wouy

(involves: 129P2/OlaHsd)
abnormal cellular extravasation J:209569
increased susceptibility to experimental autoimmune encephalomyelitis J:209569
\Lyz2tm1(HBEGF)Mtka/\Lyz2+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
abnormal alveolar macrophage morphology J:145285
\Lyz2tm1.1Graf/\Lyz2tm1.1Graf
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
increased inflammatory response J:82642
\Lztr1em2Tumg/\Lztr1+
(C57BL/6J-Lztr1em2Tumg)
abnormal lymphatic vessel morphology J:361054
enlarged spleen J:361054
\Lztr1em2Tumg/\Lztr1em2Tumg
(C57BL/6J-Lztr1em2Tumg)
abnormal lymphatic vessel morphology J:361054
\m1Hefl/\m1Hefl
(C3HeB/FeJ-m1Hefl)
decreased B cell number J:137446
X/\m1Nish
(involves: BALB/c * C57BL/6N)
absent B cells J:204833
absent Peyer's patches J:204833
decreased NK cell number J:204833
X/\m1Nish
(involves: C57BL/6N)
abnormal B cell differentiation J:204833
abnormal NK cell differentiation J:204833
absent B cells J:204833
absent B-1 B cells J:204833
absent B-2 B cells J:204833
absent Peyer's patches J:204833
decreased B cell number J:204833
decreased B-1 B cell number J:204833
decreased IgG level J:204833
decreased IgM level J:204833
decreased immature B cell number J:204833
decreased NK cell number J:204833
decreased T cell proliferation J:204833
immune system phenotype J:204833
small lymph nodes J:204833
\m1Nish/\m1Nish+
(involves: BALB/c * C57BL/6N)
immune system phenotype J:204833
\m1Nish/\m1Nish+
(involves: C57BL/6N)
immune system phenotype J:204833
\m2Hefl/\m2Hefl
(C3HeB/FeJ-m2Hefl)
absent B cells J:137446
absent T cells J:137446
\m3Hefl/\m3Hefl
(C3HeB/FeJ-m3Hefl)
decreased CD8-positive, alpha-beta T cell number J:137446
decreased NK cell number J:137446
\m4Hefl/\m4Hefl
(C3HeB/FeJ-m4Hefl)
decreased T cell number J:137446
\m5Hefl/\m5Hefl
(C3HeB/FeJ-m5Hefl)
decreased T cell number J:137446
\M6prem1(IMPC)Mbp/\M6prem1(IMPC)Mbp
(C57BL/6N-M6prem1(IMPC)Mbp/MbpMmucd)
small spleen J:211773
\M7321Wlst/\M7321Wlst+
(involves: 129S1/SvImJ * C57BL/6J)
abnormal thrombopoiesis J:189491
\M7324Wlst/\M7324Wlst+
(involves: 129S1/SvImJ * C57BL/6J)
abnormal thrombopoiesis J:189491
\M7325Wlst/\M7325Wlst+
(involves: 129S1/SvImJ * C57BL/6J)
abnormal thrombopoiesis J:189491
\m12137Asr/\m12137Asr+
(C57BL/6J-m12137Asr)
decreased osteoclast cell number J:132290
\Macroh2a1tm1.1Oxbo/\Macroh2a1tm1.1Oxbo
(B6.Cg-Macroh2a1tm1.1Oxbo)
decreased B cell number J:293382
decreased neutrophil cell number J:293382
increased eosinophil cell number J:293382
increased lymphocyte cell number J:293382
\Macroh2a1tm1Peh/\Macroh2a1tm1Peh
\Macroh2a2tm1.1Peh/\Macroh2a2tm1.1Peh

(129S6.Cg-Macroh2a2tm1.1Peh Macroh2a1tm1Peh)
blepharitis J:220524
\Macroh2a2em1(IMPC)Hmgu/\Macroh2a2em1(IMPC)Hmgu
(C57BL/6NCrl-Macroh2a2em1(IMPC)Hmgu/Ieg)
abnormal thymus morphology J:211773
enlarged lymph nodes J:211773
enlarged spleen J:211773
\Mad2l1tm1Sorg/\Mad2l1+
(involves: 129S2/SvPas * C57BL/6)
increased spleen germinal center number J:62829
\Madcam1tm1.2Nwag/\Madcam1tm1.2Nwag
(B6.129P2-Madcam1tm1.2Nwag)
abnormal B cell physiology J:169739
decreased B cell number J:169739
decreased IgA level J:169739
decreased plasma cell number J:169739
increased plasma cell number J:169739
small Peyer's patches J:169739
\MaeaGt(XG702)Byg/\MaeaGt(XG702)Byg
(involves: 129P2/OlaHsd * C57BL/6J)
decreased macrophage cell number J:114865
\Mafem1(IMPC)Mbp/\Maf+
(C57BL/6N-Mafem1(IMPC)Mbp/MbpMmucd)
abnormal spleen morphology J:211773
enlarged spleen J:211773
small spleen J:211773
\MafOfl/\MafOfl
(either: 102/ElH or C3H/HeH)
tubular nephritis J:82475
\Maftm1Glm/\Maftm1Glm
(involves: 129/Sv * BALB/c)
decreased interleukin-4 secretion J:78382
\Mafbtm1Jeng/\Mafbtm1Jeng
(involves: 129P2/OlaHsd * C57BL/6J)
immune system phenotype J:111415
\Mafgtm1Jeng/\Mafgtm1Jeng
\Mafktm1Jeng/\Mafktm1Jeng

(involves: 129S1/Sv * 129X1/SvJ)
enlarged spleen J:61142
\Magtm1.1(KOMP)Vlcg/\Magtm1.1(KOMP)Vlcg
(C57BL/6N-Magtm1.1(KOMP)Vlcg/J)
decreased leukocyte cell number J:211773
\Magtm1Rod/\Magtm1Rod
(involves: 129S1/Sv * 129X1/SvJ)
increased B cell proliferation J:217719
\Maged1tm1.1Urfm/\Maged1tm1.1Urfm
(involves: 129P2/OlaHsd)
abnormal tumor necrosis factor level J:157549
\Magi2tm1Key/\Magi2tm1Key
(involves: 129S4/SvJae)
tubulointerstitial nephritis J:213553
\Magixem1(IMPC)Hmgu/Y
(C57BL/6NCrl-Magixem1(IMPC)Hmgu/Ieg)
decreased leukocyte cell number J:211773
\Magt1Gt(IST13422E1)Tigm/Y
(involves: C57BL/6N)
abnormal B cell morphology J:260923
decreased plasma cell number J:260923
decreased T cell number J:260923
increased B cell number J:260923
increased B cell proliferation J:260923
increased marginal zone B cell number J:260923
\Malat1tm1.2Dlsp/\Malat1tm1.2Dlsp
(B6J.Cg-Malat1tm1.2Dlsp)
brain inflammation J:239375
\Malt1m1Btlr/\Malt1+
(C57BL/6J-Malt1m1Btlr)
impaired humoral immune response J:221474
\Malt1m1Btlr/\Malt1m1Btlr
(C57BL/6J-Malt1m1Btlr)
impaired humoral immune response J:221474
\Malt1m2Btlr/\Malt1+
(C57BL/6J-Malt1m2Btlr)
decreased IgM level J:224671
impaired humoral immune response J:224671
\Malt1m2Btlr/\Malt1m2Btlr
(C57BL/6J-Malt1m2Btlr)
decreased IgG level J:224671
decreased IgM level J:224671
impaired humoral immune response J:224671
\Malt1m3Btlr/\Malt1+
(C57BL/6J-Malt1m3Btlr)
decreased IgM level J:224672
impaired humoral immune response J:224672
\Malt1m3Btlr/\Malt1m3Btlr
(C57BL/6J-Malt1m3Btlr)
decreased IgG level J:224672
decreased IgM level J:224672
impaired humoral immune response J:224672
\Malt1tm1Mak/\Malt1tm1Mak
(involves: 129P2/OlaHsd)
abnormal dendritic cell physiology J:111706
decreased IgG level J:109545
decreased IgM level J:109545
decreased T cell proliferation J:109545
\Malt1tm1Vmd/\Malt1tm1Vmd
(involves: C57BL/6N)
abnormal B cell differentiation J:86770
abnormal double-negative T cell morphology J:86770
abnormal immune system morphology J:86770
abnormal spleen marginal zone morphology J:86770
abnormal T cell differentiation J:86770
abnormal T cell proliferation J:86770
absent B-1a cells J:86770
decreased immunoglobulin level J:86770
decreased interleukin-2 secretion J:86770
\Maml1tm1Mkit/\Maml1tm1Mkit
(involves: 129P2/OlaHsd * C57BL/6)
decreased marginal zone B cell number J:122286
decreased thymocyte number J:122286
increased double-negative T cell number J:122286
\Mamld1tm1.1(NCOM)Mfgc/Y
(C57BL/6N-Mamld1tm1.1(NCOM)Mfgc/Tcp)
increased leukocyte cell number J:211773
increased lymphocyte cell number J:211773
\Man2a1tm1Jxm/\Man2a1tm1Jxm
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
abnormal immune serum protein physiology J:74579
abnormal immune system physiology J:74579
abnormal self tolerance J:74579
abnormal spleen morphology J:74579
enlarged spleen J:41621
glomerulonephritis J:74579
immune system phenotype J:74579
increased IgA level J:74579
increased IgG level J:74579
increased IgM level J:74579
increased memory T cell number J:74579
liver inflammation J:74579
lung inflammation J:74579
\Man2a1tm1Jxm/\Man2a1tm1Jxm
\Rag1tm1Mom/\Rag1tm1Mom

(B6.129-Rag1tm1Mom Man2a1tm1Jxm)
kidney inflammation J:124348
\Man2b1tm1Psa/\Man2b1tm1Psa
(involves: 129 * C57BL/6J)
abnormal Kupffer cell morphology J:56659
abnormal spleen red pulp morphology J:56659
\Man2b2tm1b(KOMP)Wtsi/\Man2b2tm1b(KOMP)Wtsi
(C57BL/6N-Man2b2tm1b(KOMP)Wtsi/Tcp)
decreased lymphocyte cell number J:211773
enlarged lymph nodes J:211773
increased eosinophil cell number J:211773
increased neutrophil cell number J:211773
\Man2c1tm1.1Tbec/\Man2c1tm1.1Tbec
(B6N.129P2-Man2c1tm1.1Tbec)
abnormal microglial cell activation J:205550
\Manbatm1Khf/\Manbatm1Khf
(B6.129-Manbatm1Khf)
abnormal Kupffer cell morphology J:105427
\Map2k3tm1Flv/\Map2k3tm1Flv
(involves: 129S1/Sv)
abnormal CD4-positive, alpha-beta T cell physiology J:85266
decreased T cell apoptosis J:85266
\Map2k3tm1Flv/\Map2k3tm1Flv
(B6.129S1-Map2k3tm1Flv)
increased susceptibility to bacterial infection J:124327
\Map2k6tm1Flv/\Map2k6tm1Flv
(involves: 129S1/Sv)
abnormal thymocyte apoptosis J:85266
\Map2k6tm1Ina/\Map2k6tm1Ina
\Tg(TcraH-Y,TcrbH-Y)71Vbo/0

(involves: 129P2/OlaHsd * C57BL/6J * DBA/2J)
abnormal thymus cell ratio J:100093
\Map3k1tm1Glj/\Map3k1tm1Glj
(involves: 129S/SvEv)
heart inflammation J:78068
immune system phenotype J:62909
\Map3k2tm1Bisu/\Map3k2tm1Bisu
(Not Specified)
abnormal cytokine secretion J:78072
abnormal T cell activation J:78072
increased T cell proliferation J:78072
\Map3k3tm1Bisu/\Map3k3tm2Bisu
\Tg(Lck-cre)548Jxm/0

(involves: C57BL/6 * CBA)
abnormal T cell physiology J:145923
abnormal T cell proliferation J:145923
decreased CD4-positive, alpha-beta T cell number J:145923
decreased CD8-positive, alpha-beta T cell number J:145923
spleen hypoplasia J:145923
\Map3k3tm1Kuro/\Map3k3tm1Kuro
\Tg(Lck-cre)1Jtak/0

(involves: C57BL/6)
decreased CD4-positive, alpha-beta T cell number J:147103
decreased CD8-positive, alpha-beta T cell number J:147103
decreased double-positive T cell number J:147103
decreased interferon-gamma secretion J:147103
decreased interleukin-2 secretion J:147103
decreased single-positive T cell number J:147103
decreased T cell proliferation J:147103
decreased thymocyte number J:147103
increased double-negative T cell number J:147103
\Map3k4tm1Flv/\Map3k4tm1Flv
(involves: 129S6/SvEvTac * C57BL/6)
abnormal T-helper 1 physiology J:90112
decreased interferon-gamma secretion J:90112
\Map3k5tm1Hijo/\Map3k5tm1Hijo
(involves: 129S4/SvJae * C57BL/6J)
immune system phenotype J:251158
\Map3k7tm1.1Gkl/\Map3k7tm1.1Gkl
\Lyz2tm1(cre)Ifo/\Lyz2+

(involves: 129P2/OlaHsd * C57BL/6)
decreased circulating interleukin-10 level J:211916
decreased interleukin-10 secretion J:211916
increased circulating interleukin-1 beta level J:211916
increased circulating tumor necrosis factor level J:211916
increased inflammatory response J:211916
increased interleukin-1 beta secretion J:211916
increased interleukin-6 secretion J:211916
increased interleukin-10 secretion J:211916
increased susceptibility to endotoxin shock J:211916
increased tumor necrosis factor secretion J:211916
\Map3k7tm1Aki/\Map3k7tm1Aki
\Tg(Alb1-cre)7Gsc/0

(involves: 129P2/OlaHsd * FVB/N)
liver inflammation J:160521
\Map3k7tm1Aki/\Map3k7tm1Aki
\Tg(Lck-cre)1Jtak/0

(involves: 129P2/OlaHsd)
abnormal spleen morphology J:112837
abnormal T cell activation J:112837
absent regulatory T cells J:112837
colitis J:112837
decreased CD4-positive, alpha-beta T cell number J:112837
decreased CD8-positive, alpha-beta T cell number J:112837
decreased single-positive T cell number J:112837
decreased T cell number J:112837
decreased T cell proliferation J:112837
enlarged lymph nodes J:112837
enlarged spleen J:112837
increased memory T cell number J:112837
spleen hyperplasia J:112837
\Map3k7tm1Aki/\Map3k7tm1Aki
\Tg(Lck-cre)1Jtak/0

(involves: 129P2/OlaHsd * C57BL/6)
abnormal alpha-beta intraepithelial T cell morphology J:238318
abnormal CD4-positive, alpha-beta T cell physiology J:238318
abnormal cytokine level J:238318
abnormal intraepithelial T cell number J:238318
abnormal regulatory T cell number J:238318
abnormal regulatory T cell physiology J:238318
abnormal T cell morphology J:238318
colitis J:238318
decreased CD4-positive, CD25-positive, alpha-beta regulatory T cell number J:238318
decreased NK T cell number J:238318
increased CD4-positive, alpha-beta T cell number J:238318
increased gamma-delta intraepithelial T cell number J:238318
increased interferon-gamma secretion J:238318
increased interleukin-17 secretion J:238318
\Map3k7tm1Zjc/\Map3k7tm1Zjc
\Tg(Lck-cre)548Jxm/0

(involves: 129S7/SvEvBrd * C57BL/6 * CBA)
decreased CD4-positive, alpha-beta T cell number J:111794
decreased CD8-positive, alpha-beta T cell number J:111794
decreased T cell number J:111794
increased thymocyte apoptosis J:111794
\Map3k8M1Btlr/\Map3k8+
(C57BL/6J-Map3k8M1Btlr)
abnormal tumor necrosis factor secretion J:140986
decreased tumor necrosis factor secretion J:140986
\Map3k8M1Btlr/\Map3k8M1Btlr
(C57BL/6J-Map3k8M1Btlr)
abnormal response to infection J:140986
decreased interferon-alpha secretion J:140986
decreased interferon-beta secretion J:140986
decreased interleukin-1 beta secretion J:140986
decreased interleukin-6 secretion J:140986
decreased tumor necrosis factor secretion J:140986
impaired natural killer cell mediated cytotoxicity J:140986
increased interleukin-12b secretion J:140986
\Map3k8m2Btlr/\Map3k8m2Btlr
(C57BL/6J-Map3k8m2Btlr)
abnormal response to infection J:212899
\Map3k8m3Btlr/\Map3k8+
(C57BL/6J-Map3k8m3Btlr)
decreased macrophage cytokine production J:224668
decreased tumor necrosis factor secretion J:224668
\Map3k8m3Btlr/\Map3k8m3Btlr
(C57BL/6J-Map3k8m3Btlr)
decreased macrophage cytokine production J:224668
decreased tumor necrosis factor secretion J:224668
\Map3k8M4Btlr/\Map3k8+
(C57BL/6J-Map3k8M4Btlr)
decreased tumor necrosis factor secretion J:254880
\Map3k8M4Btlr/\Map3k8M4Btlr
(C57BL/6J-Map3k8M4Btlr)
decreased tumor necrosis factor secretion J:254880
\Map3k8tm1.2Gkl/\Map3k8tm1.2Gkl
(involves: 129 * C57BL/6J * FVB/N)
decreased tumor necrosis factor secretion J:193546
\Map3k8tm1Pnt/\Map3k8tm1Pnt
(involves: 129S1/Sv * C57BL/6J)
decreased susceptibility to endotoxin shock J:66503
decreased tumor necrosis factor secretion J:66503
immune system phenotype J:66503
\Map3k8tm1Pnt/\Map3k8tm1Pnt
(involves: 129S1/Sv)
immune system phenotype J:142340, J:196528
\Map3k8tm1Pnt/\Map3k8tm1Pnt
\Nfkb1tm1Sley/\Nfkb1tm1Sley

(involves: 129S1/Sv * 129S4/SvJae)
decreased circulating interleukin-12b level J:196528
decreased interleukin-12b secretion J:196528
decreased tumor necrosis factor secretion J:196528
\Map3k8tm1Pnt/\Map3k8tm1Pnt
\Tnftm2Gkl/\Tnf+

(involves: 129P2/OlaHsd * 129S/SvEv * C57BL/6J)
increased CD8-positive, alpha-beta T cell number J:108572
increased single-positive T cell number J:108572
small intestinal inflammation J:108572
\Map3k8tm1Sley/\Map3k8tm1Sley
\Nfkb1tm1Sley/\Nfkb1tm1Sley

(involves: 129S4/SvJae)
decreased tumor necrosis factor secretion J:196528
\Map3k8tm1Tmat/\Map3k8tm1Tmat
(involves: 129S/SvEv * C57BL/6)
abnormal cytokine secretion J:92844
abnormal dendritic cell antigen presentation J:92844
decreased IgE level J:92844
decreased IgG1 level J:92844
increased IgG2a level J:92844
increased T cell proliferation J:92844
\Map3k9em1(IMPC)Mbp/\Map3k9em1(IMPC)Mbp
(C57BL/6N-Map3k9em1(IMPC)Mbp/MbpMmucd)
increased neutrophil cell number J:211773
\Map3k10tm1Dsd/\Map3k10tm1Dsd
\Map3k11tm1Rjd/\Map3k11tm1Rjd

(involves: 129 * 129S6/SvEvTac * C57BL/6J)
abnormal circulating chemokine level J:177426
abnormal circulating cytokine level J:177426
abnormal response to infection J:177426
\Map3k10tm1Dsd/\Map3k10tm1Dsd
\Map3k11tm2.1Rjd/\Map3k11tm2.1Rjd

(involves: 129 * C57BL/6J)
abnormal circulating chemokine level J:177426
abnormal circulating cytokine level J:177426
abnormal response to infection J:177426
\Map3k14aly/\Map3k14+
\RelbTg(H2-K1/GH1)106Bri/\Relb+

(involves: C57BL/6 * C57BL/6J)
decreased circulating interferon-gamma level J:120659
decreased NK T cell number J:120659
decreased Peyer's patch number J:120659
small Peyer's patches J:120659
\Map3k14aly/\Map3k14aly
(involves: C57BL/6J)
abnormal CD4-positive, CD25-positive, alpha-beta regulatory T cell morphology J:87993, J:128211
abnormal dendritic cell antigen presentation J:128211
abnormal dendritic cell physiology J:128211
abnormal immune system morphology J:147681
abnormal immune system physiology J:147681
abnormal NK T cell morphology J:120659
abnormal T cell activation J:38580
abnormal thymus corticomedullary boundary morphology J:87993
abnormal thymus medulla morphology J:87993
absent Peyer's patches J:120659
bile duct inflammation J:48224
decreased circulating interferon-gamma level J:120659
decreased circulating interleukin-4 level J:120659
decreased dendritic cell number J:128211
decreased IgE level J:135748
decreased mast cell number J:135748
decreased NK T cell number J:120659
decreased regulatory T cell number J:128211
increased eosinophil cell number J:135748
increased inflammatory response J:38580, J:48224
increased susceptibility to parasitic infection J:135748
kidney inflammation J:38580
lacrimal gland inflammation J:38580
liver inflammation J:48224
lung inflammation J:48224
pancreas inflammation J:48224
small thymus J:147681
thymus cyst J:147681
\Map3k14aly/\Map3k14aly
(involves: AEJ/GnRk * C57BL/6J)
abnormal immune system morphology J:54529
abnormal lymphocyte morphology J:16865
abnormal lymphopoiesis J:16865
abnormal spleen primary B follicle morphology J:54529
absent follicular dendritic cells J:54529
absent lymph nodes J:16865, J:54529
absent Peyer's patches J:16865, J:54529
absent spleen marginal zone J:54529
absent thymus corticomedullary boundary J:16865, J:54529
decreased B cell number J:54529
decreased IgA level J:16865, J:54529
decreased IgG level J:16865, J:54529
decreased IgM level J:16865, J:54529
decreased spleen B cell follicle number J:16865
increased length of allograft survival J:16865
\Map3k14aly/\Map3k14aly
(C57BL/6J-Map3k14aly)
absent lymph nodes J:16865
increased susceptibility to infection J:16865
\Map3k14m1Btlr/\Map3k14m1Btlr
(C57BL/6J-Map3k14m1Btlr)
abnormal B cell activation J:152065
absent lymph nodes J:152065
arrested B cell differentiation J:152065
decreased B cell number J:152065
decreased IgG level J:152065
\Map3k14m1Btlr/\Map3k14m1Btlr
(involves: C57BL/6J)
abnormal class switch recombination J:185495
arrested B cell differentiation J:185495
decreased IgG level J:185495
\Map3k14tm1.1Gne/\Map3k14tm1.1Gne
\Cd19tm1(cre)Cgn/\Cd19+

(involves: 129P2/OlaHsd * C57BL/6 * C57BL/6NTac)
decreased B cell number J:280549
\Map3k14tm1.1Gne/\Map3k14tm1.1Gne
\Otub1tm1c(EUCOMM)Hmgu/\Otub1tm1c(EUCOMM)Hmgu
\Cd19tm1(cre)Cgn/\Cd19+

(involves: 129P2/OlaHsd * C57BL/6 * C57BL/6N * C57BL/6NTac)
immune system phenotype J:280549
\Map3k14tm1.2Gne/\Map3k14tm1.2Gne
(B6(Cg)-Map3k14tm1.2Gne)
abnormal B cell physiology J:240453
abnormal spleen marginal zone morphology J:240453
abnormal thymus cell ratio J:240453
absent inguinal lymph nodes J:240453
absent Peyer's patches J:240453
absent popliteal lymph nodes J:240453
decreased B cell number J:240453
decreased B-2 B cell number J:240453
decreased follicular B cell number J:240453
decreased germinal center B cell number J:240453
decreased IgA level J:240453
decreased marginal zone B cell number J:240453
decreased transitional stage T1 B cell number J:240453
decreased transitional stage T2 B cell number J:240453
small axillary lymph nodes J:240453
small brachial lymph nodes J:240453
\Map3k14tm1Rds/\Map3k14tm1Rds
(involves: 129/Sv * C57BL/6)
abnormal spleen morphology J:68125
abnormal thymus morphology J:68125
absent axillary lymph nodes J:68125
absent cervical lymph nodes J:68125
absent inguinal lymph nodes J:68125
absent lymph nodes J:68125
absent mesenteric lymph nodes J:68125
absent Peyer's patches J:68125
absent popliteal lymph nodes J:68125
decreased IgA level J:68125
decreased IgG2b level J:68125
decreased immunoglobulin level J:68125
\Map3k14tm1Rds/\Map3k14tm1Rds
(involves: 129)
abnormal class switch recombination J:188560
\Map4k1m1Anu/\Map4k1m1Anu
(C57BL/6NCrlAnu-Map4k1m1Anu)
immune system phenotype J:104190
\Map4k1tm1Ssaw/\Map4k1tm1Ssaw
(B6.Cg-Map4k1tm1Ssaw)
abnormal dendritic cell antigen presentation J:150295
abnormal dendritic cell physiology J:150295
increased interleukin-1 beta secretion J:150295
increased interleukin-6 secretion J:150295
increased interleukin-12 secretion J:150295
increased tumor necrosis factor secretion J:150295
\Map4k1tm1Tht/\Map4k1tm1Tht
(B6.129S7-Map4k1tm1Tht)
increased susceptibility to experimental autoimmune encephalomyelitis J:116613
\Map4k1tm1Tht/\Map4k1tm1Tht
(involves: 129S7/SvEvBrd)
abnormal cytokine secretion J:116613
abnormal humoral immune response J:116613
increased T cell proliferation J:116613
\Map4k3Gt(RRO270)Byg/\Map4k3Gt(RRO270)Byg
(involves: 129P2/OlaHsd)
abnormal interleukin secretion J:177642
abnormal T-helper 1 cell differentiation J:177642
abnormal T-helper 2 cell differentiation J:177642
abnormal T-helper 17 cell differentiation J:177642
decreased IgG1 level J:177642
decreased IgG2a level J:177642
decreased IgG2b level J:177642
decreased IgG3 level J:177642
decreased IgM level J:177642
decreased immunoglobulin level J:177642
decreased interferon-gamma secretion J:177642
decreased interleukin-2 secretion J:177642
decreased interleukin-4 secretion J:177642
decreased interleukin-17 secretion J:177642
decreased susceptibility to experimental autoimmune encephalomyelitis J:177642
decreased T cell proliferation J:177642
immune system phenotype J:177642
\Map4k5Gt(OST218153)Lex/\Map4k5Gt(OST218153)Lex
(B6;129S5-Map4k5Gt(OST218153)Lex/Ieg)
increased CD4-positive, alpha-beta T cell number J:82809
increased IgG1 level J:82809
\Map7mshi/\Map7mshi
(involves: BALB/cBy)
decreased length of allograft survival J:37165
\Mapk1tm1.1Hed/\Mapk1tm1.1Hed
\Tg(Lck-cre)1Cwi/0

(involves: C57BL/6 * DBA/2)
abnormal T cell subpopulation ratio J:113280
decreased CD4-positive, alpha-beta T cell number J:113280
decreased CD8-positive, alpha-beta T cell number J:113280
\Mapk1tm1Gela/\Mapk1tm1Gela
\H2az2Tg(Wnt1-cre)11Rth/0

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * CBA/J)
abnormal thymus morphology J:144862
\Mapk1tm1Gela/\Mapk1tm1Gela
\Mapk3tm1Gela/\Mapk3+
\H2az2Tg(Wnt1-cre)11Rth/\H2az2+

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * CBA/J)
abnormal thymus morphology J:144862
\Mapk1tm1Gela/\Mapk1tm1Gela
\Mapk3tm1Gela/\Mapk3tm1Gela
\H2az2Tg(Wnt1-cre)11Rth/0

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * CBA/J)
athymia J:144862
\Mapk1tm1Hed/\Mapk1tm1Hed
\Mapk3tm1Gpg/\Mapk3tm1Gpg
\Tg(Cd4-cre)1Cwi/0

(involves: 129/Sv * C57BL/6 * DBA/2)
abnormal positive T cell selection J:113280
\Mapk1tm1Hed/\Mapk1tm1Hed
\Mapk3tm1Gpg/\Mapk3tm1Gpg
\Tg(Cd4-cre)1Cwi/0
\Tg(TcrAND)53Hed/0

(involves: 129/Sv * C57BL/6 * DBA/2 * SJL)
abnormal positive T cell selection J:113280
abnormal T cell subpopulation ratio J:113280
\Mapk1tm1Hed/\Mapk1tm1Hed
\Mapk3tm1Gpg/\Mapk3tm1Gpg
\Tg(Lck-cre)1Cwi/0

(involves: 129/Sv * C57BL/6 * DBA/2)
abnormal T cell proliferation J:113280
decreased thymocyte number J:113280
increased double-positive T cell number J:113280
small thymus J:113280
\Mapk1tm1Hed/\Mapk1tm1Hed
\Mapk3tm1Gpg/\Mapk3tm1Gpg
\Tg(TcraTcrb)1100Mjb/0

(involves: 129/Sv * C57BL/6)
decreased thymocyte number J:113280
\Mapk1tm1Hed/\Mapk1tm1Hed
\Tg(Cd4-cre)1Cwi/0

(involves: C57BL/6 * DBA/2)
abnormal positive T cell selection J:113280
decreased CD4-positive, alpha-beta T cell number J:113280
decreased CD8-positive, alpha-beta T cell number J:113280
increased double-positive T cell number J:113280
\Mapk1tm1Hed/\Mapk1tm1Hed
\Tg(Lck-cre)1Cwi/0

(involves: C57BL/6 * DBA/2)
abnormal T cell subpopulation ratio J:113280
decreased double-positive T cell number J:113280
decreased T cell proliferation J:113280
\Mapk1tm1Hed/\Mapk1tm1Hed
\Tg(Lck-cre)1Cwi/0
\Tg(TcrAND)53Hed/0

(involves: C57BL/6 * DBA/2 * SJL)
abnormal positive T cell selection J:113280
abnormal T cell subpopulation ratio J:113280
\Mapk1tm1Hed/\Mapk1tm1Hed
\Tg(TcrAND)53Hed/0

(involves: C57BL/6 * DBA/2 * SJL)
abnormal double-positive T cell morphology J:113280
abnormal positive T cell selection J:113280
\Mapk1tm1Hed/\Mapk1tm1Hed
\Tg(TcraTcrb)1100Mjb/0

(involves: C57BL/6)
decreased thymocyte number J:113280
\Mapk1tm2Moga/\Mapk1tm2Moga
\Mapk3tm1Gpg/\Mapk3tm1Gpg
\Tg(Mx1-cre)1Cgn/?

(involves: 129/Sv * 129P2/OlaHsd * C57BL/6 * CBA)
abnormal pro-B cell differentiation J:134528
abnormal pro-B cell morphology J:134528
decreased pre-B cell number J:134528
\Mapk3m1Btlr/\Mapk3m1Btlr
(C57BL/6J-Mapk3m1Btlr)
decreased interleukin-1 beta secretion J:221481
\Mapk3tm1Gela/\Mapk3tm1Gela
(either: 129(Cg)-Mapk3tm1Gela or B6.129-Mapk3tm1Gela)
abnormal cytokine secretion J:107504
increased susceptibility to experimental autoimmune encephalomyelitis J:107504
\Mapk3tm1Gpg/\Mapk3tm1Gpg
(involves: 129)
decreased T cell number J:58468
decreased T cell proliferation J:58468
\Mapk8tm1Flv/\Mapk8tm1Flv
(involves: 129S1/Sv)
abnormal cytokine secretion J:51510
abnormal T-helper 1 cell differentiation J:51510
increased T cell proliferation J:51510
\Mapk8tm1Rjd/\Mapk8tm1Rjd
\Mapk9tm2.1Rjd/\Mapk9tm2.1Rjd
\Lyz2tm1(cre)Ifo/\Lyz2+

(B6J.Cg-Lyz2tm1(cre)Ifo Mapk9tm2.1Rjd Mapk8tm1Rjd)
abnormal chemokine level J:192551
abnormal circulating chemokine level J:192551
abnormal circulating cytokine level J:192551
abnormal macrophage differentiation J:192551
abnormal macrophage physiology J:192551
decreased inflammatory response J:192551
decreased macrophage cell number J:192551
decreased macrophage cytokine production J:192551
impaired macrophage chemotaxis J:192551
\Mapk8tm1Wag/\Mapk8+
\Mapk9tm1Mka/\Mapk9+

(involves: 129)
abnormal T cell activation J:78190
decreased T cell apoptosis J:78190
decreased T cell proliferation J:78190
\Mapk8tm1Wag/\Mapk8+
\Mapk9tm1Mka/\Mapk9tm1Mka

(involves: 129)
abnormal T cell activation J:78190
decreased T cell apoptosis J:78190
decreased T cell proliferation J:78190
\Mapk8tm1Wag/\Mapk8tm1Wag
(involves: 129P2/OlaHsd)
abnormal T cell activation J:78190
decreased T cell apoptosis J:78190
decreased T cell proliferation J:78190
\Mapk8tm1Wag/\Mapk8tm1Wag
\Mapk9tm1Mka/\Mapk9+

(involves: 129)
abnormal T cell activation J:78190
decreased T cell apoptosis J:78190
decreased T cell proliferation J:78190
\Mapk9tm1Flv/\Mapk9tm1Flv
(involves: 129S2/SvPas)
abnormal T-helper 1 cell differentiation J:50628
\Mapk9tm1Flv/\Mapk9tm1Flv
\Tnftm2Gkl/\Tnf+

(involves: 129P2/OlaHsd * 129S/SvEv * C57BL/6J)
immune system phenotype J:108572
small intestinal inflammation J:108572
\Mapk9tm1Mka/\Mapk9tm1Mka
(either: (involves: 129S2/SvPas) or (involves: 129S1/Sv * 129X1/SvJ))
abnormal T cell activation J:78129
decreased T cell apoptosis J:78129
decreased T cell proliferation J:78129
\Mapk11tm1Jda/\Mapk11tm1Jda
(B6.Cg-Mapk11tm1Jda)
immune system phenotype J:165966
\Mapk11tm1Jda/\Mapk11tm1Jda
\Mapk14tm1Jda/\Mapk14tm1Jda

(involves: 129 * C57BL/6)
abnormal T-helper 1 cell differentiation J:165966
abnormal T-helper 2 cell differentiation J:165966
abnormal T-helper 17 cell differentiation J:165966
decreased interferon-gamma secretion J:165966
decreased susceptibility to experimental autoimmune encephalomyelitis J:165966
decreased susceptibility to induced arthritis J:165966
decreased T cell proliferation J:165966
decreased tumor necrosis factor secretion J:165966
increased interleukin-10 secretion J:165966
\Mapk11tm1Jsca/\Mapk11tm1Jsca
(involves: 129P2/OlaHsd * C57BL/6)
immune system phenotype J:107771
\Mapk11tm1Jsca/\Mapk11tm1Jsca
\Tnftm2Gkl/\Tnf+

(involves: 129P2/OlaHsd * 129S/SvEv * C57BL/6)
autoimmune arthritis J:107771
ileum inflammation J:107771
\Mapk14tm1Jda/\Mapk14tm1Jda
(B6.Cg-Mapk14tm1Jda)
abnormal T-helper 1 physiology J:146088
decreased interferon-alpha secretion J:146088
decreased interferon-gamma secretion J:146088
decreased T cell proliferation J:146088
increased double-negative T cell number J:146088
\Mapkapk2tm1.2Gkl/\Mapkapk2tm1.2Gkl
(involves: BALB/cJ * C57BL/6)
decreased circulating tumor necrosis factor level J:262876
decreased tumor necrosis factor secretion J:262876
\Mapkapk2tm1b(EUCOMM)Hmgu/\Mapkapk2tm1b(EUCOMM)Hmgu
(C57BL/6N-Mapkapk2tm1b(EUCOMM)Hmgu/H)
increased eosinophil cell number J:211773
increased large unstained cell number J:211773
increased leukocyte cell number J:211773
\Mapkapk2tm1Mgl/\Mapkapk2tm1Mgl
(involves: 129P2/OlaHsd * C57BL/6J)
abnormal cytokine level J:59678
abnormal macrophage derived foam cell morphology J:142788
decreased circulating tumor necrosis factor level J:59678
decreased susceptibility to endotoxin shock J:59678
increased spleen germinal center size J:59678
\Mapkapk2tm1Mgl/\Mapkapk2tm1Mgl
(involves: 129S * C57BL/6)
decreased interferon-gamma secretion J:76161
decreased tumor necrosis factor secretion J:76161
impaired macrophage phagocytosis J:76161
increased interleukin-1 beta secretion J:76161
increased susceptibility to bacterial infection J:76161
increased susceptibility to bacterial infection induced morbidity/mortality J:76161
\Mapkapk2tm1Mgl/\Mapkapk2tm1Mgl
(involves: 129P2/OlaHsd * 129S/SvEvBrd * C57BL/6)
abnormal cytokine secretion J:117668
\Mapkapk2tm1Mgl/\Mapkapk2tm1Mgl
\Mapkapk3tm1.1Lex/\Mapkapk3tm1.1Lex

(involves: 129P2/OlaHsd * 129S/SvEvBrd * C57BL/6)
abnormal cytokine secretion J:117668
\Mapkapk2tm1Mgl/\Mapkapk2tm1Mgl
\Tnftm2Gkl/\Tnf+

(involves: 129P2/OlaHsd * 129S/SvEv * C57BL/6J)
granulomatous inflammation J:108572
immune system phenotype J:108572
small intestinal inflammation J:108572
\Mapkapk3em1(IMPC)Ccpcz/\Mapkapk3em1(IMPC)Ccpcz
(C57BL/6N-Mapkapk3em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged spleen J:211773
enlarged thymus J:211773
\Mapkapk3tm1.1Lex/\Mapkapk3tm1.1Lex
(involves: 129S/SvEvBrd * C57BL/6)
immune system phenotype J:117668
\Mapkbp1tm1b(EUCOMM)Hmgu/\Mapkbp1tm1b(EUCOMM)Hmgu
(C57BL/6N-Mapkbp1tm1b(EUCOMM)Hmgu/H)
increased spleen weight J:211773
\Mapttm1(EGFP)Klt/\Mapttm1(EGFP)Klt
\Tg(MAPT)8cPdav/?

(involves: 129S4/SvJae * C57BL/6 * Swiss Webster)
abnormal spleen B cell follicle morphology J:174270
abnormal spleen B cell follicle shape J:174270
abnormal spleen red pulp morphology J:174270
increased spleen B cell follicle size J:174270
\Mapttm2.1(FUS)Neas/\Mapt+
(B6J.129P2(129S)-Mapttm2.1(FUS)Neas)
microgliosis J:232167
\Mapttm3.1(FUS)Neas/\Mapt+
(B6J.129P2(129S)-Mapttm3.1(FUS)Neas)
microgliosis J:232167
\Mar1tm1Wtg/\Mar1+
(involves: 129S6/SvEvTac * C57BL/6)
abnormal immune system physiology J:68024
abnormal somatic hypermutation frequency J:68024
\Mar1tm1Wtg/\Mar1tm1Wtg
(involves: 129S6/SvEvTac * C57BL/6)
abnormal somatic hypermutation frequency J:68024
\Marchf1tm1.1Sish/\Marchf1tm1.1Sish
(involves: 129S1/Sv * 129X1/SvJ)
abnormal B cell physiology J:119918
abnormal dendritic cell antigen presentation J:201198, J:157516
abnormal dendritic cell morphology J:119918
abnormal level of surface class II molecules J:119918
abnormal T cell differentiation J:201198
decreased interleukin-12 secretion J:157516
decreased regulatory T cell number J:201198
decreased tumor necrosis factor secretion J:157516
immune system phenotype J:201198
\Marchf2em1Cnu/\Marchf2em1Cnu
(C57BL/6-Marchf2em1Cnu)
decreased susceptibility to bacterial infection J:297482
decreased susceptibility to viral infection J:297482
increased circulating interferon-beta level J:297482
increased circulating interleukin-6 level J:297482
increased circulating interleukin-12 level J:297482
increased circulating tumor necrosis factor level J:297482
increased interleukin-6 secretion J:297482
increased interleukin-12 secretion J:297482
increased susceptibility to bacterial infection induced morbidity/mortality J:297482
increased susceptibility to endotoxin shock J:297482
\Marchf3em1Hbsh/\Marchf3em1Hbsh
(involves: C57BL/6J)
abnormal circulating cytokine level J:267641
increased susceptibility to infection induced morbidity/mortality J:267641
\Marchf3tm1b(EUCOMM)Hmgu/\Marchf3tm1b(EUCOMM)Hmgu
(C57BL/6N-Marchf3tm1b(EUCOMM)Hmgu/Ccpcz)
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged spleen J:211773
enlarged thymus J:211773
\Marchf5tm1.1Ygi/\Marchf5tm1.1Ygi
\Tg(Emx1-cre)#Ito/0

(involves: C57BL/6)
increased microglial cell activation J:284572
\Marchf5tm1a(EUCOMM)Wtsi/\Marchf5+
(C57BL/6-Marchf5tm1a(EUCOMM)Wtsi)
decreased susceptibility to Riboviria infection induced morbidity/mortality J:225000
increased circulating interferon-beta level J:225000
increased circulating interleukin-6 level J:225000
\Marchf6tm1b(EUCOMM)Hmgu/\Marchf6tm1b(EUCOMM)Hmgu
(C57BL/6N-Marchf6tm1b(EUCOMM)Hmgu/Ccpcz)
decreased CD4-positive, alpha-beta T cell number J:211773
decreased T-helper cell number J:211773
\Marchf7Gt(ROSABetageo)1Summ/\Marchf7+
(involves: BALB/c)
abnormal cytokine secretion J:96167
abnormal interleukin level J:96167
increased interleukin-10 secretion J:96167
increased T cell proliferation J:96167
\Marchf7Gt(ROSABetageo)1Summ/\Marchf7Gt(ROSABetageo)1Summ
(involves: BALB/c)
abnormal cytokine secretion J:96167
abnormal interleukin level J:96167
increased interleukin-10 secretion J:96167
increased T cell proliferation J:96167
\Marchf8em2(IMPC)Ccpcz/\Marchf8em2(IMPC)Ccpcz
(C57BL/6N-Marchf8em2(IMPC)Ccpcz/Ccpcz)
decreased eosinophil cell number J:211773
\Marchf8tm1.1Lkle/\Marchf8tm1.1Lkle
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
immune system phenotype J:236611
\Marchf9tm1a(EUCOMM)Wtsi/\Marchf9tm1a(EUCOMM)Wtsi
(Not Specified)
decreased B cell number J:165965
\Marcksl1tm1Fsh/\Marcksl1tm1Fsh
(involves: 129S4/SvJae)
abnormal macrophage physiology J:115146
\Marcotm1Ktry/\Marcotm1Ktry
(B6.129S6-Marcotm1Ktry)
abnormal macrophage physiology J:115081
abnormal spleen marginal zone morphology J:122271
impaired macrophage phagocytosis J:115081
increased inflammatory response J:115081
increased susceptibility to bacterial infection J:115081, J:122271
\Marcotm1Ktry/\Marcotm1Ktry
\Msr1tm1Csk/\Msr1tm1Csk

(B6.129-Marcotm1Ktry Msr1tm1Csk)
abnormal macrophage physiology J:122271
abnormal spleen marginal zone morphology J:122271
increased IgM level J:122271
increased susceptibility to bacterial infection J:122271
\Marcotm1Spt/\Marcotm1Spt
(C57BL/6-Marcotm1Spt)
abnormal dendritic cell chemotaxis J:204315
abnormal dendritic cell physiology J:204315
increased interferon-gamma secretion J:204315
\Marif1C57BL/10J/\Marif1C57BL/10J
(involves: O20/A * NXT-10/Dem)
abnormal immune serum protein physiology J:90251
decreased interleukin-12 secretion J:90251
decreased tumor necrosis factor secretion J:90251
\Marif2C57BL/10J/\Marif2C57BL/10J
(involves: O20/A * NXT-10/Dem)
abnormal immune serum protein physiology J:90251
decreased interleukin-12 secretion J:90251
increased tumor necrosis factor secretion J:90251
\Marif3C57BL/10J/\Marif3C57BL/10J
(involves: O20/A * NXT-10/Dem)
increased interleukin-12 secretion J:90251
\Mark2tm1Hpw/\Mark2tm1Hpw
(involves: 129X1/SvJ * C57BL/6)
abnormal CD4-positive, alpha beta T cell morphology J:68830
abnormal humoral immune response J:68830
abnormal immune system physiology J:68830
abnormal spleen B cell follicle morphology J:68830
decreased B cell proliferation J:68830
decreased IgG3 level J:68830
decreased IgM level J:68830
enlarged lymph nodes J:68830
enlarged spleen J:68830
glomerulonephritis J:68830
increased B cell number J:68830
increased B cell proliferation J:68830
increased interferon-gamma secretion J:68830
increased interleukin-4 secretion J:68830
increased spleen weight J:68830
kidney inflammation J:68830
lung inflammation J:68830
lymph node hyperplasia J:68830
salivary gland inflammation J:68830
spleen hyperplasia J:68830
\Mark4em1(IMPC)Mbp/\Mark4em1(IMPC)Mbp
(C57BL/6N-Mark4em1(IMPC)Mbp/Ucd)
abnormal spleen morphology J:211773
enlarged spleen J:211773
\Marveld2tm1.1Sria/\Marveld2tm1.1Sria
(involves: 129X1/SvJ * C57BL/6J)
increased spleen weight J:201580
\Marveld3em1(IMPC)Ccpcz/\Marveld3em1(IMPC)Ccpcz
(C57BL/6NCrl-Marveld3em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged thymus J:211773
\Masp1tm1Tefu/\Masp1tm1Tefu
(B6.129S4-Masp1tm1Tefu)
impaired complement alternative pathway J:177350
impaired lectin complement pathway J:134537
\Masp2tm1Tefu/\Masp2tm1Tefu
(involves: 129 * C57BL/6)
abnormal complement pathway J:140667
\Masp2tm1Wjsc/\Masp2tm1Wjsc
(B6.129P2-Masp2tm1Wjsc)
impaired lectin complement pathway J:172218
\Mast4m1Anu/\Mast4m1Anu
(C57BL/6NCrlAnu-Mast4m1Anu)
immune system phenotype J:104190
\Mat1atm1Jmm/\Mat1atm1Jmm
(involves: 129/Sv * C57BL/6)
liver inflammation J:69408
\Matn1tm1Ref/\Matn1tm1Ref
\Matn2tm1Asz/\Matn2tm1Asz
\Matn3tm1Asz/\Matn3tm1Asz
\Matn4tm1.1Asz/\Matn4tm1.1Asz

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
decreased double-positive T cell number J:237230
increased granulocyte number J:237230
\Matn3tm1Brd/\Matn3tm1Brd
(involves: 129S7/SvEvBrd * C57BL/6)
osteoarthritis J:112002
\Matr3em1Tcp/\Matr3em1Tcp
(C57BL/6J-Matr3em1Tcp)
increased microglial cell activation J:298091
\Mavstm1Aki/\Mavstm1Aki
(Not Specified)
abnormal cytokine secretion J:124405
abnormal response to infection J:124405
decreased circulating interleukin-6 level J:124405
decreased interferon-alpha secretion J:124405
decreased interferon-beta secretion J:124405
decreased interleukin-6 secretion J:124405
increased susceptibility to Picornaviridae infection J:124405
\Mavstm1Aki/\Mavstm1Aki
(involves: 129P2/OlaHsd * C57BL/6)
decreased CD8-positive, alpha-beta T cell number J:130954
decreased circulating interferon-alpha level J:130954
decreased circulating interferon-beta level J:130954
decreased circulating interferon-gamma level J:130954
decreased circulating interleukin-6 level J:130954
decreased IgG1 level J:130954
decreased IgG2a level J:130954
decreased IgG level J:130954
decreased interferon-beta secretion J:130954
decreased interleukin-12b secretion J:130954
\Mavstm1Aki/\Mavstm1Aki
(involves: C57BL/6)
immune system phenotype J:132662
\Mavstm1Aki/\Mavstm1Aki
(involves: 129S/SvEv * C57BL/6)
abnormal circulating interferon level J:162888
abnormal dendritic cell physiology J:162888
abnormal macrophage physiology J:162888
brain inflammation J:162888
CNS inflammation J:162888
decreased CD4-positive, alpha-beta T cell number J:162888
decreased CD8-positive, alpha-beta T cell number J:162888
decreased interferon-beta secretion J:162888
enlarged spleen J:162888
immune system phenotype J:162888
increased circulating interferon-gamma level J:162888
increased circulating interleukin-6 level J:162888
increased circulating tumor necrosis factor level J:162888
increased dendritic cell number J:162888
increased IgG2a level J:162888
increased IgG level J:162888
increased IgM level J:162888
increased susceptibility to Flaviviridae infection J:162888
increased susceptibility to Flaviviridae infection induced morbidity/mortality J:162888
\Mavstm1Aki/\Mavstm1Aki
\Ifna6tm1Aki/\Ifna6+

(involves: 129P2/OlaHsd)
abnormal alveolar macrophage morphology J:124340
abnormal macrophage morphology J:124340
abnormal myeloid dendritic cell morphology J:124340
decreased interferon-alpha secretion J:124340
\Mavstm1Aki/\Mavstm1Aki
\Ticam1tm1Aki/\Ticam1tm1Aki

(involves: 129P2/OlaHsd * C57BL/6)
decreased CD8-positive, alpha-beta T cell number J:130954
decreased circulating interferon-alpha level J:130954
decreased circulating interferon-beta level J:130954
decreased circulating interferon-gamma level J:130954
decreased circulating interleukin-6 level J:130954
decreased circulating interleukin-12b level J:130954
decreased cytotoxic T cell cytolysis J:130954
decreased IgG1 level J:130954
decreased IgG2a level J:130954
decreased IgG level J:130954
decreased interferon-beta secretion J:130954
decreased interleukin-12b secretion J:130954
\Mavstm1Camb/\Mavstm1Camb
(involves: 129S6/SvEvTac * C57BL/6)
abnormal B cell calcium ion homeostasis J:180356
decreased B cell proliferation J:180356
decreased interleukin-12 secretion J:180356
decreased tumor necrosis factor secretion J:180356
\Mavstm1Itl/\Mavstm1Itl
\Trex1tm1Tld/\Trex1tm1Tld

(involves: 129P2/OlaHsd * C57BL/6)
increased inflammatory response J:181257
myocarditis J:181257
myositis J:181257
skin inflammation J:181257
stomach inflammation J:181257
\Mavstm1Tsc/\Mavstm1Tsc
(Not Specified)
decreased interferon-beta secretion J:136289
\Mavstm1Tsse/\Mavstm1Tsse
\Tg(PVR)1Kkst/0

(involves: 129 * C57BL/6 * ICR)
abnormal interferon-alpha secretion J:179625
decreased susceptibility to Picornaviridae infection induced morbidity/mortality J:179625
\Mavstm1Zjc/\Mavs+
(involves: 129/Sv * C57BL/6)
abnormal innate immunity J:110905
increased susceptibility to Riboviria infection J:110905
\Mavstm1Zjc/\Mavstm1Zjc
(involves: 129/Sv * C57BL/6)
abnormal dendritic cell physiology J:110905
abnormal innate immunity J:110905
abnormal macrophage physiology J:110905
increased susceptibility to Riboviria infection J:110905
\Mavstm1Zjc/\Mavstm1Zjc
(B6.Cg-Mavstm1Zjc)
abnormal circulating interferon level J:243916
\Mavstm1Zjc/\Mavstm1Zjc
\Rnaseh2atm1Crh/\Rnaseh2atm1Crh

(Not Specified)
abnormal innate immunity J:232933
\Mb21d2em1(IMPC)Mbp/\Mb21d2em1(IMPC)Mbp
(C57BL/6N-Mb21d2em1(IMPC)Mbp/MbpMmucd)
abnormal spleen morphology J:211773
\Mbd2tm1Bh/\Mbd2tm1Bh
(NOD.129P2(B6)-Mbd2tm1Bh)
abnormal CD4-positive, alpha-beta T cell physiology J:323838
abnormal CD8-positive, alpha-beta cytotoxic T cell morphology J:323838
abnormal effector T cell morphology J:323838
enlarged lymph nodes J:323838
enlarged spleen J:323838
increased T cell proliferation J:323838
increased T-helper 1 cell number J:323838
increased T-helper 2 cell number J:323838
insulitis J:323838
salivary gland inflammation J:323838
\Mbd3tm2Bh/\Mbd3tm2Bh
\Tg(Vil1-cre)20Syr/0

(involves: 129P2/OlaHsd * C57BL/6 * DBA/2)
increased susceptibility to induced colitis J:167984
\Mbd5tm1b(EUCOMM)Wtsi/\Mbd5+
(C57BL/6N-Mbd5tm1b(EUCOMM)Wtsi/Ics)
decreased leukocyte cell number J:211773
decreased lymphocyte cell number J:211773
\Mbipem1(IMPC)J/\Mbip+
(C57BL/6NJ-Mbipem1(IMPC)J/Mmjax)
decreased leukocyte cell number J:211773
\Mbis1NOD/ShiLt/\Mbis1NOD/ShiLt
(involves: BALB/c * NOD/Lt)
increased susceptibility to bacterial infection J:75276
\Mbis2BALB/c/\Mbis2BALB/c
(involves: BALB/c * NOD/Lt)
increased susceptibility to bacterial infection J:75276
\Mbis2BALB/c/\Mbis2NOD/ShiLt
(involves: BALB/c * NOD/Lt)
increased susceptibility to bacterial infection J:75276
\Mbis3BALB/c/?
(involves: BALB/c * NOD/Lt)
increased susceptibility to bacterial infection J:75276
\Mbis4NOD/ShiLt/\Mbis4NOD/ShiLt
(involves: BALB/c * NOD/Lt)
increased susceptibility to bacterial infection J:75276
\Mbl1tm1.1Mnz/\Mbl1tm1.1Mnz
(B6.129-Mbl1tm1.1Mnz)
immune system phenotype J:84540
\Mbl1tm1Kata/\Mbl1tm1Kata
(involves: 129S4/SvJae * C57BL/6J)
decreased circulating tumor necrosis factor level J:90437
\Mbl1tm1Kata/\Mbl1tm1Kata
\Mbl2tm1Kata/\Mbl2tm1Kata

(involves: 129 * C57BL/6)
abnormal B cell number J:97686
abnormal circulating interleukin-6 level J:98124
abnormal circulating tumor necrosis factor level J:98124
decreased germinal center B cell number J:97686
decreased macrophage cell number J:98124
decreased monocyte cell number J:98124
impaired macrophage phagocytosis J:97686, J:98124
increased B-1 B cell number J:97686
increased susceptibility to bacterial infection J:98124
\Mbl1tm1Kata/\Mbl1tm1Kata
\Mbl2tm1Kata/\Mbl2tm1Kata

(involves: 129 * C57BL/6J)
abnormal complement pathway J:106351
abnormal response to infection J:106352
increased susceptibility to bacterial infection J:106353
\Mbl1tm1Rala/\Mbl1tm1Rala
(involves: 129X1/SvJ * C57BL/6J)
abnormal immunoglobulin level J:145279
decreased IgG2b level J:145279
decreased IgM level J:145279
increased IgG1 level J:145279
increased IgG2a level J:145279
increased IgG3 level J:145279
increased susceptibility to parasitic infection J:145279
\Mboat2em1(IMPC)Mbp/\Mboat2em1(IMPC)Mbp
(C57BL/6N-Mboat2em1(IMPC)Mbp/Ucd)
abnormal lymph node morphology J:211773
abnormal spleen morphology J:211773
enlarged lymph nodes J:211773
enlarged spleen J:211773
\Mboat7tm1b(KOMP)Wtsi/\Mboat7+
(C57BL/6N-Mboat7tm1b(KOMP)Wtsi/H)
increased lymphocyte cell number J:211773
\Mbpshi/\Mbpshi
(C3Fe.SWV-Mbpshi/J)
decreased susceptibility to Picornaviridae infection J:41447
immune system phenotype J:41447
\Mbpshi/\Mbpshi
(involves: BALB/c * C3HeB/Fe * SWV)
increased interferon-gamma secretion J:48412
increased interleukin-2 secretion J:48412
increased interleukin-4 secretion J:48412
increased susceptibility to experimental autoimmune encephalomyelitis J:48412
increased T cell proliferation J:48412
\Mbtps1wrt/\Mbtps1wrt
(C57BL/6J-Mbtps1wrt)
decreased cytotoxic T cell cytolysis J:94077
decreased susceptibility to bacterial infection J:123123
increased interleukin-1 beta secretion J:146454
increased interleukin-6 secretion J:146454
increased susceptibility to Herpesvirales infection J:94077, J:123123
increased susceptibility to induced colitis J:146454
\Mc2rtm1Dchi/\Mc2rtm1Dchi
(B6.129P2-Mc2rtm1Dchi)
increased spleen weight J:127445
increased thymus weight J:127445
\Mc3rtm1Butl/\Mc3rtm1Butl
(B6.Cg-Mc3rtm1Butl)
increased inflammatory response J:178147
\Mc4rtm1Dhu/\Mc4rtm1Dhu
(involves: 129S4/SvJae * C57BL/6J)
decreased osteoclast cell number J:97566
\Mc4rtm1Lowl/\Mc4rtm1Lowl
(involves: 129S4/SvJae * C57BL/6J)
increased circulating interleukin-6 level J:177386
liver inflammation J:177386
white adipose tissue inflammation J:177386
\Mc4rtm1Matsu/\Mc4rtm1Matsu
(C57BL/6J-Mc4rtm1Matsu)
liver inflammation J:285412
\Mcamtm1Lex/\Mcamtm1Lex
(involves: 129S/SvEvBrd)
abnormal cytokine level J:193167
abnormal response to infection J:193167
decreased macrophage cytokine production J:193167
\Mcattm1.1Ssmi/\Mcattm1.1Ssmi
\Tg(CAG-cre/Esr1*)5Amc/0

(involves: 129P2/OlaHsd * C57BL/6 * C57BL/6J * CBA)
abnormal immune system organ morphology J:192213
abnormal myelopoiesis J:192213
decreased leukocyte cell number J:192213
decreased lymphocyte cell number J:192213
enlarged spleen J:192213
\Mcemp1em1Jngj/\Mcemp1em1Jngj
(C57BL/6-Mcemp1em1Jngj)
abnormal mast cell differentiation J:335318
abnormal type I hypersensitivity reaction J:335318
\Mcidasem2(IMPC)Tcp/\Mcidasem2(IMPC)Tcp
(C57BL/6NCrl-Mcidasem2(IMPC)Tcp/Tcp)
abnormal spleen morphology J:211773
increased leukocyte cell number J:211773
\Mcl1em1(IMPC)Mbp/\Mcl1+
(C57BL/6N-Mcl1em1(IMPC)Mbp/MbpMmucd)
abnormal lymph node morphology J:211773
enlarged lymph nodes J:211773
small spleen J:211773
\Mcl1tm1Dmta/\Mcl1+
\Gt(ROSA)26Sortm9(cre/ESR1)Arte/\Gt(ROSA)26Sor+

(B6.Cg-Mcl1tm1Dmta Gt(ROSA)26Sortm9(cre/ESR1)Arte)
decreased germinal center B cell number J:166069
decreased memory B cell number J:166069
\Mcl1tm1Dmta/\Mcl1+
\Tg(Aicda-cre)9Mbu/0

(B6.Cg-Mcl1tm1Dmta Tg(Aicda-cre)9Mbu)
decreased germinal center B cell number J:166069
decreased memory B cell number J:166069
\Mcl1tm1Dmta/\Mcl1tm1Dmta
\Gt(ROSA)26Sortm9(cre/ESR1)Arte/\Gt(ROSA)26Sor+

(B6.Cg-Mcl1tm1Dmta Gt(ROSA)26Sortm9(cre/ESR1)Arte)
abnormal B cell differentiation J:166069
absent germinal center B cells J:166069
absent memory B cells J:166069
decreased naive B cell number J:166069
\Mcl1tm1Dmta/\Mcl1tm1Dmta
\Tg(Aicda-cre)9Mbu/0

(B6.Cg-Mcl1tm1Dmta Tg(Aicda-cre)9Mbu)
absent germinal center B cells J:166069
absent memory B cells J:166069
decreased IgG1 level J:166069
immune system phenotype J:166069
\Mcl1tm1Yen/\Mcl1tm1Yen
(B6.129-Mcl1tm1Yen)
abnormal CD8-positive, alpha-beta T cell physiology J:146246
abnormal double-positive T cell morphology J:146246
decreased CD8-positive, alpha-beta T cell number J:146246
decreased double-negative T cell number J:146246
decreased single-positive T cell number J:146246
\Mcl1tm1Yen/\Mcl1tm1Yen
\Tg(TcraH-Y,TcrbH-Y)71Vbo/?

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2)
abnormal double-positive T cell morphology J:146246
decreased CD8-positive, alpha-beta T cell number J:146246
\Mcl1tm1Yen/\Mcl1tm1Yen
\Tg(TcraTcrb)425Cbn/?

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
abnormal double-positive T cell morphology J:146246
decreased CD4-positive, alpha-beta T cell number J:146246
\Mcl1tm1Ywh/\Mcl1tm1Ywh
\Lyz2tm1(cre)Ifo/\Lyz2+

(involves: 129P2/OlaHsd * 129S4/SvJae * 129S6/SvEvTac * C57BL/6)
abnormal neutrophil physiology J:137502
decreased granulocyte number J:137502
decreased neutrophil cell number J:137502
immune system phenotype J:137502
impaired neutrophil recruitment J:137502
increased eosinophil cell number J:137502
\Mcl1tm1Ywh/\Mcl1tm1Ywh
\Tg(Cd4-cre)1Cwi/0

(involves: 129S6/SvEvTac * C57BL/6 * DBA/2)
decreased CD4-positive, alpha-beta T cell number J:137400
decreased CD8-positive, alpha-beta T cell number J:137400
decreased T cell number J:137400
increased double-positive T cell number J:137400
increased T cell apoptosis J:137400
\Mcl1tm1Ywh/\Mcl1tm1Ywh
\Tg(Lck-cre)548Jxm/0

(involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6 * CBA)
abnormal T cell differentiation J:137400
decreased CD4-positive, alpha-beta T cell number J:137400
decreased CD8-positive, alpha-beta T cell number J:137400
decreased double-negative T cell number J:137400
decreased double-positive T cell number J:137400
decreased T cell number J:137400
increased T cell apoptosis J:137400
thymus hypoplasia J:137400
\Mcl1tm2Sjk/\Mcl1tm3Sjk
\Tg(Lck-cre)1Cwi/0

(involves: 129X1/SvJ * C57BL/6 * DBA/2)
arrested T cell differentiation J:86906
decreased double-negative T cell number J:86906
decreased double-positive T cell number J:86906
decreased T cell number J:86906
decreased thymocyte number J:86906
increased T cell apoptosis J:86906
\Mcl1tm2Sjk/\Mcl1tm3Sjk
\Tg(Mx1-cre)1Cgn/0

(involves: 129X1/SvJ * C57BL/6 * CBA)
decreased B cell number J:86906
decreased T cell number J:86906
\Mcl1tm3Sjk/\Mcl1tm3Sjk
\Tg(Cpa3-cre)3Glli/0

(involves: 129X1/Sv * C57BL/6)
decreased basophil cell number J:179080
decreased inflammatory response J:179080
decreased mast cell number J:179080
decreased susceptibility to type I hypersensitivity reaction J:179080
\MclrRF/J/\MclrSWR/J
(involves: RF/J * SWR/J)
increased T cell derived lymphoma incidence J:9614
\MclrSWR/J/\MclrSWR/J
(involves: RF/J * SWR/J)
increased T cell derived lymphoma incidence J:9614
\Mcm2Gt(AB0178)Wtsi/\Mcm2+
\Mcm4chaos3/\Mcm4chaos3

(involves: 129P2/OlaHsd * C3HeB/FeJ * C57BL/6J)
increased T cell derived lymphoma incidence J:165667
\Mcm2tm1(cre/ERT2)Scpr/\Mcm2tm1(cre/ERT2)Scpr
(involves: 129S6/SvEvTac)
enlarged spleen J:141493
\Mcm3aptm1Imku/\Mcm3aptm1Imku
\Cd19tm1(cre)Cgn/\Cd19+

(involves: 129P2/OlaHsd * C57BL/6 * CBA)
abnormal germinal center B cell physiology J:88276
abnormal memory B cell number J:88276
abnormal spleen germinal center morphology J:88276
decreased B cell number J:88276
decreased B cell proliferation J:88276
decreased germinal center B cell number J:88276
decreased IgG level J:88276
\Mcm4chaos3/\Mcm4chaos3
(involves: C57BL/6J)
increased T cell derived lymphoma incidence J:165667
\Mcm4Sdla/\Mcm4+
(involves: C57BL/6)
decreased DN1 thymic pro-T cell number J:194117
enlarged lymph nodes J:194117
enlarged spleen J:194117
\Mcoln1tm1Sasl/\Mcoln1tm1Sasl
(involves: 129S6/SvEvTac * C57BL/6)
abnormal macrophage physiology J:189070
\Mcoln2tm1e.1(KOMP)Wtsi/\Mcoln2tm1e.1(KOMP)Wtsi
(involves: C57BL/6J * C57BL/6N)
abnormal chemokine level J:239875
abnormal chemokine secretion J:239875
abnormal innate immunity J:239875
impaired macrophage chemotaxis J:239875
impaired neutrophil chemotaxis J:239875
\Mcph1Tg(HLA-A2.1)1Enge/\Mcph1+
(involves: C57BL/6)
abnormal immune tolerance J:52612
\Mcph1Tg(HLA-A2.1)1Enge/\Mcph1+
(NOD.B6-Mcph1Tg(HLA-A2.1)1Enge)
increased susceptibility to autoimmune diabetes J:109851
\Mcph1Tg(HLA-A2.1)1Enge/\Mcph1Tg(HLA-A2.1)1Enge
(NOD.B6-Mcph1Tg(HLA-A2.1)1Enge)
immune system phenotype J:109851
increased susceptibility to autoimmune diabetes J:109851
\Mcph1tm1.2Kali/\Mcph1tm1.2Kali
(involves: 129S7/SvEvBrd * C57BL/6J)
abnormal T cell physiology J:156371
\Mcph1tm1a(EUCOMM)Wtsi/\Mcph1tm1a(EUCOMM)Wtsi
(involves: C57BL/6 * C57BL/6N)
increased B cell number J:213427
\Mcpt1tm1Hrpm/\Mcpt1tm1Hrpm
(involves: 129P2/OlaHsd * MF1)
abnormal mast cell morphology J:93795
decreased circulating tumor necrosis factor level J:93616
increased susceptibility to parasitic infection J:93616, J:93795
\Mcpt4tm1Mabr/\Mcpt4tm1Mabr
(involves: 129X1/SvJ * C57BL/6J)
abnormal mast cell physiology J:84839
\Mcpt8tm1.1(HBEGF)Hkar/\Mcpt8tm1.1(HBEGF)Hkar
(B6.Cg-Mcpt8tm1.1(HBEGF)Hkar)
decreased basophil cell number J:163761
immune system phenotype J:163761
increased susceptibility to parasitic infection J:163761
\McrC57BL/10J/\McrNC
(involves: C57BL/10J * NC)
cutaneous mastocytosis J:8804
\McrNC/\McrNC
(involves: C57BL/10J * NC)
cutaneous mastocytosis J:8804
\Mcts1em1(IMPC)Mbp/Y
(C57BL/6N-Mcts1em1(IMPC)Mbp/Ucd)
enlarged spleen J:211773
\Mdc1Gt(OST441263)Lex/\Mdc1Gt(OST441263)Lex
(involves: 129S5/SvEvBrd * C57BL/6)
abnormal class switch recombination J:137341
small spleen J:137341
small thymus J:137341
\Mdficem1Nlh/\Mdficem2Nlh
(C57BL/6J-Mdficem1Nlh/Mdficem2Nlh)
abnormal lymph circulation J:326462
abnormal lymphatic vessel morphology J:326462
\Mdga2Tg(Prnp-PFN1*G118V)838Kiaei/\Mdga2+
(involves: C57BL/6N)
microgliosis J:241428
\Mdktm1Tmu/\Mdktm1Tmu
(129S2-Mdktm1Tmu)
tubular nephritis J:93637
\Mdktm1Tmu/\Mdktm1Tmu
(B6.129S2-Mdktm1Tmu)
abnormal macrophage chemotaxis J:102069
decreased macrophage cell number J:102069
impaired neutrophil chemotaxis J:102069
\Mdm2tm1.1Ypz/\Mdm2tm1.1Ypz
\Tg(IghMyc)22Bri/0

(B6.Cg-Mdm2tm1.1Ypz Tg(IghMyc)22Bri)
enlarged lymph nodes J:164200
enlarged Peyer's patches J:164200
enlarged thymus J:164200
spleen hyperplasia J:164200
\Mdm2tm1Bay/\Mdm2tm1Mep
(involves: 129S7/SvEvBrd * C57BL/6)
abnormal B cell differentiation J:81065
decreased double-negative T cell number J:81065
decreased double-positive T cell number J:81065
decreased granulocyte number J:81065
decreased immature B cell number J:81065
decreased leukocyte cell number J:81065
decreased lymphocyte cell number J:81065
decreased neutrophil cell number J:81065
decreased spleen weight J:81065
decreased T cell number J:81065
decreased thymocyte number J:81065
decreased thymus weight J:81065
spleen hypoplasia J:81065
thymus hypoplasia J:81065
\Mdm2tm1Glo/\Mdm2+
\Mdm4tm1Glo/\Mdm4+

(involves: 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6)
decreased leukocyte cell number J:123661
spleen atrophy J:123661
spleen hypoplasia J:123661
thymus atrophy J:123661
thymus hypoplasia J:123661
\Mdm2tm1Glo/\Mdm2+
\Trp53tm2Wahl/\Trp53tm2Wahl

(involves: 129S4/SvJae * 129S7/SvEvBrd * C57BL/6)
decreased leukocyte cell number J:174375
small thymus J:174375
spleen atrophy J:174375
\Mdm2tm1Mep/\Mdm2tm1.1Mep
(involves: 129S7/SvEvBrd * C57BL/6 * FVB)
decreased spleen weight J:81065
decreased thymus weight J:81065
\Mdm2tm2.1Snj/\Mdm2tm2.1Snj
(involves: 129S4/SvJae * C57BL/6)
decreased thymocyte apoptosis J:189297
enlarged spleen J:189297
increased T cell derived lymphoma incidence J:189297
\Mdm2tm3.1Snj/\Mdm2tm3.1Snj
(involves: 129S4/SvJae * C57BL/6)
immune system phenotype J:189297
\Mdm4m1Btlr/\Mdm4m1Btlr
(C57BL/6J-Mdm4m1Btlr)
decreased CD8-positive, alpha-beta T cell number J:265262
decreased single-positive T cell number J:265262
increased CD4-positive, alpha-beta T cell number J:265262
increased single-positive T cell number J:265262
\Mdm4m2Btlr/\Mdm4m2Btlr
(C57BL/6J-Mdm4m2Btlr)
decreased CD8-positive, alpha-beta T cell number J:272830
increased CD4-positive, alpha-beta T cell number J:272830
\Mdm4tm1.1Wahl/\Mdm4tm1.1Wahl
(involves: 129S/Sv * C57BL/6)
decreased thymocyte apoptosis J:150341
increased leukocyte cell number J:150341
\Me1em1(IMPC)Tcp/\Me1em1(IMPC)Tcp
(C57BL/6NCrl-Me1em1(IMPC)Tcp/Tcp)
enlarged lymph nodes J:211773
\MecomJbo/\Mecom+
(C3N.C-MecomJbo)
abnormal neutrophil differentiation J:113445
immune system phenotype J:113445
increased susceptibility to otitis media J:113445
respiratory system inflammation J:113445
\MecomJbo/\Mecom+
(involves: BALB/c)
increased susceptibility to otitis media J:250208
\Mecomtm1Aspe/\Mecomtm1Aspe
(involves: 129S6/SvEvTac * C57BL/6)
increased leukocyte cell number J:178429
\Mecomtm2.2Aspe/\Mecomtm2.2Aspe
(involves: 129 * C57BL/6J * FVB/N)
abnormal immune system organ morphology J:213829
decreased B cell number J:213829
decreased leukocyte cell number J:213829
\Mecp2tm1.1Bird/Y
\SqleSum3-Jus/\Sqle+

(involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6J)
dermatitis J:198551
\Mecp2tm1.1Bird/Y
\Sum2M1Jus/\Sum2+

(involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6J)
dermatitis J:198551
eye inflammation J:198551
\Mecp2tm1.1Bird/Y
\Sum4M1Jus/\Sum4+

(involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6J)
dermatitis J:198551
eye inflammation J:198551
\Mecp2tm1.1Bird/Y
\Sum5M1Jus/\Sum5+

(involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6J)
eye inflammation J:198551
\Med18tm1a(EUCOMM)Wtsi/\Med18+
(C57BL/6N-Med18tm1a(EUCOMM)Wtsi/H)
decreased leukocyte cell number J:165965
\Med19tm1c(EUCOMM)Wtsi/\Med19tm1c(EUCOMM)Wtsi
\Tg(Adipoq-icre/ERT2)1Soff/0

(involves: C57BL/6J * C57BL/6N)
white adipose tissue inflammation J:298822
\Med20em1(IMPC)J/\Med20+
(C57BL/6NJ-Med20em1(IMPC)J/J)
decreased leukocyte cell number J:211773
\Med28tm1.1(KOMP)Vlcg/\Med28+
(C57BL/6N-Med28tm1.1(KOMP)Vlcg/Ucd)
abnormal spleen morphology J:211773
small spleen J:211773
\Mef2btm2Rdf/\Mef2b+
\Tg(Cr2-cre)3Cgn/0

(involves: C57BL/6)
abnormal mature B cell morphology J:265465
enlarged lymph nodes J:265465
enlarged mesenteric lymph nodes J:265465
enlarged spleen J:265465
increased germinal center B cell number J:265465
\Mef2ctm1Jjs/\Mef2ctm1Jjs
\Mir223tm1Fcam/\Mir223tm1Fcam
\Lyz2tm1(cre)Ifo/\Lyz2+

(involves: 129 * C57BL/6)
abnormal neutrophil differentiation J:140009
abnormal neutrophil physiology J:140009
increased neutrophil cell number J:140009
\Mefvtm1Bhk/\Mefvtm1Bhk
(129S6/SvEvTac-Mefvtm1Bhk)
immune system phenotype J:192443
increased interleukin-1 beta secretion J:192443
increased interleukin-18 secretion J:192443
\Mefvtm1Chae/\Mefvtm1Chae
(either: (involves: 129S6/SvEvTac) or (involves: 129S6/SvEvTac * C57BL/6))
decreased macrophage apoptosis J:82763
increased inflammatory response J:82763
increased susceptibility to endotoxin shock J:82763
\Mefvtm3.1(MEFV)Chae/\Mefvtm3.1(MEFV)Chae
(B6.129S6-Mefvtm3.1(MEFV)Chae)
autoimmune arthritis J:172117
dermatitis J:172117
increased inflammatory response J:172117
increased leukocyte cell number J:172117
\Mefvtm4.1(MEFV)Chae/\Mefvtm4.1(MEFV)Chae
(B6.129S6-Mefvtm4.1(MEFV)Chae)
autoimmune arthritis J:172117
dermatitis J:172117
increased inflammatory response J:172117
increased leukocyte cell number J:172117
\Mefvtm5.1(MEFV)Chae/\Mefvtm5.1(MEFV)Chae
(B6.129S6-Mefvtm5.1(MEFV)Chae)
abnormal cytokine secretion J:172117
abnormal spleen germinal center morphology J:172117
autoimmune arthritis J:172117
decreased B cell number J:172117
decreased interleukin-3 secretion J:172117
decreased lymphocyte cell number J:172117
decreased T cell number J:172117
dermatitis J:172117
enlarged lymph nodes J:172117
enlarged spleen J:172117
increased circulating interleukin-1 beta level J:172117
increased circulating interleukin-6 level J:172117
increased circulating tumor necrosis factor level J:172117
increased granulocyte number J:172117
increased inflammatory response J:172117
increased interferon-gamma secretion J:172117
increased interleukin-1 alpha secretion J:172117
increased interleukin-1 beta secretion J:172117
increased interleukin-2 secretion J:172117
increased interleukin-4 secretion J:172117
increased interleukin-5 secretion J:172117
increased interleukin-9 secretion J:172117
increased interleukin-10 secretion J:172117
increased interleukin-12 secretion J:172117
increased interleukin-12b secretion J:172117
increased interleukin-13 secretion J:172117
increased interleukin-17 secretion J:172117
increased leukocyte cell number J:172117
increased macrophage cell number J:172117
increased monocyte cell number J:172117
increased neutrophil cell number J:172117
joint inflammation J:172117
liver inflammation J:172117
skin inflammation J:172117
\Mefvtm5.1(MEFV)Chae/\Mefvtm5.1(MEFV)Chae
\Nlrp3tm1Tsc/\Nlrp3tm1Tsc

(involves: 129S6/SvEvTac * C57BL/6)
increased inflammatory response J:172117
increased interleukin-1 beta secretion J:172117
\Mefvtm5.1(MEFV)Chae/\Mefvtm5.1(MEFV)Chae
\Pycardtm1Tno/\Pycardtm1Tno

(involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6)
decreased interleukin-1 beta secretion J:172117
immune system phenotype J:172117
\Mefvtm5.1(MEFV)Chae/\Mefvtm5.1(MEFV)Chae
\Rag1tm1Mom/\Rag1tm1Mom

(involves: 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6)
abnormal cytokine secretion J:172117
increased circulating interleukin-1 beta level J:172117
increased circulating interleukin-6 level J:172117
increased circulating tumor necrosis factor level J:172117
increased inflammatory response J:172117
increased interferon-gamma secretion J:172117
increased interleukin-1 beta secretion J:172117
increased interleukin-2 secretion J:172117
increased interleukin-4 secretion J:172117
increased interleukin-5 secretion J:172117
increased interleukin-9 secretion J:172117
increased interleukin-10 secretion J:172117
increased interleukin-12 secretion J:172117
increased interleukin-13 secretion J:172117
increased interleukin-17 secretion J:172117
\Megf8b2b1702.2Clo/\Megf8b2b1702.2Clo
(C57BL/6J-Megf8b2b1702.2Clo)
spleen hypoplasia J:175213
thymus hypoplasia J:175213
\Megf8hlb611/\Megf8hlb611
(involves: C57BL/6J)
absent spleen J:146805
accessory spleen J:146805
\Megf8hlb611/\Megf8hlb611
(involves: C57BL/6J * C3H/HeJ)
absent spleen J:146957
accessory spleen J:146957
\Meis3tm1b(EUCOMM)Hmgu/\Meis3tm1b(EUCOMM)Hmgu
(C57BL/6N-Meis3tm1b(EUCOMM)Hmgu/Ccpcz)
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged thymus J:211773
\Men1tm1.2Zqw/\Men1tm1.2Zqw
\Pgrtm2(cre)Lyd/\Pgr+

(involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6)
decreased uterine NK cell number J:322043
\Men1tm1Ctre/\Men1+
(either: (involves: 129S6/SvEvTac * FVB/N) or (involves: 129S6/SvEvTac * Black Swiss * FVB/N))
pancreas inflammation J:67128
\Meox2tm1(cre)Sor/\Meox2+
\Procrtm2Cte/\Procrtm2Cte

(involves: 129S4/SvJaeSor * 129S7/SvEvBrd * Black Swiss * C57BL/6)
decreased circulating fibrinogen level J:119529
increased circulating C-reactive protein level J:119529
\Meox2tm1(cre)Sor/\Meox2+
\Slc40a1tm2Nca/\Slc40a1tm2Nca

(involves: 129S4/SvJae * 129S6/SvEvTac)
increased spleen iron level J:129846
\Meox2tm1(cre)Sor/\Meox2+
\Tg(CAG-lacZ,-FUS*R521G,-EGFP)682Gyu/0

(involves: 129S4/SvJaeSor * C57BL/6)
microgliosis J:216672
\Meox2tm1(cre)Sor/\Meox2+
\Tg(CAG-lacZ,-FUS,-EGFP)629Gyu/0

(involves: 129S4/SvJaeSor * C57BL/6)
microgliosis J:216672
\Mep1atm1Bond/\Mep1atm1Bond
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
abnormal chemokine level J:145685
abnormal circulating interleukin-1 beta level J:145037
abnormal cytokine level J:145037, J:145685
abnormal leukocyte physiology J:145037
abnormal tumor necrosis factor level J:145037
increased circulating interleukin-1 beta level J:145685
increased circulating interleukin-6 level J:145685
increased susceptibility to induced colitis J:145685
urinary bladder inflammation J:145037
\Mep1btm1Bond/\Mep1btm1Bond
(B6.129-Mep1btm1Bond)
immune system phenotype J:145037
\Mep1btm1Bond/\Mep1btm1Bond
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
decreased inflammatory response J:132021
\Mepetm1Tbrw/\Mepetm1Tbrw
(involves: 129P2/OlaHsd * C57BL/6)
abnormal osteoclast morphology J:81218
\Mertknmf12/\Mertknmf12
(involves: C57BL/6J)
abnormal tumor necrosis factor level J:175587
\Mertktm1Gkm/\Mertktm1Gkm
(involves: 129P2/OlaHsd * C57BL/6 * DBA/2)
increased circulating tumor necrosis factor level J:53423
increased susceptibility to endotoxin shock J:53423
increased tumor necrosis factor secretion J:53423
\Mertktm1Gkm/\Mertktm1Gkm
(NOD.129P2-Mertktm1Gkm)
abnormal mononuclear cell morphology J:147153
decreased susceptibility to autoimmune diabetes J:147153
decreased T cell number J:147153
increased T cell apoptosis J:147153
insulitis J:147153
\Mertktm1Gkm/\Mertktm1Gkm
(B6.129P2-Mertktm1Gkm)
decreased autoantibody level J:136377
decreased susceptibility to graft versus host disease J:136377
\Mertktm1Gkm/\Mertktm1Gkm
\Tg(TcraBDC2.5,TcrbBDC2.5)1Doi/0

(NOD.Cg-Mertktm1Gkm Tg(TcraBDC2.5,TcrbBDC2.5)1Doi)
decreased double-positive T cell number J:147153
increased CD8-positive, alpha-beta T cell number J:147153
increased T cell apoptosis J:147153
\Mertktm1Grl/\Mertktm1Grl
(involves: 129P2/OlaHsd)
enlarged spleen J:54681
\Mesp1tm2(cre)Ysa/\Mesp1+
\Tbx1tm1Bld/\Tbx1tm3Bld

(involves: 129S7/SvEvBrd * C57BL/6 * CBA)
athymia J:112457
thymus hypoplasia J:112457
\Mesp1tm2(cre)Ysa/\Mesp1+
\Tbx1tm1Bld/\Tbx1tm5Bld

(involves: 129S7/SvEvBrd * C57BL/6 * CBA)
athymia J:112457
\Mettm1Gvw/\Met+
(involves: 129 * C57BL/6J)
glomerulonephritis J:94722
\Mettm2Gvw/\Met+
(involves: 129 * C57BL/6J)
glomerulonephritis J:94722
\Mettm4Gvw/\Met+
(involves: 129 * C57BL/6J)
glomerulonephritis J:94722
\Metap1em1(IMPC)Tcp/\Metap1+
(C57BL/6NCrl-Metap1em1(IMPC)Tcp/Cmmr)
small spleen J:211773
\Metrnem1(IMPC)Mbp/\Metrnem1(IMPC)Mbp
(C57BL/6NCrl-Metrnem1(IMPC)Mbp/MbpMmucd)
abnormal spleen morphology J:211773
enlarged lymph nodes J:211773
enlarged spleen J:211773
increased neutrophil cell number J:211773
\Metrnltm1d(KOMP)Wtsi/\Metrnltm1d(KOMP)Wtsi
(involves: C57BL/6J * C57BL/6N)
decreased IgG level J:268270
increased IgM level J:268270
increased susceptibility to endotoxin shock J:268270
kidney inflammation J:268270
liver inflammation J:268270
uterus inflammation J:268270
\Mettl4em1Dfel/\Mettl4em1Dfel
(involves: 129/Sv * C57BL/6N)
decreased leukocyte cell number J:278437
enlarged spleen J:278437
\Mettl5em1(IMPC)Hmgu/\Mettl5em1(IMPC)Hmgu
(C57BL/6N-Mettl5em1(IMPC)Hmgu/Ieg)
increased spleen weight J:211773
\Mettl14em1(IMPC)Tcp/\Mettl14+
(C57BL/6NCrl-Mettl14em1(IMPC)Tcp/Tcp)
abnormal spleen morphology J:211773
small spleen J:211773
\Mettl23em1(IMPC)Hmgu/\Mettl23em1(IMPC)Hmgu
(C57BL/6NCrl-Mettl23em1(IMPC)Hmgu/Ieg)
enlarged spleen J:211773
increased spleen weight J:211773
\Mettl25em1(IMPC)Bay/\Mettl25em1(IMPC)Bay
(C57BL/6N-Mettl25em1(IMPC)Bay/BayMmucd)
increased spleen weight J:211773
\Mex3btm1.1Mbld/\Mex3btm1.1Mbld
\Plekha5Tg(AMH-cre)1Flor/\Plekha5+

(involves: C57BL/6 * SJL)
increased anti-sperm antibody level J:213588
\Mex3btm1.2Mbld/\Mex3btm1.2Mbld
(involves: C57BL/6 * CBA)
impaired macrophage phagocytosis J:213588
\Mex3ctm1Aki/\Mex3ctm1Aki
(involves: 129X1/SvJ * C57BL/6)
abnormal cytokine secretion J:208870
decreased interferon-beta secretion J:208870
decreased interleukin-6 secretion J:208870
decreased interleukin-12 secretion J:208870
\Mexistm1.1Pton/\Mexistm1.1Pton
(involves: C57BL/6)
increased macrophage derived foam cell number J:264834
\Mfap2tm1a(KOMP)Wtsi/\Mfap2tm1a(KOMP)Wtsi
(involves: C57BL/6J * C57BL/6N)
decreased B cell number J:236092
decreased leukocyte cell number J:236092
decreased neutrophil cell number J:236092
increased B cell number J:236092
increased macrophage cell number J:236092
increased monocyte cell number J:236092
increased myeloid dendritic cell number J:236092
increased splenocyte number J:236092
\Mfap2tm1Mech/\Mfap2tm1Mech
(involves: 129X1/SvJ)
decreased macrophage cell number J:203960
decreased monocyte cell number J:203960
\Mfap2tm1Mech/\Mfap2tm1Mech
\Mfap5tm1Mech/\Mfap5tm1Mech

(involves: 129X1/SvJ)
decreased monocyte cell number J:203960
decreased neutrophil cell number J:203960
immune system phenotype J:203960
\Mfap4tm1b(NCOM)Mfgc/\Mfap4tm1b(NCOM)Mfgc
(C57BL/6N-Mfap4tm1b(NCOM)Mfgc/Tcp)
enlarged lymph nodes J:211773
\Mfap5tm1Mech/\Mfap5tm1Mech
(Not Specified)
decreased neutrophil cell number J:203960
immune system phenotype J:203960
\Mfge8Gt(KST227)Byg/\Mfge8Gt(KST227)Byg
(B6.129P2-Mfge8Gt(KST227)Byg)
enlarged spleen J:98314
impaired macrophage phagocytosis J:98314
\Mfge8Gt(KST227)Byg/\Mfge8Gt(KST227)Byg
(involves: 129P2/OlaHsd * C57BL/6)
enlarged spleen J:107106
impaired macrophage phagocytosis J:107106
mastitis J:107106
\Mfge8tm1Mcu/\Mfge8tm1Mcu
(involves: 129X1/SvJ * C57BL/6NCr)
enlarged spleen J:123138
\Mfge8tm1Mcu/\Mfge8tm1Mcu
\Tg(RIP1-Tag)2Dh/?

(involves: 129X1/SvJ * C57BL/6J * C57BL/6NCr * DBA/2J)
decreased Langerhans cell number J:123138
\Mfge8tm1Osa/\Mfge8tm1Osa
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
abnormal spleen morphology J:90633
enlarged spleen J:90633
impaired macrophage phagocytosis J:90633
increased anti-double stranded DNA antibody level J:225063
increased spleen B cell follicle size J:90633
increased spleen weight J:90633
increased spleen white pulp amount J:90633
spleen hyperplasia J:90633
\Mfge8tm1Osa/\Mfge8tm1Osa
(B6.129-Mfge8tm1Osa)
immune system phenotype J:187181
\Mfge8tm1Osa/\Mfge8tm1Osa
\Timd4tm1Osa/\Timd4tm1Osa

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
impaired macrophage phagocytosis J:187181
increased anti-double stranded DNA antibody level J:187181
increased anti-nuclear antigen antibody level J:187181
\Mfge8tm1Shur/\Mfge8tm1Shur
(B6.129-Mfge8tm1Shur)
spermatic granuloma J:145962
\Mfn1tm2Dcc/\Mfn1tm2Dcc
\Mfn2tm3Dcc/\Mfn2tm3Dcc
\Tg(Cd4-cre)1Cwi/0

(involves: 129 * C57BL/6 * C57BL/6J * DBA/2)
abnormal CD4-positive, alpha-beta T cell physiology J:339075
\Mfngem1(IMPC)Ccpcz/\Mfngem1(IMPC)Ccpcz
(C57BL/6NCrl-Mfngem1(IMPC)Ccpcz/Ccpcz)
abnormal thymus morphology J:211773
decreased NK T cell number J:211773
enlarged thymus J:211773
\Mfngtm1.1Cfg/\Mfngtm1.1Cfg
(involves: C57BL/6)
decreased macrophage cell number J:217719
decreased mature B cell number J:217719
decreased neutrophil cell number J:217719
increased B cell number J:217719
increased B cell proliferation J:217719
increased lymphocyte cell number J:217719
\Mfngtm1Cjg/\Mfngtm1Cjg
(B6.Cg-Mfngtm1Cjg)
abnormal marginal zone B cell morphology J:146621
\Mfsd1em1(IMPC)Tcp/\Mfsd1+
(C57BL/6N-Mfsd1em1(IMPC)Tcp/Tcp)
enlarged lymph nodes J:211773
\Mfsd1em1(IMPC)Tcp/\Mfsd1em1(IMPC)Tcp
(C57BL/6N-Mfsd1em1(IMPC)Tcp/Tcp)
decreased leukocyte cell number J:211773
decreased lymphocyte cell number J:211773
enlarged spleen J:211773
increased neutrophil cell number J:211773
\Mfsd1tm1a(KOMP)Wtsi/\Mfsd1tm1a(KOMP)Wtsi
(involves: C57BL/6N)
enlarged spleen J:280713
\Mfsd2atm1Dls/\Mfsd2atm1Dls
(B6.Cg-Mfsd2atm1Dls)
abnormal microglial cell activation J:234197
\Mfsd2btm1a(KOMP)Wtsi/\Mfsd2btm1a(KOMP)Wtsi
(C57BL/6-Mfsd2btm1a(KOMP)Wtsi)
decreased B cell number J:250123
decreased leukocyte cell number J:250123
decreased T cell number J:250123
enlarged spleen J:250123
increased susceptibility to type I hypersensitivity reaction J:250123
\Mfsd6tm1Ryosh/\Mfsd6tm1Ryosh
(B6.129S2-Mfsd6tm1Ryosh)
abnormal leukocyte physiology J:260694
immune system phenotype J:260694
increased length of allograft survival J:260694
\Mfsd8tm1a(EUCOMM)Hmgu/\Mfsd8tm1a(EUCOMM)Hmgu
(involves: C57BL/6N)
abnormal spleen morphology J:211608
CNS inflammation J:211608
microgliosis J:211608
\Mfsd10tm1.1(KOMP)Vlcg/\Mfsd10tm1.1(KOMP)Vlcg
(C57BL/6N-Mfsd10tm1.1(KOMP)Vlcg/J)
decreased leukocyte cell number J:211773
\Mgat2tm1.1Jxm/\Mgat2tm1.1Jxm
(involves: 129S1/Sv * 129X1/SvJ * ICR)
abnormal B cell differentiation J:80661
decreased T cell number J:80661
enlarged lymph nodes J:80661
enlarged spleen J:80661
glomerulonephritis J:80661
\Mgat4btm1.1Jxm/\Mgat4btm1.1Jxm
(B6.129-Mgat4btm1.1Jxm)
decreased neutrophil cell number J:212313
increased leukocyte cell number J:212313
\Mgat4dtm1b(KOMP)Wtsi/\Mgat4dtm1b(KOMP)Wtsi
(C57BL/6N-Mgat4dtm1b(KOMP)Wtsi/Bay)
abnormal spleen morphology J:211773
\Mgat5tm1Jwd/\Mgat5tm1Jwd
(involves: 129S1/Sv * 129X1/SvJ)
abnormal inflammatory response J:60960
abnormal leukocyte physiology J:94864
abnormal T cell physiology J:60960
decreased interleukin-2 secretion J:94864
decreased interleukin-4 secretion J:94864
increased interleukin-10 secretion J:94864
increased tumor necrosis factor secretion J:94864
\Mgat5btm1.1Cfg/\Mgat5btm1.1Cfg
(involves: 129S6/SvEvTac)
decreased pre-B cell number J:217719
enhanced humoral immune response J:217719
increased IgG2b level J:217719
\Mgat5btm1Nta/\Mgat5btm1Nta
(Not Specified)
brain inflammation J:199165
\Mgl2tm1.1(HBEGF/EGFP)Aiwsk/\Mgl2+
(involves: C57BL/6 * FVB/N)
abnormal immune system physiology J:201044
abnormal lymph node size J:201044
abnormal T-helper 2 cell morphology J:201044
decreased B cell number J:201044
decreased CD4-positive, alpha-beta T cell number J:201044
decreased CD8-positive, alpha-beta T cell number J:201044
decreased dendritic cell number J:201044
decreased interleukin-4 secretion J:201044
decreased Langerhans cell number J:201044
increased susceptibility to parasitic infection J:201044
\Mgmttm1Mse/\Mgmttm1Mse
(involves: 129S/SvEv)
increased T cell derived lymphoma incidence J:47642
\Mgmttm1Mse/\Mgmttm1Mse
\Mlh1tm1Mse/\Mlh1tm1Mse

(involves: 129S/SvEv)
increased T cell derived lymphoma incidence J:47642
\Mgrn1em1(IMPC)Tcp/\Mgrn1+
(C57BL/6NCrl-Mgrn1em1(IMPC)Tcp/Tcp)
decreased lymphocyte cell number J:211773
increased lymphocyte cell number J:211773
increased neutrophil cell number J:211773
increased spleen weight J:211773
\Mgrn1em1(IMPC)Tcp/\Mgrn1em1(IMPC)Tcp
(C57BL/6NCrl-Mgrn1em1(IMPC)Tcp/Tcp)
enlarged lymph nodes J:211773
\Mgst2em1(IMPC)Mbp/\Mgst2em1(IMPC)Mbp
(C57BL/6N-Mgst2em1(IMPC)Mbp/MbpMmucd)
abnormal spleen morphology J:211773
small spleen J:211773
\Mical2em1(IMPC)Tcp/\Mical2em1(IMPC)Tcp
(C57BL/6NCrl-Mical2em1(IMPC)Tcp/Tcp)
enlarged lymph nodes J:211773
\Mical3em1(IMPC)J/\Mical3em1(IMPC)J
(C57BL/6NJ-Mical3em1(IMPC)J/Mmjax)
increased leukocyte cell number J:211773
\Micu1em#Fink/\Micu1em#Fink
(C57BL/6N-Micu1em#Fink)
decreased B cell number J:238984
decreased follicular B cell number J:238984
increased B cell apoptosis J:238984
\Micu1em#Fink/\Micu1em#Fink
\Smdt1em1Fink/\Smdt1+

(involves: C57BL/6J * C57BL/6N * CBA)
decreased B cell number J:238984
\Micu1tm1bNarl/\Micu1+
(C57BL/6N-Micu1tm1bNarl/Narl)
decreased monocyte cell number J:211773
\Mid2tm1b(KOMP)Wtsi/Y
(C57BL/6N-Mid2tm1b(KOMP)Wtsi/Ucd)
abnormal spleen morphology J:211773
enlarged spleen J:211773
\Mideasem1Shmc/\Mideasem1Shmc
(C57BL/6J-Mideasem1Shmc)
immune system phenotype J:291786
\Miftm1Dvd/\Miftm1Dvd
(involves: 129S4/SvJae * C57BL/6)
decreased circulating tumor necrosis factor level J:52300
decreased susceptibility to bacterial infection J:52300
decreased susceptibility to endotoxin shock J:52300
increased interleukin-4 secretion J:52300
increased susceptibility to parasitic infection J:52300
\Miftm1Mky/\Miftm1Mky
(C.129-Miftm1Mky)
abnormal cytokine secretion J:106380
abnormal inflammatory response J:106380
decreased eosinophil cell number J:106380
\Miga2tm1a(KOMP)Wtsi/\Miga2tm1a(KOMP)Wtsi
(C57BL/6N-Miga2tm1a(KOMP)Wtsi/Mmucd)
abnormal CD4-positive, alpha beta T cell morphology J:339075
\Miga2tm1a(KOMP)Wtsi/\Miga2tm1a(KOMP)Wtsi
\Pnp2em1Smoc/\Pnp2em1Smoc

(C57BL/6-Miga2tm1a(KOMP)Wtsi Pnp2em1Smoc)
abnormal CD4-positive, alpha-beta T cell physiology J:339075
\Miga2tm1c(KOMP)Wtsi/\Miga2tm1c(KOMP)Wtsi
\Tg(Cd4-cre)1Cwi/0

(B6.Cg-Miga2tm1c(KOMP)Wtsi Tg(Cd4-cre)1Cwi)
abnormal CD4-positive, alpha-beta T cell physiology J:339075
abnormal immune system morphology J:339075
immune system phenotype J:339075
\MijuC3HeB/FeJ/\MijuC57BL/6J
(involves: C3HeB/FeJ * C57BL/6J)
increased IgA level J:91062
\Milr1tm1Shib/\Milr1tm1Shib
(involves: C57BL/6N)
decreased mast cell degranulation J:161854
increased susceptibility to type I hypersensitivity reaction J:161854
\Minar1em1(IMPC)Tcp/\Minar1em1(IMPC)Tcp
(C57BL/6NCrl-Minar1em1(IMPC)Tcp/Tcp)
abnormal thymus morphology J:211773
\Mink1em1(IMPC)Tcp/\Mink1em1(IMPC)Tcp
(C57BL/6N-Mink1em1(IMPC)Tcp/Tcp)
enlarged lymph nodes J:211773
\Mipeptm1.1Yhig/\Mipeptm1.1Yhig
\Tg(Adipoq-cre)1Evdr/0

(involves: C57BL/6J * C57BL/6N * FVB/NJ)
decreased T cell number J:365489
increased cytokine level J:365489
increased granulocyte number J:365489
increased inflammatory response J:365489
increased macrophage cell number J:365489
increased monocyte cell number J:365489
increased spleen weight J:365489
white adipose tissue inflammation J:365489
\Mir10bem1Rosay/\Mir10bem1Rosay
(C57BL/6J-Mir10bem1Rosay)
large intestinal inflammation J:342486
\Mir21atm1.1Mer/\Mir21atm1.1Mer
(involves: 129S1/Sv * C57BL/6 * FVB/N)
abnormal cytokine level J:179235
abnormal cytokine secretion J:179235
abnormal interferon level J:179235
abnormal interleukin level J:179235
decreased interleukin-4 secretion J:179235
increased interferon-gamma secretion J:179235
increased interleukin-12 secretion J:179235
increased susceptibility to type I hypersensitivity reaction J:179235
\Mir21atm1.1Mer/\Mir21atm1.1Mer
(B6.129S1-Mir21atm1.1Mer)
increased susceptibility to type IV hypersensitivity reaction J:179235
\Mir27aem1Bge/\Mir27aem1Bge
(C57BL/6-Mir27aem1Bge)
abnormal macrophage physiology J:267961
decreased susceptibility to bacterial infection J:267961
\Mir33tm1.1Koho/\Mir33tm1.1Koho
(involves: C57BL/6)
abnormal macrophage physiology J:165420
\Mir34atm1.1Pisc/\Mir34atm1.1Pisc
\Mirc21tm1.1Pisc/\Mirc21tm1.1Pisc
\Mirc34tm1.1Pisc/\Mirc34tm1.1Pisc

(involves: 129S4/SvJae * C57BL/6 * C57BL/6J)
increased susceptibility to bacterial infection induced morbidity/mortality J:256929
nasal inflammation J:256929
\Mir34atm1.2Arte/\Mir34atm1.2Arte
(involves: C57BL/6N)
abnormal immune system cell morphology J:221990
increased B cell number J:221990
\Mir100em1Nju/\Mir100em1Nju
\Speer6-ps1Tg(Alb-cre)21Mgn/\Speer6-ps1+

(involves: C57BL/6 * DBA)
liver inflammation J:281439
\Mir122tm1.1Apts/\Mir122tm1.1Apts
(involves: 129 * C57BL/6)
increased circulating interleukin-6 level J:190066
increased macrophage cell number J:190066
increased monocyte cell number J:190066
liver inflammation J:190066
\Mir122tm1.1Kgh/\Mir122tm1.1Kgh
(involves: 129S1/Sv * 129X1/SvJ)
increased circulating interleukin-6 level J:190067
liver inflammation J:190067
\Mir122tm1.2Kgh/\Mir122tm1.2Kgh
\Speer6-ps1Tg(Alb-cre)21Mgn/\Speer6-ps1+

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA)
increased circulating interleukin-6 level J:190067
increased interleukin-6 secretion J:190067
increased monocyte cell number J:190067
increased neutrophil cell number J:190067
increased tumor necrosis factor secretion J:190067
liver inflammation J:190067
\Mir125atm1Smoc/\Mir125atm1Smoc
(involves: C57BL/6)
abnormal regulatory T cell physiology J:224880
decreased regulatory T cell number J:224880
immune system phenotype J:224880
increased interferon-gamma secretion J:224880
increased interleukin-17 secretion J:224880
increased susceptibility to experimental autoimmune encephalomyelitis J:224880
\Mir126atm2.1Smoc/\Mir126atm2.1Smoc
\Tg(Cd4-cre)1Cwi/0

(involves: C57BL/6J * C57BL/6N * DBA/2)
decreased T-helper 2 cell number J:355195
dermatitis J:355195
enlarged spleen J:355195
increased T-helper 1 cell number J:355195
increased T-helper 17 cell number J:355195
\Mir139em1Jwli/\Mir139em1Jwli
(C57BL/6J-Mir139em1Jwli)
abnormal cytokine level J:248779
increased susceptibility to colitis induced morbidity/mortality J:280467, J:248779
increased susceptibility to induced colitis J:248779
\Mir140tm1.1Asah/\Mir140tm1.1Asah
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA)
increased susceptibility to induced arthritis J:160358
osteoarthritis J:160358
\Mir142tm1.1Sbel/\Mir142tm1.1Sbel
(involves: C57BL/6N)
decreased eosinophil cell number J:227228
decreased leukocyte cell number J:227228
decreased lymphocyte cell number J:227228
decreased monocyte cell number J:227228
\Mir142tm1Teyo/\Mir142tm1Teyo
(involves: C57BL/6)
decreased mast cell degranulation J:211850
\Mir142hgGt(IST11580H2)Tigm/\Mir142hgGt(IST11580H2)Tigm
(involves: C57BL/6N)
abnormal dendritic cell differentiation J:207516
abnormal dendritic cell morphology J:207516
decreased dendritic cell number J:207516
enlarged spleen J:207516
immune system phenotype J:207516
increased dendritic cell number J:207516
increased neutrophil cell number J:207516
\Mir144/Mir451atm1.1Mjwe/\Mir144/Mir451atm1.1Mjwe
(Not Specified)
increased spleen weight J:163250
spleen hyperplasia J:163250
\Mir144/Mir451atm1.1Mjwe/\Mir144/Mir451atm1.1Mjwe
(Not Specified)
increased spleen weight J:163250
spleen hyperplasia J:163250
\Mir144/Mir451atm1.2Doca/\Mir144/Mir451atm1.2Doca
(involves: 129P2/OlaHsd * 129S4/SvJaeSor * BALB/cJ)
enlarged spleen J:163418
\Mir144/Mir451atm1.2Doca/\Mir144/Mir451atm1.2Doca
(involves: 129P2/OlaHsd * 129S4/SvJaeSor * BALB/cJ)
enlarged spleen J:163418
\Mir146tm1.1Bal/\Mir146tm1.1Bal
(involves: C57BL/6)
abnormal lymphopoiesis J:167922
abnormal regulatory T cell physiology J:167922
decreased interferon-gamma secretion J:167922
decreased leukocyte cell number J:173230
decreased lymphocyte cell number J:173230
decreased monocyte cell number J:173230
enlarged spleen J:173230
increased regulatory T cell number J:167922
increased spleen weight J:173230
increased T cell derived lymphoma incidence J:173230
myeloid hyperplasia J:167922, J:173230
\Mir146tm1.1Bal/\Mir146tm1.1Bal
(involves: C57BL/6 * FVB/N)
abnormal immune system physiology J:173671
abnormal immune tolerance J:173671
abnormal macrophage physiology J:173671
abnormal T cell activation J:173671
increased circulating interleukin-1 beta level J:173671
increased circulating interleukin-6 level J:173671
increased circulating interleukin-10 level J:173671
increased circulating tumor necrosis factor level J:173671
increased interleukin-1 beta secretion J:173671
increased interleukin-6 secretion J:173671
increased macrophage nitric oxide production J:173671
increased susceptibility to bacterial infection induced morbidity/mortality J:173671
increased susceptibility to endotoxin shock J:173671
increased tumor necrosis factor secretion J:173671
myeloid hyperplasia J:173671
\Mir146tm1.1Bal/\Mir146tm1.1Bal
\Tifabtm1.1Dsta/\Tifabtm1.1Dsta

(involves: 129 * C57BL/6 * C57BL/6J)
decreased lymphocyte cell number J:229024
decreased neutrophil cell number J:229024
\Mir146tm1.1Lfl/\Mir146tm1.1Lfl
\Ighg1tm1(cre)Cgn/\Ighg1+

(involves: 129P2/OlaHsd * C57BL/6)
increased germinal center B cell number J:266124
increased T follicular helper cell number J:266124
\Mir146tm1.1Lfl/\Mir146tm1.1Lfl
\Mir146btm1.1Lfl/\Mir146btm1.1Lfl
\Tg(Cd4-cre)1Cwi/0

(involves: C57BL/6 * DBA/2)
increased germinal center B cell number J:266124
increased IgG level J:266124
increased T follicular helper cell number J:266124
\Mir146tm1.1Lfl/\Mir146tm1.1Lfl
\Tg(CD2-icre)4Kio/0

(involves: C57BL/6 * C57BL/10 * CBA/Ca)
increased germinal center B cell number J:266124
increased T follicular helper cell number J:266124
\Mir146tm1.1Lfl/\Mir146tm1.1Lfl
\Tg(Cd4-cre)1Cwi/0

(involves: C57BL/6 * DBA/2)
immune system phenotype J:266124
\Mir146tm1.1Lfl/\Mir146tm1.1Lfl
\Tg(Cr2-cre)3Cgn/0

(involves: C57BL/6)
increased anti-double stranded DNA antibody level J:266124
increased germinal center B cell number J:266124
increased IgG1 level J:266124
increased IgG level J:266124
increased plasma cell number J:266124
increased T follicular helper cell number J:266124
\Mir146tm2.1Bal/\Mir146tm2.1Bal
(involves: 129S1/Sv * C57BL/6 * FVB/N)
abnormal immune system physiology J:173671
abnormal immune tolerance J:173671
abnormal macrophage physiology J:173671
abnormal spleen B cell follicle morphology J:173671
abnormal T cell activation J:173671
decreased lymphocyte cell number J:173671
decreased monocyte cell number J:173671
enlarged lymph nodes J:173671
enlarged spleen J:173671
immune system phenotype J:173671
increased acute inflammation J:173671
increased anti-double stranded DNA antibody level J:173671
increased circulating interleukin-1 beta level J:173671
increased circulating interleukin-6 level J:173671
increased circulating interleukin-10 level J:173671
increased circulating tumor necrosis factor level J:173671
increased interleukin-1 beta secretion J:173671
increased interleukin-6 secretion J:173671
increased macrophage nitric oxide production J:173671
increased spleen germinal center number J:173671
increased spleen germinal center size J:173671
increased spleen weight J:173671
increased susceptibility to bacterial infection induced morbidity/mortality J:173671
increased susceptibility to endotoxin shock J:173671
increased tumor necrosis factor secretion J:173671
myeloid hyperplasia J:173671
\Mir146btm1.1Lfl/\Mir146btm1.1Lfl
\Tg(Cd4-cre)1Cwi/0

(involves: C57BL/6 * DBA/2)
immune system phenotype J:266124
\Mir147tm1.2Xyn/\Mir147tm1.2Xyn
(involves: C57BL/6)
immune system phenotype J:332925
\Mir148atm2942.1Arte/\Mir148atm2942.1Arte
\Cd19tm1(cre)Cgn/\Cd19+

(involves: 129P2/OlaHsd * C57BL/6)
abnormal plasmablast number J:307366
decreased IgA level J:307366
decreased IgG level J:307366
decreased IgM level J:307366
decreased plasma cell number J:307366
impaired humoral immune response J:307366
increased memory B cell number J:307366
\Mir148atm2942.1Arte/\Mir148atm2942.1Arte
\Gt(ROSA)26Sortm9(cre/ESR1)Arte/\Gt(ROSA)26Sor+

(involves: C57BL/6 * C57BL/6NTac)
abnormal B cell physiology J:307366
abnormal plasmablast number J:307366
decreased plasma cell number J:307366
impaired humoral immune response J:307366
increased plasma cell number J:307366
\Mir148atm2942.2Arte/\Mir148atm2942.2Arte
(involves: C57BL/6 * FVB/N)
abnormal B cell physiology J:307366
decreased plasma cell number J:307366
\Mir149em1Ydw/\Mir149em1Ydw
(C57BL/6J-Mir149em1Ydw)
increased susceptibility to endotoxin shock J:294318
\Mir150tm1Rsky/\Mir150tm1Rsky
(involves: C57BL/6)
decreased B-2 B cell number J:127234
increased B-1 B cell number J:127234
increased IgA level J:127234
increased IgG1 level J:127234
increased IgG2b level J:127234
increased IgM level J:127234
\Mir155tm1.1Brd/\Mir155tm1.1Brd
(B6.Cg-Mir155tm1.1Brd Tyrc-Brd)
abnormal CD4-positive, alpha beta T cell morphology J:121095
abnormal CD4-positive, alpha-beta T cell physiology J:121095
abnormal dendritic cell physiology J:121095
abnormal T-helper 1 cell morphology J:121095
decreased IgG1 level J:121095
immune system phenotype J:121095
increased susceptibility to bacterial infection J:121095
increased T-helper 2 cell number J:121095
\Mir155tm1.1Brd/\Mir155tm1.1Brd
(B6.129S7-Mir155tm1.1Brd)
decreased regulatory T cell number J:146268
\Mir155tm1.1Rsky/\Mir155tm1.1Rsky
(involves: 129 * C57BL/6)
abnormal B cell physiology J:121084
abnormal cytokine secretion J:121084
abnormal germinal center B cell physiology J:121084
abnormal humoral immune response J:121084
abnormal T cell physiology J:121084
decreased germinal center B cell number J:121084
\Mir155tm1.1Rsky/\Mir155tm1.1Rsky
(B6.Cg-Mir155tm1Rsky/J)
abnormal T cell physiology J:226678
abnormal T-helper 17 cell differentiation J:226678
decreased effector memory T-helper cell number J:226678
decreased interleukin-6 secretion J:226678
decreased regulatory T cell number J:226678
decreased susceptibility to experimental autoimmune encephalomyelitis J:226678
decreased T-helper 17 cell number J:226678
\Mir155tm1Brd/\Mir155tm1Brd
(involves: 129S7/SvEvBrd * C57BL/6)
abnormal B cell physiology J:121095
abnormal class switch recombination J:121095
abnormal cytokine secretion J:121095
decreased IgM level J:121095
immune system phenotype J:121095
intestinal inflammation J:121095
lung inflammation J:121095
\Mir155tm1Rsky/\Mir155tm1Rsky
(involves: 129/Sv * C57BL/6)
abnormal cytokine secretion J:121084
abnormal gut-associated lymphoid tissue morphology J:121084
abnormal humoral immune response J:121084
abnormal immune system morphology J:121084
abnormal immune system physiology J:121084
abnormal Peyer's patch germinal center morphology J:121084
decreased interferon-gamma secretion J:121084
decreased interleukin-4 secretion J:121084
decreased spleen germinal center number J:121084
decreased spleen germinal center size J:121084
decreased tumor necrosis factor secretion J:121084
increased interleukin-10 secretion J:121084
\Mir155tm1Rsky/\Mir155tm1Rsky
(involves: 129 * C57BL/6)
abnormal class switch recombination J:136224
\Mir181dtm1.1Oers/\Mir181dtm1.1Oers
(involves: C57BL/6)
immune system phenotype J:212571
increased T cell number J:212571
\Mir204tm1.2Dic/\Mir204tm1.2Dic
\Mir211tm1.2Dic/\Mir211tm1.2Dic

(involves: 129S4/SvJaeSor * BALB/cJ * C57BL/6)
increased susceptibility to induced arthritis J:345335
\Mir205hgtm1.1Oers/\Mir205hgtm1.1Oers
(B6(Cg)-Mir205hgtm1.1Oers)
small thymus J:278363
\Mir210tm1.1Wtsi/\Mir210tm1.1Wtsi
(involves: C57BL/6J * C57BL/6N)
decreased germinal center B cell number J:205868
immune system phenotype J:205868
increased anti-chromatin antibody level J:205868
increased anti-double stranded DNA antibody level J:205868
increased anti-nuclear antigen antibody level J:205868
\Mir216aem1Uf/\Mir216aem1Uf
(C57BL/6-Mir216aem1Uf)
increased susceptibility to induced pancreatitis J:278847
\Mir216aem2Uf/\Mir216aem2Uf
(C57BL/6-Mir216aem2Uf)
increased susceptibility to induced pancreatitis J:278847
\Mir216bem1Uf/\Mir216bem1Uf
(C57BL/6-Mir216bem1Uf)
increased susceptibility to induced pancreatitis J:278847
\Mir217em1Uf/\Mir217em1Uf
(C57BL/6-Mir217em1Uf)
increased susceptibility to induced pancreatitis J:278847
\Mir217em2Uf/\Mir217em2Uf
(C57BL/6-Mir217em2Uf)
increased susceptibility to induced pancreatitis J:278847
\Mir223tm1Fcam/\Mir223tm1Fcam
(involves: 129S4/SvJae * C57BL/6)
abnormal granulocyte physiology J:140009
abnormal neutrophil differentiation J:140009
abnormal neutrophil physiology J:140009
increased acute inflammation J:140009
increased granulocyte number J:140009
increased neutrophil cell number J:140009
lung inflammation J:140009
\Mir301tm1Yoli/\Mir301tm1Yoli
(involves: C57BL/6J)
abnormal response to transplant J:237900
\Mir338em1Zchn/\Mir338em1Zchn
(C57BL/6-Mir338em1Zchn)
decreased osteoclast cell number J:285968
\Mir378bem#Yoo/\Mir378bem#Yoo
(C57BL/6J-Mir378bem#Yoo)
abnormal chemokine secretion J:307588
abnormal susceptibility to bacterial infection J:307588
decreased interferon-gamma secretion J:307588
decreased interleukin-12 secretion J:307588
decreased tumor necrosis factor secretion J:307588
\Mir425em1Nju/\Mir425+
(involves: C57BL/6)
increased tumor necrosis factor secretion J:280159
\Mir451atm1.2Doca/\Mir451atm1.2Doca
(involves: 129P2/OlaHsd * 129S4/SvJaeSor * BALB/cJ)
enlarged spleen J:163418
\Mir451atm1Eno/\Mir451atm1Eno
(involves: C57BL/6)
enlarged spleen J:163251
\Mir497em1Hgyu/\Mir497em1Hgyu
(C57BL/6-Mir497em1Hgyu)
increased susceptibility to induced colitis J:357958
\Mir511em1Clib/\Mir511em1Clib
(C57BL/6J-Mir511em1Clib)
abnormal macrophage physiology J:345580
decreased susceptibility to induced colitis J:345580
\Mir592em1Jzhan/\Mir592em1Jzhan
(Not Specified)
abnormal microglial cell morphology J:323615
\Mirc1tm1.1Aven/\Mirc1tm1.1Aven
(involves: 129S4/SvJae * C57BL/6 * SJL/J)
decreased alpha-beta T cell number J:223213
decreased B cell number J:223213
decreased pre-B cell number J:223213
decreased pro-B cell number J:223213
increased B cell apoptosis J:223213
small spleen J:223213
\Mirc1tm1.2Tyj/\Mirc1tm1.2Tyj
(involves: 129S4/SvJae * C57BL/6 * FVB/N * SJL)
abnormal B cell differentiation J:134861
decreased pre-B cell number J:134861
increased B cell apoptosis J:134861
\Mirc1tm1.3Tyj/\Mirc1tm1.3Tyj
(involves: 129S4/SvJae * C57BL/6 * FVB/N)
abnormal B cell differentiation J:134861
decreased pre-B cell number J:134861
increased B cell apoptosis J:134861
\Mirc1tm1Tyj/\Mirc1tm1Tyj
\Tg(Mx1-cre)1Cgn/0

(involves: 129S4/SvJae * C57BL/6 * CBA * SJL)
abnormal immunoglobulin heavy chain V(D)J recombination J:134861
decreased pre-B cell number J:134861
increased B cell apoptosis J:134861
\Mirc1tm2.1Aven/\Mirc1tm2.1Aven
(involves: 129S4/SvJae * C57BL/6 * SJL/J)
decreased B cell number J:223213
\Mirc1tm2.1Aven/\Mirc1tm2.1Aven
\Tg(IghMyc)22Bri/?

(involves: 129S4/SvJae * C57BL/6 * SJL/J)
abnormal pre-B cell morphology J:223213
increased B cell apoptosis J:223213
\Mirc1tm3.1Aven/\Mirc1tm3.1Aven
(involves: 129S4/SvJae * C57BL/6 * SJL/J)
decreased alpha-beta T cell number J:223213
decreased B cell number J:223213
decreased pre-B cell number J:223213
decreased pro-B cell number J:223213
increased B cell apoptosis J:223213
small spleen J:223213
\Mirc11tm1Rdhl/\Mirc11tm1Rdhl
(B6.129-Mirc11tm1Rdhl)
abnormal B cell differentiation J:243248
immune system phenotype J:243248
impaired myelopoiesis J:243248
increased B cell number J:243248
increased follicular B cell number J:243248
increased immature B cell number J:243248
increased mature B cell number J:243248
increased plasma cell number J:243248
increased pre-pro B cell number J:243248
increased pro-B cell number J:243248
increased transitional stage T1 B cell number J:243248
\Mirc13tm1.1Mtm/\Mirc13tm1.1Mtm
(Not Specified)
abnormal macrophage activation involved in immune response J:256444
\Mirc14tm1.1Ankr/\Mirc14tm1.1Ankr
(involves: C57BL/6)
abnormal alpha-beta intraepithelial T cell morphology J:196134
abnormal NK T cell morphology J:196134
abnormal T cell differentiation J:196134
decreased double-positive T cell number J:196134
decreased interferon-gamma secretion J:196134
decreased interleukin-4 secretion J:196134
decreased interleukin-13 secretion J:196134
decreased NK T cell number J:196134
immune system phenotype J:196134
increased CD4-positive, alpha-beta T cell number J:196134
\Mirc14tm1.1Czc/\Mirc14tm1.1Czc
\Gt(ROSA)26Sortm1(cre/ERT2)Tyj/\Gt(ROSA)26Sor+

(either: (involves: 129P2/OlaHsd * 129S4/SvJae * 129S4/SvJaeSor) or (involves: 129P2/OlaHsd * 129S4/SvJae * 129S4/SvJaeSor * C57BL/6))
decreased double-positive T cell number J:188125
thymus hypoplasia J:188125
\Mirc14tm1.1Flv/\Mirc14tm1.1Flv
\Ptentm1Hwu/\Ptentm1Hwu
\Tg(Cd4-cre)1Cwi/0

(involves: 129S4/SvJae * C57BL/6 * C57BL/6N * DBA/2 * SJL)
immune system phenotype J:203157
\Mirc14tm1.1Flv/\Mirc14tm1.1Flv
\Tg(Cd4-cre)1Cwi/0

(involves: C57BL/6 * C57BL/6N * DBA/2 * SJL)
decreased NK T cell number J:203157
\Mirc14tm1.2Czc/\Mirc14tm1.2Czc
(either: (involves: 129P2/OlaHsd * 129S1/Sv * 129S4/SvJaeSor) or (involves: 129P2/OlaHsd * 129S1/Sv * 129S4/SvJaeSor * C57BL/6))
decreased B cell number J:188125
decreased DN3 thymocyte number J:188125
decreased double-positive T cell number J:188125
decreased germinal center B cell number J:188125
decreased thymocyte number J:188125
increased CD4-positive, alpha-beta T cell number J:188125
increased marginal zone B cell number J:188125
\Mirc14tm1.2Flv/\Mirc14tm1.2Flv
(involves: C57BL/6 * C57BL/6N * FVB/N * SJL)
abnormal T cell differentiation J:203157
abnormal T cell physiology J:203157
abnormal T cell receptor V(D)J recombination J:203157
decreased B cell number J:203157
decreased CD4-positive, alpha-beta T cell number J:203157
decreased CD8-positive, alpha-beta T cell number J:203157
decreased DN1 thymic pro-T cell number J:203157
decreased double-positive T cell number J:203157
decreased NK T cell number J:203157
decreased T cell proliferation J:203157
decreased thymocyte apoptosis J:203157
decreased thymocyte number J:203157
\Mirc14tm1.2Flv/\Mirc14tm1.2Flv
\Mirc15tm1.2Flv/\Mirc15tm1.2Flv

(involves: C57BL/6 * C57BL/6N * FVB/N * SJL)
decreased B cell number J:203157
decreased immature B cell number J:203157
decreased pre-B cell number J:203157
increased pro-B cell number J:203157
\Mirc14tm1.2Flv/\Mirc14tm1.2Flv
\Tg(Cd4-TcraDN32D3)1Aben/0

(involves: C57BL/6 * C57BL/6N * FVB/N * SJL)
abnormal NK T cell physiology J:203157
decreased NK T cell number J:203157
\Mirc14tm1.2Flv/\Mirc14tm1.2Flv
\Tg(LCKprBCL2L1)12Sjk/0

(involves: C57BL/6 * C57BL/6N * FVB/N * SJL)
decreased NK T cell number J:203157
\Mirc15tm1.2Czc/\Mirc15tm1.2Czc
(either: (involves: 129P2/OlaHsd * 129S1/Sv * 129S4/SvJaeSor) or (involves: 129P2/OlaHsd * 129S1/Sv * 129S4/SvJaeSor * C57BL/6))
immune system phenotype J:188125
\Mirc16tm1.2Czc/\Mirc16tm1.2Czc
(either: (involves: 129P2/OlaHsd * 129S1/Sv * 129S4/SvJaeSor) or (involves: 129P2/OlaHsd * 129S1/Sv * 129S4/SvJaeSor * C57BL/6))
immune system phenotype J:188125
increased CD8-positive, alpha-beta T cell number J:188125
\Mirc19tm1.2Arte/\Mirc19tm1.2Arte
(involves: C57BL/6N)
immune system phenotype J:200865
\Mirc27em1Hhzg/\Mirc27em1Hhzg
\Tg(Vav1-cre)#Cgp/0

(involves: 129S4/SvJae * C57BL/6 * C57BL/6NRj)
immune system phenotype J:320883
\Mirc29tm1.1Cwh/\Mirc29tm1.1Cwh
(involves: 129X1/SvJ)
immune system phenotype J:189763
\Mirc30em1Hhzg/\Mirc30em1Hhzg
\Tg(Vav1-cre)#Cgp/0

(involves: 129S4/SvJae * C57BL/6 * C57BL/6NRj)
abnormal NK cell morphology J:320883
increased B cell number J:320883
increased pre-B cell number J:320883
increased pro-B cell number J:320883
increased spleen weight J:320883
\Mirc30tm1.2Rdf/\Mirc30tm1.2Rdf
(involves: 129S1/Sv * 129S4/SvJaeSor * C57BL/6)
abnormal B cell proliferation J:156946
increased B cell number J:156946
increased B-1a cell number J:156946
increased spleen white pulp amount J:156946
\Mirc32tm1.1Jtm/\Mirc32tm1.1Jtm
\Tg(Myh11-cre,-EGFP)2Mik/?

(B6.Cg-Mirc32tm1.1Jtm Tg(Myh11-cre,-EGFP)2Mik)
increased susceptibility to induced colitis J:214382
\Mirc32tm1.1Jtm/\Mirc32tm1.1Jtm
\Twist2tm1(cre)Dor/\Twist2+

(B6.129(Cg)-Twist2tm1.1(cre)Dor Mirc32tm1.1Jtm)
increased susceptibility to induced colitis J:214382
\Mirc32tm1.2Jtm/\Mirc32tm1.2Jtm
(B6.129(Cg)-Mirc32tm1.2Jtm)
increased susceptibility to induced colitis J:214382
\Mirc33tm1.1Cwh/\Mirc33tm1.1Cwh
(involves: 129X1/SvJ)
abnormal T cell morphology J:189763
decreased susceptibility to experimental autoimmune encephalomyelitis J:189763
increased interferon-gamma secretion J:189763
increased interleukin-17 secretion J:189763
increased T-helper 1 cell number J:189763
lymph node hypoplasia J:189763
lymphoid hypoplasia J:189763
spleen hypoplasia J:189763
thymus hypoplasia J:189763
\Mirc33tm1Bdes/\Mirc33tm1Bdes
(Not Specified)
abnormal thymus involution J:180783
\Mirc40tm1Jzb/\Mirc40tm1Jzb
(Not Specified)
increased microglial cell activation J:244554
\Mispem2Nsas/\Mispem2Nsas
(FVB/NJcl-Mispem2Nsas)
abnormal interleukin level J:333842
increased susceptibility to induced colitis J:333842
\Mitfmi-di/\Mitfmi-di
((PT x C3H/HeH)F1)
abnormal spleen germinal center morphology J:8196
abnormal spleen morphology J:8196
abnormal spleen red pulp morphology J:8196
abnormal spleen white pulp morphology J:8196
\Mitfmi-ew/\Mitfmi-ew
\Tfe3tm1Est/\Tfe3tm1Est

(either: (involves: 129/Sv * 129S1/Sv * C57BL/6Bn * NAW) or (involves: 129S1/Sv * C57BL/6Bn * C57BL/6J * NAW))
abnormal osteoclast morphology J:89821
\MitfMi-Or/\MitfMi-Or
(involves: 101/Rl * C3H/Rl)
abnormal osteoclast morphology J:30149
abnormal osteoclast physiology J:30149
decreased osteoclast cell number J:30149
increased osteoclast cell number J:30149
\Mitfmi-tg/\Mitfmi-tg
(B6.Cg-Mitfmi-tg)
abnormal mast cell physiology J:53161
\Mitfmi-vga9/\Mitfmi-vga9
\Tfe3tm1Est/\Tfe3tm1Est

(either: (involves: 129/Sv * 129S1/Sv * C57BL/6 * CBA) or (involves: 129S1/Sv * C57BL/6 * C57BL/6J * CBA))
abnormal osteoclast morphology J:89821
\Mitfmi-vit/\Mitfmi-vit
(C57BL/6J-Mitfmi-vit)
abnormal Langerhans cell physiology J:102101
\MitfMi/\MitfMi
(Not Specified)
abnormal osteoclast morphology J:5046
decreased mast cell number J:6889
increased osteoclast cell number J:5046
\MitfMi/\MitfMi
(B6.Cg-MitfMi)
abnormal mast cell physiology J:53161
\MitfMi/\MitfMi
(involves: C57BL/6J)
abnormal osteoclast morphology J:89821
\MitfMi/\MitfMi
\Tfe3tm1Est/\Tfe3tm1Est

(either: (involves: 129/Sv * 129S1/Sv * C57BL/6J) or (involves: 129S1/Sv * C57BL/6J))
abnormal osteoclast morphology J:89821
\MitfTg(Tff3-Tmem207)2Tamo/\Mitf+
(involves: C57BL/6)
kidney inflammation J:244533
\Mki67em1(IMPC)Mbp/\Mki67em1(IMPC)Mbp
(C57BL/6NCrl-Mki67em1(IMPC)Mbp/MbpMmucd)
decreased leukocyte cell number J:211773
decreased lymphocyte cell number J:211773
increased basophil cell number J:211773
increased eosinophil cell number J:211773
increased neutrophil cell number J:211773
\Mki67em1Dfis/\Mki67em1Dfis
(involves: C57BL/6J)
immune system phenotype J:304800
\Mkrn2tm1b(KOMP)Wtsi/\Mkrn2tm1b(KOMP)Wtsi
(C57BL/6N-Mkrn2tm1b(KOMP)Wtsi/Wtsi)
decreased dendritic epidermal T cell number J:211773
\Mks1hlb614/\Mks1hlb614
(involves: C3H * C57BL/6)
absent spleen J:167534
accessory spleen J:167534
\Mlf1tm1Swm/\Mlf1tm1Swm
(involves: 129 * C57BL/6)
decreased splenocyte apoptosis J:266833
increased B cell number J:266833
\Mlh1m1Btlr/\Mlh1m1Btlr
(C57BL/6J-Mlh1m1Btlr)
abnormal humoral immune response J:265206
increased IgM level J:265206
\Mlh1m2Btlr/\Mlh1m2Btlr
(C57BL/6J-Mlh1m2Btlr)
abnormal humoral immune response J:265207
decreased IgE level J:265207
increased IgM level J:265207
\Mlh1m3Btlr/\Mlh1m3Btlr
(C57BL/6J-Mlh1m3Btlr)
abnormal humoral immune response J:265208
decreased IgE level J:265208
increased IgM level J:265208
\Mlh1tm1b(EUCOMM)Hmgu/\Mlh1tm1b(EUCOMM)Hmgu
(C57BL/6N-Mlh1tm1b(EUCOMM)Hmgu/H)
increased spleen weight J:211773
\Mlh1tm1Mse/\Mlh1tm1Mse
(involves: 129S/SvEv)
increased T cell derived lymphoma incidence J:47642
\Mlh1tm1Rak/\Mlh1+
(involves: 129P2/OlaHsd * C57BL/6)
increased T cell derived lymphoma incidence J:53451
\Mlh1tm1Rak/\Mlh1tm1Rak
(involves: 129P2/OlaHsd * C57BL/6)
increased T cell derived lymphoma incidence J:53451
\Mlh1tm1Rak/\Mlh1tm1Rak
(involves: 129P2/OlaHsd * C57BL/6 * C57BL/6J)
increased T cell derived lymphoma incidence J:153684
\Mlklem1(IMPC)Ccpcz/\Mlklem1(IMPC)Ccpcz
(C57BL/6NCrl-Mlklem1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
enlarged spleen J:211773
\Mlklem1Jhan/\Mlklem1Jhan
(involves: C57BL/6)
abnormal macrophage physiology J:204622
immune system phenotype J:204622
\Mlklm1Btlr/\Mlkl+
(C57BL/6J-Mlklm1Btlr)
decreased inflammatory response J:225934
\Mlklm1Btlr/\Mlklm1Btlr
(C57BL/6J-Mlklm1Btlr)
decreased inflammatory response J:225934
\Mlklm2Btlr/\Mlkl+
(C57BL/6J-Mlklm2Btlr)
decreased inflammatory response J:234252
\Mlklm2Btlr/\Mlklm2Btlr
(C57BL/6J-Mlklm2Btlr)
decreased inflammatory response J:234252
\Mlklm3Btlr/\Mlkl+
(C57BL/6J-Mlklm3Btlr)
decreased inflammatory response J:234251
\Mlklm3Btlr/\Mlklm3Btlr
(C57BL/6J-Mlklm3Btlr)
decreased inflammatory response J:234251
\Mlkltm1.1Wsa/\Mlkltm1.1Wsa
\Otulintm1c(EUCOMM)Hmgu/\Otulintm1c(EUCOMM)Hmgu
\Tg(KRT14-cre)1Cgn/0

(involves: C57BL/6 * C57BL/6N * DBA/2)
dermatitis J:312394
\Mllt6em1(IMPC)Tcp/\Mllt6em1(IMPC)Tcp
(C57BL/6NCrl-Mllt6em1(IMPC)Tcp/Tcp)
decreased lymphocyte cell number J:211773
enlarged spleen J:211773
increased neutrophil cell number J:211773
increased spleen weight J:211773
\Mllt10em1(IMPC)Mbp/\Mllt10+
(C57BL/6N-Mllt10em1(IMPC)Mbp/MbpMmucd)
abnormal lymph node morphology J:211773
abnormal spleen morphology J:211773
decreased lymphocyte cell number J:211773
enlarged lymph nodes J:211773
enlarged spleen J:211773
increased neutrophil cell number J:211773
\Mlphln-Btlr/\Mlphln-Btlr
(C57BL/6J-Mlphln-Btlr)
immune system phenotype J:133625
\MlrrqDBA/2/\MlrrqDBA/2
(C.D2-Mtv7DBA/2)
decreased susceptibility to parasitic infection J:41574
\Mmabem1(IMPC)Hmgu/\Mmab+
(C57BL/6NCrl-Mmabem1(IMPC)Hmgu/Ieg)
abnormal spleen morphology J:211773
\Mmachctm1.1(NCOM)Mfgc/\Mmachc+
(C57BL/6N-Mmachctm1.1(NCOM)Mfgc/Tcp)
enlarged lymph nodes J:211773
\Mmdtm1Beij/\Mmdtm1Beij
(Not Specified)
abnormal macrophage differentiation J:304637
decreased susceptibility to induced arthritis J:304637
increased macrophage apoptosis J:304637
small inguinal lymph nodes J:304637
\Mmetm1Cge/\Mmetm1Cge
(B6.129S4-Mmetm1Cge)
dermatitis J:66854
increased susceptibility to type I hypersensitivity reaction J:66854
\Mmgt2tm1b(EUCOMM)Wtsi/\Mmgt2tm1b(EUCOMM)Wtsi
(C57BL/6N-Mmgt2tm1b(EUCOMM)Wtsi/Bay)
decreased lymphocyte cell number J:211773
increased basophil cell number J:211773
\Mmp1atm1Otin/\Mmp1atm1Otin
(involves: 129P2/OlaHsd * C57BL/6J)
abnormal interleukin secretion J:198586
decreased inflammatory response J:198586
increased interferon-gamma secretion J:198586
increased interleukin-1 alpha secretion J:198586
increased interleukin-2 secretion J:198586
increased interleukin-17 secretion J:198586
\Mmp2em1(IMPC)Mbp/\Mmp2em1(IMPC)Mbp
(C57BL/6N-Mmp2em1(IMPC)Mbp/MbpMmucd)
abnormal lymph node morphology J:211773
abnormal spleen morphology J:211773
enlarged lymph nodes J:211773
enlarged spleen J:211773
\Mmp2tm1Ito/\Mmp2tm1Ito
(involves: 129P2/OlaHsd * C57BL/6J)
abnormal inflammatory response J:46091
brain inflammation J:94099
decreased inflammatory response J:46091
increased susceptibility to experimental autoimmune encephalomyelitis J:94099
\Mmp2tm1Ito/\Mmp2tm1Ito
(involves: 129P2/OlaHsd)
autoimmune arthritis J:121780
decreased osteoclast cell number J:121780
\Mmp2tm1Ito/\Mmp2tm1Ito
\Timp1tm1Pds/\Timp1tm1Pds

(either: (involves: 129S4/SvJae) or (involves: C57BL/6))
decreased susceptibility to bacterial infection J:94836
\Mmp2tm1Ito/\Mmp2tm1Ito
\Timp3tm1Osya/\Timp3tm1Osya

(involves: 129P2/OlaHsd * C57BL/6)
aortitis J:193744
\Mmp3tm1Mrl/\Mmp3tm1Mrl
(either: (129S7/SvEvBrd X B10.RIII)N2 or ((involves: 129S7/SvEvBrd * C57BL/6) X B10.RIII)N2)
autoimmune arthritis J:46038
joint inflammation J:46038
osteoarthritis J:46038
\Mmp3tm1Mrl/\Mmp3tm1Mrl
(either: 129S7/SvEvBrd or (involves: 129S7/SvEvBrd * C57BL/6))
abnormal CD4-positive, alpha-beta T cell physiology J:93706
increased susceptibility to bacterial infection J:93706
\Mmp3tm1Mrl/\Mmp3tm1Mrl
(involves: 129S7/SvEvBrd * C57BL/10ScSn * RIII)
abnormal lymphocyte physiology J:55723
decreased susceptibility to type IV hypersensitivity reaction J:55723
\Mmp3tm1Mrl/\Mmp3tm1Mrl
(involves: 129S7/SvEvBrd)
immune system phenotype J:124841
\Mmp3tm1Mrl/\Mmp3tm1Mrl
\Timp1tm1Pds/\Timp1tm1Pds

(involves: C57BL/6)
decreased susceptibility to bacterial infection J:94836
\Mmp7tm1Lmm/\Mmp7tm1Lmm
(involves: 129S1/Sv * 129X1/SvJ)
decreased susceptibility to bacterial infection J:153651
immune system phenotype J:55723
\Mmp7tm1Lmm/\Mmp7tm1Lmm
(B6.129-Mmp7tm1Lmm)
increased interleukin-1 beta secretion J:149388
increased susceptibility to induced colitis J:149388
\Mmp7tm1Lmm/\Mmp7tm1Lmm
(involves: 129S/SvEv * 129S1/Sv * 129X1/SvJ)
abnormal macrophage physiology J:124841
decreased tumor necrosis factor secretion J:124841
impaired macrophage chemotaxis J:124841
\Mmp7tm1Lmm/\Mmp7tm1Lmm
\Timp1tm1Pds/\Timp1tm1Pds

(involves: 129S4/SvJae)
decreased susceptibility to bacterial infection J:94836
\Mmp8tm1Otin/\Mmp8tm1Otin
(involves: 129X1/SvJ * C57BL/6J)
abnormal inflammatory response J:86393
chronic inflammation J:86393
increased susceptibility to bacterial infection J:97118
\Mmp8tm1Otin/\Mmp8tm1Otin
(involves: 129X1/SvJ * C57BL/6)
immune system phenotype J:113463
\Mmp8tm1Otin/\Mmp8tm1Otin
(involves: 129X1/SvJ)
immune system phenotype J:148442
\Mmp8tm1Otin/\Mmp8tm1Otin
\Mmp9tm1Tvu/\Mmp9tm1Tvu

(involves: 129S6/SvEvTac * 129X1/SvJ * C57BL/6)
immune system phenotype J:113463
\Mmp9tm1Arnd/\Mmp9tm1Arnd
(involves: 129P2/OlaHsd)
decreased susceptibility to experimental autoimmune encephalomyelitis J:58833
\Mmp9tm1Tvu/\Mmp9tm1Tvu
(involves: 129S6/SvEvTac)
abnormal chemokine level J:84293
abnormal dendritic cell physiology J:84293
abnormal Langerhans cell physiology J:76157
decreased dendritic cell number J:84293
decreased IgE level J:84293
decreased inflammatory response J:84293
increased circulating interferon-beta level J:148442
increased circulating interferon-gamma level J:148442
increased susceptibility to Picornaviridae infection J:148442
increased susceptibility to Picornaviridae infection induced morbidity/mortality J:148442
myocarditis J:148442
\Mmp9tm1Tvu/\Mmp9tm1Tvu
(FVB.129S6-Mmp9tm1Tvu)
abnormal neutrophil physiology J:104644
decreased susceptibility to induced colitis J:104644
immune system phenotype J:104644
\Mmp9tm1Tvu/\Mmp9tm1Tvu
(129S6/SvEvTac-Mmp9tm1Tvu)
immune system phenotype J:113463
\Mmp9tm1Tvu/\Mmp9tm1Tvu
(involves: 129/Sv * 129S6/SvEvTac)
decreased circulating interleukin-10 level J:55723
increased susceptibility to type IV hypersensitivity reaction J:55723
\Mmp9tm1Tvu/\Mmp9tm1Tvu
(involves: 129S6/SvEvTac * CD-1)
impaired myelopoiesis J:149957
\Mmp9tm1Tvu/\Mmp9tm1Tvu
(involves: 129S6/SvEvTac * C57BL/6)
abnormal chemokine level J:88065
abnormal cytokine secretion J:88065
abnormal leukocyte morphology J:88065
abnormal response to infection J:126519
decreased interferon-gamma secretion J:88065
increased eosinophil cell number J:88065
increased IgE level J:88065
increased interferon-gamma secretion J:88065
increased interleukin-4 secretion J:88065
increased interleukin-5 secretion J:88065
increased interleukin-13 secretion J:88065
increased lymphocyte cell number J:88065
increased macrophage cell number J:88065
increased monocyte cell number J:88065
increased T cell proliferation J:88065
increased T-helper 2 cell number J:88065
lung inflammation J:88065
\Mmp9tm1Tvu/\Mmp9tm1Tvu
(FVB.129S6(Cg)-Mmp9tm1Tvu/J)
decreased susceptibility to Flaviviridae infection J:153406
decreased susceptibility to Flaviviridae infection induced morbidity/mortality J:153406
\Mmp9tm1Tvu/\Mmp9tm1Tvu
(C3N.129S6-Mmp9tm1Tvu)
decreased susceptibility to bacterial infection J:150311
decreased susceptibility to induced arthritis J:150311
joint inflammation J:150311
\Mmp9tm1Tvu/\Mmp9tm1Tvu
\Tg(SOD1*G93A)1Gur/0

(involves: 129S6/SvEvTac * C57BL/6 * CD-1 * SJL)
decreased tumor necrosis factor secretion J:141587
\Mmp9tm1Tvu/\Mmp9tm1Tvu
\Timp1tm1Pds/\Timp1tm1Pds

(involves: 129S4/SvJae * 129S6/SvEvTac)
immune system phenotype J:94836
\Mmp10tm1Jkmg/\Mmp10tm1Jkmg
(B6.129X1-Mmp10tm1Jkmg)
increased susceptibility to bacterial infection J:153651
lung inflammation J:153651
\Mmp11tm1b(EUCOMM)Hmgu/\Mmp11tm1b(EUCOMM)Hmgu
(C57BL/6N-Mmp11tm1b(EUCOMM)Hmgu/Ics)
increased monocyte cell number J:211773
\Mmp12tm1Sds/\Mmp12tm1Sds
(involves: 129X1/SvJ)
abnormal macrophage physiology J:32902
\Mmp12tm1Sds/\Mmp12tm1Sds
\Timp1tm1Pds/\Timp1tm1Pds

(either: (involves: 129S4/SvJae) or (involves: C57BL/6))
decreased susceptibility to bacterial infection J:94836
\Mmp13em1(IMPC)Ccpcz/\Mmp13em1(IMPC)Ccpcz
(C57BL/6NCrl-Mmp13em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged spleen J:211773
enlarged thymus J:211773
\Mmp14tm1Hbh/\Mmp14tm1Hbh
(involves: 129P2/OlaHsd * Black Swiss)
abnormal osteoclast physiology J:57969, J:86538
autoimmune arthritis J:57969
\Mmp14tm1Ktry/\Mmp14tm1Ktry
(involves: 129X1/SvJ)
abnormal dendritic cell physiology J:138782
\Mmp15tm1b(KOMP)Wtsi/\Mmp15tm1b(KOMP)Wtsi
(C57BL/6N-Mmp15tm1b(KOMP)Wtsi/Bay)
absent lymph nodes J:211773
athymia J:211773
enlarged spleen J:211773
\Mmp19tm1Rase/\Mmp19tm1Rase
(B6.129P2-Mmp19tm1Rase)
abnormal cytokine level J:137128
abnormal T cell activation J:137128
abnormal T cell differentiation J:137128
decreased CD4-positive, alpha-beta T cell number J:137128
decreased CD8-positive, alpha-beta T cell number J:137128
decreased inflammatory response J:137128
decreased susceptibility to type IV hypersensitivity reaction J:137128
decreased T cell proliferation J:137128
increased double-positive T cell number J:137128
\Mmp20em1(IMPC)Ccpcz/\Mmp20em1(IMPC)Ccpcz
(C57BL/6NCrl-Mmp20em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged thymus J:211773
increased CD4-positive, CD25-positive, alpha-beta regulatory T cell number J:211773
\Mmp24tm1Otin/\Mmp24tm1Otin
(involves: 129P2/OlaHsd * C57BL/6J)
abnormal mast cell degranulation J:153230
increased mast cell degranulation J:153230
\Mmp25em1(IMPC)J/\Mmp25em1(IMPC)J
(C57BL/6NJ-Mmp25em1(IMPC)J/Mmjax)
decreased leukocyte cell number J:211773
\Mmp25Gt(IST14198E10)Tigm/\Mmp25Gt(IST14198E10)Tigm
(involves: C57BL/6N)
abnormal circulating cytokine level J:347009
abnormal macrophage activation involved in immune response J:347009
abnormal neutrophil physiology J:347009
decreased circulating interleukin-1 alpha level J:347009
decreased susceptibility to endotoxin shock J:347009
increased IgG level J:347009
\Mmp28tm1Mani/\Mmp28tm1Mani
(B6.129X1-Mmp28tm1Mani)
abnormal chemokine secretion J:145912
abnormal cytokine secretion J:145912
abnormal macrophage chemotaxis J:145912
decreased susceptibility to bacterial infection J:145912
impaired neutrophil recruitment J:145912
increased interleukin-6 secretion J:145912
increased tumor necrosis factor secretion J:145912
\Mmrn1tm1b(EUCOMM)Hmgu/\Mmrn1tm1b(EUCOMM)Hmgu
(C57BL/6N-Mmrn1tm1b(EUCOMM)Hmgu/Cnrm)
increased large unstained cell number J:211773
\Mmuttm1Cpv/\Mmuttm1Cpv
(involves: 129S/SvEv * C57BL/6 * FVB/N)
tubulointerstitial nephritis J:147313
\Mmuttm1Cpv/\Mmuttm1Cpv
\Tg(Alb-Mut)#Cpv/0

(involves: C57BL/6)
tubulointerstitial nephritis J:200689
\Mnx1tm1Jhk/\Mnx1tm1Jhk
(involves: 129P2/OlaHsd)
immune system phenotype J:57314
\Mnx1tm4(cre)Tmj/\Mnx1+
\Tardbptm1.1Ckjs/\Tardbptm1.2Cjks

(involves: 129S1/Sv * C57BL/6J)
increased microglial cell activation J:190254
\Mocosem2(IMPC)Ics/\Mocosem2(IMPC)Ics
(involves: C57BL/6N)
kidney inflammation J:336718
tubulointerstitial nephritis J:336718
\Mogtm1(cre)Gkl/\Mogtm1(cre)Gkl
\Tg(Tcra2D2,Tcrb2D2)1Kuch/0

(C57BL/6-Mogtm1(cre)Gkl Tg(Tcra2D2,Tcrb2D2)1Kuch)
increased susceptibility to experimental autoimmune encephalomyelitis J:151335
\Mogtm1Dpd/\Mogtm1Dpd
(B6.129S2-Mogtm1Dpd)
decreased susceptibility to experimental autoimmune encephalomyelitis J:85155
immune system phenotype J:85155
\Mogtm1Dpd/\Mogtm1Dpd
\Rag2tm1Cgn/\Rag2tm1Cgn
\Tg(Tcra2D2,Tcrb2D2)1Kuch/0

(involves: 129S2/SvPas * C57BL/6)
increased susceptibility to experimental autoimmune encephalomyelitis J:151335
\Mogtm1Dpd/\Mogtm1Dpd
\Tg(H2-Kb-Tcra,-Tcrb)1640Kurs/0

(SJL.Cg-Mogtm1Dpd Tg(H2-Kb-Tcra,-Tcrb)1640Kurs)
decreased susceptibility to experimental autoimmune encephalomyelitis J:149511
\Mogtm1Dpd/\Mogtm1Dpd
\Tg(Tcra2D2,Tcrb2D2)1Kuch/0

(involves: 129S2/SvPas * C57BL/6)
CNS inflammation J:151335
increased susceptibility to experimental autoimmune encephalomyelitis J:151335
\Mogtm1Reid/\Mogtm1Reid
(B6.129S1/Sv-Mogtm1Reid)
increased susceptibility to experimental autoimmune encephalomyelitis J:86663
\Mogtm1Reid/\Mogtm1Reid
(129/Sv-Mogtm1Reid)
abnormal cytokine secretion J:86663
abnormal T-helper 1 physiology J:86663
increased interleukin-2 secretion J:86663
increased interleukin-6 secretion J:86663
increased susceptibility to experimental autoimmune encephalomyelitis J:86663
increased T cell proliferation J:86663
\Mogstm1(KOMP)Vlcg/\Mogs+
(C57BL/6N-Mogstm1(KOMP)Vlcg/Bay)
absent lymph nodes J:211773
enlarged thymus J:211773
\Mol1BALB/cByJ/\Mol1BALB/cByJ
(involves: BALB/cByJ * C57BL/6ByJ)
decreased B cell proliferation J:58921
\Mol2DBA/2N/\Mol2DBA/2N
(involves: BALB/cAnFcr * DBA/2N)
increased inflammatory response J:58921
\Morc2aem1(IMPC)Wtsi/\Morc2aem1(IMPC)Wtsi
(C57BL/6N-Morc2aem1(IMPC)Wtsi/WtsiOulu)
abnormal thymus topology J:239583
absent connection between subcutaneous lymph vessels and lymph sac J:239583
athymia J:239583
blood in lymph vessels J:239583
small thymus J:239583
\Morc3tm1b(EUCOMM)Hmgu/\Morc3+
(C57BL/6N-Morc3tm1b(EUCOMM)Hmgu/Ics)
decreased lymphocyte cell number J:211773
increased large unstained cell number J:211773
increased monocyte cell number J:211773
increased neutrophil cell number J:211773
\Morc4em1(IMPC)Mbp/Y
(C57BL/6N-Morc4em1(IMPC)Mbp/MbpMmucd)
abnormal lymph node morphology J:211773
enlarged lymph nodes J:211773
\Morc4em1(IMPC)Mbp/\Morc4em1(IMPC)Mbp
(C57BL/6N-Morc4em1(IMPC)Mbp/MbpMmucd)
abnormal lymph node morphology J:211773
enlarged lymph nodes J:211773
\Morf4l1tm1Kto/\Morf4l1tm1Kto
(involves: 129S7/SvEvBrd)
spleen vascular congestion J:97640
\Morrbidem1Flv/\Morrbid+
(C57BL/6N-Morrbidem1Flv)
decreased eosinophil cell number J:236609
decreased Ly6C high monocyte number J:236609
decreased neutrophil cell number J:236609
\Morrbidem1Flv/\Morrbidem1Flv
(C57BL/6N-Morrbidem1Flv)
abnormal eosinophil physiology J:236609
abnormal leukocyte physiology J:236609
abnormal myelopoiesis J:236609
abnormal neutrophil physiology J:236609
decreased eosinophil cell number J:236609
decreased Ly6C high monocyte number J:236609
decreased Ly6C low monocyte number J:236609
decreased neutrophil cell number J:236609
immune system phenotype J:236609
increased susceptibility to bacterial infection J:236609
increased susceptibility to bacterial infection induced morbidity/mortality J:236609
\mpc253H/\mpc253H
(involves: BALB/c * C3H/HeH * C57BL/6J)
colitis J:234901
\Mpdk2C57BL/6J/\Mpdk2CAST/Ei
(involves: C57BL/6J * CAST/Ei)
bile duct inflammation J:99468
\Mpdk2CAST/Ei/\Mpdk2CAST/Ei
(involves: C57BL/6J * CAST/Ei)
bile duct inflammation J:99468
\Mpdk7C57BL/6J/\Mpdk7CAST/Ei
(involves: C57BL/6J * CAST/Ei)
bile duct inflammation J:99468
\Mpdk7CAST/Ei/\Mpdk7CAST/Ei
(involves: C57BL/6J * CAST/Ei)
bile duct inflammation J:99468
\Mpdk8C57BL/6J/\Mpdk8CAST/Ei
(involves: C57BL/6J * CAST/Ei)
bile duct inflammation J:99468
\Mpdk8CAST/Ei/\Mpdk8CAST/Ei
(involves: C57BL/6J * CAST/Ei)
bile duct inflammation J:99468
\Mpeg1tm1Pod/\Mpeg1+
(involves: 129X1/SvJ * C57BL/6)
abnormal susceptibility to infection induced morbidity/mortality J:269474
\Mpeg1tm1Pod/\Mpeg1+
(129X1/SvJ-Mpeg1tm1Pod)
abnormal susceptibility to infection induced morbidity/mortality J:269474
\Mpeg1tm1Pod/\Mpeg1tm1Pod
(involves: 129X1/SvJ * C57BL/6)
abnormal susceptibility to infection induced morbidity/mortality J:269474
\Mpeg1tm1Pod/\Mpeg1tm1Pod
(129X1/SvJ-Mpeg1tm1Pod)
abnormal susceptibility to infection induced morbidity/mortality J:269474
\Mpgtm1Lds/\Mpgtm1Lds
(involves: 129P2/OlaHsd * C57BL/6)
autoimmune response J:118148
decreased susceptibility to autoimmune diabetes J:118148
\Mpgtm1Lds/\Mpgtm1Lds
(involves: 129P2/OlaHsd)
immune system phenotype J:47993
\Mpgtm1Rhe/\Mpgtm1Rhe
(involves: 129P2/OlaHsd * C57BL/6J)
increased CD4-positive, alpha-beta T cell number J:70603
\Mpig6btm1.1(KOMP)Vlcg/\Mpig6btm1.1(KOMP)Vlcg
(C57BL/6N-Mpig6btm1.1(KOMP)Vlcg/Ucd)
abnormal spleen morphology J:211773
enlarged spleen J:211773
increased spleen weight J:211773
\Mpig6btm1.1Arte/\Mpig6btm1.1Arte
(involves: C57BL/6NTac)
abnormal spleen red pulp morphology J:201266
enlarged spleen J:201266
spleen fibrosis J:201266
\Mplem1(IMPC)Ccpcz/\Mpl+
(C57BL/6NCrl-Mplem1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
enlarged spleen J:211773
\Mplem1(IMPC)Ccpcz/\Mplem1(IMPC)Ccpcz
(C57BL/6NCrl-Mplem1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged thymus J:211773
\Mplhlb219/\Mplhlb219
(C57BL/6J-Mplhlb219/J)
abnormal circulating cytokine level J:146577
decreased leukocyte cell number J:146577
enlarged spleen J:146577
\Mpltm1Mwm/\Mpltm1Mwm
(B6;129S2)
immune system phenotype J:83264
\Mpltm1Wsa/\Mpltm1Wsa
(involves: 129S1/Sv * C57BL/6)
immune system phenotype J:32131
\Mpltm1Wsa/\Mpltm1Wsa
(involves: 129S1/Sv)
abnormal circulating chemokine level J:162629
\Mpltm1Wsa/\Mpltm1Wsa
\MybPlt3/\Myb+

(involves: 129S1/Sv * C57BL/6)
abnormal thrombopoiesis J:89601
\Mpltm1Wsa/\Mpltm1Wsa
\MybPlt3/\MybPlt3

(involves: 129S1/Sv * C57BL/6)
abnormal B cell differentiation J:89601
abnormal spleen morphology J:89601
abnormal thrombopoiesis J:89601
decreased spleen B cell follicle size J:89601
increased spleen red pulp amount J:89601
\Mpltm1Wsa/\Mpltm1Wsa
\MybPlt4/\Myb+

(involves: 129S1/Sv * C57BL/6)
abnormal thrombopoiesis J:89601
\Mpltm1Wsa/\Mpltm1Wsa
\MybPlt4/\MybPlt4

(involves: 129S1/Sv * C57BL/6)
abnormal spleen morphology J:89601
abnormal thrombopoiesis J:89601
decreased leukocyte cell number J:89601
decreased spleen B cell follicle size J:89601
increased spleen red pulp amount J:89601
\Mpltm1Wsa/\Mpltm1Wsa
\Suz12Gt(Betageo)1Khe/\Suz12+

(involves: 129P2/OlaHsd * 129S1/Sv * C57BL/6)
abnormal thrombopoiesis J:136262
increased leukocyte cell number J:136262
increased lymphocyte cell number J:136262
\Mpltm1Wsa/\Mpltm1Wsa
\Suz12Plt8/\Suz12+

(B6.Cg-Mpltm1Wsa Suz12Plt8)
abnormal thrombopoiesis J:136262
increased leukocyte cell number J:136262
increased lymphocyte cell number J:136262
\Mpltm2.1Wsa/\Mpltm2.1Wsa
\Tg(Pf4-icre)Q3Rsko/0

(involves: C57BL/6)
enlarged spleen J:208120
\Mpndem1(IMPC)J/\Mpndem1(IMPC)J
(C57BL/6NJ-Mpndem1(IMPC)J/Mmjax)
decreased leukocyte cell number J:211773
\Mpotm1Lus/\Mpotm1Lus
(involves: 129X1/SvJ * C57BL/6J)
abnormal neutrophil physiology J:67586
decreased inflammatory response J:102688
increased monocyte cell number J:67586
increased susceptibility to experimental autoimmune encephalomyelitis J:102965
increased susceptibility to fungal infection J:67586
sepsis J:126649
\Mpotm1Lus/\Mpotm1Lus
(B6.129X1-Mpotm1Lus)
abnormal neutrophil physiology J:112488
\Mpotm1Mae/\Mpotm1Mae
(involves: 129P2/OlaHsd * C57BL/6)
abnormal neutrophil physiology J:53993
increased susceptibility to fungal infection J:53993
\Mpp1em1(IMPC)Ccpcz/\Mpp1em1(IMPC)Ccpcz
(C57BL/6NCrl-Mpp1em1(IMPC)Ccpcz/Ccpcz)
abnormal lymph node morphology J:211773
abnormal spleen morphology J:211773
decreased effector memory T-helper cell number J:211773
enlarged lymph nodes J:211773
enlarged spleen J:211773
increased CD4-positive, alpha-beta T cell number J:211773
increased effector memory T-helper cell number J:211773
increased T-helper cell number J:211773
\Mpp1tm1Ahc/\Mpp1tm1Ahc
(B6.129-Mpp1tm1Ahc)
abnormal neutrophil physiology J:154749
impaired neutrophil chemotaxis J:154749
\Mpped2em1(IMPC)J/\Mpped2em1(IMPC)J
(C57BL/6NJ-Mpped2em1(IMPC)J/J)
increased leukocyte cell number J:211773
\Mptx2em1Yoxi/\Mptx2em1Yoxi
(C57BL/6J-Mptx2em1Yoxi)
increased susceptibility to bacterial infection J:326562
\Mpv17l2tm1.1(KOMP)Mbp/\Mpv17l2tm1.1(KOMP)Mbp
(C57BL/6N-Mpv17l2tm1.1(KOMP)Mbp/Ucd)
abnormal spleen morphology J:211773
enlarged spleen J:211773
\Mpztm1Msch/\Mpz+
(involves: 129S7/SvEvBrd * C57BL/6)
abnormal cytokine secretion J:82432
abnormal macrophage chemotaxis J:67581
abnormal T-helper 1 physiology J:82432
increased monocyte cell number J:82432
\Mpztm1Msch/\Mpz+
(involves: 129S7/SvEvBrd)
increased macrophage cell number J:133028
\Mpztm1Msch/\Mpz+
(B6.129S7-Mpztm1Msch)
autoimmune response J:59319
\Mpztm1Msch/\Mpz+
\Rag1tm1Mom/\Rag1tm1Mom

(B6.129S7-Mpztm1Msch Rag1tm1Mom)
absent CD4-positive, alpha-beta T cells J:59319
absent CD8-positive, alpha-beta T cells J:59319
\Mpztm1Msch/\Mpz+
\Tcratm1Mjo/\Tcratm1Mjo

(involves: 129P2/OlaHsd * 129S7/SvEvBrd * BALB/c * C57BL/6)
decreased T cell number J:59319
\Mpzl2tm1Lex/\Mpzl2tm1Lex
(involves: 129S5/SvEvBrd * C57BL/6J)
decreased B cell number J:171883
increased CD8-positive, alpha-beta T cell number J:171883
\Mpzl3rc/\Mpzl3rc
(C57BL/6J-Mpzl3rc/J)
abnormal spleen morphology J:93038
dermatitis J:93038
liver inflammation J:93038
\Mpzl3tm1(KOMP)Mbp/\Mpzl3tm1(KOMP)Mbp
(C57BL/6-Tyrc-Brd Mpzl3tm1(KOMP)Mbp)
seborrheic dermatitis J:210832
skin inflammation J:210832
\Mr1tm1Gfn/\Mr1tm1Gfn
(involves: 129P2/OlaHsd * BALB/c * C57BL/6)
abnormal B cell physiology J:113083
abnormal T cell number J:113083
\Mr1tm1Gfn/\Mr1tm1Gfn
(B6.129P2-Mr1tm1Gfn)
increased susceptibility to experimental autoimmune encephalomyelitis J:112657
\Mr1tm1Gfn/\Mr1tm1Gfn
(involves: 129P2/OlaHsd)
abnormal susceptibility to bacterial infection J:276912
\MrasGt(OST108223)Lex/\MrasGt(OST108223)Lex
(B6;129S5-MrasGt(OST108223)Lex/Ieg)
decreased B cell number J:82809
\Mrc1tm1Mnz/\Mrc1tm1Mnz
(involves: 129P2/OlaHsd)
abnormal macrophage physiology J:124290
\Mrc1tm1Mnz/\Mrc1tm1Mnz
(B6.129P2-Mrc1tm1Mnz)
decreased susceptibility to parasitic infection J:194065
decreased susceptibility to parasitic infection induced morbidity/mortality J:194065
decreased T cell number J:194065
increased granulocyte number J:194065
\Mrc1tm1Mnz/\Mrc1tm1Mnz
\Mrc2tm1Cmi/\Mrc2tm1Cmi

(involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ)
abnormal macrophage physiology J:124290
\Mre11atm1.1Rchd/\Mre11atm1.1Rchd
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
abnormal class switch recombination J:184053
\Mregtm1b(EUCOMM)Hmgu/\Mregtm1b(EUCOMM)Hmgu
(C57BL/6N-Mregtm1b(EUCOMM)Hmgu/Kmpc)
abnormal lymph node morphology J:211773
\Mrfap1tm1Kto/\Mrfap1tm1Kto
(involves: 129S7/SvEvBrd * C57BL/6J)
immune system phenotype J:92967
\Mrgprb2em1(IMPC)Tcp/\Mrgprb2em1(IMPC)Tcp
(C57BL/6NCrl-Mrgprb2em1(IMPC)Tcp/Tcp)
small spleen J:211773
\Mrgprb2em1Xzd/\Mrgprb2em1Xzd
(C57BL/6-Mrgprb2em1Xzd)
decreased inflammatory response J:219209
decreased mast cell degranulation J:219209
immune system phenotype J:219209
\Mri1em1(IMPC)Bay/\Mri1em1(IMPC)Bay
(C57BL/6N-Mri1em1(IMPC)Bay/BayMmucd)
increased spleen weight J:211773
\Mroh8em1(IMPC)Ccpcz/\Mroh8em1(IMPC)Ccpcz
(C57BL/6NCrl-Mroh8em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
enlarged spleen J:211773
\Mrpl12em1(IMPC)Tcp/\Mrpl12+
(C57BL/6NCrl-Mrpl12em1(IMPC)Tcp/Tcp)
enlarged lymph nodes J:211773
\Mrps22tm1.1(KOMP)Vlcg/\Mrps22+
(B6N(Cg)-Mrps22tm1.1(KOMP)Vlcg/J)
increased leukocyte cell number J:211773
\Mrs2em1Muma/\Mrs2em1Muma
(B6.Cg-Mrs2em1Muma)
decreased susceptibility to endotoxin shock J:298361
\Ms4a1tm1Msn/\Ms4a1tm1Msn
(involves: 129S/SvEv * C57BL/6)
immune system phenotype J:48688
\Ms4a1tm1Tft/\Ms4a1tm1Tft
(involves: 129 * C57BL/6)
abnormal B cell calcium ion homeostasis J:88933
abnormal B cell number J:88933
abnormal B cell physiology J:88933
decreased B-1 B cell number J:88933
immune system phenotype J:88933
increased transitional stage B cell number J:88933
\Ms4a2tm1Chr/\Ms4a2tm1Chr
(involves: 129S1/Sv * 129X1/SvJ)
abnormal mast cell physiology J:53106
decreased susceptibility to type I hypersensitivity reaction J:53106
\Ms4a2tm1Knt/\Ms4a2tm1Knt
(involves: 129 * BALB/c)
abnormal cytokine secretion J:47138
abnormal mast cell physiology J:47138
decreased susceptibility to type I hypersensitivity reaction J:47138
\Ms4a2tm1Knt/\Ms4a2tm1Knt
\Tg(SV40/HTLV-FCER1A)1Bhk/0

(involves: 129 * BALB/c)
abnormal cytokine secretion J:47138
abnormal mast cell physiology J:47138
decreased susceptibility to type I hypersensitivity reaction J:47138
\Ms4a4aem1Wwz/\Ms4a4aem1Wwz
(C57BL/6NCrl-Ms4a4aem1Wwz)
abnormal macrophage physiology J:296429
decreased eosinophil cell number J:296429
decreased interleukin-4 secretion J:296429
decreased interleukin-13 secretion J:296429
impaired eosinophil recruitment J:296429
\Ms4a6dem1Cya/\Ms4a6dem1Cya
(involves: C57BL/6)
decreased susceptibility to endotoxin shock J:342776
\Ms4a6dem1Ywch/\Ms4a6dem1Ywch
(C57BL/6-Ms4a6dem1Ywch)
decreased susceptibility to endotoxin shock J:342776
\Ms4a6dem2Ywch/\Ms4a6dem2Ywch
(C57BL/6-Ms4a6dem2Ywch)
decreased susceptibility to endotoxin shock J:342776
\Ms4a7em1.1Jddl/\Ms4a7em1.1Jddl
(B6.Cg-Ms4a7em1.1Jddl)
abnormal macrophage physiology J:347975
decreased circulating tumor necrosis factor level J:347975
decreased cytokine level J:347975
decreased interleukin-1 beta secretion J:347975
decreased macrophage cell number J:347975
\Ms4a7em1Jddl/\Ms4a7em1Jddl
\Lyz2tm1(cre)Ifo/\Lyz2+

(B6.Cg-Lyz2tm1(cre)Ifo Ms4a7em1Jddl)
decreased circulating tumor necrosis factor level J:347975
decreased cytokine level J:347975
\Ms4a8aem1(IMPC)Tcp/\Ms4a8aem1(IMPC)Tcp
(C57BL/6NCrl-Ms4a8aem1(IMPC)Tcp/Cmmr)
increased monocyte cell number J:211773
\Ms4a12em1(IMPC)Mbp/\Ms4a12em1(IMPC)Mbp
(C57BL/6N-Ms4a12em1(IMPC)Mbp/Ucd)
abnormal lymph node morphology J:211773
enlarged lymph nodes J:211773
\Msantd3em1(IMPC)J/\Msantd3em1(IMPC)J
(C57BL/6NJ-Msantd3em1(IMPC)J/Mmjax)
decreased leukocyte cell number J:211773
\Msh2tm1Htr/\Msh2tm1Htr
(either: (involves: 129P2/OlaHsd) or (involves: 129P2/OlaHsd * FVB))
increased T cell derived lymphoma incidence J:27469
\Msh2tm1Htr/\Msh2tm1Htr
(involves: 129P2/OlaHsd)
abnormal class switch recombination J:80893
abnormal inflammatory response J:80893
abnormal somatic hypermutation frequency J:155454
decreased IgG1 level J:80893
decreased IgG3 level J:80893
immune system phenotype J:47993
increased T cell derived lymphoma incidence J:45433
\Msh2tm1Htr/\Msh2tm1Htr
(involves: 129P2/OlaHsd * FVB)
increased T cell derived lymphoma incidence J:45433
\Msh2tm1Htr/\Msh2tm1Htr
\Pcnatm1Jcbs/\Pcnatm1Jcbs

(involves: 129P2/OlaHsd)
abnormal somatic hypermutation frequency J:155454
\Msh2tm1Mak/\Msh2tm1Mak
(involves: 129P2/OlaHsd * C57BL/6J)
immune system phenotype J:28397
\Msh2tm1Mak/\Msh2tm1Mak
(C57BL/6NTac-Msh2tm1Mak)
abnormal class switch recombination J:326431
abnormal somatic hypermutation frequency J:326431
\Msh2tm1Rak/\Msh2tm1Rak
(involves: 129P2/OlaHsd)
abnormal class switch recombination J:56764
decreased mature B cell number J:56764
\Msh2tm1Wed/\Msh2tm1Wed
(involves: C57BL/6)
abnormal class switch recombination J:86278
decreased IgG level J:86278
\Msh2tm1Whl/\Msh2tm1Whl
(involves: 129P2/OlaHsd * C57BL/6J)
increased lymphoblastic lymphoma incidence J:79016
\Msh2tm1Whl/\Msh2tm1Whl
\Rb1tm1Brd/\Rb1+

(involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6J)
increased lymphoblastic lymphoma incidence J:79016
\Msh5tm1b(EUCOMM)Wtsi/\Msh5tm1b(EUCOMM)Wtsi
(C57BL/6N-Msh5tm1b(EUCOMM)Wtsi/Ieg)
increased leukocyte cell number J:211773
\Msh6m1Btlr/\Msh6m1Btlr
(C57BL/6J-Msh6m1Btlr)
decreased IgE level J:255208
\Msi2em1(IMPC)Mbp/\Msi2em1(IMPC)Mbp
(C57BL/6N-Msi2em1(IMPC)Mbp/MbpMmucd)
abnormal spleen morphology J:211773
decreased leukocyte cell number J:211773
decreased lymphocyte cell number J:211773
decreased spleen weight J:211773
small spleen J:211773
\Msi2Gt(E035H03)Wrst/\Msi2Gt(E035H03)Wrst
(B6.129P2-Msi2Gt(E035H03)Wrst)
abnormal myeloid leukocyte morphology J:174870
decreased B cell number J:174870
decreased CD4-positive, alpha-beta T cell number J:174870
decreased CD8-positive, alpha-beta T cell number J:174870
decreased DN2 thymocyte number J:174870
decreased DN3 thymocyte number J:174870
decreased double-negative T cell number J:174870
decreased double-positive T cell number J:174870
decreased granulocyte number J:174870
decreased immature B cell number J:174870
decreased leukocyte cell number J:174870
decreased macrophage cell number J:174870
decreased mature B cell number J:174870
decreased pre-B cell number J:174870
small spleen J:174870
small thymus J:174870
spleen hypoplasia J:174870
thymus hypoplasia J:174870
\Msi2tm1.1Cjl/\Msi2tm1.1Cjl
\Tg(Mx1-cre)1Cgn/0

(involves: 129S4/SvJae * C57BL/6 * CBA)
decreased spleen weight J:208349
immune system phenotype J:208349
spleen hypoplasia J:208349
\Mslnltm1b(EUCOMM)Wtsi/\Mslnltm1b(EUCOMM)Wtsi
(C57BL/6N-Mslnltm1b(EUCOMM)Wtsi/BayMmucd)
decreased monocyte cell number J:211773
\Msmbtm1Xuan/\Msmbtm1Xuan
(either: (involves: 129S1/Sv * 129X1/SvJ) or (involves: 129S1/Sv * 129X1/SvJ * CD-1))
enlarged lymph nodes J:96884
\Msmpem1Jzx/\Msmpem1Jzx
(C57BL/6-Msmpem1Jzx)
abnormal macrophage differentiation J:311042
decreased circulating interleukin-6 level J:311042
decreased circulating tumor necrosis factor level J:311042
liver inflammation J:311042
\Msntm1b(EUCOMM)Hmgu/\Msntm1b(EUCOMM)Hmgu
(C57BL/6N-Msntm1b(EUCOMM)Hmgu/J)
decreased leukocyte cell number J:211773
\Msntm1Sts/Y
(involves: 129S4/SvJae * C57BL/6)
decreased B cell number J:189837
decreased CD4-positive, alpha-beta T cell number J:189837
decreased eosinophil cell number J:189837
decreased lymphocyte cell number J:189837
decreased neutrophil cell number J:189837
impaired leukocyte migration J:189837
\Msr1tm1Csk/\Msr1tm1Csk
(involves: 129X1/SvJ * ICR)
increased interleukin-12 secretion J:110433
increased susceptibility to bacterial infection induced morbidity/mortality J:39079
increased susceptibility to Herpesvirales infection induced morbidity/mortality J:39079
\Msr1tm1Csk/\Msr1tm1Csk
(involves: 129S7/SvEvBrd * C57BL/6J)
abnormal macrophage physiology J:91911
\Msr1tm1Csk/\Msr1tm1Csk
(B6.129X1-Msr1tm1Csk)
decreased interferon-beta secretion J:251008
\Msr1tm1Csk/\Msr1tm1Csk
\Scarf1tm1Ishi/\Scarf1tm1Ishi

(involves: 129S7/SvEvBrd * 129X1/SvJ * C57BL/6J)
abnormal macrophage physiology J:91911
\Mst1tm1Jab/\Mst1tm1Jab
(involves: 129P2/OlaHsd * Black Swiss)
abnormal macrophage physiology J:46185
immune system phenotype J:46185
increased susceptibility to induced colitis J:46185
\Mst1rFv2-s/\Mst1rFv2-s
(B6.DDD-Mst1rFv2-s)
enlarged spleen J:5120
increased susceptibility to Retroviridae infection J:5120
\Mst1rFv2-s/\Mst1rFv2-s
(either: A/Crgl or C57BL/Crgl)
decreased susceptibility to Retroviridae infection J:167666
\Mst1rFv2-s/\Mst1rFv2-s
(either: BALB/cCrgl or DBA/2Crgl or Swiss)
enlarged spleen J:167666
increased susceptibility to Retroviridae infection J:167666
\Mst1rFv2-s/\Mst1rFv2-s
(C3H/Crgl)
increased susceptibility to Retroviridae infection J:167666
\Mst1rtm1.1Sew/\Mst1rtm1.1Sew
(involves: 129/Ola * CD-1 * NIH Black Swiss)
abnormal macrophage physiology J:75503
abnormal type IV hypersensitivity reaction J:75503
increased acute inflammation J:75503
increased susceptibility to endotoxin shock J:75503
\Mst1rtm1Ber/\Mst1rtm1Ber
(involves: 129S1/Sv * 129X1/SvJ * CD-1)
abnormal macrophage physiology J:76451
abnormal type IV hypersensitivity reaction J:76451
immune system phenotype J:76451
increased inflammatory response J:76451
increased susceptibility to bacterial infection J:76451
\Mst1rtm1Sjd/\Mst1r+
(either: (involves: 129 * C57BL/6) or (involves: 129 * CD-1) or (involves: 129 * NIH Black Swiss))
abnormal macrophage physiology J:54903
increased susceptibility to bacterial infection J:54903
\Mst1rtm2(Mst1r*)Sew/\Mst1rtm2(Mst1r*)Sew
(involves: 129P2/OlaHsd * Black Swiss * FVB/N)
decreased spleen weight J:215969
increased susceptibility to Retroviridae infection J:215969
\Mst1rtm2(Mst1r*)Sew/\Mst1rtm2(Mst1r*)Sew
(FVB.129P2(Cg)-Mst1rtm2(Mst1r*)Sew)
increased circulating interferon-gamma level J:215969
increased interferon-gamma secretion J:215969
\Mstnem1(IMPC)Hmgu/\Mstnem1(IMPC)Hmgu
(C57BL/6NCrl-Mstnem1(IMPC)Hmgu/Ieg)
decreased spleen weight J:211773
enlarged spleen J:211773
\Mstnlean/\Mstnlean
(C57BL/6J-Mstnlean)
abnormal circulating tumor necrosis factor level J:146513
decreased circulating tumor necrosis factor level J:146513
\Msto1em1(IMPC)Tcp/\Msto1+
(C57BL/6N-Msto1em1(IMPC)Tcp/Tcp)
enlarged lymph nodes J:211773
small spleen J:211773
\Msx1tm1Rilm/\Msx1+
\Pax9tm1Rbal/\Pax9tm1Rbal

(involves: 129 * CD-1)
ectopic thymus J:311535
thymus hypoplasia J:311535
\Msx2tm1Rilm/\Msx2tm1Rilm
(either: (involves: 129S4/SvJae) or (involves: 129S4/SvJae * BALB/c) or (involves: 129S4/SvJae * C57BL/6J))
decreased osteoclast cell number J:61509
\Mt1tm1Bri/\Mt1tm1Bri
\Mt2tm1Bri/\Mt2tm1Bri

(involves: 129S7/SvEvBrd)
abnormal microglial cell morphology J:103102, J:53929
abnormal microglial cell physiology J:53929
increased interleukin-1 beta secretion J:103102
increased interleukin-6 secretion J:103102
increased macrophage cell number J:53929
increased susceptibility to experimental autoimmune encephalomyelitis J:103102
increased tumor necrosis factor secretion J:103102
\Mt1tm1Bri/\Mt1tm1Bri
\Mt2tm1Bri/\Mt2tm1Bri

(129S7/SvEvBrd-Mt1tm1Bri Mt2tm1Bri/J)
abnormal humoral immune response J:110643
abnormal lymphocyte physiology J:110643
abnormal microglial cell morphology J:89429
decreased B cell number J:110643
decreased T cell number J:110643
enlarged spleen J:110643
increased CD4-positive, alpha-beta T cell number J:110643
increased CD8-positive, alpha-beta T cell number J:110643
increased IgG level J:110643
increased IgM level J:110643
increased lymphocyte cell number J:110643
increased neutrophil cell number J:120196
increased plasma cell number J:110643
increased spleen weight J:110643
increased thymocyte apoptosis J:57169
kidney inflammation J:126620
lung inflammation J:120196
spleen hyperplasia J:110643
\mt-Co1m1Jiha
(involves: C57BL/6J * M. m. domesticus)
heart inflammation J:132659
\mt-Nd2m1
(ALR/Lt)
decreased susceptibility to autoimmune diabetes J:117602, J:97969
\Mta1em1(IMPC)Ccpcz/\Mta1+
(C57BL/6NCrl-Mta1em1(IMPC)Ccpcz/Ccpcz)
increased effector memory CD8-positive, alpha-beta T cell number J:211773
\Mta2tm1.1Yzha/\Mta2tm1.1Yzha
(involves: 129S4/SvJae * C57BL/6 * FVB/N)
dermatitis J:137101
glomerulonephritis J:137101
increased anti-double stranded DNA antibody level J:137101
increased autoantibody level J:137101
increased circulating interferon-gamma level J:137101
increased circulating interleukin-2 level J:137101
increased circulating interleukin-4 level J:137101
increased susceptibility to systemic lupus erythematosus J:137101
increased T cell proliferation J:137101
liver inflammation J:137101
panniculitis J:137101
skin inflammation J:137101
\Mta2tm1Yzha/\Mta2tm1Yzha
\Tg(Lck-cre)#Zhu/0

(involves: 129S4/SvJae * C57BL/6 * SJL)
immune system phenotype J:137101
increased T cell proliferation J:137101
\Mtapem1(IMPC)Mbp/\Mtap+
(C57BL/6N-Mtapem1(IMPC)Mbp/MbpMmucd)
abnormal lymph node morphology J:211773
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged lymph nodes J:211773
enlarged spleen J:211773
enlarged thymus J:211773
\MtapGt(RRK081)Byg/\Mtap+
(129P2/OlaHsd-MtapGt(RRK081)Byg)
arteritis J:123675
\Mtarc1em1(IMPC)H/\Mtarc1em1(IMPC)H
(C57BL/6NTac-Mtarc1em1(IMPC)H/H)
increased spleen weight J:211773
\Mtbcq2NMRI8/Fbn/?
(involves: DBA/2OlaHsd * NMRI8/Fbn)
increased spleen weight J:122125
\Mtch2tm1b(EUCOMM)Hmgu/\Mtch2+
(C57BL/6N-Mtch2tm1b(EUCOMM)Hmgu/Cnrm)
increased monocyte cell number J:211773
\Mtdhtm1.2Dsar/\Mtdhtm1.2Dsar
(either: B6.129(FVB)-Mtdhtm1.2Dsar or (129S1/Sv * 129X1/SvJ * C57BL/6 * FVB/N))
decreased interleukin-1 beta secretion J:216688
decreased interleukin-6 secretion J:216688
decreased macrophage proliferation J:216688
\Mtf1Thyls-BALB/c/\Mtf1Thyls-BALB/c
(involves: BALB/c * MSM)
increased T cell derived lymphoma incidence J:71358
\Mtf1Thyls-BALB/c/\Mtf1Thyls-MSM
(involves: BALB/c * MSM)
increased T cell derived lymphoma incidence J:85264, J:71358
\Mtf1tm1Wsc/\Mtf1tm1Wsc
\Tg(Mx1-cre)1Cgn/0
\Tg(UBC-Mtf1)1Wsc/0

(involves: 129/Sv * C57BL/6 * CBA)
decreased leukocyte cell number J:91119
decreased lymphocyte cell number J:91119
\Mtfmtem1Heb/\Mtfmt+
(C57BL/6-Mtfmtem1Heb)
decreased circulating interleukin-1 beta level J:334467
decreased inflammatory response J:334467
\Mtgq4NMRI8/Fbn/?
(involves: DBA/2OlaHsd * NMRI8/Fbn)
increased spleen weight J:122125
\Mthfd1tm1.1Rzn/\Mthfd1+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6N)
decreased leukocyte cell number J:199578
decreased neutrophil cell number J:199578
\Mtmr4tm1a(EUCOMM)Wtsi/\Mtmr4+
(Not Specified)
decreased IgE level J:165965
\Mtmr11em1(IMPC)Tcp/\Mtmr11em1(IMPC)Tcp
(C57BL/6NCrl-Mtmr11em1(IMPC)Tcp/Tcp)
enlarged lymph nodes J:211773
enlarged spleen J:211773
\Mtorchino/\Mtorchino
(involves: C57BL/6JAnu)
decreased CD4-positive, alpha-beta T cell number J:207898
decreased splenocyte number J:207898
immune system phenotype J:207898
\Mtorchino/\Mtorchino
\Rasgrp1m1Anu/\Rasgrp1m1Anu

(involves: C57BL/6JAnu * C57BL/6JSfdAnu * CBA/J)
immune system phenotype J:207898
\Mtortm1.1Lgm/\Mtortm1.1Lgm
(involves: 129S1/Sv * C57BL/6)
immune system phenotype J:168600
\Mtortm1.2Koz/\Mtortm1.2Koz
\Tg(Cd4-cre)1Cwi/0

(involves: 129S4/SvJae * C57BL/6 * DBA/2)
abnormal T cell differentiation J:150108
abnormal T cell subpopulation ratio J:150108
abnormal thymus cell ratio J:150108
decreased interferon-gamma secretion J:150108
decreased interleukin-2 secretion J:150108
decreased interleukin-17 secretion J:150108
decreased T cell proliferation J:150108
decreased tumor necrosis factor secretion J:150108
increased regulatory T cell number J:150108
\Mtortm1Lgm/\Mtortm1Lgm
(involves: 129S1/Sv * C57BL/6)
abnormal B cell physiology J:168600
abnormal humoral immune response J:168600
abnormal T cell morphology J:168600
abnormal T cell physiology J:168600
decreased B cell number J:168600
decreased B cell proliferation J:168600
decreased double-positive T cell number J:168600
decreased follicular B cell number J:168600
decreased IgG level J:168600
decreased IgM level J:168600
decreased marginal zone B cell number J:168600
decreased monocyte cell number J:168600
decreased neutrophil cell number J:168600
decreased plasma cell number J:168600
decreased splenocyte apoptosis J:168600
decreased splenocyte proliferation J:168600
decreased thymocyte number J:168600
decreased transitional stage T1 B cell number J:168600
impaired B cell migration J:168600
increased CD4-positive, alpha-beta T cell number J:168600
increased CD8-positive, alpha-beta T cell number J:168600
small spleen J:168600
\Mtss1Gt(CSC156)Byg/\Mtss1Gt(CSC156)Byg
(B6.129P2-Mtss1Gt(CSC156)Byg)
abnormal B cell differentiation J:186118
abnormal B cell number J:186118
abnormal B cell physiology J:186118
decreased immature B cell number J:186118
enlarged spleen J:186118
increased inflammatory response J:186118
increased leukocyte cell number J:186118
increased pre-B cell number J:186118
\Mtus1Gt(RRA048)Byg/\Mtus1Gt(RRA048)Byg
(involves: 129P2/OlaHsd * C57BL/6)
glomerulonephritis J:212144
increased leukocyte cell number J:212144
increased lymphocyte cell number J:212144
increased susceptibility to systemic lupus erythematosus J:212144
insulitis J:212144
lymphoid hyperplasia J:212144
salivary gland inflammation J:212144
\Mtv7BALB/c/\Mtv7BALB/c
(involves: B10.Q * BALB/c * DBA/2)
increased susceptibility to induced arthritis J:27701
\Mtv7BALB/c/\Mtv7DBA/2
(involves: B10.Q * BALB/c * DBA/2)
decreased susceptibility to induced arthritis J:27701
\Mtv7DBA/2/\Mtv7DBA/2
(C.D2-Mtv7DBA/2)
decreased susceptibility to induced arthritis J:27701
\Mtv8em1Tvg/\Mtv8em1Tvg
(C57BL/6J-Mtv8em1Tvg)
immune system phenotype J:346992
\Mtx2em1(IMPC)J/\Mtx2+
(C57BL/6NJ-Mtx2em1(IMPC)J/Mmjax)
decreased leukocyte cell number J:211773
\Muc2eey/\Muc2eey
(C57BL/6-Muc2eey)
ileum inflammation J:194148
increased interferon-gamma secretion J:194148
increased interleukin-1 beta secretion J:194148
increased leukocyte cell number J:194148
increased susceptibility to induced colitis J:194148
increased tumor necrosis factor secretion J:194148
\Muc2keny/\Muc2keny
(C57BL/6JAnu-Muc2keny/AnuApb)
enlarged lymph nodes J:104190
\Muc2M1Btlr/\Muc2+
(C57BL/6J-Muc2M1Btlr)
increased susceptibility to induced colitis J:150326
\Muc2M1Btlr/\Muc2M1Btlr
(C57BL/6J-Muc2M1Btlr)
increased susceptibility to induced colitis J:150326
\Muc2m2Btlr/?
(C57BL/6J-Muc2m2Btlr)
increased susceptibility to induced colitis J:159359
\Muc2m3Btlr/\Muc2m3Btlr
(C57BL/6J-Muc2m3Btlr)
increased susceptibility to induced colitis J:254906
\Muc2tm1Avel/\Muc2tm1Avel
(involves: 129P2/OlaHsd * C57BL/6)
colitis J:216831
large intestinal inflammation J:216831
\Muc2wnn/\Muc2+
(C57BL/6-Muc2wnn)
increased susceptibility to induced colitis J:194148
\Muc2wnn/\Muc2wnn
(C57BL/6-Muc2wnn)
colitis J:194148
ileum inflammation J:194148
increased interferon-gamma secretion J:194148
increased interleukin-1 beta secretion J:194148
increased interleukin-13 secretion J:194148
increased leukocyte cell number J:194148
increased lymphocyte cell number J:194148
increased susceptibility to induced colitis J:194148
increased tumor necrosis factor secretion J:194148
\Muc4PWK/PhJ/\Muc4PWK/PhJ
(PWK/PhJ)
abnormal susceptibility to viral infection J:287566
\Muc4tm1Skb/\Muc4tm1Skb
(involves: 129 * C57BL/6J)
decreased susceptibility to colitis induced morbidity/mortality J:234205
decreased susceptibility to induced colitis J:234205
\Muc4tm1Unc/\Muc4tm1Unc
(B6NTac.129(FVB)-Muc4tm1Unc/Rand)
increased susceptibility to Coronaviridae infection J:287566
increased susceptibility to Coronaviridae infection induced morbidity/mortality J:287566
increased susceptibility to Togaviridae infection J:287566
\Muc5actm1.1Evns/\Muc5actm1.1Evns
(B6.129S1-Muc5actm1.1Evns)
increased circulating interferon-gamma level J:177306
increased susceptibility to parasitic infection J:177306
\Muc5btm1.2Evns/\Muc5btm1.2Evns
(B6.129S1-Muc5btm1.2Evns)
abnormal professional antigen presenting cell physiology J:207159
decreased interleukin-23 secretion J:207159
impaired macrophage phagocytosis J:207159
increased macrophage apoptosis J:207159
increased susceptibility to bacterial infection J:207159
increased susceptibility to bacterial infection induced morbidity/mortality J:207159
increased susceptibility to otitis media J:207159
respiratory system inflammation J:207159
sepsis J:207159
\Muc13tm1.1Mamg/\Muc13tm1.1Mamg
(involves: 129 * C57BL/6)
increased susceptibility to colitis induced morbidity/mortality J:313870
increased susceptibility to induced colitis J:313870
large intestinal inflammation J:313870
small intestinal inflammation J:313870
\Muc19sld/\Muc19sld
(NFS/N-Muc19sld)
increased susceptibility to autoimmune disorder J:216958, J:20364
\Mug1tm1Vln/\Mug1tm1Vln
(B.129P2-Mug1tm1Vln)
abnormal cytokine level J:57485
liver inflammation J:57485
\Mug1tm2Vln/\Mug1tm2Vln
\Pzptm1Vln/\Pzptm1Vln

(B.129P2-Pzptm1Vln Mug1tm2Vln)
abnormal cytokine level J:57485
abnormal uterine NK cell morphology J:117841
liver inflammation J:57485
\Mus81tm1Esse/\Mus81+
(involves: 129P2/OlaHsd * C57BL/6J)
increased inflammatory response J:222498
\Mus81tm1Esse/\Mus81tm1Esse
(involves: 129P2/OlaHsd * C57BL/6J)
increased interleukin-1 beta secretion J:222498
lung inflammation J:222498
\Mus81tm1Raz/\Mus81tm1Raz
(involves: 129P2/OlaHsd)
immune system phenotype J:91570
\Mx1r/\Mx1r
(B6.A2G-Mx1r)
abnormal susceptibility to infection J:120938
decreased susceptibility to Orthomyxoviridae infection induced morbidity/mortality J:23752
\Mx1r/\Mx1r
(C.A2G-Mx1r)
decreased susceptibility to Orthomyxoviridae infection J:23752
decreased susceptibility to Orthomyxoviridae infection induced morbidity/mortality J:23752
\Mx1r/\Mx1r
(A2G)
decreased susceptibility to Orthomyxoviridae infection induced morbidity/mortality J:23752
\Mx1s1/\Mx1s1
(BALB/c)
increased susceptibility to Orthomyxoviridae infection J:23752
\Mx1s1/\Mx1s1
(C57BL/6)
abnormal peritoneal macrophage morphology J:23752
abnormal susceptibility to infection J:120938
increased susceptibility to Orthomyxoviridae infection induced morbidity/mortality J:23752
\Mx1s1/\Mx1s1
\Tg(Hmgcr-MX1)LStae/?

(involves: C57BL/6 * SJL)
decreased susceptibility to Orthomyxoviridae infection J:128067
decreased susceptibility to Orthomyxoviridae infection induced morbidity/mortality J:128067
decreased susceptibility to Riboviria infection J:128067
decreased susceptibility to Riboviria infection induced morbidity/mortality J:128067
\Mx1s2/\Mx1s2
(CBA/J)
increased susceptibility to Orthomyxoviridae infection J:23752
\Mxd1tm1Rne/\Mxd1tm1Rne
(involves: 129S4/SvJaeSor * C57BL/6)
abnormal B cell physiology J:45945
abnormal myeloid leukocyte morphology J:45945
immune system phenotype J:45945
increased granulocyte number J:45945
\Mxd4em1(IMPC)J/\Mxd4em1(IMPC)J
(C57BL/6NJ-Mxd4em1(IMPC)J/Mmjax)
increased leukocyte cell number J:211773
\Mxi1tm1Rdp/\Mxi1tm1Rdp
(involves: 129/Sv * C57BL/6J * SJL)
abnormal lymphocyte morphology J:48236
enlarged spleen J:48236
increased spleen white pulp amount J:48236
increased T cell proliferation J:48236
\Mxra8em1Diam/\Mxra8+
(C57BL/6J-Mxra8em1Diam)
decreased susceptibility to Togaviridae infection J:280585
\Mxra8em1Diam/\Mxra8em1Diam
(C57BL/6J-Mxra8em1Diam)
abnormal cytokine level J:280585
decreased inflammatory response J:280585
decreased susceptibility to Togaviridae infection J:280585
\Mxra8em2Diam/\Mxra8em2Diam
(C57BL/6J-Mxra8em2Diam)
decreased susceptibility to Togaviridae infection J:280585
\Mybboo/\Mybboo
(involves: C57BL/6)
abnormal B cell differentiation J:167270
abnormal leukocyte morphology J:167270
abnormal spleen morphology J:167270
decreased neutrophil cell number J:167270
decreased spleen white pulp amount J:167270
enlarged spleen J:167270
increased spleen red pulp amount J:167270
\MybM303V/\MybM303V
(involves: 129S1/SvlmJ * C57BL/6)
arrested B cell differentiation J:96507
arrested T cell differentiation J:96507
decreased B cell number J:96507
decreased eosinophil cell number J:96507
decreased single-positive T cell number J:96507
decreased thymocyte number J:96507
\Mybtm1.1Cgn/\Myb+
(involves: 129P2/OlaHsd * C57BL/6)
arrested B cell differentiation J:127234
decreased B-1 B cell number J:127234
decreased mature B cell number J:127234
decreased pre-B cell number J:127234
\Mybtm1Cgn/\Mybtm1.1Cgn
\Tg(Lck-cre)548Jxm/0

(involves: 129P2/OlaHsd * C57BL/6 * DBA/2)
decreased CD4-positive, alpha-beta T cell number J:91122
decreased double-positive T cell number J:91122
thymus hypoplasia J:91122
\Mybtm1Cgn/\Mybtm1Cgn
\Tg(Lck-cre)1Cwi/0

(involves: 129P2/OlaHsd * C57BL/6 * DBA/2)
arrested T cell differentiation J:91122
decreased CD4-positive, alpha-beta T cell number J:91122
decreased CD8-positive, alpha-beta T cell number J:91122
decreased double-negative T cell number J:91122
decreased double-positive T cell number J:91122
decreased gamma-delta T cell number J:91122
thymus hypoplasia J:91122
\Mybtm1Cgn/\Mybtm1Cgn
\Tg(Lck-cre)548Jxm/0

(involves: 129P2/OlaHsd * C57BL/6 * DBA/2)
decreased CD4-positive, alpha-beta T cell number J:91122
decreased double-positive T cell number J:91122
thymus hypoplasia J:91122
\Mybtm1Epr/\Mybtm1Epr
\Tg(Cd4-cre)1Cwi/0

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2)
abnormal T cell differentiation J:93481
decreased CD4-positive, alpha-beta T cell number J:93481
decreased double-positive T cell number J:93481
increased CD8-positive, alpha-beta T cell number J:93481
thymus hypoplasia J:93481
\Mybtm1Epr/\Mybtm1Epr
\Tg(Lck-cre)548Jxm/0

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA)
abnormal double-negative T cell morphology J:93481
abnormal T cell differentiation J:93481
decreased double-positive T cell number J:93481
thymus hypoplasia J:93481
\Mybtm1Jof/\Mybtm1Jof
(involves: 129/Sv * C57BL/6)
abnormal B cell differentiation J:85344
abnormal double-negative T cell morphology J:85344
abnormal T cell differentiation J:85344
decreased thymocyte number J:85344
\Mybtm1Jof/\Mybtm1Ssp
(involves: 129/Sv * C57BL/6)
abnormal T cell differentiation J:85344
decreased thymocyte number J:85344
\Mybtm2.2Epr/\Mybtm2.2Epr
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
immune system phenotype J:160189
\Mybl1tm1Epr/\Mybl1tm1Epr
(involves: 129 * C57BL/6)
abnormal humoral immune response J:67604
abnormal spleen B cell follicle morphology J:67604
abnormal spleen marginal zone morphology J:67604
decreased B cell number J:67604
decreased IgG1 level J:67604
decreased IgG2a level J:67604
decreased IgG3 level J:67604
decreased spleen germinal center number J:67604
increased spleen red pulp amount J:67604
small spleen J:67604
spleen hypoplasia J:67604
\Mybl2tm1.1Epr/\Mybl2tm1.1Epr
\Tg(Mx1-cre)1Cgn/0

(involves: 129X1/SvJ * C57BL/6 * CBA * FVB/N)
abnormal myelopoiesis J:206816
decreased B cell number J:206816
decreased leukocyte cell number J:206816
decreased lymphocyte cell number J:206816
decreased neutrophil cell number J:206816
decreased splenocyte number J:206816
decreased T cell number J:206816
\Mybl2tm1.1Jof/\Mybl2+
\Tg(Zp3-cre)3Mrt/0

(involves: 129S2/SvPas * C57BL/6 * FVB/N)
abnormal myelopoiesis J:196804
decreased leukocyte cell number J:196804
decreased neutrophil cell number J:196804
enlarged spleen J:196804
increased granulocyte number J:196804
increased leukocyte cell number J:196804
increased monocyte cell number J:196804
myeloid hyperplasia J:196804
\Mybphltm1a(KOMP)Wtsi/\Mybphltm1a(KOMP)Wtsi
(C57BL/6N-Mybphltm1a(KOMP)Wtsi/Wtsi)
blood in lymph vessels J:239583
\Mybphltm1b(KOMP)Wtsi/\Mybphltm1b(KOMP)Wtsi
(C57BL/6N-Mybphltm1b(KOMP)Wtsi/Wtsi)
abnormal thymus morphology J:239583
blood in lymph vessels J:239583
\Myctm1.1(Nmyc1)Fwa/\Myctm1.1(Nmyc1)Fwa
(involves: 129P2/OlaHsd * C57BL/6)
immune system phenotype J:62573
\Myctm1.1Cksn/\Myctm1.1Cksn
(B6.129-Myctm1.1Cksn)
immune system phenotype J:170508
\Myctm1Atp/\Myc+
(involves: 129P2/OlaHsd * FVB/N)
decreased T cell proliferation J:73369
lymph node hypoplasia J:73369
lymphoid hypoplasia J:73369
small lymphoid organs J:73369
spleen hypoplasia J:73369
\Myctm1Atp/\Myc+
(B6.129P2-Myctm1Atp)
abnormal NK cell physiology J:132730
decreased memory T cell number J:132730
decreased T cell proliferation J:132730
immune system phenotype J:132730
\Myctm1Atp/\Myctm2.1Atp
(involves: 129P2/OlaHsd * C57BL/6 * FVB/N * SJL)
decreased T cell proliferation J:73369
immune system phenotype J:73369
lymph node hypoplasia J:73369
spleen hypoplasia J:73369
\Myctm1Atp/\Myctm2.1Atp
\Tg(Mx1-cre)1Cgn/0

(involves: 129P2/OlaHsd * C57BL/6 * CBA * FVB/N * SJL)
immune system phenotype J:73369
\Myctm1Lbox/\Myc+
(involves: 129S1/Sv * 129X1/SvJ * FVB/N)
enlarged lymph nodes J:97900
enlarged spleen J:97900
increased B cell number J:97900
increased spleen weight J:97900
\Myctm1Lbox/\Myctm1Lbox
(involves: 129S1/Sv * 129X1/SvJ * FVB/N)
decreased T cell number J:97900
enlarged lymph nodes J:97900
enlarged spleen J:97900
increased B cell apoptosis J:97900
increased B cell number J:97900
increased B cell proliferation J:97900
increased spleen weight J:97900
\Myctm2.1Atp/\Myc+
(involves: 129P2/OlaHsd * C57BL/6 * SJL)
decreased T cell proliferation J:73369
\Myctm2.1Atp/\Myctm2.1Atp
\Tg(Mx1-cre)1Cgn/0

(involves: 129P2/OlaHsd * C57BL/6 * CBA * FVB/N * SJL)
immune system phenotype J:73369
\Myctm2Fwa/\Myctm2Fwa
\Cd19tm1(cre)Cgn/\Cd19+

(involves: 129P2/OlaHsd * 129S6/SvEvTac)
decreased B cell proliferation J:67222
\Myctm3(Tcrb)Fwa/\Myc+
(involves: 129)
abnormal T cell receptor beta chain V(D)J recombination J:131995
\Mycltm1.1Kmm/\Mycltm1.1Kmm
(B6.129S6(C)-Mycltm1.1Kmm)
abnormal dendritic cell physiology J:206430
decreased dendritic cell number J:206430
decreased susceptibility to bacterial infection induced morbidity/mortality J:206430
\Myct1em1(IMPC)Mbp/\Myct1em1(IMPC)Mbp
(C57BL/6N-Myct1em1(IMPC)Mbp/MbpMmucd)
abnormal spleen morphology J:211773
enlarged spleen J:211773
\Myct1em1Choi/\Myct1em1Choi
(involves: C57BL/6)
abnormal macrophage cell number J:303692
decreased regulatory T cell number J:303692
increased CD8-positive, alpha-beta T cell number J:303692
\Myd88lkd/\Myd88lkd
(C57BL/6-Myd88lkd)
abnormal adaptive immunity J:110094
abnormal cell-mediated immunity J:110094
abnormal innate immunity J:110094
abnormal macrophage physiology J:110094
immune system phenotype J:110094
\Myd88m3Btlr/\Myd88m3Btlr
(C57BL/6J-Myd88m3Btlr)
immune system phenotype J:156848
\Myd88M4Btlr/\Myd88+
(C57BL/6J-Myd88M4Btlr)
decreased tumor necrosis factor secretion J:254917
\Myd88M4Btlr/\Myd88M4Btlr
(C57BL/6J-Myd88M4Btlr)
decreased tumor necrosis factor secretion J:254917
\Myd88poc/\Myd88+
(C57BL/6-Myd88poc)
immune system phenotype J:110094
\Myd88poc/\Myd88poc
(C57BL/6-Myd88poc)
abnormal immune system physiology J:110094
abnormal macrophage physiology J:110094
immune system phenotype J:110094
increased susceptibility to bacterial infection J:110094
increased susceptibility to Herpesvirales infection J:110094
\Myd88poc/\Myd88poc
\Ptpn6m1Btlr/\Ptpn6m1Btlr

(C57BL/6J-Ptpn6m1Btlr Myd88poc)
immune system phenotype J:142845
\Myd88tm1.1Defr/\Myd88tm1.1Defr
(B6.129P2(SJL)-Myd88tm1.1Defr)
abnormal CD4-positive, alpha-beta T cell physiology J:224849
abnormal macrophage physiology J:224849
abnormal microglial cell physiology J:224849
decreased effector memory CD4-positive, alpha-beta T cell number J:224849
decreased interferon-gamma secretion J:224849
decreased leukocyte cell number J:224849
decreased macrophage cell number J:224849
decreased monocyte cell number J:224849
decreased neutrophil cell number J:224849
increased susceptibility to Coronaviridae infection J:224849
increased susceptibility to Coronaviridae infection induced morbidity/mortality J:224849
\Myd88tm1.1Medz/\Myd88tm1.1Medz
\Foxp3tm4(YFP/icre)Ayr/\Foxp3+

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
immune system phenotype J:209373
\Myd88tm1.1Medz/\Myd88tm1.1Medz
\Tg(Cd4-cre)1Cwi/0

(involves: C57BL/6 * DBA/2)
abnormal CD4-positive, alpha-beta T cell physiology J:209373
abnormal memory T cell physiology J:209373
abnormal T-helper 1 physiology J:209373
abnormal T-helper 17 cell physiology J:209373
\Myd88tm1Aki/\Myd88tm1Aki
(Not Specified)
abnormal cytokine secretion J:89257, J:88906
abnormal dendritic cell physiology J:96773
abnormal macrophage physiology J:96773
abnormal NK cell physiology J:88906
abnormal NK T cell physiology J:88906
abnormal T cell physiology J:96773
decreased B cell proliferation J:96773
increased susceptibility to Herpesvirales infection J:88906
\Myd88tm1Aki/\Myd88tm1Aki
(B6.129P2-Myd88tm1Aki)
abnormal chemokine secretion J:102879
abnormal cytokine secretion J:116670, J:162707
abnormal dendritic cell differentiation J:139001
abnormal dendritic cell physiology J:116670, J:118954
abnormal immune system physiology J:121070
abnormal innate immunity J:162707
abnormal macrophage physiology J:116670
abnormal NK cell physiology J:139001
abnormal response to infection J:121070
abnormal T cell physiology J:97662
bronchiolitis J:162707
decreased inflammatory response J:123946
decreased interferon-alpha secretion J:97662
decreased interferon-gamma secretion J:116763, J:118954
decreased interleukin-6 secretion J:118954, J:121070
decreased interleukin-12 secretion J:116670
decreased interleukin-12b secretion J:116763, J:118954
decreased susceptibility to parasitic infection J:116763
decreased tumor necrosis factor secretion J:116670, J:116763, J:121070
increased dendritic cell number J:116763
increased susceptibility to Coronaviridae infection J:162707
increased susceptibility to Coronaviridae infection induced morbidity/mortality J:162707
increased susceptibility to Picornaviridae infection J:97662
\Myd88tm1Aki/\Myd88tm1Aki
(involves: 129P2/OlaHsd)
abnormal cytokine level J:174941
abnormal cytokine secretion J:167340
abnormal dendritic cell physiology J:174941, J:137522
abnormal interferon level J:137522
abnormal macrophage physiology J:174941
abnormal neutrophil physiology J:145345
abnormal tumor necrosis factor level J:103464, J:124334
decreased circulating tumor necrosis factor level J:139030
decreased interferon-alpha secretion J:144400
decreased interferon-gamma secretion J:210086
decreased interleukin-6 secretion J:167340
decreased susceptibility to experimental autoimmune encephalomyelitis J:105435
increased IgA level J:210086
increased IgE level J:115059
increased IgG1 level J:115059
increased susceptibility to bacterial infection J:210086
increased susceptibility to induced colitis J:167340
increased susceptibility to Picornaviridae infection J:137522
\Myd88tm1Aki/\Myd88tm1Aki
(involves: 129P2/OlaHsd * C57BL/6)
abnormal chemokine secretion J:141143
abnormal cytokine secretion J:117688
abnormal dendritic cell physiology J:122394
abnormal macrophage physiology J:141143, J:117688
decreased IgG2b level J:137066
decreased IgG3 level J:137066
decreased IgG level J:137066
decreased interleukin-1 beta secretion J:124226
decreased interleukin-6 secretion J:147023
immune system phenotype J:132662
\Myd88tm1Aki/\Myd88tm1Aki
(C.129P2-Myd88tm1Aki)
decreased susceptibility to induced arthritis J:178054
\Myd88tm1Aki/\Myd88tm1Aki
(B6.129-Myd88tm1Aki)
abnormal susceptibility to bacterial infection J:189854
decreased interleukin-6 secretion J:189854
decreased tumor necrosis factor secretion J:189854
\Myd88tm1Aki/\Myd88tm1Aki
\Sh3bp2tm1.1Ics/\Sh3bp2tm1.1Ics

(involves: 129P2/OlaHsd * C57BL/6)
immune system phenotype J:221901
\Myd88tm1Aki/\Myd88tm1Aki
\Tanktm1Aki/\Tanktm1Aki

(involves: 129/Sv * 129P2/OlaHsd * C57BL/6)
increased anti-double stranded DNA antibody level J:151757
\Myd88tm1Aki/\Myd88tm1Aki
\Tg(IghelMD4)4Ccg/0
\Tg(KLK4mHEL)6Ccg/0

(involves: 129P2/OlaHsd * C57BL/6)
decreased mature B cell number J:115059
increased B-1 B cell number J:115059
\Myd88tm1Aki/\Myd88tm1Aki
\Ticam1tm1Aki/\Ticam1+

(B6.129P2-Myd88tm1Aki Ticam1tm1Aki)
decreased macrophage cytokine production J:140485
decreased macrophage nitric oxide production J:140485
increased susceptibility to parasitic infection J:140485
increased susceptibility to parasitic infection induced morbidity/mortality J:140485
\Myd88tm1Aki/\Myd88tm1Aki
\Ticam1tm1Aki/\Ticam1tm1Aki

(involves: 129P2/OlaHsd)
abnormal dendritic cell physiology J:174941
abnormal macrophage physiology J:174941
\Myd88tm1Aki/\Myd88tm1Aki
\Ticam1tm1Aki/\Ticam1tm1Aki

(B6.129P2-Myd88tm1Aki Ticam1tm1Aki)
decreased macrophage cytokine production J:140485
decreased macrophage nitric oxide production J:140485
increased susceptibility to parasitic infection J:140485
increased susceptibility to parasitic infection induced morbidity/mortality J:140485
\Myd88tm1Aki/\Myd88tm1Aki
\Tnfaip3tm1.1Gvl/\Tnfaip3tm1.1Gvl
\Tg(Vil1-cre)997Gum/0

(involves: 129P2/OlaHsd * C57BL/6 * SJL)
increased susceptibility to induced colitis J:163410
\Myd88tm1Aki/\Myd88tm1Aki
\Tnip1tm1.1Pcoh/\Tnip1tm1.1Pcoh

(involves: 129P2/OlaHsd * C57BL/6)
immune system phenotype J:176826
\Myd88tm1Aki/\Myd88tm1Aki
\Traddtm1.1Mpa/\Traddtm1.1Mpa

(involves: 129P2/OlaHsd * BALB/cJ * C57BL/6)
decreased circulating tumor necrosis factor level J:139030
\Myd88tm1Defr/\Myd88tm1Defr
\Commd10Tg(Vav1-icre)A2Kio/\Commd10+

(involves: 129P2/OlaHsd * C57BL/6 * SJL)
abnormal NK cell physiology J:139001
\Myd88tm1Defr/\Myd88tm1Defr
\Tg(Itgax-cre)1-1Reiz/0

(B6.Cg-Myd88tm1Defr Tg(Itgax-cre)1-1Reiz)
abnormal dendritic cell antigen presentation J:139001
abnormal dendritic cell differentiation J:139001
abnormal dendritic cell physiology J:139001
abnormal NK cell physiology J:139001
abnormal T-helper 1 cell differentiation J:139001
decreased circulating interleukin-6 level J:139001
decreased circulating interleukin-12b level J:139001
decreased IgG1 level J:139001
decreased IgG2b level J:139001
decreased IgG2c level J:139001
\Myd88tm1Defr/\Myd88tm1Defr
\Tnip1tm1.2Ama/\Tnip1tm1.2Ama
\Tg(Itgax-cre)1-1Reiz/0

(involves: 129P2/OlaHsd * C57BL/6 * C57BL/6J * CBA)
immune system phenotype J:205446
\Myd88tm1Hlz/\Myd88tm1Hlz
(B6.129P2-Myd88tm1Hlz)
abnormal chemokine level J:188968
decreased circulating interleukin-6 level J:188968
decreased circulating interleukin-10 level J:188968
decreased circulating interleukin-12b level J:188968
decreased interleukin-6 secretion J:188968
decreased interleukin-10 secretion J:188968
decreased neutrophil cell number J:188968
decreased tumor necrosis factor secretion J:188968
\Myd88tm1Hlz/\Myd88tm1Hlz
\Lyz2tm1(cre)Ifo/\Lyz2+

(B6.129P2-Myd88tm1Hlz Lyz2tm1(cre)Ifo)
abnormal circulating chemokine level J:188968
decreased CXCL10 level J:188968
immune system phenotype J:188968
increased circulating tumor necrosis factor level J:188968
\Mydgftm1Kcw/\Mydgftm1Kcw
(BALB/c-Mydgftm1Kcw)
decreased inflammatory response J:216795
\Myh1tm1b(KOMP)Wtsi/\Myh1tm1b(KOMP)Wtsi
(C57BL/6N-Myh1tm1b(KOMP)Wtsi/J)
decreased leukocyte cell number J:211773
\Myh4arl/\Myh4arl
(involves: C3H/HeH * C57BL/6J)
myositis J:181892
\Myh6tm1Jse/\Myh6+
\Tg(Myh6-TNNI3*G203S)1Chs/0

(involves: 129X1/SvJ * C57BL/6)
liver inflammation J:153302
lung inflammation J:153302
\Myh9tm1.1Dash/\Myh9+
(involves: 129S2/SvPas * C57BL/6 * C57BL/6J * CBA)
abnormal thrombopoiesis J:204923
\Myh9tm1.1Mjk/\Myh9+
(B6.129-Myh9tm1.1Mjk)
abnormal neutrophil morphology J:175367
increased incidence of corneal inflammation J:175367
\Myh9tm1.1Mjk/\Myh9tm1.1Mjk
(B6.129-Myh9tm1.1Mjk)
abnormal neutrophil morphology J:175367
\Myh9tm5Rsad/\Myh9tm5Rsad
(involves: 129S6/SvEvTac * C57BL/6J)
abnormal leukocyte migration J:164684
abnormal T cell physiology J:164684
\Myh9tm5Rsad/\Myh9tm5Rsad
\Tg(Lck-cre)#Nik/0

(involves: 129S6/SvEvTac * C57BL/6 * C57BL/6J * DBA/2)
abnormal CD8-positive, alpha-beta T cell physiology J:164684
abnormal leukocyte adhesion J:164684
abnormal leukocyte migration J:164684
abnormal lymph node cell ratio J:164684
abnormal T cell physiology J:164684
decreased CD8-positive, alpha-beta T cell number J:164684
\Myh9tm6.1(EGFP/MYH9*)Rsad/\Myh9+
(involves: 129S4/SvJae * BALB/cJ * C57BL/6)
abnormal neutrophil morphology J:175367
\Myh9tm7.1Rsad/\Myh9+
(involves: BALB/cJ)
abnormal neutrophil morphology J:175367
\Myh9tm7.1Rsad/\Myh9tm7.1Rsad
(involves: BALB/cJ)
abnormal neutrophil morphology J:175367
\Myh10tm7Rsad/\Myh10tm7Rsad
\Tg(Myh6-cre)2182Mds/0

(involves: 129S6/SvEvTac * C57BL/6J * FVB/N)
heart inflammation J:170148
\Myh15em1(IMPC)J/\Myh15em1(IMPC)J
(C57BL/6NJ-Myh15em1(IMPC)J/Mmjax)
decreased leukocyte cell number J:211773
\Myl3tm1a(EUCOMM)Hmgu/\Myl3tm1a(EUCOMM)Hmgu
\Tg(Col2a1-cre)1Xya/0

(involves: C57BL/6J * C57BL/6N)
osteoarthritis J:343166
\Myl3tm1a(EUCOMM)Hmgu/\Myl3tm1a(EUCOMM)Hmgu
\Tg(Col2a1-cre/ERT)KA3Smac/0

(involves: C57BL/6J * C57BL/6N * FVB/N)
increased susceptibility to induced arthritis J:343166
\Mylktm1Mzhu/\Mylktm1Mzhu
\Taglntm1(cre/ERT2)Feil/?

(involves: 129S1/Sv * 129S6/SvEvTac * 129X1/SvJ * C57BL/6)
small intestinal inflammation J:141907
\Myo1dem1Btlr/\Myo1dem1Btlr
(C57BL/6J-Myo1dem1Btlr)
increased susceptibility to colitis induced morbidity/mortality J:267525
increased susceptibility to induced colitis J:267525
\Myo1dm1Btlr/\Myo1dm1Btlr
(C57BL/6J-Myo1dm1Btlr)
increased susceptibility to induced colitis J:267525
\Myo1dm1Btlr/\Myo1dm2Btlr
(C57BL/6J-Myo1dm1Btlr/Myo1dm2Btlr)
increased susceptibility to induced colitis J:267525
\Myo1dm2Btlr/\Myo1dm2Btlr
(C57BL/6J-Myo1dm2Btlr)
increased susceptibility to induced colitis J:267525
\Myo1dm3Btlr/\Myo1dm3Btlr
(C57BL/6J-Myo1dm3Btlr)
increased susceptibility to induced colitis J:267525
\Myo1dm4Btlr/\Myo1dm4Btlr
(C57BL/6J-Myo1dm4Btlr)
increased susceptibility to induced colitis J:267525
\Myo1ftm1.1Flv/\Myo1ftm1.1Flv
(involves: 129S6/SvEvTac)
impaired neutrophil chemotaxis J:113020
\Myo1gtm1.2Mfk/\Myo1gtm1.2Mfk
(Not Specified)
abnormal B cell physiology J:209304
decreased B cell number J:209304
decreased tumor necrosis factor secretion J:209304
immune system phenotype J:209304
impaired B cell migration J:209304
increased B cell number J:209304
\Myo1gtm1.2Mfk/\Myo1gtm1.2Mfk
(involves: C57BL/6 * FVB/N * SJL)
abnormal T cell physiology J:212451
\Myo1gtm1.2Mfk/\Myo1gtm1.2Mfk
\Tg(TcraTcrb)1100Mjb/0

(involves: C57BL/6 * FVB/N * SJL)
abnormal T cell physiology J:212451
\Myo3btm1b(EUCOMM)Hmgu/\Myo3btm1b(EUCOMM)Hmgu
(C57BL/6N-Myo3btm1b(EUCOMM)Hmgu/J)
decreased leukocyte cell number J:211773
\Myo5ad-2Btlr/\Myo5ad-2Btlr
(C57BL/6J-Myo5ad-2Btlr)
immune system phenotype J:133118
\Myo5ad-Btlr/\Myo5ad-Btlr
(C57BL/6J-Myo5ad-Btlr)
immune system phenotype J:133117
\Myo5ad-l20J/\Myo5ad-l20J
(involves: C57BL/6J)
immune system phenotype J:111253
\Myo6em1(IMPC)Tcp/\Myo6em1(IMPC)Tcp
(C57BL/6N-Myo6em1(IMPC)Tcp/Tcp)
decreased leukocyte cell number J:211773
\Myo9atm1b(EUCOMM)Wtsi/\Myo9atm1b(EUCOMM)Wtsi
(C57BL/6N-Myo9atm1b(EUCOMM)Wtsi/Wtsi)
blood in lymph vessels J:239583
\Myo9btm1.2Bah/\Myo9btm1.2Bah
(B6.Cg-Myo9btm1.2Bah)
abnormal macrophage physiology J:162326
decreased leukocyte cell number J:162326
impaired macrophage chemotaxis J:162326
\Myo18atm1c(KOMP)Wtsi/\Myo18atm1c(KOMP)Wtsi
\Gt(ROSA)26Sortm1(EYFP)Cos/\Gt(ROSA)26Sor+
\Lyz2tm1(cre)Ifo/\Lyz2+

(involves: 129P2/OlaHsd * 129S4/SvJaeSor * 129X1/SvJ * C57BL/6N)
immune system phenotype J:277320
\Myoz1tm1b(EUCOMM)Hmgu/\Myoz1tm1b(EUCOMM)Hmgu
(C57BL/6N-Myoz1tm1b(EUCOMM)Hmgu/Ieg)
increased marginal zone B cell number J:211773
\Mypnem1(IMPC)J/\Mypnem1(IMPC)J
(C57BL/6NJ-Mypnem1(IMPC)J/Mmjax)
decreased leukocyte cell number J:211773
\mypy/\mypy
(C57BL/6J-mypy)
abnormal macrophage physiology J:105543
increased susceptibility to Herpesvirales infection J:105543
increased susceptibility to Riboviria infection J:105543
\Mysm1tm1a(KOMP)Wtsi/\Mysm1tm1a(KOMP)Wtsi
(Not Specified)
decreased B cell number J:165965
decreased leukocyte cell number J:165965
decreased mature B cell number J:165965
increased granulocyte number J:165965
increased IgG2b level J:165965
increased T cell number J:165965
\Mysm1tm1b(KOMP)Wtsi/\Mysm1tm1b(KOMP)Wtsi
\Tg(MMTV-cre)4Mam/0

(involves: 129 * C57BL/6N * FVB/N)
abnormal T cell differentiation J:179287
arrested B cell differentiation J:179287
decreased B cell number J:179287
decreased immature B cell number J:179287
decreased pre-B cell number J:179287
decreased pro-B cell number J:179287
\Mzb1tm1.2Rug/\Mzb1tm1.2Rug
(involves: 129S2/SvPas * BALB/cJ * C57BL/6 * SJL)
decreased pre-B cell number J:211639
immune system phenotype J:211639
impaired humoral immune response J:211639
increased pro-B cell number J:211639
\Mzf1tm1Ppp/\Mzf1tm1Ppp
(involves: 129)
abnormal bone marrow development J:70407
abnormal myelopoiesis J:70407
\N4bp1em1Vmd/\N4bp1em1Vmd
(C57BL/6N-N4bp1em1Vmd)
decreased interleukin-6 secretion J:297419
immune system phenotype J:297419
\N4bp1tm1.2Vmd/\N4bp1tm1.2Vmd
(involves: C57BL/6)
abnormal macrophage physiology J:297419
decreased susceptibility to bacterial infection induced morbidity/mortality J:297419
increased activated T cell number J:297419
increased circulating interleukin-6 level J:297419
increased circulating tumor necrosis factor level J:297419
increased germinal center B cell number J:297419
increased interleukin-6 secretion J:297419
increased Ly6C high monocyte number J:297419
increased tumor necrosis factor secretion J:297419
lung inflammation J:297419
\Naa10em1(IMPC)Mbp/Y
(C57BL/6NCrl-Naa10em1(IMPC)Mbp/Mmucd)
abnormal lymph node morphology J:211773
abnormal spleen morphology J:211773
enlarged lymph nodes J:211773
small spleen J:211773
\Naa10em1(IMPC)Mbp/\Naa10em1(IMPC)Mbp
(C57BL/6NCrl-Naa10em1(IMPC)Mbp/Mmucd)
abnormal lymph node morphology J:211773
abnormal spleen morphology J:211773
enlarged lymph nodes J:211773
enlarged spleen J:211773
\Naa16em1(IMPC)J/\Naa16em1(IMPC)J
(C57BL/6NJ-Naa16em1(IMPC)J/Mmjax)
increased leukocyte cell number J:211773
\Naa25em1(IMPC)Tcp/\Naa25+
(C57BL/6NCrl-Naa25em1(IMPC)Tcp/Tcp)
enlarged lymph nodes J:211773
enlarged thymus J:211773
\Naa35em1(IMPC)J/\Naa35+
(C57BL/6NJ-Naa35em1(IMPC)J/Mmjax)
decreased leukocyte cell number J:211773
\Naa38em1(IMPC)Ccpcz/\Naa38+
(C57BL/6N-Naa38em1(IMPC)Ccpcz/Ccpcz)
abnormal lymph node morphology J:211773
abnormal thymus morphology J:211773
enlarged lymph nodes J:211773
enlarged thymus J:211773
\Naaatm1a(KOMP)Wtsi/\Naaatm1a(KOMP)Wtsi
(B6NTac;B6N-Atm1Brd Naaatm1a(KOMP)Wtsi/WtsiH)
decreased susceptibility to type IV hypersensitivity reaction J:258438
\Nabp2tm1.1Kkha/\Nabp2tm1.1Kkha
\Cd19tm1(cre)Cgn/\Cd19+

(involves: 129P2/OlaHsd * C57BL/6)
immune system phenotype J:195140
\Nabp2tm1.1Kkha/\Nabp2tm1.1Kkha
\Gt(ROSA)26Sortm9(cre/ESR1)Arte/\Gt(ROSA)26Sor+

(involves: C57BL/6 * C57BL/6NTac)
increased T cell derived lymphoma incidence J:195140
increased thymocyte apoptosis J:195140
\Nabp2tm1.1Nfel/\Nabp2tm1.2Nfel
\Cd19tm1(cre)Cgn/\Cd19+

(involves: 129P2/OlaHsd * C57BL/6 * FVB/N * SJL)
immune system phenotype J:190019
\Nabp2tm1Schg/\Nabp2tm1Schg
(involves: 129S7/SvEvBrd * C57BL/6)
increased spleen red pulp amount J:228558
\nad/\nad
(C(D2)-nad)
abnormal bronchus-associated lymphoid tissue morphology J:156089
\Nadsyn1tm1b(KOMP)Wtsi/\Nadsyn1tm1b(KOMP)Wtsi
(C57BL/6N-Nadsyn1tm1b(KOMP)Wtsi/Ucd)
enlarged spleen J:211773
\Nagktm1b(EUCOMM)Hmgu/\Nagktm1b(EUCOMM)Hmgu
(C57BL/6N-Nagktm1b(EUCOMM)Hmgu/H)
increased neutrophil cell number J:211773
\Naglutm1Efn/\Naglutm1Efn
(either: (involves: 129S/SvEv * C57BL/6) or (involves: C57BL/6))
abnormal Kupffer cell morphology J:58950
abnormal macrophage morphology J:58950
\Naglutm1Efn/\Naglutm1Efn
(involves: 129S/SvEv * C57BL/6J)
increased susceptibility to otitis media J:129390
\Naip5Lgn1-s/\Naip5Lgn1-s
(A/J)
increased susceptibility to bacterial infection J:20633
\Naip5m1Btlr/\Naip5m1Btlr
(C57BL/6J-Naip5m1Btlr)
decreased interleukin-1 beta secretion J:234250
\Naip5m2Btlr/\Naip5+
(C57BL/6J-Naip5m2Btlr)
decreased interleukin-1 beta secretion J:234248
\Naip5m2Btlr/\Naip5m2Btlr
(C57BL/6J-Naip5m2Btlr)
decreased interleukin-1 beta secretion J:234248
\Naip5tm1Vnce/\Naip5tm1Vnce
(C57BL/6-Naip5tm1Vnce)
decreased interleukin-1 beta secretion J:141008
\Naipctm1.1Kmma/\Naipctm1.1Kmma
(involves: BALB/cJ * C57BL/6)
decreased interleukin-1 beta secretion J:222114
decreased susceptibility to induced colitis J:222114
\Naipctm1Kmma/\Naipctm1Kmma
\Lyz2tm1(cre)Ifo/\Lyz2+

(B6.Cg-Lyz2tm1(cre)Ifo Naipctm1Kmma)
decreased susceptibility to induced colitis J:222114
\Naipctm1Kmma/\Naipctm1Kmma
\Tg(Vil1-cre)997Gum/0

(B6.Cg-Naipctm1Kmma Tg(Vil1-cre)997Gum)
decreased susceptibility to induced colitis J:222114
\Nalcnem1(IMPC)Mbp/\Nalcn+
(C57BL/6N-Nalcnem1(IMPC)Mbp/Ucd)
abnormal spleen morphology J:211773
enlarged spleen J:211773
increased neutrophil cell number J:211773
\NamptGt(RRR084)Byg/\Nampt+
(involves: 129P2/OlaHsd * C57BL/6)
decreased interleukin-6 secretion J:194883
decreased neutrophil cell number J:194883
\Nampttm1Oleo/\Nampttm1Oleo
\Tg(CD2-icre)4Kio/0

(involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/10 * CBA/Ca)
decreased B cell number J:141448
decreased double-negative T cell number J:141448
decreased T cell number J:141448
thymus hypoplasia J:141448
\Napaem1(IMPC)Ccpcz/\Napa+
(C57BL/6NCrl-Napaem1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
enlarged spleen J:211773
\Nat8f2tm1.1(KOMP)Vlcg/\Nat8f2tm1.1(KOMP)Vlcg
(C57BL/6N-Nat8f2tm1.1(KOMP)Vlcg/J)
enlarged lymph nodes J:211773
\Nav1em1(IMPC)Mbp/\Nav1em1(IMPC)Mbp
(C57BL/6N-Nav1em1(IMPC)Mbp/MbpMmucd)
abnormal spleen morphology J:211773
enlarged spleen J:211773
\Nav2em1(IMPC)Tcp/\Nav2em1(IMPC)Tcp
(C57BL/6NCrl-Nav2em1(IMPC)Tcp/Tcp)
increased neutrophil cell number J:211773
\Naxetm1b(EUCOMM)Hmgu/\Naxetm1b(EUCOMM)Hmgu
(C57BL/6N-Naxetm1b(EUCOMM)Hmgu/Bay)
increased spleen weight J:211773
\Nba4NZB/\Nba4NZB
(involves: NZB * SWR)
glomerulonephritis J:96060
increased anti-double stranded DNA antibody level J:96060
increased anti-histone antibody level J:96263
increased anti-single stranded DNA antibody level J:96060
increased IgG3 level J:96263
\Nba4NZB/\Nba4SWR
(involves: NZB * SWR)
increased anti-histone antibody level J:96263
increased IgG3 level J:96263
\Nba5NZB/\Nba5NZB
(C57BL/6-Nba5 Yaa)
glomerulonephritis J:95829
increased susceptibility to type III hypersensitivity reaction J:95829
\Nba8NZB/\Nba8NZB
(involves: NZB * SWR)
glomerulonephritis J:73097
\Nba10NZB/?
(involves: C57BL/6 * NZB * SB/Le)
glomerulonephritis J:95829
increased anti-chromatin antibody level J:95829
increased anti-double stranded DNA antibody level J:95829
increased susceptibility to type III hypersensitivity reaction J:95829
\Nba10NZB/\Nba10NZB
\Tg(Tnfsf13b)1Fma/0

(involves: C57BL/6 * DBA/2J * NZB)
glomerulonephritis J:134128
increased anti-chromatin antibody level J:134128
increased anti-double stranded DNA antibody level J:134128
increased B cell number J:134128
increased IgG level J:134128
increased IgM level J:134128
increased marginal zone B cell number J:134128
increased susceptibility to systemic lupus erythematosus J:134128
\Nba10NZB/\Nba10NZB
\Tlr7tm1Aki/Y
X/\Yaa

(B6.Cg-Nba10NZB Tlr7tm1Aki Yaa)
abnormal immune serum protein physiology J:137656
glomerulonephritis J:137656
increased anti-chromatin antibody level J:137656
increased monocyte cell number J:137656
\Nba10NZB/\Nba10NZB
X/\Yaa

(C57BL/6-Nba2 Yaa)
abnormal immune serum protein physiology J:137656
glomerulonephritis J:95829, J:137656
increased anti-chromatin antibody level J:137656
increased anti-nuclear antigen antibody level J:95829
increased autoantibody level J:137656
increased monocyte cell number J:137656, J:129409
increased susceptibility to autoimmune disorder J:95829
increased susceptibility to type III hypersensitivity reaction J:95829
\Nba11NZB/\Nba11NZB
(involves: NZB * SWR)
glomerulonephritis J:96263
\Nba11NZB/\Nba11SWR
(involves: NZB * SWR)
glomerulonephritis J:96263
\Nba12NZB/\Nba12NZB
(involves: NZB * SWR)
increased anti-double stranded DNA antibody level J:96263
\Nba12NZB/\Nba12SWR
(involves: NZB * SWR)
increased anti-double stranded DNA antibody level J:96263
\Nbeal2gps/\Nbeal2gps
(129S1/SvImJ-Nbeal2gps)
decreased neutrophil cell number J:236370
\Nbeal2tm1a(EUCOMM)Wtsi/\Nbeal2tm1a(EUCOMM)Wtsi
(C57BL/6N-Nbeal2tm1a(EUCOMM)Wtsi/Wtsi)
enlarged spleen J:220801
increased inflammatory response J:220801
increased leukocyte cell number J:211773
\Nbeal2tm1Lex/\Nbeal2tm1Lex
(involves: 129S5/SvEvBrd * C57BL/6J)
enlarged spleen J:201413
\Nbnem7Jpt/\Nbntm2Zqw
\Tg(VAV1-cre)1Graf/0

(involves: 129P2/OlaHsd)
abnormal T cell morphology J:277750
absent mature B cells J:277750
decreased B cell number J:277750
decreased leukocyte cell number J:277750
decreased T cell number J:277750
decreased thymocyte number J:277750
increased CD8-positive, alpha-beta T cell number J:277750
increased pro-B cell number J:277750
increased T cell derived lymphoma incidence J:277750
\Nbntm1Jpt/\Nbntm1Jpt
(involves: 129S7/SvEvBrd)
immune system phenotype J:75956
\Nbntm1Nus/\Nbntm2Nus
\Tg(CD19-cre/ERT2)1Cgn/0

(Not Specified)
abnormal B cell physiology J:96102
decreased B cell proliferation J:96102
decreased IgG1 level J:96102
decreased IgG2a level J:96102
decreased IgG2b level J:96102
decreased IgG3 level J:96102
decreased IgG level J:96102
\Nbntm1Xu/\Nbntm1Xu
(Not Specified)
abnormal cell-mediated immunity J:75272
decreased CD4-positive, alpha-beta T cell number J:75272
decreased mature B cell number J:75272
decreased pre-B cell number J:75272
decreased T cell number J:75272
increased T cell derived lymphoma incidence J:75272
thymus hypoplasia J:75272
\Nbntm1Zqw/\Nbn+
(involves: 129S2/SvPas * C57BL/6)
increased T cell derived lymphoma incidence J:86563
\Nbntm2Zqw/\Nbntm2Zqw
\Tg(VAV1-cre)1Graf/0

(involves: 129P2/OlaHsd)
abnormal bone marrow development J:251434
decreased leukocyte cell number J:251434
\Nbr1tm1.1Jmos/\Nbr1tm1.1Jmos
\Tnfrsf4tm2(cre)Nik/\Tnfrsf4+

(involves: 129X1/SvJ * C57BL/6J)
abnormal T-helper 1 cell differentiation J:165438
abnormal T-helper 2 cell differentiation J:165438
decreased inflammatory response J:165438
decreased interferon-gamma secretion J:165438
decreased interleukin-4 secretion J:165438
decreased interleukin-5 secretion J:165438
decreased interleukin-13 secretion J:165438
\Nbr1tm1Whca/\Nbr1tm1Whca
(B6.129P2-Nbr1tm1Whca)
abnormal osteoclast physiology J:162412
\Nbwa1NZB/?
(involves: BALB/c * NZB * NZW)
increased anti-chromatin antibody level J:88464
increased anti-double stranded DNA antibody level J:88464
increased anti-single stranded DNA antibody level J:88464
increased susceptibility to systemic lupus erythematosus J:88464
\Nbwa2NZB/?
(involves: BALB/c * NZB * NZW)
glomerulonephritis J:88464
increased IgG level J:88464
increased IgM level J:88464
increased susceptibility to systemic lupus erythematosus J:88464
\Nbwa2NZW/?
(involves: BALB/c * NZB * NZW)
increased anti-double stranded DNA antibody level J:88464
increased susceptibility to systemic lupus erythematosus J:88464
\Ncam2tm1b(EUCOMM)Hmgu/\Ncam2tm1b(EUCOMM)Hmgu
(C57BL/6N-Ncam2tm1b(EUCOMM)Hmgu/Orl)
increased eosinophil cell number J:211773
\Ncapd2em1Cya/\Ncapd2+
(C57BL/6N-Ncapd2em1Cya)
decreased susceptibility to induced colitis J:310248
\Ncaph2nes/\Ncaph2nes
(C57BL/6JSfdAnu-Ncaph2nes/Anu)
abnormal double-negative T cell morphology J:123300
abnormal splenic cell ratio J:123300
abnormal T cell morphology J:123300
abnormal thymus cell ratio J:123300
abnormal thymus cortex morphology J:123300
abnormal thymus corticomedullary boundary morphology J:123300
decreased CD8-positive, alpha-beta T cell number J:123300
decreased double-negative T cell number J:123300
decreased double-positive T cell number J:123300
decreased T cell number J:123300
decreased thymocyte number J:123300
thymus hypoplasia J:123300
\Ncaph2nes/\Ncaph2nes
\Tg(TcrHEL3A9)1Mmd/0

(C57BL/6-Ncaph2nes Tg(TcrHEL3A9)1Mmd)
abnormal double-negative T cell morphology J:123300
abnormal thymus cell ratio J:123300
decreased double-positive T cell number J:123300
\Nceh1tm1Ishi/\Nceh1tm1Ishi
(B6.129S7-Nceh1tm1Ishi)
abnormal macrophage physiology J:152385
\Ncf1em1(IMPC)Mbp/\Ncf1em1(IMPC)Mbp
(C57BL/6N-Ncf1em1(IMPC)Mbp/MbpMmucd)
abnormal lymph node morphology J:211773
abnormal spleen morphology J:211773
enlarged lymph nodes J:211773
enlarged spleen J:211773
\Ncf1em1Nansh/\Ncf1em1Nansh
(involves: C57BL/6J)
immune system phenotype J:329553
\Ncf1m1J/\Ncf1m1J
(B6.Cg-Dock7m +/+ Leprdb/J)
abnormal macrophage physiology J:83428
decreased susceptibility to Orthomyxoviridae infection J:145306
impaired granulocyte bactericidal activity J:83428
\Ncf1tm1Hbd/\Ncf1tm1Hbd
(involves: 129)
abnormal neutrophil physiology J:77597, J:74593
granulomatous inflammation J:74593
\Ncf1tm1Hbd/\Ncf1tm1Hbd
(involves: C57BL/6)
immune system phenotype J:118561
\Ncf1tm1Shl/\Ncf1tm1Shl
(involves: 129S2/SvPas * C57BL/6J)
abnormal response to infection J:28267
increased acute inflammation J:28267
increased susceptibility to infection J:28267
\Ncf1tm1Shl/\Ncf1tm1Shl
(B6.129S2-Ncf1tm1Shl)
abnormal inflammatory response J:142617
granulomatous inflammation J:111142
\Ncf2tm1a(EUCOMM)Wtsi/\Ncf2tm1a(EUCOMM)Wtsi
(C57BL/6N-Ncf2tm1a(EUCOMM)Wtsi/Wtsi)
decreased alpha-beta T cell number J:211773
decreased leukocyte cell number J:211773
decreased NK cell number J:211773
decreased NK T cell number J:211773
decreased regulatory T cell number J:211773
decreased T cell number J:211773
increased KLRG1-positive NK cell number J:211773
\Ncf2tm1b(EUCOMM)Wtsi/\Ncf2+
(NZM2328.B6(Cg)-Ncf2tm1b(EUCOMM)Wtsi)
abnormal spleen germinal center morphology J:260777
increased activated T cell number J:260777
increased anti-double stranded DNA antibody level J:260777
increased B cell number J:260777
increased CD4-positive, alpha-beta memory T cell number J:260777
increased CD4-positive, CD25-positive, alpha-beta regulatory T cell number J:260777
increased CD8-positive, alpha-beta T cell number J:260777
increased follicular B cell number J:260777
increased germinal center B cell number J:260777
increased susceptibility to systemic lupus erythematosus J:260777
increased T cell number J:260777
\Ncf2tm1b(EUCOMM)Wtsi/\Ncf2tm1b(EUCOMM)Wtsi
(B6(Cg)-Ncf2tm1b(EUCOMM)Wtsi)
decreased CD8-positive, alpha-beta T cell number J:260777
increased susceptibility to fungal infection J:260777
lung inflammation J:260777
\Ncf2tm1b(EUCOMM)Wtsi/\Ncf2tm1b(EUCOMM)Wtsi
(NZM2328.B6(Cg)-Ncf2tm1b(EUCOMM)Wtsi)
abnormal spleen germinal center morphology J:260777
increased activated T cell number J:260777
increased anti-double stranded DNA antibody level J:260777
increased B cell number J:260777
increased follicular B cell number J:260777
increased germinal center B cell number J:260777
increased susceptibility to systemic lupus erythematosus J:260777
increased T cell number J:260777
\Ncf4tm1Pth/\Ncf4tm2Pth
(involves: 129P2/OlaHsd * C57BL/6)
abnormal neutrophil physiology J:119217
immune system phenotype J:119217
increased susceptibility to bacterial infection J:119217
\Ncf4tm2Pth/\Ncf4tm2Pth
(involves: 129P2/OlaHsd * C57BL/6)
abnormal neutrophil physiology J:121820
increased susceptibility to bacterial infection J:121820
\Nckap1lm1Btlr/\Nckap1lm1Btlr
(C57BL/6J-Nckap1lm1Btlr)
decreased alpha-beta T cell number J:272079
decreased B cell number J:272079
decreased CD4-positive, alpha-beta T cell number J:272079
decreased CD8-positive, alpha-beta T cell number J:272079
decreased CD8-positive, naive alpha-beta T cell number J:272079
decreased central memory CD8 positive, alpha-beta T cell number J:272079
decreased NK cell number J:272079
increased alpha-beta T cell number J:272079
increased CD8-positive, alpha-beta T cell number J:272079
increased effector memory CD4-positive, alpha-beta T cell number J:272079
increased effector memory CD8-positive, alpha-beta T cell number J:272079
\Nckap1lm1Iri/\Nckap1lm1Iri
(involves: C57BL/6)
abnormal CD4-positive T cell differentiation J:141377
abnormal immune system organ morphology J:141377
abnormal lymphopoiesis J:141377
abnormal regulatory T cell number J:141377
abnormal thymus lobule morphology J:141377
decreased CD4-positive, alpha-beta T cell number J:141377
decreased CD8-positive, alpha-beta T cell number J:141377
decreased double-positive T cell number J:141377
decreased lymphocyte cell number J:141377
decreased mature B cell number J:141377
decreased mature gamma-delta T cell number J:141377
decreased T cell proliferation J:141377
heart inflammation J:141377
impaired macrophage phagocytosis J:141377
impaired neutrophil chemotaxis J:141377
impaired neutrophil phagocytosis J:141377
increased circulating interleukin-6 level J:141377
increased circulating interleukin-17 level J:141377
increased double-negative T cell number J:141377
increased interleukin-6 secretion J:141377
increased interleukin-17 secretion J:141377
increased leukocyte cell number J:141377
increased neutrophil cell number J:141377
increased tumor necrosis factor secretion J:141377
liver inflammation J:141377
lung inflammation J:141377
lymph node hypoplasia J:141377
spleen hyperplasia J:141377
thymus hypoplasia J:141377
\Ncoa1tm1Bwo/\Ncoa1tm1Bwo
(involves: 129 * C57BL/6J)
immune system phenotype J:109522
\Ncoa2em1(IMPC)Mbp/\Ncoa2+
(C57BL/6N-Ncoa2em1(IMPC)Mbp/MbpMmucd)
abnormal spleen morphology J:211773
enlarged spleen J:211773
increased neutrophil cell number J:211773
\Ncoa2tm1.2Ipc/\Ncoa2tm1.2Ipc
(involves: 129S2/SvPas * C57BL/6J)
immune system phenotype J:109522
\Ncoa3tm1Jxu/\Ncoa3tm1Jxu
(involves: 129S6/SvEvTac * C57BL/6J)
abnormal B cell morphology J:109522
abnormal lymphopoiesis J:109522
abnormal spleen red pulp morphology J:109522
decreased splenocyte apoptosis J:109522
enlarged spleen J:109522
increased B cell number J:109522
increased B cell proliferation J:109522
increased CD4-positive, alpha-beta T cell number J:109522
increased CD8-positive, alpha-beta T cell number J:109522
increased leukocyte cell number J:109522
increased lymphocyte cell number J:109522
increased spleen germinal center size J:109522
increased T cell proliferation J:109522
\Ncoa3tm1Jxu/\Ncoa3tm1Jxu
(involves: 129S6/SvEvTac * C57BL/6)
decreased interleukin-1 beta secretion J:120086
increased circulating interleukin-1 beta level J:120086
increased circulating interleukin-6 level J:120086
increased circulating tumor necrosis factor level J:120086
increased interleukin-6 secretion J:120086
increased susceptibility to bacterial infection induced morbidity/mortality J:120086
increased susceptibility to endotoxin shock J:120086
increased tumor necrosis factor secretion J:120086
\Ncoa5tm1.1(KOMP)Mbp/\Ncoa5+
(C57BL/6N-Ncoa5tm1.1(KOMP)Mbp/Tcp)
increased eosinophil cell number J:211773
\Ncoa5tm1Hxia/\Ncoa5+
(involves: 129 * C57BL/6)
chronic liver inflammation J:207622
\Ncor1tm1Rsd/\Ncor1tm1Rsd
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
arrested T cell differentiation J:65417
small thymus J:65417
\Ncor2tm1Rev/\Ncor2tm1Rev
(involves: 129/Sv * C57BL/6)
abnormal spleen morphology J:202976
enlarged spleen J:202976
increased osteoclast cell number J:202976
\Ncr1m1J/\Ncr1m1J
\Pepcb/\Pepcb
\Ptprca/\Ptprca

(B6.SJL-Ptprca Pepcb/BoyJ)
abnormal interferon level J:257226
abnormal NK cell physiology J:257226
abnormal susceptibility to infection induced morbidity/mortality J:257226
decreased susceptibility to Orthomyxoviridae infection induced morbidity/mortality J:257226
increased susceptibility to Herpesvirales infection induced morbidity/mortality J:257226
\Ncr1noe/\Ncr1noe
(involves: C57BL/6J)
abnormal NK cell physiology J:179728
decreased CD4-positive, alpha-beta T cell number J:179728
decreased CD8-positive, alpha-beta memory T cell number J:179728
decreased CD8-positive, alpha-beta T cell number J:179728
decreased susceptibility to Herpesvirales infection J:179728
decreased susceptibility to Herpesvirales infection induced morbidity/mortality J:179728
increased NK cell number J:179728
increased susceptibility to bacterial infection J:179728
\Ncr1tm1.1(icre)Viv/\Ncr1tm1.1(icre)Viv
(involves: C57BL/6)
abnormal NK cell physiology J:179728
decreased susceptibility to Herpesvirales infection induced morbidity/mortality J:179728
decreased susceptibility to Orthomyxoviridae infection induced morbidity/mortality J:179728
\Ncr1tm1Oman/\Ncr1tm1Oman
(involves: 129S1/Sv * 129X1/SvJ)
decreased NK cell number J:112394
impaired natural killer cell mediated cytotoxicity J:112394
increased susceptibility to Orthomyxoviridae infection induced morbidity/mortality J:112394
\Ncr1tm2.1Viv/\Ncr1+
(involves: C57BL/6)
immune system phenotype J:186000
\Ncstntm1.1Akli/\Ncstntm1.1Akli
\Tet2tm1.1Iaai/\Tet2tm1.1Iaai
\Tg(VAV1-cre)1Graf/0

(involves: 129S/SvEv * C57BL/6)
enlarged spleen J:196407
increased leukocyte cell number J:196407
myeloid hyperplasia J:196407
\Ncstntm1.1Akli/\Ncstntm1.1Akli
\Tg(Mx1-cre)1Cgn/0

(involves: 129 * C57BL/6 * CBA * SJL)
abnormal spleen morphology J:172442
enlarged spleen J:172442
increased leukocyte cell number J:172442
increased monocyte cell number J:172442
increased spleen red pulp amount J:172442
\Ncstntm1.1Akli/\Ncstntm1.1Akli
\Tg(VAV1-cre)1Graf/0

(involves: 129 * C57BL/6 * SJL)
abnormal spleen morphology J:172442
enlarged spleen J:172442
increased leukocyte cell number J:172442
increased monocyte cell number J:172442
increased spleen red pulp amount J:172442
\Ncstntm1.1Akli/\Ncstntm1.1Akli
\Tg(VAV1-cre)1Graf/0

(involves: 129)
abnormal splenocyte physiology J:196407
enlarged spleen J:196407
\Ndfip1Gt(RRD002)Byg/\Ndfip1Gt(RRD002)Byg
(involves: 129P2/OlaHsd * C57BL/6)
abnormal T cell physiology J:116617
abnormal T-helper 2 physiology J:116617
dermatitis J:116617
increased activated T cell number J:116617
increased inflammatory response J:116617
increased spleen weight J:116617
increased T cell proliferation J:116617
lung inflammation J:116617
\Ndfip1Gt(RRD002)Byg/\Ndfip1Gt(RRD002)Byg
(involves: 129P2/OlaHsd)
abnormal T cell physiology J:205692
increased activated T cell number J:205692
increased interleukin-2 secretion J:205692
increased T cell proliferation J:205692
\Ndfip1Gt(RRD002)Byg/\Ndfip1Gt(RRD002)Byg
\Rag1tm1Mom/\Rag1tm1Mom
\Tg(TcraTcrb)425Cbn/0

(involves: 129P2/OlaHsd * 129S7/SvEvBrd * BALB/c * C57BL/6)
immune system phenotype J:205692
\Ndfip1kru/\Ndfip1kru
(involves: C57BL/6JSfdAnu)
immune system phenotype J:188722
increased T-helper 2 cell number J:188722
\Ndfip1tm1.1Pmo/\Ndfip1tm1.1Pmo
\Tg(Cd4-cre)1Cwi/0

(involves: C57BL/6 * DBA/2)
esophageal inflammation J:205692
increased activated T cell number J:205692
increased eosinophil cell number J:205692
skin inflammation J:205692
\Ndor1Tg(UBC-cre/ERT2)1Ejb/\Ndor1+
\Rnpc3tm1c(EUCOMM)Wtsi/\Rnpc3tm1c(EUCOMM)Wtsi

(involves: 129S/SvEv * C57BL/6 * C57BL/6N)
decreased leukocyte cell number J:267519
decreased lymphocyte cell number J:267519
decreased monocyte cell number J:267519
decreased thymus weight J:267519
esophageal inflammation J:267519
small intestinal inflammation J:267519
thymus atrophy J:267519
thymus cortex atrophy J:267519
thymus medulla atrophy J:267519
\Ndor1Tg(UBC-cre/ERT2)1Ejb/\Ndor1+
\Rragatm2Dmsa/\Rragatm2Dmsa

(involves: 129S/SvEv * 129S4/SvJae * C57BL/6)
decreased B cell number J:213516
enlarged spleen J:213516
increased monocyte cell number J:213516
myeloid hyperplasia J:213516
\Ndrg2tm1.1Hori/\Ndrg2tm1.1Hori
(B6.129-Ndrg2tm1.1Hori)
abnormal microglial cell chemotaxis J:214686
decreased inflammatory response J:214686
decreased interleukin-6 secretion J:214686
\Ndrg2tm1Kmori/\Ndrg2+
(involves: C57BL/6 * C57BL/6NCrlj * CBA/JNCrlj)
increased T cell derived lymphoma incidence J:210264
\Ndrg2tm1Kmori/\Ndrg2tm1Kmori
(involves: C57BL/6 * C57BL/6NCrlj * CBA/JNCrlj)
increased T cell derived lymphoma incidence J:210264
\Ndrg3em1(IMPC)Mbp/\Ndrg3+
(C57BL/6NCrl-Ndrg3em1(IMPC)Mbp/Mmucd)
enlarged spleen J:211773
\Ndst1b2b2230Clo/\Ndst1b2b2230Clo
(C57BL/6J-Ndst1b2b2230Clo)
thymus hypoplasia J:175213
\Ndst1tm1Je/\Ndst1tm1Je
\Tg(Tek-cre)1Ywa/0

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL)
abnormal leukocyte adhesion J:100456
abnormal leukocyte migration J:100456
decreased inflammatory response J:100456
impaired leukocyte tethering or rolling J:100456
\Ndst2tm1Lkj/\Ndst2tm1Lkj
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
abnormal mast cell morphology J:57121
decreased mast cell degranulation J:57121
decreased mast cell histamine storage J:57121
decreased mast cell number J:57121
decreased mast cell protease storage J:57121
\Ndst2tm1Rls/\Ndst2tm1Rls
(Not Specified)
abnormal response to infection J:57120
decreased mast cell degranulation J:57120
decreased mast cell histamine storage J:57120
decreased mast cell protease storage J:57120
\Ndst2tm1Rls/\Ndst2tm1Rls
(B6.Cg-Ndst2tm1Rls)
abnormal mast cell differentiation J:142880
decreased susceptibility to induced arthritis J:142880
\Ndst3tm1.1Grob/\Ndst3tm1.1Grob
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * FVB/N)
decreased CD8-positive, alpha-beta T cell number J:138557
decreased lymphocyte cell number J:138557
\Ndufs4tm1.1Rpa/\Ndufs4tm1.1Rpa
(involves: 129S4/SvJaeSor)
microgliosis J:161393
\Ndufs4tm1.1Rpa/\Ndufs4tm1.1Rpa
(B6.129S4-Ndufs4tm1.1Rpa)
microgliosis J:190475
\Ndufs4tm1Rpa/\Ndufs4tm1Rpa
(B6.129S4-Ndufs4tm1Rpa)
microgliosis J:190475
\Ndufs4tm1Rpa/\Ndufs4tm1Rpa
\Tg(Nes-cre)1Kln/0

(involves: 129S4/SvJaeSor * C57BL/6 * SJL)
microgliosis J:161393
\Ndufs4tm1Rpa/\Ndufs4tm1Rpa
\Tg(Nes-cre)1Kln/0

(B6.Cg-Tg(Nes-cre)1Kln Ndufs4tm1Rpa)
microgliosis J:190475
\Nectin4em1Jaa/\Nectin4em1Jaa
(involves: C57BL/6N)
decreased susceptibility to type I hypersensitivity reaction J:336809
\Nedd1em1(IMPC)H/\Nedd1+
(C57BL/6NTac-Nedd1em1(IMPC)H/H)
increased eosinophil cell number J:211773
\Nedd4Gt(XA209)Byg/\Nedd4Gt(XA209)Byg
(involves: 129P2/OlaHsd)
abnormal T cell activation J:143560
decreased B cell number J:143560
decreased IgG1 level J:143560
decreased IgG2b level J:143560
decreased IgG3 level J:143560
decreased interleukin-2 secretion J:143560
decreased T cell proliferation J:143560
increased CD4-positive, alpha-beta T cell number J:143560
increased CD8-positive, alpha-beta T cell number J:143560
increased IgM level J:143560
increased T cell number J:143560
\Nedd4Gt(XB398)Byg/\Nedd4Gt(XB398)Byg
(involves: 129P2/OlaHsd)
decreased B cell number J:143560
decreased IgG1 level J:143560
decreased IgG2b level J:143560
decreased IgG3 level J:143560
decreased interleukin-2 secretion J:143560
decreased T cell proliferation J:143560
increased CD4-positive, alpha-beta T cell number J:143560
increased CD8-positive, alpha-beta T cell number J:143560
increased IgM level J:143560
increased T cell number J:143560
\Nedd4tm2b(EUCOMM)Hmgu/\Nedd4+
(C57BL/6N-Nedd4tm2b(EUCOMM)Hmgu/H)
increased leukocyte cell number J:211773
increased lymphocyte cell number J:211773
\Nedd4ltm1.1Hkb/\Nedd4ltm1.1Hkb
\Tg(SFTPC-rtTA)5Jaw/0
\Tg(tetO-cre)1Jaw/0

(involves: 129P2/OlaHsd * C57BL/6 * FVB/N * SJL)
lung inflammation J:169296
\Nedd4ltm1Shkr/\Nedd4ltm1Shkr
(involves: C57BL/6 * C57BL/6J)
increased neutrophil cell number J:205657
lung inflammation J:205657
\Nedd4ltm1Shkr/\Nedd4ltm1Shkr
(involves: 129 * C57BL/6 * C57BL/6J)
lung inflammation J:205657
\Nedd9m1Btlr/\Nedd9m1Btlr
(C57BL/6J-Nedd9m1Btlr)
decreased B-1a cell number J:267702
decreased B-1b cell number J:267702
increased susceptibility to Herpesvirales infection J:267702
\Nedd9tm1Miku/\Nedd9tm1Miku
(B6.CBA-Nedd9tm1Miku)
abnormal B cell number J:116716
abnormal follicular B cell physiology J:116716
abnormal leukocyte migration J:116716
abnormal T cell physiology J:116716
decreased lymphocyte cell number J:116716
decreased marginal zone B cell number J:116716
increased follicular B cell number J:116716
lymph node hypoplasia J:116716
spleen hypoplasia J:116716
\Neil1tm1Rsld/\Neil1tm1Rsld
(involves: 129S1/Sv * C57BL/6)
joint inflammation J:106077
\Neil2tm1.1Tkhz/\Neil2tm1.1Tkhz
(involves: 129S6/SvEvTac * C57BL/6J * C57BL/6NCrl)
increased neutrophil cell number J:225791
lung inflammation J:225791
\Neil3tm1Bjor/\Neil3tm1Bjor
(involves: 129 * C57BL/6)
decreased microglial cell activation J:180177
\Nek2em1(IMPC)Tcp/\Nek2em1(IMPC)Tcp
(C57BL/6NCrl-Nek2em1(IMPC)Tcp/Tcp)
enlarged lymph nodes J:211773
\Nek7M1Btlr/\Nek7+
(C57BL/6J-Nek7M1Btlr)
abnormal macrophage physiology J:226677
decreased inflammatory response J:226677
decreased interleukin-1 beta secretion J:226677
decreased interleukin-18 secretion J:226677
immune system phenotype J:226677
\Nek7M1Btlr/\Nek7M1Btlr
(C57BL/6J-Nek7M1Btlr)
abnormal macrophage physiology J:226677
decreased inflammatory response J:226677
decreased interleukin-1 beta secretion J:226677
decreased interleukin-18 secretion J:226677
decreased susceptibility to experimental autoimmune encephalomyelitis J:226677
immune system phenotype J:226677
\Nek8m1Btlr/\Nek8m1Btlr
(C57BL/6J-Nek8m1Btlr)
decreased CD8-positive, alpha-beta T cell number J:267544
decreased effector memory CD4-positive, alpha-beta T cell number J:267544
decreased effector memory CD8-positive, alpha-beta T cell number J:267544
increased CD4-positive, alpha-beta T cell number J:267544
increased susceptibility to induced colitis J:267544
\Nek9tm1a(EUCOMM)Wtsi/\Nek9+
(C57BL/6N-Nek9tm1a(EUCOMM)Wtsi/Wtsi)
increased leukocyte cell number J:211773
\Nelfaem1(IMPC)Tcp/\Nelfa+
(C57BL/6NCrl-Nelfaem1(IMPC)Tcp/Tcp)
increased spleen weight J:211773
\Nell1em1(IMPC)Mbp/\Nell1em1(IMPC)Mbp
(C57BL/6N-Nell1em1(IMPC)Mbp/MbpMmucd)
abnormal lymph node morphology J:211773
\Nemp1em1(IMPC)Mbp/\Nemp1em1(IMPC)Mbp
(C57BL/6NCrl-Nemp1em1(IMPC)Mbp/Mmucd)
abnormal spleen morphology J:211773
enlarged spleen J:211773
increased spleen weight J:211773
\Nemp2em1(IMPC)Tcp/\Nemp2em1(IMPC)Tcp
(C57BL/6N-Nemp2em1(IMPC)Tcp/Tcp)
abnormal spleen morphology J:211773
\Neu1a/\Neu1a
(SM/J)
abnormal Kupffer cell morphology J:147881
\Neu1tm1Adz/\Neu1tm1Adz
(either: (involves: 129S1/Sv * C57BL/6) or (involves: 129S1/Sv * NMRI))
abnormal Kupffer cell morphology J:76937
abnormal microglial cell morphology J:76937
enlarged spleen J:76937
spleen hyperplasia J:76937
\Neurl2tm1.1(KOMP)Vlcg/\Neurl2tm1.1(KOMP)Vlcg
(C57BL/6N-Neurl2tm1.1(KOMP)Vlcg/J)
decreased leukocyte cell number J:211773
\Neurl3em1Luda/\Neurl3em1Luda
(B6N.Cg-Neurl3em1Luda)
increased susceptibility to Riboviria infection J:344721
increased susceptibility to Riboviria infection induced morbidity/mortality J:344721
\Neurl4em1(IMPC)Mbp/\Neurl4em1(IMPC)Mbp
(C57BL/6NCrl-Neurl4em1(IMPC)Mbp/Mmucd)
abnormal spleen morphology J:211773
decreased leukocyte cell number J:211773
enlarged spleen J:211773
small spleen J:211773
\Nexmifem1(IMPC)Tcp/Y
(C57BL/6N-Nexmifem1(IMPC)Tcp/Tcp)
increased basophil cell number J:211773
increased eosinophil cell number J:211773
increased monocyte cell number J:211773
small spleen J:211773
\Nexmifem1(IMPC)Tcp/\Nexmif+
(C57BL/6N-Nexmifem1(IMPC)Tcp/Tcp)
increased neutrophil cell number J:211773
\Nf1tm1.1Kest/\Nf1tm1c(KOMP)Wtsi
\Tg(Dhh-cre)1Mejr/0

(involves: 129S4/SvJaeSor * C57BL/6 * C57BL/6N * C57BL/6NTac * FVB/N)
dermatitis J:234172
\Nf1tm1c(KOMP)Wtsi/\Nf1tm1c(KOMP)Wtsi
\Tg(Dhh-cre)1Mejr/0

(involves: 129S4/SvJaeSor * C57BL/6 * C57BL/6N * FVB/N)
dermatitis J:234172
\Nf1tm1Fcr/\Nf1+
\Ptentm1Hwu/\Ptentm1Hwu
\Tg(Mx1-cre)1Cgn/0

(B6.Cg-Tg(Mx1-cre)1Cgn Nf1tm1Fcr Ptentm1Hwu)
abnormal spleen morphology J:232645
decreased B cell number J:232645
decreased lymphocyte cell number J:232645
decreased T cell number J:232645
enlarged spleen J:232645
increased granulocyte number J:232645
increased leukocyte cell number J:232645
increased macrophage cell number J:232645
increased monocyte cell number J:232645
increased spleen weight J:232645
\Nf1tm1Fcr/\Nf1tm1Fcr
(either: (involves: 129S/SvEv) or (involves: 129S/SvEv * C57BL/6J))
abnormal lymphatic vessel morphology J:18048
\Nf1tm1Fcr/\Nf1tm1Par
\Tg(Tek-cre)1Ywa/0

(involves: 129S/SvEv * 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL)
abnormal spleen morphology J:114455
absent spleen germinal center J:114455
enlarged spleen J:114455
spleen fibrosis J:114455
\Nf1tm1Par/\Nf1tm1Fcr
\Tg(GFAP-cre)#Gtm/0

(involves: 129S/SvEv * 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA)
abnormal microglial cell morphology J:165209
\Nf1tm1Par/\Nf1tm1Par
\Tg(Mx1-cre)1Cgn/0

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA)
abnormal myeloid leukocyte morphology J:90973
abnormal myelopoiesis J:90973
abnormal spleen morphology J:90973
enlarged spleen J:90973
increased granulocyte number J:90973
increased leukocyte cell number J:90973
increased lymphocyte cell number J:90973
increased monocyte cell number J:90973
increased neutrophil cell number J:90973
\Nf1tm1Par/\Nf1tm1Par
\Tg(Prrx1-cre)1Cjt/0

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * C57BL/6N * SJL/J)
increased osteoclast cell number J:193350
\Nf1tm1Tyj/\Nf1+
(involves: 129S2/SvPas)
abnormal mast cell physiology J:142439
increased mast cell degranulation J:142439
\Nf1tm1Tyj/\Nf1+
\Pak1tm1Cher/\Pak1tm1Cher

(involves: 129S2/SvPas * C57BL/6)
abnormal mast cell physiology J:142439
\Nf1tm1Tyj/\Nf1+
\Trp53tm1Tyj/\Trp53+

(involves: 129S2/SvPas * C57BL/6)
spleen hyperplasia J:228258
\Nf2tm1Gth/\Nf2tm2Gth
\Tg(Mpz-cre)2Brn/0

(involves: 129P2/OlaHsd * FVB/N)
increased susceptibility to otitis media J:63264
\Nf2tm2Gth/\Nf2tm2Gth
\Tg(Mpz-cre)1Brn/0

(involves: 129P2/OlaHsd * FVB/N)
increased susceptibility to otitis media J:63264
\Nf2tm2Gth/\Nf2tm2Gth
\Tg(Mpz-cre)2Brn/0

(involves: 129P2/OlaHsd * FVB/N)
increased susceptibility to otitis media J:63264
\Nf2tm2Gth/\Nf2tm2Gth
\Trp53tm1Brn/\Trp53tm1Brn

(involves: 129P2/OlaHsd * 129S7/SvEvBrd)
increased T cell derived lymphoma incidence J:132943
\Nfam1em1(IMPC)Ccpcz/\Nfam1em1(IMPC)Ccpcz
(C57BL/6N-Nfam1em1(IMPC)Ccpcz/Ccpcz)
abnormal thymus morphology J:211773
enlarged thymus J:211773
\Nfat5tm1.1Itl/\Nfat5tm1.1Itl
\Lyz2tm1(cre)Ifo/\Lyz2+

(involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6NTac * FVB/N)
abnormal lymphatic vessel morphology J:201429
\Nfat5tm1.1Joar/\Nfat5tm1.1Joar
\Tg(Cd4-cre)1Cwi/0

(involves: C57BL/6 * DBA/2 * SJL)
abnormal T cell physiology J:148271
\Nfat5tm1Rao/\Nfat5tm1Rao
(B6.129-Nfat5tm1Rao)
tubulointerstitial nephritis J:88636
\Nfat5tm1Snh/\Nfat5+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
abnormal immunoglobulin level J:91482
decreased IgG level J:91482
decreased T cell proliferation J:91482
spleen hypoplasia J:91482
thymus hypoplasia J:91482
\Nfatc1tm1.1Fbs/\Nfatc1tm1.1Fbs
(C57BL/6-Nfatc1tm1.1Fbs)
decreased interferon-gamma secretion J:305649
decreased interleukin-17 secretion J:305649
decreased susceptibility to experimental autoimmune encephalomyelitis J:305649
decreased susceptibility to graft versus host disease J:305649
immune system phenotype J:305649
increased interleukin-2 secretion J:305649
increased regulatory T cell number J:305649
\Nfatc1tm1Glm/\Nfatc1tm2Glm
(chimera involves: 129S2/SvPas)
abnormal B cell physiology J:78376
abnormal immune system physiology J:78376
abnormal immunoglobulin level J:78376
abnormal interferon-gamma secretion J:78376
abnormal interleukin-2 secretion J:78376
abnormal lymphocyte cell number J:78376
abnormal lymphocyte physiology J:78376
abnormal T cell physiology J:78376
abnormal T-helper 2 physiology J:78376
decreased double-positive T cell number J:78376
decreased IgE level J:78376
decreased IgG1 level J:78376
decreased IgG2b level J:78376
decreased IgG3 level J:78376
decreased immunoglobulin level J:78376
decreased interleukin-4 secretion J:78376
decreased lymphocyte cell number J:78376
increased double-negative T cell number J:78376
increased IgA level J:78376
increased IgG2a level J:78376
increased IgM level J:78376
increased immunoglobulin level J:78376
\Nfatc1tm1Rao/\Nfatc1tm1Rao
\Cd79atm1(cre)Reth/\Cd79a+

(involves: BALB/c)
abnormal B cell calcium ion homeostasis J:177319
abnormal class switch recombination J:177319
abnormal marginal zone B cell physiology J:177319
decreased B cell number J:177319
decreased B cell proliferation J:177319
decreased B-1a cell number J:177319
decreased susceptibility to experimental autoimmune encephalomyelitis J:177319
increased B cell apoptosis J:177319
\Nfatc1tm1Rao/\Nfatc1tm1Rao
\Nfatc2tm1Rao/\Nfatc2tm1Rao
\Cd79atm1(cre)Reth/\Cd79a+

(involves: BALB/c)
abnormal B cell physiology J:177319
decreased interleukin-2 secretion J:177319
\Nfatc1tm1Rao/\Nfatc1tm1Rao
\Tg(Fcer2a-cre)5Mbu/0

(involves: C57BL/6 * CBA)
abnormal B cell physiology J:177319
abnormal class switch recombination J:177319
decreased B cell proliferation J:177319
decreased IgG2a level J:177319
decreased IgG3 level J:177319
decreased IgM level J:177319
decreased interleukin-2 secretion J:177319
increased IgM level J:177319
increased interleukin-10 secretion J:177319
\Nfatc1tm3Glm/\Nfatc1tm3Glm
\Sh3bp2tm1Bjro/\Sh3bp2tm1Bjro
\Tg(Mx1-cre)1Cgn/0

(involves: 129S4/SvJae * C57BL/6 * CBA)
abnormal osteoclast differentiation J:144598
decreased osteoclast cell number J:144598
liver inflammation J:144598
lung inflammation J:144598
lymph node inflammation J:144598
stomach inflammation J:144598
\Nfatc1tm3Glm/\Nfatc1tm3Glm
\Tg(Mx1-cre)1Cgn/0

(involves: C57BL/6 * CBA)
abnormal osteoclast differentiation J:144598
decreased osteoclast cell number J:144598
\Nfatc2m1Anu/\Nfatc2m1Anu
(C57BL/6NCrlAnu-Nfatc2m1Anu)
immune system phenotype J:104190
\Nfatc2tm1Glm/\Nfatc2tm1Glm
\Nfatc3tm1c(EUCOMM)Hmgu/\Nfatc3tm1c(EUCOMM)Hmgu
\Tg(Itgax-cre)1-1Reiz/0

(involves: C57BL/6 * C57BL/6N * CBA)
decreased interleukin-2 secretion J:346703
\Nfatc2tm1Glm/\Nfatc2tm1Glm
\Nfatc3tm1Glm/\Nfatc3tm1Glm

(involves: 129S2/SvPas)
abnormal lymph node morphology J:51339
abnormal lymphocyte cell number J:51339
blepharitis J:51339
decreased T cell number J:51339
enlarged spleen J:51339
increased B cell number J:51339
increased inflammatory response J:51339
increased T cell number J:51339
interstitial pneumonia J:51339
\Nfatc2tm1Rao/\Nfatc2tm1Rao
(B6.Cg-Nfatc2tm1Rao)
abnormal mast cell physiology J:78089
decreased interleukin-4 secretion J:78089
decreased interleukin-13 secretion J:78089
decreased tumor necrosis factor secretion J:78089
\Nfatc2tm1Rao/\Nfatc2tm1Rao
\Nfatc3tm1Grc/\Nfatc3tm1Grc
\Tg(Lck-cre)I57Jxm/0

(involves: ICR)
abnormal double-negative T cell morphology J:141917
abnormal T cell differentiation J:141917
increased T cell apoptosis J:141917
\Nfatc2tm1Srf/\Nfatc2tm1Srf
(involves: 129P2/OlaHsd * C57BL/6)
abnormal B cell number J:110686
abnormal B cell physiology J:110686
abnormal lymph node B cell domain morphology J:110686
abnormal lymphocyte physiology J:110686
abnormal spleen germinal center morphology J:110686
abnormal T cell physiology J:110686
abnormal thymus involution J:110686
enlarged spleen J:110686
enlarged thymus J:110686
increased activated T cell number J:110686
thymus hyperplasia J:110686
\Nfatc2tm1Srf/\Nfatc2tm1Srf
(involves: 129P2/OlaHsd)
abnormal immune system organ morphology J:45252
abnormal immune system physiology J:45252
abnormal interleukin secretion J:45252
abnormal lymph node morphology J:45252
abnormal T cell physiology J:45252
enlarged lymph nodes J:45252
enlarged spleen J:45252
increased B cell number J:45252
increased lymphocyte cell number J:45252
increased T cell number J:45252
lymph node hyperplasia J:45252
\Nfatc2tm1Srf/\Nfatc2tm1Srf
(B6.Cg-Nfatc2tm1Srf)
abnormal CD4-positive, alpha-beta T cell physiology J:86279
abnormal T-helper 1 physiology J:86279
abnormal T-helper 2 physiology J:86279
decreased interferon-gamma secretion J:86279
increased IgE level J:86279
increased IgG1 level J:86279
increased immunoglobulin level J:86279
increased interleukin-4 secretion J:86279
increased interleukin-5 secretion J:86279
\Nfatc2ipem1(IMPC)Ics/\Nfatc2ipem1(IMPC)Ics
(C57BL/6N-Nfatc2ipem1(IMPC)Ics/Ics)
increased eosinophil cell number J:211773
\Nfatc2iptm1.1Glm/\Nfatc2iptm1.1Glm
(either: B6.129-Nfatc2iptm1.1Glm or C.129-Nfatc2iptm1.1Glm)
abnormal interleukin secretion J:157559
abnormal leukocyte morphology J:157559
abnormal T-helper 2 physiology J:157559
decreased circulating interleukin-4 level J:157559
decreased interferon-gamma secretion J:157559
decreased interleukin-3 secretion J:157559
decreased interleukin-4 secretion J:157559
decreased interleukin-5 secretion J:157559
decreased interleukin-13 secretion J:157559
decreased mast cell number J:157559
decreased T-helper 2 cell number J:157559
increased susceptibility to parasitic infection J:157559
\Nfatc3tm1.1Grc/\Nfatc3tm1.1Grc
(involves: C57BL/6)
immune system phenotype J:141917
lymph node hypoplasia J:141917
\Nfatc3tm1Glm/\Nfatc3tm1Glm
\Tg(DO11.10)10Dlo/?

(involves: 129S2/SvPas * BALB/c * C3H * C57BL/6)
decreased double-positive T cell number J:50124
increased double-negative T cell number J:50124
small thymus J:50124
\Nfatc3tm1Grc/\Nfatc3tm1Grc
\Tg(Lck-cre)I57Jxm/0

(involves: ICR)
abnormal T cell differentiation J:141917
decreased CD4-positive, alpha-beta T cell number J:141917
decreased CD8-positive, alpha-beta T cell number J:141917
decreased thymocyte number J:141917
increased double-negative T cell number J:141917
increased T cell apoptosis J:141917
lymph node hypoplasia J:141917
thymus hypoplasia J:141917
\Nfe2em1(IMPC)Ccpcz/\Nfe2+
(C57BL/6NCrl-Nfe2em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
\Nfe2tm1Sho/\Nfe2+
(C.129S4-Nfe2tm1Sho)
enlarged spleen J:125982
increased susceptibility to Retroviridae infection J:125982
\Nfe2tm1Sho/\Nfe2tm1Sho
(involves: 129/Sv * 129S4/SvJae)
increased osteoclast cell number J:111270
\Nfe2l1tm1Jefc/\Nfe2l1tm1Ywk
\Speer6-ps1Tg(Alb-cre)21Mgn/\Speer6-ps1+

(involves: 129X1/SvJ * C57BL/6J)
liver inflammation J:97188
\Nfe2l2em1(IMPC)Ccpcz/\Nfe2l2em1(IMPC)Ccpcz
(C57BL/6NCrl-Nfe2l2em1(IMPC)Ccpcz/Ccpcz)
abnormal lymph node morphology J:211773
abnormal thymus morphology J:211773
enlarged lymph nodes J:211773
enlarged thymus J:211773
\Nfe2l2tm1.1Sred/\Nfe2l2tm1.1Sred
\Tg(Scgb1a1-cre)1Grau/0

(involves: C57BL/6 * C57BL/6J)
decreased interleukin-1 beta secretion J:191916
decreased tumor necrosis factor secretion J:191916
\Nfe2l2tm1Mym/\Nfe2l2tm1Mym
(involves: 129P2/OlaHsd * ICR)
abnormal macrophage physiology J:118068
decreased CD4-positive, alpha-beta T cell number J:104016
decreased T cell number J:104016
enlarged lymph nodes J:104016
glomerulonephritis J:104016
increased anti-double stranded DNA antibody level J:104016
increased anti-nuclear antigen antibody level J:104016
increased IgG level J:104016
increased IgM level J:104016
increased spleen weight J:104016
lung inflammation J:118068
\Nfe2l2tm1Mym/\Nfe2l2tm1Mym
(involves: 129P2/OlaHsd * C57BL/6J)
increased susceptibility to induced colitis J:116676
\Nfe2l2tm1Mym/\Nfe2l2tm1Mym
(involves: 129P2/OlaHsd * CD-1)
increased acute inflammation J:122813
\Nfe2l2tm1Mym/\Nfe2l2tm1Mym
(involves: 129P2/OlaHsd * C57BL/6)
abnormal leukocyte adhesion J:150597
increased circulating interleukin-6 level J:136120
increased circulating tumor necrosis factor level J:136120
increased susceptibility to experimental autoimmune uveoretinitis J:150597
liver inflammation J:136120
\Nfe2l2tm1Ywk/\Nfe2l2tm1Ywk
(involves: 129X1/SvJ)
abnormal spleen physiology J:91407
abnormal splenocyte physiology J:91407
decreased circulating interleukin-1 beta level J:100106
enlarged spleen J:91407
increased circulating interleukin-1 beta level J:100106
increased macrophage cell number J:100106
increased spleen weight J:91407
increased splenocyte apoptosis J:91407
\Nfe2l2tm1Ywk/\Nfe2l2tm1Ywk
(B6.129X1-Nfe2l2tm1Ywk/J)
abnormal neutrophil physiology J:233699
\Nfe2l2tm1Ywk/\Nfe2l2tm1Ywk
(B6.129X1-Nfe2l2tm1Ywk)
increased anti-double stranded DNA antibody level J:165602
\Nficem1(IMPC)Ccpcz/\Nficem1(IMPC)Ccpcz
(C57BL/6NCrl-Nficem1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
increased CD4-positive, CD25-positive, alpha-beta regulatory T cell number J:211773
\Nfil3tm1.1(KOMP)Vlcg/\Nfil3tm1.1(KOMP)Vlcg
(C57BL/6N-Nfil3tm1.1(KOMP)Vlcg/Ucd)
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged spleen J:211773
increased spleen weight J:211773
small thymus J:211773
\Nfil3tm1.1Brad/\Nfil3+
(B6.Cg-Nfil3tm1.1Brad)
decreased NK cell number J:152774
\Nfil3tm1.1Brad/\Nfil3tm1.1Brad
(B6.Cg-Nfil3tm1.1Brad)
abnormal NK cell differentiation J:152774
decreased interferon-gamma secretion J:152774
decreased NK cell number J:152774
immune system phenotype J:152774
impaired natural killer cell mediated cytotoxicity J:152774
increased memory T cell number J:152774
increased NK T cell number J:152774
\Nfil3tm1.1Kubo/\Nfil3tm1.1Kubo
(B6.Cg-Nfil3tm1.1Kubo)
abnormal interleukin secretion J:184570
decreased interleukin-9 secretion J:184570
decreased interleukin-10 secretion J:172134, J:184570
decreased interleukin-13 secretion J:172134, J:184570
decreased interleukin-17 secretion J:184570
increased susceptibility to experimental autoimmune encephalomyelitis J:172134
increased susceptibility to induced colitis J:172134
\Nfil3tm1.2Kubo/\Nfil3tm1.2Kubo
\Tg(Itgax-cre)1-1Reiz/0

(involves: 129 * C57BL/6 * CBA)
immune system phenotype J:334296
\Nfil3tm1Look/\Nfil3tm1Look
(B6.129X1-Nfil3tm1Look)
abnormal NK cell differentiation J:155677
decreased interferon-gamma secretion J:155677
decreased NK cell number J:155677
impaired natural killer cell mediated cytotoxicity J:155677
\Nfil3tm1Look/\Nfil3tm1Look
(involves: 129X1/SvJ)
immune system phenotype J:209365
\Nfil3tm1Pbro/\Nfil3tm1Pbro
(involves: 129S6/SvEvTac * C57BL/6)
abnormal class switch recombination J:156521
decreased IgE level J:156521
decreased IgG1 level J:156521
decreased interleukin-4 secretion J:156521
immune system phenotype J:156521
\Nfil3tm1Pbro/\Nfil3tm1Pbro
(B6.129S6-Nfil3tm1Pbro)
abnormal circulating cytokine level J:209365
abnormal cytokine secretion J:209365
abnormal leukocyte morphology J:209365
abnormal plasma cell morphology J:209365
colitis J:209365
decreased NK cell number J:209365
increased circulating interferon-gamma level J:209365
increased circulating interleukin-10 level J:209365
increased circulating interleukin-12b level J:209365
increased circulating interleukin-17 level J:209365
increased circulating tumor necrosis factor level J:209365
increased interferon-gamma secretion J:209365
increased interleukin-10 secretion J:209365
increased interleukin-12b secretion J:209365
increased interleukin-17 secretion J:209365
increased macrophage cytokine production J:209365
increased T-helper 17 cell number J:209365
increased tumor necrosis factor secretion J:209365
\Nfil3tm1Pbro/\Nfil3tm1Pbro
\Rag1tm1Mom/\Rag1tm1Mom

(involves: 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6)
immune system phenotype J:209365
\Nfkb1M1Btlr/\Nfkb1+
(C57BL/6J-Nfkb1M1Btlr)
decreased IgG level J:216054
impaired humoral immune response J:216054
\Nfkb1M1Btlr/\Nfkb1M1Btlr
(C57BL/6J-Nfkb1M1Btlr)
decreased IgG level J:216054
impaired humoral immune response J:216054
\Nfkb1m2Btlr/\Nfkb1+
(C57BL/6J-Nfkb1m2Btlr)
abnormal humoral immune response J:254822
decreased central memory CD4-positive, alpha-beta T cell number J:254822
decreased effector memory CD4-positive, alpha-beta T cell number J:254822
decreased IgM level J:254822
\Nfkb1m2Btlr/\Nfkb1m2Btlr
(C57BL/6J-Nfkb1m2Btlr)
abnormal humoral immune response J:254822
decreased CD8-positive, naive alpha-beta T cell number J:254822
decreased central memory CD4-positive, alpha-beta T cell number J:254822
decreased effector memory CD4-positive, alpha-beta T cell number J:254822
decreased IgE level J:254822
decreased IgG level J:254822
decreased IgM level J:254822
increased central memory CD8 positive, alpha-beta T cell number J:254822
\Nfkb1M3Btlr/\Nfkb1+
(C57BL/6J-Nfkb1M3Btlr)
abnormal humoral immune response J:254821
decreased IgE level J:254821
decreased IgG level J:254821
increased central memory CD8 positive, alpha-beta T cell number J:254821
\Nfkb1M3Btlr/\Nfkb1M3Btlr
(C57BL/6J-Nfkb1M3Btlr)
abnormal humoral immune response J:254821
decreased IgE level J:254821
decreased IgG level J:254821
increased central memory CD8 positive, alpha-beta T cell number J:254821
increased susceptibility to induced colitis J:254821
\Nfkb1M4Btlr/\Nfkb1M4Btlr
(C57BL/6J-Nfkb1M4Btlr)
decreased B-1 B cell number J:265169
\Nfkb1M5Btlr/\Nfkb1M5Btlr
(C57BL/6J-Nfkb1M5Btlr)
decreased B-1a cell number J:272117
decreased IgE level J:272117
decreased interleukin-1 beta secretion J:272117
\Nfkb1M6Btlr/\Nfkb1M6Btlr
(C57BL/6J-Nfkb1M6Btlr)
decreased IgE level J:272148
\Nfkb1tm1a(KOMP)Wtsi/\Nfkb1tm1a(KOMP)Wtsi
(B6JTyr;B6N-Nfkb1tm1a(KOMP)Wtsi/Wtsi)
increased leukocyte cell number J:175295, J:165965
\Nfkb1tm1a(KOMP)Wtsi/\Nfkb1tm1a(KOMP)Wtsi
(involves: C57BL/6 * C57BL/6N)
decreased IgA level J:213427
decreased IgG1 level J:213427
decreased NK cell number J:213427
decreased regulatory T cell number J:213427
increased leukocyte cell number J:213427
increased susceptibility to bacterial infection J:213427
lymphoid hyperplasia J:213427
\Nfkb1tm1Bal/\Nfkb1tm1Bal
(B6;129P-Nfkb1tm1Bal/J)
abnormal CD4-positive, alpha-beta T cell physiology J:118907
abnormal cytokine secretion J:79107
abnormal dendritic cell physiology J:118907
abnormal macrophage physiology J:118907
abnormal professional antigen presenting cell physiology J:118907
decreased susceptibility to autoimmune diabetes J:118907
immune system phenotype J:118907
\Nfkb1tm1Bal/\Nfkb1tm1Bal
(involves: 129P2/OlaHsd * C57BL/6)
abnormal class switch recombination J:30268
abnormal humoral immune response J:37184
abnormal Peyer's patch follicle morphology J:77049
abnormal Peyer's patch germinal center morphology J:77049
abnormal Peyer's patch T cell area morphology J:77049
cecum inflammation J:67107
decreased B cell proliferation J:37184, J:30268
decreased IgA level J:37184
decreased IgE level J:37184
decreased IgG1 level J:37184
decreased IgM level J:30268
decreased immunoglobulin level J:37184
decreased interleukin-6 secretion J:37184
decreased myeloid dendritic cell number J:77049
decreased Peyer's patch number J:77049
decreased susceptibility to Picornaviridae infection induced morbidity/mortality J:37184
increased susceptibility to bacterial infection J:37184, J:67107
increased susceptibility to bacterial infection induced morbidity/mortality J:37184
large intestinal inflammation J:67107
peritoneal inflammation J:67107
small Peyer's patches J:77049
\Nfkb1tm1Bal/\Nfkb1tm1Bal
(involves: 129P2/OlaHsd)
decreased marginal zone B cell number J:65246
immune system phenotype J:113514
\Nfkb1tm1Bal/\Nfkb1tm1Bal
(B6.Cg-Nfkb1tm1Bal/J)
abnormal B cell physiology J:113556
\Nfkb1tm1Bal/\Nfkb1tm1Bal
\Nfkb2tm1Sbn/\Nfkb2tm1Sbn

(involves: 129P2/OlaHsd * 129S4/SvJae)
abnormal immune system organ morphology J:45119
abnormal macrophage physiology J:45119
abnormal osteoclast differentiation J:45119
abnormal spleen morphology J:45119
abnormal thymus cortex morphology J:45119
abnormal thymus medulla morphology J:45119
absent lymph nodes J:45119
absent spleen white pulp J:45119
arrested B cell differentiation J:45119
decreased B cell number J:45119
decreased CD4-positive, alpha-beta T cell number J:45119
decreased CD8-positive, alpha-beta T cell number J:45119
decreased dendritic cell number J:45119
decreased double-positive T cell number J:45119
decreased mature B cell number J:45119
decreased osteoclast cell number J:45119
decreased single-positive T cell number J:45119
decreased T cell number J:45119
increased granulocyte number J:45119
increased macrophage cell number J:45119
thymus hypoplasia J:45119
\Nfkb1tm1Bal/\Nfkb1tm1Bal
\Reltm1Grd/\Reltm1Grd

(involves: 129P2/OlaHsd * 129S1/Sv)
abnormal immune system physiology J:113514
decreased interleukin-12 secretion J:113514
\Nfkb1tm1Bal/\Nfkb1tm1Bal
\Relatm1Bal/\Rela+

(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)
cecum inflammation J:67107
increased susceptibility to bacterial infection J:67107
large intestinal inflammation J:67107
peritoneal inflammation J:67107
\Nfkb1tm1Bal/\Nfkb1tm1Bal
\Relatm1Bal/\Relatm1Bal

(involves: 129P2/OlaHsd * 129S4/SvJae)
abnormal dendritic cell differentiation J:113514
decreased dendritic cell number J:113514
\Nfkb1tm1Bal/\Nfkb1tm1Bal
\Tg(Tnfsf13b)1Fma/?

(B6.Cg-Nfkb1tm1Bal Tg(Tnfsf13b)1Fma)
abnormal B cell activation J:113556
abnormal class switch recombination J:113556
decreased marginal zone B cell number J:113556
immune system phenotype J:113556
increased transitional stage B cell number J:113556
\Nfkb1tm1Brv/\Nfkb1tm1Brv
(involves: 129S1/Sv)
abnormal cytokine secretion J:46912
abnormal humoral immune response J:46912
abnormal inflammatory response J:46912
abnormal lymph organ size J:46912
abnormal lymphocyte physiology J:46912
decreased IgG3 level J:46912
decreased interleukin-2 secretion J:46912
decreased interleukin-4 secretion J:46912
decreased single-positive T cell number J:46912
decreased T cell proliferation J:46912
decreased tumor necrosis factor secretion J:46912
enlarged lymph nodes J:46912
enlarged spleen J:46912
increased B cell proliferation J:46912
increased IgE level J:46912
increased IgG1 level J:46912
increased immunoglobulin level J:46912
increased susceptibility to bacterial infection J:46912
liver inflammation J:46912
lung inflammation J:46912
myeloid hyperplasia J:46912
\Nfkb1tm1Brv/\Nfkb1tm1Brv
(involves: 129S1/Sv * C57BL/6)
decreased osteoclast cell number J:44112
\Nfkb1tm1Brv/\Nfkb1tm1Brv
\Nfkb2tm1Brv/\Nfkb2+

(involves: 129S1/Sv * C57BL/6)
abnormal osteoclast differentiation J:44112
decreased osteoclast cell number J:44112
\Nfkb1tm1Brv/\Nfkb1tm1Brv
\Nfkb2tm1Brv/\Nfkb2tm1Brv

(involves: 129S1/Sv * C57BL/6)
abnormal cytokine secretion J:44112
abnormal osteoclast differentiation J:44112
decreased interleukin-6 secretion J:44112
decreased osteoclast cell number J:44112
increased macrophage cell number J:44112
\Nfkb1tm1Sley/\Nfkb1tm1Sley
(involves: 129S4/SvJae * 129S8/SvEv)
abnormal inguinal lymph node morphology J:142340
absent inguinal lymph nodes J:142340
decreased circulating interleukin-2 level J:142340
decreased memory T cell number J:142340
decreased regulatory T cell number J:142340
decreased T cell proliferation J:142340
small inguinal lymph nodes J:142340
\Nfkb1tm1Sley/\Nfkb1tm1Sley
(involves: 129S4/SvJae * 129S8/SvEv * C57BL/6)
decreased memory T cell number J:142340
decreased NK T cell number J:142340
decreased regulatory T cell number J:142340
\Nfkb1tm1Sley/\Nfkb1tm1Sley
(involves: 129S4/SvJae)
decreased tumor necrosis factor secretion J:196528
\Nfkb2Lym1/\Nfkb2+
(BALB/c-Nfkb2Lym1)
abnormal lymph node morphology J:154812
abnormal mesenteric lymph node morphology J:154812
abnormal spleen white pulp morphology J:154812
absent axillary lymph nodes J:154812
absent brachial lymph nodes J:154812
absent cervical lymph nodes J:154812
absent inguinal lymph nodes J:154812
absent Peyer's patches J:154812
decreased lymph node number J:154812
increased lymphocyte cell number J:154812
liver inflammation J:154812
lung inflammation J:154812
\Nfkb2Lym1/\Nfkb2+
(involves: BALB/c)
abnormal B cell differentiation J:188560
\Nfkb2Lym1/\Nfkb2+
\Otub1tm1c(EUCOMM)Hmgu/\Otub1tm1c(EUCOMM)Hmgu
\Cd19tm1(cre)Cgn/\Cd19+

(involves: 129P2/OlaHsd * BALB/c * C57BL/6 * C57BL/6N)
immune system phenotype J:280549
\Nfkb2Lym1/\Nfkb2Lym1
(involves: BALB/c)
abnormal class switch recombination J:154812
abnormal lymph node morphology J:154812
abnormal osteoclast differentiation J:154812
abnormal peripheral lymph node morphology J:154812
abnormal plasma cell differentiation J:154812
abnormal spleen follicular dendritic cell network J:154812
abnormal spleen periarteriolar lymphoid sheath morphology J:154812
abnormal spleen primary B follicle morphology J:154812
abnormal spleen white pulp morphology J:154812
abnormal T cell differentiation J:154812
abnormal thymus cell ratio J:154812
abnormal thymus physiology J:154812
abnormal thymus size J:154812
absent axillary lymph nodes J:154812
absent brachial lymph nodes J:154812
absent cervical lymph nodes J:154812
absent inguinal lymph nodes J:154812
absent mesenteric lymph nodes J:154812
absent Peyer's patches J:154812
autoimmune response J:154812
decreased B cell proliferation J:154812
decreased follicular B cell number J:154812
decreased IgA level J:154812
decreased IgG1 level J:154812
decreased IgG2b level J:154812
decreased IgM level J:154812
decreased immunoglobulin level J:154812
decreased lymph node number J:154812
decreased marginal zone B cell number J:154812
decreased mature B cell number J:154812
decreased transitional stage B cell number J:154812
enlarged spleen J:154812
increased CD4-positive, alpha-beta T cell number J:154812
increased CD8-positive, alpha-beta T cell number J:154812
increased double-negative T cell number J:154812
increased double-positive T cell number J:154812
increased spleen red pulp amount J:154812
increased spleen weight J:154812
increased transitional stage B cell number J:154812
liver inflammation J:154812
lung inflammation J:154812
\Nfkb2m2Btlr/\Nfkb2m2Btlr
(C57BL/6J-Nfkb2m2Btlr)
increased B-1a cell number J:221493
\Nfkb2m3Btlr/\Nfkb2m3Btlr
(C57BL/6J-Nfkb2m3Btlr)
abnormal B cell differentiation J:274960
abnormal CD4-positive T cell differentiation J:274960
abnormal CD8-positive, alpha-beta T cell differentiation J:274960
abnormal T cell differentiation J:274960
decreased B cell number J:274960
decreased CD4-positive, alpha-beta T cell number J:274960
decreased effector memory CD8-positive, alpha-beta T cell number J:274960
decreased NK cell number J:274960
increased B-1 B cell number J:274960
increased CD4-positive, alpha-beta T cell number J:274960
increased CD8-positive, alpha-beta T cell number J:274960
increased CD8-positive, naive alpha-beta T cell number J:274960
increased T cell number J:274960
\Nfkb2M4Btlr/\Nfkb2M4Btlr
(C57BL/6J-Nfkb2M4Btlr)
increased CD4-positive, alpha-beta T cell number J:274961
increased CD8-positive, alpha-beta T cell number J:274961
increased T cell number J:274961
\Nfkb2m5Btlr/\Nfkb2m5Btlr
(C57BL/6J-Nfkb2m5Btlr)
increased B-1 B cell number J:274962
\Nfkb2tm1Brv/\Nfkb2tm1Brv
(involves: 129S1/Sv * C57BL/6)
abnormal cytokine secretion J:43469
abnormal lymph node B cell domain morphology J:43469
abnormal lymph node cortex morphology J:43469
abnormal lymphocyte cell number J:43469
abnormal T cell number J:43469
abnormal T cell subpopulation ratio J:43469
abnormal thymus corticomedullary boundary morphology J:43469
decreased double-positive T cell number J:43469
decreased spleen weight J:43469
enlarged lymph nodes J:43469
increased B cell proliferation J:43469
increased granulocyte number J:43469
increased interleukin-2 secretion J:43469
increased interleukin-4 secretion J:43469
increased interleukin-10 secretion J:43469
increased T cell proliferation J:43469
increased tumor necrosis factor secretion J:43469
intermingled spleen red and white pulp J:43469
spleen atrophy J:43469
spleen hypoplasia J:43469
thymus atrophy J:43469
\Nfkb2tm1Rsch/\Nfkb2tm1Rsch
(involves: 129P2/OlaHsd)
abnormal myeloid dendritic cell morphology J:77049
abnormal Peyer's patch follicle morphology J:77049
abnormal Peyer's patch germinal center morphology J:77049
abnormal Peyer's patch morphology J:77049
abnormal Peyer's patch T cell area morphology J:77049
decreased B cell number J:77049
decreased dendritic cell number J:77049
decreased myeloid dendritic cell number J:77049
increased plasmacytoid dendritic cell number J:77049
small Peyer's patches J:77049
\Nfkb2tm1Sbn/\Nfkb2tm1Sbn
(involves: 129S4/SvJae * C57BL/6)
abnormal class switch recombination J:45437
abnormal immunoglobulin level J:45437
abnormal lymphocyte cell number J:45437
abnormal metallophilic macrophage morphology J:45437
abnormal spleen B cell follicle morphology J:45437
abnormal spleen marginal zone macrophage morphology J:45437
abnormal spleen marginal zone morphology J:45437
abnormal spleen white pulp morphology J:45437
absent spleen germinal center J:45437
decreased B cell number J:45437
decreased IgA level J:45437
decreased IgG1 level J:45437
decreased IgG2a level J:45437
decreased IgG2b level J:45437
increased IgM level J:45437
increased susceptibility to parasitic infection J:45437
increased T cell number J:45437
\Nfkb2tm2Brv/\Nfkb2tm2Brv
(involves: 129S1/Sv * C57BL/6)
abnormal lymph node morphology J:76380
abnormal metallophilic macrophage morphology J:76380
abnormal spleen morphology J:76380
absent lymph node germinal center J:76380
absent spleen germinal center J:76380
absent spleen marginal zone J:76380
decreased B cell number J:76380
decreased B cell proliferation J:76380
decreased IgA level J:76380
decreased IgG1 level J:76380
decreased IgG3 level J:76380
increased CD4-positive, alpha-beta T cell number J:76380
increased CD8-positive, alpha-beta T cell number J:76380
increased IgG2a level J:76380
increased IgM level J:76380
increased splenocyte apoptosis J:76380
\Nfkb2tm2Brv/\Nfkb2tm2Brv
(involves: 129S1/Sv)
abnormal gamma-delta T cell morphology J:169863
decreased gamma-delta T cell number J:169863
\Nfkb2tm2Brv/\Nfkb2tm2Brv
\Tg(Tnfsf13b)1Fma/?

(B6.Cg-Nfkb2tm2Brv Tg(Tnfsf13b)1Fma)
abnormal B cell activation J:113556
absent spleen marginal zone J:113556
decreased marginal zone B cell number J:113556
immune system phenotype J:113556
\Nfkb2tm2Brv/\Nfkb2tm2Brv
\Traf3tm1Bal/\Traf3tm1Bal

(involves: 129S1/Sv * 129S4/SvJae * C57BL/6)
immune system phenotype J:124635
\Nfkb2xdr/\Nfkb2xdr
(C57BL/6JSfdAnu-Nfkb2xdr/Anu)
abnormal metallophilic macrophage morphology J:79725
abnormal peripheral lymph node morphology J:79725
abnormal spleen follicular dendritic cell network J:79725
abnormal spleen morphology J:79725
abnormal spleen secondary B follicle morphology J:79725
decreased B-2 B cell number J:79725
decreased follicular B cell number J:79725
decreased marginal zone B cell number J:79725
decreased mature B cell number J:79725
decreased transitional stage T2 B cell number J:79725
increased B-1 B cell number J:79725
\Nfkb2xdr/\Nfkb2xdr
(involves: C57BL/6JSfdAnu * C57BL/10Sg * C57BR/cd * NOD)
decreased B cell number J:79725
\Nfkbiatm1.1Kbp/\Nfkbiatm1.1Kbp
(involves: 129P2/OlaHsd * C57BL/6)
abnormal granulocyte morphology J:97945
increased granulocyte number J:97945
\Nfkbiatm1.1Pjc/\Nfkbiatm1.1Pjc
(involves: C57BL/6)
abnormal circulating cytokine level J:163686
abnormal T cell activation J:163686
abnormal T cell number J:163686
autoimmune response J:163686
chronic inflammation J:163686
decreased CD4-positive, alpha-beta T cell number J:163686
decreased CD8-positive, alpha-beta T cell number J:163686
increased activated T cell number J:163686
increased anti-insulin autoantibody level J:163686
increased anti-nuclear antigen antibody level J:163686
increased circulating interleukin-1 alpha level J:163686
increased circulating interleukin-17 level J:163686
increased circulating tumor necrosis factor level J:163686
increased double-positive T cell number J:163686
increased memory T cell number J:163686
increased susceptibility to bacterial infection induced morbidity/mortality J:163686
increased T cell apoptosis J:163686
increased T cell proliferation J:163686
increased thymocyte number J:163686
\Nfkbiatm1.1Smiy/\Nfkbia+
(B6.129-Nfkbiatm1.1Smiy)
decreased B cell number J:168977
decreased follicular B cell number J:168977
decreased marginal zone B cell number J:168977
decreased transitional stage T2 B cell number J:168977
increased pro-B cell number J:168977
small Peyer's patches J:168977
\Nfkbiatm1.1Smiy/\Nfkbiatm1.1Smiy
(B6.129-Nfkbiatm1.1Smiy)
abnormal B cell differentiation J:168977
abnormal marginal zone B cell morphology J:168977
decreased B cell number J:168977
decreased B cell proliferation J:168977
decreased B-2 B cell number J:168977
decreased CD4-positive, alpha-beta memory T cell number J:168977
decreased follicular B cell number J:168977
decreased IgA level J:168977
decreased IgG1 level J:168977
decreased IgG2b level J:168977
decreased marginal zone B cell number J:168977
decreased mature B cell number J:168977
decreased Peyer's patch number J:168977
decreased regulatory T cell number J:168977
decreased transitional stage T2 B cell number J:168977
increased activation-induced B cell apoptosis J:168977
increased immature B cell number J:168977
increased pre-B cell number J:168977
increased pro-B cell number J:168977
small Peyer's patches J:168977
\Nfkbiatm1Bal/\Nfkbiatm1Bal
(involves: 129S4/SvJae * C57BL/6J)
abnormal granulocyte differentiation J:30058
decreased double-positive T cell number J:30058
increased leukocyte cell number J:30058
spleen atrophy J:30058
thymus atrophy J:30058
\Nfkbiatm1Bal/\Nfkbiatm1Bal
\Nfkbietm1Syme/\Nfkbietm1Syme

(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * DBA/2)
abnormal B cell differentiation J:88142
abnormal T cell differentiation J:88142
decreased immature B cell number J:88142
decreased pre-B cell number J:88142
increased B cell apoptosis J:88142
increased T cell apoptosis J:88142
\Nfkbiatm1Fey/\Nfkbiatm1Fey
(involves: 129S6/SvEvTac * C57BL/6)
abnormal B cell differentiation J:110817
abnormal humoral immune response J:110817
absent spleen germinal center J:110817
decreased double-negative T cell number J:110817
decreased T cell proliferation J:110817
decreased thymocyte number J:110817
increased B cell proliferation J:110817
increased IgA level J:110817
increased IgE level J:110817
increased IgG level J:110817
increased single-positive T cell number J:110817
small spleen J:110817
thymus atrophy J:110817
\Nfkbiatm1Stw/\Nfkbiatm1Stw
(involves: 129S1/Sv)
abnormal macrophage physiology J:32527
abnormal myelopoiesis J:32527
abnormal tumor necrosis factor level J:32527
dermatitis J:32527
increased macrophage cell number J:32527
increased monocyte cell number J:32527
\Nfkbibtm1.2Rsch/\Nfkbibtm1.2Rsch
(B6.129P2-Nfkbibtm1.2Rsch)
abnormal cytokine secretion J:176877
abnormal immune system morphology J:176877
abnormal immune system physiology J:176877
abnormal interleukin-1 beta secretion J:176877
abnormal interleukin-6 secretion J:176877
abnormal tumor necrosis factor secretion J:176877
decreased B cell number J:176877
decreased susceptibility to bacterial infection induced morbidity/mortality J:176877
increased macrophage cell number J:176877
increased marginal zone B cell number J:176877
increased memory T cell number J:176877
\Nfkbibtm1Bal/\Nfkbibtm1Bal
(B6.129S1-Nfkbibtm1Bal)
decreased circulating interleukin-1 beta level J:163302
decreased circulating interleukin-6 level J:163302
decreased circulating tumor necrosis factor level J:163302
decreased susceptibility to bacterial infection induced morbidity/mortality J:163302
decreased susceptibility to endotoxin shock J:163302
decreased susceptibility to induced arthritis J:163302
decreased tumor necrosis factor secretion J:163302
\Nfkbidm1Btlr/\Nfkbidm1Btlr
(involves: C57BL/6J)
abnormal class switch recombination J:185495
absent marginal zone B cells J:185495
decreased B cell proliferation J:185495
decreased B-1 B cell number J:185495
decreased B-1a cell number J:185495
decreased IgG1 level J:185495
decreased IgG3 level J:185495
decreased IgG level J:185495
decreased IgM level J:185495
immune system phenotype J:185495
increased B cell apoptosis J:185495
\Nfkbidtm1a(EUCOMM)Wtsi/\Nfkbid+
(C57BL/6N-Nfkbidtm1a(EUCOMM)Wtsi/Cnrm)
decreased B cell number J:165965
\Nfkbidtm1a(EUCOMM)Wtsi/\Nfkbidtm1a(EUCOMM)Wtsi
(involves: C57BL/6N)
abnormal class switch recombination J:185495
decreased IgG level J:185495
decreased IgM level J:185495
\Nfkbidtm1Clay/\Nfkbidtm1Clay
(involves: 129S6/SvEvTac * C57BL/6)
abnormal NK cell physiology J:132071
abnormal thymocyte activation J:132071
decreased interferon-gamma secretion J:132071
decreased interleukin-2 secretion J:132071
decreased T cell proliferation J:132071
\Nfkbidtm1Ktak/\Nfkbidtm1Ktak
(involves: 129P2/OlaHsd * C57BL/6)
increased interferon-gamma secretion J:113334
increased interleukin-6 secretion J:113334
increased interleukin-12 secretion J:113334
increased interleukin-12b secretion J:113334
increased susceptibility to endotoxin shock J:113334
increased susceptibility to induced colitis J:113334
\Nfkbietm1Syme/\Nfkbietm1Syme
(either: (involves: 129P2/OlaHsd * C57BL/6 * DBA/2) or (involves: 129P2/OlaHsd * C57BL/6))
abnormal double-negative T cell morphology J:88538
increased IgG1 level J:88538
increased IgM level J:88538
\Nfkbiztm1.1Muta/\Nfkbiztm1.1Muta
\Tg(CAG-cre)13Miya/?

(involves: C57BL/6)
dermatitis J:194832
\Nfkbiztm1.1Muta/\Nfkbiztm1.1Muta
\Tg(KRT5-cre)1Tak/?

(involves: C3H * C57BL/6)
dermatitis J:194832
\Nfkbiztm1.1Muta/\Nfkbiztm1.1Muta
\Tg(Lck-cre)1Jtak/?

(involves: C57BL/6)
immune system phenotype J:194832
\Nfkbiztm1Aki/\Nfkbiz+
\Stat6tm1Aki/\Stat6tm1Aki

(C.129P2-Stat6tm1Aki Nfkbiztm1Aki)
skin inflammation J:141704
\Nfkbiztm1Aki/\Nfkbiztm1Aki
(involves: 129P2/OlaHsd)
abnormal cytokine secretion J:91297
abnormal immune system organ morphology J:194832
abnormal immune system physiology J:194832
abnormal leukocyte physiology J:91297
abnormal lymph node cell ratio J:194832
abnormal lymphocyte morphology J:194832
abnormal T-helper 1 cell morphology J:194832
abnormal tumor necrosis factor secretion J:91297
blepharitis J:96363
conjunctivitis J:96363
corneal limbitis J:96363
decreased interleukin-6 secretion J:91297
decreased interleukin-12 secretion J:91297
dermatitis J:194832, J:91297
enlarged lymph nodes J:194832
enlarged spleen J:194832
eye inflammation J:96363
increased immunoglobulin level J:194832
interstitial pneumonia J:194832
lacrimal gland inflammation J:194832
periocular dermatitis J:194832
\Nfkbiztm1Aki/\Nfkbiztm1Aki
(C.129P2-Nfkbiztm1Aki)
blepharitis J:141704
conjunctivitis J:141704
dermatitis J:141704
eye inflammation J:141704
increased IgE level J:141704
perioral dermatitis J:141704
skin inflammation J:141704
\Nfkbiztm1Aki/\Nfkbiztm1Aki
\Rag2tm1Fwa/\Rag2tm1Fwa

(involves: 129P2/OlaHsd * 129S/SvEv)
immune system phenotype J:194832
\Nfkbiztm1Aki/\Nfkbiztm1Aki
\Stat6tm1Aki/\Stat6tm1Aki

(C.129P2-Stat6tm1Aki Nfkbiztm1Aki)
blepharitis J:141704
dermatitis J:141704
eye inflammation J:141704
skin inflammation J:141704
\Nfkbiztm1Aki/\Nfkbiztm1Aki
\Tnftm1Sek/\Tnftm1Sek

(involves: 129P2/OlaHsd * C57BL/6NCrlj * CBA/JNCrlj)
conjunctivitis J:194832
dermatitis J:194832
\Nfkbiztm1Mamo/\Nfkbiztm1Mamo
(involves: 129S7/SvEvBrd)
dermatitis J:95040
increased IgE level J:95040
\Ngfrtm1Jae/\Ngfrtm1Jae
(B6.129S4-Ngfrtm1Jae)
abnormal Kupffer cell morphology J:120368
increased susceptibility to experimental autoimmune encephalomyelitis J:112769
\Ngfrtm1Jae/\Ngfrtm1Jae
(involves: 129S4/SvJae)
abnormal tumor necrosis factor level J:157549
\Ngptm1b(KOMP)Wtsi/\Ngptm1b(KOMP)Wtsi
(C57BL/6N-Ngptm1b(KOMP)Wtsi/Bay)
increased spleen weight J:211773
\Nhej1tm1.1Ics/\Nhej1+
(involves: 129 * C57BL/6)
decreased thymocyte number J:194422
\Nhej1tm1.1Ics/\Nhej1tm1.1Ics
(involves: 129 * C57BL/6)
abnormal T cell receptor V(D)J recombination J:194422
decreased lymphocyte cell number J:194422
decreased NK T cell number J:194422
decreased thymocyte number J:194422
increased thymocyte apoptosis J:194422
\Nhej1tm1.1Ics/\Nhej1tm1.1Ics
\Trp53tm1Tyj/\Trp53tm1Tyj

(involves: 129S2/SvPas * C57BL/6)
abnormal T cell receptor V(D)J recombination J:194422
decreased NK T cell number J:194422
decreased thymocyte apoptosis J:194422
\Nhej1tm1Fwa/\Nhej1tm1Fwa
(involves: 129)
abnormal class switch recombination J:138774
decreased IgG1 level J:138774
decreased IgG3 level J:138774
increased IgM level J:138774
spleen hypoplasia J:138774
thymus hypoplasia J:138774
\Nhej1tm1Fwa/\Nhej1tm1Fwa
\Trp53tm1Tyj/\Trp53tm1Tyj

(involves: 129)
increased T cell derived lymphoma incidence J:138774
\Nhej1tm1Fwa/\Nhej1tm1Fwa
\Xrcc5tm1Nus/\Xrcc5tm1Nus

(involves: 129S6/SvEvTac * C57BL/6)
athymia J:236776
small spleen J:236776
\Nherf1em1(IMPC)H/\Nherf1em1(IMPC)H
(C57BL/6NTac-Nherf1em1(IMPC)H/H)
increased basophil cell number J:211773
increased leukocyte cell number J:211773
\Nhlh1tm1b(KOMP)Wtsi/\Nhlh1+
(C57BL/6N-Nhlh1tm1b(KOMP)Wtsi/Tcp)
enlarged lymph nodes J:211773
\Nhlh2tm1b(KOMP)Mbp/\Nhlh2tm1b(KOMP)Mbp
(C57BL/6N-Nhlh2tm1b(KOMP)Mbp/Tcp)
increased spleen weight J:211773
\Nhsl2em1(IMPC)Tcp/Y
(C57BL/6N-Nhsl2em1(IMPC)Tcp/Tcp)
enlarged lymph nodes J:211773
enlarged spleen J:211773
\Nhsl2em1(IMPC)Tcp/\Nhsl2em1(IMPC)Tcp
(C57BL/6N-Nhsl2em1(IMPC)Tcp/Tcp)
abnormal spleen morphology J:211773
enlarged lymph nodes J:211773
\Niban1em1(IMPC)Ccpcz/\Niban1em1(IMPC)Ccpcz
(C57BL/6N-Niban1em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
\Niban3em1(IMPC)Mbp/\Niban3em1(IMPC)Mbp
(C57BL/6N-Niban3em1(IMPC)Mbp/MbpMmucd)
abnormal thymus morphology J:211773
enlarged thymus J:211773
\Niban3tm1Jyw/\Niban3tm1Jyw
(B6.Cg-Niban3tm1Jyw)
abnormal B cell calcium ion homeostasis J:282961
abnormal B cell differentiation J:282961
abnormal class switch recombination J:282961
abnormal transitional stage B cell morphology J:282961
decreased B-1a cell number J:282961
decreased IgA level J:282961
decreased IgG2c level J:282961
enhanced humoral immune response J:282961
increased B cell number J:282961
increased B cell proliferation J:282961
increased follicular B cell number J:282961
increased IgG1 level J:282961
increased IgG3 level J:282961
increased IgG level J:282961
increased IgM level J:282961
increased transitional stage T2 B cell number J:282961
\Nid2Gt(GST011)Byg/\Nid2Gt(GST011)Byg
(involves: 129P2/OlaHsd)
osteoarthritis J:229684
\Ninj1tm1Gto/\Ninj1+
(B6.129P2-Ninj1tm1Gto)
decreased susceptibility to experimental autoimmune encephalomyelitis J:209516
\Ninj1tm1Gto/\Ninj1tm1Gto
(B6.129P2-Ninj1tm1Gto)
abnormal leukocyte adhesion J:209516
abnormal leukocyte physiology J:209516
decreased susceptibility to experimental autoimmune encephalomyelitis J:209516
impaired macrophage chemotaxis J:209516
\Ninj2em1Cqxu/\Ninj2em1Cqxu
(C57BL/6-Ninj2em1Cqxu)
white adipose tissue inflammation J:332575
\Nipal2em1(IMPC)Ccpcz/\Nipal2em1(IMPC)Ccpcz
(C57BL/6NCrl-Nipal2em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
\Nipal3tm1Pbfd/\Nipal3tm1Pbfd
(either: (involves: 129S1/Sv * 129X1/SvJ) or (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J))
decreased IgM level J:152829
decreased NK cell number J:152829
increased IgA level J:152829
increased IgE level J:152829
increased IgG2a level J:152829
increased IgM level J:152829
\NipblGt(RRS564)Byg/\Nipbl+
(involves: 129P2/OlaHsd * CD-1)
abnormal inflammatory response J:154117
eye inflammation J:154117
\NipblGt(RRS564)Byg/\Nipbl+
(involves: 129P2/OlaHsd * C57BL/6J * CD-1)
abnormal chemokine level J:297059
\Nipsnap3atm1b(KOMP)Wtsi/\Nipsnap3atm1b(KOMP)Wtsi
(C57BL/6N-Nipsnap3atm1b(KOMP)Wtsi/Wtsi)
increased effector memory T-helper cell number J:211773
\Nipsnap3bem1(IMPC)J/\Nipsnap3bem1(IMPC)J
(C57BL/6NJ-Nipsnap3bem1(IMPC)J/Mmjax)
decreased leukocyte cell number J:211773
\Nischedsn/\Nischedsn
(C3H.B6-Nischedsn)
increased susceptibility to otitis media J:244907
\Nischedsn/\NischV33A
(involves: BALB/c * C3H/HeH * C57BL/6J)
increased susceptibility to otitis media J:244907
\Nischtm1b(EUCOMM)Hmgu/\Nischtm1b(EUCOMM)Hmgu
(C57BL/6N-Nischtm1b(EUCOMM)Hmgu/H)
increased spleen weight J:211773
\NischV33A/\NischV33A
(involves: BALB/c * C57BL/6J)
increased susceptibility to otitis media J:244907
\Nkaptm1.1Viss/Y
\Tg(Lck-cre)1Cwi/0

(involves: 129S1/Sv * 129X1/SvJ)
arrested T cell differentiation J:165961
decreased CD4-positive, alpha-beta T cell number J:165961
decreased CD8-positive, alpha-beta T cell number J:165961
decreased DN4 thymocyte number J:165961
decreased double-positive T cell number J:165961
decreased thymocyte number J:165961
increased DN3 thymocyte number J:165961
thymus hypoplasia J:165961
\Nkapd1tm1.1Tak/\Nkapd1tm1.1Tak
\Commd10Tg(Vav1-icre)A2Kio/\Commd10+

(involves: C57BL/6J * C57BL/10 * CBA/Ca)
abnormal B cell differentiation J:350073
\Nkapd1tm1.1Tak/\Nkapd1tm1.1Tak
\Gt(ROSA)26Sortm1(cre/ERT2)Tyj/\Gt(ROSA)26Sor+

(involves: 129S4/SvJae * C57BL/6 * C57BL/6J)
decreased leukocyte cell number J:350073
decreased lymphocyte cell number J:350073
small intestinal inflammation J:350073
\Nkg7tm1.1(KOMP)Vlcg/\Nkg7tm1.1(KOMP)Vlcg
(C57BL/6N-Nkg7tm1.1(KOMP)Vlcg/Ucd)
increased eosinophil cell number J:211773
\Nkg7tm1.1(KOMP)Vlcg/\Nkg7tm1.1(KOMP)Vlcg
(involves: C57BL/6NTac)
abnormal CD8-positive, alpha-beta cytotoxic T cell morphology J:301637
abnormal mononuclear cell morphology J:301637
decreased CD4-positive, alpha-beta T cell number J:301637
decreased circulating interferon-gamma level J:301637
decreased circulating tumor necrosis factor level J:301637
decreased susceptibility to parasitic infection induced morbidity/mortality J:301637
decreased T helper 1 cell number J:301637
increased susceptibility to parasitic infection induced morbidity/mortality J:301637
\Nktcn1C57BL/6J/\Nktcn1C57BL/6J
(involves: C57BL/6J * NOD.B6-(D6Mit105-D6Mit135))
increased NK T cell number J:85376
\Nktcn1C57BL/6J/\Nktcn1C57BL/6J
(NOD.B6-(D1Mit369-D1Mit155)(D6Mit105-D6Mit135))
abnormal T cell differentiation J:137521
increased NK T cell number J:137521
\Nktcn1C57BL/6J/\Nktcn1NOD/ShiLt
(involves: C57BL/6J * NOD.B6-(D6Mit105-D6Mit135))
increased NK T cell number J:85376
\Nktcn2C57BL/6J/\Nktcn2C57BL/6J
(involves: C57BL/6J * NOD.B6-(D6Mit105-D6Mit135))
increased NK T cell number J:85376
\Nktcn2C57BL/6J/\Nktcn2NOD/ShiLt
(involves: C57BL/6J * NOD.B6-(D6Mit105-D6Mit135))
increased NK T cell number J:85376
\Nkx2-3tm1Hha/\Nkx2-3tm1Hha
(involves: 129S4/SvJae * C57BL/6)
abnormal spleen primary B follicle morphology J:54198
abnormal splenic cell ratio J:54198
absent spleen J:54198
absent spleen marginal zone J:54198
decreased spleen white pulp amount J:54198
small spleen J:54198
\Nkx2-3tm1Hha/\Nkx2-3tm1Hha
(involves: 129S4/SvJae)
abnormal leukocyte migration J:62129
abnormal marginal zone B cell morphology J:62129
abnormal mesenteric lymph node morphology J:62129
abnormal metallophilic macrophage morphology J:62129
abnormal Peyer's patch follicle morphology J:62129
abnormal spleen marginal sinus morphology J:62129
abnormal spleen marginal zone macrophage morphology J:62129
abnormal spleen morphology J:62129
abnormal spleen periarteriolar lymphoid sheath morphology J:62129
absent marginal zone B cells J:62129
absent spleen marginal zone J:62129
decreased B cell number J:62129
decreased lymphocyte cell number J:62129
decreased Peyer's patch number J:62129
decreased spleen weight J:62129
decreased spleen white pulp amount J:62129
decreased T cell number J:62129
intermingled spleen red and white pulp J:62129
small Peyer's patches J:62129
small spleen J:62129
\Nkx2-3tm1Rph/\Nkx2-3tm1Rph
(involves: 129S1/Sv * C57BL/6)
abnormal gut-associated lymphoid tissue morphology J:64018
abnormal leukocyte migration J:64018
abnormal mesenteric lymph node morphology J:64018
abnormal metallophilic macrophage morphology J:64018
abnormal spleen B cell follicle morphology J:64018
abnormal spleen periarteriolar lymphoid sheath morphology J:64018
abnormal spleen red pulp morphology J:64018
absent spleen J:64018
absent spleen marginal zone J:64018
decreased CD4-positive, alpha-beta T cell number J:64018
decreased Peyer's patch number J:64018
decreased plasma cell number J:64018
increased leukocyte cell number J:64018
small Peyer's patches J:64018
small spleen J:64018
spleen atrophy J:64018
\Nkx2-5tm1(cre)Rjs/\Nkx2-5+
\Tbx1tm1Bld/\Tbx1tm3Bld

(involves: 129S7/SvEvBrd * C57BL/6)
small thymus J:91013
\Nkx2-5tm1Wehi/\Nkx2-5+
(involves: 129P2/OlaHsd)
spleen hypoplasia J:184521
\Nkx2-5tm2(cre)Rph/\Nkx2-5+
\Pbx1tm1.1Koss/\Pbx1tm1.1Koss

(involves: 129P2/OlaHsd * 129S1/Sv)
abnormal spleen morphology J:184521
spleen hypoplasia J:184521
\Nkx2-5tm2(cre)Rph/\Nkx2-5tm4Rph
(involves: 129S1/Sv)
spleen hypoplasia J:184521
\Nkx3-2tm1.1Tlu/\Nkx3-2tm1.1Tlu
(either: (involves: 129S1/Sv * 129X1/SvJ) or (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J))
absent spleen J:55583
\Nkx3-2tm1Bobh/\Nkx3-2tm1Bobh
(involves: 129P2/OlaHsd * C57BL/6)
absent spleen J:57112
\Nkx3-2tm1Tlu/\Nkx3-2tm1Tlu
(either: (involves: 129S1/Sv * 129X1/SvJ) or (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J))
absent spleen J:55583
\Nkx3-2tm1Tno/\Nkx3-2tm1Tno
(involves: 129S4/SvJae * C57BL/6J)
absent spleen J:77612
\Nle1tm1Cba/\Nle1tm1.1Cota
\Cd19tm1(cre)Cgn/\Cd19+

(involves: 129P2/OlaHsd * 129S2/SvPas)
immune system phenotype J:204063
\Nle1tm1Cba/\Nle1tm1.1Cota
\Gt(ROSA)26Sortm2(cre/ERT2)Brn/\Gt(ROSA)26Sor+

(involves: 129P2/OlaHsd * 129S2/SvPas)
abnormal immune system organ morphology J:204063
decreased granulocyte number J:204063
decreased macrophage cell number J:204063
decreased NK cell number J:204063
decreased T cell number J:204063
spleen hypoplasia J:204063
thymus hypoplasia J:204063
\Nlgn3em1(IMPC)Rbrc/Y
(C57BL/6NJcl-Nlgn3em1(IMPC)Rbrc/Rbrc)
increased eosinophil cell number J:211773
\Nlktm1Tbo/\Nlktm1Tbo
(129S1/Sv-Nlktm1Tbo)
abnormal bone marrow development J:73353
abnormal immune system organ morphology J:73353
decreased double-positive T cell number J:73353
decreased gamma-delta T cell number J:73353
decreased lymphocyte cell number J:73353
decreased NK cell number J:73353
decreased pro-B cell number J:73353
decreased thymocyte number J:73353
impaired myelopoiesis J:73353
small lymph nodes J:73353
spleen hypoplasia J:73353
thymus hypoplasia J:73353
\Nlrc3tm1Bhk/\Nlrc3tm1Bhk
(B6.129S6-Nlrc3tm1Bhk)
increased circulating interleukin-6 level J:187586
increased circulating tumor necrosis factor level J:187586
increased monocyte cell number J:187586
increased susceptibility to endotoxin shock J:187586
increased tumor necrosis factor secretion J:187586
\Nlrc4em1Vnce/\Nlrc4em1Vnce
(C57BL/6-Nlrc4em1Vnce)
decreased inflammatory response J:294930
increased susceptibility to bacterial infection induced morbidity/mortality J:294930
\Nlrc4em1Vnce/\Nlrc4em1Vnce
\Nlrp3tm1Vmd/\Nlrp3tm1Vmd

(involves: C57BL/6J * C57BL/6N)
decreased inflammatory response J:294930
\Nlrc4em2Vnce/\Nlrc4em2Vnce
(C57BL/6-Nlrc4em2Vnce)
decreased inflammatory response J:294930
\Nlrc4em2Vnce/\Nlrc4em2Vnce
\Nlrp3tm1Vmd/\Nlrp3tm1Vmd

(involves: C57BL/6J * C57BL/6N)
decreased inflammatory response J:294930
\Nlrc4em3Vnce/\Nlrc4em3Vnce
(C57BL/6-Nlrc4em3Vnce)
immune system phenotype J:294930
\Nlrc4m1Btlr/\Nlrc4+
(C57BL/6J-Nlrc4m1Btlr)
decreased interleukin-1 beta secretion J:225933
\Nlrc4m1Btlr/\Nlrc4m1Btlr
(C57BL/6J-Nlrc4m1Btlr)
decreased interleukin-1 beta secretion J:225933
\Nlrc4tm1Gln/\Nlrc4tm1Gln
(involves: 129S5/SvEvBrd)
immune system phenotype J:173245
\Nlrc4tm1Gln/\Nlrc4tm1Gln
\Slc11a1s/\Slc11a1s

(B6.129S5-Nlrc4tm1Gln)
increased susceptibility to bacterial infection J:124378
\Nlrc4tm1Gne/\Nlrc4tm1Gne
(involves: C57BL/6N)
immune system phenotype J:189256
\Nlrc4tm1Nnz/\Nlrc4tm1Nnz
(involves: 129 * C57BL/6J)
abnormal macrophage physiology J:112671, J:117251
increased susceptibility to bacterial infection J:117251
\Nlrc4tm1Vmd/\Nlrc4tm1Vmd
(C57BL/6N-Nlrc4tm1Vmd)
decreased interleukin-1 beta secretion J:91292
\Nlrc4tm1Vmd/\Nlrc4tm1Vmd
(involves: C57BL/6N)
abnormal cytokine secretion J:106976
abnormal response to infection J:106976
\Nlrc4tm1Vmd/\Nlrc4tm1Vmd
\Nlrp3tm1Vmd/\Nlrp3tm1Vmd

(C57BL/6-Nlrp3tm1Vmd Nlrc4tm1Vmd)
decreased interleukin-1 beta secretion J:160545
\Nlrc5tm1.1Ggaur/\Nlrc5tm1.1Ggaur
(involves: BALB/cJ)
abnormal T cell physiology J:184076
decreased CD8-positive, alpha-beta T cell number J:184076
enlarged spleen J:184076
immune system phenotype J:184076
\Nlrc5tm1Aki/\Nlrc5tm1Aki
(Not Specified)
immune system phenotype J:168788
\Nlrc5tm1Itl/\Nlrc5tm1Itl
(C57BL/6-Nlrc5tm1Itl)
decreased interferon-beta secretion J:188857
decreased interleukin-6 secretion J:188857
immune system phenotype J:188857
\Nlrp1am1Btlr/\Nlrp1am1Btlr
(C57BL/6J-Nlrp1am1Btlr)
decreased B cell number J:265173
decreased B-1 B cell number J:265173
decreased B-1b cell number J:265173
decreased B-2 B cell number J:265173
decreased CD8-positive, alpha-beta T cell number J:265173
decreased central memory CD8 positive, alpha-beta T cell number J:265173
decreased NK cell number J:265173
decreased single-positive T cell number J:265173
decreased T cell number J:265173
increased effector memory CD8-positive, alpha-beta T cell number J:265173
increased IgE level J:265173
increased macrophage apoptosis J:265173
increased tumor necrosis factor secretion J:265173
\Nlrp1am2Btlr/\Nlrp1am2Btlr
(C57BL/6J-Nlrp1am2Btlr)
decreased B cell number J:265174
decreased interleukin-1 beta secretion J:265174
decreased NK cell number J:265174
increased dendritic cell number J:265174
increased macrophage apoptosis J:265174
increased neutrophil cell number J:265174
\Nlrp1aNeut1/\Nlrp1a+
(C.B6-Nlrp1aNeut1)
increased inflammatory response J:191055
liver inflammation J:191055
lung inflammation J:191055
meningitis J:191055
myocarditis J:191055
pancreas inflammation J:191055
\Nlrp1aNeut1/\Nlrp1aNeut1
(C.B6-Nlrp1aNeut1)
decreased lymphocyte cell number J:191055
decreased macrophage cell number J:191055
enlarged spleen J:191055
increased inflammatory response J:191055
increased macrophage cytokine production J:191055
increased neutrophil cell number J:191055
liver inflammation J:191055
lung inflammation J:191055
meningitis J:191055
myocarditis J:191055
pancreas inflammation J:191055
\Nlrp1aNeut1/\Nlrp1aNeut1
\Pycardtm1Vmd/\Pycardtm1Vmd

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
abnormal inflammatory response J:191055
increased neutrophil cell number J:191055
\Nlrp1btm1Bhk/\Nlrp1btm1Bhk
(129S6/SvEvTac-Nlrp1btm1Bhk)
abnormal macrophage physiology J:189777
decreased interleukin-1 alpha secretion J:189777
decreased interleukin-1 beta secretion J:189777
\Nlrp2tm1.2Itl/\Nlrp2tm1.2Itl
(involves: C57BL/6)
immune system phenotype J:237496
\Nlrp3m1Btlr/\Nlrp3m1Btlr
(C57BL/6J-Nlrp3m1Btlr)
decreased interleukin-1 beta secretion J:159357
\Nlrp3m2Btlr/?
(C57BL/6J-Nlrp3m2Btlr)
abnormal interleukin-1 beta secretion J:164865
\Nlrp3m3Btlr/?
(C57BL/6J-Nlrp3m3Btlr)
abnormal interleukin-1 beta secretion J:164866
\Nlrp3m4Btlr/\Nlrp3m4Btlr
(involves: C57BL/6J)
decreased interleukin-1 beta secretion J:171739
\Nlrp3m5Btlr/\Nlrp3+
(C57BL/6J-Nlrp3m5Btlr)
decreased interleukin-1 beta secretion J:192651
\Nlrp3m5Btlr/\Nlrp3m5Btlr
(C57BL/6J-Nlrp3m5Btlr)
decreased interleukin-1 beta secretion J:192651
\Nlrp3M6Btlr/\Nlrp3+
(C57BL/6J-Nlrp3M6Btlr)
decreased interleukin-1 beta secretion J:216047
\Nlrp3M6Btlr/\Nlrp3M6Btlr
(C57BL/6J-Nlrp3M6Btlr)
decreased susceptibility to experimental autoimmune encephalomyelitis J:226677
\Nlrp3M7Btlr/\Nlrp3+
(C57BL/6J-Nlrp3M7Btlr)
abnormal macrophage cytokine production J:216048
decreased interleukin-1 beta secretion J:216048
\Nlrp3M7Btlr/\Nlrp3M7Btlr
(C57BL/6J-Nlrp3M7Btlr)
abnormal macrophage cytokine production J:216048
decreased interleukin-1 beta secretion J:216048
\Nlrp3M8Btlr/\Nlrp3+
(C57BL/6J-Nlrp3M8Btlr)
decreased interleukin-1 beta secretion J:217294
\Nlrp3M8Btlr/\Nlrp3M8Btlr
(C57BL/6J-Nlrp3M8Btlr)
decreased interleukin-1 beta secretion J:217294
\Nlrp3M9Btlr/\Nlrp3+
(C57BL/6J-Nlrp3M9Btlr)
decreased interleukin-1 beta secretion J:220071
\Nlrp3M9Btlr/\Nlrp3M9Btlr
(C57BL/6J-Nlrp3M9Btlr)
decreased interleukin-1 beta secretion J:220071
\Nlrp3M10Btlr/\Nlrp3+
(C57BL/6J-Nlrp3M10Btlr)
decreased interleukin-1 beta secretion J:234254
\Nlrp3M10Btlr/\Nlrp3M10Btlr
(C57BL/6J-Nlrp3M10Btlr)
decreased interleukin-1 beta secretion J:234254
\Nlrp3M11Btlr/\Nlrp3M11Btlr
(C57BL/6J-Nlrp3M11Btlr)
decreased interleukin-1 beta secretion J:255211
\Nlrp3m12Btlr/\Nlrp3m12Btlr
(C57BL/6J-Nlrp3m12Btlr)
decreased interleukin-1 beta secretion J:272150
\Nlrp3tm1Bhk/\Nlrp3tm1Bhk
(involves: 129S6/SvEvTac)
decreased interleukin-1 beta secretion J:189777
immune system phenotype J:189777
\Nlrp3tm1Bhk/\Nlrp3tm1Bhk
(B6.129S6-Nlrp3tm1Bhk/J)
decreased interleukin-1 beta secretion J:253629
white adipose tissue inflammation J:256504
\Nlrp3tm1Flv/\Nlrp3tm1Flv
(involves: 129S5/SvEvBrd * C57BL/6)
abnormal macrophage physiology J:113333
decreased circulating interleukin-1 beta level J:113333
decreased circulating interleukin-18 level J:113333
decreased susceptibility to endotoxin shock J:113333
decreased susceptibility to type IV hypersensitivity reaction J:113333
\Nlrp3tm1Flv/\Nlrp3tm1Flv
(B6.129S5-Nlrp3tm1Flv)
decreased interleukin-1 beta secretion J:164725
\Nlrp3tm1Flv/\Nlrp3tm1Flv
(involves: 129S5/SvEvBrd)
decreased susceptibility to induced colitis J:173245
\Nlrp3tm1Flv/\Nlrp3tm1Flv
\Slc11a1s/\Slc11a1s

(B6.129S5-Nlrp3tm1Flv)
increased susceptibility to bacterial infection J:124378
\Nlrp3tm1Flv/\Nlrp3tm1Hhf
\Lyz2tm1(cre)Ifo/\Lyz2+

(involves: 129 * C57BL/6)
increased inflammatory response J:150054
\Nlrp3tm1Hhf/\Nlrp3+
\Lyz2tm1(cre)Ifo/\Lyz2+

(involves: 129/Sv * 129P2/OlaHsd * C57BL/6)
abnormal circulating chemokine level J:150054
abnormal circulating cytokine level J:150054
increased circulating interleukin-1 beta level J:150054
increased circulating interleukin-6 level J:150054
increased circulating interleukin-18 level J:150054
increased circulating tumor necrosis factor level J:150054
increased inflammatory response J:150054
increased leukocyte cell number J:150054
increased neutrophil cell number J:150054
\Nlrp3tm1Hhf/\Nlrp3+
\Rag1tm1Mom/\Rag1tm1Mom
\Lyz2tm1(cre)Ifo/\Lyz2+

(involves: 129/Sv * 129P2/OlaHsd * C57BL/6)
absent B cells J:150054
absent T cells J:150054
\Nlrp3tm1Hhf/\Nlrp3+
\Tg(CAG-cre/Esr1*)5Amc/?

(involves: 129/Sv * C57BL/6 * CBA)
skin inflammation J:150054
\Nlrp3tm1Hhf/\Nlrp3+
\Tg(CAG-cre/Esr1*)5Amc/?

(involves: 129/Sv * C57BL/6 * CBA)
abnormal dendritic cell antigen presentation J:150054
abnormal dendritic cell physiology J:150054
abnormal macrophage physiology J:150054
\Nlrp3tm1Hhf/\Nlrp3+
\Tg(Zp3-cre)3Mrt/?

(involves: 129/Sv * FVB/N)
increased inflammatory response J:150054
increased leukocyte cell number J:150054
increased neutrophil cell number J:150054
\Nlrp3tm1Tsc/\Nlrp3tm1Tsc
(C57BL/6-Nlrp3tm1Tsc)
decreased interleukin-1 beta secretion J:124226
\Nlrp3tm1Tsc/\Nlrp3tm1Tsc
(involves: C57BL/6)
decreased interleukin-1 beta secretion J:172117
\Nlrp3tm1Vmd/\Nlrp3tm1Vmd
(involves: C57BL/6N)
abnormal cytokine secretion J:106976
abnormal response to infection J:106976
decreased susceptibility to endotoxin shock J:106976
\Nlrp3tm1Vmd/\Nlrp3tm1Vmd
(B6.B6N-Nlrp3tm1Vmd)
decreased circulating interleukin-1 beta level J:193522
decreased circulating interleukin-18 level J:193522
decreased interleukin-1 beta secretion J:193522
decreased susceptibility to endotoxin shock J:193522
immune system phenotype J:294930
\Nlrp3tm1Wstr/\Nlrp3+
(involves: C57BL/6)
abnormal CD4-positive, alpha-beta T cell number J:150053
abnormal dendritic cell physiology J:150053
abnormal lymph node morphology J:150053
abnormal macrophage physiology J:150053
abnormal spleen red pulp morphology J:150053
chronic inflammation J:150053
dermatitis J:150053
enlarged lymph nodes J:150053
enlarged spleen J:150053
increased activated T cell number J:150053
increased anti-double stranded DNA antibody level J:150053
increased interleukin-1 beta secretion J:150053
increased interleukin-17 secretion J:150053
increased interleukin-18 secretion J:150053
increased leukocyte cell number J:150053
increased susceptibility to type IV hypersensitivity reaction J:150053
increased T-helper 1 cell number J:150053
\Nlrp3tm2Hhf/\Nlrp3+
\Tg(CAG-cre/Esr1*)5Amc/?

(involves: 129/Sv * C57BL/6 * CBA)
skin inflammation J:150054
\Nlrp3tm2Hhf/\Nlrp3+
\Tg(CAG-cre/Esr1*)5Amc/?

(involves: 129/Sv * C57BL/6 * CBA)
abnormal dendritic cell physiology J:150054
abnormal macrophage physiology J:150054
\Nlrp3tm2Hhf/\Nlrp3tm2Hhf
\Vsig4tm1Gne/\Vsig4tm1Gne

(B6.Cg-Nlrp3tm2Hhf Vsig4tm1Gne)
decreased susceptibility to experimental autoimmune encephalomyelitis J:281762
\Nlrp3tm3.1Hhf/\Nlrp3+
(involves: 129)
abnormal circulating chemokine level J:202147
abnormal osteoclast differentiation J:202147
decreased circulating interleukin-5 level J:202147
decreased circulating interleukin-12b level J:202147
decreased lymphocyte cell number J:202147
immune system phenotype J:202147
increased circulating interleukin-1 beta level J:202147
increased circulating interleukin-3 level J:202147
increased circulating interleukin-4 level J:202147
increased circulating interleukin-6 level J:202147
increased circulating interleukin-9 level J:202147
increased circulating interleukin-13 level J:202147
increased circulating interleukin-18 level J:202147
increased circulating tumor necrosis factor level J:202147
increased granulocyte number J:202147
increased inflammatory response J:202147
increased interferon-gamma secretion J:202147
increased interleukin-1 beta secretion J:202147
increased lymphocyte cell number J:202147
increased monocyte cell number J:202147
increased neutrophil cell number J:202147
increased osteoclast cell number J:202147
joint inflammation J:202147
meningitis J:202147
osteomyelitis J:202147
\Nlrp6tm1Flv/\Nlrp6tm1Flv
(B6.Cg-Nlrp6tm1Flv)
decreased circulating interleukin-18 level J:173245
decreased interleukin-18 secretion J:173245
enlarged Peyer's patches J:173245
increased B cell number J:173245
increased IgA level J:173245
increased IgG2c level J:173245
increased leukocyte cell number J:173245
increased susceptibility to induced colitis J:173245
increased susceptibility to Riboviria infection induced morbidity/mortality J:243487
\Nlrp6tm1Macha/\Nlrp6tm1Macha
(involves: 129S5/SvEvBrd * C57BL/6J)
increased susceptibility to induced colitis J:173352
\Nlrp9bem1Flv/\Nlrp9bem1Flv
(C57BL/6N-Nlrp9bem1Flv)
increased susceptibility to Riboviria infection induced morbidity/mortality J:243487
\Nlrp9btm1b(KOMP)Wtsi/\Nlrp9btm1b(KOMP)Wtsi
(C57BL/6N-Nlrp9btm1b(KOMP)Wtsi/H)
enlarged spleen J:211773
\Nlrp10tm1Seis/\Nlrp10tm1Seis
(involves: C57BL/6)
immune system phenotype J:173245
\Nlrp10tm1Seis/\Nlrp10tm1Seis
(B6.Cg-Nlrp10tm1Seis)
abnormal adaptive immunity J:183989
abnormal dendritic cell physiology J:183989
abnormal T-helper 2 physiology J:183989
decreased dendritic cell number J:183989
decreased IgG1 level J:183989
decreased interferon-gamma secretion J:183989
decreased interleukin-17 secretion J:183989
decreased susceptibility to endotoxin shock J:183989
decreased susceptibility to experimental autoimmune encephalomyelitis J:183989
\Nlrp12tm1Jpyt/\Nlrp12tm1Jpyt
(B6.Cg-Nlrp12tm1Jpyt)
abnormal leukocyte migration J:164725
decreased neutrophil cell number J:164725
decreased susceptibility to type IV hypersensitivity reaction J:164725
impaired neutrophil chemotaxis J:164725
\Nlrp12tm1Jpyt/\Nlrp12tm1Jpyt
(Not Specified)
immune system phenotype J:173245
\Nlrp12tm1Tdk/\Nlrp12tm1Tdk
(B6.Cg-Nlrp12tm1Tdk)
abnormal chemokine level J:178951
abnormal cytokine level J:178951
enlarged spleen J:178951
increased inflammatory response J:178951
increased susceptibility to induced colitis J:178951
\Nlrx1em1(IMPC)Mbp/\Nlrx1em1(IMPC)Mbp
(C57BL/6N-Nlrx1em1(IMPC)Mbp/MbpMmucd)
small spleen J:211773
\Nlrx1tm1Jpyt/\Nlrx1tm1Jpyt
(involves: C57BL/6 * C57BL/6J)
abnormal macrophage physiology J:173995
abnormal neutrophil physiology J:173995
increased circulating interleukin-6 level J:173995
increased interferon-beta secretion J:173995
increased interleukin-1 beta secretion J:173995
increased interleukin-6 secretion J:173995
increased susceptibility to endotoxin shock J:173995
increased susceptibility to Orthomyxoviridae infection J:173995
\Nme2Gt(69C10)Cmhd/\Nme2Gt(69C10)Cmhd
(B6.129-Nme2Gt(69C10)Cmhd)
abnormal CD4-positive, alpha-beta T cell physiology J:167387
abnormal T-helper 1 physiology J:167387
abnormal T-helper 2 physiology J:167387
decreased interferon-gamma secretion J:167387
decreased interleukin-2 secretion J:167387
decreased interleukin-13 secretion J:167387
decreased tumor necrosis factor secretion J:167387
immune system phenotype J:167387
\Nme5tm1Lex/\Nme5tm1Lex
(involves: 129S5/SvEvBrd * C57BL/6J)
maxillary sinus inflammation J:185566
nasal inflammation J:185566
\nmf4/\nmf4
(C57BL/6J-nmf4/J)
small spleen J:78134
thymus cortex atrophy J:78134
\nmf356/\nmf356
(C57BL/6J-nmf356/J)
thymus atrophy J:87349
\nmf370/\nmf370
(C57BL/6J-nmf370/J)
ear inflammation J:87349
\nmf391/\nmf391
(C57BL/6J-nmf391/J)
ear inflammation J:87349
\Nmiem1Hhl/\Nmiem1Hhl
(C57BL/6-Nmiem1Hhl)
decreased circulating interleukin-6 level J:298909
decreased circulating tumor necrosis factor level J:298909
decreased susceptibility to bacterial infection induced morbidity/mortality J:298909
decreased susceptibility to endotoxin shock J:298909
\Nmnat2em1(IMPC)Mbp/\Nmnat2+
(C57BL/6N-Nmnat2em1(IMPC)Mbp/Ucd)
abnormal lymph node morphology J:211773
enlarged lymph nodes J:211773
\Nmnat3Gt(3020)Tgen/\Nmnat3Gt(3020)Tgen
(involves: C57BL/6NCrlj * CBA/JNCrlj)
enlarged spleen J:214107
increased spleen iron level J:214107
increased spleen red pulp amount J:214107
increased spleen weight J:214107
\Nmt1tm1.1Poru/\Nmt1tm1.1Poru
\Nmt2tm1.1Poru/\Nmt2tm1.1Poru
\Tg(Lck-cre)1Cwi/0

(involves: C57BL/6 * DBA/2 * SJL)
abnormal CD4-positive, alpha beta T cell morphology J:226234
abnormal CD8-positive, alpha beta T cell morphology J:226234
decreased circulating interferon-gamma level J:226234
decreased circulating interleukin-2 level J:226234
decreased circulating tumor necrosis factor level J:226234
decreased DN4 thymocyte number J:226234
decreased double-positive T cell number J:226234
decreased interferon-gamma secretion J:226234
decreased interleukin-2 secretion J:226234
decreased single-positive T cell number J:226234
decreased splenocyte proliferation J:226234
decreased susceptibility to endotoxin shock J:226234
decreased T cell number J:226234
decreased T cell proliferation J:226234
immune system phenotype J:226234
increased double-negative T cell number J:226234
increased gamma-delta T cell number J:226234
increased T cell apoptosis J:226234
small thymus medulla J:226234
\Nmt1tm1.1Poru/\Nmt1tm1.1Poru
\Tg(Lck-cre)1Cwi/0

(involves: C57BL/6 * DBA/2 * SJL)
abnormal CD4-positive, alpha beta T cell morphology J:226234
abnormal CD8-positive, alpha beta T cell morphology J:226234
decreased double-positive T cell number J:226234
decreased single-positive T cell number J:226234
decreased T cell number J:226234
\Nmt2tm1.1Poru/\Nmt2tm1.1Poru
\Tg(Lck-cre)1Cwi/0

(involves: C57BL/6 * DBA/2 * SJL)
decreased double-positive T cell number J:226234
decreased single-positive T cell number J:226234
decreased T cell number J:226234
\Nmutm1Sjab/\Nmutm1Sjab
(involves: 129P2/OlaHsd * C57BL/6)
decreased circulating interleukin-6 level J:142907
\Nnatem1(IMPC)Mbp/\Nnatem1(IMPC)Mbp
(C57BL/6NCrl-Nnatem1(IMPC)Mbp/Mmucd)
abnormal lymph node morphology J:211773
enlarged lymph nodes J:211773
\Nnmtem1(IMPC)Mbp/\Nnmtem1(IMPC)Mbp
(C57BL/6NCrl-Nnmtem1(IMPC)Mbp/Mmucd)
enlarged spleen J:211773
\Noa/\Noa+
(NOA)
cutaneous mastocytosis J:43274
increased IgE level J:43274
\Noc2ltm1.1Arte/\Noc2ltm1.1Arte
\Tg(CD2-icre)4Kio/0

(involves: C57BL/6 * C57BL/10 * CBA/Ca)
abnormal B cell morphology J:216490
abnormal T cell morphology J:216490
abnormal T cell proliferation J:216490
abnormal thymus cell ratio J:216490
abnormal thymus involution J:216490
abnormal thymus morphology J:216490
absent T cells J:216490
arrested T cell differentiation J:216490
decreased alpha-beta T cell number J:216490
decreased DN3 thymocyte number J:216490
decreased DN4 thymocyte number J:216490
decreased double-positive T cell number J:216490
decreased immature B cell number J:216490
decreased mature B cell number J:216490
decreased pre-B cell number J:216490
decreased pro-B cell number J:216490
decreased single-positive T cell number J:216490
increased thymocyte apoptosis J:216490
small thymus J:216490
spleen hypoplasia J:216490
thymus hypoplasia J:216490
\Noc2ltm1.1Arte/\Noc2ltm1.1Arte
\Trp53tm1Brn/\Trp53tm1Brn
\Tg(CD2-icre)4Kio/0

(involves: 129P2/OlaHsd * C57BL/6 * C57BL/10 * CBA/Ca)
decreased pre-B cell number J:216490
\Nod1tm1Bert/\Nod1tm1Bert
(involves: C57BL/6)
immune system phenotype J:117688
\Nod1tm1Inoh/\Nod1tm1Inoh
(involves: 129P2/OlaHsd * C57BL/6)
abnormal chemokine secretion J:118808
abnormal cytokine secretion J:118808
abnormal immune system physiology J:118808
abnormal macrophage physiology J:132126, J:118808
decreased interleukin-6 secretion J:132126
decreased tumor necrosis factor secretion J:132126
\Nod1tm1Inoh/\Nod1tm1Inoh
\Nod2tm1Flv/\Nod2tm1Flv

(involves: 129 * 129P2/OlaHsd * C57BL/6)
abnormal macrophage physiology J:132126
decreased interleukin-6 secretion J:132126
decreased tumor necrosis factor secretion J:132126
increased susceptibility to bacterial infection J:132126
\Nod2em1(IMPC)Mbp/\Nod2em1(IMPC)Mbp
(C57BL/6N-Nod2em1(IMPC)Mbp/MbpMmucd)
abnormal lymph node morphology J:211773
enlarged lymph nodes J:211773
\Nod2tm1Daph/\Nod2tm1Daph
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
abnormal macrophage physiology J:157879
\Nod2tm1Flv/\Nod2tm1Flv
(involves: 129S1/Sv * C57BL/6)
abnormal macrophage physiology J:132126, J:96035
abnormal susceptibility to infection J:96035
decreased IgG level J:96035
decreased interleukin-6 secretion J:132126
decreased susceptibility to endotoxin shock J:96035
decreased tumor necrosis factor secretion J:132126
\Nod2tm1Flv/\Nod2tm1Flv
(involves: 129S1/Sv)
abnormal response to infection J:147177
abnormal T-helper 1 physiology J:147177
impaired macrophage phagocytosis J:147177
impaired neutrophil phagocytosis J:147177
increased circulating interferon-gamma level J:147177
increased circulating interleukin-2 level J:147177
increased circulating tumor necrosis factor level J:147177
increased leukocyte cell number J:147177
increased neutrophil cell number J:147177
increased susceptibility to bacterial infection induced morbidity/mortality J:147177
\Nod2tm1Flv/\Nod2tm1Flv
(C.129S1-Nod2tm1Flv)
decreased susceptibility to induced arthritis J:178054
\Nod2tm1Jhgt/\Nod2tm1Jhgt
(B6.Cg-Nod2tm1Jhgt)
abnormal cytokine level J:124575
abnormal immune system morphology J:124575
abnormal immune system physiology J:124575
abnormal interferon level J:124575
abnormal interleukin level J:124575
abnormal lymph node B cell domain morphology J:124575
abnormal Peyer's patch morphology J:124575
abnormal response to infection J:124575
abnormal tumor necrosis factor level J:124575
enlarged Peyer's patches J:124575
increased CD4-positive, alpha-beta T cell number J:124575
increased double-negative T cell number J:124575
increased Peyer's patch number J:124575
increased susceptibility to induced colitis J:124575
\Nod2tm1Mka/\Nod2tm1Mka
(involves: C57BL/6)
abnormal cytokine level J:96128
abnormal macrophage morphology J:96128
increased interleukin-1 beta secretion J:96128
increased susceptibility to induced colitis J:96128
\Nod2tm1Pmu/\Nod2tm1Pmu
(involves: BALB/c * C57BL/6)
abnormal macrophage physiology J:86264
decreased susceptibility to endotoxin shock J:86264
\Nod2tm1Vmd/\Nod2tm1Vmd
(B6.129-Nod2tm1Vmd)
abnormal cytokine secretion J:106976
\Nodaltm1.1Mku/\Nodaltm2Mku
\Tg(T-cre)1Lwd/0

(involves: 129S1/Sv * C3H * C57BL/6)
absent spleen J:142430
small spleen J:142430
\Nodaltm1.2Rob/\Nodaltm3Rob
(involves: 129S/SvEv * MF1)
small spleen J:79098
\Nodaltm1Hmd/\Nodal+
\Tg(Rr443-Lefty1,-lacZ)36Hmd/0

(either: (involves: 129S1/Sv * 129X1/SvJ * C57BL/6N) or (involves: 129S1/Sv * 129T2/SvEms * 129X1/SvJ))
small spleen J:82703
\Nodaltm1Hmd/\Nodaltm1Hmd
(either: (involves: 129S1/Sv * 129X1/SvJ * C57BL/6N) or (involves: 129S1/Sv * 129T2/SvEms * 129X1/SvJ))
abnormal spleen morphology J:82703
spleen hypoplasia J:82703
\Nol3em1(IMPC)Mbp/\Nol3em1(IMPC)Mbp
(C57BL/6N-Nol3em1(IMPC)Mbp/MbpMmucd)
abnormal lymph node morphology J:211773
abnormal spleen morphology J:211773
enlarged lymph nodes J:211773
enlarged spleen J:211773
small spleen J:211773
\Nop53tm2.1Asuz/\Nop53tm2.1Asuz
\Tg(Lck-cre)#Jxm/0

(involves: 129P2/OlaHsd * C57BL/6 * CBA)
decreased thymocyte number J:241062
\Nop53tm2.1Asuz/\Nop53tm2.1Asuz
\Trp53tm1Tyj/\Trp53tm1Tyj
\Tg(Lck-cre)#Jxm/0

(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 * CBA)
decreased thymocyte number J:241062
\Nos1tm1Plh/\Nos1tm1Plh
(involves: 129S4/SvJae)
abnormal leukocyte adhesion J:55936
abnormal neutrophil physiology J:55936
enhanced leukocyte tethering or rolling J:55936
\Nos1tm1Plh/\Nos1tm1Plh
(B6;129S4-Nos1tm1Plh/J)
abnormal osteoclast differentiation J:105612
\Nos1tm1Plh/\Nos1tm1Plh
(B6.129S4-Nos1tm1Plh/J)
decreased inflammatory response J:103018
\Nos1tm1Plh/\Nos1tm1Plh
\Nos2tm1Mrl/\Nos2tm1Mrl
\Nos3tm1Plh/\Nos3tm1Plh

(involves: 129S4/SvJae * 129S7/SvEvBrd)
abnormal osteoclast physiology J:150159
increased osteoclast cell number J:150159
\Nos2tm1Lau/\Nos2tm1Lau
(involves: 129P2/OlaHsd * C57BL/6)
abnormal adaptive immunity J:90903
abnormal immune system morphology J:90903
enlarged inguinal lymph nodes J:90903
immune system phenotype J:64036, J:29677
increased single-positive T cell number J:90903
increased susceptibility to bacterial infection J:100513
increased T cell proliferation J:90903
skin inflammation J:64036
\Nos2tm1Lau/\Nos2tm1Lau
(B6.129P2-Nos2tm1Lau)
abnormal osteoclast morphology J:112399
decreased susceptibility to induced colitis J:87601
\Nos2tm1Lau/\Nos2tm1Lau
(B6.129P2-Nos2tm1Lau/J)
abnormal inflammatory response J:103018
decreased inflammatory response J:103018
\Nos2tm1Lau/\Nos2tm1Lau
(involves: 129P2/OlaHsd)
immune system phenotype J:55936
\Nos2tm1Liew/\Nos2tm1Liew
(involves: 129P2/Ola * MF1)
abnormal T-helper 1 physiology J:25755
decreased inflammatory response J:25755
decreased susceptibility to endotoxin shock J:25755
increased interferon-gamma secretion J:25755
increased susceptibility to parasitic infection J:25755
increased T cell proliferation J:25755
\Nos2tm1Liew/\Nos2tm1Liew
(involves: 129 * 129P2/OlaHsd)
immune system phenotype J:118561
\Nos2tm1Mrl/\Nos2tm1Mrl
(involves: 129S7/SvEvBrd)
abnormal eosinophil cell number J:51635
abnormal immune system physiology J:51635
abnormal macrophage physiology J:120499
decreased eosinophil cell number J:51635
decreased susceptibility to endotoxin shock J:25511
increased IgG2a level J:51635
increased inflammatory response J:51635
increased interferon-gamma secretion J:51635
increased susceptibility to bacterial infection J:25511
\Nos2tm1Mrl/\Nos2tm1Mrl
(involves: 129S7/SvEvBrd * C57BL/6)
increased length of allograft survival J:54764
pancreas inflammation J:65562
\Nos2tm1Mrl/\Nos2tm1Mrl
(B6.129S7-Nos2tm1Mrl)
abnormal osteoclast differentiation J:98070
abnormal osteoclast morphology J:98070
abnormal response to infection J:98070
decreased osteoclast cell number J:98070
\Nos2tm1Mrl/\Nos2tm1Mrl
(involves: 129S7/SvEvBrd * PL/J)
increased susceptibility to experimental autoimmune encephalomyelitis J:46192
\Nos3em1(IMPC)Mbp/\Nos3em1(IMPC)Mbp
(C57BL/6N-Nos3em1(IMPC)Mbp/Ucd)
abnormal lymph node morphology J:211773
abnormal spleen morphology J:211773
decreased lymphocyte cell number J:211773
enlarged lymph nodes J:211773
enlarged spleen J:211773
increased basophil cell number J:211773
increased eosinophil cell number J:211773
increased neutrophil cell number J:211773
\Nos3m1Btlr/\Nos3m1Btlr
(C57BL/6J-Nos3m1Btlr)
increased susceptibility to induced colitis J:225268
\Nos3M2Btlr/\Nos3M2Btlr
(C57BL/6J-Nos3M2Btlr)
increased susceptibility to induced colitis J:272392
\Nos3tm1Plh/\Nos3tm1Plh
(involves: 129S4/SvJae)
abnormal leukocyte adhesion J:55936
abnormal neutrophil physiology J:55936
enhanced leukocyte tethering or rolling J:55936
\Nos3tm1Plh/\Nos3tm1Plh
(involves: 129S4/SvJae * C57BL/6)
increased susceptibility to bacterial infection J:105005
increased susceptibility to bacterial infection induced morbidity/mortality J:105005
\Nos3tm1Unc/\Nos3tm1Unc
(involves: 129P2/OlaHsd * C57BL/6)
immune system phenotype J:36559
\Nos3tm1Unc/\Nos3tm1Unc
(B6.129P2-Nos3tm1Unc/J)
abnormal osteoclast physiology J:129477
increased inflammatory response J:103018
kidney inflammation J:148626
\Notch1tm1Agt/\Notch1tm1Agt
\Notch2tm1Frad/\Notch2tm1Frad
\Tg(Mx1-cre)1Cgn/0

(involves: 129 * BALB/c * C57BL/6 * CBA)
abnormal T cell differentiation J:125373
arrested T cell differentiation J:125373
\Notch1tm1Agt/\Notch1tm1Agt
\Notch2tm3Grid/\Notch2tm3Grid
\Tg(TcrAND)53Hed/?

(involves: 129/Sv * 129S1/Sv * C57BL/6 * SJL)
abnormal humoral immune response J:123631
abnormal response to infection J:123631
decreased interleukin-4 secretion J:123631
\Notch1tm1Agt/\Notch1tm1Agt
\Tg(Mx1-cre)1Cgn/0

(involves: 129 * C57BL/6 * CBA)
abnormal B cell differentiation J:125373
abnormal T cell differentiation J:125373, J:55400
abnormal thymus cell ratio J:55400, J:143472
abnormal thymus morphology J:55400
decreased CD4-positive, alpha-beta T cell number J:55400
decreased CD8-positive, alpha-beta T cell number J:55400
decreased double-negative T cell number J:55400
decreased double-positive T cell number J:55400
decreased single-positive T cell number J:55400
decreased thymocyte number J:55400
increased immature B cell number J:143472
small thymus J:55400
\Notch1tm1Con/\Notch1+
(involves: 129S1/Sv * 129X1/SvJ * CD-1)
aortic valve inflammation J:187551
\Notch1tm2Pst/\Notch1tm2Pst
(B6.Cg-Notch1tm2Pst)
abnormal T cell differentiation J:131563
decreased double-negative T cell number J:131563
decreased T cell number J:131563
decreased thymocyte number J:131563
increased T cell apoptosis J:131563
\Notch1tm2Rko/\Notch1tm2Rko
\Notch2tm1Rko/\Notch2tm1Rko
\Notch3Gt(PST033)Byg/\Notch3+
\Tg(Mx1-cre)1Cgn/0

(involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6 * CBA)
abnormal spleen morphology J:172442
enlarged spleen J:172442
increased spleen red pulp amount J:172442
\Notch1tm2Rko/\Notch1tm2Rko
\Notch2tm1Rko/\Notch2tm1Rko
\Notch3Gt(PST033)Byg/\Notch3Gt(PST033)Byg
\Tg(Mx1-cre)1Cgn/0

(involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6 * CBA)
abnormal spleen morphology J:172442
enlarged spleen J:172442
increased spleen red pulp amount J:172442
\Notch1tm2Rko/\Notch1tm3(cre)Rko
(involves: 129X1/SvJ * C57BL/6)
abnormal spleen morphology J:171829
chronic liver inflammation J:171829
enlarged spleen J:171829
\Notch2Gt(betageo)1Byg/\Notch2+
(B6.129P2-Notch2Gt(betageo)1Byg)
decreased marginal zone B cell number J:146621
\Notch2tm1.1Ecan/\Notch2+
(involves: 129 * 129S1/Sv * C57BL/6J)
abnormal osteoclast differentiation J:230045
abnormal osteoclast morphology J:230045
increased osteoclast cell number J:230045
\Notch2tm1.1Hhi/\Notch2tm1.1Hhi
\Tg(Cd8a-cre)1Itan/0

(involves: C57BL/6 * CBA)
abnormal CD8-positive, alpha-beta T cell physiology J:141009
abnormal cytotoxic T cell physiology J:141009
increased susceptibility to parasitic infection J:141009
\Notch2tm1.1Hhtg/\Notch2+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)
abnormal interleukin level J:311038
abnormal osteoclast differentiation J:311038
increased circulating interleukin-6 level J:311038
increased interleukin-6 secretion J:311038
increased osteoclast cell number J:311038
\Notch2tm1Frad/\Notch2tm1Frad
\Tg(Mx1-cre)1Cgn/0

(involves: BALB/c * C57BL/6 * CBA)
abnormal B cell differentiation J:125373
absent marginal zone B cells J:125373
\Notch2tm1Yha/\Notch2+
(B6.129-Notch2tm1Yha)
abnormal spleen marginal zone morphology J:85379
decreased B-1 B cell number J:85379
decreased marginal zone B cell number J:85379
\Notch2tm2.1Ecan/\Notch2tm2.1Ecan
\Tg(BGLAP-cre)1Clem/0

(involves: C57BL/6J * FVB/NJ)
increased osteoclast cell number J:246017
\Notch2tm2Hhi/\Notch2tm1.1Hhi
\Tg(Mx1-cre)1Cgn/0

(involves: C57BL/6 * CBA)
decreased marginal zone B cell number J:83476
immune system phenotype J:83476
\Notch3em1Ecan/\Notch3+
(C57BL/6J-Notch3em1Ecan)
abnormal osteoclast differentiation J:270682
increased osteoclast cell number J:270682
\Notch3tm1.1(KOMP)Vlcg/\Notch3tm1.1(KOMP)Vlcg
(C57BL/6N-Notch3tm1.1(KOMP)Vlcg/Ucd)
increased neutrophil cell number J:211773
increased spleen weight J:211773
\Notch3tm1Khan/\Notch3tm1Khan
(involves: C57BL/6 * CBA)
decreased thymocyte number J:98284
small thymus J:98284
\Notumem1(IMPC)Tcp/\Notum+
(C57BL/6NCrl-Notumem1(IMPC)Tcp/Tcp)
small spleen J:211773
\NotumGt(OST172035)Lex/\NotumGt(OST172035)Lex
(involves: 129S5/SvEvBrd * C57BL/6)
chronic inflammation J:274615
increased leukocyte cell number J:274615
periodontium inflammation J:266040
\Nox1tm1.1Anrt/\Nox1tm1.1Anrt
\Tg(Vil1-cre)997Gum/0

(involves: C57BL/6J * SJL)
colitis J:194294
\Nox1tm1Cyn/Y
(involves: 129S1/Sv * 129X1/SvJ)
abnormal cytokine secretion J:218649
\Nox4em1(IMPC)Mbp/\Nox4em1(IMPC)Mbp
(C57BL/6N-Nox4em1(IMPC)Mbp/MbpMmucd)
abnormal lymph node morphology J:211773
enlarged lymph nodes J:211773
\Nox4tm1Syb/\Nox4tm1Syb
(involves: 129S4/SvJae)
decreased interleukin-1 beta secretion J:298830
decreased susceptibility to endotoxin shock J:298830
decreased tumor necrosis factor secretion J:298830
\Noxa1em1(IMPC)Ccpcz/\Noxa1em1(IMPC)Ccpcz
(C57BL/6NCrl-Noxa1em1(IMPC)Ccpcz/Ccpcz)
abnormal thymus morphology J:211773
enlarged thymus J:211773
\Npas2em1(IMPC)Mbp/\Npas2em1(IMPC)Mbp
(C57BL/6N-Npas2em1(IMPC)Mbp/MbpMmucd)
abnormal lymph node morphology J:211773
decreased lymphocyte cell number J:211773
enlarged lymph nodes J:211773
increased neutrophil cell number J:211773
\Npas3tm1Mesu/\Npas3tm1Mesu
(B6.129S6-Npas3tm1Mesu)
bronchiectasis J:150793
\Npattm1b(EUCOMM)Wtsi/\Npattm1b(EUCOMM)Wtsi
(C57BL/6N-Npattm1b(EUCOMM)Wtsi/Wtsi)
blood in lymph vessels J:239583
\Npc1m1N/\Npc1m1N
(involves: BALB/c)
abnormal alveolar macrophage morphology J:204311
enlarged spleen J:76733
\Npc1m1N/\Npc1m1N
(BALB/cNctr-Npc1m1N/J)
enlarged spleen J:179744
microgliosis J:209834
nasal inflammation J:209834
\Npc1m1N/\Npc1m1N
(involves: BALB/c * C57BL/6 * CBA)
increased microglial cell activation J:144240
\Npc1m1N/\Npc1m1N
(B6.C-Npc1m1N)
microgliosis J:157113
\Npc1m1N/\Npc1m1N
(BALB/c-Npc1m1N)
abnormal macrophage morphology J:221855
abnormal microglial cell activation J:221855
increased macrophage derived foam cell number J:221855
increased microglial cell activation J:221855
\Npc1m1N/\Npc1m1N
(involves: BALB/c * C3H/HeJ * C57BL/6J)
microgliosis J:188345
\Npc1m1N/\Npc1m1N
\Tg(PRNP-APPSweInd)8Dwst/0

(involves: BALB/c * C3H/HeJ * C57BL/6J)
microgliosis J:188345
\Npc1m1N/\Npc1m1N
\Tlr4tm1Aki/\Tlr4tm1Aki

(involves: 129P2/OlaHsd * BALB/c)
abnormal cytokine secretion J:118352
\Npc1m1N/\Npc1tm1.1Apl
\Tg(CAG-cre/Esr1*)5Amc/0

(B6J.Cg-Npc1m1N/Npc1tm1.1Apl Tg(CAG-cre/Esr1*)5Amc)
microgliosis J:176888
\Npc1m1N/\Npc1tm1.1Apl
\Tg(Syn1-cre)671Jxm/0

(B6J.Cg-Npc1m1N/Npc1tm1.1Apl Tg(Syn1-cre)671Jxm)
microgliosis J:176888
\Npc1m1N/\Npc1tm1.2Apl
(B6.Cg-Npc1m1N/Npc1tm1.2Apl)
microgliosis J:157113
\Npc1nmf164/\Npc1nmf164
(C57BL/6J-Npc1nmf164/J)
enlarged spleen J:179744
increased macrophage derived foam cell number J:179744
increased microglial cell activation J:179744
\Npc1spm/\Npc1spm
(C57BLKS/J-Npc1spm/J)
enlarged spleen J:7245
increased macrophage derived foam cell number J:7245
\Npc1tm1.1Apl/\Npc1tm1.2Apl
\Tg(Pcp2-cre)2Mpin/0

(B6.Cg-Npc1tm1.1Apl/Npc1tm1.2Apl Tg(Pcp2-cre)2Mpin)
microgliosis J:157113
\Npc1tm1.1Dso/\Npc1tm1.1Dso
(B6.129-Npc1tm1.1Dso)
abnormal macrophage morphology J:221855
abnormal microglial cell activation J:221855
increased macrophage cell number J:221855
increased macrophage derived foam cell number J:221855
increased microglial cell activation J:221855
microgliosis J:221855
\Npc2Gt(LST105)Byg/\Npc2Gt(LST105)Byg
(B6.129P2-Npc2Gt(LST105)Byg)
abnormal immune system morphology J:125609
abnormal immune system physiology J:125609
\Npc2tm1Plob/\Npc2tm1Plob
(involves: 129S1/Sv * C57BL/6)
decreased NK cell number J:125609
\Npc2tm1Plob/\Npc2tm1Plob
(C.129S1-Npc2tm1Plob)
abnormal NK cell physiology J:125609
abnormal T cell physiology J:125609
decreased NK cell number J:125609
\Npc2tm1Plob/\Npc2tm1Plob
(involves: 129S1/Sv * BALB/c)
abnormal alveolar macrophage morphology J:204311
\Npeppstm1Klr/\Npeppstm1Klr
(involves: 129 * C57BL/6)
immune system phenotype J:131502
\Npffr2tm1.2Ics/\Npffr2tm1.2Ics
(involves: C57BL/6N)
abnormal macrophage activation involved in immune response J:245025
decreased macrophage cell number J:245025
decreased macrophage proliferation J:245025
\Nphp3pcy/\Nphp3pcy
(KK-Nphp3pcy)
kidney inflammation J:8302
\Nphp3pcy/\Nphp3pcy
(either: D2.KK-Nphp3pcy or (involves: DBA/2Fg * DBA/2J * KK))
kidney inflammation J:11399
\Nphp3pol/\Nphp3pol
(C57BL/6JSfdAnu-Nphp3pol/Anu)
kidney inflammation J:104190
\NplGt(OST15553)Lex/\NplGt(OST15553)Lex
(involves: 129S5/SvEvBrd * C57BL/6J)
immune system phenotype J:103485
\Npm1tm1Gsva/\Npm1+
\Tg(Mx1-cre)1Cgn/0

(involves: C57BL/6 * CBA)
decreased B cell number J:172071
enlarged spleen J:172071
increased granulocyte number J:172071
increased leukocyte cell number J:172071
increased spleen weight J:172071
\Npm1tm1Hft/\Npm1+
(involves: 129)
abnormal granulocyte differentiation J:194999
abnormal spleen B cell follicle morphology J:194999
enlarged spleen J:194999
increased granulocyte number J:194999
increased leukocyte cell number J:194999
increased monocyte cell number J:194999
increased spleen weight J:194999
myeloid hyperplasia J:194999
\Npm1tm1Ppp/\Npm1+
(involves: 129S1/Sv * C57BL/6)
abnormal thrombopoiesis J:101494
\Npr1tm1Gar/\Npr1tm1Gar
(B6.129S7-Npr1tm1Gar)
impaired neutrophil chemotaxis J:70496
\Npr2cn/\Npr2cn
(AKR/J)
small spleen J:5109
\Npr3tm1Unc/\Npr3tm1Unc
(involves: 129 * C57BL/6)
abnormal osteoclast morphology J:56058
\Nprl3tm1.1Drhi/\Nprl3tm1.1Drhi
(involves: 129P2/OlaHsd)
abnormal lymph organ development J:183988
\Npsr1tm1b(KOMP)Wtsi/\Npsr1tm1b(KOMP)Wtsi
(C57BL/6N-Npsr1tm1b(KOMP)Wtsi/Rbrc)
increased eosinophil cell number J:211773
\Npsr1tm1Bhk/\Npsr1tm1Bhk
(either: (involves: 129S6/SvEvTac * BALB/c) or (involves: 129S6/SvEvTac * C57BL/6))
immune system phenotype J:144688
\Npsr1tm1Bhk/\Npsr1tm1Bhk
(129S/SvEv-Npsr1tm1Bhk)
immune system phenotype J:144688
\Npy1rtm1.1Wpg/\Npy1rtm1.1Wpg
(involves: 129X1/SvJ * C57BL/6)
abnormal immune cell physiology J:118850
abnormal immune system organ morphology J:118850
abnormal immune system physiology J:118850
abnormal immunoglobulin level J:118850
abnormal inflammatory response J:118850
abnormal lymph node cell ratio J:118850
abnormal macrophage physiology J:118850
abnormal professional antigen presenting cell physiology J:118850
abnormal spleen morphology J:118850
abnormal splenic cell ratio J:118850
abnormal T cell activation J:118850
abnormal T cell number J:118850
abnormal T-helper 1 physiology J:118850
decreased B cell number J:118850
decreased CD8-positive, alpha-beta T cell number J:118850
decreased circulating interleukin-12 level J:118850
decreased circulating tumor necrosis factor level J:118850
decreased IgG2a level J:118850
decreased interferon-gamma secretion J:118850
decreased marginal zone B cell number J:118850
decreased mature B cell number J:118850
decreased susceptibility to type IV hypersensitivity reaction J:118850
decreased transitional stage B cell number J:118850
increased CD4-positive, alpha-beta T cell number J:118850
increased CD8-positive, alpha-beta T cell number J:118850
increased IgA level J:118850
increased IgG2b level J:118850
increased IgM level J:118850
increased immunoglobulin level J:118850
increased single-positive T cell number J:118850
small spleen J:118850
\Npy2rem1(IMPC)H/\Npy2rem1(IMPC)H
(C57BL/6N-Npy2rem1(IMPC)H/H)
enlarged spleen J:211773
increased spleen weight J:211773
\Npy2rtm1.1Hhz/\Npy2rtm1.1Hhz
(involves: 129X1/SvJ * BALB/cJ * C57BL/6)
decreased osteoclast cell number J:84570
\Npy2rtm1Hhz/\Npy2rtm1Hhz
(involves: 129X1/SvJ * C57BL/6)
decreased osteoclast cell number J:97455
\Nqo2tm1Akj/\Nqo2tm1Akj
(Not Specified)
abnormal lymphopoiesis J:80549
increased granulocyte number J:80549
\Nr1d1tm1(KOMP)Vlcg/\Nr1d1tm1(KOMP)Vlcg
(C57BL/6N-Nr1d1tm1(KOMP)Vlcg/Bay)
decreased NK cell number J:211773
\Nr1h2tm1.1Gstr/\Nr1h2tm1.1Gstr
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
increased microglial cell activation J:278794
\Nr1h2tm1.1Gstr/\Nr1h2tm1.1Gstr
\Nr1h3tm1.1Gstr/\Nr1h3tm1.1Gstr

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
increased macrophage derived foam cell number J:81790, J:234268
lung inflammation J:234268
\Nr1h2tm1Djm/\Nr1h2tm1Djm
(involves: 129S6/SvEvTac * C57BL/6)
increased susceptibility to bacterial infection J:81696
\Nr1h2tm1Djm/\Nr1h2tm1Djm
\Nr1h3tm1Djm/\Nr1h3tm1Djm

(involves: 129S6/SvEvTac * C57BL/6)
abnormal macrophage morphology J:125452
increased susceptibility to bacterial infection J:81696
\Nr1h3tm1Djm/\Nr1h3tm1Djm
(involves: 129S6/SvEvTac * C57BL/6)
increased inflammatory response J:158168
increased susceptibility to bacterial infection J:81696
\Nr1h3tm1Wexi/\Nr1h3tm1Wexi
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)
decreased susceptibility to endotoxin shock J:155709
\Nr1h4tm1.1Mbj/\Nr1h4tm1.1Mbj
(B6N.B6-Nr1h4tm1.1Mbj)
increased spleen weight J:200842
liver inflammation J:200842
\Nr1h4tm1Gonz/\Nr1h4tm1Gonz
(involves: 129X1/SvJ * C57BL/6)
liver inflammation J:118204
\Nr2c2tm1Amj/\Nr2c2tm1Amj
(B6.129-Nr2c2tm1Amj)
decreased inflammatory response J:169333
\Nr2f2tm2.1Tsa/\Nr2f2tm2.1Tsa
\Rbpjtm1Hon/\Rbpjtm1Hon
\Tg(Tek-cre)1Ywa/0

(involves: 129S1/Sv * 129S7/SvEvBrd * C57BL/6 * SJL)
decreased lymphatic vessel endothelial cell number J:158959
\Nr2f2tm2.1Tsa/\Nr2f2tm2.1Tsa
\Tg(Tek-cre)1Ywa/0

(involves: 129S1/Sv * 129S7/SvEvBrd * C57BL/6 * SJL)
decreased lymphatic vessel endothelial cell number J:158959
\Nr3c1tm1.1Jaci/\Nr3c1tm1.1Jaci
\Tg(Myh6-cre)2182Mds/0

(involves: C57BL/6 * FVB/N)
heart inflammation J:201995
\Nr3c1tm1.1Jda/\Nr3c1+
\Tg(Lck-cre)548Jxm/0

(B6.Cg-Nr3c1tm1.1Jda Tg(Lck-cre)548Jxm)
decreased thymocyte apoptosis J:189951
\Nr3c1tm1.1Jda/\Nr3c1tm1.1Jda
\Rag2tm1.1Cgn/\Rag2tm1.1Cgn
\Tg(Lck-cre)548Jxm/0
\Tg(TcrAND)53Hed/0

(B6.Cg-Rag2tm1.1Cgn Nr3c1tm1.1Jda Tg(Lck-cre)548Jxm Tg(TcrAND)53Hed)
decreased double-positive T cell number J:189951
\Nr3c1tm1.1Jda/\Nr3c1tm1.1Jda
\Tcratm1Mom/\Tcratm1Mom
\Tg(Lck-cre)548Jxm/0

(B6.Cg-Tcratm1Mom Nr3c1tm1.1Jda Tg(Lck-cre)548Jxm)
decreased double-positive T cell number J:189951
\Nr3c1tm1.1Jda/\Nr3c1tm1.1Jda
\Tg(Lck-cre)548Jxm/0

(B6.Cg-Nr3c1tm1.1Jda Tg(Lck-cre)548Jxm)
abnormal humoral immune response J:189951
decreased CD4-positive, alpha-beta T cell number J:189951
decreased CD8-positive, alpha-beta T cell number J:189951
decreased double-positive T cell number J:189951
decreased single-positive T cell number J:189951
decreased thymocyte apoptosis J:189951
thymus hypoplasia J:189951
\Nr3c1tm1Dage/\Nr3c1+
(involves: 129P1/ReJ * C57BL/6 * C57BL/6J * SJL)
decreased B cell number J:147914
\Nr3c1tm1Dage/\Nr3c1tm1Dage
(involves: 129P1/ReJ * C57BL/6 * C57BL/6J * SJL)
decreased B cell number J:147914
decreased CD4-positive, alpha-beta T cell number J:147914
decreased CD8-positive, alpha-beta T cell number J:147914
decreased macrophage cell number J:147914
\Nr3c1tm1Ljm/\Nr3c1tm1Ljm
(involves: 129S6/SvEvTac * C57BL/6)
abnormal thymocyte apoptosis J:82174
\Nr3c1tm2.1Gsc/\Nr3c1+
(B6.129P2-Nr3c1tm2.1Gsc)
decreased T cell apoptosis J:126427
increased susceptibility to experimental autoimmune encephalomyelitis J:137157
\Nr3c1tm2.1Ljm/\Nr3c1tm2.1Ljm
\Lyz2tm1(cre)Ifo/\Lyz2+

(involves: 129P2/OlaHsd * 129S6/SvEvTac)
abnormal interleukin-6 secretion J:197150
abnormal monocyte cell number J:197150
increased interleukin-1 beta secretion J:197150
\Nr3c1tm2Gsc/\Nr3c1tm2Gsc
\Lyz2tm1(cre)Ifo/\Lyz2+

(B6.129P2-Lyz2tm1(cre)Ifo Nr3c1tm2Gsc)
immune system phenotype J:137157
\Nr3c1tm2Gsc/\Nr3c1tm2Gsc
\Tg(Lck-cre)I57Jxm/0

(B6.Cg-Nr3c1tm2Gsc Tg(Lck-cre)I57Jxm)
decreased T cell apoptosis J:137157
increased susceptibility to experimental autoimmune encephalomyelitis J:137157
\Nr3c1tm2Ljm/\Nr3c1tm2Ljm
\Tg(Lck-cre)548Jxm/?

(involves: 129S6/SvEvTac * C57BL/6 * CBA)
abnormal interferon level J:97484
abnormal interleukin level J:97484
abnormal tumor necrosis factor level J:97484
cecum inflammation J:97484
increased susceptibility to endotoxin shock J:97484
\Nr4a1tm1Jmi/\Nr4a1tm1Jmi
(involves: 129S2/SvPas)
decreased B cell apoptosis J:306652
immune system phenotype J:77686
increased B cell proliferation J:306652
\Nr4a1tm1Jmi/\Nr4a1tm1Jmi
(involves: 129S2/SvPas * C57BL/6)
decreased Ly6C low monocyte number J:239509
increased susceptibility to endotoxin shock J:239509
\Nr4a1tm1Jmi/\Nr4a1tm1Jmi
\Nr4a3tm1Omc/\Nr4a3tm1Omc

(involves: 129S/SvEv * 129S2/SvPas * C57BL/6)
abnormal leukopoiesis J:121903
abnormal myelopoiesis J:121903
abnormal spleen morphology J:121903
abnormal thymus morphology J:121903
decreased lymphocyte cell number J:121903
enlarged lymph nodes J:121903
enlarged spleen J:121903
increased eosinophil cell number J:121903
increased granulocyte number J:121903
increased leukocyte cell number J:121903
increased neutrophil cell number J:121903
\Nr4a1tm1Pcn/\Nr4a1tm1Pcn
\Foxp3tm4(YFP/icre)Ayr/\Foxp3+

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
immune system phenotype J:205658
\Nr4a1tm1Pcn/\Nr4a1tm1Pcn
\Tg(Cr2-cre)3Cgn/0

(involves: 129)
increased B cell proliferation J:306652
\Nr4a2tm1.1Pcn/\Nr4a2+
\Foxp3tm4(YFP/icre)Ayr/\Foxp3+

(involves: 129S1/Sv * 129X1/SvJ)
abnormal regulatory T cell morphology J:205658
\Nr4a2tm1.1Pcn/\Nr4a2tm1.1Pcn
\Gt(ROSA)26Sortm9(cre/ESR1)Arte/\Gt(ROSA)26Sor+

(involves: C57BL/6 * C57BL/6NTac)
abnormal regulatory T cell morphology J:205658
abnormal T-helper 1 cell differentiation J:205658
abnormal T-helper 17 cell differentiation J:205658
\Nr4a2tm1.1Pcn/\Nr4a2tm1.1Pcn
\Tg(Lck-cre)1Jtak/0

(Not Specified)
abnormal regulatory T cell morphology J:205658
abnormal T-helper 1 cell differentiation J:205658
abnormal T-helper 17 cell differentiation J:205658
decreased regulatory T cell number J:205658
immune system phenotype J:205658
increased CD4-positive, alpha-beta T cell number J:205658
increased susceptibility to induced colitis J:205658
increased T-helper 1 cell number J:205658
\Nr5a2tm1Auw/\Nr5a2+
(involves: 129P2/OlaHsd)
increased susceptibility to induced colitis J:123697
\Nr5a2tm1Sjns/\Nr5a2tm1Sjns
\Tg(Vil1-cre/ERT2)23Syr/?

(involves: 129/Sv * C57BL/6 * DBA/2 * SJL)
increased susceptibility to induced colitis J:123697
\Nrastm1.1Emfu/\Nrastm1.1Emfu
(involves: 129S1/Sv * FVB/N)
abnormal granulocyte differentiation J:189834
abnormal leukocyte cell number J:189834
abnormal thymus morphology J:189834
decreased monocyte cell number J:189834
decreased spleen weight J:189834
increased granulocyte number J:189834
increased T cell number J:189834
\Nrastm1Tyj/\Nrastm1Tyj
\Tg(Mx1-cre)1Cgn/0

(involves: C57BL/6 * CBA)
abnormal myelopoiesis J:174880
enlarged spleen J:204263, J:174880
increased leukocyte cell number J:204263
increased monocyte cell number J:204263
increased neutrophil cell number J:204263
myeloid hyperplasia J:204263
\Nrbp1tm3b(EUCOMM)Wtsi/\Nrbp1+
(C57BL/6N-Nrbp1tm3b(EUCOMM)Wtsi/Wtsi)
decreased CD4-positive, alpha-beta T cell number J:211773
increased CD8-positive, alpha-beta T cell number J:211773
\Nrp1tm1Ddg/\Nrp1tm1Ddg
(involves: 129P2/OlaHsd)
abnormal dendritic cell physiology J:161856
abnormal T cell physiology J:161856
\Nrp2tm1.2Mom/\Nrp2+
\Sema3ftm1.2Ddg/\Sema3f+

(involves: 129P2/OlaHsd)
abnormal lymphatic vessel endothelial cell morphology J:226501
\Nrp2tm1.2Mom/\Nrp2tm1.2Mom
(involves: 129P2/OlaHsd)
abnormal lymphatic system physiology J:226501
abnormal lymphatic vessel endothelial cell morphology J:226501
abnormal lymphatic vessel morphology J:226501
lymphatic vessel hyperplasia J:226501
\Nrp2tm1Ddg/\Nrp2tm1Ddg
(involves: C57BL/6)
abnormal lymphangiogenesis J:156869
\Nrrostm1Lex/\Nrrostm1Lex
(B6.129S5-Nrrostm1Lex)
decreased susceptibility to infection J:209569
increased susceptibility to experimental autoimmune encephalomyelitis J:209569
\Nrsn2em1(IMPC)Kmpc/\Nrsn2em1(IMPC)Kmpc
(C57BL/6NTac-Nrsn2em1(IMPC)Kmpc/Kmpc)
abnormal lymph node morphology J:211773
\Nrtntm1Jmi/\Nrtntm1Jmi
(involves: 129X1/SvJ * C57BL/6)
increased incidence of corneal inflammation J:85753
keratoconjunctivitis sicca J:85753
\Nrxn1tm1b(KOMP)Wtsi/\Nrxn1+
(C57BL/6N-Nrxn1tm1b(KOMP)Wtsi/H)
increased neutrophil cell number J:211773
\Nrxn1tm1b(KOMP)Wtsi/\Nrxn1tm1b(KOMP)Wtsi
(C57BL/6N-Nrxn1tm1b(KOMP)Wtsi/H)
decreased lymphocyte cell number J:211773
increased monocyte cell number J:211773
increased neutrophil cell number J:211773
\Nsd3tm1b(EUCOMM)Hmgu/\Nsd3tm1b(EUCOMM)Hmgu
(C57BL/6N-Nsd3tm1b(EUCOMM)Hmgu/H)
small spleen J:211773
\Nsg1tm1.1(KOMP)Vlcg/\Nsg1tm1.1(KOMP)Vlcg
(C57BL/6N-Nsg1tm1.1(KOMP)Vlcg/Ucd)
increased basophil cell number J:211773
increased eosinophil cell number J:211773
increased leukocyte cell number J:211773
increased lymphocyte cell number J:211773
increased monocyte cell number J:211773
increased neutrophil cell number J:211773
\Nsl1em1(IMPC)J/\Nsl1+
(C57BL/6NJ-Nsl1em1(IMPC)J/Mmjax)
decreased leukocyte cell number J:211773
\Nsmaftm1Mkr/\Nsmaftm1Mkr
(involves: 129P2/OlaHsd)
abnormal T cell physiology J:54972
immune system phenotype J:54972
\Nsmaftm1Mkr/\Nsmaftm1Mkr
(B6.129P2-Nsmaftm1Mkr)
decreased susceptibility to endotoxin shock J:89524
\Nsmce1em1(IMPC)Wtsi/\Nsmce1+
(C57BL/6N-Nsmce1em1(IMPC)Wtsi/Wtsi)
abnormal spleen morphology J:211773
enlarged spleen J:211773
\Nsmce2tm2.1Ofc/\Nsmce2tm2.1Ofc
\Ndor1Tg(UBC-cre/ERT2)1Ejb/0

(involves: 129S/SvEv * C57BL/6 * SJL)
abnormal thymus physiology J:227197
\Nsrp1tm1.1Cdj/\Nsrp1tm1.1Cdj
\Tg(Cd4-cre)1Cwi/0

(involves: C57BL/6 * DBA/2 * SJL)
abnormal T cell number J:306261
decreased CD4-positive, alpha-beta T cell number J:306261
decreased CD8-positive, alpha-beta T cell number J:306261
immune system phenotype J:306261
increased memory T cell number J:306261
increased T cell apoptosis J:306261
increased T cell proliferation J:306261
\Nss1NOD/ShiLtJ/\Nss1NOD/ShiLtJ
(involves: C57BL/10 * NOD)
salivary gland inflammation J:73932
\Nsun2tm1a(EUCOMM)Wtsi/\Nsun2tm1a(EUCOMM)Wtsi
(B6JTyr;B6N-Nsun2tm1a(EUCOMM)Wtsi/Wtsi)
abnormal thymus capsule morphology J:239583
\Nsun5tm2b(EUCOMM)Wtsi/\Nsun5tm2b(EUCOMM)Wtsi
(C57BL/6N-Nsun5tm2b(EUCOMM)Wtsi/J)
decreased lymphocyte cell number J:211773
decreased spleen weight J:211773
increased neutrophil cell number J:211773
\Nsv1C57BL/6J/?
(involves: BALB/cBy * C57BL/6J)
increased susceptibility to viral infection J:71216
\Nt5c3em1(IMPC)Tcp/\Nt5c3em1(IMPC)Tcp
(C57BL/6NCrl-Nt5c3em1(IMPC)Tcp/Tcp)
enlarged lymph nodes J:211773
\Nt5eem1(IMPC)Mbp/\Nt5eem1(IMPC)Mbp
(C57BL/6NCrl-Nt5eem1(IMPC)Mbp/MbpMmucd)
abnormal spleen morphology J:211773
enlarged spleen J:211773
\Ntan1tm1Avar/\Ntan1tm1Avar
(involves: 129)
abnormal T cell physiology J:62140
decreased splenocyte proliferation J:62140
increased acute inflammation J:62140
\Ntaq1tm1.1(KOMP)Vlcg/\Ntaq1tm1.1(KOMP)Vlcg
(C57BL/6N-Ntaq1tm1.1(KOMP)Vlcg/J)
increased leukocyte cell number J:211773
\Ntn4tm1b(KOMP)Wtsi/\Ntn4tm1b(KOMP)Wtsi
(C57BL/6N-Ntn4tm1b(KOMP)Wtsi/Wtsi)
abnormal spleen morphology J:211773
\Ntrk1tm1b(EUCOMM)Wtsi/\Ntrk1+
(C57BL/6N-Ntrk1tm1b(EUCOMM)Wtsi/H)
increased basophil cell number J:211773
\Ntrk1tm1Tes/\Ntrk1tm1Tes
\Tg(Tuba1-cre)1Tes/0

(involves: 129S1/Sv)
abnormal mast cell physiology J:93578
increased B-1 B cell number J:93578
increased IgG1 level J:93578
increased IgG2a level J:93578
increased IgM level J:93578
increased immunoglobulin level J:93578
\Nub1tm1b(EUCOMM)Hmgu/\Nub1tm1b(EUCOMM)Hmgu
(C57BL/6N-Nub1tm1b(EUCOMM)Hmgu/Ccpcz)
abnormal spleen morphology J:211773
decreased CD4-negative NK T cell number J:211773
decreased CD4-positive, alpha-beta T cell number J:211773
decreased CD5-positive Ly6C-positive T cell number J:211773
decreased CD8-positive, alpha-beta T cell number J:211773
decreased CD11b-high dendritic cell number J:211773
decreased Ly6C-positive NK T cell number J:211773
decreased memory-marker CD4-negative NK T cell number J:211773
decreased NK cell number J:211773
decreased NK T cell number J:211773
enlarged spleen J:211773
immune system phenotype J:211773
increased effector memory CD8-positive, alpha-beta T cell number J:211773
increased effector memory T-helper cell number J:211773
increased Ly6C-positive NK T cell number J:211773
\Nucb1em1(IMPC)Mbp/\Nucb1em1(IMPC)Mbp
(C57BL/6NCrl-Nucb1em1(IMPC)Mbp/Mmucd)
abnormal lymph node morphology J:211773
abnormal spleen morphology J:211773
enlarged spleen J:211773
\Nucb2tm1.2Vdix/\Nucb2tm1.2Vdix
(involves: C57BL/6)
increased interleukin-1 beta secretion J:270674
increased tumor necrosis factor secretion J:270674
\Nucks1tm1b(EUCOMM)Hmgu/\Nucks1tm1b(EUCOMM)Hmgu
(C57BL/6N-Nucks1tm1b(EUCOMM)Hmgu/Ieg)
enlarged lymph nodes J:211773
increased leukocyte cell number J:211773
\Nudctm1c(KOMP)Mbp/\Nudctm1c(KOMP)Mbp
\Tg(Rho-icre)1Ck/0

(involves: C57BL/6 * C57BL/6N * SJL)
increased microglial cell activation J:346299
\Nudcd3em1(IMPC)Wtsi/\Nudcd3em1(IMPC)Wtsi
(C57BL/6N-Nudcd3em1(IMPC)Wtsi/Wtsi)
abnormal immunoglobulin light chain V-J recombination J:351330
abnormal T cell differentiation J:351330
abnormal T cell receptor V(D)J recombination J:351330
decreased NK T cell number J:351330
increased DN3 thymocyte number J:351330
increased double-negative T cell number J:351330
increased double-positive T cell number J:351330
increased IgE level J:351330
increased IgG2b level J:351330
increased IgM level J:351330
increased memory T cell number J:351330
increased pre-B cell number J:351330
thymus hypoplasia J:351330
\Nudt1tm1Tts/\Nudt1tm1Tts
\Ogg1tm1Yun/\Ogg1tm1Yun

(involves: 129S/SvEv * C57BL/6JJcl)
microgliosis J:193978
\Nudt2tm1a(EUCOMM)Wtsi/\Nudt2tm1a(EUCOMM)Wtsi
(C57BL/6-Nudt2tm1a(EUCOMM)Wtsi)
immune system phenotype J:315167
\Nudt7em1Ejj/\Nudt7em1Ejj
(involves: C57BL/6N)
increased susceptibility to induced arthritis J:266261
osteoarthritis J:266261
\Nudt15em1Maska/\Nudt15+
(C57BL/6-Nudt15em1Maska)
decreased neutrophil cell number J:285800
\Nudt15em1Maska/\Nudt15em1Maska
(C57BL/6-Nudt15em1Maska)
decreased neutrophil cell number J:285800
\Nudt21tm1.1Ejwpj/\Nudt21tm1.1Ejwpj
\Tg(Col1a1-cre/ERT2)1Crm/0

(involves: C57BL/6J * CBA/J)
increased acute inflammation J:283035
\Nuggcem1(IMPC)Ccpcz/\Nuggcem1(IMPC)Ccpcz
(C57BL/6NCrl-Nuggcem1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged thymus J:211773
\Nuggctm1Diaz/\Nuggctm1Diaz
\Edil3Tg(Sox2-cre)1Amc/\Edil3+

(involves: C57BL/6 * C57BL/6J * CBA)
abnormal somatic hypermutation frequency J:190402
immune system phenotype J:190402
\Nup35m1Apb/\Nup35m1Apb
(involves: C57BL/6N)
abnormal macrophage morphology J:235141
\Nup62clem1(IMPC)J/Y
(C57BL/6NJ-Nup62clem1(IMPC)J/Mmjax)
increased leukocyte cell number J:211773
\Nup85tm1.1Yter/\Nup85tm1.1Yter
\Tg(CAG-cre/Esr1*)5Amc/0

(involves: C57BL/6 * CBA)
decreased Ly6C high monocyte number J:292726
decreased Ly6C low monocyte number J:292726
decreased macrophage cell number J:292726
\Nup98tm1Bmaf/\Nup98+
(involves: 129S6/SvEvTac * C57BL/6)
abnormal level of surface class I molecules J:110907
abnormal level of surface class II molecules J:110907
abnormal MHC II cell surface expression on macrophages J:110907
decreased B cell number J:110907
decreased CD4-positive, alpha-beta T cell number J:110907
decreased IgG1 level J:110907
decreased IgG level J:110907
decreased T cell proliferation J:110907
increased T cell proliferation J:110907
\Nup155em1(IMPC)Mbp/\Nup155+
(C57BL/6NCrl-Nup155em1(IMPC)Mbp/Mmucd)
abnormal lymph node morphology J:211773
abnormal spleen morphology J:211773
enlarged lymph nodes J:211773
enlarged spleen J:211773
\Nup210enuI476T/\Nup210enuI476T
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
abnormal alpha-beta T cell morphology J:266693
decreased CD4-positive, alpha-beta T cell number J:266693
\Nup210enuI476T/\Nup210tm1a(EUCOMM)Hmgu
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6N)
decreased CD4-positive, alpha-beta T cell number J:266693
\Nup210tm1.1Mdan/\Nup210tm1.1Mdan
(B6.Cg-Nup210tm1.1Mdan)
abnormal CD4-positive, alpha-beta T cell number J:282451
abnormal CD4-positive, alpha-beta T cell physiology J:282451
abnormal lymphocyte morphology J:282451
abnormal T cell activation J:282451
decreased CD4-positive, alpha-beta T cell number J:282451
decreased leukocyte cell number J:282451
increased effector memory T-helper cell number J:282451
\Nup210tm1b(EUCOMM)Hmgu/\Nup210tm1b(EUCOMM)Hmgu
(involves: C57BL/6N)
decreased alpha-beta T cell number J:266693
decreased CD4-positive, alpha-beta T cell number J:266693
decreased CD8-positive, alpha-beta T cell number J:266693
decreased T cell number J:266693
immune system phenotype J:266693
increased CD4-positive, CD25-positive, alpha-beta regulatory T cell number J:266693
increased CD8-positive, alpha-beta T cell number J:266693
increased central memory CD8 positive, alpha-beta T cell number J:266693
increased T-helper 1 cell number J:266693
\Nup210tm1Mdan/\Nup210tm1Mdan
\Tg(Cd4-cre/ERT2)11Gnri/0

(involves: 129X1/SvJ * C57BL/6)
abnormal CD4-positive, alpha-beta T cell physiology J:282451
\Nus1tm1Wcsa/\Nus1tm1Wcsa
\Tg(Cdh5-cre/ERT2)1Rha/0

(Not Specified)
abnormal jugular lymph sac morphology J:230506
\Nwa2NZW/LacJ/\Nwa2NZW/LacJ
(involves: BALB/cJ * NZW/LacJ)
increased anti-histone antibody level J:35434
increased anti-single stranded DNA antibody level J:35434
\Nwd1em2.1Sisa/\Nwd1em2.1Sisa
(involves: C57BL/6 * C57BL/6N * DBA/2)
abnormal Kupffer cell morphology J:363603
increased leukocyte cell number J:363603
\Nwd2em1(IMPC)Ccpcz/\Nwd2em1(IMPC)Ccpcz
(C57BL/6N-Nwd2em1(IMPC)Ccpcz/Ccpcz)
decreased CD8-positive, naive alpha-beta T cell number J:211773
\Nxntm1b(EUCOMM)Wtsi/\Nxn+
(C57BL/6N-Nxntm1b(EUCOMM)Wtsi/Ccpcz)
increased effector memory CD8-positive, alpha-beta T cell number J:211773
\Nxnl1tm1.2Tlev/\Nxnl1tm1.2Tlev
(involves: BALB/c * BALB/cJ * C57BL/6)
microgliosis J:186370
\Nxnl2em1(IMPC)Ccpcz/\Nxnl2+
(C57BL/6NCrl-Nxnl2em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged spleen J:211773
enlarged thymus J:211773
\Nxnl2em1(IMPC)Ccpcz/\Nxnl2em1(IMPC)Ccpcz
(C57BL/6NCrl-Nxnl2em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged spleen J:211773
enlarged thymus J:211773
\Oas1bFlv-mr/\Oas1bFlv-mr
(MOLD/RkJ)
decreased susceptibility to Flaviviridae infection J:3674
\Oas1bFlv-r/\Oas1bFlv-r
(multiple strains)
decreased susceptibility to Flaviviridae infection J:15009
\Oas1bFlv-r/\Oas1bFlv-r
(C3.PRI-Oas1bFlv-r)
decreased susceptibility to Flaviviridae infection J:175365
\Oas1bFlv-s/\Oas1bFlv-s
(multiple strains)
increased susceptibility to Flaviviridae infection J:15009
\Oas1btm1.1Brin/\Oas1btm1.1Brin
(involves: 129X1/SvJ * C57BL/6J)
decreased susceptibility to Flaviviridae infection J:175365
\Oas1cem1(IMPC)Ccpcz/\Oas1cem1(IMPC)Ccpcz
(C57BL/6N-Oas1cem1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged thymus J:211773
small spleen J:211773
\Oasl1tm1Yjk/\Oasl1tm1Yjk
(B6.129P2-Oasl1tm1Yjk)
abnormal circulating interferon level J:194467
decreased susceptibility to Picornaviridae infection J:194467
decreased susceptibility to Picornaviridae infection induced morbidity/mortality J:194467
\Obp2bem1(IMPC)Kmpc/\Obp2bem1(IMPC)Kmpc
(C57BL/6NTac-Obp2bem1(IMPC)Kmpc/Kmpc)
abnormal lymph node morphology J:211773
\Oca2p-3Btlr/\Oca2p-3Btlr
(C57BL/6J-Oca2p-3Btlr)
abnormal NK cell physiology J:133623
increased susceptibility to bacterial infection J:133623
\Oca2p-4Btlr/\Oca2p-4Btlr
(C57BL/6J-Oca2p-4Btlr)
immune system phenotype J:133624
increased susceptibility to bacterial infection J:133624
\Oca2p-8Btlr/\Oca2p-8Btlr
(C57BL/6J-Oca2p-8Btlr)
increased susceptibility to induced colitis J:264643
\Oca2p-23DFiOD/\Oca2p-x
(Not Specified)
increased spleen weight J:66645
\Oca2p-30PUb/\Oca2p-x
(Not Specified)
increased spleen weight J:89922
\Oca2p-Btlr/\Oca2p-Btlr
(C57BL/6J-Oca2p-Btlr)
immune system phenotype J:133621
\Ociad1em1(IMPC)J/\Ociad1em1(IMPC)J
(C57BL/6NJ-Ociad1em1(IMPC)J/Mmjax)
increased leukocyte cell number J:211773
\Ociad1tm1.1Msin/\Ociad1tm1.1Msin
(involves: BALB/cJ * C57BL/6NCrlj * CBA/JNCrlj)
decreased B cell number J:279239
decreased T cell number J:279239
enlarged spleen J:279239
increased granulocyte number J:279239
increased macrophage cell number J:279239
increased monocyte cell number J:279239
increased neutrophil cell number J:279239
increased spleen germinal center size J:279239
\OclnGt(ROSA)39Tshi/\OclnGt(ROSA)39Tshi
(involves: DBA/2)
stomach inflammation J:110222
\Oclntm1Sts/\Oclntm1Sts
(involves: 129S4/SvJae * C57BL/6)
stomach inflammation J:99467
\Oclntm1Tshi/\Oclntm1Tshi
(involves: C57BL/6 * DBA/2)
stomach inflammation J:110222
\Oclntm2Sts/\Oclntm2Sts
(involves: 129S4/SvJae * C57BL/6)
stomach inflammation J:99467
\Ocstamptm2a(KOMP)Wtsi/\Ocstamptm2a(KOMP)Wtsi
(involves: C57BL/6J * C57BL/6N)
abnormal osteoclast morphology J:233553
\Odad2b2b227.1Clo/\Odad2b2b227.1Clo
(C57BL/6J-Odad2b2b227.1Clo)
spleen hypoplasia J:175213
\Odad2em1(IMPC)Mbp/\Odad2em1(IMPC)Mbp
(C57BL/6N-Odad2em1(IMPC)Mbp/MbpMmucd)
small spleen J:211773
\Odad3b2b1885Clo/\Odad3b2b1885Clo
(C57BL/6J-Odad3b2b1885Clo)
spleen hypoplasia J:175213
\Odad3tm1b(EUCOMM)Hmgu/\Odad3tm1b(EUCOMM)Hmgu
(C57BL/6N-Odad3tm1b(EUCOMM)Hmgu/Cnrm)
abnormal spleen morphology J:278798
absent spleen J:278798
enlarged spleen J:278798
\Odaphem1(IMPC)Ccpcz/\Odaphem1(IMPC)Ccpcz
(C57BL/6NCrl-Odaphem1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged thymus J:211773
\Odf2tm1.1Sats/\Odf2tm1.2Sats
\Tg(CAG-cre)13Miya/0

(involves: C57BL/6 * C57BL/6J)
immune system phenotype J:181294
increased susceptibility to otitis media J:181294
sinus inflammation J:181294
\oed/\oed
(STOCK pc-oed)
increased granulocyte number J:5609
increased leukocyte cell number J:5609
\Ogdhtm1e(KOMP)Wtsi/\Ogdh+
(C57BL/6N-Ogdhtm1e(KOMP)Wtsi/Wtsi)
blood in lymph vessels J:239583
\Ogg1tm1Yun/\Ogg1tm1Yun
(involves: 129S/SvEv * C57BL/6JJcl)
microgliosis J:193978
\Ogntm1b(KOMP)Wtsi/\Ogntm1b(KOMP)Wtsi
(C57BL/6N-Ogntm1b(KOMP)Wtsi/J)
decreased leukocyte cell number J:211773
\Ogttm1Gwh/Y
\Tg(Lck-cre)548Jxm/0

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA)
decreased CD4-positive, alpha-beta T cell number J:93112
decreased CD8-positive, alpha-beta T cell number J:93112
decreased double-positive T cell number J:93112
decreased T cell number J:93112
decreased thymocyte number J:93112
increased T cell apoptosis J:93112
\oh/\oh
(Not Specified)
increased macrophage cell number J:5300
\Olahem1Kedk/\Olahem1Kedk
(involves: C57BL/6)
abnormal macrophage morphology J:353571
abnormal macrophage physiology J:353571
decreased susceptibility to Orthomyxoviridae infection J:353571
decreased susceptibility to Orthomyxoviridae infection induced morbidity/mortality J:353571
spleen hyperplasia J:353571
\Olfm4tm1Gpro/\Olfm4tm1Gpro
(involves: 129X1/SvJ * Black Swiss)
abnormal cytokine level J:161279
increased circulating interleukin-3 level J:161279
increased circulating interleukin-12 level J:161279
increased susceptibility to bacterial infection J:161279
stomach inflammation J:161279
\Olr1tm1Meht/\Olr1tm1Meht
(B6.129X1-Olr1tm1Meht/Meht)
increased circulating interleukin-10 level J:130794
\Oma1tm1Otin/\Oma1tm1Otin
(involves: 129S6/SvEvTac * C57BL/6 * C57BL/6NCr)
granulomatous inflammation J:184716
\Onecut1tm1.1Mga/\Onecut1tm1.1Mga
\Tg(Pdx1-cre)89.1Dam/0

(involves: 129S6/SvEvTac * C57BL/6 * CBA * SJL)
pancreas inflammation J:155058
\Opn3em1(IMPC)Mbp/\Opn3em1(IMPC)Mbp
(C57BL/6NCrl-Opn3em1(IMPC)Mbp/Mmucd)
decreased leukocyte cell number J:211773
increased basophil cell number J:211773
\Oprl1em1(IMPC)Mbp/\Oprl1em1(IMPC)Mbp
(C57BL/6N-Oprl1em1(IMPC)Mbp/MbpMmucd)
enlarged spleen J:211773
\Oprm1tm1Lyu/\Oprm1+
(involves: Black Swiss)
increased splenocyte proliferation J:39864
\Oprm1tm1Lyu/\Oprm1tm1Lyu
(involves: Black Swiss)
increased splenocyte proliferation J:39864
\Optntm1.2Jda/\Optntm1.2Jda
(involves: 129S4/SvJae * C57BL/6J)
immune system phenotype J:207113
\Optntm1.2Jda/\Optntm1.2Jda
(B6.Cg-Optntm1.2Jda)
immune system phenotype J:207113
\Or1e1cem1(IMPC)Mbp/\Or1e1cem1(IMPC)Mbp
(C57BL/6NCrl-Or1e1cem1(IMPC)Mbp/Mmucd)
abnormal spleen morphology J:211773
enlarged spleen J:211773
\Or1e32em1(IMPC)Mbp/\Or1e32em1(IMPC)Mbp
(C57BL/6NCrl-Or1e32em1(IMPC)Mbp/Mmucd)
abnormal lymph node morphology J:211773
enlarged lymph nodes J:211773
\Or9g4em1(IMPC)Mbp/\Or9g4em1(IMPC)Mbp
(C57BL/6N-Or9g4em1(IMPC)Mbp/MbpMmucd)
abnormal lymph node morphology J:211773
abnormal spleen morphology J:211773
enlarged lymph nodes J:211773
enlarged spleen J:211773
\Orai1Gt(XL922)Byg/\Orai1+
(involves: 129P2/OlaHsd * C57BL/6 * DBA/2)
abnormal mast cell physiology J:130479
decreased interferon-gamma secretion J:130479
\Orai1Gt(XL922)Byg/\Orai1Gt(XL922)Byg
(involves: 129P2/OlaHsd * C57BL/6 * DBA/2)
abnormal mast cell physiology J:130479
decreased interferon-gamma secretion J:130479
decreased interleukin-2 secretion J:130479
decreased susceptibility to type I hypersensitivity reaction J:130479
\Orai1tm1.1Hjm/\Orai1tm1.1Hjm
\Orai2tm1.1(KOMP)Vlcg/\Orai2tm1.1(KOMP)Vlcg
\Tg(Cd4-cre)1Cwi/0

(B6.Cg-Tg(Cd4-cre)1Cwi Orai1tm1.1Hjm Orai2tm1.1(KOMP)Vlcg)
abnormal CD4-positive helper T cell morphology J:241365
abnormal T cell physiology J:241365
decreased germinal center B cell number J:241365
decreased IgG level J:241365
decreased regulatory T cell number J:241365
decreased single-positive T cell number J:241365
immune system phenotype J:241365
lymph node hyperplasia J:241365
spleen hyperplasia J:241365
\Orai1tm1.1Hjm/\Orai1tm1.1Hjm
\Tg(Cd4-cre)1Cwi/0

(B6.Cg-Orai1tm1.1Hjm Tg(Cd4-cre)1Cwi)
abnormal T cell physiology J:241365
\Orai1tm1Rao/\Orai1+
(C57BL/6-Orai1tm1Rao)
abnormal B cell activation J:139730
abnormal T cell activation J:139730
\Orai1tm1Rao/\Orai1tm1Rao
(involves: C57BL/6NTac * ICR)
abnormal B cell activation J:139730
abnormal cell-mediated immunity J:139730
abnormal cytokine secretion J:139730
abnormal mast cell physiology J:139730
abnormal T cell activation J:139730
abnormal thymocyte activation J:139730
blepharitis J:139730
decreased interferon-gamma secretion J:139730
decreased interleukin-2 secretion J:139730
decreased interleukin-4 secretion J:139730
decreased interleukin-10 secretion J:139730
\Orai2tm1.1(KOMP)Vlcg/\Orai2tm1.1(KOMP)Vlcg
(B6.Cg-Orai2tm1.1(KOMP)Vlcg)
abnormal macrophage physiology J:241365
abnormal T cell physiology J:241365
\Orai2tm1.1Itl/\Orai2tm1.1Itl
\Tg(Cma1-cre)#Roer/0

(involves: 129S4/SvJaeSor * C57BL/6 * C57BL/6N)
increased susceptibility to type I hypersensitivity reaction J:278536
\Orai2tm1.2Itl/\Orai2tm1.2Itl
(involves: 129S4/SvJaeSor * BALB/cJ * C57BL/6 * C57BL/6N)
abnormal mast cell physiology J:278536
increased mast cell degranulation J:278536
\Orch4BALB/cByJ/\Orch4BALB/cByJ
(involves: BALB/cByJ * DBA/2)
testis inflammation J:35331
\Orch4BALB/cByJ/\Orch4DBA/2J
(involves: BALB/cByJ * DBA/2)
decreased inflammatory response J:35331
\Orch4DBA/2J/\Orch4DBA/2J
(involves: BALB/cByJ * DBA/2)
decreased inflammatory response J:35331
\Orch5BALB/cByJ/\Orch5BALB/cByJ
(involves: BALB/cByJ * DBA/2)
testis inflammation J:35331
\Orch5BALB/cByJ/\Orch5DBA/2J
(involves: BALB/cByJ * DBA/2)
decreased inflammatory response J:35331
\Orch5DBA/2J/\Orch5DBA/2J
(involves: BALB/cByJ * DBA/2)
decreased inflammatory response J:35331
\Orgwq1M16i/?
(involves: CAST/Ei * M16i)
increased spleen weight J:78471
\Orgwq2M16i/?
(involves: CAST/Ei * M16i)
increased spleen weight J:78471
\Orgwq6M16i/?
(involves: CAST/Ei * M16i)
increased spleen weight J:78471
\Orgwq7M16i/?
(involves: CAST/Ei * M16i)
increased spleen weight J:78471
\Orgwq8M16i/?
(involves: CAST/Ei * M16i)
increased spleen weight J:78471
\Orm2em1Bcgen/\Orm2em1Bcgen
(involves: C57BL/6J)
liver inflammation J:333118
\Orm2tm1(KOMP)Vlcg/\Orm2tm1(KOMP)Vlcg
(C57BL/6N-Orm2tm1(KOMP)Vlcg/Mmucd)
kidney inflammation J:292194
\Ormdl1em1Pdra/\Ormdl1em1Pdra
(C57BL/6J-Ormdl1em1Pdra)
immune system phenotype J:349248
\Ormdl1em1Pdra/\Ormdl1em1Pdra
\Ormdl2em1Pdra/\Ormdl2em1Pdra

(C57BL/6-Ormdl1em1Pdra Ormdl2em1Pdra)
immune system phenotype J:349248
\Ormdl1em1Pdra/\Ormdl1em1Pdra
\Ormdl3em1Pdra/\Ormdl3em1Pdra

(C57BL/6-Ormdl1em1Pdra Ormdl3em1Pdra)
abnormal mast cell physiology J:349248
\Ormdl2em1Pdra/\Ormdl2em1Pdra
(C57BL/6-Ormdl2em1Pdra)
immune system phenotype J:349248, J:328837
\Ormdl2em1Pdra/\Ormdl2em1Pdra
\Ormdl3em1Pdra/\Ormdl3em1Pdra

(C57BL/6-Ormdl2em1Pdra Ormdl3em1Pdra)
abnormal mast cell physiology J:328837
abnormal type I hypersensitivity reaction J:328837
increased interleukin-4 secretion J:328837
increased interleukin-6 secretion J:328837
increased mast cell degranulation J:328837
increased tumor necrosis factor secretion J:328837
\Ormdl3em1Pdra/\Ormdl3em1Pdra
(C57BL/6-Ormdl3em1Pdra)
abnormal mast cell physiology J:328837
abnormal type I hypersensitivity reaction J:328837
increased mast cell degranulation J:328837
\Ormdl3em1Quli/\Ormdl3em1Quli
(Not Specified)
abnormal spleen morphology J:251260
abnormal splenic cell ratio J:251260
small spleen J:251260
\Os/\Os+
(ROP/GnLeJ)
glomerulonephritis J:28323
\Osbpem1(IMPC)Tcp/\Osbp+
(C57BL/6NCrl-Osbpem1(IMPC)Tcp/Cmmr)
enlarged lymph nodes J:211773
\Oscartm1Ywc/\Oscartm1Ywc
(involves: 129P2/OlaHsd)
abnormal osteoclast differentiation J:178250
\Oscartm1Ywc/\Oscartm1Ywc
\Tyrobptm1Ttk/\Tyrobptm1Ttk

(involves: 129P2/OlaHsd * C57BL/6)
abnormal osteoclast differentiation J:178250
abnormal osteoclast morphology J:178250
abnormal osteoclast physiology J:178250
decreased osteoclast cell number J:178250
\Osmrtm1Mtan/\Osmrtm1Mtan
(B6.129S-Osmrtm1Mtan)
increased circulating interleukin-10 level J:214124
increased circulating tumor necrosis factor level J:214124
increased inflammatory response J:214124
white adipose tissue inflammation J:214124
\Ostm1gl/\Ostm1gl
(GL/Le Edardl-J +/+ Ostm1gl/J)
eye inflammation J:13053
\Otcem1(IMPC)Tcp/\Otc+
(C57BL/6NCrl-Otcem1(IMPC)Tcp/Tcp)
enlarged thymus J:211773
\Otcspf-ash/Y
(involves: C57BL/6)
increased susceptibility to parasitic infection J:23205
\Otcspf-ash/Y
(B6EiC3Sn a/A-Otcspf-ash/J)
increased susceptibility to endotoxin shock J:108979
\Otop1em1(IMPC)Ccpcz/\Otop1em1(IMPC)Ccpcz
(C57BL/6NCrl-Otop1em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged thymus J:211773
\Otub1tm1c(EUCOMM)Hmgu/\Otub1tm1c(EUCOMM)Hmgu
\Cd19tm1(cre)Cgn/\Cd19+

(involves: 129P2/OlaHsd * C57BL/6 * C57BL/6N)
abnormal B cell activation J:280549
abnormal follicular B cell morphology J:280549
decreased B-1 B cell number J:280549
decreased immature B cell number J:280549
decreased T cell number J:280549
enlarged spleen J:280549
increased anti-double stranded DNA antibody level J:280549
increased anti-nuclear antigen antibody level J:280549
increased B cell number J:280549
increased B-2 B cell number J:280549
increased circulating interleukin-6 level J:280549
increased IgA level J:280549
increased IgG2a level J:280549
increased IgG2b level J:280549
increased IgM level J:280549
increased immunoglobulin level J:280549
increased marginal zone B cell number J:280549
increased mature B cell number J:280549
increased susceptibility to autoimmune disorder J:280549
increased susceptibility to systemic lupus erythematosus J:280549
\Otud1em2Gpt/\Otud1em2Gpt
(C57BL/6-Otud1em2Gpt)
abnormal innate immunity J:287309
decreased susceptibility to Herpesvirales infection J:287309
decreased susceptibility to Riboviria infection J:287309
increased circulating interferon-beta level J:287309
increased susceptibility to endotoxin shock J:287309
\Otud3em1Nju/\Otud3em1Nju
(involves: C57BL/6N)
abnormal chemokine secretion J:294274
decreased susceptibility to Riboviria infection J:294274
decreased susceptibility to Riboviria infection induced morbidity/mortality J:294274
increased interferon-beta secretion J:294274
\Otud5tm1Vmd/\Otud5tm1Vmd
\Tg(Cd4-cre)1Cwi/0

(involves: C57BL/6 * DBA/2)
abnormal T-helper 17 cell differentiation J:219495
decreased regulatory T cell number J:219495
decreased thymocyte number J:219495
immune system phenotype J:219495
increased circulating interleukin-17 level J:219495
increased interleukin-9 secretion J:219495
increased interleukin-17 secretion J:219495
increased interleukin-21 secretion J:219495
intestinal inflammation J:219495
\Otud5tm1Vmd/\Otud5tm1Vmd
\Tg(Vav1-cre)#Cgp/0

(involves: C57BL/6)
abnormal T-helper 17 cell differentiation J:219495
\Otud6aem1Smoc/\Otud6aem1Smoc
(C57BL/6J-Otud6aem1Smoc)
abnormal innate immunity J:345141
decreased susceptibility to Herpesvirales infection J:345141
decreased susceptibility to Riboviria infection J:345141
\Otud6atm1(KOMP)Vlcg/\Otud6atm1(KOMP)Vlcg
(C57BL/6N-Otud6atm1(KOMP)Vlcg/Nju)
increased basophil cell number J:211773
increased eosinophil cell number J:211773
\Otud6btm1b(EUCOMM)Wtsi/\Otud6b+
(C57BL/6N-Otud6btm1b(EUCOMM)Wtsi/Wtsi)
increased basophil cell number J:211773
\Otud7btm1(NCOM)Cmhd/\Otud7btm1(NCOM)Cmhd
(involves: C57BL/6N)
abnormal granulocyte physiology J:209709
\Otud7btm1Dgen/\Otud7btm1Dgen
(involves: 129 * C57BL/6)
decreased activation-induced B cell apoptosis J:194553
decreased susceptibility to bacterial infection J:194553
decreased susceptibility to bacterial infection induced morbidity/mortality J:194553
increased B cell number J:194553
increased B cell proliferation J:194553
increased IgA level J:194553
lymphoid hyperplasia J:194553
\Otulinem1(IMPC)Bay/\Otulin+
(C57BL/6N-Otulinem1(IMPC)Bay/Bay)
abnormal spleen morphology J:211773
\Otulinem1Gvl/\Otulintm1c(EUCOMM)Hmgu
\Tg(KRT14-cre)1Cgn/0

(involves: C57BL/6 * C57BL/6J * C57BL/6N * DBA/2)
dermatitis J:312394
\Otulintm1c(EUCOMM)Hmgu/\Otulintm1c(EUCOMM)Hmgu
\Tg(KRT14-cre)1Cgn/0

(involves: C57BL/6 * C57BL/6N * DBA/2)
dermatitis J:312394
\Otulintm1c(EUCOMM)Hmgu/\Otulintm1c(EUCOMM)Hmgu
\Tg(KRT14-cre)1Cgn/0
\Tnfrsf1atm1Mak/\Tnfrsf1atm1Mak

(involves: 129S2/SvPas * C57BL/6 * C57BL/6N * DBA/2)
immune system phenotype J:312394
\Oxgr1tm1(KOMP)Vlcg/\Oxgr1tm1(KOMP)Vlcg
(involves: BALB/c * C57BL/6NTac)
abnormal immune system physiology J:198383
\Oxsr1tm1.1Arte/\Oxsr1+
(involves: 129S/SvEvBrd)
abnormal dendritic cell morphology J:191351
abnormal dendritic cell physiology J:191351
\P2rx2tm1Ckn/\P2rx2tm1Ckn
\P2rx3tm1Ckn/\P2rx3tm1Ckn

(involves: 129P2/OlaHsd * C57BL/6)
lung inflammation J:86890
\P2rx4tm1Ando/\P2rx4tm1Ando
(involves: 129S4/SvJae * BALB/c * C57BL/6)
abnormal neutrophil physiology J:311564
\P2rx4tm1Dgen/\P2rx4tm1Dgen
(involves: 129P2/OlaHsd * C57BL/6)
abnormal macrophage physiology J:145232
\P2rx5tm1Lex/\P2rx5tm1Lex
(involves: 129S5/SvEvBrd * C57BL/6J)
decreased CD8-positive, alpha-beta T cell number J:82809
increased NK cell number J:82809
\P2rx7tm1Gab/\P2rx7tm1Gab
(either: (involves: 129P2/OlaHsd * C57BL/6) or (involves: 129P2/OlaHsd * C57BL/6 * DBA/2))
abnormal interleukin-6 secretion J:66835
decreased interleukin-1 beta secretion J:66835
increased osteoclast cell number J:84145
\P2rx7tm1Gab/\P2rx7tm1Gab
(B6.129P2-P2rx7tm1Gab/J)
abnormal mast cell physiology J:190651
\P2rx7tm1Ipch/\P2rx7tm1Ipch
(B6.Cg-P2rx7tm1Ipch)
abnormal inflammatory response J:101945
\P2rx7tm1Ipch/\P2rx7tm1Ipch
(involves: 129)
immune system phenotype J:97422
\P2rx7tm1Ipch/\P2rx7tm1Ipch
(involves: 129 * C57BL/6)
abnormal macrophage physiology J:118561
\P2rx7tm1Lex/\P2rx7tm1Lex
(involves: 129S5/SvEvBrd * C57BL/6)
abnormal macrophage physiology J:145020
\P2ry6tm1.1Brob/\P2ry6tm1.1Brob
(involves: 129S1/Sv * 129X1/SvJ * CD-1)
abnormal macrophage physiology J:169742
\P2ry6tm1Jabo/\P2ry6tm1Jabo
\Gt(ROSA)26Sortm9(cre/ESR1)Arte/\Gt(ROSA)26Sor+

(involves: 129 * C57BL/6 * C57BL/6NTac)
decreased IgE level J:179177
decreased T cell apoptosis J:179177
increased eosinophil cell number J:179177
increased interferon-gamma secretion J:179177
increased interleukin-4 secretion J:179177
increased interleukin-5 secretion J:179177
increased interleukin-13 secretion J:179177
increased neutrophil cell number J:179177
increased T cell proliferation J:179177
lung inflammation J:179177
\P2ry6tm1Jabo/\P2ry6tm1Jabo
\Gt(ROSA)26Sortm9(cre/ESR1)Arte/\Gt(ROSA)26Sor+

(B6.Cg-Gt(ROSA)26Sortm9(cre/ESR1)Arte P2ry6tm1Jabo)
increased eosinophil cell number J:179177
increased interferon-gamma secretion J:179177
increased interleukin-4 secretion J:179177
increased interleukin-5 secretion J:179177
increased interleukin-13 secretion J:179177
increased neutrophil cell number J:179177
lung inflammation J:179177
\P2ry14tm1.1Shbg/\P2ry14tm1.1Shbg
(involves: 129S6/SvEvTac * C57BL/6)
increased spleen weight J:223427
\P4hbtm1.1Geno/\P4hbtm1.2Geno
\Lyz2tm1(cre)Ifo/\Lyz2+

(involves: 129P2/OlaHsd)
decreased neutrophil cell number J:197556
impaired neutrophil recruitment J:197556
\p23-ST1/\p23-ST1
(C57BL/6J-p23-ST1)
microgliosis J:158278
\Paam1MRL/MpJ/\Paam1MRL/MpJ
(involves: C3H/HeJ * MRL/MpJ)
increased susceptibility to autoimmune disorder J:76107
\Paam2MRL/MpJ/\Paam2MRL/MpJ
(involves: C3H/HeJ * MRL/MpJ)
increased susceptibility to autoimmune disorder J:76107
\Pabir2em1(IMPC)Ccpcz/Y
(C57BL/6NCrl-Pabir2em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged thymus J:211773
small spleen J:211773
\Pabir2em1(IMPC)Ccpcz/\Pabir2em1(IMPC)Ccpcz
(C57BL/6NCrl-Pabir2em1(IMPC)Ccpcz/Ccpcz)
abnormal lymph node morphology J:211773
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged lymph nodes J:211773
enlarged spleen J:211773
enlarged thymus J:211773
\Pacsin1Gt(OST287788)Lex/\Pacsin1Gt(OST287788)Lex
(B6.129S5-Pacsin1Gt(OST287788)Lex)
abnormal plasmacytoid dendritic cell physiology J:187784
decreased circulating interferon-alpha level J:187784
decreased interferon-alpha secretion J:187784
immune system phenotype J:187784
\Pacsin3tm1.2Bqu/\Pacsin3tm1.2Bqu
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)
myositis J:255013
\Padi2tm1Lex/\Padi2tm1Lex
(B6.129S5-Padi2tm1Lex)
abnormal mast cell physiology J:190651
\Padi2tm1Lex/\Padi2tm1Lex
(involves: 129S5/SvEvBrd * C57BL/6)
autoimmune response J:190651
\Padi4em1(IMPC)Mbp/\Padi4em1(IMPC)Mbp
(C57BL/6N-Padi4em1(IMPC)Mbp/MbpMmucd)
abnormal lymph node morphology J:211773
abnormal spleen morphology J:211773
enlarged lymph nodes J:211773
enlarged spleen J:211773
\Padi4tm1.1Kmow/\Padi4tm1.1Kmow
(involves: BALB/cJ * C57BL/6)
abnormal neutrophil physiology J:174934
decreased susceptibility to Orthomyxoviridae infection J:174934
\Padi4tm1.1Kmow/\Padi4tm1.1Kmow
\Tg(CMV-cre)1Cgn/0

(involves: BALB/cJ * C57BL/6)
immune system phenotype J:190651
\Padi4tm1.1Ywan/\Padi4tm1.1Ywan
(involves: 129S4/SvJae)
abnormal neutrophil physiology J:165718
impaired neutrophil phagocytosis J:165718
increased susceptibility to bacterial infection J:165718
\Pag1tm1.1Tara/\Pag1tm1.1Tara
(C57BL/6-Pag1tm1.1Tara)
immune system phenotype J:159011
\Pag1tm1Kplm/\Pag1tm1Kplm
(involves: 129P2/OlaHsd * C57BL/6)
increased thymocyte number J:101365
\Pag1tm1Tara/\Pag1tm1Tara
\Tg(Cd4-cre)1Cwi/0

(involves: C57BL/6 * DBA/2)
immune system phenotype J:159011
\Pahem1(IMPC)Tcp/\Pah+
(C57BL/6NCrl-Pahem1(IMPC)Tcp/Tcp)
small spleen J:211773
\Paip1em1(IMPC)Tcp/\Paip1em1(IMPC)Tcp
(C57BL/6NCrl-Paip1em1(IMPC)Tcp/Tcp)
enlarged lymph nodes J:211773
\Pak1tm1Cher/\Pak1tm1Cher
(B6.129S2-Pak1tm1Cher)
abnormal mast cell physiology J:142439
decreased mast cell degranulation J:145444
\Pak5em1(IMPC)Mbp/\Pak5em1(IMPC)Mbp
(C57BL/6N-Pak5em1(IMPC)Mbp/Ucd)
abnormal lymph node morphology J:211773
enlarged lymph nodes J:211773
\Palmtm1.2Kili/\Palmtm1.2Kili
\Tg(Ins2-VEGFC)#Pepr/0

(involves: C57BL/6N)
abnormal lymphangiogenesis J:237034
\Palmtm1.2Kili/\Palmtm1.2Kili
\Tg(RIP1-Tag)2Dh/0
\Tg(Ins2-VEGFC)#Pepr/0

(involves: C57BL/6J * C57BL/6N * DBA/2J)
abnormal lymphangiogenesis J:237034
\Pals1tm1Caw/\Pals1tm1Caw
\Tg(rx3-icre)1Mjam/0

(Not Specified)
microgliosis J:184469
\Pals2em1(IMPC)Rbrc/\Pals2em1(IMPC)Rbrc
(C57BL/6NJcl-Pals2em1(IMPC)Rbrc/Rbrc)
abnormal spleen morphology J:211773
\Pamr1em1(IMPC)Ccpcz/\Pamr1em1(IMPC)Ccpcz
(C57BL/6NCrl-Pamr1em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
\Pan2tm1b(KOMP)Wtsi/\Pan2tm1b(KOMP)Wtsi
(C57BL/6N-Pan2tm1b(KOMP)Wtsi/Mhzh)
increased eosinophil cell number J:211773
\Pan3em1(IMPC)Tcp/\Pan3+
(C57BL/6N-Pan3em1(IMPC)Tcp/Tcp)
enlarged lymph nodes J:211773
\Pank1tm1.1Suja/\Pank1tm1.1Suja
\Pank2tm1.1Suja/\Pank2tm1.1Suja

(involves: 129S/SvEv * C57BL/6J * FVB/N)
decreased spleen weight J:189609
small spleen J:189609
\Pank2em1(IMPC)Ccpcz/\Pank2em1(IMPC)Ccpcz
(C57BL/6NCrl-Pank2em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
immune system phenotype J:211773
increased effector memory CD8-positive, alpha-beta T cell number J:211773
\Pank3tm1b(KOMP)Mbp/\Pank3tm1b(KOMP)Mbp
(C57BL/6N-Pank3tm1b(KOMP)Mbp/Bay)
decreased lymphocyte cell number J:211773
increased neutrophil cell number J:211773
\Panx1tm1.2Vmd/\Panx1tm1.2Vmd
(C57BL/6N-Panx1tm1.2Vmd)
abnormal T cell physiology J:173213
immune system phenotype J:173213
\Panx2tm1b(KOMP)Wtsi/\Panx2tm1b(KOMP)Wtsi
(C57BL/6N-Panx2tm1b(KOMP)Wtsi/Ucd)
increased spleen weight J:211773
\Panx3tm1c(KOMP)Wtsi/\Panx3tm1c(KOMP)Wtsi
\Tg(Col2a1-cre)1Star/0

(involves: C3H * C57BL/6 * C57BL/6J * C57BL/6N)
decreased susceptibility to induced arthritis J:233542
\Panx3tm1d(KOMP)Wtsi/\Panx3tm1d(KOMP)Wtsi
(involves: BALB/cJ * C3H * C57BL/6 * C57BL/6N)
decreased susceptibility to induced arthritis J:233542
\Pappa2tm1Lex/\Pappa2tm1Lex
(C57BL/6-Pappa2tm1Lex)
increased spleen weight J:174887
\Papss2bm/\Papss2bm
(involves: C57BL/6J * LDJ/Le)
autoimmune arthritis J:166514
\Pard3tm1b(KOMP)Wtsi/\Pard3+
(C57BL/6N-Pard3tm1b(KOMP)Wtsi/H)
decreased basophil cell number J:211773
\Pargtm1Zqw/\Pargtm1Zqw
(involves: 129P2/OlaHsd * C57BL/6)
increased circulating tumor necrosis factor level J:92244
increased susceptibility to endotoxin shock J:92244
\Pargtm2b(KOMP)Mbp/\Parg+
(C57BL/6N-Pargtm2b(KOMP)Mbp/J)
decreased leukocyte cell number J:211773
\Parltm1.1Bdes/\Parltm1.1Bdes
(involves: 129P2/OlaHsd * C57BL/6J)
abnormal B cell morphology J:116017
decreased B cell number J:116017
decreased double-positive T cell number J:116017
decreased lymphocyte cell number J:116017
increased T cell apoptosis J:116017
spleen atrophy J:116017
thymus atrophy J:116017
\Parltm1.1Bdes/\Parltm1.1Bdes
(involves: 129P2/OlaHsd)
abnormal thymus apoptosis J:269785
microgliosis J:269785
spleen atrophy J:269785
thymus atrophy J:269785
\Parltm1Bdes/\Parltm1Bdes
\Tg(Nes-cre)1Kln/0

(involves: 129P2/OlaHsd * C57BL/6 * SJL)
abnormal thymus apoptosis J:269785
spleen atrophy J:269785
thymus atrophy J:269785
\Parp1em1(IMPC)Ccpcz/\Parp1em1(IMPC)Ccpcz
(C57BL/6NCrl-Parp1em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
enlarged spleen J:211773
\Parp1tm1b(EUCOMM)Hmgu/\Parp1tm1b(EUCOMM)Hmgu
(C57BL/6N-Parp1tm1b(EUCOMM)Hmgu/Ics)
decreased NK cell number J:211773
immune system phenotype J:211773
increased effector memory CD8-positive, alpha-beta T cell number J:211773
\Parp1tm1Jmdm/\Parp1tm1Jmdm
(involves: 129S2/SvPas * C57BL/6)
abnormal inflammatory response J:117701
abnormal leukocyte migration J:117701
\Parp1tm1Jmdm/\Parp1tm1Jmdm
(involves: 129S2/SvPas)
immune system phenotype J:47993
\Parp1tm1Zqw/\Parp1tm1Zqw
(involves: 129/Sv * C57BL/6)
decreased inflammatory response J:94497
\Parp1tm1Zqw/\Parp1tm1Zqw
(129S-Parp1tm1Zqw/J)
abnormal microglial cell physiology J:96548
decreased inflammatory response J:95418
\Parp1tm1Zqw/\Parp1tm1Zqw
(involves: 129S2/SvPas)
immune system phenotype J:146533
\Parp1tm2Zqw/\Parp1tm2Zqw
(either: (involves: 129P2/OlaHsd * 129/Sv) or (involves: 129P2/OlaHsd * C57BL/6))
abnormal inflammatory response J:93479
abnormal macrophage physiology J:93479
decreased circulating interleukin-1 beta level J:93479
decreased circulating tumor necrosis factor level J:93479
decreased inflammatory response J:93479
decreased susceptibility to endotoxin shock J:93479
\Parp9tm1.2Arte/\Parp9tm1.2Arte
(involves: C57BL/6N * FVB/N)
abnormal circulating interferon level J:306337
abnormal interferon secretion J:306337
abnormal response to infection J:306337
\Parp12tm1.1(KOMP)Vlcg/\Parp12tm1.1(KOMP)Vlcg
(C57BL/6N-Parp12tm1.1(KOMP)Vlcg/Ucd)
increased basophil cell number J:211773
increased neutrophil cell number J:211773
\Parp14Gt(OST415485)Lex/\Parp14Gt(OST415485)Lex
(involves: 129S5/SvEvBrd * C57BL/6)
decreased B cell proliferation J:146533
decreased IgA level J:146533
decreased marginal zone B cell number J:146533
increased B cell apoptosis J:146533
increased B cell proliferation J:146533
increased follicular B cell number J:146533
\Parvaem1(IMPC)Ccpcz/\Parva+
(C57BL/6NCrl-Parvaem1(IMPC)Ccpcz/Ccpcz)
abnormal lymph node morphology J:211773
abnormal spleen morphology J:211773
enlarged lymph nodes J:211773
enlarged spleen J:211773
\Parvbtm1a(EUCOMM)Wtsi/\Parvbtm1a(EUCOMM)Wtsi
(C57BL/6N-Parvbtm1a(EUCOMM)Wtsi/Cnrm)
decreased mature B cell number J:165965
decreased NK cell number J:165965
decreased T cell number J:165965
\Patz1tm1.1Welm/\Patz1tm1.1Welm
(involves: 129P2/OlaHsd)
abnormal T cell subpopulation ratio J:158947
decreased splenocyte number J:158947
decreased thymocyte number J:158947
\Patz1tm1.1Welm/\Patz1tm1.1Welm
\Tg(TcraTcrb)425Cbn/0

(involves: C57BL/6)
abnormal T cell subpopulation ratio J:158947
decreased CD8-positive, alpha-beta T cell number J:158947
increased CD4-positive, alpha-beta T cell number J:158947
\Patz1tm1.1Welm/\Patz1tm1.1Welm
\Tg(TcraTcrb)1100Mjb/0

(involves: 129P2/OlaHsd * C57BL/6)
abnormal T cell subpopulation ratio J:158947
decreased CD8-positive, alpha-beta T cell number J:158947
increased CD4-positive, alpha-beta T cell number J:158947
\Patz1tm1.2Welm/\Patz1tm1.2Welm
\Commd10Tg(Vav1-icre)A2Kio/\Commd10+

(B6.Cg-Patz1tm1.2Welm Commd10Tg(Vav1-icre)A2Kio)
abnormal mast cell differentiation J:209168
decreased interleukin-6 secretion J:209168
immune system phenotype J:209168
\Patz1tm1.2Welm/\Patz1tm1.2Welm
\Tg(Cma1-cre)#Roer/0

(involves: 129P2/OlaHsd * C57BL/6)
immune system phenotype J:209168
\Pawrtm1Jmos/\Pawrtm1Jmos
(involves: 129/Sv * CD-1)
abnormal T-helper 2 physiology J:85495
enlarged spleen J:85495
increased B cell proliferation J:85495
increased lymphocyte cell number J:85495
increased T cell proliferation J:85495
spleen hyperplasia J:85495
\Pax1un-i/\Pax1+
(either: (involves: 129S1/Sv * 129X1/SvJ) or (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J))
decreased CD4-positive, alpha-beta T cell number J:100951
decreased CD8-positive, alpha-beta T cell number J:100951
decreased thymocyte number J:100951
\Pax1un-i/\Pax1un-i
(either: (involves: 129S1/Sv * 129X1/SvJ) or (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J))
decreased CD4-positive, alpha-beta T cell number J:100951
decreased CD8-positive, alpha-beta T cell number J:100951
decreased double-negative T cell number J:100951
decreased double-positive T cell number J:100951
decreased thymocyte number J:100951
increased double-negative T cell number J:100951
\Pax1un/\Pax1+
\Tcf3tm1Cmu/\Tcf3tm1Cmu

(involves: 129P2/OlaHsd * C3H * C57BL/6)
abnormal T cell differentiation J:103567
abnormal T cell subpopulation ratio J:103567
\Pax3Sp-1H/\Pax3Sp-1H
(involves: 101/H * C3H/HeH * C57BL/6)
abnormal thymus morphology J:88412
\Pax3tm1(FOXO1A)Gcg/\Pax3+
(either: (involves: 129X1/SvJ * C57BL/6) or (involves: 129X1/SvJ * NMRI))
abnormal thymus lobule morphology J:79365
ectopic thymus J:79365
\Pax5m1Btlr/\Pax5m1Btlr
(C57BL/6J-Pax5m1Btlr)
decreased B cell number J:220072
decreased IgA level J:220072
decreased IgG1 level J:220072
decreased IgG2a level J:220072
decreased IgG2b level J:220072
decreased IgG level J:220072
decreased IgM level J:220072
impaired humoral immune response J:220072
increased macrophage cell number J:220072
increased monocyte cell number J:220072
increased single-positive T cell number J:220072
increased T cell number J:220072
\Pax5m2Btlr/\Pax5+
(C57BL/6J-Pax5m2Btlr)
decreased B-1b cell number J:254824
\Pax5m2Btlr/\Pax5m2Btlr
(C57BL/6J-Pax5m2Btlr)
decreased B-1b cell number J:254824
increased B-1 B cell number J:254824
\Pax5m3Btlr/\Pax5+
(C57BL/6J-Pax5m3Btlr)
decreased B cell number J:254825
\Pax5m3Btlr/\Pax5m3Btlr
(C57BL/6J-Pax5m3Btlr)
abnormal humoral immune response J:254825
decreased B cell number J:254825
decreased B-1 B cell number J:254825
decreased IgG level J:254825
decreased IgM level J:254825
increased CD4-positive, CD25-positive, alpha-beta regulatory T cell number J:254825
increased CD8-positive, alpha-beta memory T cell number J:254825
\Pax5m4Btlr/\Pax5m4Btlr
(C57BL/6J-Pax5m4Btlr)
decreased IgD level J:265140
\Pax5M5Btlr/\Pax5M5Btlr
(C57BL/6J-Pax5M5Btlr)
decreased IgD level J:265141
\Pax5tm1b(EUCOMM)Wtsi/\Pax5+
(C57BL/6N-Pax5tm1b(EUCOMM)Wtsi/Ieg)
decreased leukocyte cell number J:211773
immune system phenotype J:211773
increased CD4-positive NK T cell number J:211773
increased memory-marker CD4-positive NK T cell number J:211773
\Pax5tm1Mbu/\Pax5tm1Mbu
(involves: 129S2/SvPas * C57BL/6)
abnormal B cell differentiation J:38813
abnormal lymphopoiesis J:38813
absent B-2 B cells J:113076
absent mature B cells J:113076
arrested B cell differentiation J:113076
decreased B cell number J:113076
decreased B-1 B cell number J:113076
decreased immature B cell number J:113076
decreased immunoglobulin level J:113076
increased T cell number J:113076
\Pax5tm1Mbu/\Pax5tm1Mbu
(involves: 129S2/SvPas)
abnormal B cell physiology J:123629
abnormal immunoglobulin heavy chain V(D)J recombination J:139510
arrested B cell differentiation J:75504
enhanced B cell migration J:123629
\Pax5tm1Mbu/\Pax5tm1Mbu
(either: 129 or (involves: 129S2/SvPas * C57BL/6J))
abnormal late pro-B cell J:21935
abnormal lymphopoiesis J:21935
absent late pro-B cells J:21935
arrested B cell differentiation J:21935
\Pax5tm1Mbu/\Pax5tm3Mbu
\Tg(Mx1-cre)1Cgn/?

(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 * CBA)
decreased mature B cell number J:75504
\Pax5tm3.1Mbu/\Pax5tm3.1Mbu
(involves: 129P2/OlaHsd * C57BL/6)
arrested B cell differentiation J:75504
\Pax5tm3Mbu/\Pax5+
\Tcf3tm1(PBX1)Mlc/\Tcf3+
\Cd19tm1(cre)Cgn/\Cd19+

(involves: 129P2/OlaHsd * C57BL/6)
abnormal pro-B cell morphology J:226241
arrested B cell differentiation J:226241
decreased immature B cell number J:226241
\Pax5tm4(CD2*)Mbu/\Pax5tm4(CD2*)Mbu
(B6.129P2-Pax5tm4(CD2*)Mbu)
immune system phenotype J:144100
\Pax5tm5Mbu/\Pax5tm5Mbu
(B6.129P2-Pax5tm5Mbu)
immune system phenotype J:144100
\Pax5tm6.1Mbu/\Pax5tm6.1Mbu
(B6.129P2-Pax5tm6.1Mbu)
immune system phenotype J:173158
\Pax6Sey-4H/\Pax6+
(involves: 101/H * C3H/HeCrj * C3H/HeH)
increased susceptibility to induced pancreatitis J:124276
\Pax7tm1.1(HBEGF,-EYFP)Mal/\Pax7+
(involves: C57BL/6)
myositis J:180899
\Pax9tm1.1Hpt/\Pax9tm1.1Hpt
\Tg(Pgk1-cre)1Lni/?

(involves: 129S2/SvPas * BALB/c * C57BL/6 * SJL)
abnormal thymus lobule morphology J:125026
\Pax9tm1Rbal/\Pax9tm1Rbal
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
athymia J:49857
\Pax9tm1Rbal/\Pax9tm1Rbal
(involves: 129S1/Sv * 129X1/SvJ * CD-1)
ectopic thymus J:311535
thymus hypoplasia J:311535
\Paxxem1(IMPC)Mbp/\Paxxem1(IMPC)Mbp
(C57BL/6NCrl-Paxxem1(IMPC)Mbp/Mmucd)
abnormal lymph node morphology J:211773
enlarged lymph nodes J:211773
\Paxxem1Spj/\Paxxem1Spj
(C57BL/6NTac-Paxxem1Spj)
decreased B cell number J:236776
decreased CD4-positive, alpha-beta T cell number J:236776
decreased CD8-positive, alpha-beta T cell number J:236776
decreased follicular B cell number J:236776
decreased splenocyte number J:236776
decreased T cell number J:236776
decreased transitional stage B cell number J:236776
immune system phenotype J:236776
increased mature B cell number J:236776
\Paxxem1Spj/\Paxxem1Spj
\Nhej1tm1Fwa/\Nhej1tm1Fwa

(involves: 129S6/SvEvTac * C57BL/6NTac)
abnormal thymus involution J:236776
absent lymphocyte J:236776
athymia J:236776
decreased spleen weight J:236776
decreased splenocyte number J:236776
small spleen J:236776
\Pbat1BXSB/Slc/\Pbat1BXSB/Slc
(involves: BXSB/Slc * NZW/Slc)
increased autoantibody level J:49899
\Pbat1BXSB/Slc/\Pbat1NZW/Slc
(involves: BXSB/Slc * NZW/Slc)
increased autoantibody level J:49899
\Pbat2BXSB/Slc/\Pbat2BXSB/Slc
(involves: BXSB/Slc * NZW/Slc)
increased autoantibody level J:49899
\Pbat2BXSB/Slc/\Pbat2NZW/Slc
(involves: BXSB/Slc * NZW/Slc)
increased autoantibody level J:49899
\Pbbcp1C57BL/6J/?
(involves: C57BL/6J * DBA/2J)
increased B cell number J:74270
\Pbktm1Zgdo/\Pbktm1Zgdo
(Not Specified)
decreased interleukin-6 secretion J:176985
increased interleukin-6 secretion J:176985
increased tumor necrosis factor secretion J:176985
\Pbrm1tm1Zhwa/\Pbrm1tm1Zhwa
\Tg(Cd4-cre)1Cwi/?

(involves: 129P2/OlaHsd * C57BL/6 * DBA/2)
abnormal T-helper 2 cell differentiation J:236906
decreased T cell proliferation J:236906
immune system phenotype J:236906
increased interleukin-4 secretion J:236906
increased interleukin-10 secretion J:236906
\Pbwg1.9M. m. castaneus/?
(involves: C57BL/6J * M. m. castaneus)
increased spleen weight J:121981
\Pbx1em1Dunw/\Pbx1em1Dunw
(C57BL/6J-Pbx1em1Dunw)
ectopic thymus J:320934
spleen hypoplasia J:320934
thymus hypoplasia J:320934
\Pbx1tm1.1Koss/\Pbx1tm1.1Koss
\Tg(WT1-cre)AG11Dbdr/0

(involves: 129P2/OlaHsd * C57BL/6)
spleen hypoplasia J:184521
\Pbx1tm1.1Koss/\Pbx1tm1.2Koss
\Tmem163Tg(ACTB-cre)2Mrt/0

(involves: 129P2/OlaHsd * FVB/N)
absent spleen J:184521
\Pbx1tm1Koss/\Pbx1tm1Koss
\Nkx2-5tm2(cre)Rph/\Nkx2-5+

(involves: 129P2/OlaHsd * 129S1/Sv)
abnormal spleen mesenchyme morphology J:184521
abnormal spleen morphology J:184521
spleen hypoplasia J:184521
\Pbx1tm1Koss/\Pbx1tm1Koss
\Pbx2tm1Mlc/\Pbx2+
\Nkx2-5tm2(cre)Rph/\Nkx2-5+

(involves: 129P2/OlaHsd * 129S/Sv * 129S1/Sv)
abnormal spleen morphology J:184521
spleen hypoplasia J:184521
\Pbx1tm1Mlc/\Pbx1tm1Mlc
(involves: 129S6/SvEvTac * C57BL/6)
absent spleen J:71996, J:70684
ectopic thymus J:71996
\Pbx1tm1Mlc/\Pbx1tm2.1Mlc
(involves: 129S6/SvEvTac)
abnormal lymph node primary follicle morphology J:132963
decreased CD4-positive, alpha-beta T cell number J:132963
decreased CD8-positive, alpha-beta T cell number J:132963
decreased mature B cell number J:132963
\Pbx1tm1Mlc/\Pbx1tm3.1Mlc
\Tg(Tek-cre)1Ywa/0

(involves: 129S6/SvEvTac * C57BL/6 * SJL)
abnormal spleen morphology J:149799
abnormal thymus morphology J:149799
decreased B cell number J:149799
decreased double-negative T cell number J:149799
decreased pre-B cell number J:149799
decreased pro-B cell number J:149799
decreased T cell number J:149799
small spleen J:149799
small thymus J:149799
spleen hypoplasia J:149799
thymus hypoplasia J:149799
\Pbx2tm1Mlc/\Pbx2tm1Mlc
(either: 129S/Sv or (involves: 129S/Sv * C57BL/6))
immune system phenotype J:91079
\Pbx4em2Hncs/\Pbx4em2Hncs
(involves: C57BL/6J * DBA * ICR)
decreased lymphocyte cell number J:349843
increased neutrophil cell number J:349843
\Pbxip1tm1Cya/\Pbxip1tm1Cya
\Tg(Col2a1-cre/ERT)KA3Smac/0

(involves: FVB/N)
osteoarthritis J:270267
\Pcaretm1Kpal/\Pcaretm1Kpal
(involves: C57BL/6J * C57BL/6NTac)
increased microglial cell activation J:220866
\Pcd4ts1DBA/2/?
(involves: BALB/c * C3H * C57BL/6 * DBA/2)
abnormal CD4-positive, alpha beta T cell morphology J:83220
\Pcd4ts2BALB/c/?
(involves: BALB/c * C3H * C57BL/6 * DBA/2)
abnormal CD4-positive, alpha beta T cell morphology J:83220
\Pcd4ts3BALB/c/?
(involves: BALB/c * C3H * C57BL/6 * DBA/2)
abnormal CD4-positive, alpha beta T cell morphology J:83220
\Pcd8ts1C57BL/6/?
(involves: BALB/c * C3H * C57BL/6 * DBA/2)
increased CD8-positive, alpha-beta T cell number J:83220
\Pcdh7em1Ywc/\Pcdh7em1Ywc
(Not Specified)
decreased osteoclast cell number J:298915
\Pcdha2em1(IMPC)Tcp/\Pcdha2em1(IMPC)Tcp
(C57BL/6N-Pcdha2em1(IMPC)Tcp/Tcp)
enlarged lymph nodes J:211773
\Pcdhb13em1(IMPC)Tcp/\Pcdhb13em1(IMPC)Tcp
(C57BL/6N-Pcdhb13em1(IMPC)Tcp/Tcp)
decreased basophil cell number J:211773
enlarged lymph nodes J:211773
\Pcdhgem5Rwb/\Pcdhgem5Rwb
(C57BL/6J-Pcdhgem5Rwb/Rwb)
microgliosis J:285314
\Pcdhgem41Rwb/\Pcdhgem41Rwb
(C57BL/6J-Pcdhgem41Rwb/Rwb)
microgliosis J:285314
\Pcdhgtm1.1Tman/\Pcdhgtm1.1Tman
(involves: 129S4/SvJae * C57BL/6)
microgliosis J:188341
\Pcgf2tm1b(KOMP)Mbp/\Pcgf2+
(C57BL/6N-Pcgf2tm1b(KOMP)Mbp/Tcp)
abnormal spleen morphology J:211773
small spleen J:211773
\Pcgf2tm1Hko/\Pcgf2tm1Hko
(involves: BALB/c * C57BL/6)
abnormal T-helper 2 physiology J:71268
decreased lymphocyte cell number J:71268
decreased thymocyte number J:71268
\Pcgf3TgTn(sb-cHS4,Tyr)2349AOve/\Pcgf3TgTn(sb-cHS4,Tyr)2349AOve
(FVB/N-Pcgf3TgTn(sb-cHS4,Tyr)2349AOve)
absent spleen J:175597
\Pcid2tm1Imku/\Pcid2tm1Imku
\Cd19tm1(cre)Cgn/\Cd19+

(involves: 129P2/OlaHsd * C57BL/6 * CBA)
abnormal spleen B cell follicle morphology J:166080
decreased follicular B cell number J:166080
decreased marginal zone B cell number J:166080
decreased mature B cell number J:166080
\Pck2em1(IMPC)Tcp/\Pck2em1(IMPC)Tcp
(C57BL/6N-Pck2em1(IMPC)Tcp/Tcp)
enlarged lymph nodes J:211773
\Pclaftm1.1Lkd/\Pclaftm1.1Lkd
(involves: C57BL/6)
decreased leukocyte cell number J:177782
spleen hypoplasia J:177782
thymus hypoplasia J:177782
\Pclaftm1a(EUCOMM)Wtsi/\Pclaftm1a(EUCOMM)Wtsi
(C57BL/6N-Pclaftm1a(EUCOMM)Wtsi/Wtsi)
decreased CD11b-high dendritic cell number J:211773
decreased dendritic cell number J:211773
decreased immature NK cell number J:211773
decreased plasmacytoid dendritic cell number J:211773
decreased regulatory T cell number J:211773
decreased T cell number J:211773
increased CD11b-low dendritic cell number J:211773
increased dendritic cell number J:211773
increased mature NK cell number J:211773
increased memory CD4-positive, CD25-positive, alpha-beta regulatory T cell number J:211773
increased pro-B cell number J:211773
\Pcm1em1(IMPC)Tcp/\Pcm1em1(IMPC)Tcp
(C57BL/6NCrl-Pcm1em1(IMPC)Tcp/Tcp)
decreased spleen weight J:211773
small spleen J:211773
\Pcmt1tm1Shs/\Pcmt1tm1Shs
(involves: 129P2/OlaHsd * C57BL/6)
small spleen J:46228
\Pcnatm1.1Mdsc/\Pcnatm1.1Mdsc
\Tg(Pcna*K164R)1Mdsc/0

(involves: FVB/N)
abnormal class switch recombination J:141098
abnormal somatic hypermutation frequency J:141098
\Pcnatm1Jcbs/\Pcnatm1Jcbs
(involves: 129P2/OlaHsd * C57BL/6)
abnormal somatic hypermutation frequency J:125916
\Pcnatm1Jcbs/\Pcnatm1Jcbs
(involves: 129P2/OlaHsd)
abnormal somatic hypermutation frequency J:155454, J:177630
\Pcnatm1Jcbs/\Pcnatm1Jcbs
\Ungtm1Tld/\Ungtm1Tld

(involves: 129P2/OlaHsd)
abnormal somatic hypermutation frequency J:155454
\Pcolce2tm1Ccb/\Pcolce2tm1Ccb
\Ppp1r16btm1Ccb/\Ppp1r16btm1Ccb

(involves: 129S1/Sv * 129X1/SvJ)
immune system phenotype J:124347
\Pcsk1tm1Dfs/\Pcsk1tm1Dfs
(involves: 129 * C57BL/6J)
abnormal peritoneal macrophage morphology J:184882
abnormal spleen marginal zone morphology J:184882
abnormal spleen white pulp morphology J:184882
abnormal T-helper 1 cell differentiation J:184882
decreased follicular dendritic cell number J:184882
decreased NK T cell number J:184882
decreased T cell number J:184882
enlarged spleen J:184882
increased circulating interferon-gamma level J:184882
increased circulating interleukin-1 beta level J:184882
increased circulating interleukin-6 level J:184882
increased circulating interleukin-10 level J:184882
increased circulating interleukin-12 level J:184882
increased circulating tumor necrosis factor level J:184882
increased interleukin-1 beta secretion J:184882
increased lymphocyte cell number J:184882
increased susceptibility to endotoxin shock J:184882
intermingled spleen red and white pulp J:184882
\Pcsk5vcc/\Pcsk5vcc
(involves: C57BL/6J)
abnormal thymus lobule morphology J:136243
small thymus J:136243
\Pcsk9em1(IMPC)Ccpcz/\Pcsk9em1(IMPC)Ccpcz
(C57BL/6NCrl-Pcsk9em1(IMPC)Ccpcz/Ccpcz)
abnormal lymph node morphology J:211773
abnormal thymus morphology J:211773
enlarged lymph nodes J:211773
enlarged thymus J:211773
increased CD4-positive, alpha-beta T cell number J:211773
increased T-helper cell number J:211773
\Pctptm1Bor/\Pctptm1Bor
(B6.129P2-Pctptm1Bor)
abnormal macrophage physiology J:115284
increased macrophage apoptosis J:115284
\Pcyt1atm1Irt/\Pcyt1atm1Irt
\Lyz2tm1(cre)Ifo/\Lyz2+

(involves: 129 * C57BL/6J)
abnormal immune cell physiology J:65639
abnormal macrophage physiology J:65639
\Pdap1em1Rkuhn/\Pdap1em1Rkuhn
\Cd19tm1(cre)Cgn/\Cd19+

(involves: 129P2/OlaHsd * C57BL/6 * C57BL/6N)
abnormal B cell physiology J:298705
abnormal class switch recombination J:298705
abnormal somatic hypermutation frequency J:298705
decreased germinal center B cell number J:298705
decreased mature B cell number J:298705
increased B cell apoptosis J:298705
\Pdcd1tm1.1Liux/\Pdcd1tm1.1Liux
(involves: C57BL/6)
decreased regulatory T cell number J:190150
increased T-helper 1 cell number J:190150
\Pdcd1tm1.1Liux/\Pdcd1tm1.1Liux
\Tg(MMTV-PyVT)634Mul/0

(involves: C57BL/6 * FVB/N)
decreased interleukin-17 secretion J:190150
decreased regulatory T cell number J:190150
decreased T-helper 2 cell number J:190150
decreased T-helper 17 cell number J:190150
increased interferon-gamma secretion J:190150
increased interleukin-2 secretion J:190150
increased T-helper 1 cell number J:190150
increased tumor necrosis factor secretion J:190150
\Pdcd1tm1.1Shr/\Pdcd1tm1.1Shr
(involves: C57BL/6)
decreased B-1 B cell number J:153040
increased regulatory T cell number J:153040
\Pdcd1tm1.1Shr/\Pdcd1tm1.1Shr
\Tg(TcraTcrb)1100Mjb/0

(involves: C57BL/6)
abnormal immune tolerance J:153040
decreased T cell proliferation J:153040
increased susceptibility to autoimmune diabetes J:153040
increased T cell proliferation J:153040
insulitis J:153040
pancreas inflammation J:153040
\Pdcd1tm1Hon/\Pdcd1tm1Hon
(involves: 129S2/SvPas * C57BL/6)
abnormal immunoglobulin level J:50688
abnormal leukopoiesis J:50688
abnormal myelopoiesis J:50688
enlarged spleen J:50688
increased B cell number J:50688
increased B cell proliferation J:50688
increased B-1 B cell number J:50688
increased IgA level J:50688
increased IgG2b level J:50688
increased IgG3 level J:50688
increased lymphocyte cell number J:50688
\Pdcd1tm1Hon/\Pdcd1tm1Hon
(B6.129S2-Pdcd1tm1Hon)
abnormal response to transplant J:119356
autoimmune arthritis J:78802
glomerulonephritis J:78802
\Pdcd1tm1Hon/\Pdcd1tm1Hon
(C.129S2(B6)-Pdcd1tm1Hon)
increased autoantibody level J:66979
\Pdcd1tm1Hon/\Pdcd1tm1Hon
(involves: 129S2/SvPas)
abnormal T cell activation J:222944
increased IgA level J:222944
increased IgM level J:222944
increased inflammatory response J:222944
increased interferon-gamma secretion J:222944
\Pdcd1tm1Hon/\Pdcd1tm1Hon
\Tg(Tcra2D2,Tcrb2D2)1Kuch/0

(involves: 129S2/SvPas)
decreased susceptibility to experimental autoimmune encephalomyelitis J:140751
\Pdcd1tm1Hon/\Pdcd1tm1Hon
\Vsirtm1Lex/\Vsirtm1Lex

(involves: 129S2/SvPas * 129S5/SvEvBrd * C57BL/6)
abnormal T cell activation J:222944
immune system phenotype J:222944
increased IgA level J:222944
increased IgM level J:222944
increased inflammatory response J:222944
increased interferon-gamma secretion J:222944
increased interleukin-17 secretion J:222944
increased tumor necrosis factor secretion J:222944
\Pdcd1tm1Hon/\Pdcd1tm1Hon
\Vsirtm1Lex/\Vsirtm1Lex
\Tg(Tcra2D2,Tcrb2D2)1Kuch/0

(involves: 129S2/SvPas * 129S5/SvEvBrd * C57BL/6)
increased susceptibility to experimental autoimmune encephalomyelitis J:222944
\Pdcd1tm1Llc/\Pdcd1tm1Llc
(involves: 129S5/SvEvBrd)
abnormal cytokine secretion J:126829
decreased CD8-positive, alpha-beta T cell number J:126829
increased susceptibility to experimental autoimmune encephalomyelitis J:126829
\Pdcd1lg2tm1.1Lex/\Pdcd1lg2tm1.1Lex
(involves: 129S5/SvEvBrd)
decreased CD8-positive, alpha-beta T cell number J:126829
\Pdcd1lg2tm1Dmp/\Pdcd1lg2tm1Dmp
(involves: 129X1/SvJ * 129S1/Sv * C57BL/6)
abnormal dendritic cell antigen presentation J:84457
\Pdcd1lg2tm1Dmp/\Pdcd1lg2tm1Dmp
(C.129-Pdcd1lg2tm1Dmp)
abnormal cytokine secretion J:99212
abnormal cytotoxic T cell physiology J:99212
decreased IgG2a level J:99212
decreased T cell proliferation J:99212
\Pdcd1lg2tm1Shr/\Pdcd1lg2tm1Shr
(involves: 129/Sv * 129S4/SvJae)
increased IgG2a level J:113851
increased IgM level J:113851
increased susceptibility to parasitic infection J:113851
\Pdcd1lg2tm2Shr/\Pdcd1lg2tm2Shr
(C.B6-Pdcd1lg2tm2Shr)
abnormal dendritic cell physiology J:123785
increased interferon-gamma secretion J:123785
increased interleukin-2 secretion J:123785
\Pdcd1lg2tm3Shr/\Pdcd1lg2tm3Shr
(involves: C57BL/6 * NOD/MrkTac)
abnormal CD8-positive, alpha-beta T cell physiology J:123785
increased CD4-positive, alpha-beta T cell number J:123785
increased CD8-positive, alpha-beta T cell number J:123785
increased susceptibility to autoimmune diabetes J:123785
insulitis J:123785
lymph node hyperplasia J:123785
\Pdcd4tm1Yhcn/\Pdcd4tm1Yhcn
(B6.129S6-Pdcd4tm1Yhcn)
abnormal cytokine secretion J:120583
decreased susceptibility to autoimmune diabetes J:120583
decreased susceptibility to experimental autoimmune encephalomyelitis J:120583
\Pdcd6ipem1(IMPC)Hmgu/\Pdcd6ipem1(IMPC)Hmgu
(C57BL/6N-Pdcd6ipem1(IMPC)Hmgu/Ieg)
enlarged lymph nodes J:211773
\Pdcd6ipem1(IMPC)Mbp/\Pdcd6ipem1(IMPC)Mbp
(C57BL/6NCrl-Pdcd6ipem1(IMPC)Mbp/Mmucd)
abnormal lymph node morphology J:211773
abnormal spleen morphology J:211773
enlarged lymph nodes J:211773
enlarged spleen J:211773
\Pdcd10tm1Kwhi/\Pdcd10tm1.1Kwhi
\Tg(Pdgfb-icre/ERT2,-EGFP)1Frut/?

(involves: C57BL/6 * CBA)
CNS inflammation J:173947
\Pde2aem1(IMPC)H/\Pde2a+
(C57BL/6NTac-Pde2aem1(IMPC)H/H)
increased neutrophil cell number J:211773
\Pde4atm1Mct/\Pde4atm1Mct
(involves: 129P2/OlaHsd * C57BL/6)
immune system phenotype J:106828
\Pde4btm1Mct/\Pde4b+
\Pde4dtm1Mct/\Pde4dtm1Mct

(involves: 129P2/OlaHsd * C57BL/6)
impaired neutrophil recruitment J:94853
\Pde4btm1Mct/\Pde4btm1Mct
(involves: 129X1/SvJ * C57BL/6)
decreased tumor necrosis factor secretion J:76862
\Pde4btm1Mct/\Pde4btm1Mct
(involves: 129P2/OlaHsd * C57BL/6)
decreased tumor necrosis factor secretion J:106828
impaired neutrophil chemotaxis J:94853
impaired neutrophil recruitment J:94853
\Pde4btm1Mct/\Pde4btm1Mct
\Pde4dtm1Mct/\Pde4d+

(involves: 129P2/OlaHsd * C57BL/6)
impaired neutrophil recruitment J:94853
\Pde4dtm1Mct/\Pde4dtm1Mct
(involves: 129P2/OlaHsd * C57BL/6)
abnormal tumor necrosis factor level J:94853
immune system phenotype J:106828
impaired neutrophil chemotaxis J:94853
impaired neutrophil recruitment J:94853
\Pde7aGt(Betageo-puro)1Yang/\Pde7aGt(Betageo-puro)1Yang
(involves: 129P2/OlaHsd * C57BL/6)
abnormal humoral immune response J:86923
\Pde7btm1Pfi/\Pde7btm1Pfi
(involves: 129 * C57BL/6)
immune system phenotype J:322967
\Pdgfbtm1Cbet/\Pdgfbtm2Cbet
\Tg(Tie1-cre)9Ref/0

(involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA)
abnormal microglial cell morphology J:89186
\Pdgfctm1b(EUCOMM)Hmgu/\Pdgfc+
(C57BL/6N-Pdgfctm1b(EUCOMM)Hmgu/Ieg)
enlarged spleen J:211773
increased CD4-negative, CD25-positive NK T cell number J:211773
increased granulocyte number J:211773
increased monocyte cell number J:211773
\Pdgfraem1(IMPC)Ccpcz/\Pdgfra+
(C57BL/6NCrl-Pdgfraem1(IMPC)Ccpcz/Ccpcz)
abnormal lymph node morphology J:211773
abnormal thymus morphology J:211773
decreased CD8-positive, naive alpha-beta T cell number J:211773
enlarged lymph nodes J:211773
enlarged thymus J:211773
increased CD4-positive NK T cell number J:211773
increased memory-marker CD4-positive NK T cell number J:211773
increased NK T cell number J:211773
\Pdgfratm8Sor/\Pdgfratm8Sor
\H2az2Tg(Wnt1-cre)11Rth/\H2az2+

(Not Specified)
small thymus J:81153
\Pdgfratm8Sor/\Pdgfratm8Sor
\Pdgfrbtm1Mdt/\Pdgfrbtm1Mdt
\H2az2Tg(Wnt1-cre)11Rth/\H2az2+

(involves: C57BL/6 * CBA)
abnormal thymus development J:122584
thymus hypoplasia J:122584
\Pdgfratm12.1Sor/\Pdgfra+
(involves: 129 * C57BL/6)
abnormal immune system organ morphology J:146617
\Pdgfrbb2b2903Clo/\Pdgfrbb2b2903Clo
(C57BL/6J-Pdgfrbb2b2903Clo)
thymus hypoplasia J:175213
\Pdha2em1(IMPC)Bay/\Pdha2em1(IMPC)Bay
(C57BL/6N-Pdha2em1(IMPC)Bay/Bay)
abnormal spleen morphology J:211773
\Pdia6em1Btlr/\Pdia6m1Btlr
(involves: C57BL/6J)
abnormal circulating cytokine level J:288824
abnormal T cell physiology J:288824
decreased B cell number J:288824
decreased double-negative T cell number J:288824
decreased double-positive T cell number J:288824
decreased follicular B cell number J:288824
decreased leukocyte cell number J:288824
decreased lymphocyte cell number J:288824
decreased monocyte cell number J:288824
decreased NK T cell number J:288824
decreased pre-B cell number J:288824
decreased transitional stage B cell number J:288824
increased marginal zone B cell number J:288824
increased marginal zone precursor B cell number J:288824
increased mature B cell number J:288824
spleen hypoplasia J:288824
thymus hypoplasia J:288824
\Pdia6m1Btlr/\Pdia6m1Btlr
(C57BL/6J-Pdia6m1Btlr)
immune system phenotype J:288824
\Pdia6tm1b(EUCOMM)Hmgu/\Pdia6+
(C57BL/6N-Pdia6tm1b(EUCOMM)Hmgu/Ieg)
decreased CD4-positive NK T cell number J:211773
enlarged lymph nodes J:211773
\Pdik1lem1(IMPC)Mbp/\Pdik1lem1(IMPC)Mbp
(C57BL/6NCrl-Pdik1lem1(IMPC)Mbp/Mmucd)
abnormal spleen morphology J:211773
enlarged spleen J:211773
increased spleen weight J:211773
\Pdk2em1(IMPC)Mbp/\Pdk2em1(IMPC)Mbp
(C57BL/6N-Pdk2em1(IMPC)Mbp/MbpMmucd)
abnormal lymph node morphology J:211773
abnormal spleen morphology J:211773
enlarged lymph nodes J:211773
enlarged spleen J:211773
\Pdk4tm1Tok/\Pdk4tm1Tok
(B6.129P2-Pdk4tm1Tok)
abnormal osteoclast cell number J:179789
abnormal osteoclast differentiation J:179789
abnormal osteoclast morphology J:179789
\Pdlim2tm1Gru/\Pdlim2tm1Gru
(Not Specified)
abnormal T-helper 1 physiology J:99108
increased interferon-gamma secretion J:99108
increased susceptibility to bacterial infection J:99108
\Pdlim7em1(IMPC)Mbp/\Pdlim7em1(IMPC)Mbp
(C57BL/6N-Pdlim7em1(IMPC)Mbp/MbpMmucd)
abnormal lymph node morphology J:211773
abnormal spleen morphology J:211773
enlarged lymph nodes J:211773
enlarged spleen J:211773
\Pdlim7Gt(OST445990)Lex/\Pdlim7Gt(OST445990)Lex
(B6.129S5-Pdlim7Gt(OST445990)Lex)
increased lymphocyte cell number J:209780
increased monocyte cell number J:209780
\Pdpk1tm1.1Mlw/\Pdpk1tm1.1Mlw
\Rag2tm1Fwa/\Rag2tm1Fwa
\Tnfrsf4tm2(cre)Nik/\Tnfrsf4+
\Gt(ROSA)26Sortm1(EYFP)Cos/\Gt(ROSA)26Sor+

(involves: 129S/SvEv * 129X1/SvJ * C57BL/6)
dermatitis J:226194
\Pdpk1tm1.1Mlw/\Pdpk1tm1.1Mlw
\Tnfrsf4tm2(cre)Nik/\Tnfrsf4+
\Gt(ROSA)26Sortm1(EYFP)Cos/\Gt(ROSA)26Sor+

(involves: 129X1/SvJ * C57BL/6)
abnormal regulatory T cell number J:226194
abnormal T cell physiology J:226194
dermatitis J:226194
enlarged lymph nodes J:226194
enlarged spleen J:226194
\Pdpk1tm1Dral/\Pdpk1tm1Dral
(B6.129P2-Pdpk1tm1Dral)
small spleen J:136089
\Pdpk1tm1Mlw/\Pdpk1tm1.1Daca
\Tg(Cd4-cre)1Cwi/0

(involves: 129P2/OlaHsd * BALB/c * C57BL/6 * DBA/2)
abnormal CD8-positive, alpha beta T cell morphology J:165626
decreased NK T cell number J:165626
decreased T cell number J:165626
\Pdpk1tm1Mlw/\Pdpk1tm1Mlw
\Tg(Cd4-cre)1Cwi/0

(involves: C57BL/6 * DBA/2)
abnormal CD8-positive, alpha beta T cell morphology J:165626
abnormal NK T cell morphology J:165626
abnormal T cell differentiation J:165626
absent NK T cells J:165626
decreased NK T cell number J:165626
decreased T cell number J:165626
decreased T cell proliferation J:165626
immune system phenotype J:165626
\Pdpntm1(cre)Mlkn/\Pdpntm1(cre)Mlkn
(involves: 129S4/SvJae * C57BL/6)
abnormal lymphatic vessel morphology J:162815
\Pdpntm1Mcws/\Pdpn+
(involves: 129S6/SvEvTac)
abnormal lymphatic vessel morphology J:94978
lymphangiectasis J:94978
\Pdpntm1Mcws/\Pdpntm1Mcws
(involves: 129S6/SvEvTac)
abnormal lymph circulation J:94978
abnormal lymphatic vessel morphology J:94978
lymphangiectasis J:94978
\Pdpntm2.1Mlkn/\Pdpntm2.1Mlkn
\Rag1tm1Mom/\Rag1tm1Mom
\Tg(Pdgfrb-cre)9Rha/0

(involves: 129S7/SvEvBrd * C57BL/6)
absent lymphocyte J:205423
\Pdpntm2.1Mlkn/\Pdpntm2.1Mlkn
\Tg(CAG-cre/Esr1*)5Amc/0

(involves: C57BL/6 * CBA)
abnormal lymph node morphology J:205423
absent peripheral lymph nodes J:205423
\Pdpntm2.1Mlkn/\Pdpntm2.1Mlkn
\Tg(CAG-cre/Esr1*)5Amc/0

(involves: 129 * C57BL/6)
abnormal lymphangiogenesis J:235778
\Pdpntm2.1Mlkn/\Pdpntm2.1Mlkn
\Tg(Pdgfrb-cre)9Rha/0

(involves: C57BL/6)
lymph node hemorrhage J:205423
\Pdprtm1b(EUCOMM)Wtsi/\Pdprtm1b(EUCOMM)Wtsi
(C57BL/6N-Pdprtm1b(EUCOMM)Wtsi/Ics)
decreased large unstained cell number J:211773
\Pdss2kd/\Pdss2kd
(CBA/H-Pdss2kd)
tubulointerstitial nephritis J:197578
\Pdss2kd/\Pdss2kd
(B6.CBACaH(CAST)-Pdss2kd)
tubulointerstitial nephritis J:101779
\Pdss2tm1Dalg/\Pdss2tm1Dalg
\Tg(NPHS2-cre)295Lbh/?

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
tubulointerstitial nephritis J:136670
\Pdx1tm1Ted/\Pdx1+
(involves: 129P2/OlaHsd)
pancreas inflammation J:82969
\Pdx1tm1Ted/\Pdx1tm1Ted
(involves: 129P2/OlaHsd)
immune system phenotype J:20779
\Pdxpem1(IMPC)J/\Pdxpem1(IMPC)J
(C57BL/6NJ-Pdxpem1(IMPC)J/Mmjax)
increased leukocyte cell number J:211773
\Pdzd8tm1b(EUCOMM)Wtsi/\Pdzd8+
(C57BL/6N-Pdzd8tm1b(EUCOMM)Wtsi/Wtsi)
increased large unstained cell number J:211773
\Pdzk1tm2b(EUCOMM)Wtsi/\Pdzk1tm2b(EUCOMM)Wtsi
(C57BL/6N-Pdzk1tm2b(EUCOMM)Wtsi/Wtsi)
abnormal lymphatic vessel morphology J:239583
absent connection between subcutaneous lymph vessels and lymph sac J:239583
blood in lymph vessels J:239583
\Pdzph1em1(IMPC)Ccpcz/\Pdzph1em1(IMPC)Ccpcz
(C57BL/6NCrl-Pdzph1em1(IMPC)Ccpcz/Ccpcz)
increased basophil cell number J:211773
\Pebp1em1(IMPC)Tcp/\Pebp1em1(IMPC)Tcp
(C57BL/6NCrl-Pebp1em1(IMPC)Tcp/Tcp)
decreased eosinophil cell number J:211773
enlarged lymph nodes J:211773
small spleen J:211773
\Pecam1tm1Mak/\Pecam1+
(D1.129P2-Pecam1tm1Mak)
increased susceptibility to induced arthritis J:106275
\Pecam1tm1Mak/\Pecam1tm1Mak
(D1.129P2-Pecam1tm1Mak)
abnormal leukocyte physiology J:106275
increased interferon-gamma secretion J:106275
increased susceptibility to induced arthritis J:106275
joint inflammation J:106275
\Pecam1tm1Mak/\Pecam1tm1Mak
(B6.129P2-Pecam1tm1Mak)
abnormal cytokine secretion J:95226
liver inflammation J:95226
spleen vascular congestion J:95226
\Pecam1tm1Mak/\Pecam1tm1Mak
\PitgpC57BL/6/\PitgpC57BL/6

(involves: 129P2/OlaHsd * C57BL/6 * FVB/N)
peritoneal inflammation J:144817
\Peli1tm1.1Arte/\Peli1tm1.1Arte
(involves: C57BL/6N)
abnormal cytokine secretion J:191578
abnormal peripheral lymph node morphology J:191578
decreased interferon-alpha secretion J:191578
decreased interferon-beta secretion J:191578
decreased interleukin-6 secretion J:191578
decreased interleukin-10 secretion J:191578
decreased interleukin-12 secretion J:191578
decreased tumor necrosis factor secretion J:191578
enlarged lymph nodes J:191578
immune system phenotype J:191578
lymphoid hyperplasia J:191578
\Peli1tm1b(EUCOMM)Wtsi/\Peli1tm1b(EUCOMM)Wtsi
(C57BL/6N-Peli1tm1b(EUCOMM)Wtsi/Ucd)
abnormal spleen morphology J:211773
enlarged spleen J:211773
increased neutrophil cell number J:211773
increased spleen weight J:211773
\Peli1tm1Tigm/\Peli1tm1Tigm
(involves: 129/Sv * C57BL/6)
decreased B cell proliferation J:152781
decreased circulating interferon-beta level J:152781
decreased circulating interleukin-6 level J:152781
decreased circulating interleukin-12b level J:152781
decreased circulating tumor necrosis factor level J:152781
decreased interleukin-12 secretion J:152781
decreased susceptibility to endotoxin shock J:152781
increased B cell apoptosis J:152781
\Peli2tm1.1Arte/\Peli2tm1.1Arte
(involves: C57BL/6)
abnormal circulating cytokine level J:265431
abnormal cytokine secretion J:265431
decreased circulating interleukin-1 beta level J:265431
decreased interleukin-1 beta secretion J:265431
decreased interleukin-18 secretion J:265431
increased macrophage apoptosis J:265431
\Peli3tm1.1Arte/\Peli3tm1.1Arte
(involves: C57BL/6NTac)
abnormal dendritic cell physiology J:188556
abnormal macrophage cytokine production J:188556
decreased susceptibility to Picornaviridae infection J:188556
decreased susceptibility to Picornaviridae infection induced morbidity/mortality J:188556
\Penk-rstm1Pig/\Penk-rstm1Pig
(B6.129-Penk-rstm1Pig)
abnormal T-helper 2 physiology J:62435
decreased T-helper 2 cell number J:62435
lung inflammation J:62435
\Pepdtm1a(KOMP)Wtsi/\Pepdtm1a(KOMP)Wtsi
(C57BL/6N-Pepdtm1a(KOMP)Wtsi/Ucd)
decreased immature B cell number J:211773
decreased Ly6C-positive NK T cell number J:211773
decreased transitional stage T1 B cell number J:211773
increased CD4-positive, alpha-beta T cell number J:211773
increased effector memory CD8-positive, alpha-beta T cell number J:211773
increased effector memory T-helper cell number J:211773
increased leukocyte cell number J:211773
increased memory CD4-positive, CD25-positive, alpha-beta regulatory T cell number J:211773
increased memory-marker CD4-negative NK T cell number J:211773
increased memory-marker NK cell number J:211773
\Pepdtm1b(KOMP)Wtsi/\Pepdtm1b(KOMP)Wtsi
(C57BL/6N-Pepdtm1b(KOMP)Wtsi/Ieg)
decreased B-1a cell number J:211773
decreased CD5-positive Ly6C-positive T cell number J:211773
decreased follicular B cell number J:211773
enlarged lymph nodes J:211773
\Perptm1Att/\Perptm1Att
(involves: 129S4/SvJae)
decreased thymocyte apoptosis J:86549
\Perptm2Att/\Perptm2Att
\Tg(KRT14-cre/ERT2)1Ipc/0

(involves: 129S4/SvJae)
skin inflammation J:167545
\Pex1tm1.1Hrw/\Pex1tm1.1Hrw
(involves: C57BL/6NTac)
liver inflammation J:278655
phlebitis J:278655
\Pex5tm1Pec/\Pex5tm1Pec
\Cnptm1(cre)Kan/\Cnp+

(involves: 129S1/Sv * 129X1/SvJ)
abnormal inflammatory response J:123503
microgliosis J:123503
\Pex7tm1Nbra/\Pex7tm1Nbra
(involves: 129S/SvEv * C57BL/6)
liver inflammation J:158845
\Pex7tm1Rjaw/\Pex7tm1Rjaw
(Swiss)
abnormal osteoclast morphology J:92346
\Pex26tm1.1(KOMP)Vlcg/\Pex26+
(C57BL/6N-Pex26tm1.1(KOMP)Vlcg/Ucd)
enlarged spleen J:211773
\PfasSofa-2J/\Pfas+
(B6(Cg)-PfasSofa-2J/GrsrJ)
abnormal transitional stage B cell morphology J:223062
\Pfdn1Gt(GTR1.3)1Rul/\Pfdn1Gt(GTR1.3)1Rul
(involves: 129)
abnormal B cell activation J:137415
abnormal B cell differentiation J:137415
abnormal B cell morphology J:137415
abnormal neutrophil morphology J:137415
abnormal spleen morphology J:137415
abnormal spleen red pulp morphology J:137415
abnormal spleen white pulp morphology J:137415
abnormal splenic cell ratio J:137415
abnormal T cell activation J:137415
abnormal thymus cell ratio J:137415
abnormal thymus morphology J:137415
decreased B-1 B cell number J:137415
decreased B-2 B cell number J:137415
decreased pre-B cell number J:137415
decreased thymus weight J:137415
sinus inflammation J:137415
small spleen J:137415
spleen hypoplasia J:137415
thymus hypoplasia J:137415
\Pfkfb2tm1b(KOMP)Wtsi/\Pfkfb2tm1b(KOMP)Wtsi
(C57BL/6N-Pfkfb2tm1b(KOMP)Wtsi/Nju)
decreased neutrophil cell number J:211773
increased basophil cell number J:211773
increased eosinophil cell number J:211773
increased lymphocyte cell number J:211773
\Pfkfb3tm1.1Pec/\Pfkfb3tm1.1Pec
\Tg(Pdgfb-icre/ERT2,-EGFP)1Frut/0

(involves: 129S6/SvEvTac * C57BL/6 * C57BL/6NCrl * CBA)
abnormal macrophage morphology J:296552
abnormal macrophage physiology J:296552
\Pfkmtm1Fbos/\Pfkmtm1Fbos
(involves: 129S6/SvEvTac * C57BL/6J)
enlarged spleen J:152153
increased spleen weight J:152153
\Pgam1tm1.1Hiko/\Pgam1tm1.1Hiko
\Tg(Cd4-cre)1Cwi/0

(involves: C57BL/6 * DBA/2)
abnormal CD4-positive T cell differentiation J:293746
abnormal CD8-positive, alpha-beta T cell differentiation J:293746
abnormal effector T cell number J:293746
decreased acute inflammation J:293746
decreased CD4-positive, alpha-beta T cell number J:293746
decreased CD8-positive, alpha-beta T cell number J:293746
decreased interleukin-2 secretion J:293746
decreased NK T cell number J:293746
decreased susceptibility to experimental autoimmune encephalomyelitis J:293746
decreased T-helper 2 cell number J:293746
decreased T-helper 17 cell number J:293746
\Pgam5tm1d(EUCOMM)Wtsi/\Pgam5tm1d(EUCOMM)Wtsi
(involves: C57BL/6N)
abnormal interleukin-1 beta secretion J:240016
abnormal macrophage activation involved in immune response J:240016
decreased interleukin-1 beta secretion J:240016
\Pgap3tm1.1Ymra/\Pgap3tm1.1Ymra
(involves: 129 * C57BL/6)
abnormal CD4-positive, alpha-beta T cell physiology J:181221
abnormal T cell morphology J:181221
decreased T cell proliferation J:181221
immune system phenotype J:181221
increased susceptibility to experimental autoimmune encephalomyelitis J:181221
increased T cell proliferation J:181221
\Pgap3tm1.1Ymra/\Pgap3tm1.1Ymra
(B6.Cg-Pgap3tm1.1Ymra)
abnormal T-helper 2 cell differentiation J:203443
decreased B cell proliferation J:203443
immune system phenotype J:203443
impaired macrophage phagocytosis J:203443
increased anti-double stranded DNA antibody level J:203443
increased anti-single stranded DNA antibody level J:203443
increased spleen germinal center number J:203443
\Pgap3tm1Ymra/\Pgap3tm1Ymra
\Cd19tm1(cre)Cgn/\Cd19+

(involves: 129P2/OlaHsd)
immune system phenotype J:203443
\Pgap3tm1Ymra/\Pgap3tm1Ymra
\Tg(Lck-cre)#Jxm/0

(involves: C57BL/6 * CBA)
immune system phenotype J:203443
\Pgap4em1Osbir/\Pgap4em1Osbir
(involves: C57BL/6NSlc)
increased Ly6C-positive immature NK cell number J:333707
increased susceptibility to infection induced morbidity/mortality J:333707
increased susceptibility to prion infection J:333707
\Pgbd1em1(IMPC)Tcp/\Pgbd1em1(IMPC)Tcp
(C57BL/6NCrl-Pgbd1em1(IMPC)Tcp/Tcp)
abnormal lymph node morphology J:211773
enlarged lymph nodes J:211773
\Pgcem1(IMPC)Ccpcz/\Pgcem1(IMPC)Ccpcz
(C57BL/6NCrl-Pgcem1(IMPC)Ccpcz/Ccpcz)
abnormal thymus morphology J:211773
enlarged thymus J:211773
\Pgcka1em1(IMPC)Ccpcz/\Pgcka1em1(IMPC)Ccpcz
(C57BL/6NCrl-Pgcka1em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
small spleen J:211773
\Pgdtm1.1Pse/\Pgdtm1.1Pse
\Foxp3tm4(YFP/icre)Ayr/\Foxp3+

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)
abnormal CD4-positive helper T cell morphology J:313817
abnormal regulatory T cell physiology J:313817
blepharitis J:313817
ear inflammation J:313817
enlarged lymph nodes J:313817
enlarged spleen J:313817
increased circulating interferon-gamma level J:313817
increased circulating interleukin-4 level J:313817
increased circulating interleukin-5 level J:313817
increased circulating interleukin-17 level J:313817
increased IgA level J:313817
increased IgD level J:313817
increased IgE level J:313817
increased IgG2a level J:313817
increased IgG3 level J:313817
increased IgM level J:313817
increased interferon-gamma secretion J:313817
increased susceptibility to type I hypersensitivity reaction J:313817
increased T cell number J:313817
\Pgdtm1.1Pse/\Pgdtm1.1Pse
\Tg(Cd4-cre)1Cwi/0

(involves: C57BL/6 * DBA/2)
abnormal alpha-beta T cell morphology J:306553
abnormal CD8-positive, alpha beta T cell morphology J:306553
abnormal CD8-positive, alpha-beta T cell physiology J:306553
abnormal T cell differentiation J:306553
decreased CD4-positive, alpha-beta T cell number J:306553
decreased CD8-positive, alpha-beta T cell number J:306553
\Pgdtm1.1Pse/\Pgdtm1.1Pse
\Tg(Cd4-cre)1Cwi/0
\Tg(TcraTcrb)8Rest/0

(involves: C57BL/6 * DBA/2)
abnormal CD8-positive, alpha-beta T cell physiology J:306553
\Pgdtm1.1Pse/\Pgdtm1.1Pse
\Tg(Cd4-cre)1Cwi/0
\Tg(TcraTcrb)1100Mjb/0

(involves: C57BL/6 * DBA/2)
abnormal cytotoxic T cell physiology J:306553
\Pgfem1(IMPC)Ccpcz/\Pgfem1(IMPC)Ccpcz
(C57BL/6NCrl-Pgfem1(IMPC)Ccpcz/Ccpcz)
decreased NK cell number J:211773
\Pgftm1Pec/\Pgftm1Pec
(involves: 129)
decreased susceptibility to type IV hypersensitivity reaction J:81388
\Pgia1BALB/cCrl/\Pgia1DBA/2Crl
(involves: BALB/cCrl * DBA/2Crl)
increased autoantibody level J:66460
increased susceptibility to autoimmune disorder J:66460
\Pgia2BALB/cCrl/?
(involves: BALB/cCrl * DBA/2Crl)
increased autoantibody level J:66460
\Pgia3DBA/2Crl/?
(involves: BALB/cCrl * DBA/2Crl)
increased autoantibody level J:66460
increased inflammatory response J:66460
\Pgia4BALB/cCrl/?
(involves: BALB/cCrl * DBA/2Crl)
increased autoantibody level J:66460
\Pgia5BALB/cCrl/?
(involves: BALB/cCrl * DBA/2Crl)
increased inflammatory response J:66460
\Pgia6BALB/cCrl/?
(involves: BALB/cCrl * DBA/2Crl)
increased autoantibody level J:66460
\Pgia7BALB/cCrl/?
(involves: BALB/cCrl * DBA/2Crl)
increased autoantibody level J:66460
\Pgia8DBA/2/\Pgia8DBA/2
(C.D2-(D15Mit12-D15Mit267))
decreased susceptibility to induced arthritis J:137478
\Pgia8DBA/2/\Pgia8DBA/2
(involves: BALB/c * DBA/2)
decreased interleukin-6 secretion J:137478
decreased susceptibility to induced arthritis J:137478
increased tumor necrosis factor secretion J:137478
\Pgia8DBA/2Crl/?
(involves: BALB/cCrl * DBA/2Crl)
increased inflammatory response J:66460
\Pgia9BALB/cCrl/?
(involves: BALB/cCrl * DBA/2Crl)
increased inflammatory response J:66460
\Pgia9DBA/2/\Pgia9DBA/2
(C.D2-(D15Mit267-D15Mit41))
decreased susceptibility to induced arthritis J:137478
\Pgia9DBA/2/\Pgia9DBA/2
(involves: BALB/c * DBA/2)
decreased susceptibility to induced arthritis J:137478
increased interleukin-6 secretion J:137478
increased tumor necrosis factor secretion J:137478
\Pgia10BALB/cCrl/?
(involves: BALB/cCrl * DBA/2Crl)
increased autoantibody level J:66460
increased inflammatory response J:66460
\Pgia11BALB/cCrl/?
(involves: BALB/cCrl * DBA/2Crl)
increased autoantibody level J:66460
\Pgia12BALB/cCrl/?
(involves: BALB/cCrl * DBA/2Crl)
increased inflammatory response J:66460
\Pgia13C3H/HeJCr/\Pgia13C3H/HeJCr
(involves: C3H/HeJCr * C57BL/6)
increased susceptibility to induced arthritis J:65424
\Pgia14C3H/HeJCr/\Pgia14C3H/HeJCr
(involves: C3H/HeJCr * C57BL/6)
increased susceptibility to induced arthritis J:65424
\Pgia15C3H/HeJCr/\Pgia15C3H/HeJCr
(involves: C3H/HeJCr * C57BL/6)
increased susceptibility to induced arthritis J:65424
\Pgia16C3H/HeJCr/\Pgia16C3H/HeJCr
(involves: C3H/HeJCr * C57BL/6)
increased susceptibility to autoimmune disorder J:65424
\Pgia26BALB/cCrl/?
(involves: BALB/cCrl * DBA/2Crl)
increased inflammatory response J:84150
\Pgia26DBA/2Crl/?
(involves: BALB/cCrl * DBA/2Crl)
abnormal inflammatory response J:84150
\Pgia39DBA/2Crl/?
\Pgia6BALB/cCrl/\Pgia6DBA/2Crl

(involves: BALB/cCrl * DBA/2Crl)
decreased inflammatory response J:84150
\Pgia39DBA/2Crl/\Pgia39DBA/2Crl
\Pgia6DBA/2Crl/\Pgia6DBA/2Crl

(involves: BALB/cCrl * DBA/2Crl)
increased susceptibility to induced arthritis J:84150
\Pgia39DBA/2Crl/\Pgia39DBA/2Crl
\Pgia26BALB/cCrl/\Pgia26BALB/cCrl

(involves: BALB/cCrl * DBA/2Crl)
increased susceptibility to induced arthritis J:84150
\Pgis1DBA/2/\Pgis1DBA/2
(involves: BALB/c * DBA/2)
increased susceptibility to induced arthritis J:107496
\Pgis1DBA/2/\Pgis1DBA/2
\Pgis2BALB/c/\Pgis2BALB/c

(involves: BALB/c * DBA/2)
increased susceptibility to induced arthritis J:107496
\Pgis1DBA/2/\Pgis1DBA/2
\Pgis2BALB/c/\Pgis2DBA/2

(involves: BALB/c * DBA/2)
increased susceptibility to induced arthritis J:107496
\Pgis2BALB/c/\Pgis2BALB/c
(involves: BALB/c * DBA/2)
increased susceptibility to induced arthritis J:107496
\Pgis2BALB/c/\Pgis2DBA/2
(involves: BALB/c * DBA/2)
increased susceptibility to induced arthritis J:107496
\Pglyrp1tm1.1Lky/\Pglyrp1tm1.1Lky
(B6.129S4-Pglyrp1tm1.1Lky)
abnormal neutrophil physiology J:171412
increased susceptibility to bacterial infection J:171412
\Pglyrp1tm1Rdz/\Pglyrp1tm1Rdz
(involves: 129S5/SvEvBrd)
abnormal neutrophil physiology J:84680
impaired granulocyte bactericidal activity J:84680
increased susceptibility to bacterial infection J:84680
increased susceptibility to bacterial infection induced morbidity/mortality J:84680
\Pglyrp1tm1Rdz/\Pglyrp1tm1Rdz
(C.129S-Pglyrp1tm1Rdz)
increased susceptibility to induced arthritis J:178054
\Pglyrp1tm1Rdz/\Pglyrp1tm1Rdz
(involves: 129S5/SvEvBrd * BALB/c)
abnormal chemokine secretion J:178053
increased interleukin-6 secretion J:178053
increased susceptibility to induced colitis J:178053
\Pglyrp1tm1Rdz/\Pglyrp1tm1Rdz
\Pglyrp2tm1Rdz/\Pglyrp2tm1Rdz

(C.129S-Pglyrp1tm1Rdz Pglyrp2tm1Rdz)
decreased susceptibility to induced arthritis J:178054
\Pglyrp2tm1Lky/\Pglyrp2tm1Lky
(involves: 129S4/SvJae * C57BL/6)
abnormal macrophage physiology J:159600
abnormal tumor necrosis factor level J:159600
decreased circulating interleukin-6 level J:159600
decreased susceptibility to bacterial infection induced morbidity/mortality J:159600
\Pglyrp2tm1Rdz/\Pglyrp2tm1Rdz
(C.129S-Pglyrp2tm1Rdz)
abnormal circulating chemokine level J:178054
decreased susceptibility to induced arthritis J:178054
\Pglyrp2tm1Rdz/\Pglyrp2tm1Rdz
(involves: 129S/SvEv * BALB/c)
abnormal chemokine secretion J:178053
increased interleukin-6 secretion J:178053
increased susceptibility to induced colitis J:178053
\Pglyrp3tm1Rdz/\Pglyrp3tm1Rdz
(C.129S-Pglyrp3tm1Rdz)
immune system phenotype J:178054
\Pglyrp3tm1Rdz/\Pglyrp3tm1Rdz
(involves: 129S6/SvEvTac * BALB/c)
abnormal chemokine secretion J:178053
increased interleukin-6 secretion J:178053
increased susceptibility to induced colitis J:178053
\Pglyrp4em1(IMPC)Ccpcz/\Pglyrp4em1(IMPC)Ccpcz
(C57BL/6NCrl-Pglyrp4em1(IMPC)Ccpcz/Ccpcz)
abnormal lymph node morphology J:211773
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged spleen J:211773
enlarged thymus J:211773
small thymus J:211773
\Pglyrp4tm1Rdz/\Pglyrp4tm1Rdz
(C.129S-Pglyrp4tm1Rdz)
immune system phenotype J:178054
\Pglyrp4tm1Rdz/\Pglyrp4tm1Rdz
(involves: 129S6/SvEvTac * BALB/c)
abnormal chemokine secretion J:178053
increased interleukin-6 secretion J:178053
increased susceptibility to induced colitis J:178053
\Pgm3Gt(W037B08)Wrst/\Pgm3mld1
(involves: 129S1/Sv * C57BL/6)
abnormal T cell differentiation J:125094
absent follicular B cells J:125094
decreased B cell number J:125094
decreased leukocyte cell number J:125094
decreased T cell number J:125094
glomerulonephritis J:125094
increased pro-B cell number J:125094
increased spleen red pulp amount J:125094
\Pgm3mld1/\Pgm3mld1
(C57BL/6-Pgm3mld1)
abnormal thrombopoiesis J:125094
absent follicular B cells J:125094
decreased B cell number J:125094
decreased leukocyte cell number J:125094
increased pro-B cell number J:125094
increased spleen red pulp amount J:125094
increased spleen weight J:125094
\Pgrtm1Bwo/\Pgrtm1Bwo
(either: (involves: 129S7/SvEvBrd) or (involves: 129S7/SvEvBrd * C57BL/6))
uterus inflammation J:28980
\Pgrtm1Bwo/\Pgrtm1Bwo
(involves: 129S7/SvEvBrd)
abnormal osteoclast morphology J:145383
\Pgrtm1Lyd/\Pgrtm1Lyd
(involves: 129S7/SvEvBrd)
abnormal cytokine secretion J:130208
\Pgrtm2(cre)Lyd/\Pgr+
\Criptotm2.2Mms/\Criptotm2.2Mms

(involves: 129/Sv * C57BL/6N * CD-1)
endometrium inflammation J:324146
\Pgrmc1em1Ejho/\Pgrmc1em1Ejho
(involves: C57BL/6N)
liver inflammation J:268130
\Pgrmc2tm1.1Jjp/\Pgrmc2tm1.1Jjp
\Pgrtm2(cre)Lyd/\Pgr+

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)
decreased uterine NK cell number J:247103
\Phactr1em1(IMPC)Mbp/\Phactr1em1(IMPC)Mbp
(C57BL/6NCrl-Phactr1em1(IMPC)Mbp/Mmucd)
abnormal spleen morphology J:211773
decreased leukocyte cell number J:211773
enlarged lymph nodes J:211773
enlarged spleen J:211773
\Phb1em1(IMPC)H/\Phb1+
(C57BL/6NTac-Phb1em1(IMPC)H/H)
increased large unstained cell number J:211773
\Phc1tm1Os/\Phc1tm1Os
(involves: 129S2/SvPas * C57BL/6)
abnormal B cell differentiation J:75707
decreased spleen weight J:43764
decreased thymus weight J:43764
\Phc2tm1Hko/\Phc2tm1Hko
(B6.129-Phc2tm1Hko)
immune system phenotype J:100027
\PhexHyp-Duk/Y
(involves: BALB/cAnBomUrd)
ear inflammation J:132678
increased susceptibility to otitis media J:132678
\PhexHyp/?
(involves: C57BL/6J)
enthesitis J:192371
\PhexMhdabap024/Y
(C3HeB/FeJ-PhexMhdabap024)
decreased circulating C-reactive protein level J:264682
\PhexSka1/\PhexSka1
(C57BL/6-PhexSka1)
abnormal osteoclast physiology J:79953
\Phf6em1Wencc/Y
\Tg(Vav1-cre)#Cgp/0

(Not Specified)
abnormal effector T cell number J:278804
abnormal splenic cell ratio J:278804
abnormal thymus cell ratio J:278804
decreased CD4-positive, alpha-beta T cell number J:278804
decreased CD8-positive, alpha-beta T cell number J:278804
decreased double-negative T cell number J:278804
decreased lymphocyte cell number J:278804
enlarged spleen J:278804
immune system phenotype J:278804
increased B cell number J:278804
increased CD4-positive, CD25-positive, alpha-beta regulatory T cell number J:278804
increased pro-B cell number J:278804
\Phf6em1Wencc/\Phf6em1Wencc
\Tg(Vav1-cre)#Cgp/0

(Not Specified)
abnormal effector T cell number J:278804
abnormal splenic cell ratio J:278804
abnormal thymus cell ratio J:278804
decreased CD4-positive, alpha-beta T cell number J:278804
decreased CD8-positive, alpha-beta T cell number J:278804
decreased double-negative T cell number J:278804
decreased lymphocyte cell number J:278804
enlarged spleen J:278804
immune system phenotype J:278804
increased B cell number J:278804
increased CD4-positive, CD25-positive, alpha-beta regulatory T cell number J:278804
increased leukocyte cell number J:278804
increased pro-B cell number J:278804
\Phf6tm1.1Avo/Y
\Tg(Tek-cre)1Ywa/0

(involves: C57BL/6 * SJL)
abnormal T cell differentiation J:276228
decreased DN2 thymocyte number J:276228
increased circulating interferon-alpha level J:276228
increased plasmacytoid dendritic cell number J:276228
\Phf8tm1dIcs/\Phf8tm1dIcs
(C57BL/6N-Phf8tm1dIcs/Ics)
decreased lymphocyte cell number J:211773
increased neutrophil cell number J:211773
\Phf11dm1H/\Phf11dm1H
(C3H.CAnNCrl(C3)-Phf11dm1H)
abnormal inflammatory response J:217094
\Phf19tm1.1Ldc/\Phf19tm1.1Ldc
(Not Specified)
enlarged spleen J:313068
\Phf20Gt(XN131)Byg/\Phf20Gt(XN131)Byg
(involves: 129P2/OlaHsd)
abnormal T cell differentiation J:228714
decreased double-positive T cell number J:228714
decreased thymocyte number J:228714
increased double-negative T cell number J:228714
intermingled spleen red and white pulp J:228714
small spleen J:228714
small thymus J:228714
thymus hypoplasia J:228714
\Phf20l1em1(IMPC)Tcp/\Phf20l1em1(IMPC)Tcp
(C57BL/6N-Phf20l1em1(IMPC)Tcp/Tcp)
decreased lymphocyte cell number J:211773
enlarged lymph nodes J:211773
increased spleen weight J:211773
\Phipem1(IMPC)Wtsi/\Phip+
(C57BL/6N-Phipem1(IMPC)Wtsi/Wtsi)
increased leukocyte cell number J:211773
\Phka1em1(IMPC)Tcp/Y
(C57BL/6N-Phka1em1(IMPC)Tcp/Tcp)
small spleen J:211773
\Phlda1tm1Ywc/\Phlda1tm1Ywc
(involves: 129S1/Sv * C57BL/6J)
immune system phenotype J:72947
\Phldb2em1(IMPC)H/\Phldb2em1(IMPC)H
(C57BL/6NTac-Phldb2em1(IMPC)H/H)
increased basophil cell number J:211773
\Phlpp1tm1.1Saco/\Phlpp1tm1.1Saco
(involves: 129 * C57BL/6)
immune system phenotype J:231241
\Phlpp1tm1.1Saco/\Phlpp1tm1.1Saco
\Phlpp2tm1d(EUCOMM)Hmgu/\Phlpp2tm1d(EUCOMM)Hmgu

(involves: 129 * C57BL/6N)
decreased susceptibility to induced colitis J:231241
\Phlpp2tm1d(EUCOMM)Hmgu/\Phlpp2tm1d(EUCOMM)Hmgu
(involves: C57BL/6N)
immune system phenotype J:231241
\Phrf1em1(IMPC)Tcp/\Phrf1em1(IMPC)Tcp
(C57BL/6N-Phrf1em1(IMPC)Tcp/Tcp)
enlarged lymph nodes J:211773
small spleen J:211773
\Phyhtm1b(EUCOMM)Wtsi/\Phyhtm1b(EUCOMM)Wtsi
(C57BL/6N-Phyhtm1b(EUCOMM)Wtsi/Tcp)
decreased lymphocyte cell number J:211773
increased neutrophil cell number J:211773
\Phyhtm1Safe/\Phyhtm1Safe
(involves: 129P2/OlaHsd * 129X1/SvJ * Black Swiss * FVB/N)
liver inflammation J:142512
\Pi4kam1Btlr/\Pi4kam1Btlr
(C57BL/6J-Pi4kam1Btlr)
decreased macrophage apoptosis J:265261
decreased tumor necrosis factor secretion J:265261
increased interleukin-1 beta secretion J:265261
\Pi4kam2Btlr/\Pi4kam2Btlr
(C57BL/6J-Pi4kam2Btlr)
increased alpha-beta T cell number J:272852
increased CD4-positive, alpha-beta T cell number J:272852
increased central memory CD4-positive, alpha-beta T cell number J:272852
\Pi4katm1b(EUCOMM)Wtsi/\Pi4ka+
(C57BL/6N-Pi4katm1b(EUCOMM)Wtsi/Tcp)
increased monocyte cell number J:211773
\Pi4katm2.1Arte/\Pi4ka+
\Gt(ROSA)26Sortm9(cre/ESR1)Arte/\Gt(ROSA)26Sor+

(involves: C57BL/6NTac)
abnormal spleen morphology J:188779
\Pi16Gt(OST292194)Lex/\Pi16Gt(OST292194)Lex
(involves: 129S5/SvEvBrd * C57BL/6J)
abnormal lymph node B cell domain morphology J:94077
abnormal spleen germinal center morphology J:94077
increased regulatory T cell number J:94077
\Pi16tm1.2Engl/\Pi16tm1.2Engl
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6N * SJL)
abnormal immune system physiology J:244259
\Pias1tm1Kes/\Pias1tm1Kes
(involves: 129S/Sv * C57BL/6)
decreased susceptibility to Riboviria infection induced morbidity/mortality J:92167
increased susceptibility to bacterial infection induced morbidity/mortality J:92167
increased susceptibility to endotoxin shock J:92167
\Pias4tm1Rug/\Pias4tm1Rug
(involves: 129S2/SvPas * C57BL/6)
abnormal myelopoiesis J:94291
\Picalmtm1.1Tmae/\Picalmtm1.1Tmae
\Commd10Tg(Vav1-icre)A2Kio/\Commd10+

(involves: 129S6/SvEvTac * C57BL/6 * C57BL/10 * CBA * SJL)
decreased CD4-positive, alpha-beta T cell number J:220728
decreased CD8-positive, alpha-beta T cell number J:220728
\Picalmtm1.1Tmae/\Picalmtm1.1Tmae
\Tg(Mx1-cre)1Cgn/0

(involves: C57BL/6 * CBA * SJL)
decreased CD4-positive, alpha-beta T cell number J:220728
decreased CD8-positive, alpha-beta T cell number J:220728
enlarged spleen J:220728
\Picalmtm1Towa/\Picalmtm1Towa
(involves: C57BL/6J * C57BL/6NCrlj * CBA/JNCrlj)
abnormal B cell differentiation J:185312
decreased spleen B cell follicle number J:185312
enlarged spleen J:185312
\Pierce1Gt(OST3440)Lex/\Pierce1Gt(OST3440)Lex
(either: (involves: 129S5/SvEvBrd * C57BL/6J) or (involves: 129S5/SvEvBrd * C57BL/6J * FVB/N))
abnormal spleen morphology J:252050
\Pierce1tm2b(EUCOMM)Wtsi/\Pierce1tm2b(EUCOMM)Wtsi
(C57BL/6N-Pierce1tm2b(EUCOMM)Wtsi/Wtsi)
blood in lymph vessels J:239583
\Piezo1tm2.1Apat/\Piezo1tm2.1Apat
\Commd10Tg(Vav1-icre)A2Kio/\Commd10+

(involves: C57BL/6 * C57BL/10 * CBA)
abnormal splenic cell ratio J:229436
dark spleen J:229436
\Pigatm1Tak/\Pigatm1Tak
\Tg(FES-cre)31Bsl/0

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA/Ca)
abnormal T cell activation J:162065
abnormal T cell morphology J:162065
abnormal T cell physiology J:162065
decreased CD4-positive, CD25-positive, alpha-beta regulatory T cell number J:162065
\Pigrtm1Fejo/\Pigrtm1Fejo
(involves: 129P2/OlaHsd * C57BL/6)
abnormal immunoglobulin level J:57987
abnormal immunoglobulin transcytosis J:57987
decreased IgA level J:57987
increased IgA level J:57987
increased IgG level J:57987
\Pigrtm1Fejo/\Pigrtm1Fejo
(involves: 129 * C57BL/6)
increased IgA level J:140515
increased susceptibility to parasitic infection J:140515
\Pigrtm1Ohw/\Pigrtm1Ohw
(involves: 129X1/SvJ * C57BL/6J)
decreased IgA level J:58454
increased IgA level J:58454
increased IgE level J:58454
increased IgG level J:58454
\Pigrtm1Ohw/\Pigrtm1Ohw
(B6.129X1-Pigrtm1Ohw)
abnormal CD8 positive, alpha-beta intraepithelial T cell morphology J:97824
abnormal intraepithelial T cell number J:97824
abnormal lymphocyte physiology J:97824
decreased IgA level J:108538
decreased interferon-gamma secretion J:108538
decreased tumor necrosis factor secretion J:108538
increased IgA level J:108538, J:97824
increased susceptibility to bacterial infection J:108538
\Pigrtm1Ohw/\Pigrtm1Ohw
\Tcrbtm1Mom/\Tcrbtm1Mom
\Tcrdtm1Mom/\Tcrdtm1Mom

(involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6J)
decreased lymphocyte cell number J:97824
immune system phenotype J:97824
increased IgA level J:97824
\Pigrtm1Rast/\Pigrtm1Rast
(C57BL/6-Pigrtm1Rast)
abnormal immune system cell morphology J:81984
abnormal immunoglobulin level J:81984
abnormal immunoglobulin transcytosis J:81984
decreased IgA level J:81984
increased IgA level J:81984
increased IgG level J:81984
\Pigvb2b2859Clo/\Pigvb2b2859Clo
(C57BL/6J-Pigvb2b2859Clo)
thymus hypoplasia J:175213
\Pik3ap1m1Btlr/\Pik3ap1m1Btlr
(involves: C57BL/6J)
arrested B cell differentiation J:185495
decreased IgM level J:185495
immune system phenotype J:185495
\Pik3ap1m2Btlr/\Pik3ap1m2Btlr
(C57BL/6J-Pik3ap1m2Btlr)
decreased B-1a cell number J:255271
impaired humoral immune response J:255271
increased B-1b cell number J:255271
increased IgM level J:255271
\Pik3ap1M3Btlr/\Pik3ap1M3Btlr
(C57BL/6J-Pik3ap1M3Btlr)
decreased B-1 B cell number J:272019
\Pik3ap1tm1b(KOMP)Wtsi/\Pik3ap1tm1b(KOMP)Wtsi
(C57BL/6N-Pik3ap1tm1b(KOMP)Wtsi/Orl)
decreased lymphocyte cell number J:211773
increased monocyte cell number J:211773
increased neutrophil cell number J:211773
\Pik3ap1tm1Kuro/\Pik3ap1tm1Kuro
(involves: 129P2/OlaHsd)
abnormal B cell differentiation J:75075
absent B-1a cells J:84669
decreased B cell number J:84669
decreased B cell proliferation J:84669
decreased follicular B cell number J:84669
decreased IgG2b level J:75075
decreased IgG3 level J:75075
decreased IgM level J:75075
decreased immunoglobulin level J:75075
decreased pre-B cell number J:75075
spleen hypoplasia J:75075
\Pik3c2aGt(OST288105)Lex/\Pik3c2aGt(OST288105)Lex
(involves: 129S5/SvEvBrd * C57BL/6J)
enlarged spleen J:169710
glomerulonephritis J:169710
immune system phenotype J:169710
increased anti-double stranded DNA antibody level J:169710
increased B cell number J:169710
increased CD4-positive, alpha-beta T cell number J:169710
increased CD8-positive, alpha-beta T cell number J:169710
increased granulocyte number J:169710
increased IgA level J:169710
increased IgG level J:169710
increased IgM level J:169710
increased leukocyte cell number J:169710
increased monocyte cell number J:169710
increased neutrophil cell number J:169710
\Pik3c2atm1b(EUCOMM)Hmgu/\Pik3c2a+
(C57BL/6N-Pik3c2atm1b(EUCOMM)Hmgu/Tcp)
decreased lymphocyte cell number J:211773
enlarged lymph nodes J:211773
increased neutrophil cell number J:211773
\Pik3c2atm1Bvan/\Pik3c2a+
(involves: C57BL/6)
abnormal thrombopoiesis J:226344
\Pik3c3tm1.1Flv/\Pik3c3tm1.1Flv
\Tg(Cd4-cre)1Cwi/0

(involves: C57BL/6 * C57BL/6N * DBA/2)
abnormal T cell number J:184753
decreased CD4-positive, alpha-beta T cell number J:184753
decreased CD8-positive, alpha-beta T cell number J:184753
\Pik3c3tm1.1Flv/\Pik3c3tm1.1Flv
\Tg(Cd8a-cre)1Itan/0

(involves: C57BL/6 * C57BL/6N)
abnormal CD4-positive, alpha beta T cell morphology J:184753
abnormal CD8-positive, alpha beta T cell morphology J:184753
decreased CD4-positive, alpha-beta T cell number J:184753
decreased CD8-positive, alpha-beta T cell number J:184753
decreased lymphocyte cell number J:184753
immune system phenotype J:184753
increased T cell apoptosis J:184753
\Pik3catm1Jdo/\Pik3catm1Jdo
(B6.129S7(Cg)-Pik3catm1Jdo)
abnormal lymphangiogenesis J:122866
abnormal lymphatic vessel morphology J:122866
\Pik3cdem1.1Pls/\Pik3cd+
(Not Specified)
abnormal B cell differentiation J:282486
abnormal class switch recombination J:282486
abnormal follicular B cell physiology J:282486
abnormal gut-associated lymphoid tissue morphology J:282486
abnormal IgG1 level J:282486
abnormal immune tolerance J:282486
abnormal innate immunity J:282486
abnormal lymph node germinal center morphology J:282486
abnormal mesenteric lymph node morphology J:282486
abnormal Peyer's patch germinal center morphology J:282486
abnormal Peyer's patch morphology J:282486
abnormal plasmablast number J:282486
decreased B cell apoptosis J:282486
decreased CD4-positive, alpha-beta T cell number J:282486
decreased follicular B cell number J:282486
decreased leukocyte cell number J:282486
decreased naive B cell number J:282486
enlarged lymph nodes J:282486
enlarged spleen J:282486
impaired humoral immune response J:282486
increased activated T cell number J:282486
increased anti-double stranded DNA antibody level J:282486
increased anti-nuclear antigen antibody level J:282486
increased B cell proliferation J:282486
increased B-1a cell number J:282486
increased germinal center B cell number J:282486
increased IgA level J:282486
increased IgG level J:282486
increased IgM level J:282486
increased lymphocyte activation involved in immune response J:282486
increased lymphocyte cell number J:282486
increased marginal zone B cell number J:282486
increased plasma cell number J:282486
increased response to antigen J:282486
increased T follicular helper cell number J:282486
increased transitional stage B cell number J:282486
increased transitional stage T1 B cell number J:282486
lymph node hyperplasia J:282486
lymphoid hyperplasia J:282486
spleen hyperplasia J:282486
\Pik3cdGt(OST451938)Lex/\Pik3cdGt(OST451938)Lex
(involves: 129S5/SvEvBrd * C57BL/6J)
decreased IgG1 level J:103485
increased leukocyte cell number J:103485
increased lymphocyte cell number J:103485
\Pik3cdm1Btlr/\Pik3cdm1Btlr
(C57BL/6J-Pik3cdm1Btlr)
abnormal humoral immune response J:213049
\Pik3cdm2Btlr/\Pik3cd+
(C57BL/6J-Pik3cdm2Btlr)
decreased B-1 B cell number J:236693
decreased IgG level J:236693
decreased IgM level J:236693
decreased response to antigen J:236693
\Pik3cdm2Btlr/\Pik3cdm2Btlr
(C57BL/6J-Pik3cdm2Btlr)
decreased B-1 B cell number J:236693
decreased B-1a cell number J:236693
decreased IgG level J:236693
decreased IgM level J:236693
decreased response to antigen J:236693
increased circulating interferon-alpha level J:236693
increased IgE level J:236693
increased response to antigen J:236693
increased susceptibility to Herpesvirales infection J:236693
\Pik3cdtm1.1Bvan/\Pik3cdtm1.1Bvan
(involves: 129P2/OlaHsd * BALB/c)
abnormal B cell differentiation J:78412
abnormal Peyer's patch germinal center morphology J:78412
absent spleen germinal center J:78412
decreased B-1 B cell number J:78412
decreased IgA level J:78412
decreased IgM level J:78412
decreased immunoglobulin level J:78412
increased neutrophil cell number J:78412
intestinal inflammation J:78412
spleen hypoplasia J:78412
\Pik3cdtm1Jni/\Pik3cdtm1Jni
(involves: 129P2/OlaHsd)
abnormal B cell calcium ion homeostasis J:80614
abnormal humoral immune response J:80614
absent B-1 B cells J:80614
absent spleen germinal center J:80614
decreased B cell number J:80614
decreased B cell proliferation J:80614
decreased immunoglobulin level J:80614
decreased mature B cell number J:80614
small lymph nodes J:80614
small spleen J:80614
\Pik3cdtm1Jni/\Pik3cdtm1Jni
(involves: 129P2/OlaHsd * C57BL/6)
immune system phenotype J:124330
\Pik3cdtm1Jni/\Pik3cdtm1Jni
\Pik3cgtm1Pngr/\Pik3cgtm1Pngr

(involves: 129P2/OlaHsd * C57BL/6)
abnormal NK cell differentiation J:124330
decreased cytotoxic T cell cytolysis J:124330
decreased interferon-gamma secretion J:124330
decreased NK cell number J:124330
decreased T cell number J:124330
spleen hypoplasia J:124330
\Pik3cdtm1Tnr/\Pik3cdtm1Tnr
(involves: 129S4/SvJae)
abnormal B cell physiology J:113491
abnormal humoral immune response J:79133
decreased B cell number J:79133
decreased B cell proliferation J:113491, J:79133
decreased B-1 B cell number J:79133
decreased B-2 B cell number J:79133
decreased IgG1 level J:79133
decreased IgG2a level J:79133
decreased IgG2b level J:79133
decreased IgG3 level J:79133
decreased IgM level J:79133
decreased marginal zone B cell number J:79133
\Pik3cdtm1Tnr/\Pik3cdtm1Tnr
(B6.129S4-Pik3cdtm1Tnr)
decreased inflammatory response J:134324
decreased susceptibility to induced arthritis J:134324
\Pik3cdtm1Tnr/\Pik3cdtm1Tnr
\Pik3cgtm1Pngr/\Pik3cgtm1Pngr

(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)
abnormal T cell differentiation J:125791
abnormal T cell physiology J:125791
abnormal thymus lobule morphology J:125791
decreased CD4-positive, alpha-beta T cell number J:125791
decreased CD8-positive, alpha-beta T cell number J:125791
decreased double-positive T cell number J:125791
decreased lymphocyte cell number J:125791
decreased T cell number J:125791
small thymus J:125791
thymus hypoplasia J:125791
\Pik3cdtm1Tnr/\Pik3cdtm1Tnr
\Pik3cgtm1Pngr/\Pik3cgtm1Pngr

(B6.129-Pik3cdtm1Tnr Pik3cgtm1Pngr)
decreased inflammatory response J:134324
decreased susceptibility to induced arthritis J:134324
impaired neutrophil chemotaxis J:134324
impaired neutrophil recruitment J:134324
\Pik3cdtm1Tnr/\Pik3cdtm1Tnr
\Ptentm2.1Ppp/\Ptentm2.1Ppp
\Cd19tm1(cre)Cgn/\Cd19+

(involves: 129P2/OlaHsd * 129S1/Sv * 129S4/SvJae * C57BL/6)
abnormal class switch recombination J:130950
immune system phenotype J:130950
increased marginal zone B cell number J:130950
\Pik3cdtm1Tnr/\Pik3cdtm1Tnr
\Tg(BCL2)36Wehi/0

(involves: 129S4/SvJae * C57BL/6JWehi * SJL/JWehi)
decreased follicular B cell number J:130950
\Pik3cdtm2.1Tnr/\Pik3cdtm2.1Tnr
\Cd19tm1(cre)Cgn/\Cd19+

(involves: 129P2/OlaHsd * C57BL/6)
immune system phenotype J:164283
increased IgE level J:164283
\Pik3cdtm2.1Tnr/\Pik3cdtm2.1Tnr
\Tg(Cd4-cre)1Cwi/0

(involves: 129P2/OlaHsd * C57BL/6 * DBA/2)
abnormal adaptive immunity J:164283
abnormal humoral immune response J:164283
decreased CD4-positive, alpha-beta T cell number J:164283
decreased CD8-positive, alpha-beta T cell number J:164283
decreased germinal center B cell number J:164283
decreased IgG1 level J:164283
decreased spleen germinal center number J:164283
decreased spleen germinal center size J:164283
decreased T cell number J:164283
decreased T follicular helper cell number J:164283
\Pik3cdtm2.1Tnr/\Pik3cdtm2.1Tnr
\Tnfrsf4tm2(cre)Nik/\Tnfrsf4+

(involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6)
abnormal humoral immune response J:164283
decreased germinal center B cell number J:164283
decreased IgG1 level J:164283
decreased spleen germinal center number J:164283
decreased T follicular helper cell number J:164283
\Pik3cgtm1Dwu/\Pik3cgtm1Dwu
(Not Specified)
decreased immunoglobulin level J:60348
impaired neutrophil chemotaxis J:60348
\Pik3cgtm1Dwu/\Pik3cgtm1Dwu
(B6.Cg-Pik3cgtm1Dwu)
abnormal CD8-positive, alpha-beta T cell physiology J:131923
abnormal response to infection J:131923
decreased CD8-positive, alpha-beta T cell number J:131923
immune system phenotype J:131923
increased susceptibility to Poxviridae infection J:131923
\Pik3cgtm1Dwu/\Pik3cgtm1Dwu
\Tg(TcraTcrb)1100Mjb/0

(involves: C57BL/6)
abnormal CD8-positive, alpha-beta T cell physiology J:131923
abnormal response to infection J:131923
immune system phenotype J:131923
\Pik3cgtm1Ehi/\Pik3cgtm1Ehi
(Not Specified)
impaired macrophage chemotaxis J:91945
impaired neutrophil recruitment J:91945
\Pik3cgtm1Lste/\Pik3cgtm1Lste
(involves: 129P2/OlaHsd * C57BL/6)
abnormal neutrophil physiology J:147259
impaired neutrophil chemotaxis J:147259
impaired neutrophil recruitment J:147259
\Pik3cgtm1Lste/\Pik3cgtm1Lste
(involves: 129P2/OlaHsd)
impaired neutrophil chemotaxis J:238900
\Pik3cgtm1Pngr/\Pik3cgtm1Pngr
(involves: 129P2/OlaHsd * C57BL/6)
abnormal immune cell physiology J:60347
abnormal neutrophil physiology J:60347
abnormal NK cell differentiation J:124330
abnormal T cell activation J:60347
abnormal T cell differentiation J:60347
abnormal T cell physiology J:60347
abnormal T-helper 2 physiology J:60347
decreased CD4-positive, alpha-beta T cell number J:60347
decreased cytotoxic T cell cytolysis J:124330
decreased interferon-gamma secretion J:60347, J:124330
decreased interleukin-2 secretion J:60347
decreased T cell proliferation J:60347
decreased thymocyte number J:60347
impaired neutrophil chemotaxis J:60347
impaired neutrophil recruitment J:60347
increased eosinophil cell number J:60347
increased monocyte cell number J:60347
increased neutrophil cell number J:60347
thymus hypoplasia J:60347
\Pik3cgtm1Pngr/\Pik3cgtm1Pngr
(B6.129P2-Pik3cgtm1Pngr)
decreased inflammatory response J:134324
decreased susceptibility to induced arthritis J:134324
impaired neutrophil chemotaxis J:134324
\Pik3cgtm1Wym/\Pik3cgtm1Wym
(either: 129/Sv-Pik3cgtm1Wym or (involves: 129S1/Sv * 129X1/SvJ * C57BL/6))
abnormal leukocyte physiology J:60349
abnormal neutrophil physiology J:60349
impaired macrophage chemotaxis J:60349
impaired neutrophil chemotaxis J:60349
impaired neutrophil recruitment J:60349
increased neutrophil cell number J:60349
increased susceptibility to bacterial infection J:60349
\Pik3cgtm1Wym/\Pik3cgtm1Wym
(involves: 129S1/Sv * 129X1/SvJ)
abnormal neutrophil physiology J:147259
impaired neutrophil chemotaxis J:238900
impaired neutrophil recruitment J:147259
\Pik3cgtm2Ehi/\Pik3cgtm2Ehi
(Not Specified)
abnormal inflammatory response J:124856
abnormal macrophage physiology J:124856
decreased macrophage cell number J:124856
decreased neutrophil cell number J:124856
impaired macrophage chemotaxis J:124856
impaired neutrophil chemotaxis J:124856
increased interleukin-1 beta secretion J:124856
increased interleukin-6 secretion J:124856
increased leukocyte cell number J:124856
increased tumor necrosis factor secretion J:124856
\Pik3ip1m1Anu/\Pik3ip1m1Anu
(C57BL/6NCrlAnu-Pik3ip1m1Anu)
immune system phenotype J:104190
\Pik3r1m1Btlr/\Pik3r1m1Btlr
(C57BL/6J-Pik3r1m1Btlr)
decreased B cell number J:254890
decreased B-1a cell number J:254890
increased CD4-positive, CD25-positive, alpha-beta regulatory T cell number J:254890
increased CD8-positive, alpha-beta memory T cell number J:254890
\Pik3r1M2Btlr/\Pik3r1+
(C57BL/6J-Pik3r1M2Btlr)
decreased B-1 B cell number J:254892
decreased B-1a cell number J:254892
decreased B-1b cell number J:254892
decreased B-2 B cell number J:254892
decreased NK T cell number J:254892
increased B-1b cell number J:254892
\Pik3r1m3Btlr/\Pik3r1m3Btlr
(C57BL/6J-Pik3r1m3Btlr)
increased B-1b cell number J:272853
\Pik3r1tm1Dfr/\Pik3r1tm1Dfr
(involves: 129S6/SvEvTac * C57BL/6)
arrested B cell differentiation J:52229
decreased B cell proliferation J:52229
decreased mature B cell number J:52229
\Pik3r1tm1Dfr/\Pik3r1tm1Dfr
(involves: 129S6/SvEvTac)
abnormal B cell differentiation J:104166
decreased immature B cell number J:104166
decreased mature B cell number J:104166
decreased pre-B cell number J:104166
increased pro-B cell number J:104166
\Pik3r1tm1Dfr/\Pik3r1tm1Dfr
\Plcg2tm1Jni/\Plcg2tm1Jni

(involves: 129P2/OlaHsd * 129S6/SvEvTac)
abnormal B cell differentiation J:104166
arrested B cell differentiation J:104166
decreased immature B cell number J:104166
decreased mature B cell number J:104166
decreased pre-B cell number J:104166
immune system phenotype J:104166
increased B cell apoptosis J:104166
\Pik3r1tm1Tka/\Pik3r1tm1Tka
(involves: C57BL/6 * CBA)
abnormal B cell physiology J:113491
abnormal humoral immune response J:52228
decreased B cell number J:52228
decreased B cell proliferation J:113491, J:52228
decreased mature B cell number J:52228
decreased pre-B cell number J:52228
decreased pro-B cell number J:52228
increased susceptibility to bacterial infection J:52228
\Pik3r1tm2Dfr/\Pik3r1tm2Dfr
(either: C.129S6-Pik3r1tm2Dfr or (involves: 129S6/SvEvTac * BALB/c * C57BL/6))
abnormal B cell differentiation J:94077
\Pik3r4tm1.1Mpnd/\Pik3r4tm1.1Mpnd
\Tg(ACTA1-cre)79Jme/0

(involves: 129S2/SvPas * C57BL/6J * C57BL/6N * SJL)
myositis J:198770
\Pik3r5tm1Lste/\Pik3r5tm1Lste
(involves: 129P2/OlaHsd * C57BL/6)
impaired neutrophil chemotaxis J:147259
impaired neutrophil recruitment J:147259
\Pik3r5tm1Lste/\Pik3r5tm1Lste
(involves: 129P2/OlaHsd)
impaired neutrophil chemotaxis J:238900
increased neutrophil cell number J:238900
\Pik3r6tm1.1Lste/\Pik3r6tm1.1Lste
(Not Specified)
abnormal neutrophil physiology J:238900
decreased granulocyte number J:238900
decreased lymphocyte cell number J:238900
immune system phenotype J:238900
increased neutrophil cell number J:238900
\PikfyveGt(AT0926)Wtsi/\PikfyveGt(AT0926)Wtsi
(involves: 129P2/OlaHsd * C57BL/6)
abnormal spleen morphology J:190368
abnormal thymus morphology J:190368
spleen hypoplasia J:190368
thymus hypoplasia J:190368
\Pikfyvetm2.1Tssk/\Pikfyvetm2.1Tssk
\Tg(Vil1-cre)20Syr/0

(involves: 129P2/OlaHsd * C57BL/6 * DBA/2)
intestinal inflammation J:193689
\Pilratm1Osb/\Pilratm1Osb
(B6.129-Pilratm1Osb)
abnormal leukocyte adhesion J:191085
abnormal neutrophil physiology J:191085
increased neutrophil cell number J:191085
increased susceptibility to bacterial infection induced morbidity/mortality J:191085
increased susceptibility to endotoxin shock J:191085
\Pilrb1tm1Pgh/\Pilrb1tm1Pgh
(involves: C57BL/6)
abnormal chemokine level J:157763
abnormal cytokine level J:157763
abnormal cytokine secretion J:157763
decreased circulating interleukin-1 beta level J:157763
decreased circulating interleukin-6 level J:157763
decreased circulating tumor necrosis factor level J:157763
decreased interleukin-1 beta secretion J:157763
decreased susceptibility to bacterial infection J:157763
decreased susceptibility to bacterial infection induced morbidity/mortality J:157763
decreased tumor necrosis factor secretion J:157763
increased circulating interferon-gamma level J:157763
increased circulating interleukin-12 level J:157763
increased interferon-gamma secretion J:157763
increased interleukin-10 secretion J:157763
increased interleukin-12 secretion J:157763
\Pim1tm1Pwl/\Pim1tm1Pwl
(involves: 129P2/OlaHsd * BALB/c)
abnormal mast cell physiology J:15259, J:14715
\Pim1tm1Pwl/\Pim1tm1Pwl
\Pim2tm1Brn/\Pim2tm1Brn
\Pim3tm1Brn/\Pim3tm1Brn

(involves: 129P/Ola * FVB/N)
decreased B cell number J:91592
decreased B cell proliferation J:91592
decreased pre-B cell number J:91592
decreased pro-B cell number J:91592
decreased T cell proliferation J:91592
increased early pro-B cell number J:91592
\Pim2tm1.1Lex/\Pim2tm1.1Lex
(involves: 129S/SvEvBrd * C57BL/6)
decreased interleukin-6 secretion J:166403
\Pim2tm1Brn/\Pim2tm1Brn
(involves: 129P/Ola * FVB/N)
decreased T cell proliferation J:91592
\Pink1tm1Hbu/\Pink1tm1Hbu
(involves: 129S7/SvEvBrd * C57BL/6)
increased interleukin-1 beta secretion J:169471
increased interleukin-10 secretion J:169471
increased interleukin-12 secretion J:169471
\Pip4k2ctm1b(KOMP)Wtsi/\Pip4k2ctm1b(KOMP)Wtsi
(involves: C57BL/6J * C57BL/6N)
abnormal circulating chemokine level J:234283
abnormal T cell activation J:234283
chronic inflammation J:234283
chronic liver inflammation J:234283
decreased regulatory T cell number J:234283
increased CD4-positive, alpha-beta T cell number J:234283
increased CD8-positive, alpha-beta T cell number J:234283
increased circulating interferon-gamma level J:234283
increased circulating interleukin-2 level J:234283
increased circulating interleukin-4 level J:234283
increased circulating interleukin-10 level J:234283
increased circulating interleukin-12 level J:234283
increased circulating interleukin-12b level J:234283
increased IgG3 level J:234283
increased inflammatory response J:234283
increased interferon-gamma secretion J:234283
increased interleukin-17 secretion J:234283
increased T cell proliferation J:234283
increased T-helper cell number J:234283
intestinal inflammation J:234283
kidney inflammation J:234283
lung inflammation J:234283
salivary gland inflammation J:234283
\Pip4p1em1(IMPC)Ccpcz/\Pip4p1em1(IMPC)Ccpcz
(C57BL/6N-Pip4p1em1(IMPC)Ccpcz/Ccpcz)
increased CD4-negative, CD25-positive NK T cell number J:211773
\Pip5k1btm1Tssk/\Pip5k1btm1Tssk
(involves: 129P2/OlaHsd * C57BL/6)
abnormal mast cell physiology J:97991
increased susceptibility to type I hypersensitivity reaction J:97991
\Pip5k1ctm1.2Ref/\Pip5k1ctm1.2Ref
\Tg(TcraTcrb)425Cbn/0

(involves: BALB/c * C57BL/6)
abnormal T cell physiology J:164732
decreased B cell number J:164732
decreased dendritic cell number J:164732
increased interferon-gamma secretion J:164732
increased interleukin-2 secretion J:164732
increased T cell proliferation J:164732
\Piptm1Myal/\Piptm1Myal
(involves: 129S/SvEv * C57BL/6)
abnormal thymus corticomedullary boundary morphology J:202016
arteritis J:202016
colitis J:202016
enlarged submandibular lymph nodes J:202016
enlarged thymus J:202016
enlarged thymus medulla J:202016
\Pirbem1Fgla/\Pirbem1Fgla
(C57BL/6-Pirbem1Fgla)
decreased length of allograft survival J:290663
\Pirbtm1Ttk/\Pirbtm1Ttk
(involves: 129X1/SvJ)
abnormal B cell activation J:76770
abnormal dendritic cell differentiation J:76770
abnormal immune system cell morphology J:76770
abnormal leukocyte physiology J:76770
abnormal T cell physiology J:76770
abnormal T-helper 2 physiology J:76770
increased B cell proliferation J:76770
increased B-1 B cell number J:76770
\Pitm1C57BL/FaDk/\Pitm1C57BL/FaDk
(involves: C57BL/FaDk * RIII/FaDk)
decreased susceptibility to prion infection J:70033
\Pitm1C57BL/FaDk/\Pitm1RIII/FaDk
(involves: C57BL/FaDk * RIII/FaDk)
decreased susceptibility to prion infection J:70033
\Pitm2C57BL/FaDk/\Pitm2C57BL/FaDk
(involves: C57BL/FaDk * RIII/FaDk)
decreased susceptibility to prion infection J:70033
\Pitm2C57BL/FaDk/\Pitm2RIII/FaDk
(involves: C57BL/FaDk * RIII/FaDk)
decreased susceptibility to prion infection J:70033
\Pitm3C57BL/FaDk/\Pitm3C57BL/FaDk
(involves: C57BL/FaDk * RIII/FaDk)
decreased susceptibility to prion infection J:70033
\Pitm3C57BL/FaDk/\Pitm3RIII/FaDk
(involves: C57BL/FaDk * RIII/FaDk)
decreased susceptibility to prion infection J:70033
\Pitm4C57BL/FaDk/\Pitm4C57BL/FaDk
(involves: C57BL/FaDk * RIII/FaDk)
decreased susceptibility to prion infection J:70033
\Pitm4C57BL/FaDk/\Pitm4RIII/FaDk
(involves: C57BL/FaDk * RIII/FaDk)
decreased susceptibility to prion infection J:70033
\Pitpnm1tm1a(EUCOMM)Wtsi/\Pitpnm1tm1a(EUCOMM)Wtsi
(involves: C57BL/6N)
decreased leukocyte cell number J:207051
\Pitx2tm1Hmd/\Pitx2tm1Hmd
(involves: C3H * C57BL/6 * C57BL/6J)
small spleen J:128475
\Pitx2tm1Jfm/\Pitx2tm1Jfm
(involves: 129S4/SvJaeSor)
spleen hypoplasia J:57674
\Pitx2tm1Rsd/\Pitx2tm1Rsd
(involves: 129S1/Sv * 129X1/SvJ)
abnormal spleen morphology J:57673
\Pitx2tm3.1Jfm/\Pitx2tm3.1Jfm
(involves: 129S4/SvJaeSor)
small spleen J:92872
\Pitx3eyl/\Pitx3eyl
(involves: C3H/He * C57BL/6)
abnormal immunoglobulin level J:156878
decreased IgG3 level J:156878
decreased IgM level J:156878
decreased leukocyte cell number J:156878
increased CD4-positive, alpha-beta T cell number J:156878
increased CD8-positive, alpha-beta T cell number J:156878
increased granulocyte number J:156878
\Pitx3tm1.1Cai/\Pitx3+
\Tg(tetO-SNCA*A53T)E2Cai/0

(involves: 129 * C57BL/6J * FVB/N)
microgliosis J:185958
\Pja2tm1.2Afel/\Pja2tm1.2Afel
(involves: 129S6/SvEvTac * C57BL/6J)
kidney inflammation J:345592
\Pja2tm1b(EUCOMM)Wtsi/\Pja2+
(C57BL/6N-Pja2tm1b(EUCOMM)Wtsi/Bay)
abnormal spleen morphology J:211773
\Pja2tm1b(EUCOMM)Wtsi/\Pja2tm1b(EUCOMM)Wtsi
(C57BL/6N-Pja2tm1b(EUCOMM)Wtsi/Bay)
abnormal spleen morphology J:211773
\Pkd1tm1b(EUCOMM)Hmgu/\Pkd1+
(C57BL/6N-Pkd1tm1b(EUCOMM)Hmgu/Bay)
increased neutrophil cell number J:211773
\Pkd1tm1Djmp/\Pkd1tm1Djmp
(involves: 129P2/OlaHsd * C57BL/6)
kidney inflammation J:94582
\Pkd1tm1Jzh/\Pkd1+
(either: (involves: 129S4/SvJae * C57BL/6) or (involves: 129S4/SvJae * BALB/c))
bile duct inflammation J:52573
kidney inflammation J:52573
\Pkd2tm1Dwo/\Pkd2tm1Dwo
(either: (involves: 129S1/Sv * 129X1/SvJ) or (involves: 129S1/Sv * 129X1/SvJ * C57BL/6))
absent spleen J:77401
\Pkhd1tm1.1Ggg/\Pkhd1tm1.1Ggg
(involves: 129S/SvEv * 129S4/SvJae * C57BL/6)
bile duct inflammation J:125113
\Pkhd1tm1Som/\Pkhd1tm1Som
(involves: 129S/SvEv * C57BL/6)
enlarged spleen J:131370
\Pkhd1l1em1(IMPC)H/\Pkhd1l1em1(IMPC)H
(C57BL/6N-Pkhd1l1em1(IMPC)H/H)
decreased lymphocyte cell number J:211773
increased monocyte cell number J:211773
increased neutrophil cell number J:211773
\Pklrchar4/\Pklrchar4
(involves: A/J * C57BL/6)
decreased susceptibility to parasitic infection J:141722, J:86735
decreased susceptibility to parasitic infection induced morbidity/mortality J:141722
enlarged spleen J:86735
\Pklrslc/\Pklrslc
(CBA/NSlc-Pklrslc)
decreased susceptibility to parasitic infection J:141722
decreased susceptibility to parasitic infection induced morbidity/mortality J:141722
enlarged spleen J:30035
increased susceptibility to bacterial infection induced morbidity/mortality J:128518
\Pkn1tm1b(KOMP)Wtsi/\Pkn1tm1b(KOMP)Wtsi
(C57BL/6N-Pkn1tm1b(KOMP)Wtsi/H)
decreased large unstained cell number J:211773
decreased leukocyte cell number J:211773
decreased lymphocyte cell number J:211773
decreased neutrophil cell number J:211773
\Pkn1tm1Kik/\Pkn1tm1Kik
(B6.129P2-Pkn1tm1Kik)
abnormal germinal center B cell physiology J:193187
abnormal somatic hypermutation frequency J:193187
decreased activation-induced B cell apoptosis J:193187
glomerulonephritis J:193187
immune system phenotype J:193187
increased anti-double stranded DNA antibody level J:193187
increased B cell proliferation J:193187
increased germinal center B cell number J:193187
increased IgG1 level J:193187
increased IgG2a level J:193187
increased IgG2b level J:193187
increased IgM level J:193187
increased spleen germinal center size J:193187
increased splenocyte number J:193187
\Pkn3tm1.1Mrl/\Pkn3+
\Ptentm1Hwu/\Ptentm1Hwu
\Tg(Mx1-cre)1Cgn/0

(involves: 129S4/SvJae * C57BL/6 * CBA/J)
enlarged spleen J:216983
enlarged thymus J:216983
\Pkn3tm1.1Mrl/\Pkn3tm1.1Mrl
\Ptentm1Hwu/\Ptentm1Hwu
\Tg(Mx1-cre)1Cgn/0

(involves: 129S4/SvJae * C57BL/6 * CBA/J)
enlarged spleen J:216983
enlarged thymus J:216983
\Pknox1Gt(OST71835)Lex/\Pknox1Gt(OST71835)Lex
(involves: 129S5/SvEvBrd * C57BL/6)
decreased single-positive T cell number J:103769
increased double-negative T cell number J:103769
increased T cell apoptosis J:103769
thymus hypoplasia J:103769
\Pknox1tm1Ngc/\Pknox1+
\Tg(IghMyc)22Bri/0

(involves: C57BL * SJL)
decreased B cell apoptosis J:192251
increased B cell proliferation J:192251
\Pknox1tm2.1Fbla/\Pknox1tm2.1Fbla
\Gt(ROSA)26Sortm2(cre/ERT2)Brn/\Gt(ROSA)26Sor+

(involves: 129P2/OlaHsd)
decreased pre-B cell number J:192251
increased pro-B cell number J:192251
\Pknox2em1(IMPC)Ccpcz/\Pknox2em1(IMPC)Ccpcz
(C57BL/6N-Pknox2em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
small spleen J:211773
\Pkp3tm1.1Fvr/\Pkp3tm1.1Fvr
(involves: 129P2/OlaHsd * C57BL/6 * CBA * SJL)
dermatitis J:136451
enlarged lymph nodes J:136451
\Pla1aem1(IMPC)J/\Pla1aem1(IMPC)J
(C57BL/6NJ-Pla1aem1(IMPC)J/Mmjax)
decreased leukocyte cell number J:211773
\Pla1aem1Appsc/\Pla1aem1Appsc
(C57BL/6J-Pla1aem1Appsc)
abnormal interleukin level J:333902
decreased susceptibility to chemically induced skin inflammation J:333902
decreased susceptibility to induced arthritis J:333902
increased lymphocyte cell number J:333902
\Pla2g2dtm1.1(KOMP)Vlcg/\Pla2g2dtm1.1(KOMP)Vlcg
(C57BL/6N-Pla2g2dtm1.1(KOMP)Vlcg/J)
decreased leukocyte cell number J:211773
\Pla2g2dtm1.1Mhg/\Pla2g2dtm1.1Mhg
(B6.Cg-Pla2g2dtm1.1Mhg)
immune system phenotype J:197334
\Pla2g2dtm1.1Mhg/\Pla2g2dtm1.1Mhg
(B6NCrSlc.Cg-Pla2g2dtm1.1Mhg)
abnormal cytotoxic T cell physiology J:229035
abnormal dendritic cell migration J:229035
abnormal dendritic cell physiology J:201008
abnormal effector T cell morphology J:201008
decreased interleukin-6 secretion J:201008
decreased susceptibility to Coronaviridae infection J:229035
decreased susceptibility to Coronaviridae infection induced morbidity/mortality J:229035
decreased tumor necrosis factor secretion J:201008
immune system phenotype J:201008
increased CD4-positive, alpha-beta T cell number J:229035, J:201008
increased CD8-positive, alpha-beta T cell number J:229035
increased dendritic cell number J:201008
increased interferon-gamma secretion J:229035
increased susceptibility to type IV hypersensitivity reaction J:201008
\Pla2g2etm1Mhg/\Pla2g2etm1Mhg
(B6.Cg-Pla2g2etm1Mhg)
immune system phenotype J:197334
\Pla2g2ftm1Mhg/\Pla2g2ftm1Mhg
(B6.Cg-Pla2g2ftm1Mhg)
immune system phenotype J:197334
\Pla2g3tm1Murm/\Pla2g3tm1Murm
(involves: 129S/SvEv * C57BL/6)
abnormal mast cell differentiation J:197334
abnormal mast cell morphology J:197334
decreased mast cell degranulation J:197334
decreased susceptibility to type I hypersensitivity reaction J:197334
ear inflammation J:197334
\Pla2g4atm1Jvb/\Pla2g4atm1Jvb
(involves: 129S4/SvJae)
abnormal mast cell differentiation J:54619
increased mast cell degranulation J:54619
\Pla2g4atm1Jvb/\Pla2g4atm1Jvb
(involves: 129S4/SvJae * BALB/c)
immune system phenotype J:110309
\Pla2g4atm1Tksh/\Pla2g4atm1Tksh
(involves: 129P2/OlaHsd * C57BL/6J)
increased susceptibility to type I hypersensitivity reaction J:39254
\Pla2g4atm1Tksh/\Pla2g4atm1Tksh
(NOD.129P2(B6)-Pla2g4atm1Tksh)
abnormal macrophage physiology J:99775
insulitis J:99775
\Pla2g4atm1Tksh/\Pla2g4atm1Tksh
(B6.129P2-Pla2g4atm1Tksh)
abnormal cytokine level J:107430
decreased interferon-gamma secretion J:107430
decreased susceptibility to experimental autoimmune encephalomyelitis J:107430
decreased tumor necrosis factor secretion J:107430
immune system phenotype J:197334
\Pla2g4eem1Murm/\Pla2g4eem1Murm
(C57BL/6NSlc-Pla2g4eem1Murm)
increased susceptibility to chemically induced skin inflammation J:333700
\Pla2g5em1(IMPC)Ccpcz/\Pla2g5em1(IMPC)Ccpcz
(C57BL/6NCrl-Pla2g5em1(IMPC)Ccpcz/Ccpcz)
abnormal lymph node morphology J:211773
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged lymph nodes J:211773
enlarged spleen J:211773
enlarged thymus J:211773
increased eosinophil cell number J:211773
\Pla2g5tm1Jarm/\Pla2g5tm1Jarm
(involves: 129 * C57BL/6J)
abnormal macrophage physiology J:89490
decreased acute inflammation J:89490
\Pla2g5tm1Jarm/\Pla2g5tm1Jarm
(involves: 129 * BALB/c)
impaired macrophage phagocytosis J:110309
\Pla2g5tm1Jarm/\Pla2g5tm1Jarm
(C.129-Pla2g5tm1Jarm)
impaired macrophage phagocytosis J:110309
\Pla2g5tm1Jarm/\Pla2g5tm1Jarm
(involves: 129 * C57BL/6)
impaired macrophage phagocytosis J:110309
\Pla2g5tm1Jarm/\Pla2g5tm1Jarm
(B6.129-Pla2g5tm1Jarm)
immune system phenotype J:197334
impaired macrophage phagocytosis J:110309
\Pla2g6m1Sein/\Pla2g6m1Sein
(C57BL/6JJcl-Pla2g6m1Sein)
decreased double-positive T cell number J:155328
\Pla2g7tm1.1Mcap/\Pla2g7tm1.1Mcap
(B6.Cg-Pla2g7tm1.1Mcap)
decreased susceptibility to bacterial infection induced morbidity/mortality J:228564
increased susceptibility to bacterial infection J:228564
\Pla2g10Gt712Lex/\Pla2g10Gt712Lex
(involves: 129S5/SvEvBrd * C57BL/6J)
abnormal interleukin level J:125607
decreased CD4-positive, alpha-beta T cell number J:125607
decreased CD8-positive, alpha-beta T cell number J:125607
decreased eosinophil cell number J:125607
decreased IgE level J:125607
decreased inflammatory response J:125607
decreased T cell number J:125607
\Pla2g10tm1Kiku/\Pla2g10tm1Kiku
(B6.129P2-Pla2g10tm1Kiku)
abnormal neutrophil physiology J:155082
decreased neutrophil cell number J:155082
immune system phenotype J:197334
impaired neutrophil chemotaxis J:155082
\Pla2g15tm1.1Jash/\Pla2g15tm1.1Jash
(involves: 129S1/Sv * C57BL/6)
abnormal macrophage morphology J:111561
abnormal macrophage physiology J:111561
abnormal spleen morphology J:111561
increased macrophage cell number J:111561
increased macrophage derived foam cell number J:111561
increased spleen weight J:111561
\Pla2r1tm1Itoh/\Pla2r1tm1Itoh
(involves: 129P2/OlaHsd * C57BL/6)
decreased susceptibility to endotoxin shock J:44868
\Plaat3em1(IMPC)Tcp/\Plaat3em1(IMPC)Tcp
(C57BL/6NCrl-Plaat3em1(IMPC)Tcp/Tcp)
abnormal spleen morphology J:211773
\Plaat3em1Ueda/\Plaat3em1Ueda
(C57BL/6NCrSlc-Plaat3em1Ueda)
white adipose tissue inflammation J:343807
\Plaat5em1(IMPC)Tcp/\Plaat5em1(IMPC)Tcp
(C57BL/6N-Plaat5em1(IMPC)Tcp/Tcp)
increased eosinophil cell number J:211773
\Plac8tm1Bhk/\Plac8tm1Bhk
(involves: 129S6/SvEvTac * C57BL/6)
abnormal neutrophil physiology J:145277
\Plac8tm1Bhk/\Plac8tm1Bhk
(129S/SvEv-Plac8tm1Bhk)
abnormal neutrophil physiology J:145277
increased leukocyte cell number J:145277
increased neutrophil cell number J:145277
increased susceptibility to bacterial infection J:145277
\Plac9tm1b(EUCOMM)Hmgu/\Plac9tm1b(EUCOMM)Hmgu
(C57BL/6N-Plac9tm1b(EUCOMM)Hmgu/H)
decreased neutrophil cell number J:211773
\Plag1em1(IMPC)Hmgu/\Plag1em1(IMPC)Hmgu
(C57BL/6N-Plag1em1(IMPC)Hmgu/Ieg)
decreased CD8-positive, naive alpha-beta T cell number J:211773
\Plattm1Mlg/\Plattm1Mlg
(involves: 129S2/SvPas * C57BL/6)
abnormal acute phase protein level J:63134, J:82604
immune system phenotype J:17427
increased macrophage cell number J:63134
\Plattm1Mlg/\Plattm1Mlg
(B6.Cg-Plattm1Mlg)
abnormal acute phase protein level J:75303
abnormal cytokine level J:75303
autoimmune arthritis J:75303
chronic joint inflammation J:75303
\Plattm1Mlg/\Plattm1Mlg
(involves: 129S2/SvPas)
abnormal microglial cell physiology J:144185
\Plattm1Mlg/\Plattm1Mlg
(B6.129S2-Plattm1Mlg/J)
abnormal susceptibility to Coronaviridae infection J:288556
increased susceptibility to Coronaviridae infection induced morbidity/mortality J:288556
\Plautm1.1Bug/\Plautm1.1Bug
(involves: C57BL/6)
chronic inflammation J:164542
liver inflammation J:164542
trachea inflammation J:164542
\Plautm1b(EUCOMM)Wtsi/\Plautm1b(EUCOMM)Wtsi
(C57BL/6N-Plautm1b(EUCOMM)Wtsi/H)
increased monocyte cell number J:211773
increased neutrophil cell number J:211773
\Plautm1Mlg/\Plautm1Mlg
(involves: 129S2/SvPas * C57BL/6)
abnormal acute phase protein level J:63134, J:82604
abnormal cell-mediated immunity J:87817, J:95638
abnormal macrophage physiology J:17427
abnormal neutrophil physiology J:75573, J:91980
impaired granulocyte bactericidal activity J:91980
impaired macrophage chemotaxis J:63134
impaired neutrophil phagocytosis J:91980
increased lymphocyte cell number J:63134
increased susceptibility to fungal infection J:95637
increased susceptibility to parasitic infection J:87817
\Plautm1Mlg/\Plautm1Mlg
(B6.Cg-Plautm1Mlg)
abnormal acute phase protein level J:68083
abnormal cytokine level J:75303
decreased inflammatory response J:68083
decreased susceptibility to induced arthritis J:75303
decreased T cell proliferation J:75303
impaired macrophage chemotaxis J:68083
\Plautm1Mlg/\Plautm1Mlg
(B6.129S2-Plautm1Mlg)
chronic inflammation J:164542
increased inflammatory response J:164542
liver inflammation J:164542
trachea inflammation J:164542
\Plaurtm1Jld/\Plaurtm1Jld
(involves: 129P2/OlaHsd * Black Swiss)
abnormal macrophage physiology J:26874
\Plaurtm1Jld/\Plaurtm1Jld
(B6.129P2-Plaurtm1Jld)
chronic inflammation J:164542
increased inflammatory response J:164542
liver inflammation J:164542
trachea inflammation J:164542
\Plaurtm1Jld/\Plaurtm1Jld
\Tg(MSR1-Plau)1Ddi/0

(B6.Cg-Plaurtm1Jld Tg(MSR1-Plau)1Ddi)
heart inflammation J:113474
\Plaurtm1Mlg/\Plaurtm1Mlg
(involves: 129S2/SvPas * C57BL/6)
abnormal cytokine level J:75573
abnormal macrophage physiology J:31253
abnormal neutrophil physiology J:75573, J:91980
impaired neutrophil phagocytosis J:91980
increased susceptibility to bacterial infection J:75573
\Plcb1em1(IMPC)Mbp/\Plcb1+
(C57BL/6N-Plcb1em1(IMPC)Mbp/MbpMmucd)
abnormal lymph node morphology J:211773
abnormal spleen morphology J:211773
enlarged lymph nodes J:211773
enlarged spleen J:211773
\Plcb2tm1b(KOMP)Wtsi/\Plcb2tm1b(KOMP)Wtsi
(C57BL/6N-Plcb2tm1b(KOMP)Wtsi/Ucd)
abnormal spleen morphology J:211773
enlarged spleen J:211773
\Plcb2tm1Dwu/\Plcb2tm1Dwu
(involves: 129)
abnormal leukocyte physiology J:41948
decreased susceptibility to bacterial infection J:41948
decreased susceptibility to infection J:41948
decreased susceptibility to viral infection J:41948
\Plcb2tm1Dwu/\Plcb2tm1Dwu
\Plcb3tm1Dwu/\Plcb3tm1Dwu

(involves: 129S1/Sv)
abnormal neutrophil physiology J:60348
increased immunoglobulin level J:60348
\Plcd1tm1.1Kfu/\Plcd1tm1.1Kfu
\Tg(KRT14-cre)1Amc/0

(involves: C57BL/6 * C57BL/6JJcl * CBA)
decreased B cell number J:205633
enlarged inguinal lymph nodes J:205633
increased circulating interleukin-17 level J:205633
increased granulocyte number J:205633
increased interleukin-17 secretion J:205633
increased NK T cell number J:205633
increased susceptibility to type IV hypersensitivity reaction J:205633
\Plcd1tm1Tta/\Plcd1tm1Tta
(involves: 129P2/OlaHsd)
abnormal granulocyte differentiation J:205633
decreased B cell number J:205633
enlarged axillary lymph nodes J:205633
enlarged inguinal lymph nodes J:205633
enlarged lymph nodes J:205633
enlarged spleen J:205633
increased circulating interleukin-17 level J:205633
increased granulocyte number J:205633
increased interleukin-17 secretion J:205633
increased leukocyte cell number J:205633
\Plce1em1(IMPC)Mbp/\Plce1em1(IMPC)Mbp
(C57BL/6N-Plce1em1(IMPC)Mbp/MbpMmucd)
decreased lymphocyte cell number J:211773
increased monocyte cell number J:211773
increased neutrophil cell number J:211773
\Plcg1tm1Gcrp/\Plcg1tm1Rwen
\Tg(Cd4-cre)1Cwi/0

(either: B6.Cg-Plcg1tm1Gcrp/Plcg1tm1Rwen Tg(Cd4-cre)1Cwi or (involves: 129X1/SvJ * C57BL/6 * DBA/2))
abnormal T cell activation J:157757
decreased regulatory T cell number J:157757
decreased T cell number J:157757
dermatitis J:157757
ear inflammation J:157757
increased anti-double stranded DNA antibody level J:157757
increased CD4-positive, alpha-beta T cell number J:157757
increased T cell proliferation J:157757
skin inflammation J:157757
\Plcg1tm1Gcrp/\Plcg1tm1Rwen
\Tg(Cd4-cre)1Cwi/0
\Tg(TcraH-Y,TcrbH-Y)71Vbo/0

(involves: 129X1/SvJ * C57BL/6 * DBA/2)
decreased CD8-positive, alpha-beta T cell number J:157757
decreased double-negative T cell number J:157757
increased CD8-positive, alpha-beta T cell number J:157757
increased double-positive T cell number J:157757
thymus hyperplasia J:157757
\Plcg2al/\Plcg2al
(involves: 129 * C57BL/6)
abnormal lymphatic vessel morphology J:143529
\Plcg2Ali5/\Plcg2+
(C3HeB/FeJ-Plcg2Ali5)
abnormal B cell physiology J:97930
chronic inflammation J:97930
decreased B-2 B cell number J:97930
dermatitis J:97930
osteoarthritis J:97930
\Plcg2Ali5/\Plcg2+
(involves: C57BL/6J * C3HeB/FeJ-Plcg2Ali5)
abnormal B cell physiology J:97930
glomerulonephritis J:97930
immune system phenotype J:97930
\Plcg2Ali5/\Plcg2+
\Rag1tm1Mom/\Rag1tm1Mom

(involves: 129S7/SvEvBrd * C3HeB/FeJ * C3HeB/FeJ-Plcg2Ali5)
chronic inflammation J:97930
dermatitis J:97930
osteoarthritis J:97930
\Plcg2Ali5/\Plcg2Ali5
(involves: C57BL/6J * C3HeB/FeJ-Plcg2Ali5)
abnormal B cell physiology J:97930
chronic inflammation J:97930
decreased mature B cell number J:97930
decreased transitional stage B cell number J:97930
glomerulonephritis J:97930
\Plcg2Ali14/\Plcg2+
(C3HeB/FeJ-Plcg2Ali14)
abnormal inflammatory response J:166106
\Plcg2em1Msasn/\Plcg2em1Msasn
(B6.Cg-Plcg2em1Msasn/J)
impaired macrophage phagocytosis J:308279
\Plcg2m1Btlr/\Plcg2m1Btlr
(C57BL/6J-Plcg2m1Btlr)
decreased IgM level J:165702
\Plcg2m1Btlr/\Plcg2m1Btlr
(involves: C57BL/6J)
abnormal B cell differentiation J:185495
decreased IgM level J:185495
immune system phenotype J:185495
\Plcg2M2Btlr/\Plcg2+
(C57BL/6J-Plcg2M2Btlr)
decreased tumor necrosis factor secretion J:218966
\Plcg2M2Btlr/\Plcg2M2Btlr
(C57BL/6J-Plcg2M2Btlr)
decreased tumor necrosis factor secretion J:218966
\Plcg2M3Btlr/\Plcg2M3Btlr
(C57BL/6J-Plcg2M3Btlr)
abnormal humoral immune response J:265101
decreased B-1a cell number J:265101
decreased IgM level J:265101
\Plcg2m4Btlr/\Plcg2m4Btlr
(C57BL/6J-Plcg2m4Btlr)
decreased CD8-positive, naive alpha-beta T cell number J:272862
increased effector memory CD8-positive, alpha-beta T cell number J:272862
\Plcg2tm1.1Kuro/\Plcg2tm1.1Kuro
(B6.Cg-Plcg2tm1.1Kuro)
decreased interferon-gamma secretion J:131621
impaired natural killer cell mediated cytotoxicity J:131621
\Plcg2tm1.1Kuro/\Plcg2tm1.1Kuro
(Not Specified)
abnormal B cell differentiation J:131161
abnormal NK cell physiology J:187430
increased pro-B cell number J:131161
spleen hyperplasia J:131161
\Plcg2tm1Ichi/\Plcg2tm1Ichi
(involves: 129 * C57BL/6)
abnormal lymphatic vessel morphology J:143529
\Plcg2tm1Jni/\Plcg2tm1Jni
(involves: 129P2/OlaHsd)
abnormal B cell calcium ion homeostasis J:80614
abnormal dendritic cell chemotaxis J:157619
abnormal dendritic cell morphology J:157619
abnormal dendritic cell physiology J:157619
arrested B cell differentiation J:86373
decreased B cell proliferation J:80614
decreased follicular B cell number J:86373
decreased mature B cell number J:104166
decreased susceptibility to induced arthritis J:157619
increased B cell apoptosis J:86373
increased pro-B cell number J:104166
increased transitional stage T2 B cell number J:86373
\Plcg2tm1Jni/\Plcg2tm1Jni
(involves: 129P2/OlaHsd * C57BL/6)
abnormal B cell differentiation J:117023
abnormal B cell physiology J:117023
abnormal osteoclast differentiation J:114607
decreased interferon-gamma secretion J:100716
decreased osteoclast cell number J:114607
impaired natural killer cell mediated cytotoxicity J:100716
increased B cell proliferation J:117023
increased pre-B cell number J:117023
increased susceptibility to Herpesvirales infection J:100716
\Plcg2tm1Jni/\Plcg2tm1Jni
\Tg(IghMyc)22Bri/0

(involves: 129P2/OlaHsd * C57BL * C57BL/6 * SJL)
enlarged lymph nodes J:117023
\Plcg2tm1Kuro/\Plcg2tm1Kuro
\Tg(Mx1-cre)1Cgn/0

(involves: C57BL/6 * CBA)
abnormal humoral immune response J:63744
decreased B cell proliferation J:63744
decreased mature B cell number J:63744
decreased pre-B cell number J:63744
immune system phenotype J:63744
increased B-1a cell number J:63744
increased immature B cell number J:63744
increased pro-B cell number J:63744
\Plcl2tm1Tta/\Plcl2tm1Tta
(involves: 129P2/OlaHsd)
abnormal adaptive immunity J:85960
abnormal B cell calcium ion homeostasis J:85960
decreased B-1a cell number J:85960
decreased mature B cell number J:85960
increased anti-nuclear antigen antibody level J:85960
increased B cell proliferation J:85960
increased IgM level J:85960
\Pld2tm1.1Mjow/\Pld2tm1.1Mjow
(Not Specified)
abnormal neutrophil physiology J:183062
\Pld3em1Nemz/\Pld3em1Nemz
(C57BL/6J-Pld3em1Nemz)
immune system phenotype J:281205
increased interleukin-6 secretion J:281205
\Pld3em1Nemz/\Pld3em1Nemz
\Pld4tm1.2Nemz/\Pld4tm1.2Nemz

(B6.Cg-Pld3em1Nemz Pld4tm1.1Nemz)
abnormal circulating chemokine level J:281205
hemophagocytosis J:281205
increased circulating CXCL10 level J:281205
increased circulating interferon-gamma level J:281205
increased circulating tumor necrosis factor level J:281205
liver inflammation J:281205
\Pld4em1(IMPC)Mbp/\Pld4em1(IMPC)Mbp
(C57BL/6N-Pld4em1(IMPC)Mbp/MbpMmucd)
abnormal spleen morphology J:211773
enlarged spleen J:211773
increased leukocyte cell number J:211773
increased lymphocyte cell number J:211773
increased monocyte cell number J:211773
increased spleen weight J:211773
\Pld4thss/\Pld4thss
(BALB/cJ-Pld4thss/GrsrJ)
abnormal alpha-beta T cell morphology J:278304
abnormal immunoglobulin level J:278304
enlarged lymph nodes J:278304
enlarged spleen J:278304
increased anti-nuclear antigen antibody level J:278304
increased IgA level J:278304
increased IgE level J:278304
increased IgG2b level J:278304
increased IgG3 level J:278304
increased IgG level J:278304
increased IgM level J:278304
increased macrophage cell number J:278304
increased marginal zone B cell number J:278304
increased plasma cell number J:278304
increased plasmacytoid dendritic cell number J:278304
increased spleen germinal center number J:278304
lymph node hyperplasia J:278304
spleen hyperplasia J:278304
\Pld4tm1.1Nemz/\Pld4tm1.1Nemz
\Tg(Itgax-cre)1-1Reiz/0

(involves: 129 * C57BL/6 * C57BL/6J * CBA)
abnormal peritoneal macrophage morphology J:281205
\Pld4tm1.2Nemz/\Pld4tm1.2Nemz
(B6.129(Cg)-Pld4tm1.1Nemz)
abnormal leukocyte cell number J:281205
abnormal peritoneal macrophage morphology J:281205
decreased B-1 B cell number J:281205
decreased NK T cell number J:281205
enlarged spleen J:281205
immune system phenotype J:281205
increased circulating CXCL10 level J:281205
increased circulating interferon-gamma level J:281205
increased marginal zone B cell number J:281205
increased monocyte cell number J:281205
\Pld4tm1.2Nemz/\Pld4tm1.2Nemz
\Rag1tm1Mom/\Rag1tm1Mom

(involves: 129 * 129S7/SvEvBrd * C57BL/6J * FVB/N)
abnormal peritoneal macrophage morphology J:281205
decreased NK T cell number J:281205
\Pld4tm1.2Nemz/\Pld4tm1.2Nemz
\Tlr9M7Btlr/\Tlr9M7Btlr

(involves: 129 * C57BL/6J * FVB/N)
immune system phenotype J:281205
\Plectm3Gwi/\Plectm3Gwi
(involves: 129P2/OlaHsd)
abnormal T cell physiology J:104701
impaired macrophage chemotaxis J:104701
\Plek2tm1Pji/\Plek2tm1Pji
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
abnormal granulocyte differentiation J:257910
enlarged spleen J:257910
\Plek2tm1Pji/\Plek2tm1Pji
\Jak2tm1.1Ble/\Jak2+
\Commd10Tg(Vav1-icre)A2Kio/\Commd10+

(involves: 129 * C57BL/6 * C57BL/10 * CBA/Ca)
abnormal granulocyte differentiation J:257910
immune system phenotype J:257910
\Plekha5em1(IMPC)Tcp/\Plekha5em1(IMPC)Tcp
(C57BL/6NCrl-Plekha5em1(IMPC)Tcp/Tcp)
enlarged lymph nodes J:211773
increased spleen weight J:211773
\Plekha7tm1.1Janc/\Plekha7tm1.1Janc
(involves: C57BL/6)
decreased susceptibility to bacterial infection J:227858
decreased susceptibility to bacterial infection induced morbidity/mortality J:227858
\Plekhf1tm1.1Caox/\Plekhf1tm1.1Caox
\Lyz2tm1(cre)Ifo/\Lyz2+

(B6.Cg-Plekhf1tm1.1Caox Lyz2tm1(cre)Ifo)
abnormal cytokine secretion J:277440
abnormal macrophage physiology J:277440
decreased circulating interferon-beta level J:277440
decreased circulating interleukin-6 level J:277440
decreased circulating tumor necrosis factor level J:277440
increased susceptibility to bacterial infection J:277440
increased susceptibility to bacterial infection induced morbidity/mortality J:277440
\Plekhg2em1(IMPC)J/\Plekhg2em1(IMPC)J
(C57BL/6NJ-Plekhg2em1(IMPC)J/Mmjax)
decreased leukocyte cell number J:211773
\Plekhm1tm1.2Hzhao/\Plekhm1tm1.2Hzhao
(involves: 129S1/Sv * C57BL/6J)
abnormal osteoclast morphology J:236517
abnormal osteoclast physiology J:236517
\Plekhm2tm1a(EUCOMM)Wtsi/\Plekhm2tm1a(EUCOMM)Wtsi
(B6JTyr;B6N-Plekhm2tm1a(EUCOMM)Wtsi/Wtsi)
increased leukocyte cell number J:165965
\Plekhm2tm1a(EUCOMM)Wtsi/\Plekhm2tm1a(EUCOMM)Wtsi
(involves: C57BL/6J * C57BL/6N)
decreased susceptibility to bacterial infection J:233985
decreased susceptibility to bacterial infection induced morbidity/mortality J:233985
increased leukocyte cell number J:233985
\Plekho2em1Lzhn/\Plekho2em1Lzhn
(C57BL/6-Plekho2em1Lzhn)
decreased macrophage cell number J:270531
immune system phenotype J:270531
increased macrophage apoptosis J:270531
\Plet1tm1Cupe/\Plet1tm1Cupe
(Not Specified)
abnormal dendritic cell migration J:271548
abnormal dendritic cell number J:271548
increased dendritic cell number J:271548
\Plgtm1.1Fjc/\Plgtm1.1Fjc
(involves: C57BL/6 * C57BL/6JJcl)
enlarged lymph nodes J:210802
increased circulating fibrinogen level J:210802
\Plgtm1Dco/\Plg+
(involves: 129S2/SvPas * 129X1/SvJ * C57BL/6)
abnormal inflammatory response J:80114
\Plgtm1Dco/\Plgtm1Dco
(involves: 129S2/SvPas * C57BL/6)
abnormal acute phase protein level J:82604
\Plgtm1Dco/\Plgtm1Dco
(involves: 129S2/SvPas * 129X1/SvJ * C57BL/6)
abnormal inflammatory response J:80114
\Plgtm1Dco/\Plgtm1Dco
(involves: 129S2/SvPas)
enlarged lymph nodes J:210802
increased circulating fibrinogen level J:210802
\Plgtm1Jld/\Plgtm1Jld
(involves: 129P2/OlaHsd * NIH Black Swiss)
proctitis J:39419
\Plgtm1Jld/\Plgtm1Jld
(B6.129P2-Plgtm1Jld)
conjunctivitis J:46096
eye inflammation J:46096
\Plgtm1Jld/\Plgtm1Jld
(involves: 129P2/OlaHsd * Black Swiss)
colitis J:36591
\Plgtm1Jld/\Plgtm1Jld
(B6.129P2-Plgtm1Jld/J)
abnormal microglial cell physiology J:141739
\Plgr1BALB/cJ/\Plgr1BALB/cJ
(involves: BALB/cJ * C57BL/6J)
decreased susceptibility to bacterial infection J:138895
\Plgr1BALB/cJ/\Plgr1BALB/cJ
(B6.C-Plgr1BALB/cJ)
decreased susceptibility to bacterial infection J:138895
\Plgr1BALB/cJ/\Plgr1C57BL/6J
(involves: BALB/cJ * C57BL/6J)
decreased susceptibility to bacterial infection J:138895
\Plgr1BALB/cJ/\Plgr1C57BL/6J
(B6.C-Plgr1BALB/cJ)
decreased susceptibility to bacterial infection J:138895
\Plgrkttm1Lmls/\Plgrkt+
(B6.Cg-Plgrkttm1Lmls)
dermatitis J:282437
\Plgrkttm1Lmls/\Plgrkttm1Lmls
(B6.Cg-Plgrkttm1Lmls)
abnormal macrophage physiology J:282437
dermatitis J:282437
impaired leukocyte migration J:282437
impaired macrophage chemotaxis J:282437
\Plin2tm1.1Asg/\Plin2tm1.1Asg
(B6.129S2(Cg)-Plin2tm1.1Asg)
decreased inflammatory response J:196302
\Plp1jp-rsh/\Plp1+
(either: STOCK Rb(1.3)1Bnr or (involves: BALB/c * DBA/2 * STOCK Rb(1.3)1Bnr))
abnormal microglial cell morphology J:604
\Plp1jp-rsh/\Plp1jp-rsh
(involves: 101/H * C3H)
decreased susceptibility to Picornaviridae infection J:41447
\Plp1tm1c(EUCOMM)Wtsi/Y
\Cnptm1(cre)Kan/\Cnp+

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6N)
increased T cell number J:245100
microgliosis J:245100
\Plp1tm1Kan/Y
(involves: 129S1/Sv * 129X1/SvJ)
abnormal microglial cell morphology J:48031
microgliosis J:245100
\Plp1tm1Kan/Y
(B6.129-Plp1tm1Kan)
microgliosis J:201143
\Plp1tm1Kan/Y
\Cnptm1(cre)Kan/\Cnp+

(involves: 129S1/Sv * 129X1/SvJ)
increased T cell number J:245100
microgliosis J:245100
\Plp1tm1Kan/Y
\Tspan2tm1Hbw/\Tspan2tm1Hbw

(B6.Cg-Tspan2tm1Hbw Plp1tm1Kan)
brain inflammation J:201143
microgliosis J:201143
\Plpp5tm1(KOMP)Mbp/\Plpp5tm1(KOMP)Mbp
\Prdm1tm1Nutt/\Prdm1+

(involves: C57BL/6 * C57BL/6N)
immune system phenotype J:265892
\Plppr5em1(IMPC)Ccpcz/\Plppr5em1(IMPC)Ccpcz
(C57BL/6NCrl-Plppr5em1(IMPC)Ccpcz/Ccpcz)
abnormal lymph node morphology J:211773
abnormal thymus morphology J:211773
enlarged lymph nodes J:211773
enlarged thymus J:211773
\Pls1tm1Fri/\Pls1tm1Fri
(B6.129-Pls1tm1Fri)
increased susceptibility to colitis induced morbidity/mortality J:216723
increased susceptibility to induced colitis J:216723
\Plscr1tm1Lex/\Plscr1tm1Lex
(129S/SvEvBrd-Plscr1tm1Lex)
abnormal granulocyte differentiation J:76790
abnormal myelopoiesis J:76790
abnormal neutrophil differentiation J:76790
decreased granulocyte number J:76790
decreased neutrophil cell number J:76790
\Plscr1tm1Lex/\Plscr1tm1Lex
\Plscr3tm1Sims/\Plscr3tm1Sims

(involves: 129S7/SvEvBrd * C57BL/6J)
abnormal myelopoiesis J:92404
\plt/\plt
(involves: DDD/1)
abnormal immune system organ morphology J:47819
abnormal immune system physiology J:47819
abnormal leukocyte cell number J:47819
abnormal leukocyte migration J:47819, J:47460
abnormal lymph node T cell domain morphology J:47819, J:47460
abnormal peripheral lymph node morphology J:47819
abnormal spleen red pulp morphology J:47460
abnormal spleen white pulp morphology J:47460
decreased single-positive T cell number J:15290
decreased T cell number J:47819
increased memory T cell number J:47460
increased T cell number J:47819
lymph node hypoplasia J:15290, J:47460
small Peyer's patches J:47460
\plt/\plt
(C.DDD-plt)
abnormal T cell activation J:119345
decreased single-positive T cell number J:119345
increased length of allograft survival J:119345
\plt/\plt
(B6.DDD-plt)
abnormal leukocyte migration J:93960
abnormal thymus cortex morphology J:93960
immune system phenotype J:93960
small thymus medulla J:93960
\plt/\plt
(either: B6.DDD-plt or C.DDD-plt)
abnormal leukocyte migration J:110910
increased inflammatory response J:110910
increased susceptibility to autoimmune disorder J:110910
lacrimal gland inflammation J:110910
parotid gland inflammation J:110910
salivary gland inflammation J:110910
submandibular gland inflammation J:110910
\Plvaptm1e(EUCOMM)Hmgu/\Plvaptm1e(EUCOMM)Hmgu
\Tg(TIE2GFP)287Sato/0

(involves: C57BL/6N * FVB/N)
small spleen J:203907
\Plxna1tm1Kik/\Plxna1tm1Kik
(either: B6.Cg-Plxna1tm1Kik or C.Cg-Plxna1tm1Kik)
abnormal CD4-positive, alpha-beta T cell physiology J:110786
abnormal dendritic cell physiology J:110786
\Plxna1tm1Kik/\Plxna1tm1Kik
(Not Specified)
abnormal dendritic cell physiology J:161856
\Plxna1tm1Kik/\Plxna1tm1Kik
\Tg(TcraTcrb)425Cbn/?

(involves: BALB/c * C57BL/6)
decreased T cell proliferation J:161856
\Plxna1tm1Tmj/\Plxna1tm1Tmj
(involves: 129S/SvEv)
abnormal lymphatic vessel endothelial cell morphology J:226501
abnormal lymphatic vessel morphology J:226501
\Plxna2tm1Hfu/\Plxna2tm1Hfu
(involves: C57BL/6NCrlj * CBA/JNCrlj)
abnormal lymphatic vessel morphology J:226501
\Plxna4em1(IMPC)Mbp/\Plxna4em1(IMPC)Mbp
(C57BL/6NCrl-Plxna4em1(IMPC)Mbp/MbpMmucd)
abnormal spleen morphology J:211773
small spleen J:211773
\Plxnc1em1(IMPC)Mbp/\Plxnc1em1(IMPC)Mbp
(C57BL/6N-Plxnc1em1(IMPC)Mbp/MbpMmucd)
abnormal spleen morphology J:211773
small spleen J:211773
\Plxnd1b2b1863Clo/\Plxnd1b2b1863Clo
(C57BL/6J-Plxnd1b2b1863Clo)
thymus hypoplasia J:175213
\Plxnd1b2b3150Clo/\Plxnd1b2b3150Clo
(C57BL/6J-Plxnd1b2b3150Clo)
thymus hypoplasia J:175213
\PlyidHIGA/Nsc/\PlyidHIGA/Nsc
(involves: BALB/cA * HIGA/Nsc)
abnormal humoral immune response J:91769
increased IgA level J:91769
\Pmaip1tm1Ast/\Pmaip1tm1Ast
(C57BL/6-Pmaip1tm1Ast)
abnormal NK cell morphology J:123409
\Pmaip1tm1Ast/\Pmaip1tm1Ast
(involves: C57BL/6)
immune system phenotype J:132819
\Pmepa1em1Akt/\Pmepa1em1Akt
(C57BL/6N-Pmepa1em1Akt)
abnormal osteoclast differentiation J:329578
abnormal osteoclast physiology J:329578
decreased osteoclast cell number J:329578
\Pmltm1(PML/RARA)Ley/\Pml+
\Tg(CAG-cre/Esr1*)5Amc/0

(involves: BALB/cJ * C57BL/6 * CBA)
enlarged spleen J:172024
\Pmltm1.1Ews/\Pmltm1.1Ews
(involves: 129 * 129P2/OlaHsd)
increased T cell derived lymphoma incidence J:262172
\Pmltm1.1Ews/\Pmltm1.1Ews
\Tg(PML-RARA)556Kog/0

(FVB.Cg-Pmltm1.1Ews Tg(PML-RARA)556Kog)
enlarged spleen J:262172
increased leukocyte cell number J:262172
\Pmltm1Ppp/\Pml+
\Trp53tm3.1Glo/\Trp53+

(B6.129S7(Cg)-Pmltm1Ppp Trp53tm3.1Glo)
hepatosplenomegaly J:317504
increased T cell derived lymphoma incidence J:317504
\Pmltm1Ppp/\Pmltm1Ppp
(involves: 129S7/SvEvBrd)
abnormal immune system cell morphology J:46381
abnormal myelopoiesis J:46381
decreased granulocyte number J:46381
decreased leukocyte cell number J:46381
increased susceptibility to bacterial infection J:46381
\Pmltm1Ppp/\Pmltm1Ppp
\Trp53tm3.1Glo/\Trp53+

(B6.129S7(Cg)-Pmltm1Ppp Trp53tm3.1Glo)
hepatosplenomegaly J:317504
increased T cell derived lymphoma incidence J:317504
\Pmm2tm1b(EUCOMM)Hmgu/\Pmm2+
(C57BL/6N-Pmm2tm1b(EUCOMM)Hmgu/Tcp)
enlarged lymph nodes J:211773
\Pms2tm1.1Wed/\Pms2tm1.1Wed
(involves: 129S6/SvEvTac * C57BL/6NCr)
abnormal class switch recombination J:162378
increased T cell derived lymphoma incidence J:162378
\Pms2tm1Lisk/\Pms2tm1Lisk
(involves: 129S2/SvPas)
abnormal class switch recombination J:162378
\Pnliprp2tm1Gru/\Pnliprp2tm1Gru
(involves: 129S2/SvPas * BALB/c)
decreased cytotoxic T cell cytolysis J:51627
\Pnma8bem1(IMPC)Tcp/\Pnma8bem1(IMPC)Tcp
(C57BL/6NCrl-Pnma8bem1(IMPC)Tcp/Cmmr)
decreased neutrophil cell number J:211773
increased lymphocyte cell number J:211773
\Pno1tm1Jwu/\Pno1+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
immune system phenotype J:191966
\Pnp2em1Smoc/\Pnp2em1Smoc
(C57BL/6J-Pnp2em1Smoc)
immune system phenotype J:339075
\Pnpbata/\Pnpbata
(C57BL/6JSfdAnu-Pnpbata)
decreased B cell proliferation J:104190
decreased marginal zone B cell number J:104190
increased T follicular helper cell number J:104190
\Pnpe/\Pnpe
(C57BL/6J-Pnpe)
abnormal leukocyte physiology J:39328
thymus hypoplasia J:39328
\Pnpf/\Pnpf
(involves: C3H/HeHa * C57BL/6J)
increased double-negative T cell number J:522
\Pnpf/\Pnpf
(C57BL/6J-Pnpf)
abnormal leukocyte cell number J:39328
abnormal leukocyte physiology J:39328
decreased CD8-positive, alpha-beta T cell number J:39328
decreased double-positive T cell number J:39328
thymus hypoplasia J:39328
\Pnpg/\Pnpg
(involves: C57BL/6 * DBA/2J)
abnormal leukocyte cell number J:39328
abnormal leukocyte physiology J:39328
decreased CD8-positive, alpha-beta T cell number J:39328
decreased double-positive T cell number J:39328
increased double-negative T cell number J:39328
thymus hypoplasia J:39328
\PnpM1Btlr/\PnpM1Btlr
(C57BL/6J-PnpM1Btlr)
impaired humoral immune response J:265147
increased IgM level J:265147
\Pnpm2Btlr/\Pnpm2Btlr
(C57BL/6J-Pnpm2Btlr)
decreased B-1a cell number J:265150
decreased B-2 B cell number J:265150
decreased CD4-positive, alpha-beta T cell number J:265150
decreased CD8-positive, naive alpha-beta T cell number J:265150
decreased T cell number J:265150
increased B-1b cell number J:265150
increased CD8-positive, alpha-beta memory T cell number J:265150
increased central memory CD4-positive, alpha-beta T cell number J:265150
increased central memory CD8 positive, alpha-beta T cell number J:265150
increased effector memory CD4-positive, alpha-beta T cell number J:265150
increased effector memory CD8-positive, alpha-beta T cell number J:265150
\Pnptm1Cmr/\Pnptm1Cmr
(involves: 129)
abnormal myelopoiesis J:62870
decreased CD4-positive, alpha-beta T cell number J:62870
decreased CD8-positive, alpha-beta T cell number J:62870
decreased cytotoxic T cell cytolysis J:62870
decreased double-positive T cell number J:62870
decreased single-positive T cell number J:62870
increased double-negative T cell number J:62870
increased pre-B cell number J:62870
increased thymocyte apoptosis J:62870
\Pnpla5em1(IMPC)Mbp/\Pnpla5em1(IMPC)Mbp
(C57BL/6N-Pnpla5em1(IMPC)Mbp/MbpMmucd)
abnormal spleen morphology J:211773
enlarged spleen J:211773
\Podxl2tm1.1(KOMP)Vlcg/\Podxl2tm1.1(KOMP)Vlcg
(C57BL/6N-Podxl2tm1.1(KOMP)Vlcg/Ucd)
abnormal spleen morphology J:211773
enlarged spleen J:211773
increased neutrophil cell number J:211773
\Pofut1tm2Pst/\Pofut1tm1Pst
\Shhtm2(cre/ERT2)Cjt/\Shh+

(involves: 129/Sv * 129S6/SvEvTac * C57BL/6J * SJL)
lung inflammation J:150051
\Polbtm1.1Jbsw/\Polb+
(involves: 129/Sv * C57BL/6)
dermatitis J:206872
enlarged cervical lymph nodes J:206872
glomerulonephritis J:206872
increased anti-nuclear antigen antibody level J:206872
increased IgG level J:206872
lymph node inflammation J:206872
salivary gland inflammation J:206872
\Polbtm1.1Jbsw/\Polbtm1.1Jbsw
(involves: 129/Sv * C57BL/6)
abnormal immunoglobulin heavy chain V(D)J recombination J:206872
abnormal somatic hypermutation frequency J:206872
abnormal spleen germinal center morphology J:206872
dermatitis J:206872
enlarged cervical lymph nodes J:206872
glomerulonephritis J:206872
increased anti-nuclear antigen antibody level J:206872
increased germinal center B cell number J:206872
increased IgG level J:206872
increased spleen germinal center number J:206872
increased splenocyte apoptosis J:183837, J:206872
increased susceptibility to systemic lupus erythematosus J:206872
increased T-helper 2 cell number J:206872
lymph node inflammation J:206872
salivary gland inflammation J:206872
\Polbtm1a(KOMP)Wtsi/\Polbtm1a(KOMP)Wtsi
(C57BL/6N-Polbtm1a(KOMP)Wtsi/Wtsi)
abnormal lymphatic vessel topology J:239583
\Polbtm1Rsky/\Polbtm1Rsky
\Tg(Lck-cre)I57Jxm/0

(involves: 129P2/OlaHsd * ICR)
immune system phenotype J:67942
\Pold1tm1.1Bdp/\Pold1tm1.1Bdp
(B6.129-Pold1tm1.1Bdp)
increased T cell derived lymphoma incidence J:153684
\Pold1tm1.1Bdp/\Pold1tm1.1Bdp
\Poletm1.1Bdp/\Poletm1.1Bdp

(B6.129-Poletm1.1Bdp Pold1tm1.1Bdp)
increased T cell derived lymphoma incidence J:153684
\Pold1tm1.1Uchi/\Pold1tm1.1Uchi
(C57BL/6-Pold1tm1.1Uchi)
enlarged thymus J:144992
\Pold1tm1Bdp/\Pold1tm1Bdp
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
increased T cell derived lymphoma incidence J:100685
\Pold1tm1Uchi/\Pold1tm1.1Uchi
(C57BL/6-Pold1tm1Uchi/Pold1tm1.1Uchi)
enlarged thymus J:144992
\Pold4em1(IMPC)J/\Pold4em1(IMPC)J
(C57BL/6NJ-Pold4em1(IMPC)J/Mmjax)
decreased leukocyte cell number J:211773
\Pole2em1(IMPC)Mbp/\Pole2+
(C57BL/6NCrl-Pole2em1(IMPC)Mbp/Mmucd)
abnormal spleen morphology J:211773
enlarged lymph nodes J:211773
enlarged spleen J:211773
\Pole3em1Tbo/\Pole3em1Tbo
(FVB-Pole3em1Tbo)
decreased B cell number J:298827
decreased lymphocyte cell number J:298827
decreased splenocyte number J:298827
decreased thymocyte number J:298827
\Pole3em2Tbo/\Pole3em2Tbo
(FVB-Pole3em2Tbo)
decreased B cell number J:298827
decreased lymphocyte cell number J:298827
decreased splenocyte number J:298827
decreased thymocyte number J:298827
\Pole3em3Tbo/\Pole3em3Tbo
(FVB-Pole3em3Tbo)
abnormal thymus apoptosis J:298827
decreased B cell number J:298827
decreased DN4 thymocyte number J:298827
decreased double-positive T cell number J:298827
decreased gamma-delta T cell number J:298827
decreased immature B cell number J:298827
decreased lymphocyte cell number J:298827
decreased pre-B cell number J:298827
decreased splenocyte number J:298827
decreased thymocyte number J:298827
increased DN3 thymocyte number J:298827
increased thymocyte apoptosis J:298827
small spleen J:298827
small thymus J:298827
\Pole3em4Tbo/\Pole3em4Tbo
(FVB-Pole3em4Tbo)
abnormal thymus apoptosis J:298827
decreased B cell number J:298827
decreased DN4 thymocyte number J:298827
decreased immature B cell number J:298827
decreased lymphocyte cell number J:298827
decreased pre-B cell number J:298827
decreased splenocyte number J:298827
decreased thymocyte number J:298827
increased DN3 thymocyte number J:298827
increased thymocyte apoptosis J:298827
\Pole3tm1(KOMP)Vlcg/\Pole3tm1(KOMP)Vlcg
(involves: C57BL/6NTac * FVB)
decreased DN4 thymocyte number J:298827
increased DN3 thymocyte number J:298827
\Pole4tm1(KOMP)Vlcg/\Pole4tm1(KOMP)Vlcg
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6NTac * FVB/N)
abnormal B cell differentiation J:261973
abnormal mesenteric lymph node morphology J:261973
abnormal spleen B cell follicle morphology J:261973
abnormal T cell differentiation J:261973
abnormal thymus morphology J:261973
absent thymus cortex J:261973
arrested B cell differentiation J:261973
athymia J:261973
decreased B cell number J:261973
decreased leukocyte cell number J:261973
decreased lymphocyte cell number J:261973
decreased single-positive T cell number J:261973
decreased spleen weight J:261973
increased double-negative T cell number J:261973
increased granulocyte number J:261973
increased monocyte cell number J:261973
increased T cell derived lymphoma incidence J:261973
small spleen J:261973
\Pole4tm1(KOMP)Vlcg/\Pole4tm1(KOMP)Vlcg
\Trp53tm1Brd/\Trp53+

(involves: C57BL/6J * C57BL/6NTac)
decreased leukocyte cell number J:261973
decreased lymphocyte cell number J:261973
increased granulocyte number J:261973
increased monocyte cell number J:261973
increased T cell derived lymphoma incidence J:261973
\Pole4tm1(KOMP)Vlcg/\Pole4tm1(KOMP)Vlcg
\Trp53tm1Brd/\Trp53tm1Brd

(involves: C57BL/6J * C57BL/6NTac)
immune system phenotype J:261973
\Poletm1.1Bdp/\Poletm1.1Bdp
(B6.129-Poletm1.1Bdp)
enlarged spleen J:153684
\Polgtm1.1Suom/\Polgtm1.1Suom
(involves: C57BL/6JOlaHsd)
brain inflammation J:365276
decreased circulating interferon-beta level J:365276
decreased circulating interferon-gamma level J:365276
increased circulating interleukin-6 level J:365276
increased susceptibility to Flaviviridae infection J:365276
liver inflammation J:365276
\Polgtm1Prol/\Polgtm1Prol
(involves: 129S7/SvEvBrd * C57BL/6J * ICR)
abnormal thymus involution J:99764
\Polgtm1Prol/\Polgtm1Prol
(B6J.129S7-Polgtm1Prol)
abnormal lymphopoiesis J:154187
decreased double-positive T cell number J:154187
decreased immature B cell number J:154187
decreased lymphocyte cell number J:154187
decreased mature B cell number J:154187
decreased pre-B cell number J:154187
decreased pro-B cell number J:154187
decreased thymocyte number J:154187
\Polhtm1Crey/\Polhtm1Crey
(involves: 129P2/OlaHsd * C57BL/6)
abnormal B cell physiology J:98037
\Polhtm1Crey/\Polhtm1Crey
\Polid/\Polid

(involves: 129P2/OlaHsd * C57BL/6)
abnormal B cell physiology J:98037
\Polhtm1Fmh/\Polhtm1Fmh
(involves: C57BL/6)
abnormal B cell physiology J:99721
\Polid/\Polid
\Polktm1Hohm/\Polktm1Hohm

(involves: 129X1/SvJ * C57BL/6 * CBA)
immune system phenotype J:105111
\Polktm1.1Rsky/\Polktm1.1Rsky
(involves: 129P2/OlaHsd * BALB/cJ * C57BL/6)
immune system phenotype J:80212
\Polktm1Hohm/\Polktm1Hohm
(involves: 129X1/SvJ * C57BL/6 * CBA)
immune system phenotype J:105111
\Polktm1Hohm/\Polktm1Hohm
(involves: C57BL/6 * CBA)
immune system phenotype J:83202
\Polltm1Crey/\Polltm1Crey
(involves: 129P2/OlaHsd * C57BL/6)
immune system phenotype J:75927
\Polltm1Crey/\Polltm1Crey
(involves: 129P2/OlaHsd)
abnormal immunoglobulin heavy chain V(D)J recombination J:113406
immune system phenotype J:113406
\Polltm1Crey/\Polltm1Crey
\Polmtm1Crey/\Polmtm1Crey

(involves: 129P2/OlaHsd)
abnormal B cell differentiation J:113406
abnormal immunoglobulin heavy chain V(D)J recombination J:113406
abnormal immunoglobulin light chain V-J recombination J:113406
decreased B cell number J:113406
\Polmm1Btlr/\Polmm1Btlr
(C57BL/6J-Polmm1Btlr)
decreased B cell number J:272866
\Polmm2Btlr/\Polmm2Btlr
(C57BL/6J-Polmm2Btlr)
abnormal lymphocyte morphology J:272867
decreased B cell number J:272867
\Polmtm1Abnd/\Polmtm1Abnd
(involves: 129/Sv * BALB/c)
abnormal B cell number J:97782
\Polmtm1Crey/\Polmtm1Crey
(involves: 129P2/OlaHsd * C57BL/6)
abnormal B cell proliferation J:85190
abnormal Peyer's patch morphology J:85190
decreased B cell number J:75927, J:85190
immune system phenotype J:75927
lymphoid hypoplasia J:85190
\Polmtm1Crey/\Polmtm1Crey
(involves: 129P2/OlaHsd)
abnormal immunoglobulin light chain V-J recombination J:113406
\Polqem1(IMPC)Mbp/\Polqem1(IMPC)Mbp
(C57BL/6N-Polqem1(IMPC)Mbp/MbpMmucd)
abnormal spleen morphology J:211773
small spleen J:211773
\Polqtm1Jcs/\Polqtm1Jcs
(involves: 129S4/SvJae * C57BL/6J)
abnormal somatic hypermutation frequency J:103365
\Polqtm1Jow/\Polqtm1Jow
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6N)
abnormal B cell physiology J:101409
abnormal somatic hypermutation frequency J:101409
decreased IgG1 level J:101409
decreased IgG level J:101409
decreased IgM level J:101409
decreased immunoglobulin level J:101409
\Polqtm2Jow/\Polqtm2Jow
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
abnormal somatic hypermutation frequency J:115989
\Polr1bem1(IMPC)Tcp/\Polr1b+
(C57BL/6NCrl-Polr1bem1(IMPC)Tcp/Tcp)
enlarged lymph nodes J:211773
enlarged thymus J:211773
\Polr2atm1(cre/ERT2)Bbd/\Polr2a+
\Rnf2tm1Mvi/\Rnf2tm1Mvi

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * C57BL/10 * SJL)
decreased B cell number J:130397
\Polr3aem2(IMPC)Tcp/\Polr3a+
(C57BL/6NCrl-Polr3aem2(IMPC)Tcp/Tcp)
enlarged lymph nodes J:211773
\Polr3atm1Iwil/\Polr3atm1Iwil
\Tg(CAG-cre/Esr1*)5Amc/0

(Not Specified)
increased microglial cell activation J:364909
\Polrmtem1(IMPC)Mbp/\Polrmt+
(C57BL/6N-Polrmtem1(IMPC)Mbp/Ucd)
abnormal lymph node morphology J:211773
enlarged lymph nodes J:211773
\Pomcem1(IMPC)Rbrc/\Pomc+
(C57BL/6NJcl-Pomcem1(IMPC)Rbrc/Rbrc)
abnormal spleen morphology J:211773
enlarged spleen J:211773
\Pomctm1Low/\Pomctm1Low
(involves: 129S2/SvPas * C57BL/6)
increased circulating interleukin-6 level J:102955
increased interleukin-6 secretion J:102955
increased splenocyte proliferation J:102955
increased tumor necrosis factor secretion J:102955
\Pomkem1(IMPC)Hmgu/\Pomk+
(C57BL/6NCrl-Pomkem1(IMPC)Hmgu/Ieg)
increased spleen weight J:211773
\Pomt1Gt(OST194127)Lex/\Pomt1+
(involves: 129S5/SvEvBrd * C57BL/6J)
decreased IgG level J:103485
increased neutrophil cell number J:103485
\Pon2Gt(XE661)Byg/\Pon2Gt(XE661)Byg
(B6.129P2-Pon2Gt(XE661)Byg)
abnormal macrophage chemotaxis J:116935
abnormal macrophage physiology J:116935
increased susceptibility to bacterial infection J:116935
\Pon3tm1Dmsh/\Pon3tm1Dmsh
(B6J.129X1-Pon3tm1Dmsh)
liver inflammation J:234615
\Postntm1Sjc/\Postntm1Sjc
(involves: C57BL/6)
periodontium inflammation J:103753
\Postntm1Sjc/\Postntm1Sjc
(B6.Cg-Postntm1Sjc)
increased osteoclast cell number J:200192
\Pot1btm1.1Schg/\Pot1btm1.1Schg
\Terctm1Rdp/\Terc+

(involves: 129/Sv * 129S6/SvEvTac * C57BL/6 * SJL)
abnormal granulocyte morphology J:144553
decreased granulocyte number J:144553
decreased leukocyte cell number J:144553
\Pot1btm1.1Schg/\Pot1btm1.1Schg
\Terctm1Rdp/\Terctm1Rdp

(involves: 129/Sv * 129S6/SvEvTac * C57BL/6 * SJL)
abnormal granulocyte morphology J:144553
\Pou1f1dw/\Pou1f1dw
(DW/J Pou1f1dw)
decreased B cell number J:110683
\Pou2af1tm1b(KOMP)Wtsi/\Pou2af1tm1b(KOMP)Wtsi
(C57BL/6N-Pou2af1tm1b(KOMP)Wtsi/Ucd)
decreased lymphocyte cell number J:211773
decreased spleen weight J:211773
increased neutrophil cell number J:211773
\Pou2af1tm1Pjln/\Pou2af1tm1Pjln
(C57BL/6-Pou2af1tm1Pjln)
absent spleen germinal center J:37085
decreased B cell number J:37085
decreased IgA level J:37085
decreased IgG1 level J:37085
decreased IgG2a level J:37085
decreased IgG2b level J:37085
decreased IgG3 level J:37085
spleen hypoplasia J:37085
\Pou2af1tm1Pjln/\Pou2af1tm1Pjln
(involves: C57BL/6)
abnormal B cell differentiation J:67362
abnormal T-helper 1 physiology J:123039
abnormal T-helper 2 physiology J:123039
decreased B cell number J:123039, J:67362
decreased immature B cell number J:67362
decreased interferon-gamma secretion J:123039
decreased interleukin-2 secretion J:123039
decreased mature B cell number J:67362
decreased T cell number J:123039
increased B cell apoptosis J:67362
increased interleukin-4 secretion J:123039
increased interleukin-13 secretion J:123039
increased susceptibility to parasitic infection J:123039
\Pou2af1tm1Pjln/\Pou2af1tm1Pjln
\Tg(tetO-Pou2af1)1Pjln/0
\Tg(tTA)1Pjln/0

(involves: C57BL/6)
decreased B cell number J:67362
decreased immunoglobulin level J:67362
decreased mature B cell number J:67362
immune system phenotype J:67362
\Pou2af1tm1Pmt/\Pou2af1tm1Pmt
(involves: 129P2/OlaHsd * C57BL/6)
decreased immunoglobulin level J:125114
\Pou2af1tm1Pmt/\Pou2af1tm1Pmt
\Ikzf3tm1Kge/\Ikzf3tm1Kge

(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)
absent spleen germinal center J:81805
arrested B cell differentiation J:81805
decreased IgA level J:81805
decreased IgD level J:81805
decreased IgE level J:81805
decreased IgG level J:81805
decreased IgM level J:81805
decreased immunoglobulin level J:81805
\Pou2af1tm1Rgr/\Pou2af1tm1Rgr
(either: (involves: 129P2/OlaHsd) or (involves: 129S1/Sv))
abnormal B cell differentiation J:114816, J:35785
abnormal Peyer's patch germinal center morphology J:35785
abnormal pre-B cell morphology J:114816
absent lymph node germinal center J:35785
absent spleen germinal center J:35785
arrested B cell differentiation J:114816
decreased B cell number J:114816
decreased B cell proliferation J:35785
decreased IgA level J:35785
decreased IgE level J:35785
decreased IgG1 level J:35785
decreased IgG2a level J:35785
decreased IgG2b level J:35785
decreased IgG3 level J:35785
decreased IgG level J:35785
decreased immunoglobulin level J:35785
increased B cell proliferation J:114816
increased IgM level J:35785
\Pou2af3tm1b(NCOM)Mfgc/\Pou2af3tm1b(NCOM)Mfgc
(C57BL/6N-Pou2af3tm1b(NCOM)Mfgc/Tcp)
decreased lymphocyte cell number J:211773
increased leukocyte cell number J:211773
increased neutrophil cell number J:211773
\Pou2f2tm1Bal/\Pou2f2+
(involves: 129S2/SvPas)
decreased IgG1 level J:4555
decreased IgM level J:4555
decreased mature B cell number J:4555
\Pou2f2tm1Bal/\Pou2f2tm1Bal
(involves: 129S2/SvPas * C57BL/6)
arrested B cell differentiation J:88240
decreased B cell number J:88240
decreased immunoglobulin level J:88240
\Pou2f2tm1Bal/\Pou2f2tm1Bal
(involves: 129S2/SvPas)
decreased IgG1 level J:4555
decreased IgM level J:4555
decreased mature B cell number J:4555
\Pou2f2tm1Lmc/\Pou2f2tm1Lmc
(involves: C57BL/6)
arrested B cell differentiation J:88240
decreased B cell number J:88240
decreased B-1 B cell number J:88240
decreased immunoglobulin level J:88240
\Pparatm1Gonz/\Pparatm1Gonz
(involves: 129S4/SvJae)
heart inflammation J:63801
increased susceptibility to type IV hypersensitivity reaction J:258438
\Ppardtm1Dsvg/\Ppardtm1Dsvg
(involves: 129S2/SvPas * C57BL/6)
increased osteoclast cell number J:219677
\Ppardtm1Jps/\Ppardtm1Jps
(involves: 129/Sv * C57BL/6N)
skin inflammation J:63040
\Ppargtm1.1Gonz/\Ppargtm1.1Gonz
\Lyz2tm1(cre)Ifo/\Lyz2+

(involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6)
abnormal macrophage activation involved in immune response J:168799
abnormal peritoneal macrophage morphology J:168799
glomerulonephritis J:168799
impaired macrophage phagocytosis J:168799
increased anti-double stranded DNA antibody level J:168799
increased anti-nuclear antigen antibody level J:168799
increased anti-single stranded DNA antibody level J:168799
increased autoantibody level J:168799
increased IgG level J:168799
increased IgM level J:168799
\Ppargtm1.1Gonz/\Ppargtm1.1Gonz
\Tg(Mx1-cre)1Cgn/?

(involves: 129X1/SvJ * C57BL/6 * CBA * FVB/N)
abnormal macrophage physiology J:75777
\Ppargtm1Tka/\Pparg+
(involves: C57BL/6 * CBA)
abnormal bone marrow development J:89250
leukostasis J:116269
\Ppargtm1Tka/\Pparg+
(involves: C57BL/6 * CBA * ICR)
abnormal B cell physiology J:58222
abnormal humoral immune response J:58222
immune system phenotype J:58222
increased B cell proliferation J:58222
increased IgG level J:58222
increased IgM level J:58222
increased interferon-gamma secretion J:58222
increased interleukin-2 secretion J:58222
increased susceptibility to induced arthritis J:58222
\Ppargtm1Wwah/\Pparg+
(Not Specified)
immune system phenotype J:71272
\Ppargtm2Rev/\Ppargtm2Rev
\Tg(Cd4-cre)1Cwi/?

(involves: 129S4/SvJae * C57BL/6 * DBA/2)
abnormal T-helper 17 cell differentiation J:153358
increased susceptibility to experimental autoimmune encephalomyelitis J:153358
\Ppargtm2Rev/\Ppargtm2Rev
\Tg(Krt1-15-cre/PGR*)22Cot/?

(involves: 129S4/SvJae * C57BL/6 * SJL)
skin inflammation J:150977
\Ppargtm2Rev/\Ppargtm2Rev
\Tg(Tek-cre)1Ywa/?

(involves: 129S4/SvJae * C57BL/6 * SJL)
abnormal osteoclast differentiation J:160910
abnormal osteoclast morphology J:130475
abnormal spleen morphology J:130475
abnormal splenocyte morphology J:130475
decreased osteoclast cell number J:130475
enlarged spleen J:130475
increased splenocyte number J:130475
skin inflammation J:123403
\Ppargtm2Rev/\Ppargtm2Rev
\Tg(Tek-cre)12Flv/?

(B6.Cg-Ppargtm2Rev Tg(Tek-cre)12Flv)
enlarged spleen J:154216
\Ppargc1atm1Aztc/\Ppargc1a+
(C57BL/6-Ppargc1atm1Aztc)
increased thymus weight J:82809
\Ppargc1atm1Brsp/\Ppargc1a+
(involves: 129 * FVB/N)
immune system phenotype J:127403
\Ppargc1atm1Brsp/\Ppargc1a+
(involves: 129S4/SvJae * C57BL/6)
increased inflammatory response J:264271
\Ppargc1atm1Brsp/\Ppargc1atm1Brsp
(involves: 129 * FVB/N)
increased interleukin-6 secretion J:127403
\Ppargc1atm1Brsp/\Ppargc1atm2Brsp
\Tg(Myog-cre)1Eno/0

(involves: 129 * C57BL/6 * FVB/N)
increased circulating interleukin-6 level J:127403
\Ppargc1atm2Brsp/\Ppargc1a+
\Tg(Myog-cre)1Eno/0

(involves: 129 * C57BL/6)
increased circulating interleukin-6 level J:127403
\Ppargc1btm1.2Rev/\Ppargc1btm1.2Rev
\Tg(Tek-cre)1Ywa/0

(involves: 129/Sv * C57BL/6 * C57BL/6J * SJL)
abnormal osteoclast differentiation J:160910
\Ppbptm1(KOMP)Vlcg/\Ppbptm1(KOMP)Vlcg
(involves: C57BL/6NTac)
abnormal leukocyte migration J:198197
abnormal leukocyte physiology J:198197
immune system phenotype J:198197
\Ppbptm1.1(KOMP)Vlcg/\Ppbptm1.1(KOMP)Vlcg
(C57BL/6N-Ppbptm1.1(KOMP)Vlcg/Ucd)
decreased lymphocyte cell number J:211773
increased neutrophil cell number J:211773
increased spleen weight J:211773
\Ppfibp2em1(IMPC)Tcp/\Ppfibp2em1(IMPC)Tcp
(C57BL/6NCrl-Ppfibp2em1(IMPC)Tcp/Tcp)
enlarged lymph nodes J:211773
\Ppiaem1(IMPC)Mbp/\Ppiaem1(IMPC)Mbp
(C57BL/6NCrl-Ppiaem1(IMPC)Mbp/MbpMmucd)
abnormal spleen morphology J:211773
enlarged spleen J:211773
increased spleen weight J:211773
\Ppiatm1Lubn/\Ppiatm1Lubn
(129S6.129P2-Ppiatm1Lubn)
abnormal CD4-positive, alpha-beta T cell physiology J:93591
blepharitis J:93591
heart inflammation J:93591
increased circulating interleukin-4 level J:93591
increased IgE level J:93591
increased IgG1 level J:93591
increased immunoglobulin level J:93591
increased inflammatory response J:93591
increased interleukin-2 secretion J:93591
increased interleukin-4 secretion J:93591
increased susceptibility to type I hypersensitivity reaction J:93591
increased T cell number J:93591
liver inflammation J:93591
pancreas inflammation J:93591
spleen hyperplasia J:93591
\Ppicem1Igc/\Ppicem1Igc
(C57BL/6-Ppicem1Igc)
decreased NK cell number J:321155
increased transitional stage T1 B cell number J:321155
increased transitional stage T2 B cell number J:321155
\Ppil1em1(IMPC)Mbp/\Ppil1+
(C57BL/6N-Ppil1em1(IMPC)Mbp/MbpMmucd)
small spleen J:211773
\Ppltm1b(KOMP)Wtsi/\Ppltm1b(KOMP)Wtsi
(C57BL/6N-Ppltm1b(KOMP)Wtsi/Tcp)
enlarged lymph nodes J:211773
\Ppm1atm1.2Lavi/\Ppm1atm1.2Lavi
(B.129(Cg)-Ppm1atm1.2Lavi)
increased acute inflammation J:216372
\Ppm1dtm1Lad/\Ppm1dtm1Lad
(involves: 129S7/SvEvBrd * C57BL/6)
chronic inflammation J:74284
decreased B cell proliferation J:74284
decreased CD8-positive, alpha-beta T cell number J:74284
decreased T cell proliferation J:74284
enlarged spleen J:74284
increased CD4-positive, alpha-beta T cell number J:74284
increased susceptibility to Orthomyxoviridae infection J:74284
lymphoid hyperplasia J:74284
myeloid hyperplasia J:74284
small thymus J:74284
spleen hyperplasia J:74284
\Ppm1mtm2b(EUCOMM)Hmgu/\Ppm1mtm2b(EUCOMM)Hmgu
(C57BL/6N-Ppm1mtm2b(EUCOMM)Hmgu/Bay)
decreased large unstained cell number J:211773
\Ppm1nem1(IMPC)Mbp/\Ppm1nem1(IMPC)Mbp
(C57BL/6N-Ppm1nem1(IMPC)Mbp/MbpMmucd)
increased neutrophil cell number J:211773
\Ppp1r8tm1.1Itl/\Ppp1r8tm1Ave
\Tg(Alb1-cre)7Gsc/0

(involves: 129S1/Sv * 129S6/SvEvTac * 129X1/SvJ * C57BL/6NTac * FVB/N)
liver inflammation J:238108
\Ppp1r12atm1Mzhu/\Ppp1r12atm1Mzhu
\Tg(Acta2-cre)#Xya/0

(involves: 129S6/SvEvTac * C57BL/6 * CBA)
small intestinal inflammation J:207752
\Ppp1r13btm1Suda/\Ppp1r13btm1Suda
(involves: 129S1/Sv * 129X1/SvJ * ICR)
abnormal lymph circulation J:135686
abnormal lymphatic vessel morphology J:135686
\Ppp1r13btm1Suda/\Ppp1r13btm1Suda
\Trp53tm1Sia/\Trp53tm1Sia

(involves: various)
abnormal lymphatic vessel morphology J:135686
\Ppp1r13lwa3-J/\Ppp1r13lwa3-J
(BALB/cJ-Ppp1r13lwa3-J/J)
heart inflammation J:264272
\Ppp1r14ctm1Uhl/\Ppp1r14ctm1Uhl
(B6;129S6-Ppp1r14ctm1Uhl/J)
increased susceptibility to Coronaviridae infection J:288523
\Ppp1r15atm1.1Ajf/\Ppp1r15atm1.1Ajf
(involves: 129 * C57BL/6)
abnormal splenic cell ratio J:106905
increased spleen weight J:106905
\Ppp1r17em1(IMPC)H/\Ppp1r17em1(IMPC)H
(C57BL/6NTac-Ppp1r17em1(IMPC)H/H)
increased neutrophil cell number J:211773
\Ppp1r18em1Mgin/\Ppp1r18em1Mgin
(B6J.B6N-Ppp1r18em1Mgin)
abnormal T cell physiology J:331428
decreased B cell number J:331428
decreased T cell number J:331428
immune system phenotype J:331428
impaired leukocyte migration J:331428
increased leukocyte cell number J:331428
increased neutrophil cell number J:331428
small spleen J:331428
spleen hypoplasia J:331428
\Ppp1r18em2Mgin/\Ppp1r18em2Mgin
(B6J.B6NHsd-Ppp1r18em2Mgin)
immune system phenotype J:331428
\Ppp1r18em3Mgin/\Ppp1r18em3Mgin
(B6J.B6N-Ppp1r18em3Mgin)
abnormal T cell physiology J:331428
decreased B cell number J:331428
decreased T cell number J:331428
immune system phenotype J:331428
impaired leukocyte migration J:331428
increased leukocyte cell number J:331428
increased neutrophil cell number J:331428
small spleen J:331428
spleen hypoplasia J:331428
\Ppp2r1btm1b(EUCOMM)Wtsi/\Ppp2r1btm1b(EUCOMM)Wtsi
(C57BL/6N-Ppp2r1btm1b(EUCOMM)Wtsi/Nju)
increased basophil cell number J:211773
increased eosinophil cell number J:211773
\Ppp2r2btm1b(KOMP)Wtsi/\Ppp2r2btm1b(KOMP)Wtsi
(C57BL/6N-Ppp2r2btm1b(KOMP)Wtsi/Tcp)
increased leukocyte cell number J:211773
increased monocyte cell number J:211773
\Ppp2r2dem1(IMPC)Mbp/\Ppp2r2dem1(IMPC)Mbp
(C57BL/6N-Ppp2r2dem1(IMPC)Mbp/MbpMmucd)
abnormal lymph node morphology J:211773
enlarged lymph nodes J:211773
\Ppp2r2dem1Gct/\Ppp2r2dem1Gct
\Tg(Lck-icre)3779Nik/0

(involves: C57BL/6 * DBA/2)
abnormal regulatory T cell physiology J:308373
increased interleukin-2 secretion J:308373
\Ppp2r3ctm1Imku/\Ppp2r3ctm1Imku
\Tg(CD19-cre/ERT2)1Cgn/?

(involves: C57BL/6)
abnormal B cell activation J:100706
abnormal humoral immune response J:100706
decreased B cell number J:100706
decreased B cell proliferation J:100706
decreased B-1a cell number J:100706
decreased follicular B cell number J:100706
decreased immature B cell number J:100706
decreased mature B cell number J:100706
decreased pre-B cell number J:100706
decreased spleen germinal center size J:100706
decreased transitional stage B cell number J:100706
increased pro-B cell number J:100706
increased T cell number J:100706
increased transitional stage B cell number J:100706
small spleen J:100706
\Ppp2r5aem1(IMPC)Mbp/\Ppp2r5aem1(IMPC)Mbp
(C57BL/6N-Ppp2r5aem1(IMPC)Mbp/MbpMmucd)
abnormal lymph node morphology J:211773
enlarged lymph nodes J:211773
\Ppp2r5aGt(IST13127C10)Tigm/\Ppp2r5aGt(IST13127C10)Tigm
(C57BL/6N-Ppp2r5aGt(IST13127C10)Tigm)
enlarged mesenteric lymph nodes J:254808
enlarged spleen J:254808
\Ppp2r5cem1(IMPC)Mbp/\Ppp2r5cem1(IMPC)Mbp
(C57BL/6N-Ppp2r5cem1(IMPC)Mbp/Ucd)
abnormal lymph node morphology J:211773
abnormal spleen morphology J:211773
enlarged lymph nodes J:211773
enlarged spleen J:211773
increased monocyte cell number J:211773
increased neutrophil cell number J:211773
\Ppp3catm1Jse/\Ppp3catm1Jse
(either: (involves: 129S4/SvJae * Black Swiss) or (involves: 129S4/SvJae * C57BL/6))
decreased interferon-gamma secretion J:71750
decreased interleukin-2 secretion J:71750
decreased interleukin-4 secretion J:71750
decreased T cell proliferation J:71750
\Ppp3cbem1(IMPC)Ccpcz/\Ppp3cbem1(IMPC)Ccpcz
(C57BL/6NCrl-Ppp3cbem1(IMPC)Ccpcz/Ccpcz)
decreased CD4-positive NK T cell number J:211773
decreased CD4-positive, alpha-beta T cell number J:211773
decreased CD8-positive, alpha-beta T cell number J:211773
decreased memory-marker CD4-positive NK T cell number J:211773
decreased NK T cell number J:211773
decreased T-helper cell number J:211773
immune system phenotype J:211773
increased effector memory CD8-positive, alpha-beta T cell number J:211773
increased effector memory T-helper cell number J:211773
\Ppp3cbM1Btlr/\Ppp3cb+
(C57BL/6J-Ppp3cbM1Btlr)
abnormal CD4-positive, alpha-beta T cell physiology J:236670
abnormal CD8-positive, alpha-beta T cell physiology J:236670
abnormal NK cell physiology J:236670
increased CD8-positive, alpha-beta memory T cell proliferation J:236670
\Ppp3cbM1Btlr/\Ppp3cbM1Btlr
(C57BL/6J-Ppp3cbM1Btlr)
abnormal CD4-positive, alpha-beta T cell physiology J:236670
abnormal CD8-positive, alpha-beta T cell physiology J:236670
abnormal NK cell physiology J:236670
increased CD8-positive, alpha-beta memory T cell proliferation J:236670
\Ppp3cbm2Btlr/\Ppp3cb+
(C57BL/6J-Ppp3cbm2Btlr)
abnormal CD4-positive, alpha-beta T cell physiology J:236671
abnormal CD8-positive, alpha-beta T cell physiology J:236671
increased CD8-positive, alpha-beta memory T cell proliferation J:236671
\Ppp3cbm2Btlr/\Ppp3cbm2Btlr
(C57BL/6J-Ppp3cbm2Btlr)
abnormal CD4-positive, alpha-beta T cell physiology J:236671
abnormal CD8-positive, alpha-beta T cell physiology J:236671
abnormal NK cell physiology J:236671
decreased response to antigen J:236671
increased CD8-positive, alpha-beta memory T cell proliferation J:236671
\Ppp3cbM3Btlr/\Ppp3cb+
(C57BL/6J-Ppp3cbM3Btlr)
decreased CD8-positive, alpha-beta memory T cell number J:254889
increased central memory CD4-positive, alpha-beta T cell number J:254889
\Ppp3cbM3Btlr/\Ppp3cbM3Btlr
(C57BL/6J-Ppp3cbM3Btlr)
decreased CD8-positive, alpha-beta memory T cell number J:254889
decreased CD8-positive, naive alpha-beta T cell number J:254889
increased central memory CD4-positive, alpha-beta T cell number J:254889
increased central memory CD8 positive, alpha-beta T cell number J:254889
\Ppp3cbM4Btlr/\Ppp3cb+
(C57BL/6J-Ppp3cbM4Btlr)
decreased CD8-positive, alpha-beta memory T cell number J:254905
increased central memory CD8 positive, alpha-beta T cell number J:254905
\Ppp3cbM4Btlr/\Ppp3cbM4Btlr
(C57BL/6J-Ppp3cbM4Btlr)
decreased CD8-positive, alpha-beta memory T cell number J:254905
increased central memory CD8 positive, alpha-beta T cell number J:254905
\Ppp3cbm5Btlr/\Ppp3cbm5Btlr
(C57BL/6J-Ppp3cbm5Btlr)
abnormal T cell morphology J:272839
decreased CD8-positive, alpha-beta T cell number J:272839
\Ppp3cbM6Btlr/\Ppp3cbM6Btlr
(C57BL/6J-Ppp3cbM6Btlr)
abnormal lymphocyte morphology J:272840
decreased alpha-beta T cell number J:272840
decreased CD4-positive, alpha-beta T cell number J:272840
decreased CD8-positive, alpha-beta T cell number J:272840
\Ppp3cbtm1Jmk/\Ppp3cbtm1Jmk
(involves: 129S6/SvEvTac * C57BL/6)
abnormal T cell differentiation J:77729
decreased single-positive T cell number J:77729
decreased T cell number J:77729
decreased T cell proliferation J:77729
decreased thymus weight J:75775
thymus hypoplasia J:77729
\Ppp3cbtm1Jmk/\Ppp3cbtm1Jmk
(involves: 129S6/SvEvTac)
abnormal cytokine secretion J:109586
decreased T cell proliferation J:109586
\Ppp3r1tm2Grc/\Ppp3r1tm2.1Grc
\Tg(Lck-cre)1Cwi/0

(involves: 129S6/SvEvTac * C57BL/6 * DBA/2)
abnormal lymph node cell ratio J:89771
abnormal positive T cell selection J:89771
abnormal splenic cell ratio J:89771
\Ppp3r1tm2Grc/\Ppp3r1tm2Grc
\Tg(Lck-cre)1Cwi/0

(involves: 129S6/SvEvTac * C57BL/6 * DBA/2)
decreased thymocyte number J:89771
thymus hypoplasia J:89771
\Ppp4ctm1Tht/\Ppp4ctm1Tht
\Tg(Lck-cre)548Jxm/0

(involves: C57BL/6 * CBA)
abnormal positive T cell selection J:117684
abnormal T cell activation J:117684
abnormal T cell differentiation J:117684
decreased CD4-positive, alpha-beta T cell number J:117684
decreased CD8-positive, alpha-beta T cell number J:117684
decreased double-positive T cell number J:117684
decreased single-positive T cell number J:117684
increased double-negative T cell number J:117684
\Ppp4ctm1Tht/\Ppp4ctm1Tht
\Tg(Lck-cre)548Jxm/0
\Tg(TcraTcrb)425Cbn/0

(involves: BALB/c * C57BL/6 * CBA)
abnormal positive T cell selection J:117684
decreased double-positive T cell number J:117684
decreased single-positive T cell number J:117684
\Ppp4r3btm1b(EUCOMM)Hmgu/\Ppp4r3btm1b(EUCOMM)Hmgu
(C57BL/6N-Ppp4r3btm1b(EUCOMM)Hmgu/Ieg)
abnormal thymus morphology J:211773
enlarged lymph nodes J:211773
enlarged spleen J:211773
\Ppp5ctm1.2Rhon/\Ppp5ctm1.2Rhon
(B6.129X1-Ppp5ctm1.2Rhon)
enlarged spleen J:178164
\Ppp5ctm1a(EUCOMM)Wtsi/\Ppp5ctm1a(EUCOMM)Wtsi
(involves: C57BL/6 * C57BL/6N)
increased CD4-positive, alpha-beta T cell number J:213427
increased CD8-positive, alpha-beta T cell number J:213427
increased T cell number J:213427
lymphoid hyperplasia J:213427
\Ppp6ctm1Shma/\Ppp6ctm1Shma
\Tg(KRT14-cre/ERT)20Efu/0

(involves: C57BL/6 * CBA * CD-1)
increased susceptibility to chemically induced skin inflammation J:231809
\Ppt1tm1.1Dprc/\Ppt1tm1.1Dprc
(involves: 129S6/SvEvTac * BALB/cJ * C57BL/6)
abnormal microglial cell activation J:213552
\Ppt1tm1Aj/\Ppt1tm1Aj
(involves: 129S4/SvJae * C57BL/6)
abnormal spleen morphology J:95522
brain inflammation J:95522
\Ppt1tm1Hof/\Ppt1tm1Hof
(involves: 129S6/SvEvTac * C57BL/6J)
microgliosis J:280337
\Ppt1tm1Hof/\Ppt1tm1Hof
(involves: 129P2/OlaHsd * 129S2/SvPas * 129S6/SvEvTac * C57BL/6)
abnormal cytokine level J:177265
brain inflammation J:177265
\Ppt2tm1Hof/\Ppt2tm1Hof
(involves: 129S6/SvEvTac * C57BL/6J)
abnormal spleen morphology J:86202
decreased spleen B cell follicle number J:86202
enlarged spleen J:86202
increased macrophage cell number J:86202
increased spleen weight J:86202
\Pram1tm1Gak/\Pram1tm1Gak
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
abnormal neutrophil physiology J:95253
\Pramel1em1(IMPC)Tcp/\Pramel1em1(IMPC)Tcp
(C57BL/6NCrl-Pramel1em1(IMPC)Tcp/Tcp)
enlarged lymph nodes J:211773
\Pramel12em1(IMPC)Mbp/\Pramel12em1(IMPC)Mbp
(C57BL/6N-Pramel12em1(IMPC)Mbp/MbpMmucd)
abnormal spleen morphology J:211773
enlarged spleen J:211773
\Prap1tm1Lex/\Prap1tm1Lex
(involves: 129S5/SvEvBrd * C57BL/6J)
abnormal humoral immune response J:171883
increased immunoglobulin level J:171883
\Prap1tm1Lex/\Prap1tm1Lex
(B6.129S5-Prap1tm1Lex)
increased circulating interleukin-2 level J:304152
increased circulating interleukin-4 level J:304152
increased circulating interleukin-12 level J:304152
increased inflammatory response J:304152
increased interleukin-12b secretion J:304152
\Prcdtm1Vya/\Prcdtm1Vya
(B6.Cg-Prcdtm1Vya)
increased microglial cell activation J:276708
\Prdm1tm1.1Liz/\Prdm1tm1.1Liz
(involves: 129S/SvEv)
abnormal splenocyte physiology J:163979
absent plasma cells J:196531
\Prdm1tm1Clme/\Prdm1tm1Clme
\Tg(Itgax-cre)1-1Reiz/0

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA)
abnormal CD4-positive, alpha-beta T cell physiology J:178876
abnormal germinal center B cell physiology J:178876
abnormal immune system physiology J:178876
abnormal T follicular helper cell differentiation J:178876
increased anti-double stranded DNA antibody level J:178876
increased anti-nuclear antigen antibody level J:178876
increased autoantibody level J:178876
increased germinal center B cell number J:178876
increased IgG level J:178876
increased immunoglobulin level J:178876
increased interleukin-6 secretion J:178876
increased spleen germinal center number J:178876
increased splenocyte number J:178876
increased T follicular helper cell number J:178876
kidney inflammation J:178876
\Prdm1tm2.1Liz/\Prdm1tm2.1Liz
(involves: 129S/SvEv)
immune system phenotype J:153979
\Prdm1tm2.1Nutt/\Prdm1tm2.1Nutt
\Tg(Lck-cre)1Cwi/?

(involves: C57BL/6)
increased susceptibility to Orthomyxoviridae infection J:151858
\Prdm1tm3.1Liz/\Prdm1tm3.1Liz
(involves: 129S/SvEv)
immune system phenotype J:196531
\Prdm4tm1b(EUCOMM)Hmgu/\Prdm4tm1b(EUCOMM)Hmgu
(C57BL/6N-Prdm4tm1b(EUCOMM)Hmgu/H)
absent spleen J:211773
\Prdm8em1(IMPC)Wtsi/\Prdm8+
(C57BL/6N-Prdm8em1(IMPC)Wtsi/Wtsi)
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged thymus J:211773
small spleen J:211773
\Prdm8em1(IMPC)Wtsi/\Prdm8em1(IMPC)Wtsi
(C57BL/6N-Prdm8em1(IMPC)Wtsi/Wtsi)
abnormal thymus morphology J:211773
enlarged thymus J:211773
\Prdm11tm1.1Ahl/\Prdm11tm1.1Ahl
(B6.129(C)-Prdm11tm1.1Ahl)
abnormal humoral immune response J:233986
decreased CD4-positive, alpha-beta T cell number J:233986
decreased neutrophil cell number J:233986
increased B cell number J:233986
increased interferon-gamma secretion J:233986
increased interleukin-2 secretion J:233986
\Prdm13em1(IMPC)Tcp/\Prdm13em1(IMPC)Tcp
(C57BL/6NCrl-Prdm13em1(IMPC)Tcp/Tcp)
abnormal spleen morphology J:211773
increased spleen weight J:211773
\Prdm14tm1a(EUCOMM)Wtsi/\Prdm14tm1a(EUCOMM)Wtsi
(C57BL/6N-Prdm14tm1a(EUCOMM)Wtsi/Bay)
increased effector memory T-helper cell number J:211773
\Prdm16Gt(OST67423)Lex/\Prdm16+
(involves: 129S5/SvEvBrd * C57BL/6J)
increased leukocyte cell number J:103485
\Prdm16tm1.1Brsp/\Prdm16tm1.1Brsp
\Tg(Adipoq-cre)1Evdr/0

(involves: 129/Sv * C57BL/6 * FVB/N)
increased macrophage cell number J:208683
\Prdt1CAST/EiJH/\Prdt1CAST/EiJH
(involves: CAST/Ei * NZW/OlaHsd)
decreased susceptibility to prion infection J:80787
\Prdt1NZW/OlaHsd/\Prdt1NZW/OlaHsd
(involves: CAST/Ei * NZW/OlaHsd)
increased susceptibility to prion infection J:80787
\Prdt3CAST/EiJH/\Prdt3CAST/EiJH
(involves: CAST/Ei * NZW/OlaHsd)
decreased susceptibility to prion infection J:80787
\Prdt3NZW/OlaHsd/\Prdt3NZW/OlaHsd
(involves: CAST/Ei * NZW/OlaHsd)
increased susceptibility to prion infection J:80787
\Prdx1flro/\Prdx1flro
(C57BL/10JAnu-Prdx1flro/AnuApb)
abnormal lymphocyte morphology J:104190
\Prdx1tm1Rave/\Prdx1tm1Rave
(involves: 129S6/SvEvTac * C57BL/6)
abnormal NK T cell number J:84677
abnormal spleen morphology J:84677
enlarged spleen J:84677
impaired natural killer cell mediated cytotoxicity J:84677
increased spleen weight J:84677
increased T cell derived lymphoma incidence J:84677
\Prdx2tm1Yu/\Prdx2tm1Yu
(involves: 129S4/SvJae)
enlarged spleen J:84271
increased spleen red pulp amount J:84271
increased spleen weight J:84271
\Prdx3Gt(Betageo-puro)711Lex/\Prdx3Gt(Betageo-puro)711Lex
(involves: 129S5/SvEvBrd * C57BL/6)
lung inflammation J:118595
\Prdx5tm1.1(KOMP)Vlcg/\Prdx5tm1.1(KOMP)Vlcg
(involves: C57BL/6J * C57BL/6NTac)
immune system phenotype J:271141
increased circulating interleukin-12b level J:271141
increased circulating tumor necrosis factor level J:271141
increased interleukin-6 secretion J:271141
increased interleukin-12b secretion J:271141
increased tumor necrosis factor secretion J:271141
\PrepGt(RRM213)Byg/\Prep+
(B6.129P2-PrepGt(RRM213)Byg)
increased spleen weight J:151643
\Prex1tm1Dwu/\Prex1tm1Dwu
(Not Specified)
impaired neutrophil chemotaxis J:102213
\Prex1tm1Hcew/\Prex1tm1Hcew
(involves: 129P2/OlaHsd * C57BL/6)
impaired neutrophil chemotaxis J:102214
impaired neutrophil recruitment J:102214
increased neutrophil cell number J:102214
\Prf1m1Btlr/\Prf1m1Btlr
(C57BL/6J-Prf1m1Btlr)
increased susceptibility to Herpesvirales infection J:216044
increased susceptibility to Herpesvirales infection induced morbidity/mortality J:216044
\Prf1tm1Clrk/\Prf1tm1Clrk
(involves: 129S7/SvEvBrd * C57BL/6)
decreased cytotoxic T cell cytolysis J:21531
immune system phenotype J:21531
increased susceptibility to Riboviria infection J:21531
\Prf1tm1Clrk/\Prf1tm1Clrk
(C.129S7(B6)-Prf1tm1Clrk)
abnormal cytokine secretion J:71576
immune system phenotype J:71576
increased activated T cell number J:71576
increased interferon-gamma secretion J:71576
increased susceptibility to Riboviria infection J:71576
increased tumor necrosis factor secretion J:71576
\Prf1tm1Clrk/\Prf1tm1Clrk
(involves: 129S7/SvEvBrd * BALB/c * NOD)
decreased susceptibility to autoimmune diabetes J:64051
\Prf1tm1Clrk/\Prf1tm1Clrk
\Tg(INS-Il10)#Sar/0

(involves: 129S7/SvEvBrd * BALB/c * NOD)
decreased susceptibility to autoimmune diabetes J:64051
\Prf1tm1Sdz/\Prf1+
(NOD.B6-Prf1tm1Sdz)
decreased susceptibility to autoimmune diabetes J:43468
insulitis J:43468
periinsulitis J:43468
\Prf1tm1Sdz/\Prf1+
(A.B6-Prf1tm1Sdz)
impaired natural killer cell mediated cytotoxicity J:211842
\Prf1tm1Sdz/\Prf1tm1Sdz
(C57BL/6-Prf1tm1Sdz)
abnormal inflammatory response J:17986
abnormal leukocyte physiology J:17986
abnormal NK cell physiology J:113213
decreased cytotoxic T cell cytolysis J:17986
impaired natural killer cell mediated cytotoxicity J:17986
increased interleukin-10 secretion J:123934
increased susceptibility to bacterial infection J:123934
increased susceptibility to infection J:17986
increased susceptibility to parasitic infection J:81397
increased susceptibility to Riboviria infection J:17986
\Prf1tm1Sdz/\Prf1tm1Sdz
(NOD.B6-Prf1tm1Sdz)
decreased susceptibility to autoimmune diabetes J:43468
insulitis J:43468
periinsulitis J:43468
\Prf1tm1Sdz/\Prf1tm1Sdz
(C57BL/6-Prf1tm1Sdz/J)
abnormal circulating cytokine level J:92260
abnormal cytotoxic T cell physiology J:193137
abnormal lymph node morphology J:92260
abnormal lymphocyte physiology J:120427
abnormal macrophage activation involved in immune response J:92260
abnormal spleen white pulp morphology J:92260
abnormal T cell activation J:92260
brain inflammation J:92260, J:120427
CNS inflammation J:120427
decreased circulating fibrinogen level J:92260
decreased cytotoxic T cell cytolysis J:193137
decreased interferon-gamma secretion J:92260
decreased leukocyte cell number J:193137
decreased neutrophil cell number J:193137
decreased NK cell degranulation J:193137
immune system phenotype J:120427
increased circulating interferon-alpha level J:92260
increased circulating interferon-gamma level J:92260, J:193137
increased circulating interleukin-1 beta level J:193137
increased circulating interleukin-6 level J:92260, J:193137
increased circulating interleukin-10 level J:92260
increased circulating interleukin-18 level J:92260
increased circulating tumor necrosis factor level J:92260, J:193137
increased spleen red pulp amount J:92260
increased susceptibility to Picornaviridae infection J:120427
increased susceptibility to Riboviria infection J:92260, J:193137
increased susceptibility to Riboviria infection induced morbidity/mortality J:92260
increased susceptibility to viral infection induced morbidity/mortality J:193137
liver inflammation J:92260
lymph node inflammation J:92260
lymph node necrosis J:92260
\Prf1tm1Sdz/\Prf1tm1Sdz
(involves: BALB/c * C57BL/6)
impaired natural killer cell mediated cytotoxicity J:73948
\Prf1tm1Sdz/\Prf1tm1Sdz
(C.B6-Prf1tm1Sdz)
increased T cell derived lymphoma incidence J:77491
\Prf1tm1Sdz/\Prf1tm1Sdz
(A.B6-Prf1tm1Sdz)
impaired natural killer cell mediated cytotoxicity J:211842
\Prf1tm1Sdz/\Prf1tm1Sdz
\Rag1tm1Mom/\Rag1tm1Mom

(NOD.Cg-Rag1tm1Mom Prf1tm1Sdz/SzJ)
abnormal response to transplant J:91764
\Prf1tm1Sdz/\Prf1tm1Sdz
X/\Yaa

(BXSB.B6-Prf1tm1Sdz/Dcr)
autoimmune response J:179430
\Prf1tm1Tsc/\Prf1+
(involves: 129S2/SvPas)
decreased cytotoxic T cell cytolysis J:21731
impaired natural killer cell mediated cytotoxicity J:21731
\Prf1tm1Tsc/\Prf1tm1Tsc
(involves: 129S2/SvPas)
decreased cytotoxic T cell cytolysis J:21731
decreased susceptibility to bacterial infection J:50903
impaired natural killer cell mediated cytotoxicity J:21731
\Prf1tm1Tsc/\Prf1tm1Tsc
(129X1.129S2-Prf1tm1Tsc)
abnormal NK cell physiology J:126114
decreased T cell apoptosis J:126114
\Prg2tm1Nal/\Prg2tm1Nal
(involves: 129P2/OlaHsd * 129X1/SvJ)
abnormal eosinophil morphology J:65655
abnormal inflammatory response J:65655
respiratory system inflammation J:65655
\Primpolem1Nki/\Primpolem1Nki
(C57BL/6-Primpolem1Nki)
abnormal somatic hypermutation frequency J:242620
immune system phenotype J:242620
\Prkaa1tm1Sbj/\Prkaa1tm1Sbj
(involves: 129)
increased spleen weight J:147215
\Prkaa2tm1b(EUCOMM)Hmgu/\Prkaa2tm1b(EUCOMM)Hmgu
(C57BL/6N-Prkaa2tm1b(EUCOMM)Hmgu/H)
enlarged spleen J:211773
\Prkab1em1(IMPC)Bay/\Prkab1em1(IMPC)Bay
(C57BL/6N-Prkab1em1(IMPC)Bay/Bay)
increased spleen weight J:211773
\Prkab1tm1b(KOMP)Wtsi/\Prkab1+
(C57BL/6N-Prkab1tm1b(KOMP)Wtsi/Ccpcz)
decreased Ly6C-positive mature NK cell number J:211773
decreased lymphocyte cell number J:211773
\Prkab1tm1b(KOMP)Wtsi/\Prkab1tm1b(KOMP)Wtsi
(C57BL/6N-Prkab1tm1b(KOMP)Wtsi/Wtsi)
increased memory-marker CD4-negative NK T cell number J:211773
increased memory-marker gamma-delta T cell number J:211773
\Prkab1tm1b(KOMP)Wtsi/\Prkab1tm1b(KOMP)Wtsi
(C57BL/6N-Prkab1tm1b(KOMP)Wtsi/Ucd)
abnormal spleen morphology J:211773
enlarged spleen J:211773
increased spleen weight J:211773
\Prkab1tm1b(KOMP)Wtsi/\Prkab1tm1b(KOMP)Wtsi
(C57BL/6N-Prkab1tm1b(KOMP)Wtsi/H)
decreased lymphocyte cell number J:211773
increased neutrophil cell number J:211773
increased spleen weight J:211773
\Prkab1tm1b(KOMP)Wtsi/\Prkab1tm1b(KOMP)Wtsi
(C57BL/6N-Prkab1tm1b(KOMP)Wtsi/Bay)
increased spleen weight J:211773
\Prkab1tm1b(KOMP)Wtsi/\Prkab1tm1b(KOMP)Wtsi
(involves: C57BL/6N)
enlarged spleen J:236972
increased spleen iron level J:236972
increased spleen red pulp amount J:236972
increased spleen weight J:236972
\Prkab1tm1b(KOMP)Wtsi/\Prkab1tm1b(KOMP)Wtsi
(C57BL/6N-Prkab1tm1b(KOMP)Wtsi/Ccpcz)
abnormal spleen morphology J:211773
enlarged spleen J:211773
increased spleen weight J:211773
\Prkab1tm1Eihl/\Prkab1tm1Eihl
(involves: C57BL/6)
decreased circulating interleukin-6 level J:158295
\Prkab2tm1b(EUCOMM)Hmgu/\Prkab2+
(C57BL/6N-Prkab2tm1b(EUCOMM)Hmgu/H)
increased eosinophil cell number J:211773
\Prkag1tm1.2Mfor/\Prkag1tm1.2Mfor
(involves: 129S2/SvPas * C57BL/6 * C57BL/6NTac * FVB/N)
abnormal Kupffer cell morphology J:167779
enlarged spleen J:167779
increased spleen iron level J:167779
increased spleen red pulp amount J:167779
\Prkag2tm1.1Geno/\Prkag2tm1.1Geno
(B6J.129S(Cg)-Prkag2tm1.1Geno)
abnormal inflammatory response J:235379
white adipose tissue inflammation J:235379
\Prkag2tm3.1Mrl/?
(C57BL/6-Prkag2tm3.1Mrl/Tac)
kidney inflammation J:237375
\Prkar1atm2Gsm/\Prkar1atm2Gsm
\Tg(Cr2-cre)3Cgn/0

(involves: 129X1/SvJ * C57BL/6)
abnormal class switch recombination J:147785
\Prkar1btm1Gsm/\Prkar1btm1Gsm
(Not Specified)
decreased inflammatory response J:43080
\PrkcbM1Btlr/\Prkcb+
(C57BL/6J-PrkcbM1Btlr)
decreased IgM level J:164864
\PrkcbM1Btlr/\PrkcbM1Btlr
(C57BL/6J-PrkcbM1Btlr)
decreased IgM level J:164864
\PrkcbM1Btlr/\PrkcbM1Btlr
(involves: C57BL/6J)
decreased IgM level J:185495
immune system phenotype J:185495
\PrkcbM2Btlr/\Prkcb+
(C57BL/6J-PrkcbM2Btlr)
decreased IgM level J:217791
decreased response to antigen J:217791
impaired humoral immune response J:217791
\PrkcbM2Btlr/\PrkcbM2Btlr
(C57BL/6J-PrkcbM2Btlr)
decreased IgM level J:217791
decreased response to antigen J:217791
impaired humoral immune response J:217791
\PrkcbM3Btlr/\Prkcb+
(C57BL/6J-PrkcbM3Btlr)
decreased IgM level J:217793
decreased response to antigen J:217793
impaired humoral immune response J:217793
\PrkcbM3Btlr/\PrkcbM3Btlr
(C57BL/6J-PrkcbM3Btlr)
decreased IgM level J:217793
decreased response to antigen J:217793
impaired humoral immune response J:217793
\PrkcbM4Btlr/\PrkcbM4Btlr
(C57BL/6J-PrkcbM4Btlr)
decreased B-1 B cell number J:274860
increased CD4-positive, alpha-beta T cell number J:274860
increased CD8-positive, alpha-beta T cell number J:274860
increased T cell number J:274860
\PrkcbM5Btlr/\PrkcbM5Btlr
(C57BL/6J-PrkcbM5Btlr)
decreased IgM level J:274861
impaired humoral immune response J:274861
\PrkcbM6Btlr/\PrkcbM6Btlr
(C57BL/6J-PrkcbM6Btlr)
decreased B-1 B cell number J:274862
\Prkcbtilc/\Prkcb+
(involves: C57BL/6JSfdAnu)
abnormal humoral immune response J:221236
decreased IgG3 level J:221236
decreased IgM level J:221236
\Prkcbtilc/\Prkcbtilc
(C57BL/6JSfdAnu-Prkcbtilc/AnuApb)
decreased IgM level J:104190
\Prkcbtilc/\Prkcbtilc
(involves: C57BL/6JSfdAnu)
abnormal humoral immune response J:221236
decreased B cell proliferation J:221236
decreased B-1a cell number J:221236
decreased IgG3 level J:221236
decreased IgM level J:221236
immune system phenotype J:221236
\Prkcbtm1Tara/\Prkcb+
(involves: 129)
abnormal humoral immune response J:34818
decreased IgG3 level J:34818
decreased IgM level J:34818
\Prkcbtm1Tara/\Prkcbtm1Tara
(involves: 129)
abnormal humoral immune response J:34818
decreased B cell number J:34818
decreased B cell proliferation J:34818
decreased B-1 B cell number J:34818
decreased B-1a cell number J:34818
decreased IgG3 level J:34818
decreased IgM level J:34818
immune system phenotype J:34818
\PrkcdM1Btlr/\PrkcdM1Btlr
(C57BL/6J-PrkcdM1Btlr)
increased susceptibility to induced colitis J:265145
\Prkcdm2Btlr/\Prkcdm2Btlr
(C57BL/6J-Prkcdm2Btlr)
enhanced humoral immune response J:265146
increased IgM level J:265146
increased NK cell number J:265146
increased susceptibility to induced colitis J:265146
\Prkcdtm1.1Chou/\Prkcdtm1.1Chou
(involves: C57BL/6 * C57BL/6NTac)
abnormal neutrophil physiology J:217880
\Prkcdtm1Kin/\Prkcdtm1Kin
(involves: 129P2/OlaHsd * C57BL/6)
abnormal immunoglobulin level J:143854
abnormal lymph node germinal center morphology J:76135
abnormal Peyer's patch germinal center morphology J:76135
abnormal plasma cell differentiation J:143854
enlarged lymph nodes J:76135
enlarged spleen J:76135
glomerulonephritis J:76135
increased acute inflammation J:76135
increased anti-chromatin antibody level J:76135
increased B cell number J:76135
increased B cell proliferation J:76135, J:143854
increased follicular B cell number J:143854
increased IgA level J:76135, J:143854
increased IgG1 level J:76135, J:143854
increased IgM level J:143854
increased interleukin-6 secretion J:76135
increased marginal zone B cell number J:143854
increased spleen germinal center number J:76135
increased transitional stage B cell number J:143854
\Prkcdtm1Msg/\Prkcdtm1Msg
(involves: 129X1/SvJ * C57BL/6J)
abnormal neutrophil physiology J:91377
decreased neutrophil cell number J:91377
\Prkcdtm1Qxu/\Prkcdtm1Qxu
(involves: 129P2/OlaHsd)
abnormal response to transplant J:78680
\Prkcdtm1Qxu/\Prkcdtm1Qxu
(involves: 129P2/OlaHsd * C57BL/6)
enlarged lymph nodes J:76134
enlarged spleen J:76134
immune system phenotype J:76134
increased anti-nuclear antigen antibody level J:76134
increased B cell apoptosis J:76134
increased B cell number J:76134
increased IgA level J:76134
increased IgG1 level J:76134
increased IgM level J:76134
\Prkcdtm1Qxu/\Prkcdtm1Qxu
\Tg(IghelMD4)4Ccg/0
\Tg(KLK4mHEL)6Ccg/0

(involves: 129P2/OlaHsd * C57BL/6)
immune system phenotype J:76134
\Prkcdtm1Qxu/\Prkcdtm1Qxu
\Tg(IghelMD4)4Ccg/0
\Tg(ML5sHEL)5Ccg/0

(involves: 129P2/OlaHsd * C57BL/6)
abnormal B cell physiology J:76134
abnormal B cell proliferation J:76134
abnormal self tolerance J:76134
abnormal spleen primary B follicle morphology J:76134
autoimmune response J:76134
decreased B cell number J:76134
immune system phenotype J:76134
increased spleen germinal center number J:76134
\Prkcem1Btlr/\Prkcem1Btlr
(C57BL/6J-Prkcem1Btlr)
decreased dendritic cell number J:267703
decreased NK cell number J:267703
\Prkcetm1Bai/\Prkcetm1Bai
(Not Specified)
immune system phenotype J:94663
\Prkcetm1Bsca/\Prkcetm1Bsca
(involves: 129P2/OlaHsd * C57BL/6)
decreased circulating interleukin-1 beta level J:103337
decreased circulating tumor necrosis factor level J:103337
decreased macrophage apoptosis J:103337
decreased macrophage nitric oxide production J:103337
decreased T cell proliferation J:103337
increased susceptibility to bacterial infection J:103337
\Prkcetm1Ltg/\Prkcetm1Ltg
(involves: 129P2/OlaHsd * FVB/N)
decreased tumor necrosis factor secretion J:86056
\Prkcgtm1Stl/\Prkcgtm1Stl
(Not Specified)
decreased inflammatory response J:25061
\Prkchtm1.2Gasc/\Prkchtm1.2Gasc
(involves: C57BL/6 * FVB/N * SJL)
abnormal brachial lymph node morphology J:186080
abnormal cervical lymph node morphology J:186080
abnormal effector T cell morphology J:186080
abnormal lymph node morphology J:186080
decreased B cell number J:186080
decreased CD4-positive, alpha-beta T cell number J:186080
decreased CD8-positive, alpha-beta T cell number J:186080
decreased DN1 thymic pro-T cell number J:186080
decreased DN4 thymocyte number J:186080
decreased double-positive T cell number J:186080
decreased lymphocyte cell number J:186080
decreased T cell number J:186080
decreased T cell proliferation J:186080
enlarged axillary lymph nodes J:186080
enlarged cervical lymph nodes J:186080
enlarged inguinal lymph nodes J:186080
enlarged lymph nodes J:186080
increased B cell number J:186080
increased CD4-positive, alpha-beta T cell number J:186080
increased CD8-positive, alpha-beta T cell number J:186080
increased memory T cell number J:186080
increased T cell number J:186080
thymus hypoplasia J:186080
\Prkchtm1.2Gasc/\Prkchtm1.2Gasc
\Prkcqtm1Litt/\Prkcqtm1Litt

(involves: 129P2/OlaHsd * C57BL/6 * FVB/N * SJL)
abnormal positive T cell selection J:186080
decreased CD4-positive, alpha-beta T cell number J:186080
decreased CD8-positive, alpha-beta T cell number J:186080
decreased DN1 thymic pro-T cell number J:186080
decreased DN4 thymocyte number J:186080
decreased double-negative T cell number J:186080
decreased double-positive T cell number J:186080
decreased T cell proliferation J:186080
immune system phenotype J:186080
\Prkcitm1Rfar/\Prkci+
\Tg(Ckmm-cre)5Khn/?

(involves: 129P2/OlaHsd * C57BL/6 * FVB)
increased susceptibility to autoimmune diabetes J:123964
\Prkcqm1Btlr/\Prkcqm1Btlr
(C57BL/6J-Prkcqm1Btlr)
decreased IgG level J:255214
impaired humoral immune response J:255214
\Prkcqm2Btlr/\Prkcqm2Btlr
(C57BL/6J-Prkcqm2Btlr)
decreased IgG level J:255216
impaired humoral immune response J:255216
\Prkcqtm1.1Bai/\Prkcqtm1.1Bai
(involves: 129P2/OlaHsd * C57BL/6J)
abnormal T cell physiology J:83733
decreased interleukin-2 secretion J:83733
decreased T cell proliferation J:83733
\Prkcqtm1Litt/\Prkcqtm1Litt
(involves: 129P2/OlaHsd)
abnormal T cell activation J:83922
decreased interleukin-2 secretion J:83922
decreased T cell proliferation J:83922, J:123989
immune system phenotype J:123989
\Prkcqtm1Litt/\Prkcqtm1Litt
(B6.129P2-Prkcqtm1Litt)
abnormal CD4-positive, alpha-beta T cell physiology J:94285
abnormal T-helper 1 cell differentiation J:94285
abnormal T-helper 2 physiology J:94285
decreased interferon-gamma secretion J:129421, J:94285
decreased interleukin-2 secretion J:129421, J:94285
decreased interleukin-4 secretion J:129421, J:94285
decreased interleukin-5 secretion J:94285
decreased interleukin-13 secretion J:94285
decreased interleukin-17 secretion J:129421
decreased splenocyte proliferation J:129421
decreased susceptibility to experimental autoimmune encephalomyelitis J:129421
decreased T cell proliferation J:94285
immune system phenotype J:94285
\Prkcqtm1Litt/\Prkcqtm1Litt
(involves: 129P2/OlaHsd * C57BL/6)
abnormal effector T cell morphology J:186080
abnormal positive T cell selection J:186080
decreased CD4-positive, alpha-beta T cell number J:186080
decreased CD8-positive, alpha-beta T cell number J:186080
decreased DN1 thymic pro-T cell number J:186080
decreased NK T cell number J:141128
decreased T cell proliferation J:186080
immune system phenotype J:141128
increased T cell apoptosis J:141128
\Prkcqtm1Litt/\Prkcqtm1Litt
(either: (involves: 129/Sv * 129P2/OlaHsd) or (involves: 129P2/OlaHsd * C57BL/6))
abnormal response to infection J:141930
decreased T cell apoptosis J:141930
decreased T cell proliferation J:141930
\Prkcqtm1Litt/\Prkcqtm1Litt
\Tcratm1Mom/\Tcratm1Mom

(involves: 129P2/OlaHsd * 129S2/SvPas)
decreased interleukin-4 secretion J:135589
decreased T cell proliferation J:135589
immune system phenotype J:135589
\Prkcqtm1Litt/\Prkcqtm1Litt
\Tg(DO11.10)10Dlo/0

(involves: 129 * BALB/c * C3H * C57BL/6)
decreased T cell apoptosis J:141930
\Prkcqtm1Litt/\Prkcqtm1Litt
\Tg(Lck-Notch3)#Issc/0

(involves: 129P2/OlaHsd * C57BL/6 * DBA/2)
enlarged spleen J:96010
increased spleen weight J:96010
\Prkcqtm1Litt/\Prkcqtm1Litt
\Tg(LCKprBCL2L1)12Sjk/0

(involves: 129P2/OlaHsd * C57BL/6)
decreased NK T cell number J:141128
immune system phenotype J:141128
\Prkcqtm1Litt/\Prkcqtm1Litt
\Tg(TcrLCMV)327Sdz/0

(involves: 129P2/OlaHsd * C57BL/6 * DBA/2)
abnormal T cell anergy J:123989
decreased cytotoxic T cell cytolysis J:123989
decreased splenocyte proliferation J:123989
decreased T cell proliferation J:123989
\Prkcztm1Jmos/\Prkcztm1Jmos
(involves: 129P2/OlaHsd * 129/Sv)
abnormal Peyer's patch follicle morphology J:72720
abnormal Peyer's patch morphology J:72720
abnormal spleen marginal zone morphology J:72720
decreased B cell number J:72720
decreased spleen B cell follicle size J:72720
immune system phenotype J:72720
small Peyer's patches J:72720
\Prkd1em2(IMPC)Wtsi/\Prkd1+
(C57BL/6N-Prkd1em2(IMPC)Wtsi/Wtsi)
increased leukocyte cell number J:211773
\Prkd2Gt(RRJ380)Byg/\Prkd2Gt(RRJ380)Byg
(involves: 129P2/OlaHsd * C57BL/6)
immune system phenotype J:166867
\Prkd2tm1.1Daca/\Prkd2tm1.1Daca
(involves: C57BL/6)
abnormal CD4-positive, alpha-beta T cell physiology J:166867
abnormal CD8-positive, alpha-beta T cell physiology J:166867
decreased IgG1 level J:166867
decreased IgM level J:166867
decreased interferon-gamma secretion J:166867
decreased interleukin-2 secretion J:166867
immune system phenotype J:166867
\Prkd2tm1.1Shoy/\Prkd2tm1.1Shoy
\Prkd3tm1.1Shoy/\Prkd3tm1.1Shoy
\Tg(BCL2)25Wehi/0
\Tg(Lck-cre)1Jtak/0

(involves: 129 * C57BL/6 * C57BL/6JWehi * SJL/JWehi)
decreased thymocyte number J:236298
\Prkd2tm1.1Shoy/\Prkd2tm1.1Shoy
\Prkd3tm1.1Shoy/\Prkd3tm1.1Shoy
\Tg(Lck-cre)1Jtak/0

(involves: 129 * C57BL/6)
decreased thymocyte number J:236298
small thymus medulla J:236298
\Prkd2tm1.1Shoy/\Prkd2tm1.1Shoy
\Prkd3tm1.1Shoy/\Prkd3tm1.1Shoy
\Tg(Lck-cre)1Jtak/0
\Tg(TcraH-Y,TcrbH-Y)71Vbo/0

(involves: 129 * C57BL/6 * C57BL/6J * DBA/2J)
decreased thymocyte number J:236298
increased double-positive T cell number J:236298
\Prkd2tm1.1Shoy/\Prkd2tm1.1Shoy
\Prkd3tm1.1Shoy/\Prkd3tm1.1Shoy
\Tg(Lck-cre)1Jtak/0
\Tg(TcraTcrb)425Cbn/0

(involves: 129 * BALB/c * C57BL/6)
decreased thymocyte number J:236298
\Prkd2tm1.1Shoy/\Prkd2tm1.1Shoy
\Prkd3tm1.1Shoy/\Prkd3tm1.1Shoy
\Tg(Lck-cre)1Jtak/0
\Tg(TcraTcrb)1100Mjb/0

(involves: 129 * C57BL/6)
decreased thymocyte number J:236298
\Prkd2tm1.1Shoy/\Prkd2tm1.1Shoy
\Tg(Lck-cre)1Jtak/0

(involves: 129 * C57BL/6)
immune system phenotype J:236298
\Prkdcberty/\Prkdcberty
(C57BL/6JAnu-Prkdcberty)
absent B cells J:104190
absent T cells J:104190
\Prkdcem2(IMPC)Ics/\Prkdcem2(IMPC)Ics
(C57BL/6N-Prkdcem2(IMPC)Ics/Ics)
decreased leukocyte cell number J:211773
decreased lymphocyte cell number J:211773
increased eosinophil cell number J:211773
increased monocyte cell number J:211773
increased neutrophil cell number J:211773
\Prkdchanky/\Prkdchanky
(either: C57BL/6JAnu or (involves: C57BL/6JAnu * CBA/CaJ))
cecum inflammation J:104190
colitis J:104190
decreased lymphocyte cell number J:104190
enlarged mesenteric lymph nodes J:104190
increased plasma cell number J:104190
interstitial pneumonia J:104190
liver inflammation J:104190
lymph node hyperplasia J:104190
myeloid hyperplasia J:104190
\Prkdcm1Anu/\Prkdcm1Anu
(C57BL/6JAnu-Prkdcm1Anu)
abnormal lymphocyte morphology J:104190
\Prkdcm1Btlr/\Prkdcm1Btlr
(C57BL/6J-Prkdcm1Btlr)
abnormal immune system physiology J:178522
\Prkdcm1Btlr/\Prkdcm1Btlr
(involves: C57BL/6J)
abnormal class switch recombination J:185495
decreased B cell number J:185495
decreased IgG level J:185495
decreased IgM level J:185495
\Prkdcm2Btlr/\Prkdcm2Btlr
(C57BL/6J-Prkdcm2Btlr)
abnormal B cell physiology J:204502
decreased B cell number J:204502
decreased CD4-positive, alpha-beta T cell number J:204502
decreased CD8-positive, alpha-beta T cell number J:204502
decreased IgG level J:204502
decreased IgM level J:204502
\Prkdcm3Btlr/\Prkdcm3Btlr
(C57BL/6J-Prkdcm3Btlr)
decreased IgG level J:224665
impaired humoral immune response J:224665
\Prkdcm4Btlr/\Prkdcm4Btlr
(C57BL/6J-Prkdcm4Btlr)
decreased B cell number J:255217
increased B-1b cell number J:255217
increased neutrophil cell number J:255217
\Prkdcm5Btlr/\Prkdcm5Btlr
(C57BL/6J-Prkdcm5Btlr)
increased alpha-beta T cell number J:255220
increased CD4-positive, alpha-beta T cell number J:255220
\Prkdcm6Btlr/\Prkdcm6Btlr
(C57BL/6J-Prkdcm6Btlr)
decreased CD8-positive, naive alpha-beta T cell number J:255221
increased alpha-beta T cell number J:255221
increased CD4-positive, alpha-beta T cell number J:255221
increased CD8-positive, alpha-beta T cell number J:255221
\Prkdcm7Btlr/\Prkdcm7Btlr
(C57BL/6J-Prkdcm7Btlr)
abnormal humoral immune response J:255223
decreased IgG level J:255223
increased effector memory CD4-positive, alpha-beta T cell number J:255223
\PrkdcM8Btlr/\Prkdc+
(C57BL/6J-PrkdcM8Btlr)
decreased CD8-positive, alpha-beta T cell number J:255224
\PrkdcM8Btlr/\PrkdcM8Btlr
(C57BL/6J-PrkdcM8Btlr)
decreased CD8-positive, alpha-beta T cell number J:255224
increased CD4-positive, alpha-beta T cell number J:255224
increased plasmacytoid dendritic cell number J:255224
\PrkdcM9Btlr/\Prkdc+
(C57BL/6J-PrkdcM9Btlr)
decreased B-1a cell number J:255268
decreased effector memory CD4-positive, alpha-beta T cell number J:255268
increased B cell number J:255268
increased B-1b cell number J:255268
\PrkdcM9Btlr/\PrkdcM9Btlr
(C57BL/6J-PrkdcM9Btlr)
decreased B-1a cell number J:255268
decreased effector memory CD4-positive, alpha-beta T cell number J:255268
increased B cell number J:255268
increased B-1b cell number J:255268
\PrkdcM10Btlr/\Prkdc+
(C57BL/6J-PrkdcM10Btlr)
decreased CD8-positive, alpha-beta T cell number J:255269
\PrkdcM10Btlr/\PrkdcM10Btlr
(C57BL/6J-PrkdcM10Btlr)
decreased CD8-positive, alpha-beta T cell number J:255269
\PrkdcM11Btlr/\Prkdc+
(C57BL/6J-PrkdcM11Btlr)
enhanced humoral immune response J:255270
increased IgM level J:255270
\PrkdcM11Btlr/\PrkdcM11Btlr
(C57BL/6J-PrkdcM11Btlr)
enhanced humoral immune response J:255270
increased IgM level J:255270
\Prkdcm12Btlr/\Prkdcm12Btlr
(C57BL/6J-Prkdcm12Btlr)
decreased B cell number J:264708
decreased B-1 B cell number J:264708
decreased CD4-positive, alpha-beta T cell number J:264708
decreased CD8-positive, alpha-beta T cell number J:264708
decreased CD8-positive, naive alpha-beta T cell number J:264708
decreased NK T cell number J:264708
decreased single-positive T cell number J:264708
decreased T cell number J:264708
increased central memory CD4-positive, alpha-beta T cell number J:264708
increased central memory CD8 positive, alpha-beta T cell number J:264708
increased effector memory CD4-positive, alpha-beta T cell number J:264708
increased NK cell number J:264708
\Prkdcm13Btlr/\Prkdcm13Btlr
(C57BL/6J-Prkdcm13Btlr)
increased effector memory CD4-positive, alpha-beta T cell number J:272441
\Prkdcm14Btlr/\Prkdcm14Btlr
(C57BL/6J-Prkdcm14Btlr)
abnormal CD4-positive T cell differentiation J:272442
\PrkdcM15Btlr/\PrkdcM15Btlr
(C57BL/6J-PrkdcM15Btlr)
decreased B-1 B cell number J:272445
\PrkdcM16Btlr/\PrkdcM16Btlr
(C57BL/6J-PrkdcM16Btlr)
abnormal CD8-positive, alpha-beta T cell differentiation J:272520
\Prkdcm17Btlr/\Prkdcm17Btlr
(C57BL/6J-Prkdcm17Btlr)
increased plasmacytoid dendritic cell number J:272521
\Prkdcm18Btlr/\Prkdcm18Btlr
(C57BL/6J-Prkdcm18Btlr)
abnormal B cell differentiation J:274730
abnormal CD4-positive T cell differentiation J:274730
abnormal CD8-positive, alpha-beta T cell differentiation J:274730
abnormal T cell differentiation J:274730
decreased alpha-beta T cell number J:274730
decreased B cell number J:274730
decreased B-1 B cell number J:274730
decreased CD4-positive, alpha-beta T cell number J:274730
decreased CD8-positive, alpha-beta T cell number J:274730
decreased CD8-positive, naive alpha-beta T cell number J:274730
increased CD4-positive, alpha-beta T cell number J:274730
increased CD8-positive, alpha-beta T cell number J:274730
increased central memory CD4-positive, alpha-beta T cell number J:274730
increased central memory CD8 positive, alpha-beta T cell number J:274730
increased effector memory CD4-positive, alpha-beta T cell number J:274730
increased effector memory CD8-positive, alpha-beta T cell number J:274730
increased T cell number J:274730
\Prkdcm19Btlr/\Prkdcm19Btlr
(C57BL/6J-Prkdcm19Btlr)
abnormal B cell differentiation J:274763
abnormal CD4-positive T cell differentiation J:274763
abnormal CD8-positive, alpha-beta T cell differentiation J:274763
abnormal T cell differentiation J:274763
decreased B cell number J:274763
decreased B-1 B cell number J:274763
decreased CD4-positive, alpha-beta T cell number J:274763
decreased CD8-positive, alpha-beta T cell number J:274763
decreased CD8-positive, naive alpha-beta T cell number J:274763
decreased T cell number J:274763
increased central memory CD4-positive, alpha-beta T cell number J:274763
increased central memory CD8 positive, alpha-beta T cell number J:274763
increased effector memory CD4-positive, alpha-beta T cell number J:274763
increased effector memory CD8-positive, alpha-beta T cell number J:274763
increased NK cell number J:274763
\Prkdcscid/\Prkdcscid
(C.BKa-Prkdcscid)
abnormal humoral immune response J:6958
abnormal response to transplant J:22026
abnormal spleen white pulp morphology J:6958
abnormal thymus morphology J:6958
absent B cells J:6958
absent Peyer's patches J:6958
absent pre-B cells J:6958
absent thymus cortex J:6958
decreased B cell proliferation J:6958
decreased IgG level J:6958
decreased immunoglobulin level J:6958, J:22026
decreased leukocyte cell number J:6958
decreased T cell proliferation J:6958
immune system phenotype J:22026
increased length of allograft survival J:6958, J:22026
increased T cell derived lymphoma incidence J:6958
lymph node hypoplasia J:6958
lymphoid hypoplasia J:6958
salivary gland inflammation J:21965
small lymphoid organs J:6958
small thymus J:6958
thymus cyst J:6958
\Prkdcscid/\Prkdcscid
(NOD.Cg-Prkdcscid)
abnormal lymph node morphology J:109833, J:22026
abnormal response to transplant J:109833, J:22026
abnormal spleen white pulp morphology J:109833, J:22026
abnormal thymus corticomedullary boundary morphology J:22026
abnormal thymus lobule morphology J:22026
decreased B cell number J:22026
decreased CD4-positive, alpha-beta T cell number J:109833, J:22026
decreased CD8-positive, alpha-beta T cell number J:109833, J:22026
decreased immunoglobulin level J:22026
decreased level of surface class I molecules J:22026
decreased lymphocyte cell number J:22026
decreased mature B cell number J:109833
decreased NK cell number J:22026
decreased pre-B cell number J:22026
decreased T cell number J:22026
impaired complement classical pathway J:22026
impaired natural killer cell mediated cytotoxicity J:22026
increased granulocyte number J:22026
increased length of allograft survival J:22026
increased macrophage cell number J:22026
increased T cell derived lymphoma incidence J:109833, J:22026
spleen hypoplasia J:109833, J:22026
thymus cyst J:22026
\Prkdcscid/\Prkdcscid
(B6.Cg-Prkdcscid/Sz)
abnormal complement pathway J:34814, J:22026
abnormal level of surface class II molecules J:34814
abnormal lymph node B cell domain morphology J:34814
abnormal NK cell physiology J:34814
abnormal Peyer's patch morphology J:34814
abnormal spleen white pulp morphology J:34814
abnormal thymus morphology J:34814
decreased B cell number J:34814
decreased CD4-positive, alpha-beta T cell number J:34814
decreased CD8-positive, alpha-beta T cell number J:34814
decreased immunoglobulin level J:34814
decreased lymphocyte cell number J:34814
decreased pre-B cell number J:34814
decreased T cell number J:34814
increased eosinophil cell number J:34814
increased granulocyte number J:34814
increased macrophage cell number J:34814
increased monocyte cell number J:34814
increased neutrophil cell number J:34814
increased NK cell number J:34814
small Peyer's patches J:34814
small thymus J:34814
spleen hypoplasia J:34814
stomach inflammation J:120556
thymus cyst J:34814
\Prkdcscid/\Prkdcscid
(NOD.Cg-Prkdcscid/J)
abnormal response to transplant J:91764
\Prkdcscid/\Prkdcscid
(involves: BALB/c * C57BL/6 * C57BL/Ka)
abnormal NK cell physiology J:115033
\Prkdcscid/\Prkdcscid
\Mcph1Tg(HLA-A2.1)1Enge/\Mcph1+

(NOD.Cg-Mcph1Tg(HLA-A2.1)1Enge Prkdcscid/Dvs)
abnormal splenocyte morphology J:91764
\Prkdcscid/\Prkdcscid
\Rasa3scat/\Rasa3scat

(involves: BALB/c * BALB/cBy * C57BL)
abnormal immune system morphology J:186485
\Prkdcscid/\Prkdcscid
\Sst1C57BL/6J/\Sst1C57BL/6J

(involves: C3HeB/FeJ * C57BL/6J)
decreased susceptibility to bacterial infection J:93705
\Prkdcscid/\Prkdcscid
\Tg(B2M)55Hpl/0
\Mcph1Tg(HLA-A2.1)1Enge/\Mcph1+

(NOD.Cg-Mcph1Tg(HLA-A2.1)1Enge Prkdcscid Tg(B2M)55Hpl/Sz)
abnormal response to transplant J:91764
\Prkdcscid/\Prkdcscid
\Tg(CSF2)2Ygy/0
\Tg(IL3)1Ygy/0

(CB17.Cg-Prkdcscid Tg(CSF2)2Ygy Tg(IL3)1Ygy)
abnormal response to transplant J:94302
\Prkdcscid/\Prkdcscid
\Tg(CSF2)2Ygy/0
\Tg(IL3)1Ygy/0
\Tg(KITLG)3Ygy/0

(CB17.Cg-Prkdcscid Tg(CSF2)2Ygy Tg(IL3)1Ygy Tg(KITLG)3Ygy)
abnormal response to transplant J:106416, J:94302
\Prkdcscid/\Prkdcscid
\Tg(CSF2)2Ygy/0
\Tg(IL3)1Ygy/0
\Tg(KITLG)3Ygy/0

(NOD.Cg-Prkdcscid Tg(CSF2)2Ygy Tg(IL3)1Ygy Tg(KITLG)3Ygy)
abnormal response to transplant J:107052
decreased susceptibility to graft versus host disease J:107052
\Prkdcscid/\Prkdcscid
\Tg(HLA-DRA*0101,HLA-DRB1*0101)1Dmz/\Tg(HLA-DRA*0101,HLA-DRB1*0101)1Dmz

(NOD.Cg-Tg(HLA-DRA*0101,HLA-DRB1*0101)1Dmz Prkdcscid/Gck)
abnormal professional antigen presenting cell morphology J:126700
absent T cells J:126700
\Prkdcscid/\Prkdcscid
\Tg(Ins2-Fasl)24Ach/0

(NOD.Cg-Prkdcscid Tg(Ins2-Fasl)24Ach)
decreased susceptibility to autoimmune diabetes J:81416
increased susceptibility to autoimmune diabetes J:81416
\Prkdcscid/\Prkdcscid
\Tg(INS-Il10)#Sar/0

(NOD.Cg-Prkdcscid Tg(INS-Il10)#Sar)
increased susceptibility to autoimmune diabetes J:66103
\Prkdcscid/\Prkdcscid
\Tg(TcraAI4)1Dvs/0
\Tg(TcrbAI4)1Dvs/0

(NOD.Cg-Prkdcscid Tg(TcraAI4)1Dvs Tg(TcrbAI4)1Dvs)
abnormal CD4-positive, alpha beta T cell morphology J:93553
increased susceptibility to autoimmune diabetes J:93553
\Prkdcscid/\Prkdcscid
\Tg(Tcrb)93Vbo/0

(involves: Balb/c * C57BL/Ka * C57BL/Lia * CBA/BrA)
abnormal CD4-positive, alpha beta T cell morphology J:111476
abnormal CD8-positive, alpha beta T cell morphology J:111476
abnormal double-positive T cell morphology J:111476
abnormal single-positive T cell number J:111476
abnormal T cell differentiation J:111476
\Prkdcscid/\Prkdcscid
\Tg(TcrLCMV)327Sdz/?

(NOD.Cg-Emv30b Prkdcscid Tg(TcrLCMV)327Sdz/DvsJ)
immune system phenotype J:71050
\Prkdcscid/\Prkdcscid
\Tgfb1tm1Doe/\Tgfb1tm1Doe

(involves: 129 * C3H * CF-1)
decreased spleen weight J:129629
\PrkdcTg(INS-PDE2)5-1Lmb/?
(involves: FVB/N)
abnormal thymus morphology J:108405
\Prkdctm1.1Bpcc/\Prkdctm1.1Bpcc
(involves: 129 * C57BL/6)
abnormal immunoglobulin V(D)J recombination J:171351
arrested B cell differentiation J:171351
decreased CD4-positive, alpha-beta T cell number J:171351
decreased CD8-positive, alpha-beta T cell number J:171351
decreased double-negative T cell number J:171351
decreased double-positive T cell number J:171351
decreased gamma-delta T cell number J:171351
decreased granulocyte number J:171351
decreased leukocyte cell number J:171351
decreased lymphocyte cell number J:171351
decreased macrophage cell number J:171351
decreased mature B cell number J:171351
decreased T cell number J:171351
small lymphoid organs J:171351
\Prkdctm1Fwa/\Prkdctm1Fwa
(involves: 129S6/SvEvTac * C57BL/6)
abnormal T cell receptor beta chain V(D)J recombination J:50221
abnormal T cell receptor V(D)J recombination J:50221
absent pre-B cells J:50221
arrested B cell differentiation J:50221
arrested T cell differentiation J:50221
decreased double-positive T cell number J:50221
decreased thymocyte number J:50221
\Prkdctm1Fwa/\Prkdctm1Fwa
(involves: 129S6/SvEvTac)
decreased splenocyte number J:306598
\Prkdctm1Gcl/\Prkdctm1Gcl
(involves: 129S1/Sv * C57BL/6)
abnormal immunoglobulin heavy chain V(D)J recombination J:53765
abnormal lymph node morphology J:53765
abnormal spleen morphology J:53765
abnormal T cell receptor beta chain V(D)J recombination J:53765
abnormal T cell receptor delta chain V(D)J recombination J:53765
absent mature B cells J:53765
absent Peyer's patches J:53765
absent thymus corticomedullary boundary J:53765
arrested B cell differentiation J:53765
increased T cell derived lymphoma incidence J:53765
small lymph nodes J:53765
small Peyer's patches J:53765
small spleen J:53765
small thymus J:53765
thymus hypoplasia J:53765
\Prkdctm1Gcl/\Prkdctm1Gcl
(involves: 129S1/Sv)
decreased thymocyte apoptosis J:126920
\Prkdctm1Get/\Prkdctm1Get
(involves: 129S4/SvJae * Black Swiss)
abnormal B cell differentiation J:50222
abnormal immunoglobulin heavy chain V(D)J recombination J:50222
abnormal immunoglobulin light chain V-J recombination J:50222
abnormal T cell differentiation J:50222
abnormal T cell number J:50222
abnormal T cell receptor alpha chain V-J recombination J:50222
abnormal T cell receptor beta chain V(D)J recombination J:50222
abnormal T cell receptor delta chain V(D)J recombination J:50222
abnormal thymus corticomedullary boundary morphology J:50222
arrested B cell differentiation J:50222
arrested T cell differentiation J:50222
decreased IgM level J:50222
decreased single-positive T cell number J:50222
decreased spleen white pulp amount J:50222
increased double-negative T cell number J:50222
increased double-positive T cell number J:50222
increased NK cell number J:50222
small lymph nodes J:50222
spleen hypoplasia J:50222
thymus hypoplasia J:50222
\Prkg1tm1b(KOMP)Wtsi/\Prkg1tm1b(KOMP)Wtsi
(C57BL/6N-Prkg1tm1b(KOMP)Wtsi/H)
enlarged spleen J:211773
\Prkg1tm2.1Naw/\Prkg1tm2.1Naw
(involves: 129S1/Sv * 129X1/SvJ)
enlarged spleen J:134639
\Prl7d1em1(IMPC)Tcp/\Prl7d1em1(IMPC)Tcp
(C57BL/6NCrl-Prl7d1em1(IMPC)Tcp/Tcp)
enlarged lymph nodes J:211773
\Prl7d1em1Liga/\Prl7d1em1Liga
(involves: C57BL/6)
increased uterine NK cell number J:288761
\Prltm1Hmn/\Prltm1Hmn
(involves: 129S2/SvPas)
immune system phenotype J:45243
\Prmt3tm1a(EUCOMM)Wtsi/\Prmt3tm1a(EUCOMM)Wtsi
(involves: C57BL/6 * C57BL/6N)
increased CD4-positive, alpha-beta T cell number J:213427
increased CD8-positive, alpha-beta T cell number J:213427
increased incidence of corneal inflammation J:213427
increased T cell number J:213427
\Prmt7tm1a(EUCOMM)Wtsi/\Prmt7tm1a(EUCOMM)Wtsi
(B6JTyr;B6N-Prmt7tm1a(EUCOMM)Wtsi/Wtsi)
abnormal thymus topology J:239583
blood in lymph vessels J:239583
\Prmt9em1Cya/\Prmt9em1Cya
\Lyz2tm1(cre)Ifo/\Lyz2+

(involves: 129P2/OlaHsd * C57BL/6N)
decreased susceptibility to viral infection J:328263
increased circulating interferon-beta level J:328263
increased interferon-beta secretion J:328263
\Prnp/Prndtm1Aag/\Prnp/Prndtm1Aag
(Not Specified)
immune system phenotype J:89232
\Prnp/Prndtm1Aag/\Prnp/Prndtm1Aag
(Not Specified)
immune system phenotype J:89232
\Prnpa/\Prnpa
(NZW)
increased susceptibility to prion infection J:8918
\Prnpb/\Prnpb
(I/LnJ)
decreased susceptibility to prion infection J:8918
\Prnpc/\Prnpc
(MAI/Pas)
decreased susceptibility to prion infection J:90099
\Prnpem2.1(Prnp*D178N)Jwat/\Prnpem2.1(Prnp*D178N)Jwat
(involves: 129S4/SvJae * C57BL/6)
dermatitis J:361333
\Prnpem3.1(Prnp*E200K)Jwat/\Prnpem3.1(Prnp*E200K)Jwat
(involves: 129S4/SvJae * C57BL/6)
dermatitis J:361333
\Prnptm1(PRNP)Tkit/\Prnptm1(PRNP)Tkit
(Not Specified)
decreased susceptibility to prion infection J:86603
increased susceptibility to prion infection J:86603
\Prnptm1Cwe/\Prnptm1Cwe
\Tg(Lck-Prnp)33Cwe/0

(involves: 129S7/SvEvBrd * C57BL/6)
increased CD8-positive, alpha-beta T cell number J:129512
increased gamma-delta T cell number J:129512
thymus hypoplasia J:129512
\Prnptm1Cwe/\Prnptm1Cwe
\Tg(Nefh-cre)22Jcol/?
\Tg(Prnp)37Jcol/?

(involves: 129/Sv * 129S7/SvEvBrd * C57BL/6 * FVB)
decreased susceptibility to prion infection J:126424
\Prnptm1Cwe/\Prnptm1Cwe
\Tg(Nefh-cre)22Jcol/?
\Tg(Prnp)46Jcol/?

(involves: 129/Sv * 129S7/SvEvBrd * C57BL/6 * FVB)
decreased susceptibility to prion infection J:74652
\Prnptm1Cwe/\Prnptm1Cwe
\Tg(PRNP)35Jcol/\Tg(PRNP)35Jcol

(involves: 129 * 129S7/SvEvBrd * C57BL/6 * FVB/N)
increased susceptibility to prion infection J:131494
\Prnptm1Cwe/\Prnptm1Cwe
\Tg(Prnp)37Jcol/?

(involves: 129/Sv * 129S7/SvEvBrd * C57BL/6 * FVB)
increased susceptibility to prion infection J:74652, J:126424
\Prnptm1Cwe/\Prnptm1Cwe
\Tg(PRNP)45Jcol/\Tg(PRNP)45Jcol

(involves: 129 * 129S7/SvEvBrd * C57BL/6 * FVB/N)
increased susceptibility to prion infection J:131494
\Prnptm1Cwe/\Prnptm1Cwe
\Tg(Prnp)46Jcol/?

(involves: 129/Sv * 129S7/SvEvBrd * C57BL/6 * FVB)
immune system phenotype J:74652
\Prnptm1Cwe/\Prnptm1Cwe
\Tg(Prnp)4053Sbp/0

(involves: 129S7/SvEvBrd * FVB/N)
increased susceptibility to prion infection J:136434
\Prnptm1Cwe/\Prnptm1Cwe
\Tg(PRNP)23454Sbp/0

(involves: 129S7/SvEvBrd * FVB/N)
increased susceptibility to prion infection J:236012
\Prnptm1Cwe/\Prnptm1Cwe
\Tg(Prnp)a19Cwe/0

(Not Specified)
increased susceptibility to prion infection J:32214
\Prnptm1Cwe/\Prnptm1Cwe
\Tg(Prnp)a20Cwe/0

(Not Specified)
increased susceptibility to prion infection J:32214
\Prnptm1Cwe/\Prnptm1Cwe
\Tg(Prnp)a20Cwe/0

(involves: 129S7/SvEvBrd * C57BL/6)
abnormal B cell morphology J:129512
abnormal T cell differentiation J:129512
decreased CD4-positive, alpha-beta T cell number J:129512
decreased CD8-positive, alpha-beta T cell number J:129512
decreased DN2 thymocyte number J:129512
decreased DN4 thymocyte number J:129512
decreased double-positive T cell number J:129512
decreased thymocyte number J:129512
increased DN3 thymocyte number J:129512
increased double-negative T cell number J:129512
increased gamma-delta T cell number J:129512
thymus atrophy J:129512
\Prnptm1Cwe/\Prnptm1Cwe
\Tg(Prnp)c35Cwe/0

(Not Specified)
increased susceptibility to prion infection J:32214
\Prnptm1Cwe/\Prnptm1Cwe
\Tg(Prnp*S170N*N174T)1020Aag/0

(involves: 129S7/SvEvBrd * C57BL/6)
decreased susceptibility to prion infection J:143528
microgliosis J:143528
\Prnptm1Edin/\Prnptm1Edin
(129P2/OlaHsd-Prnptm1Edin/EdinH)
abnormal susceptibility to prion infection J:58820
\Prnptm1Lnq/\Prnptm1Lnq
(involves: 129P2/OlaHsd * C57BL/6N)
decreased susceptibility to prion infection J:154937
\Prnptm1Miy/\Prnptm1Miy
(involves: 129S4/SvJae * C57BL/6)
decreased susceptibility to prion infection J:69186
\Prnptm1Rcm/\Prnptm1Rcm
(129P2/OlaHsd-Prnptm1Rcm)
abnormal susceptibility to prion infection J:45908
\Prnptm1Tuzi/\Prnp+
(involves: 129P2/OlaHsd)
decreased susceptibility to prion infection J:92302
\Prnptm1Tuzi/\Prnp+
\Tg(CMV-cre)1Cgn/?

(involves: 129P2/OlaHsd * BALB/cJ)
immune system phenotype J:92302
\Prnptm1Tuzi/\Prnptm2Edin
(involves: 129P2/OlaHsd)
decreased susceptibility to prion infection J:92302
\Prnptm1Tuzi/\Prnptm2Edin
\Tg(CMV-cre)1Cgn/?

(involves: 129P2/OlaHsd * BALB/cJ)
decreased susceptibility to prion infection J:92302
\Prnptm2(PRNP*129M)Tkit/\Prnptm2(PRNP*129M)Tkit
(Not Specified)
decreased susceptibility to prion infection J:126777, J:105882
increased susceptibility to prion infection J:126777, J:105882
\Prnptm2(PRNP*129M)Tkit/\Prnptm2(PRNP*129M)Tkit
\Tg(Prnp-PRNP*129M)1Tkit/?

(Not Specified)
decreased susceptibility to prion infection J:126777
increased susceptibility to prion infection J:126777
\Prnptm2(PRNP*129M)Tkit/\Prnptm3(PRNP*129V)Tkit
(Not Specified)
decreased susceptibility to prion infection J:105882
\Prnptm2Lnq/\Prnptm2Lnq
(involves: 129P2/OlaHsd * C57BL/6N)
immune system phenotype J:154937
\Prnptm2Tuzi/\Prnp+
(involves: 129P2/OlaHsd)
immune system phenotype J:92302
\Prnptm2Tuzi/\Prnp+
\Tg(CMV-cre)1Cgn/?

(involves: 129P2/OlaHsd * BALB/cJ)
decreased susceptibility to prion infection J:92302
\Prnptm2Tuzi/\Prnptm2Edin
(involves: 129P2/OlaHsd)
decreased susceptibility to prion infection J:92302
\Prnptm2Tuzi/\Prnptm2Edin
\Tg(CMV-cre)1Cgn/?

(involves: 129P2/OlaHsd * BALB/cJ)
decreased susceptibility to prion infection J:92302
\Prnptm3(PRNP*129V)Tkit/\Prnptm3(PRNP*129V)Tkit
(Not Specified)
abnormal spleen morphology J:126777
decreased susceptibility to prion infection J:126777, J:105882
increased susceptibility to prion infection J:126777
\Prnptm3(PRNP*129V)Tkit/\Prnptm3(PRNP*129V)Tkit
\Tg(Prnp-PRNP*129V)139Tkit/?

(Not Specified)
abnormal susceptibility to infection J:126777
decreased susceptibility to prion infection J:105882
\Prnptm3(PRNP*129V)Tkit/\Prnptm3(PRNP*129V)Tkit
\Tg(Prnp-PRNP*129V)144Tkit/?

(Not Specified)
decreased susceptibility to prion infection J:105882
\Prnptm4(PRNP)Tkit/\Prnptm4(PRNP)Tkit
(Not Specified)
increased susceptibility to prion infection J:105882
\Prnptm4(PRNP)Tkit/\Prnptm4(PRNP)Tkit
\Tg(Prnp-PRNP)32Tkit/?

(Not Specified)
increased susceptibility to prion infection J:105882
\Prnptm5(PRNP*)TKit/\Prnptm5(PRNP*)TKit
(Not Specified)
immune system phenotype J:126777
\Prnptm5(PRNP*)TKit/\Prnptm5(PRNP*)TKit
\Tg(Prnp-PRNP*)1Tkit/?

(Not Specified)
decreased susceptibility to prion infection J:126777
increased susceptibility to prion infection J:126777
\Prnr1RIII/FaDk/\Prnr1RIII/FaDk
(involves: C57BL/FaDk * RIII/FaDk)
decreased susceptibility to prion infection J:89558
\Prnr2C57BL/FaDk/\Prnr2C57BL/FaDk
(involves: C57BL/FaDk * RIII/FaDk)
decreased susceptibility to prion infection J:89558
\Prnr2C57BL/FaDk/\Prnr2RIII/FaDk
(involves: C57BL/FaDk * RIII/FaDk)
decreased susceptibility to prion infection J:89558
\Proctm1Fjc/\Proctm1Fjc
(involves: 129S1/Sv * 129X1/SvJ * Swiss)
abnormal innate immunity J:50527
liver inflammation J:50527
\Procrtm1.1Pcl/\Procrtm1.1Pcl
(involves: 129S2/SvPas * C57BL/6)
bone marrow failure J:225914
enlarged spleen J:225914
increased circulating interleukin-6 level J:225914
increased spleen red pulp amount J:225914
increased spleen weight J:225914
increased splenocyte number J:225914
increased susceptibility to endotoxin shock J:225914
\Proser2em1(IMPC)Ccpcz/\Proser2em1(IMPC)Ccpcz
(C57BL/6NCrl-Proser2em1(IMPC)Ccpcz/Ccpcz)
abnormal lymph node morphology J:211773
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged lymph nodes J:211773
enlarged spleen J:211773
enlarged thymus J:211773
\Prox1tm1Gco/\Prox1+
(involves: 129S1/Sv * 129X1/SvJ * NMRI)
abnormal lymph circulation J:102652, J:57646
abnormal lymphatic vessel morphology J:102652
increased inflammatory response J:102652
increased macrophage cell number J:102652
\Prox1tm1Gco/\Prox1+
(involves: 129S1/Sv * 129X1/SvJ)
abnormal lymph circulation J:57646
\Prox1tm1Gco/\Prox1tm1Gco
(involves: 129S1/Sv * 129X1/SvJ * NMRI)
abnormal lymph organ development J:57646
\Prox1tm1Gco/\Prox1tm2Gco
\Tg(Tek-cre)1Ywa/?

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL)
absent lymphatic vessels J:125507
\Prox1tm1Gco/\Prox1tm5(GFP/cre)Gco
(involves: 129S1/Sv * 129X1/SvJ * NMRI)
decreased lymphatic vessel endothelial cell number J:158959
\Prox1tm2Gco/\Prox1+
\Tg(Tek-cre)1Ywa/0

(involves: 129S1/Sv * C57BL/6 * NMRI * SJL)
abnormal lymph circulation J:102652
abnormal lymphatic vessel morphology J:102652
\Prox1tm4.1Gco/\Prox1tm4.1Gco
(involves: 129S1/Sv * C57BL/10 * CBA/Ca)
decreased lymphatic vessel endothelial cell number J:158959
\Prpf3tm1b(KOMP)Wtsi/\Prpf3+
(C57BL/6N-Prpf3tm1b(KOMP)Wtsi/Bay)
increased neutrophil cell number J:211773
\Prph2em1Sal/\Prph2+
(C57BL/6J-Prph2em1Sal)
eye inflammation J:342243
\Prph2em1Sal/\Prph2em1Sal
(C57BL/6J-Prph2em1Sal)
eye inflammation J:342243
increased microglial cell activation J:342243
\Prph2Rd2/\Prph2Rd2
(O20/A-Prph2Rd2)
abnormal macrophage morphology J:6432
\Prps1tm1b(EUCOMM)Wtsi/\Prps1+
(C57BL/6N-Prps1tm1b(EUCOMM)Wtsi/Ics)
decreased lymphocyte cell number J:211773
increased neutrophil cell number J:211773
\Prps2tm1a(KOMP)Wtsi/Y
(involves: C57BL/6N)
abnormal B cell physiology J:214383
\Prps2tm1a(KOMP)Wtsi/Y
\Tg(IghMyc)22Bri/0

(involves: C57BL/6N * SJL)
abnormal B cell physiology J:214383
increased B cell apoptosis J:214383
\Prr7tm1(KOMP)Vlcg/\Prr7tm1(KOMP)Vlcg
(involves: C57BL/6NTac)
decreased CD4-positive, alpha-beta T cell number J:237776
immune system phenotype J:237776
\Prr27tm1b(KOMP)Wtsi/\Prr27tm1b(KOMP)Wtsi
(C57BL/6N-Prr27tm1b(KOMP)Wtsi/Bay)
increased leukocyte cell number J:211773
\Prr30em1(IMPC)J/\Prr30em1(IMPC)J
(C57BL/6NJ-Prr30em1(IMPC)J/Mmjax)
decreased leukocyte cell number J:211773
\Prrg4em1(IMPC)Mbp/\Prrg4em1(IMPC)Mbp
(C57BL/6NCrl-Prrg4em1(IMPC)Mbp/MbpMmucd)
abnormal spleen morphology J:211773
enlarged spleen J:211773
\Prss3btm1.1Satom/\Prss3b+
(B6(FVB)-Prss3btm1.1Satom)
acute pancreas inflammation J:267764
chronic pancreas inflammation J:267764
\Prss8tm1.1Hum/\Prss8tm1.2Hum
\Tg(KRT14-cre)1Ipc/0

(involves: 129/Sv * C57BL/6 * FVB/N * SJL)
thymus medulla hypoplasia J:100139
\Prss12em1(IMPC)Ccpcz/\Prss12em1(IMPC)Ccpcz
(C57BL/6N-Prss12em1(IMPC)Ccpcz/Ccpcz)
abnormal thymus morphology J:211773
enlarged thymus J:211773
\Prss16tm1.1Mal/\Prss16+
\Rag2tm1Fwa/\Rag2tm1Fwa
\Tg(TcraH-Y,TcrbH-Y)1Pas/?

(involves: 129S/SvEv * 129S2/SvPas * C57BL/6)
abnormal positive T cell selection J:148034
decreased CD4-positive, alpha-beta T cell number J:148034
decreased single-positive T cell number J:148034
lymph node hypoplasia J:148034
\Prss16tm1.1Mal/\Prss16tm1.1Mal
(involves: 129S2/SvPas * C57BL/6)
abnormal professional antigen presenting cell morphology J:148034
abnormal thymus cortex morphology J:148034
\Prss16tm1.1Mal/\Prss16tm1.1Mal
\Rag2tm1Fwa/\Rag2tm1Fwa
\Tg(TcraH-Y,TcrbH-Y)1Pas/?

(involves: 129S/SvEv * 129S2/SvPas * C57BL/6)
abnormal positive T cell selection J:148034
decreased CD4-positive, alpha-beta T cell number J:148034
decreased double-positive T cell number J:148034
decreased single-positive T cell number J:148034
lymph node hypoplasia J:148034
spleen hypoplasia J:148034
thymus hypoplasia J:148034
\Prss16tm1Cbo/\Prss16tm1Cbo
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
immune system phenotype J:94751
\Prss21em1(IMPC)Ccpcz/\Prss21+
(C57BL/6N-Prss21em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged thymus J:211773
\Prss27tm1.1(NCOM)Mfgc/\Prss27tm1.1(NCOM)Mfgc
(C57BL/6N-Prss27tm1.1(NCOM)Mfgc/Tcp)
decreased monocyte cell number J:211773
\Prss33em1(IMPC)Ccpcz/\Prss33em1(IMPC)Ccpcz
(C57BL/6N-Prss33em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged spleen J:211773
enlarged thymus J:211773
small spleen J:211773
\Prss34tm1.1Hkar/\Prss34tm1.1Hkar
(involves: C57BL/6)
decreased inflammatory response J:238924
immune system phenotype J:238924
\Prss35em1(IMPC)Ccpcz/\Prss35em1(IMPC)Ccpcz
(C57BL/6N-Prss35em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged spleen J:211773
enlarged thymus J:211773
\Prss47em1(IMPC)Ccpcz/\Prss47em1(IMPC)Ccpcz
(C57BL/6N-Prss47em1(IMPC)Ccpcz/Ccpcz)
abnormal lymph node morphology J:211773
abnormal thymus morphology J:211773
enlarged lymph nodes J:211773
enlarged thymus J:211773
\Prss48em1(IMPC)Ccpcz/\Prss48em1(IMPC)Ccpcz
(C57BL/6NCrl-Prss48em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged thymus J:211773
\Prss50tm1a(EUCOMM)Hmgu/\Prss50tm1a(EUCOMM)Hmgu
(C57BL/6N-Prss50tm1a(EUCOMM)Hmgu/H)
decreased CD8-positive, alpha-beta T cell number J:165965
decreased T cell number J:165965
\Prss53em3(IMPC)Wtsi/\Prss53em3(IMPC)Wtsi
(C57BL/6N-Prss53em3(IMPC)Wtsi/Wtsi)
decreased leukocyte cell number J:211773
\Prss54em1(IMPC)Ccpcz/\Prss54em1(IMPC)Ccpcz
(C57BL/6N-Prss54em1(IMPC)Ccpcz/Ccpcz)
abnormal thymus morphology J:211773
decreased CD4-positive NK T cell number J:211773
decreased memory-marker CD4-positive NK T cell number J:211773
decreased NK T cell number J:211773
enlarged thymus J:211773
\Prss55em1(IMPC)Ccpcz/\Prss55em1(IMPC)Ccpcz
(C57BL/6NCrl-Prss55em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged spleen J:211773
enlarged thymus J:211773
\Prss56em1(IMPC)J/\Prss56em1(IMPC)J
(C57BL/6NJ-Prss56em1(IMPC)J/J)
decreased leukocyte cell number J:211773
\Prss57em1(IMPC)Ccpcz/\Prss57em1(IMPC)Ccpcz
(C57BL/6N-Prss57em1(IMPC)Ccpcz/Ccpcz)
abnormal thymus morphology J:211773
decreased NK T cell number J:211773
enlarged thymus J:211773
\Prss57tm1.1Gne/\Prss57tm1.1Gne
(C57BL/6N-Prss57tm1.1Gne)
abnormal mast cell morphology J:301479
abnormal mast cell physiology J:301479
decreased mast cell histamine storage J:301479
\Prss57tm1Lex/\Prss57tm1Lex
(involves: 129S5/SvEvBrd)
abnormal mast cell physiology J:301479
\Prtn3tm1.1Hrlu/\Prtn3tm1.1Hrlu
(involves: C57BL/6)
abnormal neutrophil physiology J:217636
increased neutrophil cell number J:217636
\Prxl2atm1(KOMP)Vlcg/\Prxl2atm1(KOMP)Vlcg
(C57BL/6N-Prxl2atm1(KOMP)Vlcg)
white adipose tissue inflammation J:234040
\Psaptm1Ggb/\Psaptm1Ggb
(involves: 129S/SvEv * C57BL/6J)
abnormal microglial cell physiology J:121761
dark spleen J:121761
\Psaptm1Juma/\Psaptm1Juma
(FVB.129S-Psaptm1Juma)
abnormal microglial cell physiology J:121761
\Psaptm1Suz/\Psaptm1Suz
(involves: 129P2/OlaHsd)
abnormal macrophage morphology J:113052
decreased spleen weight J:106511
\Psaptm2Ggb/\Psaptm2Ggb
(involves: 129S/SvEv * C57BL/6J)
CNS inflammation J:137650
kidney inflammation J:137650
microgliosis J:198242
\Psaptm2Suz/\Psaptm2Suz
(involves: 129S/SvEv * C57BL/6J)
abnormal macrophage morphology J:78223
CNS inflammation J:78223
microgliosis J:198242
\Psaptm4.1Ggb/\Psaptm4.1Ggb
(involves: 129S/SvEv * C57BL/6J)
microgliosis J:198242
\Pscatm1b(EUCOMM)Hmgu/\Pscatm1b(EUCOMM)Hmgu
(C57BL/6N-Pscatm1b(EUCOMM)Hmgu/Bay)
abnormal spleen morphology J:211773
\Pscr1DBA/2/\Pscr1DBA/2
(involves: BALB/c * DBA/2)
decreased susceptibility to bacterial infection J:8914
\Pscr1DBA/2/\Pscr1DBA/2
\Pscr2DBA/2/\Pscr2DBA/2
\Pscr3DBA/2/\Pscr3DBA/2

(involves: C57BL/6 * DBA/2)
decreased susceptibility to bacterial infection J:8914
\Pscr2DBA/2/\Pscr2DBA/2
(involves: BALB/c * DBA/2)
decreased susceptibility to bacterial infection J:8914
\Pscr3DBA/2/\Pscr3DBA/2
(involves: BALB/c * DBA/2)
decreased susceptibility to bacterial infection J:8914
\Psdem1(IMPC)Mbp/\Psdem1(IMPC)Mbp
(C57BL/6NCrl-Psdem1(IMPC)Mbp/Mmucd)
abnormal spleen morphology J:211773
small spleen J:211773
\Psen1tm1.1Ruvi/\Psen1tm1.1Ruvi
\Tg(APP)8.9Btla/0

(involves: 129S2/SvPas * C57BL/6J)
microgliosis J:187475
\Psen1tm1Bdes/\Psen1+
\Psen2tm1Bdes/\Psen2tm1Bdes

(involves: 129P2/OlaHsd)
abnormal T cell subpopulation ratio J:91235
arteritis J:91235
autoimmune response J:91235
chronic inflammation J:91235
dermatitis J:91235
enlarged lymph nodes J:91235
enlarged spleen J:91235
glomerulonephritis J:91235
increased anti-single stranded DNA antibody level J:91235
increased immunoglobulin level J:91235
increased incidence of corneal inflammation J:91235
increased inflammatory response J:91235
increased leukocyte cell number J:91235
increased susceptibility to autoimmune disorder J:91235
kidney inflammation J:91235
skin inflammation J:91235
\Psen1tm2Shn/\Psen1tm4.1Shn
\Psen2tm1Haa/\Psen2tm1Haa
\Tg(Camk2a-cre)1Shn/0

(involves: 129 * 129S4/SvJae * C57BL/6 * C57BL/6J * CBA)
microgliosis J:219929
\Psen2em1(IMPC)Ccpcz/\Psen2em1(IMPC)Ccpcz
(C57BL/6NCrl-Psen2em1(IMPC)Ccpcz/Ccpcz)
abnormal thymus morphology J:211773
enlarged thymus J:211773
\Psip1Gt(betageo)1Hgs/\Psip1Gt(betageo)1Hgs
(B6.129P2-Psip1Gt(betageo)1Hgs)
blepharitis J:112975
spleen atrophy J:112975
\Psip1Gt(betageo)1Hgs/\Psip1Gt(betageo)1Hgs
(either: (involves: 129P2/OlaHsd * C57BL/6) or (involves: 129P2/OlaHsd * MF1))
blepharitis J:112975
spleen atrophy J:112975
\Psma8em1(IMPC)Tcp/\Psma8em1(IMPC)Tcp
(C57BL/6N-Psma8em1(IMPC)Tcp/Tcp)
increased monocyte cell number J:211773
small thymus J:211773
\Psmb8tm1Hjf/\Psmb8tm1Hjf
(either: 129P2/OlaHsd or (involves: 129P2/OlaHsd * C57BL/6))
decreased level of surface class I molecules J:20012
defective intracellular transport of class I molecules J:20012
\Psmb8tm1Hjf/\Psmb8tm1Hjf
(involves: 129P2/OlaHsd)
abnormal dendritic cell antigen presentation J:180765
decreased level of surface class I molecules J:180765
\Psmb8tm1Hjf/\Psmb8tm1Hjf
\Tg(TcraTcrb)1100Mjb/?

(involves: 129P2/OlaHsd * C57BL/6)
decreased CD8-positive, alpha-beta T cell number J:107657
\Psmb9tm1Stl/\Psmb9tm1Stl
(involves: 129P2/OlaHsd * C57BL/6)
abnormal CD8-positive, alpha-beta cytotoxic T cell morphology J:21549
abnormal immune system physiology J:21549
decreased CD8-positive, alpha-beta T cell number J:21549
increased susceptibility to Orthomyxoviridae infection J:21549
\Psmb10tm1Mgro/\Psmb10tm1Mgro
(involves: 129S2/SvPas * C57BL/6)
abnormal CD8-positive, alpha-beta cytotoxic T cell morphology J:125058
abnormal cytotoxic T cell physiology J:125058
decreased CD8-positive, alpha-beta T cell number J:125058
decreased T cell proliferation J:125058
\Psmb10tm1Mgro/\Psmb10tm1Mgro
\Psmb9/Psmb8tm1Klr/\Psmb9/Psmb8tm1Klr

(B6.129-Psmb10tm1Mgro Psmb9/Psmb8tm1Klr)
abnormal antigen presentation via MHC class I J:180765
abnormal B lymphocyte antigen presentation J:180765
abnormal dendritic cell antigen presentation J:180765
decreased CD8-positive, alpha-beta T cell number J:180765
decreased level of surface class I molecules J:180765
\Psmb10tm1Mgro/\Psmb10tm1Mgro
\Psmb9/Psmb8tm1Klr/\Psmb9/Psmb8tm1Klr

(B6.129-Psmb10tm1Mgro Psmb9/Psmb8tm1Klr)
abnormal antigen presentation via MHC class I J:180765
abnormal B lymphocyte antigen presentation J:180765
abnormal dendritic cell antigen presentation J:180765
decreased CD8-positive, alpha-beta T cell number J:180765
decreased level of surface class I molecules J:180765
\Psmb10tm1Mgro/\Psmb10Tub6
(involves: 129S2/SvPas * C3HeB/FeJ)
decreased NK cell number J:261081
decreased T cell number J:261081
increased granulocyte number J:261081
\Psmb10Tub6/\Psmb10+
(C3HeB/FeJ-Psmb10Tub6)
abnormal T cell activation J:261081
decreased CD4-positive, alpha-beta T cell number J:261081
decreased CD8-positive, alpha-beta T cell number J:261081
decreased interferon-gamma secretion J:261081
decreased T cell number J:261081
increased susceptibility to bacterial infection induced morbidity/mortality J:261081
\Psmb10Tub6/\Psmb10Tub6
(C3HeB/FeJ-Psmb10Tub6)
absent lymph nodes J:261081
absent spleen white pulp J:261081
athymia J:261081
decreased B cell number J:261081
decreased immunoglobulin level J:261081
decreased leukocyte cell number J:261081
decreased NK cell number J:261081
decreased spleen red pulp amount J:261081
decreased T cell number J:261081
increased circulating interleukin-1 level J:261081
increased circulating interleukin-6 level J:261081
increased circulating tumor necrosis factor level J:261081
increased granulocyte number J:261081
increased inflammatory response J:261081
skin inflammation J:261081
\Psmb10Tub6/\Psmb10Tub6
(B6.C3Fe-Psmb10Tub6)
increased granulocyte number J:261081
\Psmb10Tub6/\Psmb10Tub6
(C.C3Fe-Psmb10Tub6)
increased granulocyte number J:261081
\Psmb11em1(IMPC)Ccpcz/\Psmb11em1(IMPC)Ccpcz
(C57BL/6NCrl-Psmb11em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
decreased CD8-positive, alpha-beta T cell number J:211773
decreased effector memory T-helper cell number J:211773
enlarged spleen J:211773
enlarged thymus J:211773
increased CD4-positive NK T cell number J:211773
increased CD4-positive, alpha-beta T cell number J:211773
increased effector memory CD8-positive, alpha-beta T cell number J:211773
increased effector memory T-helper cell number J:211773
increased memory-marker CD4-positive NK T cell number J:211773
increased NK T cell number J:211773
increased T-helper cell number J:211773
\Psmb11tm1(Psmb8)Khog/\Psmb11+
(involves: C57BL/6)
decreased CD8-positive, alpha-beta T cell number J:196156
\Psmb11tm1(Psmb8)Khog/\Psmb11tm1(Psmb8)Khog
(involves: C57BL/6)
abnormal CD8-positive, alpha beta T cell morphology J:196156
abnormal self tolerance J:196156
abnormal T cell differentiation J:196156
abnormal T cell receptor V(D)J recombination J:196156
decreased CD8-positive, alpha-beta T cell number J:196156
decreased memory T cell number J:196156
increased T cell proliferation J:196156
\Psmb11tm1(Psmb8)Khog/\Psmb11tm1(Psmb8)Khog
\Psmb8tm1Hjf/\Psmb8tm1Hjf

(involves: 129P2/OlaHsd * C57BL/6)
decreased CD8-positive, alpha-beta T cell number J:196156
\Psmb11tm1.1(Psmb8)Khog/\Psmb11tm1.1(Psmb8)Khog
\Psmb8tm1Hjf/\Psmb8tm1Hjf

(involves: 129P2/OlaHsd * C57BL/6 * C57BL/6NTac)
abnormal T cell receptor V(D)J recombination J:196156
decreased CD8-positive, alpha-beta T cell number J:196156
\Psmb11tm1Smta/\Psmb11tm1Smta
(involves: C57BL/6 * CBA)
decreased CD8-positive, alpha-beta T cell number J:121869
\Psmc4tm1.1Ryot/\Psmc4tm1.2Ryot
\Tg(SLC18A3-cre)KMisa/0

(involves: C57BL/6 * C57BL/6N)
microgliosis J:193770
\Psme2tm1Yya/\Psme2tm1Yya
(involves: 129P2/OlaHsd)
abnormal CD8-positive, alpha-beta T cell physiology J:58875
decreased cytotoxic T cell cytolysis J:58875
defective assembly of class I molecules J:58875
\Psme3tm1Jjm/\Psme3tm1Jjm
(B6.129X1-Psme3tm1Jjm)
decreased double-positive T cell number J:88626
increased susceptibility to fungal infection J:88626
\Psme4b2b1508Clo/\Psme4b2b1508Clo
(C57BL/6J-Psme4b2b1508Clo)
thymus hypoplasia J:175213
\Psmf1tm1c(EUCOMM)Hmgu/\Psmf1tm1c(EUCOMM)Hmgu
\Tg(Pcp2-cre)GN135Gsat/0

(involves: C57BL/6J * C57BL/6N * FVB/N)
microgliosis J:282431
\Pspc1em1(IMPC)Mbp/\Pspc1em1(IMPC)Mbp
(C57BL/6N-Pspc1em1(IMPC)Mbp/MbpMmucd)
abnormal spleen morphology J:211773
enlarged spleen J:211773
small spleen J:211773
\Psphtm1a(EUCOMM)Hmgu/\Psphtm1a(EUCOMM)Hmgu
(C57BL/6N-Psphtm1a(EUCOMM)Hmgu/Wtsi)
abnormal thymus morphology J:239583
abnormal thymus topology J:239583
absent connection between subcutaneous lymph vessels and lymph sac J:239583
athymia J:239583
blood in lymph vessels J:239583
spleen hypoplasia J:239583
\Pstpip1em1(IMPC)Ccpcz/\Pstpip1em1(IMPC)Ccpcz
(C57BL/6N-Pstpip1em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged spleen J:211773
enlarged thymus J:211773
increased CD4-positive, alpha-beta T cell number J:211773
increased spleen weight J:211773
increased T-helper cell number J:211773
\Pstpip1tm1.1Dtg/\Pstpip1tm1.1Dtg
(involves: BALB/cJ * C57BL/6)
immune system phenotype J:196002
\Pstpip1tm1Spg/\Pstpip1tm1Spg
(involves: 129S/SvEv * C57BL/6)
abnormal immune system cell morphology J:101977
abnormal T cell physiology J:101977
\Pstpip2cmo/\Pstpip2cmo
(C.D2-Qa2)
chronic inflammation J:1534
\Pstpip2cmo/\Pstpip2cmo
(C.Cg-Pstpip2cmo/J)
abnormal lymph node morphology J:104476
ear inflammation J:104476
enlarged spleen J:104476
osteomyelitis J:104476, J:105410
\Pstpip2em1(IMPC)Tcp/\Pstpip2em1(IMPC)Tcp
(C57BL/6NCrl-Pstpip2em1(IMPC)Tcp/Tcp)
enlarged lymph nodes J:211773
\Pstpip2Lupo/\Pstpip2Lupo
(either: (involves: C3HeB/FeJ) or (involves: C3HeB/FeJ * C57BL/6J))
abnormal cytokine secretion J:125785
increased autoantibody level J:125785
increased IgE level J:125785
increased IgG1 level J:125785
increased IgG2a level J:125785
increased IgG level J:125785
skin inflammation J:125785
\Pstpip2Lupo/\Pstpip2Lupo
\Rag1tm1Mom/\Rag1tm1Mom

(involves: 129S7/SvEvBrd * C3HeB/FeJ * C57BL/6J)
skin inflammation J:125785
\Pstpip2m1Bcs/\Pstpip2m1Bcs
(involves: C57BL/6)
abnormal inflammatory response J:196534
abnormal microglial cell morphology J:196534
autoimmune response J:196534
ear inflammation J:196534
skin inflammation J:196534
\pta/\pta
(C57BL/6J-pta)
thymus hypoplasia J:94456
\Ptafrtm1Tksh/\Ptafrtm1Tksh
(involves: 129P2/OlaHsd * C57BL/6)
decreased inflammatory response J:87866
increased susceptibility to parasitic infection J:87866
increased susceptibility to type I hypersensitivity reaction J:88505
\Ptafrtm1Tksh/\Ptafrtm1Tksh
(C57BL/6-Ptafrtm1Tksh)
decreased susceptibility to bacterial infection J:88589
\Ptch1tm1Bjw/\Ptch1tm1Bjw
\Tg(KRT14-cre)8Brn/0

(involves: 129T2/SvEms * FVB/N)
thymus hypoplasia J:231264
\Ptch1tm1Hahn/\Ptch1tm1Hahn
\Gt(ROSA)26Sortm2(cre/ERT2)Brn/\Gt(ROSA)26Sor+

(involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6)
abnormal double-negative T cell morphology J:127207
abnormal thymus lobule morphology J:127207
decreased B cell number J:127207
decreased double-positive T cell number J:127207
decreased immature B cell number J:127207
decreased lymphocyte cell number J:127207
decreased pre-B cell number J:127207
decreased transitional stage B cell number J:127207
increased B cell number J:127207
increased double-negative T cell number J:127207
increased mature B cell number J:127207
increased neutrophil cell number J:127207
increased single-positive T cell number J:127207
thymus hypoplasia J:127207
\Ptch2tm1Dgen/\Ptch2tm1Dgen
(involves: 129P2/OlaHsd * C57BL/6)
enlarged spleen J:101679
increased neutrophil cell number J:101679
\Ptch2tm3b(EUCOMM)Hmgu/\Ptch2tm3b(EUCOMM)Hmgu
(C57BL/6N-Ptch2tm3b(EUCOMM)Hmgu/Bay)
decreased lymphocyte cell number J:211773
increased neutrophil cell number J:211773
\Ptchd1tm1b(KOMP)IcsOrl/Y
(C57BL/6N-Ptchd1tm1b(KOMP)IcsOrl/Ics)
abnormal spleen morphology J:211773
\Ptcratm1(icre)Hjf/\Ptcratm1(icre)Hjf
(B6.129P2-Ptcratm1(icre)Hjf)
decreased DN4 thymocyte number J:197923
decreased double-positive T cell number J:197923
decreased thymocyte number J:197923
\Ptcratm1.1Shoy/\Ptcratm1.1Shoy
(involves: C57BL/6)
decreased double-positive T cell number J:166147
decreased T cell number J:166147
decreased thymocyte number J:166147
increased DN3 thymocyte number J:166147
increased gamma-delta T cell number J:166147
increased T cell number J:166147
\Ptcratm1Bjf/\Ptcra+
(involves: 129X1/SvJ)
abnormal T cell differentiation J:94338
decreased double-negative T cell number J:94338
decreased single-positive T cell number J:94338
\Ptcratm1Vbo/\Ptcratm1Vbo
(involves: 129P2/OlaHsd * C57BL/6)
arrested T cell differentiation J:91542
increased double-negative T cell number J:91542
\Ptcratm1Vbo/\Ptcratm1Vbo
(involves: 129P2/OlaHsd)
abnormal double-positive T cell morphology J:123569
decreased DN4 thymocyte number J:123569
increased DN3 thymocyte number J:123569
thymus hypoplasia J:123569
\Ptdss1tm1b(EUCOMM)Hmgu/\Ptdss1tm1b(EUCOMM)Hmgu
(C57BL/6N-Ptdss1tm1b(EUCOMM)Hmgu/Ics)
decreased large unstained cell number J:211773
\Ptentm1.1Gle/\Pten+
(involves: 129S6/SvEvTac * Black Swiss * FVB/N)
increased T cell derived lymphoma incidence J:158751
\Ptentm1.1Hwu/\Pten+
(involves: 129S4/SvJae * BALB/c)
lymphoid hyperplasia J:110567
\Ptentm1.2Mwst/\Pten+
(involves: 129S6/SvEvTac * Black Swiss * FVB/N)
increased T cell derived lymphoma incidence J:158751
\Ptentm1Engc/\Ptentm1Engc
(involves: CD-1)
abnormal microglial cell physiology J:210487
\Ptentm1Hwu/\Ptentm1Hwu
\Lyz2tm1(cre)Ifo/\Lyz2+

(involves: 129P2/OlaHsd * 129S4/SvJae)
abnormal alveolar macrophage morphology J:148947
abnormal cytokine level J:148947
abnormal macrophage chemotaxis J:148947
abnormal neutrophil physiology J:148947, J:114699, J:145331
decreased susceptibility to bacterial infection J:148947
decreased susceptibility to bacterial infection induced morbidity/mortality J:148947
impaired neutrophil recruitment J:148947
increased susceptibility to bacterial infection J:148947
increased susceptibility to bacterial infection induced morbidity/mortality J:148947
lung inflammation J:148947
\Ptentm1Hwu/\Ptentm1Hwu
\Rps6kb1tm1Gtho/\Rps6kb1tm1Gtho
\Tg(Mx1-cre)1Cgn/0

(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * CBA)
enlarged spleen J:169097
enlarged thymus J:169097
\Ptentm1Hwu/\Ptentm1Hwu
\Tg(CAG-EGFP,-PAX8/PPARG)1Rkoe/0
\Tg(TPO-cre)1Shk/0

(involves: 129S4/SvJae * FVB/NCr * FVB/NJ)
abnormal thymus physiology J:177181
\Ptentm1Hwu/\Ptentm1Hwu
\Tg(CD2-icre)4Kio/0

(involves: 129S4/SvJae * C57BL/6 * C57BL/10 * CBA/Ca)
enlarged thymus J:216983
\Ptentm1Hwu/\Ptentm1Hwu
\Tg(Cdh5-cre)7Mlia/0

(involves: 129S4/SvJae * BALB/c * C57BL/6 * FVB/N)
enlarged lymph nodes J:135172
enlarged spleen J:135172
enlarged thymus J:135172
increased leukocyte cell number J:135172
increased neutrophil cell number J:135172
\Ptentm1Hwu/\Ptentm1Hwu
\Tg(GZMB-cre)1Jcb/0

(involves: 129S4/SvJae * FVB/N)
abnormal CD8-positive, alpha-beta T cell physiology J:164425
decreased interleukin-2 secretion J:164425
\Ptentm1Hwu/\Ptentm1Hwu
\Tg(Mx1-cre)1Cgn/0

(involves: 129S4/SvJae * C57BL/6 * CBA)
enlarged spleen J:169097
enlarged thymus J:169097
\Ptentm1Hwu/\Ptentm1Hwu
\Tg(Mx1-cre)1Cgn/0

(BKS.Cg-Ptprcb Thy1a Tg(Mx1-cre)1Cgn Ptentm1Hwu)
enlarged thymus J:109085
spleen hyperplasia J:109085
\Ptentm1Hwu/\Ptentm1Hwu
\Tg(Mx1-cre)1Cgn/0

(B6.Cg-Tg(Mx1-cre)1Cgn Ptentm1Hwu)
decreased B cell number J:232645
decreased lymphocyte cell number J:232645
decreased T cell number J:232645
enlarged spleen J:232645
increased granulocyte number J:232645
increased macrophage cell number J:232645
increased monocyte cell number J:232645
increased spleen weight J:232645
\Ptentm1Hwu/\Ptentm1Hwu
\Tg(Pbsn-cre)4Prb/0

(involves: 129S4/SvJae * BALB/c * C57BL/6 * DBA/2)
prostate gland inflammation J:93902
pyelonephritis J:124208
\Ptentm1Mak/\Pten+
(involves: 129P2/OlaHsd * C57BL/6J)
enlarged Peyer's patches J:63478
increased T cell derived lymphoma incidence J:50437
\Ptentm1Rps/\Pten+
(involves: 129S1/Sv * C57BL/6J)
abnormal lymph node B cell domain morphology J:53065
enlarged spleen J:53065
enlarged thymus J:53065
lymph node hyperplasia J:53065
\Ptentm2.1Gle/\Pten+
(involves: 129S6/SvEvTac * Black Swiss * FVB/N)
increased T cell derived lymphoma incidence J:158751
\Ptentm2.1Ppp/\Ptentm2.1Ppp
\Tnfrsf4tm2(cre)Nik/\Tnfrsf4+

(involves: 129S1/Sv * 129X1/SvJ)
increased germinal center B cell number J:164283
increased IgG1 level J:164283
increased T follicular helper cell number J:164283
\Ptentm2Mak/\Ptentm2Mak
\Speer6-ps1Tg(Alb-cre)21Mgn/\Speer6-ps1+

(involves: 129P2/OlaHsd * C57BL/6 * DBA)
liver inflammation J:138099
\Ptf1atm1Pkwe/\Ptf1atm1Pkwe
(involves: 129P2/OlaHsd * C57BL/6)
abnormal spleen morphology J:51571
\Ptgdr2tm1Byl/\Ptgdr2tm1Byl
(involves: C57BL/6J)
abnormal cytokine secretion J:107519
increased eosinophil cell number J:107519
\Ptgdr2tm1Tasa/\Ptgdr2tm1Tasa
(involves: 129/Sv * BALB/c)
impaired eosinophil recruitment J:130892
\Ptgdr2tm1Tasa/\Ptgdr2tm1Tasa
(C.129-Ptgdr2tm1Tasa)
abnormal chemokine level J:131146
abnormal inflammatory response J:131146
decreased IgE level J:131146
decreased inflammatory response J:131146
decreased susceptibility to type IV hypersensitivity reaction J:131146
\Ptgdr2tm1Tasa/\Ptgdr2tm1Tasa
(B6.129-Ptgdr2tm1Tasa)
increased susceptibility to type I hypersensitivity reaction J:197334
\Ptgdrtm1Sna/\Ptgdrtm1Sna
(involves: 129P2/OlaHsd * C57BL/6)
abnormal macrophage activation involved in immune response J:243958
brain inflammation J:243958
decreased microglial cell activation J:243958
increased CD4-positive, alpha-beta T cell number J:243958
increased interleukin-1 beta secretion J:243958
increased regulatory T cell number J:243958
increased susceptibility to Coronaviridae infection J:243958
increased susceptibility to Coronaviridae infection induced morbidity/mortality J:243958
respiratory system inflammation J:61023
\Ptgdrtm1Sna/\Ptgdrtm1Sna
(B6.129P2-Ptgdrtm1Sna/Sna)
abnormal dermal mast cell morphology J:197334
abnormal mast cell physiology J:197334
decreased mast cell degranulation J:197334
decreased mast cell histamine storage J:197334
decreased susceptibility to type I hypersensitivity reaction J:197334
\Ptgdstm1Mfg/\Ptgdstm1Mfg
(involves: C57BL/6)
immune system phenotype J:98963
\Ptgdstm1Ohy/\Ptgdstm1Ohy
(B6.129P2-Ptgdstm1Ohy)
abnormal dermal mast cell morphology J:197334
decreased mast cell degranulation J:197334
decreased mast cell histamine storage J:197334
decreased susceptibility to type I hypersensitivity reaction J:197334
immune system phenotype J:197334
\Ptger1tm1Jdm/\Ptger1tm1Jdm
(DBA/1LacJ-Ptger1tm1Jdm)
immune system phenotype J:72198, J:78964
\Ptger1tm1Sna/\Ptger1tm1Sna
(B6CrSlc.129P2-Ptger1tm1Sna/Sna)
abnormal CD8-positive, alpha-beta T cell differentiation J:128435
abnormal cervical lymph node morphology J:128435
abnormal interferon-gamma secretion J:128435
abnormal lymph node morphology J:128435
abnormal response to infection J:82750
abnormal T-helper 1 cell differentiation J:128435
decreased susceptibility to type IV hypersensitivity reaction J:128435
immune system phenotype J:128435, J:197334
\Ptger2tm1.1Kand/\Ptger2tm1.1Kand
\Tg(ITGAM-cre)2781Gkl/0

(involves: C57BL/6 * CBA)
abnormal microglial cell physiology J:202677
decreased susceptibility to endotoxin shock J:202677
\Ptger2tm1Brey/\Ptger2tm1Brey
(involves: 129S6/SvEvTac * C57BL/6)
abnormal response to infection J:120725
\Ptger2tm1Brey/\Ptger2tm1Brey
(C.129S6-Ptger2tm1Brey)
abnormal microglial cell physiology J:97062
\Ptger2tm1Brey/\Ptger2tm1Brey
(involves: 129S6/SvEvTac * BALB/c)
abnormal response to infection J:164638
\Ptger2tm1Rsz/\Ptger2tm1Rsz
(involves: 129S6/SvEvTac * C57BL/6)
abnormal osteoclast differentiation J:77408
\Ptger2tm1Sna/\Ptger2tm1Sna
(B6.129P2-Ptger2tm1Sna/Sna)
immune system phenotype J:197334
\Ptger2tm2Bhk/\Ptger2tm2Bhk
(involves: 129P2/OlaHsd * 129S/SvEv)
immune system phenotype J:78964
\Ptger3tm1Cof/\Ptger3tm1Cof
(involves: 129P2/OlaHsd * 129S/SvEv)
immune system phenotype J:78964
\Ptger3tm1Sna/\Ptger3tm1Sna
(B6.129P2-Ptger3tm1Sna/Sna)
abnormal response to infection J:82750
increased susceptibility to type I hypersensitivity reaction J:197334
\Ptger4tm1.1Matb/\Ptger4tm1.1Matb
\Tg(Myh6-cre)2182Mds/0

(involves: 129S6/SvEvTac * FVB/N)
heart inflammation J:158439
\Ptger4tm1Bhk/\Ptger4tm1Bhk
(involves: 129P2/OlaHsd * 129S/SvEv)
lymphangiectasis J:44108
\Ptger4tm1Bhk/\Ptger4tm1Bhk
(involves: 129P2/OlaHsd * C57BL/6 * DBA/2)
abnormal circulating interleukin-6 level J:78964
abnormal circulating serum amyloid protein level J:78964
abnormal cytokine level J:78964
abnormal macrophage physiology J:78964
decreased susceptibility to induced arthritis J:78964
immune system phenotype J:78964
rheumatoid arthritis J:78964
\Ptger4tm1Sna/\Ptger4tm1Sna
(involves: 129P2/OlaHsd * C57BL/6)
abnormal Langerhans cell physiology J:83725
abnormal osteoclast differentiation J:63070
abnormal osteoclast physiology J:63070
abnormal T cell activation J:83725
decreased interferon-gamma secretion J:83725
decreased susceptibility to type IV hypersensitivity reaction J:83725
decreased T cell proliferation J:83725
immune system phenotype J:83725, J:197334
\Ptges2tm1Kymm/\Ptges2tm1Kymm
(B6.Cg-Ptges2tm1Kymm)
increased susceptibility to type I hypersensitivity reaction J:197334
\Ptgestm1.1Gaf/\Ptgestm1.1Gaf
\Lyz2tm1(cre)Ifo/\Lyz2+

(involves: 129 * C57BL/6)
abnormal leukocyte physiology J:210141
increased leukocyte cell number J:210141
\Ptgestm1Aki/\Ptgestm1Aki
(involves: 129X1/SvJ * C57BL/6)
abnormal inflammatory response J:91821
chronic inflammation J:91821
impaired macrophage chemotaxis J:91821
\Ptgestm1Aki/\Ptgestm1Aki
(B6.129P2-Ptgestm1Aki)
increased susceptibility to type I hypersensitivity reaction J:197334
\Ptgestm1Lpa/\Ptgestm1Lpa
(DBA/1LacJ-Ptgestm1Lpa)
decreased inflammatory response J:89960, J:90980
\Ptgfrtm1Sna/\Ptgfrtm1Sna
(B6.129P2-Ptgfrtm1Sna)
immune system phenotype J:197334
\Ptgfrnem1(IMPC)Hmgu/\Ptgfrnem1(IMPC)Hmgu
(C57BL/6NCrl-Ptgfrnem1(IMPC)Hmgu/Ieg)
increased neutrophil cell number J:211773
\Ptgirtm1Sna/\Ptgirtm1Sna
(involves: 129P2/OlaHsd * C57BL/6)
decreased acute inflammation J:42275
\Ptgirtm1Sna/\Ptgirtm1Sna
(B6.129P2-Ptgirtm1Sna/Sna)
immune system phenotype J:197334
\Ptgisem1(IMPC)Mbp/\Ptgisem1(IMPC)Mbp
(C57BL/6N-Ptgisem1(IMPC)Mbp/MbpMmucd)
abnormal lymph node morphology J:211773
abnormal thymus morphology J:211773
enlarged lymph nodes J:211773
enlarged thymus J:211773
\Ptgs1tm1Fun/\Ptgs1tm1Fun
(involves: 129S6/SvEvTac * C57BL/6)
decreased inflammatory response J:97351
\Ptgs1tm1Unc/\Ptgs1tm1Unc
(involves: 129P2/OlaHsd * C57BL/6)
decreased inflammatory response J:29511
enlarged spleen J:60668
increased susceptibility to endotoxin shock J:75611
increased susceptibility to induced colitis J:158426, J:60668
\Ptgs1tm1Unc/\Ptgs1tm1Unc
(B6.129P2-Ptgs1tm1Unc)
decreased susceptibility to induced arthritis J:110716
\Ptgs2tm1.1Fun/\Ptgs2tm1.1Fun
(involves: 129S6/SvEvTac)
kidney inflammation J:148699
\Ptgs2tm1.1Wls/\Ptgs2tm1.1Wls
(B6.129-Ptgs2tm1.1Wls)
increased susceptibility to endotoxin shock J:156331
\Ptgs2tm1Jed/\Ptgs2tm1Jed
(involves: 129S7/SvEvBrd)
immune system phenotype J:29974
pyelonephritis J:29974
\Ptgs2tm1Jed/\Ptgs2tm1Jed
(involves: 129S7/SvEvBrd * C57BL/6)
peritoneal inflammation J:118171
\Ptgs2tm1Jed/\Ptgs2tm1Jed
(involves: 129S7/SvEvBrd * CD-1)
abnormal response to infection J:120725
\Ptgs2tm1Unc/\Ptgs2+
(involves: 129/Sv * 129P2/OlaHsd * C57BL/6)
abnormal osteoclast differentiation J:124756
\Ptgs2tm1Unc/\Ptgs2tm1Unc
(involves: 129P2/OlaHsd * C57BL/6J)
abnormal macrophage physiology J:29510
abnormal mesenteric lymph node morphology J:29510
immune system phenotype J:29510
peritoneal inflammation J:29510
spleen hyperplasia J:29510
tubulointerstitial nephritis J:29510
\Ptgs2tm1Unc/\Ptgs2tm1Unc
(involves: 129/Sv * 129P2/OlaHsd * C57BL/6)
abnormal osteoclast differentiation J:124756
\Ptgs2tm1Unc/\Ptgs2tm1Unc
(involves: 129P2/OlaHsd * C57BL/6)
decreased susceptibility to endotoxin shock J:75611
enlarged spleen J:60668
increased leukocyte cell number J:60668
increased susceptibility to induced colitis J:158426, J:60668
increased tumor necrosis factor secretion J:108054
peritoneal inflammation J:60668
\Ptgs2tm1Unc/\Ptgs2tm1Unc
(B6.129P2-Ptgs2tm1Unc)
abnormal class switch recombination J:140698
abnormal memory B cell differentiation J:140698
abnormal response to infection J:140698
decreased IgG1 level J:140698
decreased IgG2a level J:140698
decreased IgG3 level J:140698
decreased susceptibility to induced arthritis J:110716
increased IgM level J:140698
\Ptgs2tm1Unc/\Ptgs2tm2.1Hahe
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)
increased susceptibility to induced colitis J:158426
\Ptgs2tm2(Ptgs1)Fun/\Ptgs2tm2(Ptgs1)Fun
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
abnormal macrophage physiology J:118171
\Ptgs2tm2.1(Ptgs1)Fun/\Ptgs2tm2.1(Ptgs1)Fun
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * FVB)
abnormal macrophage physiology J:118171
kidney inflammation J:118171
peritoneal inflammation J:118171
\Ptgs2ostm1Scrp/\Ptgs2ostm1Scrp
(Not Specified)
abnormal chemokine level J:325487
decreased CCL3 level J:325487
decreased circulating CCL3 level J:325487
decreased circulating interleukin-6 level J:325487
decreased neutrophil cell number J:325487
increased interferon-beta secretion J:325487
\Pth1rtm1a(EUCOMM)Hmgu/\Pth1rtm1a(EUCOMM)Hmgu
(C57BL/6N-Pth1rtm1a(EUCOMM)Hmgu/Wtsi)
abnormal thymus morphology J:239583
blood in lymph vessels J:239583
enlarged lymphatic vessel J:239583
\Pthtm1Dgo/\Pthtm1Dgo
(involves: 129S2/SvPas * C57BL/6J)
abnormal osteoclast morphology J:76407
decreased osteoclast cell number J:76407
\Pthtm1Dgo/\Pthtm1Dgo
\Pthlhtm1Hmk/\Pthlhtm1Hmk

(involves: 129S2/SvPas * C57BL/6J)
abnormal osteoclast morphology J:76407
decreased osteoclast cell number J:76407
\Pthlhtm1Ack/\Pthlhtm1Ack
\Tg(Col1a1-cre)1Ack/0

(involves: 129S1/Sv * 129X1/SvJ * FVB/N)
abnormal osteoclast morphology J:100918
decreased osteoclast cell number J:100918
\Pthlhtm1Ack/\Pthlhtm1Hmk
\Tg(LGB-cre)74Acl/0

(involves: 129 * C57BL/6 * CBA)
abnormal osteoclast morphology J:86536
\Pthlhtm1Hmk/\Pthlh+
(involves: 129S2/SvPas)
abnormal osteoclast morphology J:100918
\Pthlhtm1Hmk/\Pthlhtm1Hmk
(involves: 129S2/SvPas * C57BL/6J)
abnormal osteoclast morphology J:76407
decreased osteoclast cell number J:76407
\Pthlhtm1Hmk/\Pthlhtm1Hmk
\Pth1rtm1Hmk/\Pth1rtm2Hmk
\Tg(Col2a1-PTHLH)1Ecw/0

(involves: 129S2/SvPas * 129S4/SvJae * C57BL/6 * SJL)
abnormal bone marrow development J:99641
\Pthlhtm2Ack/\Pthlhtm2Ack
(involves: 129S2/SvPas * C57BL/6)
decreased osteoclast cell number J:142669
\Ptk2btm1Schl/\Ptk2btm1Schl
(involves: 129S1/Sv * 129X1/SvJ)
abnormal macrophage physiology J:99741
decreased acute inflammation J:99741
impaired macrophage chemotaxis J:99741
\Ptntm1Tmu/\Ptntm1Tmu
(B6.Cg-Ptntm1Tmu)
decreased macrophage cell number J:102069
impaired macrophage chemotaxis J:102069
impaired neutrophil recruitment J:102069
\Ptp4a1em2(IMPC)Tcp/\Ptp4a1em2(IMPC)Tcp
(C57BL/6NCrl-Ptp4a1em2(IMPC)Tcp/Tcp)
small spleen J:211773
\Ptp4a2em1(IMPC)Tcp/\Ptp4a2em1(IMPC)Tcp
(C57BL/6N-Ptp4a2em1(IMPC)Tcp/Tcp)
enlarged lymph nodes J:211773
\Ptp4a2Gt(AQ0673)Wtsi/\Ptp4a2Gt(AQ0673)Wtsi
(involves: 129P2/OlaHsd * C57BL/6)
decreased spleen weight J:190411
\Ptp4a3em1(IMPC)Mbp/\Ptp4a3em1(IMPC)Mbp
(C57BL/6N-Ptp4a3em1(IMPC)Mbp/MbpMmucd)
abnormal spleen morphology J:211773
small spleen J:211773
\Ptpmt1tm2.1Ckq/\Ptpmt1tm2.1Ckq
\Cd19tm1(cre)Cgn/\Cd19+

(involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * SJL)
immune system phenotype J:194929
\Ptpmt1tm2.1Ckq/\Ptpmt1tm2.1Ckq
\Lyz2tm1(cre)Ifo/\Lyz2+

(involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * SJL)
immune system phenotype J:194929
\Ptpmt1tm2.1Ckq/\Ptpmt1tm2.1Ckq
\Tg(Lck-cre)1Cwi/0

(involves: 129S6/SvEvTac * C57BL/6 * C57BL/6J * SJL)
immune system phenotype J:194929
\Ptpmt1tm2.1Ckq/\Ptpmt1tm2.1Ckq
\Tg(VAV1-cre)1Graf/0

(involves: 129S6/SvEvTac * C57BL/6J * SJL)
small spleen J:194929
small thymus J:194929
\Ptpn2tm1.1Kry/\Ptpn2tm1.1Kry
\Tg(Col1a1-cre)1Kry/0

(involves: 129 * C57BL/6J * FVB)
abnormal osteoclast differentiation J:183709
abnormal osteoclast physiology J:183709
\Ptpn2tm1Mtr/\Ptpn2tm1Mtr
(involves: 129S4/SvJae * BALB/c)
abnormal B cell number J:42595
abnormal inflammatory response J:90541
abnormal spleen morphology J:42595
abnormal thymus involution J:42595
decreased B cell number J:42595
decreased double-positive T cell number J:42595
enlarged lymph nodes J:42595
enlarged spleen J:42595
increased B cell number J:42595
increased inflammatory response J:90541
increased interferon-gamma secretion J:90541
increased interleukin-12 secretion J:90541
increased macrophage cell number J:42595
increased mature B cell number J:42595
increased pre-B cell number J:42595
increased spleen red pulp amount J:42595
increased tumor necrosis factor secretion J:90541
lymph node hyperplasia J:42595
spleen hyperplasia J:42595
\Ptpn2tm1Mtr/\Ptpn2tm1Mtr
(C.129S4-Ptpn2tm1Mtr)
abnormal lymph node morphology J:186843
abnormal negative T cell selection J:186843
abnormal positive T cell selection J:186843
abnormal T cell differentiation J:186843
abnormal T cell subpopulation ratio J:186843
decreased B cell number J:186843
decreased B-1 B cell number J:186843
decreased CD4-positive, alpha-beta T cell number J:186843
decreased double-positive T cell number J:186843
decreased follicular B cell number J:186843
decreased immature B cell number J:186843
decreased marginal zone B cell number J:186843
decreased mature B cell number J:186843
decreased single-positive T cell number J:186843
decreased T cell number J:186843
decreased thymocyte number J:186843
enlarged spleen J:186843
increased splenocyte number J:186843
thymus atrophy J:186843
\Ptpn2tm1Mtr/\Ptpn2tm1Mtr
(B6.129S4(C)-Ptpn2tm1Mtr)
abnormal lymph node morphology J:186843
decreased B cell number J:186843
decreased B-1 B cell number J:186843
decreased CD4-positive, alpha-beta T cell number J:186843
decreased double-positive T cell number J:186843
decreased follicular B cell number J:186843
decreased immature B cell number J:186843
decreased marginal zone B cell number J:186843
decreased mature B cell number J:186843
decreased single-positive T cell number J:186843
decreased T cell number J:186843
decreased thymocyte number J:186843
thymus atrophy J:186843
\Ptpn2tm2.1Ttig/\Ptpn2tm2.1Ttig
(B6.Cg-Ptpn2tm2.1Ttig)
abnormal negative T cell selection J:186843
abnormal positive T cell selection J:186843
abnormal T cell differentiation J:186843
abnormal T cell subpopulation ratio J:186843
decreased B cell number J:186843
decreased B-1 B cell number J:186843
decreased CD4-positive, alpha-beta T cell number J:186843
decreased double-positive T cell number J:186843
decreased follicular B cell number J:186843
decreased immature B cell number J:186843
decreased marginal zone B cell number J:186843
decreased mature B cell number J:186843
decreased single-positive T cell number J:186843
decreased thymocyte number J:186843
enlarged lymph nodes J:186843
thymus atrophy J:186843
\Ptpn3tm1Pdk/\Ptpn3tm1Pdk
\Ptpn4Gt(OST146128)Lex/\Ptpn4Gt(OST146128)Lex

(involves: 129S5/SvEvBrd * C57BL/6)
immune system phenotype J:144351
\Ptpn4Gt(OST146128)Lex/\Ptpn4Gt(OST146128)Lex
(involves: 129S5/SvEvBrd * C57BL/6)
immune system phenotype J:144351
\Ptpn4tm1.1Oers/\Ptpn4tm1.1Oers
(B6.129S6-Ptpn4tm1.1Oers)
immune system phenotype J:138871
\Ptpn6em1.1Shoy/\Ptpn6em1.1Shoy
(involves: C57BL/6)
decreased thymocyte number J:236298
\Ptpn6m1Amgn/\Ptpn6m1Amgn
(involves: C3H/HeSnJ * C57BL/6J * Swiss)
increased circulating interleukin-17 level J:168664
\Ptpn6m1Anu/\Ptpn6m1Anu
(C57BL/6JAnu-Ptpn6m1Anu)
decreased IgM level J:225105
\Ptpn6m1Btlr/\Ptpn6m1Btlr
(C57BL/6J-Ptpn6m1Btlr/Mmucd)
abnormal myeloid leukocyte morphology J:142845
decreased mature B cell number J:142845
decreased susceptibility to bacterial infection J:142845
decreased susceptibility to bacterial infection induced morbidity/mortality J:142845
enlarged spleen J:94077, J:142845
increased anti-chromatin antibody level J:142845
increased IgM level J:142845
increased inflammatory response J:94077
increased neutrophil cell number J:142845
lung inflammation J:142845
salivary gland inflammation J:142845
\Ptpn6m3Btlr/\Ptpn6+
(C57BL/6J-Ptpn6m3Btlr)
abnormal CD8-positive, alpha beta T cell morphology J:234259
decreased B cell number J:234259
decreased B-2 B cell number J:234259
decreased immature B cell number J:234259
decreased mature B cell number J:234259
increased B-1 B cell number J:234259
increased B-1a cell number J:234259
increased dendritic cell number J:234259
increased macrophage cell number J:234259
\Ptpn6m3Btlr/\Ptpn6m3Btlr
(C57BL/6J-Ptpn6m3Btlr)
abnormal CD8-positive, alpha beta T cell morphology J:234259
decreased B cell number J:234259
decreased B-2 B cell number J:234259
decreased immature B cell number J:234259
decreased mature B cell number J:234259
increased B-1 B cell number J:234259
increased B-1b cell number J:234259
increased dendritic cell number J:234259
increased macrophage cell number J:234259
\Ptpn6m4Btlr/\Ptpn6m4Btlr
(C57BL/6J-Ptpn6m4Btlr)
decreased CD4-positive, CD25-positive, alpha-beta regulatory T cell number J:264807
decreased CD8-positive, naive alpha-beta T cell number J:264807
increased B-1 B cell number J:264807
increased CD8-positive, alpha-beta memory T cell number J:264807
increased central memory CD8 positive, alpha-beta T cell number J:264807
increased effector memory CD4-positive, alpha-beta T cell number J:264807
increased effector memory CD8-positive, alpha-beta T cell number J:264807
\Ptpn6M5Btlr/\Ptpn6M5Btlr
(C57BL/6J-Ptpn6M5Btlr)
decreased B cell number J:265075
decreased B-1 B cell number J:265075
decreased CD8-positive, naive alpha-beta T cell number J:265075
decreased IgD level J:265075
decreased IgM level J:265075
increased central memory CD8 positive, alpha-beta T cell number J:265075
\Ptpn6m6Btlr/\Ptpn6m6Btlr
(C57BL/6J-Ptpn6m6Btlr)
abnormal CD8-positive, alpha-beta T cell differentiation J:272439
abnormal T cell differentiation J:272439
\Ptpn6m7Btlr/\Ptpn6m7Btlr
(C57BL/6J-Ptpn6m7Btlr)
abnormal T cell differentiation J:272440
\Ptpn6me-B2/\Ptpn6me-B2
(involves: BALB/c)
abnormal circulating chemokine level J:169850
increased circulating interferon-gamma level J:169850
increased circulating interleukin-1 beta level J:169850
increased circulating interleukin-6 level J:169850
increased circulating interleukin-10 level J:169850
increased circulating serum amyloid protein level J:169850
increased IgG level J:169850
increased IgM level J:169850
increased neutrophil cell number J:169850
interstitial pneumonia J:169850
skin inflammation J:169850
small thymus J:169850
\Ptpn6me-v/\Ptpn6+
\Tg(IghelMD4)4Ccg/0

(involves: 129P2/OlaHsd * C57BL/6)
abnormal mature B cell morphology J:110531
\Ptpn6me-v/\Ptpn6me-v
(C57BL/6J-Ptpn6me-v)
abnormal immunoglobulin level J:7665
abnormal inflammatory response J:20845
abnormal plasma cell morphology J:14936
abnormal T cell physiology J:1661
abnormal thymus development J:16613
chronic inflammation J:20845
decreased B cell number J:113218
decreased mature B cell number J:7905
increased plasma cell number J:7905
interstitial pneumonia J:7531
rheumatoid arthritis J:20845
\Ptpn6me/\Ptpn6me
(C57BL/6J-Ptpn6me/J)
abnormal granulocyte morphology J:5579
abnormal humoral immune response J:5579
abnormal immune system cell morphology J:5579
abnormal leukocyte cell number J:5579
abnormal Peyer's patch morphology J:5579
abnormal thymus morphology J:5579
autoimmune response J:5579
enlarged spleen J:5579
increased granulocyte number J:5579
increased IgA level J:5579
increased IgG level J:5579
increased IgM level J:5579
increased immunoglobulin level J:5579
increased leukocyte cell number J:5579
increased monocyte cell number J:5579
small thymus J:5579
\Ptpn6me/\Ptpn6me
(involves: C3H/HeN * C57BL/6J * NFS)
increased autoantibody level J:30994
increased IgM level J:30994
increased splenocyte proliferation J:30994
\Ptpn6me/\Ptpn6me
(involves: C3HeB/FeJ * C57BL/6)
abnormal microglial cell morphology J:72655
\Ptpn6me/\Ptpn6me
(C3FeLe.B6 a/a-Ptpn6me/J)
increased microglial cell activation J:88807
\Ptpn6me/\Ptpn6me
(either: (involves: C3H * C57BL/6J) or (involves: C57BL/6J * C57BL/6N))
lung inflammation J:5999
thymus atrophy J:5999
\Ptpn9tm1Dny/\Ptpn9tm1Dny
(B6.129-Ptpn9tm1Dny)
abnormal T cell differentiation J:118880
decreased T cell proliferation J:118880
\Ptpn11tm1.1Ics/\Ptpn11+
(involves: 129S2/SvPas * C57BL/6 * FVB/N)
enlarged spleen J:216593
\Ptpn11tm1Bgn/\Ptpn11+
(involves: 129S4/SvJae * C57BL/6J)
enlarged spleen J:91609
increased leukocyte cell number J:91609
increased lymphocyte cell number J:91609
increased neutrophil cell number J:91609
myeloid hyperplasia J:91609
\Ptpn11tm1Ckq/\Ptpn11+
\Lyz2tm1(cre)Ifo/\Lyz2+

(involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6J)
myeloid hyperplasia J:177285
\Ptpn11tm1Ckq/\Ptpn11+
\Tg(Lck-cre)1Cwi/0

(involves: 129S6/SvEvTac * C57BL/6J)
immune system phenotype J:177285
increased lymphoblastic lymphoma incidence J:177285
\Ptpn11tm1Ckq/\Ptpn11+
\Tg(Mx1-cre)1Cgn/0

(involves: 129S6/SvEvTac * C57BL/6 * C57BL/6J * CBA)
arrested B cell differentiation J:177285
enlarged spleen J:177285
increased leukocyte cell number J:177285
increased lymphoblastic lymphoma incidence J:177285
increased neutrophil cell number J:177285
increased spleen weight J:177285
myeloid hyperplasia J:177285
\Ptpn11tm1Gsf/\Ptpn11tm1Gsf
\Speer6-ps1Tg(Alb-cre)21Mgn/\Speer6-ps1+

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA)
increased acute inflammation J:172422
increased circulating interleukin-6 level J:172422
liver inflammation J:172422
\Ptpn11tm1Gsf/\Ptpn11tm1Gsf
\Stat3tm1Vpo/\Stat3tm1Vpo
\Speer6-ps1Tg(Alb-cre)21Mgn/\Speer6-ps1+

(involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA)
liver inflammation J:172422
\Ptpn11tm6Bgn/\Ptpn11+
\Tg(CAG-cre/Esr1*)5Amc/0

(involves: 129S6/SvEvTac * C57BL/6 * CBA)
abnormal leukopoiesis J:148430
\Ptpn11tm6Bgn/\Ptpn11+
\Tg(Mx1-cre)1Cgn/0

(involves: 129S6/SvEvTac * C57BL/6 * CBA)
abnormal leukopoiesis J:148430
abnormal splenic cell ratio J:148430
enlarged spleen J:148430
increased granulocyte number J:148430
increased leukocyte cell number J:148430
increased monocyte cell number J:148430
intermingled spleen red and white pulp J:148430
\Ptpn12tm1Vei/\Ptpn12tm1Vei
\Tg(Cd4-cre)1Cwi/0

(B6.Cg-Tg(Cd4-cre)1Cwi Ptpn12tm1Vei)
abnormal cytokine secretion J:163910
abnormal T cell physiology J:163910
decreased T cell proliferation J:163910
\Ptpn12tm1Vei/\Ptpn12tm1Vei
\Tg(Lck-cre)1Cwi/0

(B6.Cg-Ptpn12tm1Vei Tg(Lck-cre)1Cwi)
decreased susceptibility to experimental autoimmune encephalomyelitis J:163910
\Ptpn13tm1Gru/\Ptpn13tm1Gru
(involves: C57BL/6)
abnormal CD4-positive, alpha-beta T cell physiology J:118426
abnormal cytokine secretion J:118426
decreased susceptibility to bacterial infection J:118426
\Ptpn13tm1Wjh/\Ptpn13tm1Wjh
(involves: 129P2/OlaHsd * C57BL/6)
increased T-helper 2 cell number J:144351
\Ptpn13tm1Wjh/\Ptpn13tm1Wjh
\Ptpn3tm1Pdk/\Ptpn3tm1Pdk
\Ptpn4Gt(OST146128)Lex/\Ptpn4Gt(OST146128)Lex

(involves: 129P2/OlaHsd * 129S5/SvEvBrd * C57BL/6)
immune system phenotype J:144351
\Ptpn14Gt(RRR484)Byg/\Ptpn14Gt(RRR484)Byg
(involves: 129P2/OlaHsd)
lymphatic vessel hyperplasia J:169186
\Ptpn18em1(IMPC)J/\Ptpn18em1(IMPC)J
(C57BL/6NJ-Ptpn18em1(IMPC)J/Mmjax)
increased leukocyte cell number J:211773
\Ptpn22tm1.1Draw/\Ptpn22+
(involves: 129 * C57BL/6)
abnormal B cell differentiation J:201448
abnormal B cell morphology J:201448
abnormal B cell number J:201448
abnormal B cell physiology J:201448
abnormal T cell morphology J:201448
abnormal T cell number J:201448
abnormal T cell physiology J:201448
abnormal thymus morphology J:201448
autoimmune response J:201448
decreased B cell apoptosis J:201448
decreased follicular B cell number J:201448
decreased mature B cell number J:201448
enlarged spleen J:201448
increased anti-double stranded DNA antibody level J:201448
increased B cell number J:201448
increased B cell proliferation J:201448
increased CD4-positive, alpha-beta memory T cell number J:201448
increased double-positive T cell number J:201448
increased germinal center B cell number J:201448
increased IgG1 level J:201448
increased interleukin-2 secretion J:201448
increased regulatory T cell number J:201448
increased spleen germinal center size J:201448
increased T cell proliferation J:201448
increased transitional stage T1 B cell number J:201448
spleen hyperplasia J:201448
thymus hyperplasia J:201448
\Ptpn22tm1.1Draw/\Ptpn22tm1.1Draw
(involves: 129 * C57BL/6)
abnormal B cell activation J:201448
abnormal B cell differentiation J:201448
abnormal B cell morphology J:201448
abnormal B cell physiology J:201448
abnormal T cell differentiation J:201448
abnormal T cell morphology J:201448
abnormal T cell physiology J:201448
abnormal thymus morphology J:201448
autoimmune response J:201448
decreased B cell apoptosis J:201448
decreased follicular B cell number J:201448
decreased mature B cell number J:201448
enlarged spleen J:201448
glomerulonephritis J:201448
immune system phenotype J:201448
increased anti-double stranded DNA antibody level J:201448
increased anti-insulin autoantibody level J:201448
increased B cell number J:201448
increased B cell proliferation J:201448
increased double-positive T cell number J:201448
increased effector memory CD4-positive, alpha-beta T cell number J:201448
increased effector memory CD8-positive, alpha-beta T cell number J:201448
increased germinal center B cell number J:201448
increased IgE level J:201448
increased IgG1 level J:201448
increased IgG3 level J:201448
increased IgM level J:201448
increased inflammatory response J:201448
increased interleukin-2 secretion J:201448
increased regulatory T cell number J:201448
increased spleen germinal center size J:201448
increased T cell proliferation J:201448
increased transitional stage T1 B cell number J:201448
spleen hyperplasia J:201448
thymus hyperplasia J:201448
\Ptpn22tm1.1Kas/\Ptpn22tm1.1Kas
(involves: C57BL/6)
abnormal dendritic cell physiology J:176519
enlarged spleen J:176519
enlarged thymus J:176519
immune system phenotype J:176519
increased B cell proliferation J:176519
increased CD4-positive, alpha-beta T cell number J:176519
increased CD8-positive, alpha-beta T cell number J:176519
increased dendritic cell number J:176519
increased IgG2a level J:176519
increased IgG3 level J:176519
increased IgM level J:176519
increased interleukin-12 secretion J:176519
increased spleen germinal center number J:176519
increased spleen germinal center size J:176519
increased T cell number J:176519
increased T cell proliferation J:176519
\Ptpn22tm1.1Kas/\Ptpn22tm1.1Kas
\Tg(TcraH-Y,TcrbH-Y)71Vbo/0

(involves: C57BL/6 * C57BL/6J * DBA/2J)
immune system phenotype J:176519
\Ptpn22tm1.1Kas/\Ptpn22tm1.1Kas
\Tg(TcraTcrb)425Cbn/0

(involves: BALB/c * C57BL/6)
increased CD4-positive, alpha-beta T cell number J:176519
increased T cell proliferation J:176519
\Ptpn22tm1Achn/\Ptpn22tm1Achn
(involves: C57BL/6)
abnormal Peyer's patch germinal center morphology J:90029
abnormal T cell physiology J:90029
enlarged lymph nodes J:90029
enlarged spleen J:90029
increased B cell number J:90029
increased follicular B cell number J:90029
increased IgE level J:90029
increased IgG1 level J:90029
increased IgG2a level J:90029
increased spleen germinal center number J:90029
\Ptpn22tm2Achn/\Ptpn22tm2Achn
(involves: C57BL/6)
abnormal Peyer's patch germinal center morphology J:90029
abnormal T cell physiology J:90029
enlarged lymph nodes J:90029
enlarged spleen J:90029
increased B cell number J:90029
increased follicular B cell number J:90029
increased IgE level J:90029
increased IgG1 level J:90029
increased IgG2a level J:90029
increased spleen germinal center number J:90029
\Ptpn22tm2Achn/\Ptpn22tm2Achn
(B6.Cg-Ptpn22tm2Achn)
abnormal double-positive T cell morphology J:147129
abnormal T cell activation J:147129
abnormal T cell subpopulation ratio J:147129
abnormal thymocyte activation J:147129
enlarged lymph nodes J:147129
increased memory T cell number J:147129
\Ptpn22tm2Achn/\Ptpn22tm2Achn
\Ptprctm1Weis/\Ptprctm1Weis

(B6.Cg-Ptprctm1Weis Ptpn22tm2Achn)
abnormal B cell activation J:147129
abnormal double-positive T cell morphology J:147129
abnormal follicular B cell physiology J:147129
abnormal lymphocyte cell number J:147129
abnormal T cell activation J:147129
abnormal T cell subpopulation ratio J:147129
abnormal thymocyte activation J:147129
decreased follicular B cell number J:147129
enlarged lymph nodes J:147129
glomerulonephritis J:147129
increased autoantibody level J:147129
increased memory T cell number J:147129
increased plasma cell number J:147129
increased transitional stage B cell number J:147129
liver inflammation J:147129
lung inflammation J:147129
\Ptprcloc/\Ptprcloc
(C57BL/6JSfdAnu-Ptprcloc/AnuApb)
abnormal B cell number J:104190
abnormal double-positive T cell morphology J:104190
abnormal memory T cell number J:104190
abnormal T cell morphology J:104190
abnormal T cell selection J:104190
abnormal thymocyte activation J:104190
arrested T cell differentiation J:104190
decreased CD4-positive, alpha-beta T cell number J:104190
decreased CD8-positive, alpha-beta T cell number J:104190
decreased double-positive T cell number J:104190
decreased T cell number J:104190
\Ptprcltng/\Ptprcltng
(C57BL/6-Ptprcltng)
abnormal T cell differentiation J:158876
decreased CD4-positive, alpha-beta T cell number J:158876
decreased double-positive T cell number J:158876
thymus hypoplasia J:158876
\Ptprcltng/\Ptprctm1Mak
(involves: 129/Sv * C57BL/6)
abnormal T cell differentiation J:158876
decreased CD4-positive, alpha-beta T cell number J:158876
decreased double-positive T cell number J:158876
thymus hypoplasia J:158876
\Ptprcltng/\Ptprctm1Mak
\Tg(TcraTcrb)425Cbn/0

(involves: 129/Sv * BALB/c * C57BL/6)
decreased CD4-positive, alpha-beta T cell number J:158876
thymus hypoplasia J:158876
\Ptprcm1Btlr/\Ptprcm1Btlr
(involves: C57BL/6J)
absent T cells J:152064
\Ptprcm1Smv/\Ptprcm1Smv
(involves: C57BL/6J * C57BL/10J)
abnormal CD4-positive T cell differentiation J:214487
abnormal CD8-positive, alpha-beta T cell differentiation J:214487
abnormal immune system cell morphology J:214487
abnormal immune system physiology J:214487
CNS inflammation J:214487
decreased DN4 thymocyte number J:214487
increased DN3 thymocyte number J:214487
increased double-negative T cell number J:214487
increased susceptibility to Herpesvirales infection J:214487
\Ptprcm2Btlr/\Ptprcm2Btlr
(C57BL/6J-Ptprcm2Btlr)
abnormal humoral immune response J:216796
decreased B-1a cell number J:216796
decreased B-2 B cell number J:216796
decreased CD4-positive, alpha-beta memory T cell number J:216796
decreased CD8-positive, alpha-beta memory T cell number J:216796
decreased mature B cell number J:216796
decreased memory B cell number J:216796
decreased memory T cell number J:216796
decreased single-positive T cell number J:216796
increased B-1 B cell number J:216796
increased B-1b cell number J:216796
increased dendritic cell number J:216796
increased neutrophil cell number J:216796
increased single-positive T cell number J:216796
\Ptprcm3Btlr/\Ptprcm3Btlr
(C57BL/6J-Ptprcm3Btlr)
decreased B cell number J:254899
decreased B-1a cell number J:254899
decreased B-2 B cell number J:254899
decreased CD8-positive, alpha-beta T cell number J:254899
increased B-1b cell number J:254899
\Ptprcm4Btlr/\Ptprcm4Btlr
(C57BL/6J-Ptprcm4Btlr)
decreased B cell number J:264808
decreased CD4-positive, alpha-beta T cell number J:264808
decreased CD8-positive, alpha-beta T cell number J:264808
decreased CD8-positive, naive alpha-beta T cell number J:264808
decreased single-positive T cell number J:264808
decreased T cell number J:264808
increased B-1 B cell number J:264808
increased central memory CD4-positive, alpha-beta T cell number J:264808
increased central memory CD8 positive, alpha-beta T cell number J:264808
increased effector memory CD4-positive, alpha-beta T cell number J:264808
increased effector memory CD8-positive, alpha-beta T cell number J:264808
\PtprcM5Btlr/\PtprcM5Btlr
(C57BL/6J-PtprcM5Btlr)
increased alpha-beta T cell number J:265143
\PtprcM6Btlr/\PtprcM6Btlr
(C57BL/6J-PtprcM6Btlr)
decreased B-1a cell number J:265186
decreased B-1b cell number J:265186
decreased CD8-positive, naive alpha-beta T cell number J:265186
increased B-1 B cell number J:265186
\Ptprcm7Btlr/\Ptprcm7Btlr
(C57BL/6J-Ptprcm7Btlr)
decreased alpha-beta T cell number J:267486
decreased B cell number J:267486
decreased CD4-positive, alpha-beta T cell number J:267486
decreased CD8-positive, alpha-beta T cell number J:267486
decreased CD8-positive, naive alpha-beta T cell number J:267486
decreased NK T cell number J:267486
increased B-1 B cell number J:267486
increased central memory CD4-positive, alpha-beta T cell number J:267486
increased central memory CD8 positive, alpha-beta T cell number J:267486
increased effector memory CD4-positive, alpha-beta T cell number J:267486
increased effector memory CD8-positive, alpha-beta T cell number J:267486
\PtprcM8Btlr/\PtprcM8Btlr
(C57BL/6J-PtprcM8Btlr)
increased B-1 B cell number J:267487
increased central memory CD8 positive, alpha-beta T cell number J:267487
\PtprcM9Btlr/\PtprcM9Btlr
(C57BL/6J-PtprcM9Btlr)
abnormal B cell differentiation J:272745
abnormal CD8-positive, alpha beta T cell morphology J:272745
abnormal lymphocyte morphology J:272745
decreased B cell number J:272745
decreased NK cell number J:272745
increased CD8-positive, alpha-beta T cell number J:272745
increased effector memory CD4-positive, alpha-beta T cell number J:272745
\PtprcM10Btlr/\PtprcM10Btlr
(C57BL/6J-PtprcM10Btlr)
decreased B-1b cell number J:272777
decreased IgE level J:272777
\PtprcM11Btlr/\PtprcM11Btlr
(C57BL/6J-PtprcM11Btlr)
abnormal B cell differentiation J:274863
abnormal CD8-positive, alpha-beta T cell differentiation J:274863
increased B-1 B cell number J:274863
\Ptprcm12Btlr/\Ptprcm12Btlr
(C57BL/6J-Ptprcm12Btlr)
decreased B cell number J:274972
decreased CD4-positive, alpha-beta T cell number J:274972
decreased CD8-positive, alpha-beta T cell number J:274972
decreased CD8-positive, naive alpha-beta T cell number J:274972
decreased central memory CD8 positive, alpha-beta T cell number J:274972
decreased effector memory CD4-positive, alpha-beta T cell number J:274972
decreased T cell number J:274972
increased B-1 B cell number J:274972
\Ptprcnim/\Ptprcnim
(C57BL/6JAnu-Ptprcnim)
decreased B cell number J:225105
decreased leukocyte cell number J:225105
decreased T cell number J:225105
\Ptprcrain/\Ptprcrain
(C57BL/6JAnu-Ptprcrain/AnuApb)
abnormal leukocyte morphology J:104190
\Ptprcstrm/\Ptprcstrm
(C57BL/6JAnu-Ptprcstrm/AnuApb)
decreased B cell number J:104190
decreased T cell number J:104190
\Ptprctm1Holm/\Ptprctm1Holm
(involves: 129/Sv * C57BL/6)
abnormal B cell number J:33466
abnormal lymphopoiesis J:33466
abnormal T cell differentiation J:33466
decreased CD4-positive, alpha-beta T cell number J:33466
decreased CD8-positive, alpha-beta T cell number J:33466
decreased double-positive T cell number J:33466
decreased T cell number J:33466
decreased thymocyte number J:33466
increased double-negative T cell number J:33466
spleen hyperplasia J:33466
\Ptprctm1Holm/\Ptprctm1Holm
\Tg(Lck*F505)2964Rmp/?

(involves: 129/Sv * C57BL/6 * DBA/2)
increased T cell derived lymphoma incidence J:64671
thymus hyperplasia J:64671
\Ptprctm1Holm/\Ptprctm1Holm
\Tg(Lck*F505)3073Rmp/?

(involves: 129/Sv * C57BL/6 * DBA/2)
increased T cell derived lymphoma incidence J:64671
thymus hyperplasia J:64671
\Ptprctm1Mak/\Ptprctm1Mak
(involves: 129/Sv * C57BL/6)
abnormal response to infection J:13163
abnormal T cell subpopulation ratio J:13163
arrested T cell differentiation J:158876
decreased B cell proliferation J:13163
decreased CD4-positive, alpha-beta T cell number J:13163
decreased CD8-positive, alpha-beta T cell number J:13163
decreased cytotoxic T cell cytolysis J:13163
decreased T cell number J:13163
decreased T cell proliferation J:13163
decreased thymocyte number J:13163
increased double-negative T cell number J:13163
\Ptprctm1Mak/\Ptprctm1Mak
(involves: 129)
abnormal osteoclast morphology J:141275
abnormal osteoclast physiology J:141275
decreased mast cell degranulation J:110782
decreased susceptibility to type I hypersensitivity reaction J:110782
\Ptprctm1Mak/\Ptprctm1Mak
(B6.Cg-Ptprctm1Mak)
abnormal CD4-positive, alpha-beta intraepithelial T cell morphology J:111646
abnormal intraepithelial T cell morphology J:111646
abnormal intraepithelial T cell number J:111646
abnormal NK cell physiology J:109462
abnormal T cell differentiation J:111646
decreased cytotoxic T cell cytolysis J:111646
decreased gamma-delta intraepithelial T cell number J:111646
increased T cell apoptosis J:111646
\Ptprctm1Mak/\Ptprctm1Mak
\Ptprjtm1.2Weis/\Ptprjtm1.2Weis

(involves: 129/Sv * 129P2/OlaHsd * BALB/cJ * C57BL/6)
abnormal B cell calcium ion homeostasis J:131736
abnormal cytokine secretion J:131736
abnormal follicular B cell morphology J:131736
abnormal myelopoiesis J:131736
decreased B cell number J:131736
impaired macrophage phagocytosis J:131736
\Ptprctm1Mak/\Ptprctm1Mak
\Ptprjtm1.2Weis/\Ptprjtm1.2Weis

(B6.Cg-Ptprctm1Mak Ptprjtm1.2Weis)
abnormal B cell differentiation J:131736
abnormal follicular B cell morphology J:131736
abnormal myelopoiesis J:131736
abnormal spleen morphology J:131736
abnormal transitional stage B cell morphology J:131736
decreased B cell number J:131736
decreased immature B cell number J:131736
decreased mature B cell number J:131736
liver inflammation J:131736
lung inflammation J:131736
\Ptprctm1Mak/\Ptprctm1Mak
\Tg(TcraTcrb)425Cbn/0

(involves: 129/Sv * BALB/c * C57BL/6)
decreased CD4-positive, alpha-beta T cell number J:158876
\Ptprctm1Tyb/\Ptprctm1Tyb
(C.129S2-Ptprctm1Tyb)
abnormal positive T cell selection J:57681
abnormal T cell differentiation J:57681
abnormal T cell physiology J:57681
decreased CD4-positive, alpha-beta T cell number J:57681
decreased CD8-positive, alpha-beta T cell number J:57681
decreased double-positive T cell number J:57681
enlarged spleen J:57681
immune system phenotype J:57681
increased double-negative T cell number J:57681
thymus hypoplasia J:57681
\Ptprctm1Tyb/\Ptprctm1Tyb
(B6.129S2-Ptprctm1Tyb)
abnormal chemokine secretion J:98190
abnormal cytokine secretion J:98190
abnormal NK cell physiology J:98190
increased NK cell number J:98190
\Ptprctm1Weis/\Ptprc+
(involves: 129X1/SvJ * C57BL/6)
increased anti-double stranded DNA antibody level J:66501
increased IgG2a level J:66501
increased susceptibility to autoimmune disorder J:66501
\Ptprctm1Weis/\Ptprctm1Weis
(involves: 129X1/SvJ * C57BL/6)
abnormal B cell activation J:66501
abnormal granulocyte differentiation J:66501
abnormal immune system organ morphology J:66501
abnormal leukocyte cell number J:66501
abnormal T cell activation J:66501
enlarged lymph nodes J:66501
enlarged spleen J:66501
glomerulonephritis J:66501
increased anti-double stranded DNA antibody level J:66501
increased B cell number J:66501
increased IgA level J:66501
increased IgG2a level J:66501
increased plasmacytoid dendritic cell number J:66501
increased spleen red pulp amount J:66501
increased spleen white pulp amount J:66501
increased susceptibility to autoimmune disorder J:66501
increased T cell number J:66501
lymph node hyperplasia J:66501
\Ptprctm1Weis/\Ptprctm1Weis
(B6.129X1-Ptprctm1Weis)
abnormal B cell activation J:147129
abnormal double-positive T cell morphology J:147129
abnormal follicular B cell physiology J:147129
abnormal T cell activation J:147129
abnormal T cell subpopulation ratio J:147129
abnormal thymocyte activation J:147129
decreased follicular B cell number J:147129
enlarged lymph nodes J:147129
immune system phenotype J:109462
increased memory T cell number J:147129
increased plasma cell number J:147129
increased transitional stage B cell number J:147129
liver inflammation J:147129
lung inflammation J:147129
\Ptprcaptm1Svn/\Ptprcaptm1Svn
(involves: C57BL/6)
enlarged lymph nodes J:58712
lymphoid hyperplasia J:58712
\Ptprcaptm1Tho/\Ptprcaptm1Tho
(involves: 129X1/SvJ)
immune system phenotype J:58711
\Ptprcaptm1Tkda/\Ptprcaptm1Tkda
(involves: 129X1/SvJ)
abnormal cytotoxic T cell physiology J:48387
decreased B cell proliferation J:48387
decreased T cell proliferation J:48387
immune system phenotype J:48387
\Ptprdtm2a(KOMP)Wtsi/\Ptprdtm2a(KOMP)Wtsi
(C57BL/6N-Ptprdtm2a(KOMP)Wtsi/Wtsi)
increased leukocyte cell number J:211773
\Ptpretm1Ael/\Ptpretm1Ael
(involves: 129S6/SvEvTac * C57BL/6)
abnormal osteoclast differentiation J:90031
abnormal osteoclast physiology J:90031
\Ptprftm1Wjh/\Ptprftm1Wjh
(involves: 129P2/OlaHsd)
immune system phenotype J:119456
\Ptprjtm1.2Weis/\Ptprjtm1.2Weis
(involves: 129P2/OlaHsd * BALB/cJ * C57BL/6)
abnormal B cell differentiation J:131736
abnormal splenic cell ratio J:131736
increased B-2 B cell number J:131736
increased marginal zone B cell number J:131736
\Ptprntm1Aln/\Ptprntm1Aln
(NOD.129S4-Ptprntm1Aln)
increased susceptibility to autoimmune diabetes J:107161
insulitis J:107161
\Ptprz1em1(IMPC)Ccpcz/\Ptprz1em1(IMPC)Ccpcz
(C57BL/6NCrl-Ptprz1em1(IMPC)Ccpcz/Ccpcz)
abnormal lymph node morphology J:211773
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged lymph nodes J:211773
enlarged spleen J:211773
enlarged thymus J:211773
\Ptprz1tm1Mno/\Ptprz1tm1Mno
(B6.129-Ptprz1tm1Mno)
decreased susceptibility to bacterial infection J:85826
\Ptprz1tm1Schl/\Ptprz1tm1Schl
(involves: 129 * Swiss Webster)
increased susceptibility to experimental autoimmune encephalomyelitis J:79860
\Ptrh2tm1.1Eruo/\Ptrh2tm1.1Eruo
(C57BL/6-Ptrh2tm1.1Eruo)
decreased neutrophil cell number J:131853
\Ptstm1b(EUCOMM)Wtsi/\Pts+
(C57BL/6N-Ptstm1b(EUCOMM)Wtsi/H)
increased large unstained cell number J:211773
\Pttg1tm1b(EUCOMM)Wtsi/\Pttg1tm1b(EUCOMM)Wtsi
(C57BL/6N-Pttg1tm1b(EUCOMM)Wtsi/Tcp)
small spleen J:211773
\Pttg1tm1Sme/\Pttg1tm1Sme
(involves: 129S4/SvJae * C57BL/6)
abnormal immune system organ morphology J:72267
decreased IgG level J:72267
decreased IgM level J:72267
decreased immunoglobulin level J:72267
decreased spleen weight J:72267
increased T cell number J:72267
thymus hyperplasia J:72267
\Ptx3tm1Mant/\Ptx3tm1Mant
(either: (involves: 129S1/Sv * 129X1/SvJ) or (involves: 129S1/Sv * 129X1/SvJ * C57BL/6))
abnormal dendritic cell physiology J:85080
abnormal macrophage physiology J:85080
abnormal professional antigen presenting cell physiology J:85080
abnormal T-helper 1 physiology J:85080
impaired macrophage phagocytosis J:85080
increased susceptibility to bacterial infection J:85080
increased susceptibility to fungal infection J:85080
lung inflammation J:85080
\Ptx3tm1Zuk/\Ptx3tm1Zuk
(involves: 129S7/SvEvBrd * C57BL/6J)
increased susceptibility to Coronaviridae infection J:188421
\Puf60tm1.1Kmtsu/\Puf60+
\Trp53tm1Sia/\Trp53tm1Sia

(involves: C57BL/6NCrlj * C57BL/6NCrSlc * CBA/JNCrlj)
increased leukocyte cell number J:233347
increased spleen weight J:233347
increased T cell derived lymphoma incidence J:233347
increased thymus weight J:233347
\Puratm1Kkh/\Puratm1Kkh
(involves: 129)
abnormal spleen morphology J:85759
abnormal thymus morphology J:85759
decreased spleen weight J:85759
small spleen J:85759
\Pvrtm1Gbn/\Pvrtm1Gbn
(either: (involves: 129S2/SvPas) or (involves: 129S2/SvPas * BALB/c))
abnormal response to infection J:123540
decreased IgA level J:123540
decreased IgG1 level J:123540
decreased IgG2a level J:123540
decreased IgG2b level J:123540
decreased IgG level J:123540
\Pvrigem1(IMPC)Mbp/\Pvrigem1(IMPC)Mbp
(C57BL/6N-Pvrigem1(IMPC)Mbp/MbpMmucd)
abnormal lymph node morphology J:211773
enlarged lymph nodes J:211773
\Pvrigtm1.2Sgng/\Pvrigtm1.2Sgng
(B6(Cg)-Pvrigtm1.1Sgng)
abnormal CD8-positive, alpha-beta T cell physiology J:324171
abnormal T cell physiology J:324171
\Pwwp3aem1(IMPC)Tcp/\Pwwp3aem1(IMPC)Tcp
(C57BL/6NCrl-Pwwp3aem1(IMPC)Tcp/Tcp)
small thymus J:211773
\Pxdnmhdakta048/\Pxdnmhdakta048
(involves: C3HeB/FeJ * C57BL/6J)
eye inflammation J:213336
\Pycardtm1Ayaz/\Pycardtm1Ayaz
\Lyz2tm1(cre)Ifo/\Lyz2+

(involves: 129P2/OlaHsd * C57BL/6J)
decreased interleukin-1 alpha secretion J:191239
decreased interleukin-1 beta secretion J:191239
decreased interleukin-6 secretion J:191239
decreased tumor necrosis factor secretion J:191239
\Pycardtm1Flv/\Pycardtm1Flv
(involves: 129S5/SvEvBrd * C57BL/6)
abnormal macrophage physiology J:113333
decreased circulating interleukin-1 beta level J:113333
decreased circulating interleukin-18 level J:113333, J:158969
decreased interleukin-1 alpha secretion J:113333
decreased interleukin-1 beta secretion J:113333
decreased NK cell number J:158969
decreased susceptibility to endotoxin shock J:113333
decreased susceptibility to type IV hypersensitivity reaction J:113333
increased susceptibility to Herpesvirales infection J:158969
\Pycardtm1Flv/\Pycardtm1Flv
(B6.129S5-Pycardtm1Flv)
enlarged Peyer's patches J:173245
increased IgA level J:173245
increased IgG2c level J:173245
increased susceptibility to induced colitis J:173245
\Pycardtm1Flv/\Pycardtm1Flv
\Slc11a1s/\Slc11a1s

(B6.129S5-Pycardtm1Flv)
increased susceptibility to bacterial infection J:124378
\Pycardtm1Nnz/\Pycardtm1Nnz
(involves: 129 * C57BL/6)
decreased interleukin-1 beta secretion J:129871
decreased interleukin-18 secretion J:129871
\Pycardtm1Tno/\Pycardtm1Tno
(involves: 129S4/SvJae * C57BL/6)
decreased interferon-gamma secretion J:100807
decreased interleukin-1 beta secretion J:100807
decreased interleukin-18 secretion J:100807
decreased susceptibility to endotoxin shock J:100807
\Pycardtm1Vmd/\Pycardtm1Vmd
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6N)
decreased inflammatory response J:91292
decreased interleukin-1 alpha secretion J:91292
decreased interleukin-1 beta secretion J:91292
decreased interleukin-18 secretion J:91292
\Pycardtm1Vmd/\Pycardtm1Vmd
(involves: 129S1/Sv * 129X1/SvJ)
abnormal response to infection J:106976
decreased interleukin-1 beta secretion J:124226, J:106976
decreased interleukin-18 secretion J:106976
\Pycardtm1Vmd/\Pycardtm1Vmd
(B6.129-Pycardtm1Vmd)
abnormal macrophage physiology J:160545
decreased circulating interleukin-1 beta level J:193522
decreased circulating interleukin-18 level J:193522
decreased interleukin-1 beta secretion J:193522, J:160545
decreased susceptibility to endotoxin shock J:193522
increased interferon-beta secretion J:160545
increased tumor necrosis factor secretion J:160545
\Pycr2m1J/\Pycr2m1J
(involves: C3H/HeJ * C57BL/6J)
decreased basophil cell number J:308336
decreased leukocyte cell number J:308336
decreased lymphocyte cell number J:308336
\Pycr2tm1a(EUCOMM)Wtsi/\Pycr2tm1a(EUCOMM)Wtsi
(C57BL/6N-Pycr2tm1a(EUCOMM)Wtsi/Wtsi)
decreased Ly6C low monocyte number J:211773
decreased monocyte cell number J:211773
\Pygltm1a(KOMP)Wtsi/\Pygltm1a(KOMP)Wtsi
(C57BL/6N-Pygltm1a(KOMP)Wtsi)
liver inflammation J:284765
\Pymr129X1/SvJMs/\PymrNC/JicJcl
(involves: 129X1/SvJMs * NC/JicJcl)
decreased susceptibility to parasitic infection J:92924
\PymrNC/JicJcl/\PymrNC/JicJcl
(involves: 129X1/SvJMs * NC/JicJcl)
increased susceptibility to parasitic infection J:92924
\Pzptm1Vln/\Pzptm1Vln
(involves: 129P2/OlaHsd * C57BL)
increased susceptibility to induced pancreatitis J:28328
pancreas inflammation J:28328
\Pzptm1Vln/\Pzptm1Vln
(B.129P2-Pzptm1Vln)
abnormal cytokine level J:57485
liver inflammation J:57485
\Pzptm1Vln/\Pzptm1Vln
(B6.129P2-Pzptm1Vln)
abnormal cytokine secretion J:113532
\Qpcttm1.1Gne/\Qpcttm1.1Gne
(C57BL/6N-Qpcttm1.1Gne)
immune system phenotype J:324112
\Qpcttm1.1Gne/\Qpcttm1.1Gne
\Qpctltm1.1Gne/\Qpctltm1.1Gne

(C57BL/6N-Qpctltm1.1Gne Qpcttm1.1Gne)
decreased monocyte cell number J:324112
\Qpctltm1.1Gne/\Qpctltm1.1Gne
(C57BL/6N-Qpctltm1.1Gne)
decreased monocyte cell number J:324112
increased monocyte cell number J:324112
\QprtGt(OST337946)Lex/\QprtGt(OST337946)Lex
(involves: 129S5/SvEvBrd * C57BL/6J)
abnormal cytokine level J:282516
abnormal macrophage morphology J:282516
abnormal macrophage physiology J:282516
\Qrich1b2b2404Clo/\Qrich1b2b2404Clo
(C57BL/6J-Qrich1b2b2404Clo)
thymus hypoplasia J:175213
\Qsox1b2b2673Clo/\Qsox1b2b2673Clo
(C57BL/6J-Qsox1b2b2673Clo)
spleen hypoplasia J:175213
\Rab2aem2(IMPC)Tcp/\Rab2a+
(C57BL/6NCrl-Rab2aem2(IMPC)Tcp/Tcp)
increased spleen weight J:211773
\Rab6bGt(OST68543)Lex/\Rab6bGt(OST68543)Lex
(involves: 129S5/SvEvBrd * C57BL/6J)
immune system phenotype J:103485
\Rab7tm1.1Ale/\Rab7tm1.1Ale
\Tg(Cd4-cre)1Cwi/?

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2)
abnormal T cell morphology J:211733
abnormal T cell physiology J:211733
abnormal T cell subpopulation ratio J:211733
decreased CD4-positive, alpha-beta T cell number J:211733
decreased CD8-positive, alpha-beta T cell number J:211733
decreased T cell number J:211733
decreased T cell proliferation J:211733
\Rab7btm1Ciphe/\Rab7btm1Ciphe
\Tg(Itgax-cre)1-1Reiz/0

(involves: C57BL/6N * CBA)
abnormal dendritic cell migration J:321707
\Rab11atm1.1Ngao/\Rab11atm1.1Ngao
\Tg(Vil1-cre)997Gum/0

(involves: 129S4/SvJae * C57BL/6J * SJL)
abnormal cytokine secretion J:215917
increased cytokine level J:278932
increased interleukin-1 beta secretion J:215917
increased interleukin-6 secretion J:215917
intestinal inflammation J:215917
\Rab11atm1.1Ngao/\Rab11atm1.1Ngao
\Tg(Vil1-cre/ERT2)23Syr/0

(involves: 129S4/SvJae * C57BL/6 * DBA/2)
increased interleukin-6 secretion J:215917
\Rab11fip2em1(IMPC)Mbp/\Rab11fip2em1(IMPC)Mbp
(C57BL/6NCrl-Rab11fip2em1(IMPC)Mbp/MbpMmucd)
abnormal lymph node morphology J:211773
enlarged lymph nodes J:211773
\Rab13tm1.1Ktg/\Rab13tm1.1Ktg
(involves: C57BL/6)
abnormal leukocyte adhesion J:259093
abnormal T cell physiology J:259093
decreased lymphocyte cell number J:259093
decreased lymphocyte chemotaxis J:259093
immune system phenotype J:259093
impaired leukocyte migration J:259093
lymphoid hypoplasia J:259093
small inguinal lymph nodes J:259093
small spleen J:259093
\Rab19tm1b(EUCOMM)Hmgu/\Rab19tm1b(EUCOMM)Hmgu
(C57BL/6N-Rab19tm1b(EUCOMM)Hmgu/Ics)
decreased large unstained cell number J:211773
increased eosinophil cell number J:211773
\Rab20tm1a(EUCOMM)Hmgu/\Rab20tm1a(EUCOMM)Hmgu
(involves: C57BL/6N)
abnormal macrophage physiology J:243883
\Rab26em1Guwa/\Rab26em1Guwa
(Not Specified)
increased susceptibility to endotoxin shock J:306921
\Rab27aash/\Rab27aash
(involves: C3H/HeDiSn)
abnormal NK cell degranulation J:111253
decreased cytotoxic T cell cytolysis J:111253, J:67600
immune system phenotype J:111253
impaired natural killer cell mediated cytotoxicity J:111253
\Rab27aash/\Rab27aash
(B6.C3Sn-Rab27aash)
abnormal cytotoxic T cell physiology J:193137
decreased cytotoxic T cell cytolysis J:193137
decreased leukocyte cell number J:193137
decreased neutrophil cell number J:193137
decreased NK cell degranulation J:193137
increased circulating interferon-gamma level J:193137
increased circulating interleukin-1 beta level J:193137
increased circulating interleukin-6 level J:193137
increased circulating tumor necrosis factor level J:193137
increased susceptibility to Riboviria infection J:193137
\Rab27acct/\Rab27acct
(C57BL/6-Rab27acct)
abnormal neutrophil physiology J:114299
immune system phenotype J:114299
\Rab32tm1c(KOMP)Wtsi/\Rab32tm1c(KOMP)Wtsi
\Tg(Itgax-cre)1-1Reiz/0

(involves: 129S4/SvJaeSor * C57BL/6 * C57BL/6N * CBA)
abnormal cytokine secretion J:267497
increased neutrophil cell number J:267497
increased susceptibility to bacterial infection J:231298, J:267497
increased susceptibility to colitis induced morbidity/mortality J:267497
increased susceptibility to induced colitis J:267497
\Rab33bem1Rmr/\Rab33b+
(involves: C57BL/6)
abnormal osteoclast differentiation J:338833
abnormal osteoclast morphology J:338833
increased osteoclast cell number J:338833
\Rab33bem1Rmr/\Rab33bem1Rmr
(involves: C57BL/6)
abnormal osteoclast morphology J:338833
increased osteoclast cell number J:338833
\Rab39bem1(IMPC)Tcp/Y
(C57BL/6NCrl-Rab39bem1(IMPC)Tcp/Tcp)
decreased spleen weight J:211773
\Rab43tm1.2Kmm/\Rab43tm1.2Kmm
(B6.129S(C)-Rab43tm1.2Kmm)
abnormal dendritic cell antigen presentation J:101977
\Rab44em1Rbrc/\Rab44em1Rbrc
(Not Specified)
abnormal mast cell physiology J:304506
increased susceptibility to type I hypersensitivity reaction J:304506
\Rabgap1tm1b(EUCOMM)Hmgu/\Rabgap1tm1b(EUCOMM)Hmgu
(C57BL/6N-Rabgap1tm1b(EUCOMM)Hmgu/Ieg)
decreased effector memory T-helper cell number J:211773
enlarged spleen J:211773
increased CD8-positive, naive alpha-beta T cell number J:211773
small spleen J:211773
\Rabgef1tm1Glli/\Rabgef1tm1Glli
(either: (involves: 129P2/OlaHsd * 129S/SvEv) or (involves: 129P2/OlaHsd * C57BL/6))
abnormal inflammatory response J:91790
abnormal mast cell morphology J:91790
chronic inflammation J:91790
cutaneous mastocytosis J:91790
increased IgE level J:91790
increased interleukin-6 secretion J:91790
increased tumor necrosis factor secretion J:91790
\Rabgef1tm2Glli/\Rabgef1tm2Glli
(WBB6F1)
increased interleukin-6 secretion J:91790
increased tumor necrosis factor secretion J:91790
\Rabggtagm/\Rabggta+
(C57BL/6J-Rabggtagm)
decreased cytotoxic T cell cytolysis J:67600
\Rabggtagm/\Rabggtagm
(C57BL/6J-Rabggtagm)
decreased cytotoxic T cell cytolysis J:67600
\Rabggtatm1.1(KOMP)Vlcg/\Rabggta+
(C57BL/6N-Rabggtatm1.1(KOMP)Vlcg/Nju)
decreased neutrophil cell number J:211773
\Rabl3xm/\Rabl3em1Btlr
(C57BL/6J-Rabl3xm Rabl3em1Btlr)
decreased leukocyte cell number J:287198
decreased lymphocyte cell number J:287198
spleen hypoplasia J:287198
thymus hypoplasia J:287198
\Rabl3xm/\Rabl3xm
(C57BL/6J-Rabl3xm)
abnormal T cell morphology J:287198
abnormal T cell number J:287198
\Rac1em1(IMPC)Mbp/\Rac1+
(C57BL/6N-Rac1em1(IMPC)Mbp/MbpMmucd)
abnormal lymph node morphology J:211773
abnormal spleen morphology J:211773
enlarged lymph nodes J:211773
enlarged spleen J:211773
\Rac1tm1Djk/\Rac1tm1.1Djk
\Lyz2tm1(cre)Ifo/\Lyz2+

(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)
decreased acute inflammation J:83457
decreased leukocyte cell number J:83457
decreased neutrophil cell number J:83457
impaired neutrophil chemotaxis J:83457
impaired neutrophil recruitment J:83457
\Rac2em1Shl/\Rac2+
(involves: C57BL/6)
abnormal neutrophil morphology J:276213
decreased alpha-beta T cell number J:276213
decreased CD4-positive, alpha-beta T cell number J:276213
decreased CD8-positive, alpha-beta T cell number J:276213
decreased leukocyte cell number J:276213
decreased lymphocyte cell number J:276213
decreased T cell number J:276213
increased neutrophil cell number J:276213
\Rac2m1Btlr/\Rac2+
(C57BL/6J-Rac2m1Btlr)
decreased IgM level J:221478
impaired humoral immune response J:221478
\Rac2m1Btlr/\Rac2m1Btlr
(C57BL/6J-Rac2m1Btlr)
decreased IgM level J:221478
impaired humoral immune response J:221478
\Rac2M2Btlr/\Rac2+
(C57BL/6J-Rac2M2Btlr)
decreased B-1 B cell number J:231801
decreased B-1a cell number J:231801
increased B-1b cell number J:231801
\Rac2M2Btlr/\Rac2M2Btlr
(C57BL/6J-Rac2M2Btlr)
decreased B-1 B cell number J:231801
decreased B-1a cell number J:231801
increased B-1b cell number J:231801
\Rac2m3Btlr/\Rac2+
(C57BL/6J-Rac2m3Btlr)
decreased B-1a cell number J:236680
increased B-1 B cell number J:236680
\Rac2m3Btlr/\Rac2m3Btlr
(C57BL/6J-Rac2m3Btlr)
decreased B cell number J:236680
decreased B-1a cell number J:236680
decreased IgM level J:236680
decreased response to antigen J:236680
increased B-1b cell number J:236680
increased neutrophil cell number J:236680
\Rac2M4Btlr/\Rac2+
(C57BL/6J-Rac2M4Btlr)
abnormal cytotoxic T cell physiology J:255273
decreased alpha-beta T cell number J:255273
decreased CD4-positive, alpha-beta T cell number J:255273
decreased CD8-positive, alpha-beta T cell number J:255273
decreased CD8-positive, naive alpha-beta T cell number J:255273
decreased IgG level J:255273
decreased IgM level J:255273
impaired humoral immune response J:255273
impaired natural killer cell mediated cytotoxicity J:255273
increased alpha-beta T cell number J:255273
increased CD8-positive, alpha-beta T cell number J:255273
increased central memory CD8 positive, alpha-beta T cell number J:255273
increased effector memory CD4-positive, alpha-beta T cell number J:255273
increased effector memory CD8-positive, alpha-beta T cell number J:255273
increased IgM level J:255273
\Rac2M4Btlr/\Rac2M4Btlr
(C57BL/6J-Rac2M4Btlr)
abnormal cytotoxic T cell physiology J:255273
decreased alpha-beta T cell number J:255273
decreased CD4-positive, alpha-beta T cell number J:255273
decreased CD8-positive, alpha-beta T cell number J:255273
decreased CD8-positive, naive alpha-beta T cell number J:255273
decreased IgE level J:255273
decreased IgG level J:255273
decreased IgM level J:255273
impaired humoral immune response J:255273
impaired natural killer cell mediated cytotoxicity J:255273
increased alpha-beta T cell number J:255273
increased CD8-positive, alpha-beta T cell number J:255273
increased central memory CD4-positive, alpha-beta T cell number J:255273
increased central memory CD8 positive, alpha-beta T cell number J:255273
increased effector memory CD4-positive, alpha-beta T cell number J:255273
increased effector memory CD8-positive, alpha-beta T cell number J:255273
\Rac2M5Btlr/\Rac2+
(C57BL/6J-Rac2M5Btlr)
increased CD8-positive, alpha-beta T cell number J:255283
\Rac2M5Btlr/\Rac2M5Btlr
(C57BL/6J-Rac2M5Btlr)
decreased B-1a cell number J:255283
increased B-1b cell number J:255283
increased CD8-positive, alpha-beta T cell number J:255283
\Rac2tm1Mddw/\Rac2tm1Mddw
(involves: 129S/SvEv * C57BL/6)
abnormal granulocyte differentiation J:53362
abnormal neutrophil physiology J:53362
decreased leukocyte cell number J:53362
decreased neutrophil cell number J:53362
decreased T cell proliferation J:119437
impaired neutrophil chemotaxis J:53362
increased leukocyte cell number J:53362
increased neutrophil cell number J:53362
increased susceptibility to bacterial infection J:53362
\Rac2tm1Mddw/\Rac2tm1Mddw
(involves: 129S/SvEv)
abnormal neutrophil physiology J:131305
\Rac2tm1Mddw/\Rac2tm1Mddw
(B6.129S-Rac2tm1Mddw)
abnormal neutrophil physiology J:83457
\Rac2tm1Mddw/\Rac2tm1Mddw
\Tg(TcrAND)53Hed/0

(involves: 129S/SvEv * C57BL/6 * SJL)
abnormal T cell activation J:119437
decreased circulating interleukin-2 level J:119437
decreased T cell proliferation J:119437
\Racgap1tm1Mahi/\Racgap1tm1Mahi
\Tg(Mx1-cre)1Cgn/0

(involves: C57BL/6 * CBA)
abnormal B cell differentiation J:137760
abnormal myelopoiesis J:137760
decreased pro-B cell number J:137760
decreased transitional stage B cell number J:137760
\Rad1tm1.1Jcbs/\Rad1tm1.1Jcbs
(involves: 129P2/OlaHsd * 129S4/SvJaeSor)
immune system phenotype J:169551
\Rad21tm1.1Mmk/\Rad21tm1.1Mmk
\Tg(Cd4-cre)1Cwi/0

(involves: 129 * C57BL/6)
abnormal CD4-positive, alpha beta T cell morphology J:175827
abnormal CD4-positive, alpha-beta T cell physiology J:175827
abnormal T cell differentiation J:175827
decreased CD4-positive, alpha-beta T cell number J:175827
decreased CD8-positive, alpha-beta T cell number J:175827
decreased double-positive T cell number J:175827
\Rad23btm1Gvh/\Rad23btm1Gvh
(involves: 129P2/OlaHsd * C57BL/6)
blepharitis J:74288
conjunctivitis J:74288
\Rad50tm1Flv/\Rad50tm1Flv
(involves: 129S6/SvEvTac * C57BL/6)
abnormal T-helper 2 physiology J:94870
decreased interleukin-4 secretion J:94870
decreased interleukin-5 secretion J:94870
decreased interleukin-13 secretion J:94870
\Rad50tm2.1Flv/\Rad50tm2.1Flv
(B6.129S6-Rad50tm2.1Flv)
decreased interleukin-4 secretion J:196154
decreased interleukin-5 secretion J:196154
decreased interleukin-13 secretion J:196154
\Rad50tm2.1Flv/\Rad50tm2.2Flv
\Tg(Cd4-cre)1Cwi/0

(involves: 129S6/SvEvTac * C57BL/6 * DBA/2)
abnormal CD4-positive, alpha beta T cell morphology J:165055
abnormal T-helper 1 physiology J:165055
abnormal T-helper 2 physiology J:165055
decreased IgE level J:165055
decreased inflammatory response J:165055
decreased interferon-gamma secretion J:165055
decreased interleukin-4 secretion J:165055
decreased interleukin-5 secretion J:165055
decreased interleukin-13 secretion J:165055
immune system phenotype J:165055
\Rad50tm2Jpt/\Rad50tm2Jpt
(either: (involves: 129S6/SvEvTac * 129S7/SvEvBrd) or (involves: 129S7/SvEvBrd * C57BL/6))
abnormal immune system cell morphology J:78820
abnormal immune system organ morphology J:78820
abnormal spleen morphology J:78820
abnormal thymus morphology J:78820
decreased B cell number J:78820
decreased immature B cell number J:78820
decreased pre-B cell number J:78820
decreased T cell number J:78820
increased late pro-B cell number J:78820
increased macrophage cell number J:78820
increased T cell derived lymphoma incidence J:78820
spleen hyperplasia J:78820
\Rad50tm2Jpt/\Rad50tm2Jpt
(involves: 129S7/SvEvBrd * C57BL/6)
decreased double-negative T cell number J:103922
decreased macrophage cell number J:103922
decreased pro-B cell number J:103922
\Rad50tm2Jpt/\Rad50tm2Jpt
\Smc1atm1Mbk/\Smc1atm1Mbk

(involves: 129S1/Sv * 129S7/SvEvBrd * C57BL/6)
abnormal pro-B cell morphology J:103922
decreased double-negative T cell number J:103922
decreased macrophage cell number J:103922
\Rad50tm2Jpt/\Rad50tm2Jpt
\Trp53tm1Tyj/\Trp53tm1Tyj

(involves: 129S2/SvPas * 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6)
immune system phenotype J:78820
increased T cell derived lymphoma incidence J:78820
\Rad50tm3.1Flv/\Rad50tm3.1Flv
(B6.129S6-Rad50tm3.1Flv)
decreased interleukin-4 secretion J:196154
decreased interleukin-5 secretion J:196154
decreased interleukin-13 secretion J:196154
\Rad50tm4.1Flv/\Rad50tm4.1Flv
(B6.129S6-Rad50tm4.1Flv)
decreased interleukin-5 secretion J:196154
decreased interleukin-13 secretion J:196154
increased interleukin-4 secretion J:196154
increased interleukin-5 secretion J:196154
increased interleukin-13 secretion J:196154
\Rad52tm1Aps/\Rad52tm1Aps
(involves: 129P2/OlaHsd * C57BL/6)
immune system phenotype J:50357
\Rad54ltm1Jhjh/\Rad54ltm1Jhjh
(involves: 129P2/OlaHsd * C57BL/6)
immune system phenotype J:39642
\Rad54ltm1Jhjh/\Rad54ltm1Jhjh
(involves: 129P2/OlaHsd)
immune system phenotype J:47993
\Radilem1(IMPC)Tcp/\Radilem1(IMPC)Tcp
(C57BL/6NCrl-Radilem1(IMPC)Tcp/Tcp)
abnormal spleen morphology J:211773
\Raet1dem1Dhr/\Raet1dem1Dhr
\Raet1eem1Dhr/\Raet1eem1Dhr

(involves: C57BL/6)
increased natural killer cell mediated cytotoxicity J:221188
\Raf1tm1.1Bgn/\Raf1+
(involves: 129S6/SvEvTac * C57BL/6NCr)
enlarged spleen J:172034
increased leukocyte cell number J:172034
increased monocyte cell number J:172034
increased neutrophil cell number J:172034
\Rag1/Rag2tm1Mnz/\Rag1/Rag2tm1Mnz
(involves: 129P2/OlaHsd * C57BL/6)
abnormal double-negative T cell morphology J:90487
abnormal double-positive T cell morphology J:90487
abnormal T cell morphology J:90487
decreased T cell number J:90487
\Rag1/Rag2tm1Mnz/\Rag1/Rag2tm1Mnz
(involves: 129P2/OlaHsd * C57BL/6)
abnormal double-negative T cell morphology J:90487
abnormal double-positive T cell morphology J:90487
abnormal T cell morphology J:90487
decreased T cell number J:90487
\Rag1coln/\Rag1coln
(C57BL/6JAnu-Rag1coln/AnuApb)
absent B cells J:104190
absent T cells J:104190
\Rag1em2Mvw/\Rag1em2Mvw
(A/J-Rag1em2Mvw/MvwJ)
absent B cells J:332675
absent T cells J:332675
arrested B cell differentiation J:332675
arrested T cell differentiation J:332675
\Rag1em3Mvw/\Rag1em3Mvw
(129S1/SvImJ-Rag1em3Mvw/MvwJ)
absent B cells J:332675
absent T cells J:332675
arrested B cell differentiation J:332675
arrested T cell differentiation J:332675
\Rag1m1Anu/\Rag1m1Anu
(C57BL/6NCrlAnu-Rag1m1Anu)
decreased lymphocyte cell number J:104190
\Rag1m1Btlr/\Rag1m1Btlr
(C57BL/6J-Rag1m1Btlr)
absent late pro-B cells J:150635
decreased CD4-positive, alpha-beta T cell number J:150635
decreased CD8-positive, alpha-beta T cell number J:150635
\Rag1m2Btlr/\Rag1m2Btlr
(involves: C57BL/6J)
abnormal class switch recombination J:185495
decreased B cell number J:185495
decreased IgG level J:185495
decreased IgM level J:185495
decreased T cell number J:185495
\Rag1m3Btlr/\Rag1m3Btlr
(C57BL/6J-Rag1m3Btlr)
increased central memory CD8 positive, alpha-beta T cell number J:272858
\Rag1m4Btlr/\Rag1m4Btlr
(C57BL/6J-Rag1m4Btlr)
abnormal CD8-positive, alpha-beta T cell differentiation J:272094
abnormal T cell differentiation J:272094
decreased B cell number J:272094
decreased CD8-positive, naive alpha-beta T cell number J:272094
increased alpha-beta T cell number J:272094
increased CD8-positive, alpha-beta T cell number J:272094
increased central memory CD8 positive, alpha-beta T cell number J:272094
\Rag1tm1(cre)Thr/?
\Shcbp1tm1c(EUCOMM)Wtsi/\Shcbp1tm1c(EUCOMM)Wtsi

(involves: C57BL/6N)
immune system phenotype J:212898
\Rag1tm1(cre)Thr/\Rag1tm1(cre)Thr
(Not Specified)
abnormal lymphopoiesis J:86869
absent lymphocyte J:86869
\Rag1tm1(GFP)Imku/?
\Zfp335blt/\Zfp335blt

(involves: C57BL/6 * CBA)
abnormal CD4-positive T cell differentiation J:214793
\Rag1tm1(GFP)Imku/\Rag1tm1(GFP)Imku
(involves: C57BL/6 * CBA)
abnormal immunoglobulin V(D)J recombination J:79416
\Rag1tm1.1Sadu/\Rag1tm1.1Sadu
(involves: BALB/c)
arrested B cell differentiation J:155473
\Rag1tm1.1Sadu/\Rag1tm1.1Sadu
\Trdctm1Mal/\Trdctm1Mal
\Gt(ROSA)26Sortm2(cre/ERT2)Brn/\Gt(ROSA)26Sor+

(involves: 129P2/OlaHsd * BALB/c * C57BL/6)
absent gamma-delta T cells J:187400
decreased gamma-delta T cell number J:187400
increased gamma-delta T cell number J:187400
small thymus J:187400
\Rag1tm1Bal/\Rag1tm1Bal
\Tg(TcraTcrb)1100Mjb/?

(involves: 129S4/SvJae * C57BL/6)
abnormal CD4-positive, alpha beta T cell morphology J:133645
decreased CD4-positive, alpha-beta T cell number J:133645
increased CD8-positive, alpha-beta T cell number J:133645
\Rag1tm1Bal/\Rag1tm1Bal
\Tnfrsf1atm1.1Gkl/\Tnfrsf1atm1.1Gkl

(involves: 129/Sv * C57BL/6)
liver inflammation J:92470
\Rag1tm1Bal/\Rag1tm1Bal
\Vav1tm2Tyb/\Vav1tm2Tyb

(involves: 129S4/SvJae * 129S8/SvEv)
arrested T cell differentiation J:113270
\Rag1tm1Bal/\Rag1tm1Bal
\Vav1tm2Tyb/\Vav1tm2Tyb
\Tg(TcrAND)53Hed/0

(involves: 129S4/SvJae * 129S8/SvEv * C57BL/6 * SJL)
decreased CD4-positive, alpha-beta T cell number J:113270
\Rag1tm1Fwa/\Rag1tm1Fwa
(involves: 129)
abnormal B cell differentiation J:86464
abnormal T cell differentiation J:86464
decreased B cell number J:86464
increased double-negative T cell number J:86464
thymus hypoplasia J:86464
\Rag1tm1Jsek/\Rag1+
(involves: 129S6/SvEvTac)
abnormal B cell differentiation J:146912
abnormal immunoglobulin heavy chain V(D)J recombination J:146912
abnormal T cell differentiation J:146912
abnormal T cell receptor beta chain V(D)J recombination J:146912
decreased double-positive T cell number J:146912
\Rag1tm1Jsek/\Rag1tm1Jsek
(involves: 129S6/SvEvTac)
abnormal immunoglobulin heavy chain V(D)J recombination J:146912
abnormal immunoglobulin level J:146912
abnormal lymphopoiesis J:146912
abnormal T cell receptor beta chain V(D)J recombination J:146912
abnormal T cell receptor V(D)J recombination J:146912
absent immature B cells J:146912
absent mature B cells J:146912
arrested B cell differentiation J:146912
arrested T cell differentiation J:146912
decreased CD4-positive, alpha-beta T cell number J:146912
decreased CD8-positive, alpha-beta T cell number J:146912
decreased double-positive T cell number J:146912
decreased gamma-delta T cell number J:146912
increased double-negative T cell number J:146912
increased pro-B cell number J:146912
thymus hypoplasia J:146912
\Rag1tm1Jsek/\Rag1tm1Jsek
\Trp53tm1Tyj/\Trp53tm1Tyj

(involves: 129S2/SvPas * 129S6/SvEvTac)
increased T cell derived lymphoma incidence J:146912
\Rag1tm1Mom/\Rag1+
\Tg(LPV-TAg1135)11Tvd/0

(involves: 129/Sv * C57BL/6 * DBA/2)
increased T cell derived lymphoma incidence J:47667
\Rag1tm1Mom/\Rag1+
\Tg(LPV-TAg1135)11Tvd/0
\Tg(TcrLCMV)327Sdz/0

(involves: 129S7/SvEvBrd * C57BL/6 * DBA/2)
increased T cell derived lymphoma incidence J:47667
\Rag1tm1Mom/\Rag1tm1Mom
(involves: 129S7/SvEvBrd * CD-1)
abnormal B cell differentiation J:1934
abnormal immunoglobulin V(D)J recombination J:1934
abnormal inguinal lymph node morphology J:1934
abnormal T cell differentiation J:1934
abnormal T cell morphology J:1934
abnormal T cell receptor V(D)J recombination J:1934
absent mature B cells J:1934
decreased IgM level J:1934
spleen hypoplasia J:1934
thymus hypoplasia J:1934
\Rag1tm1Mom/\Rag1tm1Mom
(B6.129S7-Rag1tm1Mom)
decreased IgM level J:78613
decreased immunoglobulin level J:111828
dermatitis J:111828
ear inflammation J:111828
increased eosinophil cell number J:111828
\Rag1tm1Mom/\Rag1tm1Mom
(involves: 129S7/SvEvBrd * C57BL/6 * FVB * NOD)
decreased lymphocyte cell number J:111874
small thymus J:111874
\Rag1tm1Mom/\Rag1tm1Mom
(NOD.129S7(B6)-Rag1tm1Mom)
abnormal level of surface class II molecules J:109843
decreased CD4-positive, alpha-beta T cell number J:109843
decreased CD8-positive, alpha-beta T cell number J:109843
decreased immunoglobulin level J:109843
decreased mature B cell number J:109843
impaired natural killer cell mediated cytotoxicity J:109843
increased granulocyte number J:109843
increased immature B cell number J:109843
increased macrophage cell number J:109843
increased NK cell number J:109843
spleen hypoplasia J:109843
\Rag1tm1Mom/\Rag1tm1Mom
(involves: 129S7/SvEvBrd * C57BL/6)
abnormal lymphatic vessel morphology J:119344
abnormal response to infection J:119344
autoimmune response J:138466
decreased neutrophil cell number J:119344
decreased susceptibility to induced colitis J:194587
\Rag1tm1Mom/\Rag1tm1Mom
(involves: 129S7/SvEvBrd)
abnormal double-negative T cell morphology J:112990
abnormal thymus epithelium morphology J:125864
decreased inflammatory response J:94420
\Rag1tm1Mom/\Rag1tm1Mom
\Prf1tm1Sdz/\Prf1tm1Sdz

(NOD.Cg-Rag1tm1Mom Prf1tm1Sdz/Sz)
abnormal level of surface class II molecules J:109843
abnormal lymph node cortex morphology J:109843
abnormal response to transplant J:109843
abnormal spleen white pulp morphology J:109843
abnormal thymus cortex morphology J:109843
decreased CD4-positive, alpha-beta T cell number J:109843
decreased CD8-positive, alpha-beta T cell number J:109843
decreased immunoglobulin level J:109843
decreased mature B cell number J:109843
impaired natural killer cell mediated cytotoxicity J:109843
increased granulocyte number J:109843
increased immature B cell number J:109843
increased macrophage cell number J:109843
increased NK cell number J:109843
increased T cell derived lymphoma incidence J:109843
spleen hypoplasia J:109843
thymus hypoplasia J:109843
\Rag1tm1Mom/\Rag1tm1Mom
\Rasa3scat/\Rasa3scat

(involves: 129S7/SvEvBrd * BALB/cBy)
abnormal immune system morphology J:186485
\Rag1tm1Mom/\Rag1tm1Mom
\Sh3bp2tm1Bjro/\Sh3bp2tm1Bjro

(involves: 129S4/SvJae * 129S7/SvEvBrd * BALB/cJ * C57BL/6J)
abnormal osteoclast differentiation J:117880
increased circulating tumor necrosis factor level J:117880
increased inflammatory response J:117880
\Rag1tm1Mom/\Rag1tm1Mom
\Slc46a2tm1Moki/\Slc46a2+
\Tg(TcraB12,TcrbB12)1Rest/0

(involves: 129 * C57BL/6)
arrested T cell differentiation J:140121
decreased double-positive T cell number J:140121
increased T cell apoptosis J:140121
thymus hypoplasia J:140121
\Rag1tm1Mom/\Rag1tm1Mom
\Tg(CAG-Lyn*)#Paau/0

(involves: 129S7/SvEvBrd * C57BL/6)
decreased inflammatory response J:151886
\Rag1tm1Mom/\Rag1tm1Mom
\Tg(Lck-Akt1*E40K)E-3Pnt/0

(involves: 129S7/SvEvBrd * C3H/He * C57BL/6)
increased double-positive T cell number J:135903
increased thymocyte number J:135903
\Rag1tm1Mom/\Rag1tm1Mom
\Tg(LPV-TAg1135)11Tvd/0

(involves: 129/Sv * C57BL/6 * DBA/2)
abnormal T cell receptor V(D)J recombination J:47667
increased T cell derived lymphoma incidence J:47667
\Rag1tm1Mom/\Rag1tm1Mom
\Tg(LPV-TAg1135)11Tvd/0
\Tg(TcrLCMV)327Sdz/0

(involves: 129S7/SvEvBrd * C57BL/6 * DBA/2)
increased T cell derived lymphoma incidence J:47667
\Rag1tm1Mom/\Rag1tm1Mom
\Tg(Tcra,Tcrb)HRCAll/0

(B6.Cg-Rag1tm1Mom Tg(Tcra,Tcrb)HRCAll)
abnormal T cell differentiation J:131347
abnormal T cell subpopulation ratio J:131347
absent CD4-positive, alpha-beta T cells J:131347
increased CD8-positive, alpha-beta T cell number J:131347
\Rag1tm1Mom/\Rag1tm1Mom
\Tg(TcraAI4)1Dvs/0
\Tg(TcrbAI4)1Dvs/0

(NOD.Cg-Rag1tm1Mom Tg(TcraAI4)1Dvs Tg(TcrbAI4)1Dvs/Dvs)
increased susceptibility to autoimmune diabetes J:94192
\Rag1tm1Mom/\Rag1tm1Mom
\Tg(TcraBDC12-4.1)10Jos/0
\Tg(TcrbBDC12-4.1)82Gse/0

(involves: 129S7/SvEvBrd * C57BL/6 * FVB * NOD)
decreased CD4-positive, alpha-beta T cell number J:111874
decreased lymphocyte cell number J:111874
decreased thymus weight J:111874
increased double-positive T cell number J:111874
increased susceptibility to autoimmune diabetes J:111874
\Rag1tm1Mom/\Rag1tm1Mom
\Tnftm2Gkl/\Tnf+

(involves: 129S/SvEv * 129S7/SvEvBrd * C57BL/6)
rheumatoid arthritis J:54056
small intestinal inflammation J:54056
\Rag1tm1Mom/\Rag1tm1Mom
\Tnfrsf25tm1Mjo/\Tnfrsf25tm1Mjo

(involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6)
abnormal T cell differentiation J:84536
\Rag1tm1Mom/\Rag1tm1Mom
\Tnfsf14tm1Kpf/\Tnfsf14tm1Kpf

(involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6)
decreased osteoclast cell number J:294030
\Rag1tm1Mom/\Rag1tm1Mom
\Trp53tm1Brd/\Trp53tm1Brd

(involves: 129S7/SvEvBrd * C57BL)
increased T cell derived lymphoma incidence J:141515
\Rag1tm1Mom/\Rag1tm1Mom
\Trp53tm1Brd/\Trp53tm1Brd
\Xrcc5tm1Dbr/\Xrcc5tm1Dbr

(involves: 129S7/SvEvBrd * C57BL)
increased T cell derived lymphoma incidence J:141515
\Rag1tm1Mom/\Rag1tm1Mom
\Tyrobptm1.1Viv/\Tyrobptm1.1Viv

(involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6 * C57BL/10)
abnormal osteoclast physiology J:129304
\Rag1tm1Mom/\Rag1tm1Mom
\Vtcn1tm1Lpc/\Vtcn1tm1Lpc

(involves: 129S/SvEvBrd * 129S7/SvEvBrd * C57BL/6)
abnormal neutrophil differentiation J:145712
decreased susceptibility to bacterial infection J:145712
decreased susceptibility to bacterial infection induced morbidity/mortality J:145712
increased neutrophil cell number J:145712
increased spleen weight J:145712
\Rag2m1Btlr/\Rag2m1Btlr
(C57BL/6J-Rag2m1Btlr)
abnormal humoral immune response J:203045
decreased B cell number J:203045
decreased CD4-positive, alpha-beta T cell number J:203045
decreased IgG level J:203045
decreased IgM level J:203045
\Rag2tm1.1Cgn/\Rag2tm1.1Cgn
(C57BL/6-Rag2tm1.1Cgn)
arrested B cell differentiation J:72214
arrested T cell differentiation J:72214
\Rag2tm1.1Cgn/\Rag2tm1.1Cgn
\Tg(HLA-DR2)#Lfug/0
\Tg(TCROb.1A12)#Lfug/0

(involves: C57BL/6 * DBA/2)
autoimmune response J:134764
CNS inflammation J:134764
\Rag2tm1.1Cgn/\Rag2tm1.1Cgn
\Trex1tm1Tld/\Trex1tm1Tld

(involves: 129P2/OlaHsd * C57BL/6)
immune system phenotype J:181257
\Rag2tm1.1Desi/\Rag2tm1.1Desi
(involves: 129X1/SvJ * C57BL/6)
abnormal immunoglobulin V(D)J recombination J:168974
\Rag2tm1.1Desi/\Rag2tm1.1Desi
\Trp53tm1Tyj/\Trp53tm1Tyj

(involves: 129S2/SvPas * 129X1/SvJ * C57BL/6)
increased T cell derived lymphoma incidence J:168974
\Rag2tm1.1Mss/\Rag2tm1.1Mss
(involves: 129S6/SvEvTac)
abnormal lymphopoiesis J:171970
abnormal pre-B cell morphology J:171970
decreased pre-B cell number J:171970
increased DN3 thymocyte number J:171970
\Rag2tm1.1Mss/\Rag2tm1.1Mss
\Trp53tm1Tyj/\Trp53tm1Tyj

(involves: 129S2/SvPas * 129S6/SvEvTac)
increased T cell derived lymphoma incidence J:170462
\Rag2tm1Avla/\Rag2tm1Avla
(involves: 129/Sv * C57BL/6)
abnormal B cell physiology J:122108
abnormal immune system cell morphology J:122108
abnormal immune system organ morphology J:122108
abnormal lymph node morphology J:122108
abnormal lymphocyte physiology J:122108
abnormal spleen morphology J:122108
abnormal thymus morphology J:122108
absent Hassall's corpuscle J:122108
absent Peyer's patches J:122108
arrested B cell differentiation J:122108
arrested T cell differentiation J:122108
colitis J:122108
decreased double-positive T cell number J:122108
decreased IgA level J:122108
decreased IgG level J:122108
decreased lymphocyte cell number J:122108
decreased NK T cell number J:122108
decreased spleen white pulp amount J:122108
decreased T cell proliferation J:122108
erythroderma J:122108
small cervical lymph nodes J:122108
small inguinal lymph nodes J:122108
small lymph nodes J:122108
small spleen J:122108
\Rag2tm1Cgn/\Rag2tm1.1Cgn
\Tg(Mx1-cre)1Cgn/0

(involves: C57BL/6 * CBA)
abnormal B cell activation J:72214
absent immature B cells J:72214
absent pre-B cells J:72214
arrested B cell differentiation J:72214
arrested T cell differentiation J:72214
decreased follicular B cell number J:72214
decreased marginal zone B cell number J:72214
decreased mature B cell number J:72214
increased plasma cell number J:72214
\Rag2tm1Cgn/\Rag2tm1Cgn
\Xrcc4tm1Fwa/\Xrcc4tm2Fwa
\Tg(Cr2-cre)3Cgn/?

(involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6)
abnormal class switch recombination J:150339
\Rag2tm1Fwa/\Rag2+
\Tg(LPV-TAg1135)11Tvd/0

(involves: 129S/SvEv * C57BL/6 * DBA/2)
increased T cell derived lymphoma incidence J:47667
\Rag2tm1Fwa/\Rag2+
\Trp53tm1Tyj/\Trp53tm1Tyj

(involves: 129S/SvEv * 129S2/SvPas * C57BL/6J)
increased T cell derived lymphoma incidence J:47667
\Rag2tm1Fwa/\Rag2tm1Fwa
(involves: 129S/SvEv * MF1)
abnormal effector T cell morphology J:1935
abnormal immunoglobulin V(D)J recombination J:1935
abnormal spleen morphology J:1935
abnormal T cell receptor V(D)J recombination J:1935
absent mature B cells J:1935
arrested B cell differentiation J:1935
arrested T cell differentiation J:1935
decreased CD4-positive, alpha-beta T cell number J:1935
decreased CD8-positive, alpha-beta T cell number J:1935
decreased double-positive T cell number J:1935
decreased IgM level J:1935
increased granulocyte number J:1935
increased macrophage cell number J:1935
increased natural killer cell mediated cytotoxicity J:1935
increased susceptibility to infection J:1935
lymph node hypoplasia J:1935
spleen hypoplasia J:1935
thymus hypoplasia J:1935
\Rag2tm1Fwa/\Rag2tm1Fwa
(involves: 129S/SvEv)
abnormal chemokine secretion J:140483
abnormal interferon secretion J:140483
abnormal macrophage physiology J:140483
abnormal response to transplant J:116136
abnormal T-helper 1 physiology J:116136
colitis J:116136
decreased susceptibility to bacterial infection induced morbidity/mortality J:140483
decreased thymocyte number J:114561
increased susceptibility to bacterial infection J:140483
lung inflammation J:140483
\Rag2tm1Fwa/\Rag2tm1Fwa
(involves: 129S/SvEv * C57BL/6)
abnormal B cell morphology J:81133
arrested T cell differentiation J:91542
decreased double-negative T cell number J:81133, J:91542
decreased susceptibility to parasitic infection J:64283
decreased susceptibility to type IV hypersensitivity reaction J:165513
increased double-negative T cell number J:91542
\Rag2tm1Fwa/\Rag2tm1Fwa
\Cd47tm1Fpl/\Cd47tm1Fpl
\Il2rgtm1Cgn/Y

(involves: 129P2/OlaHsd * 129S/SvEv * 129S7/SvEvBrd * C57BL/6)
absent peripheral lymph nodes J:203904
decreased CD4-positive, alpha-beta T cell number J:203904
decreased lymphocyte cell number J:203904
decreased susceptibility to graft versus host disease J:203904
increased activated T cell number J:203904
increased CD8-positive, alpha-beta T cell number J:203904
increased susceptibility to Retroviridae infection J:203904
\Rag2tm1Fwa/\Rag2tm1Fwa
\Rr299391tm1.1Fwa/\Rr299391tm1.1Fwa

(involves: 129P2/OlaHsd * 129S/SvEv)
abnormal T cell receptor delta chain V(D)J recombination J:149413
\Rag2tm1Fwa/\Rag2tm1Fwa
\Sos1tm1.1Les/\Sos1tm1.1Les
\Tg(Lck-cre)1Cwi/0

(involves: 129S/SvEv * C57BL/6)
abnormal T cell differentiation J:174536
decreased T cell proliferation J:174536
\Rag2tm1Fwa/\Rag2tm1Fwa
\Tbatatm1Faf/\Tbatatm1Faf

(involves: 129P2/OlaHsd * 129S/SvEv * C57BL/6)
abnormal T cell differentiation J:166065
increased thymocyte number J:166065
\Rag2tm1Fwa/\Rag2tm1Fwa
\Tbx21tm1Glm/\Tbx21tm1Glm

(involves: 129S/SvEv * 129S6/SvEvTac)
colitis J:141481
increased tumor necrosis factor secretion J:141481
large intestinal inflammation J:141481
\Rag2tm1Fwa/\Rag2tm1Fwa
\TcraLn3Jae/\Tcra+
\TcrbLn3Jae/\Tcrb+

(involves: 129S/SvEv * 129S4/SvJae * C57BL/6)
abnormal double-negative T cell morphology J:143006
absent gamma-delta T cells J:143006
decreased CD4-positive, alpha-beta T cell number J:143006
increased CD8-positive, alpha-beta T cell number J:143006
\Rag2tm1Fwa/\Rag2tm1Fwa
\TcrbLn3Jae/\Tcrb+

(involves: 129S/SvEv * 129S4/SvJae * C57BL/6)
abnormal double-negative T cell morphology J:143006
absent gamma-delta T cells J:143006
decreased CD4-positive, alpha-beta T cell number J:143006
increased double-positive T cell number J:143006
\Rag2tm1Fwa/\Rag2tm1Fwa
\Tg(Cd4-NPM/ALK)N1Ingh/0

(involves: 129S/SvEv * C57BL/6 * Swiss Webster)
increased DN3 thymocyte number J:235890
increased T cell derived lymphoma incidence J:235890
increased thymus tumor incidence J:235890
\Rag2tm1Fwa/\Rag2tm1Fwa
\Tg(DO11.10)10Dlo/0

(involves: 129S/SvEv * BALB/c * C3H * C57BL/6)
immune system phenotype J:110446
\Rag2tm1Fwa/\Rag2tm1Fwa
\Tg(EmuSR-tTa)83Bop/0
\Tg(tetO-Nfatct1*)1Grc/0

(involves: 129S/SvEv * C57BL/6J * CBA/J * FVB/N)
abnormal double-positive T cell morphology J:141917
\Rag2tm1Fwa/\Rag2tm1Fwa
\Tg(Igh-Pim1)1Brn/0

(involves: 129S/SvEv * C57BL/6LiA * CBA)
decreased thymocyte number J:114561
\Rag2tm1Fwa/\Rag2tm1Fwa
\Tg(Lck-Akt1*)M-1Pnt/0

(involves: 129S/SvEv * C3H/He * C57BL/6)
absent CD4-positive, alpha-beta T cells J:135903
absent CD8-positive, alpha-beta T cells J:135903
increased double-positive T cell number J:135903
\Rag2tm1Fwa/\Rag2tm1Fwa
\Tg(LPV-TAg1135)11Tvd/0

(involves: 129S/SvEv * C57BL/6 * DBA/2)
increased T cell derived lymphoma incidence J:47667
\Rag2tm1Fwa/\Rag2tm1Fwa
\Tg(Tcra5CC7,Tcrb5CC7)IWep/?
\Themis5AT161/\Themis5AT161

(involves: 129S/SvEv * C57BL/6)
arrested T cell differentiation J:151076
increased double-positive T cell number J:151076
\Rag2tm1Fwa/\Rag2tm1Fwa
\Tg(Tcra51-11.5,Tcrb51-11.5)AR206Ayr/0

(involves: 129S/SvEv * C57BL/6 * C57BL/6NTac * DBA/2)
abnormal CD4-positive T cell differentiation J:125548
abnormal positive T cell selection J:125548
decreased CD4-positive, alpha-beta T cell number J:125548
increased double-positive T cell number J:125548
thymus hyperplasia J:125548
\Rag2tm1Fwa/\Rag2tm1Fwa
\Tg(TcraCN.B1,TcrbCN.B1)SM1Jen/0

(involves: 129S/SvEv * C57BL/6)
increased susceptibility to bacterial infection induced morbidity/mortality J:162539
\Rag2tm1Fwa/\Rag2tm1Fwa
\Tg(TcraH-Y,TcrbH-Y)71Vbo/?

(involves: 129S/SvEv * C57BL/6J * DBA/2J)
abnormal CD8-positive, alpha beta T cell morphology J:125259
abnormal CD8-positive, alpha-beta T cell physiology J:125259
abnormal cytotoxic T cell physiology J:66565
\Rag2tm1Fwa/\Rag2tm1Fwa
\Tg(TcraH-Y,TcrbH-Y)71Vbo/?
\Themis5AT161/\Themis5AT161

(involves: 129S/SvEv * C57BL/6 * DBA/2)
decreased single-positive T cell number J:151076
\Rag2tm1Fwa/\Rag2tm1Fwa
\Tg(TcrHEL3A9)1Mmd/0

(involves: 129S/SvEv * C57BL/6)
abnormal CD4-positive, alpha beta T cell morphology J:78309
abnormal double-positive T cell morphology J:78309
abnormal T cell activation J:78309
abnormal T cell proliferation J:78309
abnormal thymus cell ratio J:78309
decreased CD4-positive, alpha-beta T cell number J:78309
\Rag2tm1Fwa/\Rag2tm1Fwa
\Tg(TcrHEL3A9)1Mmd/0
\Tg(TLK2mHEL)2Ccg/0

(involves: 129S/SvEv * C57BL/6)
abnormal CD4-positive, alpha beta T cell morphology J:78309
abnormal CD4-positive, alpha-beta T cell physiology J:78309
abnormal T cell activation J:78309
abnormal T cell proliferation J:78309
decreased CD4-positive, alpha-beta T cell number J:78309
decreased double-positive T cell number J:78309
thyroid gland inflammation J:78309
\Rag2tm1Fwa/\Rag2tm1Fwa
\Trp53tm1Tyj/\Trp53tm1Tyj

(involves: 129S/SvEv * 129S2/SvPas * C57BL/6J)
increased T cell derived lymphoma incidence J:47667
\Rag2tm1Fwa/\Rag2tm1Fwa
\Wdr1rede/\Wdr1rede

(involves: 129S/SvEv * C57BL/6)
abnormal immune system physiology J:134092
\Rag2tm1Fwa/\Rag2tm1Mao
(involves: 129S/SvEv * C57BL/6)
abnormal B cell number J:81837
abnormal gamma-delta T cell differentiation J:81837
arrested B cell differentiation J:81837
arrested T cell differentiation J:81837
decreased double-negative T cell number J:81837
decreased immature B cell number J:81837
decreased mature B cell number J:81837
decreased pre-B cell number J:81837
increased immature B cell number J:81837
thymus hypoplasia J:81837
\Rag2tm1Libo/\Rag2tm1Libo
(involves: 129S6/SvEvTac * C57BL/6 * FVB/N)
abnormal B cell differentiation J:84563
abnormal B cell physiology J:84563
decreased B cell number J:84563
decreased monocyte cell number J:84563
decreased pre-B cell number J:84563
\Rag2tm1Mao/\Rag2tm1Mao
(involves: 129S6/SvEvTac * C57BL/6)
abnormal immune system cell morphology J:81837
\Rag2tm1Mao/\Rag2tm1Mao
(involves: 129 * C57BL/6)
abnormal B cell number J:81837
abnormal gamma-delta T cell differentiation J:81837
arrested B cell differentiation J:81837
arrested T cell differentiation J:81837
decreased double-negative T cell number J:81837
decreased immature B cell number J:81837
decreased mature B cell number J:81837
decreased pre-B cell number J:81837
increased immature B cell number J:81837
thymus hypoplasia J:81837
\Rag2tm1Tgi/\Rag2tm1Tgi
(involves: 129S1/Sv * 129X1/SvJ)
abnormal Peyer's patch morphology J:113641
arrested B cell differentiation J:113641
arrested T cell differentiation J:113641
decreased B cell number J:113641
decreased double-positive T cell number J:113641
decreased thymocyte number J:113641
\Rag2tm2.1Desi/\Rag2tm2.1Desi
\Trp53tm1Tyj/\Trp53tm1Tyj

(involves: 129S2/SvPas * 129X1/SvJ * C57BL/6)
increased T cell derived lymphoma incidence J:168974
\Ralatm1a(EUCOMM)Wtsi/\Ralatm1a(EUCOMM)Wtsi
(C57BL/6N-Ralatm1a(EUCOMM)Wtsi/Wtsi)
blood in lymph vessels J:239583
\Ralbtm1a(EUCOMM)Wtsi/\Ralbtm1a(EUCOMM)Wtsi
(C57BL/6N-Ralbtm1a(EUCOMM)Wtsi/Wtsi)
increased leukocyte cell number J:211773
\Ramp1tm1.1Tsuj/\Ramp1tm1.1Tsuj
(C.129S2-Ramp1tm1.1Tsuj)
abnormal chemokine secretion J:125974
abnormal cytokine secretion J:125974
increased circulating interferon-gamma level J:125974
increased circulating interleukin-6 level J:125974
increased circulating tumor necrosis factor level J:125974
\Ramp1tm1b(EUCOMM)Wtsi/\Ramp1tm1b(EUCOMM)Wtsi
(C57BL/6N-Ramp1tm1b(EUCOMM)Wtsi/H)
increased basophil cell number J:211773
\Ramp2tm1Kmca/\Ramp2tm1Kmca
(involves: 129S6/SvEvTac * C57BL/6)
abnormal lymph organ development J:130930
abnormal lymphatic vessel morphology J:130930
\Ranbp17em1(IMPC)Tcp/\Ranbp17em1(IMPC)Tcp
(C57BL/6N-Ranbp17em1(IMPC)Tcp/Tcp)
enlarged spleen J:211773
\Rap1atm1Laaq/\Rap1atm1Laaq
(either: B6.Cg-Rap1atm1Laaq or (involves: C57BL/6))
abnormal leukocyte migration J:140471
abnormal macrophage physiology J:140471
abnormal neutrophil physiology J:140471
immune system phenotype J:140471
\Rap1atm1Tze/\Rap1atm1Tze
(involves: 129P2/OlaHsd * C57BL/6)
abnormal leukocyte adhesion J:144145
decreased interleukin-2 secretion J:144145
decreased T cell proliferation J:144145
\Rap1gap2m1Anu/\Rap1gap2m1Anu
(C57BL/6NCrlAnu-Rap1gap2m1Anu)
immune system phenotype J:104190
\Rap1gapem1(IMPC)H/\Rap1gapem1(IMPC)H
(C57BL/6NTac-Rap1gapem1(IMPC)H/H)
decreased lymphocyte cell number J:211773
increased eosinophil cell number J:211773
increased neutrophil cell number J:211773
increased spleen weight J:211773
\Rap1gds1tm1Ytk/\Rap1gds1tm1Ytk
(involves: 129X1/SvJ * C57BL/6 * DBA)
abnormal thymus morphology J:62244
decreased thymocyte number J:62244
increased thymocyte apoptosis J:62244
small thymus J:62244
\Rapgef2tm1.1Hous/\Rapgef2tm1.1Hous
\Tg(Cd4-cre)1Cwi/0

(involves: 129S1/Sv * C57BL/6 * CBA)
immune system phenotype J:165879
\Rapgef2tm1.1Hous/\Rapgef2tm1.1Hous
\Tg(Cdh5-cre)7Mlia/0

(involves: 129S1/Sv * FVB/N)
immune system phenotype J:165879
\Rapgef2tm1.1Hous/\Rapgef2tm1.1Hous
\Tg(Mx1-cre)1Cgn/0

(involves: 129S1/Sv * C57BL/6 * CBA)
immune system phenotype J:165879
\Rapgef2tm1.1Hous/\Rapgef2tm1.1Hous
\Tg(VAV1-cre)1Graf/0

(involves: 129S1/Sv)
immune system phenotype J:165879
\Rapgef3tm1Skc/\Rapgef3tm1Skc
(Not Specified)
insulitis J:201171
\Rapgef6tm1.1Tkat/\Rapgef6tm1.1Tkat
(involves: 129P2/OlaHsd * C57BL/6)
enlarged spleen J:126164
\Rapgef6tm1.1Tkat/\Rapgef6tm1.1Tkat
(involves: 129P2/OlaHsd)
enlarged spleen J:218581
\Raph1tm1.2Fbg/\Raph1tm1.2Fbg
(involves: 129S4/SvJae * C57BL/6)
abnormal cytokine level J:238262
increased inflammatory response J:238262
increased susceptibility to bacterial infection J:238262
large intestinal inflammation J:238262
\Raratm1.1Ybe/\Raratm1.1Ybe
(involves: C57BL/6N)
abnormal lymphopoiesis J:207485
\Raratm1Ipc/\Raratm1Ipc
\Rarbtm1Ipc/\Rarbtm1Ipc

(involves: 129S2/SvPas)
persistent cervical thymus J:21034
\Raratm1Ipc/\Raratm1Ipc
\Rarbtm1Mma/\Rarbtm1Mma

(involves: 129S2/SvPas * C57BL/6)
abnormal thymus morphology J:43344
persistent cervical thymus J:43344
\Raratm1Ipc/\Raratm1Ipc
\Rargtm1Ipc/\Rargtm1Ipc

(involves: 129S2/SvPas)
persistent cervical thymus J:21034
\Raratm1Ipc/\Raratm1Ipc
\Rargtm2Ipc/\Rargtm2Ipc

(involves: 129S2/SvPas)
ectopic thymus J:42773
\Rarres1tm1.2Mhl/\Rarres1tm1.2Mhl
(involves: 129S1/SvImJ * C57BL/6 * FVB/N * NIH Black Swiss)
abnormal B cell activation J:324270
abnormal B cell differentiation J:324270
abnormal B cell physiology J:324270
abnormal plasma cell differentiation J:324270
decreased B cell apoptosis J:324270
decreased spleen germinal center number J:324270
increased B cell proliferation J:324270
\Rarres2tm1Yktk/\Rarres2tm1Yktk
(B6.Cg-Rarres2tm1Yktk)
decreased macrophage cell number J:206120
\Rasa1tm1Wid/\Rasa1tm1Wid
(involves: 129S/SvEv * 129S6/SvEvTac * C57BL/6N)
increased susceptibility to induced colitis J:189241
\Rasa3hlb381/\Rasa3hlb381
(C57BL/6J-Rasa3hlb381/J)
decreased leukocyte cell number J:301035, J:221899
enlarged spleen J:221899
increased spleen weight J:301035
\Rasa3scat/\Rasa3scat
(involves: BALB/cBy)
abnormal spleen morphology J:186485
decreased B cell number J:186485
decreased CD4-positive, alpha-beta T cell number J:186485
decreased CD8-positive, alpha-beta T cell number J:186485
decreased leukocyte cell number J:186485
decreased T cell number J:186485
enlarged spleen J:186485
increased spleen red pulp amount J:186485
pale spleen J:186485
\Rasa3scat/\Rasa3scat
(involves: BALB/cBy * BALB/cByJ)
decreased leukocyte cell number J:301035
increased spleen weight J:301035
\Rasa3tm1.1Llp/\Rasa3tm1.1Llp
\Tg(Mx1-cre)1Cgn/?

(involves: 129S1/SvImJ * C57BL/6J * CBA/J)
bone marrow failure J:301035
decreased leukocyte cell number J:301035
increased spleen weight J:301035
\Rasa4tm1Ywh/\Rasa4tm1Ywh
(B6.129S6-Rasa4tm1Ywh)
impaired macrophage phagocytosis J:100455
increased susceptibility to bacterial infection J:100455
\Rasal3tm1.1Fuj/\Rasal3tm1.1Fuj
(involves: C57BL/6N * C57BL/6NCrlj * CBA/JNCrlj)
decreased circulating interferon-gamma level J:229641
decreased circulating interleukin-4 level J:229641
decreased interferon-gamma secretion J:229641
decreased interleukin-4 secretion J:229641
decreased NK T cell number J:229641
increased granulocyte number J:229641
\Rasal3tm1b(EUCOMM)Hmgu/\Rasal3tm1b(EUCOMM)Hmgu
(C57BL/6N-Rasal3tm1b(EUCOMM)Hmgu/Orl)
decreased lymphocyte cell number J:211773
increased eosinophil cell number J:211773
\Rasgrf2tm1Esn/\Rasgrf2tm1Esn
(involves: 129S1/Sv * C57BL/10 * C57BR/cd)
decreased interleukin-2 secretion J:128985
decreased tumor necrosis factor secretion J:128985
\Rasgrf2tm1Esn/\Rasgrf2tm1Esn
\Vav1tm1Tyb/\Vav1tm1Tyb

(involves: 129S1/Sv * 129S2/SvPas * C57BL/10 * C57BR/cd)
abnormal T cell physiology J:128985
decreased interleukin-2 secretion J:128985
decreased T cell proliferation J:128985
decreased tumor necrosis factor secretion J:128985
\Rasgrp1lag/\Rasgrp1lag
(involves: 129 * C57BL/6)
abnormal lymph node morphology J:85189
abnormal positive T cell selection J:85189
abnormal T cell physiology J:85189
decreased T cell proliferation J:85189
enlarged lymph nodes J:85189
enlarged spleen J:85189
glomerulonephritis J:85189
increased B cell number J:85189
increased IgG level J:85189
increased susceptibility to systemic lupus erythematosus J:85189
increased T cell number J:85189
\Rasgrp1m1Anu/\Rasgrp1+
(involves: C57BL/6JSfdAnu * CBA/J)
increased anti-nuclear antigen antibody level J:207898
\Rasgrp1m1Anu/\Rasgrp1m1Anu
(C57BL/6JSfdAnu-Rasgrp1m1Anu)
abnormal T cell differentiation J:104190
autoimmune response J:104190
\Rasgrp1m1Anu/\Rasgrp1m1Anu
(involves: C57BL/6JSfdAnu * CBA/J)
abnormal CD4-positive, alpha beta T cell morphology J:207898
immune system phenotype J:207898
increased anti-nuclear antigen antibody level J:207898
increased effector memory CD4-positive, alpha-beta T cell number J:207898
\Rasgrp1m1Btlr/\Rasgrp1m1Btlr
(C57BL/6J-Rasgrp1m1Btlr)
abnormal humoral immune response J:265163
decreased CD4-positive, CD25-positive, alpha-beta regulatory T cell number J:265163
decreased CD8-positive, naive alpha-beta T cell number J:265163
decreased IgM level J:265163
increased CD8-positive, alpha-beta memory T cell number J:265163
increased effector memory CD4-positive, alpha-beta T cell number J:265163
increased IgA level J:265163
increased IgE level J:265163
increased IgM level J:265163
increased NK cell number J:265163
\Rasgrp1m2Anu/\Rasgrp1m2Anu
(C57BL/6NCrlAnu-Rasgrp1m2Anu)
immune system phenotype J:104190
\Rasgrp1m2Btlr/\Rasgrp1m2Btlr
(C57BL/6J-Rasgrp1m2Btlr)
decreased CD4-positive, alpha-beta T cell number J:265163
decreased CD8-positive, alpha-beta T cell number J:265163
decreased CD8-positive, naive alpha-beta T cell number J:265163
decreased single-positive T cell number J:265163
decreased T cell number J:265163
increased central memory CD4-positive, alpha-beta T cell number J:265163
increased central memory CD8 positive, alpha-beta T cell number J:265163
increased effector memory CD4-positive, alpha-beta T cell number J:265163
increased effector memory CD8-positive, alpha-beta T cell number J:265163
increased NK cell number J:265163
\Rasgrp1m3Btlr/\Rasgrp1m3Btlr
(C57BL/6J-Rasgrp1m3Btlr)
decreased CD4-positive, alpha-beta T cell number J:265255
decreased CD8-positive, alpha-beta T cell number J:265255
decreased CD8-positive, naive alpha-beta T cell number J:265255
decreased single-positive T cell number J:265255
decreased T cell number J:265255
increased B cell number J:265255
increased B-1b cell number J:265255
increased central memory CD8 positive, alpha-beta T cell number J:265255
increased effector memory CD4-positive, alpha-beta T cell number J:265255
increased effector memory CD8-positive, alpha-beta T cell number J:265255
increased IgM level J:265255
increased neutrophil cell number J:265255
increased NK cell number J:265255
\Rasgrp1M4Btlr/\Rasgrp1M4Btlr
(C57BL/6J-Rasgrp1M4Btlr)
abnormal T cell morphology J:267490
\Rasgrp1m5Btlr/\Rasgrp1m5Btlr
(C57BL/6J-Rasgrp1m5Btlr)
increased NK cell number J:272846
\Rasgrp1tm1.1Wz/\Rasgrp1tm1.1Wz
(B6.Cg-Rasgrp1tm1.1Wz)
abnormal CD4-positive T cell differentiation J:225109
abnormal CD8-positive, alpha-beta T cell differentiation J:225109
abnormal immune system cell morphology J:225109
abnormal immune system organ morphology J:225109
abnormal immune system physiology J:225109
abnormal immunoglobulin level J:225109
abnormal T cell differentiation J:225109
decreased single-positive T cell number J:225109
decreased T cell proliferation J:225109
enlarged spleen J:225109
immune system phenotype J:225109
increased autoantibody level J:225109
increased CD4-positive, alpha-beta memory T cell number J:225109
increased IgE level J:225109
increased IgG1 level J:225109
increased single-positive T cell number J:225109
increased spleen weight J:225109
\Rasgrp1tm1.1Wz/\Rasgrp1tm1.1Wz
\Tg(TcraH-Y,TcrbH-Y)71Vbo/?

(involves: C57BL/6J * DBA/2J)
decreased single-positive T cell number J:225109
increased double-positive T cell number J:225109
\Rasgrp1tm1.1Wz/\Rasgrp1tm1.1Wz
\Tg(TcraTcrb)425Cbn/?

(involves: C57BL/6 * BALB/c)
abnormal CD4-positive T cell differentiation J:225109
\Rasgrp1tm1Jstn/\Rasgrp1tm1Jstn
(involves: 129P3/J * C57BL/6J)
abnormal humoral immune response J:108677
decreased B cell number J:108677
decreased thymocyte number J:108677
enlarged spleen J:108677
increased immunoglobulin level J:108677
increased plasma cell number J:108677
\Rasgrp1tm1Jstn/\Rasgrp1tm1Jstn
(involves: 129P3/J)
abnormal CD4-positive, alpha beta T cell morphology J:207898
abnormal double-positive T cell morphology J:207898
decreased CD4-positive, alpha-beta T cell number J:207898
decreased CD8-positive, alpha-beta T cell number J:207898
\Rasgrp1tm1Jstn/\Rasgrp1tm1Jstn
\Rasgrp3tm1Jstn/\Rasgrp3tm1Jstn

(involves: 129P3/J * C57BL/6J)
abnormal humoral immune response J:108677
decreased B cell number J:108677
decreased plasma cell number J:108677
\Rasgrp2tm1Amg/\Rasgrp2tm1Amg
(Not Specified)
abnormal neutrophil physiology J:122618
impaired neutrophil recruitment J:122618
\Rasgrp3em1(IMPC)Wtsi/\Rasgrp3em1(IMPC)Wtsi
(C57BL/6N-Rasgrp3em1(IMPC)Wtsi/Wtsi)
increased CD8-positive, naive alpha-beta T cell number J:211773
increased effector memory T-helper cell number J:211773
\Rasgrp3tm1Jstn/\Rasgrp3tm1Jstn
(involves: 129P3/J * C57BL/6J)
abnormal humoral immune response J:108677
decreased B cell number J:108677
decreased IgG1 level J:108677
decreased IgG2a level J:108677
decreased IgG level J:108677
\Rasgrp4tm1(cre)Rls/\Rasgrp4tm1(cre)Rls
(C57BL/6-Rasgrp4tm1(cre)Rls)
decreased susceptibility to induced arthritis J:186519
decreased susceptibility to induced colitis J:186519
\Rasgrp4tm1a(KOMP)Lste/\Rasgrp4tm1a(KOMP)Lste
(involves: C57BL/6)
abnormal neutrophil physiology J:186412
impaired neutrophil chemotaxis J:186412
\Rasgrp4tm1d(KOMP)Lste/\Rasgrp4tm1d(KOMP)Lste
(involves: 129S4/SvJaeSor * BALB/cJ * C57BL/6)
abnormal neutrophil physiology J:186412
impaired neutrophil chemotaxis J:186412
\Rassf1tm1.2Brd/\Rassf1tm1.2Brd
(involves: 129S7/SvEvBrd * C57BL/6)
immune system phenotype J:101369
\Rassf2tm1Dlim/\Rassf2tm1Dlim
(B6.Cg-Rassf2tm1Dlim)
abnormal myeloid leukocyte morphology J:181952
abnormal osteoclast differentiation J:181952
abnormal spleen red pulp morphology J:181952
abnormal thymus epithelium morphology J:181952
decreased B cell number J:181952
decreased CD4-positive, alpha-beta T cell number J:181952
decreased CD8-positive, alpha-beta T cell number J:181952
decreased leukocyte cell number J:181952
decreased osteoclast cell number J:181952
decreased spleen weight J:181952
decreased T cell number J:181952
decreased thymus weight J:181952
spleen hypoplasia J:181952
thymus hypoplasia J:181952
\Rassf5tm1Kina/\Rassf5+
(involves: C57BL/6 * CBA * ICR)
lymphoid hypoplasia J:92670
\Rassf5tm1Kina/\Rassf5tm1Kina
(involves: C57BL/6 * CBA * ICR)
abnormal B cell differentiation J:92670
abnormal dendritic cell physiology J:92670
abnormal leukocyte migration J:92670
abnormal lymph node cell ratio J:92670
abnormal lymph node cortex morphology J:92670
abnormal spleen red pulp morphology J:92670
abnormal thymus cell ratio J:92670
abnormal thymus corticomedullary boundary morphology J:92670
abnormal thymus medulla morphology J:92670
decreased thymocyte number J:92670
spleen hypoplasia J:92670
\Rassf5tm1Kina/\Rassf5tm1Kina
(B6.Cg-Rassf5tm1Kina)
abnormal lymphocyte physiology J:168749
enlarged lymph nodes J:168749
enlarged spleen J:168749
glomerulonephritis J:168749
increased anti-double stranded DNA antibody level J:168749
increased B cell number J:168749
increased B cell proliferation J:168749
increased IgG level J:168749
increased memory T cell number J:168749
increased plasma cell number J:168749
increased T cell number J:168749
increased T cell proliferation J:168749
\Raver1em1(IMPC)Hmgu/\Raver1em1(IMPC)Hmgu
(C57BL/6NCrl-Raver1em1(IMPC)Hmgu/Ieg)
increased spleen weight J:211773
\Rb1tm1Dwg/\Rb1tm1Dwg
(involves: 129/Sv * C57BL/6)
abnormal macrophage morphology J:105548
\Rb1tm1Mlh/\Rb1tm1Mlh
(either: 129P2/OlaHsd-Rb1tm1Mlh or (involves: 129P2/OlaHsd * BALB/c) or (involves: 129P2/OlaHsd * FVB/N))
abnormal myelopoiesis J:2498
\Rb1tm1Tyj/\Rb1tm1Tyj
(involves: 129S2/SvPas)
abnormal macrophage differentiation J:105548
\Rb1tm2Mlh/\Rb1tm2Mlh
(either: 129P2/OlaHsd-Rb1tm2Mlh or (involves: 129P2/OlaHsd * BALB/c) or (involves: 129P2/OlaHsd * FVB/N))
abnormal myelopoiesis J:2498
\Rb1cc1tm1.1Guan/\Rb1cc1tm1.1Guan
\Lyz2tm1(cre)Ifo/\Lyz2+

(involves: 129P2/OlaHsd)
immune system phenotype J:235399
\Rb1cc1tm1.1Guan/\Rb1cc1tm1.1Guan
\Tg(BEST1-cre)1Jdun/0

(involves: 129P2/OlaHsd * C57BL/6)
microgliosis J:282249
\Rb1cc1tm1.1Guan/\Rb1cc1tm1.1Guan
\Tg(Tek-cre)12Flv/0

(B6.Cg-Rb1cc1tm1.1Guan Tg(Tek-cre)12Flv)
abnormal myelopoiesis J:167258
increased neutrophil cell number J:167258
\Rbbp4em1(IMPC)Mbp/\Rbbp4+
(C57BL/6NCrl-Rbbp4em1(IMPC)Mbp/Mmucd)
abnormal spleen morphology J:211773
enlarged spleen J:211773
\Rbbp8tm1Whl/\Rbbp8tm1.1Thl
\Cd19tm1(cre)Cgn/\Cd19+

(involves: 129P2/OlaHsd * 129S4/SvJaeSor)
immune system phenotype J:194603
\Rbl1tm1Mru/\Rbl1tm1Mru
(involves: 129S4/SvJae * BALB/cJ)
abnormal inflammatory response J:51060
abnormal spleen red pulp morphology J:51060
\Rbm3tm1Ttg/\Rbm3tm1Ttg
(involves: 129P2/OlaHsd)
immune system phenotype J:174947
\Rbm4tm1a(EUCOMM)Hmgu/\Rbm4+
(C57BL/6N-Rbm4tm1a(EUCOMM)Hmgu/Cnrm)
decreased IgG2b level J:165965
\Rbm7em1Aki/\Rbm7em1Aki
(B6.Cg-Rbm7em1Aki)
decreased monocyte cell number J:288329
\Rbm10em1(IMPC)Mbp/Y
(C57BL/6NCrl-Rbm10em1(IMPC)Mbp/MbpMmucd)
enlarged lymph nodes J:211773
\Rbm10em1(IMPC)Mbp/\Rbm10+
(C57BL/6NCrl-Rbm10em1(IMPC)Mbp/MbpMmucd)
abnormal spleen morphology J:211773
enlarged spleen J:211773
\Rbm15tm1Dgg/\Rbm15tm1.1Dgg
\Tg(Mx1-cre)1Cgn/0

(involves: 129/Sv * C57BL/6 * CBA * FVB/N)
abnormal B cell differentiation J:120321
decreased B cell number J:120321
decreased pre-B cell number J:120321
increased spleen red pulp amount J:120321
\Rbm15tm1Swm/\Rbm15tm1Swm
\Tg(Mx1-cre)1Cgn/0

(involves: 129X1/SvJ * C57BL/6 * CBA)
decreased leukocyte cell number J:152262
decreased lymphocyte cell number J:152262
decreased neutrophil cell number J:152262
increased spleen red pulp amount J:152262
\Rbm20em1(IMPC)Mbp/\Rbm20em1(IMPC)Mbp
(C57BL/6N-Rbm20em1(IMPC)Mbp/MbpMmucd)
small spleen J:211773
\Rbm22em1(IMPC)Mbp/\Rbm22+
(C57BL/6NCrl-Rbm22em1(IMPC)Mbp/Mmucd)
abnormal lymph node morphology J:211773
abnormal spleen morphology J:211773
enlarged lymph nodes J:211773
\Rbm38tm1.1Xch/\Rbm38tm1.1Xch
(involves: C57BL/6 * FVB/N)
enlarged spleen J:216929
increased spleen white pulp amount J:216929
\Rbm38tm1.1Xch/\Rbm38tm1.1Xch
\Trp53tm1Tyj/\Trp53+

(involves: 129S2/SvPas * C57BL/6 * FVB/N)
abnormal spleen B cell follicle morphology J:216929
\Rbm43em1Brsp/\Rbm43em1Brsp
\Tg(Adipoq-cre)1Evdr/0

(B6.Cg-Rbm43em1Brsp Tg(Adipoq-cre)1Evdr)
abnormal innate immunity J:363192
decreased inflammatory response J:363192
\Rbp1tm1Ipc/\Rbp1tm1Ipc
(involves: 129S2/SvPas)
increased granulocyte number J:67762
increased neutrophil cell number J:67762
\Rbpjtm1Hon/\Rbpjtm1Hon
(involves: 129P2/OlaHsd * C57BL/6)
immune system phenotype J:76240
\Rbpjtm1Hon/\Rbpjtm1Hon
\Tg(Cd4-cre)1Cwi/?

(involves: 129P2/OlaHsd * C57BL/6 * DBA)
abnormal T-helper 2 cell differentiation J:90018
\Rbpjtm1Hon/\Rbpjtm1Hon
\Tg(Itgax-cre)1-1Reiz/0

(involves: 129P2/OlaHsd * C57BL/6 * CBA)
abnormal cytokine secretion J:125869
decreased dendritic cell number J:125869
\Rbpjtm1Hon/\Rbpjtm1Hon
\Tg(Lck-cre)19Hhan/0

(involves: 129P2/OlaHsd * C57BL/6 * DBA)
abnormal CD4-positive helper T cell morphology J:168475
abnormal immune system physiology J:168475
abnormal regulatory T cell physiology J:168475
immune system phenotype J:168475
increased macrophage cell number J:168475
increased single-positive T cell number J:168475
increased splenocyte number J:168475
increased T cell number J:168475
increased T cell proliferation J:168475
\Rbpjtm1Hon/\Rbpjtm1Hon
\Tg(Mx1-cre)1Cgn/0

(involves: 129P2/OlaHsd * C57BL/6 * CBA)
abnormal B cell differentiation J:99747
abnormal lymphopoiesis J:99747
arrested T cell differentiation J:125869, J:99747
decreased dendritic cell number J:125869
decreased double-positive T cell number J:99747
decreased follicular dendritic cell number J:125869
decreased marginal zone B cell number J:76240, J:99747
decreased single-positive T cell number J:99747
decreased thymocyte number J:99747
increased B cell number J:125869, J:99747
increased double-negative T cell number J:99747
increased follicular B cell number J:99747
increased macrophage cell number J:125869
increased monocyte cell number J:125869
increased plasmacytoid dendritic cell number J:125869
small thymus J:99747
\Rbpjtm1Kyo/\Rbpj+
(involves: 129S2/SvPas * CD-1)
aortic valve inflammation J:187551
\Rbpjtm1Kyo/\Rbpjtm1Kyo
(involves: 129S2/SvPas)
abnormal humoral immune response J:123631
abnormal response to infection J:123631
decreased interleukin-4 secretion J:123631
\Rc3h1Gt(CC0753)Wtsi/\Rc3h1Gt(CC0753)Wtsi
(B6.129P2-Rc3h1Gt(CC0753)Wtsi)
chronic liver inflammation J:199407
ileum inflammation J:199407
intestinal inflammation J:199407
\Rc3h1san/\Rc3h1+
(involves: C57BL/6JSfdAnu)
abnormal lymph node germinal center morphology J:189087
abnormal lymph node morphology J:189087
abnormal T follicular helper cell physiology J:189087
enlarged lymph nodes J:189087
increased IgG level J:189087
increased spleen weight J:189087
increased T cell derived lymphoma incidence J:189087
increased T follicular helper cell number J:189087
\Rc3h1san/\Rc3h1san
(either: C57BL/6JSfdAnu-Rc3h1san/Anu or (involves: C57BL/6JSfdAnu * CBA/Ca))
abnormal T cell differentiation J:98938
enlarged lymph nodes J:98938
glomerulonephritis J:98938
increased anti-double stranded DNA antibody level J:98938
increased anti-nuclear antigen antibody level J:98938
liver inflammation J:98938
\Rc3h1san/\Rc3h1san
(involves: C57BL/6JSfdAnu)
abnormal effector T cell morphology J:199407
abnormal intraepithelial T cell number J:199407
cecum inflammation J:199407
chronic liver inflammation J:199407
colitis J:199407
enlarged spleen J:199407
granulomatous inflammation J:199407
ileum inflammation J:199407
increased activated T cell number J:199407
increased CD4-positive, alpha-beta T cell number J:199407
increased circulating tumor necrosis factor level J:196137
increased T cell proliferation J:199407
lymphoid hyperplasia J:199407
small intestinal inflammation J:199407
\Rc3h1san/\Rc3h1san
\Rc3h2tm1.2Cgv/\Rc3h2tm1.2Cgv

(involves: C57BL/6 * C57BL/6JSfdAnu)
increased circulating tumor necrosis factor level J:196137
increased inflammatory response J:196137
increased susceptibility to bacterial infection J:196137
increased T follicular helper cell number J:196137
kidney inflammation J:196137
\Rc3h1tm1.1Mass/\Rc3h1tm1.1Mass
\Cd19tm1(cre)Cgn/\Cd19+

(involves: 129P2/OlaHsd * C57BL/6 * NZB * SJL)
abnormal effector T cell morphology J:177784
enlarged spleen J:177784
increased B cell number J:177784
increased eosinophil cell number J:177784
increased regulatory T cell number J:177784
increased spleen weight J:177784
\Rc3h1tm1.1Mass/\Rc3h1tm1.1Mass
\Commd10Tg(Vav1-icre)A2Kio/\Commd10+

(involves: C57BL/6 * C57BL/10 * CBA/Ca * NZB * SJL)
abnormal B cell differentiation J:177784
abnormal effector T cell morphology J:177784
abnormal germinal center B cell physiology J:177784
abnormal spleen B cell follicle morphology J:177784
decreased B cell number J:177784
decreased IgA level J:177784
decreased IgG1 level J:177784
decreased IgG3 level J:177784
decreased immature B cell number J:177784
enlarged spleen J:177784
immune system phenotype J:177784
increased eosinophil cell number J:177784
increased IgG2b level J:177784
increased macrophage cell number J:177784
increased regulatory T cell number J:177784
increased spleen weight J:177784
increased splenocyte number J:177784
spleen hyperplasia J:177784
\Rc3h1tm1.1Mass/\Rc3h1tm1.1Mass
\Rc3h2tm1c(KOMP)Wtsi/\Rc3h2tm1c(KOMP)Wtsi
\Tg(Cd4-cre)1Cwi/?

(involves: C57BL/6N * DBA/2)
abnormal B cell number J:196136
abnormal immune system cell morphology J:196136
abnormal immune system organ morphology J:196136
abnormal immune system physiology J:196136
abnormal spleen B cell follicle morphology J:196136
abnormal spleen morphology J:196136
abnormal spleen periarteriolar lymphoid sheath morphology J:196136
decreased CD4-positive, alpha-beta T cell number J:196136
decreased CD8-positive, alpha-beta T cell number J:196136
decreased T cell number J:196136
enlarged lymph nodes J:196136
enlarged spleen J:196136
increased germinal center B cell number J:196136
increased T cell proliferation J:196136
increased T follicular helper cell number J:196136
\Rc3h1tm1.1Mass/\Rc3h1tm1.1Mass
\Tg(Cd4-cre)1Cwi/0

(involves: C57BL/6 * DBA/2 * NZB * SJL)
immune system phenotype J:177784
increased CD8-positive, alpha-beta T cell number J:177784
increased eosinophil cell number J:177784
increased macrophage cell number J:177784
\Rc3h1tm1.2Cgv/\Rc3h1san
(involves: C57BL/6 * C57BL/6JSfdAnu)
increased CD4-positive, alpha-beta T cell number J:196137
increased T follicular helper cell number J:196137
\Rc3h1tm1.2Mass/\Rc3h1tm1.2Mass
(involves: C57BL/6 * CBA * NZB * SJL)
abnormal thymus development J:177784
\Rc3h1tm1.2Mass/\Rc3h1tm1.2Mass
(involves: C57BL/6 * CBA * CD-1 * NZB * SJL)
abnormal effector T cell morphology J:177784
enlarged spleen J:177784
immune system phenotype J:177784
increased spleen weight J:177784
\Rc3h2tm1.2Cgv/\Rc3h2tm1.2Cgv
(involves: C57BL/6)
immune system phenotype J:196137
increased macrophage cytokine production J:196137
increased tumor necrosis factor secretion J:196137
\Rc3h2tm1a(KOMP)Wtsi/\Rc3h2tm1a(KOMP)Wtsi
(involves: C57BL/6N * NMRI)
immune system phenotype J:196136
\Rc3h2tm1c(KOMP)Wtsi/\Rc3h2tm1c(KOMP)Wtsi
\Tg(Cd4-cre)1Cwi/?

(involves: C57BL/6N * DBA/2)
immune system phenotype J:196136
\Rcan1tm1Fmc/\Rcan1tm1Fmc
(involves: 129S4/SvJae)
abnormal T cell apoptosis J:85148
abnormal T-helper 1 physiology J:85148
decreased IgG2a level J:85148
decreased interferon-gamma secretion J:85148
decreased T cell proliferation J:85148
increased susceptibility to endotoxin shock J:152536
\Rcan1tm1Jmol/\Rcan1tm1Jmol
\Rcan2tm1Jmol/\Rcan2tm1Jmol

(involves: 129 * C57BL/6)
abnormal CD4-positive, alpha-beta T cell physiology J:109586
abnormal cytokine secretion J:109586
decreased T cell proliferation J:109586
\Rcan1tm1Jmol/\Rcan1tm1Jmol
\Rcan2tm1Jmol/\Rcan2tm1Jmol
\Ppp3cbtm1Jmk/\Ppp3cbtm1Jmk

(involves: 129S6/SvEvTac * C57BL/6)
abnormal CD4-positive, alpha beta T cell morphology J:109586
abnormal CD4-positive, alpha-beta T cell physiology J:109586
abnormal CD8-positive, alpha beta T cell morphology J:109586
abnormal cytokine secretion J:109586
decreased T cell proliferation J:109586
\Rcbtb2tm1.1Xyw/\Rcbtb2+
(involves: C57BL/6 * CBA)
enlarged mesenteric lymph nodes J:282928
enlarged spleen J:282928
\Rcbtb2tm1.1Xyw/\Rcbtb2tm1.1Xyw
(involves: C57BL/6 * CBA)
abnormal splenocyte physiology J:282928
enlarged mesenteric lymph nodes J:282928
enlarged spleen J:282928
\Rcc1ltm1a(EUCOMM)Hmgu/\Rcc1l+
(Not Specified)
decreased IgG1 level J:165965
\Rdh7tm1c(KOMP)Wtsi/\Rdh7tm1c(KOMP)Wtsi
\Tg(RARE-Hspa1b/lacZ)12Jrt/0
\Tg(Vil1-cre)997Gum/0

(involves: C57BL/6J * C57BL/6N * CD-1 * SJL)
decreased lymphocyte cell number J:279231
decreased susceptibility to bacterial infection J:279231
immune system phenotype J:279231
\Rdns/\Rdns+
(C57BL/6J-Rdns/GrsrJ)
increased susceptibility to otitis media J:223062
\Rdurem1Jiche/\Rdurem1Jiche
(Not Specified)
increased circulating interleukin-1 level J:340209
increased circulating interleukin-6 level J:340209
increased susceptibility to viral infection J:340209
increased susceptibility to viral infection induced morbidity/mortality J:340209
\Recql4tm1Abe/\Recql4tm1Abe
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
abnormal thymus corticomedullary boundary morphology J:85574
decreased spleen white pulp amount J:85574
small thymus J:85574
\Reep3em1(IMPC)Tcp/\Reep3em1(IMPC)Tcp
(C57BL/6NCrl-Reep3em1(IMPC)Tcp/Cmmr)
decreased leukocyte cell number J:211773
decreased lymphocyte cell number J:211773
\Reg3gtm1.1Lvh/\Reg3gtm1.1Lvh
(B6.129-Reg3gtm1.1Lvh)
immune system phenotype J:177506
increased IgA level J:177506
increased T-helper 1 cell number J:177506
\Reg3gtm1a(KOMP)Wtsi/\Reg3gtm1a(KOMP)Wtsi
(C57BL/6-Reg3gtm1a(KOMP)Wtsi)
increased susceptibility to Orthomyxoviridae infection J:233979
\RelM1Btlr/\Rel+
(C57BL/6J-RelM1Btlr)
decreased IgE level J:236682
decreased IgG level J:236682
decreased IgM level J:236682
decreased response to antigen J:236682
increased CD4-positive, alpha-beta T cell number J:236682
increased T cell number J:236682
\RelM1Btlr/\RelM1Btlr
(C57BL/6J-RelM1Btlr)
decreased B-1 B cell number J:236682
decreased CD4-positive, alpha-beta T cell number J:236682
decreased CD8-positive, alpha-beta T cell number J:236682
decreased IgE level J:236682
decreased IgG level J:236682
decreased IgM level J:236682
decreased response to antigen J:236682
increased CD4-positive, alpha-beta T cell number J:236682
increased CD8-positive, alpha-beta T cell number J:236682
increased effector memory CD4-positive, alpha-beta T cell number J:236682
increased T cell number J:236682
\RelM2Btlr/\RelM2Btlr
(C57BL/6J-RelM2Btlr)
abnormal CD4-positive T cell differentiation J:272778
abnormal T cell differentiation J:272778
decreased alpha-beta T cell number J:272778
decreased B-1 B cell number J:272778
decreased CD4-positive, alpha-beta T cell number J:272778
decreased central memory CD4-positive, alpha-beta T cell number J:272778
decreased effector memory CD4-positive, alpha-beta T cell number J:272778
\Relm3Btlr/\Relm3Btlr
(C57BL/6J-Relm3Btlr)
decreased IgM level J:272801
impaired humoral immune response J:272801
\Reltm1b(EUCOMM)Wtsi/\Reltm1b(EUCOMM)Wtsi
(C57BL/6N-Reltm1b(EUCOMM)Wtsi/H)
decreased monocyte cell number J:211773
\Reltm1Brv/\Reltm1Brv
(involves: 129S1/Sv)
abnormal leukocyte physiology J:46911
abnormal macrophage morphology J:46911
abnormal macrophage physiology J:46911
abnormal spleen morphology J:46911
abnormal splenic cell ratio J:46911
abnormal T cell physiology J:46911
decreased IgG1 level J:46911
decreased IgG2b level J:46911
decreased IgG3 level J:46911
decreased IgG level J:46911
decreased spleen germinal center number J:46911
dermatitis J:46911
enlarged lymph nodes J:46911
enlarged spleen J:46911
impaired macrophage chemotaxis J:46911
increased IgA level J:46911
increased IgG2a level J:46911
increased IgM level J:46911
increased spleen B cell follicle size J:46911
increased susceptibility to bacterial infection J:46911
\Reltm1Grd/\Rel+
(involves: 129S1/Sv * C57BL/6)
abnormal humoral immune response J:28435
decreased B cell proliferation J:28435
\Reltm1Grd/\Reltm1Grd
(involves: 129S1/Sv * C57BL/6)
abnormal cytokine secretion J:37541, J:28435
abnormal humoral immune response J:28435
abnormal macrophage physiology J:37541
decreased B cell proliferation J:28435
decreased IgG1 level J:28435
decreased IgG2a level J:28435
decreased IgG2b level J:28435
decreased IgG3 level J:28435
decreased IgM level J:28435
decreased susceptibility to parasitic infection J:37541
decreased T cell proliferation J:28435
\Reltm1Grd/\Reltm1Grd
(involves: 129S1/Sv)
immune system phenotype J:113514
\Reltm1Grd/\Reltm1Grd
\Relatm1Bal/\Relatm1Bal

(B6.129S-Reltm1Grd Relatm1Bal)
abnormal monocyte differentiation J:111325
increased granulocyte number J:111325
\Reltm1Hcl/\Rel+
(involves: 129S4/SvJae * C57BL/6)
decreased T cell proliferation J:53513
\Reltm1Hcl/\Reltm1Hcl
(involves: 129S4/SvJae * C57BL/6)
abnormal CD4-positive, alpha-beta T cell physiology J:79107, J:118907
abnormal cytokine secretion J:53513, J:79107
abnormal dendritic cell physiology J:118907
abnormal macrophage physiology J:118907
abnormal memory B cell number J:75621
abnormal professional antigen presenting cell physiology J:118907
abnormal T-helper 1 cell differentiation J:79107
decreased B cell proliferation J:75621
decreased cytotoxic T cell cytolysis J:53513
decreased IgE level J:58987
decreased susceptibility to autoimmune diabetes J:118907
decreased susceptibility to experimental autoimmune encephalomyelitis J:79107
decreased T cell proliferation J:53513, J:79107
immune system phenotype J:53513, J:118907, J:58987
increased eosinophil cell number J:58987
\Relatm1Asba/\Relatm1Asba
\Tg(Vil1-cre)997Gum/0

(involves: 129 * C57BL/6J * SJL)
increased susceptibility to induced colitis J:131977
\Relatm1Bal/\Relatm1Bal
(involves: 129S4/SvJae)
decreased marginal zone B cell number J:65246
immune system phenotype J:113514
\Relatm1Bal/\Relatm1Bal
\Tnfrsf1atm1Imx/\Tnfrsf1atm1Imx

(involves: 129S4/SvJae * C57BL/6)
abnormal spleen germinal center morphology J:60742
abnormal thymus morphology J:60742
decreased spleen white pulp amount J:60742
heart inflammation J:60742
liver inflammation J:60742
lung inflammation J:60742
\Relatm1Mpa/\Relatm1Mpa
\Tg(Alb1-cre)7Gsc/0

(involves: FVB/N)
increased susceptibility to endotoxin shock J:137861
\Relatm1Rsch/\Relatm1Rsch
\Ptf1atm1(cre)Hnak/?

(involves: C57BL/6)
abnormal interleukin level J:122194
abnormal tumor necrosis factor level J:122194
lung inflammation J:122194
pancreas inflammation J:122194
\Relatm1Rsch/\Relatm1Rsch
\Tg(Cd4-cre)1Cwi/0

(involves: C57BL/6 * DBA/2)
abnormal gamma-delta T cell morphology J:169863
\Relatm1Rsch/\Relatm1Rsch
\Tg(Lck-cre)I57Jxm/0

(involves: ICR)
abnormal gamma-delta T cell morphology J:169863
decreased interleukin-17 secretion J:169863
immune system phenotype J:169863
increased susceptibility to bacterial infection J:169863
\Relatm1Yuo/\Relatm1Yuo
(involves: 129S/SvEv)
abnormal lymphocyte physiology J:63099
decreased B cell proliferation J:63099
decreased double-positive T cell number J:63099
decreased IgA level J:63099
decreased IgG1 level J:63099
decreased T cell proliferation J:63099
\Relatm2.1Gho/\Relatm2.1Gho
(involves: 129S6/SvEvTac * C57BL/6)
abnormal spleen morphology J:163663
increased inflammatory response J:163663
increased neutrophil cell number J:163663
interstitial pneumonia J:163663
liver inflammation J:163663
lung inflammation J:163663
myositis J:163663
\Relatm2.1Gho/\Relatm2.1Gho
\Tnfrsf1atm1Mak/\Tnfrsf1atm1Mak

(involves: 129S2/SvPas * 129S6/SvEvTac)
increased incidence of corneal inflammation J:163663
liver inflammation J:163663
\Relbshep/\Relbshep
(A;C-Relbshep/GrsrJ)
liver inflammation J:171971
\RelbTg(H2-K1/GH1)106Bri/\Relb+
(involves: C57BL/6)
decreased NK T cell number J:120659
decreased Peyer's patch number J:120659
small Peyer's patches J:120659
\RelbTg(H2-K1/GH1)106Bri/\RelbTg(H2-K1/GH1)106Bri
(C57BL/6-RelbTg(H2-K1/GH1)106Bri)
abnormal antigen presentation J:23081
abnormal lymph node morphology J:76450
abnormal Peyer's patch morphology J:76450
absent thymus medulla J:23081, J:76450
decreased B cell number J:76450
decreased pre-B cell number J:76450
decreased T cell number J:76450
decreased T cell proliferation J:76450
enlarged spleen J:76450
glomerulonephritis J:76450
increased granulocyte number J:23081, J:76450
increased inflammatory response J:23081, J:76450
increased macrophage cell number J:23081, J:76450
liver inflammation J:76450
lung inflammation J:76450
skin inflammation J:76450
\RelbTg(H2-K1/GH1)106Bri/\RelbTg(H2-K1/GH1)106Bri
(involves: C57BL/6)
absent lymph nodes J:120659
absent Peyer's patches J:120659
decreased circulating interleukin-4 level J:120659
decreased NK T cell number J:120659
increased inflammatory response J:120659
\Relbtm1.1Fwei/\Relbtm1.1Fwei
\Tg(Cd4-cre)1Cwi/0

(involves: C57BL/6 * DBA/2)
immune system phenotype J:169863
\Relbtm1.1Fwei/\Relbtm1.1Fwei
\Tg(Lck-cre)I57Jxm/0

(involves: ICR)
abnormal gamma-delta T cell morphology J:169863
decreased interleukin-17 secretion J:169863
immune system phenotype J:169863
increased susceptibility to bacterial infection J:169863
\Relbtm1Brv/\Relbtm1Brv
(involves: 129S2/SvPas * C57BL/6)
abnormal cell-mediated immunity J:22675
abnormal cytokine level J:40630
abnormal cytotoxic T cell physiology J:40630
abnormal humoral immune response J:40630
abnormal immune system organ morphology J:22675
abnormal immune system physiology J:22675, J:40630
abnormal immunoglobulin level J:40630
abnormal interferon level J:40630
abnormal interleukin level J:40630
abnormal lymph node morphology J:22675
abnormal macrophage physiology J:40630
abnormal mesenteric lymph node morphology J:22675
abnormal tumor necrosis factor level J:40630
decreased B cell proliferation J:40630
decreased dendritic cell number J:22675
decreased spleen white pulp amount J:22675
decreased susceptibility to type IV hypersensitivity reaction J:22675
decreased T cell number J:22675
epididymis inflammation J:22675
impaired neutrophil phagocytosis J:40630
increased IgE level J:40630
increased IgM level J:40630
increased spleen red pulp amount J:22675
increased spleen weight J:22675
increased susceptibility to bacterial infection J:40630
increased susceptibility to Riboviria infection J:40630
intestinal inflammation J:22675
liver inflammation J:22675
lung inflammation J:22675
myeloid hyperplasia J:22675
myositis J:22675
ovary inflammation J:22675
salivary gland inflammation J:22675
stomach inflammation J:22675
thymus atrophy J:22675
thymus hypoplasia J:22675
\Relbtm1Brv/\Relbtm1Brv
(either: (involves: 129S2/SvPas) or (involves: C57BL/6) or (involves: 129S2/SvPas * C57BL/6))
dermatitis J:63950
increased eosinophil cell number J:63950
lung inflammation J:63950
\Relbtm1Brv/\Relbtm1Brv
(involves: 129S2/SvPas)
abnormal gamma-delta T cell morphology J:169863
decreased dendritic cell number J:85808
spleen hyperplasia J:85808
\Relnem1(IMPC)Mbp/\Reln+
(C57BL/6N-Relnem1(IMPC)Mbp/MbpMmucd)
abnormal lymph node morphology J:211773
enlarged lymph nodes J:211773
\Relttm1Hlee/\Relttm1Hlee
(Not Specified)
abnormal T cell morphology J:266480
immune system phenotype J:266480
increased T cell proliferation J:266480
\Ren1tm1Tkh/\Ren1tm1Tkh
(C57BL/6-Ren1tm1Tkh)
kidney inflammation J:110082
\Rettm2.1Cos/\Rettm2.1Cos
(involves: 129S1/Sv)
immune system phenotype J:195828
\Rettm6.1Vpa/\Rettm6.2Vpa
\Tg(CD2-icre)4Kio/0

(involves: 129S1/Sv * 129X1/SvJ * C57BL/10 * CBA/Ca)
immune system phenotype J:195828
\Retntm1Laz/\Retntm1Laz
\Tg(CD68-RETN)#Laz/?

(involves: 129S6/SvEvTac * C57BL/6)
white adipose tissue inflammation J:171262
\Retnlatm1Mer/\Retnlatm1Mer
(C57BL/6-Retnlatm1Mer)
abnormal chemokine secretion J:144784
decreased interleukin-5 secretion J:144784
decreased interleukin-6 secretion J:144927
decreased susceptibility to induced colitis J:144784, J:144927
impaired eosinophil recruitment J:144784
increased interleukin-10 secretion J:144927
\Retnlatm1Mer/\Retnlatm1Mer
(C.B6-Retnlatm1Mer)
decreased susceptibility to induced colitis J:144784, J:144927
\Retnlatm1Mer/\Retnlatm1Mer
(involves: C57BL/6)
abnormal macrophage physiology J:147863
abnormal T-helper 2 physiology J:147863
increased IgE level J:147863
increased IgG1 level J:147863
increased interleukin-4 secretion J:147863
increased interleukin-5 secretion J:147863
increased interleukin-13 secretion J:147863
\Retnlbtm1Gdw/\Retnlbtm1Gdw
(involves: 129S/SvEv * C57BL/6)
decreased inflammatory response J:114507
decreased susceptibility to induced colitis J:114507
\Retnlbtm1Lex/\Retnlbtm1Lex
(FVB.129S5-Retnlbtm1Lex)
abnormal CD4-positive, alpha-beta T cell physiology J:235058
decreased circulating interleukin-6 level J:235058
increased circulating interleukin-13 level J:235058
increased neutrophil cell number J:235058
liver inflammation J:235058
white adipose tissue inflammation J:235058
\Retnlbtm1Mer/\Retnlbtm1Mer
(involves: 129S1/Sv * C57BL/6)
decreased susceptibility to induced colitis J:141524
increased susceptibility to induced colitis J:141524
\Retnlbtm1Mer/\Retnlbtm1Mer
(involves: 129S1/Sv)
decreased IgG2a level J:141446
decreased interferon-gamma secretion J:141446
decreased susceptibility to parasitic infection J:141446
decreased tumor necrosis factor secretion J:141446
increased IgG1 level J:141446
\Retreg2em2(IMPC)Ccpcz/\Retreg2em2(IMPC)Ccpcz
(C57BL/6N-Retreg2em2(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
enlarged spleen J:211773
increased leukocyte cell number J:211773
increased lymphocyte cell number J:211773
\Rev1tm1.1Jow/\Rev1tm1.1Jow
(involves: C57BL/6)
abnormal somatic hypermutation frequency J:151700
immune system phenotype J:151700
\Rev1tm1Ndew/\Rev1tm1Ndew
(involves: 129P2/OlaHsd * C57BL/6)
abnormal somatic hypermutation frequency J:119176
immune system phenotype J:119176
lymphoid hypoplasia J:119176
\Rev3ltm1.1Kunk/\Rev3ltm1.1Kunk
(involves: C57BL/6)
abnormal somatic hypermutation frequency J:188723
immune system phenotype J:188723
\Rev3ltm1Rsky/\Rev3ltm1.1Rsky
\Tg(Cr2-cre)3Cgn/?

(involves: C57BL/6)
abnormal class switch recombination J:146453
abnormal somatic hypermutation frequency J:146453
decreased B cell proliferation J:146453
decreased germinal center B cell number J:146453
decreased IgG1 level J:146453
\Rev3ltm1Rwd/\Rev3ltm2.1Rwd
\Trp53tm1Brd/\Trp53tm1Brd
\Tg(MMTV-cre)1Mam/0

(involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6 * FVB/N)
increased T cell derived lymphoma incidence J:158922
\Rexo2tm1b(EUCOMM)Wtsi/\Rexo2+
(C57BL/6N-Rexo2tm1b(EUCOMM)Wtsi/H)
decreased neutrophil cell number J:211773
increased lymphocyte cell number J:211773
\Rfflem1(IMPC)Ccpcz/\Rfflem1(IMPC)Ccpcz
(C57BL/6N-Rfflem1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged spleen J:211773
enlarged thymus J:211773
\Rfkem1(IMPC)Mbp/\Rfk+
(C57BL/6NCrl-Rfkem1(IMPC)Mbp/MbpMmucd)
abnormal spleen morphology J:211773
small spleen J:211773
\Rfktm1.1Jcbr/\Rfktm1.1Jcbr
\Tg(Mx1-cre)1Cgn/?

(involves: C57BL/6 * CBA)
decreased macrophage nitric oxide production J:151999
\Rft1tm1b(KOMP)Wtsi/\Rft1+
(C57BL/6N-Rft1tm1b(KOMP)Wtsi/Bay)
decreased lymphocyte cell number J:211773
increased basophil cell number J:211773
increased monocyte cell number J:211773
\Rftn1tm1Ayos/\Rftn1tm1Ayos
(B6.Cg-Rftn1tm1Ayos)
abnormal CD4-positive T cell differentiation J:150299
decreased IgG2a level J:150299
decreased interferon-gamma secretion J:150299
decreased interleukin-4 secretion J:150299
decreased interleukin-17 secretion J:150299
decreased splenocyte number J:150299
decreased susceptibility to experimental autoimmune encephalomyelitis J:150299
\Rfx5tm1.1Ifo/\Rfx5tm1.1Ifo
(involves: 129 * C57BL/6)
abnormal B lymphocyte antigen presentation J:67941
abnormal dendritic cell morphology J:67941
abnormal Kupffer cell morphology J:67941
abnormal level of surface class II molecules J:67941
abnormal MHC II cell surface expression on macrophages J:67941
abnormal thymus cortex morphology J:67941
decreased CD4-positive, alpha-beta T cell number J:67941
decreased IgG1 level J:67941
decreased IgM level J:67941
decreased single-positive T cell number J:67941
\Rfx5tm1Ifo/\Rfx5tm1.1Ifo
\Lyz2tm1(cre)Ifo/\Lyz2+

(involves: 129 * C57BL/6 * C.B-20)
abnormal MHC II cell surface expression on macrophages J:67924
\Rfx5tm1Ifo/\Rfx5tm1Ifo
(involves: 129P2/OlaHsd * C57BL/6J)
immune system phenotype J:282535
\Rfx7tm1.1Ggaur/\Rfx7tm1.1Ggaur
\Commd10Tg(Vav1-icre)A2Kio/\Commd10+

(involves: C57BL/6 * C57BL/10 * CBA/Ca)
abnormal NK cell morphology J:282535
decreased NK cell number J:282535
small spleen J:282535
\Rfx7tm1.1Ggaur/\Rfx7tm1.1Ggaur
\Ncr1tm1.1(icre)Viv/\Ncr1+

(involves: C57BL/6)
abnormal NK cell physiology J:282535
decreased NK cell number J:282535
increased susceptibility to viral infection J:282535
\Rfx7tm1.1Ggaur/\Rfx7tm1.1Ggaur
\Rptortm1.1Dmsa/\Rptor+
\Commd10Tg(Vav1-icre)A2Kio/\Commd10+

(involves: 129S/SvEv * C57BL/10 * CBA/Ca)
abnormal NK cell morphology J:282535
decreased NK cell number J:282535
small spleen J:282535
\Rgcctm1Hrus/\Rgcctm1Hrus
(involves: 129S6/SvEvTac * C57BL/6)
increased interleukin-2 secretion J:279555
increased T cell proliferation J:279555
\Rgl1em1(IMPC)Mbp/\Rgl1+
(C57BL/6N-Rgl1em1(IMPC)Mbp/MbpMmucd)
abnormal lymph node morphology J:211773
abnormal spleen morphology J:211773
enlarged lymph nodes J:211773
enlarged spleen J:211773
increased neutrophil cell number J:211773
\Rgs1tm1Jhk/\Rgs1tm1Jhk
(B6.129P2-Rgs1tm1Jhk)
abnormal B cell calcium ion homeostasis J:90780
abnormal dendritic cell physiology J:89680
abnormal spleen germinal center morphology J:90780
decreased plasma cell number J:90780
enhanced B cell migration J:90780
increased immunoglobulin level J:90780
increased marginal zone B cell number J:90780
small Peyer's patches J:90780
\Rgs2em1(IMPC)H/\Rgs2em1(IMPC)H
(C57BL/6NTac-Rgs2em1(IMPC)H/H)
enlarged spleen J:211773
\Rgs2tm1Pngr/\Rgs2tm1Pngr
(involves: C57BL/6J)
abnormal T cell proliferation J:77273
\Rgs3tm1Ndul/\Rgs3tm1Ndul
(B6.129-Rgs3tm1Ndul)
abnormal lymph node morphology J:210195
immune system phenotype J:210195
increased B cell number J:210195
increased CD4-positive, alpha-beta T cell number J:210195
increased CD8-positive, alpha-beta T cell number J:210195
increased susceptibility to type I hypersensitivity reaction J:210195
lung inflammation J:210195
\Rgs4em1(IMPC)H/\Rgs4em1(IMPC)H
(C57BL/6N-Rgs4em1(IMPC)H/H)
decreased lymphocyte cell number J:211773
increased eosinophil cell number J:211773
increased spleen weight J:211773
\Rgs4tm1Sdlk/\Rgs4tm1Sdlk
\Tg(Myh11-icre/ERT2)1Soff/?

(involves: FVB/N)
abnormal macrophage chemotaxis J:215588
\Rgs5tm1Jhk/\Rgs5tm1Jhk
(involves: 129S/SvEv * C57BL/6)
decreased lymphocyte cell number J:133897
\Rgs9em1(IMPC)Ccpcz/\Rgs9em1(IMPC)Ccpcz
(C57BL/6NCrl-Rgs9em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
increased leukocyte cell number J:211773
increased lymphocyte cell number J:211773
\Rgs10tm1Ypl/\Rgs10tm1Ypl
(involves: 129S4/SvJae * C57BL/6J)
abnormal osteoclast differentiation J:123167
decreased osteoclast cell number J:123167
\Rgs12tm1.1Syy/\Rgs12tm1.1Syy
\Tg(Mx1-cre)1Cgn/0

(involves: 129 * C57BL/6 * CBA)
decreased osteoclast cell number J:194057
\Rgs13tm1.1Jhk/\Rgs13tm1.1Jhk
(involves: C57BL/6)
abnormal B cell differentiation J:199530
abnormal humoral immune response J:199530
abnormal spleen morphology J:199530
decreased B cell number J:199530
immune system phenotype J:199530
increased B cell number J:199530
increased germinal center B cell number J:199530
increased IgA level J:199530
increased IgG1 level J:199530
increased IgG2b level J:199530
increased IgG2c level J:199530
increased IgG3 level J:199530
increased IgM level J:199530
increased spleen germinal center number J:199530
increased spleen germinal center size J:199530
\Rgs13tm1Drue/\Rgs13tm1Drue
(B6.129S-Rgs13tm1Drue)
abnormal mast cell physiology J:130209
increased susceptibility to type I hypersensitivity reaction J:130209
\Rgs14tm1Lex/\Rgs14tm1Lex
(involves: 129S5/SvEvBrd)
immune system phenotype J:103485
\Rgs16tm1.1Drue/\Rgs16tm1.1Drue
(involves: C57BL/6)
abnormal T-helper 1 physiology J:188966
abnormal T-helper 2 physiology J:188966
granulomatous inflammation J:188966
increased interleukin-5 secretion J:188966
increased interleukin-10 secretion J:188966
increased interleukin-13 secretion J:188966
increased susceptibility to parasitic infection J:188966
\Rgsc14/\Rgsc14+
(involves: C57BL/6JJcl * DBA/2JJcl)
increased leukocyte cell number J:133634
increased lymphocyte cell number J:133634
\Rgsc15/\Rgsc15+
(involves: C57BL/6JJcl * DBA/2JJcl)
increased leukocyte cell number J:133634
increased lymphocyte cell number J:133634
\Rgsc17/\Rgsc17+
(involves: C57BL/6JJcl * DBA/2JJcl)
decreased leukocyte cell number J:133634
decreased lymphocyte cell number J:133634
\Rgsc142/\Rgsc142+
(involves: C57BL/6JJcl * DBA/2JJcl)
increased T cell derived lymphoma incidence J:133634
\Rgsc844/\Rgsc844+
(involves: C57BL/6JJcl * DBA/2JJcl)
abnormal neutrophil physiology J:133634
\Rgsc1045/\Rgsc1045+
(involves: C57BL/6JJcl * DBA/2JJcl)
abnormal neutrophil physiology J:133634
\Rgsc1354/\Rgsc1354+
(involves: C3H * C57BL/6JJcl)
abnormal neutrophil physiology J:133634
\Rgsc1547/\Rgsc1547+
(involves: C3H * C57BL/6JJcl)
increased susceptibility to otitis media J:133634
\Rhagem1(IMPC)Ccpcz/\Rhagem1(IMPC)Ccpcz
(C57BL/6NCrl-Rhagem1(IMPC)Ccpcz/Ccpcz)
abnormal lymph node morphology J:211773
abnormal thymus morphology J:211773
enlarged lymph nodes J:211773
enlarged thymus J:211773
\Rhbdd1tm1.1Mfm/\Rhbdd1tm1.1Mfm
(involves: 129S/SvEv * C57BL/6J)
increased interleukin-6 secretion J:346394
increased susceptibility to endotoxin shock J:346394
increased tumor necrosis factor secretion J:346394
\Rhbdd3tm1Caox/\Rhbdd3tm1Caox
(B6.129S6-Rhbdd3tm1Caox)
abnormal dendritic cell physiology J:197348
immune system phenotype J:197348
increased circulating interferon-gamma level J:197348
increased circulating interleukin-6 level J:197348
increased interferon-gamma secretion J:197348
increased interleukin-6 secretion J:197348
increased natural killer cell mediated cytotoxicity J:197348
increased NK cell number J:197348
liver inflammation J:197348
\Rhbdf1tm1.1Mfm/\Rhbdf1tm1.1Mfm
(involves: 129S/SvEv * 129S6/SvEvTac * C57BL/6J)
small spleen J:203951
small thymus J:203951
\Rhbdf2cub/\Rhbdf2cub
(B6.Cg-Rhbdf2cub)
white adipose tissue inflammation J:82006
\Rhbdf2m1Btlr/\Rhbdf2m1Btlr
(C57BL/6J-Rhbdf2m1Btlr)
decreased tumor necrosis factor secretion J:187583
\Rhbdf2m1Btlr/\Rhbdf2tm1a(KOMP)Wtsi
(involves: C57BL/6J * C57BL/6N)
decreased tumor necrosis factor secretion J:187583
\Rhbdf2M2Btlr/\Rhbdf2+
(C57BL/6J-Rhbdf2M2Btlr)
abnormal immune system physiology J:213194
\Rhbdf2M3Btlr/\Rhbdf2+
(C57BL/6J-Rhbdf2M3Btlr)
abnormal immune system physiology J:220064
\Rhbdf2M3Btlr/\Rhbdf2M3Btlr
(C57BL/6J-Rhbdf2M3Btlr)
abnormal immune system physiology J:220064
\Rhbdf2tm1.1Mfm/\Rhbdf2tm1.1Mfm
(B6.129S-Rhbdf2tm1.1Mfm)
decreased circulating tumor necrosis factor level J:179654
decreased tumor necrosis factor secretion J:179654
\Rhbdf2tm1a(KOMP)Wtsi/\Rhbdf2tm1a(KOMP)Wtsi
(involves: C57BL/6N)
decreased tumor necrosis factor secretion J:187583
\Rhbdf2tm1Mak/\Rhbdf2tm1Mak
(B6.129P2-Rhbdf2tm1Mak)
abnormal B cell physiology J:179653
abnormal immune serum protein physiology J:179653
decreased circulating tumor necrosis factor level J:179653
decreased susceptibility to infection induced morbidity/mortality J:179653
decreased tumor necrosis factor secretion J:179653
increased susceptibility to bacterial infection J:179653
increased susceptibility to bacterial infection induced morbidity/mortality J:179653
\Rhbdf2tm1Mak/\Rhbdf2tm1Mak
(involves: 129P2/OlaHsd * C57BL/6)
abnormal leukocyte physiology J:221411
abnormal microglial cell physiology J:221411
decreased tumor necrosis factor secretion J:221411
\Rhebtm1Pfw/\Rhebtm1Pfw
\Tg(Cd4-cre)1Cwi/0

(involves: C57BL/6 * DBA/2)
immune system phenotype J:150108
\Rhotm2.1Kpal/\Rhotm2.1Kpal
(involves: 129S6/SvEvTac * C57BL/6J * C57BL/6NTac)
microgliosis J:194158
\Rhoatm1.1Tpal/\Rhoa+
\Tg(Cd4-cre/ERT2)11Gnri/0

(involves: C57BL/6)
increased regulatory T cell number J:257764
increased T cell proliferation J:257764
increased T follicular helper cell number J:257764
\Rhobtb1em2(IMPC)Ccpcz/\Rhobtb1em2(IMPC)Ccpcz
(C57BL/6N-Rhobtb1em2(IMPC)Ccpcz/Ccpcz)
increased Ly6C-positive NK T cell number J:211773
\Rhobtb3tm1a(KOMP)Wtsi/\Rhobtb3tm1a(KOMP)Wtsi
(involves: C57BL/6N)
decreased spleen weight J:226884
\Rhoctm1Mak/\Rhoctm1Mak
(involves: 129P2/OlaHsd)
immune system phenotype J:100482
\Rhoftm1.2Dash/\Rhoftm1.2Dash
(involves: 129)
abnormal spleen marginal zone morphology J:303076
decreased marginal zone B cell number J:303076
immune system phenotype J:303076
\Rhogtm1Tnr/\Rhogtm1Tnr
(involves: 129)
abnormal CD4-positive, alpha-beta T cell physiology J:87580
abnormal leukocyte physiology J:87580
abnormal T-helper 2 physiology J:87580
increased B cell proliferation J:87580
increased immunoglobulin level J:87580
\Rhohtm1b(EUCOMM)Hmgu/\Rhohtm1b(EUCOMM)Hmgu
(C57BL/6N-Rhohtm1b(EUCOMM)Hmgu/Bay)
decreased leukocyte cell number J:211773
\Rhohtm1Brak/\Rhohtm1Brak
(involves: 129/Sv * C57BL/6)
abnormal double-negative T cell morphology J:143161
abnormal immune system organ morphology J:143161
abnormal lymphocyte cell number J:143161
abnormal splenic cell ratio J:143161
abnormal T cell proliferation J:143161
decreased CD4-positive, alpha-beta T cell number J:143161
decreased CD8-positive, alpha-beta T cell number J:143161
decreased double-positive T cell number J:143161
decreased single-positive T cell number J:143161
decreased T cell apoptosis J:143161
decreased T cell number J:143161
decreased T cell proliferation J:143161
increased double-negative T cell number J:143161
increased gamma-delta T cell number J:143161
increased NK cell number J:143161
increased NK T cell number J:143161
increased T cell number J:143161
increased T cell proliferation J:143161
spleen hypoplasia J:143161
thymus hypoplasia J:143161
\Rhohtm1Brak/\Rhohtm1Brak
\Itgb2tm2Bay/\Itgb2tm2Bay

(involves: 129/Sv * C57BL/6)
decreased CD4-positive, alpha-beta T cell number J:143161
decreased CD8-positive, alpha-beta T cell number J:143161
decreased double-positive T cell number J:143161
decreased single-positive T cell number J:143161
increased double-negative T cell number J:143161
\Rhohtm1Brak/\Rhohtm1Brak
\Tg(TcraTcrb)425Cbn/?

(involves: 129/Sv * C57BL/6)
decreased CD4-positive, alpha-beta T cell number J:143161
immune system phenotype J:143161
\Rhohtm1Daw/\Rhohtm1Daw
(involves: 129 * C57BL/6)
arrested T cell differentiation J:113565
decreased double-positive T cell number J:113565
decreased T cell number J:113565
thymus hypoplasia J:113565
\Rhohtm1Hasu/\Rhohtm1Hasu
(B6.Cg-Rhohtm1Hasu)
abnormal mast cell physiology J:143491
decreased mast cell degranulation J:143491
decreased susceptibility to type I hypersensitivity reaction J:143491
immune system phenotype J:143491
\Rhs1C57BL/6/\Rhs1C57BL/6
(involves: BALB/c * C57BL/6)
decreased susceptibility to Herpesvirales infection J:69352
\Ric1tm1a(EUCOMM)Hmgu/\Ric1tm1a(EUCOMM)Hmgu
(C57BL/6N-Ric1tm1a(EUCOMM)Hmgu/H)
decreased B cell number J:165965
decreased leukocyte cell number J:165965
decreased mature B cell number J:165965
\Ric8btm1b(EUCOMM)Hmgu/\Ric8b+
(C57BL/6N-Ric8btm1b(EUCOMM)Hmgu/Cnrm)
increased basophil cell number J:211773
increased leukocyte cell number J:211773
increased lymphocyte cell number J:211773
\Rictortm1.1Klg/\Rictortm1.1Klg
\Tg(Mx1-cre)1Cgn/0

(B6.Cg-Rictortm1.1Klg Tg(Mx1-cre)1Cgn)
abnormal double-negative T cell morphology J:189736
decreased DN1 thymic pro-T cell number J:189736
decreased DN2 thymocyte number J:189736
decreased DN3 thymocyte number J:189736
decreased DN4 thymocyte number J:189736
decreased double-positive T cell number J:189736
decreased single-positive T cell number J:189736
decreased T cell proliferation J:189736
decreased thymus weight J:189736
immune system phenotype J:189736
increased double-negative T cell number J:189736
thymus hypoplasia J:189736
\Rictortm1.1Mnh/\Rictortm1.1Mnh
\Tg(Fabp4-cre)1Rev/0

(B6.Cg-Rictortm1.1Mnh Tg(Fabp4-cre)1Rev)
increased spleen weight J:150064
\Rif1Gt(XT0278)Wtsi/\Rif1Gt(XT0278)Wtsi
(involves: 129P2/OlaHsd * CD-1 * MF1)
abnormal class switch recombination J:195061
decreased IgA level J:195061
decreased IgG1 level J:195061
decreased IgG2b level J:195061
decreased IgG3 level J:195061
decreased IgG level J:195061
immune system phenotype J:195061
increased susceptibility to bacterial infection J:195061
\Rigitm1Aki/\Rigitm1Aki
(involves: 129/Sv * C57BL/6)
abnormal dendritic cell physiology J:137522
\Rigitm1Aki/\Rigitm1Aki
(involves: 129/Sv * C57BL/6 * ICR)
abnormal interferon level J:137522
increased susceptibility to Flaviviridae infection induced morbidity/mortality J:137522
\Rigitm1Zgwg/\Rigitm1Zgwg
(involves: 129S1/Sv)
abnormal B cell differentiation J:139016
abnormal granulocyte morphology J:139016
abnormal granulocyte physiology J:139016
colitis J:139868
decreased Peyer's patch number J:139868
decreased T cell number J:139868
enlarged spleen J:139016
immune system phenotype J:139016
increased activated T cell number J:139868
increased granulocyte number J:139016
increased memory T cell number J:139868
increased susceptibility to induced colitis J:139868
small Peyer's patches J:139868
\Rin3tm1.1(KOMP)Vlcg/\Rin3tm1.1(KOMP)Vlcg
(involves: 129P2/OlaHsd * C57BL/6N)
abnormal osteoclast morphology J:358899
\Rinltm1.1Boun/\Rinltm1.1Boun
(B6.Cg-Rinltm1.1Boun)
abnormal susceptibility to Riboviria infection J:346452
enlarged spleen J:346452
immune system phenotype J:346452
increased B cell number J:346452
increased CD4-positive, alpha-beta T cell number J:346452
increased germinal center B cell number J:346452
increased splenocyte number J:346452
increased T follicular helper cell number J:346452
\Rinltm1.1Boun/\Rinltm1.1Boun
\Tg(TcraTcrb)425Cbn/0

(involves: C57BL/6)
abnormal T follicular helper cell differentiation J:346452
increased CD4-positive, alpha-beta T cell number J:346452
increased T follicular helper cell number J:346452
\Riok2tm1c(KOMP)Wtsi/\Riok2+
\Commd10Tg(Vav1-icre)A2Kio/\Commd10+

(involves: C57BL/6N * C57BL/10 * CBA/Ca)
abnormal CD4-positive, alpha beta T cell morphology J:305794
abnormal CD4-positive, alpha-beta T cell physiology J:305794
abnormal circulating interleukin level J:305794
abnormal immune system morphology J:305794
abnormal interleukin secretion J:305794
decreased neutrophil cell number J:305794
increased monocyte cell number J:305794
increased NK T cell number J:305794
\Riox1tm1Qch/\Riox1tm1Qch
\Tg(Prrx1-cre)1Cjt/0

(involves: 129S6/SvEvTac * C57BL/6J * C57BL/6NCrl * SJL/J)
decreased osteoclast cell number J:224562
\Riox2tm1Mtsun/\Riox2tm1Mtsun
(B6CrSlc.Cg-Riox2tm1Mtsun)
abnormal circulating interferon-gamma level J:201871
abnormal circulating interleukin-4 level J:201871
abnormal immunoglobulin level J:201871
decreased eosinophil cell number J:201871
decreased inflammatory response J:201871
decreased macrophage cell number J:201871
decreased neutrophil cell number J:201871
\Ripk1tm1.1Vmd/\Ripk1tm1.1Vmd
(involves: C57BL/6N)
increased thymocyte apoptosis J:209137
\Ripk1tm1Led/\Ripk1tm1Led
(involves: 129S6/SvEvTac)
abnormal immune system organ morphology J:46522
abnormal leukocyte cell number J:46522
abnormal lymph node morphology J:46522
abnormal thymus morphology J:46522
decreased thymocyte number J:46522
increased spleen red pulp amount J:46522
lymph node inflammation J:46522
lymph node necrosis J:46522
\Ripk2tm1Cfl/\Ripk2tm1Cfl
(involves: 129S5/SvEvBrd)
abnormal macrophage physiology J:107130
\Ripk2tm1Flv/\Ripk2tm1Flv
(involves: 129S1/Sv)
abnormal cytokine secretion J:75400
abnormal T-helper 1 physiology J:75400
decreased interleukin-6 secretion J:75400
decreased T cell proliferation J:75400
decreased tumor necrosis factor secretion J:75400
\Ripk2tm1Flv/\Ripk2tm1Flv
(involves: 129S1/Sv * C57BL/6)
abnormal macrophage physiology J:132126
decreased interleukin-6 secretion J:132126
decreased tumor necrosis factor secretion J:132126
\Ripk2tm1Flv/\Ripk2tm1Flv
\Tnip1tm1.1Pcoh/\Tnip1tm1.1Pcoh

(involves: 129P2/OlaHsd * 129S1/Sv * C57BL/6)
enlarged lymph nodes J:176826
enlarged spleen J:176826
\Ripk2tm1Ghc/\Ripk2tm1Ghc
(involves: 129S4/SvJae * C57BL/6)
decreased IgG2a level J:75401
decreased interferon-gamma secretion J:75401
decreased T cell proliferation J:75401
increased susceptibility to infection J:75401
\Ripk2tm2Cfl/\Ripk2tm2Cfl
(involves: 129S5/SvEvBrd)
immune system phenotype J:107130
\Ripk3tm1Vmd/\Ripk3tm1Vmd
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6N)
immune system phenotype J:87683
\Ripk3tm1Vmd/\Ripk3tm1Vmd
(B6.129-Ripk3tm1Vmd)
decreased inflammatory response J:179279
\Ripk4tm1Pmh/\Ripk4tm1Pmh
(involves: 129 * C57BL/6)
immune system phenotype J:78593
\Ripply3tm1Sjt/\Ripply3tm1Sjt
(involves: 129S1/Sv * C57BL/6)
abnormal thymus development J:167713
ectopic thymus J:167713
small thymus J:167713
\Rit1tm1.1Tumg/\Rit1+
(B6.Cg-Rit1tm1.1Tumg)
enlarged spleen J:277548
\Rlimem1(IMPC)Rbrc/\Rlim+
(C57BL/6NJcl-Rlimem1(IMPC)Rbrc/Rbrc)
abnormal lymph node morphology J:211773
abnormal thymus morphology J:211773
enlarged lymph nodes J:211773
enlarged thymus J:211773
\Rmcfr/\Rmcfr
(DBA/1J)
decreased susceptibility to Retroviridae infection J:7108
\Rmcfr/\Rmcfr
(DBA/2J)
decreased susceptibility to Retroviridae infection J:7108
\Rmcfr/\Rmcfr
(CBA/N)
decreased susceptibility to Retroviridae infection J:7108
\Rmcfs/\Rmcfs
(CBA/J)
increased susceptibility to Retroviridae infection J:7108
\Rmcfs/\Rmcfs
(C57L/J)
increased susceptibility to Retroviridae infection J:7108
\Rmcfs/\Rmcfs
(C57BR/cdJ)
increased susceptibility to Retroviridae infection J:7108
\Rmp1DBA/2J/\Rmp1DBA/2J
(involves: C57BL/6J * DBA/2J)
increased susceptibility to Poxviridae infection J:28150
\Rmp2DBA/2J/\Rmp2DBA/2J
(involves: C57BL/6J * DBA/2J)
increased susceptibility to Poxviridae infection J:11032
\Rmp3DBA/2J/\Rmp3DBA/2J
(involves: C57BL/6J * DBA/2J)
increased susceptibility to Poxviridae infection J:11032
\Rmp4C57BL/6NCr/\Rmp4C57BL/6NCr
(involves: C57BL/6NCr * DBA/2NCr)
decreased susceptibility to Poxviridae infection J:29241
\Rmp5C57BL/6NCr/\Rmp5C57BL/6NCr
(involves: C57BL/6NCr * DBA/2NCr)
decreased susceptibility to Poxviridae infection J:3240
\Rmp6C57BL/6NCr/\Rmp6C57BL/6NCr
(involves: C57BL/6NCr * DBA/2NCr)
decreased susceptibility to Poxviridae infection J:3240
\Rmrpem1(IMPC)Ccpcz/\Rmrp+
(C57BL/6NCrl-Rmrpem1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
\Rnase4em1Zpxu/\Rnase4em1Zpxu
(Not Specified)
increased susceptibility to induced colitis J:354138
\Rnase4em2Zpxu/\Rnase4em2Zpxu
\Tg(Vil1-cre)DNju/0

(involves: C57BL/6 * C57BL/6J)
increased susceptibility to induced colitis J:354138
\Rnase6em1(IMPC)Tcp/\Rnase6em1(IMPC)Tcp
(C57BL/6N-Rnase6em1(IMPC)Tcp/Tcp)
increased monocyte cell number J:211773
\Rnase11em1(IMPC)Mbp/\Rnase11em1(IMPC)Mbp
(C57BL/6N-Rnase11em1(IMPC)Mbp/MbpMmucd)
abnormal lymph node morphology J:211773
abnormal spleen morphology J:211773
enlarged lymph nodes J:211773
increased lymphocyte cell number J:211773
small spleen J:211773
\Rnase12em1(IMPC)Mbp/\Rnase12em1(IMPC)Mbp
(C57BL/6N-Rnase12em1(IMPC)Mbp/MbpMmucd)
abnormal lymph node morphology J:211773
enlarged lymph nodes J:211773
\Rnaseh2aem1(IMPC)Tcp/\Rnaseh2a+
(C57BL/6NCrl-Rnaseh2aem1(IMPC)Tcp/Tcp)
increased monocyte cell number J:211773
increased spleen weight J:211773
\Rnaseh2atm1Crh/\Rnaseh2atm1Crh
(Not Specified)
abnormal innate immunity J:232933
decreased susceptibility to Riboviria infection J:232933
\Rnaseh2atm1Crh/\Rnaseh2atm1Crh
\Sting1tm1Gnb/\Sting1tm1Gnb

(involves: 129P2/OlaHsd)
immune system phenotype J:232933
\Rnaseh2bem1Anu/\Rnaseh2b+
\Tlr7em2Anu/\Tlr7+

(C57BL/6NCrl-Rnaseh2bem1Anu Tlr7em2Anu)
abnormal immune system morphology J:324448
abnormal mature B cell morphology J:324448
increased autoantibody level J:324448
increased CD4-positive, alpha-beta T cell number J:324448
increased germinal center B cell number J:324448
increased plasma cell number J:324448
increased T follicular helper cell number J:324448
\Rnaseh2btm1a(EUCOMM)Wtsi/\Rnaseh2btm1a(EUCOMM)Wtsi
(involves: C57BL/6N)
thymus hypoplasia J:186986
\Rnaseh2btm1c(EUCOMM)Wtsi/\Rnaseh2btm1c(EUCOMM)Wtsi
\Cd19tm1(cre)Cgn/\Cd19+

(involves: 129P2/OlaHsd * C57BL/6 * C57BL/6N * SJL)
decreased B cell proliferation J:186986
immune system phenotype J:186986
\Rnaseltm1Slvm/\Rnaseltm1Slvm
(involves: 129P2/OlaHsd)
abnormal thymus morphology J:44292
decreased T cell apoptosis J:44292
enlarged thymus J:44292
increased susceptibility to Picornaviridae infection J:44292
thymus hyperplasia J:44292
\Rnaset2btm1b(EUCOMM)Hmgu/\Rnaset2btm1b(EUCOMM)Hmgu
(C57BL/6N-Rnaset2btm1b(EUCOMM)Hmgu/H)
enlarged spleen J:211773
\Rnd2em1(IMPC)Mbp/\Rnd2em1(IMPC)Mbp
(C57BL/6NCrl-Rnd2em1(IMPC)Mbp/Mmucd)
abnormal spleen morphology J:211773
enlarged spleen J:211773
\Rnd3tm1b(EUCOMM)Hmgu/\Rnd3+
(C57BL/6N-Rnd3tm1b(EUCOMM)Hmgu/H)
increased large unstained cell number J:211773
\Rnf2tm1Mvi/\Rnf2tm1Mvi
\Tg(Mx1-cre)1Cgn/0

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * C57BL/10 * CBA)
abnormal B cell differentiation J:130397
decreased B cell number J:130397
decreased monocyte cell number J:130397
\Rnf5tm1.1(KOMP)Vlcg/\Rnf5+
(C57BL/6N-Rnf5tm1.1(KOMP)Vlcg/Ccpcz)
abnormal thymus morphology J:211773
enlarged thymus J:211773
\Rnf5tm1.1(KOMP)Vlcg/\Rnf5tm1.1(KOMP)Vlcg
(C57BL/6N-Rnf5tm1.1(KOMP)Vlcg/Ccpcz)
abnormal spleen morphology J:211773
\Rnf8Gt(AS0574)Wtsi/\Rnf8+
(involves: 129P2/OlaHsd * C57BL/6)
abnormal class switch recombination J:161240
\Rnf8Gt(AS0574)Wtsi/\Rnf8Gt(AS0574)Wtsi
(involves: 129P2/OlaHsd * C57BL/6)
abnormal class switch recombination J:161240
decreased B cell number J:161240
decreased CD4-positive, alpha-beta T cell number J:161240
decreased CD8-positive, alpha-beta T cell number J:161240
decreased double-negative T cell number J:161240
decreased double-positive T cell number J:161240
decreased IgG1 level J:161240
decreased IgG2b level J:161240
decreased IgG3 level J:161240
decreased immature B cell number J:161240
decreased pre-B cell number J:161240
decreased pro-B cell number J:161240
decreased splenocyte number J:161240
decreased T cell number J:161240
decreased thymocyte number J:161240
increased T cell derived lymphoma incidence J:161240
increased thymocyte apoptosis J:161240
\Rnf8Gt(RRR260)Byg/\Rnf8Gt(RRR260)Byg
(involves: 129P2/OlaHsd * C57BL/6)
abnormal class switch recombination J:161240
decreased B cell number J:161240
decreased CD4-positive, alpha-beta T cell number J:161240
decreased CD8-positive, alpha-beta T cell number J:161240
decreased double-negative T cell number J:161240
decreased double-positive T cell number J:161240
decreased IgG1 level J:161240
decreased IgG2b level J:161240
decreased IgG3 level J:161240
decreased immature B cell number J:161240
decreased pre-B cell number J:161240
decreased pro-B cell number J:161240
decreased splenocyte number J:161240
decreased T cell number J:161240
decreased thymocyte number J:161240
increased T cell derived lymphoma incidence J:161240
increased thymocyte apoptosis J:161240
\Rnf10tm1b(KOMP)Wtsi/\Rnf10tm1b(KOMP)Wtsi
(C57BL/6N-Rnf10tm1b(KOMP)Wtsi/Ics)
decreased lymphocyte cell number J:211773
increased monocyte cell number J:211773
\Rnf10tm1b(KOMP)Wtsi/\Rnf10tm1b(KOMP)Wtsi
(C57BL/6N-Rnf10tm1b(KOMP)Wtsi/H)
increased large unstained cell number J:211773
\Rnf10tm1b(KOMP)Wtsi/\Rnf10tm1b(KOMP)Wtsi
(C57BL/6N-Rnf10tm1b(KOMP)Wtsi/Bay)
abnormal spleen morphology J:211773
\Rnf19bem1(IMPC)Ccpcz/\Rnf19b+
(C57BL/6N-Rnf19bem1(IMPC)Ccpcz/Ccpcz)
increased eosinophil cell number J:211773
\Rnf19btm1Jkorn/\Rnf19btm1Jkorn
(B6.129S-Rnf19btm1Jkorn)
decreased interferon-gamma secretion J:157393
impaired natural killer cell mediated cytotoxicity J:157393
\Rnf20Gt(RRJ249)Byg/\Rnf20+
(involves: 129P2/OlaHsd)
abnormal leukocyte physiology J:268221
abnormal T cell physiology J:268221
enlarged spleen J:268221
increased interferon-gamma secretion J:268221
increased spleen weight J:268221
increased susceptibility to induced colitis J:268221
increased tumor necrosis factor secretion J:268221
\Rnf31tm1.1Kiwa/\Rnf31tm1.1Kiwa
\Cd79atm1(cre)Reth/\Cd79a+

(involves: BALB/c * C57BL/6NCrlj * CBA/JNCrlj)
abnormal B-1 B cell morphology J:201885
abnormal humoral immune response J:201885
decreased B-1a cell number J:201885
decreased B-1b cell number J:201885
decreased IgA level J:201885
decreased IgG1 level J:201885
decreased IgG2a level J:201885
decreased IgG2b level J:201885
decreased IgG3 level J:201885
decreased IgM level J:201885
immune system phenotype J:201885
\Rnf34tm1a(EUCOMM)Hmgu/\Rnf34tm1a(EUCOMM)Hmgu
(C57BL/6NCrl-Rnf34tm1a(EUCOMM)Hmgu/Ccpcz)
abnormal lymph node morphology J:211773
abnormal thymus morphology J:211773
enlarged lymph nodes J:211773
enlarged thymus J:211773
\Rnf39em1Zwei/\Rnf39em1Zwei
(involves: C57BL/6)
decreased susceptibility to Riboviria infection J:357975
decreased susceptibility to Riboviria infection induced morbidity/mortality J:357975
increased interferon-beta secretion J:357975
increased interleukin-6 secretion J:357975
\Rnf40tm1.1Sajo/\Rnf40tm1.1Sajo
\Tg(Car1-cre)5Flt/0

(involves: 129S2/SvPas * C57BL/6J)
decreased susceptibility to induced colitis J:311838
\Rnf43em1(IMPC)Tcp/\Rnf43em1(IMPC)Tcp
(C57BL/6NCrl-Rnf43em1(IMPC)Tcp/Tcp)
enlarged spleen J:211773
\Rnf43em1Mage/\Rnf43em1Mage
(Not Specified)
immune system phenotype J:276360
\Rnf43em2Mage/\Rnf43em2Mage
(Not Specified)
immune system phenotype J:276360
increased interferon-gamma secretion J:285428
stomach inflammation J:285428
\Rnf115em1(IMPC)H/\Rnf115em1(IMPC)H
(C57BL/6N-Rnf115em1(IMPC)H/H)
increased spleen weight J:211773
\Rnf115em1Gpt/\Rnf115em1Gpt
(C57BL/6JGpt-Rnf115em1Gpt/Gpt)
decreased susceptibility to viral infection J:297834
decreased susceptibility to viral infection induced morbidity/mortality J:297834
increased circulating interferon-beta level J:297834
increased interferon-beta secretion J:297834
increased susceptibility to viral infection induced morbidity/mortality J:297834
\Rnf122em1Caox/\Rnf122em1Caox
(involves: C57BL/6J)
decreased susceptibility to Riboviria infection induced morbidity/mortality J:344769
immune system phenotype J:344769
increased circulating interferon-alpha level J:344769
increased circulating interferon-beta level J:344769
increased circulating interleukin-6 level J:344769
increased interferon-alpha secretion J:344769
increased interferon-beta secretion J:344769
increased interleukin-6 secretion J:344769
increased tumor necrosis factor secretion J:344769
\Rnf123em1Nmea/\Rnf123em1Nmea
(NC/Jic-Rnf123em1Nmea)
decreased susceptibility to parasitic infection J:327312
decreased susceptibility to parasitic infection induced morbidity/mortality J:327312
\Rnf123em2Nmea/\Rnf123em2Nmea
(NC/Jic-Rnf123em2Nmea)
decreased susceptibility to parasitic infection J:327312
decreased susceptibility to parasitic infection induced morbidity/mortality J:327312
\Rnf128tm1.1(KOMP)Vlcg/Y
(C57BL/6N-Rnf128tm1.1(KOMP)Vlcg/Ccpcz)
increased effector memory T-helper cell number J:211773
\Rnf128tm1.1Flv/Y
(involves: 129S6/SvEvTac * C57BL/6)
abnormal CD4-positive, alpha-beta T cell physiology J:153216
abnormal peripheral T cell anergy J:153216
increased circulating interleukin-2 level J:153216
increased interferon-gamma secretion J:153216
increased T cell proliferation J:153216
\Rnf128tm1.1Flv/Y
\Tg(TcraTcrb)425Cbn/0

(involves: 129S6/SvEvTac * BALB/c * C57BL/6)
abnormal peripheral T cell anergy J:153216
decreased T cell proliferation J:153216
increased circulating interleukin-2 level J:153216
\Rnf128tm1.1Flv/\Rnf128tm1.1Flv
(involves: 129S6/SvEvTac * C57BL/6)
abnormal CD4-positive, alpha-beta T cell physiology J:153216
abnormal peripheral T cell anergy J:153216
increased circulating interleukin-2 level J:153216
increased interferon-gamma secretion J:153216
increased T cell proliferation J:153216
\Rnf128tm1.1Flv/\Rnf128tm1.1Flv
\Tg(TcraTcrb)425Cbn/0

(involves: 129S6/SvEvTac * BALB/c * C57BL/6)
abnormal peripheral T cell anergy J:153216
decreased T cell proliferation J:153216
increased circulating interleukin-2 level J:153216
\Rnf128tm1.2Cmse/\Rnf128tm1.2Cmse
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
abnormal macrophage physiology J:245025
\Rnf128tm1Cdon/\Rnf128+
(involves: 129 * C57BL/6)
increased susceptibility to experimental autoimmune encephalomyelitis J:160681
\Rnf128tm1Cdon/\Rnf128tm1Cdon
(involves: C57BL/6)
increased anti-double stranded DNA antibody level J:160681
increased interferon-gamma secretion J:160681
increased interleukin-2 secretion J:160681
increased interleukin-17 secretion J:160681
increased T cell proliferation J:160681
\Rnf128tm1Cdon/\Rnf128tm1Cdon
(involves: 129 * C57BL/6)
abnormal immune tolerance J:160681
abnormal interleukin secretion J:160681
abnormal regulatory T cell physiology J:160681
CNS inflammation J:160681
decreased interleukin-4 secretion J:160681
decreased interleukin-5 secretion J:160681
decreased interleukin-13 secretion J:160681
enlarged mesenteric lymph nodes J:160681
enlarged spleen J:160681
increased anti-double stranded DNA antibody level J:160681
increased IgG1 level J:160681
increased IgM level J:160681
increased interferon-gamma secretion J:160681
increased interleukin-2 secretion J:160681
increased interleukin-4 secretion J:160681
increased interleukin-17 secretion J:160681
increased interleukin-21 secretion J:160681
increased splenocyte proliferation J:160681
increased susceptibility to experimental autoimmune encephalomyelitis J:160681
lung inflammation J:160681
\Rnf128tm1Cdon/\Rnf128tm1Cdon
\Tg(TcraTcrb)425Cbn/0

(involves: 129 * BALB/c * C57BL/6)
abnormal immune tolerance J:160681
increased interferon-gamma secretion J:160681
increased interleukin-2 secretion J:160681
increased splenocyte proliferation J:160681
\Rnf135em1(IMPC)Tcp/\Rnf135em1(IMPC)Tcp
(C57BL/6NCrl-Rnf135em1(IMPC)Tcp/Tcp)
enlarged lymph nodes J:211773
\Rnf139tm1(KOMP)Wtsi/\Rnf139tm1(KOMP)Wtsi
(involves: C57BL/6J * C57BL/6N)
liver inflammation J:231404
\Rnf144aem1Smoc/\Rnf144aem1Smoc
(C57BL/6JSmoc-Rnf144aem1Smoc/Smoc)
abnormal innate immunity J:347002
increased susceptibility to Herpesvirales infection J:347002
increased susceptibility to Herpesvirales infection induced morbidity/mortality J:347002
\Rnf144bem1Cya/\Rnf144bem1Cya
(C57BL/6J-Rnf144bem1Cya/Cya)
decreased susceptibility to Picornaviridae infection J:357974
decreased susceptibility to Picornaviridae infection induced morbidity/mortality J:357974
decreased susceptibility to Riboviria infection J:357974
\Rnf146tm1.1Rtpl/\Rnf146tm1.1Rtpl
\Lyz2tm1(cre)Ifo/\Lyz2+

(involves: 129P2/OlaHsd * C57BL/6J)
abnormal osteoclast differentiation J:243612
increased circulating tumor necrosis factor level J:243612
increased osteoclast cell number J:243612
\Rnf148em1(IMPC)Ccpcz/\Rnf148em1(IMPC)Ccpcz
(C57BL/6N-Rnf148em1(IMPC)Ccpcz/Ccpcz)
abnormal thymus morphology J:211773
enlarged thymus J:211773
\Rnf149em1Staa/\Rnf149em1Staa
(involves: BALB/c * C57BL/6)
increased leukocyte cell number J:335358
increased lymphocyte cell number J:335358
increased monocyte cell number J:335358
increased neutrophil cell number J:335358
\Rnf168Gt(156B6)Cmhd/\Rnf168Gt(156B6)Cmhd
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
abnormal class switch recombination J:198260
abnormal T cell receptor delta chain V(D)J recombination J:198260
decreased gamma-delta T cell number J:198260
decreased IgG1 level J:198260
decreased IgG2a level J:198260
decreased IgG3 level J:198260
decreased IgG level J:198260
immune system phenotype J:198260
increased DN3 thymocyte number J:198260
increased double-negative T cell number J:198260
\Rnf168Gt(405F11)Cmhd/\Rnf168Gt(405F11)Cmhd
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
abnormal class switch recombination J:198260
abnormal T cell receptor delta chain V(D)J recombination J:198260
decreased gamma-delta T cell number J:198260
decreased IgG1 level J:198260
decreased IgG2a level J:198260
decreased IgG3 level J:198260
decreased IgG level J:198260
immune system phenotype J:198260
increased DN3 thymocyte number J:198260
increased double-negative T cell number J:198260
\Rnf168tm2b(EUCOMM)Hmgu/\Rnf168tm2b(EUCOMM)Hmgu
(C57BL/6N-Rnf168tm2b(EUCOMM)Hmgu/Ccpcz)
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged thymus J:211773
increased eosinophil cell number J:211773
\Rnf169tm1a(EUCOMM)Hmgu/\Rnf169tm1a(EUCOMM)Hmgu
(B6NTac;B6N-Rnf169tm1a(EUCOMM)Hmgu/H)
increased monocyte cell number J:165965
\Rnf186em1Ktak/\Rnf186em1Ktak
(involves: C57BL/6 * DBA/2)
increased susceptibility to colitis induced morbidity/mortality J:258197
increased susceptibility to induced colitis J:258197
\Rnf186tm1Ktak/\Rnf186tm1Ktak
(involves: 129S4/SvJae * C57BL/6)
increased susceptibility to colitis induced morbidity/mortality J:258197
increased susceptibility to induced colitis J:258197
\Rnf208em1(IMPC)Ccpcz/\Rnf208em1(IMPC)Ccpcz
(C57BL/6N-Rnf208em1(IMPC)Ccpcz/Ccpcz)
abnormal lymph node morphology J:211773
abnormal thymus morphology J:211773
enlarged lymph nodes J:211773
enlarged thymus J:211773
increased eosinophil cell number J:211773
\Rnf216tm1b(EUCOMM)Wtsi/\Rnf216tm1b(EUCOMM)Wtsi
(C57BL/6N-Rnf216tm1b(EUCOMM)Wtsi/Tcp)
decreased lymphocyte cell number J:211773
increased monocyte cell number J:211773
\Rnf223em1(IMPC)Ccpcz/\Rnf223em1(IMPC)Ccpcz
(C57BL/6N-Rnf223em1(IMPC)Ccpcz/Ccpcz)
abnormal lymph node morphology J:211773
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged lymph nodes J:211773
enlarged spleen J:211773
enlarged thymus J:211773
\Rnft2tm1b(EUCOMM)Hmgu/\Rnft2tm1b(EUCOMM)Hmgu
(C57BL/6N-Rnft2tm1b(EUCOMM)Hmgu/Bay)
abnormal spleen morphology J:211773
\Rnpepl1em1(IMPC)Mbp/\Rnpepl1em1(IMPC)Mbp
(C57BL/6N-Rnpepl1em1(IMPC)Mbp/MbpMmucd)
abnormal lymph node morphology J:211773
enlarged lymph nodes J:211773
\Ro60tm1Woln/\Ro60+
(involves: 129S1/Sv * C57BL/6)
increased anti-nuclear antigen antibody level J:84627
increased IgG2a level J:84627
\Ro60tm1Woln/\Ro60tm1Woln
(involves: 129S1/Sv * C57BL/6)
glomerulonephritis J:84627
increased anti-chromatin antibody level J:84627
increased anti-double stranded DNA antibody level J:84627
increased anti-histone antibody level J:84627
increased anti-nuclear antigen antibody level J:84627
increased anti-single stranded DNA antibody level J:84627
increased IgG2a level J:84627
increased IgM level J:84627
\Rock1tm1Liao/\Rock1+
(C57BL/6-Rock1tm1Liao)
abnormal leukocyte adhesion J:135152
abnormal leukocyte migration J:135152
impaired macrophage chemotaxis J:135152
impaired neutrophil recruitment J:135152
\Rock1tm1Sna/\Rock1tm1Sna
(B6N.129X1-Rock1tm1Sna)
blepharitis J:98250
\Rock2tm1.1Itl/\Rock2+
\Tg(Tagln-cre)1Her/0

(B6.Cg-Rock2tm1.1Itl Tg(Tagln-cre)1Her)
abnormal cytokine secretion J:222206
\Ror1em1(IMPC)Ccpcz/\Ror1+
(C57BL/6NCrl-Ror1em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged spleen J:211773
enlarged thymus J:211773
\Rorasg/\Rorasg
(involves: C57BL/6)
abnormal immune system organ morphology J:2228
abnormal immune system physiology J:2228
abnormal macrophage physiology J:28095
immune system phenotype J:52105
increased IgE level J:135863
increased interleukin-1 secretion J:28095
lung inflammation J:135863
spleen atrophy J:2228
thymus atrophy J:2228
\Rorcm1Btlr/\Rorcm1Btlr
(C57BL/6J-Rorcm1Btlr)
decreased CD4-positive, alpha-beta T cell number J:203039
decreased CD8-positive, alpha-beta T cell number J:203039
\Rorcm2Btlr/\Rorcm2Btlr
(C57BL/6J-Rorcm2Btlr)
decreased IgM level J:217792
decreased response to antigen J:217792
impaired humoral immune response J:217792
\Rorcm3Btlr/\Rorcm3Btlr
(C57BL/6J-Rorcm3Btlr)
abnormal CD4-positive, alpha beta T cell morphology J:234257
decreased B-2 B cell number J:234257
decreased CD4-positive, alpha-beta T cell number J:234257
decreased CD8-positive, naive alpha-beta T cell number J:234257
decreased IgG level J:234257
decreased IgM level J:234257
decreased response to antigen J:234257
impaired humoral immune response J:234257
increased B-1a cell number J:234257
increased B-1b cell number J:234257
increased CD8-positive, alpha-beta T cell number J:234257
increased effector memory CD4-positive, alpha-beta T cell number J:234257
increased effector memory CD8-positive, alpha-beta T cell number J:234257
\Rorctm1.1Zsun/\Rorctm1.1Zsun
(B6(129S4)-Rorctm1.1Zsun)
abnormal T-helper 17 cell differentiation J:248565
absent Peyer's patches J:248565
decreased susceptibility to experimental autoimmune encephalomyelitis J:248565
small inguinal lymph nodes J:248565
\Rorctm1Amj/\Rorctm1Amj
(either: (involves: 129/Sv * C57BL/6) or (involves: 129/Sv * C57BL/6 * DBA/2))
abnormal interleukin level J:123351
abnormal lymph organ development J:64381
abnormal splenic cell ratio J:64381
abnormal T cell physiology J:64381
absent lymph nodes J:64381
absent Peyer's patches J:64381
decreased CD4-positive, alpha-beta T cell number J:64381
decreased CD8-positive, alpha-beta T cell number J:64381
decreased double-positive T cell number J:64381
decreased T cell number J:64381
decreased thymus weight J:64381
enlarged spleen J:64381
increased double-negative T cell number J:64381
increased T cell apoptosis J:64381
thymus hypoplasia J:64381
\Rorctm1Litt/\Rorctm1Litt
(involves: 129P2/OlaHsd)
abnormal CD8-positive, alpha-beta T cell differentiation J:248565
abnormal T cell differentiation J:128344, J:248565
abnormal T cell morphology J:248565
abnormal T-helper 17 cell differentiation J:248565
absent lymph nodes J:248565
colitis J:158663
decreased CD4-positive, alpha-beta T cell number J:248565
decreased double-positive T cell number J:248565
decreased susceptibility to experimental autoimmune encephalomyelitis J:248565
decreased thymocyte number J:248565
increased susceptibility to bacterial infection J:158663
increased susceptibility to bacterial infection induced morbidity/mortality J:158663
increased thymocyte apoptosis J:248565
\Rorctm1Litt/\Rorctm1Litt
\Tcra-Jtm3.1Krg/\Tcra-Jtm3.1Krg

(involves: 129P2/OlaHsd * 129S6/SvEvTac)
abnormal T cell differentiation J:128344
\Rorctm2Litt/\Rorctm2Litt
(involves: 129P2/OlaHsd)
abnormal CD4-positive, alpha-beta intraepithelial T cell morphology J:91566
abnormal CD8 positive, alpha-beta intraepithelial T cell morphology J:91566
abnormal gut-associated lymphoid tissue morphology J:87395, J:91566
abnormal lymph organ development J:87395
absent lymph nodes J:87395
absent Peyer's patches J:87395
decreased double-negative T cell number J:91566
decreased double-positive T cell number J:87395
decreased NK cell number J:142654
increased thymocyte apoptosis J:87395
\Rosq1DBA/1J/\Rosq1DBA/1J
(involves: DBA/1J * FVB/NJ)
abnormal neutrophil physiology J:122919
\Rosq1DBA/1J/\Rosq1FVB/NJ
(involves: DBA/1J * FVB/NJ)
abnormal neutrophil physiology J:122919
\Rpa1tm1Wed/\Rpa1+
(involves: 129/Sv * C57BL/6J * SJL)
increased lymphocyte cell number J:99303
\Rpap3em1(IMPC)Mbp/\Rpap3+
(C57BL/6N-Rpap3em1(IMPC)Mbp/Ucd)
abnormal thymus morphology J:211773
enlarged thymus J:211773
\Rpap3tm1c(KOMP)Wtsi/\Rpap3tm1c(KOMP)Wtsi
\Tg(Vil1-cre/ERT2)23Syr/0

(involves: C57BL/6N * DBA/2)
small intestinal inflammation J:314346
\Rpe65tm1a(EUCOMM)Hmgu/\Rpe65tm1a(EUCOMM)Hmgu
(C57BL/6N-Rpe65tm1a(EUCOMM)Hmgu/H)
decreased leukocyte cell number J:165965
increased leukocyte cell number J:165965
\Rpeem1(IMPC)Mbp/\Rpe+
(C57BL/6NCrl-Rpeem1(IMPC)Mbp/Mmucd)
abnormal spleen morphology J:211773
enlarged spleen J:211773
\Rpgrip1ltm1a(EUCOMM)Wtsi/\Rpgrip1ltm1a(EUCOMM)Wtsi
(C57BL/6N-Rpgrip1ltm1a(EUCOMM)Wtsi/Wtsi)
absent connection between subcutaneous lymph vessels and lymph sac J:239583
absent spleen J:239583
spleen hypoplasia J:239583
\Rpl12em1(IMPC)Mbp/\Rpl12+
(C57BL/6NCrl-Rpl12em1(IMPC)Mbp/Mmucd)
abnormal lymph node morphology J:211773
abnormal spleen morphology J:211773
enlarged lymph nodes J:211773
enlarged spleen J:211773
\Rpl13atm1.1Jesc/\Rpl13atm1.1Jesc
(NOD.129S5(Cg)-Rpl13atm1.1Jesc)
decreased susceptibility to autoimmune diabetes J:237822
\Rpl13atm1.1Mazu/\Rpl13atm1.1Mazu
\Lyz2tm1(cre)Ifo/\Lyz2+

(involves: C57BL/6)
abnormal cytokine level J:194920
abnormal macrophage chemotaxis J:194920
increased circulating tumor necrosis factor level J:194920
\Rpl22Gt(GST000137)Lex/\Rpl22Gt(GST000137)Lex
(involves: 129S5/SvEvBrd)
abnormal T cell differentiation J:123569
abnormal T cell number J:123569
arrested T cell differentiation J:123569
decreased CD4-positive, alpha-beta T cell number J:123569
decreased CD8-positive, alpha-beta T cell number J:123569
decreased double-negative T cell number J:123569
decreased T cell number J:123569
glomerulonephritis J:123569
increased T cell apoptosis J:123569
thymus hypoplasia J:123569
\Rpl22Gt(YHB332)Byg/\Rpl22Gt(YHB332)Byg
(involves: 129P2/OlaHsd * C57BL/6)
abnormal thymus development J:201164
decreased B cell number J:201164
decreased T cell number J:201164
\Rpl27aSfa/\Rpl27a+
(C57BL/6J-Rpl27aSfa)
decreased leukocyte cell number J:174216
small spleen J:174216
small thymus J:174216
\Rpl38Ts/\Rpl38+
(TSJ/Le)
increased susceptibility to otitis media J:168509
\Rplp1tm1.1Melt/\Rplp1tm1.2Melt
(Not Specified)
small thymus J:218949
\Rprd1btm1Tshu/\Rprd1btm1Tshu
\Tg(Vil1-cre)20Syr/0

(involves: C57BL/6 * DBA/2)
increased susceptibility to colitis induced morbidity/mortality J:300857
\Rps6ka3tm1.1Kry/\Rps6ka3+
(involves: 129X1/SvJ)
immune system phenotype J:89403
\Rps6ka3tm1.1Kry/\Rps6ka3tm1.1Kry
(involves: 129X1/SvJ)
immune system phenotype J:89403
\Rps6ka4tm1Jsca/\Rps6ka4tm1Jsca
\Rps6ka5tm1Jsca/\Rps6ka5tm1Jsca

(Not Specified)
decreased T cell proliferation J:124301
spleen hypoplasia J:124301
\Rps6ka4tm1Jsca/\Rps6ka4tm1Jsca
\Rps6ka5tm1Jsca/\Rps6ka5tm1Jsca

(B6.Cg-Rps6ka5tm1Jsca Rps6ka4tm1Jsca)
abnormal cytokine level J:139576
abnormal cytokine secretion J:139576
decreased circulating interleukin-10 level J:139576
decreased interleukin-10 secretion J:139576
increased circulating interleukin-6 level J:139576
increased circulating interleukin-12a level J:139576
increased circulating interleukin-12b level J:139576
increased circulating tumor necrosis factor level J:139576
increased interleukin-6 secretion J:139576
increased interleukin-12a secretion J:139576
increased interleukin-12b secretion J:139576
increased susceptibility to endotoxin shock J:139576
increased tumor necrosis factor secretion J:139576
skin inflammation J:139576
\Rps9tm1.1Geno/\Rps9tm1.1Geno
(involves: C57BL/6)
decreased leukocyte cell number J:329922
increased monocyte cell number J:329922
\Rps12em1.1Nbakr/\Rps12+
(involves: C57BL/6J * FVB/N)
decreased leukocyte cell number J:338970
decreased spleen weight J:338970
\Rps14tm1.1Ble/\Rps14+
\Tg(Mx1-cre)1Cgn/0

(involves: C57BL/6J * C57BL/6NTac * CBA/J)
enlarged spleen J:233322
\Rps14tm1.1Ble/\Rps14+
\Tg(Mx1-cre)1Cgn/0
\Trp53tm2.1Tyj/\Trp53+

(involves: 129S4/SvJae * C57BL/6J * C57BL/6NTac * CBA/J)
immune system phenotype J:233322
\Rps19bp1tm1.1(KOMP)Wtsi/\Rps19bp1+
(C57BL/6N-Rps19bp1tm1.1(KOMP)Wtsi/Bay)
abnormal spleen morphology J:211773
\Rps27lGt(IST11658B7)Tigm/\Rps27lGt(IST11658B7)Tigm
(C57BL/6-Rps27lGt(IST11658B7)Tigm)
decreased spleen weight J:223276
decreased thymus weight J:223276
increased thymocyte apoptosis J:223276
thymus cortex hypoplasia J:223276
\Rps27lGt(IST11658B7)Tigm/\Rps27lGt(IST11658B7)Tigm
(involves: 129 * C57BL/6N)
spleen hypoplasia J:223276
thymus hypoplasia J:223276
\Rps27lGt(IST11658B7)Tigm/\Rps27lGt(IST11658B7)Tigm
\Trp53tm1Tyj/\Trp53+

(involves: 129S2/SvPas * C57BL/6N)
enlarged lymph nodes J:223276
enlarged spleen J:223276
increased T cell derived lymphoma incidence J:223276
\Rptortm1Ahir/\Rptortm1Ahir
\Tg(Itgax-cre)1-1Reiz/0

(B6.Cg-Rptortm1Ahir Tg(Itgax-cre)1-1Reiz)
increased dendritic cell number J:188676
increased susceptibility to induced colitis J:188676
\Rpusd2tm1b(KOMP)Wtsi/\Rpusd2tm1b(KOMP)Wtsi
(C57BL/6N-Rpusd2tm1b(KOMP)Wtsi/Bay)
increased spleen weight J:211773
\Rr7tm1.1Kio/\Rr7tm1.1Kio
(involves: 129S4/SvJae * C57BL/6)
abnormal CD4-positive, alpha beta T cell morphology J:179326, J:164573
immune system phenotype J:164573
\Rr7tm2.1Kio/\Rr7tm2.1Kio
(involves: 129S4/SvJae * C57BL/6)
abnormal CD4-positive, alpha beta T cell morphology J:164573
immune system phenotype J:164573
\Rr7tm3.1Kio/\Rr7+
(B6.129S4-Rr7tm3.1Kio)
abnormal CD4-positive, alpha beta T cell morphology J:179326
\Rr7tm3.1Kio/\Rr7+
\Commd10Tg(Vav1-icre)A2Kio/\Commd10+

(involves: 129S4/SvJae * C57BL/6 * C57BL/10 * CBA/Ca)
immune system phenotype J:179326
\Rr7tm3.1Kio/\Rr7+
\Tg(CD2-icre)4Kio/0

(involves: 129S4/SvJae * C57BL/6 * C57BL/10 * CBA/Ca)
immune system phenotype J:179326
\Rr7tm3.1Kio/\Rr7+
\Tg(Lck-cre)#Nik/0

(involves: 129S4/SvJae * C57BL/6 * DBA/2)
abnormal CD4-positive, alpha beta T cell morphology J:179326
\Rr7tm4.1Kio/\Rr7tm4.1Kio
(involves: 129S4/SvJae * C57BL/6)
abnormal CD4-positive, alpha beta T cell morphology J:179326
\Rr7tm5.1Kio/\Rr7tm5.1Kio
(involves: 129S4/SvJae * C57BL/6)
immune system phenotype J:179326
\Rr9tm1.1Kubo/\Rr9tm1.1Kubo
(C57BL/6-Rr9tm1.1Kubo)
decreased interleukin-13 secretion J:167446
immune system phenotype J:167446
\Rr10tm1.1Kubo/\Rr10tm1.1Kubo
(B6.Cg-Rr10tm1.1Kubo)
immune system phenotype J:167446
\Rr17tm1.1Cdon/\Rr17tm1.1Cdon
(involves: 129S6/SvEvTac * C57BL/6)
decreased interleukin-17 secretion J:181186
decreased susceptibility to experimental autoimmune encephalomyelitis J:181186
immune system phenotype J:181186
increased interleukin-17 secretion J:181186
\Rr32tm1.1Weav/\Rr32tm1.1Weav
(involves: C57BL/6)
decreased interferon-gamma secretion J:208819
immune system phenotype J:208819
\Rr38tm1.2Aafo/\Rr38+
(involves: 129S4/SvJaeSor * BALB/cJ * C57BL/6)
decreased thymocyte number J:227747
immune system phenotype J:227747
\Rr38tm1.2Aafo/\Rr38tm1.2Aafo
(involves: 129S4/SvJaeSor * BALB/cJ * C57BL/6)
abnormal thymus physiology J:227747
decreased CD4-positive, alpha-beta T cell number J:227747
decreased CD8-positive, alpha-beta T cell number J:227747
decreased double-positive T cell number J:227747
decreased single-positive T cell number J:227747
decreased thymocyte number J:227747
decreased thymus weight J:227747
immune system phenotype J:227747
increased DN3 thymocyte number J:227747
small thymus J:227747
thymus hypoplasia J:227747
\Rr39em1Ched/\Rr39em1Ched
(C57BL/6-Rr39em1Ched)
decreased Ly6C low monocyte number J:239509
immune system phenotype J:239509
\Rr79em2Rtew/\Rr79em2Rtew
(C57BL/6J-Rr79em2Rtew/J)
abnormal T cell activation J:332957
abnormal T cell physiology J:332957
abnormal T cell subpopulation ratio J:332957
\Rr79em2Rtew/\Rr79em2Rtew
\Tg(TcraTcrb)1100Mjb/?

(involves: C57BL/6J)
abnormal T cell activation J:332957
\Rr94tm3.1Litt/\Rr94+
\Rr112tm4.1Litt/\Rr112+

(involves: 129P2/OlaHsd * 129S4/SvJaeSor * FVB/N)
immune system phenotype J:158962
\Rr94tm3.1Litt/\Rr94+
\Tg(Cd4-cre)1Cwi/0
\Rr112tm4.1Litt/\Rr112+

(involves: 129P2/OlaHsd * 129S4/SvJaeSor * FVB/N)
abnormal T cell differentiation J:158962
abnormal T cell subpopulation ratio J:158962
decreased CD4-positive, alpha-beta T cell number J:158962
increased CD8-positive, alpha-beta T cell number J:158962
\Rr94tm3.1Litt/\Rr94tm3.1Litt
(involves: 129P2/OlaHsd * FVB/N)
immune system phenotype J:158962
\Rr94tm3.1Litt/\Rr94tm3.1Litt
\Tg(Cd4-cre)1Cwi/0

(involves: 129P2/OlaHsd * C57BL/6 * DBA/2 * FVB/N)
abnormal T cell differentiation J:158962
abnormal T cell subpopulation ratio J:158962
decreased CD4-positive, alpha-beta T cell number J:158962
decreased double-positive T cell number J:158962
increased CD8-positive, alpha-beta T cell number J:158962
\Rr94tm3.2Litt/\Rr94+
\Rr112tm4.1Litt/\Rr112+

(involves: 129P2/OlaHsd * 129S4/SvJaeSor * FVB/N)
abnormal T cell differentiation J:158962
abnormal T cell subpopulation ratio J:158962
decreased CD4-positive, alpha-beta T cell number J:158962
increased CD8-positive, alpha-beta T cell number J:158962
\Rr94tm3.2Litt/\Rr94tm3.2Litt
(involves: 129P2/OlaHsd * FVB/N)
abnormal CD4-positive, alpha beta T cell morphology J:158962
abnormal double-positive T cell morphology J:158962
abnormal T cell differentiation J:158962
abnormal T cell subpopulation ratio J:158962
decreased CD4-positive, alpha-beta T cell number J:158962
decreased double-positive T cell number J:158962
immune system phenotype J:158962
increased CD8-positive, alpha-beta T cell number J:158962
\Rr94tm3.2Litt/\Rr94tm3.2Litt
\H2-Ab1b-tm1Gru/\H2-Ab1b-tm1Gru

(involves: 129P2/OlaHsd * 129S2/SvPas * FVB/N)
abnormal T cell subpopulation ratio J:158962
decreased CD4-positive, alpha-beta T cell number J:158962
immune system phenotype J:158962
increased CD8-positive, alpha-beta T cell number J:158962
\Rr95em1Pdi/\Rr95em1Pdi
(Not Specified)
immune system phenotype J:333574
\Rr96tm1.1Tich/\Rr96+
\Gt(ROSA)26Sortm1(cre/ERT2)Thl/\Gt(ROSA)26Sortm1(rtTA*M2)Jae

(involves: 129 * 129S4/SvJae * C57BL/6)
abnormal T cell differentiation J:191711
\Rr96tm1.1Tich/\Rr96+
\Gt(ROSA)26Sortm1(rtTA*M2)Jae/\Gt(ROSA)26Sor+

(involves: 129 * 129S4/SvJae * C57BL/6)
abnormal CD4-positive T cell differentiation J:191711
\Rr96tm1.1Tich/\Rr96tm1.1Tich
\Gt(ROSA)26Sortm1(rtTA*M2)Jae/\Gt(ROSA)26Sortm1(rtTA*M2)Jae

(involves: 129 * 129S4/SvJae * C57BL/6)
abnormal T cell differentiation J:191711
\Rr96tm1.1Tich/\Rr96tm1.1Tich
\Tg(ACTB-tTS)1Mllo/?

(involves: 129 * C57BL/6)
decreased double-positive T cell number J:191711
\Rr96tm1.1Yzo/\Rr96tm1.1Yzo
(involves: 129P2/OlaHsd)
abnormal T cell differentiation J:130559
increased CD4-positive, alpha-beta T cell number J:130559
increased double-positive T cell number J:130559
\Rr96tm1.1Yzo/\Rr96tm1.1Yzo
\H2-Ab1b-tm1Gru/\H2-Ab1b-tm1Gru

(involves: 129P2/OlaHsd * 129S2/SvPas)
abnormal T cell differentiation J:130559
\Rr96tm1Yzo/\Rr96tm1Yzo
\Tg(Cd4-cre)1Cwi/?

(involves: 129P2/OlaHsd * C57BL/6 * DBA/2)
abnormal T cell differentiation J:130559
increased double-positive T cell number J:130559
\Rr96tm1Yzo/\Rr96tm1Yzo
\Tg(Cd8a-cre,-GFP)1Yzo/?

(involves: 129P2/OlaHsd)
increased double-positive T cell number J:130559
\Rr96tm2Litt/\Rr96+
\Zbtb7btm1.1Tani/\Zbtb7btm1.1Tani

(involves: 129 * 129P2/OlaHsd * C57BL/6)
increased double-negative T cell number J:141142
\Rr96tm2Litt/\Rr96+
\Zbtb7btm1Itan/\Zbtb7btm1.1Tani

(involves: 129 * 129P2/OlaHsd * C57BL/6)
abnormal double-negative T cell morphology J:141142
decreased CD8-positive, alpha-beta T cell number J:141142
\Rr96tm2Litt/\Rr96tm2Litt
(involves: 129P2/OlaHsd)
abnormal CD8-positive, alpha beta T cell morphology J:80690
\Rr96tm2Litt/\Rr96tm2Litt
\Tfap4tm1.1Litt/\Tfap4tm1.1Litt

(involves: 129P2/OlaHsd * C57BL/6 * FVB/N)
abnormal T cell differentiation J:176461
\Rr97tm3Welm/\Rr97tm3Welm
(involves: 129 * C57BL/6)
abnormal CD4-positive T cell differentiation J:126027
abnormal CD8-positive, alpha-beta T cell differentiation J:126027
abnormal dendritic cell morphology J:126027
abnormal double-positive T cell morphology J:126027
abnormal gamma-delta intraepithelial T cell morphology J:126027
abnormal T cell differentiation J:126027
\Rr98tm1Welm/\Rr98tm1Welm
(involves: 129P2/OlaHsd * C57BL/6)
immune system phenotype J:113136
\Rr99tm1Litt/\Rr99tm1Litt
(either: (involves: 129P2/OlaHsd * AKR) or (involves: 129P2/OlaHsd * C57BL/6))
abnormal CD8-positive, alpha beta T cell morphology J:50624
\Rr100tm2.1Welm/\Rr100+
(involves: 129P2/OlaHsd * AKR.1 * C57BL/6)
abnormal T cell differentiation J:113136
\Rr100tm2.1Welm/\Rr100tm2.1Welm
(involves: 129P2/OlaHsd * C57BL/6)
abnormal T cell differentiation J:113136
abnormal T cell subpopulation ratio J:113136
decreased CD8-positive, alpha-beta T cell number J:113136
decreased double-positive T cell number J:113136
increased CD4-positive, alpha-beta T cell number J:113136
\Rr100tm2.1Welm/\Rr100tm2.1Welm
(involves: 129P2/OlaHsd)
abnormal T cell differentiation J:158947
decreased CD8-positive, alpha-beta T cell number J:158947
decreased double-positive T cell number J:158947
immune system phenotype J:158947
increased CD4-positive, alpha-beta T cell number J:158947
\Rr100tm2.1Welm/\Rr100tm2.1Welm
\Patz1tm1.1Welm/\Patz1tm1.1Welm

(involves: 129P2/OlaHsd * C57BL/6)
immune system phenotype J:158947
\Rr100tm2.1Welm/\Rr100tm2.1Welm
\Tcratm1Mom/\Tcratm1Mom

(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6)
abnormal T cell morphology J:113136
\Rr101tm2Kio/\Rr101tm2Kio
(involves: 129S2/SvPas * C57BL/6 * DBA/2)
immune system phenotype J:110530
\Rr104tm1.2Mym/\Rr104tm1.2Mym
\Tg(Epo*)458Mym/0

(involves: C57BL/6 * DBA/2)
abnormal spleen morphology J:231255
\Rr123tm1.1Vbo/\Rr123tm1.1Vbo
(involves: 129S4/SvJae * C57BL/6 * FVB/N)
abnormal regulatory T cell morphology J:191815
immune system phenotype J:191815
increased regulatory T cell number J:191815
\Rr148tm1.1Fwa/\Rr148tm1.1Fwa
(involves: 129S6/SvEvTac)
abnormal B cell differentiation J:101400
arrested B cell differentiation J:101400
decreased immature B cell number J:101400
immune system phenotype J:101400
small spleen J:101400
spleen hypoplasia J:101400
\Rr148tm1.1Fwa/\Rr148tm1.1Fwa
\Rag2tm1Fwa/\Rag2tm1Fwa

(involves: 129S/SvEv * 129S6/SvEvTac)
abnormal B cell differentiation J:101400
\Rr148tm1Anbo/\Rr148tm1Anbo
(involves: 129/Sv * C57BL/6 * FVB/N)
abnormal immunoglobulin heavy chain V(D)J recombination J:136307
decreased immature B cell number J:136307
decreased mature B cell number J:136307
decreased pre-B cell number J:136307
\Rr148tm1Fwa/\Rr148tm1Fwa
(129S6/SvEvTac-Rr148tm1Fwa)
abnormal immature B cell morphology J:101400
absent B cells J:101400
absent Peyer's patches J:101400
arrested B cell differentiation J:101400
immune system phenotype J:101400
small spleen J:101400
spleen hypoplasia J:101400
\Rr148tm1Fwa/\Rr148tm1Fwa
\Rag2tm1Fwa/\Rag2tm1Fwa

(involves: 129S/SvEv * 129S6/SvEvTac)
abnormal B cell differentiation J:101400
\Rr148tm2Anbo/\Rr148tm2Anbo
(involves: 129/Sv * C57BL/6 * FVB/N)
abnormal immunoglobulin heavy chain V(D)J recombination J:136307
decreased immature B cell number J:136307
decreased mature B cell number J:136307
decreased pre-B cell number J:136307
\Rr152tm2Cog/\Rr152+
(involves: 129S2/SvPas * C57BL/6)
decreased IgG1 level J:90548
decreased IgG2b level J:90548
decreased IgG3 level J:90548
decreased IgG level J:90548
\Rr152tm2Cog/\Rr152tm2Cog
(involves: 129S2/SvPas * C57BL/6)
decreased IgG1 level J:90548
decreased IgG2a level J:90548
decreased IgG2b level J:90548
decreased IgG3 level J:90548
decreased IgG level J:90548
increased pre-B cell number J:90548
\Rr152tm3.1Cog/\Rr152tm3.1Cog
(involves: 129P2/OlaHsd * C57BL/6 * FVB/N)
abnormal class switch recombination J:71300
decreased IgA level J:71300
decreased IgE level J:71300
decreased IgG2a level J:71300
decreased IgG2b level J:71300
decreased IgG3 level J:71300
decreased IgG level J:71300
decreased immunoglobulin level J:71300
immune system phenotype J:71300
\Rr152tm3Cog/\Rr152tm3Cog
(involves: 129P2/OlaHsd * C57BL/6)
abnormal B cell morphology J:71300
abnormal class switch recombination J:71300
decreased IgA level J:71300
decreased IgE level J:71300
decreased IgG1 level J:71300
decreased IgG2a level J:71300
decreased IgG2b level J:71300
decreased IgG3 level J:71300
decreased IgG level J:71300
decreased IgM level J:71300
decreased immunoglobulin level J:71300
immune system phenotype J:71300
\Rr152tm5.1Cog/\Rr152tm5.1Cog
(involves: 129P2/OlaHsd * C57BL/6)
abnormal class switch recombination J:164513
abnormal somatic hypermutation frequency J:164513, J:333348
decreased IgA level J:164513
decreased IgE level J:164513
decreased IgG2b level J:164513
decreased IgG3 level J:164513
decreased IgM level J:164513
\Rr155tm1.1Erpi/\Rr155tm1.1Erpi
(involves: 129P2/OlaHsd * C57BL/6 * FVB/N)
abnormal immunoglobulin level J:160101
decreased IgG1 level J:160101
decreased IgG2a level J:160101
immune system phenotype J:160101
\Rr156tm6.1Cog/\Rr156tm6.1Cog
(involves: 129P2/OlaHsd * C57BL/6)
decreased B cell number J:165617
decreased IgM level J:165617
immune system phenotype J:165617
\Rr156tm6Cog/\Rr156tm6Cog
(involves: 129P2/OlaHsd * C57BL/6)
decreased B cell number J:165617
decreased IgM level J:165617
immune system phenotype J:165617
\Rr158tm1(Igh)Xu/\Rr158tm1(Igh)Xu
(Not Specified)
abnormal immune system morphology J:124407
decreased B cell number J:124407
decreased immature B cell number J:124407
increased pre-B cell number J:124407
\Rr158tm1Cgn/\Rr158tm1Cgn
(either: (involves: 129P2/OlaHsd * C57BL/6) or (involves: 129S2/SvPas * C57BL/6))
abnormal B cell differentiation J:12574, J:64287
decreased mature B cell number J:64287
increased mature B cell number J:64287
spleen hypoplasia J:64287
\Rr158tm2Cgn/\Rr158tm2Cgn
(either: (involves: 129P2/OlaHsd * C57BL/6) or (involves: 129S2/SvPas * C57BL/6))
abnormal B cell differentiation J:12574
\Rr158tm2Xu/\Rr158tm2Xu
(Not Specified)
decreased B cell number J:124407
\Rr159tm1.1Fwa/\Rr159+
(involves: 129P2/OlaHsd * C57BL/6)
abnormal B cell differentiation J:113715
\Rr159tm1.1Fwa/\Rr159tm1.1Fwa
(involves: 129P2/OlaHsd * C57BL/6)
abnormal B cell differentiation J:113715
decreased B cell number J:113715
\Rr159tm1Fwa/\Rr159+
(involves: 129P2/OlaHsd * C57BL/6)
increased B cell number J:113715
\Rr159tm1Fwa/\Rr159tm1Fwa
(involves: 129P2/OlaHsd * C57BL/6)
abnormal B cell differentiation J:113715
decreased B cell number J:113715
\Rr160tm1Wtg/\Rr160tm1Wtg
(involves: 129S6/SvEvTac * C57BL/6)
abnormal immunoglobulin level J:134885
abnormal mature B cell morphology J:134885
abnormal somatic hypermutation frequency J:134885
decreased follicular B cell number J:134885
increased transitional stage B cell number J:134885
\Rr161tm2.2Wtg/\Rr161tm2.2Wtg
(involves: 129S4/SvJaeSor * 129S6/SvEvTac * C57BL/6)
abnormal B cell differentiation J:167472
abnormal immunoglobulin V(D)J recombination J:167472
decreased B cell number J:167472
decreased pro-B cell number J:167472
increased pre-B cell number J:167472
\Rr162tm3.1Wtg/\Rr162tm3.1Wtg
(involves: 129S4/SvJaeSor * 129S6/SvEvTac * C57BL/6)
abnormal immunoglobulin V(D)J recombination J:172855
immune system phenotype J:172855
\Rr163tm1Lfdn/\Rr163+
(either: (involves: 129P2/OlaHsd * C57BL/6) or (involves: 129P2/OlaHsd * CB20))
abnormal immune system physiology J:31727
immune system phenotype J:31727
\Rr163tm1Lfdn/\Rr163tm1Lfdn
(either: (involves: 129P2/OlaHsd * C57BL/6) or (involves: 129P2/OlaHsd * CB20))
abnormal immune system physiology J:31727
immune system phenotype J:31727
\Rr166tm4.1Wtg/\Rr166tm4.1Wtg
(involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6)
abnormal B cell differentiation J:193015
abnormal B cell physiology J:193015
abnormal immunoglobulin level J:193015
abnormal immunoglobulin light chain V-J recombination J:193015
abnormal pre-B cell morphology J:193015
\Rr169tm2Rao/\Rr169+
(involves: 129S6/SvEvTac * C57BL/6J)
abnormal T-helper 1 cell differentiation J:94039
\Rr169tm2Rao/\Rr169tm2Rao
(involves: 129S6/SvEvTac * C57BL/6J)
abnormal T-helper 1 cell differentiation J:94039
increased susceptibility to parasitic infection J:94039
\Rr170tm1.1Iku/\Rr170tm1.1Iku
(B6.Cg-Rr170tm1.1Iku)
decreased T cell number J:333539
decreased T cell proliferation J:333539
immune system phenotype J:333539
increased T cell apoptosis J:333539
\Rr172em1Kmm/\Rr172em1Kmm
\Rr253em6Kmm/\Rr253em6Kmm

(C57BL/6J-Rr253em6Kmm Rr172em1Kmm)
decreased dendritic cell number J:334296
decreased monocyte cell number J:334296
immune system phenotype J:334296
increased dendritic cell number J:334296
\Rr253em1Kmm/\Rr253em1Kmm
(C57BL/6-Rr253em1Kmm)
abnormal class switch recombination J:316113
abnormal effector T cell number J:316113
abnormal peritoneal macrophage morphology J:316113
abnormal spleen B cell follicle morphology J:316113
decreased B cell number J:316113
decreased mature NK cell number J:316113
decreased monocyte cell number J:316113
decreased plasmacytoid dendritic cell number J:316113
decreased spleen B cell follicle number J:316113
decreased spleen B cell follicle size J:316113
increased dendritic cell number J:316113
increased lymphocyte cell number J:316113
increased neutrophil cell number J:316113
increased NK cell number J:316113
increased susceptibility to viral infection induced morbidity/mortality J:316113
increased T cell number J:316113
spleen hypoplasia J:316113
\Rr253em3Kmm/\Rr253em3Kmm
(C57BL/6J-Rr253em3Kmm)
decreased dendritic cell number J:334296
\Rr253em4Kmm/\Rr253em4Kmm
(C57BL/6J-Rr253em4Kmm)
immune system phenotype J:334296
\Rr253em5Kmm/\Rr253em5Kmm
(C57BL/6J-Rr253em5Kmm)
decreased dendritic cell number J:334296
increased dendritic cell number J:334296
\Rr253em6Kmm/\Rr253em6Kmm
(C57BL/6J-Rr253em6Kmm)
abnormal T-helper 2 physiology J:334296
decreased dendritic cell number J:334296
decreased monocyte cell number J:334296
decreased plasmacytoid dendritic cell number J:334296
immune system phenotype J:334296
increased dendritic cell number J:334296
increased susceptibility to parasitic infection induced morbidity/mortality J:334296
\Rr270em1Mgn/\Rr270em1Mgn
(involves: CD-1)
abnormal embryonic lymph sac morphology J:328045
\Rr308tm1.1Fwa/\Rr308tm1.1Fwa
(involves: 129P2/OlaHsd)
abnormal T cell differentiation J:82616, J:82395
abnormal T cell receptor alpha chain V-J recombination J:82616
\Rr308tm1Fwa/\Rr308tm1Fwa
(involves: 129P2/OlaHsd)
abnormal T cell differentiation J:82616
abnormal T cell receptor alpha chain V-J recombination J:82616
\Rr308tm2Fwa/\Rr308tm2Fwa
(Not Specified)
abnormal T cell differentiation J:82395
\Rr338em1Jeng/\Rr338em1Jeng
(Not Specified)
abnormal T cell differentiation J:232438
abnormal T cell number J:232438
decreased CD4-positive, alpha-beta T cell number J:232438
\Rr347em1Prdns/\Rr347em1Prdns
(CBA/Ca-Rr347em1Prdns)
absent Langerhans cell J:281171
decreased macrophage cell number J:281171
decreased microglial cell number J:281171
immune system phenotype J:281171
increased Ly6C low monocyte number J:281171
\Rr364tm1.1Aak/\Rr364tm1.1Aak
(129.129S2(Cg)-Rr364tm1.1Aak)
abnormal class switch recombination J:242276
decreased IgG3 level J:242276
increased IgG2a level J:242276
increased IgG2b level J:242276
\Rr381em1Kap/\Rr381em1Kap
(involves: C57BL/6)
absent CD8-positive, alpha-beta T cells J:333471
\Rr381em4Kap/\Rr381em4Kap
(involves: C57BL/6)
absent CD8-positive, alpha-beta T cells J:333471
\Rr381em5Kap/\Rr381em5Kap
(involves: C57BL/6)
absent CD8-positive, alpha-beta T cells J:333471
\Rr381tm1.1Tani/\Rr381+
(Not Specified)
decreased CD8-positive, alpha-beta T cell number J:131081
\Rr383tm1Caob/\Rr383tm1Caob
(B6.Cg-Rr383tm1Caob)
decreased osteoclast cell number J:131132
\Rr386em1Pdi/\Rr386em1Pdi
(involves: C57BL/6J)
immune system phenotype J:333574
\Rr394em1Bhao/\Rr394em1Bhao
(Not Specified)
abnormal T cell receptor alpha chain V-J recombination J:333961
decreased thymocyte number J:333961
increased DN3 thymocyte number J:333961
\Rr395em1Bhao/\Rr395em1Bhao
(Not Specified)
decreased double-positive T cell number J:333961
decreased thymocyte number J:333961
increased DN4 thymocyte number J:333961
increased thymocyte apoptosis J:333961
\Rr149356tm1.1Pf/\Rr149356tm1.1Pf
(either: 129P2/OlaHsd-Rr149356tm1.1Pf or (involves: 129P2/OlaHsd * BALB/c))
abnormal T cell differentiation J:34311
abnormal thymus cortex morphology J:34311
abnormal thymus medulla morphology J:34311
abnormal thymus morphology J:34311
arrested T cell differentiation J:34311
decreased double-positive T cell number J:34311
decreased single-positive T cell number J:34311
decreased T cell number J:34311
decreased thymocyte number J:34311
increased double-negative T cell number J:34311
increased gamma-delta T cell number J:34311
lymph node hypoplasia J:34311
\Rr149356tm1Abnd/\Rr149356tm1Abnd
(involves: 129S1/Sv * 129X1/SvJ)
abnormal T cell differentiation J:137580
abnormal thymus morphology J:137580
arrested T cell differentiation J:137580
decreased double-positive T cell number J:137580
decreased single-positive T cell number J:137580
decreased T cell number J:137580
increased double-negative T cell number J:137580
increased gamma-delta T cell number J:137580
thymus hypoplasia J:137580
\Rr149356tm1Che/\Rr149356tm1Che
(involves: 129S4/SvJae * C57BL/6)
abnormal double-negative T cell morphology J:106246, J:107306
abnormal double-positive T cell morphology J:106246, J:107306
\Rr149356tm1Che/\Rr149356tm1Che
\Tcrdtm1Mom/\Tcrdtm1Mom
\Trp53tm1Tyj/\Trp53tm1Tyj

(involves: 129P2/OlaHsd * 129S2/SvPas * 129S4/SvJae * C57BL/6)
abnormal double-negative T cell morphology J:106246
increased T cell derived lymphoma incidence J:106246
\Rr149356tm1Che/\Rr149356tm1Che
\Trp53tm1Tyj/\Trp53tm1Tyj

(involves: 129S2/SvPas * 129S4/SvJae * C57BL/6)
abnormal double-negative T cell morphology J:106246
abnormal double-positive T cell morphology J:106246
increased T cell derived lymphoma incidence J:106246
\Rr250409tm1Lky/\Rr250409+
(involves: 129X1/SvJ * BALB/c * C57BL/6 * FVB)
decreased interleukin-4 secretion J:125684
\Rr250409tm1Lky/\Rr250409tm1Lky
(involves: 129X1/SvJ * BALB/c * C57BL/6 * FVB)
abnormal response to infection J:125684
decreased IgE level J:125684
decreased interleukin-4 secretion J:125684
decreased interleukin-5 secretion J:125684
decreased interleukin-13 secretion J:125684
decreased susceptibility to parasitic infection J:125684
\Rr250409tm1Lky/\Rr250409tm1Lky
(involves: 129X1/SvJ * BALB/c)
decreased interleukin-4 secretion J:167446
\Rr275254tm2.1Dhr/\Rr275254tm2.1Dhr
(involves: 129S4/SvJae * C57BL/6)
abnormal gamma-delta T cell differentiation J:75624
abnormal T cell receptor gamma chain V-J recombination J:75624
\Rr275254tm2Dhr/\Rr275254tm2Dhr
(involves: 129S4/SvJae)
abnormal gamma-delta T cell differentiation J:75624
abnormal T cell receptor gamma chain V-J recombination J:75624
\Rr282726tm1Dhr/\Rr282726tm1Dhr
(involves: 129S4/SvJae * C57BL/6)
abnormal gamma-delta T cell differentiation J:75624
abnormal T cell receptor gamma chain V-J recombination J:75624
\Rr282729tm1.1Iku/\Rr282729tm1.1Iku
(C57BL/6J-Rr316tm1.1Iku)
abnormal T cell receptor gamma chain V-J recombination J:288442
decreased gamma-delta T cell number J:288442
\Rr299391tm1.1Fwa/\Rr299391+
(involves: 129P2/OlaHsd * FVB/N)
decreased T cell number J:55401
decreased thymocyte number J:55401
\Rr299391tm1.1Fwa/\Rr299391tm1.1Fwa
(involves: 129P2/OlaHsd * FVB/N)
decreased T cell number J:55401
decreased thymocyte number J:55401
\Rragcem1Efe/\Rragc+
(Not Specified)
abnormal B cell activation J:320567
abnormal B cell physiology J:320567
abnormal class switch recombination J:320567
decreased B cell proliferation J:320567
decreased germinal center B cell number J:320567
decreased IgG1 level J:320567
decreased IgM level J:320567
decreased plasma cell number J:320567
decreased spleen germinal center size J:320567
impaired humoral immune response J:320567
\Rragcem1Efe/\Rragc+
\Tg(Vav-BCL2)69Jad/0

(Not Specified)
decreased germinal center B cell number J:320567
decreased spleen germinal center size J:320567
decreased susceptibility to autoimmune disorder J:320567
\Rras2em1(IMPC)Ccpcz/\Rras2em1(IMPC)Ccpcz
(C57BL/6NCrl-Rras2em1(IMPC)Ccpcz/Ccpcz)
abnormal thymus morphology J:211773
enlarged thymus J:211773
increased NK cell number J:211773
\Rras2Gt(OST361011)Lex/\Rras2+
(involves: 129S5/SvEvBrd)
decreased B cell number J:151653
decreased follicular B cell number J:151653
decreased marginal zone B cell number J:151653
decreased memory T cell number J:151653
decreased spleen B cell follicle size J:151653
decreased spleen weight J:151653
decreased T cell number J:151653
spleen hypoplasia J:151653
\Rras2Gt(OST361011)Lex/\Rras2Gt(OST361011)Lex
(involves: 129S5/SvEvBrd)
abnormal B cell activation J:151653
abnormal B cell physiology J:151653
abnormal CD4-positive, alpha-beta T cell physiology J:151653
abnormal CD8-positive, alpha-beta T cell physiology J:151653
abnormal lymph node germinal center morphology J:151653
decreased B cell number J:151653
decreased B cell proliferation J:151653
decreased follicular B cell number J:151653
decreased marginal zone B cell number J:151653
decreased memory T cell number J:151653
decreased spleen B cell follicle size J:151653
decreased spleen weight J:151653
decreased T cell number J:151653
spleen hypoplasia J:151653
\Rras2Gt(OST361011)Lex/\Rras2Gt(OST361011)Lex
(B6.129S5-Rras2Gt(OST361011)Lex)
decreased B cell number J:151653
decreased memory T cell number J:151653
decreased T cell number J:151653
\RrasGt(OST24882)Lex/\RrasGt(OST24882)Lex
(B6;129S5-RrasGt(OST24882)Lex/Ieg)
decreased B cell number J:82809
increased CD4-positive, alpha-beta T cell number J:82809
increased CD8-positive, alpha-beta T cell number J:82809
\Rrastm1Itl/\Rrastm1Itl
(either: (involves: 129S6/SvEvTac) or (involves: 129S6/SvEvTac * C57BL/6))
immune system phenotype J:181730
\Rrastm1Itl/\Rrastm1Itl
(involves: 129S6/SvEvTac * C57BL/6)
abnormal dendritic cell morphology J:181730
abnormal dendritic cell physiology J:181730
\Rreb1tm1b(EUCOMM)Wtsi/\Rreb1+
(C57BL/6N-Rreb1tm1b(EUCOMM)Wtsi/Wtsi)
increased leukocyte cell number J:211773
\Rrm2bGt(OST85254)Lex/\Rrm2bGt(OST85254)Lex
(involves: 129S5/SvEvBrd * C57BL/6J)
spleen atrophy J:186071
thymus atrophy J:186071
\Rrm2btm1Ynak/\Rrm2btm1Ynak
(involves: 129 * C57BL/6J)
abnormal mesenteric lymph node morphology J:84841
decreased spleen white pulp amount J:84841
thymus cortex hypoplasia J:84841
\Rsad1tm1.1(KOMP)Vlcg/\Rsad1+
(C57BL/6N-Rsad1tm1.1(KOMP)Vlcg/Ucd)
enlarged lymph nodes J:211773
small thymus J:211773
\Rsad1tm1.1(KOMP)Vlcg/\Rsad1tm1.1(KOMP)Vlcg
(C57BL/6N-Rsad1tm1.1(KOMP)Vlcg/Ucd)
enlarged lymph nodes J:211773
\Rsad2tm1Aki/\Rsad2tm1Aki
(involves: 129/Sv * C57BL/6)
decreased circulating interferon-alpha level J:169840
decreased interferon-alpha secretion J:169840
decreased interferon-beta secretion J:169840
\Rsad2tm1Kchc/\Rsad2tm1Kchc
(B6.129-Rsad2tm1Kchc)
abnormal T-helper 2 cell differentiation J:148305
decreased IgG1 level J:148305
decreased interleukin-4 secretion J:148305
decreased interleukin-5 secretion J:148305
decreased interleukin-13 secretion J:148305
increased interferon-gamma secretion J:148305
\rsm1/\rsm1
(either: P/J or P/N)
abnormal cell-mediated immunity J:8396
\Rsph9em1Jwji/\Rsph9em1Jwji
(B6.Cg-Rsph9em1Jwji)
increased microglial cell activation J:294184
microgliosis J:294184
sinus inflammation J:294184
\Rspo1tm2b(KOMP)Wtsi/\Rspo1tm2b(KOMP)Wtsi
(C57BL/6N-Rspo1tm2b(KOMP)Wtsi/Ics)
increased lymphocyte cell number J:211773
\Rtcbtm1c(KOMP)Wtsi/\Rtcbtm1c(KOMP)Wtsi
\Tg(Fcer2a-cre)5Mbu/0

(involves: C57BL/6 * CBA * SJL)
abnormal B cell number J:216740
abnormal B cell physiology J:216740
abnormal plasma cell morphology J:216740
decreased IgM level J:216740
\Rthyd1NOD/MrkTac/?
(involves: B10.Br/SgSnJ * NOD-H2k)
abnormal T cell clonal deletion J:94684
\Rthyd2B10.Br/SgSnJ/?
(involves: B10.Br/SgSnJ * NOD-H2k)
abnormal T cell clonal deletion J:94684
\Rthyd3B10.Br/SgSnJ/?
(involves: B10.Br/SgSnJ * NOD-H2k)
abnormal T cell clonal deletion J:94684
\Rthyd5NOD/MrkTac/?
(involves: B10.Br/SgSnJ * NOD-H2k)
abnormal T cell clonal deletion J:94684
\Rtl5em1Tmki/\Rtl5em1Tmki
\Rtl6tm2.1Tmki/\Rtl6tm2.1Tmki

(involves: C57BL/6NCrlj * C57BL/6NSlc * CBA/JNCrlj)
abnormal inflammatory response J:329352
decreased susceptibility to endotoxin shock J:329352
\Rtl5tm1.1Tmki/\Rtl5tm1.1Tmki
(involves: C57BL/6NCrlj * CBA/JNCrlj)
immune system phenotype J:329352
\Rtl5tm1.1Tmki/\Rtl5tm1.1Tmki
\Rtl6tm1.1Tmki/\Rtl6tm1.1Tmki

(involves: C57BL/6NCrlj * C57BL/6NSlc * CBA/JNCrlj)
abnormal inflammatory response J:329352
\Rtl9em2Tmki/\Rtl9em2Tmki
(C57BL/6N-Rtl9em2Tmki)
abnormal innate immunity J:343808
\Rtp4em#Xzs/\Rtp4em#Xzs
(involves: C57BL/6)
decreased susceptibility to parasitic infection J:293929
decreased susceptibility to parasitic infection induced morbidity/mortality J:293929
decreased susceptibility to viral infection J:293929
\Rtraftm1b(EUCOMM)Hmgu/\Rtraf+
(C57BL/6N-Rtraftm1b(EUCOMM)Hmgu/H)
increased eosinophil cell number J:211773
\Rttnem1(IMPC)Tcp/\Rttn+
(C57BL/6NCrl-Rttnem1(IMPC)Tcp/Tcp)
abnormal spleen morphology J:211773
\Rubcnem1Dgre/\Rubcnem1Dgre
(C57BL/6-Rubcnem1Dgre)
abnormal macrophage physiology J:261225
immune system phenotype J:261225
\Rubcnem1Dgre/\Rubcnem1Dgre
(involves: C57BL/6 * C57BL/6N)
abnormal circulating chemokine level J:235399
abnormal macrophage physiology J:235399
abnormal spleen morphology J:235399
decreased circulating interleukin-10 level J:235399
glomerulonephritis J:235399
increased anti-double stranded DNA antibody level J:235399
increased anti-nuclear antigen antibody level J:235399
increased autoantibody level J:235399
increased CD8-positive, alpha-beta T cell number J:235399
increased circulating interleukin-1 beta level J:235399
increased circulating interleukin-6 level J:235399
increased circulating interleukin-12b level J:235399
increased IgG level J:235399
increased lymphocyte cell number J:235399
increased monocyte cell number J:235399
increased neutrophil cell number J:235399
increased susceptibility to systemic lupus erythematosus J:235399
\Rubcnem1Dgre/\Rubcnem1Dgre
\Tg(CAG-EGFP/Map1lc3b)53Nmz/0

(involves: C57BL/6 * C57BL/6J * C57BL/6N * C57BL/6NCrlj * DBA/2)
abnormal macrophage morphology J:261225
abnormal macrophage physiology J:261225
\Rubcnem1Dgre/\Rubcnem1Dgre
\Tg(CAG-EGFP/Map1lc3b)53Nmz/0

(involves: C57BL/6 * C57BL/6N * DBA/2)
abnormal circulating chemokine level J:235399
abnormal macrophage physiology J:235399
decreased circulating interleukin-10 level J:235399
increased circulating interleukin-1 beta level J:235399
increased circulating interleukin-6 level J:235399
\Runx1tm1(RUNX1)Gcg/\Runx1tm1(RUNX1)Gcg
\Tg(Mx1-cre)1Cgn/0

(involves: 129S1/Sv * C57BL/6 * CBA)
abnormal granulocyte differentiation J:106800
abnormal myelopoiesis J:106801
abnormal T cell differentiation J:106800
decreased CD4-positive, alpha-beta T cell number J:106800
decreased double-positive T cell number J:106800
increased CD8-positive, alpha-beta T cell number J:106800
increased T cell derived lymphoma incidence J:106800
\Runx1tm1(RUNX1/EVI1)Kmit/\Runx1+
(involves: C57BL/6 * CBA)
abnormal myelopoiesis J:118892
\Runx1tm1Itan/\Runx1tm1Itan
(involves: 129P2/OlaHsd)
immune system phenotype J:132661
\Runx1tm1Soga/\Runx1tm1.1Soga
\Tg(Mx1-cre)1Cgn/0

(involves: C57BL/6 * CBA)
abnormal B cell differentiation J:88511
abnormal T cell differentiation J:88511
\Runx1tm1Soga/\Runx1tm1Soga
\Stag2tm1.1Soga/Y
\Tg(Mx1-cre)1Cgn/0

(involves: C57BL/6J * C57BL/6N * CBA/J)
decreased leukocyte cell number J:289000
\Runx1tm1Spe/\Runx1+
(either: (involves: 129S4/SvJae * BALB/c * C57BL/6 * CBA/Ca) or (involves: 129S4/SvJae * C57BL/6 * CBA/Ca))
increased T cell derived lymphoma incidence J:80829
\Runx1tm1Spe/\Runx1+
(either: (involves: 129S4/SvJae * BALB/c) or (involves: 129S4/SvJae * C57BL/6))
decreased CD4-positive, alpha-beta T cell number J:120100
\Runx1tm1Spe/\Runx1tm1Spe
(either: (involves: 129S4/SvJae * BALB/c) or (involves: 129S4/SvJae * C57BL/6))
impaired myelopoiesis J:35115
\Runx1tm1Tani/\Runx1tm1Tani
\Runx3tm1Itan/\Runx3tm1Itan
\Tg(Cd4-cre)1Cwi/?

(involves: 129P2/OlaHsd * C57BL/6 * DBA/2)
decreased CD8-positive, alpha-beta T cell number J:125959
\Runx1tm1Tani/\Runx1tm1Tani
\Tg(Cd4-cre)1Cwi/?

(involves: 129P2/OlaHsd * C57BL/6 * DBA/2)
abnormal CD4-positive T cell differentiation J:125959
abnormal CD8-positive, alpha-beta T cell differentiation J:125959
abnormal double-positive T cell morphology J:125959
decreased CD4-positive, alpha-beta T cell number J:125959
\Runx1tm1Tani/\Runx1tm1Tani
\Tg(Lck-cre)1Cwi/?

(involves: 129P2/OlaHsd)
arrested T cell differentiation J:125959
decreased double-positive T cell number J:125959
decreased thymocyte number J:125959
increased double-negative T cell number J:125959
\Runx1tm1Toku/\Runx1+
\Runx3tm1Itan/\Runx3tm1Itan
\Tg(Cd4-cre)1Cwi/0

(involves: 129P2/OlaHsd * C57BL/6 * DBA/2)
decreased CD8-positive, alpha-beta T cell number J:131081
\Runx1tm1Toku/\Runx1tm1Toku
(involves: 129P2/OlaHsd * C57BL/6)
abnormal T cell subpopulation ratio J:87697
increased CD4-positive, alpha-beta T cell number J:87697
small thymus J:87697
thymus hypoplasia J:87697
\Runx1tm1Toku/\Runx1tm1Toku
\Runx3tm1Itan/\Runx3+
\Tg(Cd4-cre)1Cwi/0

(involves: 129P2/OlaHsd * C57BL/6 * DBA/2)
decreased CD4-positive, alpha-beta T cell number J:131081
decreased CD8-positive, alpha-beta T cell number J:131081
\Runx1tm1Toku/\Runx1tm1Toku
\Runx3tm1Itan/\Runx3tm1Itan
\Tg(Cd4-cre)1Cwi/0

(involves: 129P2/OlaHsd * C57BL/6 * DBA/2)
decreased CD4-positive, alpha-beta T cell number J:131081
decreased CD8-positive, alpha-beta T cell number J:131081
\Runx1tm1Toku/\Runx1tm1Toku
\Tg(Cd4-cre)1Cwi/0

(involves: 129P2/OlaHsd * C57BL/6 * DBA/2)
decreased CD8-positive, alpha-beta T cell number J:131081
\Runx1tm1Yg/\Runx1tm1Yg
(either: (involves: 129/Sv * 129S1/Sv * 129X1/SvJ) or (involves: 129S1/Sv * 129X1/SvJ * ICR) or (involves: 129S1/Sv * 129X1/SvJ * MF1))
abnormal leukopoiesis J:125830
abnormal T cell differentiation J:125830
abnormal thymus corticomedullary boundary morphology J:125830
abnormal thymus lobule morphology J:125830
decreased single-positive T cell number J:125830
decreased thymocyte number J:125830
increased double-positive T cell number J:125830
increased thymocyte apoptosis J:125830
small thymus J:125830
thymus cyst J:125830
thymus hypoplasia J:125830
\Runx1tm1Yg/\Runx1tm1Yg
\Tg(Lck-cre)1Jtak/?

(either: (involves: 129/Sv * 129S1/Sv * 129X1/SvJ) or (involves: 129S1/Sv * 129X1/SvJ * ICR) or (involves: 129S1/Sv * 129X1/SvJ * MF1))
decreased T cell number J:125830
\Runx1tm2(Runx1)Toku/\Runx1tm2(Runx1)Toku
(involves: 129P2/OlaHsd * C57BL/6)
abnormal T cell subpopulation ratio J:87697
\Runx1tm2.1Gss/\Runx1tm2.1Gss
(involves: 129S4/SvJae * C57BL/6)
abnormal leukocyte morphology J:214025
abnormal spleen white pulp morphology J:214025
decreased CD8-positive, alpha-beta T cell number J:214025
decreased immature B cell number J:214025
decreased pre-pro B cell number J:214025
enlarged spleen J:214025
increased granulocyte number J:214025
increased macrophage cell number J:214025
increased mature B cell number J:214025
increased monocyte cell number J:214025
increased pro-B cell number J:214025
myeloid hyperplasia J:214025
\Runx1tm2Buch/\Runx1tm2Buch
\Tg(Mx1-cre)1Cgn/?

(involves: 129P2/OlaHsd * C57BL/6 * CBA)
abnormal immune system organ morphology J:105709
abnormal leukocyte morphology J:105709
abnormal lymph node size J:105709
abnormal thymus lobule morphology J:105709
decreased CD4-positive, alpha-beta T cell number J:105709
decreased CD8-positive, alpha-beta T cell number J:105709
decreased double-positive T cell number J:105709
decreased lymphocyte cell number J:105709
decreased mature B cell number J:105709
decreased spleen white pulp amount J:105709
decreased T cell number J:105709
decreased thymus weight J:105709
impaired myelopoiesis J:105709
increased mast cell number J:105709
increased monocyte cell number J:105709
increased neutrophil cell number J:105709
increased spleen red pulp amount J:105709
increased spleen weight J:105709
increased T cell derived lymphoma incidence J:105709
small Peyer's patches J:105709
\Runx1tm2Itan/\Runx1tm2Itan
(involves: 129P2/OlaHsd)
immune system phenotype J:132661
\Runx1tm3(Runx3)Toku/\Runx1tm3(Runx3)Toku
(involves: 129P2/OlaHsd)
abnormal thymus medulla morphology J:98965
decreased leukocyte cell number J:98965
decreased lymphocyte cell number J:98965
decreased thymocyte number J:98965
small spleen J:98965
small thymus J:98965
thymus hypoplasia J:98965
\Runx1tm3Dow/\Runx1+
\Tg(Mx1-cre)1Cgn/0

(involves: C57BL/6 * CBA)
increased T cell derived lymphoma incidence J:77129
\Runx1tm3Itan/\Runx1tm3Itan
(involves: 129P2/OlaHsd * C57BL/6)
decreased leukocyte cell number J:160791
\Runx1tm3Itan/\Runx1tm3Itan
(involves: 129P2/OlaHsd)
abnormal axillary lymph node morphology J:168918
abnormal inguinal lymph node morphology J:168918
abnormal lymph organ development J:168918
abnormal Peyer's patch morphology J:168918
decreased CD4-positive, alpha-beta T cell number J:168918
decreased Peyer's patch number J:168918
decreased thymocyte number J:168918
small Peyer's patches J:168918
\Runx1tm3Spe/\Runx1tm3Spe
\Spi1tm2.1Dgt/\Spi1tm2.1Dgt
\Tg(Mx1-cre)1Cgn/0

(involves: 129S4/SvJae * C57BL/6 * CBA)
decreased B cell number J:131217
decreased thymus weight J:131217
increased granulocyte number J:131217
increased spleen weight J:131217
\Runx1tm3Spe/\Runx1tm3Spe
\Tg(Mx1-cre)1Cgn/0

(involves: 129S4/SvJae * C57BL/6 * CBA)
arrested T cell differentiation J:131217
decreased B cell number J:151639
decreased double-negative T cell number J:131217
decreased thymus weight J:131217
increased double-negative T cell number J:131217
increased spleen weight J:131217
\Runx1tm3Spe/\Runx1tm3Spe
\Tg(VAV1-cre)1Graf/0

(involves: 129S4/SvJae)
decreased B cell number J:145700
decreased double-positive T cell number J:145700
decreased lymphocyte cell number J:145700
decreased thymocyte number J:145700
increased granulocyte number J:145700
increased monocyte cell number J:145700
\Runx1tm4(Runx2)Toku/\Runx1tm4(Runx2)Toku
(involves: 129P2/OlaHsd)
decreased leukocyte cell number J:98965
\Runx1tm4Spe/\Runx1+
(involves: 129/Sv * C57BL/6)
decreased CD4-positive, alpha-beta T cell number J:120100
\Runx1tm4Spe/\Runx1tm4Spe
(involves: 129/Sv * C57BL/6)
decreased leukocyte cell number J:120100
decreased lymphocyte cell number J:120100
increased monocyte cell number J:120100
\Runx1tm5Spe/\Runx1+
(involves: 129/Sv * C57BL/6)
decreased CD4-positive, alpha-beta T cell number J:120100
\Runx1tm6Spe/\Runx1+
(involves: 129/Sv * C57BL/6)
decreased CD4-positive, alpha-beta T cell number J:120100
\Runx1tm7Spe/\Runx1+
(involves: 129/Sv * C57BL/6)
decreased CD4-positive, alpha-beta T cell number J:120100
\Runx1tm8Spe/\Runx1+
(involves: 129/Sv * C57BL/6)
decreased CD4-positive, alpha-beta T cell number J:120100
\Runx1tm8Spe/\Runx1tm8Spe
(involves: 129/Sv * C57BL/6)
lung inflammation J:120100
\Runx2tm1Kish/\Runx2+
(involves: 129P2/OlaHsd * C57BL/6)
enlarged thymus J:162258
\Runx2tm1Kish/\Runx2tm1Kish
(involves: 129P2/OlaHsd * C57BL/6)
abnormal osteoclast differentiation J:59821, J:40783
abnormal splenic cell ratio J:53069
decreased B cell number J:53069
decreased thymocyte number J:40783
enlarged spleen J:53069
increased granulocyte number J:53069
\Runx3tm1Itan/\Runx3tm1Itan
\Tg(Cd4-cre)1Cwi/0

(involves: 129P2/OlaHsd * C57BL/6 * DBA/2)
abnormal CD8-positive, alpha beta T cell morphology J:125953
abnormal CD8-positive, alpha-beta T cell differentiation J:125953
decreased CD8-positive, alpha-beta T cell number J:131081
increased IgA level J:125953
lung inflammation J:125953
\Runx3tm1Litt/\Runx3tm1Litt
(involves: 129P2/OlaHsd)
abnormal CD8-positive, alpha-beta T cell differentiation J:141144
abnormal double-positive T cell morphology J:141144
\Runx3tm1Yg/\Runx3tm1Yg
(either: (involves: 129S1/Sv * 129X1/SvJ * ICR) or (involves: 129S1/Sv * 129X1/SvJ * MF1))
abnormal cytokine level J:93240
abnormal dendritic cell differentiation J:88424
abnormal dendritic cell morphology J:88424
abnormal dendritic cell physiology J:88424, J:100348
abnormal inflammatory response J:93240
abnormal interferon level J:93240
abnormal interleukin level J:93240
abnormal mesenteric lymph node morphology J:93240
abnormal tumor necrosis factor level J:93240
absent Langerhans cell J:88424
colitis J:93240
increased dendritic cell number J:88424, J:100348
increased IgE level J:100348
intestinal inflammation J:93240
lung inflammation J:88424
small intestinal inflammation J:93240
stomach inflammation J:93240
\Runx3tm1Yg/\Runx3tm1Yg
(involves: 129S1/Sv * 129X1/SvJ)
abnormal CD8-positive, alpha beta T cell morphology J:109584
\Runx3tm2Yg/\Runx3tm2Yg
(involves: 129S1/Sv * 129X1/SvJ * BALB/c * C57BL/6 * ICR)
abnormal CD8-positive, alpha beta T cell morphology J:109584
abnormal dendritic cell differentiation J:109584
\Runx3tm3.1Yg/\Runx3tm3.1Yg
(Not Specified)
abnormal immune system physiology J:224898
absent Langerhans cell J:224898
intestinal inflammation J:224898
\Ruvbl1tm1.1Oxbk/\Ruvbl1tm1.1Oxbk
\Tg(Mx1-cre)1Cgn/0

(involves: 129P2/OlaHsd * C57BL/6 * C57BL/6J * CBA/J * SJL)
bone marrow failure J:220926
\Ruvbl2M1Btlr/\Ruvbl2+
(involves: C57BL/6J)
abnormal class switch recombination J:185495
decreased CD4-positive, alpha-beta T cell number J:185495
decreased CD8-positive, alpha-beta T cell number J:185495
decreased double-positive T cell number J:185495
decreased IgG1 level J:185495
decreased IgG level J:185495
decreased IgM level J:185495
decreased T cell number J:185495
immune system phenotype J:185495
increased thymocyte number J:185495
\Rwdd1tm1b(KOMP)Wtsi/\Rwdd1tm1b(KOMP)Wtsi
(C57BL/6N-Rwdd1tm1b(KOMP)Wtsi/Wtsi)
decreased CD8-positive, alpha-beta T cell number J:211773
decreased Ly6C-positive mature NK cell number J:211773
decreased regulatory T cell number J:211773
increased CD4-positive, alpha-beta T cell number J:211773
increased memory-marker gamma-delta T cell number J:211773
\Rwdd2aem1(IMPC)J/\Rwdd2aem1(IMPC)J
(C57BL/6NJ-Rwdd2aem1(IMPC)J/Mmjax)
decreased leukocyte cell number J:211773
\Rxfp2tm1a(EUCOMM)Wtsi/\Rxfp2tm1a(EUCOMM)Wtsi
(C57BL/6N-Rxfp2tm1a(EUCOMM)Wtsi/Ieg)
decreased IgE level J:165965
increased monocyte cell number J:165965
\Rxfp4tm1.1(KOMP)Vlcg/\Rxfp4tm1.1(KOMP)Vlcg
(C57BL/6N-Rxfp4tm1.1(KOMP)Vlcg/J)
decreased leukocyte cell number J:211773
\Rxrapke/\Rxrapke
(C57BL/6J-Rxrapke)
abnormal dendritic cell physiology J:103186
abnormal regulatory T cell physiology J:103186
abnormal T-helper 2 cell morphology J:103186
\Rxratm1Ipc/\Rxratm4Ipc
\Rxrbtm1Mma/\Rxrbtm1Pcn
\Tg(KRT14-cre/ERT2)1Ipc/0

(involves: 129S2/SvPas)
increased immunoglobulin level J:102470
\Rxratm1Krc/\Rxratm1Krc
\Lyz2tm1(cre)Ifo/\Lyz2+

(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)
abnormal macrophage activation involved in immune response J:168799
abnormal peritoneal macrophage morphology J:168799
glomerulonephritis J:168799
impaired macrophage phagocytosis J:168799
increased anti-double stranded DNA antibody level J:168799
increased anti-nuclear antigen antibody level J:168799
increased anti-single stranded DNA antibody level J:168799
increased autoantibody level J:168799
increased IgG level J:168799
increased IgM level J:168799
\Rxratm2Ipc/\Rxratm4Ipc
\Tg(KRT14-cre)1Ipc/0

(involves: 129S2/SvPas * C57BL/6 * SJL)
abnormal Langerhans cell morphology J:67149
skin inflammation J:67149
\Rxratm4Ipc/\Rxratm4Ipc
\Rxrbtm1Pcn/\Rxrbtm1Pcn
\Tg(KRT14-cre/ERT2)1Ipc/0

(involves: 129S2/SvPas)
dermatitis J:102470
ear inflammation J:102470
enlarged cervical lymph nodes J:102470
enlarged spleen J:102470
increased leukocyte cell number J:102470
lymph node hyperplasia J:102470
\Rykem1(IMPC)Mbp/\Ryk+
(C57BL/6NCrl-Rykem1(IMPC)Mbp/MbpMmucd)
increased leukocyte cell number J:211773
increased lymphocyte cell number J:211773
increased monocyte cell number J:211773
\Ryr1tm1b(EUCOMM)Hmgu/\Ryr1+
(C57BL/6N-Ryr1tm1b(EUCOMM)Hmgu/H)
increased spleen weight J:211773
\Ryr2tm1(CAG-KRAS*G12V,-lacZ)Nobs/\Ryr2tm1(CAG-KRAS*G12V,-lacZ)Nobs
\Trp53tm1Sia/\Trp53tm1Sia

(involves: 129X1/SvJ * C57BL/6 * CBA)
myositis J:117828
\Ryr2tm1.1Hnis/\Ryr2tm1.1Hnis
(involves: C57BL/6)
abnormal mesenteric lymph node morphology J:228787
abnormal spleen white pulp morphology J:228787
enlarged mesenteric lymph nodes J:228787
immune system phenotype J:228787
increased spleen weight J:228787
increased thymus weight J:228787
large lymphoid organs J:228787
thymus cortex hyperplasia J:228787
\S1pr1tm1.1Cys/\S1pr1tm1.1Cys
(involves: 129P2/OlaHsd * C3H * C57BL/6)
abnormal B cell physiology J:176118
decreased B cell number J:176118
immune system phenotype J:176118
\S1pr1tm1.1Thla/\S1pr1tm1.1Thla
(B6.Cg-S1pr1tm1.1Thla)
abnormal leukocyte migration J:163389
abnormal lymphocyte physiology J:163389
increased CD4-positive, alpha-beta T cell number J:163389
increased CD8-positive, alpha-beta T cell number J:163389
\S1pr1tm1Cys/\S1pr1tm1Cys
(involves: 129P2/OlaHsd * C57BL/6)
abnormal B cell physiology J:176118
decreased B cell number J:176118
immune system phenotype J:176118
\S1pr1tm1Jch/\S1pr1tm1Jch
\Tg(GFAP-cre)25Mes/?

(involves: C57BL/6J * FVB/N)
decreased susceptibility to experimental autoimmune encephalomyelitis J:168824
\S1pr1tm1Jch/\S1pr1tm1Jch
\Tg(Nes-cre)1Kln/0

(involves: C57BL/6J * SJL)
decreased susceptibility to experimental autoimmune encephalomyelitis J:168824
\S1pr1tm1Jch/\S1pr1tm1Jch
\Tg(Syn1-cre)671Jxm/?

(involves: C57BL/6J * CBA)
immune system phenotype J:168824
\S1pr1tm1Rlp/\S1pr1tm1Rlp
(involves: 129S6/SvEvTac)
abnormal NK cell differentiation J:154069
decreased NK cell number J:154069
\S1pr1tm3.1(tTA,-Arrb2)Rlp/\S1pr1+
\Tg(tetO-HIST1H2BJ/GFP)47Efu/0

(involves: 129S6/SvEvTac * C57BL/6 * CD-1 * FVB/N)
immune system phenotype J:212772
\S1pr2tm1Ajml/\S1pr2tm1Ajml
(involves: 129S5/SvEvBrd * C57BL/6)
abnormal spleen marginal zone morphology J:154439
increased germinal center B cell number J:154439
increased spleen germinal center number J:154439
increased spleen germinal center size J:154439
increased T cell number J:154439
\S1pr2tm1Rlp/\S1pr2tm1Rlp
(involves: 129S6/SvEvTac * C57BL/6)
abnormal spleen germinal center morphology J:174313
decreased B cell apoptosis J:174313
increased B cell number J:174313
increased B cell proliferation J:174313
increased germinal center B cell number J:174313
increased T cell number J:174313
\S1pr3tm1Jch/\S1pr3tm1Jch
(involves: 129S1/Sv * 129X1/SvJ)
abnormal cytokine level J:133917
decreased susceptibility to endotoxin shock J:133917
enlarged mesenteric lymph nodes J:133917
\S1pr3tm1Rlp/\S1pr3tm1Rlp
(involves: 129S6/SvEvTac * C57BL/6)
abnormal B cell physiology J:91161
\S1pr4tm1Lipp/\S1pr4tm1Lipp
(involves: 129X1/SvJ * C57BL/6J)
abnormal thrombopoiesis J:179199
\S1pr5tm1Club/\S1pr5tm1Club
(B6.129P2-S1pr5tm1Club)
abnormal NK cell morphology J:178789
abnormal NK cell physiology J:178789
decreased NK cell number J:178789
\S1pr5tm1Jch/\S1pr5tm1Jch
(involves: 129P2/OlaHsd * C57BL/6)
abnormal NK cell differentiation J:154069
\S100a3em1(IMPC)Mbp/\S100a3em1(IMPC)Mbp
(C57BL/6NCrl-S100a3em1(IMPC)Mbp/MbpMmucd)
abnormal spleen morphology J:211773
\S100a4tm1.1Abres/\S100a4tm1.1Abres
(B6.Cg-S100a4tm1.1Abres)
abnormal eosinophil physiology J:182865
impaired macrophage chemotaxis J:182865
\S100a9tm1Hogg/\S100a9tm1Hogg
(involves: 129P2/OlaHsd * C57BL/6)
abnormal neutrophil morphology J:82513
abnormal neutrophil physiology J:82513
immune system phenotype J:82513
\S100a9tm1Nck/\S100a9tm1Nck
(B6.129P2-S100a9tm1Nck)
decreased circulating tumor necrosis factor level J:125179
decreased susceptibility to bacterial infection induced morbidity/mortality J:125179
decreased susceptibility to endotoxin shock J:125179
decreased susceptibility to fungal infection J:209808
\S100a9tm1Nck/\S100a9tm1Nck
(involves: 129P2/OlaHsd * C57BL/6)
abnormal cellular extravasation J:81642
\Saa3tm1(KOMP)Vlcg/\Saa3tm1(KOMP)Vlcg
(involves: C57BL/6NTac)
decreased circulating serum amyloid protein level J:220630
\Sac3d1tm1Hnaka/\Sac3d1+
(involves: 129P2/OlaHsd)
abnormal mast cell physiology J:144601
\Sac3d1tm1Hnaka/\Sac3d1tm1Hnaka
(involves: 129P2/OlaHsd)
abnormal B cell physiology J:144601
abnormal mast cell physiology J:144601
increased T cell proliferation J:144601
spleen hyperplasia J:144601
thymus hyperplasia J:144601
\Sacsem1(IMPC)Tcp/\Sacsem1(IMPC)Tcp
(C57BL/6NCrl-Sacsem1(IMPC)Tcp/Tcp)
abnormal spleen morphology J:211773
\Sall3tm1.1(KOMP)Mbp/\Sall3+
(C57BL/6NCrl-Sall3tm1.1(KOMP)Mbp/Ccpcz)
abnormal lymph node morphology J:211773
abnormal thymus morphology J:211773
enlarged lymph nodes J:211773
enlarged thymus J:211773
\Sall4tm1Brd/\Sall4+
(involves: 129S7/SvEvBrd * C57BL/6J)
ear inflammation J:117866
increased susceptibility to otitis media J:117866
\Samd3tm1.1(HBEGF)Wfkr/\Samd3+
(C57BL/6J-Samd3tm1.1(HBEGF)Wfkr)
abnormal NK cell differentiation J:322359
decreased memory T cell number J:322359
decreased NK cell number J:322359
\Samd3tm1.1(HBEGF)Wfkr/\Samd3tm1.1(HBEGF)Wfkr
(C57BL/6J-Samd3tm1.1(HBEGF)Wfkr)
decreased CD8-positive, alpha-beta memory T cell number J:322359
immune system phenotype J:322359
\Samd8tm1Jia/\Samd8tm1Jia
(involves: 129S6/SvEvTac * C57BL/6J)
immune system phenotype J:220024
\Samd9ltm1Homy/\Samd9l+
(involves: 129P2/OlaHsd)
abnormal myelopoiesis J:202604
abnormal neutrophil morphology J:202604
decreased neutrophil cell number J:202604
enlarged spleen J:202604
increased leukocyte cell number J:202604
increased susceptibility to Retroviridae infection J:202604
\Samd9ltm1Homy/\Samd9ltm1Homy
(involves: 129P2/OlaHsd)
abnormal myelopoiesis J:202604
abnormal neutrophil morphology J:202604
decreased neutrophil cell number J:202604
enlarged spleen J:202604
increased leukocyte cell number J:202604
increased susceptibility to Retroviridae infection J:202604
\Samhd1tm1.2Crs/\Samhd1tm1.2Crs
(involves: C57BL/6N * C57BL/6NTac)
increased susceptibility to Retroviridae infection J:201909
\Samhd1tm1d(EUCOMM)Wtsi/\Samhd1tm1d(EUCOMM)Wtsi
(involves: C57BL/6N)
abnormal response to infection J:202757
immune system phenotype J:202757
\Samhd1tm2.2Crs/\Samhd1tm2.2Crs
(involves: 129S6/SvEvTac * C57BL/6J)
increased susceptibility to Retroviridae infection J:201909
\Samsn1tm1Xyw/\Samsn1tm1Xyw
(B6.129P2-Samsn1tm1Xyw)
abnormal dendritic cell physiology J:158032
abnormal T-helper 1 physiology J:158032
abnormal T-helper 2 physiology J:158032
increased B cell proliferation J:158032
increased B-1a cell number J:158032
increased circulating interferon-gamma level J:158032
increased IgG3 level J:158032
increased IgM level J:158032
increased interleukin-4 secretion J:158032
increased interleukin-12 secretion J:158032
increased T cell proliferation J:158032
\Sap130tm1a(KOMP)Mbp/\Sap130+
(C57BL/6N-Sap130tm1a(KOMP)Mbp/Wtsi)
decreased leukocyte cell number J:211773
\Sarm1tm1.1Diam/\Sarm1tm1.1Diam
(involves: 129X1/SvJ * C57BL/6)
abnormal circulating tumor necrosis factor level J:200140
decreased microglial cell activation J:200140
immune system phenotype J:200140, J:196200
increased susceptibility to Flaviviridae infection J:200140
increased susceptibility to Flaviviridae infection induced morbidity/mortality J:200140
\Sarm1tm1Aidi/\Sarm1tm1Aidi
(involves: 129X1/SvJ * C57BL/6J)
immune system phenotype J:126083
\Sash3tm1Hlz/\Sash3tm1Hlz
(B6.129P2-Sash3tm1Hlz)
abnormal B cell morphology J:102171
abnormal B cell physiology J:102171
abnormal CD4-positive T cell differentiation J:102171
abnormal CD8-positive, alpha-beta T cell differentiation J:102171
abnormal humoral immune response J:102171
abnormal immune system organ morphology J:102171
abnormal inflammatory response J:102171
abnormal marginal zone B cell physiology J:102171
abnormal T cell morphology J:102171
decreased double-positive T cell number J:102171
decreased IgG1 level J:102171
decreased IgG2a level J:102171
decreased IgG level J:102171
decreased IgM level J:102171
decreased interferon-gamma secretion J:102171
decreased interleukin-2 secretion J:102171
decreased interleukin-4 secretion J:102171
decreased interleukin-10 secretion J:102171
decreased marginal zone B cell number J:102171
decreased Peyer's patch number J:102171
decreased T cell proliferation J:102171
decreased tumor necrosis factor secretion J:102171
increased length of allograft survival J:102171
lymphoid hypoplasia J:102171
\Satb1m1Anu/\Satb1+
(C57L/6JAnu-Satb1m1Anu)
abnormal CD4-positive, alpha beta T cell morphology J:104190
abnormal CD8-positive, alpha beta T cell morphology J:104190
\Satb1m1Anu/\Satb1m1Anu
(C57L/6JAnu-Satb1m1Anu)
abnormal CD4-positive, alpha beta T cell morphology J:104190
abnormal CD8-positive, alpha beta T cell morphology J:104190
\Satb1tm1Kos/\Satb1tm1Kos
(involves: 129P2/OlaHsd * C57BL/6)
abnormal T cell differentiation J:61085
abnormal T cell proliferation J:61085
arrested T cell differentiation J:61085
decreased thymocyte number J:61085
small lymph nodes J:61085
small spleen J:61085
small thymus J:61085
\Satb1tm2Kos/\Satb1tm2Kos
\Commd10Tg(Vav1-icre)A2Kio/\Commd10+

(involves: C57BL/6 * C57BL/10 * CBA/Ca)
absent regulatory T cells J:252606
increased anti-nuclear antigen antibody level J:252606
increased autoantibody level J:252606
increased susceptibility to autoimmune disorder J:252606
kidney inflammation J:252606
pancreas inflammation J:252606
salivary gland inflammation J:252606
\Satb2tm1b(KOMP)Wtsi/\Satb2+
(C57BL/6N-Satb2tm1b(KOMP)Wtsi/Ucd)
enlarged lymph nodes J:211773
\Saxo1tm1b(EUCOMM)Hmgu/\Saxo1tm1b(EUCOMM)Hmgu
(C57BL/6N-Saxo1tm1b(EUCOMM)Hmgu/Ics)
decreased lymphocyte cell number J:211773
increased eosinophil cell number J:211773
\Saysd1em1(IMPC)J/\Saysd1em1(IMPC)J
(C57BL/6NJ-Saysd1em1(IMPC)J/Mmjax)
increased leukocyte cell number J:211773
\Sbdstm1Dats/\Sbdstm1Dats
\Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0

(involves: C57BL/6 * CD-1)
abnormal myeloid leukocyte morphology J:158901
abnormal neutrophil morphology J:158901
decreased B cell number J:158901
decreased leukocyte cell number J:158901
decreased lymphocyte cell number J:158901
\Sbf1em1(IMPC)Mbp/\Sbf1em1(IMPC)Mbp
(C57BL/6N-Sbf1em1(IMPC)Mbp/MbpMmucd)
decreased lymphocyte cell number J:211773
increased neutrophil cell number J:211773
\Sbk1tm1b(EUCOMM)Wtsi/\Sbk1+
(C57BL/6N-Sbk1tm1b(EUCOMM)Wtsi/Bay)
decreased leukocyte cell number J:211773
\Sbno1tm1b(EUCOMM)Hmgu/\Sbno1+
(C57BL/6N-Sbno1tm1b(EUCOMM)Hmgu/H)
increased leukocyte cell number J:211773
\Sbno2tm1.1Aki/\Sbno2tm1.1Aki
(involves: 129 * C57BL/6)
abnormal osteoclast morphology J:202853
abnormal osteoclast physiology J:202853
immune system phenotype J:202853
\Sbsnem1Ham/\Sbsnem1Ham
(C57BL/6N-Sbsnem1Ham)
decreased interleukin-4 secretion J:296400
decreased susceptibility to type IV hypersensitivity reaction J:296400
immune system phenotype J:296400
increased susceptibility to type IV hypersensitivity reaction J:296400
\Sbw1NZB/BlScr/\Sbw1NZB/BlScr
(involves: NZB/BlScr * NZW/LacScr)
enlarged spleen J:20991
\Sbw2NZB/BlScr/\Sbw2NZB/BlScr
(involves: NZB * NZW)
enlarged spleen J:20991
\Sbw2NZB/BlScr/\Sbw2NZW/LacScr
(involves: NZB * NZW)
enlarged spleen J:20991
\Scaitm1b(EUCOMM)Hmgu/\Scaitm1b(EUCOMM)Hmgu
(involves: C57BL/6N * FVB/N)
immune system phenotype J:240463
\Scara5tm1Ktry/\Scara5tm1Ktry
(B6N.129X1-Scara5tm1Ktry)
adipose tissue inflammation J:195536
increased anti-nuclear antigen antibody level J:195536
interstitial pneumonia J:195536
liver inflammation J:195536
lung inflammation J:195536
skin inflammation J:195536
urinary bladder inflammation J:195536
\Scarb1tm1.1Thh/\Scarb1tm1.1Thh
(B6.129X1-Scarb1tm1.1Thh)
increased circulating interleukin-6 level J:114663
\Scarb1tm1b(EUCOMM)Wtsi/\Scarb1tm1b(EUCOMM)Wtsi
(C57BL/6N-Scarb1tm1b(EUCOMM)Wtsi/Bay)
enlarged spleen J:211773
increased spleen weight J:211773
\Scarb1tm1Thh/\Scarb1tm1Thh
\Speer6-ps1Tg(Alb-cre)21Mgn/\Speer6-ps1+

(B6.Cg-Scarb1tm1Thh Speer6-ps1Tg(Alb-cre)21Mgn)
increased circulating interleukin-6 level J:114663
\Scarb2em2(IMPC)Tcp/\Scarb2em2(IMPC)Tcp
(C57BL/6NCrl-Scarb2em2(IMPC)Tcp/Tcp)
decreased monocyte cell number J:211773
enlarged lymph nodes J:211773
increased leukocyte cell number J:211773
increased lymphocyte cell number J:211773
increased neutrophil cell number J:211773
\Scarb2tm1Psa/\Scarb2tm1Psa
(involves: 129P2/OlaHsd * C57BL/6N)
microgliosis J:216676
\Scarf1tm1Tkms/\Scarf1tm1Tkms
(involves: C57BL/6)
abnormal B cell physiology J:208237
abnormal dendritic cell physiology J:208237
abnormal spleen morphology J:208237
enlarged spleen J:208237
glomerulonephritis J:208237
immune system phenotype J:208237
impaired macrophage phagocytosis J:208237
increased anti-histone antibody level J:208237
increased anti-nuclear antigen antibody level J:208237
increased anti-single stranded DNA antibody level J:208237
increased B cell number J:208237
increased CD4-positive, alpha-beta T cell number J:208237
increased IgG level J:208237
increased lymphocyte cell number J:208237
increased spleen germinal center size J:208237
increased susceptibility to systemic lupus erythematosus J:208237
increased T follicular helper cell number J:208237
skin inflammation J:208237
\Scd1ab-2J/\Scd1ab-2J
(DBA/1LacJ-Scd1ab-2J/J)
granulomatous inflammation J:62699
\Scd1flk/\Scd1flk
(C57BL/6J-Scd1flk)
increased susceptibility to bacterial infection J:100424
\Scd2swty/\Scd2swty
(C57BL/6JSfdAnu-Scd2swty/Anu)
blepharitis J:104190
\Scelem1(IMPC)Ccpcz/\Scelem1(IMPC)Ccpcz
(C57BL/6NCrl-Scelem1(IMPC)Ccpcz/Ccpcz)
abnormal thymus morphology J:211773
enlarged thymus J:211773
\Scg5em1(IMPC)Mbp/\Scg5em1(IMPC)Mbp
(C57BL/6NCrl-Scg5em1(IMPC)Mbp/MbpMmucd)
increased monocyte cell number J:211773
\Scg5tm1Led/\Scg5tm1Led
(either: 129S6/SvEvTac or (involves: 129S6/SvEvTac * FVB) or (involves: 129S6/SvEvTac * C57BL/6))
spleen atrophy J:53349
\Scgb1a1tm1Abm/\Scgb1a1+
(involves: 129S1/Sv * 129X1/SvJ)
abnormal complement protein level J:57504
increased IgA level J:57504
\Scgb1a1tm1Abm/\Scgb1a1tm1Abm
(involves: 129S1/Sv * 129X1/SvJ)
abnormal complement protein level J:57504
increased IgA level J:57504
\Scgnem1Ezb/\Scgnem1Ezb
(C57BL/6-Scgnem1Ezb)
increased susceptibility to colitis induced morbidity/mortality J:285572
\Scgnem2Ezb/\Scgnem2Ezb
(C57BL/6-Scgnem2Ezb)
increased susceptibility to colitis induced morbidity/mortality J:285572
\Scintm1Glog/\Scintm1Glog
\Tg(Acp5-cre)4Rda/0

(either: (involves: 129 * C57BL/6) or (involves: 129 * C57BL/6 * CBA))
abnormal osteoclast differentiation J:223220
abnormal osteoclast morphology J:223220
abnormal osteoclast physiology J:223220
\Scl2C57BL/6J/\Scl2C57BL/6J
(involves: C57BL/6J * DBA/2J)
increased susceptibility to parasitic infection J:12046
\Scmh1tm1Yota/\Scmh1tm1Yota
(involves: 129X1/SvJ * C57BL/6)
decreased B cell number J:194424
decreased T cell number J:194424
myeloid hyperplasia J:194424
\Scml4em1(IMPC)J/\Scml4em1(IMPC)J
(C57BL/6NJ-Scml4em1(IMPC)J/Mmjax)
increased leukocyte cell number J:211773
\Scn3btm1a(KOMP)Wtsi/\Scn3btm1a(KOMP)Wtsi
(C57BL/6N-Scn3btm1a(KOMP)Wtsi/Wtsi)
myositis J:232539
\Scn8aem1(IMPC)Bay/\Scn8a+
(C57BL/6N-Scn8aem1(IMPC)Bay/BayMmucd)
increased spleen weight J:211773
\Scn9atm1Dgen/\Scn9atm1Dgen
(either: (involves: 129P2/OlaHsd * BALB/c * C57BL/6) or (involves: 129P2/OlaHsd * C57BL/6 * CD-1))
dermatitis J:223425
\Sco1tm1c(KOMP)Wtsi/\Sco1tm1c(KOMP)Wtsi
\Speer6-ps1Tg(Alb-cre)21Mgn/\Speer6-ps1+

(involves: C57BL/6 * C57BL/6N * DBA)
decreased leukocyte cell number J:222036
decreased spleen white pulp amount J:222036
increased spleen iron level J:222036
spleen atrophy J:222036
\Scp2tm1Kier/\Scp2tm1Kier
(involves: 129P2/OlaHsd * C57BL/6NCr)
liver inflammation J:124895
\Scr/\Scr
(involves: 101/H * C3H/HeH)
small thymus J:3458
\Sctrtm1Bkcc/\Sctrtm1Bkcc
(B6.129S7-Sctrtm1Bkcc)
abnormal cytokine secretion J:121376
increased macrophage cell number J:121376
kidney inflammation J:121376
\Scyl1tm1.1Spel/\Scyl1tm1.1Spel
(involves: 129S6/SvEvTac * C57BL/6J)
microgliosis J:192445
\Scyl1tm1Spel/\Scyl1tm1Spel
\Tg(Nes-cre)1Kln/0

(involves: 129S6/SvEvTac * C57BL/6 * C57BL/6J * SJL)
microgliosis J:192445
\Scyl2tm1.1Spel/\Scyl2tm1.1Spel
\Tg(Nes-cre)1Kln/0

(involves: 129S6/SvEvTac * C57BL/6 * SJL)
microgliosis J:225808
\Scyl3tm1.1Spel/\Scyl3tm1.1Spel
(involves: 129S6/SvEvTac * C57BL/6J)
immune system phenotype J:262629
\Sdc1tm1Cma/\Sdc1tm1Cma
(either: (involves: 129S4/SvJae * BALB/c) or (involves: 129S4/SvJae * C57BL/6))
decreased susceptibility to bacterial infection J:69845
\Sdc1tm1Cma/\Sdc1tm1Cma
(either: C.Cg-Sdc1tm1Cma or B6.Cg-Sdc1tm1Cma)
increased inflammatory response J:80682
\Sdc1tm1Cma/\Sdc1tm1Cma
(B6.Cg-Sdc1tm1Cma)
decreased susceptibility to bacterial infection J:104294
decreased susceptibility to bacterial infection induced morbidity/mortality J:104294
\Sdc1tm1Cma/\Sdc1tm1Cma
(involves: 129S4/SvJae)
decreased IgG1 level J:107378
decreased interleukin-10 secretion J:107378
decreased interleukin-13 secretion J:107378
increased susceptibility to parasitic infection J:107378
\Sdc4tm2b(KOMP)Wtsi/\Sdc4tm2b(KOMP)Wtsi
(C57BL/6N-Sdc4tm2b(KOMP)Wtsi/H)
decreased lymphocyte cell number J:211773
increased neutrophil cell number J:211773
\Sdhbtm1b(EUCOMM)Hmgu/\Sdhb+
(C57BL/6N-Sdhbtm1b(EUCOMM)Hmgu/Ieg)
decreased neutrophil cell number J:211773
\seb/\seb
(Him:OF1)
dermatitis J:64455
lymph node hyperplasia J:20987
lymph node inflammation J:20987
skin inflammation J:8983
\Sec1em1Cya/\Sec1em1Cya
(C57BL/6-Sec1em1Cya)
decreased susceptibility to bacterial infection induced morbidity/mortality J:325740
\Sec22btm1c(EUCOMM)Wtsi/\Sec22btm1c(EUCOMM)Wtsi
\Tg(Itgax-cre)1-1Reiz/0

(involves: C57BL/6 * C57BL/6N * CBA * SJL)
immune system phenotype J:255769
\Sec23bGt(AD0407)Wtsi/\Sec23bGt(AD0407)Wtsi
(B6J.129P2-Sec23bGt(AD0407)Wtsi)
pancreas inflammation J:186391
\Sec24bem1(IMPC)Tcp/\Sec24b+
(C57BL/6NCrl-Sec24bem1(IMPC)Tcp/Tcp)
enlarged lymph nodes J:211773
enlarged spleen J:211773
\Sec63tm1b(EUCOMM)Hmgu/\Sec63+
(C57BL/6N-Sec63tm1b(EUCOMM)Hmgu/Bay)
decreased lymphocyte cell number J:211773
increased neutrophil cell number J:211773
\Secia1DBA/1J/?
(involves: DBA/1J * FVB/NJ)
increased susceptibility to induced arthritis J:123131
\Secia2DBA/1J/?
(involves: DBA/1J * FVB/NJ)
increased susceptibility to induced arthritis J:123131
\Secia3FVB/NJ/?
(involves: DBA/1J * FVB/NJ)
increased susceptibility to induced arthritis J:123131
\Secia4DBA/1J/?
(involves: DBA/1J * FVB/NJ)
increased susceptibility to induced arthritis J:123131
\Secia5DBA/1J/?
(involves: DBA/1J * FVB/NJ)
increased susceptibility to induced arthritis J:123131
\Secia6DBA/1J/?
(involves: DBA/1J * FVB/NJ)
increased susceptibility to induced arthritis J:123131
\Secia7FVB/NJ/?
(involves: DBA/1J * FVB/NJ)
increased susceptibility to induced arthritis J:123131
\Secia8FVB/NJ/?
(involves: DBA/1J * FVB/NJ)
increased susceptibility to induced arthritis J:123131
\Secisbp2tm1a(EUCOMM)Wtsi/\Secisbp2+
(Not Specified)
increased NK cell number J:165965
\Secisbp2tm1c(EUCOMM)Wtsi/\Secisbp2tm1c(EUCOMM)Wtsi
(C57BL/6N-Secisbp2tm1a(EUCOMM)Wtsi/H)
increased leukocyte cell number J:211773
\Sectm1aem1Gcfa/\Sectm1aem1Gcfa
(C57BL/6-Sectm1aem1Gcfa)
abnormal interleukin level J:317204
abnormal macrophage physiology J:317204
abnormal tumor necrosis factor level J:317204
heart inflammation J:317204
increased circulating interleukin-1 beta level J:317204
increased circulating interleukin-6 level J:317204
increased circulating tumor necrosis factor level J:317204
increased susceptibility to endotoxin shock J:317204
\Seletm1Alb/\Seletm1Alb
(involves: 129S7/SvEvBrd * C57BL/6J)
abnormal spleen morphology J:101979
eye inflammation J:101979
increased susceptibility to bacterial infection J:101979
\Seletm1Alb/\Seletm1Alb
(involves: 129S7/SvEvBrd * C57BL/6)
increased neutrophil cell number J:112286
\Seletm1Dmil/\Seletm1Dmil
(involves: 129S4/SvJae * C57BL/6J)
abnormal leukocyte adhesion J:113169
\Seletm1Hyn/\Seletm1Hyn
\Selltm1Hyn/\Selltm1Hyn
\Selptm1Hyn/\Selptm1Hyn

(involves: 129S2/SvPas * C57BL/6)
impaired eosinophil recruitment J:57973
impaired leukocyte tethering or rolling J:57973
impaired neutrophil recruitment J:57973
increased eosinophil cell number J:57973
increased leukocyte cell number J:57973
increased monocyte cell number J:57973
increased neutrophil cell number J:57973
\Seletm1Hyn/\Seletm1Hyn
\Selptm1Hyn/\Selptm1Hyn

(involves: 129S2/SvPas)
abnormal cytokine level J:31626
abnormal granulocyte differentiation J:31626
abnormal myelopoiesis J:31626
impaired leukocyte tethering or rolling J:31626
impaired neutrophil recruitment J:31626
increased circulating interleukin-3 level J:31626
increased eosinophil cell number J:31626
increased leukocyte cell number J:31626
increased lymphocyte cell number J:31626
increased monocyte cell number J:31626
increased neutrophil cell number J:31626
increased spleen red pulp amount J:31626
increased spleen weight J:31626
increased susceptibility to bacterial infection J:31626
spleen hyperplasia J:31626
\Seletm1Hyn/\Seletm1Hyn
\Selptm1Hyn/\Selptm1Hyn

(involves: 129S2/SvPas * C57BL/6)
impaired eosinophil recruitment J:57973
impaired leukocyte tethering or rolling J:57973
impaired neutrophil recruitment J:57973
increased eosinophil cell number J:57973
increased leukocyte cell number J:57973
increased monocyte cell number J:57973
increased neutrophil cell number J:57973
\Seletm1Roml/\Seletm1Roml
(involves: 129S1/Sv * C57BL/6)
abnormal T cell physiology J:113536
\Seletm1Roml/\Seletm1Roml
(involves: 129S1/Sv)
abnormal T cell physiology J:113536
\Seletm2Alb/\Seletm2Alb
\Selltm2Alb/\Selltm2Alb
\Selptm1Bay/\Selptm1Bay

(involves: 129S7/SvEvBrd * C57BL/6)
abnormal cellular extravasation J:70682
abnormal cervical lymph node morphology J:70682
abnormal spleen B cell follicle morphology J:70682
abnormal spleen B cell follicle shape J:106550
abnormal spleen morphology J:70682
decreased spleen B cell follicle number J:106550
enlarged lymph nodes J:70682
immune system phenotype J:70682
impaired leukocyte tethering or rolling J:70682
increased eosinophil cell number J:70682
increased leukocyte cell number J:70682
increased monocyte cell number J:70682
increased neutrophil cell number J:106550, J:70682
lung inflammation J:70682
\Seletm2Alb/\Seletm2Alb
\Selptm1Bay/\Selptm1Bay

(involves: 129S7/SvEvBrd * C57BL/6J)
abnormal leukocyte cell number J:101979
eye inflammation J:101979
increased neutrophil cell number J:101979
increased susceptibility to bacterial infection J:101979
\Seletm2Alb/\Seletm2Alb
\Selptm1Bay/\Selptm1Bay

(involves: 129S7/SvEvBrd * C57BL/6)
abnormal cytokine secretion J:70682
abnormal lymph node germinal center morphology J:70682
abnormal lymph node secondary follicle morphology J:70682
abnormal neutrophil physiology J:112286
abnormal spleen B cell follicle morphology J:70682
decreased acute inflammation J:112286
decreased spleen B cell follicle number J:70682
enlarged lymph nodes J:70682
impaired leukocyte tethering or rolling J:70682
increased eosinophil cell number J:70682
increased leukocyte cell number J:70682
increased monocyte cell number J:70682
increased neutrophil cell number J:70682, J:112286
\Seletm2Hyn/\Seletm2Hyn
(involves: 129S2/SvPas * C57BL/6)
enhanced leukocyte tethering or rolling J:57973
impaired neutrophil recruitment J:57973
\Seletm2Hyn/\Seletm2Hyn
(B6.129S2-Seletm2Hyn)
abnormal type IV hypersensitivity reaction J:121083
decreased mast cell number J:121083
increased mast cell number J:121083
\Selenbp1tm1Hyama/\Selenbp1tm1Hyama
(C57BL/6-Selenbp1tm1Hyama)
decreased spleen weight J:202420
increased thymus weight J:202420
\Selenoktm1.2Itl/\Selenoktm1.2Itl
(involves: BALB/cJ * C57BL/6)
abnormal circulating chemokine level J:169169
abnormal macrophage physiology J:169169
abnormal neutrophil physiology J:169169
abnormal T cell physiology J:169169
decreased interleukin-6 secretion J:169169
decreased T cell proliferation J:169169
decreased tumor necrosis factor secretion J:169169
impaired neutrophil chemotaxis J:169169
increased susceptibility to Flaviviridae infection J:169169
increased susceptibility to Flaviviridae infection induced morbidity/mortality J:169169
\Selenoptm1Rfb/\Selenoptm1Rfb
(B6.129-Selenoptm1Rfb)
increased susceptibility to parasitic infection J:134536
\Selenowem#Hwl/\Selenowem#Hwl
(C57BL/6-Selenowem#Hwl)
abnormal osteoclast differentiation J:317012
decreased osteoclast cell number J:317012
\Sellm1Btlr/\Sellm1Btlr
(C57BL/6J-Sellm1Btlr)
decreased single-positive T cell number J:217794
\Sellm2Btlr/\Sellm2Btlr
(C57BL/6J-Sellm2Btlr)
decreased response to antigen J:231806
decreased single-positive T cell number J:231806
\Selltm1.1Rpmc/\Selltm1.1Rpmc
(involves: 129S1/Sv * C57BL/6J * FVB/N)
abnormal granulocyte physiology J:249558
abnormal neutrophil physiology J:249558
immune system phenotype J:249558
increased inflammatory response J:249558
\Selltm1Alb/\Selltm1Alb
(involves: 129S7/SvEvBrd * C57BL/6)
intermingled spleen red and white pulp J:70682
\Selltm1b(EUCOMM)Hmgu/\Selltm1b(EUCOMM)Hmgu
(C57BL/6N-Selltm1b(EUCOMM)Hmgu/H)
increased spleen weight J:211773
\Selltm1Flv/\Sell+
(involves: C57BL/6 * NOD)
decreased susceptibility to autoimmune diabetes J:88947
pancreas inflammation J:88947
\Selltm1Flv/\Sell+
(NOD.Cg-Selltm1Flv)
immune system phenotype J:88974
\Selltm1Flv/\Selltm1Flv
(involves: 129S2/SvPas * C57BL/6)
abnormal type IV hypersensitivity reaction J:89253
decreased activated T cell number J:89253
\Selltm1Flv/\Selltm1Flv
(involves: C57BL/6 * NOD)
decreased susceptibility to autoimmune disorder J:88947
pancreas inflammation J:88947
\Selltm1Flv/\Selltm1Flv
(NOD.Cg-Selltm1Flv)
immune system phenotype J:88974
\Selltm1Pest/\Sell+
(involves: 129S4/SvJae * C57BL/6)
abnormal hypersensitivity reaction J:112550
impaired leukocyte tethering or rolling J:112550
\Selltm1Pest/\Selltm1Pest
(involves: 129S4/SvJae)
abnormal hypersensitivity reaction J:111233
abnormal leukocyte adhesion J:111233
impaired leukocyte tethering or rolling J:111233
increased T cell proliferation J:111233
\Selltm1Pest/\Selltm1Pest
(involves: 129S4/SvJae * C57BL/6)
abnormal cell-mediated immunity J:112550
abnormal dendritic cell physiology J:112550
abnormal hypersensitivity reaction J:112550
abnormal leukocyte migration J:112550
abnormal splenic cell ratio J:112550
decreased T cell proliferation J:112550
enlarged spleen J:112550
immune system phenotype J:112550
impaired leukocyte tethering or rolling J:112550
lymph node hypoplasia J:112550
small popliteal lymph nodes J:112550
\Selltm1Tft/\Selltm1Tft
(involves: 129P2/OlaHsd * C57BL/6)
abnormal cellular extravasation J:25005
abnormal leukocyte migration J:25005
enlarged spleen J:25005
impaired leukocyte tethering or rolling J:25005
\Selltm1Tft/\Selltm1Tft
(B6.129-Selltm1Tft)
abnormal cellular extravasation J:66107
abnormal leukocyte migration J:66107
\Selltm1Tft/\Selltm1Tft
(B6.129P2-Selltm1Tft)
abnormal cellular extravasation J:48271
abnormal regulatory T cell number J:141931
abnormal regulatory T cell physiology J:141931
impaired leukocyte tethering or rolling J:48271
increased monocyte cell number J:48271, J:142184
lymph node hypoplasia J:141931, J:142184
spleen hyperplasia J:141931
\Selltm2.1Tft/\Selltm2.1Tft
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
abnormal neutrophil physiology J:142184
spleen hyperplasia J:142184
\Selltm2Hyn/\Selltm2Hyn
(involves: 129S2/SvPas * C57BL/6)
decreased monocyte cell number J:57973
immune system phenotype J:106550
impaired leukocyte tethering or rolling J:57973
impaired neutrophil recruitment J:57973
\Selltm2Hyn/\Selltm2Hyn
(involves: 129S2/SvPas * BALB/c)
impaired leukocyte tethering or rolling J:114317
\Selltm2Tft/\Selltm2.1Tft
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
abnormal leukocyte migration J:142184
abnormal neutrophil physiology J:142184
abnormal regulatory T cell number J:141931
abnormal regulatory T cell physiology J:141931
impaired leukocyte tethering or rolling J:142184
\Selltm2Tft/\Selltm2Tft
(involves: 129S1/Sv * 129X1/SvJ)
lymph node hypoplasia J:142184
spleen hyperplasia J:142184
\Selltm3Hyn/\Selltm3Hyn
\Selptm1Hyn/\Selptm1Hyn

(involves: 129S2/SvPas * C57BL/6)
impaired eosinophil recruitment J:57973
impaired leukocyte tethering or rolling J:57973
impaired neutrophil recruitment J:57973
increased eosinophil cell number J:57973
increased leukocyte cell number J:57973
increased neutrophil cell number J:57973
\Selltm4Hyn/\Selltm4Hyn
\Selptm1Hyn/\Selptm1Hyn

(involves: 129S2/SvPas * C57BL/6)
impaired leukocyte tethering or rolling J:57973
impaired neutrophil recruitment J:57973
increased eosinophil cell number J:57973
\Selptm1.1Rpmc/\Selptm1.1Rpmc
(B6.129S1-Selptm1.1Rpmc)
impaired leukocyte tethering or rolling J:230041
\Selptm1Bay/\Selptm1Bay
(involves: 129S7/SvEvBrd * C57BL/6J)
abnormal leukocyte migration J:24239
abnormal spleen morphology J:101979
eye inflammation J:101979
increased leukocyte cell number J:101979
increased neutrophil cell number J:101979, J:24239
increased susceptibility to bacterial infection J:101979
\Selptm1Bay/\Selptm1Bay
(D1.129S7(B6J)-Selptm1Bay)
abnormal cytokine secretion J:57086
increased IgG level J:57086
increased susceptibility to induced arthritis J:57086
\Selptm1Bay/\Selptm1Bay
(B6.129S7-Selptm1Bay/J)
abnormal T cell physiology J:113536
\Selptm1Bay/\Selptm1Bay
(either: B6.129S7-Selptm1Bay or (involves: 129S7/SvEvBrd * C57BL/6))
abnormal leukocyte tethering or rolling J:31374
increased leukocyte cell number J:31374
\Selptm1Bay/\Selptm1Bay
(involves: 129S7/SvEvBrd * C57BL/6)
increased neutrophil cell number J:112286
\Selptm1Bay/\Selptm1Bay
(B6.129S7-Selptm1Bay)
decreased mast cell number J:121083
decreased susceptibility to type IV hypersensitivity reaction J:121083
\Selptm1Hyn/\Selptm1Hyn
(involves: 129S2/SvPas * C57BL/6J)
impaired leukocyte tethering or rolling J:77329
impaired neutrophil recruitment J:77329
increased neutrophil cell number J:77329
\Selptm1Hyn/\Selptm1Hyn
(involves: 129S2/SvPas)
impaired leukocyte tethering or rolling J:29814
impaired macrophage chemotaxis J:29814
increased neutrophil cell number J:29814
\Selptm1Hyn/\Selptm1Hyn
(involves: 129S2/SvPas * C57BL/6)
impaired eosinophil recruitment J:57973
impaired leukocyte tethering or rolling J:57973
impaired neutrophil recruitment J:57973
increased eosinophil cell number J:57973
increased neutrophil cell number J:57973
\Selptm2Hyn/\Selptm2Hyn
(involves: 129S2/SvPas * C57BL/6J)
impaired leukocyte tethering or rolling J:51068
impaired neutrophil recruitment J:51068
\Selplgtm1Fur/\Selplgtm1Fur
(involves: 129/Sv * C57BL/6J * SJL)
impaired leukocyte tethering or rolling J:75412
impaired neutrophil chemotaxis J:75412
increased eosinophil cell number J:75412
increased neutrophil cell number J:75412
\Selplgtm1Rpmc/\Selplgtm1Rpmc
(involves: 129S1/Sv * C57BL/6J)
abnormal leukocyte adhesion J:75829
impaired leukocyte tethering or rolling J:75829, J:138731
increased eosinophil cell number J:75829
increased leukocyte cell number J:75829
increased lymphocyte cell number J:75829
increased neutrophil cell number J:75829
\Selplgtm1Rpmc/\Selplgtm1Rpmc
(involves: 129S1/Sv)
abnormal chemokine secretion J:115682
immune system phenotype J:115682
\Selplgtm2Rpmc/\Selplgtm2Rpmc
(B6.Cg-Selplgtm2Rpmc)
impaired leukocyte tethering or rolling J:138731
\Sema3atm1.1Tyag/\Sema3atm1.1Tyag
(involves: C57BL/6 * CBA)
abnormal dendritic cell physiology J:161856
abnormal T cell physiology J:161856
\Sema3ftm1.2Ddg/\Sema3ftm1.2Ddg
(Not Specified)
abnormal lymphatic system physiology J:226501
abnormal lymphatic vessel endothelial cell morphology J:226501
abnormal lymphatic vessel morphology J:226501
\Sema3ftm1.2Ddg/\Sema3ftm1.2Ddg
\Sema3gtm1(KOMP)Vlcg/\Sema3gtm1(KOMP)Vlcg

(involves: C57BL/6NTac)
abnormal lymphatic vessel endothelial cell morphology J:226501
abnormal lymphatic vessel morphology J:226501
lymphatic vessel hyperplasia J:226501
\Sema3gtm1(KOMP)Vlcg/\Sema3gtm1(KOMP)Vlcg
(involves: C57BL/6NTac)
abnormal lymphatic vessel morphology J:226501
\Sema4atm1Kik/\Sema4atm1Kik
(either: B6.Cg-Sema4atm1Kik or C.Cg-Sema4atm1Kik)
abnormal CD4-positive, alpha-beta T cell physiology J:97027
abnormal cytokine secretion J:97027
abnormal dendritic cell antigen presentation J:97027
abnormal T-helper 1 cell differentiation J:97027
decreased susceptibility to type IV hypersensitivity reaction J:97027
\Sema4btm1Akum/\Sema4btm1Akum
(either: B6.Cg-Sema4btm1Akum or C.Cg-Sema4btm1Akum)
abnormal immune system physiology J:169386
increased IgE level J:169386
increased IgG1 level J:169386
\Sema4dtm1b(EUCOMM)Wtsi/\Sema4dtm1b(EUCOMM)Wtsi
(C57BL/6N-Sema4dtm1b(EUCOMM)Wtsi/H)
enlarged spleen J:211773
\Sema4dtm1Kik/\Sema4dtm1Kik
(involves: 129P2/OlaHsd * C57BL/6)
abnormal B-1 B cell morphology J:66033
abnormal immunoglobulin level J:66033
decreased B cell proliferation J:66033
decreased B-1a cell number J:66033
decreased CD4-positive, alpha-beta T cell number J:66033
decreased spleen germinal center size J:66033
decreased T cell number J:66033
increased B cell number J:66033
\Sema4fem1(IMPC)J/\Sema4fem1(IMPC)J
(C57BL/6NJ-Sema4fem1(IMPC)J/Mmjax)
decreased leukocyte cell number J:211773
\Sema5btm1a(EUCOMM)Wtsi/\Sema5btm1a(EUCOMM)Wtsi
(C57BL/6N-Sema5btm1a(EUCOMM)Wtsi/Cnrm)
decreased T cell number J:165965
\Sema6ctm1Matl/\Sema6ctm1Matl
(Not Specified)
immune system phenotype J:161856
\Sema6dtm1Kik/\Sema6dtm1Kik
(Not Specified)
immune system phenotype J:161856
\Senp1tm1.1Wami/\Senp1tm1.1Wami
(involves: 129 * C57BL/6)
abnormal granulocyte differentiation J:163428
abnormal monocyte differentiation J:163428
\Senp1tm1Wami/\Senp1tm1Wami
\Tg(Fabp4-cre)#Abel/0

(B6.Cg-Senp1tm1Wami Tg(Fabp4-cre)#Abel)
abnormal chemokine level J:228009
abnormal circulating cytokine level J:228009
abnormal cytokine level J:228009
increased anti-insulin autoantibody level J:228009
increased circulating C-reactive protein level J:228009
increased circulating interleukin-1 beta level J:228009
increased circulating interleukin-6 level J:228009
increased circulating tumor necrosis factor level J:228009
increased susceptibility to autoimmune diabetes J:228009
myocarditis J:228009
pancreas inflammation J:228009
\Septin2em1(IMPC)Tcp/\Septin2+
(C57BL/6NCrl-Septin2em1(IMPC)Tcp/Tcp)
increased monocyte cell number J:211773
\Septin5tm1b(EUCOMM)Hmgu/\Septin5+
(C57BL/6N-Septin5tm1b(EUCOMM)Hmgu/Rbrc)
small spleen J:211773
\Septin7tm1Mgl/\Septin7tm1Mgl
\Tg(CD2-icre)4Kio/0

(involves: 129P2/OlaHsd * C3H * C57BL/6 * C57BL/10 * CBA/Ca)
immune system phenotype J:223786
\Septin9tm2.1Emfu/\Septin9tm2.1Emfu
\Tg(Lck-cre)548Jxm/0

(involves: C57BL/6 * CBA)
abnormal T cell differentiation J:205027
decreased CD4-positive, alpha-beta memory T cell number J:205027
decreased CD4-positive, alpha-beta T cell number J:205027
decreased CD8-positive, alpha-beta memory T cell number J:205027
decreased CD8-positive, alpha-beta T cell number J:205027
decreased DN4 thymocyte number J:205027
decreased regulatory T cell number J:205027
decreased single-positive T cell number J:205027
decreased T cell number J:205027
decreased T cell proliferation J:205027
increased CD8-positive, alpha-beta memory T cell number J:205027
increased DN3 thymocyte number J:205027
increased double-negative T cell number J:205027
\Septin9tm2.1Emfu/\Septin9tm2.1Emfu
\Tg(Mx1-cre)1Cgn/0

(involves: C57BL/6 * CBA)
decreased CD8-positive, alpha-beta T cell number J:205027
\Serac1em1(IMPC)Tcp/\Serac1em1(IMPC)Tcp
(C57BL/6NCrl-Serac1em1(IMPC)Tcp/Tcp)
enlarged lymph nodes J:211773
\Serf1tm1a(EUCOMM)Hmgu/\Serf1tm1a(EUCOMM)Hmgu
(C57BL/6N-Serf1tm1a(EUCOMM)Hmgu/H)
decreased CD8-positive, alpha-beta T cell number J:165965
decreased T cell number J:165965
\Serinc5em1Spst/\Serinc5em1Spst
(C57BL/6-Serinc5em1Spst)
immune system phenotype J:291232
\Serpina1em#Chmu/\Serpina1em#Chmu
(involves: C57BL/6J)
increased susceptibility to endotoxin shock J:259615
respiratory system inflammation J:259615
\Serpina3cem1Smoc/\Serpina3cem1Smoc
(C57BL/6-Serpina3cem1Smoc)
white adipose tissue inflammation J:343846
\Serpina3gtm1.1Arp/\Serpina3gtm1.1Arp
(involves: C57BL/6)
abnormal memory T cell morphology J:189782
abnormal response to infection J:189782
decreased CD8-positive, alpha-beta memory T cell number J:189782
decreased T cell proliferation J:189782
\Serpina3gtm1.1Arp/\Serpina3gtm1.1Arp
\Tg(TcrLCMV)#Sdz/0

(involves: C57BL/6 * DBA/2)
decreased T cell proliferation J:189782
\Serpina3iem1(IMPC)J/\Serpina3iem1(IMPC)J
(C57BL/6NJ-Serpina3iem1(IMPC)J/Mmjax)
decreased leukocyte cell number J:211773
\Serpina6tm1Tew/\Serpina6tm1Tew
(involves: 129/SvEmcTer * C57BL/6N)
abnormal circulating cytokine level J:112974
abnormal cytokine level J:112974
increased susceptibility to endotoxin shock J:112974
\Serpinb1atm1.1Cben/\Serpinb1atm1.1Cben
(129S6/SvEvTac-Serpinb1atm1.1Cben)
abnormal chemokine secretion J:125918
abnormal circulating cytokine level J:125918
abnormal neutrophil physiology J:125918
decreased neutrophil cell number J:125918
impaired neutrophil chemotaxis J:125918
increased interleukin-1 beta secretion J:125918
increased susceptibility to bacterial infection J:125918
increased susceptibility to bacterial infection induced morbidity/mortality J:125918
increased tumor necrosis factor secretion J:125918
lung inflammation J:125918
sepsis J:125918
\Serpinb2tm1Dgi/\Serpinb2tm1Dgi
(involves: 129S2/SvPas * C57BL/6J * DBA/2J)
abnormal leukocyte cell number J:52283
decreased lymphocyte cell number J:52283
decreased monocyte cell number J:52283
decreased neutrophil cell number J:52283
immune system phenotype J:52283
\Serpinb2tm2Dgi/\Serpinb2tm2Dgi
(involves: 129S2/SvPas * C57BL/6J * DBA/2J)
abnormal leukocyte cell number J:52283
decreased lymphocyte cell number J:52283
decreased monocyte cell number J:52283
decreased neutrophil cell number J:52283
immune system phenotype J:52283
\Serpinb3atm1Gsil/\Serpinb3atm1Gsil
(C.129-Serpinb3atm1Gsil)
decreased susceptibility to type I hypersensitivity reaction J:189949
\Serpinb9em1(IMPC)Ccpcz/\Serpinb9em1(IMPC)Ccpcz
(C57BL/6NCrl-Serpinb9em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
decreased effector memory T-helper cell number J:211773
\Serpinb9tm1.1Pib/\Serpinb9tm1.1Pib
(involves: BALB/cJ * C57BL/6J)
abnormal dendritic cell antigen presentation J:252016
abnormal immune system morphology J:252016
abnormal immune system physiology J:252016
decreased cytotoxic T cell apoptosis J:252016
immune system phenotype J:252016
\Serpinb9tm1Arp/\Serpinb9tm1Arp
(involves: C57BL/6)
abnormal CD8-positive, alpha-beta cytotoxic T cell morphology J:113349
abnormal cytotoxic T cell physiology J:113349
decreased cytotoxic T cell cytolysis J:113349
increased susceptibility to Riboviria infection J:113349
\Serpinb9tm1Arp/\Serpinb9tm1Arp
\Tg(TcrLCMV)327Sdz/0

(involves: C57BL/6)
abnormal response to transplant J:113349
\Serpinb10em1(IMPC)Mbp/\Serpinb10em1(IMPC)Mbp
(C57BL/6NCrl-Serpinb10em1(IMPC)Mbp/Mmucd)
abnormal lymph node morphology J:211773
abnormal spleen morphology J:211773
enlarged lymph nodes J:211773
enlarged spleen J:211773
increased spleen weight J:211773
\Serpinc1tm1Dwr/\Serpinc1tm1Dwr
(involves: 129S1/Sv * 129X1/SvJ)
enlarged spleen J:115658
liver inflammation J:115658
\Serpine1em1(IMPC)Tcp/\Serpine1em1(IMPC)Tcp
(C57BL/6N-Serpine1em1(IMPC)Tcp/Tcp)
enlarged lymph nodes J:211773
\Serpine1tm1.1Vlp/\Serpine1tm1.1Vlp
(involves: 129 * C57BL/6)
decreased susceptibility to endotoxin shock J:229191
\Serpine1tm1Mlg/\Serpine1tm1Mlg
(involves: 129S2/SvPas * C57BL/6)
abnormal acute inflammation J:133227
abnormal interleukin level J:133227
decreased circulating interleukin-6 level J:133227
glomerulonephritis J:85989
immune system phenotype J:133227
increased acute inflammation J:133227
increased granulocyte number J:133227
respiratory system inflammation J:66093
\Serpine1tm1Mlg/\Serpine1tm1Mlg
(B6.129S2-Serpine1tm1Mlg/J)
heart inflammation J:101486
increased susceptibility to bacterial infection J:124327
increased susceptibility to Coronaviridae infection J:288556
increased susceptibility to Coronaviridae infection induced morbidity/mortality J:288556
\Serpine1tm1Mlg/\Serpine1tm1Mlg
(involves: 129S2/SvPas)
decreased susceptibility to endotoxin shock J:229191
\Serpine2tm1Dmn/\Serpine2tm1Dmn
(B6.129P2-Serpine2tm1Dmn)
abnormal acute phase protein level J:121263
\Serpinf1tm1e.1(KOMP)Wtsi/\Serpinf1tm1e.1(KOMP)Wtsi
(C57BL/6N-Serpinf1tm1e.1(KOMP)Wtsi/Bay)
abnormal spleen morphology J:211773
\Serpini2pq/\Serpini2pq
(involves: C57BL/6J)
abnormal B cell differentiation J:115744
abnormal pre-B cell morphology J:115744
abnormal pro-B cell morphology J:115744
decreased B cell number J:115744
decreased immature B cell number J:115744
decreased lymphocyte cell number J:115744
decreased pre-B cell number J:115744
decreased pro-B cell number J:115744
decreased T cell number J:115744
decreased thymocyte number J:115744
small spleen J:115744
small thymus J:115744
spleen hypoplasia J:115744
thymus hypoplasia J:115744
\Sertad2Gt(OST98734)Lex/\Sertad2Gt(OST98734)Lex
(B6.129S5-Sertad2Gt(OST98734)Lex)
abnormal macrophage physiology J:194928
\Sertad3em1Bcgen/\Sertad3em1Bcgen
(involves: C57BL/6N)
increased susceptibility to Orthomyxoviridae infection induced morbidity/mortality J:300469
\Ses1aC57BL/6J/\Ses1aC57BL/6J
(involves: 129 * C57BL/6J)
decreased susceptibility to bacterial infection J:81412
\Ses1aC57BL/6J/\Ses1aC57BL/6J
(involves: 129S6/SvEvTac * C57BL/6J)
decreased susceptibility to bacterial infection J:100367
\Ses1aC57BL/6J/\Ses1aC57BL/6J
(129.B6-Ses1aC57BL/6J)
decreased susceptibility to bacterial infection J:100367
\Ses1aC57BL/6J/\Ses1aC57BL/6J
\Ses4C57BL/6J/\Ses4C57BL/6J

(involves: 129S6/SvEvTac * C57BL/6J)
decreased susceptibility to bacterial infection J:100367
\Ses1aC57BL/6J/\Ses1aC57BL/6J
\Ses5C57BL/6J/\Ses5C57BL/6J

(involves: 129S6/SvEvTac * C57BL/6J)
decreased susceptibility to bacterial infection J:100367
\Ses1aC57BL/6J/\Ses1aC57BL/6J
\Ses6C57BL/6J/\Ses6C57BL/6J

(involves: 129S6/SvEvTac * C57BL/6J)
decreased susceptibility to bacterial infection J:100367
\Ses1bC57BL/6J/\Ses1bC57BL/6J
(involves: 129S6/SvEvTac * C57BL/6J)
decreased susceptibility to bacterial infection J:100367
\Ses1bC57BL/6J/\Ses1bC57BL/6J
(129.B6-Ses1bC57BL/6J)
decreased susceptibility to bacterial infection J:100367
\Ses2C57BL/6J/\Ses2C57BL/6J
(involves: 129 * C57BL/6J)
decreased susceptibility to bacterial infection J:81412
\Ses3C57BL/6J/\Ses3C57BL/6J
(involves: 129 * C57BL/6J)
decreased susceptibility to bacterial infection J:81412
\Ses7129S6/SvEvTac/\Ses7C57BL/6J
\Ses8C57BL/6J/\Ses8C57BL/6J

(involves: 129S6/SvEvTac * C57BL/6J)
decreased susceptibility to bacterial infection J:100367
\Ses7C57BL/6J/\Ses7C57BL/6J
\Ses8C57BL/6J/\Ses8C57BL/6J

(involves: 129S6/SvEvTac * C57BL/6J)
decreased susceptibility to bacterial infection J:100367
\Ses9C57BL/6J/\Ses9C57BL/6J
\Ses10C57BL/6J/\Ses10C57BL/6J

(involves: 129S6/SvEvTac * C57BL/6J)
decreased susceptibility to bacterial infection J:100367
\Sesn1tm1a(EUCOMM)Wtsi/\Sesn1tm1a(EUCOMM)Wtsi
(involves: C57BL/6N)
abnormal class switch recombination J:240602
abnormal effector T cell number J:240602
decreased B cell number J:240602
enlarged spleen J:240602
increased immunoglobulin level J:240602
increased interferon-gamma secretion J:240602
increased interleukin-2 secretion J:240602
increased NK T cell number J:240602
increased single-positive T cell number J:240602
increased splenocyte number J:240602
increased T cell proliferation J:240602
\Setd1atm1a(EUCOMM)Wtsi/\Setd1a+
(C57BL/6N-Setd1atm1a(EUCOMM)Wtsi/Wtsi)
decreased leukocyte cell number J:175295
\Setd2tm1c(NCOM)Mfgc/\Setd2tm1c(NCOM)Mfgc
\Tg(Lck-cre)#Zhu/0

(involves: C57BL/6 * SJL/J)
increased gamma-delta T cell number J:243973
\Setd3tm1.1(NCOM)Mfgc/\Setd3tm1.1(NCOM)Mfgc
(C57BL/6N-Setd3tm1.1(NCOM)Mfgc/Tcp)
increased leukocyte cell number J:211773
increased lymphocyte cell number J:211773
\Setd3tm1.1(NCOM)Mfgc/\Setd3tm1.1(NCOM)Mfgc
(involves: C57BL/6NCrl)
decreased susceptibility to Riboviria infection J:293475
\Setd4tm1b(KOMP)Wtsi/\Setd4tm1b(KOMP)Wtsi
(involves: C57BL/6N)
decreased macrophage cytokine production J:304151
\Setd5tm1a(EUCOMM)Wtsi/\Setd5+
(C57BL/6N-Setd5tm1a(EUCOMM)Wtsi/Wtsi)
abnormal thymus morphology J:239583
blood in lymph vessels J:239583
enlarged lymphatic vessel J:239583
increased monocyte cell number J:211773
increased regulatory T cell number J:211773
small thymus J:239583
\Setd7tm1Frga/\Setd7+
(involves: 129 * C57BL/6)
abnormal spleen physiology J:136558
\Setd7tm1Frga/\Setd7tm1Frga
(involves: 129 * C57BL/6)
abnormal spleen physiology J:136558
\Setdb2tm1Desr/\Setdb2tm1Desr
(B6.Cg-Setdb2tm1Desr)
abnormal response to infection J:222611
increased neutrophil cell number J:222611
increased susceptibility to bacterial infection J:222611
\Setxtm1b(EUCOMM)Wtsi/\Setxtm1b(EUCOMM)Wtsi
(C57BL/6N-Setxtm1b(EUCOMM)Wtsi/Ics)
decreased leukocyte cell number J:211773
decreased lymphocyte cell number J:211773
increased eosinophil cell number J:211773
increased monocyte cell number J:211773
increased neutrophil cell number J:211773
increased NK cell number J:211773
\sevr/\sevr
(C3H/HeJ-sevr/GrsrJ)
thymus atrophy J:109437
\Sf3b1tm1.1Mdf/\Sf3b1+
\Tet2tm1.1Iaai/\Tet2tm1.1Iaai
\Tg(Mx1-cre)1Cgn/?

(involves: 129S/SvEv * 129S4/SvJae * C57BL/6 * CBA/J)
abnormal myelopoiesis J:234976
decreased B cell number J:234976
enlarged spleen J:234976
increased granulocyte number J:234976
\Sf3b1tm1.1Mdf/\Sf3b1+
\Tg(Mx1-cre)1Cgn/?

(involves: 129S4/SvJae * C57BL/6 * CBA/J)
abnormal myelopoiesis J:234976
\Sf3b1tm1Hko/\Sf3b1+
(Not Specified)
increased spleen red pulp amount J:324276
\Sfmbt2em1(IMPC)Mbp/\Sfmbt2+
(C57BL/6NCrl-Sfmbt2em1(IMPC)Mbp/Mmucd)
abnormal lymph node morphology J:211773
enlarged lymph nodes J:211773
\Sfntm1Mak/\Sfntm1Mak
(involves: 129P2/OlaHsd * C57BL/6)
abnormal B cell differentiation J:168328
abnormal spleen B cell follicle morphology J:168328
abnormal spleen morphology J:168328
absent spleen marginal zone J:168328
decreased B cell number J:168328
decreased B-1a cell number J:168328
decreased follicular B cell number J:168328
decreased IgG level J:168328
decreased IgM level J:168328
decreased marginal zone B cell number J:168328
immune system phenotype J:168328
increased B cell apoptosis J:168328
increased B cell proliferation J:168328
increased susceptibility to Riboviria infection J:168328
increased susceptibility to Riboviria infection induced morbidity/mortality J:168328
\Sfrp1tm1Bsk/\Sfrp1tm1Bsk
(involves: 129S5/SvEvBrd * C57BL/6)
decreased leukocyte cell number J:89547
decreased lymphocyte cell number J:89547
decreased neutrophil cell number J:89547
\Sfrp4tm1.1Blan/\Sfrp4tm1.1Blan
(Not Specified)
increased osteoclast cell number J:234467
\Sfrp4tm1.1Lex/\Sfrp4tm1.1Lex
(Not Specified)
increased osteoclast cell number J:234467
\Sftpa1tm1Haw/\Sftpa1tm1Haw
(involves: 129/Sv * C57BL/6 * CD-1)
abnormal cytokine level J:86024
abnormal inflammatory response J:85432
abnormal interferon level J:86024
abnormal interleukin level J:86024
increased susceptibility to Orthomyxoviridae infection J:86024
\Sftpa1tm1Kor/\Sftpa1tm1Kor
(involves: 129P2/OlaHsd * NIH Black Swiss)
immune system phenotype J:35250
increased susceptibility to bacterial infection J:120552, J:110382
lung inflammation J:110382
\Sftpa1tm1Kor/\Sftpa1tm1Kor
(involves: 129P2/OlaHsd)
immune system phenotype J:130958
lung inflammation J:107841
\Sftpa1tm1Kor/\Sftpa1tm1Kor
(involves: 129P2/OlaHsd * Black Swiss * C3H/HeN)
increased susceptibility to bacterial infection J:130297
\Sftpa1tm2Haw/\Sftpa1tm2Haw
\Sftpdtm2Haw/\Sftpdtm2Haw

(involves: C57BL/6J * CD-1)
abnormal alveolar macrophage morphology J:86022
increased monocyte cell number J:86022
\Sftpctm1Swg/\Sftpctm1Swg
(either: 129 or (involves: 129 * Black Swiss))
conjunctivitis J:82925
\Sftpdtm1Haw/\Sftpdtm1Haw
(involves: C57BL/6J * CD-1)
abnormal alveolar macrophage morphology J:98220, J:50147
abnormal macrophage physiology J:98220
\Sftpdtm1Jhf/\Sftpdtm1Jhf
(involves: 129P2/OlaHsd * Black Swiss)
abnormal alveolar macrophage morphology J:50436
abnormal chemokine level J:72681
abnormal cytokine level J:72681, J:62282
abnormal macrophage morphology J:62282, J:50436
abnormal macrophage physiology J:62282
abnormal neutrophil physiology J:72681
increased macrophage cell number J:62282, J:50436
increased neutrophil cell number J:72681
increased susceptibility to Orthomyxoviridae infection J:72681
lung inflammation J:62282, J:50436
\Sfxn4tm1b(KOMP)Wtsi/\Sfxn4tm1b(KOMP)Wtsi
(C57BL/6N-Sfxn4tm1b(KOMP)Wtsi/J)
decreased leukocyte cell number J:211773
\Sgcatm1Kcam/\Sgcatm1Kcam
(involves: 129S1/Sv * 129X1/SvJ)
heart inflammation J:177563
\Sgcatm1Kcam/\Sgcatm1Kcam
\Sgcetm1Vinni/\Sgcetm1Vinni

(involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6J)
heart inflammation J:177563
\Sgcbtm1Oza/\Sgcbtm1Oza
(involves: 129S4/SvJae * C57BL/6J)
myositis J:57590
\Sgceem1(IMPC)H/\Sgceem1(IMPC)H
(C57BL/6N-Sgceem1(IMPC)H/H)
increased eosinophil cell number J:211773
\Sgk3fz-ica/\Sgk3fz-ica
(Swiss albino)
abnormal inflammatory response J:107373
\sgl/\sgl
(involves: C3H * C57BL/6J)
abnormal lymph node morphology J:56826
conjunctivitis J:56826
\Sgms1tm1Jia/\Sgms1tm1Jia
(involves: C57BL/6)
abnormal cytokine level J:201497
abnormal cytokine secretion J:201497
decreased circulating interleukin-6 level J:201497
decreased circulating tumor necrosis factor level J:201497
decreased interleukin-6 secretion J:201497
decreased tumor necrosis factor secretion J:201497
\Sgms2tm1Jia/\Sgms2tm1Jia
(involves: 129 * C57BL/6)
abnormal macrophage morphology J:162226
abnormal macrophage physiology J:162192, J:162226
\Sgp5NZB/?
(involves: C57BL/6 * NZB * SB/Le)
abnormal immune serum protein physiology J:95829
glomerulonephritis J:95829
increased susceptibility to type III hypersensitivity reaction J:95829
\Sgp5NZB/\Sgp5NZB
(C57BL/6-Nba2 Yaa)
abnormal immune serum protein physiology J:95829
\Sgpl1Gt(OST58278)Lex/\Sgpl1Gt(OST58278)Lex
(involves: 129S5/SvEvBrd * C57BL/6J)
abnormal lymph node morphology J:145159
abnormal lymphopoiesis J:145159
abnormal osteoclast morphology J:145159
abnormal spleen periarteriolar lymphoid sheath morphology J:145159
decreased B cell number J:145159
decreased double-positive T cell number J:145159
decreased lymphocyte cell number J:145159
decreased neutrophil cell number J:145159
decreased pre-B cell number J:145159
decreased T cell number J:145159
increased CD4-positive, alpha-beta T cell number J:145159
increased CD8-positive, alpha-beta T cell number J:145159
increased granulocyte number J:145159
increased monocyte cell number J:145159
increased osteoclast cell number J:145159
lymph node hypoplasia J:145159
lymphoid hypoplasia J:145159
spleen hypoplasia J:145159
thymus cortex hypoplasia J:145159
thymus hypoplasia J:145159
thymus medulla hyperplasia J:145159
\Sgpl1Gt(OST58278)Lex/\Sgpl1tm1(SGPL1)Lex
(involves: 129S5/SvEvBrd * C57BL/6J)
abnormal immune system organ morphology J:145159
abnormal osteoclast morphology J:145159
decreased T cell number J:145159
thymus cortex hypoplasia J:145159
thymus medulla hyperplasia J:145159
\Sgpl1Gt(ROSA)78Sor/\Sgpl1Gt(ROSA)78Sor
(involves: 129S4/SvJaeSor)
kidney inflammation J:117491
\Sgpl1Gt(ROSA)78Sor/\Sgpl1Gt(ROSA)78Sor
(involves: 129S4/SvJaeSor * C57BL/6)
abnormal immune system physiology J:187619
abnormal leukocyte migration J:187619
abnormal T cell physiology J:187619
decreased lymphocyte cell number J:187619
\Sgpl1tm1(SGPL1)Lex/\Sgpl1tm1(SGPL1)Lex
(involves: 129S4/SvJae * 129S5/SvEvBrd * C57BL/6J)
abnormal immune system organ morphology J:145159
abnormal lymph node morphology J:145159
abnormal thymus lobule morphology J:145159
decreased B cell number J:145159
decreased CD4-positive, alpha-beta T cell number J:145159
decreased CD8-positive, alpha-beta T cell number J:145159
decreased lymphocyte cell number J:145159
decreased T cell number J:145159
increased single-positive T cell number J:145159
\Sgpl1tm1.2Npa/\Sgpl1tm1.2Npa
(involves: BALB/cJ * C57BL/6)
spleen hypoplasia J:199525
\Sgshmps3a/\Sgshmps3a
(involves: 129X1/SvJ * CD-1 * C57BL/6 * SJL)
enlarged spleen J:72142
\Sgsm1tm1b(EUCOMM)Wtsi/\Sgsm1tm1b(EUCOMM)Wtsi
(C57BL/6N-Sgsm1tm1b(EUCOMM)Wtsi/Wtsi)
decreased CD4-positive, alpha-beta T cell number J:211773
increased CD8-positive, alpha-beta T cell number J:211773
\Sh2b1tm1Ayos/\Sh2b1tm1Ayos
(involves: C57BL/6)
immune system phenotype J:78931
\Sh2b2tm1Yeb/\Sh2b2tm1Yeb
(involves: C57BL/6)
abnormal B cell differentiation J:88527
increased B-1 B cell number J:88527
increased IgG3 level J:88527
\Sh2b3tm1Paw/\Sh2b3tm1Paw
(either: (involves: 129S1/Sv * 129X1/SvJ) or (involves: 129S1/Sv * 129X1/SvJ * C57BL/6))
abnormal granulocyte differentiation J:77248
abnormal leukocyte cell number J:77248
abnormal monocyte differentiation J:77248
enlarged lymph nodes J:77248
enlarged spleen J:77248
increased B cell number J:77248
spleen fibrosis J:77248
\Sh2b3tm1Paw/\Sh2b3tm1Paw
(B6.129-Sh2b3tm1Paw)
spleen hyperplasia J:107464
\Sh2b3tm1Paw/\Sh2b3tm1Paw
(involves: 129S1/Sv * 129X1/SvJ)
decreased B cell number J:161643
enlarged spleen J:161643
increased granulocyte number J:161643
increased leukocyte cell number J:161643
increased lymphocyte cell number J:161643
increased monocyte cell number J:161643
increased neutrophil cell number J:161643
myeloid hyperplasia J:161643
\Sh2d1atm1.1Knic/Y
\Gt(ROSA)26Sortm1(EYFP)Cos/\Gt(ROSA)26Sor+
\Ndor1Tg(UBC-cre/ERT2)1Ejb/0

(involves: 129S/SvEv * 129X1/SvJ * C57BL/6)
abnormal NK T cell physiology J:196692
decreased circulating interleukin-4 level J:196692
decreased interferon-gamma secretion J:196692
immune system phenotype J:196692
\Sh2d1atm1.1Knic/\Sh2d1atm1.1Knic
\Gt(ROSA)26Sortm1(EYFP)Cos/\Gt(ROSA)26Sor+
\Ndor1Tg(UBC-cre/ERT2)1Ejb/0

(involves: 129S/SvEv * 129X1/SvJ * C57BL/6)
abnormal NK T cell physiology J:196692
decreased circulating interleukin-4 level J:196692
decreased interferon-gamma secretion J:196692
immune system phenotype J:196692
\Sh2d1atm1Cpt/Y
(involves: 129S4/SvJae * C57BL/6)
abnormal cytokine secretion J:97756
abnormal germinal center B cell physiology J:189126
abnormal humoral immune response J:189126
abnormal immunoglobulin level J:189126
abnormal NK T cell physiology J:189126
decreased NK T cell number J:189126
increased susceptibility to Riboviria infection J:97756
increased T cell proliferation J:97756
\Sh2d1atm1Cpt/Y
(involves: 129S4/SvJae * BALB/c)
abnormal cytokine secretion J:97756
abnormal germinal center B cell morphology J:189126
decreased germinal center B cell number J:189126
decreased IgE level J:97756
decreased IgG level J:189126
decreased NK T cell number J:189126
decreased susceptibility to parasitic infection J:97756
immune system phenotype J:189126
\Sh2d1atm1Cpt/Y
\Tcra-Jtm1Tgi/\Tcra-Jtm1Tgi

(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * BALB/c)
decreased germinal center B cell number J:189126
decreased IgG level J:189126
\Sh2d1atm1Cpt/\Sh2d1a+
(involves: 129S4/SvJae * C57BL/6)
abnormal cytokine secretion J:97756
increased T cell proliferation J:97756
\Sh2d1atm1Cpt/\Sh2d1atm1Cpt
(B6.129S4-Sh2d1atm1Cpt)
abnormal humoral immune response J:97388
absent NK T cells J:97690
decreased IgG1 level J:97388
decreased IgM level J:97388
decreased NK T cell number J:97690
decreased transitional stage B cell number J:97690
increased B cell number J:97388
increased IgG2a level J:97388
\Sh2d1atm1Cpt/\Sh2d1atm1Cpt
(C.129S4-Sh2d1atm1Cpt)
decreased IgG level J:97388
decreased IgM level J:97388
decreased spleen germinal center number J:97388
\Sh2d1atm1Cpt/\Sh2d1atm1Cpt
(involves: 129S4/SvJae * C57BL/6)
abnormal cytokine secretion J:97756
abnormal germinal center B cell physiology J:189126
abnormal humoral immune response J:189126
abnormal immunoglobulin level J:189126
abnormal NK T cell physiology J:189126
decreased NK T cell number J:189126
increased susceptibility to Riboviria infection J:97756
increased T cell proliferation J:97756
\Sh2d1atm1Cpt/\Sh2d1atm1Cpt
(involves: 129S4/SvJae * BALB/c)
abnormal cytokine secretion J:97756
abnormal germinal center B cell morphology J:189126
decreased germinal center B cell number J:189126
decreased IgE level J:97756
decreased IgG level J:189126
decreased NK T cell number J:189126
decreased susceptibility to parasitic infection J:97756
immune system phenotype J:189126
\Sh2d1atm1Cpt/\Sh2d1atm1Cpt
(involves: 129S4/SvJae)
impaired natural killer cell mediated cytotoxicity J:166054
\Sh2d1atm1Cpt/\Sh2d1atm1Cpt
\Sh2d1b1/Sh2d1b2tm1.1Cpt/\Sh2d1b1/Sh2d1b2tm1.1Cpt

(involves: 129S4/SvJae * BALB/cJ)
impaired natural killer cell mediated cytotoxicity J:166054
\Sh2d1atm1Cpt/\Sh2d1atm1Cpt
\Sh2d1b1/Sh2d1b2tm1.1Cpt/\Sh2d1b1/Sh2d1b2tm1.1Cpt

(involves: 129S4/SvJae * BALB/cJ)
impaired natural killer cell mediated cytotoxicity J:166054
\Sh2d1atm1Cpt/\Sh2d1atm1Cpt
\Tcra-Jtm1Tgi/\Tcra-Jtm1Tgi

(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * BALB/c)
decreased germinal center B cell number J:189126
decreased IgG level J:189126
\Sh2d1atm1Lyin/Y
(involves: 129S2/SvPas * C57BL/6)
abnormal immune system physiology J:97346
chronic inflammation J:97346
decreased IgE level J:97346
decreased IgG level J:97346
decreased immunoglobulin level J:97346
increased CD8-positive, alpha-beta T cell number J:97346
\Sh2d1atm1Lyin/\Sh2d1atm1Lyin
(involves: 129S2/SvPas * C57BL/6)
abnormal immune system physiology J:97346
chronic inflammation J:97346
decreased IgE level J:97346
decreased IgG level J:97346
decreased immunoglobulin level J:97346
increased CD8-positive, alpha-beta T cell number J:97346
\Sh2d1atm1Lyin/\Sh2d1atm1Lyin
(involves: 129S1/Sv * 129X1/SvJ)
impaired natural killer cell mediated cytotoxicity J:110195
\Sh2d1atm1Pls/Y
(involves: 129S6/SvEvTac)
abnormal CD4-positive, alpha-beta T cell physiology J:157915
abnormal cytotoxic T cell physiology J:187431
abnormal long lived plasma cell morphology J:157915
abnormal NK T cell morphology J:196692
decreased CD4-positive, alpha-beta T cell number J:157915
decreased IgG level J:157915
decreased interleukin-21 secretion J:157915
\Sh2d1atm1Pls/\Sh2d1atm1Pls
(either: 129S6/SvEvTac or (involves: 129S6/SvEvTac * C57BL/6))
abnormal lymphocyte cell number J:70032
abnormal T-helper 1 cell morphology J:70032
abnormal T-helper 2 cell morphology J:70032
decreased IgE level J:70032
increased susceptibility to infection J:70032
increased susceptibility to parasitic infection J:70032
increased susceptibility to Riboviria infection J:70032
increased T cell proliferation J:70032
\Sh2d1atm1Pls/\Sh2d1atm1Pls
(involves: BALB/c)
decreased susceptibility to parasitic infection J:90484
\Sh2d1atm1Pls/\Sh2d1atm1Pls
(involves: 129S6/SvEvTac * C57BL/6)
immune system phenotype J:92740
\Sh2d1atm1Pls/\Sh2d1atm1Pls
(B6.129S6-Sh2d1atm1Pls)
abnormal CD4-positive, alpha-beta T cell physiology J:93886
abnormal NK cell physiology J:187430
decreased IgE level J:93886
decreased interferon-gamma secretion J:187430
\Sh2d1atm1Pls/\Sh2d1atm1Pls
(involves: 129S6/SvEvTac)
abnormal CD4-positive, alpha-beta T cell physiology J:157915
abnormal cytotoxic T cell physiology J:187431
abnormal long lived plasma cell morphology J:157915
abnormal NK T cell morphology J:196692
decreased CD4-positive, alpha-beta T cell number J:157915
decreased IgG level J:157915
decreased interleukin-21 secretion J:157915
\Sh2d1atm1Pls/\Sh2d1atm1Pls
\Sh2d1b1tm3Vei/\Sh2d1b1tm3Vei

(involves: 129S6/SvEvTac * C57BL/6)
abnormal NK cell physiology J:187430
\Sh2d1atm1Pls/\Sh2d1atm1Pls
\Slamf6tm1Lex/\Slamf6tm1Lex

(B6.129S-Slamf6tm1Lex Sh2d1atm1Pls)
immune system phenotype J:187429
\Sh2d1atm1Pls/\Sh2d1atm1Pls
\Slamf6tm1Pls/\Slamf6tm1Pls
\Tg(TcraTcrb)1100Mjb/0

(involves: 129S6/SvEvTac * C57BL/6 * C57BL/6J)
immune system phenotype J:187431
\Sh2d1atm1Pls/\Sh2d1atm1Pls
\Tg(DO11.10)10Dlo/\Tg(DO11.10)10Dlo

(involves: BALB/c * C3H * C57BL/6)
abnormal cytokine secretion J:90484
\Sh2d1atm1Pls/\Sh2d1atm1Pls
\Tg(TcraTcrb)425Cbn/?

(involves: 129S6/SvEvTac * C57BL/6)
abnormal CD4-positive, alpha-beta T cell physiology J:157915
\Sh2d1atm1Pls/\Sh2d1atm1Pls
\Tg(TcraTcrb)1100Mjb/0

(involves: 129S6/SvEvTac * C57BL/6)
abnormal cytotoxic T cell physiology J:187431
decreased cytotoxic T cell cytolysis J:187431
decreased interferon-gamma secretion J:187431
\Sh2d1atm1Vei/\Sh2d1atm1Vei
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
abnormal CD4-positive, alpha-beta T cell physiology J:93886
abnormal memory T cell physiology J:93886
decreased IgE level J:93886
\Sh2d1atm1Vei/\Sh2d1atm1Vei
(B6.129-Sh2d1atm1Vei)
abnormal NK cell physiology J:187430
decreased interferon-gamma secretion J:187430
\Sh2d1atm1Vei/\Sh2d1atm1Vei
\Sh2d1b1tm3Vei/\Sh2d1b1tm3Vei

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
abnormal NK cell physiology J:187430
\Sh2d1atm2.1Cpt/Y
\Gt(ROSA)26Sortm9(cre/ESR1)Arte/\Gt(ROSA)26Sor+

(involves: C57BL/6 * C57BL/6NTac)
abnormal germinal center B cell physiology J:189126
abnormal humoral immune response J:189126
decreased IgG level J:189126
decreased IgM level J:189126
immune system phenotype J:189126
\Sh2d1atm2.1Cpt/\Sh2d1atm2.1Cpt
\Gt(ROSA)26Sortm9(cre/ESR1)Arte/\Gt(ROSA)26Sor+

(involves: C57BL/6 * C57BL/6NTac)
abnormal germinal center B cell physiology J:189126
abnormal humoral immune response J:189126
decreased IgG level J:189126
decreased IgM level J:189126
immune system phenotype J:189126
\Sh2d1atm2.1Vei/\Sh2d1atm2.1Vei
(involves: C57BL/6)
decreased germinal center B cell number J:131618
decreased IgE level J:131618
decreased IgG1 level J:131618
decreased IgG2a level J:131618
decreased IgG2b level J:131618
decreased IgG3 level J:131618
decreased IgM level J:131618
decreased NK T cell number J:131618
\Sh2d1atm2Vei/\Sh2d1atm2Vei
\Cd19tm1(cre)Cgn/\Cd19+

(involves: 129P2/OlaHsd * C57BL/6)
immune system phenotype J:131618
\Sh2d1atm2Vei/\Sh2d1atm2Vei
\Tg(Cd4-cre)1Cwi/0

(involves: C57BL/6 * DBA/2)
decreased germinal center B cell number J:131618
decreased IgE level J:131618
decreased IgG1 level J:131618
decreased IgG2a level J:131618
decreased IgG2b level J:131618
decreased IgG3 level J:131618
decreased IgM level J:131618
decreased NK T cell number J:131618
\Sh2d1atm2Vei/\Sh2d1atm2Vei
\Tg(Lck-cre)1Cwi/0

(involves: C57BL/6)
decreased germinal center B cell number J:131618
decreased IgE level J:131618
decreased IgG1 level J:131618
decreased IgG2a level J:131618
decreased IgG2b level J:131618
decreased IgG3 level J:131618
decreased IgM level J:131618
decreased NK T cell number J:131618
\Sh2d1b1/Sh2d1b2tm1.1Cpt/\Sh2d1b1/Sh2d1b2tm1.1Cpt
(involves: BALB/cJ)
decreased interferon-gamma secretion J:166054
impaired natural killer cell mediated cytotoxicity J:166054
\Sh2d1b1/Sh2d1b2tm1.1Cpt/\Sh2d1b1/Sh2d1b2tm1.1Cpt
(involves: BALB/cJ)
decreased interferon-gamma secretion J:166054
impaired natural killer cell mediated cytotoxicity J:166054
\Sh2d1b1tm1.1Cpt/\Sh2d1b1tm1.1Cpt
(involves: BALB/cJ * C57BL/6)
impaired natural killer cell mediated cytotoxicity J:166054
\Sh2d1b1tm1Vei/\Sh2d1b1tm1Vei
(involves: 129S1/Sv * 129X1/SvJ)
increased interferon-gamma secretion J:110195
increased natural killer cell mediated cytotoxicity J:110195
\Sh2d1b1tm2Vei/\Sh2d1b1tm2Vei
\Sh2d1b2tm1Vei/\Sh2d1b2tm1Vei

(involves: 129S1/Sv * 129X1/SvJ)
impaired natural killer cell mediated cytotoxicity J:145969
\Sh2d1b1tm3Vei/\Sh2d1b1tm3Vei
(involves: C57BL/6)
abnormal NK cell physiology J:187430
\Sh2d1b2tm1.1Cpt/\Sh2d1b2tm1.1Cpt
(involves: BALB/cJ * C57BL/6)
impaired natural killer cell mediated cytotoxicity J:166054
\Sh2d1b2tm1Vei/\Sh2d1b2tm1Vei
(involves: 129S1/Sv * 129X1/SvJ)
impaired natural killer cell mediated cytotoxicity J:145969
increased natural killer cell mediated cytotoxicity J:110195
\Sh2d2atm1Jbs/\Sh2d2atm1Jbs
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
decreased interferon-gamma secretion J:64938
decreased interleukin-2 secretion J:64938
decreased T cell proliferation J:64938
immune system phenotype J:64938
increased interleukin-4 secretion J:64938
\Sh2d3ctm1Lex/\Sh2d3ctm1Lex
(involves: 129S5/SvEvBrd * C57BL/6)
abnormal B cell physiology J:161448
abnormal humoral immune response J:161448
abnormal leukocyte migration J:161448
abnormal marginal zone B cell physiology J:161448
decreased IgG1 level J:161448
decreased IgG2b level J:161448
decreased IgG3 level J:161448
decreased IgM level J:161448
decreased interleukin-6 secretion J:161448
decreased marginal zone B cell number J:161448
\Sh3bp2tm1.1Ics/\Sh3bp2+
(involves: 129S2/SvPas * C57BL/6)
abnormal circulating cytokine level J:221901
abnormal macrophage physiology J:221901
increased susceptibility to bacterial infection J:221901
increased tumor necrosis factor secretion J:221901
\Sh3bp2tm1.1Ics/\Sh3bp2tm1.1Ics
(involves: 129S2/SvPas * C57BL/6)
abnormal circulating cytokine level J:221901
enlarged lymph nodes J:221901
increased circulating interleukin-6 level J:221901
increased circulating interleukin-12 level J:221901
increased circulating tumor necrosis factor level J:221901
increased inflammatory response J:221901
increased monocyte cell number J:221901
increased tumor necrosis factor secretion J:221901
\Sh3bp2tm1Bjro/\Sh3bp2+
(involves: 129S4/SvJae * BALB/cJ * C57BL/6J)
abnormal osteoclast differentiation J:117880
abnormal osteoclast physiology J:117880
immune system phenotype J:117880
increased osteoclast cell number J:117880
\Sh3bp2tm1Bjro/\Sh3bp2tm1Bjro
(involves: 129S4/SvJae * BALB/cJ * C57BL/6J)
abnormal B cell number J:117880
abnormal immune system organ morphology J:117880
abnormal macrophage physiology J:117880
abnormal osteoclast differentiation J:117880
abnormal osteoclast physiology J:117880
blepharitis J:117880
dermatitis J:117880
enlarged lymph nodes J:117880
increased circulating tumor necrosis factor level J:117880
increased inflammatory response J:117880
increased osteoclast cell number J:117880
increased spleen red pulp amount J:117880
joint inflammation J:117880
liver inflammation J:117880
lung inflammation J:117880
myositis J:117880
osteomyelitis J:117880
spinal cord inflammation J:117880
stomach inflammation J:117880
\Sh3bp2tm1Bjro/\Sh3bp2tm1Bjro
\Tnftm1Gkl/\Tnftm1Gkl

(involves: 129S/SvEv * 129S4/SvJae * BALB/cJ * C57BL/6J)
abnormal osteoclast differentiation J:117880
immune system phenotype J:117880
\Sh3bp2tm1Geha/\Sh3bp2tm1Geha
(Not Specified)
abnormal B cell number J:110319
abnormal B cell physiology J:110319
decreased B cell proliferation J:110319
immune system phenotype J:110319
increased pre-B cell number J:110319
\Sh3bp2tm1Rtpl/\Sh3bp2tm1Rtpl
(B6.129P2-Sh3bp2tm1Rtpl)
abnormal B cell number J:121380
abnormal marginal zone B cell physiology J:121380
abnormal spleen marginal zone morphology J:121380
decreased B cell proliferation J:121380
decreased B-1 B cell number J:121380
decreased IgA level J:121380
decreased IgG1 level J:121380
decreased IgG3 level J:121380
decreased IgM level J:121380
decreased immunoglobulin level J:121380
decreased pro-B cell number J:121380
decreased transitional stage B cell number J:121380
increased B cell apoptosis J:121380
increased marginal zone B cell number J:121380
\Sh3bp2tm1Rtpl/\Sh3bp2tm1Rtpl
(involves: 129P2/OlaHsd * C57BL/6)
abnormal circulating cytokine level J:221901
abnormal interleukin-6 secretion J:221901
abnormal macrophage physiology J:221901
decreased tumor necrosis factor secretion J:221901
impaired macrophage phagocytosis J:221901
\Sh3glb2Gt(OST224737)Lex/\Sh3glb2Gt(OST224737)Lex
(B6.129S5-Sh3glb2Gt(OST224737)Lex)
abnormal response to infection J:246421
\Sh3kbp1tm1Kuro/\Sh3kbp1tm1Kuro
\Cd79atm1(cre)Reth/\Cd79a+

(involves: BALB/c * C57BL/6 * NZB)
abnormal B cell physiology J:176805
abnormal humoral immune response J:176805
abnormal lymphocyte cell number J:176805
decreased B cell number J:176805
decreased B-1a cell number J:176805
decreased follicular B cell number J:176805
decreased immature B cell number J:176805
decreased transitional stage T2 B cell number J:176805
decreased transitional stage T3 B cell number J:176805
immune system phenotype J:176805
\Sh3kbp1tm1Kuro/\Sh3kbp1tm1Kuro
\Cd79atm1(cre)Reth/\Cd79a+
\Gt(ROSA)26Sortm4(Ikbkb)Rsky/?

(involves: BALB/c * C57BL/6 * NZB)
decreased B-1a cell number J:176805
immune system phenotype J:176805
\Sh3pxd2atm1b(EUCOMM)Wtsi/\Sh3pxd2atm1b(EUCOMM)Wtsi
(C57BL/6N-Sh3pxd2atm1b(EUCOMM)Wtsi/Wtsi)
abnormal lymphatic vessel morphology J:239583
abnormal thymus topology J:239583
absent connection between subcutaneous lymph vessels and lymph sac J:239583
blood in lymph vessels J:239583
\Sh3pxd2bnee/\Sh3pxd2bnee
(B10.Cg-H2h4 Sh3pxd2bnee/GrsrJ)
eye inflammation J:262132
hypopyon J:262132
increased susceptibility to otitis media J:153369
\Sh3tc1tm1b(EUCOMM)Hmgu/\Sh3tc1tm1b(EUCOMM)Hmgu
(C57BL/6N-Sh3tc1tm1b(EUCOMM)Hmgu/Orl)
increased monocyte cell number J:211773
increased neutrophil cell number J:211773
\Sh3yl1em1(IMPC)Mbp/\Sh3yl1em1(IMPC)Mbp
(C57BL/6NCrl-Sh3yl1em1(IMPC)Mbp/MbpMmucd)
increased monocyte cell number J:211773
\Sh3yl1tm1Syb/\Sh3yl1tm1Syb
(involves: C57BL/6N)
decreased interleukin-1 beta secretion J:298830
decreased susceptibility to endotoxin shock J:298830
decreased tumor necrosis factor secretion J:298830
\Sharpincpdm-Dem/\Sharpincpdm-Dem
(CBy.OcB3-Sharpincpdm-Dem)
abnormal immune system organ morphology J:121810
dermatitis J:121810
skin inflammation J:121810
\Sharpincpdm/\Sharpincpdm
(C57BL/KaLawRij-Sharpincpdm)
abnormal humoral immune response J:53575
abnormal immune system organ morphology J:14539
abnormal lymph node morphology J:14539
abnormal mesenteric lymph node morphology J:53575
abnormal peripheral lymph node morphology J:53575
abnormal spleen morphology J:53575
abnormal spleen white pulp morphology J:31745, J:53575
absent Peyer's patches J:53575
absent spleen B cell follicles J:53575
absent spleen germinal center J:53575
absent spleen marginal zone J:53575
cutaneous mastocytosis J:31745, J:14539
decreased B cell number J:53575
decreased CD4-positive, alpha-beta T cell number J:53575
decreased IgA level J:53575
decreased IgE level J:31745, J:53575
decreased IgG level J:53575
decreased immunoglobulin level J:53575
decreased T cell number J:53575
dermatitis J:14539
enlarged spleen J:14539, J:53575
esophageal inflammation J:31745
folliculitis J:31745
increased eosinophil cell number J:31745, J:14539
increased IgM level J:53575
joint inflammation J:14539
large lymphoid organs J:31745
lung inflammation J:31745
lymph node inflammation J:31745
stomach inflammation J:31745
\Sharpincpdm/\Sharpincpdm
(involves: C57BL/KaLawRij * FVB/NJ)
absent Peyer's patches J:121810
absent spleen B cell follicles J:121810
absent spleen germinal center J:121810
skin inflammation J:121810
\Shc1tm1Ravi/\Shc1tm1Ravi
\Tg(Lck-cre)1Cwi/?

(involves: 129 * C57BL/6)
abnormal double-negative T cell morphology J:78180
decreased double-positive T cell number J:78180
decreased single-positive T cell number J:78180
thymus hypoplasia J:78180
\Shcbp1tm1c(EUCOMM)Wtsi/\Shcbp1tm1c(EUCOMM)Wtsi
\Tg(Lck-cre)1Cwi/?

(involves: C57BL/6 * DBA/2)
decreased susceptibility to experimental autoimmune encephalomyelitis J:212898
immune system phenotype J:212898
\Shcbp1tm1d(EUCOMM)Wtsi/\Shcbp1tm1d(EUCOMM)Wtsi
(involves: C57BL/6N * FVB/N)
decreased B cell number J:212898
decreased CD4-positive, alpha-beta T cell number J:212898
decreased macrophage cell number J:212898
decreased susceptibility to experimental autoimmune encephalomyelitis J:212898
decreased T cell number J:212898
immune system phenotype J:212898
\Shisa6em1(IMPC)Tcp/\Shisa6em1(IMPC)Tcp
(C57BL/6N-Shisa6em1(IMPC)Tcp/Tcp)
decreased leukocyte cell number J:211773
decreased lymphocyte cell number J:211773
increased neutrophil cell number J:211773
\Shisal1em1(IMPC)Ccpcz/\Shisal1em1(IMPC)Ccpcz
(C57BL/6N-Shisal1em1(IMPC)Ccpcz/Ccpcz)
abnormal thymus morphology J:211773
enlarged thymus J:211773
\Shld1em1(IMPC)Mbp/\Shld1em1(IMPC)Mbp
(C57BL/6NCrl-Shld1em1(IMPC)Mbp/Mmucd)
abnormal lymph node morphology J:211773
abnormal spleen morphology J:211773
enlarged lymph nodes J:211773
enlarged spleen J:211773
\Shld1em1Nus/\Shld1em1Nus
(involves: C57BL/6NCrl)
abnormal class switch recombination J:307190
\Shmt2em1(IMPC)Bay/\Shmt2+
(C57BL/6N-Shmt2em1(IMPC)Bay/Bay)
increased spleen weight J:211773
\sho/\sho
(Not Specified)
small thymus J:255
\Shprhem1(IMPC)Tcp/\Shprhem1(IMPC)Tcp
(C57BL/6NCrl-Shprhem1(IMPC)Tcp/Tcp)
enlarged thymus J:211773
\Siaetm1.2Avrk/\Siaetm1.2Avrk
(B6J.129(Cg)-Siaetm1.2Avrk)
immune system phenotype J:231437
\Siaetm1a(EUCOMM)Wtsi/\Siaetm1a(EUCOMM)Wtsi
(involves: C57BL/6N * C57BL/6NTac)
immune system phenotype J:231437
\SialsMRL/MpJ/\SialsMRL/MpJ
(involves: C3H/HeJ * MRL/MpJ)
salivary gland inflammation J:66636
\Sidt1tm1.1(KOMP)Vlcg/\Sidt1tm1.1(KOMP)Vlcg
(C57BL/6N-Sidt1tm1.1(KOMP)Vlcg/Ucd)
abnormal lymph node morphology J:211773
\Sidt2tm1.1Hzha/\Sidt2tm1.1Hzha
(involves: 129S6/SvEvTac * C57BL/6J)
liver inflammation J:236042
\Sigirrtm1Lix/\Sigirrtm1Lix
(involves: 129S6/SvEvTac * BALB/c)
abnormal chemokine secretion J:85151
abnormal splenocyte proliferation J:85151
increased inflammatory response J:85151
increased susceptibility to endotoxin shock J:85151
\Sigirrtm1Mant/\Sigirrtm1Mant
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)
abnormal chemokine secretion J:88907
abnormal dendritic cell physiology J:88907
abnormal interleukin secretion J:88907
immune system phenotype J:88907
increased interleukin-6 secretion J:88907
increased susceptibility to induced colitis J:88907
\Siglec1tm1(HBEGF)Mtka/\Siglec1tm1(HBEGF)Mtka
\1700016L21RikTg(Itgax-HBEGF/EGFP)57Lan/?

(involves: 129S1/Sv * 129X1/SvJ * FVB/N)
abnormal dendritic cell physiology J:123958
abnormal immune system physiology J:123958
abnormal immune tolerance J:123958
abnormal macrophage physiology J:123958
abnormal metallophilic macrophage morphology J:123958
abnormal spleen marginal zone macrophage morphology J:123958
\Siglec1tm1Croc/\Siglec1tm1Croc
(B6.129-Siglec1tm1Croc)
abnormal B cell number J:105546
abnormal T cell subpopulation ratio J:105546
decreased circulating interleukin-6 level J:189854
decreased circulating tumor necrosis factor level J:189854
decreased follicular B cell number J:105546
decreased IgM level J:105546
decreased interleukin-6 secretion J:189854
decreased interleukin-10 secretion J:189854
decreased interleukin-12 secretion J:189854
decreased tumor necrosis factor secretion J:189854
impaired macrophage phagocytosis J:189854
increased CD8-positive, alpha-beta T cell number J:105546
increased marginal zone B cell number J:105546
increased susceptibility to bacterial infection J:189854
\Siglec1tm2.1Croc/\Siglec1tm2.1Croc
(B6.129P2(C)-Siglec1tm2.1Croc)
decreased circulating interleukin-6 level J:189854
decreased circulating tumor necrosis factor level J:189854
decreased susceptibility to bacterial infection J:189854
impaired macrophage phagocytosis J:189854
\Siglec15tm1Yohi/\Siglec15tm1Yohi
(B6.129S6-Siglec15tm1Yohi)
abnormal osteoclast differentiation J:193852
\Siglecetm1.1(SIGLEC16)Avrk/\Siglecetm1.1(SIGLEC16)Avrk
(involves: C57BL/6)
abnormal cytokine level J:264224
decreased susceptibility to bacterial infection J:264224
increased circulating interleukin-6 level J:264224
increased circulating interleukin-12 level J:264224
\Siglecetm1Arte/\Siglecetm1Arte
(involves: C57BL/6)
abnormal macrophage physiology J:195429
abnormal neutrophil physiology J:195429
\Siglecetm1Croc/\Siglecetm1Croc
(B6.129P2-Siglecetm1Croc)
abnormal macrophage physiology J:195429
abnormal neutrophil physiology J:195429
\Siglecftm1.2Avrk/\Siglecftm1.2Avrk
(B6.129(FVB)-Siglecftm1.2Avrk)
abnormal eosinophil differentiation J:204811
abnormal eosinophil physiology J:204811
immune system phenotype J:204811
increased eosinophil cell number J:204811
lung inflammation J:204811
\SiglecgM1Btlr/\SiglecgM1Btlr
(C57BL/6J-SiglecgM1Btlr)
increased B-1 B cell number J:265179
\Siglecgm2Btlr/\Siglecgm2Btlr
(C57BL/6J-Siglecgm2Btlr)
decreased CD8-positive, alpha-beta memory T cell number J:265183
increased B-1 B cell number J:265183
increased CD4-positive, CD25-positive, alpha-beta regulatory T cell number J:265183
\SiglecgM3Btlr/\SiglecgM3Btlr
(C57BL/6J-SiglecgM3Btlr)
decreased B-2 B cell number J:265185
decreased IgM level J:265185
increased B-1 B cell number J:265185
increased B-1a cell number J:265185
\SiglecgM4Btlr/\SiglecgM4Btlr
(C57BL/6J-SiglecgM4Btlr)
increased B-1 B cell number J:272021
\SiglecgM5Btlr/\SiglecgM5Btlr
(C57BL/6J-SiglecgM5Btlr)
increased B-1a cell number J:272022
\Siglecgtm1Lnit/\Siglecgtm1Lnit
(involves: BALB/c)
abnormal plasma cell differentiation J:123353
autoimmune response J:123353
decreased IgG2a level J:123353
increased B-1 B cell number J:123353
increased B-1a cell number J:123353
increased B-1b cell number J:123353
increased IgM level J:123353
\Siglecgtm1Yliu/\Siglecgtm1Yliu
(C57BL/6-Siglecgtm1Yliu)
increased B-1a cell number J:130017
increased IgM level J:130017
increased pre-B cell number J:130017
\Siglechtm1.1Cfg/\Siglechtm1.1Cfg
(involves: C57BL/6)
immune system phenotype J:214874
increased T cell proliferation J:217719
\Siglechtm1.1Cln/\Siglech+
\Tg(CLEC4C-HBEGF)956Cln/0

(involves: C57BL/6)
decreased plasmacytoid dendritic cell number J:166504
\Siglechtm1.1Ksat/\Siglechtm1.1Ksat
(B6.Cg-Siglechtm1.1Ksat)
abnormal circulating cytokine level J:179283
abnormal dendritic cell antigen presentation J:179283
abnormal plasmacytoid dendritic cell physiology J:179283
abnormal regulatory T cell morphology J:179283
decreased circulating interferon-alpha level J:179283
decreased circulating interleukin-12b level J:179283
decreased plasmacytoid dendritic cell number J:179283
decreased susceptibility to bacterial infection induced morbidity/mortality J:179283
decreased susceptibility to infection induced morbidity/mortality J:179283
decreased T-helper 17 cell number J:179283
increased circulating interferon-alpha level J:179283
increased circulating interleukin-12b level J:179283
increased T-helper 17 cell number J:179283
\Sik2tm1Lex/\Sik2tm1Lex
(involves: 129S/SvEvBrd)
increased inflammatory response J:229999
\Sik3tm1a(EUCOMM)Hmgu/\Sik3tm1a(EUCOMM)Hmgu
(C57BL/6N-Sik3tm1a(EUCOMM)Hmgu/Wtsi)
decreased alpha-beta T cell number J:211773
decreased CD4-positive NK T cell number J:211773
decreased CD4-positive, alpha-beta T cell number J:211773
decreased CD5-positive gamma-delta T cell number J:211773
decreased early germinal center B cell number J:211773
decreased effector memory T-helper cell number J:211773
decreased gamma-delta T cell number J:211773
decreased germinal center B cell number J:211773
decreased KLRG1-positive NK cell number J:211773
decreased KLRG1-positive T-helper cell number J:211773
decreased Ly6C-positive mature NK cell number J:211773
decreased memory-marker CD4-negative NK T cell number J:211773
decreased memory-marker CD4-positive NK T cell number J:211773
decreased NK cell number J:211773
decreased NK T cell number J:211773
decreased regulatory T cell number J:211773
decreased T cell number J:211773
decreased T-helper cell number J:211773
increased CD4-negative NK T cell number J:211773
increased CD4-positive, CD25-positive, alpha-beta regulatory T cell number J:211773
increased CD8-positive, alpha-beta T cell number J:211773
increased CD8-positive, naive alpha-beta T cell number J:211773
increased effector memory T-helper cell number J:211773
increased eosinophil cell number J:211773
increased follicular B cell number J:211773
increased granulocyte number J:211773
increased KLRG1+ CD8 alpha-beta T cell number J:211773
increased KLRG1-positive CD4-negative NK T cell number J:211773
increased KLRG1-positive CD4-positive, CD25-positive, alpha-beta regulatory T cell number J:211773
increased KLRG1-positive T-helper cell number J:211773
increased Ly6C-positive NK T cell number J:211773
increased memory-marker gamma-delta T cell number J:211773
increased memory-marker NK cell number J:211773
increased NK cell number J:211773
increased plasmacytoid dendritic cell number J:211773
\Sin3btm1.2Rdp/\Sin3btm1.2Rdp
(involves: 129 * C57BL/6 * FVB/N * SJL)
abnormal granulocyte differentiation J:154855
decreased granulocyte number J:154855
\Sinhcaftm1.2Hmd/\Sinhcaftm1.2Hmd
(involves: 129 * C57BL/6)
spleen hypoplasia J:313620
\Sipa1tm1Nm/\Sipa1+
(involves: 129P2/OlaHsd * C57BL/6)
enlarged spleen J:97239
increased leukocyte cell number J:97239
\Sipa1tm1Nm/\Sipa1tm1Nm
(involves: 129P2/OlaHsd * C57BL/6)
enlarged spleen J:97239
increased granulocyte number J:97239
increased leukocyte cell number J:97239
spleen hyperplasia J:97239
\Sirpatm1b(EUCOMM)Hmgu/\Sirpatm1b(EUCOMM)Hmgu
(C57BL/6N-Sirpatm1b(EUCOMM)Hmgu/Bay)
enlarged spleen J:211773
increased spleen weight J:211773
\Sirpatm1Nog/\Sirpatm1Nog
(involves: 129P2/OlaHsd * C57BL/6)
abnormal Langerhans cell physiology J:88694
abnormal macrophage physiology J:79592
decreased T cell number J:79592
\Sirt1tm1b(EUCOMM)Wtsi/\Sirt1+
(C57BL/6N-Sirt1tm1b(EUCOMM)Wtsi/H)
increased basophil cell number J:211773
\Sirt1tm1Fwa/\Sirt1tm1Fwa
(involves: 129/Sv * 129S6/SvEvTac)
immune system phenotype J:85542
\Sirt1tm1Mcby/\Sirt1tm1Mcby
(involves: 129)
decreased CD8-positive, alpha-beta T cell number J:81010
interstitial pneumonia J:81010
lung inflammation J:81010
\Sirt1tm1Mcby/\Sirt1tm1Mcby
(involves: 129S1/Sv * 129X1/SvJ * CD-1)
decreased CD8-positive, alpha-beta T cell number J:81010
glomerulonephritis J:160869
increased anti-nuclear antigen antibody level J:160869
increased immunoglobulin level J:160869
interstitial pneumonia J:81010
lung inflammation J:81010
\Sirt1tm1Mcby/\Sirt1tm1Mcby
(involves: 129S1/Sv * 129X1/SvJ)
increased autoantibody level J:241633
\Sirt1tm2.1Mcby/\Sirt1tm2.1Mcby
(involves: 129S1/Sv * 129X1/SvJ * CD-1)
enlarged spleen J:180628
\Sirt3tm1.1Fwa/\Sirt3tm1.1Fwa
(involves: 129S6/SvEvTac)
abnormal cytokine level J:178653
increased circulating interferon-gamma level J:178653
increased circulating interleukin-6 level J:178653
increased circulating interleukin-10 level J:178653
increased circulating interleukin-12 level J:178653
increased circulating tumor necrosis factor level J:178653
liver inflammation J:178653
\Sirt6tm1Fwa/\Sirt6tm1Fwa
(involves: 129S6/SvEvTac * 129X1/SvJ)
abnormal B cell differentiation J:112817
abnormal lymphopoiesis J:112817
colitis J:112817
decreased double-positive T cell number J:112817
decreased leukocyte cell number J:112817
spleen hypoplasia J:112817
\Sirt6tm2.1Cxd/\Sirt6tm2.1Cxd
(involves: 129S6/SvEvTac * NIH Black Swiss)
abnormal spleen physiology J:167023
\Sirt6tm2.2Cxd/\Sirt6tm2.2Cxd
(involves: 129S6/SvEvTac * FVB/N * NIH Black Swiss)
abnormal spleen physiology J:167023
\Sirt7tm1Evbo/\Sirt7tm1Evbo
(involves: 129/Sv * C57BL/6)
abnormal cytokine level J:147652
increased granulocyte number J:147652
increased interleukin-4 secretion J:147652
increased interleukin-12 secretion J:147652
increased interleukin-13 secretion J:147652
\Sirt7tm1Fwa/\Sirt7tm1Fwa
(involves: 129S1/Sv)
increased macrophage cell number J:205529
liver inflammation J:205529
\Sit1tm1Lsmn/\Sit1tm1Lsmn
(B6.Cg-Sit1tm1Lsmn)
abnormal cytokine secretion J:100408
abnormal lymphocyte cell number J:100408
abnormal T cell differentiation J:100408
abnormal T-helper 1 cell differentiation J:100408
decreased CD4-positive, alpha-beta T cell number J:100408
decreased CD8-positive, alpha-beta T cell number J:100408
increased double-positive T cell number J:100408
increased interferon-gamma secretion J:100408
increased interleukin-2 secretion J:100408
increased mature gamma-delta T cell number J:100408
increased susceptibility to experimental autoimmune encephalomyelitis J:100408
increased T cell proliferation J:100408
increased tumor necrosis factor secretion J:100408
lymph node hypoplasia J:100408
thymus hyperplasia J:100408
\Sit1tm1Lsmn/\Sit1tm1Lsmn
\Tg(TcraH-Y,TcrbH-Y)71Vbo/?

(involves: C57BL/6 * C57BL/6J * DBA/2J)
abnormal CD8-positive, alpha beta T cell morphology J:100408
abnormal positive T cell selection J:100408
abnormal T cell differentiation J:100408
\Sit1tm1Lsmn/\Sit1tm1Lsmn
\Tg(TcrLCMV)327Sdz/0

(involves: C57BL/6)
abnormal positive T cell selection J:100408
abnormal T cell selection J:100408
thymus hypoplasia J:100408
\Six1em1(IMPC)Mbp/\Six1+
(C57BL/6N-Six1em1(IMPC)Mbp/MbpMmucd)
abnormal spleen morphology J:211773
decreased leukocyte cell number J:211773
enlarged spleen J:211773
small spleen J:211773
\Six1tm1Kwk/\Six1tm1Kwk
(involves: 129P2/OlaHsd * C57BL/6)
athymia J:104488
\Six1tm1Mair/\Six1tm1Mair
(involves: 129S2/SvPas)
athymia J:84417
\Ska1em1(IMPC)Ccpcz/\Ska1+
(C57BL/6NCrl-Ska1em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
\Skap1Gt713Lex/\Skap1Gt713Lex
(B6.129S5-Skap1Gt713Lex)
abnormal CD4-positive, alpha-beta T cell physiology J:126545
abnormal immune system physiology J:126545
abnormal T cell physiology J:126545
decreased interferon-gamma secretion J:126545
decreased interleukin-2 secretion J:126545
decreased T cell proliferation J:126545
immune system phenotype J:126545
\Skap2Gt(VICTR20)21Lex/\Skap2Gt(VICTR20)21Lex
(B6.129S5-Skap2Gt(VICTR20)21Lex)
abnormal B cell activation J:101373
abnormal dendritic cell antigen presentation J:151350
abnormal dendritic cell physiology J:151350
decreased B cell proliferation J:101373
decreased IgG2a level J:101373
decreased IgM level J:101373
decreased susceptibility to experimental autoimmune encephalomyelitis J:101373
\Skic8em1(IMPC)Tcp/\Skic8+
(C57BL/6NCrl-Skic8em1(IMPC)Tcp/Tcp)
abnormal spleen morphology J:211773
enlarged lymph nodes J:211773
increased monocyte cell number J:211773
\Skida1tm1.1(KOMP)Wtsi/\Skida1+
(C57BL/6N-Skida1tm1.1(KOMP)Wtsi/Ucd)
enlarged lymph nodes J:211773
enlarged thymus J:211773
\Skida1tm1.1(KOMP)Wtsi/\Skida1tm1.1(KOMP)Wtsi
(C57BL/6N-Skida1tm1.1(KOMP)Wtsi/Ucd)
enlarged thymus J:211773
small spleen J:211773
\Skiltm1Sis/\Skil+
(involves: C57BL/6 * CBA)
increased T cell derived lymphoma incidence J:62174
\Skiltm1Spw/\Skiltm1Spw
(either: (involves: 129S1/Sv * 129X1/SvJ) or (involves: 129S1/Sv * 129X1/SvJ * C57BL/6))
abnormal immune system cell morphology J:84554
abnormal immune system organ morphology J:84554
decreased T cell proliferation J:84554
enlarged spleen J:84554
\Skiltm2Spw/\Skiltm2Spw
(either: (involves: 129S1/Sv * 129X1/SvJ) or (involves: 129S1/Sv * 129X1/SvJ * C57BL/6))
decreased T cell proliferation J:84554
immune system phenotype J:84554
\Skint1m1Tac/\Skint1m1Tac
(FVB/NTac)
abnormal T cell differentiation J:139711
abnormal T cell morphology J:139711
\Skint2em2Htaka/\Skint2em2Htaka
(C57BL/6-Skint2em2Htaka)
decreased dendritic epidermal T cell number J:291989
\skp/\skp
(CXB5/ByJ-skp/GrsrJ)
thymus atrophy J:153578
\Skp2tm1Kin/\Skp2tm1Kin
(involves: 129P2/OlaHsd)
abnormal immunoglobulin V(D)J recombination J:168974
\Sla2em1(IMPC)Ccpcz/\Sla2em1(IMPC)Ccpcz
(C57BL/6N-Sla2em1(IMPC)Ccpcz/Ccpcz)
decreased NK cell number J:211773
\Sla2tm1Amch/\Sla2tm1Amch
(involves: 129)
immune system phenotype J:169170
\Slatm1Weis/\Slatm1Weis
(involves: 129 * C57BL/6)
abnormal double-positive T cell morphology J:71804
\Slatm1Weis/\Slatm1Weis
\Sla2tm1Amch/\Sla2tm1Amch

(involves: 129)
abnormal dendritic cell differentiation J:169170
abnormal dendritic cell physiology J:169170
decreased interleukin-12 secretion J:169170
decreased tumor necrosis factor secretion J:169170
\Slatm1Weis/\Slatm1Weis
\Tg(DO11.10)10Dlo/0

(involves: 129 * BALB/c * C3H * C57BL/6)
abnormal positive T cell selection J:71804
abnormal T cell differentiation J:71804
\Slatm1Weis/\Slatm1Weis
\Zap70tm1Weis/\Zap70tm1Weis

(involves: 129 * 129X1/SvJ * C57BL/6)
abnormal T cell differentiation J:71804
decreased CD4-positive, alpha-beta T cell number J:71804
\Slamf1tm1Cpt/\Slamf1tm1Cpt
(B6.129S4-Slamf1tm1Cpt)
abnormal cytokine secretion J:90484
abnormal macrophage physiology J:90484
increased susceptibility to parasitic infection J:90484
\Slamf1tm1Cpt/\Slamf1tm1Cpt
(C.129S4-Slamf1tm1Cpt)
abnormal cytokine secretion J:90484
abnormal macrophage physiology J:90484
\Slamf1tm1Cpt/\Slamf1tm1Cpt
\Tg(DO11.10)10Dlo/\Tg(DO11.10)10Dlo

(involves: BALB/c * C3H * C57BL/6)
abnormal cytokine secretion J:90484
\Slamf1tm1Oono/\Slamf1tm1Oono
(B6.129-Slamf1tm1Oono)
increased susceptibility to Paramyxoviridae infection J:117810
\Slamf1tm1Vei/\Slamf1tm1Vei
(involves: 129 * C57BL/6)
abnormal CD4-positive, alpha-beta T cell physiology J:133047, J:93886
immune system phenotype J:133047
\Slamf6tm1Dhow/\Slamf6tm1Dhow
(involves: 129/Sv * C57BL/6)
abnormal neutrophil physiology J:98995
abnormal T-helper 2 physiology J:98995
decreased interleukin-4 secretion J:98995
decreased susceptibility to parasitic infection J:98995
impaired granulocyte bactericidal activity J:98995
increased circulating interleukin-12b level J:98995
increased circulating interleukin-16 level J:98995
increased circulating tumor necrosis factor level J:98995
increased susceptibility to bacterial infection J:98995
increased susceptibility to bacterial infection induced morbidity/mortality J:98995
\Slamf6tm1Lex/\Slamf6tm1Lex
(B6.129S5-Slamf6tm1Lex)
immune system phenotype J:187429
\Slamf6tm1Pls/\Slamf6tm1Pls
\Tg(TcraTcrb)1100Mjb/0

(involves: C57BL/6 * C57BL/6J)
immune system phenotype J:187431
\Slamf7tm1Vei/\Slamf7tm1Vei
(involves: 129S1/Sv * 129X1/SvJ)
impaired natural killer cell mediated cytotoxicity J:145969
\Slamf8tm1Mill/\Slamf8tm1Mill
(involves: BALB/c)
abnormal macrophage physiology J:188963
increased susceptibility to bacterial infection J:188963
\Slamf9em1Isha/\Slamf9em1Isha
(involves: C57BL/6)
abnormal plasmacytoid dendritic cell physiology J:279164
decreased susceptibility to experimental autoimmune encephalomyelitis J:279164
increased plasmacytoid dendritic cell number J:279164
\Slc1a5tm1Tac/\Slc1a5tm1Tac
(involves: 129S/SvEv * C57BL/6)
abnormal T cell physiology J:254980
abnormal T-helper 1 cell differentiation J:254980
abnormal T-helper 2 cell differentiation J:254980
abnormal T-helper 17 cell differentiation J:254980
decreased B cell number J:254980
decreased CD4-positive, alpha-beta memory T cell number J:254980
decreased susceptibility to experimental autoimmune encephalomyelitis J:254980
decreased T helper 1 cell number J:254980
decreased T-helper 17 cell number J:254980
immune system phenotype J:254980
increased CD4-positive, alpha-beta T cell number J:254980
\Slc2a4tm1Mch/\Slc2a4+
(involves: 129/Sv * C57BL/6J * CD-1 * SJL)
heart inflammation J:43650
\Slc2a5tm1b(EUCOMM)Wtsi/\Slc2a5tm1b(EUCOMM)Wtsi
(C57BL/6N-Slc2a5tm1b(EUCOMM)Wtsi/Ieg)
enlarged lymph nodes J:211773
enlarged spleen J:211773
\Slc2a6em1Kusu/\Slc2a6em1Kusu
(involves: C57BL/6JCrlj)
abnormal macrophage physiology J:270487
increased circulating tumor necrosis factor level J:270487
increased susceptibility to endotoxin shock J:270487
\Slc2a9tm1.2Thor/\Slc2a9tm1.2Thor
(involves: C57BL/6 * C57BL/6N)
kidney inflammation J:153089
tubulointerstitial nephritis J:153089
\Slc2a10G128E/\Slc2a10G128E
(C3HeB/FeJ-Slc2a10G128E)
abnormal spleen morphology J:161835
\Slc3a1pbl/\Slc3a1pbl
(C3HeB/FeJ-Slc3a1pbl)
tubulointerstitial nephritis J:85461
\Slc3a1pbl/\Slc3a1pbl
(involves: C3HeB/FeJ * MRL/MpJ)
kidney inflammation J:85461
\Slc3a1tm1.1(KOMP)Vlcg/\Slc3a1tm1.1(KOMP)Vlcg
(C57BL/6N-Slc3a1tm1.1(KOMP)Vlcg/Ucd)
abnormal spleen morphology J:211773
enlarged spleen J:211773
increased eosinophil cell number J:211773
increased spleen weight J:211773
\Slc3a2tm1.1Merl/\Slc3a2+
\Tg(Vil1-cre)997Gum/0

(B6.Cg-Slc3a2tm1.1Merl Tg(Vil1-cre)997Gum)
decreased susceptibility to induced colitis J:173946
\Slc3a2tm1.1Yait/\Slc3a2tm1.1Yait
\Lyz2tm1(cre)Ifo/\Lyz2+

(involves: 129P2/OlaHsd * C57BL/6NCrSlc)
abnormal macrophage antigen presentation J:188365
abnormal macrophage differentiation J:188365
abnormal macrophage morphology J:188365
abnormal macrophage physiology J:188365
impaired macrophage phagocytosis J:188365
\Slc4a1tm1Ahc/\Slc4a1tm1Ahc
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)
abnormal immune system organ morphology J:35637
enlarged spleen J:35637
\Slc4a1tm1Dmb/\Slc4a1tm1Dmb
(involves: 129S6/SvEvTac)
abnormal splenic cell ratio J:145243
\Slc4a1tm1Llp/\Slc4a1tm1Llp
(involves: 129S4/SvJae * C57BL/6J)
enlarged spleen J:35487
\Slc4a1tm1Phsl/\Slc4a1tm1Phsl
(involves: 129 * 129S6/SvEvTac * Black Swiss)
enlarged spleen J:152245
\Slc4a2tm1Ges/\Slc4a2tm1Ges
(involves: 129S6/SvEvTac)
abnormal osteoclast morphology J:193823
abnormal osteoclast physiology J:193823
\Slc4a2tm2Ges/\Slc4a2tm2Ges
\Ctsktm1(cre)Ska/\Ctsk+

(involves: C57BL/6NCrlj * CBA/JNCrlj)
abnormal osteoclast morphology J:193823
abnormal osteoclast physiology J:193823
\Slc4a2tm2Ges/\Slc4a2tm2Ges
\Tg(Mx1-cre)1Cgn/0

(involves: C57BL/6 * CBA)
abnormal osteoclast morphology J:193823
abnormal osteoclast physiology J:193823
\Slc4a4tm1.1Slin/\Slc4a4tm1.1Slin
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
enlarged spleen J:186877
increased spleen weight J:186877
\Slc4a4tm1Ges/\Slc4a4tm1Ges
(involves: 129S6/SvEvTac * Black Swiss)
decreased lymphocyte cell number J:120867
disorganized spleen B cell follicle J:120867
enlarged spleen J:120867
increased spleen red pulp amount J:120867
increased spleen white pulp amount J:120867
\Slc4a10tm1b(KOMP)Wtsi/\Slc4a10tm1b(KOMP)Wtsi
(C57BL/6N-Slc4a10tm1b(KOMP)Wtsi/H)
small spleen J:211773
\Slc5a2m2Btlr/\Slc5a2m2Btlr
(C57BL/6J-Slc5a2m2Btlr)
increased susceptibility to induced colitis J:265117
increased tumor necrosis factor secretion J:265117
\Slc5a2tm1Lex/\Slc5a2tm1Lex
(involves: 129S5/SvEvBrd * C57BL/6J)
decreased susceptibility to autoimmune diabetes J:195941
\Slc5a6tm1.1Said/\Slc5a6tm1.1Said
\Tg(Vil1-cre)997Gum/?

(involves: C57BL/6)
immune system phenotype J:194700
\Slc5a6tm1.1Said/\Slc5a6tm1.1Said
\Tg(Vil1-cre/ERT2)23Syr/0

(involves: C57BL/6 * DBA/2)
cecum inflammation J:307482
small intestinal inflammation J:307482
\Slc5a7tm1a(KOMP)Wtsi/\Slc5a7tm1a(KOMP)Wtsi
(C57BL/6N-Slc5a7tm1a(KOMP)Wtsi/Wtsi)
blood in lymph vessels J:239583
\Slc6a6em1(IMPC)Mbp/\Slc6a6em1(IMPC)Mbp
(C57BL/6N-Slc6a6em1(IMPC)Mbp/MbpMmucd)
abnormal lymph node morphology J:211773
enlarged lymph nodes J:211773
increased monocyte cell number J:211773
\Slc6a8tm1.2Lbar/Y
(involves: 129 * 129S1/Sv * C57BL/6J * C57BL/6N)
microgliosis J:238578
\Slc6a14tm1Gana/\Slc6a14tm1Gana
(Not Specified)
abnormal circulating chemokine level J:226105
abnormal circulating cytokine level J:226105
decreased circulating interleukin-1 alpha level J:226105
decreased circulating interleukin-4 level J:226105
\Slc6a14tm1Gana/\Slc6a14tm1Gana
\Tg(MMTV-PyVT)634Mul/0

(Not Specified)
abnormal immunoglobulin level J:226105
\Slc7a2tm1Clm/\Slc7a2tm1Clm
(involves: 129S7/SvEvBrd * C57BL/6)
abnormal immune system physiology J:69414
\Slc7a5em1(IMPC)H/\Slc7a5+
(C57BL/6NTac-Slc7a5em1(IMPC)H/H)
increased basophil cell number J:211773
\Slc7a7em1Lbu/\Slc7a7em1Lbu
(involves: 129/SvEv * C57BL/6)
abnormal spleen germinal center morphology J:293773
decreased lymphocyte cell number J:293773
decreased spleen weight J:293773
increased neutrophil cell number J:293773
increased spleen red pulp amount J:293773
\Slc7a7Gt(OST41878)Lex/\Slc7a7Gt(OST41878)Lex
(B6.129S-Slc7a7Gt(OST41878)Lex)
increased spleen weight J:125847
\Slc7a9tm1Nune/\Slc7a9tm1Nune
(involves: 129P2/OlaHsd * C57BL/6J)
tubulointerstitial nephritis J:85462
\Slc7a11m1Mtka/\Slc7a11m1Mtka
(C57BL/6-Slc7a11m1Mtka)
abnormal dendritic cell physiology J:159323
abnormal macrophage physiology J:159323
immune system phenotype J:159323
\Slc9a2tm1Ges/\Slc9a2tm1Ges
(involves: 129X1/SvJ * Black Swiss)
stomach inflammation J:65754
\Slc9a4tm1Ges/\Slc9a4tm1Ges
(involves: 129S6/SvEvTac * Black Swiss)
stomach inflammation J:98566
\Slc9a6tm1Dgen/Y
(B6.129P2-Slc9a6tm1Dgen/J)
microgliosis J:262453
\Slc9a8m1Btlr/\Slc9a8m1Btlr
(C57BL/6J-Slc9a8m1Btlr)
increased susceptibility to induced colitis J:267481
\Slc9b1em1(IMPC)Mbp/\Slc9b1em1(IMPC)Mbp
(C57BL/6N-Slc9b1em1(IMPC)Mbp/MbpMmucd)
abnormal lymph node morphology J:211773
abnormal spleen morphology J:211773
enlarged lymph nodes J:211773
enlarged spleen J:211773
\Slc11a1em1(IMPC)Mbp/\Slc11a1em1(IMPC)Mbp
(C57BL/6N-Slc11a1em1(IMPC)Mbp/MbpMmucd)
abnormal spleen morphology J:211773
decreased lymphocyte cell number J:211773
enlarged spleen J:211773
increased neutrophil cell number J:211773
\Slc11a1r/\Slc11a1r
(C3H/HeJ-Slc11a1r)
decreased susceptibility to bacterial infection J:35004
\Slc11a1r/\Slc11a1r
(129/Sv)
decreased susceptibility to bacterial infection J:81412
\Slc11a1r/\Slc11a1s
((129/Sv x BALB/c)F1)
decreased susceptibility to bacterial infection J:28278
\Slc11a1s/\Slc11a1r
((129/Sv x C57BL/6J)F1)
abnormal susceptibility to bacterial infection J:81412
\Slc11a1s/\Slc11a1s
(C57BL/6J)
increased susceptibility to bacterial infection J:81412
\Slc11a1s/\Slc11a1s
(BALB/c)
increased susceptibility to bacterial infection J:28278
\Slc11a1tm1Mcg/\Slc11a1s
(involves: 129S4/SvJae * BALB/c)
increased susceptibility to bacterial infection J:28278
\Slc11a1tm1Mcg/\Slc11a1tm1Mcg
(involves: 129S4/SvJae * BALB/c)
increased susceptibility to bacterial infection J:28278
\Slc11a2mk/\Slc11a2mk
(MK/ReJ)
increased spleen weight J:5167
\Slc11a2mk/\Slc11a2mk
(SEC.Cg-Slc11a2mk)
increased spleen weight J:5167
\Slc11a2tm2Nca/\Slc11a2tm2Nca
\Tg(Vil1-cre)20Syr/?

(involves: 129S6.129S4-Slc11a2tm2Nca * C57BL/6 * DBA/2)
abnormal spleen morphology J:98088
decreased spleen iron level J:98088
enlarged spleen J:98088
increased spleen red pulp amount J:98088
\Slc12a1urehr3/\Slc12a1urehr3
(involves: C3HeB/FeJ)
pyelitis J:159994
pyelonephritis J:159994
\Slc12a2em1Dlp/\Slc12a2+
(involves: C57BL/6J * DBA/2J)
increased susceptibility to bacterial infection J:285398
\Slc12a2em1Dlp/\Slc12a2em1Dlp
(involves: C57BL/6J * DBA/2J)
increased lymphocyte cell number J:285398
increased susceptibility to bacterial infection J:285398
large intestinal inflammation J:285398
\Slc12a5em1(IMPC)Mbp/\Slc12a5+
(C57BL/6N-Slc12a5em1(IMPC)Mbp/MbpMmucd)
abnormal spleen morphology J:211773
enlarged spleen J:211773
small spleen J:211773
\Slc13a3tm1b(KOMP)Wtsi/\Slc13a3tm1b(KOMP)Wtsi
(C57BL/6N-Slc13a3tm1b(KOMP)Wtsi/Ucd)
decreased lymphocyte cell number J:211773
increased monocyte cell number J:211773
increased neutrophil cell number J:211773
\Slc13a5tm1b(EUCOMM)Hmgu/\Slc13a5tm1b(EUCOMM)Hmgu
(C57BL/6N-Slc13a5tm1b(EUCOMM)Hmgu/Ieg)
increased leukocyte cell number J:211773
\Slc14a1tm1Ask/\Slc14a1tm1Ask
(involves: C57BL/6J * CD-1)
decreased spleen weight J:125840
\Slc15a1em1(IMPC)Ccpcz/\Slc15a1em1(IMPC)Ccpcz
(C57BL/6NCrl-Slc15a1em1(IMPC)Ccpcz/Ccpcz)
abnormal thymus morphology J:211773
enlarged thymus J:211773
\Slc15a3tm1a(KOMP)Wtsi/\Slc15a3tm1a(KOMP)Wtsi
(C57BL/6N-Slc15a3tm1a(KOMP)Wtsi)
abnormal myeloid dendritic cell morphology J:210445
\Slc15a3tm1b(KOMP)Wtsi/\Slc15a3tm1b(KOMP)Wtsi
(C57BL/6N-Slc15a3tm1b(KOMP)Wtsi/H)
increased monocyte cell number J:211773
\Slc15a4m1Btlr/\Slc15a4m1Btlr
(C57BL/6J-Slc15a4m1Btlr)
abnormal interferon secretion J:166600
decreased interleukin-6 secretion J:166600
decreased interleukin-12 secretion J:166600
decreased tumor necrosis factor secretion J:166600
\Slc15a4tm1Tkyo/\Slc15a4tm1Tkyo
(involves: C57BL/6)
abnormal circulating cytokine level J:270965
abnormal cytokine secretion J:270965
decreased circulating interleukin-1 beta level J:270965
decreased circulating interleukin-6 level J:270965
decreased interferon-beta secretion J:270965
decreased interleukin-1 beta secretion J:270965
decreased interleukin-6 secretion J:270965
decreased interleukin-12 secretion J:270965
decreased interleukin-12b secretion J:270965
decreased interleukin-15 secretion J:270965
decreased interleukin-18 secretion J:270965
decreased susceptibility to induced colitis J:270965
decreased tumor necrosis factor secretion J:270965
\Slc17a1em1(IMPC)J/\Slc17a1em1(IMPC)J
(C57BL/6NJ-Slc17a1em1(IMPC)J/Mmjax)
decreased leukocyte cell number J:211773
\Slc17a8em1(IMPC)Mbp/\Slc17a8em1(IMPC)Mbp
(C57BL/6N-Slc17a8em1(IMPC)Mbp/MbpMmucd)
abnormal lymph node morphology J:211773
enlarged lymph nodes J:211773
\Slc19a1tm1Gold/\Slc19a1tm1Gold
(involves: 129/Sv * C57BL/6 * SJL)
abnormal lymphopoiesis J:68666
decreased lymphocyte cell number J:68666
small spleen J:68666
small thymus J:68666
\Slc19a2tm1Gelb/\Slc19a2tm1Gelb
(involves: 129X1/SvJ)
abnormal myelopoiesis J:79974
\Slc19a3tm1Said/\Slc19a3tm1Said
(involves: C57BL/6)
chronic liver inflammation J:170952
kidney inflammation J:170952
\Slc20a1tm1.1Lbek/\Slc20a1tm1.1Lbek
\Tg(Mx1-cre)1Cgn/0

(involves: 129S2/SvPas * C57BL/6 * C57BL/6J * CBA)
enlarged spleen J:194198
increased leukocyte cell number J:194198
intermingled spleen red and white pulp J:194198
spleen hyperplasia J:194198
\Slc20a1tm1Lbek/\Slc20a1tm1Lbek
(involves: 129S2/SvPas * C57BL/6J)
abnormal spleen morphology J:194198
enlarged spleen J:194198
increased spleen weight J:157997
\Slc20a2tm1a(EUCOMM)Wtsi/\Slc20a2tm1a(EUCOMM)Wtsi
(C57BL/6NTac-Slc20a2tm1a(EUCOMM)Wtsi/Ieg)
microgliosis J:223197
\Slc22a4tm1Atsu/\Slc22a4tm1Atsu
(involves: C57BL/6J)
intestinal inflammation J:207006
\Slc22a6tm1Dgen/\Slc22a6tm1Dgen
(involves: 129P2/OlaHsd * C57BL/6)
increased thymus weight J:101679
\Slc22a7em1(IMPC)Tcp/\Slc22a7em1(IMPC)Tcp
(C57BL/6NCrl-Slc22a7em1(IMPC)Tcp/Tcp)
enlarged lymph nodes J:211773
\Slc22a29em1(IMPC)Mbp/\Slc22a29em1(IMPC)Mbp
(C57BL/6N-Slc22a29em1(IMPC)Mbp/MbpMmucd)
abnormal spleen morphology J:211773
enlarged spleen J:211773
\Slc23a4tm1a(KOMP)Wtsi/\Slc23a4tm1a(KOMP)Wtsi
(C57BL/6N-2010107G12Riktm1a(KOMP)Wtsi/Wtsi)
decreased leukocyte cell number J:175295
\Slc24a3em#Ebje/\Slc24a3em#Ebje
(C57BL/6J-Slc24a3em#Ebje)
increased susceptibility to induced colitis J:308448
\Slc24a4tm1b(KOMP)Wtsi/\Slc24a4+
(C57BL/6N-Slc24a4tm1b(KOMP)Wtsi/H)
enlarged thymus J:211773
\Slc25a17Gt(XB686)Byg/\Slc25a17Gt(XB686)Byg
(involves: 129P2/OlaHsd * C57BL/6 * Swiss Webster)
abnormal Kupffer cell morphology J:291257
liver inflammation J:291257
\Slc25a37tm1.1Kapl/\Slc25a37tm1.2Kapl
\Speer6-ps1Tg(Alb-cre)21Mgn/?

(involves: 129S4/SvJaeSor * 129S6/SvEvTac * C57BL/6J * C57BL/6NCr * DBA)
enlarged spleen J:173284
\Slc25a37tm1.1Kapl/\Slc25a37tm1.2Kapl
\Tg(Mx1-cre)1Cgn/?

(involves: 129S4/SvJaeSor * 129S6/SvEvTac * C57BL/6J * C57BL/6NCr * CBA)
abnormal B cell morphology J:173284
abnormal lymphocyte morphology J:173284
abnormal spleen morphology J:173284
abnormal T cell morphology J:173284
enlarged spleen J:173284
\Slc25a42em1(IMPC)J/\Slc25a42+
(C57BL/6NJ-Slc25a42em1(IMPC)J/Mmjax)
decreased leukocyte cell number J:211773
\Slc25a46atc/\Slc25a46atc
(B6.Cg-Slc25a46atc)
decreased spleen weight J:242350
decreased thymus weight J:242350
microgliosis J:242350
spleen hypoplasia J:242350
thymus hypoplasia J:242350
\Slc26a1tm1Mark/\Slc26a1tm1Mark
(involves: 129X1/SvJ * CD-1)
kidney inflammation J:158567
\Slc26a4m2Btlr/\Slc26a4m2Btlr
(C57BL/6J-Slc26a4m2Btlr)
increased susceptibility to induced colitis J:236690
\Slc28a3em1(IMPC)H/\Slc28a3em1(IMPC)H
(C57BL/6N-Slc28a3em1(IMPC)H/H)
increased large unstained cell number J:211773
increased monocyte cell number J:211773
\Slc29a1tm2Msg/\Slc29a1tm2Msg
\Eportm1.1(EGFP/icre)Uk/\Epor+

(involves: 129X1/SvJ * BALB/cJ)
decreased interleukin-6 secretion J:244602
\Slc29a2Gt(OST207791)Lex/\Slc29a2Gt(OST207791)Lex
(involves: 129S5/SvEvBrd)
decreased interleukin-6 secretion J:203572
\Slc29a3em1(IMPC)Mbp/\Slc29a3em1(IMPC)Mbp
(C57BL/6NCrl-Slc29a3em1(IMPC)Mbp/MbpMmucd)
abnormal lymph node morphology J:211773
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged lymph nodes J:211773
enlarged spleen J:211773
increased spleen weight J:211773
small thymus J:211773
\Slc29a3em1(IMPC)Wtsi/\Slc29a3em1(IMPC)Wtsi
(C57BL/6N-Slc29a3em1(IMPC)Wtsi/Wtsi)
increased leukocyte cell number J:211773
\Slc29a3tm1Lex/\Slc29a3tm1Lex
(involves: 129S5/SvEvBrd * C57BL/6)
abnormal macrophage morphology J:179286
abnormal macrophage physiology J:179286
enlarged lymph nodes J:179286
enlarged spleen J:179286
immune system phenotype J:179286
increased macrophage apoptosis J:179286
increased macrophage cell number J:179286
increased susceptibility to bacterial infection J:179286
increased susceptibility to bacterial infection induced morbidity/mortality J:179286
myeloid hyperplasia J:179286
\Slc30a2tm1Kgna/\Slc30a2tm1Kgna
(involves: 129 * C57BL/6)
abnormal macrophage physiology J:264481
\Slc30a4em1(IMPC)Tcp/\Slc30a4em1(IMPC)Tcp
(C57BL/6NCrl-Slc30a4em1(IMPC)Tcp/Tcp)
small thymus J:211773
\Slc30a4lm/\Slc30a4lm
(C57BL/6J-Slc30a4lm)
dermatitis J:5911, J:7690
\Slc31a1tm2Djt/\Slc31a1tm2Djt
\Tg(Vil1-cre)997Gum/0

(involves: 129 * C57BL/6 * FVB/N * SJL)
decreased spleen weight J:129741
\Slc33a1tm1.1Lpu/\Slc33a1+
(involves: 129S7/SvEvBrd * C57BL/6)
abnormal circulating cytokine level J:211266
abnormal cytokine secretion J:211266
abnormal T cell activation J:211266
brain inflammation J:211266
conjunctivitis J:211266
decreased B cell number J:211266
dermatitis J:211266
immune system phenotype J:211266
increased B cell number J:211266
increased circulating interleukin-17 level J:211266
increased circulating interleukin-18 level J:211266
increased inflammatory response J:211266
increased interferon-gamma secretion J:211266
increased interleukin-4 secretion J:211266
increased interleukin-17 secretion J:211266
increased neutrophil cell number J:211266
increased susceptibility to infection J:211266
microgliosis J:211266
preputial gland inflammation J:211266
prostate gland inflammation J:211266
salivary gland inflammation J:211266
stomach inflammation J:211266
urinary bladder inflammation J:211266
\Slc35c1tm1Cknr/\Slc35c1tm1Cknr
(involves: 129/Sv * 129P2/OlaHsd * C57BL/6)
abnormal leukocyte adhesion J:121151
abnormal lymph node primary follicle morphology J:121151
impaired leukocyte tethering or rolling J:121151
increased eosinophil cell number J:121151
increased leukocyte cell number J:121151
increased lymphocyte cell number J:121151
increased monocyte cell number J:121151
increased neutrophil cell number J:121151
lymph node hypoplasia J:121151
\Slc37a2em1(IMPC)Mbp/\Slc37a2em1(IMPC)Mbp
(C57BL/6NCrl-Slc37a2em1(IMPC)Mbp/MbpMmucd)
abnormal lymph node morphology J:211773
\Slc37a2tm1Dgen/\Slc37a2tm1Dgen
(involves: 129P2/OlaHsd * C57BL/6J)
abnormal macrophage physiology J:311521
increased interleukin-1 beta secretion J:311521
increased interleukin-6 secretion J:311521
increased susceptibility to endotoxin shock J:311521
increased tumor necrosis factor secretion J:311521
\Slc37a4tm1Jyc/\Slc37a4tm1Jyc
(involves: 129S4/SvJae * C57BL/6)
abnormal chemokine secretion J:86005
abnormal inflammatory response J:86005
abnormal myelopoiesis J:86005
abnormal neutrophil physiology J:86005
abnormal spleen morphology J:86005
absent spleen white pulp J:86005
decreased inflammatory response J:86005
decreased lymphocyte cell number J:86005
decreased neutrophil cell number J:86005
impaired neutrophil chemotaxis J:86005
small spleen J:86005
\Slc38a2tm1a(KOMP)Wtsi/\Slc38a2+
(C57BL/6N-Slc38a2tm1a(KOMP)Wtsi/Wtsi)
increased leukocyte cell number J:211773
\Slc38a7em1(IMPC)Ccpcz/\Slc38a7em1(IMPC)Ccpcz
(C57BL/6NCrl-Slc38a7em1(IMPC)Ccpcz/Ccpcz)
abnormal lymph node morphology J:211773
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged lymph nodes J:211773
enlarged spleen J:211773
enlarged thymus J:211773
\Slc38a8em1Cya/\Slc38a8em1Cya
(C57BL/6J-Slc38a8em1Cya)
decreased susceptibility to viral infection J:336781
decreased susceptibility to viral infection induced morbidity/mortality J:336781
\Slc39a3tm1Gka/\Slc39a3tm1Gka
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
abnormal CD8-positive, alpha-beta cytotoxic T cell morphology J:99161
decreased double-positive T cell number J:99161
increased CD4-positive, alpha-beta T cell number J:99161
\Slc39a5tm1.1Gka/\Slc39a5tm1.1Gka
(involves: 129P2/OlaHsd * C57BL/6 * FVB/N)
increased susceptibility to induced pancreatitis J:209760
\Slc39a5tm1Gka/\Slc39a5tm1Gka
\Tg(Cela1-cre/ERT)1Lgdn/0

(involves: 129P2/OlaHsd * C57BL/6)
increased susceptibility to induced pancreatitis J:209760
\Slc39a10tm1.1Tfk/\Slc39a10tm1.1Tfk
\Tg(Foxn1-cre)8Ghr/0

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2)
increased thymocyte apoptosis J:254216
thymus hypoplasia J:254216
\Slc40a1ffe/\Slc40a1+
(either: (involves: 129X1/SvJ * C57BL/6J) or (involves: C3H/HeJ * C57BL/6J))
abnormal macrophage physiology J:118592
\Slc40a1Pcm/\Slc40a1+
(A.Cg-Slc40a1Pcm)
abnormal spleen development J:98335
abnormal spleen physiology J:98335
decreased spleen iron level J:98335
increased splenocyte apoptosis J:98335
small spleen J:98335
\Slc40a1Pcm/\Slc40a1Pcm
(A.Cg-Slc40a1Pcm)
abnormal spleen development J:98335
decreased spleen iron level J:98335
increased splenocyte apoptosis J:98335
small spleen J:98335
\Slc40a1tm1.1Mmfe/\Slc40a1+
(involves: 129P2/OlaHsd * C57BL/6)
decreased spleen iron level J:215585
\Slc40a1tm1.1Mmfe/\Slc40a1tm1.1Mmfe
(involves: 129P2/OlaHsd * C57BL/6)
decreased spleen iron level J:215585
\Slc40a1tm1Nca/\Slc40a1+
(involves: 129S4/SvJae * 129S6/SvEvTac)
increased spleen iron level J:129846
\Slc40a1tm2Nca/\Slc40a1tm2Nca
\Tg(Vil1-cre/ERT2)23Syr/0

(involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6 * DBA/2)
decreased spleen iron level J:129846
\Slc43a2Gt(258C1)Cmhd/\Slc43a2Gt(258C1)Cmhd
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CD-1)
liver inflammation J:237439
\Slc44a4tm1.2Said/\Slc44a4tm1.2Said
(involves: BALB/cJ * C57BL/6J * C57BL/6N)
increased susceptibility to induced colitis J:351314
\Slc46a2tm1Moki/\Slc46a2tm1Moki
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
thymus hypoplasia J:140121
\Slc48a1em1Ih/\Slc48a1em1Ih
(involves: 129 * C57BL/6J)
abnormal macrophage morphology J:282829
abnormal macrophage physiology J:282829
dark spleen J:282829
decreased macrophage cell number J:282829
enlarged spleen J:282829
increased spleen iron level J:282829
\Slc51bem1(IMPC)Mbp/\Slc51bem1(IMPC)Mbp
(C57BL/6NCrl-Slc51bem1(IMPC)Mbp/Mmucd)
abnormal spleen morphology J:211773
enlarged spleen J:211773
\Slc52a2tm1.1(KOMP)Vlcg/\Slc52a2+
(C57BL/6N-Slc52a2tm1.1(KOMP)Vlcg/Ucd)
enlarged lymph nodes J:211773
\Slco1a5tm1Lex/\Slco1a5tm1Lex
(involves: 129S5/SvEvBrd * C57BL/6J)
abnormal CD8-positive, alpha beta T cell morphology J:103485
increased B cell number J:103485
\Slco4c1em1(IMPC)Ccpcz/\Slco4c1em1(IMPC)Ccpcz
(C57BL/6NCrl-Slco4c1em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
increased effector memory CD8-positive, alpha-beta T cell number J:211773
\Sle1NZM2410/Aeg/\Sle1NZM2410/Aeg
\Sle3NZM2410/Aeg/\Sle3NZM2410/Aeg

(B6;NZM-Sle1NZM2410/Aeg Sle2NZM2410/Aeg Sle3NZM2410/Aeg/LmoJ)
abnormal marginal zone B cell physiology J:138314
increased marginal zone B cell number J:138314
\Sle1NZW/\Sle1NZW
\Sles1NZW/\Sles1NZW

(involves: C57BL/6 * NZW)
abnormal T cell physiology J:100678
decreased susceptibility to systemic lupus erythematosus J:100678
\Sle1NZW/\Sle1NZW
\Tg(Tnfsf13b)1Fma/0

(involves: C57BL/6 * DBA/2J * NZW)
glomerulonephritis J:134128
increased B cell number J:134128
increased IgG level J:134128
increased IgM level J:134128
increased marginal zone B cell number J:134128
increased susceptibility to systemic lupus erythematosus J:134128
\Sle1aC57BL/6J/\Sle1aNZM2410/J
(involves: C57BL/6J * NZM2410/J)
increased anti-chromatin antibody level J:67544
\Sle1aNZM2410/J/\Sle1aNZM2410/J
(involves: C57BL/6J * NZM2410/J)
increased anti-chromatin antibody level J:67544
\Sle1bC57BL/6J/\Sle1bNZM2410/J
(involves: C57BL/6J * NZM2410/J)
increased anti-chromatin antibody level J:67544
\Sle1bNZM2410/J/\Sle1bNZM2410/J
(involves: C57BL/6J * NZM2410/J)
increased anti-chromatin antibody level J:67544
\Sle1cC57BL/6J/\Sle1cNZM2410/J
(involves: C57BL/6J * NZM2410/J)
increased anti-chromatin antibody level J:67544
\Sle1cNZB/\Sle1cNZM2410/J
(involves: C57BL/6J * NZB * NZM2410/J)
glomerulonephritis J:145133
increased autoantibody level J:145133
\Sle1cNZM2410/J/\Sle1cNZM2410/J
(involves: C57BL/6J * NZM2410/J)
increased anti-chromatin antibody level J:67544
\Sle2NZM2410/Aeg/\Sle2NZM2410/Aeg
(involves: C57BL/6J * NZM2410/Aeg)
glomerulonephritis J:25006
\Sle3NZM2410/Aeg/?
(involves: C57BL/6J * NZM2410/Aeg)
glomerulonephritis J:52863
increased IgG level J:52863
increased IgM level J:52863
\Sle6NZW/\Sle6NZW
(involves: C57BL/6 * NZW)
increased susceptibility to systemic lupus erythematosus J:57246
\Sle7BXSB/J/\Sle7BXSB/J
(involves: BXSB/J * C57BL/10Ola)
glomerulonephritis J:60445
\Sle8BXSB/J/\Sle8BXSB/J
(involves: BXSB/J * C57BL/10Ola)
glomerulonephritis J:60445
\Sle9BXSB/J/\Sle9BXSB/J
(involves: BXSB/J * C57BL/10Ola)
increased anti-nuclear antigen antibody level J:60445
\Sle10BXSB/J/\Sle10BXSB/J
(involves: BXSB/J * C57BL/10Ola)
enlarged lymph nodes J:60445
\Sle11BXSB/J/\Sle11BXSB/J
(involves: BXSB/J * C57BL/10Ola)
increased IgG3 level J:60445
\Sle12C57BL/6J/\Sle12C57BL/6J
(involves: C57BL/6J * NZM2410/Aeg)
glomerulonephritis J:52863
\Sle12C57BL/6J/\Sle12NZM2410/Aeg
(involves: C57BL/6J * NZM2410/Aeg)
glomerulonephritis J:52863
\Sle12NZM2410/Aeg/\Sle12NZM2410/Aeg
(involves: C57BL/6J * NZM2410/Aeg)
glomerulonephritis J:52863
\Sle16129S6/SvEvTac/?
(involves: 129X1/Sv * C57BL/6)
abnormal immune serum protein physiology J:93297
\Sle16129S6/SvEvTac/\Sle16129S6/SvEvTac
(B6.129-Sle16129S6/SvEvTac)
increased autoantibody level J:122132
increased susceptibility to systemic lupus erythematosus J:122132
\Sle17129S6/SvEvTac/?
(involves: 129S6/SvEvTac * C57BL/6)
abnormal immune serum protein physiology J:93297
\Sle18C57BL/6/?
(involves: 129X1/Sv * C57BL/6)
abnormal immune serum protein physiology J:93297
\Sles1C57BL/6/\Sles1C57BL/6
(involves: C57BL/6 * NZW)
increased susceptibility to systemic lupus erythematosus J:57246
\Sles1C57BL/6/\Sles1NZW
(involves: C57BL/6 * NZW)
abnormal immune system physiology J:57246
\Sles1NZW/\Sles1NZW
(involves: C57BL/6 * NZW)
decreased susceptibility to systemic lupus erythematosus J:57246
\Sles2C57BL/6/\Sles2C57BL/6
(involves: C57BL/6 * NZW)
increased susceptibility to systemic lupus erythematosus J:57246
\Sles2C57BL/6/\Sles2NZW
(involves: C57BL/6 * NZW)
increased susceptibility to systemic lupus erythematosus J:57246
\Sles2NZW/\Sles2NZW
(involves: C57BL/6 * NZW)
decreased susceptibility to systemic lupus erythematosus J:57246
\Sles3C57BL/6/\Sles3C57BL/6
(involves: C57BL/6 * NZW)
increased susceptibility to systemic lupus erythematosus J:57246
\Sles3C57BL/6/\Sles3NZW
(involves: C57BL/6 * NZW)
increased susceptibility to systemic lupus erythematosus J:57246
\Sles3NZW/\Sles3NZW
(involves: C57BL/6 * NZW)
decreased susceptibility to systemic lupus erythematosus J:57246
\Sles4C57BL/6/\Sles4C57BL/6
(involves: C57BL/6 * NZW)
increased susceptibility to systemic lupus erythematosus J:57246
\Sles4C57BL/6/\Sles4NZW
(involves: C57BL/6 * NZW)
increased susceptibility to systemic lupus erythematosus J:57246
\Sles4NZW/\Sles4NZW
(involves: C57BL/6 * NZW)
decreased susceptibility to systemic lupus erythematosus J:57246
\Slfn1tm1Aki/\Slfn1tm1Aki
(Not Specified)
immune system phenotype J:158985, J:258797
\Slfn2m1Btlr/\Slfn2m1Btlr
(C57BL/6J-Slfn2m1Btlr)
abnormal leukocyte physiology J:158985
abnormal T cell activation J:158985
abnormal T cell proliferation J:158985
decreased CD4-positive, alpha-beta T cell number J:158985
decreased CD8-positive, alpha-beta T cell number J:158985
decreased monocyte cell number J:158985
decreased T cell proliferation J:158985
increased neutrophil cell number J:158985
increased susceptibility to bacterial infection J:158985
increased susceptibility to bacterial infection induced morbidity/mortality J:158985
increased susceptibility to Herpesvirales infection induced morbidity/mortality J:158985
increased susceptibility to Riboviria infection J:158985
increased T cell apoptosis J:158985
\Slfn2m2Btlr/\Slfn2m2Btlr
(C57BL/6J-Slfn2m2Btlr)
decreased IgG level J:234262
decreased response to antigen J:234262
impaired humoral immune response J:234262
\Slfn3tm1Aki/\Slfn3tm1Aki
(Not Specified)
immune system phenotype J:158985, J:258797
\Slfn4tm1c(EUCOMM)Wtsi/\Slfn4tm1c(EUCOMM)Wtsi
\Gli1tm3(cre/ERT2)Alj/\Gli1+

(involves: 129S6/SvEvTac * Black Swiss * C57BL/6 * Swiss Webster)
abnormal CD8-positive, alpha-beta cytotoxic T cell morphology J:337060
abnormal interleukin level J:337060
abnormal tumor necrosis factor level J:337060
decreased susceptibility to bacterial infection J:337060
\Slfn5tm1Aki/\Slfn5tm1Aki
(Not Specified)
immune system phenotype J:258797
\Slfn8tm1Aki/\Slfn8tm1Aki
(involves: 129X1/SvJ * C57BL/6)
decreased interferon-gamma secretion J:258797
decreased interleukin-1 beta secretion J:258797
decreased interleukin-6 secretion J:258797
decreased interleukin-17 secretion J:258797
decreased susceptibility to experimental autoimmune encephalomyelitis J:258797
immune system phenotype J:258797
\Slfn9em1Liudp/\Slfn9em1Liudp
(C57BL/6-Slfn9em1Liudp)
abnormal innate immunity J:351319
abnormal macrophage activation involved in immune response J:351319
\Slfn14em1Nvm/\Slfn14+
(C57BL/6J-Slfn14em1Nvm)
enlarged spleen J:325381
increased spleen weight J:325381
\Slitrk5em1(IMPC)Mbp/\Slitrk5em1(IMPC)Mbp
(C57BL/6N-Slitrk5em1(IMPC)Mbp/MbpMmucd)
abnormal lymph node morphology J:211773
abnormal spleen morphology J:211773
enlarged lymph nodes J:211773
\Slpd1NZB/BlNJ/\Slpd1NZB/BlNJ
(involves: DBA/2J * NZB/BlNJ)
increased B cell proliferation J:124364
\Slpitm1Ktak/\Slpitm1Ktak
(B6.129P2-Slpitm1Ktak)
increased susceptibility to bacterial infection J:132933
\Slpitm1Nkw/\Slpitm1Nkw
(involves: 129P2/OlaHsd * C57BL/6)
abnormal macrophage physiology J:82214
increased B cell proliferation J:82214
increased interleukin-6 secretion J:82214
increased susceptibility to endotoxin shock J:82214
\Slu7tm1a(KOMP)Wtsi/\Slu7+
(C57BL/6N-Slu7tm1a(KOMP)Wtsi/Wtsi)
decreased leukocyte cell number J:211773
\Slurp2tm1Lex/\Slurp2tm1Lex
(involves: 129P2/OlaHsd * 129S5/SvEvBrd * C57BL/6)
immune system phenotype J:231067
\Slx4tm1a(EUCOMM)Wtsi/\Slx4tm1a(EUCOMM)Wtsi
(C57BL/6N-Slx4tm1a(EUCOMM)Wtsi)
abnormal lymphopoiesis J:168567
decreased leukocyte cell number J:168567
\Smad2tm3Rob/\Smad2tm3Rob
\Smad3tm1Xfw/\Smad3tm1Xfw

(involves: 129/Sv * 129S/SvEv * C57BL/6 * ICR)
osteoarthritis J:95374
\Smad3em1(IMPC)H/\Smad3+
(C57BL/6NTac-Smad3em1(IMPC)H/H)
decreased lymphocyte cell number J:211773
\Smad3tm1Cxd/\Smad3tm1Cxd
(either: (involves: 129S6/SvEvTac * C57BL/6) or (involves: 129S6/SvEvTac * NIH Black Swiss))
abnormal immune system morphology J:53510
abnormal T cell activation J:53510
abnormal T cell physiology J:53510
abnormal thymus involution J:53510
colitis J:53510
enlarged lymph nodes J:53510
enlarged mesenteric lymph nodes J:53510
impaired neutrophil chemotaxis J:53510
increased inflammatory response J:53510
increased leukocyte cell number J:53510
increased monocyte cell number J:53510
increased neutrophil cell number J:53510
pancreas inflammation J:53510
small intestinal inflammation J:53510
small spleen J:53510
spleen hypoplasia J:53510
stomach inflammation J:53510
thymus hypoplasia J:53510
\Smad3tm1Cxd/\Smad3tm1Cxd
(B6.129S6-Smad3tm1Cxd)
tubulointerstitial nephritis J:102084
\Smad3tm1Cxd/\Smad3tm1Cxd
(involves: 129S6/SvEvTac)
abnormal leukocyte physiology J:59673
decreased B cell apoptosis J:140567
osteoarthritis J:68792
\Smad3tm1Cxd/\Smad3tm1Cxd
(involves: 129S6/SvEvTac * C57BL/6)
abnormal CD4-positive T cell differentiation J:136955
\Smad3tm1Par/\Smad3tm1Par
(129-Smad3tm1Par/J)
abnormal circulating interleukin-6 level J:175290
abnormal cytokine secretion J:175290
decreased interleukin-6 secretion J:175290
increased inflammatory response J:106572
\Smad3tm1Xfw/\Smad3tm1Xfw
(involves: 129/Sv * C57BL/6)
abnormal B cell proliferation J:53948
abnormal cytokine secretion J:53948
abnormal T cell proliferation J:53948
immune system phenotype J:53948
\Smad4tm1.1Gsu/\Smad4tm1.1Gsu
\Ptf1atm1.1(cre)Cvw/\Ptf1a+
\Tg(MtTGFA)Lmb/0

(involves: 129S1/Sv * 129X1/SvJ * CD-1)
chronic pancreas inflammation J:229184
\Smad4tm2.1Cxd/\Smad4tm2.1Cxd
\Tg(Foxn1-cre)8Ghr/0

(B6.Cg-Smad4tm2.1Cxd Tg(Foxn1-cre)8Ghr)
abnormal thymus physiology J:138837
small thymus J:138837
\Smad4tm2.1Cxd/\Smad4tm2.1Cxd
\Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0

(involves: 129S6/SvEvTac * C57BL/6J * CD-1)
decreased osteoclast cell number J:211171
\Smad7Gt(YHC053)Byg/\Smad7Gt(YHC053)Byg
(involves: 129P2/OlaHsd * C57BL/6J)
abnormal thymus morphology J:212881
thymus hypoplasia J:212881
\Smad7tm1.1Ink/\Smad7tm1.1Ink
\Tg(Cd4-cre)1Cwi/0

(involves: C57BL/6 * DBA/2)
abnormal T-helper 1 cell differentiation J:184670
decreased activated T cell number J:184670
decreased interferon-gamma secretion J:184670
decreased interleukin-9 secretion J:184670
decreased susceptibility to experimental autoimmune encephalomyelitis J:184670
decreased T cell proliferation J:184670
immune system phenotype J:184670
\Smad7tm1Rheu/\Smad7tm1Rheu
(involves: 129S1/Sv * 129X1/SvJ * CD-1)
abnormal class switch recombination J:120714
decreased B cell proliferation J:120714
increased B cell apoptosis J:120714
\Smad9tm3Jfm/\Smad9tm3Jfm
(involves: 129S4/SvJaeSor)
lung inflammation J:150213
\Smap1tm1.1Sata/\Smap1tm1.1Sata
(B6.Cg-Smap1tm1.1Sata)
abnormal myelopoiesis J:196385
abnormal neutrophil morphology J:196385
enlarged spleen J:196385
increased neutrophil cell number J:196385
\Smarca4tm1.2Pcn/\Smarca4tm1.2Pcn
\Tg(Lck-cre)1Cwi/0

(Not Specified)
abnormal T cell morphology J:144072
decreased double-negative T cell number J:144072
\Smarca4tm1.2Pcn/\Smarca4tm1.2Pcn
\Tg(Lck-cre)1Cwi/0
\Tg(LCKprBCL2L1)12Sjk/0

(Not Specified)
abnormal T cell morphology J:144072
decreased double-positive T cell number J:144072
increased double-negative T cell number J:144072
increased thymocyte number J:144072
\Smarca4tm1.2Pcn/\Smarca4tm1Mag
\Tg(Lck-cre)1Cwi/?

(involves: 129S/Sv * C57BL/6 * DBA/2)
abnormal T cell differentiation J:85191
absent CD8-positive, alpha-beta T cells J:85191
arrested T cell differentiation J:85191
decreased CD4-positive, alpha-beta T cell number J:85191
decreased double-negative T cell number J:85191
decreased double-positive T cell number J:85191
thymus hypoplasia J:85191
\Smarca4tm1.2Pcn/\Smarca4tm1Mag
\Tg(Lck-cre)1Cwi/?
\Tg(LCKprBCL2)36Sjk/?

(involves: 129S/Sv * C57BL/6 * DBA/2)
arrested T cell differentiation J:85191
\Smarca4tm1.2Pcn/\Smarca4tm1Tich
\Tg(Lck-cre)1Cwi/0

(involves: 129)
abnormal T cell morphology J:144072
decreased double-negative T cell number J:144072
decreased thymocyte number J:144072
\Smarca4tm1.2Pcn/\Smarca4tm1Tich
\Tg(Lck-cre)1Cwi/0
\Tg(LCKprBCL2L1)12Sjk/0

(involves: 129)
abnormal T cell morphology J:144072
decreased double-positive T cell number J:144072
increased double-negative T cell number J:144072
increased thymocyte number J:144072
\Smarca4tm1Tich/\Smarca4+
(involves: 129)
immune system phenotype J:144072
\Smarca4tm1Tich/\Smarca4+
\Tg(Lck-cre)1Cwi/0

(involves: 129)
decreased double-negative T cell number J:144072
decreased double-positive T cell number J:144072
decreased single-positive T cell number J:144072
decreased thymocyte number J:144072
\Smarcad1tm1Gos/\Smarcad1tm1Gos
(129S2/SvPas-Smarcad1tm1Gos)
immune system phenotype J:56661
\Smarcal1tm1.1Cfbo/\Smarcal1tm1.1Cfbo
(either: B6.129-Smarcal1tm1.1Cfbo or (involves: 129 * C57BL/6))
decreased B cell number J:183899
\Smarcb1tm1b(EUCOMM)Hmgu/\Smarcb1+
(C57BL/6N-Smarcb1tm1b(EUCOMM)Hmgu/Bay)
decreased leukocyte cell number J:211773
\Smarcb1tm1Sho/\Smarcb1tm3Sho
\Tg(Mx1-cre)1Cgn/?

(involves: 129S1/Sv * 129S6/SvEvTac * C57BL/6 * CBA)
abnormal lymph node morphology J:80224
abnormal spleen morphology J:80224
enlarged lymph nodes J:80224
enlarged spleen J:80224
increased eosinophil cell number J:80224
increased T cell derived lymphoma incidence J:80224
\Smarcc1tm2.1Rhs/\Smarcc1tm2.1Rhs
\Tg(Mx1-cre)1Cgn/0

(involves: BALB/c * C57BL/6 * CBA)
abnormal immature B cell morphology J:184060
abnormal immunoglobulin heavy chain V(D)J recombination J:184060
abnormal pre-B cell morphology J:184060
abnormal pro-B cell morphology J:184060
arrested B cell differentiation J:184060
decreased B cell number J:184060
decreased B cell proliferation J:184060
decreased early pro-B cell number J:184060
decreased follicular B cell number J:184060
decreased late pro-B cell number J:184060
decreased pro-B cell number J:184060
increased B cell apoptosis J:184060
\Smarce1tm1Tich/\Smarce1tm2.1Tich
\Gt(ROSA)26Sortm3(CAG-flpo/ERT2)Alj/\Gt(ROSA)26Sor+
\Tg(Cd4-cre)1Cwi/0

(involves: 129S6/SvEvTac * C57BL/6 * DBA/2)
immune system phenotype J:194195
\Smc3tm1a(EUCOMM)Wtsi/\Smc3+
(involves: C57BL/6N)
increased T cell number J:200082
\Smc5tm1b(KOMP)Wtsi/\Smc5+
(C57BL/6N-Smc5tm1b(KOMP)Wtsi/Ics)
decreased lymphocyte cell number J:211773
increased eosinophil cell number J:211773
increased neutrophil cell number J:211773
\Smc6tm1.1Arln/\Smc6tm1.1Arln
(involves: 129P2/OlaHsd * C57BL/6 * FVB)
decreased IgG2b level J:220422
increased leukocyte cell number J:220422
\Smcr8em1Btlr/\Smcr8em1Btlr
(C57BL/6J-Smcr8em1Btlr)
enlarged lymph nodes J:268243
enlarged spleen J:268243
increased CD4-positive, alpha-beta T cell number J:268243
increased CD8-positive, alpha-beta T cell number J:268243
increased circulating interleukin-12b level J:268243
increased interleukin-6 secretion J:268243
increased susceptibility to induced colitis J:268243
increased tumor necrosis factor secretion J:268243
\Smcr8em1Btlr/\Smcr8em1Btlr
\Tlr3tm1Flv/\Tlr3tm1Flv
\Tlr7tm1Aki/\Tlr7tm1Aki
\Tlr9tm1Aki/\Tlr9tm1Aki

(involves: 129P2/OlaHsd * 129S1/Sv * C57BL/6J)
immune system phenotype J:268243
\Smcr8em2Btlr/\Smcr8em2Btlr
(C57BL/6J-Smcr8em2Btlr)
enlarged lymph nodes J:268243
enlarged spleen J:268243
increased CD4-positive, alpha-beta T cell number J:268243
increased CD8-positive, alpha-beta T cell number J:268243
increased circulating interleukin-12b level J:268243
increased interleukin-6 secretion J:268243
increased susceptibility to induced colitis J:268243
increased tumor necrosis factor secretion J:268243
\Smcr8m1Btlr/\Smcr8+
(C57BL/6J-Smcr8m1Btlr)
increased susceptibility to induced colitis J:268243
\Smcr8m1Btlr/\Smcr8m1Btlr
(C57BL/6J-Smcr8m1Btlr)
increased susceptibility to induced colitis J:268243
increased tumor necrosis factor secretion J:268243
\Smcr8m2Btlr/\Smcr8m2Btlr
(C57BL/6J-Smcr8m2Btlr)
increased susceptibility to induced colitis J:268243
increased tumor necrosis factor secretion J:268243
\Smcr8m3Btlr/\Smcr8m3Btlr
(C57BL/6J-Smcr8m3Btlr)
increased susceptibility to induced colitis J:268243
increased tumor necrosis factor secretion J:268243
\Smg1Gt(AG0297)Wtsi/\Smg1+
(involves: 129P2/OlaHsd * C57BL/6)
chronic inflammation J:193626
decreased circulating interleukin-1 beta level J:193626
enlarged spleen J:193626
increased circulating interleukin-6 level J:193626
\Smg6em1(IMPC)Mbp/\Smg6+
(C57BL/6NCrl-Smg6em1(IMPC)Mbp/Mmucd)
abnormal spleen morphology J:211773
enlarged spleen J:211773
\Smg9tm1b(EUCOMM)Wtsi/\Smg9tm1b(EUCOMM)Wtsi
(C57BL/6N-Smg9tm1b(EUCOMM)Wtsi/Wtsi)
absent connection between subcutaneous lymph vessels and lymph sac J:239583
blood in lymph vessels J:239583
\Smim3tm1Anjm/\Smim3+
\Cd74tm1Anjm/\Cd74+
\Lmo2tm2(cre)Thr/\Lmo2+

(involves: 129P2/OlaHsd * C57BL/6)
abnormal mast cell morphology J:155870
decreased granulocyte number J:155870
decreased monocyte cell number J:155870
\Smim20em1(IMPC)J/\Smim20+
(C57BL/6NJ-Smim20em1(IMPC)J/Mmjax)
immune system phenotype J:350521
\Smim20em1(IMPC)J/\Smim20em1(IMPC)J
(C57BL/6NJ-Smim20em1(IMPC)J/Mmjax)
immune system phenotype J:350521
\Smim23em1(IMPC)Mbp/\Smim23em1(IMPC)Mbp
(C57BL/6N-Smim23em1(IMPC)Mbp/MbpMmucd)
abnormal lymph node morphology J:211773
enlarged lymph nodes J:211773
\Smoc1tm1b(EUCOMM)Wtsi/\Smoc1+
(C57BL/6N-Smoc1tm1b(EUCOMM)Wtsi/H)
decreased lymphocyte cell number J:211773
increased basophil cell number J:211773
increased large unstained cell number J:211773
increased neutrophil cell number J:211773
\Smoc1tm1b(EUCOMM)Wtsi/\Smoc1tm1b(EUCOMM)Wtsi
(C57BL/6N-Smoc1tm1b(EUCOMM)Wtsi/H)
decreased lymphocyte cell number J:211773
increased neutrophil cell number J:211773
\Smpd1tm1Esc/\Smpd1+
(involves: 129S1/Sv * C57BL/6J)
abnormal immune system cell morphology J:70489
\Smpd1tm1Esc/\Smpd1tm1Esc
(involves: 129S1/Sv * C57BL/6J)
abnormal granulocyte physiology J:81982
immune system phenotype J:44401
increased macrophage derived foam cell number J:81982
increased susceptibility to bacterial infection J:81982
\Smpd1tm1Wst/\Smpd1tm1Wst
(involves: 129P2/OlaHsd * C57BL/6)
enlarged spleen J:26748
hepatosplenomegaly J:26748
increased macrophage derived foam cell number J:26748
\Smpdl3btm1a(EUCOMM)Wtsi/\Smpdl3btm1a(EUCOMM)Wtsi
(C57BL/6-Smpdl3btm1a(EUCOMM)Wtsi)
abnormal chemokine secretion J:224870
abnormal circulating chemokine level J:224870
abnormal macrophage morphology J:224870
increased circulating interleukin-6 level J:224870
increased circulating interleukin-12b level J:224870
increased circulating tumor necrosis factor level J:224870
increased neutrophil cell number J:224870
increased susceptibility to endotoxin shock J:224870
\Smstm1a(EUCOMM)Wtsi/Y
(involves: C57BL/6 * C57BL/6N)
increased NK cell number J:213427
increased NK T cell number J:213427
\Smtntm1Gve/\Smtntm1Gve
(involves: 129/Sv * C57BL/6)
intestinal inflammation J:104648
sepsis J:104648
\Smurf2Gt(RRA098)Byg/\Smurf2Gt(RRA098)Byg
(involves: 129P2/OlaHsd * C57BL/6)
enlarged spleen J:189320
\Smyd5tm1a(EUCOMM)Wtsi/\Smyd5tm1a(EUCOMM)Wtsi
\Tg(Vil1-cre)997Gum/0

(B6.Cg-Smyd5tm1a(EUCOMM)Wtsi Tg(Vil1-cre)997Gum)
decreased susceptibility to induced colitis J:339411
\Snai2tm1Look/\Snai2tm1Look
(involves: 129X1/SvJ * C57BL/6)
blepharitis J:80652
immune system phenotype J:80652
\Snai2tm2Grid/\Snai2+
\Snai3tm1.2Jhws/\Snai3tm1.2Jhws

(involves: 129/Sv * 129S1/Sv * C57BL/6)
abnormal thymus cortex morphology J:204710
abnormal thymus medulla morphology J:204710
decreased B cell number J:204710
disorganized spleen B cell follicle J:204710
\Snai2tm2Grid/\Snai2tm2Grid
(involves: 129S1/Sv)
abnormal T cell differentiation J:78323
blepharitis J:48521
conjunctivitis J:48521
decreased leukocyte cell number J:78323
small thymus J:78323
\Snai2tm2Grid/\Snai2tm2Grid
\Snai3tm1.2Jhws/\Snai3+

(involves: 129/Sv * 129S1/Sv * C57BL/6)
abnormal thymus cortex morphology J:204710
abnormal thymus medulla morphology J:204710
decreased B cell number J:204710
disorganized spleen B cell follicle J:204710
increased macrophage cell number J:204710
increased neutrophil cell number J:204710
\Snai2tm2Grid/\Snai2tm2Grid
\Snai3tm1.2Jhws/\Snai3tm1.2Jhws

(involves: 129/Sv * 129S1/Sv * C57BL/6)
abnormal thymus cortex morphology J:204710
abnormal thymus involution J:204710
abnormal thymus medulla morphology J:204710
decreased B cell number J:204710
decreased double-positive T cell number J:204710
disorganized spleen B cell follicle J:204710
increased macrophage cell number J:204710
increased neutrophil cell number J:204710
increased single-positive T cell number J:204710
small spleen J:204710
small thymus J:204710
thymus fibrosis J:204710
\Snai3tm1.1Jhws/\Snai3tm1.1Jhws
\Tg(Lck-cre)548Jxm/0

(involves: 129/Sv * C57BL/6 * CBA)
immune system phenotype J:204710
\Sncaem1(IMPC)H/\Sncaem1(IMPC)H
(C57BL/6NTac-Sncaem1(IMPC)H/H)
increased spleen weight J:211773
\Sncatm1Rosl/\Sncatm1Rosl
(involves: 129X1/SvJ)
decreased susceptibility to bacterial infection J:138194
\Sncatm1Rosl/\Sncatm1Rosl
\Tg(Prnp-SNCA)7Vle/\Tg(Prnp-SNCA)7Vle

(involves: 129X1/SvJ * C3H * C57BL/6)
abnormal response to infection J:138194
\Sncatm1Rosl/\Sncatm1Rosl
\Tg(Prnp-SNCA*A53T)83Vle/\Tg(Prnp-SNCA*A53T)83Vle

(involves: 129X1/SvJ * C3H * C57BL/6)
increased susceptibility to bacterial infection J:138194
\Snd1em1(IMPC)Tcp/\Snd1+
(C57BL/6NCrl-Snd1em1(IMPC)Tcp/Tcp)
decreased lymphocyte cell number J:211773
decreased spleen weight J:211773
increased neutrophil cell number J:211773
small thymus J:211773
\Snd1tm1.2Elws/\Snd1tm1.2Elws
(involves: C57BL/6)
immune system phenotype J:324590
\Snhg15tm1Nju/\Snhg15tm1Nju
(involves: C57BL/6J)
immune system phenotype J:291983
\Snord50a/Snord50btm1.1Soen/\Snord50a/Snord50btm1.1Soen
(B6.129P2-Snord50a/Snord50btm1.1Soen)
enlarged lymph nodes J:206419
enlarged spleen J:206419
\Snord50a/Snord50btm1.1Soen/\Snord50a/Snord50btm1.1Soen
(B6.129P2-Snord50a/Snord50btm1.1Soen)
enlarged lymph nodes J:206419
enlarged spleen J:206419
\Snrktm1.1Hxu/\Snrktm1.1Hxu
\Tg(Adipoq-cre)1Evdr/0

(B6.Cg-Snrktm1.1Hxu Tg(Adipoq-cre)1Evdr)
abnormal circulating chemokine level J:257980
brown adipose tissue inflammation J:257980
increased circulating interleukin-6 level J:257980
increased circulating tumor necrosis factor level J:257980
white adipose tissue inflammation J:257980
\Snrnp40em1Btlr/\Snrnp40swp
(C57BL/6J-Snrnp40em1Btlr/Snrnp40swp)
abnormal CD4-positive, alpha-beta T cell physiology J:282417
abnormal CD8-positive, alpha-beta T cell physiology J:282417
abnormal thymus development J:282417
decreased B cell number J:282417
decreased CD4-positive, alpha-beta T cell number J:282417
decreased CD8-positive, alpha-beta T cell number J:282417
decreased DN1 thymic pro-T cell number J:282417
decreased DN4 thymocyte number J:282417
decreased lymphocyte cell number J:282417
decreased monocyte cell number J:282417
decreased NK cell number J:282417
decreased T cell number J:282417
decreased T cell proliferation J:282417
immune system phenotype J:282417
impaired natural killer cell mediated cytotoxicity J:282417
increased central memory CD8 positive, alpha-beta T cell number J:282417
increased circulating interferon-beta level J:282417
increased circulating interferon-gamma level J:282417
increased circulating interleukin-6 level J:282417
increased circulating interleukin-12 level J:282417
increased circulating interleukin-17 level J:282417
increased circulating tumor necrosis factor level J:282417
increased effector memory CD8-positive, alpha-beta T cell number J:282417
increased susceptibility to viral infection J:282417
increased susceptibility to viral infection induced morbidity/mortality J:282417
small thymus J:282417
thymus hypoplasia J:282417
\Snx8tm1Hbsh/\Snx8tm1Hbsh
(Not Specified)
abnormal chemokine secretion J:254306
abnormal circulating chemokine level J:254306
abnormal dendritic cell physiology J:254306
abnormal macrophage physiology J:254306
decreased circulating CXCL10 level J:254306
decreased circulating tumor necrosis factor level J:254306
decreased CXCL10 secretion J:254306
decreased macrophage cytokine production J:254306
immune system phenotype J:254306
increased susceptibility to bacterial infection J:254306
increased susceptibility to bacterial infection induced morbidity/mortality J:254306
\Snx8tm2a(EUCOMM)Hmgu/\Snx8tm2a(EUCOMM)Hmgu
(C57BL/6N-Snx8tm2a(EUCOMM)Hmgu/Wtsi)
increased leukocyte cell number J:211773
\Snx10em1Ael/\Snx10em1Ael
(involves: 129 * C57BL/6J * C57BL/6JOlaHsd)
abnormal osteoclast morphology J:289051
abnormal osteoclast physiology J:289051
decreased osteoclast cell number J:289051
osteomyelitis J:289051
\Snx10em2Ael/\Snx10em2Ael
(involves: 129 * C57BL/6J * C57BL/6JOlaHsd)
abnormal osteoclast morphology J:289051
abnormal osteoclast physiology J:289051
decreased osteoclast cell number J:289051
osteomyelitis J:289051
\Snx10tm1a(EUCOMM)Raba/\Snx10tm1a(EUCOMM)Raba
(involves: 129S4/SvJae * C57BL/6 * C57BL/6J)
abnormal osteoclast physiology J:224711
\Snx13tm1b(EUCOMM)Hmgu/\Snx13+
(C57BL/6N-Snx13tm1b(EUCOMM)Hmgu/Ieg)
increased leukocyte cell number J:211773
\Snx15tm1.1(KOMP)Vlcg/\Snx15tm1.1(KOMP)Vlcg
(C57BL/6N-Snx15tm1.1(KOMP)Vlcg/J)
decreased leukocyte cell number J:211773
\Snx20tm1Lex/\Snx20tm1Lex
\Tg(Prm-cre)58Og/0

(involves: 129S/SvEvBrd * 129S4/SvJae)
immune system phenotype J:131282
\Snx27tm1Lslo/\Snx27tm1Lslo
(involves: 129P2/OlaHsd)
small spleen J:171001
\Soat1ald/\Soat1ald
(AKR/O)
thymus hyperplasia J:12157
\Soat1m1Anu/\Soat1m1Anu
(C57BL/6NCrlAnu-Soat1m1Anu)
immune system phenotype J:104190
\Soat1tm1Far/\Soat1tm1Far
(involves: 129S4/SvJae * C57BL/6)
abnormal macrophage morphology J:37049
\Socs1tm1.1Ayr/\Socs1tm1.1Ayr
(involves: C57BL/6)
abnormal T cell physiology J:226678
decreased effector memory T-helper cell number J:226678
decreased susceptibility to experimental autoimmune encephalomyelitis J:226678
\Socs1tm1Ayos/\Socs1tm1Ayos
\Foxp3tm4(YFP/icre)Ayr/\Foxp3+

(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ)
blepharitis J:167922
conjunctivitis J:167922
dermatitis J:167922
increased regulatory T cell number J:167922
\Socs1tm1Ayos/\Socs1tm1Ayos
\Tg(Lck-cre)1Jtak/0

(involves: 129S4/SvJae * C57BL/6)
abnormal CD4-positive T cell differentiation J:132905
abnormal CD4-positive, alpha-beta T cell physiology J:132905
decreased susceptibility to experimental autoimmune encephalomyelitis J:132905
\Socs1tm1Ayos/\Socs1tm1Ayos
\Tg(Tek-cre)1Ywa/0

(involves: 129S4/SvJae * C57BL/6 * SJL)
decreased CD4-positive, alpha-beta T cell number J:132905
increased CD8-positive, alpha-beta T cell number J:132905
\Socs1tm1Jni/\Socs1+
(Not Specified)
abnormal cytokine level J:91651
abnormal interleukin level J:91651
\Socs1tm1Jni/\Socs1tm1Jni
(Not Specified)
abnormal cytokine secretion J:57475
abnormal T cell differentiation J:57475
decreased B cell number J:57475
decreased thymocyte number J:57475
\Socs1tm1Kish/\Socs1tm1Kish
(involves: 129P2/OlaHsd * C57BL/6J)
abnormal spleen morphology J:51685
abnormal spleen white pulp morphology J:51685
absent thymus corticomedullary boundary J:51685
decreased lymphocyte cell number J:51685
\Socs1tm1Kish/\Socs1tm1Kish
(B6.129P2-Socs1tm1Kish)
abnormal lymphocyte physiology J:69472
increased activated T cell number J:69472
increased NK T cell number J:69472
liver inflammation J:69472
thymus atrophy J:69472
\Socs1tm1Kish/\Socs1tm1Kish
\Stat1tm1Rds/\Stat1tm1Rds

(involves: 129/Sv * 129P2/OlaHsd * C57BL/6)
immune system phenotype J:69472
increased activated T cell number J:69472
liver inflammation J:69472
thymus atrophy J:69472
\Socs1tm1Kish/\Socs1tm1Kish
\Stat6tm1Aki/\Stat6tm1Aki

(involves: 129P2/OlaHsd * C57BL/6)
immune system phenotype J:69472
increased activated T cell number J:69472
liver inflammation J:69472
thymus atrophy J:69472
\Socs1tm1Wehi/\Socs1tm1Wehi
(involves: 129S1/Sv * C57BL/6)
abnormal follicular B cell morphology J:51281
abnormal inflammatory response J:57474
abnormal lymph node B cell domain morphology J:51281
abnormal macrophage physiology J:57474
abnormal mature B cell morphology J:51281
abnormal Peyer's patch morphology J:51281
abnormal spleen white pulp morphology J:57474
decreased B cell number J:51281
decreased eosinophil cell number J:51281
decreased leukocyte cell number J:57474
decreased lymphocyte cell number J:51281
decreased pre-B cell number J:51281
decreased susceptibility to Togaviridae infection induced morbidity/mortality J:57474
heart inflammation J:51281
increased inflammatory response J:72528
increased spleen red pulp amount J:51281
liver inflammation J:51281
pancreas inflammation J:51281
small thymus J:51281
thymus cortex atrophy J:57474, J:51281
\Socs1tm1Wehi/\Socs1tm3Wehi
\Tg(Lck-cre)I57Jxm/0

(involves: 129P2/OlaHsd * C57BL/6 * ICR)
abnormal CD4-positive, alpha beta T cell morphology J:83009
abnormal CD8-positive, alpha beta T cell morphology J:83009
abnormal T cell activation J:83009
abnormal T cell differentiation J:83009
abnormal T cell subpopulation ratio J:83009
decreased B cell number J:83009
enlarged lymph nodes J:83009
enlarged thymus medulla J:83009
increased CD4-positive, alpha-beta T cell number J:83009
increased CD8-positive, alpha-beta T cell number J:83009
lymph node hyperplasia J:83009
thymus hyperplasia J:83009
\Socs1tm2Wehi/\Socs1tm2Wehi
(C57BL/6-Socs1tm2Wehi)
absent spleen germinal center J:72528
glomerulonephritis J:72528
increased incidence of corneal inflammation J:72528
increased inflammatory response J:72528
intestinal inflammation J:72528
liver inflammation J:72528
myocarditis J:72528
myositis J:72528
pancreas inflammation J:72528
salivary gland inflammation J:72528
skin inflammation J:72528
thymus atrophy J:72528
\Socs1tm3.1Wehi/\Socs1tm3.1Wehi
(C57BL/6-Socs1tm3.1Wehi)
abnormal inflammatory response J:83009
increased circulating interferon-gamma level J:83009
\Socs2tm1Wehi/\Socs2tm1Wehi
(involves: C57BL/6 * C57BL/6J)
abnormal circulating cytokine level J:186227
abnormal macrophage physiology J:186227
increased circulating interferon-gamma level J:186227
increased circulating interleukin-1 beta level J:186227
increased interferon-gamma secretion J:186227
increased interleukin-1 beta secretion J:186227
increased tumor necrosis factor secretion J:186227
liver inflammation J:186227
\Socs3tm1Ayos/\Socs3tm1Ayos
\Lyz2tm1(cre)Ifo/\Lyz2+

(involves: 129 * C57BL/6)
decreased susceptibility to endotoxin shock J:92040
\Socs3tm1Jni/\Socs3+
(involves: 129P2/OlaHsd)
increased interleukin-2 secretion J:128797
\Socs3tm1Robb/\Socs3tm1Robb
(involves: C57BL/6)
enlarged spleen J:145513
increased neutrophil cell number J:145513
increased susceptibility to induced arthritis J:145513
\Socs3tm1Wsa/\Socs3tm2Wsa
\Lyz2tm1(cre)Ifo/?

(involves: 129P2/OlaHsd * C57BL/6)
abnormal macrophage physiology J:83645
\Socs3tm1Wsa/\Socs3tm2Wsa
\Tg(Vav1-cre)1Awr/0

(involves: C57BL/6)
abnormal granulocyte differentiation J:89785
abnormal myelopoiesis J:89785
enlarged spleen J:89785
increased inflammatory response J:89785
increased neutrophil cell number J:89785
liver inflammation J:89785
lung inflammation J:89785
peritoneal inflammation J:89785
\Socs4m1Nch/\Socs4m1Nch
(C.C3Fe-Socs4m1Nch)
abnormal chemokine secretion J:241977
abnormal T cell activation J:241977
decreased T cell number J:241977
immune system phenotype J:241977
increased interferon-gamma secretion J:241977
increased interleukin-1 secretion J:241977
increased interleukin-4 secretion J:241977
increased interleukin-5 secretion J:241977
increased interleukin-6 secretion J:241977
increased interleukin-12b secretion J:241977
increased interleukin-13 secretion J:241977
increased susceptibility to Orthomyxoviridae infection induced morbidity/mortality J:241977
increased T cell number J:241977
\Socs4m1Nch/\Socs4m1Nch
(C3H/He-Socs4m1Nch)
immune system phenotype J:241977
increased susceptibility to Orthomyxoviridae infection induced morbidity/mortality J:241977
\Socs4m1Nch/\Socs4m1Nch
(C6.C3Fe-Socs4m1Nch)
immune system phenotype J:241977
increased susceptibility to Orthomyxoviridae infection induced morbidity/mortality J:241977
\Socs6tm1Dlk/\Socs6tm1Dlk
(involves: C57BL/6)
immune system phenotype J:77039
\Sod1m1H/\Sod1m1H
(involves: C3H/HeH * C57BL/6J)
liver inflammation J:219360
microgliosis J:219360
\Sod1tm1Leb/\Sod1tm1Leb
(involves: 129S7/SvEvBrd * C57BL/6)
blepharitis J:219024
increased circulating interleukin-6 level J:219024
increased circulating tumor necrosis factor level J:219024
increased interleukin-6 secretion J:219024
increased tumor necrosis factor secretion J:219024
Meibomian gland inflammation J:219024
\Sod2tm1Leb/\Sod2tm1Leb
(B6.129S7-Sod2tm1Leb/J)
impaired myelopoiesis J:36148
\Sod3tm1Mrkl/\Sod3tm1Mrkl
(D1.129P2-Sod3tm1Mrkl)
autoimmune arthritis J:106273
increased susceptibility to induced arthritis J:106273
increased tumor necrosis factor secretion J:106273
\Sod3tm1Svp/\Sod3tm1Svp
(involves: 129S6/SvEvTac * C57BL/6NTac)
decreased susceptibility to endotoxin shock J:285340
\Sonem1.1Bcgen/\Son+
(B6(Cg)-Sonem1.1Bcgen)
abnormal B cell differentiation J:347709
abnormal naive B cell morphology J:347709
abnormal transitional stage B cell morphology J:347709
decreased follicular B cell number J:347709
decreased IgA level J:347709
decreased IgM level J:347709
decreased leukocyte cell number J:347709
decreased lymphocyte cell number J:347709
decreased monocyte cell number J:347709
decreased neutrophil cell number J:347709
decreased transitional stage T2 B cell number J:347709
increased marginal zone B cell number J:347709
increased pre-B cell number J:347709
increased transitional stage T1 B cell number J:347709
\Sorbs1tm1Krc/\Sorbs1tm1Krc
(B6.129-Sorbs1tm1Krc)
decreased leukocyte cell number J:121762
decreased lymphocyte cell number J:121762
decreased monocyte cell number J:121762
\Sordem1(IMPC)Ccpcz/\Sordem1(IMPC)Ccpcz
(C57BL/6NCrl-Sordem1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
\Sort1tm1Camo/\Sort1tm1Camo
(B6.129X1-Sort1tm1Camo)
abnormal tumor necrosis factor level J:157549
\Sos1tm1.1Les/\Sos1tm1.1Les
\Tg(Lck-cre)1Cwi/0

(involves: 129 * C57BL/6)
decreased CD4-positive, alpha-beta T cell number J:174536
decreased CD8-positive, alpha-beta T cell number J:174536
decreased DN4 thymocyte number J:174536
decreased double-negative T cell number J:174536
decreased double-positive T cell number J:174536
decreased gamma-delta T cell number J:174536
decreased T cell proliferation J:174536
decreased thymocyte number J:174536
\Sos1tm1.2Rak/\Sos1+
(involves: 129S/Sv * C57BL/6 * FVB/N * SJL)
enlarged spleen J:171873
increased leukocyte cell number J:171873
increased neutrophil cell number J:171873
increased spleen red pulp amount J:171873
\Sostdc1tm1Snd/\Sostdc1tm1Snd
(involves: C57BL/6)
decreased osteoclast cell number J:216098
\Sox2tm3(TK)Hoch/\Sox2+
(involves: 129S4/SvJae * C57BL/6)
stomach inflammation J:177655
tongue inflammation J:177655
\Sox4Igt4/\Del(13)36H
(involves: 101/H * C3H/HeH * C57BL/6)
thymus hypoplasia J:141688
\Sox4tm1Cle/\Sox4tm1Cle
(involves: 129P2/OlaHsd * C57BL/6)
abnormal B cell differentiation J:32741
absent pre-B cells J:32741
decreased pro-B cell number J:32741
\Sox4tm2Cle/\Sox4tm2Cle
(involves: 129P2/OlaHsd * C57BL/6)
abnormal B cell differentiation J:32741
absent pre-B cells J:32741
decreased pro-B cell number J:32741
\Sox9em1(cre/ERT2)Smoc/\Sox9+
\Tnfsf18em1Pwan/\Tnfsf18em1Pwan

(involves: C57BL/6J)
abnormal T cell activation J:346395
decreased CD8-positive, alpha-beta T cell number J:346395
decreased inflammatory response J:346395
\Sox11tm1.2Vlf/\Sox11+
\Sox4tm1.1Vlf/\Sox4+

(involves: 129 * C57BL/6 * FVB/N)
small spleen J:175338
\Sox11tm1.2Vlf/\Sox11+
\Sox12tm1.1Vlf/\Sox12tm1.1Vlf
\Sox4tm1.1Vlf/\Sox4+

(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6)
small spleen J:175338
\Sox11tm1.2Vlf/\Sox11tm1.2Vlf
(involves: 129 * C57BL/6)
absent spleen J:175338
\Sox11tm1Weg/\Sox11tm1Weg
(involves: 129S1/Sv * 129X1/SvJ)
absent spleen J:92251
\Sox13tm1Jskg/\Sox13+
(involves: C57BL/6)
decreased gamma-delta T cell number J:117301
\Sox13tm1Jskg/\Sox13tm1Jskg
(involves: C57BL/6)
decreased gamma-delta T cell number J:117301
increased T cell proliferation J:117301
\Sox14em1(IMPC)Ccpcz/\Sox14+
(C57BL/6N-Sox14em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged thymus J:211773
\Sox14em1(IMPC)Ccpcz/\Sox14em1(IMPC)Ccpcz
(C57BL/6N-Sox14em1(IMPC)Ccpcz/Ccpcz)
abnormal lymph node morphology J:211773
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged lymph nodes J:211773
enlarged thymus J:211773
\Sox17tm1Sjm/\Sox17tm2Sjm
\Tg(Mx1-cre)1Cgn/0

(involves: 129/Sv * C3H * C57BL/6 * C57BL/Ka * CBA)
decreased leukocyte cell number J:123050
spleen hypoplasia J:123050
thymus hypoplasia J:123050
\Sox17tm1Ysk/\Sox17+
(involves: 129S1/Sv * C57BL/6)
liver inflammation J:194071
\Sox17tm1Ysk/\Sox17+
(B6.129S1-Sox17tm1Ysk)
gallbladder inflammation J:241569
liver inflammation J:194071
\Sox17tm2Sjm/\Sox17+
\Tg(Pdx1-cre)6Tuv/0

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * FVB/N)
liver inflammation J:241569
\Sox18Ra-Op/\Sox18Ra-Op
(B6D2-Sox18Ra-Op/J)
abnormal lymphatic vessel morphology J:143564
\Sox18tm1Koop/\Sox18tm1Koop
(B6.129-Sox18tm1Koop)
abnormal lymphatic vessel morphology J:143564
\Sox21em1(IMPC)Mbp/\Sox21em1(IMPC)Mbp
(C57BL/6NCrl-Sox21em1(IMPC)Mbp/MbpMmucd)
abnormal lymph node morphology J:211773
decreased lymphocyte cell number J:211773
enlarged lymph nodes J:211773
increased monocyte cell number J:211773
increased neutrophil cell number J:211773
\Sp3tm1Sus/\Sp3tm1Sus
(involves: 129P2/OlaHsd * C57BL/6)
abnormal B cell differentiation J:84837
decreased CD4-positive, alpha-beta T cell number J:84837
small thymus J:84837
\Sp4tm1Sus/\Sp4tm1Sus
(involves: 129P2/OlaHsd * C57BL/6)
spleen hypoplasia J:77894
thymus hypoplasia J:77894
\Sp7em1(IMPC)Ccpcz/\Sp7+
(C57BL/6NCrl-Sp7em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
\Sp110em1Vnce/\Sp110em1Vnce
(C57BL/6J-Sp110em1Vnce)
immune system phenotype J:313901
\Sp140em1Vnce/\Sp140em1Vnce
(C57BL/6J-Sp140em1Vnce)
increased susceptibility to bacterial infection J:313901
increased susceptibility to bacterial infection induced morbidity/mortality J:313901
\Spag11aem1(IMPC)Mbp/\Spag11aem1(IMPC)Mbp
(C57BL/6NCrl-Spag11aem1(IMPC)Mbp/Mmucd)
increased monocyte cell number J:211773
\Spag11aem2Mgef/\Spag11a+
(C57BL/6NJNcbs-Spag11aem2Mgef)
epididymis inflammation J:363226
\Spag11aem2Mgef/\Spag11aem2Mgef
(C57BL/6NJNcbs-Spag11aem2Mgef)
spermatic granuloma J:363226
\Sparctm1Hwe/\Sparctm1Hwe
(involves: 129S/SvEv * C57BL/6J)
abnormal osteoclast morphology J:61480
decreased osteoclast cell number J:61480
eye inflammation J:52120
vitreous body inflammation J:52120
\Spata2tm1(KOMP)Vlcg/\Spata2tm1(KOMP)Vlcg
(C57BL/6-Spata2tm1(KOMP)Vlcg)
increased inflammatory response J:244164
\Spata2tm1.1(KOMP)Vlcg/\Spata2tm1.1(KOMP)Vlcg
(C57BL/6N-Spata2tm1.1(KOMP)Vlcg/Ucd)
decreased lymphocyte cell number J:211773
increased eosinophil cell number J:211773
\Spata24tm1b(EUCOMM)Wtsi/\Spata24tm1b(EUCOMM)Wtsi
(C57BL/6N-Spata24tm1b(EUCOMM)Wtsi/BayMmucd)
decreased neutrophil cell number J:211773
\Spata31f3em1(IMPC)Ccpcz/\Spata31f3em1(IMPC)Ccpcz
(C57BL/6NCrl-Spata31f3em1(IMPC)Ccpcz/Ccpcz)
abnormal lymph node morphology J:211773
abnormal thymus morphology J:211773
enlarged lymph nodes J:211773
enlarged thymus J:211773
increased CD8-positive, alpha-beta T cell number J:211773
increased CD8-positive, naive alpha-beta T cell number J:211773
\spcy/\spcy
(C57BL/6J-spcy)
abnormal innate immunity J:94077
\Spdeftm1Shiv/\Spdeftm1Shiv
(involves: 129S4/SvJae)
small intestinal inflammation J:166876
stomach inflammation J:166876
\Spdye4btm3b(EUCOMM)Wtsi/\Spdye4btm3b(EUCOMM)Wtsi
(C57BL/6N-Spdye4btm3b(EUCOMM)Wtsi/Bay)
abnormal spleen morphology J:211773
\Speer6-ps1Tg(Alb-cre)21Mgn/\Speer6-ps1+
\Trmutm1Tomik/\Trmutm1Tomik

(involves: C57BL/6 * DBA)
abnormal inflammatory response J:235644
\Spef2bgh/\Spef2bgh
(involves: 129S6/SvEvTac * C57BL/6J * C57BL/10J)
sinus inflammation J:176695
\Spegtm1b(KOMP)Wtsi/\Speg+
(C57BL/6N-Spegtm1b(KOMP)Wtsi/Nju)
increased basophil cell number J:211773
\Spentm1Hon/\Spentm1Hon
(involves: 129P2/OlaHsd * C57BL/6J)
abnormal B cell differentiation J:82332
\Spg11em1(IMPC)J/\Spg11em1(IMPC)J
(C57BL/6NJ-Spg11em1(IMPC)J/Mmjax)
increased leukocyte cell number J:211773
\Sphk1tm1.1Cgh/\Sphk1tm2Cgh
\Sphk2tm1.1Cgh/\Sphk2tm1.1Cgh
\Tg(Mx1-cre)1Cgn/0

(involves: 129S4/SvJae * C57BL/6 * CBA)
abnormal immune serum protein physiology J:120783
abnormal NK cell differentiation J:154069
abnormal T cell differentiation J:120783
abnormal thymus cell ratio J:120783
decreased B cell number J:120783
decreased NK cell number J:154069
decreased T cell number J:120783
increased NK cell number J:154069
\Sphk1tm1Npa/\Sphk1tm1Npa
(BALB/c-Sphk1tm1Npa)
increased B cell number J:129314
\Sphk1tm1Rlp/\Sphk1tm1Rlp
(involves: 129S6/SvEvTac)
abnormal cytokine level J:133917
decreased susceptibility to endotoxin shock J:133917
enlarged mesenteric lymph nodes J:133917
\Sphk2Gt(NPX039)Byg/\Sphk2Gt(NPX039)Byg
(involves: 129P2/OlaHsd * C57BL/6)
immune system phenotype J:102911
\Sphk2tm1.1Stlp/\Sphk2tm1.1Stlp
(involves: BALB/c)
abnormal CD4-positive, alpha-beta T cell physiology J:153014
\Sphk2tm1Npa/\Sphk2tm1Npa
(BALB/c-Sphk2tm1Npa)
abnormal B cell migration J:129314
increased B cell number J:129314
\Spi1tm1.1Dgt/\Spi1tm1.1Dgt
(involves: 129S1/Sv * 129X1/SvJ)
abnormal spleen morphology J:90331
decreased B cell number J:90331
enlarged spleen J:90331
increased T cell derived lymphoma incidence J:90331
spleen hyperplasia J:90331
\Spi1tm1.2Nutt/\Spi1tm1.2Nutt
\Tg(Mx1-cre)1Cgn/0

(involves: C57BL/6 * CBA)
abnormal granulocyte differentiation J:98188
abnormal spleen morphology J:98188
decreased B cell number J:98188
increased granulocyte number J:98188
\Spi1tm1.3Dgt/\Spi1tm1.3Dgt
(involves: 129S1/Sv * 129X1/SvJ * BALB/c * C57BL/6)
abnormal double-negative T cell morphology J:106040
abnormal T cell subpopulation ratio J:106040
arrested B cell differentiation J:106040
decreased B-1a cell number J:106040
decreased granulocyte number J:106040
decreased mature B cell number J:106040
decreased pre-B cell number J:106040
decreased pro-B cell number J:106040
decreased T cell number J:106040
decreased thymocyte number J:106040
increased B-1 B cell number J:106040
increased B-1b cell number J:106040
increased IgM level J:106040
increased lymphocyte cell number J:106040
increased T cell derived lymphoma incidence J:106040
increased T cell number J:106040
small thymus J:106040
\Spi1tm1.3Dgt/\Spi1tm1.3Dgt
(involves: 129 * BALB/c * C57BL/6)
abnormal spleen morphology J:90331
decreased B cell number J:90331
enlarged spleen J:90331
increased neutrophil cell number J:90331
increased spleen weight J:90331
increased T cell derived lymphoma incidence J:90331
spleen hyperplasia J:90331
\Spi1tm1Kast/\Spi1tm1Kast
(B6.129S2-Spi1tm1Kast)
absent B cells J:90543
failure of myelopoiesis J:90543
\Spi1tm1Ram/\Spi1tm1Ram
(involves: 129S2/SvPas)
decreased macrophage cell number J:101493
\Spi1tm1Ram/\Spi1tm1Ram
(involves: 129S2/SvPas * C57BL/6)
abnormal B cell number J:36473
abnormal macrophage differentiation J:36473
abnormal microglial cell morphology J:116087
abnormal neutrophil differentiation J:36473
abnormal T cell differentiation J:36473
abnormal T cell number J:36473
absent mature B cells J:36473
decreased CD4-positive, alpha-beta T cell number J:36473
decreased CD8-positive, alpha-beta T cell number J:36473
decreased double-positive T cell number J:36473
decreased macrophage cell number J:36473
decreased neutrophil cell number J:36473
decreased spleen red pulp amount J:36473
decreased thymocyte number J:36473
sepsis J:36473
\Spi1tm1Rpd/\Spi1tm1Rpd
(involves: 129/Sv * C57BL/6 * Black Swiss)
abnormal myelopoiesis J:123079
arrested B cell differentiation J:123079
enlarged spleen J:123079
impaired myelopoiesis J:123079
\Spi1tm1Sing/\Spi1+
\Spibtm1Mcs/\Spib+

(involves: 129S/SvEv * 129X1/SvJ)
abnormal spleen germinal center morphology J:88257
decreased B cell proliferation J:88257
\Spi1tm1Sing/\Spi1+
\Spibtm1Mcs/\Spibtm1Mcs

(involves: 129S/SvEv * 129X1/SvJ)
abnormal B cell differentiation J:88257
abnormal immature B cell morphology J:88257
absent spleen germinal center J:88257
decreased B cell number J:88257
decreased B cell proliferation J:88257
immune system phenotype J:88257
increased B cell apoptosis J:88257
\Spi1tm1Sing/\Spi1tm1Sing
(involves: 129S/SvEv)
abnormal B cell differentiation J:20348
abnormal granulocyte morphology J:20348
abnormal leukopoiesis J:20348
abnormal monocyte morphology J:20348
abnormal T cell differentiation J:20348
\Spi1tm3Dgt/\Spi1tm3Dgt
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
decreased B cell number J:131217
decreased double-negative T cell number J:131217
increased double-negative T cell number J:131217
increased granulocyte number J:131217
\Spibtm1Ksho/\Spibtm1Ksho
(involves: C57BL/6J)
abnormal Peyer's patch morphology J:187649
increased susceptibility to bacterial infection J:187649
\Spibtm1Mcs/\Spibtm1Mcs
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
abnormal immature B cell morphology J:88257
decreased B cell proliferation J:88257
\Spibtm1Mcs/\Spibtm1Mcs
(involves: 129S1/Sv * 129X1/SvJ)
abnormal humoral immune response J:45245
abnormal spleen B cell follicle morphology J:45245
abnormal spleen germinal center morphology J:45245
abnormal spleen white pulp morphology J:45245
decreased B cell proliferation J:45245
decreased IgG1 level J:45245
decreased IgG2a level J:45245
decreased IgG2b level J:45245
increased B cell apoptosis J:45245
increased IgM level J:45245
\Spictm1.1Kmm/\Spictm1.1Kmm
(involves: 129S6/SvEvTac * C57BL/6)
abnormal macrophage morphology J:143900
impaired macrophage phagocytosis J:143900
increased spleen iron level J:143900
increased spleen weight J:143900
\Spictm1Kmm/\Spictm1Kmm
(involves: 129S6/SvEvTac * C57BL/6)
abnormal macrophage morphology J:143900
impaired macrophage phagocytosis J:143900
increased spleen iron level J:143900
increased spleen weight J:143900
\Spin4em1Jbn/Y
(involves: C57BL/6J)
increased spleen weight J:347154
\Spin4em2Jbn/Y
(involves: C57BL/6J)
increased spleen weight J:347154
\Spink1tm1Kymm/\Spink1tm1Kymm
(involves: C57BL/6NCrlj * CBA/JNCrlj)
small spleen J:104647
\Spink2tm1.1(KOMP)Vlcg/\Spink2tm1.1(KOMP)Vlcg
(C57BL/6N-Spink2tm1.1(KOMP)Vlcg/Ucd)
increased basophil cell number J:211773
\Spink5m1Btlr/\Spink5m1Btlr
(involves: C57BL/6J)
increased neutrophil cell number J:183755
\Spink5tm2.1Hov/\Spink5tm2.1Hov
\Tg(KRT5-cre/ERT2)2Ipc/0

(involves: C57BL/6 * C57BL/6JRj * SJL)
abnormal lymph node B cell domain morphology J:357366
abnormal lymph node germinal center morphology J:357366
abnormal spleen marginal zone morphology J:357366
abnormal spleen morphology J:357366
abnormal thymus morphology J:357366
arrested T cell differentiation J:357366
decreased double-positive T cell number J:357366
decreased spleen B cell follicle number J:357366
enlarged lymph nodes J:357366
enlarged spleen J:357366
increased chemokine level J:357366
increased IgE level J:357366
increased neutrophil cell number J:357366
increased spleen white pulp amount J:357366
lymph node hyperplasia J:357366
myeloid hyperplasia J:357366
skin inflammation J:357366
small thymus J:357366
spleen hypoplasia J:357366
thymus atrophy J:357366
thymus cortex hypoplasia J:357366
thymus hypoplasia J:357366
\Spink6em1(IMPC)Ccpcz/\Spink6em1(IMPC)Ccpcz
(C57BL/6N-Spink6em1(IMPC)Ccpcz/Ccpcz)
decreased Ly6C-positive immature NK cell number J:211773
decreased macrophage cell number J:211773
increased Ly6C-positive mature NK cell number J:211773
increased monocyte cell number J:211773
\Spink7em1Cya/\Spink7em1Cya
(C57BL/6N-Spink7em1Cya/Cya)
increased interleukin-1 beta secretion J:310883
increased interleukin-6 secretion J:310883
increased susceptibility to induced colitis J:310883
\Spink13em1(IMPC)Ccpcz/\Spink13em1(IMPC)Ccpcz
(C57BL/6N-Spink13em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged thymus J:211773
\Spink14tm1e(KOMP)Wtsi/\Spink14tm1e(KOMP)Wtsi
(C57BL/6N-Spink14tm1e(KOMP)Wtsi/Wtsi)
decreased immature NK cell number J:211773
decreased macrophage cell number J:211773
decreased mature NK cell number J:211773
decreased NK cell number J:211773
increased anti-nuclear antigen antibody level J:211773
increased memory-marker NK cell number J:211773
\Spint1tm2.1Hk/\Spint1tm2.1Hk
\Tg(Vil1-cre)997Gum/0

(involves: C57BL/6 * C57BL/6J * SJL)
increased susceptibility to induced colitis J:179937
\Spir1BALB/cOlaHsd/\Spir1BALB/cOlaHsd
(involves: BALB/cOlaHsd * CBA/CaOlaHsd)
decreased susceptibility to bacterial infection J:84089
\Spir1BALB/cOlaHsd/\Spir1CBA/CaOlaHsd
(involves: BALB/cOlaHsd * CBA/CaOlaHsd)
decreased susceptibility to bacterial infection J:84089
\Spir1CBA/CaOlaHsd/\Spir1CBA/CaOlaHsd
(involves: BALB/cOlaHsd * CBA/CaOlaHsd)
increased susceptibility to bacterial infection J:84089
\Splq1L6/\Splq1L6
(involves: L6 * M16i)
decreased spleen weight J:87793
\Splq1L6/\Splq1M16i
(involves: L6 * M16i)
decreased spleen weight J:87793
\Splq2L6/\Splq2L6
(involves: L6 * M16i)
decreased spleen weight J:87793
\Splq2L6/\Splq2M16i
(involves: L6 * M16i)
decreased spleen weight J:87793
\Splq3L6/\Splq3L6
(involves: L6 * M16i)
decreased spleen weight J:87793
\Splq4L6/\Splq4L6
(involves: L6 * M16i)
decreased spleen weight J:87793
\Splq4L6/\Splq4M16i
(involves: L6 * M16i)
decreased spleen weight J:87793
\Splq5L6/\Splq5L6
(involves: L6 * M16i)
decreased spleen weight J:87793
\Splq5L6/\Splq5M16i
(involves: L6 * M16i)
decreased spleen weight J:87793
\Splq6L6/\Splq6L6
(involves: L6 * M16i)
decreased spleen weight J:87793
\Splq6L6/\Splq6M16i
(involves: L6 * M16i)
decreased spleen weight J:87793
\Splq7L6/\Splq7L6
(involves: L6 * M16i)
decreased spleen weight J:87793
\Splq8L6/\Splq8L6
(involves: L6 * M16i)
decreased spleen weight J:87793
\Splq8L6/\Splq8M16i
(involves: L6 * M16i)
decreased spleen weight J:87793
\Splq9L6/\Splq9L6
(involves: L6 * M16i)
decreased spleen weight J:87793
\Splwt1LG/J/?
(involves: LG/J * SM/J)
increased spleen weight J:94605
\Spm1C57BL/6/?
(involves: C57BL/6 * NZB)
abnormal immune system organ morphology J:59427
\Spmip2tm1b(EUCOMM)Hmgu/\Spmip2tm1b(EUCOMM)Hmgu
(C57BL/6N-Spmip2tm1b(EUCOMM)Hmgu/Bay)
abnormal spleen morphology J:211773
\Spntm1Bam/\Spntm1Bam
(involves: 129S4/SvJae * C57BL/6)
abnormal T cell physiology J:29272
increased T cell proliferation J:29272, J:88252
\Spntm1Bam/\Spntm1Bam
(B6;129S4-Spntm1Bam/J)
decreased susceptibility to experimental autoimmune encephalomyelitis J:86932
immune system phenotype J:66401
\Spns2tm1.1Nmoc/\Spns2tm1.1Nmoc
\Tg(Tek-cre)1Ywa/0

(involves: C57BL/6 * C57BL/6NCrlj * CBA/JNCrlj * SJL)
abnormal B cell physiology J:184558
abnormal effector T cell morphology J:184558
abnormal T cell physiology J:184558
decreased CD4-positive, alpha-beta T cell number J:184558
decreased CD8-positive, alpha-beta T cell number J:184558
decreased mature B cell number J:184558
increased CD4-positive, alpha-beta T cell number J:184558
increased CD8-positive, alpha-beta T cell number J:184558
\Spns2tm1.2Nmoc/\Spns2tm1.2Nmoc
(involves: C57BL/6NCrlj * CBA/JNCrlj)
abnormal B cell physiology J:184558
abnormal T cell physiology J:184558
decreased B-1 B cell number J:184558
decreased CD4-positive, alpha-beta T cell number J:184558
decreased CD8-positive, alpha-beta T cell number J:184558
decreased follicular B cell number J:184558
decreased immature B cell number J:184558
decreased leukocyte cell number J:184558
decreased mature B cell number J:184558
decreased transitional stage T1 B cell number J:184558
increased CD4-positive, alpha-beta T cell number J:184558
increased CD8-positive, alpha-beta T cell number J:184558
increased single-positive T cell number J:184558
\Spns2tm1a(KOMP)Wtsi/\Spns2tm1a(KOMP)Wtsi
(B6JTyr;B6N-Spns2tm1a(KOMP)Wtsi/Wtsi)
decreased leukocyte cell number J:165965
\Spns2tm1a(KOMP)Wtsi/\Spns2tm1a(KOMP)Wtsi
(involves: C57BL/6 * C57BL/6N)
abnormal humoral immune response J:188933
decreased B cell number J:188933, J:213427
decreased B-1 B cell number J:188933
decreased CD4-positive, alpha-beta T cell number J:188933, J:213427
decreased CD8-positive, alpha-beta T cell number J:188933, J:213427
decreased follicular B cell number J:188933
decreased IgG1 level J:188933
decreased IgG level J:188933
decreased leukocyte cell number J:188933, J:213427
decreased mature B cell number J:213427
decreased T cell number J:213427
immune system phenotype J:188933
increased CD4-positive, alpha-beta T cell number J:188933
increased CD8-positive, alpha-beta T cell number J:188933
increased granulocyte number J:213427
increased incidence of corneal inflammation J:213427
increased monocyte cell number J:213427
increased NK cell number J:213427
increased NK T cell number J:213427
increased susceptibility to bacterial infection J:213427
\Spns2tm1b(KOMP)Wtsi/\Spns2tm1b(KOMP)Wtsi
(involves: 129S7/SvEvBrd * C57BL/6 * C57BL/6N)
decreased B cell number J:188933
decreased CD4-positive, alpha-beta T cell number J:188933
decreased CD8-positive, alpha-beta T cell number J:188933
increased CD4-positive, alpha-beta T cell number J:188933
increased CD8-positive, alpha-beta T cell number J:188933
\Spns2tm1b(KOMP)Wtsi/\Spns2tm1b(KOMP)Wtsi
(B6Brd;B6Dnk;B6N-Tyrc-Brd Spns2tm1b(KOMP)Wtsi/WtsiH)
decreased leukocyte cell number J:211773
\Spns2tm1c(KOMP)Wtsi/\Spns2tm1c(KOMP)Wtsi
(involves: 129S4/SvJaeSor * C57BL/6 * C57BL/6N)
immune system phenotype J:188933
\Spns2tm1Tni/\Spns2tm1Tni
(B6.Cg-Spns2tm1Tni)
abnormal leukocyte cell number J:225108
abnormal mature B cell number J:225108
abnormal thymus morphology J:225108
decreased leukocyte cell number J:225108
decreased lymphocyte cell number J:225108
decreased monocyte cell number J:225108
decreased single-positive T cell number J:225108
decreased thymocyte number J:225108
\Spns3em1(IMPC)Tcp/\Spns3em1(IMPC)Tcp
(C57BL/6NCrl-Spns3em1(IMPC)Tcp/Tcp)
increased eosinophil cell number J:211773
\Spnw1DBA/2/\Spnw1DBA/2
\Spnw4DU6i/\Spnw4DU6i

(involves: DBA/2 * DU6i)
increased spleen weight J:101006
\Spo11tm1Mjn/\Spo11tm1Mjn
(involves: 129X1/SvJ * C57BL/6)
immune system phenotype J:74754
\Spo11tm2b(KOMP)Wtsi/\Spo11tm2b(KOMP)Wtsi
(C57BL/6N-Spo11tm2b(KOMP)Wtsi/Bay)
abnormal spleen morphology J:211773
increased spleen weight J:211773
\Spon2tm1Mjb/\Spon2tm1Mjb
(involves: 129S6/SvEvTac * C57BL/6)
abnormal interleukin level J:87393
abnormal susceptibility to infection J:87393
abnormal tumor necrosis factor level J:87393
\Spoptm1b(KOMP)Wtsi/\Spop+
(C57BL/6N-Spoptm1b(KOMP)Wtsi/Tcp)
enlarged lymph nodes J:211773
small thymus J:211773
\Spp1Ric-r/\Spp1+
(AKR/J)
decreased susceptibility to bacterial infection J:5949
\Spp1Ric-r/\Spp1+
(A/J)
decreased susceptibility to bacterial infection J:5949
\Spp1Ric-r/\Spp1+
(BALB/cJ)
decreased susceptibility to bacterial infection J:5949
\Spp1Ric-r/\Spp1+
(C57BL/6J)
decreased susceptibility to bacterial infection J:5949
\Spp1Ric-r/\Spp1+
(C57L/J)
decreased susceptibility to bacterial infection J:5949
\Spp1Ric-r/\Spp1+
(SWR/J)
decreased susceptibility to bacterial infection J:5949
\Spp1Ric-r/\Spp1+
(C3H/Rv)
decreased susceptibility to bacterial infection induced morbidity/mortality J:7240
increased macrophage cell number J:7240
\Spp1Ric-s/\Spp1+
(A/HeJ)
increased susceptibility to bacterial infection J:5949
\Spp1Ric-s/\Spp1+
(C3H/HeJ)
increased susceptibility to bacterial infection J:5949
\Spp1Ric-s/\Spp1+
(C3H/HeN)
increased susceptibility to bacterial infection J:5949
\Spp1Ric-s/\Spp1+
(C3H/St)
increased susceptibility to bacterial infection J:5949
\Spp1Ric-s/\Spp1+
(CBA/J)
increased susceptibility to bacterial infection J:5949
\Spp1Ric-s/\Spp1+
(DBA/1J)
increased susceptibility to bacterial infection J:5949
\Spp1Ric-s/\Spp1+
(DBA/2J)
increased susceptibility to bacterial infection J:5949
\Spp1Ric-s/\Spp1+
(SJL/J)
increased susceptibility to bacterial infection J:5949
\Spp1tm1.1Dhd/\Spp1tm1.1Dhd
(involves: 129P2/OlaHsd * C57BL/6)
abnormal macrophage morphology J:237104
abnormal osteoclast physiology J:237104
decreased osteoclast cell number J:237104
\Spp1tm1Blh/\Spp1+
(BKSW.129S6-Spp1tm1Blh)
abnormal immune system physiology J:113585
\Spp1tm1Blh/\Spp1+
(involves: 129S6/SvEvTac * Black Swiss)
abnormal leukocyte migration J:86531
\Spp1tm1Blh/\Spp1tm1Blh
(involves: 129S6/SvEvTac * Black Swiss)
abnormal chemokine level J:127389
abnormal leukocyte migration J:86531
abnormal leukocyte physiology J:86531
abnormal macrophage chemotaxis J:140014
abnormal macrophage physiology J:127389
abnormal response to infection J:103013
abnormal susceptibility to infection J:140014
decreased circulating interleukin-6 level J:127389
decreased leukocyte cell number J:86531
decreased macrophage cell number J:127389
granulomatous inflammation J:140014
increased lymphocyte cell number J:103050
\Spp1tm1Blh/\Spp1tm1Blh
(B6.129S6-Spp1tm1Blh)
abnormal microglial cell morphology J:118432
decreased susceptibility to experimental autoimmune uveoretinitis J:116272
granulomatous inflammation J:116272
\Spp1tm1Blh/\Spp1tm1Blh
(involves: 129S6/SvEvTac * C57BL/6)
abnormal immune system physiology J:119298
decreased dendritic cell number J:119298
\Spp1tm1Blh/\Spp1tm1Blh
(BKSW.129S6-Spp1tm1Blh)
abnormal immune system physiology J:113585
impaired macrophage chemotaxis J:113585
\Spp1tm1Rit/\Spp1tm1Rit
(involves: 129S7/SvEvBrd * C57BL/6)
abnormal inflammatory response J:60284
abnormal osteoclast physiology J:68872, J:56353
abnormal response to infection J:60284
decreased interferon-gamma secretion J:60284
decreased interleukin-12 secretion J:60284
decreased osteoclast cell number J:115395
decreased susceptibility to Herpesvirales infection J:60284
decreased susceptibility to type IV hypersensitivity reaction J:60284
increased interleukin-4 secretion J:60284
increased interleukin-10 secretion J:60284
increased osteoclast cell number J:56353, J:56535
\Spp1tm1Rit/\Spp1tm1Rit
(B6.129S7-Spp1tm1Rit)
decreased acute inflammation J:93915
decreased interferon-gamma secretion J:93915
decreased tumor necrosis factor secretion J:93915
\Sppl2achompB/\Sppl2achompB
(involves: C57BL/6)
abnormal class switch recombination J:194595
abnormal humoral immune response J:194595
decreased activation-induced B cell apoptosis J:194595
decreased B cell proliferation J:194595
decreased follicular B cell number J:194595
decreased IgG1 level J:194595
decreased IgG2b level J:194595
decreased IgG3 level J:194595
decreased IgM level J:194595
decreased marginal zone B cell number J:194595
decreased mature B cell number J:194595
decreased myeloid dendritic cell number J:194595
decreased plasmacytoid dendritic cell number J:194595
decreased transitional stage T2 B cell number J:194595
immune system phenotype J:194595
\Sppl2am1Anu/\Sppl2am1Anu
(involves: C57BL/6JAnu)
abnormal immunoglobulin level J:194663
abnormal mature B cell morphology J:194663
abnormal transitional stage B cell morphology J:194663
decreased IgG1 level J:194663
decreased IgM level J:194663
decreased marginal zone B cell number J:194663
decreased transitional stage T2 B cell number J:194663
decreased transitional stage T3 B cell number J:194663
\Sppl2am1Anu/\Sppl2am1Anu
\Tg(Vav-BCL2)69Jad/?

(involves: C57BL/6JAnu)
abnormal T cell number J:194663
decreased CD4-positive, alpha-beta T cell number J:194663
decreased double-negative T cell number J:194663
increased mature B cell number J:194663
increased plasmacytoid dendritic cell number J:194663
\Sppl2am1Btlr/\Sppl2am1Btlr
(C57BL/6J-Sppl2am1Btlr)
decreased IgG level J:236687
decreased response to antigen J:236687
\Sppl2am2Btlr/\Sppl2am2Btlr
(C57BL/6J-Sppl2am2Btlr)
decreased IgG level J:236688
decreased IgM level J:236688
decreased response to antigen J:236688
\Sppl2atm1Basc/\Sppl2atm1Basc
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6NCrl)
abnormal B cell calcium ion homeostasis J:194664
abnormal B cell physiology J:194664
arrested B cell differentiation J:194664
decreased B cell number J:194664
decreased B-1 B cell number J:194664
decreased B-2 B cell number J:194664
decreased follicular B cell number J:194664
decreased IgA level J:194664
decreased IgG1 level J:194664
decreased IgG2a level J:194664
decreased IgG2b level J:194664
decreased IgG3 level J:194664
decreased IgM level J:194664
decreased marginal zone B cell number J:194664
decreased mature B cell number J:194664
decreased Peyer's patch number J:194664
decreased T cell number J:194664
decreased transitional stage T2 B cell number J:194664
small Peyer's patches J:194664
small spleen J:194664
\Sppl2atm1Basc/\Sppl2atm1Basc
\Sppl2bGt(Ayu21-T160)Imeg/\Sppl2bGt(Ayu21-T160)Imeg

(B6N.Cg-Sppl2atm1Basc Sppl2bGt(Ayu21-T160)Imeg)
abnormal mature B cell morphology J:213519
decreased B cell number J:213519
decreased immunoglobulin level J:213519
\Sppl2atm1Dgen/\Sppl2atm1Dgen
(B6.129P2-Sppl2atm1Dgen)
decreased B cell number J:194595
decreased B-1 B cell number J:194595
decreased follicular B cell number J:194595
decreased IgA level J:194595
decreased IgG1 level J:194595
decreased IgG2b level J:194595
decreased IgG3 level J:194595
decreased IgM level J:194595
decreased myeloid dendritic cell number J:194595
decreased transitional stage T2 B cell number J:194595
\Sppl2bGt(Ayu21-T160)Imeg/\Sppl2bGt(Ayu21-T160)Imeg
(B6N.Cg-Sppl2bGt(Ayu21-T160)Imeg)
immune system phenotype J:213519
\Sppl3tm1Itl/\Sppl3em1Pomz
\Ncr1tm1.1(icre)Viv/\Ncr1+

(involves: 129S/SvEv * C57BL/6 * C57BL/6J)
abnormal NK cell differentiation J:280182
decreased mature NK cell number J:280182
decreased NK cell number J:280182
increased immature NK cell number J:280182
\Sppl3tm1Itl/\Sppl3tm1Itl
\Commd10Tg(Vav1-icre)A2Kio/\Commd10+

(involves: 129S/SvEv * C57BL/6 * C57BL/10 * CBA/Ca)
abnormal NK cell differentiation J:280182
decreased mature NK cell number J:280182
decreased NK cell number J:280182
immune system phenotype J:280182
impaired natural killer cell mediated cytotoxicity J:280182
increased immature NK cell number J:280182
\Sppl3tm1Itl/\Sppl3tm1Itl
\Ncr1tm1.1(icre)Viv/\Ncr1+

(involves: 129S/SvEv * C57BL/6)
abnormal NK cell differentiation J:280182
abnormal NK cell physiology J:280182
decreased mature NK cell number J:280182
decreased NK cell number J:280182
impaired natural killer cell mediated cytotoxicity J:280182
increased immature NK cell number J:280182
\Sprem1(IMPC)H/\Spr+
(C57BL/6N-Sprem1(IMPC)H/H)
increased neutrophil cell number J:211773
\Spred1em1(IMPC)Ccpcz/\Spred1em1(IMPC)Ccpcz
(C57BL/6N-Spred1em1(IMPC)Ccpcz/Ccpcz)
abnormal lymph node morphology J:211773
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
decreased lymphocyte cell number J:211773
enlarged lymph nodes J:211773
enlarged spleen J:211773
enlarged thymus J:211773
increased CD4-positive NK T cell number J:211773
increased CD4-positive, CD25-positive, alpha-beta regulatory T cell number J:211773
increased effector memory CD8-positive, alpha-beta T cell number J:211773
increased effector memory T-helper cell number J:211773
increased memory-marker CD4-positive NK T cell number J:211773
increased neutrophil cell number J:211773
increased NK T cell number J:211773
increased spleen weight J:211773
\Spred1tm1.1Ayos/\Spred1tm1.1Ayos
(involves: 129 * C57BL/6 * SJL)
increased mast cell degranulation J:186742
increased mast cell number J:186742
\Spred1tm1Hiin/\Spred1tm1Hiin
(involves: C57BL/6)
abnormal cytokine secretion J:95263
abnormal eosinophil physiology J:95263
increased eosinophil cell number J:95263
\Spred2em1(IMPC)Mbp/\Spred2em1(IMPC)Mbp
(C57BL/6N-Spred2em1(IMPC)Mbp/MbpMmucd)
enlarged lymph nodes J:211773
enlarged spleen J:211773
\Spred3em1(IMPC)Tcp/\Spred3+
(C57BL/6NCrl-Spred3em1(IMPC)Tcp/Tcp)
enlarged lymph nodes J:211773
\Sprol1STS/A/?
(involves: B10.O20/Dem * O20/A)
increased lymphocyte cell number J:56029
\Spryd4em1(IMPC)Ccpcz/\Spryd4em1(IMPC)Ccpcz
(C57BL/6N-Spryd4em1(IMPC)Ccpcz/Ccpcz)
abnormal thymus morphology J:211773
enlarged thymus J:211773
\Spta1ihj/\Spta1ihj
(involves: HRS/J * LAH)
abnormal spleen morphology J:105409
enlarged spleen J:105409
\Spta1sph-2Bc/\Spta1sph-2Bc
(involves: SELH)
dark spleen J:7048
enlarged spleen J:7048
increased leukocyte cell number J:7048
\Spta1sph-3J/\Spta1sph-3J
(NOD.Cg-H2b Spta1sph-3J)
decreased spleen iron level J:157766
enlarged spleen J:157766
increased spleen weight J:157766
\Spta1sph-4J/\Spta1sph-4J
(C57BL/6J-Spta1sph-4J/Llp)
enlarged spleen J:157766
increased spleen weight J:157766
\Spta1sph-Dem/\Spta1sph-Dem
(CcS3/Dem-Spta1sph-Dem)
enlarged spleen J:66966
\Spta1sph-ha/\Spta1sph-ha
(involves: DBA/1J)
enlarged spleen J:30699, J:14946
\Spta1sph-ha/\Spta1sph-ha
(either: (B6.D1-Spta1sph-ha x WB.D1-Spta1sph-ha)F1 or (WB.D1-Spta1sph-ha x B6.D1-Spta1sph-ha)F1)
abnormal lymph node cell ratio J:1967
abnormal spleen morphology J:6695
abnormal splenic cell ratio J:1967
alveolitis J:12830
enlarged spleen J:6695
increased B cell number J:1967
increased B cell proliferation J:1967
increased CD4-positive, alpha-beta T cell number J:1967
increased CD8-positive, alpha-beta T cell number J:1967
increased IgA level J:12830
increased IgG level J:12830
increased leukocyte cell number J:12830
increased lymphocyte cell number J:12830, J:1967
increased monocyte cell number J:12830
increased neutrophil cell number J:12830
increased susceptibility to bacterial infection J:12830
increased T cell number J:1967
increased T cell proliferation J:1967
interstitial pneumonia J:12830
lymph node hyperplasia J:12830, J:1967
\Spta1sph-ha/\Spta1sph-ha
((WB.D1-Spta1sph-ha/Brk x B6.D1-Spta1sph-ha/Brk)F1)
enlarged spleen J:162532
\Spta1sph/\Spta1sph
(either: (B6.C3-Spta1sph x WB.C3-Spta1sph)F1 or (WB.C3-Spta1sph x B6.C3-Spta1sph)F1)
abnormal spleen morphology J:6695
decreased susceptibility to parasitic infection J:111131
enlarged spleen J:6695
\Spta1sph/\Spta1sph
((WB.C3-Spta1sph x B6.C3-Spta1sph)F1)
enlarged spleen J:162532, J:44313
glomerulonephritis J:44313
tubular nephritis J:44313
\Sptbja/\Sptbja
(129/Sv-Sptbja)
enlarged spleen J:305
\Sptbja/\Sptbja
((WB.129-Sptbja/J x B6.129-Sptbja/J)F1)
enlarged spleen J:162532, J:44313
glomerulonephritis J:44313
increased spleen red pulp amount J:44313
tubular nephritis J:44313
\Sptbm1Jus/\Sptbm1Jus
(involves: 129S6/SvEvTac * C57BL/6)
enlarged spleen J:159750
\Sptbn4qv/\Sptbn4qv
(either: (involves: BALB/c) or (involves: C57BL/10))
eye inflammation J:167
\Sptlc2tm1Yhir/\Sptlc2tm1Yhir
\Gt(ROSA)26Sortm9(cre/ESR1)Arte/\Gt(ROSA)26Sor+

(involves: C57BL/6 * C57BL/6NTac)
abnormal spleen morphology J:202954
abnormal thymus morphology J:202954
decreased lymphocyte cell number J:202954
decreased spleen weight J:202954
decreased thymus weight J:202954
increased neutrophil cell number J:202954
\Sptlc2tm1Yhir/\Sptlc2tm1Yhir
\Tg(KRT5-cre)1Tak/0

(involves: C3H * C57BL/6)
abnormal dendritic epidermal T cell morphology J:202388
abnormal Langerhans cell morphology J:202388
abnormal Langerhans cell physiology J:202388
increased dendritic cell number J:202388
increased gamma-delta T cell number J:202388
increased T-helper 17 cell number J:202388
skin inflammation J:202388
\Spw1SWR/J/\Spw1SWR/J
\Tg(CTSG-PML/RARA)135Ley/0

(involves: C3H/HeJ * C57BL/6J * SWR/J)
decreased spleen weight J:139159
\Spw2SWR/J/?
\Tg(CTSG-PML/RARA)135Ley/0

(involves: C3H/HeJ * C57BL/6J * SWR/J)
decreased spleen weight J:139159
\Spw3SWR/J/\Spw3SWR/J
\Tg(CTSG-PML/RARA)135Ley/0

(involves: C3H/HeJ * C57BL/6J * SWR/J)
increased spleen weight J:139159
\Spw4SWR/J/\Spw4SWR/J
\Tg(CTSG-PML/RARA)135Ley/0

(involves: C3H/HeJ * C57BL/6J * SWR/J)
decreased spleen weight J:139159
\Spw5SWR/J/\Spw5SWR/J
\Tg(CTSG-PML/RARA)135Ley/0

(involves: C3H/HeJ * C57BL/6J * SWR/J)
decreased spleen weight J:139159
increased spleen weight J:139159
\Spz1em1(IMPC)Mbp/\Spz1em1(IMPC)Mbp
(C57BL/6N-Spz1em1(IMPC)Mbp/MbpMmucd)
increased neutrophil cell number J:211773
\Sqstm1tm1.1Sral/\Sqstm1+
(involves: 129/Sv * 129P2/OlaHsd * C57BL/6)
abnormal osteoclast differentiation J:173755
increased osteoclast cell number J:173755
\Sqstm1tm1.1Sral/\Sqstm1tm1.1Sral
(involves: 129/Sv * 129P2/OlaHsd * C57BL/6)
abnormal osteoclast differentiation J:173755
abnormal osteoclast morphology J:173755
increased osteoclast cell number J:173755
\Sqstm1tm1Jjw/\Sqstm1tm1Jjw
(involves: 129 * C57BL/6)
abnormal osteoclast differentiation J:141179
abnormal osteoclast physiology J:141179
\Sqstm1tm1Jmos/\Sqstm1tm1Jmos
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
abnormal osteoclast differentiation J:90010
decreased interleukin-6 secretion J:90010
decreased osteoclast cell number J:90010
\Sqstm1tm1Keta/\Sqstm1tm1Keta
(involves: 129 * C57BL/6N)
abnormal osteoclast differentiation J:264183
abnormal osteoclast physiology J:264183
\Sra1tm1a(EUCOMM)Hmgu/\Sra1tm1a(EUCOMM)Hmgu
(involves: C57BL/6J * C57BL/6N)
decreased circulating tumor necrosis factor level J:214131
\Srctm1Sor/\Srctm1Sor
(either: 129S7/SvEvBrd-Srctm1Sor or (involves: 129S7/SvEvBrd * C57BL/6J))
increased inflammatory response J:67040
periodontium inflammation J:67040
\Srcr/\Srcr+
(BALB/c-Srcr/Cui)
abnormal innate immunity J:83618
\Srd5a2em1(IMPC)Mbp/\Srd5a2em1(IMPC)Mbp
(C57BL/6N-Srd5a2em1(IMPC)Mbp/MbpMmucd)
small spleen J:211773
\Srftm1Rmn/\Srftm1Rmn
\H2az2Tg(Wnt1-cre)11Rth/\H2az2+

(involves: 129S6/SvEvTac * C57BL/6J * CBA/J)
athymia J:144862
\Srftm2Nor/\Srftm2Nor
\Cd19tm1(cre)Cgn/\Cd19+

(involves: 129P2/OlaHsd)
abnormal mature B cell morphology J:124767
absent marginal zone B cells J:124767
decreased B cell number J:124767
decreased B-1 B cell number J:124767
\Srftm2Nor/\Srftm2Nor
\Tg(Cd4-cre)1Cwi/?

(involves: 129P2/OlaHsd * C57BL/6 * DBA/2)
decreased CD4-positive, alpha-beta T cell number J:124767
decreased CD8-positive, alpha-beta T cell number J:124767
decreased T cell number J:124767
decreased thymocyte number J:124767
\Srfbp1em1(IMPC)J/\Srfbp1+
(C57BL/6NJ-Srfbp1em1(IMPC)J/Mmjax)
decreased leukocyte cell number J:211773
\Srgntm1Mabr/\Srgntm1Mabr
(involves: 129X1/SvJ)
abnormal mast cell morphology J:93338
decreased mast cell number J:93338
\Sros1em1Caox/\Sros1em1Caox
(involves: C57BL/6J)
abnormal circulating chemokine level J:306407
decreased susceptibility to bacterial infection J:306407
decreased susceptibility to bacterial infection induced morbidity/mortality J:306407
increased circulating CXCL10 level J:306407
\Srp14em1(IMPC)Mbp/\Srp14+
(C57BL/6NCrl-Srp14em1(IMPC)Mbp/MbpMmucd)
abnormal spleen morphology J:211773
enlarged spleen J:211773
\Srpk3tm1b(KOMP)Wtsi/Y
(C57BL/6N-Srpk3tm1b(KOMP)Wtsi/Ucd)
increased monocyte cell number J:211773
\Srpxtm1Hzi/\Srpxtm1Hzi
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
abnormal lymphocyte morphology J:119999
enlarged spleen J:119999
increased T cell derived lymphoma incidence J:119999
\SrrRgsc34/\Srr+
(involves: C57BL/6JJcl * DBA/2JJcl)
abnormal neutrophil physiology J:133634
\Srrttm1.1Thsn/\Srrttm1.2Thsn
\Tg(Mx1-cre)1Cgn/0

(involves: C57BL/6 * CBA)
abnormal thymus physiology J:152729
increased splenocyte apoptosis J:152729
\Srsf2tm1.1Oaw/\Srsf2+
\Tg(Mx1-cre)1Cgn/?

(B6.Cg-Tg(Mx1-cre)1Cgn Srsf2tm1.1Oaw)
abnormal myelopoiesis J:221404
abnormal neutrophil morphology J:221404
decreased B cell number J:221404
failure of myelopoiesis J:221404
\Srsf2tm1Xdfu/\Srsf2+
\Tg(Lck-cre)I57Jxm/?

(involves: 129S4/SvJae * 129X1/SvJ * ICR)
decreased thymocyte number J:88668
decreased thymus weight J:88668
\Srsf2tm1Xdfu/\Srsf2tm1Xdfu
\Tg(Lck-cre)I57Jxm/?

(involves: 129S4/SvJae * 129X1/SvJ * ICR)
abnormal spleen white pulp morphology J:88668
abnormal T cell differentiation J:88668
absent thymus corticomedullary boundary J:88668
decreased double-positive T cell number J:88668
decreased T cell number J:88668
decreased thymocyte number J:88668
increased double-negative T cell number J:88668
small thymus J:88668
\Srsf2tm1Xdfu/\Srsf2tm1Xdfu
\Tg(Mx1-cre)1Cgn/?

(involves: 129S4/SvJae * C57BL/6J * CBA/J)
bone marrow failure J:221404
\Srsf3tm1Pjln/\Srsf3tm1Pjln
\Cd79atm1(cre)Reth/\Cd79a+

(involves: 129P2/OlaHsd * BALB/c)
decreased B cell number J:113645
decreased pre-B cell number J:113645
decreased pro-B cell number J:113645
\Srsf3tm1Pjln/\Srsf3tm1Pjln
\Speer6-ps1Tg(Alb-cre)21Mgn/\Speer6-ps1+

(involves: BALB/c * C57BL/6 * DBA)
abnormal thymus development J:205756
\Srsf5em1Nju/\Srsf5em1Nju
(C57BL/6JGpt-Srsf5em1Nju)
small spleen J:311867
\Srxn1tm1Mtol/\Srxn1tm1Mtol
(either: B6.129S2-Srxn1tm1Mtol or (involves: 129S2/SvPasCrl * C57BL/6))
increased susceptibility to endotoxin shock J:199277
\Ss18l1em1Zqi/\Ss18l1+
(involves: C57BL/6)
increased microglial cell activation J:278840
\Ss18l1em1Zqi/\Ss18l1em1Zqi
(involves: C57BL/6)
increased microglial cell activation J:278840
\Ss18l1em2Zqi/\Ss18l1em2Zqi
(involves: C57BL/6)
increased microglial cell activation J:278840
\Ssbtm1Rjma/\Ssbtm2.1Rjma
\Cd79atm1(cre)Reth/\Cd79a+

(involves: 129S/SvEv * BALB/c)
arrested B cell differentiation J:207687
decreased B cell number J:207687
decreased IgG level J:207687
decreased IgM level J:207687
decreased spleen weight J:207687
immune system phenotype J:207687
small spleen J:207687
\Ssbp2tm1Lana/\Ssbp2tm1Lana
(involves: 129S/SvEv * C57BL/6)
arteritis J:162035
decreased lymphocyte cell number J:162035
increased pre-B cell number J:162035
\Ssbp2tm1Lana/\Ssbp2tm1Lana
\Trp53tm1Tyj/\Trp53tm1Tyj

(involves: 129S/SvEv * 129S2/SvPas * BALB/c * C57BL/6)
increased T cell derived lymphoma incidence J:162035
thymus hypoplasia J:162035
\Ssh2em1(IMPC)J/\Ssh2em1(IMPC)J
(C57BL/6NJ-Ssh2em1(IMPC)J/Mmjax)
increased leukocyte cell number J:211773
\Ssial1NOD/\Ssial1NOD
(involves: C57BL/6J * NOD)
periinsulitis J:11442
salivary gland inflammation J:75908
\Ssial2NOD/?
(involves: C57BL/6J * NOD)
salivary gland inflammation J:75908
\Ssial3NOD/\Ssial3NOD
(involves: C57BL/6J * NOD)
salivary gland inflammation J:75908
\Ssial4C57BL/6/\Ssial4NOD
(involves: C57BL/6J * NOD)
salivary gland inflammation J:75908
\Ssial4NOD/\Ssial4NOD
(involves: C57BL/6J * NOD)
salivary gland inflammation J:75908
\Sspntm1b(EUCOMM)Hmgu/\Sspntm1b(EUCOMM)Hmgu
(C57BL/6N-Sspntm1b(EUCOMM)Hmgu/Ieg)
increased leukocyte cell number J:211773
\Ssr2tm1b(EUCOMM)Wtsi/\Ssr2tm1b(EUCOMM)Wtsi
(C57BL/6N-Ssr2tm1b(EUCOMM)Wtsi/Wtsi)
abnormal thymus morphology J:239583
\Sst1C3HeB/FeJ/\Sst1C3HeB/FeJ
(involves: C3HeB/FeJ * C57BL/6J)
increased susceptibility to bacterial infection J:63410
\Sst1C3HeB/FeJ/\Sst1C3HeB/FeJ
(B6.C3-Sst1C3HeB/FejKrmn/Mmnc)
increased susceptibility to bacterial infection J:313901
increased susceptibility to bacterial infection induced morbidity/mortality J:313901
\Sst1C3HeB/FeJ/\Sst1C57BL/6J
(involves: C3HeB/FeJ * C57BL/6J)
decreased susceptibility to bacterial infection J:63410
\Sst1C57BL/6J/\Sst1C57BL/6J
(involves: C3HeB/FeJ * C57BL/6J)
decreased susceptibility to bacterial infection J:63410, J:93705
\Ssttm1Low/\Ssttm1Low
(B6.129P2-Ssttm1Low)
immune system phenotype J:126384
\Sstr2em1(IMPC)Mbp/\Sstr2em1(IMPC)Mbp
(C57BL/6N-Sstr2em1(IMPC)Mbp/MbpMmucd)
abnormal spleen morphology J:211773
enlarged spleen J:211773
small spleen J:211773
\Sstr4tm1Szo/\Sstr4tm1Szo
(B6.129P2-Sstr4tm1Szo)
abnormal granulocyte morphology J:152015
abnormal neutrophil physiology J:152015
increased interferon-gamma secretion J:152015
increased interleukin-1 beta secretion J:152015
increased susceptibility to type IV hypersensitivity reaction J:152015
increased tumor necrosis factor secretion J:152015
\Ssu2em1(IMPC)Ccpcz/\Ssu2em1(IMPC)Ccpcz
(C57BL/6NCrl-Ssu2em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
enlarged spleen J:211773
\Ssu72tm1Cwl/\Ssu72tm1Cwl
\Speer6-ps1Tg(Alb-cre)21Mgn/\Speer6-ps1+

(B6.Cg-Ssu72tm1Cwl Speer6-ps1Tg(Alb-cre)21Mgn)
liver inflammation J:309624
\St3gal2tm1Jxm/\St3gal2tm1Jxm
(Not Specified)
decreased T cell proliferation J:217719
increased spleen germinal center size J:217719
increased T cell number J:217719
\St3gal4tm1.1Jxm/\St3gal4tm1.1Jxm
(B6.129-St3gal4tm1.1Jxm)
abnormal leukocyte tethering or rolling J:117085
abnormal response to infection J:136946
\St3gal4tm1.1Jxm/\St3gal4tm1.1Jxm
(involves: 129S1/Sv * 129X1/SvJ)
abnormal leukocyte migration J:189086
decreased lymphocyte cell number J:189086
immune system phenotype J:189086
\St3gal4tm1.1Jxm/\St3gal4tm1.1Jxm
\St3gal6tm1.1Jxm/\St3gal6tm1.1Jxm

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
abnormal leukocyte migration J:189086
decreased lymphocyte cell number J:189086
impaired leukocyte tethering or rolling J:189086
impaired neutrophil recruitment J:189086
increased leukocyte cell number J:189086
increased neutrophil cell number J:189086
\St3gal6tm1.1Jxm/\St3gal6tm1.1Jxm
(B6.Cg-St3gal6tm1.1Jxm)
immune system phenotype J:189086
impaired leukocyte tethering or rolling J:189086
impaired neutrophil recruitment J:189086
\St6gal1tm1Jlau/\St6gal1tm1Jlau
(129S4/SvJae-St6gal1tm1Jlau)
abnormal neutrophil physiology J:140702
increased susceptibility to bacterial infection J:140702
\St6gal1tm1Jlau/\St6gal1tm1Jlau
(B6.129S4-St6gal1tm1Jlau)
abnormal myelopoiesis J:140547
abnormal neutrophil physiology J:140547
increased neutrophil cell number J:140547
peritoneal inflammation J:140547
\St6gal1tm1Jxm/\St6gal1tm1Jxm
(involves: 129S1/Sv * 129X1/SvJ)
abnormal dendritic cell physiology J:132991
decreased marginal zone B cell number J:132991
decreased transitional stage B cell number J:132991
increased neutrophil cell number J:140547
peritoneal inflammation J:140547
\St6galnac1em1Len/\St6galnac1em1Len
(Not Specified)
increased susceptibility to colitis induced morbidity/mortality J:324883
\St6galnac2tm1.1Cfg/\St6galnac2tm1.1Cfg
(involves: 129S1/Sv * 129X1/SvJ)
decreased IgA level J:217719
increased B cell proliferation J:217719
increased pre-B cell number J:217719
increased spleen germinal center size J:217719
\St6galnac3em1Staka/\St6galnac3em1Staka
\St6galnac4em1Staka/\St6galnac4em1Staka

(C57BL/6J-St6galnac3em1Staka St6galnac4em1Staka)
lymph node hemorrhage J:340690
\St8sia1tm1Kfk/\St8sia1tm1Kfk
(Not Specified)
decreased CD8-positive, alpha-beta T cell number J:73818
immune system phenotype J:73818
increased T cell proliferation J:73818
\St8sia6em1(IMPC)Mbp/\St8sia6em1(IMPC)Mbp
(C57BL/6N-St8sia6em1(IMPC)Mbp/MbpMmucd)
abnormal spleen morphology J:211773
enlarged spleen J:211773
\St13em1Gwzh/\St13em1Gwzh
\Tg(PRSS1/lacZ)#Gwzh/0

(Not Specified)
increased susceptibility to induced pancreatitis J:345508
\St14tm1Bug/\St14tm1Bug
(involves: 129P2/OlaHsd * Black Swiss)
decreased double-positive T cell number J:87125
increased thymocyte apoptosis J:87125
\St14tm2Bug/\St14tm3Bug
\Tg(MMTV-cre)4Mam/0

(involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6J * FVB/NJ * N:Black Swiss)
abnormal chemokine secretion J:213072
abnormal cytokine secretion J:213072
decreased CD4-positive, alpha-beta T cell number J:213072
decreased CD4-positive, CD25-positive, alpha-beta regulatory T cell number J:213072
decreased CD8-positive, alpha-beta T cell number J:213072
decreased regulatory T cell number J:213072
increased anti-nuclear antigen antibody level J:213072
increased autoantibody level J:213072
increased CD4-positive, CD25-positive, alpha-beta regulatory T cell number J:213072
increased effector memory CD4-positive, alpha-beta T cell number J:213072
increased effector memory CD8-positive, alpha-beta T cell number J:213072
lacrimal gland inflammation J:213072
submandibular gland inflammation J:213072
\St14tm2Bug/\St14tm3Bug
\Tg(Vil1-cre)997Gum/0

(involves: 129P2/OlaHsd * 129S6/SvEvTac * Black Swiss * C57BL/6 * SJL)
colitis J:153070
\St14tm3Bug/\St14tm3Bug
(involves: 129S6/SvEvTac)
immune system phenotype J:213072
\Stag1em1(IMPC)Mbp/\Stag1+
(C57BL/6N-Stag1em1(IMPC)Mbp/MbpMmucd)
abnormal lymph node morphology J:211773
abnormal spleen morphology J:211773
enlarged lymph nodes J:211773
enlarged spleen J:211773
small spleen J:211773
\Stag2tm1.1Soga/Y
\Tg(Mx1-cre)1Cgn/0

(involves: C57BL/6J * C57BL/6N * CBA/J)
decreased B cell number J:289000
decreased leukocyte cell number J:289000
enlarged spleen J:289000
increased granulocyte number J:289000
increased monocyte cell number J:289000
\Stamtm2Sug/\Stamtm2Sug
\Stam2tm1Sug/\Stam2tm1Sug
\Tg(Lck-cre)I57Jxm/0

(involves: 129S4/SvJae * C57BL/6 * ICR)
decreased T cell number J:80617
decreased T cell proliferation J:80617
\Stambptm1Sug/\Stambptm1Sug
(involves: 129S4/SvJae * C57BL/6)
immune system phenotype J:72940
\Stard7tm1a(EUCOMM)Wtsi/\Stard7+
(involves: C57BL/6N)
dermatitis J:242746
immune system phenotype J:242746
increased CD11b-high dendritic cell number J:242746
increased susceptibility to type I hypersensitivity reaction J:242746
lung inflammation J:242746
\Stard13tm1a(KOMP)Wtsi/\Stard13tm1a(KOMP)Wtsi
(involves: C57BL/6 * C57BL/6N)
increased susceptibility to bacterial infection J:213427
lymphoid hyperplasia J:213427
\Stat1fae/\Stat1fae
(C57BL/6JSfdAnu-Stat1fae/Anu)
abnormal T cell activation J:105311
abnormal T-helper 2 physiology J:105311
increased IgG level J:105311
\Stat1m1Anu/\Stat1m1Anu
(C57BL/6JSfdAnu-Stat1m1Anu)
abnormal response to infection J:104190
\Stat1m1Btlr/\Stat1m1Btlr
(C57BL/6J-Stat1m1Btlr)
abnormal macrophage physiology J:105543
increased susceptibility to Herpesvirales infection J:105543
increased susceptibility to Riboviria infection J:105543
\Stat1m2Btlr/\Stat1m2Btlr
(C57BL/6J-Stat1m2Btlr)
decreased interferon-gamma secretion J:134096
decreased NK cell degranulation J:134096
impaired natural killer cell mediated cytotoxicity J:134096
increased susceptibility to Herpesvirales infection J:134096
\Stat1m3Btlr/\Stat1m3Btlr
(C57BL/6J-Stat1m3Btlr)
impaired natural killer cell mediated cytotoxicity J:254835
\Stat1m4Btlr/\Stat1m4Btlr
(C57BL/6J-Stat1m4Btlr)
abnormal CD8-positive, naive alpha-beta T cell number J:264800
decreased B cell number J:264800
decreased B-1 B cell number J:264800
decreased CD8-positive, alpha-beta T cell number J:264800
decreased NK cell number J:264800
decreased single-positive T cell number J:264800
increased CD4-positive, alpha-beta T cell number J:264800
increased effector memory CD8-positive, alpha-beta T cell number J:264800
increased NK T cell number J:264800
\Stat1m5Btlr/\Stat1m5Btlr
(C57BL/6J-Stat1m5Btlr)
abnormal CD4-positive T cell differentiation J:274938
abnormal CD8-positive, alpha-beta T cell differentiation J:274938
abnormal T cell differentiation J:274938
decreased CD8-positive, naive alpha-beta T cell number J:274938
decreased cytotoxic T cell cytolysis J:274938
increased CD4-positive, alpha-beta T cell number J:274938
increased effector memory CD4-positive, alpha-beta T cell number J:274938
increased effector memory CD8-positive, alpha-beta T cell number J:274938
increased T cell number J:274938
\Stat1tm1Dlv/\Stat1tm1Dlv
(either: (involves: 129S/SvEv * C57BL/6) or (involves: 129S/SvEv * C57BL/6 * CD-1))
abnormal leukocyte physiology J:31325
increased susceptibility to Coronaviridae infection J:31325
increased susceptibility to Riboviria infection J:31325
\Stat1tm1Dlv/\Stat1tm1Dlv
(B6.129-Stat1tm1Dlv)
increased susceptibility to Herpesvirales infection J:81243
increased susceptibility to Togaviridae infection J:81243
\Stat1tm1Dlv/\Stat1tm1Dlv
(involves: 129S/SvEv)
abnormal MHC II cell surface expression on macrophages J:130622
decreased level of surface class I molecules J:130622
decreased susceptibility to endotoxin shock J:130622
immune system phenotype J:99728
increased circulating interferon-gamma level J:130622
increased susceptibility to bacterial infection J:130622
increased susceptibility to Riboviria infection J:130622
\Stat1tm1Dlv/\Stat1tm1Dlv
(B6.129S-Stat1tm1Dlv)
abnormal NK cell physiology J:79552
impaired natural killer cell mediated cytotoxicity J:79552
increased circulating interferon-gamma level J:79552
increased circulating interleukin-12b level J:79552
\Stat1tm1Dlv/\Stat1tm1Dlv
\Tg(ANPEP)270Mmul/\Tg(ANPEP)270Mmul

(involves: 129S/SvEv * ICR)
increased susceptibility to Coronaviridae infection J:99728
\Stat1tm1Dlv/\Stat1tm1Dlv
\Tg(ANPEP)861Mmul/\Tg(ANPEP)861Mmul

(involves: 129S/SvEv * ICR)
increased susceptibility to Coronaviridae infection J:99728
\Stat1tm1Rds/\Stat1tm1Rds
(either: (involves: 129/Sv) or (involves: 129/Sv * C57BL/6))
increased susceptibility to bacterial infection J:31326
increased susceptibility to Riboviria infection J:31326
\Stat1tm1Rds/\Stat1tm1Rds
(involves: 129)
increased susceptibility to Herpesvirales infection J:81243
increased susceptibility to Riboviria infection J:66564
increased susceptibility to Togaviridae infection J:81243
\Stat1tm1Rds/\Stat1tm1Rds
(129S6/SvEv-Stat1tm1Rds/Tac)
abnormal macrophage physiology J:136368
abnormal osteoclast differentiation J:131353
bronchiolitis J:286237
decreased circulating interferon-gamma level J:122801
decreased interleukin-1 beta secretion J:136368
increased NK T cell number J:122801
increased susceptibility to Coronaviridae infection J:286237
increased susceptibility to Coronaviridae infection induced morbidity/mortality J:286237
lung inflammation J:286237
peritoneal inflammation J:286237
pleuritis J:286237
\Stat1tm1Rds/\Stat1tm1Rds
(B6.129-Stat1tm1Rds)
increased osteoclast cell number J:84894
\Stat1tm1Rds/\Stat1tm1Rds
\Stat2tm1Shnd/\Stat2tm1Shnd

(involves: 129/Sv * 129S1/Sv * 129X1/SvJ)
increased susceptibility to Riboviria infection J:66564
\Stat1tm1Rds/\Stat1tm1Rds
\Stat3tm2Aki/\Stat3tm2Aki
\Lyz2tm1(cre)Ifo/\Lyz2+

(involves: 129/Sv * 129P2/OlaHsd * C57BL/6)
colitis J:83280
increased CD4-positive, alpha-beta T cell number J:83280
increased interferon-gamma secretion J:83280
increased interleukin-6 secretion J:83280
increased tumor necrosis factor secretion J:83280
\Stat1tm1Tdec/\Stat1tm1Tdec
(involves: 129P2/OlaHsd * BALB/c)
abnormal macrophage physiology J:130622
abnormal MHC II cell surface expression on macrophages J:130622
decreased susceptibility to endotoxin shock J:130622
increased susceptibility to bacterial infection J:130622
increased susceptibility to Riboviria infection J:130622
\Stat1tm1Uvin/\Stat1tm1Uvin
(involves: 129 * C57BL/6)
increased macrophage nitric oxide production J:174863
\Stat1tm2.1Uvin/\Stat1tm2.1Uvin
(B6.129P2-Stat1tm2.1Uvin)
decreased susceptibility to endotoxin shock J:209388
immune system phenotype J:209388
increased susceptibility to bacterial infection J:209388
increased susceptibility to bacterial infection induced morbidity/mortality J:209388
\Stat1tm2b(EUCOMM)Wtsi/\Stat1tm2b(EUCOMM)Wtsi
(C57BL/6N-Stat1tm2b(EUCOMM)Wtsi/Orl)
decreased lymphocyte cell number J:211773
enlarged lymph nodes J:211773
increased basophil cell number J:211773
increased eosinophil cell number J:211773
increased large unstained cell number J:211773
increased leukocyte cell number J:211773
increased lymphocyte cell number J:211773
increased monocyte cell number J:211773
increased neutrophil cell number J:211773
\Stat2m1Btlr/\Stat2m1Btlr
(C57BL/6J-Stat2m1Btlr)
decreased CD8-positive, alpha-beta T cell number J:265265
decreased central memory CD8 positive, alpha-beta T cell number J:265265
decreased single-positive T cell number J:265265
\Stat2p117/\Stat2p117
(C57BL/6J-Stat2P117)
abnormal level of surface class II molecules J:164049
decreased dendritic cell number J:164049
decreased level of surface class I molecules J:164049
decreased plasmacytoid dendritic cell number J:164049
increased susceptibility to Picornaviridae infection induced morbidity/mortality J:164049
\Stat2tm1.1(STAT2)Diam/\Stat2tm1.1(STAT2)Diam
(C57BL/6-Stat2tm1.1(STAT2)Diam)
increased susceptibility to Flaviviridae infection J:261503
increased susceptibility to Flaviviridae infection induced morbidity/mortality J:261503
\Stat2tm1Jdf/\Stat2tm1Jdf
\Tg(DO11.10)10Dlo/0

(C.Cg-Stat2tm1Jdf Tg(DO11.10)10Dlo)
immune system phenotype J:95855
\Stat2tm1Shnd/\Stat2tm1Shnd
(involves: 129S1/Sv * 129X1/SvJ)
abnormal T cell differentiation J:66564
increased susceptibility to Riboviria infection J:66564
\Stat3tm1Aki/\Stat3tm1Aki
\Tg(Tek-cre)12Flv/0

(involves: 129P2/OlaHsd * C3H * C57BL/6)
abnormal interleukin level J:123351
\Stat3tm1Desi/\Stat3tm1Desi
(involves: 129X1/SvJ * C57BL/6)
increased susceptibility to endotoxin shock J:77307
\Stat3tm1Dlv/\Stat3tm1Dlv
\Tg(Cd4-cre)1Cwi/?

(involves: 129 * C57BL/6 * DBA/2)
abnormal CD4-positive T cell differentiation J:124293
abnormal gut-associated lymphoid tissue morphology J:124293
decreased interleukin-17 secretion J:124293
increased interferon-gamma secretion J:124293
\Stat3tm1Dlv/\Stat3tm1Dlv
\Tg(Csf1r-icre)1Jwp/0

(involves: 129P2/OlaHsd * C57BL/6 * FVB)
abnormal acute inflammation J:156593
abnormal inflammatory response J:156593
colitis J:156593
increased granulocyte number J:156593
increased macrophage cell number J:156593
increased T cell number J:156593
\Stat3tm1Dlv/\Stat3tm1Dlv
\Tg(MMTV-cre)4Mam/0

(involves: 129P2/OlaHsd * C57BL/6J * FVB)
decreased T-helper 17 cell number J:120176
\Stat3tm1Dnl/\Stat3tm1Dlv
(involves: C57BL/6)
decreased thymocyte number J:87599
increased thymocyte apoptosis J:87599
\Stat3tm1Flv/\Stat3tm1Flv
\Tg(Tek-cre)1Xyfu/0

(involves: C57BL/6)
abnormal cytokine secretion J:86655
increased susceptibility to endotoxin shock J:86655
\Stat3tm1Flv/\Stat3tm1Flv
\Tg(Tek-cre)12Flv/0

(involves: 129 * C3H * C57BL/6)
abnormal inflammatory response J:81973
abnormal innate immunity J:81973
abnormal T-helper 1 physiology J:81973
cecum inflammation J:81973
colitis J:81973
granulomatous inflammation J:81973
ileum inflammation J:81973
increased circulating interferon-gamma level J:81973
increased circulating tumor necrosis factor level J:81973
increased leukocyte cell number J:81973
intestinal inflammation J:81973
liver inflammation J:81973
\Stat3tm1Vpo/\Stat3tm1Vpo
\Tg(Mx1-cre)1Cgn/0

(involves: 129P2/OlaHsd * BALB/cAn * C57BL/6 * CBA)
abnormal macrophage physiology J:89194
increased interleukin-6 secretion J:89194
increased tumor necrosis factor secretion J:89194
\Stat3tm1Vpo/\Stat3tm2Vpo
\Tg(Mx1-cre)1Cgn/0

(involves: C57BL/6 * CBA * BALB/cAn)
abnormal macrophage physiology J:89194
increased interleukin-6 secretion J:89194
increased tumor necrosis factor secretion J:89194
\Stat3tm1Xyfu/\Stat3+
\Tg(Myh6-cre)2182Mds/0

(involves: 129S1/Sv * FVB/N)
increased susceptibility to endotoxin shock J:86400
increased tumor necrosis factor secretion J:86400
\Stat3tm1Xyfu/\Stat3tm1.1Xyfu
\Tg(Myh6-cre)2182Mds/0

(involves: 129S1/Sv * FVB/N)
increased susceptibility to endotoxin shock J:86400
increased tumor necrosis factor secretion J:86400
\Stat3tm1Xyfu/\Stat3tm1.1Xyfu
\Tg(Ttr-cre)10-3Xyfu/?

(involves: 129S1/Sv * C57BL/6)
increased monocyte cell number J:128719
increased neutrophil cell number J:128719
\Stat3tm2Aki/\Stat3tm2Aki
(involves: 129P2/OlaHsd * BALB/c * C57BL/6)
abnormal response to infection J:122213
\Stat3tm2Aki/\Stat3tm2Aki
\Lyz2tm1(cre)Ifo/\Lyz2+

(involves: 129P2/OlaHsd * C57BL/6)
colitis J:83280
increased CD4-positive, alpha-beta T cell number J:83280
increased dendritic cell number J:83280
increased interferon-gamma secretion J:83280
increased interleukin-12 secretion J:83280
increased macrophage cell number J:83280
\Stat3tm2Aki/\Stat3tm2Aki
\Tg(KRT5-cre)1Tak/0

(involves: 129P2/OlaHsd * C3H * C57BL/6)
conjunctivitis J:194832
dermatitis J:194832
lacrimal gland inflammation J:194832
\Stat3tm2Aki/\Stat3tm2Aki
\Tg(Lck-cre)1Jtak/0

(involves: 129P2/OlaHsd)
decreased T cell proliferation J:50443
increased T cell apoptosis J:50443
\Stat3tm2Aki/\Stat3tm2Aki
\Tg(SFTPC-rtTA)5Jaw/0
\Tg(tetO-cre)1Jaw/0

(involves: 129 * 129P2/OlaHsd * C57BL/6)
abnormal cytokine level J:87622
lung inflammation J:87622
\Stat3tm2Aki/\Stat3tm2Aki
\Tlr4tm1Aki/\Tlr4tm1Aki
\Lyz2tm1(cre)Ifo/\Lyz2+

(involves: 129P2/OlaHsd * C57BL/6)
colitis J:83280
decreased interferon-gamma secretion J:83280
decreased susceptibility to endotoxin shock J:83280
\Stat3tm2Aki/\Stat3tm2Aki
\Tnftm1Sek/\Tnftm1Sek
\Lyz2tm1(cre)Ifo/\Lyz2+

(involves: 129P2/OlaHsd * C57BL/6 * CBA)
colitis J:83280
increased interferon-gamma secretion J:83280
increased interleukin-6 secretion J:83280
increased interleukin-12b secretion J:83280
\Stat3tm3Vpo/\Stat3tm3Vpo
(involves: C57BL/6 * CBA * BALB/cAn)
abnormal macrophage physiology J:89194
\Stat4ity14/\Stat4ity14
(involves: 129S1/Sv * 129X1/SvJ)
decreased circulating interferon-gamma level J:207092
decreased interferon-gamma secretion J:207092
increased circulating interleukin-12 level J:207092
increased susceptibility to bacterial infection J:207092
increased susceptibility to bacterial infection induced morbidity/mortality J:207092
\Stat4ity14/\Stat4tm1Gru
(involves: 129S1/Sv * 129S2/SvPas * 129X1/SvJ)
increased susceptibility to bacterial infection induced morbidity/mortality J:207092
\Stat4tm1Gru/\Stat4tm1Gru
(involves: 129S2/SvPas * BALB/c)
abnormal lymphocyte physiology J:34059
abnormal NK cell physiology J:34059
abnormal T cell proliferation J:34059
abnormal T-helper 1 physiology J:34059
abnormal T-helper 2 physiology J:34059
decreased circulating interferon-gamma level J:163843
decreased interferon-gamma secretion J:34059
increased susceptibility to bacterial infection J:163843
increased susceptibility to bacterial infection induced morbidity/mortality J:163843
\Stat4tm1Gru/\Stat4tm1Gru
(NOD.129S2-Stat4tm1Gru)
abnormal inflammatory response J:90600
decreased circulating interferon-gamma level J:90600
decreased circulating interleukin-2 level J:90600
decreased susceptibility to autoimmune diabetes J:90600
\Stat4tm1Gru/\Stat4tm1Gru
(C.129S2-Stat4tm1Gru)
abnormal CD4-positive T cell differentiation J:143729
decreased circulating interferon-gamma level J:90600
decreased circulating interleukin-2 level J:90600
\Stat4tm1Gru/\Stat4tm1Gru
(involves: 129S2/SvPas)
abnormal cytokine secretion J:112600
\Stat4tm1Gru/\Stat4tm1Gru
\Tg(Ins2-GP)34-20Olds/0

(involves: 129S2/SvPas * BALB/c * C57BL/6)
abnormal susceptibility to autoimmune disorder J:107047
\Stat4tm1Gru/\Stat4tm1Gru
\Tg(Ins2-NP)25-3Olds/0

(involves: 129S2/SvPas * BALB/c * C57BL/6)
abnormal cytotoxic T cell physiology J:107047
decreased interferon-gamma secretion J:107047
decreased susceptibility to autoimmune diabetes J:107047
insulitis J:107047
\Stat4tm1Jni/\Stat4tm1Jni
(involves: 129P2/OlaHsd * C57BL/6)
abnormal NK cell physiology J:79552
decreased circulating interferon-gamma level J:79552
decreased susceptibility to autoimmune diabetes J:96338
increased interleukin-4 secretion J:96338
\Stat4tm1Jni/\Stat4tm1Jni
\Stat6tm1Jni/\Stat6tm1Jni

(involves: 129P2/OlaHsd * 129S/SvEv * C57BL/6)
decreased interleukin-4 secretion J:96338
increased interferon-gamma secretion J:96338
increased susceptibility to autoimmune diabetes J:96338
\Stat5atm1.1Wjl/\Stat5atm1.1Wjl
\Stat5btm2.1Wjl/\Stat5btm2.1Wjl

(involves: 129S6/SvEvTac * C57BL/6J * FVB/N)
abnormal leukocyte morphology J:187325
abnormal regulatory T cell physiology J:187325
abnormal T cell subpopulation ratio J:187325
decreased CD8-positive, alpha-beta T cell number J:187325
decreased NK cell number J:187325
decreased T cell proliferation J:187325
increased T cell apoptosis J:187325
\Stat5atm1Jni/\Stat5atm1Jni
\Stat5btm2Jni/\Stat5btm2Jni

(either: (involves: 129P2/OlaHsd) or (involves: 129X1/SvJ))
abnormal myelopoiesis J:77412
decreased leukocyte cell number J:77412
decreased T cell number J:77412
increased neutrophil cell number J:77412
\Stat5atm1Jni/\Stat5atm1Jni
\Stat5btm2Jni/\Stat5btm2Jni

(involves: 129 * C57BL/6)
abnormal mast cell differentiation J:84889
abnormal mast cell physiology J:84889
absent mast cells J:84889
decreased CD4-positive, CD25-positive, alpha-beta regulatory T cell number J:122463
\Stat5atm1Mam/\Stat5atm1Mam
(C.129S6-Stat5atm1Mam)
abnormal mast cell differentiation J:101855
abnormal mast cell morphology J:101855
decreased mast cell number J:101855
\Stat5atm1Mam/\Stat5atm1Mam
(involves: 129S6/SvEvTac * C57BL/6)
decreased NK cell number J:112035
decreased splenocyte number J:112035
impaired natural killer cell mediated cytotoxicity J:112035
\Stat5atm2Mam/\Stat5atm2Mam
\Stat5btm1Mam/\Stat5b+

(involves: 129S6/SvEvTac)
abnormal lymphopoiesis J:258967
\Stat5atm2Mam/\Stat5atm2Mam
\Stat5btm1Mam/\Stat5btm1Mam
\Tg(Cd4-cre)1Cwi/0

(involves: 129S6/SvEvTac * C57BL/6 * C57BL/6J * DBA/2)
increased circulating interleukin-17 level J:120176
increased interleukin-17 secretion J:120176
\Stat5atm2Mam/\Stat5atm2Mam
\Stat5btm1Mam/\Stat5btm1Mam
\Tg(Lck-cre)I57Jxm/0

(involves: 129 * 129S6/SvEvTac * C57BL/6 * ICR)
abnormal acute inflammation J:122463
abnormal T cell subpopulation ratio J:122463
decreased CD8-positive, alpha-beta T cell number J:122463
enlarged spleen J:122463
\Stat5atm2Mam/\Stat5atm2Mam
\Stat5btm1Mam/\Stat5btm1Mam
\Tg(Mx1-cre)1Cgn/0

(involves: 129S6/SvEvTac * C57BL/6 * CBA)
abnormal leukopoiesis J:155489
abnormal neutrophil differentiation J:155489
abnormal neutrophil physiology J:155489
decreased leukocyte cell number J:155489
decreased lymphocyte cell number J:155489
decreased monocyte cell number J:155489
decreased neutrophil cell number J:155489
\Stat5btm1Hwd/\Stat5btm1Hwd
(involves: C57BL/6)
abnormal double-negative T cell morphology J:112035
abnormal lymphocyte cell number J:112035
abnormal lymphocyte morphology J:112035
decreased CD8-positive, alpha-beta T cell number J:112035
decreased NK cell number J:112035
decreased splenocyte number J:112035
decreased T cell proliferation J:112035
decreased thymocyte number J:112035
impaired natural killer cell mediated cytotoxicity J:112035
\Stat5btm1Mam/\Stat5btm1Mam
\Tg(Cd4-cre)1Cwi/0

(involves: 129S6/SvEvTac * C57BL/6 * C57BL/6J * DBA/2)
increased circulating interleukin-17 level J:120176
increased interleukin-17 secretion J:120176
\Stat5btm1Mam/\Stat5btm1Mam
\Tg(Lck-cre)I57Jxm/0

(involves: 129 * 129S6/SvEvTac * C57BL/6 * ICR)
abnormal acute inflammation J:122463
abnormal T cell subpopulation ratio J:122463
decreased CD8-positive, alpha-beta T cell number J:122463
enlarged spleen J:122463
\Stat5btm1Mam/\Stat5btm1Mam
\Tg(Mx1-cre)1Cgn/0

(involves: 129S6/SvEvTac * C57BL/6 * CBA)
abnormal leukopoiesis J:155489
abnormal neutrophil differentiation J:155489
abnormal neutrophil physiology J:155489
decreased leukocyte cell number J:155489
decreased lymphocyte cell number J:155489
decreased monocyte cell number J:155489
decreased neutrophil cell number J:155489
\Stat6tm1Aki/\Stat6tm1Aki
(involves: 129P2/OlaHsd)
abnormal T-helper 2 physiology J:32561
decreased B cell proliferation J:32561
decreased IgE level J:32561
decreased IgG1 level J:32561
decreased T cell proliferation J:32561
decreased T-helper 2 cell number J:172134
increased IgA level J:32561
increased IgG level J:32561
\Stat6tm1Aki/\Stat6tm1Aki
(C.129P2-Stat6tm1Aki Nfkbiztm1Aki)
skin inflammation J:141704
\Stat6tm1Aki/\Stat6tm1Aki
\Tg(KRT14-CASP1)1Miz/0

(involves: 129P2/OlaHsd * C57BL/6)
decreased IgE level J:78602
decreased IgG1 level J:78602
dermatitis J:78602
increased circulating interleukin-18 level J:78602
\Stat6tm1Gru/\Stat6+
\Tg(Scgb1a1-Il13)2Eli/?

(involves: 129S2/SvPas * C57BL/6 * CBA)
respiratory system inflammation J:132385
\Stat6tm1Gru/\Stat6tm1Gru
(C.129S2-Stat6tm1Gru/J)
abnormal CD4-positive T cell differentiation J:204829
abnormal CD8-positive, alpha beta T cell morphology J:125259
abnormal humoral immune response J:107370
decreased IgA level J:107370
decreased IgG3 level J:107370
decreased IgM level J:107370
decreased interleukin-4 secretion J:107370
decreased susceptibility to Herpesvirales infection J:107370
increased interferon-gamma secretion J:107370
increased interleukin-2 secretion J:107370
\Stat6tm1Gru/\Stat6tm1Gru
(129S2/SvPas-Stat6tm1Gru)
abnormal interleukin secretion J:31932
abnormal T-helper 2 cell differentiation J:31932
decreased IgE level J:31932
decreased interleukin-4 secretion J:31932
decreased interleukin-5 secretion J:31932
decreased T cell proliferation J:31932
\Stat6tm1Gru/\Stat6tm1Gru
(involves: 129S2/SvPas)
abnormal cytokine secretion J:112600
\Stat6tm1Gru/\Stat6tm1Gru
(involves: 129S2/SvPas * BALB/c)
abnormal acute inflammation J:85386
abnormal granulocyte physiology J:85386
abnormal macrophage physiology J:85386
immune system phenotype J:85386
impaired eosinophil chemotaxis J:85386
impaired neutrophil chemotaxis J:85386
increased circulating tumor necrosis factor level J:85386
\Stat6tm1Gru/\Stat6tm1Gru
(C.129S2-Stat6tm1Gru)
abnormal circulating interleukin level J:66222
abnormal circulating interleukin-4 level J:66222
abnormal circulating interleukin-5 level J:66222
abnormal cytotoxic T cell physiology J:65894
abnormal immune serum protein physiology J:66222
abnormal immunoglobulin level J:66222
abnormal leukocyte migration J:74497
abnormal leukocyte physiology J:74497
decreased IgE level J:74497, J:66222
decreased IgG1 level J:66222
impaired eosinophil recruitment J:66222
increased IgG2a level J:66222
\Stat6tm1Jni/\Stat6tm1Jni
(involves: 129S/SvEv)
abnormal B cell physiology J:32607
abnormal B cell proliferation J:32607
abnormal class switch recombination J:32607
abnormal level of surface class II molecules J:32607
abnormal T-helper 1 cell differentiation J:32607
abnormal T-helper 2 cell differentiation J:32607
increased B cell apoptosis J:146533
\Stat6tm1Jni/\Stat6tm1Jni
(involves: 129S/SvEv * C57BL/6)
abnormal mast cell morphology J:110429
abnormal T-helper 1 cell differentiation J:51096
decreased IgE level J:51096
decreased IgG1 level J:51096
decreased interleukin-4 secretion J:96338
decreased susceptibility to autoimmune diabetes J:96338
increased IgE level J:110429
increased IgG1 level J:110429
increased IgG2a level J:51096
increased interferon-gamma secretion J:51096, J:96338
increased interleukin-12 secretion J:51096
increased susceptibility to parasitic infection J:110429
\Stau2em1(IMPC)Mbp/\Stau2em1(IMPC)Mbp
(C57BL/6N-Stau2em1(IMPC)Mbp/MbpMmucd)
increased monocyte cell number J:211773
\Steap3fred/\Steap3fred
(C57BL/6-Steap3fred)
enlarged spleen J:145194
\Steap3tm1.1Atel/\Steap3tm1.1Atel
(involves: C57BL/6)
abnormal spleen morphology J:154356
abnormal spleen red pulp morphology J:154356
decreased splenocyte apoptosis J:154356
increased spleen weight J:154356
increased spleen white pulp amount J:154356
\Steap4tm1Dgen/\Steap4tm1Dgen
(involves: 129P2/OlaHsd)
increased macrophage cell number J:187736
\Stia1NOD/ShiLtDoi/?
(involves: C57BL/6J * NOD/LtDoi)
increased inflammatory response J:70882
\Stia2C57BL/6J/\Stia2C57BL/6J
(involves: C57BL/6J * NOD/LtDoi)
increased inflammatory response J:70882
\Stia2C57BL/6J/\Stia2NOD/ShiLtDoi
(involves: C57BL/6J * NOD/LtDoi)
increased inflammatory response J:70882
\Stim1em1(IMPC)Mbp/\Stim1+
(C57BL/6N-Stim1em1(IMPC)Mbp/MbpMmucd)
abnormal lymph node morphology J:211773
abnormal spleen morphology J:211773
enlarged lymph nodes J:211773
enlarged spleen J:211773
increased leukocyte cell number J:211773
increased lymphocyte cell number J:211773
increased neutrophil cell number J:211773
\Stim1Sax/\Stim1+
(involves: C3HeB/FeJ * C57BL/6)
abnormal thrombopoiesis J:127381
enlarged spleen J:127381
immune system phenotype J:127381
increased spleen red pulp amount J:127381
\Stim1tm1.1Kuro/\Stim1+
(C57BL/6-Stim1tm1.1Kuro)
decreased susceptibility to type I hypersensitivity reaction J:130477
\Stim1tm1.1Kuro/\Stim1tm1.1Kuro
(C57BL/6-Stim1tm1.1Kuro)
abnormal cytokine secretion J:130477
abnormal interleukin secretion J:130477
decreased interleukin-6 secretion J:130477
decreased interleukin-13 secretion J:130477
decreased mast cell degranulation J:130477
decreased tumor necrosis factor secretion J:130477
\Stim1tm1.1Pg/\Stim1+
(involves: C57BL/6)
decreased Ly6C low monocyte number J:285187
decreased NK cell number J:285187
enlarged spleen J:285187
increased Ly6C high monocyte number J:285187
\Stim1tm1Kuro/\Stim1tm1Kuro
\Cd79atm1(cre)Reth/\Cd79a+

(involves: BALB/c * C57BL/6)
abnormal B cell calcium ion homeostasis J:172608
decreased B cell proliferation J:172608
decreased interleukin-10 secretion J:172608
\Stim1tm1Kuro/\Stim1tm1Kuro
\Stim2tm1.1Kuro/\Stim2tm1.1Kuro
\Cd79atm1(cre)Reth/\Cd79a+

(involves: BALB/c * C57BL/6)
abnormal B cell calcium ion homeostasis J:172608
abnormal B cell physiology J:172608
decreased B cell proliferation J:172608
decreased interleukin-10 secretion J:172608
immune system phenotype J:172608
increased CD4-positive, alpha-beta T cell number J:172608
increased CD8-positive, alpha-beta T cell number J:172608
increased interferon-gamma secretion J:172608
increased interleukin-10 secretion J:172608
increased interleukin-17 secretion J:172608
increased regulatory T cell number J:172608
increased susceptibility to experimental autoimmune encephalomyelitis J:172608
\Stim1tm1Rao/\Stim1tm1Rao
\Stim2tm1Rao/\Stim2tm1Rao
\Tg(Cd4-cre)1Cwi/0

(involves: C57BL/6 * DBA/2 * SJL)
abnormal B cell differentiation J:133262
abnormal CD4-positive, alpha-beta T cell physiology J:133262
abnormal granulocyte morphology J:133262
abnormal immune system morphology J:133262
abnormal immune system physiology J:133262
abnormal lymph organ size J:133262
abnormal T cell differentiation J:133262
blepharitis J:133262
decreased interferon-gamma secretion J:133262
decreased interleukin-2 secretion J:133262
decreased regulatory T cell number J:133262
decreased T cell proliferation J:133262
dermatitis J:133262
enlarged lymph nodes J:133262
enlarged spleen J:133262
increased germinal center B cell number J:133262
increased IgG1 level J:133262
increased lymphocyte cell number J:133262
increased spleen germinal center number J:133262
\Stim1tm1Rao/\Stim1tm1Rao
\Tg(Cd4-cre)1Cwi/0

(involves: C57BL/6 * DBA/2 * SJL)
abnormal CD4-positive, alpha-beta T cell physiology J:133262
decreased interleukin-2 secretion J:133262
increased lymphocyte cell number J:133262
\Stim1tm3Ics/\Stim1+
(involves: C57BL/6N)
decreased lymphocyte cell number J:277842
decreased NK T cell number J:277842
decreased regulatory T cell number J:277842
increased monocyte cell number J:277842
increased neutrophil cell number J:277842
increased spleen weight J:277842
myositis J:277842
\Stim2tm1.1Kuro/\Stim2tm1.1Kuro
\Cd79atm1(cre)Reth/\Cd79a+

(involves: BALB/c * C57BL/6)
abnormal B cell calcium ion homeostasis J:172608
immune system phenotype J:172608
\Stim2tm1Rao/\Stim2tm1Rao
\Tg(Cd4-cre)1Cwi/0

(involves: C57BL/6 * DBA/2 * SJL)
abnormal CD4-positive, alpha-beta T cell physiology J:133262
abnormal T-helper 1 physiology J:133262
abnormal T-helper 2 physiology J:133262
decreased interferon-gamma secretion J:133262
decreased interleukin-2 secretion J:133262
decreased interleukin-4 secretion J:133262
\Sting1em1Jmin/\Sting1+
(involves: C57BL/6N)
abnormal cytokine level J:251372
abnormal spleen morphology J:251372
decreased single-positive T cell number J:251372
enlarged spleen J:251372
increased circulating interleukin-10 level J:251372
increased circulating interleukin-13 level J:251372
increased circulating tumor necrosis factor level J:251372
increased IgM level J:251372
lung inflammation J:251372
\Sting1gt/\Sting1gt
(C57BL/6-Sting1gt)
abnormal dendritic cell physiology J:201167
abnormal humoral immune response J:201167
abnormal immune cell physiology J:201167
abnormal macrophage physiology J:201167
abnormal plasmacytoid dendritic cell physiology J:201167
abnormal response to infection J:168746
decreased circulating interferon-alpha level J:201167
decreased circulating interferon-beta level J:201167, J:168746
increased susceptibility to Herpesvirales infection J:201167
increased susceptibility to Herpesvirales infection induced morbidity/mortality J:201167
\Sting1gt/\Sting1gt
(involves: C57BL/6)
immune system phenotype J:265023
increased susceptibility to Retroviridae infection J:265023
\Sting1gt/\Sting1gt
(C57BL/6J-Sting1gt/J)
abnormal interferon-beta secretion J:354143
abnormal level of surface class I molecules J:363611
abnormal MHC II cell surface expression on macrophages J:363611
abnormal response to infection J:354143
increased susceptibility to Retroviridae infection J:354143
\Sting1tm1Camb/\Sting1tm1Camb
(involves: C57BL/6N)
decreased circulating interferon-beta level J:179270
decreased circulating interleukin-6 level J:179270
immune system phenotype J:179270
\Sting1tm1Gnb/\Sting1tm1Gnb
(involves: 129P2/OlaHsd * C57BL/6)
abnormal innate immunity J:141011
abnormal susceptibility to Herpesvirales infection J:141011
increased susceptibility to Riboviria infection J:141011
\Sting1tm1Gnb/\Sting1tm1Gnb
(involves: 129P2/OlaHsd)
abnormal response to infection J:168746
\Sting1tm1Gnb/\Sting1tm1Gnb
\Trex1tm1Tld/\Trex1tm1Tld

(involves: 129P2/OlaHsd * C57BL/6)
immune system phenotype J:181257
\Stip1tm1.2Mamp/\Stip1tm1.2Mamp
(involves: C57BL/6)
increased acute inflammation J:201097
\Stk3tm1.1Jav/\Stk3tm1.1Jav
(involves: 129 * C57BL/6)
immune system phenotype J:153945
\Stk3tm1.1Jav/\Stk3tm1.1Jav
\Stk4tm1Kina/\Stk4tm1Kina
\Tg(Nkx2-1-cre)2Sand/?

(involves: 129 * C57BL/6)
lung inflammation J:197340
\Stk3tm1.1Yy/\Stk3tm1Yy
\Stk4tm1.1Yy/\Stk4tm1.1Yy
\Tg(CAG-cre/Esr1*)5Amc/0

(involves: C57BL/6 * CBA)
enlarged spleen J:156541
\Stk4Gt(AJ0315)Wtsi/\Stk4Gt(AJ0315)Wtsi
(B6.129P2-Stk4Gt(AJ0315)Wtsi)
abnormal memory T cell number J:142674
abnormal T cell differentiation J:142674
decreased CD4-positive, alpha-beta T cell number J:142674
decreased CD8-positive, alpha-beta T cell number J:142674
decreased spleen white pulp amount J:142674
increased interferon-gamma secretion J:142674
increased interleukin-2 secretion J:142674
increased interleukin-4 secretion J:142674
increased T cell apoptosis J:142674
increased T cell proliferation J:142674
\Stk4m1Btlr/\Stk4m1Btlr
(C57BL/6J-Stk4m1Btlr)
abnormal humoral immune response J:265233
decreased B cell number J:265233
decreased CD4-positive, alpha-beta T cell number J:265233
decreased CD8-positive, alpha-beta T cell number J:265233
decreased IgD level J:265233
decreased single-positive T cell number J:265233
decreased T cell number J:265233
increased IgE level J:265233
increased IgM level J:265233
increased macrophage cell number J:265233
increased neutrophil cell number J:265233
increased NK cell number J:265233
\Stk4m2Btlr/\Stk4m2Btlr
(C57BL/6J-Stk4m2Btlr)
decreased B-1 B cell number J:265237
decreased B-2 B cell number J:265237
decreased CD4-positive, alpha-beta T cell number J:265237
decreased CD8-positive, alpha-beta T cell number J:265237
decreased CD8-positive, naive alpha-beta T cell number J:265237
decreased IgD level J:265237
decreased single-positive T cell number J:265237
decreased T cell number J:265237
increased B-1b cell number J:265237
increased central memory CD4-positive, alpha-beta T cell number J:265237
increased central memory CD8 positive, alpha-beta T cell number J:265237
increased dendritic cell number J:265237
increased effector memory CD4-positive, alpha-beta T cell number J:265237
increased effector memory CD8-positive, alpha-beta T cell number J:265237
increased IgE level J:265237
increased macrophage cell number J:265237
increased neutrophil cell number J:265237
increased NK cell number J:265237
\Stk4m3Btlr/\Stk4m3Btlr
(C57BL/6J-Stk4m3Btlr)
decreased CD4-positive, alpha-beta T cell number J:265245
decreased CD8-positive, alpha-beta T cell number J:265245
decreased single-positive T cell number J:265245
decreased T cell number J:265245
\Stk4m4Btlr/\Stk4m4Btlr
(C57BL/6J-Stk4m4Btlr)
decreased CD11b-high dendritic cell number J:272536
decreased IgD level J:272536
decreased IgG level J:272536
impaired humoral immune response J:272536
increased B-1b cell number J:272536
increased dendritic cell number J:272536
\Stk4m5Btlr/\Stk4m5Btlr
(C57BL/6J-Stk4m5Btlr)
abnormal CD4-positive T cell differentiation J:272743
abnormal T cell differentiation J:272743
decreased CD4-positive, alpha-beta T cell number J:272743
increased central memory CD4-positive, alpha-beta T cell number J:272743
\Stk4tm1.1Kina/\Stk4tm1.1Kina
(involves: C57BL/6)
abnormal B cell physiology J:148791
abnormal dendritic cell physiology J:148791
abnormal immune system organ morphology J:148791
abnormal leukocyte adhesion J:148791
abnormal leukocyte migration J:148791
abnormal marginal zone B cell morphology J:148791
abnormal Peyer's patch germinal center morphology J:148791
abnormal Peyer's patch T cell area morphology J:148791
abnormal spleen B cell follicle morphology J:148791
abnormal T cell physiology J:148791
decreased B cell number J:148791
decreased lymphocyte cell number J:148791
decreased marginal zone B cell number J:148791
decreased myeloid dendritic cell number J:148791
decreased spleen B cell follicle size J:148791
decreased T cell number J:148791
increased single-positive T cell number J:148791
increased T cell proliferation J:148791
thymus hyperplasia J:148791
\Stk4tm1.1Wtao/\Stk4tm1.2Wtao
\Tg(Lck-cre)#Zhu/0

(involves: 129S4/SvJaeSor * 129S6/SvEvTac * C57BL/6 * SJL/J)
decreased CD4-positive, alpha-beta T cell number J:152323
decreased CD8-positive, alpha-beta T cell number J:152323
decreased T cell number J:152323
increased single-positive T cell number J:152323
increased thymocyte number J:152323
\Stk4tm1.2Wtao/\Stk4tm1.2Wtao
(involves: 129S4/SvJaeSor * 129S6/SvEvTac)
abnormal CD4-positive, alpha-beta T cell physiology J:152323
abnormal CD8-positive, alpha-beta T cell physiology J:152323
abnormal T cell physiology J:152323
decreased B cell number J:152323
decreased CD4-positive, alpha-beta T cell number J:152323
decreased CD8-positive, alpha-beta T cell number J:152323
decreased lymphocyte cell number J:152323
increased single-positive T cell number J:152323
increased thymocyte number J:152323
\Stk4tm1Dlim/\Stk4tm1Dlim
(Not Specified)
abnormal T cell physiology J:155001
decreased T cell number J:155001
\Stk10em1(IMPC)Ccpcz/\Stk10em1(IMPC)Ccpcz
(C57BL/6NCrl-Stk10em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
decreased lymphocyte cell number J:211773
increased eosinophil cell number J:211773
increased monocyte cell number J:211773
\Stk10tm1Hkar/\Stk10tm1Hkar
(involves: 129S1/Sv)
abnormal T cell physiology J:60738
\Stk11tm1.1Mlfr/\Stk11+
(involves: 129S2/SvPas * 129S7/SvEvBrd * C57BL/6J)
enlarged spleen J:104347
\Stk11tm1.1Rdp/\Stk11tm1.1Rdp
\Tg(Pdx1-cre)89.1Dam/0

(involves: 129S6/SvEvTac * C57BL/6 * CBA * FVB/N * ICR)
pancreas inflammation J:134078
\Stk11tm1.1Rdp/\Stk11tm1.1Rdp
\Tg(Sprr2f-cre)1Dcas/0

(involves: 129S6/SvEvTac * FVB/N)
peritoneal inflammation J:158190
sepsis J:158190
\Stk11tm1.1Sjm/\Stk11tm1.1Sjm
\Tg(Mx1-cre)1Cgn/0

(involves: C57BL/6 * CBA * SJL)
decreased leukocyte cell number J:165090
thymus hypoplasia J:165090
\Stk11tm1Keis/\Stk11tm1Keis
\Lyz2tm1(cre)Ifo/\Lyz2+

(involves: 129P2/OlaHsd)
increased circulating interleukin-10 level J:191723
\Stk17btm1Hed/\Stk17btm1Hed
(involves: 129X1/SvJ * C57BL/6)
increased T cell proliferation J:94685
\Stk17btm1Hed/\Stk17btm1Hed
(B6.129X1-Stk17btm1Hed)
abnormal cytokine secretion J:94685
decreased double-positive T cell number J:94685
decreased susceptibility to experimental autoimmune encephalomyelitis J:94685
increased CD4-positive, alpha-beta T cell number J:94685
increased interferon-gamma secretion J:94685
increased interleukin-2 secretion J:94685
increased memory T cell number J:94685
increased T cell proliferation J:94685
increased tumor necrosis factor secretion J:94685
\Stk24Gt(AM0826)Wtsi/\Stk24Gt(AM0826)Wtsi
(B6.129P2-Stk24Gt(AM0826)Wtsi)
abnormal neutrophil morphology J:256076
abnormal neutrophil physiology J:256076
immune system phenotype J:256076
\Stk26tm1b(EUCOMM)Hmgu/Y
(C57BL/6N-Stk26tm1b(EUCOMM)Hmgu/Ccpcz)
increased NK T cell number J:211773
\Stk26tm1b(EUCOMM)Hmgu/\Stk26tm1b(EUCOMM)Hmgu
(C57BL/6N-Stk26tm1b(EUCOMM)Hmgu/Ccpcz)
decreased monocyte cell number J:211773
\Stk36tm1Fjs/\Stk36tm1Fjs
(involves: 129S1/Sv * C57BL/6)
rhinitis J:116391
spleen atrophy J:116391
thymus atrophy J:116391
\Stk36tm1Lex/\Stk36tm1Lex
(involves: 129S5/SvEvBrd * C57BL/6J)
increased susceptibility to otitis media J:185566
\Stk38tm1b(KOMP)Wtsi/\Stk38+
(C57BL/6N-Stk38tm1b(KOMP)Wtsi/J)
increased leukocyte cell number J:211773
\Stk38tm1Hem/\Stk38+
(involves: 129P2/Ola * C57BL/6)
increased T cell derived lymphoma incidence J:185408
\Stk38tm1Hem/\Stk38tm1Hem
(involves: 129P2/Ola * C57BL/6)
abnormal T cell physiology J:185408
decreased thymocyte apoptosis J:185408
increased T cell derived lymphoma incidence J:185408
\Stk38tm1Xen/\Stk38tm1Xen
(involves: 129S5/SvEvBrd * C57BL/6)
immune system phenotype J:224932
increased circulating interleukin-6 level J:224932
increased circulating tumor necrosis factor level J:224932
increased interleukin-6 secretion J:224932
increased susceptibility to bacterial infection J:224932
increased susceptibility to bacterial infection induced morbidity/mortality J:224932
increased tumor necrosis factor secretion J:224932
\Stoml1em1(IMPC)Tcp/\Stoml1em1(IMPC)Tcp
(C57BL/6N-Stoml1em1(IMPC)Tcp/Tcp)
enlarged lymph nodes J:211773
enlarged spleen J:211773
\Stoml2tm1Jmad/\Stoml2tm1Jmad
\Tg(Cd4-cre)1Cwi/0

(B6.Cg-Tg(Cd4-cre)1Cwi Stoml2tm1Jmad)
immune system phenotype J:187226
\Stra6tm1Jwu/\Stra6tm1Jwu
(B6.129-Stra6tm1Jwu)
immune system phenotype J:211118
\Stra6ltm1b(KOMP)Wtsi/\Stra6ltm1b(KOMP)Wtsi
(C57BL/6N-Stra6ltm1b(KOMP)Wtsi/Ucd)
decreased lymphocyte cell number J:211773
increased basophil cell number J:211773
increased neutrophil cell number J:211773
\Stub1tm1Cpat/\Stub1tm1Cpat
(involves: 129S/SvEv * C57BL/6)
increased thymocyte apoptosis J:86213
thymus atrophy J:86213
thymus hypoplasia J:86213
\Stx2tm1Dcru/\Stx2tm1Dcru
(involves: 129X1/SvJ * C57BL/6J)
decreased susceptibility to induced colitis J:110376
\Stx3Gt(EUCE320f12)1.1Hmgu/\Stx3Gt(EUCE320f12)1.1Hmgu
(B6.129P2(129S4)-Stx3Gt(EUCE320f12)1.1Hmgu)
immune system phenotype J:275367
\Stx3Gt(EUCE320f12)1.1Hmgu/\Stx3Gt(EUCE320f12)1.1Hmgu
\Tg(Cma1-cre)ARoer/0

(B6.Cg-Stx3Gt(EUCE320f12)1.1Hmgu Tg(Cma1-cre)ARoer)
abnormal mast cell degranulation J:275367
decreased mast cell degranulation J:275367
immune system phenotype J:275367
\Stx3Gt(EUCE320f12)1.2Hmgu/\Stx3+
(B6.129P2(Cg)-Stx3Gt(EUCE320f12)1.2Hmgu)
abnormal mast cell degranulation J:275367
immune system phenotype J:275367
\Stx4atm1.1Radac/\Stx4atm1.1Radac
(involves: 129S4/SvJaeSor * C57BL/6J)
immune system phenotype J:275367
\Stx4atm1.1Radac/\Stx4atm1.1Radac
\Tg(Cma1-cre)ARoer/0

(involves: 129S4/SvJaeSor * C57BL/6 * C57BL/6J)
immune system phenotype J:275367
\Stx4atm1.2Radac/\Stx4a+
(involves: 129S4/SvJaeSor * BALB/cJ * C57BL/6J)
immune system phenotype J:275367
\Stx7em1(IMPC)Rbrc/\Stx7em1(IMPC)Rbrc
(C57BL/6NJcl-Stx7em1(IMPC)Rbrc/Rbrc)
abnormal thymus morphology J:211773
decreased large unstained cell number J:211773
small thymus J:211773
\Stx11em1(IMPC)Mbp/\Stx11em1(IMPC)Mbp
(C57BL/6N-Stx11em1(IMPC)Mbp/MbpMmucd)
increased lymphocyte cell number J:211773
\Stx11tm1.2Ics/\Stx11tm1.2Ics
(involves: C57BL/6NTac)
abnormal cytotoxic T cell physiology J:193137
decreased cytotoxic T cell cytolysis J:193137
decreased leukocyte cell number J:193137
decreased neutrophil cell number J:193137
decreased NK cell degranulation J:193137
increased circulating interferon-gamma level J:193137
increased circulating interleukin-1 beta level J:193137
increased circulating interleukin-6 level J:193137
increased circulating tumor necrosis factor level J:193137
increased susceptibility to Riboviria infection J:193137
\Stx11tm1Bupa/\Stx11tm1Bupa
(B6.129-Stx11tm1Bupa)
abnormal cell-mediated immunity J:191103
abnormal cytokine secretion J:191103
abnormal lymphocyte physiology J:191103
abnormal neutrophil physiology J:191103
impaired natural killer cell mediated cytotoxicity J:191103
increased interferon-gamma secretion J:191103
increased tumor necrosis factor secretion J:191103
\Stxbp2tm1Bdic/\Stxbp2+
(involves: 129S * C57BL/6)
decreased mast cell degranulation J:188931
decreased susceptibility to type I hypersensitivity reaction J:188931
\sty/\sty
(Not Specified)
small thymus J:3675
\Styk1tm1Twa/\Styk1tm1Twa
(C57BL/6N-Styk1tm1Twa)
immune system phenotype J:277150
\Styk1tm1Twa/\Styk1tm1Twa
(B6J.B6N-Styk1tm1Twa)
immune system phenotype J:277150
\Styxl2em1(IMPC)Mbp/\Styxl2em1(IMPC)Mbp
(C57BL/6N-Styxl2em1(IMPC)Mbp/Ucd)
abnormal lymph node morphology J:211773
\Sucnr1tm1Dgen/\Sucnr1tm1Dgen
(B6.129P2-Sucnr1tm1Dgen)
abnormal dendritic cell physiology J:143337
abnormal interleukin-2 secretion J:143337
abnormal Langerhans cell physiology J:143337
abnormal T cell activation J:143337
decreased T cell proliferation J:143337
increased length of allograft survival J:143337
\SucoGt(KST050)Byg/\SucoGt(KST050)Byg
(involves: 129P2/OlaHsd * C57BL/6 * CD-1)
abnormal osteoclast physiology J:159823
decreased osteoclast cell number J:159823
\Sufutm1b(KOMP)Wtsi/\Sufu+
(C57BL/6N-Sufutm1b(KOMP)Wtsi/Ucd)
enlarged lymph nodes J:211773
\Sugcttm1.2Kald/\Sugcttm1.2Kald
(B6.Cg-Sugcttm1.2Kald)
increased macrophage cell number J:293423
kidney inflammation J:293423
white adipose tissue inflammation J:293423
\Sugp1em1(IMPC)Mbp/\Sugp1+
(C57BL/6NCrl-Sugp1em1(IMPC)Mbp/Mmucd)
abnormal lymph node morphology J:211773
abnormal spleen morphology J:211773
enlarged lymph nodes J:211773
enlarged spleen J:211773
\Sulf1Gt(OST352220)Lex/\Sulf1Gt(OST352220)Lex
(involves: 129S5/SvEvBrd * C57BL/6N)
decreased susceptibility to bacterial infection J:171883
\Sulf2em1(IMPC)Ccpcz/\Sulf2em1(IMPC)Ccpcz
(C57BL/6NCrl-Sulf2em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
enlarged spleen J:211773
\Sult1a1em1(IMPC)Ccpcz/\Sult1a1em1(IMPC)Ccpcz
(C57BL/6NCrl-Sult1a1em1(IMPC)Ccpcz/Ccpcz)
abnormal lymph node morphology J:211773
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged lymph nodes J:211773
enlarged spleen J:211773
enlarged thymus J:211773
\Sumf1Gt(RST760)Byg/\Sumf1Gt(RST760)Byg
(involves: 129P2/OlaHsd * C57BL/6)
abnormal macrophage morphology J:120146
abnormal microglial cell morphology J:120146
CNS inflammation J:120146
increased macrophage cell number J:120146
\Sun1tm1b(EUCOMM)Wtsi/\Sun1tm1b(EUCOMM)Wtsi
(C57BL/6N-Sun1tm1b(EUCOMM)Wtsi/Orl)
decreased lymphocyte cell number J:211773
increased leukocyte cell number J:211773
increased lymphocyte cell number J:211773
increased monocyte cell number J:211773
increased neutrophil cell number J:211773
\Sun2tm1b(EUCOMM)Hmgu/\Sun2tm1b(EUCOMM)Hmgu
(C57BL/6N-Sun2tm1b(EUCOMM)Hmgu/Bay)
increased large unstained cell number J:211773
\Sun5em1(IMPC)Mbp/\Sun5em1(IMPC)Mbp
(C57BL/6N-Sun5em1(IMPC)Mbp/MbpMmucd)
abnormal lymph node morphology J:211773
abnormal spleen morphology J:211773
enlarged lymph nodes J:211773
enlarged spleen J:211773
\Supv3l1tm2.1Jkl/\Supv3l1tm2.2Jkl
\Tg(CAG-cre/Esr1*)5Amc/0

(involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6 * FVB/N)
abnormal T cell differentiation J:144991
decreased CD4-positive, alpha-beta T cell number J:144991
decreased CD8-positive, alpha-beta T cell number J:144991
decreased double-negative T cell number J:144991
decreased double-positive T cell number J:144991
increased macrophage derived foam cell number J:144991
lung inflammation J:144991
thymus atrophy J:144991
thymus hypoplasia J:144991
\Supv3l1tm2Jkl/\Supv3l1tm2Jkl
\Tg(CAG-cre/Esr1*)5Amc/0

(involves: 129P2/OlaHsd * C57BL/6)
abnormal T cell differentiation J:144991
decreased CD4-positive, alpha-beta T cell number J:144991
decreased CD8-positive, alpha-beta T cell number J:144991
decreased double-negative T cell number J:144991
decreased double-positive T cell number J:144991
increased macrophage derived foam cell number J:144991
lung inflammation J:144991
thymus atrophy J:144991
thymus hypoplasia J:144991
\Supv3l1tm2Jkl/\Supv3l1tm2Jkl
\Tg(Mx1-cre)1Cgn/0

(involves: 129P2/OlaHsd * C57BL/6 * CBA)
increased macrophage derived foam cell number J:144991
increased plasma cell number J:144991
interstitial pneumonia J:144991
\Susd4tm1Lex/\Susd4tm1Lex
(B6.129S5-Susd4tm1Lex)
abnormal complement protein level J:306852
abnormal microglial cell morphology J:306852
increased microglial cell activation J:306852
\Susd6tm1b(KOMP)Wtsi/\Susd6tm1b(KOMP)Wtsi
(C57BL/6N-Susd6tm1b(KOMP)Wtsi/Bay)
decreased monocyte cell number J:211773
decreased neutrophil cell number J:211773
enlarged spleen J:211773
increased lymphocyte cell number J:211773
\Suv39h1tm1Jnw/\Suv39h1tm1Jnw
(involves: 129)
abnormal T-helper 2 physiology J:186702
decreased susceptibility to type I hypersensitivity reaction J:186702
\Suz12Plt8/\Suz12+
(involves: 129 * C57BL/6)
increased leukocyte cell number J:136262
increased lymphocyte cell number J:136262
\Svep1tm1a(EUCOMM)Hmgu/\Svep1tm1a(EUCOMM)Hmgu
(involves: C57BL/6N)
abnormal lymphangiogenesis J:244466
abnormal lymphatic vessel morphology J:244466
\Swap70tm1Jess/\Swap70tm1Jess
(involves: 129T2/SvEms * 129X1/SvJ)
abnormal class switch recombination J:71160
decreased IgE level J:71160
increased autoantibody level J:71160
\Swq6C57BL/6J/\Swq6CAST/EiJ
(involves: C57BL/6J * CAST/EiJ)
increased spleen weight J:117545
\Swq6CAST/EiJ/\Swq6CAST/EiJ
(involves: C57BL/6J * CAST/EiJ)
increased spleen weight J:117545
\Swqnd1NMRI8/Fbn/?
(involves: DBA/2OlaHsd * NMRI8/Fbn)
decreased spleen weight J:122125
\Swqnd2NMRI8/Fbn/?
(involves: DBA/2OlaHsd * NMRI8/Fbn)
decreased spleen weight J:122125
\Swrl1NZB/\Swrl1NZB
(involves: NZB * SWR)
abnormal type II hypersensitivity reaction J:73097
\Swrl1NZB/\Swrl1SWR
(involves: NZB * SWR)
abnormal type II hypersensitivity reaction J:73097
\Swrl1SWR/\Swrl1SWR
(involves: NZB * SWR)
increased IgG3 level J:96263
\Swrl2NZB/\Swrl2SWR
(involves: NZB * SWR)
glomerulonephritis J:73097
\Swrl2SWR/\Swrl2SWR
(involves: NZB * SWR)
glomerulonephritis J:73097
increased anti-single stranded DNA antibody level J:96060
\Swrl3NZB/\Swrl3SWR
(involves: NZB * SWR)
increased anti-double stranded DNA antibody level J:96060
increased anti-histone antibody level J:96060
increased anti-nuclear antigen antibody level J:73097
\Swrl3SWR/\Swrl3SWR
(involves: NZB * SWR)
increased anti-double stranded DNA antibody level J:96060
increased anti-histone antibody level J:96060
increased anti-nuclear antigen antibody level J:73097
\Swt1em1(IMPC)J/\Swt1em1(IMPC)J
(C57BL/6NJ-Swt1em1(IMPC)J/Mmjax)
increased leukocyte cell number J:211773
\Sycntm1Rja/\Sycntm1Rja
(involves: 129P2/OlaHsd)
increased susceptibility to induced pancreatitis J:74654
\Sykm1Btlr/\Sykm1Btlr
(involves: C57BL/6J)
decreased B cell number J:199281
increased neutrophil cell number J:199281
increased tumor necrosis factor secretion J:199281
\SykM2Btlr/\Syk+
(C57BL/6J-SykM2Btlr)
abnormal NK cell differentiation J:231803
decreased inflammatory response J:231803
\SykM2Btlr/\SykM2Btlr
(C57BL/6J-SykM2Btlr)
abnormal NK cell differentiation J:231803
decreased inflammatory response J:231803
\Syktm1.1(cre)Fkfr/\Syktm1.1(cre)Fkfr
\Gt(ROSA)26Sortm1(EYFP)Cos/\Gt(ROSA)26Sortm1(EYFP)Cos

(involves: 129S1/Sv * 129X1/SvJ)
abnormal lymphangiogenesis J:159112
decreased leukocyte cell number J:159112
increased leukocyte cell number J:159112
\Syktm1.1Nns/\Syktm1.1Nns
\Commd10Tg(Vav1-icre)A2Kio/\Commd10+

(involves: C57BL/10 * CBA/Ca)
abnormal lymphatic vessel morphology J:181715
\Syktm1.1Nns/\Syktm1.1Nns
\Lyz2tm1(cre)Ifo/\Lyz2+

(involves: 129P2/OlaHsd)
immune system phenotype J:181715
\Syktm1.1Nns/\Syktm1.1Nns
\Tg(CD2-icre)4Kio/0

(involves: C57BL/10 * CBA/Ca)
immune system phenotype J:181715
\Syktm1.1Nns/\Syktm1.1Nns
\Tg(Pf4-icre)Q3Rsko/0

(involves: C57BL/6)
abnormal lymphatic vessel endothelial cell morphology J:181715
abnormal lymphatic vessel morphology J:181715
\Syktm1.1Nns/\Syktm1.1Nns
\Tg(Tie1-cre)9Ref/0
\Commd10Tg(Vav1-icre)A2Kio/\Commd10+

(involves: 129S1/Sv * 129X1/SvJ * C57BL/10 * CBA/Ca)
abnormal lymphatic vessel morphology J:181715
\Syktm1.1Tara/\Syktm1.1Tara
(involves: 129P2/OlaHsd * C57BL/6)
arrested B cell differentiation J:115080
increased B cell proliferation J:114816
\Syktm1.2Tara/\Syktm1.2Tara
\Tg(Cr2-cre)3Cgn/0

(involves: 129P2/OlaHsd)
abnormal B cell morphology J:208904
\Syktm1.2Tara/\Syktm1.2Tara
\Tg(Itgax-cre)1-1Reiz/0

(involves: 129P2/OlaHsd * C57BL/6 * CBA)
immune system phenotype J:181715
\Syktm1Kuro/\Syktm1Kuro
\Zap70tm1Dlo/\Zap70tm1Dlo
\Cd79atm1(cre)Reth/?

(involves: 129P2/OlaHsd * BALB/c * C57BL/6)
abnormal pro-B cell differentiation J:134528
\Syktm1Paw/\Syktm1Paw
(involves: 129S1/Sv * 129X1/SvJ)
abnormal B cell differentiation J:29797
abnormal lymphangiogenesis J:159112
abnormal lymphatic vessel endothelium morphology J:159112
abnormal lymphatic vessel morphology J:159112
absent pre-B cells J:29797
decreased late pro-B cell number J:29797
enlarged lymphatic vessel J:159112
lymphatic vessel hyperplasia J:159112
\Syktm1Tyb/\Syktm1.2Tara
\Lyz2tm1(cre)Ifo/\Lyz2+

(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6)
abnormal neutrophil physiology J:155479
impaired granulocyte bactericidal activity J:155479
\Syktm1Tyb/\Syktm1.2Tara
\Tg(S100A8-cre,-EGFP)1Ilw/0

(involves: 129P2/OlaHsd * 129S2/SvPas * C3H * C57BL/6)
impaired granulocyte bactericidal activity J:155479
\Syktm1Tyb/\Syktm1Tyb
(involves: 129S2/SvPas * C57BL/6 * DBA/2)
abnormal T cell number J:29796
arrested B cell differentiation J:29796
\Syktm1Tyb/\Syktm1Tyb
(involves: 129S2/SvPas * C57BL/6)
abnormal osteoclast differentiation J:89583
\Syktm1Tyb/\Syktm1Tyb
(involves: 129S2/SvPas)
abnormal dendritic cell antigen presentation J:147472
abnormal neutrophil physiology J:155479
decreased tumor necrosis factor secretion J:155479
impaired granulocyte bactericidal activity J:155479
impaired neutrophil phagocytosis J:155479
\Syktm1Tyb/\Syktm1Tyb
(involves: 129S2/SvPas * C57BL/6J)
abnormal lymphatic vessel morphology J:181715
decreased lymphatic vessel endothelial cell number J:181715
\Syktm2.1(ZAP70)Fkfr/\Syktm2.1(ZAP70)Fkfr
(B6.129-Syktm2.1(ZAP70)Fkfr)
abnormal B cell physiology J:188422
abnormal neutrophil physiology J:188422
arrested B cell differentiation J:188422
decreased B cell number J:188422
decreased DN1 thymic pro-T cell number J:188422
decreased IgG1 level J:188422
decreased IgG2a level J:188422
decreased IgG2b level J:188422
decreased marginal zone B cell number J:188422
decreased mature B cell number J:188422
decreased transitional stage B cell number J:188422
decreased transitional stage T1 B cell number J:188422
decreased transitional stage T2 B cell number J:188422
glomerulonephritis J:188422
immune system phenotype J:188422
increased anti-insulin autoantibody level J:188422
increased B cell apoptosis J:188422
increased CD4-positive, alpha-beta memory T cell number J:188422
increased CD4-positive, alpha-beta T cell number J:188422
increased CD8-positive, alpha-beta memory T cell number J:188422
increased CD8-positive, alpha-beta T cell number J:188422
increased DN3 thymocyte number J:188422
increased IgM level J:188422
\Syne1tm1.1Mcn/\Syne1tm1.1Mcn
(involves: 129S4/SvJae * 129S6/SvEvTac * C57BL)
conjunctivitis J:144757
\Syngr1em1(IMPC)Ccpcz/\Syngr1em1(IMPC)Ccpcz
(C57BL/6NCrl-Syngr1em1(IMPC)Ccpcz/Ccpcz)
abnormal lymph node morphology J:211773
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged lymph nodes J:211773
enlarged spleen J:211773
enlarged thymus J:211773
\Syngr3em1Pave/\Syngr3+
\Tg(Prnp-MAPT*P301S)PS19Vle/0

(involves: C3H * C57BL/6)
microgliosis J:303506
\Synj1tm1b(EUCOMM)Wtsi/\Synj1+
(C57BL/6N-Synj1tm1b(EUCOMM)Wtsi/H)
decreased monocyte cell number J:211773
decreased neutrophil cell number J:211773
increased lymphocyte cell number J:211773
\Synpo2tm1b(EUCOMM)Wtsi/\Synpo2+
(C57BL/6N-Synpo2tm1b(EUCOMM)Wtsi/Ics)
decreased leukocyte cell number J:211773
decreased lymphocyte cell number J:211773
increased neutrophil cell number J:211773
\Syt7tm1Nan/\Syt7tm1Nan
(involves: 129S1/Sv * C57BL/6)
increased anti-nuclear antigen antibody level J:85201
increased inflammatory response J:85201
increased susceptibility to autoimmune disorder J:85201
myositis J:85201
\Sytl1tm1a(KOMP)Wtsi/\Sytl1tm1a(KOMP)Wtsi
(involves: C57BL/6 * C57BL/6N)
decreased CD4-positive, alpha-beta T cell number J:213427
decreased IgG2b level J:213427
decreased mature B cell number J:213427
decreased T cell number J:213427
epididymis inflammation J:213427
increased regulatory T cell number J:213427
meningitis J:213427
\Syvn1tm1Tn/\Syvn1+
(D1.Cg-Syvn1tm1Tn)
decreased susceptibility to induced arthritis J:86009
\tAE5/\tAE5
(Not Specified)
abnormal spleen morphology J:83862
abnormal thymus cortex morphology J:83862
abnormal thymus morphology J:83862
decreased spleen white pulp amount J:83862
increased mast cell number J:83862
increased susceptibility to infection J:83862
thymus cortex hypoplasia J:83862
\Tab2tm2.1Aki/\Tab2tm2.1Aki
\Tab3tm1Aki/\Tab3tm1Aki
\Cd19tm1(cre)Cgn/\Cd19+

(involves: 129P2/OlaHsd * C57BL/6)
abnormal B cell physiology J:195289
abnormal immune serum protein physiology J:195289
decreased B cell proliferation J:195289
decreased B-1a cell number J:195289
decreased circulating interleukin-6 level J:195289
decreased IgD level J:195289
decreased IgE level J:195289
decreased IgG level J:195289
decreased immunoglobulin level J:195289
decreased mature B cell number J:195289
decreased plasma cell number J:195289
increased B cell apoptosis J:195289
\Tab2tm2.1Aki/\Tab2tm2.1Aki
\Tab3tm1Aki/\Tab3tm1Aki
\Lyz2tm1(cre)Ifo/\Lyz2+

(involves: 129P2/OlaHsd * C57BL/6)
immune system phenotype J:195289
\Tac4tm1Albe/\Tac4tm1Albe
(B6.129P2-Tac4tm1Albe)
increased pro-B cell number J:166471
\Tacc3tm1Jni/\Tacc3tm1Jni
(involves: 129P2/OlaHsd * C57BL/6)
decreased thymocyte number J:74762
small thymus J:74762
\Tacr1tm1Nge/\Tacr1tm1Nge
(involves: 129S4/SvJae)
abnormal humoral immune response J:35529
\Tacr1tm1Nge/\Tacr1tm1Nge
(involves: 129S4/SvJae * C57BL)
abnormal mast cell physiology J:84660
\Tacr1tm1Sph/\Tacr1tm1Sph
(involves: 129P2/OlaHsd * C57BL/6)
decreased inflammatory response J:46629
joint inflammation J:103700
\Taf4tm1Idvd/\Taf4tm1Idvd
\Tg(KRT14-cre/ERT2)1Ipc/0

(involves: C57BL/6 * SJL)
chronic inflammation J:124111
\Taf7tm1.1Dss/\Taf7tm1.2Dss
\Tg(Cd8a*-cre)B8Asin/0

(involves: C57BL/6)
abnormal T cell differentiation J:185745
decreased CD4-positive, alpha-beta T cell number J:185745
decreased CD8-positive, alpha-beta T cell number J:185745
decreased double-positive T cell number J:185745
decreased single-positive T cell number J:185745
decreased T cell number J:185745
decreased T cell proliferation J:185745
decreased thymocyte number J:185745
\Taf7tm1.1Dss/\Taf7tm1.2Dss
\Tg(Lck-cre)1Cwi/0

(involves: C57BL/6)
abnormal T cell differentiation J:185745
abnormal thymus physiology J:185745
decreased CD4-positive, alpha-beta T cell number J:185745
decreased CD8-positive, alpha-beta T cell number J:185745
decreased double-positive T cell number J:185745
decreased thymocyte number J:185745
increased double-negative T cell number J:185745
small thymus J:185745
\Taf15em1(IMPC)Mbp/\Taf15em1(IMPC)Mbp
(C57BL/6NCrl-Taf15em1(IMPC)Mbp/MbpMmucd)
increased lymphocyte cell number J:211773
\Tagap1em1(IMPC)Tcp/\Tagap1+
(C57BL/6N-Tagap1em1(IMPC)Tcp/Tcp)
enlarged lymph nodes J:211773
enlarged spleen J:211773
\Tagln2em1(IMPC)Tcp/\Tagln2em1(IMPC)Tcp
(C57BL/6N-Tagln2em1(IMPC)Tcp/Tcp)
decreased lymphocyte cell number J:211773
enlarged spleen J:211773
increased neutrophil cell number J:211773
\Tagln2tm1Cdj/\Tagln2tm1Cdj
(involves: 129S4/SvJae * C57BL/6)
abnormal cytotoxic T cell physiology J:256656
abnormal T cell physiology J:256656
immune system phenotype J:256656
\Tagln2tm1Cdj/\Tagln2tm1Cdj
\Tg(TcraTcrb)425Cbn/0

(involves: 129S4/SvJae * C57BL/6)
abnormal T cell activation J:256656
\Tagln2tm1Cdj/\Tagln2tm1Cdj
\Tg(TcraTcrb)1100Mjb/0

(involves: 129S4/SvJae * C57BL/6)
abnormal T cell activation J:256656
\Tal1Hpt/\Tal1+
(HPT/Le)
decreased leukocyte cell number J:1780
\Tal1tm1Por/\Tal1tm1Por
(involves: 129P2/OlaHsd)
increased spleen weight J:139179
\Tal1tm3Wehi/\Tal1tm2Wehi
\Tg(Mx1-cre)1Cgn/0

(involves: 129S1/Sv * C57BL/6 * CBA)
abnormal splenic cell ratio J:81826
\Tanktm1Aki/\Tanktm1Aki
(involves: 129/Sv * C57BL/6)
abnormal dendritic cell physiology J:151757
abnormal macrophage physiology J:151757
abnormal plasmacytoid dendritic cell physiology J:151757
glomerulonephritis J:151757
increased anti-double stranded DNA antibody level J:151757
increased anti-nuclear antigen antibody level J:151757
increased B cell proliferation J:151757
increased IgA level J:151757
increased IgG1 level J:151757
increased IgG2a level J:151757
increased IgG2b level J:151757
increased IgM level J:151757
increased interferon-alpha secretion J:151757
increased interleukin-6 secretion J:151757
increased mature B cell number J:151757
increased plasma cell number J:151757
increased tumor necrosis factor secretion J:151757
liver inflammation J:151757
lung inflammation J:151757
lymph node hyperplasia J:151757
spleen hyperplasia J:151757
\Taok1em1(IMPC)Tcp/\Taok1+
(C57BL/6NCrl-Taok1em1(IMPC)Tcp/Tcp)
increased monocyte cell number J:211773
\Tap1m1Btlr/\Tap1m1Btlr
(C57BL/6J-Tap1m1Btlr)
decreased CD8-positive, alpha-beta memory T cell number J:254888
increased CD4-positive, CD25-positive, alpha-beta regulatory T cell number J:254888
\Tap1m2Btlr/\Tap1m2Btlr
(C57BL/6J-Tap1m2Btlr)
decreased CD8-positive, alpha-beta T cell number J:236697
increased susceptibility to Herpesvirales infection J:236697
\Tap1rose/\Tap1rose
(C57BL/6JAnu-Tap1rose/AnuApb)
decreased CD8-positive, alpha-beta T cell number J:166104
\Tap1tm1Arp/\Tap1tm1Arp
(involves: 129S2/SvPas * C57BL/6)
abnormal antigen presentation J:122479
abnormal dendritic cell antigen presentation J:112436
abnormal lymphocyte physiology J:122479
absent CD8-positive, alpha-beta T cells J:3524
decreased double-negative T cell number J:3524
decreased level of surface class I molecules J:3524
defective intracellular transport of class I molecules J:3524
\Tap1tm1Arp/\Tap1tm1Arp
(involves: 129S2/SvPas)
abnormal antigen presentation via MHC class I J:64349
abnormal dendritic cell antigen presentation J:64349
decreased CD8-positive, alpha-beta T cell number J:64177, J:64349
decreased cytotoxic T cell cytolysis J:64349
decreased level of surface class I molecules J:64177, J:64349
defective assembly of class I molecules J:64177
defective intracellular transport of class I molecules J:64177
\Tap1tm1Arp/\Tap1tm1Arp
(B6.129S2-Tap1tm1Arp/J)
decreased CD8-positive, alpha-beta T cell number J:123934
decreased susceptibility to bacterial infection J:123934
decreased susceptibility to bacterial infection induced morbidity/mortality J:123934
increased T-helper 1 cell number J:123934
\Tap1tm1Arp/\Tap1tm1Arp
X/\Yaa

(BXSB.129S2(B6)-Tap1tm1Arp/Dcr)
increased susceptibility to systemic lupus erythematosus J:179430
\Tap1tm1Hpl/\Tap1tm1Hpl
(either: (involves: 129S2/SvPas * 129/Ola) or (involves: 129S2/SvPas * FVB))
immune system phenotype J:60782
\Tap2jas/\Tap2jas
(C57BL/6JSfdAnu-Tap2jas/AnuApb)
absent CD8-positive, alpha-beta T cells J:104190
decreased CD8-positive, alpha-beta T cell number J:166104
\Tap2m1Btlr/\Tap2m1Btlr
(C57BL/6J-Tap2m1Btlr)
abnormal cytotoxic T cell physiology J:159355
abnormal NK cell physiology J:159355
absent CD8-positive, alpha-beta T cells J:159355
decreased level of surface class I molecules J:159355
defective assembly of class I molecules J:159355
\Tap2m2Btlr/\Tap2m2Btlr
(C57BL/6J-Tap2m2Btlr)
decreased CD8-positive, alpha-beta T cell number J:217145
increased CD4-positive, alpha-beta T cell number J:217145
\Tap2m3Btlr/\Tap2m3Btlr
(C57BL/6J-Tap2m3Btlr)
decreased CD8-positive, alpha-beta T cell number J:254929
decreased CD8-positive, naive alpha-beta T cell number J:254929
decreased effector memory CD4-positive, alpha-beta T cell number J:254929
decreased NK T cell number J:254929
increased CD4-positive, alpha-beta T cell number J:254929
increased central memory CD8 positive, alpha-beta T cell number J:254929
\Tap2M4Btlr/\Tap2M4Btlr
(C57BL/6J-Tap2M4Btlr)
increased CD4-positive, alpha-beta T cell number J:272847
\Tapbptm1Gjh/\Tapbptm1Gjh
(involves: 129S2/SvPas)
abnormal antigen presentation via MHC class I J:64349
abnormal dendritic cell antigen presentation J:64349
abnormal NK cell physiology J:64349
decreased cytotoxic T cell cytolysis J:64349
decreased level of surface class I molecules J:64349
decreased T cell number J:64349
\Tapbptm1Luc/\Tapbptm1Luc
(involves: 129S6/SvEvTac * C57BL/6)
abnormal lymphocyte physiology J:122479
\Tapbptm1Luc/\Tapbptm1Luc
(involves: 129S6/SvEvTac)
abnormal antigen presentation via MHC class I J:64177
abnormal cytotoxic T cell physiology J:64177
decreased CD8-positive, alpha-beta T cell number J:64177
decreased level of surface class I molecules J:64177
defective assembly of class I molecules J:64177
\Tapbptm1Luc/\Tapbptm1Luc
\Tg(TcraTcrb)1100Mjb/?

(involves: 129S6/SvEvTac * C57BL/6)
abnormal CD4-positive, alpha beta T cell morphology J:64177
abnormal CD8-positive, alpha beta T cell morphology J:64177
abnormal negative T cell selection J:64177
abnormal positive T cell selection J:64177
immune system phenotype J:64177
\Tapbptm1Luc/\Tapbptm1Luc
\Tg(TcraTcrb)1100Mjb/?

(involves: 129S6/SvEvTac)
immune system phenotype J:64177
\TaprBALB/c/?
(involves: BALB/c * DBA/2)
abnormal inflammatory response J:72894
\Tardbptm1.1Neas/\Tardbptm1.1Neas
(B6(C3)-Tardbptm1.1Neas)
microgliosis J:283769
\Tardbptm2.1Neas/\Tardbptm2.1Neas
(B6(C3)-Tardbptm2.1Neas)
microgliosis J:283769
\Tarm1tm1Yiw/\Tarm1tm1Yiw
(involves: C57BL/6 * C57BL/6NSlc)
abnormal dendritic cell antigen presentation J:301164
abnormal dendritic cell differentiation J:301164
abnormal interleukin-6 secretion J:301164
abnormal lymphocyte physiology J:301164
abnormal tumor necrosis factor secretion J:301164
decreased B cell number J:301164
decreased CD4-positive, alpha-beta T cell number J:301164
decreased dendritic cell number J:301164
decreased IgG2a level J:301164
decreased IgG2b level J:301164
decreased IgG3 level J:301164
decreased interferon-gamma secretion J:301164
decreased interleukin-17 secretion J:301164
decreased susceptibility to induced arthritis J:301164
decreased T cell proliferation J:301164
decreased tumor necrosis factor secretion J:301164
immune system phenotype J:301164
\Tars3em1(IMPC)J/\Tars3em1(IMPC)J
(C57BL/6NJ-Tars3em1(IMPC)J/Mmjax)
increased leukocyte cell number J:211773
\Tas2r131em1(IMPC)Bay/\Tas2r131em1(IMPC)Bay
(C57BL/6N-Tas2r131em1(IMPC)Bay/Bay)
abnormal spleen morphology J:211773
\Tas2r139em1(IMPC)Mbp/\Tas2r139em1(IMPC)Mbp
(C57BL/6NCrl-Tas2r139em1(IMPC)Mbp/Mmucd)
abnormal spleen morphology J:211773
small spleen J:211773
\Taslem1Bcgen/\Taslem1Bcgen
(BALB/cJ-Taslem1Bcgen)
abnormal immune cell physiology J:363059
decreased interferon level J:363059
decreased susceptibility to systemic lupus erythematosus J:363059
\Tasp1tm1Jjdh/\Tasp1tm1Jjdh
\Tg(Mx1-cre)1Cgn/?

(involves: 129X1/SvJ * C57BL/6 * CBA)
decreased double-positive T cell number J:112159
decreased thymocyte number J:112159
decreased thymus weight J:112159
\Tax1bp1tm1Ktj/\Tax1bp1tm1Ktj
(B6.129P2-Tax1bp1tm1Ktj)
abnormal hypersensitivity reaction J:131849
abnormal leukocyte physiology J:131849
abnormal macrophage chemotaxis J:131849
abnormal neutrophil physiology J:131849
abnormal T cell physiology J:131849
cardiovalvulitis J:131849
increased interleukin-1 beta secretion J:131849
increased interleukin-2 secretion J:131849
increased tumor necrosis factor secretion J:131849
skin inflammation J:131849
\tb/\tb
(Not Specified)
abnormal thymus involution J:12166
\Tbatatm1Faf/\Tbatatm1Faf
(involves: 129P2/OlaHsd * C57BL/6)
abnormal thymus epithelium morphology J:166065
enlarged thymus J:166065
immune system phenotype J:166065
increased double-negative T cell number J:166065
increased thymocyte number J:166065
thymus hyperplasia J:166065
\Tbc1d4tm1.1Arte/\Tbc1d4tm1.1Arte
(involves: C57BL/6)
decreased spleen weight J:169477
\Tbc1d4tm1b(EUCOMM)Hmgu/\Tbc1d4tm1b(EUCOMM)Hmgu
(C57BL/6N-Tbc1d4tm1b(EUCOMM)Hmgu/J)
decreased leukocyte cell number J:211773
\Tbc1d7em1(IMPC)Bay/\Tbc1d7+
(C57BL/6N-Tbc1d7em1(IMPC)Bay/Bay)
abnormal lymph node morphology J:211773
enlarged spleen J:211773
\Tbc1d8bem1(IMPC)Bay/Y
(C57BL/6N-Tbc1d8bem1(IMPC)Bay/BayMmucd)
decreased spleen weight J:211773
\Tbc1d10ctm1.1Psou/\Tbc1d10ctm1.2Psou
\Cd79atm1(cre)Reth/\Cd79a+

(involves: 129S2/SvPas * BALB/c * C57BL/6J)
abnormal B cell physiology J:211913
increased anti-double stranded DNA antibody level J:211913
increased IgG level J:211913
increased IgM level J:211913
increased susceptibility to systemic lupus erythematosus J:211913
\Tbc1d10ctm1.1Psou/\Tbc1d10ctm1.2Psou
\Tg(Lck-cre)#Nik/0

(involves: 129S2/SvPas * C57BL/6 * C57BL/6J * DBA/2)
immune system phenotype J:211913
\Tbc1d10ctm1.2Psou/\Tbc1d10ctm1.2Psou
(involves: 129S2/SvPas * C57BL/6J)
abnormal B cell physiology J:211913
abnormal response to infection J:211913
abnormal T cell activation J:211913
immune system phenotype J:211913
increased anti-double stranded DNA antibody level J:211913
increased IgG level J:211913
increased susceptibility to systemic lupus erythematosus J:211913
increased T cell proliferation J:211913
\Tbc1d23Gt(BA0556)Wtsi/\Tbc1d23Gt(BA0556)Wtsi
(B6.129P2-Tbc1d23Gt(BA0556)Wtsi)
abnormal tumor necrosis factor level J:181861
increased circulating interleukin-6 level J:181861
increased circulating tumor necrosis factor level J:181861
increased inflammatory response J:181861
\Tbc1d32b2b2284Clo/\Tbc1d32b2b2284Clo
(C57BL/6J-Tbc1d32b2b2284Clo)
spleen hypoplasia J:175213
\Tbk1M1Btlr/\Tbk1+
(involves: C57BL/6J)
abnormal interferon secretion J:188770
abnormal macrophage physiology J:188770
\Tbk1tm1.1Lex/\Tbk1+
(involves: 129S4/SvJae * 129S5/SvEvBrd)
abnormal inflammatory response J:166476
decreased basophil cell number J:166476
decreased eosinophil cell number J:166476
\Tbk1tm1.1Lex/\Tbk1tm1.1Lex
(involves: 129S4/SvJae * 129S5/SvEvBrd)
abnormal cytokine level J:166476
abnormal cytokine secretion J:166476
abnormal inflammatory response J:166476
decreased interferon-beta secretion J:166476
decreased NK T cell number J:166476
increased circulating interleukin-1 beta level J:166476
increased circulating interleukin-6 level J:166476
increased circulating interleukin-10 level J:166476
increased circulating tumor necrosis factor level J:166476
increased IgA level J:166476
increased interleukin-6 secretion J:166476
increased monocyte cell number J:166476
increased NK T cell number J:166476
increased spleen weight J:166476
increased susceptibility to bacterial infection induced morbidity/mortality J:166476
increased susceptibility to endotoxin shock J:166476
increased tumor necrosis factor secretion J:166476
lymphoid hyperplasia J:166476
skin inflammation J:166476
\Tbk1tm1Aki/\Tbk1tm1Aki
\Tnftm1Sek/\Tnftm1Sek

(involves: 129P2/OlaHsd * C57BL/6 * CBA)
abnormal cytotoxic T cell physiology J:132662
decreased cytotoxic T cell cytolysis J:132662
decreased IgG1 level J:132662
decreased IgG2a level J:132662
decreased IgG level J:132662
decreased interferon-gamma secretion J:132662
\Tbk1tm1Arte/\Tbk1tm1Arte
\Cd19tm1(cre)Cgn/\Cd19+

(involves: 129/SvEv * 129P2/OlaHsd * C57BL/6)
abnormal B cell physiology J:188560
abnormal class switch recombination J:188560
increased anti-double stranded DNA antibody level J:188560
increased anti-nuclear antigen antibody level J:188560
increased IgA level J:188560
increased IgM level J:188560
increased mature B cell number J:188560
\Tbk1tm1Arte/\Tbk1tm1Arte
\Map3k14tm1Rds/\Map3k14tm1Rds
\Cd19tm1(cre)Cgn/\Cd19+

(involves: 129/SvEv * 129P2/OlaHsd * C57BL/6)
abnormal B cell differentiation J:188560
abnormal immunoglobulin level J:188560
\Tbkbp1tm1Aki/\Tbkbp1tm1Aki
(Not Specified)
immune system phenotype J:204786
\Tbkbp1tm1b(EUCOMM)Wtsi/\Tbkbp1tm1b(EUCOMM)Wtsi
(C57BL/6N-Tbkbp1tm1b(EUCOMM)Wtsi/H)
increased leukocyte cell number J:211773
increased lymphocyte cell number J:211773
\Tbptm1.1Ees/\Tbptm1.1Ees
(B6.129X1(Cg)-Tbptm1.1Ees)
hemophagocytosis J:77714
\Tbrg1tm1a(KOMP)Wtsi/\Tbrg1tm1a(KOMP)Wtsi
(C57BL/6N-Tbrg1tm1a(KOMP)Wtsi)
enlarged spleen J:225146
increased marginal zone B cell number J:225146
increased spleen white pulp amount J:225146
\Tbrs1C57BL/6J/\Tbrs1C57BL/6J
(involves: C57BL/6J * DBA/2J)
decreased susceptibility to bacterial infection J:67658
\Tbrs2C57BL/6J/\Tbrs2C57BL/6J
(involves: C57BL/6J * DBA/2J)
decreased susceptibility to bacterial infection J:67658
\Tbrs2C57BL/6J/\Tbrs2DBA/2J
(involves: C57BL/6J * DBA/2J)
decreased susceptibility to bacterial infection J:67658
\Tbrs3C57BL/6J/\Tbrs3C57BL/6J
(involves: C57BL/6J * DBA/2J)
decreased susceptibility to bacterial infection J:67658
\Tbrs3C57BL/6J/\Tbrs3C57BL/6J
\Tbrs4C57BL/6J/\Tbrs4C57BL/6J

(involves: C57BL/6J * DBA/2J)
decreased susceptibility to bacterial infection J:83619
\Tbrs3C57BL/6J/\Tbrs3DBA/2J
(involves: C57BL/6J * DBA/2J)
decreased susceptibility to bacterial infection J:67658
\Tbrs4C57BL/6J/\Tbrs4C57BL/6J
(involves: C57BL/6J * DBA/2J)
decreased susceptibility to bacterial infection J:83619
\Tbs1I/StSnEgYCit/\Tbs1A/SnYCit
(involves: A/SnYCit * I/StSnEgYCit)
decreased susceptibility to bacterial infection J:80972
\Tbs2I/StSnEgYCit/\Tbs2A/SnYCit
(involves: A/SnYCit * I/StSnEgYCit)
decreased susceptibility to bacterial infection J:80972
\Tbx1m1H/\Tbx1m1H
(involves: C3H/HeH * C57BL/6J)
small thymus J:169366
\Tbx1m1Jlk/\Tbx1m1Jlk
(129/Sv-Tbx1m1Jlk)
athymia J:146769
\Tbx1m1Jlk/\Tbx1tm1Bld
(involves: 129)
athymia J:146769
\Tbx1tm1.1Dsr/\Tbx1tm1.1Dsr
(either: 129/Sv or (involves: 129/Sv * C57BL/6))
athymia J:93588
\Tbx1tm1Bem/\Tbx1+
(FVB.Cg-Tbx1tm1Bem)
increased susceptibility to otitis media J:91664
\Tbx1tm1Bem/\Tbx1tm1Bem
(FVB.Cg-Tbx1tm1Bem)
athymia J:91664
thymus hypoplasia J:91664
\Tbx1tm1Bld/\Tbx1tm1Bld
(involves: 129S7/SvEvBrd)
abnormal lymphangiogenesis J:159824
abnormal lymphatic vessel morphology J:159824
athymia J:146769
lymphangiectasis J:159824
\Tbx1tm1Bld/\Tbx1tm2.1Bem
\Tfap2atm1(cre)Moon/\Tfap2a+

(either: (involves: 129/Sv * C57BL/6 * SJL) or (involves: 129/Sv * C57BL/6J * CBA * SJL))
athymia J:154590
thymus hypoplasia J:154590
\Tbx1tm1Bld/\Tbx1tm3Bld
\Tg(CAG-cre/Esr1*)5Amc/0

(involves: 129S7/SvEvBrd * C57BL/6 * CBA)
abnormal lymphangiogenesis J:159824
abnormal lymphatic vessel morphology J:159824
\Tbx1tm1Bld/\Tbx1tm3Bld
\Tg(Tek-cre)1Ywa/0

(involves: 129S7/SvEvBrd * C57BL/6 * SJL)
abnormal lymphangiogenesis J:159824
abnormal lymphatic vessel morphology J:159824
\Tbx1tm1Bld/\Tbx1tm5Bld
(involves: 129S7/SvEvBrd * C57BL/6)
athymia J:112457
\Tbx1tm1Dsr/\Tbx1tm1Dsr
(either: 129/Sv or (involves: 129/Sv * C57BL/6))
athymia J:93588
\Tbx1tm1Pa/\Tbx1tm1Pa
(either: (involves: 129) or (involves: 129 * C57BL/6) or (involves: 129 * C57BL/6 * Swiss Webster))
abnormal thymus development J:70730
athymia J:70730
\Tbx1tm2.1Bem/\Tbx1tm2.2Bem
\Foxg1tm1(cre)Skm/\Foxg1+

(involves: 129 * C57BL/6J * SJL * Swiss Webster)
athymia J:105980
\Tbx3em1(IMPC)Mbp/\Tbx3+
(C57BL/6NCrl-Tbx3em1(IMPC)Mbp/MbpMmucd)
abnormal lymph node morphology J:211773
\Tbx20em1(IMPC)Mbp/\Tbx20+
(C57BL/6N-Tbx20em1(IMPC)Mbp/MbpMmucd)
increased neutrophil cell number J:211773
\Tbx21duane/\Tbx21duane
(C57BL/6-Tbx21duane)
abnormal NK cell differentiation J:154069
absent NK T cells J:154069
decreased NK cell number J:154069
increased NK cell number J:154069
\Tbx21m1Btlr/\Tbx21m1Btlr
(C57BL/6J-Tbx21m1Btlr)
increased CD8-positive, alpha-beta T cell number J:267478
increased effector memory CD8-positive, alpha-beta T cell number J:267478
increased IgM level J:267478
\Tbx21tm1.1(flpe/ERT2)Gmld/\Tbx21tm1.1(flpe/ERT2)Gmld
(involves: 129S2/SvPas * C57BL/6)
decreased interferon-gamma secretion J:207104
\Tbx21tm1Glm/\Tbx21+
(involves: 129S6/SvEvTac * C57BL/6)
abnormal cytokine level J:73833
abnormal interleukin level J:73832
abnormal NK cell physiology J:73833
abnormal tumor necrosis factor level J:73832
decreased T helper 1 cell number J:73833
\Tbx21tm1Glm/\Tbx21tm1Glm
(involves: 129S6/SvEvTac * C57BL/6)
abnormal CD8-positive, alpha-beta cytotoxic T cell morphology J:73833
abnormal cytokine level J:73832
abnormal immunoglobulin level J:73833
abnormal interleukin level J:73832
abnormal NK cell physiology J:73833
abnormal T-helper 1 cell differentiation J:73833
abnormal tumor necrosis factor level J:73832
decreased interferon-gamma secretion J:73833
decreased T helper 1 cell number J:73833
impaired natural killer cell mediated cytotoxicity J:73833
increased natural killer cell mediated cytotoxicity J:73833
increased susceptibility to parasitic infection J:73833
increased T-helper 2 cell number J:73833
respiratory system inflammation J:73832
\Tbx21tm1Glm/\Tbx21tm1Glm
(C.129S6-Tbx21tm1Glm/J)
abnormal CD4-positive, alpha-beta T cell physiology J:111932
abnormal cytokine secretion J:111932
CNS inflammation J:111932
decreased susceptibility to experimental autoimmune encephalomyelitis J:111932
\Tbx21tm1Glm/\Tbx21tm1Glm
(B6.129S6-Tbx21tm1Glm)
abnormal CD4-positive T cell differentiation J:143729
\Tbx21tm1Glm/\Tbx21tm1Glm
(involves: 129S6/SvEvTac)
abnormal cytokine level J:112600
abnormal leukocyte migration J:163822
decreased CD4-positive, alpha-beta T cell number J:163822
decreased memory T cell number J:163822
increased interleukin-17 secretion J:163822
increased susceptibility to induced colitis J:141481
\Tbx21tm1Srnr/\Tbx21+
(involves: C57BL/6)
absent NK T cells J:112679
decreased NK cell number J:112679
\Tbx21tm1Srnr/\Tbx21tm1Srnr
(involves: C57BL/6)
abnormal T-helper 1 cell morphology J:112679
decreased NK T cell number J:112679
\Tbx21tm2Srnr/\Tbx21+
\Tg(Cd4-cre)1Cwi/0

(involves: 129 * C57BL/6 * DBA/2)
decreased CD8-positive, alpha-beta T cell number J:174315
increased susceptibility to Riboviria infection J:174315
\Tbx21tm2Srnr/\Tbx21tm2Srnr
\Tg(Cd4-cre)1Cwi/0

(involves: 129 * C57BL/6 * DBA/2)
decreased CD8-positive, alpha-beta T cell number J:174315
immune system phenotype J:137655
increased interleukin-2 secretion J:174315
increased interleukin-17 secretion J:174315
increased susceptibility to Riboviria infection J:174315
increased tumor necrosis factor secretion J:174315
\Tbxa2rtm1Cof/\Tbxa2rtm1Cof
(either: (involves: 129P2/OlaHsd * C57BL/6 * DBA/2) or (involves: 129P2/OlaHsd * 129S/SvEv))
immune system phenotype J:52125
\Tbxa2rtm1Sna/\Tbxa2rtm1Sna
(either: (involves: 129/Ola * BALB/c) or (involves: 129/Ola * C57BL/6))
abnormal cervical lymph node morphology J:84085
abnormal immune serum protein physiology J:84085
abnormal immune system organ morphology J:84085
abnormal immune system physiology J:84085
abnormal lymph node morphology J:84085
abnormal type I hypersensitivity reaction J:84085
enlarged lymph nodes J:84085
enlarged spleen J:84085
\Tbxa2rtm1Sna/\Tbxa2rtm1Sna
(B6.Cg-Tbxa2rtm1Sna)
increased susceptibility to type I hypersensitivity reaction J:197334
\Tbxas1tm1Swl/\Tbxas1tm1Swl
(involves: 129P2/OlaHsd * BALB/c * C57BL/6J)
decreased inflammatory response J:90922
\Tcaf2em1(IMPC)Ccpcz/\Tcaf2em1(IMPC)Ccpcz
(C57BL/6NCrl-Tcaf2em1(IMPC)Ccpcz/Ccpcz)
abnormal lymph node morphology J:211773
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged lymph nodes J:211773
enlarged spleen J:211773
enlarged thymus J:211773
\Tcaimtm1b(EUCOMM)Wtsi/\Tcaimtm1b(EUCOMM)Wtsi
(C57BL/6N-Tcaimtm1b(EUCOMM)Wtsi/H)
decreased lymphocyte cell number J:211773
increased neutrophil cell number J:211773
\Tcdel1C57BL/6/\Tcdel1NOD/ShiLtDoi
(involves: C57BL/6 * NOD/ShLtDoi * SJL)
decreased double-negative T cell number J:97046
increased double-positive T cell number J:97046
\Tcdel1NOD/ShiLtDoi/\Tcdel1NOD/ShiLtDoi
(involves: C57BL/6 * NOD/ShLtDoi * SJL)
decreased double-negative T cell number J:97046
increased double-positive T cell number J:97046
\Tcdel2C57BL/6/\Tcdel2NOD/ShiLtDoi
(involves: C57BL/6 * NOD/ShLtDoi * SJL)
decreased double-negative T cell number J:97046
increased double-positive T cell number J:97046
\Tcdel2NOD/ShiLtDoi/\Tcdel2NOD/ShiLtDoi
(involves: C57BL/6 * NOD/ShLtDoi * SJL)
decreased double-negative T cell number J:97046
increased double-positive T cell number J:97046
\Tcea2em1(IMPC)J/\Tcea2em1(IMPC)J
(C57BL/6NJ-Tcea2em1(IMPC)J/Mmjax)
decreased leukocyte cell number J:211773
\Tceal3em1(IMPC)Tcp/Y
(C57BL/6NCrl-Tceal3em1(IMPC)Tcp/Tcp)
enlarged lymph nodes J:211773
\Tcf3tm1(PBX1)Mlc/\Tcf3+
\Cd19tm1(cre)Cgn/\Cd19+

(involves: 129P2/OlaHsd * C57BL/6)
abnormal B cell physiology J:226241
abnormal pro-B cell differentiation J:226241
abnormal pro-B cell morphology J:226241
arrested B cell differentiation J:226241
decreased B cell number J:226241
decreased immature B cell number J:226241
enlarged lymph nodes J:226241
enlarged spleen J:226241
increased leukocyte cell number J:226241
\Tcf3tm1(PBX1)Mlc/\Tcf3+
\Cd79atm1(cre)Reth/\Cd79a+

(involves: BALB/c * C57BL/6)
arrested B cell differentiation J:226241
decreased B cell number J:226241
decreased immature B cell number J:226241
enlarged lymph nodes J:226241
enlarged spleen J:226241
increased leukocyte cell number J:226241
\Tcf3tm1(PBX1)Mlc/\Tcf3+
\Tg(Mx1-cre)1Cgn/0

(involves: C57BL/6 * C57BL/6J * CBA/J)
arrested B cell differentiation J:226241
decreased B cell number J:226241
decreased immature B cell number J:226241
enlarged lymph nodes J:226241
enlarged spleen J:226241
increased leukocyte cell number J:226241
\Tcf3tm1(TCF3/HLF)Homy/\Tcf3+
\Tg(Mx1-cre)1Cgn/0

(involves: 129P2/OlaHsd * C57BL/6 * CBA)
abnormal B cell differentiation J:160392
increased B cell number J:160392
\Tcf3tm1.1Mbu/\Tcf3+
(involves: 129P2/OlaHsd * C57BL/6)
abnormal B cell differentiation J:137719
\Tcf3tm1Cmu/\Tcf3+
(either: 129P2/OlaHsd-Tcf3tm1Cmu or (involves: 129P2/OlaHsd * FVB/N))
decreased B cell number J:67011
\Tcf3tm1Cmu/\Tcf3tm1Cmu
(either: 129P2/OlaHsd-Tcf3tm1Cmu or (involves: 129P2/OlaHsd * FVB/N))
abnormal immunoglobulin heavy chain V(D)J recombination J:67011
abnormal immunoglobulin V(D)J recombination J:67011
abnormal T cell subpopulation ratio J:67011
decreased B cell number J:67011
decreased lymphocyte cell number J:67011
\Tcf3tm1Mbu/\Tcf3tm1.2Mbu
\Tg(Aicda-cre)9Mbu/0

(involves: 129P2/OlaHsd * C57BL/6 * CBA * SJL)
abnormal germinal center B cell morphology J:137719
decreased B cell number J:137719
decreased germinal center B cell number J:137719
immune system phenotype J:137719
\Tcf3tm1Mbu/\Tcf3tm1.2Mbu
\Tg(Fcer2a-cre)5Mbu/0

(involves: 129P2/OlaHsd * C57BL/6 * CBA * SJL)
abnormal germinal center B cell morphology J:137719
decreased B cell number J:137719
decreased germinal center B cell number J:137719
immune system phenotype J:137719
increased marginal zone B cell number J:137719
\Tcf3tm1Mbu/\Tcf3tm1Mbu
\Commd10Tg(Vav1-icre)A2Kio/\Commd10+

(involves: 129P2/OlaHsd * C57BL/10 * CBA/Ca)
decreased pro-B cell number J:137719
\Tcf3tm1Mbu/\Tcf3tm1Mbu
\Tg(Ikzf1-Tcfe2a,-GFP)1Mbu/0
\Commd10Tg(Vav1-icre)A2Kio/\Commd10+

(involves: 129P2/OlaHsd * C57BL * CBA)
immune system phenotype J:137719
\Tcf3tm1Wein/\Tcf3+
(either: (involves: 129/Sv * 129S4/SvJaeSor) or (involves: 129S4/SvJaeSor * C57BL/6J))
decreased B cell number J:22134
\Tcf3tm1Wein/\Tcf3+
(involves: 129S4/SvJaeSor)
abnormal B cell number J:91042
decreased pre-B cell number J:91042
\Tcf3tm1Wein/\Tcf3tm1Wein
(either: (involves: 129 * 129S4/SvJaeSor) or (involves: 129S4/SvJaeSor * C57BL/6J))
abnormal B cell number J:22134
abnormal lymphocyte cell number J:22134
spleen atrophy J:22134
\Tcf3tm1Wein/\Tcf3tm1Wein
(involves: 129S4/SvJaeSor * C57BL/6)
enlarged thymus J:44278
increased T cell derived lymphoma incidence J:44278
\Tcf3tm1Wein/\Tcf3tm3Zhu
(involves: 129/Sv * 129S4/SvJaeSor * C57BL/6)
decreased pro-B cell number J:47671
\Tcf3tm1Xhsu/\Tcf3tm1Xhsu
(B6.129X1-Tcf3tm1Xhsu)
immune system phenotype J:132669
increased B cell number J:132669
\Tcf3tm1Xhsu/\Tcf3tm1Xhsu
\Tg(Lck-Stat5b*)1Mafa/0

(involves: 129X1/SvJ * C57BL/6 * FVB/N)
increased B cell proliferation J:132669
\Tcf3tm1Zhu/\Tcf3tm1Zhu
(involves: 129)
decreased B cell number J:47671
\Tcf3tm1Zhu/\Tcf3tm1Zhu
(involves: 129 * C57BL/6J)
decreased double-positive T cell number J:136143
increased double-negative T cell number J:136143
increased single-positive T cell number J:136143
thymus hypoplasia J:136143
\Tcf3tm1Zhu/\Tcf3tm2Zhu
(involves: 129 * C57BL/6)
decreased B cell number J:47671
\Tcf3tm2Cmu/\Tcf3tm2Cmu
(involves: 129P2/OlaHsd)
abnormal lymphopoiesis J:118827
absent pre-B cells J:118827
absent pro-B cells J:118827
decreased dendritic cell number J:118827
decreased NK cell number J:118827
\Tcf3tm2Wein/\Tcf3tm2Wein
(Not Specified)
abnormal immune system morphology J:47671
increased T cell derived lymphoma incidence J:47671
\Tcf3tm2Zhu/\Tcf3tm2Zhu
(involves: 129 * C57BL/6)
decreased pre-B cell number J:47671
decreased pro-B cell number J:47671
\Tcf3tm3.1Cmu/\Tcf3tm3.1Cmu
(involves: 129S/SvEv * FVB/N)
abnormal B cell differentiation J:153423
abnormal immunoglobulin light chain V-J recombination J:153423
decreased pre-B cell number J:153423
\Tcf3tm3Zhu/\Tcf3tm3Zhu
(involves: 129/Sv * C57BL/6)
decreased B cell number J:47671
immune system phenotype J:47671
\Tcf3tm4.1Cmu/\Tcf3tm4.1Cmu
(involves: 129S/SvEv * FVB/N)
abnormal immunoglobulin light chain V-J recombination J:153423
absent B cells J:153423
arrested B cell differentiation J:153423
decreased pro-B cell number J:153423
\Tcf3tm4Zhu/\Tcf3tm4Zhu
\Tg(Lck-cre)#Zhu/0

(involves: 129S4/SvJae * C57BL/6 * SJL)
immune system phenotype J:75746
\Tcf3tm4Zhu/\Tcf3tm4Zhu
\Tg(Lck-cre)#Zhu/0
\Tg(TcrAND)53Hed/0

(involves: 129S4/SvJae * C57BL/6 * SJL)
immune system phenotype J:75746
\Tcf3tm5.1Cmu/\Tcf3tm5.1Cmu
(involves: 129S/SvEv * C57BL/6)
immune system phenotype J:183781
\Tcf3tm6(Esr1*)Zhu/\Tcf3tm6(Esr1*)Zhu
(involves: 129/Sv * C57BL/6)
abnormal immunoglobulin heavy chain V(D)J recombination J:154788
arrested B cell differentiation J:154788
\Tcf4tm1.1Hmb/\Tcf4+
(involves: 129P2/OlaHsd * C57BL/6J)
increased double-negative T cell number J:136143
\Tcf4tm1.1Hmb/\Tcf4tm1.1Hmb
(involves: 129P2/OlaHsd * C57BL/6J)
abnormal T cell differentiation J:136143
abnormal T cell physiology J:136143
immune system phenotype J:136143
increased double-negative T cell number J:136143
\Tcf4tm1Hmb/\Tcf4tm1Zhu
\Tg(Kit-cre)143Hmb/?

(involves: 129P2/OlaHsd * C57BL/6 * CBA)
abnormal B cell differentiation J:65236
decreased double-positive T cell number J:65236
decreased thymocyte number J:65236
spleen hypoplasia J:65236
\Tcf4tm1Zhu/\Tcf4+
\Tcf3tm1Wein/\Tcf3+

(involves: 129P2/OlaHsd)
decreased pro-B cell number J:43324
\Tcf4tm1Zhu/\Tcf4tm1Zhu
(involves: 129P2/OlaHsd * C57BL/6)
decreased pro-B cell number J:43324
\Tcf7tm1a(EUCOMM)Wtsi/\Tcf7tm1a(EUCOMM)Wtsi
(C57BL/6N-Tcf7tm1a(EUCOMM)Wtsi/Ics)
decreased CD4-positive, alpha-beta T cell number J:165965
decreased T cell number J:165965
increased B cell number J:165965
\Tcf7tm1Cle/\Tcf7tm1Cle
(involves: 129P2/OlaHsd)
abnormal memory T cell physiology J:189838
abnormal T cell differentiation J:23255
decreased CD8-positive, alpha-beta T cell number J:189838
decreased double-positive T cell number J:23255
decreased single-positive T cell number J:23255
decreased T cell number J:23255
increased osteoclast cell number J:98430
thymus cortex hypoplasia J:23255
thymus hypoplasia J:23255
\Tcf7tm2Cle/\Tcf7tm2Cle
(involves: 129P2/OlaHsd)
decreased double-positive T cell number J:23255
decreased single-positive T cell number J:23255
thymus hypoplasia J:23255
\Tcf7l2m1Btlr/\Tcf7l2m1Btlr
(C57BL/6J-Tcf7l2m1Btlr)
increased susceptibility to induced colitis J:267536
\Tcf12m1Btlr/\Tcf12m1Btlr
(C57BL/6J-Tcf12M1Btlr)
increased CD8-positive, alpha-beta T cell number J:267564
\Tcf12M2Btlr/\Tcf12M2Btlr
(C57BL/6J-Tcf12M2Btlr)
decreased CD4-positive, alpha-beta T cell number J:267666
increased CD8-positive, alpha-beta T cell number J:267666
increased effector memory CD4-positive, alpha-beta T cell number J:267666
\Tcf12M3Btlr/\Tcf12M3Btlr
(C57BL/6J-Tcf12M3Btlr)
decreased B cell number J:271971
decreased CD4-positive, alpha-beta T cell number J:271971
increased CD8-positive, alpha-beta T cell number J:271971
\Tcf12m4Btlr/\Tcf12m4Btlr
(C57BL/6J-Tcf12m4Btlr)
abnormal B cell morphology J:271972
abnormal T cell morphology J:271972
decreased CD4-positive, alpha-beta T cell number J:271972
increased CD8-positive, alpha-beta T cell number J:271972
\Tcf12tm1Zhu/\Tcf12+
\Tcf3tm1Wein/\Tcf3+

(involves: 129S4/SvJaeSor)
decreased pro-B cell number J:43324
\Tcf12tm1Zhu/\Tcf12+
\Tcf3tm4Zhu/\Tcf3tm4Zhu
\Tg(Lck-cre)#Zhu/0

(involves: 129S4/SvJae * 129S7/SvEvBrd * C57BL/6 * SJL)
abnormal T cell differentiation J:75746
increased double-negative T cell number J:75746
increased single-positive T cell number J:75746
\Tcf12tm1Zhu/\Tcf12+
\Tcf4tm1Zhu/\Tcf4+

(involves: 129P2/OlaHsd * 129S7/SvEvBrd)
decreased pro-B cell number J:43324
\Tcf12tm1Zhu/\Tcf12tm1Zhu
(involves: 129/Sv * C57BL/6)
decreased pro-B cell number J:43324
\Tcf12tm1Zhu/\Tcf12tm1Zhu
(involves: 129S7/SvEvBrd)
arrested T cell differentiation J:120411
decreased thymocyte number J:120411
\Tcf12tm1Zhu/\Tcf12tm1Zhu
(involves: 129S7/SvEvBrd * C57BL/6J)
decreased double-positive T cell number J:136143
increased CD8-positive, alpha-beta T cell number J:136143
increased double-negative T cell number J:136143
thymus hypoplasia J:136143
\Tcf12tm1Zhu/\Tcf12tm2Zhu
(involves: 129S7/SvEvBrd)
arrested T cell differentiation J:120411
\Tcf12tm2Zhu/\Tcf12tm2Zhu
(Not Specified)
abnormal B cell differentiation J:120411
abnormal response to transplant J:120411
abnormal T cell differentiation J:120411
absent T cells J:120411
arrested T cell differentiation J:120411
decreased double-positive T cell number J:120411
decreased immature B cell number J:120411
decreased pre-B cell number J:120411
decreased pro-B cell number J:120411
decreased thymocyte number J:120411
increased double-negative T cell number J:120411
thymus hypoplasia J:120411
\Tcf12tm2Zhu/\Tcf12tm2Zhu
\Tg(TcrAND)53Hed/0

(involves: C57BL/6 * SJL)
abnormal CD4-positive, alpha beta T cell morphology J:120411
abnormal T cell subpopulation ratio J:120411
arrested T cell differentiation J:120411
increased T cell number J:120411
\Tcf12tm3Zhu/\Tcf12tm3Zhu
\Tcf3tm4Zhu/\Tcf3tm4Zhu
\Tg(Cd4-cre)1Cwi/0

(involves: 129S4/SvJae * C57BL/6 * DBA/2)
abnormal CD8-positive, alpha beta T cell morphology J:129171
abnormal T cell differentiation J:129171
decreased CD4-positive, alpha-beta T cell number J:129171
increased CD8-positive, alpha-beta T cell number J:129171
\Tcf12tm3Zhu/\Tcf12tm3Zhu
\Tcf3tm4Zhu/\Tcf3tm4Zhu
\Tg(Lck-cre)#Zhu/0

(involves: 129S4/SvJae * C57BL/6 * SJL/J)
decreased double-positive T cell number J:129570
decreased T cell number J:129570
increased double-negative T cell number J:129570
increased T cell proliferation J:129570
thymus hypoplasia J:129570
\Tcf12tm3Zhu/\Tcf12tm3Zhu
\Tg(Lck-cre)#Zhu/0

(involves: C57BL/6 * SJL/J)
decreased thymocyte number J:129570
increased CD8-positive, alpha-beta T cell number J:129570
\Tcf21em1(IMPC)Mbp/\Tcf21+
(C57BL/6NCrl-Tcf21em1(IMPC)Mbp/MbpMmucd)
abnormal spleen morphology J:211773
small spleen J:211773
\Tcf21tm1Eno/\Tcf21tm1Eno
(involves: 129 * Black Swiss)
abnormal spleen development J:64068
absent spleen J:64068
\Tcf21tm2Eno/\Tcf21tm2Eno
(involves: 129 * Black Swiss)
abnormal spleen development J:64068
absent spleen J:64068
\Tcimtm1Icle/\Tcimtm1Icle
(B6.129-Tcimtm1Icle)
abnormal mononuclear cell morphology J:217318
increased eosinophil cell number J:217318
increased leukocyte cell number J:217318
increased lymphocyte cell number J:217318
increased monocyte cell number J:217318
increased neutrophil cell number J:217318
lymphoid hyperplasia J:217318
myeloid hyperplasia J:217318
\Tcirg1M1Jeau/\Tcirg1+
(either: (involves: C3H/HeJ * C57BL/6) or (involves: C3H/HeJ * C57BL/6 * FVB/N))
abnormal osteoclast morphology J:196503
abnormal osteoclast physiology J:196503
increased osteoclast cell number J:196503
\Tcirg1oc/\Tcirg1oc
(B6C3Fe a/a-Tcirg1oc/J)
abnormal osteoclast morphology J:7870
\Tcirg1tm1.2Ywd/\Tcirg1tm1.2Ywd
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * FVB/N * SJL)
abnormal macrophage physiology J:150327
\Tcirg1tm1Utku/\Tcirg1tm1Utku
(involves: 129X1/SvJ * C57BL/6)
abnormal immune serum protein physiology J:92730
abnormal immune system physiology J:92730
abnormal mesenteric lymph node morphology J:92730
abnormal peripheral lymph node morphology J:92730
abnormal Peyer's patch morphology J:92730
abnormal spleen B cell corona morphology J:92730
abnormal spleen morphology J:92730
abnormal spleen periarteriolar lymphoid sheath morphology J:92730
abnormal spleen red pulp morphology J:92730
abnormal spleen white pulp morphology J:92730
decreased B cell number J:92730
decreased lymphocyte cell number J:92730
decreased spleen B cell follicle size J:92730
decreased T cell number J:92730
increased granulocyte number J:92730
increased IgG1 level J:92730
increased IgG2a level J:92730
increased IgM level J:92730
increased immunoglobulin level J:92730
increased spleen germinal center number J:92730
thymus atrophy J:92730
\Tcirg1tm1Ypl/\Tcirg1tm1Ypl
(involves: 129S4/SvJae * C57BL/6J)
abnormal osteoclast physiology J:58795
\Tcpm1BALB/c/\Tcpm1BALB/c
(involves: BALB/c * C57BL/10)
abnormal effector T cell morphology J:36255
\Tcpm1BALB/c/\Tcpm1C57BL/10Sn
(involves: BALB/c * C57BL/10)
abnormal effector T cell morphology J:36255
\Tcra-Jtm1Jpdv/\Tcra-Jtm1Jpdv
(involves: 129P2/OlaHsd)
abnormal T cell differentiation J:77518
\Tcra-Jtm1Kgwa/\Tcra-Jtm1Kgwa
\Tg(Tcrb2B4)1Mmd/0

(involves: 129P2/OlaHsd * C3H/HeJ * C57BL/6J)
abnormal T cell differentiation J:50143
increased double-positive T cell number J:50143
\Tcra-Jtm1Slek/\Tcra-Jtm1Slek
(involves: 129P2/OlaHsd)
abnormal T cell differentiation J:101398
decreased double-positive T cell number J:101398
decreased single-positive T cell number J:101398
increased double-negative T cell number J:101398
increased thymocyte number J:101398
\Tcra-Jtm1Tgi/\Tcra-Jtm1Tgi
(B6.129-Tcra-Jtm1Tgi)
decreased activated T cell number J:99107
decreased B cell number J:99107
decreased circulating interleukin-5 level J:121037
decreased IgE level J:121037
decreased IgG level J:99107
decreased susceptibility to induced arthritis J:99107
increased incidence of corneal inflammation J:132503
liver inflammation J:135830
lung inflammation J:121037
\Tcra-Jtm1Tgi/\Tcra-Jtm1Tgi
(involves: 129S1/Sv * 129X1/SvJ)
decreased circulating interferon-gamma level J:155199
decreased interferon-gamma secretion J:155199
decreased susceptibility to bacterial infection J:155199
\Tcra-Jtm1Tgi/\Tcra-Jtm1Tgi
(involves: 129S1/Sv * 129X1/SvJ * BALB/c)
abnormal eosinophil cell number J:84720
abnormal immune serum protein physiology J:84720
abnormal interleukin secretion J:84720
decreased IgE level J:84720
decreased interleukin-4 secretion J:84720
decreased interleukin-13 secretion J:84720
liver inflammation J:105977
\Tcra-Jtm1Tgi/\Tcra-Jtm1Tgi
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
decreased NK T cell number J:89695
lung inflammation J:89695
\Tcra-Jtm1Tgi/\Tcra-Jtm1Tgi
(C.129-Tcra-Jtm1Tgi)
abnormal interleukin secretion J:184570
decreased interleukin-5 secretion J:184570
decreased interleukin-9 secretion J:184570
decreased interleukin-10 secretion J:184570
decreased interleukin-13 secretion J:184570
decreased interleukin-17 secretion J:184570
\Tcra-Jtm2.3Krg/\Tcra-Jtm2.3Krg
(involves: 129S/SvEv * C57BL/6)
abnormal T cell receptor alpha chain V-J recombination J:147326
\Tcra-Jtm3.1Krg/\Tcra-Jtm3.1Krg
(involves: 129S6/SvEvTac)
abnormal T cell differentiation J:128344
\Tcra-Jtm4.1Krg/\Tcra-Jtm4.1Krg
(involves: 129S6/SvEvTac)
abnormal T cell receptor alpha chain V-J recombination J:147326
\Tcra-Jtm5Krg/\Tcra-Jtm5Krg
(involves: 129S6/SvEvTac)
abnormal T cell receptor alpha chain V-J recombination J:147326
\TcraLn1Ogu/\Tcra+
(involves: 129/Sv * C57BL/6)
abnormal cytokine secretion J:152041
abnormal NK T cell morphology J:152041
abnormal T cell subpopulation ratio J:152041
decreased IgG2a level J:152041
decreased splenocyte number J:152041
decreased thymocyte number J:152041
increased IgG1 level J:152041
increased interferon-gamma secretion J:152041
increased interleukin-2 secretion J:152041
increased interleukin-4 secretion J:152041
increased interleukin-10 secretion J:152041
increased NK T cell number J:152041
\TcraLn1Ogu/\Tcra+
\TcrbLn1Ogu/\Tcrb+

(involves: 129/Sv * C57BL/6)
abnormal T cell morphology J:152069
\TcraLn2Ogu/\Tcra+
\TcrbLn2Ogu/\Tcrb+

(involves: 129/Sv * C57BL/6)
abnormal T cell morphology J:152069
\TcraLn3Jae/\Tcra+
(B6.Cg-TcraLn3Jae)
abnormal double-negative T cell morphology J:143006
decreased CD4-positive, alpha-beta T cell number J:143006
decreased double-positive T cell number J:143006
increased CD8-positive, alpha-beta T cell number J:143006
thymus hypoplasia J:143006
\TcraLn3Jae/\Tcra+
\TcrbLn3Jae/\Tcrb+

(B6.Cg-TcrbLn3Jae TcraLn3Jae)
abnormal double-negative T cell morphology J:143006
abnormal T cell differentiation J:143006
absent gamma-delta T cells J:143006
decreased CD4-positive, alpha-beta T cell number J:143006
decreased double-positive T cell number J:143006
increased CD8-positive, alpha-beta T cell number J:143006
thymus hypoplasia J:143006
\Tcratm1Cgn/\Tcratm1Cgn
\Tg(Mx1-cre)1Cgn/0

(involves: 129S7/SvEvBrd * C57BL/6 * CBA)
abnormal CD4-positive, alpha beta T cell morphology J:79298
abnormal CD8-positive, alpha beta T cell morphology J:79298
abnormal memory T cell morphology J:79298
abnormal T cell morphology J:79298
\Tcratm1Cgn/\Tcratm1Cgn
\Tg(Mx1-cre)1Cgn/0

(involves: C57BL/6 * CBA)
immune system phenotype J:201417
\Tcratm1Cgn/\Tcratm1Mass
\Tg(Mx1-cre)1Cgn/0

(involves: C57BL/6 * CBA)
abnormal T cell physiology J:201417
increased T cell number J:201417
\Tcratm1Mass/\Tcra+
\Tg(Cd4-cre)1Cwi/0

(involves: C57BL/6 * DBA/2)
abnormal NK T cell morphology J:201417
decreased NK cell number J:201417
increased NK T cell number J:201417
\Tcratm1Mass/\Tcra+
\Tg(Nes-cre)Wme/0

(involves: C57BL/6 * CBA)
abnormal positive T cell selection J:201417
decreased NK T cell number J:201417
decreased thymocyte number J:201417
increased double-negative T cell number J:201417
\Tcratm1Mass/\Tcratm1Mass
(involves: C57BL/6)
arrested T cell differentiation J:201417
\Tcratm1Mjo/\Tcra+
(NOD.129P2-Tcratm1Mjo)
abnormal T cell physiology J:108590
decreased susceptibility to autoimmune diabetes J:108590
\Tcratm1Mjo/\Tcra+
(SJL.129P2-Tcratm1Mjo)
immune system phenotype J:108590
\Tcratm1Mjo/\Tcratm1Mjo
(involves: 129P2/OlaHsd * BALB/c)
abnormal immune system organ morphology J:1292
abnormal splenic cell ratio J:1292
abnormal T cell morphology J:1292
abnormal thymus cortex morphology J:1292
absent thymus medulla J:1292
enlarged thymus cortex J:1292
increased activated T cell number J:111129
increased anti-double stranded DNA antibody level J:111129
increased anti-nuclear antigen antibody level J:111129
increased autoantibody level J:111129
increased B cell number J:111129
increased IgE level J:111129
increased IgG1 level J:111129
increased immunoglobulin level J:111129
small Peyer's patches J:1292
\Tcratm1Mjo/\Tcratm1Mjo
(NOD.129P2-Tcratm1Mjo)
increased activated T cell number J:52940
\Tcratm1Mjo/\Tcratm1Mjo
(involves: 129P2/OlaHsd)
colitis J:37699
decreased T cell proliferation J:110898
enlarged mesenteric lymph nodes J:110898
enlarged spleen J:110898
increased activated T cell number J:110898
increased gamma-delta T cell number J:110898
increased T cell number J:110898
spleen hyperplasia J:110898
\Tcratm1Mjo/\Tcratm1Mjo
X/\Yaa

(BXSB.129P2(Cg)-Tcratm1Mjo/Theo)
immune system phenotype J:120153
\Tcratm1Mom/\Tcra/Tcrdtm1.1(Tcra)Rsky
\H2b/\H2b
\Tg(Tcrb)93Vbo/?

(involves: 129P2/OlaHsd * C57BL/6J * DBA/2J)
abnormal double-negative T cell morphology J:131357
abnormal double-positive T cell morphology J:81564
abnormal negative T cell selection J:81564
abnormal T cell differentiation J:81564
decreased double-positive T cell number J:131357
decreased thymocyte number J:131357
\Tcratm1Mom/\Tcra/Tcrdtm1.1(Tcra)Rsky
\H2d/\H2d
\Ptcratm1Vbo/\Ptcratm1Vbo
\Tg(Tcrb)93Vbo/?

(involves: 129P2/OlaHsd * C57BL/6J * DBA/2J)
abnormal T cell differentiation J:131357
decreased thymocyte number J:131357
\Tcratm1Mom/\Tcratm1Mom
(involves: 129S2/SvPas)
absent T cells J:88620
\Tcratm1Mom/\Tcratm1Mom
(B6.129S2-Tcratm1Mom)
abnormal response to transplant J:91742
colitis J:135597
increased mature gamma-delta T cell number J:135597
increased susceptibility to bacterial infection J:106241
\Tcratm1Mom/\Tcratm1Mom
(involves: 129S2/SvPas * C57BL/6)
abnormal response to infection J:119344
arrested T cell differentiation J:3206
colitis J:15221
decreased CD4-positive, alpha-beta T cell number J:3206
decreased CD8-positive, alpha-beta T cell number J:3206
decreased IgG level J:119344
increased gamma-delta intraepithelial T cell number J:15221
\Tcratm1Mom/\Tcratm1Mom
\Tcra-Jtm1Kgwa/\Tcra-Jtm1Kgwa

(involves: 129P2/OlaHsd * 129S2/SvPas * C3H/HeJ * C57BL/6J)
increased double-negative T cell number J:50143
\Tcratm1Mom/\Tcratm1Mom
\Tcrbtm1Mom/\Tcrbtm1Mom

(involves: 129 * BALB/c * C57BL/6)
arrested T cell differentiation J:3206
decreased double-positive T cell number J:3206
thymus hypoplasia J:3206
\Tcratm1Mom/\Tcratm1Mom
\Tcrgtm1.1Hish/\Tcrgtm1.1Hish

(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6)
absent gamma-delta T cells J:135597
colitis J:135597
impaired macrophage chemotaxis J:135597
impaired neutrophil recruitment J:135597
\Tcratm1Mom/\Tcratm1Mom
\Tg(CD19-Tnfsf7)#Rvl/0

(involves: 129P2/OlaHsd * C57BL/6)
absent T cells J:88620
\Tcratm1Mom/\Tcratm1Mom
\Tg(Lck-Akt1*E40K)E-3Pnt/0

(involves: 129S2/SvPas * C3H/He * C57BL/6)
arrested T cell differentiation J:135903
\Tcratm1Mom/\Tcratm1Mom
\Tg(TcraAV19AJ33)1Shima/?

(involves: 129S2/SvPas * C57BL/6)
abnormal NK T cell morphology J:140924
abnormal NK T cell physiology J:140924
\Tcratm1Mom/\Tcratm1Mom
\Trex1tm1Tld/\Trex1tm1Tld

(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6)
colitis J:181257
immune system phenotype J:181257
increased inflammatory response J:181257
myositis J:181257
skin inflammation J:181257
\Tcratm1Slek/\Tcratm1Slek
(Not Specified)
immune system phenotype J:101719
\TcrbLn3Jae/\Tcrb+
(B6.Cg-TcrbLn3Jae)
abnormal double-negative T cell morphology J:143006
absent gamma-delta T cells J:143006
\Tcrbtm1(Tcrb)Chb/\Tcrbtm1(Tcrb)Chb
(Not Specified)
abnormal double-negative T cell morphology J:147947
abnormal T cell morphology J:147947
decreased CD8-positive, alpha-beta T cell number J:147947
increased single-positive T cell number J:147947
\Tcrbtm1(Tcrb)Chb/\Tcrbtm1Slek
(Not Specified)
abnormal double-negative T cell morphology J:147947
abnormal T cell morphology J:147947
abnormal T cell receptor beta chain V(D)J recombination J:147947
decreased CD8-positive, alpha-beta T cell number J:147947
increased single-positive T cell number J:147947
\Tcrbtm1(Tcrb)Fwa/\Tcrbtm1(Tcrb)Fwa
(involves: 129)
abnormal T cell receptor beta chain V(D)J recombination J:131995
\Tcrbtm1Mom/\Tcrb+
\Tg(SOD1*G93A)1Gur/0

(B6.Cg-Tcrbtm1Mom Tg(SOD1*G93A)1Gur/J)
abnormal microglial cell physiology J:143173
\Tcrbtm1Mom/\Tcrbtm1Mom
(involves: 129P2/OlaHsd * BALB/c)
arrested T cell differentiation J:3206
colitis J:15221
decreased CD4-positive, alpha-beta T cell number J:3206
decreased CD8-positive, alpha-beta T cell number J:3206
decreased double-positive T cell number J:3206
thymus hypoplasia J:3206
\Tcrbtm1Mom/\Tcrbtm1Mom
\Tcrdtm1Mom/\Tcrdtm1Mom

(FVB.129P2-Tcrbtm1Mom Tcrdtm1Mom)
immune system phenotype J:75915
\Tcrbtm1Mom/\Tcrbtm1Mom
\Tcrdtm1Mom/\Tcrdtm1Mom

(involves: 129P2/OlaHsd * C57BL/6)
abnormal response to infection J:119344
decreased IgG level J:119344
immune system phenotype J:126867
\Tcrbtm1Mom/\Tcrbtm1Mom
\Tcrdtm1Mom/\Tcrdtm1Mom

(B6.129P2-Tcrbtm1Mom Tcrdtm1Mom/J)
abnormal transitional stage B cell morphology J:187766
decreased autoantibody level J:187766
decreased IgE level J:125656
decreased IgG1 level J:125656
decreased IgG level J:125656, J:187766
decreased plasma cell number J:187766
decreased T cell number J:187766
increased B cell number J:187766
increased follicular B cell number J:187766
increased IgM level J:187766
increased immature B cell number J:187766
increased marginal zone B cell number J:187766
increased mature B cell number J:187766
increased transitional stage T2 B cell number J:187766
increased transitional stage T3 B cell number J:187766
\Tcrbtm1Mom/\Tcrbtm1Mom
\Tcrdtm1Mom/\Tcrdtm1Mom

(involves: 129 * BALB/c * C57BL/6)
absent CD4-positive, alpha-beta T cells J:3206
absent CD8-positive, alpha-beta T cells J:3206
arrested T cell differentiation J:3206
colitis J:15221
decreased double-positive T cell number J:3206
thymus hypoplasia J:3206
\Tcrbtm1Mom/\Tcrbtm1Mom
\Tcrdtm1Mom/\Tcrdtm1Mom

(involves: 129P2/OlaHsd)
decreased IgA level J:97824
decreased lymphocyte cell number J:97824
immune system phenotype J:97824
increased T cell number J:97824
\Tcrbtm1Mom/\Tcrbtm1Mom
\Tcrdtm1Mom/\Tcrdtm1Mom
\Igh-Jtm2(3H9-VDJ*)Mwg/\Igh-J+

(B6.129P2-Tcrbtm1Mom Igh-Jtm2(3H9-VDJ*)Mwg Tcrdtm1Mom)
increased anti-double stranded DNA antibody level J:142389
increased marginal zone B cell number J:142389
spleen hypoplasia J:142389
\Tcrbtm1Mom/\Tcrbtm1Mom
\Tcrdtm1Mom/\Tcrdtm1Mom
\Traf3ip2tm1.1Lix/\Traf3ip2tm1.1Lix

(B6.129-Tcrbtm1Mom Traf3ip2tm1.1Lix Tcrdtm1Mom)
abnormal transitional stage B cell morphology J:187766
decreased IgG level J:187766
decreased T cell number J:187766
immune system phenotype J:187766
increased anti-chromatin antibody level J:187766
increased anti-double stranded DNA antibody level J:187766
increased anti-histone antibody level J:187766
increased autoantibody level J:187766
increased IgM level J:187766
increased immature B cell number J:187766
increased marginal zone B cell number J:187766
\Tcrbtm1Mom/\Tcrbtm1Mom
\Tg(H2-K-Cd86)7All/0

(involves: 129P2/OlaHsd * C57BL/6 * CBA)
abnormal B cell differentiation J:112475
abnormal B cell morphology J:112475
decreased B cell number J:112475
\Tcrbtm1Mom/\Tcrbtm1Mom
\Tg(KRT5-rtTA)1Glk/0
\Tg(tetO/CMV-Tslp)#Sfz/0

(involves: 129P2/OlaHsd * C3H * C57BL/6 * FVB/N)
decreased IgE level J:100506
skin inflammation J:100506
\Tcrbtm1Slek/\Tcrbtm1Slek
(Not Specified)
immune system phenotype J:119552
\Tcrbtm1Slek/\Tcrbtm5Slek
(Not Specified)
abnormal T cell receptor beta chain V(D)J recombination J:143738
\Tcrbtm1Slek/\Tcrbtm6Slek
(Not Specified)
abnormal T cell receptor beta chain V(D)J recombination J:143738
\Tcrbtm2(Tcrb)Fwa/\Tcrbtm3Slek
(involves: 129)
abnormal T cell receptor beta chain V(D)J recombination J:132446
\Tcrbtm2Slek/\Tcrbtm2Slek
(Not Specified)
arrested T cell differentiation J:119552
decreased T cell number J:119552
\Tcrbtm2Slek/\Tcrbtm2Slek
\Trbv13-2tm1(CD2)Zhu/\Trbv13-2tm1(CD2)Zhu

(involves: 129 * C57BL/6)
abnormal T cell differentiation J:121608
\Tcrbtm3.1Che/\Tcrbtm3.1Che
(involves: 129S4/SvJae)
immune system phenotype J:120387
\Tcrbtm3Che/\Tcrbtm3Che
(involves: 129S4/SvJae)
immune system phenotype J:120387
\Tcrbtm3Slek/\Tcrbtm3Slek
(Not Specified)
arrested T cell differentiation J:119552
decreased T cell number J:119552
\Tcrbtm4Slek/\Tcrbtm4Slek
(Not Specified)
immune system phenotype J:119552
\Tcrbtm5Slek/\Tcrbtm5Slek
(Not Specified)
abnormal T cell receptor beta chain V(D)J recombination J:143738
\Tcrbtm6Slek/\Tcrbtm6Slek
(Not Specified)
abnormal T cell receptor beta chain V(D)J recombination J:143738
\Tcrbtm7Slek/\Tcrbtm7Slek
(Not Specified)
abnormal T cell receptor beta chain V(D)J recombination J:143738
\Tcrbtm8.1Slek/\Tcrbtm8.1Slek
(Not Specified)
immune system phenotype J:176070
\Tcrbtm9.1Slek/\Tcrbtm9.1Slek
(Not Specified)
immune system phenotype J:176070
\Tcrd-V1tm1Kjk/\Tcrd-V1tm1Kjk
(involves: 129P2/OlaHsd * C57BL/6)
abnormal gamma-delta T cell differentiation J:64863
abnormal mature gamma-delta T cell morphology J:64863
abnormal T cell receptor delta chain V(D)J recombination J:64863
decreased gamma-delta intraepithelial T cell number J:64863
\Tcrd-V1tm1Kjk/\Tcrd-V1tm1Kjk
(B6.129P2-Tcrd-V1tm1Kjk)
abnormal T cell receptor delta chain V(D)J recombination J:128525
decreased gamma-delta intraepithelial T cell number J:128525
\Tcrdtm1Mom/\Tcrdtm1Mom
(FVB.129P2-Tcrdtm1Mom)
dermatitis J:75915
increased susceptibility to type IV hypersensitivity reaction J:75915
\Tcrdtm1Mom/\Tcrdtm1Mom
(NOD.129P2-Tcrdtm1Mom)
dermatitis J:75915
\Tcrdtm1Mom/\Tcrdtm1Mom
(B6.129P2-Tcrdtm1Mom)
immune system phenotype J:75915
\Tcrdtm1Mom/\Tcrdtm1Mom
(either: (involves: 129P2/OlaHsd * BALB/cJ) or (involves: 129P2/OlaHsd * C57BL/6))
abnormal gamma-delta T cell differentiation J:3865
absent gamma-delta T cells J:3865
\Tcrdtm1Mom/\Tcrdtm1Mom
\Tcrgtm2.1Dhr/\Tcrgtm2.1Dhr

(involves: 129 * C57BL/6)
abnormal T cell receptor gamma chain V-J recombination J:75624
\Tcrdtm1Mom/\Tcrdtm1Mom
\Tnftm2Gkl/\Tnf+

(involves: 129P2/OlaHsd * 129S/SvEv * C57BL/6J)
small intestinal inflammation J:108572
\Tcrgtm1.1Dhr/\Tcrgtm1.1Dhr
(involves: 129)
abnormal T cell receptor gamma chain V-J recombination J:133974
\Tcrgtm1.1Hish/\Tcrgtm1.1Hish
(involves: 129P2/OlaHsd * C57BL/6)
absent gamma-delta T cells J:135597
\Tcrgtm1Dhr/\Tcrgtm1Dhr
(involves: 129)
abnormal T cell receptor gamma chain V-J recombination J:133974
\Tcrgtm1Iku/\Tcrgtm1Iku
(involves: 129P2/OlaHsd * C57BL/6)
immune system phenotype J:39791
\Tcrgtm1Scar/\Tcrgtm1Scar
(B6.Cg-Tcrgtm1Scar)
abnormal immune system organ morphology J:105477
enlarged spleen J:105477
enlarged thymus J:105477
impaired granulocyte bactericidal activity J:105477
increased macrophage cell number J:105477
increased T cell number J:105477
spleen hyperplasia J:105477
thymus hyperplasia J:105477
\Tcrgtm2.1Dhr/\Tcrgtm2.1Dhr
(involves: 129S4/SvJae * C57BL/6)
abnormal gamma-delta T cell differentiation J:75624
abnormal T cell receptor gamma chain V-J recombination J:75624
\Tdp1em1(IMPC)Tcp/\Tdp1em1(IMPC)Tcp
(C57BL/6NCrl-Tdp1em1(IMPC)Tcp/Tcp)
enlarged lymph nodes J:211773
\Tdp2tm1.1Huy/\Tdp2tm1.1Huy
(involves: 129P2/OlaHsd * CD-1)
abnormal immature B cell morphology J:195301
abnormal immune system organ morphology J:195301
abnormal lymphopoiesis J:195301
decreased double-positive T cell number J:195301
spleen atrophy J:195301
thymus atrophy J:195301
\Tdrd3Gt(RRK474)Byg/\Tdrd3Gt(RRK474)Byg
(involves: 129P2/OlaHsd)
abnormal B cell differentiation J:210647
abnormal B cell physiology J:210647
\Tdrd7nmf166/\Tdrd7nmf166
(involves: C3H * C57BL/6J)
uveitis J:169836
\Tectm1Welm/\Tectm1Welm
(involves: 129P2/OlaHsd * C57BL/6)
immune system phenotype J:66080
\Tecpr1tm1Chsa/\Tecpr1tm1Chsa
(involves: 129S4/SvJae)
abnormal susceptibility to infection J:198333
\Tedc1em1(IMPC)Tcp/\Tedc1+
(C57BL/6NCrl-Tedc1em1(IMPC)Tcp/Tcp)
enlarged lymph nodes J:211773
\Teddm1aem1(IMPC)Tcp/\Teddm1aem1(IMPC)Tcp
(C57BL/6N-Teddm1aem1(IMPC)Tcp/Tcp)
decreased leukocyte cell number J:211773
\Tekt1em1(IMPC)Ccpcz/\Tekt1em1(IMPC)Ccpcz
(C57BL/6NCrl-Tekt1em1(IMPC)Ccpcz/Ccpcz)
abnormal lymph node morphology J:211773
abnormal thymus morphology J:211773
enlarged thymus J:211773
small lymph nodes J:211773
\Ten1em1(IMPC)Hmgu/\Ten1em1(IMPC)Hmgu
(involves: C57BL/6NCrl)
abnormal cytokine secretion J:365069
abnormal thymus medulla morphology J:365069
bone marrow failure J:365069
increased inflammatory response J:365069
thymus atrophy J:365069
thymus cortex hypoplasia J:365069
\Tenm4em1(IMPC)Tcp/\Tenm4em1(IMPC)Tcp
(C57BL/6NCrl-Tenm4em1(IMPC)Tcp/Tcp)
decreased spleen weight J:211773
\Tent2em1(IMPC)Ccpcz/\Tent2+
(C57BL/6NCrl-Tent2em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged thymus J:211773
\Tent2em1(IMPC)Ccpcz/\Tent2em1(IMPC)Ccpcz
(C57BL/6NCrl-Tent2em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
\Tent5aem1(IMPC)Ccpcz/\Tent5aem1(IMPC)Ccpcz
(C57BL/6N-Tent5aem1(IMPC)Ccpcz/Ccpcz)
decreased Ly6C-positive mature NK cell number J:211773
decreased lymphocyte cell number J:211773
increased granulocyte number J:211773
increased leukocyte cell number J:211773
increased monocyte cell number J:211773
increased neutrophil cell number J:211773
\Tent5cem1Adki/\Tent5cem1Adki
(involves: C57BL/6JTar * CBA/WTar)
decreased B cell proliferation J:252302
\Tent5ctm1b(KOMP)Wtsi/\Tent5ctm1b(KOMP)Wtsi
(C57BL/6N-Tent5ctm1b(KOMP)Wtsi/Wtsi)
absent connection between subcutaneous lymph vessels and lymph sac J:239583
blood in lymph vessels J:239583
\Terb1tm1b(KOMP)Mbp/\Terb1+
(C57BL/6N-Terb1tm1b(KOMP)Mbp/Ucd)
abnormal thymus morphology J:211773
enlarged thymus J:211773
\Terctm1Rdp/\Terctm1Rdp
(involves: 129/Sv * C57BL/6J * SJL)
decreased B cell proliferation J:60223
decreased spleen B cell follicle number J:60223
decreased spleen germinal center number J:60223
decreased T cell proliferation J:60223
increased B cell apoptosis J:60223
\Terf1tm1.1Blas/\Terf1tm1.1Blas
\Tg(KRT5-cre)1Tak/0

(involves: 129 * C3H * C57BL/6 * SJL)
skin inflammation J:152077
\Terf2ipGt(XD108)Byg/\Terf2ip+
(involves: 129P2/OlaHsd * C57BL/6)
decreased susceptibility to bacterial infection induced morbidity/mortality J:163158
decreased susceptibility to endotoxin shock J:163158
\Terttm2.1Rdp/\Terttm2.1Rdp
(involves: C57BL/6)
decreased spleen weight J:167227
spleen atrophy J:167227
\Tespa1tm1Smoc/\Tespa1tm1Smoc
(B6.129-Tespa1tmSmoc)
abnormal T cell differentiation J:186446
abnormal thymus morphology J:186446
decreased CD4-positive, alpha-beta T cell number J:186446
decreased CD8-positive, alpha-beta T cell number J:186446
decreased interferon-gamma secretion J:186446
decreased interleukin-2 secretion J:186446
decreased regulatory T cell number J:186446
decreased T cell number J:186446
decreased T cell proliferation J:186446
increased memory T cell number J:186446
increased T cell proliferation J:186446
small thymus medulla J:186446
\Tespa1tm1Smoc/\Tespa1tm1Smoc
\Tg(TcraH-Y,TcrbH-Y)71Vbo/0

(involves: 129 * C57BL/6 * DBA/2J)
decreased CD8-positive, alpha-beta T cell number J:186446
\Tespa1tm1Smoc/\Tespa1tm1Smoc
\Tg(TcraTcrb)425Cbn/0

(B6.Cg-Tespa1tm1Smoc Tg(TcraTcrb)425Cbn)
abnormal T cell differentiation J:186446
decreased CD4-positive, alpha-beta T cell number J:186446
decreased CD8-positive, alpha-beta T cell number J:186446
\Tespa1tm1Smoc/\Tespa1tm1Smoc
\Tg(TcraTcrb)1100Mjb/0

(B6.Cg-Tespa1tm1Smoc Tg(TcraTcrb)1100Mjb)
abnormal T cell differentiation J:186446
decreased CD4-positive, alpha-beta T cell number J:186446
decreased CD8-positive, alpha-beta T cell number J:186446
\Tet1tm1.1Gxu/\Tet1tm1.1Gxu
(involves: 129 * 129P2/OlaHsd * C57BL/6J)
decreased spleen iron level J:315675
\Tet1tm1.1Jae/\Tet1tm1.1Jae
(involves: 129S4/SvJae * C57BL/6)
decreased neutrophil cell number J:175858
\Tet1tm1.2Jae/\Tet1tm1.2Jae
\Tet2tm1.1Iaai/\Tet2+
\Tet3tm1.1Yzhg/\Tet3tm1.1Yzhg
\Tg(Rorc-cre)1Litt/0

(involves: 129 * 129S/SvEv * 129S4/SvJae * C57BL/6 * FVB)
decreased effector memory T-helper cell number J:333574
immune system phenotype J:333574
\Tet1tm1.2Jae/\Tet1tm1.2Jae
\Tet2tm1.1Iaai/\Tet2tm1.1Iaai
\Tet3tm1.1Yzhg/\Tet3tm1.1Yzhg
\Tg(Rorc-cre)1Litt/0

(involves: 129 * 129S/SvEv * 129S4/SvJae * C57BL/6 * FVB)
enlarged lymph nodes J:333574
enlarged spleen J:333574
increased susceptibility to autoimmune disorder J:333574
\Tet2Gt(AN0709)Wtsi/\Tet2+
(B6.129P2-Tet2Gt(AN0709)Wtsi)
abnormal monocyte differentiation J:174052
abnormal spleen morphology J:174052
enlarged spleen J:174052
increased B cell number J:174052
increased leukocyte cell number J:174052
increased monocyte cell number J:174052
liver inflammation J:174052
\Tet2Gt(AN0709)Wtsi/\Tet2Gt(AN0709)Wtsi
(B6.129P2-Tet2Gt(AN0709)Wtsi)
abnormal monocyte differentiation J:174052
abnormal spleen morphology J:174052
decreased pre-B cell number J:174052
decreased pro-B cell number J:174052
enlarged spleen J:174052
increased B cell number J:174052
increased DN1 thymic pro-T cell number J:174052
increased double-negative T cell number J:174052
increased leukocyte cell number J:174052
increased monocyte cell number J:174052
liver inflammation J:174052
\Tet2tm1.1Iaai/\Tet2+
\Tg(VAV1-cre)1Graf/0

(involves: 129S/SvEv * C57BL/6)
increased leukocyte cell number J:174053
increased monocyte cell number J:174053
\Tet2tm1.1Iaai/\Tet2tm1.1Iaai
\Tg(Mx1-cre)1Cgn/0

(involves: 129S/SvEv * C57BL/6 * CBA)
abnormal myelopoiesis J:234976
decreased B cell number J:234976
enlarged spleen J:234976
increased granulocyte number J:234976
\Tet2tm1.1Iaai/\Tet2tm1.1Iaai
\Tg(VAV1-cre)1Graf/0

(involves: 129S/SvEv * C57BL/6)
abnormal myeloid leukocyte morphology J:174053
enlarged spleen J:174053
increased leukocyte cell number J:174053
increased monocyte cell number J:174053
increased spleen weight J:174053
myeloid hyperplasia J:174053
\Tet2tm1.1Mjxu/\Tet2+
(involves: 129 * C57BL/6)
enlarged spleen J:178415
increased leukocyte cell number J:178415
increased monocyte cell number J:178415
myeloid hyperplasia J:178415
\Tet2tm1.1Mjxu/\Tet2tm1.1Mjxu
(involves: 129 * C57BL/6)
enlarged spleen J:178415
increased leukocyte cell number J:178415
increased monocyte cell number J:178415
increased neutrophil cell number J:178415
myeloid hyperplasia J:178415
\Tet2tm1.2Rao/\Tet2tm1.2Rao
(involves: C57BL/6NTac)
abnormal myelopoiesis J:175222
increased splenocyte number J:175222
\Tet2tm1Ics/\Tet2tm1Ics
\Tg(Mx1-cre)1Cgn/0

(involves: C57BL/6 * CBA)
abnormal spleen morphology J:174052
decreased pre-B cell number J:174052
decreased pro-B cell number J:174052
enlarged spleen J:174052
increased B cell number J:174052
increased DN1 thymic pro-T cell number J:174052
increased double-negative T cell number J:174052
increased leukocyte cell number J:174052
increased monocyte cell number J:174052
increased spleen red pulp amount J:174052
\Tex2tm1.1(KOMP)Vlcg/\Tex2+
(C57BL/6N-Tex2tm1.1(KOMP)Vlcg/J)
decreased leukocyte cell number J:211773
\Tex29tm1.1(KOMP)Vlcg/\Tex29tm1.1(KOMP)Vlcg
(C57BL/6N-Tex29tm1.1(KOMP)Vlcg/J)
decreased leukocyte cell number J:211773
\Tex261tm1b(EUCOMM)Wtsi/\Tex261tm1b(EUCOMM)Wtsi
(C57BL/6N-Tex261tm1b(EUCOMM)Wtsi/Wtsi)
increased leukocyte cell number J:211773
\Tfap4tm1.1Litt/\Tfap4tm1.1Litt
(involves: 129P2/OlaHsd * C57BL/6 * FVB/N)
abnormal T cell differentiation J:176461
immune system phenotype J:176461
\Tfebem1Xinli/\Tfebem1Xinli
(involves: C57BL/6J)
increased susceptibility to bacterial infection induced morbidity/mortality J:342735
\Tff2tm1Blin/\Tff2tm1Blin
(involves: 129S7/SvEvBrd * C57BL/6)
abnormal adaptive immunity J:105277
abnormal innate immunity J:105277
\Tff3tm1Dkpy/\Tff3tm1Dkpy
(involves: 129S4/SvJae)
increased susceptibility to induced colitis J:35882
\Tfpi2tm1Dgen/\Tfpi2tm1Dgen
(involves: 129P2/OlaHsd * C57BL/6J)
immune system phenotype J:301794
increased circulating interleukin-6 level J:301794
increased circulating interleukin-10 level J:301794
increased interleukin-10 secretion J:301794
increased susceptibility to bacterial infection J:301794
increased susceptibility to bacterial infection induced morbidity/mortality J:301794
\Tfpitm1Gjb/\Tfpitm1Gjb
(involves: 129)
abnormal acute phase protein level J:51137
\Tfr2tm1.1Anro/\Tfr2tm1.1Anro
(129.Cg-Tfr2tm1.1Anro)
increased spleen iron level J:160785
\Tfr2tm1.1Nsub/\Tfr2tm1.1Nsub
(involves: 129T2/SvEms * C57BL/6)
decreased spleen iron level J:114330
\Tfr2tm1.1Nsub/\Tfr2tm1.1Nsub
(involves: 129T2/SvEms)
increased spleen iron level J:160785
\Tfr2tm1Slu/\Tfr2tm1Slu
(involves: 129X1/SvJ * C57BL/6J)
decreased spleen iron level J:78360
\Tfrctm1Nca/\Tfrc+
(either: (involves: 129S4/SvJae * 129S6/SvEvTac) or (involves: 129S4/SvJae * C57BL/6))
decreased spleen iron level J:54107
\Tg(Ace2-ACE2)1Cqin/0
(involves: ICR)
alveolitis J:141460
increased susceptibility to Coronaviridae infection J:141460, J:287631, J:288244
interstitial pneumonia J:141460, J:287631
lymph node hemorrhage J:141460
lymph node necrosis J:287631
pyelitis J:141460
submandibular gland inflammation J:141460
\Tg(Acp5-Adam8)#Rood/0
(involves: BALB/c * C57BL/6)
abnormal osteoclast differentiation J:172936
abnormal osteoclast morphology J:172936
increased osteoclast cell number J:172936
\Tg(Acp5-Selenow)#Djeo/0
(involves: FVB/N)
abnormal osteoclast differentiation J:317012
increased osteoclast cell number J:317012
\Tg(ACTA1-Il15)10941Lsq/0
(involves: C3H * C57BL/6)
abnormal interleukin level J:145611
\Tg(ACTA1-Il15*)11650Lsq/0
(involves: C3H * C57BL/6)
abnormal interleukin level J:145611
increased circulating interleukin-15 level J:145611
\Tg(Acta2-cre/ERT2)#Pcn/0
\Tgfbr2tm1Karl/\Tgfbr2tm1Karl
\Tg(H2-K-Fosl2,-EGFP)13Wag/0

(B6.Cg-Tgfbr2tm1Karl Tg(Acta2-cre/ERT2)#Pcn Tg(H2-K-Fosl2,-EGFP)13Wag)
lung inflammation J:238723
\Tg(Acta2-RAC1*G12V)33Pjgc/\Tg(Acta2-RAC1*G12V)33Pjgc
(involves: C57BL/6 * FVB/N)
abnormal chemokine secretion J:150015
increased interleukin-6 secretion J:150015
increased tumor necrosis factor secretion J:150015
\Tg(ACTB-eGFP,-RAMP1)#Afru/0
\Tg(Nes-cre)1Kln/0

(involves: C57BL/6J * SJL/J)
increased inflammatory response J:120077
\Tg(ACTB-Eif4e)#Ppp/0
\Tg(IghMyc)22Bri/0

(involves: C57BL * SJL)
decreased B cell apoptosis J:89878
\Tg(ACTB-Fpr2)#Jimw/0
(involves: FVB)
abnormal dendritic cell physiology J:160074
respiratory system inflammation J:160074
\Tg(ACTB-Mgat3)2Nta/0
(involves: C57BL/6 * DBA/2)
decreased leukocyte cell number J:80227
decreased lymphocyte cell number J:80227
decreased neutrophil cell number J:80227
decreased spleen B cell follicle number J:80227
spleen atrophy J:80227
\Tg(ACTB-TNFRSF6B)754Jwu/?
(B6.Cg-Tg(Actb-TNFRSF6B)754Jwu)
abnormal CD4-positive, alpha beta T cell morphology J:148162
abnormal type IV hypersensitivity reaction J:148162
decreased leukocyte cell number J:148162
enlarged lymph nodes J:148162
enlarged spleen J:148162
increased anti-double stranded DNA antibody level J:148162
increased autoantibody level J:148162
increased B-1a cell number J:148162
increased IgE level J:148162
increased IgG1 level J:148162
increased IgG2b level J:148162
increased interleukin-4 secretion J:148162
\Tg(Actb-Tnfsf4)1Nish/0
(B6.D2-Tg(Actb-Tnfsf4)1Nish)
abnormal cytokine secretion J:80214
increased susceptibility to type IV hypersensitivity reaction J:80214
increased T cell proliferation J:80214
\Tg(Adipoq-Apol6)#Hsul/0
(C57BL/6J-Tg(Adipoq-Apol6)#Hsul)
white adipose tissue inflammation J:344362
\Tg(Adipoq-cre)1Evdr/0
\Tg(CAG-Jmjd8)#Kaso/0

(involves: C57BL/6 * FVB/NJ)
white adipose tissue inflammation J:319518
\Tg(AGER)#Eca/0
(C57BL/6J-Tg(AGER)#Eca)
lung inflammation J:205092
\Tg(AGT)2-5Afu/0
(involves: C57BL/6)
heart inflammation J:194606
\Tg(Alb1-GP33/H2-Kb)1Hpi/0
(B6.Cg-Tg(Alb1-GP33/H2-Kb)1Hpi)
abnormal cytotoxic T cell physiology J:162605
decreased cytotoxic T cell cytolysis J:162605
\Tg(Alb1-GP33/H2-Kb)1Hpi/0
\Tg(Alb1-HBV)66Bri/0

(involves: C57BL/6 * C57BL/10 * DBA/2)
liver inflammation J:162605
\Tg(Alb1-GP33/H2-Kb)1Hpi/0
\Tg(Alb1-HBV)66Bri/0
\Tg(TcrLCMV)318Sdz/0

(involves: C57BL/6 * C57BL/10 * DBA/2)
liver inflammation J:162605
\Tg(Alb1-GP33/H2-Kb)1Hpi/0
\Tg(TcrLCMV)318Sdz/0

(involves: C57BL/6 * DBA/2)
decreased CD8-positive, alpha-beta T cell number J:162605
\Tg(Alb1-Myc)#Sst/0
\Tg(MtTGFA)Lmb/0

(involves: C57BL/6 * CBA * CD-1)
decreased NK cell number J:176432
increased NK T cell number J:176432
\Tg(Alb1-Ren)1Unc/0
(involves: 129S6/SvEvTac * C57BL/6)
kidney inflammation J:89252
\Tg(Alb1-Ren)2Unc/0
(involves: 129S6/SvEvTac * C57BL/6)
kidney inflammation J:89252
\Tg(Alb1HBV)44Bri/0
(C57BL/6J-Tg(Alb1HBV)44Bri/J)
liver inflammation J:223921
\Tg(Alb-PDGFC)#Jcam/0
(involves: C57BL/6)
chronic liver inflammation J:211984
enlarged spleen J:211984
increased circulating interleukin-6 level J:211984
\Tg(Alb-PLG)1Dgi/0
(involves: C57BL/6 * C57BL/6J * SJL)
increased susceptibility to bacterial infection J:120780
\Tg(Alb-SND1)3aDsar/0
(involves: C57BL/6 * CBA)
chronic liver inflammation J:242582
\Tg(Alb-TAg)#Arnd/0
((C3Fe.Cg-Tg(Alb-TAg)#Arnd x C57BL/6N)F1)
abnormal immune system physiology J:171880
\Tg(Amy1TAg)501Knw/0
(involves: C57BL/6)
abnormal CD8-positive, alpha-beta T cell physiology J:84288
\Tg(ANPEP)270Mmul/\Tg(ANPEP)270Mmul
(involves: ICR)
immune system phenotype J:99728
\Tg(ANPEP)861Mmul/\Tg(ANPEP)861Mmul
(involves: ICR)
immune system phenotype J:99728
\Tg(ANX6)2Agh/0
(FVB/N-Tg(ANX6)2Agh)
myocarditis J:92579
thymus cortex hypoplasia J:92579
\Tg(aP2-SREBF1c)9884Reh/0
(involves: C57BL/6J * SJL)
abnormal abdominal lymph node morphology J:50770
decreased interleukin-6 secretion J:249664
decreased tumor necrosis factor secretion J:249664
enlarged spleen J:50770
liver inflammation J:249664
\Tg(APCS-Ifng)5Imeg/0
(involves: C57BL/6 * DBA/2)
abnormal cytokine level J:135124
chronic liver inflammation J:135124
increased circulating interleukin-12 level J:135124
liver inflammation J:16979
myocarditis J:135124
pancreas inflammation J:135124
\Tg(APCS-Tnfsf11*)#aKhs/0
(C57BL/6J-Tg(APCS-Tnfsf11*)#aKhs)
abnormal osteoclast morphology J:264357
enlarged thymus medulla J:264357
increased osteoclast cell number J:264357
\Tg(APOA1)1Rub/\Tg(APOA1)1Rub
(C57BL/6-Tg(APOA1)1Rub/J)
abnormal circulating interleukin-17 level J:190966
abnormal spleen weight J:190966
\Tg(APOC1)1Lmh/\Tg(APOC1)1Lmh
(C57BL/6-Tg(APOC1)1Lmh)
dermatitis J:65036
enlarged spleen J:65036
folliculitis J:65036
\Tg(APOC1)1Lmh/\Tg(APOC1)1Lmh
(involves: C57BL/6)
dermatitis J:135501
increased IgE level J:135501
increased mast cell degranulation J:135501
skin inflammation J:135501
\Tg(APOE-DGAT1)1Far/0
(involves: C57BL/6NHsd)
liver inflammation J:124005
\Tg(APOE-DGAT2)1Far/0
(involves: C57BL/6NHsd)
liver inflammation J:124005
\Tg(APOE-FGF23*R176Q)#Ack/0
(involves: C57BL/6J * CBA)
decreased osteoclast cell number J:93981
enthesitis J:192371
\Tg(APP695)3Dbo/0
\Tg(PSEN1dE9)S9Dbo/0

(Not Specified)
abnormal microglial cell morphology J:139070
\Tg(APPSWE)2576Kha/0
(involves: C57BL/6 * SJL)
microgliosis J:159623
\Tg(APPswe,PSEN1dE9)85Dbo/0
(D2.Cg-Tg(APPswe,PSEN1dE9)85Dbo)
microgliosis J:227541
\Tg(APPSwFlLon,PSEN1*M146L*L286V)6799Vas/0
(involves: C57BL/6 * SJL)
brain inflammation J:112949
\Tg(APPSwFlLon,PSEN1*M146L*L286V)6799Vas/?
(involves: C57BL/6 * SJL)
increased microglial cell activation J:208030
\Tg(ARR2/Pbsn-FGF8)3Prb/0
(involves: C57BL/6 * DBA/2)
increased inflammatory response J:78918
prostate gland inflammation J:78918
\Tg(B2M)55Hpl/?
\Tg(CD8aCD8b)57Scr/?
\Tg(HLA-B)22Hpl/?

(involves: C57BL/6 * C57BL/LiA * CBA)
abnormal cytotoxic T cell physiology J:127813
\Tg(B2M,HLA-B*27:05)56-3Trg/0
(involves: C57BL/6 * SJL/J)
immune system phenotype J:74451
\Tg(B19-RNAi:Il3)241Ckn/?
(involves: BALB/cJ * C57BL/6J * FVB/N)
abnormal B cell differentiation J:107618
decreased interleukin-3 secretion J:107618
enlarged lymph nodes J:107618
enlarged spleen J:107618
increased pre-B cell number J:107618
\Tg(BCL2)22Wehi/0
(involves: C57BL/6JWehi * SJL/JWehi)
abnormal B cell differentiation J:93111
abnormal B cell physiology J:93111
increased B cell number J:93111
increased susceptibility to autoimmune disorder J:93111
\Tg(BCL2)22Wehi/0
(involves: C57BL/6J * C57BL/6JWehi)
increased B cell number J:88565
\Tg(BCL2)22Wehi/0
\Tg(IghMyc)22Bri/0

(involves: C57BL/6 * C57BL/6JWehi * SJL/J * SJL/JWehi)
abnormal B cell morphology J:69571
abnormal pre-B cell morphology J:69571
enlarged lymph nodes J:69571
enlarged spleen J:69571
enlarged thymus J:69571
increased B cell number J:69571
increased leukocyte cell number J:69571
increased pre-B cell number J:69571
\Tg(BCL2)25Wehi/0
(involves: C57BL/6JWehi * SJL/JWehi)
abnormal B cell differentiation J:131912
abnormal plasma cell differentiation J:131912
abnormal T cell physiology J:93111
increased T cell number J:93111
\Tg(BCL2)36Wehi/0
(involves: C57BL/6JWehi * SJL/JWehi)
abnormal B cell physiology J:93111
abnormal T cell physiology J:93111
increased B cell number J:93111
increased immunoglobulin level J:93111
increased susceptibility to autoimmune disorder J:93111
increased T cell derived lymphoma incidence J:93111
increased T cell number J:93111
\Tg(BCL2)36Wehi/?
(B6.Cg-Tg(BCL2)36Wehi/J)
abnormal B cell proliferation J:90963
decreased B cell apoptosis J:90963
\Tg(BCL2/IGH)1Tjd/?
(involves: C3H/He * C57BL/6)
abnormal B cell physiology J:81147
abnormal lymph node morphology J:81147
abnormal mononuclear cell differentiation J:81147
enlarged lymph nodes J:81147
enlarged spleen J:81147
increased B cell number J:81147
increased spleen white pulp amount J:81147
spleen hyperplasia J:81147
\Tg(BCL2/IGH)#Jcre/0
\Tg(H2-K/Igh-Traf2*)#Ywc/0

(involves: BALB/c * C57BL/6 * CBA/J * FVB/N * SJL/J * SWR/J)
abnormal spleen marginal zone morphology J:94116
decreased B cell apoptosis J:94116
enlarged lymph nodes J:94116
enlarged spleen J:94116
increased B cell number J:94116
increased B-1a cell number J:94116
increased B-1b cell number J:94116
increased marginal zone B cell number J:94116
increased spleen weight J:94116
\Tg(BCL2/IGH)M23Tjd/?
(involves: C3H/He * C57BL/6)
abnormal B cell physiology J:81147
abnormal lymph node morphology J:81147
abnormal mononuclear cell differentiation J:81147
enlarged lymph nodes J:81147
enlarged spleen J:81147
increased B cell number J:81147
increased spleen white pulp amount J:81147
spleen hyperplasia J:81147
\Tg(BLG-STAT5A)15Itb/0
(involves: FVB/N)
increased inflammatory response J:80588
\Tg(C9orf72)500Lpwr/0
(FVB/NJ-Tg(C9orf72)500Lpwr)
microgliosis J:239579
\Tg(CAG-ACE2)AC63Ctkt/0
(either: (involves: BALB/c * C3H/HeJ * C57BL/6J) or (involves: C3H/HeJ * C57BL/6 * C57BL/6J))
increased susceptibility to Coronaviridae infection J:117824
\Tg(CAG-ACE2)AC70Ctkt/0
(either: (involves: BALB/c * C3H/HeJ * C57BL/6J) or (involves: C3H/HeJ * C57BL/6 * C57BL/6J))
abnormal cytokine level J:117824
increased susceptibility to Coronaviridae infection J:117824
increased susceptibility to Coronaviridae infection induced morbidity/mortality J:117824
interstitial pneumonia J:117824
\Tg(CAG-APP)0304Shoj/0
(involves: C3H * C57BL/6N)
abnormal circulating serum amyloid protein level J:100977
\Tg(CAG-Bgeo,-Hras1,-EGFP)#Ichi/0
\Tg(Flt4-cre)44Ichi/0

(involves: 129P2/OlaHsd * C57BL/6J)
lymphatic vessel hyperplasia J:159024
\Tg(CAG-Bgeo,-Hras1,-EGFP)#Ichi/0
\Tg(Tek-cre)12Flv/0

(involves: 129P2/OlaHsd * C3H * C57BL/6)
lymphatic vessel hyperplasia J:159024
\Tg(CAG-Btc)2Ewo/0
(FVB/N-Tg(CAG-Btc)2Ewo)
increased spleen weight J:103364
\Tg(CAG-Btc)4Ewo/0
(FVB/N-Tg(CAG-Btc)4Ewo)
increased spleen weight J:103364
\Tg(CAG-C1qtnf6)#Yiw/0
(involves: C57BL/6JJcl)
abnormal complement protein level J:227217
decreased IgG level J:227217
decreased susceptibility to induced arthritis J:227217
impaired complement alternative pathway J:227217
\Tg(CAG-cat,-Il18)#Thos/0
\Tg(SFTPC-rtTA)5Jaw/0
\Tg(tetO-cre)1Jaw/0

(involves: 129 * C57BL/6)
increased interferon-gamma secretion J:147547
interstitial pneumonia J:147547
\Tg(CAG-cre/Esr1*)5Amc/0
\Tgfbr2tm1.2Hlm/\Tgfbr2tm1.2Hlm

(involves: 129S6/SvEvTac * C57BL/6 * CBA)
microgliosis J:221181
\Tg(CAG-DPP4)4Yuzh/0
(C57BL/6-Tg(CAG-DPP4)4Yuzh)
abnormal circulating cytokine level J:286175
abnormal spleen morphology J:286175
brain inflammation J:286175
increased circulating interferon-gamma level J:286175
increased circulating interleukin-17 level J:286175
increased susceptibility to Coronaviridae infection J:286175
increased susceptibility to Coronaviridae infection induced morbidity/mortality J:286175
kidney inflammation J:286175
liver inflammation J:286175
lung inflammation J:286175
\Tg(CAG-DPP4)52Ctkt/0
(involves: C3H/HeJ * C57BL/6J)
abnormal mononuclear cell morphology J:227925
brain inflammation J:227925
increased inflammatory response J:227925
increased microglial cell activation J:227925
increased susceptibility to Coronaviridae infection J:227925, J:258199
increased susceptibility to Coronaviridae infection induced morbidity/mortality J:227925, J:258199
interstitial pneumonia J:258199
lung inflammation J:227925
\Tg(CAG-dsRed2/RNAi:Tardbp)6Zxu/0
(involves: C57BL/6 * C57BL/6J * FVB/NJ * SJL)
microgliosis J:207750
\Tg(CAG-Has2)99Nita/0
\Tg(MMTV-cre)4Mam/0
\Tg(MMTVneu)202Mul/0

(FVB.Cg-Tg(CAG-Has2)99Nita Tg(MMTV-cre)4Mam Tg(MMTVneu)202Mul)
abnormal lymphatic vessel morphology J:130531
impaired macrophage chemotaxis J:164205
increased macrophage cell number J:164205
\Tg(CAG-Has2)99Nita/0
\Tg(MMTVneu)202Mul/0

(FVB.Cg-Tg(CAG-Has2)99Nita Tg(MMTVneu)202Mul)
abnormal lymphatic vessel morphology J:130531
\Tg(CAG-LacZ,-ACVR1*,-EGFP)35-1Mis/0
(involves: C57BL/6 * DBA/2)
myositis J:142253
\Tg(CAG-Lyn*)#Paau/0
(B6.Cg-Tg(CAG-Lyn*)#Paau)
skin inflammation J:151886
\Tg(CAG-Ncoa6)71Hwl/0
(involves: FVB)
lung inflammation J:80609
spleen atrophy J:80609
thymus atrophy J:80609
\Tg(CAG-Ncoa6)87Hwl/0
(involves: FVB)
lung inflammation J:80609
spleen atrophy J:80609
thymus atrophy J:80609
\Tg(CAG-Ncoa6)104Hwl/0
(involves: FVB)
spleen atrophy J:80609
thymus atrophy J:80609
\Tg(CAG-NRIP1)51Row/0
(involves: FVB/N)
lung inflammation J:175885
\Tg(CAG-OVAL)916Jen/?
(C57BL/6-Tg(CAG-OVAL)916Jen)
abnormal dendritic cell antigen presentation J:91742
decreased length of allograft survival J:91742
\Tg(CAG-p35)1Miur/0
(involves: C57BL/6)
autoimmune response J:126593
\Tg(CAG-p35)1Miur/0
\Tg(Mbp-cre)29Miur/0

(involves: C57BL/6)
decreased susceptibility to experimental autoimmune encephalomyelitis J:126593
\Tg(CAG-Pgam2)#Hiko/0
(involves: C57BL/6)
increased susceptibility to chemically induced skin inflammation J:306793
\Tg(CAG-PGDS)1Groy/0
(involves: FVB/N)
abnormal cytokine secretion J:107651
abnormal lymph node morphology J:107651
decreased inflammatory response J:107651
\Tg(CAG-PLA2G3)#aMurm/0
(Not Specified)
increased mast cell degranulation J:197334
increased susceptibility to type I hypersensitivity reaction J:197334
\Tg(CAG-Ptafr)1Tksh/0
(B6;D2-Tg(CAG-Ptafr)1Tksh/TkshRbrc)
increased mast cell number J:38639
increased susceptibility to endotoxin shock J:38639
\Tg(CAG-Romo1)#Xiwa/0
(involves: C57BL/6J)
decreased monocyte cell number J:367536
decreased neutrophil cell number J:367536
\Tg(CAG-SPTLC1*C133W)8EAmcc/0
(involves: C3H * C57BL/6)
microgliosis J:155748
\Tg(CAG-SYVN1)1Tn/?
(D1.Cg-Tg(CAG-SYVN1)1Tn)
rheumatoid arthritis J:86009
\Tg(Camk2a-cre)2Gsc/0
\Tg(H2-Ld)LoxNibl/0

(involves: C57BL/6 * FVB/N)
immune system phenotype J:284394
\Tg(Camk2a-tTA)1Mmay/0
\Tg(tetO-APPSwInd)107Dbo/0

(involves: C3H/HeJ * C57BL/6 * CBA)
CNS inflammation J:109829
\Tg(Camk2a-tTA)1Mmay/0
\Tg(tetO-APPSwInd)Dbo/0

(involves: C3H/HeJ * C57BL/6J)
microgliosis J:236737
\Tg(Camk2a-tTA)1Mmay/0
\Tg(tetO-LRRK2)C77Cai/0
\Tg(tetO-SNCA*A53T)E2Cai/0

(involves: C57BL/6)
microgliosis J:156512
\Tg(Camk2a-tTA)1Mmay/0
\Tg(tetO-LRRK2)C7874Cai/0
\Tg(tetO-SNCA*A53T)E2Cai/0

(involves: C57BL/6)
microgliosis J:156512
\Tg(Camk2a-tTA)1Mmay/0
\Tg(tetO-LRRK2*G2019S)E3Cai/0
\Tg(tetO-SNCA*A53T)E2Cai/0

(involves: C57BL/6)
microgliosis J:156512
\Tg(Camk2a-tTA)1Mmay/0
\Tg(tetO-Mtor*)#Atai/0

(involves: C57BL/6 * DBA/2 * ICR)
microgliosis J:211789
\Tg(Camk2a-tTA)1Mmay/0
\Tg(tetO-SNCA*A53T)E2Cai/0

(involves: C57BL/6)
microgliosis J:156512
\Tg(Camk2a-tTA)1Mmay/0
\Tg(tetO-TARDBP)12Vle/0

(involves: C3H/HeJ * C57BL/6J)
microgliosis J:170756
\Tg(CD2-Ccdc86)1Hfuj/?
(B6.FVB-Tg(CD2-Ccdc86)1Hfuj)
abnormal T cell morphology J:151722
increased T cell apoptosis J:151722
\Tg(CD2-CD4,HLA-DQA1,HLA-DQB1)1Ell/\Tg(CD2-CD4,HLA-DQA1,HLA-DQB1)1Ell
(NOD/MrkTac-Tg(CD2-CD4,HLA-DQA1,HLA-DQB1)1Ell)
immune system phenotype J:86540
\Tg(CD2-Ceacam1*4L)1Rsb/0
(involves: C57BL/6)
abnormal T cell physiology J:116136
decreased interleukin-2 secretion J:116136
decreased T cell number J:116136
decreased T cell proliferation J:116136
\Tg(CD2-Ceacam1*4L)1Rsb/0
\Tg(TcraTcrb)425Cbn/0

(involves: BALB/c * C57BL/6)
abnormal CD4-positive, alpha-beta T cell physiology J:116136
\Tg(CD2-Foxj1)#Stlp/0
(C57BL/6-Tg(CD2-Foxj1)#Stlp)
abnormal T cell physiology J:122222
decreased CD4-positive, alpha-beta T cell number J:122222
decreased CD8-positive, alpha-beta T cell number J:122222
immune system phenotype J:122222
increased single-positive T cell number J:122222
lymphoid hypoplasia J:122222
\Tg(CD2-Ifngr2)1Pbro/?
(B6.Cg-Tg(CD2-Ifngr2)1Pbro)
abnormal T-helper 1 cell differentiation J:134448
abnormal T-helper 1 physiology J:134448
decreased susceptibility to type IV hypersensitivity reaction J:134448
immune system phenotype J:134448
increased susceptibility to parasitic infection J:134448
\Tg(CD2-Ifngr2)2Pbro/?
(B6.Cg-Tg(CD2-Ifngr2)2Pbro)
abnormal T-helper 1 cell differentiation J:134448
abnormal T-helper 1 physiology J:134448
immune system phenotype J:134448
increased susceptibility to parasitic infection J:134448
\Tg(CD2-Ifngr2)2Pbro/?
(NOD.Cg-Tg(CD2-Ifngr2)2Pbro)
abnormal splenic cell ratio J:81981
abnormal T-helper 1 physiology J:81981
decreased interferon-gamma secretion J:81981
decreased interleukin-4 secretion J:81981
decreased tumor necrosis factor secretion J:81981
immune system phenotype J:81981
insulitis J:81981
myositis J:81981
ovary inflammation J:81981
\Tg(CD2-LAT2)1Wz/0
(Not Specified)
abnormal CD8-positive, alpha-beta T cell physiology J:116157
\Tg(CD2-Lmo2)#Thr/0
(involves: C57BL/6 * CBA)
enlarged spleen J:102058
enlarged thymus J:102058
\Tg(CD2-Lrch1)#Liux/0
(involves: C57BL/6)
abnormal cellular extravasation J:238772
decreased susceptibility to experimental autoimmune encephalomyelitis J:238772
immune system phenotype J:238772
\Tg(CD2-Mir181d)38Oers/0
(involves: C57BL/6)
decreased CD8-positive, alpha-beta T cell number J:212571
decreased double-positive T cell number J:212571
decreased T cell number J:212571
immune system phenotype J:212571
thymus atrophy J:212571
\Tg(CD2-Mir181d)38Oers/0
\Tg(TcraTcrb)425Cbn/0

(involves: C3H * C57BL/6)
decreased T cell number J:212571
\Tg(CD2-Myb/en)2Kmw/?
(involves: C57BL/10 * CBA)
abnormal single-positive T cell number J:126456
decreased T cell number J:126456
decreased T cell proliferation J:126456
increased double-negative T cell number J:126456
\Tg(CD2-Myb/en)2Kmw/\Tg(CD2-Myb/en)2Kmw
(involves: C57BL/10 * CBA)
decreased double-positive T cell number J:126456
decreased T cell number J:126456
decreased T cell proliferation J:126456
increased double-negative T cell number J:126456
small spleen J:126456
small thymus J:126456
\Tg(CD2-Nfat5)1Snh/0
(involves: BALB/c * C57BL/6)
abnormal cytotoxic T cell physiology J:80066
abnormal T cell differentiation J:80066
abnormal T cell physiology J:80066
decreased CD4-positive, alpha-beta T cell number J:80066
decreased CD8-positive, alpha-beta T cell number J:80066
decreased splenocyte proliferation J:80066
decreased T cell number J:80066
decreased T cell proliferation J:80066
spleen hypoplasia J:80066
thymus hypoplasia J:80066
\Tg(CD2-Ppp2ca)#Gct/0
(involves: C57BL/6J)
abnormal T cell subpopulation ratio J:184067
enlarged lymph nodes J:184067
enlarged spleen J:184067
glomerulonephritis J:184067
increased germinal center B cell number J:184067
increased interleukin-17 secretion J:184067
increased neutrophil cell number J:184067
\Tg(CD2-Rorc)#Staka/0
(involves: C57BL/6)
abnormal CD4-positive, alpha beta T cell morphology J:236222
abnormal susceptibility to Picornaviridae infection J:236222
abnormal T-helper 17 cell physiology J:236222
decreased CD4-positive, CD25-positive, alpha-beta regulatory T cell number J:230700
decreased CD8-positive, alpha-beta T cell number J:236222
decreased IgG2c level J:236222
decreased IgG3 level J:236222
decreased IgG level J:236222
decreased interferon-gamma secretion J:236222
decreased interleukin-10 secretion J:236222
increased anti-nuclear antigen antibody level J:230700
increased autoantibody level J:230700
increased effector memory CD4-positive, alpha-beta T cell number J:230700
increased interferon-gamma secretion J:236222
increased interleukin-17 secretion J:236222
increased susceptibility to autoimmune disorder J:230700
lacrimal gland inflammation J:230700
lung inflammation J:230700
salivary gland inflammation J:230700
\Tg(CD2-S1PR1)1Ejg/?
(involves: C57BL/6 * DBA/2)
abnormal humoral immune response J:96558
abnormal lymphocyte chemotaxis J:96558
decreased activated T cell number J:96558
decreased susceptibility to type IV hypersensitivity reaction J:96558
decreased T cell proliferation J:96558
impaired leukocyte migration J:96558
increased activated T cell number J:96558
increased IgE level J:96558
increased T cell number J:96558
\Tg(CD2-Sh2d1a)#Vei/0
(involves: 129S1/Sv * 129X1/SvJ)
increased natural killer cell mediated cytotoxicity J:110195
\Tg(CD2-Sh2d1b1)#Vei/0
(B6.Cg-Tg(CD2-Sh2d1b1)#Vei)
decreased interferon-gamma secretion J:110195
impaired natural killer cell mediated cytotoxicity J:110195
\Tg(CD2-Sh2d1b2)#Vei/0
(B6.Cg-Tg(CD2-Sh2d1b2)#Vei)
impaired natural killer cell mediated cytotoxicity J:110195
\Tg(Cd2-Smad7)#Chbe/0
(involves: C57BL/6)
abnormal T-helper 1 cell differentiation J:184670
decreased interleukin-9 secretion J:184670
decreased interleukin-10 secretion J:184670
decreased interleukin-17 secretion J:184670
increased interferon-gamma secretion J:184670
increased susceptibility to experimental autoimmune encephalomyelitis J:184670
\Tg(CD2-Stat6*V625A*T626A)78Mhk/0
(involves: C3H * C57BL/6)
dermatitis J:160119
\Tg(CD2-TcraF5,CD2-TcrbF5)1Kio/0
(involves: C57BL/10)
abnormal positive T cell selection J:113713
increased CD8-positive, alpha-beta T cell number J:113713
\Tg(CD2-TcraF5,CD2-TcrbF5)1Kio/0
(involves: C57BL/10 * CBA/Ca)
decreased CD8-positive, alpha-beta T cell number J:113713
\Tg(CD2-TcraF5,CD2-TcrbF5)1Kio/0
(involves: BALB/c * C57BL/10)
decreased CD8-positive, alpha-beta T cell number J:113713
\Tg(CD2-TcraF5,CD2-TcrbF5)1Kio/?
(involves: 129S1/Sv * 129X1/SvJ * C57BL/10 * FVB/N)
abnormal positive T cell selection J:126026
decreased CD4-positive, alpha-beta T cell number J:126026
increased CD8-positive, alpha-beta T cell number J:126026
\Tg(CD2-TcraF5,CD2-TcrbF5)1Kio/0
\Tg(Cd4-BCL2*G101A*D102A*D103A)AWnt/0

(involves: C57BL/6 * C57BL/10)
abnormal T cell clonal deletion J:217939
decreased thymocyte apoptosis J:217939
enlarged lymph nodes J:217939
increased T cell number J:217939
\Tg(CD2-TcraF5,CD2-TcrbF5)1Kio/0
\Tg(LCKprBCL2)36Sjk/0

(involves: C57BL/6 * C57BL/10)
abnormal T cell clonal deletion J:217939
decreased thymocyte apoptosis J:217939
\Tg(CD2-Tgfbr2)1Grs/0
(C57BL/6-Tg(CD2-Tgfbr2)1Grs/Nci)
enlarged lymph nodes J:97523
enlarged spleen J:97523
increased T cell proliferation J:97523
\Tg(CD2-Tgfbr2)1Grs/?
(C57BL/6-Tg(CD2-Tgfbr2)1Grs/Nci)
abnormal CD8-positive, alpha beta T cell morphology J:93665
increased T cell derived lymphoma incidence J:93665
increased T cell proliferation J:93665
\Tg(CD2-Zbtb7b)C8Rbo/?
(involves: C57BL/6)
absent CD8-positive, alpha-beta T cells J:97610
increased CD4-positive, alpha-beta T cell number J:97610
\Tg(CD2-Zbtb7b)C8Rbo/?
\Tg(TcraH-Y,TcrbH-Y)71Vbo/?

(involves: C57BL/6 * DBA/2J)
abnormal T cell differentiation J:97610
\Tg(CD2-Zbtb7b)C8Rbo/?
\Tg(TcrLCMV)327Sdz/?

(involves: C57BL/6 * DBA/2J)
abnormal T cell differentiation J:97610
\Tg(CD2-Zbtb7b)C8Rbo/?
\Themistm1Lov/\Themistm1Lov

(involves: 129)
abnormal T cell differentiation J:151075
\Tg(Cd3d-Il5)NJ.1638Nal/?
(involves: C57BL/6J * CBA/J)
abnormal eosinophil differentiation J:123440
abnormal spleen morphology J:123440
abnormal T cell number J:123440
enlarged lymph nodes J:123440
increased eosinophil cell number J:123440
increased leukocyte cell number J:123440
increased mature B cell number J:123440
increased monocyte cell number J:123440
increased neutrophil cell number J:123440
increased spleen weight J:123440
peritoneal inflammation J:123440
\Tg(CD3E)26Cpt/\Tg(CD3E)26Cpt
(involves: C57BL/6J * CBA/J)
abnormal thymus corticomedullary boundary morphology J:81711
absent NK cells J:81711
arrested T cell differentiation J:81711
decreased double-positive T cell number J:54756
decreased T cell number J:54756
decreased thymocyte number J:81711
decreased uterine NK cell number J:134589
thymus hypoplasia J:54756
\Tg(Cd4-BCL2*G101A*D102A*D103A)AWnt/0
(involves: C57BL/6)
abnormal CD4-positive, alpha-beta T cell number J:217939
abnormal mesenteric lymph node morphology J:217939
abnormal splenic cell ratio J:217939
abnormal T cell clonal deletion J:217939
abnormal T cell proliferation J:217939
abnormal T cell subpopulation ratio J:217939
decreased double-positive T cell number J:217939
decreased thymocyte apoptosis J:217939
enlarged lymph nodes J:217939
enlarged spleen J:217939
glomerulonephritis J:217939
increased activated T cell number J:217939
increased anti-nuclear antigen antibody level J:217939
increased autoantibody level J:217939
increased B cell number J:217939
increased central memory CD8 positive, alpha-beta T cell number J:217939
increased interferon-gamma secretion J:217939
increased regulatory T cell number J:217939
increased single-positive T cell number J:217939
increased susceptibility to autoimmune disorder J:217939
increased T cell number J:217939
kidney inflammation J:217939
liver inflammation J:217939
lung inflammation J:217939
lymphoid hyperplasia J:217939
skin inflammation J:217939
\Tg(Cd4-BCL2*G101A*D102A*D103A)AWnt/0
(involves: C57BL/6 * CBA/J)
abnormal T cell clonal deletion J:217939
decreased thymocyte apoptosis J:217939
\Tg(Cd4-BCL2*G101A*D102A*D103A)AWnt/0
\Tg(Nr4a1-EGFP/cre)820Khog/0

(involves: C57BL/6 * C57BL/6J)
abnormal T cell clonal deletion J:217939
decreased thymocyte apoptosis J:217939
\Tg(Cd4-BCL2*G101A*D102A*D103A)AWnt/0
\Tg(TcraH-Y,TcrbH-Y)71Vbo/0

(involves: C57BL/6 * C57BL/6J * DBA/2J)
abnormal T cell clonal deletion J:217939
decreased thymocyte apoptosis J:217939
\Tg(Cd4-CD4)2362Litt/0
(involves: C57BL/6 * SJL)
immune system phenotype J:50435
\Tg(Cd4-CD4)2362Litt/0
\Tg(HLA-DR2)#Lfug/0
\Tg(TCROb.1A12)#Lfug/0

(involves: C57BL/6 * DBA/2 * SJL)
CNS inflammation J:134764
increased susceptibility to experimental autoimmune encephalomyelitis J:134764
\Tg(CD4-CIITA)357Ccum/?
(involves: C57BL/6 * C57BL/6J * SJL)
increased osteoclast cell number J:233241
\Tg(Cd4-cre)1Cwi/?
\Tg(TcraTcrb)425Cbn/?
\Traf6tm2Ywc/\Traf6tm2Ywc

(involves: C57BL/6 * DBA/2)
abnormal lymphocyte anergy J:130882
increased interleukin-2 secretion J:130882
\Tg(Cd4-cre)1Cwi/0
\Trmt6em1Hbgl/\Trmt6em1Hbgl

(involves: C57BL/6 * DBA/2J)
decreased CD4-positive, alpha-beta T cell number J:336736
decreased T cell proliferation J:336736
\Tg(Cd4-cre)1Cwi/0
\Trmt61aem1Hbgl/\Trmt61aem1Hbgl

(involves: C57BL/6 * DBA/2J)
abnormal CD4-positive T cell differentiation J:336736
abnormal T cell activation J:336736
colitis J:336736
decreased CD4-positive, alpha-beta T cell number J:336736
decreased CD8-positive, alpha-beta T cell number J:336736
decreased T cell proliferation J:336736
increased CD4-positive, alpha-beta T cell number J:336736
increased CD8-positive, alpha-beta T cell number J:336736
\Tg(Cd4-DsRed)4Lt/0
(NOD/ShiLt-Tg(Cd4-DsRed)4Lt)
decreased susceptibility to autoimmune diabetes J:127785
\Tg(Cd4-Dtx1)1Mzl/?
(involves: C57BL/6)
abnormal T cell activation J:151605
abnormal thymocyte activation J:151605
decreased interleukin-2 secretion J:151605
decreased T cell proliferation J:151605
\Tg(CD4-HIV)F21380Pjo/0
(involves: C3H * C57BL/6)
interstitial pneumonia J:78756
lymph node atrophy J:78756
spleen atrophy J:78756
thymus atrophy J:78756
tubular nephritis J:78756
\Tg(CD4-HIV)F21388Pjo/0
(involves: C3H * C57BL/6)
interstitial pneumonia J:78756
lymph node atrophy J:78756
spleen atrophy J:78756
thymus atrophy J:78756
tubular nephritis J:78756
\Tg(CD4-HIV)F21407Pjo/0
(involves: C3H * C57BL/6)
interstitial pneumonia J:78756
lymph node atrophy J:78756
spleen atrophy J:78756
thymus atrophy J:78756
tubular nephritis J:78756
\Tg(CD4-HIV)F26605Pjo/0
(involves: C3H * C57BL/6)
interstitial pneumonia J:78756
lymph node atrophy J:78756
spleen atrophy J:78756
thymus atrophy J:78756
tubular nephritis J:78756
\Tg(CD4-HIV)F26622Pjo/0
(involves: C3H * C57BL/6)
interstitial pneumonia J:78756
lymph node atrophy J:78756
spleen atrophy J:78756
thymus atrophy J:78756
tubular nephritis J:78756
\Tg(CD4-HIV)F26990Pjo/0
(involves: C3H * C57BL/6)
interstitial pneumonia J:78756
lymph node atrophy J:78756
spleen atrophy J:78756
thymus atrophy J:78756
tubular nephritis J:78756
\Tg(CD4-HIV)F27011Pjo/0
(involves: C3H * C57BL/6)
interstitial pneumonia J:78756
lymph node atrophy J:78756
spleen atrophy J:78756
thymus atrophy J:78756
tubular nephritis J:78756
\Tg(CD4-HIV)F27367Pjo/0
(involves: C3H * C57BL/6)
interstitial pneumonia J:78756
lymph node atrophy J:78756
spleen atrophy J:78756
thymus atrophy J:78756
tubular nephritis J:78756
\Tg(Cd4-Il17rb)#Cdon/?
(involves: C57BL/6)
abnormal T cell differentiation J:158594
decreased interferon-gamma secretion J:158594
increased eosinophil cell number J:158594
increased interleukin-5 secretion J:158594
increased interleukin-9 secretion J:158594
increased interleukin-13 secretion J:158594
increased susceptibility to type I hypersensitivity reaction J:158594
lung inflammation J:158594
\Tg(CD4-Il17re)#Cdon/0
(involves: C57BL/6)
abnormal interleukin secretion J:177650
decreased interleukin-17 secretion J:177650
increased susceptibility to experimental autoimmune encephalomyelitis J:177650
\Tg(Cd4-NPM/ALK)N1Ingh/0
(either: (involves: BALB/c * Swiss Webster) or (involves: C57BL/6 * Swiss Webster))
increased immunoglobulin level J:82127
increased lymphoblastic lymphoma incidence J:82127
\Tg(Cd4-NPM/ALK)N1Ingh/0
(involves: C57BL/6 * Swiss Webster)
abnormal T cell differentiation J:235890
abnormal T cell morphology J:235890
increased DN3 thymocyte number J:235890
increased thymus tumor incidence J:235890
\Tg(Cd4-NPM/ALK)N1Ingh/0
\Tg(TcraTcrb)1100Mjb/0

(involves: C57BL/6 * Swiss Webster)
abnormal double-negative T cell morphology J:235890
abnormal thymus morphology J:235890
increased T cell derived lymphoma incidence J:235890
\Tg(Cd4-TGFBR2)16Flv/?
(involves: C3H * C57BL/6 * C57BL/10 * C57BR/cd)
abnormal T cell activation J:97554
abnormal T cell proliferation J:97554
abnormal thymus involution J:97554
colitis J:97554
decreased B cell number J:97554
glomerulonephritis J:97554
increased anti-nuclear antigen antibody level J:97554
increased IgA level J:97554
increased IgG1 level J:97554
increased IgG2a level J:97554
increased immunoglobulin level J:97554
increased inflammatory response J:97554
increased memory T cell number J:97554
liver inflammation J:97554
lung inflammation J:97554
lymph node hyperplasia J:97554
pancreas inflammation J:97554
spleen hyperplasia J:97554
\Tg(Cd4-TGFBR2)16Flv/?
(involves: C3H * C57BL/6)
abnormal CD8-positive, alpha-beta regulatory T cell morphology J:134473
abnormal T cell proliferation J:134473
colitis J:134156
increased interferon-gamma secretion J:134156
increased tumor necrosis factor secretion J:134156
\Tg(Cd4-Zbtb16)1797Aben/?
(C57BL/6-Tg(Cd4-Zbtb16)1797Aben)
decreased CD4-positive, alpha-beta T cell number J:139690
increased CD4-positive, alpha-beta memory T cell number J:139690
increased T-helper 2 cell number J:139690
\Tg(Cd8aCd8b)3Erob/0
(involves: C57BL/6 * DBA/2)
abnormal CD8-positive, alpha-beta T cell differentiation J:93004
abnormal double-positive T cell morphology J:93004
decreased CD4-positive, alpha-beta T cell number J:93004
decreased double-negative T cell number J:93004
increased CD8-positive, alpha-beta T cell number J:93004
\Tg(Cd8aCd8b)3Erob/0
\Tg(TcraH-Y,TcrbH-Y)71Vbo/0

(involves: C57BL/6 * DBA/2)
abnormal CD4-positive, alpha beta T cell morphology J:93004
abnormal CD8-positive, alpha-beta T cell differentiation J:93004
increased CD8-positive, alpha-beta T cell number J:93004
\Tg(CD8aCD8b)57Scr/?
(B6;SJL-Tg(CD8aCD8b)57Scr/J)
abnormal cytotoxic T cell physiology J:92994
abnormal effector T cell morphology J:92994
\Tg(Cd8b1)46Erob/0
(involves: 129S4/SvJae * C57BL/6 * CBA)
abnormal T cell subpopulation ratio J:110916
decreased T cell number J:110916
decreased thymocyte number J:110916
\Tg(CD19)1Tft/0
(involves: C57BL/6 * C57BL/6J * SJL)
decreased B cell number J:27236
increased B cell proliferation J:27236
\Tg(CD19)1Tft/\Tg(CD19)1Tft
(involves: C57BL/6 * C57BL/6J * SJL)
decreased B cell number J:27236
decreased IgG1 level J:27236
decreased IgG3 level J:27236
decreased immature B cell number J:27236
increased B cell proliferation J:27236
increased IgG2a level J:27236
increased IgG2b level J:27236
increased IgM level J:27236
\Tg(CD19-Tnfsf7)#Rvl/0
(involves: C57BL/6)
abnormal metallophilic macrophage morphology J:88620
abnormal spleen marginal zone macrophage morphology J:88620
abnormal spleen marginal zone morphology J:88620
decreased B cell number J:88620
decreased mature B cell number J:88620
decreased transitional stage B cell number J:88620
\Tg(CD46)2Gsv/0
(involves: C57BL/6 * FVB/N)
abnormal cell-mediated immunity J:109895
abnormal chemokine level J:109895
abnormal cytokine secretion J:109895
abnormal humoral immune response J:109895
abnormal response to transplant J:113644
decreased cytotoxic T cell cytolysis J:109895
increased susceptibility to Paramyxoviridae infection J:109895
\Tg(CD46)373Zbz/\Tg(CD46)373Zbz
(involves: C3H/He * C57BL/6)
immune system phenotype J:160878
\Tg(Cd68-BCL2)526Medz/0
(involves: 129 * C57BL/6)
abnormal immune cell physiology J:82809
increased inflammatory response J:82809
\Tg(Cd68-BCL2)533Medz/0
(involves: 129 * C57BL/6)
abnormal immune system cell morphology J:82809
\Tg(Cd68-BCL2)535Medz/0
(involves: 129 * C57BL/6)
abnormal dendritic cell physiology J:211458
decreased dendritic cell apoptosis J:211458
enlarged lymph nodes J:82809
enlarged spleen J:82809
increased inflammatory response J:82809
\Tg(Cd68-Fem1a)1Seno/0
(C57BL/6-Tg(Cd68-Fem1a)1Seno)
abnormal susceptibility to induced colitis J:228893
\Tg(Cd74-Nlrc4*)1Kyas/0
(involves: C57BL/6N)
abnormal spleen morphology J:219652
autoimmune arthritis J:219652
dermatitis J:219652
enlarged spleen J:219652
increased circulating interleukin-1 beta level J:219652
increased circulating interleukin-17 level J:219652
increased inflammatory response J:219652
increased interleukin-1 beta secretion J:219652
increased neutrophil cell number J:219652
increased splenocyte number J:219652
increased T cell number J:219652
joint inflammation J:219652
skin inflammation J:219652
\Tg(Cd79b-TCL1A)BKTeit/0
(involves: C3H * C57BL/6)
abnormal lymph node morphology J:79703
abnormal spleen morphology J:79703
abnormal thymus morphology J:79703
decreased B cell apoptosis J:79703
decreased T cell apoptosis J:79703
enlarged lymph nodes J:79703
enlarged spleen J:79703
increased B cell proliferation J:79703
increased lymphocyte cell number J:79703
increased T cell proliferation J:79703
\Tg(Cd152Ig)1Jbs/0
(involves: C3H * NOD)
increased susceptibility to autoimmune diabetes J:35353
\Tg(CD207-Dta)312Dhka/?
(FVB-Tg(CD207-Dta)312Dhka)
absent Langerhans cell J:113309
increased susceptibility to type IV hypersensitivity reaction J:113309
\Tg(Cebpb-tTA)5Bjd/0
\Tg(tetO-MYC,-OVAL)#Gtgm/0

(B6J.Cg-Tg(Cebpb-tTA)5Bjd Tg(tetO-MYC,-OVAL)#Gtgm)
abnormal immune tolerance J:186226
\Tg(Cga-LHB/CGB)94Jhn/?
(involves: C57BL/6 * SJL)
pyelonephritis J:55157
tubulointerstitial nephritis J:55157
\Tg(Chst4-cre)1Hkwa/0
(involves: C3H/HeN * C57BL/6)
immune system phenotype J:147714
\Tg(Ckm-APPSw)A2Lfa/0
(involves: C57BL/6 * SJL)
myositis J:76338
\Tg(Ckm-APPSw)A6Lfa/0
(involves: C57BL/6 * SJL)
myositis J:76338
\Tg(CKMM-tTA)A3Rhvh/0
\Tg(tetO-H2-K1)#Papl/0

(B6.Cg-Tg(CKMM-tTA)A3Rhvh Tg(tetO-H2-K1)#Papl)
abnormal cytokine level J:205907
increased anti-nuclear antigen antibody level J:205907
increased autoantibody level J:205907
myositis J:205907
\Tg(CLEC4C-HBEGF)956Cln/0
(C57BL/6-Tg(CLEC4C-HBEGF)956Cln)
abnormal chemokine secretion J:166504
abnormal cytotoxic T cell physiology J:166504
abnormal NK cell physiology J:166504
abnormal NK T cell physiology J:166504
decreased CD8-positive, alpha-beta T cell number J:166504
decreased interferon-alpha secretion J:166504
decreased plasmacytoid dendritic cell number J:166504
decreased splenocyte number J:166504
impaired natural killer cell mediated cytotoxicity J:166504
increased interferon-gamma secretion J:166504
increased interleukin-12 secretion J:166504
increased susceptibility to Herpesvirales infection J:166504
small spleen J:166504
\Tg(Cma1-cre)ARoer/0
\Tg(Kit*D814V)1Roer/0

(involves: C57BL/6)
colitis J:169611
increased mast cell number J:169611
\Tg(Cma1-cre)ARoer/0
\Tg(Kit*D814V)3Roer/0

(involves: C57BL/6)
increased mast cell number J:169611
\Tg(CMV-cre)1Cgn/0
\Tg(Kit*D814V)1Roer/0

(involves: BALB/cJ * C57BL/6)
increased mast cell number J:169611
large intestinal inflammation J:169611
\Tg(CMV-cre)1Cgn/0
\Tg(Kit*D814V)3Roer/0

(involves: BALB/cJ * C57BL/6)
increased mast cell number J:169611
\Tg(CMV-cre)1Cgn/0
\Trp53tm4Att/\Trp53+

(involves: 129S4/SvJae * BALB/cJ * C57BL/6J)
small thymus J:217080
\Tg(CMV-IghvaD11)CCat/0
\Tg(CMV-IgkvaD11)BCat/0

(involves: C57BL/6 * SJL)
abnormal splenic cell ratio J:79946
increased splenocyte apoptosis J:79946
\Tg(CMV-IghvaD11)DCat/0
\Tg(CMV-IgkvaD11)ACat/0

(involves: C57BL/6 * SJL)
abnormal splenic cell ratio J:79946
increased splenocyte apoptosis J:79946
\Tg(CMV-SALL4_iB)#Chai/?
(Not Specified)
abnormal leukocyte morphology J:115037
abnormal myelopoiesis J:115037
abnormal neutrophil morphology J:115037
decreased leukocyte cell number J:115037
decreased neutrophil cell number J:115037
myeloid hyperplasia J:115037
\Tg(CMV-tTA)3Bjd/0
\Tg(tetO-Prkar1a*x2as)1Stra/0

(involves: C57BL/6 * NMRI * SJL)
abnormal lymph node morphology J:94953
pancreas inflammation J:94953
\Tg(Cnp-EGFR)10Nrat/0
(involves: C57BL/6 * SJL)
increased mast cell number J:95933
\Tg(Cnp-Gpr17)1Qrlu/0
(Not Specified)
microgliosis J:154602
\Tg(Col1a1-cre)1Kry/0
\Vdrtm2Ska/\Vdrtm2Ska

(involves: C57BL/6J * C57BL/6NCrlj * CBA/JNCrlj * FVB/N)
abnormal osteoclast differentiation J:196471
decreased osteoclast cell number J:196471
\Tg(Col1a1-Dkk1)1Hmk/?
(B6.FVB-Tg(Col1a1-Dkk1)1Hmk)
abnormal osteoclast physiology J:158620
abnormal response to transplant J:238121
increased osteoclast cell number J:158620
\Tg(Col1a1-FGF2*,-Sapphire)203Mmh/\Tg(Col1a1-FGF2*,-Sapphire)203Mmh
(involves: FVB/N)
increased osteoclast cell number J:159949
osteoarthritis J:240777
\Tg(Col1a1-Runx2)#Pmt/0
(involves: BALB/c * C57BL/6)
increased osteoclast cell number J:167992
\Tg(Col1a1-TK*)#Rowe/0
(involves: CD-1)
decreased osteoclast cell number J:112520, J:217781
increased spleen weight J:112520
\Tg(Col1a1-tTA)139Niss/0
\Tg(tetO-HTR4*D100A)7Niss/0

(FVB/N-Tg(Col1a1-tTA)139Niss Tg(tetO-HTR4*D100A)7Niss)
increased osteoclast cell number J:131617
\Tg(Col2a1-cre/ERT2)1Dic/0
\Tgfbr1tm1.1Karl/\Tgfbr1tm1.1Karl

(involves: 129 * C57BL/6)
osteoarthritis J:271724
\Tg(Col2a1-Fgfr3/GH)BDor/0
(FVB/N-Tg(Col2a1-Fgfr3/GH)BDor)
abnormal osteoclast differentiation J:50292
\Tg(Col2a1-Mir140)#Asah/0
(C57BL/6-Tg(Col2a1-Mir140)#Asah)
decreased susceptibility to induced arthritis J:160358
\Tg(Col2a1-rtTA,tetO-COMP*)2Jath/0
(C57BL/6-Tg(Col2a1-rtTA,tetO-COMP*)2Jath)
increased inflammatory response J:233238
\Tg(Col10a1-Tg*L2263P)1Rpbh/0
(Not Specified)
decreased osteoclast cell number J:154052
\Tg(Col10a1-Tg*L2263P)1Rpbh/\Tg(Col10a1-Tg*L2263P)1Rpbh
(Not Specified)
decreased osteoclast cell number J:154052
\Tg(Comp-tTA)#Yeli/0
\Tg(tetO-DDR2)#Yeli/0

(Not Specified)
osteoarthritis J:176308
\Tg(Cr2-cre)3Cgn/?
\Xrcc4tm1Fwa/\Xrcc4tm2Fwa

(involves: 129P2/OlaHsd * 129S6/SvEvTac)
abnormal class switch recombination J:150339
\Tg(Crh)227.1Pbl/0
(involves: C57BL/6 * SJL)
decreased spleen weight J:92996
decreased thymus weight J:92996
\Tg(Csf1r-Tnfsf15,-EGFP)#Targ/0
(involves: C57BL/6)
increased interferon-gamma secretion J:169462
small intestinal inflammation J:169462
\Tg(CSF2)2Ygy/0
\Tg(IL3)1Ygy/0
\Tg(KITLG)3Ygy/0

(C.Cg-Tg(CSF2)2Ygy Tg(IL3)1Ygy Tg(KITLG)3Ygy)
abnormal response to transplant J:107052
decreased susceptibility to graft versus host disease J:107052
\Tg(CSTG-NPM1/RARA)#Sjch/0
(involves: C57BL/6)
enlarged spleen J:55196
increased spleen red pulp amount J:55196
\Tg(CTSG-NUMA1/RARA)#Skr/0
(involves: C57BL/6)
abnormal spleen morphology J:88103
abnormal spleen red pulp morphology J:88103
enlarged spleen J:88103
increased granulocyte number J:88103
increased leukocyte cell number J:88103
increased neutrophil cell number J:88103
increased spleen germinal center size J:88103
increased spleen white pulp amount J:88103
\Tg(CTSG-PML/RARA)135Ley/?
(Not Specified)
abnormal leukocyte cell number J:77881
abnormal spleen red pulp morphology J:77881
enlarged spleen J:77881
spleen hyperplasia J:77881
\Tg(CTSG-PML/RARA)135Ley/?
(involves: C3H * C57BL/6)
abnormal spleen red pulp morphology J:59080
enlarged spleen J:59080
immune system phenotype J:59080
increased leukocyte cell number J:59080
\Tg(CTSG-PML/RARA)135Ley/0
\Tg(CTSG-RARA/PML)#Ley/0

(involves: C3H * C57BL/6)
abnormal spleen red pulp morphology J:59080
enlarged spleen J:59080
immune system phenotype J:59080
increased leukocyte cell number J:59080
\Tg(CTSG-PML/RARA)135Ley/0
\Wbcc1SWR/J/?

(involves: C3H/HeJ * C57BL/6J * SWR/J)
decreased leukocyte cell number J:139159
\Tg(CTSG-PML/RARA)135Ley/0
\Wbcc2SWR/J/?

(involves: C3H/HeJ * C57BL/6J * SWR/J)
increased leukocyte cell number J:139159
\Tg(CTSG-PML/RARA)135Ley/0
\Wbcc3SWR/J/?

(involves: C3H/HeJ * C57BL/6J * SWR/J)
increased leukocyte cell number J:139159
\Tg(CTSG-PML/RARA)6179Ppp/0
(Not Specified)
abnormal myelopoiesis J:40373
increased granulocyte number J:40373
increased leukocyte cell number J:40373
\Tg(CTSG-PML/RARA)#Ppp/0
(Not Specified)
abnormal myelopoiesis J:78201, J:40373
increased granulocyte number J:40373
increased leukocyte cell number J:40373
\Tg(CTSG-RARA/ZBTB16)#Ppp/0
(Not Specified)
abnormal myelopoiesis J:65878
enlarged spleen J:65878
myeloid hyperplasia J:65878
\Tg(CTSG-RARA/ZBTB16)#Ppp/0
\Tg(CTSG-ZBTB16/RARA)#Ppp/0

(Not Specified)
abnormal myelopoiesis J:65878
increased leukocyte cell number J:65878
\Tg(CTSG-ZBTB16/RARA)#Ppp/0
(Not Specified)
abnormal myelopoiesis J:78201
increased leukocyte cell number J:65878, J:78201
\Tg(CTSG-ZBTB16/RARA)#Sjch/0
(involves: C57BL/6)
abnormal myelopoiesis J:55196
abnormal spleen morphology J:55196
abnormal spleen red pulp morphology J:55196
enlarged spleen J:55196
increased leukocyte cell number J:55196
myeloid hyperplasia J:55196
\Tg(CYP1A1-PPARD)#Jfoe/0
(involves: C57BL/6J * CBA)
increased T cell proliferation J:158907
skin inflammation J:158907
\Tg(Dct-Grm1)ESzc/0
(involves: C57BL/6J)
enlarged inguinal lymph nodes J:83183
enlarged submandibular lymph nodes J:83183
\Tg(DMD-APP*)7Neve/0
(involves: C57BL/6 * SJL)
abnormal microglial cell morphology J:100978
\Tg(DMD-APP*)18Neve/0
(involves: C57BL/6 * SJL)
abnormal microglial cell morphology J:100978
\Tg(DO11.10)10Dlo/?
(involves: BALB/c * C3H * C57BL/6)
abnormal thymus physiology J:70572
decreased CD4-positive, alpha-beta T cell number J:70572
decreased double-positive T cell number J:70572
\Tg(DO11.10)10Dlo/0
\Crlf2tm1Wjl/\Crlf2tm1Wjl

(involves: 129 * BALB/c * C3H * C57BL/6)
decreased inflammatory response J:107431
\Tg(DO11.10)10Dlo/?
\Toxtm1.1Kay/\Toxtm1.1Kay

(involves: 129S/Sv * BALB/c * C3H * C57BL/6)
arrested T cell differentiation J:131287
decreased T cell number J:131287
\Tg(DPP4)2Nnag/0
(B6.Cg-Tg(DPP4)2Nnag)
abnormal cytokine level J:286321
increased susceptibility to Coronaviridae infection J:286321
lung inflammation J:286321
\Tg(DPP4)2Nnag/0
\Tmprss2tm1(KOMP)Vlcg/\Tmprss2tm1(KOMP)Vlcg

(involves: C57BL/6NCr * C57BL/6NTac * DBA)
abnormal cytokine secretion J:283077
decreased susceptibility to Coronaviridae infection J:283077
\Tg(DUX4*)1Maar/?
(involves: C57BL/6J * CBA/J)
increased incidence of corneal inflammation J:195481
\Tg(ED-L2-IL1RN/IL1B)#Tcw/?
(B6.Cg-Tg(ED-L2-IL1RN/IL1B)#Tcw)
abnormal interleukin level J:180282
enlarged spleen J:180282
esophageal inflammation J:180282
increased circulating interleukin-6 level J:180282
increased inflammatory response J:180282
\Tg(EEF1A1-SHC1*)1Ravi/?
\Tg(Lck-cre)1Cwi/?

(involves: 129 * C57BL/6)
abnormal double-negative T cell morphology J:78180
decreased double-positive T cell number J:78180
decreased single-positive T cell number J:78180
thymus hypoplasia J:78180
\Tg(EIF1AX-Il31ra)1Jagr/0
(involves: C3H * C57BL/6)
abnormal immune system physiology J:91124
abnormal leukopoiesis J:91124
conjunctivitis J:91124
cutaneous mastocytosis J:91124
decreased T cell number J:91124
dermatitis J:91124
enlarged lymph nodes J:91124
increased activated T cell number J:91124
increased B cell number J:91124
increased memory T cell number J:91124
\Tg(Ela1-TAg)18Bri/0
(involves: C57BL/6 * SJL)
pancreas inflammation J:107545
\Tg(Ela1-TAg*)79Mjt/0
\Tg(MUC1)79.24Gend/0

(involves: C57BL/6 * DBA/2)
immune system phenotype J:64570
\Tg(Ela2a-Prss1*,-GFP)1Dbs/0
(C57BL/6-Tg(Ela2a-Prss1*,-GFP)1Dbs)
chronic pancreas inflammation J:144663
increased susceptibility to induced pancreatitis J:144663
\Tg(Ela-KRAS*G12D)9Eps/0
(involves: C57BL/6 * FVB)
increased regulatory T cell number J:231759
pancreas inflammation J:231759
\Tg(Ela-KRAS*G12D)9Eps/0
\Tg(Mt1-TGFBR2*)AM3Epb/0

(involves: C57BL/6 * FVB)
increased regulatory T cell number J:231759
pancreas inflammation J:231759
\Tg(Ela-KRAS*G12D)9Eps/0
\Tgfbr1tm1Bopa/\Tgfbr1+

(involves: 129S1/SvImJ * C57BL/6 * FVB)
increased CD8-positive, alpha-beta T cell number J:231759
\Tg(Emu-FGFR3)A5Wmk/0
(FVB/N-Tg(Emu-FGFR3)A5Wmk)
lymphoid hyperplasia J:160845
\Tg(Emu-FGFR3)D3Wmk/0
(FVB/N-Tg(Emu-FGFR3)D3Wmk)
lymphoid hyperplasia J:160845
\Tg(Emu-Pim1)64aBrn/0
(involves: C57BL/6LiA * CBA)
enlarged lymph nodes J:79624
enlarged spleen J:79624
enlarged thymus J:79624
increased T cell derived lymphoma incidence J:79624
\Tg(Emu-TXLNA)1Amjr/0
(B6.Cg-Tg(Emu-TXLNA)1Amjr)
abnormal B cell physiology J:117018
enhanced humoral immune response J:145185
enlarged spleen J:117018
increased autoantibody level J:117018
increased B cell number J:117018
increased B-1 B cell number J:117018
increased B-2 B cell number J:117018
increased circulating interferon-alpha level J:117018
increased germinal center B cell number J:117018
increased IgA level J:117018
increased IgG2a level J:117018
increased IgM level J:117018
increased immunoglobulin level J:117018
increased marginal zone B cell number J:117018
increased plasma cell number J:117018
increased susceptibility to autoimmune disorder J:117018, J:145185
interstitial pneumonia J:145185
kidney inflammation J:117018
lacrimal gland inflammation J:145185
lymphoid hyperplasia J:117018
parotid gland inflammation J:145185
salivary gland inflammation J:117018, J:145185
submandibular gland inflammation J:145185
\Tg(Emu-Zfp521)1Homy/0
(Not Specified)
abnormal B cell differentiation J:160392
increased B cell number J:160392
\Tg(EmuSR-HDAC9)1468Kpet/0
(involves: C57BL/6 * CBA)
abnormal lymphocyte physiology J:237420
abnormal spleen marginal zone morphology J:237420
enlarged spleen J:237420
increased B cell number J:237420
increased B cell proliferation J:237420
\Tg(EmuSR-tTa)83Bop/0
\Tg(IghMyc)22Bri/0
\Tg(tetO-RNAi:Trp53)ASlowe/0

(involves: C57BL * C57BL/6 * FVB/N * SJL)
enlarged spleen J:123006
\Tg(EmuSR-tTa)83Bop/\Tg(EmuSR-tTa)83Bop
\Tg(tetO-NPM1/ALK,-luc)2Gde/0

(involves: FVB/N)
enlarged lymph nodes J:160236
enlarged spleen J:160236
\Tg(EmuSR-tTa)83Bop/\Tg(EmuSR-tTa)83Bop
\Tg(tetO-TPM3/ALK,-luc)2Gde/0

(involves: FVB/N)
enlarged lymph nodes J:160236
enlarged spleen J:160236
\Tg(Eno2-Hgf)1Tnak/0
\Tg(SOD1*G93A)dl1Gur/0

(involves: C57BL/6 * C57BL/6J * SJL/J)
microgliosis J:128738
\Tg(Eno2-Hmox1)2Main/\Tg(Eno2-Hmox1)2Main
(involves: C57BL/6J)
enlarged spleen J:120240
\Tg(EPO33)72Ptc/0
(involves: C57BL/6J * SJL/J)
enlarged spleen J:92650
\Tg(F2RL1)1Mslb/0
(involves: FVB/NCrl)
increased inflammatory response J:79757
respiratory system inflammation J:79757
\Tg(Fabp1-cre)1Jig/0
\Vhltm1Jae/\Vhltm1Jae

(involves: 129S4/SvJae * BALB/c * FVB/N)
decreased susceptibility to induced colitis J:93476
\Tg(Fabp2-Arg1)1Wla/\Tg(Fabp2-Arg1)1Wla
(involves: FVB)
abnormal B cell differentiation J:80204
abnormal Peyer's patch morphology J:80204, J:80556
decreased B cell number J:80204
decreased IgM level J:80204
decreased Peyer's patch number J:80556
decreased pre-B cell number J:80204
decreased spleen B cell follicle number J:80204
decreased spleen weight J:80556
decreased transitional stage B cell number J:80204
small Peyer's patches J:80556
small spleen J:80204
\Tg(Fabp4-Angptl2)5Yo/0
(involves: C57BL/6)
abnormal macrophage chemotaxis J:152387
chronic inflammation J:152387
white adipose tissue inflammation J:152387
\Tg(Fabp4-Apol6)#Hsul/0
(C57BL/6J-Tg(Fabp4-Apol6)#Hsul)
white adipose tissue inflammation J:344362
\Tg(Fabp4-Phb*Y114F)#Smis/0
(Not Specified)
abnormal circulating chemokine level J:227976
abnormal circulating cytokine level J:227976
abnormal lymph node morphology J:227976
abnormal spleen morphology J:227976
enlarged lymph nodes J:227976
enlarged spleen J:227976
increased lymphocyte cell number J:227976
\Tg(FCGR2A)11Mkz/0
\Tg(PF4)#Zcy/0

(involves: C57BL/6 * SJL)
increased acute inflammation J:72220
\Tg(FCGR2A)11Mkz/\Tg(FCGR2A)11Mkz
(involves: C57BL/6 * SJL)
abnormal macrophage physiology J:136516
autoimmune arthritis J:136516
glomerulonephritis J:136516
increased anti-histone antibody level J:136516
increased IgG2a level J:136516
increased susceptibility to induced arthritis J:136516
increased tumor necrosis factor secretion J:136516
interstitial pneumonia J:136516
\Tg(Fga,Fgb,Fgg)1Unc/?
(C57BL/6-Tg(Fga,Fgb,Fgg)1Unc)
increased circulating fibrinogen level J:118353
\Tg(Fli1)1Ber/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CD-1)
increased thymocyte number J:33052
\Tg(FOXJ1-ACE2)1Rba/0
(involves: C3H * C57BL/6)
decreased lymphocyte cell number J:288386
increased susceptibility to Coronaviridae infection J:287092, J:288386
increased susceptibility to Coronaviridae infection induced morbidity/mortality J:287092, J:288386
interstitial pneumonia J:288386
\Tg(Foxp3-HBEGF/EGFP)23.2Spar/0
(involves: C57BL/6NCrl)
decreased regulatory T cell number J:125295
enlarged lymph nodes J:125295
enlarged spleen J:125295
immune system phenotype J:125295
increased inflammatory response J:125295
increased spleen red pulp amount J:125295
increased spleen white pulp amount J:125295
increased susceptibility to type IV hypersensitivity reaction J:125295
insulitis J:125295
lung inflammation J:125295
lymph node hyperplasia J:125295
skin inflammation J:125295
\Tg(Gfap-gp120)2Lms/0
(involves: C57BL/6 * SJL)
abnormal microglial cell morphology J:146427
microgliosis J:146427
\Tg(Gfap-gp120)10Lms/0
(involves: C57BL/6 * SJL)
microgliosis J:146427
\Tg(Gfap-Ifna1)12Ilc/0
(involves: BALB/c * C57BL/6J)
CNS inflammation J:68811
decreased susceptibility to Riboviria infection J:68811
decreased susceptibility to Riboviria infection induced morbidity/mortality J:68811
meningoencephalitis J:68811
\Tg(Gfap-Ifna1)39Ilc/0
(involves: BALB/c * C57BL/6J)
CNS inflammation J:68811
meningoencephalitis J:68811
\Tg(Gfap-Il6)G16Lms/0
\Tg(Gfap-lacZ)1Lms/0

(involves: C57BL/6J * SJL)
immune system phenotype J:125549
\Tg(Gfap-Il6)G369Lms/0
(involves: C57BL/6J * SJL)
immune system phenotype J:125549
\Tg(Gfap-rtTA,tetO-MAOB,-lacZ)1Jkan/0
(involves: C57BL/6)
abnormal microglial cell activation J:132679
abnormal microglial cell morphology J:132679
\Tg(Gfap-TGFB1)64Lms/0
(involves: BALB/c * SJL)
immune system phenotype J:27781
\Tg(Gfap-TGFB1)64Lms/\Tg(Gfap-TGFB1)64Lms
(involves: BALB/c * SJL)
immune system phenotype J:27781
\Tg(Gfap-TK)7.1Mvs/0
(involves: C57BL/10 * CBA * CFLP)
abnormal inflammatory response J:104241
brain inflammation J:113202
increased neutrophil cell number J:104241
small intestinal inflammation J:104241
\Tg(Gfap-TNF*)K21Gkl/0
(involves: C57BL/6 * CBA)
CNS inflammation J:106592
\Tg(GFAP-tTA)78Pop/0
\Tg(tetO-Ifng)184Pop/0

(B6.Cg-Tg(GFAP-tTA)78Pop Tg(tetO-Ifng)184Pop)
abnormal interferon-gamma secretion J:109838
CNS inflammation J:109838
\Tg(GNB1L,TBX1,GP1BB,SEPT5)23Bem/0
(either: FVB-Tg(GNB1L,TBX1,GP1BB,SEPT5)23Bem or (involves: C57BL/6 * FVB))
abnormal thymus development J:67796
abnormal thymus lobule morphology J:67796
decreased thymocyte number J:67796
thymus hypoplasia J:67796
\Tg(H2-Aa)26Dim/?
\Tg(H2-Ab1)62Dim/?

(B6.Cg-Tg(H2-Aa)26Dim Tg(H2-Ab1)62Dim)
abnormal antigen presentation via MHC class II J:110897
abnormal level of surface class II molecules J:110897
immune system phenotype J:110897
increased immunoglobulin level J:110897
\Tg(H2-Aa)26Dim/?
\Tg(H2-Ab1)62Dim/?

(SJL.Cg-Tg(H2-Aa)26Dim Tg(H2-Ab1)62Dim)
abnormal level of surface class II molecules J:110897
immune system phenotype J:110897
\Tg(H2-D-Il15)3304Clgr/?
(FVB/N-Tg(H2-D-Il15)3304Clgr)
abnormal inflammatory response J:67478
abnormal lymphocyte physiology J:67478
abnormal T cell morphology J:67478
abnormal T cell subpopulation ratio J:67478
dermatitis J:67478
enlarged lymph nodes J:67478
enlarged spleen J:67478
increased lymphocyte cell number J:67478
increased memory T cell number J:67478
increased NK cell number J:67478
increased spleen white pulp amount J:67478
\Tg(H2-Db)2Bujf/0
(FVB/NPas-Tg(H2-Db)2Bujf)
decreased susceptibility to Picornaviridae infection J:18556
\Tg(H2-Ea)16Dim/?
(involves: C57BL/6 * SJL)
increased immunoglobulin level J:111128
\Tg(H2-Ea-G6pc2)69Tkay/?
(NOD-Tg(H2-Ea-G6pc2)69Tkay)
abnormal CD4-positive, alpha-beta T cell physiology J:117352
abnormal CD8-positive, alpha beta T cell morphology J:117352
abnormal immune tolerance J:117352
decreased T cell proliferation J:117352
increased anti-insulin autoantibody level J:117352
increased susceptibility to autoimmune diabetes J:117352
insulitis J:117352
\Tg(H2-Ea-HA)HACIIAjca/0
\Tg(Tcra/Tcrb)1Vbo/0

(C.Cg-Tg(H2-Ea-HA)HACIIAjca Tg(Tcra/Tcrb)1Vbo)
abnormal CD4-positive, alpha beta T cell morphology J:209872
abnormal circulating cytokine level J:209872
autoimmune arthritis J:209872
heart inflammation J:209872
increased circulating interleukin-6 level J:209872
increased IgG level J:209872
joint inflammation J:209872
kidney inflammation J:209872
\Tg(H2-Ea-HA)HACIIAjca/0
\Tg(TcraS106-1,TcrbS106-1)TS1SWAjca/0

(C.Cg-Tg(H2-Ea-HA)HACIIAjca Tg(TcraS106-1,TcrbS106-1)TS1SWAjca)
abnormal CD4-positive, alpha beta T cell morphology J:209872
abnormal CD4-positive, alpha-beta T cell physiology J:209872
abnormal circulating cytokine level J:209872
autoimmune arthritis J:209872
decreased circulating interleukin-6 level J:209872
enlarged lymph nodes J:209872
immune system phenotype J:209872
increased circulating interleukin-17 level J:209872
increased IgG level J:209872
joint inflammation J:209872
\Tg(H2-Ea-Il7)10Rhdr/0
(involves: C57BL/6)
abnormal B cell morphology J:81133
abnormal double-negative T cell morphology J:81133
\Tg(H2-Ea-Il7)10Rhdr/0
(involves: C57BL/6 * DBA/2)
increased pre-B cell number J:171924
increased pro-B cell number J:171924
\Tg(H2-Ea-Ins2)1Wehi/0
(NOD/ShiLtJWehi-Tg(H2-Ea-Ins2)1Wehi)
abnormal T cell proliferation J:100232
immune system phenotype J:100232
salivary gland inflammation J:100232
\Tg(H2-Ea-Ins2)1Wehi/\Tg(H2-Ea-Ins2)1Wehi
(NOD/ShiLtJWehi-Tg(H2-Ea-Ins2)1Wehi)
abnormal CD8-positive, alpha beta T cell morphology J:117352
decreased anti-insulin autoantibody level J:117352
decreased T cell proliferation J:117352
immune system phenotype J:117352
\Tg(H2-Ea-LACK)1Ngkh/0
(C.Cg-Tg(H2-Ea-LACK)1Ngkh)
abnormal immune system physiology J:181384
abnormal T-helper 1 physiology J:181384
abnormal T-helper 2 physiology J:181384
decreased susceptibility to parasitic infection J:181384
decreased susceptibility to parasitic infection induced morbidity/mortality J:181384
decreased T-helper 2 cell number J:181384
increased T-helper 1 cell number J:181384
\Tg(H2-Ea-Tnfsf9)16Lpc/0
(involves: C57BL/6)
abnormal B cell physiology J:132372
abnormal lymph node B cell domain morphology J:132372
decreased B cell number J:132372
decreased IgG level J:132372
decreased spleen B cell follicle number J:132372
enlarged spleen J:132372
increased granulocyte number J:132372
increased lymphocyte cell number J:132372
increased macrophage cell number J:132372
increased memory T cell number J:145439
increased NK cell number J:132372
spleen hyperplasia J:132372
\Tg(H2-Ead)5Lt/0
(NOD/ShiLt-Tg(H2-Ead)5Lt)
autoimmune response J:36435
decreased interferon-gamma secretion J:36435
decreased susceptibility to autoimmune diabetes J:36435
increased interleukin-4 secretion J:36435
periinsulitis J:36435
\Tg(H2-Ead)12Lt/0
(NOD/ShiLt-Tg(H2-Ead)12Lt)
autoimmune response J:36435
decreased interferon-gamma secretion J:36435
decreased susceptibility to autoimmune diabetes J:36435
increased interleukin-4 secretion J:36435
insulitis J:36435
\Tg(H2-K1-HLA-A*)28Mpla/0
(B10.Cg-Tg(H2-K1-HLA-A*)28Mpla)
choroid inflammation J:67871
eye inflammation J:67871
\Tg(H2-K-BCL2)1Josd/0
(involves: C57BL/6 * C57BL/Ka * C3H)
abnormal lymph organ size J:80894
enlarged lymph nodes J:80894
enlarged spleen J:80894
enlarged thymus J:80894
increased leukocyte cell number J:80894
\Tg(H2-K-Cd86)7All/0
(involves: C57BL/6J * CBA)
abnormal B cell differentiation J:112475
decreased B cell number J:112475
increased CD4-positive, alpha-beta T cell number J:112475
increased CD8-positive, alpha-beta T cell number J:112475
\Tg(H2-K-Cd86)7All/0
(B6.Cg-Tg(H2-K-Cd86)7All)
abnormal inflammatory response J:112266
decreased B cell number J:112266
decreased CD4-positive, alpha-beta T cell number J:112266
increased CD8-positive, alpha-beta T cell number J:112266
increased T cell number J:112266
lymph node hyperplasia J:112266
lymphoid hyperplasia J:112266
\Tg(H2-K-Cd86)7All/0
(involves: BALB/c * C57BL/6 * CBA)
increased splenocyte number J:112266
lymph node hyperplasia J:112266
spleen hyperplasia J:112266
\Tg(H2-K-Cd86)27All/0
(involves: C57BL/6J * CBA)
abnormal B cell differentiation J:112475
decreased B cell number J:112475
\Tg(H2-K-Cd86)31All/0
(involves: C57BL/6J * CBA)
increased CD4-positive, alpha-beta T cell number J:112475
increased CD8-positive, alpha-beta T cell number J:112475
\Tg(H2-K-DUSP5)21Wjl/0
(involves: C57BL/6J * CBA)
abnormal T cell number J:138077
decreased single-positive T cell number J:138077
decreased T cell proliferation J:138077
dermatitis J:138077
increased CD4-positive, alpha-beta T cell number J:138077
increased CD8-positive, alpha-beta T cell number J:138077
increased double-positive T cell number J:138077
increased plasma cell number J:138077
increased single-positive T cell number J:138077
skin inflammation J:138077
\Tg(H2-K-Fosl1)1Wag/0
(involves: C57BL/6 * CBA)
enlarged spleen J:64494
\Tg(H2-K-Fosl2,-EGFP)13Wag/0
(either: 129.Cg-Tg(H2-K-Fosl2,-EGFP)13Wag or B6.Cg-Tg(H2-K-Fosl2,-EGFP)13Wag)
thymus fibrosis J:139032
\Tg(H2-K-Fosl2,-EGFP)13Wag/0
(B6.Cg-Tg(H2-K-Fosl2,-EGFP)13Wag)
lung inflammation J:238723
\Tg(H2-K-HLA-G,B2M)1Alm/0
(CBA/Ca-Tg(H2-K-HLA-G,B2M)1Alm/CmwJ)
abnormal cytotoxic T cell physiology J:140016
increased T cell proliferation J:140016
\Tg(H2-K-Hmga1)#Lmsr/0
(involves: C57BL/6 * SJL)
increased leukocyte cell number J:90252
\Tg(H2-K-IL6)2Srj/0
(B6.Cg-Tg(H2-K-IL6)2Srj)
abnormal granulocyte morphology J:185153
abnormal lymph node germinal center morphology J:185153
abnormal lymph node morphology J:185153
abnormal spleen germinal center morphology J:185153
abnormal spleen red pulp morphology J:185153
enlarged lymph nodes J:185153
enlarged spleen J:185153
increased IgG level J:185153
increased plasma cell number J:185153
\Tg(H2-K-MC159/EGFP)13Fkmc/0
(involves: C57BL/6)
abnormal lymphopoiesis J:138050
decreased B cell apoptosis J:138050
decreased T cell apoptosis J:138050
enlarged spleen J:138050
immune system phenotype J:138050
increased B cell proliferation J:138050
increased follicular B cell number J:138050
\Tg(H2-K-MC159/EGFP)13Fkmc/\Tg(H2-K-MC159/EGFP)13Fkmc
(involves: C57BL/6)
increased anti-double stranded DNA antibody level J:138050
increased double-negative T cell number J:138050
increased IgG2b level J:138050
increased T cell number J:138050
\Tg(H2-K-TcrbP14)128Mak/?
(involves: C57BL/6 * C57L * DBA/2)
abnormal CD8-positive, alpha-beta T cell differentiation J:111265
abnormal T cell clonal deletion J:111265
abnormal T cell differentiation J:111265
increased CD8-positive, alpha-beta T cell number J:111265
\Tg(H2-Kb-IL21)5Wjl/0
(involves: 129)
abnormal B cell differentiation J:93740
abnormal class switch recombination J:93740
decreased follicular B cell number J:93740
decreased marginal zone B cell number J:93740
decreased mature B cell number J:93740
decreased transitional stage T2 B cell number J:93740
increased B cell apoptosis J:93740
increased IgG1 level J:93740
increased IgM level J:93740
increased immature B cell number J:93740
increased transitional stage T1 B cell number J:93740
\Tg(H2-Kb-Jak2*V617F)2Shmd/0
(involves: C57BL/6 * DBA/2)
abnormal spleen morphology J:130189
enlarged spleen J:130189
increased leukocyte cell number J:130189
increased neutrophil cell number J:130189
increased spleen red pulp amount J:130189
increased spleen weight J:130189
myeloid hyperplasia J:130189
spleen fibrosis J:130189
\Tg(H2-Kb-Tcra,-Tcrb)1640Kurs/0
(SJL.FVB-Tg(H2-Kb-Tcra,-Tcrb)1640Kurs)
abnormal cytokine level J:149511
brain inflammation J:149511
CNS inflammation J:149511
increased autoantibody level J:149511
increased susceptibility to experimental autoimmune encephalomyelitis J:149511
increased T-helper 1 cell number J:149511
increased T-helper 17 cell number J:149511
\Tg(H2-L-IL6)1Kish/\Tg(H2-L-IL6)1Kish
(C57BL/6-Tg(H2-L-IL6)1Kish)
abnormal myelopoiesis J:128016
enlarged lymph nodes J:128016, J:138762
enlarged spleen J:128016, J:138762
glomerulonephritis J:128016, J:138762
increased IgG1 level J:128016
increased monocyte cell number J:128016
increased neutrophil cell number J:128016
increased plasma cell number J:128016, J:138762
\Tg(H2-L-IL6)40Csk/0
(involves: C57BL/6)
enlarged lymph nodes J:207264
enlarged spleen J:207264
increased spleen weight J:207264
\Tg(H2-L-IL6)46Kish/\Tg(H2-L-IL6)46Kish
(C57BL/6-Tg(H2-L-IL6)46Kish)
enlarged axillary lymph nodes J:40405
enlarged mesenteric lymph nodes J:40405
glomerulonephritis J:40405
increased immunoglobulin level J:40405
increased plasma cell number J:40405
\Tg(H2-L-IL6)46Kish/\Tg(H2-L-IL6)46Kish
(involves: BALB/c * C57BL/6)
abnormal immune system organ morphology J:40405
abnormal lymph node morphology J:40405
enlarged mesenteric lymph nodes J:40405
increased IgA level J:40405
increased immunoglobulin level J:40405
\Tg(H2-L-IL6)46Kish/\Tg(H2-L-IL6)46Kish
(C.B6-Tg(H2-L-IL6)46Kish)
abnormal spleen trabecular artery morphology J:177820
abnormal spleen trabecular vein morphology J:177820
enlarged spleen J:177820
increased IgG1 level J:74377
increased IgG2b level J:74377
increased IgG level J:74377
\Tg(H2-Ld)LoxNibl/0
(C57BL/6-Tg(H2-Ld)LoxNibl)
decreased susceptibility to parasitic infection induced morbidity/mortality J:284394
increased response to antigen J:284394
\Tg(H2KePCC)2403Stoe/?
(involves: C57BL/6 * SJL)
abnormal immune tolerance J:92997
\Tg(H2KePCC)2403Stoe/?
\Tg(TcraTcrbAD10)1Hed/?

(involves: C57BL/6 * SJL)
abnormal immune tolerance J:92997
abnormal T cell anergy J:92997
decreased CD4-positive, alpha-beta T cell number J:92997
\Tg(H2KmPCC)2939Stoe/?
(involves: C57BL/6 * SJL)
abnormal immune tolerance J:92997
\Tg(H2KmPCC)2939Stoe/0
\Tg(Tcra2B4)1Mmd/0
\Tg(Tcrb2B4)1Mmd/0

(involves: C3H/HeJ * C57BL/6 * SJL)
abnormal T cell differentiation J:50143
decreased T cell proliferation J:50143
decreased thymocyte number J:50143
\Tg(H2KmPCC)2939Stoe/?
\Tg(TcrAND)53Hed/?

(involves: C57BL/6 * SJL)
abnormal immune tolerance J:92997
abnormal T cell anergy J:92997
decreased CD4-positive, alpha-beta T cell number J:92997
\Tg(H2KmPCC)2939Stoe/?
\Tg(TcraTcrbAD10)1Hed/?

(involves: C57BL/6 * SJL)
abnormal immune tolerance J:92997
abnormal T cell anergy J:92997
decreased CD4-positive, alpha-beta T cell number J:92997
\Tg(HBB-Myc)#Cos/0
(involves: C57BL/6J * CBA/J)
abnormal immune system organ morphology J:276641
kidney inflammation J:276641
\Tg(HBV)10Imeg/0
(involves: C57BL/6)
abnormal cytokine secretion J:95283
abnormal dendritic cell physiology J:95283
\Tg(HBVX*,-Myc)#Skp/\Tg(HBVX*,-Myc)#Skp
(Not Specified)
increased macrophage cell number J:81098
\Tg(HCRT-tTA)1Ahky/0
\Tg(tetO-DTA)1Gfi/0

(B6.Cg-Tg(HCRT-tTA)1Ahky Tg(tetO-DTA)1Gfi)
increased microglial cell activation J:211045
\Tg(HIV)26Aln/0
(involves: FVB/N)
kidney inflammation J:90297
myositis J:90297
uveitis J:136652
\Tg(HLA-A2/H2-K)1Scr/?
(involves: C57BL/6)
abnormal cytotoxic T cell physiology J:127813
\Tg(HLA-A/H2-D/B2M)1Dvs/0
(NOD/ShiLtDvs-Tg(HLA-A/H2-D/B2M)1Dvs)
increased susceptibility to autoimmune diabetes J:121685
\Tg(HLA-B27)1Trg/0
(involves: C57BL/6 * SJL/J)
immune system phenotype J:74451
\Tg(HLA-B27)30-4Trg/?
(involves: C57BL/6J * NOD)
decreased susceptibility to autoimmune diabetes J:109851
\Tg(HLA-DQA1,HLA-DQB1)1Dv/0
\Tg(Ins2-CD80)3B7Flv/0

(B6.Cg-Tg(HLA-DQA1,HLA-DQB1)1Dv Tg(Ins2-CD80)3B7Flv)
decreased susceptibility to autoimmune diabetes J:59245
\Tg(HLA-DR2)#Lfug/0
\Tg(TCROb.1A12)#Lfug/0

(involves: C57BL/6 * DBA/2)
CNS inflammation J:134764
increased susceptibility to experimental autoimmune encephalomyelitis J:134764
\Tg(HLA-DRA*0101,HLA-DRB1*0101)1Dmz/\Tg(HLA-DRA*0101,HLA-DRB1*0101)1Dmz
(involves: C57BL/6 * C57BL/10Sn * SJL/J)
abnormal T cell physiology J:108635
increased autoantibody level J:108635
increased susceptibility to induced arthritis J:108635
\Tg(Hmgcr-MX1)LStae/\Tg(Hmgcr-MX1)LStae
(involves: 129S2/SvPas * BALB/c * C57BL/6 * SJL)
decreased susceptibility to Orthomyxoviridae infection J:119783
decreased susceptibility to Orthomyxoviridae infection induced morbidity/mortality J:119783
\Tg(HTT*)NXwy/0
(involves: FVB/NJ)
CNS inflammation J:219890
\Tg(ICAM1)4Grom/?
(involves: BALB/cAnNTac)
increased susceptibility to Picornaviridae infection J:92607
\Tg(Igh3H9)41Mwg/?
(involves: C57BL/6 * SJL)
abnormal B cell differentiation J:119625
decreased IgD level J:119625
increased anti-single stranded DNA antibody level J:119625
\Tg(Igh*-Mir125b-1)5Toki/0
(Not Specified)
enlarged spleen J:178816
\Tg(Igh*-Mir125b-1)116Toki/0
(Not Specified)
decreased B cell apoptosis J:178816
enlarged spleen J:178816
increased B cell number J:178816
increased T cell derived lymphoma incidence J:178816
\Tg(Igh-3/Igh-6VD93)1241Ust/?
(C57BL/6-Tg(Igh-3/Igh-6VD93)1241Ust)
abnormal B cell morphology J:135209
decreased pre-B cell number J:135209
\Tg(Igh-3VD93)343Ust/?
(involves: C57BL/6 * SJL)
abnormal B cell morphology J:135209
decreased pre-B cell number J:135209
\Tg(Igh-6-Cd80)1Gjf/0
(involves: FVB)
abnormal CD4-positive, alpha-beta T cell physiology J:44271
abnormal humoral immune response J:112474
abnormal T cell activation J:44271
decreased B cell number J:44271
decreased immunoglobulin level J:112474
\Tg(Igh-6-Cd80)1Gjf/0
(B6.Cg-Tg(Igh-6-Cd80)1Gjf)
abnormal T cell number J:112266
\Tg(Igh-6-Cd80)1Gjf/0
(NOD.FVB-Tg(Igh-6-Cd80)1Gjf/JbsJ)
abnormal B cell activation J:131077
abnormal CD8-positive, alpha-beta T cell physiology J:131077
abnormal level of surface class II molecules J:131077
decreased B cell number J:131077
decreased B-2 B cell number J:131077
decreased follicular B cell number J:131077
decreased IgG1 level J:131077
decreased IgG2b level J:131077
decreased IgG3 level J:131077
decreased IgM level J:131077
decreased immature B cell number J:131077
decreased immunoglobulin level J:131077
decreased mature B cell number J:131077
decreased susceptibility to autoimmune diabetes J:131077
insulitis J:131077
\Tg(Igh-6-Cd86)1Akab/0
(involves: FVB)
abnormal CD4-positive, alpha-beta T cell physiology J:44271
decreased B cell number J:44271
\Tg(Igh-6/Igh-V125)2Jwt/0
\Tg(Igk-C/Igk-V125)1Jwt/0

(NOD.B6-Tg(Igh-6/Igh-V125)2Jwt Tg(Igk-C/Igk-V125)1Jwt)
abnormal B cell number J:91865
increased susceptibility to autoimmune diabetes J:91865
insulitis J:91865
\Tg(Igh-6/Igh-V281)3Jwt/0
(NOD.B6-Tg(Igh-6/Igh-V281)3Jwt)
decreased susceptibility to autoimmune diabetes J:91865
insulitis J:91865
\Tg(Igh-Abl1)40Sco/0
(involves: C57BL/6JWehi * SJL/JWehi)
abnormal peripheral lymph node morphology J:78204
enlarged mesenteric lymph nodes J:78204
enlarged spleen J:78204
\Tg(Igh-Abl1)40Sco/0
\Tg(IghMyc)22Bri/0

(involves: C57BL/6 * C57BL/6JWehi * SJL/J * SJL/JWehi)
enlarged mesenteric lymph nodes J:78204
\Tg(Igh-HMGA2)#Cro/0
(FVB/N-Tg(Igh-HMGA2)#Cro)
abnormal splenic cell ratio J:233225
decreased B cell number J:233225
decreased IgG1 level J:233225
decreased IgG2a level J:233225
decreased IgG2b level J:233225
decreased IgG3 level J:233225
decreased response to antigen J:233225
decreased T cell number J:233225
enlarged lymph nodes J:233225
enlarged spleen J:233225
increased circulating interleukin-6 level J:233225
increased circulating tumor necrosis factor level J:233225
increased T cell number J:233225
\Tg(Igh-HOX11)11Idd/0
(CD-1)
abnormal immunoglobulin V(D)J recombination J:52782
increased leukocyte cell number J:52782
myeloid hyperplasia J:52782
spleen hyperplasia J:52782
\Tg(Igh-Lmp2a)ERlon/0
(involves: C57BL/6 * SJL)
abnormal B cell proliferation J:129571
decreased B cell number J:129571
\Tg(Igh-Maf)68Staka/0
(C57BL/6-Tg(Igh-Maf)68Staka)
abnormal spleen morphology J:168074
enlarged spleen J:168074
increased IgG level J:168074
increased IgM level J:168074
increased immunoglobulin level J:168074
increased plasma cell number J:168074
\Tg(Igh-Maf)524Staka/0
(involves: C57BL/6 * C57BL/6J * DBA/2)
abnormal spleen morphology J:168074
enlarged spleen J:168074
increased IgG level J:168074
increased IgM level J:168074
increased immunoglobulin level J:168074
increased plasma cell number J:168074
\Tg(Igh-Mir29a,-Mir29b-1,-hrGFP)#Cro/0
(FVB/N-Tg(Igh-Mir29a,-Mir29b-1,-hrGFP)#Cro)
abnormal B cell physiology J:162077
abnormal lymphopoiesis J:162077
abnormal spleen morphology J:162077
decreased IgG1 level J:162077
decreased IgG2a level J:162077
decreased IgG2b level J:162077
enlarged spleen J:162077
increased B cell proliferation J:162077
increased B-1a cell number J:162077
spleen hyperplasia J:162077
\Tg(Igh-Mir29a,-Mir29b-1,-hrGFP)#Cro/0
\Tg(Igh-V186.2-TCL1A)3Cro/0

(involves: C3H * C57BL/6 * FVB/N)
increased B-1a cell number J:162077
spleen hyperplasia J:162077
\Tg(Igh-Mir155)8Cro/0
(involves: FVB/N)
abnormal lymphopoiesis J:109591
abnormal spleen B cell follicle morphology J:109591
decreased leukocyte cell number J:109591
decreased spleen white pulp amount J:109591
enlarged spleen J:109591
increased B cell number J:109591
increased B cell proliferation J:109591
increased lymphoblastic lymphoma incidence J:109591
increased pre-B cell number J:109591
increased spleen white pulp amount J:109591
intermingled spleen red and white pulp J:109591
\Tg(Igh-Mir155)10Cro/0
(involves: FVB/N)
enlarged spleen J:109591
\Tg(Igh-Mir210)#aKgcs/\Tg(Igh-Mir210)#aKgcs
(B6.Cg-Tg(Igh-Mir210)#aKgcs)
abnormal class switch recombination J:205868
abnormal spleen marginal zone morphology J:205868
decreased IgA level J:205868
decreased IgG1 level J:205868
decreased IgG2a level J:205868
decreased IgG2b level J:205868
decreased IgG3 level J:205868
decreased marginal zone B cell number J:205868
decreased mature B cell number J:205868
decreased pre-B cell number J:205868
decreased pro-B cell number J:205868
immune system phenotype J:205868
increased B-1a cell number J:205868
\Tg(Igh-Nfil3)#Kubo/0
(B6.Cg-Tg(Igh-Nfil3)#Kubo)
increased interleukin-3 secretion J:172134
increased interleukin-10 secretion J:172134
increased interleukin-13 secretion J:172134
\Tg(Igh-Pim1)1Brn/0
(involves: C57BL/6LiA * CBA)
enlarged lymph nodes J:79624
enlarged spleen J:79624
enlarged thymus J:79624
increased T cell derived lymphoma incidence J:79624
\Tg(Igh-ROR1)1Kip/0
(C57BL/6-Tg(Igh-ROR1)1Kip)
enlarged spleen J:206368
increased lymphocyte cell number J:206368
increased mature B cell number J:206368
\Tg(Igh-ROR1)1Kip/0
\Tg(Igh-V186.2-TCL1A)3Cro/0

(B6.Cg-Tg(Igh-ROR1)1Kip Tg(Igh-V186.2-TCL1A)3Cro)
enlarged spleen J:206368
increased lymphocyte cell number J:206368
increased mature B cell number J:206368
\Tg(Igh-TCL1A)1Ypek/0
(FVB/N-Tg(Igh-TCL1A)1Ypek)
abnormal circulating chemokine level J:160184
abnormal humoral immune response J:160184
abnormal lymphocyte physiology J:160184
decreased IgG1 level J:160184
decreased IgG2a level J:160184
decreased IgG2b level J:160184
decreased IgG3 level J:160184
decreased IgM level J:160184
enlarged spleen J:160184
increased circulating tumor necrosis factor level J:160184
\Tg(Igh-V186.2-TCL1A)3Cro/0
(involves: C3H * C57BL/6)
abnormal B cell morphology J:76574
increased marginal zone B cell number J:76574
peritoneal inflammation J:76574
spleen hyperplasia J:76574
\Tg(Igh-V-CD40lg)#Tsub/0
(C57BL/6-Tg(Igh-V-CD40lg)#Tsub)
glomerulonephritis J:128824
increased anti-double stranded DNA antibody level J:128824
increased anti-histone antibody level J:128824
increased anti-single stranded DNA antibody level J:128824
\Tg(Igh-V-CD40lg)#Tsub/0
(involves: C57BL/6)
abnormal bronchus-associated lymphoid tissue morphology J:89855
colitis J:89855
enlarged lymph nodes J:89855
enlarged spleen J:89855
glomerulonephritis J:89855
increased autoantibody level J:89855
increased IgG level J:89855
increased IgM level J:89855
increased interferon-gamma secretion J:89855
increased splenocyte number J:89855
increased splenocyte proliferation J:89855
\Tg(IGH@*)SALed/0
(involves: C57BL/6 * CD-1)
abnormal mature B cell morphology J:131938
\Tg(IGH@yH1)2BJkbv/0
(involves: 129P2/OlaHsd)
abnormal B cell morphology J:23827
abnormal immunoglobulin heavy chain V(D)J recombination J:23827
abnormal immunoglobulin level J:23827
\Tg(IGH@yH1)2BJkbv/0
\Tg(IGK@yK1)9.2CJkbv/0

(involves: 129P2/OlaHsd)
abnormal B cell morphology J:23827
abnormal immunoglobulin level J:23827
\Tg(IghelMD4)4Ccg/0
(involves: C3H/HeJ * C57BL/6)
decreased pre-B cell number J:115059
decreased pro-B cell number J:115059
\Tg(IghelMD4)4Ccg/0
(involves: C57BL/6)
abnormal B cell activation J:73608
decreased pre-B cell number J:115059
decreased pro-B cell number J:115059
\Tg(IghelMD4)4Ccg/0
(C57BL/6-Tg(IghelMD4)4Ccg)
abnormal B cell morphology J:78308, J:109923, J:132538
abnormal B-2 B cell morphology J:132538
abnormal germinal center B cell morphology J:109923
abnormal immature B cell morphology J:109923
abnormal mature B cell morphology J:89156, J:109923
abnormal plasma cell morphology J:109923
abnormal pro-B cell morphology J:109923
increased IgG2b level J:132538
increased IgM level J:78308, J:132538
increased immature B cell number J:78308, J:132538
\Tg(IghelMD4)4Ccg/0
\Tg(KLK4mHEL)6Ccg/0

(NOD.B6-Tg(IghelMD4)4Ccg Tg(KLK4mHEL)6Ccg/Dvs)
decreased B cell number J:89156
\Tg(IghelMD4)4Ccg/0
\Tg(KLK4mHEL)6Ccg/0

(C57BL/6-Tg(IghelMD4)4Ccg Tg(KLK4mHEL)6Ccg)
decreased B cell number J:89156
\Tg(IghelMD4)4Ccg/?
\Tg(KLK4mHEL)6Ccg/?

(involves: C57BL/6)
arrested B cell differentiation J:78307
decreased mature B cell number J:78307
increased immature B cell number J:78307
\Tg(IghelMD4)4Ccg/0
\Tg(ML5sHEL)5Ccg/0

(NOD.B6-Tg(IghelMD4)4Ccg Tg(ML5sHEL)5Ccg/Dvs)
abnormal B cell anergy J:89156
abnormal B cell clonal deletion J:89156
abnormal B cell morphology J:89156
decreased IgM level J:89156
\Tg(IghelMD4)4Ccg/0
\Tg(ML5sHEL)5Ccg/0

(C57BL/6-Tg(IghelMD4)4Ccg Tg(ML5sHEL)5Ccg)
abnormal B cell anergy J:89156, J:78308
abnormal central B cell anergy J:109923
abnormal germinal center B cell morphology J:109923
abnormal immature B cell morphology J:109923
abnormal mature B cell morphology J:109923
abnormal plasma cell morphology J:109923
abnormal pro-B cell morphology J:109923
abnormal spleen B cell follicle morphology J:109923
decreased B cell number J:89156
decreased IgM level J:89156, J:78308
\Tg(IghelMD4)4Ccg/0
\Tg(ML5sHEL)5Ccg/0

(involves: C57BL/6)
abnormal B cell anergy J:73608, J:132538
abnormal B cell physiology J:76134
abnormal spleen primary B follicle morphology J:76134
decreased B cell number J:76134
decreased marginal zone B cell number J:132538
\Tg(IghelMD4)4Ccg/\Tg(IghelMD4)4Ccg
(NOD.B6-Tg(IghelMD4)4Ccg/DvsJ)
abnormal mature B cell morphology J:80859, J:89156
abnormal T cell proliferation J:80859
decreased CD8-positive, alpha-beta T cell number J:80859
increased susceptibility to autoimmune diabetes J:80859
\Tg(IghelMD4)4Ccg/\Tg(IghelMD4)4Ccg
(involves: C57BL/6)
decreased pre-B cell number J:171924
decreased pro-B cell number J:171924
\Tg(IghH280)48Dvs/?
(NOD/ShiLtDvs-Tg(IghH280)48Dvs/J)
increased susceptibility to autoimmune diabetes J:274578
insulitis J:274578
\Tg(IghH280)48Dvs/?
\Tg(IgkH280)934Dvs/?

(NOD/ShiLtDvs-Tg(IghH280)48Dvs Tg(IgkH280)934Dvs/Dvs)
increased susceptibility to autoimmune diabetes J:274578
\Tg(Ighm-Ctla4Ig/Cd80)1Jbs/0
(involves: FVB/N)
abnormal B cell physiology J:113109
immune system phenotype J:113109
\Tg(Ighm-Ctla4Ig/Cd80)1Jbs/0
(NOD.FVB-Tg(Ighm-Ctla4Ig/Cd80)1Jbs)
decreased susceptibility to autoimmune diabetes J:113109
immune system phenotype J:113109
\Tg(IghMyc)22Bri/?
(involves: C57BL * C57BL/6 * SJL)
enlarged spleen J:121564
increased lymphocyte cell number J:121564
\Tg(IghMyc)22Bri/0
(involves: C57BL/6 * SJL)
abnormal lymphopoiesis J:78177
enlarged lymph nodes J:78177
enlarged spleen J:78177
enlarged thymus J:78177
increased leukocyte cell number J:186117
increased pre-B cell number J:223213
\Tg(IghMyc)22Bri/0
(B6.Cg-Tg(IghMyc)22Bri/J)
enlarged lymph nodes J:354285, J:164200
spleen hyperplasia J:164200
\Tg(IghMyc)22Bri/0
(involves: C57BL/6N * SJL)
increased B cell apoptosis J:214383
\Tg(IghMyc)22Bri/0
\Tg(Igk-V21-Bax)1967Bvn/0

(involves: C57BL/6 * FVB/N)
enlarged spleen J:89049
increased transitional stage B cell number J:89049
\Tg(IghMyc)22Bri/0
\Xiaptm1Hs/\Xiaptm1Hs

(B6.Cg-Xiaptm1Hs Tg(IghMyc)22Bri)
decreased B cell proliferation J:138979
decreased leukocyte cell number J:138979
increased B cell apoptosis J:138979
\Tg(IghMyc)186Brn/0
\Rpl24Bst/\Rpl24+

(involves: C57BL/LiA * C57BLKS * CBA/BrA)
immune system phenotype J:142390
\Tg(Igk-Lta/Ltb)4Cys/0
(involves: C57BL/6J * DBA/2J)
abnormal B cell morphology J:73100
\Tg(Igk-Lta/Ltb)10Cys/0
(involves: C57BL/6J * DBA/2J)
abnormal B cell morphology J:73100
\Tg(Igk-V21-Bax)1967Bvn/0
(involves: FVB/N)
abnormal plasma cell morphology J:89049
increased IgA level J:89049
increased IgE level J:89049
increased IgG1 level J:89049
increased IgG2a level J:89049
increased IgG level J:89049, J:90901
increased IgM level J:89049
increased immunoglobulin level J:89049
increased transitional stage B cell number J:89049
\Tg(IGK@yK1)9.2CJkbv/0
(involves: 129P2/OlaHsd)
abnormal B cell morphology J:23827
abnormal immunoglobulin level J:23827
abnormal immunoglobulin light chain V-J recombination J:23827
\Tg(IgkH280)934Dvs/?
(NOD/ShiLtDvs-Tg(IgkH280)934Dvs/J)
increased susceptibility to autoimmune diabetes J:274578
insulitis J:274578
\Tg(Igkv3-5*-MYC)24Plbe/0
(C57BL/6J-Tg(Igkv3-5*-MYC)DLoxP4Plbe/PlbeMmmh)
abnormal humoral immune response J:131912
abnormal immunoglobulin level J:131912
abnormal plasma cell differentiation J:131912
increased IgG1 level J:131912
increased IgG3 level J:131912
increased plasma cell number J:131912
\Tg(Igl-2MOPC315)1275Ust/?
(C57BL/6-Tg(Igl-2MOPC315)1275Ust)
abnormal B cell morphology J:134666
decreased IgM level J:134666
decreased immature B cell number J:134666
\Tg(IGL-MYC)3Hm/0
(C57BL/6N-Tg(IGL-MYC)3Hm/Nci)
enlarged lymph nodes J:65245
\Tg(Il1rn)1Dih/0
(involves: C57BL/6 * CBA)
decreased circulating interleukin-6 level J:88605
decreased circulating serum amyloid protein level J:61600
decreased inflammatory response J:88605
decreased susceptibility to endotoxin shock J:36387
decreased susceptibility to Herpesvirales infection J:88605
increased susceptibility to bacterial infection J:36387
\Tg(Il1rn)1Dih/\Tg(Il1rn)1Dih
(involves: C57BL/6 * CBA)
decreased susceptibility to endotoxin shock J:36387
increased circulating interleukin-1 level J:36387
increased susceptibility to bacterial infection J:36387
\Tg(IL2-Il10)1Kro/0
(involves: C3H * C57BL/6)
abnormal cytokine secretion J:41588
decreased susceptibility to parasitic infection J:41588
increased susceptibility to bacterial infection J:80569
\Tg(IL3,CSF2)C42Pnc/0
(involves: C57BL/6 * CBA)
immune system phenotype J:219403
\Tg(ILK3mHEL)3Ccg/0
\Tg(TcrHEL3A9)1Mmd/0

(involves: C57BL/6JSfd * C57BL/10Sg * C57BR/cd)
abnormal CD4-positive, alpha beta T cell morphology J:78309
abnormal CD4-positive, alpha-beta T cell physiology J:78309
abnormal T cell activation J:78309
abnormal T cell proliferation J:78309
decreased CD4-positive, alpha-beta T cell number J:78309
insulitis J:78309
\Tg(Ins1-Cat,Tyr)25Pne/0
(NOD.FVB-Tg(Ins1-Cat,Tyr)25Pne)
increased susceptibility to autoimmune diabetes J:108415
\Tg(Ins1-Cd80)378Psoh/0
\Tg(Ins2-GP)#Psoh/0
\Tg(TcrLCMV)327Sdz/0

(involves: C57BL/6 * DBA/2 * FVB/N)
insulitis J:209714
periinsulitis J:209714
\Tg(Ins1-EGFP/GH1)14Hara/0
(NOD/ShiLtJ-Tg(Ins1-EGFP/GH1)14Hara)
increased susceptibility to autoimmune diabetes J:127015
\Tg(Ins1-EGFP/GH1)14Hara/\Tg(Ins1-EGFP/GH1)14Hara
(NOD/ShiLtJ-Tg(Ins1-EGFP/GH1)14Hara)
decreased susceptibility to autoimmune disorder J:127015
insulitis J:127015
\Tg(Ins2*Y16A)1Ell/0
(NOD-Tg(Ins2*Y16A)1Ell)
increased susceptibility to autoimmune diabetes J:98583
\Tg(Ins2*Y16A)3Ell/0
(NOD-Tg(Ins2*Y16A)3Ell)
increased susceptibility to autoimmune diabetes J:98583
\Tg(Ins2-Ccl19)2Cys/0
(involves: C57BL/6 * DBA/2)
abnormal lymph organ development J:77238
\Tg(Ins2-Ccl21b)2Cys/0
(involves: C57BL/6 * DBA/2)
abnormal lymph organ development J:77238
\Tg(Ins2-CD80)3B7Flv/?
(involves: C57BL/6 * CBA/Ca * NOD/Caj)
increased susceptibility to autoimmune diabetes J:26618
insulitis J:26618
\Tg(Ins2-CD80)3B7Flv/0
\Tg(Ins2-H2-Ead,Ins2-H2-Eb1b)187-7Bri/0

(involves: C57BL/6 * CBA/Ca * SJL)
increased susceptibility to autoimmune diabetes J:93555
insulitis J:93555
\Tg(Ins2-CD80)3B7Flv/0
\Tg(Ins2-Tnf)17Flv/0

(involves: C57BL/6 * CBA/Ca)
abnormal cytokine secretion J:93555
increased susceptibility to autoimmune diabetes J:93555
\Tg(Ins2-CD86)12B70Flv/0
(involves: C57BL/6 * CBA/Ca)
abnormal cytokine secretion J:93555
decreased susceptibility to autoimmune diabetes J:93555
periinsulitis J:93555
\Tg(Ins2-CD86)12B70Flv/0
\Tg(Ins2-H2-Ead,Ins2-H2-Eb1b)187-7Bri/0

(involves: C57BL/6 * CBA/Ca * SJL)
abnormal cytokine secretion J:93555
increased susceptibility to autoimmune diabetes J:93555
insulitis J:93555
\Tg(Ins2-CD86)12B70Flv/0
\Tg(Ins2-Tnf)17Flv/0

(involves: C57BL/6 * CBA/Ca)
abnormal cytokine secretion J:93555
increased susceptibility to autoimmune diabetes J:93555
\Tg(Ins2-Cd274)2Mdos/?
(NOD/ShiLt-Tg(Ins2-Cd274)2Mdos)
increased susceptibility to autoimmune diabetes J:118934
\Tg(Ins2-cre)5Lt/0
(NOD/ShiLt-Tg(Ins2-cre)5Lt)
increased susceptibility to autoimmune diabetes J:127015
\Tg(Ins2-cre)5Lt/\Tg(Ins2-cre)5Lt
(NOD/ShiLt-Tg(Ins2-cre)5Lt)
decreased susceptibility to autoimmune disorder J:127015
insulitis J:127015
\Tg(Ins2-crmA)27Ngkh/?
(NOD-Tg(Ins2-CrmA)27Ngkh)
increased susceptibility to autoimmune diabetes J:132052
\Tg(Ins2-Cxcl13)1Cys/0
(involves: C57BL/6 * DBA/2)
abnormal lymph organ development J:110548
\Tg(Ins2-E3)1Dvs/?
(NOD.Cg-Tg(Ins2-E3)1Dvs)
decreased susceptibility to autoimmune diabetes J:68996
\Tg(Ins2-E3*309)5Dvs/?
(NOD/ShiLtDvs-Tg(Ins2-E3*309)5Dvs/Dvs)
decreased susceptibility to autoimmune diabetes J:83195
\Tg(Ins2-E3*704)2Dvs/?
(NOD/ShiLtDvs-Tg(Ins2-E3*704)2Dvs)
decreased susceptibility to autoimmune diabetes J:83195
\Tg(Ins2-E3*734)3Dvs/0
(NOD/ShiLtDvs-Tg(Ins2-E3*734)3Dvs/DvsJ)
decreased susceptibility to autoimmune diabetes J:106340
\Tg(Ins2-E3*734)4Dvs/?
(NOD/ShiLtDvs-Tg(Ins2-E3*734)4Dvs/DvsJ)
decreased susceptibility to autoimmune diabetes J:106340
\Tg(Ins2-Fas*I246N)1Ach/0
(NOD-Tg(Ins2-Fas*I246N)1Ach)
decreased susceptibility to autoimmune diabetes J:81416
\Tg(Ins2-Fas*I246N)1Ach/0
\Tg(Ins2-Fasl)24Ach/0

(NOD-Tg(Ins2-Fas*I246N)1Ach Tg(Ins2-Fasl)24Ach)
decreased susceptibility to autoimmune diabetes J:81416
\Tg(Ins2-Fasl)24Ach/0
(NOD-Tg(Ins2-Fasl)24Ach/J)
increased susceptibility to autoimmune diabetes J:78679, J:81416
\Tg(Ins2-GAD2)1Lt/0
(NOD/ShiLt-Tg(Ins2-GAD2)1Lt)
insulitis J:100251
\Tg(Ins2-GAD2)2Lt/0
(NOD/ShiLt-Tg(Ins2-GAD2)2Lt)
abnormal cytokine secretion J:100251
decreased susceptibility to autoimmune diabetes J:100251
insulitis J:100251
\Tg(Ins2-GP)34-20Olds/0
(involves: BALB/c * C57BL/6)
abnormal lymphocyte physiology J:81287
abnormal T cell physiology J:81287
increased susceptibility to autoimmune diabetes J:81287
\Tg(Ins2-GP)#Psoh/0
(involves: C57BL/6)
insulitis J:81285
\Tg(Ins2-GP)#Psoh/0
\Tg(TcrLCMV)327Sdz/0

(involves: C57BL/6 * DBA/2)
abnormal B cell selection J:81285
\Tg(Ins2-H2-Ead,Ins2-H2-Eb1b)187-7Bri/0
(involves: C57BL/6 * SJL)
decreased susceptibility to autoimmune diabetes J:93555
\Tg(Ins2-HA)165Bri/0
(B10.Cg- H2d Tg(Ins2-HA)165Bri/ShrmJ)
abnormal CD4-positive, alpha-beta T cell physiology J:86430
decreased T cell proliferation J:86430
immune system phenotype J:86430
\Tg(Ins2-HA)165Bri/0
\Tg(TcraCl4,TcrbCl4)1Shrm/0

(involves: BALB/c * C57BL/6 * C57BL/10 * DBA/2)
insulitis J:99756
\Tg(Ins2-HA)165Bri/?
\Tg(TcraCl4,TcrbCl4)1Shrm/?

(involves: BALB/c * C57BL/6 * C57BL/10)
insulitis J:99756
\Tg(Ins2-Iapp)6Soel/\Tg(Ins2-Iapp)6Soel
(involves: FVB/N)
decreased susceptibility to autoimmune diabetes J:130022
\Tg(Ins2-IAPP)RHFSoel/\Tg(Ins2-IAPP)RHFSoel
(involves: FVB/N)
increased susceptibility to autoimmune diabetes J:130022
\Tg(Ins2-Lta)#Flv/0
(involves: NOD)
insulitis J:91820
kidney inflammation J:91820
periinsulitis J:91820
\Tg(Ins2-Lta)#Flv/0
(involves: C57BL/6)
insulitis J:91820
kidney inflammation J:91820
periinsulitis J:91820
\Tg(Ins2-Lta)#Flv/0
(involves: C57BL/6 * CBA)
insulitis J:127705
periinsulitis J:127705
\Tg(Ins2-NP)25-3Olds/0
(involves: BALB/c * C57BL/6)
decreased susceptibility to autoimmune diabetes J:81287
increased susceptibility to autoimmune diabetes J:81287
\Tg(Ins2-OVA)59Wehi/?
(involves: BALB/c * C57BL/6)
abnormal T cell activation J:99560
increased susceptibility to autoimmune diabetes J:99560
\Tg(Ins2-OVA)307Wehi/?
(involves: BALB/c * C57BL/6)
increased susceptibility to autoimmune diabetes J:99560
\Tg(Ins2-OVA)307Wehi/0
\Tg(TcraTcrb)1100Mjb/0

(involves: C57BL/6 * C57BL/6JWehi)
autoimmune response J:99451
\Tg(Ins2-TFRC/OVA)296Wehi/0
(involves: C57BL/6)
abnormal CD8-positive, alpha beta T cell morphology J:98589
abnormal leukocyte migration J:98589
decreased interferon-gamma secretion J:122114
increased susceptibility to autoimmune diabetes J:122114
\Tg(Ins2-TFRC/OVA)296Wehi/0
\1700016L21RikTg(Itgax-HBEGF/EGFP)57Lan/0

(involves: C57BL/6 * FVB)
decreased T cell proliferation J:122114
\Tg(Ins2-TFRC/OVA)296Wehi/0
\Tg(TcraTcrb)425Cbn/0

(involves: 129P2/OlaHsd * C57BL/6)
decreased CD4-positive, alpha-beta T cell number J:135154
increased double-positive T cell number J:135154
\Tg(Ins2-Tnf)17Flv/0
(involves: C57BL/6 * CBA * NOD)
immune system phenotype J:91820
insulitis J:91820
\Tg(Ins2-Tnf)17Flv/0
(involves: C57BL/6 * CBA)
insulitis J:91820
\Tg(Ins2-Tnf)17Flv/0
(involves: C57BL/6)
decreased CD8-positive, alpha-beta T cell number J:93555
increased CD4-positive, alpha-beta T cell number J:93555
\Tg(INS-Il10)#Sar/0
(involves: BALB/c)
pancreas inflammation J:107927
periinsulitis J:107927
\Tg(INS-Il10)#Sar/0
\Tnfrsf1atm1Mak/\Tnfrsf1atm1Mak

(involves: 129S2/SvPas * C57BL/6J * NOD)
increased susceptibility to autoimmune diabetes J:64051
\Tg(INS-Il10)#Sar/0
\Tnfrsf1btm1Mwm/\Tnfrsf1btm1Mwm

(involves: 129S2/SvPas * C57BL/6J * NOD)
increased susceptibility to autoimmune diabetes J:64051
\Tg(INS-MT2A,Tyr)1Pne/0
(FVB-Tg(INS-MT2A,Tyr)1Pne)
abnormal response to transplant J:95089
\Tg(ITGA2)1067Fmw/0
\Tg(ITGB1)0840Fmw/0

(involves: C57BL/10 * CBA)
dermatitis J:30249
eye inflammation J:30249
\Tg(ITGA2)1067Fmw/0
\Tg(ITGB1)0869Fmw/0

(involves: C57BL/10 * CBA)
dermatitis J:30249
eye inflammation J:30249
\Tg(ITGA2)1067Fmw/0
\Tg(ITGB1)0870Fmw/0

(involves: C57BL/10 * CBA)
dermatitis J:30249
eye inflammation J:30249
\Tg(ITGA2)1070Fmw/0
\Tg(ITGB1)0840Fmw/0

(involves: C57BL/10 * CBA)
dermatitis J:30249
eye inflammation J:30249
\Tg(ITGA2)1070Fmw/0
\Tg(ITGB1)0869Fmw/0

(involves: C57BL/10 * CBA)
dermatitis J:30249
eye inflammation J:30249
\Tg(ITGA2)1070Fmw/0
\Tg(ITGB1)0870Fmw/0

(involves: C57BL/10 * CBA)
dermatitis J:30249
eye inflammation J:30249
\Tg(ITGA2)1075Fmw/0
\Tg(ITGB1)0840Fmw/0

(involves: C57BL/10 * CBA)
dermatitis J:30249
eye inflammation J:30249
\Tg(ITGA2)1075Fmw/0
\Tg(ITGB1)0869Fmw/0

(involves: C57BL/10 * CBA)
dermatitis J:30249
eye inflammation J:30249
\Tg(ITGA2)1075Fmw/0
\Tg(ITGB1)0870Fmw/0

(involves: C57BL/10 * CBA)
dermatitis J:30249
eye inflammation J:30249
\Tg(ITGA5)0794Fmw/0
\Tg(ITGB1)0840Fmw/0

(involves: C57BL/10 * CBA)
dermatitis J:30249
eye inflammation J:30249
\Tg(ITGA5)0794Fmw/0
\Tg(ITGB1)0869Fmw/0

(involves: C57BL/10 * CBA)
dermatitis J:30249
eye inflammation J:30249
\Tg(ITGA5)0794Fmw/0
\Tg(ITGB1)0870Fmw/0

(involves: C57BL/10 * CBA)
dermatitis J:30249
eye inflammation J:30249
\Tg(ITGA5)0844Fmw/0
\Tg(ITGB1)0840Fmw/0

(involves: C57BL/10 * CBA)
dermatitis J:30249
eye inflammation J:30249
\Tg(ITGA5)0844Fmw/0
\Tg(ITGB1)0869Fmw/0

(involves: C57BL/10 * CBA)
dermatitis J:30249
eye inflammation J:30249
\Tg(ITGA5)0844Fmw/0
\Tg(ITGB1)0870Fmw/0

(involves: C57BL/10 * CBA)
dermatitis J:30249
eye inflammation J:30249
\Tg(ITGA5)0858Fmw/0
\Tg(ITGB1)0840Fmw/0

(involves: C57BL/10 * CBA)
dermatitis J:30249
eye inflammation J:30249
\Tg(ITGA5)0858Fmw/0
\Tg(ITGB1)0869Fmw/0

(involves: C57BL/10 * CBA)
dermatitis J:30249
eye inflammation J:30249
\Tg(ITGA5)0858Fmw/0
\Tg(ITGB1)0870Fmw/0

(involves: C57BL/10 * CBA)
dermatitis J:30249
eye inflammation J:30249
\Tg(ITGAL-Hhex)2Hro/0
(C3HeB/FeJ-Tg(ITGAL-Hhex)2Hro)
abnormal double-negative T cell morphology J:80777
abnormal thymus corticomedullary boundary morphology J:80777
decreased double-positive T cell number J:80777
decreased leukocyte cell number J:80777
decreased lymphocyte cell number J:80777
decreased T cell number J:80777
increased CD8-positive, alpha-beta T cell number J:80777
thymus hypoplasia J:80777
\Tg(ITGAL-Ptprca)FRasch/\Tg(ITGAL-Ptprca)FRasch
(involves: BALB/c * C57BL/6)
abnormal T cell differentiation J:158876
\Tg(Itgam-FCAR)83Rcmo/0
(involves: C57BL/6 * NOD)
glomerulonephritis J:120534
increased IgA level J:120534
\Tg(ITGAM-HBEGF/EGFP)34Lan/0
(involves: FVB/N)
abnormal macrophage morphology J:95141
decreased macrophage cell number J:95141
increased neutrophil cell number J:95141
\Tg(ITGAM-HBEGF/EGFP)34Lan/0
(NOD.FVB-Tg(ITGAM-HBEGF/EGFP)34Lan/Jdk)
decreased macrophage cell number J:137009
immune system phenotype J:137009
\Tg(Itgax-EGFP,-cre,-HBEGF,-luc)2Gjh/0
(C57BL/6-Tg(Itgax-EGFP,-cre,-HBEGF,-luc)2Gjh)
abnormal susceptibility to infection J:194800
immune system phenotype J:194800
increased monocyte cell number J:194800
increased neutrophil cell number J:194800
\Tg(Itgax-HBEGF/OVA/EGFP)1Garbi/0
(C57BL/6-Tg(Itgax-HBEGF/OVA/EGFP)1Garbi)
abnormal susceptibility to infection J:194800
decreased dendritic cell number J:194800
increased neutrophil cell number J:194800
\Tg(Itgax-TGFBR2)1Flv/0
(C.Cg-Tg(Itgax-TGFBR2)1Flv)
abnormal immune system physiology J:98953
abnormal interferon level J:98953
abnormal NK cell differentiation J:98953
decreased susceptibility to parasitic infection J:98953
immune system phenotype J:98953
increased NK cell number J:98953
\Tg(ITGB1)0840Fmw/0
(involves: C57BL/10 * CBA)
dermatitis J:30249
eye inflammation J:30249
\Tg(ITGB1)0869Fmw/0
(involves: C57BL/10 * CBA)
dermatitis J:30249
eye inflammation J:30249
\Tg(ITGB1)0870Fmw/0
(involves: C57BL/10 * CBA)
dermatitis J:30249
eye inflammation J:30249
\Tg(IVL-KLK5)#Hov/0
(involves: C57BL/6 * CBA)
abnormal circulating cytokine level J:210758
abnormal inguinal lymph node morphology J:210758
enlarged lymph nodes J:210758
enlarged spleen J:210758
erythroderma J:210758
increased activated T cell number J:210758
increased IgE level J:210758
lymph node inflammation J:210758
skin inflammation J:210758
\Tg(JAK2*V617F)FF1Rsko/0
\Commd10Tg(Vav1-icre)A2Kio/\Commd10+

(involves: C57BL/6 * C57BL/10 * CBA/Ca)
abnormal myelopoiesis J:134364
abnormal spleen morphology J:134364
decreased B cell number J:134364
decreased T cell number J:134364
enlarged spleen J:134364
increased neutrophil cell number J:134364
spleen fibrosis J:134364
\Tg(JAK2*V617F)FF1Rsko/0
\Tg(Mx1-cre)1Cgn/0

(involves: C57BL/6 * CBA)
abnormal myelopoiesis J:134364
abnormal spleen morphology J:134364
decreased B cell number J:134364
decreased T cell number J:134364
enlarged spleen J:134364
increased neutrophil cell number J:134364
spleen fibrosis J:134364
\Tg(JAK2*V617F)FF1Rsko/0
\Tg(Tek-cre)1Arnd/0

(involves: C57BL/6 * CBA * DBA/2)
decreased T cell number J:206659
enlarged spleen J:206659
increased neutrophil cell number J:206659
\Tg(K18-ACE2)2Prlmn/0
(involves: C57BL/6J * SJL/J)
increased susceptibility to Coronaviridae infection J:283648
increased susceptibility to Coronaviridae infection induced morbidity/mortality J:283648
\Tg(K18-ACE2)2Prlmn/0
(B6.Cg-Tg(K18-ACE2)2Prlmn/J)
abnormal chemokine level J:302313
abnormal circulating chemokine level J:294084
abnormal circulating cytokine level J:302313
abnormal cytokine level J:294084, J:302313
abnormal interferon level J:300960, J:302313
abnormal interleukin level J:300960, J:302313
abnormal tumor necrosis factor level J:300960, J:302313
blood vessel inflammation J:300960
brain inflammation J:294084
bronchiolitis J:302313
conjunctivitis J:294084
cytokine storm J:300960
enhanced humoral immune response J:302313
increased circulating CXCL10 level J:302313
increased circulating interferon-gamma level J:302313
increased circulating interleukin-6 level J:294084
increased circulating interleukin-10 level J:294084, J:302313
increased circulating tumor necrosis factor level J:294084
increased CXCL10 level J:300960
increased IgG level J:302313
increased IgM level J:302313
increased leukocyte cell number J:294084
increased lymphocyte cell number J:302313
increased macrophage cell number J:294084, J:302313
increased neutrophil cell number J:294084, J:300960, J:302313
increased susceptibility to Coronaviridae infection J:294084, J:300960, J:302313, J:296067
increased susceptibility to Coronaviridae infection induced morbidity/mortality J:294084, J:300960
increased susceptibility to Orthomyxoviridae infection J:296067
increased susceptibility to viral infection J:296067
increased susceptibility to viral infection induced morbidity/mortality J:296067
increased T cell number J:300960
interstitial pneumonia J:300960, J:302313
liver inflammation J:300960
lung inflammation J:294084, J:302313
meningitis J:294084, J:302313
meningoencephalitis J:300960, J:296067
microgliosis J:294084
rhinitis J:300960
\Tg(Kit*D814V)1Roer/0
\Tg(Mx1-cre)1Cgn/0

(involves: C57BL/6 * CBA)
abnormal mast cell morphology J:169611
colitis J:169611
enlarged spleen J:169611
increased mast cell number J:169611
large intestinal inflammation J:169611
small intestinal inflammation J:169611
\Tg(Kit*D814V)2Roer/0
\Tg(Mx1-cre)1Cgn/0

(involves: C57BL/6 * CBA)
abnormal mast cell morphology J:169611
colitis J:169611
increased mast cell number J:169611
large intestinal inflammation J:169611
small intestinal inflammation J:169611
\Tg(Kit*D814V)3Roer/0
\Tg(Mx1-cre)1Cgn/0

(involves: C57BL/6 * CBA)
abnormal mast cell morphology J:169611
colitis J:169611
enlarged spleen J:169611
increased mast cell number J:169611
large intestinal inflammation J:169611
\Tg(KLK4mHEL)6Ccg/0
\Tg(TcrHEL3A9)1Mmd/0

(involves: C57BL/6 * C57BL/10 * C57BR/cd)
decreased CD4-positive, alpha-beta T cell number J:78309
decreased double-positive T cell number J:78309
\Tg(KRT5-IKBKB)1Armz/0
(involves: C57BL/6 * DBA/2)
increased interleukin-1 alpha secretion J:160072
increased interleukin-6 secretion J:160072
increased tumor necrosis factor secretion J:160072
\Tg(KRT5-IKBKB)2Armz/0
(involves: C57BL/6 * DBA/2)
abnormal cytokine level J:160072
abnormal immune serum protein physiology J:160072
abnormal melanophage morphology J:160072
dermatitis J:160072
increased circulating interferon-gamma level J:160072
increased circulating interleukin-1 alpha level J:160072
increased circulating interleukin-2 level J:160072
increased circulating interleukin-4 level J:160072
increased circulating interleukin-5 level J:160072
increased circulating interleukin-6 level J:160072
increased circulating interleukin-10 level J:160072
increased circulating tumor necrosis factor level J:160072
increased interleukin-1 alpha secretion J:160072
increased interleukin-6 secretion J:160072
increased tumor necrosis factor secretion J:160072
\Tg(KRT5-Nfkbia*)3Rto/0
\Tg(Krt5-Tnfr1)#Rsab/0
\Tnfrsf1atm1Mak/\Tnfrsf1atm1Mak

(involves: 129S2/SvPas * C57BL/6 * CBA)
skin inflammation J:208995
\Tg(KRT5-rtTA)1Glk/0
\Tg(tetO-Tfrc/EGFP/Ova)#Sfz/0

(involves: FVB/N)
immune system phenotype J:199558
\Tg(KRT5-rtTA)1Glk/0
\Tg(tetO-Tfrc/EGFP/Ova)#Sfz/0
\Tg(tetO/CMV-Tslp)#Sfz/0

(involves: C3H * C57BL/6 * FVB/N)
increased T cell proliferation J:199558
respiratory system inflammation J:199558
skin inflammation J:199558
\Tg(KRT5-rtTA)1Glk/0
\Tg(tetO-TGFB1*C223S*C225S)1Glk/0

(involves: FVB/N)
dermatitis J:70670
skin inflammation J:70670
\Tg(KRT5-rtTA)1Glk/0
\Tg(tetO/CMV-Tslp)#Sfz/0

(involves: C3H * C57BL/6 * FVB/N)
abnormal cytokine level J:100506
abnormal lymph node morphology J:100506
conjunctivitis J:100506
decreased IgG2a level J:100506
dermatitis J:100506
enlarged lymph nodes J:100506
enlarged spleen J:100506
increased CD4-positive, alpha-beta T cell number J:100506
increased IgE level J:100506
increased IgG1 level J:100506
\Tg(KRT5-rtTA)1Glk/0
\Tg(tetO/CMV-Tslp)#Sfz/0

(C.Cg-Tg(KRT5-rtTA)1Glk Tg(tetO/CMV-Tslp)#Sfz)
abnormal B cell activation J:182756
increased autoantibody level J:182756
increased B cell proliferation J:182756
increased circulating interleukin-4 level J:182756
increased susceptibility to autoimmune hemolytic anemia J:182756
\Tg(KRT5-rtTA)#Glk/0
\Tg(tetO-cre)1Jaw/0
\Wlstm1.1Lan/\Wlstm1.1Lan

(involves: 129S6/SvEvTac * C57BL/6 * FVB/N)
cutaneous mastocytosis J:204142
\Tg(KRT5-rtTA)#Glk/0
\Tg(tetO-S100a7a)#Yus/0

(involves: FVB/N)
abnormal chemokine secretion J:168000
increased interleukin-1 alpha secretion J:168000
increased tumor necrosis factor secretion J:168000
\Tg(KRT5-TGFB1)F2020Xjw/0
(involves: C57BL/6 * DBA/2 * ICR)
abnormal Langerhans cell morphology J:90118
abnormal Langerhans cell physiology J:90118
cutaneous mastocytosis J:90118
decreased Langerhans cell number J:90118
skin inflammation J:90118
\Tg(KRT5-tTA)1216Glk/0
\Tg(tetO-Il13)1Tazh/0

(B6.Cg-Tg(KRT5-tTA)1216Glk Tg(tetO-Il13)1Tazh)
cutaneous mastocytosis J:150232
dermatitis J:150232
increased IgE level J:150232
increased IgG1 level J:150232
increased interleukin-4 secretion J:150232
increased interleukin-13 secretion J:150232
\Tg(KRT5-tTA)1216Glk/0
\Tg(tetO-LMNA*G608G,-EGFP)VF1-07Maer/0

(involves: FVB/N)
periodontium inflammation J:145312
skin inflammation J:145312
\Tg(KRT5-tTA)1216Glk/0
\Tg(tetO-Tek)1Dmt/0

(involves: CD-1 * FVB/N)
abnormal interleukin secretion J:147438
increased interferon-gamma secretion J:147438
increased interleukin-12 secretion J:147438
increased interleukin-17 secretion J:147438
increased interleukin-23 secretion J:147438
skin inflammation J:147438
\Tg(KRT5-tTA)1216Glk/0
\Tg(tetO-TGFB1*C223S*C225S)1Glk/0

(involves: FVB/N)
dermatitis J:70670
skin inflammation J:70670
\Tg(Krt14-Angptl2)1Yo/0
(C.Cg-Tg(Krt14-Angptl2)1Yo)
skin inflammation J:152387, J:181261
\Tg(KRT14-CASP1)1Miz/0
(involves: C57BL/6)
abnormal T cell physiology J:78602
decreased T cell number J:78602
dermatitis J:78602, J:79706
increased circulating interleukin-18 level J:78602, J:79706
increased IgE level J:78602
increased IgG1 level J:78602
increased neutrophil cell number J:78602
increased susceptibility to bacterial infection J:79706
increased susceptibility to bacterial infection induced morbidity/mortality J:79706
\Tg(KRT14-cre)1Amc/0
\Trpv3tm1.1Clph/\Trpv3tm1.1Clph

(involves: 129S4/SvJae * 129S4/SvJaeSor * C57BL/6 * C57BL/6J * CBA * Swiss Webster)
erythroderma J:164741
\Tg(KRT14-FIGF)2Ali/0
(involves: FVB/N)
lymphatic vessel hyperplasia J:137909, J:68138
\Tg(KRT14-FLT4/IGHG1)#Ali/0
(either: (involves: FVB/N) or (involves: BALB/c * DBA))
abnormal lymphatic vessel morphology J:201429
abnormal mononuclear phagocyte morphology J:201429
\Tg(Krt14-Ifnk)#Cya/0
(C57BL/6N-Tg(Krt14-Ifnk)#Cya)
enlarged spleen J:322130
increased susceptibility to chemically induced skin inflammation J:322130
\Tg(KRT14-Il1f6)1Hblu/?
(involves: C57BL/6 * DBA/2)
abnormal chemokine level J:126327
skin inflammation J:126327
\Tg(KRT14-Il4)#Lsch/0
(involves: BALB/cBy * C57BL/6)
blepharitis J:126285
conjunctivitis J:126285
decreased IgG2a level J:126285
dermatitis J:126285
increased IgE level J:126285
increased IgG1 level J:126285
increased mast cell degranulation J:126285
increased susceptibility to bacterial infection J:126285
skin inflammation J:126285
\Tg(KRT14-Il7)1Tsk/0
(FVB/N-Tg(KRT14-Il7)1Tsk)
blepharitis J:42565
skin inflammation J:42565
\Tg(KRT14-Il7)1Tsk/\Tg(KRT14-Il7)1Tsk
(FVB/N-Tg(KRT14-Il7)1Tsk)
skin inflammation J:42565
\Tg(KRT14-Il18)#Knak/0
(C57BL/6-Tg(KRT14-Il18)#Knak)
abnormal T cell physiology J:78602
decreased T cell number J:78602
dermatitis J:78602
increased circulating interleukin-18 level J:78602
increased IgE level J:78602
increased IgG1 level J:78602
increased neutrophil cell number J:78602
\Tg(Krt14-Rac1*G12V)#Mrnk/0
(involves: CBA/CaJ)
abnormal circulating interleukin level J:237134
joint inflammation J:237134
skin inflammation J:237134
\Tg(KRT14-Tslp)1Pcn/0
(involves: C57BL/6 * SJL)
abnormal lymphocyte physiology J:102470
enlarged spleen J:102470
increased immunoglobulin level J:102470
lymph node hyperplasia J:102470
\Tg(KRT14-Vegfa)3Dtm/0
(FVB/N-Tg(KRT14-Vegfa)3Dtm)
abnormal leukocyte adhesion J:104245
abnormal lymphatic vessel morphology J:111924
enhanced leukocyte tethering or rolling J:104245
enlarged lymph nodes J:92643
enlarged lymphatic vessel J:92643
increased macrophage cell number J:111924
increased mast cell number J:104245
\Tg(KRT14-VEGFC*)1Ali/0
(involves: FVB/N)
lymphatic vessel hyperplasia J:68138
\Tg(KRT14-Vegfd)1Ali/0
\Vegfctm1Ali/\Vegfc+

(involves: 129S1/Sv * 129X1/SvJ * FVB)
abnormal lymphatic vessel morphology J:137909
\Tg(KRT14-VP16/NR1I2)13Sdub/?
(involves: C57BL/6)
abnormal CD4-positive, alpha-beta T cell number J:258435
abnormal CD8-positive, alpha beta T cell morphology J:258435
abnormal dendritic cell migration J:258435
abnormal innate immunity J:258435
decreased interleukin-1 beta secretion J:258435
dermatitis J:258435
enhanced humoral immune response J:258435
enlarged lymph nodes J:258435
increased dendritic cell number J:258435
increased effector memory T-helper cell number J:258435
increased gamma-delta T cell number J:258435
increased IgE level J:258435
increased IgG1 level J:258435
increased leukocyte cell number J:258435
skin inflammation J:258435
\Tg(KRT18*R89C)22Rgo/0
(involves: FVB/N)
chronic liver inflammation J:241700
\Tg(KRT18*R89C)30Rgo/0
(involves: FVB/N)
chronic liver inflammation J:241700
\Tg(KRT18*R89C)50Rgo/0
(involves: FVB/N)
chronic liver inflammation J:241700
\Tg(KRT18-DPP4)3Pbmj/0
(involves: C57BL/6J * SJL/J)
abnormal cytokine secretion J:285467
abnormal mononuclear cell morphology J:286231
brain inflammation J:285467
increased lymphocyte cell number J:286231
increased susceptibility to Coronaviridae infection J:286231, J:285467
increased susceptibility to Coronaviridae infection induced morbidity/mortality J:286231, J:285467
interstitial pneumonia J:286231
lung inflammation J:286231, J:285467
\Tg(LANA,vFLIP,vCYC)801Dtmr/?
(involves: C57BL/6)
abnormal B cell activation J:196403
abnormal B cell differentiation J:196403
abnormal germinal center B cell physiology J:196403
abnormal marginal zone B cell morphology J:196403
abnormal marginal zone B cell physiology J:196403
abnormal spleen morphology J:196403
enlarged spleen J:196403
increased B cell proliferation J:196403
increased germinal center B cell number J:196403
increased IgG1 level J:196403
increased IgG3 level J:196403
increased marginal zone B cell number J:196403
increased mature B cell number J:196403
increased plasma cell number J:196403
\Tg(Lck)4220Rmp/0
(involves: C57BL/6J * DBA/2)
increased T cell derived lymphoma incidence J:88120
\Tg(Lck-Akt1*)M-1Pnt/0
(involves: C3H/He * C57BL/6)
decreased thymocyte number J:73487
enlarged spleen J:73487
increased double-negative T cell number J:135903
increased single-positive T cell number J:135903
increased T cell derived lymphoma incidence J:73487
\Tg(Lck-Akt1*E40K)E-3Pnt/0
(involves: C3H/He * C57BL/6)
decreased thymocyte number J:73487
enlarged spleen J:73487
increased T cell derived lymphoma incidence J:73487
\Tg(Lck-Akt1*E40K)E-3Pnt/0
(Not Specified)
abnormal T cell differentiation J:144975
increased T cell derived lymphoma incidence J:144975
\Tg(Lck-Akt2*)#Test/0
(Not Specified)
increased T cell derived lymphoma incidence J:153923
\Tg(Lck-Bcl2l1)1Cant/?
(B6.Cg-Tg(Lck-Bcl2l1)1Cant)
increased interleukin-2 secretion J:77507
increased memory T cell number J:77507
increased T cell proliferation J:77507
\Tg(Lck-cre)1Cwi/0
(involves: C57BL/6 * DBA/2)
decreased thymocyte number J:226234
\Tg(Lck-cre)548Jxm/?
\Tgfb1tm2.1Doe/\Tgfb1tm2.1Doe

(involves: 129S6/SvEvTac * Black Swiss * C57BL/6 * CBA)
abnormal immune system organ morphology J:150024
abnormal T cell activation J:150024
abnormal T cell subpopulation ratio J:150024
decreased spleen weight J:150024
decreased thymus weight J:150024
increased inflammatory response J:150024
increased interferon-gamma secretion J:150024
increased interleukin-2 secretion J:150024
lung inflammation J:150024
salivary gland inflammation J:150024
spleen hypoplasia J:150024
thymus hypoplasia J:150024
\Tg(Lck-cre)548Jxm/?
\Upf2tm1Btp/\Upf2tm1Btp

(involves: 129P2/OlaHsd * C57BL/6 * CBA)
abnormal T cell receptor beta chain V(D)J recombination J:134765
decreased CD4-positive, alpha-beta T cell number J:134765
decreased CD8-positive, alpha-beta T cell number J:134765
decreased double-positive T cell number J:134765
thymus hypoplasia J:134765
\Tg(Lck-cre)I57Jxm/?
\Traf2tm1Rbr/\Traf2tm1Rbr

(involves: C57BL/6 * ICR)
absent follicular B cells J:132877
absent marginal zone B cells J:132877
decreased mature B cell number J:132877
\Tg(Lck-cre)I57Jxm/?
\Traf3tm1Rbr/\Traf3tm1Rbr

(involves: C57BL/6 * ICR * SJL)
abnormal T cell physiology J:132877
decreased CD4-positive, alpha-beta T cell number J:132877
decreased CD8-positive, alpha-beta T cell number J:132877
\Tg(Lck-CrmA)1Hed/0
(involves: BALB/c * C57BL/6J)
decreased T cell apoptosis J:100451
immune system phenotype J:100451
\Tg(Lck-CrmA)1Hed/?
(involves: BALB/c * C57BL/6J)
decreased thymocyte apoptosis J:100451
\Tg(Lck-CrmA)1Hed/0
\Tg(TcraH-Y,TcrbH-Y)71Vbo/0

(BALB/c * C57BL/6)
immune system phenotype J:100451
\Tg(Lck-CrmA)1Hed/\Tg(Lck-CrmA)1Hed
(involves: BALB/c * C57BL/6J)
immune system phenotype J:100451
\Tg(Lck-Cxadr)1Jdgr/0
(FVB-Tg(Lck-Cxadr)1Jdgr)
abnormal T cell physiology J:109884
decreased T cell apoptosis J:109884
decreased T cell proliferation J:109884
\Tg(Lck-FADD)1Hed/0
(involves: BALB/c * C57BL/6)
abnormal T cell proliferation J:100451
arrested T cell differentiation J:100451
decreased T cell number J:100451
decreased thymocyte number J:100451
\Tg(Lck-FADD)1Hed/?
(involves: BALB/c * C57BL/6)
abnormal T cell physiology J:100451
decreased thymocyte apoptosis J:100451
immune system phenotype J:100451
\Tg(Lck-FADD)1Hed/0
\Tg(TcraH-Y,TcrbH-Y)71Vbo/0

(involves: BALB/c * C57BL/6J * C57L/J * DBA/2J)
immune system phenotype J:100451
\Tg(Lck-FADD)1Hed/\Tg(Lck-FADD)1Hed
(involves: BALB/c * C57BL/6)
abnormal T cell differentiation J:100451
decreased T cell number J:100451
decreased thymocyte number J:100451
immune system phenotype J:100451
\Tg(Lck-Hhex)1Hro/0
(C3HeB/FeJ-Tg(Lck-Hhex)1Hro)
abnormal double-negative T cell morphology J:80777
decreased double-positive T cell number J:80777
decreased leukocyte cell number J:80777
decreased lymphocyte cell number J:80777
decreased T cell number J:80777
increased CD8-positive, alpha-beta T cell number J:80777
thymus hyperplasia J:80777
\Tg(Lck-Id1)28Xhsu/0
(Not Specified)
increased T cell derived lymphoma incidence J:58607
\Tg(Lck-Il31)1Jagr/0
(involves: C3H * C57BL/6)
abnormal immune system physiology J:91124
abnormal leukopoiesis J:91124
conjunctivitis J:91124
cutaneous mastocytosis J:91124
decreased T cell number J:91124
dermatitis J:91124
enlarged lymph nodes J:91124
increased activated T cell number J:91124
increased B cell number J:91124
increased memory T cell number J:91124
\Tg(Lck-LMO1)11Sjk/0
\Tg(STIL-TAL1)A5.3Alpa/0

(involves: C3H * C3H/HeRos * C57BL/6 * C57BL/10Ros)
abnormal inflammatory response J:40868
enlarged lymph nodes J:40868
enlarged spleen J:40868
enlarged thymus J:40868
increased leukocyte cell number J:40868
increased T cell derived lymphoma incidence J:40868
\Tg(Lck-Map3k8)3456Ngc/?
(involves: C3H/HeJ * C57BL/6J)
increased T cell derived lymphoma incidence J:39450
\Tg(LCK-NFKBIA)5Dwb/0
(involves: C57BL/6 * DBA/2)
abnormal CD8-positive, alpha-beta T cell differentiation J:93003
decreased CD4-positive, alpha-beta T cell number J:93003
decreased CD8-positive, alpha-beta T cell number J:93003
decreased interleukin-2 secretion J:93003
decreased T cell proliferation J:93003
increased T cell apoptosis J:93003
\Tg(LCK-NFKBIA)5Dwb/?
(involves: BALB/c * C57BL/6 * DBA/2)
abnormal T-helper 1 physiology J:145531
decreased interferon-gamma secretion J:145531
decreased susceptibility to type I hypersensitivity reaction J:145531
decreased susceptibility to type IV hypersensitivity reaction J:145531
\Tg(LCK-NFKBIA)5Dwb/?
\Tg(Tcra,Tcrb)1Mcd/?

(involves: BALB/c * C57BL/6 * DBA/2)
decreased interferon-gamma secretion J:145531
\Tg(Lck-Notch3)#Issc/0
(involves: C57BL/6 * DBA/2)
abnormal T cell differentiation J:63300
enlarged lymph nodes J:63300
enlarged spleen J:63300
increased double-negative T cell number J:63300
increased lymphoblastic lymphoma incidence J:63300
increased T cell derived lymphoma incidence J:96010
increased thymocyte number J:63300
thymus hyperplasia J:63300
\Tg(Lck-Socs3)1Kubo/0
(Not Specified)
abnormal CD4-positive T cell differentiation J:132905
decreased interleukin-2 secretion J:128797
decreased susceptibility to experimental autoimmune encephalomyelitis J:132905
decreased T cell number J:128797
decreased T cell proliferation J:128797
decreased thymocyte number J:128797
\Tg(Lck-Sox13)#Jskg/0
(involves: C57BL/6)
decreased double-positive T cell number J:117301
decreased T cell proliferation J:117301
decreased thymocyte number J:117301
increased thymocyte apoptosis J:117301
\Tg(Lck-Stat5b*)1Mafa/0
(Not Specified)
decreased mature B cell number J:132669
increased B cell proliferation J:132669
\Tg(Lck-Stk17b)26.1Wals/?
(B6.Cg-Tg(Lck-Stk17b)26.1Wals)
decreased CD4-positive, alpha-beta T cell number J:149973
decreased CD8-positive, alpha-beta T cell number J:149973
decreased single-positive T cell number J:149973
decreased thymocyte number J:149973
enlarged spleen J:149973
increased anti-nuclear antigen antibody level J:149973
increased CD4-positive, CD25-positive, alpha-beta regulatory T cell number J:149973
increased double-positive T cell number J:149973
increased interleukin-2 secretion J:149973
increased spleen weight J:149973
increased susceptibility to experimental autoimmune encephalomyelitis J:149973
increased T cell proliferation J:149973
spleen hyperplasia J:149973
\Tg(Lck-Stk17b)26.1Wals/?
\Tg(TcraH-Y,TcrbH-Y)71Vbo/?

(involves: C57BL/6 * C57BL/10)
abnormal T cell differentiation J:149973
decreased CD8-positive, alpha-beta T cell number J:149973
decreased thymocyte number J:149973
increased CD8-positive, alpha-beta T cell number J:149973
\Tg(Lck-Tal1)4709Led/0
(FVB/N-Tg(Lck-Tal1)4709Led)
abnormal thymus morphology J:36076
enlarged spleen J:36076
increased lymphoblastic lymphoma incidence J:36076
\Tg(Lck-Tax)53Hall/0
(involves: C57BL/6)
enlarged lymph nodes J:129531
enlarged spleen J:129531
hepatosplenomegaly J:129531
increased susceptibility to fungal infection J:129531
increased T cell derived lymphoma incidence J:129531
\Tg(Lck-Tnfsf4)1Nish/0
(B6.Cg-Tg(Lck-Tnfsf4)1Nish)
abnormal CD4-positive, alpha-beta T cell physiology J:194882
abnormal cytokine secretion J:80214
abnormal T cell subpopulation ratio J:194882
increased CD4-positive, alpha-beta T cell number J:194882
increased interleukin-13 secretion J:194882
increased regulatory T cell number J:194882
increased susceptibility to type IV hypersensitivity reaction J:80214
increased T cell proliferation J:80214
lung inflammation J:194882
\Tg(Lck-Tnfsf4)1Nish/0
(C.Cg-Tg(Lck-Tnfsf4)1Nish)
abnormal CD4-positive, alpha-beta T cell physiology J:194882
increased CD4-positive, alpha-beta T cell number J:194882
increased interleukin-13 secretion J:194882
increased regulatory T cell number J:194882
\Tg(Lck-TNFSF13)3919Mhah/0
(B6.Cg-Tg(Lck-TNFSF13)3919Mhah)
abnormal immune system organ morphology J:94628
abnormal mesenteric lymph node morphology J:94628
abnormal spleen morphology J:94628
decreased B cell apoptosis J:94628
enlarged mesenteric lymph nodes J:94628
enlarged Peyer's patches J:94628
increased B cell number J:94628
increased B-1 B cell number J:94628
increased CD4-positive, alpha-beta T cell number J:94628
increased CD8-positive, alpha-beta T cell number J:94628
increased IgA level J:94628
intermingled spleen red and white pulp J:94628
spleen hyperplasia J:94628
\Tg(Lck-Tnfsf14)24Yxf/?
(C57BL/6-Tg(Lck-Tnfsf14)24Yxf)
abnormal complement protein level J:128976
abnormal inflammatory response J:128976
abnormal lymph node cell ratio J:129951
abnormal T cell physiology J:120962, J:129951
colitis J:129951
glomerulonephritis J:129951
increased anti-double stranded DNA antibody level J:129951
increased anti-nuclear antigen antibody level J:128976
increased autoantibody level J:129951
increased IgA level J:128976
increased IgG level J:128976
increased spleen weight J:129951
increased T cell proliferation J:129951
intestinal inflammation J:128976
liver inflammation J:129951
lung inflammation J:129951
lymph node hyperplasia J:129951
myositis J:129951
small intestinal inflammation J:120962
spleen hyperplasia J:129951
\Tg(Lck-Tnfsf15,-EGFP)#Targ/0
(involves: C57BL/6)
increased CD4-positive, alpha-beta memory T cell number J:169462
increased CD8-positive, alpha-beta memory T cell number J:169462
increased interferon-gamma secretion J:169462
increased interleukin-17 secretion J:169462
small intestinal inflammation J:169462
\Tg(Lck-Tslp)1Chea/0
(B6.Cg-Tg(Lck-Tslp)1Chea)
enlarged lymph nodes J:72982
enlarged spleen J:72982
glomerulonephritis J:72982
increased anti-nuclear antigen antibody level J:72982
increased immunoglobulin level J:72982
increased spleen weight J:72982
liver inflammation J:72982
lung inflammation J:72982
\Tg(Lck-VIPR2)1Ejg/0
(C57BL/6-Tg(Lck-VIPR2)1Ejg)
decreased interferon-gamma secretion J:127974
decreased susceptibility to type IV hypersensitivity reaction J:127974
increased eosinophil cell number J:127974
increased IgE level J:127974
increased IgG1 level J:127974
increased interleukin-4 secretion J:127974
increased interleukin-5 secretion J:127974
increased susceptibility to type I hypersensitivity reaction J:127974
\Tg(Lck/Emu-Rftn1)1Ayos/?
(involves: C57BL/6)
increased IgG1 level J:150299
increased IgG2a level J:150299
increased IgG3 level J:150299
increased IgM level J:150299
increased interferon-gamma secretion J:150299
increased interleukin-4 secretion J:150299
increased interleukin-17 secretion J:150299
increased susceptibility to experimental autoimmune encephalomyelitis J:150299
increased T cell proliferation J:150299
\Tg(LckIl4)1315Dbl/0
(involves: C57BL/6J * DBA/2J)
abnormal osteoclast physiology J:107359
abnormal T cell activation J:92453
abnormal T cell differentiation J:92453
abnormal T cell number J:92453
abnormal thymocyte activation J:92453
abnormal thymus cell ratio J:92453
abnormal thymus morphology J:92453
absent CD8-positive, alpha-beta T cells J:92453
decreased CD4-positive, alpha-beta T cell number J:92453
decreased double-positive T cell number J:92453
increased CD4-positive, alpha-beta T cell number J:92453
increased CD8-positive, alpha-beta T cell number J:92453
increased double-negative T cell number J:92453
increased IgG2a level J:92453
increased interleukin-4 secretion J:92453
increased susceptibility to parasitic infection J:92453
thymus cortex hypoplasia J:92453
thymus hypoplasia J:92453
\Tg(LckNotch1)9Erob/?
(involves: C57BL/6 * CBA/J)
abnormal CD8-positive, alpha-beta T cell differentiation J:93005
abnormal thymus cell ratio J:93005
decreased CD4-positive, alpha-beta T cell number J:93005
increased CD8-positive, alpha-beta T cell number J:93005
increased T cell derived lymphoma incidence J:93005
\Tg(LCKprBCL2)36Sjk/?
(involves: C3H * C57BL/6)
abnormal T cell number J:28635
abnormal T cell subpopulation ratio J:11548
abnormal thymus cell ratio J:11548
decreased T cell apoptosis J:11548
increased CD8-positive, alpha-beta T cell number J:11548
increased T cell derived lymphoma incidence J:28635
increased T cell number J:11548
\Tg(LCKprBCL2)36Sjk/0
(B6.Cg-Tg(LCKprBCL2)36Sjk)
abnormal CD4-positive, alpha-beta T cell number J:217939
abnormal T cell subpopulation ratio J:217939
increased regulatory T cell number J:217939
\Tg(LCKprBCL2)36Sjk/0
(involves: C57BL/6 * CBA/J)
abnormal T cell clonal deletion J:217939
decreased thymocyte apoptosis J:217939
\Tg(LCKprBCL2)36Sjk/0
\Tg(Nr4a1-EGFP/cre)820Khog/0

(involves: C57BL/6 * C57BL/6J)
abnormal T cell clonal deletion J:217939
decreased thymocyte apoptosis J:217939
\Tg(LCKprBCL2)36Sjk/0
\Tg(TcraH-Y,TcrbH-Y)71Vbo/0

(involves: C57BL/6 * C57BL/6J * DBA/2J)
abnormal T cell clonal deletion J:217939
decreased thymocyte apoptosis J:217939
\Tg(LCR-HBA2,LCR-HBB*)1Cos/0
(involves: C57BL/6J * CBA/J)
enlarged spleen J:94193
\Tg(Ly6a-BCR/ABL1)IS1AIsg/0
(involves: C57BL/6J * CBA)
abnormal lymph node morphology J:144382
abnormal spleen morphology J:144382
increased leukocyte cell number J:144382
increased neutrophil cell number J:144382
increased spleen red pulp amount J:144382
increased spleen weight J:144382
\Tg(Ly6a-BCR/ABL1)IS1BIsg/0
(involves: C57BL/6J * CBA)
abnormal lymph node morphology J:144382
abnormal spleen morphology J:144382
increased leukocyte cell number J:144382
increased neutrophil cell number J:144382
increased spleen red pulp amount J:144382
increased spleen weight J:144382
\Tg(Ly6a-GCSAM)102AIsg/0
(involves: C57BL/6J * CBA)
abnormal spleen morphology J:221238
decreased B-1 B cell number J:221238
enlarged Peyer's patches J:221238
enlarged spleen J:221238
increased B cell proliferation J:221238
increased B-1 B cell number J:221238
increased IgG level J:221238
increased inflammatory response J:221238
increased spleen white pulp amount J:221238
lymphoid hyperplasia J:221238
\Tg(Ly6a-SET/NUP214)2969Gcg/0
(involves: FVB/NJ)
abnormal B cell differentiation J:142938
decreased leukocyte cell number J:142938
decreased lymphocyte cell number J:142938
decreased pre-B cell number J:142938
decreased pro-B cell number J:142938
increased B cell apoptosis J:142938
\Tg(Ly6a-TK,-BCR/ABL1)IS9AIsg/0
(involves: C57BL/6J * CBA)
increased leukocyte cell number J:144382
increased neutrophil cell number J:144382
\Tg(Ly6e-MALT1)#Isg/0
(involves: C57BL/6 * CBA)
increased mature B cell number J:185590
increased pre-B cell number J:185590
increased pro-B cell number J:185590
\Tg(LYZ-rtTA2S*M2,tetO-ELAVL1)632Dkon/0
(B6.Cg-Tg(LYZ-rtTA2S*M2,tetO-ELAVL1)632Dkon)
decreased susceptibility to induced colitis J:184388
\Tg(Mbp-Pad2)28Fgm/0
(involves: CD-1)
abnormal tumor necrosis factor level J:142650
\Tg(Mbp-SNCA)1Ema/0
(involves: C57BL/6 * DBA/2)
brain inflammation J:207162
\Tg(MCL1)8Caig/0
(involves: C57BL/6 * SJL)
abnormal immature B cell morphology J:50604
abnormal leukocyte physiology J:50604
abnormal macrophage apoptosis J:95913
abnormal mast cell differentiation J:50604
abnormal monocyte differentiation J:50604
decreased B cell apoptosis J:50604
decreased splenocyte apoptosis J:50604
decreased T cell apoptosis J:50604
increased spleen white pulp amount J:50604
increased susceptibility to bacterial infection J:95913
increased T cell derived lymphoma incidence J:69755
increased thymocyte number J:50604
spleen hyperplasia J:50604
\Tg(Mcpt8-cre)1Voeh/0
(involves: C57BL/6)
decreased basophil cell number J:164432
decreased inflammatory response J:164432
immune system phenotype J:164432
\Tg(Mir125a)#Smoc/0
(involves: C57BL/6)
decreased interferon-gamma secretion J:224880
decreased susceptibility to experimental autoimmune encephalomyelitis J:224880
\Tg(ML5sHEL)5Ccg/0
(C57BL/6-Tg(ML5sHEL)5Ccg)
abnormal B cell anergy J:78308
\Tg(ML5sHEL)5Ccg/0
(involves: C57BL/6JSfd * CBA)
abnormal B cell anergy J:78308
abnormal T cell anergy J:78308
\Tg(ML5sHEL)5Ccg/0
\Tg(TcrHEL3A9)1Mmd/0

(involves: C57BL/6 * C57BL/10 * C57BR/cd)
abnormal CD4-positive, alpha beta T cell morphology J:78309
abnormal CD4-positive, alpha-beta T cell physiology J:78309
abnormal T cell activation J:78309
abnormal T cell proliferation J:78309
decreased CD4-positive, alpha-beta T cell number J:78309
decreased double-positive T cell number J:78309
\Tg(ML5sHEL)5Ccg/0
\Tg(TcrHEL3A9)1Mmd/0
\Tg(TLK2mHEL)2Ccg/0

(involves: C57BL/6JSfd * C57BL/10 * C57BR/cd)
abnormal CD4-positive, alpha beta T cell morphology J:78309
abnormal CD4-positive, alpha-beta T cell physiology J:78309
abnormal T cell activation J:78309
abnormal T cell proliferation J:78309
decreased CD4-positive, alpha-beta T cell number J:78309
decreased double-positive T cell number J:78309
thyroid gland inflammation J:78309
\Tg(MMTV-ENPP2)#Gbm/0
(FVB/N-Tg(MMTV-ENPP2)#Gbm)
mastitis J:149661
\Tg(MMTV-Erbb2)9Pjo/0
(involves: BALB/c * C3H * C57BL/6)
enlarged spleen J:72129
increased spleen red pulp amount J:72129
\Tg(MMTV-Erbb2)10Pjo/0
(involves: BALB/c * C3H * C57BL/6)
enlarged spleen J:72129
increased spleen red pulp amount J:72129
\Tg(MMTV-Erbb2)12Pjo/0
(involves: BALB/c * C3H * C57BL/6)
enlarged spleen J:72129
increased spleen red pulp amount J:72129
\Tg(MMTV-Erbb2)17Pjo/0
(involves: BALB/c * C3H * C57BL/6)
enlarged spleen J:72129
increased spleen red pulp amount J:72129
\Tg(MMTV-LPAR1)2Gbm/\Tg(MMTV-LPAR1)2Gbm
(FVB/N-Tg(MMTV-LPAR1)2Gbm)
mastitis J:149661
\Tg(MMTV-LPAR1)7Gbm/\Tg(MMTV-LPAR1)7Gbm
(FVB/N-Tg(MMTV-LPAR1)7Gbm)
mastitis J:149661
\Tg(MMTV-LPAR1)#Gbm/\Tg(MMTV-LPAR1)#Gbm
(FVB/N-Tg(MMTV-LPAR1)#Gbm)
mastitis J:149661
\Tg(MMTV-LPAR2)3Gbm/\Tg(MMTV-LPAR2)3Gbm
(FVB/N-Tg(MMTV-LPAR2)3Gbm)
mastitis J:149661
\Tg(MMTV-LPAR2)6Gbm/\Tg(MMTV-LPAR2)6Gbm
(FVB/N-Tg(MMTV-LPAR2)6Gbm)
mastitis J:149661
\Tg(MMTV-LPAR2)#Gbm/\Tg(MMTV-LPAR2)#Gbm
(FVB/N-Tg(MMTV-LPAR2)#Gbm)
mastitis J:149661
\Tg(MMTV-LPAR3)3Gbm/\Tg(MMTV-LPAR3)3Gbm
(FVB/N-Tg(MMTV-LPAR3)3Gbm)
mastitis J:149661
\Tg(MMTV-LPAR3)#Gbm/\Tg(MMTV-LPAR3)#Gbm
(FVB/N-Tg(MMTV-LPAR3)#Gbm)
mastitis J:149661
\Tg(MMTV-PyVT)#Mul/0
(B6.FVB-Tg(MMTV-PyVT)#Mul)
abnormal circulating cytokine level J:147923
abnormal lymph node cell ratio J:147923
abnormal lymph node morphology J:147923
abnormal splenic cell ratio J:147923
abnormal T cell physiology J:147923
decreased B cell proliferation J:147923
decreased splenocyte proliferation J:147923
decreased T cell proliferation J:147923
enlarged spleen J:147923
increased circulating tumor necrosis factor level J:147923
increased regulatory T cell number J:147923
increased splenocyte number J:147923
\Tg(MMTV-Scgb1a1)#Abm/0
(involves: C57BL/6 * SJL)
increased IgA level J:57504
\Tg(Mpz-RAF1/ESR1)A668Ayld/0
(involves: C57BL/6J * CBA/J)
increased inflammatory response J:182703
increased macrophage cell number J:182703
increased mast cell number J:182703
increased neutrophil cell number J:182703
increased T cell number J:182703
\Tg(Msmb-TAg)183-2Xuan/0
(involves: C57BL/6 * CBA)
enlarged lymph nodes J:80313
\Tg(Msr1-MMP9)#Apar/0
(B6.Cg-Tg(Msr1-MMP9)#Apar)
abnormal macrophage physiology J:136830
decreased inflammatory response J:129959
immune system phenotype J:136830
\Tg(MSR1-Plau)1Ddi/0
(involves: C57BL/6 * SJL)
heart inflammation J:101486
\Tg(Mt1-Crry)26Quig/?
(involves: CD-1)
abnormal inflammatory response J:117777
\Tg(Mt1-IL6)28Gci/0
(involves: C57BL/6 * DBA/2)
abnormal spleen morphology J:18424
enlarged lymph nodes J:18424
enlarged spleen J:177825, J:18424
increased circulating interleukin-6 level J:177825
increased circulating serum amyloid protein level J:177825
increased granulocyte number J:177825
increased IgG1 level J:18424
increased IgG level J:177825, J:18424
increased leukocyte cell number J:18424
increased neutrophil cell number J:18424
increased plasma cell number J:177825, J:18424
increased plasmacytoid dendritic cell number J:177825
\Tg(Mt1-TGFBR2*)AM3Epb/0
(involves: FVB/N)
pancreas inflammation J:76993
\Tg(MT2A-TGFBR2)4Rser/0
(involves: C57BL/6 * DBA)
osteoarthritis J:44579
\Tg(MtTGFA)42Lmb/\Tg(MtTGFA)42Lmb
(involves: CD-1)
immune system phenotype J:28452
\Tg(MUC1)79.24Gend/0
(involves: C57BL/6)
abnormal humoral immune response J:128899
increased IgG level J:154046
increased IgM level J:154046
\Tg(Mup3-Plau)350-2Eps/?
(C57BL/6-Tg(Mup3-Plau)350-2Eps)
increased interleukin-1 beta secretion J:233146
increased tumor necrosis factor secretion J:233146
liver inflammation J:233146
\Tg(Mx1-cre)1Cgn/0
\Tg(Tal1-tTA)19Dgt/0
\Tg(tetO-BCR/ABL1)2Dgt/0
\TgTn(pb-sb-GrOnc)#aGsva/0

(involves: C57BL/6 * CBA/J * DBA/2 * FVB/N)
increased granulocyte number J:227558
increased leukocyte cell number J:227558
\Tg(Mx1-cre)1Cgn/0
\Thoc5tm1Tate/\Thoc5tm1Tate

(involves: C57BL/6 * CBA)
abnormal lymphopoiesis J:169944
decreased leukocyte cell number J:169944
decreased spleen weight J:169944
\Tg(Mx1-cre)1Cgn/0
\Tnfrsf13ctm2.1Mass/\Tnfrsf13ctm2.1Mass

(involves: C57BL/6 * CBA)
increased immature B cell number J:170519
increased pre-B cell number J:170519
increased pro-B cell number J:170519
\Tg(Mx1-cre)1Cgn/0
\Traf2tm1Rbr/\Traf2tm1Rbr

(involves: C57BL/6 * CBA)
abnormal spleen marginal zone morphology J:93890
abnormal spleen morphology J:93890
enlarged lymph nodes J:93890
enlarged spleen J:93890
increased B cell number J:93890
increased marginal zone B cell number J:93890
\Tg(Mx1-cre)1Cgn/0
\U2af1tm1.1Hev/\U2af1+

(involves: 129S6/SvEvTac * BALB/c * C57BL/6 * C57BL/6J * CBA/J)
decreased leukocyte cell number J:267082
\Tg(Mx1-cre)1Cgn/0
\U2af1tm1Mohi/\U2af1tm1Mohi

(involves: C57BL/6J * CBA/J)
bone marrow failure J:308564
decreased leukocyte cell number J:308564
decreased neutrophil cell number J:308564
\Tg(Mx1-cre)1Cgn/0
\Zmiz1tm1c(EUCOMM)Hmgu/\Zmiz1tm1c(EUCOMM)Hmgu

(involves: C57BL/6 * C57BL/6J * C57BL/6N * CBA/J)
decreased B cell number J:234445
decreased NK cell number J:234445
decreased T cell number J:234445
thymus hypoplasia J:234445
\Tg(Mx1-cre)1Cgn/0
\Znrf1tm1Lchs/\Znrf1tm1Lchs

(involves: C57BL/6)
decreased susceptibility to endotoxin shock J:250572
\Tg(Myh6*/tetO-Capn1)L3Gwd/0
(involves: FVB/N)
heart inflammation J:133797
\Tg(Myh6-BAG3*P209L)#Mswi/0
(involves: C57BL/6 * DBA/2)
heart inflammation J:234278
\Tg(Myh6-Grem2)1Akh/0
(involves: C57BL/6)
decreased inflammatory response J:250034
decreased interleukin-10 secretion J:250034
\Tg(Myh6-IGF1)34Pia/0
(FVB/N-Tg(Myh6-IGF1)34Pia)
increased spleen weight J:35215
\Tg(Myh6-JUP*)1Dpju/0
(FVB/N-Tg(Myh6-JUP*)1Dpju)
heart inflammation J:235770
\Tg(Myh6-Tnf)1Brgi/?
(involves: C57BL/6J * SJL)
myocarditis J:84829, J:100006
\Tg(Myh6-Tnf)2Brgi/?
(involves: C57BL/6J * SJL)
myocarditis J:84829, J:100006
\Tg(Myh6-Tnnt2*R92Q)2Lnwd/0
(involves: C57BL/6)
heart inflammation J:56911
\Tg(Myh6-Tnnt2*R92Q)3Lnwd/0
(involves: C57BL/6)
heart inflammation J:56911
\Tg(Myh6-tTA)6Smbf/0
\Tg(tetO-EDN1,-lacZ)9Mhus/0

(involves: C57BL/6 * CBA)
heart inflammation J:131245
\Tg(Myh6-tTA)6Smbf/0
\Tg(tetO-HDAC5*)1Eno/0

(involves: C3H * C57BL/6 * CBA)
myocarditis J:81967
\Tg(Myh6-tTA)6Smbf/0
\Tg(tetO-NOS2,-lacZ)240iMhus/0

(involves: C57BL/6 * CBA)
heart inflammation J:132082
\Tg(Myh6-tTA)6Smbf/0
\Tg(tetO-Spp1)5Gad/0

(involves: C57BL/6 * CBA)
heart inflammation J:194810
myocarditis J:194810
\Tg(Myl1-SOD1*G93A)#Amu/0
(FVB/NJ-Tg(Myl1-SOD1*G93A)#Amu)
increased microglial cell activation J:143747
\Tg(Nlrp1b)1Die/0
(involves: 129S1/SvImJ * C57BL/6 * SJL)
abnormal macrophage physiology J:99748
\Tg(Nr4a1-EGFP/cre)820Khog/0
(C57BL/6-Tg(Nr4a1-EGFP/cre)820Khog)
immune system phenotype J:172415
\Tg(OMP-SV40T)13Bse/0
(involves: C57BL/6 * SJL)
abnormal immune tolerance J:54269
\Tg(Pcp2-TBP*)69Hmhl/0
(involves: FVB/N)
brain inflammation J:174239
\Tg(PF4-tTA/VP16)42Kra/0
\Tg(tetO-Aurkb,lacZ)41Kra/0

(FVB/NJ-Tg(tetO-Aurkb,lacZ)41Kra Tg(PF4-tTA/VP16)42Kra)
abnormal thrombopoiesis J:104239
\Tg(PF4MER)6Kra/?
(FVB/N-Tg(PF4MER)6Kra)
enlarged spleen J:35507
\Tg(Pgk1-HA)1.1Vbo/?
\Tg(Tcra/Tcrb)1Vbo/?

(involves: 129 * BALB/c * C57BL/6J * DBA/2J)
decreased CD4-positive, alpha-beta T cell number J:125750
increased double-positive T cell number J:125750
increased regulatory T cell number J:125750
\Tg(Pgk1-HA)1.1Vbo/?
\Tg(Tcra/Tcrb)1Vbo/?

(C.Cg-Tg(Pgk1-HA)1.1Vbo Tg(Tcra/Tcrb)1Vbo)
abnormal regulatory T cell physiology J:112603
increased regulatory T cell number J:112603
\Tg(PGK1-KITLG*220)441Daw/\Tg(PGK1-KITLG*220)441Daw
(C3H/HeJ-Tg(PGK1-KITLG*220)441Daw)
abnormal thymus morphology J:32600
\Tg(Pim1-Il9)5Jcrd/0
(involves: BALB/c * FVB/N)
increased susceptibility to type I hypersensitivity reaction J:100568
\Tg(Pim1-Il9)5Jcrd/0
(involves: FVB/N)
increased interleukin-5 secretion J:115764
increased susceptibility to type I hypersensitivity reaction J:100568
increased T cell derived lymphoma incidence J:17848
\Tg(Pklr-HRAS*G12V)21Ak/0
(involves: C57BL/6 * DBA/2)
abnormal thymus morphology J:44803
enlarged thymus J:44803
\Tg(Pklr-Myc)73Ak/0
(B6.Cg-Tg(Pklr-Myc)73Ak)
decreased NK T cell number J:184496
\Tg(PLA2G2A)703Dsg/?
(involves: C57BL/6 * C57BL/6J * SJL)
immune system phenotype J:113573
\Tg(PLP1*)4Rsj/0
(involves: CD-1)
CNS inflammation J:161344
\Tg(Plp1-Eif2ak3*)18Pop/0
(C57BL/6J-Tg(Plp1-Eif2ak3*)18Pop)
decreased susceptibility to experimental autoimmune encephalomyelitis J:238042
\Tg(Plp1-LMNB1)1108Qsp/0
(involves: FVB/N)
microgliosis J:226169
\Tg(Plp1-SNCA)1Haa/0
(involves: C57BL/6 * DBA/2)
microgliosis J:96778
\Tg(PML-RARA)556Kog/?
(involves: FVB/N)
abnormal neutrophil differentiation J:39327
\Tg(PML-RARA)556Kog/0
(FVB/N-Tg(PML-RARA)556Kog)
enlarged spleen J:262172
increased leukocyte cell number J:262172
\Tg(PMP22)C61Clh/0
(B6.Cg-Tg(PMP22)C61Clh)
increased macrophage cell number J:158350
\Tg(Prdx6)153Pgn/0
(C57BL/6-Tg(Prdx6)153Pgn/Pgn)
abnormal macrophage physiology J:86528
\Tg(PRG1)18Wlad/0
(involves: C57BL/6J * CBA/J)
decreased susceptibility to Picornaviridae infection J:127826
increased susceptibility to Picornaviridae infection J:92990
increased susceptibility to Picornaviridae infection induced morbidity/mortality J:92990
\Tg(PRG3)9Wlad/0
(involves: C57BL/6J * CBA/J)
increased susceptibility to Picornaviridae infection J:92990, J:127826
\Tg(Prnp)4053Sbp/0
(involves: FVB/N)
increased susceptibility to prion infection J:136434
\Tg(Prnp)a20Cwe/0
(Not Specified)
increased susceptibility to prion infection J:130657, J:143528
\Tg(Prnp-APP*)1Hmor/0
(B6.Cg-Tg(Prnp-APP*)1Hmor)
microgliosis J:159623
\Tg(Prnp-ATXN7*92Q)6529Als/Y
(involves: C3H/HeJ * C57BL/6J)
colitis J:135615
\Tg(Prnp-FUS)WT3Cshw/0
(involves: C57BL/6 * Crl:CD-1(ICR))
microgliosis J:189360
\Tg(Prnp-FUS)WT3Cshw/\Tg(Prnp-FUS)WT3Cshw
(involves: C57BL/6 * Crl:CD-1(ICR))
microgliosis J:189360
\Tg(Prnp-Immt/SOD1*G93A)7Gmnf/\Tg(Prnp-Immt/SOD1*G93A)7Gmnf
(involves: C57BL/6 * CBA * SJL)
dermatitis J:177846
\Tg(Prnp-ITM2B*)1Ruvi/\Tg(Prnp-ITM2B*)1Ruvi
\Tg(Prnp-MAPT*P301L)#Ruvi/\Tg(Prnp-MAPT*P301L)#Ruvi

(involves: C3HeB/FeJ * C57BL/6)
increased inflammatory response J:197198
\Tg(Prnp-ITM2B*)7Jckr/0
(C57BL/6-Tg(Prnp-ITM2B*)7Jckr)
microgliosis J:159279
\Tg(Prnp-MAPT*P301L)JNPL3Hlmc/?
(involves: C57BL/6 * DBA/2)
eye inflammation J:63887
\Tg(Prnp-MAPT*R406W)21807Dwst/?
(FVB/N-Tg(Prnp-MAPT*R406W)21807Dwst)
microgliosis J:95971
\Tg(Prnp-PFN1*C71G)22Zxu/0
\Tg(Thy1-PFN1*C71G)67Zxu/\Tg(Thy1-PFN1*C71G)67Zxu

(involves: FVB/N)
microgliosis J:235427
\Tg(Prnp-TARDBP)96Dwc/0
\Tg(Prnp-TARDBP*Q331K)31Dwc/0

(involves: C3H * C57BL/6)
microgliosis J:239141
\Tg(Prnp-TARDBP*Q331K)31Dwc/?
(involves: C3H * C57BL/6)
microgliosis J:239141
\Tg(Prox1-EGFP)KY221Gsat/0
(involves: FVB/NTac)
abnormal lymphangiogenesis J:235778
abnormal lymphatic vessel endothelial cell morphology J:235778
\Tg(PRSS1/lacZ)#Gwzh/0
(Not Specified)
increased susceptibility to induced pancreatitis J:345508
\Tg(Psp-Rbbp4)1Yoha/0
(involves: C57BL/6)
abnormal antigen presentation J:141378
abnormal T cell activation J:141378
increased autoantibody level J:141378
increased interferon-gamma secretion J:141378
increased interleukin-2 secretion J:141378
increased interleukin-18 secretion J:141378
increased marginal zone B cell number J:141378
increased susceptibility to autoimmune disorder J:141378
lacrimal gland inflammation J:141378
salivary gland inflammation J:141378
\Tg(PTH-CCND1)PC2Anar/0
(FVB/N-Tg(PTH-CCND1)PC2Anar)
increased osteoclast cell number J:69423
\Tg(PVR)1Kkst/0
(involves: ICR)
increased susceptibility to Picornaviridae infection J:153943
\Tg(RIP1-Tag)5Dh/?
(C3HeB/FeJ-Tg(RIP1-Tag)5Dh)
pancreas inflammation J:80168
\Tg(Rr158-H2-Ead)1Flv/0
\Tg(Tcra1H3.1,Tcrb1H3.1)1Vire/0

(involves: C57BL/6 * SJL)
decreased double-positive T cell number J:124574
thymus hypoplasia J:124574
\Tg(rv-CYCLIN)29Dlh/0
(involves: C57BL/6 * SJL)
lymphoid hyperplasia J:62478
spleen hyperplasia J:62478
\Tg(Scgb1a1-IL6)9Flv/0
(involves: C57BL/6 * CBA)
lung inflammation J:128762, J:156430
\Tg(Scgb1a1-Il13)2Eli/?
(involves: C57BL/6 * CBA)
abnormal leukocyte physiology J:53612
respiratory system inflammation J:53612
\Tg(Scgb1a1-Il17a)3Cdon/0
(C57BL/6-Tg(Scgb1a1-Il17a)3Cdon)
abnormal chemokine level J:112600
lung inflammation J:112600
\Tg(Scgb1a1-Il17f,GFP)1Cdon/?
(C57BL/6-Tg(Scgb1a1-Il17f,GFP)1Cdon)
lung inflammation J:136279
\Tg(Scgb1a1-Muc5b,-AcGFP)#Evns/0
(involves: C57BL/6J * C57BL/6N)
decreased susceptibility to bacterial infection J:207159
\Tg(Scgb1a1-PLUNC)#Chuh/0
(involves: FVB/N)
decreased susceptibility to bacterial infection J:171589
\Tg(Scgb1a1-rtTA)1Jaw/0
\Tg(tetO-Aimp1)29872Mcla/0

(involves: 129 * C57BL/6)
increased macrophage cell number J:173904
\Tg(Scgb1a1-rtTA)1Jaw/0
\Tg(tetO-EGFR*T790M*L858R)19Kkw/0

(involves: 129 * C57BL/6 * FVB/N)
interstitial pneumonia J:122849
\Tg(Scgb1a1-rtTA)1Jaw/0
\Tg(tetO-IL1B)KBry/0

(involves: 129 * C57BL/6)
abnormal chemokine level J:107601, J:130523
lung inflammation J:107601, J:130523
\Tg(Scgb1a1-rtTA,-tTS,tetO-CHI3L1)1Eli/0
(Not Specified)
abnormal macrophage morphology J:148490
decreased T cell apoptosis J:148490
increased T-helper 2 cell number J:148490
\Tg(Scgb1a1-rtTA,-tTS,tetO-TGFB1*)1Eli/0
(involves: C57BL/6)
lung inflammation J:92469
\Tg(Scgb1a1-rtTA,tetO-Ifng)14Eli/0
(involves: C57BL/6 * CBA)
increased lymphocyte cell number J:100854
increased macrophage cell number J:100854
increased neutrophil cell number J:100854
\Tg(Scgb1a1-rtTA,tetO-Il13)1Eli/0
(involves: C57BL/6 * CBA)
abnormal T-helper 2 physiology J:148490
increased T-helper 2 cell number J:148490
\Tg(Scgb1a1-Scnn1b)6608Bouc/0
(involves: C3H * C57BL/6)
bronchitis J:91139
\Tg(Scgb1a1-Scnn1b)6608Bouc/0
(B6.Cg-Tg(Scgb1a1-Scnn1b)6608Bouc)
respiratory system inflammation J:191673
\Tg(Scgb1a1-Scnn1b)6608Bouc/0
(C.Cg-Tg(Scgb1a1-Scnn1b)6608Bouc)
respiratory system inflammation J:191673
\Tg(SERPINA1*E342K)#Slcw/0
(involves: C57BL/6 * ICR)
liver inflammation J:149132
\Tg(SERPINA1-HBVX)1655Jtsb/0
(involves: C3H * C57BL/6 * ICR)
liver inflammation J:90305
\Tg(SERPINA1-IGHG1/Il1rl1)423Zbz/?
(involves: C3H * C57BL/6)
abnormal eosinophil physiology J:63507
abnormal response to infection J:63507
decreased interleukin-5 secretion J:63507
increased eosinophil cell number J:63507
X/\Tg(SERPINC1-SV40)BPbr
(involves: C57BL/6 * DBA/2)
increased macrophage cell number J:84204
\Tg(SFTPC-DPP4)3Pbmj/0
(involves: C57BL/6J * SJL/J)
abnormal susceptibility to Coronaviridae infection J:285467
\Tg(SFTPC-Il18)AThos/0
(B6N.Cg-Tg(SFTPC-Il18)AThos)
abnormal spleen morphology J:147547
enlarged spleen J:147547
increased interferon-gamma secretion J:147547
increased interleukin-13 secretion J:147547
lung inflammation J:147547
\Tg(SFTPC-rtTA)2Jaw/0
\Tg(tetO-CTGF)#Swu/0

(involves: 129 * C57BL/6 * C57BL/6J)
lung inflammation J:171151
\Tg(SFTPC-rtTA,tetO-Tnf)320-1Gwho/0
(involves: C57BL/6 * SJL)
abnormal B cell morphology J:97297
abnormal bronchus-associated lymphoid tissue morphology J:97297
abnormal CD4-positive, alpha beta T cell morphology J:97297
abnormal dendritic cell morphology J:97297
abnormal T cell morphology J:97297
increased CD8-positive, alpha-beta T cell number J:97297
increased lymphocyte cell number J:97297
increased neutrophil cell number J:97297
lung inflammation J:97297
\Tg(SFTPC-Tnf)2Pva/0
(involves: C57BL/6 * DBA/2)
alveolitis J:28120
interstitial pneumonia J:28120
\Tg(Sirt1)ASrn/?
(involves: C57BL/6 * CBA)
increased susceptibility to endotoxin shock J:137868
\Tg(SOD1*G93A)1Gur/0
(B6.Cg-Tg(SOD1*G93A)1Gur/J)
abnormal spleen morphology J:138237
abnormal T cell physiology J:138237
decreased spleen weight J:138237
decreased splenocyte number J:138237
\Tg(SOD1*G93A)1Gur/0
(B6SJL-Tg(SOD1*G93A)1Gur/J)
abnormal lymphocyte morphology J:129215
abnormal microglial cell morphology J:165019, J:143173
abnormal spleen morphology J:138237
abnormal splenic cell ratio J:138237
abnormal splenocyte morphology J:138237
CNS inflammation J:110437
decreased eosinophil cell number J:129215
decreased leukocyte cell number J:129215
decreased lymphocyte cell number J:129215
decreased monocyte cell number J:129215
decreased spleen weight J:138237
increased basophil cell number J:129215
microgliosis J:146652, J:165019, J:110437, J:143173
small spleen J:138237
\Tg(SOD1*G93A)dl1Gur/0
(involves: C57BL/6 * C57BL/6J * SJL/J)
microgliosis J:128738
\Tg(SOD1*H46R)LAra/0
(involves: C57BL/6 * DBA/2)
microgliosis J:221350
\Tg(SOD1*H46R*C111S)PAra/0
(involves: C57BL/6 * DBA/2)
microgliosis J:221350
\Tg(SOD1*H46R*C111S)PAra/\Tg(SOD1*H46R*C111S)PAra
(involves: C57BL/6 * DBA/2)
microgliosis J:221350
\Tg(SOD1*H46R*C111S)QAra/0
(involves: C57BL/6 * DBA/2)
microgliosis J:221350
\Tg(SOD1*L126Z)45Dbo/0
(involves: C3H/HeJ * C57BL/6J)
microgliosis J:219482
\Tg(Stat3*)9199Alau/0
(involves: C57BL/6)
abnormal CD4-positive, alpha-beta T cell physiology J:210877
abnormal T-helper 17 cell differentiation J:210877
decreased IgG1 level J:210877
decreased IgG3 level J:210877
increased IgE level J:210877
increased inflammatory response J:210877
increased neutrophil cell number J:210877
increased susceptibility to bacterial infection J:210877
increased susceptibility to bacterial infection induced morbidity/mortality J:210877
increased susceptibility to endotoxin shock J:210877
intestinal inflammation J:210877
\Tg(SV40-Ahr)1Poe/0
(involves: C57BL/6 * CBA)
absent B-1a cells J:82428
decreased B-1 B cell number J:82428
decreased thymus weight J:77977
increased B-2 B cell number J:82428
increased mature B cell number J:82428
increased pre-B cell number J:82428
increased pro-B cell number J:82428
\Tg(SV40-Igh-64C8)H3Hon/0
\Tg(SV40-Igk4C8)L1Hon/0

(involves: C57BL/6)
abnormal B cell clonal deletion J:139864
abnormal B cell number J:139864
increased anti-erythrocyte antigen antibody level J:139864
\Tg(SV40-KLK7)1010Teg/0
(involves: C57BL/6J * CBA)
dermatitis J:75714
\Tg(SV40-NRAS*G12D)1Sco/?
(Not Specified)
increased T cell derived lymphoma incidence J:125150
\Tg(SV40/HTLV-FCER1A)1Bhk/0
(involves: 129)
immune system phenotype J:47138
\Tg(SV)419Bri/\Tg(SV)419Bri
(C57BL/6J-Tg(SV)419Bri)
increased T cell derived lymphoma incidence J:147031
\Tg(SV)427Bri/0
(C57BL/6J-Tg(SV)427Bri)
enlarged thymus J:79096
\Tg(TARDBP)#Jpj/0
(involves: C3H * C57BL/6)
microgliosis J:195184
\Tg(TARDBP*A315T)#Jpj/0
(involves: C3H * C57BL/6)
microgliosis J:195184
\Tg(TARDBP*G348C)#Jpj/0
(involves: C3H * C57BL/6)
abnormal cytokine level J:195184
microgliosis J:195184
\Tg(TCF3/HLF)1Mlc/0
(involves: FVB/N)
abnormal CD4-positive, alpha beta T cell morphology J:55022
abnormal thymus involution J:55022
arrested T cell differentiation J:55022
decreased CD4-positive, alpha-beta T cell number J:55022
decreased CD8-positive, alpha-beta T cell number J:55022
decreased double-positive T cell number J:55022
decreased T cell number J:55022
decreased thymocyte number J:55022
increased T cell derived lymphoma incidence J:55022
thymus hypoplasia J:55022
\Tg(Tcra2B4)1Mmd/?
(involves: C3H/HeJ * C57BL/6)
abnormal thymus cell ratio J:92992
decreased CD4-positive, alpha-beta T cell number J:92992
decreased double-positive T cell number J:92992
decreased thymocyte number J:92992
increased double-negative T cell number J:92992
\Tg(Tcra2C,Tcrb2C)1Dlo/?
(involves: C57BL/6 * SJL)
abnormal CD8-positive, alpha beta T cell morphology J:125259
\Tg(Tcra2C,Tcrb2C)1Dlo/?
(involves: C57L * DBA/2 * SJL)
abnormal memory T cell physiology J:95380
decreased lymphocyte cell number J:95380
decreased thymocyte number J:95380
increased CD4-positive, alpha-beta T cell number J:95380
seborrheic dermatitis J:95380
\Tg(Tcra2D2,Tcrb2D2)1Kuch/0
(involves: C57BL/6)
abnormal CD4-positive, alpha beta T cell morphology J:83278
abnormal cytokine secretion J:83278
blepharitis J:83278
CNS inflammation J:83278
increased susceptibility to autoimmune disorder J:83278
increased susceptibility to experimental autoimmune encephalomyelitis J:83278
\Tg(Tcra2D2,Tcrb2D2)1Kuch/?
(involves: C57BL/6 * CD-1)
decreased interleukin-17 secretion J:125296
\Tg(Tcra2D2,Tcrb2D2)1Kuch/0
(involves: 129P2/OlaHsd * C57BL/6)
abnormal T-helper 1 cell number J:189919
decreased interferon-gamma secretion J:189919
decreased interleukin-2 secretion J:189919
decreased interleukin-10 secretion J:189919
decreased T cell proliferation J:189919
decreased T-helper 2 cell number J:189919
decreased T-helper 17 cell number J:189919
increased interferon-gamma secretion J:189919
increased interleukin-6 secretion J:189919
increased interleukin-17 secretion J:189919
increased T cell apoptosis J:189919
increased T cell proliferation J:189919
\Tg(Tcra5CC7,Tcrb5CC7)IWep/0
(involves: C57BL/6)
abnormal T cell activation J:73608
\Tg(Tcra51-11.5,Tcrb51-11.5)AR206Ayr/0
(involves: C57BL/6 * DBA/2)
abnormal positive T cell selection J:125548
\Tg(Tcra,Tcrb)3Ayr/0
(involves: C57BL/6 * DBA/2)
abnormal lymphocyte anergy J:80775
abnormal positive T cell selection J:125548
decreased T cell proliferation J:80775
\Tg(Tcra,Tcrb)24Efro/0
(D1.Cg-Tg(Tcra,Tcrb)24Efro)
abnormal cytokine secretion J:104243
abnormal T cell differentiation J:104243
autoimmune response J:104243
decreased T cell proliferation J:104243
increased autoantibody level J:104243
increased memory T cell number J:104243
increased susceptibility to autoimmune disorder J:104243
increased T cell proliferation J:104243
\Tg(Tcra,Tcrb)HRCAll/0
(B6.Cg-Tg(Tcra,Tcrb)HRCAll)
abnormal T cell subpopulation ratio J:131347
decreased CD4-positive, alpha-beta T cell number J:131347
decreased cytotoxic T cell cytolysis J:131347
decreased interferon-gamma secretion J:131347
increased CD8-positive, alpha-beta T cell number J:131347
\Tg(Tcra,Tcrb)HRVAll/0
(B6.Cg-Tg(Tcra,Tcrb)HRVAll)
abnormal T cell subpopulation ratio J:131347
decreased CD4-positive, alpha-beta T cell number J:131347
increased CD8-positive, alpha-beta T cell number J:131347
\Tg(TcraAI4)1Dvs/0
(NOD-Tg(TcraAI4)1Dvs)
abnormal CD4-positive, alpha beta T cell morphology J:93553
increased susceptibility to autoimmune diabetes J:93553
\Tg(TcraAI4)1Dvs/0
\Tg(TcrbAI4)1Dvs/0

(NOD-Tg(TcraAI4)1Dvs Tg(TcrbAI4)1Dvs)
abnormal CD4-positive, alpha beta T cell morphology J:93553
abnormal CD8-positive, alpha beta T cell morphology J:94192
abnormal cytotoxic T cell physiology J:94192
increased susceptibility to autoimmune diabetes J:94192
\Tg(TcraAV19AJ33)1Shima/?
(involves: 129S4/SvJae * C57BL/6)
abnormal NK T cell morphology J:112657
abnormal NK T cell physiology J:112657
decreased susceptibility to experimental autoimmune encephalomyelitis J:112657
\Tg(TcraBDC2.5,TcrbBDC2.5)1Doi/0
(NOD.Cg-Tg(TcraBDC2.5,TcrbBDC2.5)1Doi)
decreased susceptibility to autoimmune diabetes J:87251
increased activated T cell number J:52940
insulitis J:52940
\Tg(TcraBDC2.5,TcrbBDC2.5)1Doi/0
(involves: C57BL/6 * NOD * SJL)
decreased dendritic cell number J:137009
immune system phenotype J:135214
insulitis J:137009
\Tg(TcraCl1,TcrbCl1)1Shrm/0
(B10.Cg-Thy1a H2d Tg(TcraCl1,TcrbCl1)1Shrm)
abnormal T cell subpopulation ratio J:97745
\Tg(TcraCl4,TcrbCl4)1Shrm/?
(B10.Cg-H2d Tg(TcraCl4,TcrbCl4)1Shrm)
abnormal CD8-positive, alpha-beta T cell differentiation J:99756
abnormal T cell subpopulation ratio J:99756
\Tg(TcraDN32D3)#Alhn/0
(involves: NOD)
decreased NK cell number J:201417
decreased thymocyte number J:201417
increased double-negative T cell number J:201417
\Tg(TcraH-Y,TcrbH-Y)71Vbo/?
(involves: C57BL/6J * C57L/J * DBA/2J)
abnormal double-negative T cell morphology J:79738
abnormal T cell differentiation J:79738, J:90776
decreased thymocyte number J:79738
thymus hypoplasia J:79738
\Tg(TcraH-Y,TcrbH-Y)71Vbo/?
(involves: C57BL/6 * DBA/2J)
abnormal cytotoxic T cell physiology J:66565
abnormal T cell differentiation J:97610
\Tg(TcraH-Y,TcrbH-Y)71Vbo/?
\Themistm1Gasc/\Themistm1Gasc

(involves: 129S6/SvEvTac * C57BL/6 * DBA/2)
abnormal negative T cell selection J:151074
abnormal positive T cell selection J:151074
\Tg(TcraH-Y,TcrbH-Y)71Vbo/?
\Themistm1Lov/\Themistm1Lov

(involves: 129 * C57BL/6 * DBA/2)
abnormal negative T cell selection J:151075
abnormal positive T cell selection J:151075
decreased single-positive T cell number J:151075
increased double-positive T cell number J:151075
\Tg(TcraH-Y,TcrbH-Y)71Vbo/0
\Tnfrsf25tm1Mjo/\Tnfrsf25tm1Mjo

(involves: 129P2/OlaHsd * C57BL/6J * DBA/2J)
abnormal negative T cell selection J:84536
abnormal thymus morphology J:84536
increased thymocyte number J:84536
\Tg(TcrAND)53Hed/?
(involves: A/WySnSg * C57BL/6 * C57BL/10SnSg * SJL)
abnormal positive T cell selection J:85777
abnormal T cell differentiation J:85777
abnormal T cell proliferation J:85777
abnormal T cell subpopulation ratio J:85777
abnormal thymocyte activation J:85777
decreased CD8-positive, alpha-beta T cell number J:85777
decreased double-positive T cell number J:85777
increased CD4-positive, alpha-beta T cell number J:85777
\Tg(TcrAND)53Hed/?
(involves: C57BL/6 * SJL)
abnormal lymph node cell ratio J:124701
increased CD4-positive, alpha-beta T cell number J:124701
\Tg(TcrAND)53Hed/?
\Themistm1Gasc/\Themistm1Gasc

(involves: 129S6/SvEvTac * C57BL/6 * SJL)
abnormal positive T cell selection J:151074
decreased CD4-positive, alpha-beta T cell number J:151074
decreased CD8-positive, alpha-beta T cell number J:151074
increased double-positive T cell number J:151074
\Tg(TcrAND)53Hed/?
\Themistm1Lov/\Themistm1Lov

(involves: 129 * C57BL/6 * SJL)
abnormal positive T cell selection J:151075
decreased single-positive T cell number J:151075
increased double-positive T cell number J:151075
\Tg(TcrAND)53Hed/?
\Zbtb7btm1.1Rbo/\Zbtb7btm1.1Rbo

(involves: C57BL/6 * SJL)
abnormal T cell differentiation J:141145
\Tg(TcraR28,TcrbR28)KRNDim/0
(involves: C57BL/6 * NOD * SJL)
abnormal lymphocyte cell number J:36815
abnormal macrophage chemotaxis J:36815
abnormal T cell activation J:36815
abnormal T cell anergy J:36815
abnormal T cell clonal deletion J:36815
abnormal T cell proliferation J:36815
chronic joint inflammation J:36815
decreased CD4-positive, alpha-beta T cell number J:36815
decreased CD8-positive, alpha-beta T cell number J:36815
enlarged spleen J:36815
glomerulonephritis J:36815
impaired neutrophil recruitment J:36815
increased B cell number J:36815
increased IgG1 level J:36815
kidney inflammation J:36815
rheumatoid arthritis J:36815
\Tg(TcraTcrb)8Rest/?
(C57BL/6-Tg(TcraTcrb)8Rest)
abnormal CD8-positive, alpha-beta cytotoxic T cell morphology J:85058
abnormal cytotoxic T cell physiology J:85058
increased interferon-gamma secretion J:85058
\Tg(TcraTcrb)425Cbn/0
(involves: BALB/c * C57BL/6)
abnormal positive T cell selection J:125548
\Tg(TcraTcrb)425Cbn/?
(involves: BALB/c * C57BL/6)
abnormal positive T cell selection J:87876
increased CD4-positive, alpha-beta T cell number J:87876
\Tg(TcraTcrb)425Cbn/0
(involves: C57BL/6)
abnormal cytokine level J:112600
\Tg(TcraTcrb)425Cbn/0
\Trim30atm1Yjk/\Trim30atm1Yjk

(involves: 129P2/OlaHsd * BALB/c * C57BL/6)
increased T cell proliferation J:215171
\Tg(TcraTcrb)425Cbn/0
\Trip10tm1.1Geha/\Trip10tm1.1Geha

(B6.Cg-Trip10tm1.1Geha Tg(TcraTcrb)425Cbn)
abnormal effector T cell morphology J:164363
decreased CD4-positive, alpha-beta T cell number J:164363
immune system phenotype J:164363
\Tg(TcraTcrb)1100Mjb/?
(involves: C57BL/6)
abnormal CD8-positive, alpha beta T cell morphology J:92867
abnormal cytotoxic T cell physiology J:92867, J:133645
abnormal positive T cell selection J:92867, J:133645
abnormal T cell clonal deletion J:92867
abnormal T cell subpopulation ratio J:92867, J:133645
decreased CD4-positive, alpha-beta T cell number J:133645
increased CD8-positive, alpha-beta T cell number J:92867, J:133645
increased T cell proliferation J:92867
\Tg(TcraTcrb)1100Mjb/?
(involves: C57BL/6 * MRL/Mp)
liver inflammation J:72817
\Tg(TcraTcrb)1100Mjb/?
\Themistm1Gasc/\Themistm1Gasc

(involves: 129S6/SvEvTac * C57BL/6)
abnormal positive T cell selection J:151074
decreased CD8-positive, alpha-beta T cell number J:151074
increased double-positive T cell number J:151074
\Tg(TcraTcrbNY4.1)1Pesa/0
(NOD.Cg-Tg(TcraTcrbNY4.1)1Pesa)
increased susceptibility to autoimmune diabetes J:108768
insulitis J:108768
\Tg(TcraTcrbNY8.3)1Pesa/?
(involves: C57BL/6 * NOD * SJL)
pancreas inflammation J:44202
\Tg(TcraY1,TcrbY1)416Tev/0
(involves: C57BL/6J * DBA/2J)
abnormal immune tolerance J:84288
\Tg(Tcrb)93Vbo/0
(involves: C57BL/LiA * CBA/BrA)
abnormal T cell morphology J:93247
abnormal T cell receptor beta chain V(D)J recombination J:93247
\Tg(Tcrb)93Vbo/0
(involves: C57BL/6 * C57BL/LiA * CBA/BrA)
abnormal CD8-positive, alpha-beta T cell differentiation J:66565
abnormal cytotoxic T cell physiology J:66565
abnormal T cell clonal deletion J:66565
\Tg(Tcrb)HRBAll/0
(B6.Cg-Tg(Tcrb)HRBAll)
immune system phenotype J:131347
\Tg(Tcrb-TCF3/PBX1)19Gusa/0
(involves: C3H * C57BL/6 * C57BL/6J)
decreased thymocyte number J:95693
\Tg(Tcrb-TCF3/PBX1)23Gusa/0
(involves: C3H * C57BL/6 * C57BL/6J)
decreased thymocyte number J:95693
\Tg(TcrbAI4)1Dvs/0
(NOD-Tg(TcrbAI4)1Dvs)
abnormal CD4-positive, alpha beta T cell morphology J:93553
\Tg(TcrbBL17)1Lmor/0
(involves: DBA/1J * SWR/J)
increased susceptibility to induced arthritis J:134111
\Tg(TcrbBL17)1Lmor/\Tg(TcrbBL17)1Lmor
(involves: DBA/1J * SWR/J)
increased susceptibility to induced arthritis J:134111
\Tg(TcrHEL3A9)1Mmd/0
(involves: C57BL/6)
abnormal CD4-positive, alpha beta T cell morphology J:73608
abnormal interleukin secretion J:73608
abnormal T cell activation J:73608
increased T cell proliferation J:73608
\Tg(TcrHEL3A9)1Mmd/0
(involves: C57BL/6 * C57BL/10 * C57BR/cd)
abnormal CD4-positive, alpha beta T cell morphology J:78309
abnormal double-positive T cell morphology J:78309
abnormal T cell activation J:78309
abnormal T cell proliferation J:78309
abnormal thymus cell ratio J:78309
decreased CD4-positive, alpha-beta T cell number J:78309
\Tg(TcrHEL3A9)1Mmd/0
\Tg(TLK2mHEL)2Ccg/0

(involves: C57BL/6 * C57BL/10 * C57BR/cd)
abnormal CD4-positive, alpha beta T cell morphology J:78309
abnormal CD4-positive, alpha-beta T cell physiology J:78309
abnormal T cell activation J:78309
abnormal T cell proliferation J:78309
decreased CD4-positive, alpha-beta T cell number J:78309
decreased double-positive T cell number J:78309
thyroid gland inflammation J:78309
\Tg(TcrLCMV)1Aox/?
(C57BL/6-Tg(TcrLCMV)1Aox)
abnormal cytotoxic T cell physiology J:92228
decreased CD8-positive, alpha-beta T cell number J:92228
decreased double-positive T cell number J:92228
increased CD4-positive, alpha-beta T cell number J:92228
increased double-negative T cell number J:92228
increased IgG level J:92228
\Tg(TcrLCMV)2Aox/?
(C57BL/6-Tg(TcrLCMV)2Aox)
abnormal cytotoxic T cell physiology J:92228
decreased CD8-positive, alpha-beta T cell number J:92228
decreased double-positive T cell number J:92228
increased CD4-positive, alpha-beta T cell number J:92228
increased double-negative T cell number J:92228
\Tg(TcrLCMV)327Sdz/0
(involves: C57BL/6 * DBA/2)
decreased CD8-positive, alpha-beta T cell number J:77696
decreased cytotoxic T cell cytolysis J:77696
decreased double-positive T cell number J:77696
decreased T cell proliferation J:77696
thymus hypoplasia J:77696
\Tg(TcrLCMV)327Sdz/?
(involves: C57BL/6 * DBA/2J)
abnormal T cell differentiation J:97610
decreased CD4-positive, alpha-beta T cell number J:97610
\Tg(TcrLCMV)327Sdz/\Tg(TcrLCMV)327Sdz
(NOD.Cg-Tg(TcrLCMV)327Sdz/Dvs)
autoimmune response J:71050
\Tg(Tek-cre)1Ywa/0
\Thbdtm2Rdr/\Thbdtm2Wlr

(involves: 129S2/SvPas * C57BL/6 * SJL)
abnormal acute phase protein level J:71269
increased circulating interleukin-6 level J:71269
increased spleen weight J:71269
\Tg(Tek-cre)1Ywa/0
\Trp53tm1Brn/\Trp53tm1Brn

(involves: 129P2/OlaHsd * C57BL/6 * CD-1 * SJL)
increased T cell derived lymphoma incidence J:263520
\Tg(Tek-Jam3)1Maal/?
(B6.Cg-Tg(Tek-Jam3)1Maal)
abnormal cellular extravasation J:99020
abnormal leukocyte adhesion J:99020
abnormal leukocyte physiology J:99020
impaired neutrophil chemotaxis J:99020
lung inflammation J:99020
peritoneal inflammation J:99020
\Tg(Tek-Procr)1Cte/0
(B6.FVB-Tg(Tek-Procr)1Cte)
abnormal acute phase protein level J:119637
abnormal immune system physiology J:119637
abnormal inflammatory response J:119637
\Tg(Tek-Tnf*)5382Mcla/0
(B6.Cg-Tg(Tek-Tnf*)5382Mcla)
chronic inflammation J:71622
chronic liver inflammation J:71622
decreased inflammatory response J:71622
kidney inflammation J:71622
lung inflammation J:71622
\Tg(Tek-tTA)1Dmt/0
\Tg(tetO-Tek)1Dmt/0

(involves: CD-1)
abnormal spleen red pulp morphology J:137745
abnormal spleen white pulp morphology J:137745
enlarged spleen J:137745
increased eosinophil cell number J:137745
increased T cell number J:137745
skin inflammation J:96718, J:137745
\Tg(tetO-BCR/ABL1)2Dgt/0
\Tg(MMTVtTA)1Mam/0

(involves: C57BL/6 * FVB/N * SJL)
enlarged lymph nodes J:72377
enlarged spleen J:72377
increased leukocyte cell number J:72377
\Tg(tetO-BCR/ABL1)2Dgt/0
\Tg(Tal1-tTA)19Dgt/0

(involves: C57BL/6 * DBA/2 * FVB/N)
abnormal lymph node morphology J:96511
abnormal lymphopoiesis J:96511
abnormal spleen red pulp morphology J:96511
abnormal splenic cell ratio J:96511
enlarged spleen J:96511
increased leukocyte cell number J:96511
increased neutrophil cell number J:96511
\Tg(tetO-BCR/ABL1)27Dgt/0
\Tg(MMTVtTA)1Mam/0

(involves: C57BL/6 * FVB/N * SJL)
enlarged lymph nodes J:72377
enlarged spleen J:72377
increased leukocyte cell number J:72377
\Tg(tetO-MAP2K1)#Ahsa/?
\Tg(CD2-rtTA)CRza/?

(involves: C57BL/6 * C57BL/10 * CBA * SJL)
immune system phenotype J:174339
increased anti-double stranded DNA antibody level J:174339
\Tg(tetO/CMV-CD200)1Rmgo/\Tg(tetO/CMV-CD200)1Rmgo
(involves: C57BL/6)
abnormal dendritic cell physiology J:134313
\Tg(TetOp-Polb/tTA)2Sbl/0
(B6.Cg-Tg(TetOp-Polb/tTA)2Sbl)
glomerulonephritis J:152481
\Tg(TG-SV40)#Cled/0
(involves: C57BL/6J * DBA/2J)
spleen hypoplasia J:209788
thymus hypoplasia J:209788
\Tg(TG-TSHR)51.9Smcl/?
(involves: BALB/c * C57BL/6)
immune system phenotype J:118100
\Tg(Tgfa)1Efu/0
(Not Specified)
ear inflammation J:65045
\Tg(Th-SNCA)5Eric/\Tg(Th-SNCA)5Eric
(involves: C57BL/6)
abnormal microglial cell physiology J:140907
\Tg(THY1-APP)2Somm/0
(involves: C57BL/6J * DBA/2)
brain inflammation J:44603
\Tg(Thy1-APP)3Somm/0
(involves: C57BL/6J * DBA/2)
brain inflammation J:44603
microgliosis J:134832
\Tg(Thy1-App*R609D*K612E)2Vln/0
(involves: C57BL * CBA/J)
abnormal microglial cell morphology J:32213
\Tg(Thy1-App*R609D*K612E)4Vln/0
(involves: FVB)
abnormal microglial cell morphology J:32213
\Tg(Thy1-App*R609D*K612E)6Vln/0
(involves: FVB)
abnormal microglial cell morphology J:32213
\Tg(Thy1-APPDutch)#Jckr/0
(involves: C57BL/6J)
microgliosis J:92796
\Tg(Thy1-APPSw)10Jiri/0
(involves: C3H * C57BL/6)
microgliosis J:128647
\Tg(Thy1-APPSw)10Jiri/0
\Tg(Thy1-PSEN1*M146V)#Jiri/0

(B6.Cg-Tg(Thy1-APPSw)10Jiri Tg(Thy1-PSEN1*M146V)#Jiri)
microgliosis J:156577
\Tg(Thy1-APPSwDutIowa)BWevn/0
(involves: C57BL/6)
abnormal microglial cell physiology J:124911
\Tg(Thy1-APPSweLon)41Ema/0
(involves: C57BL/6 * DBA/2)
microgliosis J:162842
\Tg(Thy1-cmyc)6Kio/0
(Not Specified)
increased T cell derived lymphoma incidence J:129440
\Tg(Thy1-cmyc)6LKio/0
(Not Specified)
increased T cell derived lymphoma incidence J:129440
\Tg(Thy1-Fcer2a)2431Putt/?
(involves: BALB/c * C57BL/6)
abnormal immune system physiology J:129296
decreased IgE level J:20421
decreased IgG1 level J:20421
increased eosinophil cell number J:20421
\Tg(Thy1-Fcer2a)2733Putt/?
(involves: BALB/c * C57BL/6)
immune system phenotype J:20421
\Tg(Thy1-FUS*)1Dit/0
(B6.Cg-Tg(Thy1-FUS*)1Dit)
microgliosis J:287782
\Tg(Thy1-FUS*)1Dit/0
\Tg(Thy1-TARDBP)4Singh/0

(involves: C57BL/6J * DBA/2J * SJL/J)
microgliosis J:287782
\Tg(Thy1-FUS*)19Vlb/0
(B6.Cg-Tg(Thy1-FUS*)19Vlb)
microgliosis J:203550
\Tg(Thy1-MAPT*)1Avil/\Tg(Thy1-MAPT*)1Avil
(involves: C57BL/6 * CBA)
microgliosis J:201700
\Tg(Thy1-MAPT*P301S)2541Godt/\Tg(Thy1-MAPT*P301S)2541Godt
(involves: C57BL/6J * CBA/Ca)
eye inflammation J:108870
\Tg(Thy1-PSEN1*M146V,-APP*Swe)10Arte/\Tg(Thy1-PSEN1*M146V,-APP*Swe)10Arte
(involves: C57BL/6 * CBA)
microgliosis J:155410
\Tg(Thy1-Snca)1S13Putt/?
(involves: C57BL/6)
microgliosis J:177661
\Tg(Thy1-SNCA)61Ema/0
(involves: C57BL/6 * DBA/2)
abnormal microglial cell activation J:238066
abnormal microglial cell morphology J:238066
\Tg(Thy1-Sncg)HvP36Putt/?
(C57BL/6-Tg(Thy1-Sncg)HvP36Putt)
microgliosis J:185793
\Tg(Thy1-TARDBP)4Singh/0
(involves: C57BL/6J * SJL/J)
microgliosis J:157550
\Tg(Thy1-TARDBP)4Singh/\Tg(Thy1-TARDBP)4Singh
(involves: C57BL/6J * SJL/J)
microgliosis J:157550
\Tg(Thy1-TARDBP)6Singh/\Tg(Thy1-TARDBP)6Singh
(involves: C57BL/6 * C57BL/6J * SJL)
microgliosis J:157550
\Tg(Thy1-UBQLN2*P497S)3Mont/?
(involves: C3H * C57BL/6 * C57BL/6J)
increased microglial cell activation J:239510
\Tg(Thy1-UBQLN2*P506T)6Mont/?
(involves: C3H * C57BL/6 * C57BL/6J)
decreased microglial cell activation J:239510
\Tg(Thy1/THY1)T6Gsv/0
(involves: C57BL/10 * CBA)
abnormal mononuclear cell morphology J:294621
increased macrophage derived foam cell number J:294621
increased neutrophil cell number J:294621
\Tg(Thy1/THY1)T12Gsv/0
(involves: C57BL/10 * CBA)
increased IgG level J:133943
increased IgM level J:133943
\Tg(Tk1-DPP4)27Ysj/0
(involves: C57BL/6 * FVB/N)
abnormal chemokine level J:290259
abnormal innate immunity J:290259
abnormal interleukin level J:290259
abnormal macrophage activation involved in immune response J:290259
abnormal tumor necrosis factor level J:290259
increased susceptibility to Coronaviridae infection J:290259
increased susceptibility to Coronaviridae infection induced morbidity/mortality J:290259
lung inflammation J:290259
\Tg(Tlr7)1Boll/0
(involves: C57BL/6)
abnormal circulating chemokine level J:127600
abnormal dendritic cell morphology J:127600
abnormal spleen morphology J:127600
autoimmune response J:127600
decreased spleen white pulp amount J:127600
enlarged spleen J:127600
glomerulonephritis J:127600
increased anti-nuclear antigen antibody level J:127600
increased circulating interleukin-6 level J:127600
increased circulating tumor necrosis factor level J:127600
liver inflammation J:127600
X/\Tg(Tlr7)6Boll
(involves: C57BL/6)
abnormal B cell activation J:127600
abnormal B cell morphology J:127600
abnormal dendritic cell morphology J:127600
abnormal T cell activation J:127600
autoimmune response J:127600
decreased marginal zone B cell number J:127600
enlarged spleen J:127600
glomerulonephritis J:127600
increased anti-nuclear antigen antibody level J:127600
increased mature B cell number J:127600
increased splenocyte proliferation J:127600
liver inflammation J:127600
lung inflammation J:127600
\Tg(TNF)197Gkl/0
(involves: C57BL/6 * CBA)
abnormal osteoclast differentiation J:97992
autoimmune arthritis J:97992, J:92576
increased osteoclast cell number J:97992
\Tg(TNF)197Gkl/0
\Tnfrsf1atm1.1Gkl/\Tnfrsf1atm1.1Gkl

(involves: 129 * C57BL/6 * CBA)
autoimmune arthritis J:92470
\Tg(TNF)3647Gkl/0
(involves: C57BL/6 * CBA)
autoimmune arthritis J:190204
\Tg(Tnf)6074Gkl/0
(involves: C57BL/6 * CBA)
abnormal microglial cell morphology J:106592
brain inflammation J:106592
\Tg(Tnf)6074Gkl/0
\Tnfrsf1btm1Mwm/\Tnfrsf1btm1Mwm

(involves: 129S2/SvPas * C57BL/6 * CBA)
CNS inflammation J:106592
\Tg(TNFSF11)5516Edou/0
\Tnfsf11tles/\Tnfsf11tles

(involves: 129S6/SvEvTac * C57BL/6J * CBA/J)
absent lymph nodes J:233240
\Tg(TNFSF11)5519Edou/0
(involves: C57BL/6J * CBA/J)
increased osteoclast cell number J:233240
\Tg(Tnfsf13b)1Fma/0
(involves: C57BL/6 * DBA/2J)
abnormal B cell morphology J:58798
abnormal B cell physiology J:58798
abnormal spleen follicular dendritic cell network J:58798
abnormal spleen morphology J:58798
abnormal spleen periarteriolar lymphoid sheath morphology J:58798
abnormal T cell number J:58798
abnormal T cell physiology J:58798
abnormal T cell subpopulation ratio J:58798
enlarged lymph nodes J:58798
enlarged Peyer's patches J:58798
enlarged spleen J:58798
increased anti-double stranded DNA antibody level J:58798
increased anti-single stranded DNA antibody level J:58798
increased autoantibody level J:58798
increased B cell number J:58798
increased IgG level J:58798
increased IgM level J:58798
increased immunoglobulin level J:58798
increased lymphocyte cell number J:58798
increased marginal zone B cell number J:58798
increased mature B cell number J:58798
increased plasma cell number J:58798
increased spleen B cell follicle size J:58798
increased spleen germinal center size J:58798
increased T cell number J:58798
\Tg(Tnfsf13b)1Fma/0
(B6.Cg-Tg(Tnfsf13b)1Fma)
abnormal B cell differentiation J:73711
abnormal B-1 B cell morphology J:114782
abnormal spleen germinal center morphology J:114782
abnormal spleen marginal zone morphology J:114782
increased autoantibody level J:114782
increased B cell number J:114782
increased B-1a cell number J:114782
increased B-1b cell number J:114782
increased IgA level J:114782
increased plasma cell number J:114782
kidney inflammation J:73711
salivary gland inflammation J:73711
\Tg(Tnfsf13b)1Fma/0
(involves: C57BL/6J * DBA/2J)
abnormal B cell differentiation J:115788
abnormal B-1 B cell morphology J:115788
\Tg(Tnfsf13b)1Fma/?
(B6.Cg-Tg(Tnfsf13b)1Fma)
abnormal B cell activation J:113556
abnormal marginal zone B cell physiology J:113556
abnormal spleen marginal zone morphology J:113556
glomerulonephritis J:113556
increased anti-double stranded DNA antibody level J:113556
increased B cell number J:113556
increased marginal zone B cell number J:113556
increased transitional stage B cell number J:113556
\Tg(Tnfsf13b)1Fma/?
\Tnfrsf13btm1Rjb/\Tnfrsf13btm1Rjb

(B6.Cg-Tnfrsf13btm1Rjb Tg(Tnfsf13b)1Fma)
abnormal class switch recombination J:113556
\Tg(Tnfsf13b)1Fma/?
\Tnfrsf13ctm1Mass/\Tnfrsf13ctm1Mass

(B6.Cg-Tnfrsf13ctm1Mass Tg(Tnfsf13b)1Fma)
abnormal class switch recombination J:113556
\Tg(Tnfsf13b)1Fma/0
\Tnfsf14tm1Kpf/\Tnfsf14tm1Kpf

(involves: 129P2/OlaHsd * C57BL/6 * DBA/2J)
abnormal spleen germinal center morphology J:114782
abnormal spleen marginal zone morphology J:114782
increased B cell number J:114782
increased IgA level J:114782
increased plasma cell number J:114782
\Tg(Tnfsf13b)1Fma/\Tg(Tnfsf13b)1Fma
(involves: C57BL/6 * DBA/2)
abnormal immunoglobulin level J:178227
increased B cell number J:178227
increased IgA level J:178227
increased IgM level J:178227
increased immunoglobulin level J:178227
increased marginal zone B cell number J:178227
increased transitional stage T2 B cell number J:178227
kidney inflammation J:178227
\Tg(Tox)1Kay/?
\Toxtm1.1Kay/\Toxtm1.1Kay

(involves: 129S6/SvEvTac * C57BL/6)
abnormal T cell number J:131287
\Tg(Trp53)1Srn/0
(involves: C57BL/6 * CBA)
increased thymocyte apoptosis J:80311
\Tg(Trp53)1Srn/0
\Trp53tm1Tyj/\Trp53tm1Tyj

(involves: 129S2/SvPas * C57BL/6 * CBA)
decreased thymocyte apoptosis J:80311
\Tg(Trp53)bSrn/0
(involves: C57BL/6 * CBA)
increased thymocyte apoptosis J:80311
\Tg(Trp53A135V)L3Ber/0
(involves: C57BL/6 * CD-1)
decreased spleen weight J:73757
\Tg(Ttr-IGF1)1Sykr/0
(FVB/N-Tg(Ttr-IGF1)1Sykr)
increased spleen weight J:157350
\Tg(Tyr-NRAS*Q61K)1Bee/?
(involves: BALB/c * C57BL/6J * DBA/2)
skin inflammation J:98545
\Tg(Tyr-NRAS*Q61K)1Bee/?
(involves: C57BL/6J * DBA/2)
skin inflammation J:98545
\Tg(UBC-scFv)2Nemz/0
(involves: C57BL/6 * DBA/2)
abnormal B cell differentiation J:96759
abnormal B cell morphology J:96759
abnormal B cell receptor editing J:96759
abnormal B-1 B cell morphology J:96759
abnormal immune tolerance J:96759
abnormal immunoglobulin level J:96759
abnormal mature B cell morphology J:96759
decreased mature B cell number J:96759
decreased splenocyte number J:96759
spleen hypoplasia J:96759
\Tg(Umod*C147W)958Lura/0
(involves: FVB)
kidney inflammation J:161532
\Tg(Vav1-Asxl1*Y588X)#Fcy/0
(C57BL/6-Tg(Vav1-Asxl1*Y588X)#Fcy)
abnormal neutrophil morphology J:257690
abnormal spleen morphology J:257690
decreased leukocyte cell number J:257690
decreased lymphocyte cell number J:257690
enlarged spleen J:257690
hepatosplenomegaly J:257690
increased leukocyte cell number J:257690
increased monocyte cell number J:257690
increased neutrophil cell number J:257690
\Tg(VAV1-cre)1Graf/?
\Gt(ROSA)26Sortm4(ACTB-tdTomato,-EGFP)Luo/?
\Trip11tm1.1Psmi/\Trip11tm1.2Psmi

(involves: 129/Sv * C57BL/6)
immune system phenotype J:253969
\Tg(Vav1-ERG)#Jpim/0
(involves: C57BL/6)
abnormal thymus morphology J:174808
enlarged spleen J:174808
enlarged thymus J:174808
\Tg(Vav1-JAK2*V617F)AZjz/0
(involves: C57BL/6 * DBA/2)
enlarged spleen J:135993
increased granulocyte number J:135993
increased leukocyte cell number J:135993
increased spleen weight J:135993
spleen fibrosis J:135993
\Tg(Vav1-Lin28b)C3Apla/0
(involves: C57BL/6)
abnormal cytokine level J:189197
abnormal inflammatory response J:189197
abnormal T cell differentiation J:189197
abnormal thymus cell ratio J:189197
abnormal thymus cortex morphology J:189197
abnormal thymus corticomedullary boundary morphology J:189197
decreased CD4-positive, alpha-beta T cell number J:189197
decreased CD8-positive, alpha-beta T cell number J:189197
decreased double-positive T cell number J:189197
decreased leukocyte cell number J:189197
decreased lymphocyte cell number J:189197
decreased thymocyte number J:189197
enlarged lymph nodes J:189197
enlarged spleen J:189197
enlarged thymus medulla J:189197
increased CD8-positive, alpha-beta T cell number J:189197
increased effector memory CD4-positive, alpha-beta T cell number J:189197
increased effector memory CD8-positive, alpha-beta T cell number J:189197
increased eosinophil cell number J:189197
increased IgG level J:189197
increased neutrophil cell number J:189197
increased T cell derived lymphoma incidence J:189197
increased T cell proliferation J:189197
\Tg(Vav1-NUP98/HOXD13)C1Apla/0
(FVB/N-Tg(Vav1-NUP98/HOXD13)C1Apla)
abnormal neutrophil morphology J:107446
decreased leukocyte cell number J:107446
\Tg(Vav1-NUP98/HOXD13)G2Apla/0
(C57BL/6-Tg(Vav1-NUP98/HOXD13)G2Apla)
abnormal neutrophil morphology J:107446
decreased leukocyte cell number J:107446
decreased lymphocyte cell number J:107446
decreased neutrophil cell number J:107446
\Tg(Vav1-STAT5B*N642H)726Biat/0
(C57BL/6NCrl-Tg(Vav1-STAT5B*N642H)726Biat)
abnormal effector T cell number J:257519
abnormal lymph node morphology J:257519
abnormal spleen morphology J:257519
enlarged spleen J:257519
increased CD4-positive, alpha-beta T cell number J:257519
increased CD8-positive, alpha-beta T cell number J:257519
increased leukocyte cell number J:257519
increased T cell proliferation J:257519
\Tg(Vav-BCL2)69Jad/0
(involves: C57BL/6J)
abnormal class switch recombination J:88565
abnormal lymphocyte cell number J:88565
abnormal somatic hypermutation frequency J:88565
abnormal spleen germinal center morphology J:88565
enlarged lymph nodes J:88565
enlarged spleen J:88565
glomerulonephritis J:88565
increased B cell number J:88565
increased CD4-positive, alpha-beta T cell number J:88565
increased CD8-positive, alpha-beta T cell number J:88565
increased spleen germinal center number J:88565
increased spleen germinal center size J:88565
increased T cell derived lymphoma incidence J:88565
increased T cell number J:88565
\Tg(Vil1-cre)997Gum/?
\Tlr4lps-del/\Tlr4lps-del
\Tlr5tm1.1Gewr/\Tlr5tm1.1Gewr

(involves: C57BL/6J * C57BL/6NTac * C57BL/10ScN * SJL)
large intestinal inflammation J:229155
\Tg(Vil1-cre)997Gum/?
\Tlr5tm1.1Gewr/\Tlr5tm1.1Gewr

(involves: C57BL/6J * C57BL/6NTac * SJL/J)
enlarged spleen J:229155
increased interleukin-1 beta secretion J:229155
increased susceptibility to colitis induced morbidity/mortality J:229155
large intestinal inflammation J:229155
\Tg(Vil1-cre)997Gum/0
\Tnfrsf11atm1.1Irw/\Tnfrsf11atm1.1Irw

(involves: 129S6/SvEvTac * C57BL/6 * C57BL/6NTac * SJL)
abnormal Peyer's patch epithelium morphology J:219915, J:226603
abnormal Peyer's patch follicle morphology J:226603
abnormal Peyer's patch germinal center morphology J:226603
abnormal Peyer's patch morphology J:226603
abnormal Peyer's patch T cell area morphology J:226603
decreased IgA level J:226603
decreased plasma cell number J:226603
\Tg(Vil-SLC3A2)HEMerl/0
(involves: FVB/N)
colitis J:173946
increased circulating tumor necrosis factor level J:173946
increased susceptibility to induced colitis J:173946
\Tg(VIM-Tag)3Pau/0
(involves: C57BL/6 * SJL/J)
enlarged thymus J:91542
increased double-negative T cell number J:91542
thymus hyperplasia J:91542
\Tg(VIM-Tag)3Pau/0
(either: (involves: C57BL/6 * CBA * SJL/J) or (involves: C57BL/6 * SJL/J))
glomerulonephritis J:92226
\Tg(Wnt1)1Hev/0
\Zfp451em1Ssli/\Zfp451em1Ssli

(involves: C57BL/6 * SJL)
abnormal macrophage morphology J:338905
decreased chemokine level J:338905
\Tgm3Btlr/\Tgm3Btlr
(C57BL/6J-Tgm3Btlr)
decreased B cell number J:265197
decreased IgE level J:265197
increased susceptibility to induced colitis J:265197
\Tgm4Btlr/\Tgm4Btlr
(C57BL/6J-Tgm4Btlr)
decreased B cell number J:272522
decreased B-2 B cell number J:272522
increased alpha-beta T cell number J:272522
increased B-1a cell number J:272522
increased CD4-positive, alpha-beta T cell number J:272522
increased CD8-positive, alpha-beta T cell number J:272522
increased central memory CD4-positive, alpha-beta T cell number J:272522
increased IgE level J:272522
increased macrophage cell number J:272522
\TgM5Btlr/\TgM5Btlr
(C57BL/6J-TgM5Btlr)
increased central memory CD4-positive, alpha-beta T cell number J:272523
\Tgm6Btlr/\Tgm6Btlr
(C57BL/6J-Tgm6Btlr)
increased alpha-beta T cell number J:272525
\tga/\tga
(C57BL/6J-tga)
thymus hypoplasia J:94456
\Tgfatm1Ard/\Tgfatm1Ard
(involves: 129P2/OlaHsd * C57BL/6)
increased incidence of corneal inflammation J:4606
\Tgfatm1Unc/\Tgfatm1Unc
(involves: 129P2/OlaHsd * C57BL/6J)
immune system phenotype J:4605
\Tgfawa1/\Tgfawa1
(Not Specified)
conjunctivitis J:13115
keratoconjunctivitis J:13115
\Tgfb1tm1(Tgfb3)Kul/\Tgfb1tm1(Tgfb3)Kul
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
abnormal T cell morphology J:204892
immune system phenotype J:204892
increased monocyte cell number J:204892
increased regulatory T cell number J:204892
\Tgfb1tm1Doe/\Tgfb1tm1Doe
(involves: 129S2/SvPas * CF-1)
abnormal inflammatory response J:2892
abnormal Peyer's patch germinal center morphology J:2892
brain inflammation J:2892
conjunctivitis J:2892
decreased Peyer's patch number J:2892
diaphragmitis J:2892
enlarged lymph nodes J:2892
eye inflammation J:2892
heart inflammation J:2892
increased leukocyte cell number J:2892
lacrimal gland inflammation J:2892
liver inflammation J:2892
lung inflammation J:2892
myositis J:2892
pancreas inflammation J:2892
salivary gland inflammation J:2892
skin inflammation J:2892
small spleen J:2892
stomach inflammation J:2892
\Tgfb1tm1Doe/\Tgfb1tm1Doe
(involves: 129S2/SvPas * BALB/c * CF-1)
heart inflammation J:69346
increased interferon-gamma secretion J:69346
liver inflammation J:69346
lung inflammation J:69346
\Tgfb1tm1Doe/\Tgfb1tm1Doe
(C.129S2-Tgfb1tm1Doe)
decreased CD4-positive, alpha-beta T cell number J:69346
heart inflammation J:69346
increased CD4-positive, alpha-beta T cell number J:69346
increased interferon-gamma secretion J:69346
increased T-helper 1 cell number J:69346
liver inflammation J:69346
\Tgfb1tm1Doe/\Tgfb1tm2.1Doe
\Tg(Lck-cre)548Jxm/?

(involves: 129S2/SvPas * 129S6/SvEvTac * Black Swiss * BALB/c * C57BL/6 * CBA)
lung inflammation J:150024
salivary gland inflammation J:150024
\Tgfb1tm1Jmu/\Tgfb1tm1Jmu
(involves: 129S6/SvEvTac * C57BL/6)
abnormal immune system physiology J:120085
absent Langerhans cell J:120085
heart inflammation J:120085
liver inflammation J:120085
lung inflammation J:120085
pancreas inflammation J:120085
stomach inflammation J:120085
\Tgfb1tm1Jmu/\Tgfb1tm1Jmu
(involves: 129S6/SvEvTac * C57BL/6 * Swiss Webster)
abnormal immune system physiology J:120085
absent Langerhans cell J:120085
\Tgfb1tm1N/\Tgfb1tm1N
(involves: 129S/SvEv)
abnormal immune system physiology J:120085
absent Langerhans cell J:120085
atrial endocarditis J:50848
increased inflammatory response J:50848
interstitial pneumonia J:50848
lymph node inflammation J:50848
myocarditis J:50848
pancreas inflammation J:50848
pericarditis J:50848
phlebitis J:50848
salivary gland inflammation J:50848
\Tgfb1tm1Rif/\Tgfb1tm1Rif
(Not Specified)
abnormal immune system physiology J:141786
\Tgfb1tm1Rif/\Tgfb1tm1Rif
(either: (involves: 129) or (involves: 129S/SvEv * C57BL/6))
absent Langerhans cell J:142353
cecum inflammation J:142353
heart inflammation J:142353
increased inflammatory response J:142353
large intestinal inflammation J:142353
lung inflammation J:142353
proctitis J:142353
small intestinal inflammation J:142353
stomach inflammation J:142353
\Tgfb1tm2Flv/\B9d2/Tgfb1tm1Flv
\Tg(CD207-cre)1Dhka/?

(involves: 129S6/SvEvTac * C57BL/6J * SJL/J)
decreased Langerhans cell number J:126147
\Tgfb1tm3.1Flv/\Tgfb1tm3.1Flv
\Tg(Cd4-cre)1Cwi/0

(involves: 129 * C57BL/6 * DBA/2 * NOD)
increased regulatory T cell number J:196160
increased T-helper 1 cell number J:196160
\Tgfb1tm3.1Flv/\Tgfb1tm3.1Flv
\Tg(Cd4-cre)1Cwi/0
\Tg(TcraBDC2.5,TcrbBDC2.5)1Doi/0

(involves: 129 * C57BL/6 * DBA/2 * NOD * SJL)
increased regulatory T cell number J:196160
increased susceptibility to autoimmune diabetes J:196160
increased T-helper 1 cell number J:196160
\Tgfb2tm1Doe/\Tgfb2tm1Doe
(involves: 129P2/OlaHsd * Black Swiss)
abnormal macrophage physiology J:73681
\Tgfb3tm1.1(KOMP)Vlcg/\Tgfb3+
(C57BL/6N-Tgfb3tm1.1(KOMP)Vlcg/Tcp)
enlarged lymph nodes J:211773
\Tgfbitm1Zhao/\Tgfbitm1Zhao
(involves: 129 * C57BL/6J)
enlarged spleen J:143036
increased B cell number J:143036
\Tgfbr2tm1.2Hlm/\Tgfbr2tm1.2Hlm
\Tg(Cd4-cre)1Cwi/0

(involves: 129S6/SvEvTac * C57BL/6 * DBA/2)
abnormal T cell activation J:148747
autoimmune response J:148747
liver inflammation J:148747
\Tgfbr2tm1.2Hlm/\Tgfbr2tm1.2Hlm
\Tg(Cd4-cre)1Cwi/0

(involves: 129 * C57BL/6 * DBA/2 * NOD)
increased inflammatory response J:196160
\Tgfbr2tm1.2Hlm/\Tgfbr2tm1.2Hlm
\Tg(Cd4-cre)1Cwi/0
\Tg(TcraBDC2.5,TcrbBDC2.5)1Doi/0

(involves: 129 * C57BL/6 * DBA/2 * NOD * SJL)
abnormal abdominal lymph node morphology J:196160
abnormal immune serum protein physiology J:196160
abnormal immune system morphology J:196160
abnormal immune system organ morphology J:196160
abnormal immune system physiology J:196160
abnormal interleukin secretion J:196160
abnormal spleen morphology J:196160
decreased interleukin-9 secretion J:196160
decreased interleukin-17 secretion J:196160
decreased regulatory T cell number J:196160
immune system phenotype J:196160
increased interferon-gamma secretion J:196160
increased interleukin-2 secretion J:196160
increased interleukin-21 secretion J:196160
increased regulatory T cell number J:196160
increased susceptibility to autoimmune diabetes J:196160
pancreas inflammation J:196160
\Tgfbr2tm1.2Hlm/\Tgfbr2tm1.2Hlm
\Tg(CD207-cre)1Dhka/?

(involves: 129S6/SvEvTac * C57BL/6J * SJL/J)
decreased Langerhans cell number J:126147
\Tgfbr2tm1.2Hlm/\Tgfbr2tm1.2Hlm
\Tg(Foxp3-EGFP/cre)1cJbs/0
\Tg(TcraBDC2.5,TcrbBDC2.5)1Doi/0

(involves: 129S6/SvEvTac * C57BL/6 * NOD * SJL)
immune system phenotype J:196160
increased regulatory T cell number J:196160
\Tgfbr2tm1.2Hlm/\Tgfbr2tm1.2Hlm
\Tnfrsf4tm2(cre)Nik/\Tnfrsf4+
\Tg(TcraBDC2.5,TcrbBDC2.5)1Doi/0

(involves: 129 * C57BL/6 * NOD * SJL)
immune system phenotype J:196160
increased susceptibility to autoimmune diabetes J:196160
\Tgfbr2tm1Karl/\Tgfbr2tm1Karl
\H2az2Tg(Wnt1-cre)11Rth/\H2az2+

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA)
small thymus J:96359
\Tgfbr2tm1Karl/\Tgfbr2tm1Karl
\Tg(Mx1-cre)1Cgn/0

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA)
eye inflammation J:77844
increased inflammatory response J:77844
liver inflammation J:77844
pancreas inflammation J:77844
small thymus J:77844
stomach inflammation J:77844
\Tgfbr3tm1Stv/\Tgfbr3tm1Stv
(involves: 129/Sv * C57BL/6)
abnormal spleen morphology J:83727
decreased spleen white pulp amount J:83727
\Tgif1tm1.1Caw/\Tgif1tm1.1Caw
(B6.129S-Tgif1tm1.1Caw)
abnormal cytokine level J:198238
increased susceptibility to otitis media J:198238
\Tgm2tm1.1Rmgr/\Tgm2tm1.1Rmgr
(involves: 129S1/SvImJ * C57BL/6)
abnormal T cell physiology J:95130
\Tgm2tm1Gml/\Tgm2tm1Gml
(involves: C57BL/6)
decreased susceptibility to endotoxin shock J:131975
immune system phenotype J:131975
increased macrophage cell number J:131975
\Tgm2tm1Gml/\Tgm2tm1Gml
(involves: C57BL/6 * DBA/1LacJ)
abnormal thymus morphology J:132254
impaired macrophage phagocytosis J:132254
\Tgm6em1Bge/\Tgm6em1Bge
(C57BL/6N-Tgm6em1Bge)
increased susceptibility to bacterial infection J:268324
\TgTn(pb-CAG-Gm614)#Cya/0
(involves: C57BL/6)
decreased B cell apoptosis J:307345
immune system phenotype J:307345
increased susceptibility to systemic lupus erythematosus J:307345
\TgTn(pb-CAG-Gm40600)#Rew/0
(C57BL/6-TgTn(pb-CAG-Gm40600)#Rew)
abnormal plasmablast number J:311878
decreased B cell number J:311878
decreased IgA level J:311878
decreased IgE level J:311878
decreased IgG1 level J:311878
decreased IgG2b level J:311878
decreased IgG2c level J:311878
decreased IgG3 level J:311878
decreased IgG level J:311878
decreased IgM level J:311878
decreased plasma cell number J:311878
increased B cell number J:311878
increased IgA level J:311878
increased IgE level J:311878
increased IgG1 level J:311878
increased IgG2b level J:311878
increased IgG2c level J:311878
increased IgG3 level J:311878
increased IgG level J:311878
increased IgM level J:311878
increased plasma cell number J:311878
\Thap4em1Nvl/\Thap4em1Nvl
(C57BL/6JJcl-Thap4em1Nvl)
increased thymus weight J:350810
\Thbdtm1.1Hlwu/\Thbdtm1.1Hlwu
\Lyz2tm1(cre)Ifo/\Lyz2+

(B6.129-Thbdtm1.1Hlwu Lyz2tm1(cre)Ifo)
decreased circulating interleukin-6 level J:188879
decreased circulating tumor necrosis factor level J:188879
decreased susceptibility to bacterial infection J:188879
decreased susceptibility to bacterial infection induced morbidity/mortality J:188879
decreased tumor necrosis factor secretion J:188879
\Thbdtm1Wlr/\Thbdtm1Wlr
(B6.129S2-Thbdtm1Wlr)
abnormal spleen morphology J:111502
decreased circulating tumor necrosis factor level J:111502
increased circulating interleukin-1 beta level J:111502
increased circulating interleukin-6 level J:111502
increased susceptibility to endotoxin shock J:111502
\Thbdtm1Wlr/\Thbdtm2Rdr
(involves: 129S2/SvPas * C57BL/6)
abnormal spleen morphology J:111502, J:47676
\Thbdtm2.1Emc/\Thbdtm2.1Emc
(involves: 129/Sv * BALB/c * C57BL/6)
abnormal leukocyte adhesion J:118000
abnormal leukocyte physiology J:118000
increased circulating interleukin-1 beta level J:118000
increased circulating tumor necrosis factor level J:118000
increased susceptibility to endotoxin shock J:118000
\Thbdtm2Emc/\Thbdtm2Emc
(either: (involves: 129S1/Sv * 129X1/SvJ) or (involves: 129S1/Sv * 129X1/SvJ * C57BL/6))
abnormal leukocyte physiology J:118000
\Thbs1tm1Hyn/\Thbs1tm1Hyn
(either: (involves: 129S2/SvPas * 129/Sv) or (involves: 129S2/SvPas * C57BL/6))
increased eosinophil cell number J:46182
increased leukocyte cell number J:46182
increased lymphocyte cell number J:46182
increased monocyte cell number J:46182
increased neutrophil cell number J:46182
lung inflammation J:46182, J:48446
pancreas inflammation J:48446
\Thbs1tm1Hyn/\Thbs1tm1Hyn
(involves: 129S2/SvPas * C57BL/6)
decreased interferon-gamma secretion J:153126
decreased regulatory T cell number J:153126
increased anti-single stranded DNA antibody level J:153126
increased CD4-positive, alpha-beta T cell number J:153126
increased interleukin-17 secretion J:153126
lacrimal gland inflammation J:153126
\Thbs1tm1Hyn/\Thbs1tm1Hyn
\Thbs2tm1Bst/\Thbs2tm1Bst

(involves: 129T2/SvEms * 129X1/SvJ)
impaired macrophage chemotaxis J:78876
lung inflammation J:78876
\Thbs2em1(IMPC)Mbp/\Thbs2em1(IMPC)Mbp
(C57BL/6NCrl-Thbs2em1(IMPC)Mbp/MbpMmucd)
abnormal spleen morphology J:211773
enlarged spleen J:211773
\Thbs4tm1Dgen/\Thbs4tm1Dgen
(involves: 129P2/OlaHsd * C57BL/6)
immune system phenotype J:301049
increased macrophage cell number J:301049
\Thbs4tm1Olsa/\Thbs4tm1Olsa
(C57BL/6J-Thbs4tm1Olsa)
decreased macrophage cell number J:301049
\ThcrBALB/cJ/?
(involves: BALB/cJ * C57BL/10J * DBA/2J)
decreased interferon-gamma secretion J:86188
increased interleukin-4 secretion J:86188
\ThcrC57BL/10Sn/?
(involves: BALB/cJ * C57BL/10J * DBA/2J)
decreased interleukin-4 secretion J:86188
increased interferon-gamma secretion J:86188
\Themis2tm1d(KOMP)Wtsi/\Themis2tm1d(KOMP)Wtsi
(involves: 129S4/SvJae * C57BL/6 * C57BL/6N * SJL)
immune system phenotype J:232061
\Themis5AT161/\Themis5AT161
(involves: C57BL/6)
decreased CD4-positive, alpha-beta T cell number J:151076
decreased CD8-positive, alpha-beta T cell number J:151076
decreased regulatory T cell number J:151076
decreased single-positive T cell number J:151076
\Themism1Btlr/\Themism1Btlr
(C57BL/6J-Themism1Btlr)
abnormal lymphocyte morphology J:211400
decreased B-1a cell number J:211400
decreased CD4-positive, alpha-beta T cell number J:211400
decreased CD8-positive, alpha-beta T cell number J:211400
immune system phenotype J:211400
impaired humoral immune response J:211400
\Themism2Btlr/\Themism2Btlr
(C57BL/6J-Themism2Btlr)
decreased CD4-positive, alpha-beta T cell number J:236691
decreased T cell number J:236691
increased CD8-positive, alpha-beta T cell number J:236691
increased effector memory CD4-positive, alpha-beta T cell number J:236691
\Themism3Btlr/\Themism3Btlr
(C57BL/6J-Themism3Btlr)
abnormal CD8-positive, alpha-beta cytotoxic T cell morphology J:254834
decreased CD4-positive, CD25-positive, alpha-beta regulatory T cell number J:254834
decreased CD8-positive, alpha-beta memory T cell number J:254834
decreased CD8-positive, naive alpha-beta T cell number J:254834
increased CD4-positive, CD25-positive, alpha-beta regulatory T cell number J:254834
increased CD8-positive, alpha-beta memory T cell number J:254834
increased central memory CD4-positive, alpha-beta T cell number J:254834
increased central memory CD8 positive, alpha-beta T cell number J:254834
increased effector memory CD4-positive, alpha-beta T cell number J:254834
\ThemisM4Btlr/\ThemisM4Btlr
(C57BL/6J-ThemisM4Btlr)
decreased CD4-positive, alpha-beta T cell number J:272849
\Themism5Btlr/\Themism5Btlr
(C57BL/6J-Themism5Btlr)
abnormal CD4-positive T cell differentiation J:274716
abnormal CD8-positive, alpha-beta T cell differentiation J:274716
abnormal T cell differentiation J:274716
decreased alpha-beta T cell number J:274716
decreased CD4-positive, alpha-beta T cell number J:274716
decreased CD8-positive, alpha-beta T cell number J:274716
decreased CD8-positive, naive alpha-beta T cell number J:274716
increased CD8-positive, alpha-beta memory T cell number J:274716
increased central memory CD4-positive, alpha-beta T cell number J:274716
increased central memory CD8 positive, alpha-beta T cell number J:274716
increased effector memory CD4-positive, alpha-beta T cell number J:274716
increased effector memory CD8-positive, alpha-beta T cell number J:274716
increased NK T cell number J:274716
\ThemisSpotr/\Themis+
(C57BL/6-ThemisSpotr)
decreased CD4-positive, alpha-beta T cell number J:152601
decreased CD8-positive, alpha-beta T cell number J:152601
\ThemisSpotr/\ThemisSpotr
(C57BL/6-ThemisSpotr)
abnormal T cell differentiation J:152601
decreased CD4-positive, alpha-beta T cell number J:152601
decreased CD8-positive, alpha-beta T cell number J:152601
small thymus medulla J:152601
\Themistm1.1Hko/\Themis+
(Not Specified)
decreased CD4-positive, alpha-beta T cell number J:152601
decreased CD8-positive, alpha-beta T cell number J:152601
\Themistm1.1Hko/\Themistm1.1Hko
(Not Specified)
decreased CD4-positive, alpha-beta T cell number J:152601
decreased CD8-positive, alpha-beta T cell number J:152601
decreased single-positive T cell number J:152601
\Themistm1Gasc/\Themistm1Gasc
(B6.129S-Themistm1Gasc)
abnormal memory T cell morphology J:151074
abnormal positive T cell selection J:151074
abnormal regulatory T cell morphology J:151074
abnormal thymus medulla morphology J:151074
decreased CD4-positive, alpha-beta T cell number J:151074
decreased CD8-positive, alpha-beta T cell number J:151074
decreased T cell proliferation J:151074
decreased thymocyte number J:151074
increased double-positive T cell number J:151074
\Themistm1Hasu/\Themis+
(involves: C57BL/6 * CBA)
decreased CD4-positive, alpha-beta T cell number J:153235
decreased CD8-positive, alpha-beta T cell number J:153235
\Themistm1Hasu/\Themistm1Hasu
(involves: C57BL/6 * CBA)
abnormal T cell differentiation J:153235
decreased CD4-positive, alpha-beta T cell number J:153235
decreased CD8-positive, alpha-beta T cell number J:153235
decreased splenocyte number J:153235
decreased thymocyte number J:153235
increased memory T cell number J:153235
increased T cell proliferation J:153235
\Themistm1Lov/\Themistm1Lov
(involves: 129)
abnormal negative T cell selection J:151075
abnormal T cell differentiation J:151075
decreased CD4-positive, alpha-beta T cell number J:151075
decreased CD8-positive, alpha-beta T cell number J:151075
decreased regulatory T cell number J:151075
decreased single-positive T cell number J:151075
increased memory T cell number J:151075
\ThimTg(Myh6-TGFB1)1Ljf/\Thim+
(involves: C3HeB/FeJ)
increased T cell derived lymphoma incidence J:59903
\thnh/\thnh
(NOD.Cg-H2b thnh/J)
folliculitis J:142872
\Thnsl2em1(IMPC)Tcp/\Thnsl2em1(IMPC)Tcp
(C57BL/6NCrl-Thnsl2em1(IMPC)Tcp/Tcp)
enlarged lymph nodes J:211773
\Thoc1em1(IMPC)Ccpcz/\Thoc1+
(C57BL/6NCrl-Thoc1em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged thymus J:211773
\Thoc6em5(IMPC)Tcp/\Thoc6+
(C57BL/6NCrl-Thoc6em5(IMPC)Tcp/Tcp)
enlarged lymph nodes J:211773
\Thop1em1(IMPC)Mbp/\Thop1em1(IMPC)Mbp
(C57BL/6NCrl-Thop1em1(IMPC)Mbp/MbpMmucd)
decreased leukocyte cell number J:211773
\Thop1Gt(CSG163)Byg/\Thop1Gt(CSG163)Byg
(B6.129P2-Thop1Gt(CSG163)Byg)
decreased lymphocyte cell number J:290567
decreased susceptibility to infection J:290567
decreased susceptibility to infection induced morbidity/mortality J:290567
increased granulocyte number J:290567
increased monocyte cell number J:290567
increased susceptibility to experimental autoimmune encephalomyelitis J:290567
\Thpotm1Mwm/\Thpotm1Mwm
(involves: 129S2/SvPas * C57BL/6)
immune system phenotype J:83262
\Thratm1Ffla/\Thra+
\Tg(Sycp1-cre)4Min/?

(involves: 129/Sv * C57BL/6 * DBA/2)
decreased spleen weight J:125353
\Thratm1Syc/\Thra+
(involves: 129S6/SvEvTac * C57BL/6J * NIH Black Swiss)
abnormal osteoclast physiology J:217018
decreased osteoclast cell number J:217018
\Thratm2Jas/\Thratm2Jas
(involves: 129)
abnormal osteoclast physiology J:120899
decreased osteoclast cell number J:120899
\Thratm2Ven/\Thratm2Ven
(involves: 129P2/OlaHsd * BALB/c)
abnormal osteoclast physiology J:72959
\Thrbtm1Olc/\Thrbtm1Olc
(involves: 129)
abnormal osteoclast physiology J:120899
increased osteoclast cell number J:120899
\Thtpaem1(IMPC)Tcp/\Thtpaem1(IMPC)Tcp
(C57BL/6NCrl-Thtpaem1(IMPC)Tcp/Tcp)
enlarged lymph nodes J:211773
\Thyct1C57BL/6J/\Thyct1C57BL/6J
\Thyct2C57BL/6J/\Thyct2C57BL/6J

(involves: C57BL/6J * DBA/2J)
thymus hyperplasia J:85261
\Thyct1DBA/2J/\Thyct1DBA/2J
\Thyct2DBA/2J/\Thyct2DBA/2J

(involves: C57BL/6J * DBA/2J)
thymus hypoplasia J:85261
\Thyls2MSM/\Thyls2MSM
(involves: BALB/c * MSM)
increased T cell derived lymphoma incidence J:87704
\Thypr1DBA/2J/?
(involves: C57BL/6J * DBA/2J)
increased T cell proliferation J:76931
\Thypr2DBA/2J/?
(involves: C57BL/6J * DBA/2J)
increased T cell proliferation J:76931
\Tia1tm1Andp/\Tia1tm1Andp
(C.129S2-Tia1tm1Andp)
abnormal macrophage physiology J:88770
immune system phenotype J:88770
increased susceptibility to endotoxin shock J:88770
\Tia1tm1Andp/\Tia1tm1Andp
(B6.Cg-Tia1tm1Andp)
autoimmune arthritis J:88443
\Tia1tm1Andp/\Tia1tm1Andp
\Zfp36tm1Pjb/\Zfp36tm1Pjb

(B6.Cg-Tia1tm1Andp Zfp36tm1Pjb)
abnormal macrophage physiology J:88443
autoimmune arthritis J:88443
increased neutrophil cell number J:88443
\Ticam1Lps2/\Ticam1Lps2
(involves: C57BL/6)
abnormal cytokine secretion J:110201
abnormal macrophage physiology J:84896
decreased circulating tumor necrosis factor level J:86521
decreased macrophage apoptosis J:84896, J:92674
decreased macrophage cytokine production J:84896
decreased macrophage nitric oxide production J:84896
decreased susceptibility to bacterial infection J:86521, J:92674
decreased susceptibility to endotoxin shock J:84896
decreased tumor necrosis factor secretion J:84896
increased susceptibility to Herpesvirales infection J:84896
\Ticam1Lps2/\Ticam1Lps2
(C57BL/6J-Ticam1Lps2)
abnormal circulating tumor necrosis factor level J:138963
abnormal cytokine secretion J:167340
decreased interleukin-6 secretion J:167340
decreased susceptibility to induced colitis J:167340
immune system phenotype J:131353
\Ticam1Lps2/\Ticam1Lps2
(C57BL/6J-Ticam1Lps2/J)
abnormal chemokine level J:288471
decreased CD8-positive, alpha-beta T cell number J:288471
decreased Ly6C low monocyte number J:288471
increased interferon-beta secretion J:288471
increased Ly6C high monocyte number J:288471
increased macrophage cell number J:288471
increased neutrophil cell number J:288471
increased plasmacytoid dendritic cell number J:288471
increased susceptibility to Coronaviridae infection J:288471
increased susceptibility to Coronaviridae infection induced morbidity/mortality J:288471
\Ticam1Lps2/\Ticam1Lps2
\Myd88tm1Aki/\Myd88tm1Aki

(involves: 129P2/OlaHsd * C57BL/6)
abnormal macrophage physiology J:84896
decreased tumor necrosis factor secretion J:84896
\Ticam1M2Btlr/\Ticam1+
(C57BL/6J-Ticam1M2Btlr)
abnormal cytokine secretion J:234240
abnormal macrophage physiology J:234240
decreased macrophage cytokine production J:234240
decreased tumor necrosis factor secretion J:234240
\Ticam1M2Btlr/\Ticam1M2Btlr
(C57BL/6J-Ticam1M2Btlr)
abnormal cytokine secretion J:234240
abnormal macrophage physiology J:234240
decreased macrophage cytokine production J:234240
decreased tumor necrosis factor secretion J:234240
\Ticam1M3Btlr/\Ticam1+
(C57BL/6J-Ticam1M3Btlr)
decreased tumor necrosis factor secretion J:255300
\Ticam1M3Btlr/\Ticam1M3Btlr
(C57BL/6J-Ticam1M3Btlr)
decreased tumor necrosis factor secretion J:255300
\Ticam1tm1Aki/\Ticam1tm1Aki
(involves: 129P2/OlaHsd)
abnormal B cell activation J:174941
abnormal B cell physiology J:84679
abnormal cytokine level J:174941
abnormal cytokine secretion J:84679
abnormal dendritic cell physiology J:174941
abnormal interleukin level J:137522
abnormal macrophage physiology J:174941, J:84679
abnormal microglial cell physiology J:185198
abnormal NK cell physiology J:174941
abnormal NK T cell physiology J:174941
decreased circulating interleukin-6 level J:145306
decreased splenocyte proliferation J:84679
decreased susceptibility to endotoxin shock J:84679
decreased susceptibility to Orthomyxoviridae infection J:145306
impaired macrophage phagocytosis J:185198
\Ticam1tm1Aki/\Ticam1tm1Aki
(involves: 129P2/OlaHsd * C57BL/6)
abnormal cytokine level J:169158
abnormal susceptibility to Poxviridae infection J:162716
decreased CD8-positive, alpha-beta T cell number J:130954
decreased circulating interferon-gamma level J:130954
decreased circulating interleukin-6 level J:130954
decreased circulating interleukin-12b level J:130954
decreased IgG2a level J:130954
decreased IgG level J:130954
decreased interferon-beta secretion J:130954
decreased interleukin-12b secretion J:130954
decreased susceptibility to type I hypersensitivity reaction J:161445
immune system phenotype J:132662
increased susceptibility to Picornaviridae infection J:169158
increased susceptibility to Picornaviridae infection induced morbidity/mortality J:169158
myocarditis J:169158
\Ticam1tm1Aki/\Ticam1tm1Aki
(B6.129P2-Ticam1tm1Aki)
abnormal cytokine level J:144301
abnormal response to infection J:144301
decreased circulating tumor necrosis factor level J:144301
decreased macrophage cytokine production J:144301
impaired neutrophil recruitment J:144301
increased susceptibility to bacterial infection J:144301
\Ticam1tm1Tsse/\Ticam1tm1Tsse
(B6.129-Ticam1tm1Tsse)
impaired natural killer cell mediated cytotoxicity J:118750
\Ticam1tm1Tsse/\Ticam1tm1Tsse
\Tg(PVR)1Kkst/0

(involves: 129 * C57BL/6 * ICR)
abnormal interferon-alpha secretion J:179625
increased susceptibility to Picornaviridae infection J:179625
increased susceptibility to Picornaviridae infection induced morbidity/mortality J:179625
\Ticam2M1Btlr/\Ticam2+
(C57BL/6J-Ticam2M1Btlr)
decreased tumor necrosis factor secretion J:215010
\Ticam2M1Btlr/\Ticam2M1Btlr
(C57BL/6J-Ticam2M1Btlr)
decreased tumor necrosis factor secretion J:215010
\Ticam2M2Btlr/\Ticam2+
(C57BL/6J-Ticam2M2Btlr)
decreased interleukin-1 beta secretion J:254908
\Ticam2M2Btlr/\Ticam2M2Btlr
(C57BL/6J-Ticam2M2Btlr)
decreased interleukin-1 beta secretion J:254908
\Ticam2M3Btlr/\Ticam2+
(C57BL/6J-Ticam2M3Btlr)
decreased tumor necrosis factor secretion J:254912
\Ticam2M3Btlr/\Ticam2M3Btlr
(C57BL/6J-Ticam2M3Btlr)
decreased tumor necrosis factor secretion J:254912
\Ticam2tm1Aki/\Ticam2tm1Aki
(involves: C57BL/6)
abnormal immune system physiology J:86256
decreased interleukin-6 secretion J:86256
increased susceptibility to Coronaviridae infection J:270045
\Ticam2tm1Btlr/\Ticam2tm1Btlr
(C57BL/6J-Ticam2tm1Btlr)
abnormal interferon secretion J:133619
decreased tumor necrosis factor secretion J:133619
\Tie1tm1.1Scba/\Tie1tm1.1Scba
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * FVB/N)
abnormal lymphangiogenesis J:158668
abnormal lymphatic vessel morphology J:158668
lymphatic vessel hyperplasia J:158668
\Tie1tm1Geno/\Tie1tm1Geno
(involves: ICR)
abnormal lymphangiogenesis J:159507
\Tie1tm1Jpa/\Tie1tm1Jpa
(involves: 129S1/Sv * 129X1/SvJ * ICR)
abnormal lymphangiogenesis J:159507
\Tie1tm1Scba/\Tie1tm1Scba
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
abnormal lymph circulation J:158668
abnormal lymphangiogenesis J:158668
abnormal lymphatic vessel morphology J:158668
lymphatic vessel hyperplasia J:158668
\Tifabem1(IMPC)J/\Tifabem1(IMPC)J
(C57BL/6NJ-Tifabem1(IMPC)J/Mmjax)
increased leukocyte cell number J:211773
\Tifabtm1.1Dsta/\Tifab+
(involves: 129 * C57BL/6 * C57BL/6J)
enlarged spleen J:229024
\Tifabtm1.1Dsta/\Tifabtm1.1Dsta
(involves: 129 * C57BL/6 * C57BL/6J)
abnormal neutrophil morphology J:229024
decreased leukocyte cell number J:229024
decreased lymphocyte cell number J:229024
decreased monocyte cell number J:229024
decreased neutrophil cell number J:229024
enlarged spleen J:229024
\TigarGt(EUCE0047g05)Hmgu/\TigarGt(EUCE0047g05)Hmgu
(involves: 129P2/OlaHsd)
increased susceptibility to induced colitis J:198650
\Tigartm1.1Khv/\Tigartm1.1Khv
\Tg(CMV-cre)1Cgn/0

(involves: 129P2/OlaHsd * BALB/cJ * C57BL/6 * SJL)
increased susceptibility to induced colitis J:198650
\Tigittm1Sdl/\Tigittm1Sdl
(involves: C57BL/6)
abnormal professional antigen presenting cell physiology J:168902
decreased interleukin-10 secretion J:168902
immune system phenotype J:209990
increased susceptibility to experimental autoimmune encephalomyelitis J:168902
increased T cell proliferation J:168902
\Tigittm1Sdl/\Tigittm1Sdl
\Tg(Tcra2D2,Tcrb2D2)1Kuch/0

(involves: C57BL/6)
decreased interleukin-10 secretion J:168902
increased susceptibility to experimental autoimmune encephalomyelitis J:168902
\Timd2tm1(GAL4)Pdre/\Timd2tm1(GAL4)Pdre
(C.129S4-Timd2tm1(GAL4)Pdre)
abnormal inflammatory response J:125054
abnormal interleukin secretion J:125054
increased eosinophil cell number J:125054
increased interferon-gamma secretion J:125054
increased lymphocyte cell number J:125054
increased tumor necrosis factor secretion J:125054
\Timd4tm1Kuch/\Timd4tm1Kuch
(C57BL/6-Timd4tm1Kuch)
abnormal B cell physiology J:160747
abnormal macrophage physiology J:160747
increased anti-double stranded DNA antibody level J:160747
increased IgA level J:160747
increased IgG2a level J:160747
increased IgG2b level J:160747
increased interferon-gamma secretion J:160747
increased interleukin-17 secretion J:160747
increased splenocyte proliferation J:160747
\Timd4tm1Kuch/\Timd4tm1Kuch
(involves: C57BL/6)
abnormal circulating chemokine level J:235399
decreased circulating interleukin-10 level J:235399
increased anti-double stranded DNA antibody level J:235399
increased circulating interleukin-1 beta level J:235399
increased circulating interleukin-6 level J:235399
increased circulating interleukin-12b level J:235399
increased susceptibility to systemic lupus erythematosus J:235399
\Timd4tm1Osa/\Timd4tm1Osa
(involves: C57BL/6)
immune system phenotype J:187181
impaired macrophage phagocytosis J:187181
\Timd4tm1Wouy/\Timd4tm1Wouy
(involves: 129)
abnormal macrophage physiology J:160304
decreased tumor necrosis factor secretion J:160304
impaired macrophage phagocytosis J:160304
increased IgG2a level J:160304
increased leukocyte cell number J:160304
increased lymphocyte cell number J:160304
increased tumor necrosis factor secretion J:160304
\Timd6tm1b(KOMP)Wtsi/\Timd6+
(C57BL/6N-Timd6tm1b(KOMP)Wtsi/H)
decreased lymphocyte cell number J:211773
increased neutrophil cell number J:211773
increased spleen weight J:211773
\Timm13em1(IMPC)Tcp/\Timm13+
(C57BL/6NCrl-Timm13em1(IMPC)Tcp/Tcp)
abnormal spleen morphology J:211773
enlarged thymus J:211773
\Timmdc1Gt(OST407011)Lex/\Timmdc1+
(B6;129S5-Timmdc1Gt(OST407011)Lex/Mmucd)
increased CD4-positive, alpha-beta T cell number J:171883
\Timp1tm1Pds/\Timp1tm1Pds
(involves: 129S4/SvJae)
decreased susceptibility to bacterial infection J:94836
\Timp1tm1Pds/\Timp1tm1Pds
(involves: C57BL/6)
decreased susceptibility to bacterial infection J:94836
\Timp1tm1Pds/\Timp1tm1Pds
(involves: 129S4/SvJae * C57BL/6)
increased neutrophil cell number J:112941
lung inflammation J:112941
\Timp2em1(IMPC)Hmgu/\Timp2em1(IMPC)Hmgu
(C57BL/6N-Timp2em1(IMPC)Hmgu/Ieg)
increased follicular B cell number J:211773
\Timp2tm1Pds/\Timp2tm1Pds
(involves: 129S4/SvJae * C57BL/6)
increased neutrophil cell number J:112941
\Timp3tm1Osya/\Timp3tm1Osya
(B6.129P2-Timp3tm1Osya)
aortitis J:193744
\Timp3tm1Rkho/\Timp3tm1Rkho
(B6.129-Timp3tm1Rkho)
increased tumor necrosis factor secretion J:92948
liver inflammation J:92948
\Timp3tm1Rkho/\Timp3tm1Rkho
\Tnftm1Gkl/\Tnftm1Gkl

(involves: 129 * 129S/SvEv * C57BL/6)
increased neutrophil cell number J:112033
\Timp4em1(IMPC)Mbp/\Timp4em1(IMPC)Mbp
(C57BL/6N-Timp4em1(IMPC)Mbp/MbpMmucd)
small spleen J:211773
\Tincrem1(IMPC)Ccpcz/\Tincrem1(IMPC)Ccpcz
(C57BL/6NCrl-Tincrem1(IMPC)Ccpcz/Ccpcz)
abnormal lymph node morphology J:211773
abnormal spleen morphology J:211773
enlarged lymph nodes J:211773
enlarged spleen J:211773
\Tinf2tm2.2Tdl/\Tinf2+
(involves: BALB/cJ * C57BL/6)
dermatitis J:207367
lymphoid hyperplasia J:207367
myeloid hyperplasia J:207367
\TiparpGt(ROSA)79Sor/\TiparpGt(ROSA)79Sor
(involves: 129S4/SvJaeSor)
kidney inflammation J:117491
\TiparpGt(ROSA)79Sor/\TiparpGt(ROSA)79Sor
(involves: 129S4/SvJaeSor * C57BL/6 * C57BL/6J)
abnormal thymus involution J:250417
\Tiparptm1b(EUCOMM)Wtsi/\Tiparptm1b(EUCOMM)Wtsi
(C57BL/6N-Tiparptm1b(EUCOMM)Wtsi/Tcp)
abnormal spleen morphology J:211773
enlarged spleen J:211773
\Tir2BALB/cOlaHsd/\Tir2C57BL/6JOlaHsd
(involves: BALB/cOlaHsd * C57BL/6JOlaHsd)
abnormal immune serum protein physiology J:40771
\Tir2C57BL/6JOlaHsd/\Tir2C57BL/6JOlaHsd
(involves: A/JOlaHsd * C57BL/6JOlaHsd)
decreased susceptibility to parasitic infection J:40771
\Tir2C57BL/6JOlaHsd/\Tir2C57BL/6JOlaHsd
(involves: BALB/cOlaHsd * C57BL/6JOlaHsd)
decreased susceptibility to parasitic infection J:40771
\Tir2C57BL/6JOlaHsd/\Tir2C57BL/6JOlaHsd
(A.B6-Tir2)
decreased susceptibility to parasitic infection J:97672
\Tir2C57BL/6JOlaHsd/\Tir2C57BL/6JOlaHsd
(A.B6-(D5Mit200-D5Mit10))
decreased susceptibility to parasitic infection J:135428
\Tir3BALB/cOlaHsd/\Tir3C57BL/6JOlaHsd
(involves: BALB/cOlaHsd * C57BL/6JOlaHsd)
decreased susceptibility to parasitic infection J:40771
\Tir3C57BL/6JOlaHsd/\Tir3C57BL/6JOlaHsd
(involves: BALB/cOlaHsd * C57BL/6JOlaHsd)
decreased susceptibility to parasitic infection J:40771
\Tir3C57BL/6JOlaHsd/\Tir3C57BL/6JOlaHsd
(A.B6-Tir3)
decreased susceptibility to parasitic infection J:97672
\Tir3C57BL/6JOlaHsd/\Tir3C57BL/6JOlaHsd
(A.B6-(D1Mit60-D1Mit217))
decreased susceptibility to parasitic infection J:135428
\Tir4C57BL/6JOlaHsd/?
(involves: BALB/cOlaHsd * C57BL/6JOlaHsd)
decreased susceptibility to parasitic infection J:40771
\Tir4C57BL/6JOlaHsd/\Tir4C57BL/6JOlaHsd
(involves: A/JOlaHsd * C57BL/6JOlaHsd)
decreased susceptibility to parasitic infection J:40771
\Tir4C57BL/6JOlaHsd/\Tir4C57BL/6JOlaHsd
(involves: BALB/cOlaHsd * C57BL/6JOlaHsd)
decreased susceptibility to parasitic infection J:40771
\Tir4C57BL/6JOlaHsd/\Tir4C57BL/6JOlaHsd
(A.B6-Tir1)
decreased susceptibility to parasitic infection J:97672
\Tir4C57BL/6JOlaHsd/\Tir4C57BL/6JOlaHsd
(A.B6-(D17Mit29-D17Mit11))
decreased susceptibility to parasitic infection J:135428
\Tir9C57BL/6/\Tir9C57BL/6
(involves: C57BL/6 * DBA/2)
increased susceptibility to parasitic infection J:84716
\Tir10C57BL/6/\Tir10C57BL/6
(involves: C57BL/6 * DBA/2)
increased susceptibility to parasitic infection J:84716
\Tirapm1Btlr/\Tirapm1Btlr
(C57BL/6J-Tirapm1Btlr)
abnormal interferon secretion J:133618
decreased tumor necrosis factor secretion J:133618
\Tiraptm1Aki/\Tiraptm1Aki
(involves: 129P2/OlaHsd * C57BL/6)
abnormal cytokine secretion J:111205
abnormal level of surface class II molecules J:111205
decreased IgG3 level J:137066
\Tiraptm1Aki/\Tiraptm1Aki
(B6.129P2-Tiraptm1Aki)
abnormal dendritic cell physiology J:118954
decreased interleukin-6 secretion J:118954
decreased interleukin-12b secretion J:118954
\Tiraptm1Medz/\Tiraptm1Medz
(involves: 129S1/Sv * C57BL/6)
abnormal dendritic cell physiology J:96773
abnormal macrophage physiology J:96773
decreased B cell proliferation J:96773
\Tiraptm1Medz/\Tiraptm1Medz
(involves: 129S1/Sv)
abnormal macrophage physiology J:96018
increased susceptibility to bacterial infection J:96018
\Tk1tm1Vnd/\Tk1tm1Vnd
(involves: 129P2/OlaHsd * C57BL/6)
arteritis J:101669
liver inflammation J:101669
lung inflammation J:101669
lymph node atrophy J:101669
small spleen J:101669
spleen hypoplasia J:101669
thyroid gland inflammation J:101669
\Tkfcem1(IMPC)Ccpcz/\Tkfcem1(IMPC)Ccpcz
(C57BL/6NCrl-Tkfcem1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged spleen J:211773
enlarged thymus J:211773
\Tktl1tm1Arte/\Tktl1tm1Arte
(C57BL/6-Tktl1tm1Arte)
increased susceptibility to induced colitis J:171154
\Tlag2AKR/J/\Tlag2C57L/J
(involves: AKR/J * C57L/J)
increased T cell derived lymphoma incidence J:74369
\Tlag2AKR/J/\Tlag2C57L/J
\Tlag1AKR/J/\Tlag1AKR/J

(involves: AKR/J * C57L/J)
increased T cell derived lymphoma incidence J:74369
\Tle3em1(IMPC)Mbp/\Tle3em1(IMPC)Mbp
(C57BL/6N-Tle3em1(IMPC)Mbp/MbpMmucd)
abnormal spleen morphology J:211773
small spleen J:211773
\Tle4em1(IMPC)Mbp/\Tle4em1(IMPC)Mbp
(C57BL/6NCrl-Tle4em1(IMPC)Mbp/Mmucd)
abnormal lymph node morphology J:211773
enlarged lymph nodes J:211773
\Tle4tm1.2Dasw/\Tle4tm1.2Dasw
(B6.129S6(Cg)-Tle4tm1.2Dasw)
abnormal lymphopoiesis J:219243
abnormal thymus morphology J:219243
decreased B cell number J:219243
decreased DN2 thymocyte number J:219243
decreased double-positive T cell number J:219243
decreased follicular B cell number J:219243
decreased leukocyte cell number J:219243
decreased lymphocyte cell number J:219243
decreased pre-pro B cell number J:219243
decreased spleen B cell follicle number J:219243
immune system phenotype J:219243
increased NK T cell number J:219243
increased thymocyte apoptosis J:219243
spleen hypoplasia J:219243
thymus atrophy J:219243
thymus hypoplasia J:219243
\Tlf2NOD/Smrf/?
(involves: NOD/Smrf * NON/Lt)
increased CD8-positive, alpha-beta T cell number J:49676
\TlfNOD/Smrf/?
(involves: NOD/Smrf * NON/Lt)
increased CD4-positive, alpha-beta T cell number J:49676
\Tll1b2b2476Clo/\Tll1b2b2476Clo
(C57BL/6J-Tll1b2b2476Clo)
thymus hypoplasia J:175213
\Tln1tm4.1Crit/\Tln1tm4.1Crit
\Tg(Mx1-cre)1Cgn/0

(involves: 129/Sv * 129P2/OlaHsd * C57BL/6 * CBA)
immune system phenotype J:134784
\Tlr1tm1Aki/\Tlr1tm1Aki
(involves: 129P2/OlaHsd * C57BL/6)
abnormal cytokine secretion J:103395
decreased interleukin-6 secretion J:103395
decreased tumor necrosis factor secretion J:103395
\Tlr1tm1Flv/\Tlr1tm1Flv
(involves: 129S1/Sv)
abnormal macrophage physiology J:95726
decreased immunoglobulin level J:95726
increased susceptibility to bacterial infection J:95726
\Tlr2lngd/\Tlr2lngd
(C57BL/6J-Tlr2lngd)
abnormal macrophage physiology J:94077
increased susceptibility to bacterial infection J:94077
\Tlr2tm1Aki/\Tlr2tm1Aki
(involves: 129P2/OlaHsd * C57BL/6)
abnormal chemokine level J:88174
abnormal macrophage physiology J:76115, J:95726
abnormal tumor necrosis factor level J:124334
decreased immunoglobulin level J:95726
decreased interleukin-6 secretion J:76115, J:88174
decreased microglial cell activation J:122551
decreased susceptibility to Herpesvirales infection J:88174
decreased susceptibility to Herpesvirales infection induced morbidity/mortality J:88174
decreased tumor necrosis factor secretion J:76115
immune system phenotype J:76115
increased susceptibility to bacterial infection J:95726
\Tlr2tm1Aki/\Tlr2tm1Aki
(B6.129P2-Tlr2tm1Aki)
abnormal dendritic cell physiology J:118954
abnormal interleukin level J:118954
decreased interleukin-6 secretion J:118954
decreased interleukin-12b secretion J:118954
decreased susceptibility to parasitic infection J:116763
increased T cell number J:118954
\Tlr2tm1Aki/\Tlr2tm1Aki
(involves: 129P2/OlaHsd)
abnormal cytokine secretion J:70578
abnormal leukocyte migration J:171379
abnormal macrophage physiology J:103464, J:130138, J:70578
abnormal osteoclast physiology J:130138
decreased circulating interleukin-1 beta level J:119941
decreased circulating tumor necrosis factor level J:119941
decreased inflammatory response J:146111
decreased interleukin-6 secretion J:70578
decreased interleukin-12 secretion J:70578
decreased susceptibility to bacterial infection induced morbidity/mortality J:146111
decreased tumor necrosis factor secretion J:103395, J:70578
increased B cell apoptosis J:135830
\Tlr2tm1Aki/\Tlr2tm1Aki
(NOD.129P2-Tlr2tm1Aki)
insulitis J:124334
\Tlr2tm1Aki/\Tlr2tm1Aki
(C.129P2-Tlr2tm1Aki)
immune system phenotype J:178054
\Tlr2tm1Aki/\Tlr2tm1Aki
\Tlr4tm1Aki/\Tlr4tm1Aki

(B6.129P2-Tlr2tm1Aki Tlr4tm1Aki)
abnormal chemokine secretion J:102879
\Tlr2tm1Aki/\Tlr2tm1Aki
\Tlr4tm1Aki/\Tlr4tm1Aki

(involves: 129P2/OlaHsd * C57BL/6)
abnormal cytokine secretion J:117688
abnormal macrophage physiology J:117688
decreased IgG3 level J:117688
\Tlr2tm1Aki/\Tlr2tm1Aki
\Tlr6tm1Aki/\Tlr6tm1Aki

(involves: 129P2/OlaHsd * C57BL/6)
decreased interleukin-6 secretion J:70578
\Tlr2tm1Kir/\Tlr2tm1Kir
(either: (involves: 129/Sv * C57BL/6) or (involves: 129/Sv * C57BL/6 * C57BL/6J))
abnormal innate immunity J:85323
abnormal macrophage physiology J:85323
decreased interleukin-6 secretion J:85323
decreased interleukin-10 secretion J:85323
decreased macrophage cytokine production J:85323
decreased macrophage nitric oxide production J:85323
increased susceptibility to bacterial infection J:85323
\Tlr2tm1Kir/\Tlr2tm1Kir
(Not Specified)
abnormal macrophage physiology J:96018
increased susceptibility to bacterial infection J:96018
\Tlr2tm1Kir/\Tlr2tm1Kir
(B6.129-Tlr2tm1Kir)
abnormal cellular extravasation J:171028
abnormal cytokine secretion J:121930
decreased circulating tumor necrosis factor level J:162168
decreased interleukin-1 beta secretion J:129871
decreased interleukin-6 secretion J:129871
decreased splenocyte proliferation J:121930
decreased susceptibility to bacterial infection induced morbidity/mortality J:121930
decreased tumor necrosis factor secretion J:129871
increased susceptibility to induced colitis J:165105
\Tlr2tm1Kir/\Tlr2tm1Kir
(involves: 129)
abnormal interleukin secretion J:94463
decreased interleukin-1 secretion J:94463
decreased interleukin-6 secretion J:94463
decreased tumor necrosis factor secretion J:94463
increased susceptibility to bacterial infection induced morbidity/mortality J:147177
\Tlr2tm1Kir/\Tlr2tm1Kir
\Tlr4Lps-d/\Tlr4Lps-d

(C3.Cg-Tlr2tm1Kir Tlr4Lps-d)
abnormal macrophage physiology J:121930
\Tlr3M1Btlr/\Tlr3+
(C57BL/6J-Tlr3M1Btlr)
decreased macrophage cytokine production J:224670
decreased tumor necrosis factor secretion J:224670
\Tlr3M1Btlr/\Tlr3M1Btlr
(C57BL/6J-Tlr3M1Btlr)
decreased macrophage cytokine production J:224670
decreased tumor necrosis factor secretion J:224670
\Tlr3M2Btlr/\Tlr3+
(C57BL/6J-Tlr3M2Btlr)
decreased tumor necrosis factor secretion J:254925
\Tlr3M2Btlr/\Tlr3M2Btlr
(C57BL/6J-Tlr3M2Btlr)
decreased tumor necrosis factor secretion J:254925
\Tlr3tm1Aki/\Tlr3tm1Aki
(involves: 129P2/OlaHsd)
abnormal dendritic cell physiology J:114555
immune system phenotype J:144400
\Tlr3tm1Aki/\Tlr3tm1Aki
\Tlr7tm1Aki/\Tlr7tm1Aki

(involves: 129P2/OlaHsd)
decreased interferon-alpha secretion J:144400
\Tlr3tm1Flv/\Tlr3tm1Flv
(involves: 129S1/Sv * C57BL/6)
abnormal B cell physiology J:72167
abnormal macrophage physiology J:72167
decreased inflammatory response J:72167
immune system phenotype J:72167
\Tlr3tm1Flv/\Tlr3tm1Flv
(involves: C57BL/6)
abnormal macrophage physiology J:86617
immune system phenotype J:86617
\Tlr3tm1Flv/\Tlr3tm1Flv
(Not Specified)
abnormal cytokine secretion J:88906
abnormal NK cell physiology J:88906
abnormal NK T cell physiology J:88906
increased susceptibility to Herpesvirales infection J:88906
\Tlr3tm1Flv/\Tlr3tm1Flv
(involves: 129S1/Sv)
abnormal cytokine level J:119967
abnormal interferon level J:119967
abnormal interleukin level J:119967
abnormal tumor necrosis factor level J:119967
decreased susceptibility to Riboviria infection J:136330
decreased susceptibility to Riboviria infection induced morbidity/mortality J:136330
heart inflammation J:119967
increased susceptibility to Picornaviridae infection induced morbidity/mortality J:119967
\Tlr3tm1Flv/\Tlr3tm1Flv
(B6.129S1-Tlr3tm1Flv/Apb)
abnormal cytokine level J:129533
abnormal interleukin level J:126415
decreased interferon-beta secretion J:251008
\Tlr3tm1Flv/\Tlr3tm1Flv
(B6N.129S1-Tlr3tm1Flv/J)
increased susceptibility to Coronaviridae infection J:288471
\Tlr4Lps-2Btlr/?
(C57BL/6J-Tlr4Lps-2Btlr)
decreased tumor necrosis factor secretion J:147339
\Tlr4Lps-2Btlr/\Tlr4+
(C57BL/6J-Tlr4Lps-2Btlr)
decreased interleukin-1 beta secretion J:147339
\Tlr4lps-2J/\Tlr4lps-2J
(BXD29-Tlr4lps-2J/J)
abnormal inflammatory response J:107391
\Tlr4Lps-3Btlr/\Tlr4+
(C57BL/6J-Tlr4Lps-3Btlr)
decreased interferon-beta secretion J:217295
decreased tumor necrosis factor secretion J:217295
\Tlr4Lps-3Btlr/\Tlr4Lps-3Btlr
(C57BL/6J-Tlr4Lps-3Btlr)
decreased interferon-beta secretion J:217295
decreased tumor necrosis factor secretion J:217295
\Tlr4lps-4Btlr/\Tlr4+
(C57BL/6J-Tlr4lps-4Btlr)
decreased macrophage cytokine production J:224664
decreased tumor necrosis factor secretion J:224664
\Tlr4lps-4Btlr/\Tlr4lps-4Btlr
(C57BL/6J-Tlr4lps-4Btlr)
decreased macrophage apoptosis J:224664
decreased macrophage cytokine production J:224664
decreased tumor necrosis factor secretion J:224664
\Tlr4lps-5Btlr/\Tlr4lps-5Btlr
(C57BL/6J-Tlr4lps-5Btlr)
decreased B cell number J:224666
decreased macrophage cytokine production J:224666
decreased memory B cell number J:224666
decreased tumor necrosis factor secretion J:224666
\Tlr4Lps-6Btlr/\Tlr4+
(C57BL/6J-Tlr4Lps-6Btlr)
decreased macrophage cytokine production J:224667
decreased tumor necrosis factor secretion J:224667
\Tlr4Lps-6Btlr/\Tlr4Lps-6Btlr
(C57BL/6J-Tlr4Lps-6Btlr)
decreased macrophage cytokine production J:224667
decreased tumor necrosis factor secretion J:224667
\Tlr4lps-7Btlr/\Tlr4+
(C57BL/6J-Tlr4Lps-7Btlr)
decreased interleukin-1 beta secretion J:234239
decreased macrophage cytokine production J:234239
decreased tumor necrosis factor secretion J:234239
\Tlr4lps-7Btlr/\Tlr4lps-7Btlr
(C57BL/6J-Tlr4Lps-7Btlr)
decreased interleukin-1 beta secretion J:234239
decreased macrophage cytokine production J:234239
decreased tumor necrosis factor secretion J:234239
\Tlr4Lps-8Btlr/\Tlr4+
(C57BL/6J-Tlr4Lps-8Btlr)
decreased interleukin-1 beta secretion J:234241
decreased macrophage cytokine production J:234241
decreased tumor necrosis factor secretion J:234241
\Tlr4Lps-8Btlr/\Tlr4Lps-8Btlr
(C57BL/6J-Tlr4Lps-8Btlr)
decreased interleukin-1 beta secretion J:234241
decreased macrophage cytokine production J:234241
decreased tumor necrosis factor secretion J:234241
\Tlr4lps-Btlr/\Tlr4lps-Btlr
(C57BL/6J-Tlr4lps-Btlr)
abnormal macrophage physiology J:128416
\Tlr4Lps-d/\Tlr4Lps-d
(involves: C3H/HeJ)
abnormal osteoclast differentiation J:131353
abnormal T-helper 2 physiology J:96356
abnormal tumor necrosis factor level J:124334, J:114368
increased susceptibility to bacterial infection J:5721, J:51522, J:87807
increased susceptibility to induced arthritis J:96356
\Tlr4Lps-d/\Tlr4Lps-d
(C3H/HeJ-Tlr4Lps-d)
abnormal cytokine level J:96680
abnormal interleukin level J:96680
abnormal macrophage chemotaxis J:122597
abnormal microglial cell physiology J:99051
abnormal phagocyte morphology J:125179
abnormal spleen weight J:37271
abnormal susceptibility to infection J:162716
abnormal tumor necrosis factor level J:96680
immune system phenotype J:209808
increased circulating interleukin-6 level J:37271
increased susceptibility to Poxviridae infection induced morbidity/mortality J:162716
liver inflammation J:135830
lung inflammation J:96680
\Tlr4Lps-d/\Tlr4Lps-d
\Tg(IghelMD4)4Ccg/0
\Tg(KLK4mHEL)6Ccg/0

(involves: 129P2/OlaHsd * C3H/HeJ * C57BL/6)
decreased B cell number J:115059
increased B-1 B cell number J:115059
\Tlr4lps-del/\Tlr4lps-del
(C57BL/10ScCr)
abnormal cytokine secretion J:88996
abnormal macrophage physiology J:88996
increased susceptibility to bacterial infection J:51522, J:88996
\Tlr4lps-del/\Tlr4lps-del
(C57BL/10ScN)
increased spleen weight J:37271
\Tlr4lps-del/\Tlr4lps-del
(involves: C57BL/10ScN)
abnormal tumor necrosis factor level J:114368
decreased interleukin-6 secretion J:147023
decreased interleukin-10 secretion J:147023
\Tlr4lps-hypo/\Tlr4lps-hypo
(B6.Cg-Tlr4lps-hypo Cln8mnd)
decreased susceptibility to bacterial infection J:103167
\Tlr4lps-n/\Tlr4lps-n
(C3H/HeN)
decreased acute inflammation J:37271
immune system phenotype J:5557
increased spleen weight J:37271
\Tlr4tm1.1Djh/\Tlr4tm1.1Djh
(involves: FVB/N)
decreased susceptibility to endotoxin shock J:192520
\Tlr4tm1Aki/\Tlr4lps-2J
(involves: 129P2/OlaHsd * C57BL/6 * DBA/2J)
abnormal inflammatory response J:107391
\Tlr4tm1Aki/\Tlr4tm1Aki
(involves: 129P2/OlaHsd)
decreased circulating interleukin-6 level J:145306
decreased susceptibility to Orthomyxoviridae infection J:145306
increased susceptibility to bacterial infection J:53519
\Tlr4tm1Aki/\Tlr4tm1Aki
(involves: 129P2/OlaHsd * C57BL/6J)
abnormal acute inflammation J:98224
enlarged mesenteric lymph nodes J:98224
impaired neutrophil chemotaxis J:98224
increased susceptibility to bacterial infection J:98224
\Tlr4tm1Aki/\Tlr4tm1Aki
(involves: 129P2/OlaHsd * C57BL/6)
abnormal level of surface class II molecules J:76115
abnormal macrophage physiology J:76115
decreased B cell proliferation J:76115
decreased interleukin-6 secretion J:76115
decreased susceptibility to endotoxin shock J:76115
decreased tumor necrosis factor secretion J:76115
increased susceptibility to bacterial infection J:111778
\Tlr4tm1Aki/\Tlr4tm1Aki
(C.129P2-Tlr4tm1Aki)
decreased susceptibility to induced arthritis J:178054
\Tlr4tm1Aki/\Tlr4tm1Aki
\Tlr5tm1Flv/\Tlr5tm1Flv

(involves: 129P2/OlaHsd * 129S1/Sv * C57BL/6)
increased susceptibility to bacterial infection J:111778
\Tlr5tm1.1Gewr/\Tlr5tm1.1Gewr
\Tg(Itgax-cre,-EGFP)4097Ach/?

(involves: C57BL/6J * C57BL/6NTac)
immune system phenotype J:229155
\Tlr5tm1Aki/\Tlr5tm1Aki
(B6.129P2-Tlr5tm1Aki)
decreased interleukin-6 secretion J:112391
decreased interleukin-12b secretion J:112391
decreased susceptibility to bacterial infection J:112391
immune system phenotype J:116763
\Tlr5tm1Aki/\Tlr5tm1Aki
(involves: 129P2/OlaHsd * C57BL/6)
abnormal macrophage physiology J:112671
\Tlr5tm1Aki/\Tlr5tm1Aki
(involves: 129P2/OlaHsd)
enlarged spleen J:229155
increased interleukin-1 beta secretion J:229155
increased susceptibility to colitis induced morbidity/mortality J:229155
\Tlr5tm1Flv/\Tlr5tm1Flv
(involves: 129S1/Sv * C57BL/6)
abnormal cytokine secretion J:111778
abnormal dendritic cell physiology J:111778
abnormal response to transplant J:111778
decreased neutrophil cell number J:111778
increased susceptibility to autoimmune diabetes J:158055
increased susceptibility to bacterial infection J:111778
increased susceptibility to induced colitis J:158055
increased susceptibility to induced pancreatitis J:158055
lung inflammation J:111778
\Tlr5tm1Flv/\Tlr5tm1Flv
(involves: 129S1/Sv)
abnormal leukocyte migration J:171379
\Tlr6int/\Tlr6int
(C57BL/6-Tlr6int)
abnormal adaptive immunity J:110094
abnormal cell-mediated immunity J:110094
abnormal innate immunity J:110094
abnormal macrophage physiology J:110094
\Tlr6m2Btlr/\Tlr6m2Btlr
(C57BL/6J-Tlr6m2Btlr)
abnormal macrophage physiology J:144166
decreased tumor necrosis factor secretion J:144166
\Tlr6m3Btlr/\Tlr6m3Btlr
(C57BL/6J-Tlr6m3Btlr)
abnormal macrophage physiology J:144167
decreased tumor necrosis factor secretion J:144167
\Tlr6m4Btlr/\Tlr6m4Btlr
(C57BL/6J-Tlr6m4Btlr)
abnormal macrophage physiology J:144168
decreased tumor necrosis factor secretion J:144168
\Tlr6tm1Aki/\Tlr6tm1Aki
(involves: 129P2/OlaHsd * C57BL/6)
abnormal cytokine secretion J:70578
abnormal macrophage physiology J:70578
decreased interleukin-6 secretion J:70578
decreased interleukin-12 secretion J:70578
decreased tumor necrosis factor secretion J:70578
\Tlr7em2Anu/Y
(C57BL/6NCrl-Tlr7em2Anu)
abnormal B cell physiology J:324448
abnormal macrophage physiology J:324448
abnormal Peyer's patch morphology J:324448
decreased B cell apoptosis J:324448
decreased B cell proliferation J:324448
enlarged spleen J:324448
increased anti-double stranded DNA antibody level J:324448
increased anti-nuclear antigen antibody level J:324448
increased anti-single stranded DNA antibody level J:324448
increased autoantibody level J:324448
increased CD4-positive, alpha-beta T cell number J:324448
increased circulating interferon-gamma level J:324448
increased circulating interleukin-6 level J:324448
increased circulating interleukin-10 level J:324448
increased circulating tumor necrosis factor level J:324448
increased effector memory CD4-positive, alpha-beta T cell number J:324448
increased susceptibility to systemic lupus erythematosus J:324448
increased T follicular helper cell number J:324448
liver inflammation J:324448
lung inflammation J:324448
lymph node inflammation J:324448
\Tlr7em2Anu/\Tlr7+
(C57BL/6NCrl-Tlr7em2Anu)
abnormal mature B cell morphology J:324448
abnormal plasmacytoid dendritic cell physiology J:324448
decreased marginal zone B cell number J:324448
enlarged spleen J:324448
increased anti-double stranded DNA antibody level J:324448
increased anti-nuclear antigen antibody level J:324448
increased anti-single stranded DNA antibody level J:324448
increased autoantibody level J:324448
increased B cell number J:324448
increased CD4-positive, alpha-beta T cell number J:324448
increased circulating interferon-gamma level J:324448
increased circulating interleukin-6 level J:324448
increased circulating interleukin-10 level J:324448
increased circulating tumor necrosis factor level J:324448
increased germinal center B cell number J:324448
increased plasma cell number J:324448
increased spleen germinal center number J:324448
increased T follicular helper cell number J:324448
spleen hyperplasia J:324448
\Tlr7em2Anu/\Tlr7em2Anu
(C57BL/6NCrl-Tlr7em2Anu)
abnormal mature B cell morphology J:324448
abnormal Peyer's patch morphology J:324448
abnormal plasmacytoid dendritic cell physiology J:324448
decreased leukocyte cell number J:324448
decreased marginal zone B cell number J:324448
enlarged spleen J:324448
glomerulonephritis J:324448
increased anti-nuclear antigen antibody level J:324448
increased anti-single stranded DNA antibody level J:324448
increased B cell number J:324448
increased CD4-positive, alpha-beta T cell number J:324448
increased effector memory CD4-positive, alpha-beta T cell number J:324448
increased germinal center B cell number J:324448
increased inflammatory response J:324448
increased plasma cell number J:324448
increased spleen germinal center number J:324448
increased susceptibility to systemic lupus erythematosus J:324448
increased T follicular helper cell number J:324448
liver inflammation J:324448
lung inflammation J:324448
lymph node inflammation J:324448
pancreas inflammation J:324448
salivary gland inflammation J:324448
spleen hyperplasia J:324448
\Tlr7rsq1/Y
(C57BL/6J-Tlr7rsq1)
abnormal macrophage physiology J:128404
decreased tumor necrosis factor secretion J:128404
\Tlr7rsq1/\Tlr7rsq1
(C57BL/6J-Tlr7rsq1)
abnormal macrophage physiology J:128404
decreased tumor necrosis factor secretion J:128404
\Tlr7rsq2/Y
(C57BL/6J-Tlr7rsq2)
abnormal macrophage physiology J:140020
decreased tumor necrosis factor secretion J:140020
\Tlr7tm1Aki/\Tlr7tm1Aki
(B6.129P2-Tlr7tm1Aki)
abnormal dendritic cell physiology J:118954
decreased interleukin-12b secretion J:118954
\Tlr7tm1Aki/\Tlr7tm1Aki
(involves: 129P2/OlaHsd)
decreased interferon-alpha secretion J:144400
\Tlr7tm1Flv/Y
(B6.129S1-Tlr7tm1Flv)
decreased splenocyte proliferation J:127600
increased marginal zone B cell number J:127600
\Tlr7tm1Flv/\Tlr7tm1Flv
(involves: 129S1/Sv)
decreased circulating interferon-alpha level J:89257
\Tlr7tm1Flv/\Tlr7tm1Flv
(B6.129S1-Tlr7tm1Flv)
decreased anti-insulin autoantibody level J:165267
decreased IgG1 level J:165267
decreased IgG2a level J:165267
decreased IgG level J:165267
decreased IgM level J:165267
\Tlr8/Tlr7tm1Vlcg/\Tlr8/Tlr7tm1Vlcg
(B6.Cg-Tlr8/Tlr7tm1Vlcg)
decreased anti-insulin autoantibody level J:165267
decreased follicular B cell number J:165267
increased marginal zone B cell number J:165267
\Tlr8/Tlr7tm1Vlcg/\Tlr7+
\Tlr8/Tlr7tm1Vlcg/\Tlr8tm1Vlcg

(B6.Cg-Tlr8/Tlr7tm1Vlcg Tlr8tm1Vlcg)
abnormal spleen marginal zone morphology J:165267
decreased anti-insulin autoantibody level J:165267
decreased IgG level J:165267
decreased IgM level J:165267
decreased marginal zone B cell number J:165267
increased IgG level J:165267
increased IgM level J:165267
increased marginal zone B cell number J:165267
\Tlr8/Tlr7tm1Vlcg/\Tlr8/Tlr7tm1Vlcg
(B6.Cg-Tlr8/Tlr7tm1Vlcg Tlr8tm1Vlcg)
decreased anti-insulin autoantibody level J:165267
decreased follicular B cell number J:165267
increased marginal zone B cell number J:165267
\Tlr8tm1Vlcg/\Tlr8tm1Vlcg
(B6.129S1-Tlr8tm1Vlcg)
abnormal spleen marginal zone morphology J:165267
decreased B-1a cell number J:165267
decreased B-1b cell number J:165267
decreased dendritic cell number J:165267
decreased IgG1 level J:165267
decreased marginal zone B cell number J:165267
enlarged spleen J:165267
glomerulonephritis J:165267
increased anti-double stranded DNA antibody level J:165267
increased anti-nuclear antigen antibody level J:165267
increased B-2 B cell number J:165267
increased circulating interleukin-12 level J:165267
increased IgG2a level J:165267
increased IgG level J:165267
increased IgM level J:165267
increased interleukin-6 secretion J:165267
increased spleen weight J:165267
\Tlr9M1Btlr/\Tlr9M1Btlr
(involves: C57BL/6)
abnormal cytokine secretion J:88906
abnormal macrophage physiology J:88906
abnormal NK cell physiology J:88906
abnormal NK T cell physiology J:88906
increased susceptibility to Herpesvirales infection J:88906
increased susceptibility to Herpesvirales infection induced morbidity/mortality J:88906
\Tlr9M2Btlr/\Tlr9+
(C57BL/6J-Tlr9M2Btlr)
abnormal macrophage physiology J:128405
\Tlr9M2Btlr/\Tlr9M2Btlr
(C57BL/6J-Tlr9M2Btlr)
abnormal macrophage physiology J:128405
increased susceptibility to Herpesvirales infection J:128405
\Tlr9m3Btlr/\Tlr9m3Btlr
(C57BL/6J-Tlr9m3Btlr)
abnormal macrophage physiology J:128406
decreased B cell proliferation J:128406
\Tlr9m4Btlr/\Tlr9+
(C57BL/6J-Tlr9m4Btlr)
abnormal macrophage physiology J:132489
abnormal plasmacytoid dendritic cell physiology J:132489
decreased B cell proliferation J:132489
\Tlr9M5Btlr/?
(C57BL/6J-Tlr9M5Btlr)
abnormal macrophage physiology J:147856
decreased tumor necrosis factor secretion J:147856
\Tlr9M5Btlr/\Tlr9+
(C57BL/6J-Tlr9M5Btlr)
decreased interferon-alpha secretion J:147856
decreased interferon-beta secretion J:147856
\Tlr9m6Btlr/\Tlr9m6Btlr
(C57BL/6J-Tlr9m6Btlr)
increased susceptibility to induced colitis J:155728
\Tlr9M7Btlr/\Tlr9+
(C57BL/6J-Tlr9M7Btlr)
decreased tumor necrosis factor secretion J:165701
\Tlr9M7Btlr/\Tlr9M7Btlr
(C57BL/6J-Tlr9M7Btlr)
decreased tumor necrosis factor secretion J:165701
\Tlr9M8Btlr/\Tlr9M8Btlr
(involves: C57BL/6J)
decreased interferon-gamma secretion J:168138
\Tlr9M9Btlr/\Tlr9+
(C57BL/6J-Tlr9M9Btlr)
decreased tumor necrosis factor secretion J:220063
\Tlr9M9Btlr/\Tlr9M9Btlr
(C57BL/6J-Tlr9M9Btlr)
decreased tumor necrosis factor secretion J:220063
\Tlr9tm1Aki/\Tlr9tm1Aki
(involves: 129P2/OlaHsd * C57BL/6)
abnormal B cell physiology J:66049
abnormal dendritic cell physiology J:66049
abnormal macrophage physiology J:117688, J:66049
abnormal T-helper 1 physiology J:66049
decreased inflammatory response J:66049
immune system phenotype J:66049
\Tlr9tm1Aki/\Tlr9tm1Aki
(involves: 129P2/OlaHsd * BALB/c * C57BL/6)
abnormal dendritic cell physiology J:88244
\Tlr9tm1Aki/\Tlr9tm1Aki
(B6.129P2-Tlr9tm1Aki)
abnormal immune system physiology J:121070
abnormal response to infection J:121070
decreased interferon-alpha secretion J:125611
decreased interferon-beta secretion J:125611
decreased interleukin-12b secretion J:125611, J:118954
decreased susceptibility to experimental autoimmune encephalomyelitis J:105435
decreased susceptibility to parasitic infection J:116763
decreased tumor necrosis factor secretion J:121070
impaired natural killer cell mediated cytotoxicity J:125611
\Tlr9tm1Aki/\Tlr9tm1Aki
(involves: 129P2/OlaHsd)
abnormal leukocyte migration J:171379
\Tlr9tm1Aki/\Tlr9tm1Aki
\Tg(IghelMD4)4Ccg/0
\Tg(KLK4mHEL)6Ccg/0

(involves: 129P2/OlaHsd * C57BL/6)
decreased mature B cell number J:115059
increased B-1 B cell number J:115059
\Tlr12tm1Gho/\Tlr12tm1Gho
(Not Specified)
abnormal macrophage physiology J:89754
increased susceptibility to bacterial infection J:89754
\Tlr13m1Btlr/\Tlr13m1Btlr
(C57BL/6J-Tlr13m1Btlr)
immune system phenotype J:156849
\Tlsm1AKR/JMs/\Tlsm1AKR/JMs
(involves: AKR/JMs * SL/Kh)
increased T cell derived lymphoma incidence J:21741, J:41197, J:33016
\Tlsm1AKR/JMs/\Tlsm1SL/Kh
(involves: AKR/JMs * SL/Kh)
increased T cell derived lymphoma incidence J:21741, J:41197, J:33016
\tlss/\tlss
(Not Specified)
enlarged mesenteric lymph nodes J:169366
enlarged spleen J:169366
enlarged thymus J:169366
\Tlx1tm1.1(cre/ERT2)Rygo/\Tlx1tm1.1(cre/ERT2)Rygo
(involves: C57BL/6 * C57BL/6JJcl * C57BL/6NSlc)
absent spleen J:217489
\Tlx1tm1Sjk/\Tlx1tm1Sjk
(involves: 129S2/SvPas)
abnormal spleen development J:17695
abnormal spleen mesenchyme morphology J:17695
absent spleen J:17695
increased leukocyte cell number J:17695
increased lymphocyte cell number J:17695
increased neutrophil cell number J:17695
\Tlx1tm1Thr/\Tlx1tm1Thr
(involves: 129P2/OlaHsd * MF1)
abnormal spleen development J:28700
absent spleen J:28700
increased splenocyte apoptosis J:28700
\Tlx3tm1Sjk/\Tlx3tm1Sjk
(involves: 129X1/SvJ)
immune system phenotype J:60751
\Tm4sf19em1Sjkm/\Tm4sf19em1Sjkm
(C57BL/6J-Tm4sf19em1Sjkm)
abnormal osteoclast differentiation J:343322
abnormal osteoclast physiology J:343322
\Tm4sf19em2Sjkm/\Tm4sf19em2Sjkm
(C57BL/6J-Tm4sf19em2Sjkm)
abnormal osteoclast differentiation J:343322
abnormal osteoclast physiology J:343322
\Tm4sf20em1(IMPC)Bay/\Tm4sf20em1(IMPC)Bay
(C57BL/6N-Tm4sf20em1(IMPC)Bay/BayMmucd)
decreased spleen weight J:211773
\Tm7sf2tm1b(KOMP)Wtsi/\Tm7sf2tm1b(KOMP)Wtsi
(C57BL/6N-Tm7sf2tm1b(KOMP)Wtsi/Orl)
decreased lymphocyte cell number J:211773
increased eosinophil cell number J:211773
\Tm9sf2em1(IMPC)Tcp/\Tm9sf2+
(C57BL/6N-Tm9sf2em1(IMPC)Tcp/Tcp)
enlarged lymph nodes J:211773
\Tmc6tm1.1Les/\Tmc6tm1.1Les
(B6.129S6(Cg)-Tmc6tm1.1Les)
decreased CD4-positive, alpha-beta T cell number J:300461
decreased CD8-positive, alpha-beta T cell number J:300461
\Tmc7em1(IMPC)Mbp/\Tmc7em1(IMPC)Mbp
(C57BL/6NCrl-Tmc7em1(IMPC)Mbp/Mmucd)
abnormal spleen morphology J:211773
enlarged spleen J:211773
\Tmc8tm1.1Les/\Tmc8tm1.1Les
(B6.129S6(Cg)-Tmc8tm1.1Les)
decreased CD4-positive, alpha-beta T cell number J:300461
decreased CD8-positive, alpha-beta T cell number J:300461
\Tmcc2em1(IMPC)Mbp/\Tmcc2+
(C57BL/6N-Tmcc2em1(IMPC)Mbp/MbpMmucd)
abnormal spleen morphology J:211773
enlarged spleen J:211773
\Tmco1em1(IMPC)J/\Tmco1+
(C57BL/6NJ-Tmco1em1(IMPC)J/J)
increased leukocyte cell number J:211773
\Tmem8bem1(IMPC)Tcp/\Tmem8b+
(C57BL/6N-Tmem8bem1(IMPC)Tcp/Tcp)
increased basophil cell number J:211773
\Tmem30atm1.1Xjz/\Tmem30atm1.1Xjz
\Speer6-ps1Tg(Alb-cre)21Mgn/\Speer6-ps1+

(involves: 129S/SvEv * 129S4/SvJaeSor * C57BL/6J * DBA)
liver inflammation J:249038
\Tmem35atm1.1(KOMP)Vlcg/Y
(B6(FVB)-Tmem35atm1.1(KOMP)Vlcg)
spleen hyperplasia J:244268
\Tmem41bem1Cya/\Tmem41b+
(involves: C57BL/6)
decreased susceptibility to Coronaviridae infection J:316472
\Tmem45aem1(IMPC)Mbp/\Tmem45aem1(IMPC)Mbp
(C57BL/6N-Tmem45aem1(IMPC)Mbp/MbpMmucd)
abnormal spleen morphology J:211773
enlarged spleen J:211773
small spleen J:211773
\Tmem60em1(IMPC)Ccpcz/\Tmem60em1(IMPC)Ccpcz
(C57BL/6N-Tmem60em1(IMPC)Ccpcz/Ccpcz)
decreased effector memory T-helper cell number J:211773
\Tmem64Gt(SYA242)Byg/\Tmem64Gt(SYA242)Byg
(involves: 129P2/OlaHsd * C57BL/6)
abnormal osteoclast differentiation J:198051
decreased osteoclast cell number J:198051
\Tmem74em1(IMPC)Tcp/\Tmem74em1(IMPC)Tcp
(C57BL/6NCrl-Tmem74em1(IMPC)Tcp/Tcp)
enlarged lymph nodes J:211773
enlarged spleen J:211773
small thymus J:211773
\Tmem79ma/\Tmem79ma
(involves: C57BL/6JJcl * CBA/CaGr)
dermatitis J:202316
\Tmem79ma/\Tmem79ma
(B6.CBACaGr-Tmem79ma/J)
blepharitis J:202453
dermatitis J:202453
increased IgE level J:202453
skin inflammation J:202453
\Tmem86atm1b(KOMP)Mbp/\Tmem86atm1b(KOMP)Mbp
(C57BL/6N-Tmem86atm1b(KOMP)Mbp/Kmpc)
abnormal lymph node morphology J:211773
\Tmem100tm1e.1(KOMP)Wtsi/\Tmem100+
(C57BL/6N-Tmem100tm1e.1(KOMP)Wtsi/Tcp)
increased leukocyte cell number J:211773
increased lymphocyte cell number J:211773
\Tmem102tm1.1Jyen/\Tmem102tm1.1Jyen
(B6.Cg-Tmem102tm1.1Jyen)
abnormal leukocyte adhesion J:200103
impaired leukocyte migration J:200103
\Tmem106aem1Cheyy/\Tmem106aem1Cheyy
(B6.Cg-Tmem106aem1Cheyy)
abnormal macrophage activation involved in immune response J:345342
immune system phenotype J:345342
increased circulating interferon-beta level J:345342
increased circulating interleukin-6 level J:345342
increased circulating tumor necrosis factor level J:345342
increased interleukin-6 secretion J:345342
increased susceptibility to endotoxin shock J:345342
increased tumor necrosis factor secretion J:345342
\Tmem109tm1Yamt/\Tmem109tm1Yamt
(B6.Cg-Tmem109tm1Yamt)
decreased thymocyte apoptosis J:157864
\Tmem115tm1(KOMP)Vlcg/\Tmem115+
(C57BL/6N-Tmem115tm1(KOMP)Vlcg/MbpMmucd)
decreased neutrophil cell number J:211773
\Tmem116tm1b(EUCOMM)Hmgu/\Tmem116tm1b(EUCOMM)Hmgu
(C57BL/6N-Tmem116tm1b(EUCOMM)Hmgu/Ieg)
enlarged lymph nodes J:211773
enlarged spleen J:211773
\Tmem121bem1(IMPC)Tcp/\Tmem121bem1(IMPC)Tcp
(C57BL/6NCrl-Tmem121bem1(IMPC)Tcp/Tcp)
decreased lymphocyte cell number J:211773
increased neutrophil cell number J:211773
\Tmem126atm1a(EUCOMM)Wtsi/\Tmem126atm1a(EUCOMM)Wtsi
(C57BL/6N-Tmem126atm1a(EUCOMM)Wtsi/Wtsi)
decreased alpha-beta T cell number J:211773
decreased CD4-positive, alpha-beta T cell number J:211773
decreased T-helper cell number J:211773
\Tmem127tm1(KOMP)Wtsi/\Tmem127tm1(KOMP)Wtsi
(C57BL/6N-Tmem127tm1(KOMP)Wtsi/Wtsi)
decreased B cell number J:211773
decreased B-2 B cell number J:211773
decreased CD4-positive, alpha-beta T cell number J:211773
decreased effector memory CD8-positive, alpha-beta T cell number J:211773
decreased KLRG1-positive NK cell number J:211773
decreased KLRG1-positive T-helper cell number J:211773
decreased Ly6C high monocyte number J:211773
decreased memory-marker NK cell number J:211773
decreased monocyte cell number J:211773
decreased neutrophil cell number J:211773
decreased NK cell number J:211773
decreased plasmacytoid dendritic cell number J:211773
increased alpha-beta T cell number J:211773
increased CD4-positive, alpha-beta T cell number J:211773
increased CD8-positive, alpha-beta T cell number J:211773
increased CD8-positive, naive alpha-beta T cell number J:211773
increased KLRG1-positive NK cell number J:211773
increased Ly6C low monocyte number J:211773
increased memory-marker NK cell number J:211773
increased T cell number J:211773
\Tmem138tm1b(EUCOMM)Wtsi/\Tmem138tm1b(EUCOMM)Wtsi
(C57BL/6N-Tmem138tm1b(EUCOMM)Wtsi/BayMmucd)
increased spleen weight J:211773
\Tmem150bem1(IMPC)Ccpcz/\Tmem150bem1(IMPC)Ccpcz
(C57BL/6N-Tmem150bem1(IMPC)Ccpcz/Ccpcz)
decreased eosinophil cell number J:211773
decreased memory-marker CD4-positive NK T cell number J:211773
\Tmem160em1.1Bros/\Tmem160em1.1Bros
(involves: C57BL/6JRj * FVB/N)
abnormal cytokine level J:328221
\Tmem178tm1Lex/\Tmem178tm1Lex
(involves: 129S5/SvEvBrd * C57BL/6)
abnormal osteoclast differentiation J:228311
abnormal osteoclast physiology J:228311
increased osteoclast cell number J:228311
increased susceptibility to induced arthritis J:228311
\Tmem184btm1.1(KOMP)Vlcg/\Tmem184btm1.1(KOMP)Vlcg
(C57BL/6N-Tmem184btm1.1(KOMP)Vlcg/Ucd)
abnormal lymph node morphology J:211773
\Tmem204tm1.1Ali/\Tmem204tm1.1Ali
(involves: BALB/c * C57BL/6)
abnormal lymphatic vessel smooth muscle morphology J:159519
enlarged lymphatic vessel J:159519
\Tmem204tm1Ali/\Tmem204tm1Ali
\Tg(Tie1-cre)9Ref/0

(involves: 129S1/Sv * 129X1/SvJ)
enlarged lymphatic vessel J:159519
\Tmem209em1(IMPC)Tcp/\Tmem209+
(C57BL/6NCrl-Tmem209em1(IMPC)Tcp/Tcp)
enlarged lymph nodes J:211773
enlarged spleen J:211773
\Tmem219tm1(KOMP)Vlcg/\Tmem219tm1(KOMP)Vlcg
(B6J.B6N-Tmem219tm1(KOMP)Vlcg)
immune system phenotype J:236976
increased eosinophil cell number J:236976
increased IgE level J:236976
increased interleukin-4 secretion J:236976
increased interleukin-13 secretion J:236976
\Tmem219tm1(KOMP)Vlcg/\Tmem219tm1(KOMP)Vlcg
\Tg(Scgb1a1-rtTA,tetO-Il13)1Eli/0

(involves: C57BL/6 * C57BL/6J * C57BL/6N * CBA)
lung inflammation J:236976
\Tmem225em1(IMPC)Mbp/\Tmem225em1(IMPC)Mbp
(C57BL/6N-Tmem225em1(IMPC)Mbp/MbpMmucd)
small spleen J:211773
\Tmem234tm1Lex/\Tmem234tm1Lex
(B6;129S5-Tmem234tm1Lex/Mmucd)
increased IgG2a level J:171883
\Tmem237tm1b(EUCOMM)Hmgu/\Tmem237+
(C57BL/6N-Tmem237tm1b(EUCOMM)Hmgu/Ccpcz)
abnormal lymph node morphology J:211773
enlarged lymph nodes J:211773
\Tmem241em1Blsg/\Tmem241em1Blsg
(involves: C57BL/6J)
lung inflammation J:344360
\Tmem248tm1.1(KOMP)Vlcg/\Tmem248tm1.1(KOMP)Vlcg
(C57BL/6N-Tmem248tm1.1(KOMP)Vlcg/Ucd)
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
decreased thymus weight J:211773
increased monocyte cell number J:211773
small spleen J:211773
small thymus J:211773
\Tmem256tm1.1(KOMP)Vlcg/\Tmem256tm1.1(KOMP)Vlcg
(C57BL/6N-Tmem256tm1.1(KOMP)Vlcg/Ucd)
increased monocyte cell number J:211773
\Tmem258tm1.1(KOMP)Vlcg/\Tmem258+
(involves: C57BL/6NTac)
increased susceptibility to colitis induced morbidity/mortality J:240635
increased susceptibility to induced colitis J:240635
\Tmem263em1Gww/\Tmem263em1Gww
(C57BL/6J-Tmem263em1Gww)
decreased spleen weight J:345905
\Tmem268em1Cheyy/\Tmem268em1Cheyy
(involves: C57BL/6)
abnormal leukocyte adhesion J:350812
abnormal leukocyte physiology J:350812
abnormal macrophage physiology J:350812
abnormal monocyte cell number J:350812
abnormal neutrophil cell number J:350812
decreased macrophage cell number J:350812
immune system phenotype J:350812
impaired leukocyte migration J:350812
impaired macrophage phagocytosis J:350812
impaired neutrophil phagocytosis J:350812
increased chemokine level J:350812
increased circulating interferon-beta level J:350812
increased circulating tumor necrosis factor level J:350812
increased susceptibility to bacterial infection J:350812
increased susceptibility to bacterial infection induced morbidity/mortality J:350812
\Tmem278em1(IMPC)Mbp/\Tmem278em1(IMPC)Mbp
(C57BL/6N-Tmem278em1(IMPC)Mbp/MbpMmucd)
abnormal spleen morphology J:211773
\Tmevp2C57BL/10SnSg/\Tmevp2C57BL/10SnSg
(involves: A/WySn * C57BL/10SnSg * SJL/J * Swiss)
decreased susceptibility to Picornaviridae infection J:54593
\Tmevp3C57BL/10SnSg/\Tmevp3C57BL/10SnSg
(involves: A/WySn * C57BL/10SnSg * SJL/J * Swiss)
decreased susceptibility to Picornaviridae infection J:54593
\Tmevp3C57BL/10SnSg/\Tmevp3SJL/J
(involves: A/WySn * C57BL/10SnSg * SJL/J * Swiss)
decreased susceptibility to Picornaviridae infection J:54593
\Tmprss2em1(IMPC)Ccpcz/\Tmprss2em1(IMPC)Ccpcz
(C57BL/6NCrl-Tmprss2em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged thymus J:211773
\Tmprss2tm1(KOMP)Vlcg/\Tmprss2tm1(KOMP)Vlcg
(involves: C57BL/6NTac)
abnormal cytokine secretion J:283077
decreased susceptibility to Coronaviridae infection J:283077
decreased susceptibility to Orthomyxoviridae infection induced morbidity/mortality J:214427
lung inflammation J:214427
\Tmprss2tm1Psn/\Tmprss2tm1Psn
(B6JRj.129S1-Tmprss2tm1Psn)
decreased susceptibility to Orthomyxoviridae infection J:287633
decreased susceptibility to Orthomyxoviridae infection induced morbidity/mortality J:287633
\Tmprss2tm1Psn/\Tmprss2tm1Psn
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)
decreased susceptibility to Orthomyxoviridae infection J:244166
\Tmprss2tm2.1(ETV1)Sho/\Tmprss2tm2.1(ETV1)Sho
(involves: C57BL/6 * DBA/2)
prostate gland inflammation J:212219
\Tmprss6msk/\Tmprss6msk
(C57BL/6J-Tmprss6msk)
decreased spleen iron level J:134446
\Tmprss6tm1b(EUCOMM)Wtsi/\Tmprss6tm1b(EUCOMM)Wtsi
(C57BL/6N-Tmprss6tm1b(EUCOMM)Wtsi/Ics)
decreased CD8-positive, alpha-beta T cell number J:211773
decreased NK cell number J:211773
immune system phenotype J:211773
increased CD11b-high dendritic cell number J:211773
increased effector memory CD8-positive, alpha-beta T cell number J:211773
increased Ly6C-positive mature NK cell number J:211773
\Tmprss6tm1Dgen/\Tmprss6+
(B6.129P2-Tmprss6tm1Dgen/Crl)
decreased spleen iron level J:160248
\Tmprss6tm1Dgen/\Tmprss6tm1Dgen
(B6.129P2-Tmprss6tm1Dgen/Crl)
decreased spleen iron level J:160248
increased spleen weight J:160248
\Tmprss15tm1a(KOMP)Wtsi/\Tmprss15tm1a(KOMP)Wtsi
(C57BL/6N-Tmprss15tm1a(KOMP)Wtsi/Wtsi)
increased leukocyte cell number J:175295
\Tmub1tm1Lex/\Tmub1tm1Lex
(involves: 129S5/SvEvBrd * C57BL/6J)
increased monocyte cell number J:171883
\Tmub2tm1b(KOMP)Wtsi/\Tmub2tm1b(KOMP)Wtsi
(C57BL/6N-Tmub2tm1b(KOMP)Wtsi/Tcp)
decreased lymphocyte cell number J:211773
increased eosinophil cell number J:211773
\Tnbs1SJL/J/?
(involves: C57BL/6J * SJL/J)
increased susceptibility to induced colitis J:82095
\Tnbs2SJL/J/?
(involves: C57BL/6J * SJL/J)
increased interleukin-12b secretion J:82095
increased susceptibility to induced colitis J:82095
\TnfBpsm1/\Tnf+
(involves: C57BL/6)
aortic valve inflammation J:226052
increased circulating tumor necrosis factor level J:226052
mitral valve inflammation J:226052
rheumatoid arthritis J:226052
\TnfBpsm1/\Tnf+
(C.Cg-TnfBpsm1)
aortic valve inflammation J:226052
cardiovalvulitis J:226052
mitral valve inflammation J:226052
\TnfBpsm1/\Tnf+
\Tnfrsf1atm1Mak/\Tnfrsf1atm1Mak

(involves: 129S2/SvPas * C57BL/6)
increased circulating tumor necrosis factor level J:226052
\TnfBpsm1/\TnfBpsm1
(involves: C57BL/6)
accelerated temporomandibular joint osteoarthritis J:226052
aortic valve inflammation J:226052
increased circulating tumor necrosis factor level J:226052
mitral valve inflammation J:226052
rheumatoid arthritis J:226052
\TnfBpsm1/\TnfBpsm1
\Tnfrsf1atm1Mak/\Tnfrsf1atm1Mak

(involves: 129S2/SvPas * C57BL/6)
increased circulating tumor necrosis factor level J:226052
\Tnfem4Boui/\Tnf+
(C57BL/6-Tnfem4Boui)
autoimmune arthritis J:306876
cardiovalvulitis J:306876
colitis J:306876
esophageal inflammation J:306876
ileum inflammation J:306876
\Tnfem5Boui/\Tnf+
\Tnfrsf1atm1Mak/\Tnfrsf1a+

(involves: 129S2/SvPas * C57BL/6)
autoimmune arthritis J:306876
cardiovalvulitis J:306876
colitis J:306876
\TnfM1Btlr/\Tnf+
(C57BL/6J-TnfM1Btlr)
decreased follicular dendritic cell number J:124642
immune system phenotype J:124642
\TnfM1Btlr/\TnfM1Btlr
(C57BL/6J-TnfM1Btlr)
decreased follicular dendritic cell number J:124642
immune system phenotype J:124642
increased susceptibility to bacterial infection J:124642
\TnfM2Btlr/\Tnf+
(C57BL/6J-TnfM2Btlr)
decreased macrophage cytokine production J:213047
decreased tumor necrosis factor secretion J:213047
\TnfR8H/\TnfR8H
(involves: I/St)
increased susceptibility to bacterial infection J:114302
\Tnftm1.1Sned/\Tnftm1.1Sned
\Cd19tm1(cre)Cgn/\Cd19+

(involves: 129 * 129P2/OlaHsd * C57BL/6)
immune system phenotype J:95684
\Tnftm1.1Sned/\Tnftm1.1Sned
\Lyz2tm1(cre)Ifo/\Lyz2+

(involves: 129 * 129P2/OlaHsd * C57BL/6)
abnormal chemokine secretion J:95684
decreased circulating tumor necrosis factor level J:95684
decreased susceptibility to autoimmune disorder J:95684
decreased susceptibility to endotoxin shock J:95684
increased susceptibility to bacterial infection J:95684
\Tnftm1.1Sned/\Tnftm1.1Sned
\Tg(Cd4-cre)1Cwi/0

(involves: 129 * C57BL/6 * DBA/2)
decreased circulating tumor necrosis factor level J:95684
decreased susceptibility to autoimmune disorder J:95684
decreased susceptibility to endotoxin shock J:95684
increased susceptibility to bacterial infection J:95684
\Tnftm1.2Sned/\Tnftm1.2Sned
(involves: 129/Sv * C57BL/6)
absent Peyer's patches J:97783
decreased susceptibility to bacterial infection J:97783
increased leukocyte cell number J:97783
increased susceptibility to parasitic infection J:97783
\Tnftm1Gkl/\Tnftm1Gkl
(involves: 129S/SvEv * C57BL/6)
abnormal inflammatory response J:114740
abnormal lymph node B cell domain morphology J:40970
abnormal lymphocyte physiology J:114740
abnormal macrophage physiology J:114740
abnormal mesenteric lymph node morphology J:114740
abnormal Peyer's patch follicle morphology J:40970
abnormal Peyer's patch morphology J:40970
abnormal spleen follicular dendritic cell network J:42579
abnormal spleen primary B follicle morphology J:47673
absent follicular dendritic cells J:40970
absent spleen germinal center J:47673, J:114740
decreased inflammatory response J:56068
decreased Peyer's patch number J:40970
decreased susceptibility to experimental autoimmune encephalomyelitis J:114740
decreased susceptibility to type IV hypersensitivity reaction J:47673
immune system phenotype J:114740
increased susceptibility to bacterial infection J:47673, J:114740
\Tnftm1Gkl/\Tnftm1Gkl
(involves: 129S/SvEv)
abnormal chemokine secretion J:95684
decreased circulating tumor necrosis factor level J:95684
decreased susceptibility to autoimmune disorder J:95684
decreased susceptibility to endotoxin shock J:95684
increased susceptibility to bacterial infection J:95684
\Tnftm1Gkl/\Tnftm1Gkl
(either: B6.129-Tnftm1Gkl or (involves: 129 * C57BL/6))
decreased Peyer's patch number J:97783
decreased susceptibility to bacterial infection J:97783
increased leukocyte cell number J:97783
increased lymphocyte cell number J:97783
increased neutrophil cell number J:97783
increased susceptibility to parasitic infection J:97783
small Peyer's patches J:97783
\Tnftm1Gkl/\Tnftm1Gkl
(involves: 129S/SvEv * C57BL/6J)
abnormal metallophilic macrophage morphology J:124642
abnormal Peyer's patch follicle morphology J:124642
abnormal Peyer's patch germinal center morphology J:124642
abnormal Peyer's patch morphology J:124642
abnormal Peyer's patch T cell area morphology J:124642
abnormal spleen follicular dendritic cell network J:124642
abnormal spleen marginal sinus morphology J:124642
abnormal spleen primary B follicle morphology J:124642
absent spleen germinal center J:124642
decreased Peyer's patch number J:124642
increased susceptibility to bacterial infection J:124642
\Tnftm1Gkl/\Tnftm1Gkl
\Tnfaip3tm1Ama/\Tnfaip3tm1Ama

(involves: 129S/SvEv * C57BL/6J)
abnormal cytokine secretion J:92694
abnormal inflammatory response J:92694
\Tnftm1Gkl/\Tnftm1Gkl
\Tnfrsf1atm1.1Gkl/\Tnfrsf1atm1.1Gkl

(involves: 129S/SvEv * C57BL/6)
immune system phenotype J:92470
\Tnftm1Gkl/\Tnftm2Gkl
(involves: 129S/SvEv * C57BL/6)
increased circulating tumor necrosis factor level J:54056
increased susceptibility to endotoxin shock J:54056
increased tumor necrosis factor secretion J:54056
rheumatoid arthritis J:54056
\Tnftm1Jods/\Tnftm1Jods
(involves: C57BL/6)
abnormal immune system physiology J:98591
abnormal lymph node primary follicle morphology J:98591
abnormal metallophilic macrophage morphology J:98591
abnormal Peyer's patch follicle morphology J:43602
abnormal Peyer's patch morphology J:43602, J:98591
abnormal spleen marginal sinus morphology J:43602
abnormal spleen primary B follicle morphology J:43602, J:98591
abnormal spleen white pulp morphology J:43602, J:98591
absent spleen germinal center J:98591
decreased follicular dendritic cell number J:43602
decreased Peyer's patch number J:43602
decreased susceptibility to endotoxin shock J:98591
decreased susceptibility to experimental autoimmune encephalomyelitis J:44545, J:98591
increased leukocyte cell number J:43602
increased susceptibility to bacterial infection J:115034, J:98170
small Peyer's patches J:43602
\Tnftm1Jods/\Tnftm1Jods
(C57BL/6-Tnftm1Jods)
abnormal cytokine level J:118417
decreased susceptibility to experimental autoimmune encephalomyelitis J:118417
\Tnftm1Jods/\Tnftm1Jods
(C57BL/6-Ltatm1Jods)
abnormal spleen B cell follicle morphology J:78229
decreased susceptibility to experimental autoimmune encephalomyelitis J:47428
\Tnftm1Ljo/\Tnf+
(involves: 129S1/Sv)
increased susceptibility to bacterial infection J:41992
increased susceptibility to fungal infection J:41992
\Tnftm1Ljo/\Tnftm1Ljo
(involves: 129S1/Sv)
abnormal chemokine secretion J:95684
abnormal cytokine secretion J:41992
abnormal follicular dendritic cell physiology J:41992
abnormal susceptibility to infection J:41992
absent spleen germinal center J:80616, J:41992
decreased circulating tumor necrosis factor level J:95684
decreased IgG level J:41992
decreased spleen B cell follicle number J:95684
decreased spleen white pulp amount J:80616
decreased susceptibility to autoimmune disorder J:95684
decreased susceptibility to endotoxin shock J:95684, J:41992
increased susceptibility to bacterial infection J:80616, J:95684, J:41992
increased susceptibility to fungal infection J:41992
\Tnftm1Ljo/\Tnftm1Ljo
(either: B6.129-Tnftm1Ljo or (involves: 129 * C57BL/6))
abnormal Peyer's patch follicle morphology J:97783
abnormal Peyer's patch germinal center morphology J:97783
abnormal Peyer's patch T cell area morphology J:97783
absent follicular dendritic cells J:97783
decreased Peyer's patch number J:97783
decreased susceptibility to bacterial infection J:97783
increased leukocyte cell number J:97783
increased lymphocyte cell number J:97783
increased neutrophil cell number J:97783
increased susceptibility to parasitic infection J:97783
small Peyer's patches J:97783
\Tnftm1Ljo/\Tnftm1Ljo
(B6.129S1-Tnftm1Ljo)
lung inflammation J:127028
\Tnftm1Ljo/\Tnftm1Ljo
(involves: 129S1/Sv * C57BL/6)
abnormal lymph node cell ratio J:127028
abnormal neutrophil physiology J:127028
decreased immunoglobulin level J:127028
increased interferon-gamma secretion J:127028
increased neutrophil cell number J:127028
increased susceptibility to parasitic infection J:127028
lymph node hypoplasia J:127028
skin inflammation J:127028
\Tnftm1Sek/\Tnftm1Sek
(B6.Cg-Tnftm1Sek)
abnormal cytokine secretion J:44841
abnormal macrophage physiology J:44841
abnormal mesenteric lymph node morphology J:44841
abnormal Peyer's patch germinal center morphology J:44841
absent lymph node germinal center J:44841
absent spleen germinal center J:44841
decreased circulating interferon-gamma level J:44841
decreased circulating interleukin-1 alpha level J:44841
decreased circulating interleukin-1 beta level J:44841
decreased circulating interleukin-6 level J:44841
decreased susceptibility to endotoxin shock J:44841
immune system phenotype J:44841
\Tnftm2.1Gkl/\Tnftm2.1Gkl
\Tg(Fabp1-cre)1Jig/0

(involves: 129S/SvEv * FVB/N)
ileum inflammation J:204557
increased circulating tumor necrosis factor level J:204557
large intestinal inflammation J:204557
small intestinal inflammation J:204557
\Tnftm2.1Gkl/\Tnftm2.1Gkl
\Tg(Lck-cre)I57Jxm/0

(involves: 129S/SvEv * ICR)
small intestinal inflammation J:108572
\Tnftm2Gkl/\Tnf+
(involves: 129S/SvEv * C57BL/6)
abnormal alpha-beta intraepithelial T cell morphology J:136667
abnormal CD4-positive, alpha-beta T cell physiology J:136667
abnormal CD8-positive, alpha beta T cell morphology J:136667
abnormal circulating chemokine level J:204922
abnormal T cell physiology J:136667
abnormal T cell subpopulation ratio J:136667
abnormal T-helper 17 cell physiology J:204922
autoimmune arthritis J:92307, J:136667
decreased inflammatory response J:204922
ileum inflammation J:204922
increased circulating tumor necrosis factor level J:54056, J:204922
increased dendritic cell number J:204922
intestinal inflammation J:136667
rheumatoid arthritis J:54056
small intestinal inflammation J:92307, J:54056, J:204922
\Tnftm2Gkl/\Tnf+
(involves: 129S/SvEv * C57BL/6 * SPRET/Ei)
autoimmune arthritis J:92307
small intestinal inflammation J:92307
\Tnftm2Gkl/\Tnf+
(involves: 129S/SvEv * C57BL/6J)
abnormal cytotoxic T cell physiology J:108572
abnormal myelopoiesis J:108572
abnormal response to transplant J:108572
enlarged spleen J:108572
increased CD8-positive, alpha-beta T cell number J:108572
increased circulating tumor necrosis factor level J:264147
increased tumor necrosis factor secretion J:264147
small intestinal inflammation J:108572
\Tnftm2Gkl/\Tnf+
(involves: 129S/SvEv * C57BL/6 * CBA)
autoimmune arthritis J:131930
\Tnftm2Gkl/\Tnf+
(B6.129S-Tnftm2Gkl/Jarn)
abnormal CD4-positive, alpha-beta T cell physiology J:145626
abnormal CD8-positive, alpha beta T cell morphology J:131978
ileum inflammation J:131978, J:145626
increased CD4-positive, alpha-beta memory T cell number J:145626
increased CD4-positive, alpha-beta T cell number J:145626
increased interferon-gamma secretion J:131978
increased interleukin-2 secretion J:145626
increased tumor necrosis factor secretion J:145626
\Tnftm2Gkl/\Tnf+
\Tnfrsf1atm2Gkl/\Tnfrsf1atm2Gkl
\Tg(Col6a1-cre)1Gkl/?

(involves: 129S/SvEv * C57BL/6 * CBA)
autoimmune arthritis J:131930
small intestinal inflammation J:131930
\Tnftm2Gkl/\Tnf+
\Tnfrsf1btm1.1Gkl/\Tnfrsf1btm1.1Gkl
\Tg(Col6a1-cre)1Gkl/0

(involves: 129S/SvEv * C57BL/6 * C57BL/6J * CBA)
increased circulating tumor necrosis factor level J:264147
increased tumor necrosis factor secretion J:264147
joint inflammation J:264147
\Tnftm2Gkl/\Tnf+
\Tnfrsf1btm1.2Gkl/\Tnfrsf1btm1.2Gkl

(involves: 129S/SvEv * C57BL/6 * C57BL/6J)
aortic valve inflammation J:264147
autoimmune arthritis J:264147
increased circulating tumor necrosis factor level J:264147
increased tumor necrosis factor secretion J:264147
\Tnftm2Gkl/\Tnf+
\Tnfrsf1btm1Mwm/\Tnfrsf1btm1Mwm

(involves: 129S/SvEv * 129S2/SvPas * C57BL/6)
rheumatoid arthritis J:54056
small intestinal inflammation J:54056
\Tnftm2Gkl/\Tnftm2Gkl
(involves: 129S/SvEv * C57BL/6)
cardiovalvulitis J:226052
increased circulating tumor necrosis factor level J:54056
rheumatoid arthritis J:54056
small intestinal inflammation J:54056
thymus hypoplasia J:54056
\Tnftm2Gkl/\Tnftm2Gkl
\Tnfrsf1atm1Blt/\Tnfrsf1atm1Blt

(involves: 129P2/OlaHsd * 129S/SvEv * C57BL/6)
increased circulating tumor necrosis factor level J:54056
increased tumor necrosis factor secretion J:54056
\Tnftm2Jods/\Tnftm2Jods
(involves: C57BL/6)
abnormal lymph node cell ratio J:127028
decreased immunoglobulin level J:127028
immune system phenotype J:127028
increased susceptibility to bacterial infection J:98170
\Tnftm2Jods/\Tnftm2Jods
(C57BL/6-Tnftm2Jods)
abnormal immune system physiology J:98591
abnormal lymph node primary follicle morphology J:98591
abnormal metallophilic macrophage morphology J:98591
abnormal Peyer's patch follicle morphology J:98591
abnormal spleen follicular dendritic cell network J:98591
abnormal spleen primary B follicle morphology J:98591
abnormal spleen white pulp morphology J:98591
decreased spleen germinal center number J:98591
decreased spleen germinal center size J:98591
decreased susceptibility to endotoxin shock J:98591
decreased susceptibility to experimental autoimmune encephalomyelitis J:98591
\Tnftm3Gkl/\Tnftm3Gkl
(involves: 129S/SvEv * C57BL/6)
abnormal lymph node B cell domain morphology J:114740
abnormal lymphocyte physiology J:114740
abnormal mesenteric lymph node morphology J:114740
abnormal spleen primary B follicle morphology J:114740
absent follicular dendritic cells J:114740
absent spleen germinal center J:114740
autoimmune response J:114740
decreased circulating tumor necrosis factor level J:114740
decreased IgG1 level J:114740
decreased susceptibility to bacterial infection J:114740
decreased susceptibility to endotoxin shock J:114740
decreased susceptibility to experimental autoimmune encephalomyelitis J:114740
decreased tumor necrosis factor secretion J:114740
\Tnftm3Gkl/\Tnftm3Gkl
\Zfp36tm1Pjb/\Zfp36tm1Pjb

(involves: 129S/SvEv * C57BL/6)
immune system phenotype J:114740
myeloid hyperplasia J:114740
\Tnfaip3m1Apb/\Tnfaip3m1Apb
(C57BL/6-Tnfaip3m1Apb)
CNS inflammation J:324062
enlarged lymph nodes J:324062
increased effector memory T-helper cell number J:324062
increased macrophage cell number J:324062
increased microglial cell activation J:324062
uterus inflammation J:324062
\Tnfaip3tm1.1Gho/\Tnfaip3tm1.1Gho
(involves: C57BL/6J)
enlarged spleen J:217021
immune system phenotype J:217021
\Tnfaip3tm1.1Gvl/\Tnfaip3tm1.1Gvl
\Tg(Vil1-cre)997Gum/0

(B6.Cg-Tnfaip3tm1.1Gvl Tg(Vil1-cre)997Gum)
increased circulating interleukin-6 level J:163410
increased susceptibility to induced colitis J:163410
\Tnfaip3tm1.1Gvl/\Tnfaip3tm1.1Gvl
\Tnfrsf1atm1Mak/\Tnfrsf1atm1Mak
\Tg(Vil1-cre)997Gum/0

(involves: 129S2/SvPas * C57BL/6 * SJL)
decreased susceptibility to induced colitis J:163410
increased susceptibility to induced colitis J:163410
\Tnfaip3tm1Ama/\Tnfaip3tm1Ama
(involves: C57BL/6J)
abnormal cytokine secretion J:92694
abnormal inflammatory response J:92694
\Tnfaip3tm1Ama/\Tnfaip3tm1Ama
(Not Specified)
increased granulocyte number J:92931
increased inflammatory response J:92931
increased lymphocyte cell number J:92931
increased macrophage cell number J:92931
intestinal inflammation J:92931
joint inflammation J:92931
kidney inflammation J:92931
liver inflammation J:92931
\Tnfaip3tm1Ama/\Tnfaip3tm1Ama
\Tnfrsf1atm1Imx/\Tnfrsf1a+

(involves: C57BL/6J)
abnormal inflammatory response J:92694
\Tnfaip3tm1Ama/\Tnfaip3tm1Ama
\Tnfrsf1atm1Imx/\Tnfrsf1atm1Imx

(involves: C57BL/6J)
abnormal inflammatory response J:92694
\Tnfaip3tm1Homy/\Tnfaip3tm1Homy
\Tg(Mx1-cre)1Cgn/?

(involves: 129S6/SvEvTac * C57BL/6J * CBA/J)
abnormal B cell number J:212681
abnormal circulating cytokine level J:212681
abnormal circulating interleukin level J:212681
abnormal myelopoiesis J:212681
abnormal spleen morphology J:212681
enlarged lymph nodes J:212681
increased circulating interferon-gamma level J:212681
increased circulating interleukin-1 beta level J:212681
increased circulating interleukin-6 level J:212681
increased circulating tumor necrosis factor level J:212681
liver inflammation J:212681
lung inflammation J:212681
\Tnfaip3tm2Ama/\Tnfaip3tm2Ama
\Cd19tm1(cre)Cgn/\Cd19+

(involves: 129P2/OlaHsd * C57BL/6)
abnormal B cell activation J:163917
abnormal B cell morphology J:163917
abnormal B-1a B cell morphology J:163917
decreased B cell apoptosis J:163917
decreased B cell number J:163917
increased autoantibody level J:163917
increased B cell number J:163917
increased B cell proliferation J:163917
increased germinal center B cell number J:163917
increased IgG level J:163917
increased IgM level J:163917
increased immature B cell number J:163917
increased immunoglobulin level J:163917
increased interleukin-6 secretion J:163917
increased plasma cell number J:163917
increased susceptibility to autoimmune disorder J:163917
increased T cell number J:163917
\Tnfaip3tm3.1Ama/\Tnfaip3tm3.1Ama
(C57BL/6J-Tnfaip3tm3.1Ama)
abnormal chemokine secretion J:203160
decreased interleukin-6 secretion J:203160
enlarged spleen J:203160
increased B cell number J:203160
increased CD4-positive, alpha-beta T cell number J:203160
increased CD8-positive, alpha-beta T cell number J:203160
increased susceptibility to induced colitis J:203160
myeloid hyperplasia J:203160
\Tnfaip3tm4.1Ama/\Tnfaip3tm4.1Ama
(C57BL/6J-Tnfaip3tm4.1Ama)
abnormal chemokine secretion J:203160
decreased interleukin-6 secretion J:203160
enlarged spleen J:203160
increased B cell number J:203160
increased CD4-positive, alpha-beta T cell number J:203160
increased CD8-positive, alpha-beta T cell number J:203160
increased susceptibility to induced colitis J:203160
myeloid hyperplasia J:203160
\Tnfaip6tm1Cful/\Tnfaip6tm1Cful
(involves: 129S6/SvEvTac * BALB/c)
decreased inflammatory response J:193758
\Tnfaip8Gt(IST13629C1)Tigm/\Tnfaip8Gt(IST13629C1)Tigm
(involves: C57BL/6N)
immune system phenotype J:223320
increased circulating interleukin-6 level J:223320
increased circulating interleukin-17 level J:223320
increased interleukin-1 beta secretion J:223320
increased interleukin-6 secretion J:223320
increased interleukin-17 secretion J:223320
increased neutrophil cell number J:223320
increased susceptibility to induced colitis J:223320
small spleen J:223320
\Tnfaip8Gt(IST13629C1)Tigm/\Tnfaip8Gt(IST13629C1)Tigm
\Tnfaip8l1em1Huwa/\Tnfaip8l1em1Huwa

(involves: C57BL/6 * C57BL/6N)
colitis J:342074
decreased spleen weight J:342074
increased leukocyte cell number J:342074
increased T-helper 17 cell number J:342074
\Tnfaip8l1em1(IMPC)Mbp/\Tnfaip8l1em1(IMPC)Mbp
(C57BL/6N-Tnfaip8l1em1(IMPC)Mbp/MbpMmucd)
abnormal spleen morphology J:211773
enlarged spleen J:211773
small spleen J:211773
\Tnfaip8l1em1Huwa/\Tnfaip8l1em1Huwa
(C57BL/6-Tnfaip8l1em1Huwa)
increased susceptibility to colitis induced morbidity/mortality J:342074
increased susceptibility to induced colitis J:342074
\Tnfaip8l2tm1Yhcn/\Tnfaip8l2tm1Yhcn
(129S6/SvEvTac-Tnfaip8l2tm1Yhcn)
abnormal B cell activation J:139785
abnormal B cell physiology J:139785
abnormal CD4-positive, alpha-beta T cell physiology J:139785
abnormal cytotoxic T cell physiology J:139785
abnormal inflammatory response J:139785
abnormal leukocyte morphology J:139785
abnormal macrophage activation involved in immune response J:139785
abnormal myeloid dendritic cell morphology J:139785
abnormal spleen morphology J:139785
abnormal T cell apoptosis J:139785
chronic inflammation J:139785
decreased IgG2a level J:139785
decreased IgG2b level J:139785
enlarged spleen J:139785
increased B cell number J:139785
increased circulating interleukin-1 beta level J:139785
increased circulating interleukin-6 level J:139785
increased circulating interleukin-10 level J:139785
increased circulating interleukin-12 level J:139785
increased circulating tumor necrosis factor level J:139785
increased interferon-gamma secretion J:139785
increased interleukin-1 beta secretion J:139785
increased interleukin-2 secretion J:139785
increased interleukin-4 secretion J:139785
increased interleukin-6 secretion J:139785
increased interleukin-12 secretion J:139785
increased interleukin-17 secretion J:139785
increased spleen white pulp amount J:139785
increased susceptibility to endotoxin shock J:139785
increased T cell number J:139785
increased tumor necrosis factor secretion J:139785
intestinal inflammation J:139785
liver inflammation J:139785
lung inflammation J:139785
lymph node inflammation J:139785
spleen hyperplasia J:139785
\Tnfrsf1aem1(IMPC)Ccpcz/\Tnfrsf1aem1(IMPC)Ccpcz
(C57BL/6NCrl-Tnfrsf1aem1(IMPC)Ccpcz/Ccpcz)
increased effector memory CD8-positive, alpha-beta T cell number J:211773
increased neutrophil cell number J:211773
increased NK cell number J:211773
\Tnfrsf1atm1.1Gkl/\Tnfrsf1a+
(involves: 129/Sv * C57BL/6)
liver inflammation J:92470
\Tnfrsf1atm1.1Gkl/\Tnfrsf1atm1.1Gkl
(involves: 129/Sv * C57BL/6)
abnormal cytokine secretion J:92470
decreased susceptibility to bacterial infection J:92470
increased susceptibility to experimental autoimmune encephalomyelitis J:92470
liver inflammation J:92470
\Tnfrsf1atm1.1Gkl/\Tnfrsf1atm1.1Gkl
\Tnfrsf1btm1Mwm/\Tnfrsf1btm1Mwm

(involves: 129/Sv * C57BL/6)
liver inflammation J:92470
\Tnfrsf1atm1Blt/\Tnfrsf1a+
(involves: 129P2/OlaHsd)
decreased circulating interleukin-6 level J:210950
\Tnfrsf1atm1Blt/\Tnfrsf1atm1Blt
(involves: 129P2/OlaHsd * C57BL/6)
abnormal immune system physiology J:14424
abnormal lymph node B cell domain morphology J:40970
abnormal Peyer's patch follicle morphology J:40970
abnormal Peyer's patch morphology J:40970
absent follicular dendritic cells J:40970
decreased IgG1 level J:115225
decreased interleukin-6 secretion J:14424
decreased Peyer's patch number J:40970
decreased susceptibility to experimental autoimmune encephalomyelitis J:115225
increased susceptibility to bacterial infection J:14424
increased susceptibility to parasitic infection J:114203
increased susceptibility to type I hypersensitivity reaction J:92307
\Tnfrsf1atm1Blt/\Tnfrsf1atm1Blt
(involves: 129/Sv * 129P2/OlaHsd * C57BL/6)
decreased susceptibility to bacterial infection J:50903
\Tnfrsf1atm1Blt/\Tnfrsf1atm1Blt
(involves: 129P2/OlaHsd)
impaired humoral immune response J:210950
increased susceptibility to bacterial infection induced morbidity/mortality J:210950
\Tnfrsf1atm1Blt/\Tnfrsf1atm1Blt
\Tnfrsf1btm1Mwm/\Tnfrsf1btm1Mwm

(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6)
abnormal lymph node cortex morphology J:119206
abnormal lymph node primary follicle morphology J:119206
abnormal lymph node secondary follicle morphology J:119206
absent lymph node germinal center J:119206
absent spleen germinal center J:119206
decreased IgG1 level J:115225
decreased susceptibility to experimental autoimmune encephalomyelitis J:115225
immune system phenotype J:119206
increased susceptibility to parasitic infection J:114203
small Peyer's patches J:119206
\Tnfrsf1atm1Blt/\Tnfrsf1atm2Gkl
\Tg(Cr2-cre)3Cgn/0

(involves: 129P2/OlaHsd * 129S/SvEv)
immune system phenotype J:113314
\Tnfrsf1atm1Imx/\Tnfrsf1a+
(involves: C57BL/6)
decreased circulating interleukin-6 level J:210950
\Tnfrsf1atm1Imx/\Tnfrsf1atm1Imx
(involves: 129S7/SvEvBrd * C57BL/6)
abnormal immune system physiology J:45147
\Tnfrsf1atm1Imx/\Tnfrsf1atm1Imx
(C57BL/6-Tnfrsf1atm1Imx)
decreased inflammatory response J:45147
decreased microglial cell number J:112713
decreased susceptibility to endotoxin shock J:45147
increased circulating tumor necrosis factor level J:45147
increased susceptibility to bacterial infection J:45147
lung inflammation J:120174
\Tnfrsf1atm1Imx/\Tnfrsf1atm1Imx
(C57BL/6-Tnfrsf1atm1Imx/J)
abnormal chemokine secretion J:160543
abnormal follicular dendritic cell morphology J:160543
abnormal macrophage physiology J:160543
decreased circulating interleukin-6 level J:160543
decreased interleukin-6 secretion J:160543
decreased susceptibility to endotoxin shock J:160543
increased circulating tumor necrosis factor level J:160543
\Tnfrsf1atm1Imx/\Tnfrsf1atm1Imx
(involves: C57BL/6)
impaired humoral immune response J:210950
increased susceptibility to bacterial infection induced morbidity/mortality J:210950
\Tnfrsf1atm1Imx/\Tnfrsf1atm1Imx
\Tg(Ins2-Cxcl13)1Cys/0

(involves: C57BL/6 * DBA/2)
abnormal lymph organ development J:110548
\Tnfrsf1atm1Imx/\Tnfrsf1atm1Imx
\Tg(Thy1-APP)3Somm/0

(involves: C57BL/6 * C57BL/6J * DBA/2)
microgliosis J:134832
\Tnfrsf1atm1Imx/\Tnfrsf1atm1Imx
\Tnfrsf1btm1Imx/\Tnfrsf1btm1Imx

(involves: 129S7/SvEvBrd * C57BL/6)
decreased inflammatory response J:45147
decreased microglial cell activation J:33864
decreased susceptibility to endotoxin shock J:45147
decreased susceptibility to experimental autoimmune uveoretinitis J:115094
decreased susceptibility to induced arthritis J:120707
increased circulating tumor necrosis factor level J:45147
increased susceptibility to bacterial infection J:58851
osteomyelitis J:58851
\Tnfrsf1atm1Imx/\Tnfrsf1atm1Imx
\Tnfrsf1btm1Imx/\Tnfrsf1btm1Imx

(B6.129S-Tnfrsf1btm1Imx Tnfrsf1atm1Imx/J)
decreased susceptibility to Coronaviridae infection J:288523
\Tnfrsf1atm1Mak/\Tnfrsf1a+
(involves: 129S2/SvPas)
decreased circulating interleukin-6 level J:210950
\Tnfrsf1atm1Mak/\Tnfrsf1atm1Mak
(involves: 129S2/SvPas * C57BL/6J * DBA/2J)
granulomatous inflammation J:55889
\Tnfrsf1atm1Mak/\Tnfrsf1atm1Mak
(involves: 129S2/SvPas * C57BL/6J * NOD)
decreased susceptibility to autoimmune diabetes J:64051
\Tnfrsf1atm1Mak/\Tnfrsf1atm1Mak
(involves: 129S2/SvPas)
abnormal spleen germinal center morphology J:139030
decreased circulating interleukin-6 level J:138824
decreased IgG level J:139030
decreased susceptibility to bacterial infection J:4753, J:121930
impaired humoral immune response J:210950
increased circulating tumor necrosis factor level J:139030
increased susceptibility to bacterial infection induced morbidity/mortality J:4753, J:139030, J:210950
\Tnfrsf1atm1Mak/\Tnfrsf1atm1Mak
\Tnip1Gt(E059E05)Wrst/\Tnip1Gt(E059E05)Wrst

(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6)
glomerulonephritis J:180054
increased neutrophil cell number J:180054
increased susceptibility to systemic lupus erythematosus J:180054
spleen hyperplasia J:180054
\Tnfrsf1atm1Rsie/\Tnfrsf1a+
(B6.Cg-Tnfrsf1atm1Rsie)
increased circulating tumor necrosis factor level J:160543
increased interleukin-6 secretion J:160543
increased susceptibility to endotoxin shock J:160543
\Tnfrsf1atm1Rsie/\Tnfrsf1atm1Rsie
(B6.Cg-Tnfrsf1atm1Rsie)
abnormal chemokine secretion J:160543
abnormal follicular dendritic cell morphology J:160543
abnormal macrophage physiology J:160543
decreased circulating interleukin-1 beta level J:160543
decreased circulating interleukin-6 level J:160543
decreased interleukin-6 secretion J:160543
decreased susceptibility to endotoxin shock J:160543
increased circulating tumor necrosis factor level J:160543
\Tnfrsf1atm2.1Rsie/\Tnfrsf1a+
(B6.Cg-Tnfrsf1atm2.1Rsie)
abnormal macrophage physiology J:160543
decreased circulating interleukin-1 beta level J:160543
decreased circulating interleukin-6 level J:160543
decreased interleukin-6 secretion J:160543
increased interleukin-6 secretion J:160543
increased susceptibility to endotoxin shock J:160543
\Tnfrsf1atm2.1Rsie/\Tnfrsf1a+
(involves: 129S6/SvEvTac)
increased susceptibility to endotoxin shock J:160543
\Tnfrsf1atm2.1Rsie/\Tnfrsf1atm2.1Rsie
(B6.Cg-Tnfrsf1atm2.1Rsie)
abnormal chemokine secretion J:160543
abnormal macrophage physiology J:160543
decreased circulating interleukin-6 level J:160543
decreased interleukin-6 secretion J:160543
decreased susceptibility to endotoxin shock J:160543
increased circulating tumor necrosis factor level J:160543
\Tnfrsf1atm2b(EUCOMM)Wtsi/\Tnfrsf1atm2b(EUCOMM)Wtsi
(C57BL/6N-Tnfrsf1atm2b(EUCOMM)Wtsi/H)
decreased monocyte cell number J:211773
decreased neutrophil cell number J:211773
increased basophil cell number J:211773
increased eosinophil cell number J:211773
increased large unstained cell number J:211773
increased leukocyte cell number J:211773
increased lymphocyte cell number J:211773
\Tnfrsf1btm1a(EUCOMM)Wtsi/\Tnfrsf1btm1a(EUCOMM)Wtsi
(C57BL/6N-Tnfrsf1btm1a(EUCOMM)Wtsi/Ics)
decreased T cell number J:165965
\Tnfrsf1btm1Imx/\Tnfrsf1btm1Imx
(involves: 129S7/SvEvBrd * C57BL/6)
increased circulating tumor necrosis factor level J:45147
increased inflammatory response J:45147
lung inflammation J:120174
microgliosis J:112713
\Tnfrsf1btm1Mwm/\Tnfrsf1btm1Mwm
(B6.129S2-Tnfrsf1btm1Mwm/J)
decreased interferon-gamma secretion J:107039
decreased interleukin-2 secretion J:107039
decreased T cell proliferation J:107039
immune system phenotype J:288523
\Tnfrsf1btm1Mwm/\Tnfrsf1btm1Mwm
(involves: 129S2/SvPas * C57BL/6J)
abnormal immune system physiology J:21815
increased susceptibility to bacterial infection J:21815
\Tnfrsf1btm1Mwm/\Tnfrsf1btm1Mwm
(involves: 129S2/SvPas * C57BL/6J * NOD)
decreased susceptibility to autoimmune diabetes J:64051
periinsulitis J:64051
\Tnfrsf1btm1Mwm/\Tnfrsf1btm1Mwm
(involves: 129S2/SvPas * C57BL/6)
decreased susceptibility to bacterial infection J:50903
increased susceptibility to experimental autoimmune encephalomyelitis J:115225
increased susceptibility to parasitic infection J:114203
\Tnfrsf4tm1Mfb/\Tnfrsf4tm1Mfb
(involves: 129P2/OlaHsd * C57BL/6)
abnormal CD4-positive, alpha-beta T cell physiology J:59204
\Tnfrsf4tm1Nik/\Tnfrsf4tm1Nik
(involves: 129S4/SvJae * C57BL/6)
abnormal CD4-positive, alpha-beta T cell physiology J:64552
abnormal T-helper 2 physiology J:68588
decreased susceptibility to type I hypersensitivity reaction J:68588
decreased T cell proliferation J:58979, J:64552
immune system phenotype J:58979
\Tnfrsf8tm1Mak/\Tnfrsf8tm1Mak
(involves: 129P2/OlaHsd * C57BL/6)
enlarged thymus J:62854
immune system phenotype J:62854
increased thymocyte number J:62854
\Tnfrsf8tm1Mak/\Tnfrsf8tm1Mak
(involves: C57BL/6)
decreased susceptibility to graft versus host disease J:92723
\Tnfrsf9em1Ygch/\Tnfrsf9em1Ygch
(NOD/ShiLtDvs-Tnfrsf9em1Ygch)
abnormal T cell physiology J:208927
immune system phenotype J:208927
insulitis J:208927
\Tnfrsf9em2Ygch/\Tnfrsf9em2Ygch
(NOD/ShiLtDvs-Tnfrsf9em2Ygch)
abnormal T cell physiology J:208927
immune system phenotype J:208927
insulitis J:208927
\Tnfrsf9m1Btlr/\Tnfrsf9m1Btlr
(C57BL/6J-Tnfrsf9m1Btlr)
decreased CD8-positive, alpha-beta T cell number J:265260
decreased CD8-positive, naive alpha-beta T cell number J:265260
decreased single-positive T cell number J:265260
increased B cell number J:265260
increased effector memory CD4-positive, alpha-beta T cell number J:265260
increased effector memory CD8-positive, alpha-beta T cell number J:265260
\Tnfrsf9tm1Byk/\Tnfrsf9tm1Byk
(B6.Cg-Tnfrsf9tm1Byk)
abnormal cytotoxic T cell physiology J:83996
decreased IgG2a level J:83996
decreased IgG3 level J:83996
decreased interferon-gamma secretion J:83996
decreased interleukin-2 secretion J:83996
decreased interleukin-4 secretion J:83996
increased T cell proliferation J:83996
\Tnfrsf9tm1Byk/\Tnfrsf9tm1Byk
(C.Cg-Tnfrsf9tm1Byk)
abnormal cytotoxic T cell physiology J:83722
abnormal immunoglobulin level J:83996
decreased IgG2a level J:83996
decreased IgG3 level J:83996
decreased interferon-gamma secretion J:83996
decreased interleukin-2 secretion J:83996
decreased interleukin-4 secretion J:83996
decreased interleukin-12 secretion J:83722
increased IgA level J:83722
increased IgG2a level J:83722
increased IgG2b level J:83722
increased splenocyte proliferation J:83722
increased T cell proliferation J:83996
\Tnfrsf9tm1Lpc/\Tnfrsf9tm1Lpc
(B6.129-Tnfrsf9tm1Lpc)
abnormal memory T cell physiology J:145439
immune system phenotype J:145439
\Tnfrsf10btm1Wnt/\Tnfrsf10btm1Wnt
(involves: 129S6/SvEvTac * C57BL/6)
abnormal innate immunity J:94681
abnormal interferon level J:94681
decreased susceptibility to Herpesvirales infection J:94681
decreased susceptibility to Herpesvirales infection induced morbidity/mortality J:94681
increased circulating interferon-gamma level J:94681
increased circulating interleukin-12b level J:94681
increased interleukin-12 secretion J:94681
increased NK cell number J:94681
increased tumor necrosis factor secretion J:94681
\Tnfrsf10btm1Wsed/\Tnfrsf10btm1Wsed
(involves: 129P2/OlaHsd)
enlarged thymus J:96816
\Tnfrsf11adel8/\Tnfrsf11adel8
(involves: 129)
abnormal mesenteric lymph node morphology J:111512
decreased osteoclast cell number J:111512
enlarged spleen J:111512
\Tnfrsf11atm1.1Pngr/\Tnfrsf11atm1.2Pngr
\Tg(Gfap-cre)2Brn/0

(involves: 129 * C57BL/6 * C57BL/6NTac * FVB/N)
decreased susceptibility to endotoxin shock J:155398
\Tnfrsf11atm1.1Pngr/\Tnfrsf11atm1.2Pngr
\Tg(Nes-cre)1Kln/0

(involves: 129 * C57BL/6 * C57BL/6NTac * SJL)
decreased susceptibility to endotoxin shock J:155398
\Tnfrsf11atm1.1Sral/\Tnfrsf11a+
(B6.129P2(Cg)-Tnfrsf11atm1.1Sral)
abnormal osteoclast differentiation J:312215
abnormal osteoclast physiology J:312215
increased osteoclast cell number J:312215
\Tnfrsf11atm1.1Sral/\Tnfrsf11atm1.1Sral
(B6.129P2(Cg)-Tnfrsf11atm1.1Sral)
abnormal osteoclast differentiation J:312215
decreased osteoclast cell number J:312215
\Tnfrsf11atm1.2Pngr/\Tnfrsf11atm1.2Pngr
(B6.Cg-Tnfrsf11atm1.2Pngr)
absent lymph nodes J:155398
decreased osteoclast cell number J:155398
\Tnfrsf11atm1Imx/\Tnfrsf11atm1Imx
(involves: 129 * C57BL/6)
abnormal osteoclast differentiation J:57899
absent lymph nodes J:57899
decreased B cell number J:57899
decreased mature B cell number J:57899
decreased osteoclast cell number J:57899
decreased Peyer's patch number J:57899
decreased spleen germinal center size J:57899
increased granulocyte number J:57899
increased neutrophil cell number J:57899
small Peyer's patches J:57899
spleen hyperplasia J:57899
\Tnfrsf11atm1Imx/\Tnfrsf11atm1Imx
(involves: 129)
abnormal negative T cell selection J:125864
abnormal thymus epithelium morphology J:125864
\Tnfrsf11bem1(IMPC)Mbp/\Tnfrsf11bem1(IMPC)Mbp
(C57BL/6N-Tnfrsf11bem1(IMPC)Mbp/MbpMmucd)
enlarged lymph nodes J:211773
enlarged spleen J:211773
small spleen J:211773
\Tnfrsf11btm1Eac/\Tnfrsf11btm1Eac
(involves: 129S4/SvJaeSor)
abnormal dendritic cell antigen presentation J:67105
abnormal immune system morphology J:67105
abnormal immune system physiology J:67105
abnormal immunoglobulin level J:67105
abnormal pro-B cell differentiation J:67105
increased B cell number J:67105
increased immature B cell number J:67105
increased pro-B cell number J:67105
\Tnfrsf11btm1Khs/\Tnfrsf11btm1Khs
(involves: 129P2/OlaHsd * C57BL/6)
abnormal osteoclast differentiation J:111153, J:48325
abnormal osteoclast physiology J:111153
increased osteoclast cell number J:80503
\Tnfrsf11btm1Wss/\Tnfrsf11btm1Wss
(either: (involves: 129X1/SvJ * C57BL/6) or (involves: 129X1/SvJ * Black Swiss))
abnormal osteoclast morphology J:47602
\Tnfrsf12atm1Biib/\Tnfrsf12atm1Biib
(B6.129S4-Tnfrsf12atm1Biib)
abnormal chemokine secretion J:126416
\Tnfrsf13btm1Cmac/\Tnfrsf13btm1Cmac
(Not Specified)
enlarged spleen J:91914
immune system phenotype J:92334
increased B cell number J:91914
\Tnfrsf13btm1Rjb/\Tnfrsf13btm1Rjb
(involves: 129X1/SvJ * C57BL/6)
abnormal B cell activation J:69474
decreased IgA level J:69474
decreased IgM level J:69474
increased B cell number J:69474
increased B cell proliferation J:69474
increased spleen weight J:69474
\Tnfrsf13btm1Rjb/\Tnfrsf13btm1Rjb
(involves: 129X1/SvJ)
abnormal class switch recombination J:95288
decreased IgA level J:95288
decreased IgE level J:95288
decreased IgG1 level J:95288
\Tnfrsf13btm1Vmd/\Tnfrsf13btm1Vmd
(involves: C57BL/6)
abnormal immunoglobulin level J:70172
abnormal lymph node primary follicle morphology J:70172, J:82331
abnormal Peyer's patch follicle morphology J:70172
abnormal spleen morphology J:70172
abnormal spleen periarteriolar lymphoid sheath morphology J:70172, J:82331
abnormal spleen primary B follicle morphology J:70172
enlarged lymph nodes J:70172, J:82331
enlarged spleen J:70172, J:82331
glomerulonephritis J:82331
increased anti-double stranded DNA antibody level J:82331
increased anti-nuclear antigen antibody level J:82331
increased B cell number J:70172, J:82331
increased B cell proliferation J:70172
increased follicular B cell number J:70172
increased IgG1 level J:70172
increased marginal zone B cell number J:70172
increased mature B cell number J:70172
increased spleen germinal center size J:70172
increased spleen white pulp amount J:70172
increased transitional stage B cell number J:70172
kidney inflammation J:82331
liver inflammation J:82331
\Tnfrsf13cBcmd1/\Tnfrsf13cBcmd1
(A/WySnJ)
abnormal lymphocyte physiology J:92334
decreased B cell proliferation J:122315
decreased IgG level J:122315
decreased interferon-gamma secretion J:92334
decreased T cell proliferation J:92334
increased length of allograft survival J:92334
\Tnfrsf13cm1Btlr/\Tnfrsf13cm1Btlr
(C57BL/6J-Tnfrsf13cm1Btlr)
decreased B cell number J:265247
\Tnfrsf13cM2Btlr/\Tnfrsf13cM2Btlr
(C57BL/6J-Tnfrsf13cM2Btlr)
decreased B cell number J:265247
\Tnfrsf13ctm1Mass/\Tnfrsf13ctm1Mass
(C57BL/6-Tnfrsf13ctm1Mass)
abnormal B cell physiology J:113556
absent marginal zone B cells J:92732
arrested B cell differentiation J:92732
decreased B-2 B cell number J:92732
decreased IgG1 level J:92732
decreased IgG2a level J:92732
decreased IgG2b level J:92732
decreased IgG3 level J:92732
decreased IgG level J:92732
decreased IgM level J:92732
decreased mature B cell number J:92732
\Tnfrsf13ctm1Mass/\Tnfrsf13ctm1Mass
(involves: C57BL/6)
decreased lymphocyte cell number J:139293
decreased mature B cell number J:139293
\Tnfrsf13ctm1Mass/\Tnfrsf13ctm1Mass
\Tg(BCL2)22Wehi/0

(involves: C57BL/6 * SJL)
immune system phenotype J:92732
\Tnfrsf13ctm1Mass/\Tnfrsf13ctm1Mass
\Traf2tm1Rbr/\Traf2tm1Rbr

(involves: C57BL/6)
decreased germinal center B cell number J:172843
decreased spleen germinal center size J:172843
immune system phenotype J:172843
\Tnfrsf13ctm1Mass/\Tnfrsf13ctm1Mass
\Traf3tm1Rbr/\Traf3tm1Rbr

(involves: C57BL/6)
immune system phenotype J:172843
\Tnfrsf13ctm1Msc/\Tnfrsf13ctm1Msc
(involves: 129P2/OlaHsd * C57BL/6)
abnormal humoral immune response J:92676
absent marginal zone B cells J:92676
absent transitional stage B cells J:92676
decreased B cell number J:92676
decreased B-2 B cell number J:92676
decreased IgD level J:92676
decreased IgG1 level J:92676
decreased IgG level J:92676
decreased IgM level J:92676
\Tnfrsf14tm1Csj/\Tnfrsf14tm1Csj
(B6.Cg-Tnfrsf14tm1Csj)
decreased interferon-gamma secretion J:169369
decreased interleukin-6 secretion J:169369
decreased interleukin-10 secretion J:169369
decreased susceptibility to induced colitis J:169369
decreased tumor necrosis factor secretion J:169369
\Tnfrsf14tm1Kpf/\Tnfrsf14tm1Kpf
(B6.129P2-Tnfrsf14tm1Kpf)
abnormal T cell physiology J:99456
increased T cell proliferation J:99456
\Tnfrsf14tm1Kro/\Tnfrsf14tm1Kro
(C57BL/6-Tnfrsf14tm1Kro)
decreased susceptibility to Herpesvirales infection J:243038
\Tnfrsf14tm1Wwhk/\Tnfrsf14tm1Wwhk
(B6.Cg-Tnfrsf14tm1Wwhk)
decreased length of allograft survival J:119356
\Tnfrsf17tm1Kplm/\Tnfrsf17tm1Kplm
(involves: 129P2/OlaHsd * C57BL/6)
decreased plasma cell number J:124543
\Tnfrsf18tm1Ppp/\Tnfrsf18tm1Ppp
(involves: 129/Sv * C57BL/6)
abnormal T cell activation J:77393
immune system phenotype J:77393
increased interleukin-2 secretion J:77393
increased T cell apoptosis J:77393
increased T cell proliferation J:77393
\Tnfrsf21tm1Ddy/\Tnfrsf21tm1Ddy
(involves: 129S1/Sv * 129X1/SvJ)
abnormal T-helper 1 physiology J:70594
abnormal T-helper 2 physiology J:70594
increased B cell proliferation J:109341
increased IgG1 level J:109341
increased IgG2a level J:109341
increased IgG2b level J:109341
increased IgG3 level J:109341
increased IgM level J:109341
increased interleukin-4 secretion J:70594
increased interleukin-5 secretion J:70594
increased interleukin-10 secretion J:70594
increased interleukin-13 secretion J:70594
increased spleen germinal center size J:109341
increased T cell proliferation J:70594
\Tnfrsf21tm1Vmd/\Tnfrsf21tm1Vmd
(involves: C57BL/6)
abnormal cell-mediated immunity J:72761
abnormal T-helper 2 physiology J:72761
immune system phenotype J:72761
increased CD4-positive, alpha-beta T cell number J:72761
increased CD8-positive, alpha-beta T cell number J:72761
increased IgE level J:72761
increased IgG1 level J:72761
increased IgG2a level J:72761
increased IgM level J:72761
increased interferon-gamma secretion J:72761
increased interleukin-2 secretion J:72761
increased interleukin-4 secretion J:72761
increased T cell number J:72761
increased T cell proliferation J:72761
\Tnfrsf25tm1Mjo/\Tnfrsf25tm1Mjo
(involves: 129P2/OlaHsd)
abnormal negative T cell selection J:84536
decreased T cell apoptosis J:84536
enlarged thymus J:84536
increased thymocyte number J:84536
\Tnfsf4tm1Shr/\Tnfsf4tm1Shr
(involves: 129S4/SvJae)
abnormal cell-mediated immunity J:59203
abnormal dendritic cell antigen presentation J:59203
decreased interferon-gamma secretion J:59203
decreased interleukin-2 secretion J:59203
decreased interleukin-4 secretion J:59203
decreased susceptibility to type IV hypersensitivity reaction J:59203
decreased T cell proliferation J:59203
immune system phenotype J:59203
\Tnfsf4tm1Shr/\Tnfsf4tm1Shr
(NOD.129S4-Tnfsf4tm1Shr)
decreased susceptibility to autoimmune diabetes J:86926
\Tnfsf4tm1Shr/\Tnfsf4tm1Shr
(C.129S4-Tnfsf4tm1Shr)
abnormal cytokine secretion J:59203
abnormal dendritic cell antigen presentation J:59203
\Tnfsf4tm1Sug/\Tnfsf4tm1Sug
(B6.129S4-Tnfsf4tm1Sug)
abnormal cytokine secretion J:80214
decreased susceptibility to type IV hypersensitivity reaction J:80214
decreased T cell proliferation J:80214
\Tnfsf8tm1Pod/\Tnfsf8tm1Pod
(B6.129X1-Tnfsf8tm1Pod)
decreased susceptibility to graft versus host disease J:92723
\Tnfsf9tm1Thw/\Tnfsf9tm1Thw
(involves: 129 * C57BL/6)
abnormal cytotoxic T cell physiology J:76373
immune system phenotype J:76373
\Tnfsf10tm1Mjs/\Tnfsf10tm1Mjs
(C.129-Tnfsf10tm1Mjs)
abnormal negative T cell selection J:82145
decreased susceptibility to bacterial infection J:87620
decreased susceptibility to bacterial infection induced morbidity/mortality J:87620
immune system phenotype J:84838
impaired natural killer cell mediated cytotoxicity J:73948
liver inflammation J:87620
thymus hyperplasia J:84838, J:82145
\Tnfsf10tm1Mjs/\Tnfsf10tm1Mjs
(B6.129-Tnfsf10tm1Mjs)
abnormal negative T cell selection J:82145
immune system phenotype J:84838
increased IgG1 level J:82145
increased IgG2a level J:82145
increased interferon-gamma secretion J:82145
increased interleukin-2 secretion J:82145
increased susceptibility to autoimmune diabetes J:82145
increased susceptibility to experimental autoimmune encephalomyelitis J:101672
increased susceptibility to induced arthritis J:82145
thymus hyperplasia J:82145
\Tnfsf10tm1Sdg/\Tnfsf10tm1Sdg
(B6.129-Tnfsf10tm1Sdg)
immune system phenotype J:79085
\Tnfsf10tm1Sdg/\Tnfsf10tm1Sdg
(involves: 129 * C57BL/6)
immune system phenotype J:79085
\Tnfsf11tles/\Tnfsf11tles
(involves: 129S6/SvEvTac * C57BL/6J)
absent lymph nodes J:179743
decreased osteoclast cell number J:179743
enlarged spleen J:179743
thymus hypoplasia J:179743
\Tnfsf11tles/\Tnfsf11tm1Pngr
(involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6J)
decreased osteoclast cell number J:179743
\Tnfsf11tm1(TNFSF11)Kost/\Tnfsf11tm1(TNFSF11)Kost
(involves: 129/Sv * Black Swiss)
abnormal osteoclast morphology J:166279
\Tnfsf11tm1.1Caob/\Tnfsf11tm1.1Caob
\Tg(Dmp1-cre)1Jqfe/0

(involves: 129S1/Sv * 129S4/SvJaeSor * 129X1/SvJ * C57BL/6 * FVB)
abnormal osteoclast cell number J:177558
decreased osteoclast cell number J:177558
\Tnfsf11tm1.1Caob/\Tnfsf11tm1.1Caob
\Tg(Prrx1-cre)1Cjt/0

(involves: 129S1/Sv * 129S4/SvJaeSor * 129X1/SvJ * C57BL/6)
decreased osteoclast cell number J:177558
\Tnfsf11tm1.1Htaka/\Tnfsf11tm1.2Htaka
\Tg(Dmp1-cre)1Jqfe/0

(involves: 129P2/OlaHsd * C57BL/6 * C57BL/6J * FVB/N)
decreased osteoclast cell number J:177557
\Tnfsf11tm1.2Htaka/\Tnfsf11+
(B6.Cg-Tnfsf11tm1.2Htaka)
decreased osteoclast cell number J:177557
\Tnfsf11tm1.2Htaka/\Tnfsf11tm1.2Htaka
(B6.Cg-Tnfsf11tm1.2Htaka)
decreased osteoclast cell number J:177557
increased spleen weight J:177557
\Tnfsf11tm1Pngr/\Tnfsf11tm1Pngr
(involves: 129P2/OlaHsd * C57BL/6)
abnormal immune system morphology J:52369
abnormal immune system physiology J:52369
abnormal pro-B cell differentiation J:52369
absent mesenteric lymph nodes J:52369
absent peripheral lymph nodes J:52369
arrested T cell differentiation J:52369
decreased immature B cell number J:52369
decreased interferon-gamma secretion J:52369
decreased interleukin-2 secretion J:52369
decreased interleukin-4 secretion J:52369
decreased interleukin-5 secretion J:52369
decreased interleukin-6 secretion J:52369
decreased mature B cell number J:52369
decreased osteoclast cell number J:52369
decreased thymus weight J:52369
immune system phenotype J:52369
increased spleen weight J:52369
small Peyer's patches J:52369
thymus hypoplasia J:52369
\Tnfsf11tm1Pngr/\Tnfsf11tm1Pngr
(involves: 129P2/OlaHsd)
abnormal thymus epithelium morphology J:173115
\Tnfsf11tm1Ywc/\Tnfsf11+
(involves: 129P2/OlaHsd)
absent peripheral lymph nodes J:65888
\Tnfsf11tm1Ywc/\Tnfsf11tm1Ywc
(involves: 129P2/OlaHsd)
abnormal cervical lymph node morphology J:65888
abnormal spleen B cell follicle morphology J:65888
abnormal spleen marginal zone morphology J:65888
abnormal spleen morphology J:65888
abnormal splenic cell ratio J:233265
abnormal thymus cell ratio J:233265
absent cervical lymph nodes J:65888
absent mesenteric lymph nodes J:65888
absent peripheral lymph nodes J:65888
decreased Langerhans cell number J:137471
decreased osteoclast cell number J:65888, J:64737
decreased Peyer's patch number J:233265
decreased spleen white pulp amount J:233265
increased spleen red pulp amount J:233265
small Peyer's patches J:233265
small thymus medulla J:233265
\Tnfsf12tm1Ash/\Tnfsf12tm1Ash
(B6.129-Tnfsf12tm1Ash)
abnormal cytokine secretion J:104801
abnormal immune system organ morphology J:104801
abnormal leukocyte morphology J:104801
decreased interleukin-10 secretion J:104801
enlarged lymph nodes J:104801
enlarged spleen J:104801
increased double-positive T cell number J:104801
increased interferon-gamma secretion J:104801
increased interleukin-12 secretion J:104801
increased memory T cell number J:104801
increased NK cell number J:104801
increased susceptibility to bacterial infection J:104801
increased T-helper 1 cell number J:104801
\Tnfsf13tm1Geha/\Tnfsf13tm1Geha
(involves: 129S4/SvJae)
abnormal class switch recombination J:88910
decreased IgA level J:88910
decreased IgM level J:88910
immune system phenotype J:88910
increased IgG level J:88910
increased memory T cell number J:88910
increased spleen germinal center number J:88910
increased spleen germinal center size J:88910
\Tnfsf13tm1Pod/\Tnfsf13+
(B6.Cg-Tnfsf13tm1Pod)
decreased IgA level J:141374
\Tnfsf13tm1Pod/\Tnfsf13tm1Pod
(B6.Cg-Tnfsf13tm1Pod)
abnormal interleukin secretion J:141374
decreased IgA level J:141374
decreased IgG2a level J:141374
decreased interleukin-10 secretion J:141374
decreased interleukin-17 secretion J:141374
decreased susceptibility to induced arthritis J:141374
increased IgG1 level J:141374
increased interferon-gamma secretion J:141374
increased interleukin-4 secretion J:141374
increased interleukin-5 secretion J:141374
increased interleukin-13 secretion J:141374
increased interleukin-17 secretion J:141374
increased T cell proliferation J:141374
\Tnfsf13bm1Anu/\Tnfsf13bm1Anu
(C57BL/6JAnu-Tnfsf13bm1Anu/AnuApb)
abnormal B cell differentiation J:104190
decreased mature B cell number J:104190
increased immature B cell number J:104190
\Tnfsf13bM1Btlr/\Tnfsf13b+
(C57BL/6J-Tnfsf13bM1Btlr)
decreased B cell number J:220069
decreased IgG level J:220069
decreased IgM level J:220069
impaired humoral immune response J:220069
increased single-positive T cell number J:220069
increased T cell number J:220069
\Tnfsf13bM1Btlr/\Tnfsf13bM1Btlr
(C57BL/6J-Tnfsf13bM1Btlr)
decreased B cell number J:220069
decreased IgG level J:220069
decreased IgM level J:220069
impaired humoral immune response J:220069
increased single-positive T cell number J:220069
increased T cell number J:220069
\Tnfsf13bm2Btlr/\Tnfsf13bm2Btlr
(C57BL/6J-Tnfsf13bm2Btlr)
decreased B cell number J:220070
decreased IgG level J:220070
impaired humoral immune response J:220070
\Tnfsf13bm3Btlr/\Tnfsf13bm3Btlr
(C57BL/6J-Tnfsf13bm3Btlr)
abnormal lymphocyte morphology J:272850
decreased B cell number J:272850
\Tnfsf13btm1Cleg/\Tnfsf13btm1Cleg
(involves: 129S5/SvEvBrd)
abnormal B cell differentiation J:71301
abnormal B cell physiology J:71301
abnormal leukocyte morphology J:71301
abnormal lymph organ size J:71301
decreased follicular B cell number J:71301
decreased IgG level J:71301
decreased IgM level J:71301
decreased mature B cell number J:71301
decreased memory T cell number J:71301
increased T cell number J:71301
lymph node hypoplasia J:71301
spleen hypoplasia J:71301
\Tnfsf13btm1Msc/\Tnfsf13b+
(involves: 129S2/SvPas * C57BL/6)
decreased immunoglobulin level J:71681
\Tnfsf13btm1Msc/\Tnfsf13btm1Msc
(involves: 129S2/SvPas * C57BL/6)
abnormal B cell differentiation J:71681
abnormal humoral immune response J:71681
abnormal lymph node B cell domain morphology J:71681
arrested B cell differentiation J:71681
decreased B cell number J:71681
decreased follicular B cell number J:71681
decreased immunoglobulin level J:71681
decreased marginal zone B cell number J:71681
decreased spleen weight J:71681
\Tnfsf13btm1Msc/\Tnfsf13btm1Msc
(involves: 129S2/SvPas)
decreased B cell number J:138560
decreased follicular B cell number J:138560
decreased T cell proliferation J:92334
decreased transitional stage B cell number J:138560
increased length of allograft survival J:92334
\Tnfsf13btm1Msc/\Tnfsf13btm1Msc
\Traf2tm1Rbr/\Traf2tm1Rbr

(involves: 129S2/SvPas * C57BL/6)
absent follicular B cells J:132877
absent marginal zone B cells J:132877
decreased mature B cell number J:132877
\Tnfsf14tm1Ddy/\Tnfsf14tm1Ddy
(involves: 129S1/Sv * 129X1/SvJ)
abnormal cytotoxic T cell physiology J:84366
abnormal T cell activation J:84366
decreased T cell proliferation J:84366
immune system phenotype J:84366
\Tnfsf14tm1Kpf/\Tnfsf14tm1Kpf
(involves: 129P2/OlaHsd * C57BL/6)
abnormal T cell subpopulation ratio J:77250
decreased cytotoxic T cell cytolysis J:77250
decreased interferon-gamma secretion J:77250
decreased interleukin-2 secretion J:77250
decreased interleukin-4 secretion J:77250
decreased interleukin-10 secretion J:77250
decreased splenocyte proliferation J:77250
decreased T cell proliferation J:77250
\Tnfsf14tm1Kpf/\Tnfsf14tm1Kpf
(involves: 129P2/OlaHsd)
abnormal gamma-delta T cell morphology J:169863
\Tnfsf14tm1Kpf/\Tnfsf14tm1Kpf
(B6.129P2-Tnfsf14tm1Kpf)
abnormal osteoclast differentiation J:294030
\Tnfsf14tm1Lpc/\Tnfsf14tm1Lpc
(involves: 129X1/SvJ * C57BL/6)
abnormal cytotoxic T cell physiology J:76414
decreased cytotoxic T cell cytolysis J:76414
decreased inflammatory response J:107803
decreased interferon-gamma secretion J:76414
decreased tumor necrosis factor secretion J:76414
\Tnfsf14tm1Lpc/\Tnfsf14tm1Lpc
(B6.129X1-Tnfsf14tm1Lpc)
immune system phenotype J:158663
\Tnfsf14tm1Wwh/\Tnfsf14tm1Wwh
(involves: 129 * C57BL/6)
increased length of allograft survival J:75705
\Tnfsf15tm1Cdon/\Tnfsf15tm1Cdon
(B6.129-Tnfsf15tm1Cdon)
abnormal dendritic cell differentiation J:136280
decreased susceptibility to experimental autoimmune encephalomyelitis J:136280
\Tnfsf15tm1Hluo/\Tnfsf15tm1Hluo
(D1LacJ.129(B6)-Tnfsf15tm1Hluo)
decreased B cell number J:207029
decreased germinal center B cell number J:207029
decreased IgG2a level J:207029
decreased IgG2b level J:207029
decreased IgG level J:207029
decreased plasma cell number J:207029
decreased susceptibility to induced arthritis J:207029
decreased T cell number J:207029
decreased T follicular helper cell number J:207029
immune system phenotype J:207029
lymph node hypoplasia J:207029
\Tnfsf15tm1Lex/\Tnfsf15tm1Lex
(involves: 129S5/SvEvBrd * C57BL/6)
increased NK cell number J:82809
\Tnikm1Anu/\Tnikm1Anu
(C57BL/6NCrlAnu-Tnikm1Anu/Anu)
immune system phenotype J:104190
\Tnip1Gt(E059E05)Wrst/\Tnip1Gt(E059E05)Wrst
(involves: 129P2/OlaHsd * C57BL/6)
decreased interleukin-12 secretion J:180054
decreased interleukin-12b secretion J:180054
enlarged lymph nodes J:180054
enlarged spleen J:180054
glomerulonephritis J:180054
increased anti-double stranded DNA antibody level J:180054
increased anti-nuclear antigen antibody level J:180054
increased IgA level J:180054
increased IgG1 level J:180054
increased IgG2b level J:180054
increased IgM level J:180054
increased neutrophil cell number J:180054
increased susceptibility to systemic lupus erythematosus J:180054
lymph node hyperplasia J:180054
spleen hyperplasia J:180054
\Tnip1m1Btlr/\Tnip1m1Btlr
(C57BL/6J-Tnip1m1Btlr)
decreased B cell number J:265175
decreased B-2 B cell number J:265175
increased anti-double stranded DNA antibody level J:265175
increased B-1a cell number J:265175
increased B-1b cell number J:265175
increased dendritic cell number J:265175
increased IgA level J:265175
increased IgE level J:265175
increased macrophage cell number J:265175
increased susceptibility to induced colitis J:265175
\Tnip1tm1.1Pcoh/\Tnip1+
(involves: 129P2/OlaHsd * C57BL/6)
increased anti-double stranded DNA antibody level J:176826
\Tnip1tm1.1Pcoh/\Tnip1tm1.1Pcoh
(involves: 129P2/OlaHsd * C57BL/6)
abnormal complement pathway J:176826
abnormal effector T cell morphology J:176826
abnormal immune system morphology J:176826
abnormal Peyer's patch morphology J:176826
abnormal plasma cell morphology J:176826
abnormal spleen germinal center morphology J:176826
enlarged lymph nodes J:176826
enlarged spleen J:176826
glomerulonephritis J:176826
immune system phenotype J:176826
increased anti-double stranded DNA antibody level J:176826
increased anti-nuclear antigen antibody level J:176826
increased B cell number J:176826
increased B cell proliferation J:176826
increased germinal center B cell number J:176826
increased granulocyte number J:176826
increased IgA level J:176826
increased IgE level J:176826
increased IgG1 level J:176826
increased IgG2a level J:176826
increased IgG2b level J:176826
increased IgG3 level J:176826
increased IgG level J:176826
increased IgM level J:176826
increased immunoglobulin level J:176826
increased interleukin-6 secretion J:176826
increased interleukin-12b secretion J:176826
increased monocyte cell number J:176826
increased plasma cell number J:176826
increased spleen red pulp amount J:176826
increased spleen weight J:176826
increased spleen white pulp amount J:176826
increased T follicular helper cell number J:176826
increased tumor necrosis factor secretion J:176826
\Tnip1tm1.2Ama/\Tnip1tm1.2Ama
\Tg(Itgax-cre)1-1Reiz/0

(involves: C57BL/6 * C57BL/6J * CBA)
abnormal leukocyte morphology J:205446
enlarged lymph nodes J:205446
enlarged spleen J:205446
increased interleukin-6 secretion J:205446
increased interleukin-12 secretion J:205446
increased interleukin-23 secretion J:205446
increased memory T cell number J:205446
increased plasmacytoid dendritic cell number J:205446
increased tumor necrosis factor secretion J:205446
\Tnip1tm1.2Pcoh/\Tnip1tm1.2Pcoh
(involves: 129P2/OlaHsd * C57BL/6)
abnormal immune system morphology J:176826
\Tnip1tm1b(EUCOMM)Hmgu/\Tnip1tm1b(EUCOMM)Hmgu
(C57BL/6N-Tnip1tm1b(EUCOMM)Hmgu/H)
decreased eosinophil cell number J:211773
decreased lymphocyte cell number J:211773
increased basophil cell number J:211773
increased large unstained cell number J:211773
increased monocyte cell number J:211773
increased spleen weight J:211773
\Tnip2tm1.1Sley/\Tnip2tm1.1Sley
(involves: 129S4/SvJae * 129S8/SvEv * C57BL/6)
abnormal macrophage physiology J:112395
immune system phenotype J:112395
\Tnip3tm1Rds/\Tnip3tm1Rds
(involves: 129S6/SvEvTac)
immune system phenotype J:122758
\Tnk2em1(IMPC)Tcp/\Tnk2em1(IMPC)Tcp
(C57BL/6N-Tnk2em1(IMPC)Tcp/Tcp)
enlarged lymph nodes J:211773
\Tnk2tm1.2Npma/\Tnk2tm1.2Npma
(B6(Cg)-Tnk2tm1.2Npma)
abnormal regulatory T cell number J:341740
abnormal T cell physiology J:341740
increased activated T cell number J:341740
increased circulating interferon-gamma level J:341740
increased circulating interleukin-2 level J:341740
increased effector memory CD8-positive, alpha-beta T cell number J:341740
increased interferon level J:341740
increased interleukin level J:341740
\Tnrem1(IMPC)Rbrc/\Tnrem1(IMPC)Rbrc
(C57BL/6NJcl-Tnrem1(IMPC)Rbrc/Rbrc)
increased spleen weight J:211773
\Tns1tm1Efu/\Tns1tm1Efu
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
tubulointerstitial nephritis J:39202
\Tns2nph/\Tns2nph
(involves: ICR)
enlarged lymph nodes J:24698
glomerulonephritis J:108691
\Tns3Gt(XK294)Byg/\Tns3Gt(XK294)Byg
(involves: 129P2/OlaHsd * C57BL/6)
small spleen J:96666
\Tnxbtm1b(EUCOMM)Hmgu/\Tnxbtm1b(EUCOMM)Hmgu
(C57BL/6N-Tnxbtm1b(EUCOMM)Hmgu/H)
enlarged spleen J:211773
\Tob2tm1Tya/\Tob2tm1Tya
(involves: 129S4/SvJae * C57BL/6)
abnormal osteoclast differentiation J:134287
abnormal osteoclast physiology J:134287
increased osteoclast cell number J:134287
\Tolliptm1Kbns/\Tolliptm1Kbns
(involves: C57BL/6)
decreased circulating interleukin-6 level J:105514
decreased interleukin-6 secretion J:105514
decreased tumor necrosis factor secretion J:105514
\Tom1l2Gt(XG909)Byg/\Tom1l2+
(involves: 129P2/OlaHsd * C57BL/6J)
enlarged spleen J:133892
increased susceptibility to infection J:133892
\Tom1l2Gt(XG909)Byg/\Tom1l2Gt(XG909)Byg
(involves: 129P2/OlaHsd * C57BL/6J)
abnormal humoral immune response J:133892
abnormal immune system physiology J:133892
abnormal inflammatory response J:133892
abnormal lymph node cell ratio J:133892
abnormal spleen B cell follicle morphology J:133892
abnormal spleen morphology J:133892
abnormal spleen periarteriolar lymphoid sheath morphology J:133892
abnormal splenic cell ratio J:133892
conjunctivitis J:133892
dark spleen J:133892
dermatitis J:133892
enlarged spleen J:133892
increased B cell number J:133892
increased CD4-positive, alpha-beta T cell number J:133892
increased CD8-positive, alpha-beta T cell number J:133892
increased inflammatory response J:133892
increased leukocyte cell number J:133892
increased spleen white pulp amount J:133892
increased susceptibility to bacterial infection J:133892
increased susceptibility to infection J:133892
increased T cell number J:133892
lymphoid hyperplasia J:133892
\Tomm5Gt(OST44663)Lex/\Tomm5Gt(OST44663)Lex
(involves: 129S5/SvEvBrd * C57BL/6)
increased eosinophil cell number J:186382
lung inflammation J:186382
thymus atrophy J:186382
\Tomm6tm1a(KOMP)Wtsi/\Tomm6+
(C57BL/6N-Tomm6tm1a(KOMP)Wtsi/Wtsi)
abnormal lymph node morphology J:211773
enlarged lymph nodes J:211773
\Tomm20em1(IMPC)J/\Tomm20+
(C57BL/6NJ-Tomm20em1(IMPC)J/Mmjax)
increased leukocyte cell number J:211773
\Top2aem2(IMPC)Tcp/\Top2a+
(C57BL/6NCrl-Top2aem2(IMPC)Tcp/Tcp)
small spleen J:211773
small thymus J:211773
\Top2bem1(IMPC)Mbp/\Top2b+
(C57BL/6NCrl-Top2bem1(IMPC)Mbp/MbpMmucd)
abnormal spleen morphology J:211773
small spleen J:211773
\Top3btm1Jcw/\Top3btm1Jcw
(involves: 129S6/SvEvTac * C57BL/6)
dermatitis J:69405
enlarged axillary lymph nodes J:69405
enlarged spleen J:69405
enlarged submandibular lymph nodes J:69405
glomerulonephritis J:69405
increased inflammatory response J:69405
pancreas inflammation J:69405
stomach inflammation J:69405
\Tor1bem1(IMPC)Mbp/\Tor1bem1(IMPC)Mbp
(C57BL/6NCrl-Tor1bem1(IMPC)Mbp/MbpMmucd)
increased basophil cell number J:211773
\Tox2em1Cdon/\Tox2em1Cdon
(C57BL/6J-Tox2em1Cdon)
abnormal T follicular helper cell differentiation J:290926
decreased germinal center B cell number J:290926
\Toxtm1.1Kay/\Toxtm1.1Kay
(involves: 129S6/SvEvTac)
abnormal CD4-positive T cell differentiation J:131287
abnormal CD4-positive, CD25-positive, alpha-beta regulatory T cell morphology J:131287
abnormal CD8-positive, alpha beta T cell morphology J:131287
decreased CD4-positive, alpha-beta T cell number J:131287
decreased cytotoxic T cell cytolysis J:131287
decreased NK T cell number J:131287
\Toxtm1.1Kay/\Toxtm1.1Kay
(involves: 129S6/SvEvTac * C57BL/6)
abnormal positive T cell selection J:164687
abnormal spleen morphology J:164687
absent axillary lymph nodes J:164687
absent inguinal lymph nodes J:164687
absent mesenteric lymph nodes J:164687
absent popliteal lymph nodes J:164687
decreased NK cell number J:164687
decreased Peyer's patch number J:164687
small Peyer's patches J:164687
\Toxtm1b(KOMP)Wtsi/\Toxtm1b(KOMP)Wtsi
(C57BL/6N-Toxtm1b(KOMP)Wtsi/Tcp)
increased spleen weight J:211773
\Toxtm1Kay/\Toxtm1Kay
\Tg(Lck-cre)1Cwi/0

(involves: 129S6/SvEvTac * C57BL/6)
abnormal CD4-positive T cell differentiation J:164687
\Tpcn1tm1.1Dren/\Tpcn1tm1.1Dren
\Tpcn2tm1.1Dren/\Tpcn2tm1.1Dren

(Not Specified)
abnormal macrophage physiology J:189070
\Tpcn2tm1b(EUCOMM)Hmgu/\Tpcn2tm1b(EUCOMM)Hmgu
(C57BL/6N-Tpcn2tm1b(EUCOMM)Hmgu/H)
increased eosinophil cell number J:211773
\Tph2em1(IMPC)Mbp/\Tph2em1(IMPC)Mbp
(C57BL/6N-Tph2em1(IMPC)Mbp/MbpMmucd)
abnormal spleen morphology J:211773
enlarged spleen J:211773
increased eosinophil cell number J:211773
\Tpi1a-m6Neu/\Tpi1a-m6Neu
(involves: 101/El * C3H/El)
increased spleen weight J:163223
\Tpi1rbc19/\Tpi1rbc19
(SJL-Tpi1rbc19)
abnormal spleen red pulp morphology J:263104
enlarged spleen J:263104
\Tpm4Plt53/\Tpm4+
(BALB/c-Tpm4Plt53)
abnormal thrombopoiesis J:242938
\Tpm4Plt53/\Tpm4Plt53
(BALB/c-Tpm4Plt53)
abnormal thrombopoiesis J:242938
increased lymphocyte cell number J:242938
\TpoR479C/\TpoR479C
(involves: ICR)
small spleen J:112930
\Tpp2Gt(OST432061)Lex/\Tpp2Gt(OST432061)Lex
(B6.129S5-Tpp2Gt(OST432061)Lex)
abnormal level of surface class I molecules J:157195
\Tpp2Gt(OST432061)Lex/\Tpp2Gt(OST432061)Lex
(involves: 129S5/SvEvBrd * C57BL/6)
abnormal antigen presentation J:157195
\Tpp2tm1.1Gnie/\Tpp2tm1.1Gnie
(involves: 129S6/SvEvTac * C57BL/6)
abnormal cytotoxic T cell physiology J:133572
abnormal immune system cell morphology J:133572
abnormal immune system organ morphology J:133572
abnormal spleen morphology J:133572
abnormal splenic cell ratio J:133572
decreased CD8-positive, alpha-beta T cell number J:133572
decreased double-positive T cell number J:133572
decreased T cell number J:133572
enlarged spleen J:133572
increased double-negative T cell number J:133572
increased single-positive T cell number J:133572
increased spleen red pulp amount J:133572
increased T cell apoptosis J:133572
increased T cell number J:133572
thymus atrophy J:133572
\Tpp2tm1.1Gnie/\Tpp2tm1.1Gnie
(involves: 129S6/SvEvTac)
abnormal CD4-positive T cell differentiation J:221205
abnormal CD8-positive, alpha-beta T cell differentiation J:221205
abnormal lymphocyte physiology J:221205
decreased leukocyte cell number J:221205
enlarged lymph nodes J:221205
enlarged spleen J:221205
increased anti-nuclear antigen antibody level J:221205
increased autoantibody level J:221205
increased B cell number J:221205
increased memory T cell number J:221205
\Tppp3em1(IMPC)Ccpcz/\Tppp3+
(C57BL/6NCrl-Tppp3em1(IMPC)Ccpcz/Ccpcz)
abnormal lymph node morphology J:211773
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged lymph nodes J:211773
enlarged spleen J:211773
enlarged thymus J:211773
increased CD4-positive NK T cell number J:211773
increased memory-marker CD4-positive NK T cell number J:211773
increased NK T cell number J:211773
\Tpsab1m1/\Tpsab1m1
(involves: C57BL/6J)
abnormal mast cell differentiation J:142880
\Tpsab1m1/\Tpsab1m1
\Tpsb2tm1(cre)Adch/\Tpsb2tm1(cre)Adch

(B6.Cg-Tpsb2tm1(cre)Adch Tpsab1m1)
abnormal mast cell differentiation J:142880
decreased susceptibility to induced arthritis J:142880
\Tpsb2tm1(cre)Adch/\Tpsb2tm1(cre)Adch
(B6.Cg-Tpsb2tm1(cre)Adch)
increased susceptibility to bacterial infection J:124554
\Tpsb2tm1.1Mfg/\Tpsb2tm1.1Mfg
(B6.129-Tpsb2tm1.1Mfg)
abnormal mast cell differentiation J:142880
decreased susceptibility to induced arthritis J:142880
impaired eosinophil recruitment J:133373
impaired neutrophil chemotaxis J:142880
increased susceptibility to parasitic infection J:133373
\Tpsg1tm1.2Rls/\Tpsg1tm1.2Rls
(involves: C57BL/6 * C57BL/6NTac)
decreased susceptibility to colitis induced morbidity/mortality J:243813
immune system phenotype J:243813
\Tpx2Gt(D028B03)Wrst/\Tpx2+
(involves: 129S2/SvPas * C57BL/6J)
abnormal splenocyte morphology J:184948
granulomatous inflammation J:184948
\Tra2atm2b(EUCOMM)Hmgu/\Tra2a+
(C57BL/6N-Tra2atm2b(EUCOMM)Hmgu/Bay)
increased basophil cell number J:211773
\Trabd2bem2(IMPC)Ccpcz/\Trabd2bem2(IMPC)Ccpcz
(C57BL/6N-Trabd2bem2(IMPC)Ccpcz/Ccpcz)
abnormal thymus morphology J:211773
enlarged thymus J:211773
\Traddtm1.1Mak/\Tradd+
(either: (involves: 129P2/OlaHsd * C57BL/6) or (involves: 129P2/OlaHsd * FVB/N))
decreased acute inflammation J:138824
\Traddtm1.1Mak/\Traddtm1.1Mak
(either: (involves: 129P2/OlaHsd * C57BL/6) or (involves: 129P2/OlaHsd * FVB/N))
abnormal spleen follicular dendritic cell network J:138824
absent spleen germinal center J:138824
decreased acute inflammation J:138824
decreased circulating interleukin-6 level J:138824
decreased inflammatory response J:138824
decreased interleukin-6 secretion J:138824
\Traddtm1.1Mpa/\Traddtm1.1Mpa
(involves: C57BL/6)
decreased interferon-beta secretion J:136289
\Traddtm1.1Mpa/\Traddtm1.1Mpa
(involves: BALB/cJ * C57BL/6)
abnormal interleukin level J:139030
abnormal spleen germinal center morphology J:139030
decreased circulating tumor necrosis factor level J:139030
decreased IgG level J:139030
increased susceptibility to bacterial infection J:139030
\Traf1tm1Tsi/\Traf1tm1Tsi
(involves: 129S4/SvJae * C57BL/6)
abnormal lymph node cell ratio J:72327
immune system phenotype J:72327
increased lymphocyte cell number J:72327
increased T cell proliferation J:72327
\Traf2tm1a(EUCOMM)Wtsi/\Traf2+
(C57BL/6N-Traf2tm1a(EUCOMM)Wtsi/Wtsi)
decreased alpha-beta T cell number J:211773
decreased CD8-positive, alpha-beta T cell number J:211773
\Traf2tm1Mak/\Traf2tm1Mak
(either: (involves: 129P2/OlaHsd * C57BL/6J) or (involves: 129P2/OlaHsd * BALB/c * C57BL/6J))
absent lymph node germinal center J:44360
absent spleen germinal center J:44360
decreased double-positive T cell number J:44360
decreased immature B cell number J:44360
decreased lymphocyte cell number J:44360
decreased thymocyte number J:44360
increased circulating tumor necrosis factor level J:44360
increased granulocyte number J:44360
increased thymocyte apoptosis J:44360
lymphoid hypoplasia J:44360
spleen atrophy J:44360
thymus atrophy J:44360
\Traf3m1Btlr/\Traf3m1Btlr
(C57BL/6J-Traf3m1Btlr)
decreased mature B cell number J:212064
impaired humoral immune response J:212064
\Traf3m2Btlr/\Traf3m2Btlr
(C57BL/6J-Traf3m2Btlr)
decreased IgG level J:217797
decreased response to antigen J:217797
\Traf3tm1Bal/\Traf3tm1Bal
(involves: 129S4/SvJae * C57BL/6J)
abnormal B cell differentiation J:37065
abnormal T cell physiology J:37065
decreased double-positive T cell number J:37065
decreased leukocyte cell number J:37065
decreased thymocyte number J:37065
spleen hypoplasia J:37065
\Traf3tm1Bshp/\Traf3tm1Bshp
\Cd19tm1(cre)Cgn/\Cd19+

(involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * SJL)
abnormal adaptive immunity J:124329
abnormal immune system organ morphology J:124329
abnormal immune system physiology J:124329
abnormal leukocyte morphology J:124329
abnormal lymph node B cell domain morphology J:124329
abnormal spleen germinal center morphology J:124329
autoimmune response J:124329
decreased B cell apoptosis J:124329
decreased T cell number J:124329
enlarged lymph nodes J:124329
enlarged spleen J:124329
increased anti-double stranded DNA antibody level J:124329
increased B cell number J:124329
increased follicular B cell number J:124329
increased IgA level J:124329
increased IgG2a level J:124329
increased IgG2b level J:124329
increased IgG3 level J:124329
increased IgG level J:124329
increased IgM level J:124329
increased marginal zone B cell number J:124329
increased spleen white pulp amount J:124329
increased transitional stage B cell number J:124329
\Traf3ip2adjm/\Traf3ip2adjm
(KOR-Traf3ip2adjm)
dermatitis J:162859
increased IgE level J:162859
\Traf3ip2adjm/\Traf3ip2adjm
(A.KOR-Traf3ip2adjm)
dermatitis J:162859
increased IgE level J:162859
\Traf3ip2adjm/\Traf3ip2adjm
(B6.KOR-Traf3ip2adjm)
dermatitis J:162859
increased IgE level J:162859
\Traf3ip2adjm/\Traf3ip2adjm
(C.KOR-Traf3ip2adjm)
dermatitis J:162859
increased IgE level J:162859
\Traf3ip2adjm/\Traf3ip2adjm
(AK.KOR-Traf3ip2adjm)
dermatitis J:162859
increased IgE level J:162859
\Traf3ip2Gt(IST11484G7)Tigm/\Traf3ip2Gt(IST11484G7)Tigm
(involves: C57BL/6N)
immune system phenotype J:177650
\Traf3ip2tm1.1Lix/\Traf3ip2tm1.1Lix
(involves: 129/Sv * BALB/c)
abnormal immune system morphology J:93923
abnormal immune system physiology J:93923
abnormal spleen B cell corona morphology J:93923
enlarged lymph nodes J:93923
enlarged spleen J:93923
increased anti-double stranded DNA antibody level J:93923
increased anti-histone antibody level J:93923
increased anti-single stranded DNA antibody level J:93923
increased autoantibody level J:93923
increased B cell number J:93923
increased dendritic cell number J:93923
increased IgE level J:93923
increased IgG level J:93923
increased immunoglobulin level J:93923
increased inflammatory response J:93923
lymphoid hyperplasia J:93923
respiratory system inflammation J:93923
\Traf3ip2tm1.1Lix/\Traf3ip2tm1.1Lix
(C.129-Traf3ip2tm1.1Lix)
blepharitis J:138560
enlarged submandibular lymph nodes J:138560
glomerulonephritis J:138560
increased autoantibody level J:138560
increased follicular B cell number J:138560
increased inflammatory response J:138560
increased marginal zone B cell number J:138560
increased transitional stage B cell number J:138560
kidney inflammation J:138560
lacrimal gland inflammation J:138560
parotid gland inflammation J:138560
stomatitis J:138560
submandibular gland inflammation J:138560
\Traf3ip2tm1.1Lix/\Traf3ip2tm1.1Lix
(B6.129-Traf3ip2tm1.1Lix)
abnormal transitional stage B cell morphology J:187766
enlarged cervical lymph nodes J:187766
enlarged spleen J:187766
immune system phenotype J:187766
increased anti-chromatin antibody level J:187766
increased anti-double stranded DNA antibody level J:187766
increased anti-histone antibody level J:187766
increased anti-nuclear antigen antibody level J:187766
increased autoantibody level J:187766
increased B cell number J:187766
increased IgG1 level J:187766
increased IgG2c level J:187766
increased IgG level J:187766
increased immature B cell number J:187766
increased marginal zone B cell number J:187766
increased spleen weight J:187766
lymph node hyperplasia J:187766
spleen hyperplasia J:187766
\Traf3ip2tm1.1Lix/\Traf3ip2tm1.1Lix
\Tnfsf13btm1Msc/\Tnfsf13btm1Msc

(involves: 129 * 129S2/SvPas * BALB/c)
decreased B cell number J:138560
decreased follicular B cell number J:138560
decreased mature B cell number J:138560
decreased transitional stage B cell number J:138560
enlarged lymph nodes J:93923
enlarged spleen J:93923
increased autoantibody level J:138560
\Traf3ip2tm1Lix/\Traf3ip2tm1.1Lix
\Tg(CD19-cre/ERT2)1Cgn/0

(involves: 129/Sv * BALB/c)
enlarged lymph nodes J:93923
enlarged spleen J:93923
increased B cell number J:93923
increased dendritic cell number J:93923
increased immunoglobulin level J:93923
\Traf3ip2tm1Sbn/\Traf3ip2tm1Sbn
(either: B6.129-Traf3ip2tm1Sbn or (involves: 129) or (involves: 129 * BALB/c))
abnormal cytokine secretion J:144320
decreased interleukin-6 secretion J:144320
decreased susceptibility to autoimmune disorder J:144320
impaired eosinophil recruitment J:144320
impaired macrophage chemotaxis J:144320
impaired neutrophil recruitment J:144320
\Traf3ip2tm1Sbn/\Traf3ip2tm1Sbn
(involves: 129 * C57BL/6)
decreased inflammatory response J:191090
\Traf3ip3tm1a(KOMP)Wtsi/\Traf3ip3tm1a(KOMP)Wtsi
(C57BL/6N-Traf3ip3tm1a(KOMP)Wtsi/Wtsi)
decreased leukocyte cell number J:175295
\Traf3ip3tm1b(KOMP)Wtsi/\Traf3ip3tm1b(KOMP)Wtsi
(involves: BALB/cJ * C57BL/6N)
abnormal T cell differentiation J:226431
decreased CD4-positive, alpha-beta memory T cell number J:226431
decreased CD8-positive, alpha-beta memory T cell number J:226431
decreased regulatory T cell number J:226431
decreased T cell number J:226431
decreased thymocyte number J:226431
immune system phenotype J:226431
increased double-positive T cell number J:226431
increased gamma-delta T cell number J:226431
\Traf4tm1Lind/\Traf4tm1Lind
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
immune system phenotype J:74252
lung inflammation J:74252
\Traf4tm1Mrio/\Traf4tm1Mrio
(involves: 129X1/SvJ)
abnormal dendritic cell physiology J:142780
immune system phenotype J:142780
\Traf4tm2Lind/\Traf4tm2Lind
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
immune system phenotype J:74252
lung inflammation J:74252
\Traf5tm1Hna/\Traf5tm1Hna
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)
abnormal B cell proliferation J:57114
abnormal humoral immune response J:57114
abnormal T cell proliferation J:57114
decreased IgG1 level J:57114
decreased IgM level J:57114
\Traf6tm1.1Mpa/\Traf6tm1.1Mpa
\Lyz2tm1(cre)Ifo/\Lyz2+

(involves: 129P2/OlaHsd * C57BL/6)
decreased circulating interleukin-6 level J:145306
\Traf6tm1Jino/\Traf6tm1Jino
(involves: 129P2/OlaHsd * C57BL/6)
abnormal osteoclast differentiation J:77453
decreased immature B cell number J:77453
decreased lymph node number J:77453
\Traf6tm1Mak/\Traf6tm1Mak
(involves: 129P3/J)
abnormal macrophage physiology J:54467
abnormal osteoclast morphology J:54467
abnormal osteoclast physiology J:54467
decreased B cell proliferation J:54467
decreased tumor necrosis factor secretion J:54467
enlarged spleen J:54467
\Traf6tm1Ywc/\Traf6tm1Ywc
(Not Specified)
abnormal dendritic cell differentiation J:85808
abnormal dendritic cell physiology J:85808
abnormal lymph node morphology J:85808
abnormal spleen morphology J:85808
absent spleen white pulp J:85808
decreased dendritic cell number J:85808
decreased interleukin-6 secretion J:85808
decreased interleukin-12 secretion J:85808
enlarged spleen J:85808
thymus atrophy J:85808
\Traf6tm2a(EUCOMM)Wtsi/\Traf6tm2a(EUCOMM)Wtsi
(C57BL/6N-Traf6tm2a(EUCOMM)Wtsi/Wtsi)
blood in lymph vessels J:239583
\Traf6tm2Ywc/\Traf6tm2Ywc
\Tg(Cd4-cre)1Cwi/?

(involves: C57BL/6 * DBA/2)
abnormal lymphocyte anergy J:130882
increased activated T cell number J:130882
increased memory T cell number J:130882
\Traf7em1(IMPC)Tcp/\Traf7+
(C57BL/6NCrl-Traf7em1(IMPC)Tcp/Tcp)
enlarged lymph nodes J:211773
\Trafd1tm1Ayos/\Trafd1tm1Ayos
(involves: 129 * C57BL/6J)
decreased susceptibility to Riboviria infection J:144594
increased circulating interleukin-6 level J:144594
increased interleukin-6 secretion J:144594
increased interleukin-12 secretion J:144594
increased susceptibility to endotoxin shock J:144594
increased tumor necrosis factor secretion J:144594
\Traj18em1Hwata/\Traj18em1Hwata
(C57BL/6-Traj18em1Hwata)
abnormal cytokine secretion J:256533
absent NK T cells J:256533
\Traj18em1Hwata/\Traj18em1Hwata
(C.B6-Traj18em1Hwata)
abnormal cytokine secretion J:256533
absent NK T cells J:256533
\Traj18tm1.1Kro/\Traj18tm1.1Kro
(involves: C57BL/6NTac)
abnormal circulating interleukin-4 level J:232957
abnormal interferon-gamma secretion J:232957
absent NK T cells J:232957
decreased inflammatory response J:232957
\Traj33em#Dig/\Traj33em#Dig
(involves: C57BL/6)
decreased T cell number J:276912
immune system phenotype J:276912
\Trak1em1(IMPC)Ccpcz/\Trak1+
(C57BL/6NCrl-Trak1em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
enlarged spleen J:211773
\Trak2em1(IMPC)Mbp/\Trak2em1(IMPC)Mbp
(C57BL/6N-Trak2em1(IMPC)Mbp/MbpMmucd)
abnormal lymph node morphology J:211773
enlarged lymph nodes J:211773
\Trap1em1(IMPC)Mbp/\Trap1em1(IMPC)Mbp
(C57BL/6N-Trap1em1(IMPC)Mbp/MbpMmucd)
abnormal lymph node morphology J:211773
decreased monocyte cell number J:211773
\Trap1Gt(E150H04)Wrst/\Trap1Gt(E150H04)Wrst
(involves: 129P2/OlaHsd * C57BL/6)
decreased inflammatory response J:226880
spleen hyperplasia J:226880
\Trappc1em1(IMPC)Mbp/\Trappc1+
(C57BL/6NCrl-Trappc1em1(IMPC)Mbp/Mmucd)
enlarged spleen J:211773
\Trappc2lem1(IMPC)Mbp/\Trappc2lem1(IMPC)Mbp
(C57BL/6N-Trappc2lem1(IMPC)Mbp/Ucd)
abnormal spleen morphology J:211773
enlarged spleen J:211773
\Trappc8em1(IMPC)Tcp/\Trappc8+
(C57BL/6NCrl-Trappc8em1(IMPC)Tcp/Tcp)
increased eosinophil cell number J:211773
increased monocyte cell number J:211773
\Trappc9tm1a(EUCOMM)Wtsi/\Trappc9tm1a(EUCOMM)Wtsi
(C57BL/6N-Trappc9tm1a(EUCOMM)Wtsi/Wtsi)
blood in lymph vessels J:239583
decreased CD11b-low dendritic cell number J:211773
decreased gamma-delta T cell number J:211773
decreased KLRG1-positive NK cell number J:211773
increased CD11b-high dendritic cell number J:211773
increased Ly6C high monocyte number J:211773
increased Ly6C low monocyte number J:211773
increased monocyte cell number J:211773
\Trappc10b2b2416Clo/\Trappc10b2b2416Clo
(Trappc10b2b2416Clo)
thymus hypoplasia J:175213
\Trat1tm1Lsmn/\Trat1tm1Lsmn
(B6.129X1-Trat1tm1Lsmn)
lymph node hypoplasia J:108406
spleen hypoplasia J:108406
thymus hypoplasia J:108406
\Trbv13-2tm1(CD2)Zhu/\Trbv13-2tm1(CD2)Zhu
(involves: 129 * C57BL/6)
abnormal T cell differentiation J:121608
immune system phenotype J:121608
\Trbv13-2tm1(CD2)Zhu/\Trbv13-2tm1(CD2)Zhu
(involves: 129 * C57BL/6 * SJL)
abnormal T cell differentiation J:121608
\Trbv14tm1Che/\Trbv14tm1Che
(involves: 129S4/SvJae)
decreased T cell number J:92288
\Trbv14tm2Che/\Trbv14tm2Che
(involves: 129S4/SvJae)
decreased T cell number J:92288
\Trbv15tm1Krg/\Trbv15tm1Krg
(involves: 129S/SvEv * C57BL/6)
immune system phenotype J:95669
\Trdmt1Gt(OST19279)Lex/\Trdmt1Gt(OST19279)Lex
(involves: 129S5/SvEvBrd * C57BL/6J)
decreased NK cell number J:103485
\Trehem1(IMPC)H/\Trehem1(IMPC)H
(C57BL/6N-Trehem1(IMPC)H/H)
increased eosinophil cell number J:211773
\Trem1tm1(KOMP)Vlcg/\Trem1tm1(KOMP)Vlcg
(C57BL/6N-Trem1tm1(KOMP)Vlcg/Wtsi)
increased anti-nuclear antigen antibody level J:211773
\Trem1tm1.1Ahoru/\Trem1tm1.1Ahoru
(C57BL/6-Trem1tm1.1Ahoru)
decreased monocyte cell number J:191035
decreased neutrophil cell number J:191035
\Trem2em2Bwef/\Trem2+
(involves: C57BL/6J * DBA/2J * FVB/N)
decreased macrophage cell number J:242126
\Trem2em2Bwef/\Trem2em2Bwef
(involves: C57BL/6J * DBA/2J * FVB/N)
decreased macrophage cell number J:242126
decreased macrophage proliferation J:242126
decreased microglial cell activation J:242126
impaired macrophage phagocytosis J:242126
increased circulating interleukin-6 level J:242126
increased circulating tumor necrosis factor level J:242126
increased macrophage apoptosis J:242126
increased susceptibility to endotoxin shock J:242126
\Trem2tm1(KOMP)Vlcg/\Trem2tm1(KOMP)Vlcg
(C57BL/6N-Trem2tm1(KOMP)Vlcg)
abnormal microglial cell physiology J:239381
decreased microglial cell activation J:239381
\Trem2tm1Cln/\Trem2tm1Cln
(B6.129P2-Trem2tm1Cln)
abnormal interferon level J:138057
abnormal interleukin level J:138057
abnormal tumor necrosis factor level J:138057
\Treml1tm1Mcvic/\Treml1tm1Mcvic
(C57BL/6-Treml1tm1Mcvic)
increased susceptibility to endotoxin shock J:150578
increased tumor necrosis factor secretion J:150578
\Treml4tm1Ji/\Treml4tm1Ji
(B6(Cg)-Treml4tm1Ji)
immune system phenotype J:180744
\Trex1em1(IMPC)Ccpcz/\Trex1+
(C57BL/6NCrl-Trex1em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
enlarged spleen J:211773
\Trex1em1(IMPC)Ccpcz/\Trex1em1(IMPC)Ccpcz
(C57BL/6NCrl-Trex1em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
decreased lymphocyte cell number J:211773
decreased NK cell number J:211773
enlarged spleen J:211773
enlarged thymus J:211773
increased effector memory T-helper cell number J:211773
increased monocyte cell number J:211773
increased neutrophil cell number J:211773
increased spleen weight J:211773
\Trex1em3Gpt/\Trex1em3Gpt
(C57BL/6JGpt-Trex1em3Gpt)
enlarged spleen J:330879
increased circulating tumor necrosis factor level J:330879
increased spleen weight J:330879
increased susceptibility to autoimmune disorder J:330879
\Trex1tm1.1Fwpe/\Trex1+
(involves: 129S1/SvImJ * 129S4/SvJae * 129S6/SvEvTac)
increased CD4-positive, alpha-beta T cell number J:220965
\Trex1tm1.1Fwpe/\Trex1tm1.1Fwpe
(involves: 129S1/SvImJ * 129S4/SvJae * 129S6/SvEvTac)
abnormal immune system organ morphology J:220965
abnormal T cell activation J:220965
bronchiolitis J:220965
enlarged lymph nodes J:220965
enlarged spleen J:220965
glomerulonephritis J:220965
heart inflammation J:220965
increased anti-double stranded DNA antibody level J:220965
increased B cell number J:220965
increased CD4-positive, alpha-beta T cell number J:220965
increased IgG level J:220965
increased inflammatory response J:220965
increased plasma cell number J:220965
increased regulatory T cell number J:220965
increased spleen weight J:220965
increased splenocyte number J:220965
increased susceptibility to systemic lupus erythematosus J:220965
lacrimal gland inflammation J:220965
lymphoid hyperplasia J:220965
pancreas inflammation J:220965
salivary gland inflammation J:220965
tubulointerstitial nephritis J:220965
\Trex1tm1Tld/\Trex1tm1Tld
(involves: 129P2/OlaHsd)
abnormal interferon secretion J:234263
abnormal spleen marginal zone morphology J:92264
enlarged lymph nodes J:92264
enlarged spleen J:92264
heart inflammation J:202757
increased autoantibody level J:202757
increased spleen B cell follicle size J:92264
myocarditis J:92264
skin inflammation J:202757
thymus cortex hypoplasia J:92264
\Trex1tm1Tld/\Trex1tm1Tld
(involves: 129P2/OlaHsd * C57BL/6)
dermatitis J:181257
folliculitis J:181257
glomerulonephritis J:181257
immune system phenotype J:181257
increased anti-nuclear antigen antibody level J:181257
increased IgG level J:181257
increased inflammatory response J:181257
increased susceptibility to systemic lupus erythematosus J:181257
kidney inflammation J:181257
myocarditis J:181257
myositis J:181257
skin inflammation J:181257
stomach inflammation J:181257
\Trex1tm1Tld/\Trex1tm1Tld
(involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6N)
heart inflammation J:234263
increased autoantibody level J:234263
increased inflammatory response J:234263
kidney inflammation J:234263
myositis J:234263
stomach inflammation J:234263
\Trex1tm1Tld/\Trex1tm1Tld
(involves: 129P2/OlaHsd * C57BL/6J)
dermatitis J:243357
increased susceptibility to autoimmune disorder J:243357
\Trfem1(IMPC)Rbrc/\Trf+
(C57BL/6NJcl-Trfem1(IMPC)Rbrc/Rbrc)
increased large unstained cell number J:211773
\Trgc1tm1.2Dhr/\Trgc1tm1.2Dhr
(either: 129S4/SvJae or (involves: 129S4/SvJae * C57BL/6))
decreased gamma-delta T cell number J:91304
\Tria4STS/A/?
(involves: BALB/c * STS/A)
abnormal leukocyte physiology J:56029
\Tria5STS/A/?
(involves: BALB/cHeA * STS/A)
abnormal leukocyte physiology J:56029
\Trib1tm1Aki/\Trib1tm1Aki
(involves: 129P2/OlaHsd)
abnormal spleen red pulp morphology J:196449
decreased eosinophil cell number J:196449
decreased interleukin-12 secretion J:126085
decreased macrophage cell number J:196449
decreased spleen iron level J:196449
increased neutrophil cell number J:196449
\Trib2Tg(Thy1-Trh/APP*)2.1Ingm/\Trib2+
\Tg(Thy1-APP*)2.2Ingm/0

(involves: C57BL/6 * DBA/1)
microgliosis J:176575
\Trib2Tg(Thy1-Trh/APP*)2.1Ingm/\Trib2Tg(Thy1-Trh/APP*)2.1Ingm
(involves: C57BL/6 * DBA/1)
microgliosis J:176575
\Trib2tm1Lex/\Trib2tm1Lex
(involves: 129S5/SvEvBrd * C57BL/6J)
decreased B cell number J:82809
increased CD8-positive, alpha-beta T cell number J:82809
\Trib3tm1Tord/\Trib3tm1Tord
(involves: C57BL/6)
abnormal mast cell physiology J:192615
decreased mast cell degranulation J:192615
\Triltm1.1Kaf/\Triltm1.1Kaf
(involves: C57BL/6)
abnormal chemokine secretion J:301765
abnormal cytokine secretion J:301765
decreased interferon-beta secretion J:301765
decreased interleukin-6 secretion J:301765
decreased tumor necrosis factor secretion J:301765
\Trim6em1Raj/\Trim6em1Raj
(C57BL/6J-Trim6em1Raj)
abnormal response to infection J:326927
\Trim7em1Jiew/\Trim7em1Jiew
(C57BL/6-Trim7em1Jiew)
decreased susceptibility to Herpesvirales infection J:292408
decreased susceptibility to viral infection J:292408
\Trim8tm1Hbsh/\Trim8tm1Hbsh
(involves: 129S6/SvEvTac)
abnormal chemokine secretion J:251270
abnormal circulating chemokine level J:251270
decreased interleukin-6 secretion J:251270
decreased tumor necrosis factor secretion J:251270
immune system phenotype J:251270
increased circulating interleukin-6 level J:251270
increased circulating tumor necrosis factor level J:251270
increased interferon-beta secretion J:251270
increased interleukin-6 secretion J:251270
increased macrophage cytokine production J:251270
increased susceptibility to bacterial infection J:251270
increased susceptibility to bacterial infection induced morbidity/mortality J:251270
increased susceptibility to endotoxin shock J:251270
increased tumor necrosis factor secretion J:251270
\Trim9em1(IMPC)Ccpcz/\Trim9em1(IMPC)Ccpcz
(C57BL/6N-Trim9em1(IMPC)Ccpcz/Ccpcz)
decreased effector memory T-helper cell number J:211773
decreased spleen weight J:211773
\Trim13em1(IMPC)Tcp/\Trim13em1(IMPC)Tcp
(C57BL/6N-Trim13em1(IMPC)Tcp/Tcp)
enlarged thymus J:211773
\Trim13tm1.1Jskg/\Trim13tm1.1Jskg
(B6.129S7(Cg)-Trim13tm1.1Jskg)
abnormal circulating interferon level J:243916
decreased circulating interferon-beta level J:243916
decreased susceptibility to Picornaviridae infection induced morbidity/mortality J:243916
increased interferon-beta secretion J:243916
\Trim14em1Rfw/\Trim14em1Rfw
(involves: C57BL/6J)
decreased interferon-beta secretion J:249057
increased susceptibility to Herpesvirales infection J:249057
increased susceptibility to Herpesvirales infection induced morbidity/mortality J:249057
\Trim21tm1Mwah/\Trim21+
(C57BL/6-Trim21tm1Mwah)
dermatitis J:151775
\Trim21tm1Mwah/\Trim21tm1Mwah
(C57BL/6-Trim21tm1Mwah)
abnormal interleukin level J:151775
abnormal T cell activation J:151775
abnormal tumor necrosis factor level J:151775
autoimmune response J:151775
dermatitis J:151775
enlarged lymph nodes J:151775
enlarged spleen J:151775
increased autoantibody level J:151775
increased inflammatory response J:151775
\Trim25tm1Mura/\Trim25+
\Usp15L749R/\Usp15+

(involves: 129S1/SvImJ * 129S4/SvJae * C57BL/6J)
decreased susceptibility to experimental autoimmune encephalomyelitis J:259382
decreased susceptibility to parasitic infection induced morbidity/mortality J:259382
\Trim25tm1Mura/\Trim25tm1Mura
(involves: 129S4/SvJae)
decreased susceptibility to parasitic infection J:259382
decreased susceptibility to parasitic infection induced morbidity/mortality J:259382
\Trim27Gt(345D11)Cmhd/\Trim27Gt(345D11)Cmhd
(B6.129-Trim27Gt(345D11)Cmhd)
abnormal T-helper 1 physiology J:180433
abnormal T-helper 2 physiology J:180433
immune system phenotype J:180433
increased interferon-gamma secretion J:180433
increased tumor necrosis factor secretion J:180433
\Trim29tm1a(EUCOMM)Wtsi/\Trim29tm1a(EUCOMM)Wtsi
(involves: C57BL/6N * C57BL/6NTac)
abnormal interferon secretion J:349246
abnormal tumor necrosis factor level J:349246
decreased interleukin level J:349246
decreased susceptibility to Picornaviridae infection J:349246
decreased susceptibility to Picornaviridae infection induced morbidity/mortality J:349246
increased interferon level J:349246
increased interferon-alpha secretion J:349246
increased interferon-beta secretion J:349246
\Trim29tm1c(EUCOMM)Wtsi/\Trim29tm1c(EUCOMM)Wtsi
\Tg(Myh6-cre)2182Mds/0

(involves: C57BL/6J * C57BL/6N * C57BL/6NTac)
abnormal tumor necrosis factor level J:349246
decreased inflammatory response J:349246
decreased interleukin level J:349246
decreased susceptibility to Picornaviridae infection J:349246
decreased susceptibility to Picornaviridae infection induced morbidity/mortality J:349246
increased interferon level J:349246
increased interferon-gamma secretion J:349246
increased T cell proliferation J:349246
\Trim30atm1Yjk/\Trim30atm1Yjk
(B6.129P2-Trim30atm1Yjk)
abnormal CD4-positive, alpha-beta T cell physiology J:215171
abnormal T cell subpopulation ratio J:215171
increased CD4-positive, alpha-beta T cell number J:215171
increased T cell proliferation J:215171
\Trim31em1Cya/\Trim31em1Cya
(involves: C57BL/6)
abnormal circulating cytokine level J:243237
decreased susceptibility to induced colitis J:243237
increased circulating interleukin-1 beta level J:243237
increased Ly6C high monocyte number J:243237
increased neutrophil cell number J:243237
\Trim33em1(IMPC)Tcp/\Trim33+
(C57BL/6N-Trim33em1(IMPC)Tcp/Tcp)
enlarged lymph nodes J:211773
\Trim33tm1Los/\Trim33tm1Los
\Tg(Cd4-cre)1Cwi/0

(involves: 129S2/SvPas * C57BL/6 * DBA/2)
immune system phenotype J:149449
\Trim35em1Smoc/\Trim35em1Smoc
(C57BL/6J-Trim35em1Smoc)
decreased circulating interferon-beta level J:303214
decreased macrophage cytokine production J:303214
increased susceptibility to Orthomyxoviridae infection J:303214
increased susceptibility to Orthomyxoviridae infection induced morbidity/mortality J:303214
\Trim37Gt(RRO307)Byg/\Trim37Gt(RRO307)Byg
(B6J.129P2-Trim37Gt(RRO307)Byg)
enlarged spleen J:232482
\Trim38tm1(KOMP)Vlcg/\Trim38tm1(KOMP)Vlcg
(involves: C57BL/6N)
increased circulating interferon-alpha level J:239773
increased circulating interferon-beta level J:239773
increased circulating interleukin-6 level J:239773
increased circulating tumor necrosis factor level J:239773
increased susceptibility to bacterial infection J:239773
increased susceptibility to bacterial infection induced morbidity/mortality J:239773
increased susceptibility to infection induced morbidity/mortality J:239773
\Trim39tm1b(EUCOMM)Hmgu/\Trim39tm1b(EUCOMM)Hmgu
(C57BL/6N-Trim39tm1b(EUCOMM)Hmgu/H)
decreased monocyte cell number J:211773
increased lymphocyte cell number J:211773
\Trim40em1Caox/\Trim40em1Caox
(involves: C57BL/6J)
abnormal immune system physiology J:255265
abnormal macrophage physiology J:255265
decreased susceptibility to Riboviria infection induced morbidity/mortality J:255265
\Trim41tm1Caox/\Trim41tm1Caox
(B6.Cg-Trim41tm1Caox)
abnormal innate immunity J:340065
abnormal tumor necrosis factor level J:340065
decreased circulating interferon-beta level J:340065
decreased circulating interleukin-6 level J:340065
decreased interferon level J:340065
decreased interleukin level J:340065
increased susceptibility to bacterial infection J:340065
increased susceptibility to bacterial infection induced morbidity/mortality J:340065
increased susceptibility to Herpesvirales infection J:340065
increased susceptibility to Herpesvirales infection induced morbidity/mortality J:340065
increased susceptibility to Riboviria infection J:340065
increased susceptibility to Riboviria infection induced morbidity/mortality J:340065
\Trim45tm1a(KOMP)Wtsi/\Trim45tm1a(KOMP)Wtsi
(B6Brd;B6Dnk;B6N-Trim45tm1a(KOMP)Wtsi Tyrc-Brd/Wtsi)
blood in lymph vessels J:239583
\Trim46em1(IMPC)J/\Trim46em1(IMPC)J
(C57BL/6NJ-Trim46em1(IMPC)J/Mmjax)
increased leukocyte cell number J:211773
\Trim50tm1b(KOMP)Wtsi/\Trim50tm1b(KOMP)Wtsi
(C57BL/6N-Trim50tm1b(KOMP)Wtsi/BayMmucd)
decreased spleen weight J:211773
\Trim55tm1Slbt/\Trim55tm1Slbt
(involves: 129 * C57BL/6)
decreased susceptibility to Coronaviridae infection J:268979
\Trim56tm1a(EUCOMM)Wtsi/\Trim56tm1a(EUCOMM)Wtsi
(C57BL/6N-Trim56tm1a(EUCOMM)Wtsi/Wtsi)
decreased regulatory T cell number J:211773
\Trim58em1(IMPC)Mbp/\Trim58em1(IMPC)Mbp
(C57BL/6N-Trim58em1(IMPC)Mbp/MbpMmucd)
abnormal lymph node morphology J:211773
abnormal spleen morphology J:211773
enlarged lymph nodes J:211773
\Trim58tm2313.1Arte/\Trim58tm2313.1Arte
\Lyz2tm1(cre)Ifo/\Lyz2+

(involves: 129P2/OlaHsd * C57BL/6N)
increased susceptibility to induced colitis J:279270
\Trim58tm2313.2Arte/\Trim58tm2313.2Arte
(involves: BALB/cJ * C57BL/6N)
increased susceptibility to induced colitis J:279270
\Trim65em1Cya/\Trim65em1Cya
(involves: C57BL/6)
decreased circulating interferon-alpha level J:240099
decreased circulating interferon-beta level J:240099
decreased interferon-alpha secretion J:240099
decreased interferon-beta secretion J:240099
increased susceptibility to Picornaviridae infection J:240099
increased susceptibility to Picornaviridae infection induced morbidity/mortality J:240099
\Trim65em2Cya/\Trim65em2Cya
(involves: C57BL/6)
decreased interferon-beta secretion J:240099
\Trim65em3Cya/\Trim65em3Cya
(involves: C57BL/6)
decreased interferon-beta secretion J:240099
\Trioem1(IMPC)H/\Trio+
(C57BL/6NTac-Trioem1(IMPC)H/H)
increased neutrophil cell number J:211773
\Trip6tm1b(EUCOMM)Hmgu/\Trip6+
(C57BL/6N-Trip6tm1b(EUCOMM)Hmgu/Bay)
enlarged spleen J:211773
\Trip10tm1.1Geha/\Trip10tm1.1Geha
(B6.129S1-Trip10tm1.1Geha)
abnormal spleen germinal center morphology J:164363
abnormal T cell physiology J:164363
decreased IgE level J:164363
decreased IgG level J:164363
decreased spleen germinal center number J:164363
decreased spleen germinal center size J:164363
decreased susceptibility to type IV hypersensitivity reaction J:164363
\Trip13tm1.1(KOMP)Vlcg/\Trip13tm1.1(KOMP)Vlcg
(C57BL/6N-Trip13tm1.1(KOMP)Vlcg/Ucd)
increased leukocyte cell number J:211773
\Trmq1C57BL/6J/\Trmq1DBA/2J
(involves: C57BL/6J * DBA/2J)
abnormal CD4-positive, alpha beta T cell morphology J:77603
\Trmq1DBA/2J/\Trmq1DBA/2J
(involves: C57BL/6J * DBA/2J)
abnormal CD4-positive, alpha beta T cell morphology J:77603
\Trmq2C57BL/6J/\Trmq2C57BL/6J
(involves: C57BL/6J * DBA/2J)
abnormal CD4-positive, alpha beta T cell morphology J:77603
\Trmq2C57BL/6J/\Trmq2DBA/2J
(involves: C57BL/6J * DBA/2J)
abnormal CD4-positive, alpha beta T cell morphology J:77603
\Trmq3DBA/1J/\Trmq3FVB/N
(involves: DBA/1J * FVB/N)
abnormal CD4-positive, alpha beta T cell morphology J:116665
\Trmq3FVB/N/?
(involves: DBA/1J * FVB/N)
abnormal CD4-positive, alpha beta T cell morphology J:94347
abnormal T cell proliferation J:94347
\Trmq3FVB/N/\Trmq3FVB/N
(involves: DBA/1J * FVB/N)
abnormal CD4-positive, alpha beta T cell morphology J:116665
\Trmq4RIIIS/J/\Trmq4RIIIS/J
\Trmq5RIIIS/J/\Trmq5RIIIS/J

(involves: B10.RIII * RIIIS/J)
abnormal CD4-positive, alpha beta T cell morphology J:95848
\Trmt2atm2b(EUCOMM)Wtsi/\Trmt2atm2b(EUCOMM)Wtsi
(C57BL/6N-Trmt2atm2b(EUCOMM)Wtsi/Wtsi)
decreased leukocyte cell number J:211773
\Trp53Bbl/\Trp53+
(C57BL/6JSfdAnu-Trp53Bbl/Anu)
increased T cell derived lymphoma incidence J:104190
\Trp53bhy/\Trp53+
(C57BL/6JSfdAnu-Trp53bhy/Anu)
increased T cell derived lymphoma incidence J:104190
\Trp53tm1.1Awbr/\Trp53tm1.1Awbr
(involves: C57BL/6)
decreased thymocyte apoptosis J:173271
increased pro-B cell number J:169434
increased T cell derived lymphoma incidence J:173271
\Trp53tm1.1Manf/\Trp53tm1.1Manf
(Not Specified)
abnormal abdominal lymph node morphology J:201153
abnormal spleen morphology J:201153
abnormal spleen white pulp morphology J:201153
abnormal thymus morphology J:201153
decreased neutrophil cell number J:201153
small spleen J:201153
small thymus J:201153
\Trp53tm1.1Manf/\Trp53tm1.1Manf
(involves: C57BL/6J)
abnormal abdominal lymph node morphology J:201153
abnormal spleen morphology J:201153
abnormal spleen white pulp morphology J:201153
abnormal thymus morphology J:201153
decreased neutrophil cell number J:201153
small spleen J:201153
small thymus J:201153
\Trp53tm1.1Thst/\Trp53+
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ)
spleen hyperplasia J:198482
\Trp53tm1.1Thst/\Trp53tm1.1Thst
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ)
decreased thymocyte apoptosis J:198482
immune system phenotype J:198482
increased T cell derived lymphoma incidence J:198482
spleen hyperplasia J:198482
\Trp53tm1.1Tldo/\Trp53tm1.1Tldo
(involves: 129S2/SvPas * BALB/c * C57BL/6)
increased thymocyte apoptosis J:199308
\Trp53tm1.1Umol/\Trp53tm1.1Umol
(involves: 129S6/SvEvTac * C57BL/6 * C57BL/6NTac)
increased T cell derived lymphoma incidence J:228632
\Trp53tm1.1Wgu/\Trp53tm1.1Wgu
(involves: 129S6/SvEvTac * C57BL/6)
decreased thymocyte apoptosis J:186159
\Trp53tm1.2Awbr/\Trp53+
(involves: C57BL/6)
abnormal lymphocyte morphology J:173271
abnormal Peyer's patch morphology J:173271
increased inflammatory response J:173271
liver inflammation J:173271
\Trp53tm1.2Awbr/\Trp53tm1.2Awbr
(involves: C57BL/6)
abnormal lymphocyte morphology J:173271
abnormal Peyer's patch morphology J:173271
adipose tissue inflammation J:173271
decreased thymocyte apoptosis J:173271
enlarged spleen J:173271
increased circulating interferon-gamma level J:173271
increased circulating interleukin-3 level J:173271
increased circulating interleukin-5 level J:173271
increased circulating interleukin-6 level J:173271
increased circulating tumor necrosis factor level J:173271
increased inflammatory response J:173271
increased splenocyte proliferation J:173271
increased T cell derived lymphoma incidence J:173271
liver inflammation J:173271
lung inflammation J:173271
\Trp53tm1Brd/\Trp53tm1Brd
(involves: 129S7/SvEvBrd)
abnormal thymus physiology J:175018
decreased thymocyte apoptosis J:186159
\Trp53tm1Brd/\Trp53tm1Brd
(involves: 129S7/SvEvBrd * C57BL/6)
increased T cell derived lymphoma incidence J:126497
\Trp53tm1Brd/\Trp53tm1Brd
\Tg(Lck-cre)1Cwi/0

(involves: 129S7/SvEvBrd)
increased T cell derived lymphoma incidence J:157041
\Trp53tm1Brd/\Trp53tm1Brd
\Tg(Nes-cre)1Kln/0

(involves: 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6 * SJL)
increased T cell derived lymphoma incidence J:109585
\Trp53tm1Brd/\Trp53tm1Brd
\Trp73tm2Mak/\Trp73tm2Mak

(involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6J)
decreased thymocyte apoptosis J:157905
\Trp53tm1Brd/\Trp53tm1Ldo
(involves: 129S7/SvEvBrd * C57BL/6)
increased T cell derived lymphoma incidence J:73757
\Trp53tm1Brd/\Trp53tm8Xu
(involves: 129S7/SvEvBrd)
decreased leukocyte cell number J:170216
\Trp53tm1Gev/\Trp53tm1Gev
(involves: 129P2/OlaHsd * C57BL/6)
increased T cell derived lymphoma incidence J:99305
\Trp53tm1Glo/\Trp53tm1Glo
(involves: 129S7/SvEvBrd * C57BL/6)
increased T cell derived lymphoma incidence J:61683
\Trp53tm1Glo/\Trp53tm1Glo
(involves: 129S7/SvEvBrd * C57BL/6J)
decreased thymocyte apoptosis J:172038
\Trp53tm1Glo/\Trp53tm4Glo
(involves: 129S7/SvEvBrd * C57BL/6)
increased T cell derived lymphoma incidence J:171821
\Trp53tm1Holl/\Trp53tm7.1Xu
(involves: 129P2/OlaHsd)
decreased thymocyte apoptosis J:160414
\Trp53tm1Ldo/\Trp53+
(involves: 129S7/SvEvBrd * C57BL/6)
decreased spleen weight J:73757
spleen hypoplasia J:73757
\Trp53tm1Sia/\Trp53tm1Sia
(involves: C57BL/6 * CBA)
increased T cell derived lymphoma incidence J:36762
\Trp53tm1Sia/\Trp53tm1Sia
(involves: C57BL/6NCrlj * CBA/JNCrlj)
increased leukocyte cell number J:233347
increased spleen weight J:233347
increased T cell derived lymphoma incidence J:233347
increased thymus weight J:233347
\Trp53tm1Thst/\Trp53+
(involves: 129S1/Sv * 129X1/SvJ)
spleen hyperplasia J:198482
\Trp53tm1Thst/\Trp53tm1.1Thst
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ)
spleen hyperplasia J:198482
\Trp53tm1Thst/\Trp53tm1Thst
(involves: 129S1/Sv * 129X1/SvJ)
decreased thymocyte apoptosis J:198482
increased T cell derived lymphoma incidence J:198482
\Trp53tm1Tyj/\Trp53+
(involves: 129S2/SvPas)
decreased thymocyte apoptosis J:158953
\Trp53tm1Tyj/\Trp53+
(involves: 129S2/SvPas * C57BL/6 * CBA)
decreased thymocyte apoptosis J:80311
\Trp53tm1Tyj/\Trp53+
\Trp63tm1Fmc/\Trp63+

(involves: 129S2/SvPas * 129S4/SvJae * C57BL/6)
increased T cell derived lymphoma incidence J:98958
\Trp53tm1Tyj/\Trp53+
\Trp73tm1Fmc/\Trp73+

(involves: 129S2/SvPas * 129S4/SvJae * C57BL/6)
increased T cell derived lymphoma incidence J:98958
\Trp53tm1Tyj/\Trp53+
\Xrcc2tm1Pmc/\Xrcc2tm1Pmc

(involves: 129S1/Sv * 129S2/SvPas * C57BL/6)
increased T cell derived lymphoma incidence J:111068
\Trp53tm1Tyj/\Trp53tm1.1Umol
(involves: 129S2/SvPas * 129S6/SvEvTac * C57BL/6 * C57BL/6NTac)
increased T cell derived lymphoma incidence J:228632
\Trp53tm1Tyj/\Trp53tm1Tyj
(involves: 129S2/SvPas * C57BL/6)
increased T cell derived lymphoma incidence J:87501, J:17728
\Trp53tm1Tyj/\Trp53tm1Tyj
(involves: 129S2/SvPas)
decreased splenocyte apoptosis J:195018
decreased T cell apoptosis J:109354
decreased thymocyte apoptosis J:158953, J:195018, J:126920
increased T cell derived lymphoma incidence J:251434, J:221224, J:88120, J:95316
\Trp53tm1Tyj/\Trp53tm1Tyj
(involves: 129S2/SvPas * C57BL/6 * CBA)
decreased thymocyte apoptosis J:80311
\Trp53tm1Tyj/\Trp53tm1Tyj
\Commd10Tg(Vav1-icre)A2Kio/\Commd10+

(involves: 129S2/SvPas * C57BL/6N * C57BL/10 * CBA/Ca)
abnormal interleukin secretion J:305794
\Trp53tm1Tyj/\Trp53tm1Tyj
\Riok2tm1c(KOMP)Wtsi/\Riok2+
\Commd10Tg(Vav1-icre)A2Kio/\Commd10+

(involves: 129S2/SvPas * C57BL/6N * C57BL/10 * CBA/Ca)
immune system phenotype J:305794
\Trp53tm1Tyj/\Trp53tm1Tyj
\Xrcc2tm1Pmc/\Xrcc2tm1Pmc

(involves: 129S1/Sv * 129S2/SvPas * C57BL/6)
increased T cell derived lymphoma incidence J:111068
\Trp53tm1Tyj/\Trp53tm1Tyj
\Xrcc4tm1Fwa/\Xrcc4tm1Fwa

(involves: 129P2/OlaHsd * 129S2/SvPas)
abnormal lymphopoiesis J:61973
\Trp53tm1Tyj/\Trp53tm2.1Tyj
(involves: 129S2/SvPas * 129S4/SvJae)
increased T cell derived lymphoma incidence J:95316
\Trp53tm1Tyj/\Trp53tm2.1Umol
(involves: 129S2/SvPas * 129S6/SvEvTac * C57BL/6 * C57BL/6NTac)
increased T cell derived lymphoma incidence J:228632
\Trp53tm1Tyj/\Trp53tm3.1Tyj
(involves: 129S2/SvPas * 129S4/SvJae)
increased T cell derived lymphoma incidence J:95316
\Trp53tm1Xu/\Trp53tm1Xu
(involves: 129S4/SvJae)
abnormal thymocyte apoptosis J:86185
\Trp53tm1Yjc/\Trp53tm1Yjc
(B6.129S1-Trp53tm1Yjc)
abnormal spleen marginal zone morphology J:195018
abnormal spleen white pulp morphology J:195018
decreased splenocyte apoptosis J:195018
enlarged spleen J:195018
immune system phenotype J:195018
\Trp53tm2.1Snj/\Trp53tm2.1Snj
(involves: 129S4/SvJae * C57BL/6)
abnormal thymus physiology J:175018
\Trp53tm2.1Thst/\Trp53tm2.1Thst
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ)
increased T cell derived lymphoma incidence J:282255
\Trp53tm2.1Umol/\Trp53tm2.1Umol
(involves: 129S6/SvEvTac * C57BL/6 * C57BL/6NTac)
increased T cell derived lymphoma incidence J:228632
\Trp53tm2.1Wgu/\Trp53tm2.1Wgu
(involves: 129S6/SvEvTac * C57BL/6)
decreased thymocyte apoptosis J:186159
\Trp53tm2Thst/\Trp53tm2.1Thst
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ)
increased T cell derived lymphoma incidence J:282255
\Trp53tm2Wahl/\Trp53tm2Wahl
(involves: 129S4/SvJae * C57BL/6)
decreased leukocyte cell number J:174375
decreased spleen red pulp amount J:174375
\Trp53tm2Xu/\Trp53tm2Xu
(involves: 129S6/SvEvTac)
decreased T cell apoptosis J:109354
decreased T cell proliferation J:109354
\Trp53tm3.1Glo/\Trp53+
(B6.129S7-Trp53tm3.1Glo)
hepatosplenomegaly J:317504
increased leukocyte cell number J:317504
increased T cell derived lymphoma incidence J:317504
\Trp53tm3.1Holl/\Trp53tm3.1Holl
(Not Specified)
increased thymocyte apoptosis J:191183
\Trp53tm4Glo/\Trp53tm4Glo
(involves: 129S7/SvEvBrd * C57BL/6)
increased T cell derived lymphoma incidence J:171821
\Trp53tm4Xu/\Trp53tm4Xu
(Not Specified)
increased T cell derived lymphoma incidence J:126497
\Trp53tm6Xu/\Trp53tm6Xu
\Tg(Lck-cre)1Cwi/0

(involves: 129S4/SvJae)
increased T cell derived lymphoma incidence J:157041
\Trp53tm7.1Xu/\Trp53+
(Not Specified)
abnormal thymus physiology J:160414
\Trp53tm7.1Xu/\Trp53tm7.1Xu
(Not Specified)
abnormal thymus physiology J:160414
decreased thymocyte apoptosis J:160414
\Trp53bp1Gt(OST94324)Lex/\Trp53bp1Gt(OST94324)Lex
(involves: 129S5/SvEvBrd)
abnormal T cell differentiation J:83164
decreased mature B cell number J:83164
decreased T cell number J:83164
small thymus J:83164
thymus hypoplasia J:83164
\Trp53bp1m2Btlr/\Trp53bp1m2Btlr
(C57BL/6J-Trp53bp1m2Btlr)
decreased B cell number J:254841
decreased CD8-positive, naive alpha-beta T cell number J:254841
decreased IgD level J:254841
decreased IgG level J:254841
impaired humoral immune response J:254841
increased central memory CD4-positive, alpha-beta T cell number J:254841
\Trp53bp1m3Btlr/\Trp53bp1m3Btlr
(C57BL/6J-Trp53bp1m3Btlr)
decreased IgD level J:254848
\Trp53bp1m4Btlr/\Trp53bp1m4Btlr
(C57BL/6J-Trp53bp1m4Btlr)
decreased IgD level J:254852
\Trp53bp1m5Btlr/\Trp53bp1m5Btlr
(C57BL/6J-Trp53bp1m5Btlr)
decreased IgD level J:272848
\Trp53bp1tm1Jc/\Trp53bp1tm1Jc
(involves: 129 * C57BL/6)
decreased CD4-positive, alpha-beta T cell number J:82512
increased double-negative T cell number J:82512
increased T cell derived lymphoma incidence J:82512
thymus hypoplasia J:82512
\Trp53bp1tm1Jc/\Trp53bp1tm1Jc
(involves: 129)
abnormal class switch recombination J:194603, J:231089, J:307190
\Trp53bp2tm1Cdlo/\Trp53bp2+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
abnormal T cell physiology J:146764
\Trp53bp2tm1Cdlo/\Trp53bp2+
\Tg(EmuSR-tTa)83Bop/0
\Tg(tetO-MYC)36aBop/0

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * FVB/N)
increased T cell derived lymphoma incidence J:146764
\Trp53bp2tm1Xlu/\Trp53bp2+
(involves: 129S6/SvEvTac * C57BL/6J)
increased T cell derived lymphoma incidence J:108701
\Trp53bp2tm1Xlu/\Trp53bp2tm1Xlu
(C.129S6-Trp53bp2tm1Xlu)
small thymus J:240594
\Trp53inp1tm1Acar/\Trp53inp1tm1Acar
(involves: 129/Sv * C57BL/6)
increased susceptibility to induced colitis J:118867
large intestinal inflammation J:118867
\Trp53inp2em1(IMPC)Mbp/\Trp53inp2em1(IMPC)Mbp
(C57BL/6N-Trp53inp2em1(IMPC)Mbp/MbpMmucd)
abnormal lymph node morphology J:211773
enlarged lymph nodes J:211773
\Trp63tm1Fmc/\Trp63+
\Trp73tm1Fmc/\Trp73+

(involves: 129S4/SvJae * C57BL/6)
increased T cell derived lymphoma incidence J:98958
\Trp63tm2Brd/\Trp63+
(involves: 129S7/SvEvBrd)
enlarged lymph nodes J:100483
increased susceptibility to infection J:100483
kidney inflammation J:100483
uterine cervix inflammation J:100483
\Trp73em1(IMPC)H/\Trp73+
(C57BL/6NTac-Trp73em1(IMPC)H/H)
decreased spleen weight J:211773
\Trp73tm1Fmc/\Trp73+
(involves: 129S4/SvJae * C57BL/6)
increased T cell derived lymphoma incidence J:98958
\Trp73tm1Fmc/\Trp73tm1Fmc
(involves: 129S4/SvJae)
chronic inflammation J:60896
conjunctivitis J:60896
increased susceptibility to bacterial infection J:60896
increased susceptibility to otitis media J:60896
rhinitis J:60896
sinus inflammation J:60896
\Trp73tm1Mak/\Trp73+
(involves: 129P2/OlaHsd * C57BL/6J)
increased T cell derived lymphoma incidence J:142848
\Trp73tm1Mak/\Trp73tm1Mak
(involves: 129P2/OlaHsd * C57BL/6J)
increased T cell derived lymphoma incidence J:142848
\Trp73tm2Mak/\Trp73tm2Mak
(either: B6.129P2-Trp73tm2Mak or (involves: 129P2/OlaHsd * C57BL/6J))
increased thymocyte apoptosis J:157905
\Trpa1tm1Jul/\Trpa1+
(involves: 129P2/OlaHsd * C57BL/6)
abnormal acute inflammation J:115886
\Trpc1em1(IMPC)H/\Trpc1em1(IMPC)H
(C57BL/6N-Trpc1em1(IMPC)H/H)
increased spleen weight J:211773
\Trpc3tm1.2Akon/\Trpc3tm1.2Akon
(involves: 129S/SvEv)
immune system phenotype J:190105
\Trpm2tm1.1Alp/\Trpm2tm1.1Alp
(B6.129P2-Trpm2tm1.1Alp)
decreased circulating interferon-gamma level J:174397
decreased circulating interleukin-12 level J:174397
decreased circulating interleukin-12b level J:174397
decreased interferon-gamma secretion J:174397
decreased interleukin-12 secretion J:174397
increased susceptibility to bacterial infection J:174397
increased susceptibility to bacterial infection induced morbidity/mortality J:174397
\Trpm2tm1Lhj/\Trpm2tm1Lhj
(Not Specified)
abnormal macrophage morphology J:202791
abnormal macrophage physiology J:202791
\Trpm2tm1Yamo/\Trpm2tm1Yamo
(involves: 129S4/SvJae * C57BL/6J)
abnormal interferon level J:137676
abnormal interleukin level J:137676
abnormal leukocyte physiology J:137676
abnormal macrophage physiology J:137676
decreased inflammatory response J:137676
impaired neutrophil recruitment J:137676
\Trpm4tm1.1Knt/\Trpm4tm1.1Knt
(Not Specified)
abnormal dendritic cell physiology J:140991
decreased dendritic cell number J:140991
\Trpm4tm1.1Knt/\Trpm4tm1.1Knt
\Trpm5tm1Csz/\Trpm5tm1Csz

(involves: 129S1/Sv * 129X1/SvJ)
abnormal dendritic cell physiology J:140991
decreased dendritic cell number J:140991
\Trpm4tm1.1Mfre/\Trpm4tm1.1Mfre
(involves: 129S1/Sv * 129X1/SvJ * BALB/cJ)
increased susceptibility to type I hypersensitivity reaction J:118679
\Trpm7tm1Agry/\Trpm7+
(involves: 129)
increased susceptibility to type IV hypersensitivity reaction J:205665
\Trpm7tm1Clph/\Trpm7tm1.1Clph
\Tg(Lck-cre)548Jxm/0

(involves: 129S4/SvJae * C57BL/6 * CBA)
abnormal T cell differentiation J:140630
abnormal T cell physiology J:140630
abnormal thymus cell ratio J:140630
abnormal thymus corticomedullary boundary morphology J:140630
abnormal thymus medulla morphology J:140630
abnormal thymus morphology J:140630
decreased T cell number J:140630
decreased thymocyte number J:140630
\Trps1m1Anu/\Trps1m1Anu
(C57BL/6NCrlAnu-Trps1m1Anu)
immune system phenotype J:104190
\Trpv1tm1Jul/\Trpv1tm1Jul
(involves: 129X1/SvJ * C57BL/6)
decreased susceptibility to endotoxin shock J:104828
\Trpv1tm1Jul/\Trpv1tm1Jul
(B6.129X1-Trpv1tm1Jul)
abnormal chemokine secretion J:154624
increased interleukin-6 secretion J:154624
increased tumor necrosis factor secretion J:154624
kidney inflammation J:154624
\Trpv2tm1Mijc/\Trpv2tm1Mijc
(involves: 129S6/SvEvTac * C57BL/6)
impaired macrophage chemotaxis J:158505
impaired macrophage phagocytosis J:158505
increased susceptibility to bacterial infection J:158505
increased susceptibility to bacterial infection induced morbidity/mortality J:158505
\Trpv3Nh/\Trpv3+
(involves: DS)
dermatitis J:42153
increased susceptibility to bacterial infection J:42153
\Trpv3tm1.2Clph/\Trpv3tm1.2Clph
(involves: 129S4/SvJae * 129S4/SvJaeSor * C57BL/6 * C57BL/6J * CBA)
erythroderma J:164741
\Trpv5Hcalc1/\Trpv5+
(involves: C3H/HeH * C57BL/6J)
kidney inflammation J:196612
\Trpv5Hcalc1/\Trpv5Hcalc1
(involves: C3H/HeH * C57BL/6J)
kidney inflammation J:196612
\Trpv5m1Btlr/\Trpv5m1Btlr
(C57BL/6J-Trpv5m1Btlr)
increased susceptibility to induced colitis J:192586
intestinal inflammation J:192586
\Trpv5tm1Bind/\Trpv5tm1Bind
(involves: 129 * C57BL/6)
increased osteoclast cell number J:86949
\Try10em1(IMPC)J/\Try10em1(IMPC)J
(C57BL/6NJ-Try10em1(IMPC)J/Mmjax)
decreased leukocyte cell number J:211773
\Ts(16C-tel)1Cje/0
(involves: C57BL/6J * Rb(11.16)2H * Rb(16.17)32Lub)
abnormal spleen B cell follicle morphology J:174270
abnormal spleen B cell follicle shape J:241597
abnormal spleen red pulp morphology J:174270
increased spleen B cell follicle size J:241597
\Ts(1716)65Dn/0
(involves: C3H/HeJ * C57BL/6J * DBA/2J)
abnormal spleen B cell follicle morphology J:174270
abnormal spleen B cell follicle shape J:174270
abnormal spleen red pulp morphology J:174270
increased spleen B cell follicle size J:174270
\Tsc1em1(IMPC)Ccpcz/\Tsc1+
(C57BL/6NCrl-Tsc1em1(IMPC)Ccpcz/Ccpcz)
abnormal thymus morphology J:211773
enlarged thymus J:211773
\Tsc22d2em1(IMPC)Tcp/\Tsc22d2em1(IMPC)Tcp
(C57BL/6NCrl-Tsc22d2em1(IMPC)Tcp/Cmmr)
abnormal spleen morphology J:211773
enlarged lymph nodes J:211773
\Tsc22d3tm1.2Efmd/Y
(Not Specified)
abnormal susceptibility to autoimmune disorder J:201728
abnormal T cell subpopulation ratio J:201728
immune system phenotype J:201728
increased interferon-gamma secretion J:201728
increased interleukin-17 secretion J:201728
increased susceptibility to type IV hypersensitivity reaction J:201728
\Tsc22d3tm1.2Hum/Y
(involves: 129S1/SvImJ)
abnormal thymus cell ratio J:223992
decreased DN3 thymocyte number J:223992
decreased thymus weight J:223992
increased DN4 thymocyte number J:223992
\Tshrhyt/\Tshrhyt
(CBy.RF-Tshrhyt/J)
decreased B cell number J:111014
increased pro-B cell number J:111014
\TsilTg(Myc)12ALvn/\TsilTg(Myc)12ALvn
(involves: C57BL/6 * SJL/J)
increased double-positive T cell number J:33857
\Tsiq1BALB/cOla/\Tsiq1BALB/cOla
(involves: BALB/cOla * C57BL/6Ola)
increased interleukin-4 secretion J:99489
\Tsiq1BALB/cOla/\Tsiq1BALB/cOla
\Tsiq2BALB/cOla/\Tsiq2BALB/cOla
\Tsiq3BALB/cOla/\Tsiq3C57BL/6Ola

(involves: BALB/cOla * C57BL/6Ola)
increased interleukin-4 secretion J:99489
\Tsiq2BALB/cOla/\Tsiq2BALB/cOla
(involves: BALB/cOla * C57BL/6Ola)
increased interleukin-4 secretion J:99489
\Tsiq3BALB/cOla/\Tsiq3C57BL/6Ola
(involves: BALB/cOla * C57BL/6Ola)
increased interleukin-4 secretion J:99489
\Tslptm1(KOMP)Vlcg/\Tslptm1(KOMP)Vlcg
(involves: C57BL/6 * C57BL/6NTac)
abnormal immune system physiology J:187770
abnormal immunoglobulin level J:187770
abnormal T-helper 2 cell differentiation J:187770
decreased acute inflammation J:187770
decreased circulating interleukin-4 level J:187770
increased interferon-gamma secretion J:187770
respiratory system inflammation J:187770
\Tslptm1.1Pcn/\Tslptm1.1Pcn
\Tg(KRT14-cre)1Ipc/0

(involves: 129 * C57BL/6 * SJL)
decreased eosinophil cell number J:146511
decreased IgE level J:146511
decreased lymphocyte cell number J:146511
\Tslptm1Mak/\Tslptm1Mak
(B6.Cg-Tslptm1Mak)
colitis J:175844
immune system phenotype J:175844
\Tslptm1Sfz/\Tslptm1Sfz
(C.129(Cg)-Tslptm1Sfz)
immune system phenotype J:199558
\Tslptm1Sfz/\Tslptm1Sfz
(involves: 129)
abnormal interleukin secretion J:197193
abnormal T-helper 2 physiology J:197193
increased interleukin-5 secretion J:197193
increased interleukin-13 secretion J:197193
\TsnGt(OST63223)Lex/\TsnGt(OST63223)Lex
(involves: 129S5/SvEvBrd * C57BL/6J)
immune system phenotype J:85466
\Tspan2tm1Hbw/\Tspan2tm1Hbw
(C57BL/6-Tspan2tm1Hbw)
microgliosis J:201143
\Tspan9em1Tshu/\Tspan9em1Tshu
(C57BL/6-Tspan9em1Tshu)
abnormal macrophage morphology J:307067
abnormal neutrophil morphology J:307067
decreased neutrophil cell number J:307067
\Tspan32em1(IMPC)Mbp/\Tspan32em1(IMPC)Mbp
(C57BL/6N-Tspan32em1(IMPC)Mbp/MbpMmucd)
abnormal spleen morphology J:211773
enlarged spleen J:211773
\Tspan32Gt(pMS-1)1Jmt/\Tspan32Gt(pMS-1)1Jmt
(involves: 129S1/Sv)
increased T cell proliferation J:78033
\Tspan33tm1Stsa/\Tspan33tm1Stsa
(involves: 129S1/Sv * 129X1/SvJ)
abnormal spleen morphology J:143158
abnormal splenic cell ratio J:143158
enlarged spleen J:143158
increased monocyte cell number J:143158
\Tspotm1.1Guwu/\Tspotm1.1Guwu
(involves: C57BL/6)
increased NK cell number J:219189
\Tssk5tm1.1(KOMP)Vlcg/\Tssk5tm1.1(KOMP)Vlcg
(C57BL/6N-Tssk5tm1.1(KOMP)Vlcg/J)
decreased leukocyte cell number J:211773
\Tsttm1(KOMP)Vlcg/\Tsttm1(KOMP)Vlcg
(C57BL/6N-Tsttm1(KOMP)Vlcg/Ucd)
increased leukocyte cell number J:211773
increased lymphocyte cell number J:211773
\Tstd1em1(IMPC)J/\Tstd1em1(IMPC)J
(C57BL/6NJ-Tstd1em1(IMPC)J/Mmjax)
increased leukocyte cell number J:211773
\Ttc7fsn-Jic/\Ttc7fsn-Jic
(C3.INT-Ttc7fsn-Jic)
decreased spleen white pulp amount J:115742
decreased thymus weight J:115742
increased spleen red pulp amount J:115742
increased spleen weight J:115742
liver inflammation J:115742
\Ttc7fsn/\Ttc7fsn
(CByJ.A-Ttc7fsn)
enlarged spleen J:29200, J:30519
small thymus J:29200
thymus cortex hypoplasia J:29200
\Ttc7fsn/\Ttc7fsn
(involves: A/J)
stomach inflammation J:2777
\Ttc7fsn/\Ttc7fsn
(involves: A/J * BALB/cByJ)
increased dendritic epidermal T cell number J:14506
increased Langerhans cell number J:14506
\Ttc7hea/\Ttc7hea
(CFO)
enlarged spleen J:7515
increased leukocyte cell number J:7515
\Ttc9tm1Vcl/\Ttc9+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)
thymus hyperplasia J:241703
\Ttc9tm1Vcl/\Ttc9tm1Vcl
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)
increased spleen weight J:241703
increased thymus weight J:241703
thymus hyperplasia J:241703
\Ttc28tm1b(EUCOMM)Hmgu/\Ttc28tm1b(EUCOMM)Hmgu
(C57BL/6N-Ttc28tm1b(EUCOMM)Hmgu/Tcp)
increased leukocyte cell number J:211773
increased lymphocyte cell number J:211773
\Ttc39aos1em1Bcgen/\Ttc39aos1em1Bcgen
(involves: C57BL/6N)
increased cytokine level J:307097
increased susceptibility to induced pancreatitis J:307097
\Ttc39aos1tm1Kaf/\Ttc39aos1tm1Kaf
(C57BL/6-Ttc39aos1tm1Kaf)
increased susceptibility to endotoxin shock J:234649
\Tti1em1(IMPC)J/\Tti1+
(C57BL/6NJ-Tti1em1(IMPC)J/Mmjax)
decreased leukocyte cell number J:211773
\Tti2tm1b(KOMP)Wtsi/\Tti2+
(C57BL/6N-Tti2tm1b(KOMP)Wtsi/Ics)
decreased lymphocyte cell number J:211773
increased neutrophil cell number J:211773
\Ttkem1(IMPC)J/\Ttk+
(C57BL/6NJ-Ttkem1(IMPC)J/Mmjax)
decreased leukocyte cell number J:211773
\Ttll1Gt(OST372941)Lex/\Ttll1Gt(OST372941)Lex
(involves: 129S5/SvEvBrd * C57BL/6)
increased susceptibility to otitis media J:186050
rhinitis J:186050
\Ttll1tm1Seto/\Ttll1tm1Seto
(involves: 129S/SvEv * C57BL/6)
rhinosinusitis J:161297
\Ttll11em1(IMPC)Ccpcz/\Ttll11em1(IMPC)Ccpcz
(C57BL/6NCrl-Ttll11em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
\Ttnmdm/\Ttnmdm
(Not Specified)
myositis J:14016
\Ttntm1.1Isrd/\Ttntm1.1Isrd
(involves: 129S2/SvPas * C57BL/6)
myositis J:165576
\Tubtub/\Tubtub
(C57BL/6J-Tubtub)
abnormal Langerhans cell physiology J:13772
\Tubal3em1(IMPC)J/\Tubal3em1(IMPC)J
(C57BL/6NJ-Tubal3em1(IMPC)J/Mmjax)
decreased leukocyte cell number J:211773
\Tulp4tm1a(KOMP)Wtsi/\Tulp4+
(involves: C57BL/6N * C57BL/6NRj)
absent connection between subcutaneous lymph vessels and lymph sac J:344151
immune system phenotype J:344151
\Tulp4tm1a(KOMP)Wtsi/\Tulp4tm1a(KOMP)Wtsi
(involves: C57BL/6N * C57BL/6NRj)
abnormal thymus topology J:344151
\Tusc2tm1Avi/\Tusc2+
(involves: 129S1/Sv * C57BL/6J)
arteritis J:119985
glomerulonephritis J:119985
increased anti-nuclear antigen antibody level J:119985
increased susceptibility to autoimmune disorder J:119985
\Tusc2tm1Avi/\Tusc2tm1Avi
(involves: 129S1/Sv * C57BL/6J)
abnormal NK cell differentiation J:119985
arteritis J:119985
decreased interleukin-15 secretion J:119985
decreased NK cell number J:119985
glomerulonephritis J:119985
increased anti-nuclear antigen antibody level J:119985
increased leukocyte cell number J:119985
increased susceptibility to autoimmune disorder J:119985
\Tusc2tm1Avi/\Tusc2tm1Avi
(involves: 129S1/Sv)
arteritis J:309768
chronic inflammation J:309768
decreased T cell proliferation J:309768
decreased thymocyte number J:309768
increased macrophage cell number J:309768
increased monocyte cell number J:309768
increased susceptibility to autoimmune disorder J:309768
\Tvp23bem3Eetr/\Tvp23bem3Eetr
(C57BL/6J-Tvp23bem3Eetr)
increased susceptibility to induced colitis J:340685
\Tvp23bm1Btlr/\Tvp23bm1Btlr
(C57BL/6J-Tvp23bm1Btlr)
increased susceptibility to induced colitis J:340685
\Twist2tm1(cre)Dor/\Twist2tm1(cre)Dor
(involves: 129/Sv * 129X1/SvJ)
abnormal interleukin level J:81485
abnormal spleen morphology J:81485
abnormal spleen white pulp morphology J:81485
abnormal thymus cortex morphology J:81485
abnormal thymus medulla morphology J:81485
abnormal thymus morphology J:81485
abnormal tumor necrosis factor level J:81485
thymus atrophy J:81485
\Twsg1tm1Nosa/\Twsg1tm1Nosa
(involves: 129P2/OlaHsd * C57BL/6)
abnormal B cell differentiation J:82738
abnormal spleen development J:82738
abnormal thymus development J:82738
decreased double-positive T cell number J:82738
decreased immature B cell number J:82738
decreased lymphocyte cell number J:82738
decreased pre-B cell number J:82738
decreased pro-B cell number J:82738
decreased spleen white pulp amount J:82738
decreased splenocyte number J:82738
decreased thymocyte number J:82738
increased granulocyte number J:82738
increased monocyte cell number J:82738
increased single-positive T cell number J:82738
increased thymocyte apoptosis J:82738
thymus atrophy J:82738
\Txktm1Pls/\Txktm1Pls
(involves: 129S6/SvEvTac)
abnormal cytokine secretion J:54449
increased susceptibility to parasitic infection J:54449
\Txlnatm1b(EUCOMM)Hmgu/\Txlna+
(C57BL/6N-Txlnatm1b(EUCOMM)Hmgu/H)
increased large unstained cell number J:211773
\Txlnatm1b(EUCOMM)Hmgu/\Txlnatm1b(EUCOMM)Hmgu
(C57BL/6N-Txlnatm1b(EUCOMM)Hmgu/H)
increased large unstained cell number J:211773
increased lymphocyte cell number J:211773
\Txndc2tm1Lex/\Txndc2tm1Lex
(involves: 129S5/SvEvBrd * C57BL/6J)
decreased circulating interleukin-6 level J:103485
\Txniptm1Yu/\Txniptm1Yu
(involves: 129)
abnormal mesenteric lymph node morphology J:96677
abnormal NK cell morphology J:96677
abnormal NK cell physiology J:96677
decreased CD8-positive, alpha-beta T cell number J:96677
decreased NK cell number J:96677
decreased NK T cell number J:96677
increased lymphocyte cell number J:96677
increased regulatory T cell number J:96677
increased T cell proliferation J:96677
\Txnl1em1(IMPC)Tcp/\Txnl1em1(IMPC)Tcp
(C57BL/6NCrl-Txnl1em1(IMPC)Tcp/Tcp)
increased monocyte cell number J:211773
\Tyk2E775K/\Tyk2E775K
(B10.D1-H2q/SgJ)
abnormal T-helper 1 physiology J:69051
decreased IgG1 level J:69051
decreased IgG2a level J:69051
decreased IgG level J:69051
decreased interferon-gamma secretion J:69051, J:120304
decreased susceptibility to induced arthritis J:69051
increased circulating interleukin-12 level J:120304
increased susceptibility to parasitic infection J:120304
\Tyk2tm1Biat/\Tyk2tm1Biat
(involves: 129P2/OlaHsd * C57BL/6)
abnormal response to infection J:116703
decreased interferon-gamma secretion J:65408
decreased macrophage nitric oxide production J:65408
increased susceptibility to Herpesvirales infection J:116703
increased susceptibility to Herpesvirales infection induced morbidity/mortality J:116703
increased susceptibility to Riboviria infection J:65408
increased susceptibility to viral infection induced morbidity/mortality J:65408
\Tyk2tm1Biat/\Tyk2tm1Biat
(B6NCrl.129P2-Tyk2tm1Biat)
increased susceptibility to Picornaviridae infection induced morbidity/mortality J:187818
increased susceptibility to Riboviria infection induced morbidity/mortality J:187818
\Tyk2tm1Shmd/\Tyk2tm1Shmd
(involves: 129P2/OlaHsd)
abnormal splenocyte physiology J:65409
abnormal T cell differentiation J:65409
abnormal T cell physiology J:65409
decreased interferon-gamma secretion J:65409
\Tyk2tm2b(EUCOMM)Hmgu/\Tyk2tm2b(EUCOMM)Hmgu
(C57BL/6N-Tyk2tm2b(EUCOMM)Hmgu/Ieg)
decreased plasmacytoid dendritic cell number J:211773
enlarged spleen J:211773
enlarged thymus J:211773
\Tyk2tm3.1Biat/\Tyk2tm3.1Biat
(B6NCrl.129P2(C)-Tyk2tm3.1Biat)
increased susceptibility to Picornaviridae infection induced morbidity/mortality J:187818
increased susceptibility to Riboviria infection induced morbidity/mortality J:187818
\Tymptm1Akiy/\Tymptm1Akiy
\Upp1tm1Akiy/\Upp1tm1Akiy

(involves: 129X1/SvJ)
brain inflammation J:78036
\Tyro3em1(IMPC)Ccpcz/\Tyro3em1(IMPC)Ccpcz
(C57BL/6NCrl-Tyro3em1(IMPC)Ccpcz/Ccpcz)
abnormal lymph node morphology J:211773
abnormal thymus morphology J:211773
enlarged thymus J:211773
increased eosinophil cell number J:211773
\Tyrobptm1.1Viv/\Tyrobptm1.1Viv
(involves: 129P2/OlaHsd * C57BL/6)
decreased uterine NK cell number J:100668
\Tyrobptm1.1Viv/\Tyrobptm1.1Viv
(involves: 129P2/OlaHsd * BALB/cJ * C57BL/6)
decreased susceptibility to type IV hypersensitivity reaction J:64764
impaired natural killer cell mediated cytotoxicity J:64764
increased dendritic cell number J:64764
\Tyrobptm1.1Viv/\Tyrobptm1.1Viv
(B6.129P2-Tyrobptm1.1Viv)
abnormal microglial cell morphology J:95232
abnormal myelopoiesis J:95232
abnormal osteoclast physiology J:129304, J:95232
\Tyrobptm1Lll/\Tyrobptm1Lll
(involves: 129P2/OlaHsd * C57BL/6)
abnormal osteoclast differentiation J:89583
decreased interferon-gamma secretion J:64763
decreased susceptibility to experimental autoimmune encephalomyelitis J:64763
decreased T cell proliferation J:64763
immune system phenotype J:64763
impaired natural killer cell mediated cytotoxicity J:64763
increased dendritic cell number J:64763
increased natural killer cell mediated cytotoxicity J:64763
\Tyrobptm1Lll/\Tyrobptm1Lll
(B6.129P2-Tyrobptm1Lll)
abnormal NK T cell physiology J:147867
decreased interferon-gamma secretion J:147867
\Tyrobptm1Lll/\Tyrobptm1Lll
(involves: 129P2/OlaHsd)
decreased susceptibility to induced arthritis J:158811
\Tyrobptm1Ttk/\Tyrobptm1Ttk
(involves: 129P2/OlaHsd * C57BL/6)
abnormal dendritic cell physiology J:110786
abnormal osteoclast morphology J:81823
abnormal osteoclast physiology J:81823
\Tyrobptm1Ttk/\Tyrobptm1Ttk
(B6.129P2-Tyrobptm1Ttk)
increased anti-double stranded DNA antibody level J:177613
increased autoantibody level J:177613
increased B cell proliferation J:177613
increased germinal center B cell number J:177613
increased IgG2a level J:177613
increased IgG3 level J:177613
increased interleukin-6 secretion J:177613
increased spleen germinal center number J:177613
increased spleen germinal center size J:177613
\Tyrobptm1Viv/\Tyrobptm1Viv
(B6.129P2-Tyrobptm1Viv)
increased susceptibility to Herpesvirales infection J:124749
\U2af2em1(IMPC)J/\U2af2+
(C57BL/6NJ-U2af2em1(IMPC)J/Mmjax)
increased leukocyte cell number J:211773
\U90926em1Dnkv/\U90926em1Dnkv
(C57BL6/J-U90926em1Dnkv)
increased circulating interleukin-6 level J:340649
increased susceptibility to bacterial infection induced morbidity/mortality J:340649
increased susceptibility to endotoxin shock J:340649
\Uacatm1Kiy/\Uacatm1Kiy
(B6.129P2-Uacatm1Kiy)
abnormal Kupffer cell morphology J:157049
decreased dendritic cell number J:157049
increased tumor necrosis factor secretion J:157049
liver inflammation J:157049
lung inflammation J:157049
\Ubash3btm1Jni/\Ubash3btm1Jni
\Ubash3atm1Jni/\Ubash3atm1Jni

(Not Specified)
abnormal cytokine secretion J:89761
increased mature B cell number J:89761
increased splenocyte number J:89761
increased susceptibility to experimental autoimmune encephalomyelitis J:89761
increased T cell proliferation J:89761
\Ubdtm1b(EUCOMM)Wtsi/\Ubdtm1b(EUCOMM)Wtsi
(C57BL/6N-Ubdtm1b(EUCOMM)Wtsi/Ccpcz)
abnormal thymus morphology J:211773
decreased memory-marker CD4-positive NK T cell number J:211773
increased CD4-positive, CD25-positive NK T cell number J:211773
small thymus J:211773
\Ubdtm1Smwe/\Ubdtm1Smwe
(B6.129S6-Ubdtm1Smwe)
abnormal lymphocyte physiology J:110321
increased susceptibility to bacterial infection J:110321
\Ube2btm1b(EUCOMM)Wtsi/\Ube2b+
(C57BL/6N-Ube2btm1b(EUCOMM)Wtsi/Ics)
decreased basophil cell number J:211773
decreased neutrophil cell number J:211773
increased leukocyte cell number J:211773
increased lymphocyte cell number J:211773
\Ube2iem1(IMPC)J/\Ube2i+
(C57BL/6NJ-Ube2iem1(IMPC)J/Mmjax)
increased leukocyte cell number J:211773
\Ube2j1tm1.2Hpl/\Ube2j1tm1.2Hpl
(involves: BALB/cJ * C57BL/6 * C57BL/6N * SJL)
immune system phenotype J:218292
\Ube2j2em1(IMPC)Rbrc/\Ube2j2em1(IMPC)Rbrc
(C57BL/6NJcl-Ube2j2em1(IMPC)Rbrc/Rbrc)
decreased leukocyte cell number J:211773
decreased lymphocyte cell number J:211773
increased eosinophil cell number J:211773
\Ube2nem1(IMPC)Ccpcz/\Ube2n+
(C57BL/6N-Ube2nem1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged spleen J:211773
enlarged thymus J:211773
\Ube2nGt(OST374154)Lex/\Ube2n+
(involves: 129S5/SvEvBrd * C57BL/6)
abnormal leukocyte physiology J:120846
abnormal macrophage physiology J:120846
decreased B cell proliferation J:120846
decreased susceptibility to endotoxin shock J:120846
decreased T cell proliferation J:120846
\Ube2ntm1Aki/\Ube2ntm1Aki
\Lyz2tm1(cre)Ifo/\Lyz2+

(involves: 129P2/OlaHsd * C57BL/6)
abnormal macrophage physiology J:112287
\Ube2stm1.1Smoc/\Ube2stm1.1Smoc
(involves: C57BL/6)
abnormal macrophage physiology J:306461
decreased susceptibility to Herpesvirales infection J:306461
decreased susceptibility to Picornaviridae infection J:306461
decreased susceptibility to Picornaviridae infection induced morbidity/mortality J:306461
decreased susceptibility to Riboviria infection J:306461
increased circulating interferon-alpha level J:306461
increased circulating interferon-beta level J:306461
increased circulating interleukin-6 level J:306461
increased circulating tumor necrosis factor level J:306461
increased interferon level J:306461
increased interferon-beta secretion J:306461
\Ube2utm1e.1(KOMP)Wtsi/\Ube2utm1e.1(KOMP)Wtsi
(C57BL/6N-Ube2utm1e.1(KOMP)Wtsi/H)
increased basophil cell number J:211773
\Ube2wtm1d(EUCOMM)Wtsi/\Ube2wtm1d(EUCOMM)Wtsi
(involves: 129 * C57BL/6N)
increased neutrophil cell number J:230053
\Ube3bGt(RRJ142)Byg/\Ube3bGt(RRJ142)Byg
(involves: 129P2/OlaHsd * CBA/Ca)
eye inflammation J:203652
lymphangiectasis J:203652
\Ube3ctm1b(EUCOMM)Hmgu/\Ube3ctm1b(EUCOMM)Hmgu
(C57BL/6N-Ube3ctm1b(EUCOMM)Hmgu/Rbrc)
increased leukocyte cell number J:211773
increased lymphocyte cell number J:211773
\Ube3ctm1b(EUCOMM)Hmgu/\Ube3ctm1b(EUCOMM)Hmgu
(C57BL/6NCrl-Ube3ctm1b(EUCOMM)Hmgu/Rbrc)
decreased CD4-negative NK T cell number J:211773
decreased CD5-positive Ly6C-positive T cell number J:211773
decreased Ly6C-positive immature NK cell number J:211773
decreased Ly6C-positive NK T cell number J:211773
immune system phenotype J:211773
increased effector memory CD8-positive, alpha-beta T cell number J:211773
\Ube4aem1(IMPC)Tcp/\Ube4aem1(IMPC)Tcp
(C57BL/6N-Ube4aem1(IMPC)Tcp/Tcp)
enlarged lymph nodes J:211773
\Ubl4bem1(IMPC)Ccpcz/\Ubl4bem1(IMPC)Ccpcz
(C57BL/6N-Ubl4bem1(IMPC)Ccpcz/Ccpcz)
abnormal thymus morphology J:211773
enlarged thymus J:211773
\Ubl7em1Fanm/\Ubl7em1Fanm
(involves: C57BL/6J)
increased susceptibility to Orthomyxoviridae infection J:349835
increased susceptibility to Orthomyxoviridae infection induced morbidity/mortality J:349835
increased susceptibility to Riboviria infection J:349835
increased susceptibility to Riboviria infection induced morbidity/mortality J:349835
\Ubox5tm1b(EUCOMM)Hmgu/\Ubox5tm1b(EUCOMM)Hmgu
(C57BL/6N-Ubox5tm1b(EUCOMM)Hmgu/Tcp)
increased neutrophil cell number J:211773
\Ubqln4em1(IMPC)Mbp/\Ubqln4em1(IMPC)Mbp
(C57BL/6NCrl-Ubqln4em1(IMPC)Mbp/MbpMmucd)
abnormal spleen morphology J:211773
enlarged spleen J:211773
small spleen J:211773
\Ubr7em1(IMPC)Tcp/\Ubr7em1(IMPC)Tcp
(C57BL/6NCrl-Ubr7em1(IMPC)Tcp/Tcp)
increased leukocyte cell number J:211773
\Ubtfem1(IMPC)Mbp/\Ubtf+
(C57BL/6NCrl-Ubtfem1(IMPC)Mbp/Mmucd)
abnormal lymph node morphology J:211773
abnormal spleen morphology J:211773
enlarged lymph nodes J:211773
enlarged spleen J:211773
\Ubxn11em1(IMPC)J/\Ubxn11em1(IMPC)J
(C57BL/6NJ-Ubxn11em1(IMPC)J/Mmjax)
decreased leukocyte cell number J:211773
\Uchl3tm1Tilg/\Uchl3tm1Tilg
(involves: 129S1/Sv * C57BL/6)
immune system phenotype J:61093
\Ucp2tm1Rcq/\Ucp2tm1Rcq
(involves: 129X1/SvJ * C57BL/6J)
abnormal macrophage physiology J:66262
decreased susceptibility to bacterial infection J:66262
decreased susceptibility to infection induced morbidity/mortality J:66262
decreased susceptibility to parasitic infection J:66262
\Uevldtm1a(EUCOMM)Wtsi/\Uevldtm1a(EUCOMM)Wtsi
(C57BL/6N-Uevldtm1a(EUCOMM)Wtsi/Wtsi)
decreased leukocyte cell number J:211773
\Ufl1tm1c(EUCOMM)Wtsi/\Ufl1tm1c(EUCOMM)Wtsi
\Gt(ROSA)26Sortm1(cre/ERT2)Tyj/\Gt(ROSA)26Sor+

(involves: 129S4/SvJae * C3H * C57BL/6 * C57BL/6N)
decreased granulocyte number J:238253
decreased leukocyte cell number J:238253
decreased lymphocyte cell number J:238253
decreased monocyte cell number J:238253
\Ugcgem1(IMPC)H/\Ugcg+
(C57BL/6NTac-Ugcgem1(IMPC)H/H)
decreased lymphocyte cell number J:211773
increased neutrophil cell number J:211773
\Uggt1tm1a(KOMP)Wtsi/\Uggt1+
(involves: C57BL/6N)
abnormal susceptibility to Picornaviridae infection J:244058
decreased susceptibility to Picornaviridae infection J:244058
decreased susceptibility to Picornaviridae infection induced morbidity/mortality J:244058
\Ugt8atm1Pop/\Ugt8atm1Pop
(involves: 129P2/OlaHsd * C57BL/6)
immune system phenotype J:78426
\Uhrf1tm1a(EUCOMM)Wtsi/\Uhrf1+
(Not Specified)
increased NK cell number J:165965
\Uhrf2tm1b(EUCOMM)Wtsi/\Uhrf2tm1b(EUCOMM)Wtsi
(C57BL/6N-Uhrf2tm1b(EUCOMM)Wtsi/Tcp)
increased leukocyte cell number J:211773
increased lymphocyte cell number J:211773
\Uimc1tm1.2Amj/\Uimc1tm1.2Amj
(involves: BALB/cJ * C57BL/6)
increased T cell derived lymphoma incidence J:191827
\Ulk1tm1.1Thsn/\Ulk1tm1.1Thsn
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * FVB/N)
increased spleen weight J:139213
\Ulk1tm1.1Thsn/\Ulk1tm1.1Thsn
(involves: 129S1/Sv * 129X1/SvJ)
immune system phenotype J:235399
\Ulk3em2(IMPC)Tcp/\Ulk3em2(IMPC)Tcp
(C57BL/6NCrl-Ulk3em2(IMPC)Tcp/Tcp)
abnormal lymph node morphology J:211773
abnormal spleen morphology J:211773
enlarged lymph nodes J:211773
\Ulk4tm1Lex/\Ulk4tm1Lex
(involves: 129S5/SvEvBrd * C57BL/6J)
increased susceptibility to otitis media J:185566
maxillary sinus inflammation J:185566
nasal inflammation J:185566
\Umodem1Duf/\Umod+
(C57BL/6J-Umodem1Duf)
kidney inflammation J:252597
\Umodtm1.1Rvt/\Umod+
(either: B6J.129-Umodtm1.1Rvt or (involves: 129S1/Sv * 129X1/SvJ))
kidney inflammation J:242593
\Umodtm1.1Rvt/\Umodtm1.1Rvt
(either: B6J.129-Umodtm1.1Rvt or (involves: 129S1/Sv * 129X1/SvJ))
kidney inflammation J:242593
\Umodtm1Xrw/\Umodtm1Xrw
(involves: 129S6/SvEvTac)
increased susceptibility to bacterial infection J:95431
\Unc13dJinx/\Unc13dJinx
(C57BL/6J-Unc13dJinx/Mmucd)
abnormal cytokine secretion J:119974
abnormal macrophage physiology J:105543
abnormal NK cell physiology J:119974
absent lymph node germinal center J:119974
decreased cytotoxic T cell cytolysis J:119974
enlarged spleen J:119974
hemophagocytosis J:119974
increased CD8-positive, alpha-beta T cell number J:119974
increased monocyte cell number J:119974
increased neutrophil cell number J:119974
increased susceptibility to Herpesvirales infection J:105543, J:119974
increased susceptibility to Riboviria infection J:105543, J:119974
\Unc80em1(IMPC)Tcp/\Unc80+
(C57BL/6N-Unc80em1(IMPC)Tcp/Tcp)
enlarged lymph nodes J:211773
\Unc93b13d/\Unc93b13d
(C57BL/6J-Unc93b13d)
abnormal antigen presentation via MHC class I J:105484
abnormal antigen presentation via MHC class II J:105484
abnormal circulating interferon level J:105484
abnormal dendritic cell antigen presentation J:105484
abnormal macrophage physiology J:105484
abnormal tumor necrosis factor secretion J:105484
decreased interleukin-12b secretion J:105484
increased circulating tumor necrosis factor level J:105484
increased susceptibility to bacterial infection J:105484
increased susceptibility to Herpesvirales infection J:105484
\Unc93b13d/\Unc93b13d
(C57BL/6-Unc93b13d)
abnormal dendritic cell antigen presentation J:159599
abnormal dendritic cell morphology J:159599
decreased interleukin-6 secretion J:159599
decreased interleukin-12b secretion J:159599
\Unc93b1tm1(KOMP)Vlcg/\Unc93b1tm1(KOMP)Vlcg
(involves: C57BL/6NTac)
abnormal dendritic cell antigen presentation J:211069
abnormal dendritic cell morphology J:211069
abnormal dendritic cell physiology J:211069
abnormal tumor necrosis factor level J:211069
decreased circulating interleukin-6 level J:211069
decreased circulating interleukin-12b level J:211069
\Unc93b1tm1.1Kmiy/\Unc93b1tm1.1Kmiy
(involves: 129P2/OlaHsd * C57BL/6)
abnormal cytokine secretion J:174308
abnormal T-helper 1 cell differentiation J:174308
abnormal T-helper 17 cell differentiation J:174308
decreased B cell proliferation J:174308
decreased interferon-alpha secretion J:174308
decreased interleukin-12b secretion J:174308
decreased marginal zone B cell number J:174308
decreased tumor necrosis factor secretion J:174308
enlarged spleen J:174308
glomerulonephritis J:174308
increased anti-nuclear antigen antibody level J:174308
increased autoantibody level J:174308
increased B cell number J:174308
increased B cell proliferation J:174308
increased CD4-positive, alpha-beta memory T cell number J:174308
increased IgG2a level J:174308
increased IgG2b level J:174308
increased interferon-alpha secretion J:174308
increased interleukin-12b secretion J:174308
increased memory T cell number J:174308
increased spleen weight J:174308
increased T-helper 1 cell number J:174308
increased T-helper 17 cell number J:174308
increased tumor necrosis factor secretion J:174308
liver inflammation J:174308
\Ungtm1Tld/\Ungtm1Tld
(Not Specified)
abnormal class switch recombination J:79590
decreased IgG3 level J:79590
enlarged lymph nodes J:85353
enlarged spleen J:85353
enlarged thymus J:85353
increased IgM level J:79590
lymphoid hyperplasia J:85353
spleen hyperplasia J:85353
\Ungtm1Tld/\Ungtm1Tld
(involves: 129P2/OlaHsd)
abnormal class switch recombination J:306598
abnormal somatic hypermutation frequency J:155454
\Uoxem1Cli/\Uoxem1Cli
(C57BL/6J-Uoxem1Cli)
abnormal cytokine level J:271949
kidney inflammation J:271949
\Uoxin/\Uoxin
(involves: C57BL/6J * DBA/2J)
chronic inflammation J:70677
\Uoxtm1Bay/\Uoxtm1Bay
(involves: 129S7/SvEvBrd * C57BL/6J)
tubulointerstitial nephritis J:16490
\Upf2tm1Btp/\Upf2tm1Btp
\Lyz2tm1(cre)Ifo/?

(involves: 129P2/OlaHsd * C57BL/6 * CBA)
immune system phenotype J:134765
\Upf2tm1Btp/\Upf2tm1Btp
\Tg(Mx1-cre)1Cgn/0

(involves: 129P2/OlaHsd * C57BL/6 * CBA)
abnormal B cell number J:134765
decreased granulocyte number J:134765
decreased T cell proliferation J:134765
\Upf3bem1(IMPC)Tcp/Y
(C57BL/6NCrl-Upf3bem1(IMPC)Tcp/Tcp)
decreased leukocyte cell number J:211773
decreased lymphocyte cell number J:211773
small thymus J:211773
\Upf3bem1(IMPC)Tcp/\Upf3bem1(IMPC)Tcp
(C57BL/6NCrl-Upf3bem1(IMPC)Tcp/Tcp)
decreased lymphocyte cell number J:211773
increased neutrophil cell number J:211773
small thymus J:211773
\Upk1aem2Mgef/\Upk1aem2Mgef
(C57BL/6NJNcbs-Upk1aem2Mgef)
epididymis inflammation J:345207
increased susceptibility to bacterial infection J:345207
liver inflammation J:345207
lung inflammation J:345207
tubulointerstitial nephritis J:345207
urinary bladder inflammation J:345207
\Uqcrbtm1b(EUCOMM)Wtsi/\Uqcrb+
(C57BL/6N-Uqcrbtm1b(EUCOMM)Wtsi/Ieg)
increased leukocyte cell number J:211773
\Urahplt2/\Urahplt2
(C57BL/6-Urahplt2)
abnormal NK cell morphology J:267227
decreased CD8-positive, alpha-beta T cell number J:267227
increased T cell proliferation J:267227
\Uri1tm1.1Ndj/\Uri1tm1.1Ndj
\Albtm1(cre/ERT2)Mtz/\Alb+

(B6.Cg-Albtm1(cre/ERT2)Mtz Uri1tm1.1Ndj)
liver inflammation J:217463
\Urostm1Cged/\Urostm1Cged
(involves: 129S2/SvPas)
enlarged spleen J:105776
increased spleen red pulp amount J:105776
\Urostm2Rjde/\Urostm3Rjde
(involves: 129S6/SvEvTac * C57BL/6)
enlarged spleen J:132542
increased spleen iron level J:132542
\Usp4tm1Xilu/\Usp4tm1Xilu
(B6.129-Usp4tm1Xilu)
increased splenocyte apoptosis J:173192
increased thymocyte apoptosis J:173192
\Usp5tm1a(EUCOMM)Hmgu/\Usp5+
(C57BL/6N-Usp5tm1a(EUCOMM)Hmgu/Wtsi)
decreased leukocyte cell number J:211773
\Usp12tm1a(EUCOMM)Hmgu/\Usp12tm1a(EUCOMM)Hmgu
(Not Specified)
decreased CD8-positive, alpha-beta T cell number J:165965
decreased IgA level J:165965
\Usp13em1Nmw/\Usp13em1Nmw
(B6.Cg-Usp13em1Nmw)
increased interleukin-1 beta secretion J:285981
increased interleukin-6 secretion J:285981
increased susceptibility to bacterial infection J:285981
increased tumor necrosis factor secretion J:285981
lung inflammation J:285981
\Usp15em1Peih/\Usp15em1Peih
(involves: C57BL/6)
abnormal macrophage physiology J:306461
\Usp15L749R/\Usp15+
(involves: 129S1/SvImJ * C57BL/6J)
decreased susceptibility to experimental autoimmune encephalomyelitis J:259382
decreased susceptibility to parasitic infection induced morbidity/mortality J:259382
\Usp15L749R/\Usp15L749R
(involves: 129S1/SvImJ * C57BL/6J)
abnormal T-helper 1 physiology J:259382
decreased susceptibility to bacterial infection J:259382
decreased susceptibility to bacterial infection induced morbidity/mortality J:259382
decreased susceptibility to experimental autoimmune encephalomyelitis J:259382
decreased susceptibility to parasitic infection J:259382
decreased susceptibility to parasitic infection induced morbidity/mortality J:259382
immune system phenotype J:259382
\Usp15L749R/\Usp15tm1Pgrs
(involves: 129S1/SvImJ * C57BL/6J)
decreased susceptibility to experimental autoimmune encephalomyelitis J:259382
decreased susceptibility to parasitic infection induced morbidity/mortality J:259382
\Usp15tm1b(EUCOMM)Wtsi/\Usp15tm1b(EUCOMM)Wtsi
(C57BL/6N-Usp15tm1b(EUCOMM)Wtsi/Wtsi)
increased leukocyte cell number J:211773
\Usp15tm1Pgrs/\Usp15tm1Pgrs
(Not Specified)
decreased susceptibility to experimental autoimmune encephalomyelitis J:259382
decreased susceptibility to parasitic infection induced morbidity/mortality J:259382
\Usp16tm1b(EUCOMM)Hmgu/\Usp16+
(C57BL/6N-Usp16tm1b(EUCOMM)Hmgu/Nju)
increased basophil cell number J:211773
increased eosinophil cell number J:211773
\Usp17lctm1Khb/\Usp17lc+
(either: 129-Usp17lctm1Khb or (involves: 129S/SvEv * C57BL/6J))
decreased regulatory T cell number J:191761
increased B cell number J:191761
increased CD4-positive, alpha-beta T cell number J:191761
increased CD8-positive, alpha-beta T cell number J:191761
increased thymus weight J:191761
\Usp18ity9/\Usp18ity9
(involves: 129S1/SvImJ * C57BL/6)
abnormal lymphocyte morphology J:163843
decreased circulating interferon-gamma level J:163843
decreased interferon-gamma secretion J:163843
decreased leukocyte cell number J:163843
increased circulating interleukin-6 level J:163843
increased interleukin-6 secretion J:163843
increased susceptibility to bacterial infection J:163843
increased susceptibility to bacterial infection induced morbidity/mortality J:163843
increased susceptibility to endotoxin shock J:163843
\Usp18ity9/\Usp18tm1Dez
(involves: 129 * C57BL/6 * FVB/N)
increased susceptibility to bacterial infection J:163843
increased susceptibility to bacterial infection induced morbidity/mortality J:163843
\Usp18tm1Dez/\Usp18tm1Dez
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
abnormal cytokine level J:214425
decreased circulating interferon-alpha level J:214425
decreased circulating interferon-beta level J:214425
decreased circulating interferon-gamma level J:214425
decreased susceptibility to Coronaviridae infection J:214425
\Usp20em1Dalin/\Usp20em1Dalin
(involves: C57BL/6)
abnormal circulating chemokine level J:274572
decreased circulating interferon-beta level J:274572
decreased circulating interleukin-6 level J:274572
decreased interferon-beta secretion J:274572
decreased tumor necrosis factor secretion J:274572
increased susceptibility to Herpesvirales infection J:274572
increased susceptibility to Herpesvirales infection induced morbidity/mortality J:274572
\Usp21tm1.1Jhy/\Usp21tm1.1Jhy
(B6.129S7(Cg)-Usp21tm1.1Jhy)
abnormal interferon level J:208320
decreased susceptibility to Riboviria infection J:208320
decreased susceptibility to Riboviria infection induced morbidity/mortality J:208320
enlarged spleen J:208320
increased circulating interferon-alpha level J:208320
increased circulating interferon-beta level J:208320
increased macrophage cell number J:208320
increased neutrophil cell number J:208320
increased spleen weight J:208320
increased splenocyte number J:208320
\Usp21tm1a(EUCOMM)Wtsi/\Usp21tm1a(EUCOMM)Wtsi
(C57BL/6N-Usp21tm1a(EUCOMM)Wtsi/Wtsi)
increased leukocyte cell number J:211773
\Usp22tm1b(KOMP)Wtsi/\Usp22+
(C57BL/6N-Usp22tm1b(KOMP)Wtsi/Wtsi)
increased monocyte cell number J:211773
\Usp25Gt(RRS805)Byg/\Usp25Gt(RRS805)Byg
(involves: 129P2/OlaHsd)
decreased interferon-gamma secretion J:188557
increased interleukin-6 secretion J:188557
increased neutrophil cell number J:188557
increased susceptibility to experimental autoimmune encephalomyelitis J:188557
lung inflammation J:188557
\Usp28Gt(EUCE0037g10)Hmgu/\Usp28Gt(EUCE0037g10)Hmgu
(involves: 129P2/OlaHsd * C57BL/6J)
decreased spleen weight J:215354
decreased splenocyte number J:215354
immune system phenotype J:215354
\Usp32em1(IMPC)Mhzh/\Usp32+
(C57BL/6N-Usp32em1(IMPC)Mhzh/Mhzh)
decreased neutrophil cell number J:211773
increased leukocyte cell number J:211773
increased lymphocyte cell number J:211773
\Usp38em1Cya/\Usp38em1Cya
(C57BL/6-Usp38em1Cya)
lung inflammation J:321973
\Usp42tm2a(EUCOMM)Wtsi/\Usp42tm2a(EUCOMM)Wtsi
(involves: C57BL/6 * C57BL/6N)
increased CD4-positive, alpha-beta T cell number J:213427
increased T cell number J:213427
\Usp45em1(IMPC)H/\Usp45em1(IMPC)H
(C57BL/6NTac-Usp45em1(IMPC)H/H)
decreased neutrophil cell number J:211773
\Usp49em1Gpt/\Usp49em1Gpt
(involves: C57BL/6NGpt)
decreased susceptibility to Herpesvirales infection J:285681
decreased susceptibility to Herpesvirales infection induced morbidity/mortality J:285681
immune system phenotype J:285681
increased circulating interferon-beta level J:285681
increased circulating interleukin-6 level J:285681
increased interferon-beta secretion J:285681
increased interleukin-6 secretion J:285681
\Usp54tm1b(KOMP)Wtsi/\Usp54tm1b(KOMP)Wtsi
(C57BL/6N-Usp54tm1b(KOMP)Wtsi/H)
decreased lymphocyte cell number J:211773
increased neutrophil cell number J:211773
\Utp4em1(IMPC)J/\Utp4+
(C57BL/6NJ-Utp4em1(IMPC)J/Mmjax)
increased leukocyte cell number J:211773
\UvragTn(pb-Act-RFP)1.100107015-HRAZhu/\UvragTn(pb-Act-RFP)1.100107015-HRAZhu
(involves: FVB/NJ)
abnormal interleukin level J:219546
abnormal tumor necrosis factor level J:219546
heart inflammation J:219546
\Uxs1tm1Lex/\Uxs1+
(B6;129S5-Uxs1tm1Lex/Mmucd)
abnormal humoral immune response J:171883
increased IgG1 level J:171883
\Vamp2tm1Sud/\Vamp2tm1Sud
(involves: 129P2/OlaHsd * C57BL/6)
immune system phenotype J:131926
\Vamp3tm1Jpes/\Vamp3tm1Jpes
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
immune system phenotype J:131926
\Vamp4em1(IMPC)Ccpcz/\Vamp4em1(IMPC)Ccpcz
(C57BL/6NCrl-Vamp4em1(IMPC)Ccpcz/Ccpcz)
abnormal lymph node morphology J:211773
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged lymph nodes J:211773
enlarged spleen J:211773
enlarged thymus J:211773
\Vamp8Gt(OST20346)Lex/\Vamp8Gt(OST20346)Lex
(involves: 129S5/SvEvBrd * C57BL/6)
abnormal mast cell physiology J:131926
\Vamp8tm1Hong/\Vamp8tm1Hong
(involves: 129P2/OlaHsd * C57BL/6)
abnormal dendritic cell physiology J:131528
abnormal type I hypersensitivity reaction J:133439
decreased mast cell degranulation J:133439
immune system phenotype J:133439
\Varc/\Varc+
(C3H/HeJ-Varc/J)
increased susceptibility to otitis media J:241135
\Varc/\Varc+
(C3OuJ.C3-Varc/Kjn)
increased susceptibility to otitis media J:241135
\Vav1m1Anu/\Vav1m1Anu
(C57BL/6JAnu-Vav1m1Anu)
increased T cell number J:104190
\Vav1m1Btlr/\Vav1m1Btlr
(C57BL/6J-Vav1m1Btlr)
abnormal humoral immune response J:265128
decreased B-1 B cell number J:265128
decreased CD4-positive, alpha-beta T cell number J:265128
decreased CD8-positive, alpha-beta T cell number J:265128
decreased CD8-positive, naive alpha-beta T cell number J:265128
decreased IgD level J:265128
decreased IgG level J:265128
decreased single-positive T cell number J:265128
decreased T cell number J:265128
increased central memory CD4-positive, alpha-beta T cell number J:265128
increased central memory CD8 positive, alpha-beta T cell number J:265128
increased effector memory CD4-positive, alpha-beta T cell number J:265128
increased IgM level J:265128
\Vav1m2Btlr/\Vav1m2Btlr
(C57BL/6J-Vav1m2Btlr)
decreased B-1 B cell number J:265130
\Vav1M3Btlr/\Vav1M3Btlr
(C57BL/6J-Vav1M3Btlr)
decreased IgG level J:272527
impaired humoral immune response J:272527
\Vav1M4Btlr/\Vav1M4Btlr
(C57BL/6J-Vav1M4Btlr)
abnormal CD4-positive T cell differentiation J:272528
abnormal CD8-positive, alpha-beta T cell differentiation J:272528
abnormal T cell differentiation J:272528
decreased B-1 B cell number J:272528
decreased CD4-positive, alpha-beta T cell number J:272528
decreased CD8-positive, naive alpha-beta T cell number J:272528
increased central memory CD4-positive, alpha-beta T cell number J:272528
increased central memory CD8 positive, alpha-beta T cell number J:272528
increased effector memory CD4-positive, alpha-beta T cell number J:272528
increased effector memory CD8-positive, alpha-beta T cell number J:272528
\Vav1M5Btlr/\Vav1M5Btlr
(C57BL/6J-Vav1M5Btlr)
decreased CD8-positive, alpha-beta T cell number J:272529
\Vav1tm1Tyb/\Vav1tm1Tyb
(involves: 129S2/SvPas * 129S8/SvEv)
abnormal T cell physiology J:113270
decreased CD4-positive, alpha-beta T cell number J:113270
decreased double-negative T cell number J:113270
decreased T cell proliferation J:113270
\Vav1tm1Tyb/\Vav1tm1Tyb
(involves: 129S4/SvJae * 129S8/SvEv * C57BL/10 * C57BR/cd)
abnormal CD4-positive, alpha beta T cell morphology J:113270
abnormal negative T cell selection J:113270
\Vav1tm1Tyb/\Vav1tm1Tyb
(involves: 129S2/SvPas)
abnormal double-negative T cell morphology J:79323
abnormal T cell physiology J:86654, J:79323
decreased double-positive T cell number J:79323
decreased interferon-gamma secretion J:86654
decreased interleukin-2 secretion J:86654
decreased mature B cell number J:86654
decreased single-positive T cell number J:79323
decreased T cell proliferation J:86654
decreased thymocyte number J:86654
thymus hypoplasia J:79323
\Vav1tm1Tyb/\Vav1tm1Tyb
(C.129S2-Vav1tm1Tyb)
abnormal negative T cell selection J:79323
\Vav1tm1Tyb/\Vav1tm1Tyb
(involves: 129S2/SvPas * C57BL/10 * C57BR/cd)
abnormal CD4-positive, alpha beta T cell morphology J:79323
abnormal T cell physiology J:128985
decreased interleukin-2 secretion J:128985
decreased T cell proliferation J:128985
decreased tumor necrosis factor secretion J:128985
\Vav1tm1Tyb/\Vav1tm1Tyb
(either: (involves: 129S4/SvJae * 129S8/SvEv) or (involves: 129S4/SvJae * 129S8/SvEv * C57BL/10 * C57BR/cd))
abnormal CD8-positive, alpha-beta T cell physiology J:190087
abnormal immune system physiology J:190087
abnormal interleukin-2 secretion J:190087
abnormal lymphocyte cell number J:190087
abnormal T cell number J:190087
decreased double-positive T cell number J:190087
increased DN2 thymocyte number J:190087
increased DN3 thymocyte number J:190087
increased double-negative T cell number J:190087
\Vav1tm1Tyb/\Vav1tm1Tyb
\Vav2tm1Kdf/\Vav2tm1Kdf

(involves: 129S1/Sv * 129S2/SvPas)
decreased B cell proliferation J:86654
decreased double-negative T cell number J:86654
decreased double-positive T cell number J:86654
decreased interferon-gamma secretion J:86654
decreased interleukin-2 secretion J:86654
decreased mature B cell number J:86654
decreased single-positive T cell number J:86654
decreased T cell number J:86654
decreased T cell proliferation J:86654
decreased thymocyte number J:86654
\Vav1tm1Tyb/\Vav1tm1Tyb
\Vav2tm1Kdf/\Vav2tm1Kdf
\Vav3tm1Swat/\Vav3tm1Swat

(involves: 129S1/Sv * 129S2/SvPas * 129S6/SvEvTac * C57BL/6)
abnormal B cell calcium ion homeostasis J:86654
abnormal humoral immune response J:86654
abnormal T cell physiology J:86654
arrested B cell differentiation J:86654
arrested T cell differentiation J:86654
decreased B cell proliferation J:86654
decreased double-positive T cell number J:86654
decreased follicular B cell number J:86654
decreased IgG1 level J:86654
decreased IgG2b level J:86654
decreased IgG3 level J:86654
decreased IgM level J:86654
decreased immunoglobulin level J:86654
decreased interferon-gamma secretion J:86654
decreased interleukin-2 secretion J:86654
decreased marginal zone B cell number J:86654
decreased mature B cell number J:86654
decreased single-positive T cell number J:86654
decreased T cell number J:86654
decreased T cell proliferation J:86654
decreased thymocyte number J:86654
decreased transitional stage T2 B cell number J:86654
increased immature B cell number J:86654
increased transitional stage T1 B cell number J:86654
\Vav1tm1Tyb/\Vav1tm1Tyb
\Vav2tm1Kdf/\Vav2tm1Kdf
\Vav3tm1Swat/\Vav3tm1Swat

(involves: 129S1/Sv * 129S2/SvPas * 129S6/SvEvTac)
abnormal macrophage physiology J:145345
abnormal neutrophil physiology J:145345
abnormal NK cell physiology J:187430
decreased interleukin-10 secretion J:145345
decreased tumor necrosis factor secretion J:145345
\Vav1tm1Tyb/\Vav1tm1Tyb
\Vav2tm1Tnr/\Vav2tm1Tnr

(involves: 129P2/OlaHsd * 129S2/SvPas)
abnormal B cell calcium ion homeostasis J:69807
decreased B cell number J:69807
decreased B cell proliferation J:69807
decreased CD4-positive, alpha-beta T cell number J:69807
decreased CD8-positive, alpha-beta T cell number J:69807
decreased follicular B cell number J:69807
decreased immature B cell number J:69807
decreased mature B cell number J:69807
\Vav1tm1Tyb/\Vav1tm1Tyb
\Vav3tm1Swat/\Vav3tm1Swat

(involves: 129S2/SvPas * 129S6/SvEvTac * C57BL/6)
decreased B cell proliferation J:86654
decreased double-negative T cell number J:86654
decreased double-positive T cell number J:86654
decreased interferon-gamma secretion J:86654
decreased interleukin-2 secretion J:86654
decreased mature B cell number J:86654
decreased single-positive T cell number J:86654
decreased T cell number J:86654
decreased T cell proliferation J:86654
\Vav1tm2Bbd/\Vav1tm2Bbd
(involves: 129S1/Sv * 129X1/SvJ * CD-1)
abnormal T cell activation J:47596
abnormal T cell differentiation J:47596
decreased B-1 B cell number J:47596
decreased CD4-positive, alpha-beta T cell number J:47596
decreased CD8-positive, alpha-beta T cell number J:47596
decreased interleukin-2 secretion J:47596
decreased T cell proliferation J:47596
immune system phenotype J:47596
thymus hypoplasia J:47596
\Vav1tm2Bbd/\Vav1tm2Bbd
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
abnormal B cell number J:55647
abnormal lymph node cell ratio J:69806
abnormal response to infection J:55647
abnormal splenic cell ratio J:69806
abnormal T cell differentiation J:47596
abnormal T cell number J:47596
decreased B cell proliferation J:55647, J:69806
decreased B-1 B cell number J:55647
decreased CD4-positive, alpha-beta T cell number J:47596
decreased CD8-positive, alpha-beta T cell number J:47596
decreased IgG1 level J:55647
decreased IgG2a level J:55647
decreased IgG3 level J:69806
decreased IgG level J:55647
increased double-negative T cell number J:47596
increased transitional stage B cell number J:69806
\Vav1tm2Bbd/\Vav1tm2Bbd
(B6.129-Vav1tm2Bbd)
abnormal CD4-positive T cell differentiation J:141390
abnormal positive T cell selection J:141390
abnormal T cell physiology J:141390
decreased double-positive T cell number J:141390
decreased interleukin-4 secretion J:71161
decreased NK T cell number J:71161
decreased T cell number J:141390
immune system phenotype J:71161
impaired natural killer cell mediated cytotoxicity J:71161
\Vav1tm2Bbd/\Vav1tm2Bbd
\Vav2tm1Kdf/\Vav2tm1Kdf

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
abnormal B cell activation J:69806
abnormal B cell differentiation J:69806
abnormal lymph node cell ratio J:69806
abnormal splenic cell ratio J:69806
abnormal T cell differentiation J:69806
decreased B cell number J:69806
decreased B cell proliferation J:69806
decreased B-1 B cell number J:69806
decreased CD8-positive, alpha-beta T cell number J:69806
decreased IgG1 level J:69806
decreased IgG2b level J:69806
decreased IgG3 level J:69806
decreased IgM level J:69806
decreased immunoglobulin level J:69806
decreased mature B cell number J:69806
decreased T cell number J:69806
thymus hypoplasia J:69806
\Vav1tm2Tyb/\Vav1tm2Tyb
(involves: 129S4/SvJae * 129S8/SvEv)
abnormal T cell physiology J:113270
decreased CD4-positive, alpha-beta T cell number J:113270
decreased double-negative T cell number J:113270
decreased T cell proliferation J:113270
\Vav1tm2Tyb/\Vav1tm2Tyb
(involves: 129S4/SvJae * 129S8/SvEv * C57BL/10 * C57BR/cd)
abnormal CD4-positive, alpha beta T cell morphology J:113270
abnormal negative T cell selection J:113270
\Vav1tm4Tyb/\Vav1tm4Tyb
(either: 129S8.129S4-Vav1tm4Tyb or (involves: 129S4/SvJae * 129S8/SvEv * C57BL/10 * C57BR/cd))
abnormal CD4-positive, alpha-beta T cell physiology J:190087
abnormal CD8-positive, alpha-beta T cell physiology J:190087
abnormal immune serum protein physiology J:190087
abnormal immune system physiology J:190087
abnormal interleukin-2 secretion J:190087
abnormal lymphocyte cell number J:190087
abnormal T cell number J:190087
abnormal T cell physiology J:190087
increased circulating interferon-gamma level J:190087
increased DN2 thymocyte number J:190087
increased DN3 thymocyte number J:190087
\Vav2tm1Kdf/\Vav2tm1Kdf
(involves: 129S1/Sv * C57BL/6)
decreased B cell proliferation J:69806
decreased IgG3 level J:69806
decreased mature B cell number J:69806
\Vav2tm1Kdf/\Vav2tm1Kdf
\Vav3tm1Swat/\Vav3tm1Swat

(involves: 129S1/Sv * 129S6/SvEvTac * C57BL/6)
immune system phenotype J:86654
\Vav2tm1Tnr/\Vav2tm1Tnr
(involves: 129P2/OlaHsd)
abnormal class switch recombination J:69807
decreased B cell number J:69807
decreased B cell proliferation J:69807
decreased IgG1 level J:69807
decreased IgG2b level J:69807
decreased IgG3 level J:69807
decreased IgM level J:69807
decreased spleen germinal center number J:69807
\Vcam1tm1Dmil/\Vcam1tm1Dmil
(either: (involves: 129S4/SvJae * BALB/c) or (involves: 129S4/SvJae * C57BL/6))
increased monocyte cell number J:69597
\Vcam1tm1Dmil/\Vcam1tm1Dmil
(C.129S4-Vcam1tm1Dmil)
increased B cell number J:69597
increased leukocyte cell number J:69597
increased monocyte cell number J:69597
increased T cell number J:69597
\Vcam1tm2Flv/\Vcam1tm3Flv
\Tg(Tek-cre)12Flv/0

(involves: 129S1/Sv * C3H * C57BL/6)
abnormal CD4-positive, alpha-beta T cell physiology J:68147
abnormal CD8-positive, alpha-beta T cell physiology J:68147
abnormal lymphocyte physiology J:68147
abnormal splenic cell ratio J:107447
decreased B cell number J:68147
decreased CD4-positive, alpha-beta T cell number J:68147
decreased CD8-positive, alpha-beta T cell number J:68147
decreased immature B cell number J:68147
impaired B cell migration J:68147
increased immature B cell number J:68147
increased leukocyte cell number J:107447, J:68147
spleen hyperplasia J:107447
\Vcam1tm2Roml/\Vcam1tm2Roml
\Tg(Mx1-cre)1Cgn/?

(involves: 129S1/Sv * C57BL/6 * CBA)
abnormal humoral immune response J:68148
decreased B cell number J:68148
decreased mature B cell number J:68148
decreased transitional stage B cell number J:68148
increased B cell number J:68148
increased immature B cell number J:68148
increased mature B cell number J:68148
increased transitional stage B cell number J:68148
\Vcanem2(IMPC)Mbp/\Vcan+
(C57BL/6NCrl-Vcanem2(IMPC)Mbp/Mmucd)
abnormal spleen morphology J:211773
enlarged spleen J:211773
\Vcptm1Itl/\Vcp+
(B6.129S-Vcptm1Itl)
abnormal osteoclast differentiation J:166230
increased osteoclast cell number J:166230
\Vdac2tm1.1Ehyc/\Vdac2tm1.1Ehyc
\Bak1tm1Thsn/\Bak1tm1Thsn
\Tg(Lck-cre)1Cwi/?

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2)
immune system phenotype J:220951
\Vdac2tm1.1Ehyc/\Vdac2tm1.1Ehyc
\Baxtm2Sjk/\Baxtm2Sjk
\Tg(Lck-cre)1Cwi/?

(involves: 129X1/SvJ * C57BL/6 * DBA/2)
decreased thymocyte number J:220951
small thymus J:220951
\Vdac2tm1.1Ehyc/\Vdac2tm1.1Ehyc
\Tg(Lck-cre)1Cwi/?

(involves: 129X1/SvJ * C57BL/6 * DBA/2)
abnormal thymocyte apoptosis J:220951
decreased thymocyte number J:220951
small thymus J:220951
\Vdrtm1Gcm/\Vdrtm1Gcm
\Tg(Col2a1-cre)1Bhr/?

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL)
decreased osteoclast cell number J:117377
\Vdrtm1Mbd/\Vdrtm1Mbd
(involves: 129S4/SvJae * C57BL/6)
abnormal interleukin level J:107077
abnormal tumor necrosis factor level J:107077
immune system phenotype J:107077
increased susceptibility to induced colitis J:130511
increased thymus weight J:107077
intestinal inflammation J:107077
thymus hyperplasia J:107077
\Vdrtm1Rge/\Vdrtm1Rge
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
abnormal macrophage physiology J:134827
decreased susceptibility to parasitic infection J:134827
\Vdrtm1Ska/\Vdrtm1Ska
(involves: C57BL/6NCrlj * CBA/JNCrlj)
abnormal macrophage chemotaxis J:112519
decreased splenocyte proliferation J:112519
decreased susceptibility to autoimmune diabetes J:112519
dermatitis J:111828
\Vdrtm1Ska/\Vdrtm1Ska
(NOD.Cg-Vdrtm1Ska/CmatJ)
abnormal chemokine secretion J:127787
abnormal dendritic cell differentiation J:127787
abnormal interleukin-1 secretion J:127787
abnormal T cell number J:127787
decreased interleukin-6 secretion J:127787
decreased regulatory T cell number J:127787
increased susceptibility to autoimmune diabetes J:127787
\Vdrtm2Ska/\Vdrtm2Ska
(involves: C57BL/6NCrlj * CBA/JNCrlj)
ear inflammation J:111828
\Vegfatm1.1Nagy/\Vegfatm1.1Nagy
(involves: 129S1/Sv * 129X1/SvJ)
abnormal lymphatic vessel morphology J:64090
\Vegfatm1Pec/\Vegfatm1Pec
(involves: 129S1/Sv * 129X1/SvJ)
abnormal thymus morphology J:81698
athymia J:81698
decreased lymphocyte cell number J:81698
ectopic thymus J:81698
thymus hypoplasia J:81698
\Vegfatm2Gne/\Vegfatm2Gne
\Lyz2tm1(cre)Ifo/\Lyz2+

(involves: 129/Sv * 129P2/OlaHsd)
decreased inflammatory response J:107682
\Vegfatm2Gne/\Vegfatm2Gne
\Lyz2tm1(cre)Ifo/\Lyz2+

(involves: 129/Sv * 129P2/OlaHsd * C57BL/6)
immune system phenotype J:148597
\Vegfatm2Gne/\Vegfatm2Gne
\Tg(SFTPC-cre)#Mliu/0

(involves: 129/Sv * ICR)
lung inflammation J:158566
\Vegfctm1Ali/\Vegfc+
(involves: 129S1/Sv * 129X1/SvJ * ICR)
abnormal lymph circulation J:87394
lymphatic vessel hypoplasia J:87394
\Vegfctm1Ali/\Vegfc+
(involves: 129S1/Sv * 129X1/SvJ)
lymphatic vessel hypoplasia J:137909
\Vegfctm1Ali/\Vegfc+
\Tg(KRT14-FIGF)2Ali/0

(involves: 129S1/Sv * 129X1/SvJ * FVB/N)
lymphatic vessel hyperplasia J:137909
\Vegfctm1Ali/\Vegfctm1Ali
(involves: 129S1/Sv * 129X1/SvJ * ICR)
absent lymphatic vessels J:87394
\Vegfctm1Ali/\Vegfctm1Ali
(involves: 129S1/Sv * 129X1/SvJ)
abnormal lymphangiogenesis J:137909
abnormal lymphatic vessel morphology J:137909
\Vegfdem1(IMPC)Ccpcz/\Vegfdem1(IMPC)Ccpcz
(C57BL/6NCrl-Vegfdem1(IMPC)Ccpcz/Ccpcz)
abnormal thymus morphology J:211773
enlarged thymus J:211773
\Vegfdtm1Hrl/Y
(involves: 129S/SvEv * Swiss)
immune system phenotype J:153734
\Vegfdtm1Mach/\Vegfdtm1Mach
\Vegfctm1Ali/\Vegfctm1Ali

(involves: 129S1/Sv * 129X1/SvJ)
abnormal lymphangiogenesis J:137909
abnormal lymphatic vessel morphology J:137909
\Vezf1tm1Stmn/\Vezf1+
(B6.129-Vezf1tm1Stmn)
abnormal lymphatic vessel morphology J:99326
\Vhltm1Jae/\Vhltm1Jae
\Lyz2tm1(cre)Ifo/\Lyz2+

(involves: 129P2/OlaHsd * 129S4/SvJae)
increased inflammatory response J:107682
\Vhltm1Jae/\Vhltm1Jae
\Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0

(involves: 129S4/SvJae * CD-1)
decreased lymphocyte cell number J:186085
enlarged spleen J:186085
\Vhltm1Mcs/\Vhltm1Mcs
(involves: 129S4/SvJae * C57BL/6 * FVB/N)
dark spleen J:130780
decreased spleen white pulp amount J:130780
increased leukocyte cell number J:130780
increased spleen red pulp amount J:130780
increased spleen weight J:130780
\Vimtm1Cba/\Vimtm1Cba
(involves: 129S2/SvPas * C57BL/6)
abnormal cellular extravasation J:129405
abnormal leukocyte adhesion J:129405
abnormal leukocyte migration J:129405
abnormal leukocyte tethering or rolling J:129405
immune system phenotype J:125280
\Viptm1Clw/\Viptm1Clw
(involves: 129S/Sv * C57BL/6)
lung inflammation J:132313
\Vipr2tm1Ajh/\Vipr2tm1Ajh
(B6.129P2-Vipr2tm1Ajh)
abnormal cytokine secretion J:72933
decreased IgE level J:72933
decreased interleukin-4 secretion J:72933
decreased susceptibility to type I hypersensitivity reaction J:72933
increased interferon-gamma secretion J:72933
increased interleukin-2 secretion J:72933
increased susceptibility to type IV hypersensitivity reaction J:72933
\Vkorc1l1em1(IMPC)J/\Vkorc1l1em1(IMPC)J
(C57BL/6NJ-Vkorc1l1em1(IMPC)J/Mmjax)
decreased leukocyte cell number J:211773
\Vldlrem1(IMPC)Mbp/\Vldlrem1(IMPC)Mbp
(C57BL/6N-Vldlrem1(IMPC)Mbp/MbpMmucd)
abnormal spleen morphology J:211773
\Vms1A/J/\Vms1A/J
(involves: A/J * C57BL/10SnSg)
myocarditis J:121574
\Vnn1tm1Pna/\Vnn1tm1Pna
(involves: 129P2/OlaHsd)
immune system phenotype J:65449
\Vnn3em1(IMPC)Ccpcz/\Vnn3em1(IMPC)Ccpcz
(C57BL/6NCrl-Vnn3em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged spleen J:211773
enlarged thymus J:211773
\Vpreb1atm1Ilm/\Vpreb1a+
\Vpreb1btm1Ilm/\Vpreb1btm3Ilm

(involves: 129P2/OlaHsd * C57BL/6)
immune system phenotype J:104211
\Vpreb1atm1Ilm/\Vpreb1atm1Ilm
(involves: 129P2/OlaHsd * C57BL/6)
abnormal pre-B cell morphology J:53512
arrested B cell differentiation J:53512
immune system phenotype J:53512
\Vpreb1atm1Ilm/\Vpreb1atm1Ilm
(B6.129P2-Vpreb1atm1Ilm)
decreased pre-B cell number J:104211
increased pre-B cell number J:104211
\Vpreb1atm1Ilm/\Vpreb1atm1Ilm
\Vpreb1btm1Ilm/\Vpreb1b+

(involves: 129P2/OlaHsd * C57BL/6)
decreased mature B cell number J:104211
decreased pre-B cell number J:104211
increased pre-B cell number J:104211
\Vpreb1atm1Ilm/\Vpreb1atm1Ilm
\Vpreb1btm1Ilm/\Vpreb1btm1Ilm

(B6.129P2-Vpreb1atm1Ilm Vpreb1btm1Ilm)
abnormal B cell differentiation J:67609
abnormal immature B cell morphology J:67609
abnormal splenic cell ratio J:67609
decreased B-1a cell number J:67609
decreased IgG level J:67609
decreased mature B cell number J:67609
decreased pre-B cell number J:67609
immune system phenotype J:67609
increased pre-B cell number J:67609
\Vpreb1btm3Ilm/\Vpreb1btm3Ilm
(B6.129P2-Vpreb1btm3Ilm)
immune system phenotype J:104211
\Vps4atm1b(EUCOMM)Hmgu/\Vps4a+
(C57BL/6N-Vps4atm1b(EUCOMM)Hmgu/Bay)
enlarged spleen J:211773
increased spleen weight J:211773
\Vps13atm1b(EUCOMM)Wtsi/\Vps13atm1b(EUCOMM)Wtsi
(C57BL/6N-Vps13atm1b(EUCOMM)Wtsi/Wtsi)
decreased plasmacytoid dendritic cell number J:211773
decreased T-helper cell number J:211773
\Vps13bem1(IMPC)Tcp/\Vps13bem1(IMPC)Tcp
(C57BL/6N-Vps13bem1(IMPC)Tcp/Tcp)
decreased leukocyte cell number J:211773
decreased lymphocyte cell number J:211773
enlarged lymph nodes J:211773
small spleen J:211773
\Vps13btm1.2Ics/\Vps13btm1.2Ics
(involves: C57BL/6N)
eye inflammation J:296007
\Vps33aem2(IMPC)Tcp/\Vps33a+
(C57BL/6NCrl-Vps33aem2(IMPC)Tcp/Tcp)
decreased lymphocyte cell number J:211773
increased neutrophil cell number J:211773
increased spleen weight J:211773
\Vps33btm1.1Arte/\Vps33btm1.1Arte
\Gt(ROSA)26Sortm1(cre/ERT2)Tyj/\Gt(ROSA)26Sor+

(involves: C57BL/6 * C57BL/6J)
decreased dendritic cell number J:222766
decreased lymphocyte cell number J:222766
enlarged spleen J:222766
increased macrophage cell number J:222766
increased monocyte cell number J:222766
increased neutrophil cell number J:222766
\Vps35tm1.1Mjff/\Vps35tm1.1Mjff
(B6.Cg-Vps35tm1.1Mjff)
microgliosis J:303283
\Vps54wr/\Vps54wr
(involves: C57BL/6J * C57BL/Fa)
increased microglial cell activation J:181019
\Vrk3em1(IMPC)Mbp/\Vrk3em1(IMPC)Mbp
(C57BL/6NCrl-Vrk3em1(IMPC)Mbp/Mmucd)
abnormal spleen morphology J:211773
enlarged spleen J:211773
\Vsig4tm1Gne/\Vsig4tm1Gne
(involves: C57BL/6N)
increased susceptibility to bacterial infection J:138691
\Vsig4tm1Gne/\Vsig4tm1Gne
(C57BL/6-Vsig4tm1Gne)
abnormal macrophage physiology J:281762
decreased susceptibility to induced colitis J:281762
increased circulating interleukin-1 beta level J:281762
increased interleukin-1 beta secretion J:281762
increased susceptibility to experimental autoimmune encephalomyelitis J:281762
increased T-helper 1 cell number J:281762
increased T-helper 17 cell number J:281762
\Vsig10em1(IMPC)Wtsi/\Vsig10em1(IMPC)Wtsi
(C57BL/6N-Vsig10em1(IMPC)Wtsi/Wtsi)
increased leukocyte cell number J:211773
\Vsirtm1Lex/\Vsirtm1Lex
(involves: 129S5/SvEvBrd * C57BL/6)
abnormal T cell activation J:222944
increased IgA level J:222944
increased IgM level J:222944
increased inflammatory response J:222944
increased interferon-gamma secretion J:222944
increased interleukin-17 secretion J:222944
\Vsirtm1Lex/\Vsirtm1Lex
\Tg(Tcra2D2,Tcrb2D2)1Kuch/0

(involves: 129S5/SvEvBrd * C57BL/6)
increased susceptibility to experimental autoimmune encephalomyelitis J:222944
\Vstm5em1Cdj/\Vstm5em1Cdj
(Not Specified)
decreased interleukin-2 secretion J:267548
immune system phenotype J:267548
\Vtcn1tm1Lpc/\Vtcn1tm1Lpc
(B6.129S-Vtcn1tm1Lpc)
abnormal myelopoiesis J:145712
decreased susceptibility to bacterial infection J:145712
decreased susceptibility to bacterial infection induced morbidity/mortality J:145712
increased neutrophil cell number J:145712
\Vtcn1tm1Mak/\Vtcn1tm1Mak
(C.Cg-Vtcn1tm1Mak)
decreased interleukin-4 secretion J:112130
decreased susceptibility to parasitic infection J:112130
increased interferon-gamma secretion J:112130
\Vtcn1tm1Xxz/\Vtcn1tm1Xxz
(involves: 129S4/SvJae * BALB/c * C57BL/6)
increased CD4-positive, alpha-beta T cell number J:177612
increased interleukin-17 secretion J:177612
increased susceptibility to autoimmune diabetes J:177612
increased susceptibility to experimental autoimmune encephalomyelitis J:177612
increased T-helper 1 cell number J:177612
increased T-helper 17 cell number J:177612
\Vwftm1.1Geno/\Vwf+
(involves: C57BL/6)
increased acute inflammation J:250145
\Vwftm1.1Geno/\Vwftm1.1Geno
(involves: C57BL/6)
increased acute inflammation J:250145
\Vwftm1Wgr/\Vwftm1Wgr
(B6.129S2-Vwftm1Wgr)
increased susceptibility to bacterial infection J:140334
increased susceptibility to experimental autoimmune encephalomyelitis J:140334
\Wactm2b(EUCOMM)Wtsi/\Wac+
(C57BL/6N-Wactm2b(EUCOMM)Wtsi/Wtsi)
decreased eosinophil cell number J:211773
increased Ly6C low monocyte number J:211773
increased monocyte cell number J:211773
\Wastm1Itl/Y
(Not Specified)
abnormal dendritic cell morphology J:153247
abnormal dendritic cell physiology J:153247
abnormal lymphocyte morphology J:153247
decreased NK cell number J:153247
decreased T cell number J:153247
decreased T cell proliferation J:153247
increased anti-double stranded DNA antibody level J:153247
increased B cell number J:153247
increased follicular B cell number J:153247
increased leukocyte cell number J:153247
increased splenocyte number J:153247
spleen hyperplasia J:153247
\Wastm1Itl/\Wastm1Itl
(Not Specified)
abnormal dendritic cell morphology J:153247
abnormal dendritic cell physiology J:153247
abnormal lymphocyte morphology J:153247
decreased NK cell number J:153247
decreased T cell number J:153247
decreased T cell proliferation J:153247
increased anti-double stranded DNA antibody level J:153247
increased B cell number J:153247
increased follicular B cell number J:153247
increased leukocyte cell number J:153247
increased splenocyte number J:153247
spleen hyperplasia J:153247
\Wastm1Kas/\Wastm1Kas
(involves: 129/Sv * C57BL/6)
decreased B cell number J:87875
decreased double-positive T cell number J:87875
decreased lymphocyte cell number J:87875
decreased T cell number J:87875
lymphoid hypoplasia J:87875
thymus hypoplasia J:87875
\Wastm1Sbs/Y
(involves: 129S6/SvEvTac)
abnormal dendritic cell morphology J:153247
abnormal dendritic cell physiology J:153247
abnormal lymphocyte morphology J:153247
decreased NK cell number J:153247
decreased T cell number J:153247
decreased T cell proliferation J:153247
increased anti-double stranded DNA antibody level J:153247
increased B cell number J:153247
increased follicular B cell number J:153247
increased leukocyte cell number J:153247
increased monocyte cell number J:153247
increased splenocyte number J:153247
spleen hyperplasia J:153247
\Wastm1Sbs/Y
(involves: 129S6/SvEvTac * C57BL/6)
abnormal B cell physiology J:182528
decreased marginal zone B cell number J:182528
decreased mature B cell number J:182528
increased anti-chromatin antibody level J:182528
increased anti-double stranded DNA antibody level J:182528
increased anti-single stranded DNA antibody level J:182528
increased autoantibody level J:182528
increased germinal center B cell number J:182528
increased IgA level J:182528
increased IgE level J:182528
increased IgM level J:182528
increased plasma cell number J:182528
\Wastm1Sbs/\Wastm1Sbs
(either: (involves: 129S6/SvEvTac) or (involves: 129S6/SvEvTac * C57BL/6))
colitis J:48836
decreased B cell number J:48836
decreased lymphocyte cell number J:48836
decreased T cell number J:48836
decreased T cell proliferation J:48836
immune system phenotype J:48836
increased neutrophil cell number J:48836
\Wastm1Sbs/\Wastm1Sbs
(involves: C57BL/6 * CBA)
abnormal B cell physiology J:95909
\Wastm1Sbs/\Wastm1Sbs
(involves: 129S/SvEv)
abnormal cytokine secretion J:86835
abnormal mast cell morphology J:86835
abnormal mast cell physiology J:86835
abnormal osteoclast differentiation J:90542
abnormal osteoclast physiology J:90542
\Wastm1Sbs/\Wastm1Sbs
(involves: BALB/c)
abnormal dendritic cell antigen presentation J:84131
decreased T cell proliferation J:84131
immune system phenotype J:84131
\Wastm1Sbs/\Wastm1Sbs
(involves: 129S6/SvEvTac)
abnormal dendritic cell morphology J:153247
abnormal dendritic cell physiology J:153247
abnormal double-negative T cell morphology J:125309
abnormal double-positive T cell morphology J:125309
abnormal lymphocyte morphology J:153247
abnormal thymocyte activation J:125309
decreased NK cell number J:153247
decreased T cell number J:153247
decreased T cell proliferation J:153247
increased anti-double stranded DNA antibody level J:153247
increased B cell number J:153247
increased follicular B cell number J:153247
increased leukocyte cell number J:153247
increased monocyte cell number J:153247
increased splenocyte number J:153247
spleen hyperplasia J:153247
\Wastm1Sbs/\Wastm1Sbs
(129S6/SvEvTac-Wastm1Sbs/J)
glomerulonephritis J:180407
increased IgA level J:180407
increased IgM level J:180407
\Wastm1Sbs/\Wastm1Sbs
(involves: 129S6/SvEvTac * C57BL/6)
abnormal B cell physiology J:182528
decreased marginal zone B cell number J:182528
decreased mature B cell number J:182528
increased anti-chromatin antibody level J:182528
increased anti-double stranded DNA antibody level J:182528
increased anti-single stranded DNA antibody level J:182528
increased autoantibody level J:182528
increased germinal center B cell number J:182528
increased IgA level J:182528
increased IgE level J:182528
increased IgM level J:182528
increased plasma cell number J:182528
\Wastm1Sbs/\Wastm1Sbs
\Wasltm2Sbs/\Wasltm2Sbs
\Tg(Lck-cre)1Cwi/?

(involves: 129S6/SvEvTac * C57BL/6)
abnormal double-negative T cell morphology J:125309
abnormal double-positive T cell morphology J:125309
abnormal thymocyte activation J:125309
colitis J:125309
decreased regulatory T cell number J:125309
decreased single-positive T cell number J:125309
decreased T cell number J:125309
decreased thymocyte number J:125309
increased single-positive T cell number J:125309
\Wastm2Itl/Y
(Not Specified)
abnormal dendritic cell morphology J:153247
abnormal dendritic cell physiology J:153247
abnormal lymphocyte morphology J:153247
decreased NK cell number J:153247
decreased T cell number J:153247
decreased T cell proliferation J:153247
increased anti-double stranded DNA antibody level J:153247
increased B cell number J:153247
increased follicular B cell number J:153247
increased leukocyte cell number J:153247
increased splenocyte number J:153247
\Wastm2Itl/\Wastm2Itl
(Not Specified)
abnormal dendritic cell morphology J:153247
abnormal dendritic cell physiology J:153247
abnormal lymphocyte morphology J:153247
decreased NK cell number J:153247
decreased T cell number J:153247
decreased T cell proliferation J:153247
increased anti-double stranded DNA antibody level J:153247
increased B cell number J:153247
increased follicular B cell number J:153247
increased leukocyte cell number J:153247
increased splenocyte number J:153247
\Wasltm1.1Ttha/\Wasltm1.1Ttha
\Tg(KRT14-cre)1Amc/0

(involves: C57BL/6 * C57BL/6N * CBA)
abnormal circulating chemokine level J:271857
dermatitis J:271857
increased circulating interleukin-1 alpha level J:271857
increased circulating interleukin-6 level J:271857
increased circulating interleukin-17 level J:271857
increased circulating tumor necrosis factor level J:271857
increased susceptibility to bacterial infection J:271857
skin inflammation J:271857
\Wbcq1C57BLKS/J/\Wbcq1C57BLKS/J
(involves: C57BLKS/J * SM/J)
increased leukocyte cell number J:102636
\Wbcq1C57BLKS/J/\Wbcq1SM/J
(involves: C57BLKS/J * SM/J)
increased leukocyte cell number J:102636
\Wbcq2C57BLKS/J/\Wbcq2SM/J
(involves: C57BLKS/J * SM/J)
increased leukocyte cell number J:102636
\Wbcq2C57BLKS/J/\Wbcq2SM/J
\Wbcq3C57BLKS/J/\Wbcq3C57BLKS/J

(involves: C57BLKS/J * SM/J)
increased leukocyte cell number J:102636
\Wbcq2SM/J/\Wbcq2SM/J
(involves: C57BLKS/J * SM/J)
increased leukocyte cell number J:102636
\Wbcq2SM/J/\Wbcq2SM/J
\Wbcq3C57BLKS/J/\Wbcq3C57BLKS/J

(involves: C57BLKS/J * SM/J)
increased leukocyte cell number J:102636
\Wbcq3C57BLKS/J/\Wbcq3SM/J
(involves: C57BLKS/J * SM/J)
increased leukocyte cell number J:102636
\Wbcq3SM/J/\Wbcq3SM/J
(involves: C57BLKS/J * SM/J)
increased leukocyte cell number J:102636
\Wbcq4NZW/LacJ/\Wbcq4NZW/LacJ
(involves: NZW/LacJ * SM/J)
increased leukocyte cell number J:102636
\Wbcq4NZW/LacJ/\Wbcq4SM/J
(involves: NZW/LacJ * SM/J)
increased leukocyte cell number J:102636
\Wbcq5NZW/LacJ/\Wbcq5NZW/LacJ
(involves: NZW/LacJ * SM/J)
increased leukocyte cell number J:102636
\Wbcq6NZW/LacJ/\Wbcq6NZW/LacJ
(involves: NZW/LacJ * SM/J)
increased leukocyte cell number J:102636
\Wbcq6SM/J/\Wbcq6SM/J
(involves: NZW/LacJ * SM/J)
increased leukocyte cell number J:102636
\Wbp1em1(IMPC)Tcp/\Wbp1em1(IMPC)Tcp
(C57BL/6NCrl-Wbp1em1(IMPC)Tcp/Cmmr)
increased monocyte cell number J:211773
\Wbp1ltm2a(EUCOMM)Hmgu/\Wbp1ltm2a(EUCOMM)Hmgu
(involves: C57BL/6N)
abnormal pre-B cell morphology J:284781
decreased B cell number J:284781
decreased B-1 B cell number J:284781
decreased pre-B cell number J:284781
decreased pro-B cell number J:284781
immune system phenotype J:284781
increased dendritic cell number J:284781
increased marginal zone B cell number J:284781
\Wbp2tm2a(EUCOMM)Wtsi/\Wbp2tm2a(EUCOMM)Wtsi
(C57BL/6N-Wbp2tm2a(EUCOMM)Wtsi/Cnrm)
increased leukocyte cell number J:165965
\Wbp11em1Gcha/\Wbp11+
(involves: C57BL/6J * FVB/N)
ectopic thymus J:300837
\Wdfy3em1(IMPC)Mbp/\Wdfy3+
(C57BL/6N-Wdfy3em1(IMPC)Mbp/MbpMmucd)
abnormal lymph node morphology J:211773
abnormal spleen morphology J:211773
enlarged lymph nodes J:211773
enlarged spleen J:211773
\Wdfy4em1Jkln/\Wdfy4em1Jkln
(C57BL/6J-Wdfy4em1Jkln)
decreased dendritic cell number J:326216
immune system phenotype J:326216
\Wdr1Gt(XN462)Byg/\Wdr1rede
(involves: 129P2/OlaHsd * C57BL/6)
ear inflammation J:134092
skin inflammation J:134092
\Wdr1rede/\Wdr1rede
(Not Specified)
increased inflammatory response J:85113
\Wdr1rede/\Wdr1rede
(C57BL/6-Wdr1rede)
abnormal myelopoiesis J:134092
abnormal osteoclast physiology J:134092
abnormal thrombopoiesis J:134092
ear inflammation J:134092
impaired neutrophil chemotaxis J:134092
increased neutrophil cell number J:134092
increased osteoclast cell number J:134092
skin inflammation J:134092
\Wdr27em1(IMPC)Ccpcz/\Wdr27em1(IMPC)Ccpcz
(C57BL/6NCrl-Wdr27em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
enlarged spleen J:211773
\Wdr37tm1a(KOMP)Wtsi/\Wdr37tm1a(KOMP)Wtsi
(C57BL/6N-Wdr37tm1a(KOMP)Wtsi/Wtsi)
decreased leukocyte cell number J:211773
\Wdr41m1Btlr/\Wdr41m1Btlr
(C57BL/6J-Wdr41m1Btlr)
increased CD4-positive, alpha-beta T cell number J:268243
increased CD8-positive, alpha-beta T cell number J:268243
increased circulating interleukin-12b level J:268243
increased susceptibility to induced colitis J:268243
increased tumor necrosis factor secretion J:268243
\Wdr41m2Btlr/\Wdr41m2Btlr
(C57BL/6J-Wdr41m2Btlr)
increased CD4-positive, alpha-beta T cell number J:268243
increased CD8-positive, alpha-beta T cell number J:268243
increased tumor necrosis factor secretion J:268243
\Wdr45em1Wrst/Y
(involves: C57BL/6N * FVB)
increased leukocyte cell number J:307284
\Wdr59tm1b(EUCOMM)Wtsi/\Wdr59+
(C57BL/6N-Wdr59tm1b(EUCOMM)Wtsi/Wtsi)
decreased leukocyte cell number J:211773
\Wdr62em1(IMPC)Tcp/\Wdr62em1(IMPC)Tcp
(C57BL/6NCrl-Wdr62em1(IMPC)Tcp/Tcp)
enlarged lymph nodes J:211773
\Wdr83tm1Guwo/\Wdr83+
(involves: C57BL/6)
kidney inflammation J:153983
\Wdr89m1Anu/\Wdr89m1Anu
(C57BL/6NCrlAnu-Wdr89m1Anu)
immune system phenotype J:104190
\Wfdc1tm1Bcm/\Wfdc1tm1Bcm
(involves: 129S7/SvEvBrd * C57BL/6)
decreased susceptibility to Orthomyxoviridae infection J:216357
\Wfdc2em1(IMPC)H/\Wfdc2+
(C57BL/6NTac-Wfdc2em1(IMPC)H/H)
decreased eosinophil cell number J:211773
\Wfdc2tm1.1Ohbo/\Wfdc2tm1.1Ohbo
(involves: C57BL/6NCrlj * CBA/JNCrlj)
abnormal cytokine level J:282576
lung inflammation J:282576
\Wfdc15aem1Ohbo/\Wfdc15aem1Ohbo
(involves: Slc:ICR)
testis inflammation J:360881
\Whrnwi/\Whrnwi
(involves: C57BL/6J * STOCK a Tyrp1b Myo5ad Oca2p Ednrbs)
decreased leukocyte cell number J:5538
decreased thymus weight J:5037
\Why1MOLF/EiJ/?
(involves: C57BL/6J * MOLF/Ei)
increased interleukin-6 secretion J:131437
\Why2MOLF/EiJ/?
(involves: C57BL/6J * MOLF/Ei)
decreased interleukin-6 secretion J:131437
\Wipf1tm1Geha/\Wipf1tm1Geha
(involves: 129S6/SvEvTac)
abnormal T cell physiology J:74719
decreased T cell proliferation J:74719
decreased thymocyte number J:74719
increased B cell proliferation J:74719
increased IgE level J:74719
increased IgM level J:74719
thymus hypoplasia J:74719
\Wipf1tm1Geha/\Wipf1tm1Geha
(involves: 129S6/SvEvTac * C57BL/6)
abnormal alpha-beta T cell morphology J:116168
abnormal lymph node B cell domain morphology J:116168
abnormal lymphopoiesis J:116168
abnormal Peyer's patch T cell area morphology J:116168
abnormal spleen morphology J:116168
abnormal thymus morphology J:116168
colitis J:116168
decreased B cell number J:116168
decreased follicular B cell number J:116168
decreased lymphocyte cell number J:116168
decreased marginal zone B cell number J:116168
decreased spleen white pulp amount J:116168
decreased thymus weight J:116168
enlarged spleen J:116168
glomerulonephritis J:116168
increased autoantibody level J:116168
increased granulocyte number J:116168
increased IgA level J:116168
increased monocyte cell number J:116168
increased spleen red pulp amount J:116168
interstitial pneumonia J:116168
joint inflammation J:116168
lung inflammation J:116168
\Wlstm1.1Arte/\Wlstm1.1Arte
\Krt14tm1(cre)Wbm/\Krt14+

(involves: 129P2/OlaHsd * C57BL/6)
abnormal T cell differentiation J:202499
abnormal T cell physiology J:202499
abnormal T cell subpopulation ratio J:202499
cutaneous mastocytosis J:202499
decreased double-positive T cell number J:202499
decreased gamma-delta T cell number J:202499
decreased T cell number J:202499
decreased thymus weight J:202499
increased double-negative T cell number J:202499
increased macrophage cell number J:202499
increased neutrophil cell number J:202499
increased T cell proliferation J:202499
skin inflammation J:202499
small thymus medulla J:202499
thymus atrophy J:202499
thymus hypoplasia J:202499
\Wlstm1.1Arte/\Wlstm1.1Arte
\Tg(Foxn1-cre)1Tbo/0

(involves: C57BL/6)
immune system phenotype J:202499
\Wnt1tm1Brd/\Wnt1tm1Brd
(involves: 129S7/SvEvBrd * C57BL/6J)
decreased thymocyte number J:75999
\Wnt1tm1Brd/\Wnt1tm1Brd
\Wnt4tm1Amc/\Wnt4tm1Amc

(involves: 129S1/Sv * 129S7/SvEvBrd * C57BL/6J)
decreased thymocyte number J:75999
\Wnt2btm1b(EUCOMM)Wtsi/\Wnt2btm1b(EUCOMM)Wtsi
(C57BL/6N-Wnt2btm1b(EUCOMM)Wtsi/Tcp)
abnormal spleen morphology J:211773
enlarged spleen J:211773
small spleen J:211773
\Wnt3aem1(IMPC)Ccpcz/\Wnt3a+
(C57BL/6NCrl-Wnt3aem1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
increased eosinophil cell number J:211773
\Wnt4em1(IMPC)Hmgu/\Wnt4+
(C57BL/6NCrl-Wnt4em1(IMPC)Hmgu/Ieg)
decreased lymphocyte cell number J:211773
increased monocyte cell number J:211773
increased neutrophil cell number J:211773
\Wnt4tm1Amc/\Wnt4tm1Amc
(involves: 129S1/Sv)
decreased thymocyte number J:75999
\Wnt5ab2b3077.1Clo/\Wnt5ab2b3077.1Clo
(C57BL/6J-Wnt5ab2b3077.1Clo)
thymus hypoplasia J:175213
\Wrnb2b3121.1Clo/\Wrnb2b3121.1Clo
(C57BL/6J-Wrnb2b3121.1Clo)
thymus hypoplasia J:175213
\Wrnem1(IMPC)Ccpcz/\Wrnem1(IMPC)Ccpcz
(C57BL/6NCrl-Wrnem1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
\Wrntm1Led/\Wrntm1Led
(involves: 129S6/SvEvTac * Black Swiss)
heart inflammation J:106446
increased susceptibility to infection J:106446
\Wrntm1Lgu/\Wrntm1Lgu
(B6J.Cg-Wrntm1Lgu)
increased osteoclast cell number J:213181
\Wrnip1tm1a(EUCOMM)Wtsi/\Wrnip1tm1a(EUCOMM)Wtsi
(C57BL/6N-Wrnip1tm1a(EUCOMM)Wtsi/Cnrm)
decreased T cell number J:165965
\Wsb1tm1.1Jszh/\Wsb1tm1.1Jszh
\Ubcem1(cre/ERT2)Smoc/\Ubc+

(involves: C57BL/6J * C57BL/6N)
decreased inflammatory response J:358004
\Wt1tm1Jae/\Wt1tm1Jae
(involves: 129S4/SvJae * C57BL/6 * MF1)
abnormal spleen development J:56651
absent spleen J:56651
increased splenocyte apoptosis J:56651
\Wt1tm1Mlh/\Wt1+
(involves: 129P2/OlaHsd * C57BL/6)
glomerulonephritis J:135449
\Wt1tm1Mlh/\Wt1+
(129P2/OlaHsd-Wt1tm1Mlh)
glomerulonephritis J:135449
\Wt1tm1Mlh/\Wt1+
(involves: 129P2/OlaHsd * C57BL/6 * MF1)
glomerulonephritis J:135449
\Wwc1tm1Arsc/\Wwc1tm1Arsc
\Wwc2tm1.1Arte/\Wwc2tm1.1Arte
\Speer6-ps1Tg(Alb-cre)21Mgn/\Speer6-ps1+

(involves: 129 * C57BL/6 * C57BL/6J * DBA)
liver inflammation J:305034
\Wwoxem1Mald/\Wwoxem1Mald
(FVB/N-Wwoxem1Mald)
microgliosis J:339564
\Wwoxtm1.1Mald/\Wwoxtm1.1Mald
(involves: C57BL/6 * FVB/N)
abnormal thymus cortex morphology J:155406
decreased leukocyte cell number J:155406
decreased spleen weight J:155406
decreased thymus weight J:155406
small spleen J:155406
spleen atrophy J:155406
\Wwoxtm1Ria/\Wwox+
(involves: 129X1/SvJ * C57BL/6)
enlarged spleen J:120064
\Wwoxtm1Ria/\Wwoxtm1Ria
(involves: 129X1/SvJ * C57BL/6J)
abnormal osteoclast physiology J:138140
\Wwp2tm1.1Yyiw/\Wwp2tm1.1Yyiw
(involves: 129S/SvEv * C57BL/6 * FVB/N)
immune system phenotype J:228707
increased circulating interferon-beta level J:228707
increased circulating interleukin-6 level J:228707
increased circulating tumor necrosis factor level J:228707
\Wwtr1tm1Benj/\Wwtr1tm1Benj
(129S6/SvEvTac-Wwtr1tm1Benj)
intestinal inflammation J:125326
lung inflammation J:125326
\Wwtr1tm1Benj/\Wwtr1tm1Benj
(129S-Wwtr1tm1Benj/J)
intestinal inflammation J:156586
lung inflammation J:156586
\Wwtr1tm1Hku/\Wwtr1tm1Hku
(involves: 129 * C57BL/6 * ICR)
alveolitis J:164957
lung inflammation J:164957
\Wwtr1tm1Whun/\Wwtr1tm1Whun
(either: (involves: 129S6/SvEvTac) or (involves: 129S6/SvEvTac * C57BL/6))
tubular nephritis J:119488
\Xaf1em2.1Cya/\Xaf1em2.1Cya
(C57BL/6J-Xaf1em2.1Cya)
abnormal tumor necrosis factor level J:344340
decreased circulating CXCL10 level J:344340
decreased circulating interferon-beta level J:344340
decreased macrophage cytokine production J:344340
immune system phenotype J:344340
increased susceptibility to Riboviria infection J:344340
increased susceptibility to Riboviria infection induced morbidity/mortality J:344340
\Xbp1tm1a(EUCOMM)Wtsi/\Xbp1+
(C57BL/6N-Xbp1tm1a(EUCOMM)Wtsi/Ics)
decreased IgG1 level J:165965
decreased T cell number J:165965
\Xbp1tm1b(EUCOMM)Wtsi/\Xbp1+
(C57BL/6N-Xbp1tm1b(EUCOMM)Wtsi/Ics)
decreased large unstained cell number J:211773
decreased leukocyte cell number J:211773
decreased lymphocyte cell number J:211773
\Xbp1tm2Glm/\Xbp1+
\Tg(Vil1-cre)997Gum/0

(involves: 129S6/SvEvTac * C57BL/6J * FVB/N * SJL)
small intestinal inflammation J:188627
\Xbp1tm2Glm/\Xbp1tm2Glm
\Tg(Defa6-icre)1Rsb/0

(involves: 129S6/SvEvTac * C57BL/6)
small intestinal inflammation J:206084
\Xbp1tm2Glm/\Xbp1tm2Glm
\Tg(Nes-cre)1Kln/0

(involves: 129S6/SvEvTac * C57BL/6 * SJL)
decreased susceptibility to prion infection J:131028
\Xbp1tm2Glm/\Xbp1tm2Glm
\Tg(Vil1-cre)997Gum/0

(involves: 129S6/SvEvTac * C57BL/6J * FVB/N * SJL)
increased susceptibility to bacterial infection J:188627
increased susceptibility to induced colitis J:188627
small intestinal inflammation J:188627
\Xbp1tm2Glm/\Xbp1tm2Glm
\Tg(Vil1-cre)997Gum/0

(involves: 129S6/SvEvTac * C57BL/6 * SJL)
small intestinal inflammation J:206084
\Xbp1tm2Glm/\Xbp1tm2Glm
\Tg(Vil1-cre/ERT2)23Syr/0

(involves: 129S6/SvEvTac * C57BL/6 * DBA/2)
small intestinal inflammation J:206084
\Xbp1tm2Glm/\Xbp1tm2Glm
\Tnfrsf1atm1Imx/\Tnfrsf1atm1Imx
\Tg(Vil1-cre)997Gum/0

(involves: 129S6/SvEvTac * C57BL/6 * SJL)
small intestinal inflammation J:206084
\Xbp1tm3Glm/\Xbp1tm3Glm
\Tg(Vil1-cre/ERT2)23Syr/0

(involves: 129S6/SvEvTac * C57BL/6 * DBA/2)
small intestinal inflammation J:188627
\Xcl1tm1.1Dnax/\Xcl1tm1.1Dnax
(either: (involves: 129/Sv * BALB/c) or (involves: 129/Sv * C57BL/6))
abnormal immune system morphology J:176844
autoimmune response J:176844
decreased dendritic cell number J:176844
decreased regulatory T cell number J:176844
heart inflammation J:176844
increased dendritic cell number J:176844
increased inflammatory response J:176844
lacrimal gland inflammation J:176844
liver inflammation J:176844
salivary gland inflammation J:176844
stomach inflammation J:176844
\Xcl1tm1Rakr/\Xcl1tm1Rakr
(B6.129-Xcl1tm1Rakr)
decreased cytotoxic T cell cytolysis J:155297
immune system phenotype J:155297
\Xcl1tm1Rakr/\Xcl1tm1Rakr
\Tg(TcraTcrb)1100Mjb/0

(involves: 129/Sv * C57BL/6)
abnormal CD8-positive, alpha-beta T cell physiology J:155297
decreased cytotoxic T cell cytolysis J:155297
decreased interferon-gamma secretion J:155297
decreased T cell number J:155297
\Xcr1tm1Dgen/\Xcr1tm1Dgen
(B6.129P2-Xcr1tm1Dgen/J)
abnormal dendritic cell physiology J:155297
immune system phenotype J:155297
\Xcr1tm2(HBEGF/Venus)Ksho/\Xcr1+
(involves: C57BL/6 * C57BL/6J)
abnormal antigen presentation J:204851
abnormal CD8-positive, alpha-beta T cell physiology J:204851
decreased dendritic cell number J:204851
decreased interferon-gamma secretion J:204851
decreased susceptibility to bacterial infection J:204851
immune system phenotype J:204851
\Xdhtm1.1Takni/\Xdhtm1.1Takni
(involves: C57BL/6)
abnormal peritoneal macrophage morphology J:281671
\Xdhtm1Fink/\Xdhtm1Fink
(involves: 129X1/SvJ * C57BL/6J)
tubulointerstitial nephritis J:166326
\Xiaptm1Hs/\Xiaptm1Hs
(B6.129P2-Xiaptm1Hs)
immune system phenotype J:138979
\Xkrxtm1b(EUCOMM)Wtsi/\Xkrxtm1b(EUCOMM)Wtsi
(C57BL/6N-Xkrxtm1b(EUCOMM)Wtsi/Wtsi)
increased anti-nuclear antigen antibody level J:211773
\Xpatm1Tnka/\Xpatm1Tnka
(involves: C57BL/6 * CBA)
abnormal immune system physiology J:35054
abnormal Langerhans cell physiology J:35054
abnormal lymphocyte physiology J:55739
abnormal NK cell physiology J:55739
increased NK cell number J:55739
\Xpnpep1tm1a(KOMP)Wtsi/\Xpnpep1tm1a(KOMP)Wtsi
(C57BL/6N-Xpnpep1tm1a(KOMP)Wtsi/Wtsi)
abnormal thymus morphology J:239583
blood in lymph vessels J:239583
increased gamma-delta T cell number J:211773
increased NK cell number J:211773
\Xpo5em1(IMPC)Mbp/\Xpo5+
(C57BL/6NCrl-Xpo5em1(IMPC)Mbp/Mmucd)
abnormal spleen morphology J:211773
enlarged spleen J:211773
\Xpr1Sxv/\Xpr1Sxv
(M. spretus)
increased susceptibility to Retroviridae infection J:7951
\Xrcc4tm1Fwa/\Xrcc4tm1Fwa
(involves: 129P2/OlaHsd * C57BL/6)
thymus hypoplasia J:65218
\Xrcc5em1(IMPC)Ccpcz/\Xrcc5em1(IMPC)Ccpcz
(C57BL/6NCrl-Xrcc5em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
decreased CD4-positive NK T cell number J:211773
decreased CD4-positive, alpha-beta T cell number J:211773
decreased CD4-positive, CD25-positive, alpha-beta regulatory T cell number J:211773
decreased CD8-positive, alpha-beta T cell number J:211773
decreased CD8-positive, naive alpha-beta T cell number J:211773
decreased effector memory T-helper cell number J:211773
decreased leukocyte cell number J:211773
decreased memory-marker CD4-positive NK T cell number J:211773
decreased NK T cell number J:211773
decreased T-helper cell number J:211773
immune system phenotype J:211773
increased effector memory CD8-positive, alpha-beta T cell number J:211773
increased effector memory T-helper cell number J:211773
small spleen J:211773
small thymus J:211773
\Xrcc5m1Btlr/\Xrcc5m1Btlr
(C57BL/6J-Xrcc5m1Btlr)
abnormal B cell differentiation J:274736
abnormal CD8-positive, alpha-beta T cell differentiation J:274736
abnormal T cell differentiation J:274736
decreased B-2 B cell number J:274736
decreased CD4-positive, alpha-beta T cell number J:274736
decreased CD8-positive, alpha-beta T cell number J:274736
decreased CD8-positive, naive alpha-beta T cell number J:274736
decreased T cell number J:274736
increased B-1a cell number J:274736
increased B-1b cell number J:274736
increased CD4-positive, alpha-beta T cell number J:274736
increased dendritic cell number J:274736
increased effector memory CD4-positive, alpha-beta T cell number J:274736
increased effector memory CD8-positive, alpha-beta T cell number J:274736
increased neutrophil cell number J:274736
\Xrcc5tm1Dbr/\Xrcc5tm1Dbr
(involves: 129S1/Sv * C57BL/6)
abnormal B cell differentiation J:34834
absent T cells J:34834
arrested B cell differentiation J:34834
arrested T cell differentiation J:34834
increased double-negative T cell number J:34834
lymph node hypoplasia J:34834
thymus hypoplasia J:34834
\Xrcc5tm1Dbr/\Xrcc5tm1Dbr
\Lig4tm1Fwa/\Lig4tm1Fwa

(involves: 129S6/SvEvTac * C57BL/6)
abnormal lymphocyte morphology J:80467
\Xrcc5tm1Nus/\Xrcc5tm1Nus
(involves: 129S1/Sv * 129X1/SvJ)
abnormal class switch recombination J:120658
abnormal humoral immune response J:120658
spleen hypoplasia J:108657
thymus hypoplasia J:108657
\Xrcc6avon/\Xrcc6avon
(involves: C57BL/6JAnu)
decreased B cell number J:104190
decreased T cell number J:104190
\Xrcc6tm1Fwa/\Xrcc6tm1Fwa
(involves: 129S6/SvEvTac * C57BL/6J)
abnormal B cell differentiation J:44361
abnormal B cell morphology J:44361
abnormal T cell differentiation J:44361
abnormal T cell morphology J:44361
absent immature B cells J:44361
absent mature B cells J:44361
absent pre-B cells J:44361
arrested B cell differentiation J:44361
decreased IgM level J:44361
decreased single-positive T cell number J:44361
decreased thymocyte number J:44361
increased double-positive T cell number J:44361
increased T cell derived lymphoma incidence J:44361
\Xrcc6tm1Gcl/\Xrcc6tm1Gcl
(involves: 129S1/Sv * C57BL/6)
abnormal B cell differentiation J:108657
abnormal immune system organ morphology J:108657
absent mature B cells J:108657
decreased spleen white pulp amount J:108657
small lymph nodes J:108657
small spleen J:108657
small thymus J:108657
spleen hypoplasia J:108657
thymus hypoplasia J:108657
\Xylt1npo/\Xylt1npo
(involves: C57BL/6J * FVB/NJ)
abnormal osteoclast differentiation J:205339
X/\Yaa
((NZB x BXSB)F1)
abnormal immune cell physiology J:6235
abnormal lymph node morphology J:6235
enlarged lymph nodes J:6235
increased anti-erythrocyte antigen antibody level J:6235
increased anti-nuclear antigen antibody level J:6235
increased autoantibody level J:6235
increased spleen weight J:6235
increased susceptibility to autoimmune disorder J:6235
X/\Yaa
((SJL/J x BXSB)F1)
enlarged lymph nodes J:6235
increased susceptibility to autoimmune disorder J:6235
X/\Yaa
((C57BL/6J x BXSB)F1)
enlarged lymph nodes J:6235
increased susceptibility to autoimmune disorder J:6235
X/\Yaa
(involves: BXSB * NZB)
enlarged lymph nodes J:6235
increased susceptibility to autoimmune disorder J:6235
X/\Yaa
(BXSB/MpJ)
abnormal B cell differentiation J:108760
abnormal lymph node morphology J:6235
abnormal spleen B cell follicle morphology J:179430
abnormal T cell subpopulation ratio J:179430
enlarged lymph nodes J:6235
glomerulonephritis J:6235
increased anti-erythrocyte antigen antibody level J:6235
increased anti-nuclear antigen antibody level J:179430
increased circulating interleukin-21 level J:93740
increased IgG1 level J:179430, J:93740
increased IgG2a level J:179430
increased IgG2b level J:179430
increased IgG3 level J:93740
increased monocyte cell number J:7308
increased plasma cell number J:108760
increased spleen weight J:6235
increased splenocyte number J:179430
increased susceptibility to autoimmune disorder J:108760, J:6235
X/\Yaa
((NZW x SB)F1)
abnormal immune serum protein physiology J:7276
glomerulonephritis J:7276
increased susceptibility to autoimmune disorder J:7276
X/\Yaa
((NZW x BXSB)F1)
abnormal immune serum protein physiology J:7276
increased susceptibility to autoimmune disorder J:7276
X/\Yaa
(BXSB/MpJScr)
decreased CD4-positive, alpha-beta T cell number J:10973
glomerulonephritis J:10973
increased anti-nuclear antigen antibody level J:10973
increased IgG level J:10973
increased monocyte cell number J:10973
increased susceptibility to autoimmune disorder J:10973
X/\Yaa
((NZB x B6.SB/Le-Yaa)F1)
increased monocyte cell number J:129409
X/\Yaa
(B6.SB-Yaa/J)
decreased marginal zone B cell number J:127600
increased splenocyte proliferation J:127600
\Yaa2BXSB/J/?
(involves: BXSB/J * C57BL/10Ola)
kidney inflammation J:49868
\Yaa3BXSB/J/?
(involves: BXSB/J * C57BL/10Ola)
kidney inflammation J:49868
\Yaa4BXSB/J/?
(involves: BXSB/J * C57BL/10Ola)
kidney inflammation J:49868
\YaailNZW/Ola/?
(involves: C57BL/6Ola * NZW/Ola)
glomerulonephritis J:52110
increased anti-double stranded DNA antibody level J:52110
\Yap1M1Btlr/\Yap1M1Btlr
(C57BL/6J-Yap1M1Btlr)
increased susceptibility to induced colitis J:267549
\Yap1tm1.1Dupa/\Yap1tm1.1Dupa
\Tg(Vil1-cre)997Gum/0

(involves: 129P2/OlaHsd * C57BL/6J * SJL)
increased susceptibility to induced colitis J:165471
\Ydjctm1(KOMP)Wtsi/\Ydjctm1(KOMP)Wtsi
(C57BL/6N-Ydjctm1(KOMP)Wtsi/Wtsi)
increased effector memory T-helper cell number J:211773
increased germinal center B cell number J:211773
\Yeats4em1Zfa/\Yeats4em1Zfa
\Commd10Tg(Vav1-icre)A2Kio/\Commd10+

(involves: C57BL/6 * C57BL/10 * CBA/Ca)
abnormal acute inflammation J:282740
abnormal gut-associated lymphoid tissue morphology J:282740
abnormal interleukin secretion J:282740
abnormal lymphocyte physiology J:282740
abnormal lymphopoiesis J:282740
decreased interferon-gamma secretion J:282740
decreased interleukin-5 secretion J:282740
decreased interleukin-12 secretion J:282740
decreased lymphocyte cell number J:282740
decreased Peyer's patch number J:282740
increased susceptibility to bacterial infection J:282740
\Yipf6em1(IMPC)Mbp/\Yipf6em1(IMPC)Mbp
(C57BL/6N-Yipf6em1(IMPC)Mbp/MbpMmucd)
abnormal spleen morphology J:211773
increased monocyte cell number J:211773
\Yipf6M1Btlr/Y
(C57BL/6J-Yipf6M1Btlr/Mmucd)
colitis J:187584
increased susceptibility to induced colitis J:187584
\Yipf6M1Btlr/\Yipf6M1Btlr
(C57BL/6J-Yipf6M1Btlr/Mmucd)
colitis J:187584
increased susceptibility to induced colitis J:187584
\Ykt6em1(IMPC)J/\Ykt6+
(C57BL/6NJ-Ykt6em1(IMPC)J/Mmjax)
decreased leukocyte cell number J:211773
\Yod1em1Smoc/\Yod1em1Smoc
(C57BL/6JSmoc-Yod1em1Smoc/Smoc)
abnormal macrophage physiology J:350806
decreased circulating fibrinogen level J:350806
increased circulating interleukin-1 beta level J:350806
increased inflammatory response J:350806
increased interleukin-1 beta secretion J:350806
increased macrophage cytokine production J:350806
increased susceptibility to bacterial infection J:350806
increased susceptibility to bacterial infection induced morbidity/mortality J:350806
\Yod1tm1bNarl/\Yod1tm1bNarl
(C57BL/6N-Yod1tm1bNarl/Narl)
decreased lymphocyte cell number J:211773
increased neutrophil cell number J:211773
\Ythdf3em1(IMPC)Mbp/\Ythdf3em1(IMPC)Mbp
(C57BL/6N-Ythdf3em1(IMPC)Mbp/MbpMmucd)
abnormal thymus morphology J:211773
enlarged thymus J:211773
\Ythdf3em1Caox/\Ythdf3em1Caox
(involves: C57BL/6J)
abnormal macrophage physiology J:276397
decreased susceptibility to Riboviria infection J:276397
decreased susceptibility to Riboviria infection induced morbidity/mortality J:276397
immune system phenotype J:276397
\Ywhaztm1b(EUCOMM)Hmgu/\Ywhaz+
(C57BL/6N-Ywhaztm1b(EUCOMM)Hmgu/Tcp)
enlarged lymph nodes J:211773
increased leukocyte cell number J:211773
increased lymphocyte cell number J:211773
\Yy1tm3.1Yshi/\Yy1+
(involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6J)
immune system phenotype J:208226
\Yy2em1(IMPC)Mbp/\Yy2em1(IMPC)Mbp
(C57BL/6NCrl-Yy2em1(IMPC)Mbp/Mmucd)
abnormal lymph node morphology J:211773
enlarged lymph nodes J:211773
\Zap70m1Btlr/\Zap70m1Btlr
(involves: C57BL/6J)
abnormal class switch recombination J:185495
abnormal humoral immune response J:167119
absent CD4-positive, alpha-beta T cells J:167119
absent CD8-positive, alpha-beta T cells J:167119
decreased IgG level J:185495
decreased T cell number J:185495
immune system phenotype J:167119, J:185495
\Zap70m1Saka/\Zap70m1Saka
(involves: BALB/c)
abnormal lymph node cell ratio J:154166
abnormal positive T cell selection J:154166, J:86607
abnormal splenic cell ratio J:154166
abnormal T cell clonal deletion J:154166
abnormal T cell differentiation J:86607
abnormal T cell selection J:86607
abnormal thymocyte activation J:154166
abnormal thymus cell ratio J:154166
chronic joint inflammation J:86607
decreased CD4-positive, alpha-beta T cell number J:154166, J:86607
decreased CD8-positive, alpha-beta T cell number J:154166, J:86607
decreased interleukin-2 secretion J:154166
decreased regulatory T cell number J:154166
decreased T cell proliferation J:154166, J:86607
increased activated T cell number J:154166
increased autoantibody level J:86607
increased B cell number J:86607
increased immunoglobulin level J:86607
increased interleukin-17 secretion J:154166
increased memory T cell number J:154166
increased susceptibility to induced arthritis J:154166
lung inflammation J:86607
rheumatoid arthritis J:86607
\Zap70m1Saka/\Zap70m1Saka
\Tg(DO11.10)10Dlo/0

(involves: BALB/c * C3H * C57BL/6)
decreased T cell number J:86607
decreased T cell proliferation J:86607
\Zap70m1Saka/\Zap70m1Saka
\Tg(TcraH-Y,TcrbH-Y)71Vbo/0

(involves: BALB/c * C57BL/6J * DBA/2J)
abnormal positive T cell selection J:86607
autoimmune arthritis J:86607
\Zap70m1Saka/\Zap70tm1Dlo
(involves: 129P2/OlaHsd * BALB/c)
autoimmune arthritis J:86607
\Zap70m1Saka/\Zap70tm2.1Weis
(involves: 129S4/SvJae * BALB/c)
abnormal T cell clonal deletion J:154166
decreased susceptibility to induced arthritis J:154166
\Zap70m2Btlr/\Zap70m2Btlr
(involves: C57BL/6J)
decreased T cell number J:174837
\Zap70m3Btlr/\Zap70m3Btlr
(C57BL/6J-Zap70m3Btlr)
decreased IgG level J:225043
impaired humoral immune response J:225043
\Zap70m4Btlr/\Zap70m4Btlr
(C57BL/6J-Zap70m4Btlr)
decreased CD4-positive, alpha-beta T cell number J:236698
decreased CD8-positive, alpha-beta T cell number J:236698
decreased T cell number J:236698
\Zap70m5Btlr/\Zap70m5Btlr
(C57BL/6J-Zap70m5Btlr)
abnormal humoral immune response J:254830
decreased CD4-positive, CD25-positive, alpha-beta regulatory T cell number J:254830
decreased CD8-positive, alpha-beta T cell number J:254830
decreased CD8-positive, naive alpha-beta T cell number J:254830
decreased IgG level J:254830
increased B cell number J:254830
increased central memory CD4-positive, alpha-beta T cell number J:254830
increased central memory CD8 positive, alpha-beta T cell number J:254830
increased effector memory CD4-positive, alpha-beta T cell number J:254830
\Zap70m6Btlr/\Zap70m6Btlr
(C57BL/6J-Zap70m6Btlr)
abnormal humoral immune response J:254831
decreased CD4-positive, CD25-positive, alpha-beta regulatory T cell number J:254831
decreased CD8-positive, alpha-beta T cell number J:254831
decreased CD8-positive, naive alpha-beta T cell number J:254831
decreased IgG level J:254831
increased B cell number J:254831
increased central memory CD4-positive, alpha-beta T cell number J:254831
increased central memory CD8 positive, alpha-beta T cell number J:254831
increased effector memory CD4-positive, alpha-beta T cell number J:254831
\Zap70m6Hefl/\Zap70m6Hefl
(C3HeB/FeJ-Zap70m6Hefl)
abnormal humoral immune response J:137446
abnormal T cell differentiation J:137446
decreased CD4-positive, alpha-beta T cell number J:137446
decreased CD8-positive, alpha-beta T cell number J:137446
decreased T cell number J:137446
immune system phenotype J:137446
increased IgE level J:137446
increased IgG1 level J:137446
\Zap70m6Hefl/\Zap70tm1Weis
(involves: 129X1/SvJ * C3HeB/FeJ * C57BL/10 * DBA/2)
decreased T cell number J:137446
increased IgE level J:137446
\Zap70m7Btlr/\Zap70m7Btlr
(C57BL/6J-Zap70m7Btlr)
abnormal humoral immune response J:254832
decreased IgG level J:254832
increased CD4-positive, CD25-positive, alpha-beta regulatory T cell number J:254832
increased central memory CD8 positive, alpha-beta T cell number J:254832
\Zap70m8Btlr/\Zap70m8Btlr
(C57BL/6J-Zap70m8Btlr)
decreased CD8-positive, naive alpha-beta T cell number J:272864
increased central memory CD8 positive, alpha-beta T cell number J:272864
\Zap70mrtle/\Zap70mrtle
(C57BL/6JSfdAnu-Zap70mrtle/Apb)
abnormal positive T cell selection J:104190
abnormal T cell subpopulation ratio J:104190
absent T cells J:104190
arrested T cell differentiation J:104190
decreased T cell number J:104190
\Zap70mrtle/\Zap70mrtle
(involves: C57BL/6JSfdAnu)
abnormal double-positive T cell morphology J:211510
abnormal regulatory T cell number J:211510
decreased CD4-positive, alpha-beta T cell number J:211510
decreased CD8-positive, alpha-beta T cell number J:211510
increased double-positive T cell number J:211510
\Zap70mrtle/\Zap70rps
(involves: C57BL/6 * C57BL/6JSfdAnu)
abnormal CD4-positive, alpha beta T cell morphology J:211510
abnormal double-positive T cell morphology J:211510
abnormal regulatory T cell number J:211510
decreased CD4-positive, alpha-beta T cell number J:211510
decreased CD8-positive, alpha-beta T cell number J:211510
increased double-positive T cell number J:211510
\Zap70mur/\Zap70mur
(C57BL/6Apb-Zap70mur/ApbH)
abnormal T cell activation J:104190
abnormal T cell physiology J:104190
decreased T cell number J:104190
increased IgG2b level J:104190
\Zap70st/\Zap70st
(involves: C57BL/6)
abnormal T cell physiology J:41170
arrested T cell differentiation J:41170
decreased T cell number J:41170
thymus hypoplasia J:41170
\Zap70st/\Zap70tm1Dlo
(involves: C57BL/6)
arrested T cell differentiation J:41170
\Zap70tm1.1Mmal/\Zap70tm1.1Mmal
(B6.129P2-Zap70tm1.1Mmal)
immune system phenotype J:71099
\Zap70tm1.1Mmal/\Zap70tm1.1Mmal
\Tg(TcraH-Y,TcrbH-Y)71Vbo/0

(involves: 129P2/OlaHsd * BALB/cJ * C57BL/6J * DBA/2J)
immune system phenotype J:71099
\Zap70tm1.1Mmal/\Zap70tm1.1Mmal
\Tg(TcrLCMV)327Sdz/0

(involves: 129P2/OlaHsd * BALB/cJ * C57BL/6 * DBA/2)
abnormal cytokine secretion J:71099
abnormal T cell proliferation J:71099
immune system phenotype J:71099
\Zap70tm1Dlo/\Zap70tm1Dlo
(involves: 129P2/OlaHsd)
increased double-positive T cell number J:97610
\Zap70tm1Weis/\Zap70tm1Weis
(involves: 129X1/SvJ * C57BL/6J)
abnormal lymph node cell ratio J:74974
abnormal splenic cell ratio J:74974
abnormal T cell differentiation J:74974
arrested T cell differentiation J:74974
small lymph nodes J:74974
\Zap70tm2.1Mmal/\Zap70tm2.1Mmal
(B6.129P2-Zap70tm2.1Mmal)
immune system phenotype J:71099
\Zap70tm2.1Mmal/\Zap70tm2.1Mmal
\Tg(TcraH-Y,TcrbH-Y)71Vbo/0

(involves: 129P2/OlaHsd * BALB/cJ * C57BL/6J * DBA/2J)
abnormal lymph node cell ratio J:71099
abnormal T cell morphology J:71099
abnormal thymus cell ratio J:71099
immune system phenotype J:71099
\Zap70tm2.1Mmal/\Zap70tm2.1Mmal
\Tg(TcrLCMV)327Sdz/0

(involves: 129P2/OlaHsd * BALB/cJ * C57BL/6 * DBA/2)
abnormal T cell morphology J:71099
immune system phenotype J:71099
\Zap70tm2.1Weis/\Zap70tm2.1Weis
(B6.129S4-Zap70tm2.1Weis)
abnormal CD8-positive, alpha-beta T cell differentiation J:154166
abnormal thymus cell ratio J:154166
decreased CD4-positive, alpha-beta T cell number J:154166
decreased CD8-positive, alpha-beta T cell number J:154166
\Zap70tm2.1Weis/\Zap70tm2.1Weis
(C.129S4-Zap70tm2.1Weis)
abnormal lymph node cell ratio J:154166
abnormal positive T cell selection J:154166
abnormal regulatory T cell physiology J:154166
abnormal splenic cell ratio J:154166
abnormal T cell clonal deletion J:154166
abnormal thymocyte activation J:154166
abnormal thymus cell ratio J:154166
decreased CD4-positive, alpha-beta T cell number J:154166
decreased CD8-positive, alpha-beta T cell number J:154166
decreased interleukin-2 secretion J:154166
decreased regulatory T cell number J:154166
decreased T cell proliferation J:154166
immune system phenotype J:154166
increased activated T cell number J:154166
increased interleukin-17 secretion J:154166
increased memory T cell number J:154166
\Zap70tm2.1Weis/\Zap70tm2.1Weis
\Tg(DO11.10)10Dlo/?

(involves: 129S4/SvJae * BALB/c * C3H * C57BL/6)
abnormal positive T cell selection J:154166
\Zap70tm2.1Weis/\Zap70tm2.1Weis
\Tg(TcraH-Y,TcrbH-Y)71Vbo/?

(involves: 129S4/SvJae * C57BL/6J * DBA/2J)
abnormal positive T cell selection J:154166
abnormal T cell clonal deletion J:154166
\Zbp1tm1.1Jreh/\Zbp1tm1.1Jreh
(involves: C57BL/6 * C57BL/6N)
increased susceptibility to Herpesvirales infection J:252669
\Zbp1tm1Aki/\Zbp1tm1Aki
(involves: C57BL/6)
immune system phenotype J:132662
\Zbtb1m1Btlr/\Zbtb1m1Btlr
(involves: C3H/HeN * C57BL/6J)
abnormal B cell differentiation J:178820
abnormal immune system physiology J:178820
abnormal T cell differentiation J:178820
abnormal thymus morphology J:178820
decreased B cell number J:178820
decreased CD4-positive, alpha-beta T cell number J:178820
decreased CD8-positive, alpha-beta T cell number J:178820
decreased DN2 thymocyte number J:178820
decreased DN3 thymocyte number J:178820
decreased DN4 thymocyte number J:178820
decreased double-positive T cell number J:178820
decreased follicular B cell number J:178820
decreased NK cell number J:178820
decreased T cell number J:178820
decreased transitional stage B cell number J:178820
immune system phenotype J:178820
increased B cell number J:178820
thymus hypoplasia J:178820
\Zbtb1m2Btlr/\Zbtb1m2Btlr
(C57BL/6J-Zbtb1m2Btlr)
abnormal CD8-positive, alpha-beta T cell differentiation J:272845
increased central memory CD8 positive, alpha-beta T cell number J:272845
\Zbtb7atm1Ppp/\Zbtb7atm1Ppp
(B6.129S1-Zbtb7atm1Ppp)
abnormal lymphopoiesis J:121576
abnormal response to transplant J:121576
decreased B cell number J:121576
decreased pro-B cell number J:121576
\Zbtb7atm1Ppp/\Zbtb7atm2Ppp
\Tg(Mx1-cre)1Cgn/0

(involves: 129S1/Sv * C57BL/6 * CBA)
abnormal B cell differentiation J:121576
abnormal double-positive T cell morphology J:121576
abnormal response to transplant J:121576
decreased B cell number J:121576
decreased leukocyte cell number J:121576
immune system phenotype J:121576
\Zbtb7bhd/\Zbtb7bhd
(involves: 129/Sv * BALB/c * C3H * C57BL/6)
abnormal CD4-positive T cell differentiation J:48734
absent CD4-positive, alpha-beta T cells J:48734
increased CD8-positive, alpha-beta T cell number J:48734
\Zbtb7bhpls/\Zbtb7bhpls
(involves: C57BL/6JAnu)
abnormal humoral immune response J:104190
decreased CD4-positive, alpha-beta T cell number J:104190
\Zbtb7btm1.1Rbo/\Zbtb7btm1.1Rbo
(Not Specified)
abnormal CD8-positive, alpha-beta T cell number J:141145
abnormal T cell differentiation J:141145
decreased CD4-positive, alpha-beta T cell number J:141145
\Zbtb7btm1.1Skok/\Zbtb7btm1.1Skok
(involves: 129/Sv * C57BL/6)
decreased CD4-positive, alpha-beta T cell number J:169841
\Zbtb7btm1.1Tani/\Zbtb7btm1.1Tani
(involves: 129 * C57BL/6)
increased double-negative T cell number J:141142
\Zbtb7btm1Itan/\Zbtb7btm1.1Tani
(involves: 129 * C57BL/6)
abnormal CD4-positive, alpha beta T cell morphology J:141142
abnormal CD4-positive, alpha-beta T cell physiology J:141142
decreased CD4-positive, alpha-beta T cell number J:141142
increased CD8-positive, alpha-beta T cell number J:141142
increased double-negative T cell number J:141142
\Zbtb7btm1Itan/\Zbtb7btm2Itan
(involves: 129 * C57BL/6)
decreased CD4-positive, alpha-beta T cell number J:141142
increased CD8-positive, alpha-beta T cell number J:141142
increased double-negative T cell number J:141142
\Zbtb7btm1Litt/\Zbtb7btm1.2Litt
(involves: C57BL/6)
abnormal double-positive T cell morphology J:141144
decreased CD4-positive, alpha-beta T cell number J:141144
increased CD8-positive, alpha-beta T cell number J:141144
increased interferon-gamma secretion J:141144
\Zbtb7btm2Litt/\Zbtb7btm1.2Litt
(involves: 129P2/OlaHsd)
decreased CD4-positive, alpha-beta T cell number J:141144
\Zbtb7btm2Litt/\Zbtb7btm1.2Litt
\Tg(Lck-cre)1Cwi/?

(involves: 129P2/OlaHsd * C57BL/6)
abnormal T cell differentiation J:141144
decreased CD4-positive, alpha-beta T cell number J:141144
\Zbtb7btm2Litt/\Zbtb7btm2Litt
(involves: 129P2/OlaHsd * C57BL/6 * FVB/N)
absent CD4-positive, alpha-beta T cells J:141519
\Zbtb7btm4.1Itan/\Zbtb7btm4.1Itan
(Not Specified)
decreased CD4-positive, alpha-beta T cell number J:193321
increased CD8-positive, alpha-beta T cell number J:193321
\Zbtb7btm6.1Itan/\Zbtb7btm6.1Itan
\Tg(Cd4-cre)1Cwi/?

(involves: C57BL/6 * DBA/2)
decreased CD8-positive, alpha-beta T cell number J:195348
\Zbtb7btm6.1Itan/\Zbtb7btm6.1Itan
\Tg(Cd8a-cre)1Itan/?

(involves: C57BL/6)
immune system phenotype J:195348
\Zbtb7btm7Itan/\Zbtb7btm7Itan
(Not Specified)
decreased CD4-positive, alpha-beta T cell number J:195348
\Zbtb16em1(IMPC)Mbp/\Zbtb16em1(IMPC)Mbp
(C57BL/6NCrl-Zbtb16em1(IMPC)Mbp/MbpMmucd)
abnormal spleen morphology J:211773
small spleen J:211773
\Zbtb16lu/\Zbtb16lu
(B6.C3-Zbtb16lu/J)
decreased NK T cell number J:139690
\Zbtb17tm1Cksn/\Zbtb17tm1Cksn
\Commd10Tg(Vav1-icre)A2Kio/\Commd10+

(B6.Cg-Zbtb17tm1Cksn Commd10Tg(Vav1-icre)A2Kio)
arrested T cell differentiation J:170508
decreased DN1 thymic pro-T cell number J:170508
decreased DN2 thymocyte number J:170508
decreased DN3 thymocyte number J:170508
decreased double-negative T cell number J:170508
decreased gamma-delta T cell number J:170508
decreased T cell number J:170508
decreased thymocyte number J:170508
increased T cell apoptosis J:170508
thymus hypoplasia J:170508
\Zbtb17tm1Cksn/\Zbtb17tm1Cksn
\Tg(Lck-cre)548Jxm/0

(B6.Cg-Zbtb17tm1Cksn Tg(Lck-cre)548Jxm)
immune system phenotype J:170508
\Zbtb32tm1Iho/\Zbtb32tm1Iho
(involves: BALB/c)
abnormal cytokine secretion J:94944
increased T cell proliferation J:94944
\Zbtb32tm1Iho/\Zbtb32tm1Iho
(involves: C57BL/6)
increased T cell proliferation J:94944
\Zbtb32tm2Ppp/\Zbtb32tm2Ppp
(involves: 129S1/Sv)
abnormal cytokine secretion J:95119
increased T cell proliferation J:95119
\Zbtb38em1Dbhat/\Zbtb38em1Dbhat
\Commd10Tg(Vav1-icre)A2Kio/\Commd10+

(involves: C57BL/6J * C57BL/6N * C57BL/10 * CBA/Ca)
immune system phenotype J:296556
\Zbtb42em1(IMPC)Mbp/\Zbtb42em1(IMPC)Mbp
(C57BL/6NCrl-Zbtb42em1(IMPC)Mbp/Mmucd)
enlarged lymph nodes J:211773
\Zbtb46tm1(HBEGF)Mnz/\Zbtb46+
(C57BL/6-Zbtb46tm1(HBEGF)Mnz)
abnormal memory T cell physiology J:189122
abnormal response to infection J:189122
abnormal T-helper 1 physiology J:189122
decreased dendritic cell number J:189122
immune system phenotype J:189122
increased monocyte cell number J:189122
increased neutrophil cell number J:189122
increased susceptibility to parasitic infection J:189122
\Zbtb46tm1Kmm/\Zbtb46tm1Kmm
(129S/SvEv-Zbtb46tm1Kmm)
abnormal dendritic cell physiology J:184205
immune system phenotype J:184205
\Zbtb46tm2.1Mnz/\Zbtb46tm2.1Mnz
(involves: C57BL/6)
abnormal dendritic cell morphology J:191314
abnormal lymphangiogenesis J:191314
decreased dendritic cell number J:191314
enlarged lymph nodes J:191314
increased dendritic cell number J:191314
lymph node hyperplasia J:191314
\Zc2hc1bem1(IMPC)Ccpcz/\Zc2hc1bem1(IMPC)Ccpcz
(C57BL/6NCrl-Zc2hc1bem1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged thymus J:211773
\Zc2hc1cem1(IMPC)Ccpcz/\Zc2hc1cem1(IMPC)Ccpcz
(C57BL/6N-Zc2hc1cem1(IMPC)Ccpcz/Ccpcz)
abnormal thymus morphology J:211773
enlarged thymus J:211773
\Zc3h7aitem1Caox/\Zc3h7aitem1Caox
(C57BL/6J-Zc3h7aitem1Caox)
abnormal interferon secretion J:282488
abnormal macrophage activation involved in immune response J:282488
decreased circulating interferon-alpha level J:282488
decreased circulating interferon-beta level J:282488
decreased circulating interleukin-6 level J:282488
decreased interferon-alpha secretion J:282488
decreased interferon-beta secretion J:282488
decreased interleukin-6 secretion J:282488
immune system phenotype J:282488
increased susceptibility to Riboviria infection J:282488
increased susceptibility to Riboviria infection induced morbidity/mortality J:282488
\Zc3h7bem1(IMPC)J/\Zc3h7bem1(IMPC)J
(C57BL/6NJ-Zc3h7bem1(IMPC)J/Mmjax)
decreased leukocyte cell number J:211773
\Zc3h8em1(IMPC)Ccpcz/\Zc3h8+
(C57BL/6N-Zc3h8em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
decreased CD8-positive, naive alpha-beta T cell number J:211773
enlarged spleen J:211773
\Zc3h11aem1(IMPC)Mbp/\Zc3h11a+
(C57BL/6NCrl-Zc3h11aem1(IMPC)Mbp/Mmucd)
abnormal thymus morphology J:211773
\Zc3h12atm1Aki/\Zc3h12atm1Aki
(involves: 129X1/SvJ * C57BL/6)
abnormal acute inflammation J:147868
abnormal class switch recombination J:147868
enlarged lymph nodes J:147868
enlarged spleen J:147868
granulomatous inflammation J:147868
increased anti-double stranded DNA antibody level J:147868
increased anti-nuclear antigen antibody level J:147868
increased IgA level J:147868
increased IgG1 level J:147868
increased IgG2a level J:147868
increased IgG2b level J:147868
increased IgG3 level J:147868
increased IgM level J:147868
increased immunoglobulin level J:147868
increased interferon-gamma secretion J:147868
increased interleukin-6 secretion J:147868
increased interleukin-12b secretion J:147868
increased leukocyte cell number J:147868
increased memory T cell number J:147868
increased plasma cell number J:147868
\Zc3h12atm1c(EUCOMM)Hmgu/\Zc3h12atm1c(EUCOMM)Hmgu
\Lyz2tm1(cre)Ifo/\Lyz2+

(involves: 129P2/OlaHsd * C57BL/6N)
increased inflammatory response J:304105
\Zc3h12atm1c(EUCOMM)Hmgu/\Zc3h12atm1c(EUCOMM)Hmgu
\Speer6-ps1Tg(Alb-cre)21Mgn/\Speer6-ps1+

(involves: C57BL/6 * C57BL/6N * DBA)
bile duct inflammation J:304105
enlarged spleen J:304105
granulomatous inflammation J:304105
increased anti-nuclear antigen antibody level J:304105
increased autoantibody level J:304105
increased IgG level J:304105
increased IgM level J:304105
liver inflammation J:304105
\Zc3h12atm1Fum/\Zc3h12atm1Fum
(C57BL/6-Zc3h12atm1Fum)
abnormal chemokine secretion J:176866
abnormal circulating chemokine level J:176866
enlarged lymph nodes J:176866
enlarged spleen J:176866
increased circulating tumor necrosis factor level J:176866
increased interleukin-1 beta secretion J:176866
increased interleukin-6 secretion J:176866
increased tumor necrosis factor secretion J:176866
\Zc3h12bem1(IMPC)Tcp/\Zc3h12bem1(IMPC)Tcp
(C57BL/6NCrl-Zc3h12bem1(IMPC)Tcp/Tcp)
enlarged lymph nodes J:211773
\Zc3h12cem1(IMPC)Tcp/\Zc3h12cem1(IMPC)Tcp
(C57BL/6NCrl-Zc3h12cem1(IMPC)Tcp/Tcp)
decreased lymphocyte cell number J:211773
enlarged lymph nodes J:211773
increased neutrophil cell number J:211773
\Zc3h12ctm2c(EUCOMM)Hmgu/\Zc3h12ctm2c(EUCOMM)Hmgu
\Cd19tm1(cre)Cgn/\Cd19+

(involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6N)
immune system phenotype J:277714
\Zc3h12ctm2c(EUCOMM)Hmgu/\Zc3h12ctm2c(EUCOMM)Hmgu
\Lyz2tm1(cre)Ifo/\Lyz2+

(involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6N)
enlarged lymph nodes J:277714
increased B cell number J:277714
increased CD4-positive, alpha-beta T cell number J:277714
increased effector memory CD8-positive, alpha-beta T cell number J:277714
increased immature B cell number J:277714
increased marginal zone B cell number J:277714
\Zc3h12ctm2c(EUCOMM)Hmgu/\Zc3h12ctm2c(EUCOMM)Hmgu
\Tg(Cd4-cre)1Cwi/0

(involves: 129S4/SvJaeSor * C57BL/6N * DBA/2)
immune system phenotype J:277714
\Zc3h12ctm2d(EUCOMM)Hmgu/\Zc3h12ctm2d(EUCOMM)Hmgu
(involves: 129S4/SvJaeSor * C57BL/6N)
abnormal lymph node cortex morphology J:277714
abnormal lymph node primary follicle morphology J:277714
decreased CD8-positive, alpha-beta T cell number J:277714
decreased germinal center B cell number J:277714
decreased macrophage cell number J:277714
enlarged lymph nodes J:277714
immune system phenotype J:277714
increased B cell number J:277714
increased CD4-positive, alpha-beta T cell number J:277714
increased circulating interferon-gamma level J:277714
increased effector memory CD4-positive, alpha-beta T cell number J:277714
increased IgA level J:277714
increased IgG level J:277714
increased IgM level J:277714
increased immature B cell number J:277714
increased marginal zone B cell number J:277714
increased splenocyte number J:277714
increased T cell number J:277714
\Zc3h12dtm1b(EUCOMM)Hmgu/\Zc3h12dtm1b(EUCOMM)Hmgu
(C57BL/6N-Zc3h12dtm1b(EUCOMM)Hmgu/Orl)
decreased lymphocyte cell number J:211773
increased monocyte cell number J:211773
increased neutrophil cell number J:211773
\Zc3h12dtm1Tom/\Zc3h12dtm1Tom
(B6.Cg-Zc3h12dtm1Tom)
immune system phenotype J:209383
increased interleukin-6 secretion J:209383
increased interleukin-10 secretion J:209383
increased susceptibility to experimental autoimmune encephalomyelitis J:209383
increased T cell proliferation J:209383
increased T-helper 17 cell number J:209383
\Zc3hav1ltm1b(EUCOMM)Wtsi/\Zc3hav1ltm1b(EUCOMM)Wtsi
(C57BL/6N-Zc3hav1ltm1b(EUCOMM)Wtsi/Tcp)
increased eosinophil cell number J:211773
\Zcchc3em1Hbsh/\Zcchc3em1Hbsh
(involves: C57BL/6)
abnormal innate immunity J:271802
decreased circulating CXCL10 level J:271802
decreased circulating interferon-beta level J:271802
decreased circulating interleukin-6 level J:271802
increased susceptibility to Herpesvirales infection J:271802
increased susceptibility to Herpesvirales infection induced morbidity/mortality J:271802
increased susceptibility to Poxviridae infection induced morbidity/mortality J:271802
\Zcchc4em1(IMPC)Bay/\Zcchc4em1(IMPC)Bay
(C57BL/6N-Zcchc4em1(IMPC)Bay/Bay)
abnormal lymph node morphology J:211773
\Zcchc17em1(IMPC)Hmgu/\Zcchc17em1(IMPC)Hmgu
(C57BL/6NCrl-Zcchc17em1(IMPC)Hmgu/Ieg)
increased spleen weight J:211773
\Zcrb1em1(IMPC)Ccpcz/\Zcrb1+
(C57BL/6NCrl-Zcrb1em1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
\Zcwpw1em1(IMPC)Tcp/\Zcwpw1em1(IMPC)Tcp
(C57BL/6N-Zcwpw1em1(IMPC)Tcp/Tcp)
enlarged lymph nodes J:211773
\Zdbf2em1(IMPC)J/\Zdbf2em1(IMPC)J
(C57BL/6NJ-Zdbf2em1(IMPC)J/Mmjax)
decreased leukocyte cell number J:211773
\Zdhhc1tm1Yyiw/\Zdhhc1tm1Yyiw
(involves: 129S6/SvEvTac)
abnormal circulating cytokine level J:284987
decreased circulating interferon-alpha level J:284987
decreased circulating interferon-beta level J:284987
decreased circulating interleukin-6 level J:284987
decreased circulating tumor necrosis factor level J:284987
immune system phenotype J:284987
increased susceptibility to Herpesvirales infection J:284987
increased susceptibility to Herpesvirales infection induced morbidity/mortality J:284987
\Zdhhc2em1Eko/\Zdhhc2em1Eko
(C57BL/6-Zdhhc2em1Eko)
abnormal cytokine level J:303593
abnormal interferon level J:303593
abnormal interleukin level J:303593
abnormal plasmacytoid dendritic cell physiology J:303593
abnormal T cell activation J:303593
abnormal tumor necrosis factor level J:303593
decreased dendritic epidermal T cell number J:303593
decreased leukocyte cell number J:303593
decreased plasmacytoid dendritic cell number J:303593
decreased susceptibility to chemically induced skin inflammation J:303593
increased alpha-beta T cell number J:303593
increased gamma-delta T cell number J:303593
\Zdhhc9tm1Lex/Y
(involves: 129S5/SvEvBrd * C57BL/6)
abnormal leukocyte physiology J:231488
\Zdhhc11tm1.1(KOMP)Vlcg/\Zdhhc11tm1.1(KOMP)Vlcg
(involves: C57BL/6NTac)
decreased circulating interleukin-6 level J:310891
decreased susceptibility to endotoxin shock J:310891
decreased susceptibility to viral infection J:310891
\Zdhhc13skc4/\Zdhhc13skc4
(involves: 129S6/SvEvTac * C3H * C57BL/6)
abnormal Kupffer cell morphology J:161519
decreased leukocyte cell number J:161519
enlarged spleen J:161519
increased neutrophil cell number J:161519
\Zeb1m1Btlr/\Zeb1m1Btlr
(involves: C57BL/6J)
abnormal B cell differentiation J:185495
abnormal class switch recombination J:185495
abnormal memory B cell physiology J:185495
absent marginal zone B cells J:185495
decreased B cell proliferation J:185495
decreased B-1 B cell number J:185495
decreased B-1a cell number J:185495
decreased B-1b cell number J:185495
decreased double-positive T cell number J:185495
decreased germinal center B cell number J:185495
decreased IgG1 level J:185495
decreased IgG level J:185495
decreased IgM level J:185495
decreased NK cell number J:185495
immune system phenotype J:185495
increased single-positive T cell number J:185495
increased thymocyte number J:185495
\Zeb1m2Btlr/\Zeb1m2Btlr
(C57BL/6J-Zeb1m2Btlr)
impaired humoral immune response J:221490
\Zeb1tm1Yhi/\Zeb1tm1Yhi
(B6.129P2-Zeb1tm1Yhi)
abnormal T cell differentiation J:39865
abnormal T cell subpopulation ratio J:39865
abnormal thymus development J:39865
decreased CD8-positive, alpha-beta T cell number J:39865
decreased double-positive T cell number J:39865
decreased lymphocyte cell number J:39865
decreased splenocyte number J:39865
decreased T cell number J:39865
decreased thymocyte number J:39865
lymph node hypoplasia J:39865
small thymus J:39865
thymus hypoplasia J:39865
\Zeb1tm1Yhi/\Zeb1tm1Yhi
(either: (involves: 129 * C3H * C57BL/6) or (involves: 129 * C57BL/6 * ICR))
increased T cell derived lymphoma incidence J:139194
\Zeb1tm2Yhi/\Zeb1tm2Yhi
(B6.129-Zeb1tm2Yhi)
decreased thymocyte number J:45575
thymus hypoplasia J:45575
\Zeb1Tw/\Zeb1+
(B6.Cg-Zeb1Tw)
decreased leukocyte cell number J:177274
decreased lymphocyte cell number J:177274
decreased neutrophil cell number J:177274
small spleen J:177274
small thymus J:177274
\Zfand2btm1Otin/\Zfand2b+
(involves: 129S7/SvEvBrd * C57BL/6)
increased granulocyte number J:233169
\Zfand2btm1Otin/\Zfand2btm1Otin
(involves: 129S7/SvEvBrd * C57BL/6)
abnormal myeloid leukocyte morphology J:233169
decreased lymphocyte cell number J:233169
enlarged spleen J:233169
increased granulocyte number J:233169
increased leukocyte cell number J:233169
increased lymphocyte cell number J:233169
increased spleen weight J:233169
\Zfand3em1(IMPC)J/\Zfand3em1(IMPC)J
(C57BL/6NJ-Zfand3em1(IMPC)J/Mmjax)
decreased leukocyte cell number J:211773
\Zfand6em1(IMPC)Mbp/\Zfand6em1(IMPC)Mbp
(C57BL/6N-Zfand6em1(IMPC)Mbp/MbpMmucd)
abnormal lymph node morphology J:211773
abnormal spleen morphology J:211773
enlarged lymph nodes J:211773
enlarged spleen J:211773
\Zfatem1(IMPC)Ccpcz/\Zfat+
(C57BL/6NCrl-Zfatem1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
abnormal thymus morphology J:211773
enlarged spleen J:211773
enlarged thymus J:211773
\Zfattm2.1Sawa/\Zfattm2.1Sawa
\Tg(Cd4-cre)1Cwi/0

(involves: C57BL/6 * C57BL/6JJcl * C57BL/6NCrSlc * DBA/2)
abnormal CD4-positive, alpha-beta T cell physiology J:187164
abnormal CD8-positive, alpha-beta T cell differentiation J:187164
decreased CD4-positive, alpha-beta T cell number J:187164
decreased CD8-positive, alpha-beta T cell number J:187164
decreased interleukin-2 secretion J:187164
decreased T cell proliferation J:187164
immune system phenotype J:187164
increased T cell apoptosis J:187164
\Zfp14tm1Xch/\Zfp14+
(involves: C57BL/6)
chronic pancreas inflammation J:331393
increased inflammatory response J:331393
lymph node hyperplasia J:331393
spleen hyperplasia J:331393
thymus hyperplasia J:331393
\Zfp14tm1Xch/\Zfp14tm1Xch
(involves: C57BL/6)
chronic pancreas inflammation J:331393
increased inflammatory response J:331393
lymph node hyperplasia J:331393
spleen hyperplasia J:331393
thymus hyperplasia J:331393
\Zfp30em1Snpk/\Zfp30em1Snpk
(C57BL/6J-Zfp30em1Snpk/Mmnc)
immune system phenotype J:300801
\Zfp35tm1Naka/\Zfp35tm1Naka
(either: B6.Cg-Zfp35tm1Naka or C.Cg-Zfp35tm1Naka)
abnormal T-helper 2 cell differentiation J:153828
increased circulating interleukin-4 level J:153828
increased circulating interleukin-5 level J:153828
increased circulating interleukin-13 level J:153828
increased eosinophil cell number J:153828
\Zfp36tm1(KOMP)Vlcg/\Zfp36+
(C57BL/6N-Zfp36tm1(KOMP)Vlcg/Nju)
increased leukocyte cell number J:211773
\Zfp36tm1Pjb/\Zfp36tm1Pjb
(Not Specified)
abnormal thymus cortex morphology J:33986
abnormal thymus medulla morphology J:33986
autoimmune arthritis J:33986
conjunctivitis J:33986
dermatitis J:33986
enlarged lymph nodes J:33986
enlarged spleen J:33986
heart inflammation J:33986
increased leukocyte cell number J:33986
liver inflammation J:33986
spleen hyperplasia J:33986
thymus hypoplasia J:33986
\Zfp36tm1Pjb/\Zfp36tm1Pjb
(B6.Cg-Zfp36tm1Pjb)
abnormal macrophage physiology J:88443
autoimmune arthritis J:88443
blood vessel inflammation J:214114
decreased lymphocyte cell number J:214114
increased granulocyte number J:214114
increased monocyte cell number J:214114
increased neutrophil cell number J:214114
\Zfp36tm2.1Pjb/\Zfp36tm2.1Pjb
(involves: C57BL/6)
decreased inflammatory response J:229078
decreased susceptibility to experimental autoimmune encephalomyelitis J:229078
decreased susceptibility to induced arthritis J:229078
\Zfp36tm4.1Pjb/\Zfp36tm4.1Pjb
\Lyz2tm1(cre)Ifo/\Lyz2+

(involves: 129P2/OlaHsd * C57BL/6 * C57BL/6N)
alveolitis J:188677
autoimmune arthritis J:188677
enlarged lymph nodes J:188677
enlarged spleen J:188677
increased circulating tumor necrosis factor level J:188677
increased inflammatory response J:188677
increased spleen weight J:188677
increased susceptibility to endotoxin shock J:188677
\Zfp36l1tm1.1Tnr/\Zfp36l1tm1.1Tnr
\Zfp36l2tm1.1Tnr/\Zfp36l2tm1.1Tnr
\Tg(CD2-icre)4Kio/0

(involves: C57BL/6 * C57BL/10 * CBA/Ca * SJL)
abnormal thymus development J:162388
enlarged lymph nodes J:162388
enlarged spleen J:162388
increased T cell derived lymphoma incidence J:162388
thymus atrophy J:162388
\Zfp36l2tm2Pjb/\Zfp36l2tm2Pjb
(involves: 129S7/SvEvBrd * C57BL/6)
decreased leukocyte cell number J:152911
decreased neutrophil cell number J:152911
decreased splenocyte number J:152911
\Zfp91em1(IMPC)Tcp/\Zfp91+
(C57BL/6N-Zfp91em1(IMPC)Tcp/Tcp)
enlarged lymph nodes J:211773
\Zfp106tm1a(KOMP)Wtsi/\Zfp106tm1a(KOMP)Wtsi
(involves: C57BL/6Brd * C57BL/6Dnk * C57BL/6N)
microgliosis J:229162
\Zfp119atm1b(EUCOMM)Hmgu/\Zfp119atm1b(EUCOMM)Hmgu
(C57BL/6N-Zfp119atm1b(EUCOMM)Hmgu/Ieg)
increased leukocyte cell number J:211773
\Zfp131tm1.1Mytk/\Zfp131tm1.1Mytk
\Tg(Cd4-cre)1Cwi/0

(involves: C57BL/6 * C57BL/6N * DBA/2)
abnormal T cell subpopulation ratio J:271921
abnormal thymocyte activation J:271921
decreased CD4-positive, alpha-beta T cell number J:271921
decreased CD8-positive, alpha-beta T cell number J:271921
decreased T cell number J:271921
decreased T cell proliferation J:271921
immune system phenotype J:271921
\Zfp131tm1.1Mytk/\Zfp131tm1.2Mytk
\Tg(Lck-cre)1Jtak/0

(involves: C57BL/6N * FVB/N)
abnormal double-negative T cell morphology J:271921
abnormal T cell differentiation J:271921
arrested T cell differentiation J:271921
decreased CD4-positive, alpha-beta T cell number J:271921
decreased CD8-positive, alpha-beta T cell number J:271921
decreased DN2 thymocyte number J:271921
decreased DN3 thymocyte number J:271921
decreased DN4 thymocyte number J:271921
decreased double-negative T cell number J:271921
decreased double-positive T cell number J:271921
decreased T cell proliferation J:271921
decreased thymocyte number J:271921
\Zfp148tm1.1Jmer/\Zfp148tm1.1Jmer
\Tg(Vil1-cre)997Gum/0

(involves: C57BL/6 * C57BL/6J * SJL)
increased inflammatory response J:198847
increased susceptibility to bacterial infection J:198847
increased susceptibility to bacterial infection induced morbidity/mortality J:198847
\Zfp148tm1Djl/\Zfp148tm1Djl
(involves: 129)
increased susceptibility to induced colitis J:107441
\Zfp160tm1b(EUCOMM)Wtsi/\Zfp160tm1b(EUCOMM)Wtsi
(C57BL/6N-Zfp160tm1b(EUCOMM)Wtsi/BayMmucd)
decreased spleen weight J:211773
\Zfp207tm1b(EUCOMM)Hmgu/\Zfp207+
(C57BL/6N-Zfp207tm1b(EUCOMM)Hmgu/H)
decreased lymphocyte cell number J:211773
increased neutrophil cell number J:211773
\Zfp236em1(IMPC)Mbp/\Zfp236+
(C57BL/6NCrl-Zfp236em1(IMPC)Mbp/Mmucd)
abnormal spleen morphology J:211773
enlarged spleen J:211773
\Zfp260tm1b(NCOM)Mfgc/\Zfp260+
(C57BL/6N-Zfp260tm1b(NCOM)Mfgc/Tcp)
decreased lymphocyte cell number J:211773
increased neutrophil cell number J:211773
\Zfp281em1(IMPC)Mbp/\Zfp281+
(C57BL/6N-Zfp281em1(IMPC)Mbp/MbpMmucd)
abnormal spleen morphology J:211773
small spleen J:211773
\Zfp292em1Zfa/\Zfp292em1Zfa
(involves: C57BL/6)
increased susceptibility to bacterial infection J:259392
increased susceptibility to bacterial infection induced morbidity/mortality J:259392
\Zfp318m1Anu/\Zfp318+
(C57BL/6JAnu-Zfp318m1Anu)
decreased IgD level J:207375
increased IgM level J:207375
\Zfp318m1Anu/\Zfp318m1Anu
(C57BL/6JAnu-Zfp318m1Anu)
abnormal B cell number J:104190
abnormal follicular B cell physiology J:207375
abnormal marginal zone B cell physiology J:207375
decreased IgD level J:207375, J:104190
increased IgM level J:207375, J:104190
increased mature B cell number J:207375
\Zfp318M1Btlr/\Zfp318+
(C57BL/6J-Zfp318M1Btlr)
decreased IgD level J:218965
\Zfp318M1Btlr/\Zfp318M1Btlr
(C57BL/6J-Zfp318M1Btlr)
decreased IgD level J:218965
\Zfp318tm1.1Jhws/\Zfp318tm1.1Jhws
\Commd10Tg(Vav1-icre)A2Kio/\Commd10+

(B6.Cg-Zfp318tm1.1Jhws TgVav1-creA2Kio)
decreased IgD level J:215815
decreased transitional stage T2 B cell number J:215815
increased IgM level J:215815
\Zfp318tm1Hhag/\Zfp318tm1Hhag
(involves: 129 * C57BL/6)
decreased IgD level J:207375
increased IgM level J:207375
\Zfp335blt/\Zfp335blt
(involves: C57BL/6)
abnormal CD4-positive T cell differentiation J:214793
abnormal CD8-positive, alpha-beta T cell differentiation J:214793
abnormal T cell differentiation J:214793
decreased B cell number J:214793
decreased CD4-positive, alpha-beta memory T cell number J:214793
decreased CD4-positive, alpha-beta T cell number J:214793
decreased CD8-positive, alpha-beta memory T cell number J:214793
decreased CD8-positive, alpha-beta T cell number J:214793
decreased NK T cell number J:214793
decreased regulatory T cell number J:214793
decreased single-positive T cell number J:214793
\Zfp354aem1(IMPC)Mbp/\Zfp354aem1(IMPC)Mbp
(C57BL/6NCrl-Zfp354aem1(IMPC)Mbp/MbpMmucd)
abnormal lymph node morphology J:211773
abnormal spleen morphology J:211773
enlarged lymph nodes J:211773
enlarged spleen J:211773
\Zfp366b2b2834Clo/\Zfp366b2b2834Clo
(C57BL/6J-Zfp366b2b2834Clo)
thymus hypoplasia J:175213
\Zfp398em1(IMPC)Mbp/\Zfp398em1(IMPC)Mbp
(C57BL/6NCrl-Zfp398em1(IMPC)Mbp/Mmucd)
increased basophil cell number J:211773
\Zfp420tm1b(EUCOMM)Hmgu/\Zfp420tm1b(EUCOMM)Hmgu
(C57BL/6N-Zfp420tm1b(EUCOMM)Hmgu/Bay)
increased lymphocyte cell number J:211773
\Zfp467tm1.1(KOMP)Vlcg/\Zfp467tm1.1(KOMP)Vlcg
(B6(Cg)-Zfp467tm1.1(KOMP)Vlcg)
abnormal osteoclast physiology J:302865
increased osteoclast cell number J:302865
\Zfp469em1(IMPC)Mbp/\Zfp469em1(IMPC)Mbp
(C57BL/6N-Zfp469em1(IMPC)Mbp/MbpMmucd)
increased leukocyte cell number J:211773
increased lymphocyte cell number J:211773
\Zfp474em1(IMPC)Ccpcz/\Zfp474em1(IMPC)Ccpcz
(C57BL/6N-Zfp474em1(IMPC)Ccpcz/Ccpcz)
decreased lymphocyte cell number J:211773
increased eosinophil cell number J:211773
increased neutrophil cell number J:211773
\Zfp488em1(IMPC)Bay/\Zfp488em1(IMPC)Bay
(C57BL/6N-Zfp488em1(IMPC)Bay/Bay)
abnormal spleen morphology J:211773
\Zfp503em1(IMPC)Mbp/\Zfp503+
(C57BL/6N-Zfp503em1(IMPC)Mbp/Ucd)
abnormal lymph node morphology J:211773
enlarged lymph nodes J:211773
increased basophil cell number J:211773
\Zfp513em1(IMPC)J/\Zfp513em1(IMPC)J
(C57BL/6NJ-Zfp513em1(IMPC)J/Mmjax)
increased leukocyte cell number J:211773
\Zfp521tm1Nohk/\Zfp521tm1Nohk
(B6J.Cg-Zfp521tm1Nohk)
decreased spleen weight J:214267
decreased thymus weight J:214267
\Zfp574em1Btlr/\Zfp574em1Btlr
(C57BL/6J-Zfp574em1Btlr)
abnormal B cell physiology J:354285
abnormal class switch recombination J:354285
abnormal humoral immune response J:354285
decreased B cell number J:354285
decreased B cell proliferation J:354285
decreased B-1 B cell number J:354285
decreased IgA level J:354285
decreased IgG1 level J:354285
decreased IgG2a level J:354285
decreased IgG2b level J:354285
decreased IgG level J:354285
decreased IgM level J:354285
decreased immunoglobulin level J:354285
decreased leukocyte cell number J:354285
decreased lymphocyte cell number J:354285
decreased monocyte cell number J:354285
decreased neutrophil cell number J:354285
decreased T cell number J:354285
increased B cell apoptosis J:354285
\Zfp574em1Btlr/\Zfp574em1Btlr
\Tg(IghMyc)22Bri/0

(B6.Cg-Zfp574em1Btlr Tg(IghMyc)22Bri)
decreased pre-B cell number J:354285
\Zfp574em3Btlr/\Zfp574em3Btlr
\Ndor1Tg(UBC-cre/ERT2)1Ejb/\Ndor1+

(B6.Cg-Ndor1Tg(UBC-cre/ERT2)1Ejb Zfp574em3Btlr)
decreased B cell number J:354285
\Zfp574em3Btlr/\Zfp574em3Btlr
\Ndor1Tg(UBC-cre/ERT2)1Ejb/\Ndor1+
\Tg(IghMyc)22Bri/0

(B6.Cg-Ndor1Tg(UBC-cre/ERT2)1Ejb Zfp574em3Btlr Tg(IghMyc)22Bri)
decreased B cell number J:354285
\Zfp574m1Btlr/\Zfp574m1Btlr
(C57BL/6J-Zfp574m1Btlr)
abnormal humoral immune response J:354285
abnormal T cell physiology J:354285
decreased B cell number J:354285
\Zfp593em1(IMPC)J/\Zfp593em1(IMPC)J
(C57BL/6NJ-Zfp593em1(IMPC)J/Mmjax)
decreased leukocyte cell number J:211773
\Zfp595tm1b(KOMP)Wtsi/\Zfp595tm1b(KOMP)Wtsi
(C57BL/6N-Zfp595tm1b(KOMP)Wtsi/Bay)
decreased eosinophil cell number J:211773
decreased leukocyte cell number J:211773
decreased lymphocyte cell number J:211773
\Zfp616tm1b(KOMP)Wtsi/\Zfp616tm1b(KOMP)Wtsi
(C57BL/6N-Zfp616tm1b(KOMP)Wtsi/Wtsi)
increased KLRG1-positive T-helper cell number J:211773
\Zfp629em1(IMPC)Tcp/\Zfp629em1(IMPC)Tcp
(C57BL/6N-Zfp629em1(IMPC)Tcp/Tcp)
small spleen J:211773
\Zfp638em1(IMPC)J/\Zfp638+
(C57BL/6NJ-Zfp638em1(IMPC)J/Mmjax)
increased leukocyte cell number J:211773
\Zfp639tm1.2Jaty/\Zfp639tm1.2Jaty
(involves: 129 * BALB/cJ * C57BL/6 * SJL)
decreased susceptibility to Retroviridae infection J:305874
immune system phenotype J:305874
\Zfp644m1Anu/\Zfp644m1Anu
(C57BL/6NCrlAnu-Zfp644m1Anu)
immune system phenotype J:104190
\Zfp683Gt(OST314703)Lex/\Zfp683Gt(OST314703)Lex
(B6.129S5-Zfp683Gt(OST314703)Lex)
abnormal NK T cell morphology J:187727
abnormal susceptibility to infection J:187727
decreased NK T cell number J:187727
immune system phenotype J:187727
increased interferon-gamma secretion J:187727
\Zfp760tm1a(EUCOMM)Hmgu/\Zfp760+
(C57BL/6N-Zfp760tm1a(EUCOMM)Hmgu/Ieg)
decreased IgE level J:165965
\Zfp871tm1a(EUCOMM)Wtsi/\Zfp871+
(C57BL/6N-Zfp871tm1a(EUCOMM)Wtsi/BayMmucd)
liver inflammation J:317166
spleen hyperplasia J:317166
thymus hyperplasia J:317166
\Zfp950Gt(ROSA)76Sor/\Zfp950Gt(ROSA)76Sor
(involves: 129S4/SvJaeSor)
kidney inflammation J:117491
\Zfpm1tm1.1Esv/\Zfpm1tm1.1Esv
(involves: 129S6/SvEvTac * C57BL/6)
abnormal spleen morphology J:156475
increased granulocyte number J:156475
increased neutrophil cell number J:156475
increased spleen red pulp amount J:156475
increased spleen weight J:156475
\Zfpm1tm1.1Geab/\Zfpm1tm1.1Geab
(Not Specified)
abnormal circulating chemokine level J:162629
decreased spleen white pulp amount J:156393
enlarged spleen J:156393
increased monocyte cell number J:156393
increased neutrophil cell number J:156393
increased spleen weight J:156393
spleen hypoplasia J:156393
\Zftraf1em1(IMPC)H/\Zftraf1em1(IMPC)H
(C57BL/6NTac-Zftraf1em1(IMPC)H/H)
decreased eosinophil cell number J:211773
\Zfxtm1.1Reiz/Y
\Tg(Mx1-cre)1Cgn/0

(involves: 129S6/SvEvTac * C57BL/6 * CBA)
decreased lymphocyte cell number J:149654
\Zfxtm1.1Reiz/Y
\Tg(Tek-cre)12Flv/0

(involves: 129S6/SvEvTac * C3H * C57BL/6)
decreased mature B cell number J:149654
decreased T cell number J:149654
\Zfyve1em1Hbsh/\Zfyve1em1Hbsh
(C57BL/6J-Zfyve1em1Hbsh)
decreased susceptibility to viral infection J:292942
decreased susceptibility to viral infection induced morbidity/mortality J:292942
\Zfyve16tm2a(KOMP)Wtsi/\Zfyve16tm2a(KOMP)Wtsi
(C57BL/6N-Zfyve16tm2a(KOMP)Wtsi)
decreased B cell number J:302014
decreased B cell proliferation J:302014
increased T cell number J:302014
\Zg16tm1Lex/\Zg16tm1Lex
(B6.129S-Zg16tm1Lex)
increased circulating interferon-gamma level J:239095
increased circulating interleukin-6 level J:239095
increased susceptibility to bacterial infection J:239095
\Zic2iso/\Zic2iso
(involves: C3H/HeH * C57BL/6)
abnormal spleen morphology J:268103
abnormal spleen size J:268103
absent spleen J:268103
\Zic3tm1Bca/Y
(involves: 129S7/SvEvBrd * C57BL/6)
spleen hypoplasia J:75951
\Zic3tm1Bca/\Zic3+
(involves: 129S7/SvEvBrd * C57BL/6)
spleen hypoplasia J:75951
\Zic3tm1Bca/\Zic3tm1Bca
(involves: 129S7/SvEvBrd * C57BL/6)
spleen hypoplasia J:75951
\Zkscan3tm1.2Itl/\Zkscan3tm1.2Itl
(B6.Cg-Zkscan3tm1.2Itl)
abnormal response to infection J:318724
\Zkscan7em1(IMPC)Mbp/\Zkscan7em1(IMPC)Mbp
(C57BL/6N-Zkscan7em1(IMPC)Mbp/MbpMmucd)
abnormal lymph node morphology J:211773
abnormal spleen morphology J:211773
enlarged lymph nodes J:211773
enlarged spleen J:211773
\Zmpste24tm1Otin/\Zmpste24tm1Otin
(involves: 129P2/Ola * C57BL/6)
abnormal thymus corticomedullary boundary morphology J:76209
thymus hypoplasia J:76209
\Zmym2em1(IMPC)J/\Zmym2+
(C57BL/6NJ-Zmym2em1(IMPC)J/Mmjax)
increased leukocyte cell number J:211773
\Zmynd10tm1(KOMP)Wtsi/\Zmynd10tm1(KOMP)Wtsi
(involves: C57BL/6J * C57BL/6N)
lung inflammation J:261915
\Zmynd11em1(IMPC)Wtsi/\Zmynd11em1(IMPC)Wtsi
(C57BL/6N-Zmynd11em1(IMPC)Wtsi/WtsiIeg)
blood in lymph vessels J:239583
\Zmynd12em1(IMPC)J/\Zmynd12em1(IMPC)J
(C57BL/6NJ-Zmynd12em1(IMPC)J/Mmjax)
increased leukocyte cell number J:211773
\Znfx1em1Xua/\Znfx1em1Xua
(involves: C57BL/6J)
abnormal macrophage physiology J:345967
abnormal response to infection J:282875
decreased circulating interferon-gamma level J:345967
decreased circulating interleukin-12 level J:345967
decreased circulating tumor necrosis factor level J:345967
decreased interferon-alpha secretion J:282875
decreased interferon-beta secretion J:282875
decreased macrophage cytokine production J:282875
impaired macrophage phagocytosis J:345967
increased susceptibility to bacterial infection J:345967
increased susceptibility to Riboviria infection J:282875
\Znhit2em1(IMPC)J/\Znhit2+
(C57BL/6NJ-Znhit2em1(IMPC)J/Mmjax)
increased leukocyte cell number J:211773
\Znhit6em1(IMPC)Mbp/\Znhit6+
(C57BL/6N-Znhit6em1(IMPC)Mbp/Ucd)
abnormal lymph node morphology J:211773
enlarged lymph nodes J:211773
\Zp3rem1(IMPC)Ccpcz/\Zp3rem1(IMPC)Ccpcz
(C57BL/6NCrl-Zp3rem1(IMPC)Ccpcz/Ccpcz)
abnormal spleen morphology J:211773
\Zranb1em1Shios/\Zranb1em1Shios
(involves: C57BL/6)
increased susceptibility to colitis induced morbidity/mortality J:333468
\Zranb1tm1c(EUCOMM)Hmgu/\Zranb1tm1c(EUCOMM)Hmgu
\Tg(Cd4-cre)1Cwi/0

(involves: 129S4/SvJaeSor * C57BL/6 * C57BL/6N * DBA/2)
immune system phenotype J:235701
\Zranb1tm1c(EUCOMM)Hmgu/\Zranb1tm1c(EUCOMM)Hmgu
\Tg(Itgax-cre)1-1Reiz/0

(involves: 129S4/SvJaeSor * C57BL/6N * CBA)
abnormal dendritic cell physiology J:235701
decreased susceptibility to experimental autoimmune encephalomyelitis J:235701
decreased T helper 1 cell number J:235701
decreased T-helper 17 cell number J:235701
immune system phenotype J:235701
\Zranb1tm1d(EUCOMM)Hmgu/\Zranb1tm1d(EUCOMM)Hmgu
(involves: 129S4/SvJaeSor * BALB/cJ * C57BL/6N)
decreased CD4-positive, alpha-beta T cell number J:235701
decreased circulating interferon-gamma level J:235701
decreased circulating interleukin-17 level J:235701
decreased susceptibility to experimental autoimmune encephalomyelitis J:235701
decreased T helper 1 cell number J:235701
decreased T-helper 17 cell number J:235701
immune system phenotype J:235701
\Zrsr2em1(IMPC)Mbp/Y
(C57BL/6N-Zrsr2em1(IMPC)Mbp/MbpMmucd)
decreased lymphocyte cell number J:211773
increased neutrophil cell number J:211773
\Zscan10Gt(285B6)1.1Cmhd/\Zscan10Gt(285B6)1.1Cmhd
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * FVB/N)
abnormal IgG level J:221010
abnormal T cell subpopulation ratio J:221010
decreased spleen weight J:221010
decreased T cell number J:221010
increased B cell number J:221010
increased CD4-positive, CD25-positive, alpha-beta regulatory T cell number J:221010
increased IgG1 level J:221010
increased IgG2b level J:221010
increased mature NK cell number J:221010
\Zswim1tm1b(KOMP)Mbp/\Zswim1tm1b(KOMP)Mbp
(C57BL/6N-Zswim1tm1b(KOMP)Mbp/Nju)
decreased lymphocyte cell number J:211773
decreased monocyte cell number J:211773
increased basophil cell number J:211773
increased eosinophil cell number J:211773
increased leukocyte cell number J:211773
increased lymphocyte cell number J:211773
increased monocyte cell number J:211773
increased neutrophil cell number J:211773
\Zup1em1Lisi/\Zup1em1Lisi
(involves: C57BL/6J)
abnormal macrophage physiology J:350802
increased susceptibility to Orthomyxoviridae infection induced morbidity/mortality J:350802
increased susceptibility to Riboviria infection induced morbidity/mortality J:350802

Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support.
last database update
03/25/2025
MGI 6.24
The Jackson Laboratory